DDI-MedLine.d78.s0;;
The;O;O
fluoroquinolones;B-group;B-DDI-MedLine.d78.s0.e0
for;O;O
urinary;O;O
tract;O;O
infections;O;O
:;O;O
a;O;O
review;O;O
.;O;O
DDI-MedLine.d78.s1;;
The;O;O
fluoroquinolones;B-group;B-DDI-MedLine.d78.s1.e0
are;O;O
a;O;O
rapidly;O;O
growing;O;O
class;O;O
of;O;O
antibiotics;B-group;B-DDI-MedLine.d78.s1.e1
with;O;O
a;O;O
broad;O;O
spectrum;O;O
of;O;O
activity;O;O
against;O;O
gram;O;O
-;O;O
negative;O;O
and;O;O
some;O;O
gram;O;O
-;O;O
positive;O;O
aerobic;O;O
bacteria;O;O
.;O;O
DDI-MedLine.d78.s2;;
These;O;O
agents;O;O
,;O;O
including;O;O
norfloxacin;B-drug;B-DDI-MedLine.d78.s2.e0
,;O;O
ciprofloxacin;B-drug;B-DDI-MedLine.d78.s2.e1
,;O;O
ofloxacin;B-drug;B-DDI-MedLine.d78.s2.e2
,;O;O
enoxacin;B-drug;B-DDI-MedLine.d78.s2.e3
,;O;O
and;O;O
lomefloxacin;B-drug;B-DDI-MedLine.d78.s2.e4
,;O;O
have;O;O
been;O;O
extensively;O;O
studied;O;O
and;O;O
have;O;O
demonstrated;O;O
efficacy;O;O
and;O;O
safety;O;O
profiles;O;O
comparable;O;O
to;O;O
those;O;O
of;O;O
other;O;O
traditional;O;O
agents;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
complicated;O;O
or;O;O
uncomplicated;O;O
urinary;O;O
tract;O;O
infections;O;O
and;O;O
prostatitis;O;O
.;O;O
DDI-MedLine.d78.s3;;
Advantages;O;O
offered;O;O
by;O;O
this;O;O
class;O;O
of;O;O
antibiotics;B-group;B-DDI-MedLine.d78.s3.e0
include;O;O
optimal;O;O
pharmacokinetics;O;O
,;O;O
effectiveness;O;O
against;O;O
multidrug;O;O
-;O;O
resistant;O;O
organisms;O;O
,;O;O
and;O;O
oral;O;O
administration;O;O
even;O;O
when;O;O
parenteral;O;O
antibiotics;B-drug;B-DDI-MedLine.d78.s3.e1
are;O;O
generally;O;O
used;O;O
.;O;O
DDI-MedLine.d78.s4;;
The;O;O
fluoroquinolones;B-group;B-DDI-MedLine.d78.s4.e0
are;O;O
also;O;O
extensively;O;O
used;O;O
in;O;O
urologic;O;O
surgery;O;O
.;O;O
DDI-MedLine.d80.s0;;
Progestin;O;O
-;O;O
only;O;O
oral;O;O
contraception;O;O
:;O;O
a;O;O
comprehensive;O;O
review;O;O
.;O;O
DDI-MedLine.d80.s1;;
In;O;O
order;O;O
to;O;O
provide;O;O
information;O;O
for;O;O
the;O;O
appropriate;O;O
package;O;O
insert;O;O
labeling;O;O
of;O;O
progestin;B-group;B-DDI-MedLine.d80.s1.e0
-;I-group;I-DDI-MedLine.d80.s1.e0
only;I-group;I-DDI-MedLine.d80.s1.e0
oral;I-group;I-DDI-MedLine.d80.s1.e0
contraceptives;I-group;I-DDI-MedLine.d80.s1.e0
(;O;O
POC;B-group;B-DDI-MedLine.d80.s1.e1
);O;O
in;O;O
the;O;O
US;O;O
,;O;O
a;O;O
comprehensive;O;O
review;O;O
was;O;O
made;O;O
of;O;O
norgestrel;B-drug;B-DDI-MedLine.d80.s1.e2
(;O;O
0.075;O;O
mg;O;O
);O;O
and;O;O
norethindrone;B-drug;B-DDI-MedLine.d80.s1.e3
(;O;O
0.35;O;O
mg;O;O
);O;O
,;O;O
with;O;O
the;O;O
clinical;O;O
differences;O;O
indicated;O;O
where;O;O
applicable;O;O
.;O;O
DDI-MedLine.d80.s2;;
The;O;O
goal;O;O
of;O;O
this;O;O
review;O;O
was;O;O
to;O;O
cite;O;O
primary;O;O
sources;O;O
for;O;O
virtually;O;O
all;O;O
research;O;O
specific;O;O
to;O;O
POPs;O;O
since;O;O
1975;O;O
.;O;O
DDI-MedLine.d80.s3;;
Conclusions;O;O
and;O;O
the;O;O
types;O;O
of;O;O
studies;O;O
which;O;O
support;O;O
these;O;O
conclusions;O;O
are;O;O
given;O;O
for;O;O
each;O;O
major;O;O
section;O;O
.;O;O
DDI-MedLine.d80.s4;;
The;O;O
introductory;O;O
chapter;O;O
discusses;O;O
the;O;O
advantages;O;O
and;O;O
disadvantages;O;O
of;O;O
POCs;B-group;B-DDI-MedLine.d80.s4.e0
and;O;O
the;O;O
magnitude;O;O
and;O;O
prevalence;O;O
of;O;O
their;O;O
use;O;O
.;O;O
DDI-MedLine.d80.s5;;
Future;O;O
trends;O;O
are;O;O
also;O;O
predicted;O;O
.;O;O
DDI-MedLine.d80.s6;;
Chapter;O;O
2;O;O
considers;O;O
the;O;O
mode;O;O
of;O;O
action;O;O
,;O;O
including;O;O
ovulation;O;O
prevention;O;O
,;O;O
DDI-MedLine.d80.s7;;
suppression;O;O
of;O;O
midcycle;O;O
gonadotropin;O;O
peaks;O;O
,;O;O
DDI-MedLine.d80.s8;;
changes;O;O
in;O;O
cervical;O;O
mucus;O;O
,;O;O
the;O;O
endometrium;O;O
,;O;O
and;O;O
the;O;O
fallopian;O;O
tubes;O;O
,;O;O
DDI-MedLine.d80.s9;;
and;O;O
clinical;O;O
implications;O;O
.;O;O
DDI-MedLine.d80.s10;;
Chapter;O;O
3;O;O
covers;O;O
pharmacology;O;O
(;O;O
pharmacokinetics;O;O
,;O;O
pharmacodynamics;O;O
and;O;O
potency;O;O
,;O;O
and;O;O
clinical;O;O
implications;O;O
);O;O
.;O;O
DDI-MedLine.d80.s11;;
The;O;O
next;O;O
chapter;O;O
presents;O;O
information;O;O
on;O;O
efficacy;O;O
and;O;O
pregnancy;O;O
outcomes;O;O
in;O;O
terms;O;O
of;O;O
pregnancy;O;O
rates;O;O
,;O;O
compliance;O;O
and;O;O
efficacy;O;O
,;O;O
ectopic;O;O
pregnancies;O;O
,;O;O
the;O;O
outcome;O;O
of;O;O
pregnancies;O;O
conceived;O;O
while;O;O
using;O;O
POCs;B-group;B-DDI-MedLine.d80.s11.e0
,;O;O
and;O;O
fertility;O;O
following;O;O
discontinuation;O;O
.;O;O
DDI-MedLine.d80.s12;;
Chapter;O;O
5;O;O
focuses;O;O
on;O;O
metabolic;O;O
effects;O;O
,;O;O
specifically;O;O
lipid;O;O
metabolism;O;O
,;O;O
carbohydrate;O;O
metabolism;O;O
and;O;O
diabetes;O;O
,;O;O
coagulation;O;O
factors;O;O
,;O;O
and;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-MedLine.d80.s13;;
Cardiovascular;O;O
disease;O;O
is;O;O
considered;O;O
in;O;O
the;O;O
next;O;O
chapter;O;O
,;O;O
and;O;O
chapter;O;O
7;O;O
presents;O;O
findings;O;O
on;O;O
endometrial;O;O
,;O;O
ovarian;O;O
,;O;O
cervical;O;O
,;O;O
breast;O;O
,;O;O
and;O;O
other;O;O
cancers;O;O
.;O;O
DDI-MedLine.d80.s14;;
A;O;O
host;O;O
of;O;O
other;O;O
medical;O;O
considerations;O;O
are;O;O
discussed;O;O
in;O;O
chapter;O;O
8;O;O
,;O;O
including;O;O
persistent;O;O
ovarian;O;O
follicles;O;O
,;O;O
DDI-MedLine.d80.s15;;
reproductive;O;O
tract;O;O
infections;O;O
,;O;O
DDI-MedLine.d80.s16;;
abnormal;O;O
vaginal;O;O
bleeding;O;O
,;O;O
DDI-MedLine.d80.s17;;
uterine;O;O
fibroids;O;O
,;O;O
DDI-MedLine.d80.s18;;
gestational;O;O
trophoblastic;O;O
disease;O;O
,;O;O
DDI-MedLine.d80.s19;;
benign;O;O
breast;O;O
disease;O;O
,;O;O
DDI-MedLine.d80.s20;;
diseases;O;O
of;O;O
the;O;O
liver;O;O
,;O;O
gallbladder;O;O
,;O;O
and;O;O
bowel;O;O
,;O;O
DDI-MedLine.d80.s21;;
endocrine;O;O
dysfunction;O;O
,;O;O
DDI-MedLine.d80.s22;;
epilepsy;O;O
,;O;O
DDI-MedLine.d80.s23;;
bone;O;O
density;O;O
,;O;O
DDI-MedLine.d80.s24;;
sickle;O;O
cell;O;O
disease;O;O
,;O;O
DDI-MedLine.d80.s25;;
ocular;O;O
effects;O;O
,;O;O
DDI-MedLine.d80.s26;;
surgery;O;O
,;O;O
DDI-MedLine.d80.s27;;
and;O;O
overdose;O;O
.;O;O
DDI-MedLine.d80.s28;;
The;O;O
last;O;O
4;O;O
chapters;O;O
cover;O;O
interactions;O;O
with;O;O
drugs;O;O
and;O;O
laboratory;O;O
tests;O;O
,;O;O
common;O;O
side;O;O
effects;O;O
,;O;O
breast;O;O
feeding;O;O
,;O;O
and;O;O
effective;O;O
use;O;O
of;O;O
POCs;B-group;B-DDI-MedLine.d80.s28.e0
.;O;O
DDI-MedLine.d80.s29;;
Information;O;O
on;O;O
precautions;O;O
and;O;O
contraindications;O;O
,;O;O
indications;O;O
,;O;O
use;O;O
instructions;O;O
,;O;O
and;O;O
instructions;O;O
for;O;O
appropriate;O;O
actions;O;O
after;O;O
missing;O;O
a;O;O
pill;O;O
is;O;O
appended;O;O
.;O;O
DDI-MedLine.d84.s0;;
Antimicrobial;O;O
activity;O;O
of;O;O
Ganoderma;B-drug_n;B-DDI-MedLine.d84.s0.e0
lucidum;I-drug_n;I-DDI-MedLine.d84.s0.e0
extract;I-drug_n;I-DDI-MedLine.d84.s0.e0
alone;O;O
and;O;O
in;O;O
combination;O;O
with;O;O
some;O;O
antibiotics;B-group;B-DDI-MedLine.d84.s0.e1
.;O;O
DDI-MedLine.d84.s1;;
Antimicrobial;O;O
activity;O;O
of;O;O
GL;B-drug_n;B-DDI-MedLine.d84.s1.e0
(;O;O
the;O;O
aqueous;O;O
extract;O;O
from;O;O
the;O;O
carpophores;O;O
of;O;O
Ganoderma;O;O
lucidum;O;O
(;O;O
FR)KARST;O;O
);O;O
was;O;O
tested;O;O
in;O;O
vitro;O;O
against;O;O
Gram;O;O
positive;O;O
and;O;O
Gram;O;O
negative;O;O
bacteria;O;O
by;O;O
serial;O;O
broth;O;O
dilution;O;O
method;O;O
,;O;O
and;O;O
the;O;O
antimicrobial;O;O
activity;O;O
was;O;O
expressed;O;O
by;O;O
minimal;O;O
inhibitory;O;O
concentration;O;O
(;O;O
MIC;O;O
);O;O
.;O;O
DDI-MedLine.d84.s2;;
Among;O;O
fifteen;O;O
species;O;O
of;O;O
bacteria;O;O
tested;O;O
,;O;O
the;O;O
antimicrobial;O;O
activity;O;O
of;O;O
GL;B-drug_n;B-DDI-MedLine.d84.s2.e0
was;O;O
the;O;O
most;O;O
potent;O;O
against;O;O
Micrococcus;O;O
luteus;O;O
(;O;O
MIC;O;O
,;O;O
0.75;O;O
mg;O;O
/;O;O
ml;O;O
);O;O
.;O;O
DDI-MedLine.d84.s3;;
To;O;O
investigate;O;O
the;O;O
effects;O;O
of;O;O
antimicrobial;O;O
combinations;O;O
of;O;O
GL;B-drug_n;B-DDI-MedLine.d84.s3.e0
with;O;O
four;O;O
kinds;O;O
of;O;O
antibiotics;B-group;B-DDI-MedLine.d84.s3.e1
(;O;O
ampicillin;B-drug;B-DDI-MedLine.d84.s3.e2
,;O;O
cefazolin;B-drug;B-DDI-MedLine.d84.s3.e3
,;O;O
oxytetracycline;B-drug;B-DDI-MedLine.d84.s3.e4
and;O;O
chloramphenicol;B-drug;B-DDI-MedLine.d84.s3.e5
);O;O
,;O;O
the;O;O
fractional;O;O
inhibitory;O;O
concentration;O;O
index;O;O
(;O;O
FICI;O;O
);O;O
was;O;O
determined;O;O
by;O;O
checkerboard;O;O
assay;O;O
for;O;O
each;O;O
strain;O;O
.;O;O
DDI-MedLine.d84.s4;;
The;O;O
antimicrobial;O;O
combinations;O;O
of;O;O
GL;B-drug_n;B-DDI-MedLine.d84.s4.e0
with;O;O
four;O;O
antibiotics;B-group;B-DDI-MedLine.d84.s4.e1
resulted;O;O
in;O;O
additive;O;O
effect;O;O
in;O;O
most;O;O
instances;O;O
,;O;O
synergism;O;O
in;O;O
two;O;O
instances;O;O
,;O;O
and;O;O
antagonism;O;O
in;O;O
two;O;O
instances;O;O
.;O;O
DDI-MedLine.d84.s5;;
Synergism;O;O
was;O;O
observed;O;O
when;O;O
GL;B-drug_n;B-DDI-MedLine.d84.s5.e0
was;O;O
combined;O;O
with;O;O
cefazolin;B-drug;B-DDI-MedLine.d84.s5.e1
against;O;O
Bacillus;O;O
subtilis;O;O
and;O;O
Klebsiella;O;O
oxytoca;O;O
.;O;O
DDI-MedLine.d13.s0;;
Death;O;O
in;O;O
amphetamine;B-drug;B-DDI-MedLine.d13.s0.e0
users;O;O
:;O;O
causes;O;O
and;O;O
rates;O;O
.;O;O
DDI-MedLine.d13.s1;;
The;O;O
world;O;O
medical;O;O
literature;O;O
contains;O;O
43;O;O
reports;O;O
of;O;O
deaths;O;O
associated;O;O
with;O;O
amphetamines;B-drug;B-DDI-MedLine.d13.s1.e0
in;O;O
a;O;O
35;O;O
-;O;O
year;O;O
period;O;O
.;O;O
DDI-MedLine.d13.s2;;
These;O;O
included;O;O
seven;O;O
cerebrovascular;O;O
accidents;O;O
,;O;O
six;O;O
sudden;O;O
cardiac;O;O
deaths;O;O
,;O;O
three;O;O
cases;O;O
of;O;O
hyperpyrexia;O;O
,;O;O
eight;O;O
poisonings;O;O
of;O;O
uncertain;O;O
mechanism;O;O
and;O;O
seven;O;O
cases;O;O
of;O;O
medical;O;O
complications;O;O
of;O;O
intravenous;O;O
injection;O;O
,;O;O
DDI-MedLine.d13.s3;;
the;O;O
remainder;O;O
were;O;O
of;O;O
uncertain;O;O
cause;O;O
.;O;O
DDI-MedLine.d13.s4;;
In;O;O
contrast;O;O
,;O;O
in;O;O
Ontario;O;O
alone;O;O
,;O;O
in;O;O
1972;O;O
and;O;O
1973;O;O
there;O;O
were;O;O
26;O;O
deaths;O;O
in;O;O
amphetamine;B-drug;B-DDI-MedLine.d13.s4.e0
users;O;O
,;O;O
of;O;O
which;O;O
16;O;O
were;O;O
due;O;O
to;O;O
accident;O;O
suicide;O;O
or;O;O
homicide;O;O
.;O;O
DDI-MedLine.d13.s5;;
Of;O;O
the;O;O
remaining;O;O
cases;O;O
,;O;O
two;O;O
were;O;O
cardiac;O;O
,;O;O
two;O;O
hepatic;O;O
and;O;O
the;O;O
rest;O;O
were;O;O
mixed;O;O
drug;O;O
overdose;O;O
.;O;O
DDI-MedLine.d13.s6;;
Pulmonary;O;O
granulomata;O;O
,;O;O
subacute;O;O
hepatitis;O;O
and;O;O
other;O;O
lesions;O;O
resulting;O;O
from;O;O
intravenous;O;O
drug;O;O
use;O;O
were;O;O
common;O;O
findings;O;O
at;O;O
autopsy;O;O
.;O;O
DDI-MedLine.d13.s7;;
On;O;O
the;O;O
basis;O;O
of;O;O
the;O;O
estimated;O;O
number;O;O
of;O;O
regular;O;O
users;O;O
of;O;O
intravenous;O;O
amphetamine;B-drug;B-DDI-MedLine.d13.s7.e0
in;O;O
Ontario;O;O
,;O;O
the;O;O
mortality;O;O
rate;O;O
in;O;O
such;O;O
users;O;O
is;O;O
at;O;O
least;O;O
four;O;O
times;O;O
as;O;O
high;O;O
as;O;O
in;O;O
the;O;O
general;O;O
population;O;O
of;O;O
the;O;O
same;O;O
age;O;O
,;O;O
and;O;O
is;O;O
comparable;O;O
to;O;O
that;O;O
in;O;O
alcoholics;O;O
and;O;O
heroin;B-drug_n;B-DDI-MedLine.d13.s7.e1
addicts;O;O
.;O;O
DDI-MedLine.d13.s8;;
However;O;O
,;O;O
the;O;O
absolute;O;O
number;O;O
of;O;O
alcohol;B-drug;B-DDI-MedLine.d13.s8.e0
-;O;O
related;O;O
deaths;O;O
is;O;O
far;O;O
greater;O;O
than;O;O
the;O;O
number;O;O
of;O;O
deaths;O;O
in;O;O
amphetamine;B-drug;B-DDI-MedLine.d13.s8.e1
or;O;O
heroin;B-drug_n;B-DDI-MedLine.d13.s8.e2
users;O;O
.;O;O
DDI-MedLine.d50.s0;;
Ascorbic;B-drug;B-DDI-MedLine.d50.s0.e0
acid;I-drug;I-DDI-MedLine.d50.s0.e0
and;O;O
the;O;O
common;O;O
cold;O;O
.;O;O
DDI-MedLine.d50.s1;;
Evaluation;O;O
of;O;O
its;O;O
efficacy;O;O
and;O;O
toxicity;O;O
.;O;O

;O;O
DDI-MedLine.d50.s2;;
We;O;O
reviewed;O;O
the;O;O
clinical;O;O
data;O;O
relating;O;O
to;O;O
the;O;O
efficacy;O;O
and;O;O
safety;O;O
of;O;O
pharmacologic;O;O
doses;O;O
of;O;O
ascorbic;B-drug;B-DDI-MedLine.d50.s2.e0
acid;I-drug;I-DDI-MedLine.d50.s2.e0
in;O;O
the;O;O
prevention;O;O
and;O;O
treatment;O;O
of;O;O
the;O;O
common;O;O
cold;O;O
.;O;O
DDI-MedLine.d50.s3;;
Although;O;O
one;O;O
study;O;O
tentatively;O;O
supports;O;O
the;O;O
hypothesis;O;O
that;O;O
such;O;O
doses;O;O
of;O;O
ascorbic;B-drug;B-DDI-MedLine.d50.s3.e0
acid;I-drug;I-DDI-MedLine.d50.s3.e0
may;O;O
be;O;O
efficacious;O;O
,;O;O
a;O;O
second;O;O
study;O;O
by;O;O
the;O;O
same;O;O
group;O;O
did;O;O
not;O;O
confirm;O;O
the;O;O
significant;O;O
findings;O;O
,;O;O
and;O;O
no;O;O
clear;O;O
,;O;O
reproducible;O;O
pattern;O;O
of;O;O
efficacy;O;O
has;O;O
emerged;O;O
from;O;O
the;O;O
review;O;O
of;O;O
all;O;O
the;O;O
evidence;O;O
.;O;O
DDI-MedLine.d50.s4;;
Similarly;O;O
,;O;O
there;O;O
is;O;O
currently;O;O
little;O;O
adequate;O;O
evidence;O;O
on;O;O
either;O;O
the;O;O
presence;O;O
or;O;O
the;O;O
absence;O;O
of;O;O
serious;O;O
adverse;O;O
reactions;O;O
to;O;O
such;O;O
doses;O;O
of;O;O
ascorbic;B-drug;B-DDI-MedLine.d50.s4.e0
acid;I-drug;I-DDI-MedLine.d50.s4.e0
,;O;O
although;O;O
many;O;O
such;O;O
reactions;O;O
have;O;O
been;O;O
hypothesized;O;O
.;O;O
DDI-MedLine.d50.s5;;
The;O;O
unrestricted;O;O
use;O;O
of;O;O
ascorbic;B-drug;B-DDI-MedLine.d50.s5.e0
acid;I-drug;I-DDI-MedLine.d50.s5.e0
for;O;O
these;O;O
purposes;O;O
can;O;O
not;O;O
be;O;O
advocated;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
the;O;O
evidence;O;O
currently;O;O
available;O;O
.;O;O
DDI-MedLine.d26.s0;;
Optimal;O;O
designs;O;O
for;O;O
the;O;O
individual;O;O
and;O;O
joint;O;O
exposure;O;O
general;O;O
logistic;O;O
regression;O;O
models;O;O
.;O;O

;O;O
DDI-MedLine.d26.s1;;
Interest;O;O
in;O;O
administering;O;O
compounds;O;O
in;O;O
combination;O;O
lies;O;O
both;O;O
in;O;O
enhancing;O;O
efficacious;O;O
effects;O;O
and;O;O
in;O;O
limiting;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-MedLine.d26.s2;;
Although;O;O
much;O;O
statistical;O;O
work;O;O
has;O;O
focused;O;O
on;O;O
developing;O;O
mathematical;O;O
functions;O;O
to;O;O
model;O;O
the;O;O
joint;O;O
dose;O;O
-;O;O
response;O;O
curves;O;O
,;O;O
relatively;O;O
little;O;O
work;O;O
exists;O;O
in;O;O
regard;O;O
to;O;O
designing;O;O
experiments;O;O
for;O;O
assessing;O;O
joint;O;O
action;O;O
.;O;O
DDI-MedLine.d26.s3;;
A;O;O
variety;O;O
of;O;O
parametric;O;O
dose;O;O
-;O;O
response;O;O
models;O;O
based;O;O
on;O;O
either;O;O
the;O;O
normal;O;O
or;O;O
logistic;O;O
probability;O;O
distribution;O;O
have;O;O
been;O;O
proposed;O;O
in;O;O
the;O;O
literature;O;O
.;O;O
DDI-MedLine.d26.s4;;
These;O;O
models;O;O
are;O;O
typically;O;O
nonlinear;O;O
in;O;O
the;O;O
parameters;O;O
,;O;O
and;O;O
as;O;O
such;O;O
,;O;O
a;O;O
nonlinear;O;O
weighted;O;O
least;O;O
squares;O;O
approach;O;O
can;O;O
be;O;O
employed;O;O
for;O;O
the;O;O
purpose;O;O
of;O;O
designing;O;O
experiments;O;O
.;O;O
DDI-MedLine.d26.s5;;
The;O;O
approach;O;O
is;O;O
applicable;O;O
across;O;O
a;O;O
wide;O;O
variety;O;O
of;O;O
settings;O;O
commonly;O;O
associated;O;O
with;O;O
joint;O;O
action;O;O
data;O;O
,;O;O
including;O;O
continuous;O;O
and;O;O
discrete;O;O
responses;O;O
,;O;O
alternative;O;O
error;O;O
structures;O;O
,;O;O
and;O;O
nonzero;O;O
background;O;O
response;O;O
.;O;O
DDI-MedLine.d26.s6;;
Further;O;O
,;O;O
designs;O;O
can;O;O
be;O;O
expressed;O;O
in;O;O
terms;O;O
of;O;O
proportionate;O;O
responses;O;O
associated;O;O
with;O;O
the;O;O
individual;O;O
compounds;O;O
rather;O;O
than;O;O
dose;O;O
levels;O;O
,;O;O
thereby;O;O
providing;O;O
for;O;O
results;O;O
that;O;O
are;O;O
applicable;O;O
across;O;O
compounds;O;O
.;O;O
DDI-MedLine.d26.s7;;
As;O;O
a;O;O
precursor;O;O
to;O;O
this;O;O
effort;O;O
,;O;O
optimal;O;O
and;O;O
minimal;O;O
experimental;O;O
designs;O;O
for;O;O
the;O;O
case;O;O
in;O;O
which;O;O
a;O;O
single;O;O
compound;O;O
is;O;O
administered;O;O
have;O;O
also;O;O
been;O;O
developed;O;O
.;O;O
DDI-MedLine.d26.s8;;
Although;O;O
the;O;O
proposed;O;O
methodology;O;O
for;O;O
deriving;O;O
experimental;O;O
designs;O;O
can;O;O
be;O;O
applied;O;O
to;O;O
any;O;O
nonlinear;O;O
regression;O;O
model;O;O
,;O;O
primary;O;O
focus;O;O
is;O;O
given;O;O
to;O;O
the;O;O
additive;O;O
and;O;O
nonadditive;O;O
independent;O;O
joint;O;O
action;O;O
(;O;O
IJA;O;O
);O;O
models;O;O
for;O;O
individual;O;O
and;O;O
combined;O;O
exposures;O;O
proposed;O;O
by;O;O
Barton;O;O
,;O;O
Braunberg;O;O
,;O;O
and;O;O
Friedman;O;O
(;O;O
1;O;O
);O;O
.;O;O
DDI-MedLine.d69.s0;;
Differential;O;O
regulation;O;O
of;O;O
tyrosine;O;O
phosphorylation;O;O
in;O;O
tumor;O;O
cells;O;O
by;O;O
contortrostatin;B-drug_n;B-DDI-MedLine.d69.s0.e0
,;O;O
a;O;O
homodimeric;O;O
disintegrin;O;O
,;O;O
and;O;O
monomeric;O;O
disintegrins;O;O
echistatin;B-drug_n;B-DDI-MedLine.d69.s0.e1
and;O;O
flavoridin;B-drug_n;B-DDI-MedLine.d69.s0.e2
.;O;O
DDI-MedLine.d69.s1;;
The;O;O
homodimeric;O;O
disintegrin;O;O
contortrostatin;B-drug_n;B-DDI-MedLine.d69.s1.e0
was;O;O
compared;O;O
directly;O;O
to;O;O
the;O;O
monomeric;O;O
disintegrins;O;O
echistatin;B-drug_n;B-DDI-MedLine.d69.s1.e1
and;O;O
flavoridin;B-drug_n;B-DDI-MedLine.d69.s1.e2
for;O;O
the;O;O
ability;O;O
to;O;O
affect;O;O
protein;O;O
tyrosine;O;O
phosphorylation;O;O
in;O;O
tumor;O;O
cells;O;O
.;O;O
DDI-MedLine.d69.s2;;
It;O;O
was;O;O
observed;O;O
that;O;O
contortrostatin;B-drug_n;B-DDI-MedLine.d69.s2.e0
had;O;O
a;O;O
dramatic;O;O
effect;O;O
on;O;O
the;O;O
tyrosine;O;O
phosphorylation;O;O
status;O;O
of;O;O
several;O;O
proteins;O;O
in;O;O
T24;O;O
human;O;O
bladder;O;O
cancer;O;O
cells;O;O
,;O;O
including;O;O
robust;O;O
induction;O;O
of;O;O
phosphorylation;O;O
of;O;O
proteins;O;O
in;O;O
the;O;O
range;O;O
of;O;O
120;O;O
-;O;O
140;O;O
kDa;O;O
.;O;O
DDI-MedLine.d69.s3;;
Echistatin;B-drug_n;B-DDI-MedLine.d69.s3.e0
alone;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
tyrosine;O;O
phosphorylation;O;O
in;O;O
T24;O;O
cells;O;O
,;O;O
but;O;O
dose;O;O
-;O;O
dependently;O;O
inhibits;O;O
the;O;O
effects;O;O
of;O;O
contortrostatin;B-drug_n;B-DDI-MedLine.d69.s3.e1
when;O;O
both;O;O
are;O;O
added;O;O
simultaneously;O;O
.;O;O
DDI-MedLine.d69.s4;;
Among;O;O
the;O;O
proteins;O;O
that;O;O
undergo;O;O
tyrosine;O;O
phosphorylation;O;O
in;O;O
response;O;O
to;O;O
contortrostatin;B-drug_n;B-DDI-MedLine.d69.s4.e0
treatment;O;O
is;O;O
CAS;O;O
,;O;O
a;O;O
130;O;O
kDa;O;O
adapter;O;O
protein;O;O
involved;O;O
in;O;O
integrin;O;O
signaling;O;O
.;O;O
DDI-MedLine.d69.s5;;
Flavoridin;B-drug_n;B-DDI-MedLine.d69.s5.e0
alone;O;O
was;O;O
found;O;O
to;O;O
have;O;O
no;O;O
effect;O;O
on;O;O
CAS;O;O
,;O;O
but;O;O
can;O;O
completely;O;O
block;O;O
contortrostatin;B-drug_n;B-DDI-MedLine.d69.s5.e1
-;O;O
induced;O;O
phosphorylation;O;O
of;O;O
this;O;O
protein;O;O
in;O;O
MDA;O;O
-;O;O
MB;O;O
-;O;O
435;O;O
cells;O;O
.;O;O
DDI-MedLine.d69.s6;;
These;O;O
observations;O;O
strongly;O;O
suggest;O;O
that;O;O
the;O;O
homodimeric;O;O
structure;O;O
of;O;O
contortrostatin;B-drug_n;B-DDI-MedLine.d69.s6.e0
functionally;O;O
distinguishes;O;O
it;O;O
from;O;O
other;O;O
monomeric;O;O
members;O;O
of;O;O
the;O;O
disintegrin;O;O
family;O;O
.;O;O
DDI-MedLine.d48.s0;;
Modification;O;O
of;O;O
surface;O;O
histidine;O;O
residues;O;O
abolishes;O;O
the;O;O
cytotoxic;O;O
activity;O;O
of;O;O
Clostridium;B-drug_n;B-DDI-MedLine.d48.s0.e0
difficile;I-drug_n;I-DDI-MedLine.d48.s0.e0
toxin;I-drug_n;I-DDI-MedLine.d48.s0.e0
A.;I-drug_n;I-DDI-MedLine.d48.s0.e0
DDI-MedLine.d48.s1;;
Clostridium;I-drug_n;I-DDI-MedLine.d48.s1.e0
difficile;I-drug_n;I-DDI-MedLine.d48.s1.e0
toxin;I-drug_n;I-DDI-MedLine.d48.s1.e0
A;I-drug_n;I-DDI-MedLine.d48.s1.e0
displays;O;O
both;O;O
cytotoxic;O;O
and;O;O
enterotoxic;O;O
activities;O;O
.;O;O
DDI-MedLine.d48.s2;;
It;O;O
has;O;O
recently;O;O
been;O;O
demonstrated;O;O
that;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s2.e0
A;I-drug_n;I-DDI-MedLine.d48.s2.e0
exerts;O;O
its;O;O
cytotoxic;O;O
effect;O;O
by;O;O
the;O;O
glucosylation;O;O
of;O;O
the;O;O
small;O;O
GTP;O;O
-;O;O
binding;O;O
proteins;O;O
of;O;O
the;O;O
Rho;O;O
family;O;O
.;O;O
DDI-MedLine.d48.s3;;
Diethyl;B-drug_n;B-DDI-MedLine.d48.s3.e0
pyrocarbonate;I-drug_n;I-DDI-MedLine.d48.s3.e0
,;O;O
at;O;O
pH;O;O
7.0;O;O
,;O;O
was;O;O
used;O;O
to;O;O
chemically;O;O
modify;O;O
exposed;O;O
histidine;O;O
residues;O;O
on;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s3.e1
A.;I-drug_n;I-DDI-MedLine.d48.s3.e1
DDI-MedLine.d48.s4;;
Modification;O;O
of;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s4.e0
A;I-drug_n;I-DDI-MedLine.d48.s4.e0
with;O;O
diethyl;B-drug_n;B-DDI-MedLine.d48.s4.e1
pyrocarbonate;I-drug_n;I-DDI-MedLine.d48.s4.e1
abolished;O;O
both;O;O
its;O;O
cytotoxic;O;O
activity;O;O
and;O;O
the;O;O
ability;O;O
of;O;O
the;O;O
toxin;O;O
to;O;O
bind;O;O
Zn;O;O
-;O;O
Sepharose;O;O
gel;O;O
.;O;O
DDI-MedLine.d48.s5;;
Treatment;O;O
of;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s5.e0
A;I-drug_n;I-DDI-MedLine.d48.s5.e0
with;O;O
[;O;O
(;O;O
14)C];O;O
-;O;O
diethyl;B-drug_n;B-DDI-MedLine.d48.s5.e1
pyrocarbonate;I-drug_n;I-DDI-MedLine.d48.s5.e1
revealed;O;O
concentration;O;O
dependent;O;O
labelling;O;O
of;O;O
histidine;O;O
residues;O;O
on;O;O
the;O;O
toxin;O;O
molecules;O;O
.;O;O
DDI-MedLine.d48.s6;;
The;O;O
effects;O;O
of;O;O
diethyl;B-drug_n;B-DDI-MedLine.d48.s6.e0
pyrocarbonate;I-drug_n;I-DDI-MedLine.d48.s6.e0
could;O;O
be;O;O
reversed;O;O
by;O;O
hydroxylamine;B-drug_n;B-DDI-MedLine.d48.s6.e1
treatment;O;O
.;O;O
DDI-MedLine.d48.s7;;
These;O;O
data;O;O
suggest;O;O
the;O;O
modified;O;O
histidine;O;O
residues;O;O
on;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s7.e0
A;I-drug_n;I-DDI-MedLine.d48.s7.e0
are;O;O
critical;O;O
to;O;O
its;O;O
cytotoxic;O;O
activity;O;O
.;O;O
DDI-MedLine.d48.s8;;
Histidine;O;O
modification;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
glucosyl;O;O
transferase;O;O
enzyme;O;O
activity;O;O
of;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s8.e0
A.;I-drug_n;I-DDI-MedLine.d48.s8.e0
DDI-MedLine.d48.s9;;
However;O;O
,;O;O
modification;O;O
abolished;O;O
the;O;O
';O;O
cold;O;O
';O;O
binding;O;O
of;O;O
toxin;O;O
to;O;O
bovine;O;O
thyroglobulin;O;O
in;O;O
an;O;O
ELISA;O;O
and;O;O
reduced;O;O
ligand;O;O
binding;O;O
activity;O;O
in;O;O
a;O;O
rabbit;O;O
erythrocyte;O;O
haemagglutination;O;O
assay;O;O
.;O;O
DDI-MedLine.d48.s10;;
The;O;O
data;O;O
suggest;O;O
that;O;O
the;O;O
histidine;O;O
residues;O;O
may;O;O
be;O;O
crucial;O;O
to;O;O
the;O;O
receptor;O;O
-;O;O
binding;O;O
activity;O;O
of;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s10.e0
A.;I-drug_n;I-DDI-MedLine.d48.s10.e0
DDI-MedLine.d48.s11;;
Exposed;O;O
histidines;O;O
on;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s11.e0
A;I-drug_n;I-DDI-MedLine.d48.s11.e0
are;O;O
available;O;O
for;O;O
zinc;B-drug;B-DDI-MedLine.d48.s11.e1
chelation;O;O
,;O;O
and;O;O
these;O;O
have;O;O
been;O;O
exploited;O;O
in;O;O
the;O;O
development;O;O
of;O;O
a;O;O
novel;O;O
purification;O;O
protocol;O;O
for;O;O
toxin;B-drug_n;B-DDI-MedLine.d48.s11.e2
A;I-drug_n;I-DDI-MedLine.d48.s11.e2
using;O;O
zinc;B-drug;B-DDI-MedLine.d48.s11.e3
-;O;O
chelating;O;O
chromatography;O;O
.;O;O
DDI-MedLine.d18.s0;;
Note;O;O
:;O;O
dissolution;O;O
of;O;O
aerosol;O;O
particles;O;O
of;O;O
budesonide;B-drug;B-DDI-MedLine.d18.s0.e0
in;O;O
Survanta;B-brand;B-DDI-MedLine.d18.s0.e1
,;O;O
a;O;O
model;O;O
lung;B-group;B-DDI-MedLine.d18.s0.e2
surfactant;I-group;I-DDI-MedLine.d18.s0.e2
.;O;O

;O;O
DDI-MedLine.d18.s1;;
The;O;O
effect;O;O
of;O;O
a;O;O
pulmonary;B-group;B-DDI-MedLine.d18.s1.e0
surfactant;I-group;I-DDI-MedLine.d18.s1.e0
extract;O;O
from;O;O
bovine;O;O
lung;O;O
,;O;O
Survanta;B-brand;B-DDI-MedLine.d18.s1.e1
,;O;O
on;O;O
the;O;O
dissolution;O;O
rate;O;O
of;O;O
aerosol;O;O
particles;O;O
of;O;O
budesonide;B-drug;B-DDI-MedLine.d18.s1.e2
was;O;O
determined;O;O
.;O;O
DDI-MedLine.d18.s2;;
Aerosol;O;O
particles;O;O
of;O;O
budesonide;B-drug;B-DDI-MedLine.d18.s2.e0
were;O;O
generated;O;O
from;O;O
an;O;O
ethanol;B-drug;B-DDI-MedLine.d18.s2.e1
solution;O;O
,;O;O
dried;O;O
,;O;O
and;O;O
collected;O;O
by;O;O
a;O;O
cascade;O;O
impactor;O;O
for;O;O
characterization;O;O
or;O;O
by;O;O
a;O;O
liquid;O;O
impinger;O;O
for;O;O
dissolution;O;O
experiments;O;O
.;O;O
DDI-MedLine.d18.s3;;
Powder;O;O
x;O;O
-;O;O
ray;O;O
diffraction;O;O
,;O;O
differential;O;O
scanning;O;O
calorimetry;O;O
,;O;O
differential;O;O
thermal;O;O
analysis;O;O
,;O;O
and;O;O
scanning;O;O
electron;O;O
microscopy;O;O
were;O;O
used;O;O
to;O;O
characterize;O;O
the;O;O
aerosol;O;O
particles;O;O
and;O;O
starting;O;O
material;O;O
.;O;O
DDI-MedLine.d18.s4;;
No;O;O
change;O;O
in;O;O
phase;O;O
was;O;O
detected;O;O
,;O;O
although;O;O
the;O;O
aerosol;O;O
particles;O;O
appeared;O;O
to;O;O
contain;O;O
residual;O;O
solvent;B-group;B-DDI-MedLine.d18.s4.e0
.;O;O
DDI-MedLine.d18.s5;;
The;O;O
dissolution;O;O
rate;O;O
of;O;O
the;O;O
aerosol;O;O
particles;O;O
in;O;O
saline;O;O
was;O;O
low;O;O
and;O;O
variable;O;O
.;O;O
DDI-MedLine.d18.s6;;
Survanta;B-brand;B-DDI-MedLine.d18.s6.e0
increased;O;O
the;O;O
extent;O;O
of;O;O
dissolution;O;O
of;O;O
budesonide;B-drug;B-DDI-MedLine.d18.s6.e1
in;O;O
proportion;O;O
to;O;O
the;O;O
added;O;O
concentration;O;O
,;O;O
which;O;O
was;O;O
also;O;O
verified;O;O
by;O;O
equilibrium;O;O
solubilization;O;O
studies;O;O
.;O;O
DDI-MedLine.d18.s7;;
Survanta;B-brand;B-DDI-MedLine.d18.s7.e0
also;O;O
increased;O;O
rate;O;O
of;O;O
dissolution;O;O
,;O;O
in;O;O
a;O;O
manner;O;O
similar;O;O
to;O;O
sodium;B-drug_n;B-DDI-MedLine.d18.s7.e1
dodecyl;I-drug_n;I-DDI-MedLine.d18.s7.e1
sulfate;I-drug_n;I-DDI-MedLine.d18.s7.e1
.;O;O
DDI-MedLine.d18.s8;;
Analysis;O;O
of;O;O
the;O;O
concentration;O;O
of;O;O
budesonide;B-drug;B-DDI-MedLine.d18.s8.e0
following;O;O
ultracentrifugation;O;O
indicated;O;O
that;O;O
there;O;O
is;O;O
rapid;O;O
equilibration;O;O
of;O;O
budesonide;B-drug;B-DDI-MedLine.d18.s8.e1
between;O;O
the;O;O
Survanta;B-brand;B-DDI-MedLine.d18.s8.e2
and;O;O
aqueous;O;O
phase;O;O
.;O;O
DDI-MedLine.d18.s9;;
These;O;O
results;O;O
show;O;O
that;O;O
lung;B-group;B-DDI-MedLine.d18.s9.e0
surfactant;I-group;I-DDI-MedLine.d18.s9.e0
has;O;O
the;O;O
potential;O;O
of;O;O
enhancing;O;O
the;O;O
rate;O;O
and;O;O
extent;O;O
of;O;O
dissolution;O;O
of;O;O
drugs;O;O
administered;O;O
to;O;O
the;O;O
lung;O;O
.;O;O
DDI-MedLine.d62.s0;;
Activation;O;O
of;O;O
an;O;O
effector;O;O
immediate;O;O
-;O;O
early;O;O
gene;O;O
arc;O;O
by;O;O
methamphetamine;B-drug;B-DDI-MedLine.d62.s0.e0
.;O;O
DDI-MedLine.d62.s1;;
As;O;O
immediate;O;O
-;O;O
early;O;O
genes;O;O
(;O;O
IEGs;O;O
);O;O
are;O;O
thought;O;O
to;O;O
play;O;O
a;O;O
critical;O;O
role;O;O
in;O;O
mediating;O;O
stimulus;O;O
-;O;O
induced;O;O
neural;O;O
plasticity;O;O
,;O;O
IEG;O;O
response;O;O
induced;O;O
by;O;O
methamphetamine;B-drug;B-DDI-MedLine.d62.s1.e0
(;O;O
METH;B-drug;B-DDI-MedLine.d62.s1.e1
);O;O
has;O;O
been;O;O
characterized;O;O
to;O;O
define;O;O
the;O;O
changes;O;O
in;O;O
gene;O;O
expression;O;O
that;O;O
may;O;O
underlie;O;O
its;O;O
long;O;O
-;O;O
lasting;O;O
behavioral;O;O
effects;O;O
.;O;O
DDI-MedLine.d62.s2;;
Although;O;O
activation;O;O
of;O;O
several;O;O
transcription;O;O
factor;O;O
IEGs;O;O
has;O;O
been;O;O
described;O;O
,;O;O
little;O;O
is;O;O
known;O;O
about;O;O
effector;O;O
IEGs;O;O
.;O;O
DDI-MedLine.d62.s3;;
Here;O;O
,;O;O
we;O;O
have;O;O
examined;O;O
whether;O;O
METH;B-drug;B-DDI-MedLine.d62.s3.e0
administration;O;O
affects;O;O
expression;O;O
of;O;O
an;O;O
effector;O;O
IEG;O;O
arc;O;O
(;O;O
activity;O;O
-;O;O
regulated;O;O
,;O;O
cytoskeleton;O;O
-;O;O
associated;O;O
);O;O
that;O;O
encodes;O;O
a;O;O
protein;O;O
with;O;O
homology;O;O
to;O;O
spectrin;O;O
.;O;O
DDI-MedLine.d62.s4;;
Using;O;O
in;O;O
situ;O;O
hybridization;O;O
,;O;O
we;O;O
observed;O;O
that;O;O
METH;B-drug;B-DDI-MedLine.d62.s4.e0
caused;O;O
a;O;O
rapid;O;O
and;O;O
transient;O;O
dose;O;O
-;O;O
dependent;O;O
increase;O;O
in;O;O
arc;O;O
mRNA;O;O
level;O;O
in;O;O
the;O;O
striatum;O;O
and;O;O
cortex;O;O
that;O;O
was;O;O
abolished;O;O
by;O;O
pretreatment;O;O
with;O;O
the;O;O
specific;O;O
dopamine;O;O
D1;O;O
receptor;O;O
antagonist;O;O
SCH;B-drug_n;B-DDI-MedLine.d62.s4.e1
-;I-drug_n;I-DDI-MedLine.d62.s4.e1
23390;I-drug_n;I-DDI-MedLine.d62.s4.e1
but;O;O
not;O;O
by;O;O
an;O;O
atypical;B-group;B-DDI-MedLine.d62.s4.e2
neuroleptic;I-group;I-DDI-MedLine.d62.s4.e2
clozapine;I-drug;I-DDI-MedLine.d62.s4.e3
.;O;O
DDI-MedLine.d62.s5;;
METH;B-drug;B-DDI-MedLine.d62.s5.e0
induced;O;O
arc;O;O
mRNA;O;O
in;O;O
layers;O;O
IV;O;O
and;O;O
VI;O;O
of;O;O
the;O;O
cortex;O;O
which;O;O
dopamine;O;O
receptor;O;O
are;O;O
localized;O;O
to;O;O
.;O;O
DDI-MedLine.d62.s6;;
These;O;O
results;O;O
suggest;O;O
that;O;O
D1;O;O
receptors;O;O
are;O;O
coupled;O;O
to;O;O
activation;O;O
of;O;O
arc;O;O
gene;O;O
,;O;O
which;O;O
may;O;O
be;O;O
involved;O;O
in;O;O
functional;O;O
or;O;O
structural;O;O
alterations;O;O
underlying;O;O
neural;O;O
plasticity;O;O
triggered;O;O
by;O;O
METH;B-drug;B-DDI-MedLine.d62.s6.e0
.;O;O
DDI-MedLine.d104.s0;;
The;O;O
effects;O;O
of;O;O
DCG;B-drug_n;B-DDI-MedLine.d104.s0.e0
-;I-drug_n;I-DDI-MedLine.d104.s0.e0
IV;I-drug_n;I-DDI-MedLine.d104.s0.e0
and;O;O
L;O;O
-;O;O
CCG;O;O
-;O;O
1;O;O
upon;O;O
phencyclidine;B-drug_n;B-DDI-MedLine.d104.s0.e2
(;O;O
PCP);B-drug_n;B-DDI-MedLine.d104.s0.e3
-;O;O
induced;O;O
locomotion;O;O
and;O;O
behavioral;O;O
changes;O;O
in;O;O
mice;O;O
.;O;O
DDI-MedLine.d104.s1;;
The;O;O
behavioral;O;O
changes;O;O
of;O;O
mice;O;O
induced;O;O
by;O;O
acute;O;O
and;O;O
repeated;O;O
i.p;O;O
.;O;O
DDI-MedLine.d104.s2;;
injection;O;O
of;O;O
phencyclidine;B-drug_n;B-DDI-MedLine.d104.s2.e0
(;O;O
PCP;B-drug_n;B-DDI-MedLine.d104.s2.e1
);O;O
were;O;O
observed;O;O
by;O;O
measuring;O;O
locomotor;O;O
activity;O;O
and;O;O
stereotyped;O;O
behavior;O;O
.;O;O
DDI-MedLine.d104.s3;;
Then;O;O
,;O;O
the;O;O
effects;O;O
of;O;O
metabotropic;O;O
glutamate;O;O
receptor;O;O
(;O;O
mGluR;O;O
);O;O
agonists;O;O
,;O;O
DCG;B-drug_n;B-DDI-MedLine.d104.s3.e0
-;I-drug_n;I-DDI-MedLine.d104.s3.e0
IV;I-drug_n;I-DDI-MedLine.d104.s3.e0
and;O;O
L;O;O
-;O;O
CCG;O;O
-;O;O
1;O;O
,;O;O
on;O;O
the;O;O
above;O;O
behavioral;O;O
changes;O;O
induced;O;O
by;O;O
PCP;B-drug_n;B-DDI-MedLine.d104.s3.e2
were;O;O
found;O;O
.;O;O
DDI-MedLine.d104.s4;;
The;O;O
effects;O;O
of;O;O
DCG;B-drug_n;B-DDI-MedLine.d104.s4.e0
-;I-drug_n;I-DDI-MedLine.d104.s4.e0
IV;I-drug_n;I-DDI-MedLine.d104.s4.e0
were;O;O
very;O;O
strong;O;O
and;O;O
completely;O;O
depressed;O;O
the;O;O
PCP;B-drug_n;B-DDI-MedLine.d104.s4.e1
-;O;O
induced;O;O
hyperlocomotion;O;O
.;O;O
DDI-MedLine.d104.s5;;
The;O;O
effects;O;O
of;O;O
L;O;O
-;O;O
CCG;O;O
-;O;O
1;O;O
were;O;O
not;O;O
so;O;O
strong;O;O
.;O;O
DDI-MedLine.d104.s6;;
Repeated;O;O
injection;O;O
of;O;O
PCP;B-drug_n;B-DDI-MedLine.d104.s6.e0
for;O;O
20;O;O
days;O;O
into;O;O
mice;O;O
induced;O;O
lower;O;O
locomotor;O;O
activity;O;O
than;O;O
that;O;O
in;O;O
acutely;O;O
injected;O;O
mice;O;O
.;O;O
DDI-MedLine.d104.s7;;
These;O;O
behavioral;O;O
changes;O;O
may;O;O
be;O;O
related;O;O
with;O;O
the;O;O
negative;O;O
symptoms;O;O
of;O;O
schizophrenia;O;O
.;O;O
DDI-MedLine.d104.s8;;
In;O;O
order;O;O
to;O;O
examine;O;O
some;O;O
molecular;O;O
mechanisms;O;O
of;O;O
PCP;B-drug_n;B-DDI-MedLine.d104.s8.e0
-;O;O
induced;O;O
behavioral;O;O
changes;O;O
,;O;O
Northern;O;O
blot;O;O
analysis;O;O
of;O;O
total;O;O
RNA;O;O
from;O;O
prefrontal;O;O
cortical;O;O
tissues;O;O
of;O;O
mice;O;O
treated;O;O
with;O;O
PCP;B-drug_n;B-DDI-MedLine.d104.s8.e1
,;O;O
DCG;B-drug_n;B-DDI-MedLine.d104.s8.e2
-;I-drug_n;I-DDI-MedLine.d104.s8.e2
IV;I-drug_n;I-DDI-MedLine.d104.s8.e2
,;O;O
and;O;O
L;O;O
-;O;O
CCG;O;O
-;O;O
1;O;O
was;O;O
carried;O;O
out;O;O
.;O;O
DDI-MedLine.d98.s0;;
Behavioral;O;O
responses;O;O
to;O;O
repeated;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s0.e0
exposure;O;O
in;O;O
mice;O;O
selectively;O;O
bred;O;O
for;O;O
differential;O;O
sensitivity;O;O
to;O;O
pentobarbital;B-drug;B-DDI-MedLine.d98.s0.e1
.;O;O
DDI-MedLine.d98.s1;;
Mice;O;O
from;O;O
the;O;O
20th;O;O
generation;O;O
of;O;O
three;O;O
lines;O;O
divergently;O;O
selected;O;O
for;O;O
response;O;O
to;O;O
pentobarbital;B-drug;B-DDI-MedLine.d98.s1.e0
-;O;O
induced;O;O
sedation;O;O
times;O;O
[;O;O
long;O;O
-;O;O
sedation;O;O
time;O;O
(;O;O
LST;O;O
);O;O
,;O;O
short;O;O
sedation;O;O
time;O;O
(;O;O
SST;O;O
);O;O
,;O;O
and;O;O
randomly;O;O
bred;O;O
control;O;O
(;O;O
RBC;O;O
);O;O
];O;O
were;O;O
used;O;O
to;O;O
study;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s1.e1
-;O;O
induced;O;O
behavioral;O;O
sensitization;O;O
.;O;O
DDI-MedLine.d98.s2;;
These;O;O
lines;O;O
showed;O;O
variable;O;O
degrees;O;O
of;O;O
locomotor;O;O
activities;O;O
in;O;O
response;O;O
to;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s2.e0
.;O;O
DDI-MedLine.d98.s3;;
At;O;O
a;O;O
low;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s3.e0
dose;O;O
and;O;O
long;O;O
withdrawal;O;O
period;O;O
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
twice;O;O
a;O;O
day;O;O
for;O;O
5;O;O
days;O;O
followed;O;O
by;O;O
a;O;O
14;O;O
-;O;O
day;O;O
withdrawal;O;O
);O;O
,;O;O
the;O;O
LST;O;O
mice;O;O
showed;O;O
tolerance;O;O
development;O;O
.;O;O
DDI-MedLine.d98.s4;;
In;O;O
response;O;O
to;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s4.e0
,;O;O
the;O;O
locomotor;O;O
activities;O;O
of;O;O
the;O;O
SST;O;O
were;O;O
not;O;O
significantly;O;O
different;O;O
from;O;O
the;O;O
RBC;O;O
group;O;O
.;O;O
DDI-MedLine.d98.s5;;
At;O;O
a;O;O
higher;O;O
dose;O;O
and;O;O
a;O;O
shorter;O;O
withdrawal;O;O
period;O;O
(;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
followed;O;O
by;O;O
a;O;O
3;O;O
-;O;O
day;O;O
withdrawal;O;O
);O;O
,;O;O
the;O;O
SST;O;O
mice;O;O
showed;O;O
behavioral;O;O
sensitization;O;O
similar;O;O
to;O;O
the;O;O
RBC;O;O
mice;O;O
,;O;O
but;O;O
the;O;O
LST;O;O
mice;O;O
did;O;O
not;O;O
develop;O;O
sensitization;O;O
.;O;O
DDI-MedLine.d98.s6;;
The;O;O
different;O;O
responses;O;O
in;O;O
locomotor;O;O
activity;O;O
induced;O;O
by;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s6.e0
suggest;O;O
that;O;O
genetic;O;O
factors;O;O
may;O;O
play;O;O
a;O;O
role;O;O
in;O;O
determining;O;O
the;O;O
magnitude;O;O
of;O;O
response;O;O
to;O;O
this;O;O
drug;O;O
.;O;O
DDI-MedLine.d98.s7;;
Dopamine;O;O
(;O;O
DA;O;O
);O;O
levels;O;O
did;O;O
not;O;O
differ;O;O
significantly;O;O
in;O;O
either;O;O
striatum;O;O
(;O;O
STR;O;O
);O;O
or;O;O
nucleus;O;O
accumbens;O;O
(;O;O
NAC;O;O
);O;O
for;O;O
the;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s7.e0
-;O;O
treated;O;O
animals;O;O
to;O;O
their;O;O
corresponding;O;O
saline;O;O
-;O;O
treated;O;O
controls;O;O
.;O;O
DDI-MedLine.d98.s8;;
The;O;O
affinity;O;O
(;O;O
Kd;O;O
);O;O
of;O;O
D2;O;O
in;O;O
the;O;O
NAC;O;O
decreased;O;O
significantly;O;O
,;O;O
without;O;O
changes;O;O
in;O;O
density;O;O
(;O;O
Bmax;O;O
);O;O
,;O;O
in;O;O
the;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s8.e0
-;O;O
treated;O;O
SST;O;O
and;O;O
RBC;O;O
mice;O;O
.;O;O
DDI-MedLine.d98.s9;;
On;O;O
the;O;O
other;O;O
hand;O;O
,;O;O
the;O;O
density;O;O
of;O;O
D2;O;O
binding;O;O
sites;O;O
in;O;O
the;O;O
SST;O;O
and;O;O
the;O;O
RBC;O;O
mice;O;O
in;O;O
the;O;O
STR;O;O
was;O;O
significantly;O;O
increased;O;O
in;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s9.e0
-;O;O
treated;O;O
groups;O;O
without;O;O
change;O;O
in;O;O
Kd;O;O
.;O;O
DDI-MedLine.d98.s10;;
The;O;O
LST;O;O
mice;O;O
did;O;O
not;O;O
show;O;O
any;O;O
changes;O;O
in;O;O
the;O;O
Kd;O;O
and;O;O
Bmax;O;O
in;O;O
either;O;O
the;O;O
STR;O;O
or;O;O
the;O;O
NAC;O;O
.;O;O
DDI-MedLine.d98.s11;;
Taken;O;O
together;O;O
,;O;O
these;O;O
findings;O;O
suggest;O;O
that;O;O
the;O;O
changes;O;O
in;O;O
the;O;O
Kd;O;O
of;O;O
D2;O;O
in;O;O
the;O;O
NAC;O;O
and;O;O
the;O;O
Bmax;O;O
of;O;O
D2;O;O
in;O;O
the;O;O
STR;O;O
may;O;O
contribute;O;O
to;O;O
the;O;O
differences;O;O
in;O;O
locomotor;O;O
responses;O;O
to;O;O
cocaine;B-drug;B-DDI-MedLine.d98.s11.e0
exposure;O;O
in;O;O
these;O;O
mouse;O;O
lines;O;O
.;O;O
DDI-MedLine.d110.s0;;
18;B-drug_n;B-DDI-MedLine.d110.s0.e0
-;I-drug_n;I-DDI-MedLine.d110.s0.e0
Methoxycoronaridine;I-drug_n;I-DDI-MedLine.d110.s0.e0
(;O;O
18;B-drug_n;B-DDI-MedLine.d110.s0.e1
-;I-drug_n;I-DDI-MedLine.d110.s0.e1
MC;I-drug_n;I-DDI-MedLine.d110.s0.e1
);O;O
and;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s0.e2
:;O;O
comparison;O;O
of;O;O
antiaddictive;O;O
efficacy;O;O
,;O;O
toxicity;O;O
,;O;O
and;O;O
mechanisms;O;O
of;O;O
action;O;O
.;O;O
DDI-MedLine.d110.s1;;
18;B-drug_n;B-DDI-MedLine.d110.s1.e0
-;I-drug_n;I-DDI-MedLine.d110.s1.e0
MC;I-drug_n;I-DDI-MedLine.d110.s1.e0
,;O;O
a;O;O
novel;O;O
iboga;O;O
alkaloid;O;O
congener;O;O
,;O;O
is;O;O
being;O;O
developed;O;O
as;O;O
a;O;O
potential;O;O
treatment;O;O
for;O;O
multiple;O;O
forms;O;O
of;O;O
drug;O;O
abuse;O;O
.;O;O
DDI-MedLine.d110.s2;;
Like;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s2.e0
(;O;O
40;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
,;O;O
18;B-drug_n;B-DDI-MedLine.d110.s2.e1
-;I-drug_n;I-DDI-MedLine.d110.s2.e1
MC;I-drug_n;I-DDI-MedLine.d110.s2.e1
(;O;O
40;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
decreases;O;O
the;O;O
intravenous;O;O
self;O;O
-;O;O
administration;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d110.s2.e2
and;O;O
cocaine;B-drug;B-DDI-MedLine.d110.s2.e3
and;O;O
the;O;O
oral;O;O
self;O;O
-;O;O
administration;O;O
of;O;O
ethanol;B-drug;B-DDI-MedLine.d110.s2.e4
and;O;O
nicotine;B-drug;B-DDI-MedLine.d110.s2.e5
in;O;O
rats;O;O
,;O;O
DDI-MedLine.d110.s3;;
unlike;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s3.e0
,;O;O
18;B-drug_n;B-DDI-MedLine.d110.s3.e1
-;I-drug_n;I-DDI-MedLine.d110.s3.e1
MC;I-drug_n;I-DDI-MedLine.d110.s3.e1
does;O;O
not;O;O
affect;O;O
responding;O;O
for;O;O
a;O;O
nondrug;O;O
reinforcer;O;O
(;O;O
water;O;O
);O;O
.;O;O
DDI-MedLine.d110.s4;;
Both;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s4.e0
and;O;O
18;B-drug_n;B-DDI-MedLine.d110.s4.e1
-;I-drug_n;I-DDI-MedLine.d110.s4.e1
MC;I-drug_n;I-DDI-MedLine.d110.s4.e1
ameliorate;O;O
opioid;B-group;B-DDI-MedLine.d110.s4.e2
withdrawal;O;O
signs;O;O
.;O;O
DDI-MedLine.d110.s5;;
Both;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s5.e0
and;O;O
18;B-drug_n;B-DDI-MedLine.d110.s5.e1
-;I-drug_n;I-DDI-MedLine.d110.s5.e1
MC;I-drug_n;I-DDI-MedLine.d110.s5.e1
decrease;O;O
extracellular;O;O
levels;O;O
of;O;O
dopamine;O;O
in;O;O
the;O;O
nucleus;O;O
accumbens;O;O
,;O;O
but;O;O
only;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s5.e2
increases;O;O
extracellular;O;O
levels;O;O
of;O;O
serotonin;O;O
in;O;O
the;O;O
nucleus;O;O
accumbens;O;O
.;O;O
DDI-MedLine.d110.s6;;
Both;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s6.e0
and;O;O
18;B-drug_n;B-DDI-MedLine.d110.s6.e1
-;I-drug_n;I-DDI-MedLine.d110.s6.e1
MC;I-drug_n;I-DDI-MedLine.d110.s6.e1
block;O;O
morphine;B-drug;B-DDI-MedLine.d110.s6.e2
-;O;O
induced;O;O
and;O;O
nicotine;B-drug;B-DDI-MedLine.d110.s6.e3
-;O;O
induced;O;O
dopamine;O;O
release;O;O
in;O;O
the;O;O
nucleus;O;O
accumbens;O;O
,;O;O
DDI-MedLine.d110.s7;;
only;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s7.e0
enhances;O;O
cocaine;B-drug;B-DDI-MedLine.d110.s7.e1
-;O;O
induced;O;O
increases;O;O
in;O;O
accumbal;O;O
dopamine;O;O
.;O;O
DDI-MedLine.d110.s8;;
Both;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s8.e0
and;O;O
18;B-drug_n;B-DDI-MedLine.d110.s8.e1
-;I-drug_n;I-DDI-MedLine.d110.s8.e1
MC;I-drug_n;I-DDI-MedLine.d110.s8.e1
enhance;O;O
the;O;O
locomotor;O;O
and/or;O;O
stereotypic;O;O
effects;O;O
of;O;O
stimulants;O;O
.;O;O
DDI-MedLine.d110.s9;;
Ibogaine;B-drug_n;B-DDI-MedLine.d110.s9.e0
attenuates;O;O
,;O;O
but;O;O
18;B-drug_n;B-DDI-MedLine.d110.s9.e1
-;I-drug_n;I-DDI-MedLine.d110.s9.e1
MC;I-drug_n;I-DDI-MedLine.d110.s9.e1
potentiates;O;O
,;O;O
the;O;O
acute;O;O
locomotor;O;O
effects;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d110.s9.e2
,;O;O
DDI-MedLine.d110.s10;;
both;O;O
compounds;O;O
attenuate;O;O
morphine;B-drug;B-DDI-MedLine.d110.s10.e0
-;O;O
induced;O;O
locomotion;O;O
in;O;O
morphine;B-drug;B-DDI-MedLine.d110.s10.e1
-;O;O
experienced;O;O
rats;O;O
.;O;O
DDI-MedLine.d110.s11;;
Ibogaine;B-drug_n;B-DDI-MedLine.d110.s11.e0
produces;O;O
whole;O;O
body;O;O
tremors;O;O
and;O;O
,;O;O
at;O;O
high;O;O
doses;O;O
(;O;O
>;O;O
or;O;O
=;O;O
100;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
,;O;O
cerebellar;O;O
damage;O;O
,;O;O
DDI-MedLine.d110.s12;;
18;B-drug_n;B-DDI-MedLine.d110.s12.e0
-;I-drug_n;I-DDI-MedLine.d110.s12.e0
MC;I-drug_n;I-DDI-MedLine.d110.s12.e0
does;O;O
not;O;O
produce;O;O
these;O;O
effects;O;O
.;O;O
DDI-MedLine.d110.s13;;
Ibogaine;B-drug_n;B-DDI-MedLine.d110.s13.e0
,;O;O
but;O;O
not;O;O
18;B-drug_n;B-DDI-MedLine.d110.s13.e1
-;I-drug_n;I-DDI-MedLine.d110.s13.e1
MC;I-drug_n;I-DDI-MedLine.d110.s13.e1
,;O;O
decreases;O;O
heart;O;O
rate;O;O
at;O;O
high;O;O
doses;O;O
.;O;O
DDI-MedLine.d110.s14;;
While;O;O
18;B-drug_n;B-DDI-MedLine.d110.s14.e0
-;I-drug_n;I-DDI-MedLine.d110.s14.e0
MC;I-drug_n;I-DDI-MedLine.d110.s14.e0
and;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s14.e1
have;O;O
similar;O;O
affinities;O;O
for;O;O
kappa;O;O
opioid;O;O
and;O;O
possibly;O;O
nicotinic;O;O
receptors;O;O
,;O;O
18;B-drug_n;B-DDI-MedLine.d110.s14.e2
-;I-drug_n;I-DDI-MedLine.d110.s14.e2
MC;I-drug_n;I-DDI-MedLine.d110.s14.e2
has;O;O
much;O;O
lower;O;O
affinities;O;O
than;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s14.e3
for;O;O
NMDA;O;O
and;O;O
sigma;O;O
-;O;O
2;O;O
receptors;O;O
,;O;O
sodium;O;O
channels;O;O
,;O;O
and;O;O
the;O;O
5;O;O
-;O;O
HT;O;O
transporter;O;O
.;O;O
DDI-MedLine.d110.s15;;
Both;O;O
18;B-drug_n;B-DDI-MedLine.d110.s15.e0
-;I-drug_n;I-DDI-MedLine.d110.s15.e0
MC;I-drug_n;I-DDI-MedLine.d110.s15.e0
and;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s15.e1
are;O;O
sequestered;O;O
in;O;O
fat;O;O
and;O;O
,;O;O
like;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s15.e2
,;O;O
18;B-drug_n;B-DDI-MedLine.d110.s15.e3
-;I-drug_n;I-DDI-MedLine.d110.s15.e3
MC;I-drug_n;I-DDI-MedLine.d110.s15.e3
probably;O;O
has;O;O
an;O;O
active;O;O
metabolite;O;O
.;O;O
DDI-MedLine.d110.s16;;
The;O;O
data;O;O
suggest;O;O
that;O;O
18;B-drug_n;B-DDI-MedLine.d110.s16.e0
-;I-drug_n;I-DDI-MedLine.d110.s16.e0
MC;I-drug_n;I-DDI-MedLine.d110.s16.e0
has;O;O
a;O;O
narrower;O;O
spectrum;O;O
of;O;O
actions;O;O
and;O;O
will;O;O
have;O;O
a;O;O
substantially;O;O
greater;O;O
therapeutic;O;O
index;O;O
than;O;O
ibogaine;B-drug_n;B-DDI-MedLine.d110.s16.e1
.;O;O
DDI-MedLine.d106.s0;;
Clinical;O;O
implications;O;O
of;O;O
warfarin;B-drug;B-DDI-MedLine.d106.s0.e0
interactions;O;O
with;O;O
five;O;O
sedatives;B-group;B-DDI-MedLine.d106.s0.e1
.;O;O

;O;O
DDI-MedLine.d106.s1;;
The;O;O
intensity;O;O
,;O;O
uniformity;O;O
and;O;O
time;O;O
course;O;O
of;O;O
anticoagulant;B-group;B-DDI-MedLine.d106.s1.e0
interference;O;O
by;O;O
phenobarbital;B-drug;B-DDI-MedLine.d106.s1.e1
,;O;O
secobarbital;B-drug;B-DDI-MedLine.d106.s1.e2
,;O;O
glutethimide;B-drug;B-DDI-MedLine.d106.s1.e3
,;O;O
chloral;B-drug;B-DDI-MedLine.d106.s1.e4
hydrate;I-drug;I-DDI-MedLine.d106.s1.e4
and;O;O
methaqualone;B-drug;B-DDI-MedLine.d106.s1.e5
were;O;O
systematically;O;O
investigated;O;O
in;O;O
16;O;O
patients;O;O
receiving;O;O
coumarin;B-group;B-DDI-MedLine.d106.s1.e6
therapy;O;O
.;O;O
DDI-MedLine.d106.s2;;
Each;O;O
subject;O;O
received;O;O
an;O;O
individualized;O;O
fixed;O;O
daily;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-MedLine.d106.s2.e0
and;O;O
served;O;O
as;O;O
his;O;O
own;O;O
pre;O;O
-;O;O
and;O;O
postsedative;O;O
treatment;O;O
control;O;O
.;O;O
DDI-MedLine.d106.s3;;
Prothrombin;O;O
times;O;O
were;O;O
measured;O;O
four;O;O
times;O;O
weekly;O;O
during;O;O
five;O;O
long;O;O
-;O;O
term;O;O
experiments;O;O
.;O;O
DDI-MedLine.d106.s4;;
Anticoagulant;O;O
inhibition;O;O
was;O;O
observed;O;O
during;O;O
the;O;O
administration;O;O
of;O;O
phenobarbital;B-drug;B-DDI-MedLine.d106.s4.e0
,;O;O
secobarbital;B-drug;B-DDI-MedLine.d106.s4.e1
and;O;O
glutethimide;B-drug;B-DDI-MedLine.d106.s4.e2
,;O;O
DDI-MedLine.d106.s5;;
there;O;O
was;O;O
no;O;O
significant;O;O
change;O;O
in;O;O
prothrombin;O;O
test;O;O
results;O;O
during;O;O
the;O;O
trials;O;O
of;O;O
chloral;B-drug;B-DDI-MedLine.d106.s5.e0
hydrate;I-drug;I-DDI-MedLine.d106.s5.e0
and;O;O
methaqualone;B-drug;B-DDI-MedLine.d106.s5.e1
.;O;O
DDI-MedLine.d106.s6;;
Barbiturates;B-group;B-DDI-MedLine.d106.s6.e0
and;O;O
glutethimide;B-drug;B-DDI-MedLine.d106.s6.e1
should;O;O
not;O;O
be;O;O
administered;O;O
to;O;O
patients;O;O
receiving;O;O
coumarin;B-group;B-DDI-MedLine.d106.s6.e2
drugs;I-group;I-DDI-MedLine.d106.s6.e2
.;O;O
DDI-MedLine.d106.s7;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
drugs;O;O
from;O;O
these;O;O
groups;O;O
is;O;O
decreasing;O;O
according;O;O
to;O;O
a;O;O
survey;O;O
of;O;O
200;O;O
hospital;O;O
medical;O;O
records;O;O
.;O;O
DDI-MedLine.d106.s8;;
Chloral;B-drug;B-DDI-MedLine.d106.s8.e0
hydrate;I-drug;I-DDI-MedLine.d106.s8.e0
and;O;O
methaqualone;B-drug;B-DDI-MedLine.d106.s8.e1
interact;O;O
pharmacologically;O;O
with;O;O
orally;O;O
administered;O;O
anticoagulant;B-group;B-DDI-MedLine.d106.s8.e2
agents;I-group;I-DDI-MedLine.d106.s8.e2
,;O;O
but;O;O
the;O;O
effect;O;O
is;O;O
not;O;O
clinically;O;O
significant;O;O
.;O;O
DDI-MedLine.d106.s9;;
It;O;O
is;O;O
concluded;O;O
that;O;O
chloral;B-drug;B-DDI-MedLine.d106.s9.e0
hydrate;I-drug;I-DDI-MedLine.d106.s9.e0
and;O;O
methaqualone;B-drug;B-DDI-MedLine.d106.s9.e1
may;O;O
be;O;O
administered;O;O
safely;O;O
without;O;O
additional;O;O
caution;O;O
in;O;O
prothrombin;O;O
test;O;O
monitoring;O;O
during;O;O
oral;O;O
anticoagulant;B-group;B-DDI-MedLine.d106.s9.e2
therapy;O;O
.;O;O
DDI-MedLine.d77.s0;;
Effects;O;O
of;O;O
low;O;O
temperatures;O;O
on;O;O
microtubules;O;O
in;O;O
the;O;O
non;O;O
-;O;O
myelinated;O;O
axons;O;O
of;O;O
post;O;O
-;O;O
ganglionic;O;O
sympathetic;O;O
nerves;O;O
.;O;O
DDI-MedLine.d77.s1;;
The;O;O
effect;O;O
of;O;O
temperature;O;O
changes;O;O
on;O;O
the;O;O
number;O;O
of;O;O
microtubules;O;O
in;O;O
non;O;O
-;O;O
myelinated;O;O
axons;O;O
has;O;O
been;O;O
studied;O;O
in;O;O
cat;O;O
inferior;O;O
mesenteric;O;O
ganglion;O;O
/;O;O
hypogastric;O;O
nerve;O;O
preparations;O;O
incubated;O;O
at;O;O
various;O;O
temperatures;O;O
in;O;O
Eagles;O;O
minimal;O;O
essential;O;O
tissue;O;O
culture;O;O
medium;O;O
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d77.s2;;
At;O;O
37;O;O
degrees;O;O
C;O;O
the;O;O
non;O;O
-;O;O
myelinated;O;O
axons;O;O
contained;O;O
28.4;O;O
plus;O;O
or;O;O
minus;O;O
0.8;O;O
S.E.M.;O;O
DDI-MedLine.d77.s3;;
(;O;O
54;O;O
);O;O
microtubules;O;O
per;O;O
axon;O;O
.;O;O
DDI-MedLine.d77.s4;;
After;O;O
incubation;O;O
at;O;O
0;O;O
degrees;O;O
C;O;O
for;O;O
4;O;O
h;O;O
this;O;O
number;O;O
fell;O;O
to;O;O
2.3;O;O
plus;O;O
or;O;O
minus;O;O
0.1;O;O
S.E.M.;O;O
DDI-MedLine.d77.s5;;
(;O;O
41;O;O
);O;O
but;O;O
returned;O;O
to;O;O
normal;O;O
levels;O;O
when;O;O
the;O;O
nerves;O;O
were;O;O
rewarmed;O;O
.;O;O
DDI-MedLine.d77.s6;;
This;O;O
loss;O;O
of;O;O
microtubules;O;O
on;O;O
cooling;O;O
the;O;O
nerves;O;O
and;O;O
their;O;O
reappearance;O;O
on;O;O
rewarming;O;O
was;O;O
a;O;O
rapid;O;O
process;O;O
,;O;O
DDI-MedLine.d77.s7;;
it;O;O
was;O;O
independent;O;O
of;O;O
the;O;O
influence;O;O
of;O;O
the;O;O
nueronal;O;O
cell;O;O
body;O;O
and;O;O
of;O;O
protein;O;O
synthesis;O;O
within;O;O
the;O;O
axon;O;O
.;O;O
DDI-MedLine.d77.s8;;
The;O;O
preservation;O;O
of;O;O
the;O;O
microtubules;O;O
was;O;O
improved;O;O
when;O;O
D2O;O;O
was;O;O
present;O;O
in;O;O
the;O;O
incubation;O;O
medium;O;O
.;O;O
DDI-MedLine.d77.s9;;
Reformed;O;O
microtubules;O;O
appeared;O;O
to;O;O
function;O;O
normally;O;O
with;O;O
respect;O;O
to;O;O
their;O;O
possible;O;O
role;O;O
in;O;O
the;O;O
transport;O;O
of;O;O
noradrenaline;O;O
storage;O;O
vesicles;O;O
along;O;O
the;O;O
axons;O;O
.;O;O
DDI-MedLine.d127.s0;;
Serum;O;O
digoxin;B-drug;B-DDI-MedLine.d127.s0.e0
levels;O;O
using;O;O
an;O;O
125I;O;O
-;O;O
labelled;O;O
antigen;O;O
:;O;O
Validation;O;O
of;O;O
method;O;O
and;O;O
observations;O;O
on;O;O
cardiac;O;O
patients;O;O
.;O;O

;O;O
DDI-MedLine.d127.s1;;
1;O;O
.;O;O
DDI-MedLine.d127.s2;;
Determinations;O;O
of;O;O
serum;O;O
digoxin;B-drug;B-DDI-MedLine.d127.s2.e0
levels;O;O
utilizing;O;O
commercially;O;O
available;O;O
kits;O;O
with;O;O
an;O;O
125I;O;O
-;O;O
labelled;O;O
antigen;O;O
were;O;O
precise;O;O
and;O;O
not;O;O
materially;O;O
different;O;O
from;O;O
results;O;O
obtained;O;O
with;O;O
a;O;O
3H;O;O
-;O;O
labelled;O;O
antigen;O;O
.;O;O
DDI-MedLine.d127.s3;;
2;O;O
.;O;O
DDI-MedLine.d127.s4;;
In;O;O
order;O;O
to;O;O
approximate;O;O
the;O;O
steady;O;O
state;O;O
level;O;O
,;O;O
serum;O;O
digoxin;B-drug;B-DDI-MedLine.d127.s4.e0
levels;O;O
should;O;O
be;O;O
drawn;O;O
either;O;O
before;O;O
or;O;O
at;O;O
least;O;O
six;O;O
hours;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
an;O;O
oral;O;O
tablet;O;O
.;O;O
DDI-MedLine.d127.s5;;
3;O;O
.;O;O
DDI-MedLine.d127.s6;;
Concomitantly;O;O
given;O;O
thiazide;B-group;B-DDI-MedLine.d127.s6.e0
diuretics;I-group;I-DDI-MedLine.d127.s6.e0
did;O;O
not;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
a;O;O
tablet;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d127.s6.e1
.;O;O
DDI-MedLine.d127.s7;;
4;O;O
.;O;O
DDI-MedLine.d127.s8;;
In;O;O
the;O;O
digitalized;O;O
patient;O;O
,;O;O
slow;O;O
alterations;O;O
in;O;O
serum;O;O
levels;O;O
after;O;O
oral;O;O
administration;O;O
appeared;O;O
well;O;O
correlated;O;O
with;O;O
,;O;O
at;O;O
least;O;O
,;O;O
the;O;O
negative;O;O
chronotropic;O;O
effects;O;O
of;O;O
the;O;O
drug;O;O
.;O;O
DDI-MedLine.d127.s9;;
5;O;O
.;O;O
DDI-MedLine.d127.s10;;
Maximal;O;O
exercise;O;O
testing;O;O
,;O;O
a;O;O
maneuver;O;O
often;O;O
applied;O;O
to;O;O
cardiac;O;O
patients;O;O
,;O;O
does;O;O
not;O;O
significantly;O;O
alter;O;O
the;O;O
serum;O;O
digoxin;B-drug;B-DDI-MedLine.d127.s10.e0
level;O;O
.;O;O
DDI-MedLine.d135.s0;;
Combinations;O;O
of;O;O
clozapine;B-drug;B-DDI-MedLine.d135.s0.e0
and;O;O
phencyclidine;B-drug_n;B-DDI-MedLine.d135.s0.e1
:;O;O
effects;O;O
on;O;O
drug;O;O
discrimination;O;O
and;O;O
behavioral;O;O
inhibition;O;O
in;O;O
rats;O;O
.;O;O
DDI-MedLine.d135.s1;;
Phencyclidine;B-drug_n;B-DDI-MedLine.d135.s1.e0
(;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s1.e1
);O;O
produces;O;O
psychotomimetic;O;O
effects;O;O
in;O;O
humans;O;O
that;O;O
resemble;O;O
schizophrenia;O;O
symptoms;O;O
.;O;O
DDI-MedLine.d135.s2;;
In;O;O
an;O;O
effort;O;O
to;O;O
screen;O;O
compounds;O;O
for;O;O
antipsychotic;O;O
activity;O;O
,;O;O
preclinical;O;O
researchers;O;O
have;O;O
investigated;O;O
whether;O;O
these;O;O
compounds;O;O
block;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s2.e0
-;O;O
induced;O;O
behaviors;O;O
in;O;O
animals;O;O
.;O;O
DDI-MedLine.d135.s3;;
In;O;O
the;O;O
present;O;O
study;O;O
,;O;O
the;O;O
atypical;B-group;B-DDI-MedLine.d135.s3.e0
antipsychotic;I-group;I-DDI-MedLine.d135.s3.e0
clozapine;I-drug;I-DDI-MedLine.d135.s3.e1
was;O;O
tested;O;O
in;O;O
combination;O;O
with;O;O
an;O;O
active;O;O
dose;O;O
of;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s3.e2
in;O;O
two;O;O
-;O;O
lever;O;O
drug;O;O
discrimination;O;O
and;O;O
mixed;O;O
signalled;O;O
-;O;O
unsignalled;O;O
differential;O;O
-;O;O
reinforcement;O;O
-;O;O
of;O;O
-;O;O
low;O;O
-;O;O
rates;O;O
(;O;O
DRL;O;O
);O;O
procedures;O;O
.;O;O
DDI-MedLine.d135.s4;;
PCP;B-drug_n;B-DDI-MedLine.d135.s4.e0
produced;O;O
distinctive;O;O
effects;O;O
in;O;O
each;O;O
task;O;O
:;O;O
it;O;O
substituted;O;O
for;O;O
the;O;O
training;O;O
dose;O;O
in;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s4.e1
discrimination;O;O
and;O;O
it;O;O
increased;O;O
the;O;O
number;O;O
of;O;O
responses;O;O
with;O;O
short;O;O
(;O;O
<3;O;O
s;O;O
);O;O
interresponse;O;O
times;O;O
as;O;O
well;O;O
as;O;O
increasing;O;O
overall;O;O
response;O;O
rates;O;O
in;O;O
the;O;O
DRL;O;O
schedule;O;O
.;O;O
DDI-MedLine.d135.s5;;
Acute;O;O
dosing;O;O
with;O;O
clozapine;B-drug;B-DDI-MedLine.d135.s5.e0
failed;O;O
to;O;O
alter;O;O
the;O;O
behavioral;O;O
effects;O;O
of;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s5.e1
in;O;O
either;O;O
procedure;O;O
even;O;O
when;O;O
tested;O;O
up;O;O
to;O;O
doses;O;O
that;O;O
produced;O;O
pharmacological;O;O
effects;O;O
alone;O;O
.;O;O
DDI-MedLine.d135.s6;;
These;O;O
results;O;O
suggest;O;O
that;O;O
acute;O;O
dosing;O;O
with;O;O
clozapine;B-drug;B-DDI-MedLine.d135.s6.e0
would;O;O
not;O;O
affect;O;O
behaviors;O;O
most;O;O
closely;O;O
associated;O;O
with;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s6.e1
intoxication;O;O
.;O;O
DDI-MedLine.d135.s7;;
Further;O;O
,;O;O
they;O;O
bring;O;O
into;O;O
question;O;O
the;O;O
utility;O;O
of;O;O
using;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s7.e0
combination;O;O
procedures;O;O
in;O;O
animals;O;O
to;O;O
screen;O;O
for;O;O
antipsychotic;O;O
potential;O;O
.;O;O
DDI-MedLine.d135.s8;;
Since;O;O
chronic;O;O
dosing;O;O
is;O;O
required;O;O
for;O;O
therapeutic;O;O
efficacy;O;O
of;O;O
antipsychotics;B-group;B-DDI-MedLine.d135.s8.e0
,;O;O
future;O;O
studies;O;O
should;O;O
focus;O;O
on;O;O
investigation;O;O
of;O;O
chronic;O;O
dosing;O;O
effects;O;O
of;O;O
these;O;O
drugs;O;O
in;O;O
combination;O;O
with;O;O
PCP;B-drug_n;B-DDI-MedLine.d135.s8.e1
.;O;O
DDI-MedLine.d95.s0;;
The;O;O
mechanism;O;O
of;O;O
resveratrol;B-drug_n;B-DDI-MedLine.d95.s0.e0
-;O;O
induced;O;O
vasorelaxation;O;O
differs;O;O
in;O;O
the;O;O
mesenteric;O;O
resistance;O;O
arteries;O;O
of;O;O
lean;O;O
and;O;O
obese;O;O
rats;O;O
.;O;O
DDI-MedLine.d95.s1;;
Resveratrol;B-drug_n;B-DDI-MedLine.d95.s1.e0
has;O;O
been;O;O
shown;O;O
to;O;O
induce;O;O
vasorelaxation;O;O
.;O;O
DDI-MedLine.d95.s2;;
In;O;O
this;O;O
study;O;O
,;O;O
we;O;O
investigated;O;O
the;O;O
mechanism(s;O;O
);O;O
of;O;O
resveratrol;B-drug_n;B-DDI-MedLine.d95.s2.e0
-;O;O
induced;O;O
vasorelaxation;O;O
in;O;O
resistance;O;O
mesenteric;O;O
arteries;O;O
from;O;O
male;O;O
lean;O;O
and;O;O
dietary;O;O
-;O;O
induced;O;O
obese;O;O
rats;O;O
.;O;O
DDI-MedLine.d95.s3;;
Compared;O;O
with;O;O
lean;O;O
rats;O;O
,;O;O
arteries;O;O
from;O;O
dietary;O;O
-;O;O
obese;O;O
rats;O;O
showed;O;O
significant;O;O
(;O;O
P<0.001;O;O
);O;O
endothelial;O;O
dysfunction;O;O
,;O;O
as;O;O
indicated;O;O
by;O;O
a;O;O
decrease;O;O
(;O;O
>;O;O
20;O;O
%;O;O
);O;O
in;O;O
maximal;O;O
acetylcholine;O;O
-;O;O
induced;O;O
vasorelaxation;O;O
.;O;O
DDI-MedLine.d95.s4;;
Resveratrol;B-drug_n;B-DDI-MedLine.d95.s4.e0
(;O;O
5;O;O
-;O;O
35;O;O
micromol;O;O
/;O;O
l;O;O
);O;O
induced;O;O
concentration;O;O
-;O;O
dependent;O;O
relaxation;O;O
of;O;O
mesenteric;O;O
arteries;O;O
preconstricted;O;O
with;O;O
noradrenaline;B-drug;B-DDI-MedLine.d95.s4.e1
(;O;O
8;O;O
micromol;O;O
/;O;O
l;O;O
);O;O
or;O;O
KCl;B-drug;B-DDI-MedLine.d95.s4.e2
(;O;O
125;O;O
mmol;O;O
/;O;O
l;O;O
);O;O
from;O;O
both;O;O
lean;O;O
and;O;O
dietary;O;O
-;O;O
obese;O;O
rats;O;O
.;O;O
DDI-MedLine.d95.s5;;
There;O;O
were;O;O
no;O;O
significant;O;O
differences;O;O
between;O;O
the;O;O
two;O;O
groups;O;O
,;O;O
achieving;O;O
a;O;O
maximum;O;O
relaxation;O;O
of;O;O
>;O;O
95;O;O
%;O;O
at;O;O
a;O;O
concentration;O;O
of;O;O
35;O;O
micromol;O;O
/;O;O
l;O;O
.;O;O
DDI-MedLine.d95.s6;;
However;O;O
,;O;O
L;B-drug_n;B-DDI-MedLine.d95.s6.e0
-;I-drug_n;I-DDI-MedLine.d95.s6.e0
NAME;I-drug_n;I-DDI-MedLine.d95.s6.e0
(;O;O
100;O;O
and;O;O
300;O;O
micromol;O;O
/;O;O
l;O;O
);O;O
did;O;O
not;O;O
alter;O;O
the;O;O
effects;O;O
of;O;O
reseveratrol;B-drug_n;B-DDI-MedLine.d95.s6.e1
on;O;O
arteries;O;O
from;O;O
dietary;O;O
-;O;O
obese;O;O
rats;O;O
,;O;O
giving;O;O
superimposed;O;O
concentration;O;O
-;O;O
responses;O;O
curves;O;O
.;O;O
DDI-MedLine.d95.s7;;
Indomethacin;B-drug;B-DDI-MedLine.d95.s7.e0
was;O;O
also;O;O
ineffective;O;O
in;O;O
altering;O;O
resveratrol;B-drug_n;B-DDI-MedLine.d95.s7.e1
activity;O;O
in;O;O
arteries;O;O
from;O;O
both;O;O
lean;O;O
and;O;O
dietary;O;O
-;O;O
obese;O;O
rats;O;O
.;O;O
DDI-MedLine.d95.s8;;
In;O;O
noradrenaline;B-drug;B-DDI-MedLine.d95.s8.e0
-;O;O
precontracted;O;O
arteries;O;O
from;O;O
dietary;O;O
-;O;O
obese;O;O
rats;O;O
,;O;O
responses;O;O
to;O;O
resveratrol;B-drug_n;B-DDI-MedLine.d95.s8.e1
were;O;O
not;O;O
attenuated;O;O
by;O;O
endothelial;O;O
denudation;O;O
,;O;O
indicating;O;O
an;O;O
action;O;O
independent;O;O
of;O;O
the;O;O
endothelium;O;O
.;O;O
DDI-MedLine.d95.s9;;
This;O;O
study;O;O
indicates;O;O
that;O;O
:;O;O
(;O;O
a;O;O
);O;O
the;O;O
maximal;O;O
effects;O;O
of;O;O
resveratrol;B-drug_n;B-DDI-MedLine.d95.s9.e0
on;O;O
resistance;O;O
arteries;O;O
from;O;O
lean;O;O
and;O;O
dietary;O;O
-;O;O
obese;O;O
rats;O;O
are;O;O
not;O;O
effected;O;O
by;O;O
endothelial;O;O
dysfunction;O;O
,;O;O
and;O;O
(;O;O
b;O;O
);O;O
the;O;O
effects;O;O
of;O;O
resveratrol;B-drug_n;B-DDI-MedLine.d95.s9.e1
in;O;O
lean;O;O
animals;O;O
(;O;O
where;O;O
endothelial;O;O
function;O;O
is;O;O
not;O;O
impaired;O;O
);O;O
,;O;O
but;O;O
not;O;O
in;O;O
dietary;O;O
-;O;O
obese;O;O
rats;O;O
,;O;O
are;O;O
mediated;O;O
via;O;O
NO;O;O
.;O;O
DDI-MedLine.d79.s0;;
If;O;O
taken;O;O
1;O;O
hour;O;O
before;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s0.e0
(;O;O
IDV;B-drug;B-DDI-MedLine.d79.s0.e1
);O;O
,;O;O
didanosine;B-drug;B-DDI-MedLine.d79.s0.e2
does;O;O
not;O;O
affect;O;O
IDV;B-drug;B-DDI-MedLine.d79.s0.e3
exposure;O;O
,;O;O
despite;O;O
persistent;O;O
buffering;O;O
effects;O;O
.;O;O
DDI-MedLine.d79.s1;;
Concurrent;O;O
administration;O;O
of;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s1.e0
and;O;O
didanosine;B-drug;B-DDI-MedLine.d79.s1.e1
significantly;O;O
reduces;O;O
the;O;O
level;O;O
of;O;O
exposure;O;O
to;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s1.e2
,;O;O
but;O;O
it;O;O
is;O;O
unclear;O;O
how;O;O
soon;O;O
after;O;O
didanosine;B-drug;B-DDI-MedLine.d79.s1.e3
administration;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s1.e4
may;O;O
be;O;O
given;O;O
safely;O;O
.;O;O
DDI-MedLine.d79.s2;;
We;O;O
compared;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s2.e0
pharmacokinetics;O;O
and;O;O
gastric;O;O
pH;O;O
in;O;O
12;O;O
human;O;O
immunodeficiency;O;O
virus;O;O
-;O;O
positive;O;O
patients;O;O
by;O;O
use;O;O
of;O;O
800;O;O
mg;O;O
of;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s2.e1
alone;O;O
versus;O;O
800;O;O
mg;O;O
of;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s2.e2
administered;O;O
1;O;O
h;O;O
after;O;O
didanosine;B-drug;B-DDI-MedLine.d79.s2.e3
administration;O;O
.;O;O
DDI-MedLine.d79.s3;;
Median;O;O
gastric;O;O
pH;O;O
was;O;O
significantly;O;O
higher;O;O
when;O;O
indinavir;B-drug;B-DDI-MedLine.d79.s3.e0
was;O;O
taken;O;O
after;O;O
didanosine;B-drug;B-DDI-MedLine.d79.s3.e1
administration;O;O
,;O;O
DDI-MedLine.d79.s4;;
however;O;O
,;O;O
no;O;O
significant;O;O
difference;O;O
in;O;O
the;O;O
maximum;O;O
concentration;O;O
in;O;O
plasma;O;O
or;O;O
the;O;O
area;O;O
under;O;O
the;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
from;O;O
time;O;O
zero;O;O
to;O;O
8;O;O
h;O;O
was;O;O
observed;O;O
.;O;O
DDI-MedLine.d79.s5;;
Indinavir;B-drug;B-DDI-MedLine.d79.s5.e0
may;O;O
be;O;O
taken;O;O
with;O;O
a;O;O
light;O;O
meal;O;O
1;O;O
h;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
400;O;O
mg;O;O
of;O;O
didanosine;B-drug;B-DDI-MedLine.d79.s5.e1
.;O;O
DDI-MedLine.d59.s0;;
A;O;O
proposed;O;O
mechanism;O;O
for;O;O
the;O;O
potentiation;O;O
of;O;O
cAMP;O;O
-;O;O
mediated;O;O
acid;O;O
secretion;O;O
by;O;O
carbachol;B-drug;B-DDI-MedLine.d59.s0.e0
.;O;O
DDI-MedLine.d59.s1;;
Acid;O;O
secretion;O;O
in;O;O
isolated;O;O
rabbit;O;O
gastric;O;O
glands;O;O
was;O;O
monitored;O;O
by;O;O
the;O;O
accumulation;O;O
of;O;O
[;O;O
(;O;O
14)C]aminopyrine;O;O
.;O;O
DDI-MedLine.d59.s2;;
Stimulation;O;O
of;O;O
the;O;O
glands;O;O
with;O;O
carbachol;B-drug;B-DDI-MedLine.d59.s2.e0
synergistically;O;O
augmented;O;O
the;O;O
response;O;O
to;O;O
dibutyryl;O;O
cAMP;O;O
.;O;O
DDI-MedLine.d59.s3;;
The;O;O
augmentation;O;O
persisted;O;O
even;O;O
after;O;O
carbachol;B-drug;B-DDI-MedLine.d59.s3.e0
was;O;O
washed;O;O
out;O;O
and;O;O
was;O;O
resistant;O;O
to;O;O
chelated;O;O
extracellular;O;O
Ca(2;O;O
+;O;O
);O;O
and;O;O
to;O;O
inhibitors;O;O
of;O;O
either;O;O
protein;O;O
kinase;O;O
C;O;O
or;O;O
calmodulin;O;O
kinase;O;O
II;O;O
.;O;O
DDI-MedLine.d59.s4;;
Cytochalasin;B-drug_n;B-DDI-MedLine.d59.s4.e0
D;I-drug_n;I-DDI-MedLine.d59.s4.e0
at;O;O
10;O;O
microM;O;O
preferentially;O;O
blocked;O;O
the;O;O
secretory;O;O
effect;O;O
of;O;O
carbachol;B-drug;B-DDI-MedLine.d59.s4.e1
and;O;O
its;O;O
synergism;O;O
with;O;O
cAMP;O;O
,;O;O
whereas;O;O
it;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
histamine;O;O
-;O;O
or;O;O
cAMP;O;O
-;O;O
stimulated;O;O
acid;O;O
secretion;O;O
within;O;O
15;O;O
min;O;O
.;O;O
DDI-MedLine.d59.s5;;
Cytochalasin;B-drug_n;B-DDI-MedLine.d59.s5.e0
D;I-drug_n;I-DDI-MedLine.d59.s5.e0
inhibited;O;O
the;O;O
carbachol;B-drug;B-DDI-MedLine.d59.s5.e1
-;O;O
stimulated;O;O
intracellular;O;O
Ca(2;O;O
+;O;O
);O;O
concentration;O;O
(;O;O
[;O;O
Ca(2+)](i;O;O
);O;O
);O;O
increase;O;O
due;O;O
to;O;O
release;O;O
from;O;O
the;O;O
Ca(2;O;O
+;O;O
);O;O
store;O;O
.;O;O
DDI-MedLine.d59.s6;;
Treatment;O;O
of;O;O
the;O;O
glands;O;O
with;O;O
cytochalasin;B-drug_n;B-DDI-MedLine.d59.s6.e0
D;I-drug_n;I-DDI-MedLine.d59.s6.e0
redistributed;O;O
type;O;O
3;O;O
inositol;O;O
1,4,5;O;O
-;O;O
trisphosphate;O;O
receptor;O;O
(;O;O
the;O;O
major;O;O
subtype;O;O
in;O;O
the;O;O
parietal;O;O
cell;O;O
);O;O
from;O;O
the;O;O
fraction;O;O
containing;O;O
membranes;O;O
of;O;O
large;O;O
size;O;O
to;O;O
the;O;O
microsomal;O;O
fraction;O;O
,;O;O
suggesting;O;O
a;O;O
dissociation;O;O
of;O;O
the;O;O
store;O;O
from;O;O
the;O;O
plasma;O;O
membrane;O;O
.;O;O
DDI-MedLine.d59.s7;;
These;O;O
findings;O;O
suggest;O;O
that;O;O
intracellular;O;O
Ca(2;O;O
+;O;O
);O;O
release;O;O
by;O;O
cholinergic;O;O
stimulation;O;O
is;O;O
critical;O;O
for;O;O
determining;O;O
synergism;O;O
with;O;O
cAMP;O;O
in;O;O
parietal;O;O
cell;O;O
activation;O;O
and;O;O
that;O;O
functional;O;O
coupling;O;O
between;O;O
the;O;O
Ca(2;O;O
+;O;O
);O;O
store;O;O
and;O;O
the;O;O
receptor;O;O
is;O;O
maintained;O;O
by;O;O
actin;O;O
microfilaments;O;O
.;O;O
DDI-MedLine.d75.s0;;
Interference;O;O
of;O;O
biocytin;O;O
with;O;O
opioid;B-group;B-DDI-MedLine.d75.s0.e0
-;O;O
evoked;O;O
hyperpolarization;O;O
and;O;O
membrane;O;O
properties;O;O
of;O;O
rat;O;O
spinal;O;O
substantia;O;O
gelatinosa;O;O
neurons;O;O
.;O;O
DDI-MedLine.d75.s1;;
In;O;O
our;O;O
laboratory;O;O
,;O;O
preliminary;O;O
whole;O;O
-;O;O
cell;O;O
,;O;O
tight;O;O
seal;O;O
recordings;O;O
of;O;O
rat;O;O
spinal;O;O
substantia;O;O
gelatinosa;O;O
neurons;O;O
including;O;O
biocytin;O;O
in;O;O
the;O;O
patch;O;O
pipette;O;O
yielded;O;O
a;O;O
significantly;O;O
smaller;O;O
proportion;O;O
of;O;O
neurons;O;O
hyperpolarized;O;O
by;O;O
selective;B-group;B-DDI-MedLine.d75.s1.e0
opioid;I-group;I-DDI-MedLine.d75.s1.e0
agonists;I-group;I-DDI-MedLine.d75.s1.e0
compared;O;O
with;O;O
recordings;O;O
without;O;O
biocytin;O;O
.;O;O
DDI-MedLine.d75.s2;;
Therefore;O;O
,;O;O
we;O;O
investigated;O;O
the;O;O
effects;O;O
of;O;O
biocytin;O;O
inclusion;O;O
on;O;O
opioid;B-group;B-DDI-MedLine.d75.s2.e0
responses;O;O
and;O;O
other;O;O
membrane;O;O
properties;O;O
during;O;O
whole;O;O
-;O;O
cell;O;O
,;O;O
tight;O;O
seal;O;O
recordings;O;O
of;O;O
these;O;O
neurons;O;O
.;O;O
DDI-MedLine.d75.s3;;
The;O;O
percentage;O;O
of;O;O
neurons;O;O
hyperpolarized;O;O
by;O;O
mu;B-group;B-DDI-MedLine.d75.s3.e0
-;I-group;I-DDI-MedLine.d75.s3.e0
,;I-group;I-DDI-MedLine.d75.s3.e0
delta(1);I-group;I-DDI-MedLine.d75.s3.e1
-;I-group;I-DDI-MedLine.d75.s3.e1
,;I-group;I-DDI-MedLine.d75.s3.e1
and;I-group;I-DDI-MedLine.d75.s3.e1
kappa;I-group;I-DDI-MedLine.d75.s3.e2
-;I-group;I-DDI-MedLine.d75.s3.e2
selective;I-group;I-DDI-MedLine.d75.s3.e2
opioids;I-group;I-DDI-MedLine.d75.s3.e2
was;O;O
significantly;O;O
reduced;O;O
when;O;O
1;O;O
%;O;O
but;O;O
not;O;O
<;O;O
DDI-MedLine.d75.s4;;
or;O;O
=;O;O
0.2;O;O
%;O;O
biocytin;O;O
was;O;O
included;O;O
in;O;O
the;O;O
recording;O;O
pipette;O;O
,;O;O
compared;O;O
with;O;O
neurons;O;O
recorded;O;O
without;O;O
biocytin;O;O
.;O;O
DDI-MedLine.d75.s5;;
However;O;O
,;O;O
a;O;O
significantly;O;O
higher;O;O
proportion;O;O
of;O;O
neurons;O;O
fired;O;O
spontaneous;O;O
action;O;O
potentials;O;O
with;O;O
either;O;O
0.05;O;O
-;O;O
0.2;O;O
or;O;O
1;O;O
%;O;O
biocytin;O;O
compared;O;O
to;O;O
no;O;O
biocytin;O;O
.;O;O
DDI-MedLine.d75.s6;;
Resting;O;O
membrane;O;O
potential;O;O
,;O;O
input;O;O
impedance;O;O
and;O;O
the;O;O
proportion;O;O
of;O;O
neurons;O;O
displaying;O;O
transient;O;O
outward;O;O
rectification;O;O
were;O;O
each;O;O
significantly;O;O
altered;O;O
for;O;O
neurons;O;O
recorded;O;O
with;O;O
1;O;O
%;O;O
but;O;O
not;O;O
0.05;O;O
-;O;O
0.2;O;O
%;O;O
biocytin;O;O
.;O;O
DDI-MedLine.d75.s7;;
These;O;O
effects;O;O
may;O;O
be;O;O
due;O;O
to;O;O
a;O;O
relatively;O;O
specific;O;O
blockade;O;O
of;O;O
diverse;O;O
potassium;O;O
channel;O;O
types;O;O
.;O;O
DDI-MedLine.d75.s8;;
Because;O;O
efficient;O;O
labeling;O;O
can;O;O
be;O;O
achieved;O;O
with;O;O
0.1;O;O
%;O;O
biocytin;O;O
with;O;O
whole;O;O
-;O;O
cell;O;O
recording;O;O
,;O;O
higher;O;O
concentrations;O;O
are;O;O
contraindicated;O;O
.;O;O
DDI-MedLine.d117.s0;;
Increased;O;O
stability;O;O
of;O;O
nucleophosmin;O;O
/;O;O
B23;O;O
in;O;O
anti;O;O
-;O;O
apoptotic;O;O
effect;O;O
of;O;O
ras;O;O
during;O;O
serum;O;O
deprivation;O;O
.;O;O
DDI-MedLine.d117.s1;;
We;O;O
obtained;O;O
evidence;O;O
that;O;O
increased;O;O
stability;O;O
of;O;O
nucleophosmin;O;O
/;O;O
B23;O;O
is;O;O
involved;O;O
in;O;O
antiapoptotic;O;O
effect;O;O
of;O;O
ras;O;O
during;O;O
serum;O;O
deprivation;O;O
.;O;O
DDI-MedLine.d117.s2;;
Nucleophosmin;O;O
/;O;O
B23;O;O
in;O;O
serum;O;O
-;O;O
deprived;O;O
(;O;O
0;O;O
%;O;O
serum;O;O
);O;O
NIH;O;O
-;O;O
3T3;O;O
cells;O;O
was;O;O
found;O;O
to;O;O
be;O;O
highly;O;O
unstable;O;O
with;O;O
a;O;O
half;O;O
-;O;O
life;O;O
less;O;O
than;O;O
4;O;O
h.;O;O
DDI-MedLine.d117.s3;;
In;O;O
contrast;O;O
,;O;O
nucleophosmin;O;O
/;O;O
B23;O;O
in;O;O
serum;O;O
-;O;O
deprived;O;O
ras;O;O
-;O;O
transformed;O;O
(;O;O
RAS;O;O
-;O;O
3T3;O;O
);O;O
cells;O;O
was;O;O
as;O;O
stable;O;O
as;O;O
that;O;O
in;O;O
serum;O;O
-;O;O
supplemented;O;O
NIH;O;O
-;O;O
3T3;O;O
or;O;O
RAS;O;O
-;O;O
3T3;O;O
cells;O;O
.;O;O
DDI-MedLine.d117.s4;;
Treatment;O;O
of;O;O
RAS;O;O
-;O;O
3T3;O;O
cells;O;O
with;O;O
nucleophosmin;O;O
/;O;O
B23;O;O
antisense;O;O
oligomer;O;O
significantly;O;O
potentiated;O;O
the;O;O
apoptosis;O;O
induced;O;O
by;O;O
serum;O;O
deprivation;O;O
.;O;O
DDI-MedLine.d117.s5;;
Much;O;O
less;O;O
caspase;O;O
-;O;O
3;O;O
activity;O;O
was;O;O
noted;O;O
in;O;O
the;O;O
lysate;O;O
derived;O;O
from;O;O
serum;O;O
-;O;O
deprived;O;O
RAS;O;O
-;O;O
3T3;O;O
cells;O;O
compared;O;O
with;O;O
that;O;O
in;O;O
the;O;O
lysate;O;O
of;O;O
serum;O;O
-;O;O
deprived;O;O
NIH;O;O
-;O;O
3T3;O;O
cells;O;O
.;O;O
DDI-MedLine.d117.s6;;
Cell;O;O
permeable;O;O
caspase;O;O
-;O;O
3;O;O
inhibitor;O;O
added;O;O
in;O;O
the;O;O
medium;O;O
blocked;O;O
the;O;O
decrease;O;O
of;O;O
nucleophosmin;O;O
/;O;O
B23;O;O
and;O;O
apoptosis;O;O
induced;O;O
by;O;O
serum;O;O
deprivation;O;O
in;O;O
NIH;O;O
-;O;O
3T3;O;O
cells;O;O
.;O;O
DDI-MedLine.d117.s7;;
The;O;O
inhibitor;O;O
,;O;O
on;O;O
the;O;O
other;O;O
hand;O;O
,;O;O
promoted;O;O
significant;O;O
decrease;O;O
of;O;O
nucleolin;O;O
/;O;O
C23;O;O
in;O;O
NIH;O;O
-;O;O
3T3;O;O
cells;O;O
during;O;O
serum;O;O
deprivation;O;O
.;O;O
DDI-MedLine.d117.s8;;
Unlike;O;O
nucleolin;O;O
/;O;O
C23;O;O
,;O;O
down;O;O
-;O;O
regulation;O;O
of;O;O
nucleophosmin;O;O
/;O;O
B23;O;O
was;O;O
thus;O;O
not;O;O
proliferation;O;O
-;O;O
dependent;O;O
but;O;O
caspase;O;O
-;O;O
3;O;O
-;O;O
and;O;O
apoptosis;O;O
-;O;O
dependent;O;O
.;O;O
DDI-MedLine.d117.s9;;
Our;O;O
results;O;O
indicate;O;O
important;O;O
relationships;O;O
among;O;O
ras;O;O
,;O;O
nucleophosmin;O;O
/;O;O
B23;O;O
,;O;O
activation;O;O
of;O;O
caspase;O;O
-;O;O
3;O;O
,;O;O
and;O;O
induction;O;O
of;O;O
apoptosis;O;O
.;O;O
DDI-MedLine.d133.s0;;
Suppression;O;O
by;O;O
verapamil;B-drug;B-DDI-MedLine.d133.s0.e0
of;O;O
bombesin;B-drug_n;B-DDI-MedLine.d133.s0.e1
-;O;O
enhanced;O;O
peritoneal;O;O
metastasis;O;O
of;O;O
intestinal;O;O
adenocarcinomas;O;O
induced;O;O
by;O;O
azoxymethane;B-drug_n;B-DDI-MedLine.d133.s0.e2
in;O;O
wistar;O;O
rats;O;O
.;O;O
DDI-MedLine.d133.s1;;
BACKGROUND;O;O
:;O;O
The;O;O
effects;O;O
of;O;O
combined;O;O
administration;O;O
of;O;O
bombesin;B-drug_n;B-DDI-MedLine.d133.s1.e0
and;O;O
verapamil;B-drug;B-DDI-MedLine.d133.s1.e1
hydrochloride;I-drug;I-DDI-MedLine.d133.s1.e1
(;O;O
verapamil;B-drug;B-DDI-MedLine.d133.s1.e2
);O;O
,;O;O
a;O;O
calcium;B-group;B-DDI-MedLine.d133.s1.e3
channel;I-group;I-DDI-MedLine.d133.s1.e3
blocker;I-group;I-DDI-MedLine.d133.s1.e3
,;O;O
on;O;O
the;O;O
incidence;O;O
of;O;O
peritoneal;O;O
metastasis;O;O
of;O;O
intestinal;O;O
adenocarcinomas;O;O
induced;O;O
by;O;O
azoxymethane;B-drug_n;B-DDI-MedLine.d133.s1.e4
(;O;O
AOM;B-drug_n;B-DDI-MedLine.d133.s1.e5
);O;O
and;O;O
the;O;O
labeling;O;O
index;O;O
of;O;O
intestinal;O;O
cancers;O;O
were;O;O
investigated;O;O
in;O;O
male;O;O
Wistar;O;O
rats;O;O
.;O;O
DDI-MedLine.d133.s2;;
METHODS;O;O
:;O;O
From;O;O
the;O;O
beginning;O;O
of;O;O
the;O;O
experiment;O;O
,;O;O
rats;O;O
were;O;O
given;O;O
10;O;O
weekly;O;O
subcutaneous;O;O
injections;O;O
of;O;O
AOM;B-drug_n;B-DDI-MedLine.d133.s2.e0
(;O;O
7.4;O;O
mg;O;O
/;O;O
kg;O;O
body;O;O
weight;O;O
);O;O
and;O;O
subcutaneous;O;O
injections;O;O
of;O;O
bombesin;B-drug_n;B-DDI-MedLine.d133.s2.e1
(;O;O
40;O;O
microg;O;O
/;O;O
kg;O;O
body;O;O
weight;O;O
);O;O
every;O;O
other;O;O
day;O;O
,;O;O
and;O;O
from;O;O
week;O;O
16;O;O
,;O;O
intraperitoneal;O;O
injections;O;O
of;O;O
verapamil;B-drug;B-DDI-MedLine.d133.s2.e2
(;O;O
10;O;O
or;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
body;O;O
weight;O;O
);O;O
every;O;O
other;O;O
day;O;O
until;O;O
the;O;O
end;O;O
fo;O;O
the;O;O
experiment;O;O
in;O;O
week;O;O
45;O;O
.;O;O
DDI-MedLine.d133.s3;;
RESULTS;O;O
:;O;O
Bombesin;B-drug_n;B-DDI-MedLine.d133.s3.e0
significantly;O;O
increased;O;O
the;O;O
incidence;O;O
of;O;O
intestinal;O;O
tumors;O;O
and;O;O
cancer;O;O
metastasis;O;O
to;O;O
the;O;O
peritoneum;O;O
.;O;O
DDI-MedLine.d133.s4;;
Although;O;O
verapamil;B-drug;B-DDI-MedLine.d133.s4.e0
administered;O;O
at;O;O
either;O;O
dose;O;O
had;O;O
little;O;O
or;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
enhancement;O;O
of;O;O
intestinal;O;O
carcinogenesis;O;O
by;O;O
bombesin;B-drug_n;B-DDI-MedLine.d133.s4.e1
or;O;O
on;O;O
the;O;O
location;O;O
,;O;O
histologic;O;O
type;O;O
,;O;O
depth;O;O
of;O;O
involvement;O;O
,;O;O
labeling;O;O
index;O;O
,;O;O
apoptotic;O;O
index;O;O
or;O;O
tumor;O;O
vascularity;O;O
of;O;O
intestinal;O;O
cancers;O;O
,;O;O
it;O;O
significantly;O;O
decreased;O;O
the;O;O
incidence;O;O
of;O;O
cancer;O;O
metastasis;O;O
.;O;O
DDI-MedLine.d133.s5;;
Verapamil;B-drug;B-DDI-MedLine.d133.s5.e0
also;O;O
significantly;O;O
decreased;O;O
the;O;O
incidence;O;O
of;O;O
lymphatic;O;O
invasion;O;O
of;O;O
adenocarcinomas;O;O
,;O;O
which;O;O
was;O;O
enhanced;O;O
by;O;O
bombesin;B-drug_n;B-DDI-MedLine.d133.s5.e1
.;O;O
DDI-MedLine.d133.s6;;
CONCLUSION;O;O
:;O;O
These;O;O
findings;O;O
indicate;O;O
that;O;O
verapamil;B-drug;B-DDI-MedLine.d133.s6.e0
inhibits;O;O
cancer;O;O
metastasis;O;O
through;O;O
actions;O;O
that;O;O
do;O;O
not;O;O
affect;O;O
the;O;O
growth;O;O
of;O;O
intestinal;O;O
cancers;O;O
.;O;O
DDI-MedLine.d17.s0;;
In;O;O
vitro;O;O
interaction;O;O
of;O;O
prostaglandin;B-drug;B-DDI-MedLine.d17.s0.e0
F2alpha;I-drug;I-DDI-MedLine.d17.s0.e0
and;O;O
oxytocin;B-drug;B-DDI-MedLine.d17.s0.e1
in;O;O
placental;O;O
vessels;O;O
.;O;O

;O;O
DDI-MedLine.d17.s1;;
The;O;O
interaction;O;O
of;O;O
prostaglandin;B-drug;B-DDI-MedLine.d17.s1.e0
F2alpha;I-drug;I-DDI-MedLine.d17.s1.e0
and;O;O
synthetic;O;O
oxytocin;B-drug;B-DDI-MedLine.d17.s1.e1
on;O;O
placental;O;O
vessels;O;O
was;O;O
studied;O;O
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d17.s2;;
Resistance;O;O
was;O;O
measured;O;O
near;O;O
the;O;O
placental;O;O
margin;O;O
after;O;O
spontaneous;O;O
term;O;O
delivery;O;O
.;O;O
DDI-MedLine.d17.s3;;
In;O;O
seven;O;O
experiments;O;O
reactions;O;O
to;O;O
norepinephrine;B-drug;B-DDI-MedLine.d17.s3.e0
and;O;O
oxytocin;B-drug;B-DDI-MedLine.d17.s3.e1
were;O;O
PGF2alpha;B-drug;B-DDI-MedLine.d17.s3.e2
.;O;O
DDI-MedLine.d17.s4;;
PGF2alpha;B-drug;B-DDI-MedLine.d17.s4.e0
produced;O;O
significantly;O;O
increased;O;O
vasoconstriction;O;O
after;O;O
a;O;O
single;O;O
administration;O;O
of;O;O
oxytocin;B-drug;B-DDI-MedLine.d17.s4.e1
.;O;O
DDI-MedLine.d17.s5;;
In;O;O
eight;O;O
experiments;O;O
the;O;O
perfusion;O;O
medium;O;O
contained;O;O
oxytocin;B-drug;B-DDI-MedLine.d17.s5.e0
.;O;O
DDI-MedLine.d17.s6;;
There;O;O
was;O;O
no;O;O
change;O;O
after;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
PGF2alpha;B-drug;B-DDI-MedLine.d17.s6.e0
.;O;O
DDI-MedLine.d17.s7;;
The;O;O
reaction;O;O
after;O;O
norepinephrine;B-drug;B-DDI-MedLine.d17.s7.e0
remained;O;O
the;O;O
same;O;O
in;O;O
both;O;O
groups;O;O
of;O;O
experiments;O;O
.;O;O
DDI-MedLine.d17.s8;;
There;O;O
is;O;O
thus;O;O
an;O;O
enhancement;O;O
effect;O;O
DDI-MedLine.d17.s9;;
There;O;O
is;O;O
thus;O;O
an;O;O
enhancement;O;O
effect;O;O
of;O;O
PGF2alpha;B-drug;B-DDI-MedLine.d17.s9.e0
upon;O;O
the;O;O
reaction;O;O
of;O;O
placental;O;O
vessels;O;O
to;O;O
oxytocin;B-drug;B-DDI-MedLine.d17.s9.e1
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d36.s0;;
Carbamazepine;B-drug;B-DDI-MedLine.d36.s0.e0
overdose;O;O
recognized;O;O
by;O;O
a;O;O
tricyclic;B-group;B-DDI-MedLine.d36.s0.e1
antidepressant;I-group;I-DDI-MedLine.d36.s0.e1
assay;O;O
.;O;O
DDI-MedLine.d36.s1;;
Altered;O;O
mental;O;O
status;O;O
in;O;O
an;O;O
adolescent;O;O
presents;O;O
a;O;O
diagnostic;O;O
challenge;O;O
,;O;O
and;O;O
the;O;O
clinician;O;O
depends;O;O
on;O;O
clinical;O;O
evaluation;O;O
and;O;O
laboratory;O;O
studies;O;O
to;O;O
determine;O;O
therapy;O;O
and;O;O
prognosis;O;O
.;O;O
DDI-MedLine.d36.s2;;
We;O;O
report;O;O
the;O;O
case;O;O
of;O;O
an;O;O
adolescent;O;O
with;O;O
altered;O;O
consciousness;O;O
caused;O;O
by;O;O
carbamazepine;B-drug;B-DDI-MedLine.d36.s2.e0
overdose;O;O
with;O;O
a;O;O
positive;O;O
tricyclic;B-group;B-DDI-MedLine.d36.s2.e1
antidepressant;I-group;I-DDI-MedLine.d36.s2.e1
level;O;O
to;O;O
alert;O;O
clinicians;O;O
to;O;O
the;O;O
cross;O;O
-;O;O
reactivity;O;O
of;O;O
carbamazepine;B-drug;B-DDI-MedLine.d36.s2.e2
with;O;O
a;O;O
toxicology;O;O
screen;O;O
for;O;O
tricyclic;B-group;B-DDI-MedLine.d36.s2.e3
antidepressants;I-group;I-DDI-MedLine.d36.s2.e3
.;O;O
DDI-MedLine.d126.s0;;
Cypermethrin;B-drug;B-DDI-MedLine.d126.s0.e0
-;O;O
induced;O;O
oxidative;O;O
stress;O;O
in;O;O
rat;O;O
brain;O;O
and;O;O
liver;O;O
is;O;O
prevented;O;O
by;O;O
vitamin;B-drug;B-DDI-MedLine.d126.s0.e1
E;I-drug;I-DDI-MedLine.d126.s0.e1
or;O;O
allopurinol;B-drug;B-DDI-MedLine.d126.s0.e2
.;O;O
DDI-MedLine.d126.s1;;
Considering;O;O
that;O;O
the;O;O
involvement;O;O
of;O;O
reactive;O;O
oxygen;O;O
species;O;O
(;O;O
ROS;O;O
);O;O
has;O;O
been;O;O
implicated;O;O
in;O;O
the;O;O
toxicity;O;O
of;O;O
various;O;O
pesticides;O;O
,;O;O
this;O;O
study;O;O
was;O;O
designed;O;O
to;O;O
investigate;O;O
the;O;O
possibility;O;O
of;O;O
oxidative;O;O
stress;O;O
induction;O;O
by;O;O
cypermethrin;B-drug;B-DDI-MedLine.d126.s1.e0
,;O;O
a;O;O
Type;B-drug_n;B-DDI-MedLine.d126.s1.e1
II;I-drug_n;I-DDI-MedLine.d126.s1.e1
pyrethroid;I-drug_n;I-DDI-MedLine.d126.s1.e1
.;O;O
DDI-MedLine.d126.s2;;
Either;O;O
single;O;O
(;O;O
170;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
or;O;O
repeated;O;O
(;O;O
75;O;O
mg;O;O
/;O;O
kg;O;O
per;O;O
day;O;O
for;O;O
5;O;O
days;O;O
);O;O
oral;O;O
administration;O;O
of;O;O
cypermethrin;B-drug;B-DDI-MedLine.d126.s2.e0
was;O;O
found;O;O
to;O;O
produce;O;O
significant;O;O
oxidative;O;O
stress;O;O
in;O;O
cerebral;O;O
and;O;O
hepatic;O;O
tissues;O;O
of;O;O
rats;O;O
,;O;O
as;O;O
was;O;O
evident;O;O
by;O;O
the;O;O
elevation;O;O
of;O;O
the;O;O
level;O;O
of;O;O
thiobarbituric;O;O
acid;O;O
reactive;O;O
substances;O;O
(;O;O
TBARS;O;O
);O;O
in;O;O
both;O;O
tissues;O;O
,;O;O
either;O;O
4;O;O
or;O;O
24;O;O
h;O;O
after;O;O
treatment;O;O
.;O;O
DDI-MedLine.d126.s3;;
Much;O;O
higher;O;O
changes;O;O
were;O;O
observed;O;O
in;O;O
liver;O;O
,;O;O
increasing;O;O
from;O;O
a;O;O
level;O;O
of;O;O
60;O;O
%;O;O
at;O;O
4;O;O
h;O;O
up;O;O
to;O;O
nearly;O;O
4;O;O
times;O;O
the;O;O
control;O;O
at;O;O
24;O;O
h;O;O
for;O;O
single;O;O
dose;O;O
.;O;O
DDI-MedLine.d126.s4;;
Reduced;O;O
levels;O;O
(;O;O
up;O;O
to;O;O
20;O;O
%;O;O
);O;O
of;O;O
total;O;O
glutathione;O;O
(;O;O
total;O;O
GSH;O;O
);O;O
,;O;O
and;O;O
elevation;O;O
of;O;O
conjugated;O;O
dienes;O;O
(;O;O
approximately;O;O
60;O;O
%;O;O
in;O;O
liver;O;O
by;O;O
single;O;O
dose;O;O
at;O;O
4;O;O
h;O;O
);O;O
also;O;O
indicated;O;O
the;O;O
presence;O;O
of;O;O
an;O;O
oxidative;O;O
insult;O;O
.;O;O
DDI-MedLine.d126.s5;;
Glutathione;O;O
-;O;O
S;O;O
-;O;O
transferase;O;O
(;O;O
GST;O;O
);O;O
activity;O;O
,;O;O
however;O;O
,;O;O
did;O;O
not;O;O
differ;O;O
from;O;O
control;O;O
values;O;O
for;O;O
any;O;O
dose;O;O
or;O;O
at;O;O
any;O;O
time;O;O
point;O;O
in;O;O
cerebral;O;O
and;O;O
hepatic;O;O
tissues;O;O
.;O;O
DDI-MedLine.d126.s6;;
Pretreatment;O;O
of;O;O
rats;O;O
with;O;O
allopurinol;B-drug;B-DDI-MedLine.d126.s6.e0
(;O;O
100;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
ip;O;O
);O;O
or;O;O
Vitamin;B-drug;B-DDI-MedLine.d126.s6.e1
E;I-drug;I-DDI-MedLine.d126.s6.e1
(;O;O
100;O;O
mg;O;O
/;O;O
kg;O;O
per;O;O
day;O;O
,;O;O
ig;O;O
,;O;O
for;O;O
3;O;O
days;O;O
and;O;O
a;O;O
dose;O;O
of;O;O
40;O;O
mg;O;O
/;O;O
kg;O;O
on;O;O
the;O;O
4th;O;O
day;O;O
);O;O
provided;O;O
significant;O;O
protection;O;O
against;O;O
the;O;O
elevation;O;O
of;O;O
TBARS;O;O
levels;O;O
in;O;O
cerebral;O;O
and;O;O
hepatic;O;O
tissues;O;O
,;O;O
induced;O;O
by;O;O
single;O;O
high;O;O
dose;O;O
of;O;O
oral;O;O
cypermethrin;B-drug;B-DDI-MedLine.d126.s6.e2
administration;O;O
within;O;O
4;O;O
h.;O;O
DDI-MedLine.d126.s7;;
Thus;O;O
,;O;O
the;O;O
results;O;O
suggest;O;O
that;O;O
cypermethrin;B-drug;B-DDI-MedLine.d126.s7.e0
exposure;O;O
of;O;O
rats;O;O
results;O;O
in;O;O
free;O;O
radical;O;O
-;O;O
mediated;O;O
tissue;O;O
damage;O;O
,;O;O
as;O;O
indicated;O;O
by;O;O
elevated;O;O
cerebral;O;O
and;O;O
hepatic;O;O
lipid;O;O
peroxidation;O;O
,;O;O
which;O;O
was;O;O
prevented;O;O
by;O;O
allopurinol;B-drug;B-DDI-MedLine.d126.s7.e1
and;O;O
Vitamin;B-drug;B-DDI-MedLine.d126.s7.e2
E.;I-drug;I-DDI-MedLine.d126.s7.e2
DDI-MedLine.d58.s0;;
Effect;O;O
of;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s0.e0
on;O;O
voltage;O;O
-;O;O
dependent;O;O
Ca(2;O;O
+;O;O
);O;O
channel;O;O
subtypes;O;O
in;O;O
bovine;O;O
chromaffin;O;O
cells;O;O
.;O;O
DDI-MedLine.d58.s1;;
In;O;O
previous;O;O
reports;O;O
we;O;O
have;O;O
shown;O;O
that;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s1.e0
inhibit;O;O
high;O;O
threshold;O;O
voltage;O;O
-;O;O
dependent;O;O
Ca(2;O;O
+;O;O
);O;O
channels;O;O
in;O;O
neuronal;O;O
cells;O;O
.;O;O
DDI-MedLine.d58.s2;;
However;O;O
,;O;O
these;O;O
studies;O;O
did;O;O
not;O;O
show;O;O
whether;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s2.e0
-;O;O
induced;O;O
inhibition;O;O
of;O;O
Ca(2;O;O
+;O;O
);O;O
currents;O;O
discriminates;O;O
among;O;O
the;O;O
various;O;O
Ca(2;O;O
+;O;O
);O;O
channel;O;O
subtypes;O;O
,;O;O
although;O;O
it;O;O
is;O;O
known;O;O
that;O;O
there;O;O
are;O;O
at;O;O
least;O;O
five;O;O
different;O;O
Ca(2;O;O
+;O;O
);O;O
channel;O;O
subtypes;O;O
in;O;O
neuronal;O;O
cells;O;O
.;O;O
DDI-MedLine.d58.s3;;
In;O;O
this;O;O
study;O;O
we;O;O
investigated;O;O
the;O;O
effect;O;O
of;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s3.e0
on;O;O
high;O;O
threshold;O;O
voltage;O;O
-;O;O
dependent;O;O
Ca(2;O;O
+;O;O
);O;O
channel;O;O
subtypes;O;O
using;O;O
their;O;O
selective;B-group;B-DDI-MedLine.d58.s3.e1
Ca(2;I-group;I-DDI-MedLine.d58.s3.e1
+;I-group;I-DDI-MedLine.d58.s3.e1
);I-group;I-DDI-MedLine.d58.s3.e1
channel;I-group;I-DDI-MedLine.d58.s3.e1
blockers;I-group;I-DDI-MedLine.d58.s3.e1
nimodipine;I-drug;I-DDI-MedLine.d58.s3.e2
(;O;O
L;O;O
-;O;O
type;O;O
);O;O
,;O;O
omega;B-drug_n;B-DDI-MedLine.d58.s3.e3
-;I-drug_n;I-DDI-MedLine.d58.s3.e3
conotoxin;I-drug_n;I-DDI-MedLine.d58.s3.e3
GVIA;I-drug_n;I-DDI-MedLine.d58.s3.e3
(;O;O
N;O;O
-;O;O
type;O;O
);O;O
,;O;O
or;O;O
omega;B-drug_n;B-DDI-MedLine.d58.s3.e4
-;I-drug_n;I-DDI-MedLine.d58.s3.e4
agatoxin;I-drug_n;I-DDI-MedLine.d58.s3.e4
IVA;I-drug_n;I-DDI-MedLine.d58.s3.e4
(;O;O
P;O;O
-;O;O
type;O;O
);O;O
in;O;O
bovine;O;O
chromaffin;O;O
cells;O;O
.;O;O
DDI-MedLine.d58.s4;;
We;O;O
could;O;O
observe;O;O
that;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s4.e0
inhibited;O;O
high;O;O
threshold;O;O
voltage;O;O
-;O;O
dependent;O;O
Ca(2;O;O
+;O;O
);O;O
currents;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
manner;O;O
.;O;O
DDI-MedLine.d58.s5;;
The;O;O
IC(50;O;O
);O;O
was;O;O
about;O;O
120;O;O
microgram;O;O
/;O;O
ml;O;O
.;O;O
DDI-MedLine.d58.s6;;
Nimodipine;B-drug;B-DDI-MedLine.d58.s6.e0
had;O;O
no;O;O
effect;O;O
on;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s6.e1
response;O;O
.;O;O
DDI-MedLine.d58.s7;;
These;O;O
data;O;O
suggest;O;O
that;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s7.e0
are;O;O
negatively;O;O
coupled;O;O
to;O;O
three;O;O
types;O;O
of;O;O
calcium;O;O
channels;O;O
in;O;O
bovine;O;O
chromaffin;O;O
cell;O;O
,;O;O
including;O;O
an;O;O
omega;B-drug_n;B-DDI-MedLine.d58.s7.e1
-;I-drug_n;I-DDI-MedLine.d58.s7.e1
conotoxin;I-drug_n;I-DDI-MedLine.d58.s7.e1
GVIA;I-drug_n;I-DDI-MedLine.d58.s7.e1
-;O;O
sensitive;O;O
(;O;O
N;O;O
-;O;O
type;O;O
);O;O
channel;O;O
,;O;O
an;O;O
omega;B-drug_n;B-DDI-MedLine.d58.s7.e2
-;I-drug_n;I-DDI-MedLine.d58.s7.e2
agatoxin;I-drug_n;I-DDI-MedLine.d58.s7.e2
IVA;I-drug_n;I-DDI-MedLine.d58.s7.e2
-;O;O
sensitive;O;O
(;O;O
P;O;O
-;O;O
type;O;O
);O;O
channel;O;O
and;O;O
nimodipine;B-drug;B-DDI-MedLine.d58.s7.e3
/;O;O
omega;B-drug_n;B-DDI-MedLine.d58.s7.e4
-;I-drug_n;I-DDI-MedLine.d58.s7.e4
conotoxin;I-drug_n;I-DDI-MedLine.d58.s7.e4
GVIA;I-drug_n;I-DDI-MedLine.d58.s7.e4
/;O;O
omega;B-drug_n;B-DDI-MedLine.d58.s7.e5
-;I-drug_n;I-DDI-MedLine.d58.s7.e5
agatoxin;I-drug_n;I-DDI-MedLine.d58.s7.e5
VIA;I-drug_n;I-DDI-MedLine.d58.s7.e5
-;O;O
resistant;O;O
(;O;O
presumptive;O;O
Q;O;O
-;O;O
type;O;O
);O;O
channel;O;O
.;O;O
DDI-MedLine.d58.s8;;
Thus;O;O
,;O;O
the;O;O
selective;O;O
regulation;O;O
of;O;O
voltage;O;O
-;O;O
dependent;O;O
Ca(2;O;O
+;O;O
);O;O
subtypes;O;O
by;O;O
ginsenosides;B-drug_n;B-DDI-MedLine.d58.s8.e0
in;O;O
bovine;O;O
chromaffin;O;O
cell;O;O
could;O;O
be;O;O
the;O;O
cellular;O;O
basis;O;O
of;O;O
antistress;O;O
effects;O;O
induced;O;O
by;O;O
ginseng;B-drug;B-DDI-MedLine.d58.s8.e1
.;O;O
DDI-MedLine.d8.s0;;
In;O;O
vitro;O;O
activity;O;O
of;O;O
KRM;B-drug_n;B-DDI-MedLine.d8.s0.e0
-;I-drug_n;I-DDI-MedLine.d8.s0.e0
1648;I-drug_n;I-DDI-MedLine.d8.s0.e0
,;O;O
either;O;O
singly;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
ofloxacin;B-drug;B-DDI-MedLine.d8.s0.e1
,;O;O
against;O;O
Mycobacterium;O;O
ulcerans;O;O
.;O;O

;O;O
DDI-MedLine.d8.s1;;
The;O;O
antimicrobial;O;O
effect;O;O
of;O;O
a;O;O
benzoxazinorifamycin;B-drug_n;B-DDI-MedLine.d8.s1.e0
,;O;O
KRM;B-drug_n;B-DDI-MedLine.d8.s1.e1
-;I-drug_n;I-DDI-MedLine.d8.s1.e1
1648;I-drug_n;I-DDI-MedLine.d8.s1.e1
,;O;O
either;O;O
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
ofloxacin;B-drug;B-DDI-MedLine.d8.s1.e2
,;O;O
was;O;O
evaluated;O;O
in;O;O
vitro;O;O
against;O;O
two;O;O
type;O;O
strains;O;O
and;O;O
six;O;O
clinical;O;O
isolates;O;O
of;O;O
Mycobacterium;O;O
ulcerans;O;O
.;O;O
DDI-MedLine.d8.s2;;
Growth;O;O
of;O;O
M.;O;O
DDI-MedLine.d8.s3;;
ulcerans;O;O
was;O;O
measured;O;O
by;O;O
plate;O;O
counts;O;O
and;O;O
the;O;O
BACTEC;O;O
radiometric;O;O
method;O;O
.;O;O
DDI-MedLine.d8.s4;;
The;O;O
minimal;O;O
inhibitory;O;O
concentration;O;O
as;O;O
well;O;O
as;O;O
minimal;O;O
bactericidal;O;O
concentration;O;O
of;O;O
KRM;B-drug_n;B-DDI-MedLine.d8.s4.e0
-;I-drug_n;I-DDI-MedLine.d8.s4.e0
1648;I-drug_n;I-DDI-MedLine.d8.s4.e0
against;O;O
M.;O;O
DDI-MedLine.d8.s5;;
ulcerans;O;O
was;O;O
between;O;O
0.012;O;O
and;O;O
0.025;O;O
mg;O;O
/;O;O
l;O;O
,;O;O
while;O;O
corresponding;O;O
values;O;O
for;O;O
rifampicin;B-drug;B-DDI-MedLine.d8.s5.e0
and;O;O
rifabutin;B-drug;B-DDI-MedLine.d8.s5.e1
were;O;O
in;O;O
the;O;O
range;O;O
of;O;O
0.1;O;O
-;O;O
0.8;O;O
mg;O;O
/;O;O
l;O;O
and;O;O
0.1;O;O
-;O;O
0.4;O;O
mg;O;O
/;O;O
l;O;O
respectively;O;O
.;O;O
DDI-MedLine.d8.s6;;
When;O;O
combined;O;O
with;O;O
ofloxacin;B-drug;B-DDI-MedLine.d8.s6.e0
,;O;O
KRM;B-drug_n;B-DDI-MedLine.d8.s6.e1
-;I-drug_n;I-DDI-MedLine.d8.s6.e1
1648;I-drug_n;I-DDI-MedLine.d8.s6.e1
exhibited;O;O
strong;O;O
synergistic;O;O
activity;O;O
while;O;O
only;O;O
additive;O;O
effects;O;O
were;O;O
observed;O;O
with;O;O
the;O;O
combination;O;O
of;O;O
rifampicin;B-drug;B-DDI-MedLine.d8.s6.e2
(;O;O
or;O;O
rifabutin;B-drug;B-DDI-MedLine.d8.s6.e3
);O;O
and;O;O
ofloxacin;B-drug;B-DDI-MedLine.d8.s6.e4
.;O;O
DDI-MedLine.d8.s7;;
These;O;O
results;O;O
suggest;O;O
that;O;O
KRM;B-drug_n;B-DDI-MedLine.d8.s7.e0
-;I-drug_n;I-DDI-MedLine.d8.s7.e0
1648;I-drug_n;I-DDI-MedLine.d8.s7.e0
has;O;O
a;O;O
great;O;O
potential;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
M.;O;O
DDI-MedLine.d8.s8;;
ulcerans;O;O
infection;O;O
.;O;O
DDI-MedLine.d114.s0;;
Inhibitory;O;O
effects;O;O
of;O;O
ruthenium;B-drug_n;B-DDI-MedLine.d114.s0.e0
red;I-drug_n;I-DDI-MedLine.d114.s0.e0
on;O;O
inositol;O;O
1,4;O;O
,;O;O
5;O;O
-;O;O
trisphosphate;O;O
-;O;O
induced;O;O
responses;O;O
in;O;O
rat;O;O
megakaryocytes;O;O
.;O;O
DDI-MedLine.d114.s1;;
The;O;O
effects;O;O
of;O;O
ruthenium;B-drug_n;B-DDI-MedLine.d114.s1.e0
red;I-drug_n;I-DDI-MedLine.d114.s1.e0
(;O;O
RR;B-drug_n;B-DDI-MedLine.d114.s1.e1
);O;O
on;O;O
inositol;B-drug_n;B-DDI-MedLine.d114.s1.e2
1,4,5;I-drug_n;I-DDI-MedLine.d114.s1.e2
-;I-drug_n;I-DDI-MedLine.d114.s1.e2
trisphosphate;I-drug_n;I-DDI-MedLine.d114.s1.e2
(;O;O
InsP(3));B-drug_n;B-DDI-MedLine.d114.s1.e3
-;O;O
induced;O;O
responses;O;O
were;O;O
studied;O;O
in;O;O
rat;O;O
bone;O;O
marrow;O;O
megakaryocytes;O;O
with;O;O
the;O;O
patch;O;O
-;O;O
clamp;O;O
whole;O;O
-;O;O
cell;O;O
recording;O;O
technique;O;O
in;O;O
combination;O;O
with;O;O
fura;O;O
-;O;O
2;O;O
microfluorometry;O;O
.;O;O
DDI-MedLine.d114.s2;;
Internal;O;O
application;O;O
of;O;O
InsP(3;B-drug_n;B-DDI-MedLine.d114.s2.e0
);I-drug_n;I-DDI-MedLine.d114.s2.e0
(;O;O
100;O;O
microM;O;O
);O;O
increased;O;O
intracellular;O;O
Ca(2;O;O
+;O;O
);O;O
concentration;O;O
(;O;O
[;O;O
Ca(2+)](i;O;O
);O;O
);O;O
and;O;O
activated;O;O
the;O;O
Ca(2+);O;O
-;O;O
dependent;O;O
K(+;O;O
);O;O
current;O;O
.;O;O
DDI-MedLine.d114.s3;;
Administering;O;O
InsP(3;B-drug_n;B-DDI-MedLine.d114.s3.e0
);I-drug_n;I-DDI-MedLine.d114.s3.e0
together;O;O
with;O;O
RR;B-drug_n;B-DDI-MedLine.d114.s3.e1
(;O;O
100;O;O
-;O;O
500;O;O
microM;O;O
);O;O
inhibited;O;O
InsP(3);O;O
-;O;O
induced;O;O
responses;O;O
(;O;O
both;O;O
Ca(2;O;O
+;O;O
);O;O
and;O;O
current;O;O
responses;O;O
);O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
fashion;O;O
.;O;O
DDI-MedLine.d114.s4;;
Pretreatment;O;O
of;O;O
megakaryocytes;O;O
with;O;O
extracellular;O;O
RR;B-drug_n;B-DDI-MedLine.d114.s4.e0
(;O;O
50;O;O
microM;O;O
);O;O
also;O;O
inhibited;O;O
InsP(3);B-drug_n;B-DDI-MedLine.d114.s4.e1
-;O;O
induced;O;O
responses;O;O
.;O;O
DDI-MedLine.d114.s5;;
Intracellular;O;O
and;O;O
extracellular;O;O
application;O;O
of;O;O
RR;B-drug_n;B-DDI-MedLine.d114.s5.e0
reduced;O;O
ADP;O;O
-;O;O
induced;O;O
increases;O;O
in;O;O
[;O;O
Ca(2+)](i;O;O
);O;O
.;O;O
DDI-MedLine.d114.s6;;
In;O;O
contrast;O;O
,;O;O
in;O;O
isolated;O;O
single;O;O
pancreatic;O;O
acinar;O;O
cells;O;O
,;O;O
RR;B-drug_n;B-DDI-MedLine.d114.s6.e0
had;O;O
no;O;O
effect;O;O
on;O;O
InsP(3);B-drug_n;B-DDI-MedLine.d114.s6.e1
-;O;O
induced;O;O
responses;O;O
.;O;O
DDI-MedLine.d114.s7;;
Taken;O;O
together;O;O
,;O;O
these;O;O
results;O;O
suggest;O;O
that;O;O
the;O;O
site;O;O
of;O;O
the;O;O
inhibitory;O;O
action;O;O
of;O;O
RR;B-drug_n;B-DDI-MedLine.d114.s7.e0
is;O;O
at;O;O
the;O;O
InsP(3;O;O
);O;O
receptor;O;O
,;O;O
or;O;O
its;O;O
closely;O;O
associated;O;O
proteins;O;O
.;O;O
DDI-MedLine.d114.s8;;
In;O;O
addition;O;O
,;O;O
we;O;O
have;O;O
shown;O;O
that;O;O
RR;B-drug_n;B-DDI-MedLine.d114.s8.e0
is;O;O
a;O;O
useful;O;O
pharmacological;O;O
tool;O;O
with;O;O
which;O;O
to;O;O
examine;O;O
the;O;O
InsP(3);B-drug_n;B-DDI-MedLine.d114.s8.e1
-;O;O
mediated;O;O
responses;O;O
of;O;O
megakaryocytes;O;O
.;O;O
DDI-MedLine.d109.s0;;
Effect;O;O
of;O;O
rofecoxib;B-drug;B-DDI-MedLine.d109.s0.e0
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s0.e1
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-MedLine.d109.s1;;
The;O;O
authors;O;O
examined;O;O
the;O;O
effect;O;O
of;O;O
the;O;O
cyclooxygenase;O;O
-;O;O
2;O;O
(;O;O
COX;O;O
-;O;O
2;O;O
);O;O
inhibitor;O;O
,;O;O
rofecoxib;B-drug;B-DDI-MedLine.d109.s1.e0
,;O;O
at;O;O
steady;O;O
state;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s1.e1
following;O;O
a;O;O
single;O;O
dose;O;O
in;O;O
healthy;O;O
subjects;O;O
.;O;O
DDI-MedLine.d109.s2;;
Each;O;O
healthy;O;O
subject;O;O
(;O;O
N;O;O
=;O;O
10;O;O
);O;O
received;O;O
rofecoxib;B-drug;B-DDI-MedLine.d109.s2.e0
(;O;O
75;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
or;O;O
placebo;O;O
for;O;O
11;O;O
days;O;O
in;O;O
a;O;O
double;O;O
-;O;O
blind;O;O
,;O;O
randomized;O;O
,;O;O
balanced;O;O
,;O;O
two;O;O
-;O;O
period;O;O
crossover;O;O
study;O;O
.;O;O
DDI-MedLine.d109.s3;;
A;O;O
single;O;O
0.5;O;O
mg;O;O
oral;O;O
dose;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s3.e0
elixir;O;O
was;O;O
administered;O;O
on;O;O
the;O;O
7th;O;O
day;O;O
of;O;O
each;O;O
11;O;O
-;O;O
day;O;O
period;O;O
.;O;O
DDI-MedLine.d109.s4;;
Each;O;O
treatment;O;O
period;O;O
was;O;O
separated;O;O
by;O;O
14;O;O
to;O;O
21;O;O
days;O;O
.;O;O
DDI-MedLine.d109.s5;;
Samples;O;O
for;O;O
plasma;O;O
and;O;O
urine;O;O
immunoreactive;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s5.e0
concentrations;O;O
were;O;O
collected;O;O
through;O;O
120;O;O
hours;O;O
following;O;O
the;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s5.e1
dose;O;O
.;O;O
DDI-MedLine.d109.s6;;
No;O;O
statistically;O;O
significant;O;O
differences;O;O
between;O;O
treatment;O;O
groups;O;O
were;O;O
observed;O;O
for;O;O
any;O;O
of;O;O
the;O;O
calculated;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s6.e0
pharmacokinetic;O;O
parameters;O;O
.;O;O
DDI-MedLine.d109.s7;;
For;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s7.e0
AUC(0;O;O
-;O;O
infinity;O;O
);O;O
,;O;O
AUC(0;O;O
-;O;O
24;O;O
);O;O
,;O;O
and;O;O
Cmax;O;O
,;O;O
the;O;O
geometric;O;O
mean;O;O
ratios;O;O
(;O;O
90;O;O
%;O;O
confidence;O;O
interval;O;O
);O;O
for;O;O
(;O;O
rofecoxib;B-drug;B-DDI-MedLine.d109.s7.e1
+;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s7.e2
/;O;O
placebo;O;O
+;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s7.e3
);O;O
were;O;O
1.04;O;O
(;O;O
0.94;O;O
,;O;O
1.14;O;O
);O;O
,;O;O
1.02;O;O
(;O;O
0.94;O;O
,;O;O
1.09;O;O
);O;O
,;O;O
and;O;O
1.00;O;O
(;O;O
0.91;O;O
,;O;O
1.10;O;O
);O;O
,;O;O
respectively;O;O
.;O;O
DDI-MedLine.d109.s8;;
The;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s8.e0
median;O;O
tmax;O;O
was;O;O
0.5;O;O
hours;O;O
for;O;O
both;O;O
treatments;O;O
.;O;O
DDI-MedLine.d109.s9;;
The;O;O
harmonic;O;O
mean;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
was;O;O
45.7;O;O
and;O;O
43.4;O;O
hours;O;O
for;O;O
rofecoxib;B-drug;B-DDI-MedLine.d109.s9.e0
+;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s9.e1
and;O;O
placebo;O;O
+;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s9.e2
treatments;O;O
,;O;O
respectively;O;O
.;O;O
DDI-MedLine.d109.s10;;
Digoxin;B-drug;B-DDI-MedLine.d109.s10.e0
is;O;O
eliminated;O;O
renally;O;O
.;O;O
DDI-MedLine.d109.s11;;
The;O;O
mean;O;O
(;O;O
SD;O;O
);O;O
cumulative;O;O
urinary;O;O
excretion;O;O
of;O;O
immunoreactive;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s11.e0
after;O;O
concurrent;O;O
treatment;O;O
with;O;O
rofecoxib;B-drug;B-DDI-MedLine.d109.s11.e1
or;O;O
placebo;O;O
was;O;O
228.2;O;O
(;O;O
+;O;O
/;O;O
-;O;O
30.8;O;O
);O;O
and;O;O
235.1;O;O
(;O;O
+;O;O
/;O;O
-;O;O
39.1;O;O
);O;O
micrograms;O;O
/;O;O
120;O;O
hours;O;O
,;O;O
respectively;O;O
.;O;O
DDI-MedLine.d109.s12;;
Transient;O;O
and;O;O
minor;O;O
adverse;O;O
events;O;O
occurred;O;O
with;O;O
similar;O;O
frequency;O;O
on;O;O
placebo;O;O
and;O;O
rofecoxib;B-drug;B-DDI-MedLine.d109.s12.e0
treatments;O;O
,;O;O
and;O;O
no;O;O
treatment;O;O
-;O;O
related;O;O
pattern;O;O
was;O;O
apparent;O;O
.;O;O
DDI-MedLine.d109.s13;;
Rofecoxib;B-drug;B-DDI-MedLine.d109.s13.e0
did;O;O
not;O;O
influence;O;O
the;O;O
plasma;O;O
pharmacokinetics;O;O
or;O;O
renal;O;O
elimination;O;O
of;O;O
a;O;O
single;O;O
oral;O;O
dose;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d109.s13.e1
.;O;O
DDI-MedLine.d115.s0;;
Concomitant;O;O
cyclophosphamide;B-drug;B-DDI-MedLine.d115.s0.e0
,;O;O
doxorubicin;B-drug;B-DDI-MedLine.d115.s0.e1
,;O;O
vincristine;B-drug;B-DDI-MedLine.d115.s0.e2
,;O;O
and;O;O
prednisone;B-drug;B-DDI-MedLine.d115.s0.e3
chemotherapy;O;O
plus;O;O
highly;B-group;B-DDI-MedLine.d115.s0.e4
active;I-group;I-DDI-MedLine.d115.s0.e4
antiretroviral;I-group;I-DDI-MedLine.d115.s0.e4
therapy;O;O
in;O;O
patients;O;O
with;O;O
human;O;O
immunodeficiency;O;O
virus;O;O
-;O;O
related;O;O
,;O;O
non;O;O
-;O;O
Hodgkin;O;O
lymphoma;O;O
.;O;O
DDI-MedLine.d115.s1;;
BACKGROUND;O;O
:;O;O
The;O;O
feasibility;O;O
and;O;O
efficacy;O;O
of;O;O
concomitant;O;O
chemotherapy;O;O
and;O;O
highly;B-group;B-DDI-MedLine.d115.s1.e0
active;I-group;I-DDI-MedLine.d115.s1.e0
antiretroviral;I-group;I-DDI-MedLine.d115.s1.e0
therapy;O;O
(;O;O
HAART;O;O
);O;O
is;O;O
still;O;O
unknown;O;O
in;O;O
patients;O;O
with;O;O
human;O;O
immunodeficiency;O;O
virus;O;O
(;O;O
HIV);O;O
-;O;O
related;O;O
malignancies;O;O
.;O;O
DDI-MedLine.d115.s2;;
To;O;O
evaluate;O;O
the;O;O
impact;O;O
of;O;O
chemotherapy;O;O
plus;O;O
HAART;O;O
on;O;O
the;O;O
clinical;O;O
course;O;O
of;O;O
patients;O;O
with;O;O
HIV;O;O
-;O;O
related;O;O
,;O;O
systemic;O;O
,;O;O
non;O;O
-;O;O
Hodgkin;O;O
lymphoma;O;O
(;O;O
HIV;O;O
-;O;O
NHL;O;O
);O;O
,;O;O
the;O;O
authors;O;O
compared;O;O
retrospectively;O;O
a;O;O
group;O;O
of;O;O
24;O;O
patients;O;O
with;O;O
HIV;O;O
-;O;O
NHL;O;O
who;O;O
were;O;O
treated;O;O
with;O;O
the;O;O
cyclophosphamide;B-drug;B-DDI-MedLine.d115.s2.e0
,;O;O
doxorubicin;B-drug;B-DDI-MedLine.d115.s2.e1
,;O;O
vincristine;B-drug;B-DDI-MedLine.d115.s2.e2
,;O;O
and;O;O
prednisone;B-drug;B-DDI-MedLine.d115.s2.e3
(;O;O
CHOP;O;O
);O;O
chemotherapy;O;O
regimen;O;O
plus;O;O
HAART;O;O
with;O;O
a;O;O
group;O;O
of;O;O
80;O;O
patients;O;O
who;O;O
were;O;O
treated;O;O
with;O;O
CHOP;O;O
chemotherapy;O;O
or;O;O
a;O;O
CHOP;O;O
-;O;O
like;O;O
regimen;O;O
(;O;O
i.e.;O;O
,;O;O
cyclophosphamide;B-drug;B-DDI-MedLine.d115.s2.e4
,;O;O
doxorubicin;B-drug;B-DDI-MedLine.d115.s2.e5
,;O;O
teniposide;B-drug;B-DDI-MedLine.d115.s2.e6
,;O;O
and;O;O
prednisone;B-drug;B-DDI-MedLine.d115.s2.e7
with;O;O
vincristine;B-drug;B-DDI-MedLine.d115.s2.e8
plus;O;O
bleomycin;B-drug;B-DDI-MedLine.d115.s2.e9
);O;O
without;O;O
receiving;O;O
antiretroviral;B-group;B-DDI-MedLine.d115.s2.e10
therapy;O;O
.;O;O
DDI-MedLine.d115.s3;;
METHODS;O;O
:;O;O
All;O;O
patients;O;O
were;O;O
enrolled;O;O
in;O;O
two;O;O
sequential;O;O
trials;O;O
performed;O;O
at;O;O
the;O;O
Aviano;O;O
Cancer;O;O
Center;O;O
,;O;O
Italy;O;O
,;O;O
from;O;O
April;O;O
1988;O;O
to;O;O
December;O;O
1998;O;O
.;O;O
DDI-MedLine.d115.s4;;
HAART;O;O
was;O;O
included;O;O
with;O;O
combination;O;O
therapy;O;O
from;O;O
January;O;O
1997;O;O
.;O;O
DDI-MedLine.d115.s5;;
Antiretroviral;B-group;B-DDI-MedLine.d115.s5.e0
regimens;O;O
consisted;O;O
of;O;O
two;O;O
reverse;B-group;B-DDI-MedLine.d115.s5.e1
transcriptase;I-group;I-DDI-MedLine.d115.s5.e1
inhibitors;I-group;I-DDI-MedLine.d115.s5.e1
and;O;O
one;O;O
protease;B-group;B-DDI-MedLine.d115.s5.e2
inhibitor;I-group;I-DDI-MedLine.d115.s5.e2
.;O;O
DDI-MedLine.d115.s6;;
RESULTS;O;O
:;O;O
The;O;O
two;O;O
treatment;O;O
groups;O;O
were;O;O
well;O;O
matched;O;O
with;O;O
regard;O;O
to;O;O
patient;O;O
demographics;O;O
,;O;O
NHL;O;O
characteristics;O;O
,;O;O
HIV;O;O
status;O;O
,;O;O
and;O;O
treatment;O;O
,;O;O
i.e.;O;O
,;O;O
the;O;O
number;O;O
of;O;O
cycles;O;O
and;O;O
chemotherapy;O;O
dose;O;O
.;O;O
DDI-MedLine.d115.s7;;
The;O;O
response;O;O
rates;O;O
were;O;O
similar;O;O
between;O;O
the;O;O
two;O;O
groups;O;O
.;O;O
DDI-MedLine.d115.s8;;
Severe;O;O
anemia;O;O
(;O;O
Grade;O;O
3;O;O
-;O;O
4;O;O
according;O;O
to;O;O
the;O;O
World;O;O
Health;O;O
Organization;O;O
criteria;O;O
);O;O
was;O;O
significantly;O;O
greater;O;O
in;O;O
the;O;O
patients;O;O
who;O;O
received;O;O
CHOP;O;O
-;O;O
HAART;O;O
compared;O;O
with;O;O
the;O;O
patients;O;O
who;O;O
received;O;O
CHOP;O;O
alone;O;O
(;O;O
33;O;O
%;O;O
vs.;O;O
7;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
P;O;O
=;O;O
0.001;O;O
);O;O
.;O;O
DDI-MedLine.d115.s9;;
Leukopenia;O;O
was;O;O
similar;O;O
between;O;O
the;O;O
two;O;O
groups;O;O
,;O;O
but;O;O
colony;O;O
stimulating;O;O
factor;O;O
support;O;O
was;O;O
significantly;O;O
greater;O;O
in;O;O
the;O;O
CHOP;O;O
-;O;O
HAART;O;O
group;O;O
than;O;O
in;O;O
the;O;O
control;O;O
group;O;O
(;O;O
92;O;O
%;O;O
vs.;O;O
66;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
P;O;O
=;O;O
0.03;O;O
);O;O
.;O;O
DDI-MedLine.d115.s10;;
Seventeen;O;O
percent;O;O
of;O;O
CHOP;O;O
-;O;O
HAART;O;O
patients;O;O
developed;O;O
severe;O;O
autonomic;O;O
neurotoxicity;O;O
,;O;O
whereas;O;O
none;O;O
of;O;O
the;O;O
CHOP;O;O
patients;O;O
developed;O;O
neurotoxicity;O;O
(;O;O
P;O;O
=;O;O
0.002;O;O
);O;O
.;O;O
DDI-MedLine.d115.s11;;
At;O;O
similar;O;O
median;O;O
follow;O;O
-;O;O
up;O;O
,;O;O
opportunistic;O;O
infection;O;O
(;O;O
OI;O;O
);O;O
rates;O;O
and;O;O
mortality;O;O
were;O;O
significantly;O;O
lower;O;O
in;O;O
the;O;O
CHOP;O;O
-;O;O
HAART;O;O
patients;O;O
than;O;O
in;O;O
the;O;O
CHOP;O;O
patients;O;O
(;O;O
18;O;O
%;O;O
vs.;O;O
52;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
P;O;O
=;O;O
0.05;O;O
,;O;O
and;O;O
38;O;O
%;O;O
vs.;O;O
85;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
P;O;O
=;O;O
0.001;O;O
);O;O
.;O;O
DDI-MedLine.d115.s12;;
The;O;O
median;O;O
survival;O;O
for;O;O
CHOP;O;O
-;O;O
HAART;O;O
patients;O;O
was;O;O
not;O;O
reached;O;O
,;O;O
whereas;O;O
the;O;O
medial;O;O
survival;O;O
of;O;O
CHOP;O;O
patients;O;O
was;O;O
7;O;O
months;O;O
(;O;O
P;O;O
=;O;O
0.03;O;O
);O;O
.;O;O
DDI-MedLine.d115.s13;;
CONCLUSIONS;O;O
:;O;O
The;O;O
combination;O;O
of;O;O
CHOP;O;O
plus;O;O
HAART;O;O
is;O;O
feasible;O;O
and;O;O
may;O;O
reduce;O;O
the;O;O
morbidity;O;O
from;O;O
OIs;O;O
in;O;O
HIV;O;O
-;O;O
NHL;O;O
patients;O;O
.;O;O
DDI-MedLine.d115.s14;;
However;O;O
,;O;O
careful;O;O
attention;O;O
must;O;O
be;O;O
directed;O;O
to;O;O
cross;O;O
toxicity;O;O
and;O;O
possible;O;O
pharmacokinetic;O;O
interactions;O;O
between;O;O
antiretroviral;B-group;B-DDI-MedLine.d115.s14.e0
and;I-group;I-DDI-MedLine.d115.s14.e0
antineoplastic;I-group;I-DDI-MedLine.d115.s14.e1
drugs;I-group;I-DDI-MedLine.d115.s14.e1
.;O;O
DDI-MedLine.d115.s15;;
The;O;O
impact;O;O
of;O;O
the;O;O
combined;O;O
chemotherapy;O;O
plus;O;O
HAART;O;O
treatment;O;O
on;O;O
patient;O;O
survival;O;O
needs;O;O
urgently;O;O
to;O;O
be;O;O
evaluated;O;O
in;O;O
prospective;O;O
studies;O;O
.;O;O
DDI-MedLine.d21.s0;;
Acute;O;O
effect;O;O
of;O;O
different;O;O
antidepressants;B-group;B-DDI-MedLine.d21.s0.e0
on;O;O
glycemia;O;O
in;O;O
diabetic;O;O
and;O;O
non;O;O
-;O;O
diabetic;O;O
rats;O;O
.;O;O

;O;O
DDI-MedLine.d21.s1;;
Diabetic;O;O
patients;O;O
have;O;O
a;O;O
20;O;O
%;O;O
higher;O;O
risk;O;O
of;O;O
depression;O;O
than;O;O
the;O;O
general;O;O
population;O;O
.;O;O
DDI-MedLine.d21.s2;;
Treatment;O;O
with;O;O
antidepressant;B-group;B-DDI-MedLine.d21.s2.e0
drugs;I-group;I-DDI-MedLine.d21.s2.e0
can;O;O
directly;O;O
interfere;O;O
with;O;O
blood;O;O
glucose;O;O
levels;O;O
or;O;O
may;O;O
interact;O;O
with;O;O
hypoglycemic;B-group;B-DDI-MedLine.d21.s2.e1
agents;I-group;I-DDI-MedLine.d21.s2.e1
.;O;O
DDI-MedLine.d21.s3;;
The;O;O
treatment;O;O
of;O;O
depression;O;O
in;O;O
diabetic;O;O
patients;O;O
must;O;O
take;O;O
into;O;O
account;O;O
variations;O;O
of;O;O
glycemic;O;O
levels;O;O
at;O;O
different;O;O
times;O;O
and;O;O
a;O;O
comparison;O;O
of;O;O
the;O;O
available;O;O
antidepressant;B-group;B-DDI-MedLine.d21.s3.e0
agents;I-group;I-DDI-MedLine.d21.s3.e0
is;O;O
important;O;O
.;O;O
DDI-MedLine.d21.s4;;
In;O;O
the;O;O
present;O;O
study;O;O
we;O;O
evaluated;O;O
the;O;O
interference;O;O
of;O;O
antidepressants;B-group;B-DDI-MedLine.d21.s4.e0
with;O;O
blood;O;O
glucose;O;O
levels;O;O
of;O;O
diabetic;O;O
and;O;O
non;O;O
-;O;O
diabetic;O;O
rats;O;O
.;O;O
DDI-MedLine.d21.s5;;
In;O;O
a;O;O
first;O;O
experiment;O;O
,;O;O
male;O;O
adult;O;O
Wistar;O;O
rats;O;O
were;O;O
fasted;O;O
for;O;O
12;O;O
h.;O;O
DDI-MedLine.d21.s6;;
Imipramine;B-drug;B-DDI-MedLine.d21.s6.e0
(;O;O
5;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
,;O;O
moclobemide;B-drug;B-DDI-MedLine.d21.s6.e1
(;O;O
30;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
,;O;O
clonazepam;B-drug;B-DDI-MedLine.d21.s6.e2
(;O;O
0.25;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
,;O;O
fluoxetine;B-drug;B-DDI-MedLine.d21.s6.e3
(;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
sertraline;B-drug;B-DDI-MedLine.d21.s6.e4
(;O;O
30;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
or;O;O
vehicle;O;O
was;O;O
administered;O;O
.;O;O
DDI-MedLine.d21.s7;;
After;O;O
30;O;O
min;O;O
,;O;O
fasting;O;O
glycemia;O;O
was;O;O
measured;O;O
.;O;O
DDI-MedLine.d21.s8;;
An;O;O
oral;O;O
glucose;B-drug;B-DDI-MedLine.d21.s8.e0
overload;O;O
of;O;O
1;O;O
ml;O;O
of;O;O
a;O;O
50;O;O
%;O;O
glucose;B-drug;B-DDI-MedLine.d21.s8.e1
solution;O;O
was;O;O
given;O;O
to;O;O
rats;O;O
and;O;O
blood;O;O
glucose;O;O
was;O;O
determined;O;O
after;O;O
30;O;O
,;O;O
60;O;O
and;O;O
90;O;O
min;O;O
.;O;O
DDI-MedLine.d21.s9;;
Imipramine;B-drug;B-DDI-MedLine.d21.s9.e0
and;O;O
clonazepam;B-drug;B-DDI-MedLine.d21.s9.e1
did;O;O
not;O;O
change;O;O
fasting;O;O
or;O;O
overload;O;O
glycemia;O;O
.;O;O
DDI-MedLine.d21.s10;;
Fluoxetine;B-drug;B-DDI-MedLine.d21.s10.e0
and;O;O
moclobemide;B-drug;B-DDI-MedLine.d21.s10.e1
increased;O;O
blood;O;O
glucose;B-drug;B-DDI-MedLine.d21.s10.e2
at;O;O
different;O;O
times;O;O
after;O;O
the;O;O
glucose;O;O
overload;O;O
.;O;O
DDI-MedLine.d21.s11;;
Sertraline;B-drug;B-DDI-MedLine.d21.s11.e0
neutralized;O;O
the;O;O
increase;O;O
of;O;O
glycemia;O;O
induced;O;O
by;O;O
oral;O;O
glucose;B-drug;B-DDI-MedLine.d21.s11.e1
overload;O;O
.;O;O
DDI-MedLine.d21.s12;;
In;O;O
the;O;O
second;O;O
experiment;O;O
,;O;O
non;O;O
-;O;O
diabetic;O;O
and;O;O
streptozotocin;O;O
-;O;O
induced;O;O
diabetic;O;O
rats;O;O
were;O;O
fasted;O;O
,;O;O
and;O;O
the;O;O
same;O;O
procedures;O;O
were;O;O
followed;O;O
for;O;O
estimation;O;O
of;O;O
glucose;B-drug;B-DDI-MedLine.d21.s12.e0
tolerance;O;O
30;O;O
min;O;O
after;O;O
glucose;B-drug;B-DDI-MedLine.d21.s12.e1
overload;O;O
.;O;O
DDI-MedLine.d21.s13;;
Again;O;O
,;O;O
sertraline;B-drug;B-DDI-MedLine.d21.s13.e0
neutralized;O;O
the;O;O
increase;O;O
in;O;O
glycemia;O;O
after;O;O
glucose;B-drug;B-DDI-MedLine.d21.s13.e1
overload;O;O
both;O;O
in;O;O
diabetic;O;O
and;O;O
non;O;O
-;O;O
diabetic;O;O
rats;O;O
.;O;O
DDI-MedLine.d21.s14;;
These;O;O
data;O;O
raise;O;O
the;O;O
question;O;O
of;O;O
whether;O;O
sertraline;B-drug;B-DDI-MedLine.d21.s14.e0
is;O;O
the;O;O
best;O;O
choice;O;O
for;O;O
prolonged;O;O
use;O;O
for;O;O
diabetic;O;O
individuals;O;O
,;O;O
because;O;O
of;O;O
its;O;O
antihyperglycemic;O;O
effects;O;O
.;O;O
DDI-MedLine.d21.s15;;
Clonazepam;B-drug;B-DDI-MedLine.d21.s15.e0
would;O;O
be;O;O
useful;O;O
in;O;O
cases;O;O
with;O;O
potential;O;O
risk;O;O
of;O;O
hypoglycemia;O;O
.;O;O
DDI-MedLine.d47.s0;;
Activity;O;O
of;O;O
buforin;B-drug_n;B-DDI-MedLine.d47.s0.e0
II;I-drug_n;I-DDI-MedLine.d47.s0.e0
alone;O;O
and;O;O
in;O;O
combination;O;O
with;O;O
azithromycin;B-drug;B-DDI-MedLine.d47.s0.e1
and;O;O
minocycline;B-drug;B-DDI-MedLine.d47.s0.e2
against;O;O
Cryptosporidium;O;O
parvum;O;O
in;O;O
cell;O;O
culture;O;O
.;O;O
DDI-MedLine.d47.s1;;
The;O;O
in;O;O
vitro;O;O
anti;O;O
-;O;O
cryptosporidial;O;O
activity;O;O
of;O;O
buforin;B-drug_n;B-DDI-MedLine.d47.s1.e0
II;I-drug_n;I-DDI-MedLine.d47.s1.e0
alone;O;O
and;O;O
in;O;O
combination;O;O
with;O;O
azithromycin;B-drug;B-DDI-MedLine.d47.s1.e1
and;O;O
minocycline;B-drug;B-DDI-MedLine.d47.s1.e2
was;O;O
investigated;O;O
.;O;O
DDI-MedLine.d47.s2;;
Buforin;B-drug_n;B-DDI-MedLine.d47.s2.e0
II;I-drug_n;I-DDI-MedLine.d47.s2.e0
showed;O;O
moderate;O;O
activity;O;O
,;O;O
which;O;O
increased;O;O
with;O;O
increasing;O;O
concentration;O;O
to;O;O
55.7;O;O
%;O;O
suppression;O;O
of;O;O
growth;O;O
at;O;O
20;O;O
microM.;O;O
DDI-MedLine.d47.s3;;
Moreover;O;O
,;O;O
its;O;O
activity;O;O
was;O;O
enhanced;O;O
when;O;O
it;O;O
was;O;O
combined;O;O
with;O;O
either;O;O
azithromycin;B-drug;B-DDI-MedLine.d47.s3.e0
or;O;O
minocycline;B-drug;B-DDI-MedLine.d47.s3.e1
with;O;O
90;O;O
%;O;O
parasite;O;O
reduction;O;O
at;O;O
the;O;O
highest;O;O
concentration;O;O
tested;O;O
.;O;O
DDI-MedLine.d47.s4;;
Buforin;B-drug_n;B-DDI-MedLine.d47.s4.e0
II;I-drug_n;I-DDI-MedLine.d47.s4.e0
may;O;O
be;O;O
active;O;O
in;O;O
inhibiting;O;O
Cryptosporidium;O;O
parvum;O;O
growth;O;O
in;O;O
vitro;O;O
upon;O;O
combination;O;O
with;O;O
either;O;O
azithromycin;B-drug;B-DDI-MedLine.d47.s4.e1
or;O;O
minocycline;B-drug;B-DDI-MedLine.d47.s4.e2
.;O;O
DDI-MedLine.d112.s0;;
Effect;O;O
of;O;O
dofetillide;B-drug;B-DDI-MedLine.d112.s0.e0
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d112.s0.e1
.;O;O
DDI-MedLine.d112.s1;;
The;O;O
effect;O;O
of;O;O
dofetilide;B-drug;B-DDI-MedLine.d112.s1.e0
on;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d112.s1.e1
was;O;O
evaluated;O;O
in;O;O
a;O;O
randomized;O;O
,;O;O
double;O;O
-;O;O
blind;O;O
study;O;O
.;O;O
DDI-MedLine.d112.s2;;
Five;O;O
days;O;O
of;O;O
dofetilide;B-drug;B-DDI-MedLine.d112.s2.e0
treatment;O;O
did;O;O
not;O;O
significantly;O;O
affect;O;O
steady;O;O
-;O;O
state;O;O
pharmacokinetic;O;O
variables;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d112.s2.e1
compared;O;O
with;O;O
placebo;O;O
,;O;O
DDI-MedLine.d112.s3;;
therefore;O;O
,;O;O
the;O;O
use;O;O
of;O;O
dofetilide;B-drug;B-DDI-MedLine.d112.s3.e0
does;O;O
not;O;O
necessitate;O;O
an;O;O
adjustment;O;O
in;O;O
digoxin;B-drug;B-DDI-MedLine.d112.s3.e1
dose;O;O
to;O;O
maintain;O;O
therapeutic;O;O
digoxin;O;O
levels;O;O
.;O;O
DDI-MedLine.d19.s0;;
Anaesthesia;O;O
and;O;O
the;O;O
epileptic;O;O
pateint;O;O
.;O;O
DDI-MedLine.d19.s1;;
A;O;O
review;O;O
.;O;O

;O;O
DDI-MedLine.d19.s2;;
A;O;O
review;O;O
is;O;O
presented;O;O
of;O;O
some;O;O
of;O;O
the;O;O
problems;O;O
that;O;O
may;O;O
arise;O;O
in;O;O
association;O;O
with;O;O
anaesthesia;O;O
for;O;O
epileptic;O;O
patients;O;O
.;O;O
DDI-MedLine.d19.s3;;
There;O;O
is;O;O
the;O;O
possibility;O;O
of;O;O
precipitating;O;O
anticonvulsant;O;O
drug;O;O
toxicity;O;O
.;O;O
DDI-MedLine.d19.s4;;
Numerous;O;O
drug;O;O
interactions;O;O
are;O;O
possible;O;O
with;O;O
some;O;O
anticonvulsant;B-group;B-DDI-MedLine.d19.s4.e0
agents;I-group;I-DDI-MedLine.d19.s4.e0
,;O;O
such;O;O
as;O;O
phenobarbitone;B-drug;B-DDI-MedLine.d19.s4.e1
and;O;O
phenytoin;B-drug;B-DDI-MedLine.d19.s4.e2
,;O;O
which;O;O
affect;O;O
hepatic;O;O
microsomal;O;O
enzyme;O;O
systems;O;O
.;O;O
DDI-MedLine.d19.s5;;
There;O;O
is;O;O
the;O;O
risk;O;O
of;O;O
convulsions;O;O
occurring;O;O
in;O;O
susceptible;O;O
patients;O;O
following;O;O
the;O;O
use;O;O
of;O;O
the;O;O
new;O;O
anaesthetic;B-group;B-DDI-MedLine.d19.s5.e0
agents;I-group;I-DDI-MedLine.d19.s5.e0
which;O;O
are;O;O
capable;O;O
of;O;O
inducing;O;O
CNS;O;O
excitability;O;O
.;O;O
DDI-MedLine.d16.s0;;
Interaction;O;O
of;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s0.e0
and;O;O
halothane;B-drug;B-DDI-MedLine.d16.s0.e1
in;O;O
rats;O;O
.;O;O

;O;O
DDI-MedLine.d16.s1;;
The;O;O
interaction;O;O
of;O;O
intramuscularly;O;O
injected;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s1.e0
and;O;O
its;O;O
N;O;O
-;O;O
demethylated;O;O
metabolite;O;O
(;O;O
metabolite;O;O
I;O;O
);O;O
with;O;O
halothane;B-drug;B-DDI-MedLine.d16.s1.e1
was;O;O
evaluated;O;O
in;O;O
rats;O;O
.;O;O
DDI-MedLine.d16.s2;;
Five;O;O
,;O;O
10;O;O
,;O;O
20;O;O
,;O;O
or;O;O
50;O;O
mg;O;O
/;O;O
kg;O;O
of;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s2.e0
alone;O;O
or;O;O
20;O;O
,;O;O
50;O;O
,;O;O
or;O;O
100;O;O
mg;O;O
/;O;O
kg;O;O
of;O;O
metabolite;O;O
I;O;O
alone;O;O
produced;O;O
less;O;O
than;O;O
10;O;O
minutes;O;O
of;O;O
hypnosis;O;O
.;O;O
DDI-MedLine.d16.s3;;
However;O;O
,;O;O
halothane;B-drug;B-DDI-MedLine.d16.s3.e0
anesthetic;O;O
requirement;O;O
(;O;O
i.e.;O;O
,;O;O
MAC;O;O
);O;O
was;O;O
depressed;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
fashion;O;O
as;O;O
much;O;O
as;O;O
56;O;O
%;O;O
1;O;O
-;O;O
2;O;O
hours;O;O
and;O;O
as;O;O
much;O;O
as;O;O
14;O;O
%;O;O
5;O;O
-;O;O
6;O;O
hours;O;O
after;O;O
injection;O;O
of;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s3.e1
,;O;O
50;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
i;O;O
m;O;O
.;O;O
DDI-MedLine.d16.s4;;
The;O;O
reduction;O;O
in;O;O
MAC;O;O
was;O;O
correlated;O;O
with;O;O
brain;O;O
levels;O;O
of;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s4.e0
or;O;O
metabolite;O;O
I;O;O
,;O;O
suggesting;O;O
a;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s4.e1
:;O;O
metabolite;O;O
I;O;O
potency;O;O
ration;O;O
of;O;O
3:1;O;O
.;O;O
DDI-MedLine.d16.s5;;
The;O;O
half;O;O
-;O;O
life;O;O
of;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s5.e0
in;O;O
plasma;O;O
and;O;O
brain;O;O
was;O;O
longer;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
halothane;B-drug;B-DDI-MedLine.d16.s5.e1
than;O;O
when;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s5.e2
was;O;O
given;O;O
alone;O;O
.;O;O
DDI-MedLine.d16.s6;;
It;O;O
is;O;O
concluded;O;O
that;O;O
ketamine;B-drug;B-DDI-MedLine.d16.s6.e0
is;O;O
not;O;O
a;O;O
short;O;O
-;O;O
acting;O;O
drug;O;O
and;O;O
that;O;O
concomitant;O;O
use;O;O
with;O;O
halothane;B-drug;B-DDI-MedLine.d16.s6.e1
would;O;O
be;O;O
expected;O;O
to;O;O
prolong;O;O
further;O;O
the;O;O
duration;O;O
of;O;O
its;O;O
action;O;O
on;O;O
the;O;O
central;O;O
nervous;O;O
system;O;O
.;O;O
DDI-MedLine.d116.s0;;
Rifampin;B-drug;B-DDI-MedLine.d116.s0.e0
and;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s0.e1
:;O;O
a;O;O
drug;O;O
interaction;O;O
.;O;O
DDI-MedLine.d116.s1;;
The;O;O
drug;O;O
interaction;O;O
between;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s1.e0
and;O;O
rifampin;B-drug;B-DDI-MedLine.d116.s1.e1
is;O;O
not;O;O
well;O;O
known;O;O
.;O;O
DDI-MedLine.d116.s2;;
Rifampin;B-drug;B-DDI-MedLine.d116.s2.e0
has;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
the;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s2.e1
requirements;O;O
in;O;O
human;O;O
subjects;O;O
ingesting;O;O
these;O;O
agents;O;O
simultaneously;O;O
.;O;O
DDI-MedLine.d116.s3;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
rifampin;B-drug;B-DDI-MedLine.d116.s3.e0
and;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s3.e1
resulted;O;O
in;O;O
the;O;O
need;O;O
for;O;O
an;O;O
unusually;O;O
high;O;O
maintenance;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s3.e2
(;O;O
20;O;O
mg;O;O
per;O;O
day;O;O
);O;O
in;O;O
order;O;O
to;O;O
produce;O;O
a;O;O
therapeutic;O;O
effect;O;O
.;O;O
DDI-MedLine.d116.s4;;
Withdrawal;O;O
of;O;O
rifampin;B-drug;B-DDI-MedLine.d116.s4.e0
decreased;O;O
the;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s4.e1
requirement;O;O
by;O;O
50;O;O
%;O;O
.;O;O
DDI-MedLine.d116.s5;;
This;O;O
effect;O;O
may;O;O
be;O;O
mediated;O;O
by;O;O
the;O;O
ability;O;O
of;O;O
rifampin;B-drug;B-DDI-MedLine.d116.s5.e0
to;O;O
induce;O;O
microsomal;O;O
enzymes;O;O
and;O;O
,;O;O
thus;O;O
,;O;O
the;O;O
catabolism;O;O
of;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s5.e1
.;O;O
DDI-MedLine.d116.s6;;
The;O;O
effect;O;O
of;O;O
rifampin;B-drug;B-DDI-MedLine.d116.s6.e0
on;O;O
the;O;O
warfarin;B-drug;B-DDI-MedLine.d116.s6.e1
requirement;O;O
of;O;O
our;O;O
patient;O;O
appeared;O;O
to;O;O
be;O;O
maximal;O;O
5;O;O
to;O;O
7;O;O
days;O;O
after;O;O
the;O;O
initiation;O;O
of;O;O
rifampin;B-drug;B-DDI-MedLine.d116.s6.e2
and;O;O
extended;O;O
a;O;O
similar;O;O
length;O;O
of;O;O
time;O;O
after;O;O
rifampin;B-drug;B-DDI-MedLine.d116.s6.e3
withdrawal;O;O
.;O;O
DDI-MedLine.d116.s7;;
This;O;O
interaction;O;O
appears;O;O
to;O;O
be;O;O
clinically;O;O
significant;O;O
.;O;O
DDI-MedLine.d76.s0;;
Thiolated;B-drug_n;B-DDI-MedLine.d76.s0.e0
carboxymethylcellulose;I-drug_n;I-DDI-MedLine.d76.s0.e0
:;O;O
in;O;O
vitro;O;O
evaluation;O;O
of;O;O
its;O;O
permeation;O;O
enhancing;O;O
effect;O;O
on;O;O
peptide;O;O
drugs;O;O
.;O;O
DDI-MedLine.d76.s1;;
The;O;O
purpose;O;O
of;O;O
this;O;O
study;O;O
was;O;O
to;O;O
evaluate;O;O
the;O;O
effect;O;O
of;O;O
sodium;B-drug_n;B-DDI-MedLine.d76.s1.e0
carboxymethylcellulose;I-drug_n;I-DDI-MedLine.d76.s1.e0
(;O;O
NaCMC;B-drug_n;B-DDI-MedLine.d76.s1.e1
);O;O
and;O;O
carboxymethylcellulose;B-drug_n;B-DDI-MedLine.d76.s1.e2
-;I-drug_n;I-DDI-MedLine.d76.s1.e2
cysteine;I-drug_n;I-DDI-MedLine.d76.s1.e2
(;O;O
CMC;B-drug_n;B-DDI-MedLine.d76.s1.e3
-;I-drug_n;I-DDI-MedLine.d76.s1.e3
Cys;I-drug_n;I-DDI-MedLine.d76.s1.e3
);O;O
conjugates;O;O
on;O;O
the;O;O
intestinal;O;O
permeation;O;O
of;O;O
sodium;B-drug;B-DDI-MedLine.d76.s1.e4
fluorescein;I-drug;I-DDI-MedLine.d76.s1.e4
(;O;O
NaFlu;B-drug;B-DDI-MedLine.d76.s1.e5
);O;O
and;O;O
model;O;O
peptide;O;O
drugs;O;O
,;O;O
bacitracin;B-drug;B-DDI-MedLine.d76.s1.e6
and;O;O
insulin;B-drug;B-DDI-MedLine.d76.s1.e7
.;O;O
DDI-MedLine.d76.s2;;
Cysteine;B-drug;B-DDI-MedLine.d76.s2.e0
was;O;O
covalently;O;O
linked;O;O
to;O;O
carbodiimide;O;O
activated;O;O
NaCMC;B-drug_n;B-DDI-MedLine.d76.s2.e1
.;O;O
DDI-MedLine.d76.s3;;
Iodometric;O;O
titration;O;O
of;O;O
the;O;O
polymer;O;O
conjugates;O;O
was;O;O
used;O;O
to;O;O
determine;O;O
the;O;O
extent;O;O
of;O;O
immobilised;O;O
cysteine;B-drug;B-DDI-MedLine.d76.s3.e0
.;O;O
DDI-MedLine.d76.s4;;
Permeation;O;O
studies;O;O
were;O;O
performed;O;O
on;O;O
guinea;O;O
pig;O;O
small;O;O
intestinal;O;O
mucosa;O;O
mounted;O;O
in;O;O
Ussing;O;O
-;O;O
type;O;O
chamber;O;O
.;O;O
DDI-MedLine.d76.s5;;
Unmodified;O;O
NaCMC;B-drug_n;B-DDI-MedLine.d76.s5.e0
(;O;O
1;O;O
%;O;O
m;O;O
/;O;O
v;O;O
);O;O
significantly;O;O
improved;O;O
the;O;O
transport;O;O
ratio;O;O
(;O;O
R=;O;O
P(app;O;O
);O;O
polymer;O;O
/;O;O
P(app;O;O
);O;O
control;O;O
);O;O
of;O;O
NaFlu;B-drug;B-DDI-MedLine.d76.s5.e1
to;O;O
1.3;O;O
and;O;O
1;O;O
%;O;O
(;O;O
m;O;O
/;O;O
v;O;O
);O;O
NaCMC;B-drug_n;B-DDI-MedLine.d76.s5.e2
conjugated;O;O
with;O;O
cysteine;B-drug;B-DDI-MedLine.d76.s5.e3
further;O;O
enhanced;O;O
the;O;O
permeation;O;O
.;O;O
DDI-MedLine.d76.s6;;
Cysteine;B-drug;B-DDI-MedLine.d76.s6.e0
conjugation;O;O
at;O;O
3.6;O;O
,;O;O
5.3;O;O
and;O;O
7.3;O;O
%;O;O
(;O;O
m;O;O
/;O;O
m;O;O
);O;O
resulted;O;O
in;O;O
R;O;O
-;O;O
values;O;O
of;O;O
1.4;O;O
,;O;O
1.7;O;O
and;O;O
1.8;O;O
,;O;O
respectively;O;O
.;O;O
DDI-MedLine.d76.s7;;
Decreasing;O;O
the;O;O
concentration;O;O
of;O;O
CMC;B-drug_n;B-DDI-MedLine.d76.s7.e0
-;I-drug_n;I-DDI-MedLine.d76.s7.e0
Cys;I-drug_n;I-DDI-MedLine.d76.s7.e0
,;O;O
exhibiting;O;O
7.3;O;O
%;O;O
(;O;O
m;O;O
/;O;O
m;O;O
);O;O
of;O;O
immobilised;O;O
cysteine;B-drug;B-DDI-MedLine.d76.s7.e1
(;O;O
CMC;O;O
-;O;O
Cys7.3;O;O
);O;O
from;O;O
1;O;O
%;O;O
(;O;O
m;O;O
/;O;O
v;O;O
);O;O
to;O;O
0.5;O;O
%;O;O
(;O;O
m;O;O
/;O;O
v;O;O
);O;O
decreased;O;O
the;O;O
R;O;O
-;O;O
value;O;O
of;O;O
NaFlu;B-drug;B-DDI-MedLine.d76.s7.e2
from;O;O
1.8;O;O
to;O;O
1.2;O;O
.;O;O
DDI-MedLine.d76.s8;;
NaCMC;B-drug_n;B-DDI-MedLine.d76.s8.e0
at;O;O
1;O;O
%;O;O
(;O;O
m;O;O
/;O;O
v;O;O
);O;O
in;O;O
the;O;O
presence;O;O
of;O;O
free;O;O
cysteine;B-drug;B-DDI-MedLine.d76.s8.e1
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
R;O;O
-;O;O
value;O;O
of;O;O
NaFlu;B-drug;B-DDI-MedLine.d76.s8.e2
compared;O;O
to;O;O
NaCMC;B-drug_n;B-DDI-MedLine.d76.s8.e3
alone;O;O
.;O;O
DDI-MedLine.d76.s9;;
Formulation;O;O
of;O;O
fluorescence;O;O
labelled;O;O
bacitracin;B-drug;B-DDI-MedLine.d76.s9.e0
and;O;O
insulin;B-drug;B-DDI-MedLine.d76.s9.e1
in;O;O
unconjugated;O;O
NaCMC;B-drug_n;B-DDI-MedLine.d76.s9.e2
(;O;O
1;O;O
%;O;O
m;O;O
/;O;O
v;O;O
);O;O
did;O;O
not;O;O
significantly;O;O
improve;O;O
the;O;O
permeation;O;O
,;O;O
however;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
1;O;O
%;O;O
(;O;O
m;O;O
/;O;O
v;O;O
);O;O
CMC;B-drug_n;B-DDI-MedLine.d76.s9.e3
-;I-drug_n;I-DDI-MedLine.d76.s9.e3
Cys7.3;I-drug_n;I-DDI-MedLine.d76.s9.e3
a;O;O
significantly;O;O
improved;O;O
permeation;O;O
was;O;O
observed;O;O
(;O;O
R=;O;O
1.3;O;O
);O;O
.;O;O
DDI-MedLine.d76.s10;;
Conjugation;O;O
at;O;O
NaCMC;B-drug_n;B-DDI-MedLine.d76.s10.e0
with;O;O
cysteine;B-drug;B-DDI-MedLine.d76.s10.e1
moieties;O;O
significantly;O;O
improves;O;O
the;O;O
intestinal;O;O
permeation;O;O
of;O;O
the;O;O
hydrophilic;O;O
molecule;O;O
NaFlu;B-drug;B-DDI-MedLine.d76.s10.e2
and;O;O
the;O;O
model;O;O
peptide;O;O
drugs;O;O
bacitracin;B-drug;B-DDI-MedLine.d76.s10.e3
and;O;O
insulin;B-drug;B-DDI-MedLine.d76.s10.e4
in;O;O
vitro;O;O
,;O;O
therefore;O;O
this;O;O
conjugated;O;O
system;O;O
maybe;O;O
useful;O;O
for;O;O
peroral;O;O
administration;O;O
of;O;O
peptide;O;O
drugs;O;O
in;O;O
the;O;O
future;O;O
.;O;O
DDI-MedLine.d92.s0;;
Systemic;O;O
antibiotic;B-group;B-DDI-MedLine.d92.s0.e0
agents;I-group;I-DDI-MedLine.d92.s0.e0
.;O;O
DDI-MedLine.d92.s1;;
Understanding;O;O
the;O;O
breadth;O;O
of;O;O
systemic;O;O
antimicrobial;B-group;B-DDI-MedLine.d92.s1.e0
agents;I-group;I-DDI-MedLine.d92.s1.e0
available;O;O
for;O;O
use;O;O
by;O;O
the;O;O
dermatologist;O;O
and;O;O
their;O;O
associated;O;O
side;O;O
-;O;O
effect;O;O
profiles;O;O
and;O;O
drug;O;O
interactions;O;O
allows;O;O
the;O;O
clinician;O;O
to;O;O
offer;O;O
patients;O;O
optimal;O;O
care;O;O
in;O;O
the;O;O
management;O;O
of;O;O
cutaneous;O;O
infectious;O;O
disease;O;O
.;O;O
DDI-MedLine.d65.s0;;
Drug;O;O
interactions;O;O
:;O;O
How;O;O
to;O;O
identify;O;O
them;O;O
.;O;O
DDI-MedLine.d65.s1;;
Interactions;O;O
between;O;O
theraputic;O;O
agents;O;O
have;O;O
been;O;O
recognized;O;O
as;O;O
increasingly;O;O
important;O;O
causes;O;O
of;O;O
drug;O;O
at;O;O
their;O;O
usual;O;O
recommended;O;O
dose;O;O
may;O;O
,;O;O
under;O;O
certain;O;O
conditions;O;O
,;O;O
produce;O;O
toxicity;O;O
of;O;O
life;O;O
-;O;O
endangering;O;O
proportions;O;O
.;O;O
DDI-MedLine.d65.s2;;
While;O;O
the;O;O
recognition;O;O
of;O;O
drug;O;O
toxicity;O;O
resulting;O;O
from;O;O
interactions;O;O
is;O;O
of;O;O
importance;O;O
to;O;O
all;O;O
physciains;O;O
,;O;O
it;O;O
is;O;O
especially;O;O
so;O;O
for;O;O
the;O;O
clinician;O;O
responsible;O;O
for;O;O
the;O;O
welfare;O;O
of;O;O
those;O;O
in;O;O
the;O;O
aerospace;O;O
environment;O;O
.;O;O
DDI-MedLine.d65.s3;;
This;O;O
paper;O;O
attempts;O;O
to;O;O
provide;O;O
a;O;O
basis;O;O
for;O;O
the;O;O
understanding;O;O
and;O;O
identifications;O;O
of;O;O
important;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-MedLine.d65.s4;;
Guidelines;O;O
are;O;O
provided;O;O
to;O;O
assist;O;O
the;O;O
clinician;O;O
in;O;O
his;O;O
logical;O;O
approach;O;O
to;O;O
the;O;O
identification;O;O
of;O;O
drug;O;O
interactions;O;O
when;O;O
serious;O;O
drug;O;O
toxicity;O;O
is;O;O
encountered;O;O
in;O;O
a;O;O
pateint;O;O
.;O;O
DDI-MedLine.d65.s5;;
Only;O;O
with;O;O
knowledge;O;O
of;O;O
the;O;O
interaction;O;O
can;O;O
the;O;O
therapeutic;O;O
regimen;O;O
be;O;O
altered;O;O
so;O;O
as;O;O
to;O;O
provide;O;O
therapeutic;O;O
levels;O;O
of;O;O
necessary;O;O
drugs;O;O
while;O;O
avoiding;O;O
toxicity;O;O
.;O;O
DDI-MedLine.d3.s0;;
Pharmacokinetic;O;O
Interaction;O;O
between;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s0.e0
and;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s0.e1
or;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s0.e2
in;O;O
healthy;O;O
males;O;O
.;O;O

;O;O
DDI-MedLine.d3.s1;;
The;O;O
objective;O;O
of;O;O
this;O;O
study;O;O
was;O;O
to;O;O
determine;O;O
if;O;O
there;O;O
is;O;O
a;O;O
pharmacokinetic;O;O
interaction;O;O
when;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s1.e0
is;O;O
given;O;O
with;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s1.e1
or;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s1.e2
and;O;O
to;O;O
determine;O;O
the;O;O
effects;O;O
of;O;O
these;O;O
drugs;O;O
on;O;O
the;O;O
erythromycin;O;O
breath;O;O
test;O;O
(;O;O
ERMBT;O;O
);O;O
.;O;O
DDI-MedLine.d3.s2;;
Twenty;O;O
-;O;O
four;O;O
healthy;O;O
male;O;O
subjects;O;O
were;O;O
randomized;O;O
to;O;O
one;O;O
of;O;O
two;O;O
cohorts;O;O
.;O;O
DDI-MedLine.d3.s3;;
All;O;O
subjects;O;O
received;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s3.e0
(;O;O
1,200;O;O
mg;O;O
twice;O;O
a;O;O
day;O;O
);O;O
for;O;O
4;O;O
days;O;O
,;O;O
followed;O;O
by;O;O
a;O;O
7;O;O
-;O;O
day;O;O
washout;O;O
period;O;O
,;O;O
followed;O;O
by;O;O
either;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s3.e1
(;O;O
300;O;O
mg;O;O
once;O;O
a;O;O
day;O;O
[;O;O
QD;O;O
];O;O
);O;O
(;O;O
cohort;O;O
1;O;O
);O;O
or;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s3.e2
(;O;O
600;O;O
mg;O;O
QD;O;O
);O;O
(;O;O
cohort;O;O
2;O;O
);O;O
for;O;O
14;O;O
days;O;O
.;O;O
DDI-MedLine.d3.s4;;
Cohort;O;O
1;O;O
then;O;O
received;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s4.e0
plus;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s4.e1
for;O;O
10;O;O
days;O;O
,;O;O
and;O;O
cohort;O;O
2;O;O
received;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s4.e2
plus;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s4.e3
for;O;O
4;O;O
days;O;O
.;O;O
DDI-MedLine.d3.s5;;
Serial;O;O
plasma;O;O
and;O;O
urine;O;O
samples;O;O
for;O;O
measurement;O;O
of;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s5.e0
,;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s5.e1
,;O;O
and;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s5.e2
and;O;O
their;O;O
25;B-drug_n;B-DDI-MedLine.d3.s5.e3
-;I-drug_n;I-DDI-MedLine.d3.s5.e3
O;I-drug_n;I-DDI-MedLine.d3.s5.e3
-;I-drug_n;I-DDI-MedLine.d3.s5.e3
desacetyl;I-drug_n;I-DDI-MedLine.d3.s5.e3
metabolites;I-drug_n;I-DDI-MedLine.d3.s5.e3
,;O;O
were;O;O
measured;O;O
by;O;O
high;O;O
-;O;O
performance;O;O
liquid;O;O
chromatography;O;O
.;O;O
DDI-MedLine.d3.s6;;
Rifabutin;B-drug;B-DDI-MedLine.d3.s6.e0
did;O;O
not;O;O
significantly;O;O
affect;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s6.e1
's;O;O
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d3.s7;;
Amprenavir;B-drug;B-DDI-MedLine.d3.s7.e0
significantly;O;O
increased;O;O
the;O;O
area;O;O
under;O;O
the;O;O
curve;O;O
at;O;O
steady;O;O
state;O;O
(;O;O
AUC(ss;O;O
);O;O
);O;O
of;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s7.e1
by;O;O
2.93;O;O
-;O;O
fold;O;O
and;O;O
the;O;O
AUC(ss;O;O
);O;O
of;O;O
25;B-drug_n;B-DDI-MedLine.d3.s7.e2
-;I-drug_n;I-DDI-MedLine.d3.s7.e2
O;I-drug_n;I-DDI-MedLine.d3.s7.e2
-;I-drug_n;I-DDI-MedLine.d3.s7.e2
desacetylrifabutin;I-drug_n;I-DDI-MedLine.d3.s7.e2
by;O;O
13.3;O;O
-;O;O
fold;O;O
.;O;O
DDI-MedLine.d3.s8;;
Rifampin;B-drug;B-DDI-MedLine.d3.s8.e0
significantly;O;O
decreased;O;O
the;O;O
AUC(ss;O;O
);O;O
of;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s8.e1
by;O;O
82;O;O
%;O;O
,;O;O
but;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s8.e2
had;O;O
no;O;O
effect;O;O
on;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s8.e3
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d3.s9;;
Amprenavir;B-drug;B-DDI-MedLine.d3.s9.e0
decreased;O;O
the;O;O
results;O;O
of;O;O
the;O;O
ERMBT;O;O
by;O;O
83;O;O
%;O;O
.;O;O
DDI-MedLine.d3.s10;;
The;O;O
results;O;O
of;O;O
the;O;O
ERMBT;O;O
after;O;O
2;O;O
weeks;O;O
of;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s10.e0
and;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s10.e1
therapy;O;O
were;O;O
increased;O;O
187;O;O
and;O;O
156;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-MedLine.d3.s11;;
Amprenavir;B-drug;B-DDI-MedLine.d3.s11.e0
plus;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s11.e1
was;O;O
well;O;O
tolerated;O;O
.;O;O
DDI-MedLine.d3.s12;;
Amprenavir;B-drug;B-DDI-MedLine.d3.s12.e0
plus;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s12.e1
was;O;O
poorly;O;O
tolerated;O;O
,;O;O
and;O;O
5;O;O
of;O;O
11;O;O
subjects;O;O
discontinued;O;O
therapy;O;O
.;O;O
DDI-MedLine.d3.s13;;
Rifampin;B-drug;B-DDI-MedLine.d3.s13.e0
markedly;O;O
increases;O;O
the;O;O
metabolic;O;O
clearance;O;O
of;O;O
amprenavir;B-drug;B-DDI-MedLine.d3.s13.e1
,;O;O
and;O;O
coadministration;O;O
is;O;O
contraindicated;O;O
.;O;O
DDI-MedLine.d3.s14;;
Amprenavir;B-drug;B-DDI-MedLine.d3.s14.e0
significantly;O;O
decreases;O;O
clearance;O;O
of;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s14.e1
and;O;O
25;B-drug_n;B-DDI-MedLine.d3.s14.e2
-;I-drug_n;I-DDI-MedLine.d3.s14.e2
O;I-drug_n;I-DDI-MedLine.d3.s14.e2
-;I-drug_n;I-DDI-MedLine.d3.s14.e2
desacetylrifabutin;I-drug_n;I-DDI-MedLine.d3.s14.e2
,;O;O
and;O;O
the;O;O
combination;O;O
is;O;O
poorly;O;O
tolerated;O;O
.;O;O
DDI-MedLine.d3.s15;;
Amprenavir;B-drug;B-DDI-MedLine.d3.s15.e0
inhibits;O;O
the;O;O
ERMBT;O;O
,;O;O
and;O;O
rifampin;B-drug;B-DDI-MedLine.d3.s15.e1
and;O;O
rifabutin;B-drug;B-DDI-MedLine.d3.s15.e2
are;O;O
equipotent;O;O
inducers;O;O
of;O;O
the;O;O
ERMBT;O;O
.;O;O
DDI-MedLine.d28.s0;;
New;O;O
oral;O;O
therapies;O;O
for;O;O
type;O;O
2;O;O
diabetes;O;O
mellitus;O;O
:;O;O
The;O;O
glitazones;B-group;B-DDI-MedLine.d28.s0.e0
or;O;O
insulin;O;O
sensitizers;O;O
.;O;O

;O;O
DDI-MedLine.d28.s1;;
Type;O;O
2;O;O
diabetes;O;O
mellitus;O;O
is;O;O
a;O;O
growing;O;O
problem;O;O
not;O;O
only;O;O
in;O;O
the;O;O
United;O;O
States;O;O
but;O;O
also;O;O
across;O;O
the;O;O
world;O;O
.;O;O
DDI-MedLine.d28.s2;;
There;O;O
is;O;O
now;O;O
strong;O;O
evidence;O;O
that;O;O
intensive;O;O
control;O;O
of;O;O
blood;O;O
glucose;O;O
can;O;O
significantly;O;O
reduce;O;O
and;O;O
retard;O;O
the;O;O
microvascular;O;O
complications;O;O
of;O;O
retinopathy;O;O
,;O;O
nephropathy;O;O
,;O;O
and;O;O
neuropathy;O;O
.;O;O
DDI-MedLine.d28.s3;;
Ultimately;O;O
however;O;O
,;O;O
up;O;O
to;O;O
80;O;O
%;O;O
of;O;O
type;O;O
2;O;O
diabetics;O;O
die;O;O
from;O;O
macrovascular;O;O
cardiovascular;O;O
disease;O;O
.;O;O
DDI-MedLine.d28.s4;;
This;O;O
increased;O;O
incidence;O;O
of;O;O
atherosclerotic;O;O
disease;O;O
is;O;O
intricately;O;O
associated;O;O
with;O;O
insulin;O;O
resistance;O;O
,;O;O
which;O;O
is;O;O
a;O;O
major;O;O
pathophysiologic;O;O
abnormality;O;O
in;O;O
type;O;O
2;O;O
diabetes;O;O
.;O;O
DDI-MedLine.d28.s5;;
There;O;O
is;O;O
strong;O;O
evidence;O;O
that;O;O
insulin;O;O
resistance;O;O
is;O;O
involved;O;O
in;O;O
the;O;O
development;O;O
of;O;O
not;O;O
only;O;O
hyperglycemia;O;O
,;O;O
but;O;O
also;O;O
dyslipidemia;O;O
,;O;O
hypertension;O;O
,;O;O
hypercoagulation;O;O
,;O;O
vasculopathy;O;O
,;O;O
and;O;O
ultimately;O;O
atherosclerotic;O;O
cardiovascular;O;O
disease;O;O
.;O;O
DDI-MedLine.d28.s6;;
This;O;O
cluster;O;O
of;O;O
metabolic;O;O
abnormalities;O;O
has;O;O
been;O;O
termed;O;O
the;O;O
insulin;O;O
resistance;O;O
or;O;O
cardiovascular;O;O
dysmetabolic;O;O
syndrome;O;O
.;O;O
DDI-MedLine.d28.s7;;
The;O;O
thiazolidinediones;B-group;B-DDI-MedLine.d28.s7.e0
(;O;O
rosiglitazone;B-drug;B-DDI-MedLine.d28.s7.e1
and;O;O
pioglitazone;B-drug;B-DDI-MedLine.d28.s7.e2
);O;O
,;O;O
a;O;O
new;O;O
class;O;O
of;O;O
oral;O;O
antidiabetic;B-group;B-DDI-MedLine.d28.s7.e3
agents;I-group;I-DDI-MedLine.d28.s7.e3
,;O;O
are;O;O
";O;O
insulin;O;O
sensitizers;O;O
";O;O
DDI-MedLine.d28.s8;;
and;O;O
exert;O;O
direct;O;O
effects;O;O
on;O;O
the;O;O
mechanisms;O;O
of;O;O
insulin;O;O
resistance;O;O
.;O;O
DDI-MedLine.d28.s9;;
These;O;O
effects;O;O
not;O;O
only;O;O
improve;O;O
insulin;O;O
sensitivity;O;O
and;O;O
glycemic;O;O
control;O;O
with;O;O
reduced;O;O
insulin;O;O
requirements;O;O
,;O;O
but;O;O
also;O;O
have;O;O
potentially;O;O
favorable;O;O
effects;O;O
on;O;O
other;O;O
components;O;O
of;O;O
the;O;O
cardiovascular;O;O
dysmetabolic;O;O
syndrome;O;O
.;O;O
DDI-MedLine.d28.s10;;
Long;O;O
-;O;O
term;O;O
studies;O;O
are;O;O
needed;O;O
to;O;O
determine;O;O
whether;O;O
the;O;O
insulin;O;O
-;O;O
sensitizing;O;O
effects;O;O
of;O;O
the;O;O
glitazones;B-group;B-DDI-MedLine.d28.s10.e0
can;O;O
prevent;O;O
or;O;O
delay;O;O
premature;O;O
atherosclerotic;O;O
cardiovascular;O;O
disease;O;O
,;O;O
morbidity;O;O
,;O;O
and;O;O
death;O;O
.;O;O
DDI-MedLine.d74.s0;;
Responses;O;O
to;O;O
arginine;B-drug;B-DDI-MedLine.d74.s0.e0
of;O;O
the;O;O
perfused;O;O
pancreas;O;O
of;O;O
the;O;O
genetically;O;O
diabetic;O;O
Chinese;O;O
hamster;O;O
.;O;O

;O;O
DDI-MedLine.d74.s1;;
Nonketotic;O;O
,;O;O
genetically;O;O
diabetic;O;O
Cinese;O;O
hamsters;O;O
show;O;O
subnormal;O;O
pancreatic;O;O
insulin;O;O
release;O;O
and;O;O
impaired;O;O
suppression;O;O
of;O;O
glucagon;O;O
in;O;O
response;O;O
to;O;O
glucose;O;O
.;O;O
DDI-MedLine.d74.s2;;
To;O;O
study;O;O
the;O;O
pancreatic;O;O
effects;O;O
of;O;O
other;O;O
agents;O;O
,;O;O
dynamic;O;O
insulin;O;O
and;O;O
glucagon;O;O
release;O;O
was;O;O
measured;O;O
from;O;O
the;O;O
in;O;O
vitro;O;O
perfused;O;O
pancreases;O;O
of;O;O
normal;O;O
and;O;O
diabetic;O;O
Chinese;O;O
hamsters;O;O
in;O;O
response;O;O
to;O;O
various;O;O
combinations;O;O
of;O;O
arginine;B-drug;B-DDI-MedLine.d74.s2.e0
(;O;O
20mM;O;O
);O;O
,;O;O
glucose;B-drug;B-DDI-MedLine.d74.s2.e1
(;O;O
100;O;O
or;O;O
150;O;O
mg;O;O
.;O;O
per;O;O
100;O;O
ml;O;O
.;O;O
);O;O
,;O;O
and;O;O
theophylline;B-drug;B-DDI-MedLine.d74.s2.e2
(;O;O
10;O;O
mM;O;O
);O;O
.;O;O
DDI-MedLine.d74.s3;;
Theophylline;B-drug;B-DDI-MedLine.d74.s3.e0
alone;O;O
caused;O;O
identical;O;O
insulin;O;O
and;O;O
glucagon;O;O
release;O;O
in;O;O
diabetics;O;O
and;O;O
normals;O;O
.;O;O
DDI-MedLine.d74.s4;;
Glucose;B-drug;B-DDI-MedLine.d74.s4.e0
,;O;O
alone;O;O
and;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
theophylline;B-drug;B-DDI-MedLine.d74.s4.e1
,;O;O
caused;O;O
subnormal;O;O
insulin;O;O
release;O;O
and;O;O
less;O;O
suppression;O;O
of;O;O
glucagon;O;O
release;O;O
in;O;O
the;O;O
diabectics;O;O
than;O;O
in;O;O
the;O;O
normals;O;O
.;O;O
DDI-MedLine.d74.s5;;
Arginine;B-drug;B-DDI-MedLine.d74.s5.e0
,;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
glucose;B-drug;B-DDI-MedLine.d74.s5.e1
and;O;O
theophylline;B-drug;B-DDI-MedLine.d74.s5.e2
,;O;O
caused;O;O
excessive;O;O
glucagon;O;O
release;O;O
but;O;O
nearly;O;O
normal;O;O
insulin;O;O
release;O;O
in;O;O
the;O;O
diabetics;O;O
.;O;O
DDI-MedLine.d74.s6;;
Arginine;B-drug;B-DDI-MedLine.d74.s6.e0
,;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
glucose;B-drug;B-DDI-MedLine.d74.s6.e1
or;O;O
theophylline;B-drug;B-DDI-MedLine.d74.s6.e2
,;O;O
caused;O;O
excessive;O;O
glucagon;O;O
release;O;O
in;O;O
the;O;O
diabetics;O;O
and;O;O
undetectable;O;O
insulin;O;O
release;O;O
in;O;O
either;O;O
diabetics;O;O
or;O;O
normals;O;O
.;O;O
DDI-MedLine.d74.s7;;
Pancreatic;O;O
content;O;O
after;O;O
perfusion;O;O
did;O;O
not;O;O
correlate;O;O
with;O;O
release;O;O
during;O;O
perfusion;O;O
.;O;O
DDI-MedLine.d74.s8;;
Infusion;O;O
of;O;O
arginine;B-drug;B-DDI-MedLine.d74.s8.e0
alone;O;O
markedly;O;O
decreased;O;O
the;O;O
amount;O;O
of;O;O
extractable;O;O
pancreatic;O;O
insulin;O;O
and;O;O
glucagon;O;O
.;O;O
DDI-MedLine.d74.s9;;
These;O;O
results;O;O
indicate;O;O
that;O;O
the;O;O
pancreatic;O;O
alpha;O;O
cell;O;O
of;O;O
the;O;O
diabetic;O;O
Chinese;O;O
hamster;O;O
responds;O;O
excessively;O;O
to;O;O
arginine;B-drug;B-DDI-MedLine.d74.s9.e0
,;O;O
as;O;O
is;O;O
seen;O;O
in;O;O
the;O;O
human;O;O
diabetic;O;O
.;O;O
DDI-MedLine.d74.s10;;
This;O;O
defect;O;O
is;O;O
not;O;O
related;O;O
to;O;O
acute;O;O
insulin;O;O
release;O;O
or;O;O
the;O;O
presence;O;O
of;O;O
glucose;B-drug;B-DDI-MedLine.d74.s10.e0
.;O;O
DDI-MedLine.d74.s11;;
Further;O;O
,;O;O
these;O;O
results;O;O
confirm;O;O
that;O;O
the;O;O
diabetic;O;O
Chinese;O;O
hamster;O;O
's;O;O
alpha;O;O
and;O;O
beta;O;O
cells;O;O
respond;O;O
normally;O;O
to;O;O
theophylline;B-drug;B-DDI-MedLine.d74.s11.e0
,;O;O
but;O;O
are;O;O
relatively;O;O
insensitive;O;O
to;O;O
glucose;B-drug;B-DDI-MedLine.d74.s11.e1
.;O;O
DDI-MedLine.d44.s0;;
Effects;O;O
of;O;O
etofibrate;B-drug;B-DDI-MedLine.d44.s0.e0
upon;O;O
the;O;O
metabolism;O;O
of;O;O
chylomicron;O;O
-;O;O
like;O;O
emulsions;O;O
in;O;O
patients;O;O
with;O;O
coronary;O;O
artery;O;O
disease;O;O
.;O;O
DDI-MedLine.d44.s1;;
Slow;O;O
chylomicron;O;O
intravascular;O;O
catabolism;O;O
has;O;O
been;O;O
associated;O;O
with;O;O
coronary;O;O
artery;O;O
disease;O;O
and;O;O
screening;O;O
for;O;O
drugs;O;O
that;O;O
can;O;O
speed;O;O
-;O;O
up;O;O
this;O;O
process;O;O
can;O;O
be;O;O
important;O;O
.;O;O
DDI-MedLine.d44.s2;;
In;O;O
this;O;O
study;O;O
,;O;O
the;O;O
effects;O;O
of;O;O
etofibrate;B-drug;B-DDI-MedLine.d44.s2.e0
upon;O;O
chylomicron;O;O
metabolism;O;O
was;O;O
tested;O;O
by;O;O
determination;O;O
of;O;O
the;O;O
plasma;O;O
kinetics;O;O
of;O;O
a;O;O
chylomicron;O;O
-;O;O
like;O;O
emulsion;O;O
model;O;O
in;O;O
12;O;O
patients;O;O
with;O;O
coronary;O;O
artery;O;O
disease;O;O
,;O;O
aged;O;O
59+;O;O
/;O;O
-;O;O
11;O;O
years;O;O
,;O;O
(;O;O
total;O;O
cholesterol;O;O
:;O;O
240+;O;O
/;O;O
-;O;O
41;O;O
mg;O;O
/;O;O
dl;O;O
,;O;O
triglycerides;O;O
:;O;O
188+;O;O
/;O;O
-;O;O
42;O;O
mg;O;O
/;O;O
dl;O;O
);O;O
submitted;O;O
to;O;O
a;O;O
randomized;O;O
,;O;O
crossover;O;O
,;O;O
double;O;O
-;O;O
blind;O;O
,;O;O
placebo;O;O
-;O;O
controlled;O;O
study;O;O
with;O;O
administration;O;O
of;O;O
1;O;O
g;O;O
per;O;O
day;O;O
etofibrate;B-drug;B-DDI-MedLine.d44.s2.e1
or;O;O
placebo;O;O
for;O;O
1;O;O
-;O;O
month;O;O
.;O;O
DDI-MedLine.d44.s3;;
A;O;O
1;O;O
-;O;O
month;O;O
washout;O;O
period;O;O
was;O;O
inserted;O;O
between;O;O
the;O;O
treatment;O;O
periods;O;O
.;O;O
DDI-MedLine.d44.s4;;
Patients;O;O
were;O;O
intravenously;O;O
injected;O;O
a;O;O
chylomicron;O;O
-;O;O
like;O;O
emulsion;O;O
doubly;O;O
labeled;O;O
with;O;O
14C;O;O
-;O;O
cholesteryl;O;O
oleate;O;O
and;O;O
3H;O;O
-;O;O
triolein;O;O
at;O;O
baseline;O;O
and;O;O
after;O;O
treatments;O;O
.;O;O
DDI-MedLine.d44.s5;;
After;O;O
etofibrate;B-drug;B-DDI-MedLine.d44.s5.e0
treatment;O;O
,;O;O
there;O;O
was;O;O
decrease;O;O
of;O;O
total;O;O
cholesterol;O;O
and;O;O
triglyceride;O;O
plasma;O;O
levels;O;O
and;O;O
a;O;O
trend;O;O
to;O;O
increase;O;O
high;O;O
-;O;O
density;O;O
lipoprotein;O;O
cholesterol;O;O
plasma;O;O
levels;O;O
.;O;O
DDI-MedLine.d44.s6;;
Etofibrate;B-drug;B-DDI-MedLine.d44.s6.e0
elicited;O;O
62;O;O
%;O;O
enhancement;O;O
of;O;O
post;O;O
-;O;O
heparin;B-drug;B-DDI-MedLine.d44.s6.e1
lipolytic;O;O
activity;O;O
and;O;O
100;O;O
%;O;O
increase;O;O
of;O;O
3H;O;O
-;O;O
triglyceride;O;O
fractional;O;O
clearance;O;O
rate;O;O
compared;O;O
with;O;O
placebo;O;O
treatment;O;O
.;O;O
DDI-MedLine.d44.s7;;
14C;O;O
-;O;O
cholesterol;O;O
ester;O;O
fractional;O;O
clearance;O;O
rate;O;O
was;O;O
260;O;O
%;O;O
greater;O;O
after;O;O
etofibrate;B-drug;B-DDI-MedLine.d44.s7.e0
than;O;O
after;O;O
placebo;O;O
.;O;O
DDI-MedLine.d44.s8;;
Therefore;O;O
,;O;O
a;O;O
potent;O;O
effect;O;O
of;O;O
etofibrate;B-drug;B-DDI-MedLine.d44.s8.e0
on;O;O
both;O;O
chylomicron;O;O
lipolysis;O;O
and;O;O
remnant;O;O
removal;O;O
was;O;O
achieved;O;O
,;O;O
indicating;O;O
that;O;O
this;O;O
drug;O;O
can;O;O
be;O;O
used;O;O
to;O;O
improve;O;O
this;O;O
metabolism;O;O
in;O;O
future;O;O
prospective;O;O
studies;O;O
.;O;O
DDI-MedLine.d125.s0;;
The;O;O
mode;O;O
of;O;O
toxic;O;O
action;O;O
of;O;O
the;O;O
pesticide;O;O
gliftor;B-drug_n;B-DDI-MedLine.d125.s0.e0
:;O;O
the;O;O
metabolism;O;O
of;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s0.e1
-;I-drug_n;I-DDI-MedLine.d125.s0.e1
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s0.e1
to;O;O
(;B-drug_n;B-DDI-MedLine.d125.s0.e2
-);I-drug_n;I-DDI-MedLine.d125.s0.e2
-;I-drug_n;I-DDI-MedLine.d125.s0.e2
erythro;I-drug_n;I-DDI-MedLine.d125.s0.e2
-;I-drug_n;I-DDI-MedLine.d125.s0.e2
fluorocitrate;I-drug_n;I-DDI-MedLine.d125.s0.e2
.;O;O
DDI-MedLine.d125.s1;;
The;O;O
biochemical;O;O
toxicology;O;O
of;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s1.e0
-;I-drug_n;I-DDI-MedLine.d125.s1.e0
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s1.e0
,;O;O
a;O;O
known;O;O
metabolite;O;O
of;O;O
the;O;O
major;O;O
ingredient;O;O
of;O;O
the;O;O
pesticide;O;O
Gliftor;B-drug_n;B-DDI-MedLine.d125.s1.e1
(;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s1.e2
-;I-drug_n;I-DDI-MedLine.d125.s1.e2
difluoro;I-drug_n;I-DDI-MedLine.d125.s1.e2
-;I-drug_n;I-DDI-MedLine.d125.s1.e2
2;I-drug_n;I-DDI-MedLine.d125.s1.e2
-;I-drug_n;I-DDI-MedLine.d125.s1.e2
propanol;I-drug_n;I-DDI-MedLine.d125.s1.e2
);O;O
,;O;O
was;O;O
investigated;O;O
in;O;O
vivo;O;O
and;O;O
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d125.s2;;
Rat;O;O
kidney;O;O
homogenates;O;O
supplemented;O;O
with;O;O
coenzyme;O;O
A;O;O
,;O;O
ATP;O;O
,;O;O
oxaloacetate;O;O
,;O;O
and;O;O
Mg2;O;O
+;O;O
converted;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s2.e0
-;I-drug_n;I-DDI-MedLine.d125.s2.e0
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s2.e0
to;O;O
(;B-drug_n;B-DDI-MedLine.d125.s2.e1
-);I-drug_n;I-DDI-MedLine.d125.s2.e1
-;I-drug_n;I-DDI-MedLine.d125.s2.e1
erythro;I-drug_n;I-DDI-MedLine.d125.s2.e1
-;I-drug_n;I-DDI-MedLine.d125.s2.e1
fluorocitrate;I-drug_n;I-DDI-MedLine.d125.s2.e1
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d125.s3;;
Administration;O;O
of;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s3.e0
-;I-drug_n;I-DDI-MedLine.d125.s3.e0
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s3.e0
(;O;O
100;O;O
mg;O;O
kg(;O;O
-;O;O
1;O;O
);O;O
body;O;O
weight;O;O
);O;O
to;O;O
rats;O;O
in;O;O
vivo;O;O
resulted;O;O
in;O;O
(;B-drug_n;B-DDI-MedLine.d125.s3.e1
-);I-drug_n;I-DDI-MedLine.d125.s3.e1
-;I-drug_n;I-DDI-MedLine.d125.s3.e1
erythro;I-drug_n;I-DDI-MedLine.d125.s3.e1
-;I-drug_n;I-DDI-MedLine.d125.s3.e1
fluorocitrate;I-drug_n;I-DDI-MedLine.d125.s3.e1
synthesis;O;O
in;O;O
the;O;O
kidney;O;O
,;O;O
which;O;O
was;O;O
preceded;O;O
by;O;O
an;O;O
elevation;O;O
in;O;O
fluoride;O;O
levels;O;O
and;O;O
followed;O;O
by;O;O
citrate;O;O
accumulation;O;O
.;O;O
DDI-MedLine.d125.s4;;
Animals;O;O
dosed;O;O
with;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s4.e0
-;I-drug_n;I-DDI-MedLine.d125.s4.e0
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s4.e0
did;O;O
not;O;O
display;O;O
the;O;O
2;O;O
-;O;O
3;O;O
hour;O;O
lag;O;O
phase;O;O
in;O;O
either;O;O
(;B-drug_n;B-DDI-MedLine.d125.s4.e1
-);I-drug_n;I-DDI-MedLine.d125.s4.e1
-;I-drug_n;I-DDI-MedLine.d125.s4.e1
erythro;I-drug_n;I-DDI-MedLine.d125.s4.e1
-;I-drug_n;I-DDI-MedLine.d125.s4.e1
fluorocitrate;I-drug_n;I-DDI-MedLine.d125.s4.e1
synthesis;O;O
or;O;O
in;O;O
citrate;O;O
and;O;O
fluoride;O;O
accumulation;O;O
characteristic;O;O
of;O;O
animals;O;O
dosed;O;O
with;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s4.e2
-;I-drug_n;I-DDI-MedLine.d125.s4.e2
difluoro;I-drug_n;I-DDI-MedLine.d125.s4.e2
-;I-drug_n;I-DDI-MedLine.d125.s4.e2
2;I-drug_n;I-DDI-MedLine.d125.s4.e2
-;I-drug_n;I-DDI-MedLine.d125.s4.e2
propanol;I-drug_n;I-DDI-MedLine.d125.s4.e2
.;O;O
DDI-MedLine.d125.s5;;
We;O;O
demonstrate;O;O
that;O;O
the;O;O
conversion;O;O
of;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s5.e0
-;I-drug_n;I-DDI-MedLine.d125.s5.e0
difluoro;I-drug_n;I-DDI-MedLine.d125.s5.e0
-;I-drug_n;I-DDI-MedLine.d125.s5.e0
2;I-drug_n;I-DDI-MedLine.d125.s5.e0
-;I-drug_n;I-DDI-MedLine.d125.s5.e0
propanol;I-drug_n;I-DDI-MedLine.d125.s5.e0
to;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s5.e1
-;I-drug_n;I-DDI-MedLine.d125.s5.e1
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s5.e1
by;O;O
an;O;O
NAD+;O;O
-;O;O
dependent;O;O
oxidation;O;O
is;O;O
the;O;O
rate;O;O
-;O;O
limiting;O;O
step;O;O
in;O;O
the;O;O
synthesis;O;O
of;O;O
the;O;O
toxic;O;O
product;O;O
,;O;O
(;B-drug_n;B-DDI-MedLine.d125.s5.e2
-);I-drug_n;I-DDI-MedLine.d125.s5.e2
-;I-drug_n;I-DDI-MedLine.d125.s5.e2
erythro;I-drug_n;I-DDI-MedLine.d125.s5.e2
-;I-drug_n;I-DDI-MedLine.d125.s5.e2
fluorocitrate;I-drug_n;I-DDI-MedLine.d125.s5.e2
from;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s5.e3
-;I-drug_n;I-DDI-MedLine.d125.s5.e3
difluoro;I-drug_n;I-DDI-MedLine.d125.s5.e3
-;I-drug_n;I-DDI-MedLine.d125.s5.e3
2;I-drug_n;I-DDI-MedLine.d125.s5.e3
-;I-drug_n;I-DDI-MedLine.d125.s5.e3
propanol;I-drug_n;I-DDI-MedLine.d125.s5.e3
.;O;O
DDI-MedLine.d125.s6;;
Prior;O;O
administration;O;O
of;O;O
4;B-drug;B-DDI-MedLine.d125.s6.e0
-;I-drug;I-DDI-MedLine.d125.s6.e0
methylpyrazole;I-drug;I-DDI-MedLine.d125.s6.e0
(;O;O
90;O;O
mg;O;O
kg(;O;O
-;O;O
1;O;O
);O;O
body;O;O
weight;O;O
);O;O
was;O;O
shown;O;O
to;O;O
prevent;O;O
the;O;O
conversion;O;O
of;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s6.e1
-;I-drug_n;I-DDI-MedLine.d125.s6.e1
difluoro;I-drug_n;I-DDI-MedLine.d125.s6.e1
-;I-drug_n;I-DDI-MedLine.d125.s6.e1
2;I-drug_n;I-DDI-MedLine.d125.s6.e1
-;I-drug_n;I-DDI-MedLine.d125.s6.e1
propanol;I-drug_n;I-DDI-MedLine.d125.s6.e1
(;O;O
100;O;O
mg;O;O
kg(;O;O
-;O;O
1;O;O
);O;O
body;O;O
weight;O;O
);O;O
to;O;O
(;B-drug_n;B-DDI-MedLine.d125.s6.e2
-);I-drug_n;I-DDI-MedLine.d125.s6.e2
-;I-drug_n;I-DDI-MedLine.d125.s6.e2
erythro;I-drug_n;I-DDI-MedLine.d125.s6.e2
-;I-drug_n;I-DDI-MedLine.d125.s6.e2
fluorocitrate;I-drug_n;I-DDI-MedLine.d125.s6.e2
in;O;O
vivo;O;O
and;O;O
to;O;O
eliminate;O;O
the;O;O
fluoride;O;O
and;O;O
citrate;O;O
elevations;O;O
seen;O;O
in;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s6.e3
-;I-drug_n;I-DDI-MedLine.d125.s6.e3
difluoro;I-drug_n;I-DDI-MedLine.d125.s6.e3
-;I-drug_n;I-DDI-MedLine.d125.s6.e3
2;I-drug_n;I-DDI-MedLine.d125.s6.e3
-;I-drug_n;I-DDI-MedLine.d125.s6.e3
propanol;I-drug_n;I-DDI-MedLine.d125.s6.e3
-;O;O
intoxicated;O;O
animals;O;O
.;O;O
DDI-MedLine.d125.s7;;
However;O;O
,;O;O
administration;O;O
of;O;O
4;B-drug;B-DDI-MedLine.d125.s7.e0
-;I-drug;I-DDI-MedLine.d125.s7.e0
methylpyrazole;I-drug;I-DDI-MedLine.d125.s7.e0
(;O;O
90;O;O
mg;O;O
kg(;O;O
-;O;O
1;O;O
);O;O
body;O;O
weight;O;O
);O;O
to;O;O
rats;O;O
2;O;O
hours;O;O
prior;O;O
to;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s7.e1
-;I-drug_n;I-DDI-MedLine.d125.s7.e1
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s7.e1
(;O;O
100;O;O
mg;O;O
kg(;O;O
-;O;O
1;O;O
);O;O
body;O;O
weight;O;O
);O;O
was;O;O
ineffective;O;O
in;O;O
preventing;O;O
(;B-drug_n;B-DDI-MedLine.d125.s7.e2
-);I-drug_n;I-DDI-MedLine.d125.s7.e2
-;I-drug_n;I-DDI-MedLine.d125.s7.e2
erythro;I-drug_n;I-DDI-MedLine.d125.s7.e2
-;I-drug_n;I-DDI-MedLine.d125.s7.e2
fluorocitrate;I-drug_n;I-DDI-MedLine.d125.s7.e2
synthesis;O;O
and;O;O
did;O;O
not;O;O
diminish;O;O
fluoride;O;O
or;O;O
citrate;O;O
accumulation;O;O
in;O;O
vivo;O;O
.;O;O
DDI-MedLine.d125.s8;;
We;O;O
conclude;O;O
that;O;O
the;O;O
prophylactic;O;O
and;O;O
antidotal;O;O
properties;O;O
of;O;O
4;B-drug;B-DDI-MedLine.d125.s8.e0
-;I-drug;I-DDI-MedLine.d125.s8.e0
methylpyrazole;I-drug;I-DDI-MedLine.d125.s8.e0
seen;O;O
in;O;O
animals;O;O
treated;O;O
with;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s8.e1
-;I-drug_n;I-DDI-MedLine.d125.s8.e1
difluoro;I-drug_n;I-DDI-MedLine.d125.s8.e1
-;I-drug_n;I-DDI-MedLine.d125.s8.e1
2;I-drug_n;I-DDI-MedLine.d125.s8.e1
-;I-drug_n;I-DDI-MedLine.d125.s8.e1
propanol;I-drug_n;I-DDI-MedLine.d125.s8.e1
derive;O;O
from;O;O
its;O;O
capacity;O;O
to;O;O
inhibit;O;O
the;O;O
NAD+;O;O
-;O;O
dependent;O;O
oxidation;O;O
responsible;O;O
for;O;O
converting;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s8.e2
-;I-drug_n;I-DDI-MedLine.d125.s8.e2
difluoro;I-drug_n;I-DDI-MedLine.d125.s8.e2
-;I-drug_n;I-DDI-MedLine.d125.s8.e2
2;I-drug_n;I-DDI-MedLine.d125.s8.e2
-;I-drug_n;I-DDI-MedLine.d125.s8.e2
propanol;I-drug_n;I-DDI-MedLine.d125.s8.e2
to;O;O
1,3;B-drug_n;B-DDI-MedLine.d125.s8.e3
-;I-drug_n;I-DDI-MedLine.d125.s8.e3
difluoroacetone;I-drug_n;I-DDI-MedLine.d125.s8.e3
in;O;O
the;O;O
committed;O;O
step;O;O
of;O;O
the;O;O
toxic;O;O
pathway;O;O
.;O;O
DDI-MedLine.d101.s0;;
Pharmacology;O;O
and;O;O
pharmacotherapy;O;O
of;O;O
cardiovascular;O;O
drugs;O;O
in;O;O
patients;O;O
with;O;O
chronic;O;O
renal;O;O
disease;O;O
.;O;O

;O;O
DDI-MedLine.d101.s1;;
Cardiovascular;O;O
disease;O;O
is;O;O
a;O;O
common;O;O
comorbidity;O;O
and;O;O
a;O;O
major;O;O
cause;O;O
of;O;O
mortality;O;O
in;O;O
patients;O;O
with;O;O
chronic;O;O
renal;O;O
disease;O;O
.;O;O
DDI-MedLine.d101.s2;;
Drug;O;O
regimens;O;O
in;O;O
patients;O;O
with;O;O
cardiovascular;O;O
disease;O;O
are;O;O
frequently;O;O
complex;O;O
and;O;O
can;O;O
be;O;O
significantly;O;O
affected;O;O
by;O;O
alterations;O;O
in;O;O
renal;O;O
function;O;O
.;O;O
DDI-MedLine.d101.s3;;
In;O;O
addition;O;O
,;O;O
several;O;O
cardiovascular;O;O
drugs;O;O
directly;O;O
affect;O;O
renal;O;O
function;O;O
and;O;O
the;O;O
management;O;O
of;O;O
patients;O;O
with;O;O
renal;O;O
disease;O;O
.;O;O
DDI-MedLine.d101.s4;;
This;O;O
article;O;O
reviews;O;O
the;O;O
impact;O;O
of;O;O
renal;O;O
disease;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
cardiovascular;O;O
drugs;O;O
and;O;O
identifies;O;O
clinically;O;O
important;O;O
interactions;O;O
between;O;O
these;O;O
and;O;O
other;O;O
drugs;O;O
commonly;O;O
used;O;O
in;O;O
the;O;O
management;O;O
of;O;O
chronic;O;O
renal;O;O
disease;O;O
.;O;O
DDI-MedLine.d101.s5;;
Several;O;O
classes;O;O
of;O;O
cardiovascular;O;O
drugs;O;O
are;O;O
also;O;O
discussed;O;O
in;O;O
relationship;O;O
to;O;O
their;O;O
differential;O;O
effects;O;O
on;O;O
the;O;O
management;O;O
and;O;O
progression;O;O
of;O;O
renal;O;O
disease;O;O
.;O;O
DDI-MedLine.d129.s0;;
Green;B-drug;B-DDI-MedLine.d129.s0.e0
tea;I-drug;I-DDI-MedLine.d129.s0.e0
polyphenols;I-drug;I-DDI-MedLine.d129.s0.e0
as;O;O
potent;O;O
enhancers;B-drug;B-DDI-MedLine.d129.s0.e1
of;O;O
glucocorticoid;O;O
-;O;O
induced;O;O
mouse;O;O
mammary;O;O
tumor;O;O
virus;O;O
gene;O;O
expression;O;O
.;O;O

;O;O
DDI-MedLine.d129.s1;;
The;O;O
effect;O;O
of;O;O
natural;O;O
and;O;O
synthetic;O;O
galloyl;O;O
esters;O;O
on;O;O
glucocorticoid;O;O
-;O;O
induced;O;O
gene;O;O
expression;O;O
was;O;O
evaluated;O;O
by;O;O
using;O;O
rat;O;O
fibroblast;O;O
3Y1;O;O
cells;O;O
stably;O;O
transfected;O;O
with;O;O
a;O;O
luciferase;O;O
reporter;O;O
gene;O;O
under;O;O
the;O;O
transcriptional;O;O
regulation;O;O
of;O;O
the;O;O
mouse;O;O
mammary;O;O
tumor;O;O
virus;O;O
promoter;B-drug;B-DDI-MedLine.d129.s1.e0
.;O;O
DDI-MedLine.d129.s2;;
The;O;O
glucocorticoid;O;O
-;O;O
induced;O;O
gene;O;O
transcription;O;O
was;O;O
strongly;O;O
suppressed;O;O
by;O;O
synthetic;O;O
alkyl;O;O
esters;O;O
,;O;O
DDI-MedLine.d129.s3;;
n;B-drug;B-DDI-MedLine.d129.s3.e0
-;I-drug;I-DDI-MedLine.d129.s3.e0
dodecyl;I-drug;I-DDI-MedLine.d129.s3.e0
gallate;I-drug;I-DDI-MedLine.d129.s3.e0
showed;O;O
the;O;O
most;O;O
potent;O;O
inhibition;O;O
(;O;O
66;O;O
%;O;O
inhibition;O;O
at;O;O
10;O;O
microM;O;O
);O;O
,;O;O
which;O;O
was;O;O
far;O;O
more;O;O
potent;O;O
than;O;O
that;O;O
of;O;O
crude;O;O
tannic;B-drug;B-DDI-MedLine.d129.s3.e1
acid;I-drug;I-DDI-MedLine.d129.s3.e1
.;O;O
DDI-MedLine.d129.s4;;
n;O;O
-;O;O
Octyl;O;O
and;O;O
n;O;O
-;O;O
cetyl;O;O
gallate;O;O
also;O;O
showed;O;O
good;O;O
inhibition;O;O
,;O;O
while;O;O
gallic;O;O
acid;O;O
itself;O;O
was;O;O
not;O;O
so;O;O
active;O;O
,;O;O
suggesting;O;O
that;O;O
the;O;O
presence;O;O
of;O;O
hydrophobic;O;O
side;O;O
chain;O;O
is;O;O
important;O;O
for;O;O
the;O;O
suppressive;O;O
effect;O;O
.;O;O
DDI-MedLine.d129.s5;;
On;O;O
the;O;O
other;O;O
hand;O;O
,;O;O
surprisingly;O;O
,;O;O
green;B-drug;B-DDI-MedLine.d129.s5.e0
tea;I-drug;I-DDI-MedLine.d129.s5.e0
gallocatechins;I-drug;I-DDI-MedLine.d129.s5.e0
,;O;O
(;O;O
-);O;O
-;O;O
epigallocatechin;O;O
-;O;O
3;O;O
-;O;O
O;O;O
-;O;O
gallate;O;O
and;O;O
theasinensin;O;O
A;O;O
,;O;O
potently;O;O
enhanced;O;O
the;O;O
promoter;O;O
activity;O;O
(;O;O
182;O;O
and;O;O
247;O;O
%;O;O
activity;O;O
at;O;O
1;O;O
microM;O;O
,;O;O
respectively;O;O
);O;O
.;O;O
DDI-MedLine.d129.s6;;
The;O;O
regulation;O;O
of;O;O
the;O;O
level;O;O
of;O;O
the;O;O
glucocorticoid;O;O
-;O;O
induced;O;O
gene;O;O
expression;O;O
by;O;O
the;O;O
antioxidative;O;O
gallates;O;O
is;O;O
of;O;O
great;O;O
interest;O;O
from;O;O
a;O;O
therapeutic;O;O
point;O;O
of;O;O
view;O;O
.;O;O
DDI-MedLine.d86.s0;;
Pharmacokinetic;O;O
interaction;O;O
between;O;O
single;O;O
oral;O;O
doses;O;O
of;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s0.e0
and;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s0.e1
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-MedLine.d86.s1;;
AIM;O;O
AND;O;O
BACKGROUND;O;O
:;O;O
The;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s1.e0
,;O;O
a;O;O
macrolide;B-group;B-DDI-MedLine.d86.s1.e1
immunosuppressant;I-group;I-DDI-MedLine.d86.s1.e1
metabolized;O;O
by;O;O
CYP3A4;O;O
,;O;O
and;O;O
the;O;O
calcium;B-group;B-DDI-MedLine.d86.s1.e2
channel;I-group;I-DDI-MedLine.d86.s1.e2
blocker;I-group;I-DDI-MedLine.d86.s1.e2
diltiazem;I-drug;I-DDI-MedLine.d86.s1.e3
was;O;O
studied;O;O
in;O;O
18;O;O
healthy;O;O
subjects;O;O
.;O;O
DDI-MedLine.d86.s2;;
Several;O;O
clinically;O;O
important;O;O
interactions;O;O
have;O;O
previously;O;O
been;O;O
reported;O;O
for;O;O
other;O;O
immunosuppressive;B-group;B-DDI-MedLine.d86.s2.e0
drugs;I-group;I-DDI-MedLine.d86.s2.e0
that;O;O
are;O;O
metabolized;O;O
by;O;O
the;O;O
same;O;O
enzyme;O;O
and;O;O
for;O;O
calcium;B-group;B-DDI-MedLine.d86.s2.e1
antagonists;I-group;I-DDI-MedLine.d86.s2.e1
.;O;O
DDI-MedLine.d86.s3;;
METHODS;O;O
:;O;O
Healthy;O;O
subjects;O;O
who;O;O
were;O;O
20;O;O
to;O;O
43;O;O
years;O;O
old;O;O
participated;O;O
in;O;O
an;O;O
open;O;O
,;O;O
three;O;O
-;O;O
period;O;O
,;O;O
randomized;O;O
,;O;O
crossover;O;O
study;O;O
of;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
a;O;O
single;O;O
10;O;O
-;O;O
mg;O;O
oral;O;O
dose;O;O
of;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s3.e0
,;O;O
a;O;O
single;O;O
oral;O;O
120;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s3.e1
,;O;O
and;O;O
the;O;O
two;O;O
drugs;O;O
given;O;O
together;O;O
.;O;O
DDI-MedLine.d86.s4;;
The;O;O
three;O;O
study;O;O
periods;O;O
were;O;O
separated;O;O
by;O;O
a;O;O
21;O;O
-;O;O
day;O;O
washout;O;O
phase;O;O
.;O;O
DDI-MedLine.d86.s5;;
RESULTS;O;O
:;O;O
The;O;O
geometric;O;O
mean;O;O
(;O;O
90;O;O
%;O;O
confidence;O;O
interval;O;O
);O;O
whole;O;O
blood;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s5.e0
area;O;O
under;O;O
the;O;O
plasma;O;O
concentration;O;O
time;O;O
-;O;O
curve;O;O
increased;O;O
60;O;O
%;O;O
(;O;O
35%;O;O
-;O;O
90;O;O
%;O;O
);O;O
,;O;O
from;O;O
736;O;O
to;O;O
1178;O;O
ng;O;O
x;O;O
h;O;O
/;O;O
mL;O;O
,;O;O
and;O;O
maximum;O;O
concentration;O;O
increased;O;O
43;O;O
%;O;O
(;O;O
14%;O;O
-;O;O
81;O;O
%;O;O
);O;O
,;O;O
from;O;O
67;O;O
to;O;O
96;O;O
ng;O;O
/;O;O
mL;O;O
,;O;O
with;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s5.e1
coadministration;O;O
,;O;O
whereas;O;O
the;O;O
mean;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
of;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s5.e2
decreased;O;O
slightly;O;O
,;O;O
from;O;O
79;O;O
to;O;O
67;O;O
hours;O;O
.;O;O
DDI-MedLine.d86.s6;;
Apparent;O;O
oral;O;O
clearance;O;O
and;O;O
volume;O;O
of;O;O
distribution;O;O
of;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s6.e0
decreased;O;O
with;O;O
38;O;O
%;O;O
and;O;O
45;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
when;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s6.e1
was;O;O
given;O;O
with;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s6.e2
.;O;O
DDI-MedLine.d86.s7;;
The;O;O
plasma;O;O
maximum;O;O
concentration;O;O
and;O;O
area;O;O
under;O;O
the;O;O
plasma;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
of;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s7.e0
,;O;O
desacetyldiltiazem;B-drug_n;B-DDI-MedLine.d86.s7.e1
,;O;O
and;O;O
desmethyldiltiazem;B-drug_n;B-DDI-MedLine.d86.s7.e2
were;O;O
unchanged;O;O
after;O;O
coadministration;O;O
of;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s7.e3
,;O;O
and;O;O
no;O;O
potentiation;O;O
of;O;O
the;O;O
effects;O;O
of;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s7.e4
on;O;O
diastolic;O;O
or;O;O
systolic;O;O
blood;O;O
pressure;O;O
or;O;O
on;O;O
the;O;O
electrocardiographic;O;O
parameters;O;O
was;O;O
seen;O;O
.;O;O
DDI-MedLine.d86.s8;;
CONCLUSIONS;O;O
:;O;O
Single;O;O
-;O;O
dose;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s8.e0
coadministration;O;O
leads;O;O
to;O;O
higher;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s8.e1
exposure;O;O
,;O;O
presumably;O;O
by;O;O
inhibition;O;O
of;O;O
the;O;O
first;O;O
-;O;O
pass;O;O
metabolism;O;O
of;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s8.e2
.;O;O
DDI-MedLine.d86.s9;;
Because;O;O
of;O;O
the;O;O
pronounced;O;O
intersubject;O;O
variability;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
the;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s9.e0
-;O;O
diltiazem;B-drug;B-DDI-MedLine.d86.s9.e1
interaction;O;O
,;O;O
whole;O;O
blood;O;O
sirolimus;B-drug;B-DDI-MedLine.d86.s9.e2
concentrations;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
the;O;O
two;O;O
drugs;O;O
.;O;O
DDI-MedLine.d99.s0;;
Fluvoxamine;B-drug;B-DDI-MedLine.d99.s0.e0
inhibits;O;O
the;O;O
CYP2C9;O;O
catalyzed;O;O
biotransformation;O;O
of;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s0.e1
.;O;O

;O;O
DDI-MedLine.d99.s1;;
OBJECTIVE;O;O
:;O;O
Our;O;O
objective;O;O
was;O;O
to;O;O
examine;O;O
the;O;O
interaction;O;O
between;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d99.s1.e0
and;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s1.e1
to;O;O
confirm;O;O
that;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d99.s1.e2
inhibits;O;O
CYP2C9;O;O
.;O;O
DDI-MedLine.d99.s2;;
METHODS;O;O
:;O;O
The;O;O
study;O;O
was;O;O
carried;O;O
out;O;O
as;O;O
an;O;O
open;O;O
,;O;O
randomized;O;O
,;O;O
crossover;O;O
design;O;O
with;O;O
14;O;O
healthy;O;O
participants;O;O
.;O;O
DDI-MedLine.d99.s3;;
In;O;O
period;O;O
A;O;O
,;O;O
all;O;O
volunteers;O;O
took;O;O
500;O;O
mg;O;O
of;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s3.e0
orally;O;O
.;O;O
DDI-MedLine.d99.s4;;
In;O;O
period;O;O
B;O;O
,;O;O
the;O;O
volunteers;O;O
were;O;O
randomly;O;O
assigned;O;O
to;O;O
one;O;O
of;O;O
two;O;O
groups;O;O
.;O;O
DDI-MedLine.d99.s5;;
Each;O;O
group;O;O
took;O;O
either;O;O
150;O;O
mg;O;O
or;O;O
75;O;O
mg;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d99.s5.e0
a;O;O
day;O;O
for;O;O
5;O;O
days;O;O
(;O;O
day;O;O
-3;O;O
to;O;O
day;O;O
2;O;O
);O;O
.;O;O
DDI-MedLine.d99.s6;;
The;O;O
groups;O;O
then;O;O
took;O;O
500;O;O
mg;O;O
of;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s6.e0
as;O;O
a;O;O
single;O;O
dose;O;O
(;O;O
day;O;O
0;O;O
);O;O
.;O;O
DDI-MedLine.d99.s7;;
In;O;O
both;O;O
periods;O;O
,;O;O
blood;O;O
and;O;O
urine;O;O
were;O;O
sampled;O;O
at;O;O
regular;O;O
intervals;O;O
.;O;O
DDI-MedLine.d99.s8;;
Plasma;O;O
was;O;O
analyzed;O;O
for;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s8.e0
,;O;O
and;O;O
urine;O;O
was;O;O
analyzed;O;O
for;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s8.e1
and;O;O
its;O;O
two;O;O
metabolites;O;O
,;O;O
4;B-drug_n;B-DDI-MedLine.d99.s8.e2
-;I-drug_n;I-DDI-MedLine.d99.s8.e2
hydroxytolbutamide;I-drug_n;I-DDI-MedLine.d99.s8.e2
and;O;O
carboxytolbutamide;B-drug_n;B-DDI-MedLine.d99.s8.e3
by;O;O
means;O;O
of;O;O
HPLC;O;O
.;O;O
DDI-MedLine.d99.s9;;
RESULTS;O;O
:;O;O
During;O;O
treatment;O;O
with;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d99.s9.e0
,;O;O
there;O;O
was;O;O
a;O;O
statistically;O;O
significant;O;O
decrease;O;O
in;O;O
the;O;O
median;O;O
of;O;O
the;O;O
total;O;O
clearance;O;O
of;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s9.e1
,;O;O
from;O;O
845;O;O
mL;O;O
/;O;O
h;O;O
to;O;O
688;O;O
mL;O;O
/;O;O
h;O;O
,;O;O
among;O;O
the;O;O
volunteers;O;O
who;O;O
received;O;O
75;O;O
mg;O;O
/;O;O
d;O;O
.;O;O
DDI-MedLine.d99.s10;;
There;O;O
was;O;O
a;O;O
reduction;O;O
that;O;O
reached;O;O
borderline;O;O
statistical;O;O
significance;O;O
in;O;O
the;O;O
group;O;O
that;O;O
received;O;O
150;O;O
mg;O;O
/;O;O
d;O;O
of;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s10.e0
.;O;O
DDI-MedLine.d99.s11;;
The;O;O
clearance;O;O
by;O;O
means;O;O
of;O;O
4;B-drug_n;B-DDI-MedLine.d99.s11.e0
-;I-drug_n;I-DDI-MedLine.d99.s11.e0
hydroxytolbutamide;I-drug_n;I-DDI-MedLine.d99.s11.e0
and;O;O
carboxytolbutamide;B-drug_n;B-DDI-MedLine.d99.s11.e1
was;O;O
significantly;O;O
reduced;O;O
in;O;O
both;O;O
groups;O;O
(;O;O
ie;O;O
,;O;O
from;O;O
901;O;O
mL;O;O
/;O;O
h;O;O
to;O;O
318;O;O
mL;O;O
/;O;O
h;O;O
in;O;O
the;O;O
group;O;O
that;O;O
received;O;O
150;O;O
mg;O;O
of;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s11.e2
per;O;O
day;O;O
and;O;O
from;O;O
723;O;O
mL;O;O
/;O;O
h;O;O
to;O;O
457;O;O
mL;O;O
/;O;O
h;O;O
in;O;O
the;O;O
group;O;O
that;O;O
received;O;O
75;O;O
mg;O;O
of;O;O
tolbutamide;B-drug;B-DDI-MedLine.d99.s11.e3
per;O;O
day;O;O
);O;O
.;O;O
DDI-MedLine.d99.s12;;
Thus;O;O
there;O;O
was;O;O
a;O;O
tendency;O;O
toward;O;O
a;O;O
more;O;O
pronounced;O;O
inhibition;O;O
of;O;O
the;O;O
4;O;O
-;O;O
hydroxylation;O;O
during;O;O
treatment;O;O
with;O;O
150;O;O
mg;O;O
/;O;O
d;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d99.s12.e0
compared;O;O
with;O;O
75;O;O
mg;O;O
/;O;O
d;O;O
,;O;O
but;O;O
the;O;O
difference;O;O
was;O;O
not;O;O
statistically;O;O
significant;O;O
.;O;O
DDI-MedLine.d99.s13;;
CONCLUSION;O;O
:;O;O
Fluvoxamine;B-drug;B-DDI-MedLine.d99.s13.e0
is;O;O
a;O;O
moderate;O;O
inhibitor;O;O
of;O;O
CYP2C9;O;O
in;O;O
vivo;O;O
.;O;O
DDI-MedLine.d140.s0;;
Longitudinal;O;O
assessment;O;O
of;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s0.e0
in;O;O
de;O;O
novo;O;O
renal;O;O
transplant;O;O
recipients;O;O
over;O;O
the;O;O
first;O;O
post;O;O
-;O;O
transplant;O;O
year;O;O
:;O;O
pharmacokinetics;O;O
,;O;O
exposure;O;O
-;O;O
response;O;O
relationships;O;O
,;O;O
and;O;O
influence;O;O
on;O;O
cyclosporine;B-drug;B-DDI-MedLine.d140.s0.e1
.;O;O
DDI-MedLine.d140.s1;;
OBJECTIVE;O;O
:;O;O
Our;O;O
objective;O;O
was;O;O
to;O;O
characterize;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
pharmacokinetics;O;O
of;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s1.e0
and;O;O
cyclosporine;B-drug;B-DDI-MedLine.d140.s1.e1
(;O;O
INN;O;O
,;O;O
ciclosporin;B-drug;B-DDI-MedLine.d140.s1.e2
);O;O
when;O;O
coadministered;O;O
in;O;O
de;O;O
novo;O;O
kidney;O;O
allograft;O;O
recipients;O;O
during;O;O
the;O;O
first;O;O
year;O;O
after;O;O
transplantation;O;O
.;O;O
DDI-MedLine.d140.s2;;
METHOD;O;O
:;O;O
This;O;O
study;O;O
was;O;O
a;O;O
multicenter;O;O
randomized;O;O
double;O;O
-;O;O
blind;O;O
study;O;O
of;O;O
101;O;O
patients;O;O
who;O;O
were;O;O
randomly;O;O
assigned;O;O
1:1:1;O;O
to;O;O
receive;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s2.e0
tablets;O;O
at;O;O
doses;O;O
of;O;O
0.5;O;O
mg;O;O
,;O;O
1;O;O
mg;O;O
,;O;O
or;O;O
2;O;O
mg;O;O
twice;O;O
daily;O;O
with;O;O
cyclosporine;B-drug;B-DDI-MedLine.d140.s2.e1
and;O;O
prednisone;B-drug;B-DDI-MedLine.d140.s2.e2
.;O;O
DDI-MedLine.d140.s3;;
Blood;O;O
sampling;O;O
for;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s3.e0
and;O;O
cyclosporine;B-drug;B-DDI-MedLine.d140.s3.e1
was;O;O
performed;O;O
on;O;O
day;O;O
1;O;O
,;O;O
on;O;O
weeks;O;O
1;O;O
,;O;O
2;O;O
,;O;O
3;O;O
,;O;O
and;O;O
4;O;O
,;O;O
and;O;O
on;O;O
months;O;O
2;O;O
,;O;O
3;O;O
,;O;O
6;O;O
,;O;O
9;O;O
,;O;O
and;O;O
12;O;O
.;O;O
DDI-MedLine.d140.s4;;
Everolimus;B-drug;B-DDI-MedLine.d140.s4.e0
dose;O;O
-;O;O
proportionality;O;O
and;O;O
stability;O;O
over;O;O
time;O;O
were;O;O
assessed;O;O
in;O;O
the;O;O
context;O;O
of;O;O
linear;O;O
regression;O;O
and;O;O
ANOVA;O;O
models;O;O
.;O;O
DDI-MedLine.d140.s5;;
Everolimus;B-drug;B-DDI-MedLine.d140.s5.e0
exposure;O;O
-;O;O
response;O;O
relationships;O;O
between;O;O
area;O;O
under;O;O
the;O;O
blood;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
(;O;O
AUC;O;O
);O;O
and;O;O
changes;O;O
in;O;O
platelets;O;O
,;O;O
leukocytes;O;O
,;O;O
and;O;O
lipids;O;O
were;O;O
explored;O;O
with;O;O
the;O;O
median;O;O
-;O;O
effect;O;O
model;O;O
.;O;O
DDI-MedLine.d140.s6;;
Potential;O;O
differences;O;O
in;O;O
cyclosporine;B-drug;B-DDI-MedLine.d140.s6.e0
dosing;O;O
and;O;O
pharmacokinetics;O;O
at;O;O
different;O;O
levels;O;O
of;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s6.e1
exposure;O;O
were;O;O
assessed;O;O
in;O;O
the;O;O
context;O;O
of;O;O
ANOVA;O;O
.;O;O
DDI-MedLine.d140.s7;;
RESULTS;O;O
:;O;O
Everolimus;B-drug;B-DDI-MedLine.d140.s7.e0
steady;O;O
state;O;O
was;O;O
reached;O;O
on;O;O
or;O;O
before;O;O
day;O;O
7;O;O
,;O;O
with;O;O
a;O;O
median;O;O
3;O;O
-;O;O
fold;O;O
accumulation;O;O
of;O;O
drug;O;O
exposure;O;O
compared;O;O
with;O;O
that;O;O
after;O;O
the;O;O
first;O;O
postoperative;O;O
dose;O;O
.;O;O
DDI-MedLine.d140.s8;;
Both;O;O
steady;O;O
-;O;O
state;O;O
maximum;O;O
concentration;O;O
and;O;O
AUC;O;O
were;O;O
dose;O;O
proportional;O;O
over;O;O
the;O;O
full;O;O
dose;O;O
range;O;O
when;O;O
assessed;O;O
on;O;O
day;O;O
1;O;O
,;O;O
as;O;O
well;O;O
as;O;O
for;O;O
the;O;O
full;O;O
duration;O;O
of;O;O
the;O;O
study;O;O
at;O;O
steady;O;O
state;O;O
.;O;O
DDI-MedLine.d140.s9;;
There;O;O
was;O;O
evidence;O;O
for;O;O
longitudinal;O;O
stability;O;O
in;O;O
AUC;O;O
of;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s9.e0
during;O;O
the;O;O
course;O;O
of;O;O
the;O;O
study;O;O
.;O;O
DDI-MedLine.d140.s10;;
The;O;O
interindividual;O;O
pharmacokinetic;O;O
variability;O;O
for;O;O
AUC;O;O
was;O;O
85.4;O;O
%;O;O
and;O;O
intraindividual;O;O
,;O;O
interoccasion;O;O
variability;O;O
was;O;O
40.8;O;O
%;O;O
.;O;O
DDI-MedLine.d140.s11;;
Age;O;O
(;O;O
range;O;O
,;O;O
17;O;O
-;O;O
69;O;O
years;O;O
);O;O
,;O;O
weight;O;O
(;O;O
range;O;O
,;O;O
49;O;O
-;O;O
106;O;O
kg;O;O
);O;O
,;O;O
and;O;O
sex;O;O
(;O;O
65;O;O
men;O;O
and;O;O
36;O;O
women;O;O
);O;O
were;O;O
not;O;O
significant;O;O
contributors;O;O
to;O;O
variability;O;O
.;O;O
DDI-MedLine.d140.s12;;
There;O;O
was;O;O
an;O;O
increasing;O;O
incidence;O;O
of;O;O
transient;O;O
thrombocytopenia;O;O
(;O;O
or;O;O
=;O;O
100;O;O
x;O;O
10(9);O;O
/;O;O
L;O;O
);O;O
with;O;O
increasing;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s12.e0
AUC;O;O
(;O;O
P;O;O
=;O;O
.03;O;O
);O;O
.;O;O
DDI-MedLine.d140.s13;;
Cyclosporine;B-drug;B-DDI-MedLine.d140.s13.e0
doses;O;O
,;O;O
trough;O;O
concentrations;O;O
,;O;O
and;O;O
AUC;O;O
exhibited;O;O
similar;O;O
temporal;O;O
patterns;O;O
during;O;O
the;O;O
course;O;O
of;O;O
the;O;O
study;O;O
regardless;O;O
of;O;O
the;O;O
co;O;O
-;O;O
administered;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s13.e1
dose;O;O
level;O;O
(;O;O
P;O;O
=;O;O
.13;O;O
,;O;O
.82;O;O
,;O;O
and;O;O
.76;O;O
,;O;O
respectively;O;O
);O;O
.;O;O
DDI-MedLine.d140.s14;;
CONCLUSIONS;O;O
:;O;O
Everolimus;B-drug;B-DDI-MedLine.d140.s14.e0
exhibited;O;O
dose;O;O
-;O;O
proportional;O;O
,;O;O
stable;O;O
exposure;O;O
during;O;O
the;O;O
first;O;O
post;O;O
-;O;O
transplant;O;O
year;O;O
.;O;O
DDI-MedLine.d140.s15;;
For;O;O
a;O;O
4;O;O
-;O;O
fold;O;O
range;O;O
of;O;O
everolimus;B-drug;B-DDI-MedLine.d140.s15.e0
doses;O;O
there;O;O
were;O;O
no;O;O
differential;O;O
effects;O;O
on;O;O
cyclosporine;B-drug;B-DDI-MedLine.d140.s15.e1
dosing;O;O
or;O;O
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d87.s0;;
ADL;B-drug;B-DDI-MedLine.d87.s0.e0
8;I-drug;I-DDI-MedLine.d87.s0.e0
-;I-drug;I-DDI-MedLine.d87.s0.e0
2698;I-drug;I-DDI-MedLine.d87.s0.e0
,;O;O
a;O;O
trans;O;O
-;O;O
3,4;O;O
-;O;O
dimethyl;O;O
-;O;O
4;O;O
-;O;O
(3;O;O
-;O;O
hydroxyphenyl;O;O
);O;O
piperidine;O;O
,;O;O
prevents;O;O
gastrointestinal;O;O
effects;O;O
of;O;O
intravenous;O;O
morphine;B-drug;B-DDI-MedLine.d87.s0.e1
without;O;O
affecting;O;O
analgesia;O;O
.;O;O
DDI-MedLine.d87.s1;;
ADL;B-drug;B-DDI-MedLine.d87.s1.e0
-;I-drug;I-DDI-MedLine.d87.s1.e0
8;I-drug;I-DDI-MedLine.d87.s1.e0
-;I-drug;I-DDI-MedLine.d87.s1.e0
2698;I-drug;I-DDI-MedLine.d87.s1.e0
is;O;O
a;O;O
novel;O;O
peripherally;B-group;B-DDI-MedLine.d87.s1.e1
restricted;I-group;I-DDI-MedLine.d87.s1.e1
opioid;I-group;I-DDI-MedLine.d87.s1.e1
antagonist;I-group;I-DDI-MedLine.d87.s1.e1
that;O;O
may;O;O
selectively;O;O
prevent;O;O
opioid;B-group;B-DDI-MedLine.d87.s1.e2
-;O;O
induced;O;O
gastrointestinal;O;O
effects;O;O
without;O;O
reversing;O;O
analgesia;O;O
.;O;O
DDI-MedLine.d87.s2;;
Gastrointestinal;O;O
transit;O;O
time;O;O
(;O;O
lactulose;O;O
hydrogen;O;O
breath;O;O
test;O;O
);O;O
was;O;O
measured;O;O
in;O;O
14;O;O
volunteers;O;O
with;O;O
oral;O;O
and;O;O
intravenous;O;O
placebo;O;O
,;O;O
oral;O;O
placebo;O;O
and;O;O
intravenous;O;O
morphine;B-drug;B-DDI-MedLine.d87.s2.e0
(;O;O
0.05;O;O
mg;O;O
x;O;O
kg(;O;O
-;O;O
1;O;O
);O;O
);O;O
,;O;O
and;O;O
oral;O;O
ADL;B-drug;B-DDI-MedLine.d87.s2.e1
8;I-drug;I-DDI-MedLine.d87.s2.e1
-;I-drug;I-DDI-MedLine.d87.s2.e1
2698;I-drug;I-DDI-MedLine.d87.s2.e1
(;O;O
4;O;O
mg;O;O
);O;O
and;O;O
intravenous;O;O
morphine;B-drug;B-DDI-MedLine.d87.s2.e2
(;O;O
0.05;O;O
mg;O;O
x;O;O
kg(;O;O
-;O;O
1;O;O
);O;O
);O;O
in;O;O
a;O;O
double;O;O
blind;O;O
,;O;O
cross;O;O
-;O;O
over;O;O
study;O;O
.;O;O
DDI-MedLine.d87.s3;;
Morphine;B-drug;B-DDI-MedLine.d87.s3.e0
prolonged;O;O
gastrointestinal;O;O
transit;O;O
time;O;O
from;O;O
69;O;O
to;O;O
103;O;O
minutes;O;O
(;O;O
P;O;O
=;O;O
.005;O;O
);O;O
,;O;O
DDI-MedLine.d87.s4;;
Morphine;B-drug;B-DDI-MedLine.d87.s4.e0
prolonged;O;O
gastrointestinal;O;O
transit;O;O
time;O;O
from;O;O
69;O;O
to;O;O
103;O;O
minutes;O;O
(;O;O
P;O;O
=;O;O
.005;O;O
);O;O
,;O;O
this;O;O
was;O;O
prevented;O;O
by;O;O
ADL;B-drug;B-DDI-MedLine.d87.s4.e1
8;I-drug;I-DDI-MedLine.d87.s4.e1
-;I-drug;I-DDI-MedLine.d87.s4.e1
2698;I-drug;I-DDI-MedLine.d87.s4.e1
(;O;O
P;O;O
=;O;O
.004;O;O
);O;O
.;O;O
DDI-MedLine.d87.s5;;
Postoperatively;O;O
,;O;O
45;O;O
patients;O;O
were;O;O
randomly;O;O
assigned;O;O
in;O;O
a;O;O
double;O;O
-;O;O
blind;O;O
fashion;O;O
to;O;O
receive;O;O
ADL;B-drug;B-DDI-MedLine.d87.s5.e0
8;I-drug;I-DDI-MedLine.d87.s5.e0
-;I-drug;I-DDI-MedLine.d87.s5.e0
2698;I-drug;I-DDI-MedLine.d87.s5.e0
(;O;O
4;O;O
mg;O;O
);O;O
or;O;O
placebo;O;O
and;O;O
intravenous;O;O
morphine;B-drug;B-DDI-MedLine.d87.s5.e1
(;O;O
0.15;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
or;O;O
to;O;O
receive;O;O
oral;O;O
and;O;O
intravenous;O;O
placebo;O;O
.;O;O
DDI-MedLine.d87.s6;;
Analgesia;O;O
and;O;O
pupil;O;O
constriction;O;O
were;O;O
measured;O;O
.;O;O
DDI-MedLine.d87.s7;;
Morphine;B-drug;B-DDI-MedLine.d87.s7.e0
analgesia;O;O
and;O;O
pupil;O;O
constriction;O;O
were;O;O
unaffected;O;O
by;O;O
ADL;B-drug;B-DDI-MedLine.d87.s7.e1
8;I-drug;I-DDI-MedLine.d87.s7.e1
-;I-drug;I-DDI-MedLine.d87.s7.e1
2698;I-drug;I-DDI-MedLine.d87.s7.e1
and;O;O
differed;O;O
from;O;O
placebo;O;O
(;O;O
P;O;O
<;O;O
.002;O;O
);O;O
.;O;O
DDI-MedLine.d87.s8;;
We;O;O
conclude;O;O
that;O;O
ADL;B-drug;B-DDI-MedLine.d87.s8.e0
8;I-drug;I-DDI-MedLine.d87.s8.e0
-;I-drug;I-DDI-MedLine.d87.s8.e0
2698;I-drug;I-DDI-MedLine.d87.s8.e0
prevents;O;O
morphine;B-drug;B-DDI-MedLine.d87.s8.e1
-;O;O
induced;O;O
increases;O;O
in;O;O
gastrointestinal;O;O
transit;O;O
time;O;O
by;O;O
means;O;O
of;O;O
selective;O;O
peripheral;O;O
opioid;O;O
anitagonism;O;O
without;O;O
affecting;O;O
central;O;O
opioid;O;O
analgesia;O;O
.;O;O
DDI-MedLine.d52.s0;;
Restoration;O;O
of;O;O
vancomycin;B-drug;B-DDI-MedLine.d52.s0.e0
susceptibility;O;O
in;O;O
Enterococcus;O;O
faecalis;O;O
by;O;O
antiresistance;O;O
determinant;O;O
gene;O;O
transfer;O;O
.;O;O
DDI-MedLine.d52.s1;;
We;O;O
assessed;O;O
the;O;O
ability;O;O
of;O;O
gene;O;O
transfer;O;O
to;O;O
reverse;O;O
vancomycin;B-drug;B-DDI-MedLine.d52.s1.e0
resistance;O;O
in;O;O
class;O;O
A;O;O
(;O;O
VanA;O;O
);O;O
glycopeptide;O;O
-;O;O
resistant;O;O
Enterococcus;O;O
faecalis;O;O
.;O;O
DDI-MedLine.d52.s2;;
Recombinant;O;O
shuttle;O;O
vectors;O;O
containing;O;O
a;O;O
vanH;O;O
promoter;O;O
-;O;O
vanA;O;O
antisense;O;O
gene;O;O
cassette;O;O
fully;O;O
restored;O;O
vancomycin;B-drug;B-DDI-MedLine.d52.s2.e0
susceptibility;O;O
through;O;O
a;O;O
combined;O;O
transcriptional;O;O
activator;O;O
binding;O;O
domain;O;O
decoy;O;O
and;O;O
inducible;O;O
vanA;O;O
antisense;O;O
RNA;O;O
effect;O;O
.;O;O
DDI-MedLine.d25.s0;;
Rhabdomyolysis;O;O
secondary;O;O
to;O;O
a;O;O
drug;O;O
interaction;O;O
between;O;O
simvastatin;B-drug;B-DDI-MedLine.d25.s0.e0
and;O;O
clarithromycin;B-drug;B-DDI-MedLine.d25.s0.e1
.;O;O
DDI-MedLine.d25.s1;;
OBJECTIVE;O;O
:;O;O
To;O;O
report;O;O
a;O;O
case;O;O
of;O;O
rhabdomyolysis;O;O
resulting;O;O
from;O;O
concomitant;O;O
use;O;O
of;O;O
clarithromycin;B-drug;B-DDI-MedLine.d25.s1.e0
and;O;O
simvastatin;B-drug;B-DDI-MedLine.d25.s1.e1
.;O;O
DDI-MedLine.d25.s2;;
CASE;O;O
SUMMARY;O;O
:;O;O
A;O;O
64;O;O
-;O;O
year;O;O
-;O;O
old;O;O
African;O;O
-;O;O
American;O;O
man;O;O
was;O;O
admitted;O;O
to;O;O
the;O;O
hospital;O;O
for;O;O
worsening;O;O
renal;O;O
failure;O;O
,;O;O
elevated;O;O
creatine;O;O
phosphokinase;O;O
,;O;O
diffuse;O;O
muscle;O;O
pain;O;O
,;O;O
and;O;O
severe;O;O
muscle;O;O
weakness;O;O
.;O;O
DDI-MedLine.d25.s3;;
About;O;O
three;O;O
weeks;O;O
prior;O;O
to;O;O
admission;O;O
,;O;O
the;O;O
patient;O;O
was;O;O
started;O;O
on;O;O
clarithromycin;B-drug;B-DDI-MedLine.d25.s3.e0
for;O;O
sinusitis;O;O
.;O;O
DDI-MedLine.d25.s4;;
The;O;O
patient;O;O
had;O;O
been;O;O
receiving;O;O
simvastatin;B-drug;B-DDI-MedLine.d25.s4.e0
for;O;O
approximately;O;O
six;O;O
months;O;O
.;O;O
DDI-MedLine.d25.s5;;
He;O;O
was;O;O
treated;O;O
aggressively;O;O
with;O;O
intravenous;O;O
hydration;O;O
,;O;O
sodium;B-drug;B-DDI-MedLine.d25.s5.e0
bicarbonate;I-drug;I-DDI-MedLine.d25.s5.e0
,;O;O
and;O;O
hemodialysis;O;O
.;O;O
DDI-MedLine.d25.s6;;
A;O;O
muscle;O;O
biopsy;O;O
revealed;O;O
necrotizing;O;O
myopathy;O;O
secondary;O;O
to;O;O
a;O;O
toxin;O;O
.;O;O
DDI-MedLine.d25.s7;;
The;O;O
patient;O;O
continued;O;O
to;O;O
receive;O;O
intermittent;O;O
hemodialysis;O;O
until;O;O
his;O;O
death;O;O
from;O;O
infectious;O;O
complications;O;O
that;O;O
occurred;O;O
three;O;O
months;O;O
after;O;O
admission;O;O
.;O;O
DDI-MedLine.d25.s8;;
There;O;O
were;O;O
several;O;O
factors;O;O
that;O;O
could;O;O
have;O;O
increased;O;O
his;O;O
risk;O;O
for;O;O
developing;O;O
rhabdomyolysis;O;O
,;O;O
including;O;O
chronic;O;O
renal;O;O
failure;O;O
.;O;O
DDI-MedLine.d25.s9;;
DISCUSSION;O;O
:;O;O
Clarithromycin;B-drug;B-DDI-MedLine.d25.s9.e0
is;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
,;O;O
the;O;O
major;O;O
enzyme;O;O
responsible;O;O
for;O;O
simvastatin;B-drug;B-DDI-MedLine.d25.s9.e1
metabolism;O;O
.;O;O
DDI-MedLine.d25.s10;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
macrolide;B-group;B-DDI-MedLine.d25.s10.e0
antibiotics;I-group;I-DDI-MedLine.d25.s10.e0
and;O;O
other;O;O
hydroxymethylglutaryl;B-group;B-DDI-MedLine.d25.s10.e1
coenzyme;I-group;I-DDI-MedLine.d25.s10.e1
A;I-group;I-DDI-MedLine.d25.s10.e1
(;I-group;I-DDI-MedLine.d25.s10.e1
HMG;I-group;I-DDI-MedLine.d25.s10.e1
-;I-group;I-DDI-MedLine.d25.s10.e1
CoA;I-group;I-DDI-MedLine.d25.s10.e1
);I-group;I-DDI-MedLine.d25.s10.e1
reductase;I-group;I-DDI-MedLine.d25.s10.e1
inhibitors;I-group;I-DDI-MedLine.d25.s10.e1
have;O;O
resulted;O;O
in;O;O
previous;O;O
reports;O;O
of;O;O
rhabdomyolysis;O;O
.;O;O
DDI-MedLine.d25.s11;;
Other;O;O
factors;O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
this;O;O
drug;O;O
interaction;O;O
,;O;O
including;O;O
the;O;O
administration;O;O
of;O;O
other;O;O
medications;O;O
that;O;O
are;O;O
associated;O;O
with;O;O
myopathy;O;O
,;O;O
underlying;O;O
renal;O;O
insufficiency;O;O
,;O;O
and;O;O
administration;O;O
of;O;O
high;O;O
doses;O;O
of;O;O
HMG;B-group;B-DDI-MedLine.d25.s11.e0
-;I-group;I-DDI-MedLine.d25.s11.e0
CoA;I-group;I-DDI-MedLine.d25.s11.e0
reductase;I-group;I-DDI-MedLine.d25.s11.e0
inhibitors;I-group;I-DDI-MedLine.d25.s11.e0
.;O;O
DDI-MedLine.d25.s12;;
CONCLUSIONS;O;O
:;O;O
Macrolide;B-group;B-DDI-MedLine.d25.s12.e0
antibiotics;I-group;I-DDI-MedLine.d25.s12.e0
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
HMG;B-group;B-DDI-MedLine.d25.s12.e1
-;I-group;I-DDI-MedLine.d25.s12.e1
CoA;I-group;I-DDI-MedLine.d25.s12.e1
reductase;I-group;I-DDI-MedLine.d25.s12.e1
inhibitors;I-group;I-DDI-MedLine.d25.s12.e1
that;O;O
are;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
(;O;O
i.e.;O;O
,;O;O
atorvastatin;B-drug;B-DDI-MedLine.d25.s12.e2
,;O;O
cerivastatin;B-drug;B-DDI-MedLine.d25.s12.e3
,;O;O
lovastatin;B-drug;B-DDI-MedLine.d25.s12.e4
,;O;O
simvastatin;B-drug;B-DDI-MedLine.d25.s12.e5
);O;O
.;O;O
DDI-MedLine.d25.s13;;
This;O;O
interaction;O;O
may;O;O
result;O;O
in;O;O
myopathy;O;O
and;O;O
rhabdomyolysis;O;O
,;O;O
particularly;O;O
in;O;O
patients;O;O
with;O;O
renal;O;O
insufficiency;O;O
or;O;O
those;O;O
who;O;O
are;O;O
concurrently;O;O
taking;O;O
medications;O;O
associated;O;O
with;O;O
myopathy;O;O
.;O;O
DDI-MedLine.d141.s0;;
Toxicity;O;O
of;O;O
cadmium;O;O
and;O;O
zinc;B-drug;B-DDI-MedLine.d141.s0.e0
to;O;O
encystment;O;O
and;O;O
in;O;O
vitro;O;O
excystment;O;O
of;O;O
Parorchis;O;O
acanthus;O;O
(;O;O
Digenea;O;O
:;O;O
Philophthalmidae;O;O
);O;O
.;O;O

;O;O
DDI-MedLine.d141.s1;;
The;O;O
toxicity;O;O
of;O;O
cadmium;O;O
,;O;O
zinc;B-drug;B-DDI-MedLine.d141.s1.e0
and;O;O
cadmium;O;O
/;O;O
zinc;O;O
mixtures;O;O
at;O;O
concentrations;O;O
ranging;O;O
from;O;O
1000;O;O
to;O;O
50000;O;O
microg;O;O
/;O;O
l;O;O
were;O;O
investigated;O;O
against;O;O
cercariae;O;O
and;O;O
metacercariae;O;O
of;O;O
Parorchis;O;O
acanthus;O;O
obtained;O;O
from;O;O
the;O;O
dog;O;O
whelk;O;O
Nucella;O;O
lapillus;O;O
.;O;O
DDI-MedLine.d141.s2;;
Cercarial;O;O
encystment;O;O
at;O;O
concentrations;O;O
of;O;O
25000;O;O
microg;O;O
/;O;O
l;O;O
or;O;O
higher;O;O
was;O;O
significantly;O;O
impaired;O;O
by;O;O
all;O;O
test;O;O
metals;O;O
,;O;O
DDI-MedLine.d141.s3;;
however;O;O
,;O;O
at;O;O
lower;O;O
concentrations;O;O
only;O;O
zinc;B-drug;B-DDI-MedLine.d141.s3.e0
demonstrated;O;O
toxicity;O;O
.;O;O
DDI-MedLine.d141.s4;;
Mixtures;O;O
of;O;O
cadmium;O;O
and;O;O
zinc;B-drug;B-DDI-MedLine.d141.s4.e0
had;O;O
a;O;O
synergistic;O;O
effect;O;O
compared;O;O
with;O;O
single;O;O
metal;O;O
toxicity;O;O
but;O;O
only;O;O
at;O;O
50000;O;O
microg;O;O
/;O;O
l;O;O
.;O;O
DDI-MedLine.d141.s5;;
Excystment;O;O
in;O;O
vitro;O;O
was;O;O
only;O;O
significantly;O;O
affected;O;O
by;O;O
cercariae;O;O
exposed;O;O
to;O;O
cadmium;O;O
/;O;O
zinc;O;O
mixtures;O;O
whilst;O;O
encysting;O;O
.;O;O
DDI-MedLine.d141.s6;;
Twenty;O;O
-;O;O
four;O;O
h;O;O
exposures;O;O
of;O;O
fully;O;O
formed;O;O
cysts;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
excystment;O;O
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d141.s7;;
Effects;O;O
on;O;O
in;O;O
vitro;O;O
excystment;O;O
rates;O;O
over;O;O
a;O;O
2;O;O
h;O;O
period;O;O
demonstrated;O;O
widespread;O;O
effects;O;O
for;O;O
cercariae;O;O
-;O;O
exposed;O;O
P.;O;O
DDI-MedLine.d141.s8;;
acanthus;O;O
.;O;O
DDI-MedLine.d141.s9;;
No;O;O
effects;O;O
were;O;O
evident;O;O
on;O;O
excystment;O;O
rates;O;O
of;O;O
cyst;O;O
-;O;O
exposed;O;O
parasites;O;O
.;O;O
DDI-MedLine.d70.s0;;
Toxicity;O;O
of;O;O
cadmium;O;O
and;O;O
zinc;B-drug;B-DDI-MedLine.d70.s0.e0
to;O;O
miracidia;O;O
of;O;O
Schistosoma;O;O
mansoni;O;O
.;O;O

;O;O
DDI-MedLine.d70.s1;;
The;O;O
specific;O;O
objectives;O;O
of;O;O
this;O;O
study;O;O
were;O;O
to;O;O
elucidate;O;O
metal;O;O
toxicity;O;O
to;O;O
hatching;O;O
,;O;O
survival;O;O
and;O;O
avoidance;O;O
behaviour;O;O
of;O;O
Schistosoma;O;O
mansoni;O;O
miracidia;O;O
.;O;O
DDI-MedLine.d70.s2;;
The;O;O
toxicity;O;O
of;O;O
cadmium;O;O
,;O;O
zinc;B-drug;B-DDI-MedLine.d70.s2.e0
,;O;O
and;O;O
cadmium;O;O
/;O;O
zinc;O;O
mixtures;O;O
at;O;O
concentrations;O;O
ranging;O;O
from;O;O
10000;O;O
to;O;O
10;O;O
microg;O;O
/;O;O
l;O;O
was;O;O
investigated;O;O
.;O;O
DDI-MedLine.d70.s3;;
Metal;O;O
mixture;O;O
toxicity;O;O
investigation;O;O
was;O;O
undertaken;O;O
with;O;O
equal;O;O
concentrations;O;O
of;O;O
the;O;O
metals;O;O
.;O;O
DDI-MedLine.d70.s4;;
The;O;O
hatching;O;O
of;O;O
miracidia;O;O
from;O;O
eggs;O;O
was;O;O
inhibited;O;O
by;O;O
concentrations;O;O
of;O;O
1000;O;O
-;O;O
10000;O;O
microg;O;O
/;O;O
l;O;O
of;O;O
single;O;O
metals;O;O
.;O;O
DDI-MedLine.d70.s5;;
Metal;O;O
mixtures;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
egg;B-drug;B-DDI-MedLine.d70.s5.e0
hatching;O;O
.;O;O
DDI-MedLine.d70.s6;;
Survival;O;O
of;O;O
miracidia;O;O
was;O;O
reduced;O;O
by;O;O
increasing;O;O
metal;O;O
concentration;O;O
except;O;O
at;O;O
concentrations;O;O
of;O;O
10;O;O
microg;O;O
/;O;O
l;O;O
for;O;O
single;O;O
metal;O;O
toxicity;O;O
where;O;O
survival;O;O
was;O;O
increased;O;O
above;O;O
the;O;O
control;O;O
.;O;O
DDI-MedLine.d70.s7;;
Miracidia;O;O
demonstrated;O;O
a;O;O
rapid;O;O
avoidance;O;O
behaviour;O;O
when;O;O
briefly;O;O
exposed;O;O
to;O;O
heavy;O;O
metals;O;O
.;O;O
DDI-MedLine.d70.s8;;
The;O;O
mechanisms;O;O
of;O;O
metal;O;O
toxicity;O;O
to;O;O
miracidia;O;O
are;O;O
briefly;O;O
discussed;O;O
.;O;O
DDI-MedLine.d35.s0;;
[;O;O
Importance;O;O
of;O;O
pharmacogenetics];O;O
,;O;O
Pharmacogenetics;O;O
deals;O;O
with;O;O
the;O;O
differences;O;O
in;O;O
effect;O;O
of;O;O
drugs;O;O
caused;O;O
by;O;O
genetic;O;O
variation;O;O
.;O;O
DDI-MedLine.d35.s1;;
Differences;O;O
can;O;O
occur;O;O
in;O;O
therapeutic;O;O
effect;O;O
and;O;O
in;O;O
adverse;O;O
events;O;O
.;O;O
DDI-MedLine.d35.s2;;
Genetic;O;O
variation;O;O
in;O;O
metabolism;O;O
may;O;O
result;O;O
in;O;O
high;O;O
concentrations;O;O
of;O;O
drugs;O;O
and;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
adverse;O;O
effects;O;O
in;O;O
slow;O;O
metabolizers;O;O
,;O;O
which;O;O
is;O;O
important;O;O
when;O;O
using;O;O
for;O;O
example;O;O
antidepressants;B-group;B-DDI-MedLine.d35.s2.e0
or;O;O
chemotherapy;O;O
.;O;O
DDI-MedLine.d35.s3;;
Genetic;O;O
variation;O;O
also;O;O
occurs;O;O
in;O;O
proteins;O;O
interacting;O;O
with;O;O
drugs;O;O
,;O;O
which;O;O
may;O;O
change;O;O
the;O;O
effect;O;O
of;O;O
e.g.;O;O
DDI-MedLine.d35.s4;;
asthma;O;O
drugs;O;O
and;O;O
antipsychotics;B-group;B-DDI-MedLine.d35.s4.e0
.;O;O
DDI-MedLine.d35.s5;;
The;O;O
selection;O;O
of;O;O
drugs;O;O
and;O;O
their;O;O
dosages;O;O
may;O;O
be;O;O
improved;O;O
,;O;O
and;O;O
the;O;O
number;O;O
of;O;O
adverse;O;O
effects;O;O
reduced;O;O
by;O;O
pharmacogenetic;O;O
investigations;O;O
.;O;O
DDI-MedLine.d35.s6;;
However;O;O
,;O;O
it;O;O
may;O;O
be;O;O
important;O;O
also;O;O
in;O;O
case;O;O
of;O;O
medical;O;O
examinations;O;O
for;O;O
insurances;O;O
and;O;O
job;O;O
appointments;O;O
,;O;O
since;O;O
some;O;O
patients;O;O
may;O;O
turn;O;O
out;O;O
to;O;O
need;O;O
expensive;O;O
drugs;O;O
or;O;O
to;O;O
be;O;O
susceptible;O;O
to;O;O
a;O;O
certain;O;O
disease;O;O
.;O;O
DDI-MedLine.d35.s7;;
Therefore;O;O
,;O;O
the;O;O
use;O;O
of;O;O
genetic;O;O
data;O;O
in;O;O
these;O;O
instances;O;O
has;O;O
to;O;O
be;O;O
regulated;O;O
.;O;O
DDI-MedLine.d0.s0;;
The;O;O
effects;O;O
of;O;O
concomitant;O;O
phenytoin;B-drug;B-DDI-MedLine.d0.s0.e0
administration;O;O
on;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
pharmacokinetics;O;O
of;O;O
quetiapine;B-drug;B-DDI-MedLine.d0.s0.e1
.;O;O
DDI-MedLine.d0.s1;;
Quetiapine;B-drug;B-DDI-MedLine.d0.s1.e0
fumarate;I-drug;I-DDI-MedLine.d0.s1.e0
(;O;O
';O;O
Seroquel;B-brand;B-DDI-MedLine.d0.s1.e1
';O;O
);O;O
is;O;O
a;O;O
newly;O;O
introduced;O;O
atypical;B-group;B-DDI-MedLine.d0.s1.e2
antipsychotic;I-group;I-DDI-MedLine.d0.s1.e2
with;O;O
demonstrated;O;O
efficacy;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
positive;O;O
and;O;O
negative;O;O
symptoms;O;O
of;O;O
schizophrenia;O;O
.;O;O
DDI-MedLine.d0.s2;;
It;O;O
is;O;O
extensively;O;O
metabolized;O;O
,;O;O
predominantly;O;O
by;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
.;O;O
DDI-MedLine.d0.s3;;
Therefore;O;O
,;O;O
concurrent;O;O
administration;O;O
of;O;O
drugs;O;O
that;O;O
induce;O;O
or;O;O
inhibit;O;O
this;O;O
enzyme;O;O
may;O;O
affect;O;O
quetiapine;B-drug;B-DDI-MedLine.d0.s3.e0
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d0.s4;;
This;O;O
study;O;O
demonstrated;O;O
that;O;O
the;O;O
potent;O;O
cytochrome;O;O
P450;O;O
enzyme;O;O
-;O;O
inducer;O;O
phenytoin;B-drug;B-DDI-MedLine.d0.s4.e0
did;O;O
indeed;O;O
have;O;O
a;O;O
marked;O;O
effect;O;O
on;O;O
the;O;O
metabolism;O;O
of;O;O
quetiapine;B-drug;B-DDI-MedLine.d0.s4.e1
,;O;O
resulting;O;O
in;O;O
a;O;O
5;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
clearance;O;O
when;O;O
administered;O;O
concomitantly;O;O
to;O;O
patients;O;O
with;O;O
DSM;O;O
-;O;O
IV;O;O
-;O;O
diagnosed;O;O
schizophrenia;O;O
,;O;O
schizoaffective;O;O
disorder;O;O
,;O;O
or;O;O
bipolar;O;O
disorder;O;O
.;O;O
DDI-MedLine.d0.s5;;
These;O;O
results;O;O
indicate;O;O
that;O;O
dosage;O;O
adjustment;O;O
of;O;O
quetiapine;B-drug;B-DDI-MedLine.d0.s5.e0
may;O;O
be;O;O
necessary;O;O
when;O;O
the;O;O
two;O;O
drugs;O;O
are;O;O
given;O;O
concurrently;O;O
and;O;O
that;O;O
caution;O;O
may;O;O
be;O;O
required;O;O
when;O;O
administering;O;O
other;O;O
drugs;O;O
that;O;O
inhibit;O;O
or;O;O
induce;O;O
cytochromes;O;O
,;O;O
particularly;O;O
P450;O;O
3A4;O;O
.;O;O
DDI-MedLine.d111.s0;;
Effect;O;O
of;O;O
coadministered;O;O
drugs;O;O
and;O;O
ethanol;B-drug;B-DDI-MedLine.d111.s0.e0
on;O;O
the;O;O
binding;O;O
of;O;O
therapeutic;O;O
drugs;O;O
to;O;O
human;O;O
serum;O;O
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d111.s1;;
The;O;O
effects;O;O
of;O;O
coadministered;O;O
drugs;O;O
and;O;O
ethanol;B-drug;B-DDI-MedLine.d111.s1.e0
on;O;O
the;O;O
binding;O;O
of;O;O
therapeutic;O;O
drugs;O;O
to;O;O
human;O;O
serum;O;O
in;O;O
vitro;O;O
was;O;O
investigated;O;O
.;O;O
DDI-MedLine.d111.s2;;
Acetaminophen;B-drug;B-DDI-MedLine.d111.s2.e0
,;O;O
lidocaine;B-drug;B-DDI-MedLine.d111.s2.e1
,;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s2.e2
,;O;O
quinidine;B-drug;B-DDI-MedLine.d111.s2.e3
,;O;O
theophylline;B-drug;B-DDI-MedLine.d111.s2.e4
,;O;O
and;O;O
valproic;B-drug;B-DDI-MedLine.d111.s2.e5
acid;I-drug;I-DDI-MedLine.d111.s2.e5
were;O;O
added;O;O
to;O;O
pooled;O;O
human;O;O
serum;O;O
at;O;O
therapeutic;O;O
concentrations;O;O
.;O;O
DDI-MedLine.d111.s3;;
To;O;O
each;O;O
preparation;O;O
was;O;O
added;O;O
one;O;O
additional;O;O
drug;O;O
at;O;O
three;O;O
concentrations;O;O
ranging;O;O
from;O;O
therapeutic;O;O
to;O;O
toxic;O;O
.;O;O
DDI-MedLine.d111.s4;;
The;O;O
following;O;O
eight;O;O
target;O;O
drug;O;O
/;O;O
added;O;O
drug;O;O
combinations;O;O
were;O;O
studied;O;O
:;O;O
acetaminophen;B-drug;B-DDI-MedLine.d111.s4.e0
/;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s4.e1
.;O;O
DDI-MedLine.d111.s5;;
acetaminophen;B-drug;B-DDI-MedLine.d111.s5.e0
/;O;O
theophylline;B-drug;B-DDI-MedLine.d111.s5.e1
,;O;O
lidocaine;B-drug;B-DDI-MedLine.d111.s5.e2
/;O;O
quinidine;B-drug;B-DDI-MedLine.d111.s5.e3
,;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s5.e4
/;O;O
acetaminophen;B-drug;B-DDI-MedLine.d111.s5.e5
,;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s5.e6
/;O;O
valproic;B-drug;B-DDI-MedLine.d111.s5.e7
acid;I-drug;I-DDI-MedLine.d111.s5.e7
,;O;O
quinidine;B-drug;B-DDI-MedLine.d111.s5.e8
/;O;O
lidocaine;B-drug;B-DDI-MedLine.d111.s5.e9
,;O;O
theophylline;B-drug;B-DDI-MedLine.d111.s5.e10
/;O;O
acetaminophen;B-drug;B-DDI-MedLine.d111.s5.e11
,;O;O
and;O;O
valproic;B-drug;B-DDI-MedLine.d111.s5.e12
acid;I-drug;I-DDI-MedLine.d111.s5.e12
/;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s5.e13
.;O;O
DDI-MedLine.d111.s6;;
Each;O;O
serum;O;O
without;O;O
the;O;O
other;O;O
added;O;O
drug;O;O
as;O;O
well;O;O
as;O;O
the;O;O
serum;O;O
supplemented;O;O
with;O;O
the;O;O
other;O;O
drug;O;O
at;O;O
the;O;O
three;O;O
concentrations;O;O
was;O;O
dialyzed;O;O
against;O;O
phosphate;O;O
buffer;O;O
.;O;O
DDI-MedLine.d111.s7;;
Similarly;O;O
dialyzed;O;O
were;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s7.e0
,;O;O
quinidine;B-drug;B-DDI-MedLine.d111.s7.e1
,;O;O
and;O;O
theophylline;B-drug;B-DDI-MedLine.d111.s7.e2
,;O;O
both;O;O
alone;O;O
at;O;O
therapeutic;O;O
concentrations;O;O
in;O;O
serum;O;O
and;O;O
with;O;O
ethanol;B-drug;B-DDI-MedLine.d111.s7.e3
at;O;O
three;O;O
different;O;O
concentrations;O;O
in;O;O
serum;O;O
.;O;O
DDI-MedLine.d111.s8;;
The;O;O
percentage;O;O
of;O;O
drug;O;O
binding;O;O
in;O;O
each;O;O
preparation;O;O
was;O;O
calculated;O;O
.;O;O
DDI-MedLine.d111.s9;;
Acetaminophen;B-drug;B-DDI-MedLine.d111.s9.e0
diminished;O;O
the;O;O
binding;O;O
of;O;O
theophylline;B-drug;B-DDI-MedLine.d111.s9.e1
to;O;O
human;O;O
serum;O;O
by;O;O
a;O;O
net;O;O
change;O;O
of;O;O
5.7;O;O
%;O;O
(;O;O
percentage;O;O
increase;O;O
in;O;O
free;O;O
drug;O;O
fraction;O;O
[;O;O
FDF;O;O
];O;O
,;O;O
11.0;O;O
%;O;O
);O;O
at;O;O
662;O;O
micromol;O;O
/;O;O
L;O;O
and;O;O
by;O;O
a;O;O
net;O;O
change;O;O
of;O;O
7.1;O;O
%;O;O
(;O;O
percentage;O;O
increase;O;O
in;O;O
FDF;O;O
,;O;O
13.7;O;O
%;O;O
);O;O
at;O;O
1324;O;O
micromol;O;O
/;O;O
L.;O;O
DDI-MedLine.d111.s10;;
Theophylline;B-drug;B-DDI-MedLine.d111.s10.e0
decreased;O;O
the;O;O
binding;O;O
of;O;O
acetaminophen;B-drug;B-DDI-MedLine.d111.s10.e1
by;O;O
a;O;O
net;O;O
change;O;O
of;O;O
6.8;O;O
%;O;O
(;O;O
percentage;O;O
increase;O;O
in;O;O
FDF;O;O
,;O;O
8.8;O;O
%;O;O
);O;O
at;O;O
277.5;O;O
micromol;O;O
/;O;O
L;O;O
,;O;O
DDI-MedLine.d111.s11;;
phenobarbital;B-drug;B-DDI-MedLine.d111.s11.e0
reduced;O;O
it;O;O
by;O;O
a;O;O
net;O;O
change;O;O
of;O;O
6.6;O;O
%;O;O
(;O;O
percentage;O;O
increase;O;O
in;O;O
FDF;O;O
,;O;O
8.5;O;O
%;O;O
);O;O
at;O;O
431;O;O
micromol;O;O
/;O;O
L.;O;O
DDI-MedLine.d111.s12;;
Valproic;B-drug;B-DDI-MedLine.d111.s12.e0
acid;I-drug;I-DDI-MedLine.d111.s12.e0
diminished;O;O
binding;O;O
of;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s12.e1
by;O;O
a;O;O
net;O;O
change;O;O
of;O;O
9.9;O;O
%;O;O
(;O;O
percentage;O;O
increase;O;O
in;O;O
FDF;O;O
,;O;O
21.2;O;O
%;O;O
);O;O
at;O;O
1732;O;O
micromol;O;O
/;O;O
L.;O;O
DDI-MedLine.d111.s13;;
No;O;O
significant;O;O
effects;O;O
were;O;O
noted;O;O
with;O;O
other;O;O
drug;O;O
combinations;O;O
or;O;O
with;O;O
the;O;O
addition;O;O
of;O;O
ethanol;B-drug;B-DDI-MedLine.d111.s13.e0
.;O;O
DDI-MedLine.d111.s14;;
Coingestion;O;O
of;O;O
acetaminophen;B-drug;B-DDI-MedLine.d111.s14.e0
with;O;O
theophylline;B-drug;B-DDI-MedLine.d111.s14.e1
,;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s14.e2
with;O;O
acetaminophen;B-drug;B-DDI-MedLine.d111.s14.e3
,;O;O
and;O;O
valproic;B-drug;B-DDI-MedLine.d111.s14.e4
acid;I-drug;I-DDI-MedLine.d111.s14.e4
with;O;O
phenobarbital;B-drug;B-DDI-MedLine.d111.s14.e5
at;O;O
high;O;O
to;O;O
toxic;O;O
concentrations;O;O
decreases;O;O
the;O;O
binding;O;O
of;O;O
the;O;O
target;O;O
drug;O;O
.;O;O
DDI-MedLine.d111.s15;;
The;O;O
resulting;O;O
increase;O;O
in;O;O
free;O;O
drug;O;O
concentration;O;O
may;O;O
lead;O;O
to;O;O
enhanced;O;O
drug;O;O
effect;O;O
in;O;O
vivo;O;O
.;O;O
DDI-MedLine.d60.s0;;
Phenytoin;O;O
intoxication;O;O
induced;O;O
by;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d60.s0.e0
.;O;O

;O;O
DDI-MedLine.d60.s1;;
A;O;O
patient;O;O
had;O;O
phenytoin;O;O
intoxication;O;O
after;O;O
administration;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d60.s1.e0
,;O;O
a;O;O
selective;O;O
serotonin;O;O
reuptake;O;O
inhibitor;O;O
.;O;O
DDI-MedLine.d60.s2;;
The;O;O
serum;O;O
concentration;O;O
of;O;O
phenytoin;B-drug;B-DDI-MedLine.d60.s2.e0
increased;O;O
dramatically;O;O
from;O;O
16.6;O;O
to;O;O
49.1;O;O
microg;O;O
/;O;O
mL;O;O
when;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d60.s2.e1
was;O;O
coadministered;O;O
,;O;O
although;O;O
the;O;O
daily;O;O
dosage;O;O
of;O;O
phenytoin;B-drug;B-DDI-MedLine.d60.s2.e2
and;O;O
other;O;O
drugs;B-drug;B-DDI-MedLine.d60.s2.e3
had;O;O
not;O;O
changed;O;O
.;O;O
DDI-MedLine.d60.s3;;
During;O;O
phenytoin;B-drug;B-DDI-MedLine.d60.s3.e0
and;O;O
fluvoxamine;O;O
treatment;O;O
,;O;O
ataxia;O;O
,;O;O
a;O;O
typical;O;O
side;O;O
effect;O;O
of;O;O
phenytoin;B-drug;B-DDI-MedLine.d60.s3.e1
,;O;O
was;O;O
observed;O;O
.;O;O
DDI-MedLine.d60.s4;;
The;O;O
genotypes;O;O
of;O;O
CYP2C9;B-drug;B-DDI-MedLine.d60.s4.e0
and;O;O
2C19;O;O
,;O;O
the;O;O
enzymes;O;O
responsible;O;O
for;O;O
phenytoin;O;O
metabolism;O;O
,;O;O
were;O;O
homozygous;O;O
for;O;O
the;O;O
wild;O;O
-;O;O
type;O;O
alleles;O;O
(;O;O
CYP2C9;B-drug;B-DDI-MedLine.d60.s4.e1
*;O;O
1;O;O
/;O;O
*;O;O
1;O;O
and;O;O
2C19;O;O
*;O;O
1;O;O
/;O;O
*;O;O
1;O;O
);O;O
.;O;O
DDI-MedLine.d60.s5;;
The;O;O
interaction;O;O
may;O;O
be;O;O
a;O;O
result;O;O
of;O;O
inhibition;O;O
of;O;O
both;O;O
CYP2C9;B-drug;B-DDI-MedLine.d60.s5.e0
and;O;O
2C19;O;O
by;O;O
fluvoxamine;B-drug;B-DDI-MedLine.d60.s5.e1
.;O;O
DDI-MedLine.d123.s0;;
Vancomycin;O;O
resistance;O;O
reversal;O;O
in;O;O
enterococci;O;O
by;O;O
flavonoids;O;O
.;O;O

;O;O
DDI-MedLine.d123.s1;;
The;O;O
development;O;O
of;O;O
clinical;O;O
vancomycin;O;O
-;O;O
resistant;O;O
strains;O;O
of;O;O
enterococci;O;O
(;O;O
VRE;O;O
);O;O
is;O;O
a;O;O
major;O;O
cause;O;O
for;O;O
concern;O;O
.;O;O
DDI-MedLine.d123.s2;;
Here;O;O
we;O;O
show;O;O
that;O;O
a;O;O
combination;O;O
of;O;O
galangin;B-drug;B-DDI-MedLine.d123.s2.e0
or;O;O
3,7;O;O
-;O;O
dihydroxyflavone;O;O
with;O;O
vancomycin;B-drug;B-DDI-MedLine.d123.s2.e1
may;O;O
be;O;O
used;O;O
to;O;O
sensitize;O;O
resistant;O;O
strains;O;O
of;O;O
Enterococcus;O;O
faecalis;O;O
and;O;O
Enterococcus;O;O
faecium;O;O
to;O;O
the;O;O
level;O;O
of;O;O
vancomycin;O;O
-;O;O
sensitive;O;O
strains;O;O
.;O;O
DDI-MedLine.d123.s3;;
Minimum;O;O
inhibitory;O;O
concentrations;O;O
(;O;O
MICs;O;O
);O;O
and;O;O
viable;O;O
counts;O;O
were;O;O
determined;O;O
in;O;O
Iso;O;O
-;O;O
sensitest;O;O
broth;O;O
using;O;O
a;O;O
microtitre;O;O
method;O;O
.;O;O
DDI-MedLine.d123.s4;;
MICs;O;O
of;O;O
vancomycin;B-drug;B-DDI-MedLine.d123.s4.e0
against;O;O
67;O;O
%;O;O
of;O;O
resistant;O;O
clinical;O;O
isolates;O;O
and;O;O
a;O;O
type;O;O
strain;O;O
of;O;O
enterococci;O;O
were;O;O
lowered;O;O
from;O;O
>;O;O
250;O;O
microg;O;O
mL(;O;O
-;O;O
1;O;O
);O;O
to;O;O
1;O;O
DDI-MedLine.d123.s5;;
4;O;O
microg;O;O
mL(;O;O
-;O;O
1;O;O
);O;O
in;O;O
the;O;O
presence;O;O
of;O;O
galangin;B-drug;B-DDI-MedLine.d123.s5.e0
(;O;O
12.5;O;O
microg;O;O
mL(;O;O
-;O;O
1;O;O
);O;O
);O;O
or;O;O
3,7;O;O
-;O;O
dihydroxyflavone;O;O
(;O;O
6.25;O;O
microg;O;O
mL(;O;O
-;O;O
1;O;O
);O;O
);O;O
.;O;O
DDI-MedLine.d123.s6;;
Viable;O;O
counts;O;O
for;O;O
type;O;O
culture;O;O
E.;O;O
DDI-MedLine.d123.s7;;
faecalis;O;O
ATCC;O;O
51299;O;O
showed;O;O
the;O;O
flavonoids;O;O
alone;O;O
significantly;O;O
lowered;O;O
numbers;O;O
of;O;O
colony;O;O
forming;O;O
units;O;O
(;O;O
CFUs;O;O
);O;O
.;O;O
DDI-MedLine.d123.s8;;
CFUs;O;O
were;O;O
maintained;O;O
at;O;O
low;O;O
levels;O;O
(;O;O
10(3;O;O
);O;O
CFU;O;O
mL(;O;O
-;O;O
1;O;O
);O;O
);O;O
for;O;O
24;O;O
h;O;O
by;O;O
vancomycin;B-drug;B-DDI-MedLine.d123.s8.e0
/;O;O
flavone;O;O
combinations;O;O
.;O;O
DDI-MedLine.d123.s9;;
This;O;O
combinational;O;O
action;O;O
in;O;O
reversing;O;O
vancomycin;O;O
resistance;O;O
of;O;O
enterococci;O;O
highlights;O;O
novel;O;O
drug;O;O
targets;O;O
and;O;O
has;O;O
importance;O;O
in;O;O
the;O;O
design;O;O
of;O;O
new;O;O
therapeutic;O;O
regimes;O;O
against;O;O
resistant;O;O
pathogens;O;O
.;O;O
DDI-MedLine.d137.s0;;
Glucose;B-drug;B-DDI-MedLine.d137.s0.e0
and;O;O
insulin;B-drug;B-DDI-MedLine.d137.s0.e1
exert;O;O
additive;O;O
ocular;O;O
and;O;O
renal;O;O
vasodilator;O;O
effects;O;O
on;O;O
healthy;O;O
humans;O;O
.;O;O

;O;O
DDI-MedLine.d137.s1;;
AIMS;O;O
/;O;O
HYPOTHESIS;O;O
:;O;O
There;O;O
is;O;O
evidence;O;O
that;O;O
insulin;B-drug;B-DDI-MedLine.d137.s1.e0
and;O;O
glucose;B-drug;B-DDI-MedLine.d137.s1.e1
cause;O;O
renal;O;O
and;O;O
ocular;O;O
vasodilation;O;O
.;O;O
DDI-MedLine.d137.s2;;
There;O;O
is;O;O
,;O;O
however;O;O
,;O;O
currently;O;O
no;O;O
data;O;O
on;O;O
the;O;O
effect;O;O
of;O;O
combined;O;O
hyperglycaemia;O;O
and;O;O
hyperinsulinaemia;O;O
on;O;O
the;O;O
renal;O;O
and;O;O
ocular;O;O
blood;O;O
flow;O;O
seen;O;O
in;O;O
diabetic;O;O
patients;O;O
on;O;O
insulin;O;O
therapy;O;O
.;O;O
DDI-MedLine.d137.s3;;
METHODS;O;O
:;O;O
We;O;O
carried;O;O
out;O;O
two;O;O
different;O;O
3;O;O
-;O;O
way;O;O
crossover;O;O
studies;O;O
in;O;O
healthy;O;O
subjects;O;O
(;O;O
each;O;O
,;O;O
n;O;O
=;O;O
9;O;O
);O;O
.;O;O
DDI-MedLine.d137.s4;;
In;O;O
study;O;O
one;O;O
,;O;O
hyperglycaemic;O;O
clamps;O;O
(;O;O
5.6;O;O
mmol;O;O
/;O;O
l;O;O
,;O;O
11.1;O;O
mmol;O;O
/;O;O
1;O;O
,;O;O
16.7;O;O
mmol;O;O
/;O;O
l;O;O
);O;O
were;O;O
carried;O;O
out;O;O
during;O;O
placebo;O;O
or;O;O
insulin;B-drug;B-DDI-MedLine.d137.s4.e0
(;O;O
dose;O;O
1;O;O
:;O;O
1;O;O
mU;O;O
/;O;O
kg;O;O
/;O;O
min;O;O
,;O;O
dose;O;O
2;O;O
:;O;O
2;O;O
mU;O;O
/;O;O
kg;O;O
/;O;O
min;O;O
);O;O
infusion;O;O
.;O;O
DDI-MedLine.d137.s5;;
The;O;O
second;O;O
study;O;O
was;O;O
identical;O;O
but;O;O
endogenous;O;O
insulin;O;O
secretion;O;O
was;O;O
blocked;O;O
with;O;O
somatostatin;B-drug;B-DDI-MedLine.d137.s5.e0
.;O;O
DDI-MedLine.d137.s6;;
The;O;O
renal;O;O
plasma;O;O
flow;O;O
,;O;O
glomerular;O;O
filtration;O;O
rate;O;O
and;O;O
pulsatile;O;O
choroidal;O;O
blood;O;O
flow;O;O
were;O;O
measured;O;O
using;O;O
the;O;O
paraaminohippurate;O;O
method;O;O
,;O;O
the;O;O
inulin;O;O
method;O;O
and;O;O
a;O;O
laser;O;O
interferometric;O;O
measurement;O;O
of;O;O
fundus;O;O
pulsation;O;O
amplitude;O;O
,;O;O
respectively;O;O
.;O;O
DDI-MedLine.d137.s7;;
RESULTS;O;O
:;O;O
Insulin;B-drug;B-DDI-MedLine.d137.s7.e0
increased;O;O
renal;O;O
plasma;O;O
flow;O;O
and;O;O
fundus;O;O
pulsation;O;O
amplitude;O;O
but;O;O
not;O;O
the;O;O
glomerular;O;O
filtration;O;O
rate;O;O
.;O;O
DDI-MedLine.d137.s8;;
Hyperglycaemia;O;O
increased;O;O
all;O;O
the;O;O
renal;O;O
and;O;O
ocular;O;O
parameters;O;O
studied;O;O
.;O;O
DDI-MedLine.d137.s9;;
Haemodynamic;O;O
effects;O;O
of;O;O
glucose;B-drug;B-DDI-MedLine.d137.s9.e0
and;O;O
insulin;B-drug;B-DDI-MedLine.d137.s9.e1
were;O;O
additive;O;O
when;O;O
somatostatin;B-drug;B-DDI-MedLine.d137.s9.e2
was;O;O
co;O;O
-;O;O
administered;O;O
but;O;O
not;O;O
under;O;O
basal;O;O
conditions;O;O
.;O;O
DDI-MedLine.d137.s10;;
CONCLUSIONS;O;O
/;O;O
INTERPRETATION;O;O
:;O;O
Glucose;B-drug;B-DDI-MedLine.d137.s10.e0
and;O;O
insulin;B-drug;B-DDI-MedLine.d137.s10.e1
can;O;O
exert;O;O
additive;O;O
vasodilator;O;O
properties;O;O
on;O;O
renal;O;O
and;O;O
ocular;O;O
circulation;O;O
.;O;O
DDI-MedLine.d137.s11;;
To;O;O
find;O;O
out;O;O
whether;O;O
this;O;O
observation;O;O
is;O;O
related;O;O
to;O;O
the;O;O
increased;O;O
regional;O;O
perfusion;O;O
in;O;O
diabetes;O;O
longitudinal;O;O
studies;O;O
on;O;O
patients;O;O
with;O;O
Type;O;O
I;O;O
(;O;O
insulin;O;O
-;O;O
dependent;O;O
);O;O
diabetes;O;O
mellitus;O;O
are;O;O
needed;O;O
.;O;O
DDI-MedLine.d124.s0;;
Lack;O;O
of;O;O
interaction;O;O
between;O;O
levofloxacin;B-drug;B-DDI-MedLine.d124.s0.e0
and;O;O
oxycodone;B-drug;B-DDI-MedLine.d124.s0.e1
:;O;O
pharmacokinetics;O;O
and;O;O
drug;O;O
disposition;O;O
.;O;O
DDI-MedLine.d124.s1;;
Previous;O;O
studies;O;O
have;O;O
demonstrated;O;O
a;O;O
significant;O;O
reduction;O;O
in;O;O
the;O;O
oral;O;O
bioavailability;O;O
of;O;O
trovafloxacin;B-drug;B-DDI-MedLine.d124.s1.e0
and;O;O
ciprofloxacin;B-drug;B-DDI-MedLine.d124.s1.e1
when;O;O
administered;O;O
concomitantly;O;O
with;O;O
an;O;O
intravenous;O;O
opiate;B-group;B-DDI-MedLine.d124.s1.e2
such;O;O
as;O;O
morphine;B-drug;B-DDI-MedLine.d124.s1.e3
.;O;O
DDI-MedLine.d124.s2;;
This;O;O
decrease;O;O
in;O;O
absorption;O;O
results;O;O
in;O;O
a;O;O
36;O;O
%;O;O
and;O;O
50;O;O
%;O;O
lower;O;O
AUC;O;O
for;O;O
trovafloxacin;B-drug;B-DDI-MedLine.d124.s2.e0
and;O;O
ciprofloxacin;B-drug;B-DDI-MedLine.d124.s2.e1
,;O;O
respectively;O;O
,;O;O
which;O;O
could;O;O
cause;O;O
clinical;O;O
failures;O;O
.;O;O
DDI-MedLine.d124.s3;;
The;O;O
authors;O;O
investigated;O;O
the;O;O
possibility;O;O
of;O;O
a;O;O
similar;O;O
interaction;O;O
between;O;O
oxycodone;B-drug;B-DDI-MedLine.d124.s3.e0
and;O;O
levofloxacin;B-drug;B-DDI-MedLine.d124.s3.e1
.;O;O
DDI-MedLine.d124.s4;;
Eight;O;O
healthy;O;O
volunteers;O;O
were;O;O
randomized;O;O
in;O;O
an;O;O
open;O;O
-;O;O
label;O;O
,;O;O
two;O;O
-;O;O
way;O;O
crossover;O;O
study;O;O
to;O;O
receive;O;O
oxycodone;B-drug;B-DDI-MedLine.d124.s4.e0
,;O;O
5;O;O
mg;O;O
p.o;O;O
.;O;O
DDI-MedLine.d124.s5;;
Q4H;O;O
,;O;O
and;O;O
levofloxacin;B-drug;B-DDI-MedLine.d124.s5.e0
,;O;O
500;O;O
mg;O;O
p.o;O;O
.;O;O
DDI-MedLine.d124.s6;;
1;O;O
hour;O;O
after;O;O
starting;O;O
the;O;O
oxycodone;B-drug;B-DDI-MedLine.d124.s6.e0
or;O;O
levofloxacin;B-drug;B-DDI-MedLine.d124.s6.e1
500;O;O
mg;O;O
p.o;O;O
.;O;O
DDI-MedLine.d124.s7;;
alone;O;O
.;O;O
DDI-MedLine.d124.s8;;
Blood;O;O
samples;O;O
were;O;O
drawn;O;O
at;O;O
0;O;O
,;O;O
0.5;O;O
,;O;O
1;O;O
,;O;O
1.5;O;O
,;O;O
2;O;O
,;O;O
3;O;O
,;O;O
4;O;O
,;O;O
6;O;O
,;O;O
8;O;O
,;O;O
12;O;O
,;O;O
18;O;O
,;O;O
and;O;O
24;O;O
hours;O;O
for;O;O
Cmax;O;O
,;O;O
tmax;O;O
,;O;O
and;O;O
AUC;O;O
determinations;O;O
.;O;O
DDI-MedLine.d124.s9;;
There;O;O
was;O;O
not;O;O
a;O;O
significant;O;O
difference;O;O
(;O;O
p;O;O
>;O;O
0.05;O;O
);O;O
in;O;O
AUC;O;O
(;O;O
48.59;O;O
+;O;O
/;O;O
-;O;O
8.52;O;O
vs.;O;O
49.9;O;O
+;O;O
/;O;O
-;O;O
9.93;O;O
);O;O
,;O;O
Cmax;O;O
(;O;O
7.73;O;O
+;O;O
/;O;O
-;O;O
2.6;O;O
vs.;O;O
6.6;O;O
+;O;O
/;O;O
-;O;O
2.0;O;O
);O;O
,;O;O
and;O;O
tmax;O;O
(;O;O
1.1;O;O
+;O;O
/;O;O
-;O;O
0.6;O;O
vs.;O;O
1.6;O;O
+;O;O
/;O;O
-;O;O
1.1;O;O
);O;O
for;O;O
levofloxacin;B-drug;B-DDI-MedLine.d124.s9.e0
versus;O;O
levofloxacin;B-drug;B-DDI-MedLine.d124.s9.e1
/;O;O
oxycodone;B-drug;B-DDI-MedLine.d124.s9.e2
regimens;O;O
.;O;O
DDI-MedLine.d124.s10;;
It;O;O
was;O;O
concluded;O;O
that;O;O
oral;O;O
oxycodone;B-drug;B-DDI-MedLine.d124.s10.e0
and;O;O
levofloxacin;B-drug;B-DDI-MedLine.d124.s10.e1
can;O;O
be;O;O
administered;O;O
concomitantly;O;O
without;O;O
a;O;O
significant;O;O
decrease;O;O
in;O;O
AUC;O;O
,;O;O
Cmax;O;O
,;O;O
or;O;O
tmax;O;O
.;O;O
DDI-MedLine.d105.s0;;
Lack;O;O
of;O;O
an;O;O
effect;O;O
of;O;O
azithromycin;B-drug;B-DDI-MedLine.d105.s0.e0
on;O;O
the;O;O
disposition;O;O
of;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s0.e1
and;O;O
dideoxyinosine;B-drug;B-DDI-MedLine.d105.s0.e2
in;O;O
HIV;O;O
-;O;O
infected;O;O
patients;O;O
.;O;O
DDI-MedLine.d105.s1;;
Two;O;O
studies;O;O
were;O;O
conducted;O;O
in;O;O
HIV;O;O
-;O;O
infected;O;O
subjects;O;O
to;O;O
assess;O;O
the;O;O
potential;O;O
for;O;O
azithromycin;B-drug;B-DDI-MedLine.d105.s1.e0
to;O;O
interact;O;O
with;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s1.e1
and;O;O
dideoxyinosine;B-drug;B-DDI-MedLine.d105.s1.e2
.;O;O
DDI-MedLine.d105.s2;;
Both;O;O
studies;O;O
used;O;O
12;O;O
subjects;O;O
.;O;O
DDI-MedLine.d105.s3;;
The;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s3.e0
study;O;O
dosed;O;O
subjects;O;O
with;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
azithromycin;B-drug;B-DDI-MedLine.d105.s3.e1
(;O;O
n;O;O
=;O;O
7;O;O
);O;O
(;O;O
later;O;O
changed;O;O
to;O;O
600;O;O
mg;O;O
/;O;O
day;O;O
[;O;O
n;O;O
=;O;O
5;O;O
];O;O
);O;O
for;O;O
Days;O;O
8;O;O
to;O;O
21;O;O
of;O;O
a;O;O
21;O;O
-;O;O
day;O;O
course;O;O
of;O;O
100;O;O
mg;O;O
,;O;O
five;O;O
times;O;O
/;O;O
day;O;O
of;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s3.e2
.;O;O
DDI-MedLine.d105.s4;;
Subjects;O;O
treated;O;O
with;O;O
200;O;O
mg;O;O
of;O;O
dideoxyinosine;B-drug;B-DDI-MedLine.d105.s4.e0
twice;O;O
daily;O;O
for;O;O
21;O;O
days;O;O
received;O;O
1200;O;O
mg;O;O
of;O;O
azithromycin;B-drug;B-DDI-MedLine.d105.s4.e1
or;O;O
an;O;O
equivalent;O;O
amount;O;O
of;O;O
placebo;O;O
/;O;O
day;O;O
for;O;O
Days;O;O
8;O;O
to;O;O
21;O;O
.;O;O
DDI-MedLine.d105.s5;;
Antiretroviral;B-group;B-DDI-MedLine.d105.s5.e0
plasma;O;O
and;O;O
urine;O;O
sampling;O;O
were;O;O
conducted;O;O
on;O;O
Days;O;O
1;O;O
,;O;O
7;O;O
,;O;O
and;O;O
21;O;O
for;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s5.e1
and;O;O
on;O;O
Days;O;O
7;O;O
and;O;O
21;O;O
for;O;O
dideoxyinosine;B-drug;B-DDI-MedLine.d105.s5.e2
.;O;O
DDI-MedLine.d105.s6;;
Peripheral;O;O
mononuclear;O;O
cells;O;O
were;O;O
also;O;O
collected;O;O
for;O;O
quantitation;O;O
of;O;O
phosphorylated;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s6.e0
.;O;O
DDI-MedLine.d105.s7;;
Azithromycin;B-drug;B-DDI-MedLine.d105.s7.e0
had;O;O
no;O;O
significant;O;O
impact;O;O
on;O;O
the;O;O
Cmax;O;O
and;O;O
AUC;O;O
of;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s7.e1
,;O;O
although;O;O
it;O;O
significantly;O;O
decreased;O;O
the;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s7.e2
tmax;O;O
by;O;O
44;O;O
%;O;O
and;O;O
increased;O;O
the;O;O
intracellular;O;O
exposure;O;O
to;O;O
phosphorylated;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s7.e3
by;O;O
110;O;O
%;O;O
.;O;O
DDI-MedLine.d105.s8;;
Azithromycin;B-drug;B-DDI-MedLine.d105.s8.e0
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
dideoxyinosine;B-drug;B-DDI-MedLine.d105.s8.e1
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d105.s9;;
Based;O;O
on;O;O
the;O;O
results;O;O
of;O;O
these;O;O
studies;O;O
,;O;O
it;O;O
is;O;O
concluded;O;O
that;O;O
azithromycin;B-drug;B-DDI-MedLine.d105.s9.e0
may;O;O
be;O;O
safely;O;O
coadministered;O;O
with;O;O
both;O;O
zidovudine;B-drug;B-DDI-MedLine.d105.s9.e1
and;O;O
dideoxyinosine;B-drug;B-DDI-MedLine.d105.s9.e2
.;O;O
DDI-MedLine.d67.s0;;
Effect;O;O
of;O;O
diazepam;B-drug;B-DDI-MedLine.d67.s0.e0
and;O;O
midazolam;B-drug;B-DDI-MedLine.d67.s0.e1
on;O;O
the;O;O
antinociceptive;O;O
effect;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d67.s0.e2
,;O;O
metamizol;B-drug;B-DDI-MedLine.d67.s0.e3
and;O;O
indomethacin;B-drug;B-DDI-MedLine.d67.s0.e4
in;O;O
mice;O;O
.;O;O
DDI-MedLine.d67.s1;;
The;O;O
influence;O;O
of;O;O
midazolam;B-drug;B-DDI-MedLine.d67.s1.e0
and;O;O
diazepam;B-drug;B-DDI-MedLine.d67.s1.e1
on;O;O
antinociceptive;O;O
effect;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d67.s1.e2
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
,;O;O
metamizol;B-drug;B-DDI-MedLine.d67.s1.e3
(;O;O
500;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
and;O;O
indomethacin;B-drug;B-DDI-MedLine.d67.s1.e4
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
was;O;O
investigated;O;O
in;O;O
a;O;O
mouse;O;O
model;O;O
using;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
and;O;O
hot;O;O
-;O;O
plate;O;O
tests;O;O
.;O;O
DDI-MedLine.d67.s2;;
All;O;O
drugs;O;O
were;O;O
injected;O;O
intraperitoneally;O;O
.;O;O
DDI-MedLine.d67.s3;;
Benzodiazepines;B-group;B-DDI-MedLine.d67.s3.e0
were;O;O
administered;O;O
to;O;O
mice;O;O
30;O;O
min;O;O
before;O;O
applying;O;O
the;O;O
analgesic;B-group;B-DDI-MedLine.d67.s3.e1
drugs;I-group;I-DDI-MedLine.d67.s3.e1
.;O;O
DDI-MedLine.d67.s4;;
Measurement;O;O
of;O;O
nociception;O;O
was;O;O
performed;O;O
within;O;O
2;O;O
h;O;O
after;O;O
benzodiazepine;B-group;B-DDI-MedLine.d67.s4.e0
administration;O;O
.;O;O
DDI-MedLine.d67.s5;;
Diazepam;B-drug;B-DDI-MedLine.d67.s5.e0
at;O;O
doses;O;O
of;O;O
0.25;O;O
mg;O;O
/;O;O
kg;O;O
and;O;O
2.5;O;O
mg;O;O
/;O;O
kg;O;O
injected;O;O
with;O;O
morphine;B-drug;B-DDI-MedLine.d67.s5.e1
was;O;O
found;O;O
to;O;O
decrease;O;O
the;O;O
antinociceptive;O;O
effect;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d67.s5.e2
.;O;O
DDI-MedLine.d67.s6;;
Similarly;O;O
,;O;O
diazepam;B-drug;B-DDI-MedLine.d67.s6.e0
decreased;O;O
the;O;O
antinociceptive;O;O
effect;O;O
of;O;O
metamizol;B-drug;B-DDI-MedLine.d67.s6.e1
(;O;O
only;O;O
in;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
test;O;O
);O;O
and;O;O
indomethacin;B-drug;B-DDI-MedLine.d67.s6.e2
.;O;O
DDI-MedLine.d67.s7;;
Midazolam;B-drug;B-DDI-MedLine.d67.s7.e0
used;O;O
at;O;O
doses;O;O
of;O;O
1.25;O;O
mg;O;O
/;O;O
kg;O;O
and;O;O
2.5;O;O
mg;O;O
/;O;O
kg;O;O
decreased;O;O
the;O;O
antinociceptive;O;O
effect;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d67.s7.e1
,;O;O
metamizol;B-drug;B-DDI-MedLine.d67.s7.e2
(;O;O
only;O;O
in;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
test;O;O
);O;O
and;O;O
indomethacin;B-drug;B-DDI-MedLine.d67.s7.e3
.;O;O
DDI-MedLine.d64.s0;;
Pharmacological;O;O
treatment;O;O
of;O;O
depression;O;O
:;O;O
the;O;O
role;O;O
of;O;O
paroxetine;B-drug;B-DDI-MedLine.d64.s0.e0
.;O;O
DDI-MedLine.d64.s1;;
Depression;O;O
is;O;O
reaching;O;O
epidemic;O;O
proportions;O;O
in;O;O
the;O;O
western;O;O
world;O;O
.;O;O
DDI-MedLine.d64.s2;;
With;O;O
each;O;O
successive;O;O
generation;O;O
more;O;O
people;O;O
are;O;O
becoming;O;O
more;O;O
severely;O;O
depressed;O;O
at;O;O
a;O;O
younger;O;O
age;O;O
.;O;O
DDI-MedLine.d102.s0;;
Influence;O;O
of;O;O
estradiol;B-drug;B-DDI-MedLine.d102.s0.e0
and;O;O
progesterone;B-drug;B-DDI-MedLine.d102.s0.e1
on;O;O
the;O;O
sensitivity;O;O
of;O;O
rat;O;O
thoracic;O;O
aorta;O;O
to;O;O
noradrenaline;B-drug;B-DDI-MedLine.d102.s0.e2
.;O;O
DDI-MedLine.d102.s1;;
The;O;O
aim;O;O
of;O;O
this;O;O
study;O;O
was;O;O
to;O;O
investigate;O;O
the;O;O
effects;O;O
of;O;O
low;O;O
and;O;O
high;O;O
doses;O;O
of;O;O
estradiol;B-drug;B-DDI-MedLine.d102.s1.e0
,;O;O
and;O;O
of;O;O
progesterone;B-drug;B-DDI-MedLine.d102.s1.e1
on;O;O
the;O;O
response;O;O
to;O;O
noradrenaline;B-drug;B-DDI-MedLine.d102.s1.e2
in;O;O
rat;O;O
thoracic;O;O
aorta;O;O
.;O;O
DDI-MedLine.d102.s2;;
Two;O;O
weeks;O;O
after;O;O
bilateral;O;O
ovariectomy;O;O
,;O;O
female;O;O
rats;O;O
received;O;O
a;O;O
s.c;O;O
.;O;O
DDI-MedLine.d102.s3;;
injection;O;O
of;O;O
vehicle;O;O
(;O;O
corn;O;O
oil;O;O
,;O;O
0.1;O;O
mL;O;O
/;O;O
day;O;O
);O;O
,;O;O
estradiol;B-drug;B-DDI-MedLine.d102.s3.e0
(;O;O
10;O;O
microg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
or;O;O
4;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
and/or;O;O
progesterone;B-drug;B-DDI-MedLine.d102.s3.e1
(;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
,;O;O
for;O;O
eight;O;O
days;O;O
.;O;O
DDI-MedLine.d102.s4;;
On;O;O
the;O;O
ninth;O;O
day;O;O
,;O;O
the;O;O
rats;O;O
were;O;O
sacrificed;O;O
and;O;O
aortic;O;O
rings;O;O
,;O;O
with;O;O
or;O;O
without;O;O
endothelium;O;O
,;O;O
were;O;O
used;O;O
to;O;O
generate;O;O
concentration;O;O
-;O;O
response;O;O
curves;O;O
to;O;O
noradrenaline;B-drug;B-DDI-MedLine.d102.s4.e0
.;O;O
DDI-MedLine.d102.s5;;
Aortic;O;O
rings;O;O
with;O;O
intact;O;O
endothelium;O;O
from;O;O
the;O;O
high;O;O
-;O;O
dose;O;O
(;O;O
4;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
estradiol;B-drug;B-DDI-MedLine.d102.s5.e0
group;O;O
were;O;O
supersensitive;O;O
to;O;O
noradrenaline;B-drug;B-DDI-MedLine.d102.s5.e1
compared;O;O
to;O;O
the;O;O
vehicle;O;O
or;O;O
low;O;O
-;O;O
dose;O;O
(;O;O
10;O;O
microg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
estradiol;O;O
groups;O;O
(;O;O
pD2;O;O
values;O;O
=;O;O
7.86+;O;O
/;O;O
-;O;O
0.09;O;O
,;O;O
7.30+;O;O
/;O;O
-;O;O
0.11;O;O
and;O;O
7.35+;O;O
/;O;O
-;O;O
0.04;O;O
,;O;O
respectively;O;O
);O;O
.;O;O
DDI-MedLine.d102.s6;;
Endothelium;O;O
-;O;O
intact;O;O
aortic;O;O
rings;O;O
from;O;O
high;O;O
-;O;O
estradiol;B-drug;B-DDI-MedLine.d102.s6.e0
rats;O;O
were;O;O
supersensitive;O;O
to;O;O
noradrenaline;B-drug;B-DDI-MedLine.d102.s6.e1
when;O;O
compared;O;O
to;O;O
vehicle;O;O
-;O;O
,;O;O
progesterone;B-drug;B-DDI-MedLine.d102.s6.e2
-;O;O
and;O;O
progesterone;B-drug;B-DDI-MedLine.d102.s6.e3
+;O;O
high;O;O
-;O;O
estradiol;B-drug;B-DDI-MedLine.d102.s6.e4
-;O;O
treated;O;O
rats;O;O
(;O;O
pD2;O;O
values;O;O
=;O;O
7.77+;O;O
/;O;O
-;O;O
0.12;O;O
,;O;O
7.21+;O;O
/;O;O
-;O;O
0.13;O;O
,;O;O
6.93+;O;O
/;O;O
-;O;O
0.04;O;O
and;O;O
7.22+;O;O
/;O;O
-;O;O
0.18;O;O
,;O;O
respectively;O;O
);O;O
.;O;O
DDI-MedLine.d102.s7;;
There;O;O
were;O;O
no;O;O
significant;O;O
differences;O;O
among;O;O
the;O;O
pD2;O;O
values;O;O
for;O;O
noradrenaline;B-drug;B-DDI-MedLine.d102.s7.e0
in;O;O
aortic;O;O
rings;O;O
without;O;O
endothelium;O;O
.;O;O
DDI-MedLine.d102.s8;;
Both;O;O
of;O;O
these;O;O
effects;O;O
were;O;O
endothelium;O;O
-;O;O
dependent;O;O
.;O;O
DDI-MedLine.d1.s0;;
[;O;O
Drug;O;O
treatment;O;O
of;O;O
erection;O;O
disorders;O;O
in;O;O
patients;O;O
with;O;O
cardiovascular;O;O
disease;O;O
];O;O

;O;O
Erectile;O;O
dysfunction;O;O
is;O;O
a;O;O
frequent;O;O
condition;O;O
in;O;O
cardiovascular;O;O
patients;O;O
.;O;O
DDI-MedLine.d1.s1;;
Since;O;O
the;O;O
arrival;O;O
of;O;O
oral;O;O
erection;B-group;B-DDI-MedLine.d1.s1.e0
-;I-group;I-DDI-MedLine.d1.s1.e0
supporting;I-group;I-DDI-MedLine.d1.s1.e0
medication;I-group;I-DDI-MedLine.d1.s1.e0
,;O;O
patients;O;O
want;O;O
to;O;O
know;O;O
how;O;O
safe;O;O
sexual;O;O
activity;O;O
is;O;O
in;O;O
cardiovascular;O;O
disease;O;O
in;O;O
general;O;O
and;O;O
during;O;O
use;O;O
of;O;O
erection;B-group;B-DDI-MedLine.d1.s1.e1
-;I-group;I-DDI-MedLine.d1.s1.e1
supporting;I-group;I-DDI-MedLine.d1.s1.e1
medication;I-group;I-DDI-MedLine.d1.s1.e1
in;O;O
particular;O;O
.;O;O
DDI-MedLine.d1.s2;;
Sexual;O;O
intercourse;O;O
with;O;O
a;O;O
steady;O;O
partner;O;O
causes;O;O
no;O;O
more;O;O
cardiovascular;O;O
risk;O;O
than;O;O
normal;O;O
daily;O;O
activities;O;O
such;O;O
as;O;O
ironing;O;O
,;O;O
2;O;O
kilometers;O;O
of;O;O
walking;O;O
without;O;O
climbing;O;O
,;O;O
paperhanging;O;O
,;O;O
playing;O;O
golf;O;O
or;O;O
gardening;O;O
.;O;O
DDI-MedLine.d1.s3;;
The;O;O
relative;O;O
risk;O;O
of;O;O
myocardial;O;O
infarction;O;O
during;O;O
sexual;O;O
activity;O;O
is;O;O
not;O;O
significantly;O;O
higher;O;O
than;O;O
for;O;O
healthy;O;O
persons;O;O
.;O;O
DDI-MedLine.d1.s4;;
The;O;O
incidence;O;O
of;O;O
cardiovascular;O;O
morbidity;O;O
and;O;O
mortality;O;O
is;O;O
not;O;O
higher;O;O
among;O;O
users;O;O
of;O;O
sildenafil;B-drug;B-DDI-MedLine.d1.s4.e0
.;O;O
DDI-MedLine.d1.s5;;
Sildenafil;B-drug;B-DDI-MedLine.d1.s5.e0
is;O;O
contraindicated;O;O
in;O;O
patients;O;O
using;O;O
long;B-group;B-DDI-MedLine.d1.s5.e1
-;I-group;I-DDI-MedLine.d1.s5.e1
acting;I-group;I-DDI-MedLine.d1.s5.e1
nitrates;I-group;I-DDI-MedLine.d1.s5.e1
or;O;O
who;O;O
may;O;O
need;O;O
to;O;O
use;O;O
short;B-group;B-DDI-MedLine.d1.s5.e2
-;I-group;I-DDI-MedLine.d1.s5.e2
acting;I-group;I-DDI-MedLine.d1.s5.e2
nitrates;I-group;I-DDI-MedLine.d1.s5.e2
,;O;O
because;O;O
the;O;O
combination;O;O
may;O;O
cause;O;O
a;O;O
sharp;O;O
fall;O;O
of;O;O
the;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-MedLine.d1.s6;;
No;O;O
interactions;O;O
have;O;O
been;O;O
observed;O;O
with;O;O
beta;B-group;B-DDI-MedLine.d1.s6.e0
-;I-group;I-DDI-MedLine.d1.s6.e0
receptor;I-group;I-DDI-MedLine.d1.s6.e0
blockers;I-group;I-DDI-MedLine.d1.s6.e0
,;O;O
calcium;B-group;B-DDI-MedLine.d1.s6.e1
antagonists;I-group;I-DDI-MedLine.d1.s6.e1
,;O;O
thiazide;B-group;B-DDI-MedLine.d1.s6.e2
and;I-group;I-DDI-MedLine.d1.s6.e2
loop;I-group;I-DDI-MedLine.d1.s6.e3
diuretics;I-group;I-DDI-MedLine.d1.s6.e3
and;O;O
ACE;B-group;B-DDI-MedLine.d1.s6.e4
inhibitors;I-group;I-DDI-MedLine.d1.s6.e4
.;O;O
DDI-MedLine.d1.s7;;
Before;O;O
prescribing;O;O
a;O;O
symptomatic;O;O
(;O;O
pharmaceutical;O;O
);O;O
treatment;O;O
for;O;O
patients;O;O
with;O;O
an;O;O
erection;O;O
disorder;O;O
,;O;O
attention;O;O
should;O;O
be;O;O
given;O;O
tot;O;O
the;O;O
sexological;O;O
,;O;O
psychological;O;O
and;O;O
medical;O;O
backgrounds;O;O
of;O;O
the;O;O
disorder;O;O
.;O;O
DDI-MedLine.d1.s8;;
Secondary;O;O
prevention;O;O
of;O;O
atherosclerotic;O;O
risk;O;O
factors;O;O
is;O;O
also;O;O
important;O;O
:;O;O
regulation;O;O
of;O;O
blood;O;O
pressure;O;O
and;O;O
blood;O;O
sugar;O;O
level;O;O
,;O;O
hyperlipidaemia;O;O
and;O;O
obesity;O;O
,;O;O
as;O;O
well;O;O
as;O;O
a;O;O
change;O;O
of;O;O
lifestyle;O;O
(;O;O
giving;O;O
up;O;O
smoking;O;O
,;O;O
adapting;O;O
of;O;O
diet;O;O
and;O;O
more;O;O
physical;O;O
exertion;O;O
);O;O
.;O;O
DDI-MedLine.d1.s9;;
Patients;O;O
with;O;O
a;O;O
very;O;O
low;O;O
cardiac;O;O
capacity;O;O
should;O;O
be;O;O
advised;O;O
to;O;O
refrain;O;O
from;O;O
treatment;O;O
of;O;O
the;O;O
erection;O;O
disorder;O;O
.;O;O
DDI-MedLine.d46.s0;;
Influence;O;O
of;O;O
coadministration;O;O
of;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s0.e0
on;O;O
cisapride;B-drug;B-DDI-MedLine.d46.s0.e1
pharmacokinetics;O;O
and;O;O
QTc;O;O
intervals;O;O
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-MedLine.d46.s1;;
STUDY;O;O
OBJECTIVE;O;O
:;O;O
To;O;O
evaluate;O;O
the;O;O
effect;O;O
of;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s1.e0
on;O;O
the;O;O
pharmacokinetics;O;O
and;O;O
cardiovascular;O;O
safety;O;O
of;O;O
cisapride;B-drug;B-DDI-MedLine.d46.s1.e1
at;O;O
steady;O;O
state;O;O
in;O;O
healthy;O;O
men;O;O
.;O;O
DDI-MedLine.d46.s2;;
DESIGN;O;O
:;O;O
Open;O;O
-;O;O
label;O;O
,;O;O
three;O;O
-;O;O
phase;O;O
,;O;O
sequential;O;O
study;O;O
.;O;O
DDI-MedLine.d46.s3;;
SETTING;O;O
:;O;O
Clinical;O;O
research;O;O
center;O;O
.;O;O
DDI-MedLine.d46.s4;;
SUBJECTS;O;O
:;O;O
Twelve;O;O
healthy;O;O
male;O;O
volunteers;O;O
.;O;O
DDI-MedLine.d46.s5;;
INTERVENTIONS;O;O
:;O;O
Each;O;O
subject;O;O
was;O;O
treated;O;O
according;O;O
to;O;O
the;O;O
following;O;O
sequence;O;O
:;O;O
baseline;O;O
,;O;O
DDI-MedLine.d46.s6;;
phase;O;O
1;O;O
(;O;O
days;O;O
1;O;O
-;O;O
6;O;O
);O;O
:;O;O
cisapride;B-drug;B-DDI-MedLine.d46.s6.e0
10;O;O
mg;O;O
4;O;O
times;O;O
/;O;O
day;O;O
,;O;O
DDI-MedLine.d46.s7;;
washout;O;O
(;O;O
days;O;O
7;O;O
-;O;O
13;O;O
);O;O
,;O;O
DDI-MedLine.d46.s8;;
phase;O;O
2;O;O
(;O;O
days;O;O
14;O;O
-;O;O
44;O;O
);O;O
:;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s8.e0
20;O;O
mg;O;O
/;O;O
day;O;O
,;O;O
DDI-MedLine.d46.s9;;
and;O;O
phase;O;O
3;O;O
(;O;O
days;O;O
45;O;O
-;O;O
52;O;O
);O;O
:;O;O
cisapride;B-drug;B-DDI-MedLine.d46.s9.e0
10;O;O
mg;O;O
4;O;O
times;O;O
/;O;O
day;O;O
(;O;O
days;O;O
45;O;O
-;O;O
51;O;O
);O;O
plus;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s9.e1
20;O;O
mg;O;O
/;O;O
day;O;O
(;O;O
days;O;O
45;O;O
-;O;O
52;O;O
);O;O
.;O;O
DDI-MedLine.d46.s10;;
MEASUREMENTS;O;O
and;O;O
MAIN;O;O
RESULTS;O;O
:;O;O
Blood;O;O
samples;O;O
were;O;O
drawn;O;O
and;O;O
12;O;O
-;O;O
lead;O;O
electrocardiograms;O;O
performed;O;O
at;O;O
specified;O;O
time;O;O
points;O;O
after;O;O
the;O;O
last;O;O
morning;O;O
dose;O;O
of;O;O
cisapride;B-drug;B-DDI-MedLine.d46.s10.e0
in;O;O
phases;O;O
1;O;O
and;O;O
3;O;O
.;O;O
DDI-MedLine.d46.s11;;
Blood;O;O
samples;O;O
also;O;O
were;O;O
taken;O;O
before;O;O
morning;O;O
doses;O;O
on;O;O
the;O;O
3rd;O;O
,;O;O
4th;O;O
,;O;O
and;O;O
5th;O;O
days;O;O
of;O;O
phases;O;O
1;O;O
and;O;O
3;O;O
.;O;O
DDI-MedLine.d46.s12;;
Electrocardiograms;O;O
were;O;O
done;O;O
at;O;O
baseline;O;O
and;O;O
on;O;O
the;O;O
last;O;O
day;O;O
of;O;O
the;O;O
washout;O;O
period;O;O
and;O;O
phase;O;O
2;O;O
.;O;O
DDI-MedLine.d46.s13;;
Coadministration;O;O
of;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s13.e0
significantly;O;O
decreased;O;O
cisapride;B-drug;B-DDI-MedLine.d46.s13.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-MedLine.d46.s14;;
There;O;O
were;O;O
no;O;O
clinically;O;O
significant;O;O
changes;O;O
in;O;O
corrected;O;O
QT;O;O
intervals;O;O
during;O;O
administration;O;O
of;O;O
cisapride;B-drug;B-DDI-MedLine.d46.s14.e0
alone;O;O
or;O;O
with;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s14.e1
.;O;O
DDI-MedLine.d46.s15;;
Cisapride;B-drug;B-DDI-MedLine.d46.s15.e0
was;O;O
well;O;O
tolerated;O;O
when;O;O
administered;O;O
alone;O;O
or;O;O
with;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s15.e1
.;O;O
DDI-MedLine.d46.s16;;
CONCLUSION;O;O
:;O;O
Cisapride;B-drug;B-DDI-MedLine.d46.s16.e0
can;O;O
be;O;O
administered;O;O
safely;O;O
to;O;O
patients;O;O
receiving;O;O
low;O;O
therapeutic;O;O
dosages;O;O
of;O;O
fluoxetine;B-drug;B-DDI-MedLine.d46.s16.e1
.;O;O
DDI-MedLine.d83.s0;;
Olanzapine;B-drug;B-DDI-MedLine.d83.s0.e0
:;O;O
an;O;O
updated;O;O
review;O;O
of;O;O
its;O;O
use;O;O
in;O;O
the;O;O
management;O;O
of;O;O
schizophrenia;O;O
.;O;O

;O;O
DDI-MedLine.d83.s1;;
Olanzapine;B-drug;B-DDI-MedLine.d83.s1.e0
,;O;O
a;O;O
thienobenzodiazepine;B-group;B-DDI-MedLine.d83.s1.e1
derivative;I-group;I-DDI-MedLine.d83.s1.e1
,;O;O
is;O;O
a;O;O
second;B-group;B-DDI-MedLine.d83.s1.e2
generation;I-group;I-DDI-MedLine.d83.s1.e2
(;I-group;I-DDI-MedLine.d83.s1.e2
atypical;I-group;I-DDI-MedLine.d83.s1.e2
);I-group;I-DDI-MedLine.d83.s1.e2
antipsychotic;I-group;I-DDI-MedLine.d83.s1.e2
agent;I-group;I-DDI-MedLine.d83.s1.e2
which;O;O
has;O;O
proven;O;O
efficacy;O;O
against;O;O
the;O;O
positive;O;O
and;O;O
negative;O;O
symptoms;O;O
of;O;O
schizophrenia;O;O
.;O;O
DDI-MedLine.d83.s2;;
Compared;O;O
with;O;O
conventional;B-group;B-DDI-MedLine.d83.s2.e0
antipsychotics;I-group;I-DDI-MedLine.d83.s2.e0
,;O;O
it;O;O
has;O;O
greater;O;O
affinity;O;O
for;O;O
serotonin;O;O
5;O;O
-;O;O
HT2A;O;O
than;O;O
for;O;O
dopamine;O;O
D2;O;O
receptors;O;O
.;O;O
DDI-MedLine.d83.s3;;
In;O;O
large;O;O
,;O;O
well;O;O
controlled;O;O
trials;O;O
in;O;O
patients;O;O
with;O;O
schizophrenia;O;O
or;O;O
related;O;O
psychoses;O;O
,;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s3.e0
5;O;O
to;O;O
20;O;O
mg;O;O
/;O;O
day;O;O
was;O;O
significantly;O;O
superior;O;O
to;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s3.e1
5;O;O
to;O;O
20;O;O
mg;O;O
/;O;O
day;O;O
in;O;O
overall;O;O
improvements;O;O
in;O;O
psychopathology;O;O
rating;O;O
scales;O;O
and;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
depressive;O;O
and;O;O
negative;O;O
symptoms;O;O
,;O;O
and;O;O
was;O;O
comparable;O;O
in;O;O
effects;O;O
on;O;O
positive;O;O
psychotic;O;O
symptoms;O;O
.;O;O
DDI-MedLine.d83.s4;;
The;O;O
1;O;O
-;O;O
year;O;O
risk;O;O
of;O;O
relapse;O;O
(;O;O
rehospitalisation;O;O
);O;O
was;O;O
significantly;O;O
lower;O;O
with;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s4.e0
than;O;O
with;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s4.e1
treatment;O;O
.;O;O
DDI-MedLine.d83.s5;;
In;O;O
the;O;O
first;O;O
double;O;O
-;O;O
blind;O;O
comparative;O;O
study;O;O
(;O;O
28;O;O
-;O;O
week;O;O
);O;O
of;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s5.e0
and;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s5.e1
,;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s5.e2
10;O;O
to;O;O
20;O;O
mg;O;O
/;O;O
day;O;O
proved;O;O
to;O;O
be;O;O
significantly;O;O
more;O;O
effective;O;O
than;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s5.e3
4;O;O
to;O;O
12;O;O
mg;O;O
/;O;O
day;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
negative;O;O
and;O;O
depressive;O;O
symptoms;O;O
but;O;O
not;O;O
on;O;O
overall;O;O
psychopathology;O;O
symptoms;O;O
.;O;O
DDI-MedLine.d83.s6;;
In;O;O
contrast;O;O
,;O;O
preliminary;O;O
results;O;O
from;O;O
an;O;O
8;O;O
-;O;O
week;O;O
controlled;O;O
study;O;O
suggested;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s6.e0
2;O;O
to;O;O
6;O;O
mg;O;O
/;O;O
day;O;O
was;O;O
superior;O;O
to;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s6.e1
5;O;O
to;O;O
20;O;O
mg;O;O
/;O;O
day;O;O
against;O;O
positive;O;O
and;O;O
anxiety;O;O
/;O;O
depressive;O;O
symptoms;O;O
(;O;O
p;O;O
<;O;O
0.05;O;O
);O;O
,;O;O
although;O;O
consistent;O;O
with;O;O
the;O;O
first;O;O
study;O;O
,;O;O
both;O;O
agents;O;O
demonstrated;O;O
similar;O;O
efficacy;O;O
on;O;O
measures;O;O
of;O;O
overall;O;O
psychopathology;O;O
.;O;O
DDI-MedLine.d83.s7;;
Improvements;O;O
in;O;O
general;O;O
cognitive;O;O
function;O;O
seen;O;O
with;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s7.e0
treatment;O;O
in;O;O
a;O;O
1;O;O
-;O;O
year;O;O
controlled;O;O
study;O;O
of;O;O
patients;O;O
with;O;O
early;O;O
-;O;O
phase;O;O
schizophrenia;O;O
,;O;O
were;O;O
significantly;O;O
greater;O;O
than;O;O
changes;O;O
seen;O;O
with;O;O
either;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s7.e1
or;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s7.e2
.;O;O
DDI-MedLine.d83.s8;;
However;O;O
,;O;O
preliminary;O;O
results;O;O
from;O;O
an;O;O
8;O;O
-;O;O
week;O;O
trial;O;O
showed;O;O
comparable;O;O
cognitive;O;O
enhancing;O;O
effects;O;O
of;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s8.e0
and;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s8.e1
treatment;O;O
in;O;O
patients;O;O
with;O;O
schizophrenia;O;O
or;O;O
schizoaffective;O;O
disorder;O;O
.;O;O
DDI-MedLine.d83.s9;;
Several;O;O
studies;O;O
indicate;O;O
that;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s9.e0
has;O;O
benefits;O;O
against;O;O
symptoms;O;O
of;O;O
aggression;O;O
and;O;O
agitation;O;O
,;O;O
while;O;O
other;O;O
studies;O;O
strongly;O;O
support;O;O
the;O;O
effectiveness;O;O
of;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s9.e1
in;O;O
the;O;O
treatment;O;O
of;O;O
depressive;O;O
symptomatology;O;O
.;O;O
DDI-MedLine.d83.s10;;
Olanzapine;B-drug;B-DDI-MedLine.d83.s10.e0
is;O;O
associated;O;O
with;O;O
significantly;O;O
fewer;O;O
extrapyramidal;O;O
symptoms;O;O
than;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s10.e1
and;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s10.e2
.;O;O
DDI-MedLine.d83.s11;;
In;O;O
addition;O;O
,;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s11.e0
is;O;O
not;O;O
associated;O;O
with;O;O
a;O;O
risk;O;O
of;O;O
agranulocytosis;O;O
as;O;O
seen;O;O
with;O;O
clozapine;B-drug;B-DDI-MedLine.d83.s11.e1
or;O;O
clinically;O;O
significant;O;O
hyperprolactinaemia;O;O
as;O;O
seen;O;O
with;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s11.e2
or;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
.;O;O
DDI-MedLine.d83.s12;;
The;O;O
most;O;O
common;O;O
adverse;O;O
effects;O;O
reported;O;O
with;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s12.e0
are;O;O
bodyweight;O;O
gain;O;O
,;O;O
somnolence;O;O
,;O;O
dizziness;O;O
,;O;O
anticholinergic;O;O
effects;O;O
(;O;O
constipation;O;O
and;O;O
dry;O;O
mouth;O;O
);O;O
and;O;O
transient;O;O
asymptomatic;O;O
liver;O;O
enzyme;O;O
elevations;O;O
.;O;O
DDI-MedLine.d83.s13;;
In;O;O
comparison;O;O
with;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s13.e0
,;O;O
the;O;O
adverse;O;O
events;O;O
reported;O;O
significantly;O;O
more;O;O
frequently;O;O
with;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s13.e1
in;O;O
>;O;O
or;O;O
=;O;O
3.5;O;O
%;O;O
of;O;O
patients;O;O
were;O;O
dry;O;O
mouth;O;O
,;O;O
bodyweight;O;O
gain;O;O
and;O;O
increased;O;O
appetite;O;O
and;O;O
compared;O;O
with;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s13.e2
,;O;O
only;O;O
bodyweight;O;O
gain;O;O
occurred;O;O
significantly;O;O
more;O;O
frequently;O;O
with;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s13.e3
.;O;O
DDI-MedLine.d83.s14;;
The;O;O
high;O;O
acquisition;O;O
cost;O;O
of;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s14.e0
is;O;O
offset;O;O
by;O;O
reductions;O;O
in;O;O
other;O;O
treatment;O;O
costs;O;O
(;O;O
inpatient;O;O
and/or;O;O
outpatient;O;O
services;O;O
);O;O
of;O;O
schizophrenia;O;O
.;O;O
DDI-MedLine.d83.s15;;
Pharmacoeconomic;O;O
analyses;O;O
indicate;O;O
that;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s15.e0
does;O;O
not;O;O
significantly;O;O
increase;O;O
,;O;O
and;O;O
may;O;O
even;O;O
decrease;O;O
,;O;O
the;O;O
overall;O;O
direct;O;O
treatment;O;O
costs;O;O
of;O;O
schizophrenia;O;O
,;O;O
compared;O;O
with;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s15.e1
.;O;O
DDI-MedLine.d83.s16;;
Compared;O;O
with;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s16.e0
,;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s16.e1
has;O;O
also;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
overall;O;O
treatment;O;O
costs;O;O
,;O;O
despite;O;O
the;O;O
several;O;O
-;O;O
fold;O;O
higher;O;O
daily;O;O
acquisition;O;O
cost;O;O
of;O;O
the;O;O
drug;O;O
.;O;O
DDI-MedLine.d83.s17;;
Olanzapine;B-drug;B-DDI-MedLine.d83.s17.e0
treatment;O;O
improves;O;O
quality;O;O
of;O;O
life;O;O
in;O;O
patients;O;O
with;O;O
schizophrenia;O;O
and;O;O
related;O;O
psychoses;O;O
to;O;O
a;O;O
greater;O;O
extent;O;O
than;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s17.e1
,;O;O
and;O;O
to;O;O
broadly;O;O
the;O;O
same;O;O
extent;O;O
as;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s17.e2
.;O;O
DDI-MedLine.d83.s18;;
CONCLUSIONS;O;O
:;O;O
Olanzapine;B-drug;B-DDI-MedLine.d83.s18.e0
demonstrated;O;O
superior;O;O
antipsychotic;O;O
efficacy;O;O
compared;O;O
with;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s18.e1
in;O;O
the;O;O
treatment;O;O
of;O;O
acute;O;O
phase;O;O
schizophrenia;O;O
,;O;O
and;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
some;O;O
patients;O;O
with;O;O
first;O;O
-;O;O
episode;O;O
or;O;O
treatment;O;O
-;O;O
resistant;O;O
schizophrenia;O;O
.;O;O
DDI-MedLine.d83.s19;;
The;O;O
reduced;O;O
risk;O;O
of;O;O
adverse;O;O
events;O;O
and;O;O
therapeutic;O;O
superiority;O;O
compared;O;O
with;O;O
haloperidol;B-drug;B-DDI-MedLine.d83.s19.e0
and;O;O
risperidone;B-drug;B-DDI-MedLine.d83.s19.e1
in;O;O
the;O;O
treatment;O;O
of;O;O
negative;O;O
and;O;O
depressive;O;O
symptoms;O;O
support;O;O
the;O;O
choice;O;O
of;O;O
olanzapine;B-drug;B-DDI-MedLine.d83.s19.e2
as;O;O
a;O;O
first;O;O
-;O;O
line;O;O
option;O;O
in;O;O
the;O;O
management;O;O
of;O;O
schizophrenia;O;O
in;O;O
the;O;O
acute;O;O
phase;O;O
and;O;O
for;O;O
the;O;O
maintenance;O;O
of;O;O
treatment;O;O
response;O;O
.;O;O
DDI-MedLine.d132.s0;;
The;O;O
emerging;O;O
roles;O;O
of;O;O
non;B-group;B-DDI-MedLine.d132.s0.e0
-;I-group;I-DDI-MedLine.d132.s0.e0
nucleoside;I-group;I-DDI-MedLine.d132.s0.e0
reverse;I-group;I-DDI-MedLine.d132.s0.e0
transcriptase;I-group;I-DDI-MedLine.d132.s0.e0
inhibitors;I-group;I-DDI-MedLine.d132.s0.e0
in;O;O
antiretroviral;B-group;B-DDI-MedLine.d132.s0.e1
therapy;O;O
.;O;O
DDI-MedLine.d132.s1;;
The;O;O
availability;O;O
of;O;O
potent;O;O
non;B-group;B-DDI-MedLine.d132.s1.e0
-;I-group;I-DDI-MedLine.d132.s1.e0
nucleoside;I-group;I-DDI-MedLine.d132.s1.e0
reverse;I-group;I-DDI-MedLine.d132.s1.e0
transcriptase;I-group;I-DDI-MedLine.d132.s1.e0
inhibitor;I-group;I-DDI-MedLine.d132.s1.e0
(;O;O
NNRTI);B-group;B-DDI-MedLine.d132.s1.e1
-;O;O
based;O;O
regimens;O;O
for;O;O
antiretroviral;B-group;B-DDI-MedLine.d132.s1.e2
therapy;O;O
and;O;O
concerns;O;O
regarding;O;O
protease;B-group;B-DDI-MedLine.d132.s1.e3
inhibitor;I-group;I-DDI-MedLine.d132.s1.e3
(;O;O
PI);B-group;B-DDI-MedLine.d132.s1.e4
-;O;O
related;O;O
metabolic;O;O
disturbances;O;O
have;O;O
led;O;O
to;O;O
significant;O;O
shifts;O;O
in;O;O
treatment;O;O
practices;O;O
in;O;O
HIV;O;O
infection;O;O
.;O;O
DDI-MedLine.d132.s2;;
NNRTI;B-group;B-DDI-MedLine.d132.s2.e0
-;O;O
based;O;O
regimens;O;O
may;O;O
have;O;O
several;O;O
advantages;O;O
over;O;O
PI;B-group;B-DDI-MedLine.d132.s2.e1
-;O;O
based;O;O
therapy;O;O
for;O;O
initial;O;O
or;O;O
prolonged;O;O
therapy;O;O
,;O;O
including;O;O
more;O;O
convenient;O;O
administration;O;O
regimens;O;O
,;O;O
lower;O;O
tablet;O;O
volume;O;O
,;O;O
fewer;O;O
drug;O;O
interactions;O;O
,;O;O
and;O;O
central;O;O
nervous;O;O
system;O;O
penetration;O;O
.;O;O
DDI-MedLine.d132.s3;;
No;O;O
data;O;O
from;O;O
prospective;O;O
clinical;O;O
trials;O;O
currently;O;O
exist;O;O
comparing;O;O
the;O;O
3;O;O
approved;O;O
agents;O;O
(;O;O
efavirenz;B-drug;B-DDI-MedLine.d132.s3.e0
,;O;O
nevirapine;B-drug;B-DDI-MedLine.d132.s3.e1
or;O;O
delavirdine;B-drug;B-DDI-MedLine.d132.s3.e2
);O;O
.;O;O
DDI-MedLine.d132.s4;;
Both;O;O
efavirenz;B-drug;B-DDI-MedLine.d132.s4.e0
and;O;O
nevirapine;B-drug;B-DDI-MedLine.d132.s4.e1
have;O;O
been;O;O
compared;O;O
to;O;O
triple;O;O
therapy;O;O
with;O;O
the;O;O
PI;B-group;B-DDI-MedLine.d132.s4.e2
indinavir;I-drug;I-DDI-MedLine.d132.s4.e3
over;O;O
48;O;O
weeks;O;O
as;O;O
initial;O;O
therapy;O;O
,;O;O
with;O;O
similar;O;O
responses;O;O
being;O;O
observed;O;O
with;O;O
nevirapine;B-drug;B-DDI-MedLine.d132.s4.e4
regimens;O;O
and;O;O
superiority;O;O
observed;O;O
with;O;O
efavirenz;B-drug;B-DDI-MedLine.d132.s4.e5
.;O;O
DDI-MedLine.d132.s5;;
A;O;O
smaller;O;O
24;O;O
-;O;O
week;O;O
study;O;O
has;O;O
suggested;O;O
nevirapine;B-drug;B-DDI-MedLine.d132.s5.e0
may;O;O
be;O;O
superior;O;O
to;O;O
the;O;O
PI;B-group;B-DDI-MedLine.d132.s5.e1
nelfinavir;I-drug;I-DDI-MedLine.d132.s5.e2
.;O;O
DDI-MedLine.d132.s6;;
Limited;O;O
comparative;O;O
data;O;O
in;O;O
patients;O;O
with;O;O
high;O;O
viral;O;O
loads;O;O
treated;O;O
with;O;O
nevirapine;B-drug;B-DDI-MedLine.d132.s6.e0
-;O;O
or;O;O
delavirdine;B-drug;B-DDI-MedLine.d132.s6.e1
-;O;O
based;O;O
regimens;O;O
currently;O;O
exist;O;O
.;O;O
DDI-MedLine.d132.s7;;
However;O;O
,;O;O
cohort;O;O
data;O;O
and;O;O
selected;O;O
patient;O;O
data;O;O
from;O;O
clinical;O;O
trials;O;O
suggest;O;O
comparable;O;O
activity;O;O
to;O;O
PI;B-group;B-DDI-MedLine.d132.s7.e0
-;O;O
based;O;O
regimens;O;O
in;O;O
these;O;O
patients;O;O
.;O;O
DDI-MedLine.d132.s8;;
The;O;O
superiority;O;O
of;O;O
efavirenz;B-drug;B-DDI-MedLine.d132.s8.e0
over;O;O
indinavir;B-drug;B-DDI-MedLine.d132.s8.e1
-;O;O
based;O;O
regimens;O;O
has;O;O
been;O;O
observed;O;O
in;O;O
comparative;O;O
data;O;O
in;O;O
a;O;O
subset;O;O
of;O;O
patients;O;O
with;O;O
high;O;O
viral;O;O
loads;O;O
.;O;O
DDI-MedLine.d132.s9;;
In;O;O
treatment;O;O
-;O;O
experienced;O;O
patients;O;O
,;O;O
available;O;O
uncontrolled;O;O
data;O;O
suggest;O;O
these;O;O
agents;O;O
contribute;O;O
to;O;O
regimen;O;O
efficacy;O;O
in;O;O
NNRTI;B-group;B-DDI-MedLine.d132.s9.e0
-;O;O
na;O;O
ve;O;O
,;O;O
treatment;O;O
-;O;O
experienced;O;O
patients;O;O
.;O;O
DDI-MedLine.d132.s10;;
Efavirenz;B-drug;B-DDI-MedLine.d132.s10.e0
has;O;O
demonstrated;O;O
superiority;O;O
over;O;O
nelfinavir;B-drug;B-DDI-MedLine.d132.s10.e1
in;O;O
nucleoside;O;O
-;O;O
experienced;O;O
patients;O;O
,;O;O
although;O;O
combining;O;O
these;O;O
2;O;O
agents;O;O
may;O;O
represent;O;O
the;O;O
best;O;O
approach;O;O
in;O;O
these;O;O
circumstances;O;O
.;O;O
DDI-MedLine.d132.s11;;
The;O;O
tolerability;O;O
of;O;O
NNRTIs;B-group;B-DDI-MedLine.d132.s11.e0
appears;O;O
generally;O;O
good;O;O
with;O;O
few;O;O
individuals;O;O
discontinuing;O;O
in;O;O
clinical;O;O
studies;O;O
as;O;O
a;O;O
result;O;O
of;O;O
adverse;O;O
drug;O;O
events;O;O
.;O;O
DDI-MedLine.d132.s12;;
The;O;O
majority;O;O
of;O;O
adverse;O;O
events;O;O
with;O;O
NNRTIs;B-group;B-DDI-MedLine.d132.s12.e0
occur;O;O
within;O;O
the;O;O
first;O;O
month;O;O
,;O;O
and;O;O
are;O;O
predictable;O;O
and;O;O
manageable;O;O
without;O;O
therapy;O;O
interruption;O;O
.;O;O
DDI-MedLine.d72.s0;;
[;O;O
Pharmacologic;O;O
interactions;O;O
in;O;O
chronic;O;O
treatments;O;O
:;O;O
corrective;O;O
measures;O;O
for;O;O
its;O;O
prevention;O;O
in;O;O
a;O;O
basic;O;O
area;O;O
of;O;O
rural;O;O
health;O;O
];O;O
OBJECTIVES;O;O
:;O;O
To;O;O
identify;O;O
the;O;O
pharmacological;O;O
interactions;O;O
of;O;O
clinical;O;O
relevance;O;O
(;O;O
PICR;O;O
);O;O
in;O;O
the;O;O
medication;O;O
authorization;O;O
cards;O;O
(;O;O
MAC;O;O
);O;O
of;O;O
the;O;O
chronically;O;O
ill;O;O
and;O;O
to;O;O
establish;O;O
strategies;O;O
to;O;O
minimise;O;O
their;O;O
appearance;O;O
.;O;O
DDI-MedLine.d72.s1;;
DESIGN;O;O
:;O;O
Cross;O;O
-;O;O
sectional;O;O
descriptive;O;O
study;O;O
.;O;O
DDI-MedLine.d72.s2;;
SETTING;O;O
:;O;O
Rural;O;O
primary;O;O
care;O;O
centre;O;O
.;O;O
DDI-MedLine.d72.s3;;
PATIENTS;O;O
:;O;O
Random;O;O
sample;O;O
of;O;O
626;O;O
MAC;O;O
out;O;O
of;O;O
a;O;O
total;O;O
of;O;O
1306;O;O
.;O;O
DDI-MedLine.d72.s4;;
MEASUREMENTS;O;O
AND;O;O
MAIN;O;O
RESULTS;O;O
:;O;O
In;O;O
December;O;O
1998;O;O
,;O;O
the;O;O
following;O;O
was;O;O
gathered;O;O
for;O;O
every;O;O
MAC;O;O
with;O;O
more;O;O
than;O;O
one;O;O
drug;O;O
treatment;O;O
:;O;O
age;O;O
,;O;O
sex;O;O
,;O;O
number;O;O
of;O;O
drugs;O;O
,;O;O
intrinsic;O;O
value;O;O
,;O;O
drugs;O;O
prescribed;O;O
,;O;O
daily;O;O
dose;O;O
and;O;O
pharmacological;O;O
interactions;O;O
(;O;O
PI;O;O
);O;O
,;O;O
classified;O;O
(;O;O
using;O;O
the;O;O
scale;O;O
of;O;O
Hansten;O;O
1996;O;O
);O;O
into;O;O
light;O;O
and;O;O
clinically;O;O
relevant;O;O
.;O;O
DDI-MedLine.d72.s5;;
Statistical;O;O
analysis;O;O
:;O;O
Mantel;O;O
-;O;O
Haenszel;O;O
(;O;O
alpha;O;O
=;O;O
0.05;O;O
);O;O
.;O;O
DDI-MedLine.d72.s6;;
Patients;O;O
';O;O
mean;O;O
age;O;O
was;O;O
69.1;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
1.2;O;O
);O;O
.;O;O
DDI-MedLine.d72.s7;;
Mean;O;O
number;O;O
of;O;O
drugs;O;O
per;O;O
MAC;O;O
was;O;O
4;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
0.2;O;O
);O;O
.;O;O
DDI-MedLine.d72.s8;;
341;O;O
PI;O;O
affecting;O;O
197;O;O
patients;O;O
(;O;O
31.5;O;O
%;O;O
,;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
3.6;O;O
);O;O
were;O;O
identified;O;O
.;O;O
DDI-MedLine.d72.s9;;
24.9;O;O
%;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
4.5;O;O
);O;O
were;O;O
PICR;O;O
,;O;O
detected;O;O
in;O;O
11.7;O;O
%;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
2.5;O;O
);O;O
of;O;O
the;O;O
MAC;O;O
.;O;O
DDI-MedLine.d72.s10;;
The;O;O
existence;O;O
of;O;O
PI;O;O
was;O;O
related;O;O
to;O;O
the;O;O
number;O;O
of;O;O
drugs;O;O
prescribed;O;O
to;O;O
each;O;O
patient;O;O
(;O;O
p;O;O
<;O;O
0.01;O;O
);O;O
.;O;O
DDI-MedLine.d72.s11;;
There;O;O
were;O;O
26;O;O
PI;O;O
with;O;O
drugs;O;O
of;O;O
low;O;O
intrinsic;O;O
value;O;O
(;O;O
7.6;O;O
%;O;O
,;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
2.8;O;O
);O;O
.;O;O
DDI-MedLine.d72.s12;;
74.1;O;O
%;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
9.3;O;O
);O;O
of;O;O
the;O;O
total;O;O
PICR;O;O
could;O;O
be;O;O
avoided;O;O
by;O;O
simple;O;O
recommendations;O;O
,;O;O
DDI-MedLine.d72.s13;;
and;O;O
the;O;O
remaining;O;O
25.9;O;O
%;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
,;O;O
+;O;O
/;O;O
-;O;O
9.3;O;O
);O;O
by;O;O
monitoring;O;O
and;O;O
follow;O;O
-;O;O
up;O;O
of;O;O
patients;O;O
.;O;O
DDI-MedLine.d72.s14;;
CONCLUSIONS;O;O
:;O;O
It;O;O
is;O;O
important;O;O
to;O;O
identify;O;O
the;O;O
medications;O;O
most;O;O
commonly;O;O
involved;O;O
in;O;O
the;O;O
PICR;O;O
so;O;O
as;O;O
to;O;O
establish;O;O
corrective;O;O
measures;O;O
to;O;O
minimise;O;O
the;O;O
risks;O;O
arising;O;O
from;O;O
multiple;O;O
medication;O;O
.;O;O
DDI-MedLine.d72.s15;;
Four;O;O
educational;O;O
messages;O;O
advise;O;O
on;O;O
over;O;O
60;O;O
%;O;O
of;O;O
the;O;O
PICR;O;O
detected;O;O
.;O;O
DDI-MedLine.d32.s0;;
Prescribing;O;O
.;O;O
DDI-MedLine.d32.s1;;
Keys;O;O
to;O;O
maximizing;O;O
benefit;O;O
while;O;O
avoiding;O;O
adverse;O;O
drug;O;O
effects;O;O
.;O;O

;O;O
DDI-MedLine.d32.s2;;
When;O;O
prescribing;O;O
for;O;O
older;O;O
patients;O;O
,;O;O
some;O;O
physicians;O;O
are;O;O
overly;O;O
cautious;O;O
,;O;O
and;O;O
this;O;O
strategy;O;O
can;O;O
result;O;O
in;O;O
a;O;O
less;O;O
than;O;O
optimal;O;O
treatment;O;O
outcome;O;O
.;O;O
DDI-MedLine.d32.s3;;
The;O;O
reluctance;O;O
to;O;O
treat;O;O
aggressively;O;O
is;O;O
understandable;O;O
because;O;O
the;O;O
geriatric;O;O
population;O;O
is;O;O
susceptible;O;O
to;O;O
adverse;O;O
drug;O;O
reactions;O;O
.;O;O
DDI-MedLine.d32.s4;;
The;O;O
key;O;O
to;O;O
maximizing;O;O
therapy;O;O
lies;O;O
in;O;O
individualizing;O;O
it;O;O
as;O;O
much;O;O
as;O;O
possible;O;O
.;O;O
DDI-MedLine.d32.s5;;
There;O;O
are;O;O
a;O;O
number;O;O
of;O;O
steps;O;O
physicians;O;O
can;O;O
take;O;O
to;O;O
ensure;O;O
that;O;O
their;O;O
patients;O;O
are;O;O
not;O;O
being;O;O
undertreated;O;O
.;O;O
DDI-MedLine.d32.s6;;
These;O;O
steps;O;O
include;O;O
regular;O;O
reevaluations;O;O
of;O;O
dosages;O;O
and;O;O
plasma;O;O
drug;O;O
concentrations;O;O
,;O;O
recognition;O;O
and;O;O
understanding;O;O
of;O;O
drug;O;O
side;O;O
effects;O;O
,;O;O
and;O;O
avoidance;O;O
of;O;O
certain;O;O
agents;O;O
.;O;O
DDI-MedLine.d32.s7;;
Close;O;O
monitoring;O;O
allows;O;O
physicians;O;O
to;O;O
minimize;O;O
risks;O;O
,;O;O
maximize;O;O
benefits;O;O
,;O;O
and;O;O
get;O;O
the;O;O
most;O;O
out;O;O
of;O;O
what;O;O
modern;O;O
medications;O;O
can;O;O
do;O;O
to;O;O
help;O;O
older;O;O
patients;O;O
.;O;O
DDI-MedLine.d42.s0;;
Sildenafil;B-drug;B-DDI-MedLine.d42.s0.e0
citrate;I-drug;I-DDI-MedLine.d42.s0.e0
:;O;O
a;O;O
therapeutic;O;O
update;O;O
.;O;O

;O;O
DDI-MedLine.d42.s1;;
BACKGROUND;O;O
:;O;O
Since;O;O
its;O;O
approval;O;O
by;O;O
the;O;O
US;O;O
Food;O;O
and;O;O
Drug;O;O
Administration;O;O
in;O;O
March;O;O
1998;O;O
,;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s1.e0
citrate;I-drug;I-DDI-MedLine.d42.s1.e0
has;O;O
been;O;O
used;O;O
by;O;O
millions;O;O
of;O;O
men;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
erectile;O;O
dysfunction;O;O
.;O;O
DDI-MedLine.d42.s2;;
Recent;O;O
studies;O;O
and;O;O
consensus;O;O
reports;O;O
have;O;O
expanded;O;O
our;O;O
understanding;O;O
of;O;O
its;O;O
efficacy;O;O
,;O;O
safety;O;O
,;O;O
contraindications;O;O
,;O;O
and;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-MedLine.d42.s3;;
OBJECTIVE;O;O
:;O;O
This;O;O
paper;O;O
reviews;O;O
recent;O;O
studies;O;O
of;O;O
the;O;O
efficacy;O;O
of;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s3.e0
,;O;O
its;O;O
adverse;O;O
effects;O;O
and;O;O
drug;O;O
interactions;O;O
,;O;O
and;O;O
socioeconomic;O;O
factors;O;O
involved;O;O
in;O;O
its;O;O
use;O;O
,;O;O
with;O;O
a;O;O
focus;O;O
on;O;O
specific;O;O
patient;O;O
populations;O;O
(;O;O
prostate;O;O
cancer;O;O
,;O;O
diabetes;O;O
mellitus;O;O
,;O;O
ischemic;O;O
heart;O;O
disease;O;O
,;O;O
spinal;O;O
cord;O;O
injuries;O;O
,;O;O
neurologic;O;O
disorders;O;O
);O;O
.;O;O
DDI-MedLine.d42.s4;;
METHODS;O;O
:;O;O
Clinical;O;O
studies;O;O
,;O;O
case;O;O
reports;O;O
,;O;O
and;O;O
commentaries;O;O
and;O;O
editorials;O;O
concerning;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s4.e0
published;O;O
in;O;O
the;O;O
international;O;O
literature;O;O
between;O;O
January;O;O
1999;O;O
and;O;O
August;O;O
2000;O;O
were;O;O
identified;O;O
through;O;O
searches;O;O
of;O;O
MEDLINE;O;O
,;O;O
PREMEDLINE;O;O
,;O;O
and;O;O
International;O;O
Pharmaceutical;O;O
Abstracts;O;O
,;O;O
using;O;O
the;O;O
terms;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s4.e1
,;O;O
Viagra;B-brand;B-DDI-MedLine.d42.s4.e2
,;O;O
and;O;O
erectile;O;O
dysfunction;O;O
.;O;O
DDI-MedLine.d42.s5;;
RESULTS;O;O
:;O;O
Sildenafil;B-drug;B-DDI-MedLine.d42.s5.e0
has;O;O
demonstrated;O;O
effectiveness;O;O
in;O;O
men;O;O
with;O;O
erectile;O;O
dysfunction;O;O
associated;O;O
with;O;O
prostatectomy;O;O
,;O;O
radiation;O;O
therapy;O;O
,;O;O
diabetes;O;O
mellitus;O;O
,;O;O
certain;O;O
neurologic;O;O
disorders;O;O
,;O;O
and;O;O
drug;O;O
therapy;O;O
(;O;O
eg;O;O
,;O;O
selective;B-group;B-DDI-MedLine.d42.s5.e1
serotonin;I-group;I-DDI-MedLine.d42.s5.e1
reuptake;I-group;I-DDI-MedLine.d42.s5.e1
inhibitors;I-group;I-DDI-MedLine.d42.s5.e1
[;O;O
SSRIs;B-group;B-DDI-MedLine.d42.s5.e2
];O;O
);O;O
.;O;O
DDI-MedLine.d42.s6;;
It;O;O
has;O;O
not;O;O
been;O;O
as;O;O
effective;O;O
in;O;O
women;O;O
with;O;O
sexual;O;O
dysfunction;O;O
,;O;O
with;O;O
the;O;O
exception;O;O
of;O;O
SSRI;B-group;B-DDI-MedLine.d42.s6.e0
-;O;O
associated;O;O
sexual;O;O
dysfunction;O;O
.;O;O
DDI-MedLine.d42.s7;;
Some;O;O
disorders;O;O
unrelated;O;O
to;O;O
sexual;O;O
dysfunction;O;O
(;O;O
eg;O;O
,;O;O
esophageal;O;O
motility;O;O
dysfunction;O;O
);O;O
may;O;O
also;O;O
respond;O;O
to;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s7.e0
.;O;O
DDI-MedLine.d42.s8;;
In;O;O
the;O;O
general;O;O
population;O;O
,;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s8.e0
is;O;O
considered;O;O
to;O;O
have;O;O
an;O;O
acceptable;O;O
tolerability;O;O
profile;O;O
,;O;O
DDI-MedLine.d42.s9;;
however;O;O
,;O;O
patients;O;O
with;O;O
moderate;O;O
to;O;O
severe;O;O
cardiovascular;O;O
disease;O;O
or;O;O
those;O;O
taking;O;O
nitrate;B-group;B-DDI-MedLine.d42.s9.e0
therapy;O;O
are;O;O
at;O;O
increased;O;O
risk;O;O
for;O;O
potentially;O;O
serious;O;O
cardiovascular;O;O
adverse;O;O
effects;O;O
with;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s9.e1
therapy;O;O
.;O;O
DDI-MedLine.d42.s10;;
In;O;O
addition;O;O
,;O;O
patients;O;O
taking;O;O
drugs;O;O
that;O;O
inhibit;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
isozyme;O;O
,;O;O
which;O;O
metabolizes;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s10.e0
,;O;O
may;O;O
experience;O;O
increased;O;O
drug;O;O
concentrations;O;O
and;O;O
possible;O;O
toxicity;O;O
from;O;O
normal;O;O
doses;O;O
of;O;O
sildenafil;B-drug;B-DDI-MedLine.d42.s10.e1
.;O;O
DDI-MedLine.d42.s11;;
CONCLUSIONS;O;O
:;O;O
Sildenafil;B-drug;B-DDI-MedLine.d42.s11.e0
is;O;O
an;O;O
effective;O;O
first;O;O
-;O;O
line;O;O
therapy;O;O
for;O;O
erectile;O;O
dysfunction;O;O
in;O;O
men;O;O
.;O;O
DDI-MedLine.d42.s12;;
The;O;O
decision;O;O
to;O;O
prescribe;O;O
this;O;O
agent;O;O
should;O;O
include;O;O
such;O;O
considerations;O;O
as;O;O
the;O;O
cost;O;O
-;O;O
risk;O;O
-;O;O
benefit;O;O
balance;O;O
,;O;O
patient;O;O
access;O;O
,;O;O
drug;O;O
distribution;O;O
pathways;O;O
,;O;O
and;O;O
prescription;O;O
drug;O;O
coverage;O;O
.;O;O
DDI-MedLine.d38.s0;;
Acute;O;O
hydrocortisone;B-drug;B-DDI-MedLine.d38.s0.e0
administration;O;O
does;O;O
not;O;O
affect;O;O
subjective;O;O
responses;O;O
to;O;O
d;B-drug;B-DDI-MedLine.d38.s0.e1
-;I-drug;I-DDI-MedLine.d38.s0.e1
amphetamine;I-drug;I-DDI-MedLine.d38.s0.e1
in;O;O
humans;O;O
.;O;O
DDI-MedLine.d38.s1;;
RATIONALE;O;O
:;O;O
Stress;O;O
and;O;O
glucocorticoids;B-group;B-DDI-MedLine.d38.s1.e0
facilitate;O;O
and;O;O
reinstate;O;O
psychostimulant;O;O
self;O;O
-;O;O
administration;O;O
in;O;O
rodents;O;O
.;O;O
DDI-MedLine.d38.s2;;
However;O;O
,;O;O
the;O;O
effects;O;O
of;O;O
stress;O;O
and;O;O
glucocorticoids;B-group;B-DDI-MedLine.d38.s2.e0
on;O;O
the;O;O
subjective;O;O
and;O;O
behavioral;O;O
effects;O;O
of;O;O
psychostimulants;B-group;B-DDI-MedLine.d38.s2.e1
have;O;O
not;O;O
been;O;O
well;O;O
studied;O;O
in;O;O
humans;O;O
.;O;O
DDI-MedLine.d38.s3;;
OBJECTIVES;O;O
:;O;O
To;O;O
examine;O;O
the;O;O
effects;O;O
of;O;O
acute;O;O
hydrocortisone;B-drug;B-DDI-MedLine.d38.s3.e0
pretreatment;O;O
on;O;O
the;O;O
subjective;O;O
and;O;O
behavioral;O;O
effects;O;O
of;O;O
d;B-drug;B-DDI-MedLine.d38.s3.e1
-;I-drug;I-DDI-MedLine.d38.s3.e1
amphetamine;I-drug;I-DDI-MedLine.d38.s3.e1
.;O;O
DDI-MedLine.d38.s4;;
METHODS;O;O
:;O;O
Hydrocortisone;B-drug;B-DDI-MedLine.d38.s4.e0
(;O;O
100;O;O
mg;O;O
);O;O
and;O;O
d;B-drug;B-DDI-MedLine.d38.s4.e1
-;I-drug;I-DDI-MedLine.d38.s4.e1
amphetamine;I-drug;I-DDI-MedLine.d38.s4.e1
(;O;O
20;O;O
mg;O;O
);O;O
were;O;O
administered;O;O
orally;O;O
to;O;O
16;O;O
healthy;O;O
male;O;O
and;O;O
female;O;O
volunteers;O;O
in;O;O
a;O;O
four;O;O
-;O;O
session;O;O
,;O;O
placebo;O;O
-;O;O
controlled;O;O
,;O;O
within;O;O
-;O;O
subject;O;O
,;O;O
crossover;O;O
design;O;O
.;O;O
DDI-MedLine.d38.s5;;
To;O;O
prevent;O;O
stomach;O;O
irritation;O;O
,;O;O
subjects;O;O
received;O;O
rantidine;B-drug;B-DDI-MedLine.d38.s5.e0
hydrochloride;I-drug;I-DDI-MedLine.d38.s5.e0
before;O;O
each;O;O
experimental;O;O
session;O;O
.;O;O
DDI-MedLine.d38.s6;;
Dependent;O;O
measures;O;O
included;O;O
self;O;O
-;O;O
reported;O;O
mood;O;O
and;O;O
subjective;O;O
effects;O;O
(;O;O
Addiction;O;O
Research;O;O
Center;O;O
inventory;O;O
,;O;O
the;O;O
profile;O;O
of;O;O
mood;O;O
states;O;O
,;O;O
and;O;O
a;O;O
series;O;O
of;O;O
visual;O;O
analogue;O;O
scales;O;O
);O;O
,;O;O
vital;O;O
signs;O;O
,;O;O
salivary;O;O
cortisol;O;O
,;O;O
and;O;O
psychomotor;O;O
performance;O;O
.;O;O
DDI-MedLine.d38.s7;;
RESULTS;O;O
:;O;O
Hydrocortisone;B-drug;B-DDI-MedLine.d38.s7.e0
elevated;O;O
salivary;O;O
cortisol;O;O
levels;O;O
,;O;O
produced;O;O
modest;O;O
dysphoria;O;O
,;O;O
and;O;O
reduced;O;O
subjects;O;O
';O;O
reports;O;O
of;O;O
wanting;O;O
more;O;O
drug;O;O
.;O;O
DDI-MedLine.d38.s8;;
However;O;O
,;O;O
hydrocortisone;B-drug;B-DDI-MedLine.d38.s8.e0
pretreatment;O;O
did;O;O
not;O;O
affect;O;O
any;O;O
of;O;O
the;O;O
physiological;O;O
,;O;O
behavioral;O;O
,;O;O
or;O;O
subjective;O;O
effects;O;O
of;O;O
d;B-drug;B-DDI-MedLine.d38.s8.e1
-;I-drug;I-DDI-MedLine.d38.s8.e1
amphetamine;I-drug;I-DDI-MedLine.d38.s8.e1
.;O;O
DDI-MedLine.d38.s9;;
CONCLUSIONS;O;O
:;O;O
In;O;O
contrast;O;O
to;O;O
the;O;O
effects;O;O
of;O;O
glucocorticoids;B-group;B-DDI-MedLine.d38.s9.e0
in;O;O
rodent;O;O
studies;O;O
,;O;O
these;O;O
results;O;O
indicate;O;O
that;O;O
an;O;O
acute;O;O
increase;O;O
in;O;O
cortisol;O;O
does;O;O
not;O;O
enhance;O;O
the;O;O
psychostimulant;O;O
effects;O;O
of;O;O
d;B-drug;B-DDI-MedLine.d38.s9.e1
-;I-drug;I-DDI-MedLine.d38.s9.e1
amphetamine;I-drug;I-DDI-MedLine.d38.s9.e1
in;O;O
humans;O;O
.;O;O
DDI-MedLine.d23.s0;;
The;O;O
effects;O;O
of;O;O
ketamine;B-drug;B-DDI-MedLine.d23.s0.e0
and;O;O
of;O;O
Innovar;B-brand;B-DDI-MedLine.d23.s0.e1
anesthesia;O;O
on;O;O
digitalis;B-group;B-DDI-MedLine.d23.s0.e2
tolerance;O;O
in;O;O
dogs;O;O
.;O;O
DDI-MedLine.d23.s1;;
In;O;O
a;O;O
comparison;O;O
of;O;O
digitalis;B-group;B-DDI-MedLine.d23.s1.e0
tolerance;O;O
in;O;O
dogs;O;O
anesthetized;O;O
with;O;O
ketamine;B-drug;B-DDI-MedLine.d23.s1.e1
,;O;O
Innovar;B-brand;B-DDI-MedLine.d23.s1.e2
Vet;I-brand;I-DDI-MedLine.d23.s1.e2
,;O;O
or;O;O
pentobarbital;B-drug;B-DDI-MedLine.d23.s1.e3
,;O;O
the;O;O
dosage;O;O
of;O;O
ouabain;B-drug;B-DDI-MedLine.d23.s1.e4
needed;O;O
to;O;O
cause;O;O
ventricular;O;O
tachycardia;O;O
was;O;O
significantly;O;O
higher;O;O
,;O;O
as;O;O
was;O;O
the;O;O
LD50;O;O
of;O;O
ouabain;B-drug;B-DDI-MedLine.d23.s1.e5
,;O;O
with;O;O
ketamine;B-drug;B-DDI-MedLine.d23.s1.e6
or;O;O
Innovar;B-brand;B-DDI-MedLine.d23.s1.e7
than;O;O
with;O;O
pentobarbital;B-drug;B-DDI-MedLine.d23.s1.e8
.;O;O
DDI-MedLine.d23.s2;;
Ventricular;O;O
tachycardia;O;O
induced;O;O
by;O;O
ouabain;B-drug;B-DDI-MedLine.d23.s2.e0
was;O;O
generally;O;O
converted;O;O
to;O;O
sinus;O;O
rhythm;O;O
following;O;O
administration;O;O
of;O;O
Innovar;B-brand;B-DDI-MedLine.d23.s2.e1
,;O;O
ketamine;B-drug;B-DDI-MedLine.d23.s2.e2
,;O;O
or;O;O
droperidol;B-drug;B-DDI-MedLine.d23.s2.e3
but;O;O
not;O;O
after;O;O
administration;O;O
of;O;O
fentayl;B-drug;B-DDI-MedLine.d23.s2.e4
alone;O;O
or;O;O
after;O;O
pentobarbital;B-drug;B-DDI-MedLine.d23.s2.e5
.;O;O
DDI-MedLine.d138.s0;;
Interaction;O;O
between;O;O
oxytocin;B-drug;B-DDI-MedLine.d138.s0.e0
and;O;O
antidiuretic;O;O
hormone;O;O
and;O;O
its;O;O
effect;O;O
on;O;O
the;O;O
milk;O;O
secretion;O;O
by;O;O
alveoli;O;O
of;O;O
the;O;O
mammary;O;O
gland;O;O
of;O;O
lactating;O;O
rats;O;O
.;O;O
DDI-MedLine.d138.s1;;
Interaction;O;O
between;O;O
exogenous;O;O
and;O;O
endogenous;O;O
oxytocin;B-drug;B-DDI-MedLine.d138.s1.e0
and;O;O
vasopressin;O;O
was;O;O
found;O;O
to;O;O
affect;O;O
the;O;O
mechanism;O;O
of;O;O
milk;O;O
ejection;O;O
by;O;O
the;O;O
alveoli;O;O
of;O;O
the;O;O
mammary;O;O
gland;O;O
in;O;O
lactating;O;O
rats;O;O
.;O;O
DDI-MedLine.d138.s2;;
Inhibition;O;O
and;O;O
stimulation;O;O
of;O;O
the;O;O
effect;O;O
of;O;O
oxytocin;B-drug;B-DDI-MedLine.d138.s2.e0
on;O;O
milk;O;O
ejection;O;O
by;O;O
vasopressin;O;O
was;O;O
demonstrated;O;O
.;O;O
DDI-MedLine.d138.s3;;
On;O;O
the;O;O
basis;O;O
of;O;O
the;O;O
principles;O;O
observed;O;O
the;O;O
concentrations;O;O
fo;O;O
these;O;O
hormones;O;O
were;O;O
investigated;O;O
in;O;O
the;O;O
plasma;O;O
of;O;O
dogs;O;O
deprived;O;O
of;O;O
water;O;O
for;O;O
3;O;O
days;O;O
and;O;O
then;O;O
allowed;O;O
to;O;O
drink;O;O
.;O;O
DDI-MedLine.d49.s0;;
Interaction;O;O
of;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s0.e0
and;O;O
gentamicin;B-drug;B-DDI-MedLine.d49.s0.e1
in;O;O
vitro;O;O
.;O;O

;O;O
DDI-MedLine.d49.s1;;
The;O;O
minimal;O;O
inhibitory;O;O
concentrations;O;O
of;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s1.e0
and;O;O
gentamicin;B-drug;B-DDI-MedLine.d49.s1.e1
alone;O;O
and;O;O
in;O;O
combinations;O;O
were;O;O
determined;O;O
by;O;O
a;O;O
microdilution;O;O
method;O;O
for;O;O
163;O;O
aerobic;O;O
,;O;O
facultative;O;O
,;O;O
and;O;O
anaerobic;O;O
clinical;O;O
isolates;O;O
.;O;O
DDI-MedLine.d49.s2;;
All;O;O
77;O;O
strains;O;O
of;O;O
Staphylococcus;O;O
aureus;O;O
,;O;O
Diplococcus;O;O
pneumoniae;O;O
,;O;O
Streptococcus;O;O
pyogenes;O;O
,;O;O
and;O;O
anaerobic;O;O
bacteria;O;O
(;O;O
except;O;O
for;O;O
three;O;O
strains;O;O
of;O;O
Clostridium;O;O
);O;O
were;O;O
inhibited;O;O
by;O;O
1.6;O;O
mug;O;O
or;O;O
less;O;O
of;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s2.e0
per;O;O
ml;O;O
.;O;O
DDI-MedLine.d49.s3;;
Gentamicin;B-drug;B-DDI-MedLine.d49.s3.e0
did;O;O
not;O;O
interfere;O;O
with;O;O
the;O;O
activity;O;O
of;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s3.e1
within;O;O
the;O;O
range;O;O
of;O;O
concentrations;O;O
tested;O;O
(;O;O
0.1;O;O
to;O;O
100;O;O
mug;O;O
/;O;O
ml;O;O
);O;O
,;O;O
DDI-MedLine.d49.s4;;
for;O;O
some;O;O
strains;O;O
combinations;O;O
were;O;O
synergistic;O;O
.;O;O
DDI-MedLine.d49.s5;;
Sixty;O;O
-;O;O
two;O;O
(;O;O
94;O;O
%;O;O
);O;O
of;O;O
66;O;O
strains;O;O
of;O;O
Enterobacteriaceae;O;O
and;O;O
Pseudomonas;O;O
aeruginosa;O;O
were;O;O
inhibited;O;O
by;O;O
6.2;O;O
mug;O;O
or;O;O
less;O;O
of;O;O
gentamicin;B-drug;B-DDI-MedLine.d49.s5.e0
per;O;O
ml;O;O
.;O;O
DDI-MedLine.d49.s6;;
Combinations;O;O
of;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s6.e0
and;O;O
gentamicin;B-drug;B-DDI-MedLine.d49.s6.e1
were;O;O
indifferent;O;O
for;O;O
29;O;O
strains;O;O
and;O;O
synergistic;O;O
for;O;O
33;O;O
strains;O;O
.;O;O
DDI-MedLine.d49.s7;;
All;O;O
20;O;O
strains;O;O
of;O;O
enterococcus;O;O
,;O;O
three;O;O
strains;O;O
of;O;O
Clostridium;O;O
,;O;O
three;O;O
strains;O;O
of;O;O
Escherichia;O;O
coli;O;O
,;O;O
and;O;O
one;O;O
strain;O;O
of;O;O
Proteus;O;O
rettgeri;O;O
were;O;O
resistant;O;O
to;O;O
both;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s7.e0
(;O;O
minimal;O;O
inhibitory;O;O
concentration;O;O
greater;O;O
than;O;O
3.1;O;O
mug;O;O
/;O;O
ml;O;O
);O;O
and;O;O
gentamicin;B-drug;B-DDI-MedLine.d49.s7.e1
(;O;O
minimal;O;O
inhibitory;O;O
concentration;O;O
greater;O;O
than;O;O
6.2;O;O
mug;O;O
/;O;O
ml;O;O
);O;O
.;O;O
DDI-MedLine.d49.s8;;
Combinations;O;O
of;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s8.e0
and;O;O
gentamicin;B-drug;B-DDI-MedLine.d49.s8.e1
were;O;O
indifferent;O;O
for;O;O
16;O;O
and;O;O
synergistic;O;O
for;O;O
11;O;O
of;O;O
the;O;O
resistant;O;O
strains;O;O
.;O;O
DDI-MedLine.d49.s9;;
Except;O;O
for;O;O
clindamycin;B-drug;B-DDI-MedLine.d49.s9.e0
-;O;O
sensitive;O;O
isolates;O;O
,;O;O
synergy;O;O
was;O;O
usually;O;O
observed;O;O
only;O;O
at;O;O
concentrations;O;O
of;O;O
one;O;O
or;O;O
both;O;O
drugs;O;O
which;O;O
are;O;O
not;O;O
readily;O;O
obtainable;O;O
in;O;O
vivo;O;O
.;O;O
DDI-MedLine.d49.s10;;
Antagonism;O;O
was;O;O
never;O;O
observed;O;O
.;O;O
DDI-MedLine.d120.s0;;
Molecular;O;O
basis;O;O
for;O;O
the;O;O
selective;O;O
toxicity;O;O
of;O;O
amphotericin;B-drug;B-DDI-MedLine.d120.s0.e0
B;I-drug;I-DDI-MedLine.d120.s0.e0
for;O;O
yeast;O;O
and;O;O
filipin;B-drug_n;B-DDI-MedLine.d120.s0.e1
for;O;O
animal;O;O
cells;O;O
.;O;O
DDI-MedLine.d120.s1;;
Among;O;O
the;O;O
polyene;B-group;B-DDI-MedLine.d120.s1.e0
antibiotics;I-group;I-DDI-MedLine.d120.s1.e0
,;O;O
many;O;O
,;O;O
like;O;O
filipin;B-drug_n;B-DDI-MedLine.d120.s1.e1
,;O;O
can;O;O
not;O;O
be;O;O
used;O;O
clinically;O;O
because;O;O
they;O;O
are;O;O
toxic;O;O
,;O;O
DDI-MedLine.d120.s2;;
amphotericin;B-drug;B-DDI-MedLine.d120.s2.e0
B;I-drug;I-DDI-MedLine.d120.s2.e0
,;O;O
however;O;O
,;O;O
is;O;O
useful;O;O
in;O;O
therapy;O;O
of;O;O
human;O;O
fungal;O;O
infections;O;O
because;O;O
it;O;O
is;O;O
less;O;O
toxic;O;O
.;O;O
DDI-MedLine.d120.s3;;
Both;O;O
the;O;O
toxicity;O;O
of;O;O
filipin;B-drug_n;B-DDI-MedLine.d120.s3.e0
and;O;O
the;O;O
therapeutic;O;O
value;O;O
of;O;O
amphotericin;B-drug;B-DDI-MedLine.d120.s3.e1
B;I-drug;I-DDI-MedLine.d120.s3.e1
can;O;O
be;O;O
rationalized;O;O
at;O;O
the;O;O
cellular;O;O
and;O;O
molecular;O;O
level;O;O
by;O;O
the;O;O
following;O;O
observations;O;O
:;O;O
(;O;O
i;O;O
);O;O
these;O;O
polyene;B-group;B-DDI-MedLine.d120.s3.e2
antibiotics;I-group;I-DDI-MedLine.d120.s3.e2
showed;O;O
differential;O;O
effects;O;O
on;O;O
cells;O;O
,;O;O
DDI-MedLine.d120.s4;;
filipin;B-drug_n;B-DDI-MedLine.d120.s4.e0
was;O;O
more;O;O
potent;O;O
in;O;O
lysing;O;O
human;O;O
red;O;O
blood;O;O
cells;O;O
,;O;O
whereas;O;O
amphotericin;B-drug;B-DDI-MedLine.d120.s4.e1
B;I-drug;I-DDI-MedLine.d120.s4.e1
was;O;O
more;O;O
potent;O;O
in;O;O
inhibiting;O;O
yeast;O;O
cell;O;O
growth;O;O
,;O;O
DDI-MedLine.d120.s5;;
and;O;O
(;O;O
ii;O;O
);O;O
the;O;O
effects;O;O
of;O;O
filipin;B-drug_n;B-DDI-MedLine.d120.s5.e0
were;O;O
more;O;O
efficiently;O;O
inhibited;O;O
by;O;O
added;O;O
cholesterol;O;O
,;O;O
the;O;O
major;O;O
membrane;O;O
sterol;O;O
in;O;O
human;O;O
cells;O;O
,;O;O
whereas;O;O
the;O;O
effects;O;O
of;O;O
amphotericin;B-drug;B-DDI-MedLine.d120.s5.e1
B;I-drug;I-DDI-MedLine.d120.s5.e1
were;O;O
more;O;O
efficiently;O;O
inhibited;O;O
by;O;O
ergosterol;O;O
,;O;O
the;O;O
major;O;O
membrane;O;O
sterol;O;O
in;O;O
yeast;O;O
.;O;O
DDI-MedLine.d120.s6;;
The;O;O
simplest;O;O
inference;O;O
is;O;O
that;O;O
the;O;O
toxicity;O;O
and;O;O
effectiveness;O;O
of;O;O
polyenes;O;O
are;O;O
determined;O;O
by;O;O
their;O;O
relative;O;O
avidities;O;O
for;O;O
the;O;O
predominant;O;O
sterol;O;O
in;O;O
cell;O;O
membranes;O;O
.;O;O
DDI-MedLine.d40.s0;;
Studies;O;O
on;O;O
the;O;O
mechanism;O;O
of;O;O
action;O;O
of;O;O
miconazole;B-drug;B-DDI-MedLine.d40.s0.e0
:;O;O
effect;O;O
of;O;O
miconazole;B-drug;B-DDI-MedLine.d40.s0.e1
on;O;O
respiration;O;O
and;O;O
cell;O;O
permeability;O;O
of;O;O
Candida;O;O
albicans;O;O
.;O;O
DDI-MedLine.d40.s1;;
The;O;O
antifungal;B-group;B-DDI-MedLine.d40.s1.e0
drug;I-group;I-DDI-MedLine.d40.s1.e0
,;O;O
miconazole;B-drug;B-DDI-MedLine.d40.s1.e1
nitrate;I-drug;I-DDI-MedLine.d40.s1.e1
,;O;O
inhibits;O;O
the;O;O
growth;O;O
of;O;O
several;O;O
species;O;O
of;O;O
Candida;O;O
.;O;O
DDI-MedLine.d40.s2;;
Candida;O;O
albicans;O;O
,;O;O
one;O;O
of;O;O
the;O;O
pathogenic;O;O
species;O;O
,;O;O
was;O;O
totally;O;O
inhibited;O;O
at;O;O
a;O;O
concentration;O;O
of;O;O
approximately;O;O
10;O;O
mug;O;O
/;O;O
ml;O;O
.;O;O
DDI-MedLine.d40.s3;;
Endogenous;O;O
respiration;O;O
was;O;O
unaffected;O;O
by;O;O
the;O;O
drug;O;O
at;O;O
a;O;O
concentration;O;O
as;O;O
high;O;O
as;O;O
100;O;O
mug;O;O
/;O;O
ml;O;O
,;O;O
whereas;O;O
exogenous;O;O
respiration;O;O
was;O;O
markedly;O;O
sensitive;O;O
and;O;O
inhibited;O;O
to;O;O
an;O;O
extent;O;O
of;O;O
85;O;O
%;O;O
.;O;O
DDI-MedLine.d40.s4;;
The;O;O
permeability;O;O
of;O;O
the;O;O
cell;O;O
membrane;O;O
was;O;O
changed;O;O
as;O;O
evidenced;O;O
by;O;O
the;O;O
leakage;O;O
of;O;O
260;O;O
-;O;O
nm;O;O
absorbing;O;O
materials;O;O
,;O;O
amino;O;O
acids;O;O
,;O;O
proteins;O;O
,;O;O
and;O;O
inorganic;O;O
cations;O;O
.;O;O
DDI-MedLine.d40.s5;;
The;O;O
results;O;O
we;O;O
present;O;O
clearly;O;O
show;O;O
that;O;O
the;O;O
drug;O;O
alters;O;O
the;O;O
cellular;O;O
permeability;O;O
,;O;O
and;O;O
thus;O;O
the;O;O
exogenous;O;O
respiration;O;O
becomes;O;O
sensitive;O;O
to;O;O
the;O;O
drug;O;O
.;O;O
DDI-MedLine.d29.s0;;
Effect;O;O
of;O;O
probenecid;B-drug;B-DDI-MedLine.d29.s0.e0
on;O;O
the;O;O
apparent;O;O
volume;O;O
of;O;O
distribution;O;O
and;O;O
elimination;O;O
of;O;O
cloxacillin;B-drug;B-DDI-MedLine.d29.s0.e1
.;O;O
DDI-MedLine.d29.s1;;
According;O;O
to;O;O
Gibaldi;O;O
et;O;O
al;O;O
.;O;O
DDI-MedLine.d29.s2;;
(;O;O
1968;O;O
,;O;O
1970;O;O
);O;O
,;O;O
the;O;O
higher;O;O
serum;O;O
concentrations;O;O
of;O;O
penicillins;B-group;B-DDI-MedLine.d29.s2.e0
and;O;O
cephaloridine;B-drug;B-DDI-MedLine.d29.s2.e1
reached;O;O
after;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-MedLine.d29.s2.e2
are;O;O
due;O;O
not;O;O
only;O;O
to;O;O
slower;O;O
renal;O;O
elimination;O;O
but;O;O
also;O;O
to;O;O
an;O;O
altered;O;O
distribution;O;O
in;O;O
the;O;O
body;O;O
.;O;O
DDI-MedLine.d29.s3;;
To;O;O
determine;O;O
whether;O;O
probenecid;B-drug;B-DDI-MedLine.d29.s3.e0
has;O;O
a;O;O
direct;O;O
effect;O;O
on;O;O
the;O;O
distribution;O;O
of;O;O
cloxacillin;B-drug;B-DDI-MedLine.d29.s3.e1
,;O;O
the;O;O
elimination;O;O
and;O;O
distribution;O;O
of;O;O
cloxacillin;B-drug;B-DDI-MedLine.d29.s3.e2
was;O;O
studied;O;O
in;O;O
six;O;O
patients;O;O
,;O;O
five;O;O
lacking;O;O
kidney;O;O
function;O;O
and;O;O
one;O;O
with;O;O
a;O;O
partially;O;O
impaired;O;O
renal;O;O
function;O;O
,;O;O
in;O;O
the;O;O
presence;O;O
or;O;O
absence;O;O
of;O;O
probenecid;B-drug;B-DDI-MedLine.d29.s3.e3
.;O;O
DDI-MedLine.d29.s4;;
No;O;O
significant;O;O
difference;O;O
was;O;O
found;O;O
between;O;O
the;O;O
mean;O;O
values;O;O
of;O;O
the;O;O
volume;O;O
of;O;O
distribution;O;O
of;O;O
cloxacillin;B-drug;B-DDI-MedLine.d29.s4.e0
with;O;O
and;O;O
without;O;O
probenecid;B-drug;B-DDI-MedLine.d29.s4.e1
(;O;O
13.0;O;O
and;O;O
12.6;O;O
liters;O;O
,;O;O
respectively;O;O
);O;O
.;O;O
DDI-MedLine.d29.s5;;
Thus;O;O
,;O;O
the;O;O
hypothesis;O;O
of;O;O
Gibaldi;O;O
et;O;O
al;O;O
.;O;O
DDI-MedLine.d29.s6;;
could;O;O
not;O;O
be;O;O
confirmed;O;O
for;O;O
cloxacillin;B-drug;B-DDI-MedLine.d29.s6.e0
in;O;O
patients;O;O
lacking;O;O
kidney;O;O
function;O;O
.;O;O
DDI-MedLine.d29.s7;;
In;O;O
spite;O;O
of;O;O
the;O;O
absence;O;O
of;O;O
kidney;O;O
function;O;O
,;O;O
the;O;O
value;O;O
of;O;O
the;O;O
elimination;O;O
rate;O;O
constant;O;O
was;O;O
significantly;O;O
decreased;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
probenecid;B-drug;B-DDI-MedLine.d29.s7.e0
(;O;O
from;O;O
0.326;O;O
to;O;O
0.263;O;O
/;O;O
h;O;O
);O;O
.;O;O
DDI-MedLine.d29.s8;;
This;O;O
might;O;O
be;O;O
explained;O;O
by;O;O
a;O;O
blockade;O;O
by;O;O
probenecid;B-drug;B-DDI-MedLine.d29.s8.e0
of;O;O
the;O;O
elimination;O;O
of;O;O
cloxacillin;B-drug;B-DDI-MedLine.d29.s8.e1
by;O;O
the;O;O
liver;O;O
.;O;O
DDI-MedLine.d122.s0;;
Behavioral;O;O
mechanisms;O;O
underlying;O;O
the;O;O
link;O;O
between;O;O
smoking;O;O
and;O;O
drinking;O;O
.;O;O
DDI-MedLine.d122.s1;;
Many;O;O
people;O;O
use;O;O
both;O;O
alcohol;B-drug;B-DDI-MedLine.d122.s1.e0
and;O;O
nicotine;B-drug;B-DDI-MedLine.d122.s1.e1
(;O;O
i.e.;O;O
,;O;O
cigarettes;O;O
and;O;O
other;O;O
tobacco;O;O
products;O;O
);O;O
.;O;O
DDI-MedLine.d122.s2;;
The;O;O
behavioral;O;O
effects;O;O
of;O;O
these;O;O
two;O;O
drugs;O;O
differ;O;O
,;O;O
and;O;O
they;O;O
do;O;O
not;O;O
act;O;O
on;O;O
the;O;O
same;O;O
target;O;O
sites;O;O
in;O;O
the;O;O
brain;O;O
,;O;O
although;O;O
they;O;O
may;O;O
share;O;O
,;O;O
or;O;O
partly;O;O
share;O;O
,;O;O
certain;O;O
properties;O;O
.;O;O
DDI-MedLine.d122.s3;;
The;O;O
initiation;O;O
of;O;O
alcohol;B-drug;B-DDI-MedLine.d122.s3.e0
or;O;O
nicotine;B-drug;B-DDI-MedLine.d122.s3.e1
use;O;O
may;O;O
be;O;O
precipitated;O;O
by;O;O
similar;O;O
personality;O;O
characteristics;O;O
in;O;O
the;O;O
user;O;O
,;O;O
such;O;O
as;O;O
impulsivity;O;O
and;O;O
sensation;O;O
seeking;O;O
.;O;O
DDI-MedLine.d122.s4;;
Moreover;O;O
,;O;O
the;O;O
mechanisms;O;O
underlying;O;O
the;O;O
development;O;O
of;O;O
dependence;O;O
may;O;O
be;O;O
similar;O;O
for;O;O
alcohol;B-drug;B-DDI-MedLine.d122.s4.e0
and;O;O
nicotine;B-drug;B-DDI-MedLine.d122.s4.e1
.;O;O
DDI-MedLine.d122.s5;;
Thus;O;O
,;O;O
certain;O;O
factors;O;O
,;O;O
such;O;O
as;O;O
reinforcing;O;O
drug;O;O
effects;O;O
,;O;O
conditioning;O;O
processes;O;O
,;O;O
automatic;O;O
behavior;O;O
,;O;O
and;O;O
stress;O;O
,;O;O
may;O;O
influence;O;O
the;O;O
development;O;O
of;O;O
dependence;O;O
on;O;O
both;O;O
drugs;O;O
.;O;O
DDI-MedLine.d122.s6;;
Other;O;O
factors;O;O
,;O;O
such;O;O
as;O;O
tolerance;O;O
and;O;O
sensitization;O;O
to;O;O
the;O;O
drugs;O;O
';O;O
actions;O;O
and;O;O
the;O;O
development;O;O
of;O;O
withdrawal;O;O
symptoms;O;O
,;O;O
may;O;O
also;O;O
contribute;O;O
to;O;O
dependence;O;O
.;O;O
DDI-MedLine.d122.s7;;
This;O;O
review;O;O
discusses;O;O
the;O;O
actions;O;O
of;O;O
the;O;O
two;O;O
drugs;O;O
on;O;O
certain;O;O
brain;O;O
chemical;O;O
(;O;O
i.e.;O;O
,;O;O
neurotransmitter;O;O
);O;O
systems;O;O
and;O;O
the;O;O
extent;O;O
to;O;O
which;O;O
the;O;O
effects;O;O
of;O;O
the;O;O
two;O;O
drugs;O;O
may;O;O
interact;O;O
.;O;O
DDI-MedLine.d134.s0;;
[;O;O
Dose;O;O
-;O;O
time;O;O
effects;O;O
of;O;O
competitive;O;O
displacement;O;O
of;O;O
radiopertechnetate;B-drug;B-DDI-MedLine.d134.s0.e0
by;O;O
sodium;B-drug_n;B-DDI-MedLine.d134.s0.e1
perchlorate;I-drug_n;I-DDI-MedLine.d134.s0.e1
following;O;O
oral;O;O
and;O;O
intravenous;O;O
administration;O;O
];O;O
The;O;O
effect;O;O
of;O;O
various;O;O
doses;O;O
of;O;O
sodium;B-drug_n;B-DDI-MedLine.d134.s0.e2
perchlorate;I-drug_n;I-DDI-MedLine.d134.s0.e2
in;O;O
several;O;O
dose;O;O
fractions;O;O
on;O;O
the;O;O
extent;O;O
and;O;O
the;O;O
time;O;O
scale;O;O
of;O;O
displacement;O;O
of;O;O
radiopertechnetate;B-drug;B-DDI-MedLine.d134.s0.e3
,;O;O
in;O;O
dependence;O;O
on;O;O
application;O;O
mode;O;O
,;O;O
was;O;O
studied;O;O
.;O;O
DDI-MedLine.d134.s1;;
An;O;O
intravenous;O;O
dose;O;O
of;O;O
50;O;O
mg;O;O
perchlorate;B-drug_n;B-DDI-MedLine.d134.s1.e0
was;O;O
in;O;O
respect;O;O
of;O;O
competitive;O;O
suppression;O;O
of;O;O
organs;O;O
actively;O;O
concentrating;O;O
pertechnetate;B-drug;B-DDI-MedLine.d134.s1.e1
as;O;O
effective;O;O
as;O;O
intravenous;O;O
1000;O;O
mg;O;O
ClO;O;O
-;O;O
4;O;O
-;O;O
simultaneously;O;O
or;O;O
1000;O;O
mg;O;O
orally;O;O
30;O;O
min;O;O
before;O;O
the;O;O
injection;O;O
of;O;O
radiopertechnetate;B-drug;B-DDI-MedLine.d134.s1.e2
.;O;O
DDI-MedLine.d134.s2;;
An;O;O
intravenous;O;O
injection;O;O
of;O;O
perchlorate;B-drug_n;B-DDI-MedLine.d134.s2.e0
given;O;O
later;O;O
also;O;O
produces;O;O
a;O;O
complete;O;O
and;O;O
immediately;O;O
beginning;O;O
depletion;O;O
of;O;O
pertechnetate;B-drug;B-DDI-MedLine.d134.s2.e1
already;O;O
accumulated;O;O
in;O;O
the;O;O
thyroid;O;O
,;O;O
within;O;O
a;O;O
period;O;O
of;O;O
195;O;O
min;O;O
after;O;O
99m;O;O
-;O;O
TcO;O;O
-;O;O
4;O;O
-;O;O
injection;O;O
with;O;O
a;O;O
corresponding;O;O
increase;O;O
in;O;O
blood;O;O
levels;O;O
.;O;O
DDI-MedLine.d134.s3;;
20;O;O
mg;O;O
result;O;O
in;O;O
incomplete;O;O
depletion;O;O
which;O;O
becomes;O;O
complete;O;O
after;O;O
a;O;O
second;O;O
additional;O;O
dose;O;O
.;O;O
DDI-MedLine.d134.s4;;
The;O;O
intravenous;O;O
application;O;O
of;O;O
perchlorate;B-drug_n;B-DDI-MedLine.d134.s4.e0
offers;O;O
advantages;O;O
in;O;O
clinical;O;O
use;O;O
.;O;O
DDI-MedLine.d10.s0;;
Herbal;O;O
remedies;O;O
,;O;O
nephropathies;O;O
,;O;O
and;O;O
renal;O;O
disease;O;O
.;O;O

;O;O
DDI-MedLine.d10.s1;;
The;O;O
use;O;O
of;O;O
herbal;O;O
remedies;O;O
is;O;O
becoming;O;O
increasingly;O;O
popular;O;O
in;O;O
the;O;O
United;O;O
States;O;O
.;O;O
DDI-MedLine.d10.s2;;
Research;O;O
has;O;O
shown;O;O
that;O;O
herbal;O;O
remedy;O;O
use;O;O
may;O;O
be;O;O
associated;O;O
with;O;O
acute;O;O
renal;O;O
failure;O;O
.;O;O
DDI-MedLine.d10.s3;;
In;O;O
addition;O;O
,;O;O
the;O;O
use;O;O
of;O;O
herbal;O;O
remedies;O;O
may;O;O
be;O;O
detrimental;O;O
for;O;O
the;O;O
patient;O;O
with;O;O
compromised;O;O
renal;O;O
function;O;O
.;O;O
DDI-MedLine.d10.s4;;
Patients;O;O
with;O;O
renal;O;O
insufficiency;O;O
or;O;O
renal;O;O
failure;O;O
may;O;O
be;O;O
at;O;O
risk;O;O
for;O;O
further;O;O
kidney;O;O
damage;O;O
as;O;O
well;O;O
as;O;O
complications;O;O
related;O;O
to;O;O
interactions;O;O
of;O;O
herbal;O;O
remedies;O;O
with;O;O
complex;O;O
renal;O;O
therapy;O;O
regimens;O;O
.;O;O
DDI-MedLine.d10.s5;;
This;O;O
article;O;O
will;O;O
describe;O;O
the;O;O
escalating;O;O
use;O;O
of;O;O
herbal;O;O
therapy;O;O
and;O;O
the;O;O
hazards;O;O
of;O;O
herbal;O;O
remedy;O;O
use;O;O
among;O;O
patients;O;O
.;O;O
DDI-MedLine.d118.s0;;
Sirolimus;B-drug;B-DDI-MedLine.d118.s0.e0
:;O;O
mammalian;O;O
target;O;O
of;O;O
rapamycin;B-drug;B-DDI-MedLine.d118.s0.e1
inhibitor;O;O
to;O;O
prevent;O;O
kidney;O;O
rejection;O;O
.;O;O
DDI-MedLine.d118.s1;;
Current;O;O
immunosuppressive;O;O
therapies;O;O
are;O;O
effective;O;O
but;O;O
can;O;O
be;O;O
associated;O;O
with;O;O
significant;O;O
adverse;O;O
reactions;O;O
.;O;O
DDI-MedLine.d118.s2;;
Sirolimus;B-drug;B-DDI-MedLine.d118.s2.e0
works;O;O
differently;O;O
from;O;O
the;O;O
immunosuppressants;B-group;B-DDI-MedLine.d118.s2.e1
currently;O;O
available;O;O
,;O;O
and;O;O
except;O;O
for;O;O
increased;O;O
lipid;O;O
levels;O;O
,;O;O
the;O;O
adverse;O;O
reaction;O;O
profile;O;O
of;O;O
sirolimus;B-drug;B-DDI-MedLine.d118.s2.e2
does;O;O
not;O;O
appear;O;O
to;O;O
overlap;O;O
to;O;O
any;O;O
great;O;O
extent;O;O
with;O;O
that;O;O
associated;O;O
with;O;O
cyclosporine;B-drug;B-DDI-MedLine.d118.s2.e3
or;O;O
tacrolimus;B-drug;B-DDI-MedLine.d118.s2.e4
.;O;O
DDI-MedLine.d118.s3;;
While;O;O
additional;O;O
research;O;O
is;O;O
needed;O;O
,;O;O
the;O;O
initial;O;O
clinical;O;O
data;O;O
in;O;O
kidney;O;O
recipients;O;O
suggest;O;O
that;O;O
sirolimus;B-drug;B-DDI-MedLine.d118.s3.e0
,;O;O
in;O;O
combination;O;O
with;O;O
cyclosporine;B-drug;B-DDI-MedLine.d118.s3.e1
or;O;O
tacrolimus;B-drug;B-DDI-MedLine.d118.s3.e2
,;O;O
might;O;O
have;O;O
the;O;O
potential;O;O
to;O;O
reduce;O;O
the;O;O
frequency;O;O
of;O;O
rejection;O;O
episodes;O;O
,;O;O
permit;O;O
reductions;O;O
in;O;O
cyclosporine;B-drug;B-DDI-MedLine.d118.s3.e3
or;O;O
tacrolimus;B-drug;B-DDI-MedLine.d118.s3.e4
dosage;O;O
,;O;O
and;O;O
permit;O;O
steroid;O;O
withdrawal;O;O
(;O;O
Kelly;O;O
,;O;O
1999;O;O
);O;O
.;O;O
DDI-MedLine.d88.s0;;
The;O;O
effects;O;O
of;O;O
chlordiazepoxide;B-drug;B-DDI-MedLine.d88.s0.e0
,;O;O
amphetamine;B-drug;B-DDI-MedLine.d88.s0.e1
and;O;O
cocaine;B-drug;B-DDI-MedLine.d88.s0.e2
on;O;O
bar;O;O
-;O;O
press;O;O
behavior;O;O
in;O;O
normal;O;O
and;O;O
genetically;O;O
nervous;O;O
dogs;O;O
.;O;O
DDI-MedLine.d88.s1;;
Studies;O;O
on;O;O
two;O;O
strains;O;O
of;O;O
pointer;O;O
dogs;O;O
have;O;O
demonstrated;O;O
that;O;O
administration;O;O
of;O;O
a;O;O
benzodiazepine;B-group;B-DDI-MedLine.d88.s1.e0
(;O;O
chlordiazepoxide;B-drug;B-DDI-MedLine.d88.s1.e1
);O;O
facilitates;O;O
acquisition;O;O
of;O;O
goal;O;O
-;O;O
directed;O;O
behavior;O;O
in;O;O
";O;O
genetically;O;O
nervous;O;O
";O;O
DDI-MedLine.d88.s2;;
subjects;O;O
.;O;O
DDI-MedLine.d88.s3;;
Continued;O;O
admistration;O;O
of;O;O
the;O;O
drug;O;O
is;O;O
required;O;O
to;O;O
maintain;O;O
barpress;O;O
response;O;O
in;O;O
this;O;O
strain;O;O
of;O;O
dogs;O;O
.;O;O
DDI-MedLine.d88.s4;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
either;O;O
cocaine;B-drug;B-DDI-MedLine.d88.s4.e0
or;O;O
amphetamine;B-drug;B-DDI-MedLine.d88.s4.e1
,;O;O
compounds;O;O
which;O;O
inhibit;O;O
neuronal;O;O
reuptake;O;O
of;O;O
norepinephrine;O;O
,;O;O
disrupts;O;O
the;O;O
behavioral;O;O
response;O;O
of;O;O
the;O;O
genetically;O;O
nervous;O;O
E;O;O
-;O;O
strain;O;O
subjects;O;O
to;O;O
a;O;O
far;O;O
greater;O;O
extent;O;O
than;O;O
the;O;O
stable;O;O
A;O;O
-;O;O
strain;O;O
subjects;O;O
.;O;O
DDI-MedLine.d88.s5;;
It;O;O
is;O;O
also;O;O
shown;O;O
that;O;O
after;O;O
14;O;O
days;O;O
of;O;O
daily;O;O
administration;O;O
of;O;O
chlordiazepoxide;B-drug;B-DDI-MedLine.d88.s5.e0
,;O;O
withdrawal;O;O
of;O;O
the;O;O
drug;O;O
not;O;O
only;O;O
re;O;O
-;O;O
results;O;O
in;O;O
almost;O;O
complete;O;O
loss;O;O
of;O;O
bar;O;O
-;O;O
press;O;O
response;O;O
in;O;O
the;O;O
E;O;O
-;O;O
strain;O;O
subjects;O;O
but;O;O
also;O;O
results;O;O
in;O;O
a;O;O
temporary;O;O
decrease;O;O
in;O;O
the;O;O
acquired;O;O
behavioral;O;O
response;O;O
of;O;O
the;O;O
stable;O;O
A;O;O
-;O;O
strain;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d436.s0;;
No;O;O
drug;O;O
,;O;O
nutritional;O;O
supplement;O;O
,;O;O
food;O;O
or;O;O
herb;O;O
interactions;O;O
have;O;O
yet;O;O
been;O;O
reported;O;O
.;O;O
DDI-MedLine.d119.s0;;
Development;O;O
and;O;O
pharmacology;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s0.e0
.;O;O

;O;O
DDI-MedLine.d119.s1;;
Fluvastatin;B-drug;B-DDI-MedLine.d119.s1.e0
is;O;O
the;O;O
first;O;O
synthetic;B-group;B-DDI-MedLine.d119.s1.e1
3;I-group;I-DDI-MedLine.d119.s1.e1
-;I-group;I-DDI-MedLine.d119.s1.e1
hydroxy;I-group;I-DDI-MedLine.d119.s1.e1
-;I-group;I-DDI-MedLine.d119.s1.e1
3;I-group;I-DDI-MedLine.d119.s1.e1
-;I-group;I-DDI-MedLine.d119.s1.e1
methylglutaryl;I-group;I-DDI-MedLine.d119.s1.e1
coenzyme;I-group;I-DDI-MedLine.d119.s1.e1
A;I-group;I-DDI-MedLine.d119.s1.e1
(;I-group;I-DDI-MedLine.d119.s1.e1
HMGCoA;I-group;I-DDI-MedLine.d119.s1.e1
);I-group;I-DDI-MedLine.d119.s1.e1
reductase;I-group;I-DDI-MedLine.d119.s1.e1
inhibitor;I-group;I-DDI-MedLine.d119.s1.e1
to;O;O
be;O;O
approved;O;O
for;O;O
clinical;O;O
use;O;O
,;O;O
and;O;O
has;O;O
been;O;O
studied;O;O
extensively;O;O
in;O;O
humans;O;O
since;O;O
1986;O;O
.;O;O
DDI-MedLine.d119.s2;;
It;O;O
is;O;O
structurally;O;O
distinct;O;O
from;O;O
the;O;O
other;O;O
currently;O;O
available;O;O
HMGCoA;B-group;B-DDI-MedLine.d119.s2.e0
reductase;I-group;I-DDI-MedLine.d119.s2.e0
inhibitors;I-group;I-DDI-MedLine.d119.s2.e0
(;O;O
lovastatin;B-drug;B-DDI-MedLine.d119.s2.e1
,;O;O
simvastatin;B-drug;B-DDI-MedLine.d119.s2.e2
,;O;O
and;O;O
pravastatin;B-drug;B-DDI-MedLine.d119.s2.e3
);O;O
,;O;O
leading;O;O
to;O;O
unique;O;O
biopharmaceutical;O;O
properties;O;O
relative;O;O
to;O;O
the;O;O
other;O;O
agents;O;O
of;O;O
this;O;O
class;O;O
.;O;O
DDI-MedLine.d119.s3;;
Absorption;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s3.e0
is;O;O
virtually;O;O
complete;O;O
across;O;O
all;O;O
species;O;O
,;O;O
including;O;O
man;O;O
,;O;O
and;O;O
is;O;O
not;O;O
affected;O;O
by;O;O
the;O;O
presence;O;O
of;O;O
food;O;O
.;O;O
DDI-MedLine.d119.s4;;
Systemic;O;O
exposure;O;O
is;O;O
limited;O;O
,;O;O
as;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s4.e0
is;O;O
subject;O;O
to;O;O
first;O;O
-;O;O
pass;O;O
metabolism;O;O
,;O;O
and;O;O
the;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
of;O;O
the;O;O
drug;O;O
is;O;O
approximately;O;O
30;O;O
minutes;O;O
.;O;O
DDI-MedLine.d119.s5;;
Some;O;O
95;O;O
%;O;O
of;O;O
a;O;O
single;O;O
dosage;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s5.e0
is;O;O
excreted;O;O
via;O;O
the;O;O
biliary;O;O
route;O;O
,;O;O
with;O;O
less;O;O
than;O;O
2;O;O
%;O;O
of;O;O
this;O;O
being;O;O
the;O;O
parent;O;O
compound;O;O
.;O;O
DDI-MedLine.d119.s6;;
Additionally;O;O
,;O;O
there;O;O
is;O;O
no;O;O
evidence;O;O
of;O;O
circulating;O;O
active;O;O
metabolites;O;O
or;O;O
accumulation;O;O
during;O;O
chronic;O;O
dosing;O;O
.;O;O
DDI-MedLine.d119.s7;;
Studies;O;O
of;O;O
the;O;O
effect;O;O
of;O;O
food;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s7.e0
have;O;O
demonstrated;O;O
marked;O;O
reductions;O;O
in;O;O
the;O;O
rate;O;O
of;O;O
bioavailability;O;O
--;O;O
from;O;O
40;O;O
%;O;O
to;O;O
60;O;O
%;O;O
,;O;O
DDI-MedLine.d119.s8;;
however;O;O
,;O;O
a;O;O
comparison;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s8.e0
administration;O;O
with;O;O
the;O;O
evening;O;O
meal;O;O
or;O;O
at;O;O
bedtime;O;O
has;O;O
revealed;O;O
no;O;O
significant;O;O
differences;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
bioavailability;O;O
(;O;O
area;O;O
under;O;O
the;O;O
curve;O;O
);O;O
of;O;O
these;O;O
two;O;O
regimens;O;O
.;O;O
DDI-MedLine.d119.s9;;
Furthermore;O;O
,;O;O
no;O;O
significant;O;O
difference;O;O
in;O;O
pharmacodynamic;O;O
effect;O;O
(;O;O
reduction;O;O
in;O;O
low;O;O
-;O;O
density;O;O
lipoprotein;O;O
cholesterol;O;O
levels;O;O
);O;O
could;O;O
be;O;O
ascertained;O;O
between;O;O
mealtime;O;O
dosing;O;O
and;O;O
bedtime;O;O
dosing;O;O
.;O;O
DDI-MedLine.d119.s10;;
The;O;O
pharmacokinetics;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s10.e0
have;O;O
also;O;O
been;O;O
assessed;O;O
in;O;O
various;O;O
demographic;O;O
groups;O;O
.;O;O
DDI-MedLine.d119.s11;;
Relative;O;O
to;O;O
the;O;O
general;O;O
population;O;O
,;O;O
plasma;O;O
concentrations;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s11.e0
do;O;O
not;O;O
vary;O;O
as;O;O
a;O;O
function;O;O
of;O;O
either;O;O
age;O;O
or;O;O
gender;O;O
.;O;O
DDI-MedLine.d119.s12;;
In;O;O
addition;O;O
,;O;O
administration;O;O
to;O;O
a;O;O
patient;O;O
population;O;O
with;O;O
hepatic;O;O
insufficiency;O;O
resulted;O;O
in;O;O
a;O;O
2.5;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
both;O;O
the;O;O
rate;O;O
and;O;O
extent;O;O
of;O;O
bioavailability;O;O
relative;O;O
to;O;O
controls;O;O
.;O;O
DDI-MedLine.d119.s13;;
Also;O;O
,;O;O
although;O;O
minimal;O;O
alterations;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s13.e0
clearance;O;O
in;O;O
patients;O;O
with;O;O
renal;O;O
insufficiency;O;O
are;O;O
anticipated;O;O
due;O;O
to;O;O
limited;O;O
renal;O;O
excretion;O;O
(;O;O
5;O;O
%;O;O
);O;O
,;O;O
a;O;O
study;O;O
in;O;O
this;O;O
patient;O;O
group;O;O
is;O;O
currently;O;O
underway;O;O
to;O;O
examine;O;O
this;O;O
further;O;O
.;O;O
DDI-MedLine.d119.s14;;
Interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
with;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s14.e0
and;O;O
several;O;O
drugs;O;O
with;O;O
which;O;O
it;O;O
might;O;O
be;O;O
coadministered;O;O
.;O;O
DDI-MedLine.d119.s15;;
Cholestyramine;B-drug;B-DDI-MedLine.d119.s15.e0
,;O;O
an;O;O
anionic;O;O
-;O;O
binding;O;O
resin;O;O
,;O;O
has;O;O
a;O;O
considerable;O;O
effect;O;O
in;O;O
lowering;O;O
the;O;O
rate;O;O
and;O;O
extent;O;O
of;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s15.e1
bioavailability;O;O
.;O;O
DDI-MedLine.d119.s16;;
Although;O;O
this;O;O
effect;O;O
was;O;O
noted;O;O
even;O;O
when;O;O
cholestyramine;B-drug;B-DDI-MedLine.d119.s16.e0
was;O;O
given;O;O
4;O;O
hours;O;O
prior;O;O
to;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s16.e1
,;O;O
this;O;O
regimen;O;O
did;O;O
not;O;O
result;O;O
in;O;O
diminished;O;O
efficacy;O;O
.;O;O
DDI-MedLine.d119.s17;;
Further;O;O
,;O;O
no;O;O
effects;O;O
on;O;O
either;O;O
warfarin;B-drug;B-DDI-MedLine.d119.s17.e0
levels;O;O
or;O;O
prothrombin;O;O
times;O;O
were;O;O
observed;O;O
in;O;O
a;O;O
study;O;O
involving;O;O
concomitant;O;O
administration;O;O
of;O;O
warfarin;B-drug;B-DDI-MedLine.d119.s17.e1
and;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s17.e2
.;O;O
DDI-MedLine.d119.s18;;
Moreover;O;O
,;O;O
additional;O;O
interaction;O;O
studies;O;O
with;O;O
niacin;B-drug;B-DDI-MedLine.d119.s18.e0
and;O;O
propranolol;B-drug;B-DDI-MedLine.d119.s18.e1
have;O;O
not;O;O
demonstrated;O;O
any;O;O
effect;O;O
on;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s18.e2
plasma;O;O
levels;O;O
,;O;O
and;O;O
administration;O;O
to;O;O
a;O;O
patient;O;O
population;O;O
chronically;O;O
receiving;O;O
digoxin;B-drug;B-DDI-MedLine.d119.s18.e3
resulted;O;O
in;O;O
no;O;O
difference;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
bioavailability;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d119.s18.e4
relative;O;O
to;O;O
control;O;O
data;O;O
.;O;O
DDI-MedLine.d119.s19;;
The;O;O
results;O;O
generated;O;O
to;O;O
date;O;O
in;O;O
clinical;O;O
pharmacokinetic;O;O
studies;O;O
with;O;O
fluvastatin;B-drug;B-DDI-MedLine.d119.s19.e0
thus;O;O
support;O;O
its;O;O
use;O;O
in;O;O
a;O;O
broad;O;O
population;O;O
of;O;O
hypercholesterolaemic;O;O
patients;O;O
.;O;O
DDI-MedLine.d43.s0;;
Tumor;O;O
phenotype;O;O
and;O;O
susceptibility;O;O
to;O;O
progression;O;O
as;O;O
an;O;O
expression;O;O
of;O;O
subpopulations;O;O
of;O;O
initiated;O;O
murine;O;O
cells;O;O
.;O;O

;O;O
DDI-MedLine.d43.s1;;
Currently;O;O
,;O;O
it;O;O
is;O;O
conceived;O;O
that;O;O
a;O;O
number;O;O
of;O;O
events;O;O
,;O;O
or;O;O
hits;O;O
,;O;O
are;O;O
required;O;O
for;O;O
the;O;O
induction;O;O
of;O;O
tumors;O;O
by;O;O
chemical;O;O
agents;O;O
.;O;O
DDI-MedLine.d43.s2;;
The;O;O
first;O;O
phase;O;O
of;O;O
this;O;O
sequence;O;O
,;O;O
initiation;O;O
,;O;O
is;O;O
considered;O;O
to;O;O
result;O;O
from;O;O
at;O;O
least;O;O
one;O;O
event;O;O
in;O;O
the;O;O
genetic;O;O
apparatus;O;O
.;O;O
DDI-MedLine.d43.s3;;
Analyses;O;O
of;O;O
this;O;O
sequence;O;O
,;O;O
however;O;O
,;O;O
usually;O;O
give;O;O
little;O;O
consideration;O;O
to;O;O
the;O;O
nature;O;O
of;O;O
the;O;O
target;O;O
cell;O;O
or;O;O
to;O;O
the;O;O
characteristics;O;O
of;O;O
the;O;O
resultant;O;O
tumors;O;O
.;O;O
DDI-MedLine.d43.s4;;
Vesselinovitch;O;O
et;O;O
al;O;O
.;O;O
DDI-MedLine.d43.s5;;
(;O;O
Cancer;O;O
Res;O;O
.;O;O
,;O;O
38;O;O
:;O;O
2003;O;O
-;O;O
2010;O;O
,;O;O
1978;O;O
);O;O
have;O;O
reported;O;O
that;O;O
a;O;O
single;O;O
,;O;O
small;O;O
pulse;O;O
of;O;O
carcinogen;O;O
can;O;O
induce;O;O
early;O;O
and;O;O
numerous;O;O
liver;O;O
tumors;O;O
when;O;O
administered;O;O
neonatally;O;O
to;O;O
mice;O;O
with;O;O
a;O;O
genetic;O;O
predisposition;O;O
to;O;O
hepatotumorigenesis;O;O
.;O;O
DDI-MedLine.d43.s6;;
In;O;O
the;O;O
current;O;O
study;O;O
,;O;O
the;O;O
nonpredisposed;O;O
strain;O;O
C57BL;O;O
/;O;O
6N;O;O
was;O;O
also;O;O
shown;O;O
to;O;O
be;O;O
highly;O;O
susceptible;O;O
to;O;O
diethylnitrosamine;O;O
during;O;O
the;O;O
neonatal;O;O
period;O;O
.;O;O
DDI-MedLine.d43.s7;;
C57BL;O;O
/;O;O
6N;O;O
demonstrated;O;O
large;O;O
numbers;O;O
of;O;O
two;O;O
of;O;O
the;O;O
three;O;O
types;O;O
of;O;O
liver;O;O
tumors;O;O
seen;O;O
in;O;O
livers;O;O
of;O;O
genetically;O;O
predisposed;O;O
mice;O;O
,;O;O
one;O;O
of;O;O
which;O;O
required;O;O
the;O;O
additional;O;O
stimulus;O;O
of;O;O
dietary;O;O
phenobarbital;B-drug;B-DDI-MedLine.d43.s7.e0
for;O;O
growth;O;O
.;O;O
DDI-MedLine.d43.s8;;
Tumors;O;O
of;O;O
more;O;O
malignant;O;O
phenotype;O;O
were;O;O
demonstrated;O;O
only;O;O
in;O;O
genetically;O;O
predisposed;O;O
mice;O;O
(;O;O
C57BL;O;O
/;O;O
6N;O;O
X;O;O
C3H;O;O
/;O;O
HeN;O;O
F1;O;O
);O;O
that;O;O
received;O;O
one;O;O
dose;O;O
of;O;O
carcinogen;O;O
.;O;O
DDI-MedLine.d43.s9;;
These;O;O
findings;O;O
suggest;O;O
that;O;O
the;O;O
phenotype;O;O
of;O;O
a;O;O
tumor;O;O
that;O;O
results;O;O
from;O;O
a;O;O
pulse;O;O
of;O;O
a;O;O
chemical;O;O
carcinogen;O;O
may;O;O
depend;O;O
upon;O;O
the;O;O
target;O;O
cell;O;O
.;O;O
DDI-MedLine.d43.s10;;
The;O;O
initiated;O;O
cells;O;O
that;O;O
result;O;O
from;O;O
this;O;O
hit;O;O
may;O;O
vary;O;O
from;O;O
those;O;O
that;O;O
demonstrate;O;O
very;O;O
little;O;O
progression;O;O
in;O;O
cell;O;O
type;O;O
and;O;O
may;O;O
or;O;O
may;O;O
not;O;O
require;O;O
exogenous;O;O
enhancement;O;O
of;O;O
growth;O;O
to;O;O
those;O;O
that;O;O
can;O;O
progress;O;O
very;O;O
rapidly;O;O
to;O;O
fully;O;O
malignant;O;O
behavior;O;O
.;O;O
DDI-MedLine.d43.s11;;
The;O;O
latter;O;O
might;O;O
arise;O;O
from;O;O
a;O;O
hit;O;O
in;O;O
a;O;O
genetically;O;O
initiated;O;O
cell;O;O
,;O;O
the;O;O
result;O;O
of;O;O
which;O;O
is;O;O
a;O;O
more;O;O
rapid;O;O
progression;O;O
in;O;O
tumor;O;O
type;O;O
.;O;O
DDI-MedLine.d57.s0;;
Analgesic;O;O
effects;O;O
of;O;O
antihistaminics;B-group;B-DDI-MedLine.d57.s0.e0
.;O;O

;O;O
DDI-MedLine.d57.s1;;
The;O;O
literature;O;O
provides;O;O
considerable;O;O
evidence;O;O
indicating;O;O
that;O;O
several;O;O
,;O;O
but;O;O
not;O;O
all;O;O
antihistaminics;B-group;B-DDI-MedLine.d57.s1.e0
,;O;O
are;O;O
indeed;O;O
analgesic;B-group;B-DDI-MedLine.d57.s1.e1
agents;I-group;I-DDI-MedLine.d57.s1.e1
and;O;O
some;O;O
are;O;O
analgesic;B-group;B-DDI-MedLine.d57.s1.e2
adjuvants;I-group;I-DDI-MedLine.d57.s1.e2
as;O;O
well;O;O
.;O;O
DDI-MedLine.d57.s2;;
Those;O;O
for;O;O
which;O;O
effectiveness;O;O
is;O;O
reported;O;O
includes;O;O
diphenhydramine;B-drug;B-DDI-MedLine.d57.s2.e0
,;O;O
hydroxyzine;B-drug;B-DDI-MedLine.d57.s2.e1
,;O;O
orphenadrine;B-drug;B-DDI-MedLine.d57.s2.e2
,;O;O
pyrilamine;B-drug;B-DDI-MedLine.d57.s2.e3
,;O;O
phenyltoloxamine;B-drug_n;B-DDI-MedLine.d57.s2.e4
,;O;O
promethazine;B-drug;B-DDI-MedLine.d57.s2.e5
,;O;O
methdilazine;B-drug;B-DDI-MedLine.d57.s2.e6
,;O;O
and;O;O
tripelennamine;B-drug;B-DDI-MedLine.d57.s2.e7
.;O;O
DDI-MedLine.d57.s3;;
The;O;O
proposed;O;O
mechanisms;O;O
of;O;O
analgesic;O;O
action;O;O
of;O;O
antihistaminics;B-group;B-DDI-MedLine.d57.s3.e0
are;O;O
reviewed;O;O
and;O;O
discussed;O;O
.;O;O
DDI-MedLine.d57.s4;;
The;O;O
literature;O;O
suggests;O;O
that;O;O
more;O;O
than;O;O
one;O;O
mechanism;O;O
of;O;O
action;O;O
exists;O;O
for;O;O
them;O;O
.;O;O
DDI-MedLine.d57.s5;;
There;O;O
is;O;O
considerable;O;O
evidence;O;O
suggesting;O;O
that;O;O
histaminergic;O;O
and;O;O
serotoninergic;O;O
central;O;O
pathways;O;O
are;O;O
involved;O;O
in;O;O
nociception;O;O
and;O;O
that;O;O
antihistaminic;B-group;B-DDI-MedLine.d57.s5.e0
drugs;O;O
can;O;O
modulate;O;O
their;O;O
responses;O;O
(;O;O
1;O;O
);O;O
.;O;O
DDI-MedLine.d57.s6;;
The;O;O
evidence;O;O
for;O;O
a;O;O
role;O;O
for;O;O
norepinephrine;O;O
and;O;O
dopamine;O;O
and;O;O
the;O;O
effects;O;O
of;O;O
antihistaminics;B-group;B-DDI-MedLine.d57.s6.e0
on;O;O
them;O;O
are;O;O
less;O;O
well;O;O
established;O;O
.;O;O
DDI-MedLine.d57.s7;;
Still;O;O
other;O;O
pathways;O;O
have;O;O
been;O;O
proposed;O;O
.;O;O
DDI-MedLine.d57.s8;;
A;O;O
greater;O;O
understanding;O;O
of;O;O
pain;O;O
mechanisms;O;O
will;O;O
aid;O;O
in;O;O
elucidating;O;O
the;O;O
role;O;O
of;O;O
antihistaminics;B-group;B-DDI-MedLine.d57.s8.e0
in;O;O
analgesia;O;O
.;O;O
DDI-MedLine.d27.s0;;
[;O;O
The;O;O
GABA;O;O
-;O;O
ergic;O;O
system;O;O
and;O;O
brain;O;O
edema;O;O
];O;O
It;O;O
has;O;O
been;O;O
shown;O;O
in;O;O
rats;O;O
with;O;O
experimental;O;O
toxic;O;O
and;O;O
traumatic;O;O
edemas;O;O
that;O;O
picrotoxin;B-drug_n;B-DDI-MedLine.d27.s0.e0
(;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
removes;O;O
the;O;O
antiedematous;O;O
action;O;O
of;O;O
diazepam;B-drug;B-DDI-MedLine.d27.s0.e1
,;O;O
phenazepam;B-drug_n;B-DDI-MedLine.d27.s0.e2
,;O;O
phenibut;B-drug_n;B-DDI-MedLine.d27.s0.e3
and;O;O
amizyl;B-drug_n;B-DDI-MedLine.d27.s0.e4
and;O;O
reduces;O;O
the;O;O
action;O;O
of;O;O
phentolamine;B-drug;B-DDI-MedLine.d27.s0.e5
.;O;O
DDI-MedLine.d27.s1;;
When;O;O
the;O;O
dose;O;O
of;O;O
picrotoxin;B-drug_n;B-DDI-MedLine.d27.s1.e0
is;O;O
minimized;O;O
to;O;O
0.5;O;O
mg;O;O
/;O;O
kg;O;O
such;O;O
an;O;O
effect;O;O
is;O;O
not;O;O
observed;O;O
.;O;O
DDI-MedLine.d27.s2;;
Prolonged;O;O
daily;O;O
administration;O;O
of;O;O
picrotoxin;B-drug_n;B-DDI-MedLine.d27.s2.e0
in;O;O
a;O;O
dose;O;O
of;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
results;O;O
in;O;O
the;O;O
development;O;O
of;O;O
brain;O;O
edema;O;O
.;O;O
DDI-MedLine.d27.s3;;
It;O;O
is;O;O
recommended;O;O
that;O;O
GABA;O;O
-;O;O
positive;O;O
drugs;O;O
be;O;O
included;O;O
into;O;O
a;O;O
complex;O;O
of;O;O
treatment;O;O
measures;O;O
for;O;O
edema;O;O
.;O;O
DDI-MedLine.d15.s0;;
[;O;O
Stimulation;O;O
by;O;O
cerulein;B-drug_n;B-DDI-MedLine.d15.s0.e0
--;O;O
an;O;O
analog;O;O
of;O;O
the;O;O
octapeptide;O;O
cholecystokinin;O;O
--;O;O
of;O;O
3H;B-drug_n;B-DDI-MedLine.d15.s0.e1
-;I-drug_n;I-DDI-MedLine.d15.s0.e1
spiroperidol;I-drug_n;I-DDI-MedLine.d15.s0.e1
binding;O;O
after;O;O
the;O;O
long;O;O
-;O;O
term;O;O
administration;O;O
of;O;O
neuroleptics;B-group;B-DDI-MedLine.d15.s0.e2
];O;O
It;O;O
has;O;O
been;O;O
established;O;O
in;O;O
experiments;O;O
on;O;O
white;O;O
male;O;O
rats;O;O
that;O;O
prolonged;O;O
administration;O;O
(;O;O
twice;O;O
a;O;O
day;O;O
for;O;O
14;O;O
days;O;O
);O;O
of;O;O
haloperidol;B-drug;B-DDI-MedLine.d15.s0.e3
(;O;O
0.25;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
and;O;O
pyreneperone;B-drug_n;B-DDI-MedLine.d15.s0.e4
(;O;O
0.25;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
resulted;O;O
in;O;O
the;O;O
reduced;O;O
interaction;O;O
between;O;O
3H;B-drug_n;B-DDI-MedLine.d15.s0.e5
-;I-drug_n;I-DDI-MedLine.d15.s0.e5
spiroperidol;I-drug_n;I-DDI-MedLine.d15.s0.e5
and;O;O
low;O;O
affinity;O;O
binding;O;O
sites;O;O
for;O;O
apomorphine;B-drug;B-DDI-MedLine.d15.s0.e6
in;O;O
subcortical;O;O
structures;O;O
,;O;O
whereas;O;O
3H;B-drug_n;B-DDI-MedLine.d15.s0.e7
-;I-drug_n;I-DDI-MedLine.d15.s0.e7
spiroperidol;I-drug_n;I-DDI-MedLine.d15.s0.e7
binding;O;O
with;O;O
high;O;O
affinity;O;O
binding;O;O
sites;O;O
for;O;O
apomorphine;B-drug;B-DDI-MedLine.d15.s0.e8
increased;O;O
both;O;O
in;O;O
the;O;O
frontal;O;O
cortex;O;O
and;O;O
subcortical;O;O
structures;O;O
of;O;O
the;O;O
forebrain;O;O
.;O;O
DDI-MedLine.d15.s1;;
After;O;O
prolonged;O;O
administration;O;O
of;O;O
neuroleptics;B-group;B-DDI-MedLine.d15.s1.e0
the;O;O
displacing;O;O
effect;O;O
of;O;O
cerulein;B-drug_n;B-DDI-MedLine.d15.s1.e1
,;O;O
an;O;O
analog;O;O
of;O;O
cholecystokinin;O;O
octapeptide;O;O
,;O;O
was;O;O
replaced;O;O
by;O;O
the;O;O
stimulant;O;O
action;O;O
on;O;O
3H;B-drug_n;B-DDI-MedLine.d15.s1.e2
-;I-drug_n;I-DDI-MedLine.d15.s1.e2
spiroperidol;I-drug_n;I-DDI-MedLine.d15.s1.e2
binding;O;O
.;O;O
DDI-MedLine.d15.s2;;
It;O;O
is;O;O
assumed;O;O
that;O;O
increased;O;O
interaction;O;O
between;O;O
3H;B-drug_n;B-DDI-MedLine.d15.s2.e0
-;I-drug_n;I-DDI-MedLine.d15.s2.e0
spiroperidol;I-drug_n;I-DDI-MedLine.d15.s2.e0
and;O;O
high;O;O
affinity;O;O
binding;O;O
sites;O;O
for;O;O
apomorphine;B-drug;B-DDI-MedLine.d15.s2.e1
on;O;O
dopamine2;O;O
-;O;O
and;O;O
serotonin2;O;O
-;O;O
receptors;O;O
underlies;O;O
the;O;O
antipsychotic;O;O
action;O;O
of;O;O
neuroleptics;B-group;B-DDI-MedLine.d15.s2.e2
after;O;O
their;O;O
prolonged;O;O
administration;O;O
.;O;O
DDI-MedLine.d15.s3;;
Cholecystokinin;O;O
octapeptide;O;O
is;O;O
a;O;O
necessary;O;O
factor;O;O
for;O;O
realization;O;O
of;O;O
this;O;O
action;O;O
of;O;O
neuroleptics;B-group;B-DDI-MedLine.d15.s3.e0
.;O;O
DDI-MedLine.d56.s0;;
Dual;O;O
effect;O;O
of;O;O
ouabain;B-drug;B-DDI-MedLine.d56.s0.e0
on;O;O
the;O;O
palytoxin;B-drug_n;B-DDI-MedLine.d56.s0.e1
-;O;O
induced;O;O
contraction;O;O
and;O;O
norepinephrine;O;O
release;O;O
in;O;O
the;O;O
guinea;O;O
-;O;O
pig;O;O
vas;O;O
deferens;O;O
.;O;O
DDI-MedLine.d56.s1;;
Palytoxin;B-drug_n;B-DDI-MedLine.d56.s1.e0
(;O;O
PTX;B-drug_n;B-DDI-MedLine.d56.s1.e1
);O;O
,;O;O
C129H223N3O54;O;O
,;O;O
isolated;O;O
from;O;O
marine;O;O
coelenterates;O;O
of;O;O
Palythoa;O;O
tuberculosa;O;O
,;O;O
caused;O;O
a;O;O
first;O;O
rapid;O;O
contraction;O;O
followed;O;O
by;O;O
the;O;O
slow;O;O
phasic;O;O
contraction;O;O
of;O;O
guinea;O;O
-;O;O
pig;O;O
vas;O;O
deferens;O;O
.;O;O
DDI-MedLine.d56.s2;;
In;O;O
the;O;O
presence;O;O
of;O;O
ouabain;B-drug;B-DDI-MedLine.d56.s2.e0
(;O;O
10(;O;O
-;O;O
5;O;O
);O;O
M;O;O
);O;O
,;O;O
PTX;B-drug_n;B-DDI-MedLine.d56.s2.e1
(;O;O
10(;O;O
-;O;O
8;O;O
);O;O
M;O;O
);O;O
failed;O;O
to;O;O
cause;O;O
the;O;O
first;O;O
contraction;O;O
,;O;O
DDI-MedLine.d56.s3;;
however;O;O
,;O;O
the;O;O
second;O;O
contraction;O;O
was;O;O
potentiated;O;O
.;O;O
DDI-MedLine.d56.s4;;
In;O;O
the;O;O
presence;O;O
of;O;O
phentolamine;B-drug;B-DDI-MedLine.d56.s4.e0
(;O;O
10(;O;O
-;O;O
6;O;O
);O;O
M;O;O
);O;O
,;O;O
the;O;O
second;O;O
contraction;O;O
was;O;O
inhibited;O;O
selectively;O;O
.;O;O
DDI-MedLine.d56.s5;;
When;O;O
ouabain;B-drug;B-DDI-MedLine.d56.s5.e0
was;O;O
applied;O;O
to;O;O
the;O;O
muscle;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
phentolamine;B-drug;B-DDI-MedLine.d56.s5.e1
,;O;O
both;O;O
first;O;O
and;O;O
second;O;O
contractile;O;O
responses;O;O
to;O;O
PTX;B-drug_n;B-DDI-MedLine.d56.s5.e2
were;O;O
abolished;O;O
.;O;O
DDI-MedLine.d56.s6;;
When;O;O
the;O;O
muscle;O;O
was;O;O
exposed;O;O
to;O;O
the;O;O
potassium;O;O
-;O;O
depleted;O;O
solution;O;O
,;O;O
the;O;O
first;O;O
contractile;O;O
response;O;O
to;O;O
PTX;B-drug_n;B-DDI-MedLine.d56.s6.e0
was;O;O
rather;O;O
potentiated;O;O
.;O;O
DDI-MedLine.d56.s7;;
PTX;B-drug_n;B-DDI-MedLine.d56.s7.e0
caused;O;O
the;O;O
release;O;O
of;O;O
norepinephrine;O;O
from;O;O
the;O;O
muscle;O;O
.;O;O
DDI-MedLine.d56.s8;;
Exposure;O;O
of;O;O
the;O;O
muscle;O;O
to;O;O
ouabain;B-drug;B-DDI-MedLine.d56.s8.e0
(;O;O
10(;O;O
-;O;O
5;O;O
);O;O
M;O;O
);O;O
markedly;O;O
increased;O;O
the;O;O
PTX;B-drug_n;B-DDI-MedLine.d56.s8.e1
-;O;O
induced;O;O
release;O;O
.;O;O
DDI-MedLine.d56.s9;;
It;O;O
is;O;O
indicated;O;O
that;O;O
the;O;O
first;O;O
and;O;O
second;O;O
contractile;O;O
responses;O;O
to;O;O
PTX;B-drug_n;B-DDI-MedLine.d56.s9.e0
have;O;O
entirely;O;O
different;O;O
properties;O;O
.;O;O
DDI-MedLine.d56.s10;;
The;O;O
second;O;O
response;O;O
is;O;O
due;O;O
to;O;O
a;O;O
release;O;O
of;O;O
norepinephrine;O;O
from;O;O
nerves;O;O
and;O;O
was;O;O
potentiated;O;O
by;O;O
ouabain;B-drug;B-DDI-MedLine.d56.s10.e0
through;O;O
the;O;O
increase;O;O
in;O;O
the;O;O
norepinephrine;O;O
release;O;O
,;O;O
whereas;O;O
the;O;O
first;O;O
response;O;O
was;O;O
not;O;O
due;O;O
to;O;O
the;O;O
norepinephrine;O;O
release;O;O
but;O;O
presumably;O;O
to;O;O
a;O;O
direct;O;O
action;O;O
on;O;O
smooth;O;O
muscle;O;O
cell;O;O
and;O;O
was;O;O
inhibited;O;O
by;O;O
ouabain;B-drug;B-DDI-MedLine.d56.s10.e1
.;O;O
DDI-MedLine.d56.s11;;
The;O;O
mechanism;O;O
of;O;O
the;O;O
action;O;O
of;O;O
PTX;B-drug_n;B-DDI-MedLine.d56.s11.e0
was;O;O
discussed;O;O
in;O;O
the;O;O
relation;O;O
with;O;O
Na;O;O
,;O;O
K;O;O
-;O;O
ATPase;O;O
.;O;O
DDI-MedLine.d139.s0;;
[;O;O
Quantitative;O;O
approach;O;O
to;O;O
treatment;O;O
with;O;O
incisive;O;O
neuroleptics;B-group;B-DDI-MedLine.d139.s0.e0
by;O;O
therapeutic;O;O
monitoring;O;O
];O;O
,;O;O
The;O;O
problems;O;O
encountered;O;O
during;O;O
the;O;O
longterm;O;O
treatment;O;O
of;O;O
psychotic;O;O
patients;O;O
with;O;O
neuroleptics;B-group;B-DDI-MedLine.d139.s0.e1
are;O;O
illustrated;O;O
by;O;O
six;O;O
typical;O;O
case;O;O
reports;O;O
.;O;O
DDI-MedLine.d139.s1;;
A;O;O
group;O;O
of;O;O
patients;O;O
who;O;O
had;O;O
had;O;O
a;O;O
new;O;O
acute;O;O
episode;O;O
despite;O;O
seemingly;O;O
adequate;O;O
treatment;O;O
were;O;O
selected;O;O
.;O;O
DDI-MedLine.d139.s2;;
In;O;O
these;O;O
six;O;O
cases;O;O
it;O;O
was;O;O
demonstrated;O;O
that;O;O
the;O;O
neuroleptics;B-group;B-DDI-MedLine.d139.s2.e0
dosage;O;O
was;O;O
inappropriate;O;O
,;O;O
being;O;O
either;O;O
too;O;O
high;O;O
or;O;O
too;O;O
low;O;O
as;O;O
judged;O;O
from;O;O
the;O;O
plasma;O;O
concentrations;O;O
.;O;O
DDI-MedLine.d139.s3;;
Ways;O;O
of;O;O
improving;O;O
the;O;O
adequacy;O;O
of;O;O
the;O;O
treatment;O;O
of;O;O
psychotic;O;O
patients;O;O
with;O;O
neuroleptics;B-group;B-DDI-MedLine.d139.s3.e0
are;O;O
discussed;O;O
.;O;O
DDI-MedLine.d82.s0;;
Intestinal;O;O
absorption;O;O
of;O;O
arsenate;B-drug_n;B-DDI-MedLine.d82.s0.e0
in;O;O
the;O;O
chick;O;O
.;O;O

;O;O
DDI-MedLine.d82.s1;;
The;O;O
intestinal;O;O
absorption;O;O
of;O;O
arsenate(As(V;B-drug_n;B-DDI-MedLine.d82.s1.e0
);O;O
);O;O
has;O;O
been;O;O
investigated;O;O
in;O;O
the;O;O
chick;O;O
by;O;O
means;O;O
of;O;O
the;O;O
in;O;O
situ;O;O
ligated;O;O
duodenal;O;O
loop;O;O
technique;O;O
.;O;O
DDI-MedLine.d82.s2;;
By;O;O
this;O;O
procedure;O;O
,;O;O
it;O;O
was;O;O
observed;O;O
that;O;O
arsenate;B-drug_n;B-DDI-MedLine.d82.s2.e0
is;O;O
rapidly;O;O
and;O;O
essentially;O;O
completely;O;O
absorbed;O;O
(;O;O
80;O;O
-;O;O
95;O;O
%;O;O
);O;O
from;O;O
the;O;O
lumen;O;O
at;O;O
As(V;B-drug_n;B-DDI-MedLine.d82.s2.e1
);I-drug_n;I-DDI-MedLine.d82.s2.e1
concentrations;O;O
up;O;O
to;O;O
5;O;O
mM;O;O
,;O;O
declining;O;O
to;O;O
about;O;O
50;O;O
%;O;O
absorption;O;O
at;O;O
50;O;O
mM.;O;O
DDI-MedLine.d82.s3;;
Transfer;O;O
from;O;O
the;O;O
intestinal;O;O
lumen;O;O
to;O;O
the;O;O
mucosal;O;O
cells;O;O
at;O;O
low;O;O
As(V;B-drug_n;B-DDI-MedLine.d82.s3.e0
);I-drug_n;I-DDI-MedLine.d82.s3.e0
concentration;O;O
(;O;O
0.1;O;O
mM;O;O
);O;O
is;O;O
rapid;O;O
,;O;O
while;O;O
transfer;O;O
from;O;O
the;O;O
mucosal;O;O
cells;O;O
to;O;O
the;O;O
body;O;O
occurs;O;O
more;O;O
slowly;O;O
.;O;O
DDI-MedLine.d82.s4;;
At;O;O
stable;O;O
As(V;B-drug_n;B-DDI-MedLine.d82.s4.e0
);I-drug_n;I-DDI-MedLine.d82.s4.e0
concentrations;O;O
greater;O;O
than;O;O
1;O;O
mM;O;O
,;O;O
fractional;O;O
mucosal;O;O
cell;O;O
accumulation;O;O
of;O;O
As(V;B-drug_n;B-DDI-MedLine.d82.s4.e1
);I-drug_n;I-DDI-MedLine.d82.s4.e1
remains;O;O
constant;O;O
,;O;O
while;O;O
fractional;O;O
transfer;O;O
to;O;O
the;O;O
body;O;O
declines;O;O
.;O;O
DDI-MedLine.d82.s5;;
However;O;O
,;O;O
total;O;O
mucosal;O;O
accumulation;O;O
of;O;O
As(V;B-drug_n;B-DDI-MedLine.d82.s5.e0
);I-drug_n;I-DDI-MedLine.d82.s5.e0
and;O;O
that;O;O
transferred;O;O
to;O;O
the;O;O
body;O;O
increase;O;O
in;O;O
a;O;O
linear;O;O
logarithmic;O;O
fashion;O;O
from;O;O
0.05;O;O
to;O;O
5;O;O
mm;O;O
As(V;B-drug_n;B-DDI-MedLine.d82.s5.e1
);I-drug_n;I-DDI-MedLine.d82.s5.e1
.;O;O
DDI-MedLine.d82.s6;;
The;O;O
results;O;O
indicate;O;O
that;O;O
As(V;B-drug_n;B-DDI-MedLine.d82.s6.e0
);I-drug_n;I-DDI-MedLine.d82.s6.e0
readily;O;O
penetrates;O;O
both;O;O
the;O;O
mucosal;O;O
and;O;O
serosal;O;O
surfaces;O;O
of;O;O
the;O;O
epithelial;O;O
membrane;O;O
.;O;O
DDI-MedLine.d82.s7;;
Furthermore;O;O
,;O;O
arsenate;B-drug_n;B-DDI-MedLine.d82.s7.e0
and;O;O
phosphate;B-drug;B-DDI-MedLine.d82.s7.e1
do;O;O
not;O;O
appear;O;O
to;O;O
share;O;O
a;O;O
common;O;O
transport;O;O
pathway;O;O
in;O;O
the;O;O
duodenum;O;O
and;O;O
no;O;O
evidence;O;O
was;O;O
obtained;O;O
for;O;O
any;O;O
interaction;O;O
between;O;O
the;O;O
two;O;O
at;O;O
this;O;O
level;O;O
.;O;O
DDI-MedLine.d82.s8;;
Vitamin;B-drug;B-DDI-MedLine.d82.s8.e0
D3;I-drug;I-DDI-MedLine.d82.s8.e0
administration;O;O
to;O;O
rachitic;O;O
chicks;O;O
was;O;O
effective;O;O
in;O;O
significantly;O;O
elevating;O;O
duodenal;O;O
arsenate;B-drug_n;B-DDI-MedLine.d82.s8.e1
absorption;O;O
,;O;O
acting;O;O
primarily;O;O
to;O;O
enhance;O;O
serosal;O;O
transport;O;O
.;O;O
DDI-MedLine.d22.s0;;
Spermine;B-drug;B-DDI-MedLine.d22.s0.e0
promotes;O;O
the;O;O
translocation;O;O
of;O;O
phosphatidate;O;O
phosphohydrolase;O;O
from;O;O
the;O;O
cytosol;O;O
to;O;O
the;O;O
microsomal;O;O
fraction;O;O
of;O;O
rat;O;O
liver;O;O
and;O;O
it;O;O
enhances;O;O
the;O;O
effects;O;O
of;O;O
oleate;O;O
in;O;O
this;O;O
respect;O;O
.;O;O
DDI-MedLine.d22.s1;;
Spermine;B-drug;B-DDI-MedLine.d22.s1.e0
(;O;O
0.5;O;O
-;O;O
2;O;O
mM;O;O
);O;O
promoted;O;O
the;O;O
translocation;O;O
of;O;O
phosphatidate;O;O
phosphohydrolase;O;O
from;O;O
the;O;O
soluble;O;O
to;O;O
the;O;O
microsomal;O;O
fraction;O;O
in;O;O
a;O;O
cell;O;O
-;O;O
free;O;O
system;O;O
derived;O;O
from;O;O
rat;O;O
liver;O;O
.;O;O
DDI-MedLine.d22.s2;;
By;O;O
contrast;O;O
,;O;O
spermidine;B-drug_n;B-DDI-MedLine.d22.s2.e0
(;O;O
1;O;O
mM;O;O
);O;O
and;O;O
putrescine;B-drug_n;B-DDI-MedLine.d22.s2.e1
(;O;O
1;O;O
mM;O;O
);O;O
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
translocation;O;O
when;O;O
added;O;O
alone;O;O
.;O;O
DDI-MedLine.d22.s3;;
Spermine;B-drug;B-DDI-MedLine.d22.s3.e0
,;O;O
and;O;O
to;O;O
a;O;O
lesser;O;O
extent;O;O
,;O;O
spermidine;B-drug_n;B-DDI-MedLine.d22.s3.e1
,;O;O
enhanced;O;O
the;O;O
translocating;O;O
action;O;O
of;O;O
oleate;O;O
and;O;O
increased;O;O
its;O;O
effectiveness;O;O
in;O;O
transferring;O;O
the;O;O
phosphohydrolase;O;O
from;O;O
the;O;O
soluble;O;O
to;O;O
the;O;O
microsomal;O;O
fraction;O;O
.;O;O
DDI-MedLine.d22.s4;;
It;O;O
is;O;O
proposed;O;O
that;O;O
the;O;O
phosphohydrolase;O;O
becomes;O;O
metabolically;O;O
active;O;O
when;O;O
it;O;O
combines;O;O
with;O;O
membranes;O;O
and;O;O
that;O;O
polyamines;O;O
might;O;O
help;O;O
to;O;O
regulate;O;O
this;O;O
interaction;O;O
.;O;O
DDI-MedLine.d22.s5;;
This;O;O
could;O;O
facilitate;O;O
the;O;O
action;O;O
of;O;O
fatty;O;O
acids;O;O
and;O;O
enable;O;O
cells;O;O
to;O;O
increase;O;O
their;O;O
capacity;O;O
for;O;O
triacylglycerol;O;O
synthesis;O;O
to;O;O
match;O;O
an;O;O
increased;O;O
availability;O;O
of;O;O
fatty;O;O
acids;O;O
.;O;O
DDI-MedLine.d100.s0;;
Influence;O;O
of;O;O
calcium;B-group;B-DDI-MedLine.d100.s0.e0
-;I-group;I-DDI-MedLine.d100.s0.e0
channel;I-group;I-DDI-MedLine.d100.s0.e0
blockers;I-group;I-DDI-MedLine.d100.s0.e0
on;O;O
platelet;O;O
function;O;O
and;O;O
arachidonic;O;O
acid;O;O
metabolism;O;O
.;O;O
DDI-MedLine.d100.s1;;
Available;O;O
data;O;O
indicate;O;O
that;O;O
platelet;O;O
function;O;O
and;O;O
arachidonic;O;O
acid;O;O
metabolism;O;O
are;O;O
important;O;O
factors;O;O
in;O;O
hemostasis;O;O
and;O;O
regulation;O;O
of;O;O
vascular;O;O
tone;O;O
.;O;O
DDI-MedLine.d100.s2;;
Plasma;O;O
membrane;O;O
and;O;O
intracellular;O;O
mobilization;O;O
of;O;O
calcium;O;O
ions;O;O
are;O;O
intimately;O;O
related;O;O
to;O;O
platelet;O;O
activation;O;O
and;O;O
release;O;O
of;O;O
platelet;O;O
contents;O;O
.;O;O
DDI-MedLine.d100.s3;;
Release;O;O
of;O;O
arachidonic;O;O
acid;O;O
from;O;O
membrane;O;O
phospholipids;O;O
as;O;O
well;O;O
as;O;O
subsequent;O;O
synthesis;O;O
and;O;O
release;O;O
of;O;O
vasoconstrictor;O;O
thromboxane;O;O
A2;O;O
are;O;O
also;O;O
regulated;O;O
by;O;O
movement;O;O
of;O;O
calcium;O;O
ions;O;O
.;O;O
DDI-MedLine.d100.s4;;
Adenosine;O;O
3':5';O;O
-;O;O
cyclic;O;O
phosphate;O;O
in;O;O
turn;O;O
controls;O;O
levels;O;O
of;O;O
free;O;O
calcium;O;O
ions;O;O
in;O;O
platelets;O;O
and;O;O
regulates;O;O
calcium;O;O
-;O;O
dependent;O;O
reactions;O;O
.;O;O
DDI-MedLine.d100.s5;;
Slow;B-group;B-DDI-MedLine.d100.s5.e0
-;I-group;I-DDI-MedLine.d100.s5.e0
channel;I-group;I-DDI-MedLine.d100.s5.e0
calcium;I-group;I-DDI-MedLine.d100.s5.e0
blockers;I-group;I-DDI-MedLine.d100.s5.e0
,;O;O
such;O;O
as;O;O
verapamil;B-drug;B-DDI-MedLine.d100.s5.e1
,;O;O
diltiazem;B-drug;B-DDI-MedLine.d100.s5.e2
and;O;O
nifedipine;B-drug;B-DDI-MedLine.d100.s5.e3
,;O;O
inhibit;O;O
platelet;O;O
activation;O;O
in;O;O
vitro;O;O
,;O;O
and;O;O
decrease;O;O
platelet;O;O
adhesion;O;O
intravascularly;O;O
.;O;O
DDI-MedLine.d100.s6;;
These;O;O
agents;O;O
have;O;O
also;O;O
been;O;O
shown;O;O
to;O;O
decrease;O;O
platelet;O;O
nucleotide;O;O
release;O;O
and;O;O
thromboxane;O;O
A2;O;O
generation;O;O
.;O;O
DDI-MedLine.d100.s7;;
Some;O;O
preliminary;O;O
data;O;O
suggest;O;O
that;O;O
calcium;B-group;B-DDI-MedLine.d100.s7.e0
blockers;I-group;I-DDI-MedLine.d100.s7.e0
also;O;O
increase;O;O
generation;O;O
of;O;O
vasodilator;O;O
and;O;O
platelet;O;O
antiaggregant;O;O
prostacyclin;O;O
,;O;O
which;O;O
could;O;O
contribute;O;O
to;O;O
decrease;O;O
in;O;O
platelet;O;O
function;O;O
.;O;O
DDI-MedLine.d100.s8;;
These;O;O
effects;O;O
of;O;O
calcium;B-group;B-DDI-MedLine.d100.s8.e0
blockers;I-group;I-DDI-MedLine.d100.s8.e0
on;O;O
platelet;O;O
function;O;O
and;O;O
arachidonic;O;O
acid;O;O
metabolism;O;O
could;O;O
contribute;O;O
in;O;O
part;O;O
to;O;O
their;O;O
efficacy;O;O
in;O;O
patients;O;O
with;O;O
ischemic;O;O
heart;O;O
disease;O;O
.;O;O
DDI-MedLine.d63.s0;;
Differential;O;O
actions;O;O
of;O;O
intrathecal;O;O
naloxone;B-drug;B-DDI-MedLine.d63.s0.e0
on;O;O
blocking;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
inhibition;O;O
induced;O;O
by;O;O
intraventricular;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s0.e1
-;I-drug_n;I-DDI-MedLine.d63.s0.e1
endorphin;I-drug_n;I-DDI-MedLine.d63.s0.e1
and;O;O
morphine;B-drug;B-DDI-MedLine.d63.s0.e2
in;O;O
rats;O;O
.;O;O
DDI-MedLine.d63.s1;;
In;O;O
the;O;O
present;O;O
study;O;O
,;O;O
it;O;O
is;O;O
proposed;O;O
that;O;O
the;O;O
opioids;B-group;B-DDI-MedLine.d63.s1.e0
applied;O;O
to;O;O
supraspinal;O;O
brain;O;O
sites;O;O
produced;O;O
their;O;O
analgesic;O;O
effects;O;O
by;O;O
the;O;O
activation;O;O
of;O;O
different;O;O
descending;O;O
pain;O;O
inhibitory;O;O
systems;O;O
.;O;O
DDI-MedLine.d63.s2;;
The;O;O
blockade;O;O
of;O;O
the;O;O
spinal;O;O
endorphinergic;O;O
system;O;O
by;O;O
intrathecal;O;O
naloxone;B-drug;B-DDI-MedLine.d63.s2.e0
on;O;O
the;O;O
production;O;O
of;O;O
tail;O;O
-;O;O
flick;O;O
inhibition;O;O
induced;O;O
by;O;O
intraventricular;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s2.e1
-;I-drug_n;I-DDI-MedLine.d63.s2.e1
endorphin;I-drug_n;I-DDI-MedLine.d63.s2.e1
and;O;O
morphine;B-drug;B-DDI-MedLine.d63.s2.e2
was;O;O
then;O;O
studied;O;O
.;O;O
DDI-MedLine.d63.s3;;
Intraventricular;O;O
injection;O;O
of;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s3.e0
-;I-drug_n;I-DDI-MedLine.d63.s3.e0
endorphin;I-drug_n;I-DDI-MedLine.d63.s3.e0
and;O;O
morphine;B-drug;B-DDI-MedLine.d63.s3.e1
produced;O;O
an;O;O
inhibition;O;O
of;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
response;O;O
to;O;O
the;O;O
heat;O;O
stimulus;O;O
in;O;O
rats;O;O
.;O;O
DDI-MedLine.d63.s4;;
Intrathecal;O;O
injection;O;O
of;O;O
naloxone;B-drug;B-DDI-MedLine.d63.s4.e0
at;O;O
doses;O;O
of;O;O
0.4;O;O
to;O;O
40;O;O
micrograms;O;O
caused;O;O
a;O;O
dose;O;O
-;O;O
related;O;O
blockade;O;O
of;O;O
the;O;O
inhibition;O;O
of;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
response;O;O
induced;O;O
by;O;O
intraventricular;O;O
injection;O;O
of;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s4.e1
-;I-drug_n;I-DDI-MedLine.d63.s4.e1
endorphin;I-drug_n;I-DDI-MedLine.d63.s4.e1
,;O;O
and;O;O
a;O;O
high;O;O
dose;O;O
of;O;O
naloxone;B-drug;B-DDI-MedLine.d63.s4.e2
(;O;O
40;O;O
micrograms;O;O
);O;O
completely;O;O
blocked;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
inhibition;O;O
induced;O;O
by;O;O
intraventricular;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s4.e3
-;I-drug_n;I-DDI-MedLine.d63.s4.e3
endorphin;I-drug_n;I-DDI-MedLine.d63.s4.e3
(;O;O
16;O;O
micrograms;O;O
);O;O
.;O;O
DDI-MedLine.d63.s5;;
On;O;O
the;O;O
other;O;O
hand;O;O
,;O;O
intrathecal;O;O
naloxone;B-drug;B-DDI-MedLine.d63.s5.e0
(;O;O
12;O;O
-;O;O
120;O;O
micrograms;O;O
);O;O
had;O;O
only;O;O
a;O;O
very;O;O
weak;O;O
effect;O;O
on;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
inhibition;O;O
induced;O;O
by;O;O
intraventricular;O;O
morphine;B-drug;B-DDI-MedLine.d63.s5.e1
(;O;O
40;O;O
micrograms;O;O
);O;O
.;O;O
DDI-MedLine.d63.s6;;
Intraventricular;O;O
injection;O;O
of;O;O
naloxone;B-drug;B-DDI-MedLine.d63.s6.e0
at;O;O
doses;O;O
of;O;O
1.2;O;O
to;O;O
12;O;O
micrograms;O;O
equally;O;O
antagonized;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
manner;O;O
the;O;O
tail;O;O
-;O;O
flick;O;O
inhibition;O;O
induced;O;O
by;O;O
intraventricular;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s6.e1
-;I-drug_n;I-DDI-MedLine.d63.s6.e1
endorphin;I-drug_n;I-DDI-MedLine.d63.s6.e1
and;O;O
morphine;B-drug;B-DDI-MedLine.d63.s6.e2
.;O;O
DDI-MedLine.d63.s7;;
The;O;O
results;O;O
indicate;O;O
that;O;O
a;O;O
spinal;O;O
naloxone;B-drug;B-DDI-MedLine.d63.s7.e0
-;O;O
sensitive;O;O
endorphinergic;O;O
system;O;O
is;O;O
involved;O;O
in;O;O
the;O;O
production;O;O
of;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s7.e1
-;I-drug_n;I-DDI-MedLine.d63.s7.e1
endorphin;I-drug_n;I-DDI-MedLine.d63.s7.e1
but;O;O
not;O;O
morphine;B-drug;B-DDI-MedLine.d63.s7.e2
-;O;O
induced;O;O
tail;O;O
-;O;O
flick;O;O
inhibition;O;O
,;O;O
and;O;O
suggest;O;O
that;O;O
intraventricular;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s7.e3
-;I-drug_n;I-DDI-MedLine.d63.s7.e3
endorphin;I-drug_n;I-DDI-MedLine.d63.s7.e3
and;O;O
morphine;B-drug;B-DDI-MedLine.d63.s7.e4
elicit;O;O
their;O;O
pharmacological;O;O
actions;O;O
via;O;O
the;O;O
activation;O;O
of;O;O
different;O;O
descending;O;O
pain;O;O
inhibitory;O;O
systems;O;O
,;O;O
DDI-MedLine.d63.s8;;
descending;O;O
epsilon;O;O
and;O;O
mu;O;O
systems;O;O
for;O;O
beta;B-drug_n;B-DDI-MedLine.d63.s8.e0
-;I-drug_n;I-DDI-MedLine.d63.s8.e0
endorphin;I-drug_n;I-DDI-MedLine.d63.s8.e0
and;O;O
morphine;B-drug;B-DDI-MedLine.d63.s8.e1
,;O;O
respectively;O;O
,;O;O
are;O;O
proposed;O;O
.;O;O
DDI-MedLine.d73.s0;;
Neurochemical;O;O
and;O;O
functional;O;O
consequences;O;O
following;O;O
1;B-drug_n;B-DDI-MedLine.d73.s0.e0
-;I-drug_n;I-DDI-MedLine.d73.s0.e0
methyl;I-drug_n;I-DDI-MedLine.d73.s0.e0
-;I-drug_n;I-DDI-MedLine.d73.s0.e0
4;I-drug_n;I-DDI-MedLine.d73.s0.e0
-;I-drug_n;I-DDI-MedLine.d73.s0.e0
phenyl;I-drug_n;I-DDI-MedLine.d73.s0.e0
-;I-drug_n;I-DDI-MedLine.d73.s0.e0
1,2,5,6;I-drug_n;I-DDI-MedLine.d73.s0.e0
-;I-drug_n;I-DDI-MedLine.d73.s0.e0
tetrahydropyridine;I-drug_n;I-DDI-MedLine.d73.s0.e0
(;O;O
MPTP;B-drug_n;B-DDI-MedLine.d73.s0.e1
);O;O
and;O;O
methamphetamine;B-drug;B-DDI-MedLine.d73.s0.e2
.;O;O
DDI-MedLine.d73.s1;;
The;O;O
neurochemical;O;O
and;O;O
functional;O;O
consequences;O;O
following;O;O
MPTP;B-drug_n;B-DDI-MedLine.d73.s1.e0
administration;O;O
to;O;O
the;O;O
rat;O;O
were;O;O
evaluated;O;O
and;O;O
compared;O;O
to;O;O
similar;O;O
effects;O;O
following;O;O
methamphetamine;B-drug;B-DDI-MedLine.d73.s1.e1
administration;O;O
.;O;O
DDI-MedLine.d73.s2;;
It;O;O
was;O;O
observed;O;O
that;O;O
MPTP;B-drug_n;B-DDI-MedLine.d73.s2.e0
induced;O;O
long;O;O
lasting;O;O
depletions;O;O
of;O;O
striatal;O;O
dopamine;O;O
concentrations;O;O
and;O;O
this;O;O
neurotoxic;O;O
effect;O;O
could;O;O
be;O;O
prevented;O;O
by;O;O
pargyline;B-drug;B-DDI-MedLine.d73.s2.e1
pretreatment;O;O
.;O;O
DDI-MedLine.d73.s3;;
The;O;O
MPTP;B-drug;B-DDI-MedLine.d73.s3.e0
-;O;O
induced;O;O
neuronal;O;O
damage;O;O
produced;O;O
a;O;O
tolerance;O;O
to;O;O
the;O;O
disruptive;O;O
effects;O;O
of;O;O
amphetamine;B-drug;B-DDI-MedLine.d73.s3.e1
and;O;O
a;O;O
supersensitivity;O;O
to;O;O
the;O;O
disruptive;O;O
effects;O;O
of;O;O
apomorphine;B-drug;B-DDI-MedLine.d73.s3.e2
in;O;O
rats;O;O
responding;O;O
in;O;O
a;O;O
schedule;O;O
controlled;O;O
paradigm;O;O
.;O;O
DDI-MedLine.d73.s4;;
Methamphetamine;B-drug;B-DDI-MedLine.d73.s4.e0
,;O;O
like;O;O
MPTP;B-drug_n;B-DDI-MedLine.d73.s4.e1
,;O;O
produced;O;O
depletions;O;O
of;O;O
striatal;O;O
dopamine;O;O
but;O;O
these;O;O
actions;O;O
were;O;O
potentiated;O;O
by;O;O
pargyline;B-drug;B-DDI-MedLine.d73.s4.e2
pretreatment;O;O
.;O;O
DDI-MedLine.d73.s5;;
These;O;O
observations;O;O
are;O;O
discussed;O;O
in;O;O
reference;O;O
to;O;O
possible;O;O
deleterious;O;O
effects;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
pargyline;B-drug;B-DDI-MedLine.d73.s5.e0
to;O;O
patients;O;O
with;O;O
Parkinson;O;O
's;O;O
Disease;O;O
.;O;O
DDI-MedLine.d96.s0;;
Jacalin;B-drug_n;B-DDI-MedLine.d96.s0.e0
:;O;O
an;O;O
IgA;O;O
-;O;O
binding;O;O
lectin;O;O
.;O;O
DDI-MedLine.d96.s1;;
We;O;O
previously;O;O
reported;O;O
that;O;O
seeds;O;O
of;O;O
Artocarpus;O;O
integrifolia;O;O
(;O;O
jackfruit;O;O
);O;O
contain;O;O
a;O;O
lectin;O;O
,;O;O
which;O;O
we;O;O
call;O;O
jacalin;B-drug_n;B-DDI-MedLine.d96.s1.e0
,;O;O
that;O;O
is;O;O
both;O;O
a;O;O
potent;O;O
T;O;O
cell;O;O
mitogen;O;O
and;O;O
an;O;O
apparently;O;O
T;O;O
cell;O;O
-;O;O
independent;O;O
activator;O;O
of;O;O
human;O;O
B;O;O
cells;O;O
for;O;O
the;O;O
secretion;O;O
of;O;O
immunoglobulins;O;O
.;O;O
DDI-MedLine.d96.s2;;
During;O;O
the;O;O
above;O;O
experiments;O;O
we;O;O
noted;O;O
a;O;O
massive;O;O
precipitation;O;O
in;O;O
cell;O;O
cultures;O;O
stimulated;O;O
with;O;O
greater;O;O
than;O;O
or;O;O
equal;O;O
to;O;O
100;O;O
micrograms;O;O
of;O;O
lectin;O;O
.;O;O
DDI-MedLine.d96.s3;;
In;O;O
this;O;O
paper;O;O
,;O;O
we;O;O
show;O;O
that;O;O
the;O;O
precipitate;O;O
is;O;O
formed;O;O
after;O;O
the;O;O
interaction;O;O
of;O;O
jacalin;B-drug_n;B-DDI-MedLine.d96.s3.e0
and;O;O
the;O;O
serum;O;O
protein;O;O
added;O;O
to;O;O
the;O;O
culture;O;O
medium;O;O
.;O;O
DDI-MedLine.d96.s4;;
More;O;O
importantly;O;O
,;O;O
we;O;O
demonstrate;O;O
that;O;O
IgA;O;O
is;O;O
probably;O;O
the;O;O
major;O;O
serum;O;O
constituent;O;O
precipitated;O;O
by;O;O
the;O;O
lectin;O;O
and;O;O
that;O;O
no;O;O
IgG;O;O
or;O;O
IgM;O;O
can;O;O
be;O;O
detected;O;O
in;O;O
the;O;O
precipitates;O;O
.;O;O
DDI-MedLine.d96.s5;;
In;O;O
secretions;O;O
such;O;O
as;O;O
colostrum;O;O
,;O;O
IgA;O;O
is;O;O
the;O;O
only;O;O
protein;O;O
precipitated;O;O
by;O;O
jacalin;B-drug_n;B-DDI-MedLine.d96.s5.e0
.;O;O
DDI-MedLine.d96.s6;;
On;O;O
the;O;O
basis;O;O
of;O;O
this;O;O
specificity;O;O
we;O;O
describe;O;O
a;O;O
simple;O;O
and;O;O
reliable;O;O
affinity;O;O
chromatography;O;O
procedure;O;O
for;O;O
the;O;O
purification;O;O
of;O;O
both;O;O
human;O;O
serum;O;O
and;O;O
colostrum;O;O
IgA.;O;O
DDI-MedLine.d96.s7;;
Jacalin;B-drug_n;B-DDI-MedLine.d96.s7.e0
is;O;O
a;O;O
D;O;O
-;O;O
Gal;O;O
binding;O;O
lectin;O;O
and;O;O
should;O;O
be;O;O
a;O;O
useful;O;O
tool;O;O
for;O;O
studying;O;O
of;O;O
serum;O;O
and;O;O
secretory;O;O
IgA.;O;O
DDI-MedLine.d31.s0;;
Cancer;O;O
in;O;O
the;O;O
elderly;O;O
:;O;O
basic;O;O
science;O;O
and;O;O
clinical;O;O
aspects;O;O
.;O;O

;O;O
DDI-MedLine.d31.s1;;
The;O;O
incidence;O;O
of;O;O
cancer;O;O
increases;O;O
progressively;O;O
with;O;O
age;O;O
.;O;O
DDI-MedLine.d31.s2;;
Rearrangements;O;O
of;O;O
genomes;O;O
have;O;O
been;O;O
found;O;O
to;O;O
accompany;O;O
cellular;O;O
aging;O;O
.;O;O
DDI-MedLine.d31.s3;;
These;O;O
factors;O;O
,;O;O
in;O;O
concert;O;O
with;O;O
age;O;O
-;O;O
dependent;O;O
alterations;O;O
in;O;O
immune;O;O
function;O;O
and;O;O
host;O;O
defense;O;O
,;O;O
may;O;O
help;O;O
to;O;O
explain;O;O
the;O;O
increased;O;O
risk;O;O
of;O;O
malignant;O;O
disease;O;O
in;O;O
aged;O;O
persons;O;O
.;O;O
DDI-MedLine.d31.s4;;
The;O;O
clinical;O;O
presentation;O;O
and;O;O
natural;O;O
history;O;O
of;O;O
neoplasia;O;O
are;O;O
also;O;O
affected;O;O
by;O;O
aging;O;O
.;O;O
DDI-MedLine.d31.s5;;
This;O;O
conference;O;O
reviews;O;O
recent;O;O
developments;O;O
in;O;O
these;O;O
areas;O;O
,;O;O
examines;O;O
the;O;O
effects;O;O
of;O;O
drug;O;O
use;O;O
in;O;O
the;O;O
elderly;O;O
and;O;O
implications;O;O
for;O;O
management;O;O
,;O;O
and;O;O
discusses;O;O
current;O;O
information;O;O
on;O;O
how;O;O
age;O;O
may;O;O
influence;O;O
the;O;O
response;O;O
of;O;O
cancer;O;O
to;O;O
therapy;O;O
.;O;O
DDI-MedLine.d12.s0;;
Dexamethasone;B-drug;B-DDI-MedLine.d12.s0.e0
and;O;O
retinyl;B-drug;B-DDI-MedLine.d12.s0.e1
acetate;I-drug;I-DDI-MedLine.d12.s0.e1
similarly;O;O
inhibit;O;O
and;O;O
stimulate;O;O
EGF;B-drug_n;B-DDI-MedLine.d12.s0.e2
-;O;O
or;O;O
insulin;B-drug;B-DDI-MedLine.d12.s0.e3
-;O;O
induced;O;O
proliferation;O;O
of;O;O
prostatic;O;O
epithelium;O;O
.;O;O
DDI-MedLine.d12.s1;;
Prostatic;O;O
epithelium;O;O
proliferates;O;O
in;O;O
a;O;O
defined;O;O
medium;O;O
consisting;O;O
of;O;O
basal;O;O
medium;O;O
RPMI1640;O;O
containing;O;O
transferrin;B-drug_n;B-DDI-MedLine.d12.s1.e0
(;O;O
1;O;O
microgram;O;O
/;O;O
ml;O;O
);O;O
,;O;O
EGF;B-drug_n;B-DDI-MedLine.d12.s1.e1
(;O;O
10;O;O
ng;O;O
/;O;O
ml;O;O
);O;O
,;O;O
and;O;O
insulin;B-drug;B-DDI-MedLine.d12.s1.e2
(;O;O
3.7;O;O
micrograms;O;O
/;O;O
ml;O;O
or;O;O
0.1;O;O
IU;O;O
/;O;O
ml;O;O
);O;O
.;O;O
DDI-MedLine.d12.s2;;
Although;O;O
neither;O;O
dexamethasone;B-drug;B-DDI-MedLine.d12.s2.e0
nor;O;O
retinyl;B-drug;B-DDI-MedLine.d12.s2.e1
acetate;I-drug;I-DDI-MedLine.d12.s2.e1
affected;O;O
the;O;O
proliferation;O;O
of;O;O
prostatic;O;O
epithelium;O;O
in;O;O
RPMI1640;O;O
containing;O;O
transferrin;B-drug_n;B-DDI-MedLine.d12.s2.e2
alone;O;O
,;O;O
they;O;O
modify;O;O
the;O;O
mitogenic;O;O
effect;O;O
of;O;O
EGF;B-drug_n;B-DDI-MedLine.d12.s2.e3
and;O;O
insulin;B-drug;B-DDI-MedLine.d12.s2.e4
.;O;O
DDI-MedLine.d12.s3;;
Dexamethasone;B-drug;B-DDI-MedLine.d12.s3.e0
at;O;O
10(;O;O
-;O;O
10;O;O
);O;O
M;O;O
or;O;O
retinyl;B-drug;B-DDI-MedLine.d12.s3.e1
acetate;I-drug;I-DDI-MedLine.d12.s3.e1
at;O;O
about;O;O
3;O;O
X;O;O
10(;O;O
-;O;O
9;O;O
);O;O
M;O;O
inhibits;O;O
proliferation;O;O
stimulated;O;O
by;O;O
EGF;B-drug_n;B-DDI-MedLine.d12.s3.e2
.;O;O
DDI-MedLine.d12.s4;;
Higher;O;O
concentrations;O;O
of;O;O
dexamethasone;B-drug;B-DDI-MedLine.d12.s4.e0
(;O;O
10(;O;O
-;O;O
8;O;O
);O;O
-;O;O
10(;O;O
-;O;O
6;O;O
);O;O
M;O;O
);O;O
or;O;O
retinyl;B-drug;B-DDI-MedLine.d12.s4.e1
acetate;I-drug;I-DDI-MedLine.d12.s4.e1
(;O;O
3;O;O
X;O;O
10(;O;O
-;O;O
8;O;O
);O;O
-;O;O
10(;O;O
-;O;O
7;O;O
);O;O
M;O;O
);O;O
enhance;O;O
the;O;O
mitogenic;O;O
activity;O;O
of;O;O
EGF;B-drug_n;B-DDI-MedLine.d12.s4.e2
.;O;O
DDI-MedLine.d12.s5;;
Dexamethasone;B-drug;B-DDI-MedLine.d12.s5.e0
had;O;O
a;O;O
similar;O;O
effect;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
insulin;B-drug;B-DDI-MedLine.d12.s5.e1
.;O;O
DDI-MedLine.d12.s6;;
However;O;O
,;O;O
retinyl;B-drug;B-DDI-MedLine.d12.s6.e0
acetate;I-drug;I-DDI-MedLine.d12.s6.e0
stimulated;O;O
,;O;O
but;O;O
did;O;O
not;O;O
significantly;O;O
inhibit;O;O
,;O;O
proliferation;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
insulin;B-drug;B-DDI-MedLine.d12.s6.e1
.;O;O
DDI-MedLine.d12.s7;;
These;O;O
results;O;O
suggest;O;O
that;O;O
both;O;O
dexamethasone;B-drug;B-DDI-MedLine.d12.s7.e0
and;O;O
retinyl;B-drug;B-DDI-MedLine.d12.s7.e1
acetate;I-drug;I-DDI-MedLine.d12.s7.e1
,;O;O
and;O;O
possibly;O;O
other;O;O
glucocorticoids;B-group;B-DDI-MedLine.d12.s7.e2
and;O;O
retinoids;B-group;B-DDI-MedLine.d12.s7.e3
,;O;O
may;O;O
regulate;O;O
the;O;O
proliferation;O;O
of;O;O
prostate;O;O
epithelium;O;O
by;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
modification;O;O
of;O;O
the;O;O
activity;O;O
of;O;O
insulin;B-drug;B-DDI-MedLine.d12.s7.e4
and;O;O
EGF;B-drug_n;B-DDI-MedLine.d12.s7.e5
.;O;O
DDI-MedLine.d9.s0;;
Pharmacokinetics;O;O
of;O;O
calcium;B-group;B-DDI-MedLine.d9.s0.e0
-;I-group;I-DDI-MedLine.d9.s0.e0
entry;I-group;I-DDI-MedLine.d9.s0.e0
blockers;I-group;I-DDI-MedLine.d9.s0.e0
.;O;O

;O;O
DDI-MedLine.d9.s1;;
Effective;O;O
use;O;O
of;O;O
drugs;O;O
in;O;O
therapy;O;O
depends;O;O
not;O;O
only;O;O
on;O;O
clinical;O;O
acumen;O;O
but;O;O
also;O;O
on;O;O
the;O;O
availability;O;O
of;O;O
relevant;O;O
pharmacokinetic;O;O
and;O;O
pharmacodynamic;O;O
data;O;O
.;O;O
DDI-MedLine.d9.s2;;
Such;O;O
information;O;O
assists;O;O
in;O;O
development;O;O
of;O;O
safe;O;O
dosing;O;O
regimens;O;O
,;O;O
prediction;O;O
of;O;O
abnormal;O;O
handling;O;O
of;O;O
drugs;O;O
in;O;O
states;O;O
of;O;O
disease;O;O
and;O;O
disorder;O;O
and;O;O
anticipation;O;O
of;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-MedLine.d9.s3;;
For;O;O
the;O;O
calcium;B-group;B-DDI-MedLine.d9.s3.e0
-;I-group;I-DDI-MedLine.d9.s3.e0
entry;I-group;I-DDI-MedLine.d9.s3.e0
blocking;I-group;I-DDI-MedLine.d9.s3.e0
agents;I-group;I-DDI-MedLine.d9.s3.e0
now;O;O
available;O;O
in;O;O
the;O;O
United;O;O
States;O;O
(;O;O
verapamil;B-drug;B-DDI-MedLine.d9.s3.e1
,;O;O
nifedipine;B-drug;B-DDI-MedLine.d9.s3.e2
and;O;O
diltiazem;B-drug;B-DDI-MedLine.d9.s3.e3
);O;O
,;O;O
these;O;O
data;O;O
appeared;O;O
well;O;O
after;O;O
clinical;O;O
patterns;O;O
of;O;O
use;O;O
evolved;O;O
.;O;O
DDI-MedLine.d9.s4;;
Nonetheless;O;O
,;O;O
their;O;O
relevance;O;O
continues;O;O
to;O;O
be;O;O
demonstrated;O;O
by;O;O
the;O;O
dependence;O;O
of;O;O
each;O;O
agent;O;O
on;O;O
intact;O;O
liver;O;O
blood;O;O
flow;O;O
and;O;O
function;O;O
for;O;O
normal;O;O
rates;O;O
of;O;O
elimination;O;O
,;O;O
DDI-MedLine.d9.s5;;
by;O;O
the;O;O
nonlinear;O;O
kinetic;O;O
characteristics;O;O
for;O;O
verapamil;B-drug;B-DDI-MedLine.d9.s5.e0
and;O;O
diltiazem;B-drug;B-DDI-MedLine.d9.s5.e1
(;O;O
and;O;O
probably;O;O
for;O;O
nifedipine;B-drug;B-DDI-MedLine.d9.s5.e2
,;O;O
as;O;O
well;O;O
);O;O
and;O;O
the;O;O
derivative;O;O
implications;O;O
for;O;O
decreased;O;O
dosing;O;O
frequency;O;O
requirements;O;O
,;O;O
DDI-MedLine.d9.s6;;
and;O;O
by;O;O
observations;O;O
now;O;O
appearing;O;O
on;O;O
the;O;O
relation;O;O
between;O;O
plasma;O;O
drug;O;O
levels;O;O
and;O;O
drug;O;O
effects;O;O
,;O;O
both;O;O
therapeutic;O;O
and;O;O
toxic;O;O
.;O;O
DDI-MedLine.d9.s7;;
Such;O;O
data;O;O
are;O;O
discussed;O;O
herein;O;O
,;O;O
with;O;O
emphasis;O;O
on;O;O
those;O;O
aspects;O;O
that;O;O
impact;O;O
on;O;O
the;O;O
clinical;O;O
use;O;O
of;O;O
the;O;O
calcium;B-group;B-DDI-MedLine.d9.s7.e0
-;I-group;I-DDI-MedLine.d9.s7.e0
entry;I-group;I-DDI-MedLine.d9.s7.e0
antagonists;I-group;I-DDI-MedLine.d9.s7.e0
.;O;O
DDI-MedLine.d45.s0;;
Selective;O;O
survival;O;O
in;O;O
pentazocine;B-drug;B-DDI-MedLine.d45.s0.e0
and;O;O
tripelennamine;B-drug;B-DDI-MedLine.d45.s0.e1
of;O;O
Pseudomonas;O;O
aeruginosa;O;O
serotype;O;O
O11;O;O
from;O;O
drug;O;O
addicts;O;O
.;O;O
DDI-MedLine.d45.s1;;
The;O;O
growth;O;O
of;O;O
Pseudomonas;O;O
aeruginosa;O;O
,;O;O
particularly;O;O
serotype;O;O
O11;O;O
,;O;O
in;O;O
pentazocine;B-drug;B-DDI-MedLine.d45.s1.e0
and;O;O
tripelennamine;B-drug;B-DDI-MedLine.d45.s1.e1
DDI-MedLine.d45.s2;;
was;O;O
evaluated;O;O
as;O;O
a;O;O
possible;O;O
explanation;O;O
for;O;O
the;O;O
association;O;O
of;O;O
deep;O;O
-;O;O
seated;O;O
infection;O;O
with;O;O
this;O;O
organism;O;O
and;O;O
abuse;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-MedLine.d45.s3;;
The;O;O
mean;O;O
reduction;O;O
of;O;O
growth;O;O
caused;O;O
by;O;O
the;O;O
drugs;O;O
was;O;O
1,000;O;O
-;O;O
fold;O;O
greater;O;O
for;O;O
49;O;O
Pseudomonas;O;O
strains;O;O
from;O;O
normal;O;O
subjects;O;O
than;O;O
for;O;O
32;O;O
strains;O;O
from;O;O
drug;O;O
addicts;O;O
(;O;O
4.2;O;O
vs.;O;O
1.3;O;O
logs;O;O
of;O;O
reduction;O;O
at;O;O
2;O;O
hr;O;O
,;O;O
P;O;O
less;O;O
than;O;O
.0005;O;O
);O;O
.;O;O
DDI-MedLine.d45.s4;;
A;O;O
common;O;O
phenotypic;O;O
subset;O;O
of;O;O
the;O;O
serotype;O;O
O11;O;O
strains;O;O
from;O;O
drug;O;O
addicts;O;O
was;O;O
especially;O;O
resistant;O;O
to;O;O
the;O;O
inhibitory;O;O
effects;O;O
.;O;O
DDI-MedLine.d45.s5;;
Twelve;O;O
strains;O;O
of;O;O
Staphylococcus;O;O
aureus;O;O
(;O;O
a;O;O
frequent;O;O
cause;O;O
of;O;O
infection;O;O
in;O;O
heroin;B-drug_n;B-DDI-MedLine.d45.s5.e0
,;O;O
but;O;O
not;O;O
in;O;O
pentazocine;B-drug;B-DDI-MedLine.d45.s5.e1
and;O;O
tripelennamine;B-drug;B-DDI-MedLine.d45.s5.e2
,;O;O
addicts;O;O
);O;O
were;O;O
completely;O;O
inhibited;O;O
by;O;O
the;O;O
drug;O;O
combination;O;O
.;O;O
DDI-MedLine.d45.s6;;
Dose;O;O
-;O;O
response;O;O
curves;O;O
(;O;O
derived;O;O
from;O;O
the;O;O
results;O;O
of;O;O
using;O;O
the;O;O
tablets;O;O
as;O;O
well;O;O
as;O;O
pure;O;O
powders;O;O
);O;O
showed;O;O
that;O;O
tripelennamine;B-drug;B-DDI-MedLine.d45.s6.e0
was;O;O
responsible;O;O
for;O;O
the;O;O
inhibitory;O;O
activity;O;O
,;O;O
which;O;O
was;O;O
partially;O;O
antagonized;O;O
by;O;O
pentazocine;B-drug;B-DDI-MedLine.d45.s6.e1
.;O;O
DDI-MedLine.d45.s7;;
We;O;O
conclude;O;O
that;O;O
an;O;O
ability;O;O
of;O;O
some;O;O
P.;O;O
DDI-MedLine.d45.s8;;
aeruginosa;O;O
serotype;O;O
O11;O;O
strains;O;O
,;O;O
but;O;O
not;O;O
S.;O;O
DDI-MedLine.d45.s9;;
aureus;O;O
,;O;O
to;O;O
survive;O;O
in;O;O
pentazocine;B-drug;B-DDI-MedLine.d45.s9.e0
and;O;O
tripelennamine;B-drug;B-DDI-MedLine.d45.s9.e1
may;O;O
explain;O;O
in;O;O
part;O;O
a;O;O
shift;O;O
from;O;O
S.;O;O
DDI-MedLine.d45.s10;;
aureus;O;O
to;O;O
P.;O;O
DDI-MedLine.d45.s11;;
aeruginosa;O;O
as;O;O
common;O;O
pathogens;O;O
of;O;O
drug;O;O
addicts;O;O
in;O;O
areas;O;O
where;O;O
abuse;O;O
of;O;O
this;O;O
combination;O;O
of;O;O
drugs;O;O
has;O;O
increased;O;O
.;O;O
DDI-MedLine.d61.s0;;
Pharmacokinetic;O;O
evaluation;O;O
of;O;O
the;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s0.e0
-;O;O
amiodarone;B-drug;B-DDI-MedLine.d61.s0.e1
interaction;O;O
.;O;O

;O;O
DDI-MedLine.d61.s1;;
Amiodarone;B-drug;B-DDI-MedLine.d61.s1.e0
is;O;O
known;O;O
to;O;O
raise;O;O
serum;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s1.e1
levels;O;O
.;O;O
DDI-MedLine.d61.s2;;
This;O;O
study;O;O
was;O;O
designed;O;O
to;O;O
evaluate;O;O
the;O;O
pharmacokinetic;O;O
basis;O;O
of;O;O
this;O;O
interaction;O;O
in;O;O
10;O;O
normal;O;O
subjects;O;O
.;O;O
DDI-MedLine.d61.s3;;
The;O;O
pharmacokinetic;O;O
variables;O;O
for;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s3.e0
were;O;O
determined;O;O
after;O;O
a;O;O
1.0;O;O
mg;O;O
intravenous;O;O
dose;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s3.e1
in;O;O
each;O;O
subject;O;O
,;O;O
before;O;O
and;O;O
after;O;O
oral;O;O
amiodarone;B-drug;B-DDI-MedLine.d61.s3.e2
,;O;O
400;O;O
mg;O;O
daily;O;O
for;O;O
3;O;O
weeks;O;O
.;O;O
DDI-MedLine.d61.s4;;
During;O;O
amiodarone;B-drug;B-DDI-MedLine.d61.s4.e0
administration;O;O
,;O;O
systemic;O;O
clearance;O;O
of;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s4.e1
was;O;O
reduced;O;O
from;O;O
234;O;O
+;O;O
/;O;O
-;O;O
72;O;O
ml;O;O
/;O;O
min;O;O
(;O;O
mean;O;O
+;O;O
/;O;O
-;O;O
standard;O;O
deviation;O;O
);O;O
to;O;O
172;O;O
+;O;O
/;O;O
-;O;O
33;O;O
ml;O;O
/;O;O
min;O;O
(;O;O
p;O;O
less;O;O
than;O;O
0.01;O;O
);O;O
.;O;O
DDI-MedLine.d61.s5;;
This;O;O
was;O;O
due;O;O
to;O;O
reductions;O;O
in;O;O
both;O;O
renal;O;O
clearance;O;O
(;O;O
from;O;O
105;O;O
+;O;O
/;O;O
-;O;O
39;O;O
to;O;O
84;O;O
+;O;O
/;O;O
-;O;O
15;O;O
ml;O;O
/;O;O
min;O;O
);O;O
(;O;O
p;O;O
less;O;O
than;O;O
0.05;O;O
);O;O
and;O;O
nonrenal;O;O
clearance;O;O
(;O;O
from;O;O
130;O;O
+;O;O
/;O;O
-;O;O
38;O;O
to;O;O
88;O;O
+;O;O
/;O;O
-;O;O
20;O;O
ml;O;O
/;O;O
min;O;O
);O;O
(;O;O
p;O;O
less;O;O
than;O;O
0.01;O;O
);O;O
.;O;O
DDI-MedLine.d61.s6;;
Digoxin;B-drug;B-DDI-MedLine.d61.s6.e0
half;O;O
-;O;O
life;O;O
of;O;O
elimination;O;O
was;O;O
prolonged;O;O
from;O;O
34;O;O
+;O;O
/;O;O
-;O;O
13;O;O
to;O;O
40;O;O
+;O;O
/;O;O
-;O;O
16;O;O
hours;O;O
(;O;O
p;O;O
less;O;O
than;O;O
0.05;O;O
);O;O
.;O;O
DDI-MedLine.d61.s7;;
Digoxin;B-drug;B-DDI-MedLine.d61.s7.e0
volume;O;O
of;O;O
distribution;O;O
was;O;O
not;O;O
significantly;O;O
changed;O;O
.;O;O
DDI-MedLine.d61.s8;;
Amiodarone;B-drug;B-DDI-MedLine.d61.s8.e0
caused;O;O
a;O;O
three;O;O
-;O;O
to;O;O
fivefold;O;O
increase;O;O
in;O;O
serum;O;O
reverse;O;O
triiodothyronine;O;O
levels;O;O
,;O;O
but;O;O
changes;O;O
in;O;O
thyroid;O;O
function;O;O
were;O;O
not;O;O
quantitatively;O;O
related;O;O
to;O;O
the;O;O
changes;O;O
in;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s8.e1
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d61.s9;;
These;O;O
alterations;O;O
in;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s9.e0
pharmacokinetics;O;O
produced;O;O
by;O;O
amiodarone;B-drug;B-DDI-MedLine.d61.s9.e1
explain;O;O
the;O;O
increase;O;O
in;O;O
serum;O;O
digoxin;B-drug;B-DDI-MedLine.d61.s9.e2
level;O;O
that;O;O
has;O;O
been;O;O
observed;O;O
when;O;O
this;O;O
drug;O;O
combination;O;O
has;O;O
been;O;O
used;O;O
clinically;O;O
.;O;O
DDI-MedLine.d85.s0;;
Misonidazole;B-drug_n;B-DDI-MedLine.d85.s0.e0
protects;O;O
mouse;O;O
tumour;O;O
and;O;O
normal;O;O
tissues;O;O
from;O;O
the;O;O
toxicity;O;O
of;O;O
oral;O;O
CCNU;B-drug;B-DDI-MedLine.d85.s0.e1
.;O;O
DDI-MedLine.d85.s1;;
Because;O;O
the;O;O
nitrosourea;B-group;B-DDI-MedLine.d85.s1.e0
CCNU;I-drug;I-DDI-MedLine.d85.s1.e1
is;O;O
given;O;O
exclusively;O;O
by;O;O
the;O;O
oral;O;O
route;O;O
in;O;O
man;O;O
,;O;O
we;O;O
have;O;O
carried;O;O
out;O;O
studies;O;O
in;O;O
mice;O;O
on;O;O
the;O;O
antitumour;O;O
activity;O;O
,;O;O
acute;O;O
toxicity;O;O
and;O;O
pharmacokinetics;O;O
of;O;O
oral;O;O
CCNU;B-drug;B-DDI-MedLine.d85.s1.e2
,;O;O
either;O;O
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
the;O;O
chemosensitizer;O;O
misonidazole;B-drug_n;B-DDI-MedLine.d85.s1.e3
.;O;O
DDI-MedLine.d85.s2;;
In;O;O
both;O;O
plasma;O;O
and;O;O
KHT;O;O
tumour;O;O
the;O;O
peak;O;O
concentration;O;O
and;O;O
";O;O
early;O;O
";O;O
DDI-MedLine.d85.s3;;
AUC;O;O
for;O;O
total;O;O
nitrosoureas;B-group;B-DDI-MedLine.d85.s3.e0
were;O;O
about;O;O
1.4;O;O
-;O;O
1.5;O;O
fold;O;O
greater;O;O
for;O;O
the;O;O
oral;O;O
compared;O;O
to;O;O
the;O;O
i.p;O;O
.;O;O
DDI-MedLine.d85.s4;;
route;O;O
.;O;O
DDI-MedLine.d85.s5;;
These;O;O
differences;O;O
were;O;O
reflected;O;O
in;O;O
the;O;O
roughly;O;O
twofold;O;O
greater;O;O
antitumour;O;O
activity;O;O
for;O;O
the;O;O
oral;O;O
route;O;O
.;O;O
DDI-MedLine.d85.s6;;
In;O;O
contrast;O;O
,;O;O
acute;O;O
toxicity;O;O
tests;O;O
showed;O;O
that;O;O
oral;O;O
CCNU;B-drug;B-DDI-MedLine.d85.s6.e0
was;O;O
1.45;O;O
times;O;O
less;O;O
toxic;O;O
to;O;O
normal;O;O
tissue;O;O
,;O;O
although;O;O
the;O;O
dose;O;O
-;O;O
limiting;O;O
organ;O;O
may;O;O
be;O;O
different;O;O
for;O;O
the;O;O
two;O;O
routes;O;O
.;O;O
DDI-MedLine.d85.s7;;
Misonidazole;B-drug_n;B-DDI-MedLine.d85.s7.e0
reduced;O;O
the;O;O
antitumour;O;O
activity;O;O
of;O;O
oral;O;O
CCNU;B-drug;B-DDI-MedLine.d85.s7.e1
by;O;O
dose;O;O
modifying;O;O
factors;O;O
(;O;O
DMF;O;O
);O;O
of;O;O
0.58;O;O
-;O;O
0.71;O;O
.;O;O
DDI-MedLine.d85.s8;;
Similarly;O;O
,;O;O
the;O;O
acute;O;O
toxicity;O;O
was;O;O
also;O;O
diminished;O;O
by;O;O
a;O;O
DMF;O;O
of;O;O
0.74;O;O
.;O;O
DDI-MedLine.d85.s9;;
Misonidazole;B-drug_n;B-DDI-MedLine.d85.s9.e0
has;O;O
a;O;O
complex;O;O
effect;O;O
on;O;O
oral;O;O
CCNU;B-drug;B-DDI-MedLine.d85.s9.e1
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d85.s10;;
The;O;O
plasma;O;O
and;O;O
tumour;O;O
total;O;O
nitrosourea;B-group;B-DDI-MedLine.d85.s10.e0
peak;O;O
concentrations;O;O
were;O;O
reduced;O;O
by;O;O
1.5;O;O
and;O;O
1.7;O;O
fold;O;O
respectively;O;O
.;O;O
DDI-MedLine.d85.s11;;
Misonidazole;B-drug_n;B-DDI-MedLine.d85.s11.e0
also;O;O
reduced;O;O
the;O;O
";O;O
early;O;O
";O;O
DDI-MedLine.d85.s12;;
nitrosourea;B-group;B-DDI-MedLine.d85.s12.e0
AUC;O;O
,;O;O
with;O;O
the;O;O
extent;O;O
of;O;O
the;O;O
reduction;O;O
depending;O;O
on;O;O
the;O;O
minimum;O;O
effective;O;O
concentration;O;O
(;O;O
MEC;O;O
);O;O
chosen;O;O
.;O;O
DDI-MedLine.d85.s13;;
For;O;O
example;O;O
,;O;O
the;O;O
plasma;O;O
nitrosourea;B-group;B-DDI-MedLine.d85.s13.e0
AUC;O;O
was;O;O
reduced;O;O
by;O;O
factors;O;O
of;O;O
1.05;O;O
and;O;O
9.6;O;O
for;O;O
MEC;O;O
values;O;O
of;O;O
1;O;O
and;O;O
2;O;O
micrograms;O;O
ml;O;O
-;O;O
1;O;O
respectively;O;O
.;O;O
DDI-MedLine.d85.s14;;
We;O;O
propose;O;O
these;O;O
pharmacokinetic;O;O
changes;O;O
to;O;O
be;O;O
the;O;O
underlying;O;O
mechanism;O;O
for;O;O
the;O;O
reduction;O;O
of;O;O
oral;O;O
CCNU;B-drug;B-DDI-MedLine.d85.s14.e0
cytotoxicity;O;O
by;O;O
misonidazole;B-drug_n;B-DDI-MedLine.d85.s14.e1
.;O;O
DDI-MedLine.d85.s15;;
Clinical;O;O
trials;O;O
of;O;O
such;O;O
combinations;O;O
should;O;O
be;O;O
accompanied;O;O
by;O;O
detailed;O;O
pharmacokinetic;O;O
evaluation;O;O
.;O;O
DDI-MedLine.d7.s0;;
Enhanced;O;O
theophylline;B-drug;B-DDI-MedLine.d7.s0.e0
clearance;O;O
secondary;O;O
to;O;O
phenytoin;B-drug;B-DDI-MedLine.d7.s0.e1
therapy;O;O
.;O;O
DDI-MedLine.d7.s1;;
This;O;O
report;O;O
describes;O;O
two;O;O
cases;O;O
in;O;O
which;O;O
theophylline;B-drug;B-DDI-MedLine.d7.s1.e0
clearance;O;O
accelerated;O;O
markedly;O;O
with;O;O
concomitant;O;O
phenytoin;B-drug;B-DDI-MedLine.d7.s1.e1
administration;O;O
.;O;O
DDI-MedLine.d7.s2;;
Maximum;O;O
calculated;O;O
theophylline;B-drug;B-DDI-MedLine.d7.s2.e0
clearance;O;O
ranged;O;O
from;O;O
2;O;O
1;O;O
/;O;O
2;O;O
to;O;O
3;O;O
1;O;O
/;O;O
2;O;O
times;O;O
baseline;O;O
.;O;O
DDI-MedLine.d7.s3;;
Onset;O;O
of;O;O
the;O;O
interaction;O;O
began;O;O
within;O;O
five;O;O
days;O;O
of;O;O
beginning;O;O
concurrent;O;O
therapy;O;O
.;O;O
DDI-MedLine.d7.s4;;
With;O;O
combined;O;O
use;O;O
,;O;O
clinicians;O;O
should;O;O
be;O;O
aware;O;O
,;O;O
when;O;O
phenytoin;B-drug;B-DDI-MedLine.d7.s4.e0
is;O;O
added;O;O
,;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
reexacerbation;O;O
of;O;O
pulmonary;O;O
symptomatology;O;O
due;O;O
to;O;O
lowered;O;O
serum;O;O
theophylline;B-drug;B-DDI-MedLine.d7.s4.e1
concentrations;O;O
.;O;O
DDI-MedLine.d30.s0;;
Stereoselective;O;O
behavioral;O;O
effects;O;O
of;O;O
N;B-drug_n;B-DDI-MedLine.d30.s0.e0
-;I-drug_n;I-DDI-MedLine.d30.s0.e0
allylnormetazocine;I-drug_n;I-DDI-MedLine.d30.s0.e0
in;O;O
pigeons;O;O
and;O;O
squirrel;O;O
monkeys;O;O
.;O;O
DDI-MedLine.d30.s1;;
The;O;O
behavioral;O;O
effects;O;O
of;O;O
the;O;O
stereoisomers;O;O
of;O;O
N;B-drug_n;B-DDI-MedLine.d30.s1.e0
-;I-drug_n;I-DDI-MedLine.d30.s1.e0
allylnormetazocine;I-drug_n;I-DDI-MedLine.d30.s1.e0
(;O;O
NANM;B-drug_n;B-DDI-MedLine.d30.s1.e1
);O;O
were;O;O
compared;O;O
with;O;O
those;O;O
of;O;O
phencyclidine;B-drug_n;B-DDI-MedLine.d30.s1.e2
(;O;O
PCP;B-drug_n;B-DDI-MedLine.d30.s1.e3
);O;O
in;O;O
pigeons;O;O
and;O;O
squirrel;O;O
monkeys;O;O
responding;O;O
under;O;O
a;O;O
multiple;O;O
fixed;O;O
-;O;O
interval;O;O
fixed;O;O
-;O;O
ratio;O;O
(;O;O
FI;O;O
FR;O;O
);O;O
schedule;O;O
of;O;O
food;O;O
presentation;O;O
.;O;O
DDI-MedLine.d30.s2;;
Intermediate;O;O
doses;O;O
of;O;O
(;B-drug_n;B-DDI-MedLine.d30.s2.e0
+;I-drug_n;I-DDI-MedLine.d30.s2.e0
);I-drug_n;I-DDI-MedLine.d30.s2.e0
-NANM;I-drug_n;I-DDI-MedLine.d30.s2.e0
or;O;O
PCP;B-drug_n;B-DDI-MedLine.d30.s2.e1
produced;O;O
transient;O;O
increases;O;O
in;O;O
FI;O;O
responding;O;O
in;O;O
monkeys;O;O
and;O;O
sustained;O;O
increases;O;O
in;O;O
FI;O;O
responding;O;O
in;O;O
pigeons;O;O
,;O;O
DDI-MedLine.d30.s3;;
higher;O;O
doses;O;O
decreased;O;O
FI;O;O
and;O;O
FR;O;O
responding;O;O
in;O;O
both;O;O
species;O;O
.;O;O
DDI-MedLine.d30.s4;;
In;O;O
contrast;O;O
to;O;O
its;O;O
enantiomer;O;O
,;O;O
(;B-drug_n;B-DDI-MedLine.d30.s4.e0
-);I-drug_n;I-DDI-MedLine.d30.s4.e0
-;I-drug_n;I-DDI-MedLine.d30.s4.e0
NANM;I-drug_n;I-DDI-MedLine.d30.s4.e0
failed;O;O
to;O;O
increase;O;O
FI;O;O
responding;O;O
significantly;O;O
in;O;O
either;O;O
species;O;O
,;O;O
DDI-MedLine.d30.s5;;
at;O;O
high;O;O
doses;O;O
,;O;O
(;B-drug_n;B-DDI-MedLine.d30.s5.e0
-);I-drug_n;I-DDI-MedLine.d30.s5.e0
-;I-drug_n;I-DDI-MedLine.d30.s5.e0
NANM;I-drug_n;I-DDI-MedLine.d30.s5.e0
decreased;O;O
FI;O;O
and;O;O
FR;O;O
responding;O;O
.;O;O
DDI-MedLine.d30.s6;;
In;O;O
monkeys;O;O
,;O;O
(;B-drug_n;B-DDI-MedLine.d30.s6.e0
-);I-drug_n;I-DDI-MedLine.d30.s6.e0
-;I-drug_n;I-DDI-MedLine.d30.s6.e0
NANM;I-drug_n;I-DDI-MedLine.d30.s6.e0
was;O;O
about;O;O
10;O;O
times;O;O
more;O;O
potent;O;O
than;O;O
(;B-drug_n;B-DDI-MedLine.d30.s6.e1
+;I-drug_n;I-DDI-MedLine.d30.s6.e1
);I-drug_n;I-DDI-MedLine.d30.s6.e1
-NANM;I-drug_n;I-DDI-MedLine.d30.s6.e1
in;O;O
decreasing;O;O
responding;O;O
,;O;O
whereas;O;O
in;O;O
pigeons;O;O
(;B-drug_n;B-DDI-MedLine.d30.s6.e2
-);I-drug_n;I-DDI-MedLine.d30.s6.e2
-;I-drug_n;I-DDI-MedLine.d30.s6.e2
NANM;I-drug_n;I-DDI-MedLine.d30.s6.e2
was;O;O
about;O;O
equipotent;O;O
with;O;O
(;B-drug_n;B-DDI-MedLine.d30.s6.e3
+;I-drug_n;I-DDI-MedLine.d30.s6.e3
);I-drug_n;I-DDI-MedLine.d30.s6.e3
-NANM;I-drug_n;I-DDI-MedLine.d30.s6.e3
.;O;O
DDI-MedLine.d30.s7;;
In;O;O
both;O;O
species;O;O
,;O;O
(;B-drug_n;B-DDI-MedLine.d30.s7.e0
-);I-drug_n;I-DDI-MedLine.d30.s7.e0
-;I-drug_n;I-DDI-MedLine.d30.s7.e0
NANM;I-drug_n;I-DDI-MedLine.d30.s7.e0
,;O;O
but;O;O
not;O;O
(;B-drug_n;B-DDI-MedLine.d30.s7.e1
+;I-drug_n;I-DDI-MedLine.d30.s7.e1
);I-drug_n;I-DDI-MedLine.d30.s7.e1
-NANM;I-drug_n;I-DDI-MedLine.d30.s7.e1
,;O;O
antagonized;O;O
the;O;O
rate;O;O
-;O;O
decreasing;O;O
effects;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d30.s7.e2
on;O;O
FI;O;O
and;O;O
FR;O;O
responding;O;O
.;O;O
DDI-MedLine.d30.s8;;
In;O;O
monkeys;O;O
,;O;O
the;O;O
effects;O;O
of;O;O
(;B-drug_n;B-DDI-MedLine.d30.s8.e0
-);I-drug_n;I-DDI-MedLine.d30.s8.e0
-;I-drug_n;I-DDI-MedLine.d30.s8.e0
NANM;I-drug_n;I-DDI-MedLine.d30.s8.e0
,;O;O
but;O;O
not;O;O
(;B-drug_n;B-DDI-MedLine.d30.s8.e1
+;I-drug_n;I-DDI-MedLine.d30.s8.e1
);I-drug_n;I-DDI-MedLine.d30.s8.e1
-NANM;I-drug_n;I-DDI-MedLine.d30.s8.e1
or;O;O
PCP;B-drug_n;B-DDI-MedLine.d30.s8.e2
,;O;O
were;O;O
antagonized;O;O
by;O;O
naloxone;B-drug;B-DDI-MedLine.d30.s8.e3
,;O;O
DDI-MedLine.d30.s9;;
the;O;O
doses;O;O
of;O;O
naloxone;B-drug;B-DDI-MedLine.d30.s9.e0
required;O;O
to;O;O
antagonize;O;O
the;O;O
effects;O;O
of;O;O
(;B-drug_n;B-DDI-MedLine.d30.s9.e1
-);I-drug_n;I-DDI-MedLine.d30.s9.e1
-;I-drug_n;I-DDI-MedLine.d30.s9.e1
NANM;I-drug_n;I-DDI-MedLine.d30.s9.e1
were;O;O
more;O;O
than;O;O
100;O;O
times;O;O
higher;O;O
than;O;O
those;O;O
required;O;O
to;O;O
antagonize;O;O
the;O;O
effects;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d30.s9.e2
.;O;O
DDI-MedLine.d30.s10;;
In;O;O
pigeons;O;O
,;O;O
naloxone;B-drug;B-DDI-MedLine.d30.s10.e0
did;O;O
not;O;O
systematically;O;O
alter;O;O
the;O;O
effects;O;O
of;O;O
(;B-drug_n;B-DDI-MedLine.d30.s10.e1
-);I-drug_n;I-DDI-MedLine.d30.s10.e1
-;I-drug_n;I-DDI-MedLine.d30.s10.e1
NANM;I-drug_n;I-DDI-MedLine.d30.s10.e1
,;O;O
(;B-drug_n;B-DDI-MedLine.d30.s10.e2
+;I-drug_n;I-DDI-MedLine.d30.s10.e2
);I-drug_n;I-DDI-MedLine.d30.s10.e2
-NANM;I-drug_n;I-DDI-MedLine.d30.s10.e2
or;O;O
PCP;B-drug_n;B-DDI-MedLine.d30.s10.e3
.;O;O
DDI-MedLine.d30.s11;;
Haloperidol;B-drug;B-DDI-MedLine.d30.s11.e0
reduced;O;O
or;O;O
eliminated;O;O
the;O;O
increases;O;O
in;O;O
FI;O;O
responding;O;O
produced;O;O
by;O;O
intermediate;O;O
doses;O;O
of;O;O
either;O;O
(;B-drug_n;B-DDI-MedLine.d30.s11.e1
+;I-drug_n;I-DDI-MedLine.d30.s11.e1
);I-drug_n;I-DDI-MedLine.d30.s11.e1
-NANM;I-drug_n;I-DDI-MedLine.d30.s11.e1
or;O;O
PCP;B-drug_n;B-DDI-MedLine.d30.s11.e2
in;O;O
pigeons;O;O
,;O;O
but;O;O
did;O;O
not;O;O
antagonize;O;O
the;O;O
decreases;O;O
in;O;O
FI;O;O
or;O;O
FR;O;O
responding;O;O
produced;O;O
by;O;O
high;O;O
doses;O;O
of;O;O
PCP;O;O
or;O;O
either;O;O
stereoisomer;O;O
of;O;O
NANM;B-drug_n;B-DDI-MedLine.d30.s11.e3
.;O;O
DDI-MedLine.d30.s12;;
The;O;O
results;O;O
demonstrate;O;O
a;O;O
high;O;O
degree;O;O
of;O;O
stereoselectivity;O;O
in;O;O
the;O;O
behavioral;O;O
effects;O;O
of;O;O
NANM;B-drug_n;B-DDI-MedLine.d30.s12.e0
.;O;O
DDI-MedLine.d30.s13;;
The;O;O
levorotatory;O;O
isomer;O;O
had;O;O
opioid;O;O
-;O;O
antagonist;O;O
and;O;O
non;O;O
-;O;O
opioid;O;O
agonist;O;O
effects;O;O
in;O;O
pigeons;O;O
and;O;O
mixed;O;O
opioid;O;O
agonist;O;O
-;O;O
antagonist;O;O
effects;O;O
in;O;O
monkeys;O;O
.;O;O
DDI-MedLine.d30.s14;;
The;O;O
dextrorotatory;O;O
isomer;O;O
,;O;O
on;O;O
the;O;O
other;O;O
hand;O;O
,;O;O
had;O;O
effects;O;O
similar;O;O
to;O;O
those;O;O
of;O;O
PCP;B-drug_n;B-DDI-MedLine.d30.s14.e0
in;O;O
both;O;O
species;O;O
.;O;O
DDI-MedLine.d55.s0;;
Increased;O;O
hepatotoxicity;O;O
of;O;O
acetaminophen;B-drug;B-DDI-MedLine.d55.s0.e0
by;O;O
concomitant;O;O
administration;O;O
of;O;O
caffeine;B-drug;B-DDI-MedLine.d55.s0.e1
in;O;O
the;O;O
rat;O;O
.;O;O
DDI-MedLine.d55.s1;;
Since;O;O
caffeine;B-drug;B-DDI-MedLine.d55.s1.e0
is;O;O
frequently;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
acetaminophen;B-drug;B-DDI-MedLine.d55.s1.e1
,;O;O
it;O;O
is;O;O
of;O;O
clinical;O;O
interest;O;O
to;O;O
study;O;O
the;O;O
effect;O;O
of;O;O
caffeine;B-drug;B-DDI-MedLine.d55.s1.e2
on;O;O
the;O;O
hepatotoxicity;O;O
of;O;O
acetaminophen;B-drug;B-DDI-MedLine.d55.s1.e3
.;O;O
DDI-MedLine.d55.s2;;
In;O;O
male;O;O
Sprague;O;O
-;O;O
Dawley;O;O
rats;O;O
fasted;O;O
for;O;O
18;O;O
h;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
caffeine;B-drug;B-DDI-MedLine.d55.s2.e0
(;O;O
0.1;O;O
g;O;O
/;O;O
kg;O;O
,;O;O
i.p;O;O
.;O;O
);O;O
DDI-MedLine.d55.s3;;
as;O;O
judged;O;O
by;O;O
increased;O;O
serum;O;O
enzyme;O;O
activities;O;O
and;O;O
increased;O;O
incidence;O;O
of;O;O
hepatic;O;O
necrosis;O;O
.;O;O
DDI-MedLine.d55.s4;;
Careful;O;O
observations;O;O
on;O;O
hepatotoxicity;O;O
are;O;O
suggested;O;O
when;O;O
acetaminophen;B-drug;B-DDI-MedLine.d55.s4.e0
is;O;O
prescribed;O;O
with;O;O
caffeine;B-drug;B-DDI-MedLine.d55.s4.e1
.;O;O
DDI-MedLine.d130.s0;;
High;O;O
-;O;O
dose;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s0.e0
with;O;O
sodium;B-drug;B-DDI-MedLine.d130.s0.e1
thiosulfate;I-drug;I-DDI-MedLine.d130.s0.e1
protection;O;O
.;O;O
DDI-MedLine.d130.s1;;
Nephrotoxicity;O;O
frequently;O;O
limits;O;O
the;O;O
dose;O;O
of;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s1.e0
to;O;O
less;O;O
than;O;O
120;O;O
mg;O;O
/;O;O
m2;O;O
per;O;O
injection;O;O
.;O;O
DDI-MedLine.d130.s2;;
Sodium;B-drug;B-DDI-MedLine.d130.s2.e0
thiosulfate;I-drug;I-DDI-MedLine.d130.s2.e0
is;O;O
a;O;O
neutralizing;O;O
agent;O;O
for;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s2.e1
that;O;O
protects;O;O
against;O;O
renal;O;O
damage;O;O
.;O;O
DDI-MedLine.d130.s3;;
To;O;O
determine;O;O
whether;O;O
injection;O;O
of;O;O
thiosulfate;B-drug;B-DDI-MedLine.d130.s3.e0
would;O;O
permit;O;O
larger;O;O
doses;O;O
of;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s3.e1
to;O;O
be;O;O
administered;O;O
,;O;O
a;O;O
fixed;O;O
9.9;O;O
-;O;O
g;O;O
/;O;O
m2;O;O
dose;O;O
of;O;O
thiosulfate;B-drug;B-DDI-MedLine.d130.s3.e2
was;O;O
given;O;O
intravenously;O;O
over;O;O
three;O;O
hours;O;O
concurrently;O;O
with;O;O
escalating;O;O
doses;O;O
of;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s3.e3
.;O;O
DDI-MedLine.d130.s4;;
Cisplatin;B-drug;B-DDI-MedLine.d130.s4.e0
was;O;O
administered;O;O
over;O;O
the;O;O
last;O;O
two;O;O
hours;O;O
of;O;O
the;O;O
thiosulfate;B-drug;B-DDI-MedLine.d130.s4.e1
infusion;O;O
.;O;O
DDI-MedLine.d130.s5;;
Using;O;O
this;O;O
technique;O;O
,;O;O
it;O;O
was;O;O
possible;O;O
to;O;O
escalate;O;O
the;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s5.e0
dose;O;O
to;O;O
225;O;O
mg;O;O
/;O;O
m2;O;O
before;O;O
dose;O;O
-;O;O
limiting;O;O
toxicities;O;O
were;O;O
encountered;O;O
.;O;O
DDI-MedLine.d130.s6;;
Comparison;O;O
of;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s6.e0
pharmacokinetics;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
202.5;O;O
mg;O;O
/;O;O
m2;O;O
plus;O;O
thiosulfate;B-drug;B-DDI-MedLine.d130.s6.e1
to;O;O
those;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
100;O;O
mg;O;O
/;O;O
m2;O;O
without;O;O
thiosulfate;B-drug;B-DDI-MedLine.d130.s6.e2
indicated;O;O
that;O;O
there;O;O
were;O;O
no;O;O
changes;O;O
in;O;O
the;O;O
elimination;O;O
rate;O;O
constant;O;O
,;O;O
volume;O;O
of;O;O
distribution;O;O
,;O;O
or;O;O
total;O;O
body;O;O
clearance;O;O
of;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s6.e3
.;O;O
DDI-MedLine.d130.s7;;
The;O;O
total;O;O
drug;O;O
exposure;O;O
for;O;O
the;O;O
plasma;O;O
was;O;O
approximately;O;O
twofold;O;O
at;O;O
the;O;O
higher;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s7.e0
dose;O;O
.;O;O
DDI-MedLine.d130.s8;;
This;O;O
study;O;O
demonstrates;O;O
that;O;O
concurrent;O;O
administration;O;O
of;O;O
thiosulfate;B-drug;B-DDI-MedLine.d130.s8.e0
permits;O;O
at;O;O
least;O;O
a;O;O
twofold;O;O
increase;O;O
in;O;O
dose;O;O
and;O;O
total;O;O
exposure;O;O
to;O;O
cisplatin;B-drug;B-DDI-MedLine.d130.s8.e1
.;O;O
DDI-MedLine.d41.s0;;
Interferon;O;O
induction;O;O
:;O;O
tool;O;O
for;O;O
establishing;O;O
interactions;O;O
among;O;O
homopolyribonucleotides;O;O
.;O;O

;O;O
DDI-MedLine.d41.s1;;
Hitherto;O;O
unrecognized;O;O
interactions;O;O
between;O;O
homopolyribonucleotides;O;O
and;O;O
complexes;O;O
thereof;O;O
are;O;O
suggested;O;O
by;O;O
interferon;O;O
induction;O;O
data;O;O
obtained;O;O
in;O;O
a;O;O
highly;O;O
sensitive;O;O
assay;O;O
system;O;O
of;O;O
primary;O;O
rabbit;O;O
kidney;O;O
cell;O;O
cultures;O;O
superinduced;O;O
by;O;O
metabolic;O;O
inhibitors;O;O
.;O;O
DDI-MedLine.d5.s0;;
Repeated;O;O
oral;O;O
administration;O;O
of;O;O
coumaphos;B-drug_n;B-DDI-MedLine.d5.s0.e0
in;O;O
sheep;O;O
:;O;O
interactions;O;O
of;O;O
coumaphos;B-drug_n;B-DDI-MedLine.d5.s0.e1
with;O;O
bishydroxycoumarin;B-drug;B-DDI-MedLine.d5.s0.e2
,;O;O
trichlorfon;B-drug_n;B-DDI-MedLine.d5.s0.e3
,;O;O
and;O;O
phenobarbital;B-drug;B-DDI-MedLine.d5.s0.e4
sodium;I-drug;I-DDI-MedLine.d5.s0.e4
.;O;O
DDI-MedLine.d5.s1;;
Interactions;O;O
between;O;O
treatments;O;O
with;O;O
coumaphos;B-drug_n;B-DDI-MedLine.d5.s1.e0
,;O;O
bishydroxycoumarin;B-drug;B-DDI-MedLine.d5.s1.e1
(;O;O
an;O;O
anticoagulant;B-group;B-DDI-MedLine.d5.s1.e2
);O;O
,;O;O
trichlorfon;B-drug_n;B-DDI-MedLine.d5.s1.e3
(;O;O
an;O;O
organophosphorous;B-group;B-DDI-MedLine.d5.s1.e4
compound;I-group;I-DDI-MedLine.d5.s1.e4
);O;O
,;O;O
and;O;O
phenobarbital;B-drug;B-DDI-MedLine.d5.s1.e5
sodium;I-drug;I-DDI-MedLine.d5.s1.e5
(;O;O
an;O;O
inducer;O;O
of;O;O
microsomal;O;O
enzymes;O;O
);O;O
were;O;O
investigated;O;O
in;O;O
sheep;O;O
.;O;O
DDI-MedLine.d5.s2;;
A;O;O
daily;O;O
dose;O;O
of;O;O
2;O;O
mg;O;O
of;O;O
coumaphos;B-drug_n;B-DDI-MedLine.d5.s2.e0
/;O;O
kg;O;O
of;O;O
body;O;O
weight;O;O
for;O;O
6;O;O
days;O;O
did;O;O
not;O;O
affect;O;O
the;O;O
plasma;O;O
enzymes;O;O
or;O;O
the;O;O
antiprothrombinemic;O;O
effect;O;O
of;O;O
bishydroxy;B-drug;B-DDI-MedLine.d5.s2.e1
-;I-drug;I-DDI-MedLine.d5.s2.e1
coumarin;I-drug;I-DDI-MedLine.d5.s2.e1
in;O;O
wethers;O;O
.;O;O
DDI-MedLine.d5.s3;;
The;O;O
treatment;O;O
of;O;O
ewes;O;O
with;O;O
an;O;O
intravenous;O;O
(;O;O
IV;O;O
);O;O
injection;O;O
of;O;O
trichlorfon;B-drug_n;B-DDI-MedLine.d5.s3.e0
,;O;O
insufficient;O;O
to;O;O
produce;O;O
significant;O;O
inhibition;O;O
of;O;O
erythrocyte;O;O
acetylcholinesterase;O;O
(;O;O
AChE;O;O
);O;O
activity;O;O
,;O;O
appeared;O;O
to;O;O
produce;O;O
additive;O;O
effects;O;O
with;O;O
those;O;O
produced;O;O
by;O;O
subsequent;O;O
treatment;O;O
with;O;O
4;O;O
mg;O;O
of;O;O
coumaphos;B-drug_n;B-DDI-MedLine.d5.s3.e1
/;O;O
kg;O;O
/;O;O
day;O;O
.;O;O
DDI-MedLine.d5.s4;;
In;O;O
ewes;O;O
given;O;O
40;O;O
mg;O;O
of;O;O
phenobarbital;B-drug;B-DDI-MedLine.d5.s4.e0
sodium;I-drug;I-DDI-MedLine.d5.s4.e0
/;O;O
kg;O;O
for;O;O
5;O;O
days;O;O
intraperitoneally;O;O
(;O;O
IP;O;O
);O;O
,;O;O
the;O;O
anticholinesterase;O;O
effect;O;O
of;O;O
4;O;O
mg;O;O
of;O;O
coumaphos;B-drug_n;B-DDI-MedLine.d5.s4.e1
/;O;O
kg;O;O
was;O;O
significantly;O;O
reduced;O;O
and;O;O
signs;O;O
of;O;O
toxicity;O;O
were;O;O
not;O;O
present;O;O
.;O;O
DDI-MedLine.d5.s5;;
Treatment;O;O
with;O;O
daily;O;O
doses;O;O
of;O;O
2;O;O
mg;O;O
of;O;O
coumaphos;B-drug_n;B-DDI-MedLine.d5.s5.e0
/;O;O
kg;O;O
for;O;O
6;O;O
days;O;O
did;O;O
not;O;O
modify;O;O
the;O;O
anticholinesterase;O;O
effect;O;O
of;O;O
a;O;O
2nd;O;O
series;O;O
of;O;O
treatments;O;O
given;O;O
6;O;O
weeks;O;O
later;O;O
.;O;O
DDI-MedLine.d91.s0;;
Diagnostic;O;O
,;O;O
treatment;O;O
and;O;O
aftercare;O;O
approaches;O;O
to;O;O
cocaine;B-drug;B-DDI-MedLine.d91.s0.e0
abuse;O;O
.;O;O
DDI-MedLine.d91.s1;;
The;O;O
general;O;O
public;O;O
feels;O;O
that;O;O
cocaine;B-drug;B-DDI-MedLine.d91.s1.e0
is;O;O
not;O;O
particularly;O;O
dangerous;O;O
because;O;O
it;O;O
does;O;O
not;O;O
produce;O;O
a;O;O
well;O;O
defined;O;O
physical;O;O
dependency;O;O
and;O;O
abstinence;O;O
syndrome;O;O
.;O;O
DDI-MedLine.d91.s2;;
However;O;O
,;O;O
when;O;O
addiction;O;O
is;O;O
defined;O;O
as;O;O
compulsion;O;O
,;O;O
loss;O;O
of;O;O
control;O;O
and;O;O
continued;O;O
use;O;O
in;O;O
spite;O;O
of;O;O
adverse;O;O
consequences;O;O
,;O;O
cocaine;B-drug;B-DDI-MedLine.d91.s2.e0
drug;O;O
hunger;O;O
can;O;O
be;O;O
seen;O;O
as;O;O
an;O;O
agent;O;O
of;O;O
addictive;O;O
disease;O;O
.;O;O
DDI-MedLine.d91.s3;;
Withdrawal;O;O
from;O;O
cocaine;B-drug;B-DDI-MedLine.d91.s3.e0
dependence;O;O
usually;O;O
involves;O;O
depression;O;O
,;O;O
anxiety;O;O
and;O;O
lethargy;O;O
.;O;O
DDI-MedLine.d91.s4;;
These;O;O
usually;O;O
clear;O;O
within;O;O
a;O;O
week;O;O
,;O;O
leaving;O;O
only;O;O
the;O;O
";O;O
drug;O;O
hunger;O;O
";O;O
DDI-MedLine.d91.s5;;
to;O;O
contend;O;O
with;O;O
.;O;O
DDI-MedLine.d91.s6;;
Medication;O;O
is;O;O
rarely;O;O
needed;O;O
.;O;O
DDI-MedLine.d91.s7;;
When;O;O
cocaine;B-drug;B-DDI-MedLine.d91.s7.e0
is;O;O
the;O;O
primary;O;O
addiction;O;O
,;O;O
after;O;O
withdrawal;O;O
the;O;O
most;O;O
effective;O;O
treatment;O;O
is;O;O
group;O;O
therapy;O;O
with;O;O
other;O;O
recovering;O;O
cocaine;O;O
abusers;O;O
.;O;O
DDI-MedLine.d91.s8;;
We;O;O
incorporate;O;O
the;O;O
principles;O;O
of;O;O
recovery;O;O
and;O;O
define;O;O
positive;O;O
and;O;O
constructive;O;O
alternatives;O;O
in;O;O
dealing;O;O
with;O;O
cocaine;O;O
hunger;O;O
.;O;O
DDI-MedLine.d91.s9;;
Recovery;O;O
programs;O;O
should;O;O
be;O;O
flexible;O;O
and;O;O
involve;O;O
individual;O;O
and;O;O
family;O;O
education;O;O
on;O;O
recovery;O;O
and;O;O
the;O;O
nature;O;O
of;O;O
addictive;O;O
disease;O;O
.;O;O
DDI-MedLine.d91.s10;;
Exercise;O;O
that;O;O
produces;O;O
cardiopulmonary;O;O
stimulation;O;O
is;O;O
a;O;O
helpful;O;O
means;O;O
of;O;O
reducing;O;O
drug;O;O
hunger;O;O
and;O;O
anxiety;O;O
during;O;O
recovery;O;O
therapy;O;O
.;O;O
DDI-MedLine.d2.s0;;
Failure;O;O
of;O;O
neomycin;B-drug;B-DDI-MedLine.d2.s0.e0
to;O;O
modify;O;O
ACTH;B-group;B-DDI-MedLine.d2.s0.e1
induced;O;O
hypertension;O;O
in;O;O
sheep;O;O
.;O;O
DDI-MedLine.d2.s1;;
Studies;O;O
in;O;O
rats;O;O
have;O;O
shown;O;O
that;O;O
neomycin;B-drug;B-DDI-MedLine.d2.s1.e0
administration;O;O
attenuates;O;O
certain;O;O
types;O;O
of;O;O
adrenocortical;B-group;B-DDI-MedLine.d2.s1.e1
steroid;I-group;I-DDI-MedLine.d2.s1.e1
dependent;O;O
hypertension;O;O
,;O;O
including;O;O
ACTH;B-drug;B-DDI-MedLine.d2.s1.e2
hypertension;O;O
.;O;O
DDI-MedLine.d2.s2;;
The;O;O
effects;O;O
of;O;O
oral;O;O
neomycin;B-drug;B-DDI-MedLine.d2.s2.e0
on;O;O
ACTH;B-group;B-DDI-MedLine.d2.s2.e1
induced;O;O
hypertension;O;O
were;O;O
examined;O;O
in;O;O
conscious;O;O
sheep;O;O
.;O;O
DDI-MedLine.d2.s3;;
Neomycin;B-drug;B-DDI-MedLine.d2.s3.e0
has;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
blood;O;O
pressure;O;O
or;O;O
metabolic;O;O
responses;O;O
to;O;O
ACTH;B-group;B-DDI-MedLine.d2.s3.e1
in;O;O
sheep;O;O
.;O;O
DDI-MedLine.d66.s0;;
Changes;O;O
in;O;O
urinary;O;O
homocysteine;O;O
following;O;O
synthetic;B-group;B-DDI-MedLine.d66.s0.e1
steroidal;I-group;I-DDI-MedLine.d66.s0.e1
estrogen;I-group;I-DDI-MedLine.d66.s0.e1
and;I-group;I-DDI-MedLine.d66.s0.e1
progestogen;I-group;I-DDI-MedLine.d66.s0.e1
administration;O;O
to;O;O
rats;O;O
.;O;O
DDI-MedLine.d66.s1;;
The;O;O
present;O;O
work;O;O
involved;O;O
the;O;O
administration;O;O
of;O;O
both;O;O
ethynyl;B-drug;B-DDI-MedLine.d66.s1.e0
estradiol;I-drug;I-DDI-MedLine.d66.s1.e0
and;O;O
levonorgestrel;B-drug;B-DDI-MedLine.d66.s1.e1
to;O;O
groups;O;O
of;O;O
rats;O;O
,;O;O
followed;O;O
by;O;O
determination;O;O
of;O;O
the;O;O
homocysteine;O;O
excretion;O;O
rate;O;O
in;O;O
urine;O;O
.;O;O
DDI-MedLine.d66.s2;;
The;O;O
results;O;O
indicate;O;O
that;O;O
a;O;O
statistically;O;O
significant;O;O
difference;O;O
exists;O;O
between;O;O
the;O;O
excreted;O;O
levels;O;O
of;O;O
homocysteine;O;O
in;O;O
the;O;O
urine;O;O
of;O;O
both;O;O
control;O;O
and;O;O
levonorgestrel;B-drug;B-DDI-MedLine.d66.s2.e0
-;O;O
treated;O;O
rats;O;O
and;O;O
the;O;O
levels;O;O
shown;O;O
by;O;O
rats;O;O
treated;O;O
with;O;O
ethynyl;B-drug;B-DDI-MedLine.d66.s2.e1
estradiol;I-drug;I-DDI-MedLine.d66.s2.e1
.;O;O
DDI-MedLine.d66.s3;;
The;O;O
implications;O;O
of;O;O
these;O;O
results;O;O
are;O;O
discussed;O;O
,;O;O
especially;O;O
with;O;O
respect;O;O
to;O;O
observations;O;O
which;O;O
indicate;O;O
that;O;O
homocysteine;O;O
may;O;O
be;O;O
a;O;O
precipitating;O;O
factor;O;O
in;O;O
the;O;O
development;O;O
of;O;O
thrombosis;O;O
.;O;O
DDI-MedLine.d66.s4;;
Also;O;O
included;O;O
in;O;O
this;O;O
paper;O;O
is;O;O
a;O;O
study;O;O
which;O;O
confirms;O;O
the;O;O
identity;O;O
of;O;O
the;O;O
HPLC;O;O
peak;O;O
as;O;O
being;O;O
homocysteine;O;O
by;O;O
forming;O;O
a;O;O
radioactive;O;O
derivative;O;O
of;O;O
this;O;O
particular;O;O
sulphydryl;O;O
-;O;O
containing;O;O
amino;O;O
acid;O;O
,;O;O
and;O;O
then;O;O
analysing;O;O
the;O;O
resulting;O;O
mixture;O;O
by;O;O
TLC;O;O
.;O;O
DDI-MedLine.d93.s0;;
Altered;O;O
responsiveness;O;O
to;O;O
alcohol;B-drug;B-DDI-MedLine.d93.s0.e0
after;O;O
exposure;O;O
to;O;O
organic;O;O
lead;O;O
.;O;O

;O;O
DDI-MedLine.d93.s1;;
Ethyl;B-drug;B-DDI-MedLine.d93.s1.e0
alcohol;I-drug;I-DDI-MedLine.d93.s1.e0
is;O;O
known;O;O
to;O;O
effect;O;O
the;O;O
functional;O;O
integrity;O;O
of;O;O
the;O;O
limbic;O;O
system;O;O
,;O;O
particularly;O;O
the;O;O
hippocampus;O;O
,;O;O
and;O;O
to;O;O
alter;O;O
behaviors;O;O
which;O;O
are;O;O
thought;O;O
to;O;O
be;O;O
mediated;O;O
through;O;O
limbic;O;O
function;O;O
.;O;O
DDI-MedLine.d93.s2;;
Organometals;O;O
also;O;O
compromise;O;O
the;O;O
limbic;O;O
system;O;O
and;O;O
result;O;O
in;O;O
deficits;O;O
in;O;O
learning;O;O
and;O;O
memory;O;O
.;O;O
DDI-MedLine.d93.s3;;
Since;O;O
both;O;O
alcohol;B-drug;B-DDI-MedLine.d93.s3.e0
and;O;O
organoleads;O;O
are;O;O
present;O;O
in;O;O
the;O;O
environment;O;O
and;O;O
seem;O;O
to;O;O
influence;O;O
limbic;O;O
integration;O;O
,;O;O
the;O;O
interaction;O;O
of;O;O
these;O;O
two;O;O
compounds;O;O
was;O;O
assessed;O;O
in;O;O
the;O;O
present;O;O
experiment;O;O
.;O;O
DDI-MedLine.d93.s4;;
Thirty;O;O
male;O;O
rats;O;O
of;O;O
the;O;O
Fischer;O;O
-;O;O
344;O;O
strain;O;O
were;O;O
divided;O;O
into;O;O
three;O;O
equal;O;O
groups;O;O
and;O;O
were;O;O
given;O;O
injections;O;O
of;O;O
trimethyl;B-drug_n;B-DDI-MedLine.d93.s4.e0
lead;I-drug_n;I-DDI-MedLine.d93.s4.e0
(;O;O
TML;B-drug_n;B-DDI-MedLine.d93.s4.e1
);O;O
(;O;O
8.0;O;O
or;O;O
17.0;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
ml;O;O
SC;O;O
);O;O
or;O;O
the;O;O
saline;O;O
vehicle;O;O
.;O;O
DDI-MedLine.d93.s5;;
Fourteen;O;O
days;O;O
later;O;O
,;O;O
all;O;O
animals;O;O
were;O;O
challenged;O;O
with;O;O
a;O;O
single;O;O
hypnotic;O;O
dose;O;O
of;O;O
ethanol;B-drug;B-DDI-MedLine.d93.s5.e0
(;O;O
3.5;O;O
g;O;O
/;O;O
kg;O;O
IP;O;O
);O;O
.;O;O
DDI-MedLine.d93.s6;;
The;O;O
20;O;O
%;O;O
v;O;O
/;O;O
v;O;O
solution;O;O
of;O;O
alcohol;B-drug;B-DDI-MedLine.d93.s6.e0
was;O;O
prepared;O;O
in;O;O
water;O;O
from;O;O
a;O;O
stock;O;O
solution;O;O
of;O;O
95;O;O
%;O;O
ethanol;B-drug;B-DDI-MedLine.d93.s6.e1
.;O;O
DDI-MedLine.d93.s7;;
The;O;O
latency;O;O
to;O;O
loss;O;O
of;O;O
the;O;O
righting;O;O
reflex;O;O
and;O;O
duration;O;O
of;O;O
sleep;O;O
time;O;O
were;O;O
recorded;O;O
while;O;O
the;O;O
rats;O;O
were;O;O
kept;O;O
in;O;O
sound;O;O
-;O;O
attenuating;O;O
chambers;O;O
.;O;O
DDI-MedLine.d93.s8;;
The;O;O
rats;O;O
treated;O;O
with;O;O
the;O;O
highest;O;O
dose;O;O
of;O;O
TML;B-drug_n;B-DDI-MedLine.d93.s8.e0
manifested;O;O
significantly;O;O
longer;O;O
latencies;O;O
to;O;O
lose;O;O
the;O;O
righting;O;O
reflex;O;O
and;O;O
shorter;O;O
durations;O;O
of;O;O
sleep;O;O
than;O;O
did;O;O
controls;O;O
.;O;O
DDI-MedLine.d93.s9;;
These;O;O
results;O;O
suggest;O;O
that;O;O
exposure;O;O
to;O;O
environmental;O;O
lead;B-drug_n;B-DDI-MedLine.d93.s9.e0
may;O;O
alter;O;O
the;O;O
biological;O;O
and;O;O
behavioral;O;O
responsiveness;O;O
of;O;O
an;O;O
animal;O;O
to;O;O
alcohol;B-drug;B-DDI-MedLine.d93.s9.e1
.;O;O
DDI-MedLine.d54.s0;;
Cholinergic;O;O
role;O;O
in;O;O
alcohol;B-drug;B-DDI-MedLine.d54.s0.e0
's;O;O
effects;O;O
on;O;O
evoked;O;O
potentials;O;O
in;O;O
visual;O;O
cortex;O;O
of;O;O
the;O;O
albino;O;O
rat;O;O
.;O;O
DDI-MedLine.d54.s1;;
Photic;O;O
evoked;O;O
potentials;O;O
were;O;O
recorded;O;O
from;O;O
the;O;O
visual;O;O
cortex;O;O
of;O;O
chronically;O;O
implanted;O;O
albino;O;O
rats;O;O
.;O;O
DDI-MedLine.d54.s2;;
Since;O;O
photic;O;O
evoked;O;O
potential;O;O
components;O;O
are;O;O
representations;O;O
of;O;O
neural;O;O
pathways;O;O
which;O;O
are;O;O
activated;O;O
during;O;O
photic;O;O
stimulation;O;O
,;O;O
study;O;O
of;O;O
the;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-MedLine.d54.s2.e0
on;O;O
these;O;O
components;O;O
may;O;O
help;O;O
to;O;O
trace;O;O
pathways;O;O
which;O;O
are;O;O
affected;O;O
by;O;O
alcohol;B-drug;B-DDI-MedLine.d54.s2.e1
.;O;O
DDI-MedLine.d54.s3;;
In;O;O
the;O;O
present;O;O
study;O;O
,;O;O
evoked;O;O
potentials;O;O
were;O;O
recorded;O;O
at;O;O
5;O;O
,;O;O
20;O;O
,;O;O
and;O;O
40;O;O
min;O;O
following;O;O
IP;O;O
injections;O;O
of;O;O
saline;O;O
,;O;O
ethanol;B-drug;B-DDI-MedLine.d54.s3.e0
(;O;O
2.0;O;O
g;O;O
/;O;O
kg;O;O
);O;O
,;O;O
physostigmine;B-drug;B-DDI-MedLine.d54.s3.e1
(;O;O
0.6;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
or;O;O
atropine;B-drug;B-DDI-MedLine.d54.s3.e2
(;O;O
15.0;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
on;O;O
separate;O;O
days;O;O
.;O;O
DDI-MedLine.d54.s4;;
Ethanol;B-drug;B-DDI-MedLine.d54.s4.e0
depressed;O;O
the;O;O
amplitudes;O;O
of;O;O
most;O;O
evoked;O;O
potential;O;O
components;O;O
in;O;O
comparison;O;O
to;O;O
saline;O;O
administration;O;O
.;O;O
DDI-MedLine.d54.s5;;
Component;O;O
P2;O;O
,;O;O
however;O;O
,;O;O
was;O;O
increased;O;O
in;O;O
amplitude;O;O
.;O;O
DDI-MedLine.d54.s6;;
Physostigmine;B-drug;B-DDI-MedLine.d54.s6.e0
briefly;O;O
reduced;O;O
the;O;O
amplitude;O;O
of;O;O
most;O;O
components;O;O
,;O;O
including;O;O
P2;O;O
.;O;O
DDI-MedLine.d54.s7;;
In;O;O
contrast;O;O
,;O;O
atropine;B-drug;B-DDI-MedLine.d54.s7.e0
increased;O;O
the;O;O
amplitudes;O;O
of;O;O
components;O;O
P1;O;O
and;O;O
P2;O;O
,;O;O
while;O;O
decreasing;O;O
components;O;O
N1;O;O
,;O;O
N2;O;O
and;O;O
N3;O;O
for;O;O
varying;O;O
durations;O;O
of;O;O
time;O;O
.;O;O
DDI-MedLine.d54.s8;;
Physostigmine;B-drug;B-DDI-MedLine.d54.s8.e0
pretreatment;O;O
augmented;O;O
the;O;O
depressant;O;O
effect;O;O
of;O;O
alcohol;B-drug;B-DDI-MedLine.d54.s8.e1
on;O;O
the;O;O
early;O;O
components;O;O
P1;O;O
and;O;O
N1;O;O
,;O;O
while;O;O
attenuating;O;O
alcohol;B-drug;B-DDI-MedLine.d54.s8.e2
's;O;O
influence;O;O
on;O;O
components;O;O
P2;O;O
and;O;O
P3;O;O
.;O;O
DDI-MedLine.d54.s9;;
Pretreatment;O;O
with;O;O
atropine;B-drug;B-DDI-MedLine.d54.s9.e0
likewise;O;O
further;O;O
reduced;O;O
the;O;O
amplitudes;O;O
of;O;O
components;O;O
P1;O;O
and;O;O
N1;O;O
,;O;O
and;O;O
produced;O;O
a;O;O
similar;O;O
effect;O;O
on;O;O
component;O;O
N3;O;O
.;O;O
DDI-MedLine.d54.s10;;
Atropine;B-drug;B-DDI-MedLine.d54.s10.e0
,;O;O
either;O;O
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
alcohol;B-drug;B-DDI-MedLine.d54.s10.e1
,;O;O
produced;O;O
approximately;O;O
the;O;O
same;O;O
degree;O;O
of;O;O
enhancement;O;O
of;O;O
component;O;O
P2;O;O
.;O;O
DDI-MedLine.d54.s11;;
In;O;O
comparison;O;O
to;O;O
saline;O;O
values;O;O
,;O;O
all;O;O
three;O;O
agents;O;O
produced;O;O
reliable;O;O
increases;O;O
in;O;O
peak;O;O
latency;O;O
for;O;O
most;O;O
of;O;O
the;O;O
components;O;O
,;O;O
with;O;O
only;O;O
N3;O;O
showing;O;O
no;O;O
effects;O;O
.;O;O
DDI-MedLine.d54.s12;;
The;O;O
amplitude;O;O
data;O;O
from;O;O
this;O;O
study;O;O
suggest;O;O
that;O;O
ethanol;B-drug;B-DDI-MedLine.d54.s12.e0
's;O;O
augmentation;O;O
of;O;O
component;O;O
P2;O;O
may;O;O
result;O;O
,;O;O
at;O;O
least;O;O
in;O;O
part;O;O
,;O;O
from;O;O
alterations;O;O
in;O;O
cholinergic;O;O
functions;O;O
.;O;O
DDI-MedLine.d81.s0;;
Hypothermia;O;O
as;O;O
an;O;O
index;O;O
of;O;O
the;O;O
disulfiram;B-drug;B-DDI-MedLine.d81.s0.e0
-;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s0.e1
reaction;O;O
in;O;O
the;O;O
rat;O;O
.;O;O
DDI-MedLine.d81.s1;;
Decreased;O;O
core;O;O
temperature;O;O
in;O;O
female;O;O
rats;O;O
was;O;O
investigated;O;O
as;O;O
one;O;O
possible;O;O
index;O;O
of;O;O
the;O;O
disulfiram;B-drug;B-DDI-MedLine.d81.s1.e0
-;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s1.e1
reaction;O;O
(;O;O
DER;O;O
);O;O
.;O;O
DDI-MedLine.d81.s2;;
Core;O;O
temperature;O;O
was;O;O
decreased;O;O
in;O;O
rats;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
manner;O;O
when;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s2.e0
was;O;O
administered;O;O
to;O;O
rats;O;O
treated;O;O
with;O;O
disulfiram;B-drug;B-DDI-MedLine.d81.s2.e1
8;O;O
hours;O;O
before;O;O
the;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s2.e2
challenge;O;O
.;O;O
DDI-MedLine.d81.s3;;
The;O;O
decrease;O;O
in;O;O
temperature;O;O
began;O;O
within;O;O
20;O;O
minutes;O;O
after;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s3.e0
administration;O;O
,;O;O
reaching;O;O
a;O;O
maximal;O;O
decrease;O;O
between;O;O
60;O;O
and;O;O
120;O;O
minutes;O;O
post;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s3.e1
.;O;O
DDI-MedLine.d81.s4;;
The;O;O
core;O;O
temperature;O;O
returned;O;O
to;O;O
normal;O;O
300;O;O
minutes;O;O
after;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s4.e0
.;O;O
DDI-MedLine.d81.s5;;
The;O;O
blood;O;O
pressure;O;O
(;O;O
carotid;O;O
cannulation;O;O
);O;O
decreased;O;O
along;O;O
with;O;O
the;O;O
core;O;O
temperature;O;O
.;O;O
DDI-MedLine.d81.s6;;
Maximal;O;O
hypotension;O;O
was;O;O
found;O;O
120;O;O
minutes;O;O
post;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s6.e0
,;O;O
and;O;O
returned;O;O
to;O;O
normal;O;O
300;O;O
minutes;O;O
after;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s6.e1
.;O;O
DDI-MedLine.d81.s7;;
Heart;O;O
rate;O;O
increased;O;O
initially;O;O
and;O;O
returned;O;O
to;O;O
normal;O;O
40;O;O
minutes;O;O
after;O;O
ethanol;B-drug;B-DDI-MedLine.d81.s7.e0
challenge;O;O
.;O;O
DDI-MedLine.d24.s0;;
Excretion;O;O
of;O;O
thioethers;O;O
in;O;O
urine;O;O
after;O;O
exposure;O;O
to;O;O
electrophilic;O;O
chemicals;O;O
.;O;O
DDI-MedLine.d24.s1;;
Electrophilic;O;O
agents;O;O
--;O;O
a;O;O
class;O;O
of;O;O
chemicals;O;O
that;O;O
includes;O;O
most;O;O
genotoxic;O;O
compounds;O;O
--;O;O
can;O;O
be;O;O
inactivated;O;O
by;O;O
reaction;O;O
with;O;O
glutathione;O;O
or;O;O
other;O;O
SH;O;O
-;O;O
bearing;O;O
molecules;O;O
.;O;O
DDI-MedLine.d24.s2;;
The;O;O
conjugates;O;O
so;O;O
formed;O;O
often;O;O
appear;O;O
in;O;O
the;O;O
urine;O;O
as;O;O
mercapturic;O;O
acids;O;O
or;O;O
other;O;O
thioether;O;O
products;O;O
.;O;O
DDI-MedLine.d24.s3;;
This;O;O
paper;O;O
critically;O;O
reviews;O;O
the;O;O
suitability;O;O
of;O;O
the;O;O
urinary;O;O
thioether;O;O
assay;O;O
as;O;O
a;O;O
method;O;O
for;O;O
the;O;O
detection;O;O
of;O;O
exposure;O;O
to;O;O
electrophilic;O;O
agents;O;O
or;O;O
their;O;O
precursors;O;O
.;O;O
DDI-MedLine.d24.s4;;
In;O;O
practice;O;O
,;O;O
the;O;O
greatest;O;O
value;O;O
of;O;O
the;O;O
thioether;O;O
assay;O;O
appears;O;O
to;O;O
lie;O;O
in;O;O
its;O;O
signal;O;O
function;O;O
.;O;O
DDI-MedLine.d24.s5;;
This;O;O
is;O;O
demonstrated;O;O
for;O;O
cigarette;O;O
smokers;O;O
and;O;O
industrial;O;O
workers;O;O
involved;O;O
in;O;O
chemical;O;O
waste;O;O
incineration;O;O
.;O;O
DDI-MedLine.d24.s6;;
Whenever;O;O
increased;O;O
thioether;O;O
excretion;O;O
is;O;O
observed;O;O
,;O;O
it;O;O
is;O;O
likely;O;O
to;O;O
be;O;O
due;O;O
to;O;O
exposure;O;O
to;O;O
one;O;O
or;O;O
more;O;O
suspect;O;O
compounds;O;O
.;O;O
DDI-MedLine.d24.s7;;
However;O;O
,;O;O
when;O;O
the;O;O
thioether;O;O
concentration;O;O
ranges;O;O
within;O;O
the;O;O
limits;O;O
of;O;O
the;O;O
normal;O;O
value;O;O
,;O;O
one;O;O
must;O;O
not;O;O
conclude;O;O
that;O;O
there;O;O
is;O;O
no;O;O
,;O;O
or;O;O
negligible;O;O
,;O;O
exposure;O;O
.;O;O
DDI-MedLine.d24.s8;;
More;O;O
specific;O;O
applications;O;O
of;O;O
the;O;O
assay;O;O
of;O;O
thio;O;O
compounds;O;O
in;O;O
urine;O;O
allow;O;O
development;O;O
of;O;O
selective;O;O
methods;O;O
that;O;O
may;O;O
be;O;O
useful;O;O
for;O;O
biological;O;O
monitoring;O;O
.;O;O
DDI-MedLine.d131.s0;;
Interaction;O;O
on;O;O
the;O;O
antinociceptive;O;O
effect;O;O
between;O;O
neurotensin;B-drug_n;B-DDI-MedLine.d131.s0.e0
and;O;O
enkephalins;B-drug_n;B-DDI-MedLine.d131.s0.e1
or;O;O
tuftsin;B-drug_n;B-DDI-MedLine.d131.s0.e2
.;O;O
DDI-MedLine.d131.s1;;
The;O;O
aim;O;O
of;O;O
this;O;O
paper;O;O
was;O;O
to;O;O
study;O;O
the;O;O
interaction;O;O
between;O;O
neurotensin;B-drug_n;B-DDI-MedLine.d131.s1.e0
and;O;O
both;O;O
enkephalins;B-drug_n;B-DDI-MedLine.d131.s1.e1
or;O;O
its;O;O
synthetic;O;O
analogue;O;O
D;B-drug_n;B-DDI-MedLine.d131.s1.e2
-;I-drug_n;I-DDI-MedLine.d131.s1.e2
Ala2;I-drug_n;I-DDI-MedLine.d131.s1.e2
-;I-drug_n;I-DDI-MedLine.d131.s1.e2
metenkephalinamide;I-drug_n;I-DDI-MedLine.d131.s1.e2
,;O;O
or;O;O
tuftsin;B-drug_n;B-DDI-MedLine.d131.s1.e3
,;O;O
on;O;O
the;O;O
antinonciceptive;O;O
effect;O;O
of;O;O
these;O;O
peptides;O;O
in;O;O
mice;O;O
after;O;O
intracisternal;O;O
injection;O;O
.;O;O
DDI-MedLine.d131.s2;;
Antinociception;O;O
was;O;O
measured;O;O
by;O;O
the;O;O
hot;O;O
-;O;O
plate;O;O
method;O;O
.;O;O
DDI-MedLine.d131.s3;;
It;O;O
was;O;O
shown;O;O
that;O;O
neurotensin;B-drug_n;B-DDI-MedLine.d131.s3.e0
antagonized;O;O
evidently;O;O
the;O;O
antinociceptive;O;O
effect;O;O
of;O;O
enkephalins;B-drug_n;B-DDI-MedLine.d131.s3.e1
and;O;O
their;O;O
analogue;O;O
.;O;O
DDI-MedLine.d131.s4;;
On;O;O
the;O;O
contrary;O;O
,;O;O
neurotensin;B-drug_n;B-DDI-MedLine.d131.s4.e0
and;O;O
tuftsin;B-drug_n;B-DDI-MedLine.d131.s4.e1
were;O;O
agonists;O;O
in;O;O
induction;O;O
of;O;O
analgesia;O;O
.;O;O
DDI-MedLine.d131.s5;;
It;O;O
is;O;O
concluded;O;O
that;O;O
neurotensin;B-drug_n;B-DDI-MedLine.d131.s5.e0
modulates;O;O
in;O;O
an;O;O
opposite;O;O
way;O;O
the;O;O
function;O;O
of;O;O
the;O;O
enkephalinergic;O;O
neurons;O;O
and;O;O
the;O;O
central;O;O
action;O;O
of;O;O
tuftsin;B-drug_n;B-DDI-MedLine.d131.s5.e1
.;O;O
DDI-MedLine.d71.s0;;
Drug;O;O
-;O;O
lab;O;O
interactions;O;O
:;O;O
implications;O;O
for;O;O
nutrition;O;O
support;O;O
.;O;O
DDI-MedLine.d71.s1;;
Acetylcysteine;B-drug;B-DDI-MedLine.d71.s1.e0
interference;O;O
with;O;O
urine;O;O
ketone;O;O
test;O;O
.;O;O
DDI-MedLine.d71.s2;;
It;O;O
is;O;O
important;O;O
that;O;O
health;O;O
care;O;O
professionals;O;O
be;O;O
aware;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
medications;O;O
to;O;O
interfere;O;O
with;O;O
clinical;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-MedLine.d71.s3;;
Medications;O;O
can;O;O
cause;O;O
in;O;O
vivo;O;O
effects;O;O
when;O;O
the;O;O
concentration;O;O
or;O;O
activity;O;O
of;O;O
the;O;O
analyte;O;O
is;O;O
altered;O;O
before;O;O
the;O;O
analysis;O;O
and;O;O
therefore;O;O
the;O;O
assay;O;O
result;O;O
is;O;O
true;O;O
and;O;O
accurate;O;O
.;O;O
DDI-MedLine.d71.s4;;
An;O;O
in;O;O
vitro;O;O
effect;O;O
occurs;O;O
when;O;O
the;O;O
medication;O;O
interferes;O;O
with;O;O
the;O;O
assay;O;O
,;O;O
and;O;O
the;O;O
result;O;O
is;O;O
erroneous;O;O
and;O;O
can;O;O
not;O;O
be;O;O
interpreted;O;O
.;O;O
DDI-MedLine.d71.s5;;
This;O;O
report;O;O
describes;O;O
a;O;O
recently;O;O
identified;O;O
case;O;O
of;O;O
interference;O;O
of;O;O
acetylcysteine;B-drug;B-DDI-MedLine.d71.s5.e0
with;O;O
the;O;O
urine;O;O
test;O;O
for;O;O
ketones;O;O
and;O;O
demonstrates;O;O
the;O;O
importance;O;O
of;O;O
a;O;O
thorough;O;O
medication;O;O
review;O;O
in;O;O
evaluating;O;O
abnormal;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-MedLine.d97.s0;;
[;O;O
2;O;O
epidemics;O;O
of;O;O
arsenical;O;O
encephalopathy;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
trypanosomiasis;O;O
,;O;O
Uganda;O;O
,;O;O
1992;O;O
-;O;O
1993;O;O
];O;O
Since;O;O
1988;O;O
,;O;O
the;O;O
french;O;O
non;O;O
-;O;O
governmental;O;O
organisation;O;O
M;O;O
decins;O;O
Sans;O;O
Fronti;O;O
res;O;O
is;O;O
running;O;O
a;O;O
control;O;O
program;O;O
of;O;O
human;O;O
african;O;O
trypanosomiasis;O;O
in;O;O
the;O;O
district;O;O
of;O;O
Moyo;O;O
,;O;O
North;O;O
-;O;O
Uganda;O;O
.;O;O
DDI-MedLine.d97.s1;;
Between;O;O
1988;O;O
and;O;O
1993;O;O
,;O;O
more;O;O
than;O;O
7,000;O;O
patients;O;O
were;O;O
diagnosed;O;O
and;O;O
treated;O;O
.;O;O
DDI-MedLine.d97.s2;;
Since;O;O
1988;O;O
,;O;O
it;O;O
has;O;O
been;O;O
noted;O;O
that;O;O
incidence;O;O
of;O;O
melarsoprol;B-drug;B-DDI-MedLine.d97.s2.e0
reaction;O;O
had;O;O
increased;O;O
systematically;O;O
between;O;O
June;O;O
and;O;O
October;O;O
of;O;O
each;O;O
year;O;O
,;O;O
indicating;O;O
strong;O;O
seasonal;O;O
variation;O;O
.;O;O
DDI-MedLine.d97.s3;;
In;O;O
1992;O;O
and;O;O
1993;O;O
,;O;O
two;O;O
outbreaks;O;O
of;O;O
arsenical;O;O
reactive;O;O
encephalopathy;O;O
(;O;O
ARE;O;O
);O;O
occurred;O;O
in;O;O
the;O;O
sleeping;O;O
sickness;O;O
center;O;O
of;O;O
Adjumani;O;O
.;O;O
DDI-MedLine.d97.s4;;
The;O;O
incidence;O;O
of;O;O
ARE;O;O
suddenly;O;O
exceeded;O;O
10;O;O
%;O;O
of;O;O
the;O;O
patients;O;O
treated;O;O
by;O;O
melarsoprol;B-drug;B-DDI-MedLine.d97.s4.e0
during;O;O
August;O;O
1992;O;O
and;O;O
September;O;O
1993;O;O
.;O;O
DDI-MedLine.d97.s5;;
The;O;O
onset;O;O
of;O;O
80;O;O
%;O;O
of;O;O
those;O;O
";O;O
epidemic;O;O
";O;O
DDI-MedLine.d97.s6;;
cases;O;O
,;O;O
occurred;O;O
between;O;O
the;O;O
5th;O;O
and;O;O
the;O;O
11th;O;O
day;O;O
of;O;O
treatment;O;O
.;O;O
DDI-MedLine.d97.s7;;
Two;O;O
retrospective;O;O
studies;O;O
were;O;O
conducted;O;O
in;O;O
1992;O;O
(;O;O
75;O;O
cases;O;O
);O;O
and;O;O
in;O;O
1993;O;O
(;O;O
51;O;O
cases;O;O
);O;O
.;O;O
DDI-MedLine.d97.s8;;
Among;O;O
the;O;O
risk;O;O
factors;O;O
studied;O;O
,;O;O
two;O;O
appear;O;O
to;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
ARE;O;O
:;O;O
the;O;O
prescription;O;O
of;O;O
thiabendazole;B-drug;B-DDI-MedLine.d97.s8.e0
to;O;O
treat;O;O
strongyloidiasis;O;O
during;O;O
the;O;O
melarsoprol;B-drug;B-DDI-MedLine.d97.s8.e1
cure;O;O
and;O;O
the;O;O
bad;O;O
general;O;O
clinical;O;O
conditions;O;O
of;O;O
patients;O;O
.;O;O
DDI-MedLine.d97.s9;;
These;O;O
observations;O;O
suggest;O;O
that;O;O
exogenous;O;O
co;O;O
-;O;O
factors;O;O
could;O;O
be;O;O
involved;O;O
in;O;O
the;O;O
occurrence;O;O
of;O;O
ARE;O;O
.;O;O
DDI-MedLine.d97.s10;;
Recommendations;O;O
were;O;O
to;O;O
avoid;O;O
administration;O;O
of;O;O
diffusible;O;O
anti;B-group;B-DDI-MedLine.d97.s10.e0
-;I-group;I-DDI-MedLine.d97.s10.e0
helminthic;I-group;I-DDI-MedLine.d97.s10.e0
treatment;O;O
during;O;O
the;O;O
cure;O;O
,;O;O
and;O;O
to;O;O
improve;O;O
the;O;O
general;O;O
conditions;O;O
of;O;O
patients;O;O
before;O;O
the;O;O
cure;O;O
of;O;O
melarsoprol;B-drug;B-DDI-MedLine.d97.s10.e1
.;O;O
DDI-MedLine.d34.s0;;
Interactions;O;O
of;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s0.e0
and;O;O
iron;B-drug;B-DDI-MedLine.d34.s0.e1
in;O;O
absorption;O;O
and;O;O
retention;O;O
.;O;O
DDI-MedLine.d34.s1;;
The;O;O
effects;O;O
of;O;O
supplementary;O;O
oral;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s1.e0
and;O;O
iron;B-drug;B-DDI-MedLine.d34.s1.e1
,;O;O
as;O;O
well;O;O
as;O;O
the;O;O
interaction;O;O
between;O;O
both;O;O
at;O;O
the;O;O
absorption;O;O
site;O;O
,;O;O
fecal;O;O
and;O;O
urinary;O;O
excretion;O;O
as;O;O
well;O;O
as;O;O
the;O;O
retention;O;O
of;O;O
these;O;O
trace;O;O
elements;O;O
were;O;O
determined;O;O
by;O;O
using;O;O
four;O;O
diets;O;O
containing;O;O
either;O;O
9;O;O
or;O;O
63;O;O
micrograms;O;O
/;O;O
kg;O;O
of;O;O
Co;B-drug;B-DDI-MedLine.d34.s1.e2
and;O;O
48;O;O
or;O;O
446;O;O
mg;O;O
/;O;O
kg;O;O
of;O;O
Fe;B-drug;B-DDI-MedLine.d34.s1.e3
over;O;O
a;O;O
period;O;O
of;O;O
19;O;O
days;O;O
in;O;O
a;O;O
total;O;O
of;O;O
24;O;O
rats;O;O
.;O;O
DDI-MedLine.d34.s2;;
Retention;O;O
was;O;O
calculated;O;O
by;O;O
the;O;O
balance;O;O
technique;O;O
and;O;O
by;O;O
the;O;O
comparative;O;O
slaughter;O;O
technique;O;O
.;O;O
DDI-MedLine.d34.s3;;
After;O;O
one;O;O
day;O;O
,;O;O
fecal;O;O
as;O;O
well;O;O
as;O;O
urinary;O;O
excretion;O;O
of;O;O
both;O;O
elements;O;O
had;O;O
already;O;O
responded;O;O
to;O;O
the;O;O
dietary;O;O
treatments;O;O
,;O;O
with;O;O
constant;O;O
values;O;O
being;O;O
reached;O;O
after;O;O
approximately;O;O
three;O;O
days;O;O
.;O;O
DDI-MedLine.d34.s4;;
Cobalt;B-drug;B-DDI-MedLine.d34.s4.e0
excretion;O;O
was;O;O
enhanced;O;O
by;O;O
supplementary;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s4.e1
,;O;O
DDI-MedLine.d34.s5;;
fecal;O;O
excretion;O;O
,;O;O
too;O;O
,;O;O
was;O;O
increased;O;O
by;O;O
supplementary;O;O
iron;B-drug;B-DDI-MedLine.d34.s5.e0
,;O;O
DDI-MedLine.d34.s6;;
whereas;O;O
urinary;O;O
excretion;O;O
was;O;O
decreased;O;O
in;O;O
both;O;O
cases;O;O
.;O;O
DDI-MedLine.d34.s7;;
Additional;O;O
iron;B-drug;B-DDI-MedLine.d34.s7.e0
significantly;O;O
inhibited;O;O
the;O;O
absorption;O;O
of;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s7.e1
in;O;O
both;O;O
dietary;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s7.e2
treatments;O;O
.;O;O
DDI-MedLine.d34.s8;;
The;O;O
lower;O;O
rate;O;O
of;O;O
absorption;O;O
in;O;O
the;O;O
groups;O;O
receiving;O;O
446;O;O
mg;O;O
Fe;B-drug;B-DDI-MedLine.d34.s8.e0
instead;O;O
of;O;O
48;O;O
mg;O;O
of;O;O
Fe;B-drug;B-DDI-MedLine.d34.s8.e1
per;O;O
kg;O;O
diet;O;O
resulted;O;O
in;O;O
a;O;O
decreased;O;O
renal;O;O
excretion;O;O
of;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s8.e2
.;O;O
DDI-MedLine.d34.s9;;
Consequently;O;O
,;O;O
the;O;O
effect;O;O
of;O;O
iron;B-drug;B-DDI-MedLine.d34.s9.e0
on;O;O
the;O;O
retention;O;O
of;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s9.e1
was;O;O
lower;O;O
than;O;O
on;O;O
absorption;O;O
.;O;O
DDI-MedLine.d34.s10;;
This;O;O
suggests;O;O
that;O;O
interactions;O;O
between;O;O
the;O;O
two;O;O
elements;O;O
only;O;O
take;O;O
place;O;O
at;O;O
the;O;O
site;O;O
of;O;O
absorption;O;O
.;O;O
DDI-MedLine.d34.s11;;
Because;O;O
of;O;O
the;O;O
low;O;O
dietary;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s11.e0
concentration;O;O
as;O;O
compared;O;O
to;O;O
the;O;O
iron;B-drug;B-DDI-MedLine.d34.s11.e1
contents;O;O
of;O;O
the;O;O
diets;O;O
,;O;O
no;O;O
effect;O;O
of;O;O
cobalt;B-drug;B-DDI-MedLine.d34.s11.e2
on;O;O
iron;B-drug;B-DDI-MedLine.d34.s11.e3
absorption;O;O
and;O;O
excretion;O;O
occurred;O;O
.;O;O
DDI-MedLine.d34.s12;;
Differences;O;O
in;O;O
iron;B-drug;B-DDI-MedLine.d34.s12.e0
balance;O;O
were;O;O
only;O;O
observed;O;O
between;O;O
both;O;O
dietary;O;O
concentrations;O;O
,;O;O
showing;O;O
a;O;O
higher;O;O
absolute;O;O
but;O;O
a;O;O
lower;O;O
relative;O;O
absorption;O;O
as;O;O
well;O;O
as;O;O
retention;O;O
in;O;O
the;O;O
groups;O;O
fed;O;O
further;O;O
Fe.(ABSTRACT;B-drug;B-DDI-MedLine.d34.s12.e1
TRUNCATED;O;O
AT;O;O
250;O;O
WORDS;O;O
);O;O
DDI-MedLine.d39.s0;;
Effect;O;O
of;O;O
estradiol;B-drug;B-DDI-MedLine.d39.s0.e0
on;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s0.e1
-;O;O
induced;O;O
changes;O;O
in;O;O
steroid;O;O
hormone;O;O
levels;O;O
and;O;O
lethality;O;O
in;O;O
male;O;O
rats;O;O
.;O;O
DDI-MedLine.d39.s1;;
We;O;O
examined;O;O
the;O;O
effect;O;O
of;O;O
exogenous;O;O
estradiol;B-drug;B-DDI-MedLine.d39.s1.e0
on;O;O
the;O;O
changes;O;O
in;O;O
serum;O;O
steroid;O;O
hormone;O;O
levels;O;O
induced;O;O
by;O;O
a;O;O
nonlethal;O;O
dose;O;O
of;O;O
Escherichia;O;O
coli;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s1.e1
in;O;O
male;O;O
rats;O;O
and;O;O
the;O;O
deaths;O;O
due;O;O
to;O;O
nonlethal;O;O
and;O;O
lethal;O;O
doses;O;O
of;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s1.e2
.;O;O
DDI-MedLine.d39.s2;;
Injection;O;O
of;O;O
estradiol;B-drug;B-DDI-MedLine.d39.s2.e0
5;O;O
min;O;O
before;O;O
a;O;O
nonlethal;O;O
dose;O;O
of;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s2.e1
changed;O;O
the;O;O
serum;O;O
sex;O;O
steroid;O;O
hormone;O;O
response;O;O
of;O;O
male;O;O
rats;O;O
to;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s2.e2
.;O;O
DDI-MedLine.d39.s3;;
The;O;O
serum;O;O
estrogen;O;O
concentrations;O;O
of;O;O
estradiol;B-drug;B-DDI-MedLine.d39.s3.e0
+;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s3.e1
-;O;O
treated;O;O
rats;O;O
decreased;O;O
by;O;O
50;O;O
%;O;O
,;O;O
while;O;O
those;O;O
of;O;O
the;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s3.e2
-;O;O
treated;O;O
rats;O;O
increased;O;O
(;O;O
2;O;O
-;O;O
to;O;O
5;O;O
-;O;O
fold;O;O
);O;O
.;O;O
DDI-MedLine.d39.s4;;
The;O;O
serum;O;O
androgen;O;O
concentrations;O;O
of;O;O
estradiol;B-drug;B-DDI-MedLine.d39.s4.e0
+;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s4.e1
-;O;O
treated;O;O
rats;O;O
did;O;O
not;O;O
change;O;O
significantly;O;O
,;O;O
while;O;O
those;O;O
of;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s4.e2
-;O;O
treated;O;O
rats;O;O
dropped;O;O
to;O;O
30;O;O
-;O;O
40;O;O
%;O;O
DDI-MedLine.d39.s5;;
0.001;O;O
.;O;O
DDI-MedLine.d39.s6;;
Exogenous;O;O
estradiol;B-drug;B-DDI-MedLine.d39.s6.e0
also;O;O
appeared;O;O
to;O;O
influence;O;O
the;O;O
percentage;O;O
of;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s6.e1
-;O;O
induced;O;O
deaths;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
manner;O;O
.;O;O
DDI-MedLine.d39.s7;;
It;O;O
reduced;O;O
the;O;O
number;O;O
of;O;O
deaths;O;O
induced;O;O
by;O;O
nonlethal;O;O
(;O;O
2;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
dose;O;O
of;O;O
endotoxin;B-drug_n;B-DDI-MedLine.d39.s7.e0
but;O;O
increased;O;O
the;O;O
number;O;O
of;O;O
deaths;O;O
induced;O;O
by;O;O
a;O;O
highly;O;O
lethal;O;O
dose;O;O
(;O;O
8;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
.;O;O
DDI-MedLine.d39.s8;;
These;O;O
results;O;O
,;O;O
together;O;O
with;O;O
the;O;O
known;O;O
relationships;O;O
between;O;O
estrogen;B-group;B-DDI-MedLine.d39.s8.e0
and;O;O
the;O;O
immune;O;O
response;O;O
,;O;O
suggest;O;O
that;O;O
estrogens;B-group;B-DDI-MedLine.d39.s8.e1
affect;O;O
the;O;O
course;O;O
of;O;O
septic;O;O
shock;O;O
in;O;O
a;O;O
complex;O;O
fashion;O;O
and;O;O
may;O;O
have;O;O
either;O;O
protective;O;O
or;O;O
deleterious;O;O
effect;O;O
.;O;O
DDI-MedLine.d128.s0;;
Analysis;O;O
of;O;O
16,16;B-drug_n;B-DDI-MedLine.d128.s0.e0
-;I-drug_n;I-DDI-MedLine.d128.s0.e0
dimethylprostaglandin;I-drug_n;I-DDI-MedLine.d128.s0.e0
E2;I-drug_n;I-DDI-MedLine.d128.s0.e0
-;O;O
induced;O;O
diarrhea;O;O
in;O;O
cecectomized;O;O
rats;O;O
.;O;O
DDI-MedLine.d128.s1;;
The;O;O
16,16;B-drug_n;B-DDI-MedLine.d128.s1.e0
-;I-drug_n;I-DDI-MedLine.d128.s1.e0
dimethylprostaglandin;I-drug_n;I-DDI-MedLine.d128.s1.e0
E2;I-drug_n;I-DDI-MedLine.d128.s1.e0
(;O;O
dmPGE2);B-drug_n;B-DDI-MedLine.d128.s1.e1
-;O;O
induced;O;O
diarrhea;O;O
was;O;O
analyzed;O;O
in;O;O
cecectomized;O;O
rats;O;O
prepared;O;O
by;O;O
resecting;O;O
the;O;O
cecum;O;O
and;O;O
its;O;O
vasculature;O;O
without;O;O
disturbing;O;O
the;O;O
ileocecal;O;O
junction;O;O
.;O;O
DDI-MedLine.d128.s2;;
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s2.e0
(;O;O
0.1;O;O
-;O;O
1.0;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
p.o;O;O
.;O;O
);O;O
DDI-MedLine.d128.s3;;
dose;O;O
-;O;O
dependently;O;O
increased;O;O
the;O;O
number;O;O
of;O;O
defecation;O;O
episodes;O;O
and;O;O
induced;O;O
a;O;O
soft;O;O
and;O;O
watery;O;O
stool;O;O
in;O;O
cecectomized;O;O
rats;O;O
.;O;O
DDI-MedLine.d128.s4;;
At;O;O
0.3;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
the;O;O
diarrhea;O;O
-;O;O
inducing;O;O
effects;O;O
of;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s4.e0
were;O;O
more;O;O
pronounced;O;O
in;O;O
cecectomized;O;O
than;O;O
in;O;O
control;O;O
rats;O;O
.;O;O
DDI-MedLine.d128.s5;;
When;O;O
given;O;O
i.p;O;O
.;O;O
,;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s5.e0
(;O;O
0.3;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
induced;O;O
a;O;O
watery;O;O
stool;O;O
in;O;O
cecectomized;O;O
and;O;O
control;O;O
rats;O;O
with;O;O
the;O;O
same;O;O
efficacy;O;O
,;O;O
although;O;O
these;O;O
effects;O;O
were;O;O
short;O;O
-;O;O
lasting;O;O
as;O;O
compared;O;O
to;O;O
oral;O;O
administration;O;O
.;O;O
DDI-MedLine.d128.s6;;
Castor;B-drug;B-DDI-MedLine.d128.s6.e0
oil;I-drug;I-DDI-MedLine.d128.s6.e0
(;O;O
4;O;O
ml;O;O
/;O;O
kg;O;O
,;O;O
p.o;O;O
.;O;O
);O;O
DDI-MedLine.d128.s7;;
also;O;O
induced;O;O
diarrhea;O;O
,;O;O
but;O;O
did;O;O
not;O;O
produce;O;O
a;O;O
watery;O;O
stool;O;O
in;O;O
cecectomized;O;O
rats;O;O
.;O;O
DDI-MedLine.d128.s8;;
There;O;O
were;O;O
no;O;O
differences;O;O
between;O;O
cecectomized;O;O
and;O;O
control;O;O
rats;O;O
in;O;O
basal;O;O
small;O;O
intestinal;O;O
transits;O;O
or;O;O
in;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s8.e0
(;O;O
0.3;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
p.o.);O;O
-;O;O
induced;O;O
enhancements;O;O
.;O;O
DDI-MedLine.d128.s9;;
Moreover;O;O
,;O;O
the;O;O
basal;O;O
and;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s9.e0
-;O;O
induced;O;O
jejunal;O;O
net;O;O
fluid;O;O
transfers;O;O
were;O;O
the;O;O
same;O;O
in;O;O
cecectomized;O;O
and;O;O
in;O;O
control;O;O
rats;O;O
.;O;O
DDI-MedLine.d128.s10;;
On;O;O
the;O;O
other;O;O
hand;O;O
,;O;O
the;O;O
enhanced;O;O
secretion;O;O
of;O;O
colonic;O;O
fluid;O;O
by;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s10.e0
,;O;O
given;O;O
intraluminally;O;O
,;O;O
was;O;O
only;O;O
half;O;O
of;O;O
that;O;O
in;O;O
control;O;O
rats;O;O
,;O;O
whereas;O;O
the;O;O
colonic;O;O
transit;O;O
-;O;O
enhancing;O;O
effect;O;O
of;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s10.e1
in;O;O
cecectomized;O;O
rats;O;O
was;O;O
more;O;O
pronounced;O;O
than;O;O
in;O;O
control;O;O
rats;O;O
at;O;O
15;O;O
but;O;O
not;O;O
at;O;O
30;O;O
min;O;O
after;O;O
its;O;O
administration;O;O
.;O;O
DDI-MedLine.d128.s11;;
The;O;O
basal;O;O
colonic;O;O
fluid;O;O
contents;O;O
and;O;O
transits;O;O
were;O;O
the;O;O
same;O;O
in;O;O
cecectomized;O;O
and;O;O
in;O;O
control;O;O
rats;O;O
.;O;O
DDI-MedLine.d128.s12;;
Loperamide;B-drug;B-DDI-MedLine.d128.s12.e0
and;O;O
morphine;B-drug;B-DDI-MedLine.d128.s12.e1
(;O;O
0.1;O;O
and;O;O
1.0;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
s.c;O;O
.;O;O
);O;O
DDI-MedLine.d128.s13;;
Loperamide;B-drug;B-DDI-MedLine.d128.s13.e0
and;O;O
morphine;B-drug;B-DDI-MedLine.d128.s13.e1
(;O;O
0.1;O;O
and;O;O
1.0;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
s.c;O;O
.;O;O
);O;O
inhibited;O;O
the;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s13.e2
(;O;O
0.3;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
p.o.);O;O
-;O;O
induced;O;O
diarrhea;O;O
in;O;O
cecectomized;O;O
rats;O;O
.;O;O
DDI-MedLine.d128.s14;;
N;B-drug_n;B-DDI-MedLine.d128.s14.e0
-;I-drug_n;I-DDI-MedLine.d128.s14.e0
methyllevallorphan;I-drug_n;I-DDI-MedLine.d128.s14.e0
(;O;O
5;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
s.c;O;O
.;O;O
);O;O
DDI-MedLine.d128.s15;;
N;B-drug_n;B-DDI-MedLine.d128.s15.e0
-;I-drug_n;I-DDI-MedLine.d128.s15.e0
methyllevallorphan;I-drug_n;I-DDI-MedLine.d128.s15.e0
(;O;O
5;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
s.c;O;O
.;O;O
);O;O
completely;O;O
antagonized;O;O
the;O;O
inhibitory;O;O
effect;O;O
of;O;O
loperamide;B-drug;B-DDI-MedLine.d128.s15.e1
and;O;O
partly;O;O
antagonized;O;O
the;O;O
effect;O;O
of;O;O
morphine;B-drug;B-DDI-MedLine.d128.s15.e2
.;O;O
DDI-MedLine.d128.s16;;
These;O;O
results;O;O
suggest;O;O
that;O;O
oral;O;O
administration;O;O
of;O;O
dmPGE2;B-drug_n;B-DDI-MedLine.d128.s16.e0
induces;O;O
a;O;O
more;O;O
pronounced;O;O
secretory;O;O
diarrhea;O;O
in;O;O
cecectomized;O;O
than;O;O
in;O;O
control;O;O
rats;O;O
,;O;O
probably;O;O
due;O;O
to;O;O
the;O;O
lack;O;O
of;O;O
the;O;O
reservoir;O;O
function;O;O
of;O;O
the;O;O
cecum;O;O
in;O;O
the;O;O
operated;O;O
animals;O;O
.;O;O
DDI-MedLine.d128.s17;;
This;O;O
secretory;O;O
diarrhea;O;O
model;O;O
is;O;O
suitable;O;O
for;O;O
evaluating;O;O
the;O;O
antidiarrheal;O;O
activity;O;O
of;O;O
drugs;O;O
.;O;O
DDI-MedLine.d89.s0;;
Therapeutic;O;O
drug;O;O
monitoring;O;O
can;O;O
avoid;O;O
iatrogenic;O;O
alterations;O;O
caused;O;O
by;O;O
99mTc;B-drug;B-DDI-MedLine.d89.s0.e0
-;I-drug;I-DDI-MedLine.d89.s0.e0
methylene;I-drug;I-DDI-MedLine.d89.s0.e0
diphosphonate;I-drug;I-DDI-MedLine.d89.s0.e0
(;O;O
MDP);O;O
-;O;O
gentamicin;B-drug;B-DDI-MedLine.d89.s0.e1
interaction;O;O
.;O;O
DDI-MedLine.d89.s1;;
Gentamicin;B-drug;B-DDI-MedLine.d89.s1.e0
is;O;O
an;O;O
aminoglycoside;B-group;B-DDI-MedLine.d89.s1.e1
antibiotic;I-group;I-DDI-MedLine.d89.s1.e1
used;O;O
to;O;O
treat;O;O
a;O;O
wide;O;O
variety;O;O
of;O;O
infections;O;O
caused;O;O
by;O;O
gram;O;O
-;O;O
negative;O;O
organisms;O;O
,;O;O
but;O;O
it;O;O
is;O;O
potentially;O;O
toxic;O;O
to;O;O
the;O;O
kidneys;O;O
.;O;O
DDI-MedLine.d89.s2;;
Due;O;O
to;O;O
its;O;O
nephrotoxicity;O;O
,;O;O
gentamicin;B-drug;B-DDI-MedLine.d89.s2.e0
may;O;O
cause;O;O
abnormal;O;O
renal;O;O
uptake;O;O
to;O;O
be;O;O
seen;O;O
on;O;O
99mTc;B-drug;B-DDI-MedLine.d89.s2.e1
-;I-drug;I-DDI-MedLine.d89.s2.e1
MDP;I-drug;I-DDI-MedLine.d89.s2.e1
bone;O;O
scintigraphy;O;O
.;O;O
DDI-MedLine.d89.s3;;
The;O;O
presence;O;O
of;O;O
the;O;O
radiopharmaceutical;B-group;B-DDI-MedLine.d89.s3.e0
in;O;O
the;O;O
kidneys;O;O
,;O;O
along;O;O
with;O;O
an;O;O
increase;O;O
in;O;O
renal;O;O
retention;O;O
,;O;O
tend;O;O
to;O;O
produce;O;O
scintigraphic;O;O
results;O;O
that;O;O
falsely;O;O
identify;O;O
characteristics;O;O
related;O;O
to;O;O
diseases;O;O
such;O;O
as;O;O
renal;O;O
vascular;O;O
,;O;O
or;O;O
urinary;O;O
tract;O;O
obstruction;O;O
,;O;O
and;O;O
even;O;O
renal;O;O
cancer;O;O
.;O;O
DDI-MedLine.d89.s4;;
An;O;O
altered;O;O
biodistribution;O;O
may;O;O
provide;O;O
misleading;O;O
information;O;O
that;O;O
can;O;O
either;O;O
mask;O;O
or;O;O
mimic;O;O
certain;O;O
disease;O;O
symptoms;O;O
.;O;O
DDI-MedLine.d89.s5;;
A;O;O
method;O;O
to;O;O
maximize;O;O
the;O;O
therapeutic;O;O
benefit;O;O
of;O;O
gentamicin;B-drug;B-DDI-MedLine.d89.s5.e0
while;O;O
minimizing;O;O
the;O;O
risk;O;O
of;O;O
nephrotoxicity;O;O
and;O;O
the;O;O
appearance;O;O
of;O;O
a;O;O
hot;O;O
kidney;O;O
on;O;O
scintigraphy;O;O
is;O;O
desirable;O;O
.;O;O
DDI-MedLine.d89.s6;;
Serial;O;O
pharmacokinetic;O;O
dosing;O;O
has;O;O
been;O;O
proposed;O;O
as;O;O
a;O;O
method;O;O
to;O;O
accomplish;O;O
this;O;O
goal;O;O
.;O;O
DDI-MedLine.d89.s7;;
Therapeutic;O;O
drug;O;O
monitoring;O;O
(;O;O
TDM;O;O
);O;O
of;O;O
gentamicin;B-drug;B-DDI-MedLine.d89.s7.e0
therapy;O;O
,;O;O
and;O;O
bone;O;O
scintigraphy;O;O
employing;O;O
99mTc;B-drug;B-DDI-MedLine.d89.s7.e1
-;I-drug;I-DDI-MedLine.d89.s7.e1
MDP;I-drug;I-DDI-MedLine.d89.s7.e1
as;O;O
the;O;O
radiopharmaceutical;B-group;B-DDI-MedLine.d89.s7.e2
was;O;O
carried;O;O
out;O;O
in;O;O
22;O;O
patients;O;O
.;O;O
DDI-MedLine.d89.s8;;
The;O;O
data;O;O
presented;O;O
here;O;O
demonstrate;O;O
that;O;O
with;O;O
serial;O;O
pharmacokinetic;O;O
dosing;O;O
of;O;O
gentamicin;B-drug;B-DDI-MedLine.d89.s8.e0
,;O;O
the;O;O
iatrogenic;O;O
alteration;O;O
caused;O;O
by;O;O
gentamicin;B-drug;B-DDI-MedLine.d89.s8.e1
therapy;O;O
can;O;O
be;O;O
avoided;O;O
.;O;O
DDI-MedLine.d11.s0;;
Immunosuppressive;B-group;B-DDI-MedLine.d11.s0.e0
drugs;I-group;I-DDI-MedLine.d11.s0.e0
and;O;O
their;O;O
complications;O;O
.;O;O
DDI-MedLine.d11.s1;;
Drugs;O;O
that;O;O
suppress;O;O
the;O;O
immune;O;O
system;O;O
are;O;O
widely;O;O
used;O;O
.;O;O
DDI-MedLine.d11.s2;;
They;O;O
are;O;O
part;O;O
of;O;O
the;O;O
treatment;O;O
of;O;O
patients;O;O
with;O;O
organ;O;O
transplants;O;O
,;O;O
malignancy;O;O
,;O;O
and;O;O
increasingly;O;O
those;O;O
with;O;O
conditions;O;O
such;O;O
as;O;O
psoriasis;O;O
,;O;O
rheumatoid;O;O
arthritis;O;O
,;O;O
and;O;O
liver;O;O
and;O;O
bowel;O;O
disease;O;O
in;O;O
which;O;O
inflammation;O;O
is;O;O
an;O;O
aetiological;O;O
factor;O;O
.;O;O
DDI-MedLine.d11.s3;;
Because;O;O
of;O;O
the;O;O
broadening;O;O
indications;O;O
for;O;O
immunosuppressive;B-group;B-DDI-MedLine.d11.s3.e0
drugs;I-group;I-DDI-MedLine.d11.s3.e0
,;O;O
and;O;O
the;O;O
prolonged;O;O
survival;O;O
in;O;O
conditions;O;O
for;O;O
which;O;O
they;O;O
are;O;O
being;O;O
used;O;O
,;O;O
many;O;O
patients;O;O
on;O;O
immunosuppression;O;O
are;O;O
now;O;O
cared;O;O
for;O;O
in;O;O
the;O;O
community;O;O
or;O;O
seen;O;O
in;O;O
non;O;O
-;O;O
specialist;O;O
hospitals;O;O
,;O;O
usually;O;O
in;O;O
close;O;O
collaboration;O;O
with;O;O
a;O;O
specialist;O;O
.;O;O
DDI-MedLine.d11.s4;;
This;O;O
article;O;O
looks;O;O
at;O;O
five;O;O
commonly;O;O
used;O;O
immunosuppressive;B-group;B-DDI-MedLine.d11.s4.e0
drugs;I-group;I-DDI-MedLine.d11.s4.e0
in;O;O
turn;O;O
(;O;O
corticosteroids;B-group;B-DDI-MedLine.d11.s4.e1
,;O;O
cyclosporin;B-drug;B-DDI-MedLine.d11.s4.e2
,;O;O
azathioprine;B-drug;B-DDI-MedLine.d11.s4.e3
,;O;O
methotrexate;B-drug;B-DDI-MedLine.d11.s4.e4
,;O;O
cyclophosphamide;B-drug;B-DDI-MedLine.d11.s4.e5
);O;O
,;O;O
discussing;O;O
the;O;O
main;O;O
,;O;O
non;O;O
-;O;O
infection;O;O
,;O;O
unwanted;O;O
effects;O;O
,;O;O
ways;O;O
to;O;O
avoid;O;O
them;O;O
and;O;O
what;O;O
to;O;O
do;O;O
if;O;O
problems;O;O
arise;O;O
.;O;O
DDI-MedLine.d11.s5;;
The;O;O
management;O;O
of;O;O
infection;O;O
is;O;O
dealt;O;O
with;O;O
as;O;O
a;O;O
separate;O;O
section;O;O
.;O;O
DDI-MedLine.d107.s0;;
Interaction;O;O
of;O;O
the;O;O
constituents;O;O
of;O;O
alcoholic;O;O
beverages;O;O
in;O;O
the;O;O
promotion;O;O
of;O;O
liver;O;O
damage;O;O
.;O;O
DDI-MedLine.d107.s1;;
Little;O;O
has;O;O
been;O;O
studied;O;O
of;O;O
the;O;O
adverse;O;O
effects;O;O
of;O;O
the;O;O
exposure;O;O
of;O;O
the;O;O
liver;O;O
to;O;O
the;O;O
interaction;O;O
of;O;O
ethanol;B-drug;B-DDI-MedLine.d107.s1.e0
with;O;O
its;O;O
congeners;O;O
and;O;O
acetaldehyde;B-drug_n;B-DDI-MedLine.d107.s1.e1
,;O;O
coexisting;O;O
in;O;O
the;O;O
contents;O;O
of;O;O
alcoholic;O;O
beverages;O;O
.;O;O
DDI-MedLine.d107.s2;;
Twenty;O;O
four;O;O
male;O;O
Wistar;O;O
rats;O;O
were;O;O
divided;O;O
into;O;O
four;O;O
groups;O;O
.;O;O
DDI-MedLine.d107.s3;;
Two;O;O
groups;O;O
(;O;O
SH;O;O
/;O;O
DA;O;O
,;O;O
SH;O;O
/;O;O
FA;O;O
);O;O
were;O;O
submitted;O;O
to;O;O
daily;O;O
treatment;O;O
with;O;O
synthetic;O;O
hydroalcoholic;O;O
solutions;O;O
containing;O;O
ethanol;B-drug;B-DDI-MedLine.d107.s3.e0
,;O;O
methanol;B-drug_n;B-DDI-MedLine.d107.s3.e1
,;O;O
higher;O;O
alcohols;B-drug_n;B-DDI-MedLine.d107.s3.e2
and;O;O
acetaldehyde;B-drug_n;B-DDI-MedLine.d107.s3.e3
in;O;O
the;O;O
same;O;O
proportions;O;O
as;O;O
those;O;O
found;O;O
in;O;O
most;O;O
common;O;O
distilled;O;O
and;O;O
fermented;O;O
alcoholic;O;O
beverages;O;O
,;O;O
DDI-MedLine.d107.s4;;
the;O;O
third;O;O
group;O;O
(;O;O
SH;O;O
/;O;O
EA;O;O
);O;O
was;O;O
treated;O;O
with;O;O
a;O;O
hydroalcoholic;O;O
solution;O;O
of;O;O
ethanol;B-drug;B-DDI-MedLine.d107.s4.e0
,;O;O
DDI-MedLine.d107.s5;;
the;O;O
fourth;O;O
group;O;O
served;O;O
as;O;O
control;O;O
and;O;O
received;O;O
an;O;O
equivalent;O;O
volume;O;O
of;O;O
an;O;O
isocaloric;O;O
solution;O;O
of;O;O
dextrose;B-drug;B-DDI-MedLine.d107.s5.e0
.;O;O
DDI-MedLine.d107.s6;;
All;O;O
the;O;O
animals;O;O
were;O;O
killed;O;O
at;O;O
the;O;O
end;O;O
of;O;O
the;O;O
9th;O;O
week;O;O
of;O;O
the;O;O
experiment;O;O
.;O;O
DDI-MedLine.d107.s7;;
The;O;O
ratio;O;O
between;O;O
the;O;O
liver;O;O
weight;O;O
and;O;O
body;O;O
weight;O;O
was;O;O
found;O;O
to;O;O
be;O;O
lower;O;O
in;O;O
the;O;O
treated;O;O
animals;O;O
than;O;O
in;O;O
the;O;O
control;O;O
group;O;O
.;O;O
DDI-MedLine.d107.s8;;
The;O;O
histology;O;O
of;O;O
the;O;O
liver;O;O
was;O;O
altered;O;O
in;O;O
the;O;O
three;O;O
groups;O;O
which;O;O
were;O;O
submitted;O;O
to;O;O
treatment;O;O
with;O;O
the;O;O
hydroalcoholic;O;O
solutions;O;O
,;O;O
with;O;O
quantitative;O;O
and;O;O
qualitative;O;O
differences;O;O
between;O;O
the;O;O
groups;O;O
.;O;O
DDI-MedLine.d107.s9;;
These;O;O
results;O;O
suggest;O;O
that;O;O
the;O;O
hepatoxicity;O;O
of;O;O
ethanol;B-drug;B-DDI-MedLine.d107.s9.e0
in;O;O
alcoholic;O;O
beverages;O;O
is;O;O
enhanced;O;O
by;O;O
interaction;O;O
with;O;O
its;O;O
congeners;O;O
and;O;O
acetaldehyde;B-drug_n;B-DDI-MedLine.d107.s9.e1
,;O;O
DDI-MedLine.d107.s10;;
they;O;O
also;O;O
suggest;O;O
that;O;O
alcoholic;O;O
beverages;O;O
are;O;O
not;O;O
equivalent;O;O
in;O;O
their;O;O
potential;O;O
to;O;O
cause;O;O
liver;O;O
damage;O;O
.;O;O
DDI-MedLine.d53.s0;;
Induction;O;O
of;O;O
apoptosis;O;O
in;O;O
breast;O;O
cancer;O;O
cells;O;O
in;O;O
response;O;O
to;O;O
vitamin;B-group;B-DDI-MedLine.d53.s0.e0
D;I-group;I-DDI-MedLine.d53.s0.e0
and;O;O
antiestrogens;B-group;B-DDI-MedLine.d53.s0.e1
.;O;O
DDI-MedLine.d53.s1;;
1,25;O;O
-;O;O
Dihydroxycholecalciferol;O;O
D3;O;O
(;O;O
1,25(OH)2D3;B-drug;B-DDI-MedLine.d53.s1.e1
);O;O
,;O;O
the;O;O
active;O;O
metabolite;O;O
of;O;O
vitamin;B-group;B-DDI-MedLine.d53.s1.e2
D;I-group;I-DDI-MedLine.d53.s1.e2
,;O;O
is;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
breast;O;O
cancer;O;O
cell;O;O
growth;O;O
both;O;O
in;O;O
vivo;O;O
and;O;O
in;O;O
vitro;O;O
.;O;O
DDI-MedLine.d53.s2;;
We;O;O
have;O;O
shown;O;O
that;O;O
MCF;O;O
-;O;O
7;O;O
cells;O;O
treated;O;O
with;O;O
100;O;O
nM;O;O
1,25(OH)2D3;B-drug;B-DDI-MedLine.d53.s2.e0
exhibit;O;O
characteristic;O;O
apoptotic;O;O
morphology;O;O
(;O;O
pyknotic;O;O
nuclei;O;O
,;O;O
chromatin;O;O
and;O;O
cytoplasmic;O;O
condensation;O;O
,;O;O
nuclear;O;O
matrix;O;O
protein;O;O
reorganization;O;O
);O;O
within;O;O
48;O;O
h.;O;O
DDI-MedLine.d53.s3;;
In;O;O
the;O;O
experiments;O;O
reported;O;O
here;O;O
,;O;O
we;O;O
examined;O;O
the;O;O
interactions;O;O
between;O;O
1,25(OH)2D3;B-drug;B-DDI-MedLine.d53.s3.e0
and;O;O
the;O;O
antiestrogen;B-group;B-DDI-MedLine.d53.s3.e1
4;I-drug_n;I-DDI-MedLine.d53.s3.e2
-;I-drug_n;I-DDI-MedLine.d53.s3.e2
hydroxytamoxifen;I-drug_n;I-DDI-MedLine.d53.s3.e2
(;O;O
TAM;B-drug_n;B-DDI-MedLine.d53.s3.e3
);O;O
,;O;O
which;O;O
also;O;O
induces;O;O
apoptosis;O;O
in;O;O
MCF;O;O
-;O;O
7;O;O
cells;O;O
.;O;O
DDI-MedLine.d53.s4;;
Our;O;O
data;O;O
suggest;O;O
that;O;O
TAM;B-drug_n;B-DDI-MedLine.d53.s4.e0
significantly;O;O
potentiates;O;O
the;O;O
reduction;O;O
in;O;O
cell;O;O
number;O;O
induced;O;O
by;O;O
1,25(OH)2D3;B-drug;B-DDI-MedLine.d53.s4.e1
alone;O;O
.;O;O
DDI-MedLine.d53.s5;;
Combined;O;O
treatment;O;O
with;O;O
1,25(OH)2D3;B-drug;B-DDI-MedLine.d53.s5.e0
and;O;O
TAM;B-drug_n;B-DDI-MedLine.d53.s5.e1
enhances;O;O
the;O;O
degree;O;O
of;O;O
apoptosis;O;O
assessed;O;O
using;O;O
morphological;O;O
markers;O;O
that;O;O
identify;O;O
chromatin;O;O
and;O;O
nuclear;O;O
matrix;O;O
protein;O;O
condensation;O;O
.;O;O
DDI-MedLine.d53.s6;;
We;O;O
have;O;O
selected;O;O
a;O;O
subclone;O;O
of;O;O
MCF;O;O
-;O;O
7;O;O
cells;O;O
resistant;O;O
to;O;O
1,25(OH)2D3;B-drug;B-DDI-MedLine.d53.s6.e0
(;O;O
MCF;O;O
-;O;O
7D3Res;O;O
);O;O
.;O;O
DDI-MedLine.d53.s7;;
These;O;O
cells;O;O
express;O;O
the;O;O
vitamin;O;O
D;O;O
receptor;O;O
and;O;O
exhibit;O;O
doubling;O;O
times;O;O
comparable;O;O
to;O;O
the;O;O
parental;O;O
MCF;O;O
-;O;O
7;O;O
cells;O;O
,;O;O
even;O;O
when;O;O
grown;O;O
in;O;O
100;O;O
mM;O;O
1,25(OH)2D3;B-drug;B-DDI-MedLine.d53.s7.e0
.;O;O
DDI-MedLine.d53.s8;;
Treatment;O;O
of;O;O
both;O;O
parental;O;O
and;O;O
resistant;O;O
MCF;O;O
-;O;O
7;O;O
cells;O;O
with;O;O
TAM;B-drug_n;B-DDI-MedLine.d53.s8.e0
induces;O;O
apoptosis;O;O
and;O;O
clusterin;O;O
.;O;O
DDI-MedLine.d53.s9;;
These;O;O
data;O;O
emphasize;O;O
that;O;O
apoptosis;O;O
can;O;O
be;O;O
induced;O;O
in;O;O
MCF;O;O
-;O;O
7;O;O
cells;O;O
either;O;O
by;O;O
activation;O;O
of;O;O
vitamin;O;O
-;O;O
D;O;O
-;O;O
mediated;O;O
signalling;O;O
or;O;O
disruption;O;O
of;O;O
estrogen;B-group;B-DDI-MedLine.d53.s9.e1
-;O;O
dependent;O;O
signalling;O;O
.;O;O
DDI-MedLine.d6.s0;;
Pharmacokinetic;O;O
profile;O;O
of;O;O
etodolac;B-drug;B-DDI-MedLine.d6.s0.e0
in;O;O
special;O;O
populations;O;O
.;O;O

;O;O
DDI-MedLine.d6.s1;;
The;O;O
pharmacokinetics;O;O
of;O;O
etodolac;B-drug;B-DDI-MedLine.d6.s1.e0
in;O;O
healthy;O;O
normal;O;O
volunteers;O;O
has;O;O
been;O;O
extensively;O;O
studied;O;O
and;O;O
is;O;O
well;O;O
described;O;O
.;O;O
DDI-MedLine.d6.s2;;
Etodolac;B-drug;B-DDI-MedLine.d6.s2.e0
is;O;O
characterised;O;O
by;O;O
a;O;O
high;O;O
oral;O;O
bioavailability;O;O
,;O;O
low;O;O
clearance;O;O
,;O;O
a;O;O
small;O;O
volume;O;O
of;O;O
distribution;O;O
,;O;O
and;O;O
a;O;O
7;O;O
-;O;O
hour;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-MedLine.d6.s3;;
It;O;O
is;O;O
essentially;O;O
completely;O;O
metabolised;O;O
,;O;O
therefore;O;O
little;O;O
is;O;O
excreted;O;O
unchanged;O;O
.;O;O
DDI-MedLine.d6.s4;;
Etodolac;B-drug;B-DDI-MedLine.d6.s4.e0
is;O;O
highly;O;O
protein;O;O
bound;O;O
.;O;O
DDI-MedLine.d6.s5;;
To;O;O
investigate;O;O
the;O;O
effect;O;O
of;O;O
disease;O;O
states;O;O
or;O;O
concomitant;O;O
drug;O;O
administration;O;O
on;O;O
a;O;O
patient;O;O
's;O;O
response;O;O
to;O;O
etodolac;B-drug;B-DDI-MedLine.d6.s5.e0
,;O;O
additional;O;O
pharmacokinetic;O;O
studies;O;O
were;O;O
carried;O;O
out;O;O
in;O;O
special;O;O
populations;O;O
.;O;O
DDI-MedLine.d6.s6;;
Since;O;O
etodolac;B-drug;B-DDI-MedLine.d6.s6.e0
has;O;O
a;O;O
well;O;O
-;O;O
defined;O;O
pharmacokinetic;O;O
-;O;O
pharmacodynamic;O;O
relationship;O;O
,;O;O
measurement;O;O
of;O;O
pharmacokinetic;O;O
parameters;O;O
is;O;O
clinically;O;O
relevant;O;O
.;O;O
DDI-MedLine.d6.s7;;
Data;O;O
from;O;O
studies;O;O
to;O;O
date;O;O
show;O;O
that;O;O
disease;O;O
states;O;O
,;O;O
underlying;O;O
conditions;O;O
,;O;O
and;O;O
concomitantly;O;O
administered;O;O
highly;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
have;O;O
essentially;O;O
no;O;O
effect;O;O
on;O;O
etodolac;B-drug;B-DDI-MedLine.d6.s7.e0
pharmacokinetics;O;O
.;O;O
DDI-MedLine.d6.s8;;
Therefore;O;O
,;O;O
etodolac;B-drug;B-DDI-MedLine.d6.s8.e0
can;O;O
generally;O;O
be;O;O
given;O;O
without;O;O
the;O;O
need;O;O
for;O;O
dosage;O;O
modifications;O;O
in;O;O
special;O;O
populations;O;O
such;O;O
as;O;O
uncompromised;O;O
elderly;O;O
patients;O;O
,;O;O
those;O;O
with;O;O
moderate;O;O
renal;O;O
impairment;O;O
,;O;O
and;O;O
patients;O;O
with;O;O
stable;O;O
hepatic;O;O
disease;O;O
.;O;O
DDI-MedLine.d51.s0;;
Effects;O;O
of;O;O
xanthine;B-group;B-DDI-MedLine.d51.s0.e0
derivatives;I-group;I-DDI-MedLine.d51.s0.e0
in;O;O
a;O;O
light;O;O
/;O;O
dark;O;O
test;O;O
in;O;O
mice;O;O
and;O;O
the;O;O
contribution;O;O
of;O;O
adenosine;O;O
receptors;O;O
.;O;O
DDI-MedLine.d51.s1;;
We;O;O
investigated;O;O
the;O;O
effects;O;O
of;O;O
adenosine;O;O
receptor;O;O
antagonists;O;O
,;O;O
caffeine;B-drug;B-DDI-MedLine.d51.s1.e0
,;O;O
theophylline;B-drug;B-DDI-MedLine.d51.s1.e1
,;O;O
8;B-drug_n;B-DDI-MedLine.d51.s1.e2
-;I-drug_n;I-DDI-MedLine.d51.s1.e2
phenyltheophylline;I-drug_n;I-DDI-MedLine.d51.s1.e2
,;O;O
and;O;O
8;B-drug_n;B-DDI-MedLine.d51.s1.e3
-;I-drug_n;I-DDI-MedLine.d51.s1.e3
cyclopentyl;I-drug_n;I-DDI-MedLine.d51.s1.e3
-;I-drug_n;I-DDI-MedLine.d51.s1.e3
1,3;I-drug_n;I-DDI-MedLine.d51.s1.e3
-;I-drug_n;I-DDI-MedLine.d51.s1.e3
dipropylxanthine;I-drug_n;I-DDI-MedLine.d51.s1.e3
(;O;O
DPCPX;B-drug_n;B-DDI-MedLine.d51.s1.e4
);O;O
,;O;O
in;O;O
a;O;O
light;O;O
/;O;O
dark;O;O
test;O;O
in;O;O
mice;O;O
.;O;O
DDI-MedLine.d51.s2;;
All;O;O
antagonists;O;O
decreased;O;O
the;O;O
time;O;O
spent;O;O
in;O;O
the;O;O
light;O;O
zone;O;O
in;O;O
this;O;O
test;O;O
,;O;O
which;O;O
suggested;O;O
that;O;O
these;O;O
compounds;O;O
have;O;O
anxiogenic;O;O
effects;O;O
.;O;O
DDI-MedLine.d51.s3;;
The;O;O
anxiogenic;O;O
effects;O;O
of;O;O
theophylline;B-drug;B-DDI-MedLine.d51.s3.e0
were;O;O
reduced;O;O
by;O;O
pretreatment;O;O
with;O;O
CGS;B-drug_n;B-DDI-MedLine.d51.s3.e1
21680;I-drug_n;I-DDI-MedLine.d51.s3.e1
,;O;O
an;O;O
A2;O;O
-;O;O
selective;O;O
agonist;O;O
,;O;O
but;O;O
not;O;O
by;O;O
N6;B-drug_n;B-DDI-MedLine.d51.s3.e2
-;I-drug_n;I-DDI-MedLine.d51.s3.e2
cyclopentyladenosine;I-drug_n;I-DDI-MedLine.d51.s3.e2
(;O;O
CPA;B-drug_n;B-DDI-MedLine.d51.s3.e3
);O;O
,;O;O
an;O;O
A1;O;O
-;O;O
selective;O;O
agonist;O;O
.;O;O
DDI-MedLine.d51.s4;;
However;O;O
,;O;O
the;O;O
antagonism;O;O
of;O;O
the;O;O
theophylline;B-drug;B-DDI-MedLine.d51.s4.e0
-;O;O
induced;O;O
anxiogenic;O;O
effects;O;O
by;O;O
CGS21680;B-drug_n;B-DDI-MedLine.d51.s4.e1
was;O;O
only;O;O
observed;O;O
in;O;O
the;O;O
time;O;O
spent;O;O
in;O;O
the;O;O
light;O;O
zone;O;O
,;O;O
and;O;O
DPCPX;B-drug_n;B-DDI-MedLine.d51.s4.e2
-;O;O
induced;O;O
anxiogenic;O;O
effects;O;O
were;O;O
neither;O;O
reversed;O;O
by;O;O
CGS;B-drug;B-DDI-MedLine.d51.s4.e3
21680;I-drug;I-DDI-MedLine.d51.s4.e3
nor;O;O
by;O;O
CPA;B-drug_n;B-DDI-MedLine.d51.s4.e4
.;O;O
DDI-MedLine.d51.s5;;
Finally;O;O
,;O;O
it;O;O
is;O;O
notable;O;O
that;O;O
xanthine;O;O
-;O;O
derived;O;O
adenosine;O;O
antagonists;O;O
tested;O;O
here;O;O
commonly;O;O
showed;O;O
anxiogenic;O;O
effects;O;O
in;O;O
the;O;O
light;O;O
/;O;O
dark;O;O
test;O;O
in;O;O
mice;O;O
.;O;O
DDI-MedLine.d51.s6;;
It;O;O
is;O;O
suggested;O;O
that;O;O
there;O;O
is;O;O
a;O;O
minor;O;O
contribution;O;O
of;O;O
adenosine;O;O
receptors;O;O
to;O;O
these;O;O
effects;O;O
,;O;O
although;O;O
theophylline;B-drug;B-DDI-MedLine.d51.s6.e0
-;O;O
induced;O;O
anxiogenic;O;O
effects;O;O
were;O;O
antagonized;O;O
by;O;O
an;O;O
A2;O;O
receptor;O;O
agonist;O;O
.;O;O
DDI-MedLine.d4.s0;;
[;O;O
The;O;O
effect;O;O
of;O;O
sandimmune;B-brand;B-DDI-MedLine.d4.s0.e0
on;O;O
the;O;O
activity;O;O
of;O;O
mixed;O;O
-;O;O
function;O;O
mono;O;O
-;O;O
oxidases;O;O
in;O;O
the;O;O
liver;O;O
microsomes;O;O
];O;O
The;O;O
effects;O;O
of;O;O
the;O;O
immunodepressant;B-group;B-DDI-MedLine.d4.s0.e1
--;O;O
the;O;O
drug;O;O
sandimmune;B-brand;B-DDI-MedLine.d4.s0.e2
--;O;O
on;O;O
hepatic;O;O
microsomal;O;O
monooxygenase;O;O
activities;O;O
were;O;O
studied;O;O
.;O;O
DDI-MedLine.d4.s1;;
The;O;O
agent;O;O
was;O;O
found;O;O
to;O;O
produce;O;O
some;O;O
inhibiting;O;O
activity;O;O
against;O;O
hepatic;O;O
microsomal;O;O
7;O;O
-;O;O
ethoxycoumarine;O;O
deethylase;O;O
in;O;O
male;O;O
Wistar;O;O
rats;O;O
in;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
experiments;O;O
.;O;O
DDI-MedLine.d4.s2;;
When;O;O
given;O;O
in;O;O
a;O;O
dose;O;O
of;O;O
50;O;O
mg;O;O
/;O;O
kg;O;O
,;O;O
sandimmune;B-brand;B-DDI-MedLine.d4.s2.e0
produced;O;O
no;O;O
statistically;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
duration;O;O
of;O;O
hexanal;O;O
-;O;O
induced;O;O
sleep;O;O
in;O;O
mice;O;O
.;O;O
DDI-MedLine.d4.s3;;
The;O;O
findings;O;O
suggest;O;O
that;O;O
the;O;O
agent;O;O
has;O;O
slight;O;O
effects;O;O
on;O;O
the;O;O
tested;O;O
activities;O;O
.;O;O
DDI-MedLine.d68.s0;;
[;O;O
The;O;O
effect;O;O
of;O;O
cimetidine;B-drug;B-DDI-MedLine.d68.s0.e0
on;O;O
the;O;O
renal;O;O
excretion;O;O
of;O;O
verografin;B-drug;B-DDI-MedLine.d68.s0.e1
and;O;O
iodamide;B-drug;B-DDI-MedLine.d68.s0.e2
in;O;O
dogs;O;O
];O;O
The;O;O
intravenous;O;O
injection;O;O
of;O;O
cimetidine;B-drug;B-DDI-MedLine.d68.s0.e3
in;O;O
a;O;O
dose;O;O
of;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
enhanced;O;O
verografine;B-drug;B-DDI-MedLine.d68.s0.e4
and;O;O
iodamide;B-drug;B-DDI-MedLine.d68.s0.e5
excretion;O;O
in;O;O
chronic;O;O
canine;O;O
experiments;O;O
.;O;O
DDI-MedLine.d68.s1;;
The;O;O
higher;O;O
verografine;B-drug;B-DDI-MedLine.d68.s1.e0
and;O;O
iodamide;B-drug;B-DDI-MedLine.d68.s1.e1
excretion;O;O
was;O;O
due;O;O
to;O;O
their;O;O
increased;O;O
renal;O;O
tubular;O;O
secretion;O;O
.;O;O
DDI-MedLine.d68.s2;;
In;O;O
dogs;O;O
,;O;O
cimetidine;B-drug;B-DDI-MedLine.d68.s2.e0
unchanged;O;O
the;O;O
secretion;O;O
of;O;O
cardiotrast;B-drug;B-DDI-MedLine.d68.s2.e1
,;O;O
a;O;O
test;O;O
agent;O;O
for;O;O
anionic;O;O
transport;O;O
.;O;O
DDI-MedLine.d68.s3;;
Possible;O;O
extrarenal;O;O
mechanisms;O;O
of;O;O
action;O;O
of;O;O
cimetidine;B-drug;B-DDI-MedLine.d68.s3.e0
on;O;O
verografine;B-drug;B-DDI-MedLine.d68.s3.e1
and;O;O
iodamide;B-drug;B-DDI-MedLine.d68.s3.e2
transport;O;O
were;O;O
also;O;O
examined;O;O
.;O;O
DDI-MedLine.d121.s0;;
[;O;O
Hippocampus;O;O
as;O;O
interaction;O;O
sites;O;O
between;O;O
cerebral;O;O
memory;O;O
systems;O;O
];O;O

;O;O
Most;O;O
of;O;O
the;O;O
current;O;O
theories;O;O
assume;O;O
that;O;O
there;O;O
are;O;O
multiple;O;O
forms;O;O
of;O;O
memory;O;O
that;O;O
are;O;O
supported;O;O
by;O;O
separate;O;O
brain;O;O
systems;O;O
and;O;O
have;O;O
different;O;O
characteristics;O;O
.;O;O
DDI-MedLine.d121.s1;;
Animals;O;O
studies;O;O
on;O;O
the;O;O
various;O;O
dual;O;O
-;O;O
memory;O;O
theories;O;O
have;O;O
been;O;O
carried;O;O
out;O;O
mainly;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
hippocampal;O;O
system;O;O
function;O;O
.;O;O
DDI-MedLine.d121.s2;;
Specifically;O;O
,;O;O
they;O;O
have;O;O
focused;O;O
on;O;O
aspects;O;O
of;O;O
learning;O;O
and;O;O
memory;O;O
that;O;O
are;O;O
impaired;O;O
(;O;O
vs.;O;O
spared;O;O
);O;O
by;O;O
lesions;O;O
of;O;O
the;O;O
hippocampal;O;O
formation;O;O
.;O;O
DDI-MedLine.d121.s3;;
However;O;O
,;O;O
there;O;O
are;O;O
several;O;O
instances;O;O
in;O;O
the;O;O
animal;O;O
literature;O;O
showing;O;O
that;O;O
hippocampal;O;O
lesions;O;O
actually;O;O
produced;O;O
enhanced;O;O
learning;O;O
and;O;O
memory;O;O
function;O;O
.;O;O
DDI-MedLine.d121.s4;;
Moreover;O;O
,;O;O
the;O;O
acquisition;O;O
of;O;O
tasks;O;O
that;O;O
are;O;O
facilitated;O;O
by;O;O
hippocampal;O;O
lesions;O;O
(;O;O
or;O;O
dysfunction;O;O
);O;O
is;O;O
nevertheless;O;O
associated;O;O
,;O;O
in;O;O
intact;O;O
subjects;O;O
,;O;O
with;O;O
specific;O;O
neurobiological;O;O
alterations;O;O
in;O;O
the;O;O
hippocampus;O;O
.;O;O
DDI-MedLine.d121.s5;;
This;O;O
problem;O;O
has;O;O
been;O;O
analysed;O;O
using;O;O
two;O;O
different;O;O
tasks;O;O
in;O;O
mice;O;O
:;O;O
a;O;O
bar;O;O
-;O;O
press;O;O
conditioning;O;O
and;O;O
a;O;O
spatial;O;O
discrimination;O;O
task;O;O
.;O;O
DDI-MedLine.d121.s6;;
Results;O;O
showed;O;O
that;O;O
,;O;O
depending;O;O
on;O;O
the;O;O
task;O;O
considered;O;O
,;O;O
the;O;O
same;O;O
pharmacological;O;O
treatment;O;O
produced;O;O
either;O;O
a;O;O
facilitation;O;O
or;O;O
an;O;O
impairment;O;O
of;O;O
acquisition;O;O
.;O;O
DDI-MedLine.d121.s7;;
Moreover;O;O
,;O;O
each;O;O
task;O;O
induced;O;O
significant;O;O
alterations;O;O
in;O;O
hippocampal;O;O
adenylate;O;O
cyclase;O;O
activity;O;O
but;O;O
in;O;O
opposite;O;O
directions;O;O
.;O;O
DDI-MedLine.d121.s8;;
Together;O;O
with;O;O
previous;O;O
findings;O;O
,;O;O
these;O;O
results;O;O
suggest;O;O
that;O;O
the;O;O
hippocampus;O;O
is;O;O
involved;O;O
in;O;O
both;O;O
the;O;O
so;O;O
-;O;O
called;O;O
";O;O
hippocampal;O;O
-;O;O
dependent;O;O
";O;O
DDI-MedLine.d121.s9;;
";O;O
hippocampal;O;O
-;O;O
independent;O;O
";O;O
DDI-MedLine.d121.s10;;
forms;O;O
of;O;O
memory;O;O
.;O;O
DDI-MedLine.d121.s11;;
It;O;O
is;O;O
postulated;O;O
that;O;O
some;O;O
of;O;O
the;O;O
observed;O;O
training;O;O
-;O;O
induced;O;O
neurobiological;O;O
alterations;O;O
might;O;O
reflect;O;O
the;O;O
interaction;O;O
between;O;O
two;O;O
(;O;O
or;O;O
more;O;O
);O;O
competing;O;O
memory;O;O
systems;O;O
at;O;O
the;O;O
hippocampal;O;O
level;O;O
.;O;O
DDI-MedLine.d121.s12;;
Thus;O;O
,;O;O
in;O;O
addition;O;O
to;O;O
its;O;O
proposed;O;O
specific;O;O
information;O;O
processing;O;O
functions;O;O
(;O;O
i.e.;O;O
,;O;O
relational;O;O
);O;O
,;O;O
the;O;O
hippocampus;O;O
would;O;O
play;O;O
a;O;O
role;O;O
in;O;O
addressing;O;O
information;O;O
to;O;O
the;O;O
brain;O;O
memory;O;O
system;O;O
that;O;O
,;O;O
in;O;O
a;O;O
given;O;O
situation;O;O
,;O;O
has;O;O
the;O;O
best;O;O
adaptive;O;O
value.(ABSTRACT;O;O
TRUNCATED;O;O
AT;O;O
250;O;O
WORDS;O;O
);O;O
DDI-MedLine.d103.s0;;
Magnesium;B-drug;B-DDI-MedLine.d103.s0.e0
and;O;O
therapeutics;O;O
.;O;O
DDI-MedLine.d103.s1;;
Two;O;O
different;O;O
types;O;O
of;O;O
therapy;O;O
with;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s1.e0
are;O;O
used;O;O
:;O;O
physiological;O;O
oral;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s1.e1
supplementation;O;O
which;O;O
is;O;O
totally;O;O
atoxic;O;O
since;O;O
it;O;O
palliates;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s1.e2
deficiencies;O;O
by;O;O
simply;O;O
normalizing;O;O
the;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s1.e3
intake;O;O
and;O;O
pharmacological;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s1.e4
therapy;O;O
which;O;O
may;O;O
induce;O;O
toxicity;O;O
since;O;O
it;O;O
creates;O;O
iatrogenic;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s1.e5
overload;O;O
.;O;O
DDI-MedLine.d103.s2;;
Primary;O;O
and;O;O
secondary;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s2.e0
deficiencies;O;O
constitute;O;O
the;O;O
sole;O;O
indication;O;O
of;O;O
physiological;O;O
oral;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s2.e1
therapy;O;O
.;O;O
DDI-MedLine.d103.s3;;
It;O;O
is;O;O
therefore;O;O
necessary;O;O
to;O;O
be;O;O
well;O;O
acquainted;O;O
with;O;O
the;O;O
clinical;O;O
and;O;O
paraclinical;O;O
pattern;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s3.e0
deficit;O;O
and;O;O
to;O;O
discriminate;O;O
between;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s3.e1
deficiency;O;O
due;O;O
to;O;O
an;O;O
insufficient;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s3.e2
intake;O;O
which;O;O
only;O;O
requires;O;O
oral;O;O
physiological;O;O
supplementation;O;O
and;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s3.e3
depletion;O;O
related;O;O
to;O;O
a;O;O
dysregulation;O;O
of;O;O
the;O;O
control;O;O
mechanisms;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s3.e4
status;O;O
which;O;O
requires;O;O
more;O;O
or;O;O
less;O;O
specific;O;O
regulation;O;O
of;O;O
its;O;O
causal;O;O
dysregulation;O;O
.;O;O
DDI-MedLine.d103.s4;;
Physiological;O;O
oral;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s4.e0
load;O;O
constitutes;O;O
the;O;O
best;O;O
tool;O;O
for;O;O
diagnosis;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s4.e1
deficiency;O;O
and;O;O
the;O;O
first;O;O
step;O;O
of;O;O
its;O;O
treatment;O;O
.;O;O
DDI-MedLine.d103.s5;;
Physiological;O;O
oral;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s5.e0
supplementation;O;O
(;O;O
5;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
is;O;O
easy;O;O
and;O;O
can;O;O
be;O;O
carried;O;O
out;O;O
in;O;O
the;O;O
diet;O;O
or;O;O
with;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s5.e1
salts;I-drug;I-DDI-MedLine.d103.s5.e1
,;O;O
with;O;O
practically;O;O
only;O;O
one;O;O
contra;O;O
-;O;O
indication;O;O
:;O;O
overt;O;O
renal;O;O
failure;O;O
.;O;O
DDI-MedLine.d103.s6;;
Specific;O;O
and;O;O
aspecific;O;O
treatments;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s6.e0
depletion;O;O
are;O;O
tricky;O;O
using;O;O
for;O;O
example;O;O
magnesium;B-group;B-DDI-MedLine.d103.s6.e1
sparing;I-group;I-DDI-MedLine.d103.s6.e1
diuretics;I-group;I-DDI-MedLine.d103.s6.e1
,;O;O
pharmacological;O;O
doses;O;O
of;O;O
vitamin;B-drug;B-DDI-MedLine.d103.s6.e2
B6;I-drug;I-DDI-MedLine.d103.s6.e2
,;O;O
physiological;O;O
doses;O;O
of;O;O
vitamin;B-group;B-DDI-MedLine.d103.s6.e3
D;I-group;I-DDI-MedLine.d103.s6.e3
and;O;O
of;O;O
selenium;B-drug;B-DDI-MedLine.d103.s6.e4
.;O;O
DDI-MedLine.d103.s7;;
In;O;O
order;O;O
to;O;O
use;O;O
the;O;O
pharmacological;O;O
properties;O;O
of;O;O
induced;O;O
therapeutic;O;O
hypermagnesaemia;O;O
,;O;O
high;O;O
oral;O;O
doses;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s7.e0
(;O;O
>;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
are;O;O
advisable;O;O
for;O;O
chronic;O;O
indications;O;O
and;O;O
the;O;O
parenteral;O;O
route;O;O
is;O;O
suitable;O;O
for;O;O
acute;O;O
indications;O;O
.;O;O
DDI-MedLine.d103.s8;;
There;O;O
are;O;O
3;O;O
types;O;O
of;O;O
indications;O;O
:;O;O
specific;O;O
(;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
some;O;O
forms;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s8.e0
deficit;O;O
i.e.;O;O
acute;O;O
);O;O
,;O;O
pharmacological;O;O
(;O;O
i.e.;O;O
without;O;O
alterations;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s8.e1
status;O;O
);O;O
and;O;O
mixed;O;O
--;O;O
pharmacological;O;O
and;O;O
aetiopathogenic;O;O
-;O;O
-;O;O
(for;O;O
example;O;O
complications;O;O
of;O;O
chronic;O;O
alcoholism;O;O
);O;O
.;O;O
DDI-MedLine.d103.s9;;
Today;O;O
pharmacological;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s9.e0
therapy;O;O
mainly;O;O
concerns;O;O
the;O;O
obstetrical;O;O
,;O;O
cardiological;O;O
and;O;O
anaesthesiological;O;O
fields;O;O
.;O;O
DDI-MedLine.d103.s10;;
The;O;O
main;O;O
indications;O;O
are;O;O
eclampsia;O;O
,;O;O
some;O;O
dysrhythmias;O;O
(;O;O
torsades;O;O
de;O;O
pointe;O;O
particularly;O;O
);O;O
and;O;O
myocardial;O;O
ischaemias;O;O
.;O;O
DDI-MedLine.d103.s11;;
But;O;O
it;O;O
is;O;O
now;O;O
difficult;O;O
to;O;O
situate;O;O
the;O;O
exact;O;O
place;O;O
of;O;O
the;O;O
pharmacological;O;O
indications;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s11.e0
.;O;O
DDI-MedLine.d103.s12;;
Magnesium;B-drug;B-DDI-MedLine.d103.s12.e0
infusions;O;O
can;O;O
only;O;O
be;O;O
envisaged;O;O
in;O;O
intensive;O;O
care;O;O
units;O;O
with;O;O
careful;O;O
monitoring;O;O
of;O;O
pulse;O;O
,;O;O
arterial;O;O
pressure;O;O
,;O;O
deep;O;O
tendon;O;O
reflexes;O;O
,;O;O
hourly;O;O
diuresis;O;O
,;O;O
electrocardiogram;O;O
and;O;O
respiratory;O;O
recordings;O;O
.;O;O
DDI-MedLine.d103.s13;;
High;O;O
oral;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s13.e0
doses;O;O
besides;O;O
their;O;O
laxative;O;O
action;O;O
may;O;O
bring;O;O
latent;O;O
complications;O;O
which;O;O
may;O;O
reduce;O;O
lifespan;O;O
.;O;O
DDI-MedLine.d103.s14;;
There;O;O
may;O;O
remain;O;O
some;O;O
indications;O;O
of;O;O
the;O;O
laxative;O;O
and;O;O
antacid;O;O
properties;O;O
of;O;O
non;O;O
soluble;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s14.e0
,;O;O
particularly;O;O
during;O;O
intermittent;O;O
haemodialysis;O;O
.;O;O
DDI-MedLine.d103.s15;;
Lastly;O;O
local;O;O
use;O;O
of;O;O
the;O;O
mucocutaneous;O;O
and;O;O
cytoprotective;O;O
properties;O;O
of;O;O
magnesium;B-drug;B-DDI-MedLine.d103.s15.e0
is;O;O
still;O;O
valid;O;O
,;O;O
in;O;O
cardioplegic;B-drug;B-DDI-MedLine.d103.s15.e1
solutions;I-drug;I-DDI-MedLine.d103.s15.e1
and;O;O
for;O;O
preservation;O;O
of;O;O
transplants;O;O
particularly;O;O
.;O;O
DDI-MedLine.d20.s0;;
Interaction;O;O
between;O;O
glycine;B-drug;B-DDI-MedLine.d20.s0.e0
and;O;O
glutamate;B-drug;B-DDI-MedLine.d20.s0.e1
in;O;O
the;O;O
development;O;O
of;O;O
spontaneous;O;O
motility;O;O
in;O;O
chick;O;O
embryos;O;O
.;O;O

;O;O
DDI-MedLine.d20.s1;;
In;O;O
this;O;O
study;O;O
we;O;O
investigated;O;O
whether;O;O
also;O;O
glycine;B-drug;B-DDI-MedLine.d20.s1.e0
fulfils;O;O
the;O;O
function;O;O
as;O;O
co;O;O
-;O;O
activator;O;O
in;O;O
glutamatergic;O;O
activation;O;O
of;O;O
NMDA;O;O
receptors;O;O
in;O;O
the;O;O
neuronal;O;O
apparatus;O;O
of;O;O
spontaneous;O;O
motility;O;O
in;O;O
chick;O;O
embryos;O;O
.;O;O
DDI-MedLine.d20.s2;;
The;O;O
successive;O;O
application;O;O
of;O;O
glycine;B-drug;B-DDI-MedLine.d20.s2.e0
(;O;O
5;O;O
or;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
egg;O;O
weight;O;O
(;O;O
e.w;O;O
.;O;O
);O;O
DDI-MedLine.d20.s3;;
and;O;O
glutamate;B-drug;B-DDI-MedLine.d20.s3.e0
(;O;O
15;O;O
mg;O;O
/;O;O
kg;O;O
e.w;O;O
.;O;O
);O;O
DDI-MedLine.d20.s4;;
The;O;O
successive;O;O
application;O;O
of;O;O
glycine;B-drug;B-DDI-MedLine.d20.s4.e0
(;O;O
5;O;O
or;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
egg;O;O
weight;O;O
(;O;O
e.w;O;O
.;O;O
);O;O
and;O;O
glutamate;B-drug;B-DDI-MedLine.d20.s4.e1
(;O;O
15;O;O
mg;O;O
/;O;O
kg;O;O
e.w;O;O
.;O;O
);O;O
in;O;O
a;O;O
10;O;O
min;O;O
interval;O;O
significantly;O;O
increased;O;O
the;O;O
activation;O;O
of;O;O
spontaneous;O;O
motility;O;O
of;O;O
17;O;O
-;O;O
day;O;O
-;O;O
old;O;O
chick;O;O
embryos;O;O
in;O;O
comparison;O;O
with;O;O
the;O;O
effect;O;O
of;O;O
glutamate;B-drug;B-DDI-MedLine.d20.s4.e2
alone;O;O
.;O;O
DDI-MedLine.d20.s5;;
This;O;O
effect;O;O
did;O;O
not;O;O
depend;O;O
on;O;O
the;O;O
order;O;O
of;O;O
application;O;O
of;O;O
the;O;O
drugs;O;O
.;O;O
DDI-MedLine.d20.s6;;
In;O;O
13;O;O
-;O;O
day;O;O
-;O;O
old;O;O
embryos;O;O
,;O;O
glycine;B-drug;B-DDI-MedLine.d20.s6.e0
was;O;O
ineffective;O;O
in;O;O
both;O;O
doses;O;O
.;O;O
DDI-MedLine.d20.s7;;
It;O;O
is;O;O
concluded;O;O
from;O;O
these;O;O
results;O;O
that;O;O
the;O;O
modulatory;O;O
effect;O;O
of;O;O
glycine;B-drug;B-DDI-MedLine.d20.s7.e0
is;O;O
evidently;O;O
a;O;O
later;O;O
developmental;O;O
acquisition;O;O
(;O;O
after;O;O
day;O;O
15;O;O
of;O;O
incubation;O;O
);O;O
in;O;O
the;O;O
embryogenesis;O;O
of;O;O
NMDA;O;O
-;O;O
ergic;O;O
activation;O;O
of;O;O
spontaneous;O;O
motility;O;O
in;O;O
chick;O;O
embryos;O;O
similarly;O;O
as;O;O
glycinergic;O;O
inhibition;O;O
.;O;O
DDI-MedLine.d94.s0;;
Evidence;O;O
for;O;O
reduction;O;O
of;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s0.e0
uptake;O;O
sites;O;O
in;O;O
the;O;O
failing;O;O
human;O;O
heart;O;O
.;O;O
DDI-MedLine.d94.s1;;
OBJECTIVES;O;O
.;O;O
DDI-MedLine.d94.s2;;
This;O;O
study;O;O
investigated;O;O
the;O;O
role;O;O
of;O;O
neuronal;O;O
uptake;O;O
of;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s2.e0
(;O;O
uptake;O;O
-;O;O
1;O;O
);O;O
in;O;O
human;O;O
heart;O;O
failure;O;O
as;O;O
a;O;O
local;O;O
factor;O;O
for;O;O
altering;O;O
concentrations;O;O
of;O;O
norepinephrine;O;O
at;O;O
the;O;O
cardiac;O;O
myocyte;O;O
membranes;O;O
.;O;O
DDI-MedLine.d94.s3;;
BACKGROUND;O;O
.;O;O
DDI-MedLine.d94.s4;;
Several;O;O
beta;O;O
-;O;O
adrenergic;O;O
neuroeffector;O;O
defects;O;O
occur;O;O
in;O;O
heart;O;O
failure;O;O
.;O;O
DDI-MedLine.d94.s5;;
Whether;O;O
an;O;O
alteration;O;O
in;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s5.e0
uptake;O;O
-;O;O
1;O;O
occurs;O;O
is;O;O
still;O;O
unresolved;O;O
.;O;O
DDI-MedLine.d94.s6;;
METHODS;O;O
.;O;O
DDI-MedLine.d94.s7;;
The;O;O
role;O;O
of;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s7.e0
uptake;O;O
-;O;O
1;O;O
was;O;O
studied;O;O
in;O;O
electrically;O;O
stimulated;O;O
(;O;O
1;O;O
Hz;O;O
,;O;O
37;O;O
degrees;O;O
C;O;O
);O;O
human;O;O
ventricular;O;O
cardiac;O;O
preparations;O;O
and;O;O
isolated;O;O
myocardial;O;O
membranes;O;O
.;O;O
DDI-MedLine.d94.s8;;
RESULTS;O;O
.;O;O
DDI-MedLine.d94.s9;;
The;O;O
effectiveness;O;O
of;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s9.e0
in;O;O
increasing;O;O
the;O;O
force;O;O
of;O;O
contraction;O;O
was;O;O
decreased;O;O
in;O;O
relation;O;O
to;O;O
the;O;O
degree;O;O
of;O;O
heart;O;O
failure;O;O
.;O;O
DDI-MedLine.d94.s10;;
In;O;O
contrast;O;O
,;O;O
the;O;O
potency;O;O
of;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s10.e0
was;O;O
increased;O;O
in;O;O
failing;O;O
hearts;O;O
(;O;O
New;O;O
York;O;O
Heart;O;O
Association;O;O
functional;O;O
class;O;O
IV;O;O
);O;O
in;O;O
relation;O;O
to;O;O
the;O;O
concentrations;O;O
producing;O;O
50;O;O
%;O;O
of;O;O
the;O;O
maximal;O;O
effect;O;O
(;O;O
EC50;O;O
);O;O
.;O;O
DDI-MedLine.d94.s11;;
The;O;O
EC50;O;O
values;O;O
for;O;O
isoproterenol;B-drug;B-DDI-MedLine.d94.s11.e0
,;O;O
which;O;O
is;O;O
not;O;O
a;O;O
substrate;O;O
for;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s11.e1
uptake;O;O
-;O;O
1;O;O
,;O;O
were;O;O
reduced;O;O
in;O;O
myocardium;O;O
in;O;O
functional;O;O
classes;O;O
II;O;O
to;O;O
III;O;O
and;O;O
IV;O;O
compared;O;O
with;O;O
those;O;O
in;O;O
nonfailing;O;O
myocardium;O;O
.;O;O
DDI-MedLine.d94.s12;;
The;O;O
uptake;O;O
inhibitors;O;O
cocaine;B-drug;B-DDI-MedLine.d94.s12.e0
and;O;O
desipramine;B-drug;B-DDI-MedLine.d94.s12.e1
(;O;O
3;O;O
mumol;O;O
/;O;O
liter;O;O
);O;O
potentiated;O;O
the;O;O
positive;O;O
inotropic;O;O
effects;O;O
of;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s12.e2
in;O;O
nonfailing;O;O
myocardium;O;O
(;O;O
p;O;O
<;O;O
0.05;O;O
);O;O
but;O;O
not;O;O
in;O;O
functional;O;O
class;O;O
IV;O;O
myocardium;O;O
.;O;O
DDI-MedLine.d94.s13;;
Radioligand;O;O
binding;O;O
experiments;O;O
using;O;O
the;O;O
uptake;O;O
inhibitor;O;O
hydrogen;O;O
-;O;O
3;O;O
mazindol;B-drug;B-DDI-MedLine.d94.s13.e0
revealed;O;O
a;O;O
significant;O;O
decrease;O;O
by;O;O
approximately;O;O
30;O;O
%;O;O
in;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s13.e1
uptake;O;O
-;O;O
1;O;O
carrier;O;O
density;O;O
in;O;O
functional;O;O
classes;O;O
II;O;O
to;O;O
III;O;O
and;O;O
IV;O;O
myocardium;O;O
versus;O;O
nonfailing;O;O
myocardium;O;O
(;O;O
p;O;O
<;O;O
0.05;O;O
);O;O
.;O;O
DDI-MedLine.d94.s14;;
CONCLUSIONS;O;O
.;O;O
DDI-MedLine.d94.s15;;
In;O;O
human;O;O
heart;O;O
failure;O;O
,;O;O
there;O;O
is;O;O
a;O;O
presynaptic;O;O
defect;O;O
in;O;O
the;O;O
sympathetic;O;O
nervous;O;O
system;O;O
,;O;O
leading;O;O
to;O;O
reduced;O;O
uptake;O;O
-;O;O
1;O;O
activity;O;O
.;O;O
DDI-MedLine.d94.s16;;
This;O;O
defect;O;O
in;O;O
the;O;O
failing;O;O
heart;O;O
can;O;O
be;O;O
mimicked;O;O
by;O;O
the;O;O
effects;O;O
of;O;O
uptake;O;O
blocking;O;O
agents;O;O
,;O;O
such;O;O
as;O;O
cocaine;B-drug;B-DDI-MedLine.d94.s16.e0
and;O;O
desipramine;B-drug;B-DDI-MedLine.d94.s16.e1
,;O;O
in;O;O
the;O;O
nonfailing;O;O
heart;O;O
only;O;O
.;O;O
DDI-MedLine.d94.s17;;
Compromised;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s17.e0
uptake;O;O
-;O;O
1;O;O
in;O;O
functional;O;O
class;O;O
IV;O;O
can;O;O
not;O;O
be;O;O
further;O;O
increased;O;O
by;O;O
cocaine;B-drug;B-DDI-MedLine.d94.s17.e1
and;O;O
desipramine;B-drug;B-DDI-MedLine.d94.s17.e2
.;O;O
DDI-MedLine.d94.s18;;
The;O;O
pathophysiologic;O;O
consequences;O;O
could;O;O
be;O;O
an;O;O
increased;O;O
synaptic;O;O
concentration;O;O
of;O;O
norepinephrine;B-drug;B-DDI-MedLine.d94.s18.e0
predisposing;O;O
to;O;O
adenylyl;O;O
cyclase;O;O
desensitization;O;O
.;O;O
DDI-MedLine.d14.s0;;
[;O;O
A;O;O
pharmacological;O;O
analysis;O;O
of;O;O
the;O;O
effect;O;O
of;O;O
angiotensin;B-drug_n;B-DDI-MedLine.d14.s0.e0
on;O;O
stimulated;O;O
gastric;O;O
secretion;O;O
];O;O
Chronic;O;O
experiments;O;O
on;O;O
dogs;O;O
with;O;O
gastric;O;O
fistulas;O;O
were;O;O
carried;O;O
out;O;O
to;O;O
study;O;O
the;O;O
influence;O;O
of;O;O
angiotensin;B-drug_n;B-DDI-MedLine.d14.s0.e1
1;I-drug_n;I-DDI-MedLine.d14.s0.e1
and;O;O
angiotensin;B-drug_n;B-DDI-MedLine.d14.s0.e2
2;I-drug_n;I-DDI-MedLine.d14.s0.e2
on;O;O
pentagastrin;B-drug;B-DDI-MedLine.d14.s0.e3
-;O;O
and;O;O
histamine;B-drug;B-DDI-MedLine.d14.s0.e4
-;O;O
induced;O;O
gastric;O;O
acid;O;O
secretion;O;O
.;O;O
DDI-MedLine.d14.s1;;
It;O;O
was;O;O
established;O;O
that;O;O
both;O;O
angiotensins;O;O
inhibited;O;O
gastric;O;O
acid;O;O
secretion;O;O
stimulated;O;O
by;O;O
pentagastrin;B-drug;B-DDI-MedLine.d14.s1.e0
but;O;O
not;O;O
by;O;O
histamine;B-drug;B-DDI-MedLine.d14.s1.e1
.;O;O
DDI-MedLine.d14.s2;;
Comparative;O;O
analysis;O;O
of;O;O
the;O;O
effects;O;O
of;O;O
stimulation;O;O
and;O;O
inhibition;O;O
of;O;O
cholino;O;O
-;O;O
and;O;O
adrenoreceptors;O;O
on;O;O
this;O;O
inhibitory;O;O
action;O;O
of;O;O
angiotensins;B-drug_n;B-DDI-MedLine.d14.s2.e0
suggested;O;O
the;O;O
mediation;O;O
of;O;O
angiotensin;B-drug_n;B-DDI-MedLine.d14.s2.e1
influence;O;O
through;O;O
the;O;O
modulation;O;O
of;O;O
cholinergic;O;O
reactions;O;O
of;O;O
parietal;O;O
cells;O;O
in;O;O
the;O;O
stomach;O;O
.;O;O
DDI-MedLine.d90.s0;;
Interaction;O;O
of;O;O
gentamycin;B-drug;B-DDI-MedLine.d90.s0.e0
and;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s0.e1
in;O;O
anaesthetised;O;O
horses;O;O
.;O;O
DDI-MedLine.d90.s1;;
Evoked;O;O
hind;O;O
limb;O;O
digital;O;O
extensor;O;O
tension;O;O
(;O;O
hoof;O;O
twitch;O;O
);O;O
was;O;O
maintained;O;O
at;O;O
40;O;O
%;O;O
of;O;O
baseline;O;O
for;O;O
1;O;O
h;O;O
by;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s1.e0
infusion;O;O
in;O;O
7;O;O
horses;O;O
anaesthetised;O;O
with;O;O
halothane;B-drug;B-DDI-MedLine.d90.s1.e1
.;O;O
DDI-MedLine.d90.s2;;
After;O;O
1;O;O
h;O;O
,;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s2.e0
was;O;O
discontinued;O;O
and;O;O
hoof;O;O
twitch;O;O
allowed;O;O
to;O;O
recover;O;O
to;O;O
75;O;O
%;O;O
.;O;O
DDI-MedLine.d90.s3;;
Atracurium;B-drug;B-DDI-MedLine.d90.s3.e0
was;O;O
again;O;O
given;O;O
by;O;O
infusion;O;O
to;O;O
maintain;O;O
40;O;O
%;O;O
twitch;O;O
for;O;O
a;O;O
second;O;O
hour;O;O
,;O;O
then;O;O
2;O;O
mg;O;O
gentamycin;B-drug;B-DDI-MedLine.d90.s3.e1
/;O;O
kg;O;O
bwt;O;O
were;O;O
given;O;O
i.v;O;O
.;O;O
DDI-MedLine.d90.s4;;
Atracurium;B-drug;B-DDI-MedLine.d90.s4.e0
infusion;O;O
was;O;O
continued;O;O
for;O;O
a;O;O
third;O;O
hour;O;O
,;O;O
and;O;O
then;O;O
hoof;O;O
twitch;O;O
was;O;O
again;O;O
allowed;O;O
to;O;O
recover;O;O
spontaneously;O;O
to;O;O
75;O;O
%;O;O
.;O;O
DDI-MedLine.d90.s5;;
Gentamycin;B-drug;B-DDI-MedLine.d90.s5.e0
reduced;O;O
twitch;O;O
strength;O;O
from;O;O
40;O;O
+;O;O
/;O;O
-;O;O
1;O;O
%;O;O
(;O;O
mean;O;O
+;O;O
/;O;O
-;O;O
sem;O;O
);O;O
to;O;O
29;O;O
+;O;O
/;O;O
-;O;O
4;O;O
%;O;O
within;O;O
7.0;O;O
+;O;O
/;O;O
-;O;O
1.5;O;O
min;O;O
(;O;O
P;O;O
=;O;O
0.02;O;O
);O;O
.;O;O
DDI-MedLine.d90.s6;;
Twitch;O;O
gradually;O;O
returned;O;O
to;O;O
pre;O;O
-;O;O
gentamycin;B-drug;B-DDI-MedLine.d90.s6.e0
strength;O;O
over;O;O
the;O;O
course;O;O
of;O;O
the;O;O
next;O;O
hour;O;O
.;O;O
DDI-MedLine.d90.s7;;
Recovery;O;O
of;O;O
hoof;O;O
twitch;O;O
from;O;O
50;O;O
%;O;O
to;O;O
75;O;O
%;O;O
took;O;O
7.7;O;O
+;O;O
/;O;O
-;O;O
0.7;O;O
min;O;O
for;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s7.e0
alone;O;O
and;O;O
11.5;O;O
+;O;O
/;O;O
-;O;O
2.7;O;O
min;O;O
for;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s7.e1
plus;O;O
gentamycin;B-drug;B-DDI-MedLine.d90.s7.e2
(;O;O
P;O;O
=;O;O
0.03;O;O
);O;O
.;O;O
DDI-MedLine.d90.s8;;
Recovery;O;O
from;O;O
50;O;O
%;O;O
twitch;O;O
to;O;O
75;O;O
%;O;O
fade;O;O
recovery;O;O
took;O;O
13.8;O;O
+;O;O
/;O;O
-;O;O
0.8;O;O
min;O;O
for;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s8.e0
alone;O;O
and;O;O
13.7;O;O
+;O;O
/;O;O
-;O;O
1.2;O;O
min;O;O
for;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s8.e1
plus;O;O
gentamycin;B-drug;B-DDI-MedLine.d90.s8.e2
.;O;O
DDI-MedLine.d90.s9;;
At;O;O
75;O;O
%;O;O
recovery;O;O
of;O;O
fade;O;O
,;O;O
hoof;O;O
twitch;O;O
was;O;O
87;O;O
+;O;O
/;O;O
-;O;O
3;O;O
%;O;O
for;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s9.e0
alone;O;O
and;O;O
82;O;O
+;O;O
/;O;O
-;O;O
4;O;O
%;O;O
for;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s9.e1
plus;O;O
gentamycin;B-drug;B-DDI-MedLine.d90.s9.e2
.;O;O
DDI-MedLine.d90.s10;;
Reversal;O;O
of;O;O
the;O;O
block;O;O
with;O;O
edrophonium;B-drug;B-DDI-MedLine.d90.s10.e0
and;O;O
subsequent;O;O
recovery;O;O
of;O;O
the;O;O
horses;O;O
from;O;O
anaesthesia;O;O
were;O;O
uneventful;O;O
.;O;O
DDI-MedLine.d90.s11;;
It;O;O
was;O;O
concluded;O;O
that;O;O
,;O;O
although;O;O
gentamycin;B-drug;B-DDI-MedLine.d90.s11.e0
did;O;O
augment;O;O
the;O;O
neuromuscular;O;O
blockade;O;O
of;O;O
atracurium;B-drug;B-DDI-MedLine.d90.s11.e1
,;O;O
the;O;O
effect;O;O
was;O;O
minimal;O;O
.;O;O
DDI-MedLine.d37.s0;;
Anticoagulants;B-group;B-DDI-MedLine.d37.s0.e0
.;O;O

;O;O
DDI-MedLine.d37.s1;;
Treatment;O;O
plans;O;O
for;O;O
patients;O;O
taking;O;O
anticoagulants;B-group;B-DDI-MedLine.d37.s1.e0
can;O;O
become;O;O
complicated;O;O
.;O;O
DDI-MedLine.d37.s2;;
Anticoagulants;B-group;B-DDI-MedLine.d37.s2.e0
predispose;O;O
a;O;O
patient;O;O
to;O;O
bleeding;O;O
problems;O;O
.;O;O
DDI-MedLine.d37.s3;;
Many;O;O
drugs;O;O
used;O;O
in;O;O
dentistry;O;O
can;O;O
not;O;O
be;O;O
taken;O;O
concomitantly;O;O
with;O;O
these;O;O
medications;O;O
.;O;O
DDI-MedLine.d108.s0;;
Administration;O;O
of;O;O
lithium;B-drug;B-DDI-MedLine.d108.s0.e0
prophylaxis;O;O
.;O;O
DDI-MedLine.d108.s1;;
Successful;O;O
prophylaxis;O;O
of;O;O
manic;O;O
-;O;O
depressive;O;O
disorder;O;O
requires;O;O
more;O;O
than;O;O
the;O;O
prescription;O;O
of;O;O
lithium;B-drug;B-DDI-MedLine.d108.s1.e0
carbonate;I-drug;I-DDI-MedLine.d108.s1.e0
.;O;O
DDI-MedLine.d108.s2;;
The;O;O
administrative;O;O
arrangements;O;O
in;O;O
an;O;O
area;O;O
of;O;O
Scotland;O;O
were;O;O
accompanied;O;O
by;O;O
a;O;O
300;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
frequency;O;O
of;O;O
admissions;O;O
for;O;O
mania;O;O
,;O;O
whereas;O;O
in;O;O
an;O;O
area;O;O
of;O;O
the;O;O
West;O;O
Midlands;O;O
,;O;O
a;O;O
large;O;O
decrease;O;O
was;O;O
achieved;O;O
.;O;O
DDI-MedLine.d136.s0;;
[;O;O
Multiple;O;O
occupational;O;O
exposure;O;O
to;O;O
solvents;O;O
];O;O
This;O;O
article;O;O
review;O;O
papers;O;O
published;O;O
over;O;O
the;O;O
last;O;O
20;O;O
years;O;O
on;O;O
multiple;O;O
occupational;O;O
exposure;O;O
to;O;O
solvents;O;O
.;O;O
DDI-MedLine.d136.s1;;
At;O;O
low;O;O
-;O;O
levels;O;O
of;O;O
exposure;O;O
the;O;O
toxicokinetic;O;O
interferences;O;O
between;O;O
solvents;O;O
have;O;O
generally;O;O
not;O;O
been;O;O
observed;O;O
in;O;O
man;O;O
and;O;O
presumably;O;O
a;O;O
threshold;O;O
limit;O;O
exists;O;O
.;O;O
DDI-MedLine.d136.s2;;
Conversely;O;O
,;O;O
at;O;O
exposure;O;O
levels;O;O
close;O;O
to;O;O
the;O;O
";O;O
limit;O;O
values;O;O
";O;O
DDI-MedLine.d136.s3;;
metabolic;O;O
interference;O;O
has;O;O
sometimes;O;O
been;O;O
observed;O;O
and;O;O
the;O;O
behaviour;O;O
of;O;O
the;O;O
biological;O;O
indicators;O;O
differs;O;O
from;O;O
what;O;O
would;O;O
be;O;O
expected;O;O
.;O;O
DDI-MedLine.d136.s4;;
Toxicodynamic;O;O
interference;O;O
between;O;O
solvents;O;O
can;O;O
give;O;O
rise;O;O
to;O;O
additive;O;O
,;O;O
potentiation;O;O
,;O;O
synergistic;O;O
,;O;O
antagonistic;O;O
effects;O;O
.;O;O
DDI-MedLine.d136.s5;;
For;O;O
the;O;O
identification;O;O
of;O;O
";O;O
limit;O;O
values;O;O
";O;O
,;O;O
it;O;O
has;O;O
generally;O;O
been;O;O
suggested;O;O
in;O;O
the;O;O
literature;O;O
that;O;O
the;O;O
possible;O;O
effects;O;O
deriving;O;O
from;O;O
multiple;O;O
exposure;O;O
be;O;O
considered;O;O
as;O;O
additive;O;O
.;O;O
DDI-MedLine.d136.s6;;
However;O;O
,;O;O
numerous;O;O
potentiation;O;O
effects;O;O
have;O;O
frequently;O;O
been;O;O
reported;O;O
for;O;O
combined;O;O
exposure;O;O
to;O;O
substances;O;O
of;O;O
widespread;O;O
use;O;O
.;O;O
DDI-MedLine.d136.s7;;
In;O;O
this;O;O
paper;O;O
lists;O;O
of;O;O
multiple;O;O
exposure;O;O
in;O;O
which;O;O
the;O;O
doses;O;O
of;O;O
the;O;O
substances;O;O
,;O;O
the;O;O
types;O;O
of;O;O
interferences;O;O
and;O;O
the;O;O
behaviour;O;O
of;O;O
the;O;O
biological;O;O
levels;O;O
have;O;O
been;O;O
drawn;O;O
up;O;O
and;O;O
proposed;O;O
as;O;O
a;O;O
tool;O;O
for;O;O
easy;O;O
consultation;O;O
.;O;O
DDI-MedLine.d33.s0;;
Determinants;O;O
of;O;O
cellular;O;O
sensitivity;O;O
to;O;O
topoisomerase;B-group;B-DDI-MedLine.d33.s0.e0
-;I-group;I-DDI-MedLine.d33.s0.e0
targeting;I-group;I-DDI-MedLine.d33.s0.e0
antitumor;I-group;I-DDI-MedLine.d33.s0.e0
drugs;I-group;I-DDI-MedLine.d33.s0.e0
.;O;O
DDI-MedLine.d33.s1;;
It;O;O
is;O;O
now;O;O
clear;O;O
that;O;O
topoisomerase;O;O
activity;O;O
level;O;O
is;O;O
an;O;O
important;O;O
determinant;O;O
of;O;O
sensitivity;O;O
to;O;O
topo;O;O
drugs;O;O
.;O;O
DDI-MedLine.d33.s2;;
The;O;O
regulation;O;O
of;O;O
topoisomerases;O;O
is;O;O
no;O;O
doubt;O;O
complex;O;O
and;O;O
multifaceted;O;O
and;O;O
is;O;O
probably;O;O
accomplished;O;O
through;O;O
redundancy;O;O
at;O;O
many;O;O
control;O;O
levels;O;O
.;O;O
DDI-MedLine.d33.s3;;
The;O;O
mechanism(s;O;O
);O;O
of;O;O
altered;O;O
topo;O;O
I;O;O
expression;O;O
in;O;O
certain;O;O
tumor;O;O
types;O;O
is;O;O
unknown;O;O
,;O;O
but;O;O
may;O;O
be;O;O
related;O;O
to;O;O
the;O;O
central;O;O
importance;O;O
of;O;O
topoisomerases;O;O
in;O;O
proliferating;O;O
cell;O;O
functions;O;O
(;O;O
transcription;O;O
,;O;O
replication;O;O
,;O;O
etc;O;O
.;O;O
);O;O
,;O;O
and;O;O
the;O;O
aberrant;O;O
and;O;O
chronic;O;O
activation;O;O
of;O;O
these;O;O
functions;O;O
as;O;O
a;O;O
result;O;O
of;O;O
specific;O;O
tumorigenic;O;O
alterations;O;O
.;O;O
DDI-MedLine.d33.s4;;
Small;O;O
differences;O;O
in;O;O
sensitivity;O;O
to;O;O
chemotherapy;O;O
can;O;O
have;O;O
a;O;O
dramatic;O;O
effect;O;O
on;O;O
cure;O;O
rates;O;O
,;O;O
and;O;O
therefore;O;O
subtle;O;O
cell;O;O
type;O;O
-;O;O
specific;O;O
differences;O;O
may;O;O
be;O;O
important;O;O
determinants;O;O
of;O;O
drug;O;O
sensitivity;O;O
.;O;O
DDI-MedLine.d33.s5;;
Whether;O;O
abnormal;O;O
topoisomerase;O;O
quantity;O;O
and;O;O
specific;O;O
activity;O;O
are;O;O
associated;O;O
with;O;O
resistance;O;O
or;O;O
sensitivity;O;O
to;O;O
topoisomerase;O;O
-;O;O
targeted;O;O
chemotherapy;O;O
in;O;O
the;O;O
clinic;O;O
is;O;O
now;O;O
being;O;O
studied;O;O
.;O;O
DDI-MedLine.d33.s6;;
Determinants;O;O
downstream;O;O
of;O;O
cleavable;O;O
complex;O;O
formation;O;O
that;O;O
affect;O;O
the;O;O
sensitivity;O;O
of;O;O
tumor;O;O
versus;O;O
normal;O;O
cells;O;O
to;O;O
topo;O;O
drugs;O;O
in;O;O
particular;O;O
and;O;O
DNA;O;O
-;O;O
damaging;O;O
agents;O;O
in;O;O
general;O;O
are;O;O
little;O;O
known;O;O
.;O;O
DDI-MedLine.d33.s7;;
The;O;O
goal;O;O
of;O;O
enhancing;O;O
selective;O;O
tumor;O;O
cell;O;O
killing;O;O
relative;O;O
to;O;O
the;O;O
normal;O;O
cells;O;O
that;O;O
are;O;O
dose;O;O
limiting;O;O
may;O;O
be;O;O
achieved;O;O
either;O;O
by;O;O
overcoming;O;O
tumor;O;O
cell;O;O
resistance;O;O
or;O;O
by;O;O
protecting;O;O
normal;O;O
cells;O;O
.;O;O
DDI-MedLine.d33.s8;;
Both;O;O
of;O;O
these;O;O
strategies;O;O
will;O;O
become;O;O
more;O;O
feasible;O;O
as;O;O
specific;O;O
molecular;O;O
differences;O;O
between;O;O
tumor;O;O
and;O;O
normal;O;O
cells;O;O
are;O;O
being;O;O
rapidly;O;O
identified;O;O
and;O;O
new;O;O
combination;O;O
therapies;O;O
that;O;O
take;O;O
advantage;O;O
of;O;O
these;O;O
differences;O;O
are;O;O
being;O;O
designed;O;O
and;O;O
tested;O;O
.;O;O
DDI-MedLine.d113.s0;;
Acid;O;O
-;O;O
catalyzed;O;O
ethanolysis;O;O
of;O;O
temazepam;B-drug;B-DDI-MedLine.d113.s0.e0
in;O;O
anhydrous;O;O
and;O;O
aqueous;O;O
ethanol;B-drug;B-DDI-MedLine.d113.s0.e1
solutions;O;O
.;O;O
DDI-MedLine.d113.s1;;
The;O;O
benzodiazepines;B-group;B-DDI-MedLine.d113.s1.e0
are;O;O
a;O;O
family;O;O
of;O;O
anxiolytic;B-group;B-DDI-MedLine.d113.s1.e1
and;O;O
hypnotic;B-group;B-DDI-MedLine.d113.s1.e2
drugs;I-group;I-DDI-MedLine.d113.s1.e2
.;O;O
DDI-MedLine.d113.s2;;
When;O;O
taken;O;O
concurrently;O;O
with;O;O
ethanol;B-drug;B-DDI-MedLine.d113.s2.e0
,;O;O
a;O;O
pharmacological;O;O
interaction;O;O
may;O;O
occur;O;O
,;O;O
potentiating;O;O
the;O;O
central;O;O
nervous;O;O
system;O;O
depression;O;O
produced;O;O
by;O;O
either;O;O
drug;O;O
.;O;O
DDI-MedLine.d113.s3;;
In;O;O
addition;O;O
to;O;O
this;O;O
pharmacological;O;O
interaction;O;O
,;O;O
this;O;O
report;O;O
describes;O;O
a;O;O
novel;O;O
chemical;O;O
reaction;O;O
between;O;O
temazepam;B-drug;B-DDI-MedLine.d113.s3.e0
(;O;O
a;O;O
benzodiazepine;B-group;B-DDI-MedLine.d113.s3.e1
);O;O
and;O;O
ethanol;B-drug;B-DDI-MedLine.d113.s3.e2
under;O;O
acidic;O;O
conditions;O;O
similar;O;O
to;O;O
those;O;O
found;O;O
in;O;O
vivo;O;O
,;O;O
resulting;O;O
in;O;O
a;O;O
3;O;O
-;O;O
ethoxylated;O;O
product;O;O
.;O;O
DDI-MedLine.d113.s4;;
Optimal;O;O
conditions;O;O
,;O;O
kinetics;O;O
,;O;O
equilibrium;O;O
,;O;O
and;O;O
the;O;O
mechanism;O;O
of;O;O
this;O;O
acid;O;O
-;O;O
catalyzed;O;O
ethanolysis;O;O
are;O;O
reported;O;O
.;O;O
DDI-MedLine.d113.s5;;
The;O;O
results;O;O
raise;O;O
the;O;O
possibility;O;O
that;O;O
the;O;O
ethanolysis;O;O
reaction;O;O
may;O;O
occur;O;O
in;O;O
the;O;O
stomach;O;O
of;O;O
people;O;O
who;O;O
consume;O;O
alcohol;B-drug;B-DDI-MedLine.d113.s5.e0
and;O;O
3;B-group;B-DDI-MedLine.d113.s5.e1
-;I-group;I-DDI-MedLine.d113.s5.e1
hydroxy;I-group;I-DDI-MedLine.d113.s5.e1
-;I-group;I-DDI-MedLine.d113.s5.e1
1,4;I-group;I-DDI-MedLine.d113.s5.e1
-;I-group;I-DDI-MedLine.d113.s5.e1
benzodiazepine;I-group;I-DDI-MedLine.d113.s5.e1
on;O;O
a;O;O
regular;O;O
basis;O;O
.;O;O
DDI-MedLine.d113.s6;;
The;O;O
acid;O;O
-;O;O
catalyzed;O;O
ethanol;B-drug;B-DDI-MedLine.d113.s6.e0
-;O;O
drug;O;O
reaction;O;O
is;O;O
a;O;O
relatively;O;O
unexplored;O;O
area;O;O
and;O;O
may;O;O
alter;O;O
the;O;O
pharmacological;O;O
action;O;O
of;O;O
some;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d519.s0;;
No;O;O
formal;O;O
drug;O;O
/;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
Plenaxis;B-brand;B-DDI-DrugBank.d519.s0.e0
were;O;O
performed;O;O
.;O;O
DDI-DrugBank.d519.s1;;
Cytochrome;O;O
P;O;O
-;O;O
450;O;O
is;O;O
not;O;O
known;O;O
to;O;O
be;O;O
involved;O;O
in;O;O
the;O;O
metabolism;O;O
of;O;O
Plenaxis;B-brand;B-DDI-DrugBank.d519.s1.e0
.;O;O
DDI-DrugBank.d519.s2;;
Plenaxis;B-brand;B-DDI-DrugBank.d519.s2.e0
is;O;O
highly;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
(;O;O
96;O;O
to;O;O
99;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d519.s3;;
Laboratory;O;O
Tests;O;O
Response;O;O
to;O;O
Plenaxis;B-brand;B-DDI-DrugBank.d519.s3.e0
should;O;O
be;O;O
monitored;O;O
by;O;O
measuring;O;O
serum;O;O
total;O;O
testosterone;B-drug;B-DDI-DrugBank.d519.s3.e1
concentrations;O;O
just;O;O
prior;O;O
to;O;O
administration;O;O
on;O;O
Day;O;O
29;O;O
and;O;O
every;O;O
8;O;O
weeks;O;O
thereafter;O;O
.;O;O
DDI-DrugBank.d519.s4;;
Serum;O;O
transaminase;O;O
levels;O;O
should;O;O
be;O;O
obtained;O;O
before;O;O
starting;O;O
treatment;O;O
with;O;O
Plenaxis;B-brand;B-DDI-DrugBank.d519.s4.e0
and;O;O
periodically;O;O
during;O;O
treatment;O;O
.;O;O
DDI-DrugBank.d519.s5;;
Periodic;O;O
measurement;O;O
of;O;O
serum;O;O
PSA;O;O
levels;O;O
may;O;O
also;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d297.s0;;
Formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
with;O;O
ORENCIA;B-brand;B-DDI-DrugBank.d297.s0.e0
.;O;O
DDI-DrugBank.d297.s1;;
Population;O;O
pharmacokinetic;O;O
analyses;O;O
revealed;O;O
that;O;O
MTX;B-drug;B-DDI-DrugBank.d297.s1.e0
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d297.s1.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d297.s1.e2
,;O;O
and;O;O
TNF;B-group;B-DDI-DrugBank.d297.s1.e3
blocking;I-group;I-DDI-DrugBank.d297.s1.e3
agents;I-group;I-DDI-DrugBank.d297.s1.e3
did;O;O
not;O;O
influence;O;O
abatacept;B-drug;B-DDI-DrugBank.d297.s1.e4
clearance;O;O
.;O;O
DDI-DrugBank.d297.s2;;
The;O;O
majority;O;O
of;O;O
patients;O;O
in;O;O
RA;O;O
clinical;O;O
studies;O;O
received;O;O
one;O;O
or;O;O
more;O;O
of;O;O
the;O;O
following;O;O
concomitant;O;O
medications;O;O
with;O;O
ORENCIA;B-brand;B-DDI-DrugBank.d297.s2.e0
:;O;O
MTX;B-drug;B-DDI-DrugBank.d297.s2.e1
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d297.s2.e2
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d297.s2.e3
,;O;O
TNF;B-group;B-DDI-DrugBank.d297.s2.e4
blocking;I-group;I-DDI-DrugBank.d297.s2.e4
agents;I-group;I-DDI-DrugBank.d297.s2.e4
,;O;O
azathioprine;B-drug;B-DDI-DrugBank.d297.s2.e5
,;O;O
chloroquine;B-drug;B-DDI-DrugBank.d297.s2.e6
,;O;O
gold;B-drug;B-DDI-DrugBank.d297.s2.e7
,;O;O
hydroxychloroquine;B-drug;B-DDI-DrugBank.d297.s2.e8
,;O;O
leflunomide;B-drug;B-DDI-DrugBank.d297.s2.e9
,;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d297.s2.e10
,;O;O
and;O;O
anakinra;B-drug;B-DDI-DrugBank.d297.s2.e11
.;O;O
DDI-DrugBank.d297.s3;;
Concurrent;O;O
administration;O;O
of;O;O
a;O;O
TNF;B-group;B-DDI-DrugBank.d297.s3.e0
antagonist;I-group;I-DDI-DrugBank.d297.s3.e0
with;O;O
ORENCIA;B-brand;B-DDI-DrugBank.d297.s3.e1
has;O;O
been;O;O
associated;O;O
with;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
serious;O;O
infections;O;O
and;O;O
no;O;O
significant;O;O
additional;O;O
efficacy;O;O
over;O;O
use;O;O
of;O;O
the;O;O
TNF;B-group;B-DDI-DrugBank.d297.s3.e2
antagonists;I-group;I-DDI-DrugBank.d297.s3.e2
alone;O;O
.;O;O
DDI-DrugBank.d297.s4;;
Concurrent;O;O
therapy;O;O
with;O;O
ORENCIA;B-brand;B-DDI-DrugBank.d297.s4.e0
and;O;O
TNF;B-group;B-DDI-DrugBank.d297.s4.e1
antagonists;I-group;I-DDI-DrugBank.d297.s4.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d297.s5;;
There;O;O
is;O;O
insufficient;O;O
experience;O;O
to;O;O
assess;O;O
the;O;O
safety;O;O
and;O;O
efficacy;O;O
of;O;O
ORENCIA;B-brand;B-DDI-DrugBank.d297.s5.e0
administered;O;O
concurrently;O;O
with;O;O
anakinra;B-drug;B-DDI-DrugBank.d297.s5.e1
,;O;O
and;O;O
therefore;O;O
such;O;O
use;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d532.s0;;
Formal;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
Abciximab;B-drug;B-DDI-DrugBank.d532.s0.e0
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d532.s1;;
Abciximab;B-drug;B-DDI-DrugBank.d532.s1.e0
has;O;O
been;O;O
administered;O;O
to;O;O
patients;O;O
with;O;O
ischemic;O;O
heart;O;O
disease;O;O
treated;O;O
concomitantly;O;O
with;O;O
a;O;O
broad;O;O
range;O;O
of;O;O
medications;O;O
used;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
angina;O;O
myocardial;O;O
infarction;O;O
and;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d532.s2;;
These;O;O
medications;O;O
have;O;O
included;O;O
heparin;B-drug;B-DDI-DrugBank.d532.s2.e0
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d532.s2.e1
,;O;O
beta;B-group;B-DDI-DrugBank.d532.s2.e2
-;I-group;I-DDI-DrugBank.d532.s2.e2
adrenergic;I-group;I-DDI-DrugBank.d532.s2.e2
receptor;I-group;I-DDI-DrugBank.d532.s2.e2
blockers;I-group;I-DDI-DrugBank.d532.s2.e2
,;O;O
calcium;B-group;B-DDI-DrugBank.d532.s2.e3
channel;I-group;I-DDI-DrugBank.d532.s2.e3
antagonists;I-group;I-DDI-DrugBank.d532.s2.e3
,;O;O
angiotensin;B-group;B-DDI-DrugBank.d532.s2.e4
converting;I-group;I-DDI-DrugBank.d532.s2.e4
enzyme;I-group;I-DDI-DrugBank.d532.s2.e4
inhibitors;I-group;I-DDI-DrugBank.d532.s2.e4
,;O;O
intravenous;O;O
and;O;O
oral;O;O
nitrates;B-group;B-DDI-DrugBank.d532.s2.e5
,;O;O
ticlopidine;B-drug;B-DDI-DrugBank.d532.s2.e6
,;O;O
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d532.s2.e7
.;O;O
DDI-DrugBank.d532.s3;;
Heparin;B-drug;B-DDI-DrugBank.d532.s3.e0
,;O;O
other;O;O
anticoagulants;B-group;B-DDI-DrugBank.d532.s3.e1
,;O;O
thrombolytics;B-group;B-DDI-DrugBank.d532.s3.e2
,;O;O
and;O;O
anti;B-group;B-DDI-DrugBank.d532.s3.e3
platelet;I-group;I-DDI-DrugBank.d532.s3.e3
agents;I-group;I-DDI-DrugBank.d532.s3.e3
are;O;O
associated;O;O
with;O;O
an;O;O
increase;O;O
in;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d532.s4;;
Patients;O;O
with;O;O
HACA;O;O
titers;O;O
may;O;O
have;O;O
allergic;O;O
or;O;O
hypersensitivity;O;O
reactions;O;O
when;O;O
treated;O;O
with;O;O
other;O;O
diagnostic;B-group;B-DDI-DrugBank.d532.s4.e0
or;I-group;I-DDI-DrugBank.d532.s4.e0
therapeutic;I-group;I-DDI-DrugBank.d532.s4.e1
monoclonal;I-group;I-DDI-DrugBank.d532.s4.e1
antibodies;I-group;I-DDI-DrugBank.d532.s4.e1
.;O;O
DDI-DrugBank.d0.s0;;
The;O;O
concomitant;O;O
intake;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d0.s0.e0
and;O;O
Acamprosate;B-drug;B-DDI-DrugBank.d0.s0.e1
does;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
alcohol;B-drug;B-DDI-DrugBank.d0.s0.e2
or;O;O
acamprosate;B-drug;B-DDI-DrugBank.d0.s0.e3
.;O;O
DDI-DrugBank.d0.s1;;
Pharmacokinetic;O;O
studies;O;O
indicate;O;O
that;O;O
administration;O;O
of;O;O
disulfiram;B-drug;B-DDI-DrugBank.d0.s1.e0
or;O;O
diazepam;B-drug;B-DDI-DrugBank.d0.s1.e1
does;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
acamprosate;B-drug;B-DDI-DrugBank.d0.s1.e2
.;O;O
DDI-DrugBank.d0.s2;;
Co;O;O
-;O;O
administration;O;O
of;O;O
naltrexone;B-drug;B-DDI-DrugBank.d0.s2.e0
with;O;O
Acamprosate;B-drug;B-DDI-DrugBank.d0.s2.e1
produced;O;O
a;O;O
25;O;O
%;O;O
increase;O;O
in;O;O
AUC;O;O
and;O;O
a;O;O
33;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
Cmax;O;O
of;O;O
acamprosate;B-drug;B-DDI-DrugBank.d0.s2.e2
.;O;O
DDI-DrugBank.d0.s3;;
No;O;O
adjustment;O;O
of;O;O
dosage;O;O
is;O;O
recommended;O;O
in;O;O
such;O;O
patients;O;O
.;O;O
DDI-DrugBank.d0.s4;;
The;O;O
pharmacokinetics;O;O
of;O;O
naltrexone;B-drug;B-DDI-DrugBank.d0.s4.e0
and;O;O
its;O;O
major;O;O
metabolite;O;O
6;B-drug_n;B-DDI-DrugBank.d0.s4.e1
-;I-drug_n;I-DDI-DrugBank.d0.s4.e1
beta;I-drug_n;I-DDI-DrugBank.d0.s4.e1
-;I-drug_n;I-DDI-DrugBank.d0.s4.e1
naltrexol;I-drug_n;I-DDI-DrugBank.d0.s4.e1
were;O;O
unaffected;O;O
following;O;O
co;O;O
-;O;O
administration;O;O
with;O;O
Acamprosate;B-drug;B-DDI-DrugBank.d0.s4.e2
.;O;O
DDI-DrugBank.d0.s5;;
Other;O;O
concomitant;O;O
therapies;O;O
:;O;O
In;O;O
clinical;O;O
trials;O;O
,;O;O
the;O;O
safety;O;O
profile;O;O
in;O;O
subjects;O;O
treated;O;O
with;O;O
Acamprosate;B-drug;B-DDI-DrugBank.d0.s5.e0
concomitantly;O;O
with;O;O
anxiolytics;B-group;B-DDI-DrugBank.d0.s5.e1
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d0.s5.e2
and;O;O
sedatives;B-group;B-DDI-DrugBank.d0.s5.e3
(;O;O
including;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d0.s5.e4
);O;O
,;O;O
or;O;O
non;B-group;B-DDI-DrugBank.d0.s5.e5
-;I-group;I-DDI-DrugBank.d0.s5.e5
opioid;I-group;I-DDI-DrugBank.d0.s5.e5
analgesics;I-group;I-DDI-DrugBank.d0.s5.e5
was;O;O
similar;O;O
to;O;O
that;O;O
of;O;O
subjects;O;O
taking;O;O
placebo;O;O
with;O;O
these;O;O
concomitant;O;O
medications;O;O
.;O;O
DDI-DrugBank.d0.s6;;
Patients;O;O
taking;O;O
Acamprosate;B-drug;B-DDI-DrugBank.d0.s6.e0
concomitantly;O;O
with;O;O
antidepressants;B-group;B-DDI-DrugBank.d0.s6.e1
more;O;O
commonly;O;O
reported;O;O
both;O;O
weight;O;O
gain;O;O
and;O;O
weight;O;O
loss;O;O
,;O;O
compared;O;O
with;O;O
patients;O;O
taking;O;O
either;O;O
medication;O;O
alone;O;O
.;O;O
DDI-DrugBank.d536.s0;;
Certain;O;O
drugs;O;O
tend;O;O
to;O;O
produce;O;O
hyperglycemia;O;O
and;O;O
may;O;O
lead;O;O
to;O;O
loss;O;O
of;O;O
blood;O;O
glucose;O;O
control;O;O
.;O;O
DDI-DrugBank.d536.s1;;
These;O;O
drugs;O;O
include;O;O
the;O;O
thiazides;B-group;B-DDI-DrugBank.d536.s1.e0
and;O;O
other;O;O
diuretics;B-group;B-DDI-DrugBank.d536.s1.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d536.s1.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d536.s1.e3
,;O;O
thyroid;B-group;B-DDI-DrugBank.d536.s1.e4
products;I-group;I-DDI-DrugBank.d536.s1.e4
,;O;O
estrogens;B-group;B-DDI-DrugBank.d536.s1.e5
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d536.s1.e6
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d536.s1.e7
,;O;O
nicotinic;B-drug;B-DDI-DrugBank.d536.s1.e8
acid;I-drug;I-DDI-DrugBank.d536.s1.e8
,;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d536.s1.e9
,;O;O
calcium;B-group;B-DDI-DrugBank.d536.s1.e10
channel;I-group;I-DDI-DrugBank.d536.s1.e10
-;I-group;I-DDI-DrugBank.d536.s1.e10
blocking;I-group;I-DDI-DrugBank.d536.s1.e10
drugs;I-group;I-DDI-DrugBank.d536.s1.e10
,;O;O
and;O;O
isoniazid;B-drug;B-DDI-DrugBank.d536.s1.e11
.;O;O
DDI-DrugBank.d536.s2;;
When;O;O
such;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
Acarbose;B-drug;B-DDI-DrugBank.d536.s2.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
loss;O;O
of;O;O
blood;O;O
glucose;O;O
control;O;O
.;O;O
DDI-DrugBank.d536.s3;;
When;O;O
such;O;O
drugs;O;O
are;O;O
withdrawn;O;O
from;O;O
patients;O;O
receiving;O;O
Acarbose;B-drug;B-DDI-DrugBank.d536.s3.e0
in;O;O
combination;O;O
with;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d536.s3.e1
or;O;O
insulin;B-drug;B-DDI-DrugBank.d536.s3.e2
,;O;O
patients;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
any;O;O
evidence;O;O
of;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d536.s4;;
Intestinal;B-group;B-DDI-DrugBank.d536.s4.e0
adsorbents;I-group;I-DDI-DrugBank.d536.s4.e0
(;O;O
e.;O;O
g.;O;O
,;O;O
charcoal;B-drug;B-DDI-DrugBank.d536.s4.e1
);O;O
and;O;O
digestive;B-group;B-DDI-DrugBank.d536.s4.e2
enzyme;I-group;I-DDI-DrugBank.d536.s4.e2
preparations;I-group;I-DDI-DrugBank.d536.s4.e2
containing;O;O
carbohydrate;O;O
-;O;O
splitting;O;O
enzymes;O;O
(;O;O
e.;O;O
g.;O;O
,;O;O
amylase;B-drug;B-DDI-DrugBank.d536.s4.e3
,;O;O
pancreatin;B-drug;B-DDI-DrugBank.d536.s4.e4
);O;O
may;O;O
reduce;O;O
the;O;O
effect;O;O
of;O;O
Acarbose;B-drug;B-DDI-DrugBank.d536.s4.e5
and;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d536.s5;;
Acarbose;B-drug;B-DDI-DrugBank.d536.s5.e0
has;O;O
been;O;O
shown;O;O
to;O;O
change;O;O
the;O;O
bioavailabillty;O;O
digoxin;B-drug;B-DDI-DrugBank.d536.s5.e1
when;O;O
they;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
,;O;O
which;O;O
may;O;O
require;O;O
digoxin;B-drug;B-DDI-DrugBank.d536.s5.e2
dose;O;O
adjustment;O;O
.;O;O
DDI-DrugBank.d536.s6;;
Studies;O;O
in;O;O
healthy;O;O
volunteers;O;O
have;O;O
shown;O;O
that;O;O
Acarbose;B-drug;B-DDI-DrugBank.d536.s6.e0
has;O;O
no;O;O
effect;O;O
on;O;O
either;O;O
the;O;O
pharmacokinetics;O;O
or;O;O
pharmacodynamics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d536.s6.e1
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d536.s6.e2
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d536.s6.e3
,;O;O
or;O;O
ranitidine;B-drug;B-DDI-DrugBank.d536.s6.e4
.;O;O
DDI-DrugBank.d536.s7;;
Acarbose;B-drug;B-DDI-DrugBank.d536.s7.e0
did;O;O
not;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
or;O;O
disposition;O;O
of;O;O
the;O;O
sulfonylurea;B-drug;B-DDI-DrugBank.d536.s7.e1
glyburide;I-drug;I-DDI-DrugBank.d536.s7.e2
in;O;O
diabetic;O;O
patients;O;O
.;O;O
DDI-DrugBank.d536.s8;;
Acarbose;B-drug;B-DDI-DrugBank.d536.s8.e0
may;O;O
affect;O;O
digoxin;B-drug;B-DDI-DrugBank.d536.s8.e1
bioavailabillty;O;O
and;O;O
may;O;O
require;O;O
dose;O;O
adjustment;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d536.s8.e2
by;O;O
16;O;O
%;O;O
(;O;O
90;O;O
%;O;O
confidence;O;O
interval;O;O
:;O;O
8;O;O
-;O;O
23;O;O
%;O;O
);O;O
,;O;O
decrease;O;O
mean;O;O
C;O;O
max;O;O
digoxin;B-drug;B-DDI-DrugBank.d536.s8.e3
by;O;O
26;O;O
%;O;O
(;O;O
90;O;O
%;O;O
confidence;O;O
interval;O;O
:;O;O
16;O;O
-;O;O
34;O;O
%;O;O
);O;O
and;O;O
decrease;O;O
mean;O;O
trough;O;O
concentrations;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d536.s8.e4
by;O;O
9;O;O
%;O;O
(;O;O
90;O;O
%;O;O
confidence;O;O
limit;O;O
:;O;O
19;O;O
%;O;O
decrease;O;O
to;O;O
2;O;O
%;O;O
increase;O;O
);O;O
.;O;O
DDI-DrugBank.d536.s9;;
The;O;O
amount;O;O
of;O;O
metformin;B-drug;B-DDI-DrugBank.d536.s9.e0
absorbed;O;O
while;O;O
taking;O;O
Acarbose;B-drug;B-DDI-DrugBank.d536.s9.e1
was;O;O
bioequivalent;O;O
to;O;O
the;O;O
amount;O;O
absorbed;O;O
when;O;O
taking;O;O
placebo;O;O
,;O;O
as;O;O
indicated;O;O
by;O;O
the;O;O
plasma;O;O
AUC;O;O
values;O;O
.;O;O
DDI-DrugBank.d536.s10;;
However;O;O
,;O;O
the;O;O
peak;O;O
plasma;O;O
level;O;O
of;O;O
metformin;B-drug;B-DDI-DrugBank.d536.s10.e0
was;O;O
reduced;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
when;O;O
taking;O;O
Acarbose;B-drug;B-DDI-DrugBank.d536.s10.e1
due;O;O
to;O;O
a;O;O
slight;O;O
delay;O;O
in;O;O
the;O;O
absorption;O;O
of;O;O
metformin;B-drug;B-DDI-DrugBank.d536.s10.e2
.;O;O
DDI-DrugBank.d536.s11;;
There;O;O
is;O;O
little;O;O
if;O;O
any;O;O
clinically;O;O
significant;O;O
interaction;O;O
between;O;O
Acarbose;B-drug;B-DDI-DrugBank.d536.s11.e0
and;O;O
metformin;B-drug;B-DDI-DrugBank.d536.s11.e1
.;O;O
DDI-DrugBank.d388.s0;;
Catecholamine;B-group;B-DDI-DrugBank.d388.s0.e0
-;I-group;I-DDI-DrugBank.d388.s0.e0
depleting;I-group;I-DDI-DrugBank.d388.s0.e0
drugs;I-group;I-DDI-DrugBank.d388.s0.e0
,;O;O
such;O;O
as;O;O
reserpine;B-drug;B-DDI-DrugBank.d388.s0.e1
,;O;O
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d388.s0.e2
-;I-group;I-DDI-DrugBank.d388.s0.e2
blocking;I-group;I-DDI-DrugBank.d388.s0.e2
agents;I-group;I-DDI-DrugBank.d388.s0.e2
.;O;O
DDI-DrugBank.d388.s1;;
Patients;O;O
treated;O;O
with;O;O
acebutolol;B-drug;B-DDI-DrugBank.d388.s1.e0
plus;O;O
catecholamine;B-group;B-DDI-DrugBank.d388.s1.e1
depletors;I-group;I-DDI-DrugBank.d388.s1.e1
should;O;O
,;O;O
therefore;O;O
,;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
evidence;O;O
of;O;O
marked;O;O
bradycardia;O;O
or;O;O
hypotension;O;O
which;O;O
may;O;O
present;O;O
as;O;O
vertigo;O;O
,;O;O
syncope;O;O
/;O;O
presyncope;O;O
,;O;O
or;O;O
orthostatic;O;O
changes;O;O
in;O;O
blood;O;O
pressure;O;O
without;O;O
compensatory;O;O
tachycardia;O;O
.;O;O
DDI-DrugBank.d388.s2;;
Exaggerated;O;O
hypertensive;O;O
responses;O;O
have;O;O
been;O;O
reported;O;O
from;O;O
the;O;O
combined;O;O
use;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d388.s2.e0
-;I-group;I-DDI-DrugBank.d388.s2.e0
adrenergic;I-group;I-DDI-DrugBank.d388.s2.e0
antagonists;I-group;I-DDI-DrugBank.d388.s2.e0
and;O;O
alpha;B-group;B-DDI-DrugBank.d388.s2.e1
-;I-group;I-DDI-DrugBank.d388.s2.e1
adrenergic;I-group;I-DDI-DrugBank.d388.s2.e1
stimulants;I-group;I-DDI-DrugBank.d388.s2.e1
,;O;O
including;O;O
those;O;O
contained;O;O
in;O;O
proprietary;O;O
cold;O;O
remedies;O;O
and;O;O
vasoconstrictive;O;O
nasal;O;O
drops;O;O
.;O;O
DDI-DrugBank.d388.s3;;
Patients;O;O
receiving;O;O
beta;B-group;B-DDI-DrugBank.d388.s3.e0
-;I-group;I-DDI-DrugBank.d388.s3.e0
blockers;I-group;I-DDI-DrugBank.d388.s3.e0
should;O;O
be;O;O
warned;O;O
of;O;O
this;O;O
potential;O;O
hazard;O;O
.;O;O
DDI-DrugBank.d388.s4;;
Blunting;O;O
of;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d388.s4.e0
-;I-group;I-DDI-DrugBank.d388.s4.e0
adrenoceptor;I-group;I-DDI-DrugBank.d388.s4.e0
blocking;I-group;I-DDI-DrugBank.d388.s4.e0
agents;I-group;I-DDI-DrugBank.d388.s4.e0
by;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d388.s4.e1
anti;I-group;I-DDI-DrugBank.d388.s4.e1
-;I-group;I-DDI-DrugBank.d388.s4.e1
inflammatory;I-group;I-DDI-DrugBank.d388.s4.e1
drugs;I-group;I-DDI-DrugBank.d388.s4.e1
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d388.s5;;
No;O;O
significant;O;O
interactions;O;O
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d388.s5.e0
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d388.s5.e1
,;O;O
hydralazine;B-drug;B-DDI-DrugBank.d388.s5.e2
,;O;O
sulfinpyrazone;B-drug;B-DDI-DrugBank.d388.s5.e3
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d388.s5.e4
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d388.s5.e5
,;O;O
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d388.s5.e6
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d368.s0;;
DIAMOX;B-brand;B-DDI-DrugBank.d368.s0.e0
modifies;O;O
phenytoin;B-drug;B-DDI-DrugBank.d368.s0.e1
metabolism;O;O
with;O;O
increased;O;O
serum;O;O
levels;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d368.s0.e2
.;O;O
DDI-DrugBank.d368.s1;;
This;O;O
may;O;O
increase;O;O
or;O;O
enhance;O;O
the;O;O
occurrence;O;O
of;O;O
osteomalacia;O;O
in;O;O
some;O;O
patients;O;O
receiving;O;O
chronic;O;O
phenytoin;B-drug;B-DDI-DrugBank.d368.s1.e0
therapy;O;O
.;O;O
DDI-DrugBank.d368.s2;;
Caution;O;O
is;O;O
advised;O;O
in;O;O
patients;O;O
receiving;O;O
chronic;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d368.s3;;
By;O;O
decreasing;O;O
the;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
primidone;B-drug;B-DDI-DrugBank.d368.s3.e0
,;O;O
DIAMOX;B-brand;B-DDI-DrugBank.d368.s3.e1
may;O;O
decrease;O;O
serum;O;O
concentrations;O;O
of;O;O
primidone;B-drug;B-DDI-DrugBank.d368.s3.e2
and;O;O
its;O;O
metabolites;O;O
,;O;O
with;O;O
a;O;O
consequent;O;O
possible;O;O
decrease;O;O
in;O;O
anticonvulsant;O;O
effect;O;O
.;O;O
DDI-DrugBank.d368.s4;;
Caution;O;O
is;O;O
advised;O;O
when;O;O
beginning;O;O
,;O;O
discontinuing;O;O
,;O;O
or;O;O
changing;O;O
the;O;O
dose;O;O
of;O;O
DIAMOX;B-brand;B-DDI-DrugBank.d368.s4.e0
in;O;O
patients;O;O
receiving;O;O
primidone;B-drug;B-DDI-DrugBank.d368.s4.e1
.;O;O
DDI-DrugBank.d368.s5;;
Because;O;O
of;O;O
possible;O;O
additive;O;O
effects;O;O
with;O;O
other;O;O
carbonic;B-group;B-DDI-DrugBank.d368.s5.e0
anhydrase;I-group;I-DDI-DrugBank.d368.s5.e0
inhibitors;I-group;I-DDI-DrugBank.d368.s5.e0
,;O;O
concomitant;O;O
use;O;O
is;O;O
not;O;O
advisable;O;O
.;O;O
DDI-DrugBank.d368.s6;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s6.e0
may;O;O
increase;O;O
the;O;O
effects;O;O
of;O;O
other;O;O
folic;B-group;B-DDI-DrugBank.d368.s6.e1
acid;I-group;I-DDI-DrugBank.d368.s6.e1
antagonists;I-group;I-DDI-DrugBank.d368.s6.e1
.;O;O
DDI-DrugBank.d368.s7;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s7.e0
may;O;O
increase;O;O
or;O;O
decrease;O;O
blood;O;O
glucose;O;O
levels;O;O
.;O;O
DDI-DrugBank.d368.s8;;
Consideration;O;O
should;O;O
be;O;O
taken;O;O
in;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
antidiabetic;B-drug;B-DDI-DrugBank.d368.s8.e0
agents;O;O
.;O;O
DDI-DrugBank.d368.s9;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s9.e0
decreases;O;O
urinary;O;O
excretion;O;O
of;O;O
amphetamine;B-drug;B-DDI-DrugBank.d368.s9.e1
and;O;O
may;O;O
enhance;O;O
the;O;O
magnitude;O;O
and;O;O
duration;O;O
of;O;O
their;O;O
effect;O;O
.;O;O
DDI-DrugBank.d368.s10;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s10.e0
reduces;O;O
urinary;O;O
excretion;O;O
of;O;O
quinidine;B-drug;B-DDI-DrugBank.d368.s10.e1
and;O;O
may;O;O
enhance;O;O
its;O;O
effect;O;O
.;O;O
DDI-DrugBank.d368.s11;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s11.e0
may;O;O
prevent;O;O
the;O;O
urinary;O;O
antiseptic;O;O
effect;O;O
of;O;O
methenamine;B-drug;B-DDI-DrugBank.d368.s11.e1
.;O;O
DDI-DrugBank.d368.s12;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s12.e0
increases;O;O
lithium;B-drug;B-DDI-DrugBank.d368.s12.e1
excretion;O;O
and;O;O
the;O;O
lithium;B-drug;B-DDI-DrugBank.d368.s12.e2
may;O;O
be;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d368.s13;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s13.e0
and;O;O
sodium;B-drug;B-DDI-DrugBank.d368.s13.e1
bicarbonate;I-drug;I-DDI-DrugBank.d368.s13.e1
used;O;O
concurrently;O;O
increases;O;O
the;O;O
risk;O;O
of;O;O
renal;O;O
calculus;O;O
formation;O;O
.;O;O
DDI-DrugBank.d368.s14;;
Acetazolamide;B-drug;B-DDI-DrugBank.d368.s14.e0
may;O;O
elevate;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d368.s14.e1
levels;O;O
.;O;O
DDI-DrugBank.d117.s0;;
Concomitant;O;O
use;O;O
with;O;O
iron;B-group;B-DDI-DrugBank.d117.s0.e0
supplements;I-group;I-DDI-DrugBank.d117.s0.e0
may;O;O
result;O;O
in;O;O
the;O;O
reduced;O;O
absorption;O;O
of;O;O
iron;B-drug;B-DDI-DrugBank.d117.s0.e1
.;O;O
DDI-DrugBank.d200.s0;;
Co;O;O
-;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d200.s0.e0
with;O;O
acyclovir;B-drug;B-DDI-DrugBank.d200.s0.e1
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
the;O;O
mean;O;O
half;O;O
-;O;O
life;O;O
and;O;O
the;O;O
area;O;O
under;O;O
the;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
.;O;O
DDI-DrugBank.d200.s1;;
Urinary;O;O
excretion;O;O
and;O;O
renal;O;O
clearance;O;O
were;O;O
correspondingly;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d200.s2;;
The;O;O
clinical;O;O
effects;O;O
of;O;O
this;O;O
combination;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d353.s0;;
Ethanol;B-drug;B-DDI-DrugBank.d353.s0.e0
:;O;O
Clinical;O;O
evidence;O;O
has;O;O
shown;O;O
that;O;O
etretinate;B-drug;B-DDI-DrugBank.d353.s0.e1
can;O;O
be;O;O
formed;O;O
with;O;O
concurrent;O;O
ingestion;O;O
of;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s0.e2
and;O;O
ethanol;B-drug;B-DDI-DrugBank.d353.s0.e3
.;O;O
DDI-DrugBank.d353.s1;;
Glibenclamide;B-drug;B-DDI-DrugBank.d353.s1.e0
:;O;O
In;O;O
a;O;O
study;O;O
of;O;O
7;O;O
healthy;O;O
male;O;O
volunteers;O;O
,;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s1.e1
treatment;O;O
potentiated;O;O
the;O;O
blood;O;O
glucose;O;O
lowering;O;O
effect;O;O
of;O;O
glibenclamide;B-drug;B-DDI-DrugBank.d353.s1.e2
(;O;O
a;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d353.s1.e3
similar;O;O
to;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d353.s1.e4
);O;O
in;O;O
3;O;O
of;O;O
the;O;O
7;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d353.s2;;
Repeating;O;O
the;O;O
study;O;O
with;O;O
6;O;O
healthy;O;O
male;O;O
volunteers;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
glibenclamide;B-drug;B-DDI-DrugBank.d353.s2.e0
did;O;O
not;O;O
detect;O;O
an;O;O
effect;O;O
of;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s2.e1
on;O;O
glucose;O;O
tolerance;O;O
.;O;O
DDI-DrugBank.d353.s3;;
Careful;O;O
supervision;O;O
of;O;O
diabetic;O;O
patients;O;O
under;O;O
treatment;O;O
with;O;O
Soriatane;B-brand;B-DDI-DrugBank.d353.s3.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d353.s4;;
Hormonal;B-group;B-DDI-DrugBank.d353.s4.e0
Contraceptives;I-group;I-DDI-DrugBank.d353.s4.e0
:;O;O
It;O;O
has;O;O
not;O;O
been;O;O
established;O;O
if;O;O
there;O;O
is;O;O
a;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s4.e1
and;O;O
combined;B-group;B-DDI-DrugBank.d353.s4.e2
oral;I-group;I-DDI-DrugBank.d353.s4.e2
contraceptives;I-group;I-DDI-DrugBank.d353.s4.e2
.;O;O
DDI-DrugBank.d353.s5;;
However;O;O
,;O;O
it;O;O
has;O;O
been;O;O
established;O;O
that;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s5.e0
interferes;O;O
with;O;O
the;O;O
contraceptive;O;O
effect;O;O
of;O;O
microdosed;O;O
progestin;B-drug;B-DDI-DrugBank.d353.s5.e1
minipill;O;O
preparations;O;O
.;O;O
DDI-DrugBank.d353.s6;;
Microdosed;O;O
minipill;O;O
progestin;B-drug;B-DDI-DrugBank.d353.s6.e0
preparations;O;O
are;O;O
not;O;O
recommended;O;O
for;O;O
use;O;O
with;O;O
Soriatane;B-drug;B-DDI-DrugBank.d353.s6.e1
.;O;O
DDI-DrugBank.d353.s7;;
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
other;O;O
progestational;B-group;B-DDI-DrugBank.d353.s7.e0
contraceptives;I-group;I-DDI-DrugBank.d353.s7.e0
,;O;O
such;O;O
as;O;O
implants;O;O
and;O;O
injectables;O;O
,;O;O
are;O;O
adequate;O;O
methods;O;O
of;O;O
contraception;O;O
during;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s7.e1
therapy;O;O
.;O;O
DDI-DrugBank.d353.s8;;
Methotrexate;B-drug;B-DDI-DrugBank.d353.s8.e0
:;O;O
An;O;O
increased;O;O
risk;O;O
of;O;O
hepatitis;O;O
has;O;O
been;O;O
reported;O;O
to;O;O
result;O;O
from;O;O
combined;O;O
use;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d353.s8.e1
and;O;O
etretinate;B-drug;B-DDI-DrugBank.d353.s8.e2
.;O;O
DDI-DrugBank.d353.s9;;
Consequently;O;O
,;O;O
the;O;O
combination;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d353.s9.e0
with;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s9.e1
is;O;O
also;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d353.s10;;
Phenytoin;B-drug;B-DDI-DrugBank.d353.s10.e0
:;O;O
If;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s10.e1
is;O;O
given;O;O
concurrently;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d353.s10.e2
,;O;O
the;O;O
protein;O;O
binding;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d353.s10.e3
may;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d353.s11;;
Tetracyclines;B-group;B-DDI-DrugBank.d353.s11.e0
:;O;O
Since;O;O
both;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s11.e1
and;O;O
tetracyclines;B-group;B-DDI-DrugBank.d353.s11.e2
can;O;O
cause;O;O
increased;O;O
intracranial;O;O
pressure;O;O
,;O;O
their;O;O
combined;O;O
use;O;O
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d353.s12;;
Vitamin;B-group;B-DDI-DrugBank.d353.s12.e0
A;I-group;I-DDI-DrugBank.d353.s12.e0
and;O;O
oral;O;O
retinoids;B-group;B-DDI-DrugBank.d353.s12.e1
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d353.s12.e2
A;I-group;I-DDI-DrugBank.d353.s12.e2
and/or;O;O
other;O;O
oral;O;O
retinoids;B-group;B-DDI-DrugBank.d353.s12.e3
with;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s12.e4
must;O;O
be;O;O
avoided;O;O
because;O;O
of;O;O
the;O;O
risk;O;O
of;O;O
hypervitaminosis;O;O
A.;O;O
DDI-DrugBank.d353.s13;;
Other;O;O
:;O;O
There;O;O
appears;O;O
to;O;O
be;O;O
no;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s13.e0
and;O;O
cimetidine;B-drug;B-DDI-DrugBank.d353.s13.e1
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d353.s13.e2
,;O;O
or;O;O
glyburide;B-drug;B-DDI-DrugBank.d353.s13.e3
.;O;O
DDI-DrugBank.d353.s14;;
Investigations;O;O
into;O;O
the;O;O
effect;O;O
of;O;O
acitretin;B-drug;B-DDI-DrugBank.d353.s14.e0
on;O;O
the;O;O
protein;O;O
binding;O;O
of;O;O
anticoagulants;B-group;B-DDI-DrugBank.d353.s14.e1
of;I-group;I-DDI-DrugBank.d353.s14.e1
the;I-group;I-DDI-DrugBank.d353.s14.e1
coumarin;I-group;I-DDI-DrugBank.d353.s14.e1
type;I-group;I-DDI-DrugBank.d353.s14.e1
(;O;O
warfarin;B-drug;B-DDI-DrugBank.d353.s14.e2
);O;O
revealed;O;O
no;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d353.s15;;
Laboratory;O;O
Tests;O;O
If;O;O
significant;O;O
abnormal;O;O
laboratory;O;O
results;O;O
are;O;O
obtained;O;O
,;O;O
either;O;O
dosage;O;O
reduction;O;O
with;O;O
careful;O;O
monitoring;O;O
or;O;O
treatment;O;O
discontinuation;O;O
is;O;O
recommended;O;O
,;O;O
depending;O;O
on;O;O
clinical;O;O
judgement;O;O
.;O;O
DDI-DrugBank.d353.s16;;
Blood;O;O
Sugar;O;O
:;O;O
Some;O;O
patients;O;O
receiving;O;O
retinoids;B-group;B-DDI-DrugBank.d353.s16.e0
have;O;O
experienced;O;O
problems;O;O
with;O;O
blood;O;O
sugar;O;O
control;O;O
.;O;O
DDI-DrugBank.d353.s17;;
In;O;O
addition;O;O
,;O;O
new;O;O
cases;O;O
of;O;O
diabetes;O;O
have;O;O
been;O;O
diagnosed;O;O
during;O;O
retinoid;B-group;B-DDI-DrugBank.d353.s17.e0
therapy;O;O
,;O;O
including;O;O
diabetic;O;O
ketoacidosis;O;O
.;O;O
DDI-DrugBank.d353.s18;;
In;O;O
diabetics;O;O
,;O;O
blood;O;O
-;O;O
sugar;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
very;O;O
carefully;O;O
.;O;O
DDI-DrugBank.d353.s19;;
Lipids;O;O
:;O;O
In;O;O
clinical;O;O
studies;O;O
,;O;O
the;O;O
incidence;O;O
of;O;O
hypertriglyceridemia;O;O
was;O;O
66;O;O
%;O;O
,;O;O
hypercholesterolemia;O;O
was;O;O
33;O;O
%;O;O
and;O;O
that;O;O
of;O;O
decreased;O;O
HDL;O;O
was;O;O
40;O;O
%;O;O
.;O;O
DDI-DrugBank.d353.s20;;
Pretreatment;O;O
and;O;O
follow;O;O
-;O;O
up;O;O
measurements;O;O
should;O;O
be;O;O
obtained;O;O
under;O;O
fasting;O;O
conditions;O;O
.;O;O
DDI-DrugBank.d353.s21;;
It;O;O
is;O;O
recommended;O;O
that;O;O
these;O;O
tests;O;O
be;O;O
performed;O;O
weekly;O;O
or;O;O
every;O;O
other;O;O
week;O;O
until;O;O
the;O;O
lipid;O;O
response;O;O
to;O;O
Soriatane;B-brand;B-DDI-DrugBank.d353.s21.e0
has;O;O
stabilized;O;O
.;O;O
DDI-DrugBank.d353.s22;;
Liver;O;O
Function;O;O
Tests;O;O
:;O;O
Elevations;O;O
of;O;O
AST;O;O
(;O;O
SGOT;O;O
);O;O
,;O;O
ALT;O;O
(;O;O
SGPT;O;O
);O;O
or;O;O
LDH;O;O
were;O;O
experienced;O;O
by;O;O
approximately;O;O
1;O;O
in;O;O
3;O;O
patients;O;O
treated;O;O
with;O;O
Soriatane;B-brand;B-DDI-DrugBank.d353.s22.e0
.;O;O
DDI-DrugBank.d353.s23;;
It;O;O
is;O;O
recommended;O;O
that;O;O
these;O;O
tests;O;O
be;O;O
performed;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
Soriatane;B-brand;B-DDI-DrugBank.d353.s23.e0
therapy;O;O
,;O;O
at;O;O
1;O;O
-;O;O
to;O;O
2;O;O
-;O;O
week;O;O
intervals;O;O
until;O;O
stable;O;O
and;O;O
thereafter;O;O
at;O;O
intervals;O;O
as;O;O
clinically;O;O
indicated;O;O
.;O;O
DDI-DrugBank.d493.s0;;
Methotrexate;B-drug;B-DDI-DrugBank.d493.s0.e0
:;O;O
HUMIRA;B-brand;B-DDI-DrugBank.d493.s0.e1
has;O;O
been;O;O
studied;O;O
in;O;O
rheumatoid;O;O
arthritis;O;O
patients;O;O
taking;O;O
concomitant;O;O
MTX;B-drug;B-DDI-DrugBank.d493.s0.e2
.;O;O
DDI-DrugBank.d493.s1;;
The;O;O
data;O;O
do;O;O
not;O;O
suggest;O;O
the;O;O
need;O;O
for;O;O
dose;O;O
adjustment;O;O
of;O;O
either;O;O
HUMIRA;B-brand;B-DDI-DrugBank.d493.s1.e0
or;O;O
MTX;B-drug;B-DDI-DrugBank.d493.s1.e1
.;O;O
DDI-DrugBank.d493.s2;;
Anakinra;B-drug;B-DDI-DrugBank.d493.s2.e0
:;O;O
Concurrent;O;O
administration;O;O
of;O;O
anakinra;B-drug;B-DDI-DrugBank.d493.s2.e1
(;O;O
an;O;O
interleukin;B-group;B-DDI-DrugBank.d493.s2.e2
-;I-group;I-DDI-DrugBank.d493.s2.e2
1;I-group;I-DDI-DrugBank.d493.s2.e2
antagonist;I-group;I-DDI-DrugBank.d493.s2.e2
);O;O
and;O;O
another;O;O
TNF;B-group;B-DDI-DrugBank.d493.s2.e3
-;I-group;I-DDI-DrugBank.d493.s2.e3
blocking;I-group;I-DDI-DrugBank.d493.s2.e3
agent;I-group;I-DDI-DrugBank.d493.s2.e3
has;O;O
been;O;O
associated;O;O
with;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
serious;O;O
infections;O;O
,;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
neutropenia;O;O
and;O;O
no;O;O
additional;O;O
benefit;O;O
compared;O;O
to;O;O
these;O;O
medicinal;O;O
products;O;O
alone;O;O
.;O;O
DDI-DrugBank.d493.s3;;
The;O;O
safety;O;O
and;O;O
efficacy;O;O
of;O;O
anakinra;B-drug;B-DDI-DrugBank.d493.s3.e0
used;O;O
in;O;O
combination;O;O
with;O;O
HUMIRA;B-brand;B-DDI-DrugBank.d493.s3.e1
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d493.s4;;
Therefore;O;O
the;O;O
,;O;O
combination;O;O
of;O;O
anakinra;B-drug;B-DDI-DrugBank.d493.s4.e0
with;O;O
other;O;O
TNF;B-group;B-DDI-DrugBank.d493.s4.e1
-;I-group;I-DDI-DrugBank.d493.s4.e1
blocking;I-group;I-DDI-DrugBank.d493.s4.e1
agents;I-group;I-DDI-DrugBank.d493.s4.e1
,;O;O
including;O;O
HUMIRA;B-brand;B-DDI-DrugBank.d493.s4.e2
,;O;O
may;O;O
also;O;O
result;O;O
i;O;O
n;O;O
similar;O;O
toxicities;O;O
.;O;O
DDI-DrugBank.d370.s0;;
As;O;O
DIFFERIN;B-brand;B-DDI-DrugBank.d370.s0.e0
Gel;O;O
has;O;O
the;O;O
potential;O;O
to;O;O
produce;O;O
local;O;O
irritation;O;O
in;O;O
some;O;O
patients;O;O
,;O;O
concomitant;O;O
use;O;O
of;O;O
other;O;O
potentially;O;O
irritating;O;O
topical;O;O
products;O;O
(;O;O
medicated;O;O
or;O;O
abrasive;O;O
soaps;O;O
and;O;O
cleansers;O;O
,;O;O
soaps;O;O
and;O;O
cosmetics;O;O
that;O;O
have;O;O
a;O;O
strong;O;O
drying;O;O
effect;O;O
,;O;O
and;O;O
products;O;O
with;O;O
high;O;O
concentrations;O;O
of;O;O
alcohol;O;O
,;O;O
astringents;O;O
,;O;O
spices;O;O
or;O;O
lime;O;O
);O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d370.s1;;
Particular;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
in;O;O
using;O;O
preparations;O;O
containing;O;O
sulfur;B-drug;B-DDI-DrugBank.d370.s1.e0
,;O;O
resorcinol;B-drug;B-DDI-DrugBank.d370.s1.e1
,;O;O
or;O;O
salicylic;B-drug;B-DDI-DrugBank.d370.s1.e2
acid;I-drug;I-DDI-DrugBank.d370.s1.e2
in;O;O
combination;O;O
with;O;O
DIFFERIN;B-brand;B-DDI-DrugBank.d370.s1.e3
Gel;O;O
.;O;O
DDI-DrugBank.d370.s2;;
If;O;O
these;O;O
preparations;O;O
have;O;O
been;O;O
used;O;O
it;O;O
is;O;O
advisable;O;O
not;O;O
to;O;O
start;O;O
therapy;O;O
with;O;O
DIFFERIN;B-brand;B-DDI-DrugBank.d370.s2.e0
Gel;O;O
until;O;O
the;O;O
effects;O;O
of;O;O
such;O;O
preparations;O;O
in;O;O
the;O;O
skin;O;O
have;O;O
subsided;O;O
.;O;O
DDI-DrugBank.d244.s0;;
Before;O;O
using;O;O
this;O;O
medication;O;O
,;O;O
tell;O;O
your;O;O
doctor;O;O
or;O;O
pharmacist;O;O
of;O;O
all;O;O
prescription;O;O
and;O;O
nonprescription;O;O
products;O;O
you;O;O
may;O;O
use;O;O
,;O;O
especially;O;O
of;O;O
:;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d244.s0.e0
(;O;O
e.g.;O;O
,;O;O
gentamicin;B-drug;B-DDI-DrugBank.d244.s0.e1
,;O;O
amikacin;B-drug;B-DDI-DrugBank.d244.s0.e2
);O;O
,;O;O
amphotericin;B-drug;B-DDI-DrugBank.d244.s0.e3
B;I-drug;I-DDI-DrugBank.d244.s0.e3
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d244.s0.e4
,;O;O
non;B-group;B-DDI-DrugBank.d244.s0.e5
-;I-group;I-DDI-DrugBank.d244.s0.e5
steroidal;I-group;I-DDI-DrugBank.d244.s0.e5
anti;I-group;I-DDI-DrugBank.d244.s0.e5
-;I-group;I-DDI-DrugBank.d244.s0.e5
inflammatory;I-group;I-DDI-DrugBank.d244.s0.e5
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d244.s0.e6
);O;O
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d244.s0.e7
,;O;O
vancomycin;B-drug;B-DDI-DrugBank.d244.s0.e8
.;O;O
DDI-DrugBank.d244.s1;;
Do;O;O
not;O;O
start;O;O
or;O;O
stop;O;O
any;O;O
medicine;O;O
without;O;O
doctor;O;O
or;O;O
pharmacist;O;O
approval;O;O
.;O;O
DDI-DrugBank.d226.s0;;
Intravenous;O;O
Adenocard;B-brand;B-DDI-DrugBank.d226.s0.e0
(;O;O
adenosine;B-drug;B-DDI-DrugBank.d226.s0.e1
);O;O
has;O;O
been;O;O
effectively;O;O
administered;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
other;O;O
cardioactive;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d226.s0.e2
,;O;O
beta;B-group;B-DDI-DrugBank.d226.s0.e3
-;I-group;I-DDI-DrugBank.d226.s0.e3
adrenergic;I-group;I-DDI-DrugBank.d226.s0.e3
blocking;I-group;I-DDI-DrugBank.d226.s0.e3
agents;I-group;I-DDI-DrugBank.d226.s0.e3
,;O;O
calcium;B-group;B-DDI-DrugBank.d226.s0.e4
channel;I-group;I-DDI-DrugBank.d226.s0.e4
blocking;I-group;I-DDI-DrugBank.d226.s0.e4
agents;I-group;I-DDI-DrugBank.d226.s0.e4
,;O;O
and;O;O
angiotensin;B-group;B-DDI-DrugBank.d226.s0.e5
converting;I-group;I-DDI-DrugBank.d226.s0.e5
enzyme;I-group;I-DDI-DrugBank.d226.s0.e5
inhibitors;I-group;I-DDI-DrugBank.d226.s0.e5
,;O;O
without;O;O
any;O;O
change;O;O
in;O;O
the;O;O
adverse;O;O
reaction;O;O
profile;O;O
.;O;O
DDI-DrugBank.d226.s1;;
Digoxin;B-drug;B-DDI-DrugBank.d226.s1.e0
and;O;O
verapamil;B-drug;B-DDI-DrugBank.d226.s1.e1
use;O;O
may;O;O
be;O;O
rarely;O;O
associated;O;O
with;O;O
ventricular;O;O
fibrillation;O;O
when;O;O
combined;O;O
with;O;O
Adenocard;B-brand;B-DDI-DrugBank.d226.s1.e2
.;O;O
DDI-DrugBank.d226.s2;;
Because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
additive;O;O
or;O;O
synergistic;O;O
depressant;O;O
effects;O;O
on;O;O
the;O;O
SA;O;O
and;O;O
AV;O;O
nodes;O;O
,;O;O
however;O;O
,;O;O
Adenocard;B-brand;B-DDI-DrugBank.d226.s2.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d226.s3;;
The;O;O
use;O;O
of;O;O
Adenocard;B-brand;B-DDI-DrugBank.d226.s3.e0
in;O;O
patients;O;O
receiving;O;O
digitalis;B-group;B-DDI-DrugBank.d226.s3.e1
may;O;O
be;O;O
rarely;O;O
associated;O;O
with;O;O
ventricular;O;O
fibrillation;O;O
.;O;O
DDI-DrugBank.d226.s4;;
The;O;O
effects;O;O
of;O;O
adenosine;B-drug;B-DDI-DrugBank.d226.s4.e0
are;O;O
antagonized;O;O
by;O;O
methylxanthines;B-group;B-DDI-DrugBank.d226.s4.e1
such;O;O
as;O;O
caffeine;B-drug;B-DDI-DrugBank.d226.s4.e2
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d226.s4.e3
.;O;O
DDI-DrugBank.d226.s5;;
In;O;O
the;O;O
presence;O;O
of;O;O
these;O;O
methylxanthines;B-group;B-DDI-DrugBank.d226.s5.e0
,;O;O
larger;O;O
doses;O;O
of;O;O
adenosine;B-drug;B-DDI-DrugBank.d226.s5.e1
may;O;O
be;O;O
required;O;O
or;O;O
adenosine;B-drug;B-DDI-DrugBank.d226.s5.e2
may;O;O
not;O;O
be;O;O
effective;O;O
.;O;O
DDI-DrugBank.d226.s6;;
Adenosine;B-drug;B-DDI-DrugBank.d226.s6.e0
effects;O;O
are;O;O
potentiated;O;O
by;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d226.s6.e1
.;O;O
DDI-DrugBank.d226.s7;;
Thus;O;O
,;O;O
smaller;O;O
doses;O;O
of;O;O
adenosine;B-drug;B-DDI-DrugBank.d226.s7.e0
may;O;O
be;O;O
effective;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d226.s7.e1
.;O;O
DDI-DrugBank.d226.s8;;
Carbamazepine;B-drug;B-DDI-DrugBank.d226.s8.e0
has;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
the;O;O
degree;O;O
of;O;O
heart;O;O
block;O;O
produced;O;O
by;O;O
other;O;O
agents;O;O
.;O;O
DDI-DrugBank.d226.s9;;
As;O;O
the;O;O
primary;O;O
effect;O;O
of;O;O
adenosine;B-drug;B-DDI-DrugBank.d226.s9.e0
is;O;O
to;O;O
decrease;O;O
conduction;O;O
through;O;O
the;O;O
A;O;O
-;O;O
V;O;O
node;O;O
,;O;O
higher;O;O
degrees;O;O
of;O;O
heart;O;O
block;O;O
may;O;O
be;O;O
produced;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d226.s9.e1
.;O;O
DDI-DrugBank.d449.s0;;
Co;O;O
-;O;O
administration;O;O
with;O;O
antifungal;B-group;B-DDI-DrugBank.d449.s0.e0
agents;I-group;I-DDI-DrugBank.d449.s0.e0
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d449.s0.e1
or;O;O
itraconazole;B-drug;B-DDI-DrugBank.d449.s0.e2
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d449.s1;;
Nafazodone;B-drug;B-DDI-DrugBank.d449.s1.e0
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d449.s1.e1
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d449.s1.e2
(;O;O
consider;O;O
Xanax;B-brand;B-DDI-DrugBank.d449.s1.e3
dose;O;O
reduction;O;O
);O;O
.;O;O
DDI-DrugBank.d449.s2;;
Fluoxetine;B-drug;B-DDI-DrugBank.d449.s2.e0
,;O;O
OCs;B-group;B-DDI-DrugBank.d449.s2.e1
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d449.s2.e2
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d449.s2.e3
,;O;O
macrolide;B-group;B-DDI-DrugBank.d449.s2.e4
antibiotics;I-group;I-DDI-DrugBank.d449.s2.e4
(;O;O
exercise;O;O
caution;O;O
);O;O
.;O;O
DDI-DrugBank.d164.s0;;
No;O;O
drug;O;O
interaction;O;O
studies;O;O
were;O;O
performed;O;O
.;O;O
DDI-DrugBank.d164.s1;;
No;O;O
in;O;O
vitro;O;O
metabolism;O;O
studies;O;O
were;O;O
performed;O;O
.;O;O
DDI-DrugBank.d321.s0;;
Dexamethasone;B-drug;B-DDI-DrugBank.d321.s0.e0
:;O;O
Steady;O;O
-;O;O
state;O;O
trough;O;O
concentrations;O;O
of;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s0.e1
sulfoxide;I-drug;I-DDI-DrugBank.d321.s0.e1
were;O;O
about;O;O
56;O;O
%;O;O
higher;O;O
when;O;O
8;O;O
mg;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d321.s0.e2
was;O;O
coadministered;O;O
with;O;O
each;O;O
dose;O;O
of;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s0.e3
(;O;O
15;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
in;O;O
eight;O;O
neurocysticercosis;O;O
patients;O;O
.;O;O
DDI-DrugBank.d321.s1;;
Praziquantel;B-drug;B-DDI-DrugBank.d321.s1.e0
:;O;O
In;O;O
the;O;O
fed;O;O
state;O;O
,;O;O
praziquantel;B-drug;B-DDI-DrugBank.d321.s1.e1
(;O;O
40;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
increased;O;O
mean;O;O
maximum;O;O
plasma;O;O
concentration;O;O
and;O;O
area;O;O
under;O;O
the;O;O
curve;O;O
of;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s1.e2
sulfoxide;I-drug;I-DDI-DrugBank.d321.s1.e2
by;O;O
about;O;O
50;O;O
%;O;O
in;O;O
healthy;O;O
subjects;O;O
(;O;O
n=10;O;O
);O;O
compared;O;O
with;O;O
a;O;O
separate;O;O
group;O;O
of;O;O
subjects;O;O
(;O;O
n=6;O;O
);O;O
given;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s1.e3
alone;O;O
.;O;O
DDI-DrugBank.d321.s2;;
Mean;O;O
T;O;O
max;O;O
and;O;O
mean;O;O
plasma;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
of;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s2.e0
sulfoxide;I-drug;I-DDI-DrugBank.d321.s2.e0
were;O;O
unchanged;O;O
.;O;O
DDI-DrugBank.d321.s3;;
The;O;O
pharmacokinetics;O;O
of;O;O
praziquantel;B-drug;B-DDI-DrugBank.d321.s3.e0
were;O;O
unchanged;O;O
following;O;O
coadministration;O;O
with;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s3.e1
(;O;O
400;O;O
mg;O;O
);O;O
.;O;O
DDI-DrugBank.d321.s4;;
Cimetidine;B-drug;B-DDI-DrugBank.d321.s4.e0
:;O;O
Albendazole;B-drug;B-DDI-DrugBank.d321.s4.e1
sulfoxide;I-drug;I-DDI-DrugBank.d321.s4.e1
concentrations;O;O
in;O;O
bile;O;O
and;O;O
cystic;O;O
fluid;O;O
were;O;O
increased;O;O
(;O;O
about;O;O
2;O;O
-;O;O
fold;O;O
);O;O
in;O;O
hydatid;O;O
cyst;O;O
patients;O;O
treated;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d321.s4.e2
(;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
(;O;O
n=7;O;O
);O;O
compared;O;O
with;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s4.e3
(;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
alone;O;O
(;O;O
n=12;O;O
);O;O
.;O;O
DDI-DrugBank.d321.s5;;
Albendazole;B-drug;B-DDI-DrugBank.d321.s5.e0
sulfoxide;I-drug;I-DDI-DrugBank.d321.s5.e0
plasma;O;O
concentrations;O;O
were;O;O
unchanged;O;O
4;O;O
hours;O;O
after;O;O
dosing;O;O
.;O;O
DDI-DrugBank.d321.s6;;
Theophylline;B-drug;B-DDI-DrugBank.d321.s6.e0
:;O;O
The;O;O
pharmacokinetics;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d321.s6.e1
(;O;O
aminophylline;B-drug;B-DDI-DrugBank.d321.s6.e2
5.8;O;O
mg;O;O
/;O;O
kg;O;O
infused;O;O
over;O;O
20;O;O
minutes;O;O
);O;O
were;O;O
unchanged;O;O
following;O;O
a;O;O
single;O;O
oral;O;O
dose;O;O
of;O;O
albendazole;B-drug;B-DDI-DrugBank.d321.s6.e3
(;O;O
400;O;O
mg;O;O
);O;O
in;O;O
6;O;O
healthy;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d102.s0;;
No;O;O
information;O;O
provided;O;O
DDI-DrugBank.d114.s0;;
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s0.e0
may;O;O
affect;O;O
central;O;O
nervous;O;O
function;O;O
.;O;O
DDI-DrugBank.d114.s1;;
Therefore;O;O
,;O;O
interactions;O;O
could;O;O
occur;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
psychotropic;B-group;B-DDI-DrugBank.d114.s1.e0
drugs;I-group;I-DDI-DrugBank.d114.s1.e0
(;O;O
e.g.;O;O
,;O;O
narcotics;B-group;B-DDI-DrugBank.d114.s1.e1
,;O;O
analgesics;B-group;B-DDI-DrugBank.d114.s1.e2
,;O;O
antiemetics;B-group;B-DDI-DrugBank.d114.s1.e3
,;O;O
sedatives;B-group;B-DDI-DrugBank.d114.s1.e4
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d114.s1.e5
);O;O
.;O;O
DDI-DrugBank.d114.s2;;
Concurrent;O;O
administration;O;O
of;O;O
drugs;O;O
possessing;O;O
nephrotoxic;O;O
(;O;O
e.g.;O;O
,;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d114.s2.e0
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d114.s2.e1
);O;O
,;O;O
myelotoxic;O;O
(;O;O
e.g.;O;O
,;O;O
cytotoxic;B-group;B-DDI-DrugBank.d114.s2.e2
chemotherapy;O;O
);O;O
,;O;O
cardiotoxic;O;O
(;O;O
e.g.;O;O
,;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d114.s2.e3
);O;O
or;O;O
hepatotoxic;O;O
(;O;O
e.g.;O;O
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d114.s2.e4
,;O;O
asparaginase;B-drug;B-DDI-DrugBank.d114.s2.e5
);O;O
effects;O;O
with;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s2.e6
may;O;O
increase;O;O
toxicity;O;O
in;O;O
these;O;O
organ;O;O
systems;O;O
.;O;O
DDI-DrugBank.d114.s3;;
The;O;O
safety;O;O
and;O;O
efficacy;O;O
of;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s3.e0
in;O;O
combination;O;O
with;O;O
any;O;O
antineoplastic;B-group;B-DDI-DrugBank.d114.s3.e1
agents;I-group;I-DDI-DrugBank.d114.s3.e1
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d114.s4;;
In;O;O
addition;O;O
,;O;O
reduced;O;O
kidney;O;O
and;O;O
liver;O;O
function;O;O
secondary;O;O
to;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s4.e0
treatment;O;O
may;O;O
delay;O;O
elimination;O;O
of;O;O
concomitant;O;O
medications;O;O
and;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
adverse;O;O
events;O;O
from;O;O
those;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d114.s5;;
Hypersensitivity;O;O
reactions;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
combination;O;O
regimens;O;O
containing;O;O
sequential;O;O
high;O;O
dose;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s5.e0
and;O;O
antineoplastic;B-group;B-DDI-DrugBank.d114.s5.e1
agents;I-group;I-DDI-DrugBank.d114.s5.e1
,;O;O
specifically;O;O
,;O;O
dacarbazine;B-drug;B-DDI-DrugBank.d114.s5.e2
,;O;O
cis;B-drug;B-DDI-DrugBank.d114.s5.e3
-;I-drug;I-DDI-DrugBank.d114.s5.e3
platinum;I-drug;I-DDI-DrugBank.d114.s5.e3
,;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d114.s5.e4
and;O;O
interferon;B-drug;B-DDI-DrugBank.d114.s5.e5
-;I-drug;I-DDI-DrugBank.d114.s5.e5
alfa;I-drug;I-DDI-DrugBank.d114.s5.e5
.;O;O
DDI-DrugBank.d114.s6;;
These;O;O
reactions;O;O
consisted;O;O
of;O;O
erythema;O;O
,;O;O
pruritus;O;O
,;O;O
and;O;O
hypotension;O;O
and;O;O
occurred;O;O
within;O;O
hours;O;O
of;O;O
administration;O;O
of;O;O
chemotherapy;O;O
.;O;O
DDI-DrugBank.d114.s7;;
These;O;O
events;O;O
required;O;O
medical;O;O
intervention;O;O
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d114.s8;;
Myocardial;O;O
injury;O;O
,;O;O
including;O;O
myocardial;O;O
infarction;O;O
,;O;O
myocarditis;O;O
,;O;O
ventricular;O;O
hypokinesia;O;O
,;O;O
and;O;O
severe;O;O
rhabdomyolysis;O;O
appear;O;O
to;O;O
be;O;O
increased;O;O
in;O;O
patients;O;O
receiving;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s8.e0
and;O;O
interferon;B-drug;B-DDI-DrugBank.d114.s8.e1
-;I-drug;I-DDI-DrugBank.d114.s8.e1
alfa;I-drug;I-DDI-DrugBank.d114.s8.e1
concurrently;O;O
.;O;O
DDI-DrugBank.d114.s9;;
Exacerbation;O;O
or;O;O
the;O;O
initial;O;O
presentation;O;O
of;O;O
a;O;O
number;O;O
of;O;O
autoimmune;O;O
and;O;O
inflammatory;O;O
disorders;O;O
has;O;O
been;O;O
observed;O;O
following;O;O
concurrent;O;O
use;O;O
of;O;O
interferon;B-drug;B-DDI-DrugBank.d114.s9.e0
-;I-drug;I-DDI-DrugBank.d114.s9.e0
alfa;I-drug;I-DDI-DrugBank.d114.s9.e0
and;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s9.e1
,;O;O
including;O;O
crescentic;O;O
IgA;O;O
glomerulonephritis;O;O
,;O;O
oculo;O;O
-;O;O
bulbar;O;O
myasthenia;O;O
gravis;O;O
,;O;O
inflammatory;O;O
arthritis;O;O
,;O;O
thyroiditis;O;O
,;O;O
bullous;O;O
pemphigoid;O;O
,;O;O
and;O;O
Stevens;O;O
-;O;O
Johnson;O;O
syndrome;O;O
.;O;O
DDI-DrugBank.d114.s10;;
Although;O;O
glucocorticoids;B-group;B-DDI-DrugBank.d114.s10.e0
have;O;O
been;O;O
shown;O;O
to;O;O
reduce;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s10.e1
-;O;O
induced;O;O
side;O;O
effects;O;O
including;O;O
fever;O;O
,;O;O
renal;O;O
insufficiency;O;O
,;O;O
hyperbilirubinemia;O;O
,;O;O
confusion;O;O
,;O;O
and;O;O
dyspnea;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
these;O;O
agents;O;O
with;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s10.e2
may;O;O
reduce;O;O
the;O;O
antitumor;O;O
effectiveness;O;O
of;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s10.e3
and;O;O
thus;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
12;O;O
Beta;B-group;B-DDI-DrugBank.d114.s10.e4
-;I-group;I-DDI-DrugBank.d114.s10.e4
blockers;I-group;I-DDI-DrugBank.d114.s10.e4
and;O;O
other;O;O
antihypertensives;B-group;B-DDI-DrugBank.d114.s10.e5
may;O;O
potentiate;O;O
the;O;O
hypotension;O;O
seen;O;O
with;O;O
PROLEUKIN;B-brand;B-DDI-DrugBank.d114.s10.e6
.;O;O
DDI-DrugBank.d114.s11;;
Delayed;O;O
Adverse;O;O
Reactions;O;O
to;O;O
Iodinated;B-group;B-DDI-DrugBank.d114.s11.e0
Contrast;I-group;I-DDI-DrugBank.d114.s11.e0
Media;I-group;I-DDI-DrugBank.d114.s11.e0
:;O;O
A;O;O
review;O;O
of;O;O
the;O;O
literature;O;O
revealed;O;O
that;O;O
12.6;O;O
%;O;O
(;O;O
range;O;O
11;O;O
-;O;O
28;O;O
%;O;O
);O;O
of;O;O
501;O;O
patients;O;O
treated;O;O
with;O;O
various;O;O
interleukin;O;O
-;O;O
2;O;O
containing;O;O
regimens;O;O
who;O;O
were;O;O
subsequently;O;O
administered;O;O
radiographic;B-group;B-DDI-DrugBank.d114.s11.e2
iodinated;I-group;I-DDI-DrugBank.d114.s11.e2
contrast;I-group;I-DDI-DrugBank.d114.s11.e2
media;I-group;I-DDI-DrugBank.d114.s11.e2
experienced;O;O
acute;O;O
,;O;O
atypical;O;O
adverse;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d114.s12;;
The;O;O
onset;O;O
of;O;O
symptoms;O;O
usually;O;O
occurred;O;O
within;O;O
hours;O;O
(;O;O
most;O;O
commonly;O;O
1;O;O
to;O;O
4;O;O
hours;O;O
);O;O
following;O;O
the;O;O
administration;O;O
of;O;O
contrast;O;O
media;O;O
.;O;O
DDI-DrugBank.d114.s13;;
These;O;O
reactions;O;O
include;O;O
fever;O;O
,;O;O
chills;O;O
,;O;O
nausea;O;O
,;O;O
vomiting;O;O
,;O;O
pruritus;O;O
,;O;O
rash;O;O
,;O;O
diarrhea;O;O
,;O;O
hypotension;O;O
,;O;O
edema;O;O
,;O;O
and;O;O
oliguria;O;O
.;O;O
DDI-DrugBank.d114.s14;;
Some;O;O
clinicians;O;O
have;O;O
noted;O;O
that;O;O
these;O;O
reactions;O;O
resemble;O;O
the;O;O
immediate;O;O
side;O;O
effects;O;O
caused;O;O
by;O;O
interleukin;O;O
-;O;O
2;O;O
administration;O;O
,;O;O
however;O;O
the;O;O
cause;O;O
of;O;O
contrast;O;O
reactions;O;O
after;O;O
interleukin;O;O
-;O;O
2;O;O
therapy;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d114.s15;;
Most;O;O
events;O;O
were;O;O
reported;O;O
to;O;O
occur;O;O
when;O;O
contrast;O;O
media;O;O
was;O;O
given;O;O
within;O;O
4;O;O
weeks;O;O
after;O;O
the;O;O
last;O;O
dose;O;O
of;O;O
interleukin;O;O
-;O;O
2;O;O
.;O;O
DDI-DrugBank.d114.s16;;
These;O;O
events;O;O
were;O;O
also;O;O
reported;O;O
to;O;O
occur;O;O
when;O;O
contrast;O;O
media;O;O
was;O;O
given;O;O
several;O;O
months;O;O
after;O;O
interleukin;O;O
-;O;O
2;O;O
treatment;O;O
.;O;O
DDI-DrugBank.d491.s0;;
No;O;O
formal;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d491.s1;;
The;O;O
duration;O;O
of;O;O
the;O;O
period;O;O
following;O;O
treatment;O;O
with;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s1.e0
before;O;O
one;O;O
should;O;O
consider;O;O
starting;O;O
other;O;O
immunosuppressive;B-group;B-DDI-DrugBank.d491.s1.e1
therapy;O;O
has;O;O
not;O;O
been;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d491.s2;;
Carcinogenesis;O;O
,;O;O
Mutagenesis;O;O
,;O;O
and;O;O
Fertility;O;O
DDI-DrugBank.d491.s3;;
In;O;O
a;O;O
chronic;O;O
toxicity;O;O
study;O;O
,;O;O
cynomolgus;O;O
monkeys;O;O
were;O;O
dosed;O;O
weekly;O;O
for;O;O
52;O;O
weeks;O;O
with;O;O
intravenous;O;O
alefacept;B-drug;B-DDI-DrugBank.d491.s3.e0
at;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
dose;O;O
or;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
dose;O;O
.;O;O
DDI-DrugBank.d491.s4;;
One;O;O
animal;O;O
in;O;O
the;O;O
high;O;O
dose;O;O
group;O;O
developed;O;O
a;O;O
B;O;O
-;O;O
cell;O;O
lymphoma;O;O
that;O;O
was;O;O
detected;O;O
after;O;O
28;O;O
weeks;O;O
of;O;O
dosing;O;O
.;O;O
DDI-DrugBank.d491.s5;;
Additional;O;O
animals;O;O
in;O;O
both;O;O
dose;O;O
groups;O;O
developed;O;O
B;O;O
-;O;O
cell;O;O
hyperplasia;O;O
of;O;O
the;O;O
spleen;O;O
and;O;O
lymph;O;O
nodes;O;O
.;O;O
DDI-DrugBank.d491.s6;;
All;O;O
animals;O;O
in;O;O
the;O;O
study;O;O
were;O;O
positive;O;O
for;O;O
an;O;O
endemic;O;O
primate;O;O
gammaherpes;O;O
virus;O;O
also;O;O
known;O;O
as;O;O
lymphocryptovirus;O;O
(;O;O
LCV;O;O
);O;O
.;O;O
DDI-DrugBank.d491.s7;;
Latent;O;O
LCV;O;O
infection;O;O
is;O;O
generally;O;O
asymptomatic;O;O
,;O;O
but;O;O
can;O;O
lead;O;O
to;O;O
B;O;O
-;O;O
cell;O;O
lymphomas;O;O
when;O;O
animals;O;O
are;O;O
immune;O;O
suppressed;O;O
.;O;O
DDI-DrugBank.d491.s8;;
In;O;O
a;O;O
separate;O;O
study;O;O
,;O;O
baboons;O;O
given;O;O
3;O;O
doses;O;O
of;O;O
alefacept;B-drug;B-DDI-DrugBank.d491.s8.e0
at;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
every;O;O
8;O;O
weeks;O;O
were;O;O
found;O;O
to;O;O
have;O;O
centroblast;O;O
proliferation;O;O
in;O;O
B;O;O
-;O;O
cell;O;O
dependent;O;O
areas;O;O
in;O;O
the;O;O
germinal;O;O
centers;O;O
of;O;O
the;O;O
spleen;O;O
following;O;O
a;O;O
116;O;O
-;O;O
day;O;O
washout;O;O
period;O;O
.;O;O
DDI-DrugBank.d491.s9;;
The;O;O
role;O;O
of;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s9.e0
in;O;O
the;O;O
development;O;O
of;O;O
the;O;O
lymphoid;O;O
malignancy;O;O
and;O;O
the;O;O
hyperplasia;O;O
observed;O;O
in;O;O
non;O;O
-;O;O
human;O;O
primates;O;O
and;O;O
the;O;O
relevance;O;O
to;O;O
humans;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d491.s10;;
Immunodeficiency;O;O
-;O;O
associated;O;O
lymphocyte;O;O
disorders;O;O
(;O;O
plasmacytic;O;O
hyperplasia;O;O
,;O;O
polymorphic;O;O
proliferation;O;O
,;O;O
and;O;O
B;O;O
-;O;O
cell;O;O
lymphomas;O;O
);O;O
occur;O;O
in;O;O
patients;O;O
who;O;O
have;O;O
congenital;O;O
or;O;O
acquired;O;O
immunodeficiencies;O;O
including;O;O
those;O;O
resulting;O;O
from;O;O
immunosuppressive;B-group;B-DDI-DrugBank.d491.s10.e0
therapy;O;O
.;O;O
DDI-DrugBank.d491.s11;;
No;O;O
carcinogenicity;O;O
or;O;O
fertility;O;O
studies;O;O
were;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d491.s12;;
Mutagenicity;O;O
studies;O;O
were;O;O
conducted;O;O
in;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
,;O;O
DDI-DrugBank.d491.s13;;
no;O;O
evidence;O;O
of;O;O
mutagenicity;O;O
was;O;O
observed;O;O
.;O;O
DDI-DrugBank.d491.s14;;
Pregnancy;O;O
(;O;O
Category;O;O
B;O;O
);O;O
DDI-DrugBank.d491.s15;;
Women;O;O
of;O;O
childbearing;O;O
potential;O;O
make;O;O
up;O;O
a;O;O
considerable;O;O
segment;O;O
of;O;O
the;O;O
patient;O;O
population;O;O
affected;O;O
by;O;O
psoriasis;O;O
.;O;O
DDI-DrugBank.d491.s16;;
Since;O;O
the;O;O
effect;O;O
of;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s16.e0
on;O;O
pregnancy;O;O
and;O;O
fetal;O;O
development;O;O
,;O;O
including;O;O
immune;O;O
system;O;O
development;O;O
,;O;O
is;O;O
not;O;O
known;O;O
,;O;O
health;O;O
care;O;O
providers;O;O
are;O;O
encouraged;O;O
to;O;O
enroll;O;O
patients;O;O
currently;O;O
taking;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s16.e1
who;O;O
become;O;O
pregnant;O;O
into;O;O
the;O;O
Biogen;O;O
Pregnancy;O;O
Registry;O;O
by;O;O
calling;O;O
1;O;O
-;O;O
866;O;O
-;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s16.e2
(;O;O
1;O;O
-;O;O
866;O;O
-;O;O
263;O;O
-;O;O
8483;O;O
);O;O
.;O;O
DDI-DrugBank.d491.s17;;
Reproductive;O;O
toxicology;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
in;O;O
cynomolgus;O;O
monkeys;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
5;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
week;O;O
(;O;O
about;O;O
62;O;O
times;O;O
the;O;O
human;O;O
dose;O;O
based;O;O
on;O;O
body;O;O
weight;O;O
);O;O
and;O;O
have;O;O
revealed;O;O
no;O;O
evidence;O;O
of;O;O
impaired;O;O
fertility;O;O
or;O;O
harm;O;O
to;O;O
the;O;O
fetus;O;O
due;O;O
to;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s17.e0
.;O;O
DDI-DrugBank.d491.s18;;
No;O;O
abortifacient;O;O
or;O;O
teratogenic;O;O
effects;O;O
were;O;O
observed;O;O
in;O;O
cynomolgus;O;O
monkeys;O;O
following;O;O
intravenous;O;O
bolus;O;O
injections;O;O
of;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s18.e0
administered;O;O
weekly;O;O
during;O;O
the;O;O
period;O;O
of;O;O
organogenesis;O;O
to;O;O
gestation;O;O
.;O;O
DDI-DrugBank.d491.s19;;
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s19.e0
underwent;O;O
trans;O;O
-;O;O
placental;O;O
passage;O;O
and;O;O
produced;O;O
in;O;O
utero;O;O
exposure;O;O
in;O;O
the;O;O
developing;O;O
monkeys;O;O
.;O;O
DDI-DrugBank.d491.s20;;
In;O;O
utero;O;O
,;O;O
serum;O;O
levels;O;O
of;O;O
exposure;O;O
in;O;O
these;O;O
monkeys;O;O
were;O;O
23;O;O
%;O;O
of;O;O
maternal;O;O
serum;O;O
levels;O;O
.;O;O
DDI-DrugBank.d491.s21;;
No;O;O
evidence;O;O
of;O;O
fetal;O;O
toxicity;O;O
including;O;O
adverse;O;O
effects;O;O
on;O;O
immune;O;O
system;O;O
development;O;O
was;O;O
observed;O;O
in;O;O
any;O;O
of;O;O
these;O;O
animals;O;O
.;O;O
DDI-DrugBank.d491.s22;;
Animal;O;O
reproduction;O;O
studies;O;O
,;O;O
however;O;O
,;O;O
are;O;O
not;O;O
always;O;O
predictive;O;O
of;O;O
human;O;O
response;O;O
and;O;O
there;O;O
are;O;O
no;O;O
adequate;O;O
and;O;O
well;O;O
-;O;O
controlled;O;O
studies;O;O
in;O;O
pregnant;O;O
women;O;O
.;O;O
DDI-DrugBank.d491.s23;;
Because;O;O
the;O;O
risk;O;O
to;O;O
the;O;O
development;O;O
of;O;O
the;O;O
fetal;O;O
immune;O;O
system;O;O
and;O;O
postnatal;O;O
immune;O;O
function;O;O
in;O;O
humans;O;O
is;O;O
unknown;O;O
,;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s23.e0
should;O;O
be;O;O
used;O;O
during;O;O
pregnancy;O;O
only;O;O
if;O;O
clearly;O;O
needed;O;O
.;O;O
DDI-DrugBank.d491.s24;;
If;O;O
pregnancy;O;O
occurs;O;O
while;O;O
taking;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s24.e0
,;O;O
continued;O;O
use;O;O
of;O;O
the;O;O
drug;O;O
should;O;O
be;O;O
assessed;O;O
.;O;O
DDI-DrugBank.d491.s25;;
Nursing;O;O
Mothers;O;O
DDI-DrugBank.d491.s26;;
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s26.e0
is;O;O
excreted;O;O
in;O;O
human;O;O
milk;O;O
.;O;O
DDI-DrugBank.d491.s27;;
Because;O;O
many;O;O
drugs;O;O
are;O;O
excreted;O;O
in;O;O
human;O;O
milk;O;O
,;O;O
and;O;O
because;O;O
there;O;O
exists;O;O
the;O;O
potential;O;O
for;O;O
serious;O;O
adverse;O;O
reactions;O;O
in;O;O
nursing;O;O
infants;O;O
from;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s27.e0
,;O;O
a;O;O
decision;O;O
should;O;O
be;O;O
made;O;O
whether;O;O
to;O;O
discontinue;O;O
nursing;O;O
while;O;O
taking;O;O
the;O;O
drug;O;O
or;O;O
to;O;O
discontinue;O;O
the;O;O
use;O;O
of;O;O
the;O;O
drug;O;O
,;O;O
taking;O;O
into;O;O
account;O;O
the;O;O
importance;O;O
of;O;O
the;O;O
drug;O;O
to;O;O
the;O;O
mother;O;O
.;O;O
DDI-DrugBank.d491.s28;;
Geriatric;O;O
Use;O;O
DDI-DrugBank.d491.s29;;
Of;O;O
the;O;O
1357;O;O
patients;O;O
who;O;O
received;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s29.e0
in;O;O
clinical;O;O
trials;O;O
,;O;O
a;O;O
total;O;O
of;O;O
100;O;O
patients;O;O
were;O;O
DDI-DrugBank.d491.s30;;
65;O;O
years;O;O
of;O;O
age;O;O
and;O;O
13;O;O
patients;O;O
were;O;O
DDI-DrugBank.d491.s31;;
75;O;O
years;O;O
of;O;O
age;O;O
.;O;O
DDI-DrugBank.d491.s32;;
No;O;O
differences;O;O
in;O;O
safety;O;O
or;O;O
efficacy;O;O
were;O;O
observed;O;O
between;O;O
older;O;O
and;O;O
younger;O;O
patients;O;O
,;O;O
but;O;O
there;O;O
were;O;O
not;O;O
sufficient;O;O
data;O;O
to;O;O
exclude;O;O
important;O;O
differences;O;O
.;O;O
DDI-DrugBank.d491.s33;;
Because;O;O
the;O;O
incidence;O;O
of;O;O
infections;O;O
and;O;O
certain;O;O
malignancies;O;O
is;O;O
higher;O;O
in;O;O
the;O;O
elderly;O;O
population;O;O
,;O;O
in;O;O
general;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
in;O;O
treating;O;O
the;O;O
elderly;O;O
.;O;O
DDI-DrugBank.d491.s34;;
Pediatric;O;O
Use;O;O
DDI-DrugBank.d491.s35;;
The;O;O
safety;O;O
and;O;O
efficacy;O;O
of;O;O
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s35.e0
in;O;O
pediatric;O;O
patients;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d491.s36;;
AMEVIVE;B-brand;B-DDI-DrugBank.d491.s36.e0
is;O;O
not;O;O
indicated;O;O
for;O;O
pediatric;O;O
patients;O;O
.;O;O
DDI-DrugBank.d407.s0;;
Drug;O;O
/;O;O
Laboratory;O;O
Interactions;O;O
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
with;O;O
Campath;B-brand;B-DDI-DrugBank.d407.s0.e0
.;O;O
DDI-DrugBank.d407.s1;;
An;O;O
immune;O;O
response;O;O
to;O;O
Campath;B-brand;B-DDI-DrugBank.d407.s1.e0
may;O;O
interfere;O;O
with;O;O
subsequent;O;O
diagnostic;O;O
serum;O;O
tests;O;O
that;O;O
utilize;O;O
antibodies;B-group;B-DDI-DrugBank.d407.s1.e1
DDI-DrugBank.d407.s2;;
.;O;O
DDI-DrugBank.d407.s3;;
DDI-DrugBank.d430.s0;;
Intravenous;O;O
ranitidine;B-drug;B-DDI-DrugBank.d430.s0.e0
was;O;O
shown;O;O
to;O;O
double;O;O
the;O;O
bioavailability;O;O
of;O;O
oral;O;O
alendronate;B-drug;B-DDI-DrugBank.d430.s0.e1
.;O;O
DDI-DrugBank.d430.s1;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
increased;O;O
bioavailability;O;O
and;O;O
whether;O;O
similar;O;O
increases;O;O
will;O;O
occur;O;O
in;O;O
patients;O;O
given;O;O
oral;O;O
H2;B-group;B-DDI-DrugBank.d430.s1.e0
-;I-group;I-DDI-DrugBank.d430.s1.e0
antagonists;I-group;I-DDI-DrugBank.d430.s1.e0
is;O;O
unknown;O;O
,;O;O
DDI-DrugBank.d430.s2;;
no;O;O
other;O;O
specific;O;O
drug;O;O
interaction;O;O
studies;O;O
were;O;O
performed;O;O
.;O;O
DDI-DrugBank.d430.s3;;
Products;O;O
containing;O;O
calcium;B-drug;B-DDI-DrugBank.d430.s3.e0
and;O;O
other;O;O
multivalent;B-drug;B-DDI-DrugBank.d430.s3.e1
cations;I-drug;I-DDI-DrugBank.d430.s3.e1
likely;O;O
will;O;O
interfere;O;O
with;O;O
absorption;O;O
of;O;O
alendronate;B-drug;B-DDI-DrugBank.d430.s3.e2
.;O;O
DDI-DrugBank.d8.s0;;
Both;O;O
the;O;O
magnitude;O;O
and;O;O
duration;O;O
of;O;O
central;O;O
nervous;O;O
system;O;O
and;O;O
cardiovascular;O;O
effects;O;O
may;O;O
be;O;O
enhanced;O;O
when;O;O
ALFENTA;B-brand;B-DDI-DrugBank.d8.s0.e0
is;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d8.s0.e1
depressants;I-group;I-DDI-DrugBank.d8.s0.e1
such;O;O
as;O;O
barbiturates;B-group;B-DDI-DrugBank.d8.s0.e2
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d8.s0.e3
,;O;O
opioids;B-group;B-DDI-DrugBank.d8.s0.e4
,;O;O
or;O;O
inhalation;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d8.s0.e5
.;O;O
DDI-DrugBank.d8.s1;;
Postoperative;O;O
respiratory;O;O
depression;O;O
may;O;O
be;O;O
enhanced;O;O
or;O;O
prolonged;O;O
by;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d8.s2;;
In;O;O
such;O;O
cases;O;O
of;O;O
combined;O;O
treatment;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d8.s3;;
Limited;O;O
clinical;O;O
experience;O;O
indicates;O;O
that;O;O
requirements;O;O
for;O;O
volatile;B-group;B-DDI-DrugBank.d8.s3.e0
inhalation;I-group;I-DDI-DrugBank.d8.s3.e0
anesthetics;I-group;I-DDI-DrugBank.d8.s3.e0
are;O;O
reduced;O;O
by;O;O
30;O;O
to;O;O
50;O;O
%;O;O
for;O;O
the;O;O
first;O;O
sixty;O;O
(;O;O
60;O;O
);O;O
minutes;O;O
following;O;O
ALFENTA;B-brand;B-DDI-DrugBank.d8.s3.e1
induction;O;O
The;O;O
concomitant;O;O
use;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d8.s3.e2
with;O;O
ALFENTA;B-brand;B-DDI-DrugBank.d8.s3.e3
can;O;O
significantly;O;O
inhibit;O;O
ALFENTA;B-brand;B-DDI-DrugBank.d8.s3.e4
clearance;O;O
and;O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
prolonged;O;O
or;O;O
delayed;O;O
respiratory;O;O
depression;O;O
.;O;O
DDI-DrugBank.d8.s4;;
Cimetidine;B-drug;B-DDI-DrugBank.d8.s4.e0
reduces;O;O
the;O;O
clearance;O;O
of;O;O
ALFENTA;B-brand;B-DDI-DrugBank.d8.s4.e1
.;O;O
DDI-DrugBank.d8.s5;;
Therefore;O;O
smaller;O;O
ALFENTA;B-brand;B-DDI-DrugBank.d8.s5.e0
doses;O;O
will;O;O
be;O;O
required;O;O
with;O;O
prolonged;O;O
administration;O;O
and;O;O
the;O;O
duration;O;O
of;O;O
action;O;O
of;O;O
ALFENTA;B-brand;B-DDI-DrugBank.d8.s5.e1
my;O;O
be;O;O
extended;O;O
.;O;O
DDI-DrugBank.d8.s6;;
Perioperative;O;O
administration;O;O
of;O;O
drugs;O;O
affecting;O;O
hepatic;O;O
blood;O;O
flow;O;O
or;O;O
enzyme;O;O
function;O;O
may;O;O
reduce;O;O
plasma;O;O
clearance;O;O
and;O;O
prolong;O;O
recovery;O;O
.;O;O
DDI-DrugBank.d273.s0;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
:;O;O
The;O;O
pharmacokinetic;O;O
and;O;O
pharmacodynamic;O;O
interactions;O;O
between;O;O
UROXATRAL;B-brand;B-DDI-DrugBank.d273.s0.e0
and;O;O
other;O;O
alpha;B-group;B-DDI-DrugBank.d273.s0.e1
-;I-group;I-DDI-DrugBank.d273.s0.e1
blockers;I-group;I-DDI-DrugBank.d273.s0.e1
have;O;O
not;O;O
been;O;O
determined;O;O
.;O;O
DDI-DrugBank.d273.s1;;
However;O;O
,;O;O
interactions;O;O
may;O;O
be;O;O
expected;O;O
,;O;O
and;O;O
UROXATRAL;B-brand;B-DDI-DrugBank.d273.s1.e0
should;O;O
NOT;O;O
be;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
alpha;B-group;B-DDI-DrugBank.d273.s1.e1
-;I-group;I-DDI-DrugBank.d273.s1.e1
blockers;I-group;I-DDI-DrugBank.d273.s1.e1
.;O;O
DDI-DrugBank.d90.s0;;
No;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d533.s0;;
Effects;O;O
of;O;O
Other;O;O
Drugs;O;O
on;O;O
Aliskiren;B-drug;B-DDI-DrugBank.d533.s0.e0
Based;O;O
on;O;O
in;O;O
-;O;O
vitro;O;O
studies;O;O
,;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s0.e1
is;O;O
metabolized;O;O
by;O;O
CYP;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d533.s1;;
Co;O;O
-;O;O
administration;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d533.s1.e0
,;O;O
atenolol;B-drug;B-DDI-DrugBank.d533.s1.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d533.s1.e2
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d533.s1.e3
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d533.s1.e4
,;O;O
celecoxib;B-drug;B-DDI-DrugBank.d533.s1.e5
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d533.s1.e6
,;O;O
ramipril;B-drug;B-DDI-DrugBank.d533.s1.e7
,;O;O
valsartan;B-drug;B-DDI-DrugBank.d533.s1.e8
,;O;O
metformin;B-drug;B-DDI-DrugBank.d533.s1.e9
and;O;O
amlodipine;B-drug;B-DDI-DrugBank.d533.s1.e10
did;O;O
not;O;O
result;O;O
in;O;O
clinically;O;O
significant;O;O
increases;O;O
in;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s1.e11
exposure;O;O
.;O;O
DDI-DrugBank.d533.s2;;
Co;O;O
-;O;O
administration;O;O
of;O;O
irbesartan;B-drug;B-DDI-DrugBank.d533.s2.e0
reduced;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s2.e1
Cmax;O;O
up;O;O
to;O;O
50;O;O
%;O;O
after;O;O
multiple;O;O
dosing;O;O
.;O;O
DDI-DrugBank.d533.s3;;
Co;O;O
-;O;O
administration;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d533.s3.e0
resulted;O;O
in;O;O
about;O;O
a;O;O
50;O;O
%;O;O
increase;O;O
in;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s3.e1
Cmax;O;O
and;O;O
AUC;O;O
after;O;O
multiple;O;O
dosing;O;O
.;O;O
DDI-DrugBank.d533.s4;;
Ketoconazole;B-drug;B-DDI-DrugBank.d533.s4.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
200;O;O
mg;O;O
twice;O;O
-;O;O
daily;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d533.s4.e1
with;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s4.e2
resulted;O;O
in;O;O
an;O;O
approximate;O;O
80;O;O
%;O;O
increase;O;O
in;O;O
plasma;O;O
levels;O;O
of;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s4.e3
.;O;O
DDI-DrugBank.d533.s5;;
A;O;O
400;O;O
mg;O;O
once;O;O
-;O;O
daily;O;O
dose;O;O
was;O;O
not;O;O
studied;O;O
but;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
increase;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s5.e0
blood;O;O
levels;O;O
further;O;O
.;O;O
DDI-DrugBank.d533.s6;;
Effects;O;O
of;O;O
Aliskiren;B-drug;B-DDI-DrugBank.d533.s6.e0
on;O;O
Other;O;O
Drugs;O;O
Aliskiren;B-drug;B-DDI-DrugBank.d533.s6.e1
does;O;O
not;O;O
inhibit;O;O
the;O;O
CYP450;O;O
isoenzymes;O;O
(;O;O
CYP1A2;O;O
,;O;O
2C8;O;O
,;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
2D6;O;O
,;O;O
2E1;O;O
,;O;O
and;O;O
CYP;O;O
3A;O;O
);O;O
or;O;O
induce;O;O
CYP;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d533.s7;;
Co;O;O
-;O;O
administration;O;O
of;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s7.e0
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d533.s7.e1
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d533.s7.e2
,;O;O
valsartan;B-drug;B-DDI-DrugBank.d533.s7.e3
,;O;O
amlodipine;B-drug;B-DDI-DrugBank.d533.s7.e4
,;O;O
metformin;B-drug;B-DDI-DrugBank.d533.s7.e5
,;O;O
celecoxib;B-drug;B-DDI-DrugBank.d533.s7.e6
,;O;O
atenolol;B-drug;B-DDI-DrugBank.d533.s7.e7
,;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d533.s7.e8
,;O;O
ramipril;B-drug;B-DDI-DrugBank.d533.s7.e9
or;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d533.s7.e10
.;O;O
DDI-DrugBank.d533.s8;;
Warfarin;B-drug;B-DDI-DrugBank.d533.s8.e0
:;O;O
The;O;O
effects;O;O
of;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s8.e1
on;O;O
warfarin;B-drug;B-DDI-DrugBank.d533.s8.e2
pharmacokinetics;O;O
have;O;O
not;O;O
been;O;O
evaluated;O;O
in;O;O
a;O;O
well;O;O
-;O;O
controlled;O;O
clinical;O;O
trial;O;O
.;O;O
DDI-DrugBank.d533.s9;;
Furosemide;B-drug;B-DDI-DrugBank.d533.s9.e0
:;O;O
When;O;O
aliskiren;B-drug;B-DDI-DrugBank.d533.s9.e1
was;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
furosemide;B-drug;B-DDI-DrugBank.d533.s9.e2
,;O;O
the;O;O
AUC;O;O
and;O;O
Cmax;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d533.s9.e3
were;O;O
reduced;O;O
by;O;O
about;O;O
30;O;O
%;O;O
and;O;O
50;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d392.s0;;
Patients;O;O
who;O;O
are;O;O
applying;O;O
Panretin;B-brand;B-DDI-DrugBank.d392.s0.e0
gel;O;O
should;O;O
not;O;O
concurrently;O;O
use;O;O
products;O;O
that;O;O
contain;O;O
DEET;B-drug;B-DDI-DrugBank.d392.s0.e1
(;O;O
N;O;O
,;O;O
N;B-drug;B-DDI-DrugBank.d392.s0.e2
-;I-drug;I-DDI-DrugBank.d392.s0.e2
diethyl;I-drug;I-DDI-DrugBank.d392.s0.e2
-;I-drug;I-DDI-DrugBank.d392.s0.e2
m;I-drug;I-DDI-DrugBank.d392.s0.e2
-;I-drug;I-DDI-DrugBank.d392.s0.e2
toluamide;I-drug;I-DDI-DrugBank.d392.s0.e2
);O;O
,;O;O
a;O;O
common;O;O
component;O;O
of;O;O
insect;O;O
repellent;O;O
products;O;O
.;O;O
DDI-DrugBank.d392.s1;;
Animal;O;O
toxicology;O;O
studies;O;O
showed;O;O
increased;O;O
DEET;B-drug;B-DDI-DrugBank.d392.s1.e0
toxicity;O;O
when;O;O
DEET;B-drug;B-DDI-DrugBank.d392.s1.e1
was;O;O
included;O;O
as;O;O
proof;O;O
of;O;O
the;O;O
formulation;O;O
.;O;O
DDI-DrugBank.d392.s2;;
Although;O;O
there;O;O
was;O;O
no;O;O
clinical;O;O
evidence;O;O
in;O;O
the;O;O
vehicle;O;O
-;O;O
controlled;O;O
studies;O;O
of;O;O
drug;O;O
interactions;O;O
with;O;O
systemic;O;O
antiretroviral;B-group;B-DDI-DrugBank.d392.s2.e0
agents;I-group;I-DDI-DrugBank.d392.s2.e0
,;O;O
including;O;O
protease;B-group;B-DDI-DrugBank.d392.s2.e1
inhibitors;I-group;I-DDI-DrugBank.d392.s2.e1
,;O;O
macrolide;B-group;B-DDI-DrugBank.d392.s2.e2
antibiotics;I-group;I-DDI-DrugBank.d392.s2.e2
,;O;O
and;O;O
azole;B-group;B-DDI-DrugBank.d392.s2.e3
antifungals;I-group;I-DDI-DrugBank.d392.s2.e3
,;O;O
the;O;O
effect;O;O
of;O;O
Panretin;B-brand;B-DDI-DrugBank.d392.s2.e4
gel;O;O
on;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
concentrations;O;O
of;O;O
these;O;O
drugs;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d392.s3;;
No;O;O
drug;O;O
interaction;O;O
data;O;O
are;O;O
available;O;O
on;O;O
concomitant;O;O
administration;O;O
of;O;O
Panretin;B-brand;B-DDI-DrugBank.d392.s3.e0
gel;O;O
and;O;O
systemic;O;O
anti;O;O
-;O;O
KS;O;O
agents;O;O
.;O;O
DDI-DrugBank.d413.s0;;
The;O;O
following;O;O
drug;O;O
interactions;O;O
were;O;O
observed;O;O
in;O;O
some;O;O
patients;O;O
undergoing;O;O
treatment;O;O
with;O;O
oral;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s0.e0
.;O;O
DDI-DrugBank.d413.s1;;
Although;O;O
the;O;O
pattern;O;O
of;O;O
use;O;O
for;O;O
oral;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s1.e0
includes;O;O
longer;O;O
term;O;O
therapy;O;O
,;O;O
particularly;O;O
for;O;O
gout;O;O
and;O;O
renal;O;O
calculi;O;O
,;O;O
the;O;O
experience;O;O
gained;O;O
may;O;O
be;O;O
relevant;O;O
.;O;O
DDI-DrugBank.d413.s2;;
Mercaptopurine;B-drug;B-DDI-DrugBank.d413.s2.e0
/;O;O
Azathioprine;B-drug;B-DDI-DrugBank.d413.s2.e1
:;O;O
Allopurinol;B-drug;B-DDI-DrugBank.d413.s2.e2
inhibits;O;O
the;O;O
enzymatic;O;O
oxidation;O;O
of;O;O
mercaptopurine;B-drug;B-DDI-DrugBank.d413.s2.e3
and;O;O
azathioprine;B-drug;B-DDI-DrugBank.d413.s2.e4
to;O;O
6;B-drug;B-DDI-DrugBank.d413.s2.e5
-;I-drug;I-DDI-DrugBank.d413.s2.e5
thiouric;I-drug;I-DDI-DrugBank.d413.s2.e5
acid;I-drug;I-DDI-DrugBank.d413.s2.e5
.;O;O
DDI-DrugBank.d413.s3;;
This;O;O
oxidation;O;O
,;O;O
which;O;O
is;O;O
catalyzed;O;O
by;O;O
xanthine;O;O
oxidase;O;O
,;O;O
inactivates;O;O
mercaptopurine;B-drug;B-DDI-DrugBank.d413.s3.e0
.;O;O
DDI-DrugBank.d413.s4;;
In;O;O
patients;O;O
receiving;O;O
mercaptopurine;B-drug;B-DDI-DrugBank.d413.s4.e0
(;O;O
Purinethol;B-brand;B-DDI-DrugBank.d413.s4.e1
);O;O
or;O;O
azathioprine;B-drug;B-DDI-DrugBank.d413.s4.e2
(;O;O
Imuran;B-brand;B-DDI-DrugBank.d413.s4.e3
);O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
300;O;O
-;O;O
600;O;O
mg;O;O
of;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s4.e4
per;O;O
day;O;O
will;O;O
require;O;O
a;O;O
reduction;O;O
in;O;O
dose;O;O
to;O;O
approximately;O;O
one;O;O
-;O;O
third;O;O
to;O;O
one;O;O
-;O;O
fourth;O;O
of;O;O
the;O;O
usual;O;O
dose;O;O
of;O;O
mercaptopurine;B-drug;B-DDI-DrugBank.d413.s4.e5
or;O;O
azathioprine;B-drug;B-DDI-DrugBank.d413.s4.e6
.;O;O
DDI-DrugBank.d413.s5;;
Subsequent;O;O
adjustment;O;O
of;O;O
doses;O;O
of;O;O
mercaptopurine;B-drug;B-DDI-DrugBank.d413.s5.e0
or;O;O
azathioprine;B-drug;B-DDI-DrugBank.d413.s5.e1
should;O;O
be;O;O
made;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
therapeutic;O;O
response;O;O
and;O;O
the;O;O
appearance;O;O
of;O;O
toxic;O;O
effects;O;O
.;O;O
DDI-DrugBank.d413.s6;;
Dicumarol;B-drug;B-DDI-DrugBank.d413.s6.e0
:;O;O
It;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s6.e1
prolongs;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d413.s6.e2
,;O;O
dicumarol;B-drug;B-DDI-DrugBank.d413.s6.e3
.;O;O
DDI-DrugBank.d413.s7;;
The;O;O
clinical;O;O
basis;O;O
of;O;O
this;O;O
drug;O;O
interaction;O;O
has;O;O
not;O;O
been;O;O
established;O;O
but;O;O
should;O;O
be;O;O
noted;O;O
when;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s7.e0
is;O;O
given;O;O
to;O;O
patients;O;O
already;O;O
on;O;O
dicumarol;B-drug;B-DDI-DrugBank.d413.s7.e1
therapy;O;O
.;O;O
DDI-DrugBank.d413.s8;;
Consequently;O;O
,;O;O
prothrombin;O;O
time;O;O
should;O;O
be;O;O
reassessed;O;O
periodically;O;O
in;O;O
patients;O;O
receiving;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d413.s9;;
Uricosuric;B-group;B-DDI-DrugBank.d413.s9.e0
Agents;I-group;I-DDI-DrugBank.d413.s9.e0
:;O;O
Since;O;O
the;O;O
excretion;O;O
of;O;O
oxipurinol;B-drug;B-DDI-DrugBank.d413.s9.e1
is;O;O
similar;O;O
to;O;O
that;O;O
of;O;O
urate;O;O
,;O;O
uricosuric;B-group;B-DDI-DrugBank.d413.s9.e2
agents;I-group;I-DDI-DrugBank.d413.s9.e2
,;O;O
which;O;O
increase;O;O
the;O;O
excretion;O;O
of;O;O
urate;O;O
,;O;O
are;O;O
also;O;O
likely;O;O
to;O;O
increase;O;O
the;O;O
excretion;O;O
of;O;O
oxipurinol;B-drug;B-DDI-DrugBank.d413.s9.e3
and;O;O
thus;O;O
lower;O;O
the;O;O
degree;O;O
of;O;O
inhibition;O;O
of;O;O
xanthine;O;O
oxidase;O;O
.;O;O
DDI-DrugBank.d413.s10;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
uricosuric;B-group;B-DDI-DrugBank.d413.s10.e0
agents;I-group;I-DDI-DrugBank.d413.s10.e0
and;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s10.e1
has;O;O
been;O;O
associated;O;O
with;O;O
a;O;O
decrease;O;O
in;O;O
the;O;O
excretion;O;O
of;O;O
oxypurines;O;O
(;O;O
hypoxanthine;O;O
and;O;O
xanthine;O;O
);O;O
and;O;O
an;O;O
increase;O;O
in;O;O
urinary;O;O
uric;O;O
acid;O;O
excretion;O;O
compared;O;O
with;O;O
that;O;O
observed;O;O
with;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s10.e2
alone;O;O
.;O;O
DDI-DrugBank.d413.s11;;
Although;O;O
clinical;O;O
evidence;O;O
to;O;O
date;O;O
has;O;O
not;O;O
demonstrated;O;O
renal;O;O
precipitation;O;O
of;O;O
oxypurines;O;O
in;O;O
patients;O;O
either;O;O
on;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s11.e0
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
uricosuric;B-group;B-DDI-DrugBank.d413.s11.e1
agents;I-group;I-DDI-DrugBank.d413.s11.e1
,;O;O
the;O;O
possibility;O;O
should;O;O
be;O;O
kept;O;O
in;O;O
mind;O;O
.;O;O
DDI-DrugBank.d413.s12;;
Thiazide;B-group;B-DDI-DrugBank.d413.s12.e0
Diuretics;I-group;I-DDI-DrugBank.d413.s12.e0
:;O;O
The;O;O
reports;O;O
that;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s12.e1
and;O;O
thiazide;B-group;B-DDI-DrugBank.d413.s12.e2
diuretics;I-group;I-DDI-DrugBank.d413.s12.e2
may;O;O
contribute;O;O
to;O;O
the;O;O
enhancement;O;O
of;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s12.e3
toxicity;O;O
in;O;O
some;O;O
patients;O;O
have;O;O
been;O;O
reviewed;O;O
in;O;O
an;O;O
attempt;O;O
to;O;O
establish;O;O
a;O;O
cause;O;O
-;O;O
and;O;O
-;O;O
effect;O;O
relationship;O;O
and;O;O
a;O;O
mechanism;O;O
of;O;O
causation;O;O
.;O;O
DDI-DrugBank.d413.s13;;
Review;O;O
of;O;O
these;O;O
case;O;O
reports;O;O
indicates;O;O
that;O;O
the;O;O
patients;O;O
were;O;O
mainly;O;O
receiving;O;O
thiazide;B-group;B-DDI-DrugBank.d413.s13.e0
diuretics;I-group;I-DDI-DrugBank.d413.s13.e0
for;O;O
hypertension;O;O
and;O;O
that;O;O
tests;O;O
to;O;O
rule;O;O
out;O;O
decreased;O;O
renal;O;O
function;O;O
secondary;O;O
to;O;O
hypertensive;O;O
nephropathy;O;O
were;O;O
not;O;O
often;O;O
performed;O;O
.;O;O
DDI-DrugBank.d413.s14;;
In;O;O
those;O;O
patients;O;O
in;O;O
whom;O;O
renal;O;O
insufficiency;O;O
was;O;O
documented;O;O
,;O;O
however;O;O
,;O;O
the;O;O
recommendation;O;O
to;O;O
lower;O;O
the;O;O
dose;O;O
of;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s14.e0
was;O;O
not;O;O
followed;O;O
.;O;O
DDI-DrugBank.d413.s15;;
Although;O;O
a;O;O
causal;O;O
mechanism;O;O
and;O;O
a;O;O
cause;O;O
-;O;O
and;O;O
-;O;O
effect;O;O
relationship;O;O
have;O;O
not;O;O
been;O;O
established;O;O
,;O;O
current;O;O
evidence;O;O
suggests;O;O
that;O;O
renal;O;O
function;O;O
should;O;O
be;O;O
monitored;O;O
in;O;O
patients;O;O
on;O;O
thiazide;B-group;B-DDI-DrugBank.d413.s15.e0
diuretics;I-group;I-DDI-DrugBank.d413.s15.e0
and;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s15.e1
even;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
renal;O;O
failure;O;O
,;O;O
and;O;O
dosage;O;O
levels;O;O
should;O;O
be;O;O
even;O;O
more;O;O
conservatively;O;O
adjusted;O;O
in;O;O
those;O;O
patients;O;O
on;O;O
such;O;O
combined;O;O
therapy;O;O
if;O;O
diminished;O;O
renal;O;O
function;O;O
is;O;O
detected;O;O
..;O;O
DDI-DrugBank.d413.s16;;
Ampicillin;B-drug;B-DDI-DrugBank.d413.s16.e0
/;O;O
Amoxicillin;B-drug;B-DDI-DrugBank.d413.s16.e1
:;O;O
An;O;O
increase;O;O
in;O;O
the;O;O
frequency;O;O
of;O;O
skin;O;O
rash;O;O
has;O;O
been;O;O
reported;O;O
among;O;O
patients;O;O
receiving;O;O
ampicillin;B-drug;B-DDI-DrugBank.d413.s16.e2
or;O;O
amoxicillin;B-drug;B-DDI-DrugBank.d413.s16.e3
concurrently;O;O
with;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s16.e4
compared;O;O
to;O;O
patients;O;O
who;O;O
are;O;O
not;O;O
receiving;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d413.s17;;
The;O;O
cause;O;O
of;O;O
the;O;O
reported;O;O
association;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d413.s18;;
Cytotoxic;B-group;B-DDI-DrugBank.d413.s18.e0
Agents;I-group;I-DDI-DrugBank.d413.s18.e0
:;O;O
Enhanced;O;O
bone;O;O
marrow;O;O
suppression;O;O
by;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d413.s18.e1
and;O;O
other;O;O
cytotoxic;B-group;B-DDI-DrugBank.d413.s18.e2
agents;I-group;I-DDI-DrugBank.d413.s18.e2
has;O;O
been;O;O
reported;O;O
among;O;O
patients;O;O
with;O;O
neoplastic;O;O
disease;O;O
,;O;O
except;O;O
leukemia;O;O
,;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s18.e3
.;O;O
DDI-DrugBank.d413.s19;;
However;O;O
,;O;O
in;O;O
a;O;O
well;O;O
-;O;O
controlled;O;O
study;O;O
of;O;O
patients;O;O
with;O;O
lymphoma;O;O
on;O;O
combination;O;O
therapy;O;O
,;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s19.e0
did;O;O
not;O;O
increase;O;O
the;O;O
marrow;O;O
toxicity;O;O
of;O;O
patients;O;O
treated;O;O
with;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d413.s19.e1
,;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d413.s19.e2
,;O;O
bleomycin;B-drug;B-DDI-DrugBank.d413.s19.e3
,;O;O
procarbazine;B-drug;B-DDI-DrugBank.d413.s19.e4
and/or;O;O
mechlorethamine;B-drug;B-DDI-DrugBank.d413.s19.e5
.;O;O
DDI-DrugBank.d413.s20;;
Chlorpropamide;B-drug;B-DDI-DrugBank.d413.s20.e0
:;O;O
Chlorpropamides;B-drug;B-DDI-DrugBank.d413.s20.e1
plasma;O;O
half;O;O
-;O;O
life;O;O
may;O;O
be;O;O
prolonged;O;O
by;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s20.e2
,;O;O
since;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s20.e3
and;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d413.s20.e4
may;O;O
compete;O;O
for;O;O
excretion;O;O
in;O;O
the;O;O
renal;O;O
tubule;O;O
.;O;O
DDI-DrugBank.d413.s21;;
The;O;O
risk;O;O
of;O;O
hypoglycemia;O;O
secondary;O;O
to;O;O
this;O;O
mechanism;O;O
may;O;O
be;O;O
increased;O;O
if;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s21.e0
and;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d413.s21.e1
are;O;O
given;O;O
concomitantly;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
renal;O;O
insufficiency;O;O
.;O;O
DDI-DrugBank.d413.s22;;
Cyclosporin;B-drug;B-DDI-DrugBank.d413.s22.e0
:;O;O
Reports;O;O
indicate;O;O
that;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d413.s22.e1
levels;O;O
may;O;O
be;O;O
increased;O;O
during;O;O
concomitant;O;O
treatment;O;O
with;O;O
allopurinol;B-drug;B-DDI-DrugBank.d413.s22.e2
sodium;I-drug;I-DDI-DrugBank.d413.s22.e2
for;O;O
injection;O;O
.;O;O
DDI-DrugBank.d413.s23;;
Monitoring;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d413.s23.e0
levels;O;O
and;O;O
possible;O;O
adjustment;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d413.s23.e1
dosage;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
these;O;O
drugs;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d413.s24;;
Tolbutamides;B-drug;B-DDI-DrugBank.d413.s24.e0
conversion;O;O
to;O;O
inactive;O;O
metabolites;O;O
has;O;O
been;O;O
shown;O;O
to;O;O
be;O;O
catalyzed;O;O
by;O;O
xanthine;O;O
oxidase;O;O
from;O;O
rat;O;O
liver;O;O
.;O;O
DDI-DrugBank.d413.s25;;
The;O;O
clinical;O;O
significance;O;O
,;O;O
if;O;O
any;O;O
,;O;O
of;O;O
these;O;O
observations;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d299.s0;;
Ergot;B-group;B-DDI-DrugBank.d299.s0.e0
-;I-group;I-DDI-DrugBank.d299.s0.e0
Containing;I-group;I-DDI-DrugBank.d299.s0.e0
Drugs;I-group;I-DDI-DrugBank.d299.s0.e0
:;O;O
These;O;O
drugs;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
prolonged;O;O
vasospastic;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d299.s1;;
Because;O;O
there;O;O
is;O;O
a;O;O
theoretical;O;O
basis;O;O
that;O;O
these;O;O
effects;O;O
may;O;O
be;O;O
additive;O;O
,;O;O
use;O;O
of;O;O
ergotamine;B-drug;B-DDI-DrugBank.d299.s1.e0
-;O;O
containing;O;O
or;O;O
ergot;B-group;B-DDI-DrugBank.d299.s1.e1
-;I-group;I-DDI-DrugBank.d299.s1.e1
type;I-group;I-DDI-DrugBank.d299.s1.e1
medications;I-group;I-DDI-DrugBank.d299.s1.e1
(;O;O
like;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d299.s1.e2
or;O;O
methysergide;B-drug;B-DDI-DrugBank.d299.s1.e3
);O;O
and;O;O
AXERT;B-brand;B-DDI-DrugBank.d299.s1.e4
within;O;O
24;O;O
hours;O;O
of;O;O
each;O;O
other;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d299.s2;;
Monoamine;B-group;B-DDI-DrugBank.d299.s2.e0
Oxidase;I-group;I-DDI-DrugBank.d299.s2.e0
Inhibitors;I-group;I-DDI-DrugBank.d299.s2.e0
:;O;O
Coadministration;O;O
of;O;O
moclobemide;B-drug;B-DDI-DrugBank.d299.s2.e1
resulted;O;O
in;O;O
a;O;O
27;O;O
%;O;O
decrease;O;O
in;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s2.e2
clearance;O;O
and;O;O
an;O;O
increase;O;O
in;O;O
Cmax;O;O
of;O;O
approximately;O;O
6;O;O
%;O;O
.;O;O
DDI-DrugBank.d299.s3;;
No;O;O
dose;O;O
adjustment;O;O
is;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d299.s4;;
Other;O;O
5;B-group;B-DDI-DrugBank.d299.s4.e0
-;I-group;I-DDI-DrugBank.d299.s4.e0
HT1B;I-group;I-DDI-DrugBank.d299.s4.e0
/;I-group;I-DDI-DrugBank.d299.s4.e0
1D;I-group;I-DDI-DrugBank.d299.s4.e0
Agonists;I-group;I-DDI-DrugBank.d299.s4.e0
Concomitant;O;O
use;O;O
of;O;O
other;O;O
5;B-group;B-DDI-DrugBank.d299.s4.e1
-;I-group;I-DDI-DrugBank.d299.s4.e1
HT1B;I-group;I-DDI-DrugBank.d299.s4.e1
/;I-group;I-DDI-DrugBank.d299.s4.e1
1D;I-group;I-DDI-DrugBank.d299.s4.e1
agonists;I-group;I-DDI-DrugBank.d299.s4.e1
within;O;O
24;O;O
hours;O;O
of;O;O
treatment;O;O
with;O;O
AXERT;B-brand;B-DDI-DrugBank.d299.s4.e2
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d299.s5;;
Propanolol;B-drug;B-DDI-DrugBank.d299.s5.e0
:;O;O
The;O;O
pharmacokinetics;O;O
of;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s5.e1
were;O;O
not;O;O
affected;O;O
by;O;O
coadministration;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d299.s5.e2
.;O;O
DDI-DrugBank.d299.s6;;
Selective;B-group;B-DDI-DrugBank.d299.s6.e0
Serotonin;I-group;I-DDI-DrugBank.d299.s6.e0
Reuptake;I-group;I-DDI-DrugBank.d299.s6.e0
Inhibitors;I-group;I-DDI-DrugBank.d299.s6.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d299.s6.e1
);O;O
:;O;O
SSRIs;B-group;B-DDI-DrugBank.d299.s6.e2
(;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d299.s6.e3
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d299.s6.e4
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d299.s6.e5
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d299.s6.e6
);O;O
have;O;O
been;O;O
rarely;O;O
reported;O;O
to;O;O
cause;O;O
weakness;O;O
,;O;O
hyperreflexia;O;O
,;O;O
and;O;O
incoordination;O;O
when;O;O
coadministered;O;O
with;O;O
5;B-group;B-DDI-DrugBank.d299.s6.e7
-;I-group;I-DDI-DrugBank.d299.s6.e7
HT1;I-group;I-DDI-DrugBank.d299.s6.e7
agonists;I-group;I-DDI-DrugBank.d299.s6.e7
.;O;O
DDI-DrugBank.d299.s7;;
If;O;O
concomitant;O;O
treatment;O;O
with;O;O
AXERT;B-brand;B-DDI-DrugBank.d299.s7.e0
and;O;O
an;O;O
SSRI;B-group;B-DDI-DrugBank.d299.s7.e1
is;O;O
clinically;O;O
warranted;O;O
,;O;O
appropriate;O;O
observation;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d299.s8;;
Verapamil;B-drug;B-DDI-DrugBank.d299.s8.e0
:;O;O
Coadministration;O;O
of;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s8.e1
and;O;O
verapamil;B-drug;B-DDI-DrugBank.d299.s8.e2
resulted;O;O
in;O;O
a;O;O
24;O;O
%;O;O
increase;O;O
in;O;O
plasma;O;O
concentrations;O;O
of;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s8.e3
.;O;O
DDI-DrugBank.d299.s9;;
No;O;O
dose;O;O
adjustment;O;O
is;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d299.s10;;
Coadministration;O;O
of;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s10.e0
and;O;O
the;O;O
potent;O;O
CYP3A4;O;O
inhibitor;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d299.s10.e1
(;O;O
400;O;O
mg;O;O
q.d;O;O
.;O;O
for;O;O
3;O;O
days;O;O
);O;O
resulted;O;O
in;O;O
an;O;O
approximately;O;O
60;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
area;O;O
under;O;O
the;O;O
plasma;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
and;O;O
maximal;O;O
plasma;O;O
concentrations;O;O
of;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s10.e2
.;O;O
DDI-DrugBank.d299.s11;;
Although;O;O
the;O;O
interaction;O;O
between;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s11.e0
and;O;O
other;O;O
potent;O;O
CYP3A4;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d299.s11.e1
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d299.s11.e2
,;O;O
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d299.s11.e3
);O;O
has;O;O
not;O;O
been;O;O
studied;O;O
,;O;O
increased;O;O
exposures;O;O
to;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s11.e4
may;O;O
be;O;O
expected;O;O
when;O;O
almotriptan;B-drug;B-DDI-DrugBank.d299.s11.e5
is;O;O
used;O;O
concomitantly;O;O
with;O;O
these;O;O
medications;O;O
.;O;O
DDI-DrugBank.d299.s12;;
AXERT;B-brand;B-DDI-DrugBank.d299.s12.e0
is;O;O
not;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
commonly;O;O
employed;O;O
clinical;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d364.s0;;
Because;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s0.e0
is;O;O
metabolized;O;O
by;O;O
a;O;O
variety;O;O
of;O;O
hepatic;O;O
CYP;O;O
drug;O;O
-;O;O
metabolizing;O;O
enzymes;O;O
,;O;O
inducers;O;O
or;O;O
inhibitors;O;O
of;O;O
these;O;O
enzymes;O;O
may;O;O
change;O;O
the;O;O
clearance;O;O
of;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s0.e1
.;O;O
DDI-DrugBank.d364.s1;;
Fluvoxamine;B-drug;B-DDI-DrugBank.d364.s1.e0
is;O;O
a;O;O
known;O;O
strong;O;O
inhibitor;O;O
of;O;O
CYP1A2;O;O
and;O;O
also;O;O
inhibits;O;O
CYP3A4;O;O
,;O;O
CYP2C9;O;O
,;O;O
and;O;O
CYP2C19;O;O
.;O;O
DDI-DrugBank.d364.s2;;
In;O;O
a;O;O
pharmacokinetic;O;O
study;O;O
,;O;O
40;O;O
healthy;O;O
female;O;O
subjects;O;O
received;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d364.s2.e0
in;O;O
escalating;O;O
doses;O;O
from;O;O
50;O;O
to;O;O
200;O;O
mg;O;O
per;O;O
day;O;O
for;O;O
16;O;O
days;O;O
,;O;O
with;O;O
coadministration;O;O
of;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s2.e1
1;O;O
mg;O;O
on;O;O
the;O;O
last;O;O
day;O;O
.;O;O
DDI-DrugBank.d364.s3;;
Fluvoxamine;B-drug;B-DDI-DrugBank.d364.s3.e0
increased;O;O
mean;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s3.e1
plasma;O;O
concentrations;O;O
(;O;O
AUC;O;O
);O;O
approximately;O;O
6;O;O
-;O;O
fold;O;O
and;O;O
prolonged;O;O
the;O;O
half;O;O
-;O;O
life;O;O
by;O;O
approximately;O;O
3;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d364.s4;;
Concomitant;O;O
administration;O;O
of;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s4.e0
and;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d364.s4.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d364.s5;;
Concomitant;O;O
administration;O;O
of;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s5.e0
and;O;O
moderate;O;O
CYP1A2;O;O
inhibitors;O;O
,;O;O
including;O;O
quinolone;B-group;B-DDI-DrugBank.d364.s5.e1
antibiotics;I-group;I-DDI-DrugBank.d364.s5.e1
and;O;O
cimetidine;B-drug;B-DDI-DrugBank.d364.s5.e2
,;O;O
has;O;O
not;O;O
been;O;O
evaluated;O;O
,;O;O
but;O;O
should;O;O
be;O;O
avoided;O;O
unless;O;O
clinically;O;O
necessary;O;O
because;O;O
of;O;O
similar;O;O
potential;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d364.s6;;
Ketoconazole;B-drug;B-DDI-DrugBank.d364.s6.e0
is;O;O
a;O;O
known;O;O
strong;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d364.s7;;
In;O;O
a;O;O
pharmacokinetic;O;O
study;O;O
,;O;O
38;O;O
healthy;O;O
female;O;O
subjects;O;O
received;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d364.s7.e0
200;O;O
mg;O;O
twice;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
,;O;O
with;O;O
coadministration;O;O
of;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s7.e1
1;O;O
mg;O;O
on;O;O
the;O;O
last;O;O
day;O;O
.;O;O
DDI-DrugBank.d364.s8;;
Ketoconazole;B-drug;B-DDI-DrugBank.d364.s8.e0
increased;O;O
mean;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s8.e1
plasma;O;O
concentrations;O;O
(;O;O
AUC;O;O
);O;O
by;O;O
29;O;O
%;O;O
.;O;O
DDI-DrugBank.d364.s9;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s9.e0
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d364.s9.e1
are;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d364.s10;;
Coadministration;O;O
of;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s10.e0
and;O;O
strong;O;O
CYP3A4;O;O
inhibitors;O;O
,;O;O
such;O;O
as;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d364.s10.e1
,;O;O
telithromycin;B-drug;B-DDI-DrugBank.d364.s10.e2
,;O;O
protease;B-group;B-DDI-DrugBank.d364.s10.e3
inhibitors;I-group;I-DDI-DrugBank.d364.s10.e3
,;O;O
voriconazole;B-drug;B-DDI-DrugBank.d364.s10.e4
,;O;O
and;O;O
itraconazole;B-drug;B-DDI-DrugBank.d364.s10.e5
has;O;O
not;O;O
been;O;O
evaluated;O;O
but;O;O
should;O;O
be;O;O
undertaken;O;O
with;O;O
caution;O;O
because;O;O
of;O;O
similar;O;O
potential;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d364.s11;;
The;O;O
effect;O;O
of;O;O
induction;O;O
or;O;O
inhibition;O;O
of;O;O
other;O;O
pathways;O;O
on;O;O
exposure;O;O
to;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s11.e0
and;O;O
its;O;O
metabolites;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d364.s12;;
In;O;O
vitro;O;O
human;O;O
liver;O;O
microsome;O;O
studies;O;O
and;O;O
an;O;O
in;O;O
vivo;O;O
metabolic;O;O
probe;O;O
study;O;O
demonstrated;O;O
that;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s12.e0
did;O;O
not;O;O
inhibit;O;O
CYP;O;O
enzymes;O;O
2D6;O;O
,;O;O
3A4;O;O
,;O;O
2C9;O;O
,;O;O
or;O;O
2C19;O;O
.;O;O
DDI-DrugBank.d364.s13;;
In;O;O
vitro;O;O
,;O;O
at;O;O
total;O;O
drug;O;O
concentrations;O;O
27;O;O
-;O;O
fold;O;O
higher;O;O
than;O;O
peak;O;O
plasma;O;O
concentrations;O;O
observed;O;O
with;O;O
the;O;O
1;O;O
-;O;O
mg;O;O
dosage;O;O
,;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s13.e0
inhibited;O;O
CYP;O;O
enzymes;O;O
1A2;O;O
(;O;O
60;O;O
%;O;O
);O;O
and;O;O
2E1;O;O
(;O;O
50;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d364.s14;;
In;O;O
an;O;O
in;O;O
vivo;O;O
metabolic;O;O
probe;O;O
study;O;O
,;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s14.e0
did;O;O
not;O;O
inhibit;O;O
CYP2E1;O;O
but;O;O
did;O;O
produce;O;O
30;O;O
%;O;O
inhibition;O;O
of;O;O
both;O;O
CYP1A2;O;O
and;O;O
N;O;O
-;O;O
acetyltransferase;O;O
.;O;O
DDI-DrugBank.d364.s15;;
Although;O;O
not;O;O
studied;O;O
with;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s15.e0
,;O;O
inhibition;O;O
of;O;O
N;O;O
-;O;O
acetyltransferase;O;O
may;O;O
have;O;O
clinically;O;O
relevant;O;O
consequences;O;O
for;O;O
drugs;O;O
such;O;O
as;O;O
isoniazid;B-drug;B-DDI-DrugBank.d364.s15.e1
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d364.s15.e2
,;O;O
and;O;O
hydralazine;B-drug;B-DDI-DrugBank.d364.s15.e3
.;O;O
DDI-DrugBank.d364.s16;;
The;O;O
effect;O;O
on;O;O
CYP1A2;O;O
was;O;O
explored;O;O
further;O;O
in;O;O
a;O;O
clinical;O;O
interaction;O;O
study;O;O
with;O;O
theophylline;B-drug;B-DDI-DrugBank.d364.s16.e0
and;O;O
no;O;O
effect;O;O
on;O;O
metabolism;O;O
was;O;O
observed;O;O
.;O;O
DDI-DrugBank.d364.s17;;
Another;O;O
study;O;O
showed;O;O
that;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s17.e0
had;O;O
no;O;O
clinically;O;O
significant;O;O
effect;O;O
on;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d364.s17.e1
agents;I-group;I-DDI-DrugBank.d364.s17.e1
ethinyl;I-drug;I-DDI-DrugBank.d364.s17.e2
estradiol;I-drug;I-DDI-DrugBank.d364.s17.e2
and;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d364.s17.e3
(;O;O
CYP3A4;O;O
substrates;O;O
);O;O
.;O;O
DDI-DrugBank.d364.s18;;
A;O;O
clinical;O;O
interaction;O;O
study;O;O
was;O;O
also;O;O
conducted;O;O
with;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s18.e0
and;O;O
the;O;O
CYP3A4;O;O
substrate;O;O
cisapride;B-drug;B-DDI-DrugBank.d364.s18.e1
.;O;O
DDI-DrugBank.d364.s19;;
No;O;O
significant;O;O
effects;O;O
on;O;O
cisapride;B-drug;B-DDI-DrugBank.d364.s19.e0
metabolism;O;O
or;O;O
QT;O;O
interval;O;O
were;O;O
noted;O;O
.;O;O
DDI-DrugBank.d364.s20;;
The;O;O
effect;O;O
of;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s20.e0
on;O;O
monoamine;O;O
oxidases;O;O
and;O;O
on;O;O
intestinal;O;O
first;O;O
pass;O;O
secondary;O;O
to;O;O
high;O;O
intraluminal;O;O
concentrations;O;O
have;O;O
not;O;O
been;O;O
examined;O;O
.;O;O
DDI-DrugBank.d364.s21;;
Based;O;O
on;O;O
the;O;O
above;O;O
data;O;O
from;O;O
in;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
studies;O;O
,;O;O
it;O;O
is;O;O
unlikely;O;O
that;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s21.e0
will;O;O
inhibit;O;O
the;O;O
hepatic;O;O
metabolic;O;O
clearance;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
the;O;O
major;O;O
CYP;O;O
enzyme;O;O
3A4;O;O
,;O;O
as;O;O
well;O;O
as;O;O
the;O;O
CYP;O;O
enzymes;O;O
2D6;O;O
,;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
2E1;O;O
,;O;O
or;O;O
1A2;O;O
.;O;O
DDI-DrugBank.d364.s22;;
Alosetron;B-drug;B-DDI-DrugBank.d364.s22.e0
does;O;O
not;O;O
appear;O;O
to;O;O
induce;O;O
the;O;O
major;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
drug;O;O
metabolizing;O;O
enzyme;O;O
3A.;O;O
DDI-DrugBank.d364.s23;;
Alosetron;B-drug;B-DDI-DrugBank.d364.s23.e0
also;O;O
does;O;O
not;O;O
appear;O;O
to;O;O
induce;O;O
CYP;O;O
enzymes;O;O
2E1;O;O
or;O;O
2C19;O;O
.;O;O
DDI-DrugBank.d364.s24;;
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
alosetron;B-drug;B-DDI-DrugBank.d364.s24.e0
might;O;O
induce;O;O
other;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d131.s0;;
The;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d131.s0.e0
,;O;O
including;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s0.e1
,;O;O
produce;O;O
additive;O;O
CNS;O;O
depressant;O;O
effects;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
other;O;O
psychotropic;B-group;B-DDI-DrugBank.d131.s0.e2
medications;I-group;I-DDI-DrugBank.d131.s0.e2
,;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d131.s0.e3
,;O;O
antihistaminics;B-group;B-DDI-DrugBank.d131.s0.e4
,;O;O
ethanol;B-drug;B-DDI-DrugBank.d131.s0.e5
,;O;O
and;O;O
other;O;O
drugs;O;O
which;O;O
themselves;O;O
produce;O;O
CNS;O;O
depression;O;O
.;O;O
DDI-DrugBank.d131.s1;;
The;O;O
steady;O;O
state;O;O
plasma;O;O
concentrations;O;O
of;O;O
imipramine;B-drug;B-DDI-DrugBank.d131.s1.e0
and;O;O
desipramine;B-drug;B-DDI-DrugBank.d131.s1.e1
have;O;O
been;O;O
reported;O;O
to;O;O
be;O;O
increased;O;O
an;O;O
average;O;O
of;O;O
31;O;O
%;O;O
and;O;O
20;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s1.e2
tablets;O;O
in;O;O
doses;O;O
up;O;O
to;O;O
4;O;O
mg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d131.s2;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
changes;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d131.s3;;
Drugs;O;O
That;O;O
Inhibit;O;O
Alprazolam;B-drug;B-DDI-DrugBank.d131.s3.e0
Metabolism;O;O
Via;O;O
Cytochrome;O;O
P450;O;O
3A;O;O
:;O;O
The;O;O
initial;O;O
step;O;O
in;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s3.e1
metabolism;O;O
is;O;O
hydroxylation;O;O
catalyzed;O;O
by;O;O
cytochrome;O;O
P450;O;O
3A;O;O
(;O;O
CYP;O;O
3A;O;O
);O;O
.;O;O
DDI-DrugBank.d131.s4;;
Drugs;O;O
which;O;O
inhibit;O;O
this;O;O
metabolic;O;O
pathway;O;O
may;O;O
have;O;O
a;O;O
profound;O;O
effect;O;O
on;O;O
the;O;O
clearance;O;O
of;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s4.e0
.;O;O
DDI-DrugBank.d131.s5;;
Drugs;O;O
Demonstrated;O;O
to;O;O
be;O;O
CYP;O;O
3A;O;O
Inhibitors;O;O
of;O;O
Possible;O;O
Clinical;O;O
Significance;O;O
on;O;O
the;O;O
Basis;O;O
of;O;O
Clinical;O;O
Studies;O;O
Involving;O;O
Alprazolam;B-drug;B-DDI-DrugBank.d131.s5.e0
(;O;O
caution;O;O
is;O;O
recommended;O;O
during;O;O
coadministration;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s5.e1
);O;O
:;O;O
Coadministration;O;O
of;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d131.s5.e2
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s5.e3
increased;O;O
the;O;O
maximum;O;O
plasma;O;O
concentration;O;O
of;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s5.e4
by;O;O
46;O;O
%;O;O
,;O;O
decreased;O;O
clearance;O;O
by;O;O
21;O;O
%;O;O
,;O;O
increased;O;O
half;O;O
-;O;O
life;O;O
by;O;O
17;O;O
%;O;O
,;O;O
and;O;O
decreased;O;O
measured;O;O
psychomotor;O;O
performance;O;O
.;O;O
DDI-DrugBank.d131.s6;;
Coadministration;O;O
of;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d131.s6.e0
decreased;O;O
the;O;O
maximum;O;O
plasma;O;O
concentration;O;O
of;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s6.e1
by;O;O
6;O;O
%;O;O
,;O;O
decreased;O;O
clearance;O;O
by;O;O
38;O;O
%;O;O
,;O;O
and;O;O
increased;O;O
half;O;O
-;O;O
life;O;O
by;O;O
58;O;O
%;O;O
.;O;O
DDI-DrugBank.d131.s7;;
Coadministration;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d131.s7.e0
increased;O;O
the;O;O
maximum;O;O
plasma;O;O
concentration;O;O
of;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s7.e1
by;O;O
18;O;O
%;O;O
,;O;O
decreased;O;O
clearance;O;O
by;O;O
22;O;O
%;O;O
,;O;O
and;O;O
increased;O;O
half;O;O
-;O;O
life;O;O
by;O;O
29;O;O
%;O;O
.;O;O
DDI-DrugBank.d131.s8;;
Drugs;O;O
and;O;O
other;O;O
substances;O;O
demonstrated;O;O
to;O;O
be;O;O
CYP;O;O
3A;O;O
inhibitors;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
clinical;O;O
studies;O;O
involving;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d131.s8.e0
metabolized;O;O
similarly;O;O
to;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s8.e1
or;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
in;O;O
vitro;O;O
studies;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s8.e2
or;O;O
other;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d131.s8.e3
(;O;O
caution;O;O
is;O;O
recommended;O;O
during;O;O
coadministration;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s8.e4
);O;O
:;O;O
Available;O;O
data;O;O
from;O;O
clinical;O;O
studies;O;O
of;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d131.s8.e5
other;O;O
than;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s8.e6
suggest;O;O
a;O;O
possible;O;O
drug;O;O
interaction;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s8.e7
for;O;O
the;O;O
following;O;O
:;O;O
diltiazem;B-drug;B-DDI-DrugBank.d131.s8.e8
,;O;O
isoniazid;B-drug;B-DDI-DrugBank.d131.s8.e9
,;O;O
macrolide;B-group;B-DDI-DrugBank.d131.s8.e10
antibiotics;I-group;I-DDI-DrugBank.d131.s8.e10
such;O;O
as;O;O
erythromycin;B-drug;B-DDI-DrugBank.d131.s8.e11
and;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d131.s8.e12
,;O;O
and;O;O
grapefruit;O;O
juice;O;O
.;O;O
DDI-DrugBank.d131.s9;;
Data;O;O
from;O;O
in;O;O
vitro;O;O
studies;O;O
of;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s9.e0
suggest;O;O
a;O;O
possible;O;O
drug;O;O
interaction;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s9.e1
for;O;O
the;O;O
following;O;O
:;O;O
sertraline;B-drug;B-DDI-DrugBank.d131.s9.e2
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d131.s9.e3
.;O;O
DDI-DrugBank.d131.s10;;
Data;O;O
from;O;O
in;O;O
vitro;O;O
studies;O;O
of;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d131.s10.e0
other;O;O
than;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s10.e1
suggest;O;O
a;O;O
possible;O;O
drug;O;O
interaction;O;O
for;O;O
the;O;O
following;O;O
:;O;O
ergotamine;B-drug;B-DDI-DrugBank.d131.s10.e2
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d131.s10.e3
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d131.s10.e4
,;O;O
nicardipine;B-drug;B-DDI-DrugBank.d131.s10.e5
,;O;O
and;O;O
nifedipine;B-drug;B-DDI-DrugBank.d131.s10.e6
.;O;O
DDI-DrugBank.d131.s11;;
Caution;O;O
is;O;O
recommended;O;O
during;O;O
the;O;O
coadministration;O;O
of;O;O
any;O;O
of;O;O
these;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d131.s11.e0
.;O;O
DDI-DrugBank.d290.s0;;
No;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
between;O;O
Prostin;B-brand;B-DDI-DrugBank.d290.s0.e0
VR;I-brand;I-DDI-DrugBank.d290.s0.e0
Pediatric;I-brand;I-DDI-DrugBank.d290.s0.e0
and;O;O
the;O;O
therapy;O;O
standard;O;O
in;O;O
neonates;O;O
with;O;O
restricted;O;O
pulmonary;O;O
or;O;O
systemic;O;O
blood;O;O
flow;O;O
.;O;O
DDI-DrugBank.d290.s1;;
Standard;O;O
therapy;O;O
includes;O;O
antibiotics;B-group;B-DDI-DrugBank.d290.s1.e0
,;O;O
such;O;O
as;O;O
penicillin;B-drug;B-DDI-DrugBank.d290.s1.e1
and;O;O
gentamicin;B-drug;B-DDI-DrugBank.d290.s1.e2
,;O;O
DDI-DrugBank.d290.s2;;
vasopressors;B-group;B-DDI-DrugBank.d290.s2.e0
,;O;O
such;O;O
as;O;O
dopamine;B-drug;B-DDI-DrugBank.d290.s2.e1
and;O;O
isoproterenol;B-drug;B-DDI-DrugBank.d290.s2.e2
,;O;O
DDI-DrugBank.d290.s3;;
cardiac;B-group;B-DDI-DrugBank.d290.s3.e0
glycosides;I-group;I-DDI-DrugBank.d290.s3.e0
,;O;O
DDI-DrugBank.d290.s4;;
and;O;O
diuretics;B-group;B-DDI-DrugBank.d290.s4.e0
,;O;O
such;O;O
as;O;O
furosemide;B-drug;B-DDI-DrugBank.d290.s4.e1
.;O;O
DDI-DrugBank.d290.s5;;
Caverject;B-brand;B-DDI-DrugBank.d290.s5.e0
:;O;O
The;O;O
potential;O;O
for;O;O
pharmacokinetic;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
between;O;O
alprostadil;B-drug;B-DDI-DrugBank.d290.s5.e1
and;O;O
other;O;O
agents;O;O
has;O;O
not;O;O
been;O;O
formally;O;O
studied;O;O
.;O;O
DDI-DrugBank.d508.s0;;
The;O;O
interaction;O;O
of;O;O
Activase;B-brand;B-DDI-DrugBank.d508.s0.e0
with;O;O
other;O;O
cardioactive;O;O
or;O;O
cerebroactive;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d508.s1;;
In;O;O
addition;O;O
to;O;O
bleeding;O;O
associated;O;O
with;O;O
heparin;B-drug;B-DDI-DrugBank.d508.s1.e0
and;O;O
vitamin;B-group;B-DDI-DrugBank.d508.s1.e1
K;I-group;I-DDI-DrugBank.d508.s1.e1
antagonists;I-group;I-DDI-DrugBank.d508.s1.e1
,;O;O
drugs;O;O
that;O;O
alter;O;O
platelet;O;O
function;O;O
(;O;O
such;O;O
as;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d508.s1.e2
acid;I-drug;I-DDI-DrugBank.d508.s1.e2
,;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d508.s1.e3
and;O;O
Abciximab;B-drug;B-DDI-DrugBank.d508.s1.e4
);O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
if;O;O
administered;O;O
prior;O;O
to;O;O
,;O;O
during;O;O
,;O;O
or;O;O
after;O;O
Activase;B-brand;B-DDI-DrugBank.d508.s1.e5
therapy;O;O
.;O;O
DDI-DrugBank.d508.s2;;
Use;O;O
of;O;O
Antithrombotics;B-group;B-DDI-DrugBank.d508.s2.e0
Aspirin;I-brand;I-DDI-DrugBank.d508.s2.e1
and;O;O
heparin;B-drug;B-DDI-DrugBank.d508.s2.e2
have;O;O
been;O;O
administered;O;O
concomitantly;O;O
with;O;O
and;O;O
following;O;O
infusions;O;O
of;O;O
Activase;B-brand;B-DDI-DrugBank.d508.s2.e3
in;O;O
the;O;O
management;O;O
of;O;O
acute;O;O
myocardial;O;O
infarction;O;O
or;O;O
pulmonary;O;O
embolism;O;O
.;O;O
DDI-DrugBank.d508.s3;;
Because;O;O
heparin;B-drug;B-DDI-DrugBank.d508.s3.e0
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d508.s3.e1
,;O;O
or;O;O
Activase;B-brand;B-DDI-DrugBank.d508.s3.e2
may;O;O
cause;O;O
bleeding;O;O
complications;O;O
,;O;O
careful;O;O
monitoring;O;O
for;O;O
bleeding;O;O
is;O;O
advised;O;O
,;O;O
especially;O;O
at;O;O
arterial;O;O
puncture;O;O
sites;O;O
.;O;O
DDI-DrugBank.d508.s4;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d508.s4.e0
or;O;O
aspirin;B-brand;B-DDI-DrugBank.d508.s4.e1
during;O;O
the;O;O
first;O;O
24;O;O
hours;O;O
following;O;O
symptom;O;O
onset;O;O
were;O;O
prohibited;O;O
in;O;O
The;O;O
NINDS;O;O
t;O;O
-;O;O
PA;O;O
Stroke;O;O
Trial;O;O
.;O;O
DDI-DrugBank.d508.s5;;
The;O;O
safety;O;O
of;O;O
such;O;O
concomitant;O;O
use;O;O
with;O;O
Activase;B-brand;B-DDI-DrugBank.d508.s5.e0
for;O;O
the;O;O
management;O;O
of;O;O
acute;O;O
ischemic;O;O
stroke;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d188.s0;;
Concurrent;O;O
administration;O;O
of;O;O
HEXALEN;B-brand;B-DDI-DrugBank.d188.s0.e0
and;O;O
antidepressants;B-group;B-DDI-DrugBank.d188.s0.e1
of;I-group;I-DDI-DrugBank.d188.s0.e1
the;I-group;I-DDI-DrugBank.d188.s0.e1
MAO;I-group;I-DDI-DrugBank.d188.s0.e1
inhibitor;I-group;I-DDI-DrugBank.d188.s0.e1
class;I-group;I-DDI-DrugBank.d188.s0.e1
may;O;O
cause;O;O
severe;O;O
orthostatic;O;O
hypotension;O;O
.;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d188.s0.e2
,;O;O
an;O;O
inhibitor;O;O
of;O;O
microsomal;O;O
drug;O;O
metabolism;O;O
,;O;O
increased;O;O
altretamines;B-drug;B-DDI-DrugBank.d188.s0.e3
half;O;O
-;O;O
life;O;O
and;O;O
toxicity;O;O
in;O;O
a;O;O
rat;O;O
model;O;O
.;O;O
DDI-DrugBank.d188.s1;;
Data;O;O
from;O;O
a;O;O
randomized;O;O
trial;O;O
of;O;O
HEXALEN;B-brand;B-DDI-DrugBank.d188.s1.e0
and;O;O
cisplatin;B-drug;B-DDI-DrugBank.d188.s1.e1
plus;O;O
or;O;O
minus;O;O
pyridoxine;B-drug;B-DDI-DrugBank.d188.s1.e2
in;O;O
ovarian;O;O
cancer;O;O
indicated;O;O
that;O;O
pyridoxine;B-drug;B-DDI-DrugBank.d188.s1.e3
significantly;O;O
reduced;O;O
neurotoxicity;O;O
,;O;O
DDI-DrugBank.d188.s2;;
however;O;O
,;O;O
it;O;O
adversely;O;O
affected;O;O
response;O;O
duration;O;O
suggesting;O;O
that;O;O
pyridoxine;B-drug;B-DDI-DrugBank.d188.s2.e0
should;O;O
not;O;O
be;O;O
administered;O;O
with;O;O
HEXALEN;B-brand;B-DDI-DrugBank.d188.s2.e1
and/or;O;O
cisplatin.1;B-drug;B-DDI-DrugBank.d188.s2.e2
DDI-DrugBank.d116.s0;;
Careful;O;O
observation;O;O
is;O;O
required;O;O
when;O;O
amantadine;B-drug;B-DDI-DrugBank.d116.s0.e0
is;O;O
administered;O;O
concurrently;O;O
with;O;O
central;B-group;B-DDI-DrugBank.d116.s0.e1
nervous;I-group;I-DDI-DrugBank.d116.s0.e1
system;I-group;I-DDI-DrugBank.d116.s0.e1
stimulants;I-group;I-DDI-DrugBank.d116.s0.e1
.;O;O
DDI-DrugBank.d116.s1;;
Coadministration;O;O
of;O;O
thioridazine;B-drug;B-DDI-DrugBank.d116.s1.e0
has;O;O
been;O;O
reported;O;O
to;O;O
worsen;O;O
the;O;O
tremor;O;O
in;O;O
elderly;O;O
patients;O;O
with;O;O
Parkinsons;O;O
disease;O;O
,;O;O
DDI-DrugBank.d116.s2;;
however;O;O
,;O;O
it;O;O
is;O;O
not;O;O
known;O;O
if;O;O
other;O;O
phenothiazines;B-group;B-DDI-DrugBank.d116.s2.e0
produce;O;O
a;O;O
similar;O;O
response;O;O
.;O;O
DDI-DrugBank.d563.s0;;
Special;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
the;O;O
administration;O;O
of;O;O
ETHYOL;B-brand;B-DDI-DrugBank.d563.s0.e0
in;O;O
patients;O;O
receiving;O;O
antihypertensive;B-group;B-DDI-DrugBank.d563.s0.e1
medications;I-group;I-DDI-DrugBank.d563.s0.e1
or;O;O
other;O;O
drugs;O;O
that;O;O
could;O;O
cause;O;O
or;O;O
potentiate;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d356.s0;;
When;O;O
amiloride;B-drug;B-DDI-DrugBank.d356.s0.e0
HCl;O;O
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
an;O;O
angiotensin;B-group;B-DDI-DrugBank.d356.s0.e1
-;I-group;I-DDI-DrugBank.d356.s0.e1
converting;I-group;I-DDI-DrugBank.d356.s0.e1
enzyme;I-group;I-DDI-DrugBank.d356.s0.e1
inhibitor;I-group;I-DDI-DrugBank.d356.s0.e1
,;O;O
the;O;O
risk;O;O
of;O;O
hyperkalemia;O;O
may;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d356.s1;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
is;O;O
indicated;O;O
because;O;O
of;O;O
demonstrated;O;O
hypokalemia;O;O
,;O;O
they;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
and;O;O
with;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d356.s2;;
Lithium;B-drug;B-DDI-DrugBank.d356.s2.e0
generally;O;O
should;O;O
not;O;O
be;O;O
given;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d356.s2.e1
because;O;O
they;O;O
reduce;O;O
its;O;O
renal;O;O
clearance;O;O
and;O;O
add;O;O
a;O;O
high;O;O
risk;O;O
of;O;O
lithium;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d356.s3;;
Read;O;O
circulars;O;O
for;O;O
lithium;B-drug;B-DDI-DrugBank.d356.s3.e0
preparations;O;O
before;O;O
use;O;O
of;O;O
such;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d356.s4;;
In;O;O
some;O;O
patients;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
a;O;O
non;B-group;B-DDI-DrugBank.d356.s4.e0
-;I-group;I-DDI-DrugBank.d356.s4.e0
steroidal;I-group;I-DDI-DrugBank.d356.s4.e0
anti;I-group;I-DDI-DrugBank.d356.s4.e0
-;I-group;I-DDI-DrugBank.d356.s4.e0
inflammatory;I-group;I-DDI-DrugBank.d356.s4.e0
agent;I-group;I-DDI-DrugBank.d356.s4.e0
can;O;O
reduce;O;O
the;O;O
diuretic;O;O
,;O;O
natriuretic;O;O
,;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
loop;B-group;B-DDI-DrugBank.d356.s4.e1
,;I-group;I-DDI-DrugBank.d356.s4.e1
potassium;I-group;I-DDI-DrugBank.d356.s4.e2
-;I-group;I-DDI-DrugBank.d356.s4.e2
sparing;I-group;I-DDI-DrugBank.d356.s4.e2
and;I-group;I-DDI-DrugBank.d356.s4.e2
thiazide;I-group;I-DDI-DrugBank.d356.s4.e3
diuretics;I-group;I-DDI-DrugBank.d356.s4.e3
.;O;O
DDI-DrugBank.d356.s5;;
Therefore;O;O
,;O;O
when;O;O
MIDAMOR;B-brand;B-DDI-DrugBank.d356.s5.e0
and;O;O
non;B-group;B-DDI-DrugBank.d356.s5.e1
-;I-group;I-DDI-DrugBank.d356.s5.e1
steroidal;I-group;I-DDI-DrugBank.d356.s5.e1
anti;I-group;I-DDI-DrugBank.d356.s5.e1
-;I-group;I-DDI-DrugBank.d356.s5.e1
inflammatory;I-group;I-DDI-DrugBank.d356.s5.e1
agents;I-group;I-DDI-DrugBank.d356.s5.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
effect;O;O
of;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d356.s5.e2
is;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d356.s6;;
Since;O;O
indomethacin;B-drug;B-DDI-DrugBank.d356.s6.e0
and;O;O
potassium;B-group;B-DDI-DrugBank.d356.s6.e1
-;I-group;I-DDI-DrugBank.d356.s6.e1
sparing;I-group;I-DDI-DrugBank.d356.s6.e1
diuretics;I-group;I-DDI-DrugBank.d356.s6.e1
,;O;O
including;O;O
MIDAMOR;B-brand;B-DDI-DrugBank.d356.s6.e2
,;O;O
may;O;O
each;O;O
be;O;O
associated;O;O
with;O;O
increased;O;O
serum;O;O
potassium;O;O
levels;O;O
,;O;O
the;O;O
potential;O;O
effects;O;O
on;O;O
potassium;O;O
kinetics;O;O
and;O;O
renal;O;O
function;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
these;O;O
agents;O;O
are;O;O
administered;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d553.s0;;
Drug;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
Prolongation;O;O
of;O;O
the;O;O
template;O;O
bleeding;O;O
time;O;O
has;O;O
been;O;O
reported;O;O
during;O;O
continuous;O;O
intravenous;O;O
infusion;O;O
of;O;O
AMICAR;B-brand;B-DDI-DrugBank.d553.s0.e0
at;O;O
dosages;O;O
exceeding;O;O
24;O;O
g;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d553.s1;;
Platelet;O;O
function;O;O
studies;O;O
in;O;O
these;O;O
patients;O;O
have;O;O
not;O;O
demonstrated;O;O
any;O;O
significant;O;O
platelet;O;O
dysfunction;O;O
.;O;O
DDI-DrugBank.d553.s2;;
However;O;O
,;O;O
in;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
at;O;O
high;O;O
concentrations;O;O
(;O;O
7.4;O;O
mMol;O;O
/;O;O
L;O;O
or;O;O
0.97;O;O
mg;O;O
/;O;O
mL;O;O
and;O;O
greater;O;O
);O;O
EACA;B-drug;B-DDI-DrugBank.d553.s2.e0
inhibits;O;O
ADP;O;O
and;O;O
collagen;O;O
-;O;O
induced;O;O
platelet;O;O
aggregation;O;O
,;O;O
the;O;O
release;O;O
of;O;O
ATP;O;O
and;O;O
serotonin;O;O
,;O;O
and;O;O
the;O;O
binding;O;O
of;O;O
fibrinogen;O;O
to;O;O
the;O;O
platelets;O;O
in;O;O
a;O;O
concentration;O;O
-;O;O
response;O;O
manner;O;O
.;O;O
DDI-DrugBank.d553.s3;;
Following;O;O
a;O;O
10;O;O
g;O;O
bolus;O;O
of;O;O
AMICAR;B-brand;B-DDI-DrugBank.d553.s3.e0
,;O;O
transient;O;O
peak;O;O
plasma;O;O
concentrations;O;O
of;O;O
4.6;O;O
mMol;O;O
/;O;O
L;O;O
or;O;O
0.60;O;O
mg;O;O
/;O;O
mL;O;O
have;O;O
been;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d553.s4;;
The;O;O
concentration;O;O
of;O;O
AMICAR;B-brand;B-DDI-DrugBank.d553.s4.e0
necessary;O;O
to;O;O
maintain;O;O
inhibition;O;O
of;O;O
fibrinolysis;O;O
is;O;O
0.99;O;O
mMol;O;O
/;O;O
L;O;O
or;O;O
0.13;O;O
mg;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d553.s5;;
Administration;O;O
of;O;O
a;O;O
5;O;O
g;O;O
bolus;O;O
followed;O;O
by;O;O
1;O;O
to;O;O
1.25;O;O
g;O;O
/;O;O
hr;O;O
should;O;O
achieve;O;O
and;O;O
sustain;O;O
plasma;O;O
levels;O;O
of;O;O
0.13;O;O
mg;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d553.s6;;
Thus;O;O
,;O;O
concentrations;O;O
which;O;O
have;O;O
been;O;O
obtained;O;O
in;O;O
vivo;O;O
clinically;O;O
in;O;O
patients;O;O
with;O;O
normal;O;O
renal;O;O
function;O;O
are;O;O
considerably;O;O
lower;O;O
than;O;O
the;O;O
in;O;O
vitro;O;O
concentrations;O;O
found;O;O
to;O;O
induce;O;O
abnormalities;O;O
in;O;O
platelet;O;O
function;O;O
tests;O;O
.;O;O
DDI-DrugBank.d553.s7;;
However;O;O
,;O;O
higher;O;O
plasma;O;O
concentrations;O;O
of;O;O
AMICAR;B-brand;B-DDI-DrugBank.d553.s7.e0
may;O;O
occur;O;O
in;O;O
patients;O;O
with;O;O
severe;O;O
renal;O;O
failure;O;O
.;O;O
DDI-DrugBank.d372.s0;;
Cytadren;B-brand;B-DDI-DrugBank.d372.s0.e0
accelerates;O;O
the;O;O
metabolism;O;O
of;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d372.s0.e1
,;O;O
DDI-DrugBank.d372.s1;;
therefore;O;O
,;O;O
if;O;O
glucocorticoid;B-group;B-DDI-DrugBank.d372.s1.e0
replacement;O;O
is;O;O
needed;O;O
,;O;O
hydrocortisone;B-drug;B-DDI-DrugBank.d372.s1.e1
should;O;O
be;O;O
prescribed;O;O
.;O;O
DDI-DrugBank.d372.s2;;
Aminoglutethimide;B-drug;B-DDI-DrugBank.d372.s2.e0
diminishes;O;O
the;O;O
effect;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d372.s2.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d372.s2.e2
.;O;O
DDI-DrugBank.d416.s0;;
Renal;O;O
clearance;O;O
measurements;O;O
of;O;O
PAH;B-drug;B-DDI-DrugBank.d416.s0.e0
can;O;O
not;O;O
be;O;O
made;O;O
with;O;O
any;O;O
significant;O;O
accuracy;O;O
in;O;O
patients;O;O
receiving;O;O
sulfonamides;B-group;B-DDI-DrugBank.d416.s0.e1
,;O;O
procaine;B-drug;B-DDI-DrugBank.d416.s0.e2
,;O;O
or;O;O
thiazolesulfone;B-drug;B-DDI-DrugBank.d416.s0.e3
.;O;O
DDI-DrugBank.d416.s1;;
These;O;O
compounds;O;O
interfere;O;O
with;O;O
chemical;O;O
color;O;O
development;O;O
essential;O;O
to;O;O
the;O;O
analytical;O;O
procedures;O;O
.;O;O
DDI-DrugBank.d416.s2;;
Probenecid;B-drug;B-DDI-DrugBank.d416.s2.e0
depresses;O;O
tubular;O;O
secretion;O;O
of;O;O
certain;O;O
weak;O;O
acids;O;O
such;O;O
as;O;O
PAH;B-drug;B-DDI-DrugBank.d416.s2.e1
.;O;O
DDI-DrugBank.d416.s3;;
Therefore;O;O
,;O;O
patients;O;O
receiving;O;O
probenecid;B-drug;B-DDI-DrugBank.d416.s3.e0
will;O;O
have;O;O
erroneously;O;O
low;O;O
ERPF;O;O
and;O;O
Tm;O;O
PAH;B-drug;B-DDI-DrugBank.d416.s3.e1
values;O;O
.;O;O
DDI-DrugBank.d379.s0;;
There;O;O
have;O;O
been;O;O
no;O;O
formal;O;O
studies;O;O
of;O;O
the;O;O
interaction;O;O
of;O;O
LEVULAN;B-brand;B-DDI-DrugBank.d379.s0.e0
KERASTICK;I-brand;I-DDI-DrugBank.d379.s0.e0
for;O;O
Topical;O;O
Solution;O;O
with;O;O
any;O;O
other;O;O
drugs;O;O
,;O;O
and;O;O
no;O;O
drug;O;O
-;O;O
specific;O;O
interactions;O;O
were;O;O
noted;O;O
during;O;O
any;O;O
of;O;O
the;O;O
controlled;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d379.s1;;
It;O;O
is;O;O
,;O;O
however;O;O
,;O;O
possible;O;O
that;O;O
concomitant;O;O
use;O;O
of;O;O
other;O;O
known;O;O
photosensitizing;B-group;B-DDI-DrugBank.d379.s1.e0
agents;I-group;I-DDI-DrugBank.d379.s1.e0
such;O;O
as;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d379.s1.e1
,;O;O
thiazide;B-group;B-DDI-DrugBank.d379.s1.e2
diuretics;I-group;I-DDI-DrugBank.d379.s1.e2
,;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d379.s1.e3
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d379.s1.e4
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d379.s1.e5
and;O;O
tetracyclines;B-group;B-DDI-DrugBank.d379.s1.e6
might;O;O
increase;O;O
the;O;O
photosensitivity;O;O
reaction;O;O
of;O;O
actinic;O;O
keratoses;O;O
treated;O;O
with;O;O
the;O;O
LEVULAN;B-brand;B-DDI-DrugBank.d379.s1.e7
KERASTICK;I-brand;I-DDI-DrugBank.d379.s1.e7
for;O;O
Topical;O;O
Solution;O;O
.;O;O
DDI-DrugBank.d22.s0;;
Aminosalicylic;B-drug;B-DDI-DrugBank.d22.s0.e0
acid;I-drug;I-DDI-DrugBank.d22.s0.e0
may;O;O
decrease;O;O
the;O;O
amount;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d22.s0.e1
(;O;O
Lanoxin;B-brand;B-DDI-DrugBank.d22.s0.e2
,;O;O
Lanoxicaps;B-drug;B-DDI-DrugBank.d22.s0.e3
);O;O
that;O;O
gets;O;O
absorbed;O;O
into;O;O
your;O;O
body;O;O
.;O;O
DDI-DrugBank.d22.s1;;
In;O;O
the;O;O
case;O;O
that;O;O
you;O;O
are;O;O
taking;O;O
digoxin;B-drug;B-DDI-DrugBank.d22.s1.e0
while;O;O
taking;O;O
aminosalicylic;B-drug;B-DDI-DrugBank.d22.s1.e1
acid;I-drug;I-DDI-DrugBank.d22.s1.e1
,;O;O
higher;O;O
doses;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d22.s1.e2
may;O;O
be;O;O
needed;O;O
.;O;O
DDI-DrugBank.d22.s2;;
Aminosalicylic;B-drug;B-DDI-DrugBank.d22.s2.e0
acid;I-drug;I-DDI-DrugBank.d22.s2.e0
may;O;O
also;O;O
decrease;O;O
the;O;O
absorption;O;O
of;O;O
vitamin;B-drug;B-DDI-DrugBank.d22.s2.e1
B12;I-drug;I-DDI-DrugBank.d22.s2.e1
,;O;O
which;O;O
can;O;O
lead;O;O
to;O;O
a;O;O
deficiency;O;O
.;O;O
DDI-DrugBank.d22.s3;;
Therefore;O;O
you;O;O
may;O;O
need;O;O
to;O;O
take;O;O
a;O;O
vitamin;B-drug;B-DDI-DrugBank.d22.s3.e0
B12;I-drug;I-DDI-DrugBank.d22.s3.e0
supplement;O;O
while;O;O
taking;O;O
aminosalicylic;B-drug;B-DDI-DrugBank.d22.s3.e1
acid;I-drug;I-DDI-DrugBank.d22.s3.e1
.;O;O
DDI-DrugBank.d143.s0;;
Amiodarone;B-drug;B-DDI-DrugBank.d143.s0.e0
is;O;O
metabolized;O;O
to;O;O
desethylamiodarone;B-drug;B-DDI-DrugBank.d143.s0.e1
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP450;O;O
);O;O
enzyme;O;O
group;O;O
,;O;O
specifically;O;O
cytochromes;O;O
P450;O;O
3A4;O;O
(;O;O
CYP3A4;O;O
);O;O
and;O;O
CYP2C8;O;O
.;O;O
DDI-DrugBank.d143.s1;;
The;O;O
CYP3A4;O;O
isoenzyme;O;O
is;O;O
present;O;O
in;O;O
both;O;O
the;O;O
liver;O;O
and;O;O
intestines;O;O
.;O;O
DDI-DrugBank.d143.s2;;
Amiodarone;B-drug;B-DDI-DrugBank.d143.s2.e0
is;O;O
also;O;O
known;O;O
to;O;O
be;O;O
an;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d143.s3;;
Therefore;O;O
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s3.e0
has;O;O
the;O;O
potential;O;O
for;O;O
interactions;O;O
with;O;O
drugs;O;O
or;O;O
substances;O;O
that;O;O
may;O;O
be;O;O
substrates;O;O
,;O;O
inhibitors;O;O
or;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d143.s4;;
While;O;O
only;O;O
a;O;O
limited;O;O
number;O;O
of;O;O
in;O;O
vivo;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s4.e0
have;O;O
been;O;O
reported;O;O
,;O;O
chiefly;O;O
with;O;O
the;O;O
oral;O;O
formulation;O;O
,;O;O
the;O;O
potential;O;O
for;O;O
other;O;O
interactions;O;O
should;O;O
be;O;O
anticipated;O;O
.;O;O
DDI-DrugBank.d143.s5;;
This;O;O
is;O;O
especially;O;O
important;O;O
for;O;O
drugs;O;O
associated;O;O
with;O;O
serious;O;O
toxicity;O;O
,;O;O
such;O;O
as;O;O
other;O;O
antiarrhythmics;B-group;B-DDI-DrugBank.d143.s5.e0
.;O;O
DDI-DrugBank.d143.s6;;
If;O;O
such;O;O
drugs;O;O
are;O;O
needed;O;O
,;O;O
their;O;O
dose;O;O
should;O;O
be;O;O
reassessed;O;O
and;O;O
,;O;O
where;O;O
appropriate;O;O
,;O;O
plasma;O;O
concentration;O;O
measured;O;O
.;O;O
DDI-DrugBank.d143.s7;;
In;O;O
view;O;O
of;O;O
the;O;O
long;O;O
and;O;O
variable;O;O
half;O;O
-;O;O
life;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s7.e0
,;O;O
potential;O;O
for;O;O
drug;O;O
interactions;O;O
exists;O;O
not;O;O
only;O;O
with;O;O
concomitant;O;O
medication;O;O
but;O;O
also;O;O
with;O;O
drugs;O;O
administered;O;O
after;O;O
discontinuation;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s7.e1
.;O;O
DDI-DrugBank.d143.s8;;
Since;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s8.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
CYP3A4;O;O
and;O;O
CYP2C8;O;O
,;O;O
drugs;O;O
/;O;O
substances;O;O
that;O;O
inhibit;O;O
these;O;O
isoenzymes;O;O
may;O;O
decrease;O;O
the;O;O
metabolism;O;O
and;O;O
increase;O;O
serum;O;O
concentration;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s8.e1
.;O;O
DDI-DrugBank.d143.s9;;
Reported;O;O
examples;O;O
include;O;O
the;O;O
following;O;O
:;O;O
Protease;B-group;B-DDI-DrugBank.d143.s9.e0
Inhibitors;I-group;I-DDI-DrugBank.d143.s9.e0
:;O;O
Protease;B-group;B-DDI-DrugBank.d143.s9.e1
inhibitors;I-group;I-DDI-DrugBank.d143.s9.e1
are;O;O
known;O;O
to;O;O
inhibit;O;O
CYP3A4;O;O
to;O;O
varying;O;O
degrees;O;O
.;O;O
DDI-DrugBank.d143.s10;;
A;O;O
case;O;O
report;O;O
of;O;O
one;O;O
patient;O;O
taking;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s10.e0
200;O;O
mg;O;O
and;O;O
indinavir;B-drug;B-DDI-DrugBank.d143.s10.e1
800;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
resulted;O;O
in;O;O
increases;O;O
in;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s10.e2
concentrations;O;O
from;O;O
0.9;O;O
mg;O;O
/;O;O
L;O;O
to;O;O
1.3;O;O
mg;O;O
/;O;O
L.;O;O
DDI-DrugBank.d143.s11;;
DEA;O;O
concentrations;O;O
were;O;O
not;O;O
affected;O;O
.;O;O
DDI-DrugBank.d143.s12;;
There;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d143.s13;;
Monitoring;O;O
for;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s13.e0
toxicity;O;O
and;O;O
serial;O;O
measurement;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s13.e1
serum;O;O
concentration;O;O
during;O;O
concomitant;O;O
protease;B-group;B-DDI-DrugBank.d143.s13.e2
inhibitor;I-group;I-DDI-DrugBank.d143.s13.e2
therapy;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d143.s14;;
Histamine;B-group;B-DDI-DrugBank.d143.s14.e0
H2;I-group;I-DDI-DrugBank.d143.s14.e0
antagonists;I-group;I-DDI-DrugBank.d143.s14.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d143.s14.e1
inhibits;O;O
CYP3A4;O;O
and;O;O
can;O;O
increase;O;O
serum;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s14.e2
levels;O;O
.;O;O
DDI-DrugBank.d143.s15;;
Other;O;O
substances;O;O
:;O;O
Grapefruit;O;O
juice;O;O
given;O;O
to;O;O
healthy;O;O
volunteers;O;O
increased;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s15.e0
AUC;O;O
by;O;O
50;O;O
%;O;O
and;O;O
Cmax;O;O
by;O;O
84;O;O
%;O;O
,;O;O
resulting;O;O
in;O;O
increased;O;O
plasma;O;O
levels;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s15.e1
.;O;O
DDI-DrugBank.d143.s16;;
Grapefruit;O;O
juice;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
during;O;O
treatment;O;O
with;O;O
oral;O;O
amiodarone;O;O
.;O;O
DDI-DrugBank.d143.s17;;
This;O;O
information;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
changing;O;O
from;O;O
intravenous;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s17.e0
to;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s17.e1
.;O;O
DDI-DrugBank.d143.s18;;
Amiodarone;B-drug;B-DDI-DrugBank.d143.s18.e0
may;O;O
suppress;O;O
certain;O;O
CYP450;O;O
enzymes;O;O
,;O;O
including;O;O
CYP1A2;B-drug;B-DDI-DrugBank.d143.s18.e1
,;O;O
CYP2C9;B-drug;B-DDI-DrugBank.d143.s18.e2
,;O;O
CYP2D6;B-drug;B-DDI-DrugBank.d143.s18.e3
,;O;O
and;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s18.e4
.;O;O
DDI-DrugBank.d143.s19;;
This;O;O
inhibition;O;O
can;O;O
result;O;O
in;O;O
unexpectedly;O;O
high;O;O
plasma;O;O
levels;O;O
of;O;O
other;O;O
drugs;B-drug;B-DDI-DrugBank.d143.s19.e0
which;O;O
are;O;O
metabolized;O;O
by;O;O
those;O;O
CYP450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d143.s20;;
Reported;O;O
examples;O;O
of;O;O
this;O;O
interaction;O;O
include;O;O
the;O;O
following;O;O
:;O;O
Immunosuppressives;B-drug;B-DDI-DrugBank.d143.s20.e0
:;O;O
Cyclosporine;B-drug;B-DDI-DrugBank.d143.s20.e1
(;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s20.e2
substrate;O;O
);O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s20.e3
has;O;O
been;O;O
reported;O;O
to;O;O
produce;O;O
persistently;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d143.s20.e4
resulting;O;O
in;O;O
elevated;O;O
creatinine;O;O
,;O;O
despite;O;O
reduction;O;O
in;O;O
dose;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d143.s20.e5
.;O;O
DDI-DrugBank.d143.s21;;
HMG;B-drug;B-DDI-DrugBank.d143.s21.e0
-;I-drug;I-DDI-DrugBank.d143.s21.e0
CoA;I-drug;I-DDI-DrugBank.d143.s21.e0
Reductase;I-drug;I-DDI-DrugBank.d143.s21.e0
Inhibitors;I-drug;I-DDI-DrugBank.d143.s21.e0
:;O;O
Simvastatin;B-drug;B-DDI-DrugBank.d143.s21.e1
(;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s21.e2
substrate;O;O
);O;O
in;O;O
combination;O;O
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s21.e3
has;O;O
been;O;O
associated;O;O
with;O;O
reports;O;O
of;O;O
myopathy;O;O
/;O;O
rhabdomyolysis;O;O
.;O;O
DDI-DrugBank.d143.s22;;
Cardiovasculars;O;O
:;O;O
Cardiac;B-drug;B-DDI-DrugBank.d143.s22.e0
glycosides;I-drug;I-DDI-DrugBank.d143.s22.e0
:;O;O
In;O;O
patients;O;O
receiving;O;O
digoxin;B-drug;B-DDI-DrugBank.d143.s22.e1
therapy;O;O
,;O;O
administration;O;O
of;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s22.e2
regularly;O;O
results;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d143.s22.e3
concentration;O;O
that;O;O
may;O;O
reach;O;O
toxic;O;O
levels;O;O
with;O;O
resultant;O;O
clinical;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d143.s23;;
Amiodarone;B-drug;B-DDI-DrugBank.d143.s23.e0
taken;O;O
concomitantly;O;O
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d143.s23.e1
increases;O;O
the;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d143.s23.e2
concentration;O;O
by;O;O
70;O;O
%;O;O
after;O;O
one;O;O
day;O;O
.;O;O
DDI-DrugBank.d143.s24;;
On;O;O
administration;O;O
of;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s24.e0
,;O;O
the;O;O
need;O;O
for;O;O
digitalis;B-group;B-DDI-DrugBank.d143.s24.e1
therapy;O;O
should;O;O
be;O;O
reviewed;O;O
and;O;O
the;O;O
dose;O;O
reduced;O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
or;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d143.s25;;
If;O;O
digitalis;B-drug;B-DDI-DrugBank.d143.s25.e0
treatment;O;O
is;O;O
continued;O;O
,;O;O
serum;O;O
levels;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
and;O;O
patients;O;O
observed;O;O
for;O;O
clinical;O;O
evidence;O;O
of;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d143.s26;;
These;O;O
precautions;O;O
probably;O;O
should;O;O
apply;O;O
to;O;O
digitoxin;B-drug;B-DDI-DrugBank.d143.s26.e0
administration;O;O
as;O;O
well;O;O
.;O;O
DDI-DrugBank.d143.s27;;
Antiarrhythmics;B-drug;B-DDI-DrugBank.d143.s27.e0
:;O;O
Other;O;O
antiarrhythmic;B-drug;B-DDI-DrugBank.d143.s27.e1
drugs;O;O
,;O;O
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d143.s27.e2
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d143.s27.e3
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d143.s27.e4
,;O;O
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d143.s27.e5
,;O;O
have;O;O
been;O;O
used;O;O
concurrently;O;O
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s27.e6
.;O;O
DDI-DrugBank.d143.s28;;
There;O;O
have;O;O
been;O;O
case;O;O
reports;O;O
of;O;O
increased;O;O
steady;O;O
-;O;O
state;O;O
levels;O;O
of;O;O
quinidine;B-drug;B-DDI-DrugBank.d143.s28.e0
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d143.s28.e1
,;O;O
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d143.s28.e2
during;O;O
concomitant;O;O
therapy;O;O
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s28.e3
.;O;O
DDI-DrugBank.d143.s29;;
Phenytoin;B-drug;B-DDI-DrugBank.d143.s29.e0
decreases;O;O
serum;O;O
amiodarone;O;O
levels;O;O
.;O;O
DDI-DrugBank.d143.s30;;
Amiodarone;B-drug;B-DDI-DrugBank.d143.s30.e0
taken;O;O
concomitantly;O;O
with;O;O
quinidine;B-drug;B-DDI-DrugBank.d143.s30.e1
increases;O;O
quinidine;B-drug;B-DDI-DrugBank.d143.s30.e2
serum;O;O
concentration;O;O
by;O;O
33;O;O
%;O;O
after;O;O
two;O;O
days;O;O
.;O;O
DDI-DrugBank.d143.s31;;
Amiodarone;B-drug;B-DDI-DrugBank.d143.s31.e0
taken;O;O
concomitantly;O;O
with;O;O
procainamide;B-drug;B-DDI-DrugBank.d143.s31.e1
for;O;O
less;O;O
than;O;O
seven;O;O
days;O;O
increases;O;O
plasma;O;O
concentrations;O;O
of;O;O
procainamide;B-drug;B-DDI-DrugBank.d143.s31.e2
and;O;O
n;O;O
-;O;O
acetyl;O;O
procainamide;B-drug;B-DDI-DrugBank.d143.s31.e3
by;O;O
55;O;O
%;O;O
and;O;O
33;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d143.s32;;
Quinidine;B-drug;B-DDI-DrugBank.d143.s32.e0
and;O;O
procainamide;O;O
doses;O;O
should;O;O
be;O;O
reduced;O;O
by;O;O
one;O;O
-;O;O
third;O;O
when;O;O
either;O;O
is;O;O
administered;O;O
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s32.e1
.;O;O
DDI-DrugBank.d143.s33;;
Plasma;O;O
levels;O;O
of;O;O
flecainide;B-drug;B-DDI-DrugBank.d143.s33.e0
have;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s33.e1
,;O;O
DDI-DrugBank.d143.s34;;
because;O;O
of;O;O
this;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
flecainide;B-drug;B-DDI-DrugBank.d143.s34.e0
should;O;O
be;O;O
adjusted;O;O
when;O;O
these;O;O
drugs;B-drug;B-DDI-DrugBank.d143.s34.e1
are;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d143.s35;;
In;O;O
general;O;O
,;O;O
any;O;O
added;O;O
antiarrhythmic;B-drug;B-DDI-DrugBank.d143.s35.e0
drug;I-drug;I-DDI-DrugBank.d143.s35.e0
should;O;O
be;O;O
initiated;O;O
at;O;O
a;O;O
lower;O;O
than;O;O
usual;O;O
dose;O;O
with;O;O
careful;O;O
monitoring;O;O
.;O;O
DDI-DrugBank.d143.s36;;
Combination;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s36.e0
with;O;O
other;O;O
antiarrhythmic;B-drug;B-DDI-DrugBank.d143.s36.e1
therapy;O;O
should;O;O
be;O;O
reserved;O;O
for;O;O
patients;O;O
with;O;O
life;O;O
-;O;O
threatening;O;O
ventricular;O;O
arrhythmias;O;O
who;O;O
are;O;O
incompletely;O;O
responsive;O;O
to;O;O
a;O;O
single;O;O
agent;O;O
or;O;O
incompletely;O;O
responsive;O;O
to;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s36.e2
.;O;O
DDI-DrugBank.d143.s37;;
During;O;O
transfer;O;O
to;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s37.e0
,;O;O
the;O;O
dose;O;O
levels;O;O
of;O;O
previously;O;O
administered;O;O
agents;O;O
should;O;O
be;O;O
reduced;O;O
by;O;O
30;O;O
to;O;O
50;O;O
%;O;O
several;O;O
days;O;O
after;O;O
the;O;O
addition;O;O
of;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s37.e1
.;O;O
DDI-DrugBank.d143.s38;;
The;O;O
continued;O;O
need;O;O
for;O;O
the;O;O
other;O;O
antiarrhythmic;B-drug;B-DDI-DrugBank.d143.s38.e0
agent;O;O
should;O;O
be;O;O
reviewed;O;O
after;O;O
the;O;O
effects;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s38.e1
have;O;O
been;O;O
established;O;O
,;O;O
and;O;O
discontinuation;O;O
ordinarily;O;O
should;O;O
be;O;O
attempted;O;O
.;O;O
DDI-DrugBank.d143.s39;;
If;O;O
the;O;O
treatment;O;O
is;O;O
continued;O;O
,;O;O
these;O;O
patients;O;O
should;O;O
be;O;O
particularly;O;O
carefully;O;O
monitored;O;O
for;O;O
adverse;O;O
effects;O;O
,;O;O
especially;O;O
conduction;O;O
disturbances;O;O
and;O;O
exacerbation;O;O
of;O;O
tachyarrhythmias;O;O
,;O;O
as;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s39.e0
is;O;O
continued;O;O
.;O;O
DDI-DrugBank.d143.s40;;
In;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s40.e0
-;O;O
treated;O;O
patients;O;O
who;O;O
require;O;O
additional;O;O
antiarrhythmic;B-drug;B-DDI-DrugBank.d143.s40.e1
therapy;O;O
,;O;O
the;O;O
initial;O;O
dose;O;O
of;O;O
such;O;O
agents;O;O
should;O;O
be;O;O
approximately;O;O
half;O;O
of;O;O
the;O;O
usual;O;O
recommended;O;O
dose;O;O
.;O;O
DDI-DrugBank.d143.s41;;
Antihypertensives;B-drug;B-DDI-DrugBank.d143.s41.e0
:;O;O
Amiodarone;B-drug;B-DDI-DrugBank.d143.s41.e1
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
-receptor;O;O
blocking;O;O
agents;O;O
(;O;O
e.g.;O;O
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d143.s41.e3
,;O;O
a;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s41.e4
inhibitor;O;O
);O;O
or;O;O
calcium;B-drug;B-DDI-DrugBank.d143.s41.e5
channel;I-drug;I-DDI-DrugBank.d143.s41.e5
antagonists;O;O
(;O;O
e.g.;O;O
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d143.s41.e6
,;O;O
a;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s41.e7
substrate;O;O
,;O;O
and;O;O
diltiazem;B-drug;B-DDI-DrugBank.d143.s41.e8
,;O;O
a;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s41.e9
inhibitor;O;O
);O;O
because;O;O
of;O;O
the;O;O
possible;O;O
potentiation;O;O
of;O;O
bradycardia;O;O
,;O;O
sinus;O;O
arrest;O;O
,;O;O
and;O;O
AV;O;O
block;O;O
,;O;O
DDI-DrugBank.d143.s42;;
if;O;O
necessary;O;O
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s42.e0
can;O;O
continue;O;O
to;O;O
be;O;O
used;O;O
after;O;O
insertion;O;O
of;O;O
a;O;O
pacemaker;O;O
in;O;O
patients;O;O
with;O;O
severe;O;O
bradycardia;O;O
or;O;O
sinus;O;O
arrest;O;O
.;O;O
DDI-DrugBank.d143.s43;;
Anticoagulants;B-drug;B-DDI-DrugBank.d143.s43.e0
:;O;O
Potentiation;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d143.s43.e1
-;O;O
type;O;O
(;O;O
CYP2C9;B-drug;B-DDI-DrugBank.d143.s43.e2
and;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s43.e3
substrate;O;O
);O;O
anticoagulant;B-drug;B-DDI-DrugBank.d143.s43.e4
response;O;O
is;O;O
almost;O;O
always;O;O
seen;O;O
in;O;O
patients;O;O
receiving;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s43.e5
and;O;O
can;O;O
result;O;O
in;O;O
serious;O;O
or;O;O
fatal;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d143.s44;;
Since;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d143.s44.e0
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s44.e1
increases;O;O
the;O;O
prothrombin;O;O
time;O;O
by;O;O
100;O;O
%;O;O
after;O;O
3;O;O
to;O;O
4;O;O
days;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
anticoagulant;B-drug;B-DDI-DrugBank.d143.s44.e2
should;O;O
be;O;O
reduced;O;O
by;O;O
one;O;O
-;O;O
third;O;O
to;O;O
one;O;O
-;O;O
half;O;O
,;O;O
and;O;O
prothrombin;O;O
times;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
.;O;O
DDI-DrugBank.d143.s45;;
Some;O;O
drugs;B-drug;B-DDI-DrugBank.d143.s45.e0
/;O;O
substances;O;O
are;O;O
known;O;O
to;O;O
accelerate;O;O
the;O;O
metabolism;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s45.e1
by;O;O
stimulating;O;O
the;O;O
synthesis;O;O
of;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s45.e2
(;O;O
enzyme;O;O
induction;O;O
);O;O
.;O;O
DDI-DrugBank.d143.s46;;
This;O;O
may;O;O
lead;O;O
to;O;O
low;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s46.e0
serum;O;O
levels;O;O
and;O;O
potential;O;O
decrease;O;O
in;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d143.s47;;
Reported;O;O
examples;O;O
of;O;O
this;O;O
interaction;O;O
include;O;O
the;O;O
following;O;O
:;O;O
Antibiotics;B-drug;B-DDI-DrugBank.d143.s47.e0
:;O;O
Rifampin;B-drug;B-DDI-DrugBank.d143.s47.e1
is;O;O
a;O;O
potent;O;O
inducer;O;O
of;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s47.e2
.;O;O
DDI-DrugBank.d143.s48;;
Administration;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d143.s48.e0
concomitantly;O;O
with;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s48.e1
has;O;O
been;O;O
shown;O;O
to;O;O
result;O;O
in;O;O
decreases;O;O
in;O;O
serum;O;O
concentrations;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s48.e2
and;O;O
desethylamiodarone;B-drug;B-DDI-DrugBank.d143.s48.e3
.;O;O
DDI-DrugBank.d143.s49;;
Other;O;O
substances;O;O
,;O;O
including;O;O
herbal;O;O
preparations;O;O
:;O;O
St.;O;O
John;O;O
s;O;O
Wort;O;O
(;O;O
Hypericum;O;O
perforatum;O;O
);O;O
induces;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d143.s50;;
Since;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s50.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s50.e1
,;O;O
there;O;O
is;O;O
the;O;O
potential;O;O
that;O;O
the;O;O
use;O;O
of;O;O
St.;O;O
John;O;O
s;O;O
Wort;O;O
in;O;O
patients;O;O
receiving;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s50.e2
could;O;O
result;O;O
in;O;O
reduced;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s50.e3
levels;O;O
.;O;O
DDI-DrugBank.d143.s51;;
Other;O;O
reported;O;O
interactions;O;O
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s51.e0
:;O;O
Fentanyl;B-drug;B-DDI-DrugBank.d143.s51.e1
(;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s51.e2
substrate;O;O
);O;O
in;O;O
combination;O;O
with;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s51.e3
may;O;O
cause;O;O
hypotension;O;O
,;O;O
bradycardia;O;O
,;O;O
and;O;O
decreased;O;O
cardiac;O;O
output;O;O
.;O;O
DDI-DrugBank.d143.s52;;
Sinus;O;O
bradycardia;O;O
has;O;O
been;O;O
reported;O;O
with;O;O
oral;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s52.e0
in;O;O
combination;O;O
with;O;O
lidocaine;B-drug;B-DDI-DrugBank.d143.s52.e1
(;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s52.e2
substrate;O;O
);O;O
given;O;O
for;O;O
local;O;O
anesthesia;B-drug;B-DDI-DrugBank.d143.s52.e3
.;O;O
DDI-DrugBank.d143.s53;;
Seizure;O;O
,;O;O
associated;O;O
with;O;O
increased;O;O
lidocaine;B-drug;B-DDI-DrugBank.d143.s53.e0
concentrations;O;O
,;O;O
has;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
intravenous;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s53.e1
.;O;O
DDI-DrugBank.d143.s54;;
Dextromethorphan;B-drug;B-DDI-DrugBank.d143.s54.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
both;O;O
CYP2D6;B-drug;B-DDI-DrugBank.d143.s54.e1
and;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d143.s54.e2
.;O;O
DDI-DrugBank.d143.s55;;
Amiodarone;B-drug;B-DDI-DrugBank.d143.s55.e0
inhibits;O;O
CYP2D6;B-drug;B-DDI-DrugBank.d143.s55.e1
.;O;O
DDI-DrugBank.d143.s56;;
Cholestyramine;B-drug;B-DDI-DrugBank.d143.s56.e0
increases;O;O
enterohepatic;O;O
elimination;O;O
of;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s56.e1
and;O;O
may;O;O
reduce;O;O
its;O;O
serum;O;O
levels;O;O
and;O;O
t1;B-drug;B-DDI-DrugBank.d143.s56.e2
/;O;O
2;O;O
.;O;O
DDI-DrugBank.d143.s57;;
Disopyramide;B-drug;B-DDI-DrugBank.d143.s57.e0
increases;O;O
QT;O;O
prolongation;O;O
which;O;O
could;O;O
cause;O;O
arrhythmia;O;O
.;O;O
DDI-DrugBank.d143.s58;;
Fluoroquinolones;B-drug;B-DDI-DrugBank.d143.s58.e0
,;O;O
macrolide;B-drug;B-DDI-DrugBank.d143.s58.e1
antibiotics;I-drug;I-DDI-DrugBank.d143.s58.e1
,;O;O
and;O;O
azoles;O;O
are;O;O
known;O;O
to;O;O
cause;O;O
QTc;O;O
prolongation;O;O
.;O;O
DDI-DrugBank.d143.s59;;
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
QTc;O;O
prolongation;O;O
,;O;O
with;O;O
or;O;O
without;O;O
TdP;O;O
,;O;O
in;O;O
patients;O;O
taking;O;O
amiodarone;B-drug;B-DDI-DrugBank.d143.s59.e0
when;O;O
fluoroquinolones;B-drug;B-DDI-DrugBank.d143.s59.e1
,;O;O
macrolide;B-drug;B-DDI-DrugBank.d143.s59.e2
antibiotics;I-drug;I-DDI-DrugBank.d143.s59.e2
,;O;O
or;O;O
azoles;O;O
were;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d143.s60;;
Hemodynamic;O;O
and;O;O
electrophysiologic;O;O
interactions;O;O
have;O;O
also;O;O
been;O;O
observed;O;O
after;O;O
concomitant;O;O
administration;O;O
with;O;O
propranolol;B-drug;B-DDI-DrugBank.d143.s60.e0
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d143.s60.e1
,;O;O
and;O;O
verapamil;B-drug;B-DDI-DrugBank.d143.s60.e2
.;O;O
DDI-DrugBank.d143.s61;;
Volatile;O;O
Anesthetic;B-drug;B-DDI-DrugBank.d143.s61.e0
Agents;O;O
:;O;O
.;O;O
DDI-DrugBank.d143.s62;;
In;O;O
addition;O;O
to;O;O
the;O;O
interactions;O;O
noted;O;O
above;O;O
,;O;O
chronic;O;O
(;O;O
2;O;O
weeks;O;O
);O;O
oral;O;O
Cordarone;B-drug;B-DDI-DrugBank.d143.s62.e0
administration;O;O
impairs;O;O
metabolism;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d143.s62.e1
,;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d143.s62.e2
,;O;O
and;O;O
methotrexate;B-drug;B-DDI-DrugBank.d143.s62.e3
.;O;O
DDI-DrugBank.d143.s63;;
Electrolyte;O;O
Disturbances;O;O
Patients;O;O
with;O;O
hypokalemia;O;O
or;O;O
hypomagnesemia;O;O
should;O;O
have;O;O
the;O;O
condition;O;O
corrected;O;O
whenever;O;O
possible;O;O
before;O;O
being;O;O
treated;O;O
with;O;O
Cordarone;B-drug;B-DDI-DrugBank.d143.s63.e0
I.V.;I-drug;I-DDI-DrugBank.d143.s63.e0
,;O;O
as;O;O
these;O;O
disorders;O;O
can;O;O
exaggerate;O;O
the;O;O
degree;O;O
of;O;O
QTc;O;O
prolongation;O;O
and;O;O
increase;O;O
the;O;O
potential;O;O
for;O;O
TdP.;O;O
DDI-DrugBank.d143.s64;;
Special;O;O
attention;O;O
should;O;O
be;O;O
given;O;O
to;O;O
electrolyte;O;O
and;O;O
acid;O;O
-;O;O
base;O;O
balance;O;O
in;O;O
patients;O;O
experiencing;O;O
severe;O;O
or;O;O
prolonged;O;O
diarrhea;O;O
or;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
diuretics;B-drug;B-DDI-DrugBank.d143.s64.e0
.;O;O
DDI-DrugBank.d99.s0;;
Drugs;O;O
Metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
-;O;O
The;O;O
biochemical;O;O
activity;O;O
of;O;O
the;O;O
drug;O;O
metabolizing;O;O
isozyme;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
(;O;O
debrisoquin;O;O
hydroxylase;O;O
);O;O
is;O;O
reduced;O;O
in;O;O
a;O;O
subset;O;O
of;O;O
the;O;O
caucasian;O;O
population;O;O
(;O;O
about;O;O
7;O;O
-;O;O
10;O;O
%;O;O
of;O;O
caucasians;O;O
are;O;O
so;O;O
called;O;O
poor;O;O
metabolizers;O;O
);O;O
,;O;O
DDI-DrugBank.d99.s1;;
reliable;O;O
estimates;O;O
of;O;O
the;O;O
prevalence;O;O
of;O;O
reduced;O;O
P450;O;O
2D6;O;O
isozyme;O;O
activity;O;O
among;O;O
Asian;O;O
,;O;O
African;O;O
and;O;O
other;O;O
populations;O;O
are;O;O
not;O;O
yet;O;O
available;O;O
.;O;O
DDI-DrugBank.d99.s2;;
Poor;O;O
metabolizers;O;O
have;O;O
higher;O;O
than;O;O
expected;O;O
plasma;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d99.s2.e0
antidepressants;I-group;I-DDI-DrugBank.d99.s2.e0
(;O;O
TCAs;B-group;B-DDI-DrugBank.d99.s2.e1
);O;O
when;O;O
given;O;O
usual;O;O
doses;O;O
.;O;O
DDI-DrugBank.d99.s3;;
Depending;O;O
on;O;O
the;O;O
fraction;O;O
of;O;O
drug;O;O
metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
,;O;O
the;O;O
increase;O;O
in;O;O
plasma;O;O
concentration;O;O
may;O;O
be;O;O
small;O;O
,;O;O
or;O;O
quite;O;O
large;O;O
(;O;O
8;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
plasma;O;O
AUC;O;O
of;O;O
the;O;O
TCA;B-group;B-DDI-DrugBank.d99.s3.e0
);O;O
.;O;O
DDI-DrugBank.d99.s4;;
In;O;O
addition;O;O
,;O;O
certain;O;O
drugs;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
this;O;O
isozyme;O;O
and;O;O
make;O;O
normal;O;O
metabolizers;O;O
resemble;O;O
poor;O;O
metabolizers;O;O
.;O;O
DDI-DrugBank.d99.s5;;
An;O;O
individual;O;O
who;O;O
is;O;O
stable;O;O
on;O;O
a;O;O
given;O;O
dose;O;O
of;O;O
TCA;B-group;B-DDI-DrugBank.d99.s5.e0
may;O;O
become;O;O
abruptly;O;O
toxic;O;O
when;O;O
given;O;O
one;O;O
of;O;O
these;O;O
inhibiting;O;O
drugs;O;O
as;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d99.s6;;
The;O;O
drugs;O;O
that;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
include;O;O
some;O;O
that;O;O
are;O;O
not;O;O
metabolized;O;O
by;O;O
the;O;O
enzyme;O;O
(;O;O
quinidine;B-drug;B-DDI-DrugBank.d99.s6.e0
,;O;O
DDI-DrugBank.d99.s7;;
cimetidine;B-drug;B-DDI-DrugBank.d99.s7.e0
);O;O
and;O;O
many;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
P450;O;O
2D6;O;O
(;O;O
many;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d99.s7.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d99.s7.e2
,;O;O
and;O;O
the;O;O
Type;B-group;B-DDI-DrugBank.d99.s7.e3
1C;I-group;I-DDI-DrugBank.d99.s7.e3
antiarrhythmics;I-group;I-DDI-DrugBank.d99.s7.e3
propafenone;I-drug;I-DDI-DrugBank.d99.s7.e4
and;O;O
flecainide;B-drug;B-DDI-DrugBank.d99.s7.e5
);O;O
.;O;O
DDI-DrugBank.d99.s8;;
While;O;O
all;O;O
the;O;O
selective;O;O
serotonin;B-group;B-DDI-DrugBank.d99.s8.e0
reuptake;I-group;I-DDI-DrugBank.d99.s8.e0
inhibitors;I-group;I-DDI-DrugBank.d99.s8.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d99.s8.e1
);O;O
,;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d99.s8.e2
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d99.s8.e3
,;O;O
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d99.s8.e4
,;O;O
inhibit;O;O
P450;O;O
2D6;O;O
,;O;O
they;O;O
may;O;O
vary;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d99.s9;;
The;O;O
extent;O;O
to;O;O
which;O;O
SSRI;B-group;B-DDI-DrugBank.d99.s9.e0
-;O;O
TCA;B-group;B-DDI-DrugBank.d99.s9.e1
interactions;O;O
may;O;O
pose;O;O
clinical;O;O
problems;O;O
will;O;O
depend;O;O
on;O;O
the;O;O
degree;O;O
of;O;O
inhibition;O;O
and;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
the;O;O
SSRI;B-group;B-DDI-DrugBank.d99.s9.e2
involved;O;O
.;O;O
DDI-DrugBank.d99.s10;;
Nevertheless;O;O
,;O;O
caution;O;O
is;O;O
indicated;O;O
in;O;O
the;O;O
coadministration;O;O
of;O;O
TCAs;B-group;B-DDI-DrugBank.d99.s10.e0
with;O;O
any;O;O
of;O;O
the;O;O
SSRIs;B-group;B-DDI-DrugBank.d99.s10.e1
and;O;O
also;O;O
in;O;O
switching;O;O
from;O;O
one;O;O
class;O;O
to;O;O
the;O;O
other;O;O
.;O;O
DDI-DrugBank.d99.s11;;
Of;O;O
particular;O;O
importance;O;O
,;O;O
sufficient;O;O
time;O;O
must;O;O
elapse;O;O
before;O;O
initiating;O;O
TCA;O;O
treatment;O;O
in;O;O
a;O;O
patient;O;O
being;O;O
withdrawn;O;O
from;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d99.s11.e0
,;O;O
given;O;O
the;O;O
long;O;O
half;O;O
-;O;O
life;O;O
of;O;O
the;O;O
parent;O;O
and;O;O
active;O;O
metabolite;O;O
(;O;O
at;O;O
least;O;O
5;O;O
weeks;O;O
may;O;O
be;O;O
necessary;O;O
);O;O
.;O;O
DDI-DrugBank.d99.s12;;
Concomitant;O;O
use;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d99.s12.e0
antidepressants;I-group;I-DDI-DrugBank.d99.s12.e0
with;O;O
drugs;O;O
that;O;O
can;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
may;O;O
require;O;O
lower;O;O
doses;O;O
than;O;O
usually;O;O
prescribed;O;O
for;O;O
either;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d99.s12.e1
antidepressant;I-group;I-DDI-DrugBank.d99.s12.e1
or;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d99.s13;;
Furthermore;O;O
,;O;O
whenever;O;O
one;O;O
of;O;O
these;O;O
other;O;O
drugs;O;O
is;O;O
withdrawn;O;O
from;O;O
co;O;O
-;O;O
therapy;O;O
,;O;O
an;O;O
increased;O;O
dose;O;O
of;O;O
tricyclic;B-drug;B-DDI-DrugBank.d99.s13.e0
antidepressant;I-drug;I-DDI-DrugBank.d99.s13.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d99.s14;;
It;O;O
is;O;O
desirable;O;O
to;O;O
monitor;O;O
TCA;B-group;B-DDI-DrugBank.d99.s14.e0
plasma;O;O
levels;O;O
whenever;O;O
a;O;O
TCA;B-group;B-DDI-DrugBank.d99.s14.e1
is;O;O
going;O;O
to;O;O
be;O;O
coadministered;O;O
with;O;O
another;O;O
drug;O;O
known;O;O
to;O;O
be;O;O
an;O;O
inhibitor;O;O
of;O;O
P450;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d99.s15;;
Monoamine;B-drug;B-DDI-DrugBank.d99.s15.e0
Oxidase;I-drug;I-DDI-DrugBank.d99.s15.e0
Inhibitors;I-drug;I-DDI-DrugBank.d99.s15.e0
:;O;O
Guanethidine;B-drug;B-DDI-DrugBank.d99.s15.e1
or;O;O
similarly;O;O
acting;O;O
compounds;O;O
,;O;O
DDI-DrugBank.d99.s16;;
thyroid;B-drug;B-DDI-DrugBank.d99.s16.e0
medication;O;O
,;O;O
DDI-DrugBank.d99.s17;;
alcohol;B-drug;B-DDI-DrugBank.d99.s17.e0
,;O;O
barbiturates;B-drug;B-DDI-DrugBank.d99.s17.e1
and;O;O
other;O;O
CNS;B-drug;B-DDI-DrugBank.d99.s17.e2
depressants;I-drug;I-DDI-DrugBank.d99.s17.e2
,;O;O
DDI-DrugBank.d99.s18;;
and;O;O
disulfiram;B-drug;B-DDI-DrugBank.d99.s18.e0
When;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d99.s18.e1
HCl;I-drug;I-DDI-DrugBank.d99.s18.e1
is;O;O
given;O;O
with;O;O
anticholinergic;B-drug;B-DDI-DrugBank.d99.s18.e2
agents;O;O
or;O;O
sympathomimetic;B-drug;B-DDI-DrugBank.d99.s18.e3
drugs;O;O
,;O;O
including;O;O
epinephrine;B-drug;B-DDI-DrugBank.d99.s18.e4
combined;O;O
with;O;O
local;O;O
anesthetics;B-drug;B-DDI-DrugBank.d99.s18.e5
,;O;O
close;O;O
supervision;O;O
and;O;O
careful;O;O
adjustment;O;O
of;O;O
dosages;O;O
are;O;O
required;O;O
.;O;O
DDI-DrugBank.d99.s19;;
Hyperpyrexia;O;O
has;O;O
been;O;O
reported;O;O
when;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d99.s19.e0
HCl;I-drug;I-DDI-DrugBank.d99.s19.e0
is;O;O
administered;O;O
with;O;O
anticholinergic;B-drug;B-DDI-DrugBank.d99.s19.e1
agents;O;O
or;O;O
with;O;O
neuroleptic;B-drug;B-DDI-DrugBank.d99.s19.e2
drugs;O;O
,;O;O
particularly;O;O
during;O;O
hot;O;O
weather;O;O
.;O;O
DDI-DrugBank.d99.s20;;
Paralytic;O;O
ileus;O;O
may;O;O
occur;O;O
in;O;O
patients;O;O
taking;O;O
tricyclic;B-drug;B-DDI-DrugBank.d99.s20.e0
antidepressants;I-drug;I-DDI-DrugBank.d99.s20.e0
in;O;O
combination;O;O
with;O;O
anticholinergic;B-drug;B-DDI-DrugBank.d99.s20.e1
-;O;O
type;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d99.s21;;
Cimetidine;B-drug;B-DDI-DrugBank.d99.s21.e0
is;O;O
reported;O;O
to;O;O
reduce;O;O
hepatic;O;O
metabolism;O;O
of;O;O
certain;O;O
tricyclic;B-drug;B-DDI-DrugBank.d99.s21.e1
antidepressants;I-drug;I-DDI-DrugBank.d99.s21.e1
,;O;O
thereby;O;O
delaying;O;O
elimination;O;O
and;O;O
increasing;O;O
steady;O;O
-;O;O
state;O;O
concentrations;O;O
of;O;O
these;O;O
drugs;B-drug;B-DDI-DrugBank.d99.s21.e2
.;O;O
DDI-DrugBank.d99.s22;;
Clinically;O;O
significant;O;O
effects;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
the;O;O
tricyclic;B-drug;B-DDI-DrugBank.d99.s22.e0
antidepressants;I-drug;I-DDI-DrugBank.d99.s22.e0
when;O;O
used;O;O
concomitantly;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d99.s22.e1
.;O;O
DDI-DrugBank.d99.s23;;
Increases;O;O
in;O;O
plasma;O;O
levels;O;O
of;O;O
tricyclic;B-drug;B-DDI-DrugBank.d99.s23.e0
antidepressants;I-drug;I-DDI-DrugBank.d99.s23.e0
,;O;O
and;O;O
in;O;O
the;O;O
frequency;O;O
and;O;O
severity;O;O
of;O;O
side;O;O
effects;O;O
,;O;O
particularly;O;O
anticholinergic;B-drug;B-DDI-DrugBank.d99.s23.e1
,;O;O
have;O;O
been;O;O
reported;O;O
when;O;O
cimetidine;B-drug;B-DDI-DrugBank.d99.s23.e2
was;O;O
added;O;O
to;O;O
the;O;O
drug;B-drug;B-DDI-DrugBank.d99.s23.e3
regimen;O;O
.;O;O
DDI-DrugBank.d99.s24;;
Discontinuation;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d99.s24.e0
in;O;O
well;O;O
-;O;O
controlled;O;O
patients;O;O
receiving;O;O
tricyclic;B-drug;B-DDI-DrugBank.d99.s24.e1
antidepressants;I-drug;I-DDI-DrugBank.d99.s24.e1
and;O;O
cimetidine;B-drug;B-DDI-DrugBank.d99.s24.e2
may;O;O
decrease;O;O
the;O;O
plasma;O;O
levels;O;O
and;O;O
efficacy;O;O
of;O;O
the;O;O
antidepressants;B-drug;B-DDI-DrugBank.d99.s24.e3
.;O;O
DDI-DrugBank.d99.s25;;
Caution;O;O
is;O;O
advised;O;O
if;O;O
patients;O;O
receive;O;O
large;O;O
doses;O;O
of;O;O
ethchlorvynol;B-drug;B-DDI-DrugBank.d99.s25.e0
concurrently;O;O
.;O;O
DDI-DrugBank.d99.s26;;
Transient;O;O
delirium;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
who;O;O
were;O;O
treated;O;O
with;O;O
one;O;O
gram;O;O
of;O;O
ethchlorvynol;B-drug;B-DDI-DrugBank.d99.s26.e0
and;O;O
75;O;O
-;O;O
150;O;O
mg;O;O
of;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d99.s26.e1
HCl;I-drug;I-DDI-DrugBank.d99.s26.e1
.;O;O
DDI-DrugBank.d318.s0;;
When;O;O
administered;O;O
concurrently;O;O
,;O;O
the;O;O
following;O;O
drugs;O;O
may;O;O
interact;O;O
with;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s0.e0
B;I-drug;I-DDI-DrugBank.d318.s0.e0
:;O;O
Antineoplastic;B-group;B-DDI-DrugBank.d318.s0.e1
agents;I-group;I-DDI-DrugBank.d318.s0.e1
:;O;O
may;O;O
enhance;O;O
the;O;O
potential;O;O
for;O;O
renal;O;O
toxicity;O;O
,;O;O
bronchospasm;O;O
and;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d318.s1;;
Antineoplastic;B-group;B-DDI-DrugBank.d318.s1.e0
agents;I-group;I-DDI-DrugBank.d318.s1.e0
(;O;O
e.;O;O
g.;O;O
,;O;O
nitrogen;B-drug;B-DDI-DrugBank.d318.s1.e1
mustard;I-drug;I-DDI-DrugBank.d318.s1.e1
,;O;O
etc;O;O
.;O;O
);O;O
should;O;O
be;O;O
given;O;O
concomitantly;O;O
only;O;O
with;O;O
great;O;O
caution;O;O
.;O;O
DDI-DrugBank.d318.s2;;
Corticosteroids;B-group;B-DDI-DrugBank.d318.s2.e0
and;O;O
Corticotropin;B-drug;B-DDI-DrugBank.d318.s2.e1
(;O;O
ACTH;B-group;B-DDI-DrugBank.d318.s2.e2
);O;O
:;O;O
may;O;O
potentiate;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s2.e3
B;I-drug;I-DDI-DrugBank.d318.s2.e3
-;O;O
induced;O;O
hypokalemia;O;O
which;O;O
may;O;O
predispose;O;O
the;O;O
patient;O;O
to;O;O
cardiac;O;O
dysfunction;O;O
.;O;O
DDI-DrugBank.d318.s3;;
Avoid;O;O
concomitant;O;O
use;O;O
unless;O;O
necessary;O;O
to;O;O
control;O;O
side;O;O
effects;O;O
of;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s3.e0
B.;I-drug;I-DDI-DrugBank.d318.s3.e0
DDI-DrugBank.d318.s4;;
If;O;O
used;O;O
concomitantly;O;O
,;O;O
closely;O;O
monitor;O;O
serum;O;O
electrolytes;O;O
and;O;O
cardiac;O;O
function;O;O
.;O;O
DDI-DrugBank.d318.s5;;
Digitalis;B-group;B-DDI-DrugBank.d318.s5.e0
glycosides;I-group;I-DDI-DrugBank.d318.s5.e0
:;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s5.e1
B;I-drug;I-DDI-DrugBank.d318.s5.e1
-;O;O
induced;O;O
hypokalemia;O;O
may;O;O
potentiate;O;O
digitalis;B-group;B-DDI-DrugBank.d318.s5.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d318.s6;;
Serum;O;O
potassium;O;O
levels;O;O
and;O;O
cardiac;O;O
function;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
and;O;O
any;O;O
deficit;O;O
promptly;O;O
corrected;O;O
.;O;O
DDI-DrugBank.d318.s7;;
Flucytosine;B-drug;B-DDI-DrugBank.d318.s7.e0
:;O;O
while;O;O
a;O;O
synergistic;O;O
relationship;O;O
with;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s7.e1
B;I-drug;I-DDI-DrugBank.d318.s7.e1
has;O;O
been;O;O
reported;O;O
,;O;O
concomitant;O;O
use;O;O
may;O;O
increase;O;O
the;O;O
toxicity;O;O
of;O;O
flucytosine;B-drug;B-DDI-DrugBank.d318.s7.e2
by;O;O
possibly;O;O
increasing;O;O
its;O;O
cellular;O;O
uptake;O;O
and/or;O;O
impairing;O;O
its;O;O
renal;O;O
excretion;O;O
.;O;O
DDI-DrugBank.d318.s8;;
Imidazoles;B-group;B-DDI-DrugBank.d318.s8.e0
(;O;O
e.;O;O
g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d318.s8.e1
,;O;O
miconazole;B-drug;B-DDI-DrugBank.d318.s8.e2
,;O;O
clotrimazole;B-drug;B-DDI-DrugBank.d318.s8.e3
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d318.s8.e4
,;O;O
etc;O;O
.;O;O
);O;O
:;O;O
in;O;O
vitro;O;O
and;O;O
animal;O;O
studies;O;O
with;O;O
the;O;O
combination;O;O
of;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s8.e5
B;I-drug;I-DDI-DrugBank.d318.s8.e5
and;O;O
imidazoles;B-group;B-DDI-DrugBank.d318.s8.e6
suggest;O;O
that;O;O
imidazoles;B-group;B-DDI-DrugBank.d318.s8.e7
may;O;O
induce;O;O
fungal;O;O
resistance;O;O
to;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s8.e8
B.;I-drug;I-DDI-DrugBank.d318.s8.e8
DDI-DrugBank.d318.s9;;
Combination;O;O
therapy;O;O
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
,;O;O
especially;O;O
in;O;O
immunocompromised;O;O
patients;O;O
.;O;O
DDI-DrugBank.d318.s10;;
Other;O;O
nephrotoxic;O;O
medications;O;O
:;O;O
agents;O;O
such;O;O
as;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d318.s10.e0
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d318.s10.e1
,;O;O
and;O;O
pentamidine;B-drug;B-DDI-DrugBank.d318.s10.e2
may;O;O
enhance;O;O
the;O;O
potential;O;O
for;O;O
drug;O;O
-;O;O
induced;O;O
renal;O;O
toxicity;O;O
,;O;O
and;O;O
should;O;O
be;O;O
used;O;O
concomitantly;O;O
only;O;O
with;O;O
great;O;O
caution;O;O
.;O;O
DDI-DrugBank.d318.s11;;
Intensive;O;O
monitoring;O;O
of;O;O
renal;O;O
function;O;O
is;O;O
recommended;O;O
in;O;O
patients;O;O
requiring;O;O
any;O;O
combination;O;O
of;O;O
nephrotoxic;O;O
medications;O;O
.;O;O
DDI-DrugBank.d318.s12;;
Skeletal;B-group;B-DDI-DrugBank.d318.s12.e0
muscle;I-group;I-DDI-DrugBank.d318.s12.e0
relaxants;I-group;I-DDI-DrugBank.d318.s12.e0
:;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s12.e1
B;I-drug;I-DDI-DrugBank.d318.s12.e1
-;O;O
induced;O;O
hypokalemia;O;O
may;O;O
enhance;O;O
the;O;O
curariform;O;O
effect;O;O
of;O;O
skeletal;B-group;B-DDI-DrugBank.d318.s12.e2
muscle;I-group;I-DDI-DrugBank.d318.s12.e2
relaxants;I-group;I-DDI-DrugBank.d318.s12.e2
(;O;O
e.g.;O;O
,;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d318.s12.e3
);O;O
.;O;O
DDI-DrugBank.d318.s13;;
Serum;O;O
potassium;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
and;O;O
deficiencies;O;O
corrected;O;O
.;O;O
DDI-DrugBank.d318.s14;;
Leukocyte;B-drug_n;B-DDI-DrugBank.d318.s14.e0
transfusions;I-drug_n;I-DDI-DrugBank.d318.s14.e0
:;O;O
acute;O;O
pulmonary;O;O
toxicity;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
intravenous;O;O
amphotericin;B-drug;B-DDI-DrugBank.d318.s14.e1
B;I-drug;I-DDI-DrugBank.d318.s14.e1
and;O;O
leukocyte;B-drug_n;B-DDI-DrugBank.d318.s14.e2
transfusions;I-drug_n;I-DDI-DrugBank.d318.s14.e2
.;O;O
DDI-DrugBank.d211.s0;;
When;O;O
administered;O;O
concurrently;O;O
,;O;O
the;O;O
following;O;O
drugs;O;O
may;O;O
interact;O;O
with;O;O
ampicillin;B-drug;B-DDI-DrugBank.d211.s0.e0
.;O;O
DDI-DrugBank.d211.s1;;
Allopurinol;B-drug;B-DDI-DrugBank.d211.s1.e0
:;O;O
Increased;O;O
possibility;O;O
of;O;O
skin;O;O
rash;O;O
,;O;O
particularly;O;O
in;O;O
hyperuricemic;O;O
patients;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d211.s2;;
Bacteriostatic;B-group;B-DDI-DrugBank.d211.s2.e0
Antibiotics;I-group;I-DDI-DrugBank.d211.s2.e0
:;O;O
Chloramphenicol;B-drug;B-DDI-DrugBank.d211.s2.e1
,;O;O
erythromycins;B-drug;B-DDI-DrugBank.d211.s2.e2
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d211.s2.e3
,;O;O
or;O;O
tetracyclines;B-group;B-DDI-DrugBank.d211.s2.e4
may;O;O
interfere;O;O
with;O;O
the;O;O
bactericidal;O;O
effect;O;O
of;O;O
penicillins;B-group;B-DDI-DrugBank.d211.s2.e5
.;O;O
DDI-DrugBank.d211.s3;;
This;O;O
has;O;O
been;O;O
demonstrated;O;O
in;O;O
view;O;O
,;O;O
however;O;O
,;O;O
the;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
interaction;O;O
is;O;O
not;O;O
well;O;O
documented;O;O
.;O;O
DDI-DrugBank.d211.s4;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d211.s4.e0
:;O;O
May;O;O
be;O;O
less;O;O
effective;O;O
and;O;O
increased;O;O
breakthrough;O;O
bleeding;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d211.s5;;
Probenecid;B-drug;B-DDI-DrugBank.d211.s5.e0
:;O;O
May;O;O
decrease;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
ampicillin;B-drug;B-DDI-DrugBank.d211.s5.e1
resulting;O;O
in;O;O
increased;O;O
blood;O;O
levels;O;O
and/or;O;O
ampicillin;B-drug;B-DDI-DrugBank.d211.s5.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d211.s6;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interaction;O;O
After;O;O
treatment;O;O
with;O;O
ampicillin;B-drug;B-DDI-DrugBank.d211.s6.e0
,;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
with;O;O
copper;B-drug_n;B-DDI-DrugBank.d211.s6.e1
sulfate;I-drug_n;I-DDI-DrugBank.d211.s6.e1
tests;O;O
(;O;O
Benedicts;O;O
solution;O;O
,;O;O
Fehlings;O;O
solution;O;O
,;O;O
or;O;O
Clinitest;O;O
tablets;O;O
);O;O
but;O;O
not;O;O
with;O;O
enzyme;O;O
based;O;O
tests;O;O
such;O;O
as;O;O
Clinistix;O;O
and;O;O
Glucose;O;O
Enzymatic;O;O
Test;O;O
Strip;O;O
USP;O;O
.;O;O
DDI-DrugBank.d437.s0;;
Amprenavir;B-drug;B-DDI-DrugBank.d437.s0.e0
is;O;O
metabolized;O;O
in;O;O
the;O;O
liver;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
enzyme;O;O
system;O;O
.;O;O
DDI-DrugBank.d437.s1;;
Amprenavir;B-drug;B-DDI-DrugBank.d437.s1.e0
inhibits;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d437.s2;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
coadministering;O;O
medications;O;O
that;O;O
are;O;O
substrates;O;O
,;O;O
inhibitors;O;O
,;O;O
or;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
,;O;O
or;O;O
potentially;O;O
toxic;O;O
medications;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d437.s3;;
Amprenavir;B-drug;B-DDI-DrugBank.d437.s3.e0
does;O;O
not;O;O
inhibit;O;O
CYP2D6;O;O
,;O;O
CYP1A2;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
CYP2E1;O;O
,;O;O
or;O;O
uridine;O;O
glucuronosyltransferase;O;O
(;O;O
UDPGT;O;O
);O;O
.;O;O
DDI-DrugBank.d437.s4;;
HIV;B-group;B-DDI-DrugBank.d437.s4.e0
Protease;I-group;I-DDI-DrugBank.d437.s4.e0
Inhibitors;I-group;I-DDI-DrugBank.d437.s4.e0
:;O;O
The;O;O
effect;O;O
of;O;O
amprenavir;B-drug;B-DDI-DrugBank.d437.s4.e1
on;O;O
total;O;O
drug;O;O
concentrations;O;O
of;O;O
other;O;O
HIV;B-group;B-DDI-DrugBank.d437.s4.e2
protease;I-group;I-DDI-DrugBank.d437.s4.e2
inhibitors;I-group;I-DDI-DrugBank.d437.s4.e2
in;O;O
subjects;O;O
receiving;O;O
both;O;O
agents;O;O
was;O;O
evaluated;O;O
using;O;O
comparisons;O;O
to;O;O
historical;O;O
data;O;O
.;O;O
DDI-DrugBank.d437.s5;;
Indinavir;B-drug;B-DDI-DrugBank.d437.s5.e0
steady;O;O
-;O;O
state;O;O
Cmax;O;O
,;O;O
A.C.;O;O
and;O;O
Cmin;O;O
were;O;O
decreased;O;O
by;O;O
22;O;O
%;O;O
,;O;O
38;O;O
%;O;O
,;O;O
and;O;O
27;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
by;O;O
concomitant;O;O
amprenavir;B-drug;B-DDI-DrugBank.d437.s5.e1
.;O;O
DDI-DrugBank.d437.s6;;
Similar;O;O
decreases;O;O
in;O;O
Cmax;O;O
and;O;O
AUC;O;O
were;O;O
seen;O;O
after;O;O
the;O;O
first;O;O
dose;O;O
.;O;O
DDI-DrugBank.d437.s7;;
Saquinavir;B-drug;B-DDI-DrugBank.d437.s7.e0
steady;O;O
-;O;O
state;O;O
Cmax;O;O
,;O;O
A.C.;O;O
and;O;O
Cmin;O;O
were;O;O
increased;O;O
21;O;O
%;O;O
,;O;O
decreased;O;O
19;O;O
%;O;O
,;O;O
and;O;O
decreased;O;O
48;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
by;O;O
concomitant;O;O
amprenavir;B-drug;B-DDI-DrugBank.d437.s7.e1
.;O;O
DDI-DrugBank.d437.s8;;
Nelfinavir;B-drug;B-DDI-DrugBank.d437.s8.e0
steady;O;O
-;O;O
state;O;O
Cmax;O;O
,;O;O
A.C.;O;O
and;O;O
Cmin;O;O
were;O;O
increased;O;O
by;O;O
12;O;O
%;O;O
,;O;O
15;O;O
%;O;O
,;O;O
and;O;O
14;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
by;O;O
concomitant;O;O
amprenavir;B-drug;B-DDI-DrugBank.d437.s8.e1
.;O;O
DDI-DrugBank.d437.s9;;
Methadone;B-drug;B-DDI-DrugBank.d437.s9.e0
:;O;O
Coadministration;O;O
of;O;O
amprenavir;B-drug;B-DDI-DrugBank.d437.s9.e1
and;O;O
methadone;B-drug;B-DDI-DrugBank.d437.s9.e2
can;O;O
decrease;O;O
plasma;O;O
levels;O;O
of;O;O
methadone;B-drug;B-DDI-DrugBank.d437.s9.e3
.;O;O
DDI-DrugBank.d437.s10;;
Coadministration;O;O
of;O;O
amprenavir;B-drug;B-DDI-DrugBank.d437.s10.e0
and;O;O
methadone;B-drug;B-DDI-DrugBank.d437.s10.e1
as;O;O
compared;O;O
to;O;O
a;O;O
non;O;O
-;O;O
matched;O;O
historicalcontrol;O;O
group;O;O
resulted;O;O
in;O;O
a;O;O
30;O;O
%;O;O
,;O;O
27;O;O
%;O;O
,;O;O
and;O;O
25;O;O
%;O;O
decrease;O;O
in;O;O
serum;O;O
amprenavir;B-drug;B-DDI-DrugBank.d437.s10.e2
AUC;O;O
,;O;O
Cmax;O;O
,;O;O
andCmin;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d437.s11;;
Amprenavir;B-drug;B-DDI-DrugBank.d437.s11.e0
is;O;O
an;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
C.P.A.;O;O
metabolism;O;O
and;O;O
therefore;O;O
should;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
with;O;O
medications;O;O
with;O;O
narrow;O;O
therapeutic;O;O
windows;O;O
that;O;O
are;O;O
substrates;O;O
of;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d437.s12;;
There;O;O
are;O;O
other;O;O
agents;O;O
that;O;O
may;O;O
result;O;O
in;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d437.s13;;
Laboratory;O;O
Tests;O;O
:;O;O
The;O;O
combination;O;O
of;O;O
Amprenavir;B-drug;B-DDI-DrugBank.d437.s13.e0
and;O;O
low;O;O
-;O;O
dose;O;O
ritonavir;B-drug;B-DDI-DrugBank.d437.s13.e1
has;O;O
been;O;O
associated;O;O
with;O;O
elevations;O;O
of;O;O
cholesterol;O;O
and;O;O
triglycerides;O;O
,;O;O
SGOT;O;O
(;O;O
AST;O;O
);O;O
,;O;O
and;O;O
SGPT;O;O
(;O;O
ALT;O;O
);O;O
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d437.s14;;
Appropriate;O;O
laboratory;O;O
testing;O;O
should;O;O
be;O;O
considered;O;O
prior;O;O
to;O;O
initiating;O;O
combination;O;O
therapy;O;O
with;O;O
Amprenavir;B-drug;B-DDI-DrugBank.d437.s14.e0
and;O;O
ritonavir;B-drug;B-DDI-DrugBank.d437.s14.e1
and;O;O
at;O;O
periodic;O;O
intervals;O;O
or;O;O
if;O;O
any;O;O
clinical;O;O
signs;O;O
or;O;O
symptoms;O;O
of;O;O
hyperlipidemia;O;O
or;O;O
elevated;O;O
liver;O;O
function;O;O
tests;O;O
occur;O;O
during;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d437.s15;;
For;O;O
comprehensive;O;O
information;O;O
concerning;O;O
laboratory;O;O
test;O;O
alterations;O;O
associated;O;O
with;O;O
ritonavir;B-drug;B-DDI-DrugBank.d437.s15.e0
,;O;O
physicians;O;O
should;O;O
refer;O;O
to;O;O
the;O;O
complete;O;O
prescribing;O;O
information;O;O
for;O;O
NORVIR;B-brand;B-DDI-DrugBank.d437.s15.e1
(;O;O
ritonavir;B-drug;B-DDI-DrugBank.d437.s15.e2
);O;O
.;O;O
DDI-DrugBank.d56.s0;;
Taking;O;O
amyl;B-drug;B-DDI-DrugBank.d56.s0.e0
nitrite;I-drug;I-DDI-DrugBank.d56.s0.e0
after;O;O
drinking;O;O
alcohol;B-drug;B-DDI-DrugBank.d56.s0.e1
may;O;O
worsen;O;O
side;O;O
effects;O;O
and;O;O
may;O;O
cause;O;O
severe;O;O
hypotension;O;O
and;O;O
cardiovascular;O;O
collapse;O;O
.;O;O
DDI-DrugBank.d75.s0;;
Limited;O;O
PK;O;O
and/or;O;O
PD;O;O
studies;O;O
investigating;O;O
possible;O;O
interactions;O;O
between;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s0.e0
and;O;O
other;O;O
medicinal;O;O
products;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d75.s1;;
In;O;O
vivo;O;O
interaction;O;O
studies;O;O
in;O;O
humans;O;O
have;O;O
demonstrated;O;O
that;O;O
digoxin;B-drug;B-DDI-DrugBank.d75.s1.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d75.s1.e1
do;O;O
not;O;O
affect;O;O
the;O;O
PK;O;O
properties;O;O
of;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s1.e2
,;O;O
nor;O;O
does;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s1.e3
affect;O;O
the;O;O
PK;O;O
properties;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d75.s1.e4
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d75.s1.e5
.;O;O
DDI-DrugBank.d75.s2;;
Although;O;O
additional;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
,;O;O
the;O;O
most;O;O
common;O;O
medications;O;O
used;O;O
concomitantly;O;O
with;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s2.e0
in;O;O
clinical;O;O
trials;O;O
were;O;O
aspirin;B-brand;B-DDI-DrugBank.d75.s2.e1
,;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d75.s2.e2
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d75.s2.e3
,;O;O
iron;B-drug;B-DDI-DrugBank.d75.s2.e4
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d75.s2.e5
,;O;O
hydroxyurea;B-drug;B-DDI-DrugBank.d75.s2.e6
,;O;O
and;O;O
allopurinol;B-drug;B-DDI-DrugBank.d75.s2.e7
.;O;O
DDI-DrugBank.d75.s3;;
There;O;O
is;O;O
no;O;O
clinical;O;O
evidence;O;O
to;O;O
suggest;O;O
that;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s3.e0
interacts;O;O
with;O;O
any;O;O
of;O;O
these;O;O
compounds;O;O
.;O;O
DDI-DrugBank.d75.s4;;
An;O;O
in;O;O
vivo;O;O
interaction;O;O
study;O;O
in;O;O
humans;O;O
demonstrated;O;O
that;O;O
a;O;O
single;O;O
1;O;O
mg;O;O
dose;O;O
of;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s4.e0
administered;O;O
concomitantly;O;O
with;O;O
a;O;O
single;O;O
900;O;O
mg;O;O
dose;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d75.s4.e1
was;O;O
generally;O;O
well;O;O
tolerated;O;O
.;O;O
DDI-DrugBank.d75.s5;;
There;O;O
was;O;O
no;O;O
effect;O;O
on;O;O
bleeding;O;O
time;O;O
,;O;O
PT;O;O
or;O;O
aPTT;O;O
.;O;O
DDI-DrugBank.d75.s6;;
No;O;O
clinically;O;O
relevant;O;O
pharmacokinetic;O;O
interactions;O;O
between;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s6.e0
and;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d75.s6.e1
acid;I-drug;I-DDI-DrugBank.d75.s6.e1
were;O;O
observed;O;O
.;O;O
DDI-DrugBank.d75.s7;;
In;O;O
that;O;O
same;O;O
study;O;O
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d75.s7.e0
alone;O;O
produced;O;O
a;O;O
marked;O;O
inhibition;O;O
in;O;O
platelet;O;O
aggregation;O;O
ex;O;O
vivo;O;O
.;O;O
DDI-DrugBank.d75.s8;;
Anagrelide;B-drug;B-DDI-DrugBank.d75.s8.e0
alone;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
platelet;O;O
aggregation;O;O
,;O;O
but;O;O
did;O;O
slightly;O;O
enhance;O;O
the;O;O
inhibition;O;O
of;O;O
platelet;O;O
aggregation;O;O
by;O;O
aspirin;B-brand;B-DDI-DrugBank.d75.s8.e1
.;O;O
DDI-DrugBank.d75.s9;;
Anagrelide;B-drug;B-DDI-DrugBank.d75.s9.e0
is;O;O
metabolized;O;O
at;O;O
least;O;O
in;O;O
part;O;O
by;O;O
CYP1A2;O;O
.;O;O
DDI-DrugBank.d75.s10;;
It;O;O
is;O;O
known;O;O
that;O;O
CYP1A2;O;O
is;O;O
inhibited;O;O
by;O;O
several;O;O
medicinal;O;O
products;O;O
,;O;O
including;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d75.s10.e0
,;O;O
and;O;O
such;O;O
medicinal;O;O
products;O;O
could;O;O
theoretically;O;O
adversely;O;O
influence;O;O
the;O;O
clearance;O;O
of;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s10.e1
.;O;O
DDI-DrugBank.d75.s11;;
Anagrelide;B-drug;B-DDI-DrugBank.d75.s11.e0
demonstrates;O;O
some;O;O
limited;O;O
inhibitory;O;O
activity;O;O
towards;O;O
CYP1A2;O;O
which;O;O
may;O;O
present;O;O
a;O;O
theoretical;O;O
potential;O;O
for;O;O
interaction;O;O
with;O;O
other;O;O
coadministered;O;O
medicinal;O;O
products;O;O
sharing;O;O
that;O;O
clearance;O;O
mechanism;O;O
e.g.;O;O
DDI-DrugBank.d75.s12;;
Anagrelide;B-drug;B-DDI-DrugBank.d75.s12.e0
demonstrates;O;O
some;O;O
limited;O;O
inhibitory;O;O
activity;O;O
towards;O;O
CYP1A2;O;O
which;O;O
may;O;O
present;O;O
a;O;O
theoretical;O;O
potential;O;O
for;O;O
interaction;O;O
with;O;O
other;O;O
coadministered;O;O
medicinal;O;O
products;O;O
sharing;O;O
that;O;O
clearance;O;O
mechanism;O;O
e.g.;O;O
theophylline;B-drug;B-DDI-DrugBank.d75.s12.e1
.;O;O
DDI-DrugBank.d75.s13;;
Anagrelide;B-drug;B-DDI-DrugBank.d75.s13.e0
is;O;O
an;O;O
inhibitor;O;O
of;O;O
cyclic;O;O
AMP;O;O
PDE;O;O
III;O;O
.;O;O
DDI-DrugBank.d75.s14;;
The;O;O
effects;O;O
of;O;O
medicinal;O;O
products;O;O
with;O;O
similar;O;O
properties;O;O
such;O;O
as;O;O
inotropes;O;O
milrinone;B-drug;B-DDI-DrugBank.d75.s14.e0
,;O;O
enoximone;B-drug;B-DDI-DrugBank.d75.s14.e1
,;O;O
amrinone;B-drug;B-DDI-DrugBank.d75.s14.e2
,;O;O
olprinone;B-drug_n;B-DDI-DrugBank.d75.s14.e3
and;O;O
cilostazol;B-drug;B-DDI-DrugBank.d75.s14.e4
may;O;O
be;O;O
exacerbated;O;O
by;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s14.e5
.;O;O
DDI-DrugBank.d75.s15;;
There;O;O
is;O;O
a;O;O
single;O;O
case;O;O
report;O;O
,;O;O
which;O;O
suggests;O;O
that;O;O
sucralfate;B-drug;B-DDI-DrugBank.d75.s15.e0
may;O;O
interfere;O;O
with;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s15.e1
absorption;O;O
.;O;O
DDI-DrugBank.d75.s16;;
Food;O;O
has;O;O
no;O;O
clinically;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
bioavailability;O;O
of;O;O
anagrelide;B-drug;B-DDI-DrugBank.d75.s16.e0
.;O;O
DDI-DrugBank.d275.s0;;
No;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
in;O;O
human;O;O
subjects;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d275.s1;;
Toxicologic;O;O
and;O;O
toxicokinetic;O;O
studies;O;O
in;O;O
rats;O;O
did;O;O
not;O;O
demonstrate;O;O
any;O;O
alterations;O;O
in;O;O
the;O;O
clearance;O;O
or;O;O
toxicologic;O;O
profile;O;O
of;O;O
either;O;O
methotrexate;B-drug;B-DDI-DrugBank.d275.s1.e0
or;O;O
Kineret;B-brand;B-DDI-DrugBank.d275.s1.e1
when;O;O
the;O;O
two;O;O
agents;O;O
were;O;O
administered;O;O
together;O;O
.;O;O
DDI-DrugBank.d275.s2;;
In;O;O
a;O;O
study;O;O
in;O;O
which;O;O
patients;O;O
with;O;O
active;O;O
RA;O;O
were;O;O
treated;O;O
for;O;O
up;O;O
to;O;O
24;O;O
weeks;O;O
with;O;O
concurrent;O;O
Kineret;B-brand;B-DDI-DrugBank.d275.s2.e0
and;O;O
etanercept;B-drug;B-DDI-DrugBank.d275.s2.e1
therapy;O;O
,;O;O
a;O;O
7;O;O
%;O;O
rate;O;O
of;O;O
serious;O;O
infections;O;O
was;O;O
observed;O;O
,;O;O
which;O;O
was;O;O
higher;O;O
than;O;O
that;O;O
observed;O;O
with;O;O
etanercept;B-drug;B-DDI-DrugBank.d275.s2.e2
alone;O;O
(;O;O
0;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d275.s3;;
Two;O;O
percent;O;O
of;O;O
patients;O;O
treated;O;O
concurrently;O;O
with;O;O
Kineret;B-brand;B-DDI-DrugBank.d275.s3.e0
and;O;O
etanercept;B-drug;B-DDI-DrugBank.d275.s3.e1
developed;O;O
neutropenia;O;O
(;O;O
ANC;O;O
1;O;O
x;O;O
109;O;O
/;O;O
L;O;O
);O;O
.;O;O
DDI-DrugBank.d195.s0;;
Anastrozole;B-drug;B-DDI-DrugBank.d195.s0.e0
inhibited;O;O
in;O;O
vitro;O;O
metabolic;O;O
reactions;O;O
catalyzed;O;O
by;O;O
cytochromes;O;O
P450;O;O
1A2;O;O
,;O;O
2C8;O;O
/;O;O
9;O;O
,;O;O
and;O;O
3A4;O;O
but;O;O
only;O;O
at;O;O
relatively;O;O
high;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d195.s1;;
Anastrozole;B-drug;B-DDI-DrugBank.d195.s1.e0
did;O;O
not;O;O
inhibit;O;O
P450;O;O
2A6;O;O
or;O;O
the;O;O
polymorphic;O;O
P450;O;O
2D6;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
.;O;O
DDI-DrugBank.d195.s2;;
Anastrozole;B-drug;B-DDI-DrugBank.d195.s2.e0
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
antipyrine;B-drug;B-DDI-DrugBank.d195.s2.e1
.;O;O
DDI-DrugBank.d195.s3;;
Although;O;O
there;O;O
have;O;O
been;O;O
no;O;O
formal;O;O
interaction;O;O
studies;O;O
other;O;O
than;O;O
with;O;O
antipyrine;B-drug;B-DDI-DrugBank.d195.s3.e0
,;O;O
based;O;O
on;O;O
these;O;O
in;O;O
vivo;O;O
and;O;O
in;O;O
vitro;O;O
studies;O;O
,;O;O
it;O;O
is;O;O
unlikely;O;O
that;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
a;O;O
1;O;O
mg;O;O
dose;O;O
of;O;O
ARIMIDEX;B-brand;B-DDI-DrugBank.d195.s3.e1
with;O;O
other;O;O
drugs;O;O
will;O;O
result;O;O
in;O;O
clinically;O;O
significant;O;O
drug;O;O
inhibition;O;O
of;O;O
cytochrome;O;O
P450;O;O
-;O;O
mediated;O;O
metabolism;O;O
of;O;O
the;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d195.s4;;
An;O;O
interaction;O;O
study;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d195.s4.e0
showed;O;O
no;O;O
clinically;O;O
significant;O;O
effect;O;O
of;O;O
anastrozole;B-drug;B-DDI-DrugBank.d195.s4.e1
on;O;O
warfarin;B-drug;B-DDI-DrugBank.d195.s4.e2
pharmacokinetics;O;O
or;O;O
anticoagulant;O;O
activity;O;O
.;O;O
DDI-DrugBank.d195.s5;;
At;O;O
a;O;O
median;O;O
follow;O;O
-;O;O
up;O;O
of;O;O
33;O;O
months;O;O
,;O;O
the;O;O
combination;O;O
of;O;O
ARIMIDEX;B-brand;B-DDI-DrugBank.d195.s5.e0
and;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d195.s5.e1
did;O;O
not;O;O
demonstrate;O;O
any;O;O
efficacy;O;O
benefit;O;O
when;O;O
compared;O;O
with;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d195.s5.e2
in;O;O
all;O;O
patients;O;O
as;O;O
well;O;O
as;O;O
in;O;O
the;O;O
hormone;O;O
receptor;O;O
-;O;O
positive;O;O
subpopulation;O;O
.;O;O
DDI-DrugBank.d195.s6;;
This;O;O
treatment;O;O
arm;O;O
was;O;O
discontinued;O;O
from;O;O
the;O;O
trial;O;O
.;O;O
DDI-DrugBank.d195.s7;;
Based;O;O
on;O;O
clinical;O;O
and;O;O
pharmacokinetic;O;O
results;O;O
from;O;O
the;O;O
ATAC;O;O
trial;O;O
,;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d195.s7.e0
should;O;O
not;O;O
be;O;O
administered;O;O
with;O;O
anastrozole;B-drug;B-DDI-DrugBank.d195.s7.e1
(;O;O
see;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
Drug;O;O
Interactions;O;O
and;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
-;O;O
Clinical;O;O
Studies;O;O
-;O;O
Adjuvant;O;O
Treatment;O;O
of;O;O
Breast;O;O
Cancer;O;O
in;O;O
Postmenopausal;O;O
Women;O;O
subsections;O;O
);O;O
.;O;O
DDI-DrugBank.d195.s8;;
Co;O;O
-;O;O
administration;O;O
of;O;O
anastrozole;B-drug;B-DDI-DrugBank.d195.s8.e0
and;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d195.s8.e1
resulted;O;O
in;O;O
a;O;O
reduction;O;O
of;O;O
anastrozole;B-drug;B-DDI-DrugBank.d195.s8.e2
plasma;O;O
levels;O;O
by;O;O
27;O;O
%;O;O
compared;O;O
with;O;O
those;O;O
achieved;O;O
with;O;O
anastrozole;B-drug;B-DDI-DrugBank.d195.s8.e3
alone;O;O
.;O;O
DDI-DrugBank.d195.s9;;
Estrogen;B-group;B-DDI-DrugBank.d195.s9.e0
-;O;O
containing;O;O
therapies;O;O
should;O;O
not;O;O
be;O;O
used;O;O
with;O;O
ARIMIDEX;B-brand;B-DDI-DrugBank.d195.s9.e1
as;O;O
they;O;O
may;O;O
diminish;O;O
its;O;O
pharmacologic;O;O
action;O;O
.;O;O
DDI-DrugBank.d195.s10;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
No;O;O
clinically;O;O
significant;O;O
changes;O;O
in;O;O
the;O;O
results;O;O
of;O;O
clinical;O;O
laboratory;O;O
tests;O;O
have;O;O
been;O;O
observed;O;O
DDI-DrugBank.d195.s11;;
.;O;O
DDI-DrugBank.d195.s12;;
DDI-DrugBank.d445.s0;;
No;O;O
clinically;O;O
relevant;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
observed;O;O
with;O;O
drugs;O;O
likely;O;O
to;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
anidulafungin;B-drug;B-DDI-DrugBank.d445.s0.e0
.;O;O
DDI-DrugBank.d215.s0;;
Caution;O;O
should;O;O
be;O;O
observed;O;O
when;O;O
anileridine;B-drug;B-DDI-DrugBank.d215.s0.e0
is;O;O
coadministered;O;O
with;O;O
other;O;O
opioids;B-group;B-DDI-DrugBank.d215.s0.e1
,;O;O
sedatives;B-group;B-DDI-DrugBank.d215.s0.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d215.s0.e3
,;O;O
or;O;O
anesthetics;B-group;B-DDI-DrugBank.d215.s0.e4
,;O;O
as;O;O
these;O;O
agents;O;O
may;O;O
increase;O;O
respiratory;O;O
and;O;O
circulatory;O;O
depression;O;O
.;O;O
DDI-DrugBank.d64.s0;;
Addition;O;O
or;O;O
deletion;O;O
of;O;O
any;O;O
drug;O;O
from;O;O
the;O;O
therapeutic;O;O
regimen;O;O
of;O;O
patients;O;O
receiving;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d64.s0.e0
may;O;O
affect;O;O
patient;O;O
response;O;O
to;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s0.e1
.;O;O
DDI-DrugBank.d64.s1;;
Frequent;O;O
determination;O;O
of;O;O
prothrombin;O;O
time;O;O
and;O;O
close;O;O
monitoring;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
essential;O;O
to;O;O
ascertain;O;O
when;O;O
adjustment;O;O
of;O;O
dosage;O;O
of;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s1.e0
may;O;O
be;O;O
needed;O;O
.;O;O
DDI-DrugBank.d64.s2;;
Because;O;O
of;O;O
the;O;O
variability;O;O
of;O;O
individual;O;O
patient;O;O
response;O;O
,;O;O
multiple;O;O
interacting;O;O
mechanisms;O;O
with;O;O
some;O;O
drugs;O;O
,;O;O
the;O;O
dependency;O;O
of;O;O
the;O;O
extent;O;O
of;O;O
the;O;O
interaction;O;O
on;O;O
the;O;O
dosage;O;O
and;O;O
duration;O;O
of;O;O
therapy;O;O
,;O;O
and;O;O
the;O;O
possible;O;O
administration;O;O
of;O;O
several;O;O
interacting;O;O
drugs;O;O
simultaneously;O;O
,;O;O
it;O;O
is;O;O
difficult;O;O
to;O;O
predict;O;O
the;O;O
direction;O;O
and;O;O
degree;O;O
of;O;O
the;O;O
ultimate;O;O
effect;O;O
of;O;O
concomitant;O;O
medications;O;O
on;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s2.e0
response;O;O
.;O;O
DDI-DrugBank.d64.s3;;
For;O;O
example;O;O
,;O;O
since;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d64.s3.e0
may;O;O
reduce;O;O
the;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
both;O;O
the;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d64.s3.e1
and;O;O
vitamin;B-group;B-DDI-DrugBank.d64.s3.e2
K;I-group;I-DDI-DrugBank.d64.s3.e2
,;O;O
the;O;O
net;O;O
effects;O;O
are;O;O
unpredictable;O;O
.;O;O
DDI-DrugBank.d64.s4;;
Chloral;B-drug;B-DDI-DrugBank.d64.s4.e0
hydrate;I-drug;I-DDI-DrugBank.d64.s4.e0
may;O;O
cause;O;O
an;O;O
increased;O;O
prothrombin;O;O
response;O;O
by;O;O
displacing;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s4.e1
from;O;O
protein;O;O
binding;O;O
sites;O;O
or;O;O
a;O;O
diminished;O;O
prothrombin;O;O
response;O;O
through;O;O
increased;O;O
metabolism;O;O
of;O;O
the;O;O
unbound;O;O
drug;O;O
by;O;O
hepatic;O;O
enzyme;O;O
induction;O;O
,;O;O
thus;O;O
leading;O;O
to;O;O
inter;O;O
-;O;O
patient;O;O
variation;O;O
in;O;O
ultimate;O;O
prothrombin;O;O
effect;O;O
.;O;O
DDI-DrugBank.d64.s5;;
An;O;O
interacting;O;O
drug;O;O
which;O;O
leads;O;O
to;O;O
a;O;O
decrease;O;O
in;O;O
prothrombin;O;O
time;O;O
necessitating;O;O
an;O;O
increased;O;O
dose;O;O
of;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s5.e0
to;O;O
maintain;O;O
an;O;O
adequate;O;O
degree;O;O
of;O;O
anticoagulation;O;O
may;O;O
,;O;O
if;O;O
abruptly;O;O
discontinued;O;O
,;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
subsequent;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d64.s6;;
Drugs;O;O
that;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
diminish;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s6.e0
response;O;O
,;O;O
ie;O;O
,;O;O
decreased;O;O
prothrom;O;O
-;O;O
bin;O;O
time;O;O
response;O;O
,;O;O
in;O;O
man;O;O
significantly;O;O
include;O;O
:;O;O
adrenocortical;B-group;B-DDI-DrugBank.d64.s6.e1
steroids;I-group;I-DDI-DrugBank.d64.s6.e1
,;O;O
DDI-DrugBank.d64.s7;;
alcohol;B-drug;B-DDI-DrugBank.d64.s7.e0
*;O;O
,;O;O
DDI-DrugBank.d64.s8;;
antacids;B-group;B-DDI-DrugBank.d64.s8.e0
,;O;O
DDI-DrugBank.d64.s9;;
antihistamines;B-group;B-DDI-DrugBank.d64.s9.e0
,;O;O
DDI-DrugBank.d64.s10;;
barbiturates;B-group;B-DDI-DrugBank.d64.s10.e0
,;O;O
DDI-DrugBank.d64.s11;;
carbamazepine;B-drug;B-DDI-DrugBank.d64.s11.e0
,;O;O
DDI-DrugBank.d64.s12;;
chloral;B-drug;B-DDI-DrugBank.d64.s12.e0
hydrate;I-drug;I-DDI-DrugBank.d64.s12.e0
*;O;O
,;O;O
DDI-DrugBank.d64.s13;;
chlordiazepoxide;B-drug;B-DDI-DrugBank.d64.s13.e0
,;O;O
DDI-DrugBank.d64.s14;;
cholestyramine;B-drug;B-DDI-DrugBank.d64.s14.e0
,;O;O
DDI-DrugBank.d64.s15;;
diet;O;O
high;O;O
in;O;O
vitamin;B-group;B-DDI-DrugBank.d64.s15.e0
K;I-group;I-DDI-DrugBank.d64.s15.e0
,;O;O
DDI-DrugBank.d64.s16;;
diuretics;B-group;B-DDI-DrugBank.d64.s16.e0
*;O;O
,;O;O
DDI-DrugBank.d64.s17;;
ethchlorvynol;B-drug;B-DDI-DrugBank.d64.s17.e0
,;O;O
DDI-DrugBank.d64.s18;;
glutethimide;B-drug;B-DDI-DrugBank.d64.s18.e0
,;O;O
DDI-DrugBank.d64.s19;;
griseofulvin;B-drug;B-DDI-DrugBank.d64.s19.e0
,;O;O
DDI-DrugBank.d64.s20;;
haloperidol;B-drug;B-DDI-DrugBank.d64.s20.e0
,;O;O
DDI-DrugBank.d64.s21;;
meprobamate;B-drug;B-DDI-DrugBank.d64.s21.e0
,;O;O
DDI-DrugBank.d64.s22;;
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d64.s22.e0
,;O;O
DDI-DrugBank.d64.s23;;
paraldehyde;B-drug;B-DDI-DrugBank.d64.s23.e0
,;O;O
DDI-DrugBank.d64.s24;;
primidone;B-drug;B-DDI-DrugBank.d64.s24.e0
,;O;O
DDI-DrugBank.d64.s25;;
ranitidine;B-drug;B-DDI-DrugBank.d64.s25.e0
*;O;O
,;O;O
DDI-DrugBank.d64.s26;;
rifampin;B-drug;B-DDI-DrugBank.d64.s26.e0
,;O;O
DDI-DrugBank.d64.s27;;
unreliable;O;O
prothrombin;O;O
time;O;O
determinations;O;O
,;O;O
DDI-DrugBank.d64.s28;;
vitamin;B-drug;B-DDI-DrugBank.d64.s28.e0
C;I-drug;I-DDI-DrugBank.d64.s28.e0
,;O;O
DDI-DrugBank.d64.s29;;
Drugs;O;O
that;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
diminish;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s29.e0
response;O;O
,;O;O
ie;O;O
,;O;O
decreased;O;O
prothrom;O;O
-;O;O
bin;O;O
time;O;O
response;O;O
,;O;O
in;O;O
man;O;O
significantly;O;O
include;O;O
:;O;O
adrenocortical;B-group;B-DDI-DrugBank.d64.s29.e1
steroids;I-group;I-DDI-DrugBank.d64.s29.e1
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d64.s29.e2
*;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d64.s29.e3
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d64.s29.e4
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d64.s29.e5
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d64.s29.e6
,;O;O
chloral;B-drug;B-DDI-DrugBank.d64.s29.e7
hydrate;I-drug;I-DDI-DrugBank.d64.s29.e7
*;O;O
,;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d64.s29.e8
,;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d64.s29.e9
,;O;O
diet;O;O
high;O;O
in;O;O
vitamin;B-group;B-DDI-DrugBank.d64.s29.e10
K;I-group;I-DDI-DrugBank.d64.s29.e10
,;O;O
diuretics;B-group;B-DDI-DrugBank.d64.s29.e11
*;O;O
,;O;O
ethchlorvynol;B-drug;B-DDI-DrugBank.d64.s29.e12
,;O;O
glutethimide;B-drug;B-DDI-DrugBank.d64.s29.e13
,;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d64.s29.e14
,;O;O
haloperidol;B-drug;B-DDI-DrugBank.d64.s29.e15
,;O;O
meprobamate;B-drug;B-DDI-DrugBank.d64.s29.e16
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d64.s29.e17
,;O;O
paraldehyde;B-drug;B-DDI-DrugBank.d64.s29.e18
,;O;O
primidone;B-drug;B-DDI-DrugBank.d64.s29.e19
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d64.s29.e20
*;O;O
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d64.s29.e21
,;O;O
unreliable;O;O
prothrombin;O;O
time;O;O
determinations;O;O
,;O;O
vitamin;B-drug;B-DDI-DrugBank.d64.s29.e22
C;I-drug;I-DDI-DrugBank.d64.s29.e22
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d64.s29.e23
sodium;I-drug;I-DDI-DrugBank.d64.s29.e23
under;O;O
-;O;O
dosage;O;O
.;O;O
DDI-DrugBank.d64.s30;;
Drugs;O;O
that;O;O
reportedly;O;O
may;O;O
increase;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s30.e0
response;O;O
,;O;O
ie;O;O
,;O;O
increased;O;O
prothrombin;O;O
response;O;O
,;O;O
in;O;O
man;O;O
include;O;O
:;O;O
alcohol;B-drug;B-DDI-DrugBank.d64.s30.e1
*;O;O
,;O;O
DDI-DrugBank.d64.s31;;
allopurinol;B-drug;B-DDI-DrugBank.d64.s31.e0
,;O;O
DDI-DrugBank.d64.s32;;
aminosalicylic;B-drug;B-DDI-DrugBank.d64.s32.e0
acid;I-drug;I-DDI-DrugBank.d64.s32.e0
,;O;O
DDI-DrugBank.d64.s33;;
amiodarone;B-drug;B-DDI-DrugBank.d64.s33.e0
,;O;O
DDI-DrugBank.d64.s34;;
anabolic;B-group;B-DDI-DrugBank.d64.s34.e0
steroids;I-group;I-DDI-DrugBank.d64.s34.e0
,;O;O
DDI-DrugBank.d64.s35;;
antibiotics;B-group;B-DDI-DrugBank.d64.s35.e0
,;O;O
DDI-DrugBank.d64.s36;;
bromelains;B-drug;B-DDI-DrugBank.d64.s36.e0
,;O;O
DDI-DrugBank.d64.s37;;
chloral;B-drug;B-DDI-DrugBank.d64.s37.e0
hydrate;I-drug;I-DDI-DrugBank.d64.s37.e0
*;O;O
,;O;O
DDI-DrugBank.d64.s38;;
chlorpropamide;B-drug;B-DDI-DrugBank.d64.s38.e0
,;O;O
DDI-DrugBank.d64.s39;;
chymotrypsin;B-drug;B-DDI-DrugBank.d64.s39.e0
,;O;O
DDI-DrugBank.d64.s40;;
cimetidine;B-drug;B-DDI-DrugBank.d64.s40.e0
,;O;O
DDI-DrugBank.d64.s41;;
cinchophen;B-drug;B-DDI-DrugBank.d64.s41.e0
,;O;O
DDI-DrugBank.d64.s42;;
clofibrate;B-drug;B-DDI-DrugBank.d64.s42.e0
,;O;O
DDI-DrugBank.d64.s43;;
dextran;B-drug;B-DDI-DrugBank.d64.s43.e0
,;O;O
DDI-DrugBank.d64.s44;;
dextrothyroxine;B-drug;B-DDI-DrugBank.d64.s44.e0
,;O;O
DDI-DrugBank.d64.s45;;
diazoxide;B-drug;B-DDI-DrugBank.d64.s45.e0
,;O;O
DDI-DrugBank.d64.s46;;
dietary;O;O
deficiencies;O;O
,;O;O
DDI-DrugBank.d64.s47;;
diflunisal;B-drug;B-DDI-DrugBank.d64.s47.e0
,;O;O
DDI-DrugBank.d64.s48;;
diuretics;B-group;B-DDI-DrugBank.d64.s48.e0
*;O;O
,;O;O
DDI-DrugBank.d64.s49;;
disulfiram;B-drug;B-DDI-DrugBank.d64.s49.e0
,;O;O
DDI-DrugBank.d64.s50;;
drugs;O;O
affecting;O;O
blood;O;O
elements;O;O
,;O;O
DDI-DrugBank.d64.s51;;
ethacrynic;B-drug;B-DDI-DrugBank.d64.s51.e0
acid;I-drug;I-DDI-DrugBank.d64.s51.e0
,;O;O
DDI-DrugBank.d64.s52;;
fenoprofen;B-drug;B-DDI-DrugBank.d64.s52.e0
,;O;O
DDI-DrugBank.d64.s53;;
glucagon;B-drug;B-DDI-DrugBank.d64.s53.e0
,;O;O
DDI-DrugBank.d64.s54;;
hepatotoxic;O;O
drugs;O;O
,;O;O
DDI-DrugBank.d64.s55;;
ibuprofen;B-drug;B-DDI-DrugBank.d64.s55.e0
,;O;O
DDI-DrugBank.d64.s56;;
indomethacin;B-drug;B-DDI-DrugBank.d64.s56.e0
,;O;O
DDI-DrugBank.d64.s57;;
influenza;B-group;B-DDI-DrugBank.d64.s57.e0
virus;I-group;I-DDI-DrugBank.d64.s57.e0
vaccine;I-group;I-DDI-DrugBank.d64.s57.e0
,;O;O
DDI-DrugBank.d64.s58;;
inhalation;O;O
anesthetics;B-group;B-DDI-DrugBank.d64.s58.e0
,;O;O
DDI-DrugBank.d64.s59;;
mefenamic;B-drug;B-DDI-DrugBank.d64.s59.e0
acid;I-drug;I-DDI-DrugBank.d64.s59.e0
,;O;O
DDI-DrugBank.d64.s60;;
methyldopa;B-drug;B-DDI-DrugBank.d64.s60.e0
,;O;O
DDI-DrugBank.d64.s61;;
methylphenidate;B-drug;B-DDI-DrugBank.d64.s61.e0
,;O;O
DDI-DrugBank.d64.s62;;
metronidazole;B-drug;B-DDI-DrugBank.d64.s62.e0
,;O;O
DDI-DrugBank.d64.s63;;
miconazole;B-drug;B-DDI-DrugBank.d64.s63.e0
,;O;O
DDI-DrugBank.d64.s64;;
monoamine;B-group;B-DDI-DrugBank.d64.s64.e0
oxidase;I-group;I-DDI-DrugBank.d64.s64.e0
inhibitors;I-group;I-DDI-DrugBank.d64.s64.e0
,;O;O
DDI-DrugBank.d64.s65;;
nalidixic;B-drug;B-DDI-DrugBank.d64.s65.e0
acid;I-drug;I-DDI-DrugBank.d64.s65.e0
,;O;O
DDI-DrugBank.d64.s66;;
naproxen;B-drug;B-DDI-DrugBank.d64.s66.e0
,;O;O
DDI-DrugBank.d64.s67;;
oxolinic;B-drug;B-DDI-DrugBank.d64.s67.e0
acid;I-drug;I-DDI-DrugBank.d64.s67.e0
,;O;O
DDI-DrugBank.d64.s68;;
oxyphenbutazone;B-drug;B-DDI-DrugBank.d64.s68.e0
,;O;O
DDI-DrugBank.d64.s69;;
pentoxifylline;B-drug;B-DDI-DrugBank.d64.s69.e0
,;O;O
DDI-DrugBank.d64.s70;;
phenylbutazone;B-drug;B-DDI-DrugBank.d64.s70.e0
,;O;O
DDI-DrugBank.d64.s71;;
phenyramidol;B-drug_n;B-DDI-DrugBank.d64.s71.e0
,;O;O
DDI-DrugBank.d64.s72;;
phenytoin;B-drug;B-DDI-DrugBank.d64.s72.e0
,;O;O
DDI-DrugBank.d64.s73;;
prolonged;O;O
hot;O;O
weather;O;O
,;O;O
DDI-DrugBank.d64.s74;;
prolonged;B-group;B-DDI-DrugBank.d64.s74.e0
narcotics;I-group;I-DDI-DrugBank.d64.s74.e0
,;O;O
DDI-DrugBank.d64.s75;;
pyrazolones;B-group;B-DDI-DrugBank.d64.s75.e0
,;O;O
DDI-DrugBank.d64.s76;;
quinidine;B-drug;B-DDI-DrugBank.d64.s76.e0
,;O;O
DDI-DrugBank.d64.s77;;
quinine;B-drug;B-DDI-DrugBank.d64.s77.e0
,;O;O
DDI-DrugBank.d64.s78;;
ranitidine;B-drug;B-DDI-DrugBank.d64.s78.e0
*;O;O
,;O;O
DDI-DrugBank.d64.s79;;
salicylates;B-group;B-DDI-DrugBank.d64.s79.e0
,;O;O
sulfinpyrazone;B-drug;B-DDI-DrugBank.d64.s79.e1
,;O;O
DDI-DrugBank.d64.s80;;
sulfonamides;B-group;B-DDI-DrugBank.d64.s80.e0
,;O;O
long;O;O
acting;O;O
,;O;O
DDI-DrugBank.d64.s81;;
sulindac;B-drug;B-DDI-DrugBank.d64.s81.e0
,;O;O
DDI-DrugBank.d64.s82;;
thyroid;B-group;B-DDI-DrugBank.d64.s82.e0
drugs;I-group;I-DDI-DrugBank.d64.s82.e0
,;O;O
DDI-DrugBank.d64.s83;;
tolbutamide;B-drug;B-DDI-DrugBank.d64.s83.e0
,;O;O
DDI-DrugBank.d64.s84;;
triclofos;B-drug;B-DDI-DrugBank.d64.s84.e0
sodium;I-drug;I-DDI-DrugBank.d64.s84.e0
,;O;O
DDI-DrugBank.d64.s85;;
trimethoprim;B-drug;B-DDI-DrugBank.d64.s85.e0
/;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d64.s85.e1
,;O;O
DDI-DrugBank.d64.s86;;
unreliable;O;O
prothrombin;O;O
time;O;O
determinations;O;O
,;O;O
DDI-DrugBank.d64.s87;;
Drugs;O;O
that;O;O
reportedly;O;O
may;O;O
increase;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s87.e0
response;O;O
,;O;O
ie;O;O
,;O;O
increased;O;O
prothrombin;O;O
response;O;O
,;O;O
in;O;O
man;O;O
include;O;O
:;O;O
alcohol;B-drug;B-DDI-DrugBank.d64.s87.e1
*;O;O
,;O;O
allopurinol;B-drug;B-DDI-DrugBank.d64.s87.e2
,;O;O
aminosalicylic;B-drug;B-DDI-DrugBank.d64.s87.e3
acid;I-drug;I-DDI-DrugBank.d64.s87.e3
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d64.s87.e4
,;O;O
anabolic;B-group;B-DDI-DrugBank.d64.s87.e5
steroids;I-group;I-DDI-DrugBank.d64.s87.e5
,;O;O
antibiotics;B-group;B-DDI-DrugBank.d64.s87.e6
,;O;O
bromelains;B-drug;B-DDI-DrugBank.d64.s87.e7
,;O;O
chloral;B-drug;B-DDI-DrugBank.d64.s87.e8
hydrate;I-drug;I-DDI-DrugBank.d64.s87.e8
*;O;O
,;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d64.s87.e9
,;O;O
chymotrypsin;B-drug;B-DDI-DrugBank.d64.s87.e10
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d64.s87.e11
,;O;O
cinchophen;B-drug;B-DDI-DrugBank.d64.s87.e12
,;O;O
clofibrate;B-drug;B-DDI-DrugBank.d64.s87.e13
,;O;O
dextran;B-drug;B-DDI-DrugBank.d64.s87.e14
,;O;O
dextrothyroxine;B-drug;B-DDI-DrugBank.d64.s87.e15
,;O;O
diazoxide;B-drug;B-DDI-DrugBank.d64.s87.e16
,;O;O
dietary;O;O
deficiencies;O;O
,;O;O
diflunisal;B-drug;B-DDI-DrugBank.d64.s87.e17
,;O;O
disulfiram;B-drug;B-DDI-DrugBank.d64.s87.e18
,;O;O
drugs;O;O
affecting;O;O
blood;O;O
elements;O;O
,;O;O
ethacrynic;B-drug;B-DDI-DrugBank.d64.s87.e19
acid;I-drug;I-DDI-DrugBank.d64.s87.e19
,;O;O
fenoprofen;B-drug;B-DDI-DrugBank.d64.s87.e20
,;O;O
glucagon;B-drug;B-DDI-DrugBank.d64.s87.e21
,;O;O
hepatotoxic;O;O
drugs;O;O
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d64.s87.e22
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d64.s87.e23
,;O;O
influenza;B-group;B-DDI-DrugBank.d64.s87.e24
virus;I-group;I-DDI-DrugBank.d64.s87.e24
vaccine;I-group;I-DDI-DrugBank.d64.s87.e24
,;O;O
inhalation;O;O
anesthetics;B-group;B-DDI-DrugBank.d64.s87.e25
,;O;O
mefenamic;B-drug;B-DDI-DrugBank.d64.s87.e26
acid;I-drug;I-DDI-DrugBank.d64.s87.e26
,;O;O
methyldopa;B-drug;B-DDI-DrugBank.d64.s87.e27
,;O;O
methylphenidate;B-drug;B-DDI-DrugBank.d64.s87.e28
,;O;O
metronidazole;B-drug;B-DDI-DrugBank.d64.s87.e29
,;O;O
miconazole;B-drug;B-DDI-DrugBank.d64.s87.e30
,;O;O
monoamine;B-group;B-DDI-DrugBank.d64.s87.e31
oxidase;I-group;I-DDI-DrugBank.d64.s87.e31
inhibitors;I-group;I-DDI-DrugBank.d64.s87.e31
,;O;O
nalidixic;B-drug;B-DDI-DrugBank.d64.s87.e32
acid;I-drug;I-DDI-DrugBank.d64.s87.e32
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d64.s87.e33
,;O;O
oxolinic;B-drug;B-DDI-DrugBank.d64.s87.e34
acid;I-drug;I-DDI-DrugBank.d64.s87.e34
,;O;O
oxyphenbutazone;B-drug;B-DDI-DrugBank.d64.s87.e35
,;O;O
pentoxifylline;B-drug;B-DDI-DrugBank.d64.s87.e36
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d64.s87.e37
,;O;O
phenyramidol;B-drug_n;B-DDI-DrugBank.d64.s87.e38
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d64.s87.e39
,;O;O
prolonged;O;O
hot;O;O
weather;O;O
,;O;O
prolonged;B-group;B-DDI-DrugBank.d64.s87.e40
narcotics;I-group;I-DDI-DrugBank.d64.s87.e40
,;O;O
pyrazolones;B-group;B-DDI-DrugBank.d64.s87.e41
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d64.s87.e42
,;O;O
quinine;B-drug;B-DDI-DrugBank.d64.s87.e43
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d64.s87.e44
*;O;O
,;O;O
salicylates;B-group;B-DDI-DrugBank.d64.s87.e45
,;O;O
sulfinpyrazone;B-drug;B-DDI-DrugBank.d64.s87.e46
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d64.s87.e47
,;O;O
long;O;O
acting;O;O
,;O;O
sulindac;B-drug;B-DDI-DrugBank.d64.s87.e48
,;O;O
thyroid;B-group;B-DDI-DrugBank.d64.s87.e49
drugs;I-group;I-DDI-DrugBank.d64.s87.e49
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d64.s87.e50
,;O;O
triclofos;B-drug;B-DDI-DrugBank.d64.s87.e51
sodium;I-drug;I-DDI-DrugBank.d64.s87.e51
,;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d64.s87.e52
/;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d64.s87.e53
,;O;O
unreliable;O;O
prothrombin;O;O
time;O;O
determinations;O;O
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d64.s87.e54
sodium;I-drug;I-DDI-DrugBank.d64.s87.e54
overdosage;O;O
.;O;O
DDI-DrugBank.d64.s88;;
Oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d64.s88.e0
may;O;O
potentiate;O;O
the;O;O
hypoglycemic;O;O
action;O;O
of;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d64.s88.e1
agents;I-group;I-DDI-DrugBank.d64.s88.e1
,;O;O
eg;O;O
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d64.s88.e2
and;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d64.s88.e3
,;O;O
by;O;O
inhibiting;O;O
their;O;O
metabolism;O;O
in;O;O
the;O;O
liver;O;O
.;O;O
DDI-DrugBank.d64.s89;;
Because;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d64.s89.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
hepatic;O;O
metabolism;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d64.s89.e1
,;O;O
toxic;O;O
levels;O;O
of;O;O
the;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d64.s89.e2
may;O;O
occur;O;O
when;O;O
an;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d64.s89.e3
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d64.s89.e4
are;O;O
administered;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d64.s90;;
Drugs;O;O
that;O;O
reduce;O;O
the;O;O
number;O;O
of;O;O
blood;O;O
platelets;O;O
by;O;O
causing;O;O
bone;O;O
marrow;O;O
depression;O;O
(;O;O
such;O;O
as;O;O
antineoplastic;B-group;B-DDI-DrugBank.d64.s90.e0
agents;I-group;I-DDI-DrugBank.d64.s90.e0
);O;O
or;O;O
drugs;O;O
which;O;O
inhibit;O;O
platelet;O;O
function;O;O
(;O;O
eg;O;O
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d64.s90.e1
and;O;O
other;O;O
non;B-group;B-DDI-DrugBank.d64.s90.e2
-;I-group;I-DDI-DrugBank.d64.s90.e2
steroidal;I-group;I-DDI-DrugBank.d64.s90.e2
anti;I-group;I-DDI-DrugBank.d64.s90.e2
-;I-group;I-DDI-DrugBank.d64.s90.e2
inflammatory;I-group;I-DDI-DrugBank.d64.s90.e2
drugs;I-group;I-DDI-DrugBank.d64.s90.e2
,;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d64.s90.e3
,;O;O
hydrochloroquine;B-drug;B-DDI-DrugBank.d64.s90.e4
,;O;O
clofibrate;B-drug;B-DDI-DrugBank.d64.s90.e5
,;O;O
dextran;B-drug;B-DDI-DrugBank.d64.s90.e6
);O;O
may;O;O
increase;O;O
the;O;O
bleeding;O;O
tendency;O;O
produced;O;O
by;O;O
anticoagulants;B-group;B-DDI-DrugBank.d64.s90.e7
without;O;O
altering;O;O
prothrombin;O;O
time;O;O
determinations;O;O
.;O;O
DDI-DrugBank.d64.s91;;
The;O;O
beneficial;O;O
effects;O;O
on;O;O
arterial;O;O
thrombus;O;O
formation;O;O
from;O;O
combined;O;O
therapy;O;O
with;O;O
antiplatelet;B-group;B-DDI-DrugBank.d64.s91.e0
and;I-group;I-DDI-DrugBank.d64.s91.e0
anticoagulant;I-group;I-DDI-DrugBank.d64.s91.e1
medication;I-group;I-DDI-DrugBank.d64.s91.e1
must;O;O
be;O;O
weighed;O;O
against;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
inducing;O;O
hemorrhage;O;O
.;O;O
DDI-DrugBank.d64.s92;;
*;O;O
Increased;O;O
and;O;O
decreased;O;O
prothrombin;O;O
time;O;O
responses;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d64.s93;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interferences;O;O
:;O;O
Dicumarol;B-drug;B-DDI-DrugBank.d64.s93.e0
and;O;O
indanedione;B-group;B-DDI-DrugBank.d64.s93.e1
anticoagulants;I-group;I-DDI-DrugBank.d64.s93.e1
,;O;O
including;O;O
anisindione;B-drug;B-DDI-DrugBank.d64.s93.e2
,;O;O
or;O;O
their;O;O
metabolites;O;O
may;O;O
color;O;O
alkaline;O;O
urine;O;O
red;O;O
-;O;O
orange;O;O
,;O;O
which;O;O
may;O;O
interfere;O;O
with;O;O
spectrophotometrically;O;O
determined;O;O
urinary;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d64.s94;;
The;O;O
color;O;O
reverses;O;O
when;O;O
the;O;O
test;O;O
sample;O;O
is;O;O
acidified;O;O
in;O;O
vitro;O;O
to;O;O
a;O;O
pH;O;O
below;O;O
4;O;O
.;O;O
DDI-DrugBank.d357.s0;;
5HT3;B-group;B-DDI-DrugBank.d357.s0.e0
Antagonists;I-group;I-DDI-DrugBank.d357.s0.e0
:;O;O
Based;O;O
on;O;O
reports;O;O
of;O;O
profound;O;O
hypotension;O;O
and;O;O
loss;O;O
of;O;O
consciousness;O;O
when;O;O
apomorphine;B-drug;B-DDI-DrugBank.d357.s0.e1
was;O;O
administered;O;O
with;O;O
ondansetron;B-drug;B-DDI-DrugBank.d357.s0.e2
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
apomorphine;B-drug;B-DDI-DrugBank.d357.s0.e3
with;O;O
drugs;O;O
of;O;O
the;O;O
5HT3;B-group;B-DDI-DrugBank.d357.s0.e4
antagonist;I-group;I-DDI-DrugBank.d357.s0.e4
class;I-group;I-DDI-DrugBank.d357.s0.e4
(;O;O
including;O;O
,;O;O
for;O;O
example;O;O
,;O;O
ondansetron;B-drug;B-DDI-DrugBank.d357.s0.e5
,;O;O
granisetron;B-drug;B-DDI-DrugBank.d357.s0.e6
,;O;O
dolasetron;B-drug;B-DDI-DrugBank.d357.s0.e7
,;O;O
palonosetron;B-drug;B-DDI-DrugBank.d357.s0.e8
,;O;O
and;O;O
alosetron;B-drug;B-DDI-DrugBank.d357.s0.e9
);O;O
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d357.s1;;
Antihypertensive;B-group;B-DDI-DrugBank.d357.s1.e0
Medications;I-group;I-DDI-DrugBank.d357.s1.e0
and;O;O
Vasodilators;B-group;B-DDI-DrugBank.d357.s1.e1
:;O;O
The;O;O
following;O;O
adverse;O;O
events;O;O
were;O;O
experienced;O;O
more;O;O
commonly;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
antihypertensive;B-group;B-DDI-DrugBank.d357.s1.e2
medications;I-group;I-DDI-DrugBank.d357.s1.e2
or;O;O
vasodilators;B-group;B-DDI-DrugBank.d357.s1.e3
(;O;O
n;O;O
=;O;O
94;O;O
);O;O
compared;O;O
to;O;O
patients;O;O
not;O;O
receiving;O;O
these;O;O
concomitant;O;O
drugs;O;O
(;O;O
n;O;O
=;O;O
456;O;O
);O;O
:;O;O
hypotension;O;O
10;O;O
%;O;O
vs;O;O
4;O;O
%;O;O
,;O;O
myocardial;O;O
infarction;O;O
3;O;O
%;O;O
vs;O;O
1;O;O
%;O;O
,;O;O
serious;O;O
pneumonia;O;O
5;O;O
%;O;O
vs;O;O
3;O;O
%;O;O
,;O;O
serious;O;O
falls;O;O
9;O;O
%;O;O
vs;O;O
3;O;O
%;O;O
,;O;O
and;O;O
bone;O;O
and;O;O
joint;O;O
injuries;O;O
6;O;O
%;O;O
vs;O;O
2;O;O
%;O;O
.;O;O
DDI-DrugBank.d357.s2;;
The;O;O
mechanism;O;O
underlying;O;O
many;O;O
of;O;O
these;O;O
events;O;O
is;O;O
unknown;O;O
,;O;O
but;O;O
may;O;O
represent;O;O
increased;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d357.s3;;
Dopamine;B-group;B-DDI-DrugBank.d357.s3.e0
Antagonists;I-group;I-DDI-DrugBank.d357.s3.e0
:;O;O
Since;O;O
apomorphine;B-drug;B-DDI-DrugBank.d357.s3.e1
is;O;O
a;O;O
dopamine;B-group;B-DDI-DrugBank.d357.s3.e2
agonist;I-group;I-DDI-DrugBank.d357.s3.e2
,;O;O
it;O;O
is;O;O
possible;O;O
that;O;O
dopamine;B-group;B-DDI-DrugBank.d357.s3.e3
antagonists;I-group;I-DDI-DrugBank.d357.s3.e3
,;O;O
such;O;O
as;O;O
the;O;O
neuroleptics;B-group;B-DDI-DrugBank.d357.s3.e4
(;O;O
phenothiazines;B-group;B-DDI-DrugBank.d357.s3.e5
,;O;O
butyrophenones;B-group;B-DDI-DrugBank.d357.s3.e6
,;O;O
thioxanthenes;B-group;B-DDI-DrugBank.d357.s3.e7
);O;O
or;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d357.s3.e8
,;O;O
may;O;O
diminish;O;O
the;O;O
effectiveness;O;O
of;O;O
APOKYN;B-brand;B-DDI-DrugBank.d357.s3.e9
.;O;O
DDI-DrugBank.d357.s4;;
Patients;O;O
with;O;O
major;O;O
psychotic;O;O
disorders;O;O
,;O;O
treated;O;O
with;O;O
neuroleptics;B-group;B-DDI-DrugBank.d357.s4.e0
,;O;O
should;O;O
be;O;O
treated;O;O
with;O;O
dopamine;B-group;B-DDI-DrugBank.d357.s4.e1
agonists;I-group;I-DDI-DrugBank.d357.s4.e1
only;O;O
if;O;O
the;O;O
potential;O;O
benefits;O;O
outweigh;O;O
the;O;O
risks;O;O
.;O;O
DDI-DrugBank.d357.s5;;
Drugs;O;O
Prolonging;O;O
the;O;O
QT;O;O
/;O;O
QTc;O;O
Interval;O;O
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
prescribing;O;O
apomorphine;B-drug;B-DDI-DrugBank.d357.s5.e0
concomitantly;O;O
with;O;O
drugs;O;O
that;O;O
prolong;O;O
the;O;O
QT;O;O
/;O;O
QTc;O;O
interval;O;O
.;O;O
DDI-DrugBank.d357.s6;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
known;O;O
interactions;O;O
between;O;O
APOKYN;B-brand;B-DDI-DrugBank.d357.s6.e0
and;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d224.s0;;
Apraclonidine;B-drug;B-DDI-DrugBank.d224.s0.e0
should;O;O
not;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
receiving;O;O
MAO;B-group;B-DDI-DrugBank.d224.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d224.s0.e1
..;O;O
DDI-DrugBank.d224.s1;;
Although;O;O
no;O;O
specific;O;O
drug;O;O
interactions;O;O
with;O;O
topical;O;O
glaucoma;O;O
drugs;O;O
or;O;O
systemic;O;O
medications;O;O
were;O;O
identified;O;O
in;O;O
clinical;O;O
studies;O;O
of;O;O
IOPIDINE;B-brand;B-DDI-DrugBank.d224.s1.e0
0.5;O;O
%;O;O
Ophthalmic;O;O
Solution;O;O
,;O;O
the;O;O
possibility;O;O
of;O;O
an;O;O
additive;O;O
or;O;O
potentiating;O;O
effect;O;O
with;O;O
CNS;B-group;B-DDI-DrugBank.d224.s1.e1
depressants;I-group;I-DDI-DrugBank.d224.s1.e1
(;O;O
alcohol;B-drug;B-DDI-DrugBank.d224.s1.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d224.s1.e3
,;O;O
opiates;B-group;B-DDI-DrugBank.d224.s1.e4
,;O;O
sedatives;B-group;B-DDI-DrugBank.d224.s1.e5
,;O;O
anesthetics;B-group;B-DDI-DrugBank.d224.s1.e6
);O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d224.s2;;
Tricyclic;B-group;B-DDI-DrugBank.d224.s2.e0
antidepressants;I-group;I-DDI-DrugBank.d224.s2.e0
have;O;O
been;O;O
reported;O;O
to;O;O
blunt;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
systemic;O;O
clonidine;B-drug;B-DDI-DrugBank.d224.s2.e1
.;O;O
DDI-DrugBank.d224.s3;;
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
the;O;O
concurrent;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
with;O;O
apraclonidine;B-drug;B-DDI-DrugBank.d224.s3.e0
can;O;O
lead;O;O
to;O;O
a;O;O
reduction;O;O
in;O;O
IOP;O;O
lowering;O;O
effect;O;O
.;O;O
DDI-DrugBank.d224.s4;;
No;O;O
data;O;O
on;O;O
the;O;O
level;O;O
of;O;O
circulating;O;O
catecholamines;O;O
after;O;O
apraclonidine;B-drug;B-DDI-DrugBank.d224.s4.e0
withdrawal;O;O
are;O;O
available;O;O
.;O;O
DDI-DrugBank.d224.s5;;
Caution;O;O
,;O;O
however;O;O
,;O;O
is;O;O
advised;O;O
in;O;O
patients;O;O
taking;O;O
tricyclic;B-group;B-DDI-DrugBank.d224.s5.e0
antidepressants;I-group;I-DDI-DrugBank.d224.s5.e0
which;O;O
can;O;O
affect;O;O
the;O;O
metabolism;O;O
and;O;O
uptake;O;O
of;O;O
circulating;O;O
amines;O;O
.;O;O
DDI-DrugBank.d224.s6;;
An;O;O
additive;O;O
hypotensive;O;O
effect;O;O
has;O;O
been;O;O
reported;O;O
with;O;O
the;O;O
combination;O;O
of;O;O
systemic;O;O
clonidine;B-drug;B-DDI-DrugBank.d224.s6.e0
and;O;O
neuroleptic;B-group;B-DDI-DrugBank.d224.s6.e1
therapy;O;O
.;O;O
DDI-DrugBank.d224.s7;;
Systemic;O;O
clonidine;B-drug;B-DDI-DrugBank.d224.s7.e0
may;O;O
inhibit;O;O
the;O;O
production;O;O
of;O;O
catecholamines;O;O
in;O;O
response;O;O
to;O;O
insulin;O;O
-;O;O
induced;O;O
hypoglycemia;O;O
and;O;O
mask;O;O
the;O;O
signs;O;O
and;O;O
symptoms;O;O
of;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d224.s8;;
Since;O;O
apraclonidine;B-drug;B-DDI-DrugBank.d224.s8.e0
may;O;O
reduce;O;O
pulse;O;O
and;O;O
blood;O;O
pressure;O;O
,;O;O
caution;O;O
in;O;O
using;O;O
drugs;O;O
such;O;O
as;O;O
beta;B-group;B-DDI-DrugBank.d224.s8.e1
-;I-group;I-DDI-DrugBank.d224.s8.e1
blockers;I-group;I-DDI-DrugBank.d224.s8.e1
(;O;O
ophthalmic;O;O
and;O;O
systemic;O;O
);O;O
,;O;O
antihypertensives;B-group;B-DDI-DrugBank.d224.s8.e2
,;O;O
and;O;O
cardiac;B-group;B-DDI-DrugBank.d224.s8.e3
glycosides;I-group;I-DDI-DrugBank.d224.s8.e3
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d224.s9;;
Patients;O;O
using;O;O
cardiovascular;O;O
drugs;O;O
concurrently;O;O
with;O;O
IOPIDINE;B-brand;B-DDI-DrugBank.d224.s9.e0
0.5;O;O
%;O;O
Ophthalmic;O;O
Solution;O;O
should;O;O
have;O;O
pulse;O;O
and;O;O
blood;O;O
pressures;O;O
frequently;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d224.s10;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
with;O;O
simultaneous;O;O
use;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d224.s10.e0
and;O;O
other;O;O
similar;O;O
pharmacologic;O;O
agents;O;O
DDI-DrugBank.d224.s11;;
.;O;O
DDI-DrugBank.d224.s12;;
DDI-DrugBank.d382.s0;;
Aprepitant;B-drug;B-DDI-DrugBank.d382.s0.e0
is;O;O
a;O;O
substrate;O;O
,;O;O
a;O;O
moderate;O;O
inhibitor;O;O
,;O;O
and;O;O
an;O;O
inducer;O;O
of;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d382.s1;;
Aprepitant;B-drug;B-DDI-DrugBank.d382.s1.e0
is;O;O
also;O;O
an;O;O
inducer;O;O
of;O;O
CYP2C9;O;O
.;O;O
DDI-DrugBank.d382.s2;;
Effect;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s2.e0
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
other;O;O
agents;O;O
DDI-DrugBank.d382.s3;;
As;O;O
a;O;O
moderate;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
,;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s3.e0
can;O;O
increase;O;O
plasma;O;O
concentrations;O;O
of;O;O
coadministered;O;O
medicinal;O;O
products;O;O
that;O;O
are;O;O
metabolized;O;O
through;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d382.s4;;
Aprepitant;B-drug;B-DDI-DrugBank.d382.s4.e0
has;O;O
been;O;O
shown;O;O
to;O;O
induce;O;O
the;O;O
metabolism;O;O
of;O;O
S(;B-drug;B-DDI-DrugBank.d382.s4.e1
-;I-drug;I-DDI-DrugBank.d382.s4.e1
);I-drug;I-DDI-DrugBank.d382.s4.e1
warfarin;I-drug;I-DDI-DrugBank.d382.s4.e1
and;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d382.s4.e2
,;O;O
which;O;O
are;O;O
metabolized;O;O
through;O;O
CYP2C9;O;O
.;O;O
DDI-DrugBank.d382.s5;;
Coadministration;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s5.e0
with;O;O
these;O;O
drugs;O;O
or;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
known;O;O
to;O;O
be;O;O
metabolized;O;O
by;O;O
CYP2C9;O;O
,;O;O
such;O;O
as;O;O
phenytoin;B-drug;B-DDI-DrugBank.d382.s5.e1
,;O;O
may;O;O
result;O;O
in;O;O
lower;O;O
plasma;O;O
concentrations;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d382.s6;;
Aprepitant;B-drug;B-DDI-DrugBank.d382.s6.e0
is;O;O
unlikely;O;O
to;O;O
interact;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
the;O;O
P;O;O
-;O;O
glycoprotein;O;O
transporter;O;O
,;O;O
as;O;O
demonstrated;O;O
by;O;O
the;O;O
lack;O;O
of;O;O
interaction;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s6.e1
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d382.s6.e2
in;O;O
a;O;O
clinical;O;O
drug;O;O
interaction;O;O
study;O;O
.;O;O
DDI-DrugBank.d382.s7;;
5;B-group;B-DDI-DrugBank.d382.s7.e0
-;I-group;I-DDI-DrugBank.d382.s7.e0
HT3;I-group;I-DDI-DrugBank.d382.s7.e0
antagonists;I-group;I-DDI-DrugBank.d382.s7.e0
:;O;O
In;O;O
clinical;O;O
drug;O;O
interaction;O;O
studies;O;O
,;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s7.e1
did;O;O
not;O;O
have;O;O
clinically;O;O
important;O;O
effects;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
ondansetron;B-drug;B-DDI-DrugBank.d382.s7.e2
or;O;O
granisetron;B-drug;B-DDI-DrugBank.d382.s7.e3
.;O;O
DDI-DrugBank.d382.s8;;
No;O;O
clinical;O;O
or;O;O
drug;O;O
interaction;O;O
study;O;O
was;O;O
conducted;O;O
with;O;O
dolasetron;B-drug;B-DDI-DrugBank.d382.s8.e0
.;O;O
DDI-DrugBank.d382.s9;;
Corticosteroids;B-group;B-DDI-DrugBank.d382.s9.e0
:;O;O
Dexamethasone;B-drug;B-DDI-DrugBank.d382.s9.e1
:;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s9.e2
,;O;O
when;O;O
given;O;O
as;O;O
a;O;O
regimen;O;O
of;O;O
125;O;O
mg;O;O
with;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d382.s9.e3
coadministered;O;O
orally;O;O
as;O;O
20;O;O
mg;O;O
on;O;O
Day;O;O
1;O;O
,;O;O
and;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s9.e4
when;O;O
given;O;O
as;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
with;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d382.s9.e5
coadministered;O;O
orally;O;O
as;O;O
8;O;O
mg;O;O
on;O;O
Days;O;O
2;O;O
through;O;O
5;O;O
,;O;O
increased;O;O
the;O;O
AUC;O;O
of;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d382.s9.e6
,;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
by;O;O
2.2;O;O
-;O;O
fold;O;O
,;O;O
on;O;O
Days;O;O
1;O;O
and;O;O
5;O;O
.;O;O
DDI-DrugBank.d382.s10;;
The;O;O
oral;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d382.s10.e0
doses;O;O
should;O;O
be;O;O
reduced;O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
when;O;O
coadministered;O;O
with;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s10.e1
,;O;O
to;O;O
achieve;O;O
exposures;O;O
of;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d382.s10.e2
similar;O;O
to;O;O
those;O;O
obtained;O;O
when;O;O
it;O;O
is;O;O
given;O;O
without;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s10.e3
.;O;O
DDI-DrugBank.d382.s11;;
The;O;O
daily;O;O
dose;O;O
of;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d382.s11.e0
administered;O;O
in;O;O
clinical;O;O
studies;O;O
with;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s11.e1
reflects;O;O
an;O;O
approximate;O;O
50;O;O
%;O;O
reduction;O;O
of;O;O
the;O;O
dose;O;O
of;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d382.s11.e2
.;O;O
DDI-DrugBank.d382.s12;;
Methylprednisolone;B-drug;B-DDI-DrugBank.d382.s12.e0
DDI-DrugBank.d382.s13;;
Aprepitant;I-drug;I-DDI-DrugBank.d382.s13.e0
,;O;O
when;O;O
given;O;O
as;O;O
a;O;O
regimen;O;O
of;O;O
125;O;O
mg;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
on;O;O
Days;O;O
2;O;O
and;O;O
3;O;O
,;O;O
increased;O;O
the;O;O
AUC;O;O
of;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d382.s13.e1
,;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
,;O;O
by;O;O
1.34;O;O
-;O;O
fold;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
by;O;O
2.5;O;O
-;O;O
fold;O;O
on;O;O
Day;O;O
3;O;O
,;O;O
when;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d382.s13.e2
was;O;O
coadministered;O;O
intravenously;O;O
as;O;O
125;O;O
mg;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
orally;O;O
as;O;O
40;O;O
mg;O;O
on;O;O
Days;O;O
2;O;O
and;O;O
3;O;O
.;O;O
DDI-DrugBank.d382.s14;;
The;O;O
IV;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d382.s14.e0
dose;O;O
should;O;O
be;O;O
reduced;O;O
by;O;O
approximately;O;O
25;O;O
%;O;O
,;O;O
and;O;O
the;O;O
oral;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d382.s14.e1
dose;O;O
should;O;O
be;O;O
reduced;O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
when;O;O
coadministered;O;O
with;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s14.e2
to;O;O
achieve;O;O
exposures;O;O
of;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d382.s14.e3
similar;O;O
to;O;O
those;O;O
obtained;O;O
when;O;O
it;O;O
is;O;O
given;O;O
without;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s14.e4
.;O;O
DDI-DrugBank.d382.s15;;
Warfarin;B-drug;B-DDI-DrugBank.d382.s15.e0
:;O;O
A;O;O
single;O;O
125;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s15.e1
was;O;O
administered;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
on;O;O
Days;O;O
2;O;O
and;O;O
3;O;O
to;O;O
healthy;O;O
subjects;O;O
who;O;O
were;O;O
stabilized;O;O
on;O;O
chronic;O;O
warfarin;B-drug;B-DDI-DrugBank.d382.s15.e2
therapy;O;O
.;O;O
DDI-DrugBank.d382.s16;;
Although;O;O
there;O;O
was;O;O
no;O;O
effect;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s16.e0
on;O;O
the;O;O
plasma;O;O
AUC;O;O
of;O;O
R(+;B-drug;B-DDI-DrugBank.d382.s16.e1
);I-drug;I-DDI-DrugBank.d382.s16.e1
or;I-drug;I-DDI-DrugBank.d382.s16.e1
S(;I-drug;I-DDI-DrugBank.d382.s16.e2
-;I-drug;I-DDI-DrugBank.d382.s16.e2
);I-drug;I-DDI-DrugBank.d382.s16.e2
warfarin;I-drug;I-DDI-DrugBank.d382.s16.e2
determined;O;O
on;O;O
Day;O;O
3;O;O
,;O;O
there;O;O
was;O;O
a;O;O
34;O;O
%;O;O
decrease;O;O
in;O;O
S(;B-drug;B-DDI-DrugBank.d382.s16.e3
-;I-drug;I-DDI-DrugBank.d382.s16.e3
)warfarin;I-drug;I-DDI-DrugBank.d382.s16.e3
(;O;O
a;O;O
CYP2C9;O;O
substrate;O;O
);O;O
trough;O;O
concentration;O;O
accompanied;O;O
by;O;O
a;O;O
14;O;O
%;O;O
decrease;O;O
in;O;O
the;O;O
prothrombin;O;O
time;O;O
(;O;O
reported;O;O
as;O;O
International;O;O
Normalized;O;O
Ratio;O;O
or;O;O
INR;O;O
);O;O
5;O;O
days;O;O
after;O;O
completion;O;O
of;O;O
dosing;O;O
with;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s16.e4
.;O;O
DDI-DrugBank.d382.s17;;
In;O;O
patients;O;O
on;O;O
chronic;O;O
warfarin;B-drug;B-DDI-DrugBank.d382.s17.e0
therapy;O;O
,;O;O
the;O;O
prothrombin;O;O
time;O;O
(;O;O
INR;O;O
);O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
in;O;O
the;O;O
2;O;O
-;O;O
week;O;O
period;O;O
,;O;O
particularly;O;O
at;O;O
7;O;O
to;O;O
10;O;O
days;O;O
,;O;O
following;O;O
initiation;O;O
of;O;O
the;O;O
3;O;O
-;O;O
day;O;O
regimen;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s17.e1
with;O;O
each;O;O
chemotherapy;O;O
cycle;O;O
.;O;O
DDI-DrugBank.d382.s18;;
Tolbutamide;B-drug;B-DDI-DrugBank.d382.s18.e0
:;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s18.e1
,;O;O
when;O;O
given;O;O
as;O;O
125;O;O
mg;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
on;O;O
Days;O;O
2;O;O
and;O;O
3;O;O
,;O;O
decreased;O;O
the;O;O
AUC;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d382.s18.e2
(;O;O
a;O;O
CYP2C9;O;O
substrate;O;O
);O;O
by;O;O
23;O;O
%;O;O
on;O;O
Day;O;O
4;O;O
,;O;O
28;O;O
%;O;O
on;O;O
Day;O;O
8;O;O
,;O;O
and;O;O
15;O;O
%;O;O
on;O;O
Day;O;O
15;O;O
,;O;O
when;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d382.s18.e3
500;O;O
mg;O;O
was;O;O
admini;O;O
,;O;O
stered;O;O
orally;O;O
prior;O;O
to;O;O
the;O;O
administration;O;O
of;O;O
the;O;O
3;O;O
-;O;O
day;O;O
regimen;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s18.e4
and;O;O
on;O;O
Days;O;O
4,8;O;O
,;O;O
and;O;O
15;O;O
.;O;O
DDI-DrugBank.d382.s19;;
Oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d382.s19.e0
:;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s19.e1
,;O;O
when;O;O
given;O;O
once;O;O
daily;O;O
for;O;O
14;O;O
days;O;O
as;O;O
a;O;O
100;O;O
-;O;O
mg;O;O
capsule;O;O
with;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d382.s19.e2
containing;O;O
35;O;O
mcg;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d382.s19.e3
estradiol;I-drug;I-DDI-DrugBank.d382.s19.e3
and;O;O
1;O;O
mg;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d382.s19.e4
,;O;O
decreased;O;O
the;O;O
AUC;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d382.s19.e5
estradiol;I-drug;I-DDI-DrugBank.d382.s19.e5
by;O;O
43;O;O
%;O;O
,;O;O
and;O;O
decreased;O;O
the;O;O
AUC;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d382.s19.e6
by;O;O
8;O;O
%;O;O
,;O;O
DDI-DrugBank.d382.s20;;
therefore;O;O
,;O;O
the;O;O
efficacy;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d382.s20.e0
during;O;O
administration;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s20.e1
may;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d382.s21;;
Although;O;O
a;O;O
3;O;O
-;O;O
day;O;O
regimen;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s21.e0
given;O;O
concomitantly;O;O
with;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d382.s21.e1
has;O;O
not;O;O
been;O;O
studied;O;O
,;O;O
alternative;O;O
or;O;O
back;O;O
-;O;O
up;O;O
methods;O;O
of;O;O
contraception;O;O
should;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d382.s22;;
Midazolam;B-drug;B-DDI-DrugBank.d382.s22.e0
:;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s22.e1
increased;O;O
the;O;O
AUC;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s22.e2
,;O;O
a;O;O
sensitive;O;O
CYP3A4;O;O
substrate;O;O
,;O;O
by;O;O
2.3;O;O
-;O;O
fold;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
3.3;O;O
-;O;O
fold;O;O
on;O;O
Day;O;O
5;O;O
,;O;O
when;O;O
a;O;O
single;O;O
oral;O;O
dose;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s22.e3
2;O;O
mg;O;O
was;O;O
coadministered;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
Day;O;O
5;O;O
of;O;O
a;O;O
regimen;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s22.e4
125;O;O
mg;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
on;O;O
Days;O;O
2;O;O
through;O;O
5;O;O
.;O;O
DDI-DrugBank.d382.s23;;
The;O;O
potential;O;O
effects;O;O
of;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s23.e0
or;O;O
other;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d382.s23.e1
metabolized;O;O
via;O;O
CYP3A4;O;O
(;O;O
alprazolam;B-drug;B-DDI-DrugBank.d382.s23.e2
,;O;O
triazolam;B-drug;B-DDI-DrugBank.d382.s23.e3
);O;O
should;O;O
be;O;O
considered;O;O
when;O;O
coadministering;O;O
these;O;O
agents;O;O
with;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s23.e4
.;O;O
DDI-DrugBank.d382.s24;;
In;O;O
another;O;O
study;O;O
with;O;O
intravenous;O;O
administration;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s24.e0
,;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s24.e1
was;O;O
given;O;O
as;O;O
125;O;O
mg;O;O
on;O;O
Day;O;O
1;O;O
and;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
on;O;O
Days;O;O
2;O;O
and;O;O
3;O;O
,;O;O
and;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s24.e2
2;O;O
mg;O;O
IV;O;O
was;O;O
given;O;O
prior;O;O
to;O;O
the;O;O
administration;O;O
of;O;O
the;O;O
3;O;O
-;O;O
day;O;O
regimen;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s24.e3
and;O;O
on;O;O
Days;O;O
4;O;O
,;O;O
8;O;O
,;O;O
and;O;O
15;O;O
.;O;O
DDI-DrugBank.d382.s25;;
Aprepitant;B-drug;B-DDI-DrugBank.d382.s25.e0
increased;O;O
the;O;O
AUC;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s25.e1
by;O;O
25;O;O
%;O;O
on;O;O
Day;O;O
4;O;O
and;O;O
decreased;O;O
the;O;O
AUC;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s25.e2
by;O;O
19;O;O
%;O;O
on;O;O
Day;O;O
8;O;O
relative;O;O
to;O;O
the;O;O
dosing;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s25.e3
on;O;O
Days;O;O
1;O;O
through;O;O
3;O;O
.;O;O
DDI-DrugBank.d382.s26;;
These;O;O
effects;O;O
were;O;O
not;O;O
considered;O;O
clinically;O;O
important;O;O
.;O;O
DDI-DrugBank.d382.s27;;
The;O;O
AUC;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d382.s27.e0
on;O;O
Day;O;O
15;O;O
was;O;O
similar;O;O
to;O;O
that;O;O
observed;O;O
at;O;O
baseline;O;O
.;O;O
DDI-DrugBank.d382.s28;;
Effect;O;O
of;O;O
other;O;O
agents;O;O
on;O;O
the;O;O
pharmacokinefics;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s28.e0
DDI-DrugBank.d382.s29;;
Aprepitant;I-drug;I-DDI-DrugBank.d382.s29.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
CYP3A4;O;O
,;O;O
DDI-DrugBank.d382.s30;;
therefore;O;O
,;O;O
coadministration;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s30.e0
with;O;O
drugs;O;O
that;O;O
inhibit;O;O
CYP3A4;O;O
activity;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s30.e1
.;O;O
DDI-DrugBank.d382.s31;;
Consequently;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s31.e0
with;O;O
strong;O;O
CYP3A4;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d382.s31.e1
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d382.s31.e2
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d382.s31.e3
,;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d382.s31.e4
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d382.s31.e5
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d382.s31.e6
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d382.s31.e7
);O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d382.s32;;
Because;O;O
moderate;O;O
CYP3A4;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d382.s32.e0
);O;O
result;O;O
in;O;O
2;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
plasma;O;O
concentrations;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s32.e1
,;O;O
concomitant;O;O
administration;O;O
should;O;O
also;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d382.s33;;
Aprepitant;B-drug;B-DDI-DrugBank.d382.s33.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
CYP3A4;O;O
,;O;O
DDI-DrugBank.d382.s34;;
therefore;O;O
,;O;O
coadministration;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s34.e0
with;O;O
drugs;O;O
that;O;O
strongly;O;O
induce;O;O
CYP3A4;O;O
activity;O;O
(;O;O
e.g.;O;O
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d382.s34.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d382.s34.e2
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d382.s34.e3
);O;O
may;O;O
result;O;O
in;O;O
reduced;O;O
plasma;O;O
concentrations;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s34.e4
that;O;O
may;O;O
result;O;O
in;O;O
decreased;O;O
efficacy;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s34.e5
.;O;O
DDI-DrugBank.d382.s35;;
Ketoconazole;B-drug;B-DDI-DrugBank.d382.s35.e0
:;O;O
When;O;O
a;O;O
single;O;O
125;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s35.e1
was;O;O
administered;O;O
on;O;O
Day5;O;O
of;O;O
a;O;O
DDI-DrugBank.d382.s36;;
Ketoconazole;B-drug;B-DDI-DrugBank.d382.s36.e0
:;O;O
When;O;O
a;O;O
single;O;O
125;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s36.e1
was;O;O
administered;O;O
on;O;O
Day5;O;O
of;O;O
a;O;O
10;O;O
-;O;O
day;O;O
regimen;O;O
of;O;O
400;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d382.s36.e2
,;O;O
a;O;O
strong;O;O
CYP3A4;O;O
inhibitor;O;O
,;O;O
the;O;O
AUC;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s36.e3
increased;O;O
approximately;O;O
5;O;O
-;O;O
fold;O;O
and;O;O
the;O;O
mean;O;O
terminal;O;O
half;O;O
-;O;O
life;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s36.e4
increased;O;O
approximately;O;O
3;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d382.s37;;
Concomitant;O;O
administration;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s37.e0
with;O;O
strong;O;O
CYP3A4;O;O
inhibitors;O;O
should;O;O
be;O;O
approached;O;O
cautiously;O;O
.;O;O
DDI-DrugBank.d382.s38;;
Rifampin;B-drug;B-DDI-DrugBank.d382.s38.e0
:;O;O
When;O;O
a;O;O
single;O;O
375;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s38.e1
was;O;O
administered;O;O
on;O;O
Day9;O;O
of;O;O
a;O;O
14;O;O
-;O;O
day;O;O
regimen;O;O
of;O;O
600;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d382.s38.e2
,;O;O
a;O;O
strong;O;O
CYP3A4;O;O
inducer;O;O
,;O;O
the;O;O
AUC;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s38.e3
decreased;O;O
approximately;O;O
11;O;O
-;O;O
fold;O;O
and;O;O
the;O;O
mean;O;O
terminal;O;O
half;O;O
-;O;O
life;O;O
decreased;O;O
approximately;O;O
3;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d382.s39;;
Coadministration;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s39.e0
with;O;O
drugs;O;O
that;O;O
induce;O;O
CYP3A4;O;O
activity;O;O
may;O;O
result;O;O
in;O;O
reduced;O;O
plasma;O;O
concentrations;O;O
and;O;O
decreased;O;O
efficacy;O;O
of;O;O
Aprepitant;B-drug;B-DDI-DrugBank.d382.s39.e1
.;O;O
DDI-DrugBank.d382.s40;;
Additional;O;O
interactions;O;O
DDI-DrugBank.d382.s41;;
Diltiazem;B-drug;B-DDI-DrugBank.d382.s41.e0
:;O;O
In;O;O
patients;O;O
with;O;O
mild;O;O
to;O;O
moderate;O;O
hypertension;O;O
,;O;O
administration;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s41.e1
once;O;O
daily;O;O
,;O;O
as;O;O
a;O;O
tablet;O;O
formulation;O;O
comparable;O;O
to;O;O
230;O;O
mg;O;O
of;O;O
the;O;O
capsule;O;O
formulation;O;O
,;O;O
with;O;O
diltiazem;B-drug;B-DDI-DrugBank.d382.s41.e2
120;O;O
mg;O;O
3;O;O
times;O;O
daily;O;O
for;O;O
5;O;O
days;O;O
,;O;O
resulted;O;O
in;O;O
a;O;O
2;O;O
-;O;O
fold;O;O
increase;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s41.e3
AUC;O;O
and;O;O
a;O;O
simultaneous;O;O
1.7;O;O
-;O;O
fold;O;O
increase;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d382.s41.e4
AUC;O;O
.;O;O
DDI-DrugBank.d382.s42;;
These;O;O
pharmacokinetic;O;O
effects;O;O
did;O;O
not;O;O
result;O;O
in;O;O
clinically;O;O
meaningful;O;O
changes;O;O
in;O;O
ECG;O;O
,;O;O
heart;O;O
rate;O;O
or;O;O
blood;O;O
pressure;O;O
beyond;O;O
those;O;O
changes;O;O
induced;O;O
by;O;O
diltiazem;B-drug;B-DDI-DrugBank.d382.s42.e0
alone;O;O
.;O;O
DDI-DrugBank.d382.s43;;
Paroxetine;B-drug;B-DDI-DrugBank.d382.s43.e0
:;O;O
Coadministration;O;O
of;O;O
once;O;O
daily;O;O
doses;O;O
of;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s43.e1
,;O;O
as;O;O
a;O;O
tablet;O;O
formulation;O;O
comparable;O;O
to;O;O
85;O;O
mg;O;O
or;O;O
170;O;O
mg;O;O
of;O;O
the;O;O
capsule;O;O
formulation;O;O
,;O;O
with;O;O
paroxetine;B-drug;B-DDI-DrugBank.d382.s43.e2
20;O;O
mg;O;O
once;O;O
daily;O;O
,;O;O
resulted;O;O
in;O;O
a;O;O
decrease;O;O
in;O;O
AUC;O;O
by;O;O
approximately;O;O
25;O;O
%;O;O
and;O;O
Cmax;O;O
,;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
of;O;O
both;O;O
aprepitant;B-drug;B-DDI-DrugBank.d382.s43.e3
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d382.s43.e4
.;O;O
DDI-DrugBank.d253.s0;;
Beta;B-group;B-DDI-DrugBank.d253.s0.e0
-;I-group;I-DDI-DrugBank.d253.s0.e0
adrenergic;I-group;I-DDI-DrugBank.d253.s0.e0
blocking;I-group;I-DDI-DrugBank.d253.s0.e0
agents;I-group;I-DDI-DrugBank.d253.s0.e0
:;O;O
concurrent;O;O
use;O;O
may;O;O
blunt;O;O
the;O;O
response;O;O
to;O;O
arbutamine;B-drug;B-DDI-DrugBank.d253.s0.e1
.;O;O
DDI-DrugBank.d253.s1;;
Beta;B-group;B-DDI-DrugBank.d253.s1.e0
-;I-group;I-DDI-DrugBank.d253.s1.e0
adrenergic;I-group;I-DDI-DrugBank.d253.s1.e0
blocking;I-group;I-DDI-DrugBank.d253.s1.e0
agents;I-group;I-DDI-DrugBank.d253.s1.e0
should;O;O
be;O;O
withdrawn;O;O
at;O;O
least;O;O
48;O;O
hours;O;O
before;O;O
conducting;O;O
an;O;O
arbutamine;B-drug;B-DDI-DrugBank.d253.s1.e1
-;O;O
mediated;O;O
stress;O;O
test;O;O
.;O;O
DDI-DrugBank.d253.s2;;
Antiarrhythmic;B-drug;B-DDI-DrugBank.d253.s2.e0
agents;I-drug;I-DDI-DrugBank.d253.s2.e0
,;I-drug;I-DDI-DrugBank.d253.s2.e0
class;I-drug;I-DDI-DrugBank.d253.s2.e0
I;I-drug;I-DDI-DrugBank.d253.s2.e0
(;O;O
such;O;O
as;O;O
flecainide;B-drug;B-DDI-DrugBank.d253.s2.e1
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d253.s2.e2
,;O;O
or;O;O
quinidine;B-drug;B-DDI-DrugBank.d253.s2.e3
);O;O
:;O;O
concurrent;O;O
use;O;O
with;O;O
arbutamine;B-drug;B-DDI-DrugBank.d253.s2.e4
may;O;O
have;O;O
a;O;O
proarrhythmic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d253.s3;;
Antidepressants;B-group;B-DDI-DrugBank.d253.s3.e0
(;O;O
tricyclic;B-group;B-DDI-DrugBank.d253.s3.e1
);O;O
,;O;O
atropine;B-drug;B-DDI-DrugBank.d253.s3.e2
or;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d253.s3.e3
agents;I-group;I-DDI-DrugBank.d253.s3.e3
,;O;O
or;O;O
digitalis;B-group;B-DDI-DrugBank.d253.s3.e4
glycosides;I-group;I-DDI-DrugBank.d253.s3.e4
:;O;O
concurrent;O;O
use;O;O
with;O;O
arbutamine;B-drug;B-DDI-DrugBank.d253.s3.e5
may;O;O
produce;O;O
additive;O;O
inotropic;O;O
and/or;O;O
chronotropic;O;O
effects;O;O
.;O;O
DDI-DrugBank.d105.s0;;
Anticoagulants;B-group;B-DDI-DrugBank.d105.s0.e0
including;O;O
coumarin;O;O
derivatives;O;O
,;O;O
indandione;O;O
derivatives;O;O
,;O;O
and;O;O
platelet;B-group;B-DDI-DrugBank.d105.s0.e1
aggregation;I-group;I-DDI-DrugBank.d105.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d105.s0.e1
such;O;O
as;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d105.s0.e2
anti;I-group;I-DDI-DrugBank.d105.s0.e2
-;I-group;I-DDI-DrugBank.d105.s0.e2
inflammatory;I-group;I-DDI-DrugBank.d105.s0.e2
drugs;I-group;I-DDI-DrugBank.d105.s0.e2
(;O;O
NSAIDs;B-group;B-DDI-DrugBank.d105.s0.e3
);O;O
,;O;O
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d105.s0.e4
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
when;O;O
administered;O;O
concomitantly;O;O
with;O;O
ardeparin;B-drug;B-DDI-DrugBank.d105.s0.e5
.;O;O
DDI-DrugBank.d284.s0;;
If;O;O
additional;O;O
adrenergic;B-group;B-DDI-DrugBank.d284.s0.e0
drugs;I-group;I-DDI-DrugBank.d284.s0.e0
are;O;O
to;O;O
be;O;O
administered;O;O
by;O;O
any;O;O
route;O;O
,;O;O
they;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
because;O;O
the;O;O
pharmacologically;O;O
predictable;O;O
sympathetic;O;O
effects;O;O
of;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s0.e1
may;O;O
be;O;O
potentiated;O;O
.;O;O
DDI-DrugBank.d284.s1;;
When;O;O
paroxetine;B-drug;B-DDI-DrugBank.d284.s1.e0
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP2D6;O;O
,;O;O
was;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s1.e1
at;O;O
steady;O;O
-;O;O
state;O;O
,;O;O
exposure;O;O
to;O;O
either;O;O
drug;O;O
was;O;O
not;O;O
altered;O;O
.;O;O
DDI-DrugBank.d284.s2;;
Dosage;O;O
adjustments;O;O
of;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s2.e0
are;O;O
not;O;O
necessary;O;O
when;O;O
the;O;O
drug;O;O
is;O;O
given;O;O
concomitantly;O;O
with;O;O
potent;O;O
CYP2D6;O;O
inhibitors;O;O
.;O;O
DDI-DrugBank.d284.s3;;
Concomitant;O;O
treatment;O;O
with;O;O
methylxanthines;B-group;B-DDI-DrugBank.d284.s3.e0
(;O;O
aminophylline;B-drug;B-DDI-DrugBank.d284.s3.e1
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d284.s3.e2
);O;O
,;O;O
steroids;B-group;B-DDI-DrugBank.d284.s3.e3
,;O;O
or;O;O
diuretics;B-group;B-DDI-DrugBank.d284.s3.e4
may;O;O
potentiate;O;O
any;O;O
hypokalemic;O;O
effect;O;O
of;O;O
adrenergic;B-group;B-DDI-DrugBank.d284.s3.e5
agonists;I-group;I-DDI-DrugBank.d284.s3.e5
.;O;O
DDI-DrugBank.d284.s4;;
The;O;O
ECG;O;O
changes;O;O
and/or;O;O
hypokalemia;O;O
that;O;O
may;O;O
result;O;O
from;O;O
the;O;O
administration;O;O
of;O;O
non;B-group;B-DDI-DrugBank.d284.s4.e0
-;I-group;I-DDI-DrugBank.d284.s4.e0
potassium;I-group;I-DDI-DrugBank.d284.s4.e0
sparing;I-group;I-DDI-DrugBank.d284.s4.e0
diuretics;I-group;I-DDI-DrugBank.d284.s4.e0
(;O;O
such;O;O
as;O;O
loop;B-group;B-DDI-DrugBank.d284.s4.e1
or;I-group;I-DDI-DrugBank.d284.s4.e1
thiazide;I-group;I-DDI-DrugBank.d284.s4.e2
diuretics;I-group;I-DDI-DrugBank.d284.s4.e2
);O;O
can;O;O
be;O;O
acutely;O;O
worsened;O;O
by;O;O
beta;B-group;B-DDI-DrugBank.d284.s4.e3
-;I-group;I-DDI-DrugBank.d284.s4.e3
agonists;I-group;I-DDI-DrugBank.d284.s4.e3
,;O;O
especially;O;O
when;O;O
the;O;O
recommended;O;O
dose;O;O
of;O;O
the;O;O
beta;B-group;B-DDI-DrugBank.d284.s4.e4
-;I-group;I-DDI-DrugBank.d284.s4.e4
agonist;I-group;I-DDI-DrugBank.d284.s4.e4
is;O;O
exceeded;O;O
.;O;O
DDI-DrugBank.d284.s5;;
Although;O;O
the;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
effects;O;O
is;O;O
not;O;O
known;O;O
,;O;O
caution;O;O
is;O;O
advised;O;O
in;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d284.s5.e0
-;I-group;I-DDI-DrugBank.d284.s5.e0
agonists;I-group;I-DDI-DrugBank.d284.s5.e0
with;O;O
non;B-group;B-DDI-DrugBank.d284.s5.e1
-;I-group;I-DDI-DrugBank.d284.s5.e1
potassium;I-group;I-DDI-DrugBank.d284.s5.e1
sparing;I-group;I-DDI-DrugBank.d284.s5.e1
diuretics;I-group;I-DDI-DrugBank.d284.s5.e1
.;O;O
DDI-DrugBank.d284.s6;;
BROVANA;B-brand;B-DDI-DrugBank.d284.s6.e0
,;O;O
as;O;O
with;O;O
other;O;O
beta2;B-group;B-DDI-DrugBank.d284.s6.e1
-;I-group;I-DDI-DrugBank.d284.s6.e1
agonists;I-group;I-DDI-DrugBank.d284.s6.e1
,;O;O
should;O;O
be;O;O
administered;O;O
with;O;O
extreme;O;O
caution;O;O
to;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
monoamine;B-group;B-DDI-DrugBank.d284.s6.e2
oxidase;I-group;I-DDI-DrugBank.d284.s6.e2
inhibitors;I-group;I-DDI-DrugBank.d284.s6.e2
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d284.s6.e3
antidepressants;I-group;I-DDI-DrugBank.d284.s6.e3
,;O;O
or;O;O
drugs;O;O
known;O;O
to;O;O
prolong;O;O
the;O;O
QTc;O;O
interval;O;O
because;O;O
the;O;O
action;O;O
of;O;O
adrenergic;B-group;B-DDI-DrugBank.d284.s6.e4
agonists;I-group;I-DDI-DrugBank.d284.s6.e4
on;O;O
the;O;O
cardiovascular;O;O
system;O;O
may;O;O
be;O;O
potentiated;O;O
by;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d284.s7;;
Drugs;O;O
that;O;O
are;O;O
known;O;O
to;O;O
prolong;O;O
the;O;O
QTc;O;O
interval;O;O
have;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
ventricular;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d284.s8;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
intravenously;O;O
or;O;O
orally;O;O
administered;O;O
methylxanthines;B-group;B-DDI-DrugBank.d284.s8.e0
(;O;O
e.g.;O;O
,;O;O
aminophylline;B-drug;B-DDI-DrugBank.d284.s8.e1
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d284.s8.e2
);O;O
by;O;O
patients;O;O
receiving;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s8.e3
has;O;O
not;O;O
been;O;O
completely;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d284.s9;;
In;O;O
two;O;O
combined;O;O
12;O;O
-;O;O
week;O;O
placebo;O;O
controlled;O;O
trials;O;O
that;O;O
included;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s9.e0
doses;O;O
of;O;O
15;O;O
mcg;O;O
twice;O;O
daily;O;O
,;O;O
25;O;O
mcg;O;O
twice;O;O
daily;O;O
,;O;O
and;O;O
50;O;O
mcg;O;O
once;O;O
daily;O;O
,;O;O
54;O;O
of;O;O
873;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s9.e1
-treated;O;O
subjects;O;O
received;O;O
concomitant;O;O
theophylline;B-drug;B-DDI-DrugBank.d284.s9.e2
at;O;O
study;O;O
entry;O;O
.;O;O
DDI-DrugBank.d284.s10;;
In;O;O
a;O;O
12;O;O
-;O;O
month;O;O
controlled;O;O
trial;O;O
that;O;O
included;O;O
a;O;O
50;O;O
mcg;O;O
once;O;O
daily;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s10.e0
dose;O;O
,;O;O
30;O;O
of;O;O
the;O;O
528;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s10.e1
-treated;O;O
subjects;O;O
received;O;O
concomitant;O;O
theophylline;B-drug;B-DDI-DrugBank.d284.s10.e2
at;O;O
study;O;O
entry;O;O
.;O;O
DDI-DrugBank.d284.s11;;
In;O;O
these;O;O
trials;O;O
,;O;O
heart;O;O
rate;O;O
and;O;O
systolic;O;O
blood;O;O
pressure;O;O
were;O;O
approximately;O;O
2;O;O
-;O;O
3;O;O
bpm;O;O
and;O;O
6;O;O
-;O;O
8;O;O
mm;O;O
Hg;O;O
higher;O;O
,;O;O
respectively;O;O
,;O;O
in;O;O
subjects;O;O
on;O;O
concomitant;O;O
theophylline;B-drug;B-DDI-DrugBank.d284.s11.e0
compared;O;O
with;O;O
the;O;O
overall;O;O
population;O;O
.;O;O
DDI-DrugBank.d284.s12;;
Beta;B-group;B-DDI-DrugBank.d284.s12.e0
-;I-group;I-DDI-DrugBank.d284.s12.e0
adrenergic;I-group;I-DDI-DrugBank.d284.s12.e0
receptor;I-group;I-DDI-DrugBank.d284.s12.e0
antagonists;I-group;I-DDI-DrugBank.d284.s12.e0
(;O;O
beta;B-group;B-DDI-DrugBank.d284.s12.e1
-;I-group;I-DDI-DrugBank.d284.s12.e1
blockers;I-group;I-DDI-DrugBank.d284.s12.e1
);O;O
and;O;O
BROVANA;B-brand;B-DDI-DrugBank.d284.s12.e2
may;O;O
interfere;O;O
with;O;O
the;O;O
effect;O;O
of;O;O
each;O;O
other;O;O
when;O;O
administered;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d284.s13;;
Beta;B-group;B-DDI-DrugBank.d284.s13.e0
-;I-group;I-DDI-DrugBank.d284.s13.e0
blockers;I-group;I-DDI-DrugBank.d284.s13.e0
not;O;O
only;O;O
block;O;O
the;O;O
therapeutic;O;O
effects;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d284.s13.e1
-;I-group;I-DDI-DrugBank.d284.s13.e1
agonists;I-group;I-DDI-DrugBank.d284.s13.e1
,;O;O
but;O;O
may;O;O
produce;O;O
severe;O;O
bronchospasm;O;O
in;O;O
COPD;O;O
patients;O;O
.;O;O
DDI-DrugBank.d284.s14;;
Therefore;O;O
,;O;O
patients;O;O
with;O;O
COPD;O;O
should;O;O
not;O;O
normally;O;O
be;O;O
treated;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d284.s14.e0
-;I-group;I-DDI-DrugBank.d284.s14.e0
blockers;I-group;I-DDI-DrugBank.d284.s14.e0
.;O;O
DDI-DrugBank.d284.s15;;
However;O;O
,;O;O
under;O;O
certain;O;O
circumstances;O;O
,;O;O
e.g.;O;O
,;O;O
as;O;O
prophylaxis;O;O
after;O;O
myocardial;O;O
infarction;O;O
,;O;O
there;O;O
may;O;O
be;O;O
no;O;O
acceptable;O;O
alternatives;O;O
to;O;O
the;O;O
use;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d284.s15.e0
-;I-group;I-DDI-DrugBank.d284.s15.e0
blockers;I-group;I-DDI-DrugBank.d284.s15.e0
in;O;O
patients;O;O
with;O;O
COPD;O;O
.;O;O
DDI-DrugBank.d284.s16;;
In;O;O
this;O;O
setting;O;O
,;O;O
cardioselective;B-group;B-DDI-DrugBank.d284.s16.e0
beta;I-group;I-DDI-DrugBank.d284.s16.e0
-;I-group;I-DDI-DrugBank.d284.s16.e0
blockers;I-group;I-DDI-DrugBank.d284.s16.e0
could;O;O
be;O;O
considered;O;O
,;O;O
although;O;O
they;O;O
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d148.s0;;
Heparin;B-drug;B-DDI-DrugBank.d148.s0.e0
:;O;O
Since;O;O
heparin;B-drug;B-DDI-DrugBank.d148.s0.e1
is;O;O
contraindicated;O;O
in;O;O
patients;O;O
with;O;O
heparin;B-drug;B-DDI-DrugBank.d148.s0.e2
-;O;O
induced;O;O
thrombocytopenia;O;O
,;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s0.e3
and;O;O
heparin;B-drug;B-DDI-DrugBank.d148.s0.e4
is;O;O
unlikely;O;O
for;O;O
this;O;O
indication;O;O
.;O;O
DDI-DrugBank.d148.s1;;
However;O;O
,;O;O
if;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s1.e0
is;O;O
to;O;O
be;O;O
initiated;O;O
after;O;O
cessation;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d148.s1.e1
therapy;O;O
,;O;O
allow;O;O
sufficient;O;O
time;O;O
for;O;O
heparins;O;O
effect;O;O
on;O;O
the;O;O
aPTT;O;O
to;O;O
decrease;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s1.e2
therapy;O;O
.;O;O
DDI-DrugBank.d148.s2;;
Aspirin;B-brand;B-DDI-DrugBank.d148.s2.e0
/;O;O
Acetaminophen;B-drug;B-DDI-DrugBank.d148.s2.e1
:;O;O
Pharmacokinetic;O;O
or;O;O
pharmacodynamic;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
have;O;O
not;O;O
been;O;O
demonstrated;O;O
between;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s2.e2
and;O;O
concomitantly;O;O
administered;O;O
aspirin;B-brand;B-DDI-DrugBank.d148.s2.e3
(;O;O
162.5;O;O
mg;O;O
orally;O;O
given;O;O
26;O;O
and;O;O
2;O;O
hours;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s2.e4
1;O;O
g;O;O
/;O;O
kg;O;O
/;O;O
min;O;O
.;O;O
over;O;O
4;O;O
hours;O;O
);O;O
or;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d148.s2.e5
(;O;O
1000;O;O
mg;O;O
orally;O;O
given;O;O
12;O;O
,;O;O
6;O;O
and;O;O
0;O;O
hours;O;O
prior;O;O
to;O;O
,;O;O
and;O;O
6;O;O
and;O;O
12;O;O
hours;O;O
subsequent;O;O
to;O;O
,;O;O
initiation;O;O
of;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s2.e6
1.5;O;O
g;O;O
/;O;O
kg;O;O
/;O;O
min;O;O
.;O;O
over;O;O
18;O;O
hours;O;O
);O;O
.;O;O
DDI-DrugBank.d148.s3;;
Oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d148.s3.e0
agents;I-group;I-DDI-DrugBank.d148.s3.e0
:;O;O
Pharmacokinetic;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
between;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s3.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d148.s3.e2
(;O;O
7.5;O;O
mg;O;O
single;O;O
oral;O;O
dose;O;O
);O;O
have;O;O
not;O;O
been;O;O
demonstrated;O;O
.;O;O
DDI-DrugBank.d148.s4;;
However;O;O
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s4.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d148.s4.e1
(;O;O
5;O;O
-;O;O
7.5;O;O
mg;O;O
initial;O;O
oral;O;O
dose;O;O
followed;O;O
by;O;O
2.5;O;O
-;O;O
6;O;O
mg;O;O
/;O;O
day;O;O
orally;O;O
for;O;O
6;O;O
-;O;O
10;O;O
days;O;O
);O;O
results;O;O
in;O;O
prolongation;O;O
of;O;O
the;O;O
prothrombin;O;O
time;O;O
(;O;O
PT;O;O
);O;O
and;O;O
International;O;O
Normalized;O;O
Ratio;O;O
(;O;O
INR;O;O
);O;O
.;O;O
DDI-DrugBank.d148.s5;;
Thrombolytic;B-group;B-DDI-DrugBank.d148.s5.e0
agents;I-group;I-DDI-DrugBank.d148.s5.e0
:;O;O
The;O;O
safety;O;O
and;O;O
effectiveness;O;O
of;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s5.e1
with;O;O
thrombolytic;B-group;B-DDI-DrugBank.d148.s5.e2
agents;I-group;I-DDI-DrugBank.d148.s5.e2
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d148.s6;;
Co;O;O
-;O;O
administration;O;O
:;O;O
Concomitant;O;O
use;O;O
of;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s6.e0
with;O;O
antiplatelet;B-group;B-DDI-DrugBank.d148.s6.e1
agents;I-group;I-DDI-DrugBank.d148.s6.e1
,;O;O
thrombolytics;B-group;B-DDI-DrugBank.d148.s6.e2
,;O;O
and;O;O
other;O;O
anticoagulants;B-group;B-DDI-DrugBank.d148.s6.e3
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d148.s7;;
Drug;O;O
-;O;O
drug;O;O
interactions;O;O
have;O;O
not;O;O
been;O;O
observed;O;O
between;O;O
Argatroban;B-drug;B-DDI-DrugBank.d148.s7.e0
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d148.s7.e1
or;O;O
erythromycin;B-drug;B-DDI-DrugBank.d148.s7.e2
.;O;O
DDI-DrugBank.d509.s0;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
Given;O;O
the;O;O
primary;O;O
CNS;O;O
effects;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s0.e0
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
ABILIFY;B-brand;B-DDI-DrugBank.d509.s0.e1
is;O;O
taken;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
centrally;B-group;B-DDI-DrugBank.d509.s0.e2
acting;I-group;I-DDI-DrugBank.d509.s0.e2
drugs;I-group;I-DDI-DrugBank.d509.s0.e2
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d509.s0.e3
.;O;O
DDI-DrugBank.d509.s1;;
Due;O;O
to;O;O
its;O;O
DDI-DrugBank.d509.s2;;
1;O;O
-;O;O
adrenergic;O;O
receptor;O;O
antagonism;O;O
,;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s2.e0
has;O;O
the;O;O
potential;O;O
to;O;O
enhance;O;O
the;O;O
effect;O;O
of;O;O
certain;O;O
antihypertensive;B-group;B-DDI-DrugBank.d509.s2.e1
agents;I-group;I-DDI-DrugBank.d509.s2.e1
.;O;O
DDI-DrugBank.d509.s3;;
Potential;O;O
for;O;O
Other;O;O
Drugs;O;O
to;O;O
Affect;O;O
ABILIFY;B-brand;B-DDI-DrugBank.d509.s3.e0
Aripiprazole;I-brand;I-DDI-DrugBank.d509.s3.e1
is;O;O
not;O;O
a;O;O
substrate;O;O
of;O;O
CYP1A1;O;O
,;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2B6;O;O
,;O;O
CYP2C8;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
or;O;O
CYP2E1;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d509.s4;;
Aripiprazole;B-drug;B-DDI-DrugBank.d509.s4.e0
also;O;O
does;O;O
not;O;O
undergo;O;O
direct;O;O
glucuronidation;O;O
.;O;O
DDI-DrugBank.d509.s5;;
This;O;O
suggests;O;O
that;O;O
an;O;O
interaction;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s5.e0
with;O;O
inhibitors;O;O
or;O;O
inducers;O;O
of;O;O
these;O;O
enzymes;O;O
,;O;O
or;O;O
other;O;O
factors;O;O
,;O;O
like;O;O
smoking;O;O
,;O;O
is;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d509.s6;;
Both;O;O
CYP3A4;O;O
and;O;O
CYP2D6;O;O
are;O;O
responsible;O;O
for;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s6.e0
metabolism;O;O
.;O;O
DDI-DrugBank.d509.s7;;
Agents;O;O
that;O;O
induce;O;O
CYP3A4;O;O
(;O;O
eg;O;O
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d509.s7.e0
);O;O
could;O;O
cause;O;O
an;O;O
increase;O;O
in;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s7.e1
clearance;O;O
and;O;O
lower;O;O
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d509.s8;;
Inhibitors;O;O
of;O;O
CYP3A4;O;O
(;O;O
eg;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d509.s8.e0
);O;O
or;O;O
CYP2D6;O;O
(;O;O
eg;O;O
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d509.s8.e1
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d509.s8.e2
,;O;O
or;O;O
paroxetine;B-drug;B-DDI-DrugBank.d509.s8.e3
);O;O
can;O;O
inhibit;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s8.e4
elimination;O;O
and;O;O
cause;O;O
increased;O;O
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d509.s9;;
Ketoconazole;B-drug;B-DDI-DrugBank.d509.s9.e0
:;O;O
Coadministration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d509.s9.e1
(;O;O
200;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
14;O;O
days;O;O
);O;O
with;O;O
a;O;O
15;O;O
-;O;O
mg;O;O
single;O;O
dose;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s9.e2
increased;O;O
the;O;O
AUC;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s9.e3
and;O;O
its;O;O
active;O;O
metabolite;O;O
by;O;O
63;O;O
%;O;O
and;O;O
77;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d509.s10;;
The;O;O
effect;O;O
of;O;O
a;O;O
higher;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d509.s10.e0
dose;O;O
(;O;O
400;O;O
mg;O;O
/;O;O
day;O;O
);O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d509.s11;;
When;O;O
concomitant;O;O
administration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d509.s11.e0
with;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s11.e1
occurs;O;O
,;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s11.e2
dose;O;O
should;O;O
be;O;O
reduced;O;O
to;O;O
one;O;O
-;O;O
half;O;O
of;O;O
its;O;O
normal;O;O
dose;O;O
.;O;O
DDI-DrugBank.d509.s12;;
Other;O;O
strong;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
(;O;O
itraconazole;B-drug;B-DDI-DrugBank.d509.s12.e0
);O;O
would;O;O
be;O;O
expected;O;O
to;O;O
have;O;O
similar;O;O
effects;O;O
and;O;O
need;O;O
similar;O;O
dose;O;O
reductions;O;O
,;O;O
DDI-DrugBank.d509.s13;;
weaker;O;O
inhibitors;O;O
(;O;O
erythromycin;B-drug;B-DDI-DrugBank.d509.s13.e0
,;O;O
grapefruit;O;O
juice;O;O
);O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d509.s14;;
When;O;O
the;O;O
CYP3A4;O;O
inhibitor;O;O
is;O;O
withdrawn;O;O
from;O;O
the;O;O
combination;O;O
therapy;O;O
,;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s14.e0
dose;O;O
should;O;O
then;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d509.s15;;
Quinidine;B-drug;B-DDI-DrugBank.d509.s15.e0
:;O;O
Coadministration;O;O
of;O;O
a;O;O
10;O;O
-;O;O
mg;O;O
single;O;O
dose;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s15.e1
with;O;O
quinidine;B-drug;B-DDI-DrugBank.d509.s15.e2
(;O;O
166;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
13;O;O
days;O;O
);O;O
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP2D6;O;O
,;O;O
increased;O;O
the;O;O
AUC;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s15.e3
by;O;O
112;O;O
%;O;O
but;O;O
decreased;O;O
the;O;O
AUC;O;O
of;O;O
its;O;O
active;O;O
metabolite;O;O
,;O;O
dehydroaripiprazole;B-drug_n;B-DDI-DrugBank.d509.s15.e4
,;O;O
by;O;O
35;O;O
%;O;O
.;O;O
DDI-DrugBank.d509.s16;;
Aripiprazole;B-drug;B-DDI-DrugBank.d509.s16.e0
dose;O;O
should;O;O
be;O;O
reduced;O;O
to;O;O
one;O;O
-;O;O
half;O;O
of;O;O
its;O;O
normal;O;O
dose;O;O
when;O;O
concomitant;O;O
administration;O;O
of;O;O
quinidine;B-drug;B-DDI-DrugBank.d509.s16.e1
with;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s16.e2
occurs;O;O
.;O;O
DDI-DrugBank.d509.s17;;
Other;O;O
significant;O;O
inhibitors;O;O
of;O;O
CYP2D6;O;O
,;O;O
such;O;O
as;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d509.s17.e0
or;O;O
paroxetine;B-drug;B-DDI-DrugBank.d509.s17.e1
,;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
have;O;O
similar;O;O
effects;O;O
and;O;O
,;O;O
therefore;O;O
,;O;O
should;O;O
be;O;O
accompanied;O;O
by;O;O
similar;O;O
dose;O;O
reductions;O;O
.;O;O
DDI-DrugBank.d509.s18;;
When;O;O
the;O;O
CYP2D6;O;O
inhibitor;O;O
is;O;O
withdrawn;O;O
from;O;O
the;O;O
combination;O;O
therapy;O;O
,;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s18.e0
dose;O;O
should;O;O
then;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d509.s19;;
Carbamazepine;B-drug;B-DDI-DrugBank.d509.s19.e0
:;O;O
Coadministration;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d509.s19.e1
(;O;O
200;O;O
mg;O;O
BID;O;O
);O;O
,;O;O
a;O;O
potent;O;O
CYP3A4;O;O
inducer;O;O
,;O;O
with;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s19.e2
(;O;O
30;O;O
mg;O;O
QD;O;O
);O;O
resulted;O;O
in;O;O
an;O;O
approximate;O;O
70;O;O
%;O;O
decrease;O;O
in;O;O
Cmax;O;O
and;O;O
AUC;O;O
values;O;O
of;O;O
both;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s19.e3
and;O;O
its;O;O
active;O;O
metabolite;O;O
,;O;O
dehydro;B-drug_n;B-DDI-DrugBank.d509.s19.e4
-;I-drug_n;I-DDI-DrugBank.d509.s19.e4
aripiprazole;I-drug_n;I-DDI-DrugBank.d509.s19.e4
.;O;O
DDI-DrugBank.d509.s20;;
When;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d509.s20.e0
is;O;O
added;O;O
to;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s20.e1
therapy;O;O
,;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s20.e2
dose;O;O
should;O;O
be;O;O
doubled;O;O
.;O;O
DDI-DrugBank.d509.s21;;
Additional;O;O
dose;O;O
increases;O;O
should;O;O
be;O;O
based;O;O
on;O;O
clinical;O;O
evaluation;O;O
.;O;O
DDI-DrugBank.d509.s22;;
When;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d509.s22.e0
is;O;O
withdrawn;O;O
from;O;O
the;O;O
combination;O;O
therapy;O;O
,;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s22.e1
dose;O;O
should;O;O
then;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d509.s23;;
No;O;O
clinically;O;O
significant;O;O
effect;O;O
of;O;O
famotidine;B-drug;B-DDI-DrugBank.d509.s23.e0
,;O;O
valproate;B-drug;B-DDI-DrugBank.d509.s23.e1
,;O;O
or;O;O
lithium;B-drug;B-DDI-DrugBank.d509.s23.e2
was;O;O
seen;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s23.e3
(;O;O
see;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
:;O;O
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
);O;O
.;O;O
DDI-DrugBank.d509.s24;;
Potential;O;O
for;O;O
ABILIFY;B-brand;B-DDI-DrugBank.d509.s24.e0
to;O;O
Affect;O;O
Other;O;O
Drugs;O;O
Aripiprazole;B-drug;B-DDI-DrugBank.d509.s24.e1
is;O;O
unlikely;O;O
to;O;O
cause;O;O
clinically;O;O
important;O;O
pharmacokinetic;O;O
interactions;O;O
with;O;O
drugs;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d509.s25;;
In;O;O
in;O;O
vivo;O;O
studies;O;O
,;O;O
10;O;O
-;O;O
to;O;O
30;O;O
-;O;O
mg;O;O
/;O;O
day;O;O
doses;O;O
of;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s25.e0
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
metabolism;O;O
by;O;O
CYP2D6;O;O
(;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d509.s25.e1
);O;O
,;O;O
CYP2C9;O;O
(;O;O
warfarin;B-drug;B-DDI-DrugBank.d509.s25.e2
);O;O
,;O;O
CYP2C19;O;O
(;O;O
omeprazole;B-drug;B-DDI-DrugBank.d509.s25.e3
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d509.s25.e4
);O;O
,;O;O
and;O;O
CYP3A4;O;O
(;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d509.s25.e5
);O;O
substrates;O;O
.;O;O
DDI-DrugBank.d509.s26;;
Additionally;O;O
,;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s26.e0
and;O;O
dehydroaripiprazole;B-drug_n;B-DDI-DrugBank.d509.s26.e1
did;O;O
not;O;O
show;O;O
potential;O;O
for;O;O
altering;O;O
CYP1A2;O;O
-;O;O
mediated;O;O
metabolism;O;O
in;O;O
vitro;O;O
.;O;O
DDI-DrugBank.d509.s27;;
Alcohol;B-drug;B-DDI-DrugBank.d509.s27.e0
:;O;O
There;O;O
was;O;O
no;O;O
significant;O;O
difference;O;O
between;O;O
aripiprazole;B-drug;B-DDI-DrugBank.d509.s27.e1
coadministered;O;O
with;O;O
ethanol;B-drug;B-DDI-DrugBank.d509.s27.e2
and;O;O
placebo;O;O
coadministered;O;O
with;O;O
ethanol;B-drug;B-DDI-DrugBank.d509.s27.e3
on;O;O
performance;O;O
of;O;O
gross;O;O
motor;O;O
skills;O;O
or;O;O
stimulus;O;O
response;O;O
in;O;O
healthy;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d509.s28;;
As;O;O
with;O;O
most;O;O
psychoactive;O;O
medications;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
advised;O;O
to;O;O
avoid;O;O
alcohol;B-drug;B-DDI-DrugBank.d509.s28.e0
while;O;O
taking;O;O
ABILIFY;B-brand;B-DDI-DrugBank.d509.s28.e1
DDI-DrugBank.d509.s29;;
.;O;O
DDI-DrugBank.d509.s30;;
DDI-DrugBank.d470.s0;;
No;O;O
formal;O;O
assessments;O;O
of;O;O
pharmacokinetic;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
between;O;O
TRISENOX;B-brand;B-DDI-DrugBank.d470.s0.e0
and;O;O
other;O;O
agents;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d470.s1;;
Caution;O;O
is;O;O
advised;O;O
when;O;O
TRISENOX;B-brand;B-DDI-DrugBank.d470.s1.e0
is;O;O
coadministered;O;O
with;O;O
other;O;O
medications;O;O
that;O;O
can;O;O
prolong;O;O
the;O;O
QT;O;O
interval;O;O
(;O;O
e.g.;O;O
certain;O;O
antiarrhythmics;B-group;B-DDI-DrugBank.d470.s1.e1
or;O;O
thioridazine;B-drug;B-DDI-DrugBank.d470.s1.e2
);O;O
or;O;O
lead;O;O
to;O;O
electrolyte;O;O
abnormalities;O;O
(;O;O
such;O;O
as;O;O
diuretics;B-group;B-DDI-DrugBank.d470.s1.e3
or;O;O
amphotericin;B-drug;B-DDI-DrugBank.d470.s1.e4
B;I-drug;I-DDI-DrugBank.d470.s1.e4
);O;O
.;O;O
DDI-DrugBank.d21.s0;;
Tissue;O;O
culture;O;O
and;O;O
animal;O;O
studies;O;O
indicate;O;O
that;O;O
ELSPAR;B-brand;B-DDI-DrugBank.d21.s0.e0
can;O;O
diminish;O;O
or;O;O
abolish;O;O
the;O;O
effect;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d21.s0.e1
on;O;O
malignant;O;O
cells.14;O;O
This;O;O
effect;O;O
on;O;O
methotrexate;B-drug;B-DDI-DrugBank.d21.s0.e2
activity;O;O
persists;O;O
as;O;O
long;O;O
as;O;O
plasma;O;O
asparagine;O;O
levels;O;O
are;O;O
suppressed;O;O
.;O;O
DDI-DrugBank.d21.s1;;
These;O;O
results;O;O
would;O;O
seem;O;O
to;O;O
dictate;O;O
against;O;O
the;O;O
clinical;O;O
use;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d21.s1.e0
with;O;O
ELSPAR;B-brand;B-DDI-DrugBank.d21.s1.e1
,;O;O
or;O;O
during;O;O
the;O;O
period;O;O
following;O;O
ELSPAR;B-brand;B-DDI-DrugBank.d21.s1.e2
therapy;O;O
when;O;O
plasma;O;O
asparagine;O;O
levels;O;O
are;O;O
below;O;O
normal;O;O
.;O;O
DDI-DrugBank.d443.s0;;
Uricosuric;B-group;B-DDI-DrugBank.d443.s0.e0
Agents;I-group;I-DDI-DrugBank.d443.s0.e0
:;O;O
Aspirin;B-brand;B-DDI-DrugBank.d443.s0.e1
may;O;O
decrease;O;O
the;O;O
effects;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d443.s0.e2
,;O;O
sulfinpyrazone;B-drug;B-DDI-DrugBank.d443.s0.e3
,;O;O
and;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d443.s0.e4
.;O;O
DDI-DrugBank.d443.s1;;
Alcohol;B-drug;B-DDI-DrugBank.d443.s1.e0
:;O;O
Has;O;O
a;O;O
synergistic;O;O
effect;O;O
with;O;O
aspirin;B-brand;B-DDI-DrugBank.d443.s1.e1
in;O;O
causing;O;O
gastrointestinal;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d443.s2;;
Corticosteroids;B-group;B-DDI-DrugBank.d443.s2.e0
:;O;O
Concomitant;O;O
administration;O;O
with;O;O
aspirin;B-brand;B-DDI-DrugBank.d443.s2.e1
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
gastrointestinal;O;O
ulceration;O;O
and;O;O
may;O;O
reduce;O;O
serum;O;O
salicylate;O;O
levels;O;O
.;O;O
DDI-DrugBank.d443.s3;;
Pyrazolone;B-group;B-DDI-DrugBank.d443.s3.e0
Derivatives;I-group;I-DDI-DrugBank.d443.s3.e0
(;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d443.s3.e1
,;O;O
oxyphenbutazone;B-drug;B-DDI-DrugBank.d443.s3.e2
,;O;O
and;O;O
possibly;O;O
dipyrone;B-drug;B-DDI-DrugBank.d443.s3.e3
);O;O
:;O;O
Concomitant;O;O
administration;O;O
with;O;O
aspirin;B-drug;B-DDI-DrugBank.d443.s3.e4
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
gastrointestinal;O;O
ulceration;O;O
.;O;O
DDI-DrugBank.d443.s4;;
Nonsteroidal;B-drug;B-DDI-DrugBank.d443.s4.e0
Antiinflammatory;I-drug;I-DDI-DrugBank.d443.s4.e0
Agents;O;O
:;O;O
Aspirin;B-drug;B-DDI-DrugBank.d443.s4.e1
is;O;O
contraindicated;O;O
in;O;O
patients;O;O
who;O;O
are;O;O
hypersensitive;O;O
to;O;O
nonsteroidal;B-drug;B-DDI-DrugBank.d443.s4.e2
anti;I-drug;I-DDI-DrugBank.d443.s4.e2
-;I-drug;I-DDI-DrugBank.d443.s4.e2
inflammatory;I-drug;I-DDI-DrugBank.d443.s4.e2
agents;O;O
.;O;O
DDI-DrugBank.d443.s5;;
Urinary;O;O
Alkalinizers;O;O
:;O;O
Decrease;O;O
aspirin;B-brand;B-DDI-DrugBank.d443.s5.e0
effectiveness;O;O
by;O;O
increasing;O;O
the;O;O
rate;O;O
of;O;O
salicylate;B-group;B-DDI-DrugBank.d443.s5.e1
renal;O;O
excretion;O;O
.;O;O
DDI-DrugBank.d443.s6;;
Phenobarbital;B-drug;B-DDI-DrugBank.d443.s6.e0
:;O;O
Decreases;O;O
aspirin;B-brand;B-DDI-DrugBank.d443.s6.e1
effectiveness;O;O
by;O;O
enzyme;O;O
induction;O;O
.;O;O
DDI-DrugBank.d443.s7;;
Phenytoin;B-drug;B-DDI-DrugBank.d443.s7.e0
:;O;O
Serum;O;O
phenytoin;B-drug;B-DDI-DrugBank.d443.s7.e1
levels;O;O
may;O;O
be;O;O
increased;O;O
by;O;O
aspirin;B-brand;B-DDI-DrugBank.d443.s7.e2
.;O;O
DDI-DrugBank.d443.s8;;
Propranolol;B-drug;B-DDI-DrugBank.d443.s8.e0
:;O;O
May;O;O
decrease;O;O
aspirins;B-brand;B-DDI-DrugBank.d443.s8.e1
anti;O;O
-;O;O
inflammatory;O;O
action;O;O
by;O;O
competing;O;O
for;O;O
the;O;O
same;O;O
receptors;O;O
.;O;O
DDI-DrugBank.d443.s9;;
Antacids;B-group;B-DDI-DrugBank.d443.s9.e0
:;O;O
Enteric;O;O
Coated;O;O
Aspirin;B-brand;B-DDI-DrugBank.d443.s9.e1
should;O;O
not;O;O
be;O;O
given;O;O
concurrently;O;O
with;O;O
antacids;B-group;B-DDI-DrugBank.d443.s9.e2
,;O;O
since;O;O
an;O;O
increase;O;O
in;O;O
the;O;O
pH;O;O
of;O;O
the;O;O
stomach;O;O
may;O;O
effect;O;O
the;O;O
enteric;O;O
coating;O;O
of;O;O
the;O;O
tablets;O;O
.;O;O
DDI-DrugBank.d109.s0;;
Ketoconazole;B-drug;B-DDI-DrugBank.d109.s0.e0
/;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d109.s0.e1
,;O;O
Macrolides;B-group;B-DDI-DrugBank.d109.s0.e2
,;O;O
Including;O;O
Erythromycin;B-drug;B-DDI-DrugBank.d109.s0.e3
DDI-DrugBank.d73.s0;;
Catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
(;O;O
eg;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d73.s0.e0
);O;O
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d73.s0.e1
-;I-group;I-DDI-DrugBank.d73.s0.e1
blocking;I-group;I-DDI-DrugBank.d73.s0.e1
agents;I-group;I-DDI-DrugBank.d73.s0.e1
.;O;O
DDI-DrugBank.d73.s1;;
Patients;O;O
treated;O;O
with;O;O
TENORMIN;B-brand;B-DDI-DrugBank.d73.s1.e0
plus;O;O
a;O;O
catecholamine;O;O
depletor;O;O
should;O;O
therefore;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
evidence;O;O
of;O;O
hypotension;O;O
and/or;O;O
marked;O;O
bradycardia;O;O
which;O;O
may;O;O
produce;O;O
vertigo;O;O
,;O;O
syncope;O;O
,;O;O
or;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d73.s2;;
Calcium;B-group;B-DDI-DrugBank.d73.s2.e0
channel;I-group;I-DDI-DrugBank.d73.s2.e0
blockers;I-group;I-DDI-DrugBank.d73.s2.e0
may;O;O
also;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
TENORMIN;B-brand;B-DDI-DrugBank.d73.s2.e1
.;O;O
DDI-DrugBank.d73.s3;;
Beta;B-group;B-DDI-DrugBank.d73.s3.e0
blockers;I-group;I-DDI-DrugBank.d73.s3.e0
may;O;O
exacerbate;O;O
the;O;O
rebound;O;O
hypertension;O;O
which;O;O
can;O;O
follow;O;O
the;O;O
withdrawal;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d73.s3.e1
.;O;O
DDI-DrugBank.d73.s4;;
If;O;O
the;O;O
two;O;O
drugs;O;O
are;O;O
coadministered;O;O
,;O;O
the;O;O
beta;B-group;B-DDI-DrugBank.d73.s4.e0
blocker;I-group;I-DDI-DrugBank.d73.s4.e0
should;O;O
be;O;O
withdrawn;O;O
several;O;O
days;O;O
before;O;O
the;O;O
gradual;O;O
withdrawal;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d73.s4.e1
.;O;O
DDI-DrugBank.d73.s5;;
If;O;O
replacing;O;O
clonidine;B-drug;B-DDI-DrugBank.d73.s5.e0
by;O;O
beta;B-group;B-DDI-DrugBank.d73.s5.e1
-;I-group;I-DDI-DrugBank.d73.s5.e1
blocker;I-group;I-DDI-DrugBank.d73.s5.e1
therapy;O;O
,;O;O
the;O;O
introduction;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d73.s5.e2
blockers;I-group;I-DDI-DrugBank.d73.s5.e2
should;O;O
be;O;O
delayed;O;O
for;O;O
several;O;O
days;O;O
after;O;O
clonidine;B-drug;B-DDI-DrugBank.d73.s5.e3
administration;O;O
has;O;O
stopped;O;O
.;O;O
DDI-DrugBank.d73.s6;;
Concomitant;O;O
use;O;O
of;O;O
prostaglandin;O;O
synthase;O;O
inhibiting;O;O
drugs;O;O
,;O;O
eg;O;O
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d73.s6.e0
,;O;O
may;O;O
decrease;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d73.s6.e1
blockers;I-group;I-DDI-DrugBank.d73.s6.e1
.;O;O
DDI-DrugBank.d73.s7;;
Information;O;O
on;O;O
concurrent;O;O
usage;O;O
of;O;O
atenolol;B-drug;B-DDI-DrugBank.d73.s7.e0
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d73.s7.e1
is;O;O
limited;O;O
.;O;O
DDI-DrugBank.d73.s8;;
Data;O;O
from;O;O
several;O;O
studies;O;O
,;O;O
ie;O;O
,;O;O
TIMI;O;O
-;O;O
II;O;O
,;O;O
ISIS;O;O
-;O;O
2;O;O
,;O;O
currently;O;O
do;O;O
not;O;O
suggest;O;O
any;O;O
clinical;O;O
interaction;O;O
between;O;O
aspirin;B-brand;B-DDI-DrugBank.d73.s8.e0
and;O;O
beta;B-group;B-DDI-DrugBank.d73.s8.e1
blockers;I-group;I-DDI-DrugBank.d73.s8.e1
in;O;O
the;O;O
acute;O;O
myocardial;O;O
infarction;O;O
setting;O;O
.;O;O
DDI-DrugBank.d73.s9;;
While;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d73.s9.e0
blockers;I-group;I-DDI-DrugBank.d73.s9.e0
,;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
anaphylactic;O;O
reaction;O;O
to;O;O
a;O;O
variety;O;O
of;O;O
allergens;O;O
may;O;O
have;O;O
a;O;O
more;O;O
severe;O;O
reaction;O;O
on;O;O
repeated;O;O
challenge;O;O
,;O;O
either;O;O
accidental;O;O
,;O;O
diagnostic;O;O
or;O;O
therapeutic;O;O
.;O;O
DDI-DrugBank.d73.s10;;
Such;O;O
patients;O;O
may;O;O
be;O;O
unresponsive;O;O
to;O;O
the;O;O
usual;O;O
doses;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d73.s10.e0
used;O;O
to;O;O
treat;O;O
the;O;O
allergic;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d11.s0;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
Albuterol;B-drug;B-DDI-DrugBank.d11.s0.e0
-;O;O
STRATTERA;B-brand;B-DDI-DrugBank.d11.s0.e1
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
systemically;O;O
-;O;O
administered;O;O
(;O;O
oral;O;O
or;O;O
intravenous;O;O
);O;O
albuterol;B-drug;B-DDI-DrugBank.d11.s0.e2
(;O;O
or;O;O
other;O;O
beta2;B-group;B-DDI-DrugBank.d11.s0.e3
agonists;I-group;I-DDI-DrugBank.d11.s0.e3
);O;O
because;O;O
the;O;O
action;O;O
of;O;O
albuterol;B-drug;B-DDI-DrugBank.d11.s0.e4
on;O;O
the;O;O
cardiovascular;O;O
system;O;O
can;O;O
be;O;O
potentiated;O;O
resulting;O;O
in;O;O
increases;O;O
in;O;O
heart;O;O
rate;O;O
and;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d11.s1;;
CYP2D6;O;O
inhibitors;O;O
-;O;O
Atomoxetine;B-drug;B-DDI-DrugBank.d11.s1.e0
is;O;O
primarily;O;O
metabolized;O;O
by;O;O
the;O;O
CYP2D6;O;O
pathway;O;O
to;O;O
4;B-drug_n;B-DDI-DrugBank.d11.s1.e1
-;I-drug_n;I-DDI-DrugBank.d11.s1.e1
hydroxyatomoxetine;I-drug_n;I-DDI-DrugBank.d11.s1.e1
.;O;O
DDI-DrugBank.d11.s2;;
In;O;O
EMs;O;O
,;O;O
selective;O;O
inhibitors;O;O
of;O;O
CYP2D6;O;O
increase;O;O
atomoxetine;B-drug;B-DDI-DrugBank.d11.s2.e0
steady;O;O
-;O;O
state;O;O
plasma;O;O
concentrations;O;O
to;O;O
exposures;O;O
similar;O;O
to;O;O
those;O;O
observed;O;O
in;O;O
PMs;O;O
.;O;O
DDI-DrugBank.d11.s3;;
Dosage;O;O
adjustment;O;O
of;O;O
STRATTERA;B-brand;B-DDI-DrugBank.d11.s3.e0
may;O;O
be;O;O
necessary;O;O
when;O;O
coadministered;O;O
with;O;O
CYP2D6;O;O
inhibitors;O;O
,;O;O
e.g.;O;O
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d11.s3.e1
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d11.s3.e2
,;O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d11.s3.e3
.;O;O
DDI-DrugBank.d11.s4;;
In;O;O
EM;O;O
individuals;O;O
treated;O;O
with;O;O
paroxetine;B-drug;B-DDI-DrugBank.d11.s4.e0
or;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d11.s4.e1
,;O;O
the;O;O
AUC;O;O
of;O;O
atomoxetine;B-drug;B-DDI-DrugBank.d11.s4.e2
is;O;O
approximately;O;O
6;O;O
-;O;O
to;O;O
8;O;O
-;O;O
fold;O;O
and;O;O
Css;O;O
,;O;O
max;O;O
is;O;O
about;O;O
3;O;O
-;O;O
to;O;O
4;O;O
-;O;O
fold;O;O
greater;O;O
than;O;O
atomoxetine;B-drug;B-DDI-DrugBank.d11.s4.e3
alone;O;O
.;O;O
DDI-DrugBank.d11.s5;;
In;O;O
vitro;O;O
studies;O;O
suggest;O;O
that;O;O
coadministration;O;O
of;O;O
cytochrome;O;O
P450;O;O
inhibitors;O;O
to;O;O
PMs;O;O
will;O;O
not;O;O
increase;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
atomoxetine;B-drug;B-DDI-DrugBank.d11.s5.e0
.;O;O
DDI-DrugBank.d11.s6;;
Pressor;O;O
agents;O;O
-;O;O
Because;O;O
of;O;O
possible;O;O
effects;O;O
on;O;O
blood;O;O
pressure;O;O
,;O;O
STRATTERA;B-brand;B-DDI-DrugBank.d11.s6.e0
should;O;O
be;O;O
used;O;O
cautiously;O;O
with;O;O
pressor;O;O
agents;O;O
.;O;O
DDI-DrugBank.d140.s0;;
The;O;O
risk;O;O
of;O;O
myopathy;O;O
during;O;O
treatment;O;O
with;O;O
drugs;O;O
of;O;O
this;O;O
class;O;O
is;O;O
increased;O;O
with;O;O
concurrent;O;O
administration;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d140.s0.e0
,;O;O
fibric;B-group;B-DDI-DrugBank.d140.s0.e1
acid;I-group;I-DDI-DrugBank.d140.s0.e1
derivatives;I-group;I-DDI-DrugBank.d140.s0.e1
,;O;O
niacin;B-drug;B-DDI-DrugBank.d140.s0.e2
(;O;O
nicotinic;B-drug;B-DDI-DrugBank.d140.s0.e3
acid;I-drug;I-DDI-DrugBank.d140.s0.e3
);O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d140.s0.e4
,;O;O
azole;B-group;B-DDI-DrugBank.d140.s0.e5
antifungals;I-group;I-DDI-DrugBank.d140.s0.e5
.;O;O
DDI-DrugBank.d140.s1;;
Antacid;B-group;B-DDI-DrugBank.d140.s1.e0
:;O;O
When;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s1.e1
and;O;O
Maalox;B-brand;B-DDI-DrugBank.d140.s1.e2
TC;I-brand;I-DDI-DrugBank.d140.s1.e2
suspension;O;O
were;O;O
coadministered;O;O
,;O;O
plasma;O;O
concentrations;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s1.e3
decreased;O;O
approximately;O;O
35;O;O
%;O;O
.;O;O
DDI-DrugBank.d140.s2;;
However;O;O
,;O;O
LDL;O;O
-;O;O
C;O;O
reduction;O;O
was;O;O
not;O;O
altered;O;O
.;O;O
DDI-DrugBank.d140.s3;;
Antipyrine;B-drug;B-DDI-DrugBank.d140.s3.e0
:;O;O
Because;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s3.e1
does;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
antipyrine;B-drug;B-DDI-DrugBank.d140.s3.e2
,;O;O
interactions;O;O
with;O;O
other;O;O
drugs;B-drug;B-DDI-DrugBank.d140.s3.e3
metabolized;O;O
via;O;O
the;O;O
same;O;O
cytochrome;O;O
isozymes;O;O
are;O;O
not;O;O
expected;O;O
.;O;O
DDI-DrugBank.d140.s4;;
Colestipol;B-drug;B-DDI-DrugBank.d140.s4.e0
:;O;O
Plasma;O;O
concentrations;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s4.e1
decreased;O;O
approximately;O;O
25;O;O
%;O;O
when;O;O
colestipol;B-drug;B-DDI-DrugBank.d140.s4.e2
and;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s4.e3
were;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d140.s5;;
However;O;O
,;O;O
LDL;O;O
-;O;O
C;O;O
reduction;O;O
was;O;O
greater;O;O
when;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s5.e0
and;O;O
colestipol;B-drug;B-DDI-DrugBank.d140.s5.e1
were;O;O
coadministered;O;O
than;O;O
when;O;O
either;O;O
drug;O;O
was;O;O
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d140.s6;;
Cimetidine;B-drug;B-DDI-DrugBank.d140.s6.e0
:;O;O
Atorvastatin;B-drug;B-DDI-DrugBank.d140.s6.e1
plasma;O;O
concentrations;O;O
and;O;O
LDL;O;O
-;O;O
C;O;O
reduction;O;O
were;O;O
not;O;O
altered;O;O
by;O;O
coadministration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d140.s6.e2
.;O;O
DDI-DrugBank.d140.s7;;
Digoxin;B-drug;B-DDI-DrugBank.d140.s7.e0
:;O;O
When;O;O
multiple;O;O
doses;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s7.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d140.s7.e2
were;O;O
coadministered;O;O
,;O;O
steady;O;O
-;O;O
state;O;O
plasma;O;O
digoxin;B-drug;B-DDI-DrugBank.d140.s7.e3
concentrations;O;O
increased;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d140.s8;;
Patients;O;O
taking;O;O
digoxin;B-drug;B-DDI-DrugBank.d140.s8.e0
should;O;O
be;O;O
monitored;O;O
appropriately;O;O
.;O;O
DDI-DrugBank.d140.s9;;
Erythromycin;B-drug;B-DDI-DrugBank.d140.s9.e0
:;O;O
In;O;O
healthy;O;O
individuals;O;O
,;O;O
plasma;O;O
concentrations;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s9.e1
increased;O;O
approximately;O;O
40;O;O
%;O;O
with;O;O
coadministration;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s9.e2
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d140.s9.e3
,;O;O
a;O;O
known;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d140.s10;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d140.s10.e0
:;O;O
Coadministration;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s10.e1
and;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d140.s10.e2
increased;O;O
AUC;O;O
values;O;O
for;O;O
norethindrone;B-drug;B-DDI-DrugBank.d140.s10.e3
and;O;O
ethinyl;B-drug;B-DDI-DrugBank.d140.s10.e4
estradiol;I-drug;I-DDI-DrugBank.d140.s10.e4
by;O;O
approximately;O;O
30;O;O
%;O;O
and;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d140.s11;;
These;O;O
increases;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
selecting;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d140.s11.e0
for;O;O
a;O;O
woman;O;O
taking;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s11.e1
.;O;O
DDI-DrugBank.d140.s12;;
Warfarin;B-drug;B-DDI-DrugBank.d140.s12.e0
:;O;O
Atorvastatin;B-drug;B-DDI-DrugBank.d140.s12.e1
had;O;O
no;O;O
clinically;O;O
significant;O;O
effect;O;O
on;O;O
prothrombin;O;O
time;O;O
when;O;O
administered;O;O
to;O;O
patients;O;O
receiving;O;O
chronic;O;O
warfarin;B-drug;B-DDI-DrugBank.d140.s12.e2
treatment;O;O
.;O;O
DDI-DrugBank.d140.s13;;
Endocrine;O;O
Function;O;O
HMG;B-group;B-DDI-DrugBank.d140.s13.e0
-;I-group;I-DDI-DrugBank.d140.s13.e0
CoA;I-group;I-DDI-DrugBank.d140.s13.e0
reductase;I-group;I-DDI-DrugBank.d140.s13.e0
inhibitors;I-group;I-DDI-DrugBank.d140.s13.e0
interfere;O;O
with;O;O
cholesterol;O;O
synthesis;O;O
and;O;O
theoretically;O;O
might;O;O
blunt;O;O
adrenal;O;O
and/or;O;O
gonadal;O;O
steroid;O;O
production;O;O
.;O;O
DDI-DrugBank.d140.s14;;
Clinical;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d140.s14.e0
does;O;O
not;O;O
reduce;O;O
basal;O;O
plasma;O;O
cortisol;O;O
concentration;O;O
or;O;O
impair;O;O
adrenal;O;O
reserve;O;O
.;O;O
DDI-DrugBank.d140.s15;;
The;O;O
effects;O;O
of;O;O
HMG;B-group;B-DDI-DrugBank.d140.s15.e0
-;I-group;I-DDI-DrugBank.d140.s15.e0
CoA;I-group;I-DDI-DrugBank.d140.s15.e0
reductase;I-group;I-DDI-DrugBank.d140.s15.e0
inhibitors;I-group;I-DDI-DrugBank.d140.s15.e0
on;O;O
male;O;O
fertility;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
in;O;O
adequate;O;O
numbers;O;O
of;O;O
patients;O;O
.;O;O
DDI-DrugBank.d140.s16;;
The;O;O
effects;O;O
,;O;O
if;O;O
any;O;O
,;O;O
on;O;O
the;O;O
pituitary;O;O
-;O;O
gonadal;O;O
axis;O;O
in;O;O
premenopausal;O;O
women;O;O
are;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d140.s17;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
if;O;O
an;O;O
HMG;B-group;B-DDI-DrugBank.d140.s17.e0
-;I-group;I-DDI-DrugBank.d140.s17.e0
CoA;I-group;I-DDI-DrugBank.d140.s17.e0
reductase;I-group;I-DDI-DrugBank.d140.s17.e0
inhibitor;I-group;I-DDI-DrugBank.d140.s17.e0
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
drugs;O;O
that;O;O
may;O;O
decrease;O;O
the;O;O
levels;O;O
or;O;O
activity;O;O
of;O;O
endogenous;O;O
steroid;O;O
hormones;O;O
,;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d140.s17.e1
,;O;O
spironolactone;B-drug;B-DDI-DrugBank.d140.s17.e2
,;O;O
and;O;O
cimetidine;B-drug;B-DDI-DrugBank.d140.s17.e3
.;O;O
DDI-DrugBank.d140.s18;;
CNS;O;O
Toxicity;O;O
Brain;O;O
hemorrhage;O;O
was;O;O
seen;O;O
in;O;O
a;O;O
female;O;O
dog;O;O
treated;O;O
for;O;O
3;O;O
months;O;O
at;O;O
120;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d140.s19;;
Brain;O;O
hemorrhage;O;O
and;O;O
optic;O;O
nerve;O;O
vacuolation;O;O
were;O;O
seen;O;O
in;O;O
another;O;O
female;O;O
dog;O;O
that;O;O
was;O;O
sacrificed;O;O
in;O;O
moribund;O;O
condition;O;O
after;O;O
11;O;O
weeks;O;O
of;O;O
escalating;O;O
doses;O;O
up;O;O
to;O;O
280;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d140.s20;;
The;O;O
120;O;O
mg;O;O
/;O;O
kg;O;O
dose;O;O
resulted;O;O
in;O;O
a;O;O
systemic;O;O
exposure;O;O
approximately;O;O
16;O;O
times;O;O
the;O;O
human;O;O
plasma;O;O
area;O;O
-;O;O
under;O;O
-;O;O
the;O;O
-;O;O
curve;O;O
(;O;O
AUC;O;O
,;O;O
0;O;O
-;O;O
24;O;O
hours;O;O
);O;O
based;O;O
on;O;O
the;O;O
maximum;O;O
human;O;O
dose;O;O
of;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d140.s21;;
A;O;O
single;O;O
tonic;O;O
convulsion;O;O
was;O;O
seen;O;O
in;O;O
each;O;O
of;O;O
2;O;O
male;O;O
dogs;O;O
(;O;O
one;O;O
treated;O;O
at;O;O
10;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
and;O;O
one;O;O
at;O;O
120;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
);O;O
in;O;O
a;O;O
2;O;O
-;O;O
year;O;O
study;O;O
.;O;O
DDI-DrugBank.d140.s22;;
No;O;O
CNS;O;O
lesions;O;O
have;O;O
been;O;O
observed;O;O
in;O;O
mice;O;O
after;O;O
chronic;O;O
treatment;O;O
for;O;O
up;O;O
to;O;O
2;O;O
years;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
400;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
or;O;O
in;O;O
rats;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
100;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d140.s23;;
These;O;O
doses;O;O
were;O;O
6;O;O
to;O;O
11;O;O
times;O;O
(;O;O
mouse;O;O
);O;O
and;O;O
8;O;O
to;O;O
16;O;O
times;O;O
(;O;O
rat;O;O
);O;O
the;O;O
human;O;O
AUC;O;O
(;O;O
0;O;O
-;O;O
24;O;O
);O;O
based;O;O
on;O;O
the;O;O
maximum;O;O
recommended;O;O
human;O;O
dose;O;O
of;O;O
80;O;O
mg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d140.s24;;
CNS;O;O
vascular;O;O
lesions;O;O
,;O;O
characterized;O;O
by;O;O
perivascular;O;O
hemorrhages;O;O
,;O;O
edema;O;O
,;O;O
and;O;O
mononuclear;O;O
cell;O;O
infiltration;O;O
of;O;O
perivascular;O;O
spaces;O;O
,;O;O
have;O;O
been;O;O
observed;O;O
in;O;O
dogs;O;O
treated;O;O
with;O;O
other;O;O
members;O;O
of;O;O
this;O;O
class;O;O
.;O;O
DDI-DrugBank.d140.s25;;
A;O;O
chemically;O;O
similar;O;O
drug;O;O
in;O;O
this;O;O
class;O;O
produced;O;O
optic;O;O
nerve;O;O
degeneration;O;O
(;O;O
Wallerian;O;O
degeneration;O;O
of;O;O
retinogeniculate;O;O
fibers;O;O
);O;O
in;O;O
clinically;O;O
normal;O;O
dogs;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
fashion;O;O
at;O;O
a;O;O
dose;O;O
that;O;O
produced;O;O
plasma;O;O
drug;O;O
levels;O;O
about;O;O
30;O;O
times;O;O
higher;O;O
than;O;O
the;O;O
mean;O;O
drug;O;O
level;O;O
in;O;O
humans;O;O
taking;O;O
the;O;O
highest;O;O
recommended;O;O
dose;O;O
.;O;O
DDI-DrugBank.d424.s0;;
Atovaquone;B-drug;B-DDI-DrugBank.d424.s0.e0
is;O;O
highly;O;O
bound;O;O
to;O;O
plasma;O;O
protein;O;O
(;O;O
99.9;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d424.s1;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
administering;O;O
MEPRON;B-brand;B-DDI-DrugBank.d424.s1.e0
concurrently;O;O
with;O;O
other;O;O
highly;O;O
plasma;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
with;O;O
narrow;O;O
therapeutic;O;O
indices;O;O
,;O;O
as;O;O
competition;O;O
for;O;O
binding;O;O
sites;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d424.s2;;
The;O;O
extent;O;O
of;O;O
plasma;O;O
protein;O;O
binding;O;O
of;O;O
atovaquone;B-drug;B-DDI-DrugBank.d424.s2.e0
in;O;O
human;O;O
plasma;O;O
is;O;O
not;O;O
affected;O;O
by;O;O
the;O;O
presence;O;O
of;O;O
therapeutic;O;O
concentrations;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d424.s2.e1
(;O;O
15;O;O
mcg;O;O
/;O;O
mL;O;O
);O;O
,;O;O
nor;O;O
is;O;O
the;O;O
binding;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d424.s2.e2
affected;O;O
by;O;O
the;O;O
presence;O;O
of;O;O
atovaquone;B-drug;B-DDI-DrugBank.d424.s2.e3
.;O;O
DDI-DrugBank.d424.s3;;
Rifampin;B-drug;B-DDI-DrugBank.d424.s3.e0
:;O;O
Coadministration;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d424.s3.e1
and;O;O
MEPRON;B-brand;B-DDI-DrugBank.d424.s3.e2
Suspension;O;O
results;O;O
in;O;O
a;O;O
significant;O;O
decrease;O;O
in;O;O
average;O;O
steady;O;O
-;O;O
state;O;O
plasma;O;O
atovaquone;B-drug;B-DDI-DrugBank.d424.s3.e3
concentrations;O;O
.;O;O
DDI-DrugBank.d424.s4;;
Alternatives;O;O
to;O;O
rifampin;B-drug;B-DDI-DrugBank.d424.s4.e0
should;O;O
be;O;O
considered;O;O
during;O;O
the;O;O
course;O;O
of;O;O
PCP;O;O
treatment;O;O
with;O;O
MEPRON;B-brand;B-DDI-DrugBank.d424.s4.e1
.;O;O
DDI-DrugBank.d424.s5;;
Rifabutin;B-drug;B-DDI-DrugBank.d424.s5.e0
,;O;O
another;O;O
rifamycin;B-drug;B-DDI-DrugBank.d424.s5.e1
,;O;O
is;O;O
structurally;O;O
similar;O;O
to;O;O
rifampin;B-drug;B-DDI-DrugBank.d424.s5.e2
and;O;O
may;O;O
possibly;O;O
have;O;O
some;O;O
of;O;O
the;O;O
same;O;O
drug;O;O
interactions;O;O
as;O;O
rifampin;B-drug;B-DDI-DrugBank.d424.s5.e3
.;O;O
DDI-DrugBank.d424.s6;;
No;O;O
interaction;O;O
trials;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
MEPRON;B-brand;B-DDI-DrugBank.d424.s6.e0
and;O;O
rifabutin;B-drug;B-DDI-DrugBank.d424.s6.e1
.;O;O
DDI-DrugBank.d424.s7;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
It;O;O
is;O;O
not;O;O
known;O;O
if;O;O
MEPRON;B-brand;B-DDI-DrugBank.d424.s7.e0
interferes;O;O
with;O;O
clinical;O;O
laboratory;O;O
test;O;O
or;O;O
assay;O;O
results;O;O
.;O;O
DDI-DrugBank.d469.s0;;
Drugs;O;O
which;O;O
may;O;O
enhance;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
TRACRIUM;B-brand;B-DDI-DrugBank.d469.s0.e0
include;O;O
:;O;O
enflurane;B-drug;B-DDI-DrugBank.d469.s0.e1
,;O;O
DDI-DrugBank.d469.s1;;
isoflurane;B-drug;B-DDI-DrugBank.d469.s1.e0
,;O;O
DDI-DrugBank.d469.s2;;
halothane;B-drug;B-DDI-DrugBank.d469.s2.e0
,;O;O
DDI-DrugBank.d469.s3;;
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d469.s3.e0
,;O;O
especially;O;O
the;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d469.s3.e1
and;O;O
polymyxins;B-group;B-DDI-DrugBank.d469.s3.e2
,;O;O
DDI-DrugBank.d469.s4;;
lithium;B-drug;B-DDI-DrugBank.d469.s4.e0
,;O;O
DDI-DrugBank.d469.s5;;
magnesium;B-drug;B-DDI-DrugBank.d469.s5.e0
salts;O;O
,;O;O
DDI-DrugBank.d469.s6;;
procainamide;B-drug;B-DDI-DrugBank.d469.s6.e0
,;O;O
DDI-DrugBank.d469.s7;;
Drugs;O;O
which;O;O
may;O;O
enhance;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
TRACRIUM;B-brand;B-DDI-DrugBank.d469.s7.e0
include;O;O
:;O;O
enflurane;B-drug;B-DDI-DrugBank.d469.s7.e1
,;O;O
isoflurane;B-drug;B-DDI-DrugBank.d469.s7.e2
,;O;O
halothane;B-drug;B-DDI-DrugBank.d469.s7.e3
,;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d469.s7.e4
,;O;O
especially;O;O
the;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d469.s7.e5
and;O;O
polymyxins;B-group;B-DDI-DrugBank.d469.s7.e6
,;O;O
lithium;B-drug;B-DDI-DrugBank.d469.s7.e7
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d469.s7.e8
salts;O;O
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d469.s7.e9
,;O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d469.s7.e10
.;O;O
DDI-DrugBank.d469.s8;;
If;O;O
other;O;O
muscle;B-group;B-DDI-DrugBank.d469.s8.e0
relaxants;I-group;I-DDI-DrugBank.d469.s8.e0
are;O;O
used;O;O
during;O;O
the;O;O
same;O;O
procedure;O;O
,;O;O
the;O;O
possibility;O;O
of;O;O
a;O;O
synergistic;O;O
or;O;O
antagonist;O;O
effect;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d469.s9;;
The;O;O
prior;O;O
administration;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d469.s9.e0
does;O;O
not;O;O
enhance;O;O
the;O;O
duration;O;O
,;O;O
but;O;O
quickens;O;O
the;O;O
onset;O;O
and;O;O
may;O;O
increase;O;O
the;O;O
depth;O;O
,;O;O
of;O;O
neuromuscular;O;O
block;O;O
induced;O;O
by;O;O
TRACRIUM;B-brand;B-DDI-DrugBank.d469.s9.e1
.;O;O
DDI-DrugBank.d469.s10;;
TRACRIUM;B-brand;B-DDI-DrugBank.d469.s10.e0
should;O;O
not;O;O
be;O;O
administered;O;O
until;O;O
a;O;O
patient;O;O
has;O;O
recovered;O;O
from;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d469.s10.e1
-;O;O
induced;O;O
neuromuscular;O;O
block;O;O
.;O;O
DDI-DrugBank.d222.s0;;
When;O;O
atropine;B-drug;B-DDI-DrugBank.d222.s0.e0
and;O;O
pralidoxime;B-drug;B-DDI-DrugBank.d222.s0.e1
are;O;O
used;O;O
together;O;O
,;O;O
the;O;O
signs;O;O
of;O;O
atropinization;O;O
(;O;O
flushing;O;O
,;O;O
mydriasis;O;O
,;O;O
tachycardia;O;O
,;O;O
dryness;O;O
of;O;O
the;O;O
mouth;O;O
and;O;O
nose;O;O
);O;O
may;O;O
occur;O;O
earlier;O;O
than;O;O
might;O;O
be;O;O
expected;O;O
than;O;O
when;O;O
atropine;B-drug;B-DDI-DrugBank.d222.s0.e2
is;O;O
used;O;O
alone;O;O
because;O;O
pralidoxime;B-drug;B-DDI-DrugBank.d222.s0.e3
may;O;O
potentiate;O;O
the;O;O
effect;O;O
of;O;O
atropine;B-drug;B-DDI-DrugBank.d222.s0.e4
.;O;O
DDI-DrugBank.d222.s1;;
The;O;O
following;O;O
precautions;O;O
should;O;O
be;O;O
kept;O;O
in;O;O
mind;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
anticholinesterase;O;O
poisoning;O;O
although;O;O
they;O;O
do;O;O
not;O;O
bear;O;O
directly;O;O
on;O;O
the;O;O
use;O;O
of;O;O
atropine;B-drug;B-DDI-DrugBank.d222.s1.e0
and;O;O
pralidoxime;B-drug;B-DDI-DrugBank.d222.s1.e1
.;O;O
DDI-DrugBank.d222.s2;;
Since;O;O
barbiturates;B-group;B-DDI-DrugBank.d222.s2.e0
are;O;O
potentiated;O;O
by;O;O
the;O;O
anticholinesterases;B-group;B-DDI-DrugBank.d222.s2.e1
,;O;O
they;O;O
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
convulsions;O;O
.;O;O
DDI-DrugBank.d374.s0;;
Auranofin;B-drug;B-DDI-DrugBank.d374.s0.e0
should;O;O
be;O;O
avoided;O;O
by;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
serious;O;O
reaction;O;O
to;O;O
any;O;O
gold;B-group;B-DDI-DrugBank.d374.s0.e1
medication;I-group;I-DDI-DrugBank.d374.s0.e1
,;O;O
including;O;O
Solganal;B-brand;B-DDI-DrugBank.d374.s0.e2
and;O;O
Myochrysine;B-brand;B-DDI-DrugBank.d374.s0.e3
.;O;O
DDI-DrugBank.d374.s1;;
Auranofin;B-drug;B-DDI-DrugBank.d374.s1.e0
should;O;O
not;O;O
be;O;O
used;O;O
together;O;O
with;O;O
penicillamine;B-drug;B-DDI-DrugBank.d374.s1.e1
(;O;O
Depen;B-brand;B-DDI-DrugBank.d374.s1.e2
,;O;O
Cuprimine;B-brand;B-DDI-DrugBank.d374.s1.e3
);O;O
,;O;O
another;O;O
arthritis;O;O
medication;O;O
.;O;O
DDI-DrugBank.d374.s2;;
It;O;O
should;O;O
also;O;O
be;O;O
avoided;O;O
in;O;O
patients;O;O
with;O;O
blood;O;O
,;O;O
liver;O;O
or;O;O
kidney;O;O
diseases;O;O
,;O;O
recent;O;O
radiation;O;O
treatment;O;O
,;O;O
or;O;O
uncontrolled;O;O
diabetes;O;O
.;O;O
DDI-DrugBank.d374.s3;;
Patients;O;O
should;O;O
report;O;O
to;O;O
their;O;O
practitioners;O;O
any;O;O
new;O;O
rashes;O;O
,;O;O
itching;O;O
,;O;O
mouth;O;O
sores;O;O
,;O;O
or;O;O
unusual;O;O
taste;O;O
while;O;O
taking;O;O
auranofin;B-drug;B-DDI-DrugBank.d374.s3.e0
.;O;O
DDI-DrugBank.d374.s4;;
Gold;B-group;B-DDI-DrugBank.d374.s4.e0
is;O;O
excreted;O;O
slowly;O;O
from;O;O
the;O;O
body;O;O
.;O;O
DDI-DrugBank.d374.s5;;
Safety;O;O
and;O;O
effectiveness;O;O
in;O;O
children;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d147.s0;;
No;O;O
formal;O;O
assessments;O;O
of;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
between;O;O
Vidaza;B-brand;B-DDI-DrugBank.d147.s0.e0
and;O;O
other;O;O
agents;O;O
have;O;O
been;O;O
conducted;O;O
DDI-DrugBank.d147.s1;;
.;O;O
DDI-DrugBank.d147.s2;;
DDI-DrugBank.d448.s0;;
MAO;B-group;B-DDI-DrugBank.d448.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d448.s0.e0
prolong;O;O
and;O;O
intensify;O;O
the;O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d448.s0.e1
.;O;O
DDI-DrugBank.d448.s1;;
Concomitant;O;O
use;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d448.s1.e0
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d448.s1.e1
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d448.s1.e2
antidepressants;I-group;I-DDI-DrugBank.d448.s1.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d448.s1.e3
,;O;O
or;O;O
other;O;O
central;B-group;B-DDI-DrugBank.d448.s1.e4
nervous;I-group;I-DDI-DrugBank.d448.s1.e4
system;I-group;I-DDI-DrugBank.d448.s1.e4
depressants;I-group;I-DDI-DrugBank.d448.s1.e4
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
.;O;O
DDI-DrugBank.d448.s2;;
When;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d448.s2.e0
drugs;I-group;I-DDI-DrugBank.d448.s2.e0
are;O;O
given;O;O
to;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d448.s2.e1
oxidase;I-group;I-DDI-DrugBank.d448.s2.e1
inhibitors;I-group;I-DDI-DrugBank.d448.s2.e1
,;O;O
hypertensive;O;O
reactions;O;O
,;O;O
including;O;O
hypertensive;O;O
crises;O;O
,;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d448.s3;;
The;O;O
antihypertensive;O;O
effects;O;O
of;O;O
methyldopa;B-drug;B-DDI-DrugBank.d448.s3.e0
,;O;O
mecamylamine;B-drug;B-DDI-DrugBank.d448.s3.e1
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d448.s3.e2
,;O;O
and;O;O
veratrum;B-drug;B-DDI-DrugBank.d448.s3.e3
alkaloids;I-drug;I-DDI-DrugBank.d448.s3.e3
may;O;O
be;O;O
reduced;O;O
by;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d448.s3.e4
.;O;O
DDI-DrugBank.d448.s4;;
Beta;B-group;B-DDI-DrugBank.d448.s4.e0
-;I-group;I-DDI-DrugBank.d448.s4.e0
adrenergic;I-group;I-DDI-DrugBank.d448.s4.e0
blocking;I-group;I-DDI-DrugBank.d448.s4.e0
agents;I-group;I-DDI-DrugBank.d448.s4.e0
may;O;O
also;O;O
interact;O;O
with;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d448.s4.e1
.;O;O
DDI-DrugBank.d448.s5;;
Increased;O;O
ectopic;O;O
pacemaker;O;O
activity;O;O
can;O;O
occur;O;O
when;O;O
pseudoephedrine;B-drug;B-DDI-DrugBank.d448.s5.e0
is;O;O
used;O;O
concomitantly;O;O
with;O;O
digitalis;B-group;B-DDI-DrugBank.d448.s5.e1
.;O;O
DDI-DrugBank.d448.s6;;
Antacids;B-group;B-DDI-DrugBank.d448.s6.e0
increase;O;O
the;O;O
rate;O;O
of;O;O
absorption;O;O
of;O;O
pseudoephedrine;B-drug;B-DDI-DrugBank.d448.s6.e1
,;O;O
while;O;O
kaolin;B-drug;B-DDI-DrugBank.d448.s6.e2
decreases;O;O
it;O;O
.;O;O
DDI-DrugBank.d233.s0;;
Use;O;O
with;O;O
Allopurinol;B-drug;B-DDI-DrugBank.d233.s0.e0
:;O;O
The;O;O
principal;O;O
pathway;O;O
for;O;O
detoxification;O;O
of;O;O
azathioprine;B-drug;B-DDI-DrugBank.d233.s0.e1
is;O;O
inhibited;O;O
by;O;O
allopurinol;B-drug;B-DDI-DrugBank.d233.s0.e2
.;O;O
DDI-DrugBank.d233.s1;;
Patients;O;O
receiving;O;O
azathioprine;B-drug;B-DDI-DrugBank.d233.s1.e0
and;O;O
allopurinol;B-drug;B-DDI-DrugBank.d233.s1.e1
concomitantly;O;O
should;O;O
have;O;O
a;O;O
dose;O;O
reduction;O;O
of;O;O
azathioprine;B-drug;B-DDI-DrugBank.d233.s1.e2
,;O;O
to;O;O
approximately;O;O
1;O;O
/;O;O
3;O;O
to;O;O
1;O;O
/;O;O
4;O;O
the;O;O
usual;O;O
dose;O;O
.;O;O
DDI-DrugBank.d233.s2;;
Use;O;O
with;O;O
Other;O;O
Agents;O;O
Affecting;O;O
Myelopoesis;O;O
:;O;O
Drugs;O;O
which;O;O
may;O;O
affect;O;O
leukocyte;O;O
production;O;O
,;O;O
including;O;O
co;B-brand;B-DDI-DrugBank.d233.s2.e0
-;I-brand;I-DDI-DrugBank.d233.s2.e0
trimoxazole;I-brand;I-DDI-DrugBank.d233.s2.e0
,;O;O
may;O;O
lead;O;O
to;O;O
exaggerated;O;O
leukopenia;O;O
,;O;O
especially;O;O
in;O;O
renal;O;O
transplant;O;O
recipients;O;O
.;O;O
DDI-DrugBank.d233.s3;;
Use;O;O
with;O;O
Angiotensln;B-group;B-DDI-DrugBank.d233.s3.e0
Converting;I-group;I-DDI-DrugBank.d233.s3.e0
Enzyme;I-group;I-DDI-DrugBank.d233.s3.e0
Inhibitors;I-group;I-DDI-DrugBank.d233.s3.e0
:;O;O
The;O;O
use;O;O
of;O;O
angiotensin;B-group;B-DDI-DrugBank.d233.s3.e1
converting;I-group;I-DDI-DrugBank.d233.s3.e1
enzyme;I-group;I-DDI-DrugBank.d233.s3.e1
inhibitors;I-group;I-DDI-DrugBank.d233.s3.e1
to;O;O
control;O;O
hypertension;O;O
in;O;O
patients;O;O
on;O;O
azathioprine;B-drug;B-DDI-DrugBank.d233.s3.e2
has;O;O
been;O;O
reported;O;O
to;O;O
induce;O;O
severe;O;O
leukopenia;O;O
.;O;O
DDI-DrugBank.d383.s0;;
No;O;O
information;O;O
provided;O;O
DDI-DrugBank.d53.s0;;
Co;O;O
-;O;O
administration;O;O
of;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d53.s0.e0
at;O;O
steady;O;O
-;O;O
state;O;O
with;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s0.e1
.;O;O
DDI-DrugBank.d53.s1;;
Co;O;O
-;O;O
administration;O;O
of;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d53.s1.e0
at;O;O
steady;O;O
-;O;O
state;O;O
with;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s1.e1
(;O;O
2;O;O
x;O;O
600;O;O
mg;O;O
tablets;O;O
);O;O
results;O;O
in;O;O
increased;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s1.e2
serum;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d53.s2;;
Although;O;O
a;O;O
dose;O;O
adjustment;O;O
of;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s2.e0
is;O;O
not;O;O
recommended;O;O
when;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d53.s2.e1
,;O;O
close;O;O
monitoring;O;O
for;O;O
known;O;O
side;O;O
effects;O;O
of;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s2.e2
,;O;O
such;O;O
as;O;O
liver;O;O
enzyme;O;O
abnormalities;O;O
and;O;O
hearing;O;O
impairment;O;O
,;O;O
is;O;O
warranted;O;O
.;O;O
DDI-DrugBank.d53.s3;;
Azithromycin;B-drug;B-DDI-DrugBank.d53.s3.e0
did;O;O
not;O;O
affect;O;O
the;O;O
prothrombin;O;O
time;O;O
response;O;O
to;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d53.s3.e1
.;O;O
DDI-DrugBank.d53.s4;;
However;O;O
,;O;O
prudent;O;O
medical;O;O
practice;O;O
dictates;O;O
careful;O;O
monitoring;O;O
of;O;O
prothrombin;O;O
time;O;O
in;O;O
all;O;O
patients;O;O
treated;O;O
with;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s4.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d53.s4.e1
concomitantly;O;O
.;O;O
DDI-DrugBank.d53.s5;;
Concurrent;O;O
use;O;O
of;O;O
macrolides;B-group;B-DDI-DrugBank.d53.s5.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d53.s5.e1
in;O;O
clinical;O;O
practice;O;O
has;O;O
been;O;O
associated;O;O
with;O;O
increased;O;O
anticoagulant;O;O
effects;O;O
.;O;O
DDI-DrugBank.d53.s6;;
Drug;O;O
interaction;O;O
studies;O;O
were;O;O
performed;O;O
with;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s6.e0
and;O;O
other;O;O
drugs;O;O
likely;O;O
to;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d53.s7;;
When;O;O
used;O;O
in;O;O
therapeutic;O;O
doses;O;O
,;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s7.e0
had;O;O
a;O;O
modest;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d53.s7.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d53.s7.e2
,;O;O
cetirizine;B-drug;B-DDI-DrugBank.d53.s7.e3
,;O;O
didanosine;B-drug;B-DDI-DrugBank.d53.s7.e4
,;O;O
efavirenz;B-drug;B-DDI-DrugBank.d53.s7.e5
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d53.s7.e6
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d53.s7.e7
,;O;O
midazolam;B-drug;B-DDI-DrugBank.d53.s7.e8
,;O;O
rifabutin;B-drug;B-DDI-DrugBank.d53.s7.e9
,;O;O
sildenafil;B-drug;B-DDI-DrugBank.d53.s7.e10
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d53.s7.e11
(;O;O
intravenous;O;O
and;O;O
oral;O;O
);O;O
,;O;O
triazolam;B-drug;B-DDI-DrugBank.d53.s7.e12
,;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d53.s7.e13
/;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d53.s7.e14
or;O;O
zidovudine;B-drug;B-DDI-DrugBank.d53.s7.e15
.;O;O
DDI-DrugBank.d53.s8;;
Co;O;O
-;O;O
administration;O;O
with;O;O
efavirenz;B-drug;B-DDI-DrugBank.d53.s8.e0
or;O;O
fluconazole;B-drug;B-DDI-DrugBank.d53.s8.e1
had;O;O
a;O;O
modest;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s8.e2
.;O;O
DDI-DrugBank.d53.s9;;
No;O;O
dosage;O;O
adjustment;O;O
of;O;O
either;O;O
drug;O;O
is;O;O
recommended;O;O
when;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s9.e0
is;O;O
co;O;O
administered;O;O
with;O;O
any;O;O
of;O;O
the;O;O
above;O;O
agents;O;O
.;O;O
DDI-DrugBank.d53.s10;;
Interactions;O;O
with;O;O
the;O;O
drugs;O;O
listed;O;O
below;O;O
have;O;O
not;O;O
been;O;O
reported;O;O
in;O;O
clinical;O;O
trials;O;O
with;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s10.e0
,;O;O
DDI-DrugBank.d53.s11;;
however;O;O
,;O;O
no;O;O
specific;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
to;O;O
evaluate;O;O
potential;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d53.s12;;
Nonetheless;O;O
,;O;O
they;O;O
have;O;O
been;O;O
observed;O;O
with;O;O
macrolide;B-group;B-DDI-DrugBank.d53.s12.e0
products;I-group;I-DDI-DrugBank.d53.s12.e0
.;O;O
DDI-DrugBank.d53.s13;;
Until;O;O
further;O;O
data;O;O
are;O;O
developed;O;O
regarding;O;O
drug;O;O
interactions;O;O
when;O;O
azithromycin;B-drug;B-DDI-DrugBank.d53.s13.e0
and;O;O
these;O;O
drugs;O;O
are;O;O
used;O;O
concomitantly;O;O
,;O;O
careful;O;O
monitoring;O;O
of;O;O
patients;O;O
is;O;O
advised;O;O
:;O;O
Digoxin;B-drug;B-DDI-DrugBank.d53.s13.e1
elevated;O;O
digoxin;B-drug;B-DDI-DrugBank.d53.s13.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d53.s14;;
Ergotamine;B-drug;B-DDI-DrugBank.d53.s14.e0
or;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d53.s14.e1
acute;O;O
ergot;O;O
toxicity;O;O
characterized;O;O
by;O;O
severe;O;O
peripheral;O;O
vasospasm;O;O
and;O;O
dysesthesia;O;O
.;O;O
DDI-DrugBank.d53.s15;;
Cyclosporine;B-drug;B-DDI-DrugBank.d53.s15.e0
,;O;O
hexobarbital;B-drug;B-DDI-DrugBank.d53.s15.e1
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d53.s15.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d53.s16;;
Laboratory;O;O
Test;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
reported;O;O
laboratory;O;O
test;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d53.s17;;
Repeat;O;O
Treatment;O;O
Studies;O;O
evaluating;O;O
the;O;O
use;O;O
of;O;O
repeated;O;O
courses;O;O
of;O;O
Zmax;B-brand;B-DDI-DrugBank.d53.s17.e0
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d9.s0;;
Azlocillin;B-drug;B-DDI-DrugBank.d9.s0.e0
should;O;O
not;O;O
be;O;O
administered;O;O
concomitantly;O;O
with;O;O
amikacin;B-drug;B-DDI-DrugBank.d9.s0.e1
,;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d9.s0.e2
,;O;O
gentamicin;B-drug;B-DDI-DrugBank.d9.s0.e3
,;O;O
netilmicin;B-drug;B-DDI-DrugBank.d9.s0.e4
,;O;O
or;O;O
tobramycin;B-drug;B-DDI-DrugBank.d9.s0.e5
.;O;O
DDI-DrugBank.d523.s0;;
Injection;O;O
There;O;O
is;O;O
inadequate;O;O
systematic;O;O
experience;O;O
with;O;O
the;O;O
use;O;O
of;O;O
baclofen;B-drug;B-DDI-DrugBank.d523.s0.e0
injection;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
medications;O;O
to;O;O
predict;O;O
specific;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d523.s1;;
Interactions;O;O
attributed;O;O
to;O;O
the;O;O
combined;O;O
use;O;O
of;O;O
baclofen;B-drug;B-DDI-DrugBank.d523.s1.e0
injection;O;O
and;O;O
epidural;O;O
morphine;B-drug;B-DDI-DrugBank.d523.s1.e1
include;O;O
hypotension;O;O
and;O;O
dyspnea;O;O
.;O;O
DDI-DrugBank.d523.s2;;
SIDE;O;O
EFFECTS;O;O
(;O;O
KEMSTRO;B-brand;B-DDI-DrugBank.d523.s2.e0
);O;O
The;O;O
most;O;O
common;O;O
adverse;O;O
reaction;O;O
during;O;O
treatment;O;O
with;O;O
baclofen;B-drug;B-DDI-DrugBank.d523.s2.e1
is;O;O
transient;O;O
drowsiness;O;O
(;O;O
10;O;O
-;O;O
63;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d523.s3;;
In;O;O
one;O;O
controlled;O;O
study;O;O
of;O;O
175;O;O
patients;O;O
,;O;O
transient;O;O
drowsiness;O;O
was;O;O
observed;O;O
in;O;O
63;O;O
%;O;O
of;O;O
those;O;O
receiving;O;O
baclofen;B-drug;B-DDI-DrugBank.d523.s3.e0
tablets;O;O
compared;O;O
to;O;O
36;O;O
%;O;O
of;O;O
those;O;O
in;O;O
the;O;O
placebo;O;O
group;O;O
.;O;O
DDI-DrugBank.d523.s4;;
Other;O;O
common;O;O
adverse;O;O
reactions;O;O
are;O;O
dizziness;O;O
(;O;O
5;O;O
-;O;O
15;O;O
%;O;O
);O;O
,;O;O
weakness;O;O
(;O;O
5;O;O
-;O;O
15;O;O
%;O;O
);O;O
and;O;O
fatigue;O;O
(;O;O
2;O;O
-;O;O
4;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d523.s5;;
Others;O;O
reported;O;O
:;O;O
Neuropsychiatric;O;O
:;O;O
Confusion;O;O
(;O;O
1;O;O
-;O;O
11;O;O
%;O;O
);O;O
,;O;O
headache;O;O
(;O;O
4;O;O
-;O;O
8;O;O
%;O;O
);O;O
,;O;O
insomnia;O;O
(;O;O
2;O;O
-;O;O
7;O;O
%;O;O
);O;O
,;O;O
DDI-DrugBank.d523.s6;;
and;O;O
,;O;O
rarely;O;O
,;O;O
euphoria;O;O
,;O;O
excitement;O;O
,;O;O
depression;O;O
,;O;O
hallucinations;O;O
,;O;O
paresthesia;O;O
,;O;O
muscle;O;O
pain;O;O
,;O;O
tinnitus;O;O
,;O;O
slurred;O;O
speech;O;O
,;O;O
coordination;O;O
disorder;O;O
,;O;O
tremor;O;O
,;O;O
rigidity;O;O
,;O;O
dystonia;O;O
,;O;O
ataxia;O;O
,;O;O
blurred;O;O
vision;O;O
,;O;O
nystagmus;O;O
,;O;O
strabismus;O;O
,;O;O
miosis;O;O
,;O;O
mydriasis;O;O
,;O;O
diplopia;O;O
,;O;O
dysarthria;O;O
,;O;O
epileptic;O;O
seizure;O;O
.;O;O
DDI-DrugBank.d523.s7;;
Cardiovascular;O;O
:;O;O
Hypotension;O;O
(;O;O
0;O;O
-;O;O
9;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d523.s8;;
Rare;O;O
instances;O;O
of;O;O
dyspnea;O;O
,;O;O
palpitation;O;O
,;O;O
chest;O;O
pain;O;O
,;O;O
syncope;O;O
.;O;O
DDI-DrugBank.d523.s9;;
Gastrointestinal;O;O
:;O;O
Nausea;O;O
(;O;O
4;O;O
-;O;O
12;O;O
%;O;O
);O;O
,;O;O
constipation;O;O
(;O;O
2;O;O
-;O;O
6;O;O
%;O;O
);O;O
,;O;O
DDI-DrugBank.d523.s10;;
and;O;O
,;O;O
rarely;O;O
,;O;O
dry;O;O
mouth;O;O
,;O;O
anorexia;O;O
,;O;O
taste;O;O
disorder;O;O
,;O;O
abdominal;O;O
pain;O;O
,;O;O
vomiting;O;O
,;O;O
diarrhea;O;O
,;O;O
and;O;O
positive;O;O
test;O;O
for;O;O
occult;O;O
blood;O;O
in;O;O
stool;O;O
.;O;O
DDI-DrugBank.d523.s11;;
Genitourinary;O;O
:;O;O
Urinary;O;O
frequency;O;O
(;O;O
2;O;O
-;O;O
6;O;O
%;O;O
);O;O
,;O;O
DDI-DrugBank.d523.s12;;
and;O;O
,;O;O
rarely;O;O
,;O;O
enuresis;O;O
,;O;O
urinary;O;O
retention;O;O
,;O;O
dysuria;O;O
,;O;O
impotence;O;O
,;O;O
inability;O;O
to;O;O
ejaculate;O;O
,;O;O
nocturia;O;O
,;O;O
hematuria;O;O
.;O;O
DDI-DrugBank.d523.s13;;
Other;O;O
:;O;O
Instances;O;O
of;O;O
rash;O;O
,;O;O
pruritus;O;O
,;O;O
ankle;O;O
edema;O;O
,;O;O
excessive;O;O
perspiration;O;O
,;O;O
weight;O;O
gain;O;O
,;O;O
nasal;O;O
congestion;O;O
.;O;O
DDI-DrugBank.d523.s14;;
Some;O;O
of;O;O
the;O;O
CNS;O;O
and;O;O
genitourinary;O;O
symptoms;O;O
may;O;O
be;O;O
related;O;O
to;O;O
the;O;O
underlying;O;O
disease;O;O
rather;O;O
than;O;O
to;O;O
drug;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d523.s15;;
The;O;O
following;O;O
laboratory;O;O
tests;O;O
have;O;O
been;O;O
found;O;O
to;O;O
be;O;O
abnormal;O;O
in;O;O
a;O;O
few;O;O
patients;O;O
receiving;O;O
baclofen;B-drug;B-DDI-DrugBank.d523.s15.e0
:;O;O
increased;O;O
SGOT;O;O
,;O;O
elevated;O;O
alkaline;O;O
phosphatase;O;O
,;O;O
and;O;O
elevation;O;O
of;O;O
blood;O;O
sugar;O;O
.;O;O
DDI-DrugBank.d523.s16;;
The;O;O
adverse;O;O
experience;O;O
profile;O;O
seen;O;O
with;O;O
KEMSTROTM;B-brand;B-DDI-DrugBank.d523.s16.e0
was;O;O
similar;O;O
to;O;O
that;O;O
seen;O;O
with;O;O
baclofen;B-drug;B-DDI-DrugBank.d523.s16.e1
tablets;O;O
.;O;O
DDI-DrugBank.d486.s0;;
No;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
for;O;O
COLAZAL;B-brand;B-DDI-DrugBank.d486.s0.e0
,;O;O
however;O;O
the;O;O
use;O;O
of;O;O
orally;O;O
administered;O;O
antibiotics;B-group;B-DDI-DrugBank.d486.s0.e1
could;O;O
,;O;O
theoretically;O;O
,;O;O
interfere;O;O
with;O;O
the;O;O
release;O;O
of;O;O
mesalamine;B-drug;B-DDI-DrugBank.d486.s0.e2
in;O;O
the;O;O
colon;O;O
.;O;O
DDI-DrugBank.d544.s0;;
No;O;O
dose;O;O
adjustment;O;O
is;O;O
necessary;O;O
when;O;O
Simulect;B-brand;B-DDI-DrugBank.d544.s0.e0
is;O;O
added;O;O
to;O;O
triple;O;O
-;O;O
immunosuppression;O;O
regimens;O;O
including;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d544.s0.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d544.s0.e2
,;O;O
and;O;O
either;O;O
azathioprine;B-drug;B-DDI-DrugBank.d544.s0.e3
or;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d544.s0.e4
mofetil;I-drug;I-DDI-DrugBank.d544.s0.e4
.;O;O
DDI-DrugBank.d544.s1;;
Three;O;O
clinical;O;O
trials;O;O
have;O;O
investigated;O;O
Simulect;B-brand;B-DDI-DrugBank.d544.s1.e0
use;O;O
in;O;O
combination;O;O
with;O;O
triple;O;O
-;O;O
therapy;O;O
regimens;O;O
.;O;O
DDI-DrugBank.d544.s2;;
Pharmacokinetics;O;O
were;O;O
assessed;O;O
in;O;O
two;O;O
of;O;O
these;O;O
trials;O;O
.;O;O
DDI-DrugBank.d544.s3;;
Total;O;O
body;O;O
clearance;O;O
of;O;O
Simulect;B-brand;B-DDI-DrugBank.d544.s3.e0
was;O;O
reduced;O;O
by;O;O
an;O;O
average;O;O
22;O;O
%;O;O
and;O;O
51;O;O
%;O;O
when;O;O
azathioprine;B-drug;B-DDI-DrugBank.d544.s3.e1
and;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d544.s3.e2
mofetil;I-drug;I-DDI-DrugBank.d544.s3.e2
,;O;O
respectively;O;O
,;O;O
were;O;O
added;O;O
to;O;O
a;O;O
regimen;O;O
consisting;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d544.s3.e3
,;O;O
USP;O;O
(;O;O
MODIFIED;O;O
);O;O
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d544.s3.e4
.;O;O
DDI-DrugBank.d544.s4;;
Nonetheless;O;O
,;O;O
the;O;O
range;O;O
of;O;O
individual;O;O
Simulect;B-brand;B-DDI-DrugBank.d544.s4.e0
clearance;O;O
values;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
azathioprine;B-drug;B-DDI-DrugBank.d544.s4.e1
(;O;O
12;O;O
-;O;O
57;O;O
mL;O;O
/;O;O
h;O;O
);O;O
or;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d544.s4.e2
mofetil;I-drug;I-DDI-DrugBank.d544.s4.e2
(;O;O
7;O;O
-;O;O
54;O;O
mL;O;O
/;O;O
h;O;O
);O;O
did;O;O
not;O;O
extend;O;O
outside;O;O
the;O;O
range;O;O
observed;O;O
with;O;O
dual;O;O
therapy;O;O
(;O;O
10;O;O
-;O;O
78;O;O
mL;O;O
/;O;O
h;O;O
);O;O
.;O;O
DDI-DrugBank.d544.s5;;
The;O;O
following;O;O
medications;O;O
have;O;O
been;O;O
administered;O;O
in;O;O
clinical;O;O
trials;O;O
with;O;O
Simulect;B-brand;B-DDI-DrugBank.d544.s5.e0
with;O;O
no;O;O
increase;O;O
in;O;O
adverse;O;O
reactions;O;O
:;O;O
ATG;O;O
/;O;O
ALG;O;O
,;O;O
azathioprine;B-drug;B-DDI-DrugBank.d544.s5.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d544.s5.e2
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d544.s5.e3
,;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d544.s5.e4
mofetil;I-drug;I-DDI-DrugBank.d544.s5.e4
,;O;O
and;O;O
muromonab;B-drug;B-DDI-DrugBank.d544.s5.e5
-;I-drug;I-DDI-DrugBank.d544.s5.e5
CD3;I-drug;I-DDI-DrugBank.d544.s5.e5
.;O;O
DDI-DrugBank.d385.s0;;
It;O;O
is;O;O
not;O;O
known;O;O
if;O;O
REGRANEX;B-brand;B-DDI-DrugBank.d385.s0.e0
Gel;O;O
interacts;O;O
with;O;O
other;O;O
topical;O;O
medications;O;O
applied;O;O
to;O;O
the;O;O
ulcer;O;O
site;O;O
.;O;O
DDI-DrugBank.d385.s1;;
The;O;O
use;O;O
of;O;O
REGRANEX;B-brand;B-DDI-DrugBank.d385.s1.e0
Gel;O;O
with;O;O
other;O;O
topical;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d524.s0;;
Albuterol;B-drug;B-DDI-DrugBank.d524.s0.e0
,;O;O
Antihistamines;B-group;B-DDI-DrugBank.d524.s0.e1
,;O;O
antidiabetic;B-group;B-DDI-DrugBank.d524.s0.e2
drugs;I-group;I-DDI-DrugBank.d524.s0.e2
,;O;O
diuretics;B-group;B-DDI-DrugBank.d524.s0.e3
,;O;O
digitalis;B-group;B-DDI-DrugBank.d524.s0.e4
.;O;O
DDI-DrugBank.d561.s0;;
Diuretics;B-group;B-DDI-DrugBank.d561.s0.e0
:;O;O
Patients;O;O
on;O;O
diuretics;B-group;B-DDI-DrugBank.d561.s0.e1
,;O;O
especially;O;O
those;O;O
in;O;O
whom;O;O
diuretic;O;O
therapy;O;O
was;O;O
recently;O;O
instituted;O;O
,;O;O
may;O;O
occasionally;O;O
experience;O;O
an;O;O
excessive;O;O
reduction;O;O
of;O;O
blood;O;O
pressure;O;O
after;O;O
initiation;O;O
of;O;O
therapy;O;O
with;O;O
Lotensin;B-brand;B-DDI-DrugBank.d561.s0.e2
.;O;O
DDI-DrugBank.d561.s1;;
The;O;O
possibility;O;O
of;O;O
hypotensive;O;O
effects;O;O
with;O;O
Lotensin;B-brand;B-DDI-DrugBank.d561.s1.e0
can;O;O
be;O;O
minimized;O;O
by;O;O
either;O;O
discontinuing;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d561.s1.e1
or;O;O
increasing;O;O
the;O;O
salt;O;O
intake;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
Lotensin;B-brand;B-DDI-DrugBank.d561.s1.e2
.;O;O
DDI-DrugBank.d561.s2;;
If;O;O
this;O;O
is;O;O
not;O;O
possible;O;O
,;O;O
the;O;O
starting;O;O
dose;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d561.s3;;
Potassium;B-drug;B-DDI-DrugBank.d561.s3.e0
Supplements;O;O
and;O;O
Potassium;B-group;B-DDI-DrugBank.d561.s3.e1
-;I-group;I-DDI-DrugBank.d561.s3.e1
Sparing;I-group;I-DDI-DrugBank.d561.s3.e1
Diuretics;I-group;I-DDI-DrugBank.d561.s3.e1
Lotensin;O;O
can;O;O
attenuate;O;O
potassium;O;O
loss;O;O
caused;O;O
by;O;O
thiazide;B-group;B-DDI-DrugBank.d561.s3.e2
diuretics;I-group;I-DDI-DrugBank.d561.s3.e2
.;O;O
DDI-DrugBank.d561.s4;;
Potassium;B-group;B-DDI-DrugBank.d561.s4.e0
-;I-group;I-DDI-DrugBank.d561.s4.e0
sparing;I-group;I-DDI-DrugBank.d561.s4.e0
diuretics;I-group;I-DDI-DrugBank.d561.s4.e0
(;O;O
spironolactone;B-drug;B-DDI-DrugBank.d561.s4.e1
,;O;O
amiloride;B-drug;B-DDI-DrugBank.d561.s4.e2
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d561.s4.e3
,;O;O
and;O;O
others;O;O
);O;O
or;O;O
potassium;B-drug;B-DDI-DrugBank.d561.s4.e4
supplements;O;O
can;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
hyperkalemia;O;O
.;O;O
DDI-DrugBank.d561.s5;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
use;O;O
of;O;O
such;O;O
agents;O;O
is;O;O
indicated;O;O
,;O;O
they;O;O
should;O;O
be;O;O
given;O;O
with;O;O
caution;O;O
,;O;O
and;O;O
the;O;O
patient;O;O
's;O;O
serum;O;O
potassium;O;O
should;O;O
be;O;O
monitored;O;O
frequently;O;O
.;O;O
DDI-DrugBank.d561.s6;;
Oral;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d561.s6.e0
Interaction;O;O
studies;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d561.s6.e1
and;O;O
acenocoumarol;B-drug;B-DDI-DrugBank.d561.s6.e2
failed;O;O
to;O;O
identify;O;O
any;O;O
clinically;O;O
important;O;O
effects;O;O
on;O;O
the;O;O
serum;O;O
concentrations;O;O
or;O;O
clinical;O;O
effects;O;O
of;O;O
these;O;O
anticoagulants;B-group;B-DDI-DrugBank.d561.s6.e3
.;O;O
DDI-DrugBank.d561.s7;;
Lithium;B-drug;B-DDI-DrugBank.d561.s7.e0
:;O;O
Increased;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d561.s7.e1
levels;O;O
and;O;O
symptoms;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d561.s7.e2
toxicity;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
ACE;B-group;B-DDI-DrugBank.d561.s7.e3
inhibitors;I-group;I-DDI-DrugBank.d561.s7.e3
during;O;O
therapy;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d561.s7.e4
.;O;O
DDI-DrugBank.d561.s8;;
These;O;O
drugs;O;O
should;O;O
be;O;O
coadministered;O;O
with;O;O
caution;O;O
,;O;O
and;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d561.s8.e0
levels;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d561.s9;;
If;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d561.s9.e0
is;O;O
also;O;O
used;O;O
,;O;O
the;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d561.s9.e1
toxicity;O;O
may;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d561.s10;;
Other;O;O
No;O;O
clinically;O;O
important;O;O
pharmacokinetic;O;O
interactions;O;O
occurred;O;O
when;O;O
Lotensin;B-brand;B-DDI-DrugBank.d561.s10.e0
was;O;O
administered;O;O
concomitantly;O;O
with;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d561.s10.e1
,;O;O
chlorthalidone;B-drug;B-DDI-DrugBank.d561.s10.e2
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d561.s10.e3
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d561.s10.e4
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d561.s10.e5
,;O;O
atenolol;B-drug;B-DDI-DrugBank.d561.s10.e6
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d561.s10.e7
,;O;O
or;O;O
cimetidine;B-drug;B-DDI-DrugBank.d561.s10.e8
.;O;O
DDI-DrugBank.d561.s11;;
Lotensin;B-brand;B-DDI-DrugBank.d561.s11.e0
has;O;O
been;O;O
used;O;O
concomitantly;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d561.s11.e1
-;I-group;I-DDI-DrugBank.d561.s11.e1
adrenergic;I-group;I-DDI-DrugBank.d561.s11.e1
-;I-group;I-DDI-DrugBank.d561.s11.e1
blocking;I-group;I-DDI-DrugBank.d561.s11.e1
agents;I-group;I-DDI-DrugBank.d561.s11.e1
,;O;O
calcium;B-group;B-DDI-DrugBank.d561.s11.e2
-;I-group;I-DDI-DrugBank.d561.s11.e2
channel;I-group;I-DDI-DrugBank.d561.s11.e2
-;I-group;I-DDI-DrugBank.d561.s11.e2
blocking;I-group;I-DDI-DrugBank.d561.s11.e2
agents;I-group;I-DDI-DrugBank.d561.s11.e2
,;O;O
diuretics;B-group;B-DDI-DrugBank.d561.s11.e3
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d561.s11.e4
,;O;O
and;O;O
hydralazine;B-drug;B-DDI-DrugBank.d561.s11.e5
,;O;O
without;O;O
evidence;O;O
of;O;O
clinically;O;O
important;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d561.s12;;
Benazepril;B-drug;B-DDI-DrugBank.d561.s12.e0
,;O;O
like;O;O
other;O;O
ACE;B-group;B-DDI-DrugBank.d561.s12.e1
inhibitors;I-group;I-DDI-DrugBank.d561.s12.e1
,;O;O
has;O;O
had;O;O
less;O;O
than;O;O
additive;O;O
effects;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d561.s12.e2
-;I-group;I-DDI-DrugBank.d561.s12.e2
adrenergic;I-group;I-DDI-DrugBank.d561.s12.e2
blockers;I-group;I-DDI-DrugBank.d561.s12.e2
,;O;O
presumably;O;O
because;O;O
both;O;O
drugs;O;O
lower;O;O
blood;O;O
pressure;O;O
by;O;O
inhibiting;O;O
parts;O;O
of;O;O
the;O;O
renin;O;O
-;O;O
angiotensin;O;O
system;O;O
DDI-DrugBank.d561.s13;;
.;O;O
DDI-DrugBank.d561.s14;;
DDI-DrugBank.d304.s0;;
May;O;O
interact;O;O
with;O;O
the;O;O
following;O;O
:;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d304.s0.e0
,;O;O
colestipol;B-drug;B-DDI-DrugBank.d304.s0.e1
(;O;O
use;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d304.s0.e2
diuretics;I-group;I-DDI-DrugBank.d304.s0.e2
may;O;O
prevent;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d304.s0.e3
from;O;O
working;O;O
properly;O;O
,;O;O
DDI-DrugBank.d537.s0;;
Bentiromide;B-drug;B-DDI-DrugBank.d537.s0.e0
may;O;O
interact;O;O
with;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d537.s0.e1
(;O;O
e.g.;O;O
,;O;O
Tylenol;B-brand;B-DDI-DrugBank.d537.s0.e2
);O;O
,;O;O
chloramphenicol;B-drug;B-DDI-DrugBank.d537.s0.e3
(;O;O
e.g.;O;O
,;O;O
Chloromycetin;B-brand;B-DDI-DrugBank.d537.s0.e4
);O;O
,;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d537.s0.e5
(;O;O
e.g.;O;O
,;O;O
benzocaine;B-drug;B-DDI-DrugBank.d537.s0.e6
and;O;O
lidocaine;B-drug;B-DDI-DrugBank.d537.s0.e7
);O;O
,;O;O
para;B-drug_n;B-DDI-DrugBank.d537.s0.e8
-;I-drug_n;I-DDI-DrugBank.d537.s0.e8
aminobenzoic;I-drug_n;I-DDI-DrugBank.d537.s0.e8
acid;I-drug_n;I-DDI-DrugBank.d537.s0.e8
(;O;O
PABA);B-drug_n;B-DDI-DrugBank.d537.s0.e9
-;O;O
containing;O;O
preparations;O;O
(;O;O
e.g.;O;O
,;O;O
sunscreens;O;O
and;O;O
some;O;O
multivitamins;B-group;B-DDI-DrugBank.d537.s0.e10
);O;O
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d537.s0.e11
(;O;O
e.g.;O;O
,;O;O
Pronestyl;B-brand;B-DDI-DrugBank.d537.s0.e12
);O;O
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d537.s0.e13
(;O;O
sulfa;O;O
medicines;O;O
);O;O
,;O;O
thiazide;B-group;B-DDI-DrugBank.d537.s0.e14
diuretics;I-group;I-DDI-DrugBank.d537.s0.e14
(;O;O
use;O;O
of;O;O
these;O;O
medicines;O;O
during;O;O
the;O;O
test;O;O
period;O;O
will;O;O
affect;O;O
the;O;O
test;O;O
results;O;O
);O;O
,;O;O
and;O;O
pancreatic;O;O
supplements;O;O
(;O;O
use;O;O
of;O;O
pancreatic;O;O
supplements;O;O
may;O;O
give;O;O
false;O;O
test;O;O
results;O;O
);O;O
.;O;O
DDI-DrugBank.d173.s0;;
May;O;O
interact;O;O
with;O;O
other;O;O
creams;O;O
,;O;O
lotions;O;O
,;O;O
or;O;O
skin;O;O
medicines;O;O
when;O;O
placed;O;O
on;O;O
the;O;O
same;O;O
areas;O;O
of;O;O
your;O;O
skin;O;O
that;O;O
you;O;O
are;O;O
using;O;O
bentoquatam;B-drug_n;B-DDI-DrugBank.d173.s0.e0
.;O;O
DDI-DrugBank.d24.s0;;
No;O;O
information;O;O
is;O;O
available;O;O
.;O;O
DDI-DrugBank.d477.s0;;
Hypertensive;O;O
crises;O;O
have;O;O
resulted;O;O
when;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d477.s0.e0
amines;I-group;I-DDI-DrugBank.d477.s0.e0
have;O;O
been;O;O
used;O;O
concomitantly;O;O
within14;O;O
days;O;O
following;O;O
use;O;O
of;O;O
monoamine;B-group;B-DDI-DrugBank.d477.s0.e1
oxidase;I-group;I-DDI-DrugBank.d477.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d477.s0.e1
.;O;O
DDI-DrugBank.d477.s1;;
DIDREX;B-brand;B-DDI-DrugBank.d477.s1.e0
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
with;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d477.s1.e1
stimulants;I-group;I-DDI-DrugBank.d477.s1.e1
.;O;O
DDI-DrugBank.d477.s2;;
Amphetamines;B-group;B-DDI-DrugBank.d477.s2.e0
may;O;O
decrease;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
antihypertensives;B-group;B-DDI-DrugBank.d477.s2.e1
.;O;O
DDI-DrugBank.d477.s3;;
Amphetamines;B-group;B-DDI-DrugBank.d477.s3.e0
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d477.s3.e1
antidepressants;I-group;I-DDI-DrugBank.d477.s3.e1
.;O;O
DDI-DrugBank.d477.s4;;
Urinary;O;O
alkalinizing;O;O
agents;O;O
increase;O;O
blood;O;O
levels;O;O
and;O;O
decrease;O;O
excretion;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d477.s4.e0
.;O;O
DDI-DrugBank.d477.s5;;
Urinary;B-drug;B-DDI-DrugBank.d477.s5.e0
acidifying;I-drug;I-DDI-DrugBank.d477.s5.e0
agents;O;O
decrease;O;O
blood;O;O
levels;O;O
and;O;O
increase;O;O
excretion;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d477.s5.e1
.;O;O
DDI-DrugBank.d208.s0;;
Benzthiazide;B-drug;B-DDI-DrugBank.d208.s0.e0
may;O;O
interact;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d208.s0.e1
,;O;O
blood;B-group;B-DDI-DrugBank.d208.s0.e2
thinners;I-group;I-DDI-DrugBank.d208.s0.e2
,;O;O
decongestant;B-group;B-DDI-DrugBank.d208.s0.e3
drugs;I-group;I-DDI-DrugBank.d208.s0.e3
(;O;O
allergy;O;O
,;O;O
cold;O;O
,;O;O
and;O;O
sinus;O;O
medicines;O;O
);O;O
,;O;O
diabetic;O;O
drugs;O;O
,;O;O
lithium;B-drug;B-DDI-DrugBank.d208.s0.e4
,;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d208.s0.e5
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d208.s0.e6
like;O;O
Aleve;B-brand;B-DDI-DrugBank.d208.s0.e7
or;O;O
Ibuprofen;B-drug;B-DDI-DrugBank.d208.s0.e8
,;O;O
and;O;O
high;O;O
blood;O;O
pressure;O;O
medications;O;O
.;O;O
DDI-DrugBank.d390.s0;;
Antipsychotic;B-group;B-DDI-DrugBank.d390.s0.e0
drugs;I-group;I-DDI-DrugBank.d390.s0.e0
such;O;O
as;O;O
phenothiazines;B-group;B-DDI-DrugBank.d390.s0.e1
or;O;O
haloperidol;B-drug;B-DDI-DrugBank.d390.s0.e2
,;O;O
DDI-DrugBank.d390.s1;;
tricyclic;B-group;B-DDI-DrugBank.d390.s1.e0
antidepressants;I-group;I-DDI-DrugBank.d390.s1.e0
.;O;O
DDI-DrugBank.d137.s0;;
Nitrates;B-group;B-DDI-DrugBank.d137.s0.e0
:;O;O
The;O;O
concomitant;O;O
use;O;O
of;O;O
Bepridil;B-drug;B-DDI-DrugBank.d137.s0.e1
with;O;O
long;O;O
-;O;O
and;O;O
short;O;O
-;O;O
acting;O;O
nitrates;B-group;B-DDI-DrugBank.d137.s0.e2
has;O;O
been;O;O
safely;O;O
tolerated;O;O
in;O;O
patients;O;O
with;O;O
stable;O;O
angina;O;O
pectoris;O;O
.;O;O
DDI-DrugBank.d137.s1;;
Sublingual;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d137.s1.e0
may;O;O
be;O;O
taken;O;O
if;O;O
necessary;O;O
for;O;O
the;O;O
control;O;O
of;O;O
acute;O;O
angina;O;O
attacks;O;O
during;O;O
Bepridil;B-drug;B-DDI-DrugBank.d137.s1.e1
therapy;O;O
.;O;O
DDI-DrugBank.d137.s2;;
Beta;B-group;B-DDI-DrugBank.d137.s2.e0
-;I-group;I-DDI-DrugBank.d137.s2.e0
blocking;I-group;I-DDI-DrugBank.d137.s2.e0
Agents;I-group;I-DDI-DrugBank.d137.s2.e0
:;O;O
The;O;O
concomitant;O;O
use;O;O
of;O;O
Bepridil;B-drug;B-DDI-DrugBank.d137.s2.e1
and;O;O
beta;B-group;B-DDI-DrugBank.d137.s2.e2
-;I-group;I-DDI-DrugBank.d137.s2.e2
blocking;I-group;I-DDI-DrugBank.d137.s2.e2
agents;I-group;I-DDI-DrugBank.d137.s2.e2
has;O;O
been;O;O
well;O;O
tolerated;O;O
in;O;O
patients;O;O
with;O;O
stable;O;O
angina;O;O
.;O;O
DDI-DrugBank.d137.s3;;
Available;O;O
data;O;O
are;O;O
not;O;O
sufficient;O;O
,;O;O
however;O;O
,;O;O
to;O;O
predict;O;O
the;O;O
effects;O;O
of;O;O
concomitant;O;O
medication;O;O
on;O;O
patients;O;O
with;O;O
impaired;O;O
ventricular;O;O
function;O;O
or;O;O
cardiac;O;O
conduction;O;O
abnormalities;O;O
.;O;O
DDI-DrugBank.d137.s4;;
Digoxin;B-drug;B-DDI-DrugBank.d137.s4.e0
:;O;O
In;O;O
controlled;O;O
studies;O;O
in;O;O
healthy;O;O
volunteers;O;O
,;O;O
bepridil;B-drug;B-DDI-DrugBank.d137.s4.e1
hydrochloride;I-drug;I-DDI-DrugBank.d137.s4.e1
either;O;O
had;O;O
no;O;O
effect;O;O
(;O;O
one;O;O
study;O;O
);O;O
or;O;O
was;O;O
associated;O;O
with;O;O
modest;O;O
increases;O;O
,;O;O
about;O;O
30;O;O
%;O;O
(;O;O
two;O;O
studies;O;O
);O;O
in;O;O
steady;O;O
-;O;O
state;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d137.s4.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d137.s5;;
Limited;O;O
clinical;O;O
data;O;O
in;O;O
angina;O;O
patients;O;O
receiving;O;O
concomitant;O;O
bepridil;B-drug;B-DDI-DrugBank.d137.s5.e0
hydrochloride;I-drug;I-DDI-DrugBank.d137.s5.e0
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d137.s5.e1
therapy;O;O
indicate;O;O
no;O;O
discernible;O;O
changes;O;O
in;O;O
serum;O;O
digoxin;O;O
levels;O;O
.;O;O
DDI-DrugBank.d137.s6;;
Available;O;O
data;O;O
are;O;O
neither;O;O
sufficient;O;O
to;O;O
rule;O;O
out;O;O
possible;O;O
increases;O;O
in;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d137.s6.e0
with;O;O
concomitant;O;O
treatment;O;O
in;O;O
some;O;O
patients;O;O
,;O;O
nor;O;O
other;O;O
possible;O;O
interactions;O;O
,;O;O
particularly;O;O
in;O;O
patients;O;O
with;O;O
cardiac;O;O
conduction;O;O
abnormalities;O;O
(;O;O
Also;O;O
see;O;O
WARNINGS;O;O
Congestive;O;O
Heart;O;O
Failure;O;O
);O;O
.;O;O
DDI-DrugBank.d137.s7;;
Oral;O;O
Hypoglycemics;B-group;B-DDI-DrugBank.d137.s7.e0
:;O;O
Bepridil;B-drug;B-DDI-DrugBank.d137.s7.e1
has;O;O
been;O;O
safely;O;O
used;O;O
in;O;O
diabetic;O;O
patients;O;O
without;O;O
significantly;O;O
lowering;O;O
their;O;O
blood;O;O
glucose;O;O
levels;O;O
or;O;O
altering;O;O
their;O;O
need;O;O
for;O;O
insulin;B-drug;B-DDI-DrugBank.d137.s7.e2
or;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d137.s7.e3
agents;I-group;I-DDI-DrugBank.d137.s7.e3
.;O;O
DDI-DrugBank.d137.s8;;
General;O;O
Interactions;O;O
:;O;O
Certain;O;O
drugs;O;O
could;O;O
increase;O;O
the;O;O
likelihood;O;O
of;O;O
potentially;O;O
serious;O;O
adverse;O;O
effects;O;O
with;O;O
bepridil;B-drug;B-DDI-DrugBank.d137.s8.e0
hydrochloride;I-drug;I-DDI-DrugBank.d137.s8.e0
.;O;O
DDI-DrugBank.d137.s9;;
In;O;O
general;O;O
,;O;O
these;O;O
are;O;O
drugs;O;O
that;O;O
have;O;O
one;O;O
or;O;O
more;O;O
pharmacologic;O;O
activities;O;O
similar;O;O
to;O;O
bepridil;B-drug;B-DDI-DrugBank.d137.s9.e0
hydrochloride;I-drug;I-DDI-DrugBank.d137.s9.e0
,;O;O
including;O;O
anti;B-group;B-DDI-DrugBank.d137.s9.e1
-;I-group;I-DDI-DrugBank.d137.s9.e1
arrhythmic;I-group;I-DDI-DrugBank.d137.s9.e1
agents;I-group;I-DDI-DrugBank.d137.s9.e1
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d137.s9.e2
and;O;O
procainamide;B-drug;B-DDI-DrugBank.d137.s9.e3
,;O;O
cardiac;B-group;B-DDI-DrugBank.d137.s9.e4
glycosides;I-group;I-DDI-DrugBank.d137.s9.e4
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d137.s9.e5
anti;I-group;I-DDI-DrugBank.d137.s9.e5
-;I-group;I-DDI-DrugBank.d137.s9.e5
depressants;I-group;I-DDI-DrugBank.d137.s9.e5
.;O;O
DDI-DrugBank.d137.s10;;
Anti;B-group;B-DDI-DrugBank.d137.s10.e0
-;I-group;I-DDI-DrugBank.d137.s10.e0
arrhythmics;I-group;I-DDI-DrugBank.d137.s10.e0
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d137.s10.e1
anti;I-group;I-DDI-DrugBank.d137.s10.e1
-;I-group;I-DDI-DrugBank.d137.s10.e1
depressants;I-group;I-DDI-DrugBank.d137.s10.e1
could;O;O
exaggerate;O;O
the;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
observed;O;O
with;O;O
bepridil;B-drug;B-DDI-DrugBank.d137.s10.e2
hydrochloride;I-drug;I-DDI-DrugBank.d137.s10.e2
.;O;O
DDI-DrugBank.d137.s11;;
Cardiac;B-group;B-DDI-DrugBank.d137.s11.e0
glycosides;I-group;I-DDI-DrugBank.d137.s11.e0
could;O;O
exaggerate;O;O
the;O;O
depression;O;O
of;O;O
AV;O;O
nodal;O;O
conduction;O;O
observed;O;O
with;O;O
bepridil;B-drug;B-DDI-DrugBank.d137.s11.e1
hydrochloride;I-drug;I-DDI-DrugBank.d137.s11.e1
.;O;O
DDI-DrugBank.d432.s0;;
APRD00513_IN;O;O
,;O;O
txt;O;O
DDI-DrugBank.d489.s0;;
The;O;O
following;O;O
drugs;O;O
have;O;O
been;O;O
coadministered;O;O
with;O;O
Kerlone;B-brand;B-DDI-DrugBank.d489.s0.e0
and;O;O
have;O;O
not;O;O
altered;O;O
its;O;O
pharmacokinetics;O;O
:;O;O
cimetidine;B-drug;B-DDI-DrugBank.d489.s0.e1
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d489.s0.e2
,;O;O
chlorthalidone;B-drug;B-DDI-DrugBank.d489.s0.e3
,;O;O
and;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d489.s0.e4
.;O;O
DDI-DrugBank.d489.s1;;
Concomitant;O;O
administration;O;O
of;O;O
Kerlone;B-brand;B-DDI-DrugBank.d489.s1.e0
with;O;O
the;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d489.s1.e1
warfarin;I-drug;I-DDI-DrugBank.d489.s1.e2
has;O;O
been;O;O
shown;O;O
not;O;O
to;O;O
potentiate;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d489.s1.e3
.;O;O
DDI-DrugBank.d489.s2;;
Catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d489.s2.e0
);O;O
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
beta;B-drug;B-DDI-DrugBank.d489.s2.e1
-;I-drug;I-DDI-DrugBank.d489.s2.e1
blocking;I-drug;I-DDI-DrugBank.d489.s2.e1
agents;O;O
.;O;O
DDI-DrugBank.d489.s3;;
Patients;O;O
treated;O;O
with;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d489.s3.e0
-;I-group;I-DDI-DrugBank.d489.s3.e0
adrenergic;I-group;I-DDI-DrugBank.d489.s3.e0
receptor;I-group;I-DDI-DrugBank.d489.s3.e0
blocking;I-group;I-DDI-DrugBank.d489.s3.e0
agent;I-group;I-DDI-DrugBank.d489.s3.e0
plus;O;O
a;O;O
catecholamine;O;O
depletor;O;O
should;O;O
therefore;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
evidence;O;O
of;O;O
hypotension;O;O
or;O;O
marked;O;O
bradycardia;O;O
,;O;O
which;O;O
may;O;O
produce;O;O
vertigo;O;O
,;O;O
syncope;O;O
,;O;O
or;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d489.s4;;
Should;O;O
it;O;O
be;O;O
decided;O;O
to;O;O
discontinue;O;O
therapy;O;O
in;O;O
patients;O;O
receiving;O;O
beta;B-group;B-DDI-DrugBank.d489.s4.e0
-;I-group;I-DDI-DrugBank.d489.s4.e0
blockers;I-group;I-DDI-DrugBank.d489.s4.e0
and;O;O
clonidine;B-drug;B-DDI-DrugBank.d489.s4.e1
concurrently;O;O
,;O;O
the;O;O
beta;B-group;B-DDI-DrugBank.d489.s4.e2
-;I-group;I-DDI-DrugBank.d489.s4.e2
blocker;I-group;I-DDI-DrugBank.d489.s4.e2
should;O;O
be;O;O
discontinued;O;O
slowly;O;O
over;O;O
several;O;O
days;O;O
before;O;O
the;O;O
gradual;O;O
withdrawal;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d489.s4.e3
.;O;O
DDI-DrugBank.d489.s5;;
Literature;O;O
reports;O;O
suggest;O;O
that;O;O
oral;O;O
calcium;B-group;B-DDI-DrugBank.d489.s5.e0
antagonists;I-group;I-DDI-DrugBank.d489.s5.e0
may;O;O
be;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d489.s5.e1
-;I-group;I-DDI-DrugBank.d489.s5.e1
adrenergic;I-group;I-DDI-DrugBank.d489.s5.e1
blocking;I-group;I-DDI-DrugBank.d489.s5.e1
agents;I-group;I-DDI-DrugBank.d489.s5.e1
when;O;O
heart;O;O
function;O;O
is;O;O
normal;O;O
,;O;O
but;O;O
should;O;O
be;O;O
avoided;O;O
in;O;O
patients;O;O
with;O;O
impaired;O;O
cardiac;O;O
function;O;O
.;O;O
DDI-DrugBank.d489.s6;;
Hypotension;O;O
,;O;O
AV;O;O
conduction;O;O
disturbances;O;O
,;O;O
and;O;O
left;O;O
ventricular;O;O
failure;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
some;O;O
patients;O;O
receiving;O;O
beta;B-group;B-DDI-DrugBank.d489.s6.e0
-;I-group;I-DDI-DrugBank.d489.s6.e0
adrenergic;I-group;I-DDI-DrugBank.d489.s6.e0
blocking;I-group;I-DDI-DrugBank.d489.s6.e0
agents;I-group;I-DDI-DrugBank.d489.s6.e0
when;O;O
an;O;O
oral;O;O
calcium;B-group;B-DDI-DrugBank.d489.s6.e1
antagonist;I-group;I-DDI-DrugBank.d489.s6.e1
was;O;O
added;O;O
to;O;O
the;O;O
treatment;O;O
regimen;O;O
.;O;O
DDI-DrugBank.d489.s7;;
Hypotension;O;O
was;O;O
more;O;O
likely;O;O
to;O;O
occur;O;O
if;O;O
the;O;O
calcium;B-group;B-DDI-DrugBank.d489.s7.e0
antagonist;I-group;I-DDI-DrugBank.d489.s7.e0
were;O;O
a;O;O
dihydropyridine;B-group;B-DDI-DrugBank.d489.s7.e1
derivative;I-group;I-DDI-DrugBank.d489.s7.e1
,;O;O
e.g.;O;O
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d489.s7.e2
,;O;O
while;O;O
left;O;O
ventricular;O;O
failure;O;O
and;O;O
AV;O;O
conduction;O;O
disturbances;O;O
,;O;O
including;O;O
complete;O;O
heart;O;O
block;O;O
,;O;O
were;O;O
more;O;O
likely;O;O
to;O;O
occur;O;O
with;O;O
either;O;O
verapamil;B-drug;B-DDI-DrugBank.d489.s7.e3
or;O;O
diltiazem;B-drug;B-DDI-DrugBank.d489.s7.e4
.;O;O
DDI-DrugBank.d489.s8;;
Risk;O;O
of;O;O
Anaphylactic;O;O
Reaction;O;O
:;O;O
Although;O;O
it;O;O
is;O;O
known;O;O
that;O;O
patients;O;O
on;O;O
beta;B-group;B-DDI-DrugBank.d489.s8.e0
-;I-group;I-DDI-DrugBank.d489.s8.e0
blockers;I-group;I-DDI-DrugBank.d489.s8.e0
may;O;O
be;O;O
refractory;O;O
to;O;O
epinephrine;B-drug;B-DDI-DrugBank.d489.s8.e1
in;O;O
the;O;O
treatment;O;O
of;O;O
anaphylactic;O;O
shock;O;O
,;O;O
beta;B-group;B-DDI-DrugBank.d489.s8.e2
-;I-group;I-DDI-DrugBank.d489.s8.e2
blockers;I-group;I-DDI-DrugBank.d489.s8.e2
can;O;O
,;O;O
in;O;O
addition;O;O
,;O;O
interfere;O;O
with;O;O
the;O;O
modulation;O;O
of;O;O
allergic;O;O
reaction;O;O
and;O;O
lead;O;O
to;O;O
an;O;O
increased;O;O
severity;O;O
and/or;O;O
frequency;O;O
of;O;O
attacks;O;O
.;O;O
DDI-DrugBank.d489.s9;;
Severe;O;O
allergic;O;O
reactions;O;O
including;O;O
anaphylaxis;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
exposed;O;O
to;O;O
a;O;O
variety;O;O
of;O;O
allergens;O;O
either;O;O
by;O;O
repeated;O;O
challenge;O;O
,;O;O
or;O;O
accidental;O;O
contact;O;O
,;O;O
and;O;O
with;O;O
diagnostic;O;O
or;O;O
therapeutic;O;O
agents;O;O
while;O;O
receiving;O;O
beta;B-group;B-DDI-DrugBank.d489.s9.e0
-;I-group;I-DDI-DrugBank.d489.s9.e0
blockers;I-group;I-DDI-DrugBank.d489.s9.e0
.;O;O
DDI-DrugBank.d489.s10;;
Such;O;O
patients;O;O
may;O;O
be;O;O
unresponsive;O;O
to;O;O
the;O;O
usual;O;O
doses;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d489.s10.e0
used;O;O
to;O;O
treat;O;O
allergic;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d513.s0;;
Special;O;O
care;O;O
is;O;O
required;O;O
if;O;O
this;O;O
drug;O;O
is;O;O
given;O;O
to;O;O
patients;O;O
receiving;O;O
ganglion;B-group;B-DDI-DrugBank.d513.s0.e0
blocking;I-group;I-DDI-DrugBank.d513.s0.e0
compounds;I-group;I-DDI-DrugBank.d513.s0.e0
because;O;O
a;O;O
critical;O;O
fall;O;O
in;O;O
blood;O;O
pressure;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d513.s1;;
Usually;O;O
,;O;O
severe;O;O
abdominal;O;O
symptoms;O;O
appear;O;O
before;O;O
there;O;O
is;O;O
such;O;O
a;O;O
fall;O;O
in;O;O
the;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d312.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
anti;B-group;B-DDI-DrugBank.d312.s0.e0
-;I-group;I-DDI-DrugBank.d312.s0.e0
neoplastic;I-group;I-DDI-DrugBank.d312.s0.e0
agents;I-group;I-DDI-DrugBank.d312.s0.e0
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d312.s1;;
In;O;O
Study;O;O
1;O;O
,;O;O
patients;O;O
with;O;O
colorectal;O;O
cancer;O;O
were;O;O
given;O;O
irinotecan;B-drug;B-DDI-DrugBank.d312.s1.e0
/;O;O
5;B-drug;B-DDI-DrugBank.d312.s1.e1
-;I-drug;I-DDI-DrugBank.d312.s1.e1
FU;I-drug;I-DDI-DrugBank.d312.s1.e1
/;O;O
leucovorin;B-drug;B-DDI-DrugBank.d312.s1.e2
(;O;O
bolus;O;O
-;O;O
IFL;O;O
);O;O
with;O;O
or;O;O
without;O;O
AVASTIN;B-brand;B-DDI-DrugBank.d312.s1.e3
.;O;O
DDI-DrugBank.d312.s2;;
Irinotecan;B-drug;B-DDI-DrugBank.d312.s2.e0
concentrations;O;O
were;O;O
similar;O;O
in;O;O
patients;O;O
receiving;O;O
bolus;O;O
-;O;O
IFL;O;O
alone;O;O
and;O;O
in;O;O
combination;O;O
with;O;O
AVASTIN;B-brand;B-DDI-DrugBank.d312.s2.e1
.;O;O
DDI-DrugBank.d312.s3;;
The;O;O
concentrations;O;O
of;O;O
SN38;B-drug_n;B-DDI-DrugBank.d312.s3.e0
,;O;O
the;O;O
active;O;O
metabolite;O;O
of;O;O
irinotecan;B-drug;B-DDI-DrugBank.d312.s3.e1
,;O;O
were;O;O
on;O;O
average;O;O
33;O;O
%;O;O
higher;O;O
in;O;O
patients;O;O
receiving;O;O
bolus;O;O
-;O;O
IFL;O;O
in;O;O
combination;O;O
with;O;O
AVASTIN;B-brand;B-DDI-DrugBank.d312.s3.e2
when;O;O
compared;O;O
with;O;O
bolus;O;O
-;O;O
IFL;O;O
alone;O;O
.;O;O
DDI-DrugBank.d312.s4;;
In;O;O
Study;O;O
1;O;O
,;O;O
patients;O;O
receiving;O;O
bolus;O;O
-;O;O
IFL;O;O
plus;O;O
AVASTIN;B-brand;B-DDI-DrugBank.d312.s4.e0
had;O;O
a;O;O
higher;O;O
incidence;O;O
of;O;O
Grade;O;O
3;O;O
-;O;O
4;O;O
diarrhea;O;O
and;O;O
neutropenia;O;O
.;O;O
DDI-DrugBank.d312.s5;;
Due;O;O
to;O;O
high;O;O
inter;O;O
-;O;O
patient;O;O
variability;O;O
and;O;O
limited;O;O
sampling;O;O
,;O;O
the;O;O
extent;O;O
of;O;O
the;O;O
increase;O;O
in;O;O
SN38;B-drug_n;B-DDI-DrugBank.d312.s5.e0
levels;O;O
in;O;O
patients;O;O
receiving;O;O
concurrent;O;O
irinotecan;B-drug;B-DDI-DrugBank.d312.s5.e1
and;O;O
AVASTIN;B-brand;B-DDI-DrugBank.d312.s5.e2
is;O;O
uncertain;O;O
.;O;O
DDI-DrugBank.d467.s0;;
No;O;O
formal;O;O
studies;O;O
to;O;O
evaluate;O;O
drug;O;O
interactions;O;O
with;O;O
bexarotene;B-drug;B-DDI-DrugBank.d467.s0.e0
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d467.s1;;
Bexarotene;B-drug;B-DDI-DrugBank.d467.s1.e0
oxidative;O;O
metabolites;O;O
appear;O;O
to;O;O
be;O;O
formed;O;O
by;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d467.s2;;
On;O;O
the;O;O
basis;O;O
of;O;O
the;O;O
metabolism;O;O
of;O;O
bexarotene;B-drug;B-DDI-DrugBank.d467.s2.e0
by;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d467.s2.e1
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d467.s2.e2
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d467.s2.e3
,;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d467.s2.e4
,;O;O
grapefruit;O;O
juice;O;O
,;O;O
and;O;O
other;O;O
inhibitors;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
lead;O;O
to;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
bexarotene;B-drug;B-DDI-DrugBank.d467.s2.e5
concentrations;O;O
.;O;O
DDI-DrugBank.d467.s3;;
Furthermore;O;O
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d467.s3.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d467.s3.e1
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d467.s3.e2
,;O;O
and;O;O
other;O;O
inducers;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
may;O;O
cause;O;O
a;O;O
reduction;O;O
in;O;O
plasma;O;O
bexarotene;B-drug;B-DDI-DrugBank.d467.s3.e3
concentrations;O;O
.;O;O
DDI-DrugBank.d467.s4;;
Concomitant;O;O
administration;O;O
of;O;O
Targretin;B-brand;B-DDI-DrugBank.d467.s4.e0
capsules;O;O
and;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d467.s4.e1
resulted;O;O
in;O;O
substantial;O;O
increases;O;O
in;O;O
plasma;O;O
concentrations;O;O
of;O;O
bexarotene;B-drug;B-DDI-DrugBank.d467.s4.e2
,;O;O
probably;O;O
at;O;O
least;O;O
partially;O;O
related;O;O
to;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
inhibition;O;O
by;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d467.s4.e3
.;O;O
DDI-DrugBank.d467.s5;;
Under;O;O
similar;O;O
conditions;O;O
,;O;O
bexarotene;B-drug;B-DDI-DrugBank.d467.s5.e0
concentrations;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
concomitant;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d467.s5.e1
administration;O;O
.;O;O
DDI-DrugBank.d467.s6;;
Concomitant;O;O
administration;O;O
of;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d467.s6.e0
with;O;O
Targretin;B-brand;B-DDI-DrugBank.d467.s6.e1
capsules;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d291.s0;;
When;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s0.e0
or;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s0.e1
retard;I-brand;I-DDI-DrugBank.d291.s0.e1
is;O;O
used;O;O
at;O;O
the;O;O
same;O;O
time;O;O
as;O;O
other;O;O
medicines;O;O
or;O;O
substances;O;O
the;O;O
following;O;O
interactions;O;O
must;O;O
be;O;O
taken;O;O
into;O;O
account;O;O
:;O;O
-;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s0.e2
and;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s0.e3
retard;I-brand;I-DDI-DrugBank.d291.s0.e3
may;O;O
enhance;O;O
the;O;O
action;O;O
of;O;O
anticoagulants;B-group;B-DDI-DrugBank.d291.s0.e4
of;I-group;I-DDI-DrugBank.d291.s0.e4
the;I-group;I-DDI-DrugBank.d291.s0.e4
coumarin;I-group;I-DDI-DrugBank.d291.s0.e4
type;I-group;I-DDI-DrugBank.d291.s0.e4
.;O;O
DDI-DrugBank.d291.s1;;
For;O;O
this;O;O
reason;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
anticoagulant;B-drug;B-DDI-DrugBank.d291.s1.e0
should;O;O
be;O;O
reduced;O;O
by;O;O
30;O;O
-;O;O
50;O;O
%;O;O
at;O;O
the;O;O
start;O;O
of;O;O
treatment;O;O
with;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s1.e1
or;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s1.e2
retard;O;O
and;O;O
then;O;O
titrated;O;O
according;O;O
to;O;O
the;O;O
blood;O;O
clotting;O;O
parameters;O;O
DDI-DrugBank.d291.s2;;
.;O;O
DDI-DrugBank.d291.s3;;
-;O;O
The;O;O
action;O;O
of;O;O
sulphonylureas;B-group;B-DDI-DrugBank.d291.s3.e0
and;O;O
insulin;B-drug;B-DDI-DrugBank.d291.s3.e1
may;O;O
be;O;O
enhanced;O;O
by;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s3.e2
or;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s3.e3
retard;I-brand;I-DDI-DrugBank.d291.s3.e3
.;O;O
DDI-DrugBank.d291.s4;;
This;O;O
may;O;O
be;O;O
due;O;O
to;O;O
an;O;O
improved;O;O
glucose;O;O
utilization;O;O
with;O;O
simultaneous;O;O
reduction;O;O
in;O;O
insulin;B-drug;B-DDI-DrugBank.d291.s4.e0
requirement;O;O
DDI-DrugBank.d291.s5;;
.;O;O
DDI-DrugBank.d291.s6;;
-;O;O
In;O;O
isolated;O;O
cases;O;O
,;O;O
a;O;O
pronounced;O;O
though;O;O
reversible;O;O
,;O;O
impairment;O;O
of;O;O
renal;O;O
function;O;O
(;O;O
accompanied;O;O
by;O;O
a;O;O
corresponding;O;O
increase;O;O
in;O;O
the;O;O
serum;O;O
creatinine;O;O
level;O;O
);O;O
has;O;O
been;O;O
reported;O;O
in;O;O
organ;O;O
transplant;O;O
patients;O;O
receiving;O;O
immuno;B-group;B-DDI-DrugBank.d291.s6.e0
-;I-group;I-DDI-DrugBank.d291.s6.e0
suppressant;I-group;I-DDI-DrugBank.d291.s6.e0
therapy;O;O
and;O;O
concomitant;O;O
bezafibrate;B-drug;B-DDI-DrugBank.d291.s6.e1
.;O;O
DDI-DrugBank.d291.s7;;
Accordingly;O;O
,;O;O
renal;O;O
function;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
in;O;O
these;O;O
patients;O;O
and;O;O
,;O;O
in;O;O
the;O;O
event;O;O
of;O;O
relevant;O;O
significant;O;O
changes;O;O
in;O;O
laboratory;O;O
parameters;O;O
,;O;O
bezafibrate;B-drug;B-DDI-DrugBank.d291.s7.e0
should;O;O
,;O;O
if;O;O
necessary;O;O
,;O;O
be;O;O
discontinued;O;O
DDI-DrugBank.d291.s8;;
.;O;O
DDI-DrugBank.d291.s9;;
-;O;O
When;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s9.e0
or;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s9.e1
retard;I-brand;I-DDI-DrugBank.d291.s9.e1
is;O;O
used;O;O
concurrently;O;O
with;O;O
anion;B-group;B-DDI-DrugBank.d291.s9.e2
-;I-group;I-DDI-DrugBank.d291.s9.e2
exchange;I-group;I-DDI-DrugBank.d291.s9.e2
resins;I-group;I-DDI-DrugBank.d291.s9.e2
(;O;O
e.g.;O;O
cholestryramine;B-drug;B-DDI-DrugBank.d291.s9.e3
);O;O
,;O;O
an;O;O
interval;O;O
of;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
should;O;O
be;O;O
maintained;O;O
between;O;O
the;O;O
two;O;O
medicines;O;O
,;O;O
since;O;O
the;O;O
absorption;O;O
of;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s9.e4
or;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s9.e5
retard;I-brand;I-DDI-DrugBank.d291.s9.e5
is;O;O
impaired;O;O
DDI-DrugBank.d291.s10;;
.;O;O
DDI-DrugBank.d291.s11;;
-;O;O
Perhexiline;B-drug;B-DDI-DrugBank.d291.s11.e0
hydrogen;I-drug;I-DDI-DrugBank.d291.s11.e0
maleate;I-drug;I-DDI-DrugBank.d291.s11.e0
or;O;O
MAO;B-group;B-DDI-DrugBank.d291.s11.e1
-;I-group;I-DDI-DrugBank.d291.s11.e1
inhibitors;I-group;I-DDI-DrugBank.d291.s11.e1
(;O;O
with;O;O
hepatotoxic;O;O
potential;O;O
);O;O
must;O;O
not;O;O
be;O;O
administered;O;O
together;O;O
with;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s11.e2
or;O;O
Bezalip;B-brand;B-DDI-DrugBank.d291.s11.e3
retard;I-brand;I-DDI-DrugBank.d291.s11.e3
.;O;O
DDI-DrugBank.d266.s0;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
CASODEX;B-brand;B-DDI-DrugBank.d266.s0.e0
can;O;O
displace;O;O
coumarin;B-group;B-DDI-DrugBank.d266.s0.e1
anticoagulants;I-group;I-DDI-DrugBank.d266.s0.e1
,;O;O
such;O;O
as;O;O
warfarin;B-drug;B-DDI-DrugBank.d266.s0.e2
,;O;O
from;O;O
their;O;O
protein;O;O
-;O;O
binding;O;O
sites;O;O
.;O;O
DDI-DrugBank.d266.s1;;
It;O;O
is;O;O
recommended;O;O
that;O;O
if;O;O
CASODEX;B-brand;B-DDI-DrugBank.d266.s1.e0
is;O;O
started;O;O
in;O;O
patients;O;O
already;O;O
receiving;O;O
coumarin;B-group;B-DDI-DrugBank.d266.s1.e1
anticoagulants;I-group;I-DDI-DrugBank.d266.s1.e1
,;O;O
prothrombin;O;O
times;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
and;O;O
adjustment;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d266.s1.e2
dose;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d264.s0;;
No;O;O
Information;O;O
Provided;O;O
DDI-DrugBank.d401.s0;;
Drug;O;O
Interactions;O;O
:;O;O
The;O;O
central;O;O
anticholinergic;B-group;B-DDI-DrugBank.d401.s0.e0
syndrome;O;O
can;O;O
occur;O;O
when;O;O
anticholinergic;O;O
agents;O;O
such;O;O
as;O;O
AKINETON;B-brand;B-DDI-DrugBank.d401.s0.e1
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
drugs;O;O
that;O;O
have;O;O
secondary;O;O
anticholinergic;O;O
actions;O;O
,;O;O
e.g.;O;O
,;O;O
certain;O;O
narcotic;B-group;B-DDI-DrugBank.d401.s0.e2
analgesics;I-group;I-DDI-DrugBank.d401.s0.e2
such;O;O
as;O;O
meperidine;B-drug;B-DDI-DrugBank.d401.s0.e3
,;O;O
the;O;O
phenothiazines;B-group;B-DDI-DrugBank.d401.s0.e4
and;O;O
other;O;O
antipsychotics;B-group;B-DDI-DrugBank.d401.s0.e5
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d401.s0.e6
antidepressants;I-group;I-DDI-DrugBank.d401.s0.e6
,;O;O
certain;O;O
antiarrhythmics;B-group;B-DDI-DrugBank.d401.s0.e7
such;O;O
as;O;O
the;O;O
quinidine;B-drug;B-DDI-DrugBank.d401.s0.e8
salts;O;O
,;O;O
and;O;O
antihistamines;B-group;B-DDI-DrugBank.d401.s0.e9
.;O;O
DDI-DrugBank.d476.s0;;
ZEBETA;B-brand;B-DDI-DrugBank.d476.s0.e0
should;O;O
not;O;O
be;O;O
combined;O;O
with;O;O
other;O;O
beta;B-group;B-DDI-DrugBank.d476.s0.e1
-;I-group;I-DDI-DrugBank.d476.s0.e1
blocking;I-group;I-DDI-DrugBank.d476.s0.e1
agents;I-group;I-DDI-DrugBank.d476.s0.e1
.;O;O
DDI-DrugBank.d476.s1;;
Patients;O;O
receiving;O;O
catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
reserpine;B-drug;B-DDI-DrugBank.d476.s1.e0
or;O;O
guanethidine;B-drug;B-DDI-DrugBank.d476.s1.e1
,;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
,;O;O
because;O;O
the;O;O
added;O;O
beta;O;O
-;O;O
adrenergic;O;O
blocking;O;O
action;O;O
of;O;O
ZEBETA;B-brand;B-DDI-DrugBank.d476.s1.e2
may;O;O
produce;O;O
excessive;O;O
reduction;O;O
of;O;O
sympathetic;O;O
activity;O;O
.;O;O
DDI-DrugBank.d476.s2;;
In;O;O
patients;O;O
receiving;O;O
concurrent;O;O
therapy;O;O
with;O;O
clonidine;B-drug;B-DDI-DrugBank.d476.s2.e0
,;O;O
if;O;O
therapy;O;O
is;O;O
to;O;O
be;O;O
discontinued;O;O
,;O;O
it;O;O
is;O;O
suggested;O;O
that;O;O
ZEBETA;B-brand;B-DDI-DrugBank.d476.s2.e1
be;O;O
discontinued;O;O
for;O;O
several;O;O
days;O;O
before;O;O
the;O;O
withdrawal;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d476.s2.e2
.;O;O
DDI-DrugBank.d476.s3;;
ZEBETA;B-brand;B-DDI-DrugBank.d476.s3.e0
should;O;O
be;O;O
used;O;O
with;O;O
care;O;O
when;O;O
myocardial;B-group;B-DDI-DrugBank.d476.s3.e1
depressants;I-group;I-DDI-DrugBank.d476.s3.e1
or;O;O
inhibitors;O;O
of;O;O
AV;O;O
conduction;O;O
,;O;O
such;O;O
as;O;O
certain;O;O
calcium;B-group;B-DDI-DrugBank.d476.s3.e2
antagonists;I-group;I-DDI-DrugBank.d476.s3.e2
(;O;O
particularly;O;O
of;O;O
the;O;O
phenylalkylamine;B-group;B-DDI-DrugBank.d476.s3.e3
[;O;O
verapamil;B-drug;B-DDI-DrugBank.d476.s3.e4
];O;O
and;O;O
benzothiazepine;B-group;B-DDI-DrugBank.d476.s3.e5
[;O;O
diltiazem;B-drug;B-DDI-DrugBank.d476.s3.e6
];O;O
classes;O;O
);O;O
,;O;O
or;O;O
antiarrhythmic;B-group;B-DDI-DrugBank.d476.s3.e7
agents;I-group;I-DDI-DrugBank.d476.s3.e7
,;O;O
such;O;O
as;O;O
disopyramide;B-drug;B-DDI-DrugBank.d476.s3.e8
,;O;O
are;O;O
used;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d476.s4;;
Concurrent;O;O
use;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d476.s4.e0
increases;O;O
the;O;O
metabolic;O;O
clearance;O;O
of;O;O
ZEBETA;B-brand;B-DDI-DrugBank.d476.s4.e1
,;O;O
resulting;O;O
in;O;O
a;O;O
shortened;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
of;O;O
ZEBETA;B-brand;B-DDI-DrugBank.d476.s4.e2
.;O;O
DDI-DrugBank.d476.s5;;
However;O;O
,;O;O
initial;O;O
dose;O;O
modification;O;O
is;O;O
generally;O;O
not;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d476.s6;;
Pharmacokinetic;O;O
studies;O;O
document;O;O
no;O;O
clinically;O;O
relevant;O;O
interactions;O;O
with;O;O
other;O;O
agents;O;O
given;O;O
concomitantly;O;O
,;O;O
including;O;O
thiazide;B-group;B-DDI-DrugBank.d476.s6.e0
diuretics;I-group;I-DDI-DrugBank.d476.s6.e0
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d476.s6.e1
,;O;O
and;O;O
cimetidine;B-drug;B-DDI-DrugBank.d476.s6.e2
.;O;O
DDI-DrugBank.d476.s7;;
There;O;O
was;O;O
no;O;O
effect;O;O
of;O;O
ZEBETA;B-brand;B-DDI-DrugBank.d476.s7.e0
on;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
on;O;O
stable;O;O
doses;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d476.s7.e1
.;O;O
DDI-DrugBank.d476.s8;;
Risk;O;O
of;O;O
Anaphylactic;O;O
Reaction;O;O
:;O;O
While;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d476.s8.e0
-;I-group;I-DDI-DrugBank.d476.s8.e0
blockers;I-group;I-DDI-DrugBank.d476.s8.e0
,;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
severe;O;O
anaphylactic;O;O
reaction;O;O
to;O;O
a;O;O
variety;O;O
of;O;O
allergens;O;O
may;O;O
be;O;O
more;O;O
reactive;O;O
to;O;O
repeated;O;O
challenge;O;O
,;O;O
either;O;O
accidental;O;O
,;O;O
diagnostic;O;O
,;O;O
or;O;O
therapeutic;O;O
.;O;O
DDI-DrugBank.d476.s9;;
Such;O;O
patients;O;O
may;O;O
be;O;O
unresponsive;O;O
to;O;O
the;O;O
usual;O;O
doses;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d476.s9.e0
used;O;O
to;O;O
treat;O;O
allergic;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d560.s0;;
Use;O;O
of;O;O
MAO;B-group;B-DDI-DrugBank.d560.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d560.s0.e0
may;O;O
cause;O;O
an;O;O
excessive;O;O
increase;O;O
in;O;O
blood;O;O
pressure;O;O
and;O;O
heart;O;O
stimulation;O;O
.;O;O
DDI-DrugBank.d560.s1;;
If;O;O
you;O;O
are;O;O
also;O;O
using;O;O
a;O;O
steroid;B-group;B-DDI-DrugBank.d560.s1.e0
inhaler;O;O
,;O;O
take;O;O
bitolterol;B-drug;B-DDI-DrugBank.d560.s1.e1
first;O;O
and;O;O
then;O;O
wait;O;O
about;O;O
15;O;O
minutes;O;O
before;O;O
using;O;O
the;O;O
steroid;B-group;B-DDI-DrugBank.d560.s1.e2
inhaler;O;O
.;O;O
DDI-DrugBank.d560.s2;;
This;O;O
allows;O;O
bitolterol;B-drug;B-DDI-DrugBank.d560.s2.e0
to;O;O
open;O;O
air;O;O
passages;O;O
,;O;O
increasing;O;O
the;O;O
effectiveness;O;O
of;O;O
the;O;O
steroid;B-group;B-DDI-DrugBank.d560.s2.e1
.;O;O
DDI-DrugBank.d569.s0;;
Angiomax;B-brand;B-DDI-DrugBank.d569.s0.e0
does;O;O
not;O;O
exhibit;O;O
binding;O;O
to;O;O
plasma;O;O
proteins;O;O
(;O;O
other;O;O
than;O;O
thrombin;O;O
);O;O
or;O;O
red;O;O
blood;O;O
cells;O;O
.;O;O
DDI-DrugBank.d569.s1;;
In;O;O
clinical;O;O
trials;O;O
in;O;O
patients;O;O
undergoing;O;O
PTCA;O;O
/;O;O
PCI;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Angiomax;B-brand;B-DDI-DrugBank.d569.s1.e0
with;O;O
heparin;B-drug;B-DDI-DrugBank.d569.s1.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d569.s1.e2
,;O;O
thrombolytics;B-group;B-DDI-DrugBank.d569.s1.e3
or;O;O
glycoprotein;O;O
IIb;O;O
/;O;O
IIIa;O;O
inhibitors;O;O
was;O;O
associated;O;O
with;O;O
increased;O;O
risks;O;O
of;O;O
major;O;O
bleeding;O;O
events;O;O
compared;O;O
to;O;O
patients;O;O
not;O;O
receiving;O;O
these;O;O
concomitant;O;O
medications;O;O
.;O;O
DDI-DrugBank.d569.s2;;
There;O;O
is;O;O
no;O;O
experience;O;O
with;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Angiomax;B-brand;B-DDI-DrugBank.d569.s2.e0
and;O;O
plasma;O;O
expanders;O;O
such;O;O
as;O;O
dextran;B-drug;B-DDI-DrugBank.d569.s2.e1
.;O;O
DDI-DrugBank.d569.s3;;
Angiomax;B-brand;B-DDI-DrugBank.d569.s3.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
with;O;O
disease;O;O
states;O;O
associated;O;O
with;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d569.s4;;
Immunogenicity;O;O
/;O;O
Re;O;O
-;O;O
exposure;O;O
:;O;O
In;O;O
in;O;O
vitro;O;O
studies;O;O
,;O;O
Angiomax;B-brand;B-DDI-DrugBank.d569.s4.e0
exhibited;O;O
no;O;O
platelet;O;O
aggregation;O;O
response;O;O
against;O;O
sera;O;O
from;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
HIT;O;O
/;O;O
HITTS;O;O
.;O;O
DDI-DrugBank.d569.s5;;
Among;O;O
494;O;O
subjects;O;O
who;O;O
received;O;O
Angiomax;B-brand;B-DDI-DrugBank.d569.s5.e0
in;O;O
clinical;O;O
trials;O;O
and;O;O
were;O;O
tested;O;O
for;O;O
antibodies;O;O
,;O;O
2;O;O
subjects;O;O
had;O;O
treatment;O;O
-;O;O
emergent;O;O
positive;O;O
bivalirudin;B-drug;B-DDI-DrugBank.d569.s5.e1
antibody;O;O
tests;O;O
.;O;O
DDI-DrugBank.d569.s6;;
Neither;O;O
subject;O;O
demonstrated;O;O
clinical;O;O
evidence;O;O
of;O;O
allergic;O;O
or;O;O
anaphylactic;O;O
reactions;O;O
and;O;O
repeat;O;O
testing;O;O
was;O;O
not;O;O
performed;O;O
.;O;O
DDI-DrugBank.d569.s7;;
Nine;O;O
additional;O;O
patients;O;O
who;O;O
had;O;O
initial;O;O
positive;O;O
tests;O;O
were;O;O
negative;O;O
on;O;O
repeat;O;O
testing;O;O
.;O;O
DDI-DrugBank.d554.s0;;
Certain;O;O
antibiotic;B-group;B-DDI-DrugBank.d554.s0.e0
,;O;O
cisplatin;B-drug;B-DDI-DrugBank.d554.s0.e1
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d554.s0.e2
,;O;O
diuretic;B-group;B-DDI-DrugBank.d554.s0.e3
,;O;O
foscarnet;B-drug;B-DDI-DrugBank.d554.s0.e4
,;O;O
and;O;O
vaccines;B-group;B-DDI-DrugBank.d554.s0.e5
.;O;O
DDI-DrugBank.d571.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
VELCADE;B-brand;B-DDI-DrugBank.d571.s0.e0
.;O;O
DDI-DrugBank.d571.s1;;
In;O;O
vitro;O;O
studies;O;O
with;O;O
human;O;O
liver;O;O
microsomes;O;O
indicate;O;O
that;O;O
bortezomib;B-drug;B-DDI-DrugBank.d571.s1.e0
is;O;O
primarily;O;O
a;O;O
substrate;O;O
for;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
,;O;O
2C19;O;O
,;O;O
and;O;O
1A2;O;O
.;O;O
DDI-DrugBank.d571.s2;;
Patients;O;O
who;O;O
are;O;O
concomitantly;O;O
receiving;O;O
VELCADE;B-brand;B-DDI-DrugBank.d571.s2.e0
and;O;O
drugs;O;O
that;O;O
are;O;O
inhibitors;O;O
or;O;O
inducers;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
for;O;O
either;O;O
toxicities;O;O
or;O;O
reduced;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d571.s3;;
During;O;O
clinical;O;O
trials;O;O
,;O;O
hypoglycemia;O;O
and;O;O
hyperglycemia;O;O
were;O;O
reported;O;O
in;O;O
diabetic;O;O
patients;O;O
receiving;O;O
oral;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d571.s3.e0
.;O;O
DDI-DrugBank.d571.s4;;
Patients;O;O
on;O;O
oral;O;O
antidiabetic;B-group;B-DDI-DrugBank.d571.s4.e0
agents;I-group;I-DDI-DrugBank.d571.s4.e0
receiving;O;O
VELCADE;B-brand;B-DDI-DrugBank.d571.s4.e1
treatment;O;O
may;O;O
require;O;O
close;O;O
monitoring;O;O
of;O;O
their;O;O
blood;O;O
glucose;O;O
levels;O;O
and;O;O
adjustment;O;O
of;O;O
the;O;O
dose;O;O
of;O;O
their;O;O
antidiabetic;B-group;B-DDI-DrugBank.d571.s4.e2
medication;I-group;I-DDI-DrugBank.d571.s4.e2
.;O;O
DDI-DrugBank.d571.s5;;
Drug;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
None;O;O
known;O;O
.;O;O
DDI-DrugBank.d289.s0;;
Bosentan;B-drug;B-DDI-DrugBank.d289.s0.e0
is;O;O
metabolized;O;O
by;O;O
CYP2C9;O;O
and;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d289.s1;;
Inhibition;O;O
of;O;O
these;O;O
isoenzymes;O;O
may;O;O
increase;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s1.e0
.;O;O
DDI-DrugBank.d289.s2;;
Bosentan;B-drug;B-DDI-DrugBank.d289.s2.e0
is;O;O
an;O;O
inducer;O;O
of;O;O
CYP3A4;O;O
and;O;O
CYP2C9;O;O
.;O;O
DDI-DrugBank.d289.s3;;
Consequently;O;O
,;O;O
plasma;O;O
concentrations;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
these;O;O
two;O;O
isoenzymes;O;O
will;O;O
be;O;O
decreased;O;O
when;O;O
TRACLEER;B-brand;B-DDI-DrugBank.d289.s3.e0
is;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d289.s4;;
Bosentan;B-drug;B-DDI-DrugBank.d289.s4.e0
had;O;O
no;O;O
relevant;O;O
inhibitory;O;O
effect;O;O
on;O;O
any;O;O
CYP;O;O
isoenzymes;O;O
tested;O;O
(;O;O
CYP1A2;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP3A4;O;O
);O;O
.;O;O
DDI-DrugBank.d289.s5;;
Consequently;O;O
,;O;O
TRACLEER;B-brand;B-DDI-DrugBank.d289.s5.e0
is;O;O
not;O;O
expected;O;O
to;O;O
increase;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
these;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d289.s6;;
Hormonal;B-group;B-DDI-DrugBank.d289.s6.e0
Contraceptives;I-group;I-DDI-DrugBank.d289.s6.e0
,;O;O
Including;O;O
Oral;O;O
,;O;O
Injectable;O;O
,;O;O
Transdermal;O;O
,;O;O
and;O;O
Implantable;O;O
Contraceptives;B-group;B-DDI-DrugBank.d289.s6.e1
:;O;O
An;O;O
interaction;O;O
study;O;O
demonstrated;O;O
that;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s6.e2
and;O;O
the;O;O
oral;O;O
hormonal;B-group;B-DDI-DrugBank.d289.s6.e3
contraceptive;I-group;I-DDI-DrugBank.d289.s6.e3
Ortho;I-brand;I-DDI-DrugBank.d289.s6.e4
-;I-brand;I-DDI-DrugBank.d289.s6.e4
Novum;I-brand;I-DDI-DrugBank.d289.s6.e4
produced;O;O
average;O;O
decreases;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d289.s6.e5
and;O;O
ethinyl;B-drug;B-DDI-DrugBank.d289.s6.e6
estradiol;I-drug;I-DDI-DrugBank.d289.s6.e6
levels;O;O
of;O;O
14;O;O
%;O;O
and;O;O
31;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d289.s7;;
However;O;O
,;O;O
decreases;O;O
in;O;O
exposure;O;O
were;O;O
as;O;O
much;O;O
as;O;O
56;O;O
%;O;O
and;O;O
66;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
in;O;O
individual;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d289.s8;;
Therefore;O;O
,;O;O
hormonal;B-group;B-DDI-DrugBank.d289.s8.e0
contraceptives;I-group;I-DDI-DrugBank.d289.s8.e0
,;O;O
including;O;O
oral;O;O
,;O;O
injectable;O;O
,;O;O
transdermal;O;O
,;O;O
and;O;O
implantable;O;O
forms;O;O
,;O;O
may;O;O
not;O;O
be;O;O
reliable;O;O
when;O;O
TRACLEER;B-brand;B-DDI-DrugBank.d289.s8.e1
is;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d289.s9;;
Women;O;O
should;O;O
practice;O;O
additional;O;O
methods;O;O
of;O;O
contraception;O;O
and;O;O
not;O;O
rely;O;O
on;O;O
hormonal;O;O
contraception;O;O
alone;O;O
when;O;O
taking;O;O
TRACLEER;B-brand;B-DDI-DrugBank.d289.s9.e0
.;O;O
DDI-DrugBank.d289.s10;;
Specific;O;O
interaction;O;O
studies;O;O
have;O;O
demonstrated;O;O
the;O;O
following;O;O
:;O;O
Cyclosporine;B-drug;B-DDI-DrugBank.d289.s10.e0
A;I-drug;I-DDI-DrugBank.d289.s10.e0
:;O;O
During;O;O
the;O;O
first;O;O
day;O;O
of;O;O
concomitant;O;O
administration;O;O
,;O;O
trough;O;O
concentrations;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s10.e1
were;O;O
increased;O;O
by;O;O
about;O;O
30;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d289.s11;;
Steady;O;O
-;O;O
state;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s11.e0
plasma;O;O
concentrations;O;O
were;O;O
3;O;O
-;O;O
to;O;O
4;O;O
-;O;O
fold;O;O
higher;O;O
than;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d289.s11.e1
A.;I-drug;I-DDI-DrugBank.d289.s11.e1
DDI-DrugBank.d289.s12;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s12.e0
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d289.s12.e1
A;I-drug;I-DDI-DrugBank.d289.s12.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d289.s13;;
Co;O;O
-;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s13.e0
decreased;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d289.s13.e1
A;I-drug;I-DDI-DrugBank.d289.s13.e1
(;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
);O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d289.s14;;
Tacrolimus;B-drug;B-DDI-DrugBank.d289.s14.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d289.s14.e1
and;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s14.e2
has;O;O
not;O;O
been;O;O
studied;O;O
in;O;O
man;O;O
.;O;O
DDI-DrugBank.d289.s15;;
Co;O;O
-;O;O
administration;O;O
of;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d289.s15.e0
and;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s15.e1
resulted;O;O
in;O;O
markedly;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s15.e2
in;O;O
animals;O;O
.;O;O
DDI-DrugBank.d289.s16;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
if;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d289.s16.e0
and;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s16.e1
are;O;O
used;O;O
together;O;O
.;O;O
DDI-DrugBank.d289.s17;;
Glyburide;B-drug;B-DDI-DrugBank.d289.s17.e0
:;O;O
An;O;O
increased;O;O
risk;O;O
of;O;O
elevated;O;O
liver;O;O
aminotransferases;O;O
was;O;O
observed;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
therapy;O;O
with;O;O
glyburide;B-drug;B-DDI-DrugBank.d289.s17.e1
.;O;O
DDI-DrugBank.d289.s18;;
Therefore;O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
TRACLEER;B-brand;B-DDI-DrugBank.d289.s18.e0
and;O;O
glyburide;B-drug;B-DDI-DrugBank.d289.s18.e1
is;O;O
contraindicated;O;O
,;O;O
and;O;O
alternative;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d289.s18.e2
agents;I-group;I-DDI-DrugBank.d289.s18.e2
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d289.s19;;
Co;O;O
-;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s19.e0
decreased;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d289.s19.e1
by;O;O
approximately;O;O
40;O;O
%;O;O
.;O;O
DDI-DrugBank.d289.s20;;
The;O;O
plasma;O;O
concentrations;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s20.e0
were;O;O
also;O;O
decreased;O;O
by;O;O
approximately;O;O
30;O;O
%;O;O
.;O;O
DDI-DrugBank.d289.s21;;
Bosentan;B-drug;B-DDI-DrugBank.d289.s21.e0
is;O;O
also;O;O
expected;O;O
to;O;O
reduce;O;O
plasma;O;O
concentrations;O;O
of;O;O
other;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d289.s21.e1
agents;I-group;I-DDI-DrugBank.d289.s21.e1
that;O;O
are;O;O
predominantly;O;O
metabolized;O;O
by;O;O
CYP2C9;O;O
or;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d289.s22;;
The;O;O
possibility;O;O
of;O;O
worsened;O;O
glucose;O;O
control;O;O
in;O;O
patients;O;O
using;O;O
these;O;O
agents;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d289.s23;;
Ketoconazole;B-drug;B-DDI-DrugBank.d289.s23.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s23.e1
125;O;O
mg;O;O
b.i.d;O;O
.;O;O
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d289.s23.e2
,;O;O
a;O;O
potent;O;O
CYP3A4;O;O
inhibitor;O;O
,;O;O
increased;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s23.e3
by;O;O
approximately;O;O
2;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d289.s24;;
No;O;O
dose;O;O
adjustment;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s24.e0
is;O;O
necessary;O;O
,;O;O
but;O;O
increased;O;O
effects;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s24.e1
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d289.s25;;
Simvastatin;B-drug;B-DDI-DrugBank.d289.s25.e0
and;O;O
Other;O;O
Statins;B-group;B-DDI-DrugBank.d289.s25.e1
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s25.e2
decreased;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
simvastatin;B-drug;B-DDI-DrugBank.d289.s25.e3
(;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
);O;O
,;O;O
and;O;O
its;O;O
active;O;O
-hydroxy;O;O
acid;O;O
metabolite;O;O
,;O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d289.s26;;
The;O;O
plasma;O;O
concentrations;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s26.e0
were;O;O
not;O;O
affected;O;O
.;O;O
DDI-DrugBank.d289.s27;;
Bosentan;B-drug;B-DDI-DrugBank.d289.s27.e0
is;O;O
also;O;O
expected;O;O
to;O;O
reduce;O;O
plasma;O;O
concentrations;O;O
of;O;O
other;O;O
statins;B-group;B-DDI-DrugBank.d289.s27.e1
that;O;O
have;O;O
significant;O;O
metabolism;O;O
by;O;O
CYP3A4;O;O
,;O;O
such;O;O
as;O;O
lovastatin;B-drug;B-DDI-DrugBank.d289.s27.e2
and;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d289.s27.e3
.;O;O
DDI-DrugBank.d289.s28;;
The;O;O
possibility;O;O
of;O;O
reduced;O;O
statin;B-group;B-DDI-DrugBank.d289.s28.e0
efficacy;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d289.s29;;
Patients;O;O
using;O;O
CYP3A4;O;O
metabolized;O;O
statins;B-group;B-DDI-DrugBank.d289.s29.e0
should;O;O
have;O;O
cholesterol;O;O
levels;O;O
monitored;O;O
after;O;O
TRACLEER;B-brand;B-DDI-DrugBank.d289.s29.e1
is;O;O
initiated;O;O
to;O;O
see;O;O
whether;O;O
the;O;O
statin;B-group;B-DDI-DrugBank.d289.s29.e2
dose;O;O
needs;O;O
adjustment;O;O
.;O;O
DDI-DrugBank.d289.s30;;
Warfarin;B-drug;B-DDI-DrugBank.d289.s30.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s30.e1
500;O;O
mg;O;O
b.i.d;O;O
.;O;O
for;O;O
6;O;O
days;O;O
decreased;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
both;O;O
S;B-drug;B-DDI-DrugBank.d289.s30.e2
-;I-drug;I-DDI-DrugBank.d289.s30.e2
warfarin;I-drug;I-DDI-DrugBank.d289.s30.e2
(;O;O
a;O;O
CYP2C9;O;O
substrate;O;O
);O;O
and;O;O
R;B-drug;B-DDI-DrugBank.d289.s30.e3
-;I-drug;I-DDI-DrugBank.d289.s30.e3
warfarin;I-drug;I-DDI-DrugBank.d289.s30.e3
(;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
);O;O
by;O;O
29;O;O
and;O;O
38;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d289.s31;;
Clinical;O;O
experience;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s31.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d289.s31.e1
in;O;O
patients;O;O
with;O;O
pulmonary;O;O
arterial;O;O
hypertension;O;O
did;O;O
not;O;O
show;O;O
clinically;O;O
relevant;O;O
changes;O;O
in;O;O
INR;O;O
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d289.s31.e2
dose;O;O
(;O;O
baseline;O;O
vs.;O;O
end;O;O
of;O;O
the;O;O
clinical;O;O
studies;O;O
);O;O
,;O;O
and;O;O
the;O;O
need;O;O
to;O;O
change;O;O
the;O;O
warfarin;B-drug;B-DDI-DrugBank.d289.s31.e3
dose;O;O
during;O;O
the;O;O
trials;O;O
due;O;O
to;O;O
changes;O;O
in;O;O
INR;O;O
or;O;O
due;O;O
to;O;O
adverse;O;O
events;O;O
was;O;O
similar;O;O
among;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s31.e4
-;O;O
and;O;O
placebo;O;O
-;O;O
treated;O;O
patients;O;O
.;O;O
DDI-DrugBank.d289.s32;;
Digoxin;B-drug;B-DDI-DrugBank.d289.s32.e0
,;O;O
Nimodipine;B-drug;B-DDI-DrugBank.d289.s32.e1
and;O;O
Losartan;B-drug;B-DDI-DrugBank.d289.s32.e2
:;O;O
Bosentan;B-drug;B-DDI-DrugBank.d289.s32.e3
has;O;O
no;O;O
significant;O;O
pharmacokinetic;O;O
interactions;O;O
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d289.s32.e4
and;O;O
nimodipine;B-drug;B-DDI-DrugBank.d289.s32.e5
,;O;O
and;O;O
losartan;B-drug;B-DDI-DrugBank.d289.s32.e6
has;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
plasma;O;O
levels;O;O
of;O;O
bosentan;B-drug;B-DDI-DrugBank.d289.s32.e7
.;O;O
DDI-DrugBank.d133.s0;;
Co;O;O
-;O;O
administration;O;O
of;O;O
BOTOX;B-brand;B-DDI-DrugBank.d133.s0.e0
and;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d133.s0.e1
or;O;O
other;O;O
agents;O;O
interfering;O;O
with;O;O
neuromuscular;O;O
transmission;O;O
(;O;O
e.g.;O;O
,;O;O
curare;B-group;B-DDI-DrugBank.d133.s0.e2
-;I-group;I-DDI-DrugBank.d133.s0.e2
like;I-group;I-DDI-DrugBank.d133.s0.e2
compounds;I-group;I-DDI-DrugBank.d133.s0.e2
);O;O
should;O;O
only;O;O
be;O;O
performed;O;O
with;O;O
caution;O;O
as;O;O
the;O;O
effect;O;O
of;O;O
the;O;O
toxin;B-drug;B-DDI-DrugBank.d133.s0.e3
may;O;O
be;O;O
potentiated;O;O
.;O;O
DDI-DrugBank.d133.s1;;
The;O;O
effect;O;O
of;O;O
administering;O;O
different;O;O
botulinum;B-group;B-DDI-DrugBank.d133.s1.e0
neurotoxin;I-group;I-DDI-DrugBank.d133.s1.e0
serotypes;O;O
at;O;O
the;O;O
same;O;O
time;O;O
or;O;O
within;O;O
several;O;O
months;O;O
of;O;O
each;O;O
other;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d133.s2;;
Excessive;O;O
neuromuscular;O;O
weakness;O;O
may;O;O
be;O;O
exacerbated;O;O
by;O;O
administration;O;O
of;O;O
another;O;O
botulinum;B-group;B-DDI-DrugBank.d133.s2.e0
toxin;I-group;I-DDI-DrugBank.d133.s2.e0
prior;O;O
to;O;O
the;O;O
resolution;O;O
of;O;O
the;O;O
effects;O;O
of;O;O
a;O;O
previously;O;O
administered;O;O
botulinum;B-group;B-DDI-DrugBank.d133.s2.e1
toxin;I-group;I-DDI-DrugBank.d133.s2.e1
.;O;O
DDI-DrugBank.d323.s0;;
Co;O;O
-;O;O
administration;O;O
of;O;O
MYOBLOC;B-brand;B-DDI-DrugBank.d323.s0.e0
and;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d323.s0.e1
or;O;O
other;O;O
agents;O;O
interfering;O;O
with;O;O
neuromuscular;O;O
transmission;O;O
(;O;O
e.g.;O;O
,;O;O
curare;B-group;B-DDI-DrugBank.d323.s0.e2
-;I-group;I-DDI-DrugBank.d323.s0.e2
like;I-group;I-DDI-DrugBank.d323.s0.e2
compounds;I-group;I-DDI-DrugBank.d323.s0.e2
);O;O
should;O;O
only;O;O
be;O;O
performed;O;O
with;O;O
caution;O;O
as;O;O
the;O;O
effect;O;O
of;O;O
the;O;O
toxin;B-drug;B-DDI-DrugBank.d323.s0.e3
may;O;O
be;O;O
potentiated;O;O
.;O;O
DDI-DrugBank.d323.s1;;
The;O;O
effect;O;O
of;O;O
administering;O;O
different;O;O
botulinum;B-group;B-DDI-DrugBank.d323.s1.e0
neurotoxin;I-group;I-DDI-DrugBank.d323.s1.e0
serotypes;O;O
at;O;O
the;O;O
same;O;O
time;O;O
or;O;O
within;O;O
less;O;O
than;O;O
4;O;O
months;O;O
of;O;O
each;O;O
other;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d323.s2;;
However;O;O
,;O;O
neuromuscular;O;O
paralysis;O;O
may;O;O
be;O;O
potentiated;O;O
by;O;O
co;O;O
-;O;O
administration;O;O
or;O;O
overlapping;O;O
administration;O;O
of;O;O
different;O;O
botulinum;B-group;B-DDI-DrugBank.d323.s2.e0
toxin;I-group;I-DDI-DrugBank.d323.s2.e0
serotypes;O;O
.;O;O
DDI-DrugBank.d180.s0;;
Digitalis;B-group;B-DDI-DrugBank.d180.s0.e0
toxicity;O;O
may;O;O
be;O;O
aggravated;O;O
by;O;O
the;O;O
initial;O;O
release;O;O
of;O;O
norepinephrine;O;O
caused;O;O
by;O;O
Bretylium;B-drug;B-DDI-DrugBank.d180.s0.e1
Tosylate;I-drug;I-DDI-DrugBank.d180.s0.e1
Injection;O;O
.;O;O
DDI-DrugBank.d180.s1;;
The;O;O
pressor;O;O
effects;O;O
of;O;O
catecholamines;B-group;B-DDI-DrugBank.d180.s1.e0
such;O;O
as;O;O
dopamine;B-drug;B-DDI-DrugBank.d180.s1.e1
or;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d180.s1.e2
are;O;O
enhanced;O;O
by;O;O
Bretylium;B-drug;B-DDI-DrugBank.d180.s1.e3
Tosylate;I-drug;I-DDI-DrugBank.d180.s1.e3
.;O;O
DDI-DrugBank.d180.s2;;
When;O;O
catecholamines;B-group;B-DDI-DrugBank.d180.s2.e0
are;O;O
administered;O;O
,;O;O
dilute;O;O
solutions;O;O
should;O;O
be;O;O
used;O;O
and;O;O
blood;O;O
pressure;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
.;O;O
DDI-DrugBank.d180.s3;;
Although;O;O
there;O;O
is;O;O
little;O;O
published;O;O
information;O;O
on;O;O
concomitant;O;O
administration;O;O
of;O;O
lidocaine;B-drug;B-DDI-DrugBank.d180.s3.e0
and;O;O
Bretylium;B-drug;B-DDI-DrugBank.d180.s3.e1
Tosylate;I-drug;I-DDI-DrugBank.d180.s3.e1
,;O;O
these;O;O
drugs;O;O
are;O;O
often;O;O
administered;O;O
concurrently;O;O
without;O;O
any;O;O
evidence;O;O
of;O;O
interactions;O;O
resulting;O;O
in;O;O
adverse;O;O
effects;O;O
or;O;O
diminished;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d138.s0;;
Although;O;O
specific;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
with;O;O
ALPHAGAN;B-brand;B-DDI-DrugBank.d138.s0.e0
P;I-brand;I-DDI-DrugBank.d138.s0.e0
,;O;O
the;O;O
possibility;O;O
of;O;O
an;O;O
additive;O;O
or;O;O
potentiating;O;O
effect;O;O
with;O;O
CNS;B-group;B-DDI-DrugBank.d138.s0.e1
depressants;I-group;I-DDI-DrugBank.d138.s0.e1
(;O;O
alcohol;B-drug;B-DDI-DrugBank.d138.s0.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d138.s0.e3
,;O;O
opiates;B-group;B-DDI-DrugBank.d138.s0.e4
,;O;O
sedatives;B-group;B-DDI-DrugBank.d138.s0.e5
,;O;O
or;O;O
anesthetics;B-group;B-DDI-DrugBank.d138.s0.e6
);O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d138.s1;;
Alpha;B-group;B-DDI-DrugBank.d138.s1.e0
-;I-group;I-DDI-DrugBank.d138.s1.e0
agonists;I-group;I-DDI-DrugBank.d138.s1.e0
,;O;O
as;O;O
a;O;O
class;O;O
,;O;O
may;O;O
reduce;O;O
pulse;O;O
and;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d138.s2;;
Caution;O;O
in;O;O
using;O;O
concomitant;O;O
drugs;O;O
such;O;O
as;O;O
beta;B-group;B-DDI-DrugBank.d138.s2.e0
-;I-group;I-DDI-DrugBank.d138.s2.e0
blockers;I-group;I-DDI-DrugBank.d138.s2.e0
(;O;O
ophthalmic;O;O
and;O;O
systemic;O;O
);O;O
,;O;O
anti;B-group;B-DDI-DrugBank.d138.s2.e1
-;I-group;I-DDI-DrugBank.d138.s2.e1
hypertensives;I-group;I-DDI-DrugBank.d138.s2.e1
and/or;O;O
cardiac;B-group;B-DDI-DrugBank.d138.s2.e2
glycosides;I-group;I-DDI-DrugBank.d138.s2.e2
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d138.s3;;
Tricyclic;B-group;B-DDI-DrugBank.d138.s3.e0
antidepressants;I-group;I-DDI-DrugBank.d138.s3.e0
have;O;O
been;O;O
reported;O;O
to;O;O
blunt;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
systemic;O;O
clonidine;B-drug;B-DDI-DrugBank.d138.s3.e1
.;O;O
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
the;O;O
concurrent;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
with;O;O
ALPHAGAN;B-brand;B-DDI-DrugBank.d138.s3.e2
P;I-brand;I-DDI-DrugBank.d138.s3.e2
in;O;O
humans;O;O
can;O;O
lead;O;O
to;O;O
resulting;O;O
interference;O;O
with;O;O
the;O;O
IOP;O;O
lowering;O;O
effect;O;O
.;O;O
DDI-DrugBank.d138.s4;;
No;O;O
data;O;O
on;O;O
the;O;O
level;O;O
of;O;O
circulating;O;O
catecholamines;O;O
after;O;O
ALPHAGAN;B-brand;B-DDI-DrugBank.d138.s4.e0
P;I-brand;I-DDI-DrugBank.d138.s4.e0
administration;O;O
are;O;O
available;O;O
.;O;O
DDI-DrugBank.d138.s5;;
Caution;O;O
,;O;O
however;O;O
,;O;O
is;O;O
advised;O;O
in;O;O
patients;O;O
taking;O;O
tricyclic;B-group;B-DDI-DrugBank.d138.s5.e0
antidepressants;I-group;I-DDI-DrugBank.d138.s5.e0
which;O;O
can;O;O
affect;O;O
the;O;O
metabolism;O;O
and;O;O
uptake;O;O
of;O;O
circulating;O;O
amines;O;O
.;O;O
DDI-DrugBank.d497.s0;;
AZOPT;B-brand;B-DDI-DrugBank.d497.s0.e0
(;O;O
brinzolamide;B-drug;B-DDI-DrugBank.d497.s0.e1
ophthalmic;O;O
suspension;O;O
);O;O
1;O;O
%;O;O
contains;O;O
a;O;O
carbonic;B-group;B-DDI-DrugBank.d497.s0.e2
anhydrase;I-group;I-DDI-DrugBank.d497.s0.e2
inhibitor;I-group;I-DDI-DrugBank.d497.s0.e2
.;O;O
DDI-DrugBank.d497.s1;;
Acid;O;O
-;O;O
base;O;O
and;O;O
electrolyte;O;O
alterations;O;O
were;O;O
not;O;O
reported;O;O
in;O;O
the;O;O
clinical;O;O
trials;O;O
with;O;O
brinzolamide;B-drug;B-DDI-DrugBank.d497.s1.e0
.;O;O
DDI-DrugBank.d497.s2;;
However;O;O
,;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
oral;O;O
carbonic;B-group;B-DDI-DrugBank.d497.s2.e0
anhydrase;I-group;I-DDI-DrugBank.d497.s2.e0
inhibitors;I-group;I-DDI-DrugBank.d497.s2.e0
,;O;O
rare;O;O
instances;O;O
of;O;O
drug;O;O
interactions;O;O
have;O;O
occurred;O;O
with;O;O
high;O;O
-;O;O
dose;O;O
salicylate;B-drug;B-DDI-DrugBank.d497.s2.e1
therapy;O;O
.;O;O
DDI-DrugBank.d497.s3;;
Therefore;O;O
,;O;O
the;O;O
potential;O;O
for;O;O
such;O;O
drug;O;O
interaction;O;O
should;O;O
be;O;O
considered;O;O
in;O;O
patients;O;O
receiving;O;O
AZOPT;B-brand;B-DDI-DrugBank.d497.s3.e0
(;O;O
brinzolamide;B-drug;B-DDI-DrugBank.d497.s3.e1
ophthalmic;O;O
suspension;O;O
);O;O
1;O;O
%;O;O
.;O;O
DDI-DrugBank.d272.s0;;
The;O;O
risk;O;O
of;O;O
using;O;O
bromocriptine;B-drug;B-DDI-DrugBank.d272.s0.e0
mesylate;I-drug;I-DDI-DrugBank.d272.s0.e0
in;O;O
combination;O;O
with;O;O
other;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
systematically;O;O
evaluated;O;O
,;O;O
but;O;O
alcohol;B-drug;B-DDI-DrugBank.d272.s0.e1
may;O;O
potentiate;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
bromocriptine;B-drug;B-DDI-DrugBank.d272.s0.e2
mesylate;I-drug;I-DDI-DrugBank.d272.s0.e2
.;O;O
DDI-DrugBank.d272.s1;;
Bromocriptine;B-drug;B-DDI-DrugBank.d272.s1.e0
mesylate;I-drug;I-DDI-DrugBank.d272.s1.e0
may;O;O
interact;O;O
with;O;O
dopamine;B-group;B-DDI-DrugBank.d272.s1.e1
antagonists;I-group;I-DDI-DrugBank.d272.s1.e1
,;O;O
butyrophenones;B-group;B-DDI-DrugBank.d272.s1.e2
,;O;O
and;O;O
certain;O;O
other;O;O
agents;O;O
.;O;O
DDI-DrugBank.d272.s2;;
Compounds;O;O
in;O;O
these;O;O
categories;O;O
result;O;O
in;O;O
a;O;O
decreased;O;O
efficacy;O;O
of;O;O
bromocriptine;B-drug;B-DDI-DrugBank.d272.s2.e0
mesylate;I-drug;I-DDI-DrugBank.d272.s2.e0
:;O;O
phenothiazines;B-group;B-DDI-DrugBank.d272.s2.e1
,;O;O
haloperidol;B-drug;B-DDI-DrugBank.d272.s2.e2
,;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d272.s2.e3
,;O;O
pimozide;B-drug;B-DDI-DrugBank.d272.s2.e4
.;O;O
DDI-DrugBank.d272.s3;;
Concomitant;O;O
use;O;O
of;O;O
bromocriptine;B-drug;B-DDI-DrugBank.d272.s3.e0
mesylate;I-drug;I-DDI-DrugBank.d272.s3.e0
with;O;O
other;O;O
ergot;B-group;B-DDI-DrugBank.d272.s3.e1
alkaloids;I-group;I-DDI-DrugBank.d272.s3.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d192.s0;;
Dexbrompheniramine;B-drug;B-DDI-DrugBank.d192.s0.e0
can;O;O
interact;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d192.s0.e1
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d192.s0.e2
depressants;I-group;I-DDI-DrugBank.d192.s0.e2
(;O;O
may;O;O
potentiate;O;O
the;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
either;O;O
these;O;O
medications;O;O
or;O;O
antihistamines;B-group;B-DDI-DrugBank.d192.s0.e3
);O;O
,;O;O
anticholinergics;B-group;B-DDI-DrugBank.d192.s0.e4
or;O;O
other;O;O
medications;O;O
with;O;O
anticholinergic;O;O
activity;O;O
(;O;O
anticholinergic;O;O
effects;O;O
may;O;O
be;O;O
potentiated;O;O
when;O;O
these;O;O
medications;O;O
are;O;O
used;O;O
concurrently;O;O
with;O;O
antihistamines;B-group;B-DDI-DrugBank.d192.s0.e5
);O;O
,;O;O
and;O;O
monoamine;B-group;B-DDI-DrugBank.d192.s0.e6
oxidase;I-group;I-DDI-DrugBank.d192.s0.e6
(;I-group;I-DDI-DrugBank.d192.s0.e6
MAO;I-group;I-DDI-DrugBank.d192.s0.e6
);I-group;I-DDI-DrugBank.d192.s0.e6
inhibitors;I-group;I-DDI-DrugBank.d192.s0.e6
(;O;O
concurrent;O;O
use;O;O
with;O;O
antihistamines;B-group;B-DDI-DrugBank.d192.s0.e7
may;O;O
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
and;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d192.s0.e8
);O;O
.;O;O
DDI-DrugBank.d342.s0;;
This;O;O
drug;O;O
may;O;O
interact;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d342.s0.e0
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d342.s0.e1
depressants;I-group;I-DDI-DrugBank.d342.s0.e1
(;O;O
may;O;O
potentiate;O;O
the;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
either;O;O
these;O;O
medications;O;O
or;O;O
antihistamines;B-group;B-DDI-DrugBank.d342.s0.e2
);O;O
,;O;O
anticholinergics;B-group;B-DDI-DrugBank.d342.s0.e3
or;O;O
other;O;O
medications;O;O
with;O;O
anticholinergic;O;O
activity;O;O
(;O;O
anticholinergic;O;O
effects;O;O
may;O;O
be;O;O
potentiated;O;O
when;O;O
these;O;O
medications;O;O
are;O;O
used;O;O
concurrently;O;O
with;O;O
antihistamines;B-group;B-DDI-DrugBank.d342.s0.e4
);O;O
,;O;O
and;O;O
monoamine;B-group;B-DDI-DrugBank.d342.s0.e5
oxidase;I-group;I-DDI-DrugBank.d342.s0.e5
(;I-group;I-DDI-DrugBank.d342.s0.e5
MAO;I-group;I-DDI-DrugBank.d342.s0.e5
);I-group;I-DDI-DrugBank.d342.s0.e5
inhibitors;I-group;I-DDI-DrugBank.d342.s0.e5
(;O;O
concurrent;O;O
use;O;O
with;O;O
antihistamines;B-group;B-DDI-DrugBank.d342.s0.e6
may;O;O
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
and;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d342.s0.e7
);O;O
.;O;O
DDI-DrugBank.d144.s0;;
Concomitant;O;O
oral;O;O
administration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d144.s0.e0
(;O;O
a;O;O
known;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
activity;O;O
in;O;O
the;O;O
liver;O;O
and;O;O
in;O;O
the;O;O
intestinal;O;O
mucosa;O;O
);O;O
caused;O;O
an;O;O
eight;O;O
-;O;O
fold;O;O
increase;O;O
of;O;O
the;O;O
systemic;O;O
exposure;O;O
to;O;O
oral;O;O
budesonide;B-drug;B-DDI-DrugBank.d144.s0.e1
.;O;O
DDI-DrugBank.d144.s1;;
If;O;O
treatment;O;O
with;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
activity;O;O
(;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d144.s1.e0
,;O;O
intraconazole;B-drug;B-DDI-DrugBank.d144.s1.e1
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d144.s1.e2
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d144.s1.e3
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d144.s1.e4
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d144.s1.e5
,;O;O
etc;O;O
.;O;O
);O;O
is;O;O
indicated;O;O
,;O;O
reduction;O;O
of;O;O
the;O;O
budesonide;B-drug;B-DDI-DrugBank.d144.s1.e6
dose;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d144.s2;;
After;O;O
extensive;O;O
intake;O;O
of;O;O
grapefruit;O;O
juice;O;O
(;O;O
which;O;O
inhibits;O;O
CYP3A4;O;O
activity;O;O
predominantly;O;O
in;O;O
the;O;O
intestinal;O;O
mucosa;O;O
);O;O
,;O;O
the;O;O
systemic;O;O
exposure;O;O
for;O;O
oral;O;O
budesonide;B-drug;B-DDI-DrugBank.d144.s2.e0
increased;O;O
about;O;O
two;O;O
times;O;O
.;O;O
DDI-DrugBank.d144.s3;;
As;O;O
with;O;O
other;O;O
drugs;O;O
primarily;O;O
being;O;O
metabolized;O;O
through;O;O
CYP3A4;O;O
,;O;O
ingestion;O;O
of;O;O
grapefruit;O;O
or;O;O
grapefruit;O;O
juice;O;O
should;O;O
be;O;O
avoided;O;O
in;O;O
connection;O;O
with;O;O
budesonide;B-drug;B-DDI-DrugBank.d144.s3.e0
administration;O;O
.;O;O
DDI-DrugBank.d331.s0;;
-;O;O
Drugs;O;O
with;O;O
ototoxic;O;O
potential;O;O
:;O;O
Especially;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
impaired;O;O
renal;O;O
function;O;O
,;O;O
the;O;O
use;O;O
of;O;O
parenterally;O;O
administered;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s0.e0
in;O;O
patients;O;O
to;O;O
whom;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d331.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d331.s0.e1
are;O;O
also;O;O
being;O;O
given;O;O
should;O;O
be;O;O
avoided;O;O
,;O;O
except;O;O
in;O;O
life;O;O
-;O;O
threatening;O;O
conditions;O;O
.;O;O
DDI-DrugBank.d331.s1;;
-;O;O
Drugs;O;O
with;O;O
nephrotoxic;O;O
potential;O;O
:;O;O
There;O;O
has;O;O
been;O;O
no;O;O
experience;O;O
on;O;O
the;O;O
concurrent;O;O
use;O;O
of;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s1.e0
with;O;O
drugs;O;O
known;O;O
to;O;O
have;O;O
a;O;O
nephrotoxic;O;O
potential;O;O
.;O;O
DDI-DrugBank.d331.s2;;
Therefore;O;O
,;O;O
the;O;O
simultaneous;O;O
administration;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d331.s3;;
-;O;O
Lithium;B-drug;B-DDI-DrugBank.d331.s3.e0
:;O;O
Lithium;B-drug;B-DDI-DrugBank.d331.s3.e1
should;O;O
generally;O;O
not;O;O
be;O;O
given;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d331.s3.e2
(;O;O
such;O;O
as;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s3.e3
);O;O
because;O;O
they;O;O
reduce;O;O
its;O;O
renal;O;O
clearance;O;O
and;O;O
add;O;O
a;O;O
high;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d331.s3.e4
toxicity;O;O
.;O;O
DDI-DrugBank.d331.s4;;
-;O;O
Probenecid;B-drug;B-DDI-DrugBank.d331.s4.e0
:;O;O
Pretreatment;O;O
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d331.s4.e1
reduces;O;O
both;O;O
the;O;O
natriuresis;O;O
and;O;O
hyperreninemia;O;O
produced;O;O
by;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s4.e2
.;O;O
DDI-DrugBank.d331.s5;;
This;O;O
antagonistic;O;O
effect;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d331.s5.e0
on;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s5.e1
natriuresis;O;O
is;O;O
not;O;O
due;O;O
to;O;O
a;O;O
direct;O;O
action;O;O
on;O;O
sodium;O;O
excretion;O;O
but;O;O
is;O;O
probably;O;O
secondary;O;O
to;O;O
its;O;O
inhibitory;O;O
effect;O;O
on;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s5.e2
.;O;O
DDI-DrugBank.d331.s6;;
Thus;O;O
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d331.s6.e0
should;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
with;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s6.e1
.;O;O
DDI-DrugBank.d331.s7;;
-;O;O
Indomethacin;B-drug;B-DDI-DrugBank.d331.s7.e0
:;O;O
Indomethacin;B-drug;B-DDI-DrugBank.d331.s7.e1
blunts;O;O
the;O;O
increases;O;O
in;O;O
urine;O;O
volume;O;O
and;O;O
sodium;O;O
excretion;O;O
seen;O;O
during;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s7.e2
treatment;O;O
and;O;O
inhibits;O;O
the;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s7.e3
-;O;O
induced;O;O
increase;O;O
in;O;O
plasma;O;O
renin;O;O
activity;O;O
.;O;O
DDI-DrugBank.d331.s8;;
Concurrent;O;O
therapy;O;O
with;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s8.e0
is;O;O
thus;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d331.s9;;
-;O;O
Antihypertensives;B-group;B-DDI-DrugBank.d331.s9.e0
:;O;O
Bumetanide;B-drug;B-DDI-DrugBank.d331.s9.e1
may;O;O
potentiate;O;O
the;O;O
effect;O;O
of;O;O
various;O;O
antihypertensive;B-group;B-DDI-DrugBank.d331.s9.e2
drugs;I-group;I-DDI-DrugBank.d331.s9.e2
,;O;O
necessitating;O;O
a;O;O
reduction;O;O
in;O;O
the;O;O
dosage;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d331.s10;;
-;O;O
Digoxin;B-drug;B-DDI-DrugBank.d331.s10.e0
:;O;O
Interaction;O;O
studies;O;O
in;O;O
humans;O;O
have;O;O
shown;O;O
no;O;O
effect;O;O
on;O;O
digoxin;B-drug;B-DDI-DrugBank.d331.s10.e1
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d331.s11;;
-;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d331.s11.e0
:;O;O
Interaction;O;O
studies;O;O
in;O;O
humans;O;O
have;O;O
shown;O;O
bumetanide;B-drug;B-DDI-DrugBank.d331.s11.e1
to;O;O
have;O;O
no;O;O
effect;O;O
on;O;O
warfarin;B-drug;B-DDI-DrugBank.d331.s11.e2
metabolism;O;O
or;O;O
on;O;O
plasma;O;O
prothrombin;O;O
activity;O;O
.;O;O
DDI-DrugBank.d153.s0;;
The;O;O
administration;O;O
of;O;O
local;O;O
anesthetic;B-group;B-DDI-DrugBank.d153.s0.e0
solutions;I-group;I-DDI-DrugBank.d153.s0.e0
containing;O;O
epinephrine;B-drug;B-DDI-DrugBank.d153.s0.e1
or;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d153.s0.e2
to;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d153.s0.e3
oxidase;I-group;I-DDI-DrugBank.d153.s0.e3
inhibitors;I-group;I-DDI-DrugBank.d153.s0.e3
or;O;O
tricyclic;B-group;B-DDI-DrugBank.d153.s0.e4
antidepressants;I-group;I-DDI-DrugBank.d153.s0.e4
may;O;O
produce;O;O
severe;O;O
,;O;O
prolonged;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d153.s1;;
Concurrent;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
should;O;O
generally;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d153.s2;;
In;O;O
situations;O;O
in;O;O
which;O;O
concurrent;O;O
therapy;O;O
is;O;O
necessary;O;O
,;O;O
careful;O;O
patient;O;O
monitoring;O;O
is;O;O
essential;O;O
.;O;O
DDI-DrugBank.d153.s3;;
Concurrent;O;O
administration;O;O
of;O;O
vasopressor;B-group;B-DDI-DrugBank.d153.s3.e0
drugs;I-group;I-DDI-DrugBank.d153.s3.e0
and;O;O
of;O;O
ergot;B-group;B-DDI-DrugBank.d153.s3.e1
-;I-group;I-DDI-DrugBank.d153.s3.e1
type;I-group;I-DDI-DrugBank.d153.s3.e1
oxytocic;I-group;I-DDI-DrugBank.d153.s3.e1
drugs;I-group;I-DDI-DrugBank.d153.s3.e1
may;O;O
cause;O;O
severe;O;O
,;O;O
persistent;O;O
hypertension;O;O
or;O;O
cerebrovascular;O;O
accidents;O;O
.;O;O
DDI-DrugBank.d153.s4;;
Phenothiazines;B-group;B-DDI-DrugBank.d153.s4.e0
and;O;O
butyrophenones;B-group;B-DDI-DrugBank.d153.s4.e1
may;O;O
reduce;O;O
or;O;O
reverse;O;O
the;O;O
pressor;O;O
effect;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d153.s4.e2
.;O;O
DDI-DrugBank.d380.s0;;
Buprenorphine;B-drug;B-DDI-DrugBank.d380.s0.e0
is;O;O
metabolized;O;O
to;O;O
norbuprenorphine;B-drug_n;B-DDI-DrugBank.d380.s0.e1
by;O;O
cytochrome;O;O
CYP;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d380.s1;;
Because;O;O
CYP;O;O
3A4;O;O
inhibitors;O;O
may;O;O
increase;O;O
plasma;O;O
concentrations;O;O
of;O;O
buprenorphine;B-drug;B-DDI-DrugBank.d380.s1.e0
,;O;O
patients;O;O
already;O;O
on;O;O
CYP;O;O
3A4;O;O
inhibitors;O;O
such;O;O
as;O;O
azole;B-group;B-DDI-DrugBank.d380.s1.e1
antifungals;I-group;I-DDI-DrugBank.d380.s1.e1
(;O;O
e.g.;O;O
DDI-DrugBank.d380.s2;;
ketoconazole;B-drug;B-DDI-DrugBank.d380.s2.e0
);O;O
,;O;O
macrolide;B-group;B-DDI-DrugBank.d380.s2.e1
antibiotics;I-group;I-DDI-DrugBank.d380.s2.e1
(;O;O
e.g.;O;O
erythromycin;B-drug;B-DDI-DrugBank.d380.s2.e2
);O;O
,;O;O
and;O;O
HIV;B-group;B-DDI-DrugBank.d380.s2.e3
protease;I-group;I-DDI-DrugBank.d380.s2.e3
inhibitors;I-group;I-DDI-DrugBank.d380.s2.e3
(;O;O
e.g.;O;O
ritonavir;B-drug;B-DDI-DrugBank.d380.s2.e4
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d380.s2.e5
and;O;O
saquinavir;B-drug;B-DDI-DrugBank.d380.s2.e6
);O;O
should;O;O
have;O;O
their;O;O
dose;O;O
of;O;O
SUBUTEX;B-brand;B-DDI-DrugBank.d380.s2.e7
or;O;O
SUBOXONE;B-brand;B-DDI-DrugBank.d380.s2.e8
adjusted;O;O
.;O;O
DDI-DrugBank.d380.s3;;
Based;O;O
on;O;O
anecdotal;O;O
reports;O;O
,;O;O
there;O;O
may;O;O
be;O;O
an;O;O
interaction;O;O
between;O;O
buprenorphine;B-drug;B-DDI-DrugBank.d380.s3.e0
and;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d380.s3.e1
.;O;O
DDI-DrugBank.d380.s4;;
There;O;O
have;O;O
been;O;O
a;O;O
number;O;O
of;O;O
reports;O;O
in;O;O
the;O;O
post;O;O
-;O;O
marketing;O;O
experience;O;O
of;O;O
coma;O;O
and;O;O
death;O;O
associated;O;O
with;O;O
the;O;O
concomitant;O;O
intravenous;O;O
misuse;O;O
of;O;O
buprenorphine;B-drug;B-DDI-DrugBank.d380.s4.e0
and;O;O
benzodiazepines;B-drug;B-DDI-DrugBank.d380.s4.e1
by;O;O
addicts;O;O
.;O;O
DDI-DrugBank.d380.s5;;
In;O;O
many;O;O
of;O;O
these;O;O
cases;O;O
,;O;O
buprenorphine;B-drug;B-DDI-DrugBank.d380.s5.e0
was;O;O
misused;O;O
by;O;O
self;O;O
-;O;O
injection;O;O
of;O;O
crushed;O;O
SUBUTEX;B-brand;B-DDI-DrugBank.d380.s5.e1
tablets;O;O
.;O;O
DDI-DrugBank.d380.s6;;
SUBUTEX;B-brand;B-DDI-DrugBank.d380.s6.e0
and;O;O
SUBOXONE;B-brand;B-DDI-DrugBank.d380.s6.e1
should;O;O
be;O;O
prescribed;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
on;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d380.s6.e2
or;O;O
other;O;O
drugs;O;O
that;O;O
act;O;O
on;O;O
the;O;O
central;O;O
nervous;O;O
system;O;O
,;O;O
regardless;O;O
of;O;O
whether;O;O
these;O;O
drugs;O;O
are;O;O
taken;O;O
on;O;O
the;O;O
advice;O;O
of;O;O
a;O;O
physician;O;O
or;O;O
are;O;O
taken;O;O
as;O;O
drugs;O;O
of;O;O
abuse;O;O
.;O;O
DDI-DrugBank.d380.s7;;
Patients;O;O
should;O;O
be;O;O
warned;O;O
of;O;O
the;O;O
potential;O;O
danger;O;O
of;O;O
the;O;O
intravenous;O;O
self;O;O
-;O;O
administration;O;O
of;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d380.s7.e0
while;O;O
under;O;O
treatment;O;O
with;O;O
SUBOXONE;B-brand;B-DDI-DrugBank.d380.s7.e1
or;O;O
SUBUTEX;B-brand;B-DDI-DrugBank.d380.s7.e2
.;O;O
DDI-DrugBank.d5.s0;;
Few;O;O
systemic;O;O
data;O;O
have;O;O
been;O;O
collected;O;O
on;O;O
the;O;O
metabolism;O;O
of;O;O
WELLBUTRIN;B-brand;B-DDI-DrugBank.d5.s0.e0
following;O;O
concomitant;O;O
administration;O;O
with;O;O
other;O;O
drugs;O;O
or;O;O
,;O;O
alternatively;O;O
,;O;O
the;O;O
effect;O;O
of;O;O
concomitant;O;O
administration;O;O
of;O;O
WELLBUTRIN;B-brand;B-DDI-DrugBank.d5.s0.e1
on;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d5.s1;;
Because;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s1.e0
is;O;O
extensively;O;O
metabolized;O;O
,;O;O
the;O;O
coadministration;O;O
of;O;O
other;O;O
drugs;O;O
may;O;O
affect;O;O
its;O;O
clinical;O;O
activity;O;O
.;O;O
DDI-DrugBank.d5.s2;;
In;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s2.e0
is;O;O
primarily;O;O
metabolized;O;O
to;O;O
hydroxybupropion;B-drug_n;B-DDI-DrugBank.d5.s2.e1
by;O;O
the;O;O
CYP2B6;O;O
isoenzyme;O;O
.;O;O
DDI-DrugBank.d5.s3;;
Therefore;O;O
,;O;O
the;O;O
potential;O;O
exists;O;O
for;O;O
a;O;O
drug;O;O
interaction;O;O
between;O;O
WELLBUTRIN;B-brand;B-DDI-DrugBank.d5.s3.e0
and;O;O
drugs;O;O
that;O;O
affect;O;O
the;O;O
CYP2B6;O;O
isoenzyme;O;O
(;O;O
e.g.;O;O
,;O;O
orphenadrine;B-drug;B-DDI-DrugBank.d5.s3.e1
and;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d5.s3.e2
);O;O
.;O;O
DDI-DrugBank.d5.s4;;
The;O;O
threohydrobupropion;B-drug_n;B-DDI-DrugBank.d5.s4.e0
metabolite;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s4.e1
does;O;O
not;O;O
appear;O;O
to;O;O
be;O;O
produced;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
isoenzymes;O;O
.;O;O
DDI-DrugBank.d5.s5;;
The;O;O
effects;O;O
of;O;O
concomitant;O;O
administration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d5.s5.e0
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s5.e1
and;O;O
its;O;O
active;O;O
metabolites;O;O
were;O;O
studied;O;O
in;O;O
24;O;O
healthy;O;O
young;O;O
male;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d5.s6;;
Following;O;O
oral;O;O
administration;O;O
of;O;O
two;O;O
150;O;O
-;O;O
mg;O;O
sustained;O;O
-;O;O
release;O;O
tablets;O;O
with;O;O
and;O;O
without;O;O
800;O;O
mg;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d5.s6.e0
,;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s6.e1
and;O;O
hydroxybupropion;B-drug_n;B-DDI-DrugBank.d5.s6.e2
were;O;O
unaffected;O;O
.;O;O
DDI-DrugBank.d5.s7;;
However;O;O
,;O;O
there;O;O
were;O;O
16;O;O
%;O;O
and;O;O
32;O;O
%;O;O
increases;O;O
in;O;O
the;O;O
AUC;O;O
and;O;O
Cmax;O;O
,;O;O
respectively;O;O
,;O;O
of;O;O
the;O;O
combined;O;O
moieties;O;O
of;O;O
threohydrobupropion;B-drug_n;B-DDI-DrugBank.d5.s7.e0
and;O;O
erythrohydrobupropion;B-drug_n;B-DDI-DrugBank.d5.s7.e1
.;O;O
DDI-DrugBank.d5.s8;;
While;O;O
not;O;O
systematically;O;O
studied;O;O
,;O;O
certain;O;O
drugs;O;O
may;O;O
induce;O;O
the;O;O
metabolism;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s8.e0
(;O;O
e.g.;O;O
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d5.s8.e1
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d5.s8.e2
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d5.s8.e3
);O;O
.;O;O
DDI-DrugBank.d5.s9;;
Animal;O;O
data;O;O
indicated;O;O
that;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s9.e0
may;O;O
be;O;O
an;O;O
inducer;O;O
of;O;O
drug;O;O
-;O;O
metabolizing;O;O
enzymes;O;O
in;O;O
humans;O;O
.;O;O
DDI-DrugBank.d5.s10;;
In;O;O
one;O;O
study;O;O
,;O;O
following;O;O
chronic;O;O
administration;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s10.e0
,;O;O
100;O;O
mg;O;O
3;O;O
times;O;O
daily;O;O
to;O;O
8;O;O
healthy;O;O
male;O;O
volunteers;O;O
for;O;O
14;O;O
days;O;O
,;O;O
there;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
induction;O;O
of;O;O
its;O;O
own;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d5.s11;;
Nevertheless;O;O
,;O;O
there;O;O
may;O;O
be;O;O
the;O;O
potential;O;O
for;O;O
clinically;O;O
important;O;O
alterations;O;O
of;O;O
blood;O;O
levels;O;O
of;O;O
coadministered;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d5.s12;;
Drugs;O;O
Metabolized;O;O
by;O;O
Cytochrome;O;O
P450IID6;O;O
(;O;O
CYP2D6;O;O
);O;O
:;O;O
Many;O;O
drugs;O;O
,;O;O
including;O;O
most;O;O
antidepressants;B-group;B-DDI-DrugBank.d5.s12.e0
(;O;O
SSRIs;O;O
,;O;O
many;O;O
tricyclics;B-group;B-DDI-DrugBank.d5.s12.e1
);O;O
,;O;O
beta;B-group;B-DDI-DrugBank.d5.s12.e2
-;I-group;I-DDI-DrugBank.d5.s12.e2
blockers;I-group;I-DDI-DrugBank.d5.s12.e2
,;O;O
antiarrhythmics;B-drug;B-DDI-DrugBank.d5.s12.e3
,;O;O
and;O;O
antipsychotics;B-group;B-DDI-DrugBank.d5.s12.e4
are;O;O
metabolized;O;O
by;O;O
the;O;O
CYP2D6;O;O
isoenzyme;O;O
.;O;O
DDI-DrugBank.d5.s13;;
Although;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s13.e0
is;O;O
not;O;O
metabolized;O;O
by;O;O
this;O;O
isoenzyme;O;O
,;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s13.e1
and;O;O
hydroxybupropion;B-drug_n;B-DDI-DrugBank.d5.s13.e2
are;O;O
inhibitors;O;O
of;O;O
the;O;O
CYP2D6;O;O
isoenzyme;O;O
in;O;O
vitro;O;O
.;O;O
DDI-DrugBank.d5.s14;;
In;O;O
a;O;O
study;O;O
of;O;O
15;O;O
male;O;O
subjects;O;O
(;O;O
ages;O;O
19;O;O
to;O;O
35;O;O
years;O;O
);O;O
who;O;O
were;O;O
extensive;O;O
metabolizers;O;O
of;O;O
the;O;O
CYP2D6;O;O
isoenzyme;O;O
,;O;O
daily;O;O
doses;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s14.e0
given;O;O
as;O;O
150;O;O
mg;O;O
twice;O;O
daily;O;O
followed;O;O
by;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
50;O;O
mg;O;O
desipramine;B-drug;B-DDI-DrugBank.d5.s14.e1
increased;O;O
the;O;O
Cmax;O;O
,;O;O
AUC;O;O
,;O;O
and;O;O
t1;O;O
/;O;O
2;O;O
of;O;O
desipramine;B-drug;B-DDI-DrugBank.d5.s14.e2
by;O;O
an;O;O
average;O;O
of;O;O
approximately;O;O
2;O;O
-;O;O
,;O;O
5;O;O
-;O;O
and;O;O
2;O;O
-;O;O
fold;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d5.s15;;
The;O;O
effect;O;O
was;O;O
present;O;O
for;O;O
at;O;O
least;O;O
7;O;O
days;O;O
after;O;O
the;O;O
last;O;O
dose;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s15.e0
.;O;O
DDI-DrugBank.d5.s16;;
Concomitant;O;O
use;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s16.e0
with;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP2D6;O;O
has;O;O
not;O;O
been;O;O
formally;O;O
studied;O;O
.;O;O
DDI-DrugBank.d5.s17;;
Therefore;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s17.e0
with;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
CYP2D6;O;O
isoenzyme;O;O
including;O;O
certain;O;O
antidepressants;B-group;B-DDI-DrugBank.d5.s17.e1
(;O;O
e.g.;O;O
,;O;O
nortriptyline;B-drug;B-DDI-DrugBank.d5.s17.e2
,;O;O
imipramine;B-drug;B-DDI-DrugBank.d5.s17.e3
,;O;O
desipramine;B-drug;B-DDI-DrugBank.d5.s17.e4
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d5.s17.e5
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d5.s17.e6
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d5.s17.e7
);O;O
,;O;O
antipsychotics;B-group;B-DDI-DrugBank.d5.s17.e8
(;O;O
e.g.;O;O
,;O;O
haloperidol;B-drug;B-DDI-DrugBank.d5.s17.e9
,;O;O
risperidone;B-drug;B-DDI-DrugBank.d5.s17.e10
,;O;O
thioridazine;B-drug;B-DDI-DrugBank.d5.s17.e11
);O;O
,;O;O
beta;B-group;B-DDI-DrugBank.d5.s17.e12
-;I-group;I-DDI-DrugBank.d5.s17.e12
blockers;I-group;I-DDI-DrugBank.d5.s17.e12
(;O;O
e.g.;O;O
,;O;O
metoprolol;B-drug;B-DDI-DrugBank.d5.s17.e13
);O;O
,;O;O
and;O;O
Type;B-group;B-DDI-DrugBank.d5.s17.e14
1C;I-group;I-DDI-DrugBank.d5.s17.e14
antiarrhythmics;I-group;I-DDI-DrugBank.d5.s17.e14
(;O;O
e.g.;O;O
,;O;O
propafenone;B-drug;B-DDI-DrugBank.d5.s17.e15
,;O;O
flecainide;B-drug;B-DDI-DrugBank.d5.s17.e16
);O;O
,;O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
and;O;O
should;O;O
be;O;O
initiated;O;O
at;O;O
the;O;O
lower;O;O
end;O;O
of;O;O
the;O;O
dose;O;O
range;O;O
of;O;O
the;O;O
concomitant;O;O
medication;O;O
.;O;O
DDI-DrugBank.d5.s18;;
If;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s18.e0
is;O;O
added;O;O
to;O;O
the;O;O
treatment;O;O
regimen;O;O
of;O;O
a;O;O
patient;O;O
already;O;O
receiving;O;O
a;O;O
drug;O;O
metabolized;O;O
by;O;O
CYP2D6;O;O
,;O;O
the;O;O
need;O;O
to;O;O
decrease;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
original;O;O
medication;O;O
should;O;O
be;O;O
considered;O;O
,;O;O
particularly;O;O
for;O;O
those;O;O
concomitant;O;O
medications;O;O
with;O;O
a;O;O
narrow;O;O
therapeutic;O;O
index;O;O
.;O;O
DDI-DrugBank.d5.s19;;
MAO;B-group;B-DDI-DrugBank.d5.s19.e0
Inhibitors;I-group;I-DDI-DrugBank.d5.s19.e0
:;O;O
Studies;O;O
in;O;O
animals;O;O
demonstrate;O;O
that;O;O
the;O;O
acute;O;O
toxicity;O;O
of;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s19.e1
is;O;O
enhanced;O;O
by;O;O
the;O;O
MAO;B-group;B-DDI-DrugBank.d5.s19.e2
inhibitor;I-group;I-DDI-DrugBank.d5.s19.e2
phenelzine;I-drug;I-DDI-DrugBank.d5.s19.e3
.;O;O
DDI-DrugBank.d5.s20;;
Levodopa;B-drug;B-DDI-DrugBank.d5.s20.e0
and;O;O
Amantadine;B-drug;B-DDI-DrugBank.d5.s20.e1
:;O;O
Limited;O;O
clinical;O;O
data;O;O
suggest;O;O
a;O;O
higher;O;O
incidence;O;O
of;O;O
adverse;O;O
experiences;O;O
in;O;O
patients;O;O
receiving;O;O
bupropion;B-drug;B-DDI-DrugBank.d5.s20.e2
concurrently;O;O
with;O;O
either;O;O
levodopa;B-drug;B-DDI-DrugBank.d5.s20.e3
or;O;O
amantadine;B-drug;B-DDI-DrugBank.d5.s20.e4
.;O;O
DDI-DrugBank.d5.s21;;
Administration;O;O
of;O;O
WELLBUTRIN;B-brand;B-DDI-DrugBank.d5.s21.e0
Tablets;O;O
to;O;O
patients;O;O
receiving;O;O
either;O;O
levodopa;B-drug;B-DDI-DrugBank.d5.s21.e1
or;O;O
amantadine;B-drug;B-DDI-DrugBank.d5.s21.e2
concurrently;O;O
should;O;O
be;O;O
undertaken;O;O
with;O;O
caution;O;O
,;O;O
using;O;O
small;O;O
initial;O;O
doses;O;O
and;O;O
small;O;O
gradual;O;O
dose;O;O
increases;O;O
.;O;O
DDI-DrugBank.d5.s22;;
Drugs;O;O
that;O;O
Lower;O;O
Seizure;O;O
Threshold;O;O
:;O;O
Concurrent;O;O
administration;O;O
of;O;O
WELLBUTRIN;B-brand;B-DDI-DrugBank.d5.s22.e0
and;O;O
agents;O;O
(;O;O
e.g.;O;O
,;O;O
antipsychotics;B-group;B-DDI-DrugBank.d5.s22.e1
,;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d5.s22.e2
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d5.s22.e3
,;O;O
systemic;O;O
steroids;B-group;B-DDI-DrugBank.d5.s22.e4
,;O;O
etc;O;O
.;O;O
);O;O
that;O;O
lower;O;O
seizure;O;O
threshold;O;O
should;O;O
be;O;O
undertaken;O;O
only;O;O
with;O;O
extreme;O;O
caution;O;O
.;O;O
DDI-DrugBank.d5.s23;;
Low;O;O
initial;O;O
dosing;O;O
and;O;O
small;O;O
gradual;O;O
dose;O;O
increases;O;O
should;O;O
be;O;O
employed;O;O
.;O;O
DDI-DrugBank.d5.s24;;
Nicotine;B-drug;B-DDI-DrugBank.d5.s24.e0
Transdermal;O;O
System;O;O
:;O;O
.;O;O
DDI-DrugBank.d5.s25;;
Alcohol;B-drug;B-DDI-DrugBank.d5.s25.e0
:;O;O
In;O;O
post;O;O
-;O;O
marketing;O;O
experience;O;O
,;O;O
there;O;O
have;O;O
been;O;O
rare;O;O
reports;O;O
of;O;O
adverse;O;O
neuropsychiatric;O;O
events;O;O
or;O;O
reduced;O;O
alcohol;B-drug;B-DDI-DrugBank.d5.s25.e1
tolerance;O;O
in;O;O
patients;O;O
who;O;O
were;O;O
drinking;O;O
alcohol;B-drug;B-DDI-DrugBank.d5.s25.e2
during;O;O
treatment;O;O
with;O;O
WELLBUTRIN;B-brand;B-DDI-DrugBank.d5.s25.e3
.;O;O
DDI-DrugBank.d5.s26;;
The;O;O
consumption;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d5.s26.e0
during;O;O
treatment;O;O
with;O;O
WELLBUTRIN;B-brand;B-DDI-DrugBank.d5.s26.e1
should;O;O
be;O;O
minimized;O;O
or;O;O
avoided;O;O
(;O;O
also;O;O
see;O;O
a;O;O
href=;O;O
bupropz_od.htm#CI;O;O
CONTRAINDICATIONS;O;O
);O;O
DDI-DrugBank.d5.s27;;
.;O;O
DDI-DrugBank.d5.s28;;
DDI-DrugBank.d463.s0;;
It;O;O
is;O;O
recommended;O;O
that;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s0.e0
hydrochloride;I-drug;I-DDI-DrugBank.d463.s0.e0
not;O;O
be;O;O
used;O;O
concomitantly;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d463.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d463.s0.e1
Because;O;O
the;O;O
effects;O;O
of;O;O
concomitant;O;O
administration;O;O
of;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s0.e2
HCl;I-drug;I-DDI-DrugBank.d463.s0.e2
with;O;O
most;O;O
other;O;O
psychotropic;B-group;B-DDI-DrugBank.d463.s0.e3
drugs;I-group;I-DDI-DrugBank.d463.s0.e3
have;O;O
not;O;O
been;O;O
studied;O;O
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s0.e4
HCl;I-drug;I-DDI-DrugBank.d463.s0.e4
with;O;O
other;O;O
CNS;O;O
-;O;O
active;O;O
drugs;O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d463.s1;;
There;O;O
is;O;O
one;O;O
report;O;O
suggesting;O;O
that;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
trazodone;B-drug;B-DDI-DrugBank.d463.s1.e0
hydrochloride;I-drug;I-DDI-DrugBank.d463.s1.e0
(;O;O
Desyrel;B-brand;B-DDI-DrugBank.d463.s1.e1
);O;O
and;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s1.e2
HCl;I-drug;I-DDI-DrugBank.d463.s1.e2
may;O;O
have;O;O
caused;O;O
3;O;O
-;O;O
to;O;O
6;O;O
-;O;O
fold;O;O
elevations;O;O
on;O;O
SGPT;O;O
(;O;O
ALT;O;O
);O;O
in;O;O
a;O;O
few;O;O
patients;O;O
.;O;O
DDI-DrugBank.d463.s2;;
In;O;O
a;O;O
similar;O;O
study;O;O
,;O;O
attempting;O;O
to;O;O
replicate;O;O
this;O;O
finding;O;O
,;O;O
no;O;O
interactive;O;O
effect;O;O
on;O;O
hepatic;O;O
transaminases;O;O
was;O;O
identified;O;O
.;O;O
DDI-DrugBank.d463.s3;;
In;O;O
a;O;O
study;O;O
in;O;O
normal;O;O
volunteers;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s3.e0
HCl;I-drug;I-DDI-DrugBank.d463.s3.e0
and;O;O
haloperidol;B-drug;B-DDI-DrugBank.d463.s3.e1
resulted;O;O
in;O;O
increased;O;O
serum;O;O
haloperidol;B-drug;B-DDI-DrugBank.d463.s3.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d463.s4;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
finding;O;O
is;O;O
not;O;O
clear;O;O
.;O;O
DDI-DrugBank.d463.s5;;
In;O;O
vitro;O;O
,;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s5.e0
does;O;O
not;O;O
displace;O;O
tightly;O;O
bound;O;O
drugs;O;O
like;O;O
phenytoin;B-drug;B-DDI-DrugBank.d463.s5.e1
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d463.s5.e2
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d463.s5.e3
from;O;O
serum;O;O
proteins;O;O
.;O;O
DDI-DrugBank.d463.s6;;
However;O;O
,;O;O
there;O;O
has;O;O
been;O;O
one;O;O
report;O;O
of;O;O
prolonged;O;O
prothrombin;O;O
time;O;O
when;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s6.e0
was;O;O
added;O;O
to;O;O
the;O;O
regimen;O;O
of;O;O
a;O;O
patient;O;O
treated;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d463.s6.e1
.;O;O
DDI-DrugBank.d463.s7;;
The;O;O
patient;O;O
was;O;O
also;O;O
chronically;O;O
receiving;O;O
phenytoin;B-drug;B-DDI-DrugBank.d463.s7.e0
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d463.s7.e1
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d463.s7.e2
,;O;O
and;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d463.s7.e3
sodium;I-drug;I-DDI-DrugBank.d463.s7.e3
.;O;O
DDI-DrugBank.d463.s8;;
In;O;O
vitro;O;O
,;O;O
buspirone;B-drug;B-DDI-DrugBank.d463.s8.e0
may;O;O
displace;O;O
less;O;O
firmly;O;O
bound;O;O
drugs;O;O
like;O;O
digoxin;B-drug;B-DDI-DrugBank.d463.s8.e1
.;O;O
DDI-DrugBank.d463.s9;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
property;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d72.s0;;
Itraconazole;B-drug;B-DDI-DrugBank.d72.s0.e0
decreases;O;O
busulfan;B-drug;B-DDI-DrugBank.d72.s0.e1
clearance;O;O
by;O;O
up;O;O
to;O;O
25;O;O
%;O;O
,;O;O
and;O;O
may;O;O
produce;O;O
AUCs;O;O
1500;O;O
M;O;O
min;O;O
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d72.s1;;
Fluconazole;B-drug;B-DDI-DrugBank.d72.s1.e0
,;O;O
and;O;O
the;O;O
5;B-group;B-DDI-DrugBank.d72.s1.e1
-;I-group;I-DDI-DrugBank.d72.s1.e1
HT3;I-group;I-DDI-DrugBank.d72.s1.e1
antiemetics;I-group;I-DDI-DrugBank.d72.s1.e1
ondansetron;I-drug;I-DDI-DrugBank.d72.s1.e2
(;O;O
Zofran;B-brand;B-DDI-DrugBank.d72.s1.e3
);O;O
and;O;O
granisetron;B-drug;B-DDI-DrugBank.d72.s1.e4
(;O;O
Kytril;B-brand;B-DDI-DrugBank.d72.s1.e5
);O;O
have;O;O
all;O;O
been;O;O
used;O;O
with;O;O
BUSULFEX;B-brand;B-DDI-DrugBank.d72.s1.e6
.;O;O
DDI-DrugBank.d72.s2;;
Phenytoin;B-drug;B-DDI-DrugBank.d72.s2.e0
increases;O;O
the;O;O
clearance;O;O
of;O;O
busulfan;B-drug;B-DDI-DrugBank.d72.s2.e1
by;O;O
15;O;O
%;O;O
or;O;O
more;O;O
,;O;O
possibly;O;O
due;O;O
to;O;O
the;O;O
induction;O;O
of;O;O
glutathione;O;O
-;O;O
S;O;O
-;O;O
transferase;O;O
.;O;O
DDI-DrugBank.d72.s3;;
Since;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
BUSULFEX;B-brand;B-DDI-DrugBank.d72.s3.e0
were;O;O
studied;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d72.s3.e1
,;O;O
the;O;O
clearance;O;O
of;O;O
BUSULFEX;B-brand;B-DDI-DrugBank.d72.s3.e2
at;O;O
the;O;O
recommended;O;O
dose;O;O
may;O;O
be;O;O
lower;O;O
and;O;O
exposure;O;O
(;O;O
AUC;O;O
);O;O
higher;O;O
in;O;O
patients;O;O
not;O;O
treated;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d72.s3.e3
.;O;O
DDI-DrugBank.d72.s4;;
Because;O;O
busulfan;B-drug;B-DDI-DrugBank.d72.s4.e0
is;O;O
eliminated;O;O
from;O;O
the;O;O
body;O;O
via;O;O
conjugation;O;O
with;O;O
glutathione;O;O
,;O;O
use;O;O
of;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d72.s4.e1
prior;O;O
to;O;O
(;O;O
72;O;O
hours;O;O
);O;O
or;O;O
concurrent;O;O
with;O;O
BUSULFEX;B-brand;B-DDI-DrugBank.d72.s4.e2
may;O;O
result;O;O
in;O;O
reduced;O;O
busulfan;B-drug;B-DDI-DrugBank.d72.s4.e3
clearance;O;O
based;O;O
upon;O;O
the;O;O
known;O;O
property;O;O
of;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d72.s4.e4
to;O;O
decrease;O;O
glutathione;O;O
levels;O;O
in;O;O
the;O;O
blood;O;O
and;O;O
tissues;O;O
.;O;O
DDI-DrugBank.d184.s0;;
Interactions;O;O
may;O;O
occur;O;O
with;O;O
the;O;O
following;O;O
:;O;O
adrenocorticoids;O;O
(;O;O
cortisone;O;O
-;O;O
like;O;O
medicine;O;O
);O;O
,;O;O
anticoagulants;B-group;B-DDI-DrugBank.d184.s0.e0
(;O;O
blood;B-group;B-DDI-DrugBank.d184.s0.e1
thinners;I-group;I-DDI-DrugBank.d184.s0.e1
);O;O
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d184.s0.e2
,;O;O
corticotropin;B-drug;B-DDI-DrugBank.d184.s0.e3
(;O;O
barbiturates;B-group;B-DDI-DrugBank.d184.s0.e4
may;O;O
decrease;O;O
the;O;O
effects;O;O
of;O;O
these;O;O
medicines;O;O
);O;O
,;O;O
central;B-group;B-DDI-DrugBank.d184.s0.e5
nervous;I-group;I-DDI-DrugBank.d184.s0.e5
system;I-group;I-DDI-DrugBank.d184.s0.e5
(;I-group;I-DDI-DrugBank.d184.s0.e5
CNS;I-group;I-DDI-DrugBank.d184.s0.e5
);I-group;I-DDI-DrugBank.d184.s0.e5
depressants;I-group;I-DDI-DrugBank.d184.s0.e5
(;O;O
using;O;O
these;O;O
medicines;O;O
with;O;O
barbiturates;B-group;B-DDI-DrugBank.d184.s0.e6
may;O;O
result;O;O
in;O;O
increased;O;O
CNS;O;O
depressant;O;O
effects;O;O
);O;O
,;O;O
divalproex;B-drug;B-DDI-DrugBank.d184.s0.e7
sodium;I-drug;I-DDI-DrugBank.d184.s0.e7
,;O;O
valproic;B-drug;B-DDI-DrugBank.d184.s0.e8
acid;I-drug;I-DDI-DrugBank.d184.s0.e8
(;O;O
using;O;O
these;O;O
medicines;O;O
with;O;O
barbiturates;B-group;B-DDI-DrugBank.d184.s0.e9
may;O;O
change;O;O
the;O;O
amount;O;O
of;O;O
either;O;O
medicine;O;O
that;O;O
you;O;O
need;O;O
to;O;O
take;O;O
);O;O
,;O;O
and;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d184.s0.e10
containing;O;O
estrogens;B-group;B-DDI-DrugBank.d184.s0.e11
(;O;O
barbiturates;B-group;B-DDI-DrugBank.d184.s0.e12
may;O;O
decrease;O;O
the;O;O
effectiveness;O;O
of;O;O
these;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d184.s0.e13
,;O;O
and;O;O
you;O;O
may;O;O
need;O;O
to;O;O
change;O;O
to;O;O
a;O;O
different;O;O
type;O;O
of;O;O
birth;O;O
control;O;O
);O;O
.;O;O
DDI-DrugBank.d559.s0;;
The;O;O
CNS;O;O
effects;O;O
of;O;O
butalbital;B-drug;B-DDI-DrugBank.d559.s0.e0
may;O;O
be;O;O
enhanced;O;O
by;O;O
monoamine;B-group;B-DDI-DrugBank.d559.s0.e1
oxidase;I-group;I-DDI-DrugBank.d559.s0.e1
(;I-group;I-DDI-DrugBank.d559.s0.e1
MAO;I-group;I-DDI-DrugBank.d559.s0.e1
);I-group;I-DDI-DrugBank.d559.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d559.s0.e1
.;O;O
DDI-DrugBank.d559.s1;;
Butalbital;B-drug;B-DDI-DrugBank.d559.s1.e0
,;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d559.s1.e1
and;O;O
caffeine;B-drug;B-DDI-DrugBank.d559.s1.e2
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
:;O;O
other;O;O
narcotic;B-group;B-DDI-DrugBank.d559.s1.e3
analgesics;I-group;I-DDI-DrugBank.d559.s1.e3
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d559.s1.e4
,;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d559.s1.e5
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d559.s1.e6
such;O;O
as;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d559.s1.e7
,;O;O
sedative;B-group;B-DDI-DrugBank.d559.s1.e8
-;I-group;I-DDI-DrugBank.d559.s1.e8
hypnotics;I-group;I-DDI-DrugBank.d559.s1.e8
,;O;O
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d559.s1.e9
depressants;I-group;I-DDI-DrugBank.d559.s1.e9
,;O;O
causing;O;O
increased;O;O
CNS;O;O
depression;O;O
.;O;O
DDI-DrugBank.d559.s2;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Acetaminophen;B-drug;B-DDI-DrugBank.d559.s2.e0
may;O;O
produce;O;O
false;O;O
-;O;O
positive;O;O
test;O;O
results;O;O
for;O;O
urinary;O;O
5;O;O
-;O;O
hydroxyindoleacetic;O;O
acid;O;O
.;O;O
DDI-DrugBank.d80.s0;;
Potential;O;O
drug;O;O
interactions;O;O
between;O;O
Mentax;B-brand;B-DDI-DrugBank.d80.s0.e0
(;O;O
butenafine;B-drug;B-DDI-DrugBank.d80.s0.e1
HCl;I-drug;I-DDI-DrugBank.d80.s0.e1
cream;O;O
);O;O
Cream;O;O
,;O;O
1;O;O
%;O;O
,;O;O
and;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
systematically;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d246.s0;;
Concurrent;O;O
use;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s0.e0
with;O;O
central;B-group;B-DDI-DrugBank.d246.s0.e1
nervous;I-group;I-DDI-DrugBank.d246.s0.e1
system;I-group;I-DDI-DrugBank.d246.s0.e1
depressants;I-group;I-DDI-DrugBank.d246.s0.e1
(;O;O
e.g.;O;O
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d246.s0.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d246.s0.e3
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d246.s0.e4
,;O;O
and;O;O
antihistamines;B-group;B-DDI-DrugBank.d246.s0.e5
);O;O
may;O;O
result;O;O
in;O;O
increased;O;O
central;B-group;B-DDI-DrugBank.d246.s0.e6
nervous;I-group;I-DDI-DrugBank.d246.s0.e6
system;I-group;I-DDI-DrugBank.d246.s0.e6
depressant;I-group;I-DDI-DrugBank.d246.s0.e6
effects;O;O
.;O;O
DDI-DrugBank.d246.s1;;
When;O;O
used;O;O
concurrently;O;O
with;O;O
such;O;O
drugs;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s1.e0
should;O;O
be;O;O
the;O;O
smallest;O;O
effective;O;O
dose;O;O
and;O;O
the;O;O
frequency;O;O
of;O;O
dosing;O;O
reduced;O;O
as;O;O
much;O;O
as;O;O
possible;O;O
when;O;O
administered;O;O
concomitantly;O;O
with;O;O
drugs;O;O
that;O;O
potentiate;O;O
the;O;O
action;O;O
of;O;O
opioids;B-group;B-DDI-DrugBank.d246.s1.e1
.;O;O
DDI-DrugBank.d246.s2;;
In;O;O
healthy;O;O
volunteers;O;O
,;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
a;O;O
1;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s2.e0
administered;O;O
as;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s2.e1
NS;I-brand;I-DDI-DrugBank.d246.s2.e1
were;O;O
not;O;O
affected;O;O
by;O;O
the;O;O
coadministration;O;O
of;O;O
a;O;O
single;O;O
6;O;O
-;O;O
mg;O;O
subcutaneous;O;O
dose;O;O
of;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d246.s2.e2
.;O;O
DDI-DrugBank.d246.s3;;
However;O;O
,;O;O
in;O;O
another;O;O
study;O;O
in;O;O
healthy;O;O
volunteers;O;O
,;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s3.e0
were;O;O
significantly;O;O
altered;O;O
(;O;O
29;O;O
%;O;O
decrease;O;O
in;O;O
AUC;O;O
and;O;O
38;O;O
%;O;O
decrease;O;O
in;O;O
Cmax;O;O
);O;O
when;O;O
a;O;O
1;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s3.e1
NS;I-brand;I-DDI-DrugBank.d246.s3.e1
was;O;O
administered;O;O
1;O;O
minute;O;O
after;O;O
a;O;O
20;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d246.s3.e2
nasal;O;O
spray;O;O
.;O;O
DDI-DrugBank.d246.s4;;
(;O;O
The;O;O
two;O;O
drugs;O;O
were;O;O
administered;O;O
in;O;O
opposite;O;O
nostrils;O;O
.;O;O
);O;O
DDI-DrugBank.d246.s5;;
When;O;O
the;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s5.e0
NS;I-brand;I-DDI-DrugBank.d246.s5.e0
was;O;O
administered;O;O
30;O;O
minutes;O;O
after;O;O
the;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d246.s5.e1
nasal;O;O
spray;O;O
,;O;O
the;O;O
AUC;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s5.e2
increased;O;O
11;O;O
%;O;O
and;O;O
Cmax;O;O
decreased;O;O
18;O;O
%;O;O
.;O;O
DDI-DrugBank.d246.s6;;
In;O;O
neither;O;O
case;O;O
were;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d246.s6.e0
affected;O;O
by;O;O
coadministration;O;O
with;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s6.e1
NS;I-brand;I-DDI-DrugBank.d246.s6.e1
.;O;O
DDI-DrugBank.d246.s7;;
These;O;O
results;O;O
suggest;O;O
that;O;O
the;O;O
analgesic;O;O
effect;O;O
of;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s7.e0
NS;I-brand;I-DDI-DrugBank.d246.s7.e0
may;O;O
be;O;O
diminished;O;O
when;O;O
it;O;O
is;O;O
administered;O;O
shortly;O;O
after;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d246.s7.e1
nasal;O;O
spray;O;O
,;O;O
but;O;O
by;O;O
30;O;O
minutes;O;O
any;O;O
such;O;O
reduction;O;O
in;O;O
effect;O;O
should;O;O
be;O;O
minimal;O;O
.;O;O
DDI-DrugBank.d246.s8;;
The;O;O
safety;O;O
of;O;O
using;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s8.e0
NS;I-brand;I-DDI-DrugBank.d246.s8.e0
and;O;O
IMITREX;B-brand;B-DDI-DrugBank.d246.s8.e1
(;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d246.s8.e2
);O;O
Nasal;O;O
Spray;O;O
during;O;O
the;O;O
same;O;O
episode;O;O
of;O;O
migraine;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d246.s9;;
However;O;O
,;O;O
it;O;O
should;O;O
be;O;O
noted;O;O
that;O;O
both;O;O
products;O;O
are;O;O
capable;O;O
of;O;O
producing;O;O
transient;O;O
increases;O;O
in;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d246.s10;;
The;O;O
pharmacokinetics;O;O
of;O;O
a;O;O
1;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s10.e0
administered;O;O
as;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s10.e1
NS;I-brand;I-DDI-DrugBank.d246.s10.e1
were;O;O
not;O;O
affected;O;O
by;O;O
the;O;O
coadministration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d246.s10.e2
(;O;O
300;O;O
mg;O;O
QID;O;O
);O;O
.;O;O
DDI-DrugBank.d246.s11;;
Conversely;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s11.e0
NS;I-brand;I-DDI-DrugBank.d246.s11.e0
(;O;O
1;O;O
mg;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s11.e1
QID;O;O
);O;O
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
a;O;O
300;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d246.s11.e2
.;O;O
DDI-DrugBank.d246.s12;;
It;O;O
is;O;O
not;O;O
known;O;O
if;O;O
the;O;O
effects;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s12.e0
are;O;O
altered;O;O
by;O;O
concomitant;O;O
medications;O;O
that;O;O
affect;O;O
hepatic;O;O
metabolism;O;O
of;O;O
drugs;O;O
(;O;O
erythromycin;B-drug;B-DDI-DrugBank.d246.s12.e1
,;O;O
etc;O;O
.;O;O
);O;O
,;O;O
but;O;O
physicians;O;O
should;O;O
be;O;O
alert;O;O
to;O;O
the;O;O
possibility;O;O
that;O;O
a;O;O
smaller;O;O
initial;O;O
dose;O;O
and;O;O
longer;O;O
intervals;O;O
between;O;O
doses;O;O
may;O;O
be;O;O
needed;O;O
.;O;O
DDI-DrugBank.d246.s13;;
The;O;O
fraction;O;O
of;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s13.e0
NS;I-brand;I-DDI-DrugBank.d246.s13.e0
absorbed;O;O
is;O;O
unaffected;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
a;O;O
nasal;B-group;B-DDI-DrugBank.d246.s13.e1
vasoconstrictor;I-group;I-DDI-DrugBank.d246.s13.e1
(;O;O
oxymetazoline;B-drug;B-DDI-DrugBank.d246.s13.e2
);O;O
,;O;O
but;O;O
the;O;O
rate;O;O
of;O;O
absorption;O;O
is;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d246.s14;;
Therefore;O;O
,;O;O
a;O;O
slower;O;O
onset;O;O
can;O;O
be;O;O
anticipated;O;O
if;O;O
STADOL;B-brand;B-DDI-DrugBank.d246.s14.e0
NS;I-brand;I-DDI-DrugBank.d246.s14.e0
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
,;O;O
or;O;O
immediately;O;O
following;O;O
,;O;O
a;O;O
nasal;B-group;B-DDI-DrugBank.d246.s14.e1
vasoconstrictor;I-group;I-DDI-DrugBank.d246.s14.e1
.;O;O
DDI-DrugBank.d246.s15;;
No;O;O
information;O;O
is;O;O
available;O;O
about;O;O
the;O;O
use;O;O
of;O;O
butorphanol;B-drug;B-DDI-DrugBank.d246.s15.e0
concurrently;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d246.s15.e1
inhibitors;I-group;I-DDI-DrugBank.d246.s15.e1
.;O;O
DDI-DrugBank.d282.s0;;
DOSTINEX;B-brand;B-DDI-DrugBank.d282.s0.e0
should;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
with;O;O
D2;O;O
-;O;O
antagonists;O;O
,;O;O
such;O;O
as;O;O
phenothiazines;B-group;B-DDI-DrugBank.d282.s0.e1
,;O;O
butyrophenones;B-group;B-DDI-DrugBank.d282.s0.e2
,;O;O
thioxanthines;B-group;B-DDI-DrugBank.d282.s0.e3
,;O;O
or;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d282.s0.e4
.;O;O
DDI-DrugBank.d89.s0;;
Cytochrome;O;O
P450;O;O
1A2;O;O
(;O;O
CYP1A2;O;O
);O;O
is;O;O
known;O;O
to;O;O
be;O;O
the;O;O
major;O;O
enzyme;O;O
involved;O;O
in;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s0.e0
.;O;O
DDI-DrugBank.d89.s1;;
Therefore;O;O
,;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s1.e0
has;O;O
the;O;O
potential;O;O
to;O;O
interact;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
CYP1A2;O;O
,;O;O
inhibit;O;O
CYP1A2;O;O
,;O;O
or;O;O
induce;O;O
CYP1A2;O;O
.;O;O
DDI-DrugBank.d89.s2;;
Few;O;O
data;O;O
exist;O;O
on;O;O
drug;O;O
interactions;O;O
with;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s2.e0
in;O;O
preterm;O;O
neonates;O;O
.;O;O
DDI-DrugBank.d89.s3;;
Based;O;O
on;O;O
adult;O;O
data;O;O
,;O;O
lower;O;O
doses;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s3.e0
may;O;O
be;O;O
needed;O;O
following;O;O
coadministration;O;O
of;O;O
drugs;O;O
which;O;O
are;O;O
reported;O;O
to;O;O
decrease;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s3.e1
elimination;O;O
(;O;O
e.g.;O;O
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d89.s3.e2
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d89.s3.e3
);O;O
and;O;O
higher;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s3.e4
doses;O;O
may;O;O
be;O;O
needed;O;O
following;O;O
coadministration;O;O
of;O;O
drugs;O;O
that;O;O
increase;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s3.e5
elimination;O;O
(;O;O
e.g.;O;O
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d89.s3.e6
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d89.s3.e7
);O;O
.;O;O
DDI-DrugBank.d89.s4;;
Caffeine;B-drug;B-DDI-DrugBank.d89.s4.e0
administered;O;O
concurrently;O;O
with;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d89.s4.e1
reduced;O;O
the;O;O
urine;O;O
volume;O;O
in;O;O
4;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d89.s5;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
interaction;O;O
in;O;O
preterm;O;O
neonates;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d89.s6;;
Interconversion;O;O
between;O;O
caffeine;B-drug;B-DDI-DrugBank.d89.s6.e0
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d89.s6.e1
has;O;O
been;O;O
reported;O;O
in;O;O
preterm;O;O
neonates;O;O
.;O;O
DDI-DrugBank.d89.s7;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
these;O;O
drugs;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d98.s0;;
Interactions;O;O
for;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s0.e0
D;I-group;I-DDI-DrugBank.d98.s0.e0
analogues;I-group;I-DDI-DrugBank.d98.s0.e0
(;O;O
Vitamin;B-drug;B-DDI-DrugBank.d98.s0.e1
D2;I-drug;I-DDI-DrugBank.d98.s0.e1
,;O;O
Vitamin;B-drug;B-DDI-DrugBank.d98.s0.e2
D3;I-drug;I-DDI-DrugBank.d98.s0.e2
,;O;O
Calcitriol;B-drug;B-DDI-DrugBank.d98.s0.e3
,;O;O
and;O;O
Calcidiol;B-drug;B-DDI-DrugBank.d98.s0.e4
);O;O
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d98.s0.e5
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d98.s0.e6
has;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
intestinal;O;O
absorption;O;O
of;O;O
fat;B-group;B-DDI-DrugBank.d98.s0.e7
soluble;I-group;I-DDI-DrugBank.d98.s0.e7
vitamins;I-group;I-DDI-DrugBank.d98.s0.e7
,;O;O
DDI-DrugBank.d98.s1;;
as;O;O
such;O;O
it;O;O
may;O;O
impair;O;O
intestinal;O;O
absorption;O;O
of;O;O
any;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s1.e0
D.;I-group;I-DDI-DrugBank.d98.s1.e0
DDI-DrugBank.d98.s2;;
Phenytoin;I-drug;I-DDI-DrugBank.d98.s2.e0
/;O;O
Phenobarbital;B-drug;B-DDI-DrugBank.d98.s2.e1
:;O;O
The;O;O
coadministration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d98.s2.e2
or;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d98.s2.e3
will;O;O
not;O;O
affect;O;O
plasma;O;O
concentrations;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s2.e4
D;I-group;I-DDI-DrugBank.d98.s2.e4
,;O;O
but;O;O
may;O;O
reduce;O;O
endogenous;O;O
plasma;O;O
levels;O;O
of;O;O
calcitriol;B-drug;B-DDI-DrugBank.d98.s2.e5
/;O;O
ergocalcitriol;O;O
by;O;O
accelerating;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d98.s3;;
Since;O;O
blood;O;O
level;O;O
of;O;O
calcitriol;B-drug;B-DDI-DrugBank.d98.s3.e0
/;O;O
ergocalcitriol;O;O
will;O;O
be;O;O
reduced;O;O
,;O;O
higher;O;O
doses;O;O
of;O;O
Rocaltrol;B-brand;B-DDI-DrugBank.d98.s3.e1
may;O;O
be;O;O
necessary;O;O
if;O;O
these;O;O
drugs;O;O
are;O;O
administered;O;O
simultaneously;O;O
.;O;O
DDI-DrugBank.d98.s4;;
Thiazides;B-group;B-DDI-DrugBank.d98.s4.e0
:;O;O
Thiazides;B-group;B-DDI-DrugBank.d98.s4.e1
are;O;O
known;O;O
to;O;O
induce;O;O
hypercalcemia;O;O
by;O;O
the;O;O
reduction;O;O
of;O;O
calcium;O;O
excretion;O;O
in;O;O
urine;O;O
.;O;O
DDI-DrugBank.d98.s5;;
Some;O;O
reports;O;O
have;O;O
shown;O;O
that;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
thiazides;B-group;B-DDI-DrugBank.d98.s5.e0
with;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s5.e1
D;I-group;I-DDI-DrugBank.d98.s5.e1
causes;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d98.s6;;
Therefore;O;O
,;O;O
precaution;O;O
should;O;O
be;O;O
taken;O;O
when;O;O
coadministration;O;O
is;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d98.s7;;
Digitalis;B-group;B-DDI-DrugBank.d98.s7.e0
:;O;O
Vitamin;B-group;B-DDI-DrugBank.d98.s7.e1
D;I-group;I-DDI-DrugBank.d98.s7.e1
dosage;O;O
must;O;O
be;O;O
determined;O;O
with;O;O
care;O;O
in;O;O
patients;O;O
undergoing;O;O
treatment;O;O
with;O;O
digitalis;B-group;B-DDI-DrugBank.d98.s7.e2
,;O;O
as;O;O
hypercalcemia;O;O
in;O;O
such;O;O
patients;O;O
may;O;O
precipitate;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d98.s8;;
Ketoconazole;B-drug;B-DDI-DrugBank.d98.s8.e0
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d98.s8.e1
may;O;O
inhibit;O;O
both;O;O
synthetic;O;O
and;O;O
catabolic;O;O
enzymes;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s8.e2
D.;I-group;I-DDI-DrugBank.d98.s8.e2
DDI-DrugBank.d98.s9;;
Reductions;O;O
in;O;O
serum;O;O
endogenous;O;O
vitamin;O;O
D;O;O
concentrations;O;O
have;O;O
been;O;O
observed;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
300;O;O
mg;O;O
/;O;O
day;O;O
to;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d98.s9.e0
for;O;O
a;O;O
week;O;O
to;O;O
healthy;O;O
men;O;O
.;O;O
DDI-DrugBank.d98.s10;;
However;O;O
,;O;O
in;O;O
vivo;O;O
drug;O;O
interaction;O;O
studies;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d98.s10.e0
with;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s10.e1
D;I-group;I-DDI-DrugBank.d98.s10.e1
have;O;O
not;O;O
been;O;O
investigated;O;O
.;O;O
DDI-DrugBank.d98.s11;;
Corticosteroids;B-group;B-DDI-DrugBank.d98.s11.e0
:;O;O
A;O;O
relationship;O;O
of;O;O
functional;O;O
antagonism;O;O
exists;O;O
between;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s11.e1
D;I-group;I-DDI-DrugBank.d98.s11.e1
analogues;I-group;I-DDI-DrugBank.d98.s11.e1
,;O;O
which;O;O
promote;O;O
calcium;O;O
absorption;O;O
,;O;O
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d98.s11.e2
,;O;O
which;O;O
inhibit;O;O
calcium;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d98.s12;;
Phosphate;O;O
-;O;O
Binding;O;O
Agents;O;O
:;O;O
Since;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s12.e0
D;I-group;I-DDI-DrugBank.d98.s12.e0
also;O;O
has;O;O
an;O;O
effect;O;O
on;O;O
phosphate;O;O
transport;O;O
in;O;O
the;O;O
intestine;O;O
,;O;O
kidneys;O;O
and;O;O
bones;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
phosphate;O;O
-;O;O
binding;O;O
agents;O;O
must;O;O
be;O;O
adjusted;O;O
in;O;O
accordance;O;O
with;O;O
the;O;O
serum;O;O
phosphate;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d98.s13;;
Vitamin;B-group;B-DDI-DrugBank.d98.s13.e0
D;I-group;I-DDI-DrugBank.d98.s13.e0
:;O;O
The;O;O
coadministration;O;O
of;O;O
any;O;O
of;O;O
the;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s13.e1
D;I-group;I-DDI-DrugBank.d98.s13.e1
analogues;I-group;I-DDI-DrugBank.d98.s13.e1
should;O;O
be;O;O
avoided;O;O
as;O;O
this;O;O
could;O;O
create;O;O
possible;O;O
additive;O;O
effects;O;O
and;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d98.s14;;
Calcium;B-drug;B-DDI-DrugBank.d98.s14.e0
Supplements;O;O
:;O;O
Uncontrolled;O;O
intake;O;O
of;O;O
additional;O;O
calcium;B-drug;B-DDI-DrugBank.d98.s14.e1
-;O;O
containing;O;O
preparations;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d98.s15;;
Magnesium;B-drug;B-DDI-DrugBank.d98.s15.e0
:;O;O
Magnesium;B-drug;B-DDI-DrugBank.d98.s15.e1
-;O;O
containing;O;O
preparations;O;O
(;O;O
eg;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d98.s15.e2
);O;O
may;O;O
cause;O;O
hypermagnesemia;O;O
and;O;O
should;O;O
therefore;O;O
not;O;O
be;O;O
taken;O;O
during;O;O
therapy;O;O
with;O;O
vitamin;B-group;B-DDI-DrugBank.d98.s15.e3
D;I-group;I-DDI-DrugBank.d98.s15.e3
by;O;O
patients;O;O
on;O;O
chronic;O;O
renal;O;O
dialysis;O;O
.;O;O
DDI-DrugBank.d384.s0;;
Interactions;O;O
for;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s0.e0
D;I-group;I-DDI-DrugBank.d384.s0.e0
analogues;I-group;I-DDI-DrugBank.d384.s0.e0
(;O;O
Vitamin;B-drug;B-DDI-DrugBank.d384.s0.e1
D2;I-drug;I-DDI-DrugBank.d384.s0.e1
,;O;O
Vitamin;B-drug;B-DDI-DrugBank.d384.s0.e2
D3;I-drug;I-DDI-DrugBank.d384.s0.e2
,;O;O
Calcitriol;B-drug;B-DDI-DrugBank.d384.s0.e3
,;O;O
and;O;O
Calcidiol;B-drug;B-DDI-DrugBank.d384.s0.e4
);O;O
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d384.s0.e5
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d384.s0.e6
has;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
intestinal;O;O
absorption;O;O
of;O;O
fat;B-group;B-DDI-DrugBank.d384.s0.e7
soluble;I-group;I-DDI-DrugBank.d384.s0.e7
vitamins;I-group;I-DDI-DrugBank.d384.s0.e7
,;O;O
DDI-DrugBank.d384.s1;;
as;O;O
such;O;O
it;O;O
may;O;O
impair;O;O
intestinal;O;O
absorption;O;O
of;O;O
any;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s1.e0
D.;I-group;I-DDI-DrugBank.d384.s1.e0
DDI-DrugBank.d384.s2;;
Phenytoin;I-drug;I-DDI-DrugBank.d384.s2.e0
/;O;O
Phenobarbital;B-drug;B-DDI-DrugBank.d384.s2.e1
:;O;O
The;O;O
coadministration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d384.s2.e2
or;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d384.s2.e3
will;O;O
not;O;O
affect;O;O
plasma;O;O
concentrations;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s2.e4
D;I-group;I-DDI-DrugBank.d384.s2.e4
,;O;O
but;O;O
may;O;O
reduce;O;O
endogenous;O;O
plasma;O;O
levels;O;O
of;O;O
calcitriol;B-drug;B-DDI-DrugBank.d384.s2.e5
/;O;O
ergocalcitriol;O;O
by;O;O
accelerating;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d384.s3;;
Since;O;O
blood;O;O
level;O;O
of;O;O
calcitriol;B-drug;B-DDI-DrugBank.d384.s3.e0
/;O;O
ergocalcitriol;O;O
will;O;O
be;O;O
reduced;O;O
,;O;O
higher;O;O
doses;O;O
of;O;O
Rocaltrol;B-brand;B-DDI-DrugBank.d384.s3.e1
may;O;O
be;O;O
necessary;O;O
if;O;O
these;O;O
drugs;O;O
are;O;O
administered;O;O
simultaneously;O;O
.;O;O
DDI-DrugBank.d384.s4;;
Thiazides;B-group;B-DDI-DrugBank.d384.s4.e0
:;O;O
Thiazides;B-group;B-DDI-DrugBank.d384.s4.e1
are;O;O
known;O;O
to;O;O
induce;O;O
hypercalcemia;O;O
by;O;O
the;O;O
reduction;O;O
of;O;O
calcium;B-drug;B-DDI-DrugBank.d384.s4.e2
excretion;O;O
in;O;O
urine;O;O
.;O;O
DDI-DrugBank.d384.s5;;
Some;O;O
reports;O;O
have;O;O
shown;O;O
that;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
thiazides;B-group;B-DDI-DrugBank.d384.s5.e0
with;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s5.e1
D;I-group;I-DDI-DrugBank.d384.s5.e1
causes;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d384.s6;;
Therefore;O;O
,;O;O
precaution;O;O
should;O;O
be;O;O
taken;O;O
when;O;O
coadministration;O;O
is;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d384.s7;;
Digitalis;B-group;B-DDI-DrugBank.d384.s7.e0
:;O;O
Vitamin;B-group;B-DDI-DrugBank.d384.s7.e1
D;I-group;I-DDI-DrugBank.d384.s7.e1
dosage;O;O
must;O;O
be;O;O
determined;O;O
with;O;O
care;O;O
in;O;O
patients;O;O
undergoing;O;O
treatment;O;O
with;O;O
digitalis;B-group;B-DDI-DrugBank.d384.s7.e2
,;O;O
as;O;O
hypercalcemia;O;O
in;O;O
such;O;O
patients;O;O
may;O;O
precipitate;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d384.s8;;
Ketoconazole;B-drug;B-DDI-DrugBank.d384.s8.e0
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d384.s8.e1
may;O;O
inhibit;O;O
both;O;O
synthetic;O;O
and;O;O
catabolic;O;O
enzymes;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s8.e2
D.;I-group;I-DDI-DrugBank.d384.s8.e2
DDI-DrugBank.d384.s9;;
Reductions;O;O
in;O;O
serum;O;O
endogenous;O;O
vitamin;O;O
D;O;O
concentrations;O;O
have;O;O
been;O;O
observed;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
300;O;O
mg;O;O
/;O;O
day;O;O
to;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d384.s9.e0
for;O;O
a;O;O
week;O;O
to;O;O
healthy;O;O
men;O;O
.;O;O
DDI-DrugBank.d384.s10;;
However;O;O
,;O;O
in;O;O
vivo;O;O
drug;O;O
interaction;O;O
studies;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d384.s10.e0
with;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s10.e1
D;I-group;I-DDI-DrugBank.d384.s10.e1
have;O;O
not;O;O
been;O;O
investigated;O;O
.;O;O
DDI-DrugBank.d384.s11;;
Corticosteroids;B-group;B-DDI-DrugBank.d384.s11.e0
:;O;O
A;O;O
relationship;O;O
of;O;O
functional;O;O
antagonism;O;O
exists;O;O
between;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s11.e1
D;I-group;I-DDI-DrugBank.d384.s11.e1
analogues;I-group;I-DDI-DrugBank.d384.s11.e1
,;O;O
which;O;O
promote;O;O
calcium;O;O
absorption;O;O
,;O;O
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d384.s11.e2
,;O;O
which;O;O
inhibit;O;O
calcium;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d384.s12;;
Phosphate;O;O
-;O;O
Binding;O;O
Agents;O;O
:;O;O
Since;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s12.e0
D;I-group;I-DDI-DrugBank.d384.s12.e0
also;O;O
has;O;O
an;O;O
effect;O;O
on;O;O
phosphate;O;O
transport;O;O
in;O;O
the;O;O
intestine;O;O
,;O;O
kidneys;O;O
and;O;O
bones;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
phosphate;O;O
-;O;O
binding;O;O
agents;O;O
must;O;O
be;O;O
adjusted;O;O
in;O;O
accordance;O;O
with;O;O
the;O;O
serum;O;O
phosphate;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d384.s13;;
Vitamin;B-group;B-DDI-DrugBank.d384.s13.e0
D;I-group;I-DDI-DrugBank.d384.s13.e0
:;O;O
The;O;O
coadministration;O;O
of;O;O
any;O;O
of;O;O
the;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s13.e1
D;I-group;I-DDI-DrugBank.d384.s13.e1
analogues;I-group;I-DDI-DrugBank.d384.s13.e1
should;O;O
be;O;O
avoided;O;O
as;O;O
this;O;O
could;O;O
create;O;O
possible;O;O
additive;O;O
effects;O;O
and;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d384.s14;;
Calcium;B-drug;B-DDI-DrugBank.d384.s14.e0
Supplements;O;O
:;O;O
Uncontrolled;O;O
intake;O;O
of;O;O
additional;O;O
calcium;B-drug;B-DDI-DrugBank.d384.s14.e1
-;O;O
containing;O;O
preparations;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d384.s15;;
Magnesium;B-drug;B-DDI-DrugBank.d384.s15.e0
:;O;O
Magnesium;B-drug;B-DDI-DrugBank.d384.s15.e1
-;O;O
containing;O;O
preparations;O;O
(;O;O
eg;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d384.s15.e2
);O;O
may;O;O
cause;O;O
hypermagnesemia;O;O
and;O;O
should;O;O
therefore;O;O
not;O;O
be;O;O
taken;O;O
during;O;O
therapy;O;O
with;O;O
vitamin;B-group;B-DDI-DrugBank.d384.s15.e3
D;I-group;I-DDI-DrugBank.d384.s15.e3
by;O;O
patients;O;O
on;O;O
chronic;O;O
renal;O;O
dialysis;O;O
.;O;O
DDI-DrugBank.d494.s0;;
Concomitant;O;O
use;O;O
with;O;O
other;O;O
calcium;B-drug;B-DDI-DrugBank.d494.s0.e0
-;O;O
containing;O;O
medicines;O;O
(;O;O
including;O;O
antacids;B-group;B-DDI-DrugBank.d494.s0.e1
);O;O
may;O;O
cause;O;O
too;O;O
much;O;O
calcium;B-drug;B-DDI-DrugBank.d494.s0.e2
in;O;O
the;O;O
blood;O;O
or;O;O
urine;O;O
,;O;O
which;O;O
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
.;O;O
DDI-DrugBank.d494.s1;;
Using;O;O
calcium;B-drug;B-DDI-DrugBank.d494.s1.e0
acetate;I-drug;I-DDI-DrugBank.d494.s1.e0
with;O;O
digitalis;B-group;B-DDI-DrugBank.d494.s1.e1
glycosides;I-group;I-DDI-DrugBank.d494.s1.e1
(;O;O
heart;O;O
medicine;O;O
);O;O
may;O;O
cause;O;O
hypercalcemia;O;O
(;O;O
too;O;O
much;O;O
calcium;B-drug;B-DDI-DrugBank.d494.s1.e2
in;O;O
the;O;O
blood;O;O
);O;O
,;O;O
which;O;O
could;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
developing;O;O
an;O;O
irregular;O;O
heartbeat;O;O
.;O;O
DDI-DrugBank.d406.s0;;
May;O;O
interact;O;O
with;O;O
cefamandole;B-drug;B-DDI-DrugBank.d406.s0.e0
naftate;I-drug;I-DDI-DrugBank.d406.s0.e0
,;O;O
cephalothin;B-drug;B-DDI-DrugBank.d406.s0.e1
sodium;I-drug;I-DDI-DrugBank.d406.s0.e1
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d406.s0.e2
sulfate;I-drug;I-DDI-DrugBank.d406.s0.e2
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d406.s0.e3
sodium;I-drug;I-DDI-DrugBank.d406.s0.e3
succinate;I-drug;I-DDI-DrugBank.d406.s0.e3
,;O;O
and;O;O
prochlorperazine;B-drug;B-DDI-DrugBank.d406.s0.e4
edisylate;I-drug;I-DDI-DrugBank.d406.s0.e4
.;O;O
DDI-DrugBank.d547.s0;;
No;O;O
significant;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
studies;O;O
of;O;O
candesartan;B-drug;B-DDI-DrugBank.d547.s0.e0
cilexetil;I-drug;I-DDI-DrugBank.d547.s0.e0
given;O;O
with;O;O
other;O;O
drugs;O;O
such;O;O
as;O;O
glyburide;B-drug;B-DDI-DrugBank.d547.s0.e1
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d547.s0.e2
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d547.s0.e3
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d547.s0.e4
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d547.s0.e5
,;O;O
and;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d547.s0.e6
in;O;O
healthy;O;O
volunteers;O;O
,;O;O
or;O;O
given;O;O
with;O;O
enalapril;B-drug;B-DDI-DrugBank.d547.s0.e7
to;O;O
patients;O;O
with;O;O
heart;O;O
failure;O;O
(;O;O
NYHA;O;O
class;O;O
II;O;O
and;O;O
III;O;O
);O;O
.;O;O
DDI-DrugBank.d547.s1;;
Because;O;O
candesartan;B-drug;B-DDI-DrugBank.d547.s1.e0
is;O;O
not;O;O
significantly;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
and;O;O
at;O;O
therapeutic;O;O
concentrations;O;O
has;O;O
no;O;O
effects;O;O
on;O;O
P450;O;O
enzymes;O;O
,;O;O
interactions;O;O
with;O;O
drugs;O;O
that;O;O
inhibit;O;O
or;O;O
are;O;O
metabolized;O;O
by;O;O
those;O;O
enzymes;O;O
would;O;O
not;O;O
be;O;O
expected;O;O
.;O;O
DDI-DrugBank.d547.s2;;
Lithium;B-drug;B-DDI-DrugBank.d547.s2.e0
Reversible;O;O
increases;O;O
in;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d547.s2.e1
concentrations;O;O
and;O;O
toxicity;O;O
have;O;O
been;O;O
reported;O;O
during;O;O
concomitant;O;O
administration;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d547.s2.e2
with;O;O
ACE;B-group;B-DDI-DrugBank.d547.s2.e3
inhibitors;I-group;I-DDI-DrugBank.d547.s2.e3
,;O;O
and;O;O
with;O;O
some;O;O
angiotensin;B-group;B-DDI-DrugBank.d547.s2.e4
II;I-group;I-DDI-DrugBank.d547.s2.e4
receptor;I-group;I-DDI-DrugBank.d547.s2.e4
antagonists;I-group;I-DDI-DrugBank.d547.s2.e4
.;O;O
DDI-DrugBank.d547.s3;;
An;O;O
increase;O;O
in;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d547.s3.e0
concentration;O;O
has;O;O
been;O;O
reported;O;O
during;O;O
concomitant;O;O
administration;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d547.s3.e1
with;O;O
ATACAND;B-brand;B-DDI-DrugBank.d547.s3.e2
,;O;O
so;O;O
careful;O;O
monitoring;O;O
of;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d547.s3.e3
levels;O;O
is;O;O
recommended;O;O
during;O;O
concomitant;O;O
use;O;O
.;O;O
DDI-DrugBank.d88.s0;;
Antacid;B-group;B-DDI-DrugBank.d88.s0.e0
:;O;O
The;O;O
effect;O;O
of;O;O
an;O;O
aluminum;B-drug;B-DDI-DrugBank.d88.s0.e1
hydroxide;I-drug;I-DDI-DrugBank.d88.s0.e1
-;O;O
and;O;O
magnesium;B-drug;B-DDI-DrugBank.d88.s0.e2
hydroxide;I-drug;I-DDI-DrugBank.d88.s0.e2
-;O;O
containing;O;O
antacid;B-group;B-DDI-DrugBank.d88.s0.e3
(;O;O
Maalox;B-brand;B-DDI-DrugBank.d88.s0.e4
);O;O
*;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
capecitabine;B-drug;B-DDI-DrugBank.d88.s0.e5
was;O;O
investigated;O;O
in;O;O
12;O;O
cancer;O;O
patients;O;O
.;O;O
DDI-DrugBank.d88.s1;;
There;O;O
was;O;O
a;O;O
small;O;O
increase;O;O
in;O;O
plasma;O;O
concentrations;O;O
of;O;O
capecitabine;B-drug;B-DDI-DrugBank.d88.s1.e0
and;O;O
one;O;O
metabolite;O;O
(;O;O
5;B-drug_n;B-DDI-DrugBank.d88.s1.e1
-;I-drug_n;I-DDI-DrugBank.d88.s1.e1
DFCR;I-drug_n;I-DDI-DrugBank.d88.s1.e1
);O;O
,;O;O
DDI-DrugBank.d88.s2;;
there;O;O
was;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
3;O;O
major;O;O
metabolites;O;O
(;O;O
5;B-drug_n;B-DDI-DrugBank.d88.s2.e0
-;I-drug_n;I-DDI-DrugBank.d88.s2.e0
DFUR;I-drug_n;I-DDI-DrugBank.d88.s2.e0
,;O;O
5;B-drug_n;B-DDI-DrugBank.d88.s2.e1
-;I-drug_n;I-DDI-DrugBank.d88.s2.e1
FU;I-drug_n;I-DDI-DrugBank.d88.s2.e1
and;O;O
FBAL;B-drug_n;B-DDI-DrugBank.d88.s2.e2
);O;O
.;O;O
DDI-DrugBank.d88.s3;;
Coumarin;B-group;B-DDI-DrugBank.d88.s3.e0
Anticoagulants;I-group;I-DDI-DrugBank.d88.s3.e0
Altered;O;O
coagulation;O;O
parameters;O;O
and/or;O;O
bleeding;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
taking;O;O
capecitabine;B-drug;B-DDI-DrugBank.d88.s3.e1
concomitantly;O;O
with;O;O
coumarin;B-group;B-DDI-DrugBank.d88.s3.e2
-;I-group;I-DDI-DrugBank.d88.s3.e2
derivative;I-group;I-DDI-DrugBank.d88.s3.e2
anticoagulants;I-group;I-DDI-DrugBank.d88.s3.e2
such;O;O
as;O;O
warfarin;B-drug;B-DDI-DrugBank.d88.s3.e3
and;O;O
phenprocoumon;B-drug;B-DDI-DrugBank.d88.s3.e4
.;O;O
DDI-DrugBank.d88.s4;;
Patients;O;O
taking;O;O
coumarin;B-group;B-DDI-DrugBank.d88.s4.e0
-;I-group;I-DDI-DrugBank.d88.s4.e0
derivative;I-group;I-DDI-DrugBank.d88.s4.e0
anticoagulants;I-group;I-DDI-DrugBank.d88.s4.e0
concomitantly;O;O
with;O;O
capecitabine;B-drug;B-DDI-DrugBank.d88.s4.e1
should;O;O
be;O;O
monitored;O;O
regularly;O;O
for;O;O
alterations;O;O
in;O;O
their;O;O
coagulation;O;O
parameters;O;O
(;O;O
PT;O;O
or;O;O
INR;O;O
);O;O
.;O;O
DDI-DrugBank.d88.s5;;
Leucovorin;B-drug;B-DDI-DrugBank.d88.s5.e0
:;O;O
The;O;O
concentration;O;O
of;O;O
5;B-drug;B-DDI-DrugBank.d88.s5.e1
-;I-drug;I-DDI-DrugBank.d88.s5.e1
fluorouracil;I-drug;I-DDI-DrugBank.d88.s5.e1
is;O;O
increased;O;O
and;O;O
its;O;O
toxicity;O;O
may;O;O
be;O;O
enhanced;O;O
by;O;O
leucovorin;B-drug;B-DDI-DrugBank.d88.s5.e2
.;O;O
DDI-DrugBank.d88.s6;;
Deaths;O;O
from;O;O
severe;O;O
enterocolitis;O;O
,;O;O
diarrhea;O;O
,;O;O
and;O;O
dehydration;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
elderly;O;O
patients;O;O
receiving;O;O
weekly;O;O
leucovorin;B-drug;B-DDI-DrugBank.d88.s6.e0
and;O;O
fluorouracil;B-drug;B-DDI-DrugBank.d88.s6.e1
.;O;O
DDI-DrugBank.d175.s0;;
Hypotension;O;O
Patients;O;O
on;O;O
Diuretic;B-group;B-DDI-DrugBank.d175.s0.e0
Therapy;O;O
:;O;O
Patients;O;O
on;O;O
diuretics;B-group;B-DDI-DrugBank.d175.s0.e1
and;O;O
especially;O;O
those;O;O
in;O;O
whom;O;O
diuretic;B-group;B-DDI-DrugBank.d175.s0.e2
therapy;O;O
was;O;O
recently;O;O
instituted;O;O
,;O;O
as;O;O
well;O;O
as;O;O
those;O;O
on;O;O
severe;O;O
dietary;O;O
salt;O;O
restriction;O;O
or;O;O
dialysis;O;O
,;O;O
may;O;O
occasionally;O;O
experience;O;O
a;O;O
precipitous;O;O
reduction;O;O
of;O;O
blood;O;O
pressure;O;O
usually;O;O
within;O;O
the;O;O
first;O;O
hour;O;O
after;O;O
receiving;O;O
the;O;O
initial;O;O
dose;O;O
of;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s0.e3
.;O;O
DDI-DrugBank.d175.s1;;
The;O;O
possibility;O;O
of;O;O
hypotensive;O;O
effects;O;O
with;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s1.e0
can;O;O
be;O;O
minimized;O;O
by;O;O
either;O;O
discontinuing;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d175.s1.e1
or;O;O
increasing;O;O
the;O;O
salt;O;O
intake;O;O
approximately;O;O
one;O;O
week;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s1.e2
(;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s1.e3
tablets;O;O
,;O;O
USP;O;O
);O;O
or;O;O
initiating;O;O
therapy;O;O
with;O;O
small;O;O
doses;O;O
(;O;O
6.25;O;O
or;O;O
12.5;O;O
mg;O;O
);O;O
.;O;O
DDI-DrugBank.d175.s2;;
Alternatively;O;O
,;O;O
provide;O;O
medical;O;O
supervision;O;O
for;O;O
at;O;O
least;O;O
one;O;O
hour;O;O
after;O;O
the;O;O
initial;O;O
dose;O;O
.;O;O
DDI-DrugBank.d175.s3;;
If;O;O
hypotension;O;O
occurs;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
placed;O;O
in;O;O
a;O;O
supine;O;O
position;O;O
and;O;O
,;O;O
if;O;O
necessary;O;O
,;O;O
receive;O;O
an;O;O
intravenous;O;O
infusion;O;O
of;O;O
normal;O;O
saline;O;O
.;O;O
DDI-DrugBank.d175.s4;;
This;O;O
transient;O;O
hypotensive;O;O
response;O;O
is;O;O
not;O;O
a;O;O
contraindication;O;O
to;O;O
further;O;O
doses;O;O
which;O;O
can;O;O
be;O;O
given;O;O
without;O;O
difficulty;O;O
once;O;O
the;O;O
blood;O;O
pressure;O;O
has;O;O
increased;O;O
after;O;O
volume;O;O
expansion;O;O
.;O;O
DDI-DrugBank.d175.s5;;
Agents;O;O
Having;O;O
Vasodilator;O;O
Activity;O;O
:;O;O
Data;O;O
on;O;O
the;O;O
effect;O;O
of;O;O
concomitant;O;O
use;O;O
of;O;O
other;O;O
vasodilators;B-group;B-DDI-DrugBank.d175.s5.e0
in;O;O
patients;O;O
receiving;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s5.e1
for;O;O
heart;O;O
failure;O;O
are;O;O
not;O;O
available;O;O
,;O;O
DDI-DrugBank.d175.s6;;
therefore;O;O
,;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d175.s6.e0
or;O;O
other;O;O
nitrates;B-group;B-DDI-DrugBank.d175.s6.e1
(;O;O
as;O;O
used;O;O
for;O;O
management;O;O
of;O;O
angina;O;O
);O;O
or;O;O
other;O;O
drugs;O;O
having;O;O
vasodilator;O;O
activity;O;O
should;O;O
,;O;O
if;O;O
possible;O;O
,;O;O
be;O;O
discontinued;O;O
before;O;O
starting;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s6.e2
.;O;O
DDI-DrugBank.d175.s7;;
If;O;O
resumed;O;O
during;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s7.e0
therapy;O;O
,;O;O
such;O;O
agents;O;O
should;O;O
be;O;O
administered;O;O
cautiously;O;O
,;O;O
and;O;O
perhaps;O;O
at;O;O
lower;O;O
dosage;O;O
.;O;O
DDI-DrugBank.d175.s8;;
Agents;O;O
Causing;O;O
Renin;O;O
Release;O;O
Captopril;B-drug;B-DDI-DrugBank.d175.s8.e0
's;O;O
effect;O;O
will;O;O
be;O;O
augmented;O;O
by;O;O
antihypertensive;B-group;B-DDI-DrugBank.d175.s8.e1
agents;I-group;I-DDI-DrugBank.d175.s8.e1
that;O;O
cause;O;O
renin;O;O
release;O;O
.;O;O
DDI-DrugBank.d175.s9;;
For;O;O
example;O;O
,;O;O
diuretics;B-group;B-DDI-DrugBank.d175.s9.e0
(;O;O
e.g.;O;O
,;O;O
thiazides;B-group;B-DDI-DrugBank.d175.s9.e1
);O;O
may;O;O
activate;O;O
the;O;O
renin;O;O
-;O;O
angiotensin;O;O
-;O;O
aldosterone;O;O
system;O;O
.;O;O
DDI-DrugBank.d175.s10;;
Agents;O;O
Affecting;O;O
Sympathetic;O;O
Activity;O;O
The;O;O
sympathetic;O;O
nervous;O;O
system;O;O
may;O;O
be;O;O
especially;O;O
important;O;O
in;O;O
supporting;O;O
blood;O;O
pressure;O;O
in;O;O
patients;O;O
receiving;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s10.e0
alone;O;O
or;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d175.s10.e1
.;O;O
DDI-DrugBank.d175.s11;;
Therefore;O;O
,;O;O
agents;O;O
affecting;O;O
sympathetic;O;O
activity;O;O
(;O;O
e.g.;O;O
,;O;O
ganglionic;B-group;B-DDI-DrugBank.d175.s11.e0
blocking;I-group;I-DDI-DrugBank.d175.s11.e0
agents;I-group;I-DDI-DrugBank.d175.s11.e0
or;O;O
adrenergic;B-group;B-DDI-DrugBank.d175.s11.e1
neuron;I-group;I-DDI-DrugBank.d175.s11.e1
blocking;I-group;I-DDI-DrugBank.d175.s11.e1
agents;I-group;I-DDI-DrugBank.d175.s11.e1
);O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d175.s12;;
Beta;B-group;B-DDI-DrugBank.d175.s12.e0
-;I-group;I-DDI-DrugBank.d175.s12.e0
adrenergic;I-group;I-DDI-DrugBank.d175.s12.e0
blocking;I-group;I-DDI-DrugBank.d175.s12.e0
drugs;I-group;I-DDI-DrugBank.d175.s12.e0
add;O;O
some;O;O
further;O;O
antihypertensive;O;O
effect;O;O
to;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s12.e1
,;O;O
but;O;O
the;O;O
overall;O;O
response;O;O
is;O;O
less;O;O
than;O;O
additive;O;O
.;O;O
DDI-DrugBank.d175.s13;;
Agents;O;O
Increasing;O;O
Serum;O;O
Potassium;O;O
Since;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s13.e0
decreases;O;O
aldosterone;O;O
production;O;O
,;O;O
elevation;O;O
of;O;O
serum;O;O
potassium;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d175.s14;;
Potassium;B-group;B-DDI-DrugBank.d175.s14.e0
-;I-group;I-DDI-DrugBank.d175.s14.e0
sparing;I-group;I-DDI-DrugBank.d175.s14.e0
diuretics;I-group;I-DDI-DrugBank.d175.s14.e0
such;O;O
as;O;O
spironolactone;B-drug;B-DDI-DrugBank.d175.s14.e1
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d175.s14.e2
,;O;O
or;O;O
amiloride;B-drug;B-DDI-DrugBank.d175.s14.e3
,;O;O
or;O;O
potassium;B-drug;B-DDI-DrugBank.d175.s14.e4
supplements;O;O
should;O;O
be;O;O
given;O;O
only;O;O
for;O;O
documented;O;O
hypokalemia;O;O
,;O;O
and;O;O
then;O;O
with;O;O
caution;O;O
,;O;O
since;O;O
they;O;O
may;O;O
lead;O;O
to;O;O
a;O;O
significant;O;O
increase;O;O
of;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d175.s15;;
Salt;O;O
substitutes;O;O
containing;O;O
potassium;B-drug;B-DDI-DrugBank.d175.s15.e0
should;O;O
also;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d175.s16;;
Inhibitors;O;O
Of;O;O
Endogenous;O;O
Prostaglandin;O;O
Synthesis;O;O
It;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
indomethacin;B-drug;B-DDI-DrugBank.d175.s16.e0
may;O;O
reduce;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s16.e1
,;O;O
especially;O;O
in;O;O
cases;O;O
of;O;O
low;O;O
renin;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d175.s17;;
Other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d175.s17.e0
anti;I-group;I-DDI-DrugBank.d175.s17.e0
-;I-group;I-DDI-DrugBank.d175.s17.e0
inflammatory;I-group;I-DDI-DrugBank.d175.s17.e0
agents;I-group;I-DDI-DrugBank.d175.s17.e0
(;O;O
e.g.;O;O
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d175.s17.e1
);O;O
may;O;O
also;O;O
have;O;O
this;O;O
effect;O;O
.;O;O
DDI-DrugBank.d175.s18;;
Lithium;B-drug;B-DDI-DrugBank.d175.s18.e0
:;O;O
Increased;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d175.s18.e1
levels;O;O
and;O;O
symptoms;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d175.s18.e2
toxicity;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
lithium;B-drug;B-DDI-DrugBank.d175.s18.e3
and;O;O
ACE;B-group;B-DDI-DrugBank.d175.s18.e4
inhibitor;I-group;I-DDI-DrugBank.d175.s18.e4
therapy;O;O
.;O;O
DDI-DrugBank.d175.s19;;
These;O;O
drugs;O;O
should;O;O
be;O;O
coad;O;O
-;O;O
ministered;O;O
with;O;O
caution;O;O
and;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d175.s19.e0
levels;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d175.s20;;
If;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d175.s20.e0
is;O;O
also;O;O
used;O;O
,;O;O
it;O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d175.s20.e1
toxicity;O;O
.;O;O
DDI-DrugBank.d175.s21;;
Cardiac;B-group;B-DDI-DrugBank.d175.s21.e0
Glycosides;I-group;I-DDI-DrugBank.d175.s21.e0
:;O;O
In;O;O
a;O;O
study;O;O
of;O;O
young;O;O
healthy;O;O
male;O;O
subjects;O;O
no;O;O
evidence;O;O
of;O;O
a;O;O
direct;O;O
pharmacokinetic;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s21.e1
-;O;O
digoxin;B-drug;B-DDI-DrugBank.d175.s21.e2
interaction;O;O
could;O;O
be;O;O
found;O;O
.;O;O
DDI-DrugBank.d175.s22;;
Loop;B-group;B-DDI-DrugBank.d175.s22.e0
Diuretics;I-group;I-DDI-DrugBank.d175.s22.e0
:;O;O
Furosemide;B-drug;B-DDI-DrugBank.d175.s22.e1
administered;O;O
concurrently;O;O
with;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s22.e2
does;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s22.e3
in;O;O
renally;O;O
impaired;O;O
hypertensive;O;O
patients;O;O
.;O;O
DDI-DrugBank.d175.s23;;
Allopurinol;B-drug;B-DDI-DrugBank.d175.s23.e0
:;O;O
In;O;O
a;O;O
study;O;O
of;O;O
healthy;O;O
male;O;O
volunteers;O;O
no;O;O
significant;O;O
pharmacokinetic;O;O
interaction;O;O
occurred;O;O
when;O;O
captopril;B-drug;B-DDI-DrugBank.d175.s23.e1
and;O;O
allopurinol;B-drug;B-DDI-DrugBank.d175.s23.e2
were;O;O
administered;O;O
concomitantly;O;O
for;O;O
6;O;O
days;O;O
.;O;O
DDI-DrugBank.d175.s24;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interaction;O;O
Captopril;B-drug;B-DDI-DrugBank.d175.s24.e0
may;O;O
cause;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
urine;O;O
test;O;O
for;O;O
acetone;O;O
.;O;O
DDI-DrugBank.d94.s0;;
Clinically;O;O
meaningful;O;O
drug;O;O
interactions;O;O
have;O;O
occurred;O;O
with;O;O
concomitant;O;O
medications;O;O
and;O;O
include;O;O
,;O;O
but;O;O
are;O;O
not;O;O
limited;O;O
to;O;O
the;O;O
following;O;O
:;O;O
Agents;O;O
Highly;O;O
Bound;O;O
to;O;O
Plasma;O;O
Protein;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d94.s0.e0
is;O;O
not;O;O
highly;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
,;O;O
DDI-DrugBank.d94.s1;;
therefore;O;O
,;O;O
administration;O;O
of;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s1.e0
to;O;O
a;O;O
patient;O;O
taking;O;O
another;O;O
drug;O;O
that;O;O
is;O;O
highly;O;O
protein;O;O
bound;O;O
should;O;O
not;O;O
cause;O;O
increased;O;O
free;O;O
concentrations;O;O
of;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d94.s2;;
Agents;O;O
that;O;O
Inhibit;O;O
Cytochrome;O;O
P450;O;O
Isoenzymes;O;O
and/or;O;O
Epoxide;O;O
Hydrolase;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d94.s2.e0
is;O;O
metabolized;O;O
mainly;O;O
by;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
3A4;O;O
to;O;O
the;O;O
active;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d94.s2.e1
10,11;I-drug;I-DDI-DrugBank.d94.s2.e1
-;I-drug;I-DDI-DrugBank.d94.s2.e1
epoxide;I-drug;I-DDI-DrugBank.d94.s2.e1
,;O;O
which;O;O
is;O;O
further;O;O
metabolized;O;O
to;O;O
the;O;O
trans;O;O
-;O;O
diol;O;O
by;O;O
epoxide;O;O
hydrolase;O;O
.;O;O
DDI-DrugBank.d94.s3;;
Therefore;O;O
,;O;O
the;O;O
potential;O;O
exists;O;O
for;O;O
interaction;O;O
between;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d94.s3.e0
and;O;O
any;O;O
agent;O;O
that;O;O
inhibits;O;O
CYP3A4;O;O
and/or;O;O
epoxide;O;O
hydrolase;O;O
.;O;O
DDI-DrugBank.d94.s4;;
Agents;O;O
that;O;O
are;O;O
CYP3A4;O;O
inhibitors;O;O
that;O;O
have;O;O
been;O;O
found;O;O
,;O;O
or;O;O
are;O;O
expected;O;O
,;O;O
to;O;O
increase;O;O
plasma;O;O
levels;O;O
of;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s4.e0
are;O;O
the;O;O
following;O;O
:;O;O
Acetazolamide;B-drug;B-DDI-DrugBank.d94.s4.e1
,;O;O
azole;B-group;B-DDI-DrugBank.d94.s4.e2
antifungals;I-group;I-DDI-DrugBank.d94.s4.e2
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d94.s4.e3
,;O;O
clarithromycin(1;B-drug;B-DDI-DrugBank.d94.s4.e4
);O;O
,;O;O
dalfopristin;B-drug;B-DDI-DrugBank.d94.s4.e5
,;O;O
danazol;B-drug;B-DDI-DrugBank.d94.s4.e6
,;O;O
delavirdine;B-drug;B-DDI-DrugBank.d94.s4.e7
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d94.s4.e8
,;O;O
erythromycin(1;B-drug;B-DDI-DrugBank.d94.s4.e9
);O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d94.s4.e10
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d94.s4.e11
,;O;O
grapefruit;O;O
juice;O;O
,;O;O
isoniazid;B-drug;B-DDI-DrugBank.d94.s4.e12
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d94.s4.e13
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d94.s4.e14
,;O;O
loratadine;B-drug;B-DDI-DrugBank.d94.s4.e15
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d94.s4.e16
,;O;O
niacinamide;B-drug;B-DDI-DrugBank.d94.s4.e17
,;O;O
nicotinamide;B-drug;B-DDI-DrugBank.d94.s4.e18
,;O;O
protease;B-group;B-DDI-DrugBank.d94.s4.e19
inhibitors;I-group;I-DDI-DrugBank.d94.s4.e19
,;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d94.s4.e20
,;O;O
quinine;B-drug;B-DDI-DrugBank.d94.s4.e21
,;O;O
quinupristin;B-drug;B-DDI-DrugBank.d94.s4.e22
,;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d94.s4.e23
,;O;O
valproate(1;B-drug;B-DDI-DrugBank.d94.s4.e24
);O;O
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d94.s4.e25
,;O;O
zileuton;B-drug;B-DDI-DrugBank.d94.s4.e26
.;O;O
DDI-DrugBank.d94.s5;;
Thus;O;O
,;O;O
if;O;O
a;O;O
patient;O;O
has;O;O
been;O;O
titrated;O;O
to;O;O
a;O;O
stable;O;O
dosage;O;O
of;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s5.e0
,;O;O
and;O;O
then;O;O
begins;O;O
a;O;O
course;O;O
of;O;O
treatment;O;O
with;O;O
one;O;O
of;O;O
these;O;O
CYP3A4;O;O
or;O;O
epoxide;O;O
hydrolase;O;O
inhibitors;O;O
,;O;O
it;O;O
is;O;O
reasonable;O;O
to;O;O
expect;O;O
that;O;O
a;O;O
dose;O;O
reduction;O;O
for;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s5.e1
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d94.s6;;
Agents;O;O
that;O;O
Induce;O;O
Cytochrome;O;O
P450;O;O
Isoenzymes;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d94.s6.e0
is;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d94.s7;;
Therefore;O;O
,;O;O
the;O;O
potential;O;O
exists;O;O
for;O;O
interaction;O;O
between;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d94.s7.e0
and;O;O
any;O;O
agent;O;O
that;O;O
induces;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d94.s8;;
Agents;O;O
that;O;O
are;O;O
CYP;O;O
inducers;O;O
that;O;O
have;O;O
been;O;O
found;O;O
,;O;O
or;O;O
are;O;O
expected;O;O
,;O;O
to;O;O
decrease;O;O
plasma;O;O
levels;O;O
of;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s8.e0
are;O;O
the;O;O
following;O;O
:;O;O
Cisplatin;B-drug;B-DDI-DrugBank.d94.s8.e1
,;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d94.s8.e2
HCL;I-drug;I-DDI-DrugBank.d94.s8.e2
,;O;O
felbamate;B-drug;B-DDI-DrugBank.d94.s8.e3
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d94.s8.e4
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d94.s8.e5
,;O;O
Phenytoin(2;B-drug;B-DDI-DrugBank.d94.s8.e6
);O;O
,;O;O
primidone;B-drug;B-DDI-DrugBank.d94.s8.e7
,;O;O
methsuximide;B-drug;B-DDI-DrugBank.d94.s8.e8
,;O;O
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d94.s8.e9
Thus;O;O
,;O;O
if;O;O
a;O;O
patient;O;O
has;O;O
been;O;O
titrated;O;O
to;O;O
a;O;O
stable;O;O
dosage;O;O
on;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s8.e10
,;O;O
and;O;O
then;O;O
begins;O;O
a;O;O
course;O;O
of;O;O
treatment;O;O
with;O;O
one;O;O
of;O;O
these;O;O
CYP3A4;O;O
inducers;O;O
,;O;O
it;O;O
is;O;O
reasonable;O;O
to;O;O
expect;O;O
that;O;O
a;O;O
dose;O;O
increase;O;O
for;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s8.e11
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d94.s9;;
Agents;O;O
with;O;O
Decreased;O;O
Levels;O;O
in;O;O
the;O;O
Presence;O;O
of;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d94.s9.e0
due;O;O
to;O;O
Induction;O;O
of;O;O
Cytochrome;O;O
P450;O;O
Enzymes;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d94.s9.e1
is;O;O
known;O;O
to;O;O
induce;O;O
CYP1A2;O;O
and;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d94.s10;;
Therefore;O;O
,;O;O
the;O;O
potential;O;O
exists;O;O
for;O;O
interaction;O;O
between;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d94.s10.e0
and;O;O
any;O;O
agent;O;O
metabolized;O;O
by;O;O
one;O;O
(;O;O
or;O;O
more;O;O
);O;O
of;O;O
these;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d94.s11;;
Agents;O;O
that;O;O
have;O;O
been;O;O
found;O;O
,;O;O
or;O;O
are;O;O
expected;O;O
to;O;O
have;O;O
decreased;O;O
plasma;O;O
levels;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s11.e0
due;O;O
to;O;O
induction;O;O
of;O;O
CYP;O;O
enzymes;O;O
are;O;O
the;O;O
following;O;O
:;O;O
Acetaminophen;B-drug;B-DDI-DrugBank.d94.s11.e1
,;O;O
alprazolam;B-drug;B-DDI-DrugBank.d94.s11.e2
,;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d94.s11.e3
,;O;O
bupropion;B-drug;B-DDI-DrugBank.d94.s11.e4
,;O;O
buspirone;B-drug;B-DDI-DrugBank.d94.s11.e5
,;O;O
citalopram;B-drug;B-DDI-DrugBank.d94.s11.e6
,;O;O
clobazam;B-drug;B-DDI-DrugBank.d94.s11.e7
,;O;O
clonazepam;B-drug;B-DDI-DrugBank.d94.s11.e8
,;O;O
clozapine;B-drug;B-DDI-DrugBank.d94.s11.e9
,;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d94.s11.e10
,;O;O
delavirdine;B-drug;B-DDI-DrugBank.d94.s11.e11
,;O;O
desipramine;B-drug;B-DDI-DrugBank.d94.s11.e12
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d94.s11.e13
,;O;O
dicumarol;B-drug;B-DDI-DrugBank.d94.s11.e14
,;O;O
doxycycline;B-drug;B-DDI-DrugBank.d94.s11.e15
,;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d94.s11.e16
,;O;O
felbamate;B-drug;B-DDI-DrugBank.d94.s11.e17
,;O;O
felodipine;B-drug;B-DDI-DrugBank.d94.s11.e18
,;O;O
glucocorticoids;B-group;B-DDI-DrugBank.d94.s11.e19
,;O;O
haloperidol;B-drug;B-DDI-DrugBank.d94.s11.e20
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d94.s11.e21
,;O;O
lamotrigine;B-drug;B-DDI-DrugBank.d94.s11.e22
,;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d94.s11.e23
,;O;O
lorazepam;B-drug;B-DDI-DrugBank.d94.s11.e24
,;O;O
methadone;B-drug;B-DDI-DrugBank.d94.s11.e25
,;O;O
midazolam;B-drug;B-DDI-DrugBank.d94.s11.e26
,;O;O
mirtazapine;B-drug;B-DDI-DrugBank.d94.s11.e27
,;O;O
nortriptyline;B-drug;B-DDI-DrugBank.d94.s11.e28
,;O;O
olanzapine;B-drug;B-DDI-DrugBank.d94.s11.e29
,;O;O
oral;O;O
contraceptives(3;B-group;B-DDI-DrugBank.d94.s11.e30
);O;O
,;O;O
oxcarbazepine;B-drug;B-DDI-DrugBank.d94.s11.e31
,;O;O
Phenytoin(4;B-drug;B-DDI-DrugBank.d94.s11.e32
);O;O
,;O;O
praziquantel;B-drug;B-DDI-DrugBank.d94.s11.e33
,;O;O
protease;B-group;B-DDI-DrugBank.d94.s11.e34
inhibitors;I-group;I-DDI-DrugBank.d94.s11.e34
,;O;O
quetiapine;B-drug;B-DDI-DrugBank.d94.s11.e35
,;O;O
risperidone;B-drug;B-DDI-DrugBank.d94.s11.e36
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d94.s11.e37
,;O;O
topiramate;B-drug;B-DDI-DrugBank.d94.s11.e38
,;O;O
tiagabine;B-drug;B-DDI-DrugBank.d94.s11.e39
,;O;O
tramadol;B-drug;B-DDI-DrugBank.d94.s11.e40
,;O;O
triazolam;B-drug;B-DDI-DrugBank.d94.s11.e41
,;O;O
valproate;B-drug;B-DDI-DrugBank.d94.s11.e42
,;O;O
warfarin(5;B-drug;B-DDI-DrugBank.d94.s11.e43
);O;O
,;O;O
ziprasidone;B-drug;B-DDI-DrugBank.d94.s11.e44
,;O;O
and;O;O
zonisamide;B-drug;B-DDI-DrugBank.d94.s11.e45
.;O;O
DDI-DrugBank.d94.s12;;
Thus;O;O
,;O;O
if;O;O
a;O;O
patient;O;O
has;O;O
been;O;O
titrated;O;O
to;O;O
a;O;O
stable;O;O
dosage;O;O
on;O;O
one;O;O
of;O;O
the;O;O
agents;O;O
in;O;O
this;O;O
category;O;O
,;O;O
and;O;O
then;O;O
begins;O;O
a;O;O
course;O;O
of;O;O
treatment;O;O
with;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s12.e0
,;O;O
it;O;O
is;O;O
reasonable;O;O
to;O;O
expect;O;O
that;O;O
a;O;O
dose;O;O
increase;O;O
for;O;O
the;O;O
concomitant;O;O
agent;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d94.s13;;
Agents;O;O
with;O;O
Increased;O;O
Levels;O;O
in;O;O
the;O;O
Presence;O;O
of;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d94.s13.e0
:;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s13.e1
increases;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
the;O;O
following;O;O
agents;O;O
:;O;O
Clomipramine;B-drug;B-DDI-DrugBank.d94.s13.e2
HCl;I-drug;I-DDI-DrugBank.d94.s13.e2
,;O;O
Phenytoin(6;B-drug;B-DDI-DrugBank.d94.s13.e3
);O;O
,;O;O
and;O;O
primidone;B-drug;B-DDI-DrugBank.d94.s13.e4
Thus;O;O
,;O;O
if;O;O
a;O;O
patient;O;O
has;O;O
been;O;O
titrated;O;O
to;O;O
a;O;O
stable;O;O
dosage;O;O
on;O;O
one;O;O
of;O;O
the;O;O
agents;O;O
in;O;O
this;O;O
category;O;O
,;O;O
and;O;O
then;O;O
begins;O;O
a;O;O
course;O;O
of;O;O
the;O;O
treatment;O;O
with;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s13.e5
,;O;O
it;O;O
is;O;O
reasonable;O;O
to;O;O
expect;O;O
that;O;O
a;O;O
dose;O;O
decrease;O;O
for;O;O
the;O;O
concomitant;O;O
agent;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d94.s14;;
Pharmacological;O;O
/;O;O
Pharmacodynamic;O;O
Interactions;O;O
with;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d94.s14.e0
Concomitant;O;O
administration;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d94.s14.e1
and;O;O
lithium;B-drug;B-DDI-DrugBank.d94.s14.e2
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
neurotoxic;O;O
side;O;O
effects;O;O
.;O;O
DDI-DrugBank.d94.s15;;
Given;O;O
the;O;O
anticonvulsant;O;O
properties;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d94.s15.e0
,;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s15.e1
may;O;O
reduce;O;O
the;O;O
thyroid;O;O
function;O;O
as;O;O
has;O;O
been;O;O
reported;O;O
with;O;O
other;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d94.s15.e2
.;O;O
DDI-DrugBank.d94.s16;;
Additionally;O;O
,;O;O
anti;B-group;B-DDI-DrugBank.d94.s16.e0
-;I-group;I-DDI-DrugBank.d94.s16.e0
malarial;I-group;I-DDI-DrugBank.d94.s16.e0
drugs;I-group;I-DDI-DrugBank.d94.s16.e0
,;O;O
such;O;O
as;O;O
chloroquine;B-drug;B-DDI-DrugBank.d94.s16.e1
and;O;O
mefloquine;B-drug;B-DDI-DrugBank.d94.s16.e2
,;O;O
may;O;O
antagonize;O;O
the;O;O
activity;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d94.s16.e3
.;O;O
DDI-DrugBank.d94.s17;;
Thus;O;O
if;O;O
a;O;O
patient;O;O
has;O;O
been;O;O
titrated;O;O
to;O;O
a;O;O
stable;O;O
dosage;O;O
on;O;O
one;O;O
of;O;O
the;O;O
agents;O;O
in;O;O
this;O;O
category;O;O
,;O;O
and;O;O
then;O;O
begins;O;O
a;O;O
course;O;O
of;O;O
treatment;O;O
with;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s17.e0
,;O;O
it;O;O
is;O;O
reasonable;O;O
to;O;O
expect;O;O
that;O;O
a;O;O
dose;O;O
adjustment;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d94.s18;;
Because;O;O
of;O;O
its;O;O
primary;O;O
CNS;O;O
effect;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
EQUETROTM;B-brand;B-DDI-DrugBank.d94.s18.e0
is;O;O
taken;O;O
with;O;O
other;O;O
centrally;B-group;B-DDI-DrugBank.d94.s18.e1
acting;I-group;I-DDI-DrugBank.d94.s18.e1
drugs;I-group;I-DDI-DrugBank.d94.s18.e1
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d94.s18.e2
.;O;O
DDI-DrugBank.d545.s0;;
Geocillin;B-brand;B-DDI-DrugBank.d545.s0.e0
(;O;O
carbenicillin;B-drug;B-DDI-DrugBank.d545.s0.e1
indanyl;I-drug;I-DDI-DrugBank.d545.s0.e1
sodium;I-drug;I-DDI-DrugBank.d545.s0.e1
);O;O
blood;O;O
levels;O;O
may;O;O
be;O;O
increased;O;O
and;O;O
prolonged;O;O
by;O;O
concurrent;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d545.s0.e2
.;O;O
DDI-DrugBank.d47.s0;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
the;O;O
following;O;O
drugs;O;O
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
LODOSYN;B-brand;B-DDI-DrugBank.d47.s0.e0
(;O;O
Carbidopa;B-drug;B-DDI-DrugBank.d47.s0.e1
);O;O
given;O;O
with;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s0.e2
or;O;O
carbidopa;B-drug;B-DDI-DrugBank.d47.s0.e3
-;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s0.e4
combination;O;O
products;O;O
.;O;O
DDI-DrugBank.d47.s1;;
For;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d47.s1.e0
oxidase;I-group;I-DDI-DrugBank.d47.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d47.s1.e0
,;O;O
see;O;O
CONTRAINDICATIONS;O;O
.;O;O
DDI-DrugBank.d47.s2;;
Dopamine;B-group;B-DDI-DrugBank.d47.s2.e0
D2;I-group;I-DDI-DrugBank.d47.s2.e0
receptor;I-group;I-DDI-DrugBank.d47.s2.e0
antagonists;I-group;I-DDI-DrugBank.d47.s2.e0
(;O;O
e.g.;O;O
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d47.s2.e1
,;O;O
butyrophenones;B-group;B-DDI-DrugBank.d47.s2.e2
,;O;O
risperidone;B-drug;B-DDI-DrugBank.d47.s2.e3
);O;O
and;O;O
isoniazid;B-drug;B-DDI-DrugBank.d47.s2.e4
may;O;O
reduce;O;O
the;O;O
therapeutic;O;O
effects;O;O
of;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s2.e5
.;O;O
DDI-DrugBank.d47.s3;;
In;O;O
addition;O;O
,;O;O
the;O;O
beneficial;O;O
effects;O;O
of;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s3.e0
in;O;O
Parkinsons;O;O
disease;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
be;O;O
reversed;O;O
by;O;O
phenytoin;B-drug;B-DDI-DrugBank.d47.s3.e1
and;O;O
papaverine;B-drug;B-DDI-DrugBank.d47.s3.e2
.;O;O
DDI-DrugBank.d47.s4;;
Patients;O;O
taking;O;O
these;O;O
drugs;O;O
with;O;O
LODOSYN;B-brand;B-DDI-DrugBank.d47.s4.e0
and;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s4.e1
or;O;O
carbidopa;B-drug;B-DDI-DrugBank.d47.s4.e2
-;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s4.e3
combination;O;O
products;O;O
should;O;O
be;O;O
carefully;O;O
observed;O;O
for;O;O
loss;O;O
of;O;O
therapeutic;O;O
response;O;O
.;O;O
DDI-DrugBank.d47.s5;;
Iron;B-drug;B-DDI-DrugBank.d47.s5.e0
salts;O;O
may;O;O
reduce;O;O
the;O;O
bioavailability;O;O
of;O;O
carbidopa;B-drug;B-DDI-DrugBank.d47.s5.e1
and;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s5.e2
.;O;O
DDI-DrugBank.d47.s6;;
The;O;O
clinical;O;O
relevance;O;O
is;O;O
unclear;O;O
.;O;O
DDI-DrugBank.d47.s7;;
Although;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d47.s7.e0
may;O;O
increase;O;O
the;O;O
bioavailability;O;O
of;O;O
levodopa;B-drug;B-DDI-DrugBank.d47.s7.e1
by;O;O
increasing;O;O
gastric;O;O
emptying;O;O
,;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d47.s7.e2
may;O;O
also;O;O
adversely;O;O
affect;O;O
disease;O;O
control;O;O
by;O;O
its;O;O
dopamine;O;O
receptor;O;O
antagonistic;O;O
properties;O;O
.;O;O
DDI-DrugBank.d213.s0;;
Iodine;B-drug;B-DDI-DrugBank.d213.s0.e0
or;O;O
iodine;B-drug;B-DDI-DrugBank.d213.s0.e1
excess;O;O
may;O;O
decrease;O;O
the;O;O
effect;O;O
of;O;O
Carbimazole;B-drug;B-DDI-DrugBank.d213.s0.e2
,;O;O
and;O;O
an;O;O
iodine;B-drug;B-DDI-DrugBank.d213.s0.e3
deficiency;O;O
can;O;O
increase;O;O
the;O;O
effect;O;O
of;O;O
Carbimazole;B-drug;B-DDI-DrugBank.d213.s0.e4
.;O;O
DDI-DrugBank.d213.s1;;
Serum;O;O
concentration;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d213.s1.e0
and;O;O
digitoxin;B-drug;B-DDI-DrugBank.d213.s1.e1
may;O;O
increase;O;O
when;O;O
patients;O;O
take;O;O
antithyroid;B-group;B-DDI-DrugBank.d213.s1.e2
agents;I-group;I-DDI-DrugBank.d213.s1.e2
.;O;O
DDI-DrugBank.d213.s2;;
A;O;O
decrease;O;O
of;O;O
the;O;O
dosage;O;O
may;O;O
be;O;O
necessary;O;O
when;O;O
patient;O;O
becomes;O;O
euthyroid;O;O
.;O;O
DDI-DrugBank.d213.s3;;
Antithyroid;B-group;B-DDI-DrugBank.d213.s3.e0
agents;I-group;I-DDI-DrugBank.d213.s3.e0
may;O;O
decrease;O;O
thyroidal;O;O
uptake;O;O
of;O;O
sodium;B-drug;B-DDI-DrugBank.d213.s3.e1
iodide;I-drug;I-DDI-DrugBank.d213.s3.e1
I131;I-drug;I-DDI-DrugBank.d213.s3.e1
,;O;O
a;O;O
rebound;O;O
in;O;O
uptake;O;O
may;O;O
occur;O;O
up;O;O
to;O;O
5;O;O
days;O;O
after;O;O
sudden;O;O
withdrawal;O;O
of;O;O
Carbimazole;B-drug;B-DDI-DrugBank.d213.s3.e2
.;O;O
DDI-DrugBank.d213.s4;;
Patients;O;O
response;O;O
to;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d213.s4.e0
may;O;O
be;O;O
affected;O;O
by;O;O
his;O;O
/;O;O
her;O;O
thyroid;O;O
and;O;O
metabolic;O;O
status;O;O
.;O;O
DDI-DrugBank.d213.s5;;
An;O;O
evaluation;O;O
of;O;O
prothrombin;O;O
time;O;O
and;O;O
an;O;O
adjustment;O;O
of;O;O
anticoagulant;B-group;B-DDI-DrugBank.d213.s5.e0
dosage;O;O
are;O;O
recommended;O;O
DDI-DrugBank.d389.s0;;
Antihistamines;B-group;B-DDI-DrugBank.d389.s0.e0
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d389.s0.e1
antidepressants;I-group;I-DDI-DrugBank.d389.s0.e1
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d389.s0.e2
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d389.s0.e3
,;O;O
and;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d389.s0.e4
depressants;I-group;I-DDI-DrugBank.d389.s0.e4
.;O;O
DDI-DrugBank.d389.s1;;
MAO;B-group;B-DDI-DrugBank.d389.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d389.s1.e0
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d389.s1.e1
.;O;O
DDI-DrugBank.d389.s2;;
Sympathomimetic;B-group;B-DDI-DrugBank.d389.s2.e0
amines;I-group;I-DDI-DrugBank.d389.s2.e0
may;O;O
reduce;O;O
the;O;O
antihypertensive;O;O
effects;O;O
of;O;O
reserpine;B-drug;B-DDI-DrugBank.d389.s2.e1
,;O;O
veratrum;B-group;B-DDI-DrugBank.d389.s2.e2
alkaloids;I-group;I-DDI-DrugBank.d389.s2.e2
,;O;O
methyldopa;B-drug;B-DDI-DrugBank.d389.s2.e3
and;O;O
mecamylamine;B-drug;B-DDI-DrugBank.d389.s2.e4
.;O;O
DDI-DrugBank.d389.s3;;
Effects;O;O
of;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d389.s3.e0
are;O;O
increased;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d389.s3.e1
inhibitors;I-group;I-DDI-DrugBank.d389.s3.e1
and;O;O
beta;B-group;B-DDI-DrugBank.d389.s3.e2
adrenergic;I-group;I-DDI-DrugBank.d389.s3.e2
blockers;I-group;I-DDI-DrugBank.d389.s3.e2
.;O;O
DDI-DrugBank.d520.s0;;
The;O;O
renal;O;O
effects;O;O
of;O;O
nephrotoxic;O;O
compounds;O;O
may;O;O
be;O;O
potentiated;O;O
by;O;O
Carboplatin;B-drug;B-DDI-DrugBank.d520.s0.e0
.;O;O
DDI-DrugBank.d23.s0;;
HEMABATE;B-brand;B-DDI-DrugBank.d23.s0.e0
may;O;O
augment;O;O
the;O;O
activity;O;O
of;O;O
other;O;O
oxytocic;B-group;B-DDI-DrugBank.d23.s0.e1
agents;I-group;I-DDI-DrugBank.d23.s0.e1
.;O;O
DDI-DrugBank.d23.s1;;
Concomitant;O;O
use;O;O
with;O;O
other;O;O
oxytocic;B-group;B-DDI-DrugBank.d23.s1.e0
agents;I-group;I-DDI-DrugBank.d23.s1.e0
is;O;O
not;O;O
recommended;O;O
DDI-DrugBank.d23.s2;;
.;O;O
DDI-DrugBank.d23.s3;;
DDI-DrugBank.d502.s0;;
Ocupress;B-brand;B-DDI-DrugBank.d502.s0.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
who;O;O
are;O;O
receiving;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d502.s0.e1
-;I-group;I-DDI-DrugBank.d502.s0.e1
adrenergic;I-group;I-DDI-DrugBank.d502.s0.e1
blocking;I-group;I-DDI-DrugBank.d502.s0.e1
agent;I-group;I-DDI-DrugBank.d502.s0.e1
orally;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
additive;O;O
effects;O;O
on;O;O
systemic;O;O
beta;O;O
-;O;O
blockade;O;O
.;O;O
DDI-DrugBank.d502.s1;;
Close;O;O
observation;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
recommended;O;O
when;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d502.s1.e0
-;I-group;I-DDI-DrugBank.d502.s1.e0
blocker;I-group;I-DDI-DrugBank.d502.s1.e0
is;O;O
administered;O;O
to;O;O
patients;O;O
receiving;O;O
catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
such;O;O
as;O;O
reserpine;B-drug;B-DDI-DrugBank.d502.s1.e1
,;O;O
because;O;O
of;O;O
possible;O;O
additive;O;O
effects;O;O
and;O;O
the;O;O
production;O;O
of;O;O
hypotension;O;O
and/or;O;O
marked;O;O
bradycardia;O;O
,;O;O
which;O;O
may;O;O
produce;O;O
vertigo;O;O
,;O;O
syncope;O;O
,;O;O
or;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d269.s0;;
Inhibitors;O;O
of;O;O
CYP2D6;O;O
,;O;O
DDI-DrugBank.d269.s1;;
poor;O;O
metabolizers;O;O
of;O;O
debrisoquin;B-drug;B-DDI-DrugBank.d269.s1.e0
:;O;O
Interactions;O;O
of;O;O
carvedilol;B-drug;B-DDI-DrugBank.d269.s1.e1
with;O;O
strong;O;O
inhibitors;O;O
of;O;O
CYP2D6;O;O
(;O;O
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d269.s1.e2
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d269.s1.e3
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d269.s1.e4
,;O;O
and;O;O
propafenone;B-drug;B-DDI-DrugBank.d269.s1.e5
);O;O
have;O;O
not;O;O
been;O;O
studied;O;O
,;O;O
but;O;O
these;O;O
drugs;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
increase;O;O
blood;O;O
levels;O;O
of;O;O
the;O;O
R(+;O;O
);O;O
enantiomer;O;O
of;O;O
carvedilol;B-drug;B-DDI-DrugBank.d269.s1.e6
.;O;O
DDI-DrugBank.d269.s2;;
Retrospective;O;O
analysis;O;O
of;O;O
side;O;O
effects;O;O
in;O;O
clinical;O;O
trials;O;O
showed;O;O
that;O;O
poor;O;O
2D6;O;O
metabolizers;O;O
had;O;O
a;O;O
higher;O;O
rate;O;O
of;O;O
dizziness;O;O
during;O;O
up;O;O
-;O;O
titration;O;O
,;O;O
presumably;O;O
resulting;O;O
from;O;O
vasodilating;O;O
effects;O;O
of;O;O
the;O;O
higher;O;O
concentrations;O;O
of;O;O
the;O;O
a;O;O
-;O;O
blocking;O;O
R(+;O;O
);O;O
enantiomer;O;O
.;O;O
DDI-DrugBank.d269.s3;;
Catecholamine;O;O
-;O;O
depleting;O;O
Agents;O;O
:;O;O
Patients;O;O
taking;O;O
both;O;O
agents;B-group;B-DDI-DrugBank.d269.s3.e0
with;I-group;I-DDI-DrugBank.d269.s3.e0
b;I-group;I-DDI-DrugBank.d269.s3.e0
-;I-group;I-DDI-DrugBank.d269.s3.e0
blocking;I-group;I-DDI-DrugBank.d269.s3.e0
properties;I-group;I-DDI-DrugBank.d269.s3.e0
and;O;O
a;O;O
drug;O;O
that;O;O
can;O;O
deplete;O;O
catecholamines;O;O
(;O;O
e.g.;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d269.s3.e1
and;O;O
monoamine;B-group;B-DDI-DrugBank.d269.s3.e2
oxidase;I-group;I-DDI-DrugBank.d269.s3.e2
inhibitors;I-group;I-DDI-DrugBank.d269.s3.e2
);O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
signs;O;O
of;O;O
hypotension;O;O
and/or;O;O
severe;O;O
bradycardia;O;O
.;O;O
DDI-DrugBank.d269.s4;;
Clonidine;B-drug;B-DDI-DrugBank.d269.s4.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d269.s4.e1
with;O;O
agents;B-group;B-DDI-DrugBank.d269.s4.e2
with;I-group;I-DDI-DrugBank.d269.s4.e2
b;I-group;I-DDI-DrugBank.d269.s4.e2
-;I-group;I-DDI-DrugBank.d269.s4.e2
blocking;I-group;I-DDI-DrugBank.d269.s4.e2
properties;I-group;I-DDI-DrugBank.d269.s4.e2
may;O;O
potentiate;O;O
blood;O;O
-;O;O
pressure;O;O
-;O;O
and;O;O
heart;O;O
-;O;O
rate;O;O
-;O;O
lowering;O;O
effects;O;O
.;O;O
DDI-DrugBank.d269.s5;;
When;O;O
concomitant;O;O
treatment;O;O
with;O;O
agents;B-group;B-DDI-DrugBank.d269.s5.e0
with;I-group;I-DDI-DrugBank.d269.s5.e0
b;I-group;I-DDI-DrugBank.d269.s5.e0
-;I-group;I-DDI-DrugBank.d269.s5.e0
blocking;I-group;I-DDI-DrugBank.d269.s5.e0
properties;I-group;I-DDI-DrugBank.d269.s5.e0
and;O;O
clonidine;B-drug;B-DDI-DrugBank.d269.s5.e1
is;O;O
to;O;O
be;O;O
terminated;O;O
,;O;O
the;O;O
b;B-group;B-DDI-DrugBank.d269.s5.e2
-;I-group;I-DDI-DrugBank.d269.s5.e2
blocking;I-group;I-DDI-DrugBank.d269.s5.e2
agent;I-group;I-DDI-DrugBank.d269.s5.e2
should;O;O
be;O;O
discontinued;O;O
first;O;O
.;O;O
DDI-DrugBank.d269.s6;;
Clonidine;B-drug;B-DDI-DrugBank.d269.s6.e0
therapy;O;O
can;O;O
then;O;O
be;O;O
discontinued;O;O
several;O;O
days;O;O
later;O;O
by;O;O
gradually;O;O
decreasing;O;O
the;O;O
dosage;O;O
.;O;O
DDI-DrugBank.d269.s7;;
Cyclosporine;B-drug;B-DDI-DrugBank.d269.s7.e0
:;O;O
Modest;O;O
increases;O;O
in;O;O
mean;O;O
trough;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d269.s7.e1
concentrations;O;O
were;O;O
observed;O;O
following;O;O
initiation;O;O
of;O;O
carvedilol;B-drug;B-DDI-DrugBank.d269.s7.e2
treatment;O;O
in;O;O
21;O;O
renal;O;O
transplant;O;O
patients;O;O
suffering;O;O
from;O;O
chronic;O;O
vascular;O;O
rejection;O;O
.;O;O
DDI-DrugBank.d269.s8;;
In;O;O
about;O;O
30;O;O
%;O;O
of;O;O
patients;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d269.s8.e0
had;O;O
to;O;O
be;O;O
reduced;O;O
in;O;O
order;O;O
to;O;O
maintain;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d269.s8.e1
concentrations;O;O
within;O;O
the;O;O
therapeutic;O;O
range;O;O
,;O;O
while;O;O
in;O;O
the;O;O
remainder;O;O
no;O;O
adjustment;O;O
was;O;O
needed;O;O
.;O;O
DDI-DrugBank.d269.s9;;
On;O;O
the;O;O
average;O;O
for;O;O
the;O;O
group;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d269.s9.e0
was;O;O
reduced;O;O
about;O;O
20;O;O
%;O;O
in;O;O
these;O;O
patients;O;O
.;O;O
DDI-DrugBank.d269.s10;;
Due;O;O
to;O;O
wide;O;O
interindividual;O;O
variability;O;O
in;O;O
the;O;O
dose;O;O
adjustment;O;O
required;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d269.s10.e0
concentrations;O;O
be;O;O
monitored;O;O
closely;O;O
after;O;O
initiation;O;O
of;O;O
carvedilol;B-drug;B-DDI-DrugBank.d269.s10.e1
therapy;O;O
and;O;O
that;O;O
the;O;O
dose;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d269.s10.e2
be;O;O
adjusted;O;O
as;O;O
appropriate;O;O
.;O;O
DDI-DrugBank.d269.s11;;
Digoxin;B-drug;B-DDI-DrugBank.d269.s11.e0
:;O;O
Digoxin;B-drug;B-DDI-DrugBank.d269.s11.e1
concentrations;O;O
are;O;O
increased;O;O
by;O;O
about;O;O
15;O;O
%;O;O
when;O;O
digoxin;B-drug;B-DDI-DrugBank.d269.s11.e2
and;O;O
carvedilol;B-drug;B-DDI-DrugBank.d269.s11.e3
are;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d269.s12;;
Both;O;O
digoxin;B-drug;B-DDI-DrugBank.d269.s12.e0
and;O;O
COREG;B-brand;B-DDI-DrugBank.d269.s12.e1
slow;O;O
AV;O;O
conduction;O;O
.;O;O
DDI-DrugBank.d269.s13;;
Therefore;O;O
,;O;O
increased;O;O
monitoring;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d269.s13.e0
is;O;O
recommended;O;O
when;O;O
initiating;O;O
,;O;O
adjusting;O;O
,;O;O
or;O;O
discontinuing;O;O
COREG;B-brand;B-DDI-DrugBank.d269.s13.e1
.;O;O
DDI-DrugBank.d269.s14;;
Inducers;O;O
and;O;O
Inhibitors;O;O
of;O;O
Hepatic;O;O
Metabolism;O;O
:;O;O
Rifampin;B-drug;B-DDI-DrugBank.d269.s14.e0
reduced;O;O
plasma;O;O
concentrations;O;O
of;O;O
carvedilol;B-drug;B-DDI-DrugBank.d269.s14.e1
by;O;O
about;O;O
70;O;O
%;O;O
.;O;O
DDI-DrugBank.d269.s15;;
Cimetidine;B-drug;B-DDI-DrugBank.d269.s15.e0
increased;O;O
AUC;O;O
by;O;O
about;O;O
30;O;O
%;O;O
but;O;O
caused;O;O
no;O;O
change;O;O
in;O;O
Cmax;O;O
.;O;O
DDI-DrugBank.d269.s16;;
Calcium;B-group;B-DDI-DrugBank.d269.s16.e0
Channel;I-group;I-DDI-DrugBank.d269.s16.e0
Blockers;I-group;I-DDI-DrugBank.d269.s16.e0
:;O;O
Isolated;O;O
cases;O;O
of;O;O
conduction;O;O
disturbance;O;O
(;O;O
rarely;O;O
with;O;O
hemodynamic;O;O
compromise;O;O
);O;O
have;O;O
been;O;O
observed;O;O
when;O;O
COREG;B-brand;B-DDI-DrugBank.d269.s16.e1
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
diltiazem;B-drug;B-DDI-DrugBank.d269.s16.e2
.;O;O
DDI-DrugBank.d269.s17;;
As;O;O
with;O;O
other;O;O
agents;B-group;B-DDI-DrugBank.d269.s17.e0
with;I-group;I-DDI-DrugBank.d269.s17.e0
b;I-group;I-DDI-DrugBank.d269.s17.e0
-;I-group;I-DDI-DrugBank.d269.s17.e0
blocking;I-group;I-DDI-DrugBank.d269.s17.e0
properties;I-group;I-DDI-DrugBank.d269.s17.e0
,;O;O
if;O;O
COREG;B-brand;B-DDI-DrugBank.d269.s17.e1
is;O;O
to;O;O
be;O;O
administered;O;O
orally;O;O
with;O;O
calcium;B-group;B-DDI-DrugBank.d269.s17.e2
channel;I-group;I-DDI-DrugBank.d269.s17.e2
blockers;I-group;I-DDI-DrugBank.d269.s17.e2
of;O;O
the;O;O
verapamil;B-drug;B-DDI-DrugBank.d269.s17.e3
or;O;O
diltiazem;B-drug;B-DDI-DrugBank.d269.s17.e4
type;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
ECG;O;O
and;O;O
blood;O;O
pressure;O;O
be;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d269.s18;;
Insulin;B-drug;B-DDI-DrugBank.d269.s18.e0
or;O;O
Oral;O;O
Hypoglycemics;B-group;B-DDI-DrugBank.d269.s18.e1
:;O;O
Agents;B-group;B-DDI-DrugBank.d269.s18.e2
with;I-group;I-DDI-DrugBank.d269.s18.e2
b;I-group;I-DDI-DrugBank.d269.s18.e2
-;I-group;I-DDI-DrugBank.d269.s18.e2
blocking;I-group;I-DDI-DrugBank.d269.s18.e2
properties;I-group;I-DDI-DrugBank.d269.s18.e2
may;O;O
enhance;O;O
the;O;O
blood;O;O
-;O;O
sugar;O;O
-;O;O
reducing;O;O
effect;O;O
of;O;O
insulin;B-drug;B-DDI-DrugBank.d269.s18.e3
and;O;O
oral;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d269.s18.e4
.;O;O
DDI-DrugBank.d269.s19;;
Therefore;O;O
,;O;O
in;O;O
patients;O;O
taking;O;O
insulin;B-drug;B-DDI-DrugBank.d269.s19.e0
or;O;O
oral;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d269.s19.e1
,;O;O
regular;O;O
monitoring;O;O
of;O;O
blood;O;O
glucose;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d350.s0;;
Studies;O;O
in;O;O
vitro;O;O
show;O;O
that;O;O
caspofungin;B-drug;B-DDI-DrugBank.d350.s0.e0
acetate;I-drug;I-DDI-DrugBank.d350.s0.e0
is;O;O
not;O;O
an;O;O
inhibitor;O;O
of;O;O
any;O;O
enzyme;O;O
in;O;O
the;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
system;O;O
.;O;O
DDI-DrugBank.d350.s1;;
In;O;O
clinical;O;O
studies;O;O
,;O;O
caspofungin;B-drug;B-DDI-DrugBank.d350.s1.e0
did;O;O
not;O;O
induce;O;O
the;O;O
CYP3A4;O;O
metabolism;O;O
of;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d350.s2;;
Caspofungin;B-drug;B-DDI-DrugBank.d350.s2.e0
is;O;O
not;O;O
a;O;O
substrate;O;O
for;O;O
P;O;O
-;O;O
glycoprotein;O;O
and;O;O
is;O;O
a;O;O
poor;O;O
substrate;O;O
for;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d350.s3;;
Clinical;O;O
studies;O;O
in;O;O
healthy;O;O
volunteers;O;O
show;O;O
that;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s3.e0
are;O;O
not;O;O
altered;O;O
by;O;O
itraconazole;B-drug;B-DDI-DrugBank.d350.s3.e1
,;O;O
amphotericin;B-drug;B-DDI-DrugBank.d350.s3.e2
B;I-drug;I-DDI-DrugBank.d350.s3.e2
,;O;O
mycophenolate;B-drug;B-DDI-DrugBank.d350.s3.e3
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d350.s3.e4
,;O;O
or;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d350.s3.e5
.;O;O
DDI-DrugBank.d350.s4;;
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s4.e0
has;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d350.s4.e1
,;O;O
amphotericin;B-drug;B-DDI-DrugBank.d350.s4.e2
B;I-drug;I-DDI-DrugBank.d350.s4.e2
,;O;O
or;O;O
the;O;O
active;O;O
metabolite;O;O
of;O;O
mycophenolate;O;O
.;O;O
DDI-DrugBank.d350.s5;;
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s5.e0
reduced;O;O
the;O;O
blood;O;O
AUC0;O;O
-;O;O
12;O;O
of;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d350.s5.e1
by;O;O
approximately;O;O
20;O;O
%;O;O
,;O;O
peak;O;O
blood;O;O
concentration;O;O
(;O;O
Cmax;O;O
);O;O
by;O;O
16;O;O
%;O;O
,;O;O
and;O;O
12;O;O
-;O;O
hour;O;O
blood;O;O
concentration;O;O
(;O;O
C12hr;O;O
);O;O
by;O;O
26;O;O
%;O;O
in;O;O
healthy;O;O
subjects;O;O
when;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d350.s5.e2
(;O;O
2;O;O
doses;O;O
of;O;O
0.1;O;O
mg;O;O
/;O;O
kg;O;O
12;O;O
hours;O;O
apart;O;O
);O;O
was;O;O
administered;O;O
on;O;O
the;O;O
10th;O;O
day;O;O
of;O;O
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s5.e3
70;O;O
mg;O;O
daily;O;O
,;O;O
as;O;O
compared;O;O
to;O;O
results;O;O
from;O;O
a;O;O
control;O;O
period;O;O
in;O;O
which;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d350.s5.e4
was;O;O
administered;O;O
alone;O;O
.;O;O
DDI-DrugBank.d350.s6;;
For;O;O
patients;O;O
receiving;O;O
both;O;O
therapies;O;O
,;O;O
standard;O;O
monitoring;O;O
of;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d350.s6.e0
blood;O;O
concentrations;O;O
and;O;O
appropriate;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d350.s6.e1
dosage;O;O
adjustments;O;O
are;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d350.s7;;
In;O;O
two;O;O
clinical;O;O
studies;O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d350.s7.e0
(;O;O
one;O;O
4;O;O
mg;O;O
/;O;O
kg;O;O
dose;O;O
or;O;O
two;O;O
3;O;O
mg;O;O
/;O;O
kg;O;O
doses;O;O
);O;O
increased;O;O
the;O;O
AUC;O;O
of;O;O
caspofungin;B-drug;B-DDI-DrugBank.d350.s7.e1
by;O;O
approximately;O;O
35;O;O
%;O;O
.;O;O
DDI-DrugBank.d350.s8;;
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s8.e0
did;O;O
not;O;O
increase;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d350.s8.e1
.;O;O
DDI-DrugBank.d350.s9;;
There;O;O
were;O;O
transient;O;O
increases;O;O
in;O;O
liver;O;O
ALT;O;O
and;O;O
AST;O;O
when;O;O
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s9.e0
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d350.s9.e1
were;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d350.s10;;
A;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
study;O;O
with;O;O
rifampin;B-drug;B-DDI-DrugBank.d350.s10.e0
in;O;O
healthy;O;O
volunteers;O;O
has;O;O
shown;O;O
a;O;O
30;O;O
%;O;O
decrease;O;O
in;O;O
caspofungin;B-drug;B-DDI-DrugBank.d350.s10.e1
trough;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d350.s11;;
Patients;O;O
on;O;O
rifampin;B-drug;B-DDI-DrugBank.d350.s11.e0
should;O;O
receive;O;O
70;O;O
mg;O;O
of;O;O
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s11.e1
daily;O;O
.;O;O
DDI-DrugBank.d350.s12;;
In;O;O
addition;O;O
,;O;O
results;O;O
from;O;O
regression;O;O
analyses;O;O
of;O;O
patient;O;O
pharmacokinetic;O;O
data;O;O
suggest;O;O
that;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
other;O;O
inducers;O;O
of;O;O
drug;O;O
clearance;O;O
(;O;O
efavirenz;B-drug;B-DDI-DrugBank.d350.s12.e0
,;O;O
nevirapine;B-drug;B-DDI-DrugBank.d350.s12.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d350.s12.e2
,;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d350.s12.e3
,;O;O
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d350.s12.e4
);O;O
with;O;O
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s12.e5
may;O;O
result;O;O
in;O;O
clinically;O;O
meaningful;O;O
reductions;O;O
in;O;O
caspofungin;B-drug;B-DDI-DrugBank.d350.s12.e6
concentrations;O;O
.;O;O
DDI-DrugBank.d350.s13;;
It;O;O
is;O;O
not;O;O
known;O;O
which;O;O
drug;O;O
clearance;O;O
mechanism;O;O
involved;O;O
in;O;O
caspofungin;B-drug;B-DDI-DrugBank.d350.s13.e0
disposition;O;O
may;O;O
be;O;O
inducible;O;O
.;O;O
DDI-DrugBank.d350.s14;;
When;O;O
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s14.e0
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
inducers;O;O
of;O;O
drug;O;O
clearance;O;O
,;O;O
such;O;O
as;O;O
efavirenz;B-drug;B-DDI-DrugBank.d350.s14.e1
,;O;O
nevirapine;B-drug;B-DDI-DrugBank.d350.s14.e2
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d350.s14.e3
,;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d350.s14.e4
,;O;O
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d350.s14.e5
,;O;O
use;O;O
of;O;O
a;O;O
daily;O;O
dose;O;O
of;O;O
70;O;O
mg;O;O
of;O;O
CANCIDAS;B-brand;B-DDI-DrugBank.d350.s14.e6
should;O;O
be;O;O
considered;O;O
DDI-DrugBank.d350.s15;;
.;O;O
DDI-DrugBank.d350.s16;;
DDI-DrugBank.d557.s0;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Positive;O;O
direct;O;O
Coombs;O;O
tests;O;O
have;O;O
been;O;O
reported;O;O
during;O;O
treatment;O;O
with;O;O
the;O;O
cephalosporin;B-group;B-DDI-DrugBank.d557.s0.e0
antibiotics;I-group;I-DDI-DrugBank.d557.s0.e0
.;O;O
DDI-DrugBank.d557.s1;;
In;O;O
hematologic;O;O
studies;O;O
or;O;O
in;O;O
transfusion;O;O
cross;O;O
-;O;O
matching;O;O
procedures;O;O
when;O;O
anti;O;O
-;O;O
globulin;O;O
tests;O;O
are;O;O
performed;O;O
on;O;O
the;O;O
minor;O;O
side;O;O
or;O;O
in;O;O
Coombs;O;O
testing;O;O
of;O;O
newborns;O;O
whose;O;O
mothers;O;O
have;O;O
received;O;O
cephalosporin;B-group;B-DDI-DrugBank.d557.s1.e0
antibiotics;I-group;I-DDI-DrugBank.d557.s1.e0
before;O;O
parturition;O;O
,;O;O
it;O;O
should;O;O
be;O;O
recognized;O;O
that;O;O
a;O;O
positive;O;O
Coombs;O;O
test;O;O
may;O;O
be;O;O
due;O;O
to;O;O
the;O;O
drug;O;O
.;O;O
DDI-DrugBank.d281.s0;;
Probenecid;B-drug;B-DDI-DrugBank.d281.s0.e0
may;O;O
decrease;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
cephalosporins;B-group;B-DDI-DrugBank.d281.s0.e1
when;O;O
used;O;O
concurrently;O;O
,;O;O
resulting;O;O
in;O;O
increased;O;O
and;O;O
more;O;O
prolonged;O;O
cephalosporin;B-group;B-DDI-DrugBank.d281.s0.e2
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d281.s1;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
A;O;O
false;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
with;O;O
Benedicts;O;O
solution;O;O
,;O;O
Fehlings;O;O
solution;O;O
or;O;O
with;O;O
CLINITEST;O;O
tablets;O;O
,;O;O
but;O;O
not;O;O
with;O;O
enzyme;O;O
-;O;O
based;O;O
tests;O;O
such;O;O
as;O;O
CLINISTIX;O;O
.;O;O
DDI-DrugBank.d281.s2;;
Positive;O;O
direct;O;O
and;O;O
indirect;O;O
antiglobulin;O;O
(;O;O
Coombs;O;O
);O;O
tests;O;O
have;O;O
occurred;O;O
,;O;O
DDI-DrugBank.d281.s3;;
these;O;O
may;O;O
also;O;O
occur;O;O
in;O;O
neonates;O;O
whose;O;O
mothers;O;O
received;O;O
cephalosporins;B-group;B-DDI-DrugBank.d281.s3.e0
before;O;O
delivery;O;O
.;O;O
DDI-DrugBank.d420.s0;;
Antacids;B-group;B-DDI-DrugBank.d420.s0.e0
(;O;O
aluminum;B-drug;B-DDI-DrugBank.d420.s0.e1
-;O;O
or;O;O
magnesium;B-drug;B-DDI-DrugBank.d420.s0.e2
-;O;O
containing;O;O
);O;O
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
300;O;O
-;O;O
mg;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s0.e3
capsules;O;O
with;O;O
30;O;O
mL;O;O
Maalox;B-brand;B-DDI-DrugBank.d420.s0.e4
TC;I-brand;I-DDI-DrugBank.d420.s0.e4
suspension;O;O
reduces;O;O
the;O;O
rate;O;O
(;O;O
Cmax;O;O
);O;O
and;O;O
extent;O;O
(;O;O
AUC;O;O
);O;O
of;O;O
absorption;O;O
by;O;O
approximately;O;O
40;O;O
%;O;O
.;O;O
DDI-DrugBank.d420.s1;;
Time;O;O
to;O;O
reach;O;O
Cmax;O;O
is;O;O
also;O;O
prolonged;O;O
by;O;O
1;O;O
hour;O;O
.;O;O
DDI-DrugBank.d420.s2;;
There;O;O
are;O;O
no;O;O
significant;O;O
effects;O;O
on;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s2.e0
pharmacokinetics;O;O
if;O;O
the;O;O
antacid;B-group;B-DDI-DrugBank.d420.s2.e1
is;O;O
administered;O;O
2;O;O
hours;O;O
before;O;O
or;O;O
2;O;O
hours;O;O
after;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s2.e2
.;O;O
DDI-DrugBank.d420.s3;;
If;O;O
antacids;B-group;B-DDI-DrugBank.d420.s3.e0
are;O;O
required;O;O
during;O;O
OMNICEF;B-brand;B-DDI-DrugBank.d420.s3.e1
therapy;O;O
,;O;O
OMNICEF;B-brand;B-DDI-DrugBank.d420.s3.e2
should;O;O
be;O;O
taken;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
before;O;O
or;O;O
after;O;O
the;O;O
antacid;B-group;B-DDI-DrugBank.d420.s3.e3
.;O;O
DDI-DrugBank.d420.s4;;
Probenecid;B-drug;B-DDI-DrugBank.d420.s4.e0
:;O;O
As;O;O
with;O;O
other;O;O
b;B-group;B-DDI-DrugBank.d420.s4.e1
-;I-group;I-DDI-DrugBank.d420.s4.e1
lactam;I-group;I-DDI-DrugBank.d420.s4.e1
antibiotics;I-group;I-DDI-DrugBank.d420.s4.e1
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d420.s4.e2
inhibits;O;O
the;O;O
renal;O;O
excretion;O;O
of;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s4.e3
,;O;O
resulting;O;O
in;O;O
an;O;O
approximate;O;O
doubling;O;O
in;O;O
A.C.;O;O
a;O;O
54;O;O
%;O;O
increase;O;O
in;O;O
peak;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s4.e4
plasma;O;O
levels;O;O
,;O;O
and;O;O
a;O;O
50;O;O
%;O;O
prolongation;O;O
in;O;O
the;O;O
apparent;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d420.s5;;
Iron;B-group;B-DDI-DrugBank.d420.s5.e0
Supplements;I-group;I-DDI-DrugBank.d420.s5.e0
and;O;O
Foods;O;O
Fortified;O;O
With;O;O
Iron;B-drug;B-DDI-DrugBank.d420.s5.e1
Concomitant;O;O
administration;O;O
of;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s5.e2
with;O;O
a;O;O
therapeutic;O;O
iron;B-group;B-DDI-DrugBank.d420.s5.e3
supplement;I-group;I-DDI-DrugBank.d420.s5.e3
containing;O;O
60;O;O
mg;O;O
of;O;O
elemental;O;O
iron;B-drug;B-DDI-DrugBank.d420.s5.e4
(;O;O
as;O;O
FeSO4;O;O
);O;O
or;O;O
vitamins;B-group;B-DDI-DrugBank.d420.s5.e5
supplemented;O;O
with;O;O
10;O;O
mg;O;O
of;O;O
elemental;O;O
iron;B-drug;B-DDI-DrugBank.d420.s5.e6
reduced;O;O
extent;O;O
of;O;O
absorption;O;O
by;O;O
80;O;O
%;O;O
and;O;O
31;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d420.s6;;
If;O;O
iron;B-group;B-DDI-DrugBank.d420.s6.e0
supplements;I-group;I-DDI-DrugBank.d420.s6.e0
are;O;O
required;O;O
during;O;O
OMNICEF;B-brand;B-DDI-DrugBank.d420.s6.e1
therapy;O;O
,;O;O
OMNICEF;B-brand;B-DDI-DrugBank.d420.s6.e2
should;O;O
be;O;O
taken;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
before;O;O
or;O;O
after;O;O
the;O;O
supplement;O;O
.;O;O
DDI-DrugBank.d420.s7;;
The;O;O
effect;O;O
of;O;O
foods;O;O
highly;O;O
fortified;O;O
with;O;O
elemental;O;O
iron;B-drug_n;B-DDI-DrugBank.d420.s7.e0
(;O;O
primarily;O;O
iron;B-drug_n;B-DDI-DrugBank.d420.s7.e1
-;O;O
fortified;O;O
breakfast;O;O
cereals;O;O
);O;O
on;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s7.e2
absorption;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d420.s8;;
Concomitantly;O;O
administered;O;O
iron;B-drug_n;B-DDI-DrugBank.d420.s8.e0
-;O;O
fortified;O;O
infant;O;O
formula;O;O
(;O;O
2.2;O;O
mg;O;O
elemental;O;O
iron;B-drug_n;B-DDI-DrugBank.d420.s8.e1
/;O;O
6;O;O
oz;O;O
);O;O
has;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s8.e2
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d420.s9;;
Therefore;O;O
,;O;O
OMNICEF;B-brand;B-DDI-DrugBank.d420.s9.e0
for;O;O
Oral;O;O
Suspension;O;O
can;O;O
be;O;O
administered;O;O
with;O;O
iron;B-drug_n;B-DDI-DrugBank.d420.s9.e1
-;O;O
fortified;O;O
infant;O;O
formula;O;O
.;O;O
DDI-DrugBank.d420.s10;;
There;O;O
have;O;O
been;O;O
rare;O;O
reports;O;O
of;O;O
reddish;O;O
stools;O;O
in;O;O
patients;O;O
who;O;O
have;O;O
received;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s10.e0
in;O;O
Japan;O;O
.;O;O
DDI-DrugBank.d420.s11;;
The;O;O
reddish;O;O
color;O;O
is;O;O
due;O;O
to;O;O
the;O;O
formation;O;O
of;O;O
a;O;O
nonabsorbable;O;O
complex;O;O
between;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s11.e0
or;O;O
its;O;O
breakdown;O;O
products;O;O
and;O;O
iron;B-drug;B-DDI-DrugBank.d420.s11.e1
in;O;O
the;O;O
gastrointestinal;O;O
tract;O;O
.;O;O
DDI-DrugBank.d420.s12;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
A;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
ketones;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
with;O;O
tests;O;O
using;O;O
nitroprusside;B-drug;B-DDI-DrugBank.d420.s12.e0
,;O;O
but;O;O
not;O;O
with;O;O
those;O;O
using;O;O
nitroferricyanide;B-drug;B-DDI-DrugBank.d420.s12.e1
.;O;O
DDI-DrugBank.d420.s13;;
The;O;O
administration;O;O
of;O;O
cefdinir;B-drug;B-DDI-DrugBank.d420.s13.e0
may;O;O
result;O;O
in;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
urine;O;O
using;O;O
Clinitest;O;O
,;O;O
Benedict;O;O
s;O;O
solution;O;O
,;O;O
or;O;O
Fehlings;O;O
solution;O;O
.;O;O
DDI-DrugBank.d420.s14;;
It;O;O
is;O;O
recommended;O;O
that;O;O
glucose;O;O
tests;O;O
based;O;O
on;O;O
enzymatic;O;O
glucose;O;O
oxidase;O;O
reactions;O;O
(;O;O
such;O;O
as;O;O
Clinistix;O;O
or;O;O
Tes;O;O
-;O;O
Tape;O;O
);O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d420.s15;;
Cephalosporins;B-group;B-DDI-DrugBank.d420.s15.e0
are;O;O
known;O;O
to;O;O
occasionally;O;O
induce;O;O
a;O;O
positive;O;O
direct;O;O
Coombs;O;O
test;O;O
.;O;O
DDI-DrugBank.d550.s0;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d550.s0.e0
Multiple;O;O
doses;O;O
of;O;O
cefditoren;B-drug;B-DDI-DrugBank.d550.s0.e1
pivoxil;I-drug;I-DDI-DrugBank.d550.s0.e1
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d550.s0.e2
estradiol;I-drug;I-DDI-DrugBank.d550.s0.e2
,;O;O
the;O;O
estrogenic;O;O
component;O;O
in;O;O
most;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d550.s0.e3
.;O;O
DDI-DrugBank.d550.s1;;
Although;O;O
the;O;O
clinical;O;O
significance;O;O
is;O;O
not;O;O
known;O;O
,;O;O
it;O;O
is;O;O
not;O;O
recommended;O;O
that;O;O
cefditoren;B-drug;B-DDI-DrugBank.d550.s1.e0
pivoxil;I-drug;I-DDI-DrugBank.d550.s1.e0
be;O;O
taken;O;O
concomitantly;O;O
with;O;O
antacids;B-group;B-DDI-DrugBank.d550.s1.e1
.;O;O
DDI-DrugBank.d550.s2;;
H2;B-group;B-DDI-DrugBank.d550.s2.e0
-;I-group;I-DDI-DrugBank.d550.s2.e0
Receptor;I-group;I-DDI-DrugBank.d550.s2.e0
Antagonists;I-group;I-DDI-DrugBank.d550.s2.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
intravenously;O;O
administered;O;O
famotidine;B-drug;B-DDI-DrugBank.d550.s2.e1
(;O;O
20;O;O
mg;O;O
);O;O
reduced;O;O
the;O;O
oral;O;O
absorption;O;O
of;O;O
a;O;O
single;O;O
400;O;O
mg;O;O
dose;O;O
of;O;O
cefditoren;B-drug;B-DDI-DrugBank.d550.s2.e2
pivoxil;I-drug;I-DDI-DrugBank.d550.s2.e2
administered;O;O
following;O;O
a;O;O
meal;O;O
,;O;O
as;O;O
evidenced;O;O
by;O;O
a;O;O
27;O;O
%;O;O
decrease;O;O
in;O;O
mean;O;O
Cmax;O;O
and;O;O
a;O;O
22;O;O
%;O;O
decrease;O;O
in;O;O
mean;O;O
AUC;O;O
.;O;O
DDI-DrugBank.d550.s3;;
Although;O;O
the;O;O
clinical;O;O
significance;O;O
is;O;O
not;O;O
known;O;O
,;O;O
it;O;O
is;O;O
not;O;O
recommended;O;O
that;O;O
cefditoren;B-drug;B-DDI-DrugBank.d550.s3.e0
pivoxil;I-drug;I-DDI-DrugBank.d550.s3.e0
be;O;O
taken;O;O
concomitantly;O;O
with;O;O
H2;B-group;B-DDI-DrugBank.d550.s3.e1
receptor;I-group;I-DDI-DrugBank.d550.s3.e1
antagonists;I-group;I-DDI-DrugBank.d550.s3.e1
.;O;O
DDI-DrugBank.d550.s4;;
Probenecid;B-drug;B-DDI-DrugBank.d550.s4.e0
:;O;O
As;O;O
with;O;O
other;O;O
b;B-group;B-DDI-DrugBank.d550.s4.e1
-;I-group;I-DDI-DrugBank.d550.s4.e1
lactam;I-group;I-DDI-DrugBank.d550.s4.e1
antibiotics;I-group;I-DDI-DrugBank.d550.s4.e1
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d550.s4.e2
with;O;O
cefditoren;B-drug;B-DDI-DrugBank.d550.s4.e3
pivoxil;I-drug;I-DDI-DrugBank.d550.s4.e3
resulted;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
the;O;O
plasma;O;O
exposure;O;O
of;O;O
cefditoren;B-drug;B-DDI-DrugBank.d550.s4.e4
,;O;O
with;O;O
a;O;O
49;O;O
%;O;O
increase;O;O
in;O;O
mean;O;O
Cmax;O;O
,;O;O
a;O;O
122;O;O
%;O;O
increase;O;O
in;O;O
mean;O;O
AUC;O;O
,;O;O
and;O;O
a;O;O
53;O;O
%;O;O
increase;O;O
in;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d550.s5;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Cephalosporins;B-group;B-DDI-DrugBank.d550.s5.e0
are;O;O
known;O;O
to;O;O
occasionally;O;O
induce;O;O
a;O;O
positive;O;O
direct;O;O
Coombs;O;O
test;O;O
.;O;O
DDI-DrugBank.d550.s6;;
A;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
with;O;O
copper;O;O
reduction;O;O
tests;O;O
(;O;O
Benedicts;O;O
or;O;O
Fehlings;O;O
solution;O;O
or;O;O
with;O;O
CLINITEST;O;O
tablets;O;O
);O;O
,;O;O
but;O;O
not;O;O
with;O;O
enzyme;O;O
-;O;O
based;O;O
tests;O;O
for;O;O
glycosuria;O;O
(;O;O
e.g.;O;O
,;O;O
CLINISTIX;O;O
,;O;O
TES;O;O
-;O;O
TAPE;O;O
);O;O
.;O;O
DDI-DrugBank.d550.s7;;
As;O;O
a;O;O
false;O;O
-;O;O
negative;O;O
result;O;O
may;O;O
occur;O;O
in;O;O
the;O;O
ferricyanide;O;O
test;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
either;O;O
the;O;O
glucose;O;O
oxidase;O;O
or;O;O
hexokinase;O;O
method;O;O
be;O;O
used;O;O
to;O;O
determine;O;O
blood;O;O
/;O;O
plasma;O;O
glucose;O;O
levels;O;O
in;O;O
patients;O;O
receiving;O;O
cefditoren;B-drug;B-DDI-DrugBank.d550.s7.e0
pivoxil;I-drug;I-DDI-DrugBank.d550.s7.e0
.;O;O
DDI-DrugBank.d378.s0;;
Renal;O;O
function;O;O
should;O;O
be;O;O
monitored;O;O
carefully;O;O
if;O;O
high;O;O
doses;O;O
of;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d378.s0.e0
are;O;O
to;O;O
be;O;O
administered;O;O
with;O;O
MAXIPIME;B-brand;B-DDI-DrugBank.d378.s0.e1
because;O;O
of;O;O
the;O;O
increased;O;O
potential;O;O
of;O;O
nephrotoxicity;O;O
and;O;O
ototoxicity;O;O
of;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d378.s0.e2
antibiotics;I-group;I-DDI-DrugBank.d378.s0.e2
.;O;O
DDI-DrugBank.d378.s1;;
Nephrotoxicity;O;O
has;O;O
been;O;O
reported;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
other;O;O
cephalosporins;B-group;B-DDI-DrugBank.d378.s1.e0
with;O;O
potent;O;O
diuretics;B-group;B-DDI-DrugBank.d378.s1.e1
such;O;O
as;O;O
furosemide;B-drug;B-DDI-DrugBank.d378.s1.e2
.;O;O
DDI-DrugBank.d378.s2;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
The;O;O
administration;O;O
of;O;O
cefepime;B-drug;B-DDI-DrugBank.d378.s2.e0
may;O;O
result;O;O
in;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
when;O;O
using;O;O
Clinitest;O;O
tablets;O;O
.;O;O
DDI-DrugBank.d378.s3;;
It;O;O
is;O;O
recommended;O;O
that;O;O
glucose;O;O
tests;O;O
based;O;O
on;O;O
enzymatic;O;O
glucose;O;O
oxidase;O;O
reactions;O;O
(;O;O
such;O;O
as;O;O
Clinistix;O;O
or;O;O
Tes;O;O
-;O;O
Tape;O;O
);O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d339.s0;;
Carbamazepine;B-drug;B-DDI-DrugBank.d339.s0.e0
:;O;O
Elevated;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d339.s0.e1
levels;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
postmarketing;O;O
experience;O;O
when;O;O
SUPRAX;B-brand;B-DDI-DrugBank.d339.s0.e2
is;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d339.s1;;
Drug;O;O
monitoring;O;O
may;O;O
be;O;O
of;O;O
assistance;O;O
in;O;O
detecting;O;O
alterations;O;O
in;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d339.s1.e0
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d339.s2;;
Warfarin;B-drug;B-DDI-DrugBank.d339.s2.e0
and;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d339.s2.e1
:;O;O
Increased;O;O
prothrombin;O;O
time;O;O
,;O;O
with;O;O
or;O;O
without;O;O
clinical;O;O
bleeding;O;O
,;O;O
has;O;O
been;O;O
reported;O;O
when;O;O
cefixime;B-drug;B-DDI-DrugBank.d339.s2.e2
is;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d339.s3;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
A;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
ketones;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
with;O;O
tests;O;O
using;O;O
nitroprusside;B-drug;B-DDI-DrugBank.d339.s3.e0
but;O;O
not;O;O
with;O;O
those;O;O
using;O;O
nitroferricyanide;B-drug;B-DDI-DrugBank.d339.s3.e1
.;O;O
DDI-DrugBank.d339.s4;;
The;O;O
administration;O;O
of;O;O
SUPRAX;B-brand;B-DDI-DrugBank.d339.s4.e0
may;O;O
result;O;O
in;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
using;O;O
Clinitest;O;O
*;O;O
*;O;O
,;O;O
Benedict;O;O
s;O;O
solution;O;O
,;O;O
or;O;O
Fehling;O;O
s;O;O
solution;O;O
.;O;O
DDI-DrugBank.d339.s5;;
It;O;O
is;O;O
recommended;O;O
that;O;O
glucose;O;O
tests;O;O
based;O;O
on;O;O
enzymatic;O;O
glucose;O;O
oxidase;O;O
reactions;O;O
(;O;O
such;O;O
as;O;O
Clinistix;O;O
*;O;O
*;O;O
or;O;O
Tes;O;O
-;O;O
Tape;O;O
*;O;O
*;O;O
);O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d339.s6;;
A;O;O
false;O;O
-;O;O
positive;O;O
direct;O;O
Coombs;O;O
test;O;O
has;O;O
been;O;O
reported;O;O
during;O;O
treatment;O;O
with;O;O
other;O;O
cephalosporin;B-group;B-DDI-DrugBank.d339.s6.e0
antibiotics;I-group;I-DDI-DrugBank.d339.s6.e0
,;O;O
DDI-DrugBank.d339.s7;;
therefore;O;O
,;O;O
it;O;O
should;O;O
be;O;O
recognized;O;O
that;O;O
a;O;O
positive;O;O
Coombs;O;O
test;O;O
may;O;O
be;O;O
due;O;O
to;O;O
the;O;O
drug;O;O
.;O;O
DDI-DrugBank.d100.s0;;
Increased;O;O
nephrotoxicity;O;O
has;O;O
been;O;O
reported;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
cephalosporins;B-group;B-DDI-DrugBank.d100.s0.e0
and;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d100.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d100.s0.e1
.;O;O
DDI-DrugBank.d100.s1;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Cephalosporins;B-group;B-DDI-DrugBank.d100.s1.e0
,;O;O
including;O;O
cefotaxime;B-drug;B-DDI-DrugBank.d100.s1.e1
sodium;I-drug;I-DDI-DrugBank.d100.s1.e1
,;O;O
are;O;O
known;O;O
to;O;O
occasionally;O;O
induce;O;O
a;O;O
positive;O;O
direct;O;O
Coombs;O;O
test;O;O
.;O;O
DDI-DrugBank.d483.s0;;
Increases;O;O
in;O;O
serum;O;O
creatinine;O;O
have;O;O
occurred;O;O
when;O;O
CEFOTAN;B-brand;B-DDI-DrugBank.d483.s0.e0
was;O;O
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d483.s1;;
If;O;O
CEFOTAN;B-brand;B-DDI-DrugBank.d483.s1.e0
and;O;O
an;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d483.s1.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
renal;O;O
function;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
,;O;O
because;O;O
nephrotoxicity;O;O
may;O;O
be;O;O
potentiated;O;O
.;O;O
DDI-DrugBank.d483.s2;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
The;O;O
administration;O;O
of;O;O
CEFOTAN;B-brand;B-DDI-DrugBank.d483.s2.e0
may;O;O
result;O;O
in;O;O
a;O;O
false;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
using;O;O
Clinitest;O;O
,;O;O
Benedicts;O;O
solution;O;O
,;O;O
or;O;O
Fehlings;O;O
solution;O;O
.;O;O
DDI-DrugBank.d483.s3;;
It;O;O
is;O;O
recommended;O;O
that;O;O
glucose;O;O
tests;O;O
based;O;O
on;O;O
enzymatic;O;O
glucose;O;O
oxidase;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d483.s4;;
As;O;O
with;O;O
other;O;O
cephalosporins;B-group;B-DDI-DrugBank.d483.s4.e0
,;O;O
high;O;O
concentrations;O;O
of;O;O
cefotetan;B-drug;B-DDI-DrugBank.d483.s4.e1
may;O;O
interfere;O;O
with;O;O
measurement;O;O
of;O;O
serum;O;O
and;O;O
urine;O;O
creatinine;O;O
levels;O;O
by;O;O
Jaffe;O;O
reaction;O;O
and;O;O
produce;O;O
false;O;O
increases;O;O
in;O;O
the;O;O
levels;O;O
of;O;O
creatinine;O;O
reported;O;O
.;O;O
DDI-DrugBank.d556.s0;;
Increased;O;O
nephrotoxicity;O;O
has;O;O
been;O;O
reported;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
cephalosporins;B-group;B-DDI-DrugBank.d556.s0.e0
and;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d556.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d556.s0.e1
.;O;O
DDI-DrugBank.d556.s1;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
As;O;O
with;O;O
cephalothin;B-drug;B-DDI-DrugBank.d556.s1.e0
,;O;O
high;O;O
concentrations;O;O
of;O;O
cefoxitin;B-drug;B-DDI-DrugBank.d556.s1.e1
(;O;O
100;O;O
micrograms;O;O
/;O;O
mL;O;O
);O;O
may;O;O
interfere;O;O
with;O;O
measurement;O;O
of;O;O
serum;O;O
and;O;O
urine;O;O
creatinine;O;O
levels;O;O
by;O;O
the;O;O
Jaff;O;O
reaction;O;O
,;O;O
and;O;O
produce;O;O
false;O;O
increases;O;O
of;O;O
modest;O;O
degree;O;O
in;O;O
the;O;O
levels;O;O
of;O;O
creatinine;O;O
reported;O;O
.;O;O
DDI-DrugBank.d556.s2;;
Serum;O;O
samples;O;O
from;O;O
patients;O;O
treated;O;O
with;O;O
cefoxitin;B-drug;B-DDI-DrugBank.d556.s2.e0
should;O;O
not;O;O
be;O;O
analyzed;O;O
for;O;O
creatinine;O;O
if;O;O
withdrawn;O;O
within;O;O
2;O;O
hours;O;O
of;O;O
drug;O;O
administration;O;O
.;O;O
DDI-DrugBank.d556.s3;;
High;O;O
concentrations;O;O
of;O;O
cefoxitin;B-drug;B-DDI-DrugBank.d556.s3.e0
in;O;O
the;O;O
urine;O;O
may;O;O
interfere;O;O
with;O;O
measurement;O;O
of;O;O
urinary;O;O
17;O;O
-;O;O
hydroxy;O;O
-;O;O
corticosteroids;O;O
by;O;O
the;O;O
Porter;O;O
-;O;O
Silber;O;O
reaction;O;O
,;O;O
and;O;O
produce;O;O
false;O;O
increases;O;O
of;O;O
modest;O;O
degree;O;O
in;O;O
the;O;O
levels;O;O
reported;O;O
.;O;O
DDI-DrugBank.d556.s4;;
A;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d556.s5;;
This;O;O
has;O;O
been;O;O
observed;O;O
with;O;O
CLINITEST;O;O
reagent;O;O
tablets;O;O
DDI-DrugBank.d556.s6;;
.;O;O
DDI-DrugBank.d556.s7;;
Registered;O;O
trademark;O;O
of;O;O
Ames;O;O
Company;O;O
,;O;O
Division;O;O
of;O;O
Miles;O;O
Laboratories;O;O
,;O;O
Inc.;O;O
DDI-DrugBank.d121.s0;;
Nephrotoxicity;O;O
has;O;O
been;O;O
reported;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d121.s0.e0
antibiotics;I-group;I-DDI-DrugBank.d121.s0.e0
and;O;O
cephalosporin;B-group;B-DDI-DrugBank.d121.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d121.s0.e1
.;O;O
DDI-DrugBank.d121.s1;;
Concomitant;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d121.s1.e0
doubled;O;O
the;O;O
AUC;O;O
for;O;O
cefprozil;B-drug;B-DDI-DrugBank.d121.s1.e1
.;O;O
DDI-DrugBank.d121.s2;;
The;O;O
bioavailability;O;O
of;O;O
the;O;O
capsule;O;O
formulation;O;O
of;O;O
cefprozil;B-drug;B-DDI-DrugBank.d121.s2.e0
was;O;O
not;O;O
affected;O;O
when;O;O
administered;O;O
5;O;O
minutes;O;O
following;O;O
an;O;O
antacid;B-group;B-DDI-DrugBank.d121.s2.e1
.;O;O
DDI-DrugBank.d122.s0;;
Nephrotoxicity;O;O
has;O;O
been;O;O
reported;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
cephalosporins;B-group;B-DDI-DrugBank.d122.s0.e0
with;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d122.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d122.s0.e1
or;O;O
potent;O;O
diuretics;B-group;B-DDI-DrugBank.d122.s0.e2
such;O;O
as;O;O
furosemide;B-drug;B-DDI-DrugBank.d122.s0.e3
.;O;O
DDI-DrugBank.d122.s1;;
Renal;O;O
function;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
,;O;O
especially;O;O
if;O;O
higher;O;O
dosages;O;O
of;O;O
the;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d122.s1.e0
are;O;O
to;O;O
be;O;O
administered;O;O
or;O;O
if;O;O
therapy;O;O
is;O;O
prolonged;O;O
,;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
nephrotoxicity;O;O
and;O;O
ototoxicity;O;O
of;O;O
aminoglycosidic;B-group;B-DDI-DrugBank.d122.s1.e1
antibiotics;I-group;I-DDI-DrugBank.d122.s1.e1
.;O;O
DDI-DrugBank.d122.s2;;
Nephrotoxicity;O;O
and;O;O
ototoxicity;O;O
were;O;O
not;O;O
noted;O;O
when;O;O
ceftazidime;B-drug;B-DDI-DrugBank.d122.s2.e0
was;O;O
given;O;O
alone;O;O
in;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d122.s3;;
Chloramphenicol;B-drug;B-DDI-DrugBank.d122.s3.e0
has;O;O
been;O;O
shown;O;O
to;O;O
be;O;O
antagonistic;O;O
to;O;O
beta;B-group;B-DDI-DrugBank.d122.s3.e1
-;I-group;I-DDI-DrugBank.d122.s3.e1
lactam;I-group;I-DDI-DrugBank.d122.s3.e1
antibiotics;I-group;I-DDI-DrugBank.d122.s3.e1
,;O;O
including;O;O
ceftazidime;B-drug;B-DDI-DrugBank.d122.s3.e2
,;O;O
based;O;O
on;O;O
in;O;O
vitro;O;O
studies;O;O
and;O;O
time;O;O
kill;O;O
curves;O;O
with;O;O
enteric;O;O
gram;O;O
-;O;O
negative;O;O
bacilli;O;O
.;O;O
DDI-DrugBank.d122.s4;;
Due;O;O
to;O;O
the;O;O
possibility;O;O
of;O;O
antagonism;O;O
in;O;O
vivo;O;O
,;O;O
particularly;O;O
when;O;O
bactericidal;O;O
activity;O;O
is;O;O
desired;O;O
,;O;O
this;O;O
drug;O;O
combination;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d122.s5;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
The;O;O
administration;O;O
of;O;O
ceftazidime;B-drug;B-DDI-DrugBank.d122.s5.e0
may;O;O
result;O;O
in;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
when;O;O
using;O;O
CLINITEST;O;O
tablets;O;O
,;O;O
Benedicts;O;O
solution;O;O
,;O;O
or;O;O
Fehlings;O;O
solution;O;O
.;O;O
DDI-DrugBank.d122.s6;;
It;O;O
is;O;O
recommended;O;O
that;O;O
glucose;O;O
tests;O;O
based;O;O
on;O;O
enzymatic;O;O
glucose;O;O
oxidase;O;O
reactions;O;O
(;O;O
such;O;O
as;O;O
CLINISTIX;O;O
or;O;O
TES;O;O
-;O;O
TAPE;O;O
);O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d32.s0;;
Theophylline;B-drug;B-DDI-DrugBank.d32.s0.e0
:;O;O
Twelve;O;O
healthy;O;O
male;O;O
volunteers;O;O
were;O;O
administered;O;O
one;O;O
200;O;O
-;O;O
mg;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s0.e1
capsule;O;O
twice;O;O
daily;O;O
for;O;O
6;O;O
days;O;O
.;O;O
DDI-DrugBank.d32.s1;;
With;O;O
the;O;O
morning;O;O
dose;O;O
of;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s1.e0
on;O;O
day;O;O
6;O;O
,;O;O
each;O;O
volunteer;O;O
received;O;O
a;O;O
single;O;O
intravenous;O;O
infusion;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d32.s1.e1
(;O;O
4;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
.;O;O
DDI-DrugBank.d32.s2;;
The;O;O
pharmacokinetics;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d32.s2.e0
were;O;O
not;O;O
altered;O;O
.;O;O
DDI-DrugBank.d32.s3;;
The;O;O
effect;O;O
of;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s3.e0
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d32.s3.e1
administered;O;O
orally;O;O
has;O;O
not;O;O
been;O;O
investigated;O;O
.;O;O
DDI-DrugBank.d32.s4;;
Antacids;B-group;B-DDI-DrugBank.d32.s4.e0
or;O;O
H;B-group;B-DDI-DrugBank.d32.s4.e1
2;I-group;I-DDI-DrugBank.d32.s4.e1
-receptor;I-group;I-DDI-DrugBank.d32.s4.e1
antagonists;I-group;I-DDI-DrugBank.d32.s4.e1
:;O;O
The;O;O
effect;O;O
of;O;O
increased;O;O
gastric;O;O
pH;O;O
on;O;O
the;O;O
bioavailability;O;O
of;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s4.e2
was;O;O
evaluated;O;O
in;O;O
18;O;O
healthy;O;O
adult;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d32.s5;;
Each;O;O
volunteer;O;O
was;O;O
administered;O;O
one;O;O
400;O;O
-;O;O
mg;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s5.e0
capsule;O;O
.;O;O
DDI-DrugBank.d32.s6;;
A;O;O
single;O;O
dose;O;O
of;O;O
liquid;O;O
antacid;B-group;B-DDI-DrugBank.d32.s6.e0
did;O;O
not;O;O
affect;O;O
the;O;O
C;O;O
max;O;O
or;O;O
AUC;O;O
of;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s6.e1
,;O;O
DDI-DrugBank.d32.s7;;
however;O;O
,;O;O
150;O;O
mg;O;O
of;O;O
ranitidine;B-drug;B-DDI-DrugBank.d32.s7.e0
q12h;O;O
for;O;O
3;O;O
days;O;O
increased;O;O
the;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s7.e1
C;O;O
max;O;O
by;O;O
23;O;O
%;O;O
and;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s7.e2
AUC;O;O
by;O;O
16;O;O
%;O;O
.;O;O
DDI-DrugBank.d32.s8;;
The;O;O
clinical;O;O
relevance;O;O
of;O;O
these;O;O
increases;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d32.s9;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
There;O;O
have;O;O
been;O;O
no;O;O
chemical;O;O
or;O;O
laboratory;O;O
test;O;O
interactions;O;O
with;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s9.e0
noted;O;O
to;O;O
date;O;O
.;O;O
DDI-DrugBank.d32.s10;;
False;O;O
-;O;O
positive;O;O
direct;O;O
Coombs;O;O
tests;O;O
have;O;O
been;O;O
reported;O;O
during;O;O
treatment;O;O
with;O;O
other;O;O
cephalosporins;B-group;B-DDI-DrugBank.d32.s10.e0
.;O;O
DDI-DrugBank.d32.s11;;
Therefore;O;O
,;O;O
it;O;O
should;O;O
be;O;O
recognized;O;O
that;O;O
a;O;O
positive;O;O
Coombs;O;O
test;O;O
could;O;O
be;O;O
due;O;O
to;O;O
the;O;O
drug;O;O
.;O;O
DDI-DrugBank.d32.s12;;
The;O;O
results;O;O
of;O;O
assays;O;O
using;O;O
red;O;O
cells;O;O
from;O;O
healthy;O;O
subjects;O;O
to;O;O
determine;O;O
whether;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s12.e0
would;O;O
cause;O;O
direct;O;O
Coombs;O;O
reactions;O;O
in;O;O
vitro;O;O
showed;O;O
no;O;O
positive;O;O
reaction;O;O
at;O;O
ceftibuten;B-drug;B-DDI-DrugBank.d32.s12.e1
concentrations;O;O
as;O;O
high;O;O
as;O;O
40;O;O
g;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d33.s0;;
Although;O;O
the;O;O
occurrence;O;O
has;O;O
not;O;O
been;O;O
reported;O;O
with;O;O
Cefizox;B-brand;B-DDI-DrugBank.d33.s0.e0
,;O;O
nephrotoxicity;O;O
has;O;O
been;O;O
reported;O;O
following;O;O
concomitant;O;O
administration;O;O
of;O;O
other;O;O
cephalosporins;B-group;B-DDI-DrugBank.d33.s0.e1
and;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d33.s0.e2
.;O;O
DDI-DrugBank.d447.s0;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
A;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
with;O;O
copper;O;O
reduction;O;O
tests;O;O
(;O;O
Benedict;O;O
s;O;O
or;O;O
Fehling;O;O
s;O;O
solution;O;O
or;O;O
with;O;O
Clinitest;O;O
tablets;O;O
);O;O
but;O;O
not;O;O
with;O;O
enzyme;O;O
-;O;O
based;O;O
tests;O;O
for;O;O
glycosuria;O;O
.;O;O
DDI-DrugBank.d447.s1;;
As;O;O
a;O;O
false;O;O
-;O;O
negative;O;O
result;O;O
may;O;O
occur;O;O
in;O;O
the;O;O
ferricyanide;O;O
test;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
either;O;O
the;O;O
glucose;O;O
oxidase;O;O
or;O;O
hexokinase;O;O
method;O;O
be;O;O
used;O;O
to;O;O
determine;O;O
blood;O;O
plasma;O;O
glucose;O;O
levels;O;O
in;O;O
patients;O;O
receiving;O;O
cefuroxime;B-drug;B-DDI-DrugBank.d447.s1.e0
.;O;O
DDI-DrugBank.d447.s2;;
Cefuroxime;B-drug;B-DDI-DrugBank.d447.s2.e0
does;O;O
not;O;O
interfere;O;O
with;O;O
the;O;O
assay;O;O
of;O;O
serum;O;O
and;O;O
urine;O;O
creatinine;O;O
by;O;O
the;O;O
alkaline;O;O
picrate;O;O
method;O;O
.;O;O
DDI-DrugBank.d172.s0;;
General;O;O
:;O;O
Significant;O;O
interactions;O;O
may;O;O
occur;O;O
when;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s0.e0
is;O;O
administered;O;O
together;O;O
with;O;O
drugs;O;O
that;O;O
inhibit;O;O
P450;O;O
2C9;O;O
.;O;O
DDI-DrugBank.d172.s1;;
Celecoxib;B-drug;B-DDI-DrugBank.d172.s1.e0
metabolism;O;O
is;O;O
predominantly;O;O
mediated;O;O
via;O;O
cytochrome;O;O
P450;O;O
2C9;O;O
in;O;O
the;O;O
liver;O;O
.;O;O
DDI-DrugBank.d172.s2;;
Co;O;O
-;O;O
administration;O;O
of;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s2.e0
with;O;O
drugs;O;O
that;O;O
are;O;O
known;O;O
to;O;O
inhibit;O;O
2C9;O;O
should;O;O
be;O;O
done;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d172.s3;;
In;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s3.e0
is;O;O
not;O;O
an;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
2C9;O;O
,;O;O
2C19;O;O
or;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d172.s4;;
In;O;O
vitro;O;O
studies;O;O
also;O;O
indicate;O;O
that;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s4.e0
,;O;O
although;O;O
not;O;O
a;O;O
substrate;O;O
,;O;O
is;O;O
an;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d172.s5;;
Therefore;O;O
,;O;O
there;O;O
is;O;O
a;O;O
potential;O;O
for;O;O
an;O;O
in;O;O
vivo;O;O
drug;O;O
interaction;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d172.s6;;
Clinical;O;O
studies;O;O
with;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s6.e0
have;O;O
identified;O;O
potentially;O;O
significant;O;O
interactions;O;O
with;O;O
fluconazole;B-drug;B-DDI-DrugBank.d172.s6.e1
and;O;O
lithium;B-drug;B-DDI-DrugBank.d172.s6.e2
.;O;O
DDI-DrugBank.d172.s7;;
Experience;O;O
with;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d172.s7.e0
anti;I-group;I-DDI-DrugBank.d172.s7.e0
-;I-group;I-DDI-DrugBank.d172.s7.e0
inflammatory;I-group;I-DDI-DrugBank.d172.s7.e0
drugs;I-group;I-DDI-DrugBank.d172.s7.e0
(;O;O
NSAIDs;B-group;B-DDI-DrugBank.d172.s7.e1
);O;O
suggests;O;O
the;O;O
potential;O;O
for;O;O
interactions;O;O
with;O;O
furosemide;B-drug;B-DDI-DrugBank.d172.s7.e2
and;O;O
ACE;B-group;B-DDI-DrugBank.d172.s7.e3
inhibitors;I-group;I-DDI-DrugBank.d172.s7.e3
.;O;O
DDI-DrugBank.d172.s8;;
The;O;O
effects;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s8.e0
on;O;O
the;O;O
pharmacokinetics;O;O
and/or;O;O
pharmacodynamics;O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d172.s8.e1
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d172.s8.e2
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d172.s8.e3
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d172.s8.e4
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d172.s8.e5
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d172.s8.e6
have;O;O
been;O;O
studied;O;O
in;O;O
vivo;O;O
and;O;O
clinically;O;O
important;O;O
interactions;O;O
have;O;O
not;O;O
been;O;O
found;O;O
.;O;O
DDI-DrugBank.d172.s9;;
ACE;B-group;B-DDI-DrugBank.d172.s9.e0
inhibitors;I-group;I-DDI-DrugBank.d172.s9.e0
:;O;O
Reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d172.s9.e1
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
Angiotensin;B-group;B-DDI-DrugBank.d172.s9.e2
Converting;I-group;I-DDI-DrugBank.d172.s9.e2
Enzyme;I-group;I-DDI-DrugBank.d172.s9.e2
(;I-group;I-DDI-DrugBank.d172.s9.e2
ACE;I-group;I-DDI-DrugBank.d172.s9.e2
);I-group;I-DDI-DrugBank.d172.s9.e2
inhibitors;I-group;I-DDI-DrugBank.d172.s9.e2
.;O;O
DDI-DrugBank.d172.s10;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s10.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d172.s10.e1
-;I-group;I-DDI-DrugBank.d172.s10.e1
inhibitors;I-group;I-DDI-DrugBank.d172.s10.e1
.;O;O
DDI-DrugBank.d172.s11;;
Furosemide;B-drug;B-DDI-DrugBank.d172.s11.e0
:;O;O
Clinical;O;O
studies;O;O
,;O;O
as;O;O
well;O;O
as;O;O
post;O;O
marketing;O;O
observations;O;O
,;O;O
have;O;O
shown;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d172.s11.e1
can;O;O
reduce;O;O
the;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d172.s11.e2
and;O;O
thiazides;B-group;B-DDI-DrugBank.d172.s11.e3
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d172.s12;;
This;O;O
response;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d172.s13;;
Aspirin;B-brand;B-DDI-DrugBank.d172.s13.e0
:;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s13.e1
can;O;O
be;O;O
used;O;O
with;O;O
low;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d172.s13.e2
.;O;O
DDI-DrugBank.d172.s14;;
However;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d172.s14.e0
with;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s14.e1
may;O;O
result;O;O
in;O;O
an;O;O
increased;O;O
rate;O;O
of;O;O
GI;O;O
ulceration;O;O
or;O;O
other;O;O
complications;O;O
,;O;O
compared;O;O
to;O;O
use;O;O
of;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s14.e2
alone;O;O
.;O;O
DDI-DrugBank.d172.s15;;
Because;O;O
of;O;O
its;O;O
lack;O;O
of;O;O
platelet;O;O
effects;O;O
,;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s15.e0
is;O;O
not;O;O
a;O;O
substitute;O;O
for;O;O
aspirin;B-brand;B-DDI-DrugBank.d172.s15.e1
for;O;O
cardiovascular;O;O
prophylaxis;O;O
.;O;O
DDI-DrugBank.d172.s16;;
Fluconazole;B-drug;B-DDI-DrugBank.d172.s16.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d172.s16.e1
at;O;O
200;O;O
mg;O;O
QD;O;O
resulted;O;O
in;O;O
a;O;O
two;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s16.e2
plasma;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d172.s17;;
This;O;O
increase;O;O
is;O;O
due;O;O
to;O;O
the;O;O
inhibition;O;O
of;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s17.e0
metabolism;O;O
via;O;O
P450;O;O
2C9;O;O
by;O;O
fluconazole;B-drug;B-DDI-DrugBank.d172.s17.e1
(;O;O
see;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
-;O;O
Pharmacokinetics;O;O
:;O;O
Metabolism;O;O
);O;O
.;O;O
DDI-DrugBank.d172.s18;;
CELEBREX;B-brand;B-DDI-DrugBank.d172.s18.e0
should;O;O
be;O;O
introduced;O;O
at;O;O
the;O;O
lowest;O;O
recommended;O;O
dose;O;O
in;O;O
patients;O;O
receiving;O;O
fluconazole;B-drug;B-DDI-DrugBank.d172.s18.e1
.;O;O
DDI-DrugBank.d172.s19;;
Lithium;B-drug;B-DDI-DrugBank.d172.s19.e0
:;O;O
In;O;O
a;O;O
study;O;O
conducted;O;O
in;O;O
healthy;O;O
subjects;O;O
,;O;O
mean;O;O
steady;O;O
-;O;O
state;O;O
lithium;B-drug;B-DDI-DrugBank.d172.s19.e1
plasma;O;O
levels;O;O
increased;O;O
approximately;O;O
17;O;O
%;O;O
in;O;O
subjects;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d172.s19.e2
450;O;O
mg;O;O
BID;O;O
with;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s19.e3
200;O;O
mg;O;O
BID;O;O
as;O;O
compared;O;O
to;O;O
subjects;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d172.s19.e4
alone;O;O
.;O;O
DDI-DrugBank.d172.s20;;
Patients;O;O
on;O;O
lithium;B-drug;B-DDI-DrugBank.d172.s20.e0
treatment;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
when;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s20.e1
is;O;O
introduced;O;O
or;O;O
withdrawn;O;O
.;O;O
DDI-DrugBank.d172.s21;;
Methotrexate;B-drug;B-DDI-DrugBank.d172.s21.e0
:;O;O
In;O;O
an;O;O
interaction;O;O
study;O;O
of;O;O
rheumatoid;O;O
arthritis;O;O
patients;O;O
taking;O;O
methotrexate;B-drug;B-DDI-DrugBank.d172.s21.e1
,;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s21.e2
did;O;O
not;O;O
have;O;O
a;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d172.s21.e3
.;O;O
DDI-DrugBank.d172.s22;;
Warfarin;B-drug;B-DDI-DrugBank.d172.s22.e0
:;O;O
The;O;O
effect;O;O
of;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s22.e1
on;O;O
the;O;O
anti;O;O
-;O;O
coagulant;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d172.s22.e2
was;O;O
studied;O;O
in;O;O
a;O;O
group;O;O
of;O;O
healthy;O;O
subjects;O;O
receiving;O;O
daily;O;O
doses;O;O
of;O;O
2;O;O
-;O;O
5;O;O
mg;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d172.s22.e3
.;O;O
DDI-DrugBank.d172.s23;;
In;O;O
these;O;O
subjects;O;O
,;O;O
celecoxib;B-drug;B-DDI-DrugBank.d172.s23.e0
did;O;O
not;O;O
alter;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d172.s23.e1
as;O;O
determined;O;O
by;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d172.s24;;
However;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
administering;O;O
CELEBREX;B-brand;B-DDI-DrugBank.d172.s24.e0
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d172.s24.e1
since;O;O
these;O;O
patients;O;O
are;O;O
at;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
complications;O;O
.;O;O
DDI-DrugBank.d303.s0;;
Metformin;B-drug;B-DDI-DrugBank.d303.s0.e0
:;O;O
In;O;O
healthy;O;O
subjects;O;O
given;O;O
single;O;O
500;O;O
mg;O;O
doses;O;O
of;O;O
cephalexin;B-drug;B-DDI-DrugBank.d303.s0.e1
and;O;O
metformin;B-drug;B-DDI-DrugBank.d303.s0.e2
,;O;O
plasma;O;O
metformin;B-drug;B-DDI-DrugBank.d303.s0.e3
mean;O;O
cmax;O;O
and;O;O
AUC;O;O
increased;O;O
by;O;O
an;O;O
average;O;O
of;O;O
34;O;O
%;O;O
and;O;O
24;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
and;O;O
metformin;B-drug;B-DDI-DrugBank.d303.s0.e4
mean;O;O
renal;O;O
clearance;O;O
decreased;O;O
by;O;O
14;O;O
%;O;O
.;O;O
DDI-DrugBank.d303.s1;;
No;O;O
information;O;O
is;O;O
available;O;O
about;O;O
the;O;O
interaction;O;O
of;O;O
cephalexin;B-drug;B-DDI-DrugBank.d303.s1.e0
and;O;O
metformin;B-drug;B-DDI-DrugBank.d303.s1.e1
following;O;O
multiple;O;O
doses;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d303.s2;;
Although;O;O
not;O;O
observed;O;O
in;O;O
this;O;O
study;O;O
,;O;O
adverse;O;O
effects;O;O
could;O;O
potentially;O;O
arise;O;O
from;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
cephalexin;B-drug;B-DDI-DrugBank.d303.s2.e0
and;O;O
metformin;B-drug;B-DDI-DrugBank.d303.s2.e1
by;O;O
inhibition;O;O
of;O;O
tubular;O;O
secretion;O;O
via;O;O
organic;O;O
cationic;O;O
transporter;O;O
systems;O;O
.;O;O
DDI-DrugBank.d303.s3;;
Accordingly;O;O
,;O;O
careful;O;O
patient;O;O
monitoring;O;O
and;O;O
dose;O;O
adjustment;O;O
of;O;O
metformin;B-drug;B-DDI-DrugBank.d303.s3.e0
is;O;O
recommended;O;O
in;O;O
patients;O;O
concomitantly;O;O
taking;O;O
cephalexin;B-drug;B-DDI-DrugBank.d303.s3.e1
and;O;O
metformin;B-drug;B-DDI-DrugBank.d303.s3.e2
.;O;O
DDI-DrugBank.d303.s4;;
Probenecid;B-drug;B-DDI-DrugBank.d303.s4.e0
:;O;O
As;O;O
with;O;O
other;O;O
b;B-group;B-DDI-DrugBank.d303.s4.e1
-;I-group;I-DDI-DrugBank.d303.s4.e1
lactams;I-group;I-DDI-DrugBank.d303.s4.e1
,;O;O
the;O;O
renal;O;O
excretion;O;O
of;O;O
cephalexin;B-drug;B-DDI-DrugBank.d303.s4.e2
is;O;O
inhibited;O;O
by;O;O
probenecid;B-drug;B-DDI-DrugBank.d303.s4.e3
.;O;O
DDI-DrugBank.d303.s5;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
As;O;O
a;O;O
result;O;O
of;O;O
administration;O;O
of;O;O
Keflex;B-brand;B-DDI-DrugBank.d303.s5.e0
,;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d303.s6;;
This;O;O
has;O;O
been;O;O
observed;O;O
with;O;O
Benedict;O;O
s;O;O
and;O;O
Fehling;O;O
s;O;O
solutions;O;O
and;O;O
also;O;O
with;O;O
Clinitest;O;O
tablets;O;O
.;O;O
DDI-DrugBank.d141.s0;;
Immunosuppressive;B-group;B-DDI-DrugBank.d141.s0.e0
Drugs;I-group;I-DDI-DrugBank.d141.s0.e0
,;O;O
Fibric;B-group;B-DDI-DrugBank.d141.s0.e1
Acid;I-group;I-DDI-DrugBank.d141.s0.e1
Derivatives;I-group;I-DDI-DrugBank.d141.s0.e1
,;O;O
Niacin;B-drug;B-DDI-DrugBank.d141.s0.e2
(;O;O
Nicotinic;B-drug;B-DDI-DrugBank.d141.s0.e3
Acid;I-drug;I-DDI-DrugBank.d141.s0.e3
,;O;O
Erythromycin;B-drug;B-DDI-DrugBank.d141.s0.e4
,;O;O
Azole;B-group;B-DDI-DrugBank.d141.s0.e5
Antifungals;I-group;I-DDI-DrugBank.d141.s0.e5
:;O;O
Skeletal;O;O
Muscle;O;O
.;O;O
DDI-DrugBank.d141.s1;;
ANTACID;B-group;B-DDI-DrugBank.d141.s1.e0
(;O;O
Magnesium;B-drug;B-DDI-DrugBank.d141.s1.e1
-;I-drug;I-DDI-DrugBank.d141.s1.e1
Aluminum;I-drug;I-DDI-DrugBank.d141.s1.e1
Hydroxide;I-drug;I-DDI-DrugBank.d141.s1.e1
);O;O
:;O;O
Cerivastatin;B-drug;B-DDI-DrugBank.d141.s1.e2
plasma;O;O
concentrations;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
antacid;B-group;B-DDI-DrugBank.d141.s1.e3
.;O;O
DDI-DrugBank.d141.s2;;
CIMETlDINE;B-drug;B-DDI-DrugBank.d141.s2.e0
:;O;O
Cerivastatin;B-drug;B-DDI-DrugBank.d141.s2.e1
plasma;O;O
concentrations;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d141.s2.e2
.;O;O
DDI-DrugBank.d141.s3;;
CHOLESTYRAMINE;B-drug;B-DDI-DrugBank.d141.s3.e0
:;O;O
The;O;O
influence;O;O
of;O;O
the;O;O
bile;O;O
-;O;O
acidsequestering;O;O
agent;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d141.s3.e1
on;O;O
the;O;O
pharmacokinetits;O;O
of;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s3.e2
sodium;I-drug;I-DDI-DrugBank.d141.s3.e2
was;O;O
evaluated;O;O
in;O;O
12;O;O
healthy;O;O
males;O;O
in;O;O
2;O;O
separate;O;O
randomized;O;O
crossover;O;O
studies;O;O
.;O;O
DDI-DrugBank.d141.s4;;
In;O;O
the;O;O
first;O;O
study;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
0.2;O;O
mg;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s4.e0
sodium;I-drug;I-DDI-DrugBank.d141.s4.e0
and;O;O
12;O;O
g;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d141.s4.e1
resulted;O;O
in;O;O
decreases;O;O
of;O;O
more;O;O
than;O;O
22;O;O
%;O;O
for;O;O
AUC;O;O
and;O;O
40;O;O
%;O;O
for;O;O
Cmax;O;O
when;O;O
compared;O;O
to;O;O
dosing;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s4.e2
sodium;I-drug;I-DDI-DrugBank.d141.s4.e2
alone;O;O
.;O;O
DDI-DrugBank.d141.s5;;
However;O;O
,;O;O
in;O;O
the;O;O
second;O;O
study;O;O
,;O;O
administration;O;O
of;O;O
12;O;O
g;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d141.s5.e0
1;O;O
hour;O;O
before;O;O
the;O;O
evening;O;O
meal;O;O
and;O;O
0.3;O;O
mg;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s5.e1
sodium;I-drug;I-DDI-DrugBank.d141.s5.e1
approximately;O;O
4;O;O
hours;O;O
after;O;O
the;O;O
same;O;O
evening;O;O
meal;O;O
resulted;O;O
in;O;O
a;O;O
decrease;O;O
in;O;O
the;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s5.e2
AUC;O;O
of;O;O
less;O;O
than;O;O
8;O;O
%;O;O
,;O;O
and;O;O
a;O;O
decrease;O;O
in;O;O
Cmax;O;O
of;O;O
about;O;O
30;O;O
%;O;O
when;O;O
compared;O;O
to;O;O
dosing;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s5.e3
sodium;I-drug;I-DDI-DrugBank.d141.s5.e3
alone;O;O
.;O;O
DDI-DrugBank.d141.s6;;
Therefore;O;O
,;O;O
it;O;O
would;O;O
be;O;O
expected;O;O
that;O;O
a;O;O
dosing;O;O
schedule;O;O
of;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s6.e0
sodium;I-drug;I-DDI-DrugBank.d141.s6.e0
given;O;O
at;O;O
bedtime;O;O
and;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d141.s6.e1
given;O;O
before;O;O
the;O;O
evening;O;O
meal;O;O
would;O;O
not;O;O
result;O;O
in;O;O
a;O;O
significant;O;O
decrease;O;O
in;O;O
the;O;O
clinical;O;O
effect;O;O
of;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s6.e2
sodium;I-drug;I-DDI-DrugBank.d141.s6.e2
.;O;O
DDI-DrugBank.d141.s7;;
DIGOXIN;B-drug;B-DDI-DrugBank.d141.s7.e0
:;O;O
Plasma;O;O
digoxin;B-drug;B-DDI-DrugBank.d141.s7.e1
levels;O;O
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d141.s7.e2
clearance;O;O
at;O;O
steady;O;O
-;O;O
state;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
0.2;O;O
mg;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s7.e3
sodium;I-drug;I-DDI-DrugBank.d141.s7.e3
.;O;O
DDI-DrugBank.d141.s8;;
Cerivastatin;B-drug;B-DDI-DrugBank.d141.s8.e0
plasma;O;O
concentrations;O;O
were;O;O
also;O;O
not;O;O
affected;O;O
by;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d141.s8.e1
.;O;O
DDI-DrugBank.d141.s9;;
WARFARIN;B-drug;B-DDI-DrugBank.d141.s9.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d141.s9.e1
and;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s9.e2
to;O;O
healthy;O;O
volunteers;O;O
did;O;O
not;O;O
result;O;O
in;O;O
any;O;O
changes;O;O
in;O;O
prothrombin;O;O
time;O;O
or;O;O
clotting;O;O
factor;O;O
VII;O;O
when;O;O
compared;O;O
to;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d141.s9.e3
and;O;O
placebo;O;O
.;O;O
DDI-DrugBank.d141.s10;;
The;O;O
AUC;O;O
and;O;O
Cmax;O;O
of;O;O
both;O;O
the;O;O
(;O;O
R;O;O
);O;O
and;O;O
(;O;O
S;O;O
);O;O
isomers;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d141.s10.e0
were;O;O
unaffected;O;O
by;O;O
concurrent;O;O
dosing;O;O
of;O;O
0.3;O;O
mg;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s10.e1
sodium;I-drug;I-DDI-DrugBank.d141.s10.e1
.;O;O
DDI-DrugBank.d141.s11;;
Co;O;O
-;O;O
administration;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d141.s11.e0
and;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s11.e1
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s11.e2
sodium;I-drug;I-DDI-DrugBank.d141.s11.e2
.;O;O
DDI-DrugBank.d141.s12;;
ERYTHROMYCIN;B-drug;B-DDI-DrugBank.d141.s12.e0
:;O;O
In;O;O
hypercholesterolemic;O;O
patients;O;O
,;O;O
steady;O;O
-;O;O
state;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s12.e1
AUC;O;O
and;O;O
Cmax;O;O
increased;O;O
approximately;O;O
50;O;O
%;O;O
and;O;O
24;O;O
%;O;O
respectively;O;O
after;O;O
10;O;O
days;O;O
with;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d141.s12.e2
,;O;O
a;O;O
known;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d141.s13;;
OTHER;O;O
CONCOMITANT;O;O
THERAPY;O;O
:;O;O
Although;O;O
specific;O;O
interaction;O;O
studies;O;O
were;O;O
not;O;O
performed;O;O
,;O;O
in;O;O
clinical;O;O
studies;O;O
,;O;O
cerivastatin;B-drug;B-DDI-DrugBank.d141.s13.e0
sodium;I-drug;I-DDI-DrugBank.d141.s13.e0
was;O;O
used;O;O
concomitantly;O;O
with;O;O
angiotensin;B-group;B-DDI-DrugBank.d141.s13.e1
-;I-group;I-DDI-DrugBank.d141.s13.e1
converting;I-group;I-DDI-DrugBank.d141.s13.e1
enzyme;I-group;I-DDI-DrugBank.d141.s13.e1
(;I-group;I-DDI-DrugBank.d141.s13.e1
ACE;I-group;I-DDI-DrugBank.d141.s13.e1
);I-group;I-DDI-DrugBank.d141.s13.e1
inhibitors;I-group;I-DDI-DrugBank.d141.s13.e1
,;O;O
betablockers;B-group;B-DDI-DrugBank.d141.s13.e2
,;O;O
calcium;B-group;B-DDI-DrugBank.d141.s13.e3
-;I-group;I-DDI-DrugBank.d141.s13.e3
channel;I-group;I-DDI-DrugBank.d141.s13.e3
blockers;I-group;I-DDI-DrugBank.d141.s13.e3
,;O;O
diuretics;B-group;B-DDI-DrugBank.d141.s13.e4
,;O;O
and;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d141.s13.e5
anti;I-group;I-DDI-DrugBank.d141.s13.e5
-;I-group;I-DDI-DrugBank.d141.s13.e5
inflammatory;I-group;I-DDI-DrugBank.d141.s13.e5
drugs;I-group;I-DDI-DrugBank.d141.s13.e5
(;O;O
NSAIDs;B-group;B-DDI-DrugBank.d141.s13.e6
);O;O
without;O;O
evidence;O;O
of;O;O
clinically;O;O
significant;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d393.s0;;
Pharmacokinetic;O;O
interaction;O;O
studies;O;O
with;O;O
cetirizine;B-drug;B-DDI-DrugBank.d393.s0.e0
in;O;O
adults;O;O
were;O;O
conducted;O;O
with;O;O
pseudoephedrine;B-drug;B-DDI-DrugBank.d393.s0.e1
,;O;O
antipyrine;B-drug;B-DDI-DrugBank.d393.s0.e2
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d393.s0.e3
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d393.s0.e4
and;O;O
azithromycin;B-drug;B-DDI-DrugBank.d393.s0.e5
.;O;O
DDI-DrugBank.d393.s1;;
No;O;O
interactions;O;O
were;O;O
observed;O;O
.;O;O
DDI-DrugBank.d393.s2;;
In;O;O
a;O;O
multiple;O;O
dose;O;O
study;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d393.s2.e0
(;O;O
400;O;O
mg;O;O
once;O;O
daily;O;O
for;O;O
3;O;O
days;O;O
);O;O
and;O;O
cetirizine;B-drug;B-DDI-DrugBank.d393.s2.e1
(;O;O
20;O;O
mg;O;O
once;O;O
daily;O;O
for;O;O
3;O;O
days;O;O
);O;O
,;O;O
a;O;O
16;O;O
%;O;O
decrease;O;O
in;O;O
the;O;O
clearance;O;O
of;O;O
cetirizine;B-drug;B-DDI-DrugBank.d393.s2.e2
was;O;O
observed;O;O
.;O;O
DDI-DrugBank.d393.s3;;
The;O;O
disposition;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d393.s3.e0
was;O;O
not;O;O
altered;O;O
by;O;O
concomitant;O;O
cetirizine;B-drug;B-DDI-DrugBank.d393.s3.e1
administration;O;O
.;O;O
DDI-DrugBank.d393.s4;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
:;O;O
No;O;O
clinically;O;O
significant;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
found;O;O
with;O;O
theophylline;B-drug;B-DDI-DrugBank.d393.s4.e0
at;O;O
a;O;O
low;O;O
dose;O;O
,;O;O
azithromycin;B-drug;B-DDI-DrugBank.d393.s4.e1
,;O;O
pseudoephedrine;B-drug;B-DDI-DrugBank.d393.s4.e2
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d393.s4.e3
,;O;O
or;O;O
erythromycin;B-drug;B-DDI-DrugBank.d393.s4.e4
.;O;O
DDI-DrugBank.d393.s5;;
There;O;O
was;O;O
a;O;O
small;O;O
decrease;O;O
in;O;O
the;O;O
clearance;O;O
of;O;O
cetirizine;B-drug;B-DDI-DrugBank.d393.s5.e0
caused;O;O
by;O;O
a;O;O
400;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d393.s5.e1
,;O;O
DDI-DrugBank.d393.s6;;
it;O;O
is;O;O
possible;O;O
that;O;O
larger;O;O
theophylline;B-drug;B-DDI-DrugBank.d393.s6.e0
doses;O;O
could;O;O
have;O;O
a;O;O
greater;O;O
effect;O;O
.;O;O
DDI-DrugBank.d540.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
with;O;O
Cetrotide;B-brand;B-DDI-DrugBank.d540.s0.e0
.;O;O
DDI-DrugBank.d193.s0;;
A;O;O
drug;O;O
interaction;O;O
study;O;O
was;O;O
performed;O;O
in;O;O
which;O;O
ERBITUX;B-brand;B-DDI-DrugBank.d193.s0.e0
was;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
irinotecan;B-drug;B-DDI-DrugBank.d193.s0.e1
.;O;O
DDI-DrugBank.d193.s1;;
There;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
any;O;O
pharmacokinetic;O;O
interactions;O;O
between;O;O
ERBITUX;B-brand;B-DDI-DrugBank.d193.s1.e0
and;O;O
irinotecan;B-drug;B-DDI-DrugBank.d193.s1.e1
.;O;O
DDI-DrugBank.d287.s0;;
Cevimeline;B-drug;B-DDI-DrugBank.d287.s0.e0
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d287.s0.e1
adrenergic;I-group;I-DDI-DrugBank.d287.s0.e1
antagonists;I-group;I-DDI-DrugBank.d287.s0.e1
,;O;O
because;O;O
of;O;O
the;O;O
possibility;O;O
of;O;O
conduction;O;O
disturbances;O;O
.;O;O
DDI-DrugBank.d287.s1;;
Drugs;O;O
with;O;O
parasympathomimetic;O;O
effects;O;O
administered;O;O
concurrently;O;O
with;O;O
cevimeline;B-drug;B-DDI-DrugBank.d287.s1.e0
can;O;O
be;O;O
expected;O;O
to;O;O
have;O;O
additive;O;O
effects;O;O
.;O;O
DDI-DrugBank.d287.s2;;
Cevimeline;B-drug;B-DDI-DrugBank.d287.s2.e0
might;O;O
interfere;O;O
with;O;O
desirable;O;O
antimuscarinic;O;O
effects;O;O
of;O;O
drugs;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d287.s3;;
Drugs;O;O
which;O;O
inhibit;O;O
CYP2D6;O;O
and;O;O
CYP3A3;O;O
/;O;O
4;O;O
also;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
cevimeline;B-drug;B-DDI-DrugBank.d287.s3.e0
.;O;O
DDI-DrugBank.d287.s4;;
Cevimeline;B-drug;B-DDI-DrugBank.d287.s4.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
individuals;O;O
known;O;O
or;O;O
suspected;O;O
to;O;O
be;O;O
deficient;O;O
in;O;O
CYP2D6;O;O
activity;O;O
,;O;O
based;O;O
on;O;O
previous;O;O
experience;O;O
,;O;O
as;O;O
they;O;O
may;O;O
be;O;O
at;O;O
a;O;O
higher;O;O
risk;O;O
of;O;O
adverse;O;O
events;O;O
.;O;O
DDI-DrugBank.d287.s5;;
In;O;O
an;O;O
in;O;O
vitro;O;O
study;O;O
,;O;O
cytochrome;O;O
P450;O;O
isozymes;O;O
1A2;O;O
,;O;O
2A6;O;O
,;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
2D6;O;O
,;O;O
2E1;O;O
,;O;O
and;O;O
3A4;O;O
were;O;O
not;O;O
inhibited;O;O
by;O;O
exposure;O;O
to;O;O
cevimeline;B-drug;B-DDI-DrugBank.d287.s5.e0
.;O;O
DDI-DrugBank.d255.s0;;
There;O;O
are;O;O
no;O;O
known;O;O
drug;O;O
/;O;O
drug;O;O
interactions;O;O
with;O;O
chlorambucil;B-drug;B-DDI-DrugBank.d255.s0.e0
.;O;O
DDI-DrugBank.d336.s0;;
Although;O;O
clinical;O;O
studies;O;O
have;O;O
not;O;O
established;O;O
a;O;O
cause;O;O
and;O;O
effect;O;O
relationship;O;O
,;O;O
physicians;O;O
should;O;O
be;O;O
aware;O;O
that;O;O
variable;O;O
effects;O;O
an;O;O
blood;O;O
coagulation;O;O
have;O;O
been;O;O
reported;O;O
very;O;O
rarely;O;O
in;O;O
patients;O;O
receiving;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d336.s0.e0
and;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d336.s0.e1
.;O;O
DDI-DrugBank.d336.s1;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d336.s1.e0
or;O;O
other;O;O
central;B-group;B-DDI-DrugBank.d336.s1.e1
nervous;I-group;I-DDI-DrugBank.d336.s1.e1
system;I-group;I-DDI-DrugBank.d336.s1.e1
depressants;I-group;I-DDI-DrugBank.d336.s1.e1
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
.;O;O
DDI-DrugBank.d110.s0;;
The;O;O
administration;O;O
of;O;O
local;O;O
anesthetic;B-group;B-DDI-DrugBank.d110.s0.e0
solutions;I-group;I-DDI-DrugBank.d110.s0.e0
containing;O;O
epinephrine;B-drug;B-DDI-DrugBank.d110.s0.e1
or;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d110.s0.e2
to;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d110.s0.e3
oxidase;I-group;I-DDI-DrugBank.d110.s0.e3
inhibitors;I-group;I-DDI-DrugBank.d110.s0.e3
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d110.s0.e4
antidepressants;I-group;I-DDI-DrugBank.d110.s0.e4
or;O;O
phenothiazines;B-group;B-DDI-DrugBank.d110.s0.e5
may;O;O
produce;O;O
severe;O;O
,;O;O
prolonged;O;O
hypotension;O;O
or;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d110.s1;;
Concurrent;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
should;O;O
generally;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d110.s2;;
In;O;O
situations;O;O
when;O;O
concurrent;O;O
therapy;O;O
is;O;O
necessary;O;O
,;O;O
careful;O;O
patient;O;O
monitoring;O;O
is;O;O
essential;O;O
.;O;O
DDI-DrugBank.d110.s3;;
Concurrent;O;O
administration;O;O
of;O;O
vasopressor;B-group;B-DDI-DrugBank.d110.s3.e0
drugs;I-group;I-DDI-DrugBank.d110.s3.e0
(;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
hypotension;O;O
related;O;O
to;O;O
obstetric;O;O
blocks;O;O
);O;O
and;O;O
ergot;B-group;B-DDI-DrugBank.d110.s3.e1
-;I-group;I-DDI-DrugBank.d110.s3.e1
type;I-group;I-DDI-DrugBank.d110.s3.e1
oxytocic;I-group;I-DDI-DrugBank.d110.s3.e1
drugs;I-group;I-DDI-DrugBank.d110.s3.e1
may;O;O
cause;O;O
severe;O;O
,;O;O
persistent;O;O
hypertension;O;O
or;O;O
cerebrovascular;O;O
accidents;O;O
.;O;O
DDI-DrugBank.d110.s4;;
The;O;O
para;O;O
-;O;O
aminobenzoic;O;O
acid;O;O
metabolite;O;O
of;O;O
chloroprocaine;O;O
inhibits;O;O
the;O;O
action;O;O
of;O;O
sulfonamides;B-group;B-DDI-DrugBank.d110.s4.e0
.;O;O
DDI-DrugBank.d110.s5;;
Therefore;O;O
,;O;O
chloroprocaine;B-drug;B-DDI-DrugBank.d110.s5.e0
should;O;O
not;O;O
be;O;O
used;O;O
in;O;O
any;O;O
condition;O;O
in;O;O
which;O;O
a;O;O
sulfonamide;B-group;B-DDI-DrugBank.d110.s5.e1
drug;I-group;I-DDI-DrugBank.d110.s5.e1
is;O;O
being;O;O
employed;O;O
.;O;O
DDI-DrugBank.d429.s0;;
Antacids;B-group;B-DDI-DrugBank.d429.s0.e0
and;O;O
kaolin;B-drug;B-DDI-DrugBank.d429.s0.e1
:;O;O
Antacids;B-group;B-DDI-DrugBank.d429.s0.e2
and;O;O
kaolin;B-drug;B-DDI-DrugBank.d429.s0.e3
can;O;O
reduce;O;O
absorption;O;O
of;O;O
chloroquine;B-drug;B-DDI-DrugBank.d429.s0.e4
,;O;O
DDI-DrugBank.d429.s1;;
an;O;O
interval;O;O
of;O;O
at;O;O
least;O;O
4;O;O
hours;O;O
between;O;O
intake;O;O
of;O;O
these;O;O
agents;O;O
and;O;O
chloroquine;B-drug;B-DDI-DrugBank.d429.s1.e0
should;O;O
be;O;O
observed;O;O
.;O;O
DDI-DrugBank.d429.s2;;
Cimetidine;B-drug;B-DDI-DrugBank.d429.s2.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d429.s2.e1
can;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
chloroquine;B-drug;B-DDI-DrugBank.d429.s2.e2
,;O;O
increasing;O;O
its;O;O
plasma;O;O
level;O;O
.;O;O
DDI-DrugBank.d429.s3;;
Concomitant;O;O
use;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d429.s3.e0
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d429.s4;;
Ampicillin;B-drug;B-DDI-DrugBank.d429.s4.e0
:;O;O
In;O;O
a;O;O
study;O;O
of;O;O
healthy;O;O
volunteers;O;O
,;O;O
chloroquine;B-drug;B-DDI-DrugBank.d429.s4.e1
significantly;O;O
reduced;O;O
the;O;O
bioavailability;O;O
of;O;O
ampicillin;B-drug;B-DDI-DrugBank.d429.s4.e2
.;O;O
DDI-DrugBank.d429.s5;;
An;O;O
interval;O;O
of;O;O
at;O;O
least;O;O
two;O;O
hours;O;O
between;O;O
intake;O;O
of;O;O
this;O;O
agent;O;O
and;O;O
chloroquine;B-drug;B-DDI-DrugBank.d429.s5.e0
should;O;O
be;O;O
observed;O;O
.;O;O
DDI-DrugBank.d429.s6;;
Cyclosporin;B-drug;B-DDI-DrugBank.d429.s6.e0
:;O;O
After;O;O
introduction;O;O
of;O;O
chloroquine;B-drug;B-DDI-DrugBank.d429.s6.e1
(;O;O
oral;O;O
form;O;O
);O;O
,;O;O
a;O;O
sudden;O;O
increase;O;O
in;O;O
serum;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d429.s6.e2
level;O;O
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d429.s7;;
Therefore;O;O
,;O;O
close;O;O
monitoring;O;O
of;O;O
serum;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d429.s7.e0
level;O;O
is;O;O
recommended;O;O
and;O;O
,;O;O
if;O;O
necessary;O;O
,;O;O
chloroquine;B-drug;B-DDI-DrugBank.d429.s7.e1
should;O;O
be;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d46.s0;;
When;O;O
given;O;O
concurrently;O;O
the;O;O
following;O;O
drugs;O;O
may;O;O
interact;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d46.s0.e0
diuretics;I-group;I-DDI-DrugBank.d46.s0.e0
.;O;O
DDI-DrugBank.d46.s1;;
-;O;O
Alcohol;B-drug;B-DDI-DrugBank.d46.s1.e0
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d46.s1.e1
,;O;O
or;O;O
narcotics;B-group;B-DDI-DrugBank.d46.s1.e2
:;O;O
Potentiation;O;O
of;O;O
otthostatic;O;O
hypotension;O;O
may;O;O
occur;O;O
DDI-DrugBank.d46.s2;;
.;O;O
DDI-DrugBank.d46.s3;;
-;O;O
Antidiabetic;B-group;B-DDI-DrugBank.d46.s3.e0
drugs;I-group;I-DDI-DrugBank.d46.s3.e0
:;O;O
(;O;O
Oral;O;O
agents;O;O
and;O;O
insulin;B-drug;B-DDI-DrugBank.d46.s3.e1
);O;O
Dosage;O;O
adjustment;O;O
of;O;O
the;O;O
antidiabetic;B-group;B-DDI-DrugBank.d46.s3.e2
drug;I-group;I-DDI-DrugBank.d46.s3.e2
may;O;O
be;O;O
required;O;O
DDI-DrugBank.d46.s4;;
.;O;O
DDI-DrugBank.d46.s5;;
-;O;O
Other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d46.s5.e0
drugs;I-group;I-DDI-DrugBank.d46.s5.e0
:;O;O
Additive;O;O
effect;O;O
or;O;O
potentiation;O;O
DDI-DrugBank.d46.s6;;
.;O;O
DDI-DrugBank.d46.s7;;
-;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d46.s7.e0
and;O;O
colestipol;B-drug;B-DDI-DrugBank.d46.s7.e1
resins;I-group;I-DDI-DrugBank.d46.s7.e2
:;O;O
Cholestytamine;B-drug;B-DDI-DrugBank.d46.s7.e3
and;O;O
colestipol;B-drug;B-DDI-DrugBank.d46.s7.e4
resins;I-group;I-DDI-DrugBank.d46.s7.e5
have;O;O
the;O;O
potential;O;O
of;O;O
binding;O;O
thiazide;B-group;B-DDI-DrugBank.d46.s7.e6
diuretics;I-group;I-DDI-DrugBank.d46.s7.e6
and;O;O
reducing;O;O
diuretic;B-group;B-DDI-DrugBank.d46.s7.e7
absorption;O;O
from;O;O
the;O;O
gastrointestinal;O;O
tract;O;O
DDI-DrugBank.d46.s8;;
.;O;O
DDI-DrugBank.d46.s9;;
-;O;O
Corticosteroids;B-group;B-DDI-DrugBank.d46.s9.e0
,;O;O
ACTH;B-drug;B-DDI-DrugBank.d46.s9.e1
:;O;O
Intensified;O;O
electrolyte;O;O
depletion;O;O
,;O;O
particularly;O;O
hypokalemia;O;O
DDI-DrugBank.d46.s10;;
.;O;O
DDI-DrugBank.d46.s11;;
-;O;O
Pressor;O;O
amines;O;O
(;O;O
e.g.;O;O
,;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d46.s11.e0
);O;O
:;O;O
Possible;O;O
decreased;O;O
response;O;O
to;O;O
pressor;O;O
amines;O;O
but;O;O
not;O;O
sufficient;O;O
to;O;O
preclude;O;O
their;O;O
use;O;O
DDI-DrugBank.d46.s12;;
.;O;O
DDI-DrugBank.d46.s13;;
-;O;O
Skeletal;B-group;B-DDI-DrugBank.d46.s13.e0
muscle;I-group;I-DDI-DrugBank.d46.s13.e0
relaxants;I-group;I-DDI-DrugBank.d46.s13.e0
,;O;O
nondepolarizing;O;O
(;O;O
e.g.;O;O
,;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d46.s13.e1
);O;O
:;O;O
Possible;O;O
increased;O;O
responsiveness;O;O
to;O;O
the;O;O
muscle;B-group;B-DDI-DrugBank.d46.s13.e2
relaxant;I-group;I-DDI-DrugBank.d46.s13.e2
DDI-DrugBank.d46.s14;;
.;O;O
DDI-DrugBank.d46.s15;;
-;O;O
Lithium;B-drug;B-DDI-DrugBank.d46.s15.e0
:;O;O
Generally;O;O
should;O;O
not;O;O
be;O;O
given;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d46.s15.e1
.;O;O
DDI-DrugBank.d46.s16;;
Diuretic;B-group;B-DDI-DrugBank.d46.s16.e0
agents;I-group;I-DDI-DrugBank.d46.s16.e0
reduce;O;O
the;O;O
renal;O;O
clearance;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d46.s16.e1
and;O;O
add;O;O
a;O;O
high;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d46.s16.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d46.s17;;
Refer;O;O
to;O;O
the;O;O
package;O;O
insert;O;O
for;O;O
lithium;B-drug;B-DDI-DrugBank.d46.s17.e0
preparations;O;O
before;O;O
use;O;O
of;O;O
such;O;O
preparations;O;O
with;O;O
chlorothiazide;B-drug;B-DDI-DrugBank.d46.s17.e1
DDI-DrugBank.d46.s18;;
.;O;O
DDI-DrugBank.d46.s19;;
-;O;O
Non;B-group;B-DDI-DrugBank.d46.s19.e0
-;I-group;I-DDI-DrugBank.d46.s19.e0
steroidal;I-group;I-DDI-DrugBank.d46.s19.e0
Anti;I-group;I-DDI-DrugBank.d46.s19.e0
-;I-group;I-DDI-DrugBank.d46.s19.e0
inflammatory;I-group;I-DDI-DrugBank.d46.s19.e0
Drugs;I-group;I-DDI-DrugBank.d46.s19.e0
:;O;O
In;O;O
some;O;O
patients;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
a;O;O
non;B-group;B-DDI-DrugBank.d46.s19.e1
-;I-group;I-DDI-DrugBank.d46.s19.e1
steroidal;I-group;I-DDI-DrugBank.d46.s19.e1
anti;I-group;I-DDI-DrugBank.d46.s19.e1
-;I-group;I-DDI-DrugBank.d46.s19.e1
inflammatory;I-group;I-DDI-DrugBank.d46.s19.e1
agent;I-group;I-DDI-DrugBank.d46.s19.e1
can;O;O
reduce;O;O
the;O;O
diuretic;O;O
,;O;O
natriuretic;O;O
,;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
loop;B-group;B-DDI-DrugBank.d46.s19.e2
,;I-group;I-DDI-DrugBank.d46.s19.e2
potassium;I-group;I-DDI-DrugBank.d46.s19.e3
-;I-group;I-DDI-DrugBank.d46.s19.e3
sparing;I-group;I-DDI-DrugBank.d46.s19.e3
and;I-group;I-DDI-DrugBank.d46.s19.e3
thiazide;I-drug;I-DDI-DrugBank.d46.s19.e4
diuretics;I-drug;I-DDI-DrugBank.d46.s19.e4
.;O;O
DDI-DrugBank.d46.s20;;
Therefore;O;O
,;O;O
when;O;O
chlorothiazide;B-drug;B-DDI-DrugBank.d46.s20.e0
and;O;O
non;B-group;B-DDI-DrugBank.d46.s20.e1
-;I-group;I-DDI-DrugBank.d46.s20.e1
steroidal;I-group;I-DDI-DrugBank.d46.s20.e1
anti;I-group;I-DDI-DrugBank.d46.s20.e1
-;I-group;I-DDI-DrugBank.d46.s20.e1
inflammatory;I-group;I-DDI-DrugBank.d46.s20.e1
agents;I-group;I-DDI-DrugBank.d46.s20.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
effect;O;O
of;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d46.s20.e2
is;O;O
obtained;O;O
DDI-DrugBank.d46.s21;;
.;O;O
DDI-DrugBank.d46.s22;;
-;O;O
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
Thiazides;B-group;B-DDI-DrugBank.d46.s22.e0
should;O;O
be;O;O
discontinued;O;O
before;O;O
carrying;O;O
out;O;O
tests;O;O
for;O;O
parathyroid;O;O
function;O;O
.;O;O
DDI-DrugBank.d446.s0;;
Chlorotrianisene;B-drug;B-DDI-DrugBank.d446.s0.e0
may;O;O
interact;O;O
with;O;O
antidepressants;B-group;B-DDI-DrugBank.d446.s0.e1
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d446.s0.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d446.s0.e3
,;O;O
bromocriptine;B-drug;B-DDI-DrugBank.d446.s0.e4
,;O;O
calcium;B-drug;B-DDI-DrugBank.d446.s0.e5
supplements;O;O
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d446.s0.e6
,;O;O
corticotropin;B-drug;B-DDI-DrugBank.d446.s0.e7
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d446.s0.e8
,;O;O
dantrolene;B-drug;B-DDI-DrugBank.d446.s0.e9
,;O;O
nicotine;B-drug;B-DDI-DrugBank.d446.s0.e10
,;O;O
somatropin;B-drug;B-DDI-DrugBank.d446.s0.e11
,;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d446.s0.e12
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d446.s0.e13
.;O;O
DDI-DrugBank.d366.s0;;
May;O;O
interact;O;O
with;O;O
skin;O;O
products;O;O
or;O;O
shampoos;O;O
for;O;O
dandruff;O;O
or;O;O
psoriasis;O;O
.;O;O
DDI-DrugBank.d235.s0;;
Substrate;O;O
of;O;O
CYP2D6;O;O
(;O;O
minor;O;O
);O;O
,;O;O
3A4;O;O
(;O;O
major;O;O
);O;O
,;O;O
DDI-DrugBank.d235.s1;;
Inhibits;O;O
CYP2D6;O;O
(;O;O
weak;O;O
);O;O
.;O;O
DDI-DrugBank.d235.s2;;
Increased;O;O
toxicity;O;O
(;O;O
CNS;O;O
depression;O;O
);O;O
:;O;O
CNS;B-group;B-DDI-DrugBank.d235.s2.e0
depressants;I-group;I-DDI-DrugBank.d235.s2.e0
,;O;O
MAO;B-group;B-DDI-DrugBank.d235.s2.e1
inhibitors;I-group;I-DDI-DrugBank.d235.s2.e1
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d235.s2.e2
antidepressants;I-group;I-DDI-DrugBank.d235.s2.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d235.s2.e3
.;O;O
DDI-DrugBank.d235.s3;;
CYP3A4;O;O
inhibitors;O;O
:;O;O
May;O;O
increase;O;O
the;O;O
levels;O;O
/;O;O
effects;O;O
of;O;O
chlorpheniramine;B-drug;B-DDI-DrugBank.d235.s3.e0
.;O;O
DDI-DrugBank.d235.s4;;
Example;O;O
inhibitors;O;O
include;O;O
azole;B-group;B-DDI-DrugBank.d235.s4.e0
antifungals;I-group;I-DDI-DrugBank.d235.s4.e0
,;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d235.s4.e1
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d235.s4.e2
,;O;O
diclofenac;B-drug;B-DDI-DrugBank.d235.s4.e3
,;O;O
doxycycline;B-drug;B-DDI-DrugBank.d235.s4.e4
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d235.s4.e5
,;O;O
imatinib;B-drug;B-DDI-DrugBank.d235.s4.e6
,;O;O
isoniazid;B-drug;B-DDI-DrugBank.d235.s4.e7
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d235.s4.e8
,;O;O
nicardipine;B-drug;B-DDI-DrugBank.d235.s4.e9
,;O;O
propofol;B-drug;B-DDI-DrugBank.d235.s4.e10
,;O;O
protease;B-group;B-DDI-DrugBank.d235.s4.e11
inhibitors;I-group;I-DDI-DrugBank.d235.s4.e11
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d235.s4.e12
,;O;O
and;O;O
verapamil;B-drug;B-DDI-DrugBank.d235.s4.e13
.;O;O
DDI-DrugBank.d86.s0;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
two;O;O
or;O;O
more;O;O
drugs;O;O
with;O;O
anticholinergic;O;O
activity;O;O
--;O;O
such;O;O
as;O;O
an;O;O
antipsychotic;B-group;B-DDI-DrugBank.d86.s0.e0
drug;I-group;I-DDI-DrugBank.d86.s0.e0
(;O;O
eg;O;O
,;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d86.s0.e1
);O;O
,;O;O
an;O;O
antiparkinsonian;B-group;B-DDI-DrugBank.d86.s0.e2
drug;I-group;I-DDI-DrugBank.d86.s0.e2
(;O;O
eg;O;O
,;O;O
trihexyphenidyl;B-drug;B-DDI-DrugBank.d86.s0.e3
);O;O
,;O;O
and/or;O;O
a;O;O
tricyclic;B-group;B-DDI-DrugBank.d86.s0.e4
antidepressant;I-group;I-DDI-DrugBank.d86.s0.e4
(;O;O
eg;O;O
,;O;O
amitriptyline);B-drug;B-DDI-DrugBank.d86.s0.e5
-;O;O
-;O;O
commonly;O;O
results;O;O
in;O;O
excessive;O;O
anticholinergic;O;O
effects;O;O
,;O;O
including;O;O
dry;O;O
mouth;O;O
and;O;O
associated;O;O
dental;O;O
complications;O;O
,;O;O
blurred;O;O
vision;O;O
,;O;O
and;O;O
,;O;O
in;O;O
patients;O;O
exposed;O;O
to;O;O
high;O;O
temperature;O;O
and;O;O
humidity;O;O
,;O;O
hyperpyrexia;O;O
.;O;O
DDI-DrugBank.d86.s1;;
Interactions;O;O
may;O;O
also;O;O
occur;O;O
with;O;O
the;O;O
following;O;O
:;O;O
anti;B-group;B-DDI-DrugBank.d86.s1.e0
-;I-group;I-DDI-DrugBank.d86.s1.e0
depressants;I-group;I-DDI-DrugBank.d86.s1.e0
/;O;O
anti;B-group;B-DDI-DrugBank.d86.s1.e1
-;I-group;I-DDI-DrugBank.d86.s1.e1
anxiety;I-group;I-DDI-DrugBank.d86.s1.e1
drugs;I-group;I-DDI-DrugBank.d86.s1.e1
,;O;O
drugs;O;O
used;O;O
to;O;O
treat;O;O
an;O;O
overactive;O;O
thyroid;O;O
,;O;O
beta;B-group;B-DDI-DrugBank.d86.s1.e2
-;I-group;I-DDI-DrugBank.d86.s1.e2
blockers;I-group;I-DDI-DrugBank.d86.s1.e2
(;O;O
e.g.;O;O
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d86.s1.e3
);O;O
,;O;O
sparfloxacin;B-drug;B-DDI-DrugBank.d86.s1.e4
,;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d86.s1.e5
,;O;O
guanethidine;B-drug;B-DDI-DrugBank.d86.s1.e6
,;O;O
guanadrel;B-drug;B-DDI-DrugBank.d86.s1.e7
,;O;O
metrizamide;B-drug;B-DDI-DrugBank.d86.s1.e8
,;O;O
cabergoline;B-drug;B-DDI-DrugBank.d86.s1.e9
,;O;O
lithium;B-drug;B-DDI-DrugBank.d86.s1.e10
,;O;O
narcotic;B-group;B-DDI-DrugBank.d86.s1.e11
pain;O;O
medication;O;O
(;O;O
e.g.;O;O
,;O;O
codeine;B-drug;B-DDI-DrugBank.d86.s1.e12
);O;O
,;O;O
drugs;O;O
used;O;O
to;O;O
aid;O;O
sleep;O;O
,;O;O
drowsiness;O;O
-;O;O
causing;O;O
antihistamines;B-group;B-DDI-DrugBank.d86.s1.e13
(;O;O
e.g.;O;O
,;O;O
diphenhydramine;B-drug;B-DDI-DrugBank.d86.s1.e14
);O;O
,;O;O
any;O;O
other;O;O
drugs;O;O
that;O;O
may;O;O
make;O;O
you;O;O
drowsy;O;O
.;O;O
DDI-DrugBank.d245.s0;;
The;O;O
hypoglycemic;O;O
action;O;O
of;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d245.s0.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
certain;O;O
drugs;O;O
including;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d245.s0.e1
anti;I-group;I-DDI-DrugBank.d245.s0.e1
-;I-group;I-DDI-DrugBank.d245.s0.e1
inflammatory;I-group;I-DDI-DrugBank.d245.s0.e1
agents;I-group;I-DDI-DrugBank.d245.s0.e1
and;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
highly;O;O
protein;O;O
bound;O;O
,;O;O
salicylates;B-group;B-DDI-DrugBank.d245.s0.e2
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d245.s0.e3
,;O;O
chloramphenicol;B-drug;B-DDI-DrugBank.d245.s0.e4
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d245.s0.e5
,;O;O
coumarins;B-group;B-DDI-DrugBank.d245.s0.e6
,;O;O
monoamine;B-group;B-DDI-DrugBank.d245.s0.e7
oxidase;I-group;I-DDI-DrugBank.d245.s0.e7
inhibitors;I-group;I-DDI-DrugBank.d245.s0.e7
,;O;O
and;O;O
beta;B-group;B-DDI-DrugBank.d245.s0.e8
adrenergic;I-group;I-DDI-DrugBank.d245.s0.e8
blocking;I-group;I-DDI-DrugBank.d245.s0.e8
agents;I-group;I-DDI-DrugBank.d245.s0.e8
.;O;O
DDI-DrugBank.d245.s1;;
When;O;O
such;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
DIABINESE;B-brand;B-DDI-DrugBank.d245.s1.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d245.s2;;
When;O;O
such;O;O
drugs;O;O
are;O;O
withdrawn;O;O
from;O;O
a;O;O
patient;O;O
receiving;O;O
DIABINESE;B-brand;B-DDI-DrugBank.d245.s2.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d245.s3;;
Certain;O;O
drugs;O;O
tend;O;O
to;O;O
produce;O;O
hyperglycemia;O;O
and;O;O
may;O;O
lead;O;O
to;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d245.s4;;
These;O;O
drugs;O;O
include;O;O
the;O;O
thiazides;B-group;B-DDI-DrugBank.d245.s4.e0
and;O;O
other;O;O
diuretics;B-group;B-DDI-DrugBank.d245.s4.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d245.s4.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d245.s4.e3
,;O;O
thyroid;O;O
products;O;O
,;O;O
estrogens;B-group;B-DDI-DrugBank.d245.s4.e4
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d245.s4.e5
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d245.s4.e6
,;O;O
nicotinic;B-drug;B-DDI-DrugBank.d245.s4.e7
acid;I-drug;I-DDI-DrugBank.d245.s4.e7
,;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d245.s4.e8
,;O;O
calcium;B-group;B-DDI-DrugBank.d245.s4.e9
channel;I-group;I-DDI-DrugBank.d245.s4.e9
blocking;I-group;I-DDI-DrugBank.d245.s4.e9
drugs;I-group;I-DDI-DrugBank.d245.s4.e9
,;O;O
and;O;O
isoniazid;B-drug;B-DDI-DrugBank.d245.s4.e10
.;O;O
DDI-DrugBank.d245.s5;;
When;O;O
such;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
DIABINESE;B-brand;B-DDI-DrugBank.d245.s5.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d245.s6;;
When;O;O
such;O;O
drugs;O;O
are;O;O
withdrawn;O;O
from;O;O
a;O;O
patient;O;O
receiving;O;O
DIABINESE;B-brand;B-DDI-DrugBank.d245.s6.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d245.s7;;
Since;O;O
animal;O;O
studies;O;O
suggest;O;O
that;O;O
the;O;O
action;O;O
of;O;O
barbiturates;B-group;B-DDI-DrugBank.d245.s7.e0
may;O;O
be;O;O
prolonged;O;O
by;O;O
therapy;O;O
with;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d245.s7.e1
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d245.s7.e2
should;O;O
be;O;O
employed;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d245.s8;;
In;O;O
some;O;O
patients;O;O
,;O;O
a;O;O
disulfiram;B-drug;B-DDI-DrugBank.d245.s8.e0
-;O;O
like;O;O
reaction;O;O
may;O;O
be;O;O
produced;O;O
by;O;O
the;O;O
ingestion;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d245.s8.e1
.;O;O
DDI-DrugBank.d245.s9;;
A;O;O
potential;O;O
interaction;O;O
between;O;O
oral;O;O
miconazole;B-drug;B-DDI-DrugBank.d245.s9.e0
and;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d245.s9.e1
agents;I-group;I-DDI-DrugBank.d245.s9.e1
leading;O;O
to;O;O
severe;O;O
hypoglycemia;O;O
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d245.s10;;
Whether;O;O
this;O;O
interaction;O;O
also;O;O
occurs;O;O
with;O;O
the;O;O
intravenous;O;O
,;O;O
topical;O;O
,;O;O
or;O;O
vaginal;O;O
preparations;O;O
of;O;O
miconazole;B-drug;B-DDI-DrugBank.d245.s10.e0
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d503.s0;;
Chlorprothixene;B-drug;B-DDI-DrugBank.d503.s0.e0
may;O;O
increase;O;O
the;O;O
plasma;O;O
-;O;O
level;O;O
of;O;O
concomitantly;O;O
given;O;O
lithium;B-drug;B-DDI-DrugBank.d503.s0.e1
.;O;O
DDI-DrugBank.d503.s1;;
In;O;O
order;O;O
to;O;O
avoid;O;O
lithium;B-drug;B-DDI-DrugBank.d503.s1.e0
intoxication;O;O
,;O;O
lithium;B-drug;B-DDI-DrugBank.d503.s1.e1
plasma;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
.;O;O
DDI-DrugBank.d503.s2;;
If;O;O
chlorprothixene;B-drug;B-DDI-DrugBank.d503.s2.e0
is;O;O
given;O;O
concomitantly;O;O
with;O;O
opioids;B-group;B-DDI-DrugBank.d503.s2.e1
,;O;O
the;O;O
opioid;B-group;B-DDI-DrugBank.d503.s2.e2
dose;O;O
should;O;O
be;O;O
reduced;O;O
(;O;O
by;O;O
approx;O;O
.;O;O
50;O;O
%;O;O
);O;O
,;O;O
because;O;O
chlorprothixene;B-drug;B-DDI-DrugBank.d503.s2.e3
amplifies;O;O
the;O;O
therapeutic;O;O
actions;O;O
and;O;O
side;O;O
-;O;O
effects;O;O
of;O;O
opioids;B-group;B-DDI-DrugBank.d503.s2.e4
massively;O;O
.;O;O
DDI-DrugBank.d503.s3;;
Avoid;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
chlorprothixene;B-drug;B-DDI-DrugBank.d503.s3.e0
and;O;O
tramadol;B-drug;B-DDI-DrugBank.d503.s3.e1
(;O;O
Ultram;B-brand;B-DDI-DrugBank.d503.s3.e2
);O;O
.;O;O
DDI-DrugBank.d503.s4;;
Massive;O;O
seizures;O;O
may;O;O
be;O;O
encountered;O;O
with;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d503.s5;;
Consider;O;O
additive;O;O
sedative;O;O
effects;O;O
and;O;O
confusional;O;O
states;O;O
to;O;O
emerge;O;O
,;O;O
if;O;O
chlorprothixene;B-drug;B-DDI-DrugBank.d503.s5.e0
is;O;O
given;O;O
with;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d503.s5.e1
or;O;O
barbituates;B-group;B-DDI-DrugBank.d503.s5.e2
.;O;O
DDI-DrugBank.d503.s6;;
Choose;O;O
particular;O;O
low;O;O
doses;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d503.s7;;
Exert;O;O
particular;O;O
caution;O;O
in;O;O
combining;O;O
chlorprothixene;B-drug;B-DDI-DrugBank.d503.s7.e0
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d503.s7.e1
drugs;I-group;I-DDI-DrugBank.d503.s7.e1
(;O;O
tricyclic;B-group;B-DDI-DrugBank.d503.s7.e2
antidepressants;I-group;I-DDI-DrugBank.d503.s7.e2
and;O;O
antiparkinsonian;B-group;B-DDI-DrugBank.d503.s7.e3
agents;I-group;I-DDI-DrugBank.d503.s7.e3
);O;O
:;O;O
Particularly;O;O
the;O;O
elderly;O;O
may;O;O
develop;O;O
delirium;O;O
,;O;O
high;O;O
fever;O;O
,;O;O
severe;O;O
obstipation;O;O
,;O;O
even;O;O
ileus;O;O
and;O;O
glaucoma;O;O
.;O;O
DDI-DrugBank.d265.s0;;
Chlorthalidone;B-drug;B-DDI-DrugBank.d265.s0.e0
may;O;O
add;O;O
to;O;O
or;O;O
potentiate;O;O
the;O;O
action;O;O
of;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d265.s0.e1
drugs;I-group;I-DDI-DrugBank.d265.s0.e1
.;O;O
DDI-DrugBank.d265.s1;;
Potentiation;O;O
occurs;O;O
with;O;O
ganglionic;B-group;B-DDI-DrugBank.d265.s1.e0
peripheral;I-group;I-DDI-DrugBank.d265.s1.e0
adrenergic;I-group;I-DDI-DrugBank.d265.s1.e0
blocking;I-group;I-DDI-DrugBank.d265.s1.e0
drugs;I-group;I-DDI-DrugBank.d265.s1.e0
.;O;O
DDI-DrugBank.d265.s2;;
Medication;O;O
such;O;O
as;O;O
digitalis;B-group;B-DDI-DrugBank.d265.s2.e0
may;O;O
also;O;O
influence;O;O
serum;O;O
electrolytes;O;O
.;O;O
DDI-DrugBank.d265.s3;;
Warning;O;O
signs;O;O
,;O;O
irrespective;O;O
of;O;O
cause;O;O
,;O;O
are;O;O
:;O;O
dryness;O;O
of;O;O
mouth;O;O
,;O;O
thirst;O;O
,;O;O
weakness;O;O
,;O;O
lethargy;O;O
,;O;O
drowsiness;O;O
,;O;O
restlessness;O;O
,;O;O
muscle;O;O
pains;O;O
or;O;O
cramps;O;O
,;O;O
muscular;O;O
fatigue;O;O
,;O;O
hypotension;O;O
,;O;O
oliguria;O;O
,;O;O
tachycardia;O;O
,;O;O
and;O;O
gastrointestinal;O;O
disturbances;O;O
such;O;O
as;O;O
nausea;O;O
and;O;O
vomiting;O;O
.;O;O
DDI-DrugBank.d265.s4;;
Insulin;B-drug;B-DDI-DrugBank.d265.s4.e0
requirements;O;O
in;O;O
diabetic;O;O
patients;O;O
may;O;O
be;O;O
increased;O;O
,;O;O
decreased;O;O
,;O;O
or;O;O
unchanged;O;O
.;O;O
DDI-DrugBank.d265.s5;;
Higher;O;O
dosage;O;O
of;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d265.s5.e0
agents;I-group;I-DDI-DrugBank.d265.s5.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d265.s6;;
Latent;O;O
diabetes;O;O
mellitus;O;O
may;O;O
become;O;O
manifest;O;O
during;O;O
chlorthalidone;B-drug;B-DDI-DrugBank.d265.s6.e0
administration;O;O
.;O;O
DDI-DrugBank.d265.s7;;
Chlorthalidone;B-drug;B-DDI-DrugBank.d265.s7.e0
and;O;O
related;O;O
drugs;O;O
may;O;O
increase;O;O
the;O;O
responsiveness;O;O
to;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d265.s7.e1
.;O;O
DDI-DrugBank.d265.s8;;
Chlorthalidone;B-drug;B-DDI-DrugBank.d265.s8.e0
and;O;O
related;O;O
drugs;O;O
may;O;O
decrease;O;O
arterial;O;O
responsiveness;O;O
to;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d265.s8.e1
.;O;O
DDI-DrugBank.d265.s9;;
This;O;O
diminution;O;O
is;O;O
not;O;O
sufficient;O;O
to;O;O
preclude;O;O
effectiveness;O;O
of;O;O
the;O;O
pressor;O;O
agent;O;O
for;O;O
therapeutic;O;O
use;O;O
.;O;O
DDI-DrugBank.d262.s0;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d262.s0.e0
or;O;O
other;O;O
central;B-group;B-DDI-DrugBank.d262.s0.e1
nervous;I-group;I-DDI-DrugBank.d262.s0.e1
system;I-group;I-DDI-DrugBank.d262.s0.e1
depressants;I-group;I-DDI-DrugBank.d262.s0.e1
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
.;O;O
DDI-DrugBank.d404.s0;;
Interactions;O;O
for;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s0.e0
D;I-group;I-DDI-DrugBank.d404.s0.e0
analogues;O;O
(;O;O
Vitamin;B-drug;B-DDI-DrugBank.d404.s0.e1
D2;I-drug;I-DDI-DrugBank.d404.s0.e1
,;O;O
Vitamin;B-drug;B-DDI-DrugBank.d404.s0.e2
D3;I-drug;I-DDI-DrugBank.d404.s0.e2
,;O;O
Calcitriol;B-drug;B-DDI-DrugBank.d404.s0.e3
,;O;O
and;O;O
Calcidiol;B-drug;B-DDI-DrugBank.d404.s0.e4
);O;O
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d404.s0.e5
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d404.s0.e6
has;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
intestinal;O;O
absorption;O;O
of;O;O
fat;B-group;B-DDI-DrugBank.d404.s0.e7
soluble;I-group;I-DDI-DrugBank.d404.s0.e7
vitamins;I-group;I-DDI-DrugBank.d404.s0.e7
,;O;O
DDI-DrugBank.d404.s1;;
as;O;O
such;O;O
it;O;O
may;O;O
impair;O;O
intestinal;O;O
absorption;O;O
of;O;O
any;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s1.e0
D.;I-group;I-DDI-DrugBank.d404.s1.e0
DDI-DrugBank.d404.s2;;
Phenytoin;I-drug;I-DDI-DrugBank.d404.s2.e0
/;O;O
Phenobarbital;B-drug;B-DDI-DrugBank.d404.s2.e1
:;O;O
The;O;O
coadministration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d404.s2.e2
or;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d404.s2.e3
will;O;O
not;O;O
affect;O;O
plasma;O;O
concentrations;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s2.e4
D;I-group;I-DDI-DrugBank.d404.s2.e4
,;O;O
but;O;O
may;O;O
reduce;O;O
endogenous;O;O
plasma;O;O
levels;O;O
of;O;O
calcitriol;B-drug;B-DDI-DrugBank.d404.s2.e5
/;O;O
ergocalcitriol;O;O
by;O;O
accelerating;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d404.s3;;
Since;O;O
blood;O;O
level;O;O
of;O;O
calcitriol;B-drug;B-DDI-DrugBank.d404.s3.e0
/;O;O
ergocalcitriol;O;O
will;O;O
be;O;O
reduced;O;O
,;O;O
higher;O;O
doses;O;O
of;O;O
Rocaltrol;B-brand;B-DDI-DrugBank.d404.s3.e1
may;O;O
be;O;O
necessary;O;O
if;O;O
these;O;O
drugs;O;O
are;O;O
administered;O;O
simultaneously;O;O
.;O;O
DDI-DrugBank.d404.s4;;
Thiazides;B-group;B-DDI-DrugBank.d404.s4.e0
:;O;O
Thiazides;B-group;B-DDI-DrugBank.d404.s4.e1
are;O;O
known;O;O
to;O;O
induce;O;O
hypercalcemia;O;O
by;O;O
the;O;O
reduction;O;O
of;O;O
calcium;O;O
excretion;O;O
in;O;O
urine;O;O
.;O;O
DDI-DrugBank.d404.s5;;
Some;O;O
reports;O;O
have;O;O
shown;O;O
that;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
thiazides;B-group;B-DDI-DrugBank.d404.s5.e0
with;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s5.e1
D;I-group;I-DDI-DrugBank.d404.s5.e1
causes;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d404.s6;;
Therefore;O;O
,;O;O
precaution;O;O
should;O;O
be;O;O
taken;O;O
when;O;O
coadministration;O;O
is;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d404.s7;;
Digitalis;B-group;B-DDI-DrugBank.d404.s7.e0
:;O;O
Vitamin;B-group;B-DDI-DrugBank.d404.s7.e1
D;I-group;I-DDI-DrugBank.d404.s7.e1
dosage;O;O
must;O;O
be;O;O
determined;O;O
with;O;O
care;O;O
in;O;O
patients;O;O
undergoing;O;O
treatment;O;O
with;O;O
digitalis;B-group;B-DDI-DrugBank.d404.s7.e2
,;O;O
as;O;O
hypercalcemia;O;O
in;O;O
such;O;O
patients;O;O
may;O;O
precipitate;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d404.s8;;
Ketoconazole;B-drug;B-DDI-DrugBank.d404.s8.e0
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d404.s8.e1
may;O;O
inhibit;O;O
both;O;O
synthetic;O;O
and;O;O
catabolic;O;O
enzymes;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s8.e2
D.;I-group;I-DDI-DrugBank.d404.s8.e2
DDI-DrugBank.d404.s9;;
Reductions;O;O
in;O;O
serum;O;O
endogenous;O;O
vitamin;O;O
D;O;O
concentrations;O;O
have;O;O
been;O;O
observed;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
300;O;O
mg;O;O
/;O;O
day;O;O
to;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d404.s9.e0
for;O;O
a;O;O
week;O;O
to;O;O
healthy;O;O
men;O;O
.;O;O
DDI-DrugBank.d404.s10;;
However;O;O
,;O;O
in;O;O
vivo;O;O
drug;O;O
interaction;O;O
studies;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d404.s10.e0
with;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s10.e1
D;I-group;I-DDI-DrugBank.d404.s10.e1
have;O;O
not;O;O
been;O;O
investigated;O;O
.;O;O
DDI-DrugBank.d404.s11;;
Corticosteroids;B-group;B-DDI-DrugBank.d404.s11.e0
:;O;O
A;O;O
relationship;O;O
of;O;O
functional;O;O
antagonism;O;O
exists;O;O
between;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s11.e1
D;I-group;I-DDI-DrugBank.d404.s11.e1
analogues;O;O
,;O;O
which;O;O
promote;O;O
calcium;O;O
absorption;O;O
,;O;O
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d404.s11.e2
,;O;O
which;O;O
inhibit;O;O
calcium;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d404.s12;;
Phosphate;O;O
-;O;O
Binding;O;O
Agents;O;O
:;O;O
Since;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s12.e0
D;I-group;I-DDI-DrugBank.d404.s12.e0
also;O;O
has;O;O
an;O;O
effect;O;O
on;O;O
phosphate;O;O
transport;O;O
in;O;O
the;O;O
intestine;O;O
,;O;O
kidneys;O;O
and;O;O
bones;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
phosphate;O;O
-;O;O
binding;O;O
agents;O;O
must;O;O
be;O;O
adjusted;O;O
in;O;O
accordance;O;O
with;O;O
the;O;O
serum;O;O
phosphate;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d404.s13;;
Vitamin;B-group;B-DDI-DrugBank.d404.s13.e0
D;I-group;I-DDI-DrugBank.d404.s13.e0
:;O;O
The;O;O
coadministration;O;O
of;O;O
any;O;O
of;O;O
the;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s13.e1
D;I-group;I-DDI-DrugBank.d404.s13.e1
analogues;O;O
should;O;O
be;O;O
avoided;O;O
as;O;O
this;O;O
could;O;O
create;O;O
possible;O;O
additive;O;O
effects;O;O
and;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d404.s14;;
Calcium;B-drug;B-DDI-DrugBank.d404.s14.e0
Supplements;O;O
:;O;O
Uncontrolled;O;O
intake;O;O
of;O;O
additional;O;O
calcium;B-drug;B-DDI-DrugBank.d404.s14.e1
-;O;O
containing;O;O
preparations;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d404.s15;;
Magnesium;B-drug;B-DDI-DrugBank.d404.s15.e0
:;O;O
Magnesium;B-drug;B-DDI-DrugBank.d404.s15.e1
-;O;O
containing;O;O
preparations;O;O
(;O;O
eg;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d404.s15.e2
);O;O
may;O;O
cause;O;O
hypermagnesemia;O;O
and;O;O
should;O;O
therefore;O;O
not;O;O
be;O;O
taken;O;O
during;O;O
therapy;O;O
with;O;O
vitamin;B-group;B-DDI-DrugBank.d404.s15.e3
D;I-group;I-DDI-DrugBank.d404.s15.e3
by;O;O
patients;O;O
on;O;O
chronic;O;O
renal;O;O
dialysis;O;O
.;O;O
DDI-DrugBank.d566.s0;;
Cholestyramine;B-drug;B-DDI-DrugBank.d566.s0.e0
resin;I-group;I-DDI-DrugBank.d566.s0.e1
may;O;O
delay;O;O
or;O;O
reduce;O;O
the;O;O
absorption;O;O
of;O;O
concomitant;O;O
oral;O;O
medication;O;O
such;O;O
as;O;O
phenylbutazone;B-group;B-DDI-DrugBank.d566.s0.e2
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d566.s0.e3
,;O;O
thiazide;B-group;B-DDI-DrugBank.d566.s0.e4
diuretics;I-group;I-DDI-DrugBank.d566.s0.e4
(;O;O
acidic;O;O
);O;O
or;O;O
propranolol;B-drug;B-DDI-DrugBank.d566.s0.e5
(;O;O
basic;O;O
);O;O
,;O;O
as;O;O
well;O;O
as;O;O
tetracycline;B-drug;B-DDI-DrugBank.d566.s0.e6
penicillin;I-drug;I-DDI-DrugBank.d566.s0.e7
G;I-drug;I-DDI-DrugBank.d566.s0.e7
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d566.s0.e8
,;O;O
thyroid;O;O
and;O;O
thyroxine;B-drug;B-DDI-DrugBank.d566.s0.e9
preparations;O;O
,;O;O
estrogens;B-group;B-DDI-DrugBank.d566.s0.e10
and;O;O
progestins;B-group;B-DDI-DrugBank.d566.s0.e11
,;O;O
and;O;O
digitalis;B-group;B-DDI-DrugBank.d566.s0.e12
.;O;O
DDI-DrugBank.d566.s1;;
Interference;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
oral;O;O
phosphate;B-drug_n;B-DDI-DrugBank.d566.s1.e0
supplements;O;O
has;O;O
been;O;O
observed;O;O
with;O;O
another;O;O
positively;O;O
-;O;O
charged;O;O
bile;O;O
acid;O;O
sequestrant;O;O
.;O;O
DDI-DrugBank.d566.s2;;
Cholestyramine;B-drug;B-DDI-DrugBank.d566.s2.e0
resin;I-group;I-DDI-DrugBank.d566.s2.e1
may;O;O
interfere;O;O
with;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
drugs;O;O
that;O;O
undergo;O;O
enterohepatic;O;O
circulation;O;O
,;O;O
The;O;O
discontinuance;O;O
of;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d566.s2.e2
resin;I-group;I-DDI-DrugBank.d566.s2.e3
could;O;O
pose;O;O
a;O;O
hazard;O;O
to;O;O
health;O;O
if;O;O
a;O;O
potentially;O;O
toxic;O;O
drug;O;O
such;O;O
as;O;O
digitalis;B-group;B-DDI-DrugBank.d566.s2.e4
has;O;O
been;O;O
filtrated;O;O
to;O;O
a;O;O
maintenance;O;O
level;O;O
while;O;O
the;O;O
patient;O;O
was;O;O
taking;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d566.s2.e5
resin;I-group;I-DDI-DrugBank.d566.s2.e6
.;O;O
DDI-DrugBank.d566.s3;;
Because;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d566.s3.e0
binds;O;O
bile;O;O
acids;O;O
,;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d566.s3.e1
resin;I-group;I-DDI-DrugBank.d566.s3.e2
may;O;O
interfere;O;O
with;O;O
normal;O;O
fat;O;O
digestion;O;O
and;O;O
absorption;O;O
and;O;O
thus;O;O
may;O;O
prevent;O;O
absorption;O;O
of;O;O
fat;B-group;B-DDI-DrugBank.d566.s3.e3
soluble;I-group;I-DDI-DrugBank.d566.s3.e3
vitamins;I-group;I-DDI-DrugBank.d566.s3.e3
such;O;O
as;O;O
A;O;O
,;O;O
D;O;O
,;O;O
E;O;O
,;O;O
and;O;O
K.;O;O
DDI-DrugBank.d566.s4;;
When;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d566.s4.e0
resin;I-group;I-DDI-DrugBank.d566.s4.e1
is;O;O
given;O;O
for;O;O
long;O;O
periods;O;O
of;O;O
time;O;O
,;O;O
concomitant;O;O
supplementation;O;O
with;O;O
water;O;O
-;O;O
miscible;O;O
(;O;O
or;O;O
parenteral;O;O
);O;O
forms;O;O
of;O;O
fat;B-group;B-DDI-DrugBank.d566.s4.e2
-;I-group;I-DDI-DrugBank.d566.s4.e2
soluble;I-group;I-DDI-DrugBank.d566.s4.e2
vitamins;I-group;I-DDI-DrugBank.d566.s4.e2
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d566.s5;;
SINCE;O;O
CHOLESTYRAMINE;B-drug;B-DDI-DrugBank.d566.s5.e0
RESIN;I-group;I-DDI-DrugBank.d566.s5.e1
MAY;O;O
BIND;O;O
OTHER;O;O
DRUGS;O;O
GIVEN;O;O
CONCURRENTLY;O;O
,;O;O
IT;O;O
IS;O;O
RECOMMENDED;O;O
THAT;O;O
PATIENTS;O;O
TAKE;O;O
OTHER;O;O
DRUGS;O;O
AT;O;O
LEAST;O;O
1;O;O
HOUR;O;O
BEFORE;O;O
OR;O;O
4;O;O
TO;O;O
6;O;O
HOURS;O;O
AFTER;O;O
CHOLESTYRAMINE;B-drug;B-DDI-DrugBank.d566.s5.e2
RESIN;I-group;I-DDI-DrugBank.d566.s5.e3
(;O;O
OR;O;O
AT;O;O
AS;O;O
GREAT;O;O
AN;O;O
INTERVAL;O;O
AS;O;O
POSSIBLE;O;O
);O;O
TO;O;O
AVOID;O;O
IMPEDING;O;O
THEIR;O;O
ABSORPTION;O;O
.;O;O
DDI-DrugBank.d362.s0;;
Based;O;O
on;O;O
in;O;O
vitro;O;O
studies;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
,;O;O
des;B-drug;B-DDI-DrugBank.d362.s0.e0
-;I-drug;I-DDI-DrugBank.d362.s0.e0
ciclesonide;I-drug;I-DDI-DrugBank.d362.s0.e0
appears;O;O
to;O;O
have;O;O
no;O;O
inhibitory;O;O
or;O;O
induction;O;O
potential;O;O
on;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP;O;O
450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d362.s1;;
The;O;O
inhibitory;O;O
potential;O;O
of;O;O
ciclesonide;B-drug;B-DDI-DrugBank.d362.s1.e0
on;O;O
CYP450;O;O
isoenzymes;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d362.s2;;
In;O;O
vitro;O;O
studies;O;O
demonstrated;O;O
that;O;O
the;O;O
plasma;O;O
protein;O;O
binding;O;O
of;O;O
des;B-drug;B-DDI-DrugBank.d362.s2.e0
-;I-drug;I-DDI-DrugBank.d362.s2.e0
ciclesonide;I-drug;I-DDI-DrugBank.d362.s2.e0
was;O;O
not;O;O
affected;O;O
by;O;O
warfarin;B-drug;B-DDI-DrugBank.d362.s2.e1
or;O;O
salicylic;B-drug;B-DDI-DrugBank.d362.s2.e2
acid;I-drug;I-DDI-DrugBank.d362.s2.e2
,;O;O
indicating;O;O
no;O;O
potential;O;O
for;O;O
protein;O;O
binding;O;O
-;O;O
based;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d362.s3;;
In;O;O
a;O;O
drug;O;O
interaction;O;O
study;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
orally;O;O
inhaled;O;O
ciclesonide;B-drug;B-DDI-DrugBank.d362.s3.e0
and;O;O
oral;O;O
erythromycin;B-drug;B-DDI-DrugBank.d362.s3.e1
,;O;O
an;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
,;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
des;B-drug;B-DDI-DrugBank.d362.s3.e2
-;I-drug;I-DDI-DrugBank.d362.s3.e2
ciclesonide;I-drug;I-DDI-DrugBank.d362.s3.e2
or;O;O
erythromycin;B-drug;B-DDI-DrugBank.d362.s3.e3
.;O;O
DDI-DrugBank.d362.s4;;
In;O;O
another;O;O
drug;O;O
interaction;O;O
study;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
orally;O;O
inhaled;O;O
ciclesonide;B-drug;B-DDI-DrugBank.d362.s4.e0
and;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d362.s4.e1
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
,;O;O
increased;O;O
the;O;O
exposure;O;O
(;O;O
AUC;O;O
);O;O
of;O;O
des;B-drug;B-DDI-DrugBank.d362.s4.e2
-;I-drug;I-DDI-DrugBank.d362.s4.e2
ciclesonide;I-drug;I-DDI-DrugBank.d362.s4.e2
by;O;O
approximately;O;O
3.6;O;O
-;O;O
fold;O;O
at;O;O
steady;O;O
state;O;O
,;O;O
while;O;O
levels;O;O
of;O;O
ciclesonide;B-drug;B-DDI-DrugBank.d362.s4.e3
remained;O;O
unchanged;O;O
.;O;O
DDI-DrugBank.d362.s5;;
Therefore;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d362.s5.e0
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
with;O;O
intranasal;O;O
ciclesonide;B-drug;B-DDI-DrugBank.d362.s5.e1
.;O;O
DDI-DrugBank.d260.s0;;
Probenecid;B-drug;B-DDI-DrugBank.d260.s0.e0
:;O;O
Probenecid;B-drug;B-DDI-DrugBank.d260.s0.e1
is;O;O
known;O;O
to;O;O
interact;O;O
with;O;O
the;O;O
metabolism;O;O
or;O;O
renal;O;O
tubular;O;O
excretion;O;O
of;O;O
many;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d260.s0.e2
,;O;O
acyclovir;B-drug;B-DDI-DrugBank.d260.s0.e3
,;O;O
angiotensin;B-group;B-DDI-DrugBank.d260.s0.e4
-;I-group;I-DDI-DrugBank.d260.s0.e4
converting;I-group;I-DDI-DrugBank.d260.s0.e4
enzyme;I-group;I-DDI-DrugBank.d260.s0.e4
inhibitors;I-group;I-DDI-DrugBank.d260.s0.e4
,;O;O
aminosalicylic;B-drug;B-DDI-DrugBank.d260.s0.e5
acid;I-drug;I-DDI-DrugBank.d260.s0.e5
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d260.s0.e6
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d260.s0.e7
,;O;O
bumetanide;B-drug;B-DDI-DrugBank.d260.s0.e8
,;O;O
clofibrate;B-drug;B-DDI-DrugBank.d260.s0.e9
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d260.s0.e10
,;O;O
famotidine;B-drug;B-DDI-DrugBank.d260.s0.e11
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d260.s0.e12
,;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d260.s0.e13
anti;I-group;I-DDI-DrugBank.d260.s0.e13
-;I-group;I-DDI-DrugBank.d260.s0.e13
inflammatory;I-group;I-DDI-DrugBank.d260.s0.e13
agents;O;O
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d260.s0.e14
,;O;O
and;O;O
zidovudine;B-drug;B-DDI-DrugBank.d260.s0.e15
);O;O
.;O;O
DDI-DrugBank.d260.s1;;
Concomitant;O;O
medications;O;O
should;O;O
be;O;O
carefully;O;O
assessed;O;O
.;O;O
DDI-DrugBank.d260.s2;;
Zidovudine;B-drug;B-DDI-DrugBank.d260.s2.e0
should;O;O
either;O;O
be;O;O
temporarily;O;O
discontinued;O;O
or;O;O
decreased;O;O
by;O;O
50;O;O
%;O;O
when;O;O
coadministered;O;O
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d260.s2.e1
on;O;O
the;O;O
day;O;O
of;O;O
VISTIDE;B-brand;B-DDI-DrugBank.d260.s2.e2
infusion;O;O
.;O;O
DDI-DrugBank.d260.s3;;
Nephrotoxic;O;O
agents;O;O
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
VISTIDE;B-brand;B-DDI-DrugBank.d260.s3.e0
and;O;O
agents;O;O
with;O;O
nephrotoxic;O;O
potential;O;O
[;O;O
e.g.;O;O
,;O;O
intravenous;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d260.s3.e1
(;O;O
e.g.;O;O
,;O;O
tobramycin;B-drug;B-DDI-DrugBank.d260.s3.e2
,;O;O
gentamicin;B-drug;B-DDI-DrugBank.d260.s3.e3
,;O;O
and;O;O
amikacin;B-drug;B-DDI-DrugBank.d260.s3.e4
);O;O
,;O;O
amphotericin;B-drug;B-DDI-DrugBank.d260.s3.e5
B;I-drug;I-DDI-DrugBank.d260.s3.e5
,;O;O
foscarnet;B-drug;B-DDI-DrugBank.d260.s3.e6
,;O;O
intravenous;O;O
pentamidine;B-drug;B-DDI-DrugBank.d260.s3.e7
,;O;O
vancomycin;B-drug;B-DDI-DrugBank.d260.s3.e8
,;O;O
and;O;O
non;B-group;B-DDI-DrugBank.d260.s3.e9
-;I-group;I-DDI-DrugBank.d260.s3.e9
steroidal;I-group;I-DDI-DrugBank.d260.s3.e9
anti;I-group;I-DDI-DrugBank.d260.s3.e9
-;I-group;I-DDI-DrugBank.d260.s3.e9
inflammatory;I-group;I-DDI-DrugBank.d260.s3.e9
agents;I-group;I-DDI-DrugBank.d260.s3.e9
];O;O
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d260.s4;;
Such;O;O
agents;O;O
must;O;O
be;O;O
discontinued;O;O
at;O;O
least;O;O
seven;O;O
days;O;O
prior;O;O
to;O;O
starting;O;O
therapy;O;O
with;O;O
VISTIDE;B-brand;B-DDI-DrugBank.d260.s4.e0
.;O;O
DDI-DrugBank.d358.s0;;
Since;O;O
PLETAL;B-brand;B-DDI-DrugBank.d358.s0.e0
is;O;O
extensively;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
isoenzymes;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
PLETAL;B-brand;B-DDI-DrugBank.d358.s0.e1
is;O;O
coadministered;O;O
with;O;O
inhibitors;O;O
of;O;O
C.P.A.;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d358.s0.e2
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d358.s0.e3
or;O;O
inhibitors;O;O
of;O;O
CYP2C19;O;O
such;O;O
as;O;O
omeprazole;B-drug;B-DDI-DrugBank.d358.s0.e4
.;O;O
DDI-DrugBank.d358.s1;;
Pharmacokinetic;O;O
studies;O;O
have;O;O
demonstrated;O;O
that;O;O
omeprazole;B-drug;B-DDI-DrugBank.d358.s1.e0
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d358.s1.e1
significantly;O;O
increased;O;O
the;O;O
systemic;O;O
exposure;O;O
of;O;O
cilostazol;B-drug;B-DDI-DrugBank.d358.s1.e2
and/or;O;O
its;O;O
major;O;O
metabolites;O;O
.;O;O
DDI-DrugBank.d358.s2;;
Population;O;O
pharmacokinetic;O;O
studies;O;O
showed;O;O
higher;O;O
concentrations;O;O
of;O;O
cilostazol;B-drug;B-DDI-DrugBank.d358.s2.e0
among;O;O
patients;O;O
concurrently;O;O
treated;O;O
with;O;O
diltiazem;B-drug;B-DDI-DrugBank.d358.s2.e1
,;O;O
an;O;O
inhibitor;O;O
of;O;O
C.P.A;O;O
..;O;O
DDI-DrugBank.d358.s3;;
Pletal;B-brand;B-DDI-DrugBank.d358.s3.e0
does;O;O
not;O;O
,;O;O
however;O;O
,;O;O
appear;O;O
to;O;O
cause;O;O
increased;O;O
blood;O;O
levels;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
,;O;O
as;O;O
it;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
lovastatin;B-drug;B-DDI-DrugBank.d358.s3.e1
,;O;O
a;O;O
drug;O;O
with;O;O
metabolism;O;O
very;O;O
sensitive;O;O
to;O;O
C.P.A.;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d171.s0;;
Tagamet;B-brand;B-DDI-DrugBank.d171.s0.e0
,;O;O
apparently;O;O
through;O;O
an;O;O
effect;O;O
on;O;O
certain;O;O
microsomal;O;O
enzyme;O;O
systems;O;O
,;O;O
has;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
the;O;O
hepatic;O;O
metabolism;O;O
of;O;O
warfarin;B-group;B-DDI-DrugBank.d171.s0.e1
-;I-group;I-DDI-DrugBank.d171.s0.e1
type;I-group;I-DDI-DrugBank.d171.s0.e1
anticoagulants;I-group;I-DDI-DrugBank.d171.s0.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d171.s0.e2
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d171.s0.e3
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d171.s0.e4
,;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d171.s0.e5
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d171.s0.e6
,;O;O
certain;O;O
tricyclic;B-group;B-DDI-DrugBank.d171.s0.e7
antidepressants;I-group;I-DDI-DrugBank.d171.s0.e7
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d171.s0.e8
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d171.s0.e9
and;O;O
metronidazole;B-drug;B-DDI-DrugBank.d171.s0.e10
,;O;O
thereby;O;O
delaying;O;O
elimination;O;O
and;O;O
increasing;O;O
blood;O;O
levels;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d171.s1;;
Clinically;O;O
significant;O;O
effects;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
the;O;O
warfarin;B-group;B-DDI-DrugBank.d171.s1.e0
anticoagulants;I-group;I-DDI-DrugBank.d171.s1.e0
,;O;O
DDI-DrugBank.d171.s2;;
therefore;O;O
,;O;O
close;O;O
monitoring;O;O
of;O;O
prothrombin;O;O
time;O;O
is;O;O
recommended;O;O
,;O;O
and;O;O
adjustment;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d171.s2.e0
dose;O;O
may;O;O
be;O;O
necessary;O;O
when;O;O
Tagamet;B-brand;B-DDI-DrugBank.d171.s2.e1
is;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d171.s3;;
Interaction;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d171.s3.e0
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d171.s3.e1
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d171.s3.e2
has;O;O
also;O;O
been;O;O
reported;O;O
to;O;O
produce;O;O
adverse;O;O
clinical;O;O
effects;O;O
.;O;O
DDI-DrugBank.d171.s4;;
However;O;O
,;O;O
a;O;O
crossover;O;O
study;O;O
in;O;O
healthy;O;O
subjects;O;O
receiving;O;O
either;O;O
Tagamet;B-brand;B-DDI-DrugBank.d171.s4.e0
300;O;O
mg;O;O
q.i.d;O;O
.;O;O
or;O;O
800;O;O
mg;O;O
h.s;O;O
.;O;O
concomitantly;O;O
with;O;O
a;O;O
300;O;O
mg;O;O
b.i.d;O;O
.;O;O
dosage;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d171.s4.e1
(;O;O
Theo;B-brand;B-DDI-DrugBank.d171.s4.e2
-;I-brand;I-DDI-DrugBank.d171.s4.e2
Dur;I-brand;I-DDI-DrugBank.d171.s4.e2
,;O;O
Key;O;O
Pharmaceuticals;O;O
,;O;O
Inc.;O;O
);O;O
demonstrated;O;O
less;O;O
alteration;O;O
in;O;O
steady;O;O
-;O;O
state;O;O
theophylline;B-drug;B-DDI-DrugBank.d171.s4.e3
peak;O;O
serum;O;O
levels;O;O
with;O;O
the;O;O
800;O;O
mg;O;O
h.s;O;O
.;O;O
regimen;O;O
,;O;O
particularly;O;O
in;O;O
subjects;O;O
aged;O;O
54;O;O
years;O;O
and;O;O
older;O;O
.;O;O
DDI-DrugBank.d171.s5;;
Data;O;O
beyond;O;O
10;O;O
days;O;O
are;O;O
not;O;O
available;O;O
.;O;O
DDI-DrugBank.d171.s6;;
(;O;O
Note;O;O
:;O;O
All;O;O
patients;O;O
receiving;O;O
theophylline;B-drug;B-DDI-DrugBank.d171.s6.e0
should;O;O
be;O;O
monitored;O;O
appropriately;O;O
,;O;O
regardless;O;O
of;O;O
concomitant;O;O
drug;O;O
therapy;O;O
.;O;O
);O;O
DDI-DrugBank.d171.s7;;
Dosage;O;O
of;O;O
the;O;O
drugs;O;O
mentioned;O;O
above;O;O
and;O;O
other;O;O
similarly;O;O
metabolized;O;O
drugs;O;O
,;O;O
particularly;O;O
those;O;O
of;O;O
low;O;O
therapeutic;O;O
ratio;O;O
or;O;O
in;O;O
patients;O;O
with;O;O
renal;O;O
and/or;O;O
hepatic;O;O
impairment;O;O
,;O;O
may;O;O
require;O;O
adjustment;O;O
when;O;O
starting;O;O
or;O;O
stopping;O;O
concomitantly;O;O
administered;O;O
Tagamet;B-brand;B-DDI-DrugBank.d171.s7.e0
to;O;O
maintain;O;O
optimum;O;O
therapeutic;O;O
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d171.s8;;
Alteration;O;O
of;O;O
pH;O;O
may;O;O
affect;O;O
absorption;O;O
of;O;O
certain;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d171.s8.e0
);O;O
.;O;O
DDI-DrugBank.d171.s9;;
If;O;O
these;O;O
products;O;O
are;O;O
needed;O;O
,;O;O
they;O;O
should;O;O
be;O;O
given;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
before;O;O
cimetidine;B-drug;B-DDI-DrugBank.d171.s9.e0
administration;O;O
.;O;O
DDI-DrugBank.d171.s10;;
Additional;O;O
clinical;O;O
experience;O;O
may;O;O
reveal;O;O
other;O;O
drugs;O;O
affected;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
Tagamet;B-brand;B-DDI-DrugBank.d171.s10.e0
.;O;O
DDI-DrugBank.d512.s0;;
and/or;O;O
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
See;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
,;O;O
Pharmacokinetics;O;O
and;O;O
Drug;O;O
Interactions;O;O
.;O;O
DDI-DrugBank.d512.s1;;
Effect;O;O
of;O;O
Sensipar;B-brand;B-DDI-DrugBank.d512.s1.e0
on;O;O
other;O;O
drugs;O;O
:;O;O
Drugs;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
(;O;O
CYP2D6;O;O
);O;O
:;O;O
Sensipar;B-brand;B-DDI-DrugBank.d512.s1.e1
is;O;O
a;O;O
strong;O;O
in;O;O
vitro;O;O
inhibitor;O;O
of;O;O
CYP2D6;O;O
.;O;O
DDI-DrugBank.d512.s2;;
Therefore;O;O
,;O;O
dose;O;O
adjustments;O;O
of;O;O
concomitant;O;O
medications;O;O
that;O;O
are;O;O
predominantly;O;O
metabolized;O;O
by;O;O
CYP2D6;O;O
and;O;O
have;O;O
a;O;O
narrow;O;O
therapeutic;O;O
index;O;O
(;O;O
e.g.;O;O
,;O;O
flecainide;B-drug;B-DDI-DrugBank.d512.s2.e0
,;O;O
vinblastine;B-drug;B-DDI-DrugBank.d512.s2.e1
,;O;O
thioridazine;B-drug;B-DDI-DrugBank.d512.s2.e2
and;O;O
most;O;O
tricyclic;B-group;B-DDI-DrugBank.d512.s2.e3
antidepressants;I-group;I-DDI-DrugBank.d512.s2.e3
);O;O
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d512.s3;;
Amitriptyline;B-drug;B-DDI-DrugBank.d512.s3.e0
:;O;O
Concurrent;O;O
administration;O;O
of;O;O
25;O;O
mg;O;O
or;O;O
100;O;O
mg;O;O
cinacalcet;B-drug;B-DDI-DrugBank.d512.s3.e1
with;O;O
50;O;O
mg;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d512.s3.e2
increased;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d512.s3.e3
exposure;O;O
and;O;O
nortriptyline;B-drug_n;B-DDI-DrugBank.d512.s3.e4
(;O;O
active;O;O
metabolite;O;O
);O;O
exposure;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
in;O;O
CYP2D6;O;O
extensive;O;O
metabolizers;O;O
.;O;O
DDI-DrugBank.d512.s4;;
Effect;O;O
of;O;O
other;O;O
drugs;O;O
on;O;O
Sensipar;B-brand;B-DDI-DrugBank.d512.s4.e0
:;O;O
Sensipar;B-brand;B-DDI-DrugBank.d512.s4.e1
is;O;O
metabolized;O;O
by;O;O
multiple;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
,;O;O
primarily;O;O
CYP3A4;O;O
,;O;O
CYP2D6;O;O
,;O;O
and;O;O
CYP1A2;O;O
.;O;O
DDI-DrugBank.d512.s5;;
Ketoconazole;B-drug;B-DDI-DrugBank.d512.s5.e0
:;O;O
Sensipar;B-brand;B-DDI-DrugBank.d512.s5.e1
is;O;O
metabolized;O;O
in;O;O
part;O;O
by;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d512.s6;;
Co;O;O
-;O;O
administration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d512.s6.e0
,;O;O
a;O;O
strong;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
,;O;O
increased;O;O
cinacalcet;B-drug;B-DDI-DrugBank.d512.s6.e1
exposure;O;O
following;O;O
a;O;O
single;O;O
90;O;O
mg;O;O
dose;O;O
of;O;O
Sensipar;B-brand;B-DDI-DrugBank.d512.s6.e2
by;O;O
2.3;O;O
fold;O;O
.;O;O
DDI-DrugBank.d512.s7;;
Dose;O;O
adjustment;O;O
of;O;O
Sensipar;B-brand;B-DDI-DrugBank.d512.s7.e0
may;O;O
be;O;O
required;O;O
and;O;O
PTH;O;O
and;O;O
serum;O;O
calcium;O;O
concentrations;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
if;O;O
a;O;O
patient;O;O
initiates;O;O
or;O;O
discontinues;O;O
therapy;O;O
with;O;O
a;O;O
strong;O;O
CYP3A4;O;O
inhibitor;O;O
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d512.s7.e1
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d512.s7.e2
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d512.s7.e3
,;O;O
DDI-DrugBank.d512.s8;;
see;O;O
DOSAGE;O;O
AND;O;O
ADMINISTRATION;O;O
);O;O
.;O;O
DDI-DrugBank.d562.s0;;
Elevated;O;O
plasma;O;O
levels;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d562.s0.e0
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
some;O;O
quinolones;B-group;B-DDI-DrugBank.d562.s0.e1
.;O;O
DDI-DrugBank.d562.s1;;
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d562.s1.e0
-;O;O
related;O;O
side;O;O
-;O;O
effects;O;O
in;O;O
patients;O;O
on;O;O
concomitant;O;O
theophylline;B-drug;B-DDI-DrugBank.d562.s1.e1
-;O;O
quinolone;B-group;B-DDI-DrugBank.d562.s1.e2
therapy;O;O
.;O;O
DDI-DrugBank.d562.s2;;
Therefore;O;O
,;O;O
monitoring;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d562.s2.e0
plasma;O;O
levels;O;O
should;O;O
be;O;O
considered;O;O
and;O;O
dosage;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d562.s2.e1
adjusted;O;O
as;O;O
required;O;O
.;O;O
DDI-DrugBank.d562.s3;;
Quinolones;B-group;B-DDI-DrugBank.d562.s3.e0
have;O;O
also;O;O
been;O;O
shown;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d562.s3.e1
.;O;O
DDI-DrugBank.d562.s4;;
This;O;O
may;O;O
lead;O;O
to;O;O
reduced;O;O
clearance;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d562.s4.e0
and;O;O
a;O;O
prolongation;O;O
of;O;O
its;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d562.s5;;
Although;O;O
this;O;O
interaction;O;O
has;O;O
not;O;O
been;O;O
reported;O;O
with;O;O
cinoxacin;B-drug;B-DDI-DrugBank.d562.s5.e0
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
cinoxacin;B-drug;B-DDI-DrugBank.d562.s5.e1
is;O;O
given;O;O
concomitantly;O;O
with;O;O
caffeine;B-drug;B-DDI-DrugBank.d562.s5.e2
-;O;O
containing;O;O
products;O;O
.;O;O
DDI-DrugBank.d562.s6;;
Antacids;B-group;B-DDI-DrugBank.d562.s6.e0
or;O;O
sucralfate;B-drug;B-DDI-DrugBank.d562.s6.e1
substantially;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
some;O;O
quinolones;B-group;B-DDI-DrugBank.d562.s6.e2
,;O;O
resulting;O;O
in;O;O
low;O;O
urine;O;O
levels;O;O
.;O;O
DDI-DrugBank.d562.s7;;
Also;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d562.s7.e0
with;O;O
products;O;O
containing;O;O
iron;B-drug;B-DDI-DrugBank.d562.s7.e1
,;O;O
multivitamins;B-group;B-DDI-DrugBank.d562.s7.e2
containing;O;O
zinc;B-drug;B-DDI-DrugBank.d562.s7.e3
,;O;O
or;O;O
Videx;B-brand;B-DDI-DrugBank.d562.s7.e4
(;O;O
didanosine;B-drug;B-DDI-DrugBank.d562.s7.e5
);O;O
chewable;O;O
/;O;O
buffered;O;O
tablets;O;O
or;O;O
the;O;O
pediatric;O;O
powder;O;O
for;O;O
oral;O;O
solution;O;O
may;O;O
result;O;O
in;O;O
low;O;O
urine;O;O
levels;O;O
.;O;O
DDI-DrugBank.d562.s8;;
Quinolones;B-group;B-DDI-DrugBank.d562.s8.e0
,;O;O
including;O;O
cinoxacin;B-drug;B-DDI-DrugBank.d562.s8.e1
,;O;O
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d562.s8.e2
,;O;O
such;O;O
as;O;O
warfarin;B-drug;B-DDI-DrugBank.d562.s8.e3
or;O;O
its;O;O
derivatives;O;O
.;O;O
DDI-DrugBank.d562.s9;;
When;O;O
these;O;O
products;O;O
are;O;O
administered;O;O
concomitantly;O;O
,;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
coagulation;O;O
tests;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d562.s10;;
Seizures;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
taking;O;O
another;O;O
quinolone;B-group;B-DDI-DrugBank.d562.s10.e0
class;I-group;I-DDI-DrugBank.d562.s10.e0
antimicrobial;I-group;I-DDI-DrugBank.d562.s10.e0
and;O;O
the;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d562.s10.e1
anti;I-group;I-DDI-DrugBank.d562.s10.e1
-;I-group;I-DDI-DrugBank.d562.s10.e1
inflammatory;I-group;I-DDI-DrugBank.d562.s10.e1
drug;I-group;I-DDI-DrugBank.d562.s10.e1
fenbufen;I-drug;I-DDI-DrugBank.d562.s10.e2
concurrently;O;O
.;O;O
DDI-DrugBank.d562.s11;;
Animal;O;O
studies;O;O
also;O;O
suggest;O;O
an;O;O
increased;O;O
potential;O;O
for;O;O
seizures;O;O
when;O;O
these;O;O
2;O;O
drugs;O;O
are;O;O
given;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d562.s12;;
Fenbufen;B-drug;B-DDI-DrugBank.d562.s12.e0
is;O;O
not;O;O
approved;O;O
in;O;O
the;O;O
United;O;O
States;O;O
at;O;O
this;O;O
time;O;O
.;O;O
DDI-DrugBank.d562.s13;;
Physicians;O;O
are;O;O
provided;O;O
this;O;O
information;O;O
to;O;O
increase;O;O
awareness;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
serious;O;O
interactions;O;O
when;O;O
cinoxacin;B-drug;B-DDI-DrugBank.d562.s13.e0
and;O;O
certain;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d562.s13.e1
anti;I-group;I-DDI-DrugBank.d562.s13.e1
-;I-group;I-DDI-DrugBank.d562.s13.e1
inflammatory;I-group;I-DDI-DrugBank.d562.s13.e1
agents;I-group;I-DDI-DrugBank.d562.s13.e1
are;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d562.s14;;
Elevated;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d562.s14.e0
serum;O;O
levels;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d562.s14.e1
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d562.s14.e2
.;O;O
DDI-DrugBank.d123.s0;;
Some;O;O
quinolones;B-group;B-DDI-DrugBank.d123.s0.e0
,;O;O
including;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s0.e1
,;O;O
have;O;O
also;O;O
been;O;O
shown;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d123.s0.e2
.;O;O
DDI-DrugBank.d123.s1;;
This;O;O
may;O;O
lead;O;O
to;O;O
reduced;O;O
clearance;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d123.s1.e0
and;O;O
a;O;O
prolongation;O;O
of;O;O
its;O;O
serum;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d123.s2;;
Some;O;O
quinolones;B-group;B-DDI-DrugBank.d123.s2.e0
,;O;O
including;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s2.e1
,;O;O
have;O;O
been;O;O
associated;O;O
with;O;O
transient;O;O
elevations;O;O
in;O;O
serum;O;O
creatinine;O;O
in;O;O
patients;O;O
receiving;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d123.s2.e2
concomitantly;O;O
.;O;O
DDI-DrugBank.d123.s3;;
Glyburide;B-drug;B-DDI-DrugBank.d123.s3.e0
:;O;O
The;O;O
concomitant;O;O
administration;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s3.e1
with;O;O
the;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d123.s3.e2
glyburide;I-drug;I-DDI-DrugBank.d123.s3.e3
has;O;O
,;O;O
on;O;O
rare;O;O
occasions;O;O
,;O;O
resulted;O;O
in;O;O
severe;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d123.s4;;
Histamine;B-group;B-DDI-DrugBank.d123.s4.e0
H2;I-group;I-DDI-DrugBank.d123.s4.e0
-;I-group;I-DDI-DrugBank.d123.s4.e0
receptor;I-group;I-DDI-DrugBank.d123.s4.e0
antagonists;I-group;I-DDI-DrugBank.d123.s4.e0
:;O;O
Histamine;B-group;B-DDI-DrugBank.d123.s4.e1
H2;I-group;I-DDI-DrugBank.d123.s4.e1
-;I-group;I-DDI-DrugBank.d123.s4.e1
receptor;I-group;I-DDI-DrugBank.d123.s4.e1
antagonists;I-group;I-DDI-DrugBank.d123.s4.e1
appear;O;O
to;O;O
have;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
bioavailability;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s4.e2
.;O;O
DDI-DrugBank.d123.s5;;
Methotrexate;B-drug;B-DDI-DrugBank.d123.s5.e0
Renal;O;O
tubular;O;O
transport;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d123.s5.e1
may;O;O
be;O;O
inhibited;O;O
by;O;O
concomitant;O;O
administration;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s5.e2
,;O;O
potentially;O;O
leading;O;O
to;O;O
increased;O;O
plasma;O;O
levels;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d123.s5.e3
.;O;O
DDI-DrugBank.d123.s6;;
This;O;O
might;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d123.s6.e0
toxic;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d123.s7;;
Therefore;O;O
,;O;O
patients;O;O
under;O;O
methotrexate;B-drug;B-DDI-DrugBank.d123.s7.e0
therapy;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
when;O;O
concomitant;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s7.e1
therapy;O;O
is;O;O
indicated;O;O
.;O;O
DDI-DrugBank.d123.s8;;
Multivalent;O;O
Cation;O;O
-;O;O
Containing;O;O
Products;O;O
:;O;O
Concurrent;O;O
administration;O;O
of;O;O
a;O;O
quinolone;B-group;B-DDI-DrugBank.d123.s8.e0
,;O;O
including;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s8.e1
,;O;O
with;O;O
multivalent;O;O
cation;O;O
-;O;O
containing;O;O
products;O;O
such;O;O
as;O;O
magnesium;B-drug;B-DDI-DrugBank.d123.s8.e2
or;O;O
aluminum;B-drug;B-DDI-DrugBank.d123.s8.e3
antacids;I-group;I-DDI-DrugBank.d123.s8.e4
,;O;O
sucralfate;B-drug;B-DDI-DrugBank.d123.s8.e5
,;O;O
VIDEX;B-brand;B-DDI-DrugBank.d123.s8.e6
chewable;O;O
/;O;O
buffered;O;O
tablets;O;O
or;O;O
pediatric;O;O
powder;O;O
,;O;O
or;O;O
products;O;O
containing;O;O
calcium;B-drug;B-DDI-DrugBank.d123.s8.e7
,;O;O
iron;B-drug;B-DDI-DrugBank.d123.s8.e8
,;O;O
or;O;O
zinc;B-drug;B-DDI-DrugBank.d123.s8.e9
may;O;O
substantially;O;O
decrease;O;O
the;O;O
absorption;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s8.e10
,;O;O
resulting;O;O
in;O;O
serum;O;O
and;O;O
urine;O;O
levels;O;O
considerably;O;O
lower;O;O
than;O;O
desired;O;O
.;O;O
DDI-DrugBank.d123.s9;;
Proquin;B-brand;B-DDI-DrugBank.d123.s9.e0
XR;I-brand;I-DDI-DrugBank.d123.s9.e0
should;O;O
be;O;O
administered;O;O
at;O;O
least;O;O
4;O;O
hours;O;O
before;O;O
or;O;O
2;O;O
hours;O;O
after;O;O
these;O;O
products;O;O
.;O;O
DDI-DrugBank.d123.s10;;
This;O;O
time;O;O
window;O;O
is;O;O
different;O;O
than;O;O
for;O;O
other;O;O
oral;O;O
formulations;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s10.e0
,;O;O
which;O;O
are;O;O
usually;O;O
administered;O;O
2;O;O
hours;O;O
before;O;O
or;O;O
6;O;O
hours;O;O
after;O;O
antacids;B-group;B-DDI-DrugBank.d123.s10.e1
.;O;O
DDI-DrugBank.d123.s11;;
Non;B-group;B-DDI-DrugBank.d123.s11.e0
-;I-group;I-DDI-DrugBank.d123.s11.e0
steroidal;I-group;I-DDI-DrugBank.d123.s11.e0
anti;I-group;I-DDI-DrugBank.d123.s11.e0
-;I-group;I-DDI-DrugBank.d123.s11.e0
inflammatory;I-group;I-DDI-DrugBank.d123.s11.e0
drugs;I-group;I-DDI-DrugBank.d123.s11.e0
(;O;O
but;O;O
not;O;O
aspirin;B-brand;B-DDI-DrugBank.d123.s11.e1
);O;O
:;O;O
These;O;O
drugs;O;O
in;O;O
combination;O;O
with;O;O
very;O;O
high;O;O
doses;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d123.s11.e2
have;O;O
been;O;O
shown;O;O
to;O;O
provoke;O;O
convulsions;O;O
in;O;O
pre;O;O
-;O;O
clinical;O;O
studies;O;O
.;O;O
DDI-DrugBank.d123.s12;;
Omeprazole;B-drug;B-DDI-DrugBank.d123.s12.e0
:;O;O
The;O;O
rate;O;O
and;O;O
extent;O;O
of;O;O
absorption;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s12.e1
was;O;O
bioequivalent;O;O
when;O;O
Proquin;B-brand;B-DDI-DrugBank.d123.s12.e2
XR;I-brand;I-DDI-DrugBank.d123.s12.e2
was;O;O
given;O;O
alone;O;O
or;O;O
when;O;O
Proquin;B-brand;B-DDI-DrugBank.d123.s12.e3
XR;I-brand;I-DDI-DrugBank.d123.s12.e3
was;O;O
given;O;O
2;O;O
hours;O;O
after;O;O
omeprazole;B-drug;B-DDI-DrugBank.d123.s12.e4
at;O;O
the;O;O
dose;O;O
that;O;O
maximally;O;O
suppresses;O;O
gastric;O;O
acid;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d123.s13;;
Omeprazole;B-drug;B-DDI-DrugBank.d123.s13.e0
should;O;O
be;O;O
taken;O;O
as;O;O
directed;O;O
and;O;O
Proquin;B-brand;B-DDI-DrugBank.d123.s13.e1
XR;I-brand;I-DDI-DrugBank.d123.s13.e1
should;O;O
be;O;O
taken;O;O
with;O;O
a;O;O
main;O;O
meal;O;O
of;O;O
the;O;O
day;O;O
,;O;O
preferably;O;O
the;O;O
evening;O;O
meal;O;O
..;O;O
DDI-DrugBank.d123.s14;;
Phenytoin;B-drug;B-DDI-DrugBank.d123.s14.e0
:;O;O
Altered;O;O
serum;O;O
levels;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d123.s14.e1
(;O;O
increased;O;O
and;O;O
decreased;O;O
);O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s14.e2
.;O;O
DDI-DrugBank.d123.s15;;
Probenecid;B-drug;B-DDI-DrugBank.d123.s15.e0
:;O;O
Probenecid;B-drug;B-DDI-DrugBank.d123.s15.e1
interferes;O;O
with;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s15.e2
and;O;O
produces;O;O
an;O;O
increase;O;O
in;O;O
the;O;O
level;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s15.e3
in;O;O
serum;O;O
.;O;O
DDI-DrugBank.d123.s16;;
Theophylline;B-drug;B-DDI-DrugBank.d123.s16.e0
:;O;O
As;O;O
with;O;O
some;O;O
other;O;O
quinolones;B-group;B-DDI-DrugBank.d123.s16.e1
,;O;O
concurrent;O;O
administration;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d123.s16.e2
with;O;O
theophylline;B-drug;B-DDI-DrugBank.d123.s16.e3
may;O;O
lead;O;O
to;O;O
elevated;O;O
serum;O;O
concentrations;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d123.s16.e4
and;O;O
prolongation;O;O
of;O;O
its;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d123.s17;;
This;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
risk;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d123.s17.e0
-;O;O
related;O;O
adverse;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d123.s18;;
If;O;O
concomitant;O;O
use;O;O
can;O;O
not;O;O
be;O;O
avoided;O;O
,;O;O
serum;O;O
levels;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d123.s18.e0
should;O;O
be;O;O
monitored;O;O
and;O;O
dosage;O;O
adjustments;O;O
made;O;O
as;O;O
appropriate;O;O
.;O;O
DDI-DrugBank.d123.s19;;
Warfarin;B-drug;B-DDI-DrugBank.d123.s19.e0
:;O;O
Quinolones;B-group;B-DDI-DrugBank.d123.s19.e1
have;O;O
been;O;O
reported;O;O
to;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
the;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d123.s19.e2
warfarin;I-drug;I-DDI-DrugBank.d123.s19.e3
or;O;O
its;O;O
derivatives;O;O
.;O;O
DDI-DrugBank.d123.s20;;
When;O;O
these;O;O
products;O;O
are;O;O
administered;O;O
concomitantly;O;O
,;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
coagulation;O;O
tests;O;O
should;O;O
be;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d237.s0;;
Cisapride;B-drug;B-DDI-DrugBank.d237.s0.e0
is;O;O
metabolized;O;O
mainly;O;O
via;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
.;O;O
DDI-DrugBank.d237.s1;;
In;O;O
some;O;O
cases;O;O
where;O;O
serious;O;O
ventricular;O;O
arrhythmias;O;O
,;O;O
QT;O;O
prolongation;O;O
,;O;O
and;O;O
torsades;O;O
de;O;O
pointes;O;O
have;O;O
occurred;O;O
when;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s1.e0
was;O;O
taken;O;O
in;O;O
conjunction;O;O
with;O;O
one;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
inhibitors;O;O
,;O;O
elevated;O;O
blood;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s1.e1
levels;O;O
were;O;O
noted;O;O
at;O;O
the;O;O
time;O;O
of;O;O
the;O;O
QT;O;O
prolongation;O;O
.;O;O
DDI-DrugBank.d237.s2;;
Antibiotics;B-group;B-DDI-DrugBank.d237.s2.e0
:;O;O
In;O;O
vitro;O;O
and/or;O;O
in;O;O
vivo;O;O
data;O;O
show;O;O
that;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d237.s2.e1
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d237.s2.e2
,;O;O
and;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d237.s2.e3
markedly;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s2.e4
,;O;O
which;O;O
can;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s2.e5
levels;O;O
and;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
on;O;O
the;O;O
ECG;O;O
.;O;O
DDI-DrugBank.d237.s3;;
Anticholinergics;B-group;B-DDI-DrugBank.d237.s3.e0
:;O;O
Concurrent;O;O
administration;O;O
of;O;O
certain;O;O
anticholinergic;B-group;B-DDI-DrugBank.d237.s3.e1
compounds;I-group;I-DDI-DrugBank.d237.s3.e1
,;O;O
such;O;O
as;O;O
belladonna;B-group;B-DDI-DrugBank.d237.s3.e2
alkaloids;I-group;I-DDI-DrugBank.d237.s3.e2
and;O;O
dicyclomine;B-drug;B-DDI-DrugBank.d237.s3.e3
,;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
compromise;O;O
the;O;O
beneficial;O;O
effects;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s3.e4
.;O;O
DDI-DrugBank.d237.s4;;
Anticoagulants;B-group;B-DDI-DrugBank.d237.s4.e0
(;O;O
Oral;O;O
);O;O
:;O;O
In;O;O
patients;O;O
receiving;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d237.s4.e1
,;O;O
the;O;O
coagulation;O;O
times;O;O
were;O;O
increased;O;O
in;O;O
some;O;O
cases;O;O
.;O;O
DDI-DrugBank.d237.s5;;
It;O;O
is;O;O
advisable;O;O
to;O;O
check;O;O
coagulation;O;O
time;O;O
within;O;O
the;O;O
first;O;O
few;O;O
days;O;O
after;O;O
the;O;O
start;O;O
and;O;O
discontinuation;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s5.e0
therapy;O;O
,;O;O
with;O;O
an;O;O
appropriate;O;O
adjustment;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d237.s5.e1
dose;O;O
,;O;O
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d237.s6;;
Antidepressants;B-group;B-DDI-DrugBank.d237.s6.e0
:;O;O
In;O;O
vitro;O;O
data;O;O
indicate;O;O
that;O;O
nefazodone;B-drug;B-DDI-DrugBank.d237.s6.e1
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s6.e2
,;O;O
which;O;O
can;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s6.e3
levels;O;O
and;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
on;O;O
the;O;O
ECG;O;O
.;O;O
DDI-DrugBank.d237.s7;;
Antifungals;B-group;B-DDI-DrugBank.d237.s7.e0
:;O;O
In;O;O
vitro;O;O
and/or;O;O
in;O;O
vivo;O;O
data;O;O
indicate;O;O
that;O;O
fluconazole;B-drug;B-DDI-DrugBank.d237.s7.e1
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d237.s7.e2
,;O;O
and;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d237.s7.e3
markedly;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s7.e4
,;O;O
which;O;O
can;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s7.e5
levels;O;O
and;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
on;O;O
the;O;O
ECG;O;O
.;O;O
DDI-DrugBank.d237.s8;;
Human;O;O
pharmacokinetic;O;O
data;O;O
indicate;O;O
that;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d237.s8.e0
markedly;O;O
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s8.e1
,;O;O
resulting;O;O
in;O;O
a;O;O
mean;O;O
eight;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
AUC;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s8.e2
.;O;O
DDI-DrugBank.d237.s9;;
A;O;O
study;O;O
in;O;O
14;O;O
normal;O;O
male;O;O
and;O;O
female;O;O
volunteers;O;O
suggests;O;O
that;O;O
coadministration;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s9.e0
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d237.s9.e1
can;O;O
result;O;O
in;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
on;O;O
the;O;O
ECG;O;O
.;O;O
DDI-DrugBank.d237.s10;;
H2;B-group;B-DDI-DrugBank.d237.s10.e0
Receptor;I-group;I-DDI-DrugBank.d237.s10.e0
Antagonists;I-group;I-DDI-DrugBank.d237.s10.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d237.s10.e1
coadministration;O;O
leads;O;O
to;O;O
an;O;O
increased;O;O
peak;O;O
plasma;O;O
concentration;O;O
and;O;O
AUC;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s10.e2
,;O;O
there;O;O
is;O;O
no;O;O
effect;O;O
on;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s10.e3
absorption;O;O
when;O;O
it;O;O
is;O;O
coadministered;O;O
with;O;O
ranitidine;B-drug;B-DDI-DrugBank.d237.s10.e4
.;O;O
DDI-DrugBank.d237.s11;;
The;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d237.s11.e0
and;O;O
ranitidine;B-drug;B-DDI-DrugBank.d237.s11.e1
is;O;O
accelerated;O;O
when;O;O
they;O;O
are;O;O
coadministered;O;O
with;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s11.e2
.;O;O
DDI-DrugBank.d237.s12;;
Protease;B-group;B-DDI-DrugBank.d237.s12.e0
Inhibitors;I-group;I-DDI-DrugBank.d237.s12.e0
:;O;O
In;O;O
vitro;O;O
data;O;O
indicate;O;O
that;O;O
indinavir;B-drug;B-DDI-DrugBank.d237.s12.e1
and;O;O
ritonavir;B-drug;B-DDI-DrugBank.d237.s12.e2
markedly;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s12.e3
which;O;O
can;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s12.e4
levels;O;O
and;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
on;O;O
the;O;O
ECG;O;O
.;O;O
DDI-DrugBank.d237.s13;;
Other;O;O
:;O;O
Coadministration;O;O
of;O;O
grapefruit;O;O
juice;O;O
with;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s13.e0
increases;O;O
the;O;O
bioavailability;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s13.e1
and;O;O
concomitant;O;O
use;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d237.s14;;
Cisapride;B-drug;B-DDI-DrugBank.d237.s14.e0
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
with;O;O
other;O;O
drugs;O;O
known;O;O
to;O;O
prolong;O;O
the;O;O
QT;O;O
interval;O;O
:;O;O
certain;O;O
antiarrhythmics;B-group;B-DDI-DrugBank.d237.s14.e1
,;O;O
including;O;O
those;O;O
of;O;O
Class;O;O
IA;O;O
(;O;O
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d237.s14.e2
and;O;O
procainamide;B-drug;B-DDI-DrugBank.d237.s14.e3
);O;O
and;O;O
Class;O;O
III;O;O
(;O;O
such;O;O
as;O;O
sotalol;B-drug;B-DDI-DrugBank.d237.s14.e4
);O;O
,;O;O
DDI-DrugBank.d237.s15;;
tricyclic;B-group;B-DDI-DrugBank.d237.s15.e0
antidepressants;I-group;I-DDI-DrugBank.d237.s15.e0
(;O;O
such;O;O
as;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d237.s15.e1
);O;O
,;O;O
DDI-DrugBank.d237.s16;;
certain;O;O
tetracyclic;B-group;B-DDI-DrugBank.d237.s16.e0
antidepressants;I-group;I-DDI-DrugBank.d237.s16.e0
(;O;O
such;O;O
as;O;O
maprotiline;B-drug;B-DDI-DrugBank.d237.s16.e1
);O;O
,;O;O
DDI-DrugBank.d237.s17;;
certain;O;O
antipsychotic;B-group;B-DDI-DrugBank.d237.s17.e0
medications;I-group;I-DDI-DrugBank.d237.s17.e0
(;O;O
such;O;O
as;O;O
sertindole;B-drug;B-DDI-DrugBank.d237.s17.e1
);O;O
,;O;O
DDI-DrugBank.d237.s18;;
astemizole;B-drug;B-DDI-DrugBank.d237.s18.e0
,;O;O
bepridil;B-drug;B-DDI-DrugBank.d237.s18.e1
,;O;O
sparfloxacin;B-drug;B-DDI-DrugBank.d237.s18.e2
,;O;O
and;O;O
terodiline;B-drug;B-DDI-DrugBank.d237.s18.e3
.;O;O
DDI-DrugBank.d237.s19;;
The;O;O
preceding;O;O
lists;O;O
of;O;O
drugs;O;O
are;O;O
not;O;O
comprehensive;O;O
.;O;O
DDI-DrugBank.d237.s20;;
The;O;O
acceleration;O;O
of;O;O
gastric;O;O
emptying;O;O
by;O;O
cisapride;B-drug;B-DDI-DrugBank.d237.s20.e0
could;O;O
affect;O;O
the;O;O
rate;O;O
of;O;O
absorption;O;O
of;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d237.s21;;
Patients;O;O
receiving;O;O
narrow;O;O
therapeutic;O;O
ratio;O;O
drugs;O;O
or;O;O
other;O;O
drugs;O;O
that;O;O
require;O;O
careful;O;O
titration;O;O
should;O;O
be;O;O
followed;O;O
closely;O;O
,;O;O
DDI-DrugBank.d237.s22;;
if;O;O
plasma;O;O
levels;O;O
are;O;O
being;O;O
monitored;O;O
,;O;O
they;O;O
should;O;O
be;O;O
reassessed;O;O
.;O;O
DDI-DrugBank.d60.s0;;
Administration;O;O
of;O;O
0.1;O;O
-;O;O
mg;O;O
/;O;O
kg;O;O
(;O;O
2;O;O
x;O;O
ED95;O;O
);O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s0.e0
at;O;O
10;O;O
%;O;O
or;O;O
95;O;O
%;O;O
recovery;O;O
following;O;O
an;O;O
intubating;O;O
dose;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d60.s0.e1
(;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
produced;O;O
95;O;O
%;O;O
neuromuscular;O;O
block;O;O
.;O;O
DDI-DrugBank.d60.s1;;
The;O;O
time;O;O
to;O;O
onset;O;O
of;O;O
maximum;O;O
block;O;O
following;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s1.e0
is;O;O
approximately;O;O
2;O;O
minutes;O;O
faster;O;O
with;O;O
prior;O;O
administration;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d60.s1.e1
.;O;O
DDI-DrugBank.d60.s2;;
Prior;O;O
administration;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d60.s2.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
duration;O;O
of;O;O
neuromuscular;O;O
block;O;O
following;O;O
initial;O;O
or;O;O
maintenance;O;O
bolus;O;O
doses;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s2.e1
.;O;O
DDI-DrugBank.d60.s3;;
Infusion;O;O
requirements;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s3.e0
in;O;O
patients;O;O
administered;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d60.s3.e1
prior;O;O
to;O;O
infusions;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s3.e2
were;O;O
comparable;O;O
to;O;O
or;O;O
slightly;O;O
greater;O;O
than;O;O
when;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d60.s3.e3
was;O;O
not;O;O
administered;O;O
.;O;O
DDI-DrugBank.d60.s4;;
The;O;O
use;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s4.e0
before;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d60.s4.e1
to;O;O
attenuate;O;O
some;O;O
of;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d60.s4.e2
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d60.s5;;
Although;O;O
not;O;O
studied;O;O
systematically;O;O
in;O;O
clinical;O;O
trials;O;O
,;O;O
no;O;O
drug;O;O
interactions;O;O
were;O;O
observed;O;O
when;O;O
vecuronium;B-drug;B-DDI-DrugBank.d60.s5.e0
,;O;O
pancuronium;B-drug;B-DDI-DrugBank.d60.s5.e1
,;O;O
or;O;O
atracurium;B-drug;B-DDI-DrugBank.d60.s5.e2
were;O;O
administered;O;O
following;O;O
varying;O;O
degrees;O;O
of;O;O
recovery;O;O
from;O;O
single;O;O
doses;O;O
or;O;O
infusions;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s5.e3
.;O;O
DDI-DrugBank.d60.s6;;
Isoflurane;B-drug;B-DDI-DrugBank.d60.s6.e0
or;O;O
enflurane;B-drug;B-DDI-DrugBank.d60.s6.e1
administered;O;O
with;O;O
nitrous;B-drug;B-DDI-DrugBank.d60.s6.e2
oxide;I-drug;I-DDI-DrugBank.d60.s6.e2
/;O;O
oxygen;B-drug;B-DDI-DrugBank.d60.s6.e3
to;O;O
achieve;O;O
1.25;O;O
MAC;O;O
[;O;O
Minimum;O;O
Alveolar;O;O
Concentration;O;O
];O;O
may;O;O
prolong;O;O
the;O;O
clinically;O;O
effective;O;O
duration;O;O
of;O;O
action;O;O
of;O;O
initial;O;O
and;O;O
maintenance;O;O
doses;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s6.e4
and;O;O
decrease;O;O
the;O;O
required;O;O
infusion;O;O
rate;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s6.e5
.;O;O
DDI-DrugBank.d60.s7;;
The;O;O
magnitude;O;O
of;O;O
these;O;O
effects;O;O
may;O;O
depend;O;O
on;O;O
the;O;O
duration;O;O
of;O;O
administration;O;O
of;O;O
the;O;O
volatile;O;O
agents;O;O
.;O;O
DDI-DrugBank.d60.s8;;
Fifteen;O;O
to;O;O
30;O;O
minutes;O;O
of;O;O
exposure;O;O
to;O;O
1.25;O;O
MAC;O;O
isoflurane;B-drug;B-DDI-DrugBank.d60.s8.e0
or;O;O
enflurane;B-drug;B-DDI-DrugBank.d60.s8.e1
had;O;O
minimal;O;O
effects;O;O
on;O;O
the;O;O
duration;O;O
of;O;O
action;O;O
of;O;O
initial;O;O
doses;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s8.e2
and;O;O
therefore;O;O
,;O;O
no;O;O
adjustment;O;O
to;O;O
the;O;O
initial;O;O
dose;O;O
should;O;O
be;O;O
necessary;O;O
when;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s8.e3
is;O;O
administered;O;O
shortly;O;O
after;O;O
initiation;O;O
of;O;O
volatile;O;O
agents;O;O
.;O;O
DDI-DrugBank.d60.s9;;
In;O;O
long;O;O
surgical;O;O
procedures;O;O
during;O;O
enflurane;B-drug;B-DDI-DrugBank.d60.s9.e0
or;O;O
isoflurane;B-drug;B-DDI-DrugBank.d60.s9.e1
anesthesia;O;O
,;O;O
less;O;O
frequent;O;O
maintenance;O;O
dosing;O;O
,;O;O
lower;O;O
maintenance;O;O
doses;O;O
,;O;O
or;O;O
reduced;O;O
infusion;O;O
rates;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s9.e2
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d60.s10;;
The;O;O
average;O;O
infusion;O;O
rate;O;O
requirement;O;O
may;O;O
be;O;O
decreased;O;O
by;O;O
as;O;O
much;O;O
as;O;O
30;O;O
%;O;O
to;O;O
40;O;O
%;O;O
.;O;O
DDI-DrugBank.d60.s11;;
In;O;O
clinical;O;O
studies;O;O
propofol;B-drug;B-DDI-DrugBank.d60.s11.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
duration;O;O
of;O;O
action;O;O
or;O;O
dosing;O;O
requirements;O;O
for;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s11.e1
.;O;O
DDI-DrugBank.d60.s12;;
Other;O;O
drugs;O;O
which;O;O
may;O;O
enhance;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d60.s12.e0
agents;I-group;I-DDI-DrugBank.d60.s12.e0
such;O;O
as;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s12.e1
include;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d60.s12.e2
(;O;O
e.;O;O
g.;O;O
,;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d60.s12.e3
,;O;O
tetracyclines;B-group;B-DDI-DrugBank.d60.s12.e4
,;O;O
bacitracin;B-drug;B-DDI-DrugBank.d60.s12.e5
,;O;O
polymyxins;B-group;B-DDI-DrugBank.d60.s12.e6
,;O;O
lincomycin;B-drug;B-DDI-DrugBank.d60.s12.e7
,;O;O
clindamycin;B-drug;B-DDI-DrugBank.d60.s12.e8
,;O;O
colistin;B-drug;B-DDI-DrugBank.d60.s12.e9
,;O;O
and;O;O
sodium;B-drug;B-DDI-DrugBank.d60.s12.e10
colistemethate;I-drug;I-DDI-DrugBank.d60.s12.e10
);O;O
,;O;O
magnesium;B-group;B-DDI-DrugBank.d60.s12.e11
salts;O;O
,;O;O
lithium;B-drug;B-DDI-DrugBank.d60.s12.e12
,;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d60.s12.e13
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d60.s12.e14
,;O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d60.s12.e15
.;O;O
DDI-DrugBank.d60.s13;;
Resistance;O;O
to;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d60.s13.e0
neuromuscular;I-group;I-DDI-DrugBank.d60.s13.e0
blocking;I-group;I-DDI-DrugBank.d60.s13.e0
agents;I-group;I-DDI-DrugBank.d60.s13.e0
has;O;O
been;O;O
demonstrated;O;O
in;O;O
patients;O;O
chronically;O;O
administered;O;O
phenytoin;B-drug;B-DDI-DrugBank.d60.s13.e1
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d60.s13.e2
.;O;O
DDI-DrugBank.d60.s14;;
While;O;O
the;O;O
effects;O;O
of;O;O
chronic;O;O
phenytoin;B-drug;B-DDI-DrugBank.d60.s14.e0
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d60.s14.e1
therapy;O;O
on;O;O
the;O;O
action;O;O
of;O;O
NIMBEX;B-brand;B-DDI-DrugBank.d60.s14.e2
are;O;O
unknown;O;O
,;O;O
slightly;O;O
shorter;O;O
durations;O;O
of;O;O
neuromuscular;O;O
block;O;O
may;O;O
be;O;O
anticipated;O;O
and;O;O
infusion;O;O
rate;O;O
requirements;O;O
may;O;O
be;O;O
higher;O;O
.;O;O
DDI-DrugBank.d60.s15;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
None;O;O
known;O;O
.;O;O
DDI-DrugBank.d145.s0;;
Plasma;O;O
levels;O;O
of;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d145.s0.e0
agents;I-group;I-DDI-DrugBank.d145.s0.e0
may;O;O
become;O;O
subtherapeutic;O;O
during;O;O
cisplatin;B-drug;B-DDI-DrugBank.d145.s0.e1
therapy;O;O
.;O;O
DDI-DrugBank.d472.s0;;
Central;B-group;B-DDI-DrugBank.d472.s0.e0
nervous;I-group;I-DDI-DrugBank.d472.s0.e0
system;I-group;I-DDI-DrugBank.d472.s0.e0
depressant;I-group;I-DDI-DrugBank.d472.s0.e0
(;O;O
CNS;O;O
);O;O
drugs;O;O
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d472.s0.e1
,;O;O
antidepressants;B-group;B-DDI-DrugBank.d472.s0.e2
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d472.s0.e3
,;O;O
antipsychotics;B-group;B-DDI-DrugBank.d472.s0.e4
,;O;O
blood;O;O
pressure;O;O
medications;O;O
(;O;O
reserpine;B-drug;B-DDI-DrugBank.d472.s0.e5
,;O;O
methyldopa;B-drug;B-DDI-DrugBank.d472.s0.e6
,;O;O
beta;B-group;B-DDI-DrugBank.d472.s0.e7
-;I-group;I-DDI-DrugBank.d472.s0.e7
blockers;I-group;I-DDI-DrugBank.d472.s0.e7
);O;O
,;O;O
motion;O;O
sickness;O;O
medications;O;O
,;O;O
muscle;B-group;B-DDI-DrugBank.d472.s0.e8
relaxants;I-group;I-DDI-DrugBank.d472.s0.e8
,;O;O
narcotics;B-group;B-DDI-DrugBank.d472.s0.e9
,;O;O
sedatives;B-group;B-DDI-DrugBank.d472.s0.e10
,;O;O
sleeping;O;O
pills;O;O
and;O;O
tranquilizers;B-group;B-DDI-DrugBank.d472.s0.e11
DDI-DrugBank.d134.s0;;
There;O;O
are;O;O
no;O;O
known;O;O
drug;O;O
interactions;O;O
with;O;O
LEUSTATIN;B-brand;B-DDI-DrugBank.d134.s0.e0
Injection;O;O
.;O;O
DDI-DrugBank.d134.s1;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
if;O;O
LEUSTATIN;B-brand;B-DDI-DrugBank.d134.s1.e0
Injection;O;O
is;O;O
administered;O;O
before;O;O
,;O;O
after;O;O
,;O;O
or;O;O
in;O;O
conjunction;O;O
with;O;O
other;O;O
drugs;O;O
known;O;O
to;O;O
cause;O;O
immunosuppression;O;O
or;O;O
myelosuppression;O;O
.;O;O
DDI-DrugBank.d419.s0;;
The;O;O
concurrent;O;O
administration;O;O
of;O;O
allopurinol;B-drug;B-DDI-DrugBank.d419.s0.e0
and;O;O
ampicillin;B-drug;B-DDI-DrugBank.d419.s0.e1
increases;O;O
substantially;O;O
the;O;O
incidence;O;O
of;O;O
rashes;O;O
in;O;O
patients;O;O
receiving;O;O
both;O;O
drugs;O;O
as;O;O
compared;O;O
to;O;O
patients;O;O
receiving;O;O
ampicillin;B-drug;B-DDI-DrugBank.d419.s0.e2
alone;O;O
.;O;O
DDI-DrugBank.d419.s1;;
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
this;O;O
potentiation;O;O
of;O;O
ampicillin;B-drug;B-DDI-DrugBank.d419.s1.e0
rashes;O;O
is;O;O
due;O;O
to;O;O
allopurinol;B-drug;B-DDI-DrugBank.d419.s1.e1
or;O;O
the;O;O
hyperuricemia;O;O
present;O;O
in;O;O
these;O;O
patients;O;O
.;O;O
DDI-DrugBank.d419.s2;;
In;O;O
controlled;O;O
clinical;O;O
trials;O;O
of;O;O
AUGMENTIN;B-brand;B-DDI-DrugBank.d419.s2.e0
XR;I-brand;I-DDI-DrugBank.d419.s2.e0
,;O;O
22;O;O
patients;O;O
received;O;O
concomitant;O;O
allopurinol;B-drug;B-DDI-DrugBank.d419.s2.e1
and;O;O
AUGMENTIN;B-brand;B-DDI-DrugBank.d419.s2.e2
XR;I-brand;I-DDI-DrugBank.d419.s2.e2
.;O;O
DDI-DrugBank.d419.s3;;
No;O;O
rashes;O;O
were;O;O
reported;O;O
in;O;O
these;O;O
patients;O;O
.;O;O
DDI-DrugBank.d419.s4;;
However;O;O
,;O;O
this;O;O
sample;O;O
size;O;O
is;O;O
too;O;O
small;O;O
to;O;O
allow;O;O
for;O;O
any;O;O
conclusions;O;O
to;O;O
be;O;O
drawn;O;O
regarding;O;O
the;O;O
risk;O;O
of;O;O
rashes;O;O
with;O;O
concomitant;O;O
AUGMENTIN;B-brand;B-DDI-DrugBank.d419.s4.e0
XR;I-brand;I-DDI-DrugBank.d419.s4.e0
and;O;O
allopurinol;B-drug;B-DDI-DrugBank.d419.s4.e1
use;O;O
.;O;O
DDI-DrugBank.d419.s5;;
In;O;O
common;O;O
with;O;O
other;O;O
broad;B-group;B-DDI-DrugBank.d419.s5.e0
-;I-group;I-DDI-DrugBank.d419.s5.e0
spectrum;I-group;I-DDI-DrugBank.d419.s5.e0
antibiotics;I-group;I-DDI-DrugBank.d419.s5.e0
,;O;O
AUGMENTIN;B-brand;B-DDI-DrugBank.d419.s5.e1
XR;I-brand;I-DDI-DrugBank.d419.s5.e1
may;O;O
reduce;O;O
the;O;O
efficacy;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d419.s5.e2
DDI-DrugBank.d309.s0;;
Additive;O;O
CNS;O;O
depression;O;O
may;O;O
occur;O;O
when;O;O
antihistamines;B-group;B-DDI-DrugBank.d309.s0.e0
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d309.s0.e1
depressants;I-group;I-DDI-DrugBank.d309.s0.e1
including;O;O
barbiturates;B-group;B-DDI-DrugBank.d309.s0.e2
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d309.s0.e3
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d309.s0.e4
.;O;O
DDI-DrugBank.d309.s1;;
Patients;O;O
receiving;O;O
antihistamines;B-group;B-DDI-DrugBank.d309.s1.e0
should;O;O
be;O;O
advised;O;O
against;O;O
the;O;O
concurrent;O;O
use;O;O
of;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d309.s1.e1
depressant;I-group;I-DDI-DrugBank.d309.s1.e1
drugs;I-group;I-DDI-DrugBank.d309.s1.e1
.;O;O
DDI-DrugBank.d309.s2;;
Monoamine;B-group;B-DDI-DrugBank.d309.s2.e0
oxidase;I-group;I-DDI-DrugBank.d309.s2.e0
(;I-group;I-DDI-DrugBank.d309.s2.e0
MAO;I-group;I-DDI-DrugBank.d309.s2.e0
);I-group;I-DDI-DrugBank.d309.s2.e0
inhibitors;I-group;I-DDI-DrugBank.d309.s2.e0
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d309.s2.e1
.;O;O
DDI-DrugBank.d322.s0;;
Amantadine;B-drug;B-DDI-DrugBank.d322.s0.e0
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d322.s0.e1
antidepressants;I-group;I-DDI-DrugBank.d322.s0.e1
,;O;O
and;O;O
MAOIs;B-group;B-DDI-DrugBank.d322.s0.e2
may;O;O
increase;O;O
anticholinergic;O;O
effect;O;O
of;O;O
clidinium;B-drug;B-DDI-DrugBank.d322.s0.e3
.;O;O
DDI-DrugBank.d322.s1;;
Clidinium;B-drug;B-DDI-DrugBank.d322.s1.e0
may;O;O
decrease;O;O
the;O;O
effect;O;O
of;O;O
phenothiazines;B-group;B-DDI-DrugBank.d322.s1.e1
,;O;O
levodopa;B-drug;B-DDI-DrugBank.d322.s1.e2
,;O;O
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d322.s1.e3
.;O;O
DDI-DrugBank.d256.s0;;
Clindamycin;B-drug;B-DDI-DrugBank.d256.s0.e0
has;O;O
been;O;O
shown;O;O
to;O;O
have;O;O
neuromuscular;O;O
blocking;O;O
properties;O;O
that;O;O
may;O;O
enhance;O;O
the;O;O
action;O;O
of;O;O
other;O;O
neuromuscular;B-group;B-DDI-DrugBank.d256.s0.e1
blocking;I-group;I-DDI-DrugBank.d256.s0.e1
agents;I-group;I-DDI-DrugBank.d256.s0.e1
.;O;O
DDI-DrugBank.d256.s1;;
Therefore;O;O
,;O;O
it;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
such;O;O
agents;O;O
.;O;O
DDI-DrugBank.d256.s2;;
Antagonism;O;O
has;O;O
been;O;O
demonstrated;O;O
between;O;O
clindamycin;B-drug;B-DDI-DrugBank.d256.s2.e0
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d256.s2.e1
in;O;O
vitro;O;O
.;O;O
DDI-DrugBank.d256.s3;;
Because;O;O
of;O;O
possible;O;O
clinical;O;O
significance;O;O
,;O;O
these;O;O
two;O;O
drugs;O;O
should;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d136.s0;;
Alcohol;B-drug;B-DDI-DrugBank.d136.s0.e0
(;O;O
increases;O;O
bioavailability;O;O
by;O;O
50;O;O
%;O;O
);O;O
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d136.s0.e1
,;O;O
and;O;O
valproates;O;O
.;O;O
DDI-DrugBank.d391.s0;;
No;O;O
separate;O;O
information;O;O
available;O;O
DDI-DrugBank.d473.s0;;
Although;O;O
no;O;O
clinical;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
to;O;O
date;O;O
,;O;O
on;O;O
the;O;O
basis;O;O
of;O;O
the;O;O
in;O;O
vitro;O;O
studies;O;O
,;O;O
cytochrome;O;O
p450;O;O
inhibitors;O;O
and;O;O
inducers;O;O
are;O;O
unlikely;O;O
to;O;O
affect;O;O
the;O;O
metabolism;O;O
of;O;O
clofarabine;B-drug;B-DDI-DrugBank.d473.s0.e0
.;O;O
DDI-DrugBank.d473.s1;;
The;O;O
effect;O;O
of;O;O
clofarabine;B-drug;B-DDI-DrugBank.d473.s1.e0
on;O;O
the;O;O
metabolism;O;O
of;O;O
cytochrome;O;O
p450;O;O
substrates;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d473.s2;;
Drug;O;O
/;O;O
Laboratory;O;O
Tests;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
known;O;O
clinically;O;O
significant;O;O
interactions;O;O
of;O;O
CLOLAR;B-brand;B-DDI-DrugBank.d473.s2.e0
with;O;O
other;O;O
medications;O;O
or;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d473.s3;;
No;O;O
formal;O;O
drug;O;O
/;O;O
laboratory;O;O
test;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
CLOLAR;B-brand;B-DDI-DrugBank.d473.s3.e0
.;O;O
DDI-DrugBank.d399.s0;;
Preliminary;O;O
data;O;O
which;O;O
suggest;O;O
that;O;O
dapsone;B-drug;B-DDI-DrugBank.d399.s0.e0
may;O;O
inhibit;O;O
the;O;O
anti;O;O
-;O;O
inflammatory;O;O
activity;O;O
of;O;O
Lamprene;B-brand;B-DDI-DrugBank.d399.s0.e1
have;O;O
not;O;O
been;O;O
confirmed;O;O
.;O;O
DDI-DrugBank.d399.s1;;
If;O;O
leprosy;O;O
-;O;O
associated;O;O
inflammatory;O;O
reactions;O;O
develop;O;O
in;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
dapsone;B-drug;B-DDI-DrugBank.d399.s1.e0
and;O;O
clofazimine;B-drug;B-DDI-DrugBank.d399.s1.e1
,;O;O
it;O;O
is;O;O
still;O;O
advisable;O;O
to;O;O
continue;O;O
treatment;O;O
with;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d12.s0;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
anticoagulants;B-group;B-DDI-DrugBank.d12.s0.e0
are;O;O
given;O;O
in;O;O
conjunction;O;O
with;O;O
Atromid;O;O
-;O;O
S.;O;O
DDI-DrugBank.d12.s1;;
Usually;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d12.s1.e0
should;O;O
be;O;O
reduced;O;O
by;O;O
one;O;O
-;O;O
half;O;O
(;O;O
depending;O;O
on;O;O
the;O;O
individual;O;O
case;O;O
);O;O
to;O;O
maintain;O;O
the;O;O
prothrombin;O;O
time;O;O
at;O;O
the;O;O
desired;O;O
level;O;O
to;O;O
prevent;O;O
bleeding;O;O
complications;O;O
.;O;O
DDI-DrugBank.d12.s2;;
Frequent;O;O
prothrombin;O;O
determinations;O;O
are;O;O
advisable;O;O
until;O;O
it;O;O
has;O;O
been;O;O
determined;O;O
definitely;O;O
that;O;O
the;O;O
prothrombin;O;O
level;O;O
has;O;O
been;O;O
stabilized;O;O
.;O;O
DDI-DrugBank.d12.s3;;
Atromid;O;O
-;O;O
S;O;O
may;O;O
displace;O;O
acidic;O;O
drugs;O;O
such;O;O
as;O;O
phenytoin;B-drug;B-DDI-DrugBank.d12.s3.e1
or;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d12.s3.e2
from;O;O
their;O;O
binding;O;O
sites;O;O
.;O;O
DDI-DrugBank.d12.s4;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
treating;O;O
patients;O;O
with;O;O
either;O;O
of;O;O
these;O;O
drugs;O;O
or;O;O
other;O;O
highly;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
and;O;O
Atromid;O;O
-;O;O
S.;O;O
DDI-DrugBank.d12.s5;;
The;O;O
hypoglycemic;O;O
effect;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d12.s5.e0
has;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
when;O;O
Atromid;O;O
-;O;O
S;O;O
is;O;O
given;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d12.s6;;
Fulminant;O;O
rhabdomyolysis;O;O
has;O;O
been;O;O
seen;O;O
as;O;O
early;O;O
as;O;O
three;O;O
weeks;O;O
after;O;O
initiation;O;O
of;O;O
combined;O;O
therapy;O;O
with;O;O
another;O;O
fibrate;B-group;B-DDI-DrugBank.d12.s6.e0
and;O;O
lovastatin;B-drug;B-DDI-DrugBank.d12.s6.e1
but;O;O
may;O;O
be;O;O
seen;O;O
after;O;O
several;O;O
months;O;O
.;O;O
DDI-DrugBank.d12.s7;;
For;O;O
these;O;O
reasons;O;O
,;O;O
it;O;O
is;O;O
felt;O;O
that;O;O
,;O;O
in;O;O
most;O;O
subjects;O;O
who;O;O
have;O;O
had;O;O
an;O;O
unsatisfactory;O;O
lipid;O;O
response;O;O
to;O;O
either;O;O
drug;O;O
alone;O;O
,;O;O
the;O;O
possible;O;O
benefits;O;O
of;O;O
combined;O;O
therapy;O;O
with;O;O
lovastatin;B-drug;B-DDI-DrugBank.d12.s7.e0
and;O;O
a;O;O
fibrate;B-group;B-DDI-DrugBank.d12.s7.e1
do;O;O
not;O;O
outweigh;O;O
the;O;O
risks;O;O
of;O;O
severe;O;O
myopathy;O;O
,;O;O
rhabdomyolysis;O;O
,;O;O
and;O;O
acute;O;O
renal;O;O
failure;O;O
.;O;O
DDI-DrugBank.d12.s8;;
While;O;O
it;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
this;O;O
interaction;O;O
occurs;O;O
with;O;O
fibrates;B-group;B-DDI-DrugBank.d12.s8.e0
other;O;O
than;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d12.s8.e1
,;O;O
myopathy;O;O
and;O;O
rhabdomyolysis;O;O
have;O;O
occasionally;O;O
been;O;O
associated;O;O
with;O;O
the;O;O
use;O;O
of;O;O
fibrates;B-group;B-DDI-DrugBank.d12.s8.e2
alone;O;O
,;O;O
including;O;O
clofibrate;B-drug;B-DDI-DrugBank.d12.s8.e3
.;O;O
DDI-DrugBank.d12.s9;;
Therefore;O;O
,;O;O
the;O;O
combined;O;O
use;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d12.s9.e0
with;O;O
fibrates;B-group;B-DDI-DrugBank.d12.s9.e1
should;O;O
generally;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d451.s0;;
Drug;O;O
interactions;O;O
with;O;O
clomiphene;B-drug;B-DDI-DrugBank.d451.s0.e0
citrate;I-drug;I-DDI-DrugBank.d451.s0.e0
tablets;O;O
USP;O;O
have;O;O
not;O;O
been;O;O
documented;O;O
.;O;O
DDI-DrugBank.d238.s0;;
The;O;O
risks;O;O
of;O;O
using;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s0.e0
in;O;O
combination;O;O
with;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
systematically;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d238.s1;;
Given;O;O
the;O;O
primary;O;O
CNS;O;O
effects;O;O
of;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s1.e0
,;O;O
caution;O;O
is;O;O
advised;O;O
in;O;O
using;O;O
it;O;O
concomitantly;O;O
with;O;O
other;O;O
CNS;O;O
-;O;O
active;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d238.s2;;
Anafranil;B-brand;B-DDI-DrugBank.d238.s2.e0
should;O;O
not;O;O
be;O;O
used;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d238.s2.e1
inhibitors;I-group;I-DDI-DrugBank.d238.s2.e1
.;O;O
DDI-DrugBank.d238.s3;;
Close;O;O
supervision;O;O
and;O;O
careful;O;O
adjustment;O;O
of;O;O
dosage;O;O
are;O;O
required;O;O
when;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s3.e0
is;O;O
administered;O;O
with;O;O
anticholinergic;B-group;B-DDI-DrugBank.d238.s3.e1
or;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d238.s3.e2
drugs;I-group;I-DDI-DrugBank.d238.s3.e2
.;O;O
DDI-DrugBank.d238.s4;;
Several;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s4.e0
antidepressants;I-group;I-DDI-DrugBank.d238.s4.e0
have;O;O
been;O;O
reported;O;O
to;O;O
block;O;O
the;O;O
pharmacologic;O;O
effects;O;O
of;O;O
guanethidine;B-drug;B-DDI-DrugBank.d238.s4.e1
,;O;O
clonidine;B-drug;B-DDI-DrugBank.d238.s4.e2
,;O;O
or;O;O
similar;O;O
agents;O;O
,;O;O
and;O;O
such;O;O
an;O;O
effect;O;O
may;O;O
be;O;O
anticipated;O;O
with;O;O
CMI;B-drug;B-DDI-DrugBank.d238.s4.e3
because;O;O
of;O;O
its;O;O
structural;O;O
similarity;O;O
to;O;O
other;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s4.e4
antidepressants;I-group;I-DDI-DrugBank.d238.s4.e4
.;O;O
DDI-DrugBank.d238.s5;;
The;O;O
plasma;O;O
concentration;O;O
of;O;O
CMI;B-drug;B-DDI-DrugBank.d238.s5.e0
has;O;O
been;O;O
reported;O;O
to;O;O
be;O;O
increased;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
haloperidol;B-drug;B-DDI-DrugBank.d238.s5.e1
,;O;O
DDI-DrugBank.d238.s6;;
plasma;O;O
levels;O;O
of;O;O
several;O;O
closely;O;O
related;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s6.e0
antidepressants;I-group;I-DDI-DrugBank.d238.s6.e0
have;O;O
been;O;O
reported;O;O
to;O;O
be;O;O
increased;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
methylphenidate;B-drug;B-DDI-DrugBank.d238.s6.e1
or;O;O
hepatic;O;O
enzyme;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d238.s6.e2
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d238.s6.e3
);O;O
and;O;O
decreased;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
hepatic;O;O
enzyme;O;O
inducers;O;O
(;O;O
e.g.;O;O
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d238.s6.e4
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d238.s6.e5
);O;O
,;O;O
and;O;O
such;O;O
an;O;O
effect;O;O
may;O;O
be;O;O
anticipated;O;O
with;O;O
CMI;B-drug;B-DDI-DrugBank.d238.s6.e6
as;O;O
well;O;O
.;O;O
DDI-DrugBank.d238.s7;;
Administration;O;O
of;O;O
CMI;B-drug;B-DDI-DrugBank.d238.s7.e0
has;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d238.s7.e1
,;O;O
if;O;O
given;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d238.s8;;
Drugs;O;O
Metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
:;O;O
The;O;O
biochemical;O;O
activity;O;O
of;O;O
the;O;O
drug;O;O
metabolizing;O;O
isozyme;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
(;O;O
debrisoquin;O;O
hydroxylase;O;O
);O;O
is;O;O
reduced;O;O
in;O;O
a;O;O
subset;O;O
of;O;O
the;O;O
aucasian;O;O
population;O;O
(;O;O
about;O;O
7%;O;O
-;O;O
10;O;O
%;O;O
of;O;O
Caucasians;O;O
are;O;O
so;O;O
-;O;O
called;O;O
poor;O;O
metabolizers;O;O
);O;O
,;O;O
DDI-DrugBank.d238.s9;;
reliable;O;O
estimates;O;O
of;O;O
the;O;O
prevalence;O;O
of;O;O
reduced;O;O
P450;O;O
2D6;O;O
isozyme;O;O
activity;O;O
among;O;O
Asian;O;O
,;O;O
African;O;O
and;O;O
other;O;O
populations;O;O
are;O;O
not;O;O
yet;O;O
available;O;O
.;O;O
DDI-DrugBank.d238.s10;;
Poor;O;O
metabolizers;O;O
have;O;O
higher;O;O
than;O;O
expected;O;O
lasma;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s10.e0
antidepressants;I-group;I-DDI-DrugBank.d238.s10.e0
(;O;O
TCAs;B-group;B-DDI-DrugBank.d238.s10.e1
);O;O
when;O;O
given;O;O
usual;O;O
doses;O;O
.;O;O
DDI-DrugBank.d238.s11;;
Depending;O;O
on;O;O
the;O;O
fraction;O;O
of;O;O
drug;O;O
metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
,;O;O
the;O;O
increase;O;O
in;O;O
plasma;O;O
concentration;O;O
may;O;O
be;O;O
small;O;O
,;O;O
or;O;O
quite;O;O
large;O;O
(;O;O
8;O;O
fold;O;O
increase;O;O
in;O;O
plasma;O;O
AUC;O;O
of;O;O
the;O;O
TCA;B-group;B-DDI-DrugBank.d238.s11.e0
);O;O
.;O;O
DDI-DrugBank.d238.s12;;
In;O;O
addition;O;O
,;O;O
certain;O;O
drugs;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
this;O;O
isozyme;O;O
and;O;O
make;O;O
normal;O;O
metabolizers;O;O
resemble;O;O
poor;O;O
metabolizers;O;O
.;O;O
DDI-DrugBank.d238.s13;;
An;O;O
individual;O;O
who;O;O
is;O;O
stable;O;O
on;O;O
a;O;O
given;O;O
dose;O;O
of;O;O
TCAmay;B-group;B-DDI-DrugBank.d238.s13.e0
become;O;O
abruptly;O;O
toxic;O;O
when;O;O
given;O;O
one;O;O
of;O;O
these;O;O
inhibiting;O;O
drugs;O;O
as;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d238.s14;;
The;O;O
drugs;O;O
that;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
include;O;O
some;O;O
that;O;O
are;O;O
not;O;O
metabolized;O;O
by;O;O
the;O;O
enzyme;O;O
(;O;O
quinidine;B-drug;B-DDI-DrugBank.d238.s14.e0
,;O;O
DDI-DrugBank.d238.s15;;
cimetidine;B-drug;B-DDI-DrugBank.d238.s15.e0
);O;O
and;O;O
many;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
P450;O;O
2D6;O;O
(;O;O
many;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d238.s15.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d238.s15.e2
,;O;O
and;O;O
the;O;O
Type;B-group;B-DDI-DrugBank.d238.s15.e3
1C;I-group;I-DDI-DrugBank.d238.s15.e3
antiarrhythmics;I-group;I-DDI-DrugBank.d238.s15.e3
propafenone;I-drug;I-DDI-DrugBank.d238.s15.e4
and;O;O
flecainide;B-drug;B-DDI-DrugBank.d238.s15.e5
);O;O
.;O;O
DDI-DrugBank.d238.s16;;
While;O;O
all;O;O
the;O;O
selective;B-group;B-DDI-DrugBank.d238.s16.e0
serotonin;I-group;I-DDI-DrugBank.d238.s16.e0
reuptake;I-group;I-DDI-DrugBank.d238.s16.e0
inhibitors;I-group;I-DDI-DrugBank.d238.s16.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d238.s16.e1
);O;O
,;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d238.s16.e2
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d238.s16.e3
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d238.s16.e4
,;O;O
and;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d238.s16.e5
,;O;O
inhibit;O;O
P450;O;O
2D6;O;O
,;O;O
they;O;O
may;O;O
vary;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d238.s17;;
Fluvoxamine;B-drug;B-DDI-DrugBank.d238.s17.e0
has;O;O
also;O;O
been;O;O
shown;O;O
to;O;O
inhibit;O;O
P450;O;O
1A2;O;O
,;O;O
an;O;O
isoform;O;O
also;O;O
involved;O;O
in;O;O
TCAmetabolism;B-group;B-DDI-DrugBank.d238.s17.e1
.;O;O
DDI-DrugBank.d238.s18;;
The;O;O
extent;O;O
to;O;O
which;O;O
SSRI;B-group;B-DDI-DrugBank.d238.s18.e0
-;O;O
TCAinteractions;B-group;B-DDI-DrugBank.d238.s18.e1
may;O;O
pose;O;O
clinical;O;O
problems;O;O
will;O;O
depend;O;O
on;O;O
the;O;O
degree;O;O
of;O;O
inhibition;O;O
and;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
the;O;O
SSRI;B-group;B-DDI-DrugBank.d238.s18.e2
involved;O;O
.;O;O
DDI-DrugBank.d238.s19;;
Nevertheless;O;O
,;O;O
caution;O;O
is;O;O
indicated;O;O
in;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
TCAs;B-group;B-DDI-DrugBank.d238.s19.e0
with;O;O
any;O;O
of;O;O
the;O;O
SSRIs;B-group;B-DDI-DrugBank.d238.s19.e1
and;O;O
also;O;O
in;O;O
switching;O;O
from;O;O
one;O;O
class;O;O
to;O;O
the;O;O
other;O;O
.;O;O
DDI-DrugBank.d238.s20;;
Of;O;O
particular;O;O
importance;O;O
,;O;O
sufficient;O;O
time;O;O
must;O;O
elapse;O;O
before;O;O
initiating;O;O
TCAtreatment;B-group;B-DDI-DrugBank.d238.s20.e0
in;O;O
a;O;O
patient;O;O
being;O;O
withdrawn;O;O
from;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d238.s20.e1
,;O;O
given;O;O
the;O;O
long;O;O
half;O;O
-;O;O
life;O;O
of;O;O
the;O;O
parent;O;O
and;O;O
active;O;O
metabolite;O;O
(;O;O
at;O;O
least;O;O
5;O;O
weeks;O;O
may;O;O
be;O;O
necessary;O;O
);O;O
.;O;O
DDI-DrugBank.d238.s21;;
Concomitant;O;O
use;O;O
of;O;O
agents;O;O
in;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s21.e0
antidepressant;I-group;I-DDI-DrugBank.d238.s21.e0
class;I-group;I-DDI-DrugBank.d238.s21.e0
(;O;O
which;O;O
includes;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s21.e1
);O;O
with;O;O
drugs;O;O
that;O;O
can;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
may;O;O
require;O;O
lower;O;O
doses;O;O
than;O;O
usually;O;O
prescribed;O;O
for;O;O
either;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s21.e2
antidepressant;I-group;I-DDI-DrugBank.d238.s21.e2
agent;I-group;I-DDI-DrugBank.d238.s21.e2
or;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d238.s22;;
Furthermore;O;O
,;O;O
whenever;O;O
one;O;O
of;O;O
these;O;O
drugs;O;O
is;O;O
withdrawn;O;O
from;O;O
co;O;O
-;O;O
therapy;O;O
,;O;O
an;O;O
increased;O;O
dose;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s22.e0
antidepressant;I-group;I-DDI-DrugBank.d238.s22.e0
agent;I-group;I-DDI-DrugBank.d238.s22.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d238.s23;;
It;O;O
is;O;O
desirable;O;O
to;O;O
monitor;O;O
TCAplasma;B-group;B-DDI-DrugBank.d238.s23.e0
levels;O;O
whenever;O;O
an;O;O
agent;O;O
of;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d238.s23.e1
antidepressant;I-group;I-DDI-DrugBank.d238.s23.e1
class;I-group;I-DDI-DrugBank.d238.s23.e1
including;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s23.e2
is;O;O
going;O;O
to;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
another;O;O
drug;O;O
known;O;O
to;O;O
be;O;O
an;O;O
inhibitor;O;O
of;O;O
P450;O;O
2D6;O;O
(;O;O
and/or;O;O
P450;O;O
1A2;O;O
);O;O
.;O;O
DDI-DrugBank.d238.s24;;
Because;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s24.e0
is;O;O
highly;O;O
bound;O;O
to;O;O
serum;O;O
protein;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s24.e1
to;O;O
patients;O;O
taking;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
highly;O;O
bound;O;O
to;O;O
protein;O;O
(;O;O
e.g.;O;O
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d238.s24.e2
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d238.s24.e3
);O;O
may;O;O
cause;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
concentrations;O;O
of;O;O
these;O;O
drugs;O;O
,;O;O
potentially;O;O
resulting;O;O
in;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d238.s25;;
Conversely;O;O
,;O;O
adverse;O;O
effects;O;O
may;O;O
result;O;O
from;O;O
displacement;O;O
of;O;O
protein;O;O
-;O;O
bound;O;O
Anafranil;B-brand;B-DDI-DrugBank.d238.s25.e0
by;O;O
other;O;O
highly;O;O
bound;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d333.s0;;
Effect;O;O
of;O;O
Clonazepam;B-drug;B-DDI-DrugBank.d333.s0.e0
on;O;O
the;O;O
Pharmacokinetics;O;O
of;O;O
Other;O;O
Drugs;O;O
:;O;O
Clonazepam;B-drug;B-DDI-DrugBank.d333.s0.e1
does;O;O
not;O;O
appear;O;O
to;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d333.s0.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d333.s0.e3
,;O;O
or;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d333.s0.e4
.;O;O
DDI-DrugBank.d333.s1;;
The;O;O
effect;O;O
of;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s1.e0
on;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
investigated;O;O
.;O;O
DDI-DrugBank.d333.s2;;
Effect;O;O
of;O;O
Other;O;O
Drugs;O;O
on;O;O
the;O;O
Pharmacokinetics;O;O
of;O;O
Clonazepam;B-drug;B-DDI-DrugBank.d333.s2.e0
:;O;O
Literature;O;O
reports;O;O
suggest;O;O
that;O;O
ranitidine;B-drug;B-DDI-DrugBank.d333.s2.e1
,;O;O
an;O;O
agent;O;O
that;O;O
decreases;O;O
stomach;O;O
acidity;O;O
,;O;O
does;O;O
not;O;O
greatly;O;O
alter;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s2.e2
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d333.s3;;
In;O;O
a;O;O
study;O;O
in;O;O
which;O;O
the;O;O
2;O;O
mg;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s3.e0
orally;O;O
disintegrating;O;O
tablet;O;O
was;O;O
administered;O;O
with;O;O
and;O;O
without;O;O
propantheline;B-drug;B-DDI-DrugBank.d333.s3.e1
(;O;O
an;O;O
anticholinergic;B-group;B-DDI-DrugBank.d333.s3.e2
agent;I-group;I-DDI-DrugBank.d333.s3.e2
with;O;O
multiple;O;O
effects;O;O
on;O;O
the;O;O
GI;O;O
tract;O;O
);O;O
to;O;O
healthy;O;O
volunteers;O;O
,;O;O
the;O;O
AUC;O;O
of;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s3.e3
was;O;O
10;O;O
%;O;O
lower;O;O
and;O;O
the;O;O
Cmax;O;O
of;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s3.e4
was;O;O
20;O;O
%;O;O
lower;O;O
when;O;O
the;O;O
orally;O;O
disintegrating;O;O
tablet;O;O
was;O;O
given;O;O
with;O;O
propantheline;B-drug;B-DDI-DrugBank.d333.s3.e5
compared;O;O
to;O;O
when;O;O
it;O;O
was;O;O
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d333.s4;;
Fluoxetine;B-drug;B-DDI-DrugBank.d333.s4.e0
does;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s4.e1
.;O;O
DDI-DrugBank.d333.s5;;
Cytochrome;O;O
P;O;O
-;O;O
450;O;O
inducers;O;O
,;O;O
such;O;O
as;O;O
phenytoin;B-drug;B-DDI-DrugBank.d333.s5.e0
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d333.s5.e1
and;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d333.s5.e2
,;O;O
induce;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s5.e3
metabolism;O;O
,;O;O
causing;O;O
an;O;O
approximately;O;O
30;O;O
%;O;O
decrease;O;O
in;O;O
plasma;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s5.e4
levels;O;O
.;O;O
DDI-DrugBank.d333.s6;;
Although;O;O
clinical;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
,;O;O
based;O;O
on;O;O
the;O;O
involvement;O;O
of;O;O
the;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
3A;O;O
family;O;O
in;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s6.e0
metabolism;O;O
,;O;O
inhibitors;O;O
of;O;O
this;O;O
enzyme;O;O
system;O;O
,;O;O
notably;O;O
oral;O;O
antifungal;B-group;B-DDI-DrugBank.d333.s6.e1
agents;I-group;I-DDI-DrugBank.d333.s6.e1
,;O;O
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
patients;O;O
receiving;O;O
clonazepam;B-drug;B-DDI-DrugBank.d333.s6.e2
.;O;O
DDI-DrugBank.d333.s7;;
Pharmacodynamic;O;O
Interactions;O;O
:;O;O
The;O;O
CNS;O;O
-;O;O
depressant;O;O
action;O;O
of;O;O
the;O;O
benzodiazepine;B-group;B-DDI-DrugBank.d333.s7.e0
class;I-group;I-DDI-DrugBank.d333.s7.e0
of;O;O
drugs;O;O
may;O;O
be;O;O
potentiated;O;O
by;O;O
alcohol;B-drug;B-DDI-DrugBank.d333.s7.e1
,;O;O
narcotics;B-group;B-DDI-DrugBank.d333.s7.e2
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d333.s7.e3
,;O;O
nonbarbiturate;B-group;B-DDI-DrugBank.d333.s7.e4
hypnotics;I-group;I-DDI-DrugBank.d333.s7.e4
,;O;O
antianxiety;B-group;B-DDI-DrugBank.d333.s7.e5
agents;I-group;I-DDI-DrugBank.d333.s7.e5
,;O;O
the;O;O
phenothiazines;B-group;B-DDI-DrugBank.d333.s7.e6
,;I-group;I-DDI-DrugBank.d333.s7.e6
thioxanthene;I-group;I-DDI-DrugBank.d333.s7.e7
and;I-group;I-DDI-DrugBank.d333.s7.e7
butyrophenone;I-group;I-DDI-DrugBank.d333.s7.e8
classes;I-group;I-DDI-DrugBank.d333.s7.e8
of;I-group;I-DDI-DrugBank.d333.s7.e8
antipsychotic;I-group;I-DDI-DrugBank.d333.s7.e8
agents;I-group;I-DDI-DrugBank.d333.s7.e8
,;O;O
monoamine;B-group;B-DDI-DrugBank.d333.s7.e9
oxidase;I-group;I-DDI-DrugBank.d333.s7.e9
inhibitors;I-group;I-DDI-DrugBank.d333.s7.e9
and;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d333.s7.e10
antidepressants;I-group;I-DDI-DrugBank.d333.s7.e10
,;O;O
and;O;O
by;O;O
other;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d333.s7.e11
drugs;I-group;I-DDI-DrugBank.d333.s7.e11
.;O;O
DDI-DrugBank.d495.s0;;
Tablet;O;O
If;O;O
a;O;O
patient;O;O
receiving;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s0.e0
hydrochloride;I-drug;I-DDI-DrugBank.d495.s0.e0
is;O;O
also;O;O
taking;O;O
tricyclic;B-group;B-DDI-DrugBank.d495.s0.e1
antidepressants;I-group;I-DDI-DrugBank.d495.s0.e1
,;O;O
the;O;O
effect;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s0.e2
may;O;O
be;O;O
reduced;O;O
,;O;O
thus;O;O
necessitating;O;O
an;O;O
increase;O;O
in;O;O
dosage;O;O
.;O;O
DDI-DrugBank.d495.s1;;
Clonidine;B-drug;B-DDI-DrugBank.d495.s1.e0
hydrochloride;I-drug;I-DDI-DrugBank.d495.s1.e0
may;O;O
enhance;O;O
the;O;O
CNS;O;O
-;O;O
depressive;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d495.s1.e1
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d495.s1.e2
or;O;O
other;O;O
sedatives;B-group;B-DDI-DrugBank.d495.s1.e3
.;O;O
DDI-DrugBank.d495.s2;;
Amitriptyline;B-drug;B-DDI-DrugBank.d495.s2.e0
in;O;O
combination;O;O
with;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s2.e1
enhances;O;O
the;O;O
manifestation;O;O
of;O;O
corneal;O;O
lesions;O;O
in;O;O
rats;O;O
Epidural;O;O
Injection;O;O
Clonidine;B-drug;B-DDI-DrugBank.d495.s2.e2
may;O;O
potentiate;O;O
the;O;O
CNS;O;O
-;O;O
depressive;O;O
effect;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d495.s2.e3
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d495.s2.e4
or;O;O
other;O;O
sedating;B-group;B-DDI-DrugBank.d495.s2.e5
drugs;I-group;I-DDI-DrugBank.d495.s2.e5
.;O;O
DDI-DrugBank.d495.s3;;
Narcotic;B-group;B-DDI-DrugBank.d495.s3.e0
analgesics;I-group;I-DDI-DrugBank.d495.s3.e0
may;O;O
potentiate;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s3.e1
.;O;O
DDI-DrugBank.d495.s4;;
Tricyclic;B-group;B-DDI-DrugBank.d495.s4.e0
antidepressants;I-group;I-DDI-DrugBank.d495.s4.e0
may;O;O
antagonize;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s4.e1
.;O;O
DDI-DrugBank.d495.s5;;
The;O;O
effects;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d495.s5.e0
antidepressants;I-group;I-DDI-DrugBank.d495.s5.e0
on;O;O
clonidines;B-drug;B-DDI-DrugBank.d495.s5.e1
analgesic;O;O
actions;O;O
are;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d495.s6;;
Beta;B-group;B-DDI-DrugBank.d495.s6.e0
blockers;I-group;I-DDI-DrugBank.d495.s6.e0
may;O;O
exacerbate;O;O
the;O;O
hypertensive;O;O
response;O;O
seen;O;O
with;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s6.e1
withdrawl;O;O
.;O;O
DDI-DrugBank.d495.s7;;
Also;O;O
,;O;O
due;O;O
to;O;O
the;O;O
potential;O;O
for;O;O
additive;O;O
effects;O;O
such;O;O
as;O;O
bradycardia;O;O
and;O;O
AV;O;O
block;O;O
,;O;O
caution;O;O
is;O;O
warranted;O;O
in;O;O
patients;O;O
receiving;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s7.e0
with;O;O
agents;O;O
known;O;O
to;O;O
affect;O;O
sinus;O;O
node;O;O
function;O;O
or;O;O
AV;O;O
nodal;O;O
conduction;O;O
(;O;O
e.g.;O;O
,;O;O
digitalis;B-group;B-DDI-DrugBank.d495.s7.e1
,;O;O
calcium;B-group;B-DDI-DrugBank.d495.s7.e2
channel;I-group;I-DDI-DrugBank.d495.s7.e2
blockers;I-group;I-DDI-DrugBank.d495.s7.e2
,;O;O
and;O;O
beta;B-group;B-DDI-DrugBank.d495.s7.e3
-;I-group;I-DDI-DrugBank.d495.s7.e3
blockers;I-group;I-DDI-DrugBank.d495.s7.e3
.;O;O
);O;O
DDI-DrugBank.d495.s8;;
There;O;O
is;O;O
one;O;O
reported;O;O
case;O;O
of;O;O
a;O;O
patient;O;O
with;O;O
acute;O;O
delirium;O;O
associated;O;O
with;O;O
the;O;O
simultaneous;O;O
use;O;O
of;O;O
fluphenazine;B-drug;B-DDI-DrugBank.d495.s8.e0
and;O;O
oral;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s8.e1
.;O;O
DDI-DrugBank.d495.s9;;
Symptoms;O;O
resolved;O;O
when;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s9.e0
was;O;O
withdrawn;O;O
and;O;O
recurred;O;O
when;O;O
the;O;O
patient;O;O
was;O;O
rechallenged;O;O
with;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s9.e1
.;O;O
DDI-DrugBank.d495.s10;;
Epidural;O;O
clonidine;B-drug;B-DDI-DrugBank.d495.s10.e0
may;O;O
prolong;O;O
the;O;O
duration;O;O
of;O;O
pharmacologic;O;O
effects;O;O
of;O;O
epidural;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d495.s10.e1
,;O;O
including;O;O
both;O;O
sensory;O;O
and;O;O
motor;O;O
blockade;O;O
.;O;O
DDI-DrugBank.d343.s0;;
Aspirin;B-brand;B-DDI-DrugBank.d343.s0.e0
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d343.s0.e1
,;O;O
heparin;B-drug;B-DDI-DrugBank.d343.s0.e2
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d343.s0.e3
DDI-DrugBank.d335.s0;;
If;O;O
TRANXENE;B-brand;B-DDI-DrugBank.d335.s0.e0
is;O;O
to;O;O
be;O;O
combined;O;O
with;O;O
other;O;O
drugs;O;O
acting;O;O
on;O;O
the;O;O
central;O;O
nervous;O;O
system;O;O
,;O;O
careful;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
the;O;O
pharmacology;O;O
of;O;O
the;O;O
agents;O;O
to;O;O
be;O;O
employed;O;O
.;O;O
DDI-DrugBank.d335.s1;;
Animal;O;O
experience;O;O
indicates;O;O
that;O;O
clorazepate;B-drug;B-DDI-DrugBank.d335.s1.e0
dipotassium;I-drug;I-DDI-DrugBank.d335.s1.e0
prolongs;O;O
the;O;O
sleeping;O;O
time;O;O
after;O;O
hexobarbital;B-drug;B-DDI-DrugBank.d335.s1.e1
or;O;O
after;O;O
ethyl;B-drug;B-DDI-DrugBank.d335.s1.e2
alcohol;I-drug;I-DDI-DrugBank.d335.s1.e2
,;O;O
increases;O;O
the;O;O
inhibitory;O;O
effects;O;O
of;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d335.s1.e3
,;O;O
but;O;O
does;O;O
not;O;O
exhibit;O;O
monoamine;O;O
oxidase;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d335.s2;;
Clinical;O;O
studies;O;O
have;O;O
shown;O;O
increased;O;O
sedation;O;O
with;O;O
concurrent;O;O
hypnotic;B-group;B-DDI-DrugBank.d335.s2.e0
medications;I-group;I-DDI-DrugBank.d335.s2.e0
.;O;O
DDI-DrugBank.d335.s3;;
The;O;O
actions;O;O
of;O;O
the;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d335.s3.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
barbiturates;B-group;B-DDI-DrugBank.d335.s3.e1
,;O;O
narcotics;B-group;B-DDI-DrugBank.d335.s3.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d335.s3.e3
,;O;O
monoamine;B-group;B-DDI-DrugBank.d335.s3.e4
oxidase;I-group;I-DDI-DrugBank.d335.s3.e4
inhibitors;I-group;I-DDI-DrugBank.d335.s3.e4
or;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d335.s3.e5
.;O;O
DDI-DrugBank.d335.s4;;
If;O;O
TRANXENE;B-brand;B-DDI-DrugBank.d335.s4.e0
tablets;O;O
are;O;O
used;O;O
to;O;O
treat;O;O
anxiety;O;O
associated;O;O
with;O;O
somatic;O;O
disease;O;O
states;O;O
,;O;O
careful;O;O
attention;O;O
must;O;O
be;O;O
paid;O;O
to;O;O
possible;O;O
drug;O;O
interaction;O;O
with;O;O
concomitant;O;O
medication;O;O
.;O;O
DDI-DrugBank.d335.s5;;
In;O;O
bioavailability;O;O
studies;O;O
with;O;O
normal;O;O
subjects;O;O
,;O;O
the;O;O
concurrent;O;O
administration;O;O
of;O;O
antacids;B-group;B-DDI-DrugBank.d335.s5.e0
at;O;O
therapeutic;O;O
levels;O;O
did;O;O
not;O;O
significantly;O;O
influence;O;O
the;O;O
bioavailability;O;O
of;O;O
TRANXENE;B-brand;B-DDI-DrugBank.d335.s5.e1
tablets;O;O
.;O;O
DDI-DrugBank.d480.s0;;
The;O;O
risks;O;O
of;O;O
using;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s0.e0
in;O;O
combination;O;O
with;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
systematically;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d480.s1;;
Pharmacodynamic;O;O
-;O;O
related;O;O
Interactions;O;O
:;O;O
The;O;O
mechanism;O;O
of;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s1.e0
induced;O;O
agranulocytosis;O;O
is;O;O
unknown;O;O
,;O;O
DDI-DrugBank.d480.s2;;
nonetheless;O;O
,;O;O
the;O;O
possibility;O;O
that;O;O
causative;O;O
factors;O;O
may;O;O
interact;O;O
synergistically;O;O
to;O;O
increase;O;O
the;O;O
risk;O;O
and/or;O;O
severity;O;O
of;O;O
bone;O;O
marrow;O;O
suppression;O;O
warrants;O;O
consideration;O;O
.;O;O
DDI-DrugBank.d480.s3;;
Therefore;O;O
,;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s3.e0
should;O;O
not;O;O
be;O;O
used;O;O
with;O;O
other;O;O
agents;O;O
having;O;O
a;O;O
well;O;O
-;O;O
known;O;O
potential;O;O
to;O;O
suppress;O;O
bone;O;O
marrow;O;O
function;O;O
.;O;O
DDI-DrugBank.d480.s4;;
Given;O;O
the;O;O
primary;O;O
CNS;O;O
effects;O;O
of;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s4.e0
,;O;O
caution;O;O
is;O;O
advised;O;O
in;O;O
using;O;O
it;O;O
concomitantly;O;O
with;O;O
other;O;O
CNS;O;O
-;O;O
active;O;O
drugs;O;O
or;O;O
alcohol;B-drug;B-DDI-DrugBank.d480.s4.e1
.;O;O
DDI-DrugBank.d480.s5;;
Orthostatic;O;O
hypotension;O;O
in;O;O
patients;O;O
taking;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s5.e0
can;O;O
,;O;O
in;O;O
rare;O;O
cases;O;O
(;O;O
approximately;O;O
1;O;O
case;O;O
per;O;O
3,000;O;O
patients;O;O
);O;O
,;O;O
be;O;O
accompanied;O;O
by;O;O
profound;O;O
collapse;O;O
and;O;O
respiratory;O;O
and/or;O;O
cardiac;O;O
arrest;O;O
.;O;O
DDI-DrugBank.d480.s6;;
Some;O;O
of;O;O
the;O;O
cases;O;O
of;O;O
collapse;O;O
/;O;O
respiratory;O;O
arrest;O;O
/;O;O
cardiac;O;O
arrest;O;O
during;O;O
initial;O;O
treatment;O;O
occurred;O;O
in;O;O
patients;O;O
who;O;O
were;O;O
being;O;O
administered;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d480.s6.e0
,;O;O
DDI-DrugBank.d480.s7;;
similar;O;O
events;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
taking;O;O
other;O;O
psychotropic;B-group;B-DDI-DrugBank.d480.s7.e0
drugs;I-group;I-DDI-DrugBank.d480.s7.e0
or;O;O
even;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s7.e1
by;O;O
itself;O;O
.;O;O
DDI-DrugBank.d480.s8;;
Although;O;O
it;O;O
has;O;O
not;O;O
been;O;O
established;O;O
that;O;O
there;O;O
is;O;O
an;O;O
interaction;O;O
between;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s8.e0
and;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d480.s8.e1
or;O;O
other;O;O
psychotropics;B-group;B-DDI-DrugBank.d480.s8.e2
,;O;O
caution;O;O
is;O;O
advised;O;O
when;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s8.e3
is;O;O
initiated;O;O
in;O;O
patients;O;O
taking;O;O
a;O;O
benzodiazepine;B-group;B-DDI-DrugBank.d480.s8.e4
or;O;O
any;O;O
other;O;O
psychotropic;B-group;B-DDI-DrugBank.d480.s8.e5
drug;I-group;I-DDI-DrugBank.d480.s8.e5
.;O;O
DDI-DrugBank.d480.s9;;
Clozapine;B-drug;B-DDI-DrugBank.d480.s9.e0
may;O;O
potentiate;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
antihypertensive;B-group;B-DDI-DrugBank.d480.s9.e1
drugs;I-group;I-DDI-DrugBank.d480.s9.e1
and;O;O
the;O;O
anticholinergic;O;O
effects;O;O
of;O;O
atropine;B-drug;B-DDI-DrugBank.d480.s9.e2
-;O;O
type;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d480.s10;;
The;O;O
administration;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d480.s10.e0
should;O;O
be;O;O
avoided;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
drug;O;O
induced;O;O
hypotension;O;O
because;O;O
of;O;O
a;O;O
possible;O;O
reverse;O;O
epinephrine;B-drug;B-DDI-DrugBank.d480.s10.e1
effect;O;O
.;O;O
DDI-DrugBank.d480.s11;;
Pharmacokinetic;O;O
-;O;O
related;O;O
Interactions;O;O
:;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s11.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
many;O;O
CYP;O;O
450;O;O
isozymes;O;O
,;O;O
in;O;O
particular;O;O
1A2;O;O
,;O;O
2D6;O;O
,;O;O
and;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d480.s12;;
The;O;O
risk;O;O
of;O;O
metabolic;O;O
interactions;O;O
caused;O;O
by;O;O
an;O;O
effect;O;O
on;O;O
an;O;O
individual;O;O
isoform;O;O
is;O;O
therefore;O;O
minimized;O;O
.;O;O
DDI-DrugBank.d480.s13;;
Nevertheless;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
treatment;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
either;O;O
inhibitors;O;O
or;O;O
inducers;O;O
of;O;O
these;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d480.s14;;
Concomitant;O;O
administration;O;O
of;O;O
drugs;O;O
known;O;O
to;O;O
induce;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
may;O;O
decrease;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s14.e0
.;O;O
DDI-DrugBank.d480.s15;;
Phenytoin;B-drug;B-DDI-DrugBank.d480.s15.e0
,;O;O
nicotine;B-drug;B-DDI-DrugBank.d480.s15.e1
,;O;O
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d480.s15.e2
may;O;O
decrease;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s15.e3
plasma;O;O
levels;O;O
,;O;O
resulting;O;O
in;O;O
a;O;O
decrease;O;O
in;O;O
effectiveness;O;O
of;O;O
a;O;O
previously;O;O
effective;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s15.e4
dose;O;O
.;O;O
DDI-DrugBank.d480.s16;;
Concomitant;O;O
administration;O;O
of;O;O
drugs;O;O
known;O;O
to;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
cytochrome;O;O
P450;O;O
isozymes;O;O
may;O;O
increase;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s16.e0
.;O;O
DDI-DrugBank.d480.s17;;
Cimetidine;B-drug;B-DDI-DrugBank.d480.s17.e0
,;O;O
caffeine;B-drug;B-DDI-DrugBank.d480.s17.e1
,;O;O
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d480.s17.e2
may;O;O
increase;O;O
plasma;O;O
levels;O;O
of;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s17.e3
,;O;O
potentially;O;O
resulting;O;O
in;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d480.s18;;
Although;O;O
concomitant;O;O
use;O;O
of;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s18.e0
and;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d480.s18.e1
is;O;O
not;O;O
recommended;O;O
,;O;O
it;O;O
should;O;O
be;O;O
noted;O;O
that;O;O
discontinuation;O;O
of;O;O
concomitant;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d480.s18.e2
administration;O;O
may;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s18.e3
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d480.s19;;
In;O;O
a;O;O
study;O;O
of;O;O
schizophrenic;O;O
patients;O;O
who;O;O
received;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s19.e0
under;O;O
steady;O;O
state;O;O
conditions;O;O
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d480.s19.e1
or;O;O
paroxetine;B-drug;B-DDI-DrugBank.d480.s19.e2
was;O;O
added;O;O
in;O;O
16;O;O
and;O;O
14;O;O
patients;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d480.s20;;
After;O;O
14;O;O
days;O;O
of;O;O
co;O;O
-;O;O
administration;O;O
,;O;O
mean;O;O
trough;O;O
concentrations;O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s20.e0
and;O;O
its;O;O
metabolites;O;O
,;O;O
N;B-drug_n;B-DDI-DrugBank.d480.s20.e1
-;I-drug_n;I-DDI-DrugBank.d480.s20.e1
desmethylclozapine;I-drug_n;I-DDI-DrugBank.d480.s20.e1
and;O;O
clozapine;B-drug_n;B-DDI-DrugBank.d480.s20.e2
N;I-drug_n;I-DDI-DrugBank.d480.s20.e2
-;I-drug_n;I-DDI-DrugBank.d480.s20.e2
oxide;I-drug_n;I-DDI-DrugBank.d480.s20.e2
,;O;O
were;O;O
elevated;O;O
with;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d480.s20.e3
by;O;O
about;O;O
three;O;O
-;O;O
fold;O;O
compared;O;O
to;O;O
baseline;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d480.s21;;
Paroxetine;B-drug;B-DDI-DrugBank.d480.s21.e0
produced;O;O
only;O;O
minor;O;O
changes;O;O
in;O;O
the;O;O
levels;O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s21.e1
and;O;O
its;O;O
metabolites;O;O
.;O;O
DDI-DrugBank.d480.s22;;
However;O;O
,;O;O
other;O;O
published;O;O
reports;O;O
describe;O;O
modest;O;O
elevations;O;O
(;O;O
less;O;O
than;O;O
two;O;O
-;O;O
fold;O;O
);O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s22.e0
and;O;O
metabolite;O;O
concentrations;O;O
when;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s22.e1
was;O;O
taken;O;O
with;O;O
paroxetine;B-drug;B-DDI-DrugBank.d480.s22.e2
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d480.s22.e3
,;O;O
and;O;O
sertraline;B-drug;B-DDI-DrugBank.d480.s22.e4
.;O;O
DDI-DrugBank.d480.s23;;
Therefore;O;O
,;O;O
such;O;O
combined;O;O
treatment;O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
and;O;O
patients;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
when;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s23.e0
is;O;O
combined;O;O
with;O;O
these;O;O
drugs;O;O
,;O;O
particularly;O;O
with;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d480.s23.e1
.;O;O
DDI-DrugBank.d480.s24;;
A;O;O
reduced;O;O
Clozapine;B-drug;B-DDI-DrugBank.d480.s24.e0
dose;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d480.s25;;
A;O;O
subset;O;O
(;O;O
3%;O;O
-;O;O
10;O;O
%;O;O
);O;O
of;O;O
the;O;O
population;O;O
has;O;O
reduced;O;O
activity;O;O
of;O;O
certain;O;O
drug;O;O
metabolizing;O;O
enzymes;O;O
such;O;O
as;O;O
the;O;O
cytochrome;O;O
P450;O;O
isozyme;O;O
P450;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d480.s26;;
Such;O;O
individuals;O;O
are;O;O
referred;O;O
to;O;O
as;O;O
poor;O;O
metabolizers;O;O
of;O;O
drugs;O;O
such;O;O
as;O;O
debrisoquin;B-drug;B-DDI-DrugBank.d480.s26.e0
,;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d480.s26.e1
,;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d480.s26.e2
antidepressants;I-group;I-DDI-DrugBank.d480.s26.e2
,;O;O
and;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s26.e3
.;O;O
DDI-DrugBank.d480.s27;;
These;O;O
individuals;O;O
may;O;O
develop;O;O
higher;O;O
than;O;O
expected;O;O
plasma;O;O
concentrations;O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s27.e0
when;O;O
given;O;O
usual;O;O
doses;O;O
.;O;O
DDI-DrugBank.d480.s28;;
In;O;O
addition;O;O
,;O;O
certain;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
this;O;O
isozyme;O;O
,;O;O
including;O;O
many;O;O
antidepressants;B-group;B-DDI-DrugBank.d480.s28.e0
(;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s28.e1
,;O;O
selective;B-group;B-DDI-DrugBank.d480.s28.e2
serotonin;I-group;I-DDI-DrugBank.d480.s28.e2
reuptake;I-group;I-DDI-DrugBank.d480.s28.e2
inhibitors;I-group;I-DDI-DrugBank.d480.s28.e2
,;O;O
and;O;O
others;O;O
);O;O
,;O;O
may;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
this;O;O
isozyme;O;O
,;O;O
and;O;O
thus;O;O
may;O;O
make;O;O
normal;O;O
metabolizers;O;O
resemble;O;O
poor;O;O
metabolizers;O;O
with;O;O
regard;O;O
to;O;O
concomitant;O;O
therapy;O;O
with;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
this;O;O
enzyme;O;O
system;O;O
,;O;O
leading;O;O
to;O;O
drug;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d480.s29;;
Concomitant;O;O
use;O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s29.e0
with;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
may;O;O
require;O;O
lower;O;O
doses;O;O
than;O;O
usually;O;O
prescribed;O;O
for;O;O
either;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s29.e1
or;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d480.s30;;
Therefore;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
clozapine;B-drug;B-DDI-DrugBank.d480.s30.e0
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
this;O;O
isozyme;O;O
,;O;O
including;O;O
antidepressants;B-group;B-DDI-DrugBank.d480.s30.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d480.s30.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d480.s30.e3
,;O;O
and;O;O
Type;B-group;B-DDI-DrugBank.d480.s30.e4
1C;I-group;I-DDI-DrugBank.d480.s30.e4
antiarrhythmics;I-group;I-DDI-DrugBank.d480.s30.e4
(;O;O
e.g.;O;O
,;O;O
propafenone;B-drug;B-DDI-DrugBank.d480.s30.e5
,;O;O
flecainide;B-drug;B-DDI-DrugBank.d480.s30.e6
and;O;O
encainide;B-drug;B-DDI-DrugBank.d480.s30.e7
);O;O
,;O;O
or;O;O
that;O;O
inhibit;O;O
this;O;O
enzyme;O;O
(;O;O
e.g.;O;O
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d480.s30.e8
);O;O
,;O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d221.s0;;
The;O;O
risk;O;O
of;O;O
a;O;O
potential;O;O
interaction;O;O
between;O;O
NovoSeven;B-brand;B-DDI-DrugBank.d221.s0.e0
and;O;O
coagulation;B-group;B-DDI-DrugBank.d221.s0.e1
factor;I-group;I-DDI-DrugBank.d221.s0.e1
concentrates;O;O
has;O;O
not;O;O
been;O;O
adequately;O;O
evaluated;O;O
in;O;O
preclinical;O;O
or;O;O
clinical;O;O
studies;O;O
.;O;O
DDI-DrugBank.d221.s1;;
Simultaneous;O;O
use;O;O
of;O;O
activated;B-group;B-DDI-DrugBank.d221.s1.e0
prothrombin;I-group;I-DDI-DrugBank.d221.s1.e0
complex;I-group;I-DDI-DrugBank.d221.s1.e0
concentrates;I-group;I-DDI-DrugBank.d221.s1.e0
or;O;O
prothrombin;B-group;B-DDI-DrugBank.d221.s1.e1
complex;I-group;I-DDI-DrugBank.d221.s1.e1
concentrates;I-group;I-DDI-DrugBank.d221.s1.e1
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d221.s2;;
Although;O;O
the;O;O
specific;O;O
drug;O;O
interaction;O;O
was;O;O
not;O;O
studied;O;O
in;O;O
a;O;O
clinical;O;O
trial;O;O
,;O;O
there;O;O
have;O;O
been;O;O
more;O;O
than;O;O
50;O;O
episodes;O;O
of;O;O
concomitant;O;O
use;O;O
of;O;O
antifibrinolytic;O;O
therapies;O;O
(;O;O
i.e.;O;O
,;O;O
tranexamic;B-drug;B-DDI-DrugBank.d221.s2.e0
acid;I-drug;I-DDI-DrugBank.d221.s2.e0
,;O;O
aminocaproic;B-drug;B-DDI-DrugBank.d221.s2.e1
acid;I-drug;I-DDI-DrugBank.d221.s2.e1
);O;O
and;O;O
NovoSeven;B-brand;B-DDI-DrugBank.d221.s2.e2
.;O;O
DDI-DrugBank.d221.s3;;
NovoSeven;B-brand;B-DDI-DrugBank.d221.s3.e0
should;O;O
not;O;O
be;O;O
mixed;O;O
with;O;O
infusion;O;O
solutions;O;O
until;O;O
clinical;O;O
data;O;O
are;O;O
available;O;O
to;O;O
direct;O;O
this;O;O
use;O;O
.;O;O
DDI-DrugBank.d464.s0;;
Codeine;B-drug;B-DDI-DrugBank.d464.s0.e0
in;O;O
combination;O;O
with;O;O
other;O;O
narcotic;B-group;B-DDI-DrugBank.d464.s0.e1
analgesics;I-group;I-DDI-DrugBank.d464.s0.e1
,;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d464.s0.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d464.s0.e3
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d464.s0.e4
,;O;O
sedative;B-group;B-DDI-DrugBank.d464.s0.e5
-;I-group;I-DDI-DrugBank.d464.s0.e5
hypnotics;I-group;I-DDI-DrugBank.d464.s0.e5
,;O;O
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d464.s0.e6
depressants;I-group;I-DDI-DrugBank.d464.s0.e6
(;O;O
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d464.s0.e7
);O;O
has;O;O
additive;O;O
depressant;O;O
effects;O;O
.;O;O
DDI-DrugBank.d464.s1;;
When;O;O
s.c;O;O
.;O;O
DDI-DrugBank.d464.s2;;
combination;O;O
therapy;O;O
is;O;O
contemplated;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d146.s0;;
Colchicine;B-drug;B-DDI-DrugBank.d146.s0.e0
is;O;O
inhibited;O;O
by;O;O
acidifying;B-group;B-DDI-DrugBank.d146.s0.e1
agents;I-group;I-DDI-DrugBank.d146.s0.e1
.;O;O
DDI-DrugBank.d146.s1;;
The;O;O
action;O;O
of;O;O
colchicine;B-drug;B-DDI-DrugBank.d146.s1.e0
is;O;O
potentiated;O;O
by;O;O
alkalinizing;B-group;B-DDI-DrugBank.d146.s1.e1
agents;I-group;I-DDI-DrugBank.d146.s1.e1
.;O;O
DDI-DrugBank.d146.s2;;
Colchicine;B-drug;B-DDI-DrugBank.d146.s2.e0
may;O;O
increase;O;O
sensitivity;O;O
to;O;O
the;O;O
CNS;B-group;B-DDI-DrugBank.d146.s2.e1
depressants;I-group;I-DDI-DrugBank.d146.s2.e1
.;O;O
DDI-DrugBank.d146.s3;;
Response;O;O
to;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d146.s3.e0
agents;I-group;I-DDI-DrugBank.d146.s3.e0
may;O;O
be;O;O
enhanced;O;O
by;O;O
colchicine;B-drug;B-DDI-DrugBank.d146.s3.e1
.;O;O
DDI-DrugBank.d551.s0;;
WelChol;B-brand;B-DDI-DrugBank.d551.s0.e0
has;O;O
been;O;O
studied;O;O
in;O;O
several;O;O
human;O;O
drug;O;O
interaction;O;O
studies;O;O
in;O;O
which;O;O
it;O;O
was;O;O
administered;O;O
with;O;O
a;O;O
meal;O;O
and;O;O
the;O;O
test;O;O
drug;O;O
.;O;O
DDI-DrugBank.d551.s1;;
WelChol;B-brand;B-DDI-DrugBank.d551.s1.e0
was;O;O
found;O;O
to;O;O
have;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
bioavailability;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d551.s1.e1
,;O;O
lovastatin;B-drug;B-DDI-DrugBank.d551.s1.e2
,;O;O
metoprolol;B-drug;B-DDI-DrugBank.d551.s1.e3
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d551.s1.e4
,;O;O
valproic;B-drug;B-DDI-DrugBank.d551.s1.e5
acid;I-drug;I-DDI-DrugBank.d551.s1.e5
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d551.s1.e6
.;O;O
DDI-DrugBank.d551.s2;;
WelChol;B-brand;B-DDI-DrugBank.d551.s2.e0
decreased;O;O
the;O;O
Cmax;O;O
and;O;O
AUC;O;O
of;O;O
sustained;O;O
-;O;O
release;O;O
verapamil;B-drug;B-DDI-DrugBank.d551.s2.e1
(;O;O
Calan;B-brand;B-DDI-DrugBank.d551.s2.e2
SR;I-brand;I-DDI-DrugBank.d551.s2.e2
);O;O
by;O;O
approximately;O;O
31;O;O
%;O;O
and;O;O
11;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d551.s3;;
Since;O;O
there;O;O
is;O;O
a;O;O
high;O;O
degree;O;O
of;O;O
variability;O;O
in;O;O
the;O;O
bioavailability;O;O
of;O;O
verapamil;B-drug;B-DDI-DrugBank.d551.s3.e0
,;O;O
the;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
finding;O;O
is;O;O
unclear;O;O
.;O;O
DDI-DrugBank.d551.s4;;
In;O;O
clinical;O;O
studies;O;O
,;O;O
coadministration;O;O
of;O;O
WelChol;B-brand;B-DDI-DrugBank.d551.s4.e0
with;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d551.s4.e1
,;O;O
lovastatin;B-drug;B-DDI-DrugBank.d551.s4.e2
,;O;O
or;O;O
simvastatin;B-drug;B-DDI-DrugBank.d551.s4.e3
did;O;O
not;O;O
interfere;O;O
with;O;O
the;O;O
lipid;O;O
-;O;O
lowering;O;O
activity;O;O
of;O;O
the;O;O
HMG;B-group;B-DDI-DrugBank.d551.s4.e4
-;I-group;I-DDI-DrugBank.d551.s4.e4
CoA;I-group;I-DDI-DrugBank.d551.s4.e4
reductase;I-group;I-DDI-DrugBank.d551.s4.e4
inhibitor;I-group;I-DDI-DrugBank.d551.s4.e4
.;O;O
DDI-DrugBank.d551.s5;;
Other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d551.s6;;
When;O;O
administering;O;O
other;O;O
drugs;O;O
for;O;O
which;O;O
alterations;O;O
in;O;O
blood;O;O
levels;O;O
could;O;O
have;O;O
a;O;O
clinically;O;O
significant;O;O
effect;O;O
on;O;O
safety;O;O
or;O;O
efficacy;O;O
,;O;O
physicians;O;O
should;O;O
consider;O;O
monitoring;O;O
drug;O;O
levels;O;O
or;O;O
effects;O;O
.;O;O
DDI-DrugBank.d345.s0;;
Since;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s0.e0
hydrochloride;I-drug;I-DDI-DrugBank.d345.s0.e0
is;O;O
an;O;O
anion;B-group;B-DDI-DrugBank.d345.s0.e1
exchange;I-group;I-DDI-DrugBank.d345.s0.e1
resin;I-group;I-DDI-DrugBank.d345.s0.e1
,;O;O
it;O;O
may;O;O
have;O;O
a;O;O
strong;O;O
affinity;O;O
for;O;O
anions;O;O
other;O;O
than;O;O
the;O;O
bile;O;O
acids;O;O
.;O;O
DDI-DrugBank.d345.s1;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
indicated;O;O
that;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s1.e0
hydrochloride;I-drug;I-DDI-DrugBank.d345.s1.e0
binds;O;O
a;O;O
number;O;O
of;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d345.s2;;
Therefore;O;O
,;O;O
COLESTlD;B-brand;B-DDI-DrugBank.d345.s2.e0
Tablets;O;O
may;O;O
delay;O;O
or;O;O
reduce;O;O
the;O;O
absorption;O;O
of;O;O
concomitant;O;O
oral;O;O
medication;O;O
.;O;O
DDI-DrugBank.d345.s3;;
The;O;O
interval;O;O
between;O;O
the;O;O
administration;O;O
of;O;O
COLESTID;B-brand;B-DDI-DrugBank.d345.s3.e0
Tablets;O;O
and;O;O
any;O;O
other;O;O
medication;O;O
should;O;O
be;O;O
as;O;O
long;O;O
as;O;O
possible;O;O
.;O;O
DDI-DrugBank.d345.s4;;
Patients;O;O
should;O;O
take;O;O
other;O;O
drugs;O;O
at;O;O
least;O;O
one;O;O
hour;O;O
before;O;O
or;O;O
four;O;O
hours;O;O
after;O;O
COLESTID;B-brand;B-DDI-DrugBank.d345.s4.e0
Tablets;O;O
to;O;O
avoid;O;O
impeding;O;O
their;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d345.s5;;
Repeated;O;O
doses;O;O
of;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s5.e0
hydrochloride;I-drug;I-DDI-DrugBank.d345.s5.e0
given;O;O
prior;O;O
to;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d345.s5.e1
in;O;O
human;O;O
trials;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
propranolol;B-drug;B-DDI-DrugBank.d345.s5.e2
absorption;O;O
.;O;O
DDI-DrugBank.d345.s6;;
However;O;O
,;O;O
in;O;O
a;O;O
follow;O;O
-;O;O
up;O;O
study;O;O
in;O;O
normal;O;O
subjects;O;O
,;O;O
single;O;O
-;O;O
dose;O;O
administration;O;O
of;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s6.e0
hydrochloride;I-drug;I-DDI-DrugBank.d345.s6.e0
and;O;O
propranolol;B-drug;B-DDI-DrugBank.d345.s6.e1
and;O;O
twice;O;O
-;O;O
a;O;O
-;O;O
day;O;O
administration;O;O
for;O;O
5;O;O
days;O;O
of;O;O
both;O;O
agents;O;O
did;O;O
not;O;O
affect;O;O
the;O;O
extent;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d345.s6.e2
absorption;O;O
,;O;O
but;O;O
had;O;O
a;O;O
small;O;O
yet;O;O
statistically;O;O
significant;O;O
effect;O;O
on;O;O
its;O;O
rate;O;O
of;O;O
absorption;O;O
,;O;O
DDI-DrugBank.d345.s7;;
the;O;O
time;O;O
to;O;O
reach;O;O
maximum;O;O
concentration;O;O
was;O;O
delayed;O;O
approximately;O;O
30;O;O
minutes;O;O
.;O;O
DDI-DrugBank.d345.s8;;
Effects;O;O
on;O;O
the;O;O
absorption;O;O
of;O;O
other;O;O
beta;B-group;B-DDI-DrugBank.d345.s8.e0
-;I-group;I-DDI-DrugBank.d345.s8.e0
blockers;I-group;I-DDI-DrugBank.d345.s8.e0
have;O;O
not;O;O
been;O;O
determined;O;O
.;O;O
DDI-DrugBank.d345.s9;;
Therefore;O;O
,;O;O
patients;O;O
on;O;O
propranolol;B-drug;B-DDI-DrugBank.d345.s9.e0
should;O;O
be;O;O
observed;O;O
when;O;O
COLESTID;B-brand;B-DDI-DrugBank.d345.s9.e1
Tablets;O;O
are;O;O
either;O;O
added;O;O
or;O;O
deleted;O;O
from;O;O
a;O;O
therapeutic;O;O
regimen;O;O
.;O;O
DDI-DrugBank.d345.s10;;
Studies;O;O
in;O;O
humans;O;O
show;O;O
that;O;O
the;O;O
absorption;O;O
of;O;O
chlorothiazide;B-drug;B-DDI-DrugBank.d345.s10.e0
as;O;O
reflected;O;O
in;O;O
urinary;O;O
excretion;O;O
is;O;O
markedly;O;O
decreased;O;O
even;O;O
when;O;O
administered;O;O
one;O;O
hour;O;O
before;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s10.e1
hydrochloride;I-drug;I-DDI-DrugBank.d345.s10.e1
.;O;O
DDI-DrugBank.d345.s11;;
The;O;O
absorption;O;O
of;O;O
tetracycline;B-drug;B-DDI-DrugBank.d345.s11.e0
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d345.s11.e1
,;O;O
penicillin;B-drug;B-DDI-DrugBank.d345.s11.e2
G;I-drug;I-DDI-DrugBank.d345.s11.e2
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d345.s11.e3
,;O;O
and;O;O
gemfibrozil;B-drug;B-DDI-DrugBank.d345.s11.e4
was;O;O
significantly;O;O
decreased;O;O
when;O;O
given;O;O
simultaneously;O;O
with;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s11.e5
hydrochloride;I-drug;I-DDI-DrugBank.d345.s11.e5
,;O;O
DDI-DrugBank.d345.s12;;
these;O;O
drugs;O;O
were;O;O
not;O;O
tested;O;O
to;O;O
determine;O;O
the;O;O
effect;O;O
of;O;O
administration;O;O
one;O;O
hour;O;O
before;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s12.e0
hydrochloride;I-drug;I-DDI-DrugBank.d345.s12.e0
.;O;O
DDI-DrugBank.d345.s13;;
No;O;O
depressant;O;O
effect;O;O
on;O;O
blood;O;O
levels;O;O
in;O;O
humans;O;O
was;O;O
noted;O;O
when;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s13.e0
hydrochloride;I-drug;I-DDI-DrugBank.d345.s13.e0
was;O;O
administered;O;O
with;O;O
any;O;O
of;O;O
the;O;O
following;O;O
drugs;O;O
:;O;O
aspirin;B-brand;B-DDI-DrugBank.d345.s13.e1
,;O;O
clindamycin;B-brand;B-DDI-DrugBank.d345.s13.e2
,;O;O
clofibrate;B-drug;B-DDI-DrugBank.d345.s13.e3
,;O;O
methyldopa;B-drug;B-DDI-DrugBank.d345.s13.e4
,;O;O
nicotinic;B-drug;B-DDI-DrugBank.d345.s13.e5
acid;I-drug;I-DDI-DrugBank.d345.s13.e5
(;O;O
niacin;B-drug;B-DDI-DrugBank.d345.s13.e6
);O;O
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d345.s13.e7
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d345.s13.e8
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d345.s13.e9
.;O;O
DDI-DrugBank.d345.s14;;
Particular;O;O
caution;O;O
should;O;O
be;O;O
observed;O;O
with;O;O
digitalis;B-group;B-DDI-DrugBank.d345.s14.e0
preparations;I-group;I-DDI-DrugBank.d345.s14.e0
since;O;O
there;O;O
are;O;O
conflicting;O;O
results;O;O
for;O;O
the;O;O
effect;O;O
of;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s14.e1
hydrochloride;I-drug;I-DDI-DrugBank.d345.s14.e1
on;O;O
the;O;O
availability;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d345.s14.e2
and;O;O
digitoxin;B-drug;B-DDI-DrugBank.d345.s14.e3
.;O;O
DDI-DrugBank.d345.s15;;
The;O;O
potential;O;O
for;O;O
binding;O;O
of;O;O
these;O;O
drugs;O;O
if;O;O
given;O;O
concomitantly;O;O
is;O;O
present;O;O
.;O;O
DDI-DrugBank.d345.s16;;
Discontinuing;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s16.e0
hydrochloride;I-drug;I-DDI-DrugBank.d345.s16.e0
could;O;O
pose;O;O
a;O;O
hazard;O;O
to;O;O
health;O;O
if;O;O
a;O;O
potentially;O;O
toxic;O;O
drug;O;O
that;O;O
is;O;O
significantly;O;O
bound;O;O
to;O;O
the;O;O
resin;B-group;B-DDI-DrugBank.d345.s16.e1
has;O;O
been;O;O
titrated;O;O
to;O;O
a;O;O
maintenance;O;O
level;O;O
while;O;O
the;O;O
patient;O;O
was;O;O
taking;O;O
colestipol;B-drug;B-DDI-DrugBank.d345.s16.e2
hydrochloride;I-drug;I-DDI-DrugBank.d345.s16.e2
.;O;O
DDI-DrugBank.d345.s17;;
Bile;B-group;B-DDI-DrugBank.d345.s17.e0
acid;I-group;I-DDI-DrugBank.d345.s17.e0
binding;I-group;I-DDI-DrugBank.d345.s17.e0
resins;I-group;I-DDI-DrugBank.d345.s17.e0
may;O;O
also;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
oral;O;O
phosphate;B-drug;B-DDI-DrugBank.d345.s17.e1
supplements;O;O
and;O;O
hydrocortisone;B-drug;B-DDI-DrugBank.d345.s17.e2
.;O;O
DDI-DrugBank.d250.s0;;
Certain;O;O
other;O;O
antibiotics;B-group;B-DDI-DrugBank.d250.s0.e0
(;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d250.s0.e1
and;O;O
polymyxin;B-group;B-DDI-DrugBank.d250.s0.e2
);O;O
have;O;O
also;O;O
been;O;O
reported;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
nerve;O;O
transmission;O;O
at;O;O
the;O;O
neuromuscular;O;O
junction;O;O
.;O;O
DDI-DrugBank.d250.s1;;
Based;O;O
on;O;O
this;O;O
reported;O;O
activity;O;O
,;O;O
they;O;O
should;O;O
not;O;O
be;O;O
given;O;O
concomitantly;O;O
with;O;O
Coly;B-brand;B-DDI-DrugBank.d250.s1.e0
-;I-brand;I-DDI-DrugBank.d250.s1.e0
Mycin;I-brand;I-DDI-DrugBank.d250.s1.e0
M;I-brand;I-DDI-DrugBank.d250.s1.e0
Parenteral;O;O
except;O;O
with;O;O
the;O;O
greatest;O;O
caution;O;O
.;O;O
DDI-DrugBank.d250.s2;;
Curariform;B-brand;B-DDI-DrugBank.d250.s2.e0
muscle;I-brand;I-DDI-DrugBank.d250.s2.e0
relaxants;I-brand;I-DDI-DrugBank.d250.s2.e0
(;O;O
eg;O;O
,;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d250.s2.e1
);O;O
and;O;O
other;O;O
drugs;O;O
,;O;O
including;O;O
ether;O;O
,;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d250.s2.e2
,;O;O
gallamine;B-drug;B-DDI-DrugBank.d250.s2.e3
,;O;O
decamethonium;B-drug;B-DDI-DrugBank.d250.s2.e4
and;O;O
sodium;B-drug;B-DDI-DrugBank.d250.s2.e5
citrate;I-drug;I-DDI-DrugBank.d250.s2.e5
,;O;O
potentiate;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
effect;O;O
and;O;O
should;O;O
be;O;O
used;O;O
with;O;O
extreme;O;O
caution;O;O
in;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
Coly;B-brand;B-DDI-DrugBank.d250.s2.e6
-;I-brand;I-DDI-DrugBank.d250.s2.e6
Mycin;I-brand;I-DDI-DrugBank.d250.s2.e6
M;I-brand;I-DDI-DrugBank.d250.s2.e6
Parenteral;O;O
.;O;O
DDI-DrugBank.d250.s3;;
Sodium;B-drug;B-DDI-DrugBank.d250.s3.e0
cephalothin;I-drug;I-DDI-DrugBank.d250.s3.e0
may;O;O
enhance;O;O
the;O;O
nephrotoxicity;O;O
of;O;O
Coly;B-brand;B-DDI-DrugBank.d250.s3.e1
-;I-brand;I-DDI-DrugBank.d250.s3.e1
Mycin;I-brand;I-DDI-DrugBank.d250.s3.e1
M;I-brand;I-DDI-DrugBank.d250.s3.e1
Parenteral;O;O
.;O;O
DDI-DrugBank.d250.s4;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
sodium;B-drug;B-DDI-DrugBank.d250.s4.e0
cephalothin;I-drug;I-DDI-DrugBank.d250.s4.e0
and;O;O
Coly;B-brand;B-DDI-DrugBank.d250.s4.e1
-;I-brand;I-DDI-DrugBank.d250.s4.e1
Mycin;I-brand;I-DDI-DrugBank.d250.s4.e1
M;I-brand;I-DDI-DrugBank.d250.s4.e1
Parenteral;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d315.s0;;
Digoxin;B-drug;B-DDI-DrugBank.d315.s0.e0
:;O;O
Coadministration;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d315.s0.e1
,;O;O
a;O;O
P;O;O
-;O;O
glycoprotein;O;O
substrate;O;O
,;O;O
with;O;O
oral;O;O
conivaptan;B-drug;B-DDI-DrugBank.d315.s0.e2
resulted;O;O
in;O;O
a;O;O
reduction;O;O
in;O;O
clearance;O;O
and;O;O
an;O;O
increase;O;O
in;O;O
digoxin;B-drug;B-DDI-DrugBank.d315.s0.e3
Cmax;O;O
and;O;O
AUC;O;O
values;O;O
.;O;O
DDI-DrugBank.d315.s1;;
Therefore;O;O
,;O;O
if;O;O
digoxin;B-drug;B-DDI-DrugBank.d315.s1.e0
is;O;O
administered;O;O
with;O;O
VAPRISOL;B-brand;B-DDI-DrugBank.d315.s1.e1
,;O;O
the;O;O
clinician;O;O
should;O;O
be;O;O
alert;O;O
to;O;O
the;O;O
possibility;O;O
of;O;O
increases;O;O
in;O;O
digoxin;B-drug;B-DDI-DrugBank.d315.s1.e2
levels;O;O
.;O;O
DDI-DrugBank.d317.s0;;
DRUG;O;O
/;O;O
LABORATORY;O;O
TEST;O;O
INTERACTIONS;O;O
1;O;O
.;O;O
DDI-DrugBank.d317.s1;;
Accelerated;O;O
prothrombin;O;O
time;O;O
,;O;O
partial;O;O
thromboplastin;O;O
time;O;O
,;O;O
and;O;O
platelet;O;O
aggregation;O;O
time;O;O
,;O;O
DDI-DrugBank.d317.s2;;
increased;O;O
platelet;O;O
count;O;O
,;O;O
DDI-DrugBank.d317.s3;;
increased;O;O
factors;O;O
II;O;O
,;O;O
VII;O;O
antigen;O;O
,;O;O
VIII;O;O
antigen;O;O
,;O;O
VIII;O;O
coagulant;O;O
activity;O;O
,;O;O
IX;O;O
,;O;O
X;O;O
,;O;O
XII;O;O
,;O;O
VII;O;O
-;O;O
X;O;O
complex;O;O
,;O;O
II;O;O
-;O;O
VII;O;O
-;O;O
X;O;O
complex;O;O
,;O;O
and;O;O
beta;O;O
-;O;O
thromboglobulin;O;O
,;O;O
DDI-DrugBank.d317.s4;;
decreased;O;O
levels;O;O
of;O;O
anti;O;O
-;O;O
factor;O;O
Xa;O;O
and;O;O
antithrombin;B-drug;B-DDI-DrugBank.d317.s4.e0
III;I-drug;I-DDI-DrugBank.d317.s4.e0
,;O;O
decreased;O;O
antithrombin;B-drug;B-DDI-DrugBank.d317.s4.e1
III;I-drug;I-DDI-DrugBank.d317.s4.e1
activity;O;O
,;O;O
DDI-DrugBank.d317.s5;;
increased;O;O
levels;O;O
of;O;O
fibrinogen;B-drug;B-DDI-DrugBank.d317.s5.e0
and;O;O
fibrinogen;B-drug;B-DDI-DrugBank.d317.s5.e1
activity;O;O
,;O;O
DDI-DrugBank.d317.s6;;
increased;O;O
plasminogen;O;O
antigen;O;O
and;O;O
activity;O;O
.;O;O
DDI-DrugBank.d317.s7;;
2;O;O
.;O;O
DDI-DrugBank.d317.s8;;
Increased;O;O
thyroid;O;O
-;O;O
binding;O;O
globulin;O;O
(;O;O
TBG;O;O
);O;O
levels;O;O
leading;O;O
to;O;O
increased;O;O
circulating;O;O
total;O;O
thyroid;O;O
hormone;O;O
levels;O;O
as;O;O
measured;O;O
by;O;O
protein;O;O
-;O;O
bound;O;O
iodine;B-drug;B-DDI-DrugBank.d317.s8.e0
(;O;O
PBI;O;O
);O;O
,;O;O
T4;O;O
levels;O;O
(;O;O
by;O;O
column;O;O
or;O;O
by;O;O
radioimmunoassay;O;O
);O;O
or;O;O
T3;O;O
levels;O;O
by;O;O
radioimmunoassay;O;O
.;O;O
DDI-DrugBank.d317.s9;;
T3;O;O
resin;O;O
uptake;O;O
is;O;O
decreased;O;O
,;O;O
reflecting;O;O
the;O;O
elevated;O;O
TBG;O;O
.;O;O
DDI-DrugBank.d317.s10;;
Free;O;O
T4;O;O
and;O;O
free;O;O
T3;O;O
concentrations;O;O
are;O;O
unaltered;O;O
.;O;O
DDI-DrugBank.d317.s11;;
Patients;O;O
on;O;O
thyroid;O;O
replacement;O;O
therapy;O;O
may;O;O
require;O;O
higher;O;O
doses;O;O
of;O;O
thyroid;B-group;B-DDI-DrugBank.d317.s11.e0
hormone;I-group;I-DDI-DrugBank.d317.s11.e0
.;O;O
DDI-DrugBank.d317.s12;;
3;O;O
.;O;O
DDI-DrugBank.d317.s13;;
Other;O;O
binding;O;O
proteins;O;O
may;O;O
be;O;O
elevated;O;O
in;O;O
serum;O;O
,;O;O
(;O;O
i.e.;O;O
,;O;O
corticosteroid;O;O
binding;O;O
globulin;O;O
(;O;O
CBG;O;O
);O;O
,;O;O
sex;O;O
hormone;O;O
binding;O;O
globulin;O;O
(;O;O
SHBG;O;O
);O;O
);O;O
leading;O;O
to;O;O
increased;O;O
total;O;O
circulating;O;O
corticosteroids;B-group;B-DDI-DrugBank.d317.s13.e0
and;O;O
sex;B-group;B-DDI-DrugBank.d317.s13.e1
steroids;I-group;I-DDI-DrugBank.d317.s13.e1
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d317.s14;;
Free;O;O
hormone;O;O
concentrations;O;O
may;O;O
be;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d317.s15;;
Other;O;O
plasma;O;O
proteins;O;O
may;O;O
be;O;O
increased;O;O
(;O;O
angiotensinogen;O;O
/;O;O
renin;O;O
substrate;O;O
,;O;O
alpha;O;O
-;O;O
1;O;O
-;O;O
antitrypsin;O;O
,;O;O
ceruloplasmin;O;O
);O;O
.;O;O
DDI-DrugBank.d317.s16;;
4;O;O
.;O;O
DDI-DrugBank.d317.s17;;
Increased;O;O
plasma;O;O
HDL;O;O
and;O;O
HDL2;O;O
cholesterol;O;O
subfraction;O;O
concentrations;O;O
,;O;O
reduced;O;O
LDL;O;O
cholesterol;O;O
concentration;O;O
,;O;O
increased;O;O
triglyceride;O;O
levels;O;O
.;O;O
DDI-DrugBank.d317.s18;;
5;O;O
.;O;O
DDI-DrugBank.d317.s19;;
Impaired;O;O
glucose;O;O
tolerance;O;O
.;O;O
DDI-DrugBank.d317.s20;;
6;O;O
.;O;O
DDI-DrugBank.d317.s21;;
Reduced;O;O
response;O;O
to;O;O
metyrapone;O;O
test;O;O
.;O;O
DDI-DrugBank.d25.s0;;
Corticotropin;B-drug;B-DDI-DrugBank.d25.s0.e0
may;O;O
accentuate;O;O
the;O;O
electrolyte;O;O
loss;O;O
associated;O;O
with;O;O
diuretic;B-drug;B-DDI-DrugBank.d25.s0.e1
therapy;O;O
.;O;O
DDI-DrugBank.d487.s0;;
The;O;O
pharmacokinetic;O;O
interactions;O;O
listed;O;O
below;O;O
are;O;O
potentially;O;O
clinically;O;O
important;O;O
.;O;O
DDI-DrugBank.d487.s1;;
Drugs;O;O
that;O;O
induce;O;O
hepatic;O;O
enzymes;O;O
such;O;O
as;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d487.s1.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d487.s1.e1
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d487.s1.e2
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d487.s1.e3
and;O;O
may;O;O
require;O;O
increases;O;O
in;O;O
corticosteroid;B-group;B-DDI-DrugBank.d487.s1.e4
dose;O;O
to;O;O
achieve;O;O
the;O;O
desired;O;O
response;O;O
.;O;O
DDI-DrugBank.d487.s2;;
Drugs;O;O
such;O;O
as;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d487.s2.e0
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d487.s2.e1
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d487.s2.e2
and;O;O
thus;O;O
decrease;O;O
their;O;O
clearance;O;O
.;O;O
DDI-DrugBank.d487.s3;;
Therefore;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
corticosteroid;B-group;B-DDI-DrugBank.d487.s3.e0
should;O;O
be;O;O
titrated;O;O
to;O;O
avoid;O;O
steroid;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d487.s4;;
Corticosteroids;B-group;B-DDI-DrugBank.d487.s4.e0
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
chronic;O;O
high;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d487.s4.e1
.;O;O
DDI-DrugBank.d487.s5;;
This;O;O
could;O;O
lead;O;O
to;O;O
decreased;O;O
salicylate;B-group;B-DDI-DrugBank.d487.s5.e0
serum;O;O
levels;O;O
or;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
salicylate;B-group;B-DDI-DrugBank.d487.s5.e1
toxicity;O;O
when;O;O
corticosteroid;B-drug;B-DDI-DrugBank.d487.s5.e2
is;O;O
withdrawn;O;O
.;O;O
DDI-DrugBank.d487.s6;;
Aspirin;B-brand;B-DDI-DrugBank.d487.s6.e0
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
conjunction;O;O
with;O;O
cortico;B-group;B-DDI-DrugBank.d487.s6.e1
-;I-group;I-DDI-DrugBank.d487.s6.e1
steroids;I-group;I-DDI-DrugBank.d487.s6.e1
in;O;O
patients;O;O
suffering;O;O
from;O;O
hypopro;O;O
-;O;O
thrombinemia;O;O
.;O;O
DDI-DrugBank.d487.s7;;
The;O;O
effect;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d487.s7.e0
on;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d487.s7.e1
is;O;O
variable;O;O
.;O;O
DDI-DrugBank.d487.s8;;
There;O;O
are;O;O
reports;O;O
of;O;O
enhanced;O;O
as;O;O
well;O;O
as;O;O
diminished;O;O
effects;O;O
of;O;O
anticoagulants;B-group;B-DDI-DrugBank.d487.s8.e0
when;O;O
given;O;O
concurrently;O;O
with;O;O
corticosteroids;B-group;B-DDI-DrugBank.d487.s8.e1
.;O;O
DDI-DrugBank.d487.s9;;
Therefore;O;O
,;O;O
coagulation;O;O
indices;O;O
should;O;O
be;O;O
monitored;O;O
to;O;O
maintain;O;O
the;O;O
desired;O;O
anticoagulant;O;O
effect;O;O
.;O;O
DDI-DrugBank.d439.s0;;
Corticotropin;B-drug;B-DDI-DrugBank.d439.s0.e0
may;O;O
accentuate;O;O
the;O;O
electrolyte;O;O
loss;O;O
associated;O;O
with;O;O
diuretic;B-group;B-DDI-DrugBank.d439.s0.e1
therapy;O;O
.;O;O
DDI-DrugBank.d229.s0;;
Drug;O;O
Interaction;O;O
During;O;O
Pregnancy;O;O
:;O;O
Cromolyn;B-drug;B-DDI-DrugBank.d229.s0.e0
sodium;I-drug;I-DDI-DrugBank.d229.s0.e0
and;O;O
isoproterenol;B-drug;B-DDI-DrugBank.d229.s0.e1
were;O;O
studied;O;O
following;O;O
subcutaneous;O;O
injections;O;O
in;O;O
pregnant;O;O
mice;O;O
.;O;O
DDI-DrugBank.d229.s1;;
Cromolyn;B-drug;B-DDI-DrugBank.d229.s1.e0
sodium;I-drug;I-DDI-DrugBank.d229.s1.e0
alone;O;O
in;O;O
doses;O;O
up;O;O
to;O;O
540;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
approximately;O;O
340;O;O
times;O;O
the;O;O
maximum;O;O
recommended;O;O
daily;O;O
inhalation;O;O
dose;O;O
in;O;O
adults;O;O
on;O;O
a;O;O
mg;O;O
/;O;O
m2;O;O
basis;O;O
);O;O
did;O;O
not;O;O
cause;O;O
significant;O;O
increases;O;O
in;O;O
resorptions;O;O
or;O;O
major;O;O
malformations;O;O
.;O;O
DDI-DrugBank.d229.s2;;
Isoproterenol;B-drug;B-DDI-DrugBank.d229.s2.e0
alone;O;O
at;O;O
a;O;O
dose;O;O
of;O;O
2.7;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
approximately;O;O
7;O;O
times;O;O
the;O;O
maximum;O;O
recommended;O;O
daily;O;O
inhalation;O;O
dose;O;O
in;O;O
adults;O;O
on;O;O
a;O;O
mg;O;O
/;O;O
m2;O;O
basis;O;O
);O;O
increased;O;O
both;O;O
resorptions;O;O
and;O;O
malformations;O;O
.;O;O
DDI-DrugBank.d229.s3;;
The;O;O
addition;O;O
of;O;O
540;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
of;O;O
cromolyn;B-drug;B-DDI-DrugBank.d229.s3.e0
sodium;I-drug;I-DDI-DrugBank.d229.s3.e0
(;O;O
approximately;O;O
340;O;O
times;O;O
the;O;O
maximum;O;O
recommended;O;O
daily;O;O
inhalation;O;O
dose;O;O
in;O;O
adults;O;O
on;O;O
a;O;O
mg;O;O
/;O;O
m2;O;O
basis;O;O
);O;O
to;O;O
2.7;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
of;O;O
isoproterenol;B-drug;B-DDI-DrugBank.d229.s3.e1
(;O;O
approximately;O;O
7;O;O
times;O;O
the;O;O
maximum;O;O
recommended;O;O
daily;O;O
inhalation;O;O
dose;O;O
in;O;O
adults;O;O
on;O;O
a;O;O
mg;O;O
/;O;O
m2;O;O
basis;O;O
);O;O
appears;O;O
to;O;O
have;O;O
increased;O;O
the;O;O
incidence;O;O
of;O;O
both;O;O
resorptions;O;O
and;O;O
malformations;O;O
.;O;O
DDI-DrugBank.d349.s0;;
None;O;O
known;O;O
.;O;O
DDI-DrugBank.d39.s0;;
Persons;O;O
taking;O;O
most;O;O
antibiotics;B-group;B-DDI-DrugBank.d39.s0.e0
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d39.s0.e1
and;O;O
pyrimethamine;B-drug;B-DDI-DrugBank.d39.s0.e2
invalidate;O;O
folic;B-drug;B-DDI-DrugBank.d39.s0.e3
acid;I-drug;I-DDI-DrugBank.d39.s0.e3
and;O;O
vitamin;B-drug;B-DDI-DrugBank.d39.s0.e4
B12;I-drug;I-DDI-DrugBank.d39.s0.e4
diagnostic;O;O
blood;O;O
assays;O;O
.;O;O
DDI-DrugBank.d39.s1;;
Colchicine;B-drug;B-DDI-DrugBank.d39.s1.e0
para;I-drug;I-DDI-DrugBank.d39.s1.e1
-;I-drug;I-DDI-DrugBank.d39.s1.e1
aminosalicylic;I-drug;I-DDI-DrugBank.d39.s1.e1
acid;I-drug;I-DDI-DrugBank.d39.s1.e1
and;O;O
heavy;O;O
alcohol;B-drug;B-DDI-DrugBank.d39.s1.e2
intake;O;O
for;O;O
longer;O;O
than;O;O
2;O;O
weeks;O;O
may;O;O
produce;O;O
malabsorption;O;O
of;O;O
vitamin;B-drug;B-DDI-DrugBank.d39.s1.e3
B12;I-drug;I-DDI-DrugBank.d39.s1.e3
.;O;O
DDI-DrugBank.d150.s0;;
FLEXERIL;B-brand;B-DDI-DrugBank.d150.s0.e0
may;O;O
have;O;O
life;O;O
-;O;O
threatening;O;O
interactions;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d150.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d150.s0.e1
.;O;O
DDI-DrugBank.d150.s1;;
FLEXERIL;B-brand;B-DDI-DrugBank.d150.s1.e0
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d150.s1.e1
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d150.s1.e2
,;O;O
and;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d150.s1.e3
depressants;I-group;I-DDI-DrugBank.d150.s1.e3
.;O;O
DDI-DrugBank.d150.s2;;
Tricyclic;B-group;B-DDI-DrugBank.d150.s2.e0
antidepressants;I-group;I-DDI-DrugBank.d150.s2.e0
may;O;O
block;O;O
the;O;O
antihypertensive;O;O
action;O;O
of;O;O
guanethidine;B-drug;B-DDI-DrugBank.d150.s2.e1
and;O;O
similarly;O;O
acting;O;O
compounds;O;O
.;O;O
DDI-DrugBank.d150.s3;;
Tricyclic;B-group;B-DDI-DrugBank.d150.s3.e0
antidepressants;I-group;I-DDI-DrugBank.d150.s3.e0
may;O;O
enhance;O;O
the;O;O
seizure;O;O
risk;O;O
in;O;O
patients;O;O
taking;O;O
tramadol;B-drug;B-DDI-DrugBank.d150.s3.e1
DDI-DrugBank.d150.s4;;
.;O;O
DDI-DrugBank.d150.s5;;
DDI-DrugBank.d298.s0;;
Cyclopentolate;B-drug;B-DDI-DrugBank.d298.s0.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
anti;O;O
-;O;O
glaucoma;O;O
action;O;O
of;O;O
carbachol;B-drug;B-DDI-DrugBank.d298.s0.e1
or;O;O
pilocarpine;B-drug;B-DDI-DrugBank.d298.s0.e2
,;O;O
DDI-DrugBank.d298.s1;;
also;O;O
,;O;O
concurrent;O;O
use;O;O
of;O;O
this;O;O
medication;O;O
may;O;O
antagonise;O;O
the;O;O
anti;O;O
-;O;O
glaucoma;O;O
and;O;O
miotic;O;O
actions;O;O
of;O;O
ophthalmic;O;O
cholinesterase;B-group;B-DDI-DrugBank.d298.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d298.s1.e0
.;O;O
DDI-DrugBank.d7.s0;;
The;O;O
rate;O;O
of;O;O
metabolism;O;O
and;O;O
the;O;O
leukopenic;O;O
activity;O;O
of;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d7.s0.e0
reportedly;O;O
are;O;O
increased;O;O
by;O;O
chronic;O;O
administration;O;O
of;O;O
high;O;O
doses;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d7.s0.e1
.;O;O
DDI-DrugBank.d7.s1;;
The;O;O
physician;O;O
should;O;O
be;O;O
alert;O;O
for;O;O
possible;O;O
combined;O;O
drug;O;O
actions;O;O
,;O;O
desirable;O;O
or;O;O
undesirable;O;O
,;O;O
involving;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d7.s1.e0
even;O;O
though;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d7.s1.e1
has;O;O
been;O;O
used;O;O
successfully;O;O
concurrently;O;O
with;O;O
other;O;O
drugs;O;O
,;O;O
including;O;O
other;O;O
cytotoxic;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d7.s2;;
Cyclophosphamide;B-drug;B-DDI-DrugBank.d7.s2.e0
treatment;O;O
,;O;O
which;O;O
causes;O;O
a;O;O
marked;O;O
and;O;O
persistent;O;O
inhibition;O;O
of;O;O
cholinesterase;O;O
activity;O;O
,;O;O
potentiates;O;O
the;O;O
effect;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d7.s2.e1
chloride;I-drug;I-DDI-DrugBank.d7.s2.e1
.;O;O
DDI-DrugBank.d7.s3;;
If;O;O
a;O;O
patient;O;O
has;O;O
been;O;O
treated;O;O
with;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d7.s3.e0
within;O;O
10;O;O
days;O;O
of;O;O
general;O;O
anesthesia;O;O
,;O;O
the;O;O
anesthesiologist;O;O
should;O;O
be;O;O
alerted;O;O
.;O;O
DDI-DrugBank.d128.s0;;
May;O;O
interact;O;O
with;O;O
wthionamide;O;O
(;O;O
Trecator;B-brand;B-DDI-DrugBank.d128.s0.e0
-;I-brand;I-DDI-DrugBank.d128.s0.e0
SC;I-brand;I-DDI-DrugBank.d128.s0.e0
);O;O
and;O;O
isoniazid;B-drug;B-DDI-DrugBank.d128.s0.e1
(;O;O
Nydrazid;B-brand;B-DDI-DrugBank.d128.s0.e2
);O;O
.;O;O
DDI-DrugBank.d492.s0;;
MAO;B-group;B-DDI-DrugBank.d492.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d492.s0.e0
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d492.s0.e1
.;O;O
DDI-DrugBank.d492.s1;;
Antihistamines;B-group;B-DDI-DrugBank.d492.s1.e0
may;O;O
have;O;O
additive;O;O
effects;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d492.s1.e1
and;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d492.s1.e2
depressants;I-group;I-DDI-DrugBank.d492.s1.e2
,;O;O
e.g.;O;O
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d492.s1.e3
,;O;O
sedatives;B-group;B-DDI-DrugBank.d492.s1.e4
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d492.s1.e5
,;O;O
antianxiety;B-group;B-DDI-DrugBank.d492.s1.e6
agents;I-group;I-DDI-DrugBank.d492.s1.e6
.;O;O
DDI-DrugBank.d259.s0;;
No;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d101.s0;;
Steady;O;O
state;O;O
plasma;O;O
digitoxin;B-drug;B-DDI-DrugBank.d101.s0.e0
concentrations;O;O
did;O;O
not;O;O
appear;O;O
to;O;O
change;O;O
.;O;O
DDI-DrugBank.d101.s1;;
Therefore;O;O
,;O;O
monitoring;O;O
of;O;O
plasma;O;O
digoxin;B-drug;B-DDI-DrugBank.d101.s1.e0
levels;O;O
may;O;O
be;O;O
indicated;O;O
in;O;O
patients;O;O
receiving;O;O
similar;O;O
combination;O;O
chemotherapy;O;O
regimens;O;O
.;O;O
DDI-DrugBank.d101.s2;;
The;O;O
utilization;O;O
of;O;O
digitoxin;B-drug;B-DDI-DrugBank.d101.s2.e0
for;O;O
such;O;O
patients;O;O
may;O;O
be;O;O
considered;O;O
as;O;O
an;O;O
alternative;O;O
.;O;O
DDI-DrugBank.d101.s3;;
Also;O;O
flucytosine;B-drug;B-DDI-DrugBank.d101.s3.e0
.;O;O
DDI-DrugBank.d294.s0;;
Drug;O;O
/;O;O
LaboratoryTest;O;O
Interactions;O;O
Dactinomycin;B-drug;B-DDI-DrugBank.d294.s0.e0
may;O;O
interfere;O;O
with;O;O
bioassay;O;O
procedures;O;O
for;O;O
the;O;O
determination;O;O
of;O;O
antibacterial;B-group;B-DDI-DrugBank.d294.s0.e1
drug;I-group;I-DDI-DrugBank.d294.s0.e1
levels;O;O
.;O;O
DDI-DrugBank.d305.s0;;
Dantrium;B-brand;B-DDI-DrugBank.d305.s0.e0
is;O;O
metabolized;O;O
by;O;O
the;O;O
liver;O;O
,;O;O
and;O;O
it;O;O
is;O;O
theoretically;O;O
possible;O;O
that;O;O
its;O;O
metabolism;O;O
may;O;O
be;O;O
enhanced;O;O
by;O;O
drugs;O;O
known;O;O
to;O;O
induce;O;O
hepatic;O;O
microsomal;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d305.s1;;
However;O;O
,;O;O
neither;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d305.s1.e0
nor;O;O
diazepam;B-drug;B-DDI-DrugBank.d305.s1.e1
appears;O;O
to;O;O
affect;O;O
Dantrium;B-brand;B-DDI-DrugBank.d305.s1.e2
metabolism;O;O
.;O;O
DDI-DrugBank.d305.s2;;
Binding;O;O
to;O;O
plasma;O;O
protein;O;O
is;O;O
not;O;O
significantly;O;O
altered;O;O
by;O;O
diazepam;B-drug;B-DDI-DrugBank.d305.s2.e0
,;O;O
diphenylhydantoin;B-drug;B-DDI-DrugBank.d305.s2.e1
,;O;O
or;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d305.s2.e2
.;O;O
DDI-DrugBank.d305.s3;;
Binding;O;O
to;O;O
plasma;O;O
proteins;O;O
is;O;O
reduced;O;O
by;O;O
warfarin;B-drug;B-DDI-DrugBank.d305.s3.e0
and;O;O
clotibrate;O;O
and;O;O
increased;O;O
by;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d305.s3.e1
.;O;O
DDI-DrugBank.d305.s4;;
Cardiovascular;O;O
collapse;O;O
in;O;O
patients;O;O
treated;O;O
simultaneously;O;O
with;O;O
varapamil;O;O
and;O;O
dantrolene;B-drug;B-DDI-DrugBank.d305.s4.e0
sodium;I-drug;I-DDI-DrugBank.d305.s4.e0
is;O;O
rare;O;O
.;O;O
DDI-DrugBank.d305.s5;;
The;O;O
combination;O;O
of;O;O
therapeutic;O;O
doses;O;O
of;O;O
intravenous;O;O
dantrolene;B-drug;B-DDI-DrugBank.d305.s5.e0
sodium;I-drug;I-DDI-DrugBank.d305.s5.e0
and;O;O
verapamil;B-drug;B-DDI-DrugBank.d305.s5.e1
in;O;O
halothane;B-drug;B-DDI-DrugBank.d305.s5.e2
a;O;O
-;O;O
chloralose;O;O
anesthetized;O;O
swine;O;O
has;O;O
resulted;O;O
in;O;O
ventricular;O;O
fibrillation;O;O
and;O;O
cardiovascular;O;O
collapse;O;O
in;O;O
association;O;O
with;O;O
marked;O;O
hyperkalemia;O;O
.;O;O
DDI-DrugBank.d305.s6;;
It;O;O
is;O;O
recommended;O;O
that;O;O
the;O;O
combination;O;O
of;O;O
intravenous;O;O
dantrolene;B-drug;B-DDI-DrugBank.d305.s6.e0
sodium;I-drug;I-DDI-DrugBank.d305.s6.e0
and;O;O
calcium;B-group;B-DDI-DrugBank.d305.s6.e1
channel;I-group;I-DDI-DrugBank.d305.s6.e1
blockers;I-group;I-DDI-DrugBank.d305.s6.e1
,;O;O
such;O;O
as;O;O
verapamil;B-drug;B-DDI-DrugBank.d305.s6.e2
,;O;O
not;O;O
be;O;O
used;O;O
together;O;O
during;O;O
the;O;O
management;O;O
of;O;O
malignant;O;O
hyperthermia;O;O
crisis;O;O
until;O;O
the;O;O
relevance;O;O
of;O;O
these;O;O
findings;O;O
to;O;O
humans;O;O
is;O;O
established;O;O
.;O;O
DDI-DrugBank.d305.s7;;
Administration;O;O
of;O;O
dantrolene;B-drug;B-DDI-DrugBank.d305.s7.e0
may;O;O
potentiate;O;O
vecuronium;B-drug;B-DDI-DrugBank.d305.s7.e1
-;O;O
induced;O;O
neuromuscular;O;O
block;O;O
.;O;O
DDI-DrugBank.d185.s0;;
A;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
study;O;O
evaluated;O;O
the;O;O
effect;O;O
of;O;O
the;O;O
use;O;O
of;O;O
ACZONE;B-brand;B-DDI-DrugBank.d185.s0.e0
Gel;O;O
,;O;O
5;O;O
%;O;O
,;O;O
in;O;O
combination;O;O
with;O;O
double;O;O
strength;O;O
(;O;O
160;O;O
mg;O;O
/;O;O
800;O;O
mg;O;O
);O;O
trimethoprim;B-drug;B-DDI-DrugBank.d185.s0.e1
/;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d185.s0.e2
(;O;O
TMP;B-drug;B-DDI-DrugBank.d185.s0.e3
/;O;O
SMX;B-drug;B-DDI-DrugBank.d185.s0.e4
);O;O
.;O;O
DDI-DrugBank.d185.s1;;
During;O;O
co;O;O
-;O;O
administration;O;O
,;O;O
systemic;O;O
levels;O;O
of;O;O
TMP;B-drug;B-DDI-DrugBank.d185.s1.e0
and;O;O
SMX;B-drug;B-DDI-DrugBank.d185.s1.e1
were;O;O
essentially;O;O
unchanged;O;O
.;O;O
DDI-DrugBank.d185.s2;;
Notably;O;O
,;O;O
systemic;O;O
exposure;O;O
(;O;O
AUC0;O;O
-;O;O
12;O;O
);O;O
of;O;O
dapsone;B-drug_n;B-DDI-DrugBank.d185.s2.e0
hydroxylamine;I-drug_n;I-DDI-DrugBank.d185.s2.e0
(;O;O
DHA;B-drug_n;B-DDI-DrugBank.d185.s2.e1
);O;O
was;O;O
more;O;O
than;O;O
doubled;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
TMP;B-drug;B-DDI-DrugBank.d185.s2.e2
/;O;O
SMX;B-drug;B-DDI-DrugBank.d185.s2.e3
.;O;O
DDI-DrugBank.d185.s3;;
Exposure;O;O
from;O;O
the;O;O
proposed;O;O
topical;O;O
dose;O;O
is;O;O
about;O;O
1;O;O
%;O;O
of;O;O
that;O;O
from;O;O
the;O;O
100;O;O
mg;O;O
oral;O;O
dose;O;O
,;O;O
even;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
TMP;B-drug;B-DDI-DrugBank.d185.s3.e0
/;O;O
SMX;B-drug;B-DDI-DrugBank.d185.s3.e1
.;O;O
DDI-DrugBank.d185.s4;;
Certain;O;O
concomitant;O;O
medications;O;O
(;O;O
such;O;O
as;O;O
rifampin;B-drug;B-DDI-DrugBank.d185.s4.e0
,;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d185.s4.e1
,;O;O
St.;O;O
DDI-DrugBank.d185.s5;;
John;O;O
s;O;O
wort;O;O
);O;O
may;O;O
increase;O;O
the;O;O
formation;O;O
of;O;O
dapsone;B-drug_n;B-DDI-DrugBank.d185.s5.e0
hydroxylamine;I-drug_n;I-DDI-DrugBank.d185.s5.e0
,;O;O
a;O;O
metabolite;O;O
of;O;O
dapsone;B-drug;B-DDI-DrugBank.d185.s5.e1
associated;O;O
with;O;O
hemolysis;O;O
.;O;O
DDI-DrugBank.d185.s6;;
With;O;O
oral;O;O
dapsone;B-drug;B-DDI-DrugBank.d185.s6.e0
treatment;O;O
,;O;O
folic;B-group;B-DDI-DrugBank.d185.s6.e1
acid;I-group;I-DDI-DrugBank.d185.s6.e1
antagonists;I-group;I-DDI-DrugBank.d185.s6.e1
such;O;O
as;O;O
pyrimethamine;B-drug;B-DDI-DrugBank.d185.s6.e2
have;O;O
been;O;O
noted;O;O
to;O;O
possibly;O;O
increase;O;O
the;O;O
likelihood;O;O
of;O;O
hematologic;O;O
reactions;O;O
DDI-DrugBank.d185.s7;;
.;O;O
DDI-DrugBank.d185.s8;;
DDI-DrugBank.d337.s0;;
Warfarin;B-drug;B-DDI-DrugBank.d337.s0.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
daptomycin;B-drug;B-DDI-DrugBank.d337.s0.e1
(;O;O
6;O;O
mg;O;O
/;O;O
kg;O;O
once;O;O
every;O;O
24;O;O
hours;O;O
for;O;O
5;O;O
days;O;O
);O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d337.s0.e2
(;O;O
25;O;O
mg;O;O
single;O;O
oral;O;O
dose;O;O
);O;O
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
drug;O;O
,;O;O
and;O;O
the;O;O
INR;O;O
was;O;O
not;O;O
significantly;O;O
altered;O;O
.;O;O
DDI-DrugBank.d337.s1;;
HMG;B-group;B-DDI-DrugBank.d337.s1.e0
-;I-group;I-DDI-DrugBank.d337.s1.e0
CoA;I-group;I-DDI-DrugBank.d337.s1.e0
Reductase;I-group;I-DDI-DrugBank.d337.s1.e0
Inhibitors;I-group;I-DDI-DrugBank.d337.s1.e0
:;O;O
Inhibitors;B-group;B-DDI-DrugBank.d337.s1.e1
of;I-group;I-DDI-DrugBank.d337.s1.e1
HMG;I-group;I-DDI-DrugBank.d337.s1.e1
-;I-group;I-DDI-DrugBank.d337.s1.e1
CoA;I-group;I-DDI-DrugBank.d337.s1.e1
reductase;I-group;I-DDI-DrugBank.d337.s1.e1
may;O;O
cause;O;O
myopathy;O;O
,;O;O
which;O;O
is;O;O
manifested;O;O
as;O;O
muscle;O;O
pain;O;O
or;O;O
weakness;O;O
associated;O;O
with;O;O
elevated;O;O
levels;O;O
of;O;O
CPK;O;O
.;O;O
DDI-DrugBank.d337.s2;;
There;O;O
were;O;O
no;O;O
reports;O;O
of;O;O
skeletal;O;O
myopathy;O;O
in;O;O
a;O;O
placebo;O;O
-;O;O
controlled;O;O
Phase;O;O
I;O;O
trial;O;O
in;O;O
which;O;O
10;O;O
healthy;O;O
subjects;O;O
on;O;O
stable;O;O
simvastatin;B-drug;B-DDI-DrugBank.d337.s2.e0
therapy;O;O
were;O;O
treated;O;O
concurrently;O;O
with;O;O
daptomycin;B-drug;B-DDI-DrugBank.d337.s2.e1
(;O;O
4;O;O
mg;O;O
/;O;O
kg;O;O
once;O;O
every;O;O
24;O;O
hours;O;O
);O;O
for;O;O
14;O;O
days;O;O
.;O;O
DDI-DrugBank.d337.s3;;
Experience;O;O
with;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
HMG;B-group;B-DDI-DrugBank.d337.s3.e0
-;I-group;I-DDI-DrugBank.d337.s3.e0
CoA;I-group;I-DDI-DrugBank.d337.s3.e0
reductase;I-group;I-DDI-DrugBank.d337.s3.e0
inhibitors;I-group;I-DDI-DrugBank.d337.s3.e0
and;O;O
Fentanyl;B-drug;B-DDI-DrugBank.d337.s3.e1
in;O;O
patients;O;O
is;O;O
limited;O;O
,;O;O
therefore;O;O
,;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
temporarily;O;O
suspending;O;O
use;O;O
of;O;O
HMG;B-group;B-DDI-DrugBank.d337.s3.e2
-;I-group;I-DDI-DrugBank.d337.s3.e2
CoA;I-group;I-DDI-DrugBank.d337.s3.e2
reductase;I-group;I-DDI-DrugBank.d337.s3.e2
inhibitors;I-group;I-DDI-DrugBank.d337.s3.e2
in;O;O
patients;O;O
receiving;O;O
Fentanyl;B-drug;B-DDI-DrugBank.d337.s3.e3
.;O;O
DDI-DrugBank.d337.s4;;
Drug;O;O
-;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
There;O;O
are;O;O
no;O;O
reported;O;O
drug;O;O
-;O;O
laboratory;O;O
test;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d534.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
of;O;O
Aranesp;B-brand;B-DDI-DrugBank.d534.s0.e0
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d459.s0;;
The;O;O
daily;O;O
dose;O;O
of;O;O
ENABLEX;B-brand;B-DDI-DrugBank.d459.s0.e0
should;O;O
not;O;O
exceed;O;O
7.5;O;O
mg;O;O
when;O;O
coadministered;O;O
with;O;O
potent;O;O
CYP3A4;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d459.s0.e1
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d459.s0.e2
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d459.s0.e3
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d459.s0.e4
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d459.s0.e5
and;O;O
nefazadone;O;O
);O;O
.;O;O
DDI-DrugBank.d459.s1;;
Caution;O;O
should;O;O
be;O;O
taken;O;O
when;O;O
ENABLEX;B-brand;B-DDI-DrugBank.d459.s1.e0
is;O;O
used;O;O
concomitantly;O;O
with;O;O
medications;O;O
that;O;O
are;O;O
predominantly;O;O
metabolized;O;O
by;O;O
CYP2D6;O;O
and;O;O
which;O;O
have;O;O
a;O;O
narrow;O;O
therapeutic;O;O
window;O;O
,;O;O
such;O;O
as;O;O
flecainide;B-drug;B-DDI-DrugBank.d459.s1.e1
,;O;O
thioridazine;B-drug;B-DDI-DrugBank.d459.s1.e2
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d459.s1.e3
antidepressants;I-group;I-DDI-DrugBank.d459.s1.e3
(;O;O
see;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
);O;O
.;O;O
DDI-DrugBank.d459.s2;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
ENABLEX;B-brand;B-DDI-DrugBank.d459.s2.e0
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d459.s2.e1
agents;I-group;I-DDI-DrugBank.d459.s2.e1
may;O;O
increase;O;O
the;O;O
frequency;O;O
and/or;O;O
severity;O;O
of;O;O
dry;O;O
mouth;O;O
,;O;O
constipation;O;O
,;O;O
blurred;O;O
vision;O;O
and;O;O
other;O;O
anticholinergic;O;O
pharmacological;O;O
effects;O;O
.;O;O
DDI-DrugBank.d459.s3;;
Anticholinergic;B-group;B-DDI-DrugBank.d459.s3.e0
agents;I-group;I-DDI-DrugBank.d459.s3.e0
may;O;O
potentially;O;O
alter;O;O
the;O;O
absorption;O;O
of;O;O
some;O;O
concomitantly;O;O
administered;O;O
drugs;O;O
due;O;O
to;O;O
effects;O;O
on;O;O
gastrointestinal;O;O
motility;O;O
.;O;O
DDI-DrugBank.d459.s4;;
Drug;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Interactions;O;O
between;O;O
darifenacin;B-drug;B-DDI-DrugBank.d459.s4.e0
and;O;O
laboratory;O;O
tests;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d48.s0;;
Drugs;O;O
that;O;O
may;O;O
increase;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s0.e0
plasma;O;O
concentrations;O;O
CYP3A4;O;O
Inhibitors;O;O
:;O;O
Dasatinib;B-drug;B-DDI-DrugBank.d48.s0.e1
is;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
.;O;O
DDI-DrugBank.d48.s1;;
Concomitant;O;O
use;O;O
of;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s1.e0
and;O;O
drugs;O;O
that;O;O
inhibit;O;O
CYP3A4;O;O
(;O;O
eg;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d48.s1.e1
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d48.s1.e2
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d48.s1.e3
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d48.s1.e4
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d48.s1.e5
,;O;O
atazanavir;B-drug;B-DDI-DrugBank.d48.s1.e6
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d48.s1.e7
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d48.s1.e8
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d48.s1.e9
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d48.s1.e10
,;O;O
telithromycin;B-drug;B-DDI-DrugBank.d48.s1.e11
);O;O
may;O;O
increase;O;O
exposure;O;O
to;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s1.e12
and;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d48.s2;;
In;O;O
patients;O;O
receiving;O;O
treatment;O;O
with;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s2.e0
,;O;O
close;O;O
monitoring;O;O
for;O;O
toxicity;O;O
and;O;O
a;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s2.e1
dose;O;O
reduction;O;O
should;O;O
be;O;O
considered;O;O
if;O;O
systemic;O;O
administration;O;O
of;O;O
a;O;O
potent;O;O
CYP3A4;O;O
inhibitor;O;O
can;O;O
not;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d48.s3;;
Drugs;O;O
that;O;O
may;O;O
decrease;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s3.e0
plasma;O;O
concentrations;O;O
CYP3A4;O;O
Inducers;O;O
:;O;O
Drugs;O;O
that;O;O
induce;O;O
CYP3A4;O;O
activity;O;O
may;O;O
decrease;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s3.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d48.s4;;
In;O;O
patients;O;O
in;O;O
whom;O;O
CYP3A4;O;O
inducers;O;O
(;O;O
eg;O;O
,;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d48.s4.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d48.s4.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d48.s4.e2
,;O;O
rifampicin;B-drug;B-DDI-DrugBank.d48.s4.e3
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d48.s4.e4
);O;O
are;O;O
indicated;O;O
,;O;O
alternative;O;O
agents;O;O
with;O;O
less;O;O
enzyme;O;O
induction;O;O
potential;O;O
should;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d48.s5;;
If;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s5.e0
must;O;O
be;O;O
administered;O;O
with;O;O
a;O;O
CYP3A4;O;O
inducer;O;O
,;O;O
a;O;O
dose;O;O
increase;O;O
in;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s5.e1
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d48.s6;;
St.;O;O
Johns;O;O
wort;O;O
(;O;O
Hypericum;O;O
perforatum;O;O
);O;O
may;O;O
decrease;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s6.e0
plasma;O;O
concentrations;O;O
unpredictably;O;O
.;O;O
DDI-DrugBank.d48.s7;;
Patients;O;O
receiving;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s7.e0
should;O;O
not;O;O
take;O;O
St.;O;O
Johns;O;O
wort;O;O
.;O;O
DDI-DrugBank.d48.s8;;
Antacids;B-group;B-DDI-DrugBank.d48.s8.e0
:;O;O
Nonclinical;O;O
data;O;O
demonstrate;O;O
that;O;O
the;O;O
solubility;O;O
of;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s8.e1
is;O;O
pH;O;O
dependent;O;O
.;O;O
DDI-DrugBank.d48.s9;;
Simultaneous;O;O
administration;O;O
of;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s9.e0
with;O;O
antacids;B-group;B-DDI-DrugBank.d48.s9.e1
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d48.s10;;
If;O;O
antacid;B-group;B-DDI-DrugBank.d48.s10.e0
therapy;O;O
is;O;O
needed;O;O
,;O;O
the;O;O
antacid;O;O
dose;O;O
should;O;O
be;O;O
administered;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
prior;O;O
to;O;O
or;O;O
2;O;O
hours;O;O
after;O;O
the;O;O
dose;O;O
of;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s10.e1
.;O;O
DDI-DrugBank.d48.s11;;
H2;B-group;B-DDI-DrugBank.d48.s11.e0
Blockers;I-group;I-DDI-DrugBank.d48.s11.e0
/;O;O
Proton;B-group;B-DDI-DrugBank.d48.s11.e1
Pump;I-group;I-DDI-DrugBank.d48.s11.e1
Inhibitors;I-group;I-DDI-DrugBank.d48.s11.e1
:;O;O
Long;O;O
-;O;O
term;O;O
suppression;O;O
of;O;O
gastric;O;O
acid;O;O
secretion;O;O
by;O;O
H2;B-group;B-DDI-DrugBank.d48.s11.e2
blockers;I-group;I-DDI-DrugBank.d48.s11.e2
or;O;O
proton;B-group;B-DDI-DrugBank.d48.s11.e3
pump;I-group;I-DDI-DrugBank.d48.s11.e3
inhibitors;I-group;I-DDI-DrugBank.d48.s11.e3
(;O;O
eg;O;O
,;O;O
famotidine;B-drug;B-DDI-DrugBank.d48.s11.e4
and;O;O
omeprazole;B-drug;B-DDI-DrugBank.d48.s11.e5
);O;O
is;O;O
likely;O;O
to;O;O
reduce;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s11.e6
exposure;O;O
.;O;O
DDI-DrugBank.d48.s12;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
H2;B-group;B-DDI-DrugBank.d48.s12.e0
blockers;I-group;I-DDI-DrugBank.d48.s12.e0
or;O;O
proton;B-group;B-DDI-DrugBank.d48.s12.e1
pump;I-group;I-DDI-DrugBank.d48.s12.e1
inhibitors;I-group;I-DDI-DrugBank.d48.s12.e1
with;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s12.e2
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d48.s13;;
The;O;O
use;O;O
of;O;O
antacids;B-group;B-DDI-DrugBank.d48.s13.e0
should;O;O
be;O;O
considered;O;O
in;O;O
place;O;O
of;O;O
H2;B-group;B-DDI-DrugBank.d48.s13.e1
blockers;I-group;I-DDI-DrugBank.d48.s13.e1
or;O;O
proton;B-group;B-DDI-DrugBank.d48.s13.e2
pump;I-group;I-DDI-DrugBank.d48.s13.e2
inhibitors;I-group;I-DDI-DrugBank.d48.s13.e2
in;O;O
patients;O;O
receiving;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s13.e3
therapy;O;O
.;O;O
DDI-DrugBank.d48.s14;;
Drugs;O;O
that;O;O
may;O;O
have;O;O
their;O;O
plasma;O;O
concentration;O;O
altered;O;O
by;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s14.e0
CYP3A4;O;O
Substrates;O;O
:;O;O
Dasatinib;B-drug;B-DDI-DrugBank.d48.s14.e1
is;O;O
a;O;O
time;O;O
-;O;O
dependent;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d48.s15;;
Therefore;O;O
,;O;O
CYP3A4;O;O
substrates;O;O
known;O;O
to;O;O
have;O;O
a;O;O
narrow;O;O
therapeutic;O;O
index;O;O
such;O;O
as;O;O
alfentanil;B-drug;B-DDI-DrugBank.d48.s15.e0
,;O;O
astemizole;B-drug;B-DDI-DrugBank.d48.s15.e1
,;O;O
terfenadine;B-drug;B-DDI-DrugBank.d48.s15.e2
,;O;O
cisapride;B-drug;B-DDI-DrugBank.d48.s15.e3
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d48.s15.e4
,;O;O
fentanyl;B-drug;B-DDI-DrugBank.d48.s15.e5
,;O;O
pimozide;B-drug;B-DDI-DrugBank.d48.s15.e6
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d48.s15.e7
,;O;O
sirolimus;B-drug;B-DDI-DrugBank.d48.s15.e8
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d48.s15.e9
,;O;O
or;O;O
ergot;B-group;B-DDI-DrugBank.d48.s15.e10
alkaloids;I-group;I-DDI-DrugBank.d48.s15.e10
(;O;O
ergotamine;B-drug;B-DDI-DrugBank.d48.s15.e11
,;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d48.s15.e12
);O;O
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s15.e13
.;O;O
DDI-DrugBank.d48.s16;;
Hepatic;O;O
Impairment;O;O
There;O;O
are;O;O
currently;O;O
no;O;O
clinical;O;O
studies;O;O
with;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s16.e0
in;O;O
patients;O;O
with;O;O
impaired;O;O
liver;O;O
function;O;O
(;O;O
clinical;O;O
studies;O;O
have;O;O
excluded;O;O
patients;O;O
with;O;O
ALT;O;O
and/or;O;O
AST;O;O
2.5;O;O
times;O;O
the;O;O
upper;O;O
limit;O;O
of;O;O
the;O;O
normal;O;O
range;O;O
and/or;O;O
total;O;O
bilirubin;O;O
2;O;O
times;O;O
the;O;O
upper;O;O
limit;O;O
of;O;O
the;O;O
normal;O;O
range;O;O
);O;O
.;O;O
DDI-DrugBank.d48.s17;;
Metabolism;O;O
of;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s17.e0
is;O;O
mainly;O;O
hepatic;O;O
.;O;O
DDI-DrugBank.d48.s18;;
Caution;O;O
is;O;O
recommended;O;O
in;O;O
patients;O;O
with;O;O
hepatic;O;O
impairment;O;O
.;O;O
DDI-DrugBank.d48.s19;;
Renal;O;O
Impairment;O;O
There;O;O
are;O;O
currently;O;O
no;O;O
clinical;O;O
studies;O;O
with;O;O
SPRYCEL;B-brand;B-DDI-DrugBank.d48.s19.e0
in;O;O
patients;O;O
with;O;O
impaired;O;O
renal;O;O
function;O;O
(;O;O
clinical;O;O
studies;O;O
have;O;O
excluded;O;O
patients;O;O
with;O;O
serum;O;O
creatinine;O;O
concentration;O;O
1.5;O;O
times;O;O
the;O;O
upper;O;O
limit;O;O
of;O;O
the;O;O
normal;O;O
range;O;O
);O;O
.;O;O
DDI-DrugBank.d48.s20;;
Dasatinib;B-drug;B-DDI-DrugBank.d48.s20.e0
and;O;O
its;O;O
metabolites;O;O
are;O;O
minimally;O;O
excreted;O;O
via;O;O
the;O;O
kidney;O;O
.;O;O
DDI-DrugBank.d48.s21;;
Since;O;O
the;O;O
renal;O;O
excretion;O;O
of;O;O
unchanged;O;O
dasatinib;B-drug;B-DDI-DrugBank.d48.s21.e0
and;O;O
its;O;O
metabolites;O;O
is;O;O
4;O;O
%;O;O
,;O;O
a;O;O
decrease;O;O
in;O;O
total;O;O
body;O;O
clearance;O;O
is;O;O
not;O;O
expected;O;O
in;O;O
patients;O;O
with;O;O
renal;O;O
insufficiency;O;O
.;O;O
DDI-DrugBank.d69.s0;;
Use;O;O
of;O;O
Cerubidine;B-brand;B-DDI-DrugBank.d69.s0.e0
in;O;O
a;O;O
patient;O;O
who;O;O
has;O;O
previously;O;O
received;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d69.s0.e1
increases;O;O
the;O;O
risk;O;O
of;O;O
cardiotoxicity;O;O
.;O;O
DDI-DrugBank.d69.s1;;
Cerubidine;B-brand;B-DDI-DrugBank.d69.s1.e0
should;O;O
not;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
who;O;O
have;O;O
previously;O;O
received;O;O
the;O;O
recommended;O;O
maximum;O;O
cumulative;O;O
doses;O;O
of;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d69.s1.e1
or;O;O
Cerubidine;B-brand;B-DDI-DrugBank.d69.s1.e2
.;O;O
DDI-DrugBank.d69.s2;;
Cyclophosphamide;B-drug;B-DDI-DrugBank.d69.s2.e0
used;O;O
concurrently;O;O
with;O;O
Cerubidine;B-brand;B-DDI-DrugBank.d69.s2.e1
may;O;O
also;O;O
result;O;O
in;O;O
increased;O;O
cardiotoxicity;O;O
.;O;O
DDI-DrugBank.d69.s3;;
Dosage;O;O
reduction;O;O
of;O;O
Cerubidine;B-brand;B-DDI-DrugBank.d69.s3.e0
may;O;O
be;O;O
required;O;O
when;O;O
used;O;O
concurrently;O;O
with;O;O
other;O;O
myelosuppressive;O;O
agents;O;O
.;O;O
DDI-DrugBank.d69.s4;;
Hepatotoxic;O;O
medications;O;O
,;O;O
such;O;O
as;O;O
high;O;O
-;O;O
dose;O;O
methotrexate;B-drug;B-DDI-DrugBank.d69.s4.e0
,;O;O
may;O;O
impair;O;O
liver;O;O
function;O;O
and;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d167.s0;;
Potentially;O;O
fatal;O;O
drug;O;O
interactions;O;O
may;O;O
occur;O;O
when;O;O
coadministered;O;O
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d167.s0.e0
,;O;O
as;O;O
this;O;O
may;O;O
enhance;O;O
cardiovascular;O;O
depression;O;O
and;O;O
bradyarrhythmias;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d167.s1;;
Anticholinesterases;B-group;B-DDI-DrugBank.d167.s1.e0
(;O;O
neostgmine;O;O
,;O;O
physostigmine;B-drug;B-DDI-DrugBank.d167.s1.e1
);O;O
,;O;O
lignocaine;B-drug;B-DDI-DrugBank.d167.s1.e2
,;O;O
quinine;B-drug;B-DDI-DrugBank.d167.s1.e3
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d167.s1.e4
can;O;O
enhance;O;O
toxicity;O;O
and;O;O
cause;O;O
cardio;O;O
respiratory;O;O
depression;O;O
.;O;O
DDI-DrugBank.d167.s2;;
In;O;O
addition;O;O
,;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
is;O;O
enhanced;O;O
by;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d167.s2.e0
,;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d167.s2.e1
like;O;O
lidocaine;B-drug;B-DDI-DrugBank.d167.s2.e2
,;O;O
procaine;B-drug;B-DDI-DrugBank.d167.s2.e3
,;O;O
beta;B-group;B-DDI-DrugBank.d167.s2.e4
-;I-group;I-DDI-DrugBank.d167.s2.e4
blockers;I-group;I-DDI-DrugBank.d167.s2.e4
,;O;O
metaclopramide;B-drug;B-DDI-DrugBank.d167.s2.e5
,;O;O
lithium;B-drug;B-DDI-DrugBank.d167.s2.e6
carbonate;I-drug;I-DDI-DrugBank.d167.s2.e6
,;O;O
and;O;O
terbutaline;B-drug;B-DDI-DrugBank.d167.s2.e7
.;O;O
DDI-DrugBank.d126.s0;;
Drug;O;O
interaction;O;O
studies;O;O
with;O;O
decitabine;B-drug;B-DDI-DrugBank.d126.s0.e0
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d126.s1;;
In;O;O
vitro;O;O
studies;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
suggest;O;O
that;O;O
decitabine;B-drug;B-DDI-DrugBank.d126.s1.e0
is;O;O
unlikely;O;O
to;O;O
inhibit;O;O
or;O;O
induce;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d126.s2;;
In;O;O
vitro;O;O
metabolism;O;O
studies;O;O
have;O;O
suggested;O;O
that;O;O
decitabine;B-drug;B-DDI-DrugBank.d126.s2.e0
is;O;O
not;O;O
a;O;O
substrate;O;O
for;O;O
the;O;O
human;O;O
liver;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d126.s3;;
As;O;O
plasma;O;O
protein;O;O
binding;O;O
of;O;O
decitabine;B-drug;B-DDI-DrugBank.d126.s3.e0
is;O;O
negligible;O;O
(;O;O
1;O;O
%;O;O
);O;O
,;O;O
interactions;O;O
due;O;O
to;O;O
displacement;O;O
of;O;O
more;O;O
highly;O;O
protein;O;O
bound;O;O
drugs;O;O
from;O;O
plasma;O;O
proteins;O;O
are;O;O
not;O;O
expected;O;O
.;O;O
DDI-DrugBank.d84.s0;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
Exjade;B-brand;B-DDI-DrugBank.d84.s0.e0
and;O;O
aluminum;B-drug;B-DDI-DrugBank.d84.s0.e1
-;O;O
containing;O;O
antacid;B-group;B-DDI-DrugBank.d84.s0.e2
preparations;I-group;I-DDI-DrugBank.d84.s0.e2
has;O;O
not;O;O
been;O;O
formally;O;O
studied;O;O
.;O;O
DDI-DrugBank.d84.s1;;
Although;O;O
deferasirox;B-drug;B-DDI-DrugBank.d84.s1.e0
has;O;O
a;O;O
lower;O;O
affinity;O;O
for;O;O
aluminum;B-drug;B-DDI-DrugBank.d84.s1.e1
than;O;O
for;O;O
iron;B-drug;B-DDI-DrugBank.d84.s1.e2
,;O;O
Exjade;B-brand;B-DDI-DrugBank.d84.s1.e3
should;O;O
not;O;O
be;O;O
taken;O;O
with;O;O
aluminum;B-drug;B-DDI-DrugBank.d84.s1.e4
-;O;O
containing;O;O
antacid;B-group;B-DDI-DrugBank.d84.s1.e5
preparations;I-group;I-DDI-DrugBank.d84.s1.e5
.;O;O
DDI-DrugBank.d84.s2;;
In;O;O
healthy;O;O
volunteers;O;O
,;O;O
Exjade;B-brand;B-DDI-DrugBank.d84.s2.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d84.s2.e1
.;O;O
DDI-DrugBank.d84.s3;;
The;O;O
effect;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d84.s3.e0
on;O;O
Exjade;B-brand;B-DDI-DrugBank.d84.s3.e1
pharmacokinetics;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d84.s4;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
Exjade;B-brand;B-DDI-DrugBank.d84.s4.e0
and;O;O
vitamin;B-drug;B-DDI-DrugBank.d84.s4.e1
C;I-drug;I-DDI-DrugBank.d84.s4.e1
has;O;O
not;O;O
been;O;O
formally;O;O
studied;O;O
.;O;O
DDI-DrugBank.d84.s5;;
Doses;O;O
of;O;O
vitamin;B-drug;B-DDI-DrugBank.d84.s5.e0
C;I-drug;I-DDI-DrugBank.d84.s5.e0
up;O;O
to;O;O
200;O;O
mg;O;O
were;O;O
allowed;O;O
in;O;O
clinical;O;O
studies;O;O
without;O;O
negative;O;O
consequences;O;O
.;O;O
DDI-DrugBank.d84.s6;;
The;O;O
interaction;O;O
of;O;O
Exjade;B-brand;B-DDI-DrugBank.d84.s6.e0
with;O;O
hydroxyurea;B-drug;B-DDI-DrugBank.d84.s6.e1
has;O;O
not;O;O
been;O;O
formally;O;O
studied;O;O
.;O;O
DDI-DrugBank.d84.s7;;
No;O;O
inhibition;O;O
of;O;O
deferasirox;B-drug;B-DDI-DrugBank.d84.s7.e0
metabolism;O;O
by;O;O
hydroxyurea;B-drug;B-DDI-DrugBank.d84.s7.e1
is;O;O
expected;O;O
based;O;O
on;O;O
the;O;O
results;O;O
of;O;O
an;O;O
in;O;O
vitro;O;O
study;O;O
.;O;O
DDI-DrugBank.d84.s8;;
Exjade;B-brand;B-DDI-DrugBank.d84.s8.e0
should;O;O
not;O;O
be;O;O
combined;O;O
with;O;O
other;O;O
iron;O;O
chelator;O;O
therapies;O;O
,;O;O
as;O;O
safety;O;O
of;O;O
such;O;O
combinations;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d84.s9;;
Drug;O;O
/;O;O
Food;O;O
Interactions;O;O
The;O;O
bioavailability;O;O
(;O;O
AUC;O;O
);O;O
of;O;O
deferasirox;B-drug;B-DDI-DrugBank.d84.s9.e0
was;O;O
variably;O;O
increased;O;O
when;O;O
taken;O;O
with;O;O
a;O;O
meal;O;O
.;O;O
DDI-DrugBank.d84.s10;;
Deferasirox;B-drug;B-DDI-DrugBank.d84.s10.e0
should;O;O
be;O;O
taken;O;O
on;O;O
an;O;O
empty;O;O
stomach;O;O
30;O;O
minutes;O;O
before;O;O
eating;O;O
.;O;O
DDI-DrugBank.d84.s11;;
Exjade;B-brand;B-DDI-DrugBank.d84.s11.e0
tablets;O;O
for;O;O
oral;O;O
suspension;O;O
can;O;O
be;O;O
dispersed;O;O
in;O;O
water;O;O
,;O;O
orange;O;O
juice;O;O
,;O;O
or;O;O
apple;O;O
juice;O;O
.;O;O
DDI-DrugBank.d251.s0;;
Antiacid;O;O
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d251.s0.e0
,;O;O
Didanosine;B-drug;B-DDI-DrugBank.d251.s0.e1
,;O;O
Fluconazole;B-drug;B-DDI-DrugBank.d251.s0.e2
,;O;O
Fluoxetine;B-drug;B-DDI-DrugBank.d251.s0.e3
,;O;O
Indanavir;O;O
,;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d251.s0.e4
,;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d251.s0.e5
,;O;O
Phenobarbitol;O;O
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d251.s0.e6
,;O;O
Rifabutin;B-drug;B-DDI-DrugBank.d251.s0.e7
,;O;O
Rifampin;B-drug;B-DDI-DrugBank.d251.s0.e8
,;O;O
Ritanovir;O;O
,;O;O
Saquinavir;B-drug;B-DDI-DrugBank.d251.s0.e9
.;O;O
DDI-DrugBank.d149.s0;;
Possible;O;O
drug;O;O
interactions;O;O
of;O;O
HUMORSOL;B-brand;B-DDI-DrugBank.d149.s0.e0
with;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d149.s0.e1
or;O;O
with;O;O
other;O;O
anticholinesterase;B-group;B-DDI-DrugBank.d149.s0.e2
agents;I-group;I-DDI-DrugBank.d149.s0.e2
.;O;O
DDI-DrugBank.d409.s0;;
Because;O;O
the;O;O
tetracyclines;B-group;B-DDI-DrugBank.d409.s0.e0
have;O;O
been;O;O
shown;O;O
to;O;O
depress;O;O
plasma;O;O
prothrombin;O;O
activity;O;O
,;O;O
patients;O;O
who;O;O
are;O;O
on;O;O
anticoagulant;B-group;B-DDI-DrugBank.d409.s0.e1
therapy;O;O
may;O;O
require;O;O
downward;O;O
adjustment;O;O
of;O;O
their;O;O
anticoagulant;B-group;B-DDI-DrugBank.d409.s0.e2
dosage;O;O
.;O;O
DDI-DrugBank.d409.s1;;
Since;O;O
bacteriostatic;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
the;O;O
tetracycline;B-group;B-DDI-DrugBank.d409.s1.e0
class;I-group;I-DDI-DrugBank.d409.s1.e0
of;O;O
antibiotics;B-group;B-DDI-DrugBank.d409.s1.e1
,;O;O
may;O;O
interfere;O;O
with;O;O
the;O;O
bactericidal;O;O
action;O;O
of;O;O
penicillins;B-group;B-DDI-DrugBank.d409.s1.e2
,;O;O
it;O;O
is;O;O
not;O;O
advisable;O;O
to;O;O
administer;O;O
these;O;O
drugs;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d409.s2;;
Concurrent;O;O
use;O;O
of;O;O
tetracyclines;B-group;B-DDI-DrugBank.d409.s2.e0
with;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d409.s2.e1
may;O;O
render;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d409.s2.e2
less;O;O
effective;O;O
.;O;O
DDI-DrugBank.d409.s3;;
Breakthrough;O;O
bleeding;O;O
has;O;O
been;O;O
reported;O;O
DDI-DrugBank.d182.s0;;
No;O;O
clinical;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d182.s1;;
However;O;O
,;O;O
in;O;O
a;O;O
single;O;O
in;O;O
vivo;O;O
rodent;O;O
study;O;O
denileukin;B-drug;B-DDI-DrugBank.d182.s1.e0
diftitox;I-drug;I-DDI-DrugBank.d182.s1.e0
had;O;O
no;O;O
effect;O;O
on;O;O
P450;O;O
levels;O;O
.;O;O
DDI-DrugBank.d311.s0;;
Taking;O;O
a;O;O
rauwolfia;B-group;B-DDI-DrugBank.d311.s0.e0
alkaloid;I-group;I-DDI-DrugBank.d311.s0.e0
while;O;O
you;O;O
are;O;O
taking;O;O
or;O;O
within;O;O
2;O;O
weeks;O;O
of;O;O
taking;O;O
MAO;B-group;B-DDI-DrugBank.d311.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d311.s0.e1
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
central;O;O
nervous;O;O
system;O;O
depression;O;O
or;O;O
may;O;O
cause;O;O
a;O;O
severe;O;O
high;O;O
blood;O;O
pressure;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d363.s0;;
No;O;O
clinically;O;O
significant;O;O
adverse;O;O
interactions;O;O
with;O;O
commonly;O;O
used;O;O
preanesthetic;O;O
drugs;O;O
,;O;O
or;O;O
drugs;O;O
used;O;O
during;O;O
anesthesia;O;O
(;O;O
muscle;B-group;B-DDI-DrugBank.d363.s0.e0
relaxants;I-group;I-DDI-DrugBank.d363.s0.e0
,;O;O
intravenous;O;O
agents;O;O
,;O;O
and;O;O
local;O;O
anesthetic;B-group;B-DDI-DrugBank.d363.s0.e1
agents;I-group;I-DDI-DrugBank.d363.s0.e1
);O;O
were;O;O
reported;O;O
in;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d363.s1;;
The;O;O
effect;O;O
of;O;O
desflurane;B-drug;B-DDI-DrugBank.d363.s1.e0
on;O;O
the;O;O
disposition;O;O
of;O;O
other;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
determined;O;O
.;O;O
DDI-DrugBank.d363.s2;;
Like;O;O
isoflurane;B-drug;B-DDI-DrugBank.d363.s2.e0
,;O;O
desflurane;B-drug;B-DDI-DrugBank.d363.s2.e1
does;O;O
not;O;O
predispose;O;O
to;O;O
premature;O;O
ventricular;O;O
arrhythmias;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
exogenously;O;O
infused;O;O
epinephrine;B-drug;B-DDI-DrugBank.d363.s2.e2
in;O;O
swine;O;O
.;O;O
DDI-DrugBank.d386.s0;;
1;O;O
.;O;O
DDI-DrugBank.d386.s1;;
Drugs;O;O
Metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
:;O;O
The;O;O
biochemical;O;O
activity;O;O
of;O;O
the;O;O
drug;O;O
metabolizing;O;O
isozyme;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
(;O;O
debrisoquin;O;O
hydroxylase;O;O
);O;O
is;O;O
reduced;O;O
in;O;O
a;O;O
subset;O;O
of;O;O
the;O;O
caucasian;O;O
population;O;O
(;O;O
about;O;O
7;O;O
to;O;O
10;O;O
%;O;O
of;O;O
caucasians;O;O
are;O;O
so;O;O
called;O;O
poor;O;O
metabolizers;O;O
);O;O
,;O;O
DDI-DrugBank.d386.s2;;
reliable;O;O
estimates;O;O
of;O;O
the;O;O
prevalence;O;O
of;O;O
reduced;O;O
P450;O;O
2D6;O;O
isozyme;O;O
activity;O;O
among;O;O
Asian;O;O
,;O;O
African;O;O
and;O;O
other;O;O
populations;O;O
are;O;O
not;O;O
yet;O;O
available;O;O
.;O;O
DDI-DrugBank.d386.s3;;
Poor;O;O
metabolizers;O;O
have;O;O
higher;O;O
than;O;O
expected;O;O
plasma;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s3.e0
antidepressants;I-group;I-DDI-DrugBank.d386.s3.e0
(;O;O
TCAs;B-group;B-DDI-DrugBank.d386.s3.e1
);O;O
when;O;O
given;O;O
usual;O;O
doses;O;O
.;O;O
DDI-DrugBank.d386.s4;;
Depending;O;O
on;O;O
the;O;O
traction;O;O
of;O;O
drug;O;O
metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
,;O;O
the;O;O
increase;O;O
in;O;O
plasma;O;O
concentration;O;O
may;O;O
be;O;O
small;O;O
,;O;O
or;O;O
quite;O;O
large;O;O
(;O;O
8;O;O
fold;O;O
increase;O;O
in;O;O
plasma;O;O
AUC;O;O
of;O;O
the;O;O
TCA;B-group;B-DDI-DrugBank.d386.s4.e0
);O;O
.;O;O
DDI-DrugBank.d386.s5;;
In;O;O
addition;O;O
,;O;O
certain;O;O
drugs;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
this;O;O
isozyme;O;O
and;O;O
make;O;O
normal;O;O
metabolizers;O;O
resemble;O;O
p.o;O;O
.;O;O
DDI-DrugBank.d386.s6;;
metabolizers;O;O
.;O;O
DDI-DrugBank.d386.s7;;
An;O;O
individual;O;O
who;O;O
is;O;O
stable;O;O
on;O;O
a;O;O
given;O;O
dose;O;O
of;O;O
TCA;B-group;B-DDI-DrugBank.d386.s7.e0
may;O;O
become;O;O
abruptly;O;O
toxic;O;O
when;O;O
given;O;O
one;O;O
of;O;O
these;O;O
inhibiting;O;O
drugs;O;O
as;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d386.s8;;
The;O;O
drugs;O;O
that;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
include;O;O
some;O;O
that;O;O
are;O;O
not;O;O
metabolized;O;O
by;O;O
the;O;O
enzyme;O;O
(;O;O
quinidine;B-drug;B-DDI-DrugBank.d386.s8.e0
,;O;O
DDI-DrugBank.d386.s9;;
cimetidine;B-drug;B-DDI-DrugBank.d386.s9.e0
);O;O
and;O;O
many;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
P450;O;O
2D6;O;O
(;O;O
many;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d386.s9.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d386.s9.e2
,;O;O
and;O;O
the;O;O
Type;O;O
1C;O;O
antiarrhythrnics;O;O
propatenone;O;O
and;O;O
flecainide;B-drug;B-DDI-DrugBank.d386.s9.e3
);O;O
.;O;O
DDI-DrugBank.d386.s10;;
While;O;O
all;O;O
the;O;O
selective;B-group;B-DDI-DrugBank.d386.s10.e0
serotonin;I-group;I-DDI-DrugBank.d386.s10.e0
reuptake;I-group;I-DDI-DrugBank.d386.s10.e0
inhibitors;I-group;I-DDI-DrugBank.d386.s10.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d386.s10.e1
);O;O
,;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d386.s10.e2
,;O;O
seriraline;O;O
,;O;O
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d386.s10.e3
,;O;O
inhibit;O;O
P450;O;O
2D6;O;O
,;O;O
they;O;O
may;O;O
vary;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d386.s11;;
The;O;O
extent;O;O
to;O;O
which;O;O
SSRI;B-group;B-DDI-DrugBank.d386.s11.e0
-;O;O
TCA;B-group;B-DDI-DrugBank.d386.s11.e1
interactions;O;O
may;O;O
pose;O;O
clinical;O;O
problems;O;O
will;O;O
depend;O;O
on;O;O
the;O;O
degree;O;O
of;O;O
inhibition;O;O
and;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
the;O;O
SSRI;B-group;B-DDI-DrugBank.d386.s11.e2
involved;O;O
.;O;O
DDI-DrugBank.d386.s12;;
Nevertheless;O;O
,;O;O
caution;O;O
is;O;O
indicated;O;O
in;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
T.A.;B-group;B-DDI-DrugBank.d386.s12.e0
with;O;O
any;O;O
of;O;O
the;O;O
SSRIs;B-group;B-DDI-DrugBank.d386.s12.e1
and;O;O
also;O;O
in;O;O
switching;O;O
from;O;O
one;O;O
class;O;O
to;O;O
the;O;O
other;O;O
.;O;O
DDI-DrugBank.d386.s13;;
Of;O;O
particular;O;O
importance;O;O
,;O;O
sufficient;O;O
time;O;O
must;O;O
elapse;O;O
before;O;O
initiating;O;O
TCA;O;O
treatment;O;O
in;O;O
a;O;O
patient;O;O
being;O;O
withdrawn;O;O
from;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d386.s13.e0
,;O;O
given;O;O
the;O;O
long;O;O
half;O;O
-;O;O
life;O;O
of;O;O
the;O;O
parent;O;O
and;O;O
active;O;O
metabolite;O;O
(;O;O
at;O;O
least;O;O
5;O;O
weeks;O;O
may;O;O
be;O;O
necessary;O;O
);O;O
.;O;O
DDI-DrugBank.d386.s14;;
Concomitant;O;O
use;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s14.e0
antidepressants;I-group;I-DDI-DrugBank.d386.s14.e0
with;O;O
drugs;O;O
that;O;O
can;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
may;O;O
require;O;O
lower;O;O
doses;O;O
than;O;O
usually;O;O
prescribed;O;O
for;O;O
either;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s14.e1
antidepressant;I-group;I-DDI-DrugBank.d386.s14.e1
or;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d386.s15;;
Furthermore;O;O
,;O;O
whenever;O;O
one;O;O
of;O;O
these;O;O
other;O;O
drugs;O;O
is;O;O
withdrawn;O;O
from;O;O
co;O;O
-;O;O
therapy;O;O
,;O;O
an;O;O
increased;O;O
dose;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s15.e0
antidepressant;I-group;I-DDI-DrugBank.d386.s15.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d386.s16;;
It;O;O
is;O;O
desirable;O;O
to;O;O
monitor;O;O
TCA;B-group;B-DDI-DrugBank.d386.s16.e0
plasma;O;O
levels;O;O
whenever;O;O
a;O;O
TCA;B-group;B-DDI-DrugBank.d386.s16.e1
is;O;O
going;O;O
to;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
another;O;O
drug;O;O
known;O;O
to;O;O
be;O;O
an;O;O
inhibitor;O;O
of;O;O
P450;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d386.s17;;
2;O;O
.;O;O
DDI-DrugBank.d386.s18;;
Close;O;O
supervision;O;O
and;O;O
careful;O;O
adjustment;O;O
of;O;O
dosage;O;O
are;O;O
required;O;O
when;O;O
this;O;O
drug;O;O
is;O;O
given;O;O
concomitantly;O;O
with;O;O
anticholinergic;B-group;B-DDI-DrugBank.d386.s18.e0
or;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d386.s18.e1
drugs;I-group;I-DDI-DrugBank.d386.s18.e1
.;O;O
DDI-DrugBank.d386.s19;;
3;O;O
.;O;O
DDI-DrugBank.d386.s20;;
Clinical;O;O
experience;O;O
in;O;O
the;O;O
concurrent;O;O
administration;O;O
of;O;O
ECT;O;O
and;O;O
antidepressant;B-group;B-DDI-DrugBank.d386.s20.e0
drugs;I-group;I-DDI-DrugBank.d386.s20.e0
is;O;O
limited;O;O
.;O;O
DDI-DrugBank.d386.s21;;
Thus;O;O
,;O;O
if;O;O
such;O;O
treatment;O;O
is;O;O
essential;O;O
,;O;O
the;O;O
possibility;O;O
of;O;O
increased;O;O
risk;O;O
relative;O;O
to;O;O
benefits;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d386.s22;;
4;O;O
.;O;O
DDI-DrugBank.d386.s23;;
If;O;O
desipramine;B-drug;B-DDI-DrugBank.d386.s23.e0
hydrochloride;I-drug;I-DDI-DrugBank.d386.s23.e0
is;O;O
to;O;O
be;O;O
combined;O;O
with;O;O
other;O;O
psychotropic;B-group;B-DDI-DrugBank.d386.s23.e1
agents;I-group;I-DDI-DrugBank.d386.s23.e1
such;O;O
as;O;O
tranquilizers;B-group;B-DDI-DrugBank.d386.s23.e2
or;O;O
sedative;B-group;B-DDI-DrugBank.d386.s23.e3
/;O;O
hypnotics;B-group;B-DDI-DrugBank.d386.s23.e4
,;O;O
careful;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
the;O;O
pharmacology;O;O
of;O;O
the;O;O
agents;O;O
employed;O;O
since;O;O
the;O;O
sedative;O;O
effects;O;O
of;O;O
desipramine;B-drug;B-DDI-DrugBank.d386.s23.e5
and;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d386.s23.e6
(;O;O
e.g.;O;O
,;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d386.s23.e7
or;O;O
diazepam;B-drug;B-DDI-DrugBank.d386.s23.e8
);O;O
are;O;O
additive;O;O
.;O;O
DDI-DrugBank.d386.s24;;
Both;O;O
the;O;O
sedative;O;O
and;O;O
anticholinergic;O;O
effects;O;O
of;O;O
the;O;O
major;B-group;B-DDI-DrugBank.d386.s24.e0
tranquilizers;I-group;I-DDI-DrugBank.d386.s24.e0
are;O;O
also;O;O
additive;O;O
to;O;O
those;O;O
of;O;O
desipramine;B-drug;B-DDI-DrugBank.d386.s24.e1
.;O;O
DDI-DrugBank.d386.s25;;
5;O;O
.;O;O
DDI-DrugBank.d386.s26;;
Concurrent;O;O
administration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d386.s26.e0
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s26.e1
antidepressants;I-group;I-DDI-DrugBank.d386.s26.e1
can;O;O
produce;O;O
clinically;O;O
significant;O;O
increases;O;O
in;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s26.e2
antidepressants;I-group;I-DDI-DrugBank.d386.s26.e2
.;O;O
DDI-DrugBank.d386.s27;;
Conversely;O;O
,;O;O
decreases;O;O
in;O;O
plasma;O;O
levels;O;O
of;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s27.e0
antidepressants;I-group;I-DDI-DrugBank.d386.s27.e0
have;O;O
been;O;O
reported;O;O
upon;O;O
discontinuation;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d386.s27.e1
which;O;O
may;O;O
result;O;O
in;O;O
the;O;O
loss;O;O
of;O;O
the;O;O
therapeutic;O;O
efficacy;O;O
of;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s27.e2
antidepressant;I-group;I-DDI-DrugBank.d386.s27.e2
6;O;O
.;O;O
DDI-DrugBank.d386.s28;;
There;O;O
have;O;O
been;O;O
greater;O;O
than;O;O
two;O;O
-;O;O
fold;O;O
increases;O;O
of;O;O
previously;O;O
stable;O;O
plasma;O;O
levels;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d386.s28.e0
antidepressants;I-group;I-DDI-DrugBank.d386.s28.e0
when;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d386.s28.e1
has;O;O
been;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d67.s0;;
In;O;O
two;O;O
controlled;O;O
crossover;O;O
clinical;O;O
pharmacology;O;O
studies;O;O
in;O;O
healthy;O;O
male;O;O
(;O;O
n=12;O;O
in;O;O
each;O;O
study;O;O
);O;O
a;O;O
nd;O;O
female;O;O
(;O;O
n=12;O;O
in;O;O
each;O;O
study;O;O
);O;O
volunteers;O;O
,;O;O
desloratadine;B-drug;B-DDI-DrugBank.d67.s0.e0
7.5;O;O
mg;O;O
(;O;O
1.5;O;O
times;O;O
the;O;O
daily;O;O
dose;O;O
);O;O
once;O;O
daily;O;O
was;O;O
coadministered;O;O
with;O;O
erythromycin;B-drug;B-DDI-DrugBank.d67.s0.e1
500;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
or;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d67.s0.e2
200;O;O
mg;O;O
every;O;O
12;O;O
hours;O;O
for;O;O
10;O;O
days;O;O
.;O;O
DDI-DrugBank.d67.s1;;
In;O;O
three;O;O
separate;O;O
controlled;O;O
,;O;O
parallel;O;O
group;O;O
clinical;O;O
pharmacology;O;O
studies;O;O
,;O;O
desloratadine;B-drug;B-DDI-DrugBank.d67.s1.e0
at;O;O
the;O;O
clinical;O;O
dose;O;O
of;O;O
5;O;O
mg;O;O
has;O;O
been;O;O
coadministered;O;O
with;O;O
azithromycin;B-drug;B-DDI-DrugBank.d67.s1.e1
500;O;O
mg;O;O
followed;O;O
by;O;O
250;O;O
mg;O;O
once;O;O
daily;O;O
for;O;O
4;O;O
days;O;O
(;O;O
n=18;O;O
);O;O
or;O;O
with;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d67.s1.e2
20;O;O
mg;O;O
once;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
after;O;O
a;O;O
23;O;O
day;O;O
pretreatment;O;O
period;O;O
with;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d67.s1.e3
(;O;O
n=18;O;O
);O;O
or;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d67.s1.e4
600;O;O
mg;O;O
every;O;O
12;O;O
hours;O;O
for;O;O
14;O;O
days;O;O
(;O;O
n=18;O;O
);O;O
under;O;O
steady;O;O
state;O;O
conditions;O;O
to;O;O
normal;O;O
healthy;O;O
male;O;O
and;O;O
female;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d67.s2;;
Although;O;O
increased;O;O
plasma;O;O
concentrations;O;O
(;O;O
C;O;O
max;O;O
and;O;O
AUC;O;O
0;O;O
-;O;O
24;O;O
hrs;O;O
);O;O
of;O;O
desloratadine;B-drug;B-DDI-DrugBank.d67.s2.e0
and;O;O
3;B-drug_n;B-DDI-DrugBank.d67.s2.e1
-;I-drug_n;I-DDI-DrugBank.d67.s2.e1
hydroxydesloratadine;I-drug_n;I-DDI-DrugBank.d67.s2.e1
were;O;O
observed;O;O
,;O;O
there;O;O
were;O;O
no;O;O
clinically;O;O
relevant;O;O
changes;O;O
in;O;O
the;O;O
safety;O;O
profile;O;O
of;O;O
desloratadine;B-drug;B-DDI-DrugBank.d67.s2.e2
,;O;O
as;O;O
assessed;O;O
by;O;O
electrocardiographic;O;O
parameters;O;O
(;O;O
including;O;O
the;O;O
corrected;O;O
QT;O;O
interval;O;O
);O;O
,;O;O
clinical;O;O
laboratory;O;O
tests;O;O
,;O;O
vital;O;O
signs;O;O
,;O;O
and;O;O
adverse;O;O
events;O;O
.;O;O
DDI-DrugBank.d67.s3;;
Table;O;O
1;O;O
Changes;O;O
in;O;O
Desloratadine;B-drug;B-DDI-DrugBank.d67.s3.e0
and;O;O
3;B-drug_n;B-DDI-DrugBank.d67.s3.e1
-;I-drug_n;I-DDI-DrugBank.d67.s3.e1
Hydroxydesloratadine;I-drug_n;I-DDI-DrugBank.d67.s3.e1
Pharmacokinetics;O;O
in;O;O
Healthy;O;O
Male;O;O
and;O;O
Female;O;O
Volunteers;O;O
DDI-DrugBank.d67.s4;;
DDI-DrugBank.d67.s5;;
Desloratadine;B-drug;B-DDI-DrugBank.d67.s5.e0
3;I-drug_n;I-DDI-DrugBank.d67.s5.e1
-;I-drug_n;I-DDI-DrugBank.d67.s5.e1
Hydroxydesloratadine;I-drug_n;I-DDI-DrugBank.d67.s5.e1
DDI-DrugBank.d67.s6;;
DDI-DrugBank.d67.s7;;
C;O;O
max;O;O
AUC;O;O
0;O;O
-;O;O
24;O;O
hrs;O;O
C;O;O
max;O;O
AUC;O;O
0;O;O
-;O;O
24;O;O
hrs;O;O
DDI-DrugBank.d67.s8;;
Erythromycin;B-drug;B-DDI-DrugBank.d67.s8.e0
DDI-DrugBank.d67.s9;;
(;O;O
500;O;O
mg;O;O
Q8h;O;O
);O;O
DDI-DrugBank.d67.s10;;
+24;O;O
%;O;O
+14;O;O
%;O;O
+43;O;O
%;O;O
+40;O;O
%;O;O
DDI-DrugBank.d67.s11;;
Ketoconazole;B-drug;B-DDI-DrugBank.d67.s11.e0
DDI-DrugBank.d67.s12;;
(;O;O
200;O;O
mg;O;O
Q12h;O;O
);O;O
DDI-DrugBank.d67.s13;;
+45;O;O
%;O;O
+39;O;O
%;O;O
+43;O;O
%;O;O
+72;O;O
%;O;O
DDI-DrugBank.d67.s14;;
Azithromycin;B-drug;B-DDI-DrugBank.d67.s14.e0
DDI-DrugBank.d67.s15;;
(;O;O
500;O;O
mg;O;O
day;O;O
1;O;O
,;O;O
250;O;O
mg;O;O
QD;O;O
4;O;O
days;O;O
);O;O
DDI-DrugBank.d67.s16;;
+15;O;O
%;O;O
+5;O;O
%;O;O
+15;O;O
%;O;O
+4;O;O
%;O;O
DDI-DrugBank.d67.s17;;
Fluoxetine;B-drug;B-DDI-DrugBank.d67.s17.e0
DDI-DrugBank.d67.s18;;
(;O;O
20;O;O
mg;O;O
QD;O;O
);O;O
DDI-DrugBank.d67.s19;;
+15;O;O
%;O;O
+0;O;O
%;O;O
+17;O;O
%;O;O
+13;O;O
%;O;O
DDI-DrugBank.d67.s20;;
Cimetidine;B-drug;B-DDI-DrugBank.d67.s20.e0
DDI-DrugBank.d67.s21;;
(;O;O
600;O;O
mg;O;O
Q12h;O;O
);O;O
DDI-DrugBank.d67.s22;;
+12;O;O
%;O;O
+19;O;O
%;O;O
-11;O;O
%;O;O
-3;O;O
%;O;O
DDI-DrugBank.d348.s0;;
Although;O;O
the;O;O
pressor;O;O
activity;O;O
of;O;O
Desmopressin;B-drug;B-DDI-DrugBank.d348.s0.e0
is;O;O
very;O;O
low;O;O
compared;O;O
to;O;O
its;O;O
antidiuretic;O;O
activity;O;O
,;O;O
large;O;O
doses;O;O
of;O;O
Desmopressin;B-drug;B-DDI-DrugBank.d348.s0.e1
Tablets;O;O
should;O;O
be;O;O
used;O;O
with;O;O
other;O;O
pressor;O;O
agents;O;O
only;O;O
with;O;O
careful;O;O
patient;O;O
monitoring;O;O
.;O;O
DDI-DrugBank.d285.s0;;
Reduced;O;O
efficacy;O;O
and;O;O
increased;O;O
incidence;O;O
of;O;O
breakthrough;O;O
bleeding;O;O
and;O;O
menstrual;O;O
irregularities;O;O
have;O;O
been;O;O
associated;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d285.s0.e0
.;O;O
DDI-DrugBank.d285.s1;;
A;O;O
similar;O;O
association;O;O
,;O;O
though;O;O
less;O;O
marked;O;O
,;O;O
has;O;O
been;O;O
suggested;O;O
with;O;O
barbiturates;B-group;B-DDI-DrugBank.d285.s1.e0
,;O;O
phenyl;O;O
-;O;O
butazone;O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d285.s1.e1
sodium;I-drug;I-DDI-DrugBank.d285.s1.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d285.s1.e2
and;O;O
possibly;O;O
with;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d285.s1.e3
,;O;O
ampicillin;B-drug;B-DDI-DrugBank.d285.s1.e4
,;O;O
and;O;O
tetracyclines;B-group;B-DDI-DrugBank.d285.s1.e5
(;O;O
72;O;O
);O;O
DDI-DrugBank.d285.s2;;
.;O;O
DDI-DrugBank.d285.s3;;
DDI-DrugBank.d285.s4;;
DDI-DrugBank.d280.s0;;
No;O;O
specific;O;O
information;O;O
available;O;O
DDI-DrugBank.d280.s1;;
.;O;O
DDI-DrugBank.d280.s2;;
DDI-DrugBank.d314.s0;;
Aminoglutethimide;B-drug;B-DDI-DrugBank.d314.s0.e0
:;O;O
Aminoglutethimide;B-drug;B-DDI-DrugBank.d314.s0.e1
may;O;O
diminish;O;O
adrenal;O;O
suppression;O;O
by;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s0.e2
.;O;O
DDI-DrugBank.d314.s1;;
Amphotericin;B-drug;B-DDI-DrugBank.d314.s1.e0
B;I-drug;I-DDI-DrugBank.d314.s1.e0
injection;O;O
and;O;O
potassium;O;O
-;O;O
depleting;O;O
agents;O;O
:;O;O
When;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s1.e1
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
potassium;O;O
-;O;O
depleting;O;O
agents;O;O
(;O;O
e.g.;O;O
,;O;O
amphotericin;B-drug;B-DDI-DrugBank.d314.s1.e2
B;I-drug;I-DDI-DrugBank.d314.s1.e2
,;O;O
diuretics;B-group;B-DDI-DrugBank.d314.s1.e3
);O;O
,;O;O
patients;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
development;O;O
of;O;O
hypokalemia;O;O
.;O;O
DDI-DrugBank.d314.s2;;
In;O;O
addition;O;O
,;O;O
there;O;O
have;O;O
been;O;O
cases;O;O
reported;O;O
in;O;O
which;O;O
concomitant;O;O
use;O;O
of;O;O
amphotericin;B-drug;B-DDI-DrugBank.d314.s2.e0
B;I-drug;I-DDI-DrugBank.d314.s2.e0
and;O;O
hydrocortisone;B-drug;B-DDI-DrugBank.d314.s2.e1
was;O;O
followed;O;O
by;O;O
cardiac;O;O
enlargement;O;O
and;O;O
congestive;O;O
heart;O;O
failure;O;O
.;O;O
DDI-DrugBank.d314.s3;;
Antibiotics;B-group;B-DDI-DrugBank.d314.s3.e0
:;O;O
Macrolide;B-group;B-DDI-DrugBank.d314.s3.e1
antibiotics;I-group;I-DDI-DrugBank.d314.s3.e1
have;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
a;O;O
significant;O;O
decrease;O;O
in;O;O
corticosteroid;B-group;B-DDI-DrugBank.d314.s3.e2
clearance;O;O
.;O;O
DDI-DrugBank.d314.s4;;
Anticholinesterases;B-group;B-DDI-DrugBank.d314.s4.e0
:;O;O
Concomitant;O;O
use;O;O
of;O;O
anticholinesterase;B-group;B-DDI-DrugBank.d314.s4.e1
agents;I-group;I-DDI-DrugBank.d314.s4.e1
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s4.e2
may;O;O
produce;O;O
severe;O;O
weakness;O;O
in;O;O
patients;O;O
with;O;O
myasthenia;O;O
gravis;O;O
.;O;O
DDI-DrugBank.d314.s5;;
If;O;O
possible;O;O
,;O;O
anticholinesterase;B-group;B-DDI-DrugBank.d314.s5.e0
agents;I-group;I-DDI-DrugBank.d314.s5.e0
should;O;O
be;O;O
withdrawn;O;O
at;O;O
least;O;O
24;O;O
hours;O;O
before;O;O
initiating;O;O
corticosteroid;B-group;B-DDI-DrugBank.d314.s5.e1
therapy;O;O
.;O;O
DDI-DrugBank.d314.s6;;
Anticoagulants;B-group;B-DDI-DrugBank.d314.s6.e0
,;O;O
oral;O;O
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s6.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d314.s6.e2
usually;O;O
results;O;O
in;O;O
inhibition;O;O
of;O;O
response;O;O
to;O;O
warfarin;B-drug;B-DDI-DrugBank.d314.s6.e3
,;O;O
although;O;O
there;O;O
have;O;O
been;O;O
some;O;O
conflicting;O;O
reports;O;O
.;O;O
DDI-DrugBank.d314.s7;;
Therefore;O;O
,;O;O
coagulation;O;O
indices;O;O
should;O;O
be;O;O
monitored;O;O
frequently;O;O
to;O;O
maintain;O;O
the;O;O
desired;O;O
anticoagulant;O;O
effect;O;O
.;O;O
DDI-DrugBank.d314.s8;;
Antidiabetics;B-group;B-DDI-DrugBank.d314.s8.e0
:;O;O
Because;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s8.e1
may;O;O
increase;O;O
blood;O;O
glucose;O;O
concentrations;O;O
,;O;O
dosage;O;O
adjustments;O;O
of;O;O
antidiabetic;B-group;B-DDI-DrugBank.d314.s8.e2
agents;I-group;I-DDI-DrugBank.d314.s8.e2
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d314.s9;;
Antitubercular;O;O
drugs;O;O
:;O;O
Serum;O;O
concentrations;O;O
of;O;O
isoniazid;B-drug;B-DDI-DrugBank.d314.s9.e0
may;O;O
be;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d314.s10;;
Cholestyramine;B-drug;B-DDI-DrugBank.d314.s10.e0
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d314.s10.e1
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s10.e2
.;O;O
DDI-DrugBank.d314.s11;;
Cyclosporine;B-drug;B-DDI-DrugBank.d314.s11.e0
:;O;O
Increased;O;O
activity;O;O
of;O;O
both;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d314.s11.e1
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s11.e2
may;O;O
occur;O;O
when;O;O
the;O;O
two;O;O
are;O;O
used;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d314.s12;;
Convulsions;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
this;O;O
concurrent;O;O
use;O;O
.;O;O
DDI-DrugBank.d314.s13;;
Dexamethasone;O;O
suppression;O;O
test;O;O
(;O;O
DST;O;O
);O;O
:;O;O
False;O;O
-;O;O
negative;O;O
results;O;O
in;O;O
the;O;O
dexamethasone;O;O
suppression;O;O
test;O;O
(;O;O
DST;O;O
);O;O
in;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
indomethacin;B-drug;B-DDI-DrugBank.d314.s13.e0
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d314.s14;;
Thus;O;O
,;O;O
results;O;O
of;O;O
the;O;O
DST;O;O
should;O;O
be;O;O
interpreted;O;O
with;O;O
caution;O;O
in;O;O
these;O;O
patients;O;O
.;O;O
DDI-DrugBank.d314.s15;;
Digitalis;B-group;B-DDI-DrugBank.d314.s15.e0
glycosides;I-group;I-DDI-DrugBank.d314.s15.e0
:;O;O
Patients;O;O
on;O;O
digitalis;B-group;B-DDI-DrugBank.d314.s15.e1
glycosides;I-group;I-DDI-DrugBank.d314.s15.e1
may;O;O
be;O;O
at;O;O
increased;O;O
risk;O;O
of;O;O
arrhythmias;O;O
due;O;O
to;O;O
hypokalemia;O;O
.;O;O
DDI-DrugBank.d314.s16;;
Ephedrine;B-drug;B-DDI-DrugBank.d314.s16.e0
:;O;O
Ephedrine;B-drug;B-DDI-DrugBank.d314.s16.e1
may;O;O
enhance;O;O
the;O;O
metabolic;O;O
clearance;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s16.e2
,;O;O
resulting;O;O
in;O;O
decreased;O;O
blood;O;O
levels;O;O
and;O;O
lessened;O;O
physiologic;O;O
activity;O;O
,;O;O
thus;O;O
requiring;O;O
an;O;O
increase;O;O
in;O;O
corticosteroid;B-group;B-DDI-DrugBank.d314.s16.e3
dosage;O;O
.;O;O
DDI-DrugBank.d314.s17;;
Estrogens;B-group;B-DDI-DrugBank.d314.s17.e0
,;O;O
including;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d314.s17.e1
:;O;O
Estrogens;B-group;B-DDI-DrugBank.d314.s17.e2
may;O;O
decrease;O;O
the;O;O
hepatic;O;O
metabolism;O;O
of;O;O
certain;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s17.e3
,;O;O
thereby;O;O
increasing;O;O
their;O;O
effect;O;O
.;O;O
DDI-DrugBank.d314.s18;;
Hepatic;O;O
Enzyme;O;O
Inducers;O;O
,;O;O
Inhibitors;O;O
and;O;O
Substrates;O;O
:;O;O
Drugs;O;O
which;O;O
induce;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
(;O;O
CYP;O;O
3A4;O;O
);O;O
enzyme;O;O
activity;O;O
(;O;O
e.g.;O;O
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d314.s18.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d314.s18.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d314.s18.e2
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d314.s18.e3
);O;O
may;O;O
enhance;O;O
the;O;O
metabolism;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s18.e4
and;O;O
require;O;O
that;O;O
the;O;O
dosage;O;O
of;O;O
the;O;O
corticosteroid;B-group;B-DDI-DrugBank.d314.s18.e5
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d314.s19;;
Drugs;O;O
which;O;O
inhibit;O;O
CYP;O;O
3A4;O;O
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d314.s19.e0
,;O;O
macrolide;B-group;B-DDI-DrugBank.d314.s19.e1
antibiotics;I-group;I-DDI-DrugBank.d314.s19.e1
such;O;O
as;O;O
erythromycin;B-drug;B-DDI-DrugBank.d314.s19.e2
);O;O
have;O;O
the;O;O
potential;O;O
to;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s19.e3
.;O;O
DDI-DrugBank.d314.s20;;
Dexamethasone;B-drug;B-DDI-DrugBank.d314.s20.e0
is;O;O
a;O;O
moderate;O;O
inducer;O;O
of;O;O
CYP;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d314.s21;;
Co;O;O
-;O;O
administration;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
CYP;O;O
3A4;O;O
(;O;O
e.g.;O;O
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d314.s21.e0
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d314.s21.e1
);O;O
may;O;O
increase;O;O
their;O;O
clearance;O;O
,;O;O
resulting;O;O
in;O;O
decreased;O;O
plasma;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d314.s22;;
Ketoconazole;B-drug;B-DDI-DrugBank.d314.s22.e0
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d314.s22.e1
has;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
the;O;O
metabolism;O;O
of;O;O
certain;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s22.e2
by;O;O
up;O;O
to;O;O
60;O;O
%;O;O
,;O;O
leading;O;O
to;O;O
increased;O;O
risk;O;O
of;O;O
corticosteroid;B-group;B-DDI-DrugBank.d314.s22.e3
side;O;O
effects;O;O
.;O;O
DDI-DrugBank.d314.s23;;
In;O;O
addition;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d314.s23.e0
alone;O;O
can;O;O
inhibit;O;O
adrenal;O;O
corticosteroid;B-drug;B-DDI-DrugBank.d314.s23.e1
synthesis;O;O
and;O;O
may;O;O
cause;O;O
adrenal;O;O
insufficiency;O;O
during;O;O
corticosteroid;O;O
withdrawal;O;O
.;O;O
DDI-DrugBank.d314.s24;;
Nonsteroidal;B-group;B-DDI-DrugBank.d314.s24.e0
anti;I-group;I-DDI-DrugBank.d314.s24.e0
-;I-group;I-DDI-DrugBank.d314.s24.e0
inflammatory;I-group;I-DDI-DrugBank.d314.s24.e0
agents;I-group;I-DDI-DrugBank.d314.s24.e0
(;O;O
NSAIDS;B-group;B-DDI-DrugBank.d314.s24.e1
);O;O
:;O;O
Concomitant;O;O
use;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d314.s24.e2
(;O;O
or;O;O
other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d314.s24.e3
antiinflammatory;I-group;I-DDI-DrugBank.d314.s24.e3
agents;I-group;I-DDI-DrugBank.d314.s24.e3
);O;O
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s24.e4
increases;O;O
the;O;O
risk;O;O
of;O;O
gastrointestinal;O;O
side;O;O
effects;O;O
.;O;O
DDI-DrugBank.d314.s25;;
Aspirin;B-brand;B-DDI-DrugBank.d314.s25.e0
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
conjunction;O;O
with;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s25.e1
in;O;O
hypoprothrombinemia;O;O
.;O;O
DDI-DrugBank.d314.s26;;
The;O;O
clearance;O;O
of;O;O
salicylates;B-group;B-DDI-DrugBank.d314.s26.e0
may;O;O
be;O;O
increased;O;O
with;O;O
concurrent;O;O
use;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d314.s26.e1
.;O;O
DDI-DrugBank.d314.s27;;
Phenytoin;B-drug;B-DDI-DrugBank.d314.s27.e0
:;O;O
In;O;O
post;O;O
-;O;O
marketing;O;O
experience;O;O
,;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
both;O;O
increases;O;O
and;O;O
decreases;O;O
in;O;O
phenytoin;B-drug;B-DDI-DrugBank.d314.s27.e1
levels;O;O
with;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d314.s27.e2
co;O;O
-;O;O
administration;O;O
,;O;O
leading;O;O
to;O;O
alterations;O;O
in;O;O
seizure;O;O
control;O;O
.;O;O
DDI-DrugBank.d314.s28;;
Skin;O;O
tests;O;O
:;O;O
Corticosteroids;B-group;B-DDI-DrugBank.d314.s28.e0
may;O;O
suppress;O;O
reactions;O;O
to;O;O
skin;O;O
tests;O;O
.;O;O
DDI-DrugBank.d314.s29;;
Thalidomide;B-drug;B-DDI-DrugBank.d314.s29.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
with;O;O
thalidomide;B-drug;B-DDI-DrugBank.d314.s29.e1
should;O;O
be;O;O
employed;O;O
cautiously;O;O
,;O;O
as;O;O
toxic;O;O
epidermal;O;O
necrolysis;O;O
has;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
use;O;O
.;O;O
DDI-DrugBank.d314.s30;;
Vaccines;B-group;B-DDI-DrugBank.d314.s30.e0
:;O;O
Patients;O;O
on;O;O
corticosteroid;B-group;B-DDI-DrugBank.d314.s30.e1
therapy;O;O
may;O;O
exhibit;O;O
a;O;O
diminished;O;O
response;O;O
to;O;O
toxoids;O;O
and;O;O
live;B-group;B-DDI-DrugBank.d314.s30.e2
or;I-group;I-DDI-DrugBank.d314.s30.e2
inactivated;I-group;I-DDI-DrugBank.d314.s30.e3
vaccines;I-group;I-DDI-DrugBank.d314.s30.e3
due;O;O
to;O;O
inhibition;O;O
of;O;O
antibody;O;O
response;O;O
.;O;O
DDI-DrugBank.d314.s31;;
Corticosteroids;B-group;B-DDI-DrugBank.d314.s31.e0
may;O;O
also;O;O
potentiate;O;O
the;O;O
replication;O;O
of;O;O
some;O;O
organisms;O;O
contained;O;O
in;O;O
live;B-group;B-DDI-DrugBank.d314.s31.e1
attenuated;I-group;I-DDI-DrugBank.d314.s31.e1
vaccines;I-group;I-DDI-DrugBank.d314.s31.e1
.;O;O
DDI-DrugBank.d314.s32;;
Routine;O;O
administration;O;O
of;O;O
vaccines;B-group;B-DDI-DrugBank.d314.s32.e0
or;O;O
toxoids;O;O
should;O;O
be;O;O
deferred;O;O
until;O;O
corticosteroid;B-group;B-DDI-DrugBank.d314.s32.e1
therapy;O;O
is;O;O
discontinued;O;O
if;O;O
possible;O;O
.;O;O
DDI-DrugBank.d62.s0;;
Dexbrompheniramine;B-drug;B-DDI-DrugBank.d62.s0.e0
can;O;O
interact;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d62.s0.e1
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d62.s0.e2
depressants;I-group;I-DDI-DrugBank.d62.s0.e2
(;O;O
may;O;O
potentiate;O;O
the;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
either;O;O
these;O;O
medications;O;O
or;O;O
antihistamines;B-group;B-DDI-DrugBank.d62.s0.e3
);O;O
,;O;O
anticholinergics;B-group;B-DDI-DrugBank.d62.s0.e4
or;O;O
other;O;O
medications;O;O
with;O;O
anticholinergic;O;O
activity;O;O
(;O;O
anticholinergic;O;O
effects;O;O
may;O;O
be;O;O
potentiated;O;O
when;O;O
these;O;O
medications;O;O
are;O;O
used;O;O
concurrently;O;O
with;O;O
antihistamines;B-group;B-DDI-DrugBank.d62.s0.e5
);O;O
,;O;O
and;O;O
monoamine;B-group;B-DDI-DrugBank.d62.s0.e6
oxidase;I-group;I-DDI-DrugBank.d62.s0.e6
(;I-group;I-DDI-DrugBank.d62.s0.e6
MAO;I-group;I-DDI-DrugBank.d62.s0.e6
);I-group;I-DDI-DrugBank.d62.s0.e6
inhibitors;I-group;I-DDI-DrugBank.d62.s0.e6
(;O;O
concurrent;O;O
use;O;O
with;O;O
antihistamines;B-group;B-DDI-DrugBank.d62.s0.e7
may;O;O
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
and;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d62.s0.e8
);O;O
.;O;O
DDI-DrugBank.d423.s0;;
In;O;O
patients;O;O
receiving;O;O
nonselective;O;O
monoamine;B-group;B-DDI-DrugBank.d423.s0.e0
oxidase;I-group;I-DDI-DrugBank.d423.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d423.s0.e0
(;O;O
MAOIs;B-group;B-DDI-DrugBank.d423.s0.e1
);O;O
(;O;O
e.g.;O;O
,;O;O
selegiline;B-drug;B-DDI-DrugBank.d423.s0.e2
hydrochloride;I-drug;I-DDI-DrugBank.d423.s0.e2
);O;O
in;O;O
combination;O;O
with;O;O
serotoninergic;B-group;B-DDI-DrugBank.d423.s0.e3
agents;I-group;I-DDI-DrugBank.d423.s0.e3
(;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d423.s0.e4
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d423.s0.e5
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d423.s0.e6
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d423.s0.e7
,;O;O
venlafaxine;B-drug;B-DDI-DrugBank.d423.s0.e8
);O;O
,;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
serious;O;O
,;O;O
sometimes;O;O
fatal;O;O
,;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d423.s1;;
Because;O;O
dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s1.e0
is;O;O
a;O;O
serotonin;O;O
releaser;O;O
and;O;O
reuptake;O;O
inhibitor;O;O
,;O;O
dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s1.e1
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
with;O;O
a;O;O
MAO;B-group;B-DDI-DrugBank.d423.s1.e2
inhibitor;I-group;I-DDI-DrugBank.d423.s1.e2
.;O;O
DDI-DrugBank.d423.s2;;
At;O;O
least;O;O
14;O;O
days;O;O
should;O;O
elapse;O;O
between;O;O
discontinuation;O;O
of;O;O
a;O;O
MAO;B-group;B-DDI-DrugBank.d423.s2.e0
inhibitor;I-group;I-DDI-DrugBank.d423.s2.e0
and;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s2.e1
.;O;O
DDI-DrugBank.d423.s3;;
At;O;O
least;O;O
3;O;O
weeks;O;O
should;O;O
elapse;O;O
between;O;O
discontinuation;O;O
of;O;O
dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s3.e0
and;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
a;O;O
MAO;B-group;B-DDI-DrugBank.d423.s3.e1
inhibitor;I-group;I-DDI-DrugBank.d423.s3.e1
.;O;O
DDI-DrugBank.d423.s4;;
A;O;O
rare;O;O
,;O;O
but;O;O
serious;O;O
,;O;O
constellation;O;O
of;O;O
symptoms;O;O
,;O;O
termed;O;O
serotonin;O;O
syndrome;O;O
,;O;O
has;O;O
been;O;O
reported;O;O
with;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
selective;B-group;B-DDI-DrugBank.d423.s4.e0
serotonin;I-group;I-DDI-DrugBank.d423.s4.e0
reuptake;I-group;I-DDI-DrugBank.d423.s4.e0
inhibitors;I-group;I-DDI-DrugBank.d423.s4.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d423.s4.e1
);O;O
and;O;O
agents;O;O
for;O;O
migraine;O;O
therapy;O;O
,;O;O
such;O;O
as;O;O
Imitrex;B-brand;B-DDI-DrugBank.d423.s4.e2
(;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d423.s4.e3
succinate;I-drug;I-DDI-DrugBank.d423.s4.e3
);O;O
and;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d423.s4.e4
.;O;O
DDI-DrugBank.d423.s5;;
The;O;O
syndrome;O;O
requires;O;O
immediate;O;O
medical;O;O
attention;O;O
and;O;O
may;O;O
include;O;O
one;O;O
or;O;O
more;O;O
of;O;O
the;O;O
following;O;O
symptoms;O;O
:;O;O
excitement;O;O
,;O;O
hypomania;O;O
,;O;O
restlessness;O;O
,;O;O
loss;O;O
of;O;O
consciousness;O;O
,;O;O
confusion;O;O
,;O;O
disorientation;O;O
,;O;O
anxiety;O;O
,;O;O
agitation;O;O
,;O;O
motor;O;O
weakness;O;O
,;O;O
myoclonus;O;O
,;O;O
tremor;O;O
,;O;O
hemiballismus;O;O
,;O;O
hyperreflexia;O;O
,;O;O
ataxia;O;O
,;O;O
dysarthria;O;O
,;O;O
incoordination;O;O
,;O;O
hyperthermia;O;O
,;O;O
shivering;O;O
,;O;O
pupillary;O;O
dilation;O;O
,;O;O
diaphoresis;O;O
,;O;O
emesis;O;O
,;O;O
and;O;O
tachycardia;O;O
.;O;O
DDI-DrugBank.d423.s6;;
Dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s6.e0
should;O;O
not;O;O
be;O;O
administered;O;O
with;O;O
other;O;O
serotoninergic;B-group;B-DDI-DrugBank.d423.s6.e1
agents;I-group;I-DDI-DrugBank.d423.s6.e1
.;O;O
DDI-DrugBank.d423.s7;;
The;O;O
appropriate;O;O
interval;O;O
between;O;O
administration;O;O
of;O;O
these;O;O
agents;O;O
and;O;O
dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s7.e0
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d423.s8;;
The;O;O
use;O;O
of;O;O
dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s8.e0
with;O;O
other;O;O
CNS;O;O
-;O;O
active;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
systematically;O;O
evaluated;O;O
,;O;O
DDI-DrugBank.d423.s9;;
consequently;O;O
,;O;O
caution;O;O
is;O;O
advised;O;O
if;O;O
dexfenfluramine;B-drug;B-DDI-DrugBank.d423.s9.e0
and;O;O
such;O;O
drugs;O;O
are;O;O
prescribed;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d197.s0;;
General;O;O
In;O;O
vitro;O;O
studies;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
demonstrated;O;O
no;O;O
evidence;O;O
of;O;O
cytochrome;O;O
P450;O;O
-;O;O
mediated;O;O
drug;O;O
interactions;O;O
that;O;O
are;O;O
likely;O;O
to;O;O
be;O;O
of;O;O
clinical;O;O
relevance;O;O
.;O;O
DDI-DrugBank.d197.s1;;
Anesthetics;B-group;B-DDI-DrugBank.d197.s1.e0
/;O;O
Sedatives;B-group;B-DDI-DrugBank.d197.s1.e1
/;O;O
Hypnotics;B-group;B-DDI-DrugBank.d197.s1.e2
/;O;O
Opioids;B-group;B-DDI-DrugBank.d197.s1.e3
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
PRECEDEX;B-brand;B-DDI-DrugBank.d197.s1.e4
with;O;O
anesthetics;B-group;B-DDI-DrugBank.d197.s1.e5
,;O;O
sedatives;B-group;B-DDI-DrugBank.d197.s1.e6
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d197.s1.e7
,;O;O
and;O;O
opioids;B-group;B-DDI-DrugBank.d197.s1.e8
is;O;O
likely;O;O
to;O;O
lead;O;O
to;O;O
an;O;O
enhancement;O;O
of;O;O
effects;O;O
.;O;O
DDI-DrugBank.d197.s2;;
Specific;O;O
studies;O;O
have;O;O
confirmed;O;O
these;O;O
effects;O;O
with;O;O
sevoflurane;B-drug;B-DDI-DrugBank.d197.s2.e0
,;O;O
isoflurane;B-drug;B-DDI-DrugBank.d197.s2.e1
,;O;O
propofol;B-drug;B-DDI-DrugBank.d197.s2.e2
,;O;O
alfentanil;B-drug;B-DDI-DrugBank.d197.s2.e3
,;O;O
and;O;O
midazolam;B-drug;B-DDI-DrugBank.d197.s2.e4
.;O;O
DDI-DrugBank.d197.s3;;
No;O;O
pharmacokinetic;O;O
interactions;O;O
between;O;O
dexmedetomidine;B-drug;B-DDI-DrugBank.d197.s3.e0
and;O;O
isoflurane;B-drug;B-DDI-DrugBank.d197.s3.e1
,;O;O
propofol;B-drug;B-DDI-DrugBank.d197.s3.e2
,;O;O
alfentanil;B-drug;B-DDI-DrugBank.d197.s3.e3
,;O;O
and;O;O
midazolam;B-drug;B-DDI-DrugBank.d197.s3.e4
have;O;O
been;O;O
demonstrated;O;O
.;O;O
DDI-DrugBank.d197.s4;;
However;O;O
,;O;O
due;O;O
to;O;O
possible;O;O
pharmacodynamic;O;O
interactions;O;O
,;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
PRECEDEX;B-brand;B-DDI-DrugBank.d197.s4.e0
,;O;O
a;O;O
reduction;O;O
in;O;O
dosage;O;O
of;O;O
PRECEDEX;B-brand;B-DDI-DrugBank.d197.s4.e1
on;O;O
the;O;O
concomitant;O;O
anesthetic;B-group;B-DDI-DrugBank.d197.s4.e2
,;O;O
sedative;B-group;B-DDI-DrugBank.d197.s4.e3
,;O;O
hypnotic;B-group;B-DDI-DrugBank.d197.s4.e4
or;O;O
opioid;B-group;B-DDI-DrugBank.d197.s4.e5
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d197.s5;;
Neuromuscular;B-group;B-DDI-DrugBank.d197.s5.e0
Blockers;I-group;I-DDI-DrugBank.d197.s5.e0
:;O;O
In;O;O
one;O;O
study;O;O
of;O;O
10;O;O
healthy;O;O
volunteers;O;O
,;O;O
administration;O;O
of;O;O
PRECEDEX;B-brand;B-DDI-DrugBank.d197.s5.e1
for;O;O
45;O;O
minutes;O;O
at;O;O
a;O;O
plasma;O;O
concentration;O;O
of;O;O
1;O;O
(;O;O
one;O;O
);O;O
ng;O;O
/;O;O
mL;O;O
resulted;O;O
in;O;O
no;O;O
clinically;O;O
meaningful;O;O
increases;O;O
in;O;O
the;O;O
magnitude;O;O
or;O;O
neuromuscular;O;O
blockade;O;O
associated;O;O
with;O;O
rocuronium;B-drug;B-DDI-DrugBank.d197.s5.e2
administration;O;O
.;O;O
DDI-DrugBank.d38.s0;;
ZINECARD;B-brand;B-DDI-DrugBank.d38.s0.e0
does;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d38.s0.e1
.;O;O
DDI-DrugBank.d38.s1;;
Carcinogenesis;O;O
,;O;O
Mutagenesis;O;O
,;O;O
Impairment;O;O
of;O;O
Fertility;O;O
No;O;O
long;O;O
-;O;O
term;O;O
carcinogenicity;O;O
studies;O;O
have;O;O
been;O;O
carried;O;O
out;O;O
with;O;O
dexrazoxane;B-drug;B-DDI-DrugBank.d38.s1.e0
in;O;O
animals;O;O
.;O;O
DDI-DrugBank.d38.s2;;
Dexrazoxane;B-drug;B-DDI-DrugBank.d38.s2.e0
was;O;O
not;O;O
mutagenic;O;O
in;O;O
the;O;O
Ames;O;O
test;O;O
but;O;O
was;O;O
found;O;O
to;O;O
be;O;O
clastogenic;O;O
to;O;O
human;O;O
lymphocytes;O;O
in;O;O
vitro;O;O
and;O;O
to;O;O
mouse;O;O
bone;O;O
marrow;O;O
erythrocytes;O;O
in;O;O
vivo;O;O
(;O;O
micronucleus;O;O
test;O;O
);O;O
.;O;O
DDI-DrugBank.d38.s3;;
The;O;O
possible;O;O
adverse;O;O
effects;O;O
of;O;O
ZINECARD;B-brand;B-DDI-DrugBank.d38.s3.e0
on;O;O
the;O;O
fertility;O;O
of;O;O
humans;O;O
and;O;O
experimental;O;O
animals;O;O
,;O;O
male;O;O
or;O;O
female;O;O
,;O;O
have;O;O
not;O;O
been;O;O
adequately;O;O
studied;O;O
.;O;O
DDI-DrugBank.d38.s4;;
Testicular;O;O
atrophy;O;O
was;O;O
seen;O;O
with;O;O
dexrazoxane;B-drug;B-DDI-DrugBank.d38.s4.e0
administration;O;O
at;O;O
doses;O;O
as;O;O
low;O;O
as;O;O
30;O;O
mg;O;O
/;O;O
kg;O;O
weekly;O;O
for;O;O
6;O;O
weeks;O;O
in;O;O
rats;O;O
(;O;O
1;O;O
/;O;O
3;O;O
the;O;O
human;O;O
dose;O;O
on;O;O
a;O;O
mg;O;O
/;O;O
m;O;O
2;O;O
basis;O;O
);O;O
and;O;O
as;O;O
low;O;O
as;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
weekly;O;O
for;O;O
13;O;O
weeks;O;O
in;O;O
dogs;O;O
(;O;O
approximately;O;O
equal;O;O
to;O;O
the;O;O
human;O;O
dose;O;O
on;O;O
a;O;O
mg;O;O
/;O;O
m;O;O
2;O;O
basis;O;O
);O;O
.;O;O
DDI-DrugBank.d236.s0;;
Acidifying;B-group;B-DDI-DrugBank.d236.s0.e0
agents;I-group;I-DDI-DrugBank.d236.s0.e0
:;O;O
Gastrointestinal;B-group;B-DDI-DrugBank.d236.s0.e1
acidifying;I-group;I-DDI-DrugBank.d236.s0.e1
agents;I-group;I-DDI-DrugBank.d236.s0.e1
(;O;O
guanethidine;B-drug;B-DDI-DrugBank.d236.s0.e2
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d236.s0.e3
,;O;O
glutamic;B-drug;B-DDI-DrugBank.d236.s0.e4
acid;I-drug;I-DDI-DrugBank.d236.s0.e4
HCl;I-drug;I-DDI-DrugBank.d236.s0.e4
,;O;O
ascorbic;B-drug;B-DDI-DrugBank.d236.s0.e5
acid;I-drug;I-DDI-DrugBank.d236.s0.e5
,;O;O
fruit;O;O
juices;O;O
,;O;O
etc;O;O
.;O;O
);O;O
lower;O;O
absorption;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s0.e6
.;O;O
DDI-DrugBank.d236.s1;;
Urinary;B-group;B-DDI-DrugBank.d236.s1.e0
acidifying;I-group;I-DDI-DrugBank.d236.s1.e0
agents;I-group;I-DDI-DrugBank.d236.s1.e0
(;O;O
ammonium;B-drug;B-DDI-DrugBank.d236.s1.e1
chloride;I-drug;I-DDI-DrugBank.d236.s1.e1
,;O;O
sodium;B-drug;B-DDI-DrugBank.d236.s1.e2
acid;I-drug;I-DDI-DrugBank.d236.s1.e2
phosphate;I-drug;I-DDI-DrugBank.d236.s1.e2
,;O;O
etc;O;O
.;O;O
);O;O
increase;O;O
the;O;O
concentration;O;O
of;O;O
the;O;O
ionized;O;O
species;O;O
of;O;O
the;O;O
amphetamine;B-drug;B-DDI-DrugBank.d236.s1.e3
molecule;O;O
,;O;O
thereby;O;O
increasing;O;O
urinary;O;O
excretion;O;O
.;O;O
DDI-DrugBank.d236.s2;;
Both;O;O
groups;O;O
of;O;O
agents;O;O
lower;O;O
blood;O;O
levels;O;O
and;O;O
efficacy;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s2.e0
.;O;O
DDI-DrugBank.d236.s3;;
Adrenergic;B-group;B-DDI-DrugBank.d236.s3.e0
blockers;I-group;I-DDI-DrugBank.d236.s3.e0
:;O;O
Adrenergic;B-group;B-DDI-DrugBank.d236.s3.e1
blockers;I-group;I-DDI-DrugBank.d236.s3.e1
are;O;O
inhibited;O;O
by;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s3.e2
.;O;O
DDI-DrugBank.d236.s4;;
Alkalinizing;O;O
agents;O;O
:;O;O
Gastrointestinal;O;O
alkalinizing;O;O
agents;O;O
(;O;O
sodium;B-drug;B-DDI-DrugBank.d236.s4.e0
bicarbonate;I-drug;I-DDI-DrugBank.d236.s4.e0
,;O;O
etc;O;O
.;O;O
);O;O
increase;O;O
absorption;O;O
of;O;O
amphetamines;B-drug;B-DDI-DrugBank.d236.s4.e1
.;O;O
DDI-DrugBank.d236.s5;;
Urinary;O;O
alkalinizing;O;O
agents;O;O
(;O;O
acetazolamide;B-drug;B-DDI-DrugBank.d236.s5.e0
,;O;O
some;O;O
thiazides;B-group;B-DDI-DrugBank.d236.s5.e1
);O;O
increase;O;O
the;O;O
concentration;O;O
of;O;O
the;O;O
non;O;O
-;O;O
ionized;O;O
species;O;O
of;O;O
the;O;O
amphetamine;B-drug;B-DDI-DrugBank.d236.s5.e2
molecule;O;O
,;O;O
thereby;O;O
decreasing;O;O
urinary;O;O
excretion;O;O
.;O;O
DDI-DrugBank.d236.s6;;
Both;O;O
groups;O;O
of;O;O
agents;O;O
increase;O;O
blood;O;O
levels;O;O
and;O;O
therefore;O;O
potentiate;O;O
the;O;O
actions;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s6.e0
.;O;O
DDI-DrugBank.d236.s7;;
Antidepressants;B-group;B-DDI-DrugBank.d236.s7.e0
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d236.s7.e1
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s7.e2
may;O;O
enhance;O;O
the;O;O
activity;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d236.s7.e3
or;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d236.s7.e4
agents;I-group;I-DDI-DrugBank.d236.s7.e4
,;O;O
DDI-DrugBank.d236.s8;;
d;B-drug;B-DDI-DrugBank.d236.s8.e0
-;I-drug;I-DDI-DrugBank.d236.s8.e0
amphetamine;I-drug;I-DDI-DrugBank.d236.s8.e0
with;O;O
desipramine;B-drug;B-DDI-DrugBank.d236.s8.e1
or;O;O
protriptyline;B-drug;B-DDI-DrugBank.d236.s8.e2
and;O;O
possibly;O;O
other;O;O
tricyclics;B-group;B-DDI-DrugBank.d236.s8.e3
cause;O;O
striking;O;O
and;O;O
sustained;O;O
increases;O;O
in;O;O
the;O;O
concentration;O;O
of;O;O
d;B-drug;B-DDI-DrugBank.d236.s8.e4
-;I-drug;I-DDI-DrugBank.d236.s8.e4
amphetamine;I-drug;I-DDI-DrugBank.d236.s8.e4
in;O;O
the;O;O
brain;O;O
,;O;O
DDI-DrugBank.d236.s9;;
cardiovascular;O;O
effects;O;O
can;O;O
be;O;O
potentiated;O;O
.;O;O
DDI-DrugBank.d236.s10;;
MAO;B-group;B-DDI-DrugBank.d236.s10.e0
inhibitors;I-group;I-DDI-DrugBank.d236.s10.e0
:;O;O
MAOI;B-group;B-DDI-DrugBank.d236.s10.e1
antidepressants;I-group;I-DDI-DrugBank.d236.s10.e1
,;O;O
as;O;O
well;O;O
as;O;O
a;O;O
metabolite;O;O
of;O;O
furazolidone;B-drug;B-DDI-DrugBank.d236.s10.e2
,;O;O
slow;O;O
amphetamine;B-group;B-DDI-DrugBank.d236.s10.e3
metabolism;O;O
.;O;O
DDI-DrugBank.d236.s11;;
This;O;O
slowing;O;O
potentiates;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s11.e0
,;O;O
increasing;O;O
their;O;O
effect;O;O
on;O;O
the;O;O
release;O;O
of;O;O
norepinephrine;O;O
and;O;O
other;O;O
monoamines;O;O
from;O;O
adrenergic;O;O
nerve;O;O
endings;O;O
,;O;O
DDI-DrugBank.d236.s12;;
this;O;O
can;O;O
cause;O;O
headaches;O;O
and;O;O
other;O;O
signs;O;O
of;O;O
hypertensive;O;O
crisis;O;O
.;O;O
DDI-DrugBank.d236.s13;;
A;O;O
variety;O;O
of;O;O
neurological;O;O
toxic;O;O
effects;O;O
and;O;O
malignant;O;O
hyperpyrexia;O;O
can;O;O
occur;O;O
,;O;O
sometimes;O;O
with;O;O
fatal;O;O
results;O;O
.;O;O
DDI-DrugBank.d236.s14;;
Antihistamines;B-group;B-DDI-DrugBank.d236.s14.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s14.e1
may;O;O
counteract;O;O
the;O;O
sedative;O;O
effect;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d236.s14.e2
.;O;O
DDI-DrugBank.d236.s15;;
Antihypertensives;B-group;B-DDI-DrugBank.d236.s15.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s15.e1
may;O;O
antagonize;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
antihypertensives;B-group;B-DDI-DrugBank.d236.s15.e2
.;O;O
DDI-DrugBank.d236.s16;;
Chlorpromazine;B-drug;B-DDI-DrugBank.d236.s16.e0
:;O;O
Chlorpromazine;B-drug;B-DDI-DrugBank.d236.s16.e1
blocks;O;O
dopamine;O;O
and;O;O
norepinephrine;O;O
reuptake;O;O
,;O;O
thus;O;O
inhibiting;O;O
the;O;O
central;O;O
stimulant;O;O
effects;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s16.e2
,;O;O
and;O;O
can;O;O
be;O;O
used;O;O
to;O;O
treat;O;O
amphetamine;B-group;B-DDI-DrugBank.d236.s16.e3
poisoning;O;O
.;O;O
DDI-DrugBank.d236.s17;;
Ethosuximide;B-drug;B-DDI-DrugBank.d236.s17.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s17.e1
may;O;O
delay;O;O
intestinal;O;O
absorption;O;O
of;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d236.s17.e2
.;O;O
DDI-DrugBank.d236.s18;;
Haloperidol;B-drug;B-DDI-DrugBank.d236.s18.e0
:;O;O
Haloperidol;B-drug;B-DDI-DrugBank.d236.s18.e1
blocks;O;O
dopamine;O;O
and;O;O
norepinephrine;O;O
reuptake;O;O
,;O;O
thus;O;O
inhibiting;O;O
the;O;O
central;O;O
stimulant;O;O
effects;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s18.e2
.;O;O
DDI-DrugBank.d236.s19;;
Lithium;B-drug;B-DDI-DrugBank.d236.s19.e0
carbonate;I-drug;I-DDI-DrugBank.d236.s19.e0
:;O;O
The;O;O
stimulatory;O;O
effects;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s19.e1
may;O;O
be;O;O
inhibited;O;O
by;O;O
lithium;B-drug;B-DDI-DrugBank.d236.s19.e2
carbonate;I-drug;I-DDI-DrugBank.d236.s19.e2
.;O;O
DDI-DrugBank.d236.s20;;
Meperidine;B-drug;B-DDI-DrugBank.d236.s20.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s20.e1
potentiate;O;O
the;O;O
analgesic;O;O
effect;O;O
of;O;O
meperidine;B-drug;B-DDI-DrugBank.d236.s20.e2
.;O;O
DDI-DrugBank.d236.s21;;
Methenamine;B-drug;B-DDI-DrugBank.d236.s21.e0
therapy;O;O
:;O;O
Urinary;O;O
excretion;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d236.s21.e1
is;O;O
increased;O;O
,;O;O
and;O;O
efficacy;O;O
is;O;O
reduced;O;O
,;O;O
by;O;O
acidifying;B-group;B-DDI-DrugBank.d236.s21.e2
agents;I-group;I-DDI-DrugBank.d236.s21.e2
used;O;O
in;O;O
methenamine;B-drug;B-DDI-DrugBank.d236.s21.e3
therapy;O;O
.;O;O
DDI-DrugBank.d236.s22;;
Norepinephrine;B-drug;B-DDI-DrugBank.d236.s22.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s22.e1
enhance;O;O
the;O;O
adrenergic;O;O
effect;O;O
of;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d236.s22.e2
.;O;O
DDI-DrugBank.d236.s23;;
Phenobarbital;B-drug;B-DDI-DrugBank.d236.s23.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s23.e1
may;O;O
delay;O;O
intestinal;O;O
absorption;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d236.s23.e2
,;O;O
DDI-DrugBank.d236.s24;;
co;O;O
-;O;O
administration;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d236.s24.e0
may;O;O
produce;O;O
a;O;O
synergistic;O;O
anticonvulsant;O;O
action;O;O
.;O;O
DDI-DrugBank.d236.s25;;
Phenytoin;B-drug;B-DDI-DrugBank.d236.s25.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s25.e1
may;O;O
delay;O;O
intestinal;O;O
absorption;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d236.s25.e2
,;O;O
DDI-DrugBank.d236.s26;;
co;O;O
-;O;O
administration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d236.s26.e0
may;O;O
produce;O;O
a;O;O
synergistic;O;O
anticonvulsant;O;O
action;O;O
.;O;O
DDI-DrugBank.d236.s27;;
Propoxyphene;B-drug;B-DDI-DrugBank.d236.s27.e0
:;O;O
In;O;O
cases;O;O
of;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d236.s27.e1
overdosage;O;O
,;O;O
amphetamine;B-group;B-DDI-DrugBank.d236.s27.e2
CNS;O;O
stimulation;O;O
is;O;O
potentiated;O;O
and;O;O
fatal;O;O
convulsions;O;O
can;O;O
occur;O;O
.;O;O
DDI-DrugBank.d236.s28;;
Veratrum;B-group;B-DDI-DrugBank.d236.s28.e0
alkaloids;I-group;I-DDI-DrugBank.d236.s28.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s28.e1
inhibit;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
veratrum;B-group;B-DDI-DrugBank.d236.s28.e2
alkaloids;I-group;I-DDI-DrugBank.d236.s28.e2
.;O;O
DDI-DrugBank.d236.s29;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d236.s29.e0
can;O;O
cause;O;O
a;O;O
significant;O;O
elevation;O;O
in;O;O
plasma;O;O
corticosteroid;B-group;B-DDI-DrugBank.d236.s29.e1
levels;O;O
.;O;O
DDI-DrugBank.d236.s30;;
This;O;O
increase;O;O
is;O;O
greatest;O;O
in;O;O
the;O;O
evening;O;O
.;O;O
DDI-DrugBank.d236.s31;;
Amphetamines;B-group;B-DDI-DrugBank.d236.s31.e0
may;O;O
interfere;O;O
with;O;O
urinary;O;O
steroid;O;O
determinations;O;O
.;O;O
DDI-DrugBank.d461.s0;;
Additive;O;O
depressant;O;O
effect;O;O
when;O;O
used;O;O
with;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d461.s0.e0
,;O;O
sedatives;B-group;B-DDI-DrugBank.d461.s0.e1
,;O;O
antianxiety;B-group;B-DDI-DrugBank.d461.s0.e2
drugs;I-group;I-DDI-DrugBank.d461.s0.e2
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d461.s0.e3
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d461.s0.e4
,;O;O
and;O;O
other;O;O
opiate;B-group;B-DDI-DrugBank.d461.s0.e5
analgesics;I-group;I-DDI-DrugBank.d461.s0.e5
.;O;O
DDI-DrugBank.d293.s0;;
May;O;O
interact;O;O
with;O;O
thyroid;O;O
medication;O;O
(;O;O
e.g.;O;O
,;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d293.s0.e0
);O;O
,;O;O
iodine;B-drug;B-DDI-DrugBank.d293.s0.e1
-;O;O
containing;O;O
products;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d293.s0.e2
,;O;O
H2;B-group;B-DDI-DrugBank.d293.s0.e3
-;I-group;I-DDI-DrugBank.d293.s0.e3
antagonists;I-group;I-DDI-DrugBank.d293.s0.e3
(;O;O
e.g.;O;O
,;O;O
famotidine;B-drug;B-DDI-DrugBank.d293.s0.e4
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d293.s0.e5
);O;O
,;O;O
and;O;O
proton;B-group;B-DDI-DrugBank.d293.s0.e6
pump;I-group;I-DDI-DrugBank.d293.s0.e6
inhibitors;I-group;I-DDI-DrugBank.d293.s0.e6
(;O;O
e.g.;O;O
,;O;O
lansoprazole;B-drug;B-DDI-DrugBank.d293.s0.e7
,;O;O
omeprazole;B-drug;B-DDI-DrugBank.d293.s0.e8
);O;O
.;O;O
DDI-DrugBank.d293.s1;;
This;O;O
product;O;O
can;O;O
affect;O;O
the;O;O
results;O;O
of;O;O
certain;O;O
lab;O;O
tests;O;O
.;O;O
DDI-DrugBank.d36.s0;;
Caution;O;O
is;O;O
advised;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
high;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d36.s0.e0
and;O;O
carbonic;B-group;B-DDI-DrugBank.d36.s0.e1
anhydrase;I-group;I-DDI-DrugBank.d36.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d36.s0.e1
,;O;O
as;O;O
anorexia;O;O
,;O;O
tachypnea;O;O
,;O;O
lethargy;O;O
and;O;O
coma;O;O
have;O;O
been;O;O
rarely;O;O
reported;O;O
due;O;O
to;O;O
a;O;O
possible;O;O
drug;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d249.s0;;
Aspirin;B-brand;B-DDI-DrugBank.d249.s0.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s0.e1
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d249.s0.e2
is;O;O
not;O;O
recommended;O;O
because;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s0.e3
is;O;O
displaced;O;O
from;O;O
its;O;O
binding;O;O
sites;O;O
during;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d249.s0.e4
,;O;O
resulting;O;O
in;O;O
lower;O;O
plasma;O;O
concentrations;O;O
,;O;O
peak;O;O
plasma;O;O
levels;O;O
,;O;O
and;O;O
AUC;O;O
values;O;O
.;O;O
DDI-DrugBank.d249.s1;;
Anticoagulants;B-group;B-DDI-DrugBank.d249.s1.e0
:;O;O
While;O;O
studies;O;O
have;O;O
not;O;O
shown;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s1.e1
to;O;O
interact;O;O
with;O;O
anticoagulants;B-group;B-DDI-DrugBank.d249.s1.e2
of;I-group;I-DDI-DrugBank.d249.s1.e2
the;I-group;I-DDI-DrugBank.d249.s1.e2
warfarin;I-group;I-DDI-DrugBank.d249.s1.e2
type;I-group;I-DDI-DrugBank.d249.s1.e2
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
,;O;O
nonetheless;O;O
,;O;O
since;O;O
interactions;O;O
have;O;O
been;O;O
seen;O;O
with;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d249.s1.e3
.;O;O
DDI-DrugBank.d249.s2;;
Because;O;O
prostaglandins;O;O
play;O;O
an;O;O
important;O;O
role;O;O
in;O;O
hemostasis;O;O
,;O;O
and;O;O
NSAIDs;B-group;B-DDI-DrugBank.d249.s2.e0
affect;O;O
platelet;O;O
function;O;O
as;O;O
well;O;O
,;O;O
concurrent;O;O
therapy;O;O
with;O;O
all;O;O
NSAIDs;B-group;B-DDI-DrugBank.d249.s2.e1
,;O;O
including;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s2.e2
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d249.s2.e3
requires;O;O
close;O;O
monitoring;O;O
of;O;O
patients;O;O
to;O;O
be;O;O
certain;O;O
that;O;O
no;O;O
change;O;O
in;O;O
their;O;O
anticoagulant;B-group;B-DDI-DrugBank.d249.s2.e4
dosage;O;O
is;O;O
required;O;O
.;O;O
DDI-DrugBank.d249.s3;;
Digoxin;B-drug;B-DDI-DrugBank.d249.s3.e0
,;O;O
Methotrexate;B-drug;B-DDI-DrugBank.d249.s3.e1
,;O;O
Cyclosporine;B-drug;B-DDI-DrugBank.d249.s3.e2
:;O;O
Diclofenac;B-drug;B-DDI-DrugBank.d249.s3.e3
,;O;O
like;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d249.s3.e4
,;O;O
may;O;O
affect;O;O
renal;O;O
prostaglandins;O;O
and;O;O
increase;O;O
the;O;O
toxicity;O;O
of;O;O
certain;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d249.s4;;
Ingestion;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s4.e0
may;O;O
increase;O;O
serum;O;O
concentrations;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d249.s4.e1
and;O;O
methotrexate;B-drug;B-DDI-DrugBank.d249.s4.e2
and;O;O
increase;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d249.s4.e3
s;O;O
nephrotoxicity;O;O
.;O;O
DDI-DrugBank.d249.s5;;
Patients;O;O
who;O;O
begin;O;O
taking;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s5.e0
or;O;O
who;O;O
increase;O;O
their;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s5.e1
dose;O;O
or;O;O
any;O;O
other;O;O
NSAID;B-group;B-DDI-DrugBank.d249.s5.e2
while;O;O
taking;O;O
digoxin;B-drug;B-DDI-DrugBank.d249.s5.e3
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d249.s5.e4
,;O;O
or;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d249.s5.e5
may;O;O
develop;O;O
toxicity;O;O
characteristics;O;O
for;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d249.s6;;
They;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
,;O;O
particularly;O;O
if;O;O
renal;O;O
function;O;O
is;O;O
impaired;O;O
.;O;O
DDI-DrugBank.d249.s7;;
In;O;O
the;O;O
case;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d249.s7.e0
,;O;O
serum;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d249.s8;;
Lithium;B-drug;B-DDI-DrugBank.d249.s8.e0
:;O;O
Diclofenac;B-drug;B-DDI-DrugBank.d249.s8.e1
decreases;O;O
lithium;B-drug;B-DDI-DrugBank.d249.s8.e2
renal;O;O
clearance;O;O
and;O;O
increases;O;O
lithium;B-drug;B-DDI-DrugBank.d249.s8.e3
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d249.s9;;
In;O;O
patients;O;O
taking;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s9.e0
and;O;O
lithium;B-drug;B-DDI-DrugBank.d249.s9.e1
concomitantly;O;O
,;O;O
lithium;B-drug;B-DDI-DrugBank.d249.s9.e2
toxicity;O;O
may;O;O
develop;O;O
.;O;O
DDI-DrugBank.d249.s10;;
Oral;O;O
Hypoglycemics;B-group;B-DDI-DrugBank.d249.s10.e0
:;O;O
Diclofenac;B-drug;B-DDI-DrugBank.d249.s10.e1
does;O;O
not;O;O
alter;O;O
glucose;O;O
metabolism;O;O
in;O;O
normal;O;O
subjects;O;O
nor;O;O
does;O;O
it;O;O
alter;O;O
the;O;O
effects;O;O
of;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d249.s10.e2
agents;I-group;I-DDI-DrugBank.d249.s10.e2
.;O;O
DDI-DrugBank.d249.s11;;
There;O;O
are;O;O
rare;O;O
reports;O;O
,;O;O
however;O;O
,;O;O
from;O;O
marketing;O;O
experiences;O;O
,;O;O
of;O;O
changes;O;O
in;O;O
effects;O;O
of;O;O
insulin;B-drug;B-DDI-DrugBank.d249.s11.e0
or;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d249.s11.e1
agents;I-group;I-DDI-DrugBank.d249.s11.e1
in;O;O
the;O;O
presence;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s11.e2
that;O;O
necessitated;O;O
changes;O;O
in;O;O
the;O;O
doses;O;O
of;O;O
such;O;O
agents;O;O
.;O;O
DDI-DrugBank.d249.s12;;
Both;O;O
hypo;O;O
-;O;O
and;O;O
hyperglycemic;O;O
effects;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d249.s13;;
A;O;O
direct;O;O
causal;O;O
relationship;O;O
has;O;O
not;O;O
been;O;O
established;O;O
,;O;O
but;O;O
physicians;O;O
should;O;O
consider;O;O
the;O;O
possibility;O;O
that;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s13.e0
may;O;O
alter;O;O
a;O;O
diabetic;O;O
patient;O;O
s;O;O
response;O;O
to;O;O
insulin;B-drug;B-DDI-DrugBank.d249.s13.e1
or;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d249.s13.e2
agents;I-group;I-DDI-DrugBank.d249.s13.e2
.;O;O
DDI-DrugBank.d249.s14;;
Diuretics;B-group;B-DDI-DrugBank.d249.s14.e0
:;O;O
Diclofenac;B-drug;B-DDI-DrugBank.d249.s14.e1
and;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d249.s14.e2
can;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
diuretics;B-group;B-DDI-DrugBank.d249.s14.e3
.;O;O
DDI-DrugBank.d249.s15;;
Concomitant;O;O
treatment;O;O
with;O;O
potassium;B-group;B-DDI-DrugBank.d249.s15.e0
-;I-group;I-DDI-DrugBank.d249.s15.e0
sparing;I-group;I-DDI-DrugBank.d249.s15.e0
diuretics;I-group;I-DDI-DrugBank.d249.s15.e0
may;O;O
be;O;O
associated;O;O
with;O;O
increased;O;O
serum;O;O
potassium;O;O
levels;O;O
.;O;O
DDI-DrugBank.d249.s16;;
Other;O;O
Drugs;O;O
:;O;O
In;O;O
small;O;O
groups;O;O
of;O;O
patients;O;O
(;O;O
7;O;O
-;O;O
10;O;O
/;O;O
interaction;O;O
study;O;O
);O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
azathioprine;B-drug;B-DDI-DrugBank.d249.s16.e0
,;O;O
gold;B-group;B-DDI-DrugBank.d249.s16.e1
,;O;O
chloroquine;B-drug;B-DDI-DrugBank.d249.s16.e2
,;O;O
D;B-drug;B-DDI-DrugBank.d249.s16.e3
-;I-drug;I-DDI-DrugBank.d249.s16.e3
penicillamine;I-drug;I-DDI-DrugBank.d249.s16.e3
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d249.s16.e4
,;O;O
doxycycline;B-drug;B-DDI-DrugBank.d249.s16.e5
,;O;O
or;O;O
digitoxin;B-drug;B-DDI-DrugBank.d249.s16.e6
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
peak;O;O
levels;O;O
and;O;O
AUC;O;O
values;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s16.e7
.;O;O
DDI-DrugBank.d249.s17;;
Phenobarbital;B-drug;B-DDI-DrugBank.d249.s17.e0
toxicity;O;O
has;O;O
been;O;O
reported;O;O
to;O;O
have;O;O
occurred;O;O
in;O;O
a;O;O
patient;O;O
on;O;O
chronic;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d249.s17.e1
treatment;O;O
following;O;O
the;O;O
initiation;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s17.e2
therapy;O;O
.;O;O
DDI-DrugBank.d249.s18;;
Protein;O;O
Binding;O;O
In;O;O
vitro;O;O
,;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s18.e0
interferes;O;O
minimally;O;O
or;O;O
not;O;O
at;O;O
all;O;O
with;O;O
the;O;O
protein;O;O
binding;O;O
of;O;O
salicylic;B-drug;B-DDI-DrugBank.d249.s18.e1
acid;I-drug;I-DDI-DrugBank.d249.s18.e1
(;O;O
20;O;O
%;O;O
decrease;O;O
in;O;O
binding;O;O
);O;O
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d249.s18.e2
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d249.s18.e3
(;O;O
10;O;O
%;O;O
decrease;O;O
in;O;O
binding;O;O
);O;O
,;O;O
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d249.s18.e4
.;O;O
DDI-DrugBank.d249.s19;;
Benzylpenicillin;B-drug;B-DDI-DrugBank.d249.s19.e0
,;O;O
ampicillin;B-drug;B-DDI-DrugBank.d249.s19.e1
,;O;O
oxacillin;B-drug;B-DDI-DrugBank.d249.s19.e2
,;O;O
chlortetracycline;B-drug;B-DDI-DrugBank.d249.s19.e3
,;O;O
doxycycline;B-drug;B-DDI-DrugBank.d249.s19.e4
,;O;O
cephalothin;B-drug;B-DDI-DrugBank.d249.s19.e5
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d249.s19.e6
,;O;O
and;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d249.s19.e7
have;O;O
no;O;O
influence;O;O
in;O;O
vitro;O;O
on;O;O
the;O;O
protein;O;O
binding;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d249.s19.e8
in;O;O
human;O;O
serum;O;O
.;O;O
DDI-DrugBank.d249.s20;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Effect;O;O
on;O;O
Blood;O;O
Coagulation;O;O
:;O;O
Diclofenac;B-drug;B-DDI-DrugBank.d249.s20.e0
increases;O;O
platelet;O;O
aggregation;O;O
time;O;O
but;O;O
does;O;O
not;O;O
affect;O;O
bleeding;O;O
time;O;O
,;O;O
plasma;O;O
thrombin;O;O
clotting;O;O
time;O;O
,;O;O
plasma;O;O
fibrinogen;O;O
,;O;O
or;O;O
factors;O;O
V;O;O
and;O;O
VII;O;O
to;O;O
XII;O;O
.;O;O
DDI-DrugBank.d249.s21;;
Statistically;O;O
significant;O;O
changes;O;O
in;O;O
prothrombin;O;O
and;O;O
partial;O;O
thromboplastin;O;O
times;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
normal;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d249.s22;;
The;O;O
mean;O;O
changes;O;O
were;O;O
observed;O;O
to;O;O
be;O;O
less;O;O
than;O;O
1;O;O
second;O;O
in;O;O
both;O;O
instances;O;O
,;O;O
however;O;O
,;O;O
and;O;O
are;O;O
unlikely;O;O
to;O;O
be;O;O
clinically;O;O
important;O;O
.;O;O
DDI-DrugBank.d249.s23;;
Diclofenac;B-drug;B-DDI-DrugBank.d249.s23.e0
is;O;O
a;O;O
prostaglandin;O;O
synthetase;O;O
inhibitor;O;O
,;O;O
however;O;O
,;O;O
and;O;O
all;O;O
drugs;O;O
that;O;O
inhibit;O;O
prostaglandin;O;O
synthesis;O;O
interfere;O;O
with;O;O
platelet;O;O
function;O;O
to;O;O
some;O;O
degree;O;O
,;O;O
DDI-DrugBank.d249.s24;;
therefore;O;O
,;O;O
patients;O;O
who;O;O
may;O;O
be;O;O
adversely;O;O
affected;O;O
by;O;O
such;O;O
an;O;O
action;O;O
should;O;O
be;O;O
carefully;O;O
observed;O;O
.;O;O
DDI-DrugBank.d517.s0;;
Tetracycline;B-drug;B-DDI-DrugBank.d517.s0.e0
,;O;O
a;O;O
bacteriostatic;B-group;B-DDI-DrugBank.d517.s0.e1
antibiotic;I-group;I-DDI-DrugBank.d517.s0.e1
,;O;O
may;O;O
antagonize;O;O
the;O;O
bactercidal;O;O
effect;O;O
of;O;O
penicillin;B-drug;B-DDI-DrugBank.d517.s0.e2
and;O;O
concurrent;O;O
use;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d543.s0;;
The;O;O
following;O;O
agents;O;O
may;O;O
increase;O;O
certain;O;O
actions;O;O
or;O;O
side;O;O
effects;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d543.s0.e0
drugs;I-group;I-DDI-DrugBank.d543.s0.e0
.;O;O
amantadine;B-drug;B-DDI-DrugBank.d543.s0.e1
antiarrhythmic;I-group;I-DDI-DrugBank.d543.s0.e2
agents;I-group;I-DDI-DrugBank.d543.s0.e2
of;O;O
class;O;O
(;O;O
e.g.;O;O
quinidine;B-drug;B-DDI-DrugBank.d543.s0.e3
);O;O
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d543.s0.e4
antipsychotic;I-group;I-DDI-DrugBank.d543.s0.e5
agents;I-group;I-DDI-DrugBank.d543.s0.e5
(;O;O
e.g.;O;O
phenothiazines;B-group;B-DDI-DrugBank.d543.s0.e6
);O;O
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d543.s0.e7
.;O;O
DDI-DrugBank.d543.s1;;
MAO;B-group;B-DDI-DrugBank.d543.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d543.s1.e0
,;O;O
narcotic;B-group;B-DDI-DrugBank.d543.s1.e1
analgesics;I-group;I-DDI-DrugBank.d543.s1.e1
(;O;O
e.g.;O;O
,;O;O
meperidine;B-drug;B-DDI-DrugBank.d543.s1.e2
);O;O
,;O;O
nitrates;B-group;B-DDI-DrugBank.d543.s1.e3
and;O;O
nitrites;B-group;B-DDI-DrugBank.d543.s1.e4
,;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d543.s1.e5
agents;I-group;I-DDI-DrugBank.d543.s1.e5
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d543.s1.e6
antidepressants;I-group;I-DDI-DrugBank.d543.s1.e6
,;O;O
and;O;O
other;O;O
drugs;O;O
having;O;O
anticholinergic;O;O
activity;O;O
.;O;O
DDI-DrugBank.d543.s2;;
Anticholinergics;B-group;B-DDI-DrugBank.d543.s2.e0
antagonize;O;O
the;O;O
effects;O;O
of;O;O
antiglaucoma;B-group;B-DDI-DrugBank.d543.s2.e1
agents;I-group;I-DDI-DrugBank.d543.s2.e1
.;O;O
DDI-DrugBank.d543.s3;;
Anticholinergic;B-group;B-DDI-DrugBank.d543.s3.e0
drugs;I-group;I-DDI-DrugBank.d543.s3.e0
in;O;O
the;O;O
presence;O;O
of;O;O
increased;O;O
intraocular;O;O
pressure;O;O
may;O;O
be;O;O
hazardous;O;O
when;O;O
taken;O;O
concurrently;O;O
with;O;O
agents;O;O
such;O;O
as;O;O
corti;O;O
costeroids;O;O
..;O;O
DDI-DrugBank.d543.s4;;
Anticholinergic;B-group;B-DDI-DrugBank.d543.s4.e0
agents;I-group;I-DDI-DrugBank.d543.s4.e0
may;O;O
affect;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
various;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
slowly;O;O
dissolving;O;O
dosage;O;O
forms;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d543.s4.e1
,;O;O
DDI-DrugBank.d543.s5;;
increased;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d543.s5.e0
concentrations;O;O
may;O;O
result;O;O
.;O;O
DDI-DrugBank.d543.s6;;
Anticholinergic;B-group;B-DDI-DrugBank.d543.s6.e0
drugs;I-group;I-DDI-DrugBank.d543.s6.e0
may;O;O
antagonize;O;O
the;O;O
effects;O;O
of;O;O
the;O;O
drugs;O;O
that;O;O
alter;O;O
gastrointestinal;O;O
motility;O;O
,;O;O
such;O;O
as;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d543.s6.e1
.;O;O
DDI-DrugBank.d543.s7;;
Because;O;O
antacids;B-group;B-DDI-DrugBank.d543.s7.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d543.s7.e1
agents;I-group;I-DDI-DrugBank.d543.s7.e1
,;O;O
simultaneous;O;O
use;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d543.s8;;
The;O;O
inhibiting;O;O
effects;O;O
of;O;O
anticholinergic;B-group;B-DDI-DrugBank.d543.s8.e0
drugs;I-group;I-DDI-DrugBank.d543.s8.e0
on;O;O
gastric;O;O
hydrochloric;O;O
acid;O;O
secretion;O;O
are;O;O
antagonized;O;O
by;O;O
agents;O;O
used;O;O
to;O;O
treat;O;O
achlorhydria;O;O
and;O;O
those;O;O
used;O;O
to;O;O
test;O;O
gastric;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d43.s0;;
Coadministration;O;O
of;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s0.e0
with;O;O
drugs;O;O
that;O;O
are;O;O
known;O;O
to;O;O
cause;O;O
pancreatitis;O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
this;O;O
toxicity;O;O
(;O;O
see;O;O
WARNINGS;O;O
);O;O
and;O;O
should;O;O
be;O;O
done;O;O
with;O;O
extreme;O;O
caution;O;O
,;O;O
only;O;O
if;O;O
other;O;O
alternatives;O;O
are;O;O
not;O;O
available;O;O
,;O;O
and;O;O
only;O;O
if;O;O
clearly;O;O
indicated;O;O
.;O;O
DDI-DrugBank.d43.s1;;
Neuropathy;O;O
has;O;O
occurred;O;O
more;O;O
frequently;O;O
in;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
neuropathy;O;O
or;O;O
neurotoxic;O;O
drug;O;O
therapy;O;O
,;O;O
including;O;O
stavudine;B-drug;B-DDI-DrugBank.d43.s1.e0
,;O;O
and;O;O
these;O;O
patients;O;O
may;O;O
be;O;O
at;O;O
increased;O;O
risk;O;O
of;O;O
neuropathy;O;O
during;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s1.e1
therapy;O;O
(;O;O
see;O;O
ADVERSE;O;O
REACTIONS;O;O
);O;O
.;O;O
DDI-DrugBank.d43.s2;;
Allopurinol;B-drug;B-DDI-DrugBank.d43.s2.e0
:;O;O
The;O;O
AUC;O;O
of;O;O
didanosine;B-drug;B-DDI-DrugBank.d43.s2.e1
was;O;O
increased;O;O
about;O;O
4;O;O
-;O;O
fold;O;O
when;O;O
allopurinol;B-drug;B-DDI-DrugBank.d43.s2.e2
at;O;O
300;O;O
mg;O;O
/;O;O
day;O;O
was;O;O
coadministered;O;O
with;O;O
a;O;O
single;O;O
200;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s2.e3
to;O;O
two;O;O
patients;O;O
with;O;O
renal;O;O
impairment;O;O
(;O;O
CLcr=15;O;O
and;O;O
18;O;O
mL;O;O
/;O;O
min;O;O
);O;O
.;O;O
DDI-DrugBank.d43.s3;;
The;O;O
effects;O;O
of;O;O
allopurinol;B-drug;B-DDI-DrugBank.d43.s3.e0
on;O;O
didanosine;B-drug;B-DDI-DrugBank.d43.s3.e1
pharmacokinetics;O;O
in;O;O
subjects;O;O
with;O;O
normal;O;O
renal;O;O
function;O;O
are;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d43.s4;;
Antacids;B-group;B-DDI-DrugBank.d43.s4.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
antacids;B-group;B-DDI-DrugBank.d43.s4.e1
containing;O;O
magnesium;B-drug;B-DDI-DrugBank.d43.s4.e2
or;O;O
aluminum;B-drug;B-DDI-DrugBank.d43.s4.e3
with;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s4.e4
Chewable;O;O
/;O;O
Dispersible;O;O
Buffered;O;O
Tablets;O;O
or;O;O
Pediatric;O;O
Powder;O;O
for;O;O
Oral;O;O
Solution;O;O
may;O;O
potentiate;O;O
adverse;O;O
events;O;O
associated;O;O
with;O;O
the;O;O
antacid;B-group;B-DDI-DrugBank.d43.s4.e5
components;O;O
.;O;O
DDI-DrugBank.d43.s5;;
Drugs;O;O
Whose;O;O
Absorption;O;O
Can;O;O
Be;O;O
Affected;O;O
by;O;O
the;O;O
Level;O;O
of;O;O
Acidity;O;O
in;O;O
the;O;O
Stomach;O;O
:;O;O
Drugs;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d43.s5.e0
and;O;O
itraconazole;B-drug;B-DDI-DrugBank.d43.s5.e1
should;O;O
be;O;O
administered;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
prior;O;O
to;O;O
dosing;O;O
with;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s5.e2
.;O;O
DDI-DrugBank.d43.s6;;
Ganciclovir;B-drug;B-DDI-DrugBank.d43.s6.e0
:;O;O
Administration;O;O
of;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s6.e1
2;O;O
hours;O;O
prior;O;O
to;O;O
or;O;O
concurrent;O;O
with;O;O
oral;O;O
ganciclovir;B-drug;B-DDI-DrugBank.d43.s6.e2
was;O;O
associated;O;O
with;O;O
a;O;O
111;O;O
(;O;O
114)%;O;O
increase;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
AUC;O;O
of;O;O
didanosine;B-drug;B-DDI-DrugBank.d43.s6.e3
(;O;O
n;O;O
=;O;O
12;O;O
);O;O
.;O;O
DDI-DrugBank.d43.s7;;
A;O;O
21;O;O
(;O;O
17)%;O;O
decrease;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
AUC;O;O
of;O;O
ganciclovir;B-drug;B-DDI-DrugBank.d43.s7.e0
was;O;O
observed;O;O
when;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s7.e1
was;O;O
administered;O;O
2;O;O
hours;O;O
prior;O;O
to;O;O
ganciclovir;B-drug;B-DDI-DrugBank.d43.s7.e2
,;O;O
but;O;O
not;O;O
when;O;O
the;O;O
two;O;O
drugs;O;O
were;O;O
administered;O;O
simultaneously;O;O
(;O;O
n;O;O
=;O;O
12;O;O
);O;O
.;O;O
DDI-DrugBank.d43.s8;;
Quinolone;B-group;B-DDI-DrugBank.d43.s8.e0
Antibiotics;I-group;I-DDI-DrugBank.d43.s8.e0
:;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s8.e1
should;O;O
be;O;O
administered;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
after;O;O
or;O;O
6;O;O
hours;O;O
before;O;O
dosing;O;O
with;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s8.e2
because;O;O
plasma;O;O
concentrations;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s8.e3
are;O;O
decreased;O;O
when;O;O
administered;O;O
with;O;O
antacids;B-group;B-DDI-DrugBank.d43.s8.e4
containing;O;O
magnesium;B-drug;B-DDI-DrugBank.d43.s8.e5
,;O;O
calcium;B-drug;B-DDI-DrugBank.d43.s8.e6
,;O;O
or;O;O
aluminum;B-drug;B-DDI-DrugBank.d43.s8.e7
.;O;O
DDI-DrugBank.d43.s9;;
In;O;O
eight;O;O
HIV;O;O
-;O;O
infected;O;O
patients;O;O
,;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
AUC;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s9.e0
was;O;O
decreased;O;O
an;O;O
average;O;O
of;O;O
26;O;O
%;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
=;O;O
14;O;O
%;O;O
,;O;O
37;O;O
%;O;O
);O;O
when;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s9.e1
was;O;O
administered;O;O
2;O;O
hours;O;O
prior;O;O
to;O;O
a;O;O
marketed;O;O
chewable;O;O
/;O;O
dispersible;O;O
tablet;O;O
formulation;O;O
of;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s9.e2
.;O;O
DDI-DrugBank.d43.s10;;
The;O;O
AUC;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s10.e0
was;O;O
decreased;O;O
an;O;O
average;O;O
of;O;O
15;O;O
-;O;O
fold;O;O
in;O;O
12;O;O
healthy;O;O
subjects;O;O
given;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s10.e1
and;O;O
didanosine;B-drug;B-DDI-DrugBank.d43.s10.e2
-;O;O
placebo;O;O
tablets;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d43.s11;;
In;O;O
a;O;O
single;O;O
subject;O;O
given;O;O
one;O;O
dose;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s11.e0
2;O;O
hours;O;O
after;O;O
a;O;O
dose;O;O
of;O;O
didanosine;B-drug;B-DDI-DrugBank.d43.s11.e1
-;O;O
placebo;O;O
tablets;O;O
,;O;O
a;O;O
greater;O;O
than;O;O
50;O;O
%;O;O
reduction;O;O
in;O;O
the;O;O
AUC;O;O
of;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d43.s11.e2
was;O;O
observed;O;O
.;O;O
DDI-DrugBank.d43.s12;;
Plasma;O;O
concentrations;O;O
of;O;O
quinolone;B-group;B-DDI-DrugBank.d43.s12.e0
antibiotics;I-group;I-DDI-DrugBank.d43.s12.e0
are;O;O
decreased;O;O
when;O;O
administered;O;O
with;O;O
antacids;B-group;B-DDI-DrugBank.d43.s12.e1
containing;O;O
magnesium;B-drug;B-DDI-DrugBank.d43.s12.e2
,;O;O
calcium;B-drug;B-DDI-DrugBank.d43.s12.e3
,;O;O
or;O;O
aluminum;B-drug;B-DDI-DrugBank.d43.s12.e4
.;O;O
DDI-DrugBank.d43.s13;;
The;O;O
optimal;O;O
dosing;O;O
interval;O;O
for;O;O
coadministration;O;O
with;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s13.e0
should;O;O
be;O;O
determined;O;O
by;O;O
consulting;O;O
the;O;O
appropriate;O;O
quinolone;B-group;B-DDI-DrugBank.d43.s13.e1
package;O;O
insert;O;O
.;O;O
DDI-DrugBank.d43.s14;;
Interactions;O;O
with;O;O
Other;O;O
Antiretroviral;B-group;B-DDI-DrugBank.d43.s14.e0
Drugs;I-group;I-DDI-DrugBank.d43.s14.e0
:;O;O
Significant;O;O
decreases;O;O
in;O;O
the;O;O
AUC;O;O
of;O;O
delavirdine;B-drug;B-DDI-DrugBank.d43.s14.e1
(;O;O
20;O;O
%;O;O
);O;O
and;O;O
indinavir;B-drug;B-DDI-DrugBank.d43.s14.e2
(;O;O
84;O;O
%;O;O
);O;O
occurred;O;O
following;O;O
simultaneous;O;O
administration;O;O
of;O;O
these;O;O
agents;O;O
with;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s14.e3
.;O;O
DDI-DrugBank.d43.s15;;
To;O;O
avoid;O;O
this;O;O
interaction;O;O
,;O;O
delavirdine;B-drug;B-DDI-DrugBank.d43.s15.e0
or;O;O
indinavir;B-drug;B-DDI-DrugBank.d43.s15.e1
should;O;O
be;O;O
given;O;O
1;O;O
hour;O;O
prior;O;O
to;O;O
dosing;O;O
with;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s15.e2
.;O;O
DDI-DrugBank.d43.s16;;
The;O;O
pharmacokinetics;O;O
of;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d43.s16.e0
are;O;O
not;O;O
altered;O;O
to;O;O
a;O;O
clinically;O;O
significant;O;O
degree;O;O
when;O;O
it;O;O
is;O;O
administered;O;O
with;O;O
a;O;O
light;O;O
meal;O;O
1;O;O
hour;O;O
after;O;O
VIDEX;B-brand;B-DDI-DrugBank.d43.s16.e1
.;O;O
DDI-DrugBank.d570.s0;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Certain;O;O
endocrine;O;O
and;O;O
liver;O;O
function;O;O
tests;O;O
may;O;O
be;O;O
affected;O;O
by;O;O
estrogen;B-group;B-DDI-DrugBank.d570.s0.e0
-;O;O
containing;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d570.s0.e1
.;O;O
DDI-DrugBank.d570.s1;;
The;O;O
following;O;O
similar;O;O
changes;O;O
may;O;O
be;O;O
expected;O;O
with;O;O
larger;O;O
doses;O;O
of;O;O
estrogen;B-group;B-DDI-DrugBank.d570.s1.e0
:;O;O
-;O;O
Increased;O;O
sulfobromophthalein;O;O
retention;O;O
DDI-DrugBank.d570.s2;;
.;O;O
DDI-DrugBank.d570.s3;;
-;O;O
Increased;O;O
prothrombin;O;O
and;O;O
factors;O;O
VII;O;O
,;O;O
VIII;O;O
,;O;O
IX;O;O
,;O;O
and;O;O
X;O;O
,;O;O
DDI-DrugBank.d570.s4;;
decreased;O;O
antithrombin;B-drug;B-DDI-DrugBank.d570.s4.e0
3;I-drug;I-DDI-DrugBank.d570.s4.e0
,;O;O
DDI-DrugBank.d570.s5;;
increased;O;O
norepinephrine;O;O
-;O;O
induced;O;O
platelet;O;O
aggregability;O;O
DDI-DrugBank.d570.s6;;
.;O;O
DDI-DrugBank.d570.s7;;
-;O;O
Increased;O;O
thyroid;O;O
-;O;O
binding;O;O
globulin;O;O
(;O;O
TBG;O;O
);O;O
leading;O;O
to;O;O
in;O;O
-;O;O
creased;O;O
circulating;O;O
total;O;O
thyroid;O;O
hormone;O;O
,;O;O
DDI-DrugBank.d570.s8;;
as;O;O
measured;O;O
by;O;O
PBI;O;O
,;O;O
T4;O;O
by;O;O
column;O;O
,;O;O
or;O;O
T4;O;O
by;O;O
radioimmunoassay;O;O
.;O;O
DDI-DrugBank.d570.s9;;
Free;O;O
T3;O;O
resin;O;O
uptake;O;O
is;O;O
decreased;O;O
,;O;O
reflecting;O;O
the;O;O
elevated;O;O
TBG;O;O
,;O;O
DDI-DrugBank.d570.s10;;
free;O;O
T4;O;O
concentration;O;O
is;O;O
unaltered;O;O
DDI-DrugBank.d570.s11;;
.;O;O
DDI-DrugBank.d570.s12;;
-;O;O
Impaired;O;O
glucose;O;O
tolerance;O;O
DDI-DrugBank.d570.s13;;
.;O;O
DDI-DrugBank.d570.s14;;
-;O;O
Decreased;O;O
pregnanediol;O;O
excretion;O;O
DDI-DrugBank.d570.s15;;
.;O;O
DDI-DrugBank.d570.s16;;
-;O;O
Reduced;O;O
response;O;O
to;O;O
metyrapone;O;O
test;O;O
DDI-DrugBank.d570.s17;;
.;O;O
DDI-DrugBank.d570.s18;;
-;O;O
Reduced;O;O
serum;O;O
folate;O;O
concentration;O;O
DDI-DrugBank.d570.s19;;
.;O;O
DDI-DrugBank.d570.s20;;
-;O;O
Increased;O;O
serum;O;O
triglyceride;O;O
and;O;O
phospholipid;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d352.s0;;
Antidiabetic;B-group;B-DDI-DrugBank.d352.s0.e0
drug;I-group;I-DDI-DrugBank.d352.s0.e0
requirements;O;O
(;O;O
i.e.;O;O
,;O;O
insulin;B-drug;B-DDI-DrugBank.d352.s0.e1
);O;O
may;O;O
be;O;O
altered;O;O
.;O;O
DDI-DrugBank.d352.s1;;
Concurrent;O;O
use;O;O
with;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d352.s1.e0
may;O;O
result;O;O
in;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d352.s2;;
The;O;O
pressor;O;O
effects;O;O
of;O;O
diethylpropion;B-drug;B-DDI-DrugBank.d352.s2.e0
and;O;O
those;O;O
of;O;O
other;O;O
drugs;O;O
may;O;O
be;O;O
additive;O;O
when;O;O
the;O;O
drugs;O;O
are;O;O
used;O;O
concomitantly;O;O
,;O;O
DDI-DrugBank.d352.s3;;
conversely;O;O
,;O;O
diethylpropion;B-drug;B-DDI-DrugBank.d352.s3.e0
may;O;O
interfere;O;O
with;O;O
antihypertensive;B-group;B-DDI-DrugBank.d352.s3.e1
drugs;I-group;I-DDI-DrugBank.d352.s3.e1
(;O;O
i.e.;O;O
,;O;O
guanethidine;B-drug;B-DDI-DrugBank.d352.s3.e2
,;O;O
a;B-drug;B-DDI-DrugBank.d352.s3.e3
-;I-drug;I-DDI-DrugBank.d352.s3.e3
methyldopa;I-drug;I-DDI-DrugBank.d352.s3.e3
);O;O
.;O;O
DDI-DrugBank.d352.s4;;
Concurrent;O;O
use;O;O
of;O;O
phenothiazines;B-group;B-DDI-DrugBank.d352.s4.e0
may;O;O
antagonize;O;O
the;O;O
anorectic;O;O
effect;O;O
of;O;O
diethylpropion;B-drug;B-DDI-DrugBank.d352.s4.e1
.;O;O
DDI-DrugBank.d248.s0;;
May;O;O
interact;O;O
anticoagulants;B-group;B-DDI-DrugBank.d248.s0.e0
(;O;O
altered;O;O
hypo;O;O
-;O;O
prothrombinemic;O;O
effect;O;O
);O;O
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d248.s0.e1
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d248.s0.e2
and;O;O
other;O;O
inducers;O;O
of;O;O
hepatic;O;O
microsomal;O;O
enzyme;O;O
oxidation;O;O
system;O;O
(;O;O
decreased;O;O
effect;O;O
of;O;O
diethylstilbestrol;B-drug;B-DDI-DrugBank.d248.s0.e3
);O;O
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d248.s0.e4
(;O;O
increased;O;O
effect;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d248.s0.e5
);O;O
.;O;O
DDI-DrugBank.d132.s0;;
Oral;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d132.s0.e0
:;O;O
In;O;O
some;O;O
normal;O;O
volunteers;O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s0.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d132.s0.e2
,;O;O
acenocoumarol;B-drug;B-DDI-DrugBank.d132.s0.e3
,;O;O
or;O;O
phenprocoumon;B-drug;B-DDI-DrugBank.d132.s0.e4
resulted;O;O
in;O;O
prolongation;O;O
of;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d132.s1;;
This;O;O
may;O;O
occur;O;O
because;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s1.e0
competitively;O;O
displaces;O;O
coumarins;B-group;B-DDI-DrugBank.d132.s1.e1
from;O;O
protein;O;O
binding;O;O
sites;O;O
.;O;O
DDI-DrugBank.d132.s2;;
Accordingly;O;O
,;O;O
when;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s2.e0
is;O;O
administered;O;O
with;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d132.s2.e1
,;O;O
the;O;O
prothrombin;O;O
time;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
during;O;O
and;O;O
for;O;O
several;O;O
days;O;O
after;O;O
concomitant;O;O
drug;O;O
administration;O;O
.;O;O
DDI-DrugBank.d132.s3;;
Adjustment;O;O
of;O;O
dosage;O;O
of;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d132.s3.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d132.s4;;
Tolbutamide;B-drug;B-DDI-DrugBank.d132.s4.e0
:;O;O
In;O;O
diabetic;O;O
patients;O;O
receiving;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s4.e1
and;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d132.s4.e2
,;O;O
no;O;O
significant;O;O
effects;O;O
were;O;O
seen;O;O
on;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d132.s4.e3
plasma;O;O
levels;O;O
or;O;O
fasting;O;O
blood;O;O
glucose;O;O
.;O;O
DDI-DrugBank.d132.s5;;
Hydrochlorothiazide;B-drug;B-DDI-DrugBank.d132.s5.e0
:;O;O
In;O;O
normal;O;O
volunteers;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s5.e1
and;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d132.s5.e2
resulted;O;O
in;O;O
significantly;O;O
increased;O;O
plasma;O;O
levels;O;O
of;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d132.s5.e3
.;O;O
DDI-DrugBank.d132.s6;;
Diflunisal;B-drug;B-DDI-DrugBank.d132.s6.e0
decreased;O;O
the;O;O
hyperuricemic;O;O
effect;O;O
of;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d132.s6.e1
.;O;O
DDI-DrugBank.d132.s7;;
Furosemide;B-drug;B-DDI-DrugBank.d132.s7.e0
:;O;O
In;O;O
normal;O;O
volunteers;O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s7.e1
and;O;O
furosemide;B-drug;B-DDI-DrugBank.d132.s7.e2
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
diuretic;O;O
activity;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d132.s7.e3
.;O;O
DDI-DrugBank.d132.s8;;
Diflunisal;B-drug;B-DDI-DrugBank.d132.s8.e0
decreased;O;O
the;O;O
hyperuricemic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d132.s8.e1
.;O;O
DDI-DrugBank.d132.s9;;
Antacids;B-group;B-DDI-DrugBank.d132.s9.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
antacids;B-group;B-DDI-DrugBank.d132.s9.e1
may;O;O
reduce;O;O
plasma;O;O
levels;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s9.e2
.;O;O
DDI-DrugBank.d132.s10;;
This;O;O
effect;O;O
is;O;O
small;O;O
with;O;O
occasional;O;O
doses;O;O
of;O;O
antacids;B-group;B-DDI-DrugBank.d132.s10.e0
,;O;O
but;O;O
may;O;O
be;O;O
clinically;O;O
significant;O;O
when;O;O
antacids;B-group;B-DDI-DrugBank.d132.s10.e1
are;O;O
used;O;O
on;O;O
a;O;O
continuous;O;O
schedule;O;O
.;O;O
DDI-DrugBank.d132.s11;;
Acetaminophen;B-drug;B-DDI-DrugBank.d132.s11.e0
:;O;O
In;O;O
normal;O;O
volunteers;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s11.e1
and;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d132.s11.e2
resulted;O;O
in;O;O
an;O;O
approximate;O;O
50;O;O
%;O;O
increase;O;O
in;O;O
plasma;O;O
levels;O;O
of;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d132.s11.e3
.;O;O
DDI-DrugBank.d132.s12;;
Acetaminophen;B-drug;B-DDI-DrugBank.d132.s12.e0
had;O;O
no;O;O
effect;O;O
on;O;O
plasma;O;O
levels;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s12.e1
.;O;O
DDI-DrugBank.d132.s13;;
Since;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d132.s13.e0
in;O;O
high;O;O
doses;O;O
has;O;O
been;O;O
associated;O;O
with;O;O
hepatotoxicity;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s13.e1
and;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d132.s13.e2
should;O;O
be;O;O
used;O;O
cautiously;O;O
,;O;O
with;O;O
careful;O;O
monitoring;O;O
of;O;O
patients;O;O
.;O;O
DDI-DrugBank.d132.s14;;
Concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s14.e0
and;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d132.s14.e1
in;O;O
dogs;O;O
,;O;O
but;O;O
not;O;O
in;O;O
rats;O;O
,;O;O
at;O;O
approximately;O;O
2;O;O
times;O;O
the;O;O
recommended;O;O
maximum;O;O
human;O;O
therapeutic;O;O
dose;O;O
of;O;O
each;O;O
(;O;O
40;O;O
to;O;O
52;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s14.e2
/;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d132.s14.e3
);O;O
resulted;O;O
in;O;O
greater;O;O
gastrointestinal;O;O
toxicity;O;O
than;O;O
when;O;O
either;O;O
drug;O;O
was;O;O
administered;O;O
alone;O;O
.;O;O
DDI-DrugBank.d132.s15;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
findings;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d132.s16;;
Methotrexate;B-drug;B-DDI-DrugBank.d132.s16.e0
:;O;O
Caution;O;O
should;O;O
be;O;O
used;O;O
if;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s16.e1
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d132.s16.e2
.;O;O
DDI-DrugBank.d132.s17;;
Nonsteroidal;B-group;B-DDI-DrugBank.d132.s17.e0
anti;I-group;I-DDI-DrugBank.d132.s17.e0
-;I-group;I-DDI-DrugBank.d132.s17.e0
inflammatory;I-group;I-DDI-DrugBank.d132.s17.e0
drugs;I-group;I-DDI-DrugBank.d132.s17.e0
have;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
the;O;O
tubular;O;O
secretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d132.s17.e1
and;O;O
to;O;O
potentiate;O;O
its;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d132.s18;;
Cyclosporine;B-drug;B-DDI-DrugBank.d132.s18.e0
:;O;O
Administration;O;O
of;O;O
nonsteroial;B-group;B-DDI-DrugBank.d132.s18.e1
anti;I-group;I-DDI-DrugBank.d132.s18.e1
-;I-group;I-DDI-DrugBank.d132.s18.e1
inflammatory;I-group;I-DDI-DrugBank.d132.s18.e1
drugs;I-group;I-DDI-DrugBank.d132.s18.e1
concomitantly;O;O
with;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d132.s18.e2
has;O;O
been;O;O
associated;O;O
with;O;O
an;O;O
increase;O;O
in;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d132.s18.e3
-;O;O
induced;O;O
toxicity;O;O
,;O;O
possibly;O;O
due;O;O
to;O;O
decreased;O;O
synthesis;O;O
of;O;O
renal;O;O
prostacyclin;O;O
.;O;O
DDI-DrugBank.d132.s19;;
NSAIDs;B-group;B-DDI-DrugBank.d132.s19.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
taking;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d132.s19.e1
,;O;O
and;O;O
renal;O;O
function;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d132.s20;;
Nonsteroidal;B-group;B-DDI-DrugBank.d132.s20.e0
Anti;I-group;I-DDI-DrugBank.d132.s20.e0
-;I-group;I-DDI-DrugBank.d132.s20.e0
Inflammatory;I-group;I-DDI-DrugBank.d132.s20.e0
Drugs;I-group;I-DDI-DrugBank.d132.s20.e0
:;O;O
The;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s20.e1
to;O;O
normal;O;O
volunteers;O;O
receiving;O;O
indomethacin;B-drug;B-DDI-DrugBank.d132.s20.e2
decreased;O;O
the;O;O
renal;O;O
clearance;O;O
and;O;O
significantly;O;O
increased;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
indomethacin;B-drug;B-DDI-DrugBank.d132.s20.e3
.;O;O
DDI-DrugBank.d132.s21;;
In;O;O
some;O;O
patients;O;O
the;O;O
combined;O;O
use;O;O
of;O;O
indomethacin;B-drug;B-DDI-DrugBank.d132.s21.e0
and;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s21.e1
has;O;O
been;O;O
associated;O;O
with;O;O
fatal;O;O
gastrointestinal;O;O
hemorrhage;O;O
.;O;O
DDI-DrugBank.d132.s22;;
Therefore;O;O
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d132.s22.e0
and;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s22.e1
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d132.s23;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s23.e0
tablets;O;O
and;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d132.s23.e1
is;O;O
not;O;O
recommended;O;O
due;O;O
to;O;O
the;O;O
increased;O;O
possibility;O;O
of;O;O
gastrointestinal;O;O
toxicity;O;O
,;O;O
with;O;O
little;O;O
or;O;O
no;O;O
increase;O;O
in;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d132.s24;;
The;O;O
following;O;O
information;O;O
was;O;O
obtained;O;O
from;O;O
studies;O;O
in;O;O
normal;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d132.s25;;
Aspirin;B-brand;B-DDI-DrugBank.d132.s25.e0
:;O;O
In;O;O
normal;O;O
volunteers;O;O
,;O;O
a;O;O
small;O;O
decrease;O;O
in;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s25.e1
levels;O;O
was;O;O
observed;O;O
when;O;O
multiple;O;O
doses;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s25.e2
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d132.s25.e3
were;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d132.s26;;
Sulindac;B-drug;B-DDI-DrugBank.d132.s26.e0
:;O;O
The;O;O
concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s26.e1
and;O;O
sulindac;B-drug;B-DDI-DrugBank.d132.s26.e2
in;O;O
normal;O;O
volunteers;O;O
resulted;O;O
in;O;O
lowering;O;O
of;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
the;O;O
active;O;O
sulindac;O;O
sulfide;O;O
metabolite;O;O
by;O;O
approximately;O;O
one;O;O
-;O;O
third;O;O
.;O;O
DDI-DrugBank.d132.s27;;
Naproxen;B-drug;B-DDI-DrugBank.d132.s27.e0
:;O;O
The;O;O
concomitant;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s27.e1
and;O;O
naproxen;B-drug;B-DDI-DrugBank.d132.s27.e2
in;O;O
normal;O;O
volunteers;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
naproxen;B-drug;B-DDI-DrugBank.d132.s27.e3
,;O;O
but;O;O
significantly;O;O
decreased;O;O
the;O;O
urinary;O;O
excretion;O;O
of;O;O
naproxen;B-drug;B-DDI-DrugBank.d132.s27.e4
and;O;O
its;O;O
glucuronide;O;O
metabolite;O;O
.;O;O
DDI-DrugBank.d132.s28;;
Naproxen;B-drug;B-DDI-DrugBank.d132.s28.e0
had;O;O
no;O;O
effect;O;O
on;O;O
plasma;O;O
levels;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s28.e1
.;O;O
DDI-DrugBank.d132.s29;;
Drug;O;O
laboratory;O;O
Test;O;O
Interactions;O;O
Serum;O;O
Salicylate;O;O
Assays;O;O
:;O;O
Caution;O;O
should;O;O
be;O;O
used;O;O
in;O;O
interpreting;O;O
the;O;O
results;O;O
of;O;O
serum;O;O
salicylate;O;O
assays;O;O
when;O;O
diflunisal;B-drug;B-DDI-DrugBank.d132.s29.e0
is;O;O
present;O;O
.;O;O
DDI-DrugBank.d132.s30;;
Salicylate;B-group;B-DDI-DrugBank.d132.s30.e0
levels;O;O
have;O;O
been;O;O
found;O;O
to;O;O
be;O;O
falsely;O;O
elevated;O;O
with;O;O
some;O;O
assay;O;O
methods;O;O
.;O;O
DDI-DrugBank.d450.s0;;
Potassium;B-group;B-DDI-DrugBank.d450.s0.e0
-;I-group;I-DDI-DrugBank.d450.s0.e0
depleting;I-group;I-DDI-DrugBank.d450.s0.e0
diuretics;I-group;I-DDI-DrugBank.d450.s0.e0
are;O;O
a;O;O
major;O;O
contributing;O;O
factor;O;O
to;O;O
digitalis;B-group;B-DDI-DrugBank.d450.s0.e1
toxicity;O;O
.;O;O
DDI-DrugBank.d450.s1;;
Calcium;B-drug;B-DDI-DrugBank.d450.s1.e0
,;O;O
particularly;O;O
if;O;O
administered;O;O
rapidly;O;O
by;O;O
the;O;O
intravenous;O;O
route;O;O
,;O;O
may;O;O
produce;O;O
serious;O;O
arrhythmias;O;O
in;O;O
digitalized;O;O
patients;O;O
.;O;O
DDI-DrugBank.d450.s2;;
Quinidine;B-drug;B-DDI-DrugBank.d450.s2.e0
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d450.s2.e1
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d450.s2.e2
,;O;O
propafenone;B-drug;B-DDI-DrugBank.d450.s2.e3
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d450.s2.e4
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d450.s2.e5
,;O;O
alprazolam;B-drug;B-DDI-DrugBank.d450.s2.e6
,;O;O
and;O;O
spironolactone;B-drug;B-DDI-DrugBank.d450.s2.e7
raise;O;O
the;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s2.e8
concentration;O;O
due;O;O
to;O;O
a;O;O
reduction;O;O
in;O;O
clearance;O;O
and/or;O;O
in;O;O
volume;O;O
of;O;O
distribution;O;O
of;O;O
the;O;O
drug;O;O
,;O;O
with;O;O
the;O;O
implication;O;O
that;O;O
digitalis;B-group;B-DDI-DrugBank.d450.s2.e9
intoxication;O;O
may;O;O
result;O;O
.;O;O
DDI-DrugBank.d450.s3;;
Erythromycin;B-drug;B-DDI-DrugBank.d450.s3.e0
and;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d450.s3.e1
(;O;O
and;O;O
possibly;O;O
other;O;O
macrolide;B-group;B-DDI-DrugBank.d450.s3.e2
antibiotics;I-group;I-DDI-DrugBank.d450.s3.e2
);O;O
and;O;O
tetracycline;B-drug;B-DDI-DrugBank.d450.s3.e3
may;O;O
increase;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s3.e4
absorption;O;O
in;O;O
patients;O;O
who;O;O
inactivate;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s3.e5
by;O;O
bacterial;O;O
metabolism;O;O
in;O;O
the;O;O
lower;O;O
intestine;O;O
,;O;O
so;O;O
that;O;O
digitalis;B-group;B-DDI-DrugBank.d450.s3.e6
intoxication;O;O
may;O;O
result;O;O
.;O;O
DDI-DrugBank.d450.s4;;
The;O;O
risk;O;O
of;O;O
this;O;O
interaction;O;O
may;O;O
be;O;O
reduced;O;O
if;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s4.e0
is;O;O
given;O;O
as;O;O
capsules;O;O
.;O;O
DDI-DrugBank.d450.s5;;
Propantheline;B-drug;B-DDI-DrugBank.d450.s5.e0
and;O;O
diphenoxylate;B-drug;B-DDI-DrugBank.d450.s5.e1
,;O;O
by;O;O
decreasing;O;O
gut;O;O
motility;O;O
,;O;O
may;O;O
increase;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s5.e2
absorption;O;O
.;O;O
DDI-DrugBank.d450.s6;;
Antacids;B-group;B-DDI-DrugBank.d450.s6.e0
,;O;O
kaolin;B-drug;B-DDI-DrugBank.d450.s6.e1
-;O;O
pectin;O;O
,;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d450.s6.e2
,;O;O
neomycin;B-drug;B-DDI-DrugBank.d450.s6.e3
,;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d450.s6.e4
,;O;O
certain;O;O
anticancer;O;O
drugs;O;O
,;O;O
and;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d450.s6.e5
may;O;O
interfere;O;O
with;O;O
intestinal;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s6.e6
absorption;O;O
,;O;O
resulting;O;O
in;O;O
unexpectedly;O;O
low;O;O
serum;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d450.s7;;
Rifampin;B-drug;B-DDI-DrugBank.d450.s7.e0
may;O;O
decrease;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s7.e1
concentration;O;O
,;O;O
especially;O;O
in;O;O
patients;O;O
with;O;O
renal;O;O
dysfunction;O;O
,;O;O
by;O;O
increasing;O;O
the;O;O
non;O;O
-;O;O
renal;O;O
clearance;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s7.e2
.;O;O
DDI-DrugBank.d450.s8;;
There;O;O
have;O;O
been;O;O
inconsistent;O;O
reports;O;O
regarding;O;O
the;O;O
effects;O;O
of;O;O
other;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
quinine;B-drug;B-DDI-DrugBank.d450.s8.e0
,;O;O
penicillamine;B-drug;B-DDI-DrugBank.d450.s8.e1
);O;O
on;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s8.e2
concentration;O;O
.;O;O
DDI-DrugBank.d450.s9;;
Thyroid;B-group;B-DDI-DrugBank.d450.s9.e0
administration;O;O
to;O;O
a;O;O
digitalized;O;O
,;O;O
hypothyroid;O;O
patient;O;O
may;O;O
increase;O;O
the;O;O
dose;O;O
requirement;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s9.e1
.;O;O
DDI-DrugBank.d450.s10;;
Concomitant;O;O
use;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s10.e0
and;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d450.s10.e1
increases;O;O
the;O;O
risk;O;O
of;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d450.s11;;
Succinylcholine;B-drug;B-DDI-DrugBank.d450.s11.e0
may;O;O
cause;O;O
a;O;O
sudden;O;O
extrusion;O;O
of;O;O
potassium;O;O
from;O;O
muscle;O;O
cells;O;O
,;O;O
and;O;O
may;O;O
thereby;O;O
cause;O;O
arrhythmias;O;O
in;O;O
digitalized;O;O
patients;O;O
.;O;O
DDI-DrugBank.d450.s12;;
Although;O;O
beta;B-group;B-DDI-DrugBank.d450.s12.e0
-;I-group;I-DDI-DrugBank.d450.s12.e0
adrenergic;I-group;I-DDI-DrugBank.d450.s12.e0
blockers;I-group;I-DDI-DrugBank.d450.s12.e0
or;O;O
calcium;B-group;B-DDI-DrugBank.d450.s12.e1
channel;I-group;I-DDI-DrugBank.d450.s12.e1
blockers;I-group;I-DDI-DrugBank.d450.s12.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s12.e2
may;O;O
be;O;O
useful;O;O
in;O;O
combination;O;O
to;O;O
control;O;O
atrial;O;O
fibrillation;O;O
,;O;O
their;O;O
additive;O;O
effects;O;O
on;O;O
AV;O;O
node;O;O
conduction;O;O
can;O;O
result;O;O
in;O;O
advanced;O;O
or;O;O
complete;O;O
heart;O;O
block;O;O
.;O;O
DDI-DrugBank.d450.s13;;
Due;O;O
to;O;O
the;O;O
considerable;O;O
variability;O;O
of;O;O
these;O;O
interactions;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s13.e0
should;O;O
be;O;O
individualized;O;O
when;O;O
patients;O;O
receive;O;O
these;O;O
medications;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d450.s14;;
Furthermore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
combining;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s14.e0
with;O;O
any;O;O
drug;O;O
that;O;O
may;O;O
cause;O;O
a;O;O
significant;O;O
deterioration;O;O
in;O;O
renal;O;O
function;O;O
,;O;O
since;O;O
a;O;O
decline;O;O
in;O;O
glomerular;O;O
filtration;O;O
or;O;O
tubular;O;O
secretion;O;O
may;O;O
impair;O;O
the;O;O
excretion;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d450.s14.e1
.;O;O
DDI-DrugBank.d410.s0;;
Vasoconstrictors;B-group;B-DDI-DrugBank.d410.s0.e0
:;O;O
D.H.E.;B-brand;B-DDI-DrugBank.d410.s0.e1
45;I-brand;I-DDI-DrugBank.d410.s0.e1
(;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d410.s0.e2
mesylate;I-drug;I-DDI-DrugBank.d410.s0.e2
);O;O
Injection;O;O
,;O;O
USP;O;O
should;O;O
not;O;O
be;O;O
used;O;O
with;O;O
peripheral;B-group;B-DDI-DrugBank.d410.s0.e3
vasoconstrictors;I-group;I-DDI-DrugBank.d410.s0.e3
because;O;O
the;O;O
combination;O;O
may;O;O
cause;O;O
synergistic;O;O
elevation;O;O
of;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d410.s1;;
Sumatriptan;B-drug;B-DDI-DrugBank.d410.s1.e0
:;O;O
Sumatriptan;B-drug;B-DDI-DrugBank.d410.s1.e1
has;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
coronary;O;O
artery;O;O
vasospasm;O;O
,;O;O
and;O;O
its;O;O
effect;O;O
could;O;O
be;O;O
additive;O;O
with;O;O
D.H.E.;B-brand;B-DDI-DrugBank.d410.s1.e2
45;I-brand;I-DDI-DrugBank.d410.s1.e2
(;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d410.s1.e3
mesylate;I-drug;I-DDI-DrugBank.d410.s1.e3
);O;O
Injection;O;O
,;O;O
USP;O;O
.;O;O
DDI-DrugBank.d410.s2;;
Sumatriptan;B-drug;B-DDI-DrugBank.d410.s2.e0
and;O;O
D.H.E.;B-brand;B-DDI-DrugBank.d410.s2.e1
45;I-brand;I-DDI-DrugBank.d410.s2.e1
(;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d410.s2.e2
mesylate;I-drug;I-DDI-DrugBank.d410.s2.e2
);O;O
Injection;O;O
,;O;O
USP;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
within;O;O
24;O;O
hours;O;O
of;O;O
each;O;O
other;O;O
..;O;O
DDI-DrugBank.d410.s3;;
Beta;B-group;B-DDI-DrugBank.d410.s3.e0
Blockers;I-group;I-DDI-DrugBank.d410.s3.e0
:;O;O
Although;O;O
the;O;O
results;O;O
of;O;O
a;O;O
clinical;O;O
study;O;O
did;O;O
not;O;O
indicate;O;O
a;O;O
safe;O;O
problem;O;O
associated;O;O
with;O;O
the;O;O
administration;O;O
of;O;O
D.H.E.;B-brand;B-DDI-DrugBank.d410.s3.e1
45;I-brand;I-DDI-DrugBank.d410.s3.e1
(;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d410.s3.e2
mesylate;I-drug;I-DDI-DrugBank.d410.s3.e2
);O;O
Injection;O;O
,;O;O
USP;O;O
to;O;O
subjects;O;O
already;O;O
receiving;O;O
propranolol;B-drug;B-DDI-DrugBank.d410.s3.e3
,;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
that;O;O
propranolol;B-drug;B-DDI-DrugBank.d410.s3.e4
may;O;O
potentiate;O;O
the;O;O
vasoconstrictive;O;O
action;O;O
of;O;O
ergotamine;B-drug;B-DDI-DrugBank.d410.s3.e5
by;O;O
blocking;O;O
the;O;O
vasodilating;O;O
property;O;O
of;O;O
epinephrine;O;O
.;O;O
DDI-DrugBank.d410.s4;;
Nicotine;B-drug;B-DDI-DrugBank.d410.s4.e0
:;O;O
Nicotine;B-drug;B-DDI-DrugBank.d410.s4.e1
may;O;O
provoke;O;O
vasoconstriction;O;O
in;O;O
some;O;O
patients;O;O
,;O;O
predisposing;O;O
to;O;O
a;O;O
greater;O;O
ischemic;O;O
response;O;O
to;O;O
ergot;B-drug;B-DDI-DrugBank.d410.s4.e2
therapy;O;O
.;O;O
DDI-DrugBank.d410.s5;;
Macrolide;B-group;B-DDI-DrugBank.d410.s5.e0
Antibiotics;I-group;I-DDI-DrugBank.d410.s5.e0
(;O;O
e.;O;O
g.;O;O
erythromycin;B-drug;B-DDI-DrugBank.d410.s5.e1
and;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d410.s5.e2
);O;O
:;O;O
Agents;O;O
of;O;O
the;O;O
ergot;B-group;B-DDI-DrugBank.d410.s5.e3
alkaloid;I-group;I-DDI-DrugBank.d410.s5.e3
class;I-group;I-DDI-DrugBank.d410.s5.e3
,;O;O
of;O;O
which;O;O
D.H.E.;B-brand;B-DDI-DrugBank.d410.s5.e4
45;I-brand;I-DDI-DrugBank.d410.s5.e4
(;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d410.s5.e5
mesylate;I-drug;I-DDI-DrugBank.d410.s5.e5
);O;O
Injection;O;O
,;O;O
USP;O;O
is;O;O
a;O;O
member;O;O
,;O;O
have;O;O
been;O;O
shown;O;O
to;O;O
interact;O;O
with;O;O
antibiotics;B-group;B-DDI-DrugBank.d410.s5.e6
of;O;O
the;O;O
macrolide;B-group;B-DDI-DrugBank.d410.s5.e7
class;I-group;I-DDI-DrugBank.d410.s5.e7
,;O;O
resulting;O;O
in;O;O
increased;O;O
plasma;O;O
levels;O;O
of;O;O
unchanged;O;O
alkaloids;O;O
and;O;O
peripheral;O;O
vasoconstriction;O;O
.;O;O
DDI-DrugBank.d410.s6;;
Vasospastic;O;O
reactions;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
therapeutic;O;O
doses;O;O
of;O;O
ergotamine;B-drug;B-DDI-DrugBank.d410.s6.e0
-;O;O
containing;O;O
drugs;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
these;O;O
antibiotics;B-group;B-DDI-DrugBank.d410.s6.e1
.;O;O
DDI-DrugBank.d410.s7;;
SSRIs;B-group;B-DDI-DrugBank.d410.s7.e0
:;O;O
Weakness;O;O
hyperreflexia;O;O
,;O;O
and;O;O
incoordination;O;O
have;O;O
been;O;O
reported;O;O
rarely;O;O
when;O;O
5;B-group;B-DDI-DrugBank.d410.s7.e1
-;I-group;I-DDI-DrugBank.d410.s7.e1
HT1;I-group;I-DDI-DrugBank.d410.s7.e1
agonists;I-group;I-DDI-DrugBank.d410.s7.e1
have;O;O
been;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
SSRIs;B-group;B-DDI-DrugBank.d410.s7.e2
(;O;O
e.;O;O
g.;O;O
DDI-DrugBank.d410.s8;;
fluoxetine;B-drug;B-DDI-DrugBank.d410.s8.e0
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d410.s8.e1
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d410.s8.e2
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d410.s8.e3
);O;O
.;O;O
DDI-DrugBank.d410.s9;;
There;O;O
have;O;O
been;O;O
no;O;O
reported;O;O
cases;O;O
from;O;O
spontaneous;O;O
reports;O;O
of;O;O
drug;O;O
interaction;O;O
between;O;O
SSRIs;B-group;B-DDI-DrugBank.d410.s9.e0
and;O;O
D.H.E.;B-brand;B-DDI-DrugBank.d410.s9.e1
45;I-brand;I-DDI-DrugBank.d410.s9.e1
(;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d410.s9.e2
mesylate;I-drug;I-DDI-DrugBank.d410.s9.e2
);O;O
Injection;O;O
,;O;O
USP;O;O
.;O;O
DDI-DrugBank.d410.s10;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d410.s10.e0
:;O;O
The;O;O
effect;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d410.s10.e1
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
D.H.E.;B-brand;B-DDI-DrugBank.d410.s10.e2
45;I-brand;I-DDI-DrugBank.d410.s10.e2
(;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d410.s10.e3
mesylate;I-drug;I-DDI-DrugBank.d410.s10.e3
);O;O
Injection;O;O
,;O;O
USP;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d452.s0;;
Administration;O;O
of;O;O
thiazide;B-group;B-DDI-DrugBank.d452.s0.e0
diuretics;I-group;I-DDI-DrugBank.d452.s0.e0
to;O;O
hypoparathyroid;O;O
patients;O;O
who;O;O
are;O;O
concurrently;O;O
being;O;O
treated;O;O
with;O;O
dihydrotachysterol;B-drug;B-DDI-DrugBank.d452.s0.e1
may;O;O
cause;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d565.s0;;
Due;O;O
to;O;O
the;O;O
potential;O;O
for;O;O
additive;O;O
effects;O;O
,;O;O
caution;O;O
and;O;O
careful;O;O
titration;O;O
are;O;O
warranted;O;O
in;O;O
patients;O;O
receiving;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s0.e0
hydrochloride;I-drug;I-DDI-DrugBank.d565.s0.e0
concomitantly;O;O
with;O;O
other;O;O
agents;O;O
known;O;O
to;O;O
affect;O;O
cardiac;O;O
contractility;O;O
and/or;O;O
conduction;O;O
.;O;O
DDI-DrugBank.d565.s1;;
Pharmacologic;O;O
studies;O;O
indicate;O;O
that;O;O
there;O;O
may;O;O
be;O;O
additive;O;O
effects;O;O
in;O;O
prolonging;O;O
AV;O;O
conduction;O;O
when;O;O
using;O;O
beta;B-group;B-DDI-DrugBank.d565.s1.e0
-;I-group;I-DDI-DrugBank.d565.s1.e0
blockers;I-group;I-DDI-DrugBank.d565.s1.e0
or;O;O
digitalis;B-group;B-DDI-DrugBank.d565.s1.e1
concomitantly;O;O
with;O;O
Tiazac;B-brand;B-DDI-DrugBank.d565.s1.e2
.;O;O
DDI-DrugBank.d565.s2;;
As;O;O
with;O;O
all;O;O
drugs;O;O
,;O;O
care;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
treating;O;O
patients;O;O
with;O;O
multiple;O;O
medications;O;O
.;O;O
DDI-DrugBank.d565.s3;;
Diltiazem;B-drug;B-DDI-DrugBank.d565.s3.e0
is;O;O
both;O;O
a;O;O
substrate;O;O
and;O;O
an;O;O
inhibitor;O;O
of;O;O
the;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
3A4;O;O
enzyme;O;O
system;O;O
.;O;O
DDI-DrugBank.d565.s4;;
Other;O;O
drugs;O;O
that;O;O
are;O;O
specific;O;O
substrates;O;O
,;O;O
inhibitors;O;O
,;O;O
or;O;O
inducers;O;O
of;O;O
the;O;O
enzyme;O;O
system;O;O
may;O;O
have;O;O
a;O;O
significant;O;O
impact;O;O
on;O;O
the;O;O
efficacy;O;O
and;O;O
side;O;O
effect;O;O
profile;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s4.e0
.;O;O
DDI-DrugBank.d565.s5;;
Patients;O;O
taking;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
substrates;O;O
of;O;O
CYP450;O;O
3A4;O;O
,;O;O
especially;O;O
patients;O;O
with;O;O
renal;O;O
and/or;O;O
hepatic;O;O
impairment;O;O
,;O;O
may;O;O
require;O;O
dosage;O;O
adjustment;O;O
when;O;O
starting;O;O
or;O;O
stopping;O;O
concomitantly;O;O
administered;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s5.e0
in;O;O
order;O;O
to;O;O
maintain;O;O
optimum;O;O
therapeutic;O;O
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d565.s6;;
Beta;B-group;B-DDI-DrugBank.d565.s6.e0
Blockers;I-group;I-DDI-DrugBank.d565.s6.e0
DDI-DrugBank.d565.s7;;
Controlled;O;O
and;O;O
uncontrolled;O;O
domestic;O;O
studies;O;O
suggest;O;O
that;O;O
concomitant;O;O
use;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s7.e0
hydrochloride;I-drug;I-DDI-DrugBank.d565.s7.e0
and;O;O
beta;B-group;B-DDI-DrugBank.d565.s7.e1
-;I-group;I-DDI-DrugBank.d565.s7.e1
blockers;I-group;I-DDI-DrugBank.d565.s7.e1
is;O;O
usually;O;O
well;O;O
tolerated;O;O
,;O;O
but;O;O
available;O;O
data;O;O
are;O;O
not;O;O
sufficient;O;O
to;O;O
predict;O;O
the;O;O
effects;O;O
of;O;O
concomitant;O;O
treatment;O;O
in;O;O
patients;O;O
with;O;O
left;O;O
ventricular;O;O
dysfunction;O;O
or;O;O
cardiac;O;O
conduction;O;O
abnormalities;O;O
.;O;O
DDI-DrugBank.d565.s8;;
Administration;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s8.e0
hydrochloride;I-drug;I-DDI-DrugBank.d565.s8.e0
concomitantly;O;O
with;O;O
propranolol;B-drug;B-DDI-DrugBank.d565.s8.e1
in;O;O
five;O;O
normal;O;O
volunteers;O;O
resulted;O;O
in;O;O
increased;O;O
propranolol;B-drug;B-DDI-DrugBank.d565.s8.e2
levels;O;O
in;O;O
all;O;O
subjects;O;O
and;O;O
bioavailability;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d565.s8.e3
was;O;O
increased;O;O
approximately;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d565.s9;;
In;O;O
vitro;O;O
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d565.s9.e0
appears;O;O
to;O;O
be;O;O
displaced;O;O
from;O;O
its;O;O
binding;O;O
sites;O;O
by;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s9.e1
.;O;O
DDI-DrugBank.d565.s10;;
If;O;O
combination;O;O
therapy;O;O
is;O;O
initiated;O;O
or;O;O
withdrawn;O;O
in;O;O
conjunction;O;O
with;O;O
propranolol;B-drug;B-DDI-DrugBank.d565.s10.e0
,;O;O
an;O;O
adjustment;O;O
in;O;O
the;O;O
propranolol;B-drug;B-DDI-DrugBank.d565.s10.e1
dose;O;O
may;O;O
be;O;O
warranted;O;O
.;O;O
DDI-DrugBank.d565.s11;;
Cimetidine;B-drug;B-DDI-DrugBank.d565.s11.e0
DDI-DrugBank.d565.s12;;
A;O;O
study;O;O
in;O;O
six;O;O
healthy;O;O
volunteers;O;O
has;O;O
shown;O;O
a;O;O
significant;O;O
increase;O;O
in;O;O
peak;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s12.e0
plasma;O;O
levels;O;O
(;O;O
58;O;O
%;O;O
);O;O
and;O;O
AUC;O;O
(;O;O
53;O;O
%;O;O
);O;O
after;O;O
a;O;O
1;O;O
-;O;O
week;O;O
course;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d565.s12.e1
1200;O;O
mg;O;O
/;O;O
day;O;O
and;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s12.e2
60;O;O
mg;O;O
.;O;O
DDI-DrugBank.d565.s13;;
Ranitidine;B-drug;B-DDI-DrugBank.d565.s13.e0
produced;O;O
smaller;O;O
,;O;O
nonsignificant;O;O
increases;O;O
.;O;O
DDI-DrugBank.d565.s14;;
The;O;O
effect;O;O
may;O;O
be;O;O
mediated;O;O
by;O;O
cimetidines;B-drug;B-DDI-DrugBank.d565.s14.e0
known;O;O
inhibition;O;O
of;O;O
hepatic;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
,;O;O
the;O;O
enzyme;O;O
system;O;O
responsible;O;O
for;O;O
the;O;O
first;O;O
-;O;O
pass;O;O
metabolism;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s14.e1
.;O;O
DDI-DrugBank.d565.s15;;
Patients;O;O
currently;O;O
receiving;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s15.e0
therapy;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
for;O;O
a;O;O
change;O;O
in;O;O
pharmacological;O;O
effect;O;O
when;O;O
initiating;O;O
and;O;O
discontinuing;O;O
therapy;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d565.s15.e1
.;O;O
DDI-DrugBank.d565.s16;;
An;O;O
adjustment;O;O
in;O;O
the;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s16.e0
dose;O;O
may;O;O
be;O;O
warranted;O;O
.;O;O
DDI-DrugBank.d565.s17;;
Digitalis;B-group;B-DDI-DrugBank.d565.s17.e0
DDI-DrugBank.d565.s18;;
Administration;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s18.e0
hydrochloride;I-drug;I-DDI-DrugBank.d565.s18.e0
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d565.s18.e1
in;O;O
24;O;O
healthy;O;O
male;O;O
subjects;O;O
increased;O;O
plasma;O;O
digoxin;B-drug;B-DDI-DrugBank.d565.s18.e2
concentrations;O;O
approximately;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d565.s19;;
Another;O;O
investigator;O;O
found;O;O
no;O;O
increase;O;O
in;O;O
digoxin;B-drug;B-DDI-DrugBank.d565.s19.e0
levels;O;O
in;O;O
12;O;O
patients;O;O
with;O;O
coronary;O;O
artery;O;O
disease;O;O
.;O;O
DDI-DrugBank.d565.s20;;
Since;O;O
there;O;O
have;O;O
been;O;O
conflicting;O;O
results;O;O
regarding;O;O
the;O;O
effect;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d565.s20.e0
levels;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
digoxin;B-drug;B-DDI-DrugBank.d565.s20.e1
levels;O;O
be;O;O
monitored;O;O
when;O;O
initiating;O;O
,;O;O
adjusting;O;O
,;O;O
and;O;O
discontinuing;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s20.e2
hydrochloride;I-drug;I-DDI-DrugBank.d565.s20.e2
therapy;O;O
to;O;O
avoid;O;O
possible;O;O
over;O;O
-;O;O
or;O;O
under;O;O
-;O;O
digitalization;O;O
.;O;O
DDI-DrugBank.d565.s21;;
Anesthetics;B-group;B-DDI-DrugBank.d565.s21.e0
DDI-DrugBank.d565.s22;;
The;O;O
depression;O;O
of;O;O
cardiac;O;O
contractility;O;O
,;O;O
conductivity;O;O
,;O;O
and;O;O
automaticity;O;O
as;O;O
well;O;O
as;O;O
the;O;O
vascular;O;O
dilation;O;O
associated;O;O
with;O;O
anesthetics;B-group;B-DDI-DrugBank.d565.s22.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
calcium;B-group;B-DDI-DrugBank.d565.s22.e1
channel;I-group;I-DDI-DrugBank.d565.s22.e1
blockers;I-group;I-DDI-DrugBank.d565.s22.e1
.;O;O
DDI-DrugBank.d565.s23;;
When;O;O
used;O;O
concomitantly;O;O
,;O;O
anesthetics;B-group;B-DDI-DrugBank.d565.s23.e0
and;O;O
calcium;B-group;B-DDI-DrugBank.d565.s23.e1
channel;I-group;I-DDI-DrugBank.d565.s23.e1
blockers;I-group;I-DDI-DrugBank.d565.s23.e1
should;O;O
be;O;O
titrated;O;O
carefully;O;O
.;O;O
DDI-DrugBank.d565.s24;;
Cyclosporine;B-drug;B-DDI-DrugBank.d565.s24.e0
DDI-DrugBank.d565.s25;;
A;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s25.e0
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d565.s25.e1
has;O;O
been;O;O
observed;O;O
during;O;O
studies;O;O
involving;O;O
renal;O;O
and;O;O
cardiac;O;O
transplant;O;O
patients;O;O
.;O;O
DDI-DrugBank.d565.s26;;
In;O;O
renal;O;O
and;O;O
cardiac;O;O
transplant;O;O
recipients;O;O
,;O;O
a;O;O
reduction;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d565.s26.e0
dose;O;O
ranging;O;O
from;O;O
15;O;O
%;O;O
to;O;O
48;O;O
%;O;O
was;O;O
necessary;O;O
to;O;O
maintain;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d565.s26.e1
trough;O;O
concentrations;O;O
similar;O;O
to;O;O
those;O;O
seen;O;O
prior;O;O
to;O;O
the;O;O
addition;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s26.e2
.;O;O
DDI-DrugBank.d565.s27;;
If;O;O
these;O;O
agents;O;O
are;O;O
to;O;O
be;O;O
administered;O;O
concurrently;O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d565.s27.e0
concentrations;O;O
should;O;O
be;O;O
monitored;O;O
,;O;O
especially;O;O
when;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s27.e1
therapy;O;O
is;O;O
initiated;O;O
,;O;O
adjusted;O;O
,;O;O
or;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d565.s28;;
The;O;O
effect;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d565.s28.e0
on;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s28.e1
plasma;O;O
concentrations;O;O
has;O;O
not;O;O
been;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d565.s29;;
Carbamazepine;B-drug;B-DDI-DrugBank.d565.s29.e0
DDI-DrugBank.d565.s30;;
Concomitant;O;O
administration;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s30.e0
with;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d565.s30.e1
has;O;O
been;O;O
reported;O;O
to;O;O
result;O;O
in;O;O
elevated;O;O
serum;O;O
levels;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d565.s30.e2
(;O;O
40;O;O
%;O;O
to;O;O
72;O;O
%;O;O
increase;O;O
);O;O
,;O;O
resulting;O;O
in;O;O
toxicity;O;O
in;O;O
some;O;O
cases;O;O
.;O;O
DDI-DrugBank.d565.s31;;
Patients;O;O
receiving;O;O
these;O;O
drugs;O;O
concurrently;O;O
should;O;O
be;O;O
monitored;O;O
for;O;O
a;O;O
potential;O;O
drug;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d565.s32;;
Benzodiazepines;B-group;B-DDI-DrugBank.d565.s32.e0
DDI-DrugBank.d565.s33;;
Studies;O;O
showed;O;O
that;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s33.e0
increased;O;O
the;O;O
AUC;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d565.s33.e1
and;O;O
triazolam;B-drug;B-DDI-DrugBank.d565.s33.e2
by;O;O
3;O;O
-;O;O
4;O;O
fold;O;O
and;O;O
the;O;O
Cmax;O;O
by;O;O
2;O;O
-;O;O
fold;O;O
,;O;O
compared;O;O
to;O;O
placebo;O;O
.;O;O
DDI-DrugBank.d565.s34;;
The;O;O
elimination;O;O
half;O;O
life;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d565.s34.e0
and;O;O
triazolam;B-drug;B-DDI-DrugBank.d565.s34.e1
also;O;O
increased;O;O
(;O;O
1.5;O;O
-;O;O
2.5;O;O
fold;O;O
);O;O
during;O;O
coadministration;O;O
with;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s34.e2
.;O;O
DDI-DrugBank.d565.s35;;
These;O;O
pharmacokinetic;O;O
effects;O;O
seen;O;O
during;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s35.e0
coadministration;O;O
can;O;O
result;O;O
in;O;O
increased;O;O
clinical;O;O
effects;O;O
(;O;O
e.g.;O;O
,;O;O
prolonged;O;O
sodation)of;O;O
both;O;O
midazolam;B-drug;B-DDI-DrugBank.d565.s35.e1
and;O;O
triazolam;B-drug;B-DDI-DrugBank.d565.s35.e2
.;O;O
DDI-DrugBank.d565.s36;;
Lovastatin;B-drug;B-DDI-DrugBank.d565.s36.e0
DDI-DrugBank.d565.s37;;
In;O;O
a;O;O
ten;O;O
-;O;O
subject;O;O
study;O;O
,;O;O
coadministration;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s37.e0
(;O;O
120;O;O
mg;O;O
bid;O;O
);O;O
with;O;O
lovastatin;B-drug;B-DDI-DrugBank.d565.s37.e1
resulted;O;O
in;O;O
a;O;O
3;O;O
-;O;O
4;O;O
times;O;O
increase;O;O
in;O;O
mean;O;O
lovastatin;B-drug;B-DDI-DrugBank.d565.s37.e2
AUC;O;O
and;O;O
Cmax;O;O
vs.;O;O
lovastatin;B-drug;B-DDI-DrugBank.d565.s37.e3
alone;O;O
,;O;O
DDI-DrugBank.d565.s38;;
no;O;O
change;O;O
in;O;O
pravastatin;B-drug;B-DDI-DrugBank.d565.s38.e0
AUC;O;O
and;O;O
Cmax;O;O
was;O;O
observed;O;O
during;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s38.e1
coadministration;O;O
.;O;O
DDI-DrugBank.d565.s39;;
Diltiazem;B-drug;B-DDI-DrugBank.d565.s39.e0
plasma;O;O
levels;O;O
were;O;O
not;O;O
significantly;O;O
affected;O;O
by;O;O
lovastatin;B-drug;B-DDI-DrugBank.d565.s39.e1
or;O;O
pravastatin;B-drug;B-DDI-DrugBank.d565.s39.e2
.;O;O
DDI-DrugBank.d565.s40;;
Rifampin;B-drug;B-DDI-DrugBank.d565.s40.e0
DDI-DrugBank.d565.s41;;
Coadministration;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d565.s41.e0
with;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s41.e1
lowered;O;O
the;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s41.e2
plasma;O;O
concentrations;O;O
to;O;O
undetectable;O;O
levels;O;O
.;O;O
DDI-DrugBank.d565.s42;;
Coadministration;O;O
of;O;O
diltiazem;B-drug;B-DDI-DrugBank.d565.s42.e0
with;O;O
rifampin;B-drug;B-DDI-DrugBank.d565.s42.e1
or;O;O
any;O;O
known;O;O
CYP3A4;O;O
inducer;O;O
should;O;O
be;O;O
avoided;O;O
when;O;O
possible;O;O
,;O;O
and;O;O
alternative;O;O
therapy;O;O
considered;O;O
.;O;O
DDI-DrugBank.d96.s0;;
Dimenhydrinate;B-drug;B-DDI-DrugBank.d96.s0.e0
may;O;O
decrease;O;O
emetic;B-group;B-DDI-DrugBank.d96.s0.e1
response;O;O
to;O;O
apomorphine;B-drug;B-DDI-DrugBank.d96.s0.e2
.;O;O
DDI-DrugBank.d181.s0;;
Oxytocin;B-drug;B-DDI-DrugBank.d181.s0.e0
or;O;O
other;O;O
oxytocics;B-group;B-DDI-DrugBank.d181.s0.e1
(;O;O
concurrent;O;O
use;O;O
with;O;O
dinoprost;B-drug;B-DDI-DrugBank.d181.s0.e2
may;O;O
result;O;O
in;O;O
uterine;O;O
hypertonus;O;O
,;O;O
possibly;O;O
causing;O;O
uterine;O;O
rupture;O;O
or;O;O
cervical;O;O
laceration;O;O
,;O;O
especially;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
adequate;O;O
cervical;O;O
dilatation;O;O
,;O;O
DDI-DrugBank.d181.s1;;
although;O;O
combinations;O;O
are;O;O
sometimes;O;O
used;O;O
for;O;O
therapeutic;O;O
advantage;O;O
,;O;O
when;O;O
used;O;O
concurrently;O;O
,;O;O
patient;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d2.s0;;
PROSTIN;B-brand;B-DDI-DrugBank.d2.s0.e0
E2;I-brand;I-DDI-DrugBank.d2.s0.e0
may;O;O
augment;O;O
the;O;O
activity;O;O
of;O;O
other;O;O
oxytocic;B-group;B-DDI-DrugBank.d2.s0.e1
drugs;I-group;I-DDI-DrugBank.d2.s0.e1
.;O;O
DDI-DrugBank.d2.s1;;
Concomitant;O;O
use;O;O
with;O;O
other;O;O
oxytocic;B-group;B-DDI-DrugBank.d2.s1.e0
agents;I-group;I-DDI-DrugBank.d2.s1.e0
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d296.s0;;
Diphenhydramine;B-drug;B-DDI-DrugBank.d296.s0.e0
hydrochloride;I-drug;I-DDI-DrugBank.d296.s0.e0
has;O;O
additive;O;O
effects;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d296.s0.e1
and;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d296.s0.e2
depressants;I-group;I-DDI-DrugBank.d296.s0.e2
(;O;O
hypnotics;B-group;B-DDI-DrugBank.d296.s0.e3
,;O;O
sedatives;B-group;B-DDI-DrugBank.d296.s0.e4
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d296.s0.e5
,;O;O
etc;O;O
);O;O
.;O;O
DDI-DrugBank.d296.s1;;
MAO;B-group;B-DDI-DrugBank.d296.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d296.s1.e0
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
(;O;O
drying;O;O
);O;O
effects;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d296.s1.e1
.;O;O
DDI-DrugBank.d120.s0;;
CNS;O;O
depression;O;O
producing;O;O
medications;O;O
-;O;O
concurrent;O;O
use;O;O
may;O;O
potentiate;O;O
the;O;O
effects;O;O
of;O;O
either;O;O
these;O;O
medications;O;O
or;O;O
diphenidol;B-drug;B-DDI-DrugBank.d120.s0.e0
,;O;O
DDI-DrugBank.d120.s1;;
anticholinergics;B-group;B-DDI-DrugBank.d120.s1.e0
or;O;O
other;O;O
medications;O;O
with;O;O
anticholinergic;O;O
activity;O;O
-;O;O
anticholinergic;O;O
effects;O;O
may;O;O
be;O;O
potentiated;O;O
when;O;O
these;O;O
medications;O;O
are;O;O
used;O;O
concurrently;O;O
with;O;O
diphenidol;B-drug;B-DDI-DrugBank.d120.s1.e1
,;O;O
DDI-DrugBank.d120.s2;;
apomorphine;B-drug;B-DDI-DrugBank.d120.s2.e0
-;O;O
prior;O;O
ingestion;O;O
of;O;O
diphenidol;B-drug;B-DDI-DrugBank.d120.s2.e1
may;O;O
decrease;O;O
the;O;O
emetic;B-group;B-DDI-DrugBank.d120.s2.e2
response;O;O
to;O;O
apomorphine;B-drug;B-DDI-DrugBank.d120.s2.e3
in;O;O
the;O;O
treatment;O;O
of;O;O
poisoning;O;O
.;O;O
DDI-DrugBank.d538.s0;;
Known;O;O
drug;O;O
interactions;O;O
include;O;O
barbiturates;B-group;B-DDI-DrugBank.d538.s0.e0
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d538.s0.e1
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d538.s0.e2
.;O;O
DDI-DrugBank.d538.s1;;
Diphenoxylate;B-drug;B-DDI-DrugBank.d538.s1.e0
HCl;I-drug;I-DDI-DrugBank.d538.s1.e0
and;O;O
atropine;B-drug;B-DDI-DrugBank.d538.s1.e1
sulfate;I-drug;I-DDI-DrugBank.d538.s1.e1
may;O;O
interact;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d538.s1.e2
inhibitors;I-group;I-DDI-DrugBank.d538.s1.e2
In;O;O
studies;O;O
with;O;O
male;O;O
rats;O;O
,;O;O
diphenoxylate;B-drug;B-DDI-DrugBank.d538.s1.e3
hydrochloride;I-drug;I-DDI-DrugBank.d538.s1.e3
was;O;O
found;O;O
to;O;O
inhibit;O;O
the;O;O
hepatic;O;O
microsomal;O;O
enzyme;O;O
system;O;O
at;O;O
a;O;O
dose;O;O
of;O;O
2;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d538.s2;;
Therefore;O;O
,;O;O
diphenoxylate;B-drug;B-DDI-DrugBank.d538.s2.e0
has;O;O
the;O;O
potential;O;O
to;O;O
prolong;O;O
the;O;O
biological;O;O
half;O;O
-;O;O
lives;O;O
of;O;O
drugs;O;O
for;O;O
which;O;O
the;O;O
rate;O;O
of;O;O
elimination;O;O
is;O;O
dependent;O;O
on;O;O
the;O;O
microsomal;O;O
drug;O;O
metabolizing;O;O
enzyme;O;O
system;O;O
.;O;O
DDI-DrugBank.d168.s0;;
This;O;O
drug;O;O
may;O;O
interact;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d168.s0.e0
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d168.s0.e1
depressants;I-group;I-DDI-DrugBank.d168.s0.e1
(;O;O
may;O;O
potentiate;O;O
the;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
either;O;O
these;O;O
medications;O;O
or;O;O
antihistamines;B-group;B-DDI-DrugBank.d168.s0.e2
);O;O
,;O;O
anticholinergics;B-group;B-DDI-DrugBank.d168.s0.e3
or;O;O
other;O;O
medications;O;O
with;O;O
anticholinergic;O;O
activity;O;O
(;O;O
anticholinergic;O;O
effects;O;O
may;O;O
be;O;O
potentiated;O;O
when;O;O
these;O;O
medications;O;O
are;O;O
used;O;O
concurrently;O;O
with;O;O
antihistamines;B-group;B-DDI-DrugBank.d168.s0.e4
);O;O
,;O;O
and;O;O
monoamine;B-group;B-DDI-DrugBank.d168.s0.e5
oxidase;I-group;I-DDI-DrugBank.d168.s0.e5
(;I-group;I-DDI-DrugBank.d168.s0.e5
MAO;I-group;I-DDI-DrugBank.d168.s0.e5
);I-group;I-DDI-DrugBank.d168.s0.e5
inhibitors;I-group;I-DDI-DrugBank.d168.s0.e5
(;O;O
concurrent;O;O
use;O;O
with;O;O
antihistamines;B-drug;B-DDI-DrugBank.d168.s0.e6
may;O;O
prolong;O;O
and;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
and;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
antihistamines;B-drug;B-DDI-DrugBank.d168.s0.e7
);O;O
.;O;O
DDI-DrugBank.d505.s0;;
No;O;O
pharmacokinetic;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
were;O;O
conducted;O;O
with;O;O
PERSANTINE;B-brand;B-DDI-DrugBank.d505.s0.e0
(;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d505.s0.e1
USP;O;O
);O;O
Tablets;O;O
.;O;O
DDI-DrugBank.d505.s1;;
The;O;O
following;O;O
information;O;O
was;O;O
obtained;O;O
from;O;O
the;O;O
literature;O;O
.;O;O
DDI-DrugBank.d505.s2;;
Adenosine;B-drug;B-DDI-DrugBank.d505.s2.e0
:;O;O
Dipyridamole;B-drug;B-DDI-DrugBank.d505.s2.e1
has;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
the;O;O
plasma;O;O
levels;O;O
and;O;O
cardiovascular;O;O
effects;O;O
of;O;O
adenosine;B-drug;B-DDI-DrugBank.d505.s2.e2
.;O;O
DDI-DrugBank.d505.s3;;
Adjustment;O;O
of;O;O
adenosine;B-drug;B-DDI-DrugBank.d505.s3.e0
dosage;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d505.s4;;
Cholinesterase;B-group;B-DDI-DrugBank.d505.s4.e0
Inhibitors;I-group;I-DDI-DrugBank.d505.s4.e0
:;O;O
Dipyridamole;B-drug;B-DDI-DrugBank.d505.s4.e1
may;O;O
counteract;O;O
the;O;O
anticholinesterase;O;O
effect;O;O
of;O;O
cholinesterase;B-group;B-DDI-DrugBank.d505.s4.e2
inhibitors;I-group;I-DDI-DrugBank.d505.s4.e2
,;O;O
thereby;O;O
potentially;O;O
aggravating;O;O
myasthenia;O;O
gravis;O;O
.;O;O
DDI-DrugBank.d522.s0;;
Terfenadine;B-drug;B-DDI-DrugBank.d522.s0.e0
:;O;O
In;O;O
a;O;O
prospective;O;O
study;O;O
involving;O;O
six;O;O
-;O;O
healthy;O;O
-;O;O
male;O;O
volunteers;O;O
,;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s0.e1
did;O;O
not;O;O
affect;O;O
the;O;O
metabolism;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s0.e2
.;O;O
DDI-DrugBank.d522.s1;;
These;O;O
six;O;O
volunteers;O;O
received;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s1.e0
alone;O;O
(;O;O
60;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
for;O;O
8;O;O
days;O;O
,;O;O
followed;O;O
by;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s1.e1
in;O;O
combination;O;O
with;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s1.e2
(;O;O
500;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
for;O;O
10;O;O
days;O;O
.;O;O
DDI-DrugBank.d522.s2;;
(;O;O
Both;O;O
drugs;O;O
were;O;O
thus;O;O
dosed;O;O
to;O;O
steady;O;O
state;O;O
.;O;O
);O;O
DDI-DrugBank.d522.s3;;
The;O;O
pharmacokinetics;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s3.e0
and;O;O
its;O;O
acid;O;O
metabolite;O;O
and;O;O
the;O;O
electrocardiographic;O;O
QT;O;O
c;O;O
interval;O;O
were;O;O
measured;O;O
during;O;O
both;O;O
periods;O;O
:;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s3.e1
alone;O;O
,;O;O
and;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s3.e2
plus;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s3.e3
.;O;O
DDI-DrugBank.d522.s4;;
In;O;O
five;O;O
men;O;O
,;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s4.e0
levels;O;O
were;O;O
undetectable;O;O
(;O;O
5;O;O
ng;O;O
/;O;O
mL;O;O
);O;O
throughout;O;O
the;O;O
study;O;O
,;O;O
DDI-DrugBank.d522.s5;;
in;O;O
one;O;O
man;O;O
,;O;O
the;O;O
C;O;O
max;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s5.e0
was;O;O
8.1;O;O
ng;O;O
/;O;O
mL;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s5.e1
alone;O;O
and;O;O
7.2;O;O
ng;O;O
/;O;O
mL;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s5.e2
plus;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s5.e3
.;O;O
DDI-DrugBank.d522.s6;;
The;O;O
mean;O;O
C;O;O
max;O;O
,;O;O
T;O;O
max;O;O
,;O;O
and;O;O
AUC;O;O
of;O;O
the;O;O
acid;O;O
metabolite;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s6.e0
were;O;O
not;O;O
significantly;O;O
changed;O;O
.;O;O
DDI-DrugBank.d522.s7;;
The;O;O
mean;O;O
QT;O;O
c;O;O
interval;O;O
(;O;O
msec;O;O
);O;O
was;O;O
369;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s7.e0
alone;O;O
and;O;O
367;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s7.e1
plus;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s7.e2
.;O;O
DDI-DrugBank.d522.s8;;
Also;O;O
,;O;O
in;O;O
vitro;O;O
experiments;O;O
demonstrated;O;O
a;O;O
lack;O;O
of;O;O
interaction;O;O
between;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s8.e0
and;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s8.e1
.;O;O
DDI-DrugBank.d522.s9;;
Thus;O;O
,;O;O
the;O;O
interaction;O;O
observed;O;O
between;O;O
erythromycin;B-drug;B-DDI-DrugBank.d522.s9.e0
and;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s9.e1
is;O;O
not;O;O
expected;O;O
for;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s9.e2
.;O;O
DDI-DrugBank.d522.s10;;
Serious;O;O
cardiac;O;O
dysrhythmias;O;O
,;O;O
some;O;O
resulting;O;O
in;O;O
death;O;O
,;O;O
have;O;O
occurred;O;O
in;O;O
patients;O;O
receiving;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s10.e0
concomitantly;O;O
with;O;O
other;O;O
macrolide;B-group;B-DDI-DrugBank.d522.s10.e1
antibiotics;I-group;I-DDI-DrugBank.d522.s10.e1
.;O;O
DDI-DrugBank.d522.s11;;
In;O;O
addition;O;O
,;O;O
most;O;O
macrolides;B-group;B-DDI-DrugBank.d522.s11.e0
are;O;O
contraindicated;O;O
in;O;O
patients;O;O
receiving;O;O
terfenadine;B-drug;B-DDI-DrugBank.d522.s11.e1
therapy;O;O
who;O;O
have;O;O
pre;O;O
-;O;O
existing;O;O
cardiac;O;O
abnormalities;O;O
(;O;O
arrhythmia;O;O
,;O;O
bradycardia;O;O
,;O;O
QT;O;O
c;O;O
interval;O;O
prolongation;O;O
,;O;O
ischemic;O;O
heart;O;O
disease;O;O
,;O;O
congestive;O;O
heart;O;O
failure;O;O
,;O;O
etc;O;O
.;O;O
);O;O
or;O;O
electrolyte;O;O
disturbances;O;O
.;O;O
DDI-DrugBank.d522.s12;;
Theophylline;B-drug;B-DDI-DrugBank.d522.s12.e0
:;O;O
Following;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
two;O;O
250;O;O
-;O;O
mg;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s12.e1
tablets;O;O
administered;O;O
once;O;O
daily;O;O
with;O;O
200;O;O
-;O;O
mg;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s12.e2
tablets;O;O
administered;O;O
twice;O;O
daily;O;O
for;O;O
10;O;O
days;O;O
to;O;O
14;O;O
healthy;O;O
subjects;O;O
,;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
plasma;O;O
concentration;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s12.e3
was;O;O
not;O;O
significantly;O;O
altered;O;O
.;O;O
DDI-DrugBank.d522.s13;;
In;O;O
general;O;O
,;O;O
most;O;O
patients;O;O
treated;O;O
with;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s13.e0
who;O;O
are;O;O
receiving;O;O
concomitant;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s13.e1
therapy;O;O
may;O;O
not;O;O
require;O;O
empiric;O;O
adjustment;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s13.e2
dosage;O;O
or;O;O
monitoring;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s13.e3
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d522.s14;;
However;O;O
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s14.e0
plasma;O;O
concentrations;O;O
should;O;O
be;O;O
monitored;O;O
,;O;O
with;O;O
dosage;O;O
adjustment;O;O
as;O;O
appropriate;O;O
,;O;O
in;O;O
patients;O;O
whose;O;O
pulmonary;O;O
disease;O;O
requires;O;O
maintaining;O;O
a;O;O
given;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s14.e1
plasma;O;O
concentration;O;O
for;O;O
optimal;O;O
pulmonary;O;O
function;O;O
or;O;O
in;O;O
patients;O;O
with;O;O
theophylline;B-drug;B-DDI-DrugBank.d522.s14.e2
concentrations;O;O
at;O;O
the;O;O
higher;O;O
end;O;O
of;O;O
the;O;O
therapeutic;O;O
range;O;O
.;O;O
DDI-DrugBank.d522.s15;;
Antacids;B-group;B-DDI-DrugBank.d522.s15.e0
or;O;O
H;B-group;B-DDI-DrugBank.d522.s15.e1
2;I-group;I-DDI-DrugBank.d522.s15.e1
receptor;I-group;I-DDI-DrugBank.d522.s15.e1
antagonists;I-group;I-DDI-DrugBank.d522.s15.e1
:;O;O
When;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s15.e2
is;O;O
administered;O;O
immediately;O;O
following;O;O
antacids;B-group;B-DDI-DrugBank.d522.s15.e3
or;O;O
H;B-group;B-DDI-DrugBank.d522.s15.e4
2;I-group;I-DDI-DrugBank.d522.s15.e4
-receptor;I-group;I-DDI-DrugBank.d522.s15.e4
antagonists;I-group;I-DDI-DrugBank.d522.s15.e4
,;O;O
the;O;O
absorption;O;O
of;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s15.e5
is;O;O
slightly;O;O
enhanced;O;O
.;O;O
DDI-DrugBank.d522.s16;;
The;O;O
following;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
erythromycin;B-drug;B-DDI-DrugBank.d522.s16.e0
products;O;O
.;O;O
DDI-DrugBank.d522.s17;;
It;O;O
is;O;O
presently;O;O
not;O;O
known;O;O
whether;O;O
these;O;O
same;O;O
drug;O;O
interactions;O;O
occur;O;O
with;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s17.e0
.;O;O
DDI-DrugBank.d522.s18;;
Until;O;O
further;O;O
data;O;O
are;O;O
available;O;O
regarding;O;O
the;O;O
potential;O;O
interaction;O;O
of;O;O
dirithromycin;B-drug;B-DDI-DrugBank.d522.s18.e0
with;O;O
these;O;O
compounds;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
during;O;O
coadministration;O;O
.;O;O
DDI-DrugBank.d522.s19;;
Triazolam;B-drug;B-DDI-DrugBank.d522.s19.e0
:;O;O
Erythromycin;B-drug;B-DDI-DrugBank.d522.s19.e1
has;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
the;O;O
clearance;O;O
of;O;O
triazolam;B-drug;B-DDI-DrugBank.d522.s19.e2
and;O;O
,;O;O
thus;O;O
,;O;O
may;O;O
increase;O;O
the;O;O
pharmacologic;O;O
effect;O;O
of;O;O
triazolam;B-drug;B-DDI-DrugBank.d522.s19.e3
.;O;O
DDI-DrugBank.d522.s20;;
Digoxin;B-drug;B-DDI-DrugBank.d522.s20.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d522.s20.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d522.s20.e2
has;O;O
been;O;O
reported;O;O
to;O;O
result;O;O
in;O;O
elevated;O;O
digoxin;B-drug;B-DDI-DrugBank.d522.s20.e3
serum;O;O
levels;O;O
.;O;O
DDI-DrugBank.d522.s21;;
Anticoagulants;B-group;B-DDI-DrugBank.d522.s21.e0
:;O;O
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
increased;O;O
anticoagulant;O;O
effects;O;O
when;O;O
erythromycin;B-drug;B-DDI-DrugBank.d522.s21.e1
and;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d522.s21.e2
were;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d522.s22;;
Increased;O;O
anticoagulation;O;O
effects;O;O
due;O;O
to;O;O
a;O;O
drug;O;O
interaction;O;O
with;O;O
erythromycin;B-drug;B-DDI-DrugBank.d522.s22.e0
may;O;O
be;O;O
more;O;O
pronounced;O;O
in;O;O
the;O;O
elderly;O;O
.;O;O
DDI-DrugBank.d522.s23;;
Ergotamine;B-drug;B-DDI-DrugBank.d522.s23.e0
:;O;O
Concurrent;O;O
use;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d522.s23.e1
and;O;O
ergotamine;B-drug;B-DDI-DrugBank.d522.s23.e2
or;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d522.s23.e3
has;O;O
been;O;O
associated;O;O
in;O;O
some;O;O
patients;O;O
with;O;O
acute;O;O
ergot;O;O
toxicity;O;O
characterized;O;O
by;O;O
severe;O;O
peripheral;O;O
vasospasm;O;O
and;O;O
dysesthesia;O;O
.;O;O
DDI-DrugBank.d522.s24;;
Other;O;O
drugs;O;O
Drug;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d522.s24.e0
and;O;O
other;O;O
medications;O;O
,;O;O
including;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d522.s24.e1
,;O;O
hexobarbital;B-drug;B-DDI-DrugBank.d522.s24.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d522.s24.e3
,;O;O
alfentanil;B-drug;B-DDI-DrugBank.d522.s24.e4
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d522.s24.e5
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d522.s24.e6
,;O;O
bromocriptine;B-drug;B-DDI-DrugBank.d522.s24.e7
,;O;O
valproate;B-drug;B-DDI-DrugBank.d522.s24.e8
,;O;O
astemizole;B-drug;B-DDI-DrugBank.d522.s24.e9
,;O;O
and;O;O
lovastatin;B-drug;B-DDI-DrugBank.d522.s24.e10
.;O;O
DDI-DrugBank.d506.s0;;
If;O;O
phenytoin;B-drug;B-DDI-DrugBank.d506.s0.e0
or;O;O
other;O;O
hepatic;O;O
enzyme;O;O
inducers;O;O
are;O;O
taken;O;O
concurrently;O;O
with;O;O
Norpace;B-brand;B-DDI-DrugBank.d506.s0.e1
or;O;O
Norpace;B-brand;B-DDI-DrugBank.d506.s0.e2
CR;I-brand;I-DDI-DrugBank.d506.s0.e2
,;O;O
lower;O;O
plasma;O;O
levels;O;O
of;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s0.e3
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d506.s1;;
Monitoring;O;O
of;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s1.e0
plasma;O;O
levels;O;O
is;O;O
recommended;O;O
in;O;O
such;O;O
concurrent;O;O
use;O;O
to;O;O
avoid;O;O
ineffective;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d506.s2;;
Other;O;O
antiarrhythmic;B-group;B-DDI-DrugBank.d506.s2.e0
drugs;I-group;I-DDI-DrugBank.d506.s2.e0
(;O;O
eg;O;O
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d506.s2.e1
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d506.s2.e2
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d506.s2.e3
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d506.s2.e4
);O;O
have;O;O
occasionally;O;O
been;O;O
used;O;O
concurrently;O;O
with;O;O
Norpace;B-brand;B-DDI-DrugBank.d506.s2.e5
.;O;O
DDI-DrugBank.d506.s3;;
Excessive;O;O
widening;O;O
of;O;O
the;O;O
QRS;O;O
complex;O;O
and/or;O;O
prolongation;O;O
of;O;O
the;O;O
Q;O;O
-;O;O
T;O;O
interval;O;O
may;O;O
occur;O;O
in;O;O
these;O;O
situations;O;O
.;O;O
DDI-DrugBank.d506.s4;;
In;O;O
healthy;O;O
subjects;O;O
,;O;O
no;O;O
significant;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
was;O;O
observed;O;O
when;O;O
Norpace;B-brand;B-DDI-DrugBank.d506.s4.e0
was;O;O
coadministered;O;O
with;O;O
either;O;O
propranolol;B-drug;B-DDI-DrugBank.d506.s4.e1
or;O;O
diazepam;B-drug;B-DDI-DrugBank.d506.s4.e2
.;O;O
DDI-DrugBank.d506.s5;;
Concomitant;O;O
administration;O;O
of;O;O
Norpace;B-brand;B-DDI-DrugBank.d506.s5.e0
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d506.s5.e1
resulted;O;O
in;O;O
slight;O;O
increases;O;O
in;O;O
plasma;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s5.e2
levels;O;O
and;O;O
slight;O;O
decreases;O;O
in;O;O
plasma;O;O
quinidine;B-drug;B-DDI-DrugBank.d506.s5.e3
levels;O;O
.;O;O
DDI-DrugBank.d506.s6;;
Norpace;B-brand;B-DDI-DrugBank.d506.s6.e0
does;O;O
not;O;O
increase;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d506.s6.e1
levels;O;O
.;O;O
DDI-DrugBank.d506.s7;;
Patients;O;O
taking;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s7.e0
phosphate;I-drug;I-DDI-DrugBank.d506.s7.e0
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d506.s7.e1
concomitantly;O;O
may;O;O
develop;O;O
increased;O;O
serum;O;O
concentrations;O;O
of;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s7.e2
resulting;O;O
in;O;O
excessive;O;O
widening;O;O
of;O;O
the;O;O
QRS;O;O
complex;O;O
and/or;O;O
prolongation;O;O
of;O;O
the;O;O
Q;O;O
-;O;O
T;O;O
interval;O;O
.;O;O
DDI-DrugBank.d506.s8;;
Patients;O;O
taking;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s8.e0
phosphate;I-drug;I-DDI-DrugBank.d506.s8.e0
and;O;O
hepatic;O;O
enzyme;O;O
inhibitors;O;O
concomitantly;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d506.s9;;
Until;O;O
data;O;O
on;O;O
possible;O;O
interactions;O;O
between;O;O
verapamil;B-drug;B-DDI-DrugBank.d506.s9.e0
and;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s9.e1
phosphate;I-drug;I-DDI-DrugBank.d506.s9.e1
are;O;O
obtained;O;O
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d506.s9.e2
should;O;O
not;O;O
be;O;O
administered;O;O
within;O;O
48;O;O
hours;O;O
before;O;O
or;O;O
24;O;O
hours;O;O
after;O;O
verapamil;B-drug;B-DDI-DrugBank.d506.s9.e3
administration;O;O
.;O;O
DDI-DrugBank.d19.s0;;
Disulfiram;B-drug;B-DDI-DrugBank.d19.s0.e0
appears;O;O
to;O;O
decrease;O;O
the;O;O
rate;O;O
at;O;O
which;O;O
certain;O;O
drugs;O;O
are;O;O
metabolized;O;O
and;O;O
therefore;O;O
may;O;O
increase;O;O
the;O;O
blood;O;O
levels;O;O
and;O;O
the;O;O
possibility;O;O
of;O;O
clinical;O;O
toxicity;O;O
of;O;O
drugs;O;O
given;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d19.s1;;
DISULFIRAM;B-drug;B-DDI-DrugBank.d19.s1.e0
SHOULD;O;O
BE;O;O
USED;O;O
WITH;O;O
CAUTION;O;O
IN;O;O
THOSE;O;O
PATIENTS;O;O
REVEIVING;O;O
PHENYTOIN;B-drug;B-DDI-DrugBank.d19.s1.e1
AND;O;O
ITS;O;O
CONGENERS;O;O
.;O;O
DDI-DrugBank.d19.s2;;
SINCE;O;O
THE;O;O
CONCOMITANT;O;O
ADMINISTRATION;O;O
OF;O;O
THESE;O;O
TWO;O;O
DRUGS;O;O
CAN;O;O
LEAD;O;O
TO;O;O
PHENYTOIN;B-drug;B-DDI-DrugBank.d19.s2.e0
INTOXICATION;O;O
,;O;O
PRIOR;O;O
TO;O;O
ADMINISTERING;O;O
DISULFIRAM;B-drug;B-DDI-DrugBank.d19.s2.e1
TO;O;O
A;O;O
PATIENT;O;O
ON;O;O
PHENYTOIN;B-drug;B-DDI-DrugBank.d19.s2.e2
THERAPY;O;O
,;O;O
A;O;O
BASELINE;O;O
PHENYTOIN;B-drug;B-DDI-DrugBank.d19.s2.e3
SERUM;O;O
LEVEL;O;O
SHOULD;O;O
BE;O;O
OBTAINED;O;O
.;O;O
DDI-DrugBank.d19.s3;;
SUBSEQUENT;O;O
TO;O;O
INITIATION;O;O
OF;O;O
DISULFIRAM;B-drug;B-DDI-DrugBank.d19.s3.e0
THERAPY;O;O
.;O;O
DDI-DrugBank.d19.s4;;
SERUM;O;O
LEVELS;O;O
OF;O;O
PHENYTOIN;B-drug;B-DDI-DrugBank.d19.s4.e0
SHOULD;O;O
BE;O;O
DETERMINED;O;O
ON;O;O
DIFFERENT;O;O
DAYS;O;O
FOR;O;O
EVIDENCE;O;O
OF;O;O
AN;O;O
INCREASE;O;O
OR;O;O
FOR;O;O
A;O;O
CONTINUING;O;O
RISE;O;O
IN;O;O
LEVELS;O;O
.;O;O
DDI-DrugBank.d19.s5;;
INCREASED;O;O
PHENYTOIN;B-drug;B-DDI-DrugBank.d19.s5.e0
LEVELS;O;O
SHOULD;O;O
BE;O;O
TREATED;O;O
WITH;O;O
APPROPRIATE;O;O
DOSAGE;O;O
ADJUSTMENT;O;O
.;O;O
DDI-DrugBank.d19.s6;;
It;O;O
may;O;O
be;O;O
necessary;O;O
to;O;O
adjust;O;O
the;O;O
dosage;O;O
of;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d19.s6.e0
upon;O;O
beginning;O;O
or;O;O
stopping;O;O
disulfiram;B-drug;B-DDI-DrugBank.d19.s6.e1
.;O;O
since;O;O
disulfiram;B-drug;B-DDI-DrugBank.d19.s6.e2
may;O;O
prolong;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d19.s7;;
Patients;O;O
taking;O;O
isoniazid;B-drug;B-DDI-DrugBank.d19.s7.e0
when;O;O
disulfiram;B-drug;B-DDI-DrugBank.d19.s7.e1
is;O;O
given;O;O
should;O;O
be;O;O
observed;O;O
for;O;O
the;O;O
appearance;O;O
of;O;O
unsteady;O;O
gait;O;O
or;O;O
marked;O;O
changes;O;O
in;O;O
mental;O;O
status;O;O
,;O;O
DDI-DrugBank.d19.s8;;
the;O;O
disulfiram;B-drug;B-DDI-DrugBank.d19.s8.e0
should;O;O
be;O;O
discontinued;O;O
if;O;O
such;O;O
signs;O;O
appear;O;O
.;O;O
DDI-DrugBank.d19.s9;;
In;O;O
rats;O;O
,;O;O
simultaneous;O;O
ingestion;O;O
of;O;O
disulfiram;B-drug;B-DDI-DrugBank.d19.s9.e0
and;O;O
nitrite;B-drug;B-DDI-DrugBank.d19.s9.e1
in;O;O
the;O;O
diet;O;O
for;O;O
78;O;O
weeks;O;O
has;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
tumors;O;O
,;O;O
and;O;O
it;O;O
has;O;O
been;O;O
suggested;O;O
that;O;O
disulfiram;B-drug;B-DDI-DrugBank.d19.s9.e2
may;O;O
react;O;O
with;O;O
nitrites;B-group;B-DDI-DrugBank.d19.s9.e3
in;O;O
the;O;O
rat;O;O
stomach;O;O
to;O;O
form;O;O
a;O;O
nitrosamine;O;O
,;O;O
which;O;O
is;O;O
tumorigenic;O;O
.;O;O
DDI-DrugBank.d19.s10;;
Disulfiram;B-drug;B-DDI-DrugBank.d19.s10.e0
alone;O;O
in;O;O
the;O;O
rat;O;O
s;O;O
diet;O;O
did;O;O
not;O;O
lead;O;O
to;O;O
such;O;O
tumors;O;O
.;O;O
DDI-DrugBank.d19.s11;;
The;O;O
relevance;O;O
of;O;O
this;O;O
finding;O;O
to;O;O
humans;O;O
is;O;O
not;O;O
known;O;O
at;O;O
this;O;O
time;O;O
.;O;O
DDI-DrugBank.d274.s0;;
Animal;O;O
studies;O;O
indicate;O;O
that;O;O
dobutamine;B-drug;B-DDI-DrugBank.d274.s0.e0
may;O;O
be;O;O
ineffective;O;O
if;O;O
the;O;O
patient;O;O
has;O;O
recently;O;O
received;O;O
a;O;O
b;B-group;B-DDI-DrugBank.d274.s0.e1
-;I-group;I-DDI-DrugBank.d274.s0.e1
blocking;I-group;I-DDI-DrugBank.d274.s0.e1
drug;I-group;I-DDI-DrugBank.d274.s0.e1
.;O;O
DDI-DrugBank.d274.s1;;
In;O;O
such;O;O
a;O;O
case;O;O
,;O;O
the;O;O
peripheral;O;O
vascular;O;O
resistance;O;O
may;O;O
increase;O;O
.;O;O
DDI-DrugBank.d274.s2;;
Preliminary;O;O
studies;O;O
indicate;O;O
that;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
dobutamine;B-drug;B-DDI-DrugBank.d274.s2.e0
and;O;O
nitroprusside;B-drug;B-DDI-DrugBank.d274.s2.e1
results;O;O
in;O;O
a;O;O
higher;O;O
cardiac;O;O
output;O;O
and;O;O
,;O;O
usually;O;O
,;O;O
a;O;O
lower;O;O
pulmonary;O;O
wedge;O;O
pressure;O;O
than;O;O
when;O;O
either;O;O
drug;O;O
is;O;O
used;O;O
alone;O;O
.;O;O
DDI-DrugBank.d274.s3;;
There;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
drug;O;O
interactions;O;O
in;O;O
clinical;O;O
studies;O;O
in;O;O
which;O;O
dobutamine;B-drug;B-DDI-DrugBank.d274.s3.e0
was;O;O
administered;O;O
concurrently;O;O
with;O;O
other;O;O
drugs;O;O
,;O;O
including;O;O
digitalis;B-group;B-DDI-DrugBank.d274.s3.e1
preparations;I-group;I-DDI-DrugBank.d274.s3.e1
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d274.s3.e2
,;O;O
spironolactone;B-drug;B-DDI-DrugBank.d274.s3.e3
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d274.s3.e4
,;O;O
glyceryl;B-drug;B-DDI-DrugBank.d274.s3.e5
trinitrate;I-drug;I-DDI-DrugBank.d274.s3.e5
,;O;O
isosorbide;B-drug;B-DDI-DrugBank.d274.s3.e6
dinitrate;I-drug;I-DDI-DrugBank.d274.s3.e6
,;O;O
morphine;B-drug;B-DDI-DrugBank.d274.s3.e7
,;O;O
atropine;B-drug;B-DDI-DrugBank.d274.s3.e8
,;O;O
heparin;B-drug;B-DDI-DrugBank.d274.s3.e9
,;O;O
protamine;B-drug;B-DDI-DrugBank.d274.s3.e10
,;O;O
potassium;B-drug;B-DDI-DrugBank.d274.s3.e11
chloride;I-drug;I-DDI-DrugBank.d274.s3.e11
,;O;O
folic;B-drug;B-DDI-DrugBank.d274.s3.e12
acid;I-drug;I-DDI-DrugBank.d274.s3.e12
,;O;O
and;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d274.s3.e13
.;O;O
DDI-DrugBank.d371.s0;;
There;O;O
have;O;O
been;O;O
no;O;O
formal;O;O
clinical;O;O
studies;O;O
to;O;O
evaluate;O;O
the;O;O
drug;O;O
interactions;O;O
of;O;O
TAXOTERE;B-brand;B-DDI-DrugBank.d371.s0.e0
with;O;O
other;O;O
medications;O;O
.;O;O
DDI-DrugBank.d371.s1;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
the;O;O
metabolism;O;O
of;O;O
docetaxel;B-drug;B-DDI-DrugBank.d371.s1.e0
may;O;O
be;O;O
modified;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
compounds;O;O
that;O;O
induce;O;O
,;O;O
inhibit;O;O
,;O;O
or;O;O
are;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
,;O;O
such;O;O
as;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d371.s1.e1
,;O;O
terfenadine;B-drug;B-DDI-DrugBank.d371.s1.e2
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d371.s1.e3
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d371.s1.e4
,;O;O
and;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d371.s1.e5
.;O;O
DDI-DrugBank.d371.s2;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
with;O;O
these;O;O
drugs;O;O
when;O;O
treating;O;O
patients;O;O
receiving;O;O
TAXOTERE;B-brand;B-DDI-DrugBank.d371.s2.e0
as;O;O
there;O;O
is;O;O
a;O;O
potential;O;O
for;O;O
a;O;O
significant;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d558.s0;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
None;O;O
known;O;O
.;O;O
DDI-DrugBank.d558.s1;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d558.s1.e0
:;O;O
Concomitant;O;O
use;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d558.s1.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d558.s2;;
Cimetidine;B-drug;B-DDI-DrugBank.d558.s2.e0
at;O;O
400;O;O
mg;O;O
BID;O;O
(;O;O
the;O;O
usual;O;O
prescription;O;O
dose;O;O
);O;O
co;O;O
-;O;O
administered;O;O
with;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s2.e1
(;O;O
500;O;O
mcg;O;O
BID;O;O
);O;O
for;O;O
7;O;O
days;O;O
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s2.e2
plasma;O;O
levels;O;O
by;O;O
58;O;O
%;O;O
.;O;O
DDI-DrugBank.d558.s3;;
Cimetidine;B-drug;B-DDI-DrugBank.d558.s3.e0
at;O;O
doses;O;O
of;O;O
100;O;O
mg;O;O
BID;O;O
(;O;O
OTC;O;O
dose;O;O
);O;O
resulted;O;O
in;O;O
a;O;O
13;O;O
%;O;O
increase;O;O
in;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s3.e1
plasma;O;O
levels;O;O
(;O;O
500;O;O
mcg;O;O
single;O;O
dose;O;O
);O;O
.;O;O
DDI-DrugBank.d558.s4;;
No;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
at;O;O
intermediate;O;O
doses;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d558.s4.e0
.;O;O
DDI-DrugBank.d558.s5;;
If;O;O
a;O;O
patient;O;O
requires;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s5.e0
and;O;O
anti;B-group;B-DDI-DrugBank.d558.s5.e1
-;I-group;I-DDI-DrugBank.d558.s5.e1
ulcer;I-group;I-DDI-DrugBank.d558.s5.e1
therapy;O;O
,;O;O
it;O;O
is;O;O
suggested;O;O
that;O;O
omeprazole;B-drug;B-DDI-DrugBank.d558.s5.e2
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d558.s5.e3
,;O;O
or;O;O
antacids;B-group;B-DDI-DrugBank.d558.s5.e4
(;O;O
aluminum;B-drug;B-DDI-DrugBank.d558.s5.e5
and;I-drug;I-DDI-DrugBank.d558.s5.e5
magnesium;I-drug;I-DDI-DrugBank.d558.s5.e6
hydroxides;I-drug;I-DDI-DrugBank.d558.s5.e6
);O;O
be;O;O
used;O;O
as;O;O
alternatives;O;O
to;O;O
cimetidine;B-drug;B-DDI-DrugBank.d558.s5.e7
,;O;O
as;O;O
these;O;O
agents;O;O
have;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetic;O;O
profile;O;O
of;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s5.e8
.;O;O
DDI-DrugBank.d558.s6;;
Verapamil;B-drug;B-DDI-DrugBank.d558.s6.e0
:;O;O
Concomitant;O;O
use;O;O
of;O;O
verapamil;B-drug;B-DDI-DrugBank.d558.s6.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d558.s7;;
Co;O;O
-;O;O
administration;O;O
of;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s7.e0
with;O;O
verapamil;B-drug;B-DDI-DrugBank.d558.s7.e1
resulted;O;O
in;O;O
increases;O;O
in;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s7.e2
peak;O;O
plasma;O;O
levels;O;O
of;O;O
42;O;O
%;O;O
,;O;O
although;O;O
overall;O;O
exposure;O;O
to;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s7.e3
was;O;O
not;O;O
significantly;O;O
increased;O;O
.;O;O
DDI-DrugBank.d558.s8;;
In;O;O
an;O;O
analysis;O;O
of;O;O
the;O;O
supraventricular;O;O
arrhythmia;O;O
and;O;O
DIAMOND;O;O
patient;O;O
populations;O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
verapamil;B-drug;B-DDI-DrugBank.d558.s8.e0
with;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s8.e1
was;O;O
associated;O;O
with;O;O
a;O;O
higher;O;O
occurrence;O;O
of;O;O
torsade;O;O
de;O;O
pointes;O;O
.;O;O
DDI-DrugBank.d558.s9;;
Ketoconazole;B-drug;B-DDI-DrugBank.d558.s9.e0
:;O;O
Concomitant;O;O
use;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d558.s9.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d558.s10;;
Ketoconazole;B-drug;B-DDI-DrugBank.d558.s10.e0
at;O;O
400;O;O
mg;O;O
daily;O;O
(;O;O
the;O;O
maximum;O;O
approved;O;O
prescription;O;O
dose;O;O
);O;O
co;O;O
-;O;O
administered;O;O
with;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s10.e1
(;O;O
500;O;O
mcg;O;O
BID;O;O
);O;O
for;O;O
7;O;O
days;O;O
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s10.e2
Cmax;O;O
by;O;O
53;O;O
%;O;O
in;O;O
males;O;O
and;O;O
97;O;O
%;O;O
in;O;O
females;O;O
,;O;O
and;O;O
AUC;O;O
by;O;O
41;O;O
%;O;O
in;O;O
males;O;O
and;O;O
69;O;O
%;O;O
in;O;O
females;O;O
.;O;O
DDI-DrugBank.d558.s11;;
Trimethoprim;B-drug;B-DDI-DrugBank.d558.s11.e0
Alone;O;O
or;O;O
in;O;O
Combination;O;O
with;O;O
Sulfamethoxazole;B-drug;B-DDI-DrugBank.d558.s11.e1
:;O;O
Concomitant;O;O
use;O;O
of;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d558.s11.e2
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d558.s11.e3
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d558.s12;;
Hydrochlorothiazide;B-drug;B-DDI-DrugBank.d558.s12.e0
(;O;O
HCTZ;B-drug;B-DDI-DrugBank.d558.s12.e1
);O;O
Alone;O;O
or;O;O
in;O;O
Combination;O;O
with;O;O
Triamterene;B-drug;B-DDI-DrugBank.d558.s12.e2
:;O;O
Concomitant;O;O
use;O;O
of;O;O
HCTZ;B-drug;B-DDI-DrugBank.d558.s12.e3
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
triamterene;B-drug;B-DDI-DrugBank.d558.s12.e4
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d558.s13;;
HCTZ;B-drug;B-DDI-DrugBank.d558.s13.e0
50;O;O
mg;O;O
QD;O;O
or;O;O
HCTZ;B-drug;B-DDI-DrugBank.d558.s13.e1
/;O;O
triamterene;B-drug;B-DDI-DrugBank.d558.s13.e2
50;O;O
/;O;O
100;O;O
mg;O;O
QD;O;O
was;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s13.e3
(;O;O
500;O;O
mcg;O;O
BID;O;O
);O;O
for;O;O
5;O;O
days;O;O
(;O;O
following;O;O
2;O;O
days;O;O
of;O;O
diuretic;B-group;B-DDI-DrugBank.d558.s13.e4
use;O;O
at;O;O
half;O;O
dose;O;O
);O;O
.;O;O
DDI-DrugBank.d558.s14;;
In;O;O
patients;O;O
receiving;O;O
HCTZ;B-drug;B-DDI-DrugBank.d558.s14.e0
alone;O;O
,;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s14.e1
AUC;O;O
increased;O;O
by;O;O
27;O;O
%;O;O
and;O;O
Cmax;O;O
by;O;O
21;O;O
%;O;O
.;O;O
DDI-DrugBank.d558.s15;;
However;O;O
,;O;O
the;O;O
pharmacodynamic;O;O
effect;O;O
increased;O;O
by;O;O
197;O;O
%;O;O
(;O;O
QTc;O;O
increase;O;O
over;O;O
time;O;O
);O;O
and;O;O
by;O;O
95;O;O
%;O;O
(;O;O
maximum;O;O
QTc;O;O
increase;O;O
);O;O
.;O;O
DDI-DrugBank.d558.s16;;
However;O;O
,;O;O
the;O;O
pharmacodynamic;O;O
effect;O;O
increased;O;O
by;O;O
190;O;O
%;O;O
(;O;O
QTc;O;O
increase;O;O
over;O;O
time;O;O
);O;O
and;O;O
by;O;O
84;O;O
%;O;O
(;O;O
Maximum;O;O
QTc;O;O
increase;O;O
);O;O
.;O;O
DDI-DrugBank.d558.s17;;
The;O;O
pharmacodynamic;O;O
effects;O;O
can;O;O
be;O;O
explained;O;O
by;O;O
a;O;O
combination;O;O
of;O;O
the;O;O
increase;O;O
in;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s17.e0
exposure;O;O
and;O;O
the;O;O
reductions;O;O
in;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d558.s18;;
In;O;O
the;O;O
DIAMOND;O;O
trials;O;O
,;O;O
1252;O;O
patients;O;O
were;O;O
treated;O;O
with;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s18.e0
and;O;O
diuretics;B-group;B-DDI-DrugBank.d558.s18.e1
concomitantly;O;O
of;O;O
whom;O;O
493;O;O
died;O;O
compared;O;O
to;O;O
508;O;O
deaths;O;O
among;O;O
the;O;O
1248;O;O
patients;O;O
receiving;O;O
placebo;O;O
and;O;O
diuretics;B-group;B-DDI-DrugBank.d558.s18.e2
.;O;O
DDI-DrugBank.d558.s19;;
Of;O;O
the;O;O
229;O;O
patients;O;O
who;O;O
had;O;O
potassium;B-group;B-DDI-DrugBank.d558.s19.e0
depleting;I-group;I-DDI-DrugBank.d558.s19.e0
diuretics;I-group;I-DDI-DrugBank.d558.s19.e0
added;O;O
to;O;O
their;O;O
concomitant;O;O
medications;O;O
in;O;O
the;O;O
DIAMOND;O;O
trials;O;O
,;O;O
the;O;O
patients;O;O
on;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s19.e1
had;O;O
a;O;O
non;O;O
-;O;O
significantly;O;O
reduced;O;O
relative;O;O
risk;O;O
for;O;O
death;O;O
of;O;O
0.68;O;O
(;O;O
95;O;O
%;O;O
CI;O;O
0.376;O;O
,;O;O
1.230;O;O
);O;O
.;O;O
DDI-DrugBank.d558.s20;;
Potential;O;O
Drug;O;O
Interactions;O;O
Dofetilide;B-drug;B-DDI-DrugBank.d558.s20.e0
is;O;O
eliminated;O;O
in;O;O
the;O;O
kidney;O;O
by;O;O
cationic;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d558.s21;;
Inhibitors;O;O
of;O;O
renal;O;O
cationic;O;O
secretion;O;O
are;O;O
contraindicated;O;O
with;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s21.e0
.;O;O
DDI-DrugBank.d558.s22;;
In;O;O
addition;O;O
,;O;O
drugs;O;O
that;O;O
are;O;O
actively;O;O
secreted;O;O
via;O;O
this;O;O
route;O;O
(;O;O
e.g.;O;O
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d558.s22.e0
,;O;O
metformin;B-drug;B-DDI-DrugBank.d558.s22.e1
and;O;O
amiloride;B-drug;B-DDI-DrugBank.d558.s22.e2
);O;O
should;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
care;O;O
as;O;O
they;O;O
might;O;O
increase;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s22.e3
levels;O;O
.;O;O
DDI-DrugBank.d558.s23;;
Dofetilide;B-drug;B-DDI-DrugBank.d558.s23.e0
is;O;O
metabolized;O;O
to;O;O
a;O;O
small;O;O
extent;O;O
by;O;O
the;O;O
CYP3A4;O;O
isoenzyme;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
.;O;O
DDI-DrugBank.d558.s24;;
Inhibitors;O;O
of;O;O
the;O;O
CYP3A4;O;O
isoenzyme;O;O
could;O;O
increase;O;O
systemic;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s24.e0
exposure;O;O
.;O;O
DDI-DrugBank.d558.s25;;
Inhibitors;O;O
of;O;O
this;O;O
isoenzyme;O;O
(;O;O
e.g.;O;O
,;O;O
macrolide;B-group;B-DDI-DrugBank.d558.s25.e0
antibiotics;I-group;I-DDI-DrugBank.d558.s25.e0
,;O;O
azole;B-group;B-DDI-DrugBank.d558.s25.e1
antifungal;I-group;I-DDI-DrugBank.d558.s25.e1
agents;I-group;I-DDI-DrugBank.d558.s25.e1
,;O;O
protease;B-group;B-DDI-DrugBank.d558.s25.e2
inhibitors;I-group;I-DDI-DrugBank.d558.s25.e2
,;O;O
serotonin;B-group;B-DDI-DrugBank.d558.s25.e3
reuptake;I-group;I-DDI-DrugBank.d558.s25.e3
inhibitors;I-group;I-DDI-DrugBank.d558.s25.e3
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d558.s25.e4
,;O;O
cannabinoids;B-group;B-DDI-DrugBank.d558.s25.e5
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d558.s25.e6
,;O;O
grapefruit;O;O
juice;O;O
,;O;O
nefazadone;B-drug;B-DDI-DrugBank.d558.s25.e7
,;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d558.s25.e8
,;O;O
quinine;B-drug;B-DDI-DrugBank.d558.s25.e9
,;O;O
zafirlukast;B-drug;B-DDI-DrugBank.d558.s25.e10
);O;O
should;O;O
be;O;O
cautiously;O;O
coadministered;O;O
with;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s25.e11
as;O;O
they;O;O
can;O;O
potentially;O;O
increase;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s25.e12
levels;O;O
.;O;O
DDI-DrugBank.d558.s26;;
Dofetilide;B-drug;B-DDI-DrugBank.d558.s26.e0
is;O;O
not;O;O
an;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
nor;O;O
of;O;O
other;O;O
cytochrome;O;O
P450;O;O
isoenzymes;O;O
(;O;O
e.g.;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2D6;O;O
);O;O
and;O;O
is;O;O
not;O;O
expected;O;O
to;O;O
increase;O;O
levels;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d558.s27;;
Other;O;O
Drug;O;O
Interaction;O;O
Information;O;O
Digoxin;B-drug;B-DDI-DrugBank.d558.s27.e0
:;O;O
Studies;O;O
in;O;O
healthy;O;O
volunteers;O;O
have;O;O
shown;O;O
that;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s27.e1
does;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d558.s27.e2
.;O;O
DDI-DrugBank.d558.s28;;
In;O;O
patients;O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d558.s28.e0
with;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s28.e1
was;O;O
associated;O;O
with;O;O
a;O;O
higher;O;O
occurrence;O;O
of;O;O
torsade;O;O
de;O;O
pointes;O;O
.;O;O
DDI-DrugBank.d558.s29;;
It;O;O
is;O;O
not;O;O
clear;O;O
whether;O;O
this;O;O
represents;O;O
an;O;O
interaction;O;O
with;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s29.e0
or;O;O
the;O;O
presence;O;O
of;O;O
more;O;O
severe;O;O
structural;O;O
heart;O;O
disease;O;O
in;O;O
patients;O;O
on;O;O
digoxin;B-drug;B-DDI-DrugBank.d558.s29.e1
,;O;O
DDI-DrugBank.d558.s30;;
structural;O;O
heart;O;O
disease;O;O
is;O;O
a;O;O
known;O;O
risk;O;O
factor;O;O
for;O;O
arrhythmia;O;O
.;O;O
DDI-DrugBank.d558.s31;;
No;O;O
increase;O;O
in;O;O
mortality;O;O
was;O;O
observed;O;O
in;O;O
patients;O;O
taking;O;O
digoxin;B-drug;B-DDI-DrugBank.d558.s31.e0
as;O;O
concomitant;O;O
medication;O;O
.;O;O
DDI-DrugBank.d558.s32;;
Other;O;O
Drugs;O;O
:;O;O
In;O;O
healthy;O;O
volunteers;O;O
,;O;O
amlodipine;B-drug;B-DDI-DrugBank.d558.s32.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d558.s32.e1
,;O;O
glyburide;B-drug;B-DDI-DrugBank.d558.s32.e2
,;O;O
ranitidine;B-drug;B-DDI-DrugBank.d558.s32.e3
,;O;O
omeprazole;B-drug;B-DDI-DrugBank.d558.s32.e4
,;O;O
hormone;O;O
replacement;O;O
therapy;O;O
(;O;O
a;O;O
combination;O;O
of;O;O
conjugated;O;O
estrogens;B-group;B-DDI-DrugBank.d558.s32.e5
and;O;O
medroxyprogesterone;B-drug;B-DDI-DrugBank.d558.s32.e6
);O;O
,;O;O
antacid;B-group;B-DDI-DrugBank.d558.s32.e7
(;O;O
aluminum;B-drug;B-DDI-DrugBank.d558.s32.e8
and;I-drug;I-DDI-DrugBank.d558.s32.e8
magnesium;I-drug;I-DDI-DrugBank.d558.s32.e9
hydroxides;I-drug;I-DDI-DrugBank.d558.s32.e9
);O;O
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d558.s32.e10
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s32.e11
.;O;O
DDI-DrugBank.d558.s33;;
In;O;O
addition;O;O
,;O;O
studies;O;O
in;O;O
healthy;O;O
volunteers;O;O
have;O;O
shown;O;O
that;O;O
TIKOSYN;B-brand;B-DDI-DrugBank.d558.s33.e0
does;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
or;O;O
pharmacodynamics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d558.s33.e1
,;O;O
or;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d558.s33.e2
(;O;O
40;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d558.s33.e3
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d558.s33.e4
,;O;O
or;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d558.s33.e5
.;O;O
DDI-DrugBank.d558.s34;;
Population;O;O
pharmacokinetic;O;O
analyses;O;O
were;O;O
conducted;O;O
on;O;O
plasma;O;O
concentration;O;O
data;O;O
from;O;O
1445;O;O
patients;O;O
in;O;O
clinical;O;O
trials;O;O
to;O;O
examine;O;O
the;O;O
effects;O;O
of;O;O
concomitant;O;O
medications;O;O
on;O;O
clearance;O;O
or;O;O
volume;O;O
of;O;O
distribution;O;O
of;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s34.e0
.;O;O
DDI-DrugBank.d558.s35;;
Concomitant;O;O
medications;O;O
were;O;O
grouped;O;O
as;O;O
ACE;B-group;B-DDI-DrugBank.d558.s35.e0
inhibitors;I-group;I-DDI-DrugBank.d558.s35.e0
,;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d558.s35.e1
,;O;O
calcium;B-group;B-DDI-DrugBank.d558.s35.e2
channel;I-group;I-DDI-DrugBank.d558.s35.e2
blockers;I-group;I-DDI-DrugBank.d558.s35.e2
,;O;O
beta;B-group;B-DDI-DrugBank.d558.s35.e3
blockers;I-group;I-DDI-DrugBank.d558.s35.e3
,;O;O
cardiac;B-group;B-DDI-DrugBank.d558.s35.e4
glycosides;I-group;I-DDI-DrugBank.d558.s35.e4
,;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
,;O;O
substrates;O;O
and;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
,;O;O
substrates;O;O
and;O;O
inhibitors;O;O
of;O;O
P;O;O
-;O;O
glycoprotein;O;O
,;O;O
nitrates;B-group;B-DDI-DrugBank.d558.s35.e5
,;O;O
sulphonylureas;B-group;B-DDI-DrugBank.d558.s35.e6
,;O;O
loop;B-group;B-DDI-DrugBank.d558.s35.e7
diuretics;I-group;I-DDI-DrugBank.d558.s35.e7
,;O;O
potassium;B-group;B-DDI-DrugBank.d558.s35.e8
sparing;I-group;I-DDI-DrugBank.d558.s35.e8
diuretics;I-group;I-DDI-DrugBank.d558.s35.e8
,;O;O
thiazide;B-group;B-DDI-DrugBank.d558.s35.e9
diuretics;I-group;I-DDI-DrugBank.d558.s35.e9
,;O;O
substrates;O;O
and;O;O
inhibitors;O;O
of;O;O
tubular;O;O
organic;O;O
cation;O;O
transport;O;O
,;O;O
and;O;O
QTc;O;O
-;O;O
prolonging;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d558.s36;;
Differences;O;O
in;O;O
clearance;O;O
between;O;O
patients;O;O
on;O;O
these;O;O
medications;O;O
(;O;O
at;O;O
any;O;O
occasion;O;O
in;O;O
the;O;O
study;O;O
);O;O
and;O;O
those;O;O
off;O;O
medications;O;O
varied;O;O
between;O;O
-16;O;O
%;O;O
and;O;O
+3;O;O
%;O;O
.;O;O
DDI-DrugBank.d558.s37;;
The;O;O
mean;O;O
clearances;O;O
of;O;O
dofetilide;B-drug;B-DDI-DrugBank.d558.s37.e0
were;O;O
16;O;O
%;O;O
and;O;O
15;O;O
%;O;O
lower;O;O
in;O;O
patients;O;O
on;O;O
thiazide;B-group;B-DDI-DrugBank.d558.s37.e1
diuretics;I-group;I-DDI-DrugBank.d558.s37.e1
and;O;O
inhibitors;O;O
of;O;O
tubular;O;O
organic;O;O
cation;O;O
transport;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d42.s0;;
The;O;O
potential;O;O
for;O;O
clinically;O;O
significant;O;O
drug;O;O
-;O;O
drug;O;O
interactions;O;O
posed;O;O
by;O;O
dolasetron;B-drug;B-DDI-DrugBank.d42.s0.e0
and;O;O
hydrodolasetron;B-drug_n;B-DDI-DrugBank.d42.s0.e1
appears;O;O
to;O;O
be;O;O
low;O;O
for;O;O
drugs;O;O
commonly;O;O
used;O;O
in;O;O
chemotherapy;O;O
or;O;O
surgery;O;O
,;O;O
because;O;O
hydrodolasetron;B-drug_n;B-DDI-DrugBank.d42.s0.e2
is;O;O
eliminated;O;O
by;O;O
multiple;O;O
routes;O;O
.;O;O
DDI-DrugBank.d42.s1;;
Blood;O;O
levels;O;O
of;O;O
hydrodolasetron;B-drug_n;B-DDI-DrugBank.d42.s1.e0
increased;O;O
24;O;O
%;O;O
when;O;O
dolasetron;B-drug;B-DDI-DrugBank.d42.s1.e1
was;O;O
coadministered;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d42.s1.e2
(;O;O
nonselective;O;O
inhibitor;O;O
of;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
);O;O
for;O;O
7;O;O
days;O;O
,;O;O
and;O;O
decreased;O;O
28;O;O
%;O;O
with;O;O
coadministration;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d42.s1.e3
(;O;O
potent;O;O
inducer;O;O
of;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
);O;O
for;O;O
7;O;O
days;O;O
.;O;O
DDI-DrugBank.d42.s2;;
Dolasetron;B-drug;B-DDI-DrugBank.d42.s2.e0
has;O;O
been;O;O
safely;O;O
coadministered;O;O
with;O;O
drugs;O;O
used;O;O
in;O;O
chemotherapy;O;O
and;O;O
surgery;O;O
.;O;O
DDI-DrugBank.d42.s3;;
As;O;O
with;O;O
other;O;O
agents;O;O
which;O;O
prolong;O;O
ECG;O;O
intervals;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
in;O;O
patients;O;O
taking;O;O
drugs;O;O
which;O;O
prolong;O;O
ECG;O;O
intervals;O;O
,;O;O
particularly;O;O
QTc;O;O
.;O;O
DDI-DrugBank.d42.s4;;
In;O;O
patients;O;O
taking;O;O
furosemide;B-drug;B-DDI-DrugBank.d42.s4.e0
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d42.s4.e1
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d42.s4.e2
,;O;O
ACE;B-group;B-DDI-DrugBank.d42.s4.e3
inhibitors;I-group;I-DDI-DrugBank.d42.s4.e3
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d42.s4.e4
,;O;O
glyburide;B-drug;B-DDI-DrugBank.d42.s4.e5
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d42.s4.e6
,;O;O
and;O;O
various;O;O
chemotherapy;O;O
agents;O;O
,;O;O
no;O;O
effect;O;O
was;O;O
shown;O;O
on;O;O
the;O;O
clearance;O;O
of;O;O
hydrodolasetron;B-drug_n;B-DDI-DrugBank.d42.s4.e7
.;O;O
DDI-DrugBank.d42.s5;;
Clearance;O;O
of;O;O
hydrodolasetron;B-drug_n;B-DDI-DrugBank.d42.s5.e0
decreased;O;O
by;O;O
about;O;O
27;O;O
%;O;O
when;O;O
dolasetron;B-drug;B-DDI-DrugBank.d42.s5.e1
mesylate;I-drug;I-DDI-DrugBank.d42.s5.e1
was;O;O
administered;O;O
intravenously;O;O
concomitantly;O;O
with;O;O
atenolol;B-drug;B-DDI-DrugBank.d42.s5.e2
.;O;O
DDI-DrugBank.d42.s6;;
Dolasetron;B-drug;B-DDI-DrugBank.d42.s6.e0
does;O;O
not;O;O
influence;O;O
anesthesia;O;O
recovery;O;O
time;O;O
in;O;O
patients;O;O
.;O;O
DDI-DrugBank.d42.s7;;
Dolasetron;B-drug;B-DDI-DrugBank.d42.s7.e0
mesylate;I-drug;I-DDI-DrugBank.d42.s7.e0
did;O;O
not;O;O
inhibit;O;O
the;O;O
antitumor;O;O
activity;O;O
of;O;O
four;O;O
chemotherapeutic;B-group;B-DDI-DrugBank.d42.s7.e1
agents;I-group;I-DDI-DrugBank.d42.s7.e1
(;O;O
cisplatin;B-drug;B-DDI-DrugBank.d42.s7.e2
,;O;O
5;B-drug;B-DDI-DrugBank.d42.s7.e3
-;I-drug;I-DDI-DrugBank.d42.s7.e3
fluorouracil;I-drug;I-DDI-DrugBank.d42.s7.e3
,;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d42.s7.e4
,;O;O
cyclophosphamide;B-drug;B-DDI-DrugBank.d42.s7.e5
);O;O
in;O;O
four;O;O
murine;O;O
models;O;O
.;O;O
DDI-DrugBank.d319.s0;;
Drugs;O;O
that;O;O
inhibit;O;O
or;O;O
Induce;O;O
CYP;O;O
2D6;O;O
and;O;O
CYP;O;O
3A4;O;O
may;O;O
affect;O;O
the;O;O
concentration;O;O
on;O;O
Aricept;B-brand;B-DDI-DrugBank.d319.s0.e0
.;O;O
DDI-DrugBank.d325.s0;;
Because;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s0.e0
is;O;O
metabolized;O;O
by;O;O
monoamine;O;O
oxidase;O;O
(;O;O
MAO;O;O
);O;O
,;O;O
inhibition;O;O
of;O;O
this;O;O
enzyme;O;O
prolongs;O;O
and;O;O
potentiates;O;O
the;O;O
effect;O;O
of;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s0.e1
.;O;O
DDI-DrugBank.d325.s1;;
Patients;O;O
who;O;O
have;O;O
been;O;O
treated;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d325.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d325.s1.e0
within;O;O
two;O;O
to;O;O
three;O;O
weeks;O;O
prior;O;O
to;O;O
the;O;O
administration;O;O
of;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s1.e1
HCl;I-drug;I-DDI-DrugBank.d325.s1.e1
should;O;O
receive;O;O
initial;O;O
doses;O;O
of;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s1.e2
HCl;I-drug;I-DDI-DrugBank.d325.s1.e2
no;O;O
greater;O;O
than;O;O
one;O;O
-;O;O
tenth;O;O
(;O;O
1;O;O
/;O;O
10;O;O
);O;O
of;O;O
the;O;O
usual;O;O
dose;O;O
.;O;O
DDI-DrugBank.d325.s2;;
Concurrent;O;O
administration;O;O
of;O;O
low;O;O
-;O;O
dose;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s2.e0
HCl;I-drug;I-DDI-DrugBank.d325.s2.e0
and;O;O
diuretic;B-group;B-DDI-DrugBank.d325.s2.e1
agents;I-group;I-DDI-DrugBank.d325.s2.e1
may;O;O
produce;O;O
an;O;O
additive;O;O
or;O;O
potentiating;O;O
effect;O;O
on;O;O
urine;O;O
flow;O;O
.;O;O
DDI-DrugBank.d325.s3;;
Tricyclic;B-group;B-DDI-DrugBank.d325.s3.e0
antidepressants;I-group;I-DDI-DrugBank.d325.s3.e0
may;O;O
potentiate;O;O
the;O;O
cardiovascular;O;O
effects;O;O
of;O;O
adreneric;O;O
agents;O;O
.;O;O
DDI-DrugBank.d325.s4;;
Cardiac;O;O
effects;O;O
of;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s4.e0
are;O;O
antagonized;O;O
by;O;O
beta;B-group;B-DDI-DrugBank.d325.s4.e1
-;I-group;I-DDI-DrugBank.d325.s4.e1
adrenergic;I-group;I-DDI-DrugBank.d325.s4.e1
blocking;I-group;I-DDI-DrugBank.d325.s4.e1
agents;I-group;I-DDI-DrugBank.d325.s4.e1
,;O;O
such;O;O
as;O;O
propranolol;B-drug;B-DDI-DrugBank.d325.s4.e2
and;O;O
metoprolol;B-drug;B-DDI-DrugBank.d325.s4.e3
.;O;O
DDI-DrugBank.d325.s5;;
The;O;O
peripheral;O;O
vasoconstriction;O;O
caused;O;O
by;O;O
high;O;O
doses;O;O
of;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s5.e0
HCl;I-drug;I-DDI-DrugBank.d325.s5.e0
is;O;O
antagonized;O;O
by;O;O
alpha;B-group;B-DDI-DrugBank.d325.s5.e1
-;I-group;I-DDI-DrugBank.d325.s5.e1
adrenergic;I-group;I-DDI-DrugBank.d325.s5.e1
blocking;I-group;I-DDI-DrugBank.d325.s5.e1
agents;I-group;I-DDI-DrugBank.d325.s5.e1
.;O;O
DDI-DrugBank.d325.s6;;
Dopamine;B-drug;B-DDI-DrugBank.d325.s6.e0
-;O;O
induced;O;O
renal;O;O
and;O;O
mesenteric;O;O
vasodilation;O;O
is;O;O
not;O;O
antagonized;O;O
by;O;O
either;O;O
alpha;B-group;B-DDI-DrugBank.d325.s6.e1
-;I-group;I-DDI-DrugBank.d325.s6.e1
or;I-group;I-DDI-DrugBank.d325.s6.e1
beta;I-drug;I-DDI-DrugBank.d325.s6.e2
-;I-drug;I-DDI-DrugBank.d325.s6.e2
adrenergic;I-drug;I-DDI-DrugBank.d325.s6.e2
blocking;I-drug;I-DDI-DrugBank.d325.s6.e2
agents;I-drug;I-DDI-DrugBank.d325.s6.e2
.;O;O
DDI-DrugBank.d325.s7;;
Butyrophenones;B-group;B-DDI-DrugBank.d325.s7.e0
(;O;O
such;O;O
as;O;O
haloperidol;B-drug;B-DDI-DrugBank.d325.s7.e1
);O;O
and;O;O
phenothiazines;B-group;B-DDI-DrugBank.d325.s7.e2
can;O;O
suppress;O;O
the;O;O
dopaminergic;B-drug;B-DDI-DrugBank.d325.s7.e3
renal;O;O
and;O;O
mesenteric;O;O
vasodilation;O;O
induced;O;O
with;O;O
low;O;O
dose;O;O
dopamine;O;O
infusion;O;O
.;O;O
DDI-DrugBank.d325.s8;;
Cyclopropane;B-drug;B-DDI-DrugBank.d325.s8.e0
or;O;O
halogenated;B-group;B-DDI-DrugBank.d325.s8.e1
hydrocarbon;I-group;I-DDI-DrugBank.d325.s8.e1
anesthetics;I-group;I-DDI-DrugBank.d325.s8.e1
increase;O;O
cardiac;O;O
autonomic;O;O
irritability;O;O
and;O;O
may;O;O
sensitize;O;O
the;O;O
myocardium;O;O
to;O;O
the;O;O
action;O;O
of;O;O
certain;O;O
intravenously;O;O
administered;O;O
catecholamines;B-group;B-DDI-DrugBank.d325.s8.e2
,;O;O
such;O;O
as;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s8.e3
.;O;O
DDI-DrugBank.d325.s9;;
This;O;O
interaction;O;O
appears;O;O
to;O;O
be;O;O
related;O;O
both;O;O
to;O;O
pressor;O;O
activity;O;O
and;O;O
to;O;O
beta;O;O
-;O;O
adrenergic;O;O
stimulating;O;O
properties;O;O
of;O;O
these;O;O
catecholamines;B-group;B-DDI-DrugBank.d325.s9.e0
and;O;O
may;O;O
produce;O;O
ventricular;O;O
arrhythmias;O;O
and;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d325.s10;;
Therefore;O;O
,;O;O
EXTREME;O;O
CAUTION;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
administering;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s10.e0
HCl;I-drug;I-DDI-DrugBank.d325.s10.e0
to;O;O
patients;O;O
receiving;O;O
cyclopropane;B-drug;B-DDI-DrugBank.d325.s10.e1
or;O;O
halogenated;B-group;B-DDI-DrugBank.d325.s10.e2
hydrocarbon;I-group;I-DDI-DrugBank.d325.s10.e2
anesthetics;I-group;I-DDI-DrugBank.d325.s10.e2
.;O;O
DDI-DrugBank.d325.s11;;
It;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
results;O;O
of;O;O
studies;O;O
in;O;O
animals;O;O
indicate;O;O
that;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s11.e0
-;O;O
induced;O;O
ventricular;O;O
arrhythmias;O;O
during;O;O
anesthesia;O;O
can;O;O
be;O;O
reversed;O;O
by;O;O
propranolol;B-drug;B-DDI-DrugBank.d325.s11.e1
.;O;O
DDI-DrugBank.d325.s12;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
vasopressors;B-group;B-DDI-DrugBank.d325.s12.e0
,;O;O
vasoconstricting;O;O
agents;O;O
(;O;O
such;O;O
as;O;O
ergonovine;B-drug;B-DDI-DrugBank.d325.s12.e1
);O;O
and;O;O
some;O;O
oxytocic;B-group;B-DDI-DrugBank.d325.s12.e2
drugs;I-group;I-DDI-DrugBank.d325.s12.e2
may;O;O
result;O;O
in;O;O
severe;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d325.s13;;
Administration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d325.s13.e0
to;O;O
patients;O;O
receiving;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s13.e1
HCl;I-drug;I-DDI-DrugBank.d325.s13.e1
has;O;O
been;O;O
reported;O;O
to;O;O
lead;O;O
to;O;O
hypotension;O;O
and;O;O
bradycardia;O;O
.;O;O
DDI-DrugBank.d325.s14;;
It;O;O
is;O;O
suggested;O;O
that;O;O
in;O;O
patients;O;O
receiving;O;O
dopamine;B-drug;B-DDI-DrugBank.d325.s14.e0
HCl;I-drug;I-DDI-DrugBank.d325.s14.e0
,;O;O
alternatives;O;O
to;O;O
phenytoin;B-drug;B-DDI-DrugBank.d325.s14.e1
should;O;O
be;O;O
used;O;O
if;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d325.s14.e2
therapy;O;O
is;O;O
needed;O;O
.;O;O
DDI-DrugBank.d93.s0;;
Clinical;O;O
trials;O;O
have;O;O
indicated;O;O
that;O;O
Pulmozyme;B-brand;B-DDI-DrugBank.d93.s0.e0
can;O;O
be;O;O
effectively;O;O
and;O;O
safely;O;O
used;O;O
in;O;O
conjunction;O;O
with;O;O
standard;O;O
cystic;O;O
fibrosis;O;O
therapies;O;O
including;O;O
oral;O;O
,;O;O
inhaled;O;O
and/or;O;O
parenteral;O;O
antibiotics;B-group;B-DDI-DrugBank.d93.s0.e1
,;O;O
bronchodilators;B-group;B-DDI-DrugBank.d93.s0.e2
,;O;O
enzyme;O;O
supplements;O;O
,;O;O
vitamins;B-group;B-DDI-DrugBank.d93.s0.e3
,;O;O
oral;O;O
or;O;O
inhaled;O;O
corticosteroids;B-group;B-DDI-DrugBank.d93.s0.e4
,;O;O
and;O;O
analgesics;B-group;B-DDI-DrugBank.d93.s0.e5
.;O;O
DDI-DrugBank.d93.s1;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d34.s0;;
Although;O;O
acid;O;O
-;O;O
base;O;O
and;O;O
electrolyte;O;O
disturbances;O;O
were;O;O
not;O;O
reported;O;O
in;O;O
the;O;O
clinical;O;O
trials;O;O
with;O;O
dorzolamide;B-drug;B-DDI-DrugBank.d34.s0.e0
,;O;O
these;O;O
disturbances;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
oral;O;O
carbonic;B-group;B-DDI-DrugBank.d34.s0.e1
anhydrase;I-group;I-DDI-DrugBank.d34.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d34.s0.e1
and;O;O
have;O;O
,;O;O
in;O;O
some;O;O
instances;O;O
,;O;O
resulted;O;O
in;O;O
drug;O;O
interactions;O;O
(;O;O
e.g.;O;O
,;O;O
toxicity;O;O
associated;O;O
with;O;O
high;O;O
-;O;O
dose;O;O
salicylate;B-group;B-DDI-DrugBank.d34.s0.e2
therapy;O;O
);O;O
.;O;O
DDI-DrugBank.d34.s1;;
Therefore;O;O
,;O;O
the;O;O
potential;O;O
for;O;O
such;O;O
drug;O;O
interactions;O;O
should;O;O
be;O;O
considered;O;O
in;O;O
patients;O;O
receiving;O;O
dorzolamide;B-drug;B-DDI-DrugBank.d34.s1.e0
.;O;O
DDI-DrugBank.d267.s0;;
Prior;O;O
administration;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d267.s0.e0
has;O;O
no;O;O
clinically;O;O
important;O;O
effect;O;O
on;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
NUROMAX;B-brand;B-DDI-DrugBank.d267.s0.e1
.;O;O
DDI-DrugBank.d267.s1;;
The;O;O
use;O;O
of;O;O
NUROMAX;B-brand;B-DDI-DrugBank.d267.s1.e0
before;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d267.s1.e1
to;O;O
attenuate;O;O
some;O;O
of;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d267.s1.e2
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d267.s2;;
There;O;O
are;O;O
no;O;O
clinical;O;O
data;O;O
on;O;O
concomitant;O;O
use;O;O
of;O;O
NUROMAX;B-brand;B-DDI-DrugBank.d267.s2.e0
and;O;O
other;O;O
nondepolarizing;O;O
neuromuscular;B-group;B-DDI-DrugBank.d267.s2.e1
blocking;I-group;I-DDI-DrugBank.d267.s2.e1
agents;I-group;I-DDI-DrugBank.d267.s2.e1
.;O;O
DDI-DrugBank.d267.s3;;
Isoflurane;B-drug;B-DDI-DrugBank.d267.s3.e0
,;O;O
enflurane;B-drug;B-DDI-DrugBank.d267.s3.e1
,;O;O
and;O;O
halothane;B-drug;B-DDI-DrugBank.d267.s3.e2
decrease;O;O
the;O;O
ED50;O;O
of;O;O
NUROMAX;B-brand;B-DDI-DrugBank.d267.s3.e3
by;O;O
30;O;O
%;O;O
to;O;O
45;O;O
%;O;O
.;O;O
DDI-DrugBank.d267.s4;;
These;O;O
agents;O;O
may;O;O
also;O;O
prolong;O;O
the;O;O
clinically;O;O
effective;O;O
duration;O;O
of;O;O
action;O;O
by;O;O
up;O;O
to;O;O
25;O;O
%;O;O
.;O;O
DDI-DrugBank.d267.s5;;
Other;O;O
drugs;O;O
which;O;O
may;O;O
enhance;O;O
the;O;O
neuromuscular;O;O
blocking;O;O
action;O;O
of;O;O
nondepolarizing;O;O
agents;O;O
such;O;O
as;O;O
NUROMAX;B-brand;B-DDI-DrugBank.d267.s5.e0
include;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d267.s5.e1
(;O;O
e.;O;O
g.;O;O
,;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d267.s5.e2
,;O;O
tetracyclines;B-group;B-DDI-DrugBank.d267.s5.e3
,;O;O
bacitracin;B-group;B-DDI-DrugBank.d267.s5.e4
,;O;O
polymyxins;B-group;B-DDI-DrugBank.d267.s5.e5
,;O;O
lincomycin;B-drug;B-DDI-DrugBank.d267.s5.e6
,;O;O
clindamycin;B-drug;B-DDI-DrugBank.d267.s5.e7
,;O;O
colistin;B-drug;B-DDI-DrugBank.d267.s5.e8
,;O;O
and;O;O
sodium;B-drug;B-DDI-DrugBank.d267.s5.e9
colistimethate;I-drug;I-DDI-DrugBank.d267.s5.e9
);O;O
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d267.s5.e10
salts;O;O
,;O;O
lithium;B-drug;B-DDI-DrugBank.d267.s5.e11
,;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d267.s5.e12
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d267.s5.e13
,;O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d267.s5.e14
.;O;O
DDI-DrugBank.d267.s6;;
As;O;O
with;O;O
some;O;O
other;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d267.s6.e0
neuromuscular;I-group;I-DDI-DrugBank.d267.s6.e0
blocking;I-group;I-DDI-DrugBank.d267.s6.e0
agents;I-group;I-DDI-DrugBank.d267.s6.e0
,;O;O
the;O;O
time;O;O
of;O;O
onset;O;O
of;O;O
neuromuscular;O;O
block;O;O
induced;O;O
by;O;O
NUROMAX;B-brand;B-DDI-DrugBank.d267.s6.e1
is;O;O
lengthened;O;O
and;O;O
the;O;O
duration;O;O
of;O;O
block;O;O
is;O;O
shortened;O;O
in;O;O
patients;O;O
receiving;O;O
phenytoin;B-drug;B-DDI-DrugBank.d267.s6.e2
or;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d267.s6.e3
.;O;O
DDI-DrugBank.d332.s0;;
Administration;O;O
of;O;O
doxapram;B-drug;B-DDI-DrugBank.d332.s0.e0
to;O;O
patients;O;O
who;O;O
are;O;O
receiving;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d332.s0.e1
or;O;O
monoamine;B-group;B-DDI-DrugBank.d332.s0.e2
oxidase;I-group;I-DDI-DrugBank.d332.s0.e2
inhibiting;I-group;I-DDI-DrugBank.d332.s0.e2
drugs;I-group;I-DDI-DrugBank.d332.s0.e2
may;O;O
result;O;O
in;O;O
an;O;O
additive;O;O
pressor;O;O
effect;O;O
.;O;O
DDI-DrugBank.d332.s1;;
In;O;O
patients;O;O
who;O;O
have;O;O
received;O;O
muscle;B-group;B-DDI-DrugBank.d332.s1.e0
relaxants;I-group;I-DDI-DrugBank.d332.s1.e0
,;O;O
doxapram;B-drug;B-DDI-DrugBank.d332.s1.e1
may;O;O
temporarily;O;O
mask;O;O
the;O;O
residual;O;O
effects;O;O
of;O;O
muscle;B-group;B-DDI-DrugBank.d332.s1.e2
relaxant;I-group;I-DDI-DrugBank.d332.s1.e2
drugs;I-group;I-DDI-DrugBank.d332.s1.e2
.;O;O
DDI-DrugBank.d332.s2;;
In;O;O
patients;O;O
who;O;O
have;O;O
received;O;O
general;O;O
anesthesia;O;O
utilizing;O;O
a;O;O
volatile;O;O
agent;O;O
known;O;O
to;O;O
sensitize;O;O
the;O;O
myocardium;O;O
to;O;O
catecholamines;O;O
,;O;O
administration;O;O
of;O;O
doxapram;B-drug;B-DDI-DrugBank.d332.s2.e0
should;O;O
be;O;O
delayed;O;O
until;O;O
the;O;O
volatile;O;O
agent;O;O
has;O;O
been;O;O
excreted;O;O
in;O;O
order;O;O
to;O;O
lessen;O;O
the;O;O
potential;O;O
for;O;O
arrhythmias;O;O
,;O;O
including;O;O
ventricular;O;O
tachycardia;O;O
and;O;O
ventricular;O;O
fibrillation;O;O
.;O;O
DDI-DrugBank.d367.s0;;
Most;O;O
(;O;O
98;O;O
%;O;O
);O;O
of;O;O
plasma;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s0.e0
is;O;O
protein;O;O
bound;O;O
.;O;O
DDI-DrugBank.d367.s1;;
In;O;O
vitro;O;O
data;O;O
in;O;O
human;O;O
plasma;O;O
indicate;O;O
that;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s1.e0
mesylate;I-drug;I-DDI-DrugBank.d367.s1.e0
has;O;O
no;O;O
effect;O;O
on;O;O
protein;O;O
binding;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d367.s1.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d367.s1.e2
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d367.s1.e3
or;O;O
indomethacin;B-drug;B-DDI-DrugBank.d367.s1.e4
.;O;O
DDI-DrugBank.d367.s2;;
There;O;O
is;O;O
no;O;O
information;O;O
on;O;O
the;O;O
effect;O;O
of;O;O
other;O;O
highly;O;O
plasma;O;O
protein;O;O
bound;O;O
drugs;O;O
on;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s2.e0
binding;O;O
.;O;O
DDI-DrugBank.d367.s3;;
Doxazosin;B-drug;B-DDI-DrugBank.d367.s3.e0
mesylate;I-drug;I-DDI-DrugBank.d367.s3.e0
has;O;O
been;O;O
administered;O;O
without;O;O
any;O;O
evidence;O;O
of;O;O
an;O;O
adverse;O;O
drug;O;O
interaction;O;O
to;O;O
patients;O;O
receiving;O;O
thiazide;B-group;B-DDI-DrugBank.d367.s3.e1
diuretics;I-group;I-DDI-DrugBank.d367.s3.e1
,;O;O
beta;B-group;B-DDI-DrugBank.d367.s3.e2
-;I-group;I-DDI-DrugBank.d367.s3.e2
blocking;I-group;I-DDI-DrugBank.d367.s3.e2
agents;I-group;I-DDI-DrugBank.d367.s3.e2
,;O;O
and;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d367.s3.e3
anti;I-group;I-DDI-DrugBank.d367.s3.e3
-;I-group;I-DDI-DrugBank.d367.s3.e3
inflammatory;I-group;I-DDI-DrugBank.d367.s3.e3
drugs;I-group;I-DDI-DrugBank.d367.s3.e3
.;O;O
DDI-DrugBank.d367.s4;;
In;O;O
a;O;O
placebo;O;O
-;O;O
controlled;O;O
trial;O;O
in;O;O
normal;O;O
volunteers;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
a;O;O
single;O;O
1;O;O
mg;O;O
dose;O;O
of;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s4.e0
on;O;O
day;O;O
1;O;O
of;O;O
a;O;O
four;O;O
-;O;O
day;O;O
regimen;O;O
of;O;O
oral;O;O
cimetidine;B-drug;B-DDI-DrugBank.d367.s4.e1
(;O;O
400;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
resulted;O;O
in;O;O
a;O;O
10;O;O
%;O;O
increase;O;O
in;O;O
mean;O;O
AUC;O;O
of;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s4.e2
(;O;O
p=0.006;O;O
);O;O
,;O;O
and;O;O
a;O;O
slight;O;O
but;O;O
not;O;O
statistically;O;O
significant;O;O
increase;O;O
in;O;O
mean;O;O
Cmax;O;O
and;O;O
mean;O;O
half;O;O
-;O;O
life;O;O
of;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s4.e3
.;O;O
DDI-DrugBank.d367.s5;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
increase;O;O
in;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s5.e0
AUC;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d367.s6;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
doxazosin;B-drug;B-DDI-DrugBank.d367.s6.e0
mesylate;I-drug;I-DDI-DrugBank.d367.s6.e0
tablets;O;O
have;O;O
been;O;O
administered;O;O
to;O;O
patients;O;O
on;O;O
a;O;O
variety;O;O
of;O;O
concomitant;O;O
medications;O;O
,;O;O
DDI-DrugBank.d367.s7;;
while;O;O
no;O;O
formal;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
,;O;O
no;O;O
interactions;O;O
were;O;O
observed;O;O
.;O;O
DDI-DrugBank.d367.s8;;
Doxazosin;B-drug;B-DDI-DrugBank.d367.s8.e0
mesylate;I-drug;I-DDI-DrugBank.d367.s8.e0
tablets;O;O
have;O;O
been;O;O
used;O;O
with;O;O
the;O;O
following;O;O
drugs;O;O
or;O;O
drug;O;O
classes;O;O
:;O;O
1;O;O
.;O;O
DDI-DrugBank.d367.s9;;
Analgesic;B-group;B-DDI-DrugBank.d367.s9.e0
/;O;O
anti;B-group;B-DDI-DrugBank.d367.s9.e1
-;I-group;I-DDI-DrugBank.d367.s9.e1
inflammatory;I-group;I-DDI-DrugBank.d367.s9.e1
(;O;O
e.g.;O;O
,;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d367.s9.e2
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d367.s9.e3
,;O;O
codeine;B-drug;B-DDI-DrugBank.d367.s9.e4
and;O;O
codeine;B-drug;B-DDI-DrugBank.d367.s9.e5
combinations;O;O
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d367.s9.e6
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d367.s9.e7
);O;O
.;O;O
DDI-DrugBank.d367.s10;;
2;O;O
.;O;O
DDI-DrugBank.d367.s11;;
Antibiotics;B-group;B-DDI-DrugBank.d367.s11.e0
(;O;O
e.g.;O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d367.s11.e1
,;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d367.s11.e2
and;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d367.s11.e3
,;O;O
amoxicillin;B-drug;B-DDI-DrugBank.d367.s11.e4
);O;O
.;O;O
DDI-DrugBank.d367.s12;;
3;O;O
.;O;O
DDI-DrugBank.d367.s13;;
Antihistamines;B-group;B-DDI-DrugBank.d367.s13.e0
(;O;O
e.g.;O;O
,;O;O
chlorpheniramine;B-group;B-DDI-DrugBank.d367.s13.e1
);O;O
.;O;O
DDI-DrugBank.d367.s14;;
4;O;O
.;O;O
DDI-DrugBank.d367.s15;;
Cardiovascular;O;O
agents;O;O
(;O;O
e.g.;O;O
,;O;O
atenolol;B-drug;B-DDI-DrugBank.d367.s15.e0
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d367.s15.e1
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d367.s15.e2
);O;O
.;O;O
DDI-DrugBank.d367.s16;;
5;O;O
.;O;O
DDI-DrugBank.d367.s17;;
Corticosteroids;B-group;B-DDI-DrugBank.d367.s17.e0
.;O;O
DDI-DrugBank.d367.s18;;
6;O;O
.;O;O
DDI-DrugBank.d367.s19;;
Gastrointestinal;O;O
agents;O;O
(;O;O
e.g.;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d367.s19.e0
);O;O
.;O;O
DDI-DrugBank.d367.s20;;
7;O;O
.;O;O
DDI-DrugBank.d367.s21;;
Hypoglycemics;B-group;B-DDI-DrugBank.d367.s21.e0
and;O;O
endocrine;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d367.s22;;
8;O;O
.;O;O
DDI-DrugBank.d367.s23;;
Sedatives;B-group;B-DDI-DrugBank.d367.s23.e0
and;O;O
tranquilizers;B-group;B-DDI-DrugBank.d367.s23.e1
(;O;O
e.g.;O;O
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d367.s23.e2
);O;O
.;O;O
DDI-DrugBank.d367.s24;;
9;O;O
.;O;O
DDI-DrugBank.d367.s25;;
Cold;O;O
and;O;O
flu;O;O
remedies;O;O
.;O;O
DDI-DrugBank.d223.s0;;
Drugs;O;O
Metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
:;O;O
The;O;O
biochemical;O;O
activity;O;O
of;O;O
the;O;O
drug;O;O
metabolizing;O;O
isozyme;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
(;O;O
debrisoquin;O;O
hydroxylase;O;O
);O;O
is;O;O
reduced;O;O
in;O;O
a;O;O
subset;O;O
of;O;O
the;O;O
Caucasian;O;O
population;O;O
(;O;O
about;O;O
7;O;O
-;O;O
10;O;O
%;O;O
of;O;O
Caucasians;O;O
are;O;O
so;O;O
-;O;O
called;O;O
poor;O;O
metabolizers;O;O
);O;O
,;O;O
DDI-DrugBank.d223.s1;;
reliable;O;O
estimates;O;O
of;O;O
the;O;O
prevalence;O;O
of;O;O
reduced;O;O
P450;O;O
2D6;O;O
isozyme;O;O
activity;O;O
among;O;O
Asian;O;O
,;O;O
African;O;O
and;O;O
other;O;O
populations;O;O
are;O;O
not;O;O
yet;O;O
available;O;O
.;O;O
DDI-DrugBank.d223.s2;;
Poor;O;O
metabolizers;O;O
have;O;O
higher;O;O
than;O;O
expected;O;O
plasma;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s2.e0
antidepressants;I-group;I-DDI-DrugBank.d223.s2.e0
(;O;O
TCAs;B-group;B-DDI-DrugBank.d223.s2.e1
);O;O
when;O;O
given;O;O
usual;O;O
doses;O;O
.;O;O
DDI-DrugBank.d223.s3;;
Depending;O;O
on;O;O
the;O;O
fraction;O;O
of;O;O
drug;O;O
metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
,;O;O
the;O;O
increase;O;O
in;O;O
plasma;O;O
concentration;O;O
may;O;O
be;O;O
small;O;O
,;O;O
or;O;O
quite;O;O
large;O;O
(;O;O
8;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
plasma;O;O
AUC;O;O
of;O;O
the;O;O
TCA;O;O
);O;O
.;O;O
DDI-DrugBank.d223.s4;;
In;O;O
addition;O;O
,;O;O
certain;O;O
drugs;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
this;O;O
isozyme;O;O
and;O;O
make;O;O
normal;O;O
metabolizers;O;O
resemble;O;O
poor;O;O
metabolizers;O;O
.;O;O
DDI-DrugBank.d223.s5;;
An;O;O
individual;O;O
who;O;O
is;O;O
stable;O;O
on;O;O
a;O;O
given;O;O
dose;O;O
of;O;O
TCA;B-group;B-DDI-DrugBank.d223.s5.e0
may;O;O
become;O;O
abruptly;O;O
toxic;O;O
when;O;O
given;O;O
one;O;O
of;O;O
these;O;O
inhibiting;O;O
drugs;O;O
as;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d223.s6;;
The;O;O
drugs;O;O
that;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
include;O;O
some;O;O
that;O;O
are;O;O
not;O;O
metabolized;O;O
by;O;O
the;O;O
enzyme;O;O
(;O;O
quinidine;B-drug;B-DDI-DrugBank.d223.s6.e0
,;O;O
DDI-DrugBank.d223.s7;;
cimetidine;B-drug;B-DDI-DrugBank.d223.s7.e0
);O;O
and;O;O
many;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
P450;O;O
2D6;O;O
(;O;O
many;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d223.s7.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d223.s7.e2
,;O;O
and;O;O
the;O;O
Type;B-group;B-DDI-DrugBank.d223.s7.e3
1C;I-group;I-DDI-DrugBank.d223.s7.e3
antiarrhythmics;I-group;I-DDI-DrugBank.d223.s7.e3
propafenone;I-drug;I-DDI-DrugBank.d223.s7.e4
and;O;O
flecainide;B-drug;B-DDI-DrugBank.d223.s7.e5
);O;O
.;O;O
DDI-DrugBank.d223.s8;;
While;O;O
all;O;O
the;O;O
selective;B-group;B-DDI-DrugBank.d223.s8.e0
serotonin;I-group;I-DDI-DrugBank.d223.s8.e0
reuptake;I-group;I-DDI-DrugBank.d223.s8.e0
inhibitors;I-group;I-DDI-DrugBank.d223.s8.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d223.s8.e1
);O;O
,;O;O
e.g.;O;O
,;O;O
citalopram;B-drug;B-DDI-DrugBank.d223.s8.e2
,;O;O
escitalopram;B-drug;B-DDI-DrugBank.d223.s8.e3
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d223.s8.e4
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d223.s8.e5
,;O;O
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d223.s8.e6
,;O;O
inhibit;O;O
P450;O;O
2D6;O;O
,;O;O
they;O;O
may;O;O
vary;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d223.s9;;
The;O;O
extent;O;O
to;O;O
which;O;O
SSRI;B-group;B-DDI-DrugBank.d223.s9.e0
-;O;O
TCA;B-group;B-DDI-DrugBank.d223.s9.e1
interactions;O;O
may;O;O
pose;O;O
clinical;O;O
problems;O;O
will;O;O
depend;O;O
on;O;O
the;O;O
degree;O;O
of;O;O
inhibition;O;O
and;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
the;O;O
SSRI;B-group;B-DDI-DrugBank.d223.s9.e2
involved;O;O
.;O;O
DDI-DrugBank.d223.s10;;
Nevertheless;O;O
,;O;O
caution;O;O
is;O;O
indicated;O;O
in;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
TCAs;B-group;B-DDI-DrugBank.d223.s10.e0
with;O;O
any;O;O
of;O;O
the;O;O
SSRIs;B-group;B-DDI-DrugBank.d223.s10.e1
and;O;O
also;O;O
in;O;O
switching;O;O
from;O;O
one;O;O
class;O;O
to;O;O
the;O;O
other;O;O
.;O;O
DDI-DrugBank.d223.s11;;
Of;O;O
particular;O;O
importance;O;O
,;O;O
sufficient;O;O
time;O;O
must;O;O
elapse;O;O
before;O;O
initiating;O;O
TCA;O;O
treatment;O;O
in;O;O
a;O;O
patient;O;O
being;O;O
withdrawn;O;O
from;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d223.s11.e0
,;O;O
given;O;O
the;O;O
long;O;O
half;O;O
-;O;O
life;O;O
of;O;O
the;O;O
parent;O;O
and;O;O
active;O;O
metabolite;O;O
(;O;O
at;O;O
least;O;O
5;O;O
weeks;O;O
may;O;O
be;O;O
necessary;O;O
);O;O
.;O;O
DDI-DrugBank.d223.s12;;
Concomitant;O;O
use;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s12.e0
antidepressants;I-group;I-DDI-DrugBank.d223.s12.e0
with;O;O
drugs;O;O
that;O;O
can;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
may;O;O
require;O;O
lower;O;O
doses;O;O
than;O;O
usually;O;O
prescribed;O;O
for;O;O
either;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s12.e1
antidepressant;I-group;I-DDI-DrugBank.d223.s12.e1
or;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d223.s13;;
Furthermore;O;O
,;O;O
whenever;O;O
one;O;O
of;O;O
these;O;O
other;O;O
drugs;O;O
is;O;O
withdrawn;O;O
from;O;O
co;O;O
-;O;O
therapy;O;O
,;O;O
an;O;O
increased;O;O
dose;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s13.e0
antidepressant;I-group;I-DDI-DrugBank.d223.s13.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d223.s14;;
It;O;O
is;O;O
desirable;O;O
to;O;O
monitor;O;O
TCA;B-group;B-DDI-DrugBank.d223.s14.e0
plasma;O;O
levels;O;O
whenever;O;O
a;O;O
TCA;B-group;B-DDI-DrugBank.d223.s14.e1
is;O;O
going;O;O
to;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
another;O;O
drug;O;O
known;O;O
to;O;O
be;O;O
an;O;O
inhibitor;O;O
of;O;O
P450;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d223.s15;;
Doxepin;B-drug;B-DDI-DrugBank.d223.s15.e0
is;O;O
primarily;O;O
metabolized;O;O
by;O;O
CYP2D6;O;O
(;O;O
with;O;O
CYP1A2;O;O
and;O;O
CYP3A4;O;O
as;O;O
minor;O;O
pathways;O;O
);O;O
.;O;O
DDI-DrugBank.d223.s16;;
Inhibitors;O;O
or;O;O
substrates;O;O
of;O;O
CYP2D6;O;O
(;O;O
i.e.;O;O
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d223.s16.e0
,;O;O
selective;B-group;B-DDI-DrugBank.d223.s16.e1
serotonin;I-group;I-DDI-DrugBank.d223.s16.e1
reuptake;I-group;I-DDI-DrugBank.d223.s16.e1
inhibitors;I-group;I-DDI-DrugBank.d223.s16.e1
[;O;O
SSRIs;B-group;B-DDI-DrugBank.d223.s16.e2
];O;O
);O;O
may;O;O
increase;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
doxepin;B-drug;B-DDI-DrugBank.d223.s16.e3
when;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d223.s17;;
The;O;O
extent;O;O
of;O;O
interaction;O;O
depends;O;O
on;O;O
the;O;O
variability;O;O
of;O;O
effect;O;O
on;O;O
CYP2D6;O;O
.;O;O
DDI-DrugBank.d223.s18;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
interaction;O;O
with;O;O
doxepin;B-drug;B-DDI-DrugBank.d223.s18.e0
has;O;O
not;O;O
been;O;O
systematically;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d223.s19;;
MAO;B-group;B-DDI-DrugBank.d223.s19.e0
Inhibitors;I-group;I-DDI-DrugBank.d223.s19.e0
:;O;O
Serious;O;O
side;O;O
effects;O;O
and;O;O
even;O;O
death;O;O
have;O;O
been;O;O
reported;O;O
following;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
certain;O;O
drugs;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d223.s19.e1
inhibitors;I-group;I-DDI-DrugBank.d223.s19.e1
.;O;O
DDI-DrugBank.d223.s20;;
Therefore;O;O
,;O;O
MAO;B-group;B-DDI-DrugBank.d223.s20.e0
inhibitors;I-group;I-DDI-DrugBank.d223.s20.e0
should;O;O
be;O;O
discontinued;O;O
at;O;O
least;O;O
two;O;O
weeks;O;O
prior;O;O
to;O;O
the;O;O
cautious;O;O
initiation;O;O
of;O;O
therapy;O;O
with;O;O
SINEQUAN;B-brand;B-DDI-DrugBank.d223.s20.e1
.;O;O
DDI-DrugBank.d223.s21;;
The;O;O
exact;O;O
length;O;O
of;O;O
time;O;O
may;O;O
vary;O;O
and;O;O
is;O;O
dependent;O;O
upon;O;O
the;O;O
particular;O;O
MAO;B-group;B-DDI-DrugBank.d223.s21.e0
inhibitor;I-group;I-DDI-DrugBank.d223.s21.e0
being;O;O
used;O;O
,;O;O
the;O;O
length;O;O
of;O;O
time;O;O
it;O;O
has;O;O
been;O;O
administered;O;O
,;O;O
and;O;O
the;O;O
dosage;O;O
involved;O;O
.;O;O
DDI-DrugBank.d223.s22;;
Cimetidine;B-drug;B-DDI-DrugBank.d223.s22.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d223.s22.e1
has;O;O
been;O;O
reported;O;O
to;O;O
produce;O;O
clinically;O;O
significant;O;O
fluctuations;O;O
in;O;O
steady;O;O
-;O;O
state;O;O
serum;O;O
concentrations;O;O
of;O;O
various;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s22.e2
antidepressants;I-group;I-DDI-DrugBank.d223.s22.e2
.;O;O
DDI-DrugBank.d223.s23;;
Serious;O;O
anticholinergic;O;O
symptoms;O;O
(;O;O
i.e.;O;O
,;O;O
severe;O;O
dry;O;O
mouth;O;O
,;O;O
urinary;O;O
retention;O;O
and;O;O
blurred;O;O
vision;O;O
);O;O
have;O;O
been;O;O
associated;O;O
with;O;O
elevations;O;O
in;O;O
the;O;O
serum;O;O
levels;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s23.e0
antidepressant;I-group;I-DDI-DrugBank.d223.s23.e0
when;O;O
cimetidine;B-drug;B-DDI-DrugBank.d223.s23.e1
therapy;O;O
is;O;O
initiated;O;O
.;O;O
DDI-DrugBank.d223.s24;;
Additionally;O;O
,;O;O
higher;O;O
than;O;O
expected;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s24.e0
antidepressant;I-group;I-DDI-DrugBank.d223.s24.e0
levels;O;O
have;O;O
been;O;O
observed;O;O
when;O;O
they;O;O
are;O;O
begun;O;O
in;O;O
patients;O;O
already;O;O
taking;O;O
cimetidine;B-drug;B-DDI-DrugBank.d223.s24.e1
.;O;O
DDI-DrugBank.d223.s25;;
In;O;O
patients;O;O
who;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
be;O;O
well;O;O
controlled;O;O
on;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s25.e0
antidepressants;I-group;I-DDI-DrugBank.d223.s25.e0
receiving;O;O
concurrent;O;O
cimetidine;B-drug;B-DDI-DrugBank.d223.s25.e1
therapy;O;O
,;O;O
discontinuation;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d223.s25.e2
has;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
established;O;O
steady;O;O
-;O;O
state;O;O
serum;O;O
tricyclic;B-group;B-DDI-DrugBank.d223.s25.e3
antidepressant;I-group;I-DDI-DrugBank.d223.s25.e3
levels;O;O
and;O;O
compromise;O;O
their;O;O
therapeutic;O;O
effects;O;O
.;O;O
DDI-DrugBank.d223.s26;;
Alcohol;B-drug;B-DDI-DrugBank.d223.s26.e0
:;O;O
It;O;O
should;O;O
be;O;O
borne;O;O
in;O;O
mind;O;O
that;O;O
alcohol;B-drug;B-DDI-DrugBank.d223.s26.e1
ingestion;O;O
may;O;O
increase;O;O
the;O;O
danger;O;O
inherent;O;O
in;O;O
any;O;O
intentional;O;O
or;O;O
unintentional;O;O
SINEQUAN;B-brand;B-DDI-DrugBank.d223.s26.e2
overdosage;O;O
.;O;O
DDI-DrugBank.d223.s27;;
This;O;O
is;O;O
especially;O;O
important;O;O
in;O;O
patients;O;O
who;O;O
may;O;O
use;O;O
alcohol;B-drug;B-DDI-DrugBank.d223.s27.e0
excessively;O;O
.;O;O
DDI-DrugBank.d223.s28;;
Tolazamide;B-drug;B-DDI-DrugBank.d223.s28.e0
:;O;O
A;O;O
case;O;O
of;O;O
severe;O;O
hypoglycemia;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
a;O;O
type;O;O
II;O;O
diabetic;O;O
patient;O;O
maintained;O;O
on;O;O
tolazamide;B-drug;B-DDI-DrugBank.d223.s28.e1
(;O;O
1;O;O
gm;O;O
/;O;O
day;O;O
);O;O
11;O;O
days;O;O
after;O;O
the;O;O
addition;O;O
of;O;O
doxepin;B-drug;B-DDI-DrugBank.d223.s28.e2
(;O;O
75;O;O
mg;O;O
/;O;O
day;O;O
);O;O
.;O;O
DDI-DrugBank.d127.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
DOXIL;B-brand;B-DDI-DrugBank.d127.s0.e0
.;O;O
DDI-DrugBank.d127.s1;;
Until;O;O
specific;O;O
compatibility;O;O
data;O;O
are;O;O
available;O;O
,;O;O
it;O;O
is;O;O
not;O;O
recommended;O;O
that;O;O
DOXIL;B-brand;B-DDI-DrugBank.d127.s1.e0
be;O;O
mixed;O;O
with;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d127.s2;;
DOXIL;B-brand;B-DDI-DrugBank.d127.s2.e0
may;O;O
interact;O;O
with;O;O
drugs;O;O
known;O;O
to;O;O
interact;O;O
with;O;O
the;O;O
conventional;O;O
formulation;O;O
of;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d127.s2.e1
HCl;I-drug;I-DDI-DrugBank.d127.s2.e1
.;O;O
DDI-DrugBank.d500.s0;;
Because;O;O
tetracyclines;B-group;B-DDI-DrugBank.d500.s0.e0
have;O;O
been;O;O
shown;O;O
to;O;O
depress;O;O
plasma;O;O
prothrombin;O;O
activity;O;O
,;O;O
patients;O;O
who;O;O
are;O;O
on;O;O
anticoagulant;B-group;B-DDI-DrugBank.d500.s0.e1
therapy;O;O
may;O;O
require;O;O
downward;O;O
adjustment;O;O
of;O;O
their;O;O
anticoagulant;B-group;B-DDI-DrugBank.d500.s0.e2
dosage;O;O
.;O;O
DDI-DrugBank.d500.s1;;
Since;O;O
bacteriostatic;O;O
drugs;O;O
may;O;O
interfere;O;O
with;O;O
the;O;O
bactericidal;O;O
action;O;O
of;O;O
penicillin;B-drug;B-DDI-DrugBank.d500.s1.e0
,;O;O
it;O;O
is;O;O
advisable;O;O
to;O;O
avoid;O;O
giving;O;O
tetracyclines;B-group;B-DDI-DrugBank.d500.s1.e1
in;O;O
conjunction;O;O
with;O;O
penicillin;B-group;B-DDI-DrugBank.d500.s1.e2
.;O;O
DDI-DrugBank.d500.s2;;
Absorption;O;O
of;O;O
tetracyclines;B-group;B-DDI-DrugBank.d500.s2.e0
is;O;O
impaired;O;O
by;O;O
antacids;B-group;B-DDI-DrugBank.d500.s2.e1
containing;O;O
aluminum;B-drug;B-DDI-DrugBank.d500.s2.e2
,;O;O
calcium;B-drug;B-DDI-DrugBank.d500.s2.e3
,;O;O
or;O;O
magnesium;B-drug;B-DDI-DrugBank.d500.s2.e4
,;O;O
and;O;O
iron;B-drug;B-DDI-DrugBank.d500.s2.e5
-;O;O
containing;O;O
preparations;O;O
.;O;O
DDI-DrugBank.d500.s3;;
Absorption;O;O
of;O;O
tetracycline;B-drug;B-DDI-DrugBank.d500.s3.e0
is;O;O
impaired;O;O
by;O;O
bismuth;B-drug;B-DDI-DrugBank.d500.s3.e1
subsalicylate;I-drug;I-DDI-DrugBank.d500.s3.e1
.;O;O
DDI-DrugBank.d500.s4;;
Barbiturates;B-group;B-DDI-DrugBank.d500.s4.e0
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d500.s4.e1
,;O;O
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d500.s4.e2
decrease;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
doxycycline;B-drug;B-DDI-DrugBank.d500.s4.e3
.;O;O
DDI-DrugBank.d500.s5;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
tetracycline;B-drug;B-DDI-DrugBank.d500.s5.e0
and;O;O
Penthrane;B-brand;B-DDI-DrugBank.d500.s5.e1
(;O;O
methoxyflurane;B-drug;B-DDI-DrugBank.d500.s5.e2
);O;O
has;O;O
been;O;O
reported;O;O
to;O;O
result;O;O
in;O;O
fatal;O;O
renal;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d500.s6;;
Concurrent;O;O
use;O;O
of;O;O
tetracycline;B-drug;B-DDI-DrugBank.d500.s6.e0
may;O;O
render;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d500.s6.e1
less;O;O
effective;O;O
.;O;O
DDI-DrugBank.d500.s7;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
False;O;O
elevations;O;O
of;O;O
urinary;O;O
catecholamine;O;O
levels;O;O
may;O;O
occur;O;O
due;O;O
to;O;O
interference;O;O
with;O;O
the;O;O
fluorescence;O;O
test;O;O
.;O;O
DDI-DrugBank.d387.s0;;
Potential;O;O
drug;O;O
interactions;O;O
for;O;O
doxylamine;B-drug;B-DDI-DrugBank.d387.s0.e0
include;O;O
,;O;O
increased;O;O
sedation;O;O
if;O;O
doxylamine;B-drug;B-DDI-DrugBank.d387.s0.e1
is;O;O
combined;O;O
with;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d387.s0.e2
depressant;I-group;I-DDI-DrugBank.d387.s0.e2
drugs;I-group;I-DDI-DrugBank.d387.s0.e2
.;O;O
DDI-DrugBank.d387.s1;;
Antihistamines;B-group;B-DDI-DrugBank.d387.s1.e0
may;O;O
partially;O;O
counteract;O;O
the;O;O
anticoagulation;O;O
effects;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d387.s1.e1
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d387.s1.e2
.;O;O
DDI-DrugBank.d387.s2;;
Doxylamine;B-drug;B-DDI-DrugBank.d387.s2.e0
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d387.s2.e1
.;O;O
DDI-DrugBank.d129.s0;;
Androgens;B-group;B-DDI-DrugBank.d129.s0.e0
may;O;O
increase;O;O
sensitivity;O;O
to;O;O
oral;O;O
anticoagulahts;O;O
.;O;O
DDI-DrugBank.d129.s1;;
Dosage;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d129.s1.e0
may;O;O
require;O;O
reduction;O;O
in;O;O
order;O;O
to;O;O
maintain;O;O
satisfactory;O;O
therapeutic;O;O
hypoprothrombinemia;O;O
.;O;O
DDI-DrugBank.d129.s2;;
Concurrent;O;O
administration;O;O
of;O;O
oxyphenbutazone;B-drug;B-DDI-DrugBank.d129.s2.e0
and;O;O
androgens;B-group;B-DDI-DrugBank.d129.s2.e1
may;O;O
result;O;O
in;O;O
elevated;O;O
serum;O;O
levels;O;O
of;O;O
oxyphenbutazone;B-drug;B-DDI-DrugBank.d129.s2.e2
.;O;O
DDI-DrugBank.d129.s3;;
In;O;O
diabetic;O;O
patients;O;O
,;O;O
the;O;O
metabolic;O;O
effects;O;O
of;O;O
androgens;B-group;B-DDI-DrugBank.d129.s3.e0
may;O;O
decrease;O;O
blood;O;O
glucose;O;O
and;O;O
therefore;O;O
,;O;O
insulin;B-drug;B-DDI-DrugBank.d129.s3.e1
requirements;O;O
.;O;O
DDI-DrugBank.d254.s0;;
Other;O;O
CNS;B-group;B-DDI-DrugBank.d254.s0.e0
depressant;I-group;I-DDI-DrugBank.d254.s0.e0
drugs;I-group;I-DDI-DrugBank.d254.s0.e0
(;O;O
e.g.;O;O
barbiturates;B-group;B-DDI-DrugBank.d254.s0.e1
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d254.s0.e2
,;O;O
opioids;B-group;B-DDI-DrugBank.d254.s0.e3
and;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d254.s0.e4
);O;O
have;O;O
additive;O;O
or;O;O
potentiating;O;O
effects;O;O
with;O;O
INAPSINE;B-brand;B-DDI-DrugBank.d254.s0.e5
.;O;O
DDI-DrugBank.d254.s1;;
When;O;O
patients;O;O
have;O;O
received;O;O
such;O;O
drugs;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
INAPSINE;B-brand;B-DDI-DrugBank.d254.s1.e0
required;O;O
will;O;O
be;O;O
less;O;O
than;O;O
usual;O;O
.;O;O
DDI-DrugBank.d254.s2;;
Following;O;O
the;O;O
administration;O;O
of;O;O
INAPSINE;B-brand;B-DDI-DrugBank.d254.s2.e0
,;O;O
the;O;O
dose;O;O
of;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d254.s2.e1
depressant;I-group;I-DDI-DrugBank.d254.s2.e1
drugs;I-group;I-DDI-DrugBank.d254.s2.e1
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d190.s0;;
Drug;O;O
interaction;O;O
studies;O;O
with;O;O
Xigris;B-brand;B-DDI-DrugBank.d190.s0.e0
have;O;O
not;O;O
been;O;O
performed;O;O
in;O;O
patients;O;O
with;O;O
severe;O;O
sepsis;O;O
.;O;O
DDI-DrugBank.d190.s1;;
However;O;O
,;O;O
since;O;O
there;O;O
is;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
with;O;O
Xigris;B-brand;B-DDI-DrugBank.d190.s1.e0
,;O;O
caution;O;O
should;O;O
be;O;O
employed;O;O
when;O;O
Xigris;B-brand;B-DDI-DrugBank.d190.s1.e1
is;O;O
used;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
affect;O;O
hemostasis;O;O
.;O;O
DDI-DrugBank.d190.s2;;
Approximately;O;O
2;O;O
/;O;O
3;O;O
of;O;O
the;O;O
patients;O;O
in;O;O
the;O;O
Phase;O;O
3;O;O
study;O;O
received;O;O
either;O;O
prophylactic;O;O
low;O;O
dose;O;O
heparin;B-drug;B-DDI-DrugBank.d190.s2.e0
(;O;O
unfractionated;B-drug;B-DDI-DrugBank.d190.s2.e1
heparin;I-drug;I-DDI-DrugBank.d190.s2.e1
up;O;O
to;O;O
15,000;O;O
units;O;O
/;O;O
day;O;O
);O;O
or;O;O
prophylactic;O;O
doses;O;O
of;O;O
low;B-group;B-DDI-DrugBank.d190.s2.e2
molecular;I-group;I-DDI-DrugBank.d190.s2.e2
weight;I-group;I-DDI-DrugBank.d190.s2.e2
heparins;I-group;I-DDI-DrugBank.d190.s2.e2
as;O;O
indicated;O;O
in;O;O
the;O;O
prescribing;O;O
information;O;O
for;O;O
the;O;O
specific;O;O
products;O;O
.;O;O
DDI-DrugBank.d190.s3;;
Concomitant;O;O
use;O;O
of;O;O
prophylactic;O;O
low;O;O
dose;O;O
heparin;B-drug;B-DDI-DrugBank.d190.s3.e0
did;O;O
not;O;O
appear;O;O
to;O;O
affect;O;O
safety;O;O
,;O;O
however;O;O
,;O;O
its;O;O
effects;O;O
on;O;O
the;O;O
efficacy;O;O
of;O;O
Xigris;B-brand;B-DDI-DrugBank.d190.s3.e1
have;O;O
not;O;O
been;O;O
evaluated;O;O
in;O;O
an;O;O
adequate;O;O
and;O;O
well;O;O
-;O;O
controlled;O;O
clinical;O;O
trial;O;O
.;O;O
DDI-DrugBank.d190.s4;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interaction;O;O
Because;O;O
Xigris;B-brand;B-DDI-DrugBank.d190.s4.e0
may;O;O
affect;O;O
the;O;O
APTT;O;O
assay;O;O
,;O;O
Xigris;B-brand;B-DDI-DrugBank.d190.s4.e1
present;O;O
in;O;O
plasma;O;O
samples;O;O
may;O;O
interfere;O;O
with;O;O
one;O;O
-;O;O
stage;O;O
coagulation;O;O
assays;O;O
based;O;O
on;O;O
the;O;O
APTT;O;O
(;O;O
such;O;O
as;O;O
factor;O;O
VIII;O;O
,;O;O
IX;O;O
,;O;O
and;O;O
XI;O;O
assays;O;O
);O;O
.;O;O
DDI-DrugBank.d190.s5;;
This;O;O
interference;O;O
may;O;O
result;O;O
in;O;O
an;O;O
apparent;O;O
factor;O;O
concentration;O;O
that;O;O
is;O;O
lower;O;O
than;O;O
the;O;O
true;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d190.s6;;
Xigris;B-brand;B-DDI-DrugBank.d190.s6.e0
present;O;O
in;O;O
plasma;O;O
samples;O;O
does;O;O
not;O;O
interfere;O;O
with;O;O
one;O;O
-;O;O
stage;O;O
factor;O;O
assays;O;O
based;O;O
on;O;O
the;O;O
PT;O;O
(;O;O
such;O;O
as;O;O
factor;O;O
II;O;O
,;O;O
V;O;O
,;O;O
VII;O;O
,;O;O
and;O;O
X;O;O
assays;O;O
);O;O
.;O;O
DDI-DrugBank.d548.s0;;
Potential;O;O
for;O;O
Other;O;O
Drugs;O;O
to;O;O
Affect;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s0.e0
:;O;O
Both;O;O
CYP1A2;O;O
and;O;O
CYP2D6;O;O
are;O;O
responsible;O;O
for;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s0.e1
metabolism;O;O
.;O;O
DDI-DrugBank.d548.s1;;
Inhibitors;O;O
of;O;O
CYP1A2;O;O
:;O;O
Concomitant;O;O
use;O;O
of;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s1.e0
with;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d548.s1.e1
,;O;O
an;O;O
inhibitor;O;O
of;O;O
CYP1A2;O;O
,;O;O
results;O;O
in;O;O
approximately;O;O
a;O;O
6;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
AUC;O;O
and;O;O
about;O;O
a;O;O
2.5;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
Cmax;O;O
of;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s1.e2
.;O;O
DDI-DrugBank.d548.s2;;
Some;O;O
quinolone;B-group;B-DDI-DrugBank.d548.s2.e0
antibiotics;I-group;I-DDI-DrugBank.d548.s2.e0
would;O;O
be;O;O
expected;O;O
to;O;O
have;O;O
similar;O;O
effects;O;O
and;O;O
these;O;O
combinations;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d548.s3;;
Inhibitors;O;O
of;O;O
CYP2D6;O;O
:;O;O
Because;O;O
CYP2D6;O;O
is;O;O
involved;O;O
in;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s3.e0
metabolism;O;O
,;O;O
concomitant;O;O
use;O;O
of;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s3.e1
with;O;O
potent;O;O
inhibitors;O;O
of;O;O
CYP2D6;O;O
may;O;O
result;O;O
in;O;O
higher;O;O
concentrations;O;O
of;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s3.e2
.;O;O
DDI-DrugBank.d548.s4;;
Paroxetine;B-drug;B-DDI-DrugBank.d548.s4.e0
(;O;O
20;O;O
mg;O;O
QD;O;O
);O;O
increased;O;O
the;O;O
concentration;O;O
of;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s4.e1
(;O;O
40;O;O
mg;O;O
QD;O;O
);O;O
by;O;O
about;O;O
60;O;O
%;O;O
,;O;O
and;O;O
greater;O;O
degrees;O;O
of;O;O
inhibition;O;O
are;O;O
expected;O;O
with;O;O
higher;O;O
doses;O;O
of;O;O
paroxetine;B-drug;B-DDI-DrugBank.d548.s4.e2
.;O;O
DDI-DrugBank.d548.s5;;
Similar;O;O
effects;O;O
would;O;O
be;O;O
expected;O;O
with;O;O
other;O;O
potent;O;O
CYP2D6;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d548.s5.e0
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d548.s5.e1
);O;O
.;O;O
DDI-DrugBank.d548.s6;;
Potential;O;O
for;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s6.e0
to;O;O
Affect;O;O
Other;O;O
Drugs;O;O
:;O;O
Drugs;O;O
Metabolized;O;O
by;O;O
CYP1A2;O;O
:;O;O
In;O;O
vitro;O;O
drug;O;O
interaction;O;O
studies;O;O
demonstrate;O;O
that;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s6.e1
does;O;O
not;O;O
induce;O;O
CYP1A2;O;O
activity;O;O
,;O;O
and;O;O
it;O;O
is;O;O
unlikely;O;O
to;O;O
have;O;O
a;O;O
clinically;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
metabolism;O;O
of;O;O
CYP1A2;O;O
substrates;O;O
.;O;O
DDI-DrugBank.d548.s7;;
Drugs;O;O
Metabolized;O;O
by;O;O
CYP2D6;O;O
:;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s7.e0
is;O;O
a;O;O
moderate;O;O
inhibitor;O;O
of;O;O
CYP2D6;O;O
.;O;O
DDI-DrugBank.d548.s8;;
When;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s8.e0
was;O;O
administered;O;O
(;O;O
at;O;O
a;O;O
dose;O;O
of;O;O
60;O;O
mg;O;O
BID;O;O
);O;O
in;O;O
conjunction;O;O
with;O;O
a;O;O
single;O;O
50;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
desipramine;B-drug;B-DDI-DrugBank.d548.s8.e1
,;O;O
a;O;O
CYP2D6;O;O
substrate;O;O
,;O;O
the;O;O
AUC;O;O
of;O;O
desipramine;B-drug;B-DDI-DrugBank.d548.s8.e2
increased;O;O
3;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d548.s9;;
Therefore;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s9.e0
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
extensively;O;O
metabolized;O;O
by;O;O
this;O;O
isozyme;O;O
and;O;O
which;O;O
have;O;O
a;O;O
narrow;O;O
therapeutic;O;O
index;O;O
,;O;O
including;O;O
certain;O;O
antidepressants;B-group;B-DDI-DrugBank.d548.s9.e1
(;O;O
tricyclic;B-group;B-DDI-DrugBank.d548.s9.e2
antidepressants;I-group;I-DDI-DrugBank.d548.s9.e2
[;O;O
TCAs;B-group;B-DDI-DrugBank.d548.s9.e3
];O;O
,;O;O
such;O;O
as;O;O
nortriptyline;B-drug;B-DDI-DrugBank.d548.s9.e4
,;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d548.s9.e5
,;O;O
and;O;O
imipramine;B-drug;B-DDI-DrugBank.d548.s9.e6
);O;O
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d548.s9.e7
and;O;O
Type;B-group;B-DDI-DrugBank.d548.s9.e8
1C;I-group;I-DDI-DrugBank.d548.s9.e8
antiarrhythmics;I-group;I-DDI-DrugBank.d548.s9.e8
(;O;O
e.g.;O;O
,;O;O
propafenone;B-drug;B-DDI-DrugBank.d548.s9.e9
,;O;O
flecainide;B-drug;B-DDI-DrugBank.d548.s9.e10
);O;O
,;O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d548.s10;;
Plasma;O;O
TCA;B-group;B-DDI-DrugBank.d548.s10.e0
concentrations;O;O
may;O;O
need;O;O
to;O;O
be;O;O
monitored;O;O
and;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
TCA;B-group;B-DDI-DrugBank.d548.s10.e1
may;O;O
need;O;O
to;O;O
be;O;O
reduced;O;O
if;O;O
a;O;O
TCA;B-group;B-DDI-DrugBank.d548.s10.e2
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s10.e3
.;O;O
DDI-DrugBank.d548.s11;;
Because;O;O
of;O;O
the;O;O
risk;O;O
of;O;O
serious;O;O
ventricular;O;O
arrhythmias;O;O
and;O;O
sudden;O;O
death;O;O
potentially;O;O
associated;O;O
with;O;O
elevated;O;O
plasma;O;O
levels;O;O
of;O;O
thioridazine;B-drug;B-DDI-DrugBank.d548.s11.e0
,;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s11.e1
and;O;O
thioridazine;B-drug;B-DDI-DrugBank.d548.s11.e2
should;O;O
not;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d548.s12;;
Drugs;O;O
Metabolized;O;O
by;O;O
CYP3A;O;O
:;O;O
Results;O;O
of;O;O
in;O;O
vitro;O;O
studies;O;O
demonstrate;O;O
that;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s12.e0
does;O;O
not;O;O
inhibit;O;O
or;O;O
induce;O;O
CYP3A;O;O
activity;O;O
.;O;O
DDI-DrugBank.d548.s13;;
Duloxetine;B-drug;B-DDI-DrugBank.d548.s13.e0
May;O;O
Have;O;O
a;O;O
Clinically;O;O
Important;O;O
Interaction;O;O
with;O;O
the;O;O
Following;O;O
Other;O;O
Drugs;O;O
:;O;O
Alcohol;B-drug;B-DDI-DrugBank.d548.s13.e1
:;O;O
When;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s13.e2
and;O;O
ethanol;B-drug;B-DDI-DrugBank.d548.s13.e3
were;O;O
administered;O;O
several;O;O
hours;O;O
apart;O;O
so;O;O
that;O;O
peak;O;O
concentrations;O;O
of;O;O
each;O;O
would;O;O
coincide;O;O
,;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s13.e4
did;O;O
not;O;O
increase;O;O
the;O;O
impairment;O;O
of;O;O
mental;O;O
and;O;O
motor;O;O
skills;O;O
caused;O;O
by;O;O
alcohol;B-drug;B-DDI-DrugBank.d548.s13.e5
.;O;O
DDI-DrugBank.d548.s14;;
In;O;O
the;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s14.e0
clinical;O;O
trials;O;O
database;O;O
,;O;O
three;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s14.e1
-;O;O
treated;O;O
patients;O;O
had;O;O
liver;O;O
injury;O;O
as;O;O
manifested;O;O
by;O;O
ALT;O;O
and;O;O
total;O;O
bilirubin;O;O
elevations;O;O
,;O;O
with;O;O
evidence;O;O
of;O;O
obstruction;O;O
.;O;O
DDI-DrugBank.d548.s15;;
Substantial;O;O
intercurrent;O;O
ethanol;B-drug;B-DDI-DrugBank.d548.s15.e0
use;O;O
was;O;O
present;O;O
in;O;O
each;O;O
of;O;O
these;O;O
cases;O;O
,;O;O
and;O;O
this;O;O
may;O;O
have;O;O
contributed;O;O
to;O;O
the;O;O
abnormalities;O;O
seen;O;O
.;O;O
DDI-DrugBank.d548.s16;;
CNS;O;O
Acting;O;O
Drugs;O;O
:;O;O
Given;O;O
the;O;O
primary;O;O
CNS;O;O
effects;O;O
of;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s16.e0
,;O;O
it;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
when;O;O
it;O;O
is;O;O
taken;O;O
in;O;O
combination;O;O
with;O;O
or;O;O
substituted;O;O
for;O;O
other;O;O
centrally;O;O
acting;O;O
drugs;O;O
,;O;O
including;O;O
those;O;O
with;O;O
a;O;O
similar;O;O
mechanism;O;O
of;O;O
action;O;O
.;O;O
DDI-DrugBank.d548.s17;;
Potential;O;O
for;O;O
Interaction;O;O
with;O;O
Drugs;O;O
that;O;O
Affect;O;O
Gastric;O;O
Acidity;O;O
:;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s17.e0
has;O;O
an;O;O
enteric;O;O
coating;O;O
that;O;O
resists;O;O
dissolution;O;O
until;O;O
reaching;O;O
a;O;O
segment;O;O
of;O;O
the;O;O
gastrointestinal;O;O
tract;O;O
where;O;O
the;O;O
pH;O;O
exceeds;O;O
5.5;O;O
.;O;O
DDI-DrugBank.d548.s18;;
In;O;O
extremely;O;O
acidic;O;O
conditions;O;O
,;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s18.e0
,;O;O
unprotected;O;O
by;O;O
the;O;O
enteric;O;O
coating;O;O
,;O;O
may;O;O
undergo;O;O
hydrolysis;O;O
to;O;O
form;O;O
naphthol;O;O
.;O;O
DDI-DrugBank.d548.s19;;
Caution;O;O
is;O;O
advised;O;O
in;O;O
using;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s19.e0
in;O;O
patients;O;O
with;O;O
conditions;O;O
that;O;O
may;O;O
slow;O;O
gastric;O;O
emptying;O;O
(;O;O
e.g.;O;O
,;O;O
some;O;O
diabetics;O;O
);O;O
.;O;O
DDI-DrugBank.d548.s20;;
Drugs;O;O
that;O;O
raise;O;O
the;O;O
gastrointestinal;O;O
pH;O;O
may;O;O
lead;O;O
to;O;O
an;O;O
earlier;O;O
release;O;O
of;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s20.e0
.;O;O
DDI-DrugBank.d548.s21;;
However;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s21.e0
with;O;O
aluminum;B-drug;B-DDI-DrugBank.d548.s21.e1
-;O;O
and;O;O
magnesium;B-drug;B-DDI-DrugBank.d548.s21.e2
-;O;O
containing;O;O
antacids;B-group;B-DDI-DrugBank.d548.s21.e3
(;O;O
51;O;O
mEq;O;O
);O;O
or;O;O
Duloxetine;B-drug;B-DDI-DrugBank.d548.s21.e4
with;O;O
famotidine;B-drug;B-DDI-DrugBank.d548.s21.e5
,;O;O
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
rate;O;O
or;O;O
extent;O;O
of;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s21.e6
absorption;O;O
after;O;O
administration;O;O
of;O;O
a;O;O
40;O;O
-;O;O
mg;O;O
oral;O;O
dose;O;O
.;O;O
DDI-DrugBank.d548.s22;;
It;O;O
is;O;O
unknown;O;O
whether;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
proton;B-group;B-DDI-DrugBank.d548.s22.e0
pump;I-group;I-DDI-DrugBank.d548.s22.e0
inhibitors;I-group;I-DDI-DrugBank.d548.s22.e0
affects;O;O
duloxetine;B-drug;B-DDI-DrugBank.d548.s22.e1
absorption;O;O
.;O;O
DDI-DrugBank.d4.s0;;
Synergism;O;O
between;O;O
xanthine;B-group;B-DDI-DrugBank.d4.s0.e0
bronchodilators;I-group;I-DDI-DrugBank.d4.s0.e0
(;O;O
e.g.;O;O
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d4.s0.e1
);O;O
,;O;O
ephedrine;B-drug;B-DDI-DrugBank.d4.s0.e2
,;O;O
and;O;O
other;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d4.s0.e3
bronchodilators;I-group;I-DDI-DrugBank.d4.s0.e3
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d4.s1;;
This;O;O
should;O;O
be;O;O
considered;O;O
whenever;O;O
these;O;O
agents;O;O
are;O;O
prescribed;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d4.s2;;
Concurrent;O;O
administration;O;O
of;O;O
dyphylline;B-drug;B-DDI-DrugBank.d4.s2.e0
and;O;O
probenecid;B-drug;B-DDI-DrugBank.d4.s2.e1
,;O;O
which;O;O
competes;O;O
for;O;O
tubular;O;O
secretion;O;O
,;O;O
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
the;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
of;O;O
dyphylline;B-drug;B-DDI-DrugBank.d4.s2.e2
.;O;O
DDI-DrugBank.d377.s0;;
Phospholine;B-drug;B-DDI-DrugBank.d377.s0.e0
Iodide;I-drug;I-DDI-DrugBank.d377.s0.e0
potentiates;O;O
other;O;O
cholinesterase;B-group;B-DDI-DrugBank.d377.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d377.s0.e1
such;O;O
as;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d377.s0.e2
or;O;O
organophosphate;B-drug_n;B-DDI-DrugBank.d377.s0.e3
and;I-drug_n;I-DDI-DrugBank.d377.s0.e3
carbamate;I-drug_n;I-DDI-DrugBank.d377.s0.e4
insecticides;I-drug_n;I-DDI-DrugBank.d377.s0.e4
.;O;O
DDI-DrugBank.d377.s1;;
Patients;O;O
undergoing;O;O
systemic;O;O
anticholinesterase;O;O
treatment;O;O
should;O;O
be;O;O
warned;O;O
of;O;O
the;O;O
possible;O;O
additive;O;O
effects;O;O
of;O;O
Phospholine;B-drug;B-DDI-DrugBank.d377.s1.e0
Iodide;I-drug;I-DDI-DrugBank.d377.s1.e0
.;O;O
DDI-DrugBank.d49.s0;;
Drug;O;O
interaction;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
with;O;O
Soliris;B-brand;B-DDI-DrugBank.d49.s0.e0
.;O;O
DDI-DrugBank.d191.s0;;
There;O;O
is;O;O
no;O;O
known;O;O
drug;O;O
interference;O;O
with;O;O
standard;O;O
clinical;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d191.s1;;
Steroids;B-group;B-DDI-DrugBank.d191.s1.e0
enhance;O;O
the;O;O
renal;O;O
toxicity;O;O
of;O;O
edetate;B-drug;B-DDI-DrugBank.d191.s1.e1
calcium;I-drug;I-DDI-DrugBank.d191.s1.e1
disodium;I-drug;I-DDI-DrugBank.d191.s1.e1
in;O;O
animals;O;O
.;O;O
7;O;O
Edetate;B-drug;B-DDI-DrugBank.d191.s1.e2
calcium;I-drug;I-DDI-DrugBank.d191.s1.e2
disodium;I-drug;I-DDI-DrugBank.d191.s1.e2
interferes;O;O
with;O;O
the;O;O
action;O;O
of;O;O
zinc;B-drug;B-DDI-DrugBank.d191.s1.e3
insulin;I-drug;I-DDI-DrugBank.d191.s1.e3
preparations;O;O
by;O;O
chelating;O;O
the;O;O
zinc;B-drug;B-DDI-DrugBank.d191.s1.e4
.;O;O
7;O;O
DDI-DrugBank.d292.s0;;
Care;O;O
should;O;O
be;O;O
given;O;O
when;O;O
administering;O;O
this;O;O
drug;O;O
to;O;O
patients;O;O
with;O;O
symptoms;O;O
of;O;O
myasthenic;O;O
weakness;O;O
who;O;O
are;O;O
also;O;O
on;O;O
anticholinesterase;B-group;B-DDI-DrugBank.d292.s0.e0
drugs;I-group;I-DDI-DrugBank.d292.s0.e0
.;O;O
DDI-DrugBank.d292.s1;;
Since;O;O
symptoms;O;O
of;O;O
anticholinesterase;O;O
overdose;O;O
(;O;O
cholinergic;O;O
crisis;O;O
);O;O
may;O;O
mimic;O;O
underdosage;O;O
(;O;O
myasthenic;O;O
weakness;O;O
);O;O
,;O;O
their;O;O
condition;O;O
may;O;O
be;O;O
worsened;O;O
by;O;O
the;O;O
use;O;O
of;O;O
this;O;O
drug;O;O
.;O;O
DDI-DrugBank.d44.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
with;O;O
RAPTIVA;B-brand;B-DDI-DrugBank.d44.s0.e0
.;O;O
DDI-DrugBank.d44.s1;;
RAPTIVA;B-brand;B-DDI-DrugBank.d44.s1.e0
should;O;O
not;O;O
be;O;O
used;O;O
with;O;O
other;O;O
immunosuppressive;B-group;B-DDI-DrugBank.d44.s1.e1
drugs;I-group;I-DDI-DrugBank.d44.s1.e1
.;O;O
DDI-DrugBank.d44.s2;;
Acellular;B-group;B-DDI-DrugBank.d44.s2.e0
,;I-group;I-DDI-DrugBank.d44.s2.e0
live;I-group;I-DDI-DrugBank.d44.s2.e1
and;I-group;I-DDI-DrugBank.d44.s2.e1
live;I-group;I-DDI-DrugBank.d44.s2.e2
-;I-group;I-DDI-DrugBank.d44.s2.e2
attenuated;I-group;I-DDI-DrugBank.d44.s2.e2
vaccines;I-group;I-DDI-DrugBank.d44.s2.e2
should;O;O
not;O;O
be;O;O
administered;O;O
during;O;O
RAPTIVA;B-brand;B-DDI-DrugBank.d44.s2.e3
treatment;O;O
.;O;O
DDI-DrugBank.d44.s3;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Increases;O;O
in;O;O
lymphocyte;O;O
counts;O;O
related;O;O
to;O;O
the;O;O
pharmacologic;O;O
mechanism;O;O
of;O;O
action;O;O
are;O;O
frequently;O;O
observed;O;O
during;O;O
RAPTIVA;B-brand;B-DDI-DrugBank.d44.s3.e0
treatment;O;O
.;O;O
DDI-DrugBank.d531.s0;;
Efavirenz;B-drug;B-DDI-DrugBank.d531.s0.e0
has;O;O
been;O;O
shown;O;O
in;O;O
vivo;O;O
to;O;O
induce;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d531.s1;;
Other;O;O
compounds;O;O
that;O;O
are;O;O
substrates;O;O
of;O;O
CYP3A4;O;O
may;O;O
have;O;O
decreased;O;O
plasma;O;O
concentrations;O;O
when;O;O
coadministered;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s1.e0
(;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s1.e1
);O;O
.;O;O
DDI-DrugBank.d531.s2;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
demonstrated;O;O
that;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s2.e0
inhibits;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
and;O;O
3A4;O;O
isozymes;O;O
in;O;O
the;O;O
range;O;O
of;O;O
observed;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s2.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d531.s3;;
Coadministration;O;O
of;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s3.e0
with;O;O
drugs;O;O
primarily;O;O
metabolized;O;O
by;O;O
these;O;O
isozymes;O;O
may;O;O
result;O;O
in;O;O
altered;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
coadministered;O;O
drug;O;O
.;O;O
DDI-DrugBank.d531.s4;;
Therefore;O;O
,;O;O
appropriate;O;O
dose;O;O
adjustments;O;O
may;O;O
be;O;O
necessary;O;O
for;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d531.s5;;
Drugs;O;O
which;O;O
induce;O;O
CYP3A4;O;O
activity;O;O
(;O;O
eg;O;O
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d531.s5.e0
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d531.s5.e1
,;O;O
rifabutin;B-drug;B-DDI-DrugBank.d531.s5.e2
);O;O
would;O;O
be;O;O
expected;O;O
to;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s5.e3
resulting;O;O
in;O;O
lowered;O;O
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d531.s6;;
Drug;O;O
interactions;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s6.e0
are;O;O
summarized;O;O
in;O;O
Table;O;O
5;O;O
.;O;O
DDI-DrugBank.d531.s7;;
Table;O;O
5a;O;O
:;O;O
Drugs;O;O
That;O;O
Should;O;O
Not;O;O
Be;O;O
Coadministered;O;O
With;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s7.e0
DDI-DrugBank.d531.s8;;
Drug;O;O
Class;O;O
DDI-DrugBank.d531.s9;;
Drugs;O;O
Within;O;O
Class;O;O
Not;O;O
To;O;O
Be;O;O
Coadministered;O;O
With;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s9.e0
DDI-DrugBank.d531.s10;;
Antihistamines;I-group;I-DDI-DrugBank.d531.s10.e0
:;O;O
Benzodiazepines;B-group;B-DDI-DrugBank.d531.s10.e1
GI;O;O
Motility;O;O
Agents;O;O
Anti;B-group;B-DDI-DrugBank.d531.s10.e2
-;I-group;I-DDI-DrugBank.d531.s10.e2
Migraine;I-group;I-DDI-DrugBank.d531.s10.e2
Antifungal;I-group;I-DDI-DrugBank.d531.s10.e3
DDI-DrugBank.d531.s11;;
astemizole;I-drug;I-DDI-DrugBank.d531.s11.e0
midazolam;I-drug;I-DDI-DrugBank.d531.s11.e1
,;O;O
triazolam;B-drug;B-DDI-DrugBank.d531.s11.e2
cisapride;I-drug;I-DDI-DrugBank.d531.s11.e3
ergot;O;O
derivatives;O;O
voriconazole;B-drug;B-DDI-DrugBank.d531.s11.e4
DDI-DrugBank.d531.s12;;
Established;O;O
Drug;O;O
Interactions;O;O
DDI-DrugBank.d531.s13;;
DDI-DrugBank.d531.s14;;
Drug;O;O
Name;O;O
DDI-DrugBank.d531.s15;;
Effect;O;O
DDI-DrugBank.d531.s16;;
Clinical;O;O
Comment;O;O
DDI-DrugBank.d531.s17;;
Atazanavir;B-drug;B-DDI-DrugBank.d531.s17.e0
DDI-DrugBank.d531.s18;;
atazanavir;I-drug;I-DDI-DrugBank.d531.s18.e0
DDI-DrugBank.d531.s19;;
When;O;O
coadministered;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s19.e0
in;O;O
treatment;O;O
-;O;O
naive;O;O
patients;O;O
,;O;O
the;O;O
recommended;O;O
dose;O;O
of;O;O
atazanavir;B-drug;B-DDI-DrugBank.d531.s19.e1
is;O;O
300;O;O
mg;O;O
with;O;O
ritonavir;B-drug;B-DDI-DrugBank.d531.s19.e2
100;O;O
mg;O;O
and;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s19.e3
600;O;O
mg;O;O
(;O;O
all;O;O
once;O;O
daily;O;O
);O;O
.;O;O
DDI-DrugBank.d531.s20;;
Dosing;O;O
recommendations;O;O
for;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s20.e0
and;O;O
atazanavir;B-drug;B-DDI-DrugBank.d531.s20.e1
in;O;O
treatment;O;O
-;O;O
experienced;O;O
patients;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d531.s21;;
Established;O;O
Drug;O;O
Interactions;O;O
(;O;O
continued;O;O
);O;O
DDI-DrugBank.d531.s22;;
Drug;O;O
Name;O;O
DDI-DrugBank.d531.s23;;
Effect;O;O
DDI-DrugBank.d531.s24;;
Clinical;O;O
Comment;O;O
DDI-DrugBank.d531.s25;;
Clarithromycin;B-drug;B-DDI-DrugBank.d531.s25.e0
DDI-DrugBank.d531.s26;;
clarithromycin;I-drug;I-DDI-DrugBank.d531.s26.e0
concentration;O;O
DDI-DrugBank.d531.s27;;
Plasma;O;O
concentrations;O;O
decreased;O;O
by;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s27.e0
,;O;O
DDI-DrugBank.d531.s28;;
clinical;O;O
significance;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d531.s29;;
In;O;O
uninfected;O;O
volunteers;O;O
,;O;O
46;O;O
%;O;O
developed;O;O
rash;O;O
while;O;O
receiving;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s29.e0
and;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d531.s29.e1
.;O;O
DDI-DrugBank.d531.s30;;
No;O;O
dose;O;O
adjustment;O;O
of;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s30.e0
is;O;O
recommended;O;O
when;O;O
given;O;O
with;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d531.s30.e1
.;O;O
DDI-DrugBank.d531.s31;;
Alternatives;O;O
to;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d531.s31.e0
,;O;O
such;O;O
as;O;O
azithromycin;B-drug;B-DDI-DrugBank.d531.s31.e1
,;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d531.s32;;
Other;O;O
macrolide;B-group;B-DDI-DrugBank.d531.s32.e0
antibiotics;I-group;I-DDI-DrugBank.d531.s32.e0
,;O;O
such;O;O
as;O;O
erythromycin;B-drug;B-DDI-DrugBank.d531.s32.e1
,;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
in;O;O
combination;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s32.e2
.;O;O
DDI-DrugBank.d531.s33;;
DDI-DrugBank.d531.s34;;
14;O;O
-;O;O
OH;O;O
metabolite;O;O
concentration;O;O
DDI-DrugBank.d531.s35;;
Indinavir;B-drug;B-DDI-DrugBank.d531.s35.e0
DDI-DrugBank.d531.s36;;
indinavir;I-drug;I-DDI-DrugBank.d531.s36.e0
concentration;O;O
DDI-DrugBank.d531.s37;;
The;O;O
optimal;O;O
dose;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d531.s37.e0
,;O;O
when;O;O
given;O;O
in;O;O
combination;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s37.e1
,;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d531.s38;;
Increasing;O;O
the;O;O
indinavir;B-drug;B-DDI-DrugBank.d531.s38.e0
dose;O;O
to;O;O
1000;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
does;O;O
not;O;O
compensate;O;O
for;O;O
the;O;O
increased;O;O
indinavir;B-drug;B-DDI-DrugBank.d531.s38.e1
metabolism;O;O
due;O;O
to;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s38.e2
.;O;O
DDI-DrugBank.d531.s39;;
When;O;O
indinavir;B-drug;B-DDI-DrugBank.d531.s39.e0
at;O;O
an;O;O
increased;O;O
dose;O;O
(;O;O
1000;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
);O;O
was;O;O
given;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s39.e1
(;O;O
600;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
,;O;O
the;O;O
indinavir;B-drug;B-DDI-DrugBank.d531.s39.e2
AUC;O;O
and;O;O
Cmin;O;O
were;O;O
decreased;O;O
on;O;O
average;O;O
by;O;O
33;O;O
-;O;O
46;O;O
%;O;O
and;O;O
39;O;O
-;O;O
57;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
compared;O;O
to;O;O
when;O;O
indinavir;B-drug;B-DDI-DrugBank.d531.s39.e3
(;O;O
800;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
);O;O
was;O;O
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d531.s40;;
Lopinavir;B-drug;B-DDI-DrugBank.d531.s40.e0
/;O;O
ritonavir;B-drug;B-DDI-DrugBank.d531.s40.e1
DDI-DrugBank.d531.s41;;
lopinavir;I-drug;I-DDI-DrugBank.d531.s41.e0
concentration;O;O
DDI-DrugBank.d531.s42;;
A;O;O
dose;O;O
increase;O;O
of;O;O
lopinavir;B-drug;B-DDI-DrugBank.d531.s42.e0
/;O;O
ritonavir;B-drug;B-DDI-DrugBank.d531.s42.e1
to;O;O
533;O;O
/;O;O
133;O;O
mg;O;O
(;O;O
4;O;O
capsules;O;O
or;O;O
6.5;O;O
mL;O;O
);O;O
twice;O;O
daily;O;O
taken;O;O
with;O;O
food;O;O
is;O;O
recommended;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s42.e2
.;O;O
DDI-DrugBank.d531.s43;;
Methadone;B-drug;B-DDI-DrugBank.d531.s43.e0
DDI-DrugBank.d531.s44;;
methadone;I-drug;I-DDI-DrugBank.d531.s44.e0
concentration;O;O
DDI-DrugBank.d531.s45;;
Coadministration;O;O
in;O;O
HIV;O;O
-;O;O
infected;O;O
individuals;O;O
with;O;O
a;O;O
history;O;O
of;O;O
injection;O;O
drug;O;O
use;O;O
resulted;O;O
in;O;O
decreased;O;O
plasma;O;O
levels;O;O
of;O;O
methadone;B-drug;B-DDI-DrugBank.d531.s45.e0
and;O;O
signs;O;O
of;O;O
opiate;B-group;B-DDI-DrugBank.d531.s45.e1
withdrawal;O;O
.;O;O
DDI-DrugBank.d531.s46;;
Methadone;B-drug;B-DDI-DrugBank.d531.s46.e0
dose;O;O
was;O;O
increased;O;O
by;O;O
a;O;O
mean;O;O
of;O;O
22;O;O
%;O;O
to;O;O
alleviate;O;O
withdrawal;O;O
symptoms;O;O
.;O;O
DDI-DrugBank.d531.s47;;
Patients;O;O
should;O;O
be;O;O
monitored;O;O
for;O;O
signs;O;O
of;O;O
withdrawal;O;O
and;O;O
their;O;O
methadone;B-drug;B-DDI-DrugBank.d531.s47.e0
dose;O;O
increased;O;O
as;O;O
required;O;O
to;O;O
alleviate;O;O
withdrawal;O;O
symptoms;O;O
.;O;O
DDI-DrugBank.d531.s48;;
Ethinyl;B-drug;B-DDI-DrugBank.d531.s48.e0
estradiol;I-drug;I-DDI-DrugBank.d531.s48.e0
DDI-DrugBank.d531.s49;;
ethinyl;I-drug;I-DDI-DrugBank.d531.s49.e0
estradiol;I-drug;I-DDI-DrugBank.d531.s49.e0
concentration;O;O
DDI-DrugBank.d531.s50;;
Plasma;O;O
concentrations;O;O
increased;O;O
by;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s50.e0
(;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s50.e1
);O;O
,;O;O
DDI-DrugBank.d531.s51;;
clinical;O;O
significance;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d531.s52;;
Because;O;O
the;O;O
potential;O;O
interaction;O;O
of;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s52.e0
with;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d531.s52.e1
has;O;O
not;O;O
been;O;O
fully;O;O
characterized;O;O
,;O;O
a;O;O
reliable;O;O
method;O;O
of;O;O
barrier;O;O
contraception;O;O
should;O;O
be;O;O
used;O;O
in;O;O
addition;O;O
to;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d531.s52.e2
.;O;O
DDI-DrugBank.d531.s53;;
Rifabutin;B-drug;B-DDI-DrugBank.d531.s53.e0
DDI-DrugBank.d531.s54;;
rifabutin;I-drug;I-DDI-DrugBank.d531.s54.e0
concentration;O;O
DDI-DrugBank.d531.s55;;
Increase;O;O
daily;O;O
dose;O;O
of;O;O
rifabutin;B-drug;B-DDI-DrugBank.d531.s55.e0
by;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d531.s56;;
Consider;O;O
doubling;O;O
the;O;O
rifabutin;B-drug;B-DDI-DrugBank.d531.s56.e0
dose;O;O
in;O;O
regimens;O;O
where;O;O
rifabutin;B-drug;B-DDI-DrugBank.d531.s56.e1
is;O;O
given;O;O
2;O;O
or;O;O
3;O;O
times;O;O
a;O;O
week;O;O
.;O;O
DDI-DrugBank.d531.s57;;
Rifampin;B-drug;B-DDI-DrugBank.d531.s57.e0
DDI-DrugBank.d531.s58;;
efavirenz;I-drug;I-DDI-DrugBank.d531.s58.e0
concentration;O;O
DDI-DrugBank.d531.s59;;
Clinical;O;O
significance;O;O
of;O;O
reduced;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s59.e0
concentrations;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d531.s60;;
Ritonavir;B-drug;B-DDI-DrugBank.d531.s60.e0
DDI-DrugBank.d531.s61;;
ritonavir;I-drug;I-DDI-DrugBank.d531.s61.e0
concentration;O;O
DDI-DrugBank.d531.s62;;
Combination;O;O
was;O;O
associated;O;O
with;O;O
a;O;O
higher;O;O
frequency;O;O
of;O;O
adverse;O;O
clinical;O;O
experiences;O;O
(;O;O
eg;O;O
,;O;O
dizziness;O;O
,;O;O
nausea;O;O
,;O;O
paresthesia;O;O
);O;O
and;O;O
laboratory;O;O
abnormalities;O;O
(;O;O
elevated;O;O
liver;O;O
enzymes;O;O
);O;O
.;O;O
DDI-DrugBank.d531.s63;;
Monitoring;O;O
of;O;O
liver;O;O
enzymes;O;O
is;O;O
recommended;O;O
when;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s63.e0
is;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
ritonavir;B-drug;B-DDI-DrugBank.d531.s63.e1
.;O;O
DDI-DrugBank.d531.s64;;
efavirenz;B-drug;B-DDI-DrugBank.d531.s64.e0
concentration;O;O
DDI-DrugBank.d531.s65;;
Saquinavir;B-drug;B-DDI-DrugBank.d531.s65.e0
DDI-DrugBank.d531.s66;;
saquinavir;I-drug;I-DDI-DrugBank.d531.s66.e0
concentration;O;O
DDI-DrugBank.d531.s67;;
Should;O;O
not;O;O
be;O;O
used;O;O
as;O;O
sole;O;O
protease;B-group;B-DDI-DrugBank.d531.s67.e0
inhibitor;I-group;I-DDI-DrugBank.d531.s67.e0
in;O;O
combination;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s67.e1
.;O;O
DDI-DrugBank.d531.s68;;
Sertraline;B-drug;B-DDI-DrugBank.d531.s68.e0
DDI-DrugBank.d531.s69;;
sertraline;I-drug;I-DDI-DrugBank.d531.s69.e0
concentration;O;O
DDI-DrugBank.d531.s70;;
Increases;O;O
in;O;O
sertraline;B-drug;B-DDI-DrugBank.d531.s70.e0
dose;O;O
should;O;O
be;O;O
guided;O;O
by;O;O
clinical;O;O
response;O;O
.;O;O
DDI-DrugBank.d531.s71;;
Other;O;O
Potentially;O;O
Clinically;O;O
Significant;O;O
Drug;O;O
or;O;O
Herbal;O;O
Product;O;O
Interactions;O;O
With;O;O
SUSTIVAb;O;O
DDI-DrugBank.d531.s72;;
Anticoagulants;B-group;B-DDI-DrugBank.d531.s72.e0
:;O;O
Warfarin;B-drug;B-DDI-DrugBank.d531.s72.e1
DDI-DrugBank.d531.s73;;
Plasma;O;O
concentrations;O;O
and;O;O
effects;O;O
potentially;O;O
increased;O;O
or;O;O
decreased;O;O
by;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s73.e0
.;O;O
DDI-DrugBank.d531.s74;;
Anticonvulsants;B-group;B-DDI-DrugBank.d531.s74.e0
:;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d531.s74.e1
Phenobarbital;I-drug;I-DDI-DrugBank.d531.s74.e2
Carbamazepine;I-drug;I-DDI-DrugBank.d531.s74.e3
DDI-DrugBank.d531.s75;;
Potential;O;O
for;O;O
reduction;O;O
in;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d531.s75.e0
and/or;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s75.e1
plasma;O;O
levels;O;O
,;O;O
DDI-DrugBank.d531.s76;;
periodic;O;O
monitoring;O;O
of;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d531.s76.e0
plasma;O;O
levels;O;O
should;O;O
be;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d531.s77;;
Antifungals;B-group;B-DDI-DrugBank.d531.s77.e0
:;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d531.s77.e1
Ketoconazole;I-drug;I-DDI-DrugBank.d531.s77.e2
DDI-DrugBank.d531.s78;;
Drug;O;O
interaction;O;O
studies;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s78.e0
and;O;O
these;O;O
imidazole;B-group;B-DDI-DrugBank.d531.s78.e1
and;I-group;I-DDI-DrugBank.d531.s78.e1
triazole;I-group;I-DDI-DrugBank.d531.s78.e2
antifungals;I-group;I-DDI-DrugBank.d531.s78.e2
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d531.s79;;
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s79.e0
has;O;O
the;O;O
potential;O;O
to;O;O
decrease;O;O
plasma;O;O
concentrations;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d531.s79.e1
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d531.s79.e2
.;O;O
DDI-DrugBank.d531.s80;;
Anti;B-group;B-DDI-DrugBank.d531.s80.e0
-;I-group;I-DDI-DrugBank.d531.s80.e0
HIV;I-group;I-DDI-DrugBank.d531.s80.e0
protease;I-group;I-DDI-DrugBank.d531.s80.e0
inhibitors;I-group;I-DDI-DrugBank.d531.s80.e0
:;O;O
Saquinavir;B-drug;B-DDI-DrugBank.d531.s80.e1
/;O;O
ritonavir;B-drug;B-DDI-DrugBank.d531.s80.e2
combination;O;O
DDI-DrugBank.d531.s81;;
No;O;O
pharmacokinetic;O;O
data;O;O
are;O;O
available;O;O
.;O;O
DDI-DrugBank.d531.s82;;
Amprenavir;B-drug;B-DDI-DrugBank.d531.s82.e0
DDI-DrugBank.d531.s83;;
SUSTIVAhas;O;O
the;O;O
potential;O;O
to;O;O
decrease;O;O
serum;O;O
concentrations;O;O
of;O;O
amprenavir;B-drug;B-DDI-DrugBank.d531.s83.e0
.;O;O
DDI-DrugBank.d531.s84;;
Non;B-group;B-DDI-DrugBank.d531.s84.e0
-;I-group;I-DDI-DrugBank.d531.s84.e0
nucleoside;I-group;I-DDI-DrugBank.d531.s84.e0
reverse;I-group;I-DDI-DrugBank.d531.s84.e0
transcriptase;I-group;I-DDI-DrugBank.d531.s84.e0
inhibitors;I-group;I-DDI-DrugBank.d531.s84.e0
DDI-DrugBank.d531.s85;;
No;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
with;O;O
other;O;O
NNRTIs;B-group;B-DDI-DrugBank.d531.s85.e0
.;O;O
DDI-DrugBank.d531.s86;;
St.;O;O
John;O;O
s;O;O
wort;O;O
(;O;O
Hypericum;O;O
perforatum;O;O
);O;O
DDI-DrugBank.d531.s87;;
Expected;O;O
to;O;O
substantially;O;O
decrease;O;O
plasma;O;O
levels;O;O
of;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s87.e0
,;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
in;O;O
combination;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s87.e1
.;O;O
DDI-DrugBank.d531.s88;;
a;O;O
See;O;O
Tables;O;O
1;O;O
and;O;O
2;O;O
.;O;O
DDI-DrugBank.d531.s89;;
b;O;O
This;O;O
table;O;O
is;O;O
not;O;O
all;O;O
-;O;O
inclusive;O;O
.;O;O
DDI-DrugBank.d531.s90;;
Other;O;O
Drugs;O;O
:;O;O
Based;O;O
on;O;O
the;O;O
results;O;O
of;O;O
drug;O;O
interaction;O;O
studies;O;O
,;O;O
no;O;O
dosage;O;O
adjustment;O;O
is;O;O
recommended;O;O
when;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s90.e0
(;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s90.e1
);O;O
is;O;O
given;O;O
with;O;O
the;O;O
following;O;O
:;O;O
aluminum;B-group;B-DDI-DrugBank.d531.s90.e2
/;I-group;I-DDI-DrugBank.d531.s90.e2
magnesium;I-group;I-DDI-DrugBank.d531.s90.e2
hydroxide;I-group;I-DDI-DrugBank.d531.s90.e2
antacids;I-group;I-DDI-DrugBank.d531.s90.e2
,;O;O
azithromycin;B-drug;B-DDI-DrugBank.d531.s90.e3
,;O;O
cetirizine;B-drug;B-DDI-DrugBank.d531.s90.e4
,;O;O
famotidine;B-drug;B-DDI-DrugBank.d531.s90.e5
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d531.s90.e6
,;O;O
lamivudine;B-drug;B-DDI-DrugBank.d531.s90.e7
,;O;O
lorazepam;B-drug;B-DDI-DrugBank.d531.s90.e8
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d531.s90.e9
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d531.s90.e10
,;O;O
and;O;O
zidovudine;B-drug;B-DDI-DrugBank.d531.s90.e11
.;O;O
DDI-DrugBank.d531.s91;;
Specific;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
with;O;O
SUSTIVA;B-brand;B-DDI-DrugBank.d531.s91.e0
and;O;O
NRTIs;B-group;B-DDI-DrugBank.d531.s91.e1
other;O;O
than;O;O
lamivudine;B-drug;B-DDI-DrugBank.d531.s91.e2
and;O;O
zidovudine;B-drug;B-DDI-DrugBank.d531.s91.e3
.;O;O
DDI-DrugBank.d531.s92;;
Clinically;O;O
significant;O;O
interactions;O;O
would;O;O
not;O;O
be;O;O
expected;O;O
since;O;O
the;O;O
NRTIs;B-group;B-DDI-DrugBank.d531.s92.e0
are;O;O
metabolized;O;O
via;O;O
a;O;O
different;O;O
route;O;O
than;O;O
efavirenz;B-drug;B-DDI-DrugBank.d531.s92.e1
and;O;O
would;O;O
be;O;O
unlikely;O;O
to;O;O
compete;O;O
for;O;O
the;O;O
same;O;O
metabolic;O;O
enzymes;O;O
and;O;O
elimination;O;O
pathways;O;O
.;O;O
DDI-DrugBank.d375.s0;;
The;O;O
potential;O;O
for;O;O
drug;O;O
interactions;O;O
with;O;O
EMTRIVA;B-brand;B-DDI-DrugBank.d375.s0.e0
has;O;O
been;O;O
studied;O;O
in;O;O
combination;O;O
with;O;O
indinavir;B-drug;B-DDI-DrugBank.d375.s0.e1
,;O;O
stavudine;B-drug;B-DDI-DrugBank.d375.s0.e2
,;O;O
famciclovir;B-drug;B-DDI-DrugBank.d375.s0.e3
,;O;O
and;O;O
tenofovir;B-drug;B-DDI-DrugBank.d375.s0.e4
disoproxil;I-drug;I-DDI-DrugBank.d375.s0.e4
fumarate;I-drug;I-DDI-DrugBank.d375.s0.e4
.;O;O
DDI-DrugBank.d375.s1;;
There;O;O
were;O;O
no;O;O
clinically;O;O
significant;O;O
drug;O;O
interactions;O;O
for;O;O
any;O;O
of;O;O
these;O;O
drugs;O;O
DDI-DrugBank.d375.s2;;
.;O;O
DDI-DrugBank.d375.s3;;
DDI-DrugBank.d107.s0;;
Hypotension;O;O
:;O;O
Patients;O;O
on;O;O
Diuretic;O;O
Therapy;O;O
:;O;O
Patients;O;O
on;O;O
diuretics;B-drug;B-DDI-DrugBank.d107.s0.e0
and;O;O
especially;O;O
those;O;O
in;O;O
whom;O;O
diuretic;O;O
therapy;O;O
was;O;O
recently;O;O
instituted;O;O
,;O;O
may;O;O
occasionally;O;O
experience;O;O
an;O;O
excessive;O;O
reduction;O;O
of;O;O
blood;O;O
pressure;O;O
after;O;O
initiation;O;O
of;O;O
therapy;O;O
with;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s0.e1
or;O;O
enalaprilat;B-drug;B-DDI-DrugBank.d107.s0.e2
.;O;O
DDI-DrugBank.d107.s1;;
The;O;O
possibility;O;O
of;O;O
hypotensive;O;O
effects;O;O
with;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s1.e0
or;O;O
enalaprilat;B-drug;B-DDI-DrugBank.d107.s1.e1
can;O;O
be;O;O
minimized;O;O
by;O;O
either;O;O
discontinuing;O;O
the;O;O
diuretic;B-drug;B-DDI-DrugBank.d107.s1.e2
or;O;O
increasing;O;O
the;O;O
salt;O;O
intake;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s1.e3
or;O;O
enalaprilat;B-drug;B-DDI-DrugBank.d107.s1.e4
.;O;O
DDI-DrugBank.d107.s2;;
If;O;O
it;O;O
is;O;O
necessary;O;O
to;O;O
continue;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d107.s2.e0
,;O;O
provide;O;O
close;O;O
medical;O;O
supervision;O;O
after;O;O
the;O;O
initial;O;O
dose;O;O
for;O;O
at;O;O
least;O;O
two;O;O
hours;O;O
and;O;O
until;O;O
blood;O;O
pressure;O;O
has;O;O
stabilized;O;O
for;O;O
at;O;O
least;O;O
an;O;O
additional;O;O
hour;O;O
..;O;O
DDI-DrugBank.d107.s3;;
Agents;O;O
Causing;O;O
Renin;O;O
Release;O;O
:;O;O
The;O;O
antihypertensive;O;O
effect;O;O
of;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s3.e0
and;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s3.e1
IV;O;O
is;O;O
augmented;O;O
by;O;O
antihypertensive;B-group;B-DDI-DrugBank.d107.s3.e2
agents;I-group;I-DDI-DrugBank.d107.s3.e2
that;O;O
cause;O;O
renin;O;O
release;O;O
(;O;O
e.g.;O;O
,;O;O
diuretics;B-group;B-DDI-DrugBank.d107.s3.e3
);O;O
.;O;O
DDI-DrugBank.d107.s4;;
Non;B-group;B-DDI-DrugBank.d107.s4.e0
-;I-group;I-DDI-DrugBank.d107.s4.e0
steroidal;I-group;I-DDI-DrugBank.d107.s4.e0
Anti;I-group;I-DDI-DrugBank.d107.s4.e0
-;I-group;I-DDI-DrugBank.d107.s4.e0
inflammatory;I-group;I-DDI-DrugBank.d107.s4.e0
Agents;I-group;I-DDI-DrugBank.d107.s4.e0
:;O;O
In;O;O
some;O;O
patients;O;O
with;O;O
compromised;O;O
renal;O;O
function;O;O
who;O;O
are;O;O
being;O;O
treated;O;O
with;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d107.s4.e1
anti;I-group;I-DDI-DrugBank.d107.s4.e1
-;I-group;I-DDI-DrugBank.d107.s4.e1
inflammatory;I-group;I-DDI-DrugBank.d107.s4.e1
drugs;I-group;I-DDI-DrugBank.d107.s4.e1
,;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s4.e2
may;O;O
result;O;O
in;O;O
a;O;O
further;O;O
deterioration;O;O
of;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d107.s5;;
These;O;O
effects;O;O
are;O;O
usually;O;O
reversible;O;O
.;O;O
DDI-DrugBank.d107.s6;;
In;O;O
a;O;O
clinical;O;O
pharmacology;O;O
study;O;O
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d107.s6.e0
or;O;O
sulindac;B-drug;B-DDI-DrugBank.d107.s6.e1
was;O;O
administered;O;O
to;O;O
hypertensive;O;O
patients;O;O
receiving;O;O
VASOTEC;B-brand;B-DDI-DrugBank.d107.s6.e2
.;O;O
DDI-DrugBank.d107.s7;;
In;O;O
this;O;O
study;O;O
there;O;O
was;O;O
no;O;O
evidence;O;O
of;O;O
a;O;O
blunting;O;O
of;O;O
the;O;O
antihypertensive;O;O
action;O;O
of;O;O
VASOTEC;B-brand;B-DDI-DrugBank.d107.s7.e0
.;O;O
DDI-DrugBank.d107.s8;;
However;O;O
,;O;O
reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d107.s8.e0
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
ACE;B-group;B-DDI-DrugBank.d107.s8.e1
inhibitors;I-group;I-DDI-DrugBank.d107.s8.e1
.;O;O
DDI-DrugBank.d107.s9;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
NSAIDs;B-group;B-DDI-DrugBank.d107.s9.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d107.s9.e1
inhibitors;I-group;I-DDI-DrugBank.d107.s9.e1
.;O;O
DDI-DrugBank.d107.s10;;
Other;O;O
Cardiovascular;O;O
Agents;O;O
:;O;O
Enalapril;B-drug;B-DDI-DrugBank.d107.s10.e0
and;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s10.e1
IV;O;O
have;O;O
been;O;O
used;O;O
concomitantly;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d107.s10.e2
adrenergic;I-group;I-DDI-DrugBank.d107.s10.e2
-;I-group;I-DDI-DrugBank.d107.s10.e2
blocking;I-group;I-DDI-DrugBank.d107.s10.e2
agents;I-group;I-DDI-DrugBank.d107.s10.e2
,;O;O
methyldopa;B-drug;B-DDI-DrugBank.d107.s10.e3
,;O;O
nitrates;B-group;B-DDI-DrugBank.d107.s10.e4
,;O;O
calcium;B-group;B-DDI-DrugBank.d107.s10.e5
-;I-group;I-DDI-DrugBank.d107.s10.e5
blocking;I-group;I-DDI-DrugBank.d107.s10.e5
agents;I-group;I-DDI-DrugBank.d107.s10.e5
,;O;O
hydralazine;B-drug;B-DDI-DrugBank.d107.s10.e6
,;O;O
prazosin;B-drug;B-DDI-DrugBank.d107.s10.e7
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d107.s10.e8
without;O;O
evidence;O;O
of;O;O
clinically;O;O
significant;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d107.s11;;
Enalapril;B-drug;B-DDI-DrugBank.d107.s11.e0
IV;O;O
has;O;O
been;O;O
used;O;O
concomitantly;O;O
with;O;O
digitalis;B-group;B-DDI-DrugBank.d107.s11.e1
without;O;O
evidence;O;O
of;O;O
clinically;O;O
significant;O;O
adverse;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d107.s12;;
Agents;O;O
Increasing;O;O
Serum;O;O
Potassium;O;O
:;O;O
Enalapril;B-drug;B-DDI-DrugBank.d107.s12.e0
and;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s12.e1
IV;O;O
attenuate;O;O
potassium;O;O
loss;O;O
caused;O;O
by;O;O
thiazide;B-group;B-DDI-DrugBank.d107.s12.e2
-;I-group;I-DDI-DrugBank.d107.s12.e2
type;I-group;I-DDI-DrugBank.d107.s12.e2
diuretics;I-group;I-DDI-DrugBank.d107.s12.e2
.;O;O
DDI-DrugBank.d107.s13;;
Potassium;B-group;B-DDI-DrugBank.d107.s13.e0
-;I-group;I-DDI-DrugBank.d107.s13.e0
sparing;I-group;I-DDI-DrugBank.d107.s13.e0
diuretics;I-group;I-DDI-DrugBank.d107.s13.e0
(;O;O
e.g.;O;O
,;O;O
spironolactone;B-drug;B-DDI-DrugBank.d107.s13.e1
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d107.s13.e2
,;O;O
or;O;O
amiloride;B-drug;B-DDI-DrugBank.d107.s13.e3
);O;O
,;O;O
potassium;B-drug;B-DDI-DrugBank.d107.s13.e4
supplements;O;O
,;O;O
or;O;O
potassium;B-drug;B-DDI-DrugBank.d107.s13.e5
-;O;O
containing;O;O
salt;O;O
substitutes;O;O
may;O;O
lead;O;O
to;O;O
significant;O;O
increases;O;O
in;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d107.s14;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
is;O;O
indicated;O;O
because;O;O
of;O;O
demonstrated;O;O
hypokalemia;O;O
,;O;O
they;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
and;O;O
with;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d107.s15;;
Potassium;O;O
sparing;O;O
agents;O;O
should;O;O
generally;O;O
not;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
with;O;O
heart;O;O
failure;O;O
receiving;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s15.e0
.;O;O
DDI-DrugBank.d107.s16;;
Lithium;B-drug;B-DDI-DrugBank.d107.s16.e0
:;O;O
Lithium;B-drug;B-DDI-DrugBank.d107.s16.e1
toxicity;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d107.s16.e2
concomitantly;O;O
with;O;O
drugs;O;O
which;O;O
cause;O;O
elimination;O;O
of;O;O
sodium;O;O
,;O;O
including;O;O
ACE;B-group;B-DDI-DrugBank.d107.s16.e3
inhibitors;I-group;I-DDI-DrugBank.d107.s16.e3
.;O;O
DDI-DrugBank.d107.s17;;
It;O;O
is;O;O
recommended;O;O
that;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d107.s17.e0
levels;O;O
be;O;O
monitored;O;O
frequently;O;O
if;O;O
enalapril;B-drug;B-DDI-DrugBank.d107.s17.e1
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d107.s17.e2
.;O;O
DDI-DrugBank.d6.s0;;
The;O;O
action;O;O
of;O;O
nondepolarizing;O;O
relaxants;O;O
is;O;O
augmented;O;O
by;O;O
Enflurane;B-drug;B-DDI-DrugBank.d6.s0.e0
.;O;O
DDI-DrugBank.d6.s1;;
Less;O;O
than;O;O
the;O;O
usual;O;O
amounts;O;O
of;O;O
these;O;O
medicines;O;O
should;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d6.s2;;
If;O;O
the;O;O
usual;O;O
amounts;O;O
of;O;O
nondepolarizing;O;O
relaxants;O;O
are;O;O
given;O;O
,;O;O
the;O;O
time;O;O
for;O;O
recovery;O;O
from;O;O
neuromuscular;O;O
blockade;O;O
will;O;O
be;O;O
longer;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
Enflurane;B-drug;B-DDI-DrugBank.d6.s2.e0
than;O;O
when;O;O
halothane;B-drug;B-DDI-DrugBank.d6.s2.e1
or;O;O
nitrous;B-drug;B-DDI-DrugBank.d6.s2.e2
oxide;I-drug;I-DDI-DrugBank.d6.s2.e2
with;O;O
a;O;O
balanced;O;O
technique;O;O
are;O;O
used;O;O
.;O;O
DDI-DrugBank.d535.s0;;
CYP450;O;O
Metabolized;O;O
Drugs;O;O
Results;O;O
from;O;O
in;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
studies;O;O
suggest;O;O
that;O;O
enfuvirtide;B-drug;B-DDI-DrugBank.d535.s0.e0
is;O;O
unlikely;O;O
to;O;O
have;O;O
significant;O;O
drug;O;O
interactions;O;O
with;O;O
concomitantly;O;O
administered;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d535.s1;;
Antiretroviral;B-group;B-DDI-DrugBank.d535.s1.e0
Agents;I-group;I-DDI-DrugBank.d535.s1.e0
:;O;O
No;O;O
drug;O;O
interactions;O;O
with;O;O
other;O;O
antiretroviral;B-group;B-DDI-DrugBank.d535.s1.e1
medications;I-group;I-DDI-DrugBank.d535.s1.e1
have;O;O
been;O;O
identified;O;O
that;O;O
would;O;O
warrant;O;O
alteration;O;O
of;O;O
either;O;O
the;O;O
enfuvirtide;B-drug;B-DDI-DrugBank.d535.s1.e2
dose;O;O
or;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
other;O;O
antiretroviral;B-group;B-DDI-DrugBank.d535.s1.e3
medication;I-group;I-DDI-DrugBank.d535.s1.e3
.;O;O
DDI-DrugBank.d395.s0;;
Bismuth;B-drug;B-DDI-DrugBank.d395.s0.e0
:;O;O
Bismuth;B-drug;B-DDI-DrugBank.d395.s0.e1
subsalicylate;I-drug;I-DDI-DrugBank.d395.s0.e1
,;O;O
given;O;O
concomitantly;O;O
with;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s0.e2
or;O;O
60;O;O
minutes;O;O
following;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s0.e3
administration;O;O
,;O;O
decreased;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s0.e4
bioavailability;O;O
by;O;O
approximately;O;O
25;O;O
%;O;O
.;O;O
DDI-DrugBank.d395.s1;;
Thus;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s1.e0
and;O;O
bismuth;B-drug;B-DDI-DrugBank.d395.s1.e1
subsalicylate;I-drug;I-DDI-DrugBank.d395.s1.e1
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d395.s2;;
Caffeine;B-drug;B-DDI-DrugBank.d395.s2.e0
:;O;O
Enoxacin;B-drug;B-DDI-DrugBank.d395.s2.e1
is;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
the;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
isozymes;O;O
responsible;O;O
for;O;O
the;O;O
metabolism;O;O
of;O;O
methylxanthines;B-group;B-DDI-DrugBank.d395.s2.e2
.;O;O
DDI-DrugBank.d395.s3;;
In;O;O
a;O;O
multiple;O;O
-;O;O
dose;O;O
study;O;O
,;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s3.e0
caused;O;O
a;O;O
dose;O;O
-;O;O
related;O;O
increase;O;O
in;O;O
the;O;O
mean;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d395.s3.e1
,;O;O
thereby;O;O
decreasing;O;O
the;O;O
clearance;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d395.s3.e2
by;O;O
up;O;O
to;O;O
80;O;O
%;O;O
and;O;O
leading;O;O
to;O;O
a;O;O
five;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
the;O;O
AUC;O;O
and;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d395.s3.e3
.;O;O
DDI-DrugBank.d395.s4;;
Trough;O;O
plasma;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s4.e0
levels;O;O
were;O;O
also;O;O
20;O;O
%;O;O
higher;O;O
when;O;O
caffeine;B-drug;B-DDI-DrugBank.d395.s4.e1
and;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s4.e2
were;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d395.s5;;
Caffeine;B-drug;B-DDI-DrugBank.d395.s5.e0
-;O;O
related;O;O
adverse;O;O
effects;O;O
have;O;O
occurred;O;O
in;O;O
patients;O;O
consuming;O;O
caffeine;B-drug;B-DDI-DrugBank.d395.s5.e1
while;O;O
on;O;O
therapy;O;O
with;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s5.e2
.;O;O
DDI-DrugBank.d395.s6;;
Cyclosporine;B-drug;B-DDI-DrugBank.d395.s6.e0
:;O;O
Elevated;O;O
serum;O;O
levels;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d395.s6.e1
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d395.s6.e2
with;O;O
other;O;O
members;O;O
of;O;O
the;O;O
quinolone;B-group;B-DDI-DrugBank.d395.s6.e3
class;I-group;I-DDI-DrugBank.d395.s6.e3
.;O;O
DDI-DrugBank.d395.s7;;
Digoxin;B-drug;B-DDI-DrugBank.d395.s7.e0
:;O;O
Enoxacin;B-drug;B-DDI-DrugBank.d395.s7.e1
may;O;O
raise;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d395.s7.e2
levels;O;O
in;O;O
some;O;O
individuals;O;O
.;O;O
DDI-DrugBank.d395.s8;;
If;O;O
signs;O;O
and;O;O
symptoms;O;O
suggestive;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d395.s8.e0
toxicity;O;O
occur;O;O
when;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s8.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d395.s8.e2
are;O;O
given;O;O
concomitantly;O;O
,;O;O
physicians;O;O
are;O;O
advised;O;O
to;O;O
obtain;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d395.s8.e3
levels;O;O
and;O;O
adjust;O;O
digoxin;B-drug;B-DDI-DrugBank.d395.s8.e4
doses;O;O
appropriately;O;O
.;O;O
DDI-DrugBank.d395.s9;;
Non;B-group;B-DDI-DrugBank.d395.s9.e0
-;I-group;I-DDI-DrugBank.d395.s9.e0
steroidal;I-group;I-DDI-DrugBank.d395.s9.e0
anti;I-group;I-DDI-DrugBank.d395.s9.e0
-;I-group;I-DDI-DrugBank.d395.s9.e0
inflammatory;I-group;I-DDI-DrugBank.d395.s9.e0
agents;I-group;I-DDI-DrugBank.d395.s9.e0
:;O;O
Seizures;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
taking;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s9.e1
concomitantly;O;O
with;O;O
the;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d395.s9.e2
anti;I-group;I-DDI-DrugBank.d395.s9.e2
-;I-group;I-DDI-DrugBank.d395.s9.e2
inflammatory;I-group;I-DDI-DrugBank.d395.s9.e2
drug;I-group;I-DDI-DrugBank.d395.s9.e2
fenbufen;I-drug;I-DDI-DrugBank.d395.s9.e3
.;O;O
DDI-DrugBank.d395.s10;;
Animal;O;O
studies;O;O
also;O;O
suggest;O;O
an;O;O
increased;O;O
potential;O;O
for;O;O
seizures;O;O
when;O;O
these;O;O
two;O;O
drugs;O;O
are;O;O
given;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d395.s11;;
Fenbufen;B-drug;B-DDI-DrugBank.d395.s11.e0
is;O;O
not;O;O
approved;O;O
in;O;O
the;O;O
United;O;O
States;O;O
at;O;O
this;O;O
time;O;O
.;O;O
DDI-DrugBank.d395.s12;;
Sucralfate;B-drug;B-DDI-DrugBank.d395.s12.e0
and;O;O
antacids;B-group;B-DDI-DrugBank.d395.s12.e1
:;O;O
Quinolones;B-group;B-DDI-DrugBank.d395.s12.e2
form;O;O
chelates;O;O
with;O;O
metal;O;O
cations;O;O
.;O;O
DDI-DrugBank.d395.s13;;
Therefore;O;O
,;O;O
administration;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d395.s13.e0
with;O;O
antacids;B-group;B-DDI-DrugBank.d395.s13.e1
containing;O;O
calcium;B-drug;B-DDI-DrugBank.d395.s13.e2
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d395.s13.e3
,;O;O
or;O;O
aluminum;B-drug;B-DDI-DrugBank.d395.s13.e4
,;O;O
DDI-DrugBank.d395.s14;;
with;O;O
sucralfate;B-drug;B-DDI-DrugBank.d395.s14.e0
,;O;O
DDI-DrugBank.d395.s15;;
with;O;O
divalent;O;O
or;O;O
trivalent;O;O
cations;O;O
such;O;O
as;O;O
iron;B-drug;B-DDI-DrugBank.d395.s15.e0
,;O;O
DDI-DrugBank.d395.s16;;
or;O;O
with;O;O
multivitamins;B-group;B-DDI-DrugBank.d395.s16.e0
containing;O;O
zinc;B-drug;B-DDI-DrugBank.d395.s16.e1
may;O;O
substantially;O;O
interfere;O;O
with;O;O
drug;O;O
absorption;O;O
and;O;O
result;O;O
in;O;O
insufficient;O;O
plasma;O;O
and;O;O
tissue;O;O
quinolone;B-group;B-DDI-DrugBank.d395.s16.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d395.s17;;
Antacids;B-group;B-DDI-DrugBank.d395.s17.e0
containing;O;O
aluminum;B-drug;B-DDI-DrugBank.d395.s17.e1
hydroxide;I-drug;I-DDI-DrugBank.d395.s17.e1
and;O;O
magnesium;B-drug;B-DDI-DrugBank.d395.s17.e2
hydroxide;I-drug;I-DDI-DrugBank.d395.s17.e2
reduce;O;O
the;O;O
oral;O;O
absorption;O;O
of;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s17.e3
by;O;O
75;O;O
%;O;O
.;O;O
DDI-DrugBank.d395.s18;;
The;O;O
oral;O;O
bioavailability;O;O
of;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s18.e0
is;O;O
reduced;O;O
by;O;O
60;O;O
%;O;O
with;O;O
coadministration;O;O
of;O;O
ranitidine;B-drug;B-DDI-DrugBank.d395.s18.e1
.;O;O
DDI-DrugBank.d395.s19;;
These;O;O
agents;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
for;O;O
8;O;O
hours;O;O
before;O;O
or;O;O
for;O;O
2;O;O
hours;O;O
after;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s19.e0
administration;O;O
.;O;O
DDI-DrugBank.d395.s20;;
Theophylline;B-drug;B-DDI-DrugBank.d395.s20.e0
:;O;O
Enoxacin;B-drug;B-DDI-DrugBank.d395.s20.e1
is;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
the;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
isozymes;O;O
responsible;O;O
for;O;O
the;O;O
metabolism;O;O
of;O;O
methylxanthines;B-group;B-DDI-DrugBank.d395.s20.e2
.;O;O
DDI-DrugBank.d395.s21;;
Enoxacin;B-drug;B-DDI-DrugBank.d395.s21.e0
interferes;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d395.s21.e1
resulting;O;O
in;O;O
a;O;O
42;O;O
%;O;O
to;O;O
74;O;O
%;O;O
dose;O;O
-;O;O
related;O;O
decrease;O;O
in;O;O
theophylline;B-drug;B-DDI-DrugBank.d395.s21.e2
clearance;O;O
and;O;O
a;O;O
subsequent;O;O
260;O;O
%;O;O
to;O;O
350;O;O
%;O;O
increase;O;O
in;O;O
serum;O;O
theophylline;O;O
levels;O;O
.;O;O
DDI-DrugBank.d395.s22;;
Theophylline;B-drug;B-DDI-DrugBank.d395.s22.e0
-;O;O
related;O;O
adverse;O;O
effects;O;O
have;O;O
occurred;O;O
in;O;O
patients;O;O
when;O;O
theophylline;B-drug;B-DDI-DrugBank.d395.s22.e1
and;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s22.e2
were;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d395.s23;;
Warfarin;B-drug;B-DDI-DrugBank.d395.s23.e0
:;O;O
Quinolones;B-group;B-DDI-DrugBank.d395.s23.e1
,;O;O
including;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s23.e2
,;O;O
decrease;O;O
the;O;O
clearance;O;O
of;O;O
R;B-drug;B-DDI-DrugBank.d395.s23.e3
-;I-drug;I-DDI-DrugBank.d395.s23.e3
warfarin;I-drug;I-DDI-DrugBank.d395.s23.e3
,;O;O
the;O;O
less;O;O
active;O;O
isomer;O;O
of;O;O
racemic;O;O
warfarin;B-drug;B-DDI-DrugBank.d395.s23.e4
.;O;O
DDI-DrugBank.d395.s24;;
Enoxacin;B-drug;B-DDI-DrugBank.d395.s24.e0
does;O;O
not;O;O
affect;O;O
the;O;O
clearance;O;O
of;O;O
the;O;O
active;O;O
S;O;O
-;O;O
isomer;O;O
,;O;O
and;O;O
changes;O;O
in;O;O
clotting;O;O
time;O;O
have;O;O
not;O;O
been;O;O
observed;O;O
when;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s24.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d395.s24.e2
were;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d395.s25;;
Nevertheless;O;O
,;O;O
the;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
coagulation;O;O
test;O;O
should;O;O
be;O;O
monitored;O;O
when;O;O
warfarin;B-drug;B-DDI-DrugBank.d395.s25.e0
or;O;O
its;O;O
derivatives;O;O
and;O;O
enoxacin;B-drug;B-DDI-DrugBank.d395.s25.e1
are;O;O
given;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d474.s0;;
Unless;O;O
really;O;O
needed;O;O
,;O;O
agents;O;O
which;O;O
may;O;O
enhance;O;O
the;O;O
risk;O;O
of;O;O
hemorrhage;O;O
should;O;O
be;O;O
discontinued;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
Lovenox;B-brand;B-DDI-DrugBank.d474.s0.e0
Injection;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d474.s1;;
These;O;O
agents;O;O
include;O;O
medications;O;O
such;O;O
as;O;O
:;O;O
anticoagulants;B-group;B-DDI-DrugBank.d474.s1.e0
,;O;O
platelet;B-group;B-DDI-DrugBank.d474.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d474.s1.e1
including;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d474.s1.e2
acid;I-drug;I-DDI-DrugBank.d474.s1.e2
,;O;O
sali;O;O
-;O;O
cylates;O;O
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d474.s1.e3
(;O;O
including;O;O
ketorolac;B-drug;B-DDI-DrugBank.d474.s1.e4
tromethamine;I-drug;I-DDI-DrugBank.d474.s1.e4
);O;O
,;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d474.s1.e5
,;O;O
or;O;O
sulfinpyrazone;B-drug;B-DDI-DrugBank.d474.s1.e6
.;O;O
DDI-DrugBank.d474.s2;;
If;O;O
co;O;O
-;O;O
administration;O;O
is;O;O
essential;O;O
,;O;O
conduct;O;O
close;O;O
clinical;O;O
and;O;O
laboratory;O;O
monitoring;O;O
DDI-DrugBank.d474.s3;;
.;O;O
DDI-DrugBank.d474.s4;;
DDI-DrugBank.d455.s0;;
In;O;O
vitro;O;O
studies;O;O
of;O;O
human;O;O
CYP;O;O
enzymes;O;O
showed;O;O
that;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s0.e0
inhibited;O;O
the;O;O
CYP;O;O
enzymes;O;O
1A2;O;O
,;O;O
2A6;O;O
,;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
2D6;O;O
,;O;O
2E1;O;O
and;O;O
3A;O;O
only;O;O
at;O;O
very;O;O
high;O;O
concentrations;O;O
(;O;O
IC50;O;O
from;O;O
200;O;O
to;O;O
over;O;O
1000;O;O
uM;O;O
,;O;O
DDI-DrugBank.d455.s1;;
an;O;O
oral;O;O
200;O;O
mg;O;O
dose;O;O
achieves;O;O
a;O;O
highest;O;O
level;O;O
of;O;O
approximately;O;O
5;O;O
uM;O;O
in;O;O
people;O;O
);O;O
,;O;O
DDI-DrugBank.d455.s2;;
these;O;O
enzymes;O;O
would;O;O
therefore;O;O
not;O;O
be;O;O
expected;O;O
to;O;O
be;O;O
inhibited;O;O
in;O;O
clinical;O;O
use;O;O
.;O;O
DDI-DrugBank.d455.s3;;
Protein;O;O
Binding;O;O
:;O;O
Entacapone;B-drug;B-DDI-DrugBank.d455.s3.e0
is;O;O
highly;O;O
protein;O;O
bound;O;O
(;O;O
98;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d455.s4;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
no;O;O
binding;O;O
displacement;O;O
between;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s4.e0
and;O;O
other;O;O
highly;O;O
bound;O;O
drugs;O;O
,;O;O
such;O;O
as;O;O
warfarin;B-drug;B-DDI-DrugBank.d455.s4.e1
,;O;O
salicylic;B-drug;B-DDI-DrugBank.d455.s4.e2
acid;I-drug;I-DDI-DrugBank.d455.s4.e2
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d455.s4.e3
,;O;O
and;O;O
diazepam;B-drug;B-DDI-DrugBank.d455.s4.e4
.;O;O
DDI-DrugBank.d455.s5;;
Drugs;O;O
Metabolized;O;O
by;O;O
Catechol;O;O
-;O;O
O;O;O
-;O;O
methyltransferase;O;O
(;O;O
COMT;O;O
);O;O
:;O;O
Hormone;O;O
levels;O;O
:;O;O
Levodopa;B-drug;B-DDI-DrugBank.d455.s5.e0
is;O;O
known;O;O
to;O;O
depress;O;O
prolactin;O;O
secretion;O;O
and;O;O
increase;O;O
growth;O;O
hormone;O;O
levels;O;O
.;O;O
DDI-DrugBank.d455.s6;;
Treatment;O;O
with;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s6.e0
coadministered;O;O
with;O;O
levodopa;B-drug;B-DDI-DrugBank.d455.s6.e1
/;O;O
dopa;B-group;B-DDI-DrugBank.d455.s6.e2
decarboxylase;I-group;I-DDI-DrugBank.d455.s6.e2
inhibitor;I-group;I-DDI-DrugBank.d455.s6.e2
does;O;O
not;O;O
change;O;O
these;O;O
effects;O;O
.;O;O
DDI-DrugBank.d455.s7;;
No;O;O
interaction;O;O
was;O;O
noted;O;O
with;O;O
the;O;O
MAO;B-group;B-DDI-DrugBank.d455.s7.e0
-;I-group;I-DDI-DrugBank.d455.s7.e0
B;I-group;I-DDI-DrugBank.d455.s7.e0
inhibitor;I-group;I-DDI-DrugBank.d455.s7.e0
selegiline;I-drug;I-DDI-DrugBank.d455.s7.e1
in;O;O
two;O;O
multiple;O;O
-;O;O
dose;O;O
interaction;O;O
studies;O;O
when;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s7.e2
was;O;O
coadministered;O;O
with;O;O
a;O;O
levodopa;B-drug;B-DDI-DrugBank.d455.s7.e3
/;O;O
dopa;B-group;B-DDI-DrugBank.d455.s7.e4
decarboxylase;I-group;I-DDI-DrugBank.d455.s7.e4
inhibitor;I-group;I-DDI-DrugBank.d455.s7.e4
(;O;O
n=29;O;O
);O;O
.;O;O
DDI-DrugBank.d455.s8;;
More;O;O
than;O;O
600;O;O
Parkinsons;O;O
disease;O;O
patients;O;O
in;O;O
clinical;O;O
trials;O;O
have;O;O
used;O;O
selegiline;B-drug;B-DDI-DrugBank.d455.s8.e0
in;O;O
combination;O;O
with;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s8.e1
and;O;O
levodopa;B-drug;B-DDI-DrugBank.d455.s8.e2
/;O;O
dopa;B-group;B-DDI-DrugBank.d455.s8.e3
decarboxylase;I-group;I-DDI-DrugBank.d455.s8.e3
inhibitor;I-group;I-DDI-DrugBank.d455.s8.e3
.;O;O
DDI-DrugBank.d455.s9;;
As;O;O
most;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s9.e0
excretion;O;O
is;O;O
via;O;O
the;O;O
bile;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
drugs;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
biliary;O;O
excretion;O;O
,;O;O
glucuronidation;O;O
,;O;O
and;O;O
intestinal;O;O
beta;O;O
-;O;O
glucuronidase;O;O
are;O;O
given;O;O
concurrently;O;O
with;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s9.e1
.;O;O
DDI-DrugBank.d455.s10;;
These;O;O
include;O;O
probenecid;B-drug;B-DDI-DrugBank.d455.s10.e0
,;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d455.s10.e1
,;O;O
and;O;O
some;O;O
antibiotics;B-group;B-DDI-DrugBank.d455.s10.e2
(;O;O
e.g.;O;O
erythromycin;B-drug;B-DDI-DrugBank.d455.s10.e3
,;O;O
rifamipicin;O;O
,;O;O
ampicillin;B-drug;B-DDI-DrugBank.d455.s10.e4
and;O;O
chloramphenicol;B-drug;B-DDI-DrugBank.d455.s10.e5
);O;O
.;O;O
DDI-DrugBank.d455.s11;;
No;O;O
interaction;O;O
with;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d455.s11.e0
antidepressant;I-group;I-DDI-DrugBank.d455.s11.e0
imipramine;I-drug;I-DDI-DrugBank.d455.s11.e1
was;O;O
shown;O;O
in;O;O
a;O;O
single;O;O
-;O;O
dose;O;O
study;O;O
with;O;O
entacapone;B-drug;B-DDI-DrugBank.d455.s11.e2
without;O;O
coadministered;O;O
levodopa;B-drug;B-DDI-DrugBank.d455.s11.e3
/;O;O
dopa;B-group;B-DDI-DrugBank.d455.s11.e4
-;I-group;I-DDI-DrugBank.d455.s11.e4
decarboxylase;I-group;I-DDI-DrugBank.d455.s11.e4
inhibitor;I-group;I-DDI-DrugBank.d455.s11.e4
.;O;O
DDI-DrugBank.d295.s0;;
Since;O;O
entecavir;B-drug;B-DDI-DrugBank.d295.s0.e0
is;O;O
primarily;O;O
eliminated;O;O
by;O;O
the;O;O
kidneys;O;O
,;O;O
coadministration;O;O
of;O;O
BARACLUDE;B-brand;B-DDI-DrugBank.d295.s0.e1
with;O;O
drugs;O;O
that;O;O
reduce;O;O
renal;O;O
function;O;O
or;O;O
compete;O;O
for;O;O
active;O;O
tubular;O;O
secretion;O;O
may;O;O
increase;O;O
serum;O;O
concentrations;O;O
of;O;O
either;O;O
entecavir;B-drug;B-DDI-DrugBank.d295.s0.e2
or;O;O
the;O;O
coadministered;O;O
drug;O;O
.;O;O
DDI-DrugBank.d295.s1;;
Coadministration;O;O
of;O;O
entecavir;B-drug;B-DDI-DrugBank.d295.s1.e0
with;O;O
lamivudine;B-drug;B-DDI-DrugBank.d295.s1.e1
,;O;O
adefovir;B-drug;B-DDI-DrugBank.d295.s1.e2
dipivoxil;I-drug;I-DDI-DrugBank.d295.s1.e2
,;O;O
or;O;O
tenofovir;B-drug;B-DDI-DrugBank.d295.s1.e3
disoproxil;I-drug;I-DDI-DrugBank.d295.s1.e3
fumarate;I-drug;I-DDI-DrugBank.d295.s1.e3
did;O;O
not;O;O
result;O;O
in;O;O
significant;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d295.s2;;
The;O;O
effects;O;O
of;O;O
coadministration;O;O
of;O;O
BARACLUDE;B-brand;B-DDI-DrugBank.d295.s2.e0
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
renally;O;O
eliminated;O;O
or;O;O
are;O;O
known;O;O
to;O;O
affect;O;O
renal;O;O
function;O;O
have;O;O
not;O;O
been;O;O
evaluated;O;O
,;O;O
and;O;O
patients;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
for;O;O
adverse;O;O
events;O;O
when;O;O
BARACLUDE;B-brand;B-DDI-DrugBank.d295.s2.e1
is;O;O
coadministered;O;O
with;O;O
such;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d156.s0;;
None;O;O
Reported;O;O
DDI-DrugBank.d247.s0;;
Epinephrine;B-drug;B-DDI-DrugBank.d247.s0.e0
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
patients;O;O
with;O;O
hyperthyroidism;O;O
,;O;O
hypertension;O;O
and;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d247.s1;;
All;O;O
vasopressors;B-group;B-DDI-DrugBank.d247.s1.e0
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
patients;O;O
taking;O;O
monoamine;B-group;B-DDI-DrugBank.d247.s1.e1
oxidase;I-group;I-DDI-DrugBank.d247.s1.e1
(;I-group;I-DDI-DrugBank.d247.s1.e1
MAO;I-group;I-DDI-DrugBank.d247.s1.e1
);I-group;I-DDI-DrugBank.d247.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d247.s1.e1
.;O;O
DDI-DrugBank.d247.s2;;
Epinephrine;B-drug;B-DDI-DrugBank.d247.s2.e0
should;O;O
not;O;O
be;O;O
administered;O;O
concomitantly;O;O
with;O;O
other;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d247.s2.e1
drugs;I-group;I-DDI-DrugBank.d247.s2.e1
(;O;O
such;O;O
as;O;O
isoproterenol;B-drug;B-DDI-DrugBank.d247.s2.e2
);O;O
because;O;O
of;O;O
possible;O;O
additive;O;O
effects;O;O
and;O;O
increased;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d247.s3;;
Combined;O;O
effects;O;O
may;O;O
induce;O;O
serious;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d247.s4;;
They;O;O
may;O;O
be;O;O
administered;O;O
alternately;O;O
when;O;O
the;O;O
preceding;O;O
effect;O;O
of;O;O
other;O;O
such;O;O
drug;O;O
has;O;O
subsided;O;O
.;O;O
DDI-DrugBank.d247.s5;;
Administration;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d247.s5.e0
to;O;O
patients;O;O
receiving;O;O
cyclopropane;B-drug;B-DDI-DrugBank.d247.s5.e1
or;O;O
halogenated;B-group;B-DDI-DrugBank.d247.s5.e2
hydrocarbon;I-group;I-DDI-DrugBank.d247.s5.e2
general;I-group;I-DDI-DrugBank.d247.s5.e2
anesthetics;I-group;I-DDI-DrugBank.d247.s5.e2
such;O;O
as;O;O
halothane;B-drug;B-DDI-DrugBank.d247.s5.e3
which;O;O
sensitize;O;O
the;O;O
myocardium;O;O
,;O;O
may;O;O
induce;O;O
cardiac;O;O
arrhythmia;O;O
..;O;O
DDI-DrugBank.d247.s6;;
When;O;O
encountered;O;O
,;O;O
such;O;O
arrhythmias;O;O
may;O;O
respond;O;O
to;O;O
administration;O;O
of;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d247.s6.e0
-;I-group;I-DDI-DrugBank.d247.s6.e0
adrenergic;I-group;I-DDI-DrugBank.d247.s6.e0
blocking;I-group;I-DDI-DrugBank.d247.s6.e0
drug;I-group;I-DDI-DrugBank.d247.s6.e0
.;O;O
DDI-DrugBank.d247.s7;;
Epinephrine;B-drug;B-DDI-DrugBank.d247.s7.e0
also;O;O
should;O;O
be;O;O
used;O;O
cautiously;O;O
with;O;O
other;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
digitalis;B-group;B-DDI-DrugBank.d247.s7.e1
,;O;O
glycosides;B-group;B-DDI-DrugBank.d247.s7.e2
);O;O
that;O;O
sensitize;O;O
the;O;O
myocardium;O;O
to;O;O
the;O;O
actions;O;O
of;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d247.s7.e3
drugs;I-group;I-DDI-DrugBank.d247.s7.e3
.;O;O
DDI-DrugBank.d247.s8;;
Diuretic;B-group;B-DDI-DrugBank.d247.s8.e0
agents;I-group;I-DDI-DrugBank.d247.s8.e0
may;O;O
decrease;O;O
vascular;O;O
response;O;O
to;O;O
pressor;O;O
drugs;O;O
such;O;O
as;O;O
epinephrine;B-drug;B-DDI-DrugBank.d247.s8.e1
.;O;O
DDI-DrugBank.d247.s9;;
Epinephrine;B-drug;B-DDI-DrugBank.d247.s9.e0
may;O;O
antagonize;O;O
the;O;O
neuron;O;O
blockade;O;O
produced;O;O
by;O;O
guanethidine;B-drug;B-DDI-DrugBank.d247.s9.e1
resulting;O;O
in;O;O
decreased;O;O
antihypertensive;O;O
effect;O;O
and;O;O
requiring;O;O
increased;O;O
dosage;O;O
of;O;O
the;O;O
latter;O;O
.;O;O
DDI-DrugBank.d428.s0;;
ELLENCE;B-brand;B-DDI-DrugBank.d428.s0.e0
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
cytotoxic;O;O
drugs;O;O
may;O;O
show;O;O
on;O;O
-;O;O
treatment;O;O
additive;O;O
toxicity;O;O
,;O;O
especially;O;O
hematologic;O;O
and;O;O
gastrointestinal;O;O
effects;O;O
.;O;O
DDI-DrugBank.d428.s1;;
Concomitant;O;O
use;O;O
of;O;O
ELLENCE;B-brand;B-DDI-DrugBank.d428.s1.e0
with;O;O
other;O;O
cardioactive;O;O
compounds;O;O
that;O;O
could;O;O
cause;O;O
heart;O;O
failure;O;O
(;O;O
e.g.;O;O
,;O;O
calcium;B-group;B-DDI-DrugBank.d428.s1.e1
channel;I-group;I-DDI-DrugBank.d428.s1.e1
blockers;I-group;I-DDI-DrugBank.d428.s1.e1
);O;O
,;O;O
requires;O;O
close;O;O
monitoring;O;O
of;O;O
cardiac;O;O
function;O;O
throughout;O;O
treatment;O;O
.;O;O
DDI-DrugBank.d428.s2;;
There;O;O
are;O;O
few;O;O
data;O;O
regarding;O;O
the;O;O
coadministration;O;O
of;O;O
radiation;O;O
therapy;O;O
and;O;O
epirubicin;B-drug;B-DDI-DrugBank.d428.s2.e0
.;O;O
DDI-DrugBank.d428.s3;;
In;O;O
adjuvant;O;O
trials;O;O
of;O;O
epirubicin;B-drug;B-DDI-DrugBank.d428.s3.e0
-;O;O
containing;O;O
CEF;O;O
-;O;O
120;O;O
or;O;O
FEC;O;O
-;O;O
100;O;O
chemotherapies;O;O
,;O;O
breast;O;O
irradiation;O;O
was;O;O
delayed;O;O
until;O;O
after;O;O
chemotherapy;O;O
was;O;O
completed;O;O
.;O;O
DDI-DrugBank.d428.s4;;
This;O;O
practice;O;O
resulted;O;O
in;O;O
no;O;O
apparent;O;O
increase;O;O
in;O;O
local;O;O
breast;O;O
cancer;O;O
recurrence;O;O
relative;O;O
to;O;O
published;O;O
accounts;O;O
in;O;O
the;O;O
literature;O;O
.;O;O
DDI-DrugBank.d428.s5;;
A;O;O
small;O;O
number;O;O
of;O;O
patients;O;O
received;O;O
epirubicin;B-drug;B-DDI-DrugBank.d428.s5.e0
-;O;O
based;O;O
chemotherapy;O;O
concomitantly;O;O
with;O;O
radiation;O;O
therapy;O;O
but;O;O
had;O;O
chemotherapy;O;O
interrupted;O;O
in;O;O
order;O;O
to;O;O
avoid;O;O
potential;O;O
overlapping;O;O
toxicities;O;O
.;O;O
DDI-DrugBank.d428.s6;;
It;O;O
is;O;O
likely;O;O
that;O;O
use;O;O
of;O;O
epirubicin;B-drug;B-DDI-DrugBank.d428.s6.e0
with;O;O
radiotherapy;O;O
may;O;O
sensitize;O;O
tissues;O;O
to;O;O
the;O;O
cytotoxic;O;O
actions;O;O
of;O;O
irradiation;O;O
.;O;O
DDI-DrugBank.d428.s7;;
Administration;O;O
of;O;O
ELLENCE;B-brand;B-DDI-DrugBank.d428.s7.e0
after;O;O
previous;O;O
radiation;O;O
therapy;O;O
may;O;O
induce;O;O
an;O;O
inflammatory;O;O
recall;O;O
reaction;O;O
at;O;O
the;O;O
site;O;O
of;O;O
the;O;O
irradiation;O;O
.;O;O
DDI-DrugBank.d428.s8;;
Epirubicin;B-drug;B-DDI-DrugBank.d428.s8.e0
is;O;O
extensively;O;O
metabolized;O;O
by;O;O
the;O;O
liver;O;O
.;O;O
DDI-DrugBank.d428.s9;;
Changes;O;O
in;O;O
hepatic;O;O
function;O;O
induced;O;O
by;O;O
concomitant;O;O
therapies;O;O
may;O;O
affect;O;O
epirubicin;B-drug;B-DDI-DrugBank.d428.s9.e0
metabolism;O;O
,;O;O
pharmacokinetics;O;O
,;O;O
therapeutic;O;O
efficacy;O;O
,;O;O
and/or;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d428.s10;;
Cimetidine;B-drug;B-DDI-DrugBank.d428.s10.e0
increased;O;O
the;O;O
AUC;O;O
of;O;O
epirubicin;B-drug;B-DDI-DrugBank.d428.s10.e1
by;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d428.s11;;
Cimetidine;B-drug;B-DDI-DrugBank.d428.s11.e0
treatment;O;O
should;O;O
be;O;O
stopped;O;O
during;O;O
treatment;O;O
with;O;O
ELLENCE;B-brand;B-DDI-DrugBank.d428.s11.e1
.;O;O
DDI-DrugBank.d428.s12;;
Drug;O;O
-;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
known;O;O
interactions;O;O
between;O;O
ELLENCE;B-brand;B-DDI-DrugBank.d428.s12.e0
and;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d20.s0;;
Inhibitors;O;O
of;O;O
CYP3A4;O;O
-;O;O
Eplerenone;B-drug;B-DDI-DrugBank.d20.s0.e0
metabolism;O;O
is;O;O
predominantly;O;O
mediated;O;O
via;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d20.s1;;
A;O;O
pharmacokinetic;O;O
study;O;O
evaluating;O;O
the;O;O
administration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
INSPRA;B-brand;B-DDI-DrugBank.d20.s1.e0
100;O;O
mg;O;O
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d20.s1.e1
200;O;O
mg;O;O
BID;O;O
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
the;O;O
CYP3A4;O;O
pathway;O;O
,;O;O
showed;O;O
a;O;O
1.7;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
Cmax;O;O
of;O;O
eplerenone;B-drug;B-DDI-DrugBank.d20.s1.e2
and;O;O
a;O;O
5.4;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
AUC;O;O
of;O;O
eplerenone;B-drug;B-DDI-DrugBank.d20.s1.e3
.;O;O
DDI-DrugBank.d20.s2;;
INSPRA;B-brand;B-DDI-DrugBank.d20.s2.e0
should;O;O
not;O;O
be;O;O
used;O;O
with;O;O
drugs;O;O
described;O;O
as;O;O
strong;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
in;O;O
their;O;O
labeling;O;O
.;O;O
DDI-DrugBank.d20.s3;;
Administration;O;O
of;O;O
eplerenone;B-drug;B-DDI-DrugBank.d20.s3.e0
with;O;O
other;O;O
CYP3A4;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d20.s3.e1
500;O;O
mg;O;O
BID;O;O
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d20.s3.e2
240;O;O
mg;O;O
QD;O;O
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d20.s3.e3
1200;O;O
mg;O;O
TID;O;O
,;O;O
fluconazole;B-drug;B-DDI-DrugBank.d20.s3.e4
200;O;O
mg;O;O
QD;O;O
);O;O
resulted;O;O
in;O;O
increases;O;O
in;O;O
Cmax;O;O
of;O;O
eplerenone;B-drug;B-DDI-DrugBank.d20.s3.e5
ranging;O;O
from;O;O
1.4;O;O
-;O;O
to;O;O
1.6;O;O
-;O;O
fold;O;O
and;O;O
AUC;O;O
from;O;O
2.0;O;O
-;O;O
to;O;O
2.9;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d20.s4;;
ACE;B-group;B-DDI-DrugBank.d20.s4.e0
Inhibitors;I-group;I-DDI-DrugBank.d20.s4.e0
and;O;O
Angiotensin;B-group;B-DDI-DrugBank.d20.s4.e1
II;I-group;I-DDI-DrugBank.d20.s4.e1
Receptor;I-group;I-DDI-DrugBank.d20.s4.e1
Antagonists;I-group;I-DDI-DrugBank.d20.s4.e1
(;O;O
Congestive;O;O
Heart;O;O
Failure;O;O
Post;O;O
-;O;O
Myocardial;O;O
Infarction);O;O
-;O;O
In;O;O
EPHESUS;O;O
,;O;O
3020;O;O
(;O;O
91;O;O
%;O;O
);O;O
patients;O;O
receiving;O;O
INSPRA;B-brand;B-DDI-DrugBank.d20.s4.e2
25;O;O
to;O;O
50;O;O
mg;O;O
also;O;O
received;O;O
ACE;B-group;B-DDI-DrugBank.d20.s4.e3
inhibitors;I-group;I-DDI-DrugBank.d20.s4.e3
or;O;O
angiotensin;B-group;B-DDI-DrugBank.d20.s4.e4
II;I-group;I-DDI-DrugBank.d20.s4.e4
receptor;I-group;I-DDI-DrugBank.d20.s4.e4
antagonists;I-group;I-DDI-DrugBank.d20.s4.e4
(;O;O
ACEI;B-group;B-DDI-DrugBank.d20.s4.e5
/;O;O
ARB;B-group;B-DDI-DrugBank.d20.s4.e6
);O;O
.;O;O
DDI-DrugBank.d20.s5;;
Rates;O;O
of;O;O
patients;O;O
with;O;O
maximum;O;O
potassium;O;O
levels;O;O
5.5;O;O
mEq;O;O
/;O;O
L;O;O
were;O;O
similar;O;O
regardless;O;O
of;O;O
the;O;O
use;O;O
of;O;O
ACEI;B-group;B-DDI-DrugBank.d20.s5.e0
/;O;O
ARB;B-group;B-DDI-DrugBank.d20.s5.e1
.;O;O
DDI-DrugBank.d20.s6;;
ACE;B-group;B-DDI-DrugBank.d20.s6.e0
Inhibitors;I-group;I-DDI-DrugBank.d20.s6.e0
and;O;O
Angiotensin;B-group;B-DDI-DrugBank.d20.s6.e1
II;I-group;I-DDI-DrugBank.d20.s6.e1
Receptor;I-group;I-DDI-DrugBank.d20.s6.e1
Antagonists;I-group;I-DDI-DrugBank.d20.s6.e1
(;O;O
Hypertension);O;O
-;O;O
In;O;O
clinical;O;O
studies;O;O
of;O;O
patients;O;O
with;O;O
hypertension;O;O
,;O;O
the;O;O
addition;O;O
of;O;O
INSPRA;B-brand;B-DDI-DrugBank.d20.s6.e2
50;O;O
to;O;O
100;O;O
mg;O;O
to;O;O
ACE;B-group;B-DDI-DrugBank.d20.s6.e3
inhibitors;I-group;I-DDI-DrugBank.d20.s6.e3
and;O;O
angiotensin;B-group;B-DDI-DrugBank.d20.s6.e4
II;I-group;I-DDI-DrugBank.d20.s6.e4
receptor;I-group;I-DDI-DrugBank.d20.s6.e4
antagonists;I-group;I-DDI-DrugBank.d20.s6.e4
increased;O;O
mean;O;O
serum;O;O
potassium;O;O
slightly;O;O
(;O;O
about;O;O
0.09;O;O
-;O;O
0.13;O;O
mEq;O;O
/;O;O
L;O;O
);O;O
.;O;O
DDI-DrugBank.d20.s7;;
In;O;O
a;O;O
study;O;O
in;O;O
diabetics;O;O
with;O;O
microalbuminuria;O;O
INSPRA;B-brand;B-DDI-DrugBank.d20.s7.e0
200;O;O
mg;O;O
combined;O;O
with;O;O
the;O;O
ACE;B-group;B-DDI-DrugBank.d20.s7.e1
inhibitor;I-group;I-DDI-DrugBank.d20.s7.e1
enalapril;I-drug;I-DDI-DrugBank.d20.s7.e2
10;O;O
mg;O;O
increased;O;O
the;O;O
frequency;O;O
of;O;O
hyperkalemia;O;O
(;O;O
serum;O;O
potassium;O;O
5.5;O;O
mEq;O;O
/;O;O
L;O;O
);O;O
from;O;O
17;O;O
%;O;O
on;O;O
enalapril;B-drug;B-DDI-DrugBank.d20.s7.e3
alone;O;O
to;O;O
38;O;O
%;O;O
.;O;O
DDI-DrugBank.d20.s8;;
Lithium;B-drug;B-DDI-DrugBank.d20.s8.e0
-;O;O
A;O;O
drug;O;O
interaction;O;O
study;O;O
of;O;O
eplerenone;B-drug;B-DDI-DrugBank.d20.s8.e1
with;O;O
lithium;B-drug;B-DDI-DrugBank.d20.s8.e2
has;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d20.s9;;
Serum;O;O
lithium;B-drug;B-DDI-DrugBank.d20.s9.e0
levels;O;O
should;O;O
be;O;O
monitored;O;O
frequently;O;O
if;O;O
INSPRA;B-brand;B-DDI-DrugBank.d20.s9.e1
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d20.s9.e2
.;O;O
DDI-DrugBank.d20.s10;;
Nonsteroidal;B-group;B-DDI-DrugBank.d20.s10.e0
Anti;I-group;I-DDI-DrugBank.d20.s10.e0
-;I-group;I-DDI-DrugBank.d20.s10.e0
Inflammatory;I-group;I-DDI-DrugBank.d20.s10.e0
Drugs;I-group;I-DDI-DrugBank.d20.s10.e0
(;O;O
NSAIDs);B-group;B-DDI-DrugBank.d20.s10.e1
-;O;O
A;O;O
drug;O;O
interaction;O;O
study;O;O
of;O;O
eplerenone;B-drug;B-DDI-DrugBank.d20.s10.e2
with;O;O
an;O;O
NSAID;B-group;B-DDI-DrugBank.d20.s10.e3
has;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d20.s11;;
The;O;O
administration;O;O
of;O;O
other;O;O
potassium;B-group;B-DDI-DrugBank.d20.s11.e0
-;I-group;I-DDI-DrugBank.d20.s11.e0
sparing;I-group;I-DDI-DrugBank.d20.s11.e0
antihypertensives;I-group;I-DDI-DrugBank.d20.s11.e0
with;O;O
NSAIDs;B-group;B-DDI-DrugBank.d20.s11.e1
has;O;O
been;O;O
shown;O;O
to;O;O
reduce;O;O
the;O;O
antihypertensive;O;O
effect;O;O
in;O;O
some;O;O
patients;O;O
and;O;O
result;O;O
in;O;O
severe;O;O
hyperkalemia;O;O
in;O;O
patients;O;O
with;O;O
impaired;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d20.s12;;
Therefore;O;O
,;O;O
when;O;O
INSPRA;B-brand;B-DDI-DrugBank.d20.s12.e0
and;O;O
NSAIDs;B-group;B-DDI-DrugBank.d20.s12.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
observed;O;O
to;O;O
determine;O;O
whether;O;O
the;O;O
desired;O;O
effect;O;O
on;O;O
blood;O;O
pressure;O;O
is;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d496.s0;;
No;O;O
evidence;O;O
of;O;O
interaction;O;O
of;O;O
PROCRIT;B-brand;B-DDI-DrugBank.d496.s0.e0
with;O;O
other;O;O
drugs;O;O
was;O;O
observed;O;O
in;O;O
the;O;O
course;O;O
of;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d241.s0;;
Additional;O;O
reductions;O;O
in;O;O
blood;O;O
pressure;O;O
may;O;O
occur;O;O
when;O;O
FLOLAN;B-brand;B-DDI-DrugBank.d241.s0.e0
is;O;O
administered;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d241.s0.e1
,;O;O
antihypertensive;B-group;B-DDI-DrugBank.d241.s0.e2
agents;I-group;I-DDI-DrugBank.d241.s0.e2
,;O;O
or;O;O
other;O;O
vasodilators;B-group;B-DDI-DrugBank.d241.s0.e3
.;O;O
DDI-DrugBank.d241.s1;;
When;O;O
other;O;O
antiplatelet;B-group;B-DDI-DrugBank.d241.s1.e0
agents;I-group;I-DDI-DrugBank.d241.s1.e0
or;O;O
anticoagulants;B-group;B-DDI-DrugBank.d241.s1.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
there;O;O
is;O;O
the;O;O
potential;O;O
for;O;O
FLOLAN;B-brand;B-DDI-DrugBank.d241.s1.e2
to;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d241.s2;;
However;O;O
,;O;O
patients;O;O
receiving;O;O
infusions;O;O
of;O;O
FLOLAN;B-brand;B-DDI-DrugBank.d241.s2.e0
in;O;O
clinical;O;O
trials;O;O
were;O;O
maintained;O;O
on;O;O
anticoagulants;B-group;B-DDI-DrugBank.d241.s2.e1
without;O;O
evidence;O;O
of;O;O
increased;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d241.s3;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
FLOLAN;B-brand;B-DDI-DrugBank.d241.s3.e0
was;O;O
used;O;O
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d241.s3.e1
,;O;O
diuretics;B-group;B-DDI-DrugBank.d241.s3.e2
,;O;O
anticoagulants;B-group;B-DDI-DrugBank.d241.s3.e3
,;O;O
oral;O;O
vasodilators;B-group;B-DDI-DrugBank.d241.s3.e4
,;O;O
and;O;O
supplemental;O;O
oxygen;B-drug;B-DDI-DrugBank.d241.s3.e5
.;O;O
In;O;O
a;O;O
pharmacokinetic;O;O
substudy;O;O
in;O;O
patients;O;O
with;O;O
congestive;O;O
heart;O;O
failure;O;O
receiving;O;O
furosemide;B-drug;B-DDI-DrugBank.d241.s3.e6
or;O;O
digoxin;B-drug;B-DDI-DrugBank.d241.s3.e7
in;O;O
whom;O;O
therapy;O;O
with;O;O
FLOLAN;B-brand;B-DDI-DrugBank.d241.s3.e8
was;O;O
initiated;O;O
,;O;O
apparent;O;O
oral;O;O
clearance;O;O
values;O;O
for;O;O
furosemide;B-drug;B-DDI-DrugBank.d241.s3.e9
(;O;O
n;O;O
=;O;O
23;O;O
);O;O
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d241.s3.e10
(;O;O
n;O;O
=;O;O
30;O;O
);O;O
were;O;O
decreased;O;O
by;O;O
13;O;O
%;O;O
and;O;O
15;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
on;O;O
the;O;O
second;O;O
day;O;O
of;O;O
therapy;O;O
and;O;O
had;O;O
returned;O;O
to;O;O
baseline;O;O
values;O;O
by;O;O
day;O;O
87;O;O
.;O;O
DDI-DrugBank.d241.s4;;
The;O;O
change;O;O
in;O;O
furosemide;B-drug;B-DDI-DrugBank.d241.s4.e0
clearance;O;O
value;O;O
is;O;O
not;O;O
likely;O;O
to;O;O
be;O;O
clinically;O;O
significant;O;O
.;O;O
DDI-DrugBank.d241.s5;;
However;O;O
,;O;O
patients;O;O
on;O;O
digoxin;B-drug;B-DDI-DrugBank.d241.s5.e0
may;O;O
show;O;O
elevations;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d241.s5.e1
concentrations;O;O
after;O;O
initiation;O;O
of;O;O
therapy;O;O
with;O;O
FLOLAN;B-brand;B-DDI-DrugBank.d241.s5.e2
,;O;O
which;O;O
may;O;O
be;O;O
clinically;O;O
significant;O;O
in;O;O
patients;O;O
prone;O;O
to;O;O
digoxin;B-drug;B-DDI-DrugBank.d241.s5.e3
toxicity;O;O
.;O;O
DDI-DrugBank.d525.s0;;
Eprosartan;B-drug;B-DDI-DrugBank.d525.s0.e0
has;O;O
been;O;O
shown;O;O
to;O;O
have;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d525.s0.e1
and;O;O
the;O;O
pharmacodynamics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d525.s0.e2
and;O;O
glyburide;B-drug;B-DDI-DrugBank.d525.s0.e3
.;O;O
DDI-DrugBank.d525.s1;;
Thus;O;O
no;O;O
dosing;O;O
adjustments;O;O
are;O;O
necessary;O;O
during;O;O
concomitant;O;O
use;O;O
with;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d525.s2;;
Because;O;O
eprosartan;B-drug;B-DDI-DrugBank.d525.s2.e0
is;O;O
not;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
,;O;O
inhibitors;O;O
of;O;O
CYP450;O;O
enzyme;O;O
would;O;O
not;O;O
be;O;O
expected;O;O
to;O;O
affect;O;O
its;O;O
metabolism;O;O
,;O;O
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d525.s2.e1
and;O;O
fluconazole;B-drug;B-DDI-DrugBank.d525.s2.e2
,;O;O
potent;O;O
inhibitors;O;O
of;O;O
CYP3A;O;O
and;O;O
2C9;O;O
,;O;O
respectively;O;O
,;O;O
have;O;O
been;O;O
shown;O;O
to;O;O
have;O;O
no;O;O
effect;O;O
on;O;O
eprosartan;B-drug;B-DDI-DrugBank.d525.s2.e3
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d525.s3;;
Ranitidine;B-drug;B-DDI-DrugBank.d525.s3.e0
also;O;O
has;O;O
no;O;O
effect;O;O
on;O;O
eprosartan;B-drug;B-DDI-DrugBank.d525.s3.e1
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d525.s4;;
Eprosartan;B-drug;B-DDI-DrugBank.d525.s4.e0
(;O;O
up;O;O
to;O;O
400;O;O
mg;O;O
b.i.d;O;O
.;O;O
or;O;O
800;O;O
mg;O;O
q.d;O;O
.;O;O
);O;O
doses;O;O
have;O;O
been;O;O
safely;O;O
used;O;O
concomitantly;O;O
with;O;O
a;O;O
thiazide;B-group;B-DDI-DrugBank.d525.s4.e1
diuretic;I-group;I-DDI-DrugBank.d525.s4.e1
(;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d525.s4.e2
);O;O
.;O;O
DDI-DrugBank.d525.s5;;
Eprosartan;B-drug;B-DDI-DrugBank.d525.s5.e0
doses;O;O
of;O;O
up;O;O
to;O;O
300;O;O
mg;O;O
b.i.d;O;O
.;O;O
have;O;O
been;O;O
safely;O;O
used;O;O
concomitantly;O;O
with;O;O
sustained;O;O
-;O;O
release;O;O
calcium;B-group;B-DDI-DrugBank.d525.s5.e1
channel;I-group;I-DDI-DrugBank.d525.s5.e1
blockers;I-group;I-DDI-DrugBank.d525.s5.e1
(;O;O
sustained;O;O
-;O;O
release;O;O
nifedipine;B-drug;B-DDI-DrugBank.d525.s5.e2
);O;O
with;O;O
no;O;O
clinically;O;O
significant;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d278.s0;;
Enoxaparin;B-drug;B-DDI-DrugBank.d278.s0.e0
dosed;O;O
as;O;O
a;O;O
1.0;O;O
mg;O;O
/;O;O
kg;O;O
subcutaneous;O;O
injection;O;O
q12h;O;O
for;O;O
four;O;O
doses;O;O
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
eptifibatide;B-drug;B-DDI-DrugBank.d278.s0.e1
or;O;O
the;O;O
level;O;O
of;O;O
platelet;O;O
aggregation;O;O
in;O;O
healthy;O;O
adults;O;O
.;O;O
DDI-DrugBank.d471.s0;;
Mineral;B-drug;B-DDI-DrugBank.d471.s0.e0
oil;I-drug;I-DDI-DrugBank.d471.s0.e0
interferes;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
fat;B-group;B-DDI-DrugBank.d471.s0.e1
-;I-group;I-DDI-DrugBank.d471.s0.e1
soluble;I-group;I-DDI-DrugBank.d471.s0.e1
vitamins;I-group;I-DDI-DrugBank.d471.s0.e1
,;O;O
including;O;O
vitamin;B-group;B-DDI-DrugBank.d471.s0.e2
D;I-group;I-DDI-DrugBank.d471.s0.e2
preparations;I-group;I-DDI-DrugBank.d471.s0.e2
.;O;O
DDI-DrugBank.d471.s1;;
Administration;O;O
of;O;O
thiazide;B-group;B-DDI-DrugBank.d471.s1.e0
diuretics;I-group;I-DDI-DrugBank.d471.s1.e0
to;O;O
hypoparathyroid;O;O
patients;O;O
who;O;O
are;O;O
concurrently;O;O
being;O;O
treated;O;O
with;O;O
ergocalciferol;B-drug;B-DDI-DrugBank.d471.s1.e1
may;O;O
cause;O;O
hypercalcemia;O;O
.;O;O
DDI-DrugBank.d201.s0;;
No;O;O
reported;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d59.s0;;
The;O;O
effects;O;O
of;O;O
ERGOMAR;B-brand;B-DDI-DrugBank.d59.s0.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
triacetyloleandomycin;B-drug;B-DDI-DrugBank.d59.s0.e1
which;O;O
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
ergotamine;B-drug;B-DDI-DrugBank.d59.s0.e2
.;O;O
DDI-DrugBank.d59.s1;;
The;O;O
pressor;O;O
effects;O;O
of;O;O
ERGOMAR;B-brand;B-DDI-DrugBank.d59.s1.e0
and;O;O
other;O;O
vasoconstrictor;B-group;B-DDI-DrugBank.d59.s1.e1
drugs;I-group;I-DDI-DrugBank.d59.s1.e1
can;O;O
combine;O;O
to;O;O
cause;O;O
dangerous;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d456.s0;;
Co;O;O
-;O;O
treatment;O;O
with;O;O
the;O;O
potent;O;O
CYP3A4;O;O
inhibitor;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d456.s0.e0
increases;O;O
erlotinib;B-drug;B-DDI-DrugBank.d456.s0.e1
AUC;O;O
by;O;O
2;O;O
/;O;O
3;O;O
.;O;O
DDI-DrugBank.d456.s1;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
administering;O;O
or;O;O
taking;O;O
TARCEVA;B-brand;B-DDI-DrugBank.d456.s1.e0
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d456.s1.e1
and;O;O
other;O;O
strong;O;O
CYP3A4;O;O
inhibitors;O;O
such;O;O
as;O;O
,;O;O
but;O;O
not;O;O
limited;O;O
to;O;O
,;O;O
atazanavir;B-drug;B-DDI-DrugBank.d456.s1.e2
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d456.s1.e3
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d456.s1.e4
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d456.s1.e5
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d456.s1.e6
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d456.s1.e7
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d456.s1.e8
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d456.s1.e9
,;O;O
telithromycin;B-drug;B-DDI-DrugBank.d456.s1.e10
,;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d456.s1.e11
(;O;O
TAO;B-drug;B-DDI-DrugBank.d456.s1.e12
);O;O
,;O;O
and;O;O
voriconazole;B-drug;B-DDI-DrugBank.d456.s1.e13
.;O;O
DDI-DrugBank.d456.s2;;
Pre;O;O
-;O;O
treatment;O;O
with;O;O
the;O;O
CYP3A4;O;O
inducer;O;O
rifampicin;B-drug;B-DDI-DrugBank.d456.s2.e0
decreased;O;O
erlotinib;B-drug;B-DDI-DrugBank.d456.s2.e1
AUC;O;O
by;O;O
about;O;O
2;O;O
/;O;O
3;O;O
.;O;O
DDI-DrugBank.d456.s3;;
Alternate;O;O
treatments;O;O
lacking;O;O
CYP3A4;O;O
inducing;O;O
activity;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d456.s4;;
If;O;O
an;O;O
alternative;O;O
treatment;O;O
is;O;O
unavailable;O;O
,;O;O
a;O;O
TARCEVA;B-brand;B-DDI-DrugBank.d456.s4.e0
dose;O;O
greater;O;O
than;O;O
150;O;O
mg;O;O
should;O;O
be;O;O
considered;O;O
for;O;O
NSCLC;O;O
patients;O;O
,;O;O
and;O;O
greater;O;O
than;O;O
100;O;O
mg;O;O
considered;O;O
for;O;O
pancreatic;O;O
cancer;O;O
patients;O;O
.;O;O
DDI-DrugBank.d456.s5;;
If;O;O
the;O;O
TARCEVA;B-brand;B-DDI-DrugBank.d456.s5.e0
dose;O;O
is;O;O
adjusted;O;O
upward;O;O
,;O;O
the;O;O
dose;O;O
will;O;O
need;O;O
to;O;O
be;O;O
reduced;O;O
upon;O;O
discontinuation;O;O
of;O;O
rifampicin;B-drug;B-DDI-DrugBank.d456.s5.e1
or;O;O
other;O;O
inducers;O;O
.;O;O
DDI-DrugBank.d456.s6;;
Other;O;O
CYP3A4;O;O
inducers;O;O
include;O;O
,;O;O
but;O;O
are;O;O
not;O;O
limited;O;O
to;O;O
,;O;O
rifabutin;B-drug;B-DDI-DrugBank.d456.s6.e0
,;O;O
rifapentine;B-drug;B-DDI-DrugBank.d456.s6.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d456.s6.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d456.s6.e3
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d456.s6.e4
and;O;O
St.;O;O
Johns;O;O
Wort;O;O
.;O;O
DDI-DrugBank.d456.s7;;
Hepatotoxicity;O;O
Asymptomatic;O;O
increases;O;O
in;O;O
liver;O;O
transaminases;O;O
have;O;O
been;O;O
observed;O;O
in;O;O
TARCEVA;B-brand;B-DDI-DrugBank.d456.s7.e0
treated;O;O
patients;O;O
,;O;O
DDI-DrugBank.d456.s8;;
therefore;O;O
,;O;O
periodic;O;O
liver;O;O
function;O;O
testing;O;O
(;O;O
transaminases;O;O
,;O;O
bilirubin;O;O
,;O;O
and;O;O
alkaline;O;O
phosphatase;O;O
);O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d456.s9;;
Dose;O;O
reduction;O;O
or;O;O
interruption;O;O
of;O;O
TARCEVA;B-brand;B-DDI-DrugBank.d456.s9.e0
should;O;O
be;O;O
considered;O;O
if;O;O
changes;O;O
in;O;O
liver;O;O
function;O;O
are;O;O
severe;O;O
.;O;O
DDI-DrugBank.d456.s10;;
Patients;O;O
with;O;O
Hepatic;O;O
Impairment;O;O
In;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
evidence;O;O
suggest;O;O
that;O;O
erlotinib;B-drug;B-DDI-DrugBank.d456.s10.e0
is;O;O
cleared;O;O
primarily;O;O
by;O;O
the;O;O
liver;O;O
.;O;O
DDI-DrugBank.d456.s11;;
Therefore;O;O
,;O;O
erlotinib;B-drug;B-DDI-DrugBank.d456.s11.e0
exposure;O;O
may;O;O
be;O;O
increased;O;O
in;O;O
patients;O;O
with;O;O
hepatic;O;O
dysfunction;O;O
.;O;O
DDI-DrugBank.d456.s12;;
Elevated;O;O
International;O;O
Normalized;O;O
Ratio;O;O
and;O;O
Potential;O;O
Bleeding;O;O
International;O;O
Normalized;O;O
Ratio;O;O
(;O;O
INR;O;O
);O;O
elevations;O;O
and;O;O
infrequent;O;O
reports;O;O
of;O;O
bleeding;O;O
events;O;O
including;O;O
gastrointestinal;O;O
and;O;O
non;O;O
-;O;O
gastrointestinal;O;O
bleedings;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
clinical;O;O
studies;O;O
,;O;O
some;O;O
associated;O;O
with;O;O
concomitant;O;O
warfarin;B-drug;B-DDI-DrugBank.d456.s12.e0
administration;O;O
.;O;O
DDI-DrugBank.d456.s13;;
Patients;O;O
taking;O;O
warfarin;B-drug;B-DDI-DrugBank.d456.s13.e0
or;O;O
other;O;O
coumarin;B-group;B-DDI-DrugBank.d456.s13.e1
-;I-group;I-DDI-DrugBank.d456.s13.e1
derivative;I-group;I-DDI-DrugBank.d456.s13.e1
anticoagulants;I-group;I-DDI-DrugBank.d456.s13.e1
should;O;O
be;O;O
monitored;O;O
regularly;O;O
for;O;O
changes;O;O
in;O;O
prothrombin;O;O
time;O;O
or;O;O
INR;O;O
DDI-DrugBank.d456.s14;;
.;O;O
DDI-DrugBank.d456.s15;;
DDI-DrugBank.d329.s0;;
When;O;O
ertapenem;B-drug;B-DDI-DrugBank.d329.s0.e0
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d329.s0.e1
(;O;O
500;O;O
mg;O;O
p.o;O;O
.;O;O
every;O;O
6;O;O
hours;O;O
);O;O
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d329.s0.e2
competes;O;O
for;O;O
active;O;O
tubular;O;O
secretion;O;O
and;O;O
reduces;O;O
the;O;O
renal;O;O
clearance;O;O
of;O;O
ertapenem;B-drug;B-DDI-DrugBank.d329.s0.e3
.;O;O
DDI-DrugBank.d329.s1;;
Based;O;O
on;O;O
total;O;O
ertapenem;B-drug;B-DDI-DrugBank.d329.s1.e0
concentrations;O;O
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d329.s1.e1
increased;O;O
the;O;O
AUC;O;O
by;O;O
25;O;O
%;O;O
and;O;O
reduced;O;O
the;O;O
plasma;O;O
and;O;O
renal;O;O
clearances;O;O
by;O;O
20;O;O
%;O;O
and;O;O
35;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d329.s2;;
The;O;O
half;O;O
-;O;O
life;O;O
increased;O;O
from;O;O
4.0;O;O
to;O;O
4.8;O;O
hours;O;O
.;O;O
DDI-DrugBank.d329.s3;;
Because;O;O
of;O;O
the;O;O
small;O;O
effect;O;O
on;O;O
half;O;O
-;O;O
life;O;O
,;O;O
the;O;O
coadministration;O;O
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d329.s3.e0
to;O;O
extend;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
ertapenem;B-drug;B-DDI-DrugBank.d329.s3.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d329.s4;;
In;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
ertapenem;B-drug;B-DDI-DrugBank.d329.s4.e0
does;O;O
not;O;O
inhibit;O;O
P;O;O
-;O;O
glycoprotein;O;O
-;O;O
mediated;O;O
transport;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d329.s4.e1
or;O;O
vinblastine;B-drug;B-DDI-DrugBank.d329.s4.e2
and;O;O
that;O;O
ertapenem;B-drug;B-DDI-DrugBank.d329.s4.e3
is;O;O
not;O;O
a;O;O
substrate;O;O
for;O;O
P;O;O
-;O;O
glycoprotein;O;O
-;O;O
mediated;O;O
transport;O;O
.;O;O
DDI-DrugBank.d329.s5;;
In;O;O
vitro;O;O
studies;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
indicate;O;O
that;O;O
ertapenem;B-drug;B-DDI-DrugBank.d329.s5.e0
does;O;O
not;O;O
inhibit;O;O
metabolism;O;O
mediated;O;O
by;O;O
any;O;O
of;O;O
the;O;O
following;O;O
six;O;O
cytochrome;O;O
p450;O;O
(;O;O
CYP;O;O
);O;O
isoforms;O;O
:;O;O
1A2;O;O
,;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
2D6;O;O
,;O;O
2E1;O;O
and;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d329.s6;;
Drug;O;O
interactions;O;O
caused;O;O
by;O;O
inhibition;O;O
of;O;O
P;O;O
-;O;O
glycoprotein;O;O
-;O;O
mediated;O;O
drug;O;O
clearance;O;O
or;O;O
CYP;O;O
-;O;O
mediated;O;O
drug;O;O
clearance;O;O
with;O;O
the;O;O
listed;O;O
isoforms;O;O
are;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d329.s7;;
Other;O;O
than;O;O
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d329.s7.e0
,;O;O
no;O;O
specific;O;O
clinical;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
DDI-DrugBank.d329.s8;;
.;O;O
DDI-DrugBank.d329.s9;;
DDI-DrugBank.d397.s0;;
Erythromycin;B-drug;B-DDI-DrugBank.d397.s0.e0
use;O;O
in;O;O
patients;O;O
who;O;O
are;O;O
receiving;O;O
high;O;O
doses;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d397.s0.e1
may;O;O
be;O;O
associated;O;O
with;O;O
an;O;O
increase;O;O
in;O;O
serum;O;O
theophylline;B-drug;B-DDI-DrugBank.d397.s0.e2
levels;O;O
and;O;O
potential;O;O
theophylline;B-drug;B-DDI-DrugBank.d397.s0.e3
toxicity;O;O
.;O;O
DDI-DrugBank.d397.s1;;
In;O;O
case;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d397.s1.e0
toxicity;O;O
and/or;O;O
elevated;O;O
serum;O;O
theophylline;B-drug;B-DDI-DrugBank.d397.s1.e1
levels;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d397.s1.e2
should;O;O
be;O;O
reduced;O;O
while;O;O
the;O;O
patient;O;O
is;O;O
receiving;O;O
concomitant;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s1.e3
therapy;O;O
.;O;O
DDI-DrugBank.d397.s2;;
Concomitant;O;O
administration;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s2.e0
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d397.s2.e1
has;O;O
been;O;O
reported;O;O
to;O;O
result;O;O
in;O;O
elevated;O;O
digoxin;B-drug;B-DDI-DrugBank.d397.s2.e2
serum;O;O
levels;O;O
.;O;O
DDI-DrugBank.d397.s3;;
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
increased;O;O
anticoagulant;O;O
effects;O;O
when;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s3.e0
and;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d397.s3.e1
were;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d397.s4;;
Increased;O;O
anticoagulation;O;O
effects;O;O
due;O;O
to;O;O
interactions;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s4.e0
with;O;O
various;O;O
oral;O;O
anticoagulents;O;O
may;O;O
be;O;O
more;O;O
pronounced;O;O
in;O;O
the;O;O
elderly;O;O
.;O;O
DDI-DrugBank.d397.s5;;
Concurrent;O;O
use;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s5.e0
and;O;O
ergotamine;B-drug;B-DDI-DrugBank.d397.s5.e1
or;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d397.s5.e2
has;O;O
been;O;O
associated;O;O
in;O;O
some;O;O
patients;O;O
with;O;O
acute;O;O
ergot;O;O
toxicity;O;O
characterized;O;O
by;O;O
severe;O;O
peripheral;O;O
vasospasm;O;O
and;O;O
dysesthesia;O;O
.;O;O
DDI-DrugBank.d397.s6;;
Erythromycin;B-drug;B-DDI-DrugBank.d397.s6.e0
has;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
the;O;O
clearance;O;O
of;O;O
triazolam;B-drug;B-DDI-DrugBank.d397.s6.e1
and;O;O
midazolam;B-drug;B-DDI-DrugBank.d397.s6.e2
and;O;O
thus;O;O
may;O;O
increase;O;O
the;O;O
pharmacologic;O;O
effect;O;O
of;O;O
these;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d397.s6.e3
.;O;O
DDI-DrugBank.d397.s7;;
The;O;O
use;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s7.e0
in;O;O
patients;O;O
concurrently;O;O
taking;O;O
drugs;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
may;O;O
be;O;O
associated;O;O
with;O;O
elevations;O;O
in;O;O
serum;O;O
levels;O;O
of;O;O
these;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d397.s8;;
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
interactions;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s8.e0
with;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d397.s8.e1
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d397.s8.e2
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d397.s8.e3
,;O;O
hexobarbital;B-drug;B-DDI-DrugBank.d397.s8.e4
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d397.s8.e5
,;O;O
alfentanil;B-drug;B-DDI-DrugBank.d397.s8.e6
,;O;O
cisapride;B-drug;B-DDI-DrugBank.d397.s8.e7
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d397.s8.e8
,;O;O
lovastatin;B-drug;B-DDI-DrugBank.d397.s8.e9
,;O;O
bromocriptine;B-drug;B-DDI-DrugBank.d397.s8.e10
,;O;O
valproate;B-drug;B-DDI-DrugBank.d397.s8.e11
,;O;O
terfenadine;B-drug;B-DDI-DrugBank.d397.s8.e12
,;O;O
and;O;O
astemizole;B-drug;B-DDI-DrugBank.d397.s8.e13
.;O;O
DDI-DrugBank.d397.s9;;
Serum;O;O
concentrations;O;O
of;O;O
drugs;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
in;O;O
patients;O;O
concurrently;O;O
receiving;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s9.e0
.;O;O
DDI-DrugBank.d397.s10;;
Erythromycin;B-drug;B-DDI-DrugBank.d397.s10.e0
has;O;O
been;O;O
reported;O;O
to;O;O
significantly;O;O
alter;O;O
the;O;O
metabolism;O;O
of;O;O
nonsedating;O;O
antihistamines;B-group;B-DDI-DrugBank.d397.s10.e1
terfenadine;I-drug;I-DDI-DrugBank.d397.s10.e2
and;O;O
astemizole;B-drug;B-DDI-DrugBank.d397.s10.e3
when;O;O
taken;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d397.s11;;
Rare;O;O
cases;O;O
of;O;O
serious;O;O
cardiovascular;O;O
adverse;O;O
events;O;O
,;O;O
including;O;O
electrocardiographic;O;O
QT;O;O
/;O;O
QTc;O;O
interval;O;O
prolongation;O;O
,;O;O
cardiac;O;O
arrest;O;O
,;O;O
torsades;O;O
de;O;O
pointes;O;O
,;O;O
and;O;O
other;O;O
ventricular;O;O
arrhythmias;O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d397.s12;;
In;O;O
addition;O;O
,;O;O
deaths;O;O
have;O;O
been;O;O
reported;O;O
rarely;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d397.s12.e0
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s12.e1
.;O;O
DDI-DrugBank.d397.s13;;
There;O;O
have;O;O
been;O;O
postmarketing;O;O
reports;O;O
of;O;O
drug;O;O
interactions;O;O
when;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s13.e0
is;O;O
coadministered;O;O
with;O;O
cisapride;B-drug;B-DDI-DrugBank.d397.s13.e1
,;O;O
resulting;O;O
in;O;O
QT;O;O
prolongation;O;O
,;O;O
cardiac;O;O
arrythmias;O;O
,;O;O
ventricular;O;O
tachycardia;O;O
,;O;O
ventricular;O;O
fibrulation;O;O
,;O;O
and;O;O
torsades;O;O
de;O;O
pointes;O;O
,;O;O
most;O;O
like;O;O
due;O;O
to;O;O
inhibition;O;O
of;O;O
hepatic;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d397.s13.e2
by;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s13.e3
.;O;O
DDI-DrugBank.d397.s14;;
Fatalities;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d397.s15;;
Patients;O;O
receiving;O;O
concomitant;O;O
lovastatin;B-drug;B-DDI-DrugBank.d397.s15.e0
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d397.s15.e1
should;O;O
be;O;O
carefully;O;O
monitored;O;O
,;O;O
DDI-DrugBank.d397.s16;;
cases;O;O
of;O;O
rhabdomyolysis;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
seriously;O;O
ill;O;O
patients;O;O
.;O;O
DDI-DrugBank.d568.s0;;
CNS;O;O
Drugs;O;O
-;O;O
Given;O;O
the;O;O
primary;O;O
CNS;O;O
effects;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s0.e0
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
it;O;O
is;O;O
taken;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
centrally;O;O
acting;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d568.s1;;
Alcohol;B-drug;B-DDI-DrugBank.d568.s1.e0
-;O;O
Although;O;O
LEXAPRO;B-brand;B-DDI-DrugBank.d568.s1.e1
did;O;O
not;O;O
potentiate;O;O
the;O;O
cognitive;O;O
and;O;O
motor;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d568.s1.e2
in;O;O
a;O;O
clinical;O;O
trial;O;O
,;O;O
as;O;O
with;O;O
other;O;O
psychotropic;B-group;B-DDI-DrugBank.d568.s1.e3
medications;I-group;I-DDI-DrugBank.d568.s1.e3
,;O;O
the;O;O
use;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d568.s1.e4
by;O;O
patients;O;O
taking;O;O
LEXAPRO;B-brand;B-DDI-DrugBank.d568.s1.e5
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d568.s2;;
Monoamine;B-group;B-DDI-DrugBank.d568.s2.e0
Oxidase;I-group;I-DDI-DrugBank.d568.s2.e0
Inhibitors;I-group;I-DDI-DrugBank.d568.s2.e0
(;O;O
MAOIs;B-group;B-DDI-DrugBank.d568.s2.e1
);O;O
DDI-DrugBank.d568.s3;;
Drugs;O;O
That;O;O
Interfere;O;O
With;O;O
Hemostasis;O;O
(;O;O
NSAIDs;B-group;B-DDI-DrugBank.d568.s3.e0
,;O;O
Aspirin;B-brand;B-DDI-DrugBank.d568.s3.e1
,;O;O
Warfarin;B-drug;B-DDI-DrugBank.d568.s3.e2
,;O;O
etc;O;O
.;O;O
);O;O
DDI-DrugBank.d568.s4;;
Serotonin;O;O
release;O;O
by;O;O
platelets;O;O
plays;O;O
an;O;O
important;O;O
role;O;O
in;O;O
hemostasis;O;O
.;O;O
DDI-DrugBank.d568.s5;;
Epidemiological;O;O
studies;O;O
of;O;O
the;O;O
case;O;O
-;O;O
control;O;O
and;O;O
cohort;O;O
design;O;O
that;O;O
have;O;O
demonstrated;O;O
an;O;O
association;O;O
between;O;O
use;O;O
of;O;O
psychotropic;B-group;B-DDI-DrugBank.d568.s5.e0
drugs;I-group;I-DDI-DrugBank.d568.s5.e0
that;O;O
interfere;O;O
with;O;O
serotonin;O;O
reuptake;O;O
and;O;O
the;O;O
occurrence;O;O
of;O;O
upper;O;O
gastrointestinal;O;O
bleeding;O;O
have;O;O
also;O;O
shown;O;O
that;O;O
concurrent;O;O
use;O;O
of;O;O
an;O;O
NSAID;B-group;B-DDI-DrugBank.d568.s5.e1
or;O;O
aspirin;B-brand;B-DDI-DrugBank.d568.s5.e2
potentiated;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d568.s6;;
Thus;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
cautioned;O;O
about;O;O
the;O;O
use;O;O
of;O;O
such;O;O
drugs;O;O
concurrently;O;O
with;O;O
LEXAPRO;B-brand;B-DDI-DrugBank.d568.s6.e0
.;O;O
DDI-DrugBank.d568.s7;;
Cimetidine;B-drug;B-DDI-DrugBank.d568.s7.e0
-;O;O
In;O;O
subjects;O;O
who;O;O
had;O;O
received;O;O
21;O;O
days;O;O
of;O;O
40;O;O
mg;O;O
/;O;O
day;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s7.e1
,;O;O
combined;O;O
administration;O;O
of;O;O
400;O;O
mg;O;O
/;O;O
day;O;O
cimetidine;B-drug;B-DDI-DrugBank.d568.s7.e2
for;O;O
8;O;O
days;O;O
resulted;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s7.e3
AUC;O;O
and;O;O
Cmax;O;O
of;O;O
43;O;O
%;O;O
and;O;O
39;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d568.s8;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
findings;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d568.s9;;
Digoxin;B-drug;B-DDI-DrugBank.d568.s9.e0
-;O;O
In;O;O
subjects;O;O
who;O;O
had;O;O
received;O;O
21;O;O
days;O;O
of;O;O
40;O;O
mg;O;O
/;O;O
day;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s9.e1
,;O;O
combined;O;O
administration;O;O
of;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s9.e2
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d568.s9.e3
(;O;O
single;O;O
dose;O;O
of;O;O
1;O;O
mg;O;O
);O;O
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s9.e4
or;O;O
digoxin;B-drug;B-DDI-DrugBank.d568.s9.e5
.;O;O
DDI-DrugBank.d568.s10;;
Lithium;B-drug;B-DDI-DrugBank.d568.s10.e0
-;O;O
Coadministration;O;O
of;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s10.e1
(;O;O
40;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
10;O;O
days;O;O
);O;O
and;O;O
lithium;B-drug;B-DDI-DrugBank.d568.s10.e2
(;O;O
30;O;O
mmol;O;O
/;O;O
day;O;O
for;O;O
5;O;O
days;O;O
);O;O
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s10.e3
or;O;O
lithium;B-drug;B-DDI-DrugBank.d568.s10.e4
.;O;O
DDI-DrugBank.d568.s11;;
Nevertheless;O;O
,;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d568.s11.e0
levels;O;O
should;O;O
be;O;O
monitored;O;O
with;O;O
appropriate;O;O
adjustment;O;O
to;O;O
the;O;O
lithium;B-drug;B-DDI-DrugBank.d568.s11.e1
dose;O;O
in;O;O
accordance;O;O
with;O;O
standard;O;O
clinical;O;O
practice;O;O
.;O;O
DDI-DrugBank.d568.s12;;
Because;O;O
lithium;B-drug;B-DDI-DrugBank.d568.s12.e0
may;O;O
enhance;O;O
the;O;O
serotonergic;O;O
effects;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s12.e1
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
LEXAPRO;B-brand;B-DDI-DrugBank.d568.s12.e2
and;O;O
lithium;B-drug;B-DDI-DrugBank.d568.s12.e3
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d568.s13;;
Pimozide;B-drug;B-DDI-DrugBank.d568.s13.e0
and;O;O
Celexa;B-brand;B-DDI-DrugBank.d568.s13.e1
-;O;O
In;O;O
a;O;O
controlled;O;O
study;O;O
,;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
pimozide;B-drug;B-DDI-DrugBank.d568.s13.e2
2;O;O
mg;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s13.e3
40;O;O
mg;O;O
given;O;O
once;O;O
daily;O;O
for;O;O
11;O;O
days;O;O
was;O;O
associated;O;O
with;O;O
a;O;O
mean;O;O
increase;O;O
in;O;O
QTc;O;O
values;O;O
of;O;O
approximately;O;O
10;O;O
msec;O;O
compared;O;O
to;O;O
pimozide;B-drug;B-DDI-DrugBank.d568.s13.e4
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d568.s14;;
Racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s14.e0
did;O;O
not;O;O
alter;O;O
the;O;O
mean;O;O
AUC;O;O
or;O;O
Cmax;O;O
of;O;O
pimozide;B-drug;B-DDI-DrugBank.d568.s14.e1
.;O;O
DDI-DrugBank.d568.s15;;
The;O;O
mechanism;O;O
of;O;O
this;O;O
pharmacodynamic;O;O
interaction;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d568.s16;;
Sumatriptan;B-drug;B-DDI-DrugBank.d568.s16.e0
-;O;O
There;O;O
have;O;O
been;O;O
rare;O;O
postmarketing;O;O
reports;O;O
describing;O;O
patients;O;O
with;O;O
weakness;O;O
,;O;O
hyperreflexia;O;O
,;O;O
and;O;O
incoordination;O;O
following;O;O
the;O;O
use;O;O
of;O;O
a;O;O
selective;B-group;B-DDI-DrugBank.d568.s16.e1
serotonin;I-group;I-DDI-DrugBank.d568.s16.e1
reuptake;I-group;I-DDI-DrugBank.d568.s16.e1
inhibitor;I-group;I-DDI-DrugBank.d568.s16.e1
(;O;O
SSRI;B-group;B-DDI-DrugBank.d568.s16.e2
);O;O
and;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d568.s16.e3
.;O;O
DDI-DrugBank.d568.s17;;
If;O;O
concomitant;O;O
treatment;O;O
with;O;O
sumatriptan;B-drug;B-DDI-DrugBank.d568.s17.e0
and;O;O
an;O;O
SSRI;B-group;B-DDI-DrugBank.d568.s17.e1
(;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d568.s17.e2
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d568.s17.e3
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d568.s17.e4
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d568.s17.e5
,;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s17.e6
,;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s17.e7
);O;O
is;O;O
clinically;O;O
warranted;O;O
,;O;O
appropriate;O;O
observation;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d568.s18;;
Theophylline;B-drug;B-DDI-DrugBank.d568.s18.e0
-;O;O
Combined;O;O
administration;O;O
of;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s18.e1
(;O;O
40;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
21;O;O
days;O;O
);O;O
and;O;O
the;O;O
CYP1A2;O;O
substrate;O;O
theophylline;B-drug;B-DDI-DrugBank.d568.s18.e2
(;O;O
single;O;O
dose;O;O
of;O;O
300;O;O
mg;O;O
);O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d568.s18.e3
.;O;O
DDI-DrugBank.d568.s19;;
The;O;O
effect;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d568.s19.e0
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s19.e1
was;O;O
not;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d568.s20;;
Warfarin;B-drug;B-DDI-DrugBank.d568.s20.e0
-;O;O
Administration;O;O
of;O;O
40;O;O
mg;O;O
/;O;O
day;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s20.e1
for;O;O
21;O;O
days;O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d568.s20.e2
,;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
.;O;O
DDI-DrugBank.d568.s21;;
Prothrombin;O;O
time;O;O
was;O;O
increased;O;O
by;O;O
5;O;O
%;O;O
,;O;O
the;O;O
clinical;O;O
significance;O;O
of;O;O
which;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d568.s22;;
Carbamazepine;B-drug;B-DDI-DrugBank.d568.s22.e0
-;O;O
Combined;O;O
administration;O;O
of;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s22.e1
(;O;O
40;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
14;O;O
days;O;O
);O;O
and;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d568.s22.e2
(;O;O
titrated;O;O
to;O;O
400;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
35;O;O
days;O;O
);O;O
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d568.s22.e3
,;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
.;O;O
DDI-DrugBank.d568.s23;;
Although;O;O
trough;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s23.e0
plasma;O;O
levels;O;O
were;O;O
unaffected;O;O
,;O;O
given;O;O
the;O;O
enzyme;O;O
-;O;O
inducing;O;O
properties;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d568.s23.e1
,;O;O
the;O;O
possibility;O;O
that;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d568.s23.e2
might;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s23.e3
should;O;O
be;O;O
considered;O;O
if;O;O
the;O;O
two;O;O
drugs;O;O
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d568.s24;;
Triazolam;B-drug;B-DDI-DrugBank.d568.s24.e0
-;O;O
Combined;O;O
administration;O;O
of;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s24.e1
(;O;O
titrated;O;O
to;O;O
40;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
28;O;O
days;O;O
);O;O
and;O;O
the;O;O
CYP3A4;O;O
substrate;O;O
triazolam;B-drug;B-DDI-DrugBank.d568.s24.e2
(;O;O
single;O;O
dose;O;O
of;O;O
0.25;O;O
mg;O;O
);O;O
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s24.e3
or;O;O
triazolam;B-drug;B-DDI-DrugBank.d568.s24.e4
.;O;O
DDI-DrugBank.d568.s25;;
Ketoconazole;B-drug;B-DDI-DrugBank.d568.s25.e0
-;O;O
Combined;O;O
administration;O;O
of;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s25.e1
(;O;O
40;O;O
mg;O;O
);O;O
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d568.s25.e2
(;O;O
200;O;O
mg;O;O
);O;O
decreased;O;O
the;O;O
Cmax;O;O
and;O;O
AUC;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d568.s25.e3
by;O;O
21;O;O
%;O;O
and;O;O
10;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
and;O;O
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s25.e4
.;O;O
DDI-DrugBank.d568.s26;;
Ritonavir;B-drug;B-DDI-DrugBank.d568.s26.e0
-;O;O
Combined;O;O
administration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
ritonavir;B-drug;B-DDI-DrugBank.d568.s26.e1
(;O;O
600;O;O
mg;O;O
);O;O
,;O;O
both;O;O
a;O;O
CYP3A4;O;O
substrate;O;O
and;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
,;O;O
and;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s26.e2
(;O;O
20;O;O
mg;O;O
);O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
ritonavir;B-drug;B-DDI-DrugBank.d568.s26.e3
or;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s26.e4
.;O;O
DDI-DrugBank.d568.s27;;
CYP3A4;O;O
and;O;O
-2C19;O;O
Inhibitors;O;O
-;O;O
In;O;O
vitro;O;O
studies;O;O
indicated;O;O
that;O;O
CYP3A4;O;O
and;O;O
-2C19;O;O
are;O;O
the;O;O
primary;O;O
enzymes;O;O
involved;O;O
in;O;O
the;O;O
metabolism;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s27.e0
.;O;O
DDI-DrugBank.d568.s28;;
However;O;O
,;O;O
coadministration;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s28.e0
(;O;O
20;O;O
mg;O;O
);O;O
and;O;O
ritonavir;B-drug;B-DDI-DrugBank.d568.s28.e1
(;O;O
600;O;O
mg;O;O
);O;O
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
,;O;O
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s28.e2
.;O;O
DDI-DrugBank.d568.s29;;
Because;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s29.e0
is;O;O
metabolized;O;O
by;O;O
multiple;O;O
enzyme;O;O
systems;O;O
,;O;O
inhibition;O;O
of;O;O
a;O;O
single;O;O
enzyme;O;O
may;O;O
not;O;O
appreciably;O;O
decrease;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s29.e1
clearance;O;O
.;O;O
DDI-DrugBank.d568.s30;;
Drugs;O;O
Metabolized;O;O
by;O;O
Cytochrome;O;O
P4502D6;O;O
-;O;O
In;O;O
vitro;O;O
studies;O;O
did;O;O
not;O;O
reveal;O;O
an;O;O
inhibitory;O;O
effect;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s30.e0
on;O;O
CYP2D6;O;O
.;O;O
DDI-DrugBank.d568.s31;;
In;O;O
addition;O;O
,;O;O
steady;O;O
state;O;O
levels;O;O
of;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s31.e0
were;O;O
not;O;O
significantly;O;O
different;O;O
in;O;O
poor;O;O
metabolizers;O;O
and;O;O
extensive;O;O
CYP2D6;O;O
metabolizers;O;O
after;O;O
multiple;O;O
-;O;O
dose;O;O
administration;O;O
of;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s31.e1
,;O;O
suggesting;O;O
that;O;O
coadministration;O;O
,;O;O
with;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s31.e2
,;O;O
of;O;O
a;O;O
drug;O;O
that;O;O
inhibits;O;O
CYP2D6;O;O
,;O;O
is;O;O
unlikely;O;O
to;O;O
have;O;O
clinically;O;O
significant;O;O
effects;O;O
on;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s31.e3
metabolism;O;O
.;O;O
DDI-DrugBank.d568.s32;;
However;O;O
,;O;O
there;O;O
are;O;O
limited;O;O
in;O;O
vivo;O;O
data;O;O
suggesting;O;O
a;O;O
modest;O;O
CYP2D6;O;O
inhibitory;O;O
effect;O;O
for;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s32.e0
,;O;O
i.e.;O;O
,;O;O
coadministration;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s32.e1
(;O;O
20;O;O
mg;O;O
/;O;O
day;O;O
for;O;O
21;O;O
days;O;O
);O;O
with;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d568.s32.e2
antidepressant;I-group;I-DDI-DrugBank.d568.s32.e2
desipramine;I-drug;I-DDI-DrugBank.d568.s32.e3
(;O;O
single;O;O
dose;O;O
of;O;O
50;O;O
mg;O;O
);O;O
,;O;O
a;O;O
substrate;O;O
for;O;O
CYP2D6;O;O
,;O;O
resulted;O;O
in;O;O
a;O;O
40;O;O
%;O;O
increase;O;O
in;O;O
Cmax;O;O
and;O;O
a;O;O
100;O;O
%;O;O
increase;O;O
in;O;O
AUC;O;O
of;O;O
desipramine;B-drug;B-DDI-DrugBank.d568.s32.e4
.;O;O
DDI-DrugBank.d568.s33;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
finding;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d568.s34;;
Nevertheless;O;O
,;O;O
caution;O;O
is;O;O
indicated;O;O
in;O;O
the;O;O
coadministration;O;O
of;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s34.e0
and;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP2D6;O;O
.;O;O
DDI-DrugBank.d568.s35;;
Metoprolol;B-drug;B-DDI-DrugBank.d568.s35.e0
-;O;O
Administration;O;O
of;O;O
20;O;O
mg;O;O
/;O;O
day;O;O
LEXAPRO;B-brand;B-DDI-DrugBank.d568.s35.e1
for;O;O
21;O;O
days;O;O
in;O;O
healthy;O;O
volunteers;O;O
resulted;O;O
in;O;O
a;O;O
50;O;O
%;O;O
increase;O;O
in;O;O
Cmax;O;O
and;O;O
82;O;O
%;O;O
increase;O;O
in;O;O
AUC;O;O
of;O;O
the;O;O
beta;B-group;B-DDI-DrugBank.d568.s35.e2
-;I-group;I-DDI-DrugBank.d568.s35.e2
adrenergic;I-group;I-DDI-DrugBank.d568.s35.e2
blocker;I-group;I-DDI-DrugBank.d568.s35.e2
metoprolol;I-drug;I-DDI-DrugBank.d568.s35.e3
(;O;O
given;O;O
in;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
100;O;O
mg;O;O
);O;O
.;O;O
DDI-DrugBank.d568.s36;;
Increased;O;O
metoprolol;B-drug;B-DDI-DrugBank.d568.s36.e0
plasma;O;O
levels;O;O
have;O;O
been;O;O
associated;O;O
with;O;O
decreased;O;O
cardioselectivity;O;O
.;O;O
DDI-DrugBank.d568.s37;;
Coadministration;O;O
of;O;O
LEXAPRO;B-brand;B-DDI-DrugBank.d568.s37.e0
and;O;O
metoprolol;B-drug;B-DDI-DrugBank.d568.s37.e1
had;O;O
no;O;O
clinically;O;O
significant;O;O
effects;O;O
on;O;O
blood;O;O
pressure;O;O
or;O;O
heart;O;O
rate;O;O
.;O;O
DDI-DrugBank.d568.s38;;
Electroconvulsive;O;O
Therapy;O;O
(;O;O
ECT;O;O
);O;O
-;O;O
There;O;O
are;O;O
no;O;O
clinical;O;O
studies;O;O
of;O;O
the;O;O
combined;O;O
use;O;O
of;O;O
ECT;O;O
and;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s38.e0
.;O;O
DDI-DrugBank.d568.s39;;
Concomitant;O;O
Administration;O;O
with;O;O
Racemic;O;O
Citalopram;B-drug;B-DDI-DrugBank.d568.s39.e0
Citalopram;I-drug;I-DDI-DrugBank.d568.s39.e1
-;O;O
Since;O;O
escitalopram;B-drug;B-DDI-DrugBank.d568.s39.e2
is;O;O
the;O;O
active;O;O
isomer;O;O
of;O;O
racemic;O;O
citalopram;B-drug;B-DDI-DrugBank.d568.s39.e3
(;O;O
Celexa;B-brand;B-DDI-DrugBank.d568.s39.e4
);O;O
,;O;O
the;O;O
two;O;O
agents;O;O
should;O;O
not;O;O
be;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d422.s0;;
Catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
,;O;O
e.g.;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d422.s0.e0
,;O;O
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d422.s0.e1
blocking;I-group;I-DDI-DrugBank.d422.s0.e1
agents;I-group;I-DDI-DrugBank.d422.s0.e1
.;O;O
DDI-DrugBank.d422.s1;;
Patients;O;O
treated;O;O
concurrently;O;O
with;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s1.e0
(;O;O
esmolol;B-drug;B-DDI-DrugBank.d422.s1.e1
HCl;I-drug;I-DDI-DrugBank.d422.s1.e1
);O;O
and;O;O
a;O;O
catecholamine;O;O
depletor;O;O
should;O;O
therefore;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
evidence;O;O
of;O;O
hypotension;O;O
or;O;O
marked;O;O
bradycardia;O;O
,;O;O
which;O;O
may;O;O
result;O;O
in;O;O
vertigo;O;O
,;O;O
syncope;O;O
,;O;O
or;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d422.s2;;
A;O;O
study;O;O
of;O;O
interaction;O;O
between;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s2.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d422.s2.e1
showed;O;O
that;O;O
concomitant;O;O
administration;O;O
of;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s2.e2
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d422.s2.e3
does;O;O
not;O;O
alter;O;O
warfarin;B-drug;B-DDI-DrugBank.d422.s2.e4
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d422.s3;;
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s3.e0
concentrations;O;O
were;O;O
equivocally;O;O
higher;O;O
when;O;O
given;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d422.s3.e1
,;O;O
but;O;O
this;O;O
is;O;O
not;O;O
likely;O;O
to;O;O
be;O;O
clinically;O;O
important;O;O
.;O;O
DDI-DrugBank.d422.s4;;
When;O;O
digoxin;B-drug;B-DDI-DrugBank.d422.s4.e0
and;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s4.e1
were;O;O
concomitantly;O;O
administered;O;O
intravenously;O;O
to;O;O
normal;O;O
volunteers;O;O
,;O;O
there;O;O
was;O;O
a;O;O
10;O;O
-;O;O
20;O;O
%;O;O
increase;O;O
in;O;O
digoxin;B-drug;B-DDI-DrugBank.d422.s4.e2
blood;O;O
levels;O;O
at;O;O
some;O;O
time;O;O
points;O;O
.;O;O
DDI-DrugBank.d422.s5;;
Digoxin;B-drug;B-DDI-DrugBank.d422.s5.e0
did;O;O
not;O;O
affect;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s5.e1
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d422.s6;;
When;O;O
intravenous;O;O
morphine;B-drug;B-DDI-DrugBank.d422.s6.e0
and;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s6.e1
were;O;O
concomitantly;O;O
administered;O;O
in;O;O
normal;O;O
subjects;O;O
,;O;O
no;O;O
effect;O;O
on;O;O
morphine;B-drug;B-DDI-DrugBank.d422.s6.e2
blood;O;O
levels;O;O
was;O;O
seen;O;O
,;O;O
but;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s6.e3
steady;O;O
-;O;O
state;O;O
blood;O;O
levels;O;O
were;O;O
increased;O;O
by;O;O
46;O;O
%;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
morphine;B-drug;B-DDI-DrugBank.d422.s6.e4
.;O;O
DDI-DrugBank.d422.s7;;
No;O;O
other;O;O
pharmacokinetic;O;O
parameters;O;O
were;O;O
changed;O;O
.;O;O
DDI-DrugBank.d422.s8;;
The;O;O
effect;O;O
of;O;O
BREVIBLOC;B-drug;B-DDI-DrugBank.d422.s8.e0
on;O;O
the;O;O
duration;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d422.s8.e1
-;O;O
induced;O;O
neuromuscular;O;O
blockade;O;O
was;O;O
studied;O;O
in;O;O
patients;O;O
undergoing;O;O
surgery;O;O
.;O;O
DDI-DrugBank.d422.s9;;
The;O;O
onset;O;O
of;O;O
neuromuscular;O;O
blockade;O;O
by;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d422.s9.e0
was;O;O
unaffected;O;O
by;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s9.e1
,;O;O
but;O;O
the;O;O
duration;O;O
of;O;O
neuromuscular;O;O
blockade;O;O
was;O;O
prolonged;O;O
from;O;O
5;O;O
minutes;O;O
to;O;O
8;O;O
minutes;O;O
.;O;O
DDI-DrugBank.d422.s10;;
Although;O;O
the;O;O
interactions;O;O
observed;O;O
in;O;O
these;O;O
studies;O;O
do;O;O
not;O;O
appear;O;O
to;O;O
be;O;O
of;O;O
major;O;O
clinical;O;O
importance;O;O
,;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s10.e0
should;O;O
be;O;O
titrated;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
being;O;O
treated;O;O
concurrently;O;O
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d422.s10.e1
,;O;O
morphine;B-drug;B-DDI-DrugBank.d422.s10.e2
,;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d422.s10.e3
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d422.s10.e4
.;O;O
DDI-DrugBank.d422.s11;;
While;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d422.s11.e0
blockers;I-group;I-DDI-DrugBank.d422.s11.e0
,;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
severe;O;O
anaphylactic;O;O
reaction;O;O
to;O;O
a;O;O
variety;O;O
of;O;O
allergens;O;O
may;O;O
be;O;O
more;O;O
reactive;O;O
to;O;O
repeated;O;O
challenge;O;O
,;O;O
either;O;O
accidental;O;O
,;O;O
diagnostic;O;O
,;O;O
or;O;O
therapeutic;O;O
.;O;O
DDI-DrugBank.d422.s12;;
Such;O;O
patients;O;O
may;O;O
be;O;O
unresponsive;O;O
to;O;O
the;O;O
usual;O;O
doses;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d422.s12.e0
used;O;O
to;O;O
treat;O;O
allergic;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d422.s13;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
considering;O;O
the;O;O
use;O;O
of;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s13.e0
and;O;O
verapamil;B-drug;B-DDI-DrugBank.d422.s13.e1
in;O;O
patients;O;O
with;O;O
depressed;O;O
myocardial;O;O
function;O;O
.;O;O
DDI-DrugBank.d422.s14;;
Fatal;O;O
cardiac;O;O
arrests;O;O
have;O;O
occurred;O;O
in;O;O
patients;O;O
receiving;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d422.s15;;
Additionally;O;O
,;O;O
BREVIBLOC;B-brand;B-DDI-DrugBank.d422.s15.e0
should;O;O
not;O;O
be;O;O
used;O;O
to;O;O
control;O;O
supraventricular;O;O
tachycardia;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
agents;O;O
which;O;O
are;O;O
vasoconstrictive;O;O
and;O;O
inotropic;O;O
such;O;O
as;O;O
dopamine;B-drug;B-DDI-DrugBank.d422.s15.e1
,;O;O
epinephrine;B-drug;B-DDI-DrugBank.d422.s15.e2
,;O;O
and;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d422.s15.e3
because;O;O
of;O;O
the;O;O
danger;O;O
of;O;O
blocking;O;O
cardiac;O;O
contractility;O;O
when;O;O
systemic;O;O
vascular;O;O
resistance;O;O
is;O;O
high;O;O
.;O;O
DDI-DrugBank.d29.s0;;
Esomeprazole;B-drug;B-DDI-DrugBank.d29.s0.e0
is;O;O
extensively;O;O
metabolized;O;O
in;O;O
the;O;O
liver;O;O
by;O;O
CYP2C19;O;O
and;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d29.s1;;
In;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
esomeprazole;B-drug;B-DDI-DrugBank.d29.s1.e0
is;O;O
not;O;O
likely;O;O
to;O;O
inhibit;O;O
CYPs;O;O
1A2;O;O
,;O;O
2A6;O;O
,;O;O
2C9;O;O
,;O;O
2D6;O;O
,;O;O
2E1;O;O
and;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d29.s2;;
No;O;O
clinically;O;O
relevant;O;O
interactions;O;O
with;O;O
drugs;O;O
metabolized;O;O
by;O;O
these;O;O
CYP;O;O
enzymes;O;O
would;O;O
be;O;O
expected;O;O
.;O;O
DDI-DrugBank.d29.s3;;
Drug;O;O
interaction;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
esomeprazole;B-drug;B-DDI-DrugBank.d29.s3.e0
does;O;O
not;O;O
have;O;O
any;O;O
clinically;O;O
significant;O;O
interactions;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d29.s3.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d29.s3.e2
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d29.s3.e3
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d29.s3.e4
or;O;O
amoxicillin;B-drug;B-DDI-DrugBank.d29.s3.e5
.;O;O
DDI-DrugBank.d29.s4;;
Post;O;O
-;O;O
marketing;O;O
reports;O;O
of;O;O
changes;O;O
in;O;O
prothrombin;O;O
measures;O;O
have;O;O
been;O;O
received;O;O
among;O;O
patients;O;O
on;O;O
concomitant;O;O
warfarin;B-drug;B-DDI-DrugBank.d29.s4.e0
and;O;O
esomeprazole;B-drug;B-DDI-DrugBank.d29.s4.e1
therapy;O;O
.;O;O
DDI-DrugBank.d29.s5;;
Increases;O;O
in;O;O
INR;O;O
and;O;O
prothrombin;O;O
time;O;O
may;O;O
lead;O;O
to;O;O
abnormal;O;O
bleeding;O;O
and;O;O
even;O;O
death;O;O
.;O;O
DDI-DrugBank.d29.s6;;
Patients;O;O
treated;O;O
with;O;O
proton;B-group;B-DDI-DrugBank.d29.s6.e0
pump;I-group;I-DDI-DrugBank.d29.s6.e0
inhibitors;I-group;I-DDI-DrugBank.d29.s6.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d29.s6.e1
concomitantly;O;O
may;O;O
need;O;O
to;O;O
be;O;O
monitored;O;O
for;O;O
increases;O;O
in;O;O
INR;O;O
and;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d29.s7;;
Esomeprazole;B-drug;B-DDI-DrugBank.d29.s7.e0
may;O;O
potentially;O;O
interfere;O;O
with;O;O
CYP2C19;O;O
,;O;O
the;O;O
major;O;O
esomeprazole;B-drug;B-DDI-DrugBank.d29.s7.e1
metabolizing;O;O
enzyme;O;O
.;O;O
DDI-DrugBank.d29.s8;;
Coadministration;O;O
of;O;O
esomeprazole;B-drug;B-DDI-DrugBank.d29.s8.e0
30;O;O
mg;O;O
and;O;O
diazepam;B-drug;B-DDI-DrugBank.d29.s8.e1
,;O;O
a;O;O
CYP2C19;O;O
substrate;O;O
,;O;O
resulted;O;O
in;O;O
a;O;O
45;O;O
%;O;O
decrease;O;O
in;O;O
clearance;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d29.s8.e2
.;O;O
DDI-DrugBank.d29.s9;;
Increased;O;O
plasma;O;O
levels;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d29.s9.e0
were;O;O
observed;O;O
12;O;O
hours;O;O
after;O;O
dosing;O;O
and;O;O
onwards;O;O
.;O;O
DDI-DrugBank.d29.s10;;
However;O;O
,;O;O
at;O;O
that;O;O
time;O;O
,;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d29.s10.e0
were;O;O
below;O;O
the;O;O
therapeutic;O;O
interval;O;O
,;O;O
and;O;O
thus;O;O
this;O;O
interaction;O;O
is;O;O
unlikely;O;O
to;O;O
be;O;O
of;O;O
clinical;O;O
relevance;O;O
.;O;O
DDI-DrugBank.d29.s11;;
Esomeprazole;B-drug;B-DDI-DrugBank.d29.s11.e0
inhibits;O;O
gastric;O;O
acid;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d29.s12;;
Therefore;O;O
,;O;O
esomeprazole;B-drug;B-DDI-DrugBank.d29.s12.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
drugs;O;O
where;O;O
gastric;O;O
pH;O;O
is;O;O
an;O;O
important;O;O
determinant;O;O
of;O;O
bioavailability;O;O
(;O;O
eg;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d29.s12.e1
,;O;O
iron;B-drug;B-DDI-DrugBank.d29.s12.e2
salts;O;O
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d29.s12.e3
);O;O
.;O;O
DDI-DrugBank.d29.s13;;
Coadministration;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d29.s13.e0
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d29.s13.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d29.s13.e2
,;O;O
or;O;O
quinidine;B-drug;B-DDI-DrugBank.d29.s13.e3
did;O;O
not;O;O
seem;O;O
to;O;O
change;O;O
the;O;O
pharmacokinetic;O;O
profile;O;O
of;O;O
esomeprazole;B-drug;B-DDI-DrugBank.d29.s13.e4
.;O;O
DDI-DrugBank.d29.s14;;
Concomitant;O;O
administration;O;O
of;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d29.s14.e0
with;O;O
pimozide;B-drug;B-DDI-DrugBank.d29.s14.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d338.s0;;
If;O;O
ProSom;B-brand;B-DDI-DrugBank.d338.s0.e0
is;O;O
given;O;O
concomitantly;O;O
with;O;O
other;O;O
drugs;O;O
acting;O;O
on;O;O
the;O;O
central;O;O
nervous;O;O
system;O;O
,;O;O
careful;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
the;O;O
pharmacology;O;O
of;O;O
all;O;O
agents;O;O
.;O;O
DDI-DrugBank.d338.s1;;
The;O;O
action;O;O
of;O;O
the;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d338.s1.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d338.s1.e1
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d338.s1.e2
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d338.s1.e3
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d338.s1.e4
,;O;O
monoamine;B-group;B-DDI-DrugBank.d338.s1.e5
oxidase;I-group;I-DDI-DrugBank.d338.s1.e5
inhibitors;I-group;I-DDI-DrugBank.d338.s1.e5
,;O;O
narcotics;B-group;B-DDI-DrugBank.d338.s1.e6
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d338.s1.e7
,;O;O
psychotropic;B-group;B-DDI-DrugBank.d338.s1.e8
medications;I-group;I-DDI-DrugBank.d338.s1.e8
,;O;O
or;O;O
other;O;O
drugs;O;O
that;O;O
produce;O;O
CNS;O;O
depression;O;O
.;O;O
DDI-DrugBank.d338.s2;;
Smokers;O;O
have;O;O
an;O;O
increased;O;O
clearance;O;O
of;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d338.s2.e0
as;O;O
compared;O;O
to;O;O
nonsmokers;O;O
,;O;O
DDI-DrugBank.d338.s3;;
this;O;O
was;O;O
seen;O;O
in;O;O
studies;O;O
with;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s3.e0
.;O;O
DDI-DrugBank.d338.s4;;
While;O;O
no;O;O
in;O;O
vivo;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
were;O;O
conducted;O;O
between;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s4.e0
and;O;O
inducers;O;O
of;O;O
CYP3A;O;O
,;O;O
compounds;O;O
that;O;O
are;O;O
potent;O;O
CYP3A;O;O
inducers;O;O
(;O;O
such;O;O
as;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d338.s4.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d338.s4.e2
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d338.s4.e3
,;O;O
and;O;O
barbiturates;B-group;B-DDI-DrugBank.d338.s4.e4
);O;O
would;O;O
be;O;O
expected;O;O
to;O;O
decrease;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s4.e5
concentrations;O;O
.;O;O
DDI-DrugBank.d338.s5;;
Estazolam;B-drug;B-DDI-DrugBank.d338.s5.e0
:;O;O
Interaction;O;O
with;O;O
Drugs;O;O
that;O;O
Inhibit;O;O
Metabolism;O;O
via;O;O
Cytochrome;O;O
P450;O;O
3A;O;O
(;O;O
CYP3A;O;O
);O;O
:;O;O
The;O;O
metabolism;O;O
of;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s5.e1
to;O;O
the;O;O
major;O;O
circulating;O;O
metabolite;O;O
4;B-drug_n;B-DDI-DrugBank.d338.s5.e2
-;I-drug_n;I-DDI-DrugBank.d338.s5.e2
hydroxy;I-drug_n;I-DDI-DrugBank.d338.s5.e2
-;I-drug_n;I-DDI-DrugBank.d338.s5.e2
estazolam;I-drug_n;I-DDI-DrugBank.d338.s5.e2
and;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
triazolobenzodiazepines;B-group;B-DDI-DrugBank.d338.s5.e3
is;O;O
catalyzed;O;O
by;O;O
CYP3A.;O;O
DDI-DrugBank.d338.s6;;
Consequently;O;O
,;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s6.e0
should;O;O
be;O;O
avoided;O;O
in;O;O
patients;O;O
receiving;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d338.s6.e1
and;O;O
itraconazole;B-drug;B-DDI-DrugBank.d338.s6.e2
,;O;O
which;O;O
are;O;O
very;O;O
potent;O;O
inhibitors;O;O
of;O;O
CYP3A.;O;O
DDI-DrugBank.d338.s7;;
With;O;O
drugs;O;O
inhibiting;O;O
CYP3A;O;O
to;O;O
a;O;O
lesser;O;O
,;O;O
but;O;O
still;O;O
significant;O;O
degree;O;O
,;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s7.e0
should;O;O
be;O;O
used;O;O
only;O;O
with;O;O
caution;O;O
and;O;O
consideration;O;O
of;O;O
appropriate;O;O
dosage;O;O
reduction;O;O
.;O;O
DDI-DrugBank.d338.s8;;
The;O;O
following;O;O
are;O;O
examples;O;O
of;O;O
drugs;O;O
known;O;O
to;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
related;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d338.s8.e0
,;O;O
presumably;O;O
through;O;O
inhibition;O;O
of;O;O
CYP3A;O;O
:;O;O
nefazodone;B-drug;B-DDI-DrugBank.d338.s8.e1
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d338.s8.e2
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d338.s8.e3
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d338.s8.e4
,;O;O
isoniazide;B-drug;B-DDI-DrugBank.d338.s8.e5
,;O;O
and;O;O
some;O;O
macrolide;B-group;B-DDI-DrugBank.d338.s8.e6
antibiotics;I-group;I-DDI-DrugBank.d338.s8.e6
.;O;O
DDI-DrugBank.d338.s9;;
Drug;O;O
Interaction;O;O
with;O;O
Fluoxetine;B-drug;B-DDI-DrugBank.d338.s9.e0
:;O;O
A;O;O
multiple;O;O
-;O;O
dose;O;O
study;O;O
was;O;O
conducted;O;O
to;O;O
assess;O;O
the;O;O
effect;O;O
of;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d338.s9.e1
20;O;O
mg;O;O
BID;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s9.e2
2;O;O
mg;O;O
QHS;O;O
after;O;O
seven;O;O
days;O;O
.;O;O
DDI-DrugBank.d338.s10;;
The;O;O
pharmacokinetics;O;O
of;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s10.e0
(;O;O
Cmax;O;O
and;O;O
AUC;O;O
);O;O
were;O;O
not;O;O
affected;O;O
during;O;O
multiple;O;O
-;O;O
dose;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d338.s10.e1
,;O;O
suggesting;O;O
no;O;O
clinically;O;O
significant;O;O
pharmacokinetic;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d338.s11;;
Estazolam;B-drug;B-DDI-DrugBank.d338.s11.e0
:;O;O
Interaction;O;O
with;O;O
Other;O;O
Drugs;O;O
that;O;O
are;O;O
Metabolized;O;O
by;O;O
Cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
:;O;O
At;O;O
clinically;O;O
relevant;O;O
concentrations;O;O
,;O;O
in;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s11.e1
(;O;O
0.6;O;O
M;O;O
);O;O
was;O;O
not;O;O
inhibitory;O;O
towards;O;O
the;O;O
major;O;O
cytochrome;O;O
P450;O;O
isoforms;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP2E1;O;O
,;O;O
and;O;O
CYP3A.;O;O
DDI-DrugBank.d338.s12;;
Therefore;O;O
,;O;O
based;O;O
on;O;O
these;O;O
in;O;O
vitro;O;O
data;O;O
,;O;O
estazolam;B-drug;B-DDI-DrugBank.d338.s12.e0
is;O;O
very;O;O
unlikely;O;O
to;O;O
inhibit;O;O
the;O;O
biotransformation;O;O
of;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
these;O;O
CYP;O;O
isoforms;O;O
DDI-DrugBank.d338.s13;;
.;O;O
DDI-DrugBank.d338.s14;;
DDI-DrugBank.d301.s0;;
D.;O;O
DDI-DrugBank.d301.s1;;
Drug;O;O
and;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
1;O;O
.;O;O
DDI-DrugBank.d301.s2;;
Accelerated;O;O
prothrombin;O;O
time;O;O
,;O;O
partial;O;O
thromboplastin;O;O
time;O;O
,;O;O
and;O;O
platelet;O;O
aggregation;O;O
time;O;O
,;O;O
DDI-DrugBank.d301.s3;;
increased;O;O
platelet;O;O
count;O;O
,;O;O
DDI-DrugBank.d301.s4;;
increased;O;O
factors;O;O
II;O;O
,;O;O
VII;O;O
antigen;O;O
,;O;O
VIII;O;O
antigen;O;O
,;O;O
VIII;O;O
coagulant;O;O
activity;O;O
,;O;O
IX;O;O
,;O;O
X;O;O
,;O;O
XII;O;O
,;O;O
VII;O;O
-;O;O
X;O;O
complex;O;O
,;O;O
II;O;O
-;O;O
VII;O;O
-;O;O
X;O;O
complex;O;O
,;O;O
and;O;O
beta;O;O
-;O;O
thromboglobulin;O;O
,;O;O
DDI-DrugBank.d301.s5;;
decreased;O;O
levels;O;O
of;O;O
anti;O;O
-;O;O
factor;O;O
Xa;O;O
and;O;O
antithrombin;O;O
III;O;O
,;O;O
decreased;O;O
antithrombin;O;O
III;O;O
activity;O;O
,;O;O
DDI-DrugBank.d301.s6;;
increased;O;O
levels;O;O
of;O;O
fibrinogen;O;O
and;O;O
fibrinogen;O;O
activity;O;O
,;O;O
DDI-DrugBank.d301.s7;;
increased;O;O
plasminogen;O;O
antigen;O;O
and;O;O
activity;O;O
.;O;O
DDI-DrugBank.d301.s8;;
2;O;O
.;O;O
DDI-DrugBank.d301.s9;;
Increased;O;O
thyroid;O;O
-;O;O
binding;O;O
globulin;O;O
(;O;O
TBG;O;O
);O;O
leading;O;O
to;O;O
increased;O;O
circulating;O;O
total;O;O
thyroid;O;O
hormone;O;O
levels;O;O
,;O;O
as;O;O
measured;O;O
by;O;O
protein;O;O
-;O;O
bound;O;O
iodine;O;O
(;O;O
PBI;O;O
);O;O
,;O;O
T4;O;O
levels;O;O
(;O;O
by;O;O
column;O;O
or;O;O
by;O;O
radioimmunoassay;O;O
);O;O
or;O;O
T3;O;O
levels;O;O
by;O;O
radioimmunoassay;O;O
.;O;O
DDI-DrugBank.d301.s10;;
T3;O;O
resin;O;O
uptake;O;O
is;O;O
decreased;O;O
,;O;O
reflecting;O;O
the;O;O
elevated;O;O
TBG;O;O
.;O;O
DDI-DrugBank.d301.s11;;
Free;O;O
T4;O;O
and;O;O
T3;O;O
concentrations;O;O
are;O;O
unaltered;O;O
.;O;O
DDI-DrugBank.d301.s12;;
Patients;O;O
on;O;O
thyroid;O;O
replacement;O;O
therapy;O;O
may;O;O
require;O;O
higher;O;O
doses;O;O
of;O;O
thyroid;B-group;B-DDI-DrugBank.d301.s12.e0
hormone;I-group;I-DDI-DrugBank.d301.s12.e0
.;O;O
DDI-DrugBank.d301.s13;;
3;O;O
.;O;O
DDI-DrugBank.d301.s14;;
Other;O;O
binding;O;O
proteins;O;O
may;O;O
be;O;O
elevated;O;O
in;O;O
serum;O;O
,;O;O
i.e.;O;O
,;O;O
corticosteroid;O;O
binding;O;O
globulin;O;O
(;O;O
CBG;O;O
);O;O
,;O;O
sex;O;O
hormone;O;O
-;O;O
binding;O;O
globulin;O;O
(;O;O
SHBG;O;O
);O;O
,;O;O
leading;O;O
to;O;O
increased;O;O
total;O;O
circulating;O;O
corticosteroids;B-group;B-DDI-DrugBank.d301.s14.e0
and;O;O
sex;B-group;B-DDI-DrugBank.d301.s14.e1
steroids;I-group;I-DDI-DrugBank.d301.s14.e1
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d301.s15;;
Free;O;O
hormone;O;O
concentrations;O;O
may;O;O
be;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d301.s16;;
Other;O;O
plasma;O;O
proteins;O;O
may;O;O
be;O;O
increased;O;O
(;O;O
angiotensinogen;O;O
/;O;O
renin;O;O
substrate;O;O
,;O;O
alpha;O;O
-;O;O
1;O;O
-;O;O
antitrypsin;O;O
,;O;O
ceruloplasmin;O;O
);O;O
.;O;O
DDI-DrugBank.d301.s17;;
4;O;O
.;O;O
DDI-DrugBank.d301.s18;;
Increased;O;O
plasma;O;O
HDL;O;O
and;O;O
HDL2;O;O
cholesterol;O;O
subfraction;O;O
concentrations;O;O
,;O;O
reduced;O;O
LDL;O;O
cholesterol;O;O
concentration;O;O
,;O;O
increased;O;O
triglyceride;O;O
levels;O;O
.;O;O
DDI-DrugBank.d301.s19;;
5;O;O
.;O;O
DDI-DrugBank.d301.s20;;
Impaired;O;O
glucose;O;O
tolerance;O;O
.;O;O
DDI-DrugBank.d301.s21;;
6;O;O
.;O;O
DDI-DrugBank.d301.s22;;
Reduced;O;O
response;O;O
to;O;O
metyrapone;O;O
test;O;O
.;O;O
DDI-DrugBank.d481.s0;;
Milk;O;O
,;O;O
milk;O;O
products;O;O
,;O;O
and;O;O
calcium;B-drug;B-DDI-DrugBank.d481.s0.e0
-;O;O
rich;O;O
foods;O;O
or;O;O
drugs;O;O
may;O;O
impair;O;O
the;O;O
absorption;O;O
of;O;O
EMCYT;B-brand;B-DDI-DrugBank.d481.s0.e1
.;O;O
DDI-DrugBank.d216.s0;;
CNS;O;O
-;O;O
Active;O;O
Drugs;O;O
Ethanol;B-drug;B-DDI-DrugBank.d216.s0.e0
An;O;O
additive;O;O
effect;O;O
on;O;O
psychomotor;O;O
performance;O;O
was;O;O
seen;O;O
with;O;O
coadministration;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s0.e1
and;O;O
ethanol;B-drug;B-DDI-DrugBank.d216.s0.e2
0.70;O;O
g;O;O
/;O;O
kg;O;O
for;O;O
up;O;O
to;O;O
4;O;O
hours;O;O
after;O;O
ethanol;B-drug;B-DDI-DrugBank.d216.s0.e3
administration;O;O
.;O;O
DDI-DrugBank.d216.s1;;
Paroxetine;B-drug;B-DDI-DrugBank.d216.s1.e0
:;O;O
Coadministration;O;O
of;O;O
single;O;O
doses;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s1.e1
3;O;O
mg;O;O
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d216.s1.e2
20;O;O
mg;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
produced;O;O
no;O;O
pharmacokinetic;O;O
or;O;O
pharmacodynamic;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d216.s2;;
Lorazepam;B-drug;B-DDI-DrugBank.d216.s2.e0
:;O;O
Coadministration;O;O
of;O;O
single;O;O
doses;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s2.e1
3;O;O
mg;O;O
and;O;O
lorazepam;B-drug;B-DDI-DrugBank.d216.s2.e2
2;O;O
mg;O;O
did;O;O
not;O;O
have;O;O
clinically;O;O
relevant;O;O
effects;O;O
on;O;O
the;O;O
pharmacodynamics;O;O
or;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d216.s3;;
Olanzapine;B-drug;B-DDI-DrugBank.d216.s3.e0
:;O;O
Coadministration;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s3.e1
3;O;O
mg;O;O
and;O;O
olanzapine;B-drug;B-DDI-DrugBank.d216.s3.e2
10;O;O
mg;O;O
produced;O;O
a;O;O
decrease;O;O
in;O;O
DSST;O;O
scores;O;O
.;O;O
DDI-DrugBank.d216.s4;;
The;O;O
interaction;O;O
was;O;O
pharmacodynamic;O;O
,;O;O
DDI-DrugBank.d216.s5;;
there;O;O
was;O;O
no;O;O
alteration;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d216.s6;;
Drugs;O;O
That;O;O
Inhibit;O;O
CYP3A4;O;O
(;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d216.s6.e0
);O;O
CYP3A4;O;O
is;O;O
a;O;O
major;O;O
metabolic;O;O
pathway;O;O
for;O;O
elimination;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s6.e1
.;O;O
DDI-DrugBank.d216.s7;;
The;O;O
AUC;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s7.e0
was;O;O
increased;O;O
2.2;O;O
-;O;O
fold;O;O
by;O;O
coadministration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d216.s7.e1
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP3A4;O;O
,;O;O
400;O;O
mg;O;O
daily;O;O
for;O;O
5;O;O
days;O;O
.;O;O
DDI-DrugBank.d216.s8;;
Cmax;O;O
and;O;O
t1;O;O
/;O;O
2;O;O
were;O;O
increased;O;O
1.4;O;O
-;O;O
fold;O;O
and;O;O
1.3;O;O
-;O;O
fold;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d216.s9;;
Other;O;O
strong;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
(;O;O
e.g.;O;O
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d216.s9.e0
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d216.s9.e1
,;O;O
nefazodone;B-drug;B-DDI-DrugBank.d216.s9.e2
,;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d216.s9.e3
,;O;O
ritonavir;B-drug;B-DDI-DrugBank.d216.s9.e4
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d216.s9.e5
);O;O
would;O;O
be;O;O
expected;O;O
to;O;O
behave;O;O
similarly;O;O
.;O;O
DDI-DrugBank.d216.s10;;
Drugs;O;O
That;O;O
Induce;O;O
CYP3A4;O;O
(;O;O
Rifampicin;B-drug;B-DDI-DrugBank.d216.s10.e0
);O;O
Racemic;O;O
zopiclone;B-drug;B-DDI-DrugBank.d216.s10.e1
exposure;O;O
was;O;O
decreased;O;O
80;O;O
%;O;O
by;O;O
concomitant;O;O
useof;O;O
rifampicin;B-drug;B-DDI-DrugBank.d216.s10.e2
,;O;O
a;O;O
potent;O;O
inducer;O;O
of;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d216.s11;;
A;O;O
similar;O;O
effect;O;O
would;O;O
be;O;O
expected;O;O
with;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s11.e0
.;O;O
DDI-DrugBank.d216.s12;;
Drugs;O;O
Highly;O;O
Bound;O;O
To;O;O
Plasma;O;O
Protein;O;O
Eszopiclone;B-drug;B-DDI-DrugBank.d216.s12.e0
is;O;O
not;O;O
highly;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
(;O;O
52;O;O
-;O;O
59;O;O
%;O;O
bound;O;O
);O;O
,;O;O
DDI-DrugBank.d216.s13;;
therefore;O;O
,;O;O
the;O;O
disposition;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s13.e0
is;O;O
not;O;O
expected;O;O
to;O;O
be;O;O
sensitive;O;O
to;O;O
alterations;O;O
in;O;O
protein;O;O
binding;O;O
.;O;O
DDI-DrugBank.d216.s14;;
Administration;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s14.e0
3;O;O
mg;O;O
to;O;O
a;O;O
patient;O;O
taking;O;O
another;O;O
drug;O;O
that;O;O
is;O;O
highly;O;O
protein;O;O
-;O;O
bound;O;O
would;O;O
not;O;O
be;O;O
expected;O;O
to;O;O
cause;O;O
an;O;O
alteration;O;O
in;O;O
the;O;O
free;O;O
concentration;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d216.s15;;
Drugs;O;O
With;O;O
A;O;O
Narrow;O;O
Therapeutic;O;O
Index;O;O
Digoxin;B-drug;B-DDI-DrugBank.d216.s15.e0
A;O;O
single;O;O
dose;O;O
of;O;O
eszopiclone;B-drug;B-DDI-DrugBank.d216.s15.e1
3;O;O
mg;O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d216.s15.e2
measured;O;O
at;O;O
steady;O;O
state;O;O
following;O;O
dosing;O;O
of;O;O
0.5;O;O
mg;O;O
twice;O;O
daily;O;O
for;O;O
one;O;O
day;O;O
and;O;O
0.25;O;O
mg;O;O
daily;O;O
for;O;O
the;O;O
next;O;O
6;O;O
days;O;O
.;O;O
DDI-DrugBank.d216.s16;;
Warfarin;B-drug;B-DDI-DrugBank.d216.s16.e0
:;O;O
Eszopiclone;B-drug;B-DDI-DrugBank.d216.s16.e1
3;O;O
mg;O;O
administered;O;O
daily;O;O
for;O;O
5;O;O
days;O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
(;O;O
R);O;O
-;O;O
or;O;O
(;B-drug;B-DDI-DrugBank.d216.s16.e3
S);I-drug;I-DDI-DrugBank.d216.s16.e3
-;I-drug;I-DDI-DrugBank.d216.s16.e3
warfarin;I-drug;I-DDI-DrugBank.d216.s16.e3
,;O;O
nor;O;O
were;O;O
there;O;O
any;O;O
changes;O;O
in;O;O
the;O;O
pharmacodynamic;O;O
profile;O;O
(;O;O
prothrombin;O;O
time;O;O
);O;O
following;O;O
a;O;O
single;O;O
25;O;O
mg;O;O
oral;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d216.s16.e4
DDI-DrugBank.d216.s17;;
.;O;O
DDI-DrugBank.d216.s18;;
DDI-DrugBank.d341.s0;;
Specific;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
with;O;O
ENBREL;B-brand;B-DDI-DrugBank.d341.s0.e0
.;O;O
DDI-DrugBank.d341.s1;;
However;O;O
,;O;O
it;O;O
was;O;O
observed;O;O
that;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
ENBREL;B-brand;B-DDI-DrugBank.d341.s1.e0
was;O;O
unaltered;O;O
by;O;O
concomitant;O;O
methotrexate;B-drug;B-DDI-DrugBank.d341.s1.e1
in;O;O
rheumatoid;O;O
arthritis;O;O
patients;O;O
.;O;O
DDI-DrugBank.d341.s2;;
In;O;O
a;O;O
study;O;O
in;O;O
which;O;O
patients;O;O
with;O;O
active;O;O
RA;O;O
were;O;O
treated;O;O
for;O;O
up;O;O
to;O;O
24;O;O
weeks;O;O
with;O;O
concurrent;O;O
ENBREL;B-brand;B-DDI-DrugBank.d341.s2.e0
and;O;O
anakinra;B-drug;B-DDI-DrugBank.d341.s2.e1
therapy;O;O
,;O;O
a;O;O
7;O;O
%;O;O
rate;O;O
of;O;O
serious;O;O
infections;O;O
was;O;O
observed;O;O
,;O;O
which;O;O
was;O;O
higher;O;O
than;O;O
that;O;O
observed;O;O
with;O;O
ENBREL;B-brand;B-DDI-DrugBank.d341.s2.e2
alone;O;O
(;O;O
0;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d341.s3;;
Two;O;O
percent;O;O
of;O;O
patients;O;O
treated;O;O
concurrently;O;O
with;O;O
ENBREL;B-brand;B-DDI-DrugBank.d341.s3.e0
and;O;O
anakinra;B-drug;B-DDI-DrugBank.d341.s3.e1
developed;O;O
neutropenia;O;O
(;O;O
ANC;O;O
1;O;O
x;O;O
109;O;O
/;O;O
L;O;O
);O;O
.;O;O
DDI-DrugBank.d341.s4;;
Patients;O;O
in;O;O
a;O;O
clinical;O;O
study;O;O
who;O;O
were;O;O
on;O;O
established;O;O
therapy;O;O
with;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d341.s4.e0
,;O;O
to;O;O
which;O;O
ENBREL;B-brand;B-DDI-DrugBank.d341.s4.e1
was;O;O
added;O;O
,;O;O
were;O;O
noted;O;O
to;O;O
develop;O;O
a;O;O
mild;O;O
decrease;O;O
in;O;O
mean;O;O
neutrophil;O;O
counts;O;O
in;O;O
comparison;O;O
to;O;O
groups;O;O
treated;O;O
with;O;O
either;O;O
ENBREL;B-brand;B-DDI-DrugBank.d341.s4.e2
CI;O;O
or;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d341.s4.e3
alone;O;O
.;O;O
DDI-DrugBank.d341.s5;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
observation;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d414.s0;;
Lithium;B-drug;B-DDI-DrugBank.d414.s0.e0
generally;O;O
should;O;O
not;O;O
be;O;O
given;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d414.s0.e1
because;O;O
they;O;O
reduce;O;O
its;O;O
renal;O;O
clearance;O;O
and;O;O
add;O;O
a;O;O
high;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d414.s0.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d414.s1;;
Read;O;O
circulars;O;O
for;O;O
lithium;B-drug;B-DDI-DrugBank.d414.s1.e0
preparations;O;O
before;O;O
use;O;O
of;O;O
such;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d414.s2;;
EDECRIN;B-brand;B-DDI-DrugBank.d414.s2.e0
may;O;O
increase;O;O
the;O;O
ototoxic;O;O
potential;O;O
of;O;O
other;O;O
drugs;O;O
such;O;O
as;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d414.s2.e1
and;O;O
some;O;O
cephalosporin;B-group;B-DDI-DrugBank.d414.s2.e2
antibiotics;I-group;I-DDI-DrugBank.d414.s2.e2
.;O;O
DDI-DrugBank.d414.s3;;
Their;O;O
concurrent;O;O
use;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d414.s4;;
A;O;O
number;O;O
of;O;O
drugs;O;O
,;O;O
including;O;O
ethacrynic;B-drug;B-DDI-DrugBank.d414.s4.e0
acid;I-drug;I-DDI-DrugBank.d414.s4.e0
,;O;O
have;O;O
been;O;O
shown;O;O
to;O;O
displace;O;O
warfarin;B-drug;B-DDI-DrugBank.d414.s4.e1
from;O;O
plasma;O;O
protein;O;O
,;O;O
DDI-DrugBank.d414.s5;;
a;O;O
reduction;O;O
in;O;O
the;O;O
usual;O;O
anticoagulant;B-group;B-DDI-DrugBank.d414.s5.e0
dosage;O;O
may;O;O
be;O;O
required;O;O
in;O;O
patients;O;O
receiving;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d414.s6;;
In;O;O
some;O;O
patients;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
a;O;O
non;B-group;B-DDI-DrugBank.d414.s6.e0
-;I-group;I-DDI-DrugBank.d414.s6.e0
steroidal;I-group;I-DDI-DrugBank.d414.s6.e0
antiinflammatory;I-group;I-DDI-DrugBank.d414.s6.e0
agent;I-group;I-DDI-DrugBank.d414.s6.e0
can;O;O
reduce;O;O
the;O;O
diuretic;O;O
,;O;O
natriuretic;O;O
,;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
loop;B-group;B-DDI-DrugBank.d414.s6.e1
,;I-group;I-DDI-DrugBank.d414.s6.e1
potassium;I-group;I-DDI-DrugBank.d414.s6.e2
-;I-group;I-DDI-DrugBank.d414.s6.e2
sparing;I-group;I-DDI-DrugBank.d414.s6.e2
and;I-group;I-DDI-DrugBank.d414.s6.e2
thiazide;I-group;I-DDI-DrugBank.d414.s6.e3
diuretics;I-group;I-DDI-DrugBank.d414.s6.e3
.;O;O
DDI-DrugBank.d414.s7;;
Therefore;O;O
,;O;O
when;O;O
EDECRIN;B-brand;B-DDI-DrugBank.d414.s7.e0
and;O;O
non;B-group;B-DDI-DrugBank.d414.s7.e1
-;I-group;I-DDI-DrugBank.d414.s7.e1
steroidal;I-group;I-DDI-DrugBank.d414.s7.e1
anti;I-group;I-DDI-DrugBank.d414.s7.e1
-;I-group;I-DDI-DrugBank.d414.s7.e1
inflammatory;I-group;I-DDI-DrugBank.d414.s7.e1
agents;I-group;I-DDI-DrugBank.d414.s7.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
effect;O;O
of;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d414.s7.e2
is;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d160.s0;;
The;O;O
results;O;O
of;O;O
a;O;O
study;O;O
of;O;O
coadministration;O;O
of;O;O
ethambutol;B-drug;B-DDI-DrugBank.d160.s0.e0
(;O;O
50;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
with;O;O
an;O;O
aluminum;B-drug;B-DDI-DrugBank.d160.s0.e1
hydroxide;I-drug;I-DDI-DrugBank.d160.s0.e1
containing;O;O
antacid;B-group;B-DDI-DrugBank.d160.s0.e2
to;O;O
13;O;O
patients;O;O
with;O;O
tuberculosis;O;O
showed;O;O
a;O;O
reduction;O;O
of;O;O
mean;O;O
serum;O;O
concentrations;O;O
and;O;O
urinary;O;O
excretion;O;O
of;O;O
ethambutol;B-drug;B-DDI-DrugBank.d160.s0.e3
of;O;O
approximately;O;O
20;O;O
%;O;O
and;O;O
13;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
suggesting;O;O
that;O;O
the;O;O
oral;O;O
absorption;O;O
of;O;O
ethambutol;B-drug;B-DDI-DrugBank.d160.s0.e4
may;O;O
be;O;O
reduced;O;O
by;O;O
these;O;O
antacid;B-group;B-DDI-DrugBank.d160.s0.e5
products;I-group;I-DDI-DrugBank.d160.s0.e5
.;O;O
DDI-DrugBank.d160.s1;;
It;O;O
is;O;O
recommended;O;O
to;O;O
avoid;O;O
concurrent;O;O
administration;O;O
of;O;O
ethambutol;B-drug;B-DDI-DrugBank.d160.s1.e0
with;O;O
aluminum;B-drug;B-DDI-DrugBank.d160.s1.e1
hydroxide;I-drug;I-DDI-DrugBank.d160.s1.e1
containing;O;O
antacids;B-group;B-DDI-DrugBank.d160.s1.e2
for;O;O
at;O;O
least;O;O
4;O;O
hours;O;O
following;O;O
ethambutol;B-drug;B-DDI-DrugBank.d160.s1.e3
administration;O;O
.;O;O
DDI-DrugBank.d405.s0;;
Dicumarol;B-drug;B-DDI-DrugBank.d405.s0.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d405.s0.e1
may;O;O
decrease;O;O
hypoprothrombinemic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d405.s1;;
Other;O;O
depressasnts;O;O
such;O;O
as;O;O
alcohol;B-drug;B-DDI-DrugBank.d405.s1.e0
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d405.s1.e1
,;O;O
and;O;O
MAOIs;B-group;B-DDI-DrugBank.d405.s1.e2
may;O;O
enhance;O;O
CNS;O;O
depression;O;O
when;O;O
administered;O;O
with;O;O
ethchlorvynol;B-drug;B-DDI-DrugBank.d405.s1.e3
.;O;O
DDI-DrugBank.d376.s0;;
May;O;O
interact;O;O
with;O;O
addictive;O;O
medications;O;O
,;O;O
especially;O;O
central;B-group;B-DDI-DrugBank.d376.s0.e0
nervous;I-group;I-DDI-DrugBank.d376.s0.e0
system;I-group;I-DDI-DrugBank.d376.s0.e0
(;I-group;I-DDI-DrugBank.d376.s0.e0
CNS;I-group;I-DDI-DrugBank.d376.s0.e0
);I-group;I-DDI-DrugBank.d376.s0.e0
depressants;I-group;I-DDI-DrugBank.d376.s0.e0
with;O;O
habituating;O;O
potential;O;O
(;O;O
prolonged;O;O
concurrent;O;O
use;O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
habituation;O;O
);O;O
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d376.s0.e1
or;O;O
CNS;O;O
depression;O;O
producing;O;O
medications;O;O
(;O;O
concurrent;O;O
use;O;O
may;O;O
increase;O;O
the;O;O
CNS;O;O
depressant;O;O
effects;O;O
of;O;O
either;O;O
these;O;O
medications;O;O
or;O;O
ethinamate;B-drug;B-DDI-DrugBank.d376.s0.e2
);O;O
.;O;O
DDI-DrugBank.d152.s0;;
Certain;O;O
endocrine;O;O
and;O;O
liver;O;O
function;O;O
tests;O;O
may;O;O
be;O;O
affected;O;O
by;O;O
estrogen;B-group;B-DDI-DrugBank.d152.s0.e0
-;O;O
containing;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d152.s0.e1
.;O;O
DDI-DrugBank.d152.s1;;
The;O;O
following;O;O
similar;O;O
changes;O;O
may;O;O
be;O;O
expected;O;O
with;O;O
larger;O;O
doses;O;O
of;O;O
estrogen;B-group;B-DDI-DrugBank.d152.s1.e0
:;O;O
Increased;O;O
sulfobromophthalein;O;O
retention;O;O
,;O;O
DDI-DrugBank.d152.s2;;
increased;O;O
prothrombin;O;O
and;O;O
factors;O;O
VII;O;O
,;O;O
VIII;O;O
,;O;O
IX;O;O
,;O;O
and;O;O
X;O;O
,;O;O
DDI-DrugBank.d152.s3;;
decreased;O;O
antithrombin;O;O
3;O;O
,;O;O
DDI-DrugBank.d152.s4;;
increased;O;O
norepinephrine;O;O
-;O;O
induced;O;O
platel;O;O
et;O;O
aggregation;O;O
,;O;O
DDI-DrugBank.d152.s5;;
increased;O;O
thyroid;O;O
binding;O;O
globulin;O;O
(;O;O
TBG;O;O
);O;O
leading;O;O
to;O;O
increased;O;O
circulating;O;O
total;O;O
thyroid;O;O
hormone;O;O
,;O;O
as;O;O
measured;O;O
by;O;O
PBI;O;O
,;O;O
T4;O;O
by;O;O
column;O;O
,;O;O
or;O;O
T4;O;O
by;O;O
radioimmunoassay;O;O
.;O;O
DDI-DrugBank.d152.s6;;
Free;O;O
T3;O;O
resin;O;O
uptake;O;O
is;O;O
decreased;O;O
,;O;O
reflecting;O;O
the;O;O
elevated;O;O
TBG;O;O
,;O;O
DDI-DrugBank.d152.s7;;
free;O;O
T4;O;O
concentration;O;O
is;O;O
unaltered;O;O
:;O;O
impaired;O;O
glucose;O;O
tolerance;O;O
,;O;O
DDI-DrugBank.d152.s8;;
decreased;O;O
pregnanediol;O;O
excretion;O;O
,;O;O
DDI-DrugBank.d152.s9;;
reduced;O;O
response;O;O
to;O;O
metyrapone;O;O
test;O;O
,;O;O
DDI-DrugBank.d152.s10;;
reduced;O;O
serum;O;O
folate;O;O
concentration;O;O
,;O;O
DDI-DrugBank.d152.s11;;
increased;O;O
serum;O;O
triglyceride;O;O
and;O;O
phospholipid;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d166.s0;;
Trecator;B-brand;B-DDI-DrugBank.d166.s0.e0
has;O;O
been;O;O
found;O;O
to;O;O
temporarily;O;O
raise;O;O
serum;O;O
concentrations;O;O
of;O;O
isoniazid;B-drug;B-DDI-DrugBank.d166.s0.e1
.;O;O
DDI-DrugBank.d166.s1;;
Trecator;B-brand;B-DDI-DrugBank.d166.s1.e0
may;O;O
potentiate;O;O
the;O;O
adverse;O;O
effects;O;O
of;O;O
other;O;O
antituberculous;B-group;B-DDI-DrugBank.d166.s1.e1
drugs;I-group;I-DDI-DrugBank.d166.s1.e1
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d166.s2;;
In;O;O
particular;O;O
,;O;O
convulsions;O;O
have;O;O
been;O;O
reported;O;O
when;O;O
ethionamide;B-drug;B-DDI-DrugBank.d166.s2.e0
is;O;O
administered;O;O
with;O;O
cycloserine;B-drug;B-DDI-DrugBank.d166.s2.e1
and;O;O
special;O;O
care;O;O
should;O;O
be;O;O
taken;O;O
when;O;O
the;O;O
treatment;O;O
regimen;O;O
includes;O;O
both;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d166.s3;;
Excessive;O;O
ethanol;B-drug;B-DDI-DrugBank.d166.s3.e0
ingestion;O;O
should;O;O
be;O;O
avoided;O;O
because;O;O
a;O;O
psychotic;O;O
reaction;O;O
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d240.s0;;
Ethopropazine;B-drug;B-DDI-DrugBank.d240.s0.e0
may;O;O
interact;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d240.s0.e1
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d240.s0.e2
depressants;I-group;I-DDI-DrugBank.d240.s0.e2
,;O;O
causing;O;O
increased;O;O
sedative;O;O
effects;O;O
.;O;O
DDI-DrugBank.d240.s1;;
It;O;O
may;O;O
also;O;O
interact;O;O
with;O;O
amantadine;B-drug;B-DDI-DrugBank.d240.s1.e0
or;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d240.s1.e1
drugs;I-group;I-DDI-DrugBank.d240.s1.e1
or;O;O
MAOIs;B-group;B-DDI-DrugBank.d240.s1.e2
,;O;O
which;O;O
may;O;O
intensify;O;O
the;O;O
anticholinergic;O;O
action;O;O
.;O;O
DDI-DrugBank.d240.s2;;
Ethopropazine;B-drug;B-DDI-DrugBank.d240.s2.e0
can;O;O
interact;O;O
with;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d240.s2.e1
,;O;O
increasing;O;O
the;O;O
metabolism;O;O
of;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d240.s2.e2
.;O;O
DDI-DrugBank.d205.s0;;
Since;O;O
Zarontin;B-brand;B-DDI-DrugBank.d205.s0.e0
(;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d205.s0.e1
);O;O
may;O;O
interact;O;O
with;O;O
concurrently;O;O
administered;O;O
antiepileptic;B-group;B-DDI-DrugBank.d205.s0.e2
drugs;I-group;I-DDI-DrugBank.d205.s0.e2
,;O;O
periodic;O;O
serum;O;O
level;O;O
determinations;O;O
of;O;O
these;O;O
drugs;O;O
may;O;O
be;O;O
necessary;O;O
(;O;O
eg;O;O
,;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d205.s0.e3
may;O;O
elevate;O;O
phenytoin;B-drug;B-DDI-DrugBank.d205.s0.e4
serum;O;O
levels;O;O
and;O;O
valproic;B-drug;B-DDI-DrugBank.d205.s0.e5
acid;I-drug;I-DDI-DrugBank.d205.s0.e5
has;O;O
been;O;O
reported;O;O
to;O;O
both;O;O
increase;O;O
and;O;O
decrease;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d205.s0.e6
levels;O;O
);O;O
.;O;O
DDI-DrugBank.d359.s0;;
PEGANONE;B-brand;B-DDI-DrugBank.d359.s0.e0
used;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
drugs;O;O
known;O;O
to;O;O
adversely;O;O
affect;O;O
the;O;O
hematopoietic;O;O
system;O;O
should;O;O
be;O;O
avoided;O;O
if;O;O
possible;O;O
.;O;O
DDI-DrugBank.d359.s1;;
Considerable;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
if;O;O
PEGANONE;B-brand;B-DDI-DrugBank.d359.s1.e0
is;O;O
administered;O;O
concurrently;O;O
with;O;O
Phenurone;B-brand;B-DDI-DrugBank.d359.s1.e1
(;O;O
phenacemide;B-drug;B-DDI-DrugBank.d359.s1.e2
);O;O
since;O;O
paranoid;O;O
symptoms;O;O
have;O;O
been;O;O
reported;O;O
during;O;O
therapy;O;O
with;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d359.s2;;
A;O;O
two;O;O
-;O;O
way;O;O
interaction;O;O
between;O;O
the;O;O
hydantoin;B-group;B-DDI-DrugBank.d359.s2.e0
antiepileptic;I-group;I-DDI-DrugBank.d359.s2.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d359.s2.e1
,;O;O
and;O;O
the;O;O
coumarin;B-group;B-DDI-DrugBank.d359.s2.e2
anticoagulants;I-group;I-DDI-DrugBank.d359.s2.e2
has;O;O
been;O;O
suggested;O;O
.;O;O
DDI-DrugBank.d359.s3;;
Presumably;O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d359.s3.e0
acts;O;O
as;O;O
a;O;O
stimulator;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d359.s3.e1
metabolism;O;O
and;O;O
has;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
decreased;O;O
serum;O;O
levels;O;O
of;O;O
the;O;O
coumarin;B-group;B-DDI-DrugBank.d359.s3.e2
anticoagulants;I-group;I-DDI-DrugBank.d359.s3.e2
and;O;O
increased;O;O
prothrombin;O;O
-;O;O
proconvertin;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d359.s4;;
Conversely;O;O
,;O;O
the;O;O
coumarin;B-group;B-DDI-DrugBank.d359.s4.e0
anticoagulants;I-group;I-DDI-DrugBank.d359.s4.e0
have;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
the;O;O
serum;O;O
levels;O;O
and;O;O
prolong;O;O
the;O;O
serum;O;O
half;O;O
-;O;O
life;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d359.s4.e1
by;O;O
inhibiting;O;O
its;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d359.s5;;
Although;O;O
there;O;O
is;O;O
no;O;O
documentation;O;O
of;O;O
such;O;O
,;O;O
a;O;O
similar;O;O
interaction;O;O
between;O;O
ethotoin;B-drug;B-DDI-DrugBank.d359.s5.e0
and;O;O
the;O;O
coumarin;B-group;B-DDI-DrugBank.d359.s5.e1
anticoagulants;I-group;I-DDI-DrugBank.d359.s5.e1
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d359.s6;;
Caution;O;O
is;O;O
therefore;O;O
advised;O;O
when;O;O
administering;O;O
PEGANONE;B-brand;B-DDI-DrugBank.d359.s6.e0
to;O;O
patients;O;O
receiving;O;O
coumarin;B-group;B-DDI-DrugBank.d359.s6.e1
anticoagulants;I-group;I-DDI-DrugBank.d359.s6.e1
.;O;O
DDI-DrugBank.d286.s0;;
Ethoxzolamide;B-drug;B-DDI-DrugBank.d286.s0.e0
may;O;O
increase;O;O
the;O;O
action;O;O
of;O;O
tricyclics;B-group;B-DDI-DrugBank.d286.s0.e1
,;O;O
amphetamines;B-group;B-DDI-DrugBank.d286.s0.e2
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d286.s0.e3
,;O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d286.s0.e4
.;O;O
DDI-DrugBank.d286.s1;;
It;O;O
may;O;O
increase;O;O
excretion;O;O
of;O;O
barbiturates;B-group;B-DDI-DrugBank.d286.s1.e0
,;O;O
lithium;B-drug;B-DDI-DrugBank.d286.s1.e1
,;O;O
and;O;O
ASA;B-drug;B-DDI-DrugBank.d286.s1.e2
and;O;O
may;O;O
also;O;O
increase;O;O
the;O;O
toxicity;O;O
of;O;O
salicylates;B-group;B-DDI-DrugBank.d286.s1.e3
.;O;O
DDI-DrugBank.d286.s2;;
Coadministration;O;O
of;O;O
ethoxzolamide;B-drug;B-DDI-DrugBank.d286.s2.e0
with;O;O
other;O;O
diuretics;B-group;B-DDI-DrugBank.d286.s2.e1
,;O;O
amphotericin;B-drug;B-DDI-DrugBank.d286.s2.e2
B;I-drug;I-DDI-DrugBank.d286.s2.e2
,;O;O
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d286.s2.e3
may;O;O
cause;O;O
hypokalemia;O;O
.;O;O
DDI-DrugBank.d485.s0;;
Ethinyl;B-drug;B-DDI-DrugBank.d485.s0.e0
estradiol;I-drug;I-DDI-DrugBank.d485.s0.e0
:;O;O
Substrate;O;O
of;O;O
CYP3A4;O;O
(;O;O
major;O;O
);O;O
,;O;O
3A5;O;O
-;O;O
7;O;O
(;O;O
minor;O;O
);O;O
,;O;O
DDI-DrugBank.d485.s1;;
Inhibits;O;O
CYP1A2;O;O
(;O;O
weak;O;O
);O;O
,;O;O
2B6;O;O
(;O;O
weak;O;O
);O;O
,;O;O
2C19;O;O
(;O;O
weak;O;O
);O;O
,;O;O
3A4;O;O
(;O;O
weak;O;O
);O;O
.;O;O
DDI-DrugBank.d485.s2;;
Acetaminophen;B-drug;B-DDI-DrugBank.d485.s2.e0
:;O;O
May;O;O
increase;O;O
plasma;O;O
concentration;O;O
of;O;O
synthetic;B-group;B-DDI-DrugBank.d485.s2.e1
estrogens;I-group;I-DDI-DrugBank.d485.s2.e1
,;O;O
possibly;O;O
by;O;O
inhibiting;O;O
conjugation;O;O
.;O;O
DDI-DrugBank.d485.s3;;
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s3.e0
contraceptives;I-group;I-DDI-DrugBank.d485.s3.e0
may;O;O
also;O;O
decrease;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d485.s3.e1
.;O;O
DDI-DrugBank.d485.s4;;
Acitretin;B-drug;B-DDI-DrugBank.d485.s4.e0
:;O;O
Interferes;O;O
with;O;O
the;O;O
contraceptive;O;O
effect;O;O
of;O;O
microdosed;O;O
progestin;B-group;B-DDI-DrugBank.d485.s4.e1
-;O;O
containing;O;O
minipill;O;O
preparations;O;O
.;O;O
DDI-DrugBank.d485.s5;;
The;O;O
effect;O;O
on;O;O
other;O;O
progestational;B-group;B-DDI-DrugBank.d485.s5.e0
contraceptives;I-group;I-DDI-DrugBank.d485.s5.e0
(;O;O
eg;O;O
,;O;O
implants;O;O
,;O;O
injectables;O;O
);O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d485.s6;;
Aminoglutethimide;B-drug;B-DDI-DrugBank.d485.s6.e0
:;O;O
May;O;O
increase;O;O
CYP;O;O
metabolism;O;O
of;O;O
progestins;B-group;B-DDI-DrugBank.d485.s6.e1
leading;O;O
to;O;O
possible;O;O
decrease;O;O
in;O;O
contraceptive;O;O
effectiveness;O;O
.;O;O
DDI-DrugBank.d485.s7;;
Use;O;O
of;O;O
a;O;O
nonhormonal;B-group;B-DDI-DrugBank.d485.s7.e0
contraceptive;I-group;I-DDI-DrugBank.d485.s7.e0
product;I-group;I-DDI-DrugBank.d485.s7.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d485.s8;;
Antibiotics;B-group;B-DDI-DrugBank.d485.s8.e0
(;O;O
ampicillin;B-drug;B-DDI-DrugBank.d485.s8.e1
,;O;O
tetracycline;B-drug;B-DDI-DrugBank.d485.s8.e2
);O;O
:;O;O
Pregnancy;O;O
has;O;O
been;O;O
reported;O;O
following;O;O
concomitant;O;O
use;O;O
,;O;O
however;O;O
,;O;O
pharmacokinetic;O;O
studies;O;O
have;O;O
not;O;O
shown;O;O
consistent;O;O
effects;O;O
with;O;O
these;O;O
antibiotics;B-group;B-DDI-DrugBank.d485.s8.e3
on;O;O
plasma;O;O
concentrations;O;O
of;O;O
synthetic;B-group;B-DDI-DrugBank.d485.s8.e4
steroids;I-group;I-DDI-DrugBank.d485.s8.e4
.;O;O
DDI-DrugBank.d485.s9;;
Use;O;O
of;O;O
a;O;O
nonhormonal;B-group;B-DDI-DrugBank.d485.s9.e0
contraceptive;I-group;I-DDI-DrugBank.d485.s9.e0
product;I-group;I-DDI-DrugBank.d485.s9.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d485.s10;;
Anticoagulants;B-group;B-DDI-DrugBank.d485.s10.e0
:;O;O
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s10.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s10.e1
may;O;O
increase;O;O
or;O;O
decrease;O;O
the;O;O
effects;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d485.s10.e2
derivatives;I-group;I-DDI-DrugBank.d485.s10.e2
.;O;O
DDI-DrugBank.d485.s11;;
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s11.e0
contraceptives;I-group;I-DDI-DrugBank.d485.s11.e0
may;O;O
also;O;O
increase;O;O
risk;O;O
of;O;O
thromboembolic;O;O
disorders;O;O
.;O;O
DDI-DrugBank.d485.s12;;
Anticonvulsants;B-group;B-DDI-DrugBank.d485.s12.e0
(;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d485.s12.e1
,;O;O
felbamate;B-drug;B-DDI-DrugBank.d485.s12.e2
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d485.s12.e3
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d485.s12.e4
,;O;O
topiramate;B-drug;B-DDI-DrugBank.d485.s12.e5
);O;O
:;O;O
Increase;O;O
the;O;O
metabolism;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d485.s12.e6
estradiol;I-drug;I-DDI-DrugBank.d485.s12.e6
and/or;O;O
some;O;O
progestins;B-group;B-DDI-DrugBank.d485.s12.e7
,;O;O
leading;O;O
to;O;O
possible;O;O
decrease;O;O
in;O;O
contraceptive;O;O
effectiveness;O;O
.;O;O
DDI-DrugBank.d485.s13;;
Use;O;O
of;O;O
a;O;O
nonhormonal;B-group;B-DDI-DrugBank.d485.s13.e0
contraceptive;I-group;I-DDI-DrugBank.d485.s13.e0
product;I-group;I-DDI-DrugBank.d485.s13.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d485.s14;;
Ascorbic;B-drug;B-DDI-DrugBank.d485.s14.e0
acid;I-drug;I-DDI-DrugBank.d485.s14.e0
:;O;O
Doses;O;O
of;O;O
ascorbic;B-drug;B-DDI-DrugBank.d485.s14.e1
acid;I-drug;I-DDI-DrugBank.d485.s14.e1
(;O;O
vitamin;B-drug;B-DDI-DrugBank.d485.s14.e2
C;I-drug;I-DDI-DrugBank.d485.s14.e2
);O;O
1;O;O
g;O;O
/;O;O
day;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
plasma;O;O
concentration;O;O
of;O;O
synthetic;B-group;B-DDI-DrugBank.d485.s14.e3
estrogens;I-group;I-DDI-DrugBank.d485.s14.e3
by;O;O
~47;O;O
%;O;O
,;O;O
possibly;O;O
by;O;O
inhibiting;O;O
conjugation;O;O
,;O;O
DDI-DrugBank.d485.s15;;
clinical;O;O
implications;O;O
are;O;O
unclear;O;O
.;O;O
DDI-DrugBank.d485.s16;;
Atorvastatin;B-drug;B-DDI-DrugBank.d485.s16.e0
:;O;O
Atorvastatin;B-drug;B-DDI-DrugBank.d485.s16.e1
increases;O;O
the;O;O
AUC;O;O
for;O;O
norethindrone;B-drug;B-DDI-DrugBank.d485.s16.e2
and;O;O
ethinyl;B-drug;B-DDI-DrugBank.d485.s16.e3
estradiol;I-drug;I-DDI-DrugBank.d485.s16.e3
.;O;O
DDI-DrugBank.d485.s17;;
Benzodiazepines;B-group;B-DDI-DrugBank.d485.s17.e0
:;O;O
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s17.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s17.e1
may;O;O
decrease;O;O
the;O;O
clearance;O;O
of;O;O
some;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d485.s17.e2
(;O;O
alprazolam;B-drug;B-DDI-DrugBank.d485.s17.e3
,;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d485.s17.e4
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d485.s17.e5
);O;O
and;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
others;O;O
(;O;O
lorazepam;B-drug;B-DDI-DrugBank.d485.s17.e6
,;O;O
oxazepam;B-drug;B-DDI-DrugBank.d485.s17.e7
,;O;O
temazepam;B-drug;B-DDI-DrugBank.d485.s17.e8
);O;O
.;O;O
DDI-DrugBank.d485.s18;;
Clofibric;B-drug_n;B-DDI-DrugBank.d485.s18.e0
acid;I-drug_n;I-DDI-DrugBank.d485.s18.e0
:;O;O
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s18.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s18.e1
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
clofibric;B-drug_n;B-DDI-DrugBank.d485.s18.e2
acid;I-drug_n;I-DDI-DrugBank.d485.s18.e2
.;O;O
DDI-DrugBank.d485.s19;;
Cyclosporine;B-drug;B-DDI-DrugBank.d485.s19.e0
:;O;O
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s19.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s19.e1
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d485.s19.e2
,;O;O
leading;O;O
to;O;O
increased;O;O
plasma;O;O
concentrations;O;O
,;O;O
DDI-DrugBank.d485.s20;;
monitor;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d485.s20.e0
levels;O;O
.;O;O
DDI-DrugBank.d485.s21;;
CYP3A4;O;O
inducers;O;O
:;O;O
CYP3A4;O;O
inducers;O;O
may;O;O
decrease;O;O
the;O;O
levels;O;O
/;O;O
effects;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d485.s21.e0
estradiol;I-drug;I-DDI-DrugBank.d485.s21.e0
.;O;O
DDI-DrugBank.d485.s22;;
Example;O;O
inducers;O;O
include;O;O
aminoglutethimide;B-drug;B-DDI-DrugBank.d485.s22.e0
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d485.s22.e1
,;O;O
nafcillin;B-drug;B-DDI-DrugBank.d485.s22.e2
,;O;O
nevirapine;B-drug;B-DDI-DrugBank.d485.s22.e3
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d485.s22.e4
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d485.s22.e5
,;O;O
and;O;O
rifamycins;B-group;B-DDI-DrugBank.d485.s22.e6
.;O;O
DDI-DrugBank.d485.s23;;
Griseofulvin;B-drug;B-DDI-DrugBank.d485.s23.e0
:;O;O
Griseofulvin;B-drug;B-DDI-DrugBank.d485.s23.e1
may;O;O
induce;O;O
the;O;O
metabolism;O;O
of;O;O
combination;B-group;B-DDI-DrugBank.d485.s23.e2
hormonal;I-group;I-DDI-DrugBank.d485.s23.e2
contraceptives;I-group;I-DDI-DrugBank.d485.s23.e2
causing;O;O
menstrual;O;O
changes;O;O
,;O;O
DDI-DrugBank.d485.s24;;
pregnancies;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d485.s25;;
Use;O;O
of;O;O
barrier;O;O
form;O;O
of;O;O
contraception;O;O
is;O;O
suggested;O;O
while;O;O
on;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d485.s25.e0
therapy;O;O
.;O;O
DDI-DrugBank.d485.s26;;
Morphine;B-drug;B-DDI-DrugBank.d485.s26.e0
:;O;O
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s26.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s26.e1
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
morphine;B-drug;B-DDI-DrugBank.d485.s26.e2
.;O;O
DDI-DrugBank.d485.s27;;
Non;B-group;B-DDI-DrugBank.d485.s27.e0
-;I-group;I-DDI-DrugBank.d485.s27.e0
nucleoside;I-group;I-DDI-DrugBank.d485.s27.e0
reverse;I-group;I-DDI-DrugBank.d485.s27.e0
transcriptase;I-group;I-DDI-DrugBank.d485.s27.e0
inhibitors;I-group;I-DDI-DrugBank.d485.s27.e0
(;O;O
NNRTIs;B-group;B-DDI-DrugBank.d485.s27.e1
);O;O
:;O;O
Nevirapine;B-drug;B-DDI-DrugBank.d485.s27.e2
may;O;O
decrease;O;O
plasma;O;O
levels;O;O
of;O;O
combination;B-group;B-DDI-DrugBank.d485.s27.e3
hormonal;I-group;I-DDI-DrugBank.d485.s27.e3
contraceptives;I-group;I-DDI-DrugBank.d485.s27.e3
,;O;O
DDI-DrugBank.d485.s28;;
use;O;O
of;O;O
a;O;O
nonhormonal;B-group;B-DDI-DrugBank.d485.s28.e0
contraceptive;I-group;I-DDI-DrugBank.d485.s28.e0
product;I-group;I-DDI-DrugBank.d485.s28.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d485.s29;;
No;O;O
data;O;O
for;O;O
delavirdine;B-drug;B-DDI-DrugBank.d485.s29.e0
,;O;O
DDI-DrugBank.d485.s30;;
incomplete;O;O
data;O;O
for;O;O
efavirenz;B-drug;B-DDI-DrugBank.d485.s30.e0
.;O;O
DDI-DrugBank.d485.s31;;
Prednisolone;B-drug;B-DDI-DrugBank.d485.s31.e0
:;O;O
Ethinyl;B-drug;B-DDI-DrugBank.d485.s31.e1
estradiol;I-drug;I-DDI-DrugBank.d485.s31.e1
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
prednisolone;B-drug;B-DDI-DrugBank.d485.s31.e2
,;O;O
leading;O;O
to;O;O
increased;O;O
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d485.s32;;
Protease;B-group;B-DDI-DrugBank.d485.s32.e0
inhibitors;I-group;I-DDI-DrugBank.d485.s32.e0
:;O;O
Amprenavir;B-drug;B-DDI-DrugBank.d485.s32.e1
,;O;O
lopinavir;B-drug;B-DDI-DrugBank.d485.s32.e2
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d485.s32.e3
,;O;O
and;O;O
ritonavir;B-drug;B-DDI-DrugBank.d485.s32.e4
have;O;O
been;O;O
shown;O;O
to;O;O
decrease;O;O
plasma;O;O
levels;O;O
of;O;O
combination;B-group;B-DDI-DrugBank.d485.s32.e5
hormonal;I-group;I-DDI-DrugBank.d485.s32.e5
contraceptives;I-group;I-DDI-DrugBank.d485.s32.e5
,;O;O
DDI-DrugBank.d485.s33;;
use;O;O
of;O;O
a;O;O
nonhormonal;B-group;B-DDI-DrugBank.d485.s33.e0
contraceptive;I-group;I-DDI-DrugBank.d485.s33.e0
product;I-group;I-DDI-DrugBank.d485.s33.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d485.s34;;
Indinavir;B-drug;B-DDI-DrugBank.d485.s34.e0
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
plasma;O;O
levels;O;O
of;O;O
combination;B-group;B-DDI-DrugBank.d485.s34.e1
hormonal;I-group;I-DDI-DrugBank.d485.s34.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s34.e1
.;O;O
DDI-DrugBank.d485.s35;;
No;O;O
data;O;O
for;O;O
saquinavir;B-drug;B-DDI-DrugBank.d485.s35.e0
.;O;O
DDI-DrugBank.d485.s36;;
Rifampin;B-drug;B-DDI-DrugBank.d485.s36.e0
:;O;O
Rifampin;B-drug;B-DDI-DrugBank.d485.s36.e1
increases;O;O
the;O;O
metabolism;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d485.s36.e2
estradiol;I-drug;I-DDI-DrugBank.d485.s36.e2
and;O;O
some;O;O
progestins;B-group;B-DDI-DrugBank.d485.s36.e3
(;O;O
norethindrone;B-drug;B-DDI-DrugBank.d485.s36.e4
);O;O
resulting;O;O
in;O;O
decreased;O;O
contraceptive;O;O
effectiveness;O;O
and;O;O
increased;O;O
menstrual;O;O
irregularities;O;O
.;O;O
DDI-DrugBank.d485.s37;;
Use;O;O
of;O;O
a;O;O
nonhormonal;B-group;B-DDI-DrugBank.d485.s37.e0
contraceptive;I-group;I-DDI-DrugBank.d485.s37.e0
product;I-group;I-DDI-DrugBank.d485.s37.e0
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d485.s38;;
Salicylic;B-drug;B-DDI-DrugBank.d485.s38.e0
acid;I-drug;I-DDI-DrugBank.d485.s38.e0
:;O;O
Combination;O;O
hormonal;B-group;B-DDI-DrugBank.d485.s38.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s38.e1
may;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
salicylic;B-drug;B-DDI-DrugBank.d485.s38.e2
acid;I-drug;I-DDI-DrugBank.d485.s38.e2
.;O;O
DDI-DrugBank.d485.s39;;
Selegiline;B-drug;B-DDI-DrugBank.d485.s39.e0
:;O;O
Combination;B-group;B-DDI-DrugBank.d485.s39.e1
hormonal;I-group;I-DDI-DrugBank.d485.s39.e1
contraceptives;I-group;I-DDI-DrugBank.d485.s39.e1
may;O;O
increase;O;O
the;O;O
serum;O;O
concentration;O;O
of;O;O
selegiline;B-drug;B-DDI-DrugBank.d485.s39.e2
.;O;O
DDI-DrugBank.d485.s40;;
Theophylline;B-drug;B-DDI-DrugBank.d485.s40.e0
:;O;O
Ethinyl;B-drug;B-DDI-DrugBank.d485.s40.e1
estradiol;I-drug;I-DDI-DrugBank.d485.s40.e1
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d485.s40.e2
,;O;O
leading;O;O
to;O;O
increased;O;O
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d485.s41;;
Tricyclic;B-group;B-DDI-DrugBank.d485.s41.e0
antidepressants;I-group;I-DDI-DrugBank.d485.s41.e0
(;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d485.s41.e1
,;O;O
imipramine;B-drug;B-DDI-DrugBank.d485.s41.e2
,;O;O
nortriptyline;B-drug;B-DDI-DrugBank.d485.s41.e3
);O;O
:;O;O
Metabolism;O;O
may;O;O
be;O;O
inhibited;O;O
by;O;O
combination;B-group;B-DDI-DrugBank.d485.s41.e4
hormonal;I-group;I-DDI-DrugBank.d485.s41.e4
contraceptives;I-group;I-DDI-DrugBank.d485.s41.e4
,;O;O
increasing;O;O
plasma;O;O
levels;O;O
of;O;O
antidepressant;B-group;B-DDI-DrugBank.d485.s41.e5
,;O;O
DDI-DrugBank.d485.s42;;
use;O;O
caution;O;O
.;O;O
DDI-DrugBank.d485.s43;;
ETHANOL;B-drug;B-DDI-DrugBank.d485.s43.e0
/;O;O
NUTRITION;O;O
/;O;O
HERB;O;O
INTERACTIONS;O;O
:;O;O
Food;O;O
:;O;O
CNS;O;O
effects;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d485.s43.e1
may;O;O
be;O;O
enhanced;O;O
if;O;O
combination;B-group;B-DDI-DrugBank.d485.s43.e2
hormonal;I-group;I-DDI-DrugBank.d485.s43.e2
contraceptives;I-group;I-DDI-DrugBank.d485.s43.e2
are;O;O
used;O;O
concurrently;O;O
with;O;O
caffeine;B-drug;B-DDI-DrugBank.d485.s43.e3
.;O;O
DDI-DrugBank.d485.s44;;
Grapefruit;O;O
juice;O;O
increases;O;O
ethinyl;B-drug;B-DDI-DrugBank.d485.s44.e0
estradiol;I-drug;I-DDI-DrugBank.d485.s44.e0
concentrations;O;O
and;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
increase;O;O
progesterone;B-drug;B-DDI-DrugBank.d485.s44.e1
serum;O;O
levels;O;O
as;O;O
well;O;O
,;O;O
DDI-DrugBank.d485.s45;;
clinical;O;O
implications;O;O
are;O;O
unclear;O;O
.;O;O
DDI-DrugBank.d485.s46;;
Herb;O;O
/;O;O
Nutraceutical;O;O
:;O;O
St;O;O
Johns;O;O
wort;O;O
may;O;O
decrease;O;O
the;O;O
effectiveness;O;O
of;O;O
combination;B-group;B-DDI-DrugBank.d485.s46.e0
hormonal;I-group;I-DDI-DrugBank.d485.s46.e0
contraceptives;I-group;I-DDI-DrugBank.d485.s46.e0
by;O;O
inducing;O;O
hepatic;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d485.s47;;
Avoid;O;O
dong;O;O
quai;O;O
and;O;O
black;O;O
cohosh;O;O
(;O;O
have;O;O
estrogen;O;O
activity;O;O
);O;O
.;O;O
DDI-DrugBank.d485.s48;;
Avoid;O;O
saw;O;O
palmetto;O;O
,;O;O
red;O;O
clover;O;O
,;O;O
ginseng;O;O
.;O;O
DDI-DrugBank.d327.s0;;
There;O;O
have;O;O
been;O;O
isolated;O;O
reports;O;O
of;O;O
patients;O;O
experiencing;O;O
increases;O;O
in;O;O
their;O;O
prothrombin;O;O
times;O;O
when;O;O
etidronate;B-drug;B-DDI-DrugBank.d327.s0.e0
was;O;O
added;O;O
to;O;O
warfarin;B-drug;B-DDI-DrugBank.d327.s0.e1
therapy;O;O
.;O;O
DDI-DrugBank.d327.s1;;
The;O;O
majority;O;O
of;O;O
these;O;O
reports;O;O
concerned;O;O
variable;O;O
elevations;O;O
in;O;O
prothrombin;O;O
times;O;O
without;O;O
clinically;O;O
significant;O;O
sequelae;O;O
.;O;O
DDI-DrugBank.d327.s2;;
Although;O;O
the;O;O
relevance;O;O
of;O;O
these;O;O
reports;O;O
and;O;O
any;O;O
mechanism;O;O
of;O;O
coagulation;O;O
alterations;O;O
is;O;O
unclear;O;O
,;O;O
patients;O;O
on;O;O
warfarin;B-drug;B-DDI-DrugBank.d327.s2.e0
should;O;O
have;O;O
their;O;O
prothrombin;O;O
time;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d219.s0;;
ACE;B-group;B-DDI-DrugBank.d219.s0.e0
-;I-group;I-DDI-DrugBank.d219.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d219.s0.e0
Reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s0.e1
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
ACE;B-group;B-DDI-DrugBank.d219.s0.e2
-;I-group;I-DDI-DrugBank.d219.s0.e2
inhibitors;I-group;I-DDI-DrugBank.d219.s0.e2
.;O;O
DDI-DrugBank.d219.s1;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s1.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d219.s1.e1
-;I-group;I-DDI-DrugBank.d219.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d219.s1.e1
.;O;O
DDI-DrugBank.d219.s2;;
Antacids;B-group;B-DDI-DrugBank.d219.s2.e0
:;O;O
The;O;O
concomitant;O;O
administration;O;O
of;O;O
antacids;B-group;B-DDI-DrugBank.d219.s2.e1
has;O;O
no;O;O
apparent;O;O
effect;O;O
on;O;O
the;O;O
extent;O;O
of;O;O
absorption;O;O
of;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s2.e2
.;O;O
DDI-DrugBank.d219.s3;;
However;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d219.s3.e0
can;O;O
decrease;O;O
the;O;O
peak;O;O
concentration;O;O
reached;O;O
by;O;O
15;O;O
%;O;O
to;O;O
20;O;O
%;O;O
but;O;O
have;O;O
no;O;O
detectable;O;O
effect;O;O
on;O;O
the;O;O
time;O;O
-;O;O
to;O;O
-;O;O
peak;O;O
.;O;O
DDI-DrugBank.d219.s4;;
Aspirin;B-brand;B-DDI-DrugBank.d219.s4.e0
:;O;O
When;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s4.e1
is;O;O
administered;O;O
with;O;O
aspirin;B-brand;B-DDI-DrugBank.d219.s4.e2
,;O;O
its;O;O
protein;O;O
binding;O;O
is;O;O
reduced;O;O
,;O;O
although;O;O
the;O;O
clearance;O;O
of;O;O
free;O;O
etodolac;B-drug;B-DDI-DrugBank.d219.s4.e3
is;O;O
not;O;O
altered;O;O
.;O;O
DDI-DrugBank.d219.s5;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
interaction;O;O
is;O;O
not;O;O
known;O;O
,;O;O
DDI-DrugBank.d219.s6;;
however;O;O
,;O;O
as;O;O
with;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s6.e0
,;O;O
concomitant;O;O
administration;O;O
of;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s6.e1
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d219.s6.e2
is;O;O
not;O;O
generally;O;O
recommended;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
of;O;O
increased;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d219.s7;;
Cyclosporine;O;O
,;O;O
Digoxin;O;O
,;O;O
Methotrexate;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s7.e0
,;O;O
like;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s7.e1
,;O;O
through;O;O
effects;O;O
on;O;O
renal;O;O
prostaglandins;O;O
,;O;O
may;O;O
cause;O;O
changes;O;O
in;O;O
the;O;O
elimination;O;O
of;O;O
these;O;O
drugs;O;O
leading;O;O
to;O;O
elevated;O;O
serum;O;O
levels;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d219.s7.e2
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d219.s7.e3
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d219.s7.e4
,;O;O
and;O;O
increased;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d219.s8;;
Nephrotoxicity;O;O
associated;O;O
with;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d219.s8.e0
may;O;O
also;O;O
be;O;O
enhanced;O;O
.;O;O
DDI-DrugBank.d219.s9;;
Patients;O;O
receiving;O;O
these;O;O
drugs;O;O
who;O;O
are;O;O
given;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s9.e0
,;O;O
or;O;O
any;O;O
other;O;O
NSAID;B-group;B-DDI-DrugBank.d219.s9.e1
,;O;O
and;O;O
particularly;O;O
those;O;O
patients;O;O
with;O;O
altered;O;O
renal;O;O
function;O;O
,;O;O
should;O;O
be;O;O
observed;O;O
for;O;O
the;O;O
development;O;O
of;O;O
the;O;O
specific;O;O
toxicities;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d219.s10;;
Diuretics;B-group;B-DDI-DrugBank.d219.s10.e0
:;O;O
Etodolac;O;O
has;O;O
no;O;O
apparent;O;O
pharmacokinetic;O;O
interaction;O;O
when;O;O
administered;O;O
with;O;O
furosemide;B-drug;B-DDI-DrugBank.d219.s10.e1
or;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d219.s10.e2
.;O;O
DDI-DrugBank.d219.s11;;
Nevertheless;O;O
,;O;O
clinical;O;O
studies;O;O
,;O;O
as;O;O
well;O;O
as;O;O
postmarketing;O;O
observations;O;O
have;O;O
shown;O;O
that;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s11.e0
can;O;O
reduce;O;O
the;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d219.s11.e1
and;O;O
thiazides;B-group;B-DDI-DrugBank.d219.s11.e2
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d219.s12;;
This;O;O
response;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d219.s13;;
During;O;O
concomitant;O;O
therapy;O;O
with;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s13.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
signs;O;O
of;O;O
renal;O;O
failure;O;O
,;O;O
as;O;O
well;O;O
as;O;O
to;O;O
assure;O;O
diuretic;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d219.s14;;
Glyburide;B-drug;B-DDI-DrugBank.d219.s14.e0
:;O;O
Etodolac;B-drug;B-DDI-DrugBank.d219.s14.e1
has;O;O
no;O;O
apparent;O;O
pharmacokinetic;O;O
interaction;O;O
when;O;O
administered;O;O
with;O;O
glyburide;B-drug;B-DDI-DrugBank.d219.s14.e2
.;O;O
DDI-DrugBank.d219.s15;;
Lithium;B-drug;B-DDI-DrugBank.d219.s15.e0
:;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s15.e1
have;O;O
produced;O;O
an;O;O
elevation;O;O
of;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d219.s15.e2
levels;O;O
and;O;O
a;O;O
reduction;O;O
in;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d219.s15.e3
clearance;O;O
.;O;O
DDI-DrugBank.d219.s16;;
The;O;O
mean;O;O
minimum;O;O
lithium;B-drug;B-DDI-DrugBank.d219.s16.e0
concentration;O;O
increased;O;O
15;O;O
%;O;O
and;O;O
the;O;O
renal;O;O
clearance;O;O
was;O;O
decreased;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d219.s17;;
These;O;O
effects;O;O
have;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
by;O;O
the;O;O
NSAID;B-group;B-DDI-DrugBank.d219.s17.e0
.;O;O
DDI-DrugBank.d219.s18;;
Thus;O;O
,;O;O
when;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s18.e0
and;O;O
lithium;B-drug;B-DDI-DrugBank.d219.s18.e1
are;O;O
administered;O;O
concurrently;O;O
,;O;O
subjects;O;O
should;O;O
be;O;O
observed;O;O
carefully;O;O
for;O;O
signs;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d219.s18.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d219.s19;;
Phenylbutazone;B-drug;B-DDI-DrugBank.d219.s19.e0
:;O;O
Phenylbutazone;B-drug;B-DDI-DrugBank.d219.s19.e1
causes;O;O
increase;O;O
(;O;O
by;O;O
about;O;O
80;O;O
%;O;O
);O;O
in;O;O
the;O;O
free;O;O
fraction;O;O
of;O;O
etodolac;B-drug;B-DDI-DrugBank.d219.s19.e2
.;O;O
DDI-DrugBank.d219.s20;;
Although;O;O
in;O;O
vivo;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
done;O;O
to;O;O
see;O;O
if;O;O
etodolac;B-drug;B-DDI-DrugBank.d219.s20.e0
clearance;O;O
is;O;O
changed;O;O
by;O;O
coadministration;O;O
of;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d219.s20.e1
,;O;O
it;O;O
is;O;O
not;O;O
recommended;O;O
that;O;O
they;O;O
be;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d219.s21;;
Phenytoin;B-drug;B-DDI-DrugBank.d219.s21.e0
:;O;O
Etodolac;B-drug;B-DDI-DrugBank.d219.s21.e1
has;O;O
no;O;O
apparent;O;O
pharmacokinetic;O;O
interaction;O;O
when;O;O
administered;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d219.s21.e2
.;O;O
DDI-DrugBank.d219.s22;;
Warfarin;B-drug;B-DDI-DrugBank.d219.s22.e0
:;O;O
The;O;O
effects;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s22.e1
and;O;O
NSAIDs;B-group;B-DDI-DrugBank.d219.s22.e2
on;O;O
GI;O;O
bleeding;O;O
are;O;O
synergistic;O;O
,;O;O
such;O;O
that;O;O
users;O;O
of;O;O
both;O;O
drugs;O;O
together;O;O
have;O;O
a;O;O
risk;O;O
of;O;O
serious;O;O
GI;O;O
bleeding;O;O
higher;O;O
than;O;O
that;O;O
of;O;O
users;O;O
of;O;O
either;O;O
drug;O;O
alone;O;O
.;O;O
DDI-DrugBank.d219.s23;;
Short;O;O
-;O;O
term;O;O
pharmacokinetic;O;O
studies;O;O
have;O;O
demonstrated;O;O
that;O;O
concomitant;O;O
administration;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s23.e0
and;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s23.e1
(;O;O
etodolac;B-drug;B-DDI-DrugBank.d219.s23.e2
capsules;O;O
and;O;O
tablets;O;O
);O;O
results;O;O
in;O;O
reduced;O;O
protein;O;O
binding;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s23.e3
,;O;O
but;O;O
there;O;O
was;O;O
no;O;O
change;O;O
in;O;O
the;O;O
clearance;O;O
of;O;O
free;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s23.e4
.;O;O
DDI-DrugBank.d219.s24;;
There;O;O
was;O;O
no;O;O
significant;O;O
difference;O;O
in;O;O
the;O;O
pharmacodynamic;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s24.e0
administered;O;O
alone;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s24.e1
administered;O;O
with;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s24.e2
as;O;O
measured;O;O
by;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d219.s25;;
Thus;O;O
,;O;O
concomitant;O;O
therapy;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s25.e0
and;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s25.e1
should;O;O
not;O;O
require;O;O
dosage;O;O
adjustment;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d219.s26;;
However;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
because;O;O
there;O;O
have;O;O
been;O;O
a;O;O
few;O;O
spontaneous;O;O
reports;O;O
of;O;O
prolonged;O;O
prothrombin;O;O
times;O;O
,;O;O
with;O;O
or;O;O
without;O;O
bleeding;O;O
,;O;O
in;O;O
etodolac;B-drug;B-DDI-DrugBank.d219.s26.e0
-;O;O
treated;O;O
patients;O;O
receiving;O;O
concomitant;O;O
warfarin;B-drug;B-DDI-DrugBank.d219.s26.e1
therapy;O;O
.;O;O
DDI-DrugBank.d219.s27;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
The;O;O
urine;O;O
of;O;O
patients;O;O
who;O;O
take;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s27.e0
can;O;O
give;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
urinary;O;O
bilirubin;O;O
(;O;O
urobilin;O;O
);O;O
due;O;O
to;O;O
the;O;O
presence;O;O
of;O;O
phenolic;O;O
metabolites;O;O
of;O;O
etodolac;B-drug;B-DDI-DrugBank.d219.s27.e1
.;O;O
DDI-DrugBank.d219.s28;;
Diagnostic;O;O
dip;O;O
-;O;O
stick;O;O
methodology;O;O
,;O;O
used;O;O
to;O;O
detect;O;O
ketone;O;O
bodies;O;O
in;O;O
urine;O;O
,;O;O
has;O;O
resulted;O;O
in;O;O
false;O;O
-;O;O
positive;O;O
findings;O;O
in;O;O
some;O;O
patients;O;O
treated;O;O
with;O;O
Lodine;B-brand;B-DDI-DrugBank.d219.s28.e0
.;O;O
DDI-DrugBank.d219.s29;;
Generally;O;O
,;O;O
this;O;O
phenomenon;O;O
has;O;O
not;O;O
been;O;O
associated;O;O
with;O;O
other;O;O
clinically;O;O
significant;O;O
events;O;O
.;O;O
DDI-DrugBank.d219.s30;;
No;O;O
dose;O;O
relationship;O;O
has;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d219.s31;;
Lodine;B-brand;B-DDI-DrugBank.d219.s31.e0
treatment;O;O
is;O;O
associated;O;O
with;O;O
a;O;O
small;O;O
decrease;O;O
in;O;O
serum;O;O
uric;O;O
acid;O;O
levels;O;O
.;O;O
DDI-DrugBank.d219.s32;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
mean;O;O
decreases;O;O
of;O;O
1;O;O
to;O;O
2;O;O
mg;O;O
/;O;O
dL;O;O
were;O;O
observed;O;O
in;O;O
arthritic;O;O
patients;O;O
receiving;O;O
etodolac;B-drug;B-DDI-DrugBank.d219.s32.e0
(;O;O
600;O;O
mg;O;O
to;O;O
1000;O;O
mg;O;O
/;O;O
day;O;O
);O;O
after;O;O
4;O;O
weeks;O;O
of;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d219.s33;;
These;O;O
levels;O;O
then;O;O
remained;O;O
stable;O;O
for;O;O
up;O;O
to;O;O
1;O;O
year;O;O
of;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d219.s34;;
DDI-DrugBank.d119.s0;;
The;O;O
following;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
with;O;O
etomidate;B-drug;B-DDI-DrugBank.d119.s0.e0
.;O;O
DDI-DrugBank.d119.s1;;
Drug;O;O
Effect;O;O
DDI-DrugBank.d119.s2;;
Probenecid;B-drug;B-DDI-DrugBank.d119.s2.e0
Prolonged;O;O
action;O;O
of;O;O
etomidate;B-drug;B-DDI-DrugBank.d119.s2.e1
DDI-DrugBank.d119.s3;;
Diazoxide;I-drug;I-DDI-DrugBank.d119.s3.e0
Hypotension;O;O
DDI-DrugBank.d119.s4;;
Zimelidine;B-drug_n;B-DDI-DrugBank.d119.s4.e0
etomidate;I-drug;I-DDI-DrugBank.d119.s4.e1
antagonism;O;O
DDI-DrugBank.d119.s5;;
Opioid;B-group;B-DDI-DrugBank.d119.s5.e0
analgesics;I-group;I-DDI-DrugBank.d119.s5.e0
Decreased;O;O
antinociceptive;O;O
action;O;O
DDI-DrugBank.d119.s6;;
Aminophylline;B-drug;B-DDI-DrugBank.d119.s6.e0
Etomidate;I-drug;I-DDI-DrugBank.d119.s6.e1
antagonism;O;O
DDI-DrugBank.d119.s7;;
Midazolam;B-drug;B-DDI-DrugBank.d119.s7.e0
Synergism;O;O
DDI-DrugBank.d484.s0;;
Etonogestrel;B-drug;B-DDI-DrugBank.d484.s0.e0
may;O;O
interact;O;O
with;O;O
the;O;O
following;O;O
medications;O;O
:;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d484.s0.e1
(;O;O
Tylenol;B-brand;B-DDI-DrugBank.d484.s0.e2
);O;O
,;O;O
antibiotics;B-group;B-DDI-DrugBank.d484.s0.e3
such;O;O
as;O;O
ampicillin;B-drug;B-DDI-DrugBank.d484.s0.e4
and;O;O
tetracycline;B-drug;B-DDI-DrugBank.d484.s0.e5
,;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d484.s0.e6
(;O;O
Dilantin;B-brand;B-DDI-DrugBank.d484.s0.e7
,;O;O
Phenobarbital;B-drug;B-DDI-DrugBank.d484.s0.e8
,;O;O
Tegretol;B-brand;B-DDI-DrugBank.d484.s0.e9
,;O;O
Trileptal;B-brand;B-DDI-DrugBank.d484.s0.e10
,;O;O
Topamax;B-brand;B-DDI-DrugBank.d484.s0.e11
,;O;O
Felbatol;B-brand;B-DDI-DrugBank.d484.s0.e12
);O;O
,;O;O
antifungals;B-group;B-DDI-DrugBank.d484.s0.e13
(;O;O
Gris;B-brand;B-DDI-DrugBank.d484.s0.e14
-;I-brand;I-DDI-DrugBank.d484.s0.e14
PEG;I-brand;I-DDI-DrugBank.d484.s0.e14
,;O;O
Nizoral;B-brand;B-DDI-DrugBank.d484.s0.e15
,;O;O
Sporanox;B-brand;B-DDI-DrugBank.d484.s0.e16
);O;O
,;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d484.s0.e17
(;O;O
Lipitor;B-brand;B-DDI-DrugBank.d484.s0.e18
);O;O
,;O;O
clofibrate;B-drug;B-DDI-DrugBank.d484.s0.e19
(;O;O
Atromid;O;O
-;O;O
S;O;O
);O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d484.s0.e21
(;O;O
Neoral;B-brand;B-DDI-DrugBank.d484.s0.e22
,;O;O
Sandimmune;B-brand;B-DDI-DrugBank.d484.s0.e23
);O;O
,;O;O
HIV;O;O
drugs;O;O
classified;O;O
as;O;O
protease;B-group;B-DDI-DrugBank.d484.s0.e24
inhibitors;I-group;I-DDI-DrugBank.d484.s0.e24
(;O;O
Agenerase;B-brand;B-DDI-DrugBank.d484.s0.e25
,;O;O
Crixivan;B-brand;B-DDI-DrugBank.d484.s0.e26
,;O;O
Fortovase;B-brand;B-DDI-DrugBank.d484.s0.e27
,;O;O
Invirase;B-brand;B-DDI-DrugBank.d484.s0.e28
,;O;O
Kaletra;B-brand;B-DDI-DrugBank.d484.s0.e29
,;O;O
Norvir;B-brand;B-DDI-DrugBank.d484.s0.e30
,;O;O
Viracept;B-brand;B-DDI-DrugBank.d484.s0.e31
);O;O
,;O;O
morphine;B-drug;B-DDI-DrugBank.d484.s0.e32
(;O;O
Astramorph;B-brand;B-DDI-DrugBank.d484.s0.e33
,;O;O
Kadian;B-brand;B-DDI-DrugBank.d484.s0.e34
,;O;O
MS;B-brand;B-DDI-DrugBank.d484.s0.e35
Contin;I-brand;I-DDI-DrugBank.d484.s0.e35
);O;O
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d484.s0.e36
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d484.s0.e37
(;O;O
Prelone;B-brand;B-DDI-DrugBank.d484.s0.e38
);O;O
,;O;O
rifadin;B-brand;B-DDI-DrugBank.d484.s0.e39
(;O;O
rifampin;B-drug;B-DDI-DrugBank.d484.s0.e40
);O;O
,;O;O
St.;O;O
Johns;O;O
wort;O;O
,;O;O
temazepam;B-drug;B-DDI-DrugBank.d484.s0.e41
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d484.s0.e42
(;O;O
Theo;B-brand;B-DDI-DrugBank.d484.s0.e43
-;I-brand;I-DDI-DrugBank.d484.s0.e43
Dur;I-brand;I-DDI-DrugBank.d484.s0.e43
);O;O
,;O;O
and;O;O
vitamin;B-drug;B-DDI-DrugBank.d484.s0.e44
C.;I-drug;I-DDI-DrugBank.d484.s0.e44
DDI-DrugBank.d194.s0;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
administering;O;O
ETOPOPHOS;B-brand;B-DDI-DrugBank.d194.s0.e0
with;O;O
drugs;O;O
that;O;O
are;O;O
known;O;O
to;O;O
inhibit;O;O
phosphatase;O;O
activities;O;O
(;O;O
e.g.;O;O
,;O;O
levamisole;B-drug;B-DDI-DrugBank.d194.s0.e1
hydrochloride;I-drug;I-DDI-DrugBank.d194.s0.e1
);O;O
.;O;O
DDI-DrugBank.d194.s1;;
High;O;O
-;O;O
dose;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d194.s1.e0
A;I-drug;I-DDI-DrugBank.d194.s1.e0
resulting;O;O
in;O;O
concentrations;O;O
above;O;O
2000;O;O
ng;O;O
/;O;O
mL;O;O
administered;O;O
with;O;O
oral;O;O
etoposide;B-drug;B-DDI-DrugBank.d194.s1.e1
has;O;O
led;O;O
to;O;O
an;O;O
80;O;O
%;O;O
increase;O;O
in;O;O
etoposide;B-drug;B-DDI-DrugBank.d194.s1.e2
exposure;O;O
with;O;O
a;O;O
38;O;O
%;O;O
decrease;O;O
in;O;O
total;O;O
body;O;O
clearance;O;O
of;O;O
etoposide;B-drug;B-DDI-DrugBank.d194.s1.e3
compared;O;O
to;O;O
etoposide;B-drug;B-DDI-DrugBank.d194.s1.e4
alone;O;O
.;O;O
DDI-DrugBank.d435.s0;;
Exemestane;B-drug;B-DDI-DrugBank.d435.s0.e0
is;O;O
extensively;O;O
metabolized;O;O
by;O;O
CYP;O;O
3A4;O;O
,;O;O
but;O;O
coadministration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d435.s0.e1
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
CYP;O;O
3A4;O;O
,;O;O
has;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
exemestane;B-drug;B-DDI-DrugBank.d435.s0.e2
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d435.s1;;
Significant;O;O
pharmacokinetic;O;O
interactions;O;O
mediated;O;O
by;O;O
inhibition;O;O
of;O;O
CYP;O;O
isoenzymes;O;O
therefore;O;O
appear;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d435.s2;;
Co;O;O
-;O;O
medications;O;O
that;O;O
induce;O;O
CYP;O;O
3A4;O;O
(;O;O
e.g.;O;O
,;O;O
rifampicin;B-drug;B-DDI-DrugBank.d435.s2.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d435.s2.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d435.s2.e2
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d435.s2.e3
,;O;O
or;O;O
St.;O;O
John;O;O
s;O;O
wort;O;O
);O;O
may;O;O
significantly;O;O
decrease;O;O
exposure;O;O
to;O;O
exemestane;B-drug;B-DDI-DrugBank.d435.s2.e4
.;O;O
DDI-DrugBank.d435.s3;;
Dose;O;O
modification;O;O
is;O;O
recommended;O;O
for;O;O
patients;O;O
who;O;O
are;O;O
also;O;O
receiving;O;O
a;O;O
potent;O;O
CYP;O;O
3A4;O;O
inducer;O;O
.;O;O
DDI-DrugBank.d435.s4;;
Drug;O;O
/;O;O
Laboratory;O;O
Tests;O;O
Interactions;O;O
No;O;O
clinically;O;O
relevant;O;O
changes;O;O
in;O;O
the;O;O
results;O;O
of;O;O
clinical;O;O
laboratory;O;O
tests;O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d112.s0;;
Concurrent;O;O
use;O;O
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d112.s0.e0
or;O;O
other;O;O
drugs;O;O
significantly;O;O
eliminated;O;O
by;O;O
active;O;O
renal;O;O
tubular;O;O
secretion;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
penciclovir;B-drug;B-DDI-DrugBank.d112.s0.e1
.;O;O
DDI-DrugBank.d112.s1;;
The;O;O
conversion;O;O
of;O;O
6;B-drug_n;B-DDI-DrugBank.d112.s1.e0
-;I-drug_n;I-DDI-DrugBank.d112.s1.e0
deoxy;I-drug_n;I-DDI-DrugBank.d112.s1.e0
penciclovir;I-drug_n;I-DDI-DrugBank.d112.s1.e0
to;O;O
penciclovir;B-drug;B-DDI-DrugBank.d112.s1.e1
is;O;O
catalyzed;O;O
by;O;O
aldehyde;O;O
oxidase;O;O
.;O;O
DDI-DrugBank.d112.s2;;
Interactions;O;O
with;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
this;O;O
enzyme;O;O
could;O;O
potentially;O;O
occur;O;O
.;O;O
DDI-DrugBank.d203.s0;;
No;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
identified;O;O
.;O;O
DDI-DrugBank.d203.s1;;
Studies;O;O
with;O;O
famotidine;B-drug;B-DDI-DrugBank.d203.s1.e0
in;O;O
man;O;O
,;O;O
in;O;O
animal;O;O
models;O;O
,;O;O
and;O;O
in;O;O
vitro;O;O
have;O;O
shown;O;O
no;O;O
significant;O;O
interference;O;O
with;O;O
the;O;O
disposition;O;O
of;O;O
compounds;O;O
metabolized;O;O
by;O;O
the;O;O
hepatic;O;O
microsomal;O;O
enzymes;O;O
,;O;O
e.g.;O;O
,;O;O
cytochrome;O;O
P450;O;O
system;O;O
.;O;O
DDI-DrugBank.d203.s2;;
Compounds;O;O
tested;O;O
in;O;O
man;O;O
include;O;O
warfarin;B-drug;B-DDI-DrugBank.d203.s2.e0
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d203.s2.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d203.s2.e2
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d203.s2.e3
,;O;O
aminopyrine;B-drug;B-DDI-DrugBank.d203.s2.e4
and;O;O
antipyrine;B-drug;B-DDI-DrugBank.d203.s2.e5
.;O;O
DDI-DrugBank.d203.s3;;
Indocyanine;B-drug_n;B-DDI-DrugBank.d203.s3.e0
green;I-drug_n;I-DDI-DrugBank.d203.s3.e0
as;O;O
an;O;O
index;O;O
of;O;O
hepatic;O;O
drug;O;O
extraction;O;O
has;O;O
been;O;O
tested;O;O
and;O;O
no;O;O
significant;O;O
effects;O;O
have;O;O
been;O;O
found;O;O
.;O;O
DDI-DrugBank.d434.s0;;
The;O;O
drug;O;O
interaction;O;O
data;O;O
described;O;O
in;O;O
this;O;O
section;O;O
were;O;O
obtained;O;O
from;O;O
controlled;O;O
clinical;O;O
trials;O;O
and;O;O
studies;O;O
involving;O;O
otherwise;O;O
healthy;O;O
adults;O;O
with;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d434.s1;;
Use;O;O
in;O;O
Conjunction;O;O
with;O;O
Other;O;O
Antiepileptic;B-group;B-DDI-DrugBank.d434.s1.e0
Drugs;I-group;I-DDI-DrugBank.d434.s1.e0
:;O;O
The;O;O
addition;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s1.e1
to;O;O
antiepileptic;B-group;B-DDI-DrugBank.d434.s1.e2
drugs;I-group;I-DDI-DrugBank.d434.s1.e2
(;O;O
AEDs;B-group;B-DDI-DrugBank.d434.s1.e3
);O;O
affects;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
plasma;O;O
concentrations;O;O
of;O;O
AEDs;B-group;B-DDI-DrugBank.d434.s1.e4
.;O;O
DDI-DrugBank.d434.s2;;
The;O;O
net;O;O
effect;O;O
of;O;O
these;O;O
interactions;O;O
is;O;O
summarized;O;O
in;O;O
the;O;O
following;O;O
table;O;O
:;O;O
AED;B-group;B-DDI-DrugBank.d434.s2.e0
AED;I-group;I-DDI-DrugBank.d434.s2.e1
Felbatol;I-brand;I-DDI-DrugBank.d434.s2.e2
DDI-DrugBank.d434.s3;;
Coadministered;O;O
Concentration;O;O
Concentration;O;O
DDI-DrugBank.d434.s4;;
Phenytoin;B-drug;B-DDI-DrugBank.d434.s4.e0
DDI-DrugBank.d434.s5;;
Valproate;I-drug;I-DDI-DrugBank.d434.s5.e0
*;O;O
*;O;O
DDI-DrugBank.d434.s6;;
Carbamazepine;B-drug;B-DDI-DrugBank.d434.s6.e0
(;O;O
CBZ;B-drug;B-DDI-DrugBank.d434.s6.e1
);O;O
DDI-DrugBank.d434.s7;;
*;O;O
CBZ;O;O
epoxide;O;O
DDI-DrugBank.d434.s8;;
Phenobarbital;B-drug;B-DDI-DrugBank.d434.s8.e0
DDI-DrugBank.d434.s9;;
*;O;O
Not;O;O
administered;O;O
,;O;O
but;O;O
an;O;O
active;O;O
metabolite;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d434.s9.e0
.;O;O
DDI-DrugBank.d434.s10;;
*;O;O
*;O;O
No;O;O
significant;O;O
effect;O;O
.;O;O
DDI-DrugBank.d434.s11;;
Specific;O;O
Effects;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s11.e0
on;O;O
Other;O;O
Antiepileptic;B-group;B-DDI-DrugBank.d434.s11.e1
Drugs;I-group;I-DDI-DrugBank.d434.s11.e1
Phenytoin;I-drug;I-DDI-DrugBank.d434.s11.e2
:;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s11.e3
causes;O;O
an;O;O
increase;O;O
in;O;O
steady;O;O
-;O;O
state;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s11.e4
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d434.s12;;
In;O;O
10;O;O
otherwise;O;O
healthy;O;O
subjects;O;O
with;O;O
epilepsy;O;O
ingesting;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s12.e0
,;O;O
the;O;O
steadystate;O;O
trough;O;O
(;O;O
Cmin;O;O
);O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s12.e1
plasma;O;O
concentration;O;O
was;O;O
17;O;O
5;O;O
micrograms;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d434.s13;;
The;O;O
steady;O;O
-;O;O
state;O;O
Cmin;O;O
increased;O;O
to;O;O
21;O;O
5;O;O
micrograms;O;O
/;O;O
mL;O;O
when;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s13.e0
was;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d434.s14;;
Increasing;O;O
the;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s14.e0
dose;O;O
to;O;O
1800;O;O
mg;O;O
/;O;O
day;O;O
in;O;O
six;O;O
of;O;O
these;O;O
subjects;O;O
increased;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s14.e1
Cmin;O;O
to;O;O
25;O;O
7;O;O
micrograms;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d434.s15;;
In;O;O
order;O;O
to;O;O
maintain;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s15.e0
levels;O;O
,;O;O
limit;O;O
adverse;O;O
experiences;O;O
,;O;O
and;O;O
achieve;O;O
the;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s15.e1
dose;O;O
of;O;O
3600;O;O
mg;O;O
/;O;O
day;O;O
,;O;O
a;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s15.e2
dose;O;O
reduction;O;O
of;O;O
approximately;O;O
40;O;O
%;O;O
was;O;O
necessary;O;O
for;O;O
eight;O;O
of;O;O
these;O;O
10;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d434.s16;;
In;O;O
a;O;O
controlled;O;O
clinical;O;O
trial;O;O
,;O;O
a;O;O
20;O;O
%;O;O
reduction;O;O
of;O;O
the;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s16.e0
dose;O;O
at;O;O
the;O;O
initiation;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s16.e1
therapy;O;O
resulted;O;O
in;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s16.e2
levels;O;O
comparable;O;O
to;O;O
those;O;O
prior;O;O
to;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s16.e3
administration;O;O
.;O;O
DDI-DrugBank.d434.s17;;
Carbamazepine;B-drug;B-DDI-DrugBank.d434.s17.e0
:;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s17.e1
causes;O;O
a;O;O
decrease;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d434.s17.e2
plasma;O;O
concentrations;O;O
and;O;O
an;O;O
increase;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
carbamazepine;B-drug_n;B-DDI-DrugBank.d434.s17.e3
epoxide;I-drug_n;I-DDI-DrugBank.d434.s17.e3
plasma;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d434.s18;;
In;O;O
nine;O;O
otherwise;O;O
healthy;O;O
subjects;O;O
with;O;O
epilepsy;O;O
ingesting;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d434.s18.e0
,;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
trough;O;O
(;O;O
Cmin;O;O
);O;O
carbamazepine;B-drug;B-DDI-DrugBank.d434.s18.e1
concentration;O;O
was;O;O
8;O;O
2;O;O
micrograms;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d434.s19;;
The;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d434.s19.e0
steady;O;O
-;O;O
state;O;O
Cmin;O;O
decreased;O;O
31;O;O
%;O;O
to;O;O
5;O;O
1;O;O
micrograms;O;O
/;O;O
mL;O;O
when;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s19.e1
(;O;O
3000;O;O
mg;O;O
/;O;O
day;O;O
,;O;O
divided;O;O
into;O;O
three;O;O
doses;O;O
);O;O
was;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d434.s20;;
Carbamazepine;B-drug_n;B-DDI-DrugBank.d434.s20.e0
epoxide;I-drug_n;I-DDI-DrugBank.d434.s20.e0
steady;O;O
-;O;O
state;O;O
Cmin;O;O
concentrations;O;O
increased;O;O
57;O;O
%;O;O
from;O;O
1.0;O;O
0.3;O;O
to;O;O
1.6;O;O
0.4;O;O
micrograms;O;O
/;O;O
mL;O;O
with;O;O
the;O;O
addition;O;O
of;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s20.e1
.;O;O
DDI-DrugBank.d434.s21;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
similar;O;O
changes;O;O
in;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d434.s21.e0
and;O;O
carbamazepine;B-drug_n;B-DDI-DrugBank.d434.s21.e1
epoxide;I-drug_n;I-DDI-DrugBank.d434.s21.e1
were;O;O
seen;O;O
.;O;O
DDI-DrugBank.d434.s22;;
Valproate;B-drug;B-DDI-DrugBank.d434.s22.e0
:;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s22.e1
causes;O;O
an;O;O
increase;O;O
in;O;O
steady;O;O
-;O;O
state;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s22.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d434.s23;;
In;O;O
four;O;O
subjects;O;O
with;O;O
epilepsy;O;O
ingesting;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s23.e0
,;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
trough;O;O
(;O;O
Cmin;O;O
);O;O
valproate;B-drug;B-DDI-DrugBank.d434.s23.e1
plasma;O;O
concentration;O;O
was;O;O
63;O;O
16;O;O
micrograms;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d434.s24;;
The;O;O
steady;O;O
-;O;O
state;O;O
Cmin;O;O
increased;O;O
to;O;O
78;O;O
14;O;O
micrograms;O;O
/;O;O
mL;O;O
when;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s24.e0
was;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d434.s25;;
Increasing;O;O
the;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s25.e0
dose;O;O
to;O;O
2400;O;O
mg;O;O
/;O;O
day;O;O
increased;O;O
the;O;O
steadystate;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s25.e1
Cmin;O;O
to;O;O
96;O;O
25;O;O
micrograms;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d434.s26;;
Corresponding;O;O
values;O;O
for;O;O
free;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s26.e0
Cmin;O;O
concentrations;O;O
were;O;O
7;O;O
3;O;O
,;O;O
9;O;O
4;O;O
,;O;O
and;O;O
11;O;O
6;O;O
micrograms;O;O
/;O;O
mL;O;O
for;O;O
0;O;O
,;O;O
1200;O;O
,;O;O
and;O;O
2400;O;O
mg;O;O
/;O;O
day;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s26.e1
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d434.s27;;
The;O;O
ratios;O;O
of;O;O
the;O;O
AUCs;O;O
of;O;O
unbound;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s27.e0
to;O;O
the;O;O
AUCs;O;O
of;O;O
the;O;O
total;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s27.e1
were;O;O
11.1;O;O
%;O;O
,;O;O
13.0;O;O
%;O;O
,;O;O
and;O;O
11.5;O;O
%;O;O
,;O;O
with;O;O
coadministration;O;O
of;O;O
0;O;O
,;O;O
1200;O;O
,;O;O
and;O;O
2400;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s27.e2
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d434.s28;;
Phenobarbital;B-drug;B-DDI-DrugBank.d434.s28.e0
:;O;O
Coadministration;O;O
of;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s28.e1
with;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d434.s28.e2
causes;O;O
an;O;O
increase;O;O
in;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d434.s28.e3
plasma;O;O
concentrations;O;O
,;O;O
In;O;O
12;O;O
otherwise;O;O
healthy;O;O
male;O;O
volunteers;O;O
ingesting;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d434.s28.e4
,;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
trough;O;O
(;O;O
Cmin;O;O
);O;O
phenobarbital;B-drug;B-DDI-DrugBank.d434.s28.e5
concentration;O;O
was;O;O
14.2;O;O
micrograms;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d434.s29;;
The;O;O
steady;O;O
-;O;O
state;O;O
Cmin;O;O
concentration;O;O
increased;O;O
to;O;O
17.8;O;O
micrograms;O;O
/;O;O
mL;O;O
when;O;O
2400;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s29.e0
was;O;O
coadministered;O;O
for;O;O
one;O;O
week;O;O
.;O;O
DDI-DrugBank.d434.s30;;
Effects;O;O
of;O;O
Other;O;O
Antiepileptic;B-group;B-DDI-DrugBank.d434.s30.e0
Drugs;I-group;I-DDI-DrugBank.d434.s30.e0
on;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s30.e1
Phenytoin;I-drug;I-DDI-DrugBank.d434.s30.e2
:;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d434.s30.e3
causes;O;O
an;O;O
approximate;O;O
doubling;O;O
of;O;O
the;O;O
clearance;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s30.e4
(;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s30.e5
);O;O
at;O;O
steady;O;O
state;O;O
and;O;O
,;O;O
therefore;O;O
,;O;O
the;O;O
addition;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d434.s30.e6
causes;O;O
an;O;O
approximate;O;O
45;O;O
%;O;O
decrease;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
trough;O;O
concentrations;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s30.e7
as;O;O
compared;O;O
to;O;O
the;O;O
same;O;O
dose;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s30.e8
given;O;O
as;O;O
monotherapy;O;O
.;O;O
DDI-DrugBank.d434.s31;;
Carbamazepine;B-drug;B-DDI-DrugBank.d434.s31.e0
:;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d434.s31.e1
causes;O;O
an;O;O
approximate;O;O
50;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
clearance;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s31.e2
at;O;O
steady;O;O
state;O;O
and;O;O
,;O;O
therefore;O;O
,;O;O
the;O;O
addition;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d434.s31.e3
results;O;O
in;O;O
an;O;O
approximate;O;O
40;O;O
%;O;O
decrease;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
trough;O;O
concentrations;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s31.e4
as;O;O
compared;O;O
to;O;O
the;O;O
same;O;O
dose;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s31.e5
given;O;O
as;O;O
monotherapy;O;O
.;O;O
DDI-DrugBank.d434.s32;;
Valproate;B-drug;B-DDI-DrugBank.d434.s32.e0
:;O;O
Available;O;O
data;O;O
suggest;O;O
that;O;O
there;O;O
is;O;O
no;O;O
significant;O;O
effect;O;O
of;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s32.e1
on;O;O
the;O;O
clearance;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s32.e2
at;O;O
steady;O;O
state;O;O
,;O;O
Therefore;O;O
,;O;O
the;O;O
addition;O;O
of;O;O
valproate;B-drug;B-DDI-DrugBank.d434.s32.e3
is;O;O
not;O;O
expected;O;O
to;O;O
cause;O;O
a;O;O
clinically;O;O
important;O;O
effect;O;O
on;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s32.e4
(;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s32.e5
);O;O
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d434.s33;;
Phenobarbital;B-drug;B-DDI-DrugBank.d434.s33.e0
:;O;O
It;O;O
appears;O;O
that;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d434.s33.e1
may;O;O
reduce;O;O
plasma;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s33.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d434.s34;;
Steady;O;O
-;O;O
state;O;O
plasma;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s34.e0
concentrations;O;O
were;O;O
found;O;O
to;O;O
be;O;O
29;O;O
%;O;O
lower;O;O
than;O;O
the;O;O
mean;O;O
concentrations;O;O
of;O;O
a;O;O
group;O;O
of;O;O
newly;O;O
diagnosed;O;O
subjects;O;O
with;O;O
epilepsy;O;O
also;O;O
receiving;O;O
2400;O;O
mg;O;O
of;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s34.e1
a;O;O
day;O;O
.;O;O
DDI-DrugBank.d434.s35;;
Effects;O;O
of;O;O
Antacids;B-group;B-DDI-DrugBank.d434.s35.e0
on;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s35.e1
The;O;O
rate;O;O
and;O;O
extent;O;O
of;O;O
absorption;O;O
of;O;O
a;O;O
2400;O;O
mg;O;O
dose;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s35.e2
as;O;O
monotherapy;O;O
given;O;O
as;O;O
tablets;O;O
was;O;O
not;O;O
affected;O;O
when;O;O
coadministered;O;O
with;O;O
antacids;B-group;B-DDI-DrugBank.d434.s35.e3
.;O;O
DDI-DrugBank.d434.s36;;
Effects;O;O
of;O;O
Erythromycin;B-drug;B-DDI-DrugBank.d434.s36.e0
on;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s36.e1
The;O;O
coadministration;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d434.s36.e2
(;O;O
1000;O;O
mg;O;O
/;O;O
day;O;O
);O;O
for;O;O
10;O;O
days;O;O
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetic;O;O
parameters;O;O
of;O;O
Cmax;O;O
,;O;O
Cmin;O;O
,;O;O
AUC;O;O
,;O;O
CI;O;O
/;O;O
kg;O;O
or;O;O
tmax;O;O
at;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s36.e3
daily;O;O
doses;O;O
of;O;O
3000;O;O
or;O;O
3600;O;O
mg;O;O
/;O;O
day;O;O
in;O;O
10;O;O
otherwise;O;O
healthy;O;O
subjects;O;O
with;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d434.s37;;
Effects;O;O
of;O;O
Felbatol;B-brand;B-DDI-DrugBank.d434.s37.e0
on;O;O
Low;O;O
-;O;O
Dose;O;O
Combination;B-group;B-DDI-DrugBank.d434.s37.e1
Oral;I-group;I-DDI-DrugBank.d434.s37.e1
Contraceptives;I-group;I-DDI-DrugBank.d434.s37.e1
A;O;O
group;O;O
of;O;O
24;O;O
nonsmoking;O;O
,;O;O
healthy;O;O
white;O;O
female;O;O
volunteers;O;O
established;O;O
on;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d434.s37.e2
regimen;O;O
containing;O;O
30;O;O
mg;O;O
ethinyl;B-drug;B-DDI-DrugBank.d434.s37.e3
estradiol;I-drug;I-DDI-DrugBank.d434.s37.e3
and;O;O
75;O;O
mg;O;O
gestodene;B-drug;B-DDI-DrugBank.d434.s37.e4
for;O;O
at;O;O
least;O;O
3;O;O
months;O;O
received;O;O
2400;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s37.e5
from;O;O
midcycle;O;O
(;O;O
day;O;O
15;O;O
);O;O
to;O;O
midcycle;O;O
(;O;O
day;O;O
14;O;O
);O;O
of;O;O
two;O;O
consecutive;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d434.s37.e6
cycles;O;O
.;O;O
DDI-DrugBank.d434.s38;;
Felbamate;B-drug;B-DDI-DrugBank.d434.s38.e0
treatment;O;O
resulted;O;O
in;O;O
a;O;O
42;O;O
%;O;O
decrease;O;O
in;O;O
the;O;O
gestodene;B-drug;B-DDI-DrugBank.d434.s38.e1
AUC;O;O
0;O;O
-;O;O
24;O;O
,;O;O
but;O;O
no;O;O
clinically;O;O
relevant;O;O
effect;O;O
was;O;O
observed;O;O
on;O;O
the;O;O
pharmacokinetic;O;O
parameters;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d434.s38.e2
estradiol;I-drug;I-DDI-DrugBank.d434.s38.e2
.;O;O
DDI-DrugBank.d434.s39;;
No;O;O
volunteer;O;O
showed;O;O
hormonal;O;O
evidence;O;O
of;O;O
ovulation;O;O
,;O;O
but;O;O
one;O;O
volunteer;O;O
reported;O;O
intermenstrual;O;O
bleeding;O;O
during;O;O
felbamate;B-drug;B-DDI-DrugBank.d434.s39.e0
treatment;O;O
.;O;O
DDI-DrugBank.d316.s0;;
CYP3A4;B-drug;B-DDI-DrugBank.d316.s0.e0
Inhibitors;O;O
Felodipine;O;O
is;O;O
metabolized;O;O
by;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d316.s0.e1
.;O;O
DDI-DrugBank.d316.s1;;
Co;O;O
-;O;O
administration;O;O
of;O;O
CYP3A4;O;O
inhibitors;O;O
(;O;O
eg;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d316.s1.e0
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d316.s1.e1
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d316.s1.e2
,;O;O
grapefruit;O;O
juice;O;O
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d316.s1.e3
);O;O
with;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s1.e4
may;O;O
lead;O;O
to;O;O
several;O;O
-;O;O
fold;O;O
increases;O;O
in;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s1.e5
,;O;O
either;O;O
due;O;O
to;O;O
an;O;O
increase;O;O
in;O;O
bioavailability;O;O
or;O;O
due;O;O
to;O;O
a;O;O
decrease;O;O
in;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d316.s2;;
These;O;O
increases;O;O
in;O;O
concentration;O;O
may;O;O
lead;O;O
to;O;O
increased;O;O
effects;O;O
,;O;O
(;O;O
lower;O;O
blood;O;O
pressure;O;O
and;O;O
increased;O;O
heart;O;O
rate;O;O
);O;O
.;O;O
DDI-DrugBank.d316.s3;;
These;O;O
effects;O;O
have;O;O
been;O;O
observed;O;O
with;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d316.s3.e0
(;O;O
a;O;O
potent;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d316.s3.e1
inhibitor;O;O
);O;O
.;O;O
DDI-DrugBank.d316.s4;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
CYP3A4;B-drug;B-DDI-DrugBank.d316.s4.e0
inhibitors;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s4.e1
.;O;O
DDI-DrugBank.d316.s5;;
A;O;O
conservative;O;O
approach;O;O
to;O;O
dosing;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s5.e0
should;O;O
be;O;O
taken;O;O
.;O;O
DDI-DrugBank.d316.s6;;
The;O;O
following;O;O
specific;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
:;O;O
Itraconazole;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
another;O;O
extended;O;O
release;O;O
formulation;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s6.e0
with;O;O
itraconazole;B-drug;B-DDI-DrugBank.d316.s6.e1
resulted;O;O
in;O;O
approximately;O;O
8;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
the;O;O
AUC;O;O
,;O;O
more;O;O
than;O;O
6;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
the;O;O
Cmax;O;O
,;O;O
and;O;O
2;O;O
-;O;O
fold;O;O
prolongation;O;O
in;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s6.e2
.;O;O
DDI-DrugBank.d316.s7;;
Erythromycin;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s7.e0
(;O;O
PLENDIL;B-drug;B-DDI-DrugBank.d316.s7.e1
);O;O
with;O;O
erythromycin;B-drug;B-DDI-DrugBank.d316.s7.e2
resulted;O;O
in;O;O
approximately;O;O
2.5;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
the;O;O
AUC;O;O
and;O;O
Cmax;O;O
,;O;O
and;O;O
about;O;O
2;O;O
-;O;O
fold;O;O
prolongation;O;O
in;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s7.e3
.;O;O
DDI-DrugBank.d316.s8;;
Grapefruit;O;O
juice;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s8.e0
with;O;O
grapefruit;O;O
juice;O;O
resulted;O;O
in;O;O
more;O;O
than;O;O
2;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
the;O;O
AUC;O;O
and;O;O
Cmax;O;O
,;O;O
but;O;O
no;O;O
prolongation;O;O
in;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s8.e1
.;O;O
DDI-DrugBank.d316.s9;;
Cimetidine;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s9.e0
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d316.s9.e1
(;O;O
a;O;O
non;O;O
-;O;O
specific;O;O
CYP;O;O
-;O;O
450;O;O
inhibitor;O;O
);O;O
resulted;O;O
in;O;O
an;O;O
increase;O;O
of;O;O
approximately;O;O
50;O;O
%;O;O
in;O;O
the;O;O
AUC;O;O
and;O;O
the;O;O
Cmax;O;O
,;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s9.e2
.;O;O
DDI-DrugBank.d316.s10;;
Beta;O;O
-;O;O
Blocking;O;O
Agents;O;O
A;O;O
pharmacokinetic;O;O
study;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s10.e0
in;O;O
conjunction;O;O
with;O;O
metoprolol;B-drug;B-DDI-DrugBank.d316.s10.e1
demonstrated;O;O
no;O;O
significant;O;O
effects;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s10.e2
.;O;O
DDI-DrugBank.d316.s11;;
The;O;O
AUC;O;O
and;O;O
Cmax;O;O
of;O;O
metoprolol;B-drug;B-DDI-DrugBank.d316.s11.e0
,;O;O
however;O;O
,;O;O
were;O;O
increased;O;O
approximately;O;O
31;O;O
and;O;O
38;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d316.s12;;
In;O;O
controlled;O;O
clinical;O;O
trials;O;O
,;O;O
however;O;O
,;O;O
beta;B-drug;B-DDI-DrugBank.d316.s12.e0
blockers;I-drug;I-DDI-DrugBank.d316.s12.e0
including;O;O
metoprolol;B-drug;B-DDI-DrugBank.d316.s12.e1
were;O;O
concurrently;O;O
administered;O;O
with;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s12.e2
and;O;O
were;O;O
well;O;O
tolerated;O;O
.;O;O
DDI-DrugBank.d316.s13;;
Digoxin;O;O
When;O;O
given;O;O
concomitantly;O;O
with;O;O
PLENDIL;B-drug;B-DDI-DrugBank.d316.s13.e0
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d316.s13.e1
in;O;O
patients;O;O
with;O;O
heart;O;O
failure;O;O
were;O;O
not;O;O
significantly;O;O
altered;O;O
.;O;O
DDI-DrugBank.d316.s14;;
Anticonvulsants;B-group;B-DDI-DrugBank.d316.s14.e0
:;O;O
In;O;O
a;O;O
pharmacokinetic;O;O
study;O;O
,;O;O
maximum;O;O
plasma;O;O
concentrations;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s14.e1
were;O;O
considerably;O;O
lower;O;O
in;O;O
epileptic;O;O
patients;O;O
on;O;O
long;O;O
-;O;O
term;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d316.s14.e2
therapy;O;O
(;O;O
eg;O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d316.s14.e3
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d316.s14.e4
,;O;O
or;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d316.s14.e5
);O;O
than;O;O
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d316.s15;;
In;O;O
such;O;O
patients;O;O
,;O;O
the;O;O
mean;O;O
area;O;O
under;O;O
the;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s15.e0
plasma;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
was;O;O
also;O;O
reduced;O;O
to;O;O
approximately;O;O
6;O;O
%;O;O
of;O;O
that;O;O
observed;O;O
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d316.s16;;
Since;O;O
a;O;O
clinically;O;O
significant;O;O
interaction;O;O
may;O;O
be;O;O
anticipated;O;O
,;O;O
alternative;O;O
antihypertensive;B-drug;B-DDI-DrugBank.d316.s16.e0
therapy;O;O
should;O;O
be;O;O
considered;O;O
in;O;O
these;O;O
patients;O;O
.;O;O
DDI-DrugBank.d316.s17;;
Tacrolimus;O;O
Felodipine;B-drug;B-DDI-DrugBank.d316.s17.e0
may;O;O
increase;O;O
the;O;O
blood;O;O
concentration;O;O
of;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d316.s17.e1
.;O;O
DDI-DrugBank.d316.s18;;
When;O;O
given;O;O
concomitantly;O;O
with;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s18.e0
,;O;O
the;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d316.s18.e1
blood;O;O
concentration;O;O
should;O;O
be;O;O
followed;O;O
and;O;O
the;O;O
tacrolimus;O;O
dose;O;O
may;O;O
need;O;O
to;O;O
be;O;O
adjusted;O;O
.;O;O
DDI-DrugBank.d316.s19;;
Other;O;O
Concomitant;O;O
Therapy;O;O
In;O;O
healthy;O;O
subjects;O;O
there;O;O
were;O;O
no;O;O
clinically;O;O
significant;O;O
interactions;O;O
when;O;O
felodipine;B-drug;B-DDI-DrugBank.d316.s19.e0
was;O;O
given;O;O
concomitantly;O;O
with;O;O
indomethacin;B-drug;B-DDI-DrugBank.d316.s19.e1
or;O;O
spironolactone;B-drug;B-DDI-DrugBank.d316.s19.e2
.;O;O
DDI-DrugBank.d316.s20;;
Interaction;O;O
with;O;O
Food;O;O
See;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
,;O;O
Pharmacokinetics;O;O
and;O;O
Metabolism;O;O
.;O;O
DDI-DrugBank.d104.s0;;
Fenfluramine;B-drug;B-DDI-DrugBank.d104.s0.e0
may;O;O
increase;O;O
slightly;O;O
the;O;O
effect;O;O
of;O;O
antihypertensive;B-group;B-DDI-DrugBank.d104.s0.e1
drugs;I-group;I-DDI-DrugBank.d104.s0.e1
,;O;O
e.g.;O;O
,;O;O
guanethidine;B-drug;B-DDI-DrugBank.d104.s0.e2
,;O;O
methyldopa;B-drug;B-DDI-DrugBank.d104.s0.e3
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d104.s0.e4
.;O;O
DDI-DrugBank.d104.s1;;
Other;O;O
CNS;B-group;B-DDI-DrugBank.d104.s1.e0
depressant;I-group;I-DDI-DrugBank.d104.s1.e0
drugs;I-group;I-DDI-DrugBank.d104.s1.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
taking;O;O
fenfluramine;B-drug;B-DDI-DrugBank.d104.s1.e1
,;O;O
since;O;O
the;O;O
effects;O;O
may;O;O
be;O;O
additive;O;O
.;O;O
DDI-DrugBank.d283.s0;;
Oral;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d283.s0.e0
CAUTION;O;O
SHOULD;O;O
BE;O;O
EXERCISED;O;O
WHEN;O;O
COUMARIN;B-group;B-DDI-DrugBank.d283.s0.e1
ANTICOAGULANTS;I-group;I-DDI-DrugBank.d283.s0.e1
ARE;O;O
GIVEN;O;O
IN;O;O
CONJUNCTION;O;O
WITH;O;O
TRICOR;B-brand;B-DDI-DrugBank.d283.s0.e2
.;O;O
DDI-DrugBank.d283.s1;;
THE;O;O
DOSAGE;O;O
OF;O;O
THE;O;O
ANTICOAGULANTS;B-group;B-DDI-DrugBank.d283.s1.e0
SHOULD;O;O
BE;O;O
REDUCED;O;O
TO;O;O
MAINTAIN;O;O
THE;O;O
PROTHROMBIN;O;O
TIME;O;O
/;O;O
INR;O;O
AT;O;O
THE;O;O
DESIRED;O;O
LEVEL;O;O
TO;O;O
PREVENT;O;O
BLEEDING;O;O
COMPLICATIONS;O;O
.;O;O
DDI-DrugBank.d283.s2;;
FREQUENT;O;O
PROTHROMBIN;O;O
TIME;O;O
/;O;O
INR;O;O
DETERMINATIONS;O;O
ARE;O;O
ADVISABLE;O;O
UNTIL;O;O
IT;O;O
HAS;O;O
BEEN;O;O
DEFINITELY;O;O
DETERMINED;O;O
THAT;O;O
THE;O;O
PROTHROMBIN;O;O
TIME;O;O
/;O;O
INR;O;O
HAS;O;O
STABILIZED;O;O
.;O;O
DDI-DrugBank.d283.s3;;
HMG;B-group;B-DDI-DrugBank.d283.s3.e0
-;I-group;I-DDI-DrugBank.d283.s3.e0
CoA;I-group;I-DDI-DrugBank.d283.s3.e0
reductase;I-group;I-DDI-DrugBank.d283.s3.e0
inhibitors;I-group;I-DDI-DrugBank.d283.s3.e0
:;O;O
The;O;O
combined;O;O
use;O;O
of;O;O
TRICOR;B-brand;B-DDI-DrugBank.d283.s3.e1
and;O;O
HMG;B-group;B-DDI-DrugBank.d283.s3.e2
-;I-group;I-DDI-DrugBank.d283.s3.e2
CoA;I-group;I-DDI-DrugBank.d283.s3.e2
reductase;I-group;I-DDI-DrugBank.d283.s3.e2
inhibitors;I-group;I-DDI-DrugBank.d283.s3.e2
should;O;O
be;O;O
avoided;O;O
unless;O;O
the;O;O
benefit;O;O
of;O;O
further;O;O
alterations;O;O
in;O;O
lipid;O;O
levels;O;O
is;O;O
likely;O;O
to;O;O
outweigh;O;O
the;O;O
increased;O;O
risk;O;O
of;O;O
this;O;O
drug;O;O
combination;O;O
.;O;O
DDI-DrugBank.d283.s4;;
Resins;B-group;B-DDI-DrugBank.d283.s4.e0
:;O;O
Since;O;O
bile;B-group;B-DDI-DrugBank.d283.s4.e1
acid;I-group;I-DDI-DrugBank.d283.s4.e1
sequestrants;I-group;I-DDI-DrugBank.d283.s4.e1
may;O;O
bind;O;O
other;O;O
drugs;O;O
given;O;O
concurrently;O;O
,;O;O
patients;O;O
should;O;O
take;O;O
TRICOR;B-brand;B-DDI-DrugBank.d283.s4.e2
at;O;O
least;O;O
1;O;O
hour;O;O
before;O;O
or;O;O
4;O;O
-;O;O
6;O;O
hours;O;O
after;O;O
a;O;O
bile;B-group;B-DDI-DrugBank.d283.s4.e3
acid;I-group;I-DDI-DrugBank.d283.s4.e3
binding;I-group;I-DDI-DrugBank.d283.s4.e3
resin;I-group;I-DDI-DrugBank.d283.s4.e3
to;O;O
avoid;O;O
impeding;O;O
its;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d283.s5;;
Cyclosporine;B-drug;B-DDI-DrugBank.d283.s5.e0
:;O;O
Because;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d283.s5.e1
can;O;O
produce;O;O
nephrotoxicity;O;O
with;O;O
decreases;O;O
in;O;O
creatinine;O;O
clearance;O;O
and;O;O
rises;O;O
in;O;O
serum;O;O
creatinine;O;O
,;O;O
and;O;O
because;O;O
renal;O;O
excretion;O;O
is;O;O
the;O;O
primary;O;O
elimination;O;O
route;O;O
of;O;O
fibrate;B-group;B-DDI-DrugBank.d283.s5.e2
drugs;I-group;I-DDI-DrugBank.d283.s5.e2
including;O;O
TRICOR;B-brand;B-DDI-DrugBank.d283.s5.e3
,;O;O
there;O;O
is;O;O
a;O;O
risk;O;O
that;O;O
an;O;O
interaction;O;O
will;O;O
lead;O;O
to;O;O
deterioration;O;O
.;O;O
DDI-DrugBank.d283.s6;;
The;O;O
benefits;O;O
and;O;O
risks;O;O
of;O;O
using;O;O
TRICOR;B-brand;B-DDI-DrugBank.d283.s6.e0
with;O;O
immunosuppressants;B-group;B-DDI-DrugBank.d283.s6.e1
and;O;O
other;O;O
potentially;O;O
nephrotoxic;O;O
agents;O;O
should;O;O
be;O;O
carefully;O;O
considered;O;O
,;O;O
and;O;O
the;O;O
lowest;O;O
effective;O;O
dose;O;O
employed;O;O
DDI-DrugBank.d283.s7;;
.;O;O
DDI-DrugBank.d283.s8;;
Drug;O;O
-;O;O
drug;O;O
interactions;O;O
In;O;O
vitro;O;O
studies;O;O
using;O;O
human;O;O
liver;O;O
microsomes;O;O
indicate;O;O
that;O;O
fenofibrate;B-drug;B-DDI-DrugBank.d283.s8.e0
and;O;O
fenofibric;B-drug_n;B-DDI-DrugBank.d283.s8.e1
acid;I-drug_n;I-DDI-DrugBank.d283.s8.e1
are;O;O
not;O;O
inhibitors;O;O
of;O;O
cytochrome;O;O
(;O;O
CYP;O;O
);O;O
P450;O;O
isoforms;O;O
CYP3A4;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP2E1;O;O
,;O;O
or;O;O
CYP1A2;O;O
.;O;O
DDI-DrugBank.d283.s9;;
They;O;O
are;O;O
weak;O;O
inhibitors;O;O
of;O;O
CYP2C19;O;O
and;O;O
CYP2A6;O;O
,;O;O
and;O;O
mild;O;O
-;O;O
to;O;O
-;O;O
moderate;O;O
inhibitors;O;O
of;O;O
CYP2C9;O;O
at;O;O
therapeutic;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d283.s10;;
Potentiation;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d283.s10.e0
-;I-group;I-DDI-DrugBank.d283.s10.e0
type;I-group;I-DDI-DrugBank.d283.s10.e0
anticoagulants;I-group;I-DDI-DrugBank.d283.s10.e0
has;O;O
been;O;O
observed;O;O
with;O;O
prolongation;O;O
of;O;O
the;O;O
prothrombin;O;O
time;O;O
/;O;O
INR;O;O
.;O;O
DDI-DrugBank.d283.s11;;
Bile;B-group;B-DDI-DrugBank.d283.s11.e0
acid;I-group;I-DDI-DrugBank.d283.s11.e0
sequestrants;I-group;I-DDI-DrugBank.d283.s11.e0
have;O;O
been;O;O
shown;O;O
to;O;O
bind;O;O
other;O;O
drugs;O;O
given;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d283.s12;;
Therefore;O;O
,;O;O
fenofibrate;B-drug;B-DDI-DrugBank.d283.s12.e0
should;O;O
be;O;O
taken;O;O
at;O;O
least;O;O
1;O;O
hour;O;O
before;O;O
or;O;O
4;O;O
-;O;O
6;O;O
hours;O;O
after;O;O
a;O;O
bile;B-group;B-DDI-DrugBank.d283.s12.e1
acid;I-group;I-DDI-DrugBank.d283.s12.e1
binding;I-group;I-DDI-DrugBank.d283.s12.e1
resin;I-group;I-DDI-DrugBank.d283.s12.e1
to;O;O
avoid;O;O
impeding;O;O
its;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d283.s13;;
Concomitant;O;O
administration;O;O
of;O;O
fenofibrate;B-drug;B-DDI-DrugBank.d283.s13.e0
(;O;O
equivalent;O;O
to;O;O
145;O;O
mg;O;O
TRICOR;B-brand;B-DDI-DrugBank.d283.s13.e1
);O;O
with;O;O
pravastatin;B-drug;B-DDI-DrugBank.d283.s13.e2
(;O;O
40;O;O
mg;O;O
);O;O
once;O;O
daily;O;O
for;O;O
10;O;O
days;O;O
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
the;O;O
mean;O;O
Cmax;O;O
and;O;O
AUC;O;O
values;O;O
for;O;O
pravastatin;B-drug;B-DDI-DrugBank.d283.s13.e3
by;O;O
36;O;O
%;O;O
(;O;O
range;O;O
from;O;O
69;O;O
%;O;O
decrease;O;O
to;O;O
321;O;O
%;O;O
increase;O;O
);O;O
and;O;O
28;O;O
%;O;O
(;O;O
range;O;O
from;O;O
54;O;O
%;O;O
decrease;O;O
to;O;O
128;O;O
%;O;O
increase;O;O
);O;O
,;O;O
respectively;O;O
,;O;O
and;O;O
for;O;O
3;O;O
-hydroxy;O;O
-;O;O
iso;O;O
-;O;O
pravastatin;O;O
by;O;O
55;O;O
%;O;O
(;O;O
range;O;O
from;O;O
32;O;O
%;O;O
decrease;O;O
to;O;O
314;O;O
%;O;O
increase;O;O
);O;O
and;O;O
39;O;O
%;O;O
(;O;O
range;O;O
from;O;O
24;O;O
%;O;O
decrease;O;O
to;O;O
261;O;O
%;O;O
increase;O;O
);O;O
,;O;O
respectively;O;O
in;O;O
23;O;O
healthy;O;O
adults;O;O
.;O;O
DDI-DrugBank.d283.s14;;
A;O;O
single;O;O
dose;O;O
of;O;O
pravastatin;B-drug;B-DDI-DrugBank.d283.s14.e0
had;O;O
no;O;O
clinically;O;O
important;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
fenofibric;B-drug_n;B-DDI-DrugBank.d283.s14.e1
acid;I-drug_n;I-DDI-DrugBank.d283.s14.e1
.;O;O
DDI-DrugBank.d283.s15;;
Concomitant;O;O
administration;O;O
of;O;O
fenofibrate;B-drug;B-DDI-DrugBank.d283.s15.e0
(;O;O
equivalent;O;O
to;O;O
145;O;O
mg;O;O
TRICOR;B-brand;B-DDI-DrugBank.d283.s15.e1
);O;O
with;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d283.s15.e2
(;O;O
20;O;O
mg;O;O
);O;O
once;O;O
daily;O;O
for;O;O
10;O;O
days;O;O
resulted;O;O
in;O;O
approximately;O;O
17;O;O
%;O;O
decrease;O;O
(;O;O
range;O;O
from;O;O
67;O;O
%;O;O
decrease;O;O
to;O;O
44;O;O
%;O;O
increase;O;O
);O;O
in;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d283.s15.e3
AUC;O;O
values;O;O
in;O;O
22;O;O
healthy;O;O
males;O;O
.;O;O
DDI-DrugBank.d283.s16;;
The;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d283.s16.e0
Cmax;O;O
values;O;O
were;O;O
not;O;O
significantly;O;O
affected;O;O
by;O;O
fenofibrate;B-drug;B-DDI-DrugBank.d283.s16.e1
.;O;O
DDI-DrugBank.d283.s17;;
The;O;O
pharmacokinetics;O;O
of;O;O
fenofibric;B-drug_n;B-DDI-DrugBank.d283.s17.e0
acid;I-drug_n;I-DDI-DrugBank.d283.s17.e0
were;O;O
not;O;O
significantly;O;O
affected;O;O
by;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d283.s17.e1
DDI-DrugBank.d283.s18;;
.;O;O
DDI-DrugBank.d283.s19;;
DDI-DrugBank.d546.s0;;
Drug;O;O
Interactions;O;O
with;O;O
Beta;B-group;B-DDI-DrugBank.d546.s0.e0
-;I-group;I-DDI-DrugBank.d546.s0.e0
Blockers;I-group;I-DDI-DrugBank.d546.s0.e0
:;O;O
Concomitant;O;O
use;O;O
of;O;O
fenoldopam;B-drug;B-DDI-DrugBank.d546.s0.e1
with;O;O
beta;B-group;B-DDI-DrugBank.d546.s0.e2
-;I-group;I-DDI-DrugBank.d546.s0.e2
blockers;I-group;I-DDI-DrugBank.d546.s0.e2
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d546.s1;;
If;O;O
the;O;O
drugs;O;O
are;O;O
used;O;O
together;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
because;O;O
unexpected;O;O
hypotension;O;O
could;O;O
result;O;O
from;O;O
beta;O;O
-;O;O
blocker;O;O
inhibition;O;O
of;O;O
the;O;O
sympathetic;O;O
reflex;O;O
response;O;O
to;O;O
fenoldopam;B-drug;B-DDI-DrugBank.d546.s1.e0
.;O;O
DDI-DrugBank.d546.s2;;
Drug;O;O
Interactions;O;O
,;O;O
General;O;O
:;O;O
Although;O;O
there;O;O
have;O;O
been;O;O
no;O;O
formal;O;O
interaction;O;O
studies;O;O
,;O;O
intravenous;O;O
fenoldopam;B-drug;B-DDI-DrugBank.d546.s2.e0
has;O;O
been;O;O
administered;O;O
safely;O;O
with;O;O
drugs;O;O
such;O;O
as;O;O
digitalis;B-group;B-DDI-DrugBank.d546.s2.e1
and;O;O
sublingual;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d546.s2.e2
.;O;O
DDI-DrugBank.d546.s3;;
There;O;O
is;O;O
limited;O;O
experience;O;O
with;O;O
concomitant;O;O
antihypertensive;B-group;B-DDI-DrugBank.d546.s3.e0
agents;I-group;I-DDI-DrugBank.d546.s3.e0
such;O;O
as;O;O
alpha;B-group;B-DDI-DrugBank.d546.s3.e1
-;I-group;I-DDI-DrugBank.d546.s3.e1
blockers;I-group;I-DDI-DrugBank.d546.s3.e1
,;O;O
calcium;B-group;B-DDI-DrugBank.d546.s3.e2
channel;I-group;I-DDI-DrugBank.d546.s3.e2
-;I-group;I-DDI-DrugBank.d546.s3.e2
blockers;I-group;I-DDI-DrugBank.d546.s3.e2
,;O;O
ACE;B-group;B-DDI-DrugBank.d546.s3.e3
inhibitors;I-group;I-DDI-DrugBank.d546.s3.e3
,;O;O
and;O;O
diuretics;B-group;B-DDI-DrugBank.d546.s3.e4
(;O;O
both;O;O
thiazide;B-group;B-DDI-DrugBank.d546.s3.e5
-;O;O
like;O;O
and;O;O
loop;O;O
);O;O
.;O;O
DDI-DrugBank.d154.s0;;
The;O;O
coadministration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d154.s0.e0
decreases;O;O
the;O;O
biologic;O;O
half;O;O
-;O;O
life;O;O
of;O;O
fenoprofen;B-drug;B-DDI-DrugBank.d154.s0.e1
because;O;O
of;O;O
an;O;O
increase;O;O
in;O;O
metabolic;O;O
clearance;O;O
that;O;O
results;O;O
in;O;O
a;O;O
greater;O;O
amount;O;O
of;O;O
hydroxylated;B-drug_n;B-DDI-DrugBank.d154.s0.e2
fenoprofen;I-drug_n;I-DDI-DrugBank.d154.s0.e2
in;O;O
the;O;O
urine;O;O
.;O;O
DDI-DrugBank.d154.s1;;
Although;O;O
the;O;O
mechanism;O;O
of;O;O
interaction;O;O
between;O;O
fenoprofen;B-drug;B-DDI-DrugBank.d154.s1.e0
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d154.s1.e1
is;O;O
not;O;O
totally;O;O
known;O;O
,;O;O
enzyme;O;O
induction;O;O
and;O;O
displacement;O;O
of;O;O
fenoprofen;B-drug;B-DDI-DrugBank.d154.s1.e2
from;O;O
plasma;O;O
albumin;O;O
binding;O;O
sites;O;O
are;O;O
possibilities;O;O
.;O;O
DDI-DrugBank.d154.s2;;
Because;O;O
Nalfon;B-brand;B-DDI-DrugBank.d154.s2.e0
has;O;O
not;O;O
been;O;O
shown;O;O
to;O;O
produce;O;O
any;O;O
additional;O;O
effect;O;O
beyond;O;O
that;O;O
obtained;O;O
with;O;O
aspirin;B-brand;B-DDI-DrugBank.d154.s2.e1
alone;O;O
and;O;O
because;O;O
aspirin;B-brand;B-DDI-DrugBank.d154.s2.e2
increases;O;O
the;O;O
rate;O;O
of;O;O
excretion;O;O
of;O;O
Nalfon;B-brand;B-DDI-DrugBank.d154.s2.e3
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
Nalfon;B-brand;B-DDI-DrugBank.d154.s2.e4
and;O;O
salicylates;B-group;B-DDI-DrugBank.d154.s2.e5
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d154.s3;;
Chronic;O;O
administration;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d154.s3.e0
,;O;O
a;O;O
known;O;O
enzyme;O;O
inducer;O;O
,;O;O
may;O;O
be;O;O
associated;O;O
with;O;O
a;O;O
decrease;O;O
in;O;O
the;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
of;O;O
fenoprofen;B-drug;B-DDI-DrugBank.d154.s3.e1
.;O;O
DDI-DrugBank.d154.s4;;
When;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d154.s4.e0
is;O;O
added;O;O
to;O;O
or;O;O
withdrawn;O;O
from;O;O
treatment;O;O
,;O;O
dosage;O;O
adjustment;O;O
of;O;O
Nalfon;B-brand;B-DDI-DrugBank.d154.s4.e1
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d154.s5;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
fenoprofen;B-drug;B-DDI-DrugBank.d154.s5.e0
,;O;O
because;O;O
of;O;O
its;O;O
affinity;O;O
for;O;O
albumin;O;O
,;O;O
may;O;O
displace;O;O
from;O;O
their;O;O
binding;O;O
sites;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
also;O;O
albumin;O;O
bound;O;O
,;O;O
and;O;O
this;O;O
may;O;O
lead;O;O
to;O;O
drug;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d154.s6;;
Theoretically;O;O
,;O;O
fenoprofen;B-drug;B-DDI-DrugBank.d154.s6.e0
could;O;O
likewise;O;O
be;O;O
displaced;O;O
.;O;O
DDI-DrugBank.d154.s7;;
Patients;O;O
receiving;O;O
hydantoins;B-group;B-DDI-DrugBank.d154.s7.e0
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d154.s7.e1
,;O;O
or;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d154.s7.e2
should;O;O
be;O;O
observed;O;O
for;O;O
increased;O;O
activity;O;O
of;O;O
these;O;O
drugs;O;O
and;O;O
,;O;O
therefore;O;O
,;O;O
signs;O;O
of;O;O
toxicity;O;O
from;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d154.s8;;
In;O;O
patients;O;O
receiving;O;O
coumarin;B-group;B-DDI-DrugBank.d154.s8.e0
-;I-group;I-DDI-DrugBank.d154.s8.e0
type;I-group;I-DDI-DrugBank.d154.s8.e0
anticoagulants;I-group;I-DDI-DrugBank.d154.s8.e0
,;O;O
the;O;O
addition;O;O
of;O;O
Nalfon;B-brand;B-DDI-DrugBank.d154.s8.e1
to;O;O
therapy;O;O
could;O;O
prolong;O;O
the;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d154.s9;;
Patients;O;O
receiving;O;O
both;O;O
drugs;O;O
should;O;O
be;O;O
under;O;O
careful;O;O
observation;O;O
.;O;O
DDI-DrugBank.d154.s10;;
Patients;O;O
treated;O;O
with;O;O
Nalfon;B-brand;B-DDI-DrugBank.d154.s10.e0
may;O;O
be;O;O
resistant;O;O
to;O;O
the;O;O
effects;O;O
of;O;O
loop;B-group;B-DDI-DrugBank.d154.s10.e1
diuretics;I-group;I-DDI-DrugBank.d154.s10.e1
.;O;O
DDI-DrugBank.d154.s11;;
In;O;O
patients;O;O
receiving;O;O
Nalfon;B-brand;B-DDI-DrugBank.d154.s11.e0
and;O;O
a;O;O
steroid;B-group;B-DDI-DrugBank.d154.s11.e1
concomitantly;O;O
,;O;O
any;O;O
reduction;O;O
in;O;O
steroid;B-group;B-DDI-DrugBank.d154.s11.e2
dosage;O;O
should;O;O
be;O;O
gradual;O;O
in;O;O
order;O;O
to;O;O
avoid;O;O
the;O;O
possible;O;O
complications;O;O
of;O;O
sudden;O;O
steroid;B-group;B-DDI-DrugBank.d154.s11.e3
withdrawal;O;O
.;O;O
DDI-DrugBank.d170.s0;;
Agents;O;O
Affecting;O;O
Cytochrome;O;O
P450;O;O
3A4;O;O
Isoenzyme;O;O
System;O;O
Fentanyl;B-drug;B-DDI-DrugBank.d170.s0.e0
is;O;O
metabolized;O;O
mainly;O;O
via;O;O
the;O;O
human;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
isoenzyme;O;O
system;O;O
(;O;O
CYP3A4;O;O
);O;O
,;O;O
therefore;O;O
potential;O;O
interactions;O;O
may;O;O
occur;O;O
when;O;O
DURAGESIC;B-brand;B-DDI-DrugBank.d170.s0.e1
is;O;O
given;O;O
concurrently;O;O
with;O;O
agents;O;O
that;O;O
affect;O;O
CYP3A4;O;O
activity;O;O
.;O;O
DDI-DrugBank.d170.s1;;
Coadminstration;O;O
with;O;O
agents;O;O
that;O;O
induce;O;O
3A4;O;O
activity;O;O
may;O;O
reduce;O;O
the;O;O
efficacy;O;O
of;O;O
DURAGESIC;B-brand;B-DDI-DrugBank.d170.s1.e0
.;O;O
DDI-DrugBank.d170.s2;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
transdermal;O;O
fentanyl;B-drug;B-DDI-DrugBank.d170.s2.e0
with;O;O
ritonavir;B-drug;B-DDI-DrugBank.d170.s2.e1
or;O;O
other;O;O
potent;O;O
3A4;O;O
inhibitors;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d170.s2.e2
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d170.s2.e3
,;O;O
troleandomycin;B-drug;B-DDI-DrugBank.d170.s2.e4
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d170.s2.e5
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d170.s2.e6
,;O;O
and;O;O
nefazadone;O;O
may;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
fentanyl;B-drug;B-DDI-DrugBank.d170.s2.e7
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d170.s3;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
other;O;O
CYP3A4;O;O
inhibitors;O;O
such;O;O
as;O;O
diltiazem;B-drug;B-DDI-DrugBank.d170.s3.e0
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d170.s3.e1
with;O;O
transdermal;O;O
fentanyl;B-drug;B-DDI-DrugBank.d170.s3.e2
may;O;O
also;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
fentanyl;B-drug;B-DDI-DrugBank.d170.s3.e3
plasma;O;O
concentrations;O;O
,;O;O
which;O;O
could;O;O
increase;O;O
or;O;O
prolong;O;O
adverse;O;O
drug;O;O
effects;O;O
and;O;O
may;O;O
cause;O;O
serious;O;O
respiratory;O;O
depression;O;O
.;O;O
DDI-DrugBank.d170.s4;;
In;O;O
this;O;O
situation;O;O
,;O;O
special;O;O
patient;O;O
care;O;O
and;O;O
observation;O;O
are;O;O
appropriate;O;O
.;O;O
DDI-DrugBank.d170.s5;;
Central;B-group;B-DDI-DrugBank.d170.s5.e0
Nervous;I-group;I-DDI-DrugBank.d170.s5.e0
System;I-group;I-DDI-DrugBank.d170.s5.e0
Depressants;I-group;I-DDI-DrugBank.d170.s5.e0
:;O;O
The;O;O
concomitant;O;O
use;O;O
of;O;O
DURAGESIC;B-brand;B-DDI-DrugBank.d170.s5.e1
(;O;O
fentanyl;B-drug;B-DDI-DrugBank.d170.s5.e2
transdermal;O;O
system;O;O
);O;O
with;O;O
other;O;O
central;B-group;B-DDI-DrugBank.d170.s5.e3
nervous;I-group;I-DDI-DrugBank.d170.s5.e3
system;I-group;I-DDI-DrugBank.d170.s5.e3
depressants;I-group;I-DDI-DrugBank.d170.s5.e3
,;O;O
including;O;O
but;O;O
not;O;O
limited;O;O
to;O;O
other;O;O
opioids;B-group;B-DDI-DrugBank.d170.s5.e4
,;O;O
sedatives;B-group;B-DDI-DrugBank.d170.s5.e5
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d170.s5.e6
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d170.s5.e7
(;O;O
e.g.;O;O
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d170.s5.e8
);O;O
,;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d170.s5.e9
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d170.s5.e10
,;O;O
skeletal;B-group;B-DDI-DrugBank.d170.s5.e11
muscle;I-group;I-DDI-DrugBank.d170.s5.e11
relaxants;I-group;I-DDI-DrugBank.d170.s5.e11
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d170.s5.e12
,;O;O
may;O;O
cause;O;O
respiratory;O;O
depression;O;O
,;O;O
hypotension;O;O
,;O;O
and;O;O
profound;O;O
sedation;O;O
,;O;O
or;O;O
potentially;O;O
result;O;O
in;O;O
coma;O;O
or;O;O
death;O;O
.;O;O
DDI-DrugBank.d170.s6;;
When;O;O
such;O;O
combined;O;O
therapy;O;O
is;O;O
contemplated;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
should;O;O
be;O;O
significantly;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d170.s7;;
MAO;B-group;B-DDI-DrugBank.d170.s7.e0
Inhibitors;I-group;I-DDI-DrugBank.d170.s7.e0
:;O;O
DURAGESIC;B-brand;B-DDI-DrugBank.d170.s7.e1
is;O;O
not;O;O
recommended;O;O
for;O;O
use;O;O
in;O;O
patients;O;O
who;O;O
have;O;O
received;O;O
MAOI;B-group;B-DDI-DrugBank.d170.s7.e2
within;O;O
14;O;O
days;O;O
because;O;O
severe;O;O
and;O;O
unpredictable;O;O
potentiation;O;O
by;O;O
MAO;B-group;B-DDI-DrugBank.d170.s7.e3
inhibitors;I-group;I-DDI-DrugBank.d170.s7.e3
has;O;O
been;O;O
reported;O;O
with;O;O
opioid;B-group;B-DDI-DrugBank.d170.s7.e4
analgesics;I-group;I-DDI-DrugBank.d170.s7.e4
DDI-DrugBank.d170.s8;;
.;O;O
DDI-DrugBank.d170.s9;;
DDI-DrugBank.d466.s0;;
Drug;O;O
Interaction;O;O
with;O;O
Erythromycin;B-drug;B-DDI-DrugBank.d466.s0.e0
and;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d466.s0.e1
Fexofenadine;I-drug;I-DDI-DrugBank.d466.s0.e2
has;O;O
been;O;O
shown;O;O
to;O;O
exhibit;O;O
minimal;O;O
(;O;O
ca;O;O
.;O;O
5;O;O
%;O;O
);O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d466.s1;;
However;O;O
,;O;O
co;O;O
administration;O;O
of;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s1.e0
hydrochloride;I-drug;I-DDI-DrugBank.d466.s1.e0
with;O;O
either;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d466.s1.e1
or;O;O
erythromycin;B-drug;B-DDI-DrugBank.d466.s1.e2
led;O;O
to;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s1.e3
.;O;O
DDI-DrugBank.d466.s2;;
Fexofenadine;B-drug;B-DDI-DrugBank.d466.s2.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
erythromycin;B-drug;B-DDI-DrugBank.d466.s2.e1
or;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d466.s2.e2
.;O;O
DDI-DrugBank.d466.s3;;
In;O;O
2;O;O
separate;O;O
studies;O;O
,;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s3.e0
hydrochloride;I-drug;I-DDI-DrugBank.d466.s3.e0
120;O;O
mg;O;O
twice;O;O
daily;O;O
(;O;O
240;O;O
mg;O;O
total;O;O
daily;O;O
dose;O;O
);O;O
was;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
either;O;O
erythromycin;B-drug;B-DDI-DrugBank.d466.s3.e1
500;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
or;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d466.s3.e2
400;O;O
mg;O;O
once;O;O
daily;O;O
under;O;O
steady;O;O
-;O;O
state;O;O
conditions;O;O
to;O;O
healthy;O;O
volunteers;O;O
(;O;O
n=24;O;O
,;O;O
each;O;O
study;O;O
);O;O
.;O;O
DDI-DrugBank.d466.s4;;
No;O;O
differences;O;O
in;O;O
adverse;O;O
events;O;O
or;O;O
QTc;O;O
interval;O;O
were;O;O
observed;O;O
when;O;O
subjects;O;O
were;O;O
administered;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s4.e0
hydrochloride;I-drug;I-DDI-DrugBank.d466.s4.e0
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
either;O;O
erythromycin;B-drug;B-DDI-DrugBank.d466.s4.e1
or;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d466.s4.e2
.;O;O
DDI-DrugBank.d466.s5;;
The;O;O
findings;O;O
of;O;O
these;O;O
studies;O;O
are;O;O
summarized;O;O
in;O;O
the;O;O
following;O;O
table;O;O
:;O;O
Effects;O;O
on;O;O
steady;O;O
-;O;O
state;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s5.e0
pharmacokinetics;O;O
after;O;O
7;O;O
days;O;O
of;O;O
co;O;O
-;O;O
administration;O;O
with;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s5.e1
hydrochloride;I-drug;I-DDI-DrugBank.d466.s5.e1
120;O;O
mg;O;O
every;O;O
12;O;O
hours;O;O
(;O;O
two;O;O
times;O;O
the;O;O
recommended;O;O
twice;O;O
daily;O;O
dose;O;O
);O;O
in;O;O
healthy;O;O
volunteers;O;O
(;O;O
n=24;O;O
);O;O
DDI-DrugBank.d466.s6;;
Concomitant;O;O
Drug;O;O
DDI-DrugBank.d466.s7;;
cmaxSS;O;O
(;O;O
Peak;O;O
plasma;O;O
concentration;O;O
);O;O
DDI-DrugBank.d466.s8;;
AUCss(0;O;O
-;O;O
12h;O;O
);O;O
(;O;O
Extent;O;O
of;O;O
systemic;O;O
exposure;O;O
);O;O
DDI-DrugBank.d466.s9;;
Erythromycin;B-drug;B-DDI-DrugBank.d466.s9.e0
(;O;O
500;O;O
mg;O;O
every;O;O
8;O;O
hrs;O;O
);O;O
DDI-DrugBank.d466.s10;;
+82;O;O
%;O;O
DDI-DrugBank.d466.s11;;
+109;O;O
%;O;O
DDI-DrugBank.d466.s12;;
Ketoconazole;B-drug;B-DDI-DrugBank.d466.s12.e0
(;O;O
400;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
DDI-DrugBank.d466.s13;;
+135;O;O
%;O;O
DDI-DrugBank.d466.s14;;
+164;O;O
%;O;O
DDI-DrugBank.d466.s15;;
The;O;O
changes;O;O
in;O;O
plasma;O;O
levels;O;O
were;O;O
within;O;O
the;O;O
range;O;O
of;O;O
plasma;O;O
levels;O;O
achieved;O;O
in;O;O
adequate;O;O
and;O;O
well;O;O
-;O;O
controlled;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d466.s16;;
The;O;O
mechanism;O;O
of;O;O
these;O;O
interactions;O;O
has;O;O
been;O;O
evaluated;O;O
in;O;O
in;O;O
vitro;O;O
,;O;O
in;O;O
situ;O;O
,;O;O
and;O;O
in;O;O
vivo;O;O
animal;O;O
models;O;O
.;O;O
DDI-DrugBank.d466.s17;;
These;O;O
studies;O;O
indicate;O;O
that;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d466.s17.e0
or;O;O
erythromycin;B-drug;B-DDI-DrugBank.d466.s17.e1
co;O;O
-;O;O
administration;O;O
enhances;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s17.e2
gastrointestinal;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d466.s18;;
This;O;O
observed;O;O
increase;O;O
in;O;O
the;O;O
bioavailability;O;O
of;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s18.e0
may;O;O
be;O;O
due;O;O
to;O;O
transport;O;O
-;O;O
related;O;O
effects;O;O
,;O;O
such;O;O
as;O;O
p;O;O
-;O;O
glycoprotein;O;O
.;O;O
in;O;O
vivo;O;O
animal;O;O
studies;O;O
also;O;O
suggest;O;O
that;O;O
in;O;O
addition;O;O
to;O;O
enhancing;O;O
absorption;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d466.s18.e1
decreases;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s18.e2
gastrointestinal;O;O
secretion;O;O
,;O;O
while;O;O
erythromycin;B-drug;B-DDI-DrugBank.d466.s18.e3
may;O;O
also;O;O
decrease;O;O
biliary;O;O
excretion;O;O
.;O;O
DDI-DrugBank.d466.s19;;
Drug;O;O
Interactions;O;O
with;O;O
Antacids;B-group;B-DDI-DrugBank.d466.s19.e0
Administration;O;O
of;O;O
120;O;O
mg;O;O
of;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s19.e1
hydrochloride;I-drug;I-DDI-DrugBank.d466.s19.e1
(;O;O
2;O;O
x;O;O
60;O;O
mg;O;O
capsule;O;O
);O;O
within;O;O
15;O;O
minutes;O;O
of;O;O
an;O;O
aluminum;B-drug;B-DDI-DrugBank.d466.s19.e2
and;O;O
magnesium;B-drug;B-DDI-DrugBank.d466.s19.e3
containing;O;O
antacid;B-group;B-DDI-DrugBank.d466.s19.e4
(;O;O
Maalox;B-brand;B-DDI-DrugBank.d466.s19.e5
);O;O
decreased;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s19.e6
AUC;O;O
by;O;O
41;O;O
%;O;O
and;O;O
cmax;O;O
by;O;O
43;O;O
%;O;O
.;O;O
DDI-DrugBank.d466.s20;;
ALLEGRA;B-brand;B-DDI-DrugBank.d466.s20.e0
should;O;O
not;O;O
be;O;O
taken;O;O
closely;O;O
in;O;O
time;O;O
with;O;O
aluminum;B-drug;B-DDI-DrugBank.d466.s20.e1
and;O;O
magnesium;B-drug;B-DDI-DrugBank.d466.s20.e2
containing;O;O
antacids;B-group;B-DDI-DrugBank.d466.s20.e3
.;O;O
DDI-DrugBank.d466.s21;;
Interactions;O;O
with;O;O
Fruit;O;O
Juices;O;O
Fruit;O;O
juices;O;O
such;O;O
as;O;O
grapefruit;O;O
,;O;O
orange;O;O
and;O;O
apple;O;O
may;O;O
reduce;O;O
the;O;O
bioavailability;O;O
and;O;O
exposure;O;O
of;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s21.e0
.;O;O
DDI-DrugBank.d466.s22;;
This;O;O
is;O;O
based;O;O
on;O;O
the;O;O
results;O;O
from;O;O
3;O;O
clinical;O;O
studies;O;O
using;O;O
histamine;B-drug;B-DDI-DrugBank.d466.s22.e0
induced;O;O
skin;O;O
wheals;O;O
and;O;O
flares;O;O
coupled;O;O
with;O;O
population;O;O
pharmacokinetic;O;O
analysis;O;O
.;O;O
DDI-DrugBank.d466.s23;;
The;O;O
size;O;O
of;O;O
wheal;O;O
and;O;O
flare;O;O
were;O;O
significantly;O;O
larger;O;O
when;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s23.e0
hydrochloride;I-drug;I-DDI-DrugBank.d466.s23.e0
was;O;O
administered;O;O
with;O;O
either;O;O
grapefruit;O;O
or;O;O
orange;O;O
juices;O;O
compared;O;O
to;O;O
water;O;O
.;O;O
DDI-DrugBank.d466.s24;;
Based;O;O
on;O;O
the;O;O
literature;O;O
reports;O;O
,;O;O
the;O;O
same;O;O
effects;O;O
may;O;O
be;O;O
extrapolated;O;O
to;O;O
other;O;O
fruit;O;O
juices;O;O
such;O;O
as;O;O
apple;O;O
juice;O;O
.;O;O
DDI-DrugBank.d466.s25;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
observations;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d466.s26;;
In;O;O
addition;O;O
,;O;O
based;O;O
on;O;O
the;O;O
population;O;O
pharmacokinetics;O;O
analysis;O;O
of;O;O
the;O;O
combined;O;O
data;O;O
from;O;O
grapefruit;O;O
and;O;O
orange;O;O
juices;O;O
studies;O;O
with;O;O
the;O;O
data;O;O
from;O;O
a;O;O
bioequivalence;O;O
study;O;O
,;O;O
the;O;O
bioavailability;O;O
of;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s26.e0
was;O;O
reduced;O;O
by;O;O
36;O;O
%;O;O
.;O;O
DDI-DrugBank.d466.s27;;
Therefore;O;O
,;O;O
to;O;O
maximize;O;O
the;O;O
effects;O;O
of;O;O
fexofenadine;B-drug;B-DDI-DrugBank.d466.s27.e0
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
ALLEGRA;B-brand;B-DDI-DrugBank.d466.s27.e1
should;O;O
be;O;O
taken;O;O
with;O;O
water;O;O
DDI-DrugBank.d466.s28;;
.;O;O
DDI-DrugBank.d466.s29;;
DDI-DrugBank.d1.s0;;
Drug;O;O
interactions;O;O
between;O;O
NEUPOGEN;B-brand;B-DDI-DrugBank.d1.s0.e0
and;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
fully;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d1.s1;;
Drugs;O;O
which;O;O
may;O;O
potentiate;O;O
the;O;O
release;O;O
of;O;O
neutrophils;O;O
,;O;O
such;O;O
as;O;O
lithium;B-drug;B-DDI-DrugBank.d1.s1.e0
,;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d209.s0;;
No;O;O
drug;O;O
interactions;O;O
of;O;O
clinical;O;O
importance;O;O
have;O;O
been;O;O
identified;O;O
.;O;O
DDI-DrugBank.d209.s1;;
Finasteride;B-drug;B-DDI-DrugBank.d209.s1.e0
does;O;O
not;O;O
appear;O;O
to;O;O
affect;O;O
the;O;O
cytochrome;O;O
P450;O;O
-;O;O
linked;O;O
drug;O;O
-;O;O
metabolizing;O;O
enzyme;O;O
system;O;O
.;O;O
DDI-DrugBank.d209.s2;;
Compounds;O;O
that;O;O
have;O;O
been;O;O
tested;O;O
in;O;O
man;O;O
include;O;O
antipyrine;B-drug;B-DDI-DrugBank.d209.s2.e0
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d209.s2.e1
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d209.s2.e2
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d209.s2.e3
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d209.s2.e4
and;O;O
no;O;O
clinically;O;O
meaningful;O;O
interactions;O;O
were;O;O
found;O;O
.;O;O
DDI-DrugBank.d209.s3;;
Other;O;O
concomitant;O;O
therapy;O;O
Although;O;O
specific;O;O
interaction;O;O
studies;O;O
were;O;O
not;O;O
performed;O;O
,;O;O
finasteride;B-drug;B-DDI-DrugBank.d209.s3.e0
doses;O;O
of;O;O
1;O;O
mg;O;O
or;O;O
more;O;O
were;O;O
concomitantly;O;O
used;O;O
in;O;O
clinical;O;O
studies;O;O
with;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d209.s3.e1
,;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d209.s3.e2
acid;I-drug;I-DDI-DrugBank.d209.s3.e2
,;O;O
a;O;O
-;O;O
blockers;O;O
,;O;O
analgesics;B-group;B-DDI-DrugBank.d209.s3.e3
,;O;O
angiotensin;B-group;B-DDI-DrugBank.d209.s3.e4
-;I-group;I-DDI-DrugBank.d209.s3.e4
converting;I-group;I-DDI-DrugBank.d209.s3.e4
enzyme;I-group;I-DDI-DrugBank.d209.s3.e4
(;I-group;I-DDI-DrugBank.d209.s3.e4
ACE;I-group;I-DDI-DrugBank.d209.s3.e4
);I-group;I-DDI-DrugBank.d209.s3.e4
inhibitors;I-group;I-DDI-DrugBank.d209.s3.e4
,;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d209.s3.e5
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d209.s3.e6
,;O;O
beta;B-group;B-DDI-DrugBank.d209.s3.e7
blockers;I-group;I-DDI-DrugBank.d209.s3.e7
,;O;O
calcium;B-group;B-DDI-DrugBank.d209.s3.e8
-;I-group;I-DDI-DrugBank.d209.s3.e8
channel;I-group;I-DDI-DrugBank.d209.s3.e8
blockers;I-group;I-DDI-DrugBank.d209.s3.e8
,;O;O
cardiac;O;O
nitrates;B-group;B-DDI-DrugBank.d209.s3.e9
,;O;O
diuretics;B-group;B-DDI-DrugBank.d209.s3.e10
,;O;O
H2;B-group;B-DDI-DrugBank.d209.s3.e11
antagonists;I-group;I-DDI-DrugBank.d209.s3.e11
,;O;O
HMG;B-group;B-DDI-DrugBank.d209.s3.e12
-;I-group;I-DDI-DrugBank.d209.s3.e12
CoA;I-group;I-DDI-DrugBank.d209.s3.e12
reductase;I-group;I-DDI-DrugBank.d209.s3.e12
inhibitors;I-group;I-DDI-DrugBank.d209.s3.e12
,;O;O
prostaglandin;B-group;B-DDI-DrugBank.d209.s3.e13
synthetase;I-group;I-DDI-DrugBank.d209.s3.e13
inhibitors;I-group;I-DDI-DrugBank.d209.s3.e13
(;O;O
also;O;O
referred;O;O
to;O;O
as;O;O
NSAIDs;B-group;B-DDI-DrugBank.d209.s3.e14
);O;O
,;O;O
and;O;O
quinolone;B-group;B-DDI-DrugBank.d209.s3.e15
anti;I-group;I-DDI-DrugBank.d209.s3.e15
-;I-group;I-DDI-DrugBank.d209.s3.e15
infectives;I-group;I-DDI-DrugBank.d209.s3.e15
without;O;O
evidence;O;O
of;O;O
clinically;O;O
significant;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d209.s4;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Finasteride;B-drug;B-DDI-DrugBank.d209.s4.e0
had;O;O
no;O;O
effect;O;O
on;O;O
circulating;O;O
levels;O;O
of;O;O
cortisol;O;O
,;O;O
thyroid;O;O
-;O;O
stimulating;O;O
hormone;O;O
,;O;O
or;O;O
thyroxine;O;O
,;O;O
nor;O;O
did;O;O
it;O;O
affect;O;O
the;O;O
plasma;O;O
lipid;O;O
profile;O;O
(;O;O
e.g.;O;O
,;O;O
total;O;O
cholesterol;O;O
,;O;O
low;O;O
-;O;O
density;O;O
lipoproteins;O;O
,;O;O
high;O;O
-;O;O
density;O;O
lipoproteins;O;O
and;O;O
triglycerides;O;O
);O;O
or;O;O
bone;O;O
mineral;O;O
density;O;O
.;O;O
DDI-DrugBank.d209.s5;;
In;O;O
studies;O;O
with;O;O
finasteride;B-drug;B-DDI-DrugBank.d209.s5.e0
,;O;O
no;O;O
clinically;O;O
meaningful;O;O
changes;O;O
in;O;O
luteinizing;O;O
hormone;O;O
(;O;O
LH;O;O
);O;O
,;O;O
follicle;O;O
-;O;O
stimulating;O;O
hormone;O;O
(;O;O
FSH;O;O
);O;O
or;O;O
prolactin;O;O
were;O;O
detected;O;O
.;O;O
DDI-DrugBank.d209.s6;;
In;O;O
healthy;O;O
volunteers;O;O
,;O;O
treatment;O;O
with;O;O
finasteride;B-drug;B-DDI-DrugBank.d209.s6.e0
did;O;O
not;O;O
alter;O;O
the;O;O
response;O;O
of;O;O
LH;O;O
and;O;O
FSH;O;O
to;O;O
gonadotropin;O;O
-;O;O
releasing;O;O
hormone;O;O
indicating;O;O
that;O;O
the;O;O
hypothalamic;O;O
-;O;O
pituitary;O;O
-;O;O
testicular;O;O
axis;O;O
was;O;O
not;O;O
affected;O;O
.;O;O
DDI-DrugBank.d209.s7;;
In;O;O
clinical;O;O
studies;O;O
with;O;O
PROPECIA;B-brand;B-DDI-DrugBank.d209.s7.e0
(;O;O
finasteride;B-drug;B-DDI-DrugBank.d209.s7.e1
,;O;O
1;O;O
mg;O;O
);O;O
in;O;O
men;O;O
18;O;O
-;O;O
41;O;O
years;O;O
of;O;O
age;O;O
,;O;O
the;O;O
mean;O;O
value;O;O
of;O;O
serum;O;O
prostate;O;O
-;O;O
specific;O;O
antigen;O;O
(;O;O
PSA;O;O
);O;O
decreased;O;O
from;O;O
0.7;O;O
ng;O;O
/;O;O
mL;O;O
at;O;O
baseline;O;O
to;O;O
0.5;O;O
ng;O;O
/;O;O
mL;O;O
at;O;O
Month;O;O
12;O;O
.;O;O
DDI-DrugBank.d209.s8;;
Further;O;O
,;O;O
in;O;O
clinical;O;O
studies;O;O
with;O;O
PROSCAR;B-brand;B-DDI-DrugBank.d209.s8.e0
(;O;O
finasteride;B-drug;B-DDI-DrugBank.d209.s8.e1
,;O;O
5;O;O
mg;O;O
);O;O
when;O;O
used;O;O
in;O;O
older;O;O
men;O;O
who;O;O
have;O;O
benign;O;O
prostatic;O;O
hyperplasia;O;O
(;O;O
BPH;O;O
);O;O
,;O;O
PSA;O;O
levels;O;O
are;O;O
decreased;O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d209.s9;;
These;O;O
findings;O;O
should;O;O
be;O;O
taken;O;O
into;O;O
account;O;O
for;O;O
proper;O;O
interpretation;O;O
of;O;O
serum;O;O
PSA;O;O
when;O;O
evaluating;O;O
men;O;O
treated;O;O
with;O;O
finasteride;B-drug;B-DDI-DrugBank.d209.s9.e0
.;O;O
DDI-DrugBank.d87.s0;;
Drug;O;O
Interactions;O;O
.;O;O
DDI-DrugBank.d87.s1;;
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s1.e0
has;O;O
been;O;O
administered;O;O
to;O;O
patients;O;O
receiving;O;O
digitalis;B-group;B-DDI-DrugBank.d87.s1.e1
preparations;I-group;I-DDI-DrugBank.d87.s1.e1
or;O;O
beta;B-group;B-DDI-DrugBank.d87.s1.e2
-;I-group;I-DDI-DrugBank.d87.s1.e2
adrenergic;I-group;I-DDI-DrugBank.d87.s1.e2
blocking;I-group;I-DDI-DrugBank.d87.s1.e2
agents;I-group;I-DDI-DrugBank.d87.s1.e2
without;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d87.s2;;
During;O;O
administration;O;O
of;O;O
multiple;O;O
oral;O;O
doses;O;O
of;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s2.e0
to;O;O
healthy;O;O
subjects;O;O
stabilized;O;O
on;O;O
a;O;O
maintenance;O;O
dose;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d87.s2.e1
,;O;O
a;O;O
13%;O;O
-;O;O
19;O;O
%;O;O
increase;O;O
in;O;O
plasma;O;O
digoxin;B-drug;B-DDI-DrugBank.d87.s2.e2
levels;O;O
occurred;O;O
at;O;O
six;O;O
hours;O;O
postdose;O;O
.;O;O
DDI-DrugBank.d87.s3;;
In;O;O
a;O;O
study;O;O
involving;O;O
healthy;O;O
subjects;O;O
receiving;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s3.e0
and;O;O
propranolol;B-drug;B-DDI-DrugBank.d87.s3.e1
concurrently;O;O
,;O;O
plasma;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s3.e2
levels;O;O
were;O;O
increased;O;O
about;O;O
20;O;O
%;O;O
and;O;O
propranolol;B-drug;B-DDI-DrugBank.d87.s3.e3
levels;O;O
were;O;O
increased;O;O
about;O;O
30;O;O
%;O;O
compared;O;O
to;O;O
control;O;O
values;O;O
.;O;O
DDI-DrugBank.d87.s4;;
In;O;O
this;O;O
formal;O;O
interaction;O;O
study;O;O
,;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s4.e0
and;O;O
propranolol;B-drug;B-DDI-DrugBank.d87.s4.e1
were;O;O
each;O;O
found;O;O
to;O;O
have;O;O
negative;O;O
inotropic;O;O
effects;O;O
,;O;O
DDI-DrugBank.d87.s5;;
when;O;O
the;O;O
drugs;O;O
were;O;O
administered;O;O
together;O;O
,;O;O
the;O;O
effects;O;O
were;O;O
additive;O;O
.;O;O
DDI-DrugBank.d87.s6;;
The;O;O
effects;O;O
of;O;O
concomitant;O;O
administration;O;O
of;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s6.e0
and;O;O
propranolol;B-drug;B-DDI-DrugBank.d87.s6.e1
on;O;O
the;O;O
PR;O;O
interval;O;O
were;O;O
less;O;O
than;O;O
additive;O;O
.;O;O
DDI-DrugBank.d87.s7;;
In;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s7.e0
clinical;O;O
trials;O;O
,;O;O
patients;O;O
who;O;O
were;O;O
receiving;O;O
beta;B-group;B-DDI-DrugBank.d87.s7.e1
blockers;I-group;I-DDI-DrugBank.d87.s7.e1
concurrently;O;O
did;O;O
not;O;O
experience;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
side;O;O
effects;O;O
.;O;O
DDI-DrugBank.d87.s8;;
Nevertheless;O;O
,;O;O
the;O;O
possibility;O;O
of;O;O
additive;O;O
negative;O;O
inotropic;O;O
effects;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d87.s8.e0
blockers;I-group;I-DDI-DrugBank.d87.s8.e0
and;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s8.e1
should;O;O
be;O;O
recognized;O;O
.;O;O
DDI-DrugBank.d87.s9;;
Flecainide;B-drug;B-DDI-DrugBank.d87.s9.e0
is;O;O
not;O;O
extensively;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
.;O;O
DDI-DrugBank.d87.s10;;
In;O;O
vitro;O;O
studies;O;O
with;O;O
several;O;O
drugs;O;O
which;O;O
may;O;O
be;O;O
administered;O;O
concomitantly;O;O
showed;O;O
that;O;O
the;O;O
extent;O;O
of;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s10.e0
binding;O;O
to;O;O
human;O;O
plasma;O;O
proteins;O;O
is;O;O
either;O;O
unchanged;O;O
or;O;O
only;O;O
slightly;O;O
less;O;O
.;O;O
DDI-DrugBank.d87.s11;;
Consequently;O;O
,;O;O
interactions;O;O
with;O;O
other;O;O
drugs;O;O
which;O;O
are;O;O
highly;O;O
protein;O;O
bound;O;O
(;O;O
e.g.;O;O
,;O;O
anticoagulants;B-group;B-DDI-DrugBank.d87.s11.e0
);O;O
would;O;O
not;O;O
be;O;O
expected;O;O
.;O;O
DDI-DrugBank.d87.s12;;
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s12.e0
has;O;O
been;O;O
used;O;O
in;O;O
a;O;O
large;O;O
number;O;O
of;O;O
patients;O;O
receiving;O;O
diuretics;B-group;B-DDI-DrugBank.d87.s12.e1
without;O;O
apparent;O;O
interaction;O;O
.;O;O
DDI-DrugBank.d87.s13;;
Limited;O;O
data;O;O
in;O;O
patients;O;O
receiving;O;O
known;O;O
enzyme;O;O
inducers;O;O
(;O;O
phenytoin;B-drug;B-DDI-DrugBank.d87.s13.e0
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d87.s13.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d87.s13.e2
);O;O
indicate;O;O
only;O;O
a;O;O
30;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
rate;O;O
of;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s13.e3
elimination;O;O
.;O;O
DDI-DrugBank.d87.s14;;
In;O;O
healthy;O;O
subjects;O;O
receiving;O;O
cimetidine;B-drug;B-DDI-DrugBank.d87.s14.e0
(;O;O
1;O;O
gm;O;O
daily;O;O
);O;O
for;O;O
one;O;O
week;O;O
,;O;O
plasma;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s14.e1
levels;O;O
increased;O;O
by;O;O
about;O;O
30;O;O
%;O;O
and;O;O
half;O;O
-;O;O
life;O;O
increased;O;O
by;O;O
about;O;O
10;O;O
%;O;O
.;O;O
DDI-DrugBank.d87.s15;;
When;O;O
amiodarone;B-drug;B-DDI-DrugBank.d87.s15.e0
is;O;O
added;O;O
to;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s15.e1
therapy;O;O
,;O;O
plasma;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s15.e2
levels;O;O
may;O;O
increase;O;O
two;O;O
-;O;O
fold;O;O
or;O;O
more;O;O
in;O;O
some;O;O
patients;O;O
,;O;O
if;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s15.e3
dosage;O;O
is;O;O
not;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d87.s16;;
Drugs;O;O
that;O;O
inhibit;O;O
cytochrome;O;O
P450IID6;O;O
,;O;O
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d87.s16.e0
,;O;O
might;O;O
increase;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s16.e1
in;O;O
patients;O;O
that;O;O
are;O;O
on;O;O
chronic;O;O
flecainide;B-drug;B-DDI-DrugBank.d87.s16.e2
therapy;O;O
,;O;O
DDI-DrugBank.d87.s17;;
especially;O;O
if;O;O
these;O;O
patients;O;O
are;O;O
extensive;O;O
metabolizers;O;O
.;O;O
DDI-DrugBank.d87.s18;;
There;O;O
has;O;O
been;O;O
little;O;O
experience;O;O
with;O;O
the;O;O
coadministration;O;O
of;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s18.e0
and;O;O
either;O;O
disopyramide;B-drug;B-DDI-DrugBank.d87.s18.e1
or;O;O
verapamil;B-drug;B-DDI-DrugBank.d87.s18.e2
.;O;O
DDI-DrugBank.d87.s19;;
Because;O;O
both;O;O
of;O;O
these;O;O
drugs;O;O
have;O;O
negative;O;O
inotropic;O;O
properties;O;O
and;O;O
the;O;O
effects;O;O
of;O;O
coadministration;O;O
with;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s19.e0
are;O;O
unknown;O;O
,;O;O
neither;O;O
disopyramide;B-drug;B-DDI-DrugBank.d87.s19.e1
nor;O;O
verapamil;B-drug;B-DDI-DrugBank.d87.s19.e2
should;O;O
be;O;O
administered;O;O
concurrently;O;O
with;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s19.e3
unless;O;O
,;O;O
in;O;O
the;O;O
judgment;O;O
of;O;O
the;O;O
physician;O;O
,;O;O
the;O;O
benefits;O;O
of;O;O
this;O;O
combination;O;O
outweigh;O;O
the;O;O
risks;O;O
.;O;O
DDI-DrugBank.d87.s20;;
There;O;O
has;O;O
been;O;O
too;O;O
little;O;O
experience;O;O
with;O;O
the;O;O
coadministration;O;O
of;O;O
TAMBOCOR;B-brand;B-DDI-DrugBank.d87.s20.e0
with;O;O
nifedipine;B-drug;B-DDI-DrugBank.d87.s20.e1
or;O;O
diltiazem;B-drug;B-DDI-DrugBank.d87.s20.e2
to;O;O
recommend;O;O
concomitant;O;O
use;O;O
.;O;O
DDI-DrugBank.d361.s0;;
Combination;O;O
Therapy;O;O
:;O;O
Any;O;O
form;O;O
of;O;O
therapy;O;O
which;O;O
adds;O;O
to;O;O
the;O;O
stress;O;O
of;O;O
the;O;O
patient;O;O
,;O;O
interferes;O;O
with;O;O
nutrition;O;O
or;O;O
depresses;O;O
bone;O;O
marrow;O;O
function;O;O
will;O;O
increase;O;O
the;O;O
toxicity;O;O
of;O;O
Floxuridine;B-drug;B-DDI-DrugBank.d361.s0.e0
.;O;O
DDI-DrugBank.d453.s0;;
Cytosine;B-drug;B-DDI-DrugBank.d453.s0.e0
arabinoside;I-drug;I-DDI-DrugBank.d453.s0.e0
,;O;O
a;O;O
cytostatic;B-group;B-DDI-DrugBank.d453.s0.e1
agent;I-group;I-DDI-DrugBank.d453.s0.e1
,;O;O
has;O;O
been;O;O
reported;O;O
to;O;O
inactivate;O;O
the;O;O
antifungal;O;O
activity;O;O
of;O;O
flucytosine;B-drug;B-DDI-DrugBank.d453.s0.e2
by;O;O
competitive;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d453.s1;;
Drugs;O;O
which;O;O
impair;O;O
glomerular;O;O
filtration;O;O
may;O;O
prolong;O;O
the;O;O
biological;O;O
half;O;O
-;O;O
life;O;O
of;O;O
flucytosine;B-drug;B-DDI-DrugBank.d453.s1.e0
.;O;O
DDI-DrugBank.d453.s2;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
Measurement;O;O
of;O;O
serum;O;O
creatinine;O;O
levels;O;O
should;O;O
be;O;O
determined;O;O
by;O;O
the;O;O
Jaffe;O;O
reaction;O;O
,;O;O
since;O;O
Ancobon;B-brand;B-DDI-DrugBank.d453.s2.e0
does;O;O
not;O;O
interfere;O;O
with;O;O
the;O;O
determination;O;O
of;O;O
creatinine;O;O
values;O;O
by;O;O
this;O;O
method;O;O
.;O;O
DDI-DrugBank.d453.s3;;
Most;O;O
automated;O;O
equipment;O;O
for;O;O
measurement;O;O
of;O;O
creatinine;O;O
makes;O;O
use;O;O
of;O;O
the;O;O
Jaffe;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d444.s0;;
The;O;O
use;O;O
of;O;O
FLUDARA;B-brand;B-DDI-DrugBank.d444.s0.e0
FOR;O;O
INJECTION;O;O
in;O;O
combination;O;O
with;O;O
pentostatin;B-drug;B-DDI-DrugBank.d444.s0.e1
is;O;O
not;O;O
recommended;O;O
due;O;O
to;O;O
the;O;O
risk;O;O
of;O;O
severe;O;O
pulmonary;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d526.s0;;
When;O;O
administered;O;O
concurrently;O;O
,;O;O
the;O;O
following;O;O
drugs;O;O
may;O;O
interact;O;O
with;O;O
adrenal;B-group;B-DDI-DrugBank.d526.s0.e0
corticosteroids;I-group;I-DDI-DrugBank.d526.s0.e0
.;O;O
DDI-DrugBank.d526.s1;;
Amphotericin;B-drug;B-DDI-DrugBank.d526.s1.e0
B;I-drug;I-DDI-DrugBank.d526.s1.e0
or;O;O
potassium;B-group;B-DDI-DrugBank.d526.s1.e1
-;I-group;I-DDI-DrugBank.d526.s1.e1
depleting;I-group;I-DDI-DrugBank.d526.s1.e1
diuretics;I-group;I-DDI-DrugBank.d526.s1.e1
(;O;O
benzothiadiazines;B-group;B-DDI-DrugBank.d526.s1.e2
and;O;O
related;O;O
drugs;O;O
,;O;O
ethacrynic;B-drug;B-DDI-DrugBank.d526.s1.e3
acid;I-drug;I-DDI-DrugBank.d526.s1.e3
and;O;O
furosemide;B-drug;B-DDI-DrugBank.d526.s1.e4
);O;O
enhanced;O;O
hypokalemia;O;O
.;O;O
DDI-DrugBank.d526.s2;;
Check;O;O
serum;O;O
potassium;O;O
levels;O;O
at;O;O
frequent;O;O
intervals;O;O
,;O;O
DDI-DrugBank.d526.s3;;
use;O;O
potassium;B-drug;B-DDI-DrugBank.d526.s3.e0
supplements;O;O
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d526.s4;;
Digitalis;B-group;B-DDI-DrugBank.d526.s4.e0
glycosides;I-group;I-DDI-DrugBank.d526.s4.e0
enhanced;O;O
possibility;O;O
of;O;O
arrhythmias;O;O
or;O;O
digitalis;B-group;B-DDI-DrugBank.d526.s4.e1
toxicity;O;O
associated;O;O
with;O;O
hypokalemia;O;O
.;O;O
DDI-DrugBank.d526.s5;;
Monitor;O;O
serum;O;O
potassium;O;O
levels;O;O
,;O;O
DDI-DrugBank.d526.s6;;
use;O;O
potassium;B-drug;B-DDI-DrugBank.d526.s6.e0
supplements;O;O
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d526.s7;;
Oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d526.s7.e0
decreased;O;O
prothrombin;O;O
time;O;O
response;O;O
.;O;O
DDI-DrugBank.d526.s8;;
Monitor;O;O
prothrombin;O;O
levels;O;O
and;O;O
adjust;O;O
anticoagulant;B-group;B-DDI-DrugBank.d526.s8.e0
dosage;O;O
accordingly;O;O
.;O;O
DDI-DrugBank.d526.s9;;
Antidiabetic;B-group;B-DDI-DrugBank.d526.s9.e0
drugs;I-group;I-DDI-DrugBank.d526.s9.e0
(;O;O
oral;O;O
agents;O;O
and;O;O
insulin;B-drug;B-DDI-DrugBank.d526.s9.e1
);O;O
diminished;O;O
antidiabetic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d526.s10;;
Monitor;O;O
for;O;O
symptoms;O;O
of;O;O
hyperglycemia;O;O
,;O;O
DDI-DrugBank.d526.s11;;
adjust;O;O
dosage;O;O
of;O;O
antidiabetic;B-group;B-DDI-DrugBank.d526.s11.e0
drug;I-group;I-DDI-DrugBank.d526.s11.e0
upward;O;O
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d526.s12;;
Aspirin;B-brand;B-DDI-DrugBank.d526.s12.e0
increased;O;O
ulcerogenic;O;O
effect;O;O
,;O;O
DDI-DrugBank.d526.s13;;
decreased;O;O
pharmacologic;O;O
effect;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d526.s13.e0
.;O;O
DDI-DrugBank.d526.s14;;
Rarely;O;O
salicylate;B-group;B-DDI-DrugBank.d526.s14.e0
toxicity;O;O
may;O;O
occur;O;O
in;O;O
patients;O;O
who;O;O
discontinue;O;O
steroids;B-group;B-DDI-DrugBank.d526.s14.e1
after;O;O
concurrent;O;O
high;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d526.s14.e2
therapy;O;O
.;O;O
DDI-DrugBank.d526.s15;;
Monitor;O;O
salicylate;B-group;B-DDI-DrugBank.d526.s15.e0
levels;O;O
or;O;O
the;O;O
therapeutic;O;O
effect;O;O
for;O;O
which;O;O
aspirin;B-brand;B-DDI-DrugBank.d526.s15.e1
is;O;O
given;O;O
,;O;O
DDI-DrugBank.d526.s16;;
adjust;O;O
salicylate;B-group;B-DDI-DrugBank.d526.s16.e0
dosage;O;O
accordingly;O;O
if;O;O
effect;O;O
is;O;O
altered;O;O
.;O;O
DDI-DrugBank.d526.s17;;
Barbiturates;B-group;B-DDI-DrugBank.d526.s17.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d526.s17.e1
,;O;O
or;O;O
rifampin;B-drug;B-DDI-DrugBank.d526.s17.e2
increased;O;O
metabolic;O;O
clearance;O;O
of;O;O
fludrocortisone;B-drug;B-DDI-DrugBank.d526.s17.e3
acetate;I-drug;I-DDI-DrugBank.d526.s17.e3
because;O;O
of;O;O
the;O;O
induction;O;O
of;O;O
hepatic;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d526.s18;;
Observe;O;O
the;O;O
patient;O;O
for;O;O
possible;O;O
diminished;O;O
effect;O;O
of;O;O
steroid;B-group;B-DDI-DrugBank.d526.s18.e0
and;O;O
increase;O;O
the;O;O
steroid;B-group;B-DDI-DrugBank.d526.s18.e1
dosage;O;O
accordingly;O;O
.;O;O
DDI-DrugBank.d526.s19;;
Anabolic;B-group;B-DDI-DrugBank.d526.s19.e0
steroids;I-group;I-DDI-DrugBank.d526.s19.e0
(;O;O
particularly;O;O
C;O;O
-;O;O
17;O;O
alkylated;O;O
androgens;B-group;B-DDI-DrugBank.d526.s19.e1
such;O;O
as;O;O
oxymetholone;B-drug;B-DDI-DrugBank.d526.s19.e2
,;O;O
methandrostenolone;B-drug;B-DDI-DrugBank.d526.s19.e3
,;O;O
norethandrolone;B-drug;B-DDI-DrugBank.d526.s19.e4
,;O;O
and;O;O
similar;O;O
compounds;O;O
);O;O
enhanced;O;O
tendency;O;O
toward;O;O
edema;O;O
.;O;O
DDI-DrugBank.d526.s20;;
Use;O;O
caution;O;O
when;O;O
giving;O;O
these;O;O
drugs;O;O
together;O;O
,;O;O
especially;O;O
in;O;O
patients;O;O
with;O;O
hepatic;O;O
or;O;O
cardiac;O;O
disease;O;O
.;O;O
DDI-DrugBank.d526.s21;;
Vaccines;B-group;B-DDI-DrugBank.d526.s21.e0
neurological;O;O
complications;O;O
and;O;O
lack;O;O
of;O;O
antibody;O;O
response;O;O
.;O;O
DDI-DrugBank.d526.s22;;
Estrogen;B-group;B-DDI-DrugBank.d526.s22.e0
increased;O;O
levels;O;O
of;O;O
corticosteroid;O;O
-;O;O
binding;O;O
globulin;O;O
,;O;O
thereby;O;O
increasing;O;O
the;O;O
bound;O;O
(;O;O
inactive;O;O
);O;O
fraction;O;O
,;O;O
DDI-DrugBank.d526.s23;;
this;O;O
effect;O;O
is;O;O
at;O;O
least;O;O
balanced;O;O
by;O;O
decreased;O;O
metabolism;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d526.s23.e0
.;O;O
DDI-DrugBank.d526.s24;;
When;O;O
estrogen;B-group;B-DDI-DrugBank.d526.s24.e0
therapy;O;O
is;O;O
initiated;O;O
,;O;O
a;O;O
reduction;O;O
in;O;O
corticosteroid;B-group;B-DDI-DrugBank.d526.s24.e1
dosage;O;O
may;O;O
be;O;O
required;O;O
,;O;O
and;O;O
increased;O;O
amounts;O;O
may;O;O
be;O;O
required;O;O
when;O;O
estrogen;B-group;B-DDI-DrugBank.d526.s24.e2
is;O;O
terminated;O;O
.;O;O
DDI-DrugBank.d526.s25;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Corticosteroids;B-group;B-DDI-DrugBank.d526.s25.e0
may;O;O
affect;O;O
the;O;O
nitrobluetetrazolium;O;O
test;O;O
for;O;O
bacterial;O;O
infection;O;O
and;O;O
produce;O;O
false;O;O
-;O;O
negative;O;O
results;O;O
DDI-DrugBank.d526.s26;;
.;O;O
DDI-DrugBank.d526.s27;;
DDI-DrugBank.d234.s0;;
Interaction;O;O
with;O;O
central;B-group;B-DDI-DrugBank.d234.s0.e0
nervous;I-group;I-DDI-DrugBank.d234.s0.e0
system;I-group;I-DDI-DrugBank.d234.s0.e0
depressants;I-group;I-DDI-DrugBank.d234.s0.e0
other;O;O
than;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d234.s0.e1
has;O;O
not;O;O
been;O;O
specifically;O;O
studied;O;O
,;O;O
DDI-DrugBank.d234.s1;;
however;O;O
,;O;O
no;O;O
deleterious;O;O
interactions;O;O
were;O;O
seen;O;O
when;O;O
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s1.e0
was;O;O
administered;O;O
after;O;O
narcotics;B-group;B-DDI-DrugBank.d234.s1.e1
,;O;O
inhalational;O;O
anesthetics;B-group;B-DDI-DrugBank.d234.s1.e2
,;O;O
muscle;B-group;B-DDI-DrugBank.d234.s1.e3
relaxants;I-group;I-DDI-DrugBank.d234.s1.e3
and;O;O
muscle;O;O
relaxant;O;O
antagonists;O;O
administered;O;O
in;O;O
conjunction;O;O
with;O;O
sedation;O;O
or;O;O
anesthesia;O;O
.;O;O
DDI-DrugBank.d234.s2;;
Particular;O;O
caution;O;O
is;O;O
necessary;O;O
when;O;O
using;O;O
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s2.e0
in;O;O
cases;O;O
of;O;O
mixed;O;O
drug;O;O
overdosage;O;O
since;O;O
the;O;O
toxic;O;O
effects;O;O
(;O;O
such;O;O
as;O;O
convulsions;O;O
and;O;O
cardiac;O;O
dysrhythmias;O;O
);O;O
of;O;O
other;O;O
drugs;O;O
taken;O;O
in;O;O
overdose;O;O
(;O;O
especially;O;O
cyclic;B-group;B-DDI-DrugBank.d234.s2.e1
antidepressants;I-group;I-DDI-DrugBank.d234.s2.e1
);O;O
may;O;O
emerge;O;O
with;O;O
the;O;O
reversal;O;O
of;O;O
the;O;O
benzodiazepine;B-group;B-DDI-DrugBank.d234.s2.e2
effect;O;O
by;O;O
flumazenil;B-drug;B-DDI-DrugBank.d234.s2.e3
.;O;O
DDI-DrugBank.d234.s3;;
The;O;O
use;O;O
of;O;O
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s3.e0
is;O;O
not;O;O
recommended;O;O
in;O;O
epileptic;O;O
patients;O;O
who;O;O
have;O;O
been;O;O
receiving;O;O
benzodiazepine;O;O
treatment;O;O
for;O;O
a;O;O
prolonged;O;O
period;O;O
.;O;O
DDI-DrugBank.d234.s4;;
Although;O;O
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s4.e0
exerts;O;O
a;O;O
slight;O;O
intrinsic;O;O
anticonvulsant;O;O
effect;O;O
,;O;O
its;O;O
abrupt;O;O
suppression;O;O
of;O;O
the;O;O
protective;O;O
effect;O;O
of;O;O
a;O;O
benzodiazepine;B-group;B-DDI-DrugBank.d234.s4.e1
agonist;O;O
can;O;O
give;O;O
rise;O;O
to;O;O
convulsions;O;O
in;O;O
epileptic;O;O
patients;O;O
.;O;O
DDI-DrugBank.d234.s5;;
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s5.e0
blocks;O;O
the;O;O
central;O;O
effects;O;O
of;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d234.s5.e1
by;O;O
competitive;O;O
interaction;O;O
at;O;O
the;O;O
receptor;O;O
level;O;O
.;O;O
DDI-DrugBank.d234.s6;;
The;O;O
effects;O;O
of;O;O
nonbenzodiazepine;O;O
agonists;O;O
at;O;O
benzodiazepine;O;O
receptors;O;O
,;O;O
such;O;O
as;O;O
zopiclone;B-drug;B-DDI-DrugBank.d234.s6.e0
,;O;O
triazolopyridazines;O;O
and;O;O
others;O;O
,;O;O
are;O;O
also;O;O
blocked;O;O
by;O;O
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s6.e1
.;O;O
DDI-DrugBank.d234.s7;;
The;O;O
pharmacokinetics;O;O
of;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d234.s7.e0
are;O;O
unaltered;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
flumazenil;B-drug;B-DDI-DrugBank.d234.s7.e1
and;O;O
vice;O;O
versa;O;O
.;O;O
DDI-DrugBank.d234.s8;;
There;O;O
is;O;O
no;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
ethanol;B-drug;B-DDI-DrugBank.d234.s8.e0
and;O;O
flumazenil;B-drug;B-DDI-DrugBank.d234.s8.e1
.;O;O
DDI-DrugBank.d234.s9;;
Use;O;O
in;O;O
Ambulatory;O;O
Patients;O;O
The;O;O
effects;O;O
of;O;O
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s9.e0
may;O;O
wear;O;O
off;O;O
before;O;O
a;O;O
long;B-group;B-DDI-DrugBank.d234.s9.e1
-;I-group;I-DDI-DrugBank.d234.s9.e1
acting;I-group;I-DDI-DrugBank.d234.s9.e1
benzodiazepine;I-group;I-DDI-DrugBank.d234.s9.e1
is;O;O
completely;O;O
cleared;O;O
from;O;O
the;O;O
body;O;O
.;O;O
DDI-DrugBank.d234.s10;;
In;O;O
general;O;O
,;O;O
if;O;O
a;O;O
patient;O;O
shows;O;O
no;O;O
signs;O;O
of;O;O
sedation;O;O
within;O;O
2;O;O
hours;O;O
after;O;O
a;O;O
1;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
flumazenil;B-drug;B-DDI-DrugBank.d234.s10.e0
,;O;O
serious;O;O
resedation;O;O
at;O;O
a;O;O
later;O;O
time;O;O
is;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d234.s11;;
An;O;O
adequate;O;O
period;O;O
of;O;O
observation;O;O
must;O;O
be;O;O
provided;O;O
for;O;O
any;O;O
patient;O;O
in;O;O
whom;O;O
either;O;O
long;B-group;B-DDI-DrugBank.d234.s11.e0
-;I-group;I-DDI-DrugBank.d234.s11.e0
acting;I-group;I-DDI-DrugBank.d234.s11.e0
benzodiazepines;I-group;I-DDI-DrugBank.d234.s11.e0
(;O;O
such;O;O
as;O;O
diazepam;B-drug;B-DDI-DrugBank.d234.s11.e1
);O;O
or;O;O
large;O;O
doses;O;O
of;O;O
short;B-group;B-DDI-DrugBank.d234.s11.e2
-;I-group;I-DDI-DrugBank.d234.s11.e2
acting;I-group;I-DDI-DrugBank.d234.s11.e2
benzodiazepines;I-group;I-DDI-DrugBank.d234.s11.e2
(;O;O
such;O;O
as;O;O
10;O;O
mg;O;O
of;O;O
midazolam;B-drug;B-DDI-DrugBank.d234.s11.e3
);O;O
have;O;O
been;O;O
used;O;O
.;O;O
DDI-DrugBank.d234.s12;;
Because;O;O
of;O;O
the;O;O
increased;O;O
risk;O;O
of;O;O
adverse;O;O
reactions;O;O
in;O;O
patients;O;O
who;O;O
have;O;O
been;O;O
taking;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d234.s12.e0
on;O;O
a;O;O
regular;O;O
basis;O;O
,;O;O
it;O;O
is;O;O
particularly;O;O
important;O;O
that;O;O
physicians;O;O
query;O;O
patients;O;O
or;O;O
their;O;O
guardians;O;O
carefully;O;O
about;O;O
benzodiazepine;B-group;B-DDI-DrugBank.d234.s12.e1
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d234.s12.e2
and;O;O
sedative;B-group;B-DDI-DrugBank.d234.s12.e3
use;O;O
as;O;O
part;O;O
of;O;O
the;O;O
history;O;O
prior;O;O
to;O;O
any;O;O
procedure;O;O
in;O;O
which;O;O
the;O;O
use;O;O
of;O;O
ROMAZICON;B-brand;B-DDI-DrugBank.d234.s12.e4
is;O;O
planned;O;O
.;O;O
DDI-DrugBank.d214.s0;;
No;O;O
information;O;O
available;O;O
.;O;O
DDI-DrugBank.d482.s0;;
Do;O;O
not;O;O
take;O;O
this;O;O
medicine;O;O
with;O;O
thioridizine;O;O
,;O;O
or;O;O
within;O;O
5;O;O
weeks;O;O
of;O;O
taking;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d482.s0.e0
.;O;O
DDI-DrugBank.d482.s1;;
Talk;O;O
to;O;O
your;O;O
doctor;O;O
if;O;O
you;O;O
are;O;O
taking;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d482.s1.e0
such;O;O
as;O;O
erythromycin;B-drug;B-DDI-DrugBank.d482.s1.e1
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d482.s1.e2
or;O;O
azithromycin;B-drug;B-DDI-DrugBank.d482.s1.e3
.;O;O
DDI-DrugBank.d482.s2;;
This;O;O
medicine;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d482.s2.e0
inhibitors;I-group;I-DDI-DrugBank.d482.s2.e0
.;O;O
DDI-DrugBank.d482.s3;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
taking;O;O
this;O;O
medicine;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d482.s3.e0
,;O;O
such;O;O
as;O;O
erythromycin;B-drug;B-DDI-DrugBank.d482.s3.e1
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d482.s3.e2
,;O;O
or;O;O
azithromycin;B-drug;B-DDI-DrugBank.d482.s3.e3
.;O;O
DDI-DrugBank.d482.s4;;
This;O;O
medicine;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d482.s4.e0
inhibitors;I-group;I-DDI-DrugBank.d482.s4.e0
.;O;O
DDI-DrugBank.d482.s5;;
If;O;O
you;O;O
think;O;O
you;O;O
are;O;O
taking;O;O
an;O;O
MAO;B-group;B-DDI-DrugBank.d482.s5.e0
inhibitor;I-group;I-DDI-DrugBank.d482.s5.e0
talk;O;O
to;O;O
your;O;O
doctor;O;O
or;O;O
pharmacist;O;O
.;O;O
DDI-DrugBank.d482.s6;;
Do;O;O
not;O;O
take;O;O
this;O;O
medicine;O;O
with;O;O
St.;O;O
Johns;O;O
Wort;O;O
because;O;O
of;O;O
the;O;O
additive;O;O
effects;O;O
of;O;O
sertonin;O;O
.;O;O
DDI-DrugBank.d482.s7;;
This;O;O
medication;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d482.s7.e0
inhibitors;I-group;I-DDI-DrugBank.d482.s7.e0
.;O;O
DDI-DrugBank.d482.s8;;
Your;O;O
doctor;O;O
or;O;O
pharmacist;O;O
can;O;O
give;O;O
you;O;O
more;O;O
information;O;O
on;O;O
MAO;B-group;B-DDI-DrugBank.d482.s8.e0
inhibitors;I-group;I-DDI-DrugBank.d482.s8.e0
.;O;O
DDI-DrugBank.d482.s9;;
Wait;O;O
5;O;O
weeks;O;O
after;O;O
stopping;O;O
escitalopram;B-drug;B-DDI-DrugBank.d482.s9.e0
before;O;O
starting;O;O
a;O;O
non;B-group;B-DDI-DrugBank.d482.s9.e1
-;I-group;I-DDI-DrugBank.d482.s9.e1
selective;I-group;I-DDI-DrugBank.d482.s9.e1
MAO;I-group;I-DDI-DrugBank.d482.s9.e1
inhibitor;I-group;I-DDI-DrugBank.d482.s9.e1
.;O;O
DDI-DrugBank.d482.s10;;
Wait;O;O
2;O;O
weeks;O;O
after;O;O
stopping;O;O
an;O;O
MAO;B-group;B-DDI-DrugBank.d482.s10.e0
inhibitor;I-group;I-DDI-DrugBank.d482.s10.e0
before;O;O
starting;O;O
escitalopram;B-drug;B-DDI-DrugBank.d482.s10.e1
.;O;O
DDI-DrugBank.d482.s11;;
If;O;O
you;O;O
are;O;O
taking;O;O
medications;O;O
for;O;O
migraines;O;O
such;O;O
as;O;O
Imitrex;B-brand;B-DDI-DrugBank.d482.s11.e0
,;O;O
talk;O;O
to;O;O
your;O;O
doctor;O;O
before;O;O
starting;O;O
this;O;O
medicine;O;O
.;O;O
DDI-DrugBank.d482.s12;;
If;O;O
you;O;O
are;O;O
taking;O;O
a;O;O
tricyclic;B-group;B-DDI-DrugBank.d482.s12.e0
antidepressant;I-group;I-DDI-DrugBank.d482.s12.e0
,;O;O
talk;O;O
to;O;O
your;O;O
doctor;O;O
before;O;O
taking;O;O
this;O;O
medicine;O;O
.;O;O
DDI-DrugBank.d482.s13;;
St.;O;O
John;O;O
s;O;O
Wort;O;O
should;O;O
be;O;O
avoided;O;O
while;O;O
taking;O;O
this;O;O
medicine;O;O
due;O;O
to;O;O
the;O;O
additive;O;O
effects;O;O
of;O;O
serotonin;O;O
.;O;O
DDI-DrugBank.d482.s14;;
Tell;O;O
your;O;O
doctor;O;O
if;O;O
you;O;O
are;O;O
taking;O;O
any;O;O
of;O;O
the;O;O
following;O;O
drugs;O;O
:;O;O
blood;B-group;B-DDI-DrugBank.d482.s14.e0
thinners;I-group;I-DDI-DrugBank.d482.s14.e0
(;O;O
Coumadin;B-brand;B-DDI-DrugBank.d482.s14.e1
);O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d482.s14.e2
metoprolol;I-drug;I-DDI-DrugBank.d482.s14.e3
antihistamines;I-group;I-DDI-DrugBank.d482.s14.e4
carbamazepine;I-drug;I-DDI-DrugBank.d482.s14.e5
(;O;O
Tegretol;B-brand;B-DDI-DrugBank.d482.s14.e6
);O;O
cimetidine;B-drug;B-DDI-DrugBank.d482.s14.e7
(;O;O
Tagamet;B-brand;B-DDI-DrugBank.d482.s14.e8
);O;O
estrogens;B-group;B-DDI-DrugBank.d482.s14.e9
fluoxetine;I-drug;I-DDI-DrugBank.d482.s14.e10
(;O;O
Prozac;B-brand;B-DDI-DrugBank.d482.s14.e11
);O;O
intraconazole;O;O
(;O;O
Sporanox;B-brand;B-DDI-DrugBank.d482.s14.e12
);O;O
ketoconazole;B-drug;B-DDI-DrugBank.d482.s14.e13
(;O;O
Nizoral;B-brand;B-DDI-DrugBank.d482.s14.e14
);O;O
levodopa;B-drug;B-DDI-DrugBank.d482.s14.e15
lithium;I-drug;I-DDI-DrugBank.d482.s14.e16
muscle;I-group;I-DDI-DrugBank.d482.s14.e17
relaxants;I-group;I-DDI-DrugBank.d482.s14.e17
birth;O;O
control;O;O
pills;O;O
sleeping;O;O
pills;O;O
thyroid;O;O
medications;O;O
DDI-DrugBank.d355.s0;;
Androgens;B-group;B-DDI-DrugBank.d355.s0.e0
may;O;O
increase;O;O
sensitivity;O;O
to;O;O
oral;O;O
anticoagulahts;O;O
.;O;O
DDI-DrugBank.d355.s1;;
Dosage;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d355.s1.e0
may;O;O
require;O;O
reduction;O;O
in;O;O
order;O;O
to;O;O
maintain;O;O
satisfactory;O;O
therapeutic;O;O
hypoprothrombinemia;O;O
.;O;O
DDI-DrugBank.d355.s2;;
Concurrent;O;O
administration;O;O
of;O;O
oxyphenbutazone;B-drug;B-DDI-DrugBank.d355.s2.e0
and;O;O
androgens;B-group;B-DDI-DrugBank.d355.s2.e1
may;O;O
result;O;O
in;O;O
elevated;O;O
serum;O;O
levels;O;O
of;O;O
oxyphenbutazone;B-drug;B-DDI-DrugBank.d355.s2.e2
.;O;O
DDI-DrugBank.d355.s3;;
In;O;O
diabetic;O;O
patients;O;O
,;O;O
the;O;O
metabolic;O;O
effects;O;O
of;O;O
androgens;B-group;B-DDI-DrugBank.d355.s3.e0
may;O;O
decrease;O;O
blood;O;O
glucose;O;O
and;O;O
therefore;O;O
,;O;O
insulin;B-drug;B-DDI-DrugBank.d355.s3.e1
requirements;O;O
.;O;O
DDI-DrugBank.d13.s0;;
Drug;O;O
Interactions;O;O
:;O;O
Flupenthixol;B-drug;B-DDI-DrugBank.d13.s0.e0
may;O;O
interact;O;O
with;O;O
some;O;O
drugs;O;O
,;O;O
like;O;O
Monoamine;B-group;B-DDI-DrugBank.d13.s0.e1
oxidase;I-group;I-DDI-DrugBank.d13.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d13.s0.e1
(;O;O
MAOI;B-group;B-DDI-DrugBank.d13.s0.e2
);O;O
:;O;O
MAOI;B-group;B-DDI-DrugBank.d13.s0.e3
could;O;O
theoretically;O;O
affect;O;O
flupenthixol;B-drug;B-DDI-DrugBank.d13.s0.e4
pharmacodynamics;O;O
-;O;O
Arecoline;B-drug_n;B-DDI-DrugBank.d13.s0.e5
-;O;O
Eproxindine;O;O
-;O;O
Ethanol;B-drug;B-DDI-DrugBank.d13.s0.e6
:;O;O
Flupenthixol;B-drug;B-DDI-DrugBank.d13.s0.e7
and;O;O
Ethanol;B-drug;B-DDI-DrugBank.d13.s0.e8
cause;O;O
additive;O;O
CNS;O;O
depression;O;O
-;O;O
Tricyclic;B-group;B-DDI-DrugBank.d13.s0.e9
antidepressants;I-group;I-DDI-DrugBank.d13.s0.e9
:;O;O
Flupenthixol;B-drug;B-DDI-DrugBank.d13.s0.e10
increases;O;O
the;O;O
effect;O;O
of;O;O
Tricyclic;B-group;B-DDI-DrugBank.d13.s0.e11
antidepressants;I-group;I-DDI-DrugBank.d13.s0.e11
DDI-DrugBank.d529.s0;;
Antacids;I-group;I-DDI-DrugBank.d529.s0.e0
:;O;O
Administration;O;O
of;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s0.e1
to;O;O
volunteers;O;O
under;O;O
fasting;O;O
conditions;O;O
,;O;O
or;O;O
with;O;O
antacid;B-group;B-DDI-DrugBank.d529.s0.e2
suspension;O;O
yielded;O;O
similar;O;O
serum;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s0.e3
time;O;O
profiles;O;O
in;O;O
young;O;O
subjects;O;O
(;O;O
n=12;O;O
);O;O
.;O;O
DDI-DrugBank.d529.s1;;
In;O;O
geriatric;O;O
subjects;O;O
(;O;O
n=7;O;O
);O;O
there;O;O
was;O;O
a;O;O
reduction;O;O
in;O;O
the;O;O
rate;O;O
but;O;O
not;O;O
the;O;O
extent;O;O
of;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s1.e0
absorption;O;O
.;O;O
DDI-DrugBank.d529.s2;;
Anticoagulants;B-group;B-DDI-DrugBank.d529.s2.e0
:;O;O
Flurbiprofen;B-drug;B-DDI-DrugBank.d529.s2.e1
like;O;O
other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d529.s2.e2
anti;I-group;I-DDI-DrugBank.d529.s2.e2
-;I-group;I-DDI-DrugBank.d529.s2.e2
inflammatory;I-group;I-DDI-DrugBank.d529.s2.e2
drugs;I-group;I-DDI-DrugBank.d529.s2.e2
,;O;O
has;O;O
been;O;O
shown;O;O
to;O;O
affect;O;O
bleeding;O;O
parameters;O;O
in;O;O
patients;O;O
receiving;O;O
anti;B-group;B-DDI-DrugBank.d529.s2.e3
-;I-group;I-DDI-DrugBank.d529.s2.e3
coagulants;I-group;I-DDI-DrugBank.d529.s2.e3
,;O;O
and;O;O
serious;O;O
clinical;O;O
bleeding;O;O
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d529.s3;;
The;O;O
physician;O;O
should;O;O
be;O;O
cautious;O;O
when;O;O
administering;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s3.e0
to;O;O
patients;O;O
taking;O;O
anticoagulants;B-group;B-DDI-DrugBank.d529.s3.e1
.;O;O
DDI-DrugBank.d529.s4;;
Aspirin;B-brand;B-DDI-DrugBank.d529.s4.e0
:;O;O
Concurrent;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d529.s4.e1
and;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s4.e2
resulted;O;O
in;O;O
50;O;O
%;O;O
lower;O;O
serum;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s4.e3
concentrations;O;O
.;O;O
DDI-DrugBank.d529.s5;;
This;O;O
effect;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d529.s5.e0
(;O;O
which;O;O
also;O;O
lowers;O;O
serum;O;O
concentrations;O;O
of;O;O
other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d529.s5.e1
anti;I-group;I-DDI-DrugBank.d529.s5.e1
-;I-group;I-DDI-DrugBank.d529.s5.e1
inflammatory;I-group;I-DDI-DrugBank.d529.s5.e1
drugs;I-group;I-DDI-DrugBank.d529.s5.e1
given;O;O
with;O;O
it;O;O
);O;O
has;O;O
been;O;O
demonstrated;O;O
in;O;O
patients;O;O
with;O;O
rheumatoid;O;O
arthritis;O;O
(;O;O
n=;O;O
15;O;O
);O;O
as;O;O
well;O;O
as;O;O
normal;O;O
volunteers;O;O
(;O;O
n=;O;O
16;O;O
);O;O
.;O;O
DDI-DrugBank.d529.s6;;
Concurrent;O;O
use;O;O
of;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s6.e0
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d529.s6.e1
is;O;O
therefore;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d529.s7;;
Beta;B-group;B-DDI-DrugBank.d529.s7.e0
-;I-group;I-DDI-DrugBank.d529.s7.e0
adrenergic;I-group;I-DDI-DrugBank.d529.s7.e0
Blocking;I-group;I-DDI-DrugBank.d529.s7.e0
Agents;I-group;I-DDI-DrugBank.d529.s7.e0
:;O;O
The;O;O
effect;O;O
of;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s7.e1
on;O;O
blood;O;O
pressure;O;O
response;O;O
to;O;O
propranolol;B-drug;B-DDI-DrugBank.d529.s7.e2
and;O;O
atenolol;B-drug;B-DDI-DrugBank.d529.s7.e3
was;O;O
evaluated;O;O
in;O;O
men;O;O
with;O;O
mild;O;O
uncomplicated;O;O
hypertension;O;O
(;O;O
n;O;O
=;O;O
10;O;O
);O;O
.;O;O
DDI-DrugBank.d529.s8;;
Flurbiprofen;B-drug;B-DDI-DrugBank.d529.s8.e0
pretreatment;O;O
attenuated;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d529.s8.e1
but;O;O
not;O;O
atenolol;B-drug;B-DDI-DrugBank.d529.s8.e2
.;O;O
DDI-DrugBank.d529.s9;;
Flurbiprofen;B-drug;B-DDI-DrugBank.d529.s9.e0
did;O;O
not;O;O
appear;O;O
to;O;O
affect;O;O
the;O;O
beta;O;O
-;O;O
blocker;O;O
-;O;O
mediated;O;O
reduction;O;O
in;O;O
heart;O;O
rate;O;O
.;O;O
DDI-DrugBank.d529.s10;;
Flurbiprofen;B-drug;B-DDI-DrugBank.d529.s10.e0
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetic;O;O
profile;O;O
of;O;O
either;O;O
drug;O;O
,;O;O
and;O;O
the;O;O
mechanism;O;O
under;O;O
lying;O;O
the;O;O
interference;O;O
with;O;O
propranolols;B-drug;B-DDI-DrugBank.d529.s10.e1
hypotensive;O;O
effect;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d529.s11;;
Patients;O;O
taking;O;O
both;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s11.e0
and;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d529.s11.e1
-;I-group;I-DDI-DrugBank.d529.s11.e1
blocker;I-group;I-DDI-DrugBank.d529.s11.e1
should;O;O
be;O;O
monitored;O;O
to;O;O
ensure;O;O
that;O;O
a;O;O
satisfactory;O;O
hypotensive;O;O
effect;O;O
is;O;O
achieved;O;O
.;O;O
DDI-DrugBank.d529.s12;;
Cimetidine;B-drug;B-DDI-DrugBank.d529.s12.e0
,;O;O
Ranitidine;B-drug;B-DDI-DrugBank.d529.s12.e1
:;O;O
In;O;O
normal;O;O
volunteers;O;O
(;O;O
n=9;O;O
);O;O
,;O;O
pretreatment;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d529.s12.e2
or;O;O
ranitidine;B-drug;B-DDI-DrugBank.d529.s12.e3
did;O;O
not;O;O
affect;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s12.e4
pharmacokinetics;O;O
except;O;O
that;O;O
a;O;O
small;O;O
(;O;O
13;O;O
%;O;O
);O;O
but;O;O
statistically;O;O
significant;O;O
increase;O;O
in;O;O
the;O;O
area;O;O
under;O;O
the;O;O
serum;O;O
concentration;O;O
curve;O;O
of;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s12.e5
resulted;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d529.s12.e6
.;O;O
DDI-DrugBank.d529.s13;;
Digoxin;B-drug;B-DDI-DrugBank.d529.s13.e0
:;O;O
Studies;O;O
of;O;O
concomitant;O;O
administration;O;O
of;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s13.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d529.s13.e2
to;O;O
healthy;O;O
men;O;O
(;O;O
n=;O;O
14;O;O
);O;O
did;O;O
not;O;O
show;O;O
a;O;O
change;O;O
in;O;O
the;O;O
steady;O;O
state;O;O
serum;O;O
levels;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d529.s14;;
Diuretics;B-group;B-DDI-DrugBank.d529.s14.e0
:;O;O
Studies;O;O
in;O;O
normal;O;O
volunteers;O;O
have;O;O
shown;O;O
that;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s14.e1
like;O;O
other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d529.s14.e2
anti;I-group;I-DDI-DrugBank.d529.s14.e2
-;I-group;I-DDI-DrugBank.d529.s14.e2
inflammatory;I-group;I-DDI-DrugBank.d529.s14.e2
drugs;I-group;I-DDI-DrugBank.d529.s14.e2
,;O;O
can;O;O
interfere;O;O
with;O;O
the;O;O
effects;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d529.s14.e3
.;O;O
DDI-DrugBank.d529.s15;;
Although;O;O
results;O;O
have;O;O
varied;O;O
from;O;O
study;O;O
to;O;O
study;O;O
,;O;O
effects;O;O
have;O;O
been;O;O
shown;O;O
on;O;O
furosemide;B-drug;B-DDI-DrugBank.d529.s15.e0
-;O;O
stimulated;O;O
diuresis;O;O
,;O;O
natriuresis;O;O
,;O;O
and;O;O
kaliuresis;O;O
.;O;O
DDI-DrugBank.d529.s16;;
Other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d529.s16.e0
anti;I-group;I-DDI-DrugBank.d529.s16.e0
-;I-group;I-DDI-DrugBank.d529.s16.e0
inflammatory;I-group;I-DDI-DrugBank.d529.s16.e0
drugs;I-group;I-DDI-DrugBank.d529.s16.e0
that;O;O
inhibit;O;O
prostaglandin;O;O
synthesis;O;O
have;O;O
been;O;O
shown;O;O
to;O;O
interfere;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d529.s16.e1
diuretics;I-group;I-DDI-DrugBank.d529.s16.e1
in;O;O
some;O;O
studies;O;O
and;O;O
with;O;O
potassium;B-group;B-DDI-DrugBank.d529.s16.e2
-;I-group;I-DDI-DrugBank.d529.s16.e2
sparing;I-group;I-DDI-DrugBank.d529.s16.e2
diuretics;I-group;I-DDI-DrugBank.d529.s16.e2
.;O;O
DDI-DrugBank.d529.s17;;
Patients;O;O
receiving;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s17.e0
and;O;O
furosemide;B-drug;B-DDI-DrugBank.d529.s17.e1
or;O;O
other;O;O
diuretics;B-group;B-DDI-DrugBank.d529.s17.e2
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
effect;O;O
is;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d529.s18;;
Oral;O;O
Hypoglycemic;B-group;B-DDI-DrugBank.d529.s18.e0
Agents;I-group;I-DDI-DrugBank.d529.s18.e0
:;O;O
In;O;O
one;O;O
study;O;O
,;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s18.e1
was;O;O
given;O;O
to;O;O
adult;O;O
diabetics;O;O
who;O;O
were;O;O
already;O;O
receiving;O;O
glyburide;B-drug;B-DDI-DrugBank.d529.s18.e2
(;O;O
n=4;O;O
);O;O
,;O;O
metformin;B-drug;B-DDI-DrugBank.d529.s18.e3
(;O;O
n=2;O;O
);O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d529.s18.e4
with;O;O
phenformin;B-drug;B-DDI-DrugBank.d529.s18.e5
(;O;O
n=;O;O
3;O;O
);O;O
or;O;O
glyburide;B-drug;B-DDI-DrugBank.d529.s18.e6
with;O;O
phenformin;B-drug;B-DDI-DrugBank.d529.s18.e7
(;O;O
n=6;O;O
);O;O
.;O;O
DDI-DrugBank.d529.s19;;
Although;O;O
there;O;O
was;O;O
a;O;O
slight;O;O
reduction;O;O
in;O;O
blood;O;O
sugar;O;O
concentrations;O;O
during;O;O
concomitant;O;O
administration;O;O
of;O;O
flurbiprofen;B-drug;B-DDI-DrugBank.d529.s19.e0
and;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d529.s19.e1
agents;I-group;I-DDI-DrugBank.d529.s19.e1
,;O;O
there;O;O
were;O;O
no;O;O
signs;O;O
or;O;O
symptoms;O;O
of;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d442.s0;;
Increases;O;O
in;O;O
prothrombin;O;O
time;O;O
have;O;O
been;O;O
noted;O;O
in;O;O
patients;O;O
receiving;O;O
long;O;O
-;O;O
term;O;O
warfarin;B-drug;B-DDI-DrugBank.d442.s0.e0
therapy;O;O
after;O;O
flutamide;B-drug;B-DDI-DrugBank.d442.s0.e1
was;O;O
initiated;O;O
.;O;O
DDI-DrugBank.d442.s1;;
Therefore;O;O
,;O;O
close;O;O
monitoring;O;O
of;O;O
prothrombin;O;O
time;O;O
is;O;O
recommended;O;O
and;O;O
adjustment;O;O
of;O;O
the;O;O
anticoagulant;B-group;B-DDI-DrugBank.d442.s1.e0
dose;O;O
may;O;O
be;O;O
necessary;O;O
when;O;O
EULEXIN;B-brand;B-DDI-DrugBank.d442.s1.e1
Capsules;O;O
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d442.s1.e2
.;O;O
DDI-DrugBank.d76.s0;;
Potential;O;O
for;O;O
Interaction;O;O
with;O;O
Monoamine;B-group;B-DDI-DrugBank.d76.s0.e0
Oxidase;I-group;I-DDI-DrugBank.d76.s0.e0
Inhibitors;I-group;I-DDI-DrugBank.d76.s0.e0
DDI-DrugBank.d76.s1;;
In;O;O
patients;O;O
receiving;O;O
another;O;O
serotonin;B-group;B-DDI-DrugBank.d76.s1.e0
reuptake;I-group;I-DDI-DrugBank.d76.s1.e0
inhibitor;I-group;I-DDI-DrugBank.d76.s1.e0
drug;I-group;I-DDI-DrugBank.d76.s1.e0
in;O;O
combination;O;O
with;O;O
monoamine;B-group;B-DDI-DrugBank.d76.s1.e1
oxidase;I-group;I-DDI-DrugBank.d76.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d76.s1.e1
(;O;O
MAOI;B-group;B-DDI-DrugBank.d76.s1.e2
);O;O
,;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
serious;O;O
,;O;O
sometimes;O;O
fatal;O;O
,;O;O
reactions;O;O
including;O;O
hyperthermia;O;O
,;O;O
rigidity;O;O
,;O;O
myoclonus;O;O
,;O;O
autonomic;O;O
instability;O;O
with;O;O
possible;O;O
rapid;O;O
fluctuations;O;O
of;O;O
vital;O;O
signs;O;O
,;O;O
and;O;O
mental;O;O
status;O;O
changes;O;O
that;O;O
include;O;O
extreme;O;O
agitation;O;O
progressing;O;O
to;O;O
delirium;O;O
and;O;O
coma;O;O
.;O;O
DDI-DrugBank.d76.s2;;
These;O;O
reactions;O;O
have;O;O
also;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
who;O;O
have;O;O
discontinued;O;O
that;O;O
drug;O;O
and;O;O
have;O;O
been;O;O
started;O;O
on;O;O
a;O;O
MAOI;B-group;B-DDI-DrugBank.d76.s2.e0
.;O;O
DDI-DrugBank.d76.s3;;
Some;O;O
cases;O;O
presented;O;O
with;O;O
features;O;O
resembling;O;O
neuroleptic;O;O
malignant;O;O
syndrome;O;O
.;O;O
DDI-DrugBank.d76.s4;;
Therefore;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s4.e0
Tablets;O;O
not;O;O
be;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
MAOIs;B-group;B-DDI-DrugBank.d76.s4.e1
,;O;O
or;O;O
within;O;O
14;O;O
days;O;O
of;O;O
discontinuing;O;O
treatment;O;O
with;O;O
a;O;O
MAOI;B-group;B-DDI-DrugBank.d76.s4.e2
.;O;O
DDI-DrugBank.d76.s5;;
After;O;O
stopping;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s5.e0
Tablets;O;O
,;O;O
at;O;O
least;O;O
2;O;O
weeks;O;O
should;O;O
be;O;O
allowed;O;O
before;O;O
starting;O;O
a;O;O
MAOI;B-group;B-DDI-DrugBank.d76.s5.e1
.;O;O
DDI-DrugBank.d76.s6;;
Potential;O;O
Terfenadine;B-drug;B-DDI-DrugBank.d76.s6.e0
,;O;O
Astemizole;B-drug;B-DDI-DrugBank.d76.s6.e1
,;O;O
and;O;O
Cisapride;B-drug;B-DDI-DrugBank.d76.s6.e2
Interactions;O;O
DDI-DrugBank.d76.s7;;
Terfenadine;B-drug;B-DDI-DrugBank.d76.s7.e0
,;O;O
astemizole;B-drug;B-DDI-DrugBank.d76.s7.e1
and;O;O
cisapride;B-drug;B-DDI-DrugBank.d76.s7.e2
are;O;O
all;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450IIIA4;O;O
isozyme;O;O
,;O;O
and;O;O
it;O;O
has;O;O
been;O;O
demonstrated;O;O
that;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d76.s7.e3
,;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
IIIA4;O;O
,;O;O
blocks;O;O
the;O;O
metabolism;O;O
of;O;O
these;O;O
drugs;O;O
,;O;O
resulting;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
parent;O;O
drug;O;O
.;O;O
DDI-DrugBank.d76.s8;;
Increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d76.s8.e0
,;O;O
astemizole;B-drug;B-DDI-DrugBank.d76.s8.e1
,;O;O
and;O;O
cisapride;B-drug;B-DDI-DrugBank.d76.s8.e2
cause;O;O
QT;O;O
prolongation;O;O
and;O;O
have;O;O
been;O;O
associated;O;O
with;O;O
torsades;O;O
de;O;O
pointes;O;O
-;O;O
type;O;O
ventricular;O;O
tachycardia;O;O
,;O;O
sometimes;O;O
fatal;O;O
.;O;O
DDI-DrugBank.d76.s9;;
As;O;O
noted;O;O
below;O;O
,;O;O
a;O;O
sub;O;O
-;O;O
for;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s9.e0
in;O;O
combination;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s9.e1
,;O;O
a;O;O
drug;O;O
that;O;O
is;O;O
known;O;O
to;O;O
be;O;O
metabolized;O;O
by;O;O
the;O;O
IIIA4;O;O
isozyme;O;O
.;O;O
DDI-DrugBank.d76.s10;;
Although;O;O
it;O;O
has;O;O
not;O;O
been;O;O
definitively;O;O
demonstrated;O;O
that;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s10.e0
is;O;O
a;O;O
potent;O;O
IIIA4;O;O
inhibitor;O;O
,;O;O
it;O;O
is;O;O
likely;O;O
to;O;O
be;O;O
,;O;O
given;O;O
the;O;O
substantial;O;O
interaction;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s10.e1
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s10.e2
.;O;O
DDI-DrugBank.d76.s11;;
Consequently;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s11.e0
not;O;O
be;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
either;O;O
terbinafine;B-drug;B-DDI-DrugBank.d76.s11.e1
,;O;O
astemizole;B-drug;B-DDI-DrugBank.d76.s11.e2
,;O;O
or;O;O
cisapride;B-drug;B-DDI-DrugBank.d76.s11.e3
.;O;O
DDI-DrugBank.d76.s12;;
Other;O;O
Potentially;O;O
Important;O;O
Drug;O;O
Interactions;O;O
:;O;O
Benzodiazepines;B-group;B-DDI-DrugBank.d76.s12.e0
:;O;O
Benzodiazepines;B-group;B-DDI-DrugBank.d76.s12.e1
metabolized;O;O
by;O;O
hepatic;O;O
oxidation;O;O
(;O;O
e.g.;O;O
,;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s12.e2
,;O;O
midazolam;B-drug;B-DDI-DrugBank.d76.s12.e3
,;O;O
triazolam;B-drug;B-DDI-DrugBank.d76.s12.e4
elc;O;O
.;O;O
);O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
because;O;O
the;O;O
clearance;O;O
of;O;O
these;O;O
drugs;O;O
is;O;O
likely;O;O
to;O;O
be;O;O
reduced;O;O
by;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s12.e5
.;O;O
DDI-DrugBank.d76.s13;;
The;O;O
clearance;O;O
of;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d76.s13.e0
metabolized;O;O
by;O;O
glucuronidation;O;O
(;O;O
e.;O;O
g.;O;O
,;O;O
lorazepam;B-drug;B-DDI-DrugBank.d76.s13.e1
,;O;O
oxazepam;B-drug;B-DDI-DrugBank.d76.s13.e2
,;O;O
temazepam;B-drug;B-DDI-DrugBank.d76.s13.e3
);O;O
is;O;O
unlikely;O;O
to;O;O
be;O;O
affected;O;O
by;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s13.e4
.;O;O
DDI-DrugBank.d76.s14;;
Alprazolam;B-drug;B-DDI-DrugBank.d76.s14.e0
:;O;O
When;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s14.e1
maleate;I-drug;I-DDI-DrugBank.d76.s14.e1
(;O;O
100;O;O
mg;O;O
qd;O;O
);O;O
and;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s14.e2
(;O;O
1;O;O
mg;O;O
q.d;O;O
.;O;O
were;O;O
co;O;O
-;O;O
administered;O;O
to;O;O
steady;O;O
state;O;O
,;O;O
plasma;O;O
concentration;O;O
and;O;O
other;O;O
pharmacokinetics;O;O
parameters;O;O
(;O;O
AUC;O;O
,;O;O
Cmax;O;O
,;O;O
T1;O;O
/;O;O
2;O;O
,;O;O
);O;O
of;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s14.e3
were;O;O
approximately;O;O
twice;O;O
those;O;O
observed;O;O
when;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s14.e4
was;O;O
administered;O;O
alone;O;O
,;O;O
DDI-DrugBank.d76.s15;;
oral;O;O
clearance;O;O
was;O;O
reduced;O;O
by;O;O
about;O;O
50;O;O
%;O;O
.;O;O
DDI-DrugBank.d76.s16;;
The;O;O
elevated;O;O
plasma;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s16.e0
concentrations;O;O
resulted;O;O
in;O;O
decreased;O;O
psychomotor;O;O
performance;O;O
and;O;O
memory;O;O
.;O;O
DDI-DrugBank.d76.s17;;
This;O;O
interaction;O;O
,;O;O
which;O;O
has;O;O
not;O;O
been;O;O
investigated;O;O
using;O;O
higher;O;O
doses;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s17.e0
,;O;O
may;O;O
be;O;O
more;O;O
pronounced;O;O
if;O;O
a;O;O
300;O;O
mg;O;O
daily;O;O
dose;O;O
is;O;O
co;O;O
-;O;O
administered;O;O
,;O;O
particularly;O;O
since;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s17.e1
exhibits;O;O
non;O;O
-;O;O
linear;O;O
pharmacokinetics;O;O
over;O;O
the;O;O
dosage;O;O
range;O;O
100;O;O
-;O;O
300;O;O
mg;O;O
.;O;O
If;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s17.e2
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s17.e3
Tablets;O;O
,;O;O
the;O;O
initial;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s17.e4
dosage;O;O
should;O;O
be;O;O
at;O;O
least;O;O
halved;O;O
and;O;O
titration;O;O
to;O;O
the;O;O
lowest;O;O
effective;O;O
dose;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d76.s18;;
No;O;O
dosage;O;O
adjustment;O;O
is;O;O
required;O;O
for;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s18.e0
Tablets;O;O
.;O;O
DDI-DrugBank.d76.s19;;
Diazepam;B-drug;B-DDI-DrugBank.d76.s19.e0
:;O;O
The;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s19.e1
Tablets;O;O
and;O;O
diazepam;B-drug;B-DDI-DrugBank.d76.s19.e2
is;O;O
generally;O;O
not;O;O
advisable;O;O
.;O;O
DDI-DrugBank.d76.s20;;
Because;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s20.e0
reduces;O;O
the;O;O
clearance;O;O
of;O;O
both;O;O
diazepam;B-drug;B-DDI-DrugBank.d76.s20.e1
and;O;O
its;O;O
active;O;O
metabolite;O;O
,;O;O
N;B-drug_n;B-DDI-DrugBank.d76.s20.e2
-;I-drug_n;I-DDI-DrugBank.d76.s20.e2
desmethyldiazepam;I-drug_n;I-DDI-DrugBank.d76.s20.e2
,;O;O
there;O;O
is;O;O
a;O;O
strong;O;O
likelihood;O;O
of;O;O
substantial;O;O
accumulation;O;O
of;O;O
both;O;O
species;O;O
during;O;O
chronic;O;O
co;O;O
-;O;O
administration;O;O
.;O;O
DDI-DrugBank.d76.s21;;
Evidence;O;O
supporting;O;O
the;O;O
conclusion;O;O
that;O;O
it;O;O
is;O;O
inadvisable;O;O
to;O;O
co;O;O
-;O;O
administer;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s21.e0
and;O;O
diazepam;B-drug;B-DDI-DrugBank.d76.s21.e1
is;O;O
derived;O;O
from;O;O
a;O;O
study;O;O
in;O;O
which;O;O
healthy;O;O
volunteers;O;O
taking;O;O
150;O;O
mg;O;O
/;O;O
day;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s21.e2
were;O;O
administered;O;O
a;O;O
single;O;O
oral;O;O
dose;O;O
of;O;O
10;O;O
mg;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d76.s21.e3
.;O;O
DDI-DrugBank.d76.s22;;
In;O;O
these;O;O
subjects;O;O
(;O;O
R=;O;O
B;O;O
);O;O
,;O;O
the;O;O
clearance;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d76.s22.e0
was;O;O
reduced;O;O
by;O;O
65;O;O
%;O;O
and;O;O
that;O;O
of;O;O
N;B-drug_n;B-DDI-DrugBank.d76.s22.e1
-;I-drug_n;I-DDI-DrugBank.d76.s22.e1
desmethyldiazepam;I-drug_n;I-DDI-DrugBank.d76.s22.e1
to;O;O
a;O;O
level;O;O
that;O;O
was;O;O
too;O;O
low;O;O
to;O;O
measure;O;O
over;O;O
the;O;O
course;O;O
of;O;O
the;O;O
2;O;O
week;O;O
long;O;O
study;O;O
.;O;O
DDI-DrugBank.d76.s23;;
It;O;O
is;O;O
likely;O;O
that;O;O
experience;O;O
significantly;O;O
underestimates;O;O
the;O;O
degree;O;O
of;O;O
accumulation;O;O
that;O;O
might;O;O
occur;O;O
with;O;O
repealed;O;O
diazepam;B-drug;B-DDI-DrugBank.d76.s23.e0
administration;O;O
.;O;O
DDI-DrugBank.d76.s24;;
Moreover;O;O
,;O;O
as;O;O
noted;O;O
with;O;O
alprazolam;B-drug;B-DDI-DrugBank.d76.s24.e0
,;O;O
the;O;O
effect;O;O
of;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s24.e1
may;O;O
even;O;O
be;O;O
more;O;O
pronounced;O;O
when;O;O
it;O;O
is;O;O
administered;O;O
at;O;O
higher;O;O
doses;O;O
.;O;O
DDI-DrugBank.d76.s25;;
Accordingly;O;O
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d76.s25.e0
and;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s25.e1
should;O;O
not;O;O
ordinarily;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d76.s26;;
Theophylline;B-drug;B-DDI-DrugBank.d76.s26.e0
:;O;O
The;O;O
effect;O;O
of;O;O
steady;O;O
-;O;O
state;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s26.e1
l50;O;O
mg;O;O
bid;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
Theophylline;B-drug;B-DDI-DrugBank.d76.s26.e2
(;O;O
375;O;O
mg;O;O
);O;O
as;O;O
442;O;O
mg;O;O
aminophylline;B-drug;B-DDI-DrugBank.d76.s26.e3
was;O;O
evaluated;O;O
in;O;O
12;O;O
healthy;O;O
non;O;O
-;O;O
smoking;O;O
,;O;O
male;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d76.s27;;
The;O;O
clearance;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d76.s27.e0
was;O;O
decreased;O;O
approximately;O;O
3;O;O
-;O;O
fold;O;O
.;O;O
DDI-DrugBank.d76.s28;;
Therefore;O;O
,;O;O
if;O;O
theophylline;B-drug;B-DDI-DrugBank.d76.s28.e0
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s28.e1
maleate;I-drug;I-DDI-DrugBank.d76.s28.e1
,;O;O
its;O;O
dose;O;O
should;O;O
be;O;O
reduced;O;O
to;O;O
one;O;O
third;O;O
of;O;O
the;O;O
usual;O;O
daily;O;O
maintenance;O;O
dose;O;O
and;O;O
plasma;O;O
concentrations;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d76.s28.e2
should;O;O
to;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d76.s29;;
No;O;O
dosage;O;O
adjustment;O;O
is;O;O
required;O;O
for;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s29.e0
Tablets;O;O
.;O;O
DDI-DrugBank.d76.s30;;
Warfarin;B-drug;B-DDI-DrugBank.d76.s30.e0
:;O;O
When;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d76.s30.e1
maleate;I-drug;I-DDI-DrugBank.d76.s30.e1
(;O;O
50;O;O
mg;O;O
tid;O;O
);O;O
was;O;O
administered;O;O
concomitantly;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d76.s30.e2
for;O;O
two;O;O
weeks;O;O
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d76.s30.e3
plasma;O;O
concentrations;O;O
increased;O;O
by;O;O
98;O;O
%;O;O
and;O;O
prothrombin;O;O
times;O;O
were;O;O
prolonged;O;O
.;O;O
DDI-DrugBank.d76.s31;;
Thus;O;O
patients;O;O
receiving;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d76.s31.e0
and;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s31.e1
Tablets;O;O
should;O;O
have;O;O
their;O;O
prothrombin;O;O
time;O;O
monitored;O;O
and;O;O
their;O;O
anticoagulant;B-group;B-DDI-DrugBank.d76.s31.e2
dose;O;O
adjusted;O;O
accordingly;O;O
.;O;O
DDI-DrugBank.d76.s32;;
No;O;O
dosage;O;O
adjustment;O;O
is;O;O
required;O;O
for;O;O
Fluvoxamine;B-drug;B-DDI-DrugBank.d76.s32.e0
Tablets;O;O
.;O;O
DDI-DrugBank.d425.s0;;
Medications;O;O
that;O;O
interfere;O;O
with;O;O
your;O;O
bodys;O;O
ability;O;O
to;O;O
use;O;O
folate;O;O
may;O;O
also;O;O
increase;O;O
the;O;O
need;O;O
for;O;O
this;O;O
vitamin;B-group;B-DDI-DrugBank.d425.s0.e0
.;O;O
DDI-DrugBank.d425.s1;;
Medications;O;O
can;O;O
interfere;O;O
with;O;O
folate;O;O
utilization;O;O
,;O;O
including;O;O
:;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d425.s1.e0
medications;I-group;I-DDI-DrugBank.d425.s1.e0
(;O;O
such;O;O
as;O;O
phenytoin;B-drug;B-DDI-DrugBank.d425.s1.e1
,;O;O
and;O;O
primidone;B-drug;B-DDI-DrugBank.d425.s1.e2
);O;O
metformin;B-drug;B-DDI-DrugBank.d425.s1.e3
(;O;O
sometimes;O;O
prescribed;O;O
to;O;O
control;O;O
blood;O;O
sugar;O;O
in;O;O
type;O;O
2;O;O
diabetes;O;O
);O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d425.s1.e4
(;O;O
used;O;O
to;O;O
control;O;O
inflammation;O;O
associated;O;O
with;O;O
Crohns;O;O
disease;O;O
and;O;O
ulcerative;O;O
colitis;O;O
);O;O
triamterene;B-drug;B-DDI-DrugBank.d425.s1.e5
(;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d425.s1.e6
);O;O
Methotrexate;B-drug;B-DDI-DrugBank.d425.s1.e7
There;O;O
has;O;O
been;O;O
concern;O;O
about;O;O
the;O;O
interaction;O;O
between;O;O
vitamin;B-drug;B-DDI-DrugBank.d425.s1.e8
B12;I-drug;I-DDI-DrugBank.d425.s1.e8
and;O;O
folic;B-drug;B-DDI-DrugBank.d425.s1.e9
acid;I-drug;I-DDI-DrugBank.d425.s1.e9
.;O;O
DDI-DrugBank.d425.s2;;
Folic;B-drug;B-DDI-DrugBank.d425.s2.e0
acid;I-drug;I-DDI-DrugBank.d425.s2.e0
supplements;O;O
can;O;O
correct;O;O
the;O;O
anemia;O;O
associated;O;O
with;O;O
vitamin;O;O
B12;O;O
deficiency;O;O
.;O;O
DDI-DrugBank.d425.s3;;
Unfortunately;O;O
,;O;O
folic;B-drug;B-DDI-DrugBank.d425.s3.e0
acid;I-drug;I-DDI-DrugBank.d425.s3.e0
will;O;O
not;O;O
correct;O;O
changes;O;O
in;O;O
the;O;O
nervous;O;O
system;O;O
that;O;O
result;O;O
from;O;O
vitamin;O;O
B12;O;O
deficiency;O;O
.;O;O
DDI-DrugBank.d425.s4;;
Permanent;O;O
nerve;O;O
damage;O;O
could;O;O
theoretically;O;O
occur;O;O
if;O;O
vitamin;O;O
B12;O;O
deficiency;O;O
is;O;O
not;O;O
treated;O;O
.;O;O
DDI-DrugBank.d425.s5;;
Therefore;O;O
,;O;O
intake;O;O
of;O;O
supplemental;O;O
folic;B-drug;B-DDI-DrugBank.d425.s5.e0
acid;I-drug;I-DDI-DrugBank.d425.s5.e0
should;O;O
not;O;O
exceed;O;O
1000;O;O
micrograms;O;O
(;O;O
g;O;O
,;O;O
sometimes;O;O
mcg;O;O
);O;O
per;O;O
day;O;O
to;O;O
prevent;O;O
folic;B-drug;B-DDI-DrugBank.d425.s5.e1
acid;I-drug;I-DDI-DrugBank.d425.s5.e1
from;O;O
masking;O;O
symptoms;O;O
of;O;O
vitamin;O;O
B12;O;O
deficiency;O;O
.;O;O
DDI-DrugBank.d425.s6;;
It;O;O
is;O;O
important;O;O
for;O;O
older;O;O
adults;O;O
to;O;O
be;O;O
aware;O;O
of;O;O
the;O;O
relationship;O;O
between;O;O
folic;B-drug;B-DDI-DrugBank.d425.s6.e0
acid;I-drug;I-DDI-DrugBank.d425.s6.e0
and;O;O
vitamin;B-drug;B-DDI-DrugBank.d425.s6.e1
B12;I-drug;I-DDI-DrugBank.d425.s6.e1
because;O;O
they;O;O
are;O;O
at;O;O
greater;O;O
risk;O;O
of;O;O
having;O;O
a;O;O
vitamin;O;O
B12;O;O
deficiency;O;O
.;O;O
DDI-DrugBank.d425.s7;;
If;O;O
you;O;O
are;O;O
50;O;O
years;O;O
of;O;O
age;O;O
or;O;O
older;O;O
,;O;O
ask;O;O
your;O;O
physician;O;O
to;O;O
check;O;O
your;O;O
B12;O;O
status;O;O
before;O;O
you;O;O
take;O;O
a;O;O
supplement;O;O
that;O;O
contains;O;O
folic;B-drug;B-DDI-DrugBank.d425.s7.e0
acid;I-drug;I-DDI-DrugBank.d425.s7.e0
.;O;O
DDI-DrugBank.d402.s0;;
No;O;O
drug;O;O
/;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d228.s0;;
Oral;O;O
doses;O;O
of;O;O
Antizol;B-brand;B-DDI-DrugBank.d228.s0.e0
(;O;O
10;O;O
-;O;O
20;O;O
mg;O;O
/;O;O
kg;O;O
);O;O
,;O;O
via;O;O
alcohol;O;O
dehydrogenase;O;O
inhibition;O;O
,;O;O
significantly;O;O
reduced;O;O
the;O;O
rate;O;O
of;O;O
elimination;O;O
of;O;O
ethanol;B-drug;B-DDI-DrugBank.d228.s0.e1
(;O;O
by;O;O
approximately;O;O
40;O;O
%;O;O
);O;O
given;O;O
to;O;O
healthy;O;O
volunteers;O;O
in;O;O
moderate;O;O
doses;O;O
.;O;O
DDI-DrugBank.d228.s1;;
Similarly;O;O
,;O;O
ethanol;B-drug;B-DDI-DrugBank.d228.s1.e0
decreased;O;O
the;O;O
rate;O;O
of;O;O
elimination;O;O
of;O;O
Antizol;B-brand;B-DDI-DrugBank.d228.s1.e1
(;O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
);O;O
by;O;O
the;O;O
same;O;O
mechanism;O;O
.;O;O
DDI-DrugBank.d228.s2;;
Reciprocal;O;O
interactions;O;O
may;O;O
occur;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
Antizol;B-brand;B-DDI-DrugBank.d228.s2.e0
and;O;O
drugs;O;O
that;O;O
increase;O;O
or;O;O
inhibit;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
(;O;O
e.g.;O;O
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d228.s2.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d228.s2.e2
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d228.s2.e3
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d228.s2.e4
);O;O
,;O;O
though;O;O
this;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
DDI-DrugBank.d228.s3;;
.;O;O
DDI-DrugBank.d228.s4;;
DDI-DrugBank.d15.s0;;
In;O;O
clinical;O;O
studies;O;O
performed;O;O
with;O;O
Fondaparinux;B-drug;B-DDI-DrugBank.d15.s0.e0
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d15.s0.e1
(;O;O
warfarin;B-drug;B-DDI-DrugBank.d15.s0.e2
);O;O
,;O;O
platelet;B-group;B-DDI-DrugBank.d15.s0.e3
inhibitors;I-group;I-DDI-DrugBank.d15.s0.e3
(;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d15.s0.e4
acid;I-drug;I-DDI-DrugBank.d15.s0.e4
);O;O
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d15.s0.e5
(;O;O
piroxicam;B-drug;B-DDI-DrugBank.d15.s0.e6
);O;O
,;O;O
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d15.s0.e7
did;O;O
not;O;O
significantly;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
/;O;O
pharmacodynamics;O;O
of;O;O
fondaparinux;B-drug;B-DDI-DrugBank.d15.s0.e8
sodium;I-drug;I-DDI-DrugBank.d15.s0.e8
.;O;O
DDI-DrugBank.d15.s1;;
In;O;O
addition;O;O
,;O;O
Fondaparinux;B-drug;B-DDI-DrugBank.d15.s1.e0
neither;O;O
influenced;O;O
the;O;O
pharmacodynamics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d15.s1.e1
,;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d15.s1.e2
acid;I-drug;I-DDI-DrugBank.d15.s1.e2
,;O;O
piroxicam;B-drug;B-DDI-DrugBank.d15.s1.e3
,;O;O
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d15.s1.e4
,;O;O
nor;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d15.s1.e5
at;O;O
steady;O;O
state;O;O
.;O;O
DDI-DrugBank.d15.s2;;
Agents;O;O
that;O;O
may;O;O
enhance;O;O
the;O;O
risk;O;O
of;O;O
hemorrhage;O;O
should;O;O
be;O;O
discontinued;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
Fondaparinux;B-drug;B-DDI-DrugBank.d15.s2.e0
therapy;O;O
.;O;O
DDI-DrugBank.d15.s3;;
If;O;O
co;O;O
-;O;O
administration;O;O
is;O;O
essential;O;O
,;O;O
close;O;O
monitoring;O;O
may;O;O
be;O;O
appropriate;O;O
.;O;O
DDI-DrugBank.d15.s4;;
In;O;O
an;O;O
in;O;O
vitro;O;O
study;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
,;O;O
inhibition;O;O
of;O;O
CYP2A6;O;O
hydroxylation;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d15.s4.e0
by;O;O
fondaparinux;B-drug;B-DDI-DrugBank.d15.s4.e1
(;O;O
200;O;O
m;O;O
m;O;O
M;O;O
i.e.;O;O
,;O;O
350;O;O
mg;O;O
/;O;O
L;O;O
);O;O
was;O;O
17;O;O
-;O;O
28;O;O
%;O;O
.;O;O
DDI-DrugBank.d15.s5;;
Inhibition;O;O
of;O;O
the;O;O
other;O;O
isozymes;O;O
evaluated;O;O
(;O;O
CYPs;O;O
2A1;O;O
,;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
2D6;O;O
,;O;O
3A4;O;O
,;O;O
and;O;O
3E1;O;O
);O;O
was;O;O
0;O;O
-;O;O
16;O;O
%;O;O
.;O;O
DDI-DrugBank.d15.s6;;
Since;O;O
fondaparinux;B-drug;B-DDI-DrugBank.d15.s6.e0
does;O;O
not;O;O
markedly;O;O
inhibit;O;O
CYP450s;O;O
(;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP2E1;O;O
,;O;O
or;O;O
CYP3A4;O;O
);O;O
in;O;O
vitro;O;O
,;O;O
fondaparinux;B-drug;B-DDI-DrugBank.d15.s6.e1
sodium;I-drug;I-DDI-DrugBank.d15.s6.e1
is;O;O
not;O;O
expected;O;O
to;O;O
significantly;O;O
interact;O;O
with;O;O
other;O;O
drugs;O;O
in;O;O
vivo;O;O
by;O;O
inhibition;O;O
of;O;O
metabolism;O;O
mediated;O;O
by;O;O
these;O;O
isozymes;O;O
.;O;O
DDI-DrugBank.d15.s7;;
Since;O;O
fondaparinux;B-drug;B-DDI-DrugBank.d15.s7.e0
sodium;I-drug;I-DDI-DrugBank.d15.s7.e0
does;O;O
not;O;O
bind;O;O
significantly;O;O
to;O;O
plasma;O;O
proteins;O;O
other;O;O
than;O;O
ATIII;O;O
,;O;O
no;O;O
drug;O;O
interactions;O;O
by;O;O
protein;O;O
-;O;O
binding;O;O
displacement;O;O
are;O;O
expected;O;O
.;O;O
DDI-DrugBank.d103.s0;;
Short;B-group;B-DDI-DrugBank.d103.s0.e0
-;I-group;I-DDI-DrugBank.d103.s0.e0
Acting;I-group;I-DDI-DrugBank.d103.s0.e0
beta2;I-group;I-DDI-DrugBank.d103.s0.e0
-;I-group;I-DDI-DrugBank.d103.s0.e0
agonists;I-group;I-DDI-DrugBank.d103.s0.e0
:;O;O
Aerosol;O;O
bronchodilators;B-group;B-DDI-DrugBank.d103.s0.e1
of;O;O
the;O;O
short;O;O
-;O;O
acting;O;O
adrenergic;O;O
stimulant;O;O
type;O;O
may;O;O
be;O;O
used;O;O
for;O;O
relief;O;O
of;O;O
breakthrough;O;O
symptoms;O;O
while;O;O
using;O;O
formoterol;B-drug;B-DDI-DrugBank.d103.s0.e2
.;O;O
DDI-DrugBank.d103.s1;;
However;O;O
,;O;O
increasing;O;O
use;O;O
of;O;O
such;O;O
preparations;O;O
to;O;O
control;O;O
symptoms;O;O
indicates;O;O
deterioration;O;O
of;O;O
asthma;O;O
control;O;O
and;O;O
the;O;O
need;O;O
to;O;O
reassess;O;O
the;O;O
patient;O;O
s;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d103.s2;;
Concomitant;O;O
administration;O;O
of;O;O
other;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d103.s2.e0
agents;I-group;I-DDI-DrugBank.d103.s2.e0
may;O;O
potentiate;O;O
the;O;O
undesirable;O;O
effects;O;O
of;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s2.e1
.;O;O
DDI-DrugBank.d103.s3;;
Monoamine;B-group;B-DDI-DrugBank.d103.s3.e0
Oxidase;I-group;I-DDI-DrugBank.d103.s3.e0
Inhibitors;I-group;I-DDI-DrugBank.d103.s3.e0
and;O;O
Tricyclic;B-group;B-DDI-DrugBank.d103.s3.e1
Antidepressants;I-group;I-DDI-DrugBank.d103.s3.e1
:;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s3.e2
should;O;O
be;O;O
administered;O;O
with;O;O
extreme;O;O
caution;O;O
in;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
monoamine;B-group;B-DDI-DrugBank.d103.s3.e3
oxidase;I-group;I-DDI-DrugBank.d103.s3.e3
inhibitors;I-group;I-DDI-DrugBank.d103.s3.e3
or;O;O
tricyclic;B-group;B-DDI-DrugBank.d103.s3.e4
antidepressants;I-group;I-DDI-DrugBank.d103.s3.e4
because;O;O
the;O;O
action;O;O
of;O;O
formoterol;B-drug;B-DDI-DrugBank.d103.s3.e5
on;O;O
the;O;O
cardiovascular;O;O
system;O;O
may;O;O
be;O;O
potentiated;O;O
by;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d103.s4;;
Corticosteroids;B-group;B-DDI-DrugBank.d103.s4.e0
,;O;O
Methylxanthines;B-group;B-DDI-DrugBank.d103.s4.e1
and;O;O
Diuretics;B-group;B-DDI-DrugBank.d103.s4.e2
:;O;O
Concomitant;O;O
treatment;O;O
with;O;O
xanthine;B-group;B-DDI-DrugBank.d103.s4.e3
derivatives;I-group;I-DDI-DrugBank.d103.s4.e3
,;O;O
steroids;B-group;B-DDI-DrugBank.d103.s4.e4
,;O;O
or;O;O
diuretics;B-group;B-DDI-DrugBank.d103.s4.e5
may;O;O
potentiate;O;O
a;O;O
possible;O;O
hypokalemic;O;O
effect;O;O
of;O;O
beta2;O;O
-;O;O
agonists;O;O
.;O;O
DDI-DrugBank.d103.s5;;
Hypokalemia;O;O
may;O;O
increase;O;O
susceptibility;O;O
to;O;O
cardiac;O;O
arrhythmias;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
digitalis;B-group;B-DDI-DrugBank.d103.s5.e0
.;O;O
DDI-DrugBank.d103.s6;;
-adrenergic;O;O
Blockers;O;O
:;O;O
-adrenergic;O;O
blockers;O;O
may;O;O
weaken;O;O
or;O;O
antagonise;O;O
the;O;O
effect;O;O
of;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s6.e0
.;O;O
DDI-DrugBank.d103.s7;;
Therefore;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s7.e0
should;O;O
not;O;O
be;O;O
given;O;O
together;O;O
with;O;O
-adrenergic;O;O
blockers;O;O
(;O;O
including;O;O
eye;O;O
drops;O;O
);O;O
unless;O;O
there;O;O
are;O;O
compelling;O;O
reasons;O;O
for;O;O
their;O;O
use;O;O
.;O;O
DDI-DrugBank.d103.s8;;
Other;O;O
Drugs;O;O
:;O;O
Drugs;O;O
such;O;O
as;O;O
quinidine;B-drug;B-DDI-DrugBank.d103.s8.e0
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d103.s8.e1
,;O;O
procainamide;B-drug;B-DDI-DrugBank.d103.s8.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d103.s8.e3
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d103.s8.e4
,;O;O
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d103.s8.e5
antidepressants;I-group;I-DDI-DrugBank.d103.s8.e5
may;O;O
be;O;O
associated;O;O
with;O;O
QT;O;O
-;O;O
interval;O;O
prolongation;O;O
and;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
ventricular;O;O
arrhythmia;O;O
.;O;O
DDI-DrugBank.d103.s9;;
INFORMATION;O;O
TO;O;O
BE;O;O
PROVIDED;O;O
TO;O;O
THE;O;O
PATIENT;O;O
OR;O;O
GUARDIAN;O;O
See;O;O
illustrated;O;O
Information;O;O
For;O;O
The;O;O
Patient;O;O
or;O;O
Guardian;O;O
section;O;O
.;O;O
DDI-DrugBank.d103.s10;;
It;O;O
is;O;O
important;O;O
that;O;O
patients;O;O
understand;O;O
how;O;O
to;O;O
use;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s10.e0
(;O;O
formoterol;B-drug;B-DDI-DrugBank.d103.s10.e1
fumarate;I-drug;I-DDI-DrugBank.d103.s10.e1
);O;O
capsules;O;O
with;O;O
the;O;O
supplied;O;O
AerolizerTM;O;O
inhalation;O;O
device;O;O
and;O;O
how;O;O
it;O;O
should;O;O
be;O;O
used;O;O
in;O;O
relation;O;O
to;O;O
other;O;O
asthma;O;O
or;O;O
COPD;O;O
medications;O;O
they;O;O
are;O;O
taking;O;O
.;O;O
DDI-DrugBank.d103.s11;;
Patients;O;O
/;O;O
Guardians;O;O
should;O;O
be;O;O
given;O;O
the;O;O
following;O;O
information;O;O
:;O;O
i.;O;O
DDI-DrugBank.d103.s12;;
The;O;O
recommended;O;O
dosage;O;O
(;O;O
one;O;O
or;O;O
two;O;O
capsules;O;O
twice;O;O
daily;O;O
,;O;O
morning;O;O
and;O;O
evening;O;O
);O;O
should;O;O
not;O;O
be;O;O
exceeded;O;O
.;O;O
DDI-DrugBank.d103.s13;;
ii;O;O
.;O;O
DDI-DrugBank.d103.s14;;
FORADIL;B-brand;B-DDI-DrugBank.d103.s14.e0
is;O;O
not;O;O
meant;O;O
to;O;O
relieve;O;O
acute;O;O
asthma;O;O
or;O;O
COPD;O;O
symptoms;O;O
and;O;O
extra;O;O
doses;O;O
should;O;O
not;O;O
be;O;O
used;O;O
for;O;O
that;O;O
purpose;O;O
.;O;O
DDI-DrugBank.d103.s15;;
Acute;O;O
symptoms;O;O
should;O;O
be;O;O
treated;O;O
with;O;O
a;O;O
short;O;O
-;O;O
acting;O;O
,;O;O
inhaled;O;O
beta2;B-group;B-DDI-DrugBank.d103.s15.e0
-;I-group;I-DDI-DrugBank.d103.s15.e0
agonist;I-group;I-DDI-DrugBank.d103.s15.e0
such;O;O
as;O;O
salbutamol;B-drug;B-DDI-DrugBank.d103.s15.e1
(;O;O
the;O;O
physician;O;O
should;O;O
provide;O;O
the;O;O
patient;O;O
with;O;O
such;O;O
medication;O;O
and;O;O
instruct;O;O
the;O;O
patient;O;O
in;O;O
how;O;O
it;O;O
should;O;O
be;O;O
used;O;O
);O;O
.;O;O
DDI-DrugBank.d103.s16;;
iii;O;O
.;O;O
DDI-DrugBank.d103.s17;;
The;O;O
physician;O;O
should;O;O
be;O;O
notified;O;O
immediately;O;O
if;O;O
any;O;O
of;O;O
the;O;O
following;O;O
situations;O;O
occur;O;O
,;O;O
which;O;O
may;O;O
be;O;O
a;O;O
sign;O;O
of;O;O
seriously;O;O
worsening;O;O
asthma;O;O
:;O;O
Decreased;O;O
effectiveness;O;O
of;O;O
short;B-group;B-DDI-DrugBank.d103.s17.e0
-;I-group;I-DDI-DrugBank.d103.s17.e0
acting;I-group;I-DDI-DrugBank.d103.s17.e0
,;I-group;I-DDI-DrugBank.d103.s17.e0
inhaled;I-group;I-DDI-DrugBank.d103.s17.e0
beta2;I-group;I-DDI-DrugBank.d103.s17.e0
-;I-group;I-DDI-DrugBank.d103.s17.e0
agonists;I-group;I-DDI-DrugBank.d103.s17.e0
,;O;O
DDI-DrugBank.d103.s18;;
Need;O;O
for;O;O
more;O;O
inhalations;O;O
than;O;O
usual;O;O
of;O;O
short;B-group;B-DDI-DrugBank.d103.s18.e0
-;I-group;I-DDI-DrugBank.d103.s18.e0
acting;I-group;I-DDI-DrugBank.d103.s18.e0
,;I-group;I-DDI-DrugBank.d103.s18.e0
inhaled;I-group;I-DDI-DrugBank.d103.s18.e0
beta2;I-group;I-DDI-DrugBank.d103.s18.e0
-;I-group;I-DDI-DrugBank.d103.s18.e0
agonists;I-group;I-DDI-DrugBank.d103.s18.e0
.;O;O
DDI-DrugBank.d103.s19;;
iv;O;O
.;O;O
DDI-DrugBank.d103.s20;;
FORADIL;B-brand;B-DDI-DrugBank.d103.s20.e0
should;O;O
not;O;O
be;O;O
used;O;O
as;O;O
a;O;O
substitute;O;O
for;O;O
oral;O;O
or;O;O
inhaled;O;O
corticosteroids;B-group;B-DDI-DrugBank.d103.s20.e1
.;O;O
DDI-DrugBank.d103.s21;;
The;O;O
dosage;O;O
of;O;O
these;O;O
medications;O;O
should;O;O
not;O;O
be;O;O
changed;O;O
and;O;O
they;O;O
should;O;O
not;O;O
be;O;O
stopped;O;O
without;O;O
consulting;O;O
the;O;O
physician;O;O
,;O;O
even;O;O
if;O;O
the;O;O
patient;O;O
feels;O;O
better;O;O
after;O;O
initiating;O;O
treatment;O;O
with;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s21.e0
.;O;O
DDI-DrugBank.d103.s22;;
v.;O;O
Patients;O;O
should;O;O
be;O;O
cautioned;O;O
regarding;O;O
potential;O;O
adverse;O;O
cardiovascular;O;O
effects;O;O
,;O;O
such;O;O
as;O;O
palpitations;O;O
or;O;O
chest;O;O
pain;O;O
.;O;O
DDI-DrugBank.d103.s23;;
vi;O;O
.;O;O
DDI-DrugBank.d103.s24;;
In;O;O
patients;O;O
receiving;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s24.e0
,;O;O
other;O;O
inhaled;O;O
medications;O;O
should;O;O
be;O;O
used;O;O
only;O;O
as;O;O
directed;O;O
by;O;O
the;O;O
physician;O;O
.;O;O
DDI-DrugBank.d103.s25;;
vii;O;O
.;O;O
DDI-DrugBank.d103.s26;;
Guardians;O;O
of;O;O
children;O;O
who;O;O
have;O;O
been;O;O
prescribed;O;O
FORADIL;B-brand;B-DDI-DrugBank.d103.s26.e0
should;O;O
be;O;O
alerted;O;O
to;O;O
the;O;O
general;O;O
concern;O;O
regarding;O;O
asthma;O;O
therapy;O;O
compliance;O;O
,;O;O
especially;O;O
neglect;O;O
of;O;O
anti;O;O
-;O;O
inflammatory;O;O
therapy;O;O
and;O;O
overuse;O;O
of;O;O
short;B-group;B-DDI-DrugBank.d103.s26.e1
-;I-group;I-DDI-DrugBank.d103.s26.e1
acting;I-group;I-DDI-DrugBank.d103.s26.e1
beta2;I-group;I-DDI-DrugBank.d103.s26.e1
-;I-group;I-DDI-DrugBank.d103.s26.e1
agonists;I-group;I-DDI-DrugBank.d103.s26.e1
.;O;O
DDI-DrugBank.d511.s0;;
A;O;O
possible;O;O
drug;O;O
interaction;O;O
of;O;O
FOSCAVIR;B-brand;B-DDI-DrugBank.d511.s0.e0
and;O;O
intravenous;O;O
pentamidine;B-drug;B-DDI-DrugBank.d511.s0.e1
has;O;O
been;O;O
described;O;O
.;O;O
DDI-DrugBank.d511.s1;;
Concomitant;O;O
treatment;O;O
of;O;O
four;O;O
patients;O;O
in;O;O
the;O;O
United;O;O
Kingdom;O;O
with;O;O
FOSCAVIR;B-brand;B-DDI-DrugBank.d511.s1.e0
and;O;O
intravenous;O;O
pentamidine;B-drug;B-DDI-DrugBank.d511.s1.e1
may;O;O
have;O;O
caused;O;O
hypocalcemia;O;O
,;O;O
DDI-DrugBank.d511.s2;;
one;O;O
patient;O;O
died;O;O
with;O;O
severe;O;O
hypocalcemia;O;O
.;O;O
DDI-DrugBank.d511.s3;;
Toxicity;O;O
associated;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
aerosolized;O;O
pentamidine;B-drug;B-DDI-DrugBank.d511.s3.e0
has;O;O
not;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d511.s4;;
Because;O;O
of;O;O
foscarnets;B-drug;B-DDI-DrugBank.d511.s4.e0
tendency;O;O
to;O;O
cause;O;O
renal;O;O
impairment;O;O
,;O;O
the;O;O
use;O;O
of;O;O
FOSCAVIR;B-brand;B-DDI-DrugBank.d511.s4.e1
should;O;O
be;O;O
avoided;O;O
in;O;O
combination;O;O
with;O;O
potentially;O;O
nephrotoxic;O;O
drugs;O;O
such;O;O
as;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d511.s4.e2
,;O;O
amphotericin;B-drug;B-DDI-DrugBank.d511.s4.e3
B;I-drug;I-DDI-DrugBank.d511.s4.e3
and;O;O
intravenous;O;O
pentamidine;B-drug;B-DDI-DrugBank.d511.s4.e4
unless;O;O
the;O;O
potential;O;O
benefits;O;O
outweigh;O;O
the;O;O
risks;O;O
to;O;O
the;O;O
patient;O;O
.;O;O
DDI-DrugBank.d511.s5;;
Since;O;O
FOSCAVIR;B-brand;B-DDI-DrugBank.d511.s5.e0
decreases;O;O
serum;O;O
concentrations;O;O
of;O;O
ionized;O;O
calcium;O;O
,;O;O
concurrent;O;O
treatment;O;O
with;O;O
other;O;O
drugs;O;O
known;O;O
to;O;O
influence;O;O
serum;O;O
calcium;O;O
concentrations;O;O
should;O;O
be;O;O
used;O;O
with;O;O
particular;O;O
caution;O;O
.;O;O
DDI-DrugBank.d511.s6;;
Ganciclovir;B-drug;B-DDI-DrugBank.d511.s6.e0
:;O;O
The;O;O
pharmacokinetics;O;O
of;O;O
foscarnet;B-drug;B-DDI-DrugBank.d511.s6.e1
and;O;O
ganciclovir;B-drug;B-DDI-DrugBank.d511.s6.e2
were;O;O
not;O;O
altered;O;O
in;O;O
13;O;O
patients;O;O
receiving;O;O
either;O;O
concomitant;O;O
therapy;O;O
or;O;O
daily;O;O
alternating;O;O
therapy;O;O
for;O;O
maintenance;O;O
of;O;O
CMV;O;O
disease;O;O
.;O;O
DDI-DrugBank.d199.s0;;
Metoclopramide;B-drug;B-DDI-DrugBank.d199.s0.e0
:;O;O
When;O;O
coadministered;O;O
with;O;O
MONUROL;B-brand;B-DDI-DrugBank.d199.s0.e1
,;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d199.s0.e2
,;O;O
a;O;O
drug;O;O
which;O;O
increases;O;O
gastrointestinal;O;O
motility;O;O
,;O;O
lowers;O;O
the;O;O
serum;O;O
concentration;O;O
and;O;O
urinary;O;O
excretion;O;O
of;O;O
fosfomycin;B-drug;B-DDI-DrugBank.d199.s0.e3
.;O;O
DDI-DrugBank.d199.s1;;
Other;O;O
drugs;O;O
that;O;O
increase;O;O
gastrointestinal;O;O
motility;O;O
may;O;O
produce;O;O
similar;O;O
effects;O;O
.;O;O
DDI-DrugBank.d199.s2;;
Cimetidine;B-drug;B-DDI-DrugBank.d199.s2.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d199.s2.e1
does;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
fosfomycin;B-drug;B-DDI-DrugBank.d199.s2.e2
when;O;O
coadministered;O;O
with;O;O
MONUROL;B-brand;B-DDI-DrugBank.d199.s2.e3
.;O;O
DDI-DrugBank.d176.s0;;
Diuretics;B-group;B-DDI-DrugBank.d176.s0.e0
:;O;O
Patients;O;O
on;O;O
diuretics;B-group;B-DDI-DrugBank.d176.s0.e1
,;O;O
especially;O;O
those;O;O
with;O;O
intravascular;O;O
volume;O;O
depletion;O;O
,;O;O
may;O;O
occasionally;O;O
experience;O;O
an;O;O
excessive;O;O
reduction;O;O
of;O;O
blood;O;O
pressure;O;O
after;O;O
initiation;O;O
of;O;O
therapy;O;O
with;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s0.e2
sodium;I-drug;I-DDI-DrugBank.d176.s0.e2
.;O;O
DDI-DrugBank.d176.s1;;
The;O;O
possibility;O;O
of;O;O
hypotensive;O;O
effects;O;O
can;O;O
be;O;O
minimized;O;O
by;O;O
either;O;O
discontinuing;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d176.s1.e0
or;O;O
increasing;O;O
salt;O;O
intake;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s1.e1
sodium;I-drug;I-DDI-DrugBank.d176.s1.e1
.;O;O
DDI-DrugBank.d176.s2;;
If;O;O
this;O;O
is;O;O
not;O;O
possible;O;O
,;O;O
the;O;O
starting;O;O
dose;O;O
should;O;O
be;O;O
reduced;O;O
and;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
several;O;O
hours;O;O
following;O;O
an;O;O
initial;O;O
dose;O;O
and;O;O
until;O;O
blood;O;O
pressure;O;O
has;O;O
stabilized;O;O
(;O;O
see;O;O
DOSAGE;O;O
AND;O;O
ADMINISTRATION;O;O
.;O;O
);O;O
DDI-DrugBank.d176.s3;;
Potassium;B-drug;B-DDI-DrugBank.d176.s3.e0
Supplements;O;O
and;O;O
Potassium;B-group;B-DDI-DrugBank.d176.s3.e1
-;I-group;I-DDI-DrugBank.d176.s3.e1
Sparing;I-group;I-DDI-DrugBank.d176.s3.e1
Diuretics;I-group;I-DDI-DrugBank.d176.s3.e1
:;O;O
Fosinopril;B-drug;B-DDI-DrugBank.d176.s3.e2
sodium;I-drug;I-DDI-DrugBank.d176.s3.e2
can;O;O
attenuate;O;O
potassium;O;O
loss;O;O
caused;O;O
by;O;O
thiazide;B-group;B-DDI-DrugBank.d176.s3.e3
diuretics;I-group;I-DDI-DrugBank.d176.s3.e3
.;O;O
DDI-DrugBank.d176.s4;;
Potassium;B-group;B-DDI-DrugBank.d176.s4.e0
-;I-group;I-DDI-DrugBank.d176.s4.e0
sparing;I-group;I-DDI-DrugBank.d176.s4.e0
diuretics;I-group;I-DDI-DrugBank.d176.s4.e0
(;O;O
spironolactone;B-drug;B-DDI-DrugBank.d176.s4.e1
,;O;O
amiloride;B-drug;B-DDI-DrugBank.d176.s4.e2
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d176.s4.e3
,;O;O
and;O;O
others;O;O
);O;O
or;O;O
potassium;B-drug;B-DDI-DrugBank.d176.s4.e4
supplements;O;O
can;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
hyperkalemia;O;O
.;O;O
DDI-DrugBank.d176.s5;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
use;O;O
of;O;O
such;O;O
agents;O;O
is;O;O
indicated;O;O
,;O;O
they;O;O
should;O;O
be;O;O
given;O;O
with;O;O
caution;O;O
,;O;O
and;O;O
the;O;O
patients;O;O
serum;O;O
potassium;O;O
should;O;O
be;O;O
monitored;O;O
frequently;O;O
.;O;O
DDI-DrugBank.d176.s6;;
Lithium;B-drug;B-DDI-DrugBank.d176.s6.e0
:;O;O
Increased;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d176.s6.e1
levels;O;O
and;O;O
symptoms;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d176.s6.e2
toxicity;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
ACE;B-group;B-DDI-DrugBank.d176.s6.e3
inhibitors;I-group;I-DDI-DrugBank.d176.s6.e3
during;O;O
therapy;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d176.s6.e4
.;O;O
DDI-DrugBank.d176.s7;;
These;O;O
drugs;O;O
should;O;O
be;O;O
coadministered;O;O
with;O;O
caution;O;O
,;O;O
and;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d176.s7.e0
levels;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d176.s8;;
If;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d176.s8.e0
is;O;O
also;O;O
used;O;O
,;O;O
the;O;O
risk;O;O
of;O;O
lithium;O;O
toxicity;O;O
may;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d176.s9;;
Antacids;B-group;B-DDI-DrugBank.d176.s9.e0
:;O;O
In;O;O
a;O;O
clinical;O;O
pharmacology;O;O
study;O;O
,;O;O
coadministration;O;O
of;O;O
an;O;O
antacid;B-group;B-DDI-DrugBank.d176.s9.e1
(;O;O
aluminum;B-drug;B-DDI-DrugBank.d176.s9.e2
hydroxide;I-drug;I-DDI-DrugBank.d176.s9.e2
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d176.s9.e3
hydroxide;I-drug;I-DDI-DrugBank.d176.s9.e3
,;O;O
and;O;O
simethicone;B-drug;B-DDI-DrugBank.d176.s9.e4
);O;O
with;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s9.e5
reduced;O;O
serum;O;O
levels;O;O
and;O;O
urinary;O;O
excretion;O;O
of;O;O
fosinoprilat;B-drug_n;B-DDI-DrugBank.d176.s9.e6
as;O;O
compared;O;O
with;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s9.e7
administered;O;O
alone;O;O
,;O;O
suggesting;O;O
that;O;O
antacids;B-group;B-DDI-DrugBank.d176.s9.e8
may;O;O
impair;O;O
absorption;O;O
of;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s9.e9
.;O;O
DDI-DrugBank.d176.s10;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
administration;O;O
of;O;O
these;O;O
agents;O;O
is;O;O
indicated;O;O
,;O;O
dosing;O;O
should;O;O
be;O;O
separated;O;O
by;O;O
2;O;O
hours;O;O
.;O;O
DDI-DrugBank.d176.s11;;
Other;O;O
:;O;O
Neither;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s11.e0
sodium;I-drug;I-DDI-DrugBank.d176.s11.e0
nor;O;O
its;O;O
metabolites;O;O
have;O;O
been;O;O
found;O;O
to;O;O
interact;O;O
with;O;O
food;O;O
.;O;O
DDI-DrugBank.d176.s12;;
In;O;O
separate;O;O
single;O;O
or;O;O
multiple;O;O
dose;O;O
pharmacokinetic;O;O
interaction;O;O
studies;O;O
with;O;O
chlorthalidone;B-drug;B-DDI-DrugBank.d176.s12.e0
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d176.s12.e1
,;O;O
propanolol;B-drug;B-DDI-DrugBank.d176.s12.e2
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d176.s12.e3
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d176.s12.e4
,;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d176.s12.e5
,;O;O
propantheline;B-drug;B-DDI-DrugBank.d176.s12.e6
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d176.s12.e7
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d176.s12.e8
,;O;O
the;O;O
bioavailability;O;O
of;O;O
fosinoprilat;B-drug_n;B-DDI-DrugBank.d176.s12.e9
was;O;O
not;O;O
altered;O;O
by;O;O
coadministration;O;O
of;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s12.e10
with;O;O
any;O;O
one;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d176.s13;;
In;O;O
a;O;O
study;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d176.s13.e0
and;O;O
fosinopril;B-drug;B-DDI-DrugBank.d176.s13.e1
sodium;I-drug;I-DDI-DrugBank.d176.s13.e1
,;O;O
the;O;O
bioavailability;O;O
of;O;O
unbound;O;O
fosinoprilat;B-drug_n;B-DDI-DrugBank.d176.s13.e2
was;O;O
not;O;O
altered;O;O
.;O;O
DDI-DrugBank.d176.s14;;
In;O;O
a;O;O
pharmacokinetic;O;O
interaction;O;O
study;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d176.s14.e0
,;O;O
bioavailability;O;O
parameters;O;O
,;O;O
the;O;O
degree;O;O
of;O;O
protein;O;O
binding;O;O
,;O;O
and;O;O
the;O;O
anticoagulant;O;O
effect;O;O
(;O;O
measured;O;O
by;O;O
prothrombin;O;O
time;O;O
);O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d176.s14.e1
were;O;O
not;O;O
significantly;O;O
changed;O;O
.;O;O
DDI-DrugBank.d176.s15;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interaction;O;O
Fosinopril;B-drug;B-DDI-DrugBank.d176.s15.e0
may;O;O
cause;O;O
a;O;O
false;O;O
low;O;O
measurement;O;O
of;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d176.s15.e1
levels;O;O
with;O;O
the;O;O
Digi;O;O
-;O;O
Tab;O;O
RIA;O;O
Kit;O;O
for;O;O
Digoxin;B-drug;B-DDI-DrugBank.d176.s15.e2
.;O;O
DDI-DrugBank.d176.s16;;
Other;O;O
kits;O;O
,;O;O
such;O;O
as;O;O
the;O;O
Coat;O;O
-;O;O
A;O;O
-;O;O
Count;O;O
RIA;O;O
Kit;O;O
,;O;O
may;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d40.s0;;
No;O;O
drugs;O;O
are;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
conversion;O;O
of;O;O
fosphenytoin;B-drug;B-DDI-DrugBank.d40.s0.e0
to;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s0.e1
.;O;O
DDI-DrugBank.d40.s1;;
Conversion;O;O
could;O;O
be;O;O
affected;O;O
by;O;O
alterations;O;O
in;O;O
the;O;O
level;O;O
of;O;O
phosphatase;O;O
activity;O;O
,;O;O
but;O;O
given;O;O
the;O;O
abundance;O;O
and;O;O
wide;O;O
distribution;O;O
of;O;O
phosphatases;O;O
in;O;O
the;O;O
body;O;O
it;O;O
is;O;O
unlikely;O;O
that;O;O
drugs;O;O
would;O;O
affect;O;O
this;O;O
activity;O;O
enough;O;O
to;O;O
affect;O;O
conversion;O;O
of;O;O
fosphenytoin;B-drug;B-DDI-DrugBank.d40.s1.e0
to;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s1.e1
.;O;O
DDI-DrugBank.d40.s2;;
Drugs;O;O
highly;O;O
bound;O;O
to;O;O
albumin;O;O
could;O;O
increase;O;O
the;O;O
unbound;O;O
fraction;O;O
of;O;O
fosphenytoin;B-drug;B-DDI-DrugBank.d40.s2.e0
.;O;O
DDI-DrugBank.d40.s3;;
Although;O;O
,;O;O
it;O;O
is;O;O
unknown;O;O
whether;O;O
this;O;O
could;O;O
result;O;O
in;O;O
clinically;O;O
significant;O;O
effects;O;O
,;O;O
caution;O;O
is;O;O
advised;O;O
when;O;O
administering;O;O
Cerebyx;B-brand;B-DDI-DrugBank.d40.s3.e0
with;O;O
other;O;O
drugs;O;O
that;O;O
significantly;O;O
bind;O;O
to;O;O
serum;O;O
albumin;O;O
.;O;O
DDI-DrugBank.d40.s4;;
The;O;O
pharmacokinetics;O;O
and;O;O
protein;O;O
binding;O;O
of;O;O
fosphenytoin;B-drug;B-DDI-DrugBank.d40.s4.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s4.e1
,;O;O
and;O;O
diazepam;B-drug;B-DDI-DrugBank.d40.s4.e2
were;O;O
not;O;O
altered;O;O
when;O;O
diazepam;B-drug;B-DDI-DrugBank.d40.s4.e3
and;O;O
Cerebyx;B-brand;B-DDI-DrugBank.d40.s4.e4
were;O;O
concurrently;O;O
administered;O;O
in;O;O
single;O;O
submaximal;O;O
doses;O;O
.;O;O
DDI-DrugBank.d40.s5;;
The;O;O
most;O;O
significant;O;O
drug;O;O
interactions;O;O
following;O;O
administration;O;O
of;O;O
Cerebyx;B-brand;B-DDI-DrugBank.d40.s5.e0
are;O;O
expected;O;O
to;O;O
occur;O;O
with;O;O
drugs;O;O
that;O;O
interact;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s5.e1
.;O;O
DDI-DrugBank.d40.s6;;
Phenytoin;B-drug;B-DDI-DrugBank.d40.s6.e0
is;O;O
extensively;O;O
bound;O;O
to;O;O
serum;O;O
plasma;O;O
proteins;O;O
and;O;O
is;O;O
prone;O;O
to;O;O
competitive;O;O
displacement;O;O
.;O;O
DDI-DrugBank.d40.s7;;
Phenytoin;B-drug;B-DDI-DrugBank.d40.s7.e0
is;O;O
metabolized;O;O
by;O;O
hepatic;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
and;O;O
is;O;O
particularly;O;O
susceptible;O;O
to;O;O
inhibitory;O;O
drug;O;O
interactions;O;O
because;O;O
it;O;O
is;O;O
subject;O;O
to;O;O
saturable;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d40.s8;;
Inhibition;O;O
of;O;O
metabolism;O;O
may;O;O
produce;O;O
significant;O;O
increases;O;O
in;O;O
circulating;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s8.e0
concentrations;O;O
and;O;O
enhance;O;O
the;O;O
risk;O;O
of;O;O
drug;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d40.s9;;
Phenytoin;B-drug;B-DDI-DrugBank.d40.s9.e0
is;O;O
a;O;O
potent;O;O
inducer;O;O
of;O;O
hepatic;O;O
drug;O;O
-;O;O
metabolizing;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d40.s10;;
The;O;O
most;O;O
commonly;O;O
occurring;O;O
drug;O;O
interactions;O;O
are;O;O
listed;O;O
below;O;O
:;O;O
-;O;O
Drugs;O;O
that;O;O
may;O;O
increase;O;O
plasma;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s10.e0
concentrations;O;O
include;O;O
:;O;O
acute;O;O
alcohol;B-drug;B-DDI-DrugBank.d40.s10.e1
intake;O;O
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d40.s10.e2
,;O;O
chboramphenicol;O;O
,;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d40.s10.e3
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d40.s10.e4
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d40.s10.e5
,;O;O
dicumarol;B-drug;B-DDI-DrugBank.d40.s10.e6
,;O;O
disulfiram;B-drug;B-DDI-DrugBank.d40.s10.e7
,;O;O
estrogens;B-group;B-DDI-DrugBank.d40.s10.e8
,;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d40.s10.e9
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d40.s10.e10
,;O;O
H2;B-group;B-DDI-DrugBank.d40.s10.e11
-;I-group;I-DDI-DrugBank.d40.s10.e11
antagonists;I-group;I-DDI-DrugBank.d40.s10.e11
,;O;O
halothane;B-drug;B-DDI-DrugBank.d40.s10.e12
,;O;O
isoniazid;B-drug;B-DDI-DrugBank.d40.s10.e13
,;O;O
methylphenidate;B-drug;B-DDI-DrugBank.d40.s10.e14
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d40.s10.e15
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d40.s10.e16
,;O;O
salicylates;B-group;B-DDI-DrugBank.d40.s10.e17
,;O;O
succinimides;B-group;B-DDI-DrugBank.d40.s10.e18
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d40.s10.e19
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d40.s10.e20
,;O;O
trazodone;B-drug;B-DDI-DrugBank.d40.s10.e21
DDI-DrugBank.d40.s11;;
.;O;O
DDI-DrugBank.d40.s12;;
-;O;O
Drugs;O;O
that;O;O
may;O;O
decrease;O;O
plasma;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s12.e0
concentrations;O;O
include;O;O
:;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d40.s12.e1
,;O;O
chronic;O;O
alcohol;B-drug;B-DDI-DrugBank.d40.s12.e2
abuse;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d40.s12.e3
DDI-DrugBank.d40.s13;;
.;O;O
DDI-DrugBank.d40.s14;;
-;O;O
Drugs;O;O
that;O;O
may;O;O
either;O;O
increase;O;O
or;O;O
decrease;O;O
plasma;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s14.e0
concentrations;O;O
include;O;O
:;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d40.s14.e1
,;O;O
vaiproic;O;O
acid;O;O
,;O;O
and;O;O
sodium;B-drug;B-DDI-DrugBank.d40.s14.e2
valproate;I-drug;I-DDI-DrugBank.d40.s14.e2
.;O;O
DDI-DrugBank.d40.s15;;
Similarly;O;O
,;O;O
the;O;O
effects;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s15.e0
on;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d40.s15.e1
,;O;O
valproic;B-drug;B-DDI-DrugBank.d40.s15.e2
acid;I-drug;I-DDI-DrugBank.d40.s15.e2
and;O;O
sodium;O;O
plasma;O;O
valproate;B-drug;B-DDI-DrugBank.d40.s15.e3
concentrations;O;O
are;O;O
unpredictable;O;O
DDI-DrugBank.d40.s16;;
.;O;O
DDI-DrugBank.d40.s17;;
-;O;O
Although;O;O
not;O;O
a;O;O
true;O;O
drug;O;O
interaction;O;O
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d40.s17.e0
antidepressants;I-group;I-DDI-DrugBank.d40.s17.e0
may;O;O
precipitate;O;O
seizures;O;O
in;O;O
susceptible;O;O
patients;O;O
and;O;O
Cerebyx;B-brand;B-DDI-DrugBank.d40.s17.e1
dosage;O;O
may;O;O
need;O;O
to;O;O
be;O;O
adjusted;O;O
DDI-DrugBank.d40.s18;;
.;O;O
DDI-DrugBank.d40.s19;;
-;O;O
Drugs;O;O
whose;O;O
efficacy;O;O
is;O;O
impaired;O;O
by;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s19.e0
include;O;O
:;O;O
anticoagulants;B-group;B-DDI-DrugBank.d40.s19.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d40.s19.e2
,;O;O
coumarin;B-group;B-DDI-DrugBank.d40.s19.e3
,;O;O
digitoxin;B-drug;B-DDI-DrugBank.d40.s19.e4
,;O;O
doxycycline;B-drug;B-DDI-DrugBank.d40.s19.e5
,;O;O
estrogens;B-group;B-DDI-DrugBank.d40.s19.e6
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d40.s19.e7
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d40.s19.e8
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d40.s19.e9
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d40.s19.e10
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d40.s19.e11
,;O;O
vitamin;B-group;B-DDI-DrugBank.d40.s19.e12
D.;I-group;I-DDI-DrugBank.d40.s19.e12
DDI-DrugBank.d40.s20;;
Monitoring;O;O
of;O;O
plasma;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s20.e0
concentrations;O;O
may;O;O
be;O;O
helpful;O;O
when;O;O
possible;O;O
drug;O;O
interactions;O;O
are;O;O
suspected;O;O
.;O;O
DDI-DrugBank.d40.s21;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d40.s21.e0
may;O;O
decrease;O;O
serum;O;O
concentrations;O;O
of;O;O
14;O;O
.;O;O
DDI-DrugBank.d40.s22;;
It;O;O
may;O;O
also;O;O
produce;O;O
artifactually;O;O
low;O;O
results;O;O
in;O;O
dexamethasone;O;O
or;O;O
metyrapone;O;O
tests;O;O
.;O;O
DDI-DrugBank.d40.s23;;
Phenytoin;B-drug;B-DDI-DrugBank.d40.s23.e0
may;O;O
also;O;O
cause;O;O
increased;O;O
serum;O;O
concentrations;O;O
of;O;O
glucose;O;O
,;O;O
alkaline;O;O
phosphatase;O;O
,;O;O
and;O;O
gamma;O;O
glutamyl;O;O
transpeptidase;O;O
(;O;O
GGT;O;O
);O;O
.;O;O
DDI-DrugBank.d40.s24;;
Care;O;O
should;O;O
be;O;O
taken;O;O
when;O;O
using;O;O
immunoanalytical;O;O
methods;O;O
to;O;O
measure;O;O
plasma;O;O
phenytoin;B-drug;B-DDI-DrugBank.d40.s24.e0
concentrations;O;O
following;O;O
Cerebyx;B-brand;B-DDI-DrugBank.d40.s24.e1
administration;O;O
.;O;O
DDI-DrugBank.d426.s0;;
Ergot;O;O
-;O;O
containing;O;O
drugs;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
prolonged;O;O
vasospastic;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d426.s1;;
Due;O;O
to;O;O
a;O;O
theoretical;O;O
risk;O;O
of;O;O
a;O;O
pharmacodynamic;O;O
interaction;O;O
,;O;O
use;O;O
of;O;O
ergotamine;B-drug;B-DDI-DrugBank.d426.s1.e0
-;O;O
containing;O;O
or;O;O
ergot;B-group;B-DDI-DrugBank.d426.s1.e1
-;I-group;I-DDI-DrugBank.d426.s1.e1
type;I-group;I-DDI-DrugBank.d426.s1.e1
medications;I-group;I-DDI-DrugBank.d426.s1.e1
(;O;O
like;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d426.s1.e2
or;O;O
methysergide;B-drug;B-DDI-DrugBank.d426.s1.e3
);O;O
and;O;O
FROVA;B-brand;B-DDI-DrugBank.d426.s1.e4
within;O;O
24;O;O
hours;O;O
of;O;O
each;O;O
other;O;O
should;O;O
be;O;O
avoided;O;O
(;O;O
see;O;O
a;O;O
href=;O;O
frova_od.htm#CI;O;O
CONTRAINDICATIONS;O;O
);O;O
.;O;O
DDI-DrugBank.d426.s2;;
Concomitant;O;O
use;O;O
of;O;O
other;O;O
5;O;O
-;O;O
HT1B;O;O
/;O;O
1D;O;O
agonists;O;O
within;O;O
24;O;O
hours;O;O
of;O;O
FROVA;B-brand;B-DDI-DrugBank.d426.s2.e0
treatment;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d426.s3;;
Selective;B-group;B-DDI-DrugBank.d426.s3.e0
serotonin;I-group;I-DDI-DrugBank.d426.s3.e0
reuptake;I-group;I-DDI-DrugBank.d426.s3.e0
inhibitors;I-group;I-DDI-DrugBank.d426.s3.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d426.s3.e1
);O;O
(;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d426.s3.e2
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d426.s3.e3
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d426.s3.e4
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d426.s3.e5
);O;O
have;O;O
been;O;O
reported;O;O
,;O;O
rarely;O;O
,;O;O
to;O;O
cause;O;O
weakness;O;O
,;O;O
hyperreflexia;O;O
,;O;O
and;O;O
incoordination;O;O
when;O;O
coadministered;O;O
with;O;O
5;B-group;B-DDI-DrugBank.d426.s3.e6
-;I-group;I-DDI-DrugBank.d426.s3.e6
HT1;I-group;I-DDI-DrugBank.d426.s3.e6
agonists;I-group;I-DDI-DrugBank.d426.s3.e6
.;O;O
DDI-DrugBank.d426.s4;;
If;O;O
concomitant;O;O
treatment;O;O
with;O;O
frovatriptan;B-drug;B-DDI-DrugBank.d426.s4.e0
and;O;O
an;O;O
SSRI;B-group;B-DDI-DrugBank.d426.s4.e1
is;O;O
clinically;O;O
warranted;O;O
,;O;O
appropriate;O;O
observation;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d426.s5;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
FROVA;B-brand;B-DDI-DrugBank.d426.s5.e0
is;O;O
not;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
commonly;O;O
employed;O;O
clinical;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d70.s0;;
Fulvestrant;B-drug;B-DDI-DrugBank.d70.s0.e0
is;O;O
metabolized;O;O
by;O;O
CYP;O;O
3A4;O;O
in;O;O
vitro;O;O
.;O;O
DDI-DrugBank.d70.s1;;
Clinical;O;O
studies;O;O
of;O;O
the;O;O
effect;O;O
of;O;O
strong;O;O
CYP;O;O
3A4;O;O
inhibitors;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s1.e0
have;O;O
not;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d70.s2;;
Carcinogenesis;O;O
,;O;O
Mutagenesis;O;O
and;O;O
Impairment;O;O
of;O;O
Fertility;O;O
A;O;O
two;O;O
-;O;O
year;O;O
carcinogenesis;O;O
study;O;O
was;O;O
conducted;O;O
in;O;O
female;O;O
and;O;O
male;O;O
rats;O;O
,;O;O
at;O;O
intramuscular;O;O
doses;O;O
of;O;O
15;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
30;O;O
days;O;O
,;O;O
10;O;O
mg;O;O
/;O;O
rat;O;O
/;O;O
30;O;O
days;O;O
and;O;O
10;O;O
mg;O;O
/;O;O
rat;O;O
/;O;O
15;O;O
days;O;O
.;O;O
DDI-DrugBank.d70.s3;;
These;O;O
doses;O;O
correspond;O;O
to;O;O
approximately;O;O
1;O;O
-;O;O
,;O;O
3;O;O
-;O;O
,;O;O
and;O;O
5;O;O
-;O;O
fold;O;O
(;O;O
in;O;O
females;O;O
);O;O
and;O;O
1.3;O;O
-;O;O
,;O;O
1.3;O;O
-;O;O
,;O;O
and;O;O
1.6;O;O
-;O;O
fold;O;O
(;O;O
in;O;O
males;O;O
);O;O
the;O;O
systemic;O;O
exposure;O;O
[;O;O
AUC0;O;O
-;O;O
30;O;O
days;O;O
];O;O
];O;O
achieved;O;O
in;O;O
women;O;O
receiving;O;O
the;O;O
recommended;O;O
dose;O;O
of;O;O
250;O;O
mg;O;O
/;O;O
month;O;O
.;O;O
DDI-DrugBank.d70.s4;;
An;O;O
increased;O;O
incidence;O;O
of;O;O
benign;O;O
ovarian;O;O
granulosa;O;O
cell;O;O
tumors;O;O
and;O;O
testicular;O;O
Leydig;O;O
cell;O;O
tumors;O;O
was;O;O
evident;O;O
,;O;O
in;O;O
females;O;O
dosed;O;O
at;O;O
10;O;O
mg;O;O
/;O;O
rat;O;O
/;O;O
15;O;O
days;O;O
and;O;O
males;O;O
dosed;O;O
at;O;O
15;O;O
mg;O;O
/;O;O
rat;O;O
/;O;O
30;O;O
days;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d70.s5;;
Induction;O;O
of;O;O
such;O;O
tumors;O;O
is;O;O
consistent;O;O
with;O;O
the;O;O
pharmacology;O;O
-;O;O
related;O;O
endocrine;O;O
feedback;O;O
alterations;O;O
in;O;O
gonadotropin;O;O
levels;O;O
caused;O;O
by;O;O
an;O;O
antiestrogen;B-group;B-DDI-DrugBank.d70.s5.e0
.;O;O
DDI-DrugBank.d70.s6;;
Fulvestrant;B-drug;B-DDI-DrugBank.d70.s6.e0
was;O;O
not;O;O
mutagenic;O;O
or;O;O
clastogenic;O;O
in;O;O
multiple;O;O
in;O;O
vitro;O;O
tests;O;O
with;O;O
and;O;O
without;O;O
the;O;O
addition;O;O
of;O;O
a;O;O
mammalian;O;O
liver;O;O
metabolic;O;O
activation;O;O
factor;O;O
(;O;O
bacterial;O;O
mutation;O;O
assay;O;O
in;O;O
strains;O;O
of;O;O
Salmonella;O;O
typhimurium;O;O
and;O;O
Escherichia;O;O
coli;O;O
,;O;O
in;O;O
vitro;O;O
cytogenetics;O;O
study;O;O
in;O;O
human;O;O
lymphocytes;O;O
,;O;O
mammalian;O;O
cell;O;O
mutation;O;O
assay;O;O
in;O;O
mouse;O;O
lymphoma;O;O
cells;O;O
and;O;O
in;O;O
vivo;O;O
micronucleus;O;O
test;O;O
in;O;O
rat;O;O
.;O;O
DDI-DrugBank.d70.s7;;
In;O;O
female;O;O
rats;O;O
,;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s7.e0
administered;O;O
at;O;O
doses;O;O
0.01;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
approximately;O;O
one;O;O
-;O;O
hundredth;O;O
of;O;O
the;O;O
human;O;O
recommended;O;O
dose;O;O
based;O;O
on;O;O
body;O;O
surface;O;O
area;O;O
[;O;O
BSA;O;O
];O;O
,;O;O
for;O;O
2;O;O
weeks;O;O
prior;O;O
to;O;O
and;O;O
for;O;O
1;O;O
week;O;O
following;O;O
mating;O;O
,;O;O
caused;O;O
a;O;O
reduction;O;O
in;O;O
fertility;O;O
and;O;O
embryonic;O;O
survival;O;O
.;O;O
DDI-DrugBank.d70.s8;;
No;O;O
adverse;O;O
effects;O;O
on;O;O
female;O;O
fertility;O;O
and;O;O
embryonic;O;O
survival;O;O
were;O;O
evident;O;O
in;O;O
female;O;O
animals;O;O
dosed;O;O
at;O;O
0.001;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
approximately;O;O
one;O;O
-;O;O
thousandth;O;O
of;O;O
the;O;O
human;O;O
dose;O;O
based;O;O
on;O;O
BSA;O;O
);O;O
.;O;O
DDI-DrugBank.d70.s9;;
Restoration;O;O
of;O;O
female;O;O
fertility;O;O
to;O;O
values;O;O
similar;O;O
to;O;O
controls;O;O
was;O;O
evident;O;O
following;O;O
a;O;O
29;O;O
-;O;O
day;O;O
withdrawal;O;O
period;O;O
after;O;O
dosing;O;O
at;O;O
2;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
twice;O;O
the;O;O
human;O;O
dose;O;O
based;O;O
on;O;O
BSA;O;O
);O;O
.;O;O
DDI-DrugBank.d70.s10;;
The;O;O
effects;O;O
of;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s10.e0
on;O;O
the;O;O
fertility;O;O
of;O;O
female;O;O
rats;O;O
appear;O;O
to;O;O
be;O;O
consistent;O;O
with;O;O
its;O;O
anti;O;O
-;O;O
estrogenic;O;O
activity;O;O
.;O;O
DDI-DrugBank.d70.s11;;
The;O;O
potential;O;O
effects;O;O
of;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s11.e0
on;O;O
the;O;O
fertility;O;O
of;O;O
male;O;O
animals;O;O
were;O;O
not;O;O
studied;O;O
but;O;O
in;O;O
a;O;O
6;O;O
-;O;O
month;O;O
toxicology;O;O
study;O;O
,;O;O
male;O;O
rats;O;O
treated;O;O
with;O;O
intramuscular;O;O
doses;O;O
of;O;O
15;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
30;O;O
days;O;O
,;O;O
10;O;O
mg;O;O
/;O;O
rat;O;O
/;O;O
30;O;O
days;O;O
,;O;O
or;O;O
10;O;O
mg;O;O
/;O;O
rat;O;O
/;O;O
15;O;O
days;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s11.e1
showed;O;O
a;O;O
loss;O;O
of;O;O
spermatozoa;O;O
from;O;O
the;O;O
seminiferous;O;O
tubules;O;O
,;O;O
seminiferous;O;O
tubular;O;O
atrophy;O;O
,;O;O
and;O;O
degenerative;O;O
changes;O;O
in;O;O
the;O;O
epididymides;O;O
.;O;O
DDI-DrugBank.d70.s12;;
Changes;O;O
in;O;O
the;O;O
testes;O;O
and;O;O
epididymides;O;O
had;O;O
not;O;O
recovered;O;O
20;O;O
weeks;O;O
after;O;O
cessation;O;O
of;O;O
dosing;O;O
.;O;O
DDI-DrugBank.d70.s13;;
These;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s13.e0
doses;O;O
correspond;O;O
to;O;O
approximately;O;O
2;O;O
-;O;O
,;O;O
3;O;O
-;O;O
,;O;O
and;O;O
3;O;O
-;O;O
fold;O;O
the;O;O
systemic;O;O
exposure;O;O
[;O;O
AUC0;O;O
-;O;O
30;O;O
days;O;O
];O;O
achieved;O;O
in;O;O
women;O;O
.;O;O
DDI-DrugBank.d70.s14;;
Pregnancy;O;O
Pregnancy;O;O
Category;O;O
D;O;O
:;O;O
.;O;O
DDI-DrugBank.d70.s15;;
In;O;O
studies;O;O
in;O;O
female;O;O
rats;O;O
at;O;O
doses;O;O
0.01;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
IM;O;O
,;O;O
DDI-DrugBank.d70.s16;;
approximately;O;O
one;O;O
-;O;O
hundredth;O;O
of;O;O
the;O;O
human;O;O
recommended;O;O
dose;O;O
based;O;O
on;O;O
body;O;O
surface;O;O
area;O;O
[;O;O
BSA;O;O
];O;O
);O;O
,;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s16.e0
caused;O;O
a;O;O
reversible;O;O
reduction;O;O
in;O;O
female;O;O
fertility;O;O
,;O;O
as;O;O
well;O;O
as;O;O
effects;O;O
on;O;O
embryo;O;O
/;O;O
fetal;O;O
development;O;O
consistent;O;O
with;O;O
its;O;O
anti;O;O
-;O;O
estrogenic;O;O
activity;O;O
.;O;O
DDI-DrugBank.d70.s17;;
Fulvestrant;B-drug;B-DDI-DrugBank.d70.s17.e0
caused;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
fetal;O;O
abnormalities;O;O
in;O;O
rats;O;O
(;O;O
tarsal;O;O
flexure;O;O
of;O;O
the;O;O
hind;O;O
paw;O;O
at;O;O
2;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
IM;O;O
,;O;O
DDI-DrugBank.d70.s18;;
twice;O;O
the;O;O
human;O;O
dose;O;O
on;O;O
BSA;O;O
);O;O
and;O;O
non;O;O
-;O;O
ossification;O;O
of;O;O
the;O;O
odontoid;O;O
and;O;O
ventral;O;O
tubercle;O;O
of;O;O
the;O;O
first;O;O
cervical;O;O
vertebra;O;O
at;O;O
doses;O;O
0.1;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
IM;O;O
(;O;O
approximately;O;O
one;O;O
-;O;O
tenth;O;O
of;O;O
the;O;O
human;O;O
dose;O;O
on;O;O
BSA;O;O
);O;O
when;O;O
administered;O;O
during;O;O
the;O;O
period;O;O
of;O;O
organogenesis;O;O
.;O;O
DDI-DrugBank.d70.s19;;
Rabbits;O;O
failed;O;O
to;O;O
maintain;O;O
pregnancy;O;O
when;O;O
dosed;O;O
with;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s19.e0
IM;O;O
(;O;O
twice;O;O
the;O;O
human;O;O
dose;O;O
on;O;O
BSA;O;O
);O;O
during;O;O
the;O;O
period;O;O
of;O;O
organogenesis;O;O
.;O;O
DDI-DrugBank.d70.s20;;
Further;O;O
,;O;O
in;O;O
rabbits;O;O
dosed;O;O
at;O;O
0.25;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
(;O;O
about;O;O
one;O;O
-;O;O
half;O;O
the;O;O
human;O;O
dose;O;O
on;O;O
BSA;O;O
);O;O
,;O;O
increases;O;O
in;O;O
placental;O;O
weight;O;O
and;O;O
post;O;O
-;O;O
implantation;O;O
loss;O;O
were;O;O
observed;O;O
but;O;O
,;O;O
there;O;O
were;O;O
no;O;O
observed;O;O
effects;O;O
on;O;O
fetal;O;O
development;O;O
.;O;O
DDI-DrugBank.d70.s21;;
Fulvestrant;B-drug;B-DDI-DrugBank.d70.s21.e0
was;O;O
associated;O;O
with;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
fetal;O;O
variations;O;O
in;O;O
rabbits;O;O
(;O;O
backwards;O;O
displacement;O;O
of;O;O
the;O;O
pelvic;O;O
girdle;O;O
,;O;O
and;O;O
27;O;O
pre;O;O
-;O;O
sacral;O;O
vertebrae;O;O
at;O;O
0.25;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
IM;O;O
,;O;O
DDI-DrugBank.d70.s22;;
one;O;O
-;O;O
half;O;O
the;O;O
human;O;O
dose;O;O
on;O;O
BSA;O;O
);O;O
when;O;O
administered;O;O
during;O;O
the;O;O
period;O;O
of;O;O
organogenesis;O;O
.;O;O
DDI-DrugBank.d70.s23;;
Because;O;O
pregnancy;O;O
could;O;O
not;O;O
be;O;O
maintained;O;O
in;O;O
the;O;O
rabbit;O;O
following;O;O
doses;O;O
of;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s23.e0
of;O;O
1;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
and;O;O
above;O;O
,;O;O
this;O;O
study;O;O
was;O;O
inadequate;O;O
to;O;O
fully;O;O
define;O;O
the;O;O
possible;O;O
adverse;O;O
effects;O;O
on;O;O
fetal;O;O
development;O;O
at;O;O
clinically;O;O
relevant;O;O
exposures;O;O
.;O;O
DDI-DrugBank.d70.s24;;
Nursing;O;O
Mothers;O;O
Fulvestrant;B-drug;B-DDI-DrugBank.d70.s24.e0
is;O;O
found;O;O
in;O;O
rat;O;O
milk;O;O
at;O;O
levels;O;O
significantly;O;O
higher;O;O
(;O;O
approximately;O;O
12;O;O
-;O;O
fold;O;O
);O;O
than;O;O
plasma;O;O
after;O;O
administration;O;O
of;O;O
2;O;O
mg;O;O
/;O;O
kg;O;O
.;O;O
DDI-DrugBank.d70.s25;;
Drug;O;O
exposure;O;O
in;O;O
rodent;O;O
pups;O;O
from;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s25.e0
-;O;O
treated;O;O
lactating;O;O
dams;O;O
was;O;O
estimated;O;O
as;O;O
10;O;O
%;O;O
of;O;O
the;O;O
administered;O;O
dose;O;O
.;O;O
DDI-DrugBank.d70.s26;;
It;O;O
is;O;O
not;O;O
known;O;O
if;O;O
fulvestrant;B-drug;B-DDI-DrugBank.d70.s26.e0
is;O;O
excreted;O;O
in;O;O
human;O;O
milk;O;O
.;O;O
DDI-DrugBank.d70.s27;;
Because;O;O
many;O;O
drugs;O;O
are;O;O
excreted;O;O
in;O;O
human;O;O
milk;O;O
,;O;O
and;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
serious;O;O
adverse;O;O
reactions;O;O
from;O;O
FASLODEX;B-brand;B-DDI-DrugBank.d70.s27.e0
in;O;O
nursing;O;O
infants;O;O
,;O;O
a;O;O
decision;O;O
should;O;O
be;O;O
made;O;O
whether;O;O
to;O;O
discontinue;O;O
nursing;O;O
or;O;O
to;O;O
discontinue;O;O
the;O;O
drug;O;O
taking;O;O
into;O;O
account;O;O
the;O;O
importance;O;O
of;O;O
the;O;O
drug;O;O
to;O;O
the;O;O
mother;O;O
.;O;O
DDI-DrugBank.d70.s28;;
Pediatric;O;O
Use;O;O
The;O;O
safety;O;O
and;O;O
efficacy;O;O
of;O;O
FASLODEX;B-brand;B-DDI-DrugBank.d70.s28.e0
in;O;O
pediatric;O;O
patients;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d70.s29;;
Geriatric;O;O
Use;O;O
When;O;O
tumor;O;O
response;O;O
was;O;O
considered;O;O
by;O;O
age;O;O
,;O;O
objective;O;O
responses;O;O
were;O;O
seen;O;O
in;O;O
24;O;O
%;O;O
and;O;O
22;O;O
%;O;O
of;O;O
patients;O;O
under;O;O
65;O;O
years;O;O
of;O;O
age;O;O
and;O;O
in;O;O
16;O;O
%;O;O
and;O;O
11;O;O
%;O;O
of;O;O
patients;O;O
65;O;O
years;O;O
of;O;O
age;O;O
and;O;O
older;O;O
,;O;O
who;O;O
were;O;O
treated;O;O
with;O;O
FASLODEX;B-brand;B-DDI-DrugBank.d70.s29.e0
in;O;O
the;O;O
European;O;O
and;O;O
North;O;O
American;O;O
trials;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d231.s0;;
Furosemide;B-drug;B-DDI-DrugBank.d231.s0.e0
may;O;O
increase;O;O
the;O;O
ototoxic;O;O
potential;O;O
of;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d231.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d231.s0.e1
,;O;O
especially;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
impaired;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d231.s1;;
Except;O;O
in;O;O
life;O;O
-;O;O
threatening;O;O
situations;O;O
,;O;O
avoid;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d231.s2;;
Furosemide;B-drug;B-DDI-DrugBank.d231.s2.e0
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
with;O;O
ethacrynic;B-drug;B-DDI-DrugBank.d231.s2.e1
acid;I-drug;I-DDI-DrugBank.d231.s2.e1
because;O;O
of;O;O
the;O;O
possibility;O;O
of;O;O
ototoxicity;O;O
.;O;O
DDI-DrugBank.d231.s3;;
Patients;O;O
receiving;O;O
high;O;O
doses;O;O
of;O;O
salicylates;B-group;B-DDI-DrugBank.d231.s3.e0
concomitantly;O;O
with;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s3.e1
,;O;O
as;O;O
in;O;O
rheumatic;O;O
disease;O;O
,;O;O
may;O;O
experience;O;O
salicylate;B-group;B-DDI-DrugBank.d231.s3.e2
toxicity;O;O
at;O;O
lower;O;O
doses;O;O
because;O;O
of;O;O
competitive;O;O
renal;O;O
excretory;O;O
sites;O;O
.;O;O
DDI-DrugBank.d231.s4;;
Furosemide;B-drug;B-DDI-DrugBank.d231.s4.e0
has;O;O
a;O;O
tendency;O;O
to;O;O
antagonize;O;O
the;O;O
skeletal;O;O
muscle;O;O
relaxing;O;O
effect;O;O
of;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d231.s4.e1
and;O;O
may;O;O
potentiate;O;O
the;O;O
action;O;O
of;O;O
succinylcholine;B-drug;B-DDI-DrugBank.d231.s4.e2
.;O;O
DDI-DrugBank.d231.s5;;
Lithium;B-drug;B-DDI-DrugBank.d231.s5.e0
generally;O;O
should;O;O
not;O;O
be;O;O
given;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d231.s5.e1
because;O;O
they;O;O
reduce;O;O
lithiums;B-drug;B-DDI-DrugBank.d231.s5.e2
renal;O;O
clearance;O;O
and;O;O
add;O;O
a;O;O
high;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d231.s5.e3
toxicity;O;O
.;O;O
DDI-DrugBank.d231.s6;;
Furosemide;B-drug;B-DDI-DrugBank.d231.s6.e0
may;O;O
add;O;O
to;O;O
or;O;O
potentiate;O;O
the;O;O
therapeutic;O;O
effect;O;O
of;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d231.s6.e1
drugs;I-group;I-DDI-DrugBank.d231.s6.e1
.;O;O
DDI-DrugBank.d231.s7;;
Potentiation;O;O
occurs;O;O
with;O;O
ganglionic;B-group;B-DDI-DrugBank.d231.s7.e0
or;I-group;I-DDI-DrugBank.d231.s7.e0
peripheral;I-group;I-DDI-DrugBank.d231.s7.e1
adrenergic;I-group;I-DDI-DrugBank.d231.s7.e1
blocking;I-group;I-DDI-DrugBank.d231.s7.e1
drugs;I-group;I-DDI-DrugBank.d231.s7.e1
.;O;O
DDI-DrugBank.d231.s8;;
Furosemide;B-drug;B-DDI-DrugBank.d231.s8.e0
may;O;O
decrease;O;O
arterial;O;O
responsiveness;O;O
to;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d231.s8.e1
.;O;O
DDI-DrugBank.d231.s9;;
However;O;O
,;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d231.s9.e0
may;O;O
still;O;O
be;O;O
used;O;O
effectively;O;O
.;O;O
DDI-DrugBank.d231.s10;;
Tablets;O;O
Simultaneous;O;O
administration;O;O
of;O;O
sucralfate;B-drug;B-DDI-DrugBank.d231.s10.e0
and;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s10.e1
tablets;O;O
may;O;O
reduce;O;O
the;O;O
natriuretic;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s10.e2
.;O;O
DDI-DrugBank.d231.s11;;
Patients;O;O
receiving;O;O
both;O;O
drugs;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
diuretic;O;O
and/or;O;O
antihypertensive;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s11.e0
is;O;O
achieved;O;O
.;O;O
DDI-DrugBank.d231.s12;;
The;O;O
intake;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s12.e0
and;O;O
sucralfate;B-drug;B-DDI-DrugBank.d231.s12.e1
should;O;O
be;O;O
separated;O;O
by;O;O
at;O;O
least;O;O
two;O;O
hours;O;O
.;O;O
DDI-DrugBank.d231.s13;;
Tablets;O;O
,;O;O
Injection;O;O
,;O;O
and;O;O
Oral;O;O
Solution;O;O
One;O;O
study;O;O
in;O;O
six;O;O
subjects;O;O
demonstrated;O;O
that;O;O
the;O;O
combination;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s13.e0
and;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d231.s13.e1
acid;I-drug;I-DDI-DrugBank.d231.s13.e1
temporarily;O;O
reduced;O;O
creatinine;O;O
clearance;O;O
in;O;O
patients;O;O
with;O;O
chronic;O;O
renal;O;O
insufficiency;O;O
.;O;O
DDI-DrugBank.d231.s14;;
There;O;O
are;O;O
case;O;O
reports;O;O
of;O;O
patients;O;O
who;O;O
developed;O;O
increased;O;O
BUN;O;O
,;O;O
serum;O;O
creatinine;O;O
and;O;O
serum;O;O
potassium;O;O
levels;O;O
,;O;O
and;O;O
weight;O;O
gain;O;O
when;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s14.e0
was;O;O
used;O;O
in;O;O
conjunction;O;O
with;O;O
NSAIDs;B-group;B-DDI-DrugBank.d231.s14.e1
.;O;O
DDI-DrugBank.d231.s15;;
Literature;O;O
reports;O;O
indicate;O;O
that;O;O
coadministration;O;O
of;O;O
indomethacin;B-drug;B-DDI-DrugBank.d231.s15.e0
may;O;O
reduce;O;O
the;O;O
natriuretic;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s15.e1
in;O;O
some;O;O
patients;O;O
by;O;O
inhibiting;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d231.s16;;
Indomethacin;B-drug;B-DDI-DrugBank.d231.s16.e0
may;O;O
also;O;O
affect;O;O
plasma;O;O
renin;O;O
levels;O;O
,;O;O
aldosterone;O;O
excretion;O;O
,;O;O
and;O;O
renin;O;O
profile;O;O
evaluation;O;O
.;O;O
DDI-DrugBank.d231.s17;;
Patients;O;O
receiving;O;O
both;O;O
indomethacin;B-drug;B-DDI-DrugBank.d231.s17.e0
and;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s17.e1
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
diuretic;O;O
and/or;O;O
antihypertensive;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d231.s17.e2
is;O;O
achieved;O;O
.;O;O
DDI-DrugBank.d438.s0;;
In;O;O
vitro;O;O
studies;O;O
were;O;O
conducted;O;O
to;O;O
investigate;O;O
the;O;O
potential;O;O
of;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s0.e0
to;O;O
inhibit;O;O
the;O;O
major;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
(;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP2E1;O;O
,;O;O
and;O;O
CYP3A4;O;O
);O;O
that;O;O
mediate;O;O
drug;O;O
and;O;O
xenobiotic;O;O
metabolism;O;O
using;O;O
isoform;O;O
selective;O;O
marker;O;O
substrates;O;O
and;O;O
human;O;O
liver;O;O
microsomal;O;O
preparations;O;O
.;O;O
DDI-DrugBank.d438.s1;;
Only;O;O
at;O;O
the;O;O
highest;O;O
concentration;O;O
tested;O;O
(;O;O
171;O;O
DDI-DrugBank.d438.s2;;
g;O;O
/;O;O
mL;O;O
,;O;O
DDI-DrugBank.d438.s3;;
1;O;O
mM;O;O
);O;O
was;O;O
a;O;O
slight;O;O
degree;O;O
of;O;O
inhibition;O;O
(;O;O
14%;O;O
-;O;O
30;O;O
%;O;O
);O;O
of;O;O
isoform;O;O
CYP2A6;O;O
observed;O;O
.;O;O
DDI-DrugBank.d438.s4;;
No;O;O
inhibition;O;O
of;O;O
any;O;O
of;O;O
the;O;O
other;O;O
isoforms;O;O
tested;O;O
was;O;O
observed;O;O
at;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s4.e0
concentrations;O;O
up;O;O
to;O;O
171;O;O
mg;O;O
/;O;O
mL;O;O
(;O;O
approximately;O;O
15;O;O
times;O;O
the;O;O
Cmax;O;O
at;O;O
3600;O;O
mg;O;O
/;O;O
day;O;O
);O;O
.;O;O
DDI-DrugBank.d438.s5;;
Gabapentin;B-drug;B-DDI-DrugBank.d438.s5.e0
is;O;O
not;O;O
appreciably;O;O
metabolized;O;O
nor;O;O
does;O;O
it;O;O
interfere;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
commonly;O;O
coadministered;O;O
antiepileptic;B-group;B-DDI-DrugBank.d438.s5.e1
drugs;I-group;I-DDI-DrugBank.d438.s5.e1
.;O;O
DDI-DrugBank.d438.s6;;
The;O;O
drug;O;O
interaction;O;O
data;O;O
described;O;O
in;O;O
this;O;O
section;O;O
were;O;O
obtained;O;O
from;O;O
studies;O;O
involving;O;O
healthy;O;O
adults;O;O
and;O;O
adult;O;O
patients;O;O
with;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d438.s7;;
Phenytoin;B-drug;B-DDI-DrugBank.d438.s7.e0
:;O;O
In;O;O
a;O;O
single;O;O
(;O;O
400;O;O
mg;O;O
);O;O
and;O;O
multiple;O;O
dose;O;O
(;O;O
400;O;O
mg;O;O
TID;O;O
);O;O
study;O;O
of;O;O
Neurontin;B-brand;B-DDI-DrugBank.d438.s7.e1
in;O;O
epileptic;O;O
patients;O;O
(;O;O
N=8;O;O
);O;O
maintained;O;O
on;O;O
phenytoin;B-drug;B-DDI-DrugBank.d438.s7.e2
monotherapy;O;O
for;O;O
at;O;O
least;O;O
2;O;O
months;O;O
,;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s7.e3
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
trough;O;O
plasma;O;O
concentrations;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d438.s7.e4
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d438.s7.e5
had;O;O
no;O;O
effect;O;O
on;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s7.e6
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d438.s8;;
Carbamazepine;B-drug;B-DDI-DrugBank.d438.s8.e0
:;O;O
Steady;O;O
-;O;O
state;O;O
trough;O;O
plasma;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d438.s8.e1
and;O;O
carbamazepine;B-drug_n;B-DDI-DrugBank.d438.s8.e2
10;I-drug_n;I-DDI-DrugBank.d438.s8.e2
,;I-drug_n;I-DDI-DrugBank.d438.s8.e2
11;I-drug_n;I-DDI-DrugBank.d438.s8.e2
epoxide;I-drug_n;I-DDI-DrugBank.d438.s8.e2
concentrations;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
concomitant;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s8.e3
(;O;O
400;O;O
mg;O;O
TID;O;O
,;O;O
DDI-DrugBank.d438.s9;;
N=12;O;O
);O;O
administration;O;O
.;O;O
DDI-DrugBank.d438.s10;;
Likewise;O;O
,;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s10.e0
pharmacokinetics;O;O
were;O;O
unaltered;O;O
by;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d438.s10.e1
administration;O;O
.;O;O
DDI-DrugBank.d438.s11;;
Valproic;B-drug;B-DDI-DrugBank.d438.s11.e0
Acid;I-drug;I-DDI-DrugBank.d438.s11.e0
:;O;O
The;O;O
mean;O;O
steady;O;O
-;O;O
state;O;O
trough;O;O
serum;O;O
valproic;B-drug;B-DDI-DrugBank.d438.s11.e1
acid;I-drug;I-DDI-DrugBank.d438.s11.e1
concentrations;O;O
prior;O;O
to;O;O
and;O;O
during;O;O
concomitant;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s11.e2
administration;O;O
(;O;O
400;O;O
mg;O;O
TID;O;O
,;O;O
DDI-DrugBank.d438.s12;;
N=17;O;O
);O;O
were;O;O
not;O;O
different;O;O
and;O;O
neither;O;O
were;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s12.e0
pharmacokinetic;O;O
parameters;O;O
affected;O;O
by;O;O
valproic;B-drug;B-DDI-DrugBank.d438.s12.e1
acid;I-drug;I-DDI-DrugBank.d438.s12.e1
.;O;O
DDI-DrugBank.d438.s13;;
Phenobarbital;B-drug;B-DDI-DrugBank.d438.s13.e0
:;O;O
Estimates;O;O
of;O;O
steady;O;O
-;O;O
state;O;O
pharmacokinetic;O;O
parameters;O;O
for;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d438.s13.e1
or;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s13.e2
(;O;O
300;O;O
mg;O;O
TID;O;O
,;O;O
DDI-DrugBank.d438.s14;;
N=12;O;O
);O;O
are;O;O
identical;O;O
whether;O;O
the;O;O
drugs;O;O
are;O;O
administered;O;O
alone;O;O
or;O;O
together;O;O
.;O;O
DDI-DrugBank.d438.s15;;
Naproxen;B-drug;B-DDI-DrugBank.d438.s15.e0
:;O;O
Coadministration;O;O
(;O;O
N=18;O;O
);O;O
of;O;O
naproxen;B-drug;B-DDI-DrugBank.d438.s15.e1
sodium;I-drug;I-DDI-DrugBank.d438.s15.e1
capsules;O;O
(;O;O
250;O;O
mg;O;O
);O;O
with;O;O
Neurontin;B-brand;B-DDI-DrugBank.d438.s15.e2
(;O;O
125;O;O
mg;O;O
);O;O
appears;O;O
to;O;O
increase;O;O
the;O;O
amount;O;O
of;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s15.e3
absorbed;O;O
by;O;O
12;O;O
%;O;O
to;O;O
15;O;O
%;O;O
.;O;O
DDI-DrugBank.d438.s16;;
Gabapentin;B-drug;B-DDI-DrugBank.d438.s16.e0
had;O;O
no;O;O
effect;O;O
on;O;O
naproxen;B-drug;B-DDI-DrugBank.d438.s16.e1
pharmacokinetic;O;O
parameters;O;O
.;O;O
DDI-DrugBank.d438.s17;;
These;O;O
doses;O;O
are;O;O
lower;O;O
than;O;O
the;O;O
therapeutic;O;O
doses;O;O
for;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d438.s18;;
The;O;O
magnitude;O;O
of;O;O
interaction;O;O
within;O;O
the;O;O
recommended;O;O
dose;O;O
ranges;O;O
of;O;O
either;O;O
drug;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d438.s19;;
Hydrocodone;B-drug;B-DDI-DrugBank.d438.s19.e0
:;O;O
Coadministration;O;O
of;O;O
Neurontin;B-brand;B-DDI-DrugBank.d438.s19.e1
(;O;O
125;O;O
to;O;O
500;O;O
mg;O;O
,;O;O
DDI-DrugBank.d438.s20;;
N=48;O;O
);O;O
decreases;O;O
hydrocodone;B-drug;B-DDI-DrugBank.d438.s20.e0
(;O;O
10;O;O
mg;O;O
,;O;O
DDI-DrugBank.d438.s21;;
N=50;O;O
);O;O
Cmax;O;O
and;O;O
AUC;O;O
values;O;O
in;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
manner;O;O
relative;O;O
to;O;O
administration;O;O
of;O;O
hydrocodone;B-drug;B-DDI-DrugBank.d438.s21.e0
alone;O;O
,;O;O
DDI-DrugBank.d438.s22;;
Cmax;O;O
and;O;O
AUC;O;O
values;O;O
are;O;O
3;O;O
%;O;O
to;O;O
4;O;O
%;O;O
lower;O;O
,;O;O
respectively;O;O
,;O;O
after;O;O
administration;O;O
of;O;O
125;O;O
mg;O;O
Neurontin;B-brand;B-DDI-DrugBank.d438.s22.e0
and;O;O
21;O;O
%;O;O
to;O;O
22;O;O
%;O;O
lower;O;O
,;O;O
respectively;O;O
,;O;O
after;O;O
administration;O;O
of;O;O
500;O;O
mg;O;O
Neurontin;B-brand;B-DDI-DrugBank.d438.s22.e1
.;O;O
DDI-DrugBank.d438.s23;;
The;O;O
mechanism;O;O
for;O;O
this;O;O
interaction;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d438.s24;;
Hydrocodone;B-drug;B-DDI-DrugBank.d438.s24.e0
increases;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s24.e1
AUC;O;O
values;O;O
by;O;O
14;O;O
%;O;O
.;O;O
DDI-DrugBank.d438.s25;;
The;O;O
magnitude;O;O
of;O;O
interaction;O;O
at;O;O
other;O;O
doses;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d438.s26;;
Morphine;B-drug;B-DDI-DrugBank.d438.s26.e0
:;O;O
A;O;O
literature;O;O
article;O;O
reported;O;O
that;O;O
when;O;O
a;O;O
60;O;O
-;O;O
mg;O;O
controlled;O;O
-;O;O
release;O;O
morphine;B-drug;B-DDI-DrugBank.d438.s26.e1
capsule;O;O
was;O;O
administered;O;O
2;O;O
hours;O;O
prior;O;O
to;O;O
a;O;O
600;O;O
-;O;O
mg;O;O
Neurontin;B-brand;B-DDI-DrugBank.d438.s26.e2
capsule;O;O
(;O;O
N=12;O;O
);O;O
,;O;O
mean;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s26.e3
AUC;O;O
increased;O;O
by;O;O
44;O;O
%;O;O
compared;O;O
to;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s26.e4
administered;O;O
without;O;O
morphine;B-drug;B-DDI-DrugBank.d438.s26.e5
.;O;O
DDI-DrugBank.d438.s27;;
Morphine;B-drug;B-DDI-DrugBank.d438.s27.e0
pharmacokinetic;O;O
parameter;O;O
values;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
administration;O;O
of;O;O
Neurontin;B-brand;B-DDI-DrugBank.d438.s27.e1
2;O;O
hours;O;O
after;O;O
morphine;B-drug;B-DDI-DrugBank.d438.s27.e2
.;O;O
DDI-DrugBank.d438.s28;;
The;O;O
magnitude;O;O
of;O;O
interaction;O;O
at;O;O
other;O;O
doses;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d438.s29;;
Cimetidine;B-drug;B-DDI-DrugBank.d438.s29.e0
:;O;O
In;O;O
the;O;O
presence;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d438.s29.e1
at;O;O
300;O;O
mg;O;O
QID;O;O
(;O;O
N=12;O;O
);O;O
the;O;O
mean;O;O
apparent;O;O
oral;O;O
clearance;O;O
of;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s29.e2
fell;O;O
by;O;O
14;O;O
%;O;O
and;O;O
creatinine;O;O
clearance;O;O
fell;O;O
by;O;O
10;O;O
%;O;O
.;O;O
DDI-DrugBank.d438.s30;;
Thus;O;O
cimetidine;B-drug;B-DDI-DrugBank.d438.s30.e0
appeared;O;O
to;O;O
alter;O;O
the;O;O
renal;O;O
excretion;O;O
of;O;O
both;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s30.e1
and;O;O
creatinine;O;O
,;O;O
an;O;O
endogenous;O;O
marker;O;O
of;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d438.s31;;
This;O;O
small;O;O
decrease;O;O
in;O;O
excretion;O;O
of;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s31.e0
by;O;O
cimetidine;B-drug;B-DDI-DrugBank.d438.s31.e1
is;O;O
not;O;O
expected;O;O
to;O;O
be;O;O
of;O;O
clinical;O;O
importance;O;O
.;O;O
DDI-DrugBank.d438.s32;;
The;O;O
effect;O;O
of;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s32.e0
on;O;O
cimetidine;B-drug;B-DDI-DrugBank.d438.s32.e1
was;O;O
not;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d438.s33;;
Oral;O;O
Contraceptive;B-group;B-DDI-DrugBank.d438.s33.e0
:;O;O
Based;O;O
on;O;O
AUC;O;O
and;O;O
half;O;O
-;O;O
life;O;O
,;O;O
multiple;O;O
-;O;O
dose;O;O
pharmacokinetic;O;O
profiles;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d438.s33.e1
and;O;O
ethinyl;B-drug;B-DDI-DrugBank.d438.s33.e2
estradiol;I-drug;I-DDI-DrugBank.d438.s33.e2
following;O;O
administration;O;O
of;O;O
tablets;O;O
containing;O;O
2.5;O;O
mg;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d438.s33.e3
acetate;I-drug;I-DDI-DrugBank.d438.s33.e3
and;O;O
50;O;O
mcg;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d438.s33.e4
estradiol;I-drug;I-DDI-DrugBank.d438.s33.e4
were;O;O
similar;O;O
with;O;O
and;O;O
without;O;O
coadministration;O;O
of;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s33.e5
(;O;O
400;O;O
mg;O;O
TID;O;O
,;O;O
DDI-DrugBank.d438.s34;;
N=13;O;O
);O;O
.;O;O
DDI-DrugBank.d438.s35;;
The;O;O
Cmax;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d438.s35.e0
was;O;O
13;O;O
%;O;O
higher;O;O
when;O;O
it;O;O
was;O;O
coadministered;O;O
with;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s35.e1
,;O;O
DDI-DrugBank.d438.s36;;
this;O;O
interaction;O;O
is;O;O
not;O;O
expected;O;O
to;O;O
be;O;O
of;O;O
clinical;O;O
importance;O;O
.;O;O
DDI-DrugBank.d438.s37;;
Antacid;B-group;B-DDI-DrugBank.d438.s37.e0
(;O;O
Maalox;B-brand;B-DDI-DrugBank.d438.s37.e1
):;O;O
Maalox;B-brand;B-DDI-DrugBank.d438.s37.e2
reduced;O;O
the;O;O
bioavailability;O;O
of;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s37.e3
(;O;O
N=16;O;O
);O;O
by;O;O
about;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d438.s38;;
This;O;O
decrease;O;O
in;O;O
bioavailability;O;O
was;O;O
about;O;O
5;O;O
%;O;O
when;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s38.e0
was;O;O
administered;O;O
2;O;O
hours;O;O
after;O;O
Maalox;B-brand;B-DDI-DrugBank.d438.s38.e1
.;O;O
DDI-DrugBank.d438.s39;;
It;O;O
is;O;O
recommended;O;O
that;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s39.e0
be;O;O
taken;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
following;O;O
Maalox;B-brand;B-DDI-DrugBank.d438.s39.e1
administration;O;O
.;O;O
DDI-DrugBank.d438.s40;;
Effect;O;O
of;O;O
Probenecid;B-drug;B-DDI-DrugBank.d438.s40.e0
:;O;O
Probenecid;B-drug;B-DDI-DrugBank.d438.s40.e1
is;O;O
a;O;O
blocker;O;O
of;O;O
renal;O;O
tubular;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d438.s41;;
Gabapentin;B-drug;B-DDI-DrugBank.d438.s41.e0
pharmacokinetic;O;O
parameters;O;O
without;O;O
and;O;O
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d438.s41.e1
were;O;O
comparable;O;O
.;O;O
DDI-DrugBank.d438.s42;;
This;O;O
indicates;O;O
that;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s42.e0
does;O;O
not;O;O
undergo;O;O
renal;O;O
tubular;O;O
secretion;O;O
by;O;O
the;O;O
pathway;O;O
that;O;O
is;O;O
blocked;O;O
by;O;O
probenecid;B-drug;B-DDI-DrugBank.d438.s42.e1
.;O;O
DDI-DrugBank.d438.s43;;
Drug;O;O
/;O;O
Laboratory;O;O
Tests;O;O
Interactions;O;O
Because;O;O
false;O;O
positive;O;O
readings;O;O
were;O;O
reported;O;O
with;O;O
the;O;O
Ames;O;O
N;O;O
-;O;O
Multistix;O;O
SG;O;O
dipstick;O;O
test;O;O
for;O;O
urinary;O;O
protein;O;O
when;O;O
gabapentin;B-drug;B-DDI-DrugBank.d438.s43.e0
was;O;O
added;O;O
to;O;O
other;O;O
antiepileptic;B-group;B-DDI-DrugBank.d438.s43.e1
drugs;I-group;I-DDI-DrugBank.d438.s43.e1
,;O;O
the;O;O
more;O;O
specific;O;O
sulfosalicylic;O;O
acid;O;O
precipitation;O;O
procedure;O;O
is;O;O
recommended;O;O
to;O;O
determine;O;O
the;O;O
presence;O;O
of;O;O
urine;O;O
protein;O;O
DDI-DrugBank.d438.s44;;
.;O;O
DDI-DrugBank.d438.s45;;
DDI-DrugBank.d230.s0;;
LABORATORY;O;O
TEST;O;O
FINDINGS;O;O
Asymptomatic;O;O
,;O;O
transitory;O;O
changes;O;O
in;O;O
serum;O;O
iron;O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d230.s1;;
The;O;O
clinical;O;O
significance;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d230.s2;;
Omniscan;B-brand;B-DDI-DrugBank.d230.s2.e0
interferes;O;O
with;O;O
serum;O;O
calcium;O;O
measurements;O;O
with;O;O
some;O;O
colorimetric;O;O
(;O;O
complexometric;O;O
);O;O
methods;O;O
commonly;O;O
used;O;O
in;O;O
hospitals;O;O
,;O;O
resulting;O;O
in;O;O
serum;O;O
calcium;O;O
concentrations;O;O
lower;O;O
than;O;O
the;O;O
true;O;O
values;O;O
.;O;O
DDI-DrugBank.d230.s3;;
Thus;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
not;O;O
to;O;O
use;O;O
such;O;O
methods;O;O
for;O;O
12;O;O
-;O;O
24;O;O
hours;O;O
after;O;O
administration;O;O
of;O;O
Omniscan;B-brand;B-DDI-DrugBank.d230.s3.e0
.;O;O
DDI-DrugBank.d230.s4;;
If;O;O
such;O;O
measurements;O;O
are;O;O
necessary;O;O
,;O;O
the;O;O
use;O;O
of;O;O
other;O;O
methods;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d230.s5;;
All;O;O
patients;O;O
in;O;O
whom;O;O
this;O;O
effect;O;O
was;O;O
observed;O;O
remained;O;O
asymptomatic;O;O
.;O;O
DDI-DrugBank.d58.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d159.s0;;
No;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
observed;O;O
with;O;O
the;O;O
Vitrasert;B-brand;B-DDI-DrugBank.d159.s0.e0
Implant;O;O
.;O;O
DDI-DrugBank.d159.s1;;
There;O;O
is;O;O
limited;O;O
experience;O;O
with;O;O
use;O;O
of;O;O
retinal;O;O
tamponades;O;O
in;O;O
conjunction;O;O
with;O;O
the;O;O
Vitrasert;B-brand;B-DDI-DrugBank.d159.s1.e0
Implant;O;O
.;O;O
DDI-DrugBank.d207.s0;;
Substances;O;O
that;O;O
are;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
activity;O;O
increase;O;O
the;O;O
metabolism;O;O
of;O;O
gefitinib;B-drug;B-DDI-DrugBank.d207.s0.e0
and;O;O
decrease;O;O
its;O;O
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d207.s1;;
In;O;O
patients;O;O
receiving;O;O
a;O;O
potent;O;O
CYP3A4;O;O
inducer;O;O
such;O;O
as;O;O
rifampicin;B-drug;B-DDI-DrugBank.d207.s1.e0
or;O;O
phenytoin;B-drug;B-DDI-DrugBank.d207.s1.e1
,;O;O
a;O;O
dose;O;O
increase;O;O
to;O;O
500;O;O
mg;O;O
daily;O;O
should;O;O
be;O;O
considered;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
severe;O;O
adverse;O;O
drug;O;O
reaction;O;O
,;O;O
and;O;O
clinical;O;O
response;O;O
and;O;O
adverse;O;O
events;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
(;O;O
see;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
-;O;O
Pharmacokinetics;O;O
-;O;O
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
and;O;O
DOSAGE;O;O
AND;O;O
ADMINISTRATION;O;O
-;O;O
Dosage;O;O
Adjustment;O;O
sections;O;O
);O;O
.;O;O
DDI-DrugBank.d207.s2;;
International;O;O
Normalized;O;O
Ratio;O;O
(;O;O
INR;O;O
);O;O
elevations;O;O
and/or;O;O
bleeding;O;O
events;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
some;O;O
patients;O;O
taking;O;O
warfarin;B-drug;B-DDI-DrugBank.d207.s2.e0
while;O;O
on;O;O
IRESSA;B-brand;B-DDI-DrugBank.d207.s2.e1
therapy;O;O
.;O;O
DDI-DrugBank.d207.s3;;
Patients;O;O
taking;O;O
warfarin;B-drug;B-DDI-DrugBank.d207.s3.e0
should;O;O
be;O;O
monitored;O;O
regularly;O;O
for;O;O
changes;O;O
in;O;O
prothrombin;O;O
time;O;O
or;O;O
INR;O;O
.;O;O
DDI-DrugBank.d207.s4;;
Substances;O;O
that;O;O
are;O;O
potent;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
activity;O;O
(;O;O
eg;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d207.s4.e0
and;O;O
itraconazole;B-drug;B-DDI-DrugBank.d207.s4.e1
);O;O
decrease;O;O
gefitinib;B-drug;B-DDI-DrugBank.d207.s4.e2
metabolism;O;O
and;O;O
increase;O;O
gefitinib;B-drug;B-DDI-DrugBank.d207.s4.e3
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d207.s5;;
This;O;O
increase;O;O
may;O;O
be;O;O
clinically;O;O
relevant;O;O
as;O;O
adverse;O;O
experiences;O;O
are;O;O
related;O;O
to;O;O
dose;O;O
and;O;O
exposure;O;O
,;O;O
DDI-DrugBank.d207.s6;;
therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
administering;O;O
CYP3A4;O;O
inhibitors;O;O
with;O;O
IRESSA;B-brand;B-DDI-DrugBank.d207.s6.e0
.;O;O
DDI-DrugBank.d207.s7;;
Drugs;O;O
that;O;O
cause;O;O
significant;O;O
sustained;O;O
elevation;O;O
in;O;O
gastric;O;O
pH;O;O
(;O;O
histamine;B-group;B-DDI-DrugBank.d207.s7.e0
H2;I-group;I-DDI-DrugBank.d207.s7.e0
-;I-group;I-DDI-DrugBank.d207.s7.e0
receptor;I-group;I-DDI-DrugBank.d207.s7.e0
antagonists;I-group;I-DDI-DrugBank.d207.s7.e0
such;O;O
as;O;O
ranitidine;B-drug;B-DDI-DrugBank.d207.s7.e1
or;O;O
cimetidine;B-drug;B-DDI-DrugBank.d207.s7.e2
);O;O
may;O;O
reduce;O;O
plasma;O;O
concentrations;O;O
of;O;O
IRESSA;B-brand;B-DDI-DrugBank.d207.s7.e3
and;O;O
therefore;O;O
potentially;O;O
may;O;O
reduce;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d207.s8;;
Phase;O;O
II;O;O
clinical;O;O
trial;O;O
data;O;O
,;O;O
where;O;O
IRESSA;B-brand;B-DDI-DrugBank.d207.s8.e0
and;O;O
vinorelbine;B-drug;B-DDI-DrugBank.d207.s8.e1
have;O;O
been;O;O
used;O;O
concomitantly;O;O
,;O;O
indicate;O;O
that;O;O
IRESSA;B-brand;B-DDI-DrugBank.d207.s8.e2
may;O;O
exacerbate;O;O
the;O;O
neutropenic;O;O
effect;O;O
of;O;O
vinorelbine;B-drug;B-DDI-DrugBank.d207.s8.e3
.;O;O
DDI-DrugBank.d161.s0;;
No;O;O
specific;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d161.s1;;
For;O;O
information;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
Gemzar;B-brand;B-DDI-DrugBank.d161.s1.e0
and;O;O
cisplatin;B-drug;B-DDI-DrugBank.d161.s1.e1
in;O;O
combination;O;O
,;O;O
see;O;O
Drug;O;O
Interactions;O;O
under;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
section;O;O
.;O;O
DDI-DrugBank.d490.s0;;
);O;O
DDI-DrugBank.d490.s1;;
DDI-DrugBank.d490.s2;;
Clinical;O;O
Laboratory;O;O
DDI-DrugBank.d490.s3;;
DDI-DrugBank.d490.s4;;
increased;O;O
creatine;O;O
DDI-DrugBank.d490.s5;;
positive;O;O
antinuclear;O;O
DDI-DrugBank.d490.s6;;
DDI-DrugBank.d490.s7;;
phosphokinase;O;O
DDI-DrugBank.d490.s8;;
antibody;O;O
DDI-DrugBank.d490.s9;;
DDI-DrugBank.d490.s10;;
increased;O;O
bilirubin;O;O
DDI-DrugBank.d490.s11;;
DDI-DrugBank.d490.s12;;
DDI-DrugBank.d490.s13;;
increased;O;O
liver;O;O
DDI-DrugBank.d490.s14;;
DDI-DrugBank.d490.s15;;
DDI-DrugBank.d490.s16;;
transaminases;O;O
(;O;O
AST;O;O
DDI-DrugBank.d490.s17;;
DDI-DrugBank.d490.s18;;
DDI-DrugBank.d490.s19;;
(;O;O
SGOT;O;O
);O;O
,;O;O
ALT;O;O
(;O;O
SGPT;O;O
);O;O
DDI-DrugBank.d490.s20;;
DDI-DrugBank.d490.s21;;
DDI-DrugBank.d490.s22;;
increased;O;O
alkaline;O;O
DDI-DrugBank.d490.s23;;
DDI-DrugBank.d490.s24;;
DDI-DrugBank.d490.s25;;
phophatase;O;O
DDI-DrugBank.d490.s26;;
DDI-DrugBank.d490.s27;;
Hematopoietic;O;O
DDI-DrugBank.d490.s28;;
anemia;O;O
DDI-DrugBank.d490.s29;;
thrombocytopenia;O;O
DDI-DrugBank.d490.s30;;
DDI-DrugBank.d490.s31;;
leukopenia;O;O
DDI-DrugBank.d490.s32;;
DDI-DrugBank.d490.s33;;
DDI-DrugBank.d490.s34;;
bone;O;O
marrow;O;O
hypoplasia;O;O
DDI-DrugBank.d490.s35;;
DDI-DrugBank.d490.s36;;
DDI-DrugBank.d490.s37;;
eosinophilia;O;O
DDI-DrugBank.d490.s38;;
DDI-DrugBank.d490.s39;;
Immunologic;O;O
DDI-DrugBank.d490.s40;;
angioedema;O;O
DDI-DrugBank.d490.s41;;
anaphylaxis;O;O
DDI-DrugBank.d490.s42;;
DDI-DrugBank.d490.s43;;
laryngeal;O;O
edema;O;O
DDI-DrugBank.d490.s44;;
Lupus;O;O
-;O;O
like;O;O
syndrome;O;O
DDI-DrugBank.d490.s45;;
DDI-DrugBank.d490.s46;;
urticaria;O;O
DDI-DrugBank.d490.s47;;
vasculitis;O;O
DDI-DrugBank.d490.s48;;
Integumentary;O;O
DDI-DrugBank.d490.s49;;
exfoliative;O;O
dermatitis;O;O
DDI-DrugBank.d490.s50;;
alopecia;O;O
DDI-DrugBank.d490.s51;;
DDI-DrugBank.d490.s52;;
rash;O;O
DDI-DrugBank.d490.s53;;
DDI-DrugBank.d490.s54;;
DDI-DrugBank.d490.s55;;
dermatitis;O;O
DDI-DrugBank.d490.s56;;
DDI-DrugBank.d490.s57;;
DDI-DrugBank.d490.s58;;
pruritus;O;O
DDI-DrugBank.d490.s59;;
DDI-DrugBank.d347.s0;;
Administration;O;O
of;O;O
repeat;O;O
doses;O;O
of;O;O
FACTIVE;B-brand;B-DDI-DrugBank.d347.s0.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
repeat;O;O
dose;O;O
pharmacokinetics;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d347.s0.e1
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d347.s0.e2
or;O;O
an;O;O
ethinylestradiol;B-drug;B-DDI-DrugBank.d347.s0.e3
/;O;O
levonorgestrol;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d347.s0.e4
product;I-group;I-DDI-DrugBank.d347.s0.e4
in;O;O
healthy;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d347.s1;;
Concomitant;O;O
administration;O;O
of;O;O
FACTIVE;B-brand;B-DDI-DrugBank.d347.s1.e0
and;O;O
calcium;B-drug;B-DDI-DrugBank.d347.s1.e1
carbonate;I-drug;I-DDI-DrugBank.d347.s1.e1
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d347.s1.e2
,;O;O
omeprazole;B-drug;B-DDI-DrugBank.d347.s1.e3
,;O;O
or;O;O
an;O;O
estrogen;B-group;B-DDI-DrugBank.d347.s1.e4
/;O;O
progesterone;B-drug;B-DDI-DrugBank.d347.s1.e5
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d347.s1.e6
produced;O;O
minor;O;O
changes;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
gemifloxacin;B-drug;B-DDI-DrugBank.d347.s1.e7
,;O;O
which;O;O
were;O;O
considered;O;O
to;O;O
be;O;O
without;O;O
clinical;O;O
significance;O;O
.;O;O
DDI-DrugBank.d347.s2;;
Concomitant;O;O
administration;O;O
of;O;O
FACTIVE;B-brand;B-DDI-DrugBank.d347.s2.e0
with;O;O
probenecid;B-drug;B-DDI-DrugBank.d347.s2.e1
resulted;O;O
in;O;O
a;O;O
45;O;O
%;O;O
increase;O;O
in;O;O
systemic;O;O
exposure;O;O
to;O;O
gemifloxacin;B-drug;B-DDI-DrugBank.d347.s2.e2
.;O;O
DDI-DrugBank.d347.s3;;
FACTIVE;B-brand;B-DDI-DrugBank.d347.s3.e0
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d347.s3.e1
in;O;O
healthy;O;O
subjects;O;O
on;O;O
stable;O;O
warfarin;B-drug;B-DDI-DrugBank.d347.s3.e2
therapy;O;O
.;O;O
DDI-DrugBank.d347.s4;;
However;O;O
,;O;O
because;O;O
some;O;O
quinolones;B-group;B-DDI-DrugBank.d347.s4.e0
have;O;O
been;O;O
reported;O;O
to;O;O
enhance;O;O
the;O;O
anticoagulant;O;O
effects;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d347.s4.e1
or;O;O
its;O;O
derivatives;O;O
in;O;O
patients;O;O
,;O;O
the;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
coagulation;O;O
test;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
if;O;O
a;O;O
quinolone;B-group;B-DDI-DrugBank.d347.s4.e2
antimicrobial;I-group;I-DDI-DrugBank.d347.s4.e2
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d347.s4.e3
or;O;O
its;O;O
derivatives;O;O
.;O;O
DDI-DrugBank.d347.s5;;
Quinolones;B-group;B-DDI-DrugBank.d347.s5.e0
form;O;O
chelates;O;O
with;O;O
alkaline;O;O
earth;O;O
and;O;O
transition;O;O
metals;O;O
.;O;O
DDI-DrugBank.d347.s6;;
The;O;O
absorption;O;O
of;O;O
oral;O;O
gemifloxacin;B-drug;B-DDI-DrugBank.d347.s6.e0
is;O;O
significantly;O;O
reduced;O;O
by;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
an;O;O
antacid;B-group;B-DDI-DrugBank.d347.s6.e1
containing;O;O
aluminum;B-drug;B-DDI-DrugBank.d347.s6.e2
and;O;O
magnesium;B-drug;B-DDI-DrugBank.d347.s6.e3
.;O;O
DDI-DrugBank.d347.s7;;
Magnesium;B-drug;B-DDI-DrugBank.d347.s7.e0
-;O;O
and/or;O;O
aluminum;B-drug;B-DDI-DrugBank.d347.s7.e1
-;O;O
containing;O;O
antacids;B-group;B-DDI-DrugBank.d347.s7.e2
,;O;O
products;O;O
containing;O;O
ferrous;B-drug;B-DDI-DrugBank.d347.s7.e3
sulfate;I-drug;I-DDI-DrugBank.d347.s7.e3
(;O;O
iron;B-drug;B-DDI-DrugBank.d347.s7.e4
);O;O
,;O;O
multivitamin;B-group;B-DDI-DrugBank.d347.s7.e5
preparations;I-group;I-DDI-DrugBank.d347.s7.e5
containing;O;O
zinc;B-drug;B-DDI-DrugBank.d347.s7.e6
or;O;O
other;O;O
metal;O;O
cations;O;O
,;O;O
or;O;O
Videx;B-brand;B-DDI-DrugBank.d347.s7.e7
(;O;O
didanosine;B-drug;B-DDI-DrugBank.d347.s7.e8
);O;O
chewable;O;O
/;O;O
buffered;O;O
tablets;O;O
or;O;O
the;O;O
pediatric;O;O
powder;O;O
for;O;O
oral;O;O
solution;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
within;O;O
3;O;O
hours;O;O
before;O;O
or;O;O
2;O;O
hours;O;O
after;O;O
FACTIVE;B-brand;B-DDI-DrugBank.d347.s7.e9
.;O;O
DDI-DrugBank.d347.s8;;
Sucralfate;B-drug;B-DDI-DrugBank.d347.s8.e0
should;O;O
not;O;O
be;O;O
taken;O;O
within;O;O
2;O;O
hours;O;O
of;O;O
FACTIVE;B-brand;B-DDI-DrugBank.d347.s8.e1
.;O;O
DDI-DrugBank.d403.s0;;
There;O;O
have;O;O
been;O;O
no;O;O
formal;O;O
drug;O;O
-;O;O
interaction;O;O
studies;O;O
performed;O;O
with;O;O
Mylotarg;B-brand;B-DDI-DrugBank.d403.s0.e0
.;O;O
DDI-DrugBank.d403.s1;;
The;O;O
potential;O;O
for;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
with;O;O
drugs;O;O
affected;O;O
by;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
may;O;O
not;O;O
be;O;O
ruled;O;O
out;O;O
.;O;O
DDI-DrugBank.d403.s2;;
Laboratory;O;O
Test;O;O
Interactions;O;O
DDI-DrugBank.d403.s3;;
Mylotarg;B-brand;B-DDI-DrugBank.d403.s3.e0
is;O;O
not;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
any;O;O
routine;O;O
diagnostic;O;O
tests;O;O
.;O;O
DDI-DrugBank.d28.s0;;
Interactions;O;O
between;O;O
COPAXONE;B-brand;B-DDI-DrugBank.d28.s0.e0
and;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
fully;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d28.s1;;
Results;O;O
from;O;O
existing;O;O
clinical;O;O
trials;O;O
suggest;O;O
no;O;O
significant;O;O
interactions;O;O
between;O;O
COPAXONE;B-brand;B-DDI-DrugBank.d28.s1.e0
and;O;O
other;O;O
therapies;O;O
commonly;O;O
used;O;O
in;O;O
MS;O;O
patients;O;O
,;O;O
including;O;O
the;O;O
concurrent;O;O
use;O;O
of;O;O
corticosteroids;B-group;B-DDI-DrugBank.d28.s1.e1
for;O;O
up;O;O
to;O;O
28;O;O
days;O;O
.;O;O
DDI-DrugBank.d28.s2;;
COPAXONE;B-brand;B-DDI-DrugBank.d28.s2.e0
has;O;O
not;O;O
been;O;O
formally;O;O
evaluated;O;O
in;O;O
combination;O;O
with;O;O
Interferon;B-drug;B-DDI-DrugBank.d28.s2.e1
beta;I-drug;I-DDI-DrugBank.d28.s2.e1
.;O;O
DDI-DrugBank.d28.s3;;
However;O;O
,;O;O
10;O;O
patients;O;O
who;O;O
switched;O;O
from;O;O
therapy;O;O
with;O;O
Interferon;B-drug;B-DDI-DrugBank.d28.s3.e0
beta;I-drug;I-DDI-DrugBank.d28.s3.e0
to;O;O
COPAXONE;B-brand;B-DDI-DrugBank.d28.s3.e1
did;O;O
not;O;O
report;O;O
any;O;O
serious;O;O
and;O;O
unexpected;O;O
adverse;O;O
reactions;O;O
thought;O;O
to;O;O
be;O;O
related;O;O
to;O;O
treatment;O;O
.;O;O
DDI-DrugBank.d178.s0;;
The;O;O
hypoglycemic;O;O
action;O;O
of;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d178.s0.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
certain;O;O
drugs;O;O
including;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d178.s0.e1
anti;I-group;I-DDI-DrugBank.d178.s0.e1
-;I-group;I-DDI-DrugBank.d178.s0.e1
inflammatory;I-group;I-DDI-DrugBank.d178.s0.e1
agents;I-group;I-DDI-DrugBank.d178.s0.e1
and;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
highly;O;O
protein;O;O
bound;O;O
,;O;O
salicylates;B-group;B-DDI-DrugBank.d178.s0.e2
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d178.s0.e3
,;O;O
chloramphenicol;B-drug;B-DDI-DrugBank.d178.s0.e4
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d178.s0.e5
,;O;O
coumarins;B-group;B-DDI-DrugBank.d178.s0.e6
,;O;O
monoamine;B-group;B-DDI-DrugBank.d178.s0.e7
oxidase;I-group;I-DDI-DrugBank.d178.s0.e7
inhibitors;I-group;I-DDI-DrugBank.d178.s0.e7
,;O;O
and;O;O
beta;B-group;B-DDI-DrugBank.d178.s0.e8
adrenergic;I-group;I-DDI-DrugBank.d178.s0.e8
blocking;I-group;I-DDI-DrugBank.d178.s0.e8
agents;I-group;I-DDI-DrugBank.d178.s0.e8
.;O;O
DDI-DrugBank.d178.s1;;
When;O;O
such;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
MICRONASE;B-brand;B-DDI-DrugBank.d178.s1.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d178.s2;;
When;O;O
such;O;O
drugs;O;O
are;O;O
withdrawn;O;O
from;O;O
a;O;O
patient;O;O
receiving;O;O
MICRONASE;B-brand;B-DDI-DrugBank.d178.s2.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d178.s3;;
Certain;O;O
drugs;O;O
tend;O;O
to;O;O
produce;O;O
hyperglycemia;O;O
and;O;O
may;O;O
lead;O;O
to;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d178.s4;;
These;O;O
drugs;O;O
include;O;O
the;O;O
thiazides;B-group;B-DDI-DrugBank.d178.s4.e0
and;O;O
other;O;O
diuretics;B-group;B-DDI-DrugBank.d178.s4.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d178.s4.e2
,;O;O
phe;O;O
-;O;O
nothiazines;O;O
,;O;O
thyroid;B-group;B-DDI-DrugBank.d178.s4.e3
products;I-group;I-DDI-DrugBank.d178.s4.e3
,;O;O
estrogens;B-group;B-DDI-DrugBank.d178.s4.e4
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d178.s4.e5
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d178.s4.e6
,;O;O
nicotinic;B-drug;B-DDI-DrugBank.d178.s4.e7
acid;I-drug;I-DDI-DrugBank.d178.s4.e7
,;O;O
sympathomimet;O;O
-;O;O
ics;O;O
,;O;O
calcium;B-group;B-DDI-DrugBank.d178.s4.e8
channel;I-group;I-DDI-DrugBank.d178.s4.e8
blocking;I-group;I-DDI-DrugBank.d178.s4.e8
drugs;I-group;I-DDI-DrugBank.d178.s4.e8
,;O;O
and;O;O
isoniazid;B-drug;B-DDI-DrugBank.d178.s4.e9
.;O;O
DDI-DrugBank.d178.s5;;
When;O;O
such;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
MICRONASE;B-brand;B-DDI-DrugBank.d178.s5.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d178.s6;;
When;O;O
such;O;O
drugs;O;O
are;O;O
withdrawn;O;O
from;O;O
a;O;O
patient;O;O
receiving;O;O
MICRONASE;B-brand;B-DDI-DrugBank.d178.s6.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d178.s7;;
A;O;O
possible;O;O
interaction;O;O
between;O;O
glyburide;B-drug;B-DDI-DrugBank.d178.s7.e0
and;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d178.s7.e1
,;O;O
a;O;O
fluoroquinolone;B-group;B-DDI-DrugBank.d178.s7.e2
antibiotic;I-group;I-DDI-DrugBank.d178.s7.e2
,;O;O
has;O;O
been;O;O
reported;O;O
,;O;O
resulting;O;O
in;O;O
a;O;O
potentiation;O;O
of;O;O
the;O;O
hypoglycemic;O;O
action;O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d178.s7.e3
.;O;O
DDI-DrugBank.d178.s8;;
The;O;O
mechanism;O;O
for;O;O
this;O;O
interaction;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d178.s9;;
A;O;O
potential;O;O
interaction;O;O
between;O;O
oral;O;O
miconazole;B-drug;B-DDI-DrugBank.d178.s9.e0
and;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d178.s9.e1
agents;I-group;I-DDI-DrugBank.d178.s9.e1
leading;O;O
to;O;O
severe;O;O
hypoglycemia;O;O
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d178.s10;;
Whether;O;O
this;O;O
interaction;O;O
also;O;O
occurs;O;O
with;O;O
the;O;O
intravenous;O;O
,;O;O
topical;O;O
or;O;O
vaginal;O;O
preparations;O;O
of;O;O
miconazole;B-drug;B-DDI-DrugBank.d178.s10.e0
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d178.s11;;
Metformin;B-drug;B-DDI-DrugBank.d178.s11.e0
:;O;O
In;O;O
a;O;O
single;O;O
-;O;O
dose;O;O
interaction;O;O
study;O;O
in;O;O
NIDDM;O;O
subjects;O;O
,;O;O
decreases;O;O
in;O;O
glyburide;B-drug;B-DDI-DrugBank.d178.s11.e1
AUC;O;O
and;O;O
Cmax;O;O
were;O;O
observed;O;O
,;O;O
but;O;O
were;O;O
highly;O;O
variable;O;O
.;O;O
DDI-DrugBank.d178.s12;;
The;O;O
single;O;O
-;O;O
dose;O;O
nature;O;O
of;O;O
this;O;O
study;O;O
and;O;O
the;O;O
lack;O;O
of;O;O
correlation;O;O
between;O;O
glyburide;B-drug;B-DDI-DrugBank.d178.s12.e0
blood;O;O
levels;O;O
and;O;O
pharmaco;O;O
-;O;O
dynamic;O;O
effects;O;O
,;O;O
makes;O;O
the;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
interaction;O;O
uncertain;O;O
.;O;O
DDI-DrugBank.d178.s13;;
Coadministration;O;O
of;O;O
gly;O;O
-;O;O
buride;O;O
and;O;O
metformin;B-drug;B-DDI-DrugBank.d178.s13.e0
did;O;O
not;O;O
result;O;O
in;O;O
any;O;O
changes;O;O
in;O;O
either;O;O
metformin;B-drug;B-DDI-DrugBank.d178.s13.e1
pharmacokinetics;O;O
or;O;O
pharmaco;O;O
-;O;O
dynamics;O;O
.;O;O
DDI-DrugBank.d521.s0;;
Many;O;O
other;O;O
medicines;O;O
may;O;O
increase;O;O
or;O;O
decrease;O;O
the;O;O
effects;O;O
of;O;O
glimepiride;B-drug;B-DDI-DrugBank.d521.s0.e0
or;O;O
affect;O;O
your;O;O
condition;O;O
.;O;O
DDI-DrugBank.d521.s1;;
Before;O;O
taking;O;O
glimepiride;B-drug;B-DDI-DrugBank.d521.s1.e0
,;O;O
tell;O;O
your;O;O
doctor;O;O
if;O;O
you;O;O
are;O;O
taking;O;O
any;O;O
of;O;O
the;O;O
following;O;O
medicines;O;O
:;O;O
-;O;O
aspirin;B-brand;B-DDI-DrugBank.d521.s1.e1
or;O;O
another;O;O
salicylate;B-group;B-DDI-DrugBank.d521.s1.e2
such;O;O
as;O;O
magnesium;B-drug;B-DDI-DrugBank.d521.s1.e3
/;I-drug;I-DDI-DrugBank.d521.s1.e3
choline;I-drug;I-DDI-DrugBank.d521.s1.e3
salicylate;I-drug;I-DDI-DrugBank.d521.s1.e3
(;O;O
Trilisate;B-brand;B-DDI-DrugBank.d521.s1.e4
);O;O
,;O;O
salsalate;B-drug;B-DDI-DrugBank.d521.s1.e5
(;O;O
Disalcid;B-brand;B-DDI-DrugBank.d521.s1.e6
,;O;O
others;O;O
);O;O
,;O;O
choline;B-drug;B-DDI-DrugBank.d521.s1.e7
salicylate;I-drug;I-DDI-DrugBank.d521.s1.e7
(;O;O
Arthropan;B-drug;B-DDI-DrugBank.d521.s1.e8
);O;O
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d521.s1.e9
salicylate;I-drug;I-DDI-DrugBank.d521.s1.e9
(;O;O
Magan;B-brand;B-DDI-DrugBank.d521.s1.e10
);O;O
,;O;O
or;O;O
bismuth;B-drug;B-DDI-DrugBank.d521.s1.e11
subsalicylate;I-drug;I-DDI-DrugBank.d521.s1.e11
(;O;O
Pepto;B-brand;B-DDI-DrugBank.d521.s1.e12
-;I-brand;I-DDI-DrugBank.d521.s1.e12
Bismol;I-brand;I-DDI-DrugBank.d521.s1.e12
);O;O
,;O;O
DDI-DrugBank.d521.s2;;
-;O;O
a;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d521.s2.e0
anti;I-group;I-DDI-DrugBank.d521.s2.e0
-;I-group;I-DDI-DrugBank.d521.s2.e0
inflammatory;I-group;I-DDI-DrugBank.d521.s2.e0
drug;I-group;I-DDI-DrugBank.d521.s2.e0
(;O;O
NSAID;B-group;B-DDI-DrugBank.d521.s2.e1
);O;O
such;O;O
as;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d521.s2.e2
(;O;O
Motrin;B-brand;B-DDI-DrugBank.d521.s2.e3
,;O;O
Advil;B-brand;B-DDI-DrugBank.d521.s2.e4
,;O;O
Nuprin;B-brand;B-DDI-DrugBank.d521.s2.e5
,;O;O
others;O;O
);O;O
,;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d521.s2.e6
(;O;O
Orudis;B-brand;B-DDI-DrugBank.d521.s2.e7
,;O;O
Orudis;B-brand;B-DDI-DrugBank.d521.s2.e8
KT;I-brand;I-DDI-DrugBank.d521.s2.e8
,;O;O
Oruvail;B-brand;B-DDI-DrugBank.d521.s2.e9
);O;O
,;O;O
diclofenac;B-drug;B-DDI-DrugBank.d521.s2.e10
(;O;O
Voltaren;B-brand;B-DDI-DrugBank.d521.s2.e11
,;O;O
Cataflam;B-brand;B-DDI-DrugBank.d521.s2.e12
);O;O
,;O;O
etodolac;B-drug;B-DDI-DrugBank.d521.s2.e13
(;O;O
Lodine;B-brand;B-DDI-DrugBank.d521.s2.e14
);O;O
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d521.s2.e15
(;O;O
Indocin;B-brand;B-DDI-DrugBank.d521.s2.e16
);O;O
,;O;O
nabumetone;B-drug;B-DDI-DrugBank.d521.s2.e17
(;O;O
Relafen;B-brand;B-DDI-DrugBank.d521.s2.e18
);O;O
,;O;O
oxaprozin;B-drug;B-DDI-DrugBank.d521.s2.e19
(;O;O
Daypro;B-brand;B-DDI-DrugBank.d521.s2.e20
);O;O
,;O;O
and;O;O
naproxen;B-drug;B-DDI-DrugBank.d521.s2.e21
(;O;O
Anaprox;B-brand;B-DDI-DrugBank.d521.s2.e22
,;O;O
Naprosyn;B-brand;B-DDI-DrugBank.d521.s2.e23
,;O;O
Aleve;B-brand;B-DDI-DrugBank.d521.s2.e24
);O;O
,;O;O
DDI-DrugBank.d521.s3;;
-;O;O
a;O;O
sulfa;O;O
-;O;O
based;O;O
drug;O;O
such;O;O
as;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d521.s3.e0
-;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d521.s3.e1
(;O;O
Bactrim;B-brand;B-DDI-DrugBank.d521.s3.e2
,;O;O
Septra;B-brand;B-DDI-DrugBank.d521.s3.e3
);O;O
,;O;O
sulfisoxazole;B-drug;B-DDI-DrugBank.d521.s3.e4
(;O;O
Gantrisin;B-brand;B-DDI-DrugBank.d521.s3.e5
);O;O
,;O;O
or;O;O
sulfasalazine;B-drug;B-DDI-DrugBank.d521.s3.e6
(;O;O
Azulfidine;B-brand;B-DDI-DrugBank.d521.s3.e7
);O;O
,;O;O
DDI-DrugBank.d521.s4;;
-;O;O
a;O;O
monoamine;B-group;B-DDI-DrugBank.d521.s4.e0
oxidase;I-group;I-DDI-DrugBank.d521.s4.e0
inhibitor;I-group;I-DDI-DrugBank.d521.s4.e0
(;O;O
MAOI;B-group;B-DDI-DrugBank.d521.s4.e1
);O;O
such;O;O
as;O;O
isocarboxazid;B-drug;B-DDI-DrugBank.d521.s4.e2
(;O;O
Marplan;B-brand;B-DDI-DrugBank.d521.s4.e3
);O;O
,;O;O
tranylcypromine;B-drug;B-DDI-DrugBank.d521.s4.e4
(;O;O
Parnate;B-brand;B-DDI-DrugBank.d521.s4.e5
);O;O
,;O;O
or;O;O
phenelzine;B-drug;B-DDI-DrugBank.d521.s4.e6
(;O;O
Nardil;B-brand;B-DDI-DrugBank.d521.s4.e7
);O;O
,;O;O
DDI-DrugBank.d521.s5;;
-;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d521.s5.e0
-;I-group;I-DDI-DrugBank.d521.s5.e0
blocker;I-group;I-DDI-DrugBank.d521.s5.e0
such;O;O
as;O;O
propranolol;B-drug;B-DDI-DrugBank.d521.s5.e1
(;O;O
Inderal;B-brand;B-DDI-DrugBank.d521.s5.e2
);O;O
,;O;O
atenolol;B-drug;B-DDI-DrugBank.d521.s5.e3
(;O;O
Tenormin;B-brand;B-DDI-DrugBank.d521.s5.e4
);O;O
,;O;O
acebutolol;B-drug;B-DDI-DrugBank.d521.s5.e5
(;O;O
Sectral;B-brand;B-DDI-DrugBank.d521.s5.e6
);O;O
,;O;O
metoprolol;B-drug;B-DDI-DrugBank.d521.s5.e7
(;O;O
Lopressor;B-brand;B-DDI-DrugBank.d521.s5.e8
);O;O
,;O;O
and;O;O
others;O;O
,;O;O
DDI-DrugBank.d521.s6;;
-;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d521.s6.e0
(;O;O
water;O;O
pill;O;O
);O;O
such;O;O
as;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d521.s6.e1
(;O;O
HCTZ;B-drug;B-DDI-DrugBank.d521.s6.e2
,;O;O
Hydrodiuril;B-brand;B-DDI-DrugBank.d521.s6.e3
);O;O
,;O;O
chlorothiazide;B-drug;B-DDI-DrugBank.d521.s6.e4
(;O;O
Diuril;B-brand;B-DDI-DrugBank.d521.s6.e5
);O;O
,;O;O
and;O;O
others;O;O
,;O;O
DDI-DrugBank.d521.s7;;
-;O;O
a;O;O
steroid;B-group;B-DDI-DrugBank.d521.s7.e0
medicine;I-group;I-DDI-DrugBank.d521.s7.e0
such;O;O
as;O;O
prednisone;B-drug;B-DDI-DrugBank.d521.s7.e1
(;O;O
Deltasone;B-brand;B-DDI-DrugBank.d521.s7.e2
,;O;O
Orasone;B-brand;B-DDI-DrugBank.d521.s7.e3
,;O;O
others;O;O
);O;O
,;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d521.s7.e4
(;O;O
Medrol;B-brand;B-DDI-DrugBank.d521.s7.e5
,;O;O
others;O;O
);O;O
,;O;O
prednisolone;B-drug;B-DDI-DrugBank.d521.s7.e6
(;O;O
Prelone;B-brand;B-DDI-DrugBank.d521.s7.e7
,;O;O
Pediapred;B-brand;B-DDI-DrugBank.d521.s7.e8
,;O;O
others;O;O
);O;O
,;O;O
and;O;O
others;O;O
,;O;O
DDI-DrugBank.d521.s8;;
-;O;O
a;O;O
phenothiazine;B-group;B-DDI-DrugBank.d521.s8.e0
such;O;O
as;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d521.s8.e1
(;O;O
Thorazine;B-brand;B-DDI-DrugBank.d521.s8.e2
);O;O
,;O;O
fluphenazine;B-drug;B-DDI-DrugBank.d521.s8.e3
(;O;O
Prolixin;B-brand;B-DDI-DrugBank.d521.s8.e4
,;O;O
Permitil;B-brand;B-DDI-DrugBank.d521.s8.e5
);O;O
,;O;O
prochlorperazine;B-drug;B-DDI-DrugBank.d521.s8.e6
(;O;O
Compazine;B-brand;B-DDI-DrugBank.d521.s8.e7
);O;O
,;O;O
promethazine;B-drug;B-DDI-DrugBank.d521.s8.e8
(;O;O
Phenergan;B-brand;B-DDI-DrugBank.d521.s8.e9
);O;O
,;O;O
and;O;O
others;O;O
,;O;O
DDI-DrugBank.d521.s9;;
-;O;O
phenytoin;B-drug;B-DDI-DrugBank.d521.s9.e0
(;O;O
Dilantin;B-brand;B-DDI-DrugBank.d521.s9.e1
);O;O
,;O;O
DDI-DrugBank.d521.s10;;
-;O;O
isoniazid;B-drug;B-DDI-DrugBank.d521.s10.e0
(;O;O
Nydrazid;B-brand;B-DDI-DrugBank.d521.s10.e1
);O;O
,;O;O
DDI-DrugBank.d521.s11;;
-;O;O
rifampin;B-drug;B-DDI-DrugBank.d521.s11.e0
(;O;O
Rifadin;B-brand;B-DDI-DrugBank.d521.s11.e1
,;O;O
Rifamate;B-brand;B-DDI-DrugBank.d521.s11.e2
);O;O
,;O;O
DDI-DrugBank.d521.s12;;
or;O;O
-;O;O
over;O;O
-;O;O
the;O;O
-;O;O
counter;O;O
cough;O;O
,;O;O
cold;O;O
,;O;O
allergy;O;O
,;O;O
or;O;O
weight;O;O
loss;O;O
medications;O;O
.;O;O
DDI-DrugBank.d521.s13;;
You;O;O
may;O;O
require;O;O
a;O;O
dosage;O;O
adjustment;O;O
or;O;O
special;O;O
monitoring;O;O
if;O;O
you;O;O
are;O;O
taking;O;O
any;O;O
of;O;O
the;O;O
medicines;O;O
listed;O;O
above;O;O
.;O;O
DDI-DrugBank.d521.s14;;
Drugs;O;O
other;O;O
than;O;O
those;O;O
listed;O;O
here;O;O
may;O;O
also;O;O
interact;O;O
with;O;O
glimepiride;B-drug;B-DDI-DrugBank.d521.s14.e0
or;O;O
affect;O;O
your;O;O
condition;O;O
.;O;O
DDI-DrugBank.d521.s15;;
Talk;O;O
to;O;O
your;O;O
doctor;O;O
and;O;O
pharmacist;O;O
before;O;O
taking;O;O
any;O;O
prescription;O;O
or;O;O
over;O;O
-;O;O
the;O;O
-;O;O
counter;O;O
medicines;O;O
,;O;O
including;O;O
herbal;O;O
products;O;O
.;O;O
DDI-DrugBank.d225.s0;;
Immediate;O;O
and;O;O
Extended;O;O
Release;O;O
Tablets;O;O
The;O;O
hypoglycemic;O;O
action;O;O
of;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d225.s0.e0
may;O;O
be;O;O
potentiated;O;O
by;O;O
certain;O;O
drugs;O;O
including;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d225.s0.e1
anti;I-group;I-DDI-DrugBank.d225.s0.e1
-;I-group;I-DDI-DrugBank.d225.s0.e1
inflammatory;I-group;I-DDI-DrugBank.d225.s0.e1
agents;I-group;I-DDI-DrugBank.d225.s0.e1
,;O;O
some;O;O
azoles;B-group;B-DDI-DrugBank.d225.s0.e2
and;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
highly;O;O
protein;O;O
bound;O;O
,;O;O
salicylates;B-group;B-DDI-DrugBank.d225.s0.e3
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d225.s0.e4
,;O;O
chloramphenicol;B-drug;B-DDI-DrugBank.d225.s0.e5
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d225.s0.e6
,;O;O
coumarins;B-group;B-DDI-DrugBank.d225.s0.e7
,;O;O
monoamine;B-group;B-DDI-DrugBank.d225.s0.e8
oxidase;I-group;I-DDI-DrugBank.d225.s0.e8
inhibitors;I-group;I-DDI-DrugBank.d225.s0.e8
,;O;O
and;O;O
beta;B-group;B-DDI-DrugBank.d225.s0.e9
adrenergic;I-group;I-DDI-DrugBank.d225.s0.e9
blocking;I-group;I-DDI-DrugBank.d225.s0.e9
agents;I-group;I-DDI-DrugBank.d225.s0.e9
.;O;O
DDI-DrugBank.d225.s1;;
When;O;O
such;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s1.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d225.s2;;
When;O;O
such;O;O
drugs;O;O
are;O;O
withdrawn;O;O
from;O;O
a;O;O
patient;O;O
receiving;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s2.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d225.s3;;
In;O;O
vitro;O;O
binding;O;O
studies;O;O
with;O;O
human;O;O
serum;O;O
proteins;O;O
indicate;O;O
that;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s3.e0
binds;O;O
differently;O;O
than;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d225.s3.e1
and;O;O
does;O;O
not;O;O
interact;O;O
with;O;O
salicylate;B-group;B-DDI-DrugBank.d225.s3.e2
or;O;O
dicumarol;B-drug;B-DDI-DrugBank.d225.s3.e3
.;O;O
DDI-DrugBank.d225.s4;;
However;O;O
,;O;O
caution;O;O
must;O;O
be;O;O
exercised;O;O
in;O;O
extrapolating;O;O
these;O;O
findings;O;O
to;O;O
the;O;O
clinical;O;O
situation;O;O
and;O;O
in;O;O
the;O;O
use;O;O
of;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s4.e0
with;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d225.s5;;
Certain;O;O
drugs;O;O
tend;O;O
to;O;O
produce;O;O
hyperglycemia;O;O
and;O;O
may;O;O
lead;O;O
to;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d225.s6;;
These;O;O
drugs;O;O
include;O;O
the;O;O
thiazides;B-group;B-DDI-DrugBank.d225.s6.e0
and;O;O
other;O;O
diuretics;B-group;B-DDI-DrugBank.d225.s6.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d225.s6.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d225.s6.e3
,;O;O
thyroid;B-group;B-DDI-DrugBank.d225.s6.e4
products;I-group;I-DDI-DrugBank.d225.s6.e4
,;O;O
estrogens;B-group;B-DDI-DrugBank.d225.s6.e5
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d225.s6.e6
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d225.s6.e7
,;O;O
nicotinic;B-drug;B-DDI-DrugBank.d225.s6.e8
acid;I-drug;I-DDI-DrugBank.d225.s6.e8
,;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d225.s6.e9
,;O;O
calcium;B-group;B-DDI-DrugBank.d225.s6.e10
channel;I-group;I-DDI-DrugBank.d225.s6.e10
blocking;I-group;I-DDI-DrugBank.d225.s6.e10
drugs;I-group;I-DDI-DrugBank.d225.s6.e10
,;O;O
and;O;O
isoniazid;B-drug;B-DDI-DrugBank.d225.s6.e11
.;O;O
DDI-DrugBank.d225.s7;;
When;O;O
such;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s7.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
loss;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d225.s8;;
When;O;O
such;O;O
drugs;O;O
are;O;O
withdrawn;O;O
from;O;O
a;O;O
patient;O;O
receiving;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s8.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d225.s9;;
A;O;O
potential;O;O
interaction;O;O
between;O;O
oral;O;O
miconazole;B-drug;B-DDI-DrugBank.d225.s9.e0
and;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d225.s9.e1
agents;I-group;I-DDI-DrugBank.d225.s9.e1
leading;O;O
to;O;O
severe;O;O
hypoglycemia;O;O
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d225.s10;;
Whether;O;O
this;O;O
interaction;O;O
also;O;O
occurs;O;O
with;O;O
the;O;O
intravenous;O;O
,;O;O
topical;O;O
,;O;O
or;O;O
vaginal;O;O
preparations;O;O
of;O;O
miconazole;B-drug;B-DDI-DrugBank.d225.s10.e0
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d225.s11;;
The;O;O
effect;O;O
of;O;O
concomitant;O;O
administration;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d225.s11.e0
and;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s11.e1
has;O;O
been;O;O
demonstrated;O;O
in;O;O
a;O;O
placebo;O;O
-;O;O
controlled;O;O
crossover;O;O
study;O;O
in;O;O
normal;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d225.s12;;
All;O;O
subjects;O;O
received;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s12.e0
alone;O;O
and;O;O
following;O;O
treatment;O;O
with;O;O
100;O;O
mg;O;O
of;O;O
fluconazole;B-drug;B-DDI-DrugBank.d225.s12.e1
as;O;O
a;O;O
single;O;O
daily;O;O
oral;O;O
dose;O;O
for;O;O
seven;O;O
days;O;O
.;O;O
DDI-DrugBank.d225.s13;;
The;O;O
mean;O;O
percentage;O;O
increase;O;O
in;O;O
the;O;O
glipizide;B-drug;B-DDI-DrugBank.d225.s13.e0
AUC;O;O
after;O;O
fluconazole;B-drug;B-DDI-DrugBank.d225.s13.e1
administration;O;O
was;O;O
56.9;O;O
%;O;O
(;O;O
range;O;O
:;O;O
35;O;O
to;O;O
81;O;O
);O;O
.;O;O
DDI-DrugBank.d510.s0;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
Robinul;B-brand;B-DDI-DrugBank.d510.s0.e0
Injection;O;O
with;O;O
other;O;O
anticholinergics;B-group;B-DDI-DrugBank.d510.s0.e1
or;O;O
medications;O;O
with;O;O
anticholinergic;O;O
activity;O;O
,;O;O
such;O;O
as;O;O
phenothiazines;B-group;B-DDI-DrugBank.d510.s0.e2
,;O;O
antiparkinson;B-group;B-DDI-DrugBank.d510.s0.e3
drugs;I-group;I-DDI-DrugBank.d510.s0.e3
,;O;O
or;O;O
tricyclic;B-group;B-DDI-DrugBank.d510.s0.e4
antidepressants;I-group;I-DDI-DrugBank.d510.s0.e4
,;O;O
may;O;O
intensify;O;O
the;O;O
antimuscarinic;O;O
effects;O;O
and;O;O
may;O;O
result;O;O
in;O;O
an;O;O
increase;O;O
in;O;O
anticholinergic;O;O
side;O;O
effects;O;O
.;O;O
DDI-DrugBank.d510.s1;;
Concomitant;O;O
administration;O;O
of;O;O
Robinul;B-brand;B-DDI-DrugBank.d510.s1.e0
Injection;O;O
and;O;O
potassium;B-drug;B-DDI-DrugBank.d510.s1.e1
chloride;I-drug;I-DDI-DrugBank.d510.s1.e1
in;O;O
a;O;O
wax;O;O
matrix;O;O
may;O;O
increase;O;O
the;O;O
severity;O;O
of;O;O
potassium;O;O
chloride;O;O
-;O;O
induced;O;O
gastrointestinal;O;O
lesions;O;O
as;O;O
a;O;O
result;O;O
of;O;O
a;O;O
slower;O;O
gastrointestinal;O;O
transit;O;O
time;O;O
.;O;O
DDI-DrugBank.d369.s0;;
The;O;O
Factrel;B-brand;B-DDI-DrugBank.d369.s0.e0
test;O;O
should;O;O
be;O;O
conducted;O;O
in;O;O
the;O;O
absence;O;O
of;O;O
other;O;O
drugs;O;O
which;O;O
directly;O;O
affect;O;O
the;O;O
pituitary;O;O
secretion;O;O
of;O;O
the;O;O
gonadotropins;O;O
.;O;O
DDI-DrugBank.d369.s1;;
These;O;O
would;O;O
include;O;O
a;O;O
variety;O;O
of;O;O
preparations;O;O
which;O;O
contain;O;O
androgens;B-group;B-DDI-DrugBank.d369.s1.e0
,;O;O
estrogens;B-group;B-DDI-DrugBank.d369.s1.e1
,;O;O
progestins;B-group;B-DDI-DrugBank.d369.s1.e2
,;O;O
or;O;O
glucocorticoids;B-group;B-DDI-DrugBank.d369.s1.e3
.;O;O
DDI-DrugBank.d369.s2;;
The;O;O
gonadotropin;O;O
levels;O;O
may;O;O
be;O;O
transiently;O;O
elevated;O;O
by;O;O
spironolactone;B-drug;B-DDI-DrugBank.d369.s2.e0
,;O;O
minimally;O;O
elevated;O;O
by;O;O
levodopa;B-drug;B-DDI-DrugBank.d369.s2.e1
,;O;O
and;O;O
suppressed;O;O
by;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d369.s2.e2
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d369.s2.e3
.;O;O
DDI-DrugBank.d369.s3;;
The;O;O
response;O;O
to;O;O
Factrel;B-brand;B-DDI-DrugBank.d369.s3.e0
may;O;O
be;O;O
blunted;O;O
by;O;O
phenothiazines;B-group;B-DDI-DrugBank.d369.s3.e1
and;O;O
dopamine;B-group;B-DDI-DrugBank.d369.s3.e2
antagonists;I-group;I-DDI-DrugBank.d369.s3.e2
which;O;O
cause;O;O
a;O;O
rise;O;O
in;O;O
prolactin;O;O
.;O;O
DDI-DrugBank.d50.s0;;
No;O;O
formal;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d50.s1;;
No;O;O
confirmed;O;O
interactions;O;O
have;O;O
been;O;O
reported;O;O
between;O;O
ZOLADEX;B-brand;B-DDI-DrugBank.d50.s1.e0
and;O;O
other;O;O
drugs;O;O
DDI-DrugBank.d78.s0;;
Antacids;B-group;B-DDI-DrugBank.d78.s0.e0
,;O;O
Sucralfate;B-drug;B-DDI-DrugBank.d78.s0.e1
,;O;O
Metal;O;O
Cations;O;O
,;O;O
Multivitamins;B-group;B-DDI-DrugBank.d78.s0.e2
Quinolones;I-group;I-DDI-DrugBank.d78.s0.e3
form;O;O
chelates;O;O
with;O;O
alkaline;O;O
earth;O;O
and;O;O
transition;O;O
metal;O;O
cations;O;O
.;O;O
DDI-DrugBank.d78.s1;;
Administration;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d78.s1.e0
with;O;O
antacids;B-group;B-DDI-DrugBank.d78.s1.e1
containing;O;O
aluminum;B-drug;B-DDI-DrugBank.d78.s1.e2
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d78.s1.e3
,;O;O
or;O;O
calcium;B-drug;B-DDI-DrugBank.d78.s1.e4
,;O;O
with;O;O
sucralfate;B-drug;B-DDI-DrugBank.d78.s1.e5
,;O;O
with;O;O
metal;O;O
cations;O;O
such;O;O
as;O;O
iron;B-drug;B-DDI-DrugBank.d78.s1.e6
,;O;O
or;O;O
with;O;O
multivitamins;B-group;B-DDI-DrugBank.d78.s1.e7
containing;O;O
iron;B-drug;B-DDI-DrugBank.d78.s1.e8
or;O;O
zinc;B-drug;B-DDI-DrugBank.d78.s1.e9
,;O;O
or;O;O
with;O;O
formulations;O;O
containing;O;O
divalent;O;O
and;O;O
trivalent;O;O
cations;O;O
such;O;O
as;O;O
VIDEX;B-brand;B-DDI-DrugBank.d78.s1.e10
(;O;O
didanosine;B-drug;B-DDI-DrugBank.d78.s1.e11
);O;O
chewable;O;O
/;O;O
buffered;O;O
tablets;O;O
or;O;O
the;O;O
pediatric;O;O
powder;O;O
for;O;O
oral;O;O
solution;O;O
,;O;O
may;O;O
substantially;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d78.s1.e12
,;O;O
resulting;O;O
in;O;O
systemic;O;O
concentrations;O;O
considerably;O;O
lower;O;O
than;O;O
desired;O;O
.;O;O
DDI-DrugBank.d78.s2;;
These;O;O
agents;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
within;O;O
4;O;O
hours;O;O
before;O;O
or;O;O
4;O;O
hours;O;O
after;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s2.e0
administration;O;O
.;O;O
DDI-DrugBank.d78.s3;;
Caffeine;B-drug;B-DDI-DrugBank.d78.s3.e0
Theobromine;I-drug;I-DDI-DrugBank.d78.s3.e1
Grepafloxacin;I-drug;I-DDI-DrugBank.d78.s3.e2
,;O;O
like;O;O
other;O;O
quinolones;B-group;B-DDI-DrugBank.d78.s3.e3
,;O;O
may;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d78.s3.e4
and;O;O
theobromine;B-drug;B-DDI-DrugBank.d78.s3.e5
.;O;O
DDI-DrugBank.d78.s4;;
These;O;O
stimulants;O;O
are;O;O
commonly;O;O
found;O;O
in;O;O
coffee;O;O
and;O;O
tea;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d78.s5;;
In;O;O
some;O;O
patients;O;O
,;O;O
this;O;O
may;O;O
lead;O;O
to;O;O
reduced;O;O
clearance;O;O
,;O;O
prolongation;O;O
of;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
,;O;O
and;O;O
enhanced;O;O
effects;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d78.s5.e0
and;O;O
theobromine;B-drug;B-DDI-DrugBank.d78.s5.e1
.;O;O
DDI-DrugBank.d78.s6;;
Theophylline;B-drug;B-DDI-DrugBank.d78.s6.e0
:;O;O
Grepafloxacin;B-drug;B-DDI-DrugBank.d78.s6.e1
is;O;O
a;O;O
competitive;O;O
inhibitor;O;O
of;O;O
the;O;O
metabolism;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s6.e2
.;O;O
DDI-DrugBank.d78.s7;;
Serum;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s7.e0
concentrations;O;O
increase;O;O
when;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s7.e1
is;O;O
initiated;O;O
in;O;O
a;O;O
patient;O;O
maintained;O;O
on;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s7.e2
.;O;O
DDI-DrugBank.d78.s8;;
When;O;O
initiating;O;O
a;O;O
multi;O;O
-;O;O
day;O;O
course;O;O
of;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s8.e0
in;O;O
a;O;O
patient;O;O
maintained;O;O
on;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s8.e1
,;O;O
the;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s8.e2
maintenance;O;O
dose;O;O
should;O;O
be;O;O
halved;O;O
for;O;O
the;O;O
period;O;O
of;O;O
concurrent;O;O
use;O;O
of;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s8.e3
and;O;O
monitoring;O;O
of;O;O
serum;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s8.e4
concentrations;O;O
should;O;O
be;O;O
initiated;O;O
as;O;O
a;O;O
guide;O;O
to;O;O
further;O;O
dosage;O;O
adjustments;O;O
.;O;O
DDI-DrugBank.d78.s9;;
Warfarin;B-drug;B-DDI-DrugBank.d78.s9.e0
:;O;O
In;O;O
subjects;O;O
receiving;O;O
warfarin;B-drug;B-DDI-DrugBank.d78.s9.e1
,;O;O
no;O;O
significant;O;O
change;O;O
in;O;O
clotting;O;O
time;O;O
was;O;O
observed;O;O
when;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s9.e2
was;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d78.s10;;
However;O;O
,;O;O
because;O;O
some;O;O
quinolones;B-group;B-DDI-DrugBank.d78.s10.e0
have;O;O
been;O;O
reported;O;O
to;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d78.s10.e1
or;O;O
its;O;O
derivatives;O;O
,;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
anticoagulation;O;O
test;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
if;O;O
a;O;O
quinolone;B-group;B-DDI-DrugBank.d78.s10.e2
antimicrobial;I-group;I-DDI-DrugBank.d78.s10.e2
is;O;O
administered;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d78.s10.e3
or;O;O
its;O;O
derivatives;O;O
.;O;O
DDI-DrugBank.d78.s11;;
Drugs;O;O
Metabolized;O;O
by;O;O
Cytochrome;O;O
P450;O;O
Enzymes;O;O
The;O;O
drug;O;O
interaction;O;O
study;O;O
evaluating;O;O
the;O;O
effect;O;O
of;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s11.e0
on;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s11.e1
indicates;O;O
that;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s11.e2
inhibits;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s11.e3
metabolism;O;O
,;O;O
which;O;O
is;O;O
mediated;O;O
by;O;O
CYP1A2;O;O
.;O;O
DDI-DrugBank.d78.s12;;
While;O;O
no;O;O
clinical;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
to;O;O
evaluate;O;O
the;O;O
effect;O;O
of;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s12.e0
on;O;O
the;O;O
metabolism;O;O
of;O;O
C.P.A.;O;O
DDI-DrugBank.d78.s13;;
substrates;O;O
,;O;O
in;O;O
vitro;O;O
data;O;O
suggest;O;O
similar;O;O
effects;O;O
of;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s13.e0
in;O;O
CYP3A4;O;O
mediated;O;O
metabolism;O;O
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d78.s13.e1
metabolism;O;O
.;O;O
DDI-DrugBank.d78.s14;;
In;O;O
addition;O;O
,;O;O
other;O;O
quinolones;B-group;B-DDI-DrugBank.d78.s14.e0
have;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
the;O;O
CYP3A4;O;O
-;O;O
mediated;O;O
metabolism;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d78.s14.e1
.;O;O
DDI-DrugBank.d78.s15;;
Other;O;O
drugs;O;O
metabolized;O;O
by;O;O
C.P.A.;O;O
DDI-DrugBank.d78.s16;;
include;O;O
terfenadine;B-drug;B-DDI-DrugBank.d78.s16.e0
,;O;O
astemizole;B-drug;B-DDI-DrugBank.d78.s16.e1
,;O;O
cisapride;B-drug;B-DDI-DrugBank.d78.s16.e2
,;O;O
midazolam;B-drug;B-DDI-DrugBank.d78.s16.e3
,;O;O
and;O;O
triazolam;B-drug;B-DDI-DrugBank.d78.s16.e4
.;O;O
DDI-DrugBank.d78.s17;;
The;O;O
clinical;O;O
relevance;O;O
of;O;O
the;O;O
potential;O;O
effect;O;O
of;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s17.e0
on;O;O
the;O;O
metabolism;O;O
of;O;O
C.P.A.;O;O
substrates;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d78.s18;;
Patients;O;O
receiving;O;O
concurrent;O;O
administration;O;O
of;O;O
substrates;O;O
of;O;O
C.P.A.;O;O
were;O;O
not;O;O
excluded;O;O
from;O;O
clinical;O;O
trials;O;O
of;O;O
grepafloxacin;B-drug;B-DDI-DrugBank.d78.s18.e0
.;O;O
DDI-DrugBank.d78.s19;;
Nonsteroidal;B-group;B-DDI-DrugBank.d78.s19.e0
Anti;I-group;I-DDI-DrugBank.d78.s19.e0
-;I-group;I-DDI-DrugBank.d78.s19.e0
inflammatory;I-group;I-DDI-DrugBank.d78.s19.e0
Drugs;I-group;I-DDI-DrugBank.d78.s19.e0
(;O;O
NSAIDs;B-group;B-DDI-DrugBank.d78.s19.e1
);O;O
:;O;O
The;O;O
concomitant;O;O
administration;O;O
of;O;O
a;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d78.s19.e2
anti;I-group;I-DDI-DrugBank.d78.s19.e2
inflammatory;I-group;I-DDI-DrugBank.d78.s19.e2
drug;I-group;I-DDI-DrugBank.d78.s19.e2
with;O;O
a;O;O
quinolone;B-group;B-DDI-DrugBank.d78.s19.e3
may;O;O
increase;O;O
the;O;O
risks;O;O
of;O;O
CNS;O;O
stimulation;O;O
and;O;O
convulsions;O;O
.;O;O
DDI-DrugBank.d78.s20;;
Antidiabetic;B-group;B-DDI-DrugBank.d78.s20.e0
Agents;I-group;I-DDI-DrugBank.d78.s20.e0
:;O;O
Disturbances;O;O
of;O;O
blood;O;O
glucose;O;O
,;O;O
including;O;O
hyperglycemia;O;O
and;O;O
hypoglycemia;O;O
,;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
treated;O;O
concomitantly;O;O
with;O;O
quinolones;B-group;B-DDI-DrugBank.d78.s20.e1
and;O;O
an;O;O
antidiabetic;B-group;B-DDI-DrugBank.d78.s20.e2
agent;I-group;I-DDI-DrugBank.d78.s20.e2
.;O;O
DDI-DrugBank.d78.s21;;
Therefore;O;O
,;O;O
careful;O;O
monitoring;O;O
of;O;O
blood;O;O
glucose;O;O
is;O;O
recommended;O;O
when;O;O
these;O;O
agents;O;O
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d83.s0;;
Patients;O;O
on;O;O
warfarin;B-group;B-DDI-DrugBank.d83.s0.e0
-;I-group;I-DDI-DrugBank.d83.s0.e0
type;I-group;I-DDI-DrugBank.d83.s0.e0
anticoagulant;I-group;I-DDI-DrugBank.d83.s0.e0
therapy;O;O
may;O;O
require;O;O
dosage;O;O
adjustment;O;O
of;O;O
the;O;O
anticoagulant;O;O
during;O;O
and;O;O
after;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d83.s0.e1
therapy;O;O
.;O;O
DDI-DrugBank.d83.s1;;
Concomitant;O;O
use;O;O
of;O;O
barbiturates;B-group;B-DDI-DrugBank.d83.s1.e0
usually;O;O
depresses;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d83.s1.e1
activity;O;O
and;O;O
may;O;O
necessitate;O;O
raising;O;O
the;O;O
dosage;O;O
.;O;O
DDI-DrugBank.d83.s2;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d83.s2.e0
has;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
the;O;O
efficacy;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d83.s2.e1
and;O;O
to;O;O
increase;O;O
the;O;O
incidence;O;O
of;O;O
breakthrough;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d398.s0;;
The;O;O
use;O;O
of;O;O
codeine;B-drug;B-DDI-DrugBank.d398.s0.e0
may;O;O
result;O;O
in;O;O
additive;O;O
CNS;O;O
depressant;O;O
effects;O;O
when;O;O
coadministered;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d398.s0.e1
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d398.s0.e2
,;O;O
psychotropics;B-group;B-DDI-DrugBank.d398.s0.e3
or;O;O
other;O;O
drugs;O;O
that;O;O
produce;O;O
CNS;O;O
depression;O;O
.;O;O
DDI-DrugBank.d398.s1;;
Serious;O;O
toxicity;O;O
may;O;O
result;O;O
if;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d398.s1.e0
is;O;O
coadministered;O;O
with;O;O
monoamine;B-group;B-DDI-DrugBank.d398.s1.e1
oxidase;I-group;I-DDI-DrugBank.d398.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d398.s1.e1
(;O;O
MAOIs;B-group;B-DDI-DrugBank.d398.s1.e2
);O;O
.;O;O
DDI-DrugBank.d398.s2;;
The;O;O
use;O;O
of;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d398.s2.e0
hydrobromide;I-drug;I-DDI-DrugBank.d398.s2.e0
may;O;O
result;O;O
in;O;O
additive;O;O
CNS;O;O
depressant;O;O
effects;O;O
when;O;O
coadministered;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d398.s2.e1
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d398.s2.e2
,;O;O
psychotropics;B-group;B-DDI-DrugBank.d398.s2.e3
or;O;O
other;O;O
drugs;O;O
that;O;O
produce;O;O
CNS;O;O
depression;O;O
.;O;O
DDI-DrugBank.d302.s0;;
http://www.rxlist.com/cgi/generic3/guanethidine_od.htm;O;O
DDI-DrugBank.d507.s0;;
The;O;O
potential;O;O
for;O;O
increased;O;O
sedation;O;O
when;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s0.e0
is;O;O
given;O;O
with;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d507.s0.e1
-;I-group;I-DDI-DrugBank.d507.s0.e1
depressant;I-group;I-DDI-DrugBank.d507.s0.e1
drug;I-group;I-DDI-DrugBank.d507.s0.e1
should;O;O
be;O;O
appreciated;O;O
.;O;O
DDI-DrugBank.d507.s1;;
The;O;O
administration;O;O
of;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s1.e0
concomitantly;O;O
with;O;O
known;O;O
microsomal;O;O
enzyme;O;O
inducer;O;O
(;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d507.s1.e1
or;O;O
phenytoin;B-drug;B-DDI-DrugBank.d507.s1.e2
);O;O
to;O;O
two;O;O
patients;O;O
with;O;O
renal;O;O
impairment;O;O
reportedly;O;O
resulted;O;O
in;O;O
significant;O;O
reductions;O;O
in;O;O
elimination;O;O
half;O;O
-;O;O
life;O;O
and;O;O
plasma;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d507.s2;;
In;O;O
such;O;O
cases;O;O
,;O;O
therefore;O;O
,;O;O
more;O;O
frequent;O;O
dosing;O;O
may;O;O
be;O;O
required;O;O
to;O;O
achieve;O;O
or;O;O
maintain;O;O
the;O;O
desired;O;O
hypotensive;O;O
response;O;O
.;O;O
DDI-DrugBank.d507.s3;;
Further;O;O
,;O;O
if;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s3.e0
is;O;O
to;O;O
be;O;O
discontinued;O;O
in;O;O
such;O;O
patients;O;O
,;O;O
careful;O;O
tapering;O;O
of;O;O
the;O;O
dosage;O;O
may;O;O
be;O;O
necessary;O;O
in;O;O
order;O;O
to;O;O
avoid;O;O
rebound;O;O
phenomena;O;O
.;O;O
DDI-DrugBank.d507.s4;;
TCAs;B-group;B-DDI-DrugBank.d507.s4.e0
decrease;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s4.e1
.;O;O
DDI-DrugBank.d507.s5;;
Noncardioselective;B-group;B-DDI-DrugBank.d507.s5.e0
beta;I-group;I-DDI-DrugBank.d507.s5.e0
-;I-group;I-DDI-DrugBank.d507.s5.e0
blockers;I-group;I-DDI-DrugBank.d507.s5.e0
(;O;O
nadolol;B-drug;B-DDI-DrugBank.d507.s5.e1
,;O;O
porpranolol;O;O
,;O;O
timolol;B-drug;B-DDI-DrugBank.d507.s5.e2
);O;O
may;O;O
exacerbate;O;O
rebound;O;O
hypertension;O;O
when;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s5.e3
is;O;O
withdrawn;O;O
.;O;O
DDI-DrugBank.d507.s6;;
The;O;O
beta;B-group;B-DDI-DrugBank.d507.s6.e0
-;I-group;I-DDI-DrugBank.d507.s6.e0
blocker;I-group;I-DDI-DrugBank.d507.s6.e0
should;O;O
be;O;O
withdrawn;O;O
first;O;O
.;O;O
DDI-DrugBank.d507.s7;;
The;O;O
gradual;O;O
withdrawal;O;O
of;O;O
guafacine;B-drug;B-DDI-DrugBank.d507.s7.e0
or;O;O
a;O;O
cardioselective;B-group;B-DDI-DrugBank.d507.s7.e1
beta;I-group;I-DDI-DrugBank.d507.s7.e1
-;I-group;I-DDI-DrugBank.d507.s7.e1
blocker;I-group;I-DDI-DrugBank.d507.s7.e1
could;O;O
be;O;O
substituted;O;O
.;O;O
DDI-DrugBank.d507.s8;;
Anticoagulants;B-group;B-DDI-DrugBank.d507.s8.e0
:;O;O
Ten;O;O
patients;O;O
who;O;O
were;O;O
stabilized;O;O
on;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d507.s8.e1
were;O;O
given;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s8.e2
,;O;O
1;O;O
-;O;O
2;O;O
mg;O;O
/;O;O
day;O;O
,;O;O
for;O;O
4;O;O
weeks;O;O
.;O;O
DDI-DrugBank.d507.s9;;
No;O;O
changes;O;O
were;O;O
observed;O;O
in;O;O
the;O;O
degree;O;O
of;O;O
anticoagulation;O;O
.;O;O
DDI-DrugBank.d507.s10;;
In;O;O
several;O;O
well;O;O
-;O;O
controlled;O;O
studies;O;O
,;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s10.e0
was;O;O
administered;O;O
together;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d507.s10.e1
with;O;O
no;O;O
drug;O;O
interactions;O;O
reported;O;O
.;O;O
DDI-DrugBank.d507.s11;;
In;O;O
the;O;O
long;O;O
-;O;O
term;O;O
safety;O;O
studies;O;O
,;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s11.e0
was;O;O
given;O;O
concomitantly;O;O
with;O;O
many;O;O
drugs;O;O
without;O;O
evidence;O;O
of;O;O
any;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d507.s12;;
The;O;O
principal;O;O
drugs;O;O
given;O;O
(;O;O
number;O;O
of;O;O
patients;O;O
in;O;O
parentheses;O;O
);O;O
were;O;O
:;O;O
cardiac;B-group;B-DDI-DrugBank.d507.s12.e0
glycosides;I-group;I-DDI-DrugBank.d507.s12.e0
(;O;O
115;O;O
);O;O
,;O;O
sedatives;B-group;B-DDI-DrugBank.d507.s12.e1
and;O;O
hypnotics;B-group;B-DDI-DrugBank.d507.s12.e2
(;O;O
103;O;O
);O;O
,;O;O
coronary;B-group;B-DDI-DrugBank.d507.s12.e3
vasodilators;I-group;I-DDI-DrugBank.d507.s12.e3
(;O;O
52;O;O
);O;O
,;O;O
oral;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d507.s12.e4
(;O;O
45;O;O
);O;O
,;O;O
cough;O;O
and;O;O
cold;O;O
preparations;O;O
(;O;O
45;O;O
);O;O
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d507.s12.e5
(;O;O
38;O;O
);O;O
,;O;O
antihyperlipidemics;B-group;B-DDI-DrugBank.d507.s12.e6
(;O;O
29;O;O
);O;O
,;O;O
antigout;B-group;B-DDI-DrugBank.d507.s12.e7
drugs;I-group;I-DDI-DrugBank.d507.s12.e7
(;O;O
24;O;O
);O;O
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d507.s12.e8
(;O;O
18;O;O
);O;O
,;O;O
bronchodilators;B-group;B-DDI-DrugBank.d507.s12.e9
(;O;O
13;O;O
);O;O
,;O;O
insulin;B-drug;B-DDI-DrugBank.d507.s12.e10
(;O;O
10;O;O
);O;O
,;O;O
and;O;O
beta;B-group;B-DDI-DrugBank.d507.s12.e11
blockers;I-group;I-DDI-DrugBank.d507.s12.e11
(;O;O
10;O;O
);O;O
.;O;O
DDI-DrugBank.d507.s13;;
Laboratory;O;O
Test;O;O
In;O;O
clinical;O;O
trials;O;O
,;O;O
no;O;O
clinically;O;O
relevant;O;O
laboratory;O;O
test;O;O
abnormalities;O;O
were;O;O
identified;O;O
as;O;O
causally;O;O
related;O;O
to;O;O
drug;O;O
during;O;O
short;O;O
-;O;O
term;O;O
treatment;O;O
with;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s13.e0
.;O;O
DDI-DrugBank.d507.s14;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
No;O;O
laboratory;O;O
test;O;O
abnormalities;O;O
related;O;O
to;O;O
the;O;O
use;O;O
of;O;O
guanfacine;B-drug;B-DDI-DrugBank.d507.s14.e0
have;O;O
been;O;O
identified;O;O
.;O;O
DDI-DrugBank.d186.s0;;
An;O;O
encephalopathic;O;O
syndrome;O;O
(;O;O
characterized;O;O
by;O;O
weakness;O;O
,;O;O
lethargy;O;O
,;O;O
fever;O;O
,;O;O
tremulousness;O;O
and;O;O
confusion;O;O
,;O;O
extrapyramidal;O;O
symptoms;O;O
,;O;O
leukocytosis;O;O
,;O;O
elevated;O;O
serum;O;O
enzymes;O;O
,;O;O
BUN;O;O
,;O;O
and;O;O
FBS;O;O
);O;O
followed;O;O
by;O;O
irreversible;O;O
brain;O;O
damage;O;O
has;O;O
occurred;O;O
in;O;O
a;O;O
few;O;O
patients;O;O
treated;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d186.s0.e0
plus;O;O
HALDOL;B-brand;B-DDI-DrugBank.d186.s0.e1
.;O;O
DDI-DrugBank.d186.s1;;
A;O;O
causal;O;O
relationship;O;O
between;O;O
these;O;O
events;O;O
and;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d186.s1.e0
and;O;O
HALDOL;B-brand;B-DDI-DrugBank.d186.s1.e1
has;O;O
not;O;O
been;O;O
established;O;O
,;O;O
DDI-DrugBank.d186.s2;;
however;O;O
,;O;O
patients;O;O
receiving;O;O
such;O;O
combined;O;O
therapy;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
for;O;O
early;O;O
evidence;O;O
of;O;O
neurological;O;O
toxicity;O;O
and;O;O
treatment;O;O
discontinued;O;O
promptly;O;O
if;O;O
such;O;O
signs;O;O
appear;O;O
.;O;O
DDI-DrugBank.d186.s3;;
As;O;O
with;O;O
other;O;O
antipsychotic;B-group;B-DDI-DrugBank.d186.s3.e0
agents;I-group;I-DDI-DrugBank.d186.s3.e0
,;O;O
it;O;O
should;O;O
be;O;O
noted;O;O
that;O;O
HALDOL;B-brand;B-DDI-DrugBank.d186.s3.e1
may;O;O
be;O;O
capable;O;O
of;O;O
potentiating;O;O
CNS;B-group;B-DDI-DrugBank.d186.s3.e2
depressants;I-group;I-DDI-DrugBank.d186.s3.e2
such;O;O
as;O;O
anesthetics;B-group;B-DDI-DrugBank.d186.s3.e3
,;O;O
opiates;B-group;B-DDI-DrugBank.d186.s3.e4
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d186.s3.e5
.;O;O
DDI-DrugBank.d186.s4;;
In;O;O
a;O;O
study;O;O
of;O;O
12;O;O
schizophrenic;O;O
patients;O;O
coadministered;O;O
oral;O;O
haloperidol;B-drug;B-DDI-DrugBank.d186.s4.e0
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d186.s4.e1
,;O;O
plasma;O;O
haloperidol;B-drug;B-DDI-DrugBank.d186.s4.e2
levels;O;O
were;O;O
decreased;O;O
by;O;O
a;O;O
mean;O;O
of;O;O
70;O;O
%;O;O
and;O;O
mean;O;O
scores;O;O
on;O;O
the;O;O
Brief;O;O
Psychiatric;O;O
Rating;O;O
Scale;O;O
were;O;O
increased;O;O
from;O;O
baseline;O;O
.;O;O
DDI-DrugBank.d186.s5;;
In;O;O
5;O;O
other;O;O
schizophrenic;O;O
patients;O;O
treated;O;O
with;O;O
oral;O;O
haloperidol;B-drug;B-DDI-DrugBank.d186.s5.e0
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d186.s5.e1
,;O;O
discontinuation;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d186.s5.e2
produced;O;O
a;O;O
mean;O;O
3.3;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
haloperidol;B-drug;B-DDI-DrugBank.d186.s5.e3
concentrations;O;O
.;O;O
DDI-DrugBank.d186.s6;;
Thus;O;O
,;O;O
careful;O;O
monitoring;O;O
of;O;O
clinical;O;O
status;O;O
is;O;O
warranted;O;O
when;O;O
rifampin;B-drug;B-DDI-DrugBank.d186.s6.e0
is;O;O
administered;O;O
or;O;O
discontinued;O;O
in;O;O
haloperidol;B-drug;B-DDI-DrugBank.d186.s6.e1
-;O;O
treated;O;O
patients;O;O
.;O;O
DDI-DrugBank.d74.s0;;
FLUOTHANE;B-brand;B-DDI-DrugBank.d74.s0.e0
augments;O;O
the;O;O
action;O;O
of;O;O
non;B-group;B-DDI-DrugBank.d74.s0.e1
-;I-group;I-DDI-DrugBank.d74.s0.e1
depolarising;I-group;I-DDI-DrugBank.d74.s0.e1
muscle;I-group;I-DDI-DrugBank.d74.s0.e1
relaxants;I-group;I-DDI-DrugBank.d74.s0.e1
and;O;O
the;O;O
muscle;O;O
relaxant;O;O
effects;O;O
of;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d74.s0.e2
.;O;O
DDI-DrugBank.d74.s1;;
FLUOTHANE;B-brand;B-DDI-DrugBank.d74.s1.e0
may;O;O
augment;O;O
the;O;O
hypotension;O;O
caused;O;O
by;O;O
the;O;O
ganglionic;O;O
-;O;O
blocking;O;O
effect;O;O
of;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d74.s1.e1
.;O;O
DDI-DrugBank.d74.s2;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
during;O;O
the;O;O
administration;O;O
of;O;O
adrenaline;B-drug;B-DDI-DrugBank.d74.s2.e0
to;O;O
patients;O;O
anaesthetised;O;O
with;O;O
FLUOTHANE;B-brand;B-DDI-DrugBank.d74.s2.e1
as;O;O
arrhythmias;O;O
may;O;O
be;O;O
precipitated;O;O
.;O;O
DDI-DrugBank.d74.s3;;
For;O;O
this;O;O
reason;O;O
the;O;O
dose;O;O
of;O;O
adrenaline;B-drug;B-DDI-DrugBank.d74.s3.e0
should;O;O
be;O;O
restricted;O;O
and;O;O
an;O;O
antiarrhythmic;B-group;B-DDI-DrugBank.d74.s3.e1
agent;I-group;I-DDI-DrugBank.d74.s3.e1
administered;O;O
as;O;O
appropriate;O;O
.;O;O
DDI-DrugBank.d74.s4;;
Caution;O;O
should;O;O
also;O;O
be;O;O
applied;O;O
for;O;O
other;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d74.s4.e0
,;O;O
and;O;O
for;O;O
aminophylline;B-drug;B-DDI-DrugBank.d74.s4.e1
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d74.s4.e2
and;O;O
tricyclic;B-group;B-DDI-DrugBank.d74.s4.e3
antidepressants;I-group;I-DDI-DrugBank.d74.s4.e3
,;O;O
which;O;O
may;O;O
also;O;O
precipitate;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d488.s0;;
Drug;O;O
Interactions;O;O
:;O;O
a.;O;O
Drugs;O;O
Enhancing;O;O
Heparin;B-drug;B-DDI-DrugBank.d488.s0.e0
Effect;O;O
:;O;O
Oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d488.s0.e1
:;O;O
Heparin;B-drug;B-DDI-DrugBank.d488.s0.e2
sodium;I-drug;I-DDI-DrugBank.d488.s0.e2
may;O;O
prolong;O;O
the;O;O
one;O;O
-;O;O
stage;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d488.s1;;
Therefore;O;O
,;O;O
when;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s1.e0
sodium;I-drug;I-DDI-DrugBank.d488.s1.e0
is;O;O
given;O;O
with;O;O
dicumarol;B-drug;B-DDI-DrugBank.d488.s1.e1
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d488.s1.e2
sodium;I-drug;I-DDI-DrugBank.d488.s1.e2
,;O;O
a;O;O
period;O;O
of;O;O
at;O;O
least;O;O
5;O;O
hours;O;O
after;O;O
the;O;O
last;O;O
intravenous;O;O
dose;O;O
or;O;O
24;O;O
hours;O;O
after;O;O
the;O;O
last;O;O
subcutaneous;O;O
dose;O;O
should;O;O
elapse;O;O
before;O;O
blood;O;O
is;O;O
drawn;O;O
if;O;O
a;O;O
valid;O;O
prothrombin;O;O
time;O;O
is;O;O
to;O;O
be;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d488.s2;;
Platelet;B-group;B-DDI-DrugBank.d488.s2.e0
inhibitors;I-group;I-DDI-DrugBank.d488.s2.e0
:;O;O
Drugs;O;O
such;O;O
as;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d488.s2.e1
acid;I-drug;I-DDI-DrugBank.d488.s2.e1
,;O;O
dextran;B-drug;B-DDI-DrugBank.d488.s2.e2
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d488.s2.e3
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d488.s2.e4
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d488.s2.e5
,;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d488.s2.e6
,;O;O
hydroxychloroquine;B-drug;B-DDI-DrugBank.d488.s2.e7
and;O;O
others;O;O
that;O;O
interfere;O;O
with;O;O
platelet;O;O
-;O;O
aggregation;O;O
reactions;O;O
(;O;O
the;O;O
main;O;O
hemostatic;O;O
defense;O;O
of;O;O
heparinized;O;O
patients;O;O
);O;O
may;O;O
induce;O;O
bleeding;O;O
and;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s2.e8
sodium;I-drug;I-DDI-DrugBank.d488.s2.e8
.;O;O
DDI-DrugBank.d488.s3;;
The;O;O
anticoagulant;O;O
effect;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s3.e0
is;O;O
enhanced;O;O
by;O;O
concurrent;O;O
treatment;O;O
with;O;O
antithrombin;B-drug;B-DDI-DrugBank.d488.s3.e1
III;I-drug;I-DDI-DrugBank.d488.s3.e1
(;O;O
human;O;O
);O;O
in;O;O
patients;O;O
with;O;O
hereditary;O;O
antithrombin;O;O
III;O;O
deficiency;O;O
.;O;O
DDI-DrugBank.d488.s4;;
Thus;O;O
in;O;O
order;O;O
to;O;O
avoid;O;O
bleeding;O;O
,;O;O
reduced;O;O
dosage;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s4.e0
is;O;O
recommended;O;O
during;O;O
treatment;O;O
with;O;O
antithrombin;B-drug;B-DDI-DrugBank.d488.s4.e1
III;I-drug;I-DDI-DrugBank.d488.s4.e1
(;O;O
human;O;O
);O;O
.;O;O
DDI-DrugBank.d488.s5;;
b.;O;O
DDI-DrugBank.d488.s6;;
Drugs;O;O
Decreasing;O;O
Heparin;B-drug;B-DDI-DrugBank.d488.s6.e0
Effect;O;O
:;O;O
Digitalis;B-group;B-DDI-DrugBank.d488.s6.e1
,;O;O
tetracyclines;B-group;B-DDI-DrugBank.d488.s6.e2
,;O;O
nicotine;B-drug;B-DDI-DrugBank.d488.s6.e3
,;O;O
or;O;O
antihistamines;B-group;B-DDI-DrugBank.d488.s6.e4
may;O;O
partially;O;O
counteract;O;O
the;O;O
anticoagulant;O;O
action;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s6.e5
sodium;I-drug;I-DDI-DrugBank.d488.s6.e5
.;O;O
DDI-DrugBank.d488.s7;;
Heparin;B-drug;B-DDI-DrugBank.d488.s7.e0
Sodium;I-drug;I-DDI-DrugBank.d488.s7.e0
Injection;O;O
should;O;O
not;O;O
be;O;O
mixed;O;O
with;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d488.s7.e1
,;O;O
droperidol;B-drug;B-DDI-DrugBank.d488.s7.e2
,;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d488.s7.e3
,;O;O
or;O;O
mitoxantrone;B-drug;B-DDI-DrugBank.d488.s7.e4
,;O;O
since;O;O
it;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
these;O;O
drugs;O;O
are;O;O
incompatible;O;O
with;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s7.e5
and;O;O
a;O;O
precipitate;O;O
may;O;O
form;O;O
.;O;O
DDI-DrugBank.d488.s8;;
Drug;O;O
/;O;O
Laboratory;O;O
Tests;O;O
Interactions;O;O
Hyperaminotransferasemia;O;O
:;O;O
Significant;O;O
elevations;O;O
of;O;O
aminotransferase;O;O
(;O;O
SGOT;O;O
[;O;O
S;O;O
-;O;O
AST;O;O
];O;O
and;O;O
SGPT;O;O
[;O;O
S;O;O
-;O;O
ALT;O;O
];O;O
);O;O
levels;O;O
have;O;O
occurred;O;O
in;O;O
a;O;O
high;O;O
percentage;O;O
of;O;O
patients;O;O
(;O;O
and;O;O
healthy;O;O
subjects;O;O
);O;O
who;O;O
have;O;O
received;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s8.e0
sodium;I-drug;I-DDI-DrugBank.d488.s8.e0
.;O;O
DDI-DrugBank.d488.s9;;
Since;O;O
aminotransferase;O;O
determinations;O;O
are;O;O
important;O;O
in;O;O
the;O;O
differential;O;O
diagnosis;O;O
of;O;O
myocardial;O;O
infarction;O;O
,;O;O
liver;O;O
disease;O;O
and;O;O
pulmonary;O;O
emboli;O;O
,;O;O
rises;O;O
that;O;O
might;O;O
be;O;O
caused;O;O
by;O;O
drugs;O;O
(;O;O
heparin;B-drug;B-DDI-DrugBank.d488.s9.e0
sodium;I-drug;I-DDI-DrugBank.d488.s9.e0
);O;O
should;O;O
be;O;O
interpreted;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d514.s0;;
Opioids;B-group;B-DDI-DrugBank.d514.s0.e0
are;O;O
strong;O;O
central;B-group;B-DDI-DrugBank.d514.s0.e1
nervous;I-group;I-DDI-DrugBank.d514.s0.e1
system;I-group;I-DDI-DrugBank.d514.s0.e1
depressants;I-group;I-DDI-DrugBank.d514.s0.e1
,;O;O
but;O;O
regular;O;O
users;O;O
develop;O;O
physiological;O;O
tolerance;O;O
allowing;O;O
gradually;O;O
increased;O;O
dosages;O;O
.;O;O
DDI-DrugBank.d514.s1;;
In;O;O
combination;O;O
with;O;O
other;O;O
central;B-group;B-DDI-DrugBank.d514.s1.e0
nervous;I-group;I-DDI-DrugBank.d514.s1.e0
system;I-group;I-DDI-DrugBank.d514.s1.e0
depressants;I-group;I-DDI-DrugBank.d514.s1.e0
,;O;O
heroin;B-drug_n;B-DDI-DrugBank.d514.s1.e1
may;O;O
still;O;O
kill;O;O
even;O;O
experienced;O;O
users;O;O
,;O;O
particularly;O;O
if;O;O
their;O;O
tolerance;O;O
to;O;O
the;O;O
drug;O;O
has;O;O
reduced;O;O
or;O;O
the;O;O
strength;O;O
of;O;O
their;O;O
usual;O;O
dose;O;O
has;O;O
increased;O;O
.;O;O
DDI-DrugBank.d514.s2;;
Toxicology;O;O
studies;O;O
of;O;O
heroin;B-drug_n;B-DDI-DrugBank.d514.s2.e0
-;O;O
related;O;O
deaths;O;O
reveal;O;O
frequent;O;O
involvement;O;O
of;O;O
other;O;O
central;B-group;B-DDI-DrugBank.d514.s2.e1
nervous;I-group;I-DDI-DrugBank.d514.s2.e1
system;I-group;I-DDI-DrugBank.d514.s2.e1
depressants;I-group;I-DDI-DrugBank.d514.s2.e1
,;O;O
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d514.s2.e2
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d514.s2.e3
such;O;O
as;O;O
diazepam;B-drug;B-DDI-DrugBank.d514.s2.e4
(;O;O
Valium;B-brand;B-DDI-DrugBank.d514.s2.e5
);O;O
,;O;O
and;O;O
,;O;O
to;O;O
a;O;O
rising;O;O
degree;O;O
,;O;O
methadone;B-drug;B-DDI-DrugBank.d514.s2.e6
.;O;O
DDI-DrugBank.d514.s3;;
Ironically;O;O
,;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d514.s3.e0
are;O;O
often;O;O
used;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
heroin;B-drug;B-DDI-DrugBank.d514.s3.e1
addiction;O;O
while;O;O
they;O;O
cause;O;O
much;O;O
more;O;O
severe;O;O
withdrawal;O;O
symptoms;O;O
.;O;O
DDI-DrugBank.d514.s4;;
Cocaine;B-drug;B-DDI-DrugBank.d514.s4.e0
sometimes;O;O
proves;O;O
to;O;O
be;O;O
fatal;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
heroin;B-drug_n;B-DDI-DrugBank.d514.s4.e1
.;O;O
DDI-DrugBank.d421.s0;;
No;O;O
information;O;O
available;O;O
.;O;O
DDI-DrugBank.d457.s0;;
Barbiturates;B-group;B-DDI-DrugBank.d457.s0.e0
may;O;O
decrease;O;O
the;O;O
effectiveness;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d457.s0.e1
,;O;O
certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d457.s0.e2
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d457.s0.e3
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d457.s0.e4
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d457.s0.e5
,;O;O
anticoagulants;B-group;B-DDI-DrugBank.d457.s0.e6
,;O;O
and;O;O
beta;B-group;B-DDI-DrugBank.d457.s0.e7
blockers;I-group;I-DDI-DrugBank.d457.s0.e7
.;O;O
DDI-DrugBank.d31.s0;;
MAO;B-group;B-DDI-DrugBank.d31.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d31.s0.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
hydralazine;B-drug;B-DDI-DrugBank.d31.s0.e1
.;O;O
DDI-DrugBank.d31.s1;;
When;O;O
other;O;O
potent;O;O
parental;O;O
antihypertensive;B-group;B-DDI-DrugBank.d31.s1.e0
drugs;I-group;I-DDI-DrugBank.d31.s1.e0
,;O;O
such;O;O
as;O;O
diazoxide;B-drug;B-DDI-DrugBank.d31.s1.e1
,;O;O
are;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
hydralazine;B-drug;B-DDI-DrugBank.d31.s1.e2
,;O;O
patients;O;O
should;O;O
be;O;O
continuously;O;O
observed;O;O
for;O;O
several;O;O
hours;O;O
for;O;O
any;O;O
excessive;O;O
fall;O;O
in;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d31.s2;;
Profound;O;O
hypotensive;O;O
episodes;O;O
may;O;O
occur;O;O
when;O;O
diazoxide;B-drug;B-DDI-DrugBank.d31.s2.e0
infection;O;O
and;O;O
hydralazine;B-drug;B-DDI-DrugBank.d31.s2.e1
are;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d31.s3;;
Beta;B-group;B-DDI-DrugBank.d31.s3.e0
-;I-group;I-DDI-DrugBank.d31.s3.e0
blockers;I-group;I-DDI-DrugBank.d31.s3.e0
(;O;O
metoprolol;B-drug;B-DDI-DrugBank.d31.s3.e1
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d31.s3.e2
);O;O
serum;O;O
concentrations;O;O
and;O;O
pharmacologic;O;O
effects;O;O
may;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d31.s4;;
Monitor;O;O
cardiovascular;O;O
status;O;O
.;O;O
DDI-DrugBank.d31.s5;;
Propranolol;B-drug;B-DDI-DrugBank.d31.s5.e0
increases;O;O
hydralazines;B-drug;B-DDI-DrugBank.d31.s5.e1
serum;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d31.s6;;
Acebutolol;B-drug;B-DDI-DrugBank.d31.s6.e0
,;O;O
atenolol;B-drug;B-DDI-DrugBank.d31.s6.e1
,;O;O
and;O;O
nadolol;B-drug;B-DDI-DrugBank.d31.s6.e2
(;O;O
low;O;O
hepatic;O;O
clearance;O;O
or;O;O
no;O;O
first;O;O
-;O;O
pass;O;O
metabolism;O;O
);O;O
are;O;O
unlikely;O;O
to;O;O
be;O;O
affected;O;O
.;O;O
DDI-DrugBank.d31.s7;;
NSAIDs;B-group;B-DDI-DrugBank.d31.s7.e0
may;O;O
decrease;O;O
the;O;O
hemodynamic;O;O
effects;O;O
of;O;O
hydralazine;B-drug;B-DDI-DrugBank.d31.s7.e1
,;O;O
DDI-DrugBank.d31.s8;;
avoid;O;O
use;O;O
if;O;O
possible;O;O
or;O;O
closely;O;O
monitor;O;O
cardiovascular;O;O
status;O;O
at;O;O
the;O;O
end;O;O
of;O;O
drug;O;O
interactions;O;O
DDI-DrugBank.d162.s0;;
When;O;O
given;O;O
concurrently;O;O
the;O;O
following;O;O
drugs;O;O
may;O;O
interact;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d162.s0.e0
diuretics;I-group;I-DDI-DrugBank.d162.s0.e0
.;O;O
DDI-DrugBank.d162.s1;;
Alcohol;B-drug;B-DDI-DrugBank.d162.s1.e0
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d162.s1.e1
,;O;O
or;O;O
narcotics;B-group;B-DDI-DrugBank.d162.s1.e2
:;O;O
potentiation;O;O
of;O;O
orthostatic;O;O
hypotension;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d162.s2;;
Antidiabetic;B-group;B-DDI-DrugBank.d162.s2.e0
drugs;I-group;I-DDI-DrugBank.d162.s2.e0
:;O;O
(;O;O
oral;O;O
agents;O;O
and;O;O
insulin;B-drug;B-DDI-DrugBank.d162.s2.e1
);O;O
-;O;O
dosage;O;O
adjustment;O;O
of;O;O
the;O;O
antidiabetic;B-group;B-DDI-DrugBank.d162.s2.e2
drug;I-group;I-DDI-DrugBank.d162.s2.e2
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d162.s3;;
Other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d162.s3.e0
drugs;I-group;I-DDI-DrugBank.d162.s3.e0
:;O;O
additive;O;O
effect;O;O
or;O;O
potentiation;O;O
.;O;O
DDI-DrugBank.d162.s4;;
Cholestyramine;B-drug;B-DDI-DrugBank.d162.s4.e0
and;O;O
colestipol;B-drug;B-DDI-DrugBank.d162.s4.e1
resins;I-group;I-DDI-DrugBank.d162.s4.e2
:;O;O
Absorption;O;O
of;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d162.s4.e3
is;O;O
impaired;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
anionic;B-group;B-DDI-DrugBank.d162.s4.e4
exchange;I-group;I-DDI-DrugBank.d162.s4.e4
resins;I-group;I-DDI-DrugBank.d162.s4.e4
.;O;O
DDI-DrugBank.d162.s5;;
Single;O;O
doses;O;O
of;O;O
either;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d162.s5.e0
or;O;O
colestipol;B-drug;B-DDI-DrugBank.d162.s5.e1
resins;I-group;I-DDI-DrugBank.d162.s5.e2
bind;O;O
the;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d162.s5.e3
and;O;O
reduce;O;O
its;O;O
absorption;O;O
from;O;O
the;O;O
gastrointestinal;O;O
tract;O;O
by;O;O
up;O;O
to;O;O
85;O;O
and;O;O
43;O;O
percent;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d162.s6;;
Corticosteroids;B-group;B-DDI-DrugBank.d162.s6.e0
,;O;O
ACTH;B-drug;B-DDI-DrugBank.d162.s6.e1
:;O;O
intensified;O;O
electrolyte;O;O
depletion;O;O
,;O;O
particularly;O;O
hypokalemia;O;O
.;O;O
DDI-DrugBank.d162.s7;;
Pressor;O;O
amines;O;O
(;O;O
e.g.;O;O
,;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d162.s7.e0
);O;O
:;O;O
possible;O;O
decreased;O;O
response;O;O
to;O;O
pressor;O;O
amines;O;O
but;O;O
not;O;O
sufficient;O;O
to;O;O
preclude;O;O
their;O;O
use;O;O
.;O;O
DDI-DrugBank.d162.s8;;
Skeletal;B-group;B-DDI-DrugBank.d162.s8.e0
muscle;I-group;I-DDI-DrugBank.d162.s8.e0
relaxants;I-group;I-DDI-DrugBank.d162.s8.e0
,;O;O
nondepolarizing;O;O
(;O;O
e.g.;O;O
,;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d162.s8.e1
);O;O
:;O;O
possible;O;O
increased;O;O
responsiveness;O;O
to;O;O
the;O;O
muscle;B-group;B-DDI-DrugBank.d162.s8.e2
relaxant;I-group;I-DDI-DrugBank.d162.s8.e2
.;O;O
DDI-DrugBank.d162.s9;;
Lithium;B-drug;B-DDI-DrugBank.d162.s9.e0
:;O;O
generally;O;O
should;O;O
not;O;O
be;O;O
given;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d162.s9.e1
.;O;O
DDI-DrugBank.d162.s10;;
Diuretic;B-group;B-DDI-DrugBank.d162.s10.e0
agents;I-group;I-DDI-DrugBank.d162.s10.e0
reduce;O;O
the;O;O
renal;O;O
clearance;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d162.s10.e1
and;O;O
add;O;O
a;O;O
high;O;O
risk;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d162.s10.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d162.s11;;
Refer;O;O
to;O;O
the;O;O
package;O;O
insert;O;O
for;O;O
lithium;B-drug;B-DDI-DrugBank.d162.s11.e0
preparations;O;O
before;O;O
use;O;O
of;O;O
such;O;O
preparations;O;O
with;O;O
Hydrochlorothiazide;B-drug;B-DDI-DrugBank.d162.s11.e1
.;O;O
DDI-DrugBank.d162.s12;;
Non;B-group;B-DDI-DrugBank.d162.s12.e0
-;I-group;I-DDI-DrugBank.d162.s12.e0
steroidal;I-group;I-DDI-DrugBank.d162.s12.e0
Anti;I-group;I-DDI-DrugBank.d162.s12.e0
-;I-group;I-DDI-DrugBank.d162.s12.e0
inflammatory;I-group;I-DDI-DrugBank.d162.s12.e0
Drugs;I-group;I-DDI-DrugBank.d162.s12.e0
:;O;O
In;O;O
some;O;O
patients;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
a;O;O
non;B-group;B-DDI-DrugBank.d162.s12.e1
-;I-group;I-DDI-DrugBank.d162.s12.e1
steroidal;I-group;I-DDI-DrugBank.d162.s12.e1
anti;I-group;I-DDI-DrugBank.d162.s12.e1
-;I-group;I-DDI-DrugBank.d162.s12.e1
inflammatory;I-group;I-DDI-DrugBank.d162.s12.e1
agent;I-group;I-DDI-DrugBank.d162.s12.e1
can;O;O
reduce;O;O
the;O;O
diuretic;O;O
,;O;O
natriuretic;O;O
,;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
loop;B-group;B-DDI-DrugBank.d162.s12.e2
,;I-group;I-DDI-DrugBank.d162.s12.e2
potassium;I-group;I-DDI-DrugBank.d162.s12.e3
-;I-group;I-DDI-DrugBank.d162.s12.e3
sparing;I-group;I-DDI-DrugBank.d162.s12.e3
and;I-group;I-DDI-DrugBank.d162.s12.e3
thiazide;I-group;I-DDI-DrugBank.d162.s12.e4
diuretics;I-group;I-DDI-DrugBank.d162.s12.e4
.;O;O
DDI-DrugBank.d162.s13;;
Therefore;O;O
,;O;O
when;O;O
Hydrochlorothiazide;B-drug;B-DDI-DrugBank.d162.s13.e0
and;O;O
non;B-group;B-DDI-DrugBank.d162.s13.e1
-;I-group;I-DDI-DrugBank.d162.s13.e1
steroidal;I-group;I-DDI-DrugBank.d162.s13.e1
anti;I-group;I-DDI-DrugBank.d162.s13.e1
-;I-group;I-DDI-DrugBank.d162.s13.e1
inflammatory;I-group;I-DDI-DrugBank.d162.s13.e1
agents;I-group;I-DDI-DrugBank.d162.s13.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
effect;O;O
of;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d162.s13.e2
is;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d396.s0;;
Patients;O;O
receiving;O;O
other;O;O
narcotic;B-group;B-DDI-DrugBank.d396.s0.e0
analgesics;I-group;I-DDI-DrugBank.d396.s0.e0
,;O;O
antipsychotics;B-group;B-DDI-DrugBank.d396.s0.e1
,;O;O
antianxiety;B-group;B-DDI-DrugBank.d396.s0.e2
agents;I-group;I-DDI-DrugBank.d396.s0.e2
,;O;O
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d396.s0.e3
depressants;I-group;I-DDI-DrugBank.d396.s0.e3
(;O;O
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d396.s0.e4
);O;O
concomitantly;O;O
with;O;O
hydrocodone;B-drug;B-DDI-DrugBank.d396.s0.e5
and;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d396.s0.e6
tablets;O;O
may;O;O
exhibit;O;O
an;O;O
additive;O;O
CNS;O;O
depression;O;O
.;O;O
DDI-DrugBank.d396.s1;;
When;O;O
combined;O;O
therapy;O;O
is;O;O
contemplated;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d396.s2;;
The;O;O
use;O;O
of;O;O
MAO;B-group;B-DDI-DrugBank.d396.s2.e0
inhibitors;I-group;I-DDI-DrugBank.d396.s2.e0
or;O;O
tricyclic;B-group;B-DDI-DrugBank.d396.s2.e1
antidepressants;I-group;I-DDI-DrugBank.d396.s2.e1
with;O;O
hydrocodone;B-drug;B-DDI-DrugBank.d396.s2.e2
preparations;O;O
may;O;O
increase;O;O
the;O;O
effect;O;O
of;O;O
either;O;O
the;O;O
antidepressant;B-group;B-DDI-DrugBank.d396.s2.e3
or;O;O
hydrocodone;B-drug;B-DDI-DrugBank.d396.s2.e4
.;O;O
DDI-DrugBank.d396.s3;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
anticholinergics;B-group;B-DDI-DrugBank.d396.s3.e0
with;O;O
hydrocodone;B-drug;B-DDI-DrugBank.d396.s3.e1
may;O;O
produce;O;O
paralytic;O;O
ileus;O;O
.;O;O
DDI-DrugBank.d155.s0;;
No;O;O
information;O;O
available;O;O
.;O;O
DDI-DrugBank.d17.s0;;
Anticoagulants;B-group;B-DDI-DrugBank.d17.s0.e0
,;O;O
oral;O;O
DDI-DrugBank.d17.s1;;
(;O;O
Effects;O;O
may;O;O
be;O;O
decreased;O;O
when;O;O
used;O;O
concurrently;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s1.e0
diuretics;I-group;I-DDI-DrugBank.d17.s1.e0
,;O;O
DDI-DrugBank.d17.s2;;
dosage;O;O
adjustments;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s3;;
Antigout;B-group;B-DDI-DrugBank.d17.s3.e0
medications;I-group;I-DDI-DrugBank.d17.s3.e0
DDI-DrugBank.d17.s4;;
(;O;O
Thiazide;B-group;B-DDI-DrugBank.d17.s4.e0
diuretics;I-group;I-DDI-DrugBank.d17.s4.e0
may;O;O
raise;O;O
the;O;O
level;O;O
of;O;O
blood;O;O
uric;O;O
acid;O;O
,;O;O
DDI-DrugBank.d17.s5;;
dosage;O;O
adjustment;O;O
of;O;O
antigout;B-group;B-DDI-DrugBank.d17.s5.e0
medications;I-group;I-DDI-DrugBank.d17.s5.e0
may;O;O
be;O;O
necessary;O;O
to;O;O
control;O;O
hyperuricemia;O;O
and;O;O
gout;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s6;;
Antihypertensive;B-group;B-DDI-DrugBank.d17.s6.e0
medications;I-group;I-DDI-DrugBank.d17.s6.e0
,;O;O
other;O;O
,;O;O
especially;O;O
diazoxide;B-drug;B-DDI-DrugBank.d17.s6.e1
,;O;O
or;O;O
preanesthetic;O;O
and;O;O
anesthetic;O;O
agents;O;O
used;O;O
in;O;O
surgery;O;O
or;O;O
skeletal;B-group;B-DDI-DrugBank.d17.s6.e3
-;I-group;I-DDI-DrugBank.d17.s6.e3
muscle;I-group;I-DDI-DrugBank.d17.s6.e3
relaxants;I-group;I-DDI-DrugBank.d17.s6.e3
,;O;O
nondepolarizing;O;O
,;O;O
used;O;O
in;O;O
surgery;O;O
DDI-DrugBank.d17.s7;;
(;O;O
Effects;O;O
may;O;O
be;O;O
potentiated;O;O
when;O;O
used;O;O
concurrently;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s7.e0
diuretics;I-group;I-DDI-DrugBank.d17.s7.e0
,;O;O
DDI-DrugBank.d17.s8;;
dosage;O;O
adjustments;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s9;;
Amphotericin;B-drug;B-DDI-DrugBank.d17.s9.e0
B;I-drug;I-DDI-DrugBank.d17.s9.e0
or;O;O
Corticosteroids;B-group;B-DDI-DrugBank.d17.s9.e1
or;O;O
Corticotropin;B-drug;B-DDI-DrugBank.d17.s9.e2
(;O;O
ACTH;B-drug;B-DDI-DrugBank.d17.s9.e3
);O;O
DDI-DrugBank.d17.s10;;
(;O;O
Concurrent;O;O
use;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s10.e0
diuretics;I-group;I-DDI-DrugBank.d17.s10.e0
may;O;O
intensify;O;O
electrolyte;O;O
imbalance;O;O
,;O;O
particularly;O;O
hypokalemia;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s11;;
Cardiac;B-group;B-DDI-DrugBank.d17.s11.e0
glycosides;I-group;I-DDI-DrugBank.d17.s11.e0
DDI-DrugBank.d17.s12;;
(;O;O
Concurrent;O;O
use;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s12.e0
diuretics;I-group;I-DDI-DrugBank.d17.s12.e0
may;O;O
enhance;O;O
the;O;O
possibility;O;O
of;O;O
digitalis;B-group;B-DDI-DrugBank.d17.s12.e1
toxicity;O;O
associated;O;O
with;O;O
hypokalemia;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s13;;
Colestipol;B-drug;B-DDI-DrugBank.d17.s13.e0
DDI-DrugBank.d17.s14;;
(;O;O
May;O;O
inhibit;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
the;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s14.e0
diuretics;I-group;I-DDI-DrugBank.d17.s14.e0
,;O;O
DDI-DrugBank.d17.s15;;
administration;O;O
1;O;O
hour;O;O
before;O;O
or;O;O
4;O;O
hours;O;O
after;O;O
colestipol;B-drug;B-DDI-DrugBank.d17.s15.e0
is;O;O
recommended;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s16;;
Hypoglycemics;B-group;B-DDI-DrugBank.d17.s16.e0
DDI-DrugBank.d17.s17;;
(;O;O
Thiazide;B-group;B-DDI-DrugBank.d17.s17.e0
diuretics;I-group;I-DDI-DrugBank.d17.s17.e0
may;O;O
raise;O;O
blood;O;O
glucose;O;O
levels;O;O
,;O;O
DDI-DrugBank.d17.s18;;
for;O;O
adult;O;O
-;O;O
onset;O;O
diabetics;O;O
,;O;O
dosage;O;O
adjustment;O;O
of;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d17.s18.e0
medications;I-group;I-DDI-DrugBank.d17.s18.e0
may;O;O
be;O;O
necessary;O;O
during;O;O
and;O;O
after;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s18.e1
diuretic;I-group;I-DDI-DrugBank.d17.s18.e1
therapy;O;O
,;O;O
DDI-DrugBank.d17.s19;;
insulin;B-drug;B-DDI-DrugBank.d17.s19.e0
requirements;O;O
may;O;O
be;O;O
increased;O;O
,;O;O
decreased;O;O
,;O;O
or;O;O
unchanged;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s20;;
Lithium;B-drug;B-DDI-DrugBank.d17.s20.e0
salts;O;O
DDI-DrugBank.d17.s21;;
(;O;O
Concurrent;O;O
use;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s21.e0
diuretics;I-group;I-DDI-DrugBank.d17.s21.e0
is;O;O
not;O;O
recommended;O;O
,;O;O
as;O;O
they;O;O
may;O;O
provoke;O;O
lithium;B-drug;B-DDI-DrugBank.d17.s21.e1
toxicity;O;O
because;O;O
of;O;O
reduced;O;O
renal;O;O
clearance;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s22;;
Methenamine;B-drug;B-DDI-DrugBank.d17.s22.e0
DDI-DrugBank.d17.s23;;
(;O;O
Effectiveness;O;O
may;O;O
be;O;O
decreased;O;O
when;O;O
used;O;O
concurrently;O;O
with;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s23.e0
diuretics;I-group;I-DDI-DrugBank.d17.s23.e0
because;O;O
of;O;O
alkalinization;O;O
of;O;O
the;O;O
urine;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s24;;
Nonsteroidal;B-group;B-DDI-DrugBank.d17.s24.e0
anti;I-group;I-DDI-DrugBank.d17.s24.e0
-;I-group;I-DDI-DrugBank.d17.s24.e0
inflammatory;I-group;I-DDI-DrugBank.d17.s24.e0
agents;I-group;I-DDI-DrugBank.d17.s24.e0
DDI-DrugBank.d17.s25;;
(;O;O
In;O;O
some;O;O
patients;O;O
,;O;O
the;O;O
steroidal;B-group;B-DDI-DrugBank.d17.s25.e0
anti;I-group;I-DDI-DrugBank.d17.s25.e0
-;I-group;I-DDI-DrugBank.d17.s25.e0
inflammatory;I-group;I-DDI-DrugBank.d17.s25.e0
agent;I-group;I-DDI-DrugBank.d17.s25.e0
can;O;O
reduce;O;O
the;O;O
diuretic;O;O
,;O;O
natriuretic;O;O
,;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
loop;B-group;B-DDI-DrugBank.d17.s25.e1
,;I-group;I-DDI-DrugBank.d17.s25.e1
potassium;I-group;I-DDI-DrugBank.d17.s25.e2
sparing;I-group;I-DDI-DrugBank.d17.s25.e2
,;I-group;I-DDI-DrugBank.d17.s25.e2
and;I-group;I-DDI-DrugBank.d17.s25.e2
thiazide;I-group;I-DDI-DrugBank.d17.s25.e3
diuretics;I-group;I-DDI-DrugBank.d17.s25.e3
.;O;O
DDI-DrugBank.d17.s26;;
Therefore;O;O
,;O;O
when;O;O
hydroflumethiazide;B-drug;B-DDI-DrugBank.d17.s26.e0
and;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d17.s26.e1
anti;I-group;I-DDI-DrugBank.d17.s26.e1
-;I-group;I-DDI-DrugBank.d17.s26.e1
inflammatory;I-group;I-DDI-DrugBank.d17.s26.e1
agents;I-group;I-DDI-DrugBank.d17.s26.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
effect;O;O
of;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d17.s26.e2
is;O;O
obtained;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s27;;
Norepinephrine;B-drug;B-DDI-DrugBank.d17.s27.e0
DDI-DrugBank.d17.s28;;
(;O;O
Thiazides;B-group;B-DDI-DrugBank.d17.s28.e0
may;O;O
decrease;O;O
arterial;O;O
responsiveness;O;O
to;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d17.s28.e1
.;O;O
DDI-DrugBank.d17.s29;;
This;O;O
diminution;O;O
is;O;O
not;O;O
sufficient;O;O
to;O;O
preclude;O;O
effectiveness;O;O
of;O;O
the;O;O
pressor;O;O
agent;O;O
for;O;O
therapeutic;O;O
use;O;O
.;O;O
);O;O
DDI-DrugBank.d17.s30;;
Tubocurarine;B-drug;B-DDI-DrugBank.d17.s30.e0
DDI-DrugBank.d17.s31;;
(;O;O
Thiazide;B-group;B-DDI-DrugBank.d17.s31.e0
drugs;I-group;I-DDI-DrugBank.d17.s31.e0
may;O;O
increase;O;O
the;O;O
responsiveness;O;O
to;O;O
tubocurarine;B-drug;B-DDI-DrugBank.d17.s31.e1
.;O;O
);O;O
DDI-DrugBank.d17.s32;;
DIAGNOSTIC;O;O
INTERFERENCE;O;O
With;O;O
expected;O;O
physiologic;O;O
effects;O;O
:;O;O
Blood;O;O
and;O;O
urine;O;O
glucose;O;O
levels;O;O
(;O;O
usually;O;O
only;O;O
in;O;O
patients;O;O
with;O;O
a;O;O
predisposition;O;O
for;O;O
glucose;O;O
intolerance;O;O
);O;O
and;O;O
Serum;O;O
bilirubin;O;O
levels;O;O
(;O;O
by;O;O
displacement;O;O
from;O;O
albumin;O;O
binding;O;O
);O;O
and;O;O
Serum;O;O
calcium;O;O
levels;O;O
(;O;O
thiazide;B-group;B-DDI-DrugBank.d17.s32.e0
diuretics;I-group;I-DDI-DrugBank.d17.s32.e0
should;O;O
be;O;O
discontinued;O;O
before;O;O
parathyroid;O;O
-;O;O
function;O;O
tests;O;O
are;O;O
carried;O;O
out;O;O
);O;O
and;O;O
Serum;O;O
uric;O;O
acid;O;O
levels;O;O
(;O;O
may;O;O
be;O;O
increased;O;O
);O;O
Serum;O;O
magnesium;O;O
,;O;O
potassium;O;O
,;O;O
and;O;O
sodium;O;O
levels;O;O
(;O;O
may;O;O
be;O;O
decreased;O;O
,;O;O
DDI-DrugBank.d17.s33;;
serum;O;O
magnesium;O;O
levels;O;O
may;O;O
increase;O;O
in;O;O
uremic;O;O
patients;O;O
);O;O
Serum;O;O
protein;O;O
-;O;O
bound;O;O
iodine;O;O
(;O;O
PBI;O;O
);O;O
levels;O;O
(;O;O
may;O;O
be;O;O
decreased;O;O
);O;O
Thiazides;B-group;B-DDI-DrugBank.d17.s33.e0
should;O;O
be;O;O
discontinued;O;O
before;O;O
carrying;O;O
out;O;O
tests;O;O
for;O;O
parathyroid;O;O
function;O;O
.;O;O
DDI-DrugBank.d26.s0;;
Patients;O;O
receiving;O;O
other;O;O
narcotic;B-group;B-DDI-DrugBank.d26.s0.e0
analgesics;I-group;I-DDI-DrugBank.d26.s0.e0
,;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d26.s0.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d26.s0.e2
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d26.s0.e3
,;O;O
sedative;B-group;B-DDI-DrugBank.d26.s0.e4
-;I-group;I-DDI-DrugBank.d26.s0.e4
hypnotics;I-group;I-DDI-DrugBank.d26.s0.e4
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d26.s0.e5
antidepressants;I-group;I-DDI-DrugBank.d26.s0.e5
or;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d26.s0.e6
depressants;I-group;I-DDI-DrugBank.d26.s0.e6
(;O;O
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d26.s0.e7
);O;O
concomitantly;O;O
with;O;O
DILAUDID;B-brand;B-DDI-DrugBank.d26.s0.e8
may;O;O
exhibit;O;O
an;O;O
additive;O;O
CNS;O;O
depression;O;O
.;O;O
DDI-DrugBank.d26.s1;;
When;O;O
such;O;O
combined;O;O
therapy;O;O
is;O;O
contemplated;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d418.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
Cyanokit;B-brand;B-DDI-DrugBank.d418.s0.e0
.;O;O
DDI-DrugBank.d16.s0;;
Prospective;O;O
studies;O;O
on;O;O
the;O;O
potential;O;O
for;O;O
hydroxyurea;B-drug;B-DDI-DrugBank.d16.s0.e0
to;O;O
interact;O;O
with;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d16.s1;;
Concurrent;O;O
use;O;O
of;O;O
hydroxyurea;B-drug;B-DDI-DrugBank.d16.s1.e0
and;O;O
other;O;O
myelosuppressive;O;O
agents;O;O
or;O;O
radiation;O;O
therapy;O;O
may;O;O
increase;O;O
the;O;O
likelihood;O;O
of;O;O
bone;O;O
marrow;O;O
depression;O;O
or;O;O
other;O;O
adverse;O;O
events;O;O
.;O;O
DDI-DrugBank.d16.s2;;
Since;O;O
hydroxyurea;B-drug;B-DDI-DrugBank.d16.s2.e0
may;O;O
raise;O;O
the;O;O
serum;O;O
uric;O;O
acid;O;O
level;O;O
,;O;O
dosage;O;O
adjustment;O;O
of;O;O
uricosuric;B-group;B-DDI-DrugBank.d16.s2.e1
medication;I-group;I-DDI-DrugBank.d16.s2.e1
may;O;O
be;O;O
necessary;O;O
DDI-DrugBank.d16.s3;;
.;O;O
DDI-DrugBank.d16.s4;;
DDI-DrugBank.d308.s0;;
THE;O;O
POTENTIATING;O;O
ACTION;O;O
OF;O;O
HYDROXYZINE;B-drug;B-DDI-DrugBank.d308.s0.e0
MUST;O;O
BE;O;O
CONSIDERED;O;O
WHEN;O;O
THE;O;O
DRUG;O;O
IS;O;O
USED;O;O
IN;O;O
CONJUNCTION;O;O
WITH;O;O
CENTRAL;B-group;B-DDI-DrugBank.d308.s0.e1
NERVOUS;I-group;I-DDI-DrugBank.d308.s0.e1
SYSTEM;I-group;I-DDI-DrugBank.d308.s0.e1
DEPRESSANTS;I-group;I-DDI-DrugBank.d308.s0.e1
SUCH;O;O
AS;O;O
NARCOTICS;B-group;B-DDI-DrugBank.d308.s0.e2
,;O;O
NON;B-group;B-DDI-DrugBank.d308.s0.e3
-;I-group;I-DDI-DrugBank.d308.s0.e3
NARCOTIC;I-group;I-DDI-DrugBank.d308.s0.e3
ANALGESICS;I-group;I-DDI-DrugBank.d308.s0.e3
AND;O;O
BARBITURATES;B-group;B-DDI-DrugBank.d308.s0.e4
.;O;O
DDI-DrugBank.d308.s1;;
Therefore;O;O
when;O;O
central;B-group;B-DDI-DrugBank.d308.s1.e0
nervous;I-group;I-DDI-DrugBank.d308.s1.e0
system;I-group;I-DDI-DrugBank.d308.s1.e0
depressants;I-group;I-DDI-DrugBank.d308.s1.e0
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
hydroxyzine;B-drug;B-DDI-DrugBank.d308.s1.e1
their;O;O
dosage;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d308.s2;;
Since;O;O
drowsiness;O;O
may;O;O
occur;O;O
with;O;O
use;O;O
of;O;O
this;O;O
drug;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
warned;O;O
of;O;O
this;O;O
possibility;O;O
and;O;O
cautioned;O;O
against;O;O
driving;O;O
a;O;O
car;O;O
or;O;O
operating;O;O
dangerous;O;O
machinery;O;O
while;O;O
taking;O;O
Atarax;B-brand;B-DDI-DrugBank.d308.s2.e0
.;O;O
DDI-DrugBank.d308.s3;;
Patients;O;O
should;O;O
be;O;O
advised;O;O
against;O;O
the;O;O
simultaneous;O;O
use;O;O
of;O;O
other;O;O
CNS;B-group;B-DDI-DrugBank.d308.s3.e0
depressant;I-group;I-DDI-DrugBank.d308.s3.e0
drugs;I-group;I-DDI-DrugBank.d308.s3.e0
,;O;O
and;O;O
cautioned;O;O
that;O;O
the;O;O
effect;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d308.s3.e1
may;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d142.s0;;
Additive;O;O
adverse;O;O
effects;O;O
resulting;O;O
from;O;O
cholinergic;O;O
blockade;O;O
may;O;O
occur;O;O
when;O;O
LEVSIN;B-brand;B-DDI-DrugBank.d142.s0.e0
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
other;O;O
antimuscarinics;B-group;B-DDI-DrugBank.d142.s0.e1
,;O;O
amantadine;B-drug;B-DDI-DrugBank.d142.s0.e2
,;O;O
haloperidol;B-drug;B-DDI-DrugBank.d142.s0.e3
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d142.s0.e4
,;O;O
monoamine;B-group;B-DDI-DrugBank.d142.s0.e5
oxidase;I-group;I-DDI-DrugBank.d142.s0.e5
(;I-group;I-DDI-DrugBank.d142.s0.e5
MAO;I-group;I-DDI-DrugBank.d142.s0.e5
);I-group;I-DDI-DrugBank.d142.s0.e5
inhibitors;I-group;I-DDI-DrugBank.d142.s0.e5
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d142.s0.e6
antidepressants;I-group;I-DDI-DrugBank.d142.s0.e6
or;O;O
some;O;O
antihistamines;B-group;B-DDI-DrugBank.d142.s0.e7
.;O;O
DDI-DrugBank.d142.s1;;
Antacids;B-group;B-DDI-DrugBank.d142.s1.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
LEVSIN;B-brand;B-DDI-DrugBank.d142.s1.e1
.;O;O
DDI-DrugBank.d142.s2;;
Administer;O;O
LEVSIN;B-brand;B-DDI-DrugBank.d142.s2.e0
before;O;O
meals;O;O
,;O;O
DDI-DrugBank.d142.s3;;
antacids;B-group;B-DDI-DrugBank.d142.s3.e0
after;O;O
meals;O;O
.;O;O
DDI-DrugBank.d440.s0;;
Calcium;B-drug;B-DDI-DrugBank.d440.s0.e0
Supplements;O;O
/;O;O
Antacids;B-group;B-DDI-DrugBank.d440.s0.e1
DDI-DrugBank.d440.s1;;
Products;O;O
containing;O;O
calcium;B-drug;B-DDI-DrugBank.d440.s1.e0
and;O;O
other;O;O
multivalent;O;O
cations;O;O
(;O;O
such;O;O
as;O;O
aluminum;B-drug;B-DDI-DrugBank.d440.s1.e1
,;O;O
magnesium;B-drug;B-DDI-DrugBank.d440.s1.e2
,;O;O
iron;B-drug;B-DDI-DrugBank.d440.s1.e3
);O;O
are;O;O
likely;O;O
to;O;O
interfere;O;O
with;O;O
absorption;O;O
of;O;O
Ibandronate;B-drug;B-DDI-DrugBank.d440.s1.e4
.;O;O
DDI-DrugBank.d440.s2;;
Ibandronate;B-drug;B-DDI-DrugBank.d440.s2.e0
should;O;O
be;O;O
taken;O;O
at;O;O
least;O;O
60;O;O
minutes;O;O
before;O;O
any;O;O
oral;O;O
medications;O;O
containing;O;O
multivalent;O;O
cations;O;O
(;O;O
including;O;O
antacids;B-group;B-DDI-DrugBank.d440.s2.e1
,;O;O
supplements;O;O
or;O;O
vitamins;B-group;B-DDI-DrugBank.d440.s2.e2
);O;O
.;O;O
DDI-DrugBank.d440.s3;;
H2;B-group;B-DDI-DrugBank.d440.s3.e0
Blockers;I-group;I-DDI-DrugBank.d440.s3.e0
and;O;O
Proton;B-group;B-DDI-DrugBank.d440.s3.e1
Pump;I-group;I-DDI-DrugBank.d440.s3.e1
Inhibitors;I-group;I-DDI-DrugBank.d440.s3.e1
(;O;O
PPIs;B-group;B-DDI-DrugBank.d440.s3.e2
);O;O
DDI-DrugBank.d440.s4;;
Of;O;O
over;O;O
3500;O;O
patients;O;O
enrolled;O;O
in;O;O
the;O;O
Ibandronate;B-drug;B-DDI-DrugBank.d440.s4.e0
osteoporosis;O;O
Treatment;O;O
and;O;O
Prevention;O;O
Studies;O;O
,;O;O
15;O;O
%;O;O
used;O;O
anti;O;O
-;O;O
peptic;O;O
agents;O;O
(;O;O
primarily;O;O
H2;B-group;B-DDI-DrugBank.d440.s4.e1
blockers;I-group;I-DDI-DrugBank.d440.s4.e1
and;O;O
PPIs;B-group;B-DDI-DrugBank.d440.s4.e2
);O;O
.;O;O
DDI-DrugBank.d440.s5;;
Among;O;O
these;O;O
patients;O;O
,;O;O
the;O;O
incidence;O;O
of;O;O
upper;O;O
gastrointestinal;O;O
adverse;O;O
experiences;O;O
in;O;O
the;O;O
patients;O;O
treated;O;O
with;O;O
Ibandronate;B-drug;B-DDI-DrugBank.d440.s5.e0
was;O;O
similar;O;O
to;O;O
that;O;O
in;O;O
placebo;O;O
-;O;O
treated;O;O
patients;O;O
.;O;O
DDI-DrugBank.d440.s6;;
Similarly;O;O
,;O;O
of;O;O
over;O;O
1600;O;O
patients;O;O
enrolled;O;O
in;O;O
a;O;O
study;O;O
comparing;O;O
once;O;O
-;O;O
monthly;O;O
with;O;O
daily;O;O
dosing;O;O
regimens;O;O
of;O;O
ibandronate;B-drug;B-DDI-DrugBank.d440.s6.e0
,;O;O
14;O;O
%;O;O
of;O;O
patients;O;O
used;O;O
anti;O;O
-;O;O
peptic;O;O
agents;O;O
.;O;O
DDI-DrugBank.d440.s7;;
Among;O;O
these;O;O
patients;O;O
,;O;O
the;O;O
incidence;O;O
of;O;O
upper;O;O
gastrointestinal;O;O
adverse;O;O
experiences;O;O
in;O;O
the;O;O
patients;O;O
treated;O;O
with;O;O
Ibandronate;B-drug;B-DDI-DrugBank.d440.s7.e0
150;O;O
mg;O;O
once;O;O
monthly;O;O
was;O;O
similar;O;O
to;O;O
that;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
Ibandronate;B-drug;B-DDI-DrugBank.d440.s7.e1
2.5;O;O
mg;O;O
once;O;O
daily;O;O
.;O;O
DDI-DrugBank.d440.s8;;
Aspirin;B-brand;B-DDI-DrugBank.d440.s8.e0
/;O;O
Nonsteroidal;B-group;B-DDI-DrugBank.d440.s8.e1
Antiinflammatory;I-group;I-DDI-DrugBank.d440.s8.e1
Drugs;I-group;I-DDI-DrugBank.d440.s8.e1
(;O;O
NSAIDs;B-group;B-DDI-DrugBank.d440.s8.e2
);O;O
DDI-DrugBank.d440.s9;;
In;O;O
the;O;O
large;O;O
,;O;O
placebo;O;O
-;O;O
controlled;O;O
osteoporosis;O;O
Treatment;O;O
Study;O;O
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d440.s9.e0
and;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d440.s9.e1
anti;I-group;I-DDI-DrugBank.d440.s9.e1
-;I-group;I-DDI-DrugBank.d440.s9.e1
inflammatory;I-group;I-DDI-DrugBank.d440.s9.e1
drugs;I-group;I-DDI-DrugBank.d440.s9.e1
were;O;O
taken;O;O
by;O;O
62;O;O
%;O;O
of;O;O
the;O;O
2946;O;O
patients;O;O
.;O;O
DDI-DrugBank.d440.s10;;
Among;O;O
aspirin;B-brand;B-DDI-DrugBank.d440.s10.e0
or;O;O
NSAID;B-group;B-DDI-DrugBank.d440.s10.e1
users;O;O
,;O;O
the;O;O
incidence;O;O
of;O;O
upper;O;O
gastrointestinal;O;O
adverse;O;O
events;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
ibandronate;B-drug;B-DDI-DrugBank.d440.s10.e2
2.5;O;O
mg;O;O
daily;O;O
(;O;O
28.9;O;O
%;O;O
);O;O
was;O;O
similar;O;O
to;O;O
that;O;O
in;O;O
placebo;O;O
-;O;O
treated;O;O
patients;O;O
(;O;O
30.7;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d440.s11;;
Similarly;O;O
,;O;O
in;O;O
the;O;O
1;O;O
-;O;O
year;O;O
monthly;O;O
comparison;O;O
study;O;O
,;O;O
aspirin;B-brand;B-DDI-DrugBank.d440.s11.e0
and;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d440.s11.e1
anti;I-group;I-DDI-DrugBank.d440.s11.e1
-;I-group;I-DDI-DrugBank.d440.s11.e1
inflammatory;I-group;I-DDI-DrugBank.d440.s11.e1
drugs;I-group;I-DDI-DrugBank.d440.s11.e1
were;O;O
taken;O;O
by;O;O
39;O;O
%;O;O
of;O;O
the;O;O
1602;O;O
patients;O;O
.;O;O
DDI-DrugBank.d440.s12;;
The;O;O
incidence;O;O
of;O;O
upper;O;O
gastrointestinal;O;O
events;O;O
in;O;O
patients;O;O
concomitantly;O;O
taking;O;O
aspirin;B-brand;B-DDI-DrugBank.d440.s12.e0
or;O;O
NSAIDs;B-group;B-DDI-DrugBank.d440.s12.e1
was;O;O
similar;O;O
in;O;O
patients;O;O
taking;O;O
ibandronate;B-drug;B-DDI-DrugBank.d440.s12.e2
2.5;O;O
mg;O;O
daily;O;O
(;O;O
21.7;O;O
%;O;O
);O;O
and;O;O
150;O;O
mg;O;O
once;O;O
monthly;O;O
(;O;O
22.0;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d440.s13;;
However;O;O
,;O;O
since;O;O
aspirin;B-brand;B-DDI-DrugBank.d440.s13.e0
,;O;O
NSAIDs;B-group;B-DDI-DrugBank.d440.s13.e1
,;O;O
and;O;O
bisphosphonates;B-group;B-DDI-DrugBank.d440.s13.e2
are;O;O
all;O;O
associated;O;O
with;O;O
gastrointestinal;O;O
irritation;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
in;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d440.s13.e3
or;O;O
NSAIDs;B-group;B-DDI-DrugBank.d440.s13.e4
with;O;O
Ibandronate;B-drug;B-DDI-DrugBank.d440.s13.e5
.;O;O
DDI-DrugBank.d440.s14;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
DDI-DrugBank.d440.s15;;
Bisphosphonates;B-group;B-DDI-DrugBank.d440.s15.e0
are;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
use;O;O
of;O;O
bone;O;O
-;O;O
imaging;O;O
agents;O;O
.;O;O
DDI-DrugBank.d440.s16;;
Specific;O;O
studies;O;O
with;O;O
ibandronate;B-drug;B-DDI-DrugBank.d440.s16.e0
have;O;O
not;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d408.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
with;O;O
ZEVALIN;B-brand;B-DDI-DrugBank.d408.s0.e0
.;O;O
DDI-DrugBank.d408.s1;;
Due;O;O
to;O;O
the;O;O
frequent;O;O
occurrence;O;O
of;O;O
severe;O;O
and;O;O
prolonged;O;O
thrombocytopenia;O;O
,;O;O
the;O;O
potential;O;O
benefits;O;O
of;O;O
medications;O;O
which;O;O
interfere;O;O
with;O;O
platelet;O;O
function;O;O
and/or;O;O
anticoagulation;O;O
should;O;O
be;O;O
weighed;O;O
against;O;O
the;O;O
potential;O;O
increased;O;O
risks;O;O
of;O;O
bleeding;O;O
and;O;O
hemorrhage;O;O
.;O;O
DDI-DrugBank.d408.s2;;
Patients;O;O
receiving;O;O
medications;O;O
that;O;O
interfere;O;O
with;O;O
platelet;O;O
function;O;O
or;O;O
coagulation;O;O
should;O;O
have;O;O
more;O;O
frequent;O;O
laboratory;O;O
monitoring;O;O
for;O;O
thrombocytopenia;O;O
.;O;O
DDI-DrugBank.d408.s3;;
In;O;O
addition;O;O
,;O;O
the;O;O
transfusion;O;O
practices;O;O
for;O;O
such;O;O
patients;O;O
may;O;O
need;O;O
to;O;O
be;O;O
modified;O;O
given;O;O
the;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d408.s4;;
Patients;O;O
in;O;O
clinical;O;O
studies;O;O
were;O;O
prohibited;O;O
from;O;O
receiving;O;O
growth;O;O
factor;O;O
treatment;O;O
for;O;O
2;O;O
weeks;O;O
prior;O;O
to;O;O
the;O;O
ZEVALIN;B-brand;B-DDI-DrugBank.d408.s4.e0
therapeutic;O;O
regimen;O;O
as;O;O
well;O;O
as;O;O
for;O;O
2;O;O
weeks;O;O
following;O;O
completion;O;O
of;O;O
the;O;O
regimen;O;O
.;O;O
DDI-DrugBank.d415.s0;;
Coumarin;B-group;B-DDI-DrugBank.d415.s0.e0
-;I-group;I-DDI-DrugBank.d415.s0.e0
Type;I-group;I-DDI-DrugBank.d415.s0.e0
Anticoagulants;I-group;I-DDI-DrugBank.d415.s0.e0
:;O;O
Several;O;O
short;O;O
-;O;O
term;O;O
controlled;O;O
studies;O;O
failed;O;O
to;O;O
wshow;O;O
that;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s0.e1
significantly;O;O
affected;O;O
prothrombin;O;O
times;O;O
or;O;O
a;O;O
variety;O;O
of;O;O
other;O;O
clotting;O;O
factors;O;O
when;O;O
administered;O;O
to;O;O
individuals;O;O
on;O;O
coumarin;B-group;B-DDI-DrugBank.d415.s0.e2
-;I-group;I-DDI-DrugBank.d415.s0.e2
type;I-group;I-DDI-DrugBank.d415.s0.e2
anticoagulants;I-group;I-DDI-DrugBank.d415.s0.e2
.;O;O
DDI-DrugBank.d415.s1;;
However;O;O
,;O;O
because;O;O
bleeding;O;O
has;O;O
been;O;O
reported;O;O
when;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s1.e0
and;O;O
other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d415.s1.e1
anti;I-group;I-DDI-DrugBank.d415.s1.e1
-;I-group;I-DDI-DrugBank.d415.s1.e1
inflammatory;I-group;I-DDI-DrugBank.d415.s1.e1
agents;I-group;I-DDI-DrugBank.d415.s1.e1
have;O;O
been;O;O
administered;O;O
to;O;O
patients;O;O
on;O;O
coumarin;B-group;B-DDI-DrugBank.d415.s1.e2
-;I-group;I-DDI-DrugBank.d415.s1.e2
type;I-group;I-DDI-DrugBank.d415.s1.e2
anticoagulants;I-group;I-DDI-DrugBank.d415.s1.e2
,;O;O
the;O;O
physician;O;O
should;O;O
be;O;O
cautious;O;O
when;O;O
administering;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s1.e3
to;O;O
patients;O;O
on;O;O
anticoagulants;B-group;B-DDI-DrugBank.d415.s1.e4
.;O;O
DDI-DrugBank.d415.s2;;
Aspirin;B-brand;B-DDI-DrugBank.d415.s2.e0
:;O;O
Animal;O;O
studies;O;O
wshow;O;O
that;O;O
aspirin;B-brand;B-DDI-DrugBank.d415.s2.e1
given;O;O
with;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d415.s2.e2
anti;I-group;I-DDI-DrugBank.d415.s2.e2
-;I-group;I-DDI-DrugBank.d415.s2.e2
inflammatory;I-group;I-DDI-DrugBank.d415.s2.e2
agents;I-group;I-DDI-DrugBank.d415.s2.e2
,;O;O
including;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s2.e3
,;O;O
yields;O;O
a;O;O
net;O;O
decrease;O;O
in;O;O
anti;O;O
-;O;O
inflammatory;O;O
activity;O;O
with;O;O
lowered;O;O
blood;O;O
levels;O;O
of;O;O
the;O;O
non;O;O
-;O;O
aspirin;O;O
drug;O;O
.;O;O
DDI-DrugBank.d415.s3;;
Single;O;O
dose;O;O
bioavailability;O;O
studies;O;O
in;O;O
normal;O;O
volunteers;O;O
have;O;O
failed;O;O
to;O;O
wshow;O;O
an;O;O
effect;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d415.s3.e0
on;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s3.e1
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d415.s4;;
Correlative;O;O
clinical;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d415.s5;;
Methotrexate;B-drug;B-DDI-DrugBank.d415.s5.e0
:;O;O
Ibuprofen;B-drug;B-DDI-DrugBank.d415.s5.e1
,;O;O
as;O;O
well;O;O
as;O;O
other;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d415.s5.e2
anti;I-group;I-DDI-DrugBank.d415.s5.e2
-;I-group;I-DDI-DrugBank.d415.s5.e2
inflammatory;I-group;I-DDI-DrugBank.d415.s5.e2
drugs;I-group;I-DDI-DrugBank.d415.s5.e2
,;O;O
probably;O;O
reduces;O;O
the;O;O
tubular;O;O
secretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d415.s5.e3
based;O;O
on;O;O
in;O;O
vitro;O;O
studies;O;O
in;O;O
rabbit;O;O
kidney;O;O
slices;O;O
.;O;O
DDI-DrugBank.d415.s6;;
This;O;O
may;O;O
indicate;O;O
that;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s6.e0
could;O;O
enhance;O;O
the;O;O
toxicity;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d415.s6.e1
.;O;O
DDI-DrugBank.d415.s7;;
Caution;O;O
should;O;O
be;O;O
used;O;O
if;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s7.e0
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d415.s7.e1
.;O;O
DDI-DrugBank.d415.s8;;
H;O;O
-;O;O
2;O;O
Antagonists;O;O
:;O;O
In;O;O
studies;O;O
with;O;O
human;O;O
volunteers;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d415.s8.e0
or;O;O
ranitidine;B-drug;B-DDI-DrugBank.d415.s8.e1
with;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s8.e2
had;O;O
no;O;O
substantive;O;O
effect;O;O
on;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s8.e3
serum;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d415.s9;;
Furosemide;B-drug;B-DDI-DrugBank.d415.s9.e0
:;O;O
Clinical;O;O
studies;O;O
,;O;O
as;O;O
well;O;O
as;O;O
random;O;O
observations;O;O
,;O;O
have;O;O
shown;O;O
that;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s9.e1
can;O;O
reduce;O;O
the;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d415.s9.e2
and;O;O
thiazides;B-group;B-DDI-DrugBank.d415.s9.e3
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d415.s10;;
This;O;O
response;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d415.s11;;
During;O;O
concomitant;O;O
therapy;O;O
with;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s11.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
signs;O;O
of;O;O
renal;O;O
failure;O;O
,;O;O
as;O;O
well;O;O
as;O;O
to;O;O
assure;O;O
diuretic;B-group;B-DDI-DrugBank.d415.s11.e1
efficacy;O;O
.;O;O
DDI-DrugBank.d415.s12;;
Lithium;B-drug;B-DDI-DrugBank.d415.s12.e0
:;O;O
Ibuprofen;B-drug;B-DDI-DrugBank.d415.s12.e1
produced;O;O
an;O;O
elevation;O;O
of;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d415.s12.e2
levels;O;O
and;O;O
a;O;O
reduction;O;O
in;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d415.s12.e3
clearance;O;O
in;O;O
a;O;O
study;O;O
of;O;O
eleven;O;O
normal;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d415.s13;;
The;O;O
mean;O;O
minimum;O;O
lithium;B-drug;B-DDI-DrugBank.d415.s13.e0
concentration;O;O
increased;O;O
15;O;O
%;O;O
and;O;O
the;O;O
renal;O;O
clearance;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d415.s13.e1
was;O;O
decreased;O;O
by;O;O
19;O;O
%;O;O
during;O;O
this;O;O
period;O;O
of;O;O
concomitant;O;O
drug;O;O
administration;O;O
.;O;O
DDI-DrugBank.d415.s14;;
This;O;O
effect;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
by;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s14.e0
.;O;O
DDI-DrugBank.d415.s15;;
Thus;O;O
,;O;O
when;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d415.s15.e0
and;O;O
lithium;B-drug;B-DDI-DrugBank.d415.s15.e1
are;O;O
administered;O;O
concurrently;O;O
,;O;O
subjects;O;O
should;O;O
be;O;O
observed;O;O
carefully;O;O
for;O;O
signs;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d415.s15.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d415.s16;;
(;O;O
Read;O;O
circulars;O;O
for;O;O
lithium;B-drug;B-DDI-DrugBank.d415.s16.e0
preparation;O;O
before;O;O
use;O;O
of;O;O
such;O;O
concurrent;O;O
therapy;O;O
);O;O
.;O;O
DDI-DrugBank.d68.s0;;
No;O;O
specific;O;O
pharmacokinetic;O;O
or;O;O
other;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
were;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d68.s1;;
Digoxin;B-drug;B-DDI-DrugBank.d68.s1.e0
:;O;O
Supraventricular;O;O
arrhythmias;O;O
may;O;O
mask;O;O
the;O;O
cardiotoxicity;O;O
associated;O;O
with;O;O
excessive;O;O
digoxin;B-drug;B-DDI-DrugBank.d68.s1.e1
levels;O;O
.;O;O
DDI-DrugBank.d68.s2;;
Therefore;O;O
,;O;O
it;O;O
is;O;O
advisable;O;O
to;O;O
be;O;O
particularly;O;O
cautious;O;O
in;O;O
patients;O;O
whose;O;O
plasma;O;O
digoxin;B-drug;B-DDI-DrugBank.d68.s2.e0
levels;O;O
are;O;O
above;O;O
or;O;O
suspected;O;O
to;O;O
be;O;O
above;O;O
the;O;O
usual;O;O
therapeutic;O;O
range;O;O
.;O;O
DDI-DrugBank.d68.s3;;
Coadministration;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d68.s3.e0
did;O;O
not;O;O
have;O;O
effects;O;O
on;O;O
either;O;O
the;O;O
safety;O;O
or;O;O
efficacy;O;O
of;O;O
ibutilide;B-drug;B-DDI-DrugBank.d68.s3.e1
in;O;O
the;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d68.s4;;
Calcium;B-group;B-DDI-DrugBank.d68.s4.e0
channel;I-group;I-DDI-DrugBank.d68.s4.e0
blocking;I-group;I-DDI-DrugBank.d68.s4.e0
agents;I-group;I-DDI-DrugBank.d68.s4.e0
:;O;O
Coadministration;O;O
of;O;O
calcium;B-group;B-DDI-DrugBank.d68.s4.e1
channel;I-group;I-DDI-DrugBank.d68.s4.e1
blockers;I-group;I-DDI-DrugBank.d68.s4.e1
did;O;O
not;O;O
have;O;O
any;O;O
effect;O;O
on;O;O
either;O;O
the;O;O
safety;O;O
or;O;O
efficacy;O;O
of;O;O
ibutilide;B-drug;B-DDI-DrugBank.d68.s4.e2
in;O;O
the;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d68.s5;;
Beta;B-group;B-DDI-DrugBank.d68.s5.e0
-;I-group;I-DDI-DrugBank.d68.s5.e0
adrenergic;I-group;I-DDI-DrugBank.d68.s5.e0
blocking;I-group;I-DDI-DrugBank.d68.s5.e0
agents;I-group;I-DDI-DrugBank.d68.s5.e0
:;O;O
Coadministration;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d68.s5.e1
-;I-group;I-DDI-DrugBank.d68.s5.e1
adrenergic;I-group;I-DDI-DrugBank.d68.s5.e1
blocking;I-group;I-DDI-DrugBank.d68.s5.e1
agents;I-group;I-DDI-DrugBank.d68.s5.e1
did;O;O
not;O;O
have;O;O
any;O;O
effect;O;O
on;O;O
either;O;O
the;O;O
safety;O;O
or;O;O
efficacy;O;O
of;O;O
ibutilide;B-drug;B-DDI-DrugBank.d68.s5.e2
in;O;O
the;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d501.s0;;
General;O;O
No;O;O
clinical;O;O
drug;O;O
interaction;O;O
studies;O;O
were;O;O
performed;O;O
.;O;O
DDI-DrugBank.d501.s1;;
No;O;O
evaluation;O;O
of;O;O
EXTRANEALs;B-brand;B-DDI-DrugBank.d501.s1.e0
effects;O;O
on;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
was;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d501.s2;;
As;O;O
with;O;O
other;O;O
dialysis;B-group;B-DDI-DrugBank.d501.s2.e0
solutions;I-group;I-DDI-DrugBank.d501.s2.e0
,;O;O
blood;O;O
concentrations;O;O
of;O;O
dialyzable;O;O
drugs;O;O
may;O;O
be;O;O
reduced;O;O
by;O;O
dialysis;O;O
.;O;O
DDI-DrugBank.d501.s3;;
Dosage;O;O
adjustment;O;O
of;O;O
concomitant;O;O
medications;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d501.s4;;
In;O;O
patients;O;O
using;O;O
cardiac;B-group;B-DDI-DrugBank.d501.s4.e0
glycosides;I-group;I-DDI-DrugBank.d501.s4.e0
(;O;O
digoxin;B-drug;B-DDI-DrugBank.d501.s4.e1
and;O;O
others;O;O
);O;O
,;O;O
plasma;O;O
levels;O;O
of;O;O
calcium;O;O
,;O;O
potassium;O;O
and;O;O
magnesium;O;O
must;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d501.s5;;
Insulin;B-drug;B-DDI-DrugBank.d501.s5.e0
:;O;O
A;O;O
clinical;O;O
study;O;O
in;O;O
6;O;O
insulin;O;O
-;O;O
dependent;O;O
diabetic;O;O
patients;O;O
demonstrated;O;O
no;O;O
effect;O;O
of;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s5.e1
on;O;O
insulin;B-drug;B-DDI-DrugBank.d501.s5.e2
absorption;O;O
from;O;O
the;O;O
peritoneal;O;O
cavity;O;O
or;O;O
on;O;O
insulins;B-drug;B-DDI-DrugBank.d501.s5.e3
ability;O;O
to;O;O
control;O;O
blood;O;O
glucose;O;O
when;O;O
insulin;B-drug;B-DDI-DrugBank.d501.s5.e4
was;O;O
administered;O;O
intraperitoneally;O;O
with;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s5.e5
.;O;O
DDI-DrugBank.d501.s6;;
However;O;O
,;O;O
appropriate;O;O
monitoring;O;O
of;O;O
blood;O;O
glucose;O;O
should;O;O
be;O;O
performed;O;O
when;O;O
initiating;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s6.e0
in;O;O
diabetic;O;O
patients;O;O
and;O;O
insulin;B-drug;B-DDI-DrugBank.d501.s6.e1
dosage;O;O
should;O;O
be;O;O
adjusted;O;O
if;O;O
needed;O;O
.;O;O
DDI-DrugBank.d501.s7;;
Heparin;B-drug;B-DDI-DrugBank.d501.s7.e0
:;O;O
No;O;O
human;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
heparin;B-drug;B-DDI-DrugBank.d501.s7.e1
were;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d501.s8;;
In;O;O
vitro;O;O
studies;O;O
demonstrated;O;O
no;O;O
evidence;O;O
of;O;O
incompatibility;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d501.s8.e0
with;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s8.e1
.;O;O
DDI-DrugBank.d501.s9;;
Antibiotics;B-group;B-DDI-DrugBank.d501.s9.e0
:;O;O
No;O;O
human;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
antibiotics;B-group;B-DDI-DrugBank.d501.s9.e1
were;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d501.s10;;
In;O;O
vitro;O;O
studies;O;O
evaluating;O;O
the;O;O
minimum;O;O
inhibitory;O;O
concentration;O;O
(;O;O
MIC;O;O
);O;O
of;O;O
vancomycin;B-drug;B-DDI-DrugBank.d501.s10.e0
,;O;O
cefazolin;B-drug;B-DDI-DrugBank.d501.s10.e1
,;O;O
ampicillin;B-drug;B-DDI-DrugBank.d501.s10.e2
,;O;O
ampicillin;B-drug;B-DDI-DrugBank.d501.s10.e3
/;O;O
flucoxacillin;O;O
,;O;O
ceftazidime;B-drug;B-DDI-DrugBank.d501.s10.e4
,;O;O
gentamicin;B-drug;B-DDI-DrugBank.d501.s10.e5
,;O;O
and;O;O
amphotericin;B-drug;B-DDI-DrugBank.d501.s10.e6
demonstrated;O;O
no;O;O
evidence;O;O
of;O;O
incompatibility;O;O
of;O;O
these;O;O
antibiotics;B-group;B-DDI-DrugBank.d501.s10.e7
with;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s10.e8
.;O;O
DDI-DrugBank.d501.s11;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Blood;O;O
Glucose;O;O
Blood;O;O
glucose;O;O
measurement;O;O
must;O;O
be;O;O
done;O;O
with;O;O
a;O;O
glucose;O;O
-;O;O
specific;O;O
method;O;O
to;O;O
prevent;O;O
maltose;O;O
interference;O;O
with;O;O
test;O;O
results;O;O
.;O;O
DDI-DrugBank.d501.s12;;
Since;O;O
falsely;O;O
elevated;O;O
glucose;O;O
levels;O;O
have;O;O
been;O;O
observed;O;O
with;O;O
blood;O;O
glucose;O;O
monitoring;O;O
devices;O;O
and;O;O
test;O;O
strips;O;O
that;O;O
use;O;O
glucose;O;O
dehydrogenase;O;O
pyrroloquinolinequinone;O;O
(;O;O
GDH;O;O
PQQ);O;O
-;O;O
based;O;O
methods;O;O
,;O;O
GDH;O;O
PQQ;O;O
-;O;O
based;O;O
methods;O;O
should;O;O
not;O;O
be;O;O
used;O;O
to;O;O
measure;O;O
glucose;O;O
levels;O;O
in;O;O
patients;O;O
administered;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s12.e0
..;O;O
DDI-DrugBank.d501.s13;;
Serum;O;O
Amylase;O;O
An;O;O
apparent;O;O
decrease;O;O
in;O;O
serum;O;O
amylase;O;O
activity;O;O
has;O;O
been;O;O
observed;O;O
in;O;O
patients;O;O
administered;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s13.e0
.;O;O
DDI-DrugBank.d501.s14;;
Preliminary;O;O
investigations;O;O
indicate;O;O
that;O;O
icodextrin;B-drug;B-DDI-DrugBank.d501.s14.e0
and;O;O
its;O;O
metabolites;O;O
interfere;O;O
with;O;O
enzymatic;O;O
-;O;O
based;O;O
amylase;O;O
assays;O;O
,;O;O
resulting;O;O
in;O;O
inaccurately;O;O
low;O;O
values;O;O
.;O;O
DDI-DrugBank.d501.s15;;
This;O;O
should;O;O
be;O;O
taken;O;O
into;O;O
account;O;O
when;O;O
evaluating;O;O
serum;O;O
amylase;O;O
levels;O;O
for;O;O
diagnosis;O;O
or;O;O
monitoring;O;O
of;O;O
pancreatitis;O;O
in;O;O
patients;O;O
using;O;O
EXTRANEAL;B-brand;B-DDI-DrugBank.d501.s15.e0
.;O;O
DDI-DrugBank.d35.s0;;
Interactions;O;O
may;O;O
occur;O;O
between;O;O
EPA;B-drug;B-DDI-DrugBank.d35.s0.e0
supplements;O;O
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d35.s0.e1
and;O;O
other;O;O
non;B-group;B-DDI-DrugBank.d35.s0.e2
-;I-group;I-DDI-DrugBank.d35.s0.e2
steroidal;I-group;I-DDI-DrugBank.d35.s0.e2
anti;I-group;I-DDI-DrugBank.d35.s0.e2
-;I-group;I-DDI-DrugBank.d35.s0.e2
inflammatory;I-group;I-DDI-DrugBank.d35.s0.e2
drugs;I-group;I-DDI-DrugBank.d35.s0.e2
and;O;O
herbs;O;O
such;O;O
as;O;O
garlic;O;O
(;O;O
Allium;O;O
sativum;O;O
);O;O
and;O;O
ginkgo;B-drug;B-DDI-DrugBank.d35.s0.e3
(;O;O
Ginkgo;B-drug;B-DDI-DrugBank.d35.s0.e4
biloba;I-drug;I-DDI-DrugBank.d35.s0.e4
);O;O
.;O;O
DDI-DrugBank.d35.s1;;
Such;O;O
interactions;O;O
might;O;O
be;O;O
manifested;O;O
by;O;O
increased;O;O
susceptibility;O;O
to;O;O
bruising;O;O
,;O;O
nosebleeds;O;O
,;O;O
hemoptysis;O;O
,;O;O
hematemesis;O;O
,;O;O
hematuria;O;O
and;O;O
blood;O;O
in;O;O
the;O;O
stool;O;O
.;O;O
DDI-DrugBank.d35.s2;;
Most;O;O
who;O;O
take;O;O
EPA;B-drug;B-DDI-DrugBank.d35.s2.e0
supplements;O;O
and;O;O
the;O;O
above;O;O
drugs;O;O
or;O;O
herbs;O;O
do;O;O
not;O;O
suffer;O;O
from;O;O
these;O;O
problems;O;O
and;O;O
if;O;O
they;O;O
occur;O;O
,;O;O
they;O;O
are;O;O
rare;O;O
.;O;O
DDI-DrugBank.d35.s3;;
If;O;O
they;O;O
do;O;O
occur;O;O
,;O;O
the;O;O
EPA;B-drug;B-DDI-DrugBank.d35.s3.e0
dose;O;O
should;O;O
be;O;O
lowered;O;O
or;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d35.s4;;
Conflicting;O;O
results;O;O
have;O;O
been;O;O
reported;O;O
regarding;O;O
the;O;O
effects;O;O
of;O;O
EPA;B-drug;B-DDI-DrugBank.d35.s4.e0
supplements;O;O
on;O;O
glycemic;O;O
control;O;O
in;O;O
non;O;O
-;O;O
diabetics;O;O
with;O;O
glucose;O;O
intolerance;O;O
,;O;O
and;O;O
those;O;O
with;O;O
type;O;O
2;O;O
diabetes;O;O
.;O;O
DDI-DrugBank.d35.s5;;
Some;O;O
early;O;O
studies;O;O
indicated;O;O
that;O;O
EPA;B-drug;B-DDI-DrugBank.d35.s5.e0
supplements;O;O
might;O;O
have;O;O
detrimental;O;O
effects;O;O
in;O;O
those;O;O
groups;O;O
.;O;O
DDI-DrugBank.d35.s6;;
Recent;O;O
,;O;O
better;O;O
designed;O;O
studies;O;O
have;O;O
not;O;O
reported;O;O
these;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d35.s7;;
There;O;O
is;O;O
no;O;O
evidence;O;O
that;O;O
EPA;B-drug;B-DDI-DrugBank.d35.s7.e0
supplements;O;O
have;O;O
detrimental;O;O
effects;O;O
on;O;O
glucose;O;O
tolerance;O;O
,;O;O
insulin;O;O
secretion;O;O
or;O;O
insulin;O;O
resistance;O;O
in;O;O
non;O;O
-;O;O
diabetic;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d35.s8;;
Diabetics;O;O
should;O;O
discuss;O;O
the;O;O
use;O;O
of;O;O
these;O;O
supplements;O;O
with;O;O
their;O;O
physicians;O;O
and;O;O
note;O;O
if;O;O
the;O;O
supplements;O;O
affect;O;O
their;O;O
glycemic;O;O
control;O;O
.;O;O
DDI-DrugBank.d35.s9;;
Diabetics;O;O
who;O;O
take;O;O
EPA;B-drug;B-DDI-DrugBank.d35.s9.e0
supplements;O;O
should;O;O
be;O;O
monitored;O;O
by;O;O
their;O;O
physicians;O;O
.;O;O
DDI-DrugBank.d91.s0;;
Other;O;O
medicines;O;O
-;O;O
Although;O;O
certain;O;O
medicines;O;O
should;O;O
not;O;O
be;O;O
used;O;O
together;O;O
at;O;O
all;O;O
,;O;O
in;O;O
other;O;O
cases;O;O
two;O;O
different;O;O
medicines;O;O
may;O;O
be;O;O
used;O;O
together;O;O
even;O;O
if;O;O
an;O;O
interaction;O;O
might;O;O
occur;O;O
.;O;O
DDI-DrugBank.d91.s1;;
In;O;O
these;O;O
cases;O;O
,;O;O
your;O;O
doctor;O;O
may;O;O
want;O;O
to;O;O
change;O;O
the;O;O
dose;O;O
,;O;O
or;O;O
other;O;O
precautions;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d91.s2;;
When;O;O
you;O;O
are;O;O
using;O;O
idoxuridine;B-drug;B-DDI-DrugBank.d91.s2.e0
,;O;O
it;O;O
is;O;O
especially;O;O
important;O;O
that;O;O
your;O;O
health;O;O
care;O;O
professional;O;O
know;O;O
if;O;O
you;O;O
are;O;O
using;O;O
the;O;O
following;O;O
:;O;O
Eye;O;O
product;O;O
containing;O;O
boric;B-drug;B-DDI-DrugBank.d91.s2.e1
acid;I-drug;I-DDI-DrugBank.d91.s2.e1
.;O;O
DDI-DrugBank.d91.s3;;
Boric;B-drug;B-DDI-DrugBank.d91.s3.e0
acid;I-drug;I-DDI-DrugBank.d91.s3.e0
may;O;O
interact;O;O
with;O;O
the;O;O
idoxuridine;B-drug;B-DDI-DrugBank.d91.s3.e1
preparation;O;O
causing;O;O
a;O;O
gritty;O;O
substance;O;O
to;O;O
form;O;O
or;O;O
may;O;O
interact;O;O
with;O;O
the;O;O
preservative;O;O
in;O;O
the;O;O
idoxuridine;B-drug;B-DDI-DrugBank.d91.s3.e2
preparation;O;O
causing;O;O
a;O;O
toxic;O;O
effect;O;O
in;O;O
the;O;O
eye;O;O
.;O;O
DDI-DrugBank.d515.s0;;
The;O;O
physician;O;O
should;O;O
be;O;O
alert;O;O
for;O;O
possible;O;O
combined;O;O
drug;O;O
actions;O;O
,;O;O
desirable;O;O
or;O;O
undesirable;O;O
,;O;O
involving;O;O
ifosfamide;B-drug;B-DDI-DrugBank.d515.s0.e0
even;O;O
though;O;O
ifosfamide;B-drug;B-DDI-DrugBank.d515.s0.e1
has;O;O
been;O;O
used;O;O
successfully;O;O
concurrently;O;O
with;O;O
other;O;O
drugs;O;O
,;O;O
including;O;O
other;O;O
cytotoxic;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d549.s0;;
In;O;O
studies;O;O
in;O;O
normal;O;O
volunteers;O;O
,;O;O
there;O;O
was;O;O
no;O;O
pharmacodynamic;O;O
interaction;O;O
between;O;O
intravenous;O;O
iloprost;B-drug;B-DDI-DrugBank.d549.s0.e0
and;O;O
either;O;O
nifedipine;B-drug;B-DDI-DrugBank.d549.s0.e1
,;O;O
diltiazem;B-drug;B-DDI-DrugBank.d549.s0.e2
,;O;O
or;O;O
captopril;B-drug;B-DDI-DrugBank.d549.s0.e3
.;O;O
DDI-DrugBank.d549.s1;;
However;O;O
,;O;O
iloprost;B-drug;B-DDI-DrugBank.d549.s1.e0
has;O;O
the;O;O
potential;O;O
to;O;O
increase;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
vasodilators;B-group;B-DDI-DrugBank.d549.s1.e1
and;O;O
antihypertensive;B-group;B-DDI-DrugBank.d549.s1.e2
agents;I-group;I-DDI-DrugBank.d549.s1.e2
.;O;O
DDI-DrugBank.d549.s2;;
Since;O;O
iloprost;B-drug;B-DDI-DrugBank.d549.s2.e0
inhibits;O;O
platelet;O;O
function;O;O
,;O;O
there;O;O
is;O;O
a;O;O
potential;O;O
for;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
,;O;O
particularly;O;O
in;O;O
patients;O;O
maintained;O;O
on;O;O
anticoagulants;B-group;B-DDI-DrugBank.d549.s2.e1
.;O;O
DDI-DrugBank.d549.s3;;
During;O;O
clinical;O;O
trials;O;O
,;O;O
iloprost;B-drug;B-DDI-DrugBank.d549.s3.e0
was;O;O
used;O;O
concurrently;O;O
with;O;O
anticoagulants;B-group;B-DDI-DrugBank.d549.s3.e1
,;O;O
diuretics;B-group;B-DDI-DrugBank.d549.s3.e2
,;O;O
cardiac;B-group;B-DDI-DrugBank.d549.s3.e3
glycosides;I-group;I-DDI-DrugBank.d549.s3.e3
,;O;O
calcium;B-group;B-DDI-DrugBank.d549.s3.e4
channel;I-group;I-DDI-DrugBank.d549.s3.e4
blockers;I-group;I-DDI-DrugBank.d549.s3.e4
,;O;O
analgesics;B-group;B-DDI-DrugBank.d549.s3.e5
,;O;O
antipyretics;B-group;B-DDI-DrugBank.d549.s3.e6
,;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d549.s3.e7
antiinflammatories;I-group;I-DDI-DrugBank.d549.s3.e7
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d549.s3.e8
,;O;O
and;O;O
other;O;O
medications;O;O
.;O;O
DDI-DrugBank.d549.s4;;
Intravenous;O;O
infusion;O;O
of;O;O
iloprost;B-drug;B-DDI-DrugBank.d549.s4.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d549.s4.e1
.;O;O
DDI-DrugBank.d549.s5;;
Acetylsalicylic;B-drug;B-DDI-DrugBank.d549.s5.e0
acid;I-drug;I-DDI-DrugBank.d549.s5.e0
did;O;O
not;O;O
alter;O;O
the;O;O
clearance;O;O
(;O;O
pharmacokinetics;O;O
);O;O
of;O;O
iloprost;B-drug;B-DDI-DrugBank.d549.s5.e1
.;O;O
DDI-DrugBank.d549.s6;;
Although;O;O
clinical;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
,;O;O
in;O;O
vitro;O;O
studies;O;O
of;O;O
iloprost;B-drug;B-DDI-DrugBank.d549.s6.e0
indicate;O;O
that;O;O
no;O;O
relevant;O;O
inhibition;O;O
of;O;O
cytochrome;O;O
P450;O;O
drug;O;O
metabolism;O;O
would;O;O
be;O;O
expected;O;O
.;O;O
DDI-DrugBank.d115.s0;;
Drugs;O;O
that;O;O
may;O;O
alter;O;O
imatinib;B-drug;B-DDI-DrugBank.d115.s0.e0
plasma;O;O
concentrations;O;O
Drugs;O;O
that;O;O
may;O;O
increase;O;O
imatinib;B-drug;B-DDI-DrugBank.d115.s0.e1
plasma;O;O
concentrations;O;O
:;O;O
Caution;O;O
is;O;O
recommended;O;O
when;O;O
administering;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s0.e2
with;O;O
inhibitors;O;O
of;O;O
the;O;O
CYP3A4;O;O
family;O;O
(;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d115.s0.e3
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d115.s0.e4
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d115.s0.e5
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d115.s0.e6
);O;O
.;O;O
DDI-DrugBank.d115.s1;;
Substances;O;O
that;O;O
inhibit;O;O
the;O;O
cytochrome;O;O
P450;O;O
isoenzyme;O;O
(;O;O
CYP3A4;O;O
);O;O
activity;O;O
may;O;O
decrease;O;O
metabolism;O;O
and;O;O
increase;O;O
imatinib;B-drug;B-DDI-DrugBank.d115.s1.e0
concentrations;O;O
.;O;O
DDI-DrugBank.d115.s2;;
There;O;O
is;O;O
a;O;O
significant;O;O
increase;O;O
in;O;O
exposure;O;O
to;O;O
imatinib;B-drug;B-DDI-DrugBank.d115.s2.e0
when;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s2.e1
is;O;O
coadministered;O;O
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d115.s2.e2
(;O;O
CYP3A4;O;O
inhibitor;O;O
);O;O
.;O;O
DDI-DrugBank.d115.s3;;
Drugs;O;O
that;O;O
may;O;O
decrease;O;O
imatinib;B-drug;B-DDI-DrugBank.d115.s3.e0
plasma;O;O
concentrations;O;O
:;O;O
Substances;O;O
that;O;O
are;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
activity;O;O
may;O;O
increase;O;O
metabolism;O;O
and;O;O
decrease;O;O
imatinib;B-drug;B-DDI-DrugBank.d115.s3.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d115.s4;;
Co;O;O
-;O;O
medications;O;O
that;O;O
induce;O;O
CYP3A4;O;O
(;O;O
e.g.;O;O
,;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d115.s4.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d115.s4.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d115.s4.e2
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d115.s4.e3
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d115.s4.e4
or;O;O
St.;O;O
DDI-DrugBank.d115.s5;;
Johns;O;O
Wort;O;O
);O;O
may;O;O
significantly;O;O
reduce;O;O
exposure;O;O
to;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s5.e0
.;O;O
DDI-DrugBank.d115.s6;;
Pretreatment;O;O
of;O;O
healthy;O;O
volunteers;O;O
with;O;O
multiple;O;O
doses;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d115.s6.e0
followed;O;O
by;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s6.e1
,;O;O
increased;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s6.e2
oral;O;O
-;O;O
dose;O;O
clearance;O;O
by;O;O
3.8;O;O
-;O;O
fold;O;O
,;O;O
which;O;O
significantly;O;O
(;O;O
p;O;O
0.05;O;O
);O;O
decreased;O;O
mean;O;O
cmax;O;O
and;O;O
AUC(0;O;O
-;O;O
8;O;O
);O;O
.;O;O
DDI-DrugBank.d115.s7;;
In;O;O
patients;O;O
where;O;O
rifampin;B-drug;B-DDI-DrugBank.d115.s7.e0
or;O;O
other;O;O
CYP3A4;O;O
inducers;O;O
are;O;O
indicated;O;O
,;O;O
alternative;O;O
therapeutic;O;O
agents;O;O
with;O;O
less;O;O
enzyme;O;O
induction;O;O
potential;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d115.s8;;
Drugs;O;O
that;O;O
may;O;O
have;O;O
their;O;O
plasma;O;O
concentration;O;O
altered;O;O
by;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s8.e0
Gleevec;I-brand;I-DDI-DrugBank.d115.s8.e1
increases;O;O
the;O;O
mean;O;O
cmax;O;O
and;O;O
AUC;O;O
of;O;O
simvastatin;B-drug;B-DDI-DrugBank.d115.s8.e2
(;O;O
CYP3A4;O;O
substrate;O;O
);O;O
2;O;O
-;O;O
and;O;O
3.5;O;O
-;O;O
fold;O;O
,;O;O
respectively;O;O
,;O;O
suggesting;O;O
an;O;O
inhibition;O;O
of;O;O
the;O;O
CYP3A4;O;O
by;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s8.e3
.;O;O
DDI-DrugBank.d115.s9;;
Particular;O;O
caution;O;O
is;O;O
recommended;O;O
when;O;O
administering;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s9.e0
with;O;O
CYP3A4;O;O
substrates;O;O
that;O;O
have;O;O
a;O;O
narrow;O;O
therapeutic;O;O
window;O;O
(;O;O
e.g.;O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d115.s9.e1
or;O;O
pimozide;B-drug;B-DDI-DrugBank.d115.s9.e2
);O;O
.;O;O
DDI-DrugBank.d115.s10;;
Gleevec;B-brand;B-DDI-DrugBank.d115.s10.e0
will;O;O
increase;O;O
plasmaconcentration;O;O
of;O;O
other;O;O
CYP3A4;O;O
metabolized;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
triazolo;O;O
-;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d115.s10.e1
,;O;O
dihydropyridine;B-group;B-DDI-DrugBank.d115.s10.e2
calcium;I-group;I-DDI-DrugBank.d115.s10.e2
channel;I-group;I-DDI-DrugBank.d115.s10.e2
blockers;I-group;I-DDI-DrugBank.d115.s10.e2
,;O;O
certain;O;O
HMG;B-group;B-DDI-DrugBank.d115.s10.e3
-;I-group;I-DDI-DrugBank.d115.s10.e3
CoA;I-group;I-DDI-DrugBank.d115.s10.e3
reductase;I-group;I-DDI-DrugBank.d115.s10.e3
inhibitors;I-group;I-DDI-DrugBank.d115.s10.e3
,;O;O
etc;O;O
.;O;O
);O;O
.;O;O
DDI-DrugBank.d115.s11;;
Because;O;O
warfarin;B-drug;B-DDI-DrugBank.d115.s11.e0
is;O;O
metabolized;O;O
by;O;O
CYP2C9;O;O
and;O;O
CYP3A4;O;O
,;O;O
patients;O;O
who;O;O
require;O;O
anticoagulation;O;O
should;O;O
receive;O;O
low;O;O
-;O;O
molecular;O;O
weight;O;O
or;O;O
standard;O;O
heparin;B-drug;B-DDI-DrugBank.d115.s11.e1
.;O;O
DDI-DrugBank.d115.s12;;
in;O;O
vitro;O;O
,;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s12.e0
inhibits;O;O
the;O;O
cytochrome;O;O
P450;O;O
isoenzyme;O;O
CYP2D6;O;O
activity;O;O
at;O;O
similar;O;O
concentrations;O;O
that;O;O
affect;O;O
CYP3A4;O;O
activity;O;O
.;O;O
DDI-DrugBank.d115.s13;;
Systemic;O;O
exposure;O;O
to;O;O
substrates;O;O
of;O;O
CYP2D6;O;O
is;O;O
expected;O;O
to;O;O
be;O;O
increased;O;O
when;O;O
coadministered;O;O
with;O;O
Gleevec;O;O
.;O;O
DDI-DrugBank.d115.s14;;
No;O;O
specific;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
and;O;O
caution;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d115.s15;;
in;O;O
vitro;O;O
,;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s15.e0
inhibits;O;O
acetaminophen;O;O
O;O;O
-;O;O
glucuronidation;O;O
(;O;O
Ki;O;O
value;O;O
of;O;O
58.5;O;O
M;O;O
);O;O
at;O;O
therapeutic;O;O
levels;O;O
.;O;O
DDI-DrugBank.d115.s16;;
Systemic;O;O
exposure;O;O
to;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d115.s16.e0
is;O;O
expected;O;O
to;O;O
be;O;O
increased;O;O
when;O;O
coadministered;O;O
with;O;O
Gleevec;B-brand;B-DDI-DrugBank.d115.s16.e1
.;O;O
DDI-DrugBank.d115.s17;;
No;O;O
specific;O;O
studies;O;O
in;O;O
humans;O;O
have;O;O
been;O;O
performed;O;O
and;O;O
caution;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d115.s18;;
DDI-DrugBank.d77.s0;;
In;O;O
occasional;O;O
susceptible;O;O
patients;O;O
or;O;O
in;O;O
those;O;O
receiving;O;O
anticholinergic;B-group;B-DDI-DrugBank.d77.s0.e0
drugs;I-group;I-DDI-DrugBank.d77.s0.e0
(;O;O
including;O;O
antiparkinsonism;O;O
agents;O;O
);O;O
in;O;O
addition;O;O
,;O;O
the;O;O
atropine;O;O
-;O;O
like;O;O
effects;O;O
may;O;O
become;O;O
more;O;O
pronounced;O;O
(;O;O
e.g.;O;O
,;O;O
paralytic;O;O
ileus;O;O
);O;O
.;O;O
DDI-DrugBank.d77.s1;;
Close;O;O
supervision;O;O
and;O;O
careful;O;O
adjustment;O;O
of;O;O
dosage;O;O
is;O;O
required;O;O
when;O;O
this;O;O
drug;O;O
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
anticholinergic;B-group;B-DDI-DrugBank.d77.s1.e0
drugs;I-group;I-DDI-DrugBank.d77.s1.e0
.;O;O
DDI-DrugBank.d77.s2;;
Avoid;O;O
the;O;O
use;O;O
of;O;O
preparations;O;O
such;O;O
as;O;O
decongestants;B-group;B-DDI-DrugBank.d77.s2.e0
and;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d77.s2.e1
which;O;O
contain;O;O
any;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d77.s2.e2
amine;I-group;I-DDI-DrugBank.d77.s2.e2
(;O;O
e.g.;O;O
,;O;O
epinephrine;B-drug;B-DDI-DrugBank.d77.s2.e3
,;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d77.s2.e4
);O;O
,;O;O
since;O;O
it;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
tricyclic;B-group;B-DDI-DrugBank.d77.s2.e5
antidepressants;I-group;I-DDI-DrugBank.d77.s2.e5
can;O;O
potentiate;O;O
the;O;O
effects;O;O
of;O;O
catecholamines;O;O
.;O;O
DDI-DrugBank.d77.s3;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
imipramine;B-drug;B-DDI-DrugBank.d77.s3.e0
hydrochloride;I-drug;I-DDI-DrugBank.d77.s3.e0
is;O;O
used;O;O
with;O;O
agents;O;O
that;O;O
lower;O;O
blood;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d77.s4;;
Imipramine;B-drug;B-DDI-DrugBank.d77.s4.e0
hydrochloride;I-drug;I-DDI-DrugBank.d77.s4.e0
may;O;O
potentiate;O;O
the;O;O
effects;O;O
of;O;O
CNS;B-group;B-DDI-DrugBank.d77.s4.e1
depressant;I-group;I-DDI-DrugBank.d77.s4.e1
drugs;I-group;I-DDI-DrugBank.d77.s4.e1
.;O;O
DDI-DrugBank.d77.s5;;
The;O;O
plasma;O;O
concentration;O;O
of;O;O
imipramine;B-drug;B-DDI-DrugBank.d77.s5.e0
may;O;O
increase;O;O
when;O;O
the;O;O
drug;O;O
is;O;O
given;O;O
concomitantly;O;O
with;O;O
hepatic;O;O
enzyme;O;O
inhibitors;O;O
(;O;O
e.g.;O;O
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d77.s5.e1
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d77.s5.e2
);O;O
and;O;O
decrease;O;O
by;O;O
concomitant;O;O
administration;O;O
of;O;O
hepatic;O;O
enzyme;O;O
inducers;O;O
(;O;O
e.g.;O;O
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d77.s5.e3
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d77.s5.e4
);O;O
,;O;O
and;O;O
adjustment;O;O
of;O;O
the;O;O
dosage;O;O
of;O;O
imipramine;B-drug;B-DDI-DrugBank.d77.s5.e5
may;O;O
therefore;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d77.s6;;
Drugs;O;O
Metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
The;O;O
biochemical;O;O
activity;O;O
of;O;O
the;O;O
drug;O;O
metabolizing;O;O
isozyme;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
(;O;O
debrisoquin;O;O
hydroxylase;O;O
);O;O
is;O;O
reduced;O;O
in;O;O
a;O;O
subset;O;O
of;O;O
the;O;O
caucasian;O;O
population;O;O
(;O;O
about;O;O
7;O;O
to;O;O
10;O;O
%;O;O
of;O;O
caucasians;O;O
are;O;O
so;O;O
called;O;O
poor;O;O
metabolizers;O;O
);O;O
,;O;O
DDI-DrugBank.d77.s7;;
reliable;O;O
estimates;O;O
of;O;O
the;O;O
prevalence;O;O
of;O;O
reduced;O;O
P450;O;O
2D6;O;O
isozyme;O;O
activity;O;O
among;O;O
Asian;O;O
,;O;O
African;O;O
and;O;O
other;O;O
populations;O;O
are;O;O
not;O;O
yet;O;O
available;O;O
.;O;O
DDI-DrugBank.d77.s8;;
Poor;O;O
metabolizers;O;O
have;O;O
higher;O;O
than;O;O
expected;O;O
plasma;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d77.s8.e0
antidepressants;I-group;I-DDI-DrugBank.d77.s8.e0
(;O;O
TCAs;B-group;B-DDI-DrugBank.d77.s8.e1
);O;O
when;O;O
given;O;O
usual;O;O
doses;O;O
.;O;O
DDI-DrugBank.d77.s9;;
Depending;O;O
on;O;O
the;O;O
fraction;O;O
of;O;O
drug;O;O
metabolized;O;O
by;O;O
P450;O;O
2D6;O;O
,;O;O
the;O;O
increase;O;O
in;O;O
plasma;O;O
concentration;O;O
may;O;O
be;O;O
small;O;O
,;O;O
or;O;O
quite;O;O
large;O;O
(;O;O
8;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
plasma;O;O
AUC;O;O
of;O;O
the;O;O
TCA;B-group;B-DDI-DrugBank.d77.s9.e0
);O;O
.;O;O
DDI-DrugBank.d77.s10;;
In;O;O
addition;O;O
,;O;O
certain;O;O
drugs;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
this;O;O
isozyme;O;O
and;O;O
make;O;O
normal;O;O
metabolizers;O;O
resemble;O;O
p.o;O;O
.;O;O
DDI-DrugBank.d77.s11;;
metabolizers;O;O
.;O;O
DDI-DrugBank.d77.s12;;
An;O;O
individual;O;O
who;O;O
is;O;O
stable;O;O
on;O;O
a;O;O
given;O;O
dose;O;O
of;O;O
TCA;B-group;B-DDI-DrugBank.d77.s12.e0
may;O;O
become;O;O
abruptly;O;O
toxic;O;O
when;O;O
given;O;O
one;O;O
of;O;O
these;O;O
inhibiting;O;O
drugs;O;O
as;O;O
concomitant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d77.s13;;
The;O;O
drugs;O;O
that;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
include;O;O
some;O;O
that;O;O
are;O;O
not;O;O
metabolized;O;O
by;O;O
the;O;O
enzyme;O;O
(;O;O
quinidine;B-drug;B-DDI-DrugBank.d77.s13.e0
,;O;O
DDI-DrugBank.d77.s14;;
cimetidine;B-drug;B-DDI-DrugBank.d77.s14.e0
);O;O
and;O;O
many;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
P450;O;O
2D6;O;O
(;O;O
many;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d77.s14.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d77.s14.e2
,;O;O
and;O;O
the;O;O
Type;B-group;B-DDI-DrugBank.d77.s14.e3
1C;I-group;I-DDI-DrugBank.d77.s14.e3
antiarrhythmics;I-group;I-DDI-DrugBank.d77.s14.e3
propafenone;I-drug;I-DDI-DrugBank.d77.s14.e4
and;O;O
flecainide;B-drug;B-DDI-DrugBank.d77.s14.e5
);O;O
.;O;O
DDI-DrugBank.d77.s15;;
While;O;O
all;O;O
the;O;O
selective;B-group;B-DDI-DrugBank.d77.s15.e0
serotonin;I-group;I-DDI-DrugBank.d77.s15.e0
reuptake;I-group;I-DDI-DrugBank.d77.s15.e0
inhibitors;I-group;I-DDI-DrugBank.d77.s15.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d77.s15.e1
);O;O
,;O;O
e.;O;O
g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d77.s15.e2
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d77.s15.e3
,;O;O
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d77.s15.e4
,;O;O
inhibit;O;O
P450;O;O
2D6;O;O
,;O;O
they;O;O
may;O;O
vary;O;O
in;O;O
the;O;O
extent;O;O
of;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d77.s16;;
The;O;O
extent;O;O
to;O;O
which;O;O
SSRI;B-group;B-DDI-DrugBank.d77.s16.e0
-;O;O
TCA;B-group;B-DDI-DrugBank.d77.s16.e1
interactions;O;O
may;O;O
pose;O;O
clinical;O;O
problems;O;O
will;O;O
depend;O;O
on;O;O
the;O;O
degree;O;O
of;O;O
inhibition;O;O
,;O;O
and;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
the;O;O
SSRI;B-group;B-DDI-DrugBank.d77.s16.e2
involved;O;O
.;O;O
DDI-DrugBank.d77.s17;;
Nevertheless;O;O
,;O;O
caution;O;O
is;O;O
indicated;O;O
in;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
TCA5;O;O
with;O;O
any;O;O
of;O;O
the;O;O
SSRIs;B-group;B-DDI-DrugBank.d77.s17.e0
and;O;O
also;O;O
in;O;O
switching;O;O
from;O;O
one;O;O
class;O;O
to;O;O
the;O;O
other;O;O
.;O;O
DDI-DrugBank.d77.s18;;
Of;O;O
particular;O;O
importance;O;O
,;O;O
sufficient;O;O
time;O;O
must;O;O
elapse;O;O
before;O;O
initiating;O;O
TCA;O;O
treatment;O;O
in;O;O
a;O;O
patient;O;O
being;O;O
withdrawn;O;O
from;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d77.s18.e0
,;O;O
given;O;O
the;O;O
long;O;O
half;O;O
-;O;O
life;O;O
of;O;O
the;O;O
parent;O;O
and;O;O
active;O;O
metabolite;O;O
(;O;O
at;O;O
least;O;O
5;O;O
weeks;O;O
may;O;O
be;O;O
necessary;O;O
);O;O
.;O;O
DDI-DrugBank.d77.s19;;
Concomitant;O;O
use;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d77.s19.e0
antidepressants;I-group;I-DDI-DrugBank.d77.s19.e0
with;O;O
drugs;O;O
that;O;O
can;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
2D6;O;O
may;O;O
require;O;O
lower;O;O
doses;O;O
than;O;O
usually;O;O
prescribed;O;O
for;O;O
either;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d77.s19.e1
antidepressant;I-group;I-DDI-DrugBank.d77.s19.e1
or;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d77.s20;;
Furthermore;O;O
,;O;O
whenever;O;O
one;O;O
of;O;O
these;O;O
other;O;O
drugs;O;O
is;O;O
withdrawn;O;O
from;O;O
cotherapy;O;O
,;O;O
an;O;O
increased;O;O
dose;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d77.s20.e0
antidepressant;I-group;I-DDI-DrugBank.d77.s20.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d77.s21;;
It;O;O
is;O;O
desirable;O;O
to;O;O
monitor;O;O
TCA;B-group;B-DDI-DrugBank.d77.s21.e0
plasma;O;O
levels;O;O
whenever;O;O
a;O;O
TCA;B-group;B-DDI-DrugBank.d77.s21.e1
is;O;O
going;O;O
to;O;O
be;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
another;O;O
drug;O;O
known;O;O
to;O;O
be;O;O
an;O;O
inhibitor;O;O
of;O;O
P450;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d555.s0;;
No;O;O
information;O;O
available;O;O
DDI-DrugBank.d555.s1;;
.;O;O
DDI-DrugBank.d555.s2;;
DDI-DrugBank.d97.s0;;
Indinavir;B-drug;B-DDI-DrugBank.d97.s0.e0
is;O;O
an;O;O
inhibitor;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
isoform;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d97.s1;;
Coadministration;O;O
of;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s1.e0
and;O;O
drugs;O;O
primarily;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
other;O;O
drug;O;O
,;O;O
which;O;O
could;O;O
increase;O;O
or;O;O
prolong;O;O
its;O;O
therapeutic;O;O
and;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d97.s2;;
Indinavir;B-drug;B-DDI-DrugBank.d97.s2.e0
is;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d97.s3;;
Drugs;O;O
that;O;O
induce;O;O
CYP3A4;O;O
activity;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
increase;O;O
the;O;O
clearance;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s3.e0
,;O;O
resulting;O;O
in;O;O
lowered;O;O
plasma;O;O
concentrations;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s3.e1
.;O;O
DDI-DrugBank.d97.s4;;
Coadministration;O;O
of;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s4.e0
and;O;O
other;O;O
drugs;O;O
that;O;O
inhibit;O;O
CYP3A4;O;O
may;O;O
decrease;O;O
the;O;O
clearance;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s4.e1
and;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s4.e2
.;O;O
DDI-DrugBank.d97.s5;;
Table;O;O
8;O;O
DDI-DrugBank.d97.s6;;
Drugs;O;O
That;O;O
Should;O;O
Not;O;O
Be;O;O
Coadministered;O;O
with;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s6.e0
DDI-DrugBank.d97.s7;;
Drug;O;O
Class;O;O
:;O;O
Drug;O;O
Name;O;O
Clinical;O;O
Comment;O;O
DDI-DrugBank.d97.s8;;
Antiarrhythmics;B-group;B-DDI-DrugBank.d97.s8.e0
:;O;O
amiodarone;B-drug;B-DDI-DrugBank.d97.s8.e1
DDI-DrugBank.d97.s9;;
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d97.s10;;
Ergot;O;O
derivatives;O;O
:;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d97.s10.e0
,;O;O
ergonovine;B-drug;B-DDI-DrugBank.d97.s10.e1
,;O;O
ergotamine;B-drug;B-DDI-DrugBank.d97.s10.e2
,;O;O
methylergonovine;B-drug;B-DDI-DrugBank.d97.s10.e3
DDI-DrugBank.d97.s11;;
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
acute;O;O
ergot;O;O
toxicity;O;O
characterized;O;O
by;O;O
peripheral;O;O
vasospasm;O;O
and;O;O
ischemia;O;O
of;O;O
the;O;O
extremities;O;O
and;O;O
other;O;O
tissues;O;O
.;O;O
DDI-DrugBank.d97.s12;;
Sedative;B-group;B-DDI-DrugBank.d97.s12.e0
/;O;O
hypnotics;B-group;B-DDI-DrugBank.d97.s12.e1
:;O;O
midazolam;B-drug;B-DDI-DrugBank.d97.s12.e2
,;O;O
triazolam;B-drug;B-DDI-DrugBank.d97.s12.e3
DDI-DrugBank.d97.s13;;
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
prolonged;O;O
or;O;O
increased;O;O
sedation;O;O
or;O;O
respiratory;O;O
depression;O;O
.;O;O
DDI-DrugBank.d97.s14;;
GI;O;O
motility;O;O
agents;O;O
:;O;O
cisapride;B-drug;B-DDI-DrugBank.d97.s14.e0
DDI-DrugBank.d97.s15;;
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d97.s16;;
Neuroleptic;B-group;B-DDI-DrugBank.d97.s16.e0
:;O;O
pimozide;B-drug;B-DDI-DrugBank.d97.s16.e1
DDI-DrugBank.d97.s17;;
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d97.s18;;
Herbal;O;O
products;O;O
:;O;O
St.;O;O
John;O;O
s;O;O
wort;O;O
(;O;O
Hypericum;O;O
perforatum;O;O
);O;O
DDI-DrugBank.d97.s19;;
May;O;O
lead;O;O
to;O;O
loss;O;O
of;O;O
virologic;O;O
response;O;O
and;O;O
possible;O;O
resistance;O;O
to;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s19.e0
or;O;O
to;O;O
the;O;O
class;O;O
of;O;O
protease;B-group;B-DDI-DrugBank.d97.s19.e1
inhibitors;I-group;I-DDI-DrugBank.d97.s19.e1
.;O;O
DDI-DrugBank.d97.s20;;
Antimycobacterial;B-group;B-DDI-DrugBank.d97.s20.e0
:;O;O
rifampin;B-drug;B-DDI-DrugBank.d97.s20.e1
DDI-DrugBank.d97.s21;;
May;O;O
lead;O;O
to;O;O
loss;O;O
of;O;O
virologic;O;O
response;O;O
and;O;O
possible;O;O
resistance;O;O
to;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s21.e0
or;O;O
to;O;O
the;O;O
class;O;O
of;O;O
protease;B-group;B-DDI-DrugBank.d97.s21.e1
inhibitors;I-group;I-DDI-DrugBank.d97.s21.e1
or;O;O
other;O;O
coadministered;O;O
antiretroviral;B-group;B-DDI-DrugBank.d97.s21.e2
agents;I-group;I-DDI-DrugBank.d97.s21.e2
.;O;O
DDI-DrugBank.d97.s22;;
HMG;B-group;B-DDI-DrugBank.d97.s22.e0
-;I-group;I-DDI-DrugBank.d97.s22.e0
CoA;I-group;I-DDI-DrugBank.d97.s22.e0
Reductase;I-group;I-DDI-DrugBank.d97.s22.e0
inhibitors;I-group;I-DDI-DrugBank.d97.s22.e0
:;O;O
lovastatin;B-drug;B-DDI-DrugBank.d97.s22.e1
,;O;O
simvastatin;B-drug;B-DDI-DrugBank.d97.s22.e2
DDI-DrugBank.d97.s23;;
Potential;O;O
for;O;O
serious;O;O
reactions;O;O
such;O;O
as;O;O
risk;O;O
of;O;O
myopathy;O;O
including;O;O
rhabdomyolysis;O;O
.;O;O
DDI-DrugBank.d97.s24;;
Protease;B-group;B-DDI-DrugBank.d97.s24.e0
inhibitor;I-group;I-DDI-DrugBank.d97.s24.e0
:;O;O
atazanavir;B-drug;B-DDI-DrugBank.d97.s24.e1
DDI-DrugBank.d97.s25;;
Both;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s25.e0
and;O;O
atazanavir;B-drug;B-DDI-DrugBank.d97.s25.e1
are;O;O
associated;O;O
with;O;O
indirect;O;O
(;O;O
unconjugated;O;O
);O;O
hyperbilirubinemia;O;O
.;O;O
DDI-DrugBank.d97.s26;;
Combinations;O;O
of;O;O
these;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
and;O;O
coadministration;O;O
of;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s26.e0
and;O;O
atazanavir;B-drug;B-DDI-DrugBank.d97.s26.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d97.s27;;
Table;O;O
9;O;O
DDI-DrugBank.d97.s28;;
Established;O;O
and;O;O
Other;O;O
Potentially;O;O
Significant;O;O
Drug;O;O
Interactions;O;O
:;O;O
Alteration;O;O
in;O;O
Dose;O;O
or;O;O
Regimen;O;O
May;O;O
Be;O;O
Recommended;O;O
Based;O;O
on;O;O
Drug;O;O
Interaction;O;O
Studies;O;O
or;O;O
Predicted;O;O
Interaction;O;O
DDI-DrugBank.d97.s29;;
Drug;O;O
Name;O;O
DDI-DrugBank.d97.s30;;
Effect;O;O
DDI-DrugBank.d97.s31;;
Clinical;O;O
Comment;O;O
DDI-DrugBank.d97.s32;;
HIV;B-group;B-DDI-DrugBank.d97.s32.e0
Antiviral;I-group;I-DDI-DrugBank.d97.s32.e0
Agents;I-group;I-DDI-DrugBank.d97.s32.e0
DDI-DrugBank.d97.s33;;
Delavirdine;I-drug;I-DDI-DrugBank.d97.s33.e0
DDI-DrugBank.d97.s34;;
indinavir;I-drug;I-DDI-DrugBank.d97.s34.e0
concentration;O;O
DDI-DrugBank.d97.s35;;
Dose;O;O
reduction;O;O
of;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s35.e0
to;O;O
600;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
taking;O;O
delavirdine;B-drug;B-DDI-DrugBank.d97.s35.e1
400;O;O
mg;O;O
three;O;O
times;O;O
a;O;O
day;O;O
.;O;O
DDI-DrugBank.d97.s36;;
Didanosine;B-drug;B-DDI-DrugBank.d97.s36.e0
DDI-DrugBank.d97.s37;;
Indinavir;I-drug;I-DDI-DrugBank.d97.s37.e0
and;O;O
didanosine;B-drug;B-DDI-DrugBank.d97.s37.e1
formulations;O;O
containing;O;O
buffer;O;O
should;O;O
be;O;O
administered;O;O
at;O;O
least;O;O
one;O;O
hour;O;O
apart;O;O
on;O;O
an;O;O
empty;O;O
stomach;O;O
.;O;O
DDI-DrugBank.d97.s38;;
Efavirenz;B-drug;B-DDI-DrugBank.d97.s38.e0
DDI-DrugBank.d97.s39;;
indinavir;I-drug;I-DDI-DrugBank.d97.s39.e0
concentration;O;O
DDI-DrugBank.d97.s40;;
The;O;O
optimal;O;O
dose;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s40.e0
,;O;O
when;O;O
given;O;O
in;O;O
combination;O;O
with;O;O
efavirenz;B-drug;B-DDI-DrugBank.d97.s40.e1
,;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d97.s41;;
Increasing;O;O
the;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s41.e0
dose;O;O
to;O;O
1000;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
does;O;O
not;O;O
compensate;O;O
for;O;O
the;O;O
increased;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s41.e1
metabolism;O;O
due;O;O
to;O;O
efavirenz;B-drug;B-DDI-DrugBank.d97.s41.e2
.;O;O
DDI-DrugBank.d97.s42;;
Nelfinavir;B-drug;B-DDI-DrugBank.d97.s42.e0
DDI-DrugBank.d97.s43;;
indinavir;I-drug;I-DDI-DrugBank.d97.s43.e0
concentration;O;O
DDI-DrugBank.d97.s44;;
The;O;O
appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
,;O;O
with;O;O
respect;O;O
to;O;O
efficacy;O;O
and;O;O
safety;O;O
,;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d97.s45;;
Nevirapine;B-drug;B-DDI-DrugBank.d97.s45.e0
DDI-DrugBank.d97.s46;;
indinavir;I-drug;I-DDI-DrugBank.d97.s46.e0
concentration;O;O
DDI-DrugBank.d97.s47;;
Indinavir;B-drug;B-DDI-DrugBank.d97.s47.e0
concentrations;O;O
may;O;O
be;O;O
decreased;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
nevirapine;B-drug;B-DDI-DrugBank.d97.s47.e1
.;O;O
DDI-DrugBank.d97.s48;;
The;O;O
appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
,;O;O
with;O;O
respect;O;O
to;O;O
efficacy;O;O
and;O;O
safety;O;O
,;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d97.s49;;
Ritonavir;B-drug;B-DDI-DrugBank.d97.s49.e0
DDI-DrugBank.d97.s50;;
indinavir;I-drug;I-DDI-DrugBank.d97.s50.e0
concentration;O;O
ritonavir;B-drug;B-DDI-DrugBank.d97.s50.e1
concentration;O;O
DDI-DrugBank.d97.s51;;
The;O;O
appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
,;O;O
with;O;O
respect;O;O
to;O;O
efficacy;O;O
and;O;O
safety;O;O
,;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d97.s52;;
Preliminary;O;O
clinical;O;O
data;O;O
suggest;O;O
that;O;O
the;O;O
incidence;O;O
of;O;O
nephrolithiasis;O;O
is;O;O
higher;O;O
in;O;O
patients;O;O
receiving;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s52.e0
in;O;O
combination;O;O
with;O;O
ritonavir;B-drug;B-DDI-DrugBank.d97.s52.e1
than;O;O
those;O;O
receiving;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s52.e2
800;O;O
mg;O;O
q8h;O;O
.;O;O
DDI-DrugBank.d97.s53;;
Saquinavir;B-drug;B-DDI-DrugBank.d97.s53.e0
DDI-DrugBank.d97.s54;;
saquinavir;I-drug;I-DDI-DrugBank.d97.s54.e0
concentration;O;O
DDI-DrugBank.d97.s55;;
The;O;O
appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
,;O;O
with;O;O
respect;O;O
to;O;O
efficacy;O;O
and;O;O
safety;O;O
,;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d97.s56;;
Other;O;O
Agents;O;O
DDI-DrugBank.d97.s57;;
Antiarrhythmics;B-group;B-DDI-DrugBank.d97.s57.e0
:;O;O
bepridil;B-drug;B-DDI-DrugBank.d97.s57.e1
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d97.s57.e2
(;O;O
systemic;O;O
);O;O
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d97.s57.e3
DDI-DrugBank.d97.s58;;
antiarrhythmic;I-group;I-DDI-DrugBank.d97.s58.e0
agents;I-group;I-DDI-DrugBank.d97.s58.e0
concentration;O;O
DDI-DrugBank.d97.s59;;
Caution;O;O
is;O;O
warranted;O;O
and;O;O
therapeutic;O;O
concentration;O;O
monitoring;O;O
is;O;O
recommended;O;O
for;O;O
antiarrhythmics;B-group;B-DDI-DrugBank.d97.s59.e0
when;O;O
coadministered;O;O
with;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s59.e1
.;O;O
DDI-DrugBank.d97.s60;;
Anticonvulsants;B-group;B-DDI-DrugBank.d97.s60.e0
:;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d97.s60.e1
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d97.s60.e2
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d97.s60.e3
DDI-DrugBank.d97.s61;;
indinavir;I-drug;I-DDI-DrugBank.d97.s61.e0
concentration;O;O
DDI-DrugBank.d97.s62;;
Use;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d97.s63;;
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s63.e0
may;O;O
not;O;O
be;O;O
effective;O;O
due;O;O
to;O;O
decreased;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s63.e1
concentrations;O;O
in;O;O
patients;O;O
taking;O;O
these;O;O
agents;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d97.s64;;
Calcium;B-group;B-DDI-DrugBank.d97.s64.e0
Channel;I-group;I-DDI-DrugBank.d97.s64.e0
Blockers;I-group;I-DDI-DrugBank.d97.s64.e0
,;O;O
Dihydropyridine;B-group;B-DDI-DrugBank.d97.s64.e1
:;O;O
e.g.;O;O
,;O;O
felodipine;B-drug;B-DDI-DrugBank.d97.s64.e2
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d97.s64.e3
,;O;O
nicardipine;B-drug;B-DDI-DrugBank.d97.s64.e4
DDI-DrugBank.d97.s65;;
dihydropyridine;I-group;I-DDI-DrugBank.d97.s65.e0
calcium;I-group;I-DDI-DrugBank.d97.s65.e0
channel;I-group;I-DDI-DrugBank.d97.s65.e0
blockers;I-group;I-DDI-DrugBank.d97.s65.e0
concentration;O;O
DDI-DrugBank.d97.s66;;
Caution;O;O
is;O;O
warranted;O;O
and;O;O
clinical;O;O
monitoring;O;O
of;O;O
patients;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d97.s67;;
Clarithromycin;B-drug;B-DDI-DrugBank.d97.s67.e0
DDI-DrugBank.d97.s68;;
clarithromycin;I-drug;I-DDI-DrugBank.d97.s68.e0
concentration;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s68.e1
concentration;O;O
DDI-DrugBank.d97.s69;;
The;O;O
appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
,;O;O
with;O;O
respect;O;O
to;O;O
efficacy;O;O
and;O;O
safety;O;O
,;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d97.s70;;
HMG;B-group;B-DDI-DrugBank.d97.s70.e0
-;I-group;I-DDI-DrugBank.d97.s70.e0
CoA;I-group;I-DDI-DrugBank.d97.s70.e0
Reductase;I-group;I-DDI-DrugBank.d97.s70.e0
Inhibitor;I-group;I-DDI-DrugBank.d97.s70.e0
:;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d97.s70.e1
DDI-DrugBank.d97.s71;;
atorvastatin;I-drug;I-DDI-DrugBank.d97.s71.e0
concentration;O;O
DDI-DrugBank.d97.s72;;
Use;O;O
lowest;O;O
possible;O;O
dose;O;O
of;O;O
atorvastatin;B-drug;B-DDI-DrugBank.d97.s72.e0
with;O;O
careful;O;O
monitoring;O;O
,;O;O
or;O;O
consider;O;O
HMG;B-group;B-DDI-DrugBank.d97.s72.e1
-;I-group;I-DDI-DrugBank.d97.s72.e1
CoA;I-group;I-DDI-DrugBank.d97.s72.e1
reductase;I-group;I-DDI-DrugBank.d97.s72.e1
inhibitors;I-group;I-DDI-DrugBank.d97.s72.e1
that;O;O
are;O;O
not;O;O
primarily;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
,;O;O
such;O;O
as;O;O
pravastatin;B-drug;B-DDI-DrugBank.d97.s72.e2
,;O;O
fluvastatin;B-drug;B-DDI-DrugBank.d97.s72.e3
,;O;O
or;O;O
rosuvastatin;B-drug;B-DDI-DrugBank.d97.s72.e4
in;O;O
combination;O;O
with;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s72.e5
.;O;O
DDI-DrugBank.d97.s73;;
Immunosuppressants;B-group;B-DDI-DrugBank.d97.s73.e0
:;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d97.s73.e1
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d97.s73.e2
,;O;O
sirolimus;B-drug;B-DDI-DrugBank.d97.s73.e3
DDI-DrugBank.d97.s74;;
immunosuppressant;I-group;I-DDI-DrugBank.d97.s74.e0
agents;I-group;I-DDI-DrugBank.d97.s74.e0
concentration;O;O
DDI-DrugBank.d97.s75;;
Plasma;O;O
concentrations;O;O
may;O;O
be;O;O
increased;O;O
by;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s75.e0
.;O;O
DDI-DrugBank.d97.s76;;
Itraconazole;B-drug;B-DDI-DrugBank.d97.s76.e0
DDI-DrugBank.d97.s77;;
indinavir;I-drug;I-DDI-DrugBank.d97.s77.e0
concentration;O;O
DDI-DrugBank.d97.s78;;
Dose;O;O
reduction;O;O
of;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s78.e0
to;O;O
600;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
is;O;O
recommended;O;O
when;O;O
administering;O;O
itraconazole;B-drug;B-DDI-DrugBank.d97.s78.e1
concurrently;O;O
.;O;O
DDI-DrugBank.d97.s79;;
Ketoconazole;B-drug;B-DDI-DrugBank.d97.s79.e0
DDI-DrugBank.d97.s80;;
indinavir;I-drug;I-DDI-DrugBank.d97.s80.e0
concentration;O;O
DDI-DrugBank.d97.s81;;
Dose;O;O
reduction;O;O
of;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s81.e0
to;O;O
600;O;O
mg;O;O
every;O;O
8;O;O
hours;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d97.s82;;
Rifabutin;B-drug;B-DDI-DrugBank.d97.s82.e0
DDI-DrugBank.d97.s83;;
indinavir;I-drug;I-DDI-DrugBank.d97.s83.e0
concentration;O;O
rifabutin;B-drug;B-DDI-DrugBank.d97.s83.e1
concentration;O;O
DDI-DrugBank.d97.s84;;
Dose;O;O
reduction;O;O
of;O;O
rifabutin;B-drug;B-DDI-DrugBank.d97.s84.e0
to;O;O
half;O;O
the;O;O
standard;O;O
dose;O;O
and;O;O
a;O;O
dose;O;O
increase;O;O
of;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s84.e1
to;O;O
1000;O;O
mg;O;O
(;O;O
three;O;O
333;O;O
-;O;O
mg;O;O
capsules;O;O
);O;O
every;O;O
8;O;O
hours;O;O
are;O;O
recommended;O;O
when;O;O
rifabutin;B-drug;B-DDI-DrugBank.d97.s84.e2
and;O;O
CRIXIVAN;B-brand;B-DDI-DrugBank.d97.s84.e3
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d97.s85;;
Sildenafil;B-drug;B-DDI-DrugBank.d97.s85.e0
DDI-DrugBank.d97.s86;;
sildenafil;I-drug;I-DDI-DrugBank.d97.s86.e0
concentration;O;O
DDI-DrugBank.d97.s87;;
Sildenafil;B-drug;B-DDI-DrugBank.d97.s87.e0
dose;O;O
should;O;O
not;O;O
exceed;O;O
a;O;O
maximum;O;O
of;O;O
25;O;O
mg;O;O
in;O;O
a;O;O
48;O;O
-;O;O
hour;O;O
period;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s87.e1
therapy;O;O
.;O;O
DDI-DrugBank.d97.s88;;
Tadalafil;B-drug;B-DDI-DrugBank.d97.s88.e0
DDI-DrugBank.d97.s89;;
tadalafil;I-drug;I-DDI-DrugBank.d97.s89.e0
concentration;O;O
DDI-DrugBank.d97.s90;;
Tadalafil;B-drug;B-DDI-DrugBank.d97.s90.e0
dose;O;O
should;O;O
not;O;O
exceed;O;O
a;O;O
maximum;O;O
of;O;O
10;O;O
mg;O;O
in;O;O
a;O;O
72;O;O
-;O;O
hour;O;O
period;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s90.e1
therapy;O;O
.;O;O
DDI-DrugBank.d97.s91;;
Vardenafil;B-drug;B-DDI-DrugBank.d97.s91.e0
DDI-DrugBank.d97.s92;;
vardenafil;I-drug;I-DDI-DrugBank.d97.s92.e0
concentration;O;O
DDI-DrugBank.d97.s93;;
Vardenafil;B-drug;B-DDI-DrugBank.d97.s93.e0
dose;O;O
should;O;O
not;O;O
exceed;O;O
a;O;O
maximum;O;O
of;O;O
2.5;O;O
mg;O;O
in;O;O
a;O;O
24;O;O
-;O;O
hour;O;O
period;O;O
in;O;O
patients;O;O
receiving;O;O
concomitant;O;O
indinavir;B-drug;B-DDI-DrugBank.d97.s93.e1
therapy;O;O
.;O;O
DDI-DrugBank.d97.s94;;
Note;O;O
:;O;O
DDI-DrugBank.d97.s95;;
=;O;O
increase;O;O
,;O;O
DDI-DrugBank.d97.s96;;
=;O;O
decrease;O;O
DDI-DrugBank.d97.s97;;
DDI-DrugBank.d82.s0;;
In;O;O
normal;O;O
volunteers;O;O
receiving;O;O
indomethacin;B-drug;B-DDI-DrugBank.d82.s0.e0
,;O;O
the;O;O
administration;O;O
of;O;O
diflunisal;B-drug;B-DDI-DrugBank.d82.s0.e1
decreased;O;O
the;O;O
renal;O;O
clearance;O;O
and;O;O
significantly;O;O
increased;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
indomethacin;B-drug;B-DDI-DrugBank.d82.s0.e2
.;O;O
DDI-DrugBank.d82.s1;;
In;O;O
some;O;O
patients;O;O
,;O;O
combined;O;O
use;O;O
of;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s1.e0
and;O;O
diflunisal;B-drug;B-DDI-DrugBank.d82.s1.e1
has;O;O
been;O;O
associated;O;O
with;O;O
fatal;O;O
gastrointestinal;O;O
hemorrhage;O;O
.;O;O
DDI-DrugBank.d82.s2;;
Therefore;O;O
,;O;O
diflunisal;B-drug;B-DDI-DrugBank.d82.s2.e0
and;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s2.e1
should;O;O
not;O;O
be;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d82.s3;;
In;O;O
a;O;O
study;O;O
in;O;O
normal;O;O
volunteers;O;O
,;O;O
it;O;O
was;O;O
found;O;O
that;O;O
chronic;O;O
concurrent;O;O
administration;O;O
of;O;O
3.6;O;O
g;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d82.s3.e0
per;O;O
day;O;O
decreases;O;O
indomethacin;B-drug;B-DDI-DrugBank.d82.s3.e1
blood;O;O
levels;O;O
approximately;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d82.s4;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s4.e0
with;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d82.s4.e1
is;O;O
not;O;O
recommended;O;O
due;O;O
to;O;O
the;O;O
increased;O;O
possibility;O;O
of;O;O
gastrointestinal;O;O
toxicity;O;O
,;O;O
with;O;O
little;O;O
or;O;O
no;O;O
increase;O;O
in;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d82.s5;;
Clinical;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s5.e0
does;O;O
not;O;O
influence;O;O
the;O;O
hypoprothrombinemia;O;O
produced;O;O
by;O;O
anticoagulants;B-group;B-DDI-DrugBank.d82.s5.e1
.;O;O
DDI-DrugBank.d82.s6;;
However;O;O
,;O;O
when;O;O
any;O;O
additional;O;O
drug;O;O
,;O;O
including;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s6.e0
,;O;O
is;O;O
added;O;O
to;O;O
the;O;O
treatment;O;O
of;O;O
patients;O;O
on;O;O
anticoagulant;B-group;B-DDI-DrugBank.d82.s6.e1
therapy;O;O
,;O;O
the;O;O
patients;O;O
should;O;O
be;O;O
observed;O;O
for;O;O
alterations;O;O
of;O;O
the;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d82.s7;;
In;O;O
post;O;O
-;O;O
marketing;O;O
experience;O;O
,;O;O
bleeding;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
on;O;O
concomitant;O;O
treatment;O;O
with;O;O
anticoagulants;B-group;B-DDI-DrugBank.d82.s7.e0
and;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s7.e1
.;O;O
DDI-DrugBank.d82.s8;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s8.e0
and;O;O
anticoagulants;B-group;B-DDI-DrugBank.d82.s8.e1
are;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d82.s9;;
When;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s9.e0
is;O;O
given;O;O
to;O;O
patients;O;O
receiving;O;O
probenecid;B-drug;B-DDI-DrugBank.d82.s9.e1
,;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
indomethacin;B-drug;B-DDI-DrugBank.d82.s9.e2
are;O;O
likely;O;O
to;O;O
be;O;O
increased;O;O
.;O;O
DDI-DrugBank.d82.s10;;
Therefore;O;O
,;O;O
a;O;O
lower;O;O
total;O;O
daily;O;O
dosage;O;O
of;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s10.e0
may;O;O
produce;O;O
a;O;O
satisfactory;O;O
therapeutic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d82.s11;;
When;O;O
increases;O;O
in;O;O
the;O;O
dose;O;O
of;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s11.e0
are;O;O
made;O;O
,;O;O
they;O;O
should;O;O
be;O;O
made;O;O
carefully;O;O
and;O;O
in;O;O
small;O;O
increments;O;O
.;O;O
DDI-DrugBank.d82.s12;;
Caution;O;O
should;O;O
be;O;O
used;O;O
if;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s12.e0
is;O;O
administered;O;O
simultaneously;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d82.s12.e1
.;O;O
DDI-DrugBank.d82.s13;;
INDOCIN;B-brand;B-DDI-DrugBank.d82.s13.e0
has;O;O
been;O;O
reported;O;O
to;O;O
decrease;O;O
the;O;O
tubular;O;O
secretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d82.s13.e1
and;O;O
to;O;O
potentiate;O;O
its;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d82.s14;;
Administration;O;O
of;O;O
non;B-group;B-DDI-DrugBank.d82.s14.e0
-;I-group;I-DDI-DrugBank.d82.s14.e0
steroidal;I-group;I-DDI-DrugBank.d82.s14.e0
anti;I-group;I-DDI-DrugBank.d82.s14.e0
-;I-group;I-DDI-DrugBank.d82.s14.e0
inflammatory;I-group;I-DDI-DrugBank.d82.s14.e0
drugs;I-group;I-DDI-DrugBank.d82.s14.e0
concomitantly;O;O
with;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d82.s14.e1
has;O;O
been;O;O
associated;O;O
with;O;O
an;O;O
increase;O;O
in;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d82.s14.e2
-;O;O
induced;O;O
toxicity;O;O
,;O;O
possibly;O;O
due;O;O
to;O;O
decreased;O;O
synthesis;O;O
of;O;O
renal;O;O
prostacyclin;O;O
.;O;O
DDI-DrugBank.d82.s15;;
NSAIDs;B-group;B-DDI-DrugBank.d82.s15.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
taking;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d82.s15.e1
,;O;O
and;O;O
renal;O;O
function;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d82.s16;;
Capsules;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s16.e0
50;O;O
mg;O;O
t.i.d;O;O
.;O;O
produced;O;O
a;O;O
clinically;O;O
relevant;O;O
elevation;O;O
of;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d82.s16.e1
and;O;O
reduction;O;O
in;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d82.s16.e2
clearance;O;O
in;O;O
psychiatric;O;O
patients;O;O
and;O;O
normal;O;O
subjects;O;O
with;O;O
steady;O;O
state;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d82.s16.e3
concentrations;O;O
.;O;O
DDI-DrugBank.d82.s17;;
This;O;O
effect;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d82.s18;;
As;O;O
a;O;O
consequence;O;O
,;O;O
when;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s18.e0
and;O;O
lithium;B-drug;B-DDI-DrugBank.d82.s18.e1
are;O;O
given;O;O
concomitantly;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
carefully;O;O
observed;O;O
for;O;O
signs;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d82.s18.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d82.s19;;
(;O;O
Read;O;O
circulars;O;O
for;O;O
lithium;B-drug;B-DDI-DrugBank.d82.s19.e0
preparations;O;O
before;O;O
use;O;O
of;O;O
such;O;O
concomitant;O;O
therapy;O;O
.;O;O
);O;O
DDI-DrugBank.d82.s20;;
In;O;O
addition;O;O
,;O;O
the;O;O
frequency;O;O
of;O;O
monitoring;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d82.s20.e0
concentration;O;O
should;O;O
be;O;O
increased;O;O
at;O;O
the;O;O
outset;O;O
of;O;O
such;O;O
combination;O;O
drug;O;O
treatment;O;O
.;O;O
DDI-DrugBank.d82.s21;;
INDOCIN;B-brand;B-DDI-DrugBank.d82.s21.e0
given;O;O
concomitantly;O;O
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d82.s21.e1
has;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
the;O;O
serum;O;O
concentration;O;O
and;O;O
prolong;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d82.s21.e2
.;O;O
DDI-DrugBank.d82.s22;;
Therefore;O;O
,;O;O
when;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s22.e0
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d82.s22.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d82.s22.e2
levels;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d82.s23;;
In;O;O
some;O;O
patients;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s23.e0
can;O;O
reduce;O;O
the;O;O
diuretic;O;O
,;O;O
natriuretic;O;O
,;O;O
and;O;O
antihypertensive;O;O
effects;O;O
of;O;O
loop;B-group;B-DDI-DrugBank.d82.s23.e1
,;I-group;I-DDI-DrugBank.d82.s23.e1
potassium;I-group;I-DDI-DrugBank.d82.s23.e2
-;I-group;I-DDI-DrugBank.d82.s23.e2
sparing;I-group;I-DDI-DrugBank.d82.s23.e2
,;I-group;I-DDI-DrugBank.d82.s23.e2
and;I-group;I-DDI-DrugBank.d82.s23.e2
thiazide;I-group;I-DDI-DrugBank.d82.s23.e3
diuretics;I-group;I-DDI-DrugBank.d82.s23.e3
.;O;O
DDI-DrugBank.d82.s24;;
Therefore;O;O
,;O;O
when;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s24.e0
and;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s24.e1
.;O;O
DDI-DrugBank.d82.s25;;
(;O;O
Indomethacin;B-drug;B-DDI-DrugBank.d82.s25.e0
);O;O
diuretics;B-group;B-DDI-DrugBank.d82.s25.e1
are;O;O
used;O;O
concomitantly;O;O
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
to;O;O
determine;O;O
if;O;O
the;O;O
desired;O;O
effect;O;O
of;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d82.s25.e2
is;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d82.s26;;
INDOCIN;B-brand;B-DDI-DrugBank.d82.s26.e0
reduces;O;O
basal;O;O
plasma;O;O
renin;O;O
activity;O;O
(;O;O
PRA;O;O
);O;O
,;O;O
as;O;O
well;O;O
as;O;O
those;O;O
elevations;O;O
of;O;O
PRA;O;O
induced;O;O
by;O;O
furosemide;B-drug;B-DDI-DrugBank.d82.s26.e1
administration;O;O
,;O;O
or;O;O
salt;O;O
or;O;O
volume;O;O
depletion;O;O
.;O;O
DDI-DrugBank.d82.s27;;
These;O;O
facts;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
evaluating;O;O
plasma;O;O
renin;O;O
activity;O;O
in;O;O
hypertensive;O;O
patients;O;O
.;O;O
DDI-DrugBank.d82.s28;;
It;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
the;O;O
addition;O;O
of;O;O
triamterene;B-drug;B-DDI-DrugBank.d82.s28.e0
to;O;O
a;O;O
maintenance;O;O
schedule;O;O
of;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s28.e1
resulted;O;O
in;O;O
reversible;O;O
acute;O;O
renal;O;O
failure;O;O
in;O;O
two;O;O
of;O;O
four;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d82.s29;;
INDOCIN;B-brand;B-DDI-DrugBank.d82.s29.e0
and;O;O
triamterene;B-drug;B-DDI-DrugBank.d82.s29.e1
should;O;O
not;O;O
be;O;O
administered;O;O
together;O;O
.;O;O
DDI-DrugBank.d82.s30;;
INDOCIN;B-brand;B-DDI-DrugBank.d82.s30.e0
and;O;O
potassium;B-group;B-DDI-DrugBank.d82.s30.e1
-;I-group;I-DDI-DrugBank.d82.s30.e1
sparing;I-group;I-DDI-DrugBank.d82.s30.e1
diuretics;I-group;I-DDI-DrugBank.d82.s30.e1
each;O;O
may;O;O
be;O;O
associated;O;O
with;O;O
increased;O;O
serum;O;O
potassium;O;O
levels;O;O
.;O;O
DDI-DrugBank.d82.s31;;
The;O;O
potential;O;O
effects;O;O
of;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s31.e0
and;O;O
potassium;B-group;B-DDI-DrugBank.d82.s31.e1
-;I-group;I-DDI-DrugBank.d82.s31.e1
sparing;I-group;I-DDI-DrugBank.d82.s31.e1
diuretics;I-group;I-DDI-DrugBank.d82.s31.e1
on;O;O
potassium;O;O
kinetics;O;O
and;O;O
renal;O;O
function;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
these;O;O
agents;O;O
are;O;O
administered;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d82.s32;;
Most;O;O
of;O;O
the;O;O
above;O;O
effects;O;O
concerning;O;O
diuretics;B-group;B-DDI-DrugBank.d82.s32.e0
have;O;O
been;O;O
attributed;O;O
,;O;O
at;O;O
least;O;O
in;O;O
part;O;O
,;O;O
to;O;O
mechanisms;O;O
involving;O;O
inhibition;O;O
of;O;O
prostaglandin;O;O
synthesis;O;O
by;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s32.e1
.;O;O
DDI-DrugBank.d82.s33;;
Blunting;O;O
of;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d82.s33.e0
-;I-group;I-DDI-DrugBank.d82.s33.e0
adrenoceptor;I-group;I-DDI-DrugBank.d82.s33.e0
blocking;I-group;I-DDI-DrugBank.d82.s33.e0
agents;I-group;I-DDI-DrugBank.d82.s33.e0
by;O;O
non;B-group;B-DDI-DrugBank.d82.s33.e1
-;I-group;I-DDI-DrugBank.d82.s33.e1
steroidal;I-group;I-DDI-DrugBank.d82.s33.e1
antiinflammatory;I-group;I-DDI-DrugBank.d82.s33.e1
drugs;I-group;I-DDI-DrugBank.d82.s33.e1
including;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s33.e2
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d82.s34;;
Therefore;O;O
,;O;O
when;O;O
using;O;O
these;O;O
blocking;O;O
agents;O;O
to;O;O
treat;O;O
hypertension;O;O
,;O;O
patients;O;O
should;O;O
be;O;O
observed;O;O
carefully;O;O
in;O;O
order;O;O
to;O;O
confirm;O;O
that;O;O
the;O;O
desired;O;O
therapeutic;O;O
effect;O;O
has;O;O
been;O;O
obtained;O;O
.;O;O
DDI-DrugBank.d82.s35;;
INDOCIN;B-brand;B-DDI-DrugBank.d82.s35.e0
can;O;O
reduce;O;O
the;O;O
antihypertensive;O;O
effects;O;O
of;O;O
captopril;B-drug;B-DDI-DrugBank.d82.s35.e1
and;O;O
losartan;B-drug;B-DDI-DrugBank.d82.s35.e2
.;O;O
DDI-DrugBank.d82.s36;;
False;O;O
-;O;O
negative;O;O
results;O;O
in;O;O
the;O;O
dexamethasone;O;O
suppression;O;O
test;O;O
(;O;O
DST;O;O
);O;O
in;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
INDOCIN;B-brand;B-DDI-DrugBank.d82.s36.e0
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d82.s37;;
Thus;O;O
,;O;O
results;O;O
of;O;O
the;O;O
DST;O;O
should;O;O
be;O;O
interpreted;O;O
with;O;O
caution;O;O
in;O;O
these;O;O
patients;O;O
.;O;O
DDI-DrugBank.d45.s0;;
Concurrent;O;O
administration;O;O
of;O;O
etanercept;B-drug;B-DDI-DrugBank.d45.s0.e0
(;O;O
another;O;O
TNF;O;O
-blocking;O;O
agent;O;O
);O;O
and;O;O
anakinra;B-drug;B-DDI-DrugBank.d45.s0.e1
(;O;O
an;O;O
interleukin;B-group;B-DDI-DrugBank.d45.s0.e2
-;I-group;I-DDI-DrugBank.d45.s0.e2
1;I-group;I-DDI-DrugBank.d45.s0.e2
antagonist;I-group;I-DDI-DrugBank.d45.s0.e2
);O;O
has;O;O
been;O;O
associated;O;O
with;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
serious;O;O
infections;O;O
,;O;O
and;O;O
increased;O;O
risk;O;O
of;O;O
neutropenia;O;O
and;O;O
no;O;O
additional;O;O
benefit;O;O
compared;O;O
to;O;O
these;O;O
medicinal;O;O
products;O;O
alone;O;O
.;O;O
DDI-DrugBank.d45.s1;;
Other;O;O
TNFa;B-group;B-DDI-DrugBank.d45.s1.e0
-;I-group;I-DDI-DrugBank.d45.s1.e0
blocking;I-group;I-DDI-DrugBank.d45.s1.e0
agents;I-group;I-DDI-DrugBank.d45.s1.e0
(;O;O
including;O;O
REMICADE;B-brand;B-DDI-DrugBank.d45.s1.e1
);O;O
used;O;O
in;O;O
combination;O;O
with;O;O
anakinra;B-drug;B-DDI-DrugBank.d45.s1.e2
may;O;O
also;O;O
result;O;O
in;O;O
similar;O;O
toxicities;O;O
.;O;O
DDI-DrugBank.d45.s2;;
Specific;O;O
drug;O;O
interaction;O;O
studies;O;O
,;O;O
including;O;O
interactions;O;O
with;O;O
MTX;B-drug;B-DDI-DrugBank.d45.s2.e0
,;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d45.s3;;
The;O;O
majority;O;O
of;O;O
patients;O;O
in;O;O
rheumatoid;O;O
arthritis;O;O
or;O;O
Crohn;O;O
s;O;O
disease;O;O
clinical;O;O
studies;O;O
received;O;O
one;O;O
or;O;O
more;O;O
concomitant;O;O
medications;O;O
.;O;O
DDI-DrugBank.d45.s4;;
In;O;O
rheumatoid;O;O
arthritis;O;O
,;O;O
concomitant;O;O
medications;O;O
besides;O;O
MTX;B-drug;B-DDI-DrugBank.d45.s4.e0
were;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d45.s4.e1
anti;I-group;I-DDI-DrugBank.d45.s4.e1
-;I-group;I-DDI-DrugBank.d45.s4.e1
inflammatory;I-group;I-DDI-DrugBank.d45.s4.e1
agents;I-group;I-DDI-DrugBank.d45.s4.e1
,;O;O
folic;B-drug;B-DDI-DrugBank.d45.s4.e2
acid;I-drug;I-DDI-DrugBank.d45.s4.e2
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d45.s4.e3
and/or;O;O
narcotics;B-group;B-DDI-DrugBank.d45.s4.e4
.;O;O
DDI-DrugBank.d45.s5;;
Concomitant;O;O
Crohn;O;O
s;O;O
disease;O;O
medications;O;O
were;O;O
antibiotics;B-group;B-DDI-DrugBank.d45.s5.e0
,;O;O
antivirals;B-group;B-DDI-DrugBank.d45.s5.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d45.s5.e2
,;O;O
6;B-drug;B-DDI-DrugBank.d45.s5.e3
-;I-drug;I-DDI-DrugBank.d45.s5.e3
MP;I-drug;I-DDI-DrugBank.d45.s5.e3
/;O;O
AZA;B-drug;B-DDI-DrugBank.d45.s5.e4
and;O;O
aminosalicylates;O;O
.;O;O
DDI-DrugBank.d45.s6;;
In;O;O
psoriatic;O;O
arthritis;O;O
clinical;O;O
trials;O;O
,;O;O
concomitant;O;O
medications;O;O
included;O;O
MTX;B-drug;B-DDI-DrugBank.d45.s6.e0
in;O;O
approximately;O;O
half;O;O
of;O;O
the;O;O
patients;O;O
as;O;O
well;O;O
as;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d45.s6.e1
anti;I-group;I-DDI-DrugBank.d45.s6.e1
-;I-group;I-DDI-DrugBank.d45.s6.e1
inflammatory;I-group;I-DDI-DrugBank.d45.s6.e1
agents;I-group;I-DDI-DrugBank.d45.s6.e1
,;O;O
folic;B-drug;B-DDI-DrugBank.d45.s6.e2
acid;I-drug;I-DDI-DrugBank.d45.s6.e2
and;O;O
corticosteroids;B-group;B-DDI-DrugBank.d45.s6.e3
.;O;O
DDI-DrugBank.d45.s7;;
Patients;O;O
with;O;O
Crohn;O;O
s;O;O
disease;O;O
who;O;O
received;O;O
immunosuppressants;B-group;B-DDI-DrugBank.d45.s7.e0
tended;O;O
to;O;O
experience;O;O
fewer;O;O
infusion;O;O
reactions;O;O
compared;O;O
to;O;O
patients;O;O
on;O;O
no;O;O
immunosuppressants;B-group;B-DDI-DrugBank.d45.s7.e1
.;O;O
DDI-DrugBank.d45.s8;;
Serum;O;O
infliximab;B-drug;B-DDI-DrugBank.d45.s8.e0
concentrations;O;O
appeared;O;O
to;O;O
be;O;O
unaffected;O;O
by;O;O
baseline;O;O
use;O;O
of;O;O
medications;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
Crohn;O;O
s;O;O
disease;O;O
including;O;O
corticosteroids;B-group;B-DDI-DrugBank.d45.s8.e1
,;O;O
antibiotics;B-group;B-DDI-DrugBank.d45.s8.e2
(;O;O
metronidazole;B-drug;B-DDI-DrugBank.d45.s8.e3
or;O;O
ciprofloxacin;B-drug;B-DDI-DrugBank.d45.s8.e4
);O;O
and;O;O
aminosalicylates;O;O
.;O;O
DDI-DrugBank.d527.s0;;
A;O;O
number;O;O
of;O;O
substances;O;O
affect;O;O
glucose;O;O
metabolism;O;O
and;O;O
may;O;O
require;O;O
insulin;B-drug;B-DDI-DrugBank.d527.s0.e0
dose;O;O
adjustment;O;O
and;O;O
particularly;O;O
close;O;O
monitoring;O;O
.;O;O
DDI-DrugBank.d527.s1;;
The;O;O
following;O;O
are;O;O
examples;O;O
of;O;O
substances;O;O
that;O;O
may;O;O
increase;O;O
the;O;O
blood;O;O
-;O;O
glucose;O;O
-;O;O
lowering;O;O
effect;O;O
and;O;O
susceptibility;O;O
to;O;O
hypoglycemia;O;O
:;O;O
oral;O;O
antidiabetes;O;O
products;O;O
,;O;O
ACE;B-group;B-DDI-DrugBank.d527.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d527.s1.e0
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d527.s1.e1
,;O;O
fibrates;B-group;B-DDI-DrugBank.d527.s1.e2
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d527.s1.e3
,;O;O
MAO;B-group;B-DDI-DrugBank.d527.s1.e4
inhibitors;I-group;I-DDI-DrugBank.d527.s1.e4
,;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d527.s1.e5
,;O;O
salicylates;B-group;B-DDI-DrugBank.d527.s1.e6
,;O;O
somatostatin;B-group;B-DDI-DrugBank.d527.s1.e7
analog;I-group;I-DDI-DrugBank.d527.s1.e7
(;O;O
e.g.;O;O
,;O;O
octreotide;B-drug;B-DDI-DrugBank.d527.s1.e8
);O;O
,;O;O
sulfonamide;B-group;B-DDI-DrugBank.d527.s1.e9
antibiotics;I-group;I-DDI-DrugBank.d527.s1.e9
.;O;O
DDI-DrugBank.d527.s2;;
The;O;O
following;O;O
are;O;O
examples;O;O
of;O;O
substances;O;O
that;O;O
may;O;O
reduce;O;O
the;O;O
blood;O;O
-;O;O
glucose;O;O
-;O;O
lowering;O;O
effect;O;O
of;O;O
insulin;B-drug;B-DDI-DrugBank.d527.s2.e0
:;O;O
corticosteroids;B-group;B-DDI-DrugBank.d527.s2.e1
,;O;O
danazol;B-drug;B-DDI-DrugBank.d527.s2.e2
,;O;O
diuretics;B-group;B-DDI-DrugBank.d527.s2.e3
,;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d527.s2.e4
agents;I-group;I-DDI-DrugBank.d527.s2.e4
(;O;O
e.g.;O;O
,;O;O
epinephrine;B-drug;B-DDI-DrugBank.d527.s2.e5
,;O;O
albuterol;B-drug;B-DDI-DrugBank.d527.s2.e6
,;O;O
terbutaline;B-drug;B-DDI-DrugBank.d527.s2.e7
);O;O
,;O;O
isoniazid;B-drug;B-DDI-DrugBank.d527.s2.e8
,;O;O
phenothiazine;B-group;B-DDI-DrugBank.d527.s2.e9
derivatives;I-group;I-DDI-DrugBank.d527.s2.e9
,;O;O
somatropin;B-drug;B-DDI-DrugBank.d527.s2.e10
,;O;O
thyroid;B-group;B-DDI-DrugBank.d527.s2.e11
hormones;I-group;I-DDI-DrugBank.d527.s2.e11
,;O;O
estrogens;B-group;B-DDI-DrugBank.d527.s2.e12
,;O;O
progestogens;B-group;B-DDI-DrugBank.d527.s2.e13
(;O;O
e.g.;O;O
,;O;O
in;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d527.s2.e14
);O;O
.;O;O
DDI-DrugBank.d527.s3;;
Beta;B-group;B-DDI-DrugBank.d527.s3.e0
-;I-group;I-DDI-DrugBank.d527.s3.e0
blockers;I-group;I-DDI-DrugBank.d527.s3.e0
,;O;O
clonidine;B-drug;B-DDI-DrugBank.d527.s3.e1
,;O;O
lithium;B-drug;B-DDI-DrugBank.d527.s3.e2
salts;O;O
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d527.s3.e3
may;O;O
either;O;O
potentiate;O;O
or;O;O
weaken;O;O
the;O;O
blood;O;O
-;O;O
glucose;O;O
-;O;O
lowering;O;O
effect;O;O
of;O;O
insulin;B-drug;B-DDI-DrugBank.d527.s3.e4
.;O;O
DDI-DrugBank.d527.s4;;
Pentamidine;B-drug;B-DDI-DrugBank.d527.s4.e0
may;O;O
cause;O;O
hypoglycemia;O;O
,;O;O
which;O;O
may;O;O
sometimes;O;O
be;O;O
followed;O;O
by;O;O
hyperglycemia;O;O
.;O;O
DDI-DrugBank.d527.s5;;
In;O;O
addition;O;O
,;O;O
under;O;O
the;O;O
influence;O;O
of;O;O
sympatholytic;O;O
medicinal;O;O
products;O;O
such;O;O
as;O;O
beta;B-group;B-DDI-DrugBank.d527.s5.e0
-;I-group;I-DDI-DrugBank.d527.s5.e0
blockers;I-group;I-DDI-DrugBank.d527.s5.e0
,;O;O
clonidine;B-drug;B-DDI-DrugBank.d527.s5.e1
,;O;O
guanethidine;B-drug;B-DDI-DrugBank.d527.s5.e2
,;O;O
and;O;O
reserpine;B-drug;B-DDI-DrugBank.d527.s5.e3
,;O;O
the;O;O
signs;O;O
of;O;O
hypoglycemia;O;O
may;O;O
be;O;O
reduced;O;O
or;O;O
absent;O;O
.;O;O
DDI-DrugBank.d313.s0;;
A;O;O
number;O;O
of;O;O
substances;O;O
affect;O;O
glucose;O;O
metabolism;O;O
and;O;O
may;O;O
require;O;O
insulin;B-drug;B-DDI-DrugBank.d313.s0.e0
dose;O;O
adjustment;O;O
and;O;O
particularly;O;O
close;O;O
monitoring;O;O
.;O;O
DDI-DrugBank.d313.s1;;
The;O;O
following;O;O
are;O;O
examples;O;O
of;O;O
substances;O;O
that;O;O
may;O;O
increase;O;O
the;O;O
blood;O;O
-;O;O
glucose;O;O
-;O;O
lowering;O;O
effect;O;O
and;O;O
susceptibility;O;O
to;O;O
hypoglycemia;O;O
:;O;O
oral;O;O
antidiabetic;B-group;B-DDI-DrugBank.d313.s1.e0
products;I-group;I-DDI-DrugBank.d313.s1.e0
,;O;O
ACE;B-group;B-DDI-DrugBank.d313.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d313.s1.e1
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d313.s1.e2
,;O;O
fibrates;B-group;B-DDI-DrugBank.d313.s1.e3
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d313.s1.e4
,;O;O
monoamine;B-group;B-DDI-DrugBank.d313.s1.e5
oxidase;I-group;I-DDI-DrugBank.d313.s1.e5
(;I-group;I-DDI-DrugBank.d313.s1.e5
MAO;I-group;I-DDI-DrugBank.d313.s1.e5
);I-group;I-DDI-DrugBank.d313.s1.e5
inhibitors;I-group;I-DDI-DrugBank.d313.s1.e5
,;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d313.s1.e6
,;O;O
salicylates;B-group;B-DDI-DrugBank.d313.s1.e7
,;O;O
somatostatin;B-group;B-DDI-DrugBank.d313.s1.e8
analog;I-group;I-DDI-DrugBank.d313.s1.e8
(;O;O
e.g.;O;O
,;O;O
octreotide;B-drug;B-DDI-DrugBank.d313.s1.e9
);O;O
,;O;O
sulfonamide;B-group;B-DDI-DrugBank.d313.s1.e10
antibiotics;I-group;I-DDI-DrugBank.d313.s1.e10
.;O;O
DDI-DrugBank.d313.s2;;
The;O;O
following;O;O
are;O;O
examples;O;O
of;O;O
substances;O;O
that;O;O
may;O;O
reduce;O;O
the;O;O
blood;O;O
-;O;O
glucose;O;O
-;O;O
lowering;O;O
effect;O;O
:;O;O
corticosteroids;B-group;B-DDI-DrugBank.d313.s2.e0
,;O;O
niacin;B-drug;B-DDI-DrugBank.d313.s2.e1
,;O;O
danazol;B-drug;B-DDI-DrugBank.d313.s2.e2
,;O;O
diuretics;B-group;B-DDI-DrugBank.d313.s2.e3
,;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d313.s2.e4
agents;I-group;I-DDI-DrugBank.d313.s2.e4
(;O;O
e.g.;O;O
,;O;O
epinephrine;B-drug;B-DDI-DrugBank.d313.s2.e5
,;O;O
salbutamol;B-drug;B-DDI-DrugBank.d313.s2.e6
,;O;O
terbutaline;B-drug;B-DDI-DrugBank.d313.s2.e7
);O;O
,;O;O
isoniazid;B-drug;B-DDI-DrugBank.d313.s2.e8
,;O;O
phenothiazine;B-group;B-DDI-DrugBank.d313.s2.e9
derivatives;I-group;I-DDI-DrugBank.d313.s2.e9
,;O;O
somatropin;B-drug;B-DDI-DrugBank.d313.s2.e10
,;O;O
thyroid;B-group;B-DDI-DrugBank.d313.s2.e11
hormones;I-group;I-DDI-DrugBank.d313.s2.e11
,;O;O
estrogens;B-group;B-DDI-DrugBank.d313.s2.e12
,;O;O
progestogens;B-group;B-DDI-DrugBank.d313.s2.e13
(;O;O
e.g.;O;O
,;O;O
in;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d313.s2.e14
);O;O
.;O;O
DDI-DrugBank.d313.s3;;
Beta;B-group;B-DDI-DrugBank.d313.s3.e0
-;I-group;I-DDI-DrugBank.d313.s3.e0
blockers;I-group;I-DDI-DrugBank.d313.s3.e0
,;O;O
clonidine;B-drug;B-DDI-DrugBank.d313.s3.e1
,;O;O
lithium;B-drug;B-DDI-DrugBank.d313.s3.e2
salts;O;O
,;O;O
and;O;O
alcohol;B-drug;B-DDI-DrugBank.d313.s3.e3
may;O;O
either;O;O
potentiate;O;O
or;O;O
weaken;O;O
the;O;O
blood;O;O
-;O;O
glucose;O;O
-;O;O
lowering;O;O
effect;O;O
of;O;O
insulin;B-drug;B-DDI-DrugBank.d313.s3.e4
.;O;O
DDI-DrugBank.d313.s4;;
Pentamidine;B-drug;B-DDI-DrugBank.d313.s4.e0
may;O;O
cause;O;O
hypoglycemia;O;O
,;O;O
which;O;O
may;O;O
sometimes;O;O
be;O;O
followed;O;O
by;O;O
hyperglycemia;O;O
.;O;O
DDI-DrugBank.d313.s5;;
In;O;O
addition;O;O
,;O;O
under;O;O
the;O;O
influence;O;O
of;O;O
sympatholytic;O;O
medicinal;O;O
products;O;O
such;O;O
as;O;O
beta;B-group;B-DDI-DrugBank.d313.s5.e0
-;I-group;I-DDI-DrugBank.d313.s5.e0
blockers;I-group;I-DDI-DrugBank.d313.s5.e0
,;O;O
clonidine;B-drug;B-DDI-DrugBank.d313.s5.e1
,;O;O
guanethidine;B-drug;B-DDI-DrugBank.d313.s5.e2
,;O;O
and;O;O
reserpine;B-drug;B-DDI-DrugBank.d313.s5.e3
,;O;O
the;O;O
signs;O;O
of;O;O
hypoglycemia;O;O
may;O;O
be;O;O
reduced;O;O
or;O;O
absent;O;O
.;O;O
DDI-DrugBank.d313.s6;;
Mixing;O;O
of;O;O
Insulins;B-group;B-DDI-DrugBank.d313.s6.e0
DDI-DrugBank.d313.s7;;
A;O;O
clinical;O;O
study;O;O
in;O;O
healthy;O;O
male;O;O
volunteers;O;O
(;O;O
n=24;O;O
);O;O
demonstrated;O;O
that;O;O
mixing;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s7.e0
with;O;O
NPH;B-drug;B-DDI-DrugBank.d313.s7.e1
human;I-drug;I-DDI-DrugBank.d313.s7.e1
insulin;I-drug;I-DDI-DrugBank.d313.s7.e1
immediately;O;O
before;O;O
injection;O;O
produced;O;O
some;O;O
attenuation;O;O
in;O;O
the;O;O
peak;O;O
concentration;O;O
of;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s7.e2
,;O;O
but;O;O
that;O;O
the;O;O
time;O;O
to;O;O
peak;O;O
and;O;O
the;O;O
total;O;O
bioavailability;O;O
of;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s7.e3
were;O;O
not;O;O
significantly;O;O
affected;O;O
.;O;O
DDI-DrugBank.d313.s8;;
If;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s8.e0
is;O;O
mixed;O;O
with;O;O
NPH;B-drug;B-DDI-DrugBank.d313.s8.e1
human;I-drug;I-DDI-DrugBank.d313.s8.e1
insulin;I-drug;I-DDI-DrugBank.d313.s8.e1
,;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s8.e2
should;O;O
be;O;O
drawn;O;O
into;O;O
the;O;O
syringe;O;O
first;O;O
.;O;O
DDI-DrugBank.d313.s9;;
The;O;O
injection;O;O
should;O;O
be;O;O
made;O;O
immediately;O;O
after;O;O
mixing;O;O
.;O;O
DDI-DrugBank.d313.s10;;
Because;O;O
there;O;O
are;O;O
no;O;O
data;O;O
on;O;O
the;O;O
compatibility;O;O
of;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s10.e0
and;O;O
crystalline;O;O
zinc;B-drug;B-DDI-DrugBank.d313.s10.e1
insulin;I-drug;I-DDI-DrugBank.d313.s10.e1
preparations;O;O
,;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s10.e2
should;O;O
not;O;O
be;O;O
mixed;O;O
with;O;O
these;O;O
preparations;O;O
.;O;O
DDI-DrugBank.d313.s11;;
The;O;O
effects;O;O
of;O;O
mixing;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s11.e0
with;O;O
insulins;B-group;B-DDI-DrugBank.d313.s11.e1
of;O;O
animal;O;O
source;O;O
or;O;O
insulin;B-drug;B-DDI-DrugBank.d313.s11.e2
preparations;O;O
produced;O;O
by;O;O
other;O;O
manufacturers;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d313.s12;;
Mixtures;O;O
should;O;O
not;O;O
be;O;O
administered;O;O
intravenously;O;O
.;O;O
DDI-DrugBank.d313.s13;;
When;O;O
used;O;O
in;O;O
external;O;O
subcutaneous;O;O
infusion;O;O
pumps;O;O
for;O;O
insulin;B-drug;B-DDI-DrugBank.d313.s13.e0
,;O;O
NovoLog;B-brand;B-DDI-DrugBank.d313.s13.e1
should;O;O
not;O;O
be;O;O
mixed;O;O
with;O;O
any;O;O
other;O;O
insulins;B-group;B-DDI-DrugBank.d313.s13.e2
or;O;O
diluent;O;O
.;O;O
DDI-DrugBank.d433.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
Rebif;B-brand;B-DDI-DrugBank.d433.s0.e0
.;O;O
DDI-DrugBank.d433.s1;;
Due;O;O
to;O;O
its;O;O
potential;O;O
to;O;O
cause;O;O
neutropenia;O;O
and;O;O
lymphopenia;O;O
,;O;O
proper;O;O
monitoring;O;O
of;O;O
patients;O;O
is;O;O
required;O;O
if;O;O
Rebif;B-brand;B-DDI-DrugBank.d433.s1.e0
is;O;O
given;O;O
in;O;O
combination;O;O
with;O;O
myelosuppressive;O;O
agents;O;O
.;O;O
DDI-DrugBank.d433.s2;;
Also;O;O
,;O;O
the;O;O
potential;O;O
for;O;O
hepatic;O;O
injury;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
Rebif;B-brand;B-DDI-DrugBank.d433.s2.e0
is;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
other;O;O
products;O;O
associated;O;O
with;O;O
hepatic;O;O
injury;O;O
,;O;O
or;O;O
when;O;O
new;O;O
agents;O;O
are;O;O
added;O;O
to;O;O
the;O;O
regimen;O;O
of;O;O
patients;O;O
already;O;O
on;O;O
Rebif;B-brand;B-DDI-DrugBank.d433.s2.e1
.;O;O
DDI-DrugBank.d10.s0;;
Interactions;O;O
between;O;O
Betaseron;B-brand;B-DDI-DrugBank.d10.s0.e0
and;O;O
other;O;O
drugs;O;O
have;O;O
not;O;O
been;O;O
fully;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d10.s1;;
Although;O;O
studies;O;O
designed;O;O
to;O;O
examine;O;O
drug;O;O
interactions;O;O
have;O;O
not;O;O
been;O;O
done;O;O
,;O;O
it;O;O
was;O;O
noted;O;O
that;O;O
corticosteroid;B-group;B-DDI-DrugBank.d10.s1.e0
or;O;O
ACTH;B-drug;B-DDI-DrugBank.d10.s1.e1
treatment;O;O
of;O;O
relapses;O;O
for;O;O
periods;O;O
of;O;O
up;O;O
to;O;O
28;O;O
days;O;O
has;O;O
been;O;O
administered;O;O
to;O;O
patients;O;O
(;O;O
N=180;O;O
);O;O
receiving;O;O
Betaseron;B-brand;B-DDI-DrugBank.d10.s1.e2
.;O;O
DDI-DrugBank.d10.s2;;
Betaseron;B-brand;B-DDI-DrugBank.d10.s2.e0
administration;O;O
to;O;O
three;O;O
cancer;O;O
patients;O;O
over;O;O
a;O;O
dose;O;O
range;O;O
of;O;O
0.025;O;O
mg;O;O
to;O;O
2.2;O;O
mg;O;O
led;O;O
to;O;O
a;O;O
dose;O;O
-;O;O
dependent;O;O
inhibition;O;O
of;O;O
antipyrine;B-drug;B-DDI-DrugBank.d10.s2.e1
elimination.14;O;O
The;O;O
effect;O;O
of;O;O
alternate;O;O
-;O;O
day;O;O
administration;O;O
of;O;O
0.25;O;O
mg;O;O
of;O;O
Betaseron;B-brand;B-DDI-DrugBank.d10.s2.e2
on;O;O
drug;O;O
metabolism;O;O
in;O;O
MS;O;O
patients;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d51.s0;;
ATROVENT;B-brand;B-DDI-DrugBank.d51.s0.e0
Inhalation;O;O
Aerosol;O;O
has;O;O
been;O;O
used;O;O
concomitantly;O;O
with;O;O
other;O;O
drugs;O;O
,;O;O
including;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d51.s0.e1
bronchodilators;I-group;I-DDI-DrugBank.d51.s0.e1
,;O;O
methylxanthines;B-group;B-DDI-DrugBank.d51.s0.e2
,;O;O
and;O;O
steroids;B-group;B-DDI-DrugBank.d51.s0.e3
,;O;O
commonly;O;O
used;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
chronic;O;O
obstructive;O;O
pulmonary;O;O
disease;O;O
.;O;O
DDI-DrugBank.d51.s1;;
With;O;O
the;O;O
exception;O;O
of;O;O
albuterol;B-drug;B-DDI-DrugBank.d51.s1.e0
,;O;O
there;O;O
are;O;O
no;O;O
formal;O;O
studies;O;O
fully;O;O
evaluating;O;O
the;O;O
interaction;O;O
effects;O;O
of;O;O
ATROVENT;B-brand;B-DDI-DrugBank.d51.s1.e1
Inhalation;O;O
Aerosol;O;O
and;O;O
these;O;O
drugs;O;O
with;O;O
respect;O;O
to;O;O
effectiveness;O;O
.;O;O
DDI-DrugBank.d51.s2;;
Anticholinergic;B-group;B-DDI-DrugBank.d51.s2.e0
agents;I-group;I-DDI-DrugBank.d51.s2.e0
:;O;O
Although;O;O
ipratropium;B-drug;B-DDI-DrugBank.d51.s2.e1
bromide;I-drug;I-DDI-DrugBank.d51.s2.e1
is;O;O
minimally;O;O
absorbed;O;O
into;O;O
the;O;O
systemic;O;O
circulation;O;O
,;O;O
there;O;O
is;O;O
some;O;O
potential;O;O
for;O;O
an;O;O
additive;O;O
interaction;O;O
with;O;O
concomitantly;O;O
used;O;O
anticholinergic;B-group;B-DDI-DrugBank.d51.s2.e2
medications;I-group;I-DDI-DrugBank.d51.s2.e2
.;O;O
DDI-DrugBank.d51.s3;;
Caution;O;O
is;O;O
therefore;O;O
advised;O;O
in;O;O
the;O;O
coadministration;O;O
of;O;O
ATROVENT;B-brand;B-DDI-DrugBank.d51.s3.e0
Inhalation;O;O
Aerosol;O;O
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d51.s3.e1
-;O;O
containing;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d27.s0;;
No;O;O
significant;O;O
drug;O;O
-;O;O
drug;O;O
pharmacokinetic;O;O
(;O;O
or;O;O
pharmacodynamic;O;O
);O;O
interactions;O;O
have;O;O
been;O;O
found;O;O
in;O;O
interaction;O;O
studies;O;O
with;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d27.s0.e0
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d27.s0.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d27.s0.e2
,;O;O
and;O;O
nifedipine;B-drug;B-DDI-DrugBank.d27.s0.e3
.;O;O
DDI-DrugBank.d27.s1;;
In;O;O
vitro;O;O
studies;O;O
show;O;O
significant;O;O
inhibition;O;O
of;O;O
the;O;O
formation;O;O
of;O;O
oxidized;O;O
irbesartan;O;O
metabolites;O;O
with;O;O
the;O;O
known;O;O
cytochrome;O;O
CYP;O;O
2C9;O;O
substrates;O;O
/;O;O
inhibitors;O;O
sulphenazole;B-drug;B-DDI-DrugBank.d27.s1.e0
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d27.s1.e1
and;O;O
nifedipine;B-drug;B-DDI-DrugBank.d27.s1.e2
.;O;O
DDI-DrugBank.d27.s2;;
However;O;O
,;O;O
in;O;O
clinical;O;O
studies;O;O
the;O;O
consequences;O;O
of;O;O
concomitant;O;O
irbesartan;B-drug;B-DDI-DrugBank.d27.s2.e0
on;O;O
the;O;O
pharmacodynamics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d27.s2.e1
were;O;O
negligible;O;O
.;O;O
DDI-DrugBank.d27.s3;;
Based;O;O
on;O;O
in;O;O
vitro;O;O
data;O;O
,;O;O
no;O;O
interaction;O;O
would;O;O
be;O;O
expected;O;O
with;O;O
drugs;O;O
whose;O;O
metabolism;O;O
is;O;O
dependent;O;O
upon;O;O
cytochrome;O;O
P450;O;O
isozymes;O;O
1A1;O;O
,;O;O
1A2,2A6,2B6,2D6,2E1,or;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d27.s4;;
In;O;O
separate;O;O
studies;O;O
of;O;O
patients;O;O
receiving;O;O
maintenance;O;O
doses;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d27.s4.e0
,;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d27.s4.e1
,;O;O
or;O;O
digoxin;B-drug;B-DDI-DrugBank.d27.s4.e2
,;O;O
irbesartan;B-drug;B-DDI-DrugBank.d27.s4.e3
administration;O;O
for;O;O
7;O;O
days;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacodynamics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d27.s4.e4
(;O;O
prothrombin;O;O
time;O;O
);O;O
or;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d27.s4.e5
.;O;O
DDI-DrugBank.d27.s5;;
The;O;O
pharmacokinetics;O;O
of;O;O
irbesartan;B-drug;B-DDI-DrugBank.d27.s5.e0
were;O;O
not;O;O
affected;O;O
by;O;O
coadministration;O;O
of;O;O
nifedipine;B-drug;B-DDI-DrugBank.d27.s5.e1
or;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d27.s5.e2
DDI-DrugBank.d27.s6;;
.;O;O
DDI-DrugBank.d27.s7;;
DDI-DrugBank.d279.s0;;
The;O;O
adverse;O;O
effects;O;O
of;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s0.e0
,;O;O
such;O;O
as;O;O
myelosuppression;O;O
and;O;O
diarrhea;O;O
,;O;O
would;O;O
be;O;O
expected;O;O
to;O;O
be;O;O
exacerbated;O;O
by;O;O
other;O;O
antineoplastic;B-group;B-DDI-DrugBank.d279.s0.e1
agents;I-group;I-DDI-DrugBank.d279.s0.e1
having;O;O
similar;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d279.s1;;
Patients;O;O
who;O;O
have;O;O
previously;O;O
received;O;O
pelvic;O;O
/;O;O
abdominal;O;O
irradiation;O;O
are;O;O
at;O;O
increased;O;O
risk;O;O
of;O;O
severe;O;O
myelosuppression;O;O
following;O;O
the;O;O
administration;O;O
of;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s1.e0
.;O;O
DDI-DrugBank.d279.s2;;
The;O;O
concurrent;O;O
administration;O;O
of;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s2.e0
with;O;O
irradiation;O;O
has;O;O
not;O;O
been;O;O
adequately;O;O
studied;O;O
and;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d279.s3;;
Lymphocytopenia;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s3.e0
,;O;O
and;O;O
it;O;O
is;O;O
possible;O;O
that;O;O
the;O;O
administration;O;O
of;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d279.s3.e1
as;O;O
antiemetic;O;O
prophylaxis;O;O
may;O;O
have;O;O
enhanced;O;O
the;O;O
likelihood;O;O
of;O;O
this;O;O
effect;O;O
.;O;O
DDI-DrugBank.d279.s4;;
However;O;O
,;O;O
serious;O;O
opportunistic;O;O
infections;O;O
have;O;O
not;O;O
been;O;O
observed;O;O
,;O;O
and;O;O
no;O;O
complications;O;O
have;O;O
specifically;O;O
been;O;O
attributed;O;O
to;O;O
lymphocytopenia;O;O
.;O;O
DDI-DrugBank.d279.s5;;
Hyperglycemia;O;O
has;O;O
also;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s5.e0
.;O;O
DDI-DrugBank.d279.s6;;
Usually;O;O
,;O;O
this;O;O
has;O;O
been;O;O
observed;O;O
in;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
diabetes;O;O
mellitus;O;O
or;O;O
evidence;O;O
of;O;O
glucose;O;O
intolerance;O;O
prior;O;O
to;O;O
administration;O;O
of;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s6.e0
.;O;O
DDI-DrugBank.d279.s7;;
It;O;O
is;O;O
probable;O;O
that;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d279.s7.e0
,;O;O
given;O;O
as;O;O
antiemetic;O;O
prophylaxis;O;O
,;O;O
contributed;O;O
to;O;O
hyperglycemia;O;O
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d279.s8;;
The;O;O
incidence;O;O
of;O;O
akathisia;O;O
in;O;O
clinical;O;O
trials;O;O
of;O;O
the;O;O
weekly;O;O
dosage;O;O
schedule;O;O
was;O;O
greater;O;O
(;O;O
8.5;O;O
%;O;O
,;O;O
4;O;O
/;O;O
47;O;O
patients;O;O
);O;O
when;O;O
prochlorperazine;B-drug;B-DDI-DrugBank.d279.s8.e0
was;O;O
administered;O;O
on;O;O
the;O;O
same;O;O
day;O;O
as;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s8.e1
than;O;O
when;O;O
these;O;O
drugs;O;O
were;O;O
given;O;O
on;O;O
separate;O;O
days;O;O
(;O;O
1.3;O;O
%;O;O
,;O;O
1;O;O
/;O;O
80;O;O
patients;O;O
);O;O
.;O;O
DDI-DrugBank.d279.s9;;
The;O;O
8.5;O;O
%;O;O
incidence;O;O
of;O;O
akathisia;O;O
,;O;O
however;O;O
,;O;O
is;O;O
within;O;O
the;O;O
range;O;O
reported;O;O
for;O;O
use;O;O
of;O;O
prochlorperazine;B-drug;B-DDI-DrugBank.d279.s9.e0
when;O;O
given;O;O
as;O;O
a;O;O
premedication;O;O
for;O;O
other;O;O
chemotherapies;O;O
.;O;O
DDI-DrugBank.d279.s10;;
It;O;O
would;O;O
be;O;O
expected;O;O
that;O;O
laxative;B-group;B-DDI-DrugBank.d279.s10.e0
use;O;O
during;O;O
therapy;O;O
with;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s10.e1
would;O;O
worsen;O;O
the;O;O
incidence;O;O
or;O;O
severity;O;O
of;O;O
diarrhea;O;O
,;O;O
but;O;O
this;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d279.s11;;
In;O;O
view;O;O
of;O;O
the;O;O
potential;O;O
risk;O;O
of;O;O
dehydration;O;O
secondary;O;O
to;O;O
vomiting;O;O
and/or;O;O
diarrhea;O;O
induced;O;O
by;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s11.e0
,;O;O
the;O;O
physician;O;O
may;O;O
wish;O;O
to;O;O
withhold;O;O
diuretics;B-group;B-DDI-DrugBank.d279.s11.e1
during;O;O
dosing;O;O
with;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s11.e2
and;O;O
,;O;O
certainly;O;O
,;O;O
during;O;O
periods;O;O
of;O;O
active;O;O
vomiting;O;O
or;O;O
diarrhea;O;O
.;O;O
DDI-DrugBank.d279.s12;;
Drug;O;O
-;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
known;O;O
interactions;O;O
between;O;O
CAMPTOSAR;B-brand;B-DDI-DrugBank.d279.s12.e0
and;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d108.s0;;
Isocarboxazid;B-drug;B-DDI-DrugBank.d108.s0.e0
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
receiving;O;O
Antabuse;B-brand;B-DDI-DrugBank.d108.s0.e1
(;O;O
disulfiram;B-drug;B-DDI-DrugBank.d108.s0.e2
,;O;O
Wyeth;O;O
-;O;O
Ayerst;O;O
Laboratories;O;O
);O;O
.;O;O
DDI-DrugBank.d108.s1;;
In;O;O
a;O;O
single;O;O
study;O;O
,;O;O
rats;O;O
given;O;O
high;O;O
intraperitoneal;O;O
doses;O;O
of;O;O
an;O;O
MAO;B-group;B-DDI-DrugBank.d108.s1.e0
inhibitor;I-group;I-DDI-DrugBank.d108.s1.e0
plus;O;O
disulfiram;B-drug;B-DDI-DrugBank.d108.s1.e1
experienced;O;O
severe;O;O
toxicity;O;O
,;O;O
including;O;O
convulsions;O;O
and;O;O
death;O;O
.;O;O
DDI-DrugBank.d108.s2;;
Concomitant;O;O
use;O;O
of;O;O
Isocarboxazid;B-drug;B-DDI-DrugBank.d108.s2.e0
and;O;O
other;O;O
psychotropic;B-group;B-DDI-DrugBank.d108.s2.e1
agents;I-group;I-DDI-DrugBank.d108.s2.e1
is;O;O
generally;O;O
not;O;O
recommended;O;O
because;O;O
of;O;O
possible;O;O
potentiating;O;O
effects;O;O
.;O;O
DDI-DrugBank.d108.s3;;
This;O;O
is;O;O
especially;O;O
true;O;O
in;O;O
patients;O;O
who;O;O
may;O;O
subject;O;O
themselves;O;O
to;O;O
an;O;O
overdosage;O;O
of;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d108.s4;;
If;O;O
combination;O;O
therapy;O;O
is;O;O
needed;O;O
,;O;O
careful;O;O
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
the;O;O
pharmacology;O;O
of;O;O
all;O;O
agents;O;O
to;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d108.s5;;
The;O;O
monoamine;O;O
oxidase;O;O
inhibitory;O;O
effects;O;O
of;O;O
Isocarboxazid;B-drug;B-DDI-DrugBank.d108.s5.e0
may;O;O
persist;O;O
for;O;O
a;O;O
substantial;O;O
period;O;O
after;O;O
discontinuation;O;O
of;O;O
the;O;O
drug;O;O
,;O;O
and;O;O
this;O;O
should;O;O
be;O;O
borne;O;O
in;O;O
mind;O;O
when;O;O
another;O;O
drug;O;O
is;O;O
prescribed;O;O
following;O;O
Isocarboxazid;B-drug;B-DDI-DrugBank.d108.s5.e1
.;O;O
DDI-DrugBank.d108.s6;;
To;O;O
avoid;O;O
potentiation;O;O
,;O;O
the;O;O
physician;O;O
wishing;O;O
to;O;O
terminate;O;O
treatment;O;O
with;O;O
Isocarboxazid;B-drug;B-DDI-DrugBank.d108.s6.e0
and;O;O
begin;O;O
therapy;O;O
with;O;O
another;O;O
agent;O;O
should;O;O
allow;O;O
for;O;O
an;O;O
interval;O;O
of;O;O
10;O;O
days;O;O
.;O;O
DDI-DrugBank.d541.s0;;
May;O;O
interact;O;O
with;O;O
the;O;O
following;O;O
:;O;O
beta;B-group;B-DDI-DrugBank.d541.s0.e0
-;I-group;I-DDI-DrugBank.d541.s0.e0
adrenergic;I-group;I-DDI-DrugBank.d541.s0.e0
blocking;I-group;I-DDI-DrugBank.d541.s0.e0
agents;I-group;I-DDI-DrugBank.d541.s0.e0
(;O;O
these;O;O
medicines;O;O
may;O;O
make;O;O
your;O;O
condition;O;O
worse;O;O
and;O;O
prevent;O;O
the;O;O
adrenergic;B-group;B-DDI-DrugBank.d541.s0.e1
bronchodilators;I-group;I-DDI-DrugBank.d541.s0.e1
from;O;O
working;O;O
properly;O;O
);O;O
and;O;O
disopyramide;B-drug;B-DDI-DrugBank.d541.s0.e2
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d541.s0.e3
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d541.s0.e4
,;O;O
and;O;O
procainamide;B-drug;B-DDI-DrugBank.d541.s0.e5
(;O;O
these;O;O
medicines;O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
heart;O;O
problems;O;O
);O;O
.;O;O
DDI-DrugBank.d227.s0;;
Isoflurane;B-drug;B-DDI-DrugBank.d227.s0.e0
potentiates;O;O
the;O;O
muscle;O;O
relaxant;O;O
effect;O;O
of;O;O
all;O;O
muscle;B-group;B-DDI-DrugBank.d227.s0.e1
relaxants;I-group;I-DDI-DrugBank.d227.s0.e1
,;O;O
most;O;O
notably;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d227.s0.e2
muscle;I-group;I-DDI-DrugBank.d227.s0.e2
relaxants;I-group;I-DDI-DrugBank.d227.s0.e2
,;O;O
and;O;O
MAC;O;O
(;O;O
minimum;O;O
alveolar;O;O
concentration;O;O
);O;O
is;O;O
reduced;O;O
by;O;O
concomitant;O;O
administration;O;O
of;O;O
N;O;O
2O.;O;O
DDI-DrugBank.d227.s1;;
See;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
.;O;O
DDI-DrugBank.d187.s0;;
Food;O;O
:;O;O
Isoniazid;B-drug;B-DDI-DrugBank.d187.s0.e0
should;O;O
not;O;O
be;O;O
administered;O;O
with;O;O
food;O;O
.;O;O
DDI-DrugBank.d187.s1;;
Studies;O;O
have;O;O
shown;O;O
that;O;O
the;O;O
bioavailability;O;O
of;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s1.e0
is;O;O
reduced;O;O
significantly;O;O
when;O;O
administered;O;O
with;O;O
food;O;O
.;O;O
DDI-DrugBank.d187.s2;;
Acetaminophen;B-drug;B-DDI-DrugBank.d187.s2.e0
:;O;O
A;O;O
report;O;O
of;O;O
severe;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d187.s2.e1
toxicity;O;O
was;O;O
reported;O;O
in;O;O
a;O;O
patient;O;O
receiving;O;O
Isoniazid;B-drug;B-DDI-DrugBank.d187.s2.e2
.;O;O
DDI-DrugBank.d187.s3;;
It;O;O
is;O;O
believed;O;O
that;O;O
the;O;O
toxicity;O;O
may;O;O
have;O;O
resulted;O;O
from;O;O
a;O;O
previously;O;O
unrecognized;O;O
interaction;O;O
between;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s3.e0
and;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d187.s3.e1
and;O;O
a;O;O
molecular;O;O
basis;O;O
for;O;O
this;O;O
interaction;O;O
has;O;O
been;O;O
proposed;O;O
.;O;O
DDI-DrugBank.d187.s4;;
However;O;O
,;O;O
current;O;O
evidence;O;O
suggests;O;O
that;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s4.e0
does;O;O
induce;O;O
P;O;O
-;O;O
450IIE1;O;O
,;O;O
a;O;O
mixed;O;O
-;O;O
function;O;O
oxidase;O;O
enzyme;O;O
that;O;O
appears;O;O
to;O;O
generate;O;O
the;O;O
toxic;O;O
metabolites;O;O
,;O;O
in;O;O
the;O;O
liver;O;O
.;O;O
DDI-DrugBank.d187.s5;;
Furthermore;O;O
it;O;O
has;O;O
been;O;O
proposed;O;O
that;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s5.e0
resulted;O;O
In;O;O
induction;O;O
of;O;O
P;O;O
-;O;O
450IIE1;O;O
in;O;O
the;O;O
patients;O;O
liver;O;O
which;O;O
,;O;O
in;O;O
turn;O;O
,;O;O
resulted;O;O
in;O;O
a;O;O
greater;O;O
proportion;O;O
of;O;O
the;O;O
ingested;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d187.s5.e1
being;O;O
converted;O;O
to;O;O
the;O;O
toxic;O;O
metabolites;O;O
.;O;O
DDI-DrugBank.d187.s6;;
Studies;O;O
have;O;O
demonstrated;O;O
that;O;O
pretreatment;O;O
with;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s6.e0
potentiates;O;O
a;O;O
cetaminophen;O;O
hepatoxicity;O;O
in;O;O
rats;O;O
.;O;O
DDI-DrugBank.d187.s7;;
Carbamazepine;B-drug;B-DDI-DrugBank.d187.s7.e0
:;O;O
Isoniazid;B-drug;B-DDI-DrugBank.d187.s7.e1
is;O;O
known;O;O
to;O;O
slow;O;O
the;O;O
metabolism;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d187.s7.e2
and;O;O
increase;O;O
its;O;O
serum;O;O
levels;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d187.s7.e3
levels;O;O
should;O;O
be;O;O
determined;O;O
prior;O;O
to;O;O
concurrent;O;O
administration;O;O
with;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s7.e4
,;O;O
signs;O;O
and;O;O
symptoms;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d187.s7.e5
toxicity;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
,;O;O
and;O;O
appropriate;O;O
dosage;O;O
adjustment;O;O
of;O;O
the;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d187.s7.e6
should;O;O
be;O;O
made;O;O
.;O;O
DDI-DrugBank.d187.s8;;
Ketoconazole;B-drug;B-DDI-DrugBank.d187.s8.e0
:;O;O
Potential;O;O
interaction;O;O
of;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d187.s8.e1
and;O;O
Isoniazid;B-drug;B-DDI-DrugBank.d187.s8.e2
may;O;O
exist;O;O
.;O;O
DDI-DrugBank.d187.s9;;
Phenytoin;B-drug;B-DDI-DrugBank.d187.s9.e0
:;O;O
Isoniazid;B-drug;B-DDI-DrugBank.d187.s9.e1
may;O;O
increase;O;O
serum;O;O
levels;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d187.s9.e2
.;O;O
DDI-DrugBank.d187.s10;;
To;O;O
avoid;O;O
phenytoin;B-drug;B-DDI-DrugBank.d187.s10.e0
intoxication;O;O
,;O;O
appropriate;O;O
adjustment;O;O
of;O;O
the;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d187.s10.e1
should;O;O
be;O;O
made;O;O
.;O;O
DDI-DrugBank.d187.s11;;
Therophylline;O;O
:;O;O
A;O;O
recent;O;O
study;O;O
has;O;O
shown;O;O
that;O;O
concomitan;O;O
administration;O;O
of;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s11.e0
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d187.s11.e1
may;O;O
cause;O;O
elevated;O;O
plasma;O;O
levels;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d187.s11.e2
,;O;O
and;O;O
in;O;O
some;O;O
instances;O;O
a;O;O
slight;O;O
decrease;O;O
in;O;O
the;O;O
elimination;O;O
of;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s11.e3
.;O;O
DDI-DrugBank.d187.s12;;
Since;O;O
the;O;O
therapeutic;O;O
range;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d187.s12.e0
is;O;O
narrow;O;O
theophylline;B-drug;B-DDI-DrugBank.d187.s12.e1
serum;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
,;O;O
and;O;O
appropriate;O;O
dosage;O;O
adjustments;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d187.s12.e2
should;O;O
be;O;O
made;O;O
.;O;O
DDI-DrugBank.d187.s13;;
Valproate;B-drug;B-DDI-DrugBank.d187.s13.e0
:;O;O
A;O;O
recent;O;O
case;O;O
study;O;O
has;O;O
shown;O;O
a;O;O
possible;O;O
increase;O;O
in;O;O
the;O;O
plasma;O;O
level;O;O
of;O;O
valproate;B-drug;B-DDI-DrugBank.d187.s13.e1
when;O;O
co;O;O
administered;O;O
with;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s13.e2
.;O;O
DDI-DrugBank.d187.s14;;
Plasma;O;O
valproate;B-drug;B-DDI-DrugBank.d187.s14.e0
concentration;O;O
should;O;O
be;O;O
monitored;O;O
when;O;O
isoniazid;B-drug;B-DDI-DrugBank.d187.s14.e1
and;O;O
valproate;B-drug;B-DDI-DrugBank.d187.s14.e2
are;O;O
co;O;O
administered;O;O
,;O;O
and;O;O
appropriate;O;O
dosage;O;O
adjustments;O;O
of;O;O
valproate;B-drug;B-DDI-DrugBank.d187.s14.e3
should;O;O
be;O;O
made;O;O
.;O;O
DDI-DrugBank.d55.s0;;
Isoproterenol;B-drug;B-DDI-DrugBank.d55.s0.e0
hydrochloride;I-drug;I-DDI-DrugBank.d55.s0.e0
injection;O;O
and;O;O
epinephrine;B-drug;B-DDI-DrugBank.d55.s0.e1
should;O;O
not;O;O
be;O;O
administered;O;O
simultaneously;O;O
because;O;O
both;O;O
drugs;O;O
are;O;O
direct;O;O
cardiac;O;O
stimulants;O;O
and;O;O
their;O;O
combined;O;O
effects;O;O
may;O;O
induce;O;O
serious;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d55.s1;;
The;O;O
drugs;O;O
may;O;O
,;O;O
however;O;O
,;O;O
be;O;O
administered;O;O
alternately;O;O
provided;O;O
a;O;O
proper;O;O
interval;O;O
has;O;O
elapsed;O;O
between;O;O
doses;O;O
.;O;O
DDI-DrugBank.d55.s2;;
ISUPREL;B-brand;B-DDI-DrugBank.d55.s2.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
,;O;O
if;O;O
at;O;O
all;O;O
,;O;O
when;O;O
potent;O;O
inhalational;O;O
anesthetics;B-group;B-DDI-DrugBank.d55.s2.e1
such;O;O
as;O;O
halothane;B-drug;B-DDI-DrugBank.d55.s2.e2
are;O;O
employed;O;O
because;O;O
of;O;O
potential;O;O
to;O;O
sensitize;O;O
the;O;O
myocardium;O;O
to;O;O
effects;O;O
of;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d55.s2.e3
amines;I-group;I-DDI-DrugBank.d55.s2.e3
.;O;O
DDI-DrugBank.d465.s0;;
The;O;O
vasodilating;O;O
effects;O;O
of;O;O
isosorbide;B-drug;B-DDI-DrugBank.d465.s0.e0
dinitrate;I-drug;I-DDI-DrugBank.d465.s0.e0
may;O;O
be;O;O
additive;O;O
with;O;O
those;O;O
of;O;O
other;O;O
vasodilators;B-group;B-DDI-DrugBank.d465.s0.e1
.;O;O
DDI-DrugBank.d465.s1;;
Alcohol;B-drug;B-DDI-DrugBank.d465.s1.e0
,;O;O
in;O;O
particular;O;O
,;O;O
has;O;O
been;O;O
found;O;O
to;O;O
exhibit;O;O
additive;O;O
effects;O;O
of;O;O
this;O;O
variety;O;O
.;O;O
DDI-DrugBank.d479.s0;;
The;O;O
vasodilating;O;O
effects;O;O
of;O;O
isosorbide;B-drug;B-DDI-DrugBank.d479.s0.e0
mononitrate;I-drug;I-DDI-DrugBank.d479.s0.e0
may;O;O
be;O;O
additive;O;O
with;O;O
those;O;O
of;O;O
other;O;O
vasodilators;B-group;B-DDI-DrugBank.d479.s0.e1
.;O;O
DDI-DrugBank.d479.s1;;
Alcohol;B-drug;B-DDI-DrugBank.d479.s1.e0
,;O;O
in;O;O
particular;O;O
,;O;O
has;O;O
been;O;O
found;O;O
to;O;O
exhibit;O;O
additive;O;O
effects;O;O
of;O;O
this;O;O
variety;O;O
.;O;O
DDI-DrugBank.d479.s2;;
Marked;O;O
symptomatic;O;O
orthostatic;O;O
hypotension;O;O
has;O;O
been;O;O
reported;O;O
when;O;O
calcium;B-group;B-DDI-DrugBank.d479.s2.e0
channel;I-group;I-DDI-DrugBank.d479.s2.e0
blockers;I-group;I-DDI-DrugBank.d479.s2.e0
and;O;O
organic;B-group;B-DDI-DrugBank.d479.s2.e1
nitrates;I-group;I-DDI-DrugBank.d479.s2.e1
were;O;O
used;O;O
in;O;O
combination;O;O
.;O;O
DDI-DrugBank.d479.s3;;
Dose;O;O
adjustments;O;O
of;O;O
either;O;O
class;O;O
of;O;O
agents;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d163.s0;;
Vitamin;B-group;B-DDI-DrugBank.d163.s0.e0
A;I-group;I-DDI-DrugBank.d163.s0.e0
:;O;O
Because;O;O
of;O;O
the;O;O
relationship;O;O
of;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s0.e1
to;O;O
vitamin;B-group;B-DDI-DrugBank.d163.s0.e2
A;I-group;I-DDI-DrugBank.d163.s0.e2
,;O;O
patients;O;O
should;O;O
be;O;O
advised;O;O
against;O;O
taking;O;O
vitamin;B-group;B-DDI-DrugBank.d163.s0.e3
supplements;I-group;I-DDI-DrugBank.d163.s0.e3
containing;O;O
vitamin;B-group;B-DDI-DrugBank.d163.s0.e4
A;I-group;I-DDI-DrugBank.d163.s0.e4
to;O;O
avoid;O;O
additive;O;O
toxic;O;O
effects;O;O
DDI-DrugBank.d163.s1;;
.;O;O
DDI-DrugBank.d163.s2;;
Tetracyclines;B-group;B-DDI-DrugBank.d163.s2.e0
:;O;O
Concomitant;O;O
treatment;O;O
with;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s2.e1
and;O;O
tetracyclines;B-group;B-DDI-DrugBank.d163.s2.e2
should;O;O
be;O;O
avoided;O;O
because;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s2.e3
use;O;O
has;O;O
been;O;O
associated;O;O
with;O;O
a;O;O
number;O;O
of;O;O
cases;O;O
of;O;O
pseudotumor;O;O
cerebri;O;O
(;O;O
benign;O;O
intracranial;O;O
hypertension;O;O
);O;O
,;O;O
some;O;O
of;O;O
which;O;O
involved;O;O
concomitant;O;O
use;O;O
of;O;O
tetracyclines;B-group;B-DDI-DrugBank.d163.s2.e4
DDI-DrugBank.d163.s3;;
.;O;O
DDI-DrugBank.d163.s4;;
Micro;O;O
-;O;O
dosed;O;O
Progesterone;B-drug;B-DDI-DrugBank.d163.s4.e0
Preparations;O;O
:;O;O
Micro;O;O
-;O;O
dosed;O;O
progesterone;B-drug;B-DDI-DrugBank.d163.s4.e1
preparations;O;O
(;O;O
minipills;O;O
that;O;O
do;O;O
not;O;O
contain;O;O
an;O;O
estrogen;B-group;B-DDI-DrugBank.d163.s4.e2
);O;O
may;O;O
be;O;O
an;O;O
inadequate;O;O
method;O;O
of;O;O
contraception;O;O
during;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s4.e3
therapy;O;O
.;O;O
DDI-DrugBank.d163.s5;;
Although;O;O
other;O;O
hormonal;B-group;B-DDI-DrugBank.d163.s5.e0
contraceptives;I-group;I-DDI-DrugBank.d163.s5.e0
are;O;O
highly;O;O
effective;O;O
,;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
pregnancy;O;O
from;O;O
women;O;O
who;O;O
have;O;O
used;O;O
combined;B-group;B-DDI-DrugBank.d163.s5.e1
oral;I-group;I-DDI-DrugBank.d163.s5.e1
contraceptives;I-group;I-DDI-DrugBank.d163.s5.e1
,;O;O
as;O;O
well;O;O
as;O;O
topical;O;O
/;O;O
injectable;O;O
/;O;O
implantable;O;O
/;O;O
insertable;O;O
hormonal;O;O
birth;O;O
control;O;O
products;O;O
.;O;O
DDI-DrugBank.d163.s6;;
These;O;O
reports;O;O
are;O;O
more;O;O
frequent;O;O
for;O;O
women;O;O
who;O;O
use;O;O
only;O;O
a;O;O
single;O;O
method;O;O
of;O;O
contraception;O;O
.;O;O
DDI-DrugBank.d163.s7;;
It;O;O
is;O;O
not;O;O
known;O;O
if;O;O
hormonal;B-group;B-DDI-DrugBank.d163.s7.e0
contraceptives;I-group;I-DDI-DrugBank.d163.s7.e0
differ;O;O
in;O;O
their;O;O
effectiveness;O;O
when;O;O
used;O;O
with;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s7.e1
.;O;O
DDI-DrugBank.d163.s8;;
Therefore;O;O
,;O;O
it;O;O
is;O;O
critically;O;O
important;O;O
for;O;O
women;O;O
of;O;O
childbearing;O;O
potential;O;O
to;O;O
select;O;O
and;O;O
commit;O;O
to;O;O
use;O;O
2;O;O
forms;O;O
of;O;O
effective;O;O
contraception;O;O
simultaneously;O;O
,;O;O
at;O;O
least;O;O
1;O;O
of;O;O
which;O;O
must;O;O
be;O;O
a;O;O
primary;O;O
form;O;O
,;O;O
unless;O;O
absolute;O;O
abstinence;O;O
is;O;O
the;O;O
chosen;O;O
method;O;O
,;O;O
or;O;O
the;O;O
patient;O;O
has;O;O
undergone;O;O
a;O;O
hysterectomy;O;O
DDI-DrugBank.d163.s9;;
.;O;O
DDI-DrugBank.d163.s10;;
Phenytoin;B-drug;B-DDI-DrugBank.d163.s10.e0
:;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s10.e1
has;O;O
not;O;O
been;O;O
shown;O;O
to;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d163.s10.e2
in;O;O
a;O;O
study;O;O
in;O;O
seven;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d163.s11;;
These;O;O
results;O;O
are;O;O
consistent;O;O
with;O;O
the;O;O
in;O;O
vitro;O;O
finding;O;O
that;O;O
neither;O;O
isotretinoin;B-drug;B-DDI-DrugBank.d163.s11.e0
nor;O;O
its;O;O
metabolites;O;O
induce;O;O
or;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
the;O;O
CYP;O;O
2C9;O;O
human;O;O
hepatic;O;O
P450;O;O
enzyme;O;O
.;O;O
DDI-DrugBank.d163.s12;;
Phenytoin;B-drug;B-DDI-DrugBank.d163.s12.e0
is;O;O
known;O;O
to;O;O
cause;O;O
osteomalacia;O;O
.;O;O
DDI-DrugBank.d163.s13;;
No;O;O
formal;O;O
clinical;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
to;O;O
assess;O;O
if;O;O
there;O;O
is;O;O
an;O;O
interactive;O;O
effect;O;O
on;O;O
bone;O;O
loss;O;O
between;O;O
phenytoin;B-drug;B-DDI-DrugBank.d163.s13.e0
and;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s13.e1
.;O;O
DDI-DrugBank.d163.s14;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
using;O;O
these;O;O
drugs;O;O
together;O;O
DDI-DrugBank.d163.s15;;
.;O;O
DDI-DrugBank.d163.s16;;
Systemic;B-group;B-DDI-DrugBank.d163.s16.e0
Corticosteroids;I-group;I-DDI-DrugBank.d163.s16.e0
:;O;O
Systemic;B-group;B-DDI-DrugBank.d163.s16.e1
corticosteroids;I-group;I-DDI-DrugBank.d163.s16.e1
are;O;O
known;O;O
to;O;O
cause;O;O
osteoporosis;O;O
.;O;O
DDI-DrugBank.d163.s17;;
No;O;O
formal;O;O
clinical;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
to;O;O
assess;O;O
if;O;O
there;O;O
is;O;O
an;O;O
interactive;O;O
effect;O;O
on;O;O
bone;O;O
loss;O;O
between;O;O
systemic;B-group;B-DDI-DrugBank.d163.s17.e0
corticosteroids;I-group;I-DDI-DrugBank.d163.s17.e0
and;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s17.e1
.;O;O
DDI-DrugBank.d163.s18;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
using;O;O
these;O;O
drugs;O;O
together;O;O
.;O;O
DDI-DrugBank.d163.s19;;
Prescribers;O;O
are;O;O
advised;O;O
to;O;O
consult;O;O
the;O;O
package;O;O
insert;O;O
of;O;O
medication;O;O
administered;O;O
concomitantly;O;O
with;O;O
hormonal;B-group;B-DDI-DrugBank.d163.s19.e0
contraceptives;I-group;I-DDI-DrugBank.d163.s19.e0
,;O;O
since;O;O
some;O;O
medications;O;O
may;O;O
decrease;O;O
the;O;O
effectiveness;O;O
of;O;O
these;O;O
birth;O;O
control;O;O
products;O;O
.;O;O
DDI-DrugBank.d163.s20;;
Accutane;B-brand;B-DDI-DrugBank.d163.s20.e0
use;O;O
is;O;O
associated;O;O
with;O;O
depression;O;O
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d163.s21;;
Pregnancies;O;O
have;O;O
been;O;O
reported;O;O
by;O;O
users;O;O
of;O;O
combined;B-group;B-DDI-DrugBank.d163.s21.e0
hormonal;I-group;I-DDI-DrugBank.d163.s21.e0
contraceptives;I-group;I-DDI-DrugBank.d163.s21.e0
who;O;O
also;O;O
used;O;O
some;O;O
form;O;O
of;O;O
St.;O;O
Johns;O;O
Wort;O;O
.;O;O
DDI-DrugBank.d163.s22;;
Laboratory;O;O
Tests;O;O
Pregnancy;O;O
Test;O;O
Female;O;O
patients;O;O
of;O;O
childbearing;O;O
potential;O;O
must;O;O
have;O;O
negative;O;O
results;O;O
from;O;O
2;O;O
urine;O;O
or;O;O
serum;O;O
pregnancy;O;O
tests;O;O
with;O;O
a;O;O
sensitivity;O;O
of;O;O
at;O;O
least;O;O
25;O;O
mIU;O;O
/;O;O
mL;O;O
before;O;O
receiving;O;O
the;O;O
initial;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s22.e0
prescription;O;O
.;O;O
DDI-DrugBank.d163.s23;;
The;O;O
first;O;O
test;O;O
is;O;O
obtained;O;O
by;O;O
the;O;O
prescriber;O;O
when;O;O
the;O;O
decision;O;O
is;O;O
made;O;O
to;O;O
pursue;O;O
qualification;O;O
of;O;O
the;O;O
patient;O;O
for;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s23.e0
(;O;O
a;O;O
screening;O;O
test;O;O
);O;O
.;O;O
DDI-DrugBank.d163.s24;;
The;O;O
second;O;O
pregnancy;O;O
test;O;O
(;O;O
a;O;O
confirmation;O;O
test;O;O
);O;O
should;O;O
be;O;O
done;O;O
during;O;O
the;O;O
first;O;O
5;O;O
days;O;O
of;O;O
the;O;O
menstrual;O;O
period;O;O
immediately;O;O
preceding;O;O
the;O;O
beginning;O;O
of;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s24.e0
therapy;O;O
.;O;O
DDI-DrugBank.d163.s25;;
For;O;O
patients;O;O
with;O;O
amenorrhea;O;O
,;O;O
the;O;O
second;O;O
test;O;O
should;O;O
be;O;O
done;O;O
at;O;O
least;O;O
11;O;O
days;O;O
after;O;O
the;O;O
last;O;O
act;O;O
of;O;O
unprotected;O;O
sexual;O;O
intercourse;O;O
(;O;O
without;O;O
using;O;O
2;O;O
effective;O;O
forms;O;O
of;O;O
contraception;O;O
);O;O
.;O;O
DDI-DrugBank.d163.s26;;
Each;O;O
month;O;O
of;O;O
therapy;O;O
,;O;O
the;O;O
patient;O;O
must;O;O
have;O;O
a;O;O
negative;O;O
result;O;O
from;O;O
a;O;O
urine;O;O
or;O;O
serum;O;O
pregnancy;O;O
test;O;O
.;O;O
DDI-DrugBank.d163.s27;;
A;O;O
pregnancy;O;O
test;O;O
must;O;O
be;O;O
repeated;O;O
each;O;O
month;O;O
prior;O;O
to;O;O
the;O;O
female;O;O
patient;O;O
receiving;O;O
each;O;O
prescription;O;O
DDI-DrugBank.d163.s28;;
.;O;O
DDI-DrugBank.d163.s29;;
Lipids;O;O
:;O;O
Pretreatment;O;O
and;O;O
follow;O;O
-;O;O
up;O;O
blood;O;O
lipids;O;O
should;O;O
be;O;O
obtained;O;O
under;O;O
fasting;O;O
conditions;O;O
.;O;O
DDI-DrugBank.d163.s30;;
After;O;O
consumption;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d163.s30.e0
,;O;O
at;O;O
least;O;O
36;O;O
hours;O;O
should;O;O
elapse;O;O
before;O;O
these;O;O
determinations;O;O
are;O;O
made;O;O
.;O;O
DDI-DrugBank.d163.s31;;
It;O;O
is;O;O
recommended;O;O
that;O;O
these;O;O
tests;O;O
be;O;O
performed;O;O
at;O;O
weekly;O;O
or;O;O
biweekly;O;O
intervals;O;O
until;O;O
the;O;O
lipid;O;O
response;O;O
to;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s31.e0
is;O;O
established;O;O
.;O;O
DDI-DrugBank.d163.s32;;
The;O;O
incidence;O;O
of;O;O
hypertriglyceridemia;O;O
is;O;O
1;O;O
patient;O;O
in;O;O
4;O;O
on;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s32.e0
therapy;O;O
DDI-DrugBank.d163.s33;;
.;O;O
DDI-DrugBank.d163.s34;;
Liver;O;O
Function;O;O
Tests;O;O
:;O;O
Since;O;O
elevations;O;O
of;O;O
liver;O;O
enzymes;O;O
have;O;O
been;O;O
observed;O;O
during;O;O
clinical;O;O
trials;O;O
,;O;O
and;O;O
hepatitis;O;O
has;O;O
been;O;O
reported;O;O
,;O;O
pretreatment;O;O
and;O;O
follow;O;O
-;O;O
up;O;O
liver;O;O
function;O;O
tests;O;O
should;O;O
be;O;O
performed;O;O
at;O;O
weekly;O;O
or;O;O
biweekly;O;O
intervals;O;O
until;O;O
the;O;O
response;O;O
to;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s34.e0
has;O;O
been;O;O
established;O;O
DDI-DrugBank.d163.s35;;
.;O;O
DDI-DrugBank.d163.s36;;
Glucose;O;O
:;O;O
Some;O;O
patients;O;O
receiving;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s36.e0
have;O;O
experienced;O;O
problems;O;O
in;O;O
the;O;O
control;O;O
of;O;O
their;O;O
blood;O;O
sugar;O;O
.;O;O
DDI-DrugBank.d163.s37;;
In;O;O
addition;O;O
,;O;O
new;O;O
cases;O;O
of;O;O
diabetes;O;O
have;O;O
been;O;O
diagnosed;O;O
during;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s37.e0
therapy;O;O
,;O;O
although;O;O
no;O;O
causal;O;O
relationship;O;O
has;O;O
been;O;O
established;O;O
DDI-DrugBank.d163.s38;;
.;O;O
DDI-DrugBank.d163.s39;;
CPK;O;O
:;O;O
Some;O;O
patients;O;O
undergoing;O;O
vigorous;O;O
physical;O;O
activity;O;O
while;O;O
on;O;O
Accutane;B-brand;B-DDI-DrugBank.d163.s39.e0
therapy;O;O
have;O;O
experienced;O;O
elevated;O;O
CPK;O;O
levels;O;O
,;O;O
DDI-DrugBank.d163.s40;;
however;O;O
,;O;O
the;O;O
clinical;O;O
significance;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d163.s41;;
There;O;O
have;O;O
been;O;O
rare;O;O
postmarketing;O;O
reports;O;O
of;O;O
rhabdomyolysis;O;O
,;O;O
some;O;O
associated;O;O
with;O;O
strenuous;O;O
physical;O;O
activity;O;O
.;O;O
DDI-DrugBank.d163.s42;;
In;O;O
a;O;O
clinical;O;O
trial;O;O
of;O;O
217;O;O
pediatric;O;O
patients;O;O
(;O;O
12;O;O
to;O;O
17;O;O
years;O;O
);O;O
with;O;O
severe;O;O
recalcitrant;O;O
nodular;O;O
acne;O;O
,;O;O
transient;O;O
elevations;O;O
in;O;O
CPK;O;O
were;O;O
observed;O;O
in;O;O
12;O;O
%;O;O
of;O;O
patients;O;O
,;O;O
including;O;O
those;O;O
undergoing;O;O
strenuous;O;O
physical;O;O
activity;O;O
in;O;O
association;O;O
with;O;O
reported;O;O
musculoskeletal;O;O
adverse;O;O
events;O;O
such;O;O
as;O;O
back;O;O
pain;O;O
,;O;O
arthralgia;O;O
,;O;O
limb;O;O
injury;O;O
,;O;O
or;O;O
muscle;O;O
sprain;O;O
.;O;O
DDI-DrugBank.d163.s43;;
In;O;O
these;O;O
patients;O;O
,;O;O
approximately;O;O
half;O;O
of;O;O
the;O;O
CPK;O;O
elevations;O;O
returned;O;O
to;O;O
normal;O;O
within;O;O
2;O;O
weeks;O;O
and;O;O
half;O;O
returned;O;O
to;O;O
normal;O;O
within;O;O
4;O;O
weeks;O;O
.;O;O
DDI-DrugBank.d163.s44;;
No;O;O
cases;O;O
of;O;O
rhabdomyolysis;O;O
were;O;O
reported;O;O
in;O;O
this;O;O
trial;O;O
.;O;O
DDI-DrugBank.d81.s0;;
Nitroglycerin;B-drug;B-DDI-DrugBank.d81.s0.e0
:;O;O
DynaCirc;B-brand;B-DDI-DrugBank.d81.s0.e1
(;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s0.e2
);O;O
has;O;O
been;O;O
safely;O;O
coadministered;O;O
with;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d81.s0.e3
.;O;O
DDI-DrugBank.d81.s1;;
Hydrochlorothiazide;B-drug;B-DDI-DrugBank.d81.s1.e0
:;O;O
A;O;O
study;O;O
in;O;O
normal;O;O
healthy;O;O
volunteers;O;O
has;O;O
shown;O;O
that;O;O
concomitant;O;O
administration;O;O
of;O;O
DynaCirc;B-brand;B-DDI-DrugBank.d81.s1.e1
(;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s1.e2
);O;O
and;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d81.s1.e3
does;O;O
not;O;O
result;O;O
in;O;O
altered;O;O
pharmacoktnetics;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d81.s2;;
In;O;O
a;O;O
study;O;O
in;O;O
hypertensive;O;O
patients;O;O
,;O;O
addition;O;O
of;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s2.e0
to;O;O
existing;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d81.s2.e1
therapy;O;O
did;O;O
not;O;O
result;O;O
in;O;O
any;O;O
unexpected;O;O
adverse;O;O
effects;O;O
,;O;O
and;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s2.e2
had;O;O
an;O;O
additional;O;O
antihypertensive;O;O
effect;O;O
.;O;O
DDI-DrugBank.d81.s3;;
Propranolol;B-drug;B-DDI-DrugBank.d81.s3.e0
:;O;O
In;O;O
a;O;O
single;O;O
dose;O;O
study;O;O
in;O;O
normal;O;O
volunteers;O;O
,;O;O
coadministration;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d81.s3.e1
had;O;O
a;O;O
small;O;O
effect;O;O
on;O;O
the;O;O
rate;O;O
but;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
extent;O;O
of;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s3.e2
bioavailability;O;O
.;O;O
DDI-DrugBank.d81.s4;;
Significant;O;O
increases;O;O
In;O;O
AUC;O;O
(;O;O
27;O;O
%;O;O
);O;O
and;O;O
Cmax;O;O
(;O;O
58;O;O
%;O;O
);O;O
and;O;O
decreases;O;O
in;O;O
tmax;O;O
(;O;O
23;O;O
%;O;O
);O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d81.s4.e0
were;O;O
noted;O;O
in;O;O
this;O;O
study;O;O
.;O;O
DDI-DrugBank.d81.s5;;
However;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
5;O;O
mg;O;O
b.i.d;O;O
.;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s5.e0
and;O;O
40;O;O
mg;O;O
b.i.d;O;O
.;O;O
DDI-DrugBank.d81.s6;;
propranolol;B-drug;B-DDI-DrugBank.d81.s6.e0
to;O;O
healthy;O;O
volunteers;O;O
under;O;O
steady;O;O
-;O;O
state;O;O
conditions;O;O
had;O;O
no;O;O
relevant;O;O
effect;O;O
on;O;O
either;O;O
drug;O;O
s;O;O
bioavailability;O;O
,;O;O
AUC;O;O
and;O;O
Cmax;O;O
,;O;O
differences;O;O
were;O;O
20;O;O
%;O;O
between;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s6.e1
given;O;O
singly;O;O
and;O;O
in;O;O
combination;O;O
with;O;O
propranolol;B-drug;B-DDI-DrugBank.d81.s6.e2
,;O;O
and;O;O
between;O;O
propranolol;B-drug;B-DDI-DrugBank.d81.s6.e3
given;O;O
singly;O;O
and;O;O
in;O;O
combination;O;O
with;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s6.e4
.;O;O
DDI-DrugBank.d81.s7;;
Cimetidine;B-drug;B-DDI-DrugBank.d81.s7.e0
:;O;O
In;O;O
a;O;O
study;O;O
in;O;O
healthy;O;O
volunteers;O;O
,;O;O
a;O;O
one;O;O
-;O;O
week;O;O
course;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d81.s7.e1
at;O;O
400;O;O
mg;O;O
b.i.d;O;O
.;O;O
with;O;O
a;O;O
single;O;O
5;O;O
mg;O;O
dose;O;O
of;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s7.e2
on;O;O
the;O;O
sixth;O;O
day;O;O
showed;O;O
an;O;O
increase;O;O
in;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s7.e3
mean;O;O
peak;O;O
plasma;O;O
concentrations;O;O
(;O;O
36;O;O
%;O;O
);O;O
and;O;O
significant;O;O
increase;O;O
in;O;O
area;O;O
under;O;O
the;O;O
curve;O;O
(;O;O
50;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d81.s8;;
If;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s8.e0
therapy;O;O
is;O;O
initiated;O;O
in;O;O
a;O;O
patient;O;O
currently;O;O
receiving;O;O
cimetidine;B-drug;B-DDI-DrugBank.d81.s8.e1
careful;O;O
monitoring;O;O
for;O;O
adverse;O;O
reactions;O;O
is;O;O
advised;O;O
and;O;O
downward;O;O
dose;O;O
adjustment;O;O
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d81.s9;;
Rifampicin;B-drug;B-DDI-DrugBank.d81.s9.e0
:;O;O
In;O;O
a;O;O
study;O;O
in;O;O
healthy;O;O
volunteers;O;O
,;O;O
a;O;O
six;O;O
-;O;O
day;O;O
course;O;O
of;O;O
rifampicin;B-drug;B-DDI-DrugBank.d81.s9.e1
at;O;O
600;O;O
mg;O;O
/;O;O
day;O;O
followed;O;O
by;O;O
a;O;O
single;O;O
5;O;O
mg;O;O
dose;O;O
of;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s9.e2
resulted;O;O
in;O;O
a;O;O
reduction;O;O
in;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s9.e3
levels;O;O
to;O;O
below;O;O
detectable;O;O
limits;O;O
.;O;O
DDI-DrugBank.d81.s10;;
If;O;O
rifampicin;B-drug;B-DDI-DrugBank.d81.s10.e0
therapy;O;O
is;O;O
required;O;O
,;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s10.e1
concentrations;O;O
and;O;O
therapeutic;O;O
effects;O;O
are;O;O
likely;O;O
to;O;O
be;O;O
markedly;O;O
reduced;O;O
or;O;O
abolished;O;O
as;O;O
a;O;O
consequence;O;O
of;O;O
increased;O;O
metabolism;O;O
and;O;O
higher;O;O
clearance;O;O
of;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s10.e2
.;O;O
DDI-DrugBank.d81.s11;;
Warfarin;B-drug;B-DDI-DrugBank.d81.s11.e0
:;O;O
In;O;O
a;O;O
study;O;O
in;O;O
healthy;O;O
volunteers;O;O
,;O;O
no;O;O
clinically;O;O
relevant;O;O
pharmacokinetic;O;O
or;O;O
pharmacodynamic;O;O
interaction;O;O
between;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s11.e1
and;O;O
racemic;O;O
warfarin;B-drug;B-DDI-DrugBank.d81.s11.e2
was;O;O
seen;O;O
when;O;O
two;O;O
single;O;O
oral;O;O
doses;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d81.s11.e3
(;O;O
0.7;O;O
mg;O;O
/;O;O
kg;O;O
body;O;O
weight;O;O
);O;O
were;O;O
administered;O;O
during;O;O
11;O;O
days;O;O
of;O;O
multipledose;O;O
treatment;O;O
with;O;O
5;O;O
mg;O;O
b.i.d;O;O
.;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s11.e4
.;O;O
DDI-DrugBank.d81.s12;;
Neither;O;O
racemic;O;O
warfarin;B-drug;B-DDI-DrugBank.d81.s12.e0
nor;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s12.e1
binding;O;O
to;O;O
plasma;O;O
proteins;O;O
in;O;O
vitro;O;O
was;O;O
altered;O;O
by;O;O
the;O;O
addition;O;O
of;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d81.s13;;
Digoxin;B-drug;B-DDI-DrugBank.d81.s13.e0
:;O;O
The;O;O
concomitant;O;O
administration;O;O
of;O;O
DynaCirc;B-brand;B-DDI-DrugBank.d81.s13.e1
(;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s13.e2
);O;O
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d81.s13.e3
in;O;O
a;O;O
single;O;O
-;O;O
dose;O;O
pharmacokinetic;O;O
study;O;O
did;O;O
not;O;O
affect;O;O
renal;O;O
,;O;O
nonrenal;O;O
and;O;O
total;O;O
body;O;O
clearance;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d81.s13.e4
.;O;O
DDI-DrugBank.d81.s14;;
Fentanyl;B-drug;B-DDI-DrugBank.d81.s14.e0
Anesthesia;O;O
:;O;O
Severe;O;O
hypotension;O;O
has;O;O
been;O;O
reported;O;O
during;O;O
fentanyl;B-drug;B-DDI-DrugBank.d81.s14.e1
anesthesia;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d81.s14.e2
blocker;I-group;I-DDI-DrugBank.d81.s14.e2
and;O;O
a;O;O
calcium;B-group;B-DDI-DrugBank.d81.s14.e3
channel;I-group;I-DDI-DrugBank.d81.s14.e3
blocker;I-group;I-DDI-DrugBank.d81.s14.e3
.;O;O
DDI-DrugBank.d81.s15;;
Even;O;O
though;O;O
such;O;O
interactions;O;O
have;O;O
not;O;O
been;O;O
seen;O;O
in;O;O
clinical;O;O
studies;O;O
with;O;O
DynaCirc;B-brand;B-DDI-DrugBank.d81.s15.e0
(;O;O
isradipine;B-drug;B-DDI-DrugBank.d81.s15.e1
);O;O
,;O;O
an;O;O
increased;O;O
volume;O;O
of;O;O
circulating;O;O
fluids;O;O
might;O;O
be;O;O
required;O;O
if;O;O
such;O;O
an;O;O
interaction;O;O
were;O;O
to;O;O
occur;O;O
.;O;O
DDI-DrugBank.d165.s0;;
Both;O;O
itraconazole;B-drug;B-DDI-DrugBank.d165.s0.e0
and;O;O
its;O;O
major;O;O
metabolite;O;O
,;O;O
hydroxyitraconazole;B-drug_n;B-DDI-DrugBank.d165.s0.e1
,;O;O
are;O;O
inhibitors;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
system;O;O
.;O;O
DDI-DrugBank.d165.s1;;
Coadministration;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s1.e0
and;O;O
drugs;O;O
primarily;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
system;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
drugs;O;O
that;O;O
could;O;O
increase;O;O
or;O;O
prolong;O;O
both;O;O
therapeutic;O;O
and;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d165.s2;;
Therefore;O;O
,;O;O
unless;O;O
otherwise;O;O
specified;O;O
,;O;O
appropriate;O;O
dosage;O;O
adjustments;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d165.s3;;
Coadministration;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d165.s3.e0
with;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s3.e1
has;O;O
led;O;O
to;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d165.s3.e2
,;O;O
resulting;O;O
in;O;O
rare;O;O
instances;O;O
of;O;O
life;O;O
-;O;O
threatening;O;O
cardiac;O;O
dysrhythmias;O;O
and;O;O
one;O;O
death;O;O
.;O;O
DDI-DrugBank.d165.s4;;
Another;O;O
oral;O;O
azole;B-group;B-DDI-DrugBank.d165.s4.e0
antifungal;I-group;I-DDI-DrugBank.d165.s4.e0
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d165.s4.e1
,;O;O
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
astemizole;B-drug;B-DDI-DrugBank.d165.s4.e2
,;O;O
resulting;O;O
in;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
of;O;O
astemizole;B-drug;B-DDI-DrugBank.d165.s4.e3
and;O;O
its;O;O
active;O;O
metabolite;O;O
desmethylastermizole;B-drug_n;B-DDI-DrugBank.d165.s4.e4
which;O;O
may;O;O
prolong;O;O
QT;O;O
intervals;O;O
.;O;O
DDI-DrugBank.d165.s5;;
In;O;O
vitro;O;O
data;O;O
suggest;O;O
that;O;O
itraconazole;B-drug;B-DDI-DrugBank.d165.s5.e0
,;O;O
when;O;O
compared;O;O
to;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d165.s5.e1
,;O;O
has;O;O
a;O;O
less;O;O
pronounced;O;O
effect;O;O
on;O;O
the;O;O
biotransformation;O;O
system;O;O
responsible;O;O
for;O;O
the;O;O
metabolism;O;O
of;O;O
astemizole;B-drug;B-DDI-DrugBank.d165.s5.e2
.;O;O
DDI-DrugBank.d165.s6;;
Based;O;O
on;O;O
the;O;O
chemical;O;O
resemblance;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d165.s6.e0
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d165.s6.e1
,;O;O
coadministration;O;O
of;O;O
astemizole;B-drug;B-DDI-DrugBank.d165.s6.e2
with;O;O
itraconazole;B-drug;B-DDI-DrugBank.d165.s6.e3
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d165.s7;;
Human;O;O
pharmacokinetics;O;O
data;O;O
indicate;O;O
that;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d165.s7.e0
potently;O;O
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d165.s7.e1
resulting;O;O
in;O;O
an;O;O
eight;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
the;O;O
mean;O;O
AUC;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d165.s7.e2
.;O;O
DDI-DrugBank.d165.s8;;
Data;O;O
suggest;O;O
that;O;O
coadministration;O;O
of;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d165.s8.e0
and;O;O
cisapride;B-drug;B-DDI-DrugBank.d165.s8.e1
can;O;O
result;O;O
in;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
on;O;O
the;O;O
ECG;O;O
.;O;O
DDI-DrugBank.d165.s9;;
In;O;O
vitro;O;O
data;O;O
suggest;O;O
that;O;O
itraconazole;B-drug;B-DDI-DrugBank.d165.s9.e0
also;O;O
markedly;O;O
inhibits;O;O
the;O;O
biotransformation;O;O
system;O;O
mainly;O;O
responsible;O;O
for;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d165.s9.e1
,;O;O
DDI-DrugBank.d165.s10;;
therefore;O;O
concomitant;O;O
administration;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s10.e0
with;O;O
cisapride;B-drug;B-DDI-DrugBank.d165.s10.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d165.s11;;
Coadministration;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s11.e0
with;O;O
oral;O;O
midazolam;B-drug;B-DDI-DrugBank.d165.s11.e1
or;O;O
triazolam;B-drug;B-DDI-DrugBank.d165.s11.e2
has;O;O
resulted;O;O
in;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
latter;O;O
two;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d165.s12;;
This;O;O
may;O;O
potentiate;O;O
and;O;O
prolong;O;O
hypnotic;O;O
and;O;O
sedative;O;O
effects;O;O
.;O;O
DDI-DrugBank.d165.s13;;
These;O;O
agents;O;O
should;O;O
not;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s13.e0
.;O;O
DDI-DrugBank.d165.s14;;
If;O;O
midazolam;B-drug;B-DDI-DrugBank.d165.s14.e0
is;O;O
administered;O;O
parenterally;O;O
,;O;O
special;O;O
precaution;O;O
is;O;O
required;O;O
since;O;O
the;O;O
sedative;O;O
effect;O;O
may;O;O
be;O;O
prolonged;O;O
.;O;O
DDI-DrugBank.d165.s15;;
Coadministration;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s15.e0
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d165.s15.e1
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d165.s15.e2
or;O;O
digoxin;B-drug;B-DDI-DrugBank.d165.s15.e3
has;O;O
led;O;O
to;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
latter;O;O
three;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d165.s16;;
Cyclosporine;B-drug;B-DDI-DrugBank.d165.s16.e0
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d165.s16.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d165.s16.e2
concentrations;O;O
should;O;O
be;O;O
monitored;O;O
at;O;O
the;O;O
initiation;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s16.e3
therapy;O;O
and;O;O
frequently;O;O
thereafter;O;O
,;O;O
and;O;O
the;O;O
dose;O;O
of;O;O
these;O;O
three;O;O
drug;O;O
products;O;O
adjusted;O;O
appropriately;O;O
.;O;O
DDI-DrugBank.d165.s17;;
Rhabdomyolysis;O;O
has;O;O
been;O;O
observed;O;O
in;O;O
patients;O;O
receiving;O;O
HMG;B-group;B-DDI-DrugBank.d165.s17.e0
-;I-group;I-DDI-DrugBank.d165.s17.e0
CoA;I-group;I-DDI-DrugBank.d165.s17.e0
reductase;I-group;I-DDI-DrugBank.d165.s17.e0
inhibitors;I-group;I-DDI-DrugBank.d165.s17.e0
administered;O;O
alone;O;O
(;O;O
at;O;O
recommended;O;O
dosages;O;O
);O;O
or;O;O
concomitantly;O;O
with;O;O
immunosuppressive;B-group;B-DDI-DrugBank.d165.s17.e1
drugs;I-group;I-DDI-DrugBank.d165.s17.e1
including;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d165.s17.e2
.;O;O
DDI-DrugBank.d165.s18;;
When;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s18.e0
was;O;O
coadministered;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d165.s18.e1
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d165.s18.e2
,;O;O
or;O;O
H2antagonists;O;O
,;O;O
reduced;O;O
plasma;O;O
concentrations;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d165.s18.e3
were;O;O
reported;O;O
.;O;O
DDI-DrugBank.d165.s19;;
The;O;O
physician;O;O
is;O;O
advised;O;O
to;O;O
monitor;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
itraconazole;B-drug;B-DDI-DrugBank.d165.s19.e0
when;O;O
any;O;O
of;O;O
these;O;O
drugs;O;O
is;O;O
taken;O;O
concurrently;O;O
,;O;O
and;O;O
to;O;O
increase;O;O
the;O;O
dose;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s19.e1
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d165.s20;;
Although;O;O
no;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s20.e0
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d165.s20.e1
may;O;O
alter;O;O
the;O;O
metabolism;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d165.s20.e2
,;O;O
DDI-DrugBank.d165.s21;;
therefore;O;O
,;O;O
plasma;O;O
concentrations;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d165.s21.e0
should;O;O
also;O;O
be;O;O
monitored;O;O
when;O;O
it;O;O
is;O;O
given;O;O
concurrently;O;O
with;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s21.e1
.;O;O
DDI-DrugBank.d165.s22;;
It;O;O
has;O;O
been;O;O
reported;O;O
that;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s22.e0
enhances;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d165.s22.e1
-;O;O
like;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d165.s23;;
Therefore;O;O
,;O;O
prothrombin;O;O
time;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
in;O;O
patients;O;O
receiving;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s23.e0
and;O;O
coumarin;B-group;B-DDI-DrugBank.d165.s23.e1
-;O;O
like;O;O
drugs;O;O
simultaneously;O;O
.;O;O
DDI-DrugBank.d165.s24;;
Plasma;O;O
concentrations;O;O
of;O;O
azole;B-group;B-DDI-DrugBank.d165.s24.e0
antifungal;I-group;I-DDI-DrugBank.d165.s24.e0
agents;I-group;I-DDI-DrugBank.d165.s24.e0
are;O;O
reduced;O;O
when;O;O
given;O;O
concurrently;O;O
with;O;O
isoniazid;B-drug;B-DDI-DrugBank.d165.s24.e1
.;O;O
DDI-DrugBank.d165.s25;;
Itraconazole;B-drug;B-DDI-DrugBank.d165.s25.e0
plasma;O;O
concentrations;O;O
should;O;O
be;O;O
monitored;O;O
when;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s25.e1
and;O;O
isoniazid;B-drug;B-DDI-DrugBank.d165.s25.e2
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d165.s26;;
Severe;O;O
hypoglycemia;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
concomitantly;O;O
receiving;O;O
azole;B-group;B-DDI-DrugBank.d165.s26.e0
antifungal;I-group;I-DDI-DrugBank.d165.s26.e0
agents;I-group;I-DDI-DrugBank.d165.s26.e0
and;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d165.s26.e1
agents;I-group;I-DDI-DrugBank.d165.s26.e1
.;O;O
DDI-DrugBank.d165.s27;;
Blood;O;O
glucose;O;O
concentrations;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
when;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s27.e0
and;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d165.s27.e1
agents;I-group;I-DDI-DrugBank.d165.s27.e1
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d165.s28;;
Tinnitus;O;O
and;O;O
decreased;O;O
hearing;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
concomitantly;O;O
receiving;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s28.e0
and;O;O
quinidine;B-drug;B-DDI-DrugBank.d165.s28.e1
.;O;O
DDI-DrugBank.d165.s29;;
Edema;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
concomitantly;O;O
receiving;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s29.e0
and;O;O
dihydropyridine;B-group;B-DDI-DrugBank.d165.s29.e1
calcium;I-group;I-DDI-DrugBank.d165.s29.e1
channel;I-group;I-DDI-DrugBank.d165.s29.e1
blockers;I-group;I-DDI-DrugBank.d165.s29.e1
.;O;O
DDI-DrugBank.d165.s30;;
Appropriate;O;O
dosage;O;O
adjustments;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d165.s31;;
The;O;O
results;O;O
from;O;O
a;O;O
study;O;O
in;O;O
which;O;O
eight;O;O
HIV;O;O
-;O;O
infected;O;O
individuals;O;O
were;O;O
treated;O;O
with;O;O
zidovudine;B-drug;B-DDI-DrugBank.d165.s31.e0
,;O;O
8;O;O
+;O;O
/;O;O
-;O;O
0.4;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
,;O;O
showed;O;O
that;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
zidovudine;B-drug;B-DDI-DrugBank.d165.s31.e1
were;O;O
not;O;O
affected;O;O
during;O;O
concomitant;O;O
administration;O;O
of;O;O
Itraconazole;B-drug;B-DDI-DrugBank.d165.s31.e2
,;O;O
100;O;O
mg;O;O
b.i.d;O;O
.;O;O
DDI-DrugBank.d57.s0;;
In;O;O
vitro;O;O
mixing;O;O
of;O;O
an;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d57.s0.e0
with;O;O
beta;O;O
-;O;O
lactamtype;O;O
antibiotics;B-group;B-DDI-DrugBank.d57.s0.e1
(;O;O
penicillins;B-group;B-DDI-DrugBank.d57.s0.e2
or;O;O
cephalosporins;B-group;B-DDI-DrugBank.d57.s0.e3
);O;O
may;O;O
result;O;O
in;O;O
a;O;O
significant;O;O
mutual;O;O
inactivation;O;O
.;O;O
DDI-DrugBank.d57.s1;;
Even;O;O
when;O;O
an;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d57.s1.e0
and;O;O
a;O;O
penicillin;B-group;B-DDI-DrugBank.d57.s1.e1
-;O;O
type;O;O
drug;O;O
are;O;O
administered;O;O
separately;O;O
by;O;O
different;O;O
routes;O;O
,;O;O
a;O;O
reduction;O;O
in;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d57.s1.e2
serum;O;O
half;O;O
-;O;O
life;O;O
or;O;O
serum;O;O
levels;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
with;O;O
impaired;O;O
renal;O;O
function;O;O
and;O;O
in;O;O
some;O;O
patients;O;O
with;O;O
normal;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d57.s2;;
Usually;O;O
,;O;O
such;O;O
inactivation;O;O
of;O;O
the;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d57.s2.e0
is;O;O
clinically;O;O
significant;O;O
only;O;O
in;O;O
patients;O;O
with;O;O
severely;O;O
impaired;O;O
renal;O;O
function;O;O
..;O;O
DDI-DrugBank.d57.s3;;
See;O;O
DDI-DrugBank.d518.s0;;
Prolonged;O;O
recovery;O;O
time;O;O
may;O;O
occur;O;O
if;O;O
barbiturates;B-group;B-DDI-DrugBank.d518.s0.e0
and/or;O;O
narcotics;B-group;B-DDI-DrugBank.d518.s0.e1
are;O;O
used;O;O
concurrently;O;O
with;O;O
ketamine;B-drug;B-DDI-DrugBank.d518.s0.e2
.;O;O
DDI-DrugBank.d518.s1;;
Ketamine;B-drug;B-DDI-DrugBank.d518.s1.e0
is;O;O
clinically;O;O
compatible;O;O
with;O;O
the;O;O
commonly;O;O
used;O;O
general;O;O
and;O;O
local;O;O
anesthetic;B-group;B-DDI-DrugBank.d518.s1.e1
agents;I-group;I-DDI-DrugBank.d518.s1.e1
when;O;O
an;O;O
adequate;O;O
respiratory;O;O
exchange;O;O
is;O;O
maintained;O;O
.;O;O
DDI-DrugBank.d458.s0;;
Ketoconazole;B-drug;B-DDI-DrugBank.d458.s0.e0
is;O;O
a;O;O
potent;O;O
inhibitor;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
system;O;O
.;O;O
DDI-DrugBank.d458.s1;;
Coadministration;O;O
of;O;O
NIZORAL;B-brand;B-DDI-DrugBank.d458.s1.e0
Tablets;O;O
and;O;O
drugs;O;O
primarily;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
system;O;O
may;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
drugs;O;O
that;O;O
could;O;O
increase;O;O
or;O;O
prolong;O;O
both;O;O
therapeutic;O;O
and;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d458.s2;;
Therefore;O;O
,;O;O
unless;O;O
otherwise;O;O
specified;O;O
,;O;O
appropriate;O;O
dosage;O;O
adjustments;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d458.s3;;
The;O;O
following;O;O
drug;O;O
interactions;O;O
have;O;O
been;O;O
identified;O;O
involving;O;O
NIZORAL;B-brand;B-DDI-DrugBank.d458.s3.e0
Tablets;O;O
and;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A4;O;O
enzyme;O;O
system;O;O
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d458.s3.e1
tablets;O;O
inhibit;O;O
the;O;O
metabolism;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d458.s3.e2
,;O;O
resulting;O;O
in;O;O
an;O;O
increased;O;O
plasma;O;O
concentration;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d458.s3.e3
and;O;O
a;O;O
delay;O;O
in;O;O
the;O;O
elimination;O;O
of;O;O
its;O;O
acid;O;O
metabolite;O;O
.;O;O
DDI-DrugBank.d458.s4;;
The;O;O
increased;O;O
plasma;O;O
concentration;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d458.s4.e0
or;O;O
its;O;O
metabolite;O;O
may;O;O
result;O;O
in;O;O
prolonged;O;O
QT;O;O
intervals;O;O
.;O;O
DDI-DrugBank.d458.s5;;
Pharmacokinetic;O;O
data;O;O
indicate;O;O
that;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s5.e0
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
astemizole;B-drug;B-DDI-DrugBank.d458.s5.e1
,;O;O
resulting;O;O
in;O;O
elevated;O;O
plasma;O;O
levels;O;O
of;O;O
astemizole;B-drug;B-DDI-DrugBank.d458.s5.e2
and;O;O
its;O;O
active;O;O
metabolite;O;O
desmethylastemizole;B-drug_n;B-DDI-DrugBank.d458.s5.e3
which;O;O
may;O;O
prolong;O;O
QT;O;O
intervals;O;O
.;O;O
DDI-DrugBank.d458.s6;;
Coadministration;O;O
of;O;O
astemizole;B-drug;B-DDI-DrugBank.d458.s6.e0
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s6.e1
tablets;O;O
is;O;O
therefore;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d458.s7;;
Human;O;O
pharmacokinetics;O;O
data;O;O
indicate;O;O
that;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s7.e0
potently;O;O
inhibits;O;O
the;O;O
metabolism;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d458.s7.e1
resulting;O;O
in;O;O
a;O;O
mean;O;O
eight;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
AUC;O;O
of;O;O
cisapride;B-drug;B-DDI-DrugBank.d458.s7.e2
.;O;O
DDI-DrugBank.d458.s8;;
Data;O;O
suggest;O;O
that;O;O
coadministration;O;O
of;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s8.e0
and;O;O
cisapride;B-drug;B-DDI-DrugBank.d458.s8.e1
can;O;O
result;O;O
in;O;O
prolongation;O;O
of;O;O
the;O;O
QT;O;O
interval;O;O
on;O;O
the;O;O
ECG;O;O
.;O;O
DDI-DrugBank.d458.s9;;
Therefore;O;O
concomitant;O;O
administration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s9.e0
tablets;O;O
with;O;O
cisapride;B-drug;B-DDI-DrugBank.d458.s9.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d458.s10;;
Ketoconazole;B-drug;B-DDI-DrugBank.d458.s10.e0
tablets;O;O
may;O;O
alter;O;O
the;O;O
metabolism;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d458.s10.e1
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d458.s10.e2
,;O;O
and;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d458.s10.e3
,;O;O
resulting;O;O
in;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
latter;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d458.s11;;
Dosage;O;O
adjustment;O;O
may;O;O
be;O;O
required;O;O
if;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d458.s11.e0
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d458.s11.e1
,;O;O
or;O;O
methylprednisolone;B-drug;B-DDI-DrugBank.d458.s11.e2
are;O;O
given;O;O
concomitantly;O;O
with;O;O
NIZORAL;B-brand;B-DDI-DrugBank.d458.s11.e3
Tablets;O;O
.;O;O
DDI-DrugBank.d458.s12;;
Coadministration;O;O
of;O;O
NIZORAL;B-brand;B-DDI-DrugBank.d458.s12.e0
Tablets;O;O
with;O;O
midazolam;B-drug;B-DDI-DrugBank.d458.s12.e1
or;O;O
triazolam;B-drug;B-DDI-DrugBank.d458.s12.e2
has;O;O
resulted;O;O
in;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
latter;O;O
two;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d458.s13;;
This;O;O
may;O;O
potentiate;O;O
and;O;O
prolong;O;O
hypnotic;O;O
and;O;O
sedative;O;O
effects;O;O
,;O;O
especially;O;O
with;O;O
repeated;O;O
dosing;O;O
or;O;O
chronic;O;O
administration;O;O
of;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d458.s14;;
These;O;O
agents;O;O
should;O;O
not;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
NIZORAL;B-brand;B-DDI-DrugBank.d458.s14.e0
Tablets;O;O
.;O;O
DDI-DrugBank.d458.s15;;
If;O;O
midazolam;B-drug;B-DDI-DrugBank.d458.s15.e0
is;O;O
administered;O;O
parenterally;O;O
,;O;O
special;O;O
precaution;O;O
is;O;O
required;O;O
since;O;O
the;O;O
sedative;O;O
effect;O;O
may;O;O
be;O;O
prolonged;O;O
.;O;O
DDI-DrugBank.d458.s16;;
Rare;O;O
cases;O;O
of;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d458.s16.e0
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d458.s17;;
It;O;O
is;O;O
not;O;O
clear;O;O
whether;O;O
this;O;O
was;O;O
due;O;O
to;O;O
the;O;O
combination;O;O
of;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d458.s18;;
It;O;O
is;O;O
,;O;O
therefore;O;O
,;O;O
advisable;O;O
to;O;O
monitor;O;O
digoxin;B-drug;B-DDI-DrugBank.d458.s18.e0
concentrations;O;O
in;O;O
patients;O;O
receiving;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s18.e1
.;O;O
DDI-DrugBank.d458.s19;;
When;O;O
taken;O;O
orally;O;O
,;O;O
imidazole;B-group;B-DDI-DrugBank.d458.s19.e0
compounds;I-group;I-DDI-DrugBank.d458.s19.e0
like;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s19.e1
may;O;O
enhance;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d458.s19.e2
-;O;O
like;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d458.s20;;
In;O;O
simultaneous;O;O
treatment;O;O
with;O;O
imidazole;B-group;B-DDI-DrugBank.d458.s20.e0
drugs;I-group;I-DDI-DrugBank.d458.s20.e0
and;O;O
coumarin;B-group;B-DDI-DrugBank.d458.s20.e1
drugs;I-group;I-DDI-DrugBank.d458.s20.e1
,;O;O
the;O;O
anticoagulant;O;O
effect;O;O
should;O;O
be;O;O
carefully;O;O
titrated;O;O
and;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d458.s21;;
Because;O;O
severe;O;O
hypoglycemia;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
concomitantly;O;O
receiving;O;O
oral;O;O
miconazole;B-drug;B-DDI-DrugBank.d458.s21.e0
(;O;O
an;O;O
imidazole;B-group;B-DDI-DrugBank.d458.s21.e1
);O;O
and;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d458.s21.e2
agents;I-group;I-DDI-DrugBank.d458.s21.e2
,;O;O
such;O;O
a;O;O
potential;O;O
interaction;O;O
involving;O;O
the;O;O
latter;O;O
agents;O;O
when;O;O
used;O;O
concomitantly;O;O
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s21.e3
tablets;O;O
(;O;O
an;O;O
imidazole;B-group;B-DDI-DrugBank.d458.s21.e4
);O;O
can;O;O
not;O;O
be;O;O
ruled;O;O
out;O;O
.;O;O
DDI-DrugBank.d458.s22;;
Concomitant;O;O
administration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s22.e0
tablets;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d458.s22.e1
may;O;O
alter;O;O
the;O;O
metabolism;O;O
of;O;O
one;O;O
or;O;O
both;O;O
of;O;O
the;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d458.s23;;
It;O;O
is;O;O
suggested;O;O
to;O;O
monitor;O;O
both;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s23.e0
and;O;O
phenytoin;B-drug;B-DDI-DrugBank.d458.s23.e1
.;O;O
DDI-DrugBank.d458.s24;;
Concomitant;O;O
administration;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d458.s24.e0
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s24.e1
tablets;O;O
reduces;O;O
the;O;O
blood;O;O
levels;O;O
of;O;O
the;O;O
latter;O;O
.;O;O
DDI-DrugBank.d458.s25;;
INH;B-drug;B-DDI-DrugBank.d458.s25.e0
(;O;O
Isoniazid;B-drug;B-DDI-DrugBank.d458.s25.e1
);O;O
is;O;O
also;O;O
reported;O;O
to;O;O
affect;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s25.e2
concentrations;O;O
adversely;O;O
.;O;O
DDI-DrugBank.d458.s26;;
These;O;O
drugs;O;O
should;O;O
not;O;O
be;O;O
given;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d458.s27;;
After;O;O
the;O;O
coadministration;O;O
of;O;O
200;O;O
mg;O;O
oral;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s27.e0
twice;O;O
daily;O;O
and;O;O
one;O;O
20;O;O
mg;O;O
dose;O;O
of;O;O
loratadine;B-drug;B-DDI-DrugBank.d458.s27.e1
to;O;O
11;O;O
subjects;O;O
,;O;O
the;O;O
AUC;O;O
and;O;O
Cmax;O;O
of;O;O
loratadine;B-drug;B-DDI-DrugBank.d458.s27.e2
averaged;O;O
302;O;O
%;O;O
(;O;O
142;O;O
S.D.;O;O
);O;O
and;O;O
251;O;O
%;O;O
(;O;O
68;O;O
S.D.;O;O
);O;O
,;O;O
respectively;O;O
,;O;O
of;O;O
those;O;O
obtained;O;O
after;O;O
co;O;O
-;O;O
treatment;O;O
with;O;O
placebo;O;O
.;O;O
DDI-DrugBank.d458.s28;;
The;O;O
AUC;O;O
and;O;O
Cmax;O;O
of;O;O
descarboethoxyloratadine;B-drug_n;B-DDI-DrugBank.d458.s28.e0
,;O;O
an;O;O
active;O;O
metabolite;O;O
,;O;O
averaged;O;O
155;O;O
%;O;O
(;O;O
27;O;O
S.D.;O;O
);O;O
and;O;O
141;O;O
%;O;O
(;O;O
35;O;O
S.D.;O;O
);O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d458.s29;;
However;O;O
,;O;O
no;O;O
related;O;O
changes;O;O
were;O;O
noted;O;O
in;O;O
the;O;O
QT0;O;O
on;O;O
ECG;O;O
taken;O;O
at;O;O
2;O;O
,;O;O
6;O;O
,;O;O
and;O;O
24;O;O
hours;O;O
after;O;O
the;O;O
coadministration;O;O
.;O;O
DDI-DrugBank.d458.s30;;
Also;O;O
,;O;O
there;O;O
were;O;O
no;O;O
clinically;O;O
significant;O;O
differences;O;O
in;O;O
adverse;O;O
events;O;O
when;O;O
loratadine;B-drug;B-DDI-DrugBank.d458.s30.e0
was;O;O
administered;O;O
with;O;O
or;O;O
without;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d458.s30.e1
.;O;O
DDI-DrugBank.d458.s31;;
Rare;O;O
cases;O;O
of;O;O
a;O;O
disulfiram;O;O
-;O;O
like;O;O
reaction;O;O
to;O;O
alcohol;B-drug;B-DDI-DrugBank.d458.s31.e0
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d458.s32;;
These;O;O
experiences;O;O
have;O;O
been;O;O
characterized;O;O
by;O;O
flushing;O;O
,;O;O
rash;O;O
,;O;O
peripheral;O;O
edema;O;O
,;O;O
nausea;O;O
,;O;O
and;O;O
headache;O;O
.;O;O
DDI-DrugBank.d458.s33;;
Symptoms;O;O
resolved;O;O
within;O;O
a;O;O
few;O;O
hours;O;O
.;O;O
DDI-DrugBank.d499.s0;;
The;O;O
following;O;O
drug;O;O
interactions;O;O
were;O;O
studied;O;O
with;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s0.e0
doses;O;O
of;O;O
200;O;O
mg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d499.s1;;
The;O;O
possibility;O;O
of;O;O
increased;O;O
interaction;O;O
should;O;O
be;O;O
kept;O;O
in;O;O
mind;O;O
when;O;O
Orudis;B-brand;B-DDI-DrugBank.d499.s1.e0
doses;O;O
greater;O;O
than;O;O
50;O;O
mg;O;O
as;O;O
a;O;O
single;O;O
dose;O;O
or;O;O
200;O;O
mg;O;O
of;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s1.e1
per;O;O
day;O;O
are;O;O
used;O;O
concomitantly;O;O
with;O;O
highly;O;O
bound;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d499.s2;;
1;O;O
.;O;O
DDI-DrugBank.d499.s3;;
Antacids;B-group;B-DDI-DrugBank.d499.s3.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
magnesium;B-drug;B-DDI-DrugBank.d499.s3.e1
hydroxide;I-drug;I-DDI-DrugBank.d499.s3.e1
and;O;O
aluminum;B-drug;B-DDI-DrugBank.d499.s3.e2
hydroxide;I-drug;I-DDI-DrugBank.d499.s3.e2
does;O;O
not;O;O
interfere;O;O
with;O;O
the;O;O
rate;O;O
or;O;O
extent;O;O
of;O;O
the;O;O
absorption;O;O
of;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s3.e3
administered;O;O
as;O;O
Orudis;B-brand;B-DDI-DrugBank.d499.s3.e4
.;O;O
DDI-DrugBank.d499.s4;;
2;O;O
.;O;O
DDI-DrugBank.d499.s5;;
Aspirin;B-brand;B-DDI-DrugBank.d499.s5.e0
:;O;O
Ketoprofen;B-drug;B-DDI-DrugBank.d499.s5.e1
does;O;O
not;O;O
alter;O;O
aspirin;B-brand;B-DDI-DrugBank.d499.s5.e2
absorption;O;O
,;O;O
DDI-DrugBank.d499.s6;;
however;O;O
,;O;O
in;O;O
a;O;O
study;O;O
of;O;O
12;O;O
normal;O;O
subjects;O;O
,;O;O
concurrent;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d499.s6.e0
decreased;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s6.e1
protein;O;O
binding;O;O
and;O;O
increased;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s6.e2
plasma;O;O
clearance;O;O
from;O;O
0.07;O;O
L;O;O
/;O;O
kg;O;O
/;O;O
h;O;O
without;O;O
aspirin;B-brand;B-DDI-DrugBank.d499.s6.e3
to;O;O
0.11;O;O
L;O;O
/;O;O
kg;O;O
/;O;O
h;O;O
with;O;O
aspirin;B-brand;B-DDI-DrugBank.d499.s6.e4
.;O;O
DDI-DrugBank.d499.s7;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
changes;O;O
has;O;O
not;O;O
been;O;O
adequately;O;O
studied;O;O
.;O;O
DDI-DrugBank.d499.s8;;
Therefore;O;O
,;O;O
concurrent;O;O
use;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d499.s8.e0
and;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s8.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d499.s9;;
3;O;O
.;O;O
DDI-DrugBank.d499.s10;;
Diuretic;B-group;B-DDI-DrugBank.d499.s10.e0
:;O;O
Hydrochlorothiazide;B-drug;B-DDI-DrugBank.d499.s10.e1
,;O;O
given;O;O
concomitantly;O;O
with;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s10.e2
,;O;O
produces;O;O
a;O;O
reduction;O;O
in;O;O
urinary;O;O
potassium;O;O
and;O;O
chloride;O;O
excretion;O;O
compared;O;O
to;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d499.s10.e3
alone;O;O
.;O;O
DDI-DrugBank.d499.s11;;
Patients;O;O
taking;O;O
diuretics;B-group;B-DDI-DrugBank.d499.s11.e0
are;O;O
at;O;O
a;O;O
greater;O;O
risk;O;O
of;O;O
developing;O;O
renal;O;O
failure;O;O
secondary;O;O
to;O;O
a;O;O
decrease;O;O
in;O;O
renal;O;O
blood;O;O
flow;O;O
caused;O;O
by;O;O
prostaglandin;O;O
inhibition;O;O
.;O;O
DDI-DrugBank.d499.s12;;
4;O;O
.;O;O
DDI-DrugBank.d499.s13;;
Digoxin;B-drug;B-DDI-DrugBank.d499.s13.e0
:;O;O
In;O;O
a;O;O
study;O;O
in;O;O
12;O;O
patients;O;O
with;O;O
congestive;O;O
heart;O;O
failure;O;O
where;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s13.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d499.s13.e2
were;O;O
concomitantly;O;O
administered;O;O
,;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s13.e3
did;O;O
not;O;O
alter;O;O
the;O;O
serum;O;O
levels;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d499.s13.e4
.;O;O
DDI-DrugBank.d499.s14;;
5;O;O
.;O;O
DDI-DrugBank.d499.s15;;
Warfarin;B-drug;B-DDI-DrugBank.d499.s15.e0
:;O;O
In;O;O
a;O;O
short;O;O
-;O;O
term;O;O
controlled;O;O
study;O;O
in;O;O
14;O;O
normal;O;O
volunteers;O;O
,;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s15.e1
did;O;O
not;O;O
significantly;O;O
interfere;O;O
with;O;O
the;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d499.s15.e2
on;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d499.s16;;
Bleeding;O;O
from;O;O
a;O;O
number;O;O
of;O;O
sites;O;O
may;O;O
be;O;O
a;O;O
complication;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d499.s16.e0
treatment;O;O
and;O;O
GI;O;O
bleeding;O;O
a;O;O
complication;O;O
of;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s16.e1
treatment;O;O
.;O;O
DDI-DrugBank.d499.s17;;
Because;O;O
prostaglandina;O;O
play;O;O
an;O;O
important;O;O
role;O;O
in;O;O
hemostasis;O;O
and;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s17.e0
has;O;O
an;O;O
effect;O;O
on;O;O
platelet;O;O
function;O;O
as;O;O
well;O;O
,;O;O
concurent;O;O
therapy;O;O
with;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s17.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d499.s17.e2
requires;O;O
close;O;O
monitoring;O;O
of;O;O
patients;O;O
on;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d499.s18;;
6;O;O
.;O;O
DDI-DrugBank.d499.s19;;
Probenecid;B-drug;B-DDI-DrugBank.d499.s19.e0
:;O;O
Probenecid;B-drug;B-DDI-DrugBank.d499.s19.e1
increases;O;O
both;O;O
free;O;O
and;O;O
bound;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s19.e2
by;O;O
reducing;O;O
the;O;O
plasma;O;O
clearance;O;O
of;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s19.e3
to;O;O
about;O;O
one;O;O
-;O;O
third;O;O
,;O;O
as;O;O
well;O;O
as;O;O
decreasing;O;O
its;O;O
protein;O;O
binding;O;O
.;O;O
DDI-DrugBank.d499.s20;;
Therefore;O;O
,;O;O
the;O;O
combination;O;O
of;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s20.e0
and;O;O
probenecid;B-drug;B-DDI-DrugBank.d499.s20.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d499.s21;;
7;O;O
.;O;O
DDI-DrugBank.d499.s22;;
Methotrexate;B-drug;B-DDI-DrugBank.d499.s22.e0
:;O;O
Ketoprofen;B-drug;B-DDI-DrugBank.d499.s22.e1
,;O;O
like;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d499.s22.e2
,;O;O
may;O;O
cause;O;O
changes;O;O
in;O;O
the;O;O
elimination;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d499.s22.e3
leading;O;O
to;O;O
elevated;O;O
serum;O;O
levels;O;O
of;O;O
the;O;O
drug;O;O
and;O;O
increased;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d499.s23;;
8;O;O
.;O;O
DDI-DrugBank.d499.s24;;
Lithium;B-drug;B-DDI-DrugBank.d499.s24.e0
:;O;O
Nonsteroidal;B-group;B-DDI-DrugBank.d499.s24.e1
anti;I-group;I-DDI-DrugBank.d499.s24.e1
-;I-group;I-DDI-DrugBank.d499.s24.e1
inflammatory;I-group;I-DDI-DrugBank.d499.s24.e1
agents;I-group;I-DDI-DrugBank.d499.s24.e1
have;O;O
been;O;O
reported;O;O
to;O;O
increase;O;O
steadystate;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d499.s24.e2
levels;O;O
.;O;O
DDI-DrugBank.d499.s25;;
It;O;O
is;O;O
recommended;O;O
that;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d499.s25.e0
levels;O;O
be;O;O
monitored;O;O
when;O;O
ketoprofen;B-drug;B-DDI-DrugBank.d499.s25.e1
is;O;O
coadministered;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d499.s25.e2
.;O;O
DDI-DrugBank.d499.s26;;
DRUG;O;O
/;O;O
LABORATORY;O;O
TEST;O;O
INTERACTIONS;O;O
:;O;O
EFFECT;O;O
ON;O;O
BLOOD;O;O
COAGULATION;O;O
Ketoprofen;B-drug;B-DDI-DrugBank.d499.s26.e0
decreases;O;O
platelet;O;O
adhesion;O;O
and;O;O
aggregation;O;O
.;O;O
DDI-DrugBank.d499.s27;;
Therefore;O;O
,;O;O
it;O;O
can;O;O
prolong;O;O
bleeding;O;O
time;O;O
by;O;O
approximately;O;O
3;O;O
to;O;O
4;O;O
minutes;O;O
from;O;O
baseline;O;O
values;O;O
.;O;O
DDI-DrugBank.d499.s28;;
There;O;O
is;O;O
no;O;O
significant;O;O
change;O;O
in;O;O
platelet;O;O
count;O;O
,;O;O
prothrombin;O;O
time;O;O
,;O;O
partial;O;O
thromboplastin;O;O
time;O;O
,;O;O
or;O;O
thrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d3.s0;;
Ketorolac;B-drug;B-DDI-DrugBank.d3.s0.e0
is;O;O
highly;O;O
bound;O;O
to;O;O
human;O;O
plasma;O;O
protein;O;O
(;O;O
mean;O;O
99.2;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d3.s1;;
Warfarin;B-drug;B-DDI-DrugBank.d3.s1.e0
,;O;O
Digoxin;B-drug;B-DDI-DrugBank.d3.s1.e1
,;O;O
Salicylate;B-group;B-DDI-DrugBank.d3.s1.e2
,;O;O
and;O;O
Heparin;B-drug;B-DDI-DrugBank.d3.s1.e3
The;O;O
in;O;O
vitro;O;O
binding;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d3.s1.e4
to;O;O
plasma;O;O
proteins;O;O
is;O;O
only;O;O
slightly;O;O
reduced;O;O
by;O;O
ketorolac;B-drug;B-DDI-DrugBank.d3.s1.e5
tromethamine;I-drug;I-DDI-DrugBank.d3.s1.e5
(;O;O
99.5;O;O
%;O;O
control;O;O
vs;O;O
99.3;O;O
%;O;O
);O;O
when;O;O
ketorolac;B-drug;B-DDI-DrugBank.d3.s1.e6
plasma;O;O
concentrations;O;O
reach;O;O
5;O;O
to10;O;O
m;O;O
g;O;O
/;O;O
mL.;O;O
DDI-DrugBank.d3.s2;;
Ketorolac;B-drug;B-DDI-DrugBank.d3.s2.e0
does;O;O
not;O;O
alter;O;O
digoxin;B-drug;B-DDI-DrugBank.d3.s2.e1
protein;O;O
binding;O;O
.;O;O
DDI-DrugBank.d3.s3;;
In;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
,;O;O
at;O;O
therapeutic;O;O
concentrations;O;O
of;O;O
salicylate;B-group;B-DDI-DrugBank.d3.s3.e0
(;O;O
300;O;O
m;O;O
g;O;O
/;O;O
mL;O;O
);O;O
,;O;O
the;O;O
binding;O;O
of;O;O
ketorolac;B-drug;B-DDI-DrugBank.d3.s3.e1
was;O;O
reduced;O;O
from;O;O
approximately;O;O
99.2;O;O
%;O;O
to;O;O
97.5;O;O
%;O;O
,;O;O
representing;O;O
a;O;O
potential;O;O
twofold;O;O
increase;O;O
in;O;O
unbound;O;O
ketorolac;B-drug;B-DDI-DrugBank.d3.s3.e2
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d3.s4;;
Therapeutic;O;O
concentrations;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d3.s4.e0
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d3.s4.e1
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d3.s4.e2
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d3.s4.e3
,;O;O
piroxicam;B-drug;B-DDI-DrugBank.d3.s4.e4
,;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d3.s4.e5
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d3.s4.e6
andtolbutamide;O;O
did;O;O
not;O;O
alter;O;O
ketorolac;B-drug;B-DDI-DrugBank.d3.s4.e7
tromethamine;I-drug;I-DDI-DrugBank.d3.s4.e7
protein;O;O
binding;O;O
.;O;O
DDI-DrugBank.d3.s5;;
In;O;O
a;O;O
study;O;O
involving;O;O
12;O;O
adult;O;O
volunteers;O;O
,;O;O
TORADOLORAL;O;O
was;O;O
coadministered;O;O
with;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
25;O;O
mg;O;O
warfarin;B-drug;B-DDI-DrugBank.d3.s5.e0
,;O;O
causing;O;O
no;O;O
significant;O;O
changes;O;O
in;O;O
pharmacokinetics;O;O
or;O;O
pharmacodynamics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d3.s5.e1
.;O;O
DDI-DrugBank.d3.s6;;
In;O;O
another;O;O
study;O;O
,;O;O
TORADOLIV;O;O
/;O;O
IM;O;O
was;O;O
given;O;O
with;O;O
two;O;O
doses;O;O
of;O;O
5000;O;O
U;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d3.s6.e0
to;O;O
11;O;O
healthy;O;O
volunteers;O;O
,;O;O
resulting;O;O
in;O;O
a;O;O
mean;O;O
template;O;O
bleeding;O;O
time;O;O
of;O;O
6.4;O;O
minutes;O;O
(;O;O
3.2;O;O
to;O;O
11.4;O;O
min;O;O
);O;O
compared;O;O
to;O;O
a;O;O
mean;O;O
of;O;O
6.0;O;O
minutes;O;O
(;O;O
3.4;O;O
to;O;O
7.5;O;O
min;O;O
);O;O
for;O;O
heparin;B-drug;B-DDI-DrugBank.d3.s6.e1
alone;O;O
and;O;O
5.1;O;O
minutes;O;O
(;O;O
3.5;O;O
to;O;O
8.5;O;O
min;O;O
);O;O
for;O;O
placebo;O;O
.;O;O
DDI-DrugBank.d3.s7;;
Although;O;O
these;O;O
results;O;O
do;O;O
not;O;O
indicate;O;O
a;O;O
significant;O;O
interaction;O;O
between;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s7.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d3.s7.e1
or;O;O
heparin;B-drug;B-DDI-DrugBank.d3.s7.e2
,;O;O
the;O;O
administration;O;O
of;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s7.e3
to;O;O
patients;O;O
taking;O;O
anticoagulants;B-group;B-DDI-DrugBank.d3.s7.e4
should;O;O
be;O;O
done;O;O
extremely;O;O
cautiously;O;O
,;O;O
and;O;O
patients;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d3.s8;;
Furosemide;B-drug;B-DDI-DrugBank.d3.s8.e0
:;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s8.e1
IV;O;O
/;O;O
IM;O;O
reduced;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d3.s8.e2
response;O;O
to;O;O
furosemide;B-drug;B-DDI-DrugBank.d3.s8.e3
in;O;O
normovolemic;O;O
healthy;O;O
subjects;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
(;O;O
mean;O;O
sodium;O;O
and;O;O
urinary;O;O
output;O;O
decreased;O;O
17;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d3.s9;;
Probenecid;B-drug;B-DDI-DrugBank.d3.s9.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s9.e1
ORAL;O;O
and;O;O
probenecid;B-drug;B-DDI-DrugBank.d3.s9.e2
resulted;O;O
in;O;O
decreased;O;O
clearance;O;O
of;O;O
ketorolac;B-drug;B-DDI-DrugBank.d3.s9.e3
and;O;O
significant;O;O
increases;O;O
in;O;O
ketorolac;B-drug;B-DDI-DrugBank.d3.s9.e4
plasma;O;O
levels;O;O
(;O;O
total;O;O
AUC;O;O
increased;O;O
approximately;O;O
threefold;O;O
from;O;O
5.4;O;O
to;O;O
17.8;O;O
m;O;O
g;O;O
/;O;O
h;O;O
/;O;O
mL;O;O
);O;O
and;O;O
terminal;O;O
half;O;O
-;O;O
life;O;O
increased;O;O
approximately;O;O
twofold;O;O
from;O;O
6.6;O;O
to;O;O
15.1;O;O
hours;O;O
.;O;O
DDI-DrugBank.d3.s10;;
Therefore;O;O
,;O;O
concomitant;O;O
use;O;O
of;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s10.e0
and;O;O
probenecid;B-drug;B-DDI-DrugBank.d3.s10.e1
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d3.s11;;
Lithium;B-drug;B-DDI-DrugBank.d3.s11.e0
:;O;O
Inhibition;O;O
of;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d3.s11.e1
clearance;O;O
,;O;O
leading;O;O
to;O;O
an;O;O
increase;O;O
in;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d3.s11.e2
concentration;O;O
,;O;O
has;O;O
been;O;O
reported;O;O
with;O;O
some;O;O
prostaglandin;O;O
synthesis;O;O
-;O;O
inhibiting;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d3.s12;;
The;O;O
effect;O;O
of;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s12.e0
on;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d3.s12.e1
has;O;O
not;O;O
been;O;O
studied;O;O
,;O;O
but;O;O
cases;O;O
of;O;O
increased;O;O
lithium;B-drug;B-DDI-DrugBank.d3.s12.e2
plasma;O;O
levels;O;O
during;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s12.e3
therapy;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d3.s13;;
Methotrexate;B-drug;B-DDI-DrugBank.d3.s13.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d3.s13.e1
and;O;O
some;O;O
NSAIDs;B-group;B-DDI-DrugBank.d3.s13.e2
has;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
the;O;O
clearance;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d3.s13.e3
,;O;O
enhancing;O;O
the;O;O
toxicity;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d3.s13.e4
.;O;O
DDI-DrugBank.d3.s14;;
The;O;O
effect;O;O
of;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s14.e0
on;O;O
methotrexate;B-drug;B-DDI-DrugBank.d3.s14.e1
clearance;O;O
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d3.s15;;
Nondepolarizing;B-group;B-DDI-DrugBank.d3.s15.e0
Muscle;I-group;I-DDI-DrugBank.d3.s15.e0
Relaxants;I-group;I-DDI-DrugBank.d3.s15.e0
:;O;O
In;O;O
postmarketing;O;O
experience;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
a;O;O
possible;O;O
interaction;O;O
between;O;O
TORADOLIV;O;O
/;O;O
IM;O;O
and;O;O
nondepolarizing;B-group;B-DDI-DrugBank.d3.s15.e1
muscle;I-group;I-DDI-DrugBank.d3.s15.e1
relaxants;I-group;I-DDI-DrugBank.d3.s15.e1
that;O;O
resulted;O;O
in;O;O
apnea;O;O
.;O;O
DDI-DrugBank.d3.s16;;
The;O;O
concurrent;O;O
use;O;O
of;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s16.e0
with;O;O
muscle;B-group;B-DDI-DrugBank.d3.s16.e1
relaxants;I-group;I-DDI-DrugBank.d3.s16.e1
has;O;O
not;O;O
been;O;O
formally;O;O
studied;O;O
.;O;O
DDI-DrugBank.d3.s17;;
ACE;B-group;B-DDI-DrugBank.d3.s17.e0
Inhibitors;I-group;I-DDI-DrugBank.d3.s17.e0
:;O;O
Concomitant;O;O
use;O;O
of;O;O
ACE;B-group;B-DDI-DrugBank.d3.s17.e1
inhibitors;I-group;I-DDI-DrugBank.d3.s17.e1
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
renal;O;O
impairment;O;O
,;O;O
particularly;O;O
in;O;O
volume;O;O
-;O;O
depleted;O;O
patients;O;O
.;O;O
DDI-DrugBank.d3.s18;;
Antiepileptic;B-group;B-DDI-DrugBank.d3.s18.e0
Drugs;I-group;I-DDI-DrugBank.d3.s18.e0
:;O;O
Sporadic;O;O
cases;O;O
of;O;O
seizures;O;O
have;O;O
been;O;O
reported;O;O
during;O;O
concomitant;O;O
use;O;O
of;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s18.e1
and;O;O
antiepileptic;B-group;B-DDI-DrugBank.d3.s18.e2
drugs;I-group;I-DDI-DrugBank.d3.s18.e2
(;O;O
phenytoin;B-drug;B-DDI-DrugBank.d3.s18.e3
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d3.s18.e4
);O;O
.;O;O
DDI-DrugBank.d3.s19;;
Psychoactive;B-group;B-DDI-DrugBank.d3.s19.e0
Drugs;I-group;I-DDI-DrugBank.d3.s19.e0
:;O;O
Hallucinations;O;O
have;O;O
been;O;O
reported;O;O
when;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s19.e1
was;O;O
used;O;O
in;O;O
patients;O;O
taking;O;O
psychoactive;B-group;B-DDI-DrugBank.d3.s19.e2
drugs;I-group;I-DDI-DrugBank.d3.s19.e2
(;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d3.s19.e3
,;O;O
thiothixene;B-drug;B-DDI-DrugBank.d3.s19.e4
,;O;O
alprazolam;B-drug;B-DDI-DrugBank.d3.s19.e5
);O;O
.;O;O
DDI-DrugBank.d3.s20;;
Morphine;B-drug;B-DDI-DrugBank.d3.s20.e0
:;O;O
TORADOLIV;O;O
/;O;O
IM;O;O
has;O;O
been;O;O
administered;O;O
concurrently;O;O
with;O;O
morphine;B-drug;B-DDI-DrugBank.d3.s20.e1
in;O;O
several;O;O
clinical;O;O
trials;O;O
of;O;O
postoperative;O;O
pain;O;O
without;O;O
evidence;O;O
of;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d3.s21;;
Do;O;O
not;O;O
mix;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s21.e0
and;O;O
morphine;B-drug;B-DDI-DrugBank.d3.s21.e1
in;O;O
the;O;O
same;O;O
syringe;O;O
.;O;O
DDI-DrugBank.d3.s22;;
There;O;O
is;O;O
no;O;O
evidence;O;O
in;O;O
animal;O;O
or;O;O
human;O;O
studies;O;O
that;O;O
TORADOL;B-brand;B-DDI-DrugBank.d3.s22.e0
induces;O;O
or;O;O
inhibits;O;O
hepatic;O;O
enzymes;O;O
capable;O;O
of;O;O
metabolizing;O;O
itself;O;O
or;O;O
other;O;O
drugs;O;O
DDI-DrugBank.d3.s23;;
.;O;O
DDI-DrugBank.d3.s24;;
DDI-DrugBank.d95.s0;;
Cyclosporine;B-drug;B-DDI-DrugBank.d95.s0.e0
-;O;O
L;B-drug;B-DDI-DrugBank.d95.s0.e1
-;I-drug;I-DDI-DrugBank.d95.s0.e1
arginine;I-drug;I-DDI-DrugBank.d95.s0.e1
may;O;O
counteract;O;O
the;O;O
antinaturetic;O;O
effect;O;O
of;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d95.s0.e2
.;O;O
DDI-DrugBank.d95.s1;;
Ibuprofen;B-drug;B-DDI-DrugBank.d95.s1.e0
-;O;O
L;B-drug;B-DDI-DrugBank.d95.s1.e1
-;I-drug;I-DDI-DrugBank.d95.s1.e1
arginine;I-drug;I-DDI-DrugBank.d95.s1.e1
may;O;O
increase;O;O
the;O;O
absorption;O;O
of;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d95.s1.e2
if;O;O
taken;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d95.s2;;
Organic;O;O
nitrates;B-group;B-DDI-DrugBank.d95.s2.e0
-;O;O
L;B-drug;B-DDI-DrugBank.d95.s2.e1
-;I-drug;I-DDI-DrugBank.d95.s2.e1
arginine;I-drug;I-DDI-DrugBank.d95.s2.e1
supplements;O;O
theoretically;O;O
may;O;O
potentiate;O;O
the;O;O
effects;O;O
of;O;O
organic;O;O
nitrates;B-drug;B-DDI-DrugBank.d95.s2.e2
if;O;O
taken;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d95.s3;;
Sildenafil;B-drug;B-DDI-DrugBank.d95.s3.e0
citrate;I-drug;I-DDI-DrugBank.d95.s3.e0
-;O;O
Theoretically;O;O
,;O;O
L;B-drug;B-DDI-DrugBank.d95.s3.e1
-;I-drug;I-DDI-DrugBank.d95.s3.e1
arginine;I-drug;I-DDI-DrugBank.d95.s3.e1
supplements;O;O
taken;O;O
concomitantly;O;O
with;O;O
sildenafil;B-drug;B-DDI-DrugBank.d95.s3.e2
citrate;I-drug;I-DDI-DrugBank.d95.s3.e2
,;O;O
may;O;O
potentiate;O;O
the;O;O
effects;O;O
of;O;O
the;O;O
drug;O;O
.;O;O
DDI-DrugBank.d243.s0;;
No;O;O
drug;O;O
,;O;O
nutritional;O;O
supplement;O;O
,;O;O
food;O;O
or;O;O
herb;O;O
interactions;O;O
are;O;O
known;O;O
.;O;O
DDI-DrugBank.d539.s0;;
Interacts;O;O
with;O;O
valproic;B-drug;B-DDI-DrugBank.d539.s0.e0
acid;I-drug;I-DDI-DrugBank.d539.s0.e0
DDI-DrugBank.d92.s0;;
No;O;O
well;O;O
-;O;O
known;O;O
drug;O;O
interactions;O;O
with;O;O
glutamic;B-drug;B-DDI-DrugBank.d92.s0.e0
acid;I-drug;I-DDI-DrugBank.d92.s0.e0
DDI-DrugBank.d66.s0;;
Human;I-drug;I-DDI-DrugBank.d66.s0.e0
growth;I-drug;I-DDI-DrugBank.d66.s0.e0
hormone;I-drug;I-DDI-DrugBank.d66.s0.e0
-;O;O
Concomitant;O;O
use;O;O
of;O;O
L;B-drug;B-DDI-DrugBank.d66.s0.e1
-;I-drug;I-DDI-DrugBank.d66.s0.e1
glutamine;I-drug;I-DDI-DrugBank.d66.s0.e1
and;O;O
human;B-drug;B-DDI-DrugBank.d66.s0.e2
growth;I-drug;I-DDI-DrugBank.d66.s0.e2
hormone;I-drug;I-DDI-DrugBank.d66.s0.e2
may;O;O
enhance;O;O
nutrient;O;O
absorption;O;O
in;O;O
those;O;O
with;O;O
severe;O;O
short;O;O
bowel;O;O
syndrome;O;O
.;O;O
DDI-DrugBank.d66.s1;;
L;B-drug;B-DDI-DrugBank.d66.s1.e0
-;I-drug;I-DDI-DrugBank.d66.s1.e0
glutamine;I-drug;I-DDI-DrugBank.d66.s1.e0
has;O;O
orphan;O;O
drug;O;O
status;O;O
for;O;O
this;O;O
indication;O;O
.;O;O
DDI-DrugBank.d66.s2;;
Indomethacin;B-drug;B-DDI-DrugBank.d66.s2.e0
-;O;O
Concomitant;O;O
use;O;O
of;O;O
L;B-drug;B-DDI-DrugBank.d66.s2.e1
-;I-drug;I-DDI-DrugBank.d66.s2.e1
glutamine;I-drug;I-DDI-DrugBank.d66.s2.e1
and;O;O
indomethacin;B-drug;B-DDI-DrugBank.d66.s2.e2
may;O;O
ameliorate;O;O
increased;O;O
intestinal;O;O
permeability;O;O
caused;O;O
by;O;O
indomethacin;B-drug;B-DDI-DrugBank.d66.s2.e3
.;O;O
DDI-DrugBank.d66.s3;;
The;O;O
reported;O;O
dose;O;O
used;O;O
for;O;O
L;B-drug;B-DDI-DrugBank.d66.s3.e0
-;I-drug;I-DDI-DrugBank.d66.s3.e0
glutamine;I-drug;I-DDI-DrugBank.d66.s3.e0
was;O;O
21;O;O
grams;O;O
daily;O;O
taken;O;O
in;O;O
divided;O;O
doses;O;O
three;O;O
times;O;O
a;O;O
day;O;O
.;O;O
DDI-DrugBank.d66.s4;;
Further;O;O
,;O;O
misoprostol;B-drug;B-DDI-DrugBank.d66.s4.e0
is;O;O
reported;O;O
to;O;O
have;O;O
a;O;O
synergistic;O;O
effect;O;O
with;O;O
this;O;O
combination;O;O
in;O;O
ameliorating;O;O
intestinal;O;O
permeability;O;O
.;O;O
DDI-DrugBank.d66.s5;;
Methotrexate;B-drug;B-DDI-DrugBank.d66.s5.e0
-;O;O
There;O;O
is;O;O
one;O;O
report;O;O
that;O;O
methotrexate;B-drug;B-DDI-DrugBank.d66.s5.e1
may;O;O
decrease;O;O
the;O;O
possible;O;O
effectiveness;O;O
of;O;O
supplemental;O;O
L;B-drug;B-DDI-DrugBank.d66.s5.e2
-;I-drug;I-DDI-DrugBank.d66.s5.e2
glutamine;I-drug;I-DDI-DrugBank.d66.s5.e2
for;O;O
chemotherapy;O;O
-;O;O
induced;O;O
mucositis;O;O
.;O;O
DDI-DrugBank.d66.s6;;
In;O;O
another;O;O
report;O;O
,;O;O
nine;O;O
patients;O;O
with;O;O
breast;O;O
cancer;O;O
were;O;O
reported;O;O
to;O;O
have;O;O
decreased;O;O
symptoms;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d66.s6.e0
-;O;O
related;O;O
toxicity;O;O
when;O;O
given;O;O
supplemental;O;O
L;B-drug;B-DDI-DrugBank.d66.s6.e1
-;I-drug;I-DDI-DrugBank.d66.s6.e1
glutamine;I-drug;I-DDI-DrugBank.d66.s6.e1
at;O;O
a;O;O
dose;O;O
of;O;O
0.5;O;O
gram;O;O
/;O;O
kilogram;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d66.s7;;
Paclitaxel;B-drug;B-DDI-DrugBank.d66.s7.e0
-;O;O
In;O;O
one;O;O
report;O;O
,;O;O
L;B-drug;B-DDI-DrugBank.d66.s7.e1
-;I-drug;I-DDI-DrugBank.d66.s7.e1
glutamine;I-drug;I-DDI-DrugBank.d66.s7.e1
at;O;O
a;O;O
dose;O;O
of;O;O
10;O;O
grams;O;O
three;O;O
times;O;O
daily;O;O
,;O;O
given;O;O
24;O;O
hours;O;O
after;O;O
receiving;O;O
paclitaxel;B-drug;B-DDI-DrugBank.d66.s7.e2
,;O;O
appeared;O;O
to;O;O
prevent;O;O
the;O;O
development;O;O
of;O;O
myalgia;O;O
and;O;O
arthralgia;O;O
,;O;O
adverse;O;O
reactions;O;O
of;O;O
paclitaxel;B-drug;B-DDI-DrugBank.d66.s7.e3
.;O;O
DDI-DrugBank.d365.s0;;
Medroxyprogesterone;B-drug;B-DDI-DrugBank.d365.s0.e0
Acetate;I-drug;I-DDI-DrugBank.d365.s0.e0
-;O;O
L;B-drug;B-DDI-DrugBank.d365.s0.e1
-;I-drug;I-DDI-DrugBank.d365.s0.e1
histidine;I-drug;I-DDI-DrugBank.d365.s0.e1
was;O;O
observed;O;O
to;O;O
enhance;O;O
(;O;O
in;O;O
tissue;O;O
culture;O;O
);O;O
the;O;O
effect;O;O
of;O;O
medroxyprogesterone;B-drug;B-DDI-DrugBank.d365.s0.e2
acetate;I-drug;I-DDI-DrugBank.d365.s0.e2
in;O;O
reducing;O;O
the;O;O
number;O;O
of;O;O
human;O;O
breast;O;O
cancer;O;O
cells;O;O
that;O;O
were;O;O
in;O;O
the;O;O
S;O;O
phase;O;O
.;O;O
DDI-DrugBank.d365.s1;;
H1;B-group;B-DDI-DrugBank.d365.s1.e0
and;I-group;I-DDI-DrugBank.d365.s1.e0
H2;I-group;I-DDI-DrugBank.d365.s1.e1
Blockers;I-group;I-DDI-DrugBank.d365.s1.e1
-;O;O
Although;O;O
not;O;O
reported;O;O
,;O;O
L;B-drug;B-DDI-DrugBank.d365.s1.e2
-;I-drug;I-DDI-DrugBank.d365.s1.e2
histidine;I-drug;I-DDI-DrugBank.d365.s1.e2
,;O;O
via;O;O
its;O;O
metabolism;O;O
to;O;O
histamine;O;O
,;O;O
might;O;O
decrease;O;O
the;O;O
efficacy;O;O
of;O;O
H1;B-group;B-DDI-DrugBank.d365.s1.e3
and;I-group;I-DDI-DrugBank.d365.s1.e3
H2;I-group;I-DDI-DrugBank.d365.s1.e4
blockers;I-group;I-DDI-DrugBank.d365.s1.e4
.;O;O
DDI-DrugBank.d344.s0;;
Concomitant;O;O
use;O;O
of;O;O
calcium;B-drug;B-DDI-DrugBank.d344.s0.e0
supplements;O;O
and;O;O
L;B-drug;B-DDI-DrugBank.d344.s0.e1
-;I-drug;I-DDI-DrugBank.d344.s0.e1
lysine;I-drug;I-DDI-DrugBank.d344.s0.e1
may;O;O
increase;O;O
calcium;B-drug;B-DDI-DrugBank.d344.s0.e2
absorption;O;O
DDI-DrugBank.d528.s0;;
Acetaminophen;B-drug;B-DDI-DrugBank.d528.s0.e0
and;O;O
methotrexate;B-drug;B-DDI-DrugBank.d528.s0.e1
-;O;O
L;B-drug;B-DDI-DrugBank.d528.s0.e2
-;I-drug;I-DDI-DrugBank.d528.s0.e2
methionine;I-drug;I-DDI-DrugBank.d528.s0.e2
may;O;O
decrease;O;O
hepatic;O;O
toxicity;O;O
in;O;O
those;O;O
with;O;O
acetaminophen;B-drug;B-DDI-DrugBank.d528.s0.e3
overdosage;O;O
or;O;O
in;O;O
those;O;O
taking;O;O
methotrexate;B-drug;B-DDI-DrugBank.d528.s0.e4
.;O;O
DDI-DrugBank.d528.s1;;
Theoretically;O;O
,;O;O
it;O;O
may;O;O
decrease;O;O
hepatic;O;O
toxicity;O;O
in;O;O
the;O;O
case;O;O
of;O;O
other;O;O
potential;O;O
hepatotoxic;O;O
drugs;O;O
,;O;O
as;O;O
well;O;O
.;O;O
DDI-DrugBank.d528.s2;;
Gentamicin;B-drug;B-DDI-DrugBank.d528.s2.e0
-;O;O
Methionine;B-drug;B-DDI-DrugBank.d528.s2.e1
may;O;O
protect;O;O
against;O;O
the;O;O
ototoxic;O;O
effects;O;O
of;O;O
gentamicin;B-drug;B-DDI-DrugBank.d528.s2.e2
.;O;O
DDI-DrugBank.d530.s0;;
Non;B-group;B-DDI-DrugBank.d530.s0.e0
-;I-group;I-DDI-DrugBank.d530.s0.e0
selective;I-group;I-DDI-DrugBank.d530.s0.e0
monoamine;I-group;I-DDI-DrugBank.d530.s0.e0
oxidase;I-group;I-DDI-DrugBank.d530.s0.e0
(;I-group;I-DDI-DrugBank.d530.s0.e0
MAO;I-group;I-DDI-DrugBank.d530.s0.e0
);I-group;I-DDI-DrugBank.d530.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d530.s0.e0
-;O;O
including;O;O
phenelzine;B-drug;B-DDI-DrugBank.d530.s0.e1
sulfate;I-drug;I-DDI-DrugBank.d530.s0.e1
,;O;O
tranylcypromine;B-drug;B-DDI-DrugBank.d530.s0.e2
sulfate;I-drug;I-DDI-DrugBank.d530.s0.e2
and;O;O
pargyline;B-drug;B-DDI-DrugBank.d530.s0.e3
HC1;O;O
.;O;O
DDI-DrugBank.d530.s1;;
Concomitant;O;O
use;O;O
of;O;O
L;B-drug;B-DDI-DrugBank.d530.s1.e0
-;I-drug;I-DDI-DrugBank.d530.s1.e0
phenylalanine;I-drug;I-DDI-DrugBank.d530.s1.e0
and;O;O
non;B-group;B-DDI-DrugBank.d530.s1.e1
-;I-group;I-DDI-DrugBank.d530.s1.e1
selective;I-group;I-DDI-DrugBank.d530.s1.e1
MAO;I-group;I-DDI-DrugBank.d530.s1.e1
inhibitors;I-group;I-DDI-DrugBank.d530.s1.e1
may;O;O
cause;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d530.s2;;
Selegiline;B-drug;B-DDI-DrugBank.d530.s2.e0
-;O;O
L;B-drug;B-DDI-DrugBank.d530.s2.e1
-;I-drug;I-DDI-DrugBank.d530.s2.e1
phenylalanine;I-drug;I-DDI-DrugBank.d530.s2.e1
and;O;O
the;O;O
selective;B-group;B-DDI-DrugBank.d530.s2.e2
MAO;I-group;I-DDI-DrugBank.d530.s2.e2
inhibitor;I-group;I-DDI-DrugBank.d530.s2.e2
selegiline;I-drug;I-DDI-DrugBank.d530.s2.e3
may;O;O
have;O;O
synergistic;O;O
antidepressant;O;O
activity;O;O
if;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d530.s3;;
Neuroleptic;B-group;B-DDI-DrugBank.d530.s3.e0
Drugs;I-group;I-DDI-DrugBank.d530.s3.e0
-;O;O
L;B-drug;B-DDI-DrugBank.d530.s3.e1
-;I-drug;I-DDI-DrugBank.d530.s3.e1
phenylalanine;I-drug;I-DDI-DrugBank.d530.s3.e1
may;O;O
potentiate;O;O
the;O;O
tardive;O;O
dyskinesia;O;O
side;O;O
reactions;O;O
of;O;O
neuroleptic;B-group;B-DDI-DrugBank.d530.s3.e2
drugs;I-group;I-DDI-DrugBank.d530.s3.e2
if;O;O
used;O;O
concomitantly;O;O
with;O;O
them;O;O
.;O;O
DDI-DrugBank.d63.s0;;
Monoamine;B-group;B-DDI-DrugBank.d63.s0.e0
oxidase;I-group;I-DDI-DrugBank.d63.s0.e0
(;I-group;I-DDI-DrugBank.d63.s0.e0
MAO;I-group;I-DDI-DrugBank.d63.s0.e0
);I-group;I-DDI-DrugBank.d63.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d63.s0.e0
such;O;O
as;O;O
isocarboxazid;B-drug;B-DDI-DrugBank.d63.s0.e1
(;O;O
e.g.;O;O
,;O;O
Marplan;B-brand;B-DDI-DrugBank.d63.s0.e2
);O;O
,;O;O
phenelzine;B-drug;B-DDI-DrugBank.d63.s0.e3
(;O;O
e.g.;O;O
,;O;O
Nardil;B-brand;B-DDI-DrugBank.d63.s0.e4
);O;O
,;O;O
procarbazine;B-drug;B-DDI-DrugBank.d63.s0.e5
(;O;O
e.g.;O;O
,;O;O
Matulane;B-brand;B-DDI-DrugBank.d63.s0.e6
);O;O
,;O;O
selegiline;B-drug;B-DDI-DrugBank.d63.s0.e7
(;O;O
e.g.;O;O
,;O;O
Eldepryl;B-brand;B-DDI-DrugBank.d63.s0.e8
);O;O
,;O;O
and;O;O
tranylcypromine;B-drug;B-DDI-DrugBank.d63.s0.e9
(;O;O
e.g.;O;O
,;O;O
Parnate;B-brand;B-DDI-DrugBank.d63.s0.e10
);O;O
:;O;O
Using;O;O
these;O;O
medicines;O;O
with;O;O
L;B-drug;B-DDI-DrugBank.d63.s0.e11
-;I-drug;I-DDI-DrugBank.d63.s0.e11
tryptophan;I-drug;I-DDI-DrugBank.d63.s0.e11
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
.;O;O
DDI-DrugBank.d111.s0;;
Non;B-group;B-DDI-DrugBank.d111.s0.e0
-;I-group;I-DDI-DrugBank.d111.s0.e0
selective;I-group;I-DDI-DrugBank.d111.s0.e0
MAO;I-group;I-DDI-DrugBank.d111.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d111.s0.e0
including;O;O
tranylcypromine;B-drug;B-DDI-DrugBank.d111.s0.e1
sulfate;I-drug;I-DDI-DrugBank.d111.s0.e1
,;O;O
phenelzine;B-drug;B-DDI-DrugBank.d111.s0.e2
sulfate;I-drug;I-DDI-DrugBank.d111.s0.e2
,;O;O
and;O;O
pargyline;B-drug;B-DDI-DrugBank.d111.s0.e3
HC1;O;O
:;O;O
Concomitant;O;O
use;O;O
of;O;O
L;B-drug;B-DDI-DrugBank.d111.s0.e4
-;I-drug;I-DDI-DrugBank.d111.s0.e4
tyrosine;I-drug;I-DDI-DrugBank.d111.s0.e4
and;O;O
non;O;O
-;O;O
selective;O;O
MAO;B-group;B-DDI-DrugBank.d111.s0.e5
inhibitors;I-group;I-DDI-DrugBank.d111.s0.e5
may;O;O
cause;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d412.s0;;
In;O;O
one;O;O
survey;O;O
,;O;O
2.3;O;O
%;O;O
of;O;O
patients;O;O
taking;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s0.e0
HCl;I-drug;I-DDI-DrugBank.d412.s0.e0
in;O;O
combination;O;O
with;O;O
tricyclic;B-group;B-DDI-DrugBank.d412.s0.e1
antidepressants;I-group;I-DDI-DrugBank.d412.s0.e1
experienced;O;O
tremor;O;O
,;O;O
as;O;O
compared;O;O
to;O;O
0.7;O;O
%;O;O
reported;O;O
to;O;O
occur;O;O
with;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s0.e2
HCl;I-drug;I-DDI-DrugBank.d412.s0.e2
alone;O;O
.;O;O
DDI-DrugBank.d412.s1;;
The;O;O
contribution;O;O
of;O;O
each;O;O
of;O;O
the;O;O
treatments;O;O
to;O;O
this;O;O
adverse;O;O
reaction;O;O
is;O;O
unknown;O;O
but;O;O
the;O;O
possibility;O;O
of;O;O
a;O;O
drug;O;O
interaction;O;O
can;O;O
not;O;O
be;O;O
excluded;O;O
.;O;O
DDI-DrugBank.d412.s2;;
Drugs;O;O
possessing;O;O
beta;O;O
-;O;O
blocking;O;O
properties;O;O
can;O;O
blunt;O;O
the;O;O
bronchodilator;O;O
effect;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d412.s2.e0
-;I-group;I-DDI-DrugBank.d412.s2.e0
receptor;I-group;I-DDI-DrugBank.d412.s2.e0
agonist;I-group;I-DDI-DrugBank.d412.s2.e0
drugs;I-group;I-DDI-DrugBank.d412.s2.e0
in;O;O
patients;O;O
with;O;O
bronchospasm;O;O
,;O;O
DDI-DrugBank.d412.s3;;
therefore;O;O
,;O;O
doses;O;O
greater;O;O
than;O;O
the;O;O
normal;O;O
antiasthmatic;O;O
dose;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d412.s3.e0
-;I-group;I-DDI-DrugBank.d412.s3.e0
agonist;I-group;I-DDI-DrugBank.d412.s3.e0
bronchodilator;I-group;I-DDI-DrugBank.d412.s3.e0
drugs;I-group;I-DDI-DrugBank.d412.s3.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d412.s4;;
Cimetidine;B-drug;B-DDI-DrugBank.d412.s4.e0
has;O;O
been;O;O
shown;O;O
to;O;O
increase;O;O
the;O;O
bioavailability;O;O
of;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s4.e1
HCl;I-drug;I-DDI-DrugBank.d412.s4.e1
.;O;O
DDI-DrugBank.d412.s5;;
Since;O;O
this;O;O
could;O;O
be;O;O
explained;O;O
either;O;O
by;O;O
enhanced;O;O
absorption;O;O
or;O;O
by;O;O
an;O;O
alteration;O;O
of;O;O
hepatic;O;O
metabolism;O;O
of;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s5.e0
HCl;I-drug;I-DDI-DrugBank.d412.s5.e0
,;O;O
special;O;O
care;O;O
should;O;O
be;O;O
used;O;O
in;O;O
establishing;O;O
the;O;O
dose;O;O
required;O;O
for;O;O
blood;O;O
pressure;O;O
control;O;O
in;O;O
such;O;O
patients;O;O
.;O;O
DDI-DrugBank.d412.s6;;
Synergism;O;O
has;O;O
been;O;O
shown;O;O
between;O;O
halothane;B-drug;B-DDI-DrugBank.d412.s6.e0
anesthesia;O;O
and;O;O
intravenously;O;O
administered;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s6.e1
HCl;I-drug;I-DDI-DrugBank.d412.s6.e1
.;O;O
DDI-DrugBank.d412.s7;;
During;O;O
controlled;O;O
hypotensive;O;O
anesthesia;O;O
using;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s7.e0
HCl;I-drug;I-DDI-DrugBank.d412.s7.e0
in;O;O
association;O;O
with;O;O
halothane;B-drug;B-DDI-DrugBank.d412.s7.e1
,;O;O
high;O;O
concentrations;O;O
(;O;O
3;O;O
%;O;O
or;O;O
above;O;O
);O;O
of;O;O
halothane;B-drug;B-DDI-DrugBank.d412.s7.e2
should;O;O
not;O;O
be;O;O
used;O;O
because;O;O
the;O;O
degree;O;O
of;O;O
hypotension;O;O
will;O;O
be;O;O
increased;O;O
and;O;O
because;O;O
of;O;O
the;O;O
possibility;O;O
of;O;O
a;O;O
large;O;O
reduction;O;O
in;O;O
cardiac;O;O
output;O;O
and;O;O
an;O;O
increase;O;O
in;O;O
central;O;O
venous;O;O
pressure;O;O
.;O;O
DDI-DrugBank.d412.s8;;
The;O;O
anesthesiologist;O;O
should;O;O
be;O;O
informed;O;O
when;O;O
a;O;O
patient;O;O
is;O;O
receiving;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s8.e0
HCl;I-drug;I-DDI-DrugBank.d412.s8.e0
.;O;O
DDI-DrugBank.d412.s9;;
Labetalol;B-drug;B-DDI-DrugBank.d412.s9.e0
HCl;I-drug;I-DDI-DrugBank.d412.s9.e0
blunts;O;O
the;O;O
reflex;O;O
tachycardia;O;O
produced;O;O
by;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d412.s9.e1
without;O;O
preventing;O;O
its;O;O
hypotensive;O;O
effect;O;O
.;O;O
DDI-DrugBank.d412.s10;;
If;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s10.e0
HCl;I-drug;I-DDI-DrugBank.d412.s10.e0
is;O;O
used;O;O
with;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d412.s10.e1
in;O;O
patients;O;O
with;O;O
angina;O;O
pectoris;O;O
,;O;O
additional;O;O
antihypertensive;O;O
effects;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d412.s11;;
Care;O;O
should;O;O
be;O;O
taken;O;O
if;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s11.e0
is;O;O
used;O;O
concomitantly;O;O
with;O;O
calcium;B-group;B-DDI-DrugBank.d412.s11.e1
antagonists;I-group;I-DDI-DrugBank.d412.s11.e1
of;O;O
the;O;O
verapamil;B-drug;B-DDI-DrugBank.d412.s11.e2
type;O;O
.;O;O
DDI-DrugBank.d412.s12;;
Risk;O;O
of;O;O
Anaphylactic;O;O
Reaction;O;O
While;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d412.s12.e0
-;I-group;I-DDI-DrugBank.d412.s12.e0
blockers;I-group;I-DDI-DrugBank.d412.s12.e0
,;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
severe;O;O
anaphylactic;O;O
reaction;O;O
to;O;O
a;O;O
variety;O;O
of;O;O
allergens;O;O
may;O;O
be;O;O
more;O;O
reactive;O;O
to;O;O
repeated;O;O
challenge;O;O
,;O;O
either;O;O
accidental;O;O
,;O;O
diagnostic;O;O
,;O;O
or;O;O
therapeutic;O;O
.;O;O
DDI-DrugBank.d412.s13;;
Such;O;O
patients;O;O
may;O;O
be;O;O
unresponsive;O;O
to;O;O
the;O;O
usual;O;O
doses;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d412.s13.e0
used;O;O
to;O;O
treat;O;O
allergic;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d412.s14;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
The;O;O
presence;O;O
of;O;O
labetalol;O;O
metabolites;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
result;O;O
in;O;O
falsely;O;O
elevated;O;O
levels;O;O
of;O;O
urinary;O;O
catecholamines;O;O
,;O;O
metanephrine;O;O
,;O;O
normetanephrine;O;O
and;O;O
vanillylmandelic;O;O
acid;O;O
when;O;O
measured;O;O
by;O;O
fluorimetric;O;O
or;O;O
photometric;O;O
methods;O;O
.;O;O
DDI-DrugBank.d412.s15;;
In;O;O
screening;O;O
patients;O;O
suspected;O;O
of;O;O
having;O;O
a;O;O
pheochromocytoma;O;O
and;O;O
being;O;O
treated;O;O
with;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s15.e0
HCl;I-drug;I-DDI-DrugBank.d412.s15.e0
,;O;O
a;O;O
specific;O;O
method;O;O
,;O;O
such;O;O
as;O;O
a;O;O
high;O;O
performance;O;O
liquid;O;O
chromatographic;O;O
assay;O;O
with;O;O
solid;O;O
phase;O;O
extraction;O;O
(;O;O
e.g.;O;O
,;O;O
J;O;O
Chromatogr;O;O
385:241,1987;O;O
);O;O
should;O;O
be;O;O
employed;O;O
in;O;O
determining;O;O
levels;O;O
of;O;O
catecholamines;O;O
.;O;O
DDI-DrugBank.d412.s16;;
Labetalol;B-drug;B-DDI-DrugBank.d412.s16.e0
HCl;I-drug;I-DDI-DrugBank.d412.s16.e0
has;O;O
also;O;O
been;O;O
reported;O;O
to;O;O
produce;O;O
a;O;O
false;O;O
positive;O;O
test;O;O
for;O;O
amphetamine;B-drug;B-DDI-DrugBank.d412.s16.e1
when;O;O
screening;O;O
urine;O;O
for;O;O
the;O;O
presence;O;O
of;O;O
drugs;O;O
using;O;O
the;O;O
commercially;O;O
available;O;O
assay;O;O
methods;O;O
Toxi;O;O
-;O;O
Lab;O;O
A;O;O
(;O;O
thin;O;O
-;O;O
layer;O;O
chromatographic;O;O
assay;O;O
);O;O
and;O;O
Emit;O;O
-;O;O
d.a.u;O;O
.;O;O
(;O;O
radioenzymatic;O;O
assay;O;O
);O;O
.;O;O
DDI-DrugBank.d412.s17;;
When;O;O
patients;O;O
being;O;O
treated;O;O
with;O;O
labetalol;B-drug;B-DDI-DrugBank.d412.s17.e0
have;O;O
a;O;O
positive;O;O
urine;O;O
test;O;O
for;O;O
amphetamine;B-drug;B-DDI-DrugBank.d412.s17.e1
using;O;O
these;O;O
techniques;O;O
confirmation;O;O
should;O;O
be;O;O
made;O;O
by;O;O
using;O;O
more;O;O
specific;O;O
methods;O;O
such;O;O
as;O;O
a;O;O
gas;O;O
chromatographic;O;O
-;O;O
mass;O;O
spectrometer;O;O
technique;O;O
.;O;O
DDI-DrugBank.d206.s0;;
Results;O;O
of;O;O
preliminary;O;O
studies;O;O
in;O;O
humans;O;O
and;O;O
rats;O;O
suggest;O;O
that;O;O
nonabsorbable;O;O
antacids;B-group;B-DDI-DrugBank.d206.s0.e0
given;O;O
concurrently;O;O
with;O;O
lactulose;B-drug;B-DDI-DrugBank.d206.s0.e1
may;O;O
inhibit;O;O
the;O;O
desired;O;O
lactulose;B-drug;B-DDI-DrugBank.d206.s0.e2
-;O;O
induced;O;O
drop;O;O
in;O;O
colonic;O;O
pH.;O;O
DDI-DrugBank.d206.s1;;
Therefore;O;O
,;O;O
a;O;O
possible;O;O
lack;O;O
of;O;O
desired;O;O
effect;O;O
of;O;O
treatment;O;O
should;O;O
be;O;O
taken;O;O
into;O;O
consideration;O;O
before;O;O
such;O;O
drugs;O;O
are;O;O
given;O;O
concomitantly;O;O
with;O;O
lactulose;B-drug;B-DDI-DrugBank.d206.s1.e0
.;O;O
DDI-DrugBank.d71.s0;;
Lamivudine;B-drug;B-DDI-DrugBank.d71.s0.e0
is;O;O
predominantly;O;O
eliminated;O;O
in;O;O
the;O;O
urine;O;O
by;O;O
active;O;O
organic;O;O
cationic;O;O
secretion;O;O
.;O;O
DDI-DrugBank.d71.s1;;
The;O;O
possibility;O;O
of;O;O
interactions;O;O
with;O;O
other;O;O
drugs;O;O
administered;O;O
concurrently;O;O
should;O;O
be;O;O
considered;O;O
,;O;O
particularly;O;O
when;O;O
their;O;O
main;O;O
route;O;O
of;O;O
elimination;O;O
is;O;O
active;O;O
renal;O;O
secretion;O;O
via;O;O
the;O;O
organic;O;O
cationic;O;O
transport;O;O
system;O;O
(;O;O
e.g.;O;O
,;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d71.s1.e0
);O;O
.;O;O
DDI-DrugBank.d71.s2;;
No;O;O
change;O;O
in;O;O
dose;O;O
of;O;O
either;O;O
drug;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d71.s3;;
There;O;O
is;O;O
no;O;O
information;O;O
regarding;O;O
the;O;O
effect;O;O
on;O;O
lamivudine;B-drug;B-DDI-DrugBank.d71.s3.e0
pharmacokinetics;O;O
of;O;O
higher;O;O
doses;O;O
of;O;O
TMP;B-drug;B-DDI-DrugBank.d71.s3.e1
/;O;O
SMX;B-drug;B-DDI-DrugBank.d71.s3.e2
such;O;O
as;O;O
those;O;O
used;O;O
to;O;O
treat;O;O
Pneumocystis;O;O
carinii;O;O
pneumonia;O;O
.;O;O
DDI-DrugBank.d71.s4;;
No;O;O
data;O;O
are;O;O
available;O;O
regarding;O;O
interactions;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
have;O;O
renal;O;O
clearance;O;O
mechanisms;O;O
similar;O;O
to;O;O
that;O;O
of;O;O
lamivudine;B-drug;B-DDI-DrugBank.d71.s4.e0
.;O;O
DDI-DrugBank.d71.s5;;
Lamivudine;B-drug;B-DDI-DrugBank.d71.s5.e0
and;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d71.s5.e1
may;O;O
inhibit;O;O
the;O;O
intracellular;O;O
phosphorylation;O;O
of;O;O
one;O;O
another;O;O
.;O;O
DDI-DrugBank.d71.s6;;
Therefore;O;O
,;O;O
use;O;O
of;O;O
lamivudine;B-drug;B-DDI-DrugBank.d71.s6.e0
in;O;O
combination;O;O
with;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d71.s6.e1
is;O;O
not;O;O
recommended;O;O
DDI-DrugBank.d71.s7;;
.;O;O
DDI-DrugBank.d71.s8;;
DDI-DrugBank.d431.s0;;
Lansoprazole;B-drug;B-DDI-DrugBank.d431.s0.e0
is;O;O
metabolized;O;O
through;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
,;O;O
specifically;O;O
through;O;O
the;O;O
CYP3A;O;O
and;O;O
CYP2C19;O;O
isozymes;O;O
.;O;O
DDI-DrugBank.d431.s1;;
Studies;O;O
have;O;O
shown;O;O
that;O;O
lansoprazole;B-drug;B-DDI-DrugBank.d431.s1.e0
does;O;O
not;O;O
have;O;O
clinically;O;O
significant;O;O
interactions;O;O
with;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
,;O;O
such;O;O
as;O;O
warfarin;B-drug;B-DDI-DrugBank.d431.s1.e1
,;O;O
antipyrine;B-drug;B-DDI-DrugBank.d431.s1.e2
,;O;O
indomethacin;B-drug;B-DDI-DrugBank.d431.s1.e3
,;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d431.s1.e4
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d431.s1.e5
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d431.s1.e6
,;O;O
prednisone;B-drug;B-DDI-DrugBank.d431.s1.e7
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d431.s1.e8
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d431.s1.e9
,;O;O
or;O;O
terfenadine;B-drug;B-DDI-DrugBank.d431.s1.e10
in;O;O
healthy;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d431.s2;;
These;O;O
compounds;O;O
are;O;O
metabolized;O;O
through;O;O
various;O;O
cytochrome;O;O
P450;O;O
isozymes;O;O
including;O;O
CYP1A2;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
CYP2D6;O;O
,;O;O
and;O;O
CYP3A.;O;O
DDI-DrugBank.d431.s3;;
When;O;O
lansoprazole;B-drug;B-DDI-DrugBank.d431.s3.e0
was;O;O
administered;O;O
concomitantly;O;O
with;O;O
theophylline;B-drug;B-DDI-DrugBank.d431.s3.e1
(;O;O
CYP1A2;O;O
,;O;O
CYP3A;O;O
);O;O
,;O;O
a;O;O
minor;O;O
increase;O;O
(;O;O
10;O;O
%;O;O
);O;O
in;O;O
the;O;O
clearance;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d431.s3.e2
was;O;O
seen;O;O
.;O;O
DDI-DrugBank.d431.s4;;
Because;O;O
the;O;O
small;O;O
magnitude;O;O
and;O;O
the;O;O
direction;O;O
of;O;O
the;O;O
effect;O;O
on;O;O
theophylline;B-drug;B-DDI-DrugBank.d431.s4.e0
clearance;O;O
,;O;O
this;O;O
interaction;O;O
is;O;O
unlikely;O;O
to;O;O
be;O;O
clinical;O;O
concern;O;O
.;O;O
DDI-DrugBank.d431.s5;;
Nonetheless;O;O
,;O;O
individual;O;O
patients;O;O
may;O;O
require;O;O
additional;O;O
titration;O;O
of;O;O
their;O;O
theophylline;B-drug;B-DDI-DrugBank.d431.s5.e0
dosage;O;O
when;O;O
lansoprazole;B-drug;B-DDI-DrugBank.d431.s5.e1
is;O;O
started;O;O
or;O;O
stopped;O;O
to;O;O
ensure;O;O
clinically;O;O
effective;O;O
blood;O;O
levels;O;O
.;O;O
DDI-DrugBank.d431.s6;;
Lansoprazole;B-drug;B-DDI-DrugBank.d431.s6.e0
has;O;O
also;O;O
been;O;O
shown;O;O
to;O;O
have;O;O
no;O;O
clinically;O;O
significant;O;O
interaction;O;O
with;O;O
amoxicillin;B-drug;B-DDI-DrugBank.d431.s6.e1
.;O;O
DDI-DrugBank.d431.s7;;
In;O;O
a;O;O
single;O;O
-;O;O
dose;O;O
crossover;O;O
study;O;O
examining;O;O
lansoprazole;B-drug;B-DDI-DrugBank.d431.s7.e0
30;O;O
mg;O;O
and;O;O
omeprazole;B-drug;B-DDI-DrugBank.d431.s7.e1
20;O;O
mg;O;O
each;O;O
administered;O;O
alone;O;O
and;O;O
concomitantly;O;O
with;O;O
sucralfate;B-drug;B-DDI-DrugBank.d431.s7.e2
1;O;O
gram;O;O
,;O;O
absorption;O;O
of;O;O
the;O;O
proton;B-group;B-DDI-DrugBank.d431.s7.e3
pump;I-group;I-DDI-DrugBank.d431.s7.e3
inhibitors;I-group;I-DDI-DrugBank.d431.s7.e3
was;O;O
delayed;O;O
and;O;O
their;O;O
bioavailability;O;O
was;O;O
reduced;O;O
by;O;O
17;O;O
%;O;O
and;O;O
16;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
when;O;O
administered;O;O
concomitantly;O;O
with;O;O
sucralfate;B-drug;B-DDI-DrugBank.d431.s7.e4
.;O;O
DDI-DrugBank.d431.s8;;
Therefore;O;O
,;O;O
proton;B-group;B-DDI-DrugBank.d431.s8.e0
pump;I-group;I-DDI-DrugBank.d431.s8.e0
inhibitors;I-group;I-DDI-DrugBank.d431.s8.e0
should;O;O
be;O;O
taken;O;O
at;O;O
least;O;O
30;O;O
minutes;O;O
prior;O;O
to;O;O
sucralfate;B-drug;B-DDI-DrugBank.d431.s8.e1
.;O;O
DDI-DrugBank.d431.s9;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
antacids;B-group;B-DDI-DrugBank.d431.s9.e0
were;O;O
administered;O;O
concomitantly;O;O
with;O;O
lansoprazole;B-drug;B-DDI-DrugBank.d431.s9.e1
delayed;O;O
-;O;O
release;O;O
capsules;O;O
,;O;O
DDI-DrugBank.d431.s10;;
this;O;O
did;O;O
not;O;O
interfere;O;O
with;O;O
its;O;O
effect;O;O
.;O;O
DDI-DrugBank.d431.s11;;
Lansoprazole;B-drug;B-DDI-DrugBank.d431.s11.e0
causes;O;O
a;O;O
profound;O;O
and;O;O
long;O;O
lasting;O;O
inhibition;O;O
of;O;O
gastric;O;O
acid;O;O
secretion;O;O
,;O;O
DDI-DrugBank.d431.s12;;
therefore;O;O
,;O;O
it;O;O
is;O;O
theoretically;O;O
possible;O;O
that;O;O
lansoprazole;B-drug;B-DDI-DrugBank.d431.s12.e0
may;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
drugs;O;O
where;O;O
gastric;O;O
pH;O;O
is;O;O
an;O;O
important;O;O
determinant;O;O
of;O;O
bioavailability;O;O
(;O;O
e.g.;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d431.s12.e1
,;O;O
ampicillin;B-drug;B-DDI-DrugBank.d431.s12.e2
esters;O;O
,;O;O
iron;B-drug;B-DDI-DrugBank.d431.s12.e3
salts;O;O
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d431.s12.e4
);O;O
.;O;O
DDI-DrugBank.d135.s0;;
Effects;O;O
of;O;O
Lapatinib;B-drug;B-DDI-DrugBank.d135.s0.e0
on;O;O
Drug;O;O
Metabolizing;O;O
Enzymes;O;O
and;O;O
Drug;O;O
Transport;O;O
Systems;O;O
Lapatinib;B-drug;B-DDI-DrugBank.d135.s0.e1
inhibits;O;O
CYP3A4;O;O
and;O;O
CYP2C8;O;O
in;O;O
vitro;O;O
at;O;O
clinically;O;O
relevant;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d135.s1;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
and;O;O
dose;O;O
reduction;O;O
of;O;O
the;O;O
concomitant;O;O
substrate;O;O
drug;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
dosing;O;O
lapatinib;B-drug;B-DDI-DrugBank.d135.s1.e0
concurrently;O;O
with;O;O
medications;O;O
with;O;O
narrow;O;O
therapeutic;O;O
windows;O;O
that;O;O
are;O;O
substrates;O;O
of;O;O
CYP3A4;O;O
or;O;O
CYP2C8;O;O
.;O;O
DDI-DrugBank.d135.s2;;
Lapatinib;B-drug;B-DDI-DrugBank.d135.s2.e0
did;O;O
not;O;O
significantly;O;O
inhibit;O;O
the;O;O
following;O;O
enzymes;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
:;O;O
CYP1A2;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2C19;O;O
,;O;O
and;O;O
CYP2D6;O;O
or;O;O
UGT;O;O
enzymes;O;O
in;O;O
vitro;O;O
,;O;O
however;O;O
,;O;O
the;O;O
clinical;O;O
significance;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d135.s3;;
Lapatinib;B-drug;B-DDI-DrugBank.d135.s3.e0
inhibits;O;O
human;O;O
P;O;O
-;O;O
glycoprotein;O;O
.;O;O
DDI-DrugBank.d135.s4;;
If;O;O
TYKERB;B-brand;B-DDI-DrugBank.d135.s4.e0
is;O;O
administered;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
substrates;O;O
of;O;O
Pgp;O;O
,;O;O
increased;O;O
concentrations;O;O
of;O;O
the;O;O
substrate;O;O
drug;O;O
are;O;O
likely;O;O
,;O;O
and;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
.;O;O
DDI-DrugBank.d135.s5;;
Drugs;O;O
that;O;O
Inhibit;O;O
or;O;O
Induce;O;O
Cytochrome;O;O
P450;O;O
3A4;O;O
Enzymes;O;O
Lapatinib;B-drug;B-DDI-DrugBank.d135.s5.e0
undergoes;O;O
extensive;O;O
metabolism;O;O
by;O;O
CYP3A4;O;O
,;O;O
and;O;O
concomitant;O;O
administration;O;O
of;O;O
strong;O;O
inhibitors;O;O
or;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
alter;O;O
lapatinib;B-drug;B-DDI-DrugBank.d135.s5.e1
concentrations;O;O
significantly;O;O
.;O;O
DDI-DrugBank.d135.s6;;
Dose;O;O
adjustment;O;O
of;O;O
lapatinib;B-drug;B-DDI-DrugBank.d135.s6.e0
should;O;O
be;O;O
considered;O;O
for;O;O
patients;O;O
who;O;O
must;O;O
receive;O;O
concomitant;O;O
strong;O;O
inhibitors;O;O
or;O;O
concomitant;O;O
strong;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d135.s7;;
Ketoconazole;B-drug;B-DDI-DrugBank.d135.s7.e0
:;O;O
In;O;O
healthy;O;O
subjects;O;O
receiving;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d135.s7.e1
,;O;O
a;O;O
CYP3A4;O;O
inhibitor;O;O
,;O;O
at;O;O
200;O;O
mg;O;O
twice;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
,;O;O
systemic;O;O
exposure;O;O
(;O;O
AUC;O;O
);O;O
to;O;O
lapatinib;B-drug;B-DDI-DrugBank.d135.s7.e2
was;O;O
increased;O;O
to;O;O
approximately;O;O
3.6;O;O
-;O;O
fold;O;O
of;O;O
control;O;O
and;O;O
half;O;O
-;O;O
life;O;O
increased;O;O
to;O;O
1.7;O;O
-;O;O
fold;O;O
of;O;O
control;O;O
.;O;O
DDI-DrugBank.d135.s8;;
Carbamazepine;B-drug;B-DDI-DrugBank.d135.s8.e0
:;O;O
In;O;O
healthy;O;O
subjects;O;O
receiving;O;O
the;O;O
CYP3A4;O;O
inducer;O;O
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d135.s8.e1
,;O;O
at;O;O
100;O;O
mg;O;O
twice;O;O
daily;O;O
for;O;O
3;O;O
days;O;O
and;O;O
200;O;O
mg;O;O
twice;O;O
daily;O;O
for;O;O
17;O;O
days;O;O
,;O;O
systemic;O;O
exposure;O;O
(;O;O
AUC;O;O
);O;O
to;O;O
lapatinib;B-drug;B-DDI-DrugBank.d135.s8.e2
was;O;O
decreased;O;O
approximately;O;O
72;O;O
%;O;O
.;O;O
DDI-DrugBank.d135.s9;;
Drugs;O;O
that;O;O
Inhibit;O;O
Drug;O;O
Transport;O;O
Systems;O;O
Lapatinib;B-drug;B-DDI-DrugBank.d135.s9.e0
is;O;O
a;O;O
substrate;O;O
of;O;O
the;O;O
efflux;O;O
transporter;O;O
P;O;O
-;O;O
glycoprotein;O;O
(;O;O
Pgp;O;O
,;O;O
ABCB1;O;O
);O;O
.;O;O
DDI-DrugBank.d135.s10;;
If;O;O
TYKERB;B-brand;B-DDI-DrugBank.d135.s10.e0
is;O;O
administered;O;O
with;O;O
drugs;O;O
that;O;O
inhibit;O;O
Pgp;O;O
,;O;O
increased;O;O
concentrations;O;O
of;O;O
lapatinib;B-drug;B-DDI-DrugBank.d135.s10.e1
are;O;O
likely;O;O
,;O;O
and;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
.;O;O
DDI-DrugBank.d135.s11;;
Other;O;O
Chemotherapy;O;O
Agents;O;O
In;O;O
a;O;O
separate;O;O
study;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
lapatinib;B-drug;B-DDI-DrugBank.d135.s11.e0
with;O;O
capecitabine;B-drug;B-DDI-DrugBank.d135.s11.e1
did;O;O
not;O;O
meaningfully;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
agent;O;O
(;O;O
or;O;O
the;O;O
metabolites;O;O
of;O;O
capecitabine;B-drug;B-DDI-DrugBank.d135.s11.e2
);O;O
.;O;O
DDI-DrugBank.d300.s0;;
No;O;O
formal;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d118.s0;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
precipitation;O;O
occurs;O;O
when;O;O
eye;O;O
drops;O;O
containing;O;O
thimerosal;B-drug_n;B-DDI-DrugBank.d118.s0.e0
are;O;O
mixed;O;O
with;O;O
latanoprost;B-drug;B-DDI-DrugBank.d118.s0.e1
.;O;O
DDI-DrugBank.d118.s1;;
If;O;O
such;O;O
drugs;O;O
are;O;O
used;O;O
they;O;O
should;O;O
be;O;O
administered;O;O
with;O;O
an;O;O
interval;O;O
of;O;O
at;O;O
least;O;O
5;O;O
minutes;O;O
between;O;O
applications;O;O
.;O;O
DDI-DrugBank.d41.s0;;
Cholestyramine;B-drug;B-DDI-DrugBank.d41.s0.e0
and;O;O
Charcoal;B-drug;B-DDI-DrugBank.d41.s0.e1
Administration;O;O
of;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d41.s0.e2
or;O;O
activated;B-drug;B-DDI-DrugBank.d41.s0.e3
charcoal;I-drug;I-DDI-DrugBank.d41.s0.e3
in;O;O
patients;O;O
(;O;O
n=13;O;O
);O;O
and;O;O
volunteers;O;O
(;O;O
n=96;O;O
);O;O
resulted;O;O
in;O;O
a;O;O
rapid;O;O
and;O;O
significant;O;O
decrease;O;O
in;O;O
plasma;O;O
M1;O;O
(;O;O
the;O;O
active;O;O
metabolite;O;O
of;O;O
leflunomide;B-drug;B-DDI-DrugBank.d41.s0.e4
);O;O
concentration;O;O
.;O;O
DDI-DrugBank.d41.s1;;
Hepatotoxic;O;O
Drugs;O;O
Increased;O;O
side;O;O
effects;O;O
may;O;O
occur;O;O
when;O;O
leflunomide;B-drug;B-DDI-DrugBank.d41.s1.e0
is;O;O
given;O;O
concomitantly;O;O
with;O;O
hepatotoxic;O;O
substances;O;O
.;O;O
DDI-DrugBank.d41.s2;;
This;O;O
is;O;O
also;O;O
to;O;O
be;O;O
considered;O;O
when;O;O
leflunomide;B-drug;B-DDI-DrugBank.d41.s2.e0
treatment;O;O
is;O;O
followed;O;O
by;O;O
such;O;O
drugs;O;O
without;O;O
a;O;O
drug;O;O
elimination;O;O
procedure;O;O
.;O;O
DDI-DrugBank.d41.s3;;
In;O;O
a;O;O
small;O;O
(;O;O
n=30;O;O
);O;O
combination;O;O
study;O;O
of;O;O
ARAVA;B-brand;B-DDI-DrugBank.d41.s3.e0
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d41.s3.e1
,;O;O
a;O;O
2;O;O
-;O;O
to;O;O
3;O;O
-;O;O
fold;O;O
elevation;O;O
in;O;O
liver;O;O
enzymes;O;O
was;O;O
seen;O;O
in;O;O
5;O;O
of;O;O
30;O;O
patients;O;O
.;O;O
DDI-DrugBank.d41.s4;;
All;O;O
elevations;O;O
resolved;O;O
,;O;O
2;O;O
with;O;O
continuation;O;O
of;O;O
both;O;O
drugs;O;O
and;O;O
3;O;O
after;O;O
discontinuation;O;O
of;O;O
leflunomide;B-drug;B-DDI-DrugBank.d41.s4.e0
.;O;O
DDI-DrugBank.d41.s5;;
A;O;O
3;O;O
-;O;O
fold;O;O
increase;O;O
was;O;O
seen;O;O
in;O;O
another;O;O
5;O;O
patients;O;O
.;O;O
DDI-DrugBank.d41.s6;;
All;O;O
of;O;O
these;O;O
also;O;O
resolved;O;O
,;O;O
2;O;O
with;O;O
continuation;O;O
of;O;O
both;O;O
drugs;O;O
and;O;O
3;O;O
after;O;O
discontinuation;O;O
of;O;O
leflunomide;B-drug;B-DDI-DrugBank.d41.s6.e0
.;O;O
DDI-DrugBank.d41.s7;;
Three;O;O
patients;O;O
met;O;O
ACR;O;O
criteria;O;O
for;O;O
liver;O;O
biopsy;O;O
(;O;O
1;O;O
:;O;O
Roegnik;O;O
Grade;O;O
I;O;O
,;O;O
2;O;O
:;O;O
Roegnik;O;O
Grade;O;O
IIIa;O;O
);O;O
.;O;O
DDI-DrugBank.d41.s8;;
No;O;O
pharmacokinetic;O;O
interaction;O;O
was;O;O
identified;O;O
.;O;O
DDI-DrugBank.d41.s9;;
NSAIDs;B-group;B-DDI-DrugBank.d41.s9.e0
:;O;O
In;O;O
in;O;O
vitro;O;O
studies;O;O
,;O;O
M1;O;O
was;O;O
shown;O;O
to;O;O
cause;O;O
increases;O;O
ranging;O;O
from;O;O
13;O;O
-;O;O
50;O;O
%;O;O
in;O;O
the;O;O
free;O;O
fraction;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d41.s9.e1
and;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d41.s9.e2
at;O;O
concentrations;O;O
in;O;O
the;O;O
clinical;O;O
range;O;O
.;O;O
DDI-DrugBank.d41.s10;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
finding;O;O
is;O;O
unknown;O;O
,;O;O
DDI-DrugBank.d41.s11;;
however;O;O
,;O;O
there;O;O
was;O;O
extensive;O;O
concomitant;O;O
use;O;O
of;O;O
NSAIDs;B-group;B-DDI-DrugBank.d41.s11.e0
in;O;O
clinical;O;O
studies;O;O
and;O;O
no;O;O
differential;O;O
effect;O;O
was;O;O
observed;O;O
.;O;O
DDI-DrugBank.d41.s12;;
Tolbutamide;B-drug;B-DDI-DrugBank.d41.s12.e0
:;O;O
In;O;O
in;O;O
vitro;O;O
studies;O;O
,;O;O
M1;O;O
was;O;O
shown;O;O
to;O;O
cause;O;O
increases;O;O
ranging;O;O
from;O;O
13;O;O
-;O;O
50;O;O
%;O;O
in;O;O
the;O;O
free;O;O
fraction;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d41.s12.e1
at;O;O
concentrations;O;O
in;O;O
the;O;O
clinical;O;O
range;O;O
.;O;O
DDI-DrugBank.d41.s13;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
finding;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d41.s14;;
Rifampin;B-drug;B-DDI-DrugBank.d41.s14.e0
:;O;O
Following;O;O
concomitant;O;O
administration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
ARAVA;B-brand;B-DDI-DrugBank.d41.s14.e1
to;O;O
subjects;O;O
receiving;O;O
multiple;O;O
doses;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d41.s14.e2
,;O;O
M1;O;O
peak;O;O
levels;O;O
were;O;O
increased;O;O
(;O;O
~40;O;O
%;O;O
);O;O
over;O;O
those;O;O
seen;O;O
when;O;O
ARAVA;B-brand;B-DDI-DrugBank.d41.s14.e3
was;O;O
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d41.s15;;
Because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
ARAVA;B-brand;B-DDI-DrugBank.d41.s15.e0
levels;O;O
to;O;O
continue;O;O
to;O;O
increase;O;O
with;O;O
multiple;O;O
dosing;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
if;O;O
patients;O;O
are;O;O
to;O;O
be;O;O
receiving;O;O
both;O;O
ARAVA;B-brand;B-DDI-DrugBank.d41.s15.e1
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d41.s15.e2
.;O;O
DDI-DrugBank.d41.s16;;
Warfarin;B-drug;B-DDI-DrugBank.d41.s16.e0
:;O;O
Increased;O;O
INR;O;O
(;O;O
International;O;O
Normalized;O;O
Ratio;O;O
);O;O
when;O;O
ARAVA;B-brand;B-DDI-DrugBank.d41.s16.e1
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d41.s16.e2
were;O;O
co;O;O
-;O;O
administered;O;O
has;O;O
been;O;O
rarely;O;O
reported;O;O
.;O;O
DDI-DrugBank.d169.s0;;
Results;O;O
from;O;O
human;O;O
in;O;O
vitro;O;O
metabolism;O;O
studies;O;O
and;O;O
nonclinical;O;O
studies;O;O
show;O;O
that;O;O
REVLIMID;B-brand;B-DDI-DrugBank.d169.s0.e0
(;O;O
lenalidomide;B-drug;B-DDI-DrugBank.d169.s0.e1
);O;O
is;O;O
neither;O;O
metabolized;O;O
by;O;O
nor;O;O
inhibits;O;O
or;O;O
induces;O;O
the;O;O
cytochrome;O;O
P450;O;O
pathway;O;O
suggesting;O;O
that;O;O
lenalidomide;B-drug;B-DDI-DrugBank.d169.s0.e2
is;O;O
not;O;O
likely;O;O
to;O;O
cause;O;O
or;O;O
be;O;O
subject;O;O
to;O;O
P450;O;O
-;O;O
based;O;O
metabolic;O;O
drug;O;O
interactions;O;O
in;O;O
man;O;O
.;O;O
DDI-DrugBank.d169.s1;;
Co;O;O
-;O;O
administration;O;O
of;O;O
multiple;O;O
doses;O;O
of;O;O
10;O;O
mg;O;O
of;O;O
lenalidomide;B-drug;B-DDI-DrugBank.d169.s1.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
single;O;O
dose;O;O
pharmacokinetics;O;O
of;O;O
R;B-drug;B-DDI-DrugBank.d169.s1.e1
-;I-drug;I-DDI-DrugBank.d169.s1.e1
and;I-drug;I-DDI-DrugBank.d169.s1.e1
S;I-drug;I-DDI-DrugBank.d169.s1.e2
-;I-drug;I-DDI-DrugBank.d169.s1.e2
warfarin;I-drug;I-DDI-DrugBank.d169.s1.e2
.;O;O
DDI-DrugBank.d169.s2;;
Co;O;O
-;O;O
administration;O;O
of;O;O
single;O;O
25;O;O
-;O;O
mg;O;O
dose;O;O
warfarin;B-drug;B-DDI-DrugBank.d169.s2.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
total;O;O
lenalidomide;B-drug;B-DDI-DrugBank.d169.s2.e1
.;O;O
DDI-DrugBank.d169.s3;;
Expected;O;O
changes;O;O
in;O;O
laboratory;O;O
assessments;O;O
of;O;O
PT;O;O
and;O;O
INR;O;O
were;O;O
observed;O;O
after;O;O
warfarin;B-drug;B-DDI-DrugBank.d169.s3.e0
administration;O;O
,;O;O
but;O;O
these;O;O
changes;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
concomitant;O;O
lenalidomide;B-drug;B-DDI-DrugBank.d169.s3.e1
administration;O;O
.;O;O
DDI-DrugBank.d52.s0;;
Concomitant;O;O
treatment;O;O
with;O;O
thrombolytics;B-group;B-DDI-DrugBank.d52.s0.e0
(;O;O
eg;O;O
,;O;O
rt;O;O
-;O;O
PA;O;O
or;O;O
streptokinase;B-drug;B-DDI-DrugBank.d52.s0.e1
);O;O
may;O;O
:;O;O
-;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
complications;O;O
-;O;O
considerably;O;O
enhance;O;O
the;O;O
effect;O;O
of;O;O
REFLUDAN;B-brand;B-DDI-DrugBank.d52.s0.e2
on;O;O
aPTT;O;O
prolongation;O;O
DDI-DrugBank.d52.s1;;
Concomitant;O;O
treatment;O;O
with;O;O
coumarin;B-group;B-DDI-DrugBank.d52.s1.e0
derivatives;I-group;I-DDI-DrugBank.d52.s1.e0
(;O;O
vitamin;B-group;B-DDI-DrugBank.d52.s1.e1
K;I-group;I-DDI-DrugBank.d52.s1.e1
antagonists;I-group;I-DDI-DrugBank.d52.s1.e1
);O;O
and;O;O
drugs;O;O
that;O;O
affect;O;O
platelet;O;O
function;O;O
may;O;O
also;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
bleeding;O;O
.;O;O
DDI-DrugBank.d157.s0;;
Clinical;O;O
interaction;O;O
studies;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d157.s0.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d157.s0.e1
indicated;O;O
that;O;O
the;O;O
coadministration;O;O
of;O;O
Femara;B-brand;B-DDI-DrugBank.d157.s0.e2
with;O;O
these;O;O
drugs;O;O
does;O;O
not;O;O
result;O;O
in;O;O
clinically;O;O
-;O;O
significant;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d157.s1;;
(;O;O
See;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
);O;O
Coadministration;O;O
of;O;O
Femara;B-brand;B-DDI-DrugBank.d157.s1.e0
and;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d157.s1.e1
20;O;O
mg;O;O
daily;O;O
resulted;O;O
in;O;O
a;O;O
reduction;O;O
of;O;O
letrozole;B-drug;B-DDI-DrugBank.d157.s1.e2
plasma;O;O
levels;O;O
by;O;O
38;O;O
%;O;O
on;O;O
average;O;O
.;O;O
DDI-DrugBank.d157.s2;;
There;O;O
is;O;O
no;O;O
clinical;O;O
experience;O;O
to;O;O
date;O;O
on;O;O
the;O;O
use;O;O
of;O;O
Femara;B-brand;B-DDI-DrugBank.d157.s2.e0
in;O;O
combination;O;O
with;O;O
other;O;O
anticancer;O;O
agents;O;O
.;O;O
DDI-DrugBank.d157.s3;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
-;O;O
Interactions;O;O
None;O;O
observed;O;O
.;O;O
DDI-DrugBank.d151.s0;;
Folic;B-drug;B-DDI-DrugBank.d151.s0.e0
acid;I-drug;I-DDI-DrugBank.d151.s0.e0
in;O;O
large;O;O
amounts;O;O
may;O;O
counteract;O;O
the;O;O
antiepileptic;O;O
effect;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d151.s0.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d151.s0.e2
and;O;O
primidone;B-drug;B-DDI-DrugBank.d151.s0.e3
,;O;O
and;O;O
increase;O;O
the;O;O
frequency;O;O
of;O;O
seizures;O;O
in;O;O
susceptible;O;O
pediatric;O;O
patients;O;O
.;O;O
DDI-DrugBank.d151.s1;;
Preliminary;O;O
animal;O;O
and;O;O
human;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
small;O;O
quantities;O;O
of;O;O
systemically;O;O
administered;O;O
leucovorin;B-drug;B-DDI-DrugBank.d151.s1.e0
enter;O;O
the;O;O
CSF;O;O
primarily;O;O
as;O;O
5;O;O
-;O;O
methyltetrahydro;O;O
-;O;O
folate;O;O
and;O;O
,;O;O
in;O;O
humans;O;O
,;O;O
remain;O;O
1;O;O
to;O;O
3;O;O
orders;O;O
of;O;O
magnitude;O;O
lower;O;O
than;O;O
the;O;O
usual;O;O
methotrexate;B-drug;B-DDI-DrugBank.d151.s1.e1
concentrations;O;O
following;O;O
intrathecal;O;O
administration;O;O
.;O;O
DDI-DrugBank.d151.s2;;
However;O;O
,;O;O
high;O;O
doses;O;O
of;O;O
leucovorin;B-drug;B-DDI-DrugBank.d151.s2.e0
may;O;O
reduce;O;O
the;O;O
efficacy;O;O
of;O;O
intrathecally;O;O
administered;O;O
methotrexate;B-drug;B-DDI-DrugBank.d151.s2.e1
.;O;O
DDI-DrugBank.d151.s3;;
Leucovorin;B-drug;B-DDI-DrugBank.d151.s3.e0
may;O;O
enhance;O;O
the;O;O
toxicity;O;O
of;O;O
5;B-drug;B-DDI-DrugBank.d151.s3.e1
-;I-drug;I-DDI-DrugBank.d151.s3.e1
fluorouracil;I-drug;I-DDI-DrugBank.d151.s3.e1
.;O;O
DDI-DrugBank.d381.s0;;
ERGAMISOL;B-brand;B-DDI-DrugBank.d381.s0.e0
(;O;O
levamisole;B-drug;B-DDI-DrugBank.d381.s0.e1
hydrochloride;I-drug;I-DDI-DrugBank.d381.s0.e1
);O;O
has;O;O
been;O;O
reported;O;O
to;O;O
produce;O;O
ANTABUSE;O;O
-;O;O
like;O;O
side;O;O
effects;O;O
when;O;O
given;O;O
concomitantly;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d381.s0.e2
.;O;O
DDI-DrugBank.d381.s1;;
The;O;O
physician;O;O
is;O;O
advised;O;O
to;O;O
monitor;O;O
plasma;O;O
levels;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d381.s1.e0
and;O;O
to;O;O
decrease;O;O
the;O;O
dose;O;O
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d381.s2;;
Because;O;O
of;O;O
reports;O;O
of;O;O
prolongation;O;O
of;O;O
the;O;O
prothrombin;O;O
time;O;O
beyond;O;O
the;O;O
therapeutic;O;O
range;O;O
in;O;O
patients;O;O
taking;O;O
concurrent;O;O
levamisole;B-drug;B-DDI-DrugBank.d381.s2.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d381.s2.e1
sodium;I-drug;I-DDI-DrugBank.d381.s2.e1
,;O;O
it;O;O
is;O;O
suggested;O;O
that;O;O
the;O;O
prothrombin;O;O
time;O;O
be;O;O
monitored;O;O
carefully;O;O
,;O;O
and;O;O
the;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d381.s2.e2
sodium;I-drug;I-DDI-DrugBank.d381.s2.e2
or;O;O
other;O;O
coumarin;B-group;B-DDI-DrugBank.d381.s2.e3
-;O;O
like;O;O
drugs;O;O
should;O;O
be;O;O
adjusted;O;O
accordingly;O;O
,;O;O
in;O;O
patients;O;O
taking;O;O
both;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d212.s0;;
in;O;O
vitro;O;O
data;O;O
on;O;O
metabolic;O;O
interactions;O;O
indicate;O;O
that;O;O
Keppra;B-brand;B-DDI-DrugBank.d212.s0.e0
is;O;O
unlikely;O;O
to;O;O
produce;O;O
,;O;O
or;O;O
be;O;O
subject;O;O
to;O;O
,;O;O
pharmacokinetic;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d212.s1;;
Levetiracetam;B-drug;B-DDI-DrugBank.d212.s1.e0
and;O;O
its;O;O
major;O;O
metabolite;O;O
,;O;O
at;O;O
concentrations;O;O
well;O;O
above;O;O
cmax;O;O
levels;O;O
achieved;O;O
within;O;O
the;O;O
therapeutic;O;O
dose;O;O
range;O;O
,;O;O
are;O;O
neither;O;O
inhibitors;O;O
of;O;O
nor;O;O
high;O;O
affinity;O;O
substrates;O;O
for;O;O
human;O;O
liver;O;O
cytochrome;O;O
P450;O;O
isoforms;O;O
,;O;O
epoxide;O;O
hydrolase;O;O
or;O;O
UDP;O;O
-;O;O
glucuronidation;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d212.s2;;
In;O;O
addition;O;O
,;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s2.e0
does;O;O
not;O;O
affect;O;O
the;O;O
in;O;O
vitro;O;O
glucuronidation;O;O
of;O;O
valproic;B-drug;B-DDI-DrugBank.d212.s2.e1
acid;I-drug;I-DDI-DrugBank.d212.s2.e1
.;O;O
DDI-DrugBank.d212.s3;;
Levetiracetam;B-drug;B-DDI-DrugBank.d212.s3.e0
circulates;O;O
largely;O;O
unbound;O;O
(;O;O
10;O;O
%;O;O
bound;O;O
);O;O
to;O;O
plasma;O;O
proteins;O;O
,;O;O
DDI-DrugBank.d212.s4;;
clinically;O;O
significant;O;O
interactions;O;O
with;O;O
other;O;O
drugs;O;O
through;O;O
competition;O;O
for;O;O
protein;O;O
binding;O;O
sites;O;O
are;O;O
therefore;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d212.s5;;
Potential;O;O
pharmacokinetic;O;O
interactions;O;O
were;O;O
assessed;O;O
in;O;O
clinical;O;O
pharmacokinetic;O;O
studies;O;O
(;O;O
phenytoin;B-drug;B-DDI-DrugBank.d212.s5.e0
,;O;O
valproate;B-drug;B-DDI-DrugBank.d212.s5.e1
,;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d212.s5.e2
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d212.s5.e3
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d212.s5.e4
,;O;O
probenecid;B-drug;B-DDI-DrugBank.d212.s5.e5
);O;O
and;O;O
through;O;O
pharmacokinetic;O;O
screening;O;O
in;O;O
the;O;O
placebo;O;O
-;O;O
controlled;O;O
clinical;O;O
studies;O;O
in;O;O
epilepsy;O;O
patients;O;O
.;O;O
DDI-DrugBank.d212.s6;;
Drug;O;O
-;O;O
Drug;O;O
Interactions;O;O
Between;O;O
Keppra;B-brand;B-DDI-DrugBank.d212.s6.e0
And;O;O
Other;O;O
Antiepileptic;B-group;B-DDI-DrugBank.d212.s6.e1
Drugs;I-group;I-DDI-DrugBank.d212.s6.e1
(;O;O
AEDs;B-group;B-DDI-DrugBank.d212.s6.e2
);O;O
Phenytoin;B-drug;B-DDI-DrugBank.d212.s6.e3
Keppra;I-brand;I-DDI-DrugBank.d212.s6.e4
(;O;O
3000;O;O
mg;O;O
daily;O;O
);O;O
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetic;O;O
disposition;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d212.s6.e5
in;O;O
patients;O;O
with;O;O
refractory;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d212.s7;;
Pharmacokinetics;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s7.e0
were;O;O
also;O;O
not;O;O
affected;O;O
by;O;O
phenytoin;B-drug;B-DDI-DrugBank.d212.s7.e1
.;O;O
DDI-DrugBank.d212.s8;;
Valproate;B-drug;B-DDI-DrugBank.d212.s8.e0
Keppra;I-brand;I-DDI-DrugBank.d212.s8.e1
(;O;O
1500;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
valproate;B-drug;B-DDI-DrugBank.d212.s8.e2
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d212.s9;;
Valproate;B-drug;B-DDI-DrugBank.d212.s9.e0
500;O;O
mg;O;O
twice;O;O
daily;O;O
did;O;O
not;O;O
modify;O;O
the;O;O
rate;O;O
or;O;O
extent;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s9.e1
absorption;O;O
or;O;O
its;O;O
plasma;O;O
clearance;O;O
or;O;O
urinary;O;O
excretion;O;O
.;O;O
DDI-DrugBank.d212.s10;;
There;O;O
also;O;O
was;O;O
no;O;O
effect;O;O
on;O;O
exposure;O;O
to;O;O
and;O;O
the;O;O
excretion;O;O
of;O;O
the;O;O
primary;O;O
metabolite;O;O
,;O;O
ucb;O;O
L057;O;O
.;O;O
DDI-DrugBank.d212.s11;;
Potential;O;O
drug;O;O
interactions;O;O
between;O;O
Keppra;B-brand;B-DDI-DrugBank.d212.s11.e0
and;O;O
other;O;O
AEDs;B-group;B-DDI-DrugBank.d212.s11.e1
(;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d212.s11.e2
,;O;O
gabapentin;B-drug;B-DDI-DrugBank.d212.s11.e3
,;O;O
lamotrigine;B-drug;B-DDI-DrugBank.d212.s11.e4
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d212.s11.e5
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d212.s11.e6
,;O;O
primidone;B-drug;B-DDI-DrugBank.d212.s11.e7
and;O;O
valproate;B-drug;B-DDI-DrugBank.d212.s11.e8
);O;O
were;O;O
also;O;O
assessed;O;O
by;O;O
evaluating;O;O
the;O;O
serum;O;O
concentrations;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s11.e9
and;O;O
these;O;O
AEDs;B-group;B-DDI-DrugBank.d212.s11.e10
during;O;O
placebo;O;O
-;O;O
controlled;O;O
clinical;O;O
studies;O;O
.;O;O
DDI-DrugBank.d212.s12;;
These;O;O
data;O;O
indicate;O;O
that;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s12.e0
does;O;O
not;O;O
influence;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
other;O;O
AEDs;B-group;B-DDI-DrugBank.d212.s12.e1
and;O;O
that;O;O
these;O;O
AEDs;B-group;B-DDI-DrugBank.d212.s12.e2
do;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s12.e3
.;O;O
DDI-DrugBank.d212.s13;;
Effect;O;O
of;O;O
AEDs;B-group;B-DDI-DrugBank.d212.s13.e0
in;O;O
Pediatric;O;O
Patients;O;O
There;O;O
was;O;O
about;O;O
a;O;O
22;O;O
%;O;O
increase;O;O
of;O;O
apparent;O;O
total;O;O
body;O;O
clearance;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s13.e1
when;O;O
it;O;O
was;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
enzyme;O;O
-;O;O
inducing;O;O
AEDs;B-group;B-DDI-DrugBank.d212.s13.e2
.;O;O
DDI-DrugBank.d212.s14;;
Dose;O;O
adjustment;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
Levetiracetam;B-drug;B-DDI-DrugBank.d212.s14.e0
had;O;O
no;O;O
effect;O;O
on;O;O
plasma;O;O
concentrations;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d212.s14.e1
,;O;O
valproate;B-drug;B-DDI-DrugBank.d212.s14.e2
,;O;O
topiramate;B-drug;B-DDI-DrugBank.d212.s14.e3
,;O;O
or;O;O
lamotrigine;B-drug;B-DDI-DrugBank.d212.s14.e4
.;O;O
DDI-DrugBank.d212.s15;;
Other;O;O
Drug;O;O
Interactions;O;O
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d212.s15.e0
Keppra;I-brand;I-DDI-DrugBank.d212.s15.e1
(;O;O
500;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
did;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d212.s15.e2
containing;O;O
0.03;O;O
mg;O;O
ethinyl;B-drug;B-DDI-DrugBank.d212.s15.e3
estradiol;I-drug;I-DDI-DrugBank.d212.s15.e3
and;O;O
0.15;O;O
mg;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d212.s15.e4
,;O;O
or;O;O
of;O;O
the;O;O
luteinizing;O;O
hormone;O;O
and;O;O
progesterone;O;O
levels;O;O
,;O;O
indicating;O;O
that;O;O
impairment;O;O
of;O;O
contraceptive;O;O
efficacy;O;O
is;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d212.s16;;
Coadministration;O;O
of;O;O
this;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d212.s16.e0
did;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s16.e1
.;O;O
DDI-DrugBank.d212.s17;;
Digoxin;B-drug;B-DDI-DrugBank.d212.s17.e0
Keppra;I-brand;I-DDI-DrugBank.d212.s17.e1
(;O;O
1000;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
did;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
and;O;O
pharmacodynamics;O;O
(;O;O
ECG;O;O
);O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d212.s17.e2
given;O;O
as;O;O
a;O;O
0.25;O;O
mg;O;O
dose;O;O
every;O;O
day;O;O
.;O;O
DDI-DrugBank.d212.s18;;
Coadministration;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d212.s18.e0
did;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s18.e1
.;O;O
DDI-DrugBank.d212.s19;;
Warfarin;B-drug;B-DDI-DrugBank.d212.s19.e0
Keppra;I-brand;I-DDI-DrugBank.d212.s19.e1
(;O;O
1000;O;O
mg;O;O
twice;O;O
daily;O;O
);O;O
did;O;O
not;O;O
influence;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
R;B-drug;B-DDI-DrugBank.d212.s19.e2
and;I-drug;I-DDI-DrugBank.d212.s19.e2
S;I-drug;I-DDI-DrugBank.d212.s19.e3
warfarin;I-drug;I-DDI-DrugBank.d212.s19.e3
.;O;O
DDI-DrugBank.d212.s20;;
Prothrombin;O;O
time;O;O
was;O;O
not;O;O
affected;O;O
by;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s20.e0
.;O;O
DDI-DrugBank.d212.s21;;
Coadministration;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d212.s21.e0
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s21.e1
.;O;O
DDI-DrugBank.d212.s22;;
Probenecid;B-drug;B-DDI-DrugBank.d212.s22.e0
:;O;O
Probenecid;B-drug;B-DDI-DrugBank.d212.s22.e1
,;O;O
a;O;O
renal;O;O
tubular;O;O
secretion;O;O
blocking;O;O
agent;O;O
,;O;O
administered;O;O
at;O;O
a;O;O
dose;O;O
of;O;O
500;O;O
mg;O;O
four;O;O
times;O;O
a;O;O
day;O;O
,;O;O
did;O;O
not;O;O
change;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
levetiracetam;B-drug;B-DDI-DrugBank.d212.s22.e2
1000;O;O
mg;O;O
twice;O;O
daily;O;O
.;O;O
DDI-DrugBank.d212.s23;;
Cssmax;O;O
of;O;O
the;O;O
metabolite;O;O
,;O;O
ucb;O;O
L057;O;O
,;O;O
was;O;O
approximately;O;O
doubled;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d212.s23.e0
while;O;O
the;O;O
fraction;O;O
of;O;O
drug;O;O
excreted;O;O
unchanged;O;O
in;O;O
the;O;O
urine;O;O
remained;O;O
the;O;O
same;O;O
.;O;O
DDI-DrugBank.d212.s24;;
Renal;O;O
clearance;O;O
of;O;O
ucb;O;O
L057;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d212.s24.e0
decreased;O;O
60;O;O
%;O;O
,;O;O
probably;O;O
related;O;O
to;O;O
competitive;O;O
inhibition;O;O
of;O;O
tubular;O;O
secretion;O;O
of;O;O
ucb;O;O
L057;O;O
.;O;O
DDI-DrugBank.d212.s25;;
The;O;O
effect;O;O
of;O;O
Keppra;B-brand;B-DDI-DrugBank.d212.s25.e0
on;O;O
probenecid;B-drug;B-DDI-DrugBank.d212.s25.e1
was;O;O
not;O;O
studied;O;O
.;O;O
DDI-DrugBank.d252.s0;;
Although;O;O
BETAGAN;B-brand;B-DDI-DrugBank.d252.s0.e0
used;O;O
alone;O;O
has;O;O
little;O;O
or;O;O
no;O;O
effect;O;O
on;O;O
pupil;O;O
size;O;O
,;O;O
mydriasis;O;O
resulting;O;O
from;O;O
concomitant;O;O
therapy;O;O
with;O;O
BETAGAN;B-brand;B-DDI-DrugBank.d252.s0.e1
and;O;O
epinephrine;B-drug;B-DDI-DrugBank.d252.s0.e2
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d252.s1;;
Close;O;O
observation;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
recommended;O;O
when;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d252.s1.e0
-;I-group;I-DDI-DrugBank.d252.s1.e0
blocker;I-group;I-DDI-DrugBank.d252.s1.e0
is;O;O
administered;O;O
to;O;O
patients;O;O
receiving;O;O
catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
such;O;O
as;O;O
reserpine;B-drug;B-DDI-DrugBank.d252.s1.e1
,;O;O
because;O;O
of;O;O
possible;O;O
additive;O;O
effects;O;O
and;O;O
the;O;O
production;O;O
of;O;O
hypotension;O;O
and/or;O;O
marked;O;O
bradycardia;O;O
,;O;O
which;O;O
may;O;O
produce;O;O
vertigo;O;O
,;O;O
syncope;O;O
or;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d252.s2;;
Patients;O;O
receiving;O;O
beta;B-group;B-DDI-DrugBank.d252.s2.e0
-;I-group;I-DDI-DrugBank.d252.s2.e0
adrenergic;I-group;I-DDI-DrugBank.d252.s2.e0
blocking;I-group;I-DDI-DrugBank.d252.s2.e0
agents;I-group;I-DDI-DrugBank.d252.s2.e0
along;O;O
with;O;O
either;O;O
oral;O;O
or;O;O
intravenous;O;O
calcium;B-group;B-DDI-DrugBank.d252.s2.e1
antagonists;I-group;I-DDI-DrugBank.d252.s2.e1
should;O;O
be;O;O
monitored;O;O
for;O;O
possible;O;O
atrioventricular;O;O
conduction;O;O
disturbances;O;O
,;O;O
left;O;O
ventricular;O;O
failure;O;O
and;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d252.s3;;
In;O;O
patients;O;O
with;O;O
impaired;O;O
cardiac;O;O
function;O;O
,;O;O
simultaneous;O;O
use;O;O
should;O;O
be;O;O
avoided;O;O
altogether;O;O
.;O;O
DDI-DrugBank.d252.s4;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d252.s4.e0
-;I-group;I-DDI-DrugBank.d252.s4.e0
adrenergic;I-group;I-DDI-DrugBank.d252.s4.e0
blocking;I-group;I-DDI-DrugBank.d252.s4.e0
agents;I-group;I-DDI-DrugBank.d252.s4.e0
with;O;O
digitalis;B-group;B-DDI-DrugBank.d252.s4.e1
and;O;O
calcium;B-group;B-DDI-DrugBank.d252.s4.e2
antagonists;I-group;I-DDI-DrugBank.d252.s4.e2
may;O;O
have;O;O
additive;O;O
effects;O;O
on;O;O
prolonging;O;O
atrioventricular;O;O
conduction;O;O
time;O;O
.;O;O
DDI-DrugBank.d252.s5;;
Phenothiazine;B-group;B-DDI-DrugBank.d252.s5.e0
-;I-group;I-DDI-DrugBank.d252.s5.e0
related;I-group;I-DDI-DrugBank.d252.s5.e0
compounds;I-group;I-DDI-DrugBank.d252.s5.e0
and;O;O
beta;B-group;B-DDI-DrugBank.d252.s5.e1
-;I-group;I-DDI-DrugBank.d252.s5.e1
adrenergic;I-group;I-DDI-DrugBank.d252.s5.e1
blocking;I-group;I-DDI-DrugBank.d252.s5.e1
agents;I-group;I-DDI-DrugBank.d252.s5.e1
may;O;O
have;O;O
additive;O;O
hypotensite;O;O
effects;O;O
due;O;O
to;O;O
the;O;O
inhibition;O;O
of;O;O
each;O;O
other;O;O
s;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d320.s0;;
Chirocaine;B-brand;B-DDI-DrugBank.d320.s0.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
other;O;O
local;O;O
anesthetics;B-group;B-DDI-DrugBank.d320.s0.e1
or;O;O
agents;O;O
structurally;O;O
related;O;O
to;O;O
amide;O;O
-;O;O
type;O;O
local;O;O
anesthetics;O;O
since;O;O
the;O;O
toxic;O;O
effects;O;O
of;O;O
these;O;O
drugs;O;O
could;O;O
be;O;O
additive;O;O
.;O;O
DDI-DrugBank.d320.s1;;
In;O;O
vitro;O;O
studies;O;O
indicate;O;O
CYP3A4;O;O
isoform;O;O
and;O;O
CYP1A2;O;O
isoform;O;O
mediate;O;O
the;O;O
metabolism;O;O
of;O;O
levobupivacaine;B-drug;B-DDI-DrugBank.d320.s1.e0
to;O;O
desbutyl;B-drug_n;B-DDI-DrugBank.d320.s1.e1
levobupivacaine;I-drug_n;I-DDI-DrugBank.d320.s1.e1
and;O;O
3;B-drug_n;B-DDI-DrugBank.d320.s1.e2
-;I-drug_n;I-DDI-DrugBank.d320.s1.e2
hydroxy;I-drug_n;I-DDI-DrugBank.d320.s1.e2
levobupivacaine;I-drug_n;I-DDI-DrugBank.d320.s1.e2
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d320.s2;;
Thus;O;O
agents;O;O
likely;O;O
to;O;O
be;O;O
concomitantly;O;O
administered;O;O
with;O;O
Chirocaine;B-brand;B-DDI-DrugBank.d320.s2.e0
that;O;O
are;O;O
metabolized;O;O
by;O;O
this;O;O
isoenzyme;O;O
family;O;O
may;O;O
potentially;O;O
interact;O;O
with;O;O
Chirocaine;B-brand;B-DDI-DrugBank.d320.s2.e1
.;O;O
DDI-DrugBank.d320.s3;;
Although;O;O
no;O;O
clinical;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
,;O;O
it;O;O
is;O;O
likely;O;O
that;O;O
the;O;O
metabolism;O;O
of;O;O
levobupivacaine;B-drug;B-DDI-DrugBank.d320.s3.e0
may;O;O
be;O;O
affected;O;O
by;O;O
the;O;O
known;O;O
CYP3A4;O;O
inducers;O;O
(;O;O
such;O;O
as;O;O
phenytoin;B-drug;B-DDI-DrugBank.d320.s3.e1
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d320.s3.e2
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d320.s3.e3
);O;O
,;O;O
CYP3A4;O;O
inhibitors;O;O
(;O;O
azole;O;O
antimycotics;O;O
e.g.;O;O
,;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d320.s3.e4
,;O;O
DDI-DrugBank.d320.s4;;
certain;O;O
protease;B-group;B-DDI-DrugBank.d320.s4.e0
inhibitors;I-group;I-DDI-DrugBank.d320.s4.e0
e.g.;O;O
,;O;O
ritanovir;O;O
,;O;O
DDI-DrugBank.d320.s5;;
macrolide;B-group;B-DDI-DrugBank.d320.s5.e0
antibiotics;I-group;I-DDI-DrugBank.d320.s5.e0
e.g.;O;O
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d320.s5.e1
,;O;O
DDI-DrugBank.d320.s6;;
and;O;O
calcium;B-group;B-DDI-DrugBank.d320.s6.e0
channel;I-group;I-DDI-DrugBank.d320.s6.e0
antagonists;I-group;I-DDI-DrugBank.d320.s6.e0
e.g.;O;O
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d320.s6.e1
);O;O
,;O;O
CYP1A2;O;O
inducers;O;O
(;O;O
omeprazole;B-drug;B-DDI-DrugBank.d320.s6.e2
);O;O
and;O;O
CYP1A2;O;O
inhibitors;O;O
(;O;O
furafylline;B-drug;B-DDI-DrugBank.d320.s6.e3
and;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d320.s6.e4
);O;O
.;O;O
DDI-DrugBank.d320.s7;;
Dosage;O;O
adjustment;O;O
may;O;O
be;O;O
warranted;O;O
when;O;O
levobupivacaine;B-drug;B-DDI-DrugBank.d320.s7.e0
is;O;O
concurrently;O;O
administered;O;O
with;O;O
CYP3A4;O;O
inhibitors;O;O
and;O;O
CYP1A2;O;O
inhibitors;O;O
as;O;O
systemic;O;O
levobupivacaine;B-drug;B-DDI-DrugBank.d320.s7.e1
levels;O;O
may;O;O
rise;O;O
resulting;O;O
in;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d242.s0;;
Specific;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
with;O;O
Levofloxacin;B-drug;B-DDI-DrugBank.d242.s0.e0
.;O;O
DDI-DrugBank.d242.s1;;
However;O;O
,;O;O
the;O;O
systemic;O;O
administration;O;O
of;O;O
some;O;O
quinolones;B-group;B-DDI-DrugBank.d242.s1.e0
has;O;O
been;O;O
shown;O;O
to;O;O
elevate;O;O
plasma;O;O
concentrations;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d242.s1.e1
,;O;O
interfere;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d242.s1.e2
,;O;O
and;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
the;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d242.s1.e3
warfarin;I-drug;I-DDI-DrugBank.d242.s1.e4
and;O;O
its;O;O
derivatives;O;O
,;O;O
and;O;O
has;O;O
been;O;O
associated;O;O
with;O;O
transient;O;O
elevations;O;O
in;O;O
serum;O;O
creatinine;O;O
in;O;O
patients;O;O
receiving;O;O
systemic;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d242.s1.e5
concomitantly;O;O
.;O;O
DDI-DrugBank.d257.s0;;
Interactions;O;O
with;O;O
Other;O;O
CNS;O;O
Agents;O;O
:;O;O
Concurrent;O;O
use;O;O
of;O;O
Levo;B-brand;B-DDI-DrugBank.d257.s0.e0
-;I-brand;I-DDI-DrugBank.d257.s0.e0
Dromoran;I-brand;I-DDI-DrugBank.d257.s0.e0
with;O;O
all;O;O
central;B-group;B-DDI-DrugBank.d257.s0.e1
nervous;I-group;I-DDI-DrugBank.d257.s0.e1
system;I-group;I-DDI-DrugBank.d257.s0.e1
depressants;I-group;I-DDI-DrugBank.d257.s0.e1
(;O;O
eg;O;O
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d257.s0.e2
,;O;O
sedatives;B-group;B-DDI-DrugBank.d257.s0.e3
,;O;O
hypnotics;B-group;B-DDI-DrugBank.d257.s0.e4
,;O;O
other;O;O
opioids;B-group;B-DDI-DrugBank.d257.s0.e5
,;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d257.s0.e6
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d257.s0.e7
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d257.s0.e8
antidepressants;I-group;I-DDI-DrugBank.d257.s0.e8
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d257.s0.e9
,;O;O
tranquilizers;B-group;B-DDI-DrugBank.d257.s0.e10
,;O;O
skeletal;B-group;B-DDI-DrugBank.d257.s0.e11
muscle;I-group;I-DDI-DrugBank.d257.s0.e11
relaxants;I-group;I-DDI-DrugBank.d257.s0.e11
and;O;O
antihistamines;B-group;B-DDI-DrugBank.d257.s0.e12
);O;O
may;O;O
result;O;O
in;O;O
additive;O;O
central;O;O
nervous;O;O
system;O;O
depressant;O;O
effects;O;O
.;O;O
DDI-DrugBank.d257.s1;;
Respiratory;O;O
depression;O;O
,;O;O
hypotension;O;O
,;O;O
and;O;O
profound;O;O
sedation;O;O
or;O;O
coma;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d257.s2;;
When;O;O
such;O;O
combined;O;O
therapy;O;O
is;O;O
contemplated;O;O
,;O;O
the;O;O
dose;O;O
of;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d257.s3;;
Although;O;O
no;O;O
interaction;O;O
between;O;O
MAO;B-group;B-DDI-DrugBank.d257.s3.e0
inhibitors;I-group;I-DDI-DrugBank.d257.s3.e0
and;O;O
Levo;B-brand;B-DDI-DrugBank.d257.s3.e1
-;I-brand;I-DDI-DrugBank.d257.s3.e1
Dromoran;I-brand;I-DDI-DrugBank.d257.s3.e1
has;O;O
been;O;O
observed;O;O
,;O;O
it;O;O
is;O;O
not;O;O
recommended;O;O
for;O;O
use;O;O
with;O;O
MAO;B-group;B-DDI-DrugBank.d257.s3.e2
inhibitors;I-group;I-DDI-DrugBank.d257.s3.e2
.;O;O
DDI-DrugBank.d257.s4;;
Most;O;O
cases;O;O
of;O;O
serious;O;O
or;O;O
fatal;O;O
adverse;O;O
events;O;O
involving;O;O
Levo;B-brand;B-DDI-DrugBank.d257.s4.e0
-;I-brand;I-DDI-DrugBank.d257.s4.e0
Dromoran;I-brand;I-DDI-DrugBank.d257.s4.e0
reported;O;O
to;O;O
the;O;O
manufacturer;O;O
or;O;O
the;O;O
FDA;O;O
have;O;O
involved;O;O
either;O;O
the;O;O
administration;O;O
of;O;O
large;O;O
initial;O;O
doses;O;O
or;O;O
too;O;O
frequent;O;O
doses;O;O
of;O;O
the;O;O
drug;O;O
to;O;O
nonopioid;O;O
tolerant;O;O
patients;O;O
,;O;O
or;O;O
the;O;O
simultaneous;O;O
administration;O;O
of;O;O
levorphanol;B-drug;B-DDI-DrugBank.d257.s4.e1
with;O;O
other;O;O
drugs;O;O
affecting;O;O
respiration;O;O
.;O;O
DDI-DrugBank.d257.s5;;
The;O;O
initial;O;O
dose;O;O
of;O;O
levorphanol;B-drug;B-DDI-DrugBank.d257.s5.e0
should;O;O
be;O;O
reduced;O;O
by;O;O
approximately;O;O
50;O;O
%;O;O
or;O;O
more;O;O
when;O;O
it;O;O
is;O;O
given;O;O
to;O;O
patients;O;O
along;O;O
with;O;O
another;O;O
drug;O;O
affecting;O;O
respiration;O;O
.;O;O
DDI-DrugBank.d257.s6;;
Interactions;O;O
with;O;O
Mixed;B-group;B-DDI-DrugBank.d257.s6.e0
Agonist;I-group;I-DDI-DrugBank.d257.s6.e0
/;I-group;I-DDI-DrugBank.d257.s6.e0
Antagonist;I-group;I-DDI-DrugBank.d257.s6.e0
Opioid;I-group;I-DDI-DrugBank.d257.s6.e0
Analgesics;I-group;I-DDI-DrugBank.d257.s6.e0
:;O;O
Agonist;B-group;B-DDI-DrugBank.d257.s6.e1
/;I-group;I-DDI-DrugBank.d257.s6.e1
antagonist;I-group;I-DDI-DrugBank.d257.s6.e1
analgesics;I-group;I-DDI-DrugBank.d257.s6.e1
(;O;O
eg;O;O
,;O;O
pentazocine;B-drug;B-DDI-DrugBank.d257.s6.e2
,;O;O
nalbuphine;B-drug;B-DDI-DrugBank.d257.s6.e3
,;O;O
butorphanol;B-drug;B-DDI-DrugBank.d257.s6.e4
,;O;O
dezocine;B-drug;B-DDI-DrugBank.d257.s6.e5
and;O;O
buprenorphine;B-drug;B-DDI-DrugBank.d257.s6.e6
);O;O
should;O;O
NOT;O;O
be;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
who;O;O
has;O;O
received;O;O
or;O;O
is;O;O
receiving;O;O
a;O;O
course;O;O
of;O;O
therapy;O;O
with;O;O
a;O;O
pure;B-group;B-DDI-DrugBank.d257.s6.e7
agonist;I-group;I-DDI-DrugBank.d257.s6.e7
opioid;I-group;I-DDI-DrugBank.d257.s6.e7
analgesic;I-group;I-DDI-DrugBank.d257.s6.e7
such;O;O
as;O;O
Levo;B-brand;B-DDI-DrugBank.d257.s6.e8
-;I-brand;I-DDI-DrugBank.d257.s6.e8
Dromoran;I-brand;I-DDI-DrugBank.d257.s6.e8
.;O;O
DDI-DrugBank.d257.s7;;
In;O;O
opioid;B-group;B-DDI-DrugBank.d257.s7.e0
-;O;O
dependent;O;O
patients;O;O
,;O;O
mixed;B-group;B-DDI-DrugBank.d257.s7.e1
agonist;I-group;I-DDI-DrugBank.d257.s7.e1
/;I-group;I-DDI-DrugBank.d257.s7.e1
antagonist;I-group;I-DDI-DrugBank.d257.s7.e1
analgesics;I-group;I-DDI-DrugBank.d257.s7.e1
may;O;O
precipitate;O;O
withdrawal;O;O
symptoms;O;O
.;O;O
DDI-DrugBank.d189.s0;;
No;O;O
Important;O;O
Interactions;O;O
To;O;O
Date;O;O
Levosimendan;B-drug;B-DDI-DrugBank.d189.s0.e0
does;O;O
not;O;O
have;O;O
clinically;O;O
important;O;O
pharmacokinetic;O;O
interactions;O;O
with;O;O
captopril;B-drug;B-DDI-DrugBank.d189.s0.e1
,;O;O
beta;B-group;B-DDI-DrugBank.d189.s0.e2
-;I-group;I-DDI-DrugBank.d189.s0.e2
blockers;I-group;I-DDI-DrugBank.d189.s0.e2
,;O;O
felodipine;B-drug;B-DDI-DrugBank.d189.s0.e3
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d189.s0.e4
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d189.s0.e5
,;O;O
isosorbide;B-drug;B-DDI-DrugBank.d189.s0.e6
mononitrate;I-drug;I-DDI-DrugBank.d189.s0.e6
,;O;O
carvedilol;B-drug;B-DDI-DrugBank.d189.s0.e7
,;O;O
ethanol;B-drug;B-DDI-DrugBank.d189.s0.e8
or;O;O
itraconazole;B-drug;B-DDI-DrugBank.d189.s0.e9
.;O;O
DDI-DrugBank.d411.s0;;
The;O;O
magnitude;O;O
and;O;O
relative;O;O
importance;O;O
of;O;O
the;O;O
effects;O;O
noted;O;O
below;O;O
are;O;O
likely;O;O
to;O;O
be;O;O
patient;O;O
specific;O;O
and;O;O
may;O;O
vary;O;O
by;O;O
such;O;O
factors;O;O
as;O;O
age;O;O
,;O;O
gender;O;O
,;O;O
race;O;O
,;O;O
intercurrent;O;O
illnesses;O;O
,;O;O
dose;O;O
of;O;O
either;O;O
agent;O;O
,;O;O
additional;O;O
concomitant;O;O
medications;O;O
,;O;O
and;O;O
timing;O;O
of;O;O
drug;O;O
administration;O;O
.;O;O
DDI-DrugBank.d411.s1;;
Any;O;O
agent;O;O
that;O;O
alters;O;O
thyroid;O;O
hormone;O;O
synthesis;O;O
,;O;O
secretion;O;O
,;O;O
distribution;O;O
,;O;O
effect;O;O
on;O;O
target;O;O
tissues;O;O
,;O;O
metabolism;O;O
,;O;O
or;O;O
elimination;O;O
may;O;O
alter;O;O
the;O;O
optimal;O;O
therapeutic;O;O
dose;O;O
of;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d411.s1.e0
sodium;O;O
.;O;O
DDI-DrugBank.d411.s2;;
Levothyroxine;B-drug;B-DDI-DrugBank.d411.s2.e0
Sodium;I-drug;I-DDI-DrugBank.d411.s2.e0
Absorption;O;O
:;O;O
The;O;O
following;O;O
agents;O;O
may;O;O
bind;O;O
and;O;O
decrease;O;O
absorption;O;O
of;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d411.s2.e1
sodium;I-drug;I-DDI-DrugBank.d411.s2.e1
from;O;O
the;O;O
gastrointestinal;O;O
tract;O;O
:;O;O
aluminum;B-drug;B-DDI-DrugBank.d411.s2.e2
hydoxide;I-drug;I-DDI-DrugBank.d411.s2.e2
,;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d411.s2.e3
resin;O;O
,;O;O
colestipol;B-drug;B-DDI-DrugBank.d411.s2.e4
hydrochloride;I-drug;I-DDI-DrugBank.d411.s2.e4
,;O;O
ferrous;B-drug;B-DDI-DrugBank.d411.s2.e5
sulfate;I-drug;I-DDI-DrugBank.d411.s2.e5
,;O;O
sodium;B-drug;B-DDI-DrugBank.d411.s2.e6
polystyrene;I-drug;I-DDI-DrugBank.d411.s2.e6
sulfonate;I-drug;I-DDI-DrugBank.d411.s2.e6
,;O;O
soybean;O;O
flour;O;O
(;O;O
e.g.;O;O
,;O;O
infant;O;O
formula;O;O
);O;O
,;O;O
sucralfate;B-drug;B-DDI-DrugBank.d411.s2.e7
.;O;O
DDI-DrugBank.d411.s3;;
Binding;O;O
to;O;O
Serum;O;O
Proteins;O;O
:;O;O
The;O;O
following;O;O
agents;O;O
may;O;O
either;O;O
inhibit;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d411.s3.e0
sodium;I-drug;I-DDI-DrugBank.d411.s3.e0
binding;O;O
to;O;O
serum;O;O
proteins;O;O
or;O;O
alter;O;O
the;O;O
concentrations;O;O
of;O;O
serum;O;O
binding;O;O
proteins;O;O
:;O;O
androgens;B-group;B-DDI-DrugBank.d411.s3.e1
and;O;O
related;O;O
anabolic;B-group;B-DDI-DrugBank.d411.s3.e2
hormones;I-group;I-DDI-DrugBank.d411.s3.e2
,;O;O
asparaginase;B-drug;B-DDI-DrugBank.d411.s3.e3
,;O;O
clofibrate;B-drug;B-DDI-DrugBank.d411.s3.e4
,;O;O
estrogens;B-group;B-DDI-DrugBank.d411.s3.e5
and;O;O
estrogen;B-group;B-DDI-DrugBank.d411.s3.e6
-;I-group;I-DDI-DrugBank.d411.s3.e6
containing;I-group;I-DDI-DrugBank.d411.s3.e6
compounds;I-group;I-DDI-DrugBank.d411.s3.e6
,;O;O
5;B-drug;B-DDI-DrugBank.d411.s3.e7
-;I-drug;I-DDI-DrugBank.d411.s3.e7
fluorouracil;I-drug;I-DDI-DrugBank.d411.s3.e7
,;O;O
furosemide;B-drug;B-DDI-DrugBank.d411.s3.e8
,;O;O
glucocorticoids;B-group;B-DDI-DrugBank.d411.s3.e9
,;O;O
meclofenamic;B-drug;B-DDI-DrugBank.d411.s3.e10
acid;I-drug;I-DDI-DrugBank.d411.s3.e10
,;O;O
mefenamic;B-drug;B-DDI-DrugBank.d411.s3.e11
acid;I-drug;I-DDI-DrugBank.d411.s3.e11
,;O;O
methadone;B-drug;B-DDI-DrugBank.d411.s3.e12
,;O;O
perphenazine;B-drug;B-DDI-DrugBank.d411.s3.e13
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d411.s3.e14
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d411.s3.e15
,;O;O
salicylates;B-group;B-DDI-DrugBank.d411.s3.e16
,;O;O
tamoxifen;B-drug;B-DDI-DrugBank.d411.s3.e17
.;O;O
DDI-DrugBank.d411.s4;;
Thyroid;O;O
Physiology;O;O
:;O;O
The;O;O
following;O;O
agents;O;O
may;O;O
alter;O;O
thyroid;O;O
hormone;O;O
or;O;O
TSH;O;O
levels;O;O
,;O;O
generally;O;O
by;O;O
effects;O;O
on;O;O
thyroid;O;O
hormone;O;O
synthesis;O;O
,;O;O
secretion;O;O
,;O;O
distribution;O;O
,;O;O
metabolism;O;O
,;O;O
hormone;O;O
action;O;O
,;O;O
or;O;O
elimination;O;O
,;O;O
or;O;O
altered;O;O
TSH;O;O
secretion;O;O
:;O;O
aminoglutethimide;B-drug;B-DDI-DrugBank.d411.s4.e0
,;O;O
p;B-drug;B-DDI-DrugBank.d411.s4.e1
-;I-drug;I-DDI-DrugBank.d411.s4.e1
aminosalicylic;I-drug;I-DDI-DrugBank.d411.s4.e1
acid;I-drug;I-DDI-DrugBank.d411.s4.e1
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d411.s4.e2
,;O;O
androgens;B-group;B-DDI-DrugBank.d411.s4.e3
and;O;O
related;O;O
anabolic;O;O
hormones;O;O
,;O;O
complex;O;O
anions;O;O
(;O;O
thiocyanate;B-drug;B-DDI-DrugBank.d411.s4.e4
,;O;O
perchlorate;B-drug;B-DDI-DrugBank.d411.s4.e5
,;O;O
pertechnetate;B-drug;B-DDI-DrugBank.d411.s4.e6
);O;O
,;O;O
antithyroid;B-group;B-DDI-DrugBank.d411.s4.e7
drugs;I-group;I-DDI-DrugBank.d411.s4.e7
,;O;O
b;B-group;B-DDI-DrugBank.d411.s4.e8
-;I-group;I-DDI-DrugBank.d411.s4.e8
adrenergic;I-group;I-DDI-DrugBank.d411.s4.e8
blocking;I-group;I-DDI-DrugBank.d411.s4.e8
agents;I-group;I-DDI-DrugBank.d411.s4.e8
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d411.s4.e9
,;O;O
chloral;B-drug;B-DDI-DrugBank.d411.s4.e10
hydrate;I-drug;I-DDI-DrugBank.d411.s4.e10
,;O;O
diazepam;B-drug;B-DDI-DrugBank.d411.s4.e11
,;O;O
dopamine;B-drug;B-DDI-DrugBank.d411.s4.e12
and;O;O
dopamine;B-group;B-DDI-DrugBank.d411.s4.e13
agonists;I-group;I-DDI-DrugBank.d411.s4.e13
,;O;O
ethionamide;B-drug;B-DDI-DrugBank.d411.s4.e14
,;O;O
glucocorticoids;B-group;B-DDI-DrugBank.d411.s4.e15
,;O;O
heparin;B-drug;B-DDI-DrugBank.d411.s4.e16
,;O;O
hepatic;O;O
enzyme;O;O
inducers;O;O
,;O;O
insulin;B-drug;B-DDI-DrugBank.d411.s4.e17
,;O;O
iodinated;O;O
cholestographic;O;O
agents;O;O
,;O;O
iodine;B-group;B-DDI-DrugBank.d411.s4.e18
-;I-group;I-DDI-DrugBank.d411.s4.e18
containing;I-group;I-DDI-DrugBank.d411.s4.e18
compounds;I-group;I-DDI-DrugBank.d411.s4.e18
,;O;O
levodopa;B-drug;B-DDI-DrugBank.d411.s4.e19
,;O;O
lovastatin;B-drug;B-DDI-DrugBank.d411.s4.e20
,;O;O
lithium;B-drug;B-DDI-DrugBank.d411.s4.e21
,;O;O
6;B-drug;B-DDI-DrugBank.d411.s4.e22
-;I-drug;I-DDI-DrugBank.d411.s4.e22
mercaptopurine;I-drug;I-DDI-DrugBank.d411.s4.e22
,;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d411.s4.e23
,;O;O
mitotane;B-drug;B-DDI-DrugBank.d411.s4.e24
,;O;O
nitroprusside;B-drug;B-DDI-DrugBank.d411.s4.e25
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d411.s4.e26
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d411.s4.e27
,;O;O
resorcinol;B-drug;B-DDI-DrugBank.d411.s4.e28
,;O;O
rifampin;B-drug;B-DDI-DrugBank.d411.s4.e29
,;O;O
somatostatin;B-group;B-DDI-DrugBank.d411.s4.e30
analogs;I-group;I-DDI-DrugBank.d411.s4.e30
,;O;O
sulfonamides;B-group;B-DDI-DrugBank.d411.s4.e31
,;O;O
sulfonylureas;B-group;B-DDI-DrugBank.d411.s4.e32
,;O;O
thiazide;B-group;B-DDI-DrugBank.d411.s4.e33
diuretics;I-group;I-DDI-DrugBank.d411.s4.e33
.;O;O
DDI-DrugBank.d411.s5;;
Adrenocorticoids;O;O
:;O;O
Metabolic;O;O
clearance;O;O
of;O;O
adrenocorticoids;O;O
is;O;O
decreased;O;O
in;O;O
hypothyroid;O;O
patients;O;O
and;O;O
increased;O;O
in;O;O
hyperthyroid;O;O
patients;O;O
,;O;O
and;O;O
may;O;O
therefore;O;O
change;O;O
with;O;O
changing;O;O
thyroid;O;O
status;O;O
.;O;O
DDI-DrugBank.d411.s6;;
Amiodarone;B-drug;B-DDI-DrugBank.d411.s6.e0
:;O;O
Amiodarone;B-drug;B-DDI-DrugBank.d411.s6.e1
therapy;O;O
alone;O;O
can;O;O
cause;O;O
hypothyroidism;O;O
or;O;O
hyperthyroidism;O;O
.;O;O
DDI-DrugBank.d411.s7;;
Anticoagulants;B-group;B-DDI-DrugBank.d411.s7.e0
(;O;O
Oral;O;O
);O;O
:;O;O
The;O;O
hypoprothrombinemic;O;O
effect;O;O
of;O;O
anticoagulants;B-group;B-DDI-DrugBank.d411.s7.e1
may;O;O
be;O;O
potentiated;O;O
,;O;O
apparently;O;O
by;O;O
increased;O;O
catabloism;O;O
of;O;O
vitamin;O;O
K;O;O
-;O;O
dependent;O;O
clotting;O;O
factors;O;O
.;O;O
DDI-DrugBank.d411.s8;;
Antidiabetic;B-group;B-DDI-DrugBank.d411.s8.e0
Agents;I-group;I-DDI-DrugBank.d411.s8.e0
(;O;O
Insulin;B-drug;B-DDI-DrugBank.d411.s8.e1
,;O;O
Sulfonylureas;B-group;B-DDI-DrugBank.d411.s8.e2
);O;O
:;O;O
Requirements;O;O
for;O;O
insulin;B-drug;B-DDI-DrugBank.d411.s8.e3
or;O;O
oral;O;O
antidiabetic;B-group;B-DDI-DrugBank.d411.s8.e4
agents;I-group;I-DDI-DrugBank.d411.s8.e4
may;O;O
be;O;O
reduced;O;O
in;O;O
hypothyroid;O;O
patients;O;O
with;O;O
diabetes;O;O
mellitus;O;O
and;O;O
may;O;O
subsequently;O;O
increase;O;O
with;O;O
the;O;O
initiation;O;O
of;O;O
thyroid;O;O
hormone;O;O
replacement;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d411.s9;;
b;B-group;B-DDI-DrugBank.d411.s9.e0
-;I-group;I-DDI-DrugBank.d411.s9.e0
Adrenergic;I-group;I-DDI-DrugBank.d411.s9.e0
Blocking;I-group;I-DDI-DrugBank.d411.s9.e0
Agents;I-group;I-DDI-DrugBank.d411.s9.e0
:;O;O
Actions;O;O
of;O;O
some;O;O
of;O;O
beta;B-group;B-DDI-DrugBank.d411.s9.e1
-;I-group;I-DDI-DrugBank.d411.s9.e1
blocking;I-group;I-DDI-DrugBank.d411.s9.e1
agents;I-group;I-DDI-DrugBank.d411.s9.e1
may;O;O
be;O;O
impaired;O;O
when;O;O
hypothyroid;O;O
patients;O;O
become;O;O
euthyroid;O;O
.;O;O
DDI-DrugBank.d411.s10;;
Cytokines;B-group;B-DDI-DrugBank.d411.s10.e0
(;O;O
interferon;B-group;B-DDI-DrugBank.d411.s10.e1
,;O;O
interleukin;B-group;B-DDI-DrugBank.d411.s10.e2
);O;O
:;O;O
Cytokines;B-group;B-DDI-DrugBank.d411.s10.e3
have;O;O
been;O;O
reported;O;O
to;O;O
induce;O;O
both;O;O
hyperthyroidism;O;O
and;O;O
hypothyroidism;O;O
.;O;O
DDI-DrugBank.d411.s11;;
Digitalis;B-group;B-DDI-DrugBank.d411.s11.e0
Glycosides;I-group;I-DDI-DrugBank.d411.s11.e0
:;O;O
Therapeutic;O;O
effects;O;O
of;O;O
digitalis;B-group;B-DDI-DrugBank.d411.s11.e1
glycosides;I-group;I-DDI-DrugBank.d411.s11.e1
may;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d411.s12;;
Serum;O;O
digitalis;B-group;B-DDI-DrugBank.d411.s12.e0
levels;O;O
may;O;O
be;O;O
decreased;O;O
in;O;O
hyperthyroidism;O;O
or;O;O
when;O;O
a;O;O
hypothyroid;O;O
patient;O;O
becomes;O;O
euthyroid;O;O
.;O;O
DDI-DrugBank.d411.s13;;
Ketamine;B-drug;B-DDI-DrugBank.d411.s13.e0
:;O;O
Marked;O;O
hypertension;O;O
and;O;O
tachycardia;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
association;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d411.s13.e1
sodium;I-drug;I-DDI-DrugBank.d411.s13.e1
and;O;O
ketamine;B-drug;B-DDI-DrugBank.d411.s13.e2
.;O;O
DDI-DrugBank.d411.s14;;
Maprotiline;B-drug;B-DDI-DrugBank.d411.s14.e0
:;O;O
Risk;O;O
of;O;O
cardiac;O;O
arrhythmias;O;O
may;O;O
increase;O;O
.;O;O
DDI-DrugBank.d411.s15;;
Sodium;B-drug;B-DDI-DrugBank.d411.s15.e0
Iodide;I-drug;I-DDI-DrugBank.d411.s15.e0
(;O;O
123I;O;O
and;O;O
131I;O;O
);O;O
,;O;O
Sodium;O;O
Pertechnetate;O;O
Tc99;O;O
m;O;O
:;O;O
Uptake;O;O
of;O;O
radiolabeled;O;O
ions;O;O
may;O;O
be;O;O
decreased;O;O
.;O;O
DDI-DrugBank.d411.s16;;
Somatrem;B-drug;B-DDI-DrugBank.d411.s16.e0
/;O;O
Somatropin;B-drug;B-DDI-DrugBank.d411.s16.e1
:;O;O
Excessive;O;O
concurrent;O;O
use;O;O
of;O;O
thyroid;B-group;B-DDI-DrugBank.d411.s16.e2
hormone;I-group;I-DDI-DrugBank.d411.s16.e2
may;O;O
accelerate;O;O
epiphyseal;O;O
closure;O;O
.;O;O
DDI-DrugBank.d411.s17;;
Untreated;O;O
hypothyroidism;O;O
may;O;O
interfere;O;O
with;O;O
the;O;O
growth;O;O
response;O;O
to;O;O
somatrem;B-drug;B-DDI-DrugBank.d411.s17.e0
or;O;O
somatropin;B-drug;B-DDI-DrugBank.d411.s17.e1
.;O;O
DDI-DrugBank.d411.s18;;
Theophylline;B-drug;B-DDI-DrugBank.d411.s18.e0
:;O;O
Theophylline;B-drug;B-DDI-DrugBank.d411.s18.e1
clearance;O;O
may;O;O
decrease;O;O
in;O;O
hypothyroid;O;O
patients;O;O
and;O;O
return;O;O
toward;O;O
normal;O;O
when;O;O
a;O;O
euthyroid;O;O
state;O;O
is;O;O
achieved;O;O
.;O;O
DDI-DrugBank.d411.s19;;
Tricyclic;B-group;B-DDI-DrugBank.d411.s19.e0
Antidepressants;I-group;I-DDI-DrugBank.d411.s19.e0
:;O;O
Concurrent;O;O
use;O;O
may;O;O
increase;O;O
the;O;O
therapeutic;O;O
and;O;O
toxic;O;O
effects;O;O
of;O;O
both;O;O
drugs;O;O
,;O;O
possibly;O;O
due;O;O
to;O;O
increased;O;O
catecholamine;O;O
sensitivity;O;O
.;O;O
DDI-DrugBank.d411.s20;;
Onset;O;O
of;O;O
action;O;O
of;O;O
tricyclics;B-group;B-DDI-DrugBank.d411.s20.e0
may;O;O
be;O;O
accelerated;O;O
.;O;O
DDI-DrugBank.d411.s21;;
Sympathomimetic;B-group;B-DDI-DrugBank.d411.s21.e0
Agents;I-group;I-DDI-DrugBank.d411.s21.e0
:;O;O
Possible;O;O
increased;O;O
risk;O;O
of;O;O
coronary;O;O
insufficiency;O;O
in;O;O
patients;O;O
with;O;O
coronary;O;O
artery;O;O
disease;O;O
.;O;O
DDI-DrugBank.d564.s0;;
The;O;O
administration;O;O
of;O;O
local;O;O
anesthetic;B-group;B-DDI-DrugBank.d564.s0.e0
solutions;I-group;I-DDI-DrugBank.d564.s0.e0
containing;O;O
epinephrine;B-drug;B-DDI-DrugBank.d564.s0.e1
or;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d564.s0.e2
to;O;O
patients;O;O
receiving;O;O
monoamine;B-group;B-DDI-DrugBank.d564.s0.e3
oxidase;I-group;I-DDI-DrugBank.d564.s0.e3
inhibitors;I-group;I-DDI-DrugBank.d564.s0.e3
or;O;O
tricyclic;B-group;B-DDI-DrugBank.d564.s0.e4
antidepressants;I-group;I-DDI-DrugBank.d564.s0.e4
may;O;O
produce;O;O
severe;O;O
,;O;O
prolonged;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d564.s1;;
Phenothiazines;B-group;B-DDI-DrugBank.d564.s1.e0
and;O;O
butyrophenones;B-group;B-DDI-DrugBank.d564.s1.e1
may;O;O
reduce;O;O
or;O;O
reverse;O;O
the;O;O
pressor;O;O
effect;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d564.s1.e2
.;O;O
DDI-DrugBank.d564.s2;;
Concurrent;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
should;O;O
generally;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d564.s3;;
In;O;O
situations;O;O
when;O;O
concurrent;O;O
therapy;O;O
is;O;O
necessary;O;O
,;O;O
careful;O;O
patient;O;O
monitoring;O;O
is;O;O
essential;O;O
.;O;O
DDI-DrugBank.d564.s4;;
Concurrent;O;O
administration;O;O
of;O;O
vasopressor;B-group;B-DDI-DrugBank.d564.s4.e0
drugs;I-group;I-DDI-DrugBank.d564.s4.e0
(;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
hypotension;O;O
related;O;O
to;O;O
obstetric;O;O
blocks;O;O
);O;O
and;O;O
ergot;B-group;B-DDI-DrugBank.d564.s4.e1
-;I-group;I-DDI-DrugBank.d564.s4.e1
type;I-group;I-DDI-DrugBank.d564.s4.e1
oxytocic;I-group;I-DDI-DrugBank.d564.s4.e1
drugs;I-group;I-DDI-DrugBank.d564.s4.e1
may;O;O
cause;O;O
severe;O;O
,;O;O
persistent;O;O
hypertension;O;O
or;O;O
cerebrovascular;O;O
accidents;O;O
.;O;O
DDI-DrugBank.d130.s0;;
Lincomycin;B-drug;B-DDI-DrugBank.d130.s0.e0
has;O;O
been;O;O
shown;O;O
to;O;O
have;O;O
neuromuscular;O;O
blocking;O;O
properties;O;O
that;O;O
may;O;O
enhance;O;O
the;O;O
action;O;O
of;O;O
other;O;O
neuromuscular;B-group;B-DDI-DrugBank.d130.s0.e1
blocking;I-group;I-DDI-DrugBank.d130.s0.e1
agents;I-group;I-DDI-DrugBank.d130.s0.e1
.;O;O
DDI-DrugBank.d130.s1;;
Therefore;O;O
,;O;O
it;O;O
should;O;O
be;O;O
used;O;O
in;O;O
caution;O;O
in;O;O
patients;O;O
receiving;O;O
such;O;O
agents;O;O
.;O;O
DDI-DrugBank.d130.s2;;
Antagonism;O;O
between;O;O
lincomycin;B-drug;B-DDI-DrugBank.d130.s2.e0
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d130.s2.e1
in;O;O
vitro;O;O
has;O;O
been;O;O
demonstrated;O;O
.;O;O
DDI-DrugBank.d130.s3;;
Because;O;O
of;O;O
possible;O;O
clinical;O;O
significance;O;O
,;O;O
the;O;O
two;O;O
drugs;O;O
should;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d268.s0;;
Oils;O;O
may;O;O
enhance;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d268.s1;;
Therefore;O;O
,;O;O
simultaneous;O;O
use;O;O
of;O;O
creams;O;O
,;O;O
ointments;O;O
or;O;O
oils;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d441.s0;;
Monoamine;O;O
Oxidase;O;O
Inhibition;O;O
:;O;O
Linezolid;B-drug;B-DDI-DrugBank.d441.s0.e0
is;O;O
a;O;O
reversible;O;O
,;O;O
nonselective;O;O
inhibitor;O;O
of;O;O
monoamine;O;O
oxidase;O;O
.;O;O
DDI-DrugBank.d441.s1;;
Therefore;O;O
,;O;O
linezolid;B-drug;B-DDI-DrugBank.d441.s1.e0
has;O;O
the;O;O
potential;O;O
for;O;O
interaction;O;O
with;O;O
adrenergic;B-group;B-DDI-DrugBank.d441.s1.e1
and;O;O
serotonergic;B-group;B-DDI-DrugBank.d441.s1.e2
agents;I-group;I-DDI-DrugBank.d441.s1.e2
.;O;O
DDI-DrugBank.d441.s2;;
Adrenergic;B-group;B-DDI-DrugBank.d441.s2.e0
Agents;I-group;I-DDI-DrugBank.d441.s2.e0
:;O;O
Some;O;O
individuals;O;O
receiving;O;O
ZYVOX;B-brand;B-DDI-DrugBank.d441.s2.e1
may;O;O
experience;O;O
a;O;O
reversible;O;O
enhancement;O;O
of;O;O
the;O;O
pressor;O;O
response;O;O
to;O;O
indirect;O;O
-;O;O
acting;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d441.s2.e2
agents;I-group;I-DDI-DrugBank.d441.s2.e2
,;O;O
vasopressor;B-group;B-DDI-DrugBank.d441.s2.e3
or;O;O
dopaminergic;B-group;B-DDI-DrugBank.d441.s2.e4
agents;I-group;I-DDI-DrugBank.d441.s2.e4
.;O;O
DDI-DrugBank.d441.s3;;
Commonly;O;O
used;O;O
drugs;O;O
such;O;O
as;O;O
phenylpropanolamine;B-drug;B-DDI-DrugBank.d441.s3.e0
and;O;O
pseudoephedrine;B-drug;B-DDI-DrugBank.d441.s3.e1
have;O;O
been;O;O
specifically;O;O
studied;O;O
.;O;O
DDI-DrugBank.d441.s4;;
Initial;O;O
doses;O;O
of;O;O
adrenergic;B-group;B-DDI-DrugBank.d441.s4.e0
agents;I-group;I-DDI-DrugBank.d441.s4.e0
,;O;O
such;O;O
as;O;O
dopamine;B-drug;B-DDI-DrugBank.d441.s4.e1
or;O;O
epinephrine;B-drug;B-DDI-DrugBank.d441.s4.e2
,;O;O
should;O;O
be;O;O
reduced;O;O
and;O;O
titrated;O;O
to;O;O
achieve;O;O
the;O;O
desired;O;O
response;O;O
.;O;O
DDI-DrugBank.d441.s5;;
Serotonergic;B-group;B-DDI-DrugBank.d441.s5.e0
Agents;I-group;I-DDI-DrugBank.d441.s5.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
linezolid;B-drug;B-DDI-DrugBank.d441.s5.e1
and;O;O
serotonergic;B-group;B-DDI-DrugBank.d441.s5.e2
agents;I-group;I-DDI-DrugBank.d441.s5.e2
was;O;O
not;O;O
associated;O;O
with;O;O
serotonin;O;O
syndrome;O;O
in;O;O
Phase;O;O
1;O;O
,;O;O
2;O;O
or;O;O
3;O;O
studies;O;O
.;O;O
DDI-DrugBank.d441.s6;;
Spontaneous;O;O
reports;O;O
of;O;O
serotonin;O;O
syndrome;O;O
associated;O;O
with;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
ZYVOX;B-brand;B-DDI-DrugBank.d441.s6.e0
and;O;O
serotonergic;B-group;B-DDI-DrugBank.d441.s6.e1
agents;I-group;I-DDI-DrugBank.d441.s6.e1
,;O;O
including;O;O
antidepressants;B-group;B-DDI-DrugBank.d441.s6.e2
such;O;O
as;O;O
selective;B-group;B-DDI-DrugBank.d441.s6.e3
serotonin;I-group;I-DDI-DrugBank.d441.s6.e3
reuptake;I-group;I-DDI-DrugBank.d441.s6.e3
inhibitors;I-group;I-DDI-DrugBank.d441.s6.e3
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d441.s6.e4
);O;O
,;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d441.s7;;
Patients;O;O
who;O;O
are;O;O
treated;O;O
with;O;O
ZYVOX;B-brand;B-DDI-DrugBank.d441.s7.e0
and;O;O
concomitant;O;O
serotonergic;B-group;B-DDI-DrugBank.d441.s7.e1
agents;I-group;I-DDI-DrugBank.d441.s7.e1
should;O;O
be;O;O
closely;O;O
observed;O;O
for;O;O
signs;O;O
and;O;O
symptoms;O;O
of;O;O
serotonin;O;O
syndrome;O;O
(;O;O
e.g.;O;O
,;O;O
cognitive;O;O
dysfunction;O;O
,;O;O
hyperpyrexia;O;O
,;O;O
hyperreflexia;O;O
,;O;O
incoordination;O;O
);O;O
.;O;O
DDI-DrugBank.d441.s8;;
If;O;O
any;O;O
signs;O;O
or;O;O
symptoms;O;O
occur;O;O
physicians;O;O
should;O;O
consider;O;O
discontinuation;O;O
of;O;O
either;O;O
one;O;O
or;O;O
both;O;O
agents;O;O
(;O;O
ZYVOX;B-brand;B-DDI-DrugBank.d441.s8.e0
or;O;O
concomitant;O;O
serotonergic;B-group;B-DDI-DrugBank.d441.s8.e1
agents;I-group;I-DDI-DrugBank.d441.s8.e1
);O;O
.;O;O
DDI-DrugBank.d441.s9;;
Drug;O;O
-;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
There;O;O
are;O;O
no;O;O
reported;O;O
drug;O;O
-;O;O
laboratory;O;O
test;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d54.s0;;
Oral;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d54.s0.e0
:;O;O
Thyroid;B-group;B-DDI-DrugBank.d54.s0.e1
hormones;I-group;I-DDI-DrugBank.d54.s0.e1
appear;O;O
to;O;O
increase;O;O
catabolism;O;O
of;O;O
vitamin;O;O
K;O;O
-;O;O
dependent;O;O
clotting;O;O
factors;O;O
.;O;O
DDI-DrugBank.d54.s1;;
If;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d54.s1.e0
are;O;O
also;O;O
being;O;O
given;O;O
,;O;O
compensatory;O;O
increases;O;O
in;O;O
clotting;O;O
factor;O;O
synthesis;O;O
are;O;O
impaired;O;O
.;O;O
DDI-DrugBank.d54.s2;;
Patients;O;O
stabilized;O;O
on;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d54.s2.e0
who;O;O
are;O;O
found;O;O
to;O;O
require;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s2.e1
replacement;O;O
therapy;O;O
should;O;O
be;O;O
watched;O;O
very;O;O
closely;O;O
when;O;O
thyroid;O;O
is;O;O
started;O;O
.;O;O
DDI-DrugBank.d54.s3;;
If;O;O
a;O;O
patient;O;O
is;O;O
truly;O;O
hypothyroid;O;O
,;O;O
it;O;O
is;O;O
likely;O;O
that;O;O
a;O;O
reduction;O;O
in;O;O
anticoagulant;B-group;B-DDI-DrugBank.d54.s3.e0
dosage;O;O
will;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d54.s4;;
No;O;O
special;O;O
precautions;O;O
appear;O;O
to;O;O
be;O;O
necessary;O;O
when;O;O
oral;O;O
anticoagulant;O;O
therapy;O;O
is;O;O
begun;O;O
in;O;O
a;O;O
patient;O;O
already;O;O
stabilized;O;O
on;O;O
maintenance;O;O
thyroid;O;O
replacement;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d54.s5;;
Insulin;B-drug;B-DDI-DrugBank.d54.s5.e0
or;O;O
Oral;O;O
Hypoglycemics;B-group;B-DDI-DrugBank.d54.s5.e1
:;O;O
Initiating;O;O
thyroid;O;O
replacement;O;O
therapy;O;O
may;O;O
cause;O;O
increases;O;O
in;O;O
insulin;B-drug;B-DDI-DrugBank.d54.s5.e2
or;O;O
oral;O;O
hypoglycemic;B-group;B-DDI-DrugBank.d54.s5.e3
requirements;O;O
.;O;O
DDI-DrugBank.d54.s6;;
The;O;O
effects;O;O
seen;O;O
are;O;O
poorly;O;O
understood;O;O
and;O;O
depend;O;O
upon;O;O
a;O;O
variety;O;O
of;O;O
factors;O;O
such;O;O
as;O;O
dose;O;O
and;O;O
type;O;O
of;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s6.e0
preparations;I-group;I-DDI-DrugBank.d54.s6.e0
and;O;O
endocrine;O;O
status;O;O
of;O;O
the;O;O
patient;O;O
.;O;O
DDI-DrugBank.d54.s7;;
Patients;O;O
receiving;O;O
insulin;B-drug;B-DDI-DrugBank.d54.s7.e0
or;O;O
oral;O;O
hypoglycemics;B-group;B-DDI-DrugBank.d54.s7.e1
should;O;O
be;O;O
closely;O;O
watched;O;O
during;O;O
initiation;O;O
of;O;O
thyroid;O;O
replacement;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d54.s8;;
Cholestyramine;B-drug;B-DDI-DrugBank.d54.s8.e0
:;O;O
Cholestyramine;B-drug;B-DDI-DrugBank.d54.s8.e1
binds;O;O
both;O;O
T4;B-drug;B-DDI-DrugBank.d54.s8.e2
and;O;O
T3;B-drug;B-DDI-DrugBank.d54.s8.e3
in;O;O
the;O;O
intestine;O;O
,;O;O
thus;O;O
impairing;O;O
absorption;O;O
of;O;O
these;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s8.e4
hormones;I-group;I-DDI-DrugBank.d54.s8.e4
.;O;O
DDI-DrugBank.d54.s9;;
In;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
the;O;O
binding;O;O
is;O;O
not;O;O
easily;O;O
removed;O;O
.;O;O
DDI-DrugBank.d54.s10;;
Therefore;O;O
,;O;O
4;O;O
to;O;O
5;O;O
hours;O;O
should;O;O
elapse;O;O
between;O;O
administration;O;O
of;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d54.s10.e0
and;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s10.e1
hormones;I-group;I-DDI-DrugBank.d54.s10.e1
.;O;O
DDI-DrugBank.d54.s11;;
Estrogen;B-group;B-DDI-DrugBank.d54.s11.e0
,;O;O
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d54.s11.e1
:;O;O
Estrogens;B-group;B-DDI-DrugBank.d54.s11.e2
tend;O;O
to;O;O
increase;O;O
serum;O;O
thyroxine;O;O
-;O;O
binding;O;O
globulin;O;O
(;O;O
TBg;O;O
);O;O
.;O;O
DDI-DrugBank.d54.s12;;
In;O;O
a;O;O
patient;O;O
with;O;O
a;O;O
nonfunctioning;O;O
thyroid;O;O
gland;O;O
who;O;O
is;O;O
receiving;O;O
thyroid;O;O
replacement;O;O
therapy;O;O
,;O;O
free;O;O
levothyroxine;B-drug;B-DDI-DrugBank.d54.s12.e0
may;O;O
be;O;O
decreased;O;O
when;O;O
estrogens;B-group;B-DDI-DrugBank.d54.s12.e1
are;O;O
started;O;O
thus;O;O
increasing;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s12.e2
requirements;O;O
.;O;O
DDI-DrugBank.d54.s13;;
However;O;O
,;O;O
if;O;O
the;O;O
patients;O;O
thyroid;O;O
gland;O;O
has;O;O
sufficient;O;O
function;O;O
,;O;O
the;O;O
decreased;O;O
free;O;O
thyroxine;B-drug;B-DDI-DrugBank.d54.s13.e0
will;O;O
result;O;O
in;O;O
a;O;O
compensatory;O;O
increase;O;O
in;O;O
thyroxine;O;O
output;O;O
by;O;O
the;O;O
thyroid;O;O
.;O;O
DDI-DrugBank.d54.s14;;
Therefore;O;O
,;O;O
patients;O;O
without;O;O
a;O;O
functioning;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s14.e0
gland;O;O
who;O;O
are;O;O
on;O;O
thyroid;O;O
replacement;O;O
therapy;O;O
may;O;O
need;O;O
to;O;O
increase;O;O
their;O;O
thyroid;O;O
dose;O;O
if;O;O
estrogens;B-group;B-DDI-DrugBank.d54.s14.e1
or;O;O
estrogen;B-group;B-DDI-DrugBank.d54.s14.e2
-;O;O
containing;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d54.s14.e3
are;O;O
given;O;O
.;O;O
DDI-DrugBank.d54.s15;;
Tricyclic;B-group;B-DDI-DrugBank.d54.s15.e0
Antidepressants;I-group;I-DDI-DrugBank.d54.s15.e0
:;O;O
Use;O;O
of;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s15.e1
products;I-group;I-DDI-DrugBank.d54.s15.e1
with;O;O
imipramine;B-drug;B-DDI-DrugBank.d54.s15.e2
and;O;O
other;O;O
tricyclic;B-group;B-DDI-DrugBank.d54.s15.e3
antidepressants;I-group;I-DDI-DrugBank.d54.s15.e3
may;O;O
increase;O;O
receptor;O;O
sensitivity;O;O
and;O;O
enhance;O;O
antidepressant;O;O
activity;O;O
transient;O;O
cardiac;O;O
arrhythmias;O;O
have;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d54.s16;;
Thyroid;B-group;B-DDI-DrugBank.d54.s16.e0
hormone;I-group;I-DDI-DrugBank.d54.s16.e0
activity;O;O
may;O;O
also;O;O
be;O;O
enhanced;O;O
.;O;O
DDI-DrugBank.d54.s17;;
Digitalis;B-group;B-DDI-DrugBank.d54.s17.e0
:;O;O
Thyroid;B-group;B-DDI-DrugBank.d54.s17.e1
preparations;I-group;I-DDI-DrugBank.d54.s17.e1
may;O;O
potentiate;O;O
the;O;O
toxic;O;O
effects;O;O
of;O;O
digitalis;B-group;B-DDI-DrugBank.d54.s17.e2
.;O;O
DDI-DrugBank.d54.s18;;
Thyroid;O;O
hormonal;O;O
replacement;O;O
increases;O;O
metabolic;O;O
rate;O;O
,;O;O
which;O;O
requires;O;O
an;O;O
increase;O;O
in;O;O
digitalis;B-group;B-DDI-DrugBank.d54.s18.e0
dosage;O;O
.;O;O
DDI-DrugBank.d54.s19;;
Ketamine;B-drug;B-DDI-DrugBank.d54.s19.e0
:;O;O
When;O;O
administered;O;O
to;O;O
patients;O;O
on;O;O
a;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s19.e1
preparation;I-group;I-DDI-DrugBank.d54.s19.e1
,;O;O
this;O;O
parenteral;O;O
anesthetic;B-group;B-DDI-DrugBank.d54.s19.e2
may;O;O
cause;O;O
hypertension;O;O
and;O;O
tachycardia;O;O
.;O;O
DDI-DrugBank.d54.s20;;
Use;O;O
with;O;O
caution;O;O
and;O;O
be;O;O
prepared;O;O
to;O;O
treat;O;O
hypertension;O;O
,;O;O
if;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d54.s21;;
Vasopressors;B-group;B-DDI-DrugBank.d54.s21.e0
:;O;O
Thyroxine;B-drug;B-DDI-DrugBank.d54.s21.e1
increases;O;O
the;O;O
adrenergic;O;O
effect;O;O
of;O;O
catecholamines;O;O
such;O;O
as;O;O
epinephrine;B-drug;B-DDI-DrugBank.d54.s21.e2
and;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d54.s21.e3
.;O;O
DDI-DrugBank.d54.s22;;
Therefore;O;O
,;O;O
injection;O;O
of;O;O
these;O;O
agents;O;O
into;O;O
patients;O;O
receiving;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s22.e0
preparations;I-group;I-DDI-DrugBank.d54.s22.e0
increases;O;O
the;O;O
risk;O;O
of;O;O
precipitating;O;O
coronary;O;O
insufficiency;O;O
especially;O;O
in;O;O
patients;O;O
with;O;O
coronary;O;O
artery;O;O
disease;O;O
.;O;O
DDI-DrugBank.d54.s23;;
Careful;O;O
observation;O;O
is;O;O
required;O;O
.;O;O
DDI-DrugBank.d54.s24;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
The;O;O
following;O;O
drugs;O;O
or;O;O
moieties;O;O
are;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
laboratory;O;O
tests;O;O
performed;O;O
in;O;O
patients;O;O
on;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s24.e0
hormone;I-group;I-DDI-DrugBank.d54.s24.e0
therapy;O;O
:;O;O
androgens;B-group;B-DDI-DrugBank.d54.s24.e1
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d54.s24.e2
,;O;O
estrogens;B-group;B-DDI-DrugBank.d54.s24.e3
,;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d54.s24.e4
containing;O;O
estrogens;B-group;B-DDI-DrugBank.d54.s24.e5
,;O;O
iodine;B-group;B-DDI-DrugBank.d54.s24.e6
-;O;O
containing;O;O
preparations;O;O
and;O;O
the;O;O
numerous;O;O
preparations;O;O
containing;O;O
salicylates;B-group;B-DDI-DrugBank.d54.s24.e7
.;O;O
DDI-DrugBank.d54.s25;;
-;O;O
Changes;O;O
in;O;O
TBg;O;O
concentration;O;O
should;O;O
be;O;O
taken;O;O
into;O;O
consideration;O;O
in;O;O
the;O;O
interpretation;O;O
of;O;O
T4;O;O
and;O;O
T3;O;O
values;O;O
.;O;O
DDI-DrugBank.d54.s26;;
In;O;O
such;O;O
cases;O;O
,;O;O
the;O;O
unbound;O;O
(;O;O
free;O;O
);O;O
hormone;O;O
should;O;O
be;O;O
measured;O;O
.;O;O
DDI-DrugBank.d54.s27;;
Pregnancy;O;O
estrogens;B-group;B-DDI-DrugBank.d54.s27.e0
and;O;O
estrogen;B-group;B-DDI-DrugBank.d54.s27.e1
-;O;O
containing;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d54.s27.e2
increase;O;O
TBg;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d54.s28;;
TBg;O;O
may;O;O
also;O;O
be;O;O
increased;O;O
during;O;O
infectious;O;O
hepatitis;O;O
.;O;O
DDI-DrugBank.d54.s29;;
Decreases;O;O
in;O;O
TBg;O;O
concentrations;O;O
are;O;O
observed;O;O
in;O;O
nephrosis;O;O
,;O;O
acromegaly;O;O
and;O;O
after;O;O
androgen;B-group;B-DDI-DrugBank.d54.s29.e0
or;O;O
corticosteroid;B-group;B-DDI-DrugBank.d54.s29.e1
therapy;O;O
.;O;O
DDI-DrugBank.d54.s30;;
Familial;O;O
hyper;O;O
-;O;O
or;O;O
hypo;O;O
-;O;O
thyroxine;O;O
-;O;O
binding;O;O
-;O;O
globulinemias;O;O
have;O;O
been;O;O
described;O;O
.;O;O
DDI-DrugBank.d54.s31;;
The;O;O
incidence;O;O
of;O;O
TBg;O;O
deficiency;O;O
approximates;O;O
1;O;O
in;O;O
9000;O;O
.;O;O
DDI-DrugBank.d54.s32;;
The;O;O
binding;O;O
of;O;O
thyroxine;O;O
by;O;O
thyroxine;O;O
-;O;O
binding;O;O
prealbumin;O;O
(;O;O
TBPA;O;O
);O;O
is;O;O
inhibited;O;O
by;O;O
salicylates;B-group;B-DDI-DrugBank.d54.s32.e0
DDI-DrugBank.d54.s33;;
.;O;O
DDI-DrugBank.d54.s34;;
-;O;O
Medicinal;O;O
or;O;O
dietary;O;O
iodine;B-group;B-DDI-DrugBank.d54.s34.e0
interferes;O;O
with;O;O
all;O;O
in;O;O
vivo;O;O
tests;O;O
of;O;O
radio;O;O
-;O;O
iodine;O;O
uptake;O;O
producing;O;O
low;O;O
uptakes;O;O
which;O;O
may;O;O
not;O;O
be;O;O
reflective;O;O
of;O;O
a;O;O
true;O;O
decrease;O;O
in;O;O
hormone;O;O
synthesis;O;O
DDI-DrugBank.d54.s35;;
.;O;O
DDI-DrugBank.d54.s36;;
-;O;O
The;O;O
persistence;O;O
of;O;O
clinical;O;O
and;O;O
laboratory;O;O
evidence;O;O
of;O;O
hypothyroidism;O;O
in;O;O
spite;O;O
of;O;O
adequate;O;O
dosage;O;O
replacement;O;O
indicates;O;O
either;O;O
poor;O;O
patient;O;O
compliance;O;O
,;O;O
poor;O;O
absorption;O;O
,;O;O
excessive;O;O
fecal;O;O
loss;O;O
,;O;O
or;O;O
inactivity;O;O
of;O;O
the;O;O
preparation;O;O
.;O;O
DDI-DrugBank.d54.s37;;
Intracellular;O;O
resistance;O;O
to;O;O
thyroid;B-group;B-DDI-DrugBank.d54.s37.e0
hormone;I-group;I-DDI-DrugBank.d54.s37.e0
is;O;O
quite;O;O
rare;O;O
.;O;O
DDI-DrugBank.d158.s0;;
Urinary;O;O
acidifying;O;O
agents;O;O
These;O;O
agents;O;O
(;O;O
ammonium;B-drug;B-DDI-DrugBank.d158.s0.e0
chloride;I-drug;I-DDI-DrugBank.d158.s0.e0
,;O;O
sodium;B-drug;B-DDI-DrugBank.d158.s0.e1
acid;I-drug;I-DDI-DrugBank.d158.s0.e1
phosphate;I-drug;I-DDI-DrugBank.d158.s0.e1
,;O;O
etc;O;O
.;O;O
);O;O
increase;O;O
the;O;O
concentration;O;O
of;O;O
the;O;O
ionized;O;O
species;O;O
of;O;O
the;O;O
amphetamine;B-drug;B-DDI-DrugBank.d158.s0.e2
molecule;O;O
,;O;O
thereby;O;O
increasing;O;O
urinary;O;O
excretion;O;O
.;O;O
DDI-DrugBank.d158.s1;;
Both;O;O
groups;O;O
of;O;O
agents;O;O
lower;O;O
blood;O;O
levels;O;O
and;O;O
efficacy;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d158.s1.e0
.;O;O
DDI-DrugBank.d158.s2;;
Adrenergic;B-group;B-DDI-DrugBank.d158.s2.e0
blockers;I-group;I-DDI-DrugBank.d158.s2.e0
Adrenergic;I-group;I-DDI-DrugBank.d158.s2.e1
blockers;I-group;I-DDI-DrugBank.d158.s2.e1
are;O;O
inhibited;O;O
by;O;O
amphetamines;B-group;B-DDI-DrugBank.d158.s2.e2
.;O;O
DDI-DrugBank.d158.s3;;
Antidepressants;B-group;B-DDI-DrugBank.d158.s3.e0
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d158.s3.e1
Amphetamines;I-group;I-DDI-DrugBank.d158.s3.e2
may;O;O
enhance;O;O
the;O;O
activity;O;O
of;O;O
tricyclic;B-drug;B-DDI-DrugBank.d158.s3.e3
antidepressants;I-drug;I-DDI-DrugBank.d158.s3.e3
or;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d158.s3.e4
agents;I-group;I-DDI-DrugBank.d158.s3.e4
,;O;O
DDI-DrugBank.d158.s4;;
d;B-drug;B-DDI-DrugBank.d158.s4.e0
-;I-drug;I-DDI-DrugBank.d158.s4.e0
amphetamine;I-drug;I-DDI-DrugBank.d158.s4.e0
with;O;O
desipramine;B-drug;B-DDI-DrugBank.d158.s4.e1
or;O;O
protriptyline;B-drug;B-DDI-DrugBank.d158.s4.e2
and;O;O
possibly;O;O
other;O;O
tricyclics;B-group;B-DDI-DrugBank.d158.s4.e3
cause;O;O
striking;O;O
and;O;O
sustained;O;O
increases;O;O
in;O;O
the;O;O
concentration;O;O
of;O;O
d;B-drug;B-DDI-DrugBank.d158.s4.e4
-;I-drug;I-DDI-DrugBank.d158.s4.e4
amphetamine;I-drug;I-DDI-DrugBank.d158.s4.e4
in;O;O
the;O;O
brain;O;O
,;O;O
DDI-DrugBank.d158.s5;;
cardiovascular;O;O
effects;O;O
can;O;O
be;O;O
potentiated;O;O
.;O;O
DDI-DrugBank.d158.s6;;
MAO;B-group;B-DDI-DrugBank.d158.s6.e0
inhibitors;I-group;I-DDI-DrugBank.d158.s6.e0
MAOI;I-group;I-DDI-DrugBank.d158.s6.e1
antidepressants;I-group;I-DDI-DrugBank.d158.s6.e1
,;O;O
as;O;O
well;O;O
as;O;O
a;O;O
metabolite;O;O
of;O;O
furazolidone;B-drug;B-DDI-DrugBank.d158.s6.e2
,;O;O
slow;O;O
amphetamine;B-drug;B-DDI-DrugBank.d158.s6.e3
metabolism;O;O
.;O;O
DDI-DrugBank.d158.s7;;
This;O;O
slowing;O;O
potentiates;O;O
amphetamines;B-group;B-DDI-DrugBank.d158.s7.e0
,;O;O
increasing;O;O
their;O;O
effect;O;O
on;O;O
the;O;O
release;O;O
of;O;O
norepinephrine;O;O
and;O;O
other;O;O
monoamines;O;O
from;O;O
adrenergic;O;O
nerve;O;O
endings;O;O
,;O;O
DDI-DrugBank.d158.s8;;
this;O;O
can;O;O
cause;O;O
headaches;O;O
and;O;O
other;O;O
signs;O;O
of;O;O
hypertensive;O;O
crisis;O;O
.;O;O
DDI-DrugBank.d158.s9;;
A;O;O
variety;O;O
of;O;O
toxic;O;O
neurological;O;O
effects;O;O
and;O;O
malignant;O;O
hyperpyrexia;O;O
can;O;O
occur;O;O
,;O;O
sometimes;O;O
with;O;O
fatal;O;O
results;O;O
.;O;O
DDI-DrugBank.d158.s10;;
Antihistamines;B-group;B-DDI-DrugBank.d158.s10.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s10.e1
may;O;O
counteract;O;O
the;O;O
sedative;O;O
effect;O;O
of;O;O
antihistamines;B-group;B-DDI-DrugBank.d158.s10.e2
.;O;O
DDI-DrugBank.d158.s11;;
Antihypertensives;B-group;B-DDI-DrugBank.d158.s11.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s11.e1
may;O;O
antagonize;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
antihypertensives;B-drug;B-DDI-DrugBank.d158.s11.e2
.;O;O
DDI-DrugBank.d158.s12;;
Chlorpromazine;B-drug;B-DDI-DrugBank.d158.s12.e0
:;O;O
Chlorpromazine;B-drug;B-DDI-DrugBank.d158.s12.e1
blocks;O;O
dopamine;O;O
and;O;O
norepinephrine;O;O
receptors;O;O
,;O;O
thus;O;O
inhibiting;O;O
the;O;O
central;O;O
stimulant;O;O
effects;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d158.s12.e2
and;O;O
can;O;O
be;O;O
used;O;O
to;O;O
treat;O;O
amphetamine;B-group;B-DDI-DrugBank.d158.s12.e3
poisoning;O;O
.;O;O
DDI-DrugBank.d158.s13;;
Ethosuximide;B-drug;B-DDI-DrugBank.d158.s13.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s13.e1
may;O;O
delay;O;O
intestinal;O;O
absorption;O;O
of;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d158.s13.e2
.;O;O
DDI-DrugBank.d158.s14;;
Haloperidol;B-drug;B-DDI-DrugBank.d158.s14.e0
:;O;O
Haloperidol;B-drug;B-DDI-DrugBank.d158.s14.e1
blocks;O;O
dopamine;O;O
receptors;O;O
,;O;O
thus;O;O
inhibiting;O;O
the;O;O
central;O;O
stimulant;O;O
effects;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d158.s14.e2
.;O;O
DDI-DrugBank.d158.s15;;
Lithium;B-drug;B-DDI-DrugBank.d158.s15.e0
carbonate;I-drug;I-DDI-DrugBank.d158.s15.e0
:;O;O
The;O;O
anorectic;O;O
and;O;O
stimulatory;O;O
effects;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d158.s15.e1
may;O;O
be;O;O
inhibited;O;O
by;O;O
lithium;B-drug;B-DDI-DrugBank.d158.s15.e2
carbonate;I-drug;I-DDI-DrugBank.d158.s15.e2
.;O;O
DDI-DrugBank.d158.s16;;
Meperidine;B-drug;B-DDI-DrugBank.d158.s16.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s16.e1
potentiate;O;O
the;O;O
analgesic;O;O
effect;O;O
of;O;O
meperidine;B-drug;B-DDI-DrugBank.d158.s16.e2
.;O;O
DDI-DrugBank.d158.s17;;
Methenamine;B-drug;B-DDI-DrugBank.d158.s17.e0
therapy;O;O
Urinary;O;O
excretion;O;O
of;O;O
amphetamines;B-group;B-DDI-DrugBank.d158.s17.e1
is;O;O
increased;O;O
,;O;O
and;O;O
efficacy;O;O
is;O;O
reduced;O;O
by;O;O
acidifying;O;O
agents;O;O
used;O;O
in;O;O
methenamine;B-drug;B-DDI-DrugBank.d158.s17.e2
therapy;O;O
.;O;O
DDI-DrugBank.d158.s18;;
Norepinephrine;B-drug;B-DDI-DrugBank.d158.s18.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s18.e1
enhance;O;O
the;O;O
adrenergic;O;O
effect;O;O
of;O;O
norepinephrine;B-drug;B-DDI-DrugBank.d158.s18.e2
.;O;O
DDI-DrugBank.d158.s19;;
Phenobarbital;B-drug;B-DDI-DrugBank.d158.s19.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s19.e1
may;O;O
delay;O;O
intestinal;O;O
absorption;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d158.s19.e2
,;O;O
DDI-DrugBank.d158.s20;;
co;O;O
-;O;O
administration;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d158.s20.e0
may;O;O
produce;O;O
a;O;O
synergistic;O;O
anticonvulsant;O;O
action;O;O
.;O;O
DDI-DrugBank.d158.s21;;
Phenytoin;B-drug;B-DDI-DrugBank.d158.s21.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s21.e1
may;O;O
delay;O;O
intestinal;O;O
absorption;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d158.s21.e2
,;O;O
DDI-DrugBank.d158.s22;;
co;O;O
-;O;O
administration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d158.s22.e0
may;O;O
produce;O;O
a;O;O
synergistic;O;O
anticonvulsant;O;O
action;O;O
.;O;O
DDI-DrugBank.d158.s23;;
Propoxyphene;B-drug;B-DDI-DrugBank.d158.s23.e0
:;O;O
In;O;O
cases;O;O
of;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d158.s23.e1
overdosage;O;O
,;O;O
amphetamine;B-drug;B-DDI-DrugBank.d158.s23.e2
CNS;O;O
stimulation;O;O
is;O;O
potentiated;O;O
and;O;O
fatal;O;O
convulsions;O;O
can;O;O
occur;O;O
.;O;O
DDI-DrugBank.d158.s24;;
Veratrum;B-group;B-DDI-DrugBank.d158.s24.e0
alkaloids;I-group;I-DDI-DrugBank.d158.s24.e0
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s24.e1
inhibit;O;O
the;O;O
hypotensive;O;O
effect;O;O
of;O;O
veratrum;B-group;B-DDI-DrugBank.d158.s24.e2
alkaloids;I-group;I-DDI-DrugBank.d158.s24.e2
.;O;O
DDI-DrugBank.d158.s25;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
:;O;O
Amphetamines;B-group;B-DDI-DrugBank.d158.s25.e0
can;O;O
cause;O;O
a;O;O
significant;O;O
elevation;O;O
in;O;O
plasma;O;O
corticosteroid;O;O
levels;O;O
.;O;O
DDI-DrugBank.d158.s26;;
This;O;O
increase;O;O
is;O;O
greatest;O;O
in;O;O
the;O;O
evening;O;O
.;O;O
DDI-DrugBank.d158.s27;;
Amphetamines;B-group;B-DDI-DrugBank.d158.s27.e0
may;O;O
interfere;O;O
with;O;O
urinary;O;O
steroid;O;O
determinations;O;O
.;O;O
DDI-DrugBank.d334.s0;;
Hypotension;O;O
-;O;O
Patients;O;O
on;O;O
Diuretic;O;O
Therapy;O;O
:;O;O
Patients;O;O
on;O;O
diuretics;B-group;B-DDI-DrugBank.d334.s0.e0
,;O;O
and;O;O
especially;O;O
those;O;O
in;O;O
whom;O;O
diuretic;O;O
therapy;O;O
was;O;O
recently;O;O
instituted;O;O
,;O;O
may;O;O
occasionally;O;O
experience;O;O
an;O;O
excessive;O;O
reduction;O;O
of;O;O
blood;O;O
pressure;O;O
after;O;O
initiation;O;O
of;O;O
therapy;O;O
with;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s0.e1
.;O;O
DDI-DrugBank.d334.s1;;
The;O;O
possibility;O;O
of;O;O
hypotensive;O;O
effects;O;O
with;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s1.e0
can;O;O
be;O;O
minimized;O;O
by;O;O
either;O;O
discontinuing;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d334.s1.e1
or;O;O
increasing;O;O
the;O;O
salt;O;O
intake;O;O
prior;O;O
to;O;O
initiation;O;O
of;O;O
treatment;O;O
with;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s1.e2
.;O;O
DDI-DrugBank.d334.s2;;
If;O;O
it;O;O
is;O;O
necessary;O;O
to;O;O
continue;O;O
the;O;O
diuretic;B-group;B-DDI-DrugBank.d334.s2.e0
,;O;O
initiate;O;O
therapy;O;O
with;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s2.e1
at;O;O
a;O;O
dose;O;O
of;O;O
5;O;O
mg;O;O
daily;O;O
,;O;O
and;O;O
provide;O;O
close;O;O
medical;O;O
supervision;O;O
after;O;O
the;O;O
initial;O;O
dose;O;O
until;O;O
blood;O;O
pressure;O;O
has;O;O
stabilized;O;O
.;O;O
DDI-DrugBank.d334.s3;;
When;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d334.s3.e0
is;O;O
added;O;O
to;O;O
the;O;O
therapy;O;O
of;O;O
a;O;O
patient;O;O
receiving;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s3.e1
,;O;O
an;O;O
additional;O;O
antihypertensive;O;O
effect;O;O
is;O;O
usually;O;O
observed;O;O
.;O;O
DDI-DrugBank.d334.s4;;
Studies;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d334.s4.e0
inhibitors;I-group;I-DDI-DrugBank.d334.s4.e0
in;O;O
combination;O;O
with;O;O
diuretics;B-group;B-DDI-DrugBank.d334.s4.e1
indicate;O;O
that;O;O
the;O;O
dose;O;O
of;O;O
the;O;O
ACE;B-group;B-DDI-DrugBank.d334.s4.e2
inhibitor;I-group;I-DDI-DrugBank.d334.s4.e2
can;O;O
be;O;O
reduced;O;O
when;O;O
it;O;O
is;O;O
given;O;O
with;O;O
a;O;O
diuretic;B-group;B-DDI-DrugBank.d334.s4.e3
.;O;O
DDI-DrugBank.d334.s5;;
Non;B-group;B-DDI-DrugBank.d334.s5.e0
-;I-group;I-DDI-DrugBank.d334.s5.e0
steroidal;I-group;I-DDI-DrugBank.d334.s5.e0
Anti;I-group;I-DDI-DrugBank.d334.s5.e0
-;I-group;I-DDI-DrugBank.d334.s5.e0
inflammatory;I-group;I-DDI-DrugBank.d334.s5.e0
Agents;I-group;I-DDI-DrugBank.d334.s5.e0
:;O;O
In;O;O
some;O;O
patients;O;O
with;O;O
compromised;O;O
renal;O;O
function;O;O
who;O;O
are;O;O
being;O;O
treated;O;O
with;O;O
non;B-group;B-DDI-DrugBank.d334.s5.e1
-;I-group;I-DDI-DrugBank.d334.s5.e1
steroidal;I-group;I-DDI-DrugBank.d334.s5.e1
anti;I-group;I-DDI-DrugBank.d334.s5.e1
-;I-group;I-DDI-DrugBank.d334.s5.e1
inflammatory;I-group;I-DDI-DrugBank.d334.s5.e1
drugs;I-group;I-DDI-DrugBank.d334.s5.e1
,;O;O
the;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
lisinopril;B-drug;B-DDI-DrugBank.d334.s5.e2
may;O;O
result;O;O
in;O;O
a;O;O
further;O;O
deterioration;O;O
of;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d334.s6;;
These;O;O
effects;O;O
are;O;O
usually;O;O
reversible;O;O
.;O;O
DDI-DrugBank.d334.s7;;
Reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d334.s7.e0
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
ACE;B-group;B-DDI-DrugBank.d334.s7.e1
inhibitors;I-group;I-DDI-DrugBank.d334.s7.e1
,;O;O
including;O;O
lisinopril;B-drug;B-DDI-DrugBank.d334.s7.e2
.;O;O
DDI-DrugBank.d334.s8;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
NSAIDs;B-group;B-DDI-DrugBank.d334.s8.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d334.s8.e1
inhibitors;I-group;I-DDI-DrugBank.d334.s8.e1
.;O;O
DDI-DrugBank.d334.s9;;
In;O;O
a;O;O
study;O;O
in;O;O
36;O;O
patients;O;O
with;O;O
mild;O;O
to;O;O
moderate;O;O
hypertension;O;O
where;O;O
the;O;O
antihypertensive;O;O
effects;O;O
of;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s9.e0
alone;O;O
were;O;O
compared;O;O
to;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s9.e1
given;O;O
concomitantly;O;O
with;O;O
indomethacin;B-drug;B-DDI-DrugBank.d334.s9.e2
,;O;O
the;O;O
use;O;O
of;O;O
indomethacin;B-drug;B-DDI-DrugBank.d334.s9.e3
was;O;O
associated;O;O
with;O;O
a;O;O
reduced;O;O
antihypertensive;O;O
effect;O;O
,;O;O
although;O;O
the;O;O
difference;O;O
between;O;O
the;O;O
two;O;O
regimens;O;O
was;O;O
not;O;O
significant;O;O
.;O;O
DDI-DrugBank.d334.s10;;
Other;O;O
Agents;O;O
:;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s10.e0
has;O;O
been;O;O
used;O;O
concomitantly;O;O
with;O;O
nitrates;B-group;B-DDI-DrugBank.d334.s10.e1
and/or;O;O
digoxin;B-drug;B-DDI-DrugBank.d334.s10.e2
without;O;O
evidence;O;O
of;O;O
clinically;O;O
significant;O;O
adverse;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d334.s11;;
This;O;O
included;O;O
post;O;O
myocardial;O;O
infarction;O;O
patients;O;O
who;O;O
were;O;O
receiving;O;O
intravenous;O;O
or;O;O
transdermal;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d334.s11.e0
.;O;O
DDI-DrugBank.d334.s12;;
No;O;O
clinically;O;O
important;O;O
pharmacokinetic;O;O
interactions;O;O
occurred;O;O
when;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s12.e0
was;O;O
used;O;O
concomitantly;O;O
with;O;O
propranolol;B-drug;B-DDI-DrugBank.d334.s12.e1
or;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d334.s12.e2
.;O;O
DDI-DrugBank.d334.s13;;
The;O;O
presence;O;O
of;O;O
food;O;O
in;O;O
the;O;O
stomach;O;O
does;O;O
not;O;O
alter;O;O
the;O;O
bioavailability;O;O
of;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s13.e0
.;O;O
DDI-DrugBank.d334.s14;;
Agents;O;O
Increasing;O;O
Serum;O;O
Potassium;O;O
:;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s14.e0
attenuates;O;O
potassium;O;O
loss;O;O
caused;O;O
by;O;O
thiazide;B-group;B-DDI-DrugBank.d334.s14.e1
-;I-group;I-DDI-DrugBank.d334.s14.e1
type;I-group;I-DDI-DrugBank.d334.s14.e1
diuretics;I-group;I-DDI-DrugBank.d334.s14.e1
.;O;O
DDI-DrugBank.d334.s15;;
Use;O;O
of;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s15.e0
with;O;O
potassium;B-group;B-DDI-DrugBank.d334.s15.e1
-;I-group;I-DDI-DrugBank.d334.s15.e1
sparing;I-group;I-DDI-DrugBank.d334.s15.e1
diuretics;I-group;I-DDI-DrugBank.d334.s15.e1
(;O;O
e.g.;O;O
,;O;O
spironolactone;B-drug;B-DDI-DrugBank.d334.s15.e2
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d334.s15.e3
,;O;O
or;O;O
amiloride;B-drug;B-DDI-DrugBank.d334.s15.e4
);O;O
,;O;O
potassium;B-drug;B-DDI-DrugBank.d334.s15.e5
supplements;O;O
,;O;O
or;O;O
potassium;O;O
-;O;O
containing;O;O
salt;O;O
substitutes;O;O
may;O;O
lead;O;O
to;O;O
significant;O;O
increases;O;O
in;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d334.s16;;
Therefore;O;O
,;O;O
if;O;O
concomitant;O;O
use;O;O
of;O;O
these;O;O
agents;O;O
is;O;O
indicated;O;O
because;O;O
of;O;O
demonstrated;O;O
hypokalemia;O;O
,;O;O
they;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
and;O;O
with;O;O
frequent;O;O
monitoring;O;O
of;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d334.s17;;
Potassium;O;O
sparing;O;O
agents;O;O
should;O;O
generally;O;O
not;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
with;O;O
heart;O;O
failure;O;O
who;O;O
are;O;O
receiving;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s17.e0
.;O;O
DDI-DrugBank.d334.s18;;
Lithium;B-drug;B-DDI-DrugBank.d334.s18.e0
:;O;O
Lithium;B-drug;B-DDI-DrugBank.d334.s18.e1
toxicity;O;O
has;O;O
been;O;O
reported;O;O
in;O;O
patients;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d334.s18.e2
concomitantly;O;O
with;O;O
drugs;O;O
which;O;O
cause;O;O
elimination;O;O
of;O;O
sodium;O;O
,;O;O
including;O;O
ACE;B-group;B-DDI-DrugBank.d334.s18.e3
inhibitors;I-group;I-DDI-DrugBank.d334.s18.e3
.;O;O
DDI-DrugBank.d334.s19;;
Lithium;B-drug;B-DDI-DrugBank.d334.s19.e0
toxicity;O;O
was;O;O
usually;O;O
reversible;O;O
upon;O;O
discontinuation;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d334.s19.e1
and;O;O
the;O;O
ACE;B-group;B-DDI-DrugBank.d334.s19.e2
inhibitor;I-group;I-DDI-DrugBank.d334.s19.e2
.;O;O
DDI-DrugBank.d334.s20;;
It;O;O
is;O;O
recommended;O;O
that;O;O
serum;O;O
lithium;B-drug;B-DDI-DrugBank.d334.s20.e0
levels;O;O
be;O;O
monitored;O;O
frequently;O;O
if;O;O
PRINIVIL;B-brand;B-DDI-DrugBank.d334.s20.e1
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
lithium;B-drug;B-DDI-DrugBank.d334.s20.e2
.;O;O
DDI-DrugBank.d454.s0;;
-;O;O
Lofexidine;B-drug;B-DDI-DrugBank.d454.s0.e0
may;O;O
enhance;O;O
the;O;O
CNS;O;O
depressive;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d454.s0.e1
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d454.s0.e2
and;O;O
other;O;O
sedatives;B-group;B-DDI-DrugBank.d454.s0.e3
DDI-DrugBank.d454.s1;;
.;O;O
DDI-DrugBank.d454.s2;;
-;O;O
Lofexidine;B-drug;B-DDI-DrugBank.d454.s2.e0
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
anti;B-group;B-DDI-DrugBank.d454.s2.e1
-;I-group;I-DDI-DrugBank.d454.s2.e1
hypertensive;I-group;I-DDI-DrugBank.d454.s2.e1
drug;I-group;I-DDI-DrugBank.d454.s2.e1
therapy;O;O
DDI-DrugBank.d454.s3;;
.;O;O
DDI-DrugBank.d454.s4;;
-;O;O
Concomitant;O;O
use;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d454.s4.e0
antidepressants;I-group;I-DDI-DrugBank.d454.s4.e0
may;O;O
reduce;O;O
the;O;O
efficacy;O;O
of;O;O
lofexidine;B-drug;B-DDI-DrugBank.d454.s4.e1
.;O;O
DDI-DrugBank.d516.s0;;
Theophylline;B-drug;B-DDI-DrugBank.d516.s0.e0
:;O;O
In;O;O
three;O;O
pharmacokinetic;O;O
studies;O;O
including;O;O
46;O;O
normal;O;O
,;O;O
healthy;O;O
subjects;O;O
,;O;O
theophylline;B-drug;B-DDI-DrugBank.d516.s0.e1
clearance;O;O
and;O;O
concentration;O;O
were;O;O
not;O;O
significantly;O;O
altered;O;O
by;O;O
the;O;O
addition;O;O
of;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s0.e2
.;O;O
DDI-DrugBank.d516.s1;;
In;O;O
clinical;O;O
studies;O;O
where;O;O
patients;O;O
were;O;O
on;O;O
chronic;O;O
theophylline;B-drug;B-DDI-DrugBank.d516.s1.e0
therapy;O;O
,;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s1.e1
had;O;O
no;O;O
measurable;O;O
effect;O;O
on;O;O
the;O;O
mean;O;O
distribution;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d516.s1.e2
concentrations;O;O
or;O;O
the;O;O
mean;O;O
estimates;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d516.s1.e3
clearance;O;O
.;O;O
DDI-DrugBank.d516.s2;;
Though;O;O
individual;O;O
theophylline;B-drug;B-DDI-DrugBank.d516.s2.e0
levels;O;O
fluctuated;O;O
,;O;O
there;O;O
were;O;O
no;O;O
clinically;O;O
significant;O;O
symptoms;O;O
of;O;O
drug;O;O
inter;O;O
-;O;O
action;O;O
.;O;O
DDI-DrugBank.d516.s3;;
Antacids;B-group;B-DDI-DrugBank.d516.s3.e0
and;O;O
sucralfate;B-drug;B-DDI-DrugBank.d516.s3.e1
:;O;O
Sucralfate;B-drug;B-DDI-DrugBank.d516.s3.e2
and;O;O
antacids;B-group;B-DDI-DrugBank.d516.s3.e3
containing;O;O
magnesium;B-drug;B-DDI-DrugBank.d516.s3.e4
or;O;O
aluminum;B-drug;B-DDI-DrugBank.d516.s3.e5
,;O;O
as;O;O
well;O;O
as;O;O
formulations;O;O
containing;O;O
divalent;O;O
and;O;O
trivalent;O;O
cations;O;O
such;O;O
as;O;O
Videx;B-brand;B-DDI-DrugBank.d516.s3.e6
(;O;O
didanosine;B-drug;B-DDI-DrugBank.d516.s3.e7
);O;O
,;O;O
chewable;O;O
/;O;O
buffered;O;O
tablets;O;O
or;O;O
the;O;O
pediatric;O;O
powder;O;O
for;O;O
oral;O;O
solution;O;O
can;O;O
form;O;O
chelation;O;O
complexes;O;O
with;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s3.e8
and;O;O
interfere;O;O
with;O;O
its;O;O
bioavailability;O;O
.;O;O
DDI-DrugBank.d516.s4;;
Sucralfate;B-drug;B-DDI-DrugBank.d516.s4.e0
administered;O;O
2;O;O
hours;O;O
before;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s4.e1
resulted;O;O
in;O;O
a;O;O
slower;O;O
absorption;O;O
(;O;O
mean;O;O
C;O;O
max;O;O
decreased;O;O
by;O;O
30;O;O
%;O;O
and;O;O
mean;O;O
T;O;O
max;O;O
increased;O;O
by;O;O
1;O;O
hour;O;O
);O;O
and;O;O
a;O;O
lesser;O;O
extent;O;O
of;O;O
absorption;O;O
(;O;O
mean;O;O
AUC;O;O
decreased;O;O
by;O;O
approximately;O;O
25;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d516.s5;;
Magnesium;B-drug;B-DDI-DrugBank.d516.s5.e0
-;O;O
and;O;O
aluminum;B-drug;B-DDI-DrugBank.d516.s5.e1
-;O;O
containing;O;O
antacids;B-group;B-DDI-DrugBank.d516.s5.e2
,;O;O
administered;O;O
concomitantly;O;O
with;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s5.e3
,;O;O
significantly;O;O
decreased;O;O
the;O;O
bioavailability;O;O
(;O;O
48;O;O
%;O;O
);O;O
of;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s5.e4
.;O;O
DDI-DrugBank.d516.s6;;
Separating;O;O
the;O;O
doses;O;O
of;O;O
antacid;B-group;B-DDI-DrugBank.d516.s6.e0
and;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s6.e1
minimizes;O;O
this;O;O
decrease;O;O
in;O;O
bioavailability;O;O
,;O;O
DDI-DrugBank.d516.s7;;
therefore;O;O
,;O;O
administration;O;O
of;O;O
these;O;O
agents;O;O
should;O;O
precede;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s7.e0
dosing;O;O
by;O;O
4;O;O
hours;O;O
or;O;O
follow;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s7.e1
dosing;O;O
by;O;O
at;O;O
least;O;O
2;O;O
hours;O;O
.;O;O
DDI-DrugBank.d516.s8;;
Caffeine;B-drug;B-DDI-DrugBank.d516.s8.e0
:;O;O
Two;O;O
hundred;O;O
mg;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d516.s8.e1
(;O;O
equivalent;O;O
to;O;O
1;O;O
to;O;O
3;O;O
cups;O;O
of;O;O
American;O;O
coffee;O;O
);O;O
was;O;O
administered;O;O
to;O;O
16;O;O
normal;O;O
,;O;O
healthy;O;O
volunteers;O;O
who;O;O
had;O;O
achieved;O;O
steady;O;O
-;O;O
state;O;O
blood;O;O
concentrations;O;O
of;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s8.e2
after;O;O
being;O;O
dosed;O;O
at;O;O
400;O;O
mg;O;O
qd;O;O
.;O;O
DDI-DrugBank.d516.s9;;
This;O;O
did;O;O
not;O;O
result;O;O
in;O;O
any;O;O
statistically;O;O
or;O;O
clinically;O;O
relevant;O;O
changes;O;O
in;O;O
the;O;O
pharmacokinetic;O;O
parameters;O;O
of;O;O
either;O;O
caffeine;B-drug;B-DDI-DrugBank.d516.s9.e0
or;O;O
its;O;O
major;O;O
metabolite;O;O
,;O;O
paraxanthine;B-drug_n;B-DDI-DrugBank.d516.s9.e1
.;O;O
DDI-DrugBank.d516.s10;;
No;O;O
data;O;O
are;O;O
available;O;O
on;O;O
potential;O;O
interactions;O;O
in;O;O
individuals;O;O
who;O;O
consume;O;O
greater;O;O
than;O;O
200;O;O
mg;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d516.s10.e0
per;O;O
day;O;O
or;O;O
in;O;O
those;O;O
,;O;O
such;O;O
as;O;O
the;O;O
geriatric;O;O
population;O;O
,;O;O
who;O;O
are;O;O
generally;O;O
believed;O;O
to;O;O
be;O;O
more;O;O
susceptible;O;O
to;O;O
the;O;O
development;O;O
of;O;O
drug;O;O
-;O;O
induced;O;O
CNS;O;O
-;O;O
related;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d516.s11;;
Other;O;O
quinolones;B-group;B-DDI-DrugBank.d516.s11.e0
have;O;O
demonstrated;O;O
moderate;O;O
to;O;O
marked;O;O
interference;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d516.s11.e1
,;O;O
resulting;O;O
in;O;O
a;O;O
reduced;O;O
clearance;O;O
,;O;O
a;O;O
prolongation;O;O
of;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
,;O;O
and;O;O
an;O;O
increase;O;O
in;O;O
symptoms;O;O
that;O;O
accompany;O;O
high;O;O
levels;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d516.s11.e2
.;O;O
DDI-DrugBank.d516.s12;;
Cimetidine;B-drug;B-DDI-DrugBank.d516.s12.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d516.s12.e1
has;O;O
been;O;O
demonstrated;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
elimination;O;O
of;O;O
other;O;O
quinolones;B-group;B-DDI-DrugBank.d516.s12.e2
.;O;O
DDI-DrugBank.d516.s13;;
This;O;O
interference;O;O
has;O;O
resulted;O;O
in;O;O
significant;O;O
increases;O;O
in;O;O
half;O;O
-;O;O
life;O;O
and;O;O
AUC;O;O
.;O;O
DDI-DrugBank.d516.s14;;
The;O;O
interaction;O;O
between;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s14.e0
and;O;O
cimetidine;B-drug;B-DDI-DrugBank.d516.s14.e1
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d516.s15;;
Cyclosporine;B-drug;B-DDI-DrugBank.d516.s15.e0
:;O;O
Elevated;O;O
serum;O;O
levels;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d516.s15.e1
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d516.s15.e2
with;O;O
other;O;O
members;O;O
of;O;O
the;O;O
quinolone;B-group;B-DDI-DrugBank.d516.s15.e3
class;I-group;I-DDI-DrugBank.d516.s15.e3
.;O;O
DDI-DrugBank.d516.s16;;
Interaction;O;O
between;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s16.e0
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d516.s16.e1
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d516.s17;;
Omeprazole;B-drug;B-DDI-DrugBank.d516.s17.e0
:;O;O
No;O;O
clinically;O;O
significant;O;O
changes;O;O
in;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s17.e1
pharmacokinetics;O;O
(;O;O
AUC;O;O
,;O;O
C;O;O
max;O;O
,;O;O
or;O;O
T;O;O
max;O;O
);O;O
were;O;O
observed;O;O
when;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s17.e2
400;O;O
mg;O;O
was;O;O
given;O;O
after;O;O
multiple;O;O
doses;O;O
of;O;O
omeprazole;B-drug;B-DDI-DrugBank.d516.s17.e3
(;O;O
20;O;O
mg;O;O
qd;O;O
);O;O
in;O;O
13;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d516.s18;;
Changes;O;O
in;O;O
omeprazole;B-drug;B-DDI-DrugBank.d516.s18.e0
pharmacokinetics;O;O
were;O;O
not;O;O
studied;O;O
.;O;O
DDI-DrugBank.d516.s19;;
Phenytoin;B-drug;B-DDI-DrugBank.d516.s19.e0
:;O;O
No;O;O
significant;O;O
differences;O;O
were;O;O
observed;O;O
in;O;O
mean;O;O
phenytoin;B-drug;B-DDI-DrugBank.d516.s19.e1
AUC;O;O
,;O;O
C;O;O
max;O;O
,;O;O
C;O;O
min;O;O
or;O;O
T;O;O
max;O;O
(;O;O
although;O;O
C;O;O
max;O;O
increased;O;O
by;O;O
11;O;O
%;O;O
);O;O
when;O;O
extended;O;O
phenytoin;B-drug;B-DDI-DrugBank.d516.s19.e2
sodium;I-drug;I-DDI-DrugBank.d516.s19.e2
capsules;O;O
(;O;O
100;O;O
mg;O;O
tid;O;O
);O;O
were;O;O
coadministered;O;O
with;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s19.e3
(;O;O
400;O;O
mg;O;O
qd;O;O
);O;O
for;O;O
five;O;O
days;O;O
in;O;O
15;O;O
healthy;O;O
males;O;O
.;O;O
DDI-DrugBank.d516.s20;;
Lomefloxacin;B-drug;B-DDI-DrugBank.d516.s20.e0
is;O;O
unlikely;O;O
to;O;O
have;O;O
a;O;O
significant;O;O
effect;O;O
on;O;O
phenytoin;B-drug;B-DDI-DrugBank.d516.s20.e1
metabolism;O;O
.;O;O
DDI-DrugBank.d516.s21;;
Probenecid;B-drug;B-DDI-DrugBank.d516.s21.e0
:;O;O
Probenecid;B-drug;B-DDI-DrugBank.d516.s21.e1
slows;O;O
the;O;O
renal;O;O
elimination;O;O
of;O;O
lome;O;O
-;O;O
floxacin;O;O
.;O;O
DDI-DrugBank.d516.s22;;
An;O;O
increase;O;O
of;O;O
63;O;O
%;O;O
in;O;O
the;O;O
mean;O;O
AUC;O;O
and;O;O
increases;O;O
of;O;O
50;O;O
%;O;O
and;O;O
4;O;O
%;O;O
,;O;O
respectively;O;O
,;O;O
in;O;O
the;O;O
mean;O;O
T;O;O
max;O;O
and;O;O
mean;O;O
C;O;O
max;O;O
were;O;O
noted;O;O
in;O;O
1;O;O
study;O;O
of;O;O
6;O;O
individuals;O;O
.;O;O
DDI-DrugBank.d516.s23;;
Terfenadine;B-drug;B-DDI-DrugBank.d516.s23.e0
:;O;O
No;O;O
clinically;O;O
significant;O;O
changes;O;O
occurred;O;O
in;O;O
heart;O;O
rate;O;O
or;O;O
corrected;O;O
QT;O;O
intervals;O;O
,;O;O
or;O;O
in;O;O
terfenadine;B-drug;B-DDI-DrugBank.d516.s23.e1
metabolite;O;O
or;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s23.e2
pharmacokinetics;O;O
,;O;O
during;O;O
concurrent;O;O
administration;O;O
of;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s23.e3
and;O;O
terfenadine;B-drug;B-DDI-DrugBank.d516.s23.e4
at;O;O
steady;O;O
-;O;O
state;O;O
in;O;O
28;O;O
healthy;O;O
males;O;O
.;O;O
DDI-DrugBank.d516.s24;;
Warfarin;B-drug;B-DDI-DrugBank.d516.s24.e0
:;O;O
Quinolones;B-group;B-DDI-DrugBank.d516.s24.e1
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
the;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d516.s24.e2
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d516.s24.e3
,;O;O
or;O;O
its;O;O
derivatives;O;O
.;O;O
DDI-DrugBank.d516.s25;;
When;O;O
these;O;O
products;O;O
are;O;O
administered;O;O
concomitantly;O;O
,;O;O
prothrombin;O;O
or;O;O
other;O;O
suitable;O;O
coagulation;O;O
tests;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
.;O;O
DDI-DrugBank.d516.s26;;
However;O;O
,;O;O
no;O;O
clinically;O;O
or;O;O
statistically;O;O
significant;O;O
differences;O;O
in;O;O
prothrombin;O;O
time;O;O
ratio;O;O
or;O;O
warfarin;B-drug;B-DDI-DrugBank.d516.s26.e0
enantiomer;O;O
pharmacokinetics;O;O
were;O;O
observed;O;O
in;O;O
a;O;O
small;O;O
study;O;O
of;O;O
7;O;O
healthy;O;O
males;O;O
who;O;O
received;O;O
both;O;O
warfarin;B-drug;B-DDI-DrugBank.d516.s26.e1
and;O;O
lomefloxacin;B-drug;B-DDI-DrugBank.d516.s26.e2
under;O;O
steady;O;O
-;O;O
state;O;O
conditions;O;O
.;O;O
DDI-DrugBank.d125.s0;;
There;O;O
was;O;O
no;O;O
evidence;O;O
in;O;O
clinical;O;O
trials;O;O
of;O;O
drug;O;O
interactions;O;O
with;O;O
concurrent;O;O
medications;O;O
.;O;O
DDI-DrugBank.d351.s0;;
Probenecid;B-drug;B-DDI-DrugBank.d351.s0.e0
:;O;O
As;O;O
with;O;O
other;O;O
b;B-group;B-DDI-DrugBank.d351.s0.e1
-;I-group;I-DDI-DrugBank.d351.s0.e1
lactam;I-group;I-DDI-DrugBank.d351.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d351.s0.e1
,;O;O
renal;O;O
excretion;O;O
of;O;O
loracarbef;B-drug;B-DDI-DrugBank.d351.s0.e2
is;O;O
inhibited;O;O
by;O;O
probenecid;B-drug;B-DDI-DrugBank.d351.s0.e3
and;O;O
resulted;O;O
in;O;O
an;O;O
approximate;O;O
80;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
AUC;O;O
for;O;O
loracarbef;B-drug;B-DDI-DrugBank.d351.s0.e4
.;O;O
DDI-DrugBank.d258.s0;;
Loratadine;B-drug;B-DDI-DrugBank.d258.s0.e0
(;O;O
10;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
has;O;O
been;O;O
coadministered;O;O
with;O;O
therapeutic;O;O
doses;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d258.s0.e1
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d258.s0.e2
,;O;O
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d258.s0.e3
in;O;O
controlled;O;O
clinical;O;O
pharmacology;O;O
studies;O;O
in;O;O
adult;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d258.s1;;
Although;O;O
increased;O;O
plasma;O;O
concentrations;O;O
(;O;O
AUC;O;O
0;O;O
-;O;O
24;O;O
hrs;O;O
);O;O
of;O;O
loratadine;B-drug;B-DDI-DrugBank.d258.s1.e0
and/or;O;O
descarboethoxyloratadine;B-drug;B-DDI-DrugBank.d258.s1.e1
were;O;O
observed;O;O
following;O;O
coadministration;O;O
of;O;O
loratadine;B-drug;B-DDI-DrugBank.d258.s1.e2
with;O;O
each;O;O
of;O;O
these;O;O
drugs;O;O
in;O;O
normal;O;O
volunteers;O;O
(;O;O
n;O;O
=;O;O
24;O;O
in;O;O
each;O;O
study;O;O
);O;O
,;O;O
there;O;O
were;O;O
no;O;O
clinically;O;O
relevant;O;O
changes;O;O
in;O;O
the;O;O
safety;O;O
profile;O;O
of;O;O
loratadine;B-drug;B-DDI-DrugBank.d258.s1.e3
,;O;O
as;O;O
assessed;O;O
by;O;O
electrocardiographic;O;O
parameters;O;O
,;O;O
clinical;O;O
laboratory;O;O
tests;O;O
,;O;O
vital;O;O
signs;O;O
,;O;O
and;O;O
adverse;O;O
events;O;O
.;O;O
DDI-DrugBank.d258.s2;;
There;O;O
were;O;O
no;O;O
significant;O;O
effects;O;O
on;O;O
QTc;O;O
intervals;O;O
,;O;O
and;O;O
no;O;O
reports;O;O
of;O;O
sedation;O;O
or;O;O
syncope;O;O
.;O;O
DDI-DrugBank.d258.s3;;
No;O;O
effects;O;O
on;O;O
plasma;O;O
concentrations;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d258.s3.e0
or;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d258.s3.e1
were;O;O
observed;O;O
.;O;O
DDI-DrugBank.d258.s4;;
Plasma;O;O
concentrations;O;O
(;O;O
AUC;O;O
0;O;O
-;O;O
24;O;O
hrs;O;O
);O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d258.s4.e0
decreased;O;O
15;O;O
%;O;O
with;O;O
coadministration;O;O
of;O;O
loratadine;B-drug;B-DDI-DrugBank.d258.s4.e1
relative;O;O
to;O;O
that;O;O
observed;O;O
with;O;O
erythromycin;B-drug;B-DDI-DrugBank.d258.s4.e2
alone;O;O
.;O;O
DDI-DrugBank.d258.s5;;
The;O;O
clinical;O;O
relevance;O;O
of;O;O
this;O;O
difference;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d258.s6;;
These;O;O
above;O;O
findings;O;O
are;O;O
summarized;O;O
in;O;O
TABLE;O;O
1;O;O
.;O;O
DDI-DrugBank.d258.s7;;
TABLE;O;O
1;O;O
Effects;O;O
on;O;O
Plasma;O;O
Concentrations;O;O
(;O;O
AUC;O;O
0;O;O
-;O;O
24;O;O
hrs;O;O
);O;O
of;O;O
Loratadine;B-drug;B-DDI-DrugBank.d258.s7.e0
and;O;O
Descarboethoxyloratadine;B-drug;B-DDI-DrugBank.d258.s7.e1
After;O;O
10;O;O
Days;O;O
of;O;O
Coadministration;O;O
(;O;O
Loratadine;B-drug;B-DDI-DrugBank.d258.s7.e2
10;O;O
mg;O;O
);O;O
in;O;O
Normal;O;O
Volunteers;O;O
DDI-DrugBank.d258.s8;;
Loratadine;B-drug;B-DDI-DrugBank.d258.s8.e0
Descarboethoxyloratadine;I-drug;I-DDI-DrugBank.d258.s8.e1
DDI-DrugBank.d258.s9;;
Erythromycin;I-drug;I-DDI-DrugBank.d258.s9.e0
(;O;O
500;O;O
mg;O;O
q8h;O;O
);O;O
+;O;O
40;O;O
%;O;O
+46;O;O
%;O;O
DDI-DrugBank.d258.s10;;
Cimetidine;B-drug;B-DDI-DrugBank.d258.s10.e0
(;O;O
300;O;O
mg;O;O
qid;O;O
);O;O
+103;O;O
%;O;O
+;O;O
6;O;O
%;O;O
DDI-DrugBank.d258.s11;;
Ketoconazole;B-drug;B-DDI-DrugBank.d258.s11.e0
(;O;O
200;O;O
mg;O;O
q12h;O;O
);O;O
+307;O;O
%;O;O
+73;O;O
%;O;O
DDI-DrugBank.d258.s12;;
There;O;O
does;O;O
not;O;O
appear;O;O
to;O;O
be;O;O
an;O;O
increase;O;O
in;O;O
adverse;O;O
events;O;O
in;O;O
subjects;O;O
who;O;O
received;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d258.s12.e0
and;O;O
loratadine;B-drug;B-DDI-DrugBank.d258.s12.e1
.;O;O
DDI-DrugBank.d18.s0;;
Tablets;O;O
:;O;O
The;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d18.s0.e0
,;O;O
including;O;O
lorazepam;B-drug;B-DDI-DrugBank.d18.s0.e1
,;O;O
produce;O;O
CNS;O;O
-;O;O
depressant;O;O
effects;O;O
when;O;O
administered;O;O
with;O;O
such;O;O
medications;O;O
as;O;O
barbiturates;B-group;B-DDI-DrugBank.d18.s0.e2
or;O;O
alcohol;B-drug;B-DDI-DrugBank.d18.s0.e3
.;O;O
DDI-DrugBank.d18.s1;;
Injection;O;O
:;O;O
Lorazepam;B-drug;B-DDI-DrugBank.d18.s1.e0
injection;O;O
,;O;O
like;O;O
other;O;O
injectable;O;O
benzodiazepines;B-group;B-DDI-DrugBank.d18.s1.e1
,;O;O
produces;O;O
depression;O;O
of;O;O
the;O;O
central;O;O
nervous;O;O
system;O;O
when;O;O
administered;O;O
with;O;O
ethyl;B-drug;B-DDI-DrugBank.d18.s1.e2
alcohol;I-drug;I-DDI-DrugBank.d18.s1.e2
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d18.s1.e3
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d18.s1.e4
,;O;O
MAO;B-group;B-DDI-DrugBank.d18.s1.e5
inhibitors;I-group;I-DDI-DrugBank.d18.s1.e5
,;O;O
and;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d18.s1.e6
.;O;O
When;O;O
scopolamine;B-drug;B-DDI-DrugBank.d18.s1.e7
is;O;O
used;O;O
concomitantly;O;O
with;O;O
injectable;O;O
lorazepam;B-drug;B-DDI-DrugBank.d18.s1.e8
,;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
sedation;O;O
,;O;O
hallucinations;O;O
,;O;O
and;O;O
irrational;O;O
behavior;O;O
has;O;O
been;O;O
observed;O;O
.;O;O
DDI-DrugBank.d30.s0;;
No;O;O
significant;O;O
drug;O;O
-;O;O
drug;O;O
pharmacokinetic;O;O
interactions;O;O
have;O;O
been;O;O
found;O;O
in;O;O
interaction;O;O
studies;O;O
with;O;O
hydrochlorothiazide;B-drug;B-DDI-DrugBank.d30.s0.e0
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d30.s0.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d30.s0.e2
,;O;O
cimetidine;B-drug;B-DDI-DrugBank.d30.s0.e3
and;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d30.s0.e4
.;O;O
DDI-DrugBank.d30.s1;;
Rifampin;B-drug;B-DDI-DrugBank.d30.s1.e0
,;O;O
an;O;O
inducer;O;O
of;O;O
drug;O;O
metabolism;O;O
,;O;O
decreased;O;O
the;O;O
concentrations;O;O
of;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s1.e1
and;O;O
its;O;O
active;O;O
metabolite;O;O
.;O;O
DDI-DrugBank.d30.s2;;
In;O;O
humans;O;O
,;O;O
two;O;O
inhibitors;O;O
of;O;O
P450;O;O
3A4;O;O
have;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d30.s3;;
Ketoconazole;B-drug;B-DDI-DrugBank.d30.s3.e0
did;O;O
not;O;O
affect;O;O
the;O;O
conversion;O;O
of;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s3.e1
to;O;O
the;O;O
active;O;O
metabolite;O;O
after;O;O
intravenous;O;O
administration;O;O
of;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s3.e2
,;O;O
and;O;O
erythromycin;B-drug;B-DDI-DrugBank.d30.s3.e3
had;O;O
no;O;O
clinically;O;O
significant;O;O
effect;O;O
after;O;O
oral;O;O
administration;O;O
.;O;O
DDI-DrugBank.d30.s4;;
Fluconazole;B-drug;B-DDI-DrugBank.d30.s4.e0
,;O;O
an;O;O
inhibitor;O;O
of;O;O
P450;O;O
2C9;O;O
,;O;O
decreased;O;O
active;O;O
metabolite;O;O
concentration;O;O
and;O;O
increased;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s4.e1
concentration;O;O
.;O;O
DDI-DrugBank.d30.s5;;
The;O;O
pharmacodynamic;O;O
consequences;O;O
of;O;O
concomitant;O;O
use;O;O
of;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s5.e0
and;O;O
inhibitors;O;O
of;O;O
P450;O;O
2C9;O;O
have;O;O
not;O;O
been;O;O
examined;O;O
.;O;O
DDI-DrugBank.d30.s6;;
Subjects;O;O
who;O;O
do;O;O
not;O;O
metabolize;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s6.e0
to;O;O
active;O;O
metabolite;O;O
have;O;O
been;O;O
shown;O;O
to;O;O
have;O;O
a;O;O
specific;O;O
,;O;O
rare;O;O
defect;O;O
in;O;O
cytochrome;O;O
P450;O;O
2C9;O;O
.;O;O
DDI-DrugBank.d30.s7;;
These;O;O
data;O;O
suggest;O;O
that;O;O
the;O;O
conversion;O;O
of;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s7.e0
to;O;O
its;O;O
active;O;O
metabolite;O;O
is;O;O
mediated;O;O
primarily;O;O
by;O;O
P450;O;O
2C9;O;O
and;O;O
not;O;O
P450;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d30.s8;;
As;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
block;O;O
angiotensin;O;O
II;O;O
or;O;O
its;O;O
effects;O;O
,;O;O
concomitant;O;O
use;O;O
of;O;O
potassium;B-group;B-DDI-DrugBank.d30.s8.e0
-;I-group;I-DDI-DrugBank.d30.s8.e0
sparing;I-group;I-DDI-DrugBank.d30.s8.e0
diuretics;I-group;I-DDI-DrugBank.d30.s8.e0
(;O;O
e.g.;O;O
,;O;O
spironolactone;B-drug;B-DDI-DrugBank.d30.s8.e1
,;O;O
triamterene;B-drug;B-DDI-DrugBank.d30.s8.e2
,;O;O
amiloride;B-drug;B-DDI-DrugBank.d30.s8.e3
);O;O
,;O;O
potassium;B-drug;B-DDI-DrugBank.d30.s8.e4
supplements;O;O
,;O;O
or;O;O
salt;O;O
substitutes;O;O
containing;O;O
potassium;O;O
may;O;O
lead;O;O
to;O;O
increases;O;O
in;O;O
serum;O;O
potassium;O;O
.;O;O
DDI-DrugBank.d30.s9;;
As;O;O
with;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d30.s9.e0
agents;I-group;I-DDI-DrugBank.d30.s9.e0
,;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
losartan;B-drug;B-DDI-DrugBank.d30.s9.e1
may;O;O
be;O;O
blunted;O;O
by;O;O
the;O;O
non;B-group;B-DDI-DrugBank.d30.s9.e2
-;I-group;I-DDI-DrugBank.d30.s9.e2
steroidal;I-group;I-DDI-DrugBank.d30.s9.e2
anti;I-group;I-DDI-DrugBank.d30.s9.e2
-;I-group;I-DDI-DrugBank.d30.s9.e2
inflammatory;I-group;I-DDI-DrugBank.d30.s9.e2
drug;I-group;I-DDI-DrugBank.d30.s9.e2
indomethacin;I-drug;I-DDI-DrugBank.d30.s9.e3
DDI-DrugBank.d30.s10;;
.;O;O
DDI-DrugBank.d30.s11;;
DDI-DrugBank.d567.s0;;
CYP3A4;O;O
Interactions;O;O
DDI-DrugBank.d567.s1;;
Lovastatin;B-drug;B-DDI-DrugBank.d567.s1.e0
is;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
but;O;O
has;O;O
no;O;O
CYP3A4;O;O
inhibitory;O;O
activity;O;O
,;O;O
DDI-DrugBank.d567.s2;;
therefore;O;O
it;O;O
is;O;O
not;O;O
expected;O;O
to;O;O
affect;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d567.s3;;
Potent;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
(;O;O
below;O;O
);O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
myopathy;O;O
by;O;O
reducing;O;O
the;O;O
elimination;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s3.e0
.;O;O
DDI-DrugBank.d567.s4;;
Pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d567.s5;;
Itraconazole;B-drug;B-DDI-DrugBank.d567.s5.e0
Ketoconazole;I-drug;I-DDI-DrugBank.d567.s5.e1
Erythromycin;I-drug;I-DDI-DrugBank.d567.s5.e2
Clarithromycin;I-drug;I-DDI-DrugBank.d567.s5.e3
Telithromycin;I-drug;I-DDI-DrugBank.d567.s5.e4
HIV;I-group;I-DDI-DrugBank.d567.s5.e5
protease;I-group;I-DDI-DrugBank.d567.s5.e5
inhibitors;I-group;I-DDI-DrugBank.d567.s5.e5
Nefazodone;I-drug;I-DDI-DrugBank.d567.s5.e6
Cyclosporine;I-drug;I-DDI-DrugBank.d567.s5.e7
Large;O;O
quantities;O;O
of;O;O
grapefruit;O;O
juice;O;O
(;O;O
1;O;O
quart;O;O
daily;O;O
);O;O
DDI-DrugBank.d567.s6;;
Interactions;O;O
with;O;O
lipid;O;O
-;O;O
lowering;O;O
drugs;O;O
that;O;O
can;O;O
cause;O;O
myopathy;O;O
when;O;O
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d567.s7;;
The;O;O
risk;O;O
of;O;O
myopathy;O;O
is;O;O
also;O;O
increased;O;O
by;O;O
the;O;O
following;O;O
lipid;O;O
-;O;O
lowering;O;O
drugs;O;O
that;O;O
are;O;O
not;O;O
potent;O;O
CYP3A4;O;O
inhibitors;O;O
,;O;O
but;O;O
which;O;O
can;O;O
cause;O;O
myopathy;O;O
when;O;O
given;O;O
alone;O;O
.;O;O
DDI-DrugBank.d567.s8;;
See;O;O
WARNINGS;O;O
,;O;O
Myopathy;O;O
/;O;O
Rhabdomyolysis;O;O
.;O;O
DDI-DrugBank.d567.s9;;
Gemfibrozil;B-drug;B-DDI-DrugBank.d567.s9.e0
Other;O;O
fibrates;B-group;B-DDI-DrugBank.d567.s9.e1
Niacin;I-drug;I-DDI-DrugBank.d567.s9.e2
(;O;O
nicotinic;B-drug;B-DDI-DrugBank.d567.s9.e3
acid;I-drug;I-DDI-DrugBank.d567.s9.e3
);O;O
(;O;O
=;O;O
1;O;O
g;O;O
/;O;O
day;O;O
);O;O
DDI-DrugBank.d567.s10;;
Other;O;O
drug;O;O
interactions;O;O
DDI-DrugBank.d567.s11;;
Danazol;B-drug;B-DDI-DrugBank.d567.s11.e0
:;O;O
The;O;O
risk;O;O
of;O;O
myopathy;O;O
/;O;O
rhabdomyolysis;O;O
is;O;O
increased;O;O
by;O;O
concomitant;O;O
administration;O;O
of;O;O
danazol;B-drug;B-DDI-DrugBank.d567.s11.e1
particularly;O;O
with;O;O
higher;O;O
doses;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s11.e2
(;O;O
see;O;O
WARNINGS;O;O
,;O;O
Myopathy;O;O
/;O;O
Rhabdomyolysis;O;O
);O;O
.;O;O
DDI-DrugBank.d567.s12;;
Amiodarone;B-drug;B-DDI-DrugBank.d567.s12.e0
or;O;O
Verapamil;B-drug;B-DDI-DrugBank.d567.s12.e1
:;O;O
The;O;O
risk;O;O
of;O;O
myopathy;O;O
/;O;O
rhabdomyolysis;O;O
is;O;O
increased;O;O
when;O;O
either;O;O
amiodarone;B-drug;B-DDI-DrugBank.d567.s12.e2
or;O;O
verapamil;B-drug;B-DDI-DrugBank.d567.s12.e3
is;O;O
used;O;O
concomitantly;O;O
with;O;O
a;O;O
closely;O;O
related;O;O
member;O;O
of;O;O
the;O;O
HMG;B-group;B-DDI-DrugBank.d567.s12.e4
-;I-group;I-DDI-DrugBank.d567.s12.e4
CoA;I-group;I-DDI-DrugBank.d567.s12.e4
reductase;I-group;I-DDI-DrugBank.d567.s12.e4
inhibitor;I-group;I-DDI-DrugBank.d567.s12.e4
class;I-group;I-DDI-DrugBank.d567.s12.e4
(;O;O
see;O;O
WARNINGS;O;O
,;O;O
Myopathy;O;O
/;O;O
Rhabdomyolysis;O;O
);O;O
.;O;O
DDI-DrugBank.d567.s13;;
Coumarin;B-group;B-DDI-DrugBank.d567.s13.e0
Anticoagulants;I-group;I-DDI-DrugBank.d567.s13.e0
:;O;O
In;O;O
a;O;O
small;O;O
clinical;O;O
trial;O;O
in;O;O
which;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s13.e1
was;O;O
administered;O;O
to;O;O
warfarin;B-drug;B-DDI-DrugBank.d567.s13.e2
treated;O;O
patients;O;O
,;O;O
no;O;O
effect;O;O
on;O;O
prothrombin;O;O
time;O;O
was;O;O
detected;O;O
.;O;O
DDI-DrugBank.d567.s14;;
However;O;O
,;O;O
another;O;O
HMG;B-group;B-DDI-DrugBank.d567.s14.e0
-;I-group;I-DDI-DrugBank.d567.s14.e0
CoA;I-group;I-DDI-DrugBank.d567.s14.e0
reductase;I-group;I-DDI-DrugBank.d567.s14.e0
inhibitor;I-group;I-DDI-DrugBank.d567.s14.e0
has;O;O
been;O;O
found;O;O
to;O;O
produce;O;O
a;O;O
less;O;O
than;O;O
two;O;O
-;O;O
second;O;O
increase;O;O
in;O;O
prothrombin;O;O
time;O;O
in;O;O
healthy;O;O
volunteers;O;O
receiving;O;O
low;O;O
doses;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d567.s14.e1
.;O;O
DDI-DrugBank.d567.s15;;
Also;O;O
,;O;O
bleeding;O;O
and/or;O;O
increased;O;O
prothrombin;O;O
time;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
a;O;O
few;O;O
patients;O;O
taking;O;O
coumarin;B-group;B-DDI-DrugBank.d567.s15.e0
anticoagulants;I-group;I-DDI-DrugBank.d567.s15.e0
concomitantly;O;O
with;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s15.e1
.;O;O
DDI-DrugBank.d567.s16;;
It;O;O
is;O;O
recommended;O;O
that;O;O
in;O;O
patients;O;O
taking;O;O
anticoagulants;B-group;B-DDI-DrugBank.d567.s16.e0
,;O;O
prothrombin;O;O
time;O;O
be;O;O
determined;O;O
before;O;O
starting;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s16.e1
and;O;O
frequently;O;O
enough;O;O
during;O;O
early;O;O
therapy;O;O
to;O;O
insure;O;O
that;O;O
no;O;O
significant;O;O
alteration;O;O
of;O;O
prothrombin;O;O
time;O;O
occurs;O;O
.;O;O
DDI-DrugBank.d567.s17;;
Once;O;O
a;O;O
stable;O;O
prothrombin;O;O
time;O;O
has;O;O
been;O;O
documented;O;O
,;O;O
prothrombin;O;O
times;O;O
can;O;O
be;O;O
monitored;O;O
at;O;O
the;O;O
intervals;O;O
usually;O;O
recommended;O;O
for;O;O
patients;O;O
on;O;O
coumarin;B-group;B-DDI-DrugBank.d567.s17.e0
anticoagulants;I-group;I-DDI-DrugBank.d567.s17.e0
.;O;O
DDI-DrugBank.d567.s18;;
If;O;O
the;O;O
dose;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s18.e0
is;O;O
changed;O;O
,;O;O
the;O;O
same;O;O
procedure;O;O
should;O;O
be;O;O
repeated;O;O
.;O;O
DDI-DrugBank.d567.s19;;
Lovastatin;B-drug;B-DDI-DrugBank.d567.s19.e0
therapy;O;O
has;O;O
not;O;O
been;O;O
associated;O;O
with;O;O
bleeding;O;O
or;O;O
with;O;O
changes;O;O
in;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
not;O;O
taking;O;O
anticoagulants;B-group;B-DDI-DrugBank.d567.s19.e1
.;O;O
DDI-DrugBank.d567.s20;;
Propranolol;B-drug;B-DDI-DrugBank.d567.s20.e0
:;O;O
In;O;O
normal;O;O
volunteers;O;O
,;O;O
there;O;O
was;O;O
no;O;O
clinically;O;O
significant;O;O
pharmacokinetic;O;O
or;O;O
pharmacodynamic;O;O
interaction;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
single;O;O
doses;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s20.e1
and;O;O
propranolol;B-drug;B-DDI-DrugBank.d567.s20.e2
.;O;O
DDI-DrugBank.d567.s21;;
Digoxin;B-drug;B-DDI-DrugBank.d567.s21.e0
:;O;O
In;O;O
patients;O;O
with;O;O
hypercholesterolemia;O;O
,;O;O
concomitant;O;O
administration;O;O
of;O;O
lovastatin;B-drug;B-DDI-DrugBank.d567.s21.e1
and;O;O
digoxin;B-drug;B-DDI-DrugBank.d567.s21.e2
resulted;O;O
in;O;O
no;O;O
effect;O;O
on;O;O
digoxin;B-drug;B-DDI-DrugBank.d567.s21.e3
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d567.s22;;
Oral;O;O
Hypoglycemic;B-group;B-DDI-DrugBank.d567.s22.e0
Agents;I-group;I-DDI-DrugBank.d567.s22.e0
:;O;O
In;O;O
pharmacokinetic;O;O
studies;O;O
of;O;O
MEVACOR;B-brand;B-DDI-DrugBank.d567.s22.e1
in;O;O
hypercholesterolemic;O;O
noninsulin;O;O
dependent;O;O
diabetic;O;O
patients;O;O
,;O;O
there;O;O
was;O;O
no;O;O
drug;O;O
interaction;O;O
with;O;O
glipizide;B-drug;B-DDI-DrugBank.d567.s22.e2
or;O;O
with;O;O
chlorpropamide;B-drug;B-DDI-DrugBank.d567.s22.e3
DDI-DrugBank.d504.s0;;
There;O;O
have;O;O
been;O;O
rare;O;O
reports;O;O
of;O;O
significant;O;O
respiratory;O;O
depression;O;O
,;O;O
stupor;O;O
and/or;O;O
hypotension;O;O
with;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
loxapine;B-drug;B-DDI-DrugBank.d504.s0.e0
and;O;O
lorazepam;B-drug;B-DDI-DrugBank.d504.s0.e1
.;O;O
DDI-DrugBank.d504.s1;;
The;O;O
risk;O;O
of;O;O
using;O;O
loxapine;B-drug;B-DDI-DrugBank.d504.s1.e0
in;O;O
combination;O;O
with;O;O
CNS;O;O
-;O;O
active;O;O
drugs;O;O
has;O;O
not;O;O
been;O;O
systematically;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d504.s2;;
Therefore;O;O
,;O;O
caution;O;O
is;O;O
advised;O;O
if;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
loxapine;B-drug;B-DDI-DrugBank.d504.s2.e0
and;O;O
CNS;O;O
-;O;O
active;O;O
drugs;O;O
is;O;O
required;O;O
.;O;O
DDI-DrugBank.d79.s0;;
The;O;O
absorption;O;O
of;O;O
lymecycline;B-drug;B-DDI-DrugBank.d79.s0.e0
may;O;O
be;O;O
affected;O;O
by;O;O
the;O;O
simultaneous;O;O
administration;O;O
of;O;O
indigestion;O;O
remedies;O;O
,;O;O
iron;B-drug;B-DDI-DrugBank.d79.s0.e1
or;O;O
zinc;B-drug;B-DDI-DrugBank.d79.s0.e2
supplements;O;O
.;O;O
DDI-DrugBank.d79.s1;;
Oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d79.s1.e0
may;O;O
be;O;O
less;O;O
effective;O;O
while;O;O
you;O;O
are;O;O
taking;O;O
lymecycline;B-drug;B-DDI-DrugBank.d79.s1.e1
.;O;O
DDI-DrugBank.d113.s0;;
Warfarin;B-drug;B-DDI-DrugBank.d113.s0.e0
:;O;O
Meclofenamate;B-drug;B-DDI-DrugBank.d113.s0.e1
sodium;I-drug;I-DDI-DrugBank.d113.s0.e1
enhances;O;O
the;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d113.s0.e2
.;O;O
DDI-DrugBank.d113.s1;;
Therefore;O;O
,;O;O
when;O;O
meclofenamate;B-drug;B-DDI-DrugBank.d113.s1.e0
sodium;I-drug;I-DDI-DrugBank.d113.s1.e0
is;O;O
given;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
warfarin;B-drug;B-DDI-DrugBank.d113.s1.e1
,;O;O
the;O;O
dosage;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d113.s1.e2
should;O;O
be;O;O
reduced;O;O
to;O;O
prevent;O;O
excessive;O;O
prolongation;O;O
of;O;O
the;O;O
prothrombin;O;O
time;O;O
.;O;O
DDI-DrugBank.d113.s2;;
Aspirin;B-brand;B-DDI-DrugBank.d113.s2.e0
:;O;O
Concurrent;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d113.s2.e1
may;O;O
lower;O;O
meclofenamate;B-drug;B-DDI-DrugBank.d113.s2.e2
sodium;I-drug;I-DDI-DrugBank.d113.s2.e2
plasma;O;O
levels;O;O
,;O;O
possibly;O;O
by;O;O
competing;O;O
for;O;O
protein;O;O
-;O;O
binding;O;O
sites;O;O
.;O;O
DDI-DrugBank.d113.s3;;
The;O;O
urinary;O;O
excretion;O;O
of;O;O
meclofenamate;B-drug;B-DDI-DrugBank.d113.s3.e0
sodium;I-drug;I-DDI-DrugBank.d113.s3.e0
is;O;O
unaffected;O;O
by;O;O
aspirin;B-brand;B-DDI-DrugBank.d113.s3.e1
,;O;O
indicating;O;O
no;O;O
change;O;O
in;O;O
meclofenamate;B-drug;B-DDI-DrugBank.d113.s3.e2
sodium;I-drug;I-DDI-DrugBank.d113.s3.e2
absorption;O;O
.;O;O
DDI-DrugBank.d113.s4;;
Meclofenamate;B-drug;B-DDI-DrugBank.d113.s4.e0
sodium;I-drug;I-DDI-DrugBank.d113.s4.e0
does;O;O
not;O;O
affect;O;O
serum;O;O
salicylate;B-group;B-DDI-DrugBank.d113.s4.e1
levels;O;O
.;O;O
DDI-DrugBank.d113.s5;;
Greater;O;O
fecal;O;O
blood;O;O
loss;O;O
results;O;O
from;O;O
concomitant;O;O
administration;O;O
of;O;O
both;O;O
drugs;O;O
than;O;O
from;O;O
either;O;O
drug;O;O
alone;O;O
.;O;O
DDI-DrugBank.d113.s6;;
Propoxyphene;B-drug;B-DDI-DrugBank.d113.s6.e0
:;O;O
The;O;O
concurrent;O;O
administration;O;O
of;O;O
propoxyphene;B-drug;B-DDI-DrugBank.d113.s6.e1
hydrochloride;I-drug;I-DDI-DrugBank.d113.s6.e1
does;O;O
not;O;O
affect;O;O
the;O;O
bioavailability;O;O
of;O;O
meclofenamate;B-drug;B-DDI-DrugBank.d113.s6.e2
sodium;I-drug;I-DDI-DrugBank.d113.s6.e2
.;O;O
DDI-DrugBank.d113.s7;;
Antacids;B-group;B-DDI-DrugBank.d113.s7.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
aluminum;B-drug;B-DDI-DrugBank.d113.s7.e1
and;I-drug;I-DDI-DrugBank.d113.s7.e1
magnesium;I-drug;I-DDI-DrugBank.d113.s7.e2
hydroxides;I-drug;I-DDI-DrugBank.d113.s7.e2
does;O;O
not;O;O
interfere;O;O
with;O;O
absorption;O;O
of;O;O
meclofenamate;B-drug;B-DDI-DrugBank.d113.s7.e3
sodium;I-drug;I-DDI-DrugBank.d113.s7.e3
.;O;O
DDI-DrugBank.d400.s0;;
Aspirin;B-brand;B-DDI-DrugBank.d400.s0.e0
:;O;O
As;O;O
with;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s0.e1
,;O;O
concomitant;O;O
administration;O;O
of;O;O
Ponstel;B-brand;B-DDI-DrugBank.d400.s0.e2
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d400.s0.e3
is;O;O
not;O;O
generally;O;O
recommended;O;O
because;O;O
of;O;O
the;O;O
potential;O;O
of;O;O
increased;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d400.s1;;
Methotrexate;B-drug;B-DDI-DrugBank.d400.s1.e0
:;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s1.e1
have;O;O
been;O;O
reported;O;O
to;O;O
competitively;O;O
inhibit;O;O
methotrexate;B-drug;B-DDI-DrugBank.d400.s1.e2
accumulation;O;O
in;O;O
rabbit;O;O
kidney;O;O
slices;O;O
.;O;O
DDI-DrugBank.d400.s2;;
This;O;O
may;O;O
indicate;O;O
that;O;O
they;O;O
could;O;O
enhance;O;O
the;O;O
toxicity;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d400.s2.e0
.;O;O
DDI-DrugBank.d400.s3;;
Caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s3.e0
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d400.s3.e1
.;O;O
DDI-DrugBank.d400.s4;;
ACE;B-group;B-DDI-DrugBank.d400.s4.e0
inhibitors;I-group;I-DDI-DrugBank.d400.s4.e0
:;O;O
Reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s4.e1
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
ACE;B-group;B-DDI-DrugBank.d400.s4.e2
inhibitors;I-group;I-DDI-DrugBank.d400.s4.e2
.;O;O
DDI-DrugBank.d400.s5;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s5.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d400.s5.e1
inhibitors;I-group;I-DDI-DrugBank.d400.s5.e1
.;O;O
DDI-DrugBank.d400.s6;;
Furosemide;B-drug;B-DDI-DrugBank.d400.s6.e0
:;O;O
Clinical;O;O
studies;O;O
,;O;O
as;O;O
well;O;O
as;O;O
post;O;O
-;O;O
marketing;O;O
observations;O;O
,;O;O
have;O;O
shown;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s6.e1
can;O;O
reduce;O;O
the;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d400.s6.e2
and;O;O
thiazides;B-group;B-DDI-DrugBank.d400.s6.e3
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d400.s7;;
This;O;O
response;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d400.s8;;
During;O;O
concomitant;O;O
therapy;O;O
of;O;O
Ponstel;B-brand;B-DDI-DrugBank.d400.s8.e0
with;O;O
furosemide;B-drug;B-DDI-DrugBank.d400.s8.e1
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
signs;O;O
of;O;O
renal;O;O
failure;O;O
,;O;O
as;O;O
well;O;O
as;O;O
to;O;O
assure;O;O
diuretic;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d400.s9;;
Lithium;B-drug;B-DDI-DrugBank.d400.s9.e0
:;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s9.e1
have;O;O
produced;O;O
an;O;O
elevation;O;O
of;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d400.s9.e2
levels;O;O
and;O;O
a;O;O
reduction;O;O
in;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d400.s9.e3
clearance;O;O
.;O;O
DDI-DrugBank.d400.s10;;
The;O;O
mean;O;O
minimum;O;O
lithium;B-drug;B-DDI-DrugBank.d400.s10.e0
concentration;O;O
increased;O;O
15;O;O
%;O;O
and;O;O
the;O;O
renal;O;O
clearance;O;O
was;O;O
decreased;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d400.s11;;
These;O;O
effects;O;O
have;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
by;O;O
the;O;O
NSAID;B-group;B-DDI-DrugBank.d400.s11.e0
.;O;O
DDI-DrugBank.d400.s12;;
Thus;O;O
,;O;O
when;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s12.e0
and;O;O
lithium;B-drug;B-DDI-DrugBank.d400.s12.e1
are;O;O
administered;O;O
concurrently;O;O
,;O;O
subjects;O;O
should;O;O
be;O;O
observed;O;O
carefully;O;O
for;O;O
signs;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d400.s12.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d400.s13;;
Warfarin;B-drug;B-DDI-DrugBank.d400.s13.e0
:;O;O
The;O;O
effects;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d400.s13.e1
and;O;O
NSAIDs;B-group;B-DDI-DrugBank.d400.s13.e2
on;O;O
GI;O;O
bleeding;O;O
are;O;O
synergistic;O;O
,;O;O
such;O;O
that;O;O
users;O;O
of;O;O
both;O;O
drugs;O;O
together;O;O
have;O;O
a;O;O
risk;O;O
of;O;O
serious;O;O
GI;O;O
bleeding;O;O
higher;O;O
than;O;O
users;O;O
of;O;O
either;O;O
drug;O;O
alone;O;O
.;O;O
DDI-DrugBank.d400.s14;;
Antacids;B-group;B-DDI-DrugBank.d400.s14.e0
:;O;O
In;O;O
a;O;O
single;O;O
dose;O;O
study;O;O
(;O;O
n=6;O;O
);O;O
,;O;O
ingestion;O;O
of;O;O
an;O;O
antacid;B-group;B-DDI-DrugBank.d400.s14.e1
containing;O;O
1.7;O;O
-;O;O
gram;O;O
of;O;O
magnesium;B-drug;B-DDI-DrugBank.d400.s14.e2
hydroxide;I-drug;I-DDI-DrugBank.d400.s14.e2
with;O;O
500;O;O
-;O;O
mg;O;O
of;O;O
mefenamic;B-drug;B-DDI-DrugBank.d400.s14.e3
acid;I-drug;I-DDI-DrugBank.d400.s14.e3
increased;O;O
the;O;O
Cmax;O;O
and;O;O
AUC;O;O
of;O;O
mefenamic;B-drug;B-DDI-DrugBank.d400.s14.e4
acid;I-drug;I-DDI-DrugBank.d400.s14.e4
by;O;O
125;O;O
%;O;O
and;O;O
36;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
A;O;O
number;O;O
of;O;O
compounds;O;O
are;O;O
inhibitors;O;O
of;O;O
CYP2C9;O;O
including;O;O
fluconazole;B-drug;B-DDI-DrugBank.d400.s14.e5
,;O;O
lovastatin;B-drug;B-DDI-DrugBank.d400.s14.e6
and;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d400.s14.e7
.;O;O
DDI-DrugBank.d400.s15;;
Drug;O;O
interaction;O;O
studies;O;O
of;O;O
mefenamic;B-drug;B-DDI-DrugBank.d400.s15.e0
acid;I-drug;I-DDI-DrugBank.d400.s15.e0
and;O;O
these;O;O
compounds;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d400.s16;;
The;O;O
possibility;O;O
of;O;O
altered;O;O
safety;O;O
and;O;O
efficacy;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
Ponstel;B-brand;B-DDI-DrugBank.d400.s16.e0
is;O;O
used;O;O
concomitantly;O;O
with;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d220.s0;;
Drug;O;O
-;O;O
drug;O;O
interactions;O;O
with;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s0.e0
have;O;O
not;O;O
been;O;O
explored;O;O
in;O;O
detail;O;O
.;O;O
DDI-DrugBank.d220.s1;;
There;O;O
is;O;O
one;O;O
report;O;O
of;O;O
cardiopulmonary;O;O
arrest;O;O
,;O;O
with;O;O
full;O;O
recovery;O;O
,;O;O
in;O;O
a;O;O
patient;O;O
who;O;O
was;O;O
taking;O;O
a;O;O
beta;B-group;B-DDI-DrugBank.d220.s1.e0
blocker;I-group;I-DDI-DrugBank.d220.s1.e0
(;O;O
propranolol;B-drug;B-DDI-DrugBank.d220.s1.e1
);O;O
.;O;O
DDI-DrugBank.d220.s2;;
The;O;O
effects;O;O
of;O;O
Mefloquineuine;O;O
on;O;O
the;O;O
compromised;O;O
cardiovascular;O;O
system;O;O
have;O;O
not;O;O
been;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d220.s3;;
The;O;O
benefits;O;O
of;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s3.e0
therapy;O;O
should;O;O
be;O;O
weighed;O;O
against;O;O
the;O;O
possibility;O;O
of;O;O
adverse;O;O
effects;O;O
in;O;O
patients;O;O
with;O;O
cardiac;O;O
disease;O;O
.;O;O
DDI-DrugBank.d220.s4;;
Because;O;O
of;O;O
the;O;O
danger;O;O
of;O;O
a;O;O
potentially;O;O
fatal;O;O
prolongation;O;O
of;O;O
the;O;O
QTc;O;O
interval;O;O
,;O;O
halofantrine;B-drug;B-DDI-DrugBank.d220.s4.e0
must;O;O
not;O;O
be;O;O
given;O;O
simultaneously;O;O
with;O;O
or;O;O
subsequent;O;O
to;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s4.e1
.;O;O
DDI-DrugBank.d220.s5;;
Concomitant;O;O
administration;O;O
of;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s5.e0
and;O;O
other;O;O
related;O;O
compounds;O;O
(;O;O
eg;O;O
,;O;O
quinine;B-drug;B-DDI-DrugBank.d220.s5.e1
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d220.s5.e2
and;O;O
chloroquine;B-drug;B-DDI-DrugBank.d220.s5.e3
);O;O
may;O;O
produce;O;O
electrocardiographic;O;O
abnormalities;O;O
and;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
convulsions;O;O
.;O;O
DDI-DrugBank.d220.s6;;
If;O;O
these;O;O
drugs;O;O
are;O;O
to;O;O
be;O;O
used;O;O
in;O;O
the;O;O
initial;O;O
treatment;O;O
of;O;O
severe;O;O
malaria;O;O
,;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s6.e0
administration;O;O
should;O;O
be;O;O
delayed;O;O
at;O;O
least;O;O
12;O;O
hours;O;O
after;O;O
the;O;O
last;O;O
dose;O;O
.;O;O
DDI-DrugBank.d220.s7;;
There;O;O
is;O;O
evidence;O;O
that;O;O
the;O;O
use;O;O
of;O;O
halofantrine;B-drug;B-DDI-DrugBank.d220.s7.e0
after;O;O
Mefloquineuine;O;O
causes;O;O
a;O;O
significant;O;O
lengthening;O;O
of;O;O
the;O;O
QTc;O;O
interval;O;O
.;O;O
DDI-DrugBank.d220.s8;;
Clinically;O;O
significant;O;O
QTc;O;O
prolongation;O;O
has;O;O
not;O;O
been;O;O
found;O;O
with;O;O
Mefloquineuine;O;O
alone;O;O
.;O;O
DDI-DrugBank.d220.s9;;
This;O;O
appears;O;O
to;O;O
be;O;O
the;O;O
only;O;O
clinically;O;O
relevant;O;O
interaction;O;O
of;O;O
this;O;O
kind;O;O
with;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s9.e0
,;O;O
although;O;O
theoretically;O;O
,;O;O
coadministration;O;O
of;O;O
other;O;O
drugs;O;O
known;O;O
to;O;O
alter;O;O
cardiac;O;O
conduction;O;O
(;O;O
eg;O;O
,;O;O
anti;B-drug;B-DDI-DrugBank.d220.s9.e1
-;I-drug;I-DDI-DrugBank.d220.s9.e1
arrhythmic;I-drug;I-DDI-DrugBank.d220.s9.e1
or;O;O
beta;B-group;B-DDI-DrugBank.d220.s9.e2
-;I-group;I-DDI-DrugBank.d220.s9.e2
adrenergic;I-group;I-DDI-DrugBank.d220.s9.e2
blocking;I-group;I-DDI-DrugBank.d220.s9.e2
agents;I-group;I-DDI-DrugBank.d220.s9.e2
,;O;O
calcium;B-group;B-DDI-DrugBank.d220.s9.e3
channel;I-group;I-DDI-DrugBank.d220.s9.e3
blockers;I-group;I-DDI-DrugBank.d220.s9.e3
,;O;O
antihistamines;B-group;B-DDI-DrugBank.d220.s9.e4
or;O;O
H1;B-group;B-DDI-DrugBank.d220.s9.e5
-;I-group;I-DDI-DrugBank.d220.s9.e5
blocking;I-group;I-DDI-DrugBank.d220.s9.e5
agents;I-group;I-DDI-DrugBank.d220.s9.e5
,;O;O
tricyclic;B-group;B-DDI-DrugBank.d220.s9.e6
antidepressants;I-group;I-DDI-DrugBank.d220.s9.e6
and;O;O
phenothiazines;B-group;B-DDI-DrugBank.d220.s9.e7
);O;O
might;O;O
also;O;O
contribute;O;O
to;O;O
a;O;O
prolongation;O;O
of;O;O
the;O;O
QTc;O;O
interval;O;O
.;O;O
DDI-DrugBank.d220.s10;;
There;O;O
are;O;O
no;O;O
data;O;O
that;O;O
conclusively;O;O
establish;O;O
whether;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
Mefloquineuine;O;O
and;O;O
the;O;O
above;O;O
listed;O;O
agents;O;O
has;O;O
an;O;O
effect;O;O
on;O;O
cardiac;O;O
function;O;O
.;O;O
DDI-DrugBank.d220.s11;;
In;O;O
patients;O;O
taking;O;O
an;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d220.s11.e0
(;O;O
eg;O;O
,;O;O
valproic;B-drug;B-DDI-DrugBank.d220.s11.e1
acid;I-drug;I-DDI-DrugBank.d220.s11.e1
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d220.s11.e2
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d220.s11.e3
or;O;O
phenytoin;B-drug;B-DDI-DrugBank.d220.s11.e4
);O;O
,;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s11.e5
may;O;O
reduce;O;O
seizure;O;O
control;O;O
by;O;O
lowering;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
the;O;O
anticonvulsant;B-group;B-DDI-DrugBank.d220.s11.e6
.;O;O
DDI-DrugBank.d220.s12;;
Therefore;O;O
,;O;O
patients;O;O
concurrently;O;O
taking;O;O
antiseizure;O;O
medication;O;O
and;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s12.e0
should;O;O
have;O;O
the;O;O
blood;O;O
level;O;O
of;O;O
their;O;O
antiseizure;O;O
medication;O;O
monitored;O;O
and;O;O
the;O;O
dosage;O;O
adjusted;O;O
appropriately;O;O
.;O;O
DDI-DrugBank.d220.s13;;
When;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s13.e0
is;O;O
taken;O;O
concurrently;O;O
with;O;O
oral;O;O
live;B-group;B-DDI-DrugBank.d220.s13.e1
typhoid;I-group;I-DDI-DrugBank.d220.s13.e1
vaccines;I-group;I-DDI-DrugBank.d220.s13.e1
,;O;O
attenuation;O;O
of;O;O
immunization;O;O
can;O;O
not;O;O
be;O;O
excluded;O;O
.;O;O
DDI-DrugBank.d220.s14;;
Vaccinations;O;O
with;O;O
attenuated;O;O
live;O;O
bacteria;O;O
should;O;O
therefore;O;O
be;O;O
completed;O;O
at;O;O
least;O;O
3;O;O
days;O;O
before;O;O
the;O;O
first;O;O
dose;O;O
of;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s14.e0
.;O;O
DDI-DrugBank.d220.s15;;
No;O;O
other;O;O
drug;O;O
interactions;O;O
are;O;O
known;O;O
.;O;O
DDI-DrugBank.d220.s16;;
Nevertheless;O;O
,;O;O
the;O;O
effects;O;O
of;O;O
Mefloquine;B-drug;B-DDI-DrugBank.d220.s16.e0
on;O;O
travelers;O;O
receiving;O;O
comedication;O;O
,;O;O
particularly;O;O
diabetics;O;O
or;O;O
patients;O;O
using;O;O
anticoagulants;B-group;B-DDI-DrugBank.d220.s16.e1
,;O;O
should;O;O
be;O;O
checked;O;O
before;O;O
departure;O;O
.;O;O
DDI-DrugBank.d220.s17;;
In;O;O
clinical;O;O
trials;O;O
,;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
sulfadoxine;B-drug;B-DDI-DrugBank.d220.s17.e0
and;O;O
pyrimethamine;B-drug;B-DDI-DrugBank.d220.s17.e1
did;O;O
not;O;O
alter;O;O
the;O;O
adverse;O;O
reaction;O;O
profile;O;O
.;O;O
DDI-DrugBank.d139.s0;;
Broad;B-group;B-DDI-DrugBank.d139.s0.e0
-;I-group;I-DDI-DrugBank.d139.s0.e0
Spectrum;I-group;I-DDI-DrugBank.d139.s0.e0
Antibiotics;I-group;I-DDI-DrugBank.d139.s0.e0
-;O;O
Broad;B-group;B-DDI-DrugBank.d139.s0.e1
-;I-group;I-DDI-DrugBank.d139.s0.e1
spectrum;I-group;I-DDI-DrugBank.d139.s0.e1
antibiotics;I-group;I-DDI-DrugBank.d139.s0.e1
may;O;O
sterilize;O;O
the;O;O
bowel;O;O
and;O;O
decrease;O;O
the;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s0.e2
K;I-group;I-DDI-DrugBank.d139.s0.e2
contribution;O;O
to;O;O
the;O;O
body;O;O
by;O;O
the;O;O
intestinal;O;O
microflora;O;O
.;O;O
DDI-DrugBank.d139.s1;;
Cephalosporins;B-group;B-DDI-DrugBank.d139.s1.e0
-;O;O
Cephalosporins;B-group;B-DDI-DrugBank.d139.s1.e1
containing;O;O
side;O;O
chains;O;O
of;O;O
N;O;O
-;O;O
methylthiotetrazole;O;O
(;O;O
cefmenoxime;B-drug;B-DDI-DrugBank.d139.s1.e2
,;O;O
cefoperazone;B-drug;B-DDI-DrugBank.d139.s1.e3
,;O;O
cefotetan;B-drug;B-DDI-DrugBank.d139.s1.e4
,;O;O
cefamandole;B-drug;B-DDI-DrugBank.d139.s1.e5
,;O;O
latamoxef;B-drug;B-DDI-DrugBank.d139.s1.e6
);O;O
or;O;O
methylthiadiazole;O;O
(;O;O
cefazolin;B-drug;B-DDI-DrugBank.d139.s1.e7
);O;O
can;O;O
cause;O;O
vitamin;O;O
K;O;O
deficiency;O;O
and;O;O
hypoprothrombinemia;O;O
.;O;O
DDI-DrugBank.d139.s2;;
These;O;O
cephalosporins;B-group;B-DDI-DrugBank.d139.s2.e0
are;O;O
inhibitors;O;O
of;O;O
hepatic;O;O
vitamin;O;O
K;O;O
epoxide;O;O
reductase;O;O
.;O;O
DDI-DrugBank.d139.s3;;
Cholestyramine;B-drug;B-DDI-DrugBank.d139.s3.e0
-;O;O
Concomitant;O;O
intake;O;O
of;O;O
cholestyramine;B-drug;B-DDI-DrugBank.d139.s3.e1
and;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s3.e2
K;I-group;I-DDI-DrugBank.d139.s3.e2
may;O;O
reduce;O;O
the;O;O
absorption;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s3.e3
K.;I-group;I-DDI-DrugBank.d139.s3.e3
DDI-DrugBank.d139.s4;;
Colestipol;I-drug;I-DDI-DrugBank.d139.s4.e0
-;O;O
Concomitant;O;O
intake;O;O
of;O;O
colestipol;B-drug;B-DDI-DrugBank.d139.s4.e1
and;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s4.e2
K;I-group;I-DDI-DrugBank.d139.s4.e2
may;O;O
reduce;O;O
the;O;O
absorption;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s4.e3
K.;I-group;I-DDI-DrugBank.d139.s4.e3
DDI-DrugBank.d139.s5;;
Mineral;I-drug_n;I-DDI-DrugBank.d139.s5.e0
Oil;I-drug_n;I-DDI-DrugBank.d139.s5.e0
-;O;O
Concomitant;O;O
intake;O;O
of;O;O
mineral;B-drug_n;B-DDI-DrugBank.d139.s5.e1
oil;I-drug_n;I-DDI-DrugBank.d139.s5.e1
and;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s5.e2
K;I-group;I-DDI-DrugBank.d139.s5.e2
may;O;O
reduce;O;O
the;O;O
absorption;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s5.e3
K.;I-group;I-DDI-DrugBank.d139.s5.e3
DDI-DrugBank.d139.s6;;
Orlistat;I-drug;I-DDI-DrugBank.d139.s6.e0
-;O;O
Orlistat;B-drug;B-DDI-DrugBank.d139.s6.e1
may;O;O
decrease;O;O
the;O;O
absorption;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d139.s6.e2
K.;I-group;I-DDI-DrugBank.d139.s6.e2
DDI-DrugBank.d139.s7;;
Salicylates;I-group;I-DDI-DrugBank.d139.s7.e0
-;O;O
Salicylates;B-group;B-DDI-DrugBank.d139.s7.e1
in;O;O
large;O;O
doses;O;O
may;O;O
inhibit;O;O
vitamin;O;O
K;O;O
epoxide;O;O
reductase;O;O
resulting;O;O
in;O;O
vitamin;O;O
K;O;O
deficiency;O;O
.;O;O
DDI-DrugBank.d139.s8;;
Warfarin;B-drug;B-DDI-DrugBank.d139.s8.e0
-;O;O
Vitamin;B-group;B-DDI-DrugBank.d139.s8.e1
K;I-group;I-DDI-DrugBank.d139.s8.e1
can;O;O
antagonize;O;O
the;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d139.s8.e2
DDI-DrugBank.d552.s0;;
Nabilone;I-drug;I-DDI-DrugBank.d552.s0.e0
should;O;O
be;O;O
administered;O;O
with;O;O
caution;O;O
to;O;O
patients;O;O
who;O;O
are;O;O
taking;O;O
other;O;O
psychoactive;B-group;B-DDI-DrugBank.d552.s0.e1
drugs;I-group;I-DDI-DrugBank.d552.s0.e1
or;O;O
CNS;B-group;B-DDI-DrugBank.d552.s0.e2
depressants;I-group;I-DDI-DrugBank.d552.s0.e2
,;O;O
including;O;O
alcohol;B-drug;B-DDI-DrugBank.d552.s0.e3
,;O;O
barbiturates;B-group;B-DDI-DrugBank.d552.s0.e4
and;O;O
narcotic;B-group;B-DDI-DrugBank.d552.s0.e5
analgesics;I-group;I-DDI-DrugBank.d552.s0.e5
,;O;O
or;O;O
to;O;O
those;O;O
with;O;O
a;O;O
history;O;O
of;O;O
psychiatric;O;O
disorder;O;O
(;O;O
including;O;O
manic;O;O
-;O;O
depressive;O;O
illness;O;O
and;O;O
schizophrenia;O;O
);O;O
.;O;O
DDI-DrugBank.d552.s1;;
Nabilone;B-drug;B-DDI-DrugBank.d552.s1.e0
has;O;O
been;O;O
shown;O;O
to;O;O
have;O;O
an;O;O
additive;O;O
CNS;O;O
depressant;O;O
effect;O;O
when;O;O
given;O;O
with;O;O
either;O;O
diazepam;B-drug;B-DDI-DrugBank.d552.s1.e1
,;O;O
secobarbitone;B-brand;B-DDI-DrugBank.d552.s1.e2
sodium;I-brand;I-DDI-DrugBank.d552.s1.e2
,;O;O
alcohol;B-drug;B-DDI-DrugBank.d552.s1.e3
or;O;O
codeine;B-drug;B-DDI-DrugBank.d552.s1.e4
.;O;O
DDI-DrugBank.d174.s0;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
,;O;O
because;O;O
of;O;O
its;O;O
affinity;O;O
for;O;O
protein;O;O
,;O;O
6MNA;B-drug_n;B-DDI-DrugBank.d174.s0.e0
may;O;O
displace;O;O
other;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
from;O;O
their;O;O
binding;O;O
site;O;O
.;O;O
DDI-DrugBank.d174.s1;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
administering;O;O
nabumetone;B-drug;B-DDI-DrugBank.d174.s1.e0
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d174.s1.e1
since;O;O
interactions;O;O
have;O;O
been;O;O
seen;O;O
with;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d174.s1.e2
.;O;O
DDI-DrugBank.d174.s2;;
Concomitant;O;O
administration;O;O
of;O;O
an;O;O
aluminum;B-drug;B-DDI-DrugBank.d174.s2.e0
-;O;O
containing;O;O
antacid;B-group;B-DDI-DrugBank.d174.s2.e1
had;O;O
no;O;O
significant;O;O
effect;O;O
in;O;O
the;O;O
bioavailability;O;O
of;O;O
6MNA;B-drug_n;B-DDI-DrugBank.d174.s2.e2
.;O;O
DDI-DrugBank.d174.s3;;
When;O;O
administered;O;O
with;O;O
food;O;O
or;O;O
milk;O;O
,;O;O
there;O;O
is;O;O
more;O;O
rapid;O;O
absorption;O;O
,;O;O
DDI-DrugBank.d174.s4;;
however;O;O
,;O;O
the;O;O
total;O;O
amount;O;O
of;O;O
6MNA;B-drug_n;B-DDI-DrugBank.d174.s4.e0
in;O;O
the;O;O
plasma;O;O
is;O;O
unchanged;O;O
.;O;O
DDI-DrugBank.d204.s0;;
When;O;O
administered;O;O
concurrently;O;O
,;O;O
the;O;O
following;O;O
drugs;O;O
may;O;O
interact;O;O
with;O;O
beta;B-group;B-DDI-DrugBank.d204.s0.e0
-;I-group;I-DDI-DrugBank.d204.s0.e0
adrenergic;I-group;I-DDI-DrugBank.d204.s0.e0
receptor;I-group;I-DDI-DrugBank.d204.s0.e0
blocking;I-group;I-DDI-DrugBank.d204.s0.e0
agents;I-group;I-DDI-DrugBank.d204.s0.e0
:;O;O
Anesthetics;B-group;B-DDI-DrugBank.d204.s0.e1
,;O;O
general;O;O
:;O;O
exaggeration;O;O
of;O;O
the;O;O
hypotension;O;O
induced;O;O
by;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d204.s0.e2
.;O;O
DDI-DrugBank.d204.s1;;
Antidiabetic;B-group;B-DDI-DrugBank.d204.s1.e0
drugs;I-group;I-DDI-DrugBank.d204.s1.e0
(;O;O
oral;O;O
agents;O;O
and;O;O
insulin;B-drug;B-DDI-DrugBank.d204.s1.e1
);O;O
:;O;O
hypoglycemia;O;O
or;O;O
hyperglycemia;O;O
,;O;O
DDI-DrugBank.d204.s2;;
adjust;O;O
dosage;O;O
of;O;O
antidiabetic;B-group;B-DDI-DrugBank.d204.s2.e0
drug;I-group;I-DDI-DrugBank.d204.s2.e0
accordingly;O;O
.;O;O
DDI-DrugBank.d204.s3;;
Catecholamine;O;O
-;O;O
depleting;O;O
drugs;O;O
(;O;O
e.g.;O;O
,;O;O
reserpine;B-drug;B-DDI-DrugBank.d204.s3.e0
);O;O
:;O;O
additive;O;O
effect;O;O
,;O;O
DDI-DrugBank.d204.s4;;
monitor;O;O
closely;O;O
for;O;O
evidence;O;O
of;O;O
hypotension;O;O
and/or;O;O
excessive;O;O
bradycardia;O;O
(;O;O
e.g.;O;O
,;O;O
vertigo;O;O
,;O;O
syncope;O;O
,;O;O
postural;O;O
hypotension;O;O
);O;O
.;O;O
DDI-DrugBank.d204.s5;;
Response;O;O
to;O;O
Treatment;O;O
for;O;O
Anaphylactic;O;O
Reaction;O;O
:;O;O
While;O;O
taking;O;O
beta;B-group;B-DDI-DrugBank.d204.s5.e0
-;I-group;I-DDI-DrugBank.d204.s5.e0
blockers;I-group;I-DDI-DrugBank.d204.s5.e0
,;O;O
patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
severe;O;O
anaphylactic;O;O
reaction;O;O
to;O;O
a;O;O
variety;O;O
of;O;O
allergens;O;O
may;O;O
be;O;O
more;O;O
reactive;O;O
to;O;O
repeated;O;O
challenge;O;O
,;O;O
either;O;O
accidental;O;O
,;O;O
diagnostic;O;O
,;O;O
or;O;O
therapeutic;O;O
.;O;O
DDI-DrugBank.d204.s6;;
Such;O;O
patients;O;O
may;O;O
be;O;O
unresponsive;O;O
to;O;O
the;O;O
usual;O;O
doses;O;O
of;O;O
epinephrine;B-drug;B-DDI-DrugBank.d204.s6.e0
used;O;O
to;O;O
treat;O;O
allergic;O;O
reaction;O;O
.;O;O
DDI-DrugBank.d218.s0;;
No;O;O
pharmacokinetic;O;O
-;O;O
based;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
with;O;O
SYNAREL;B-brand;B-DDI-DrugBank.d218.s0.e0
.;O;O
DDI-DrugBank.d218.s1;;
However;O;O
,;O;O
because;O;O
nafarelin;B-drug;B-DDI-DrugBank.d218.s1.e0
acetate;I-drug;I-DDI-DrugBank.d218.s1.e0
is;O;O
a;O;O
peptide;O;O
that;O;O
is;O;O
primarily;O;O
degraded;O;O
by;O;O
peptidase;O;O
and;O;O
not;O;O
by;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
enzymes;O;O
,;O;O
and;O;O
the;O;O
drug;O;O
is;O;O
only;O;O
about;O;O
80;O;O
%;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
at;O;O
4;O;O
C;O;O
,;O;O
drug;O;O
interactions;O;O
would;O;O
not;O;O
be;O;O
expected;O;O
to;O;O
occur;O;O
.;O;O
DDI-DrugBank.d261.s0;;
Tetracycline;B-drug;B-DDI-DrugBank.d261.s0.e0
,;O;O
a;O;O
bacteriostatic;B-group;B-DDI-DrugBank.d261.s0.e1
antibiotic;I-group;I-DDI-DrugBank.d261.s0.e1
,;O;O
may;O;O
antagonize;O;O
the;O;O
bactericidal;O;O
effect;O;O
of;O;O
penicillin;B-drug;B-DDI-DrugBank.d261.s0.e2
and;O;O
concurrent;O;O
use;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d37.s0;;
No;O;O
specific;O;O
information;O;O
available;O;O
DDI-DrugBank.d37.s1;;
.;O;O
DDI-DrugBank.d37.s2;;
DDI-DrugBank.d427.s0;;
Elevated;O;O
plasma;O;O
levels;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d427.s0.e0
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
quinolone;B-group;B-DDI-DrugBank.d427.s0.e1
use;O;O
.;O;O
DDI-DrugBank.d427.s1;;
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d427.s1.e0
-;O;O
related;O;O
side;O;O
effects;O;O
in;O;O
patients;O;O
on;O;O
concomitant;O;O
therapy;O;O
with;O;O
quinolones;B-group;B-DDI-DrugBank.d427.s1.e1
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d427.s1.e2
.;O;O
DDI-DrugBank.d427.s2;;
Therefore;O;O
,;O;O
monitoring;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d427.s2.e0
plasma;O;O
levels;O;O
should;O;O
be;O;O
considered;O;O
and;O;O
dosage;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d427.s2.e1
adjusted;O;O
,;O;O
as;O;O
required;O;O
.;O;O
DDI-DrugBank.d427.s3;;
Quinolones;B-group;B-DDI-DrugBank.d427.s3.e0
have;O;O
been;O;O
shown;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d427.s3.e1
.;O;O
DDI-DrugBank.d427.s4;;
This;O;O
may;O;O
lead;O;O
to;O;O
reduced;O;O
clearance;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d427.s4.e0
and;O;O
the;O;O
prolongation;O;O
of;O;O
its;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d427.s5;;
Quinolones;B-group;B-DDI-DrugBank.d427.s5.e0
,;O;O
including;O;O
nalidixic;B-drug;B-DDI-DrugBank.d427.s5.e1
acid;I-drug;I-DDI-DrugBank.d427.s5.e1
,;O;O
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
the;O;O
oral;O;O
anticoagulant;B-group;B-DDI-DrugBank.d427.s5.e2
warfarin;I-drug;I-DDI-DrugBank.d427.s5.e3
or;O;O
its;O;O
derivatives;O;O
.;O;O
DDI-DrugBank.d427.s6;;
When;O;O
these;O;O
products;O;O
are;O;O
administered;O;O
concomitantly;O;O
,;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
coagulation;O;O
test;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d427.s7;;
Nitrofurantoin;B-drug;B-DDI-DrugBank.d427.s7.e0
interferes;O;O
with;O;O
the;O;O
therapeutic;O;O
action;O;O
of;O;O
nalidixic;B-drug;B-DDI-DrugBank.d427.s7.e1
acid;I-drug;I-DDI-DrugBank.d427.s7.e1
.;O;O
DDI-DrugBank.d427.s8;;
Antacids;B-group;B-DDI-DrugBank.d427.s8.e0
containing;O;O
magnesium;B-drug;B-DDI-DrugBank.d427.s8.e1
,;O;O
aluminum;B-drug;B-DDI-DrugBank.d427.s8.e2
,;O;O
or;O;O
calcium;B-drug;B-DDI-DrugBank.d427.s8.e3
,;O;O
DDI-DrugBank.d427.s9;;
sucralfate;B-drug;B-DDI-DrugBank.d427.s9.e0
or;O;O
divalent;O;O
or;O;O
trivalent;O;O
cations;O;O
such;O;O
as;O;O
iron;B-drug;B-DDI-DrugBank.d427.s9.e1
,;O;O
DDI-DrugBank.d427.s10;;
multivitamins;B-group;B-DDI-DrugBank.d427.s10.e0
containing;O;O
zinc;B-drug;B-DDI-DrugBank.d427.s10.e1
,;O;O
DDI-DrugBank.d427.s11;;
and;O;O
Videx;B-brand;B-DDI-DrugBank.d427.s11.e0
,;O;O
(;O;O
Didanosine;B-drug;B-DDI-DrugBank.d427.s11.e1
);O;O
,;O;O
chewable;O;O
/;O;O
buffered;O;O
tablets;O;O
or;O;O
the;O;O
pediatric;O;O
powder;O;O
for;O;O
oral;O;O
solution;O;O
may;O;O
substantially;O;O
interfere;O;O
with;O;O
the;O;O
absorption;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d427.s11.e2
,;O;O
resulting;O;O
in;O;O
systemic;O;O
levels;O;O
considerably;O;O
lower;O;O
than;O;O
desired;O;O
.;O;O
DDI-DrugBank.d427.s12;;
These;O;O
agents;O;O
should;O;O
not;O;O
be;O;O
taken;O;O
within;O;O
the;O;O
two;O;O
hour;O;O
period;O;O
before;O;O
or;O;O
within;O;O
the;O;O
two;O;O
-;O;O
hour;O;O
period;O;O
after;O;O
nalidixic;B-drug;B-DDI-DrugBank.d427.s12.e0
acid;I-drug;I-DDI-DrugBank.d427.s12.e0
administration;O;O
.;O;O
DDI-DrugBank.d427.s13;;
Elevated;O;O
serum;O;O
levels;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d427.s13.e0
have;O;O
been;O;O
reported;O;O
with;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
some;O;O
quinolones;B-group;B-DDI-DrugBank.d427.s13.e1
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d427.s13.e2
.;O;O
DDI-DrugBank.d427.s14;;
Therefore;O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d427.s14.e0
serum;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
and;O;O
appropriate;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d427.s14.e1
dosage;O;O
adjustments;O;O
made;O;O
when;O;O
these;O;O
drugs;O;O
are;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d346.s0;;
Studies;O;O
to;O;O
evaluate;O;O
possible;O;O
interactions;O;O
between;O;O
REVIA;B-brand;B-DDI-DrugBank.d346.s0.e0
and;O;O
drugs;O;O
other;O;O
than;O;O
opiates;B-group;B-DDI-DrugBank.d346.s0.e1
have;O;O
not;O;O
been;O;O
performed;O;O
.;O;O
DDI-DrugBank.d346.s1;;
Consequently;O;O
,;O;O
caution;O;O
is;O;O
advised;O;O
if;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
REVIA;B-brand;B-DDI-DrugBank.d346.s1.e0
and;O;O
other;O;O
drugs;O;O
is;O;O
required;O;O
.;O;O
DDI-DrugBank.d346.s2;;
The;O;O
safety;O;O
and;O;O
efficacy;O;O
of;O;O
concomitant;O;O
use;O;O
of;O;O
REVIA;B-brand;B-DDI-DrugBank.d346.s2.e0
and;O;O
disulfiram;B-drug;B-DDI-DrugBank.d346.s2.e1
is;O;O
unknown;O;O
,;O;O
and;O;O
the;O;O
concomitant;O;O
use;O;O
of;O;O
two;O;O
potentially;O;O
hepatotoxic;O;O
medications;O;O
is;O;O
not;O;O
ordinarily;O;O
recommended;O;O
unless;O;O
the;O;O
probable;O;O
benefits;O;O
outweigh;O;O
the;O;O
known;O;O
risks;O;O
.;O;O
DDI-DrugBank.d346.s3;;
Lethargy;O;O
and;O;O
somnolence;O;O
have;O;O
been;O;O
reported;O;O
following;O;O
doses;O;O
of;O;O
REVIA;B-brand;B-DDI-DrugBank.d346.s3.e0
and;O;O
thioridazine;B-drug;B-DDI-DrugBank.d346.s3.e1
.;O;O
DDI-DrugBank.d346.s4;;
Patients;O;O
taking;O;O
REVIA;B-brand;B-DDI-DrugBank.d346.s4.e0
may;O;O
not;O;O
benefit;O;O
from;O;O
opioid;B-group;B-DDI-DrugBank.d346.s4.e1
containing;O;O
medicines;O;O
,;O;O
such;O;O
as;O;O
cough;O;O
and;O;O
cold;O;O
preparations;O;O
,;O;O
antidiarrheal;O;O
preparations;O;O
,;O;O
and;O;O
opioid;B-group;B-DDI-DrugBank.d346.s4.e2
analgesics;I-group;I-DDI-DrugBank.d346.s4.e2
.;O;O
DDI-DrugBank.d346.s5;;
In;O;O
an;O;O
emergency;O;O
situation;O;O
when;O;O
opioid;O;O
analgesia;O;O
must;O;O
be;O;O
administered;O;O
to;O;O
a;O;O
patient;O;O
receiving;O;O
REVIA;B-brand;B-DDI-DrugBank.d346.s5.e0
,;O;O
the;O;O
amount;O;O
of;O;O
opioid;B-group;B-DDI-DrugBank.d346.s5.e1
required;O;O
may;O;O
be;O;O
greater;O;O
than;O;O
usual;O;O
,;O;O
and;O;O
the;O;O
resulting;O;O
respiratory;O;O
depression;O;O
may;O;O
be;O;O
deeper;O;O
and;O;O
more;O;O
prolonged;O;O
.;O;O
DDI-DrugBank.d85.s0;;
The;O;O
use;O;O
of;O;O
NSAIDs;B-group;B-DDI-DrugBank.d85.s0.e0
in;O;O
patients;O;O
who;O;O
are;O;O
receiving;O;O
ACE;B-group;B-DDI-DrugBank.d85.s0.e1
inhibitors;I-group;I-DDI-DrugBank.d85.s0.e1
may;O;O
potentiate;O;O
renal;O;O
disease;O;O
states;O;O
.;O;O
DDI-DrugBank.d85.s1;;
In;O;O
vitro;O;O
studies;O;O
have;O;O
shown;O;O
that;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s1.e0
anion;O;O
,;O;O
because;O;O
of;O;O
its;O;O
affinity;O;O
for;O;O
protein;O;O
,;O;O
may;O;O
displace;O;O
from;O;O
their;O;O
binding;O;O
sites;O;O
other;O;O
drugs;O;O
which;O;O
are;O;O
also;O;O
albumin;O;O
-;O;O
bound;O;O
.;O;O
DDI-DrugBank.d85.s2;;
Theoretically;O;O
,;O;O
the;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s2.e0
anion;O;O
itself;O;O
could;O;O
likewise;O;O
be;O;O
displaced;O;O
.;O;O
DDI-DrugBank.d85.s3;;
Short;O;O
-;O;O
term;O;O
controlled;O;O
studies;O;O
failed;O;O
to;O;O
show;O;O
that;O;O
taking;O;O
the;O;O
drug;O;O
significantly;O;O
affects;O;O
prothrombin;O;O
times;O;O
when;O;O
administered;O;O
to;O;O
individuals;O;O
on;O;O
coumarin;B-group;B-DDI-DrugBank.d85.s3.e0
-;I-group;I-DDI-DrugBank.d85.s3.e0
type;I-group;I-DDI-DrugBank.d85.s3.e0
anticoagulants;I-group;I-DDI-DrugBank.d85.s3.e0
.;O;O
DDI-DrugBank.d85.s4;;
Caution;O;O
is;O;O
advised;O;O
nonetheless;O;O
,;O;O
since;O;O
interactions;O;O
have;O;O
been;O;O
seen;O;O
with;O;O
other;O;O
nonsteroidal;O;O
agents;O;O
of;O;O
this;O;O
class;O;O
.;O;O
DDI-DrugBank.d85.s5;;
Similarly;O;O
,;O;O
patients;O;O
receiving;O;O
the;O;O
drug;O;O
and;O;O
a;O;O
hydantoin;B-group;B-DDI-DrugBank.d85.s5.e0
,;O;O
sulfonamide;B-group;B-DDI-DrugBank.d85.s5.e1
or;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d85.s5.e2
should;O;O
be;O;O
observed;O;O
for;O;O
signs;O;O
of;O;O
toxicity;O;O
to;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d85.s6;;
Concomitant;O;O
administration;O;O
of;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s6.e0
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d85.s6.e1
is;O;O
not;O;O
recommended;O;O
because;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s6.e2
is;O;O
displaced;O;O
from;O;O
its;O;O
binding;O;O
sites;O;O
during;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d85.s6.e3
,;O;O
resulting;O;O
in;O;O
lower;O;O
plasma;O;O
concentrations;O;O
and;O;O
peak;O;O
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d85.s7;;
The;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d85.s7.e0
has;O;O
been;O;O
reported;O;O
to;O;O
be;O;O
inhibited;O;O
by;O;O
some;O;O
drugs;O;O
of;O;O
this;O;O
class;O;O
.;O;O
DDI-DrugBank.d85.s8;;
Inhibition;O;O
of;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d85.s8.e0
clearance;O;O
leading;O;O
to;O;O
increases;O;O
in;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d85.s8.e1
concentrations;O;O
has;O;O
also;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d85.s9;;
Naproxen;B-drug;B-DDI-DrugBank.d85.s9.e0
and;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d85.s9.e1
can;O;O
reduce;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d85.s9.e2
and;O;O
other;O;O
beta;B-group;B-DDI-DrugBank.d85.s9.e3
-;I-group;I-DDI-DrugBank.d85.s9.e3
blockers;I-group;I-DDI-DrugBank.d85.s9.e3
.;O;O
DDI-DrugBank.d85.s10;;
Probenecid;B-drug;B-DDI-DrugBank.d85.s10.e0
given;O;O
concurrently;O;O
increases;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s10.e1
anion;O;O
plasma;O;O
levels;O;O
and;O;O
extends;O;O
its;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
significantly;O;O
.;O;O
DDI-DrugBank.d85.s11;;
Caution;O;O
should;O;O
be;O;O
used;O;O
if;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s11.e0
is;O;O
administered;O;O
concomitantly;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d85.s11.e1
.;O;O
DDI-DrugBank.d85.s12;;
Naproxen;B-drug;B-DDI-DrugBank.d85.s12.e0
,;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s12.e1
sodium;I-drug;I-DDI-DrugBank.d85.s12.e1
and;O;O
other;O;O
NSAIDs;B-group;B-DDI-DrugBank.d85.s12.e2
have;O;O
been;O;O
reported;O;O
to;O;O
reduce;O;O
the;O;O
tubular;O;O
secretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d85.s12.e3
in;O;O
an;O;O
animal;O;O
model;O;O
,;O;O
possibly;O;O
increasing;O;O
the;O;O
toxicity;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d85.s12.e4
.;O;O
DDI-DrugBank.d85.s13;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
Naproxen;B-drug;B-DDI-DrugBank.d85.s13.e0
may;O;O
decrease;O;O
platelet;O;O
aggregation;O;O
and;O;O
prolong;O;O
bleeding;O;O
time;O;O
.;O;O
DDI-DrugBank.d85.s14;;
This;O;O
effect;O;O
should;O;O
be;O;O
kept;O;O
in;O;O
mind;O;O
when;O;O
bleeding;O;O
times;O;O
are;O;O
determined;O;O
.;O;O
DDI-DrugBank.d85.s15;;
The;O;O
administration;O;O
of;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s15.e0
may;O;O
result;O;O
in;O;O
increased;O;O
urinary;O;O
values;O;O
for;O;O
17;O;O
-;O;O
ketogenic;O;O
steroids;O;O
because;O;O
of;O;O
an;O;O
interaction;O;O
between;O;O
the;O;O
drug;O;O
and/or;O;O
its;O;O
metabolites;O;O
with;O;O
m;O;O
-;O;O
dinitrobenzene;O;O
used;O;O
in;O;O
this;O;O
assay;O;O
.;O;O
DDI-DrugBank.d85.s16;;
Although;O;O
17;O;O
-;O;O
hydroxy;O;O
-;O;O
corticosteroid;O;O
measurements;O;O
(;O;O
Porter;O;O
-;O;O
Silber;O;O
test;O;O
);O;O
do;O;O
not;O;O
appear;O;O
to;O;O
be;O;O
artifactually;O;O
altered;O;O
,;O;O
it;O;O
is;O;O
suggested;O;O
that;O;O
therapy;O;O
with;O;O
naproxen;B-drug;B-DDI-DrugBank.d85.s16.e0
be;O;O
temporarily;O;O
discontinued;O;O
72;O;O
hours;O;O
before;O;O
adrenal;O;O
function;O;O
tests;O;O
are;O;O
performed;O;O
if;O;O
the;O;O
Porter;O;O
-;O;O
Silber;O;O
test;O;O
is;O;O
to;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d85.s17;;
Naproxen;B-drug;B-DDI-DrugBank.d85.s17.e0
may;O;O
interfere;O;O
with;O;O
some;O;O
urinary;O;O
assays;O;O
of;O;O
5;O;O
-;O;O
hydroxy;O;O
indoleacetic;O;O
acid;O;O
(;O;O
5HIAA;O;O
);O;O
.;O;O
DDI-DrugBank.d478.s0;;
Ergot;B-group;B-DDI-DrugBank.d478.s0.e0
-;O;O
containing;O;O
drugs;O;O
have;O;O
been;O;O
reported;O;O
to;O;O
cause;O;O
prolonged;O;O
vasospastic;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d478.s1;;
Because;O;O
there;O;O
is;O;O
a;O;O
theoretical;O;O
basis;O;O
that;O;O
these;O;O
effects;O;O
may;O;O
be;O;O
additive;O;O
,;O;O
use;O;O
of;O;O
ergotamine;B-drug;B-DDI-DrugBank.d478.s1.e0
-;O;O
containing;O;O
or;O;O
ergot;B-group;B-DDI-DrugBank.d478.s1.e1
-;I-group;I-DDI-DrugBank.d478.s1.e1
type;I-group;I-DDI-DrugBank.d478.s1.e1
medications;I-group;I-DDI-DrugBank.d478.s1.e1
(;O;O
like;O;O
dihydroergotamine;B-drug;B-DDI-DrugBank.d478.s1.e2
or;O;O
methysergide;B-drug;B-DDI-DrugBank.d478.s1.e3
);O;O
and;O;O
naratriptan;B-drug;B-DDI-DrugBank.d478.s1.e4
within;O;O
24;O;O
hours;O;O
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d478.s2;;
The;O;O
administration;O;O
of;O;O
naratriptan;B-drug;B-DDI-DrugBank.d478.s2.e0
with;O;O
other;O;O
5;B-group;B-DDI-DrugBank.d478.s2.e1
-;I-group;I-DDI-DrugBank.d478.s2.e1
HT1;I-group;I-DDI-DrugBank.d478.s2.e1
agonists;I-group;I-DDI-DrugBank.d478.s2.e1
has;O;O
not;O;O
been;O;O
evaluated;O;O
in;O;O
migraine;O;O
patients;O;O
.;O;O
DDI-DrugBank.d478.s3;;
Because;O;O
their;O;O
vasospastic;O;O
effects;O;O
may;O;O
be;O;O
additive;O;O
,;O;O
coadministration;O;O
of;O;O
naratriptan;B-drug;B-DDI-DrugBank.d478.s3.e0
and;O;O
other;O;O
5;B-group;B-DDI-DrugBank.d478.s3.e1
-;I-group;I-DDI-DrugBank.d478.s3.e1
HT1;I-group;I-DDI-DrugBank.d478.s3.e1
agonists;I-group;I-DDI-DrugBank.d478.s3.e1
within;O;O
24;O;O
hours;O;O
of;O;O
each;O;O
other;O;O
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d478.s4;;
Selective;B-group;B-DDI-DrugBank.d478.s4.e0
serotonin;I-group;I-DDI-DrugBank.d478.s4.e0
reuptake;I-group;I-DDI-DrugBank.d478.s4.e0
inhibitors;I-group;I-DDI-DrugBank.d478.s4.e0
(;O;O
SSRIs;B-group;B-DDI-DrugBank.d478.s4.e1
);O;O
(;O;O
e.g.;O;O
,;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d478.s4.e2
,;O;O
fluvoxamine;B-drug;B-DDI-DrugBank.d478.s4.e3
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d478.s4.e4
,;O;O
sertraline;B-drug;B-DDI-DrugBank.d478.s4.e5
);O;O
have;O;O
been;O;O
reported;O;O
,;O;O
rarely;O;O
,;O;O
to;O;O
cause;O;O
weakness;O;O
,;O;O
hyperreflexia;O;O
,;O;O
and;O;O
incoordination;O;O
when;O;O
coadministered;O;O
with;O;O
5;O;O
-;O;O
HTv;O;O
agonists;O;O
.;O;O
DDI-DrugBank.d478.s5;;
If;O;O
concomitant;O;O
treatment;O;O
with;O;O
naratriptan;B-drug;B-DDI-DrugBank.d478.s5.e0
and;O;O
an;O;O
SSRI;B-group;B-DDI-DrugBank.d478.s5.e1
is;O;O
clinically;O;O
warranted;O;O
,;O;O
appropriate;O;O
observation;O;O
of;O;O
the;O;O
patient;O;O
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d478.s6;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
AMERGE;B-brand;B-DDI-DrugBank.d478.s6.e0
Tablets;O;O
are;O;O
not;O;O
known;O;O
to;O;O
interfere;O;O
with;O;O
commonly;O;O
employed;O;O
clinical;O;O
laboratory;O;O
tests;O;O
.;O;O
DDI-DrugBank.d232.s0;;
After;O;O
multiple;O;O
dosing;O;O
,;O;O
interferon;B-drug;B-DDI-DrugBank.d232.s0.e0
beta;I-drug;I-DDI-DrugBank.d232.s0.e0
-;I-drug;I-DDI-DrugBank.d232.s0.e0
1a;I-drug;I-DDI-DrugBank.d232.s0.e0
(;O;O
AVONEX;B-brand;B-DDI-DrugBank.d232.s0.e1
30;O;O
mcg;O;O
IM;O;O
once;O;O
weekly;O;O
);O;O
reduced;O;O
TYSABRI;B-brand;B-DDI-DrugBank.d232.s0.e2
clearance;O;O
by;O;O
approximately;O;O
30;O;O
%;O;O
.;O;O
DDI-DrugBank.d232.s1;;
The;O;O
similarity;O;O
of;O;O
the;O;O
TYSABRI;B-brand;B-DDI-DrugBank.d232.s1.e0
-associated;O;O
adverse;O;O
event;O;O
profile;O;O
between;O;O
Study;O;O
1;O;O
(;O;O
without;O;O
co;O;O
-;O;O
administered;O;O
AVONEX;B-brand;B-DDI-DrugBank.d232.s1.e1
);O;O
and;O;O
Study;O;O
2;O;O
(;O;O
with;O;O
co;O;O
-;O;O
administered;O;O
AVONEX;B-brand;B-DDI-DrugBank.d232.s1.e2
);O;O
indicates;O;O
that;O;O
this;O;O
alteration;O;O
in;O;O
clearance;O;O
does;O;O
not;O;O
necessitate;O;O
reduction;O;O
of;O;O
the;O;O
TYSABRI;B-brand;B-DDI-DrugBank.d232.s1.e3
dose;O;O
to;O;O
maintain;O;O
safety;O;O
,;O;O
General;O;O
);O;O
.;O;O
DDI-DrugBank.d232.s2;;
Results;O;O
of;O;O
studies;O;O
in;O;O
multiple;O;O
sclerosis;O;O
patients;O;O
taking;O;O
TYSABRI;B-brand;B-DDI-DrugBank.d232.s2.e0
and;O;O
concomitant;O;O
interferon;B-drug;B-DDI-DrugBank.d232.s2.e1
beta;I-drug;I-DDI-DrugBank.d232.s2.e1
-;I-drug;I-DDI-DrugBank.d232.s2.e1
1a;I-drug;I-DDI-DrugBank.d232.s2.e1
(;O;O
AVONEX;B-brand;B-DDI-DrugBank.d232.s2.e2
30;O;O
mcg;O;O
IM;O;O
once;O;O
weekly;O;O
);O;O
or;O;O
glatiramer;B-drug;B-DDI-DrugBank.d232.s2.e3
acetate;I-drug;I-DDI-DrugBank.d232.s2.e3
were;O;O
inconclusive;O;O
with;O;O
regard;O;O
to;O;O
the;O;O
need;O;O
for;O;O
dose;O;O
adjustment;O;O
of;O;O
the;O;O
beta;B-drug;B-DDI-DrugBank.d232.s2.e4
-;I-drug;I-DDI-DrugBank.d232.s2.e4
interferon;I-drug;I-DDI-DrugBank.d232.s2.e4
or;O;O
glatiramer;B-drug;B-DDI-DrugBank.d232.s2.e5
acetate;I-drug;I-DDI-DrugBank.d232.s2.e5
.;O;O
DDI-DrugBank.d460.s0;;
In;O;O
vitro;O;O
drug;O;O
metabolism;O;O
studies;O;O
indicate;O;O
that;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s0.e0
is;O;O
predominantly;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
isozyme;O;O
CYP2C9;O;O
(;O;O
70;O;O
%;O;O
);O;O
and;O;O
to;O;O
a;O;O
lesser;O;O
extent;O;O
CYP3A4;O;O
(;O;O
30;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d460.s1;;
Starlix;B-brand;B-DDI-DrugBank.d460.s1.e0
is;O;O
a;O;O
potential;O;O
inhibitor;O;O
of;O;O
the;O;O
CYP2C9;O;O
isoenzyme;O;O
in;O;O
vivo;O;O
as;O;O
indicated;O;O
by;O;O
its;O;O
ability;O;O
to;O;O
inhibit;O;O
the;O;O
in;O;O
vitro;O;O
metabolism;O;O
of;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d460.s1.e1
.;O;O
DDI-DrugBank.d460.s2;;
Inhibition;O;O
of;O;O
CYP3A4;O;O
metabolic;O;O
reactions;O;O
was;O;O
not;O;O
detected;O;O
in;O;O
in;O;O
vitro;O;O
experiments;O;O
.;O;O
DDI-DrugBank.d460.s3;;
Glyburide;B-drug;B-DDI-DrugBank.d460.s3.e0
:;O;O
In;O;O
a;O;O
randomized;O;O
,;O;O
multiple;O;O
-;O;O
dose;O;O
crossover;O;O
study;O;O
,;O;O
patients;O;O
with;O;O
Type;O;O
2;O;O
diabetes;O;O
were;O;O
administered;O;O
120;O;O
mg;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s3.e1
three;O;O
times;O;O
a;O;O
day;O;O
before;O;O
meals;O;O
for;O;O
1;O;O
day;O;O
in;O;O
combination;O;O
with;O;O
glyburide;B-drug;B-DDI-DrugBank.d460.s3.e2
10;O;O
mg;O;O
daily;O;O
.;O;O
DDI-DrugBank.d460.s4;;
There;O;O
were;O;O
no;O;O
clinically;O;O
relevant;O;O
alterations;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
agent;O;O
.;O;O
DDI-DrugBank.d460.s5;;
Metformin;B-drug;B-DDI-DrugBank.d460.s5.e0
:;O;O
When;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s5.e1
120;O;O
mg;O;O
three;O;O
times;O;O
daily;O;O
before;O;O
meals;O;O
was;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
metformin;B-drug;B-DDI-DrugBank.d460.s5.e2
500;O;O
mg;O;O
three;O;O
times;O;O
daily;O;O
to;O;O
patients;O;O
with;O;O
Type;O;O
2;O;O
diabetes;O;O
,;O;O
there;O;O
were;O;O
no;O;O
clinically;O;O
relevant;O;O
changes;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
agent;O;O
.;O;O
DDI-DrugBank.d460.s6;;
Digoxin;B-drug;B-DDI-DrugBank.d460.s6.e0
:;O;O
When;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s6.e1
120;O;O
mg;O;O
before;O;O
meals;O;O
was;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
a;O;O
single;O;O
1;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d460.s6.e2
to;O;O
healthy;O;O
volunteers;O;O
,;O;O
there;O;O
were;O;O
no;O;O
clinically;O;O
relevant;O;O
changes;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
agent;O;O
.;O;O
DDI-DrugBank.d460.s7;;
Warfarin;B-drug;B-DDI-DrugBank.d460.s7.e0
:;O;O
When;O;O
healthy;O;O
subjects;O;O
were;O;O
administered;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s7.e1
120;O;O
mg;O;O
three;O;O
times;O;O
daily;O;O
before;O;O
meals;O;O
for;O;O
four;O;O
days;O;O
in;O;O
combination;O;O
with;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d460.s7.e2
30;O;O
mg;O;O
on;O;O
day;O;O
2;O;O
,;O;O
there;O;O
were;O;O
no;O;O
alterations;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
agent;O;O
.;O;O
DDI-DrugBank.d460.s8;;
Prothrombin;O;O
time;O;O
was;O;O
not;O;O
affected;O;O
.;O;O
DDI-DrugBank.d460.s9;;
Diclofenac;B-drug;B-DDI-DrugBank.d460.s9.e0
:;O;O
Administration;O;O
of;O;O
morning;O;O
and;O;O
lunch;O;O
doses;O;O
of;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s9.e1
120;O;O
mg;O;O
in;O;O
combination;O;O
with;O;O
a;O;O
single;O;O
75;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
diclofenac;B-drug;B-DDI-DrugBank.d460.s9.e2
in;O;O
healthy;O;O
volunteers;O;O
resulted;O;O
in;O;O
no;O;O
significant;O;O
changes;O;O
to;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
agent;O;O
.;O;O
DDI-DrugBank.d460.s10;;
Nateglinide;B-drug;B-DDI-DrugBank.d460.s10.e0
is;O;O
highly;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
(;O;O
98;O;O
%;O;O
);O;O
,;O;O
mainly;O;O
albumin;O;O
.;O;O
DDI-DrugBank.d460.s11;;
In;O;O
vitro;O;O
displacement;O;O
studies;O;O
with;O;O
highly;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
such;O;O
as;O;O
furosemide;B-drug;B-DDI-DrugBank.d460.s11.e0
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d460.s11.e1
,;O;O
captopril;B-drug;B-DDI-DrugBank.d460.s11.e2
,;O;O
nicardipine;B-drug;B-DDI-DrugBank.d460.s11.e3
,;O;O
pravastatin;B-drug;B-DDI-DrugBank.d460.s11.e4
,;O;O
glyburide;B-drug;B-DDI-DrugBank.d460.s11.e5
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d460.s11.e6
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d460.s11.e7
,;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d460.s11.e8
acid;I-drug;I-DDI-DrugBank.d460.s11.e8
,;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d460.s11.e9
,;O;O
and;O;O
metformin;B-drug;B-DDI-DrugBank.d460.s11.e10
showed;O;O
no;O;O
influence;O;O
on;O;O
the;O;O
extent;O;O
of;O;O
nateglinide;B-drug;B-DDI-DrugBank.d460.s11.e11
protein;O;O
binding;O;O
.;O;O
DDI-DrugBank.d460.s12;;
Similarly;O;O
,;O;O
nateglinide;B-drug;B-DDI-DrugBank.d460.s12.e0
had;O;O
no;O;O
influence;O;O
on;O;O
the;O;O
serum;O;O
protein;O;O
binding;O;O
of;O;O
propranolol;B-drug;B-DDI-DrugBank.d460.s12.e1
,;O;O
glyburide;B-drug;B-DDI-DrugBank.d460.s12.e2
,;O;O
nicardipine;B-drug;B-DDI-DrugBank.d460.s12.e3
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d460.s12.e4
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d460.s12.e5
,;O;O
acetylsalicylic;B-drug;B-DDI-DrugBank.d460.s12.e6
acid;I-drug;I-DDI-DrugBank.d460.s12.e6
,;O;O
and;O;O
tolbutamide;B-drug;B-DDI-DrugBank.d460.s12.e7
in;O;O
vitro;O;O
.;O;O
DDI-DrugBank.d460.s13;;
However;O;O
,;O;O
prudent;O;O
evaluation;O;O
of;O;O
individual;O;O
cases;O;O
is;O;O
warranted;O;O
in;O;O
the;O;O
clinical;O;O
setting;O;O
.;O;O
DDI-DrugBank.d460.s14;;
Certain;O;O
drugs;O;O
,;O;O
including;O;O
nonsteroidal;B-group;B-DDI-DrugBank.d460.s14.e0
anti;I-group;I-DDI-DrugBank.d460.s14.e0
-;I-group;I-DDI-DrugBank.d460.s14.e0
inflammatory;I-group;I-DDI-DrugBank.d460.s14.e0
agents;I-group;I-DDI-DrugBank.d460.s14.e0
(;O;O
NSAIDs;B-group;B-DDI-DrugBank.d460.s14.e1
);O;O
,;O;O
salicylates;B-group;B-DDI-DrugBank.d460.s14.e2
,;O;O
monoamine;B-group;B-DDI-DrugBank.d460.s14.e3
oxidase;I-group;I-DDI-DrugBank.d460.s14.e3
inhibitors;I-group;I-DDI-DrugBank.d460.s14.e3
,;O;O
and;O;O
non;B-group;B-DDI-DrugBank.d460.s14.e4
-;I-group;I-DDI-DrugBank.d460.s14.e4
selective;I-group;I-DDI-DrugBank.d460.s14.e4
beta;I-group;I-DDI-DrugBank.d460.s14.e4
-;I-group;I-DDI-DrugBank.d460.s14.e4
adrenergic;I-group;I-DDI-DrugBank.d460.s14.e4
-;I-group;I-DDI-DrugBank.d460.s14.e4
blocking;I-group;I-DDI-DrugBank.d460.s14.e4
agents;I-group;I-DDI-DrugBank.d460.s14.e4
may;O;O
potentiate;O;O
the;O;O
hypoglycemic;O;O
action;O;O
of;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s14.e5
and;O;O
other;O;O
oral;O;O
antidiabetic;B-group;B-DDI-DrugBank.d460.s14.e6
drugs;I-group;I-DDI-DrugBank.d460.s14.e6
.;O;O
DDI-DrugBank.d460.s15;;
Certain;O;O
drugs;O;O
including;O;O
thiazides;B-group;B-DDI-DrugBank.d460.s15.e0
,;O;O
corticosteroids;B-group;B-DDI-DrugBank.d460.s15.e1
,;O;O
thyroid;B-group;B-DDI-DrugBank.d460.s15.e2
products;I-group;I-DDI-DrugBank.d460.s15.e2
,;O;O
and;O;O
sympathomimetics;B-group;B-DDI-DrugBank.d460.s15.e3
may;O;O
reduce;O;O
the;O;O
hypoglycemic;O;O
action;O;O
of;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s15.e4
and;O;O
other;O;O
oral;O;O
antidiabetic;B-group;B-DDI-DrugBank.d460.s15.e5
drugs;I-group;I-DDI-DrugBank.d460.s15.e5
.;O;O
DDI-DrugBank.d460.s16;;
When;O;O
these;O;O
drugs;O;O
are;O;O
administered;O;O
to;O;O
or;O;O
withdrawn;O;O
from;O;O
patients;O;O
receiving;O;O
Starlix;B-brand;B-DDI-DrugBank.d460.s16.e0
,;O;O
the;O;O
patient;O;O
should;O;O
be;O;O
observed;O;O
closely;O;O
for;O;O
changes;O;O
in;O;O
glycemic;O;O
control;O;O
.;O;O
DDI-DrugBank.d61.s0;;
In;O;O
clinical;O;O
studies;O;O
,;O;O
Tilade;B-brand;B-DDI-DrugBank.d61.s0.e0
has;O;O
been;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
other;O;O
anti;O;O
-;O;O
asthma;O;O
medications;O;O
,;O;O
including;O;O
inhaled;O;O
and;O;O
oral;O;O
bronchodilators;B-group;B-DDI-DrugBank.d61.s0.e1
,;O;O
and;O;O
inhaled;O;O
corticosteroids;B-group;B-DDI-DrugBank.d61.s0.e2
,;O;O
with;O;O
no;O;O
evidence;O;O
of;O;O
increased;O;O
frequency;O;O
of;O;O
adverse;O;O
events;O;O
or;O;O
laboratory;O;O
abnormalities;O;O
.;O;O
DDI-DrugBank.d61.s1;;
No;O;O
formal;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
,;O;O
however;O;O
,;O;O
have;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d340.s0;;
Nelfinavir;B-drug;B-DDI-DrugBank.d340.s0.e0
is;O;O
an;O;O
inhibitor;O;O
of;O;O
CYP3A;O;O
(;O;O
cytochrome;O;O
P450;O;O
3A;O;O
);O;O
.;O;O
DDI-DrugBank.d340.s1;;
Coadministration;O;O
of;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s1.e0
and;O;O
drugs;O;O
primarily;O;O
metabolized;O;O
by;O;O
CYP3A;O;O
(;O;O
e.g.;O;O
,;O;O
dihydropyridine;B-group;B-DDI-DrugBank.d340.s1.e1
calcium;I-group;I-DDI-DrugBank.d340.s1.e1
channel;I-group;I-DDI-DrugBank.d340.s1.e1
blockers;I-group;I-DDI-DrugBank.d340.s1.e1
);O;O
may;O;O
result;O;O
in;O;O
increased;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
other;O;O
drug;O;O
that;O;O
could;O;O
increase;O;O
or;O;O
prolong;O;O
both;O;O
its;O;O
therapeutic;O;O
and;O;O
adverse;O;O
effects;O;O
.;O;O
DDI-DrugBank.d340.s2;;
Nelfinavir;B-drug;B-DDI-DrugBank.d340.s2.e0
is;O;O
metabolized;O;O
in;O;O
proof;O;O
by;O;O
C.P.A.;O;O
DDI-DrugBank.d340.s3;;
Coadministration;O;O
of;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s3.e0
and;O;O
drugs;O;O
that;O;O
induce;O;O
CYP3A;O;O
may;O;O
decrease;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s3.e1
plasma;O;O
concentrations;O;O
and;O;O
reduce;O;O
its;O;O
therapeutic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d340.s4;;
Coadministration;O;O
of;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s4.e0
and;O;O
drugs;O;O
that;O;O
inhibit;O;O
CYP3A;O;O
may;O;O
increase;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s4.e1
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d340.s5;;
Based;O;O
on;O;O
known;O;O
metabolic;O;O
profiles;O;O
,;O;O
clinically;O;O
significant;O;O
drug;O;O
interactions;O;O
are;O;O
not;O;O
expected;O;O
between;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s5.e0
and;O;O
dapsone;B-drug;B-DDI-DrugBank.d340.s5.e1
,;O;O
trimethoprim;B-drug;B-DDI-DrugBank.d340.s5.e2
/;O;O
sulfamethoxazole;B-drug;B-DDI-DrugBank.d340.s5.e3
,;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d340.s5.e4
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d340.s5.e5
,;O;O
itraconazole;B-drug;B-DDI-DrugBank.d340.s5.e6
or;O;O
fluconazole;B-drug;B-DDI-DrugBank.d340.s5.e7
.;O;O
DDI-DrugBank.d340.s6;;
Drugs;O;O
That;O;O
Should;O;O
Not;O;O
Be;O;O
Coadministered;O;O
With;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s6.e0
Antiarrhythmics;I-group;I-DDI-DrugBank.d340.s6.e1
:;O;O
amiodarone;B-drug;B-DDI-DrugBank.d340.s6.e2
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d340.s6.e3
Antihistamines;I-group;I-DDI-DrugBank.d340.s6.e4
:;O;O
astemizole;B-drug;B-DDI-DrugBank.d340.s6.e5
,;O;O
terfenadine;B-drug;B-DDI-DrugBank.d340.s6.e6
Antimigraine;O;O
:;O;O
ergot;B-group;B-DDI-DrugBank.d340.s6.e7
derivatives;I-group;I-DDI-DrugBank.d340.s6.e7
Antimycobacterial;I-group;I-DDI-DrugBank.d340.s6.e8
agents;I-group;I-DDI-DrugBank.d340.s6.e8
:;O;O
rifampin;B-drug;B-DDI-DrugBank.d340.s6.e9
Benzodiazepines;I-group;I-DDI-DrugBank.d340.s6.e10
midazolam;I-drug;I-DDI-DrugBank.d340.s6.e11
,;O;O
triazolam;B-drug;B-DDI-DrugBank.d340.s6.e12
GI;O;O
motility;O;O
agents;O;O
:;O;O
cisapride;B-drug;B-DDI-DrugBank.d340.s6.e13
DDI-DrugBank.d340.s7;;
Drugs;O;O
Which;O;O
Require;O;O
a;O;O
Dose;O;O
Reduction;O;O
When;O;O
Coadminstered;O;O
With;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s7.e0
Antimycobacterial;I-group;I-DDI-DrugBank.d340.s7.e1
agents;I-group;I-DDI-DrugBank.d340.s7.e1
:;O;O
rifabutin;B-drug;B-DDI-DrugBank.d340.s7.e2
DDI-DrugBank.d340.s8;;
*;O;O
This;O;O
table;O;O
is;O;O
not;O;O
all;O;O
inclusive;O;O
*;O;O
*;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s8.e0
may;O;O
not;O;O
be;O;O
effective;O;O
due;O;O
to;O;O
decreased;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s8.e1
plasma;O;O
concentrations;O;O
in;O;O
patients;O;O
taking;O;O
these;O;O
agents;O;O
concomitantly;O;O
DDI-DrugBank.d340.s9;;
Antihistamines;B-group;B-DDI-DrugBank.d340.s9.e0
DDI-DrugBank.d340.s10;;
Terfenadine;I-drug;I-DDI-DrugBank.d340.s10.e0
:;O;O
Administration;O;O
of;O;O
terfenadine;B-drug;B-DDI-DrugBank.d340.s10.e1
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s10.e2
resulted;O;O
in;O;O
the;O;O
appearance;O;O
of;O;O
unchanged;O;O
terfenadine;B-drug;B-DDI-DrugBank.d340.s10.e3
in;O;O
plasma;O;O
,;O;O
DDI-DrugBank.d340.s11;;
therefore;O;O
,;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s11.e0
should;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
with;O;O
terfenadine;B-drug;B-DDI-DrugBank.d340.s11.e1
because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d340.s12;;
Because;O;O
a;O;O
similar;O;O
interaction;O;O
is;O;O
likely;O;O
,;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s12.e0
should;O;O
also;O;O
not;O;O
be;O;O
administered;O;O
concurrently;O;O
with;O;O
astemizole;B-drug;B-DDI-DrugBank.d340.s12.e1
.;O;O
DDI-DrugBank.d340.s13;;
Anti;B-group;B-DDI-DrugBank.d340.s13.e0
-;I-group;I-DDI-DrugBank.d340.s13.e0
HIV;I-group;I-DDI-DrugBank.d340.s13.e0
Protease;I-group;I-DDI-DrugBank.d340.s13.e0
Inhibitors;I-group;I-DDI-DrugBank.d340.s13.e0
DDI-DrugBank.d340.s14;;
Indinavir;I-drug;I-DDI-DrugBank.d340.s14.e0
:;O;O
Coadministration;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d340.s14.e1
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s14.e2
resulted;O;O
in;O;O
an;O;O
83;O;O
%;O;O
increase;O;O
in;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s14.e3
plasma;O;O
AUC;O;O
and;O;O
a;O;O
51;O;O
%;O;O
increase;O;O
in;O;O
indinavir;B-drug;B-DDI-DrugBank.d340.s14.e4
plasma;O;O
A.C.;O;O
DDI-DrugBank.d340.s15;;
Currently;O;O
,;O;O
there;O;O
are;O;O
no;O;O
safety;O;O
and;O;O
efficacy;O;O
data;O;O
available;O;O
from;O;O
the;O;O
use;O;O
of;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d340.s16;;
Ritonavir;B-drug;B-DDI-DrugBank.d340.s16.e0
:;O;O
Coadministration;O;O
of;O;O
ritonavir;B-drug;B-DDI-DrugBank.d340.s16.e1
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s16.e2
resulted;O;O
in;O;O
a;O;O
152;O;O
%;O;O
increase;O;O
in;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s16.e3
plasma;O;O
AUC;O;O
and;O;O
very;O;O
little;O;O
change;O;O
in;O;O
ritonavir;B-drug;B-DDI-DrugBank.d340.s16.e4
plasma;O;O
A.C.;O;O
DDI-DrugBank.d340.s17;;
Currently;O;O
,;O;O
there;O;O
are;O;O
no;O;O
safety;O;O
and;O;O
efficacy;O;O
data;O;O
available;O;O
from;O;O
the;O;O
use;O;O
of;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d340.s18;;
Saquinavir;B-drug;B-DDI-DrugBank.d340.s18.e0
:;O;O
Coadministration;O;O
of;O;O
saquinavir;B-drug;B-DDI-DrugBank.d340.s18.e1
(;O;O
using;O;O
an;O;O
experimental;O;O
soft;O;O
-;O;O
gelatin;O;O
capsule;O;O
formulation;O;O
of;O;O
saquinavir;B-drug;B-DDI-DrugBank.d340.s18.e2
1200;O;O
mg;O;O
);O;O
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s18.e3
resulted;O;O
in;O;O
an;O;O
18;O;O
%;O;O
increase;O;O
in;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s18.e4
plasma;O;O
AUC;O;O
and;O;O
a;O;O
4;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
saquinavir;B-drug;B-DDI-DrugBank.d340.s18.e5
plasma;O;O
A.C.;O;O
DDI-DrugBank.d340.s19;;
If;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
saquinavir;B-drug;B-DDI-DrugBank.d340.s19.e0
hard;O;O
gelatin;O;O
capsules;O;O
at;O;O
the;O;O
recommended;O;O
dose;O;O
of;O;O
600;O;O
mg;O;O
tid;O;O
,;O;O
no;O;O
dose;O;O
adjustments;O;O
are;O;O
needed;O;O
.;O;O
DDI-DrugBank.d340.s20;;
Currently;O;O
,;O;O
there;O;O
are;O;O
no;O;O
safety;O;O
and;O;O
efficacy;O;O
data;O;O
available;O;O
from;O;O
the;O;O
use;O;O
of;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d340.s21;;
Antifungal;B-group;B-DDI-DrugBank.d340.s21.e0
Agents;I-group;I-DDI-DrugBank.d340.s21.e0
DDI-DrugBank.d340.s22;;
Ketoconazole;I-drug;I-DDI-DrugBank.d340.s22.e0
:;O;O
Coadministration;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d340.s22.e1
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s22.e2
resulted;O;O
in;O;O
a;O;O
35;O;O
%;O;O
increase;O;O
in;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s22.e3
plasma;O;O
A.C.;O;O
DDI-DrugBank.d340.s23;;
This;O;O
change;O;O
was;O;O
not;O;O
considered;O;O
clinically;O;O
significant;O;O
and;O;O
no;O;O
dose;O;O
adjustment;O;O
is;O;O
needed;O;O
when;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d340.s23.e0
and;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s23.e1
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d340.s24;;
Anti;B-group;B-DDI-DrugBank.d340.s24.e0
-;I-group;I-DDI-DrugBank.d340.s24.e0
HIV;I-group;I-DDI-DrugBank.d340.s24.e0
Reverse;I-group;I-DDI-DrugBank.d340.s24.e0
Transcriptase;I-group;I-DDI-DrugBank.d340.s24.e0
Inhibitors;I-group;I-DDI-DrugBank.d340.s24.e0
DDI-DrugBank.d340.s25;;
Didanosine;I-drug;I-DDI-DrugBank.d340.s25.e0
:;O;O
It;O;O
is;O;O
recommended;O;O
that;O;O
didanosine;B-drug;B-DDI-DrugBank.d340.s25.e1
be;O;O
administered;O;O
on;O;O
an;O;O
empty;O;O
stomach;O;O
,;O;O
DDI-DrugBank.d340.s26;;
therefore;O;O
,;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s26.e0
should;O;O
be;O;O
administered;O;O
(;O;O
with;O;O
food;O;O
);O;O
one;O;O
hour;O;O
after;O;O
or;O;O
more;O;O
than;O;O
two;O;O
hours;O;O
before;O;O
didanosine;B-drug;B-DDI-DrugBank.d340.s26.e1
.;O;O
DDI-DrugBank.d340.s27;;
A;O;O
dose;O;O
adjustment;O;O
is;O;O
not;O;O
needed;O;O
when;O;O
zidovudine;B-drug;B-DDI-DrugBank.d340.s27.e0
is;O;O
administered;O;O
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s27.e1
.;O;O
DDI-DrugBank.d340.s28;;
Little;O;O
or;O;O
no;O;O
change;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
drug;O;O
was;O;O
observed;O;O
when;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s28.e0
was;O;O
coadministered;O;O
with;O;O
lamivudine;B-drug;B-DDI-DrugBank.d340.s28.e1
or;O;O
stavudine;B-drug;B-DDI-DrugBank.d340.s28.e2
.;O;O
DDI-DrugBank.d340.s29;;
Antimycobacterial;B-group;B-DDI-DrugBank.d340.s29.e0
Agents;I-group;I-DDI-DrugBank.d340.s29.e0
DDI-DrugBank.d340.s30;;
Rifabutin;I-drug;I-DDI-DrugBank.d340.s30.e0
:;O;O
Coadministration;O;O
of;O;O
rifabutin;B-drug;B-DDI-DrugBank.d340.s30.e1
and;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s30.e2
resulted;O;O
in;O;O
a;O;O
32;O;O
%;O;O
decrease;O;O
in;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s30.e3
plasma;O;O
AUC;O;O
and;O;O
a;O;O
207;O;O
%;O;O
increase;O;O
in;O;O
rifabutin;B-drug;B-DDI-DrugBank.d340.s30.e4
plasma;O;O
A.C.;O;O
DDI-DrugBank.d340.s31;;
It;O;O
is;O;O
recommended;O;O
that;O;O
the;O;O
dose;O;O
of;O;O
rifabutin;B-drug;B-DDI-DrugBank.d340.s31.e0
be;O;O
reduced;O;O
to;O;O
one;O;O
-;O;O
half;O;O
the;O;O
usual;O;O
dose;O;O
when;O;O
administered;O;O
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s31.e1
.;O;O
DDI-DrugBank.d340.s32;;
Rifampin;B-drug;B-DDI-DrugBank.d340.s32.e0
:;O;O
Coadministration;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d340.s32.e1
and;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s32.e2
resulted;O;O
in;O;O
an;O;O
82;O;O
%;O;O
decrease;O;O
in;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d340.s32.e3
plasma;O;O
A.C.;O;O
DDI-DrugBank.d340.s33;;
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s33.e0
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d340.s33.e1
should;O;O
not;O;O
be;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d340.s34;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d340.s34.e0
DDI-DrugBank.d340.s35;;
Ethinyl;I-drug;I-DDI-DrugBank.d340.s35.e0
Estradiol;I-drug;I-DDI-DrugBank.d340.s35.e0
and;O;O
Norethindrone;B-drug;B-DDI-DrugBank.d340.s35.e1
:;O;O
Coadministration;O;O
of;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s35.e2
with;O;O
OVCON;B-brand;B-DDI-DrugBank.d340.s35.e3
-;I-brand;I-DDI-DrugBank.d340.s35.e3
35;I-brand;I-DDI-DrugBank.d340.s35.e3
resulted;O;O
in;O;O
a;O;O
47;O;O
%;O;O
decrease;O;O
in;O;O
ethinyl;B-drug;B-DDI-DrugBank.d340.s35.e4
estradiol;I-drug;I-DDI-DrugBank.d340.s35.e4
and;O;O
an;O;O
18;O;O
%;O;O
decrease;O;O
in;O;O
norethindrone;B-drug;B-DDI-DrugBank.d340.s35.e5
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d340.s36;;
Alternate;O;O
or;O;O
additional;O;O
contraceptive;O;O
measures;O;O
should;O;O
be;O;O
used;O;O
during;O;O
therapy;O;O
with;O;O
VIRACEPT;B-brand;B-DDI-DrugBank.d340.s36.e0
DDI-DrugBank.d330.s0;;
Caution;O;O
should;O;O
be;O;O
taken;O;O
in;O;O
concurrent;O;O
or;O;O
serial;O;O
use;O;O
of;O;O
other;O;O
neurotoxic;O;O
and;O;O
/;O;O
or;O;O
nephrotoxic;O;O
drugs;O;O
because;O;O
of;O;O
possible;O;O
enhancement;O;O
of;O;O
the;O;O
nephrotoxicity;O;O
and/or;O;O
ototoxicity;O;O
of;O;O
neomycin;B-drug;B-DDI-DrugBank.d330.s0.e0
.;O;O
DDI-DrugBank.d330.s1;;
Caution;O;O
should;O;O
also;O;O
be;O;O
taken;O;O
in;O;O
concurrent;O;O
or;O;O
serial;O;O
use;O;O
of;O;O
other;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d330.s1.e0
and;O;O
polymyxins;B-group;B-DDI-DrugBank.d330.s1.e1
because;O;O
they;O;O
may;O;O
enhance;O;O
neomycin;O;O
s;O;O
nephrotoxicity;O;O
and/or;O;O
ototoxicity;O;O
and;O;O
potentiate;O;O
neomycin;B-drug;B-DDI-DrugBank.d330.s1.e2
sulfate;I-drug;I-DDI-DrugBank.d330.s1.e2
neuromuscular;O;O
blocking;O;O
effects;O;O
.;O;O
DDI-DrugBank.d330.s2;;
Oral;O;O
neomycin;B-drug;B-DDI-DrugBank.d330.s2.e0
inhibits;O;O
the;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
penicillin;B-drug;B-DDI-DrugBank.d330.s2.e1
V;I-drug;I-DDI-DrugBank.d330.s2.e1
,;O;O
oral;O;O
vitamin;B-drug;B-DDI-DrugBank.d330.s2.e2
B;I-drug;I-DDI-DrugBank.d330.s2.e2
-;I-drug;I-DDI-DrugBank.d330.s2.e2
12;I-drug;I-DDI-DrugBank.d330.s2.e2
,;O;O
methotrexate;B-drug;B-DDI-DrugBank.d330.s2.e3
and;O;O
5;B-drug;B-DDI-DrugBank.d330.s2.e4
-;I-drug;I-DDI-DrugBank.d330.s2.e4
fluorouracil;I-drug;I-DDI-DrugBank.d330.s2.e4
.;O;O
DDI-DrugBank.d330.s3;;
The;O;O
gastrointestinal;O;O
absorption;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d330.s3.e0
also;O;O
appears;O;O
to;O;O
be;O;O
inhibited;O;O
.;O;O
DDI-DrugBank.d330.s4;;
Therefore;O;O
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d330.s4.e0
serum;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d330.s5;;
Oral;O;O
neomycin;B-drug;B-DDI-DrugBank.d330.s5.e0
sulfate;I-drug;I-DDI-DrugBank.d330.s5.e0
may;O;O
enhance;O;O
the;O;O
effect;O;O
of;O;O
coumarin;B-group;B-DDI-DrugBank.d330.s5.e1
in;O;O
anticoagulants;B-group;B-DDI-DrugBank.d330.s5.e2
by;O;O
decreasing;O;O
vitamin;O;O
K;O;O
availability;O;O
.;O;O
DDI-DrugBank.d498.s0;;
Certain;O;O
antibiotics;B-group;B-DDI-DrugBank.d498.s0.e0
,;O;O
especially;O;O
neomycin;B-drug;B-DDI-DrugBank.d498.s0.e1
,;O;O
streptomycin;B-drug;B-DDI-DrugBank.d498.s0.e2
and;O;O
kanamycin;B-drug;B-DDI-DrugBank.d498.s0.e3
,;O;O
have;O;O
a;O;O
mild;O;O
but;O;O
definite;O;O
nondepolarizing;O;O
blocking;O;O
action;O;O
which;O;O
may;O;O
accentuate;O;O
neuromuscular;O;O
block;O;O
.;O;O
DDI-DrugBank.d498.s1;;
These;O;O
antibiotics;B-group;B-DDI-DrugBank.d498.s1.e0
should;O;O
be;O;O
used;O;O
in;O;O
the;O;O
myasthenic;O;O
patient;O;O
only;O;O
where;O;O
definitely;O;O
indicated;O;O
,;O;O
and;O;O
then;O;O
careful;O;O
adjustment;O;O
should;O;O
be;O;O
made;O;O
of;O;O
adjunctive;O;O
anticholinesterase;B-group;B-DDI-DrugBank.d498.s1.e1
dosage;O;O
.;O;O
DDI-DrugBank.d498.s2;;
Local;O;O
and;O;O
some;O;O
general;O;O
anesthetics;B-group;B-DDI-DrugBank.d498.s2.e0
,;O;O
antiarrhythmic;B-group;B-DDI-DrugBank.d498.s2.e1
agents;I-group;I-DDI-DrugBank.d498.s2.e1
and;O;O
other;O;O
drugs;O;O
that;O;O
interfere;O;O
with;O;O
neuromuscular;O;O
transmission;O;O
should;O;O
be;O;O
used;O;O
cautiously;O;O
,;O;O
if;O;O
at;O;O
all;O;O
,;O;O
in;O;O
patients;O;O
with;O;O
myasthenia;O;O
gravis;O;O
,;O;O
DDI-DrugBank.d498.s3;;
the;O;O
dose;O;O
of;O;O
Prostigmin;B-brand;B-DDI-DrugBank.d498.s3.e0
may;O;O
have;O;O
to;O;O
be;O;O
increased;O;O
accordingly;O;O
.;O;O
DDI-DrugBank.d239.s0;;
No;O;O
trials;O;O
specifically;O;O
examining;O;O
potential;O;O
drug;O;O
interactions;O;O
with;O;O
Natrecor;B-brand;B-DDI-DrugBank.d239.s0.e0
were;O;O
conducted;O;O
,;O;O
although;O;O
many;O;O
concomitant;O;O
drugs;O;O
were;O;O
used;O;O
in;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d239.s1;;
No;O;O
drug;O;O
interactions;O;O
were;O;O
detected;O;O
except;O;O
for;O;O
an;O;O
increase;O;O
in;O;O
symptomatic;O;O
hypotension;O;O
in;O;O
patients;O;O
receiving;O;O
oral;O;O
ACE;B-group;B-DDI-DrugBank.d239.s1.e0
inhibitors;I-group;I-DDI-DrugBank.d239.s1.e0
.;O;O
DDI-DrugBank.d239.s2;;
The;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Natrecor;B-brand;B-DDI-DrugBank.d239.s2.e0
with;O;O
IV;O;O
vasodilators;B-group;B-DDI-DrugBank.d239.s2.e1
such;O;O
as;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d239.s2.e2
,;O;O
nitroprusside;B-drug;B-DDI-DrugBank.d239.s2.e3
,;O;O
milrinone;B-drug;B-DDI-DrugBank.d239.s2.e4
,;O;O
or;O;O
IV;O;O
ACE;B-group;B-DDI-DrugBank.d239.s2.e5
inhibitors;I-group;I-DDI-DrugBank.d239.s2.e5
has;O;O
not;O;O
been;O;O
evaluated;O;O
(;O;O
these;O;O
drugs;O;O
were;O;O
not;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Natrecor;B-brand;B-DDI-DrugBank.d239.s2.e6
in;O;O
clinical;O;O
trials;O;O
);O;O
.;O;O
DDI-DrugBank.d417.s0;;
Netilmicin;B-drug;B-DDI-DrugBank.d417.s0.e0
should;O;O
not;O;O
be;O;O
administered;O;O
concomitantly;O;O
with;O;O
potent;O;O
loop;B-group;B-DDI-DrugBank.d417.s0.e1
diuretics;I-group;I-DDI-DrugBank.d417.s0.e1
such;O;O
as;O;O
furosemide;B-drug;B-DDI-DrugBank.d417.s0.e2
and;O;O
ethacrynic;B-drug;B-DDI-DrugBank.d417.s0.e3
acid;I-drug;I-DDI-DrugBank.d417.s0.e3
as;O;O
the;O;O
potential;O;O
for;O;O
ototoxicity;O;O
is;O;O
enhanced;O;O
by;O;O
the;O;O
combination;O;O
.;O;O
DDI-DrugBank.d270.s0;;
Nevirapine;B-drug;B-DDI-DrugBank.d270.s0.e0
is;O;O
principally;O;O
metabolized;O;O
by;O;O
the;O;O
liver;O;O
via;O;O
the;O;O
cytochrome;O;O
P450;O;O
isoenzymes;O;O
,;O;O
3A4;O;O
and;O;O
2B6;O;O
.;O;O
DDI-DrugBank.d270.s1;;
Nevirapine;B-drug;B-DDI-DrugBank.d270.s1.e0
is;O;O
known;O;O
to;O;O
be;O;O
an;O;O
inducer;O;O
of;O;O
these;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d270.s2;;
As;O;O
a;O;O
result;O;O
,;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
these;O;O
enzyme;O;O
systems;O;O
may;O;O
have;O;O
lower;O;O
than;O;O
expected;O;O
plasma;O;O
levels;O;O
when;O;O
coadministered;O;O
with;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s2.e0
.;O;O
DDI-DrugBank.d270.s3;;
The;O;O
specific;O;O
pharmacokinetic;O;O
changes;O;O
that;O;O
occur;O;O
with;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s3.e0
and;O;O
other;O;O
drugs;O;O
are;O;O
listed;O;O
in;O;O
CLINICAL;O;O
PHARMACOLOGY;O;O
,;O;O
Table;O;O
1;O;O
.;O;O
DDI-DrugBank.d270.s4;;
Clinical;O;O
comments;O;O
about;O;O
possible;O;O
dosage;O;O
modifications;O;O
based;O;O
on;O;O
these;O;O
pharmacokinetic;O;O
changes;O;O
are;O;O
listed;O;O
in;O;O
Table;O;O
3;O;O
.;O;O
DDI-DrugBank.d270.s5;;
The;O;O
data;O;O
inTables;O;O
1;O;O
and;O;O
3;O;O
are;O;O
based;O;O
on;O;O
the;O;O
results;O;O
of;O;O
drug;O;O
interaction;O;O
studies;O;O
conducted;O;O
in;O;O
HIV;O;O
-;O;O
1;O;O
seropositive;O;O
subjects;O;O
unless;O;O
otherwise;O;O
indicated;O;O
.;O;O
DDI-DrugBank.d270.s6;;
In;O;O
addition;O;O
to;O;O
established;O;O
drug;O;O
interactions;O;O
,;O;O
there;O;O
may;O;O
be;O;O
potential;O;O
pharmacokinetic;O;O
interactions;O;O
between;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s6.e0
and;O;O
other;O;O
drug;O;O
classes;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
the;O;O
cytochrome;O;O
P450;O;O
system;O;O
.;O;O
DDI-DrugBank.d270.s7;;
These;O;O
potential;O;O
drug;O;O
interactions;O;O
are;O;O
listed;O;O
in;O;O
Table;O;O
4;O;O
.;O;O
DDI-DrugBank.d270.s8;;
Although;O;O
specific;O;O
drug;O;O
interaction;O;O
studies;O;O
in;O;O
HIV;O;O
-;O;O
1;O;O
seropositive;O;O
subjects;O;O
have;O;O
not;O;O
been;O;O
conducted;O;O
for;O;O
the;O;O
classes;O;O
of;O;O
drugs;O;O
listed;O;O
in;O;O
Table;O;O
4;O;O
,;O;O
additional;O;O
clinical;O;O
monitoring;O;O
may;O;O
be;O;O
warranted;O;O
when;O;O
co;O;O
-;O;O
administering;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d270.s9;;
The;O;O
in;O;O
vitro;O;O
interaction;O;O
between;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s9.e0
and;O;O
the;O;O
antithrombotic;B-group;B-DDI-DrugBank.d270.s9.e1
agent;I-group;I-DDI-DrugBank.d270.s9.e1
warfarin;I-drug;I-DDI-DrugBank.d270.s9.e2
is;O;O
complex;O;O
.;O;O
DDI-DrugBank.d270.s10;;
As;O;O
a;O;O
result;O;O
,;O;O
when;O;O
giving;O;O
these;O;O
drugs;O;O
concomitantly;O;O
,;O;O
plasma;O;O
warfarin;B-drug;B-DDI-DrugBank.d270.s10.e0
levels;O;O
may;O;O
change;O;O
with;O;O
the;O;O
potential;O;O
for;O;O
increases;O;O
in;O;O
coagulation;O;O
time;O;O
.;O;O
DDI-DrugBank.d270.s11;;
When;O;O
warfarin;B-drug;B-DDI-DrugBank.d270.s11.e0
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s11.e1
,;O;O
anticoagulation;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
frequently;O;O
.;O;O
DDI-DrugBank.d270.s12;;
Table;O;O
3;O;O
Established;O;O
Drug;O;O
Interactions;O;O
:;O;O
Alteration;O;O
in;O;O
Dose;O;O
or;O;O
Regimen;O;O
May;O;O
Be;O;O
Recommended;O;O
Based;O;O
on;O;O
Drug;O;O
Interaction;O;O
Studies;O;O
DDI-DrugBank.d270.s13;;
Drug;O;O
Name;O;O
DDI-DrugBank.d270.s14;;
Effect;O;O
on;O;O
Concentration;O;O
of;O;O
Nevirapine;B-drug;B-DDI-DrugBank.d270.s14.e0
or;O;O
Concomitant;O;O
Drug;O;O
DDI-DrugBank.d270.s15;;
Clinical;O;O
Comment;O;O
DDI-DrugBank.d270.s16;;
Clarithromycin;B-drug;B-DDI-DrugBank.d270.s16.e0
DDI-DrugBank.d270.s17;;
Clarithromycin;I-drug;I-DDI-DrugBank.d270.s17.e0
14OH;O;O
-;O;O
clarithromycin;O;O
DDI-DrugBank.d270.s18;;
Clarithromycin;B-drug;B-DDI-DrugBank.d270.s18.e0
exposure;O;O
was;O;O
significantly;O;O
decreased;O;O
by;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s18.e1
,;O;O
DDI-DrugBank.d270.s19;;
however;O;O
,;O;O
14;O;O
-;O;O
OH;O;O
metabolite;O;O
concentrations;O;O
were;O;O
increased;O;O
.;O;O
Because;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d270.s19.e0
active;O;O
metabolite;O;O
has;O;O
reduced;O;O
activity;O;O
against;O;O
Mycobacteriumavium;O;O
-;O;O
intracellulare;O;O
complex;O;O
,;O;O
overallactivity;O;O
against;O;O
this;O;O
pathogen;O;O
may;O;O
bealtered;O;O
.;O;O
DDI-DrugBank.d270.s20;;
Alternatives;O;O
to;O;O
clarithromycin;B-drug;B-DDI-DrugBank.d270.s20.e0
,;O;O
such;O;O
as;O;O
azithromycin;B-drug;B-DDI-DrugBank.d270.s20.e1
,;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d270.s21;;
Efavirenz;B-drug;B-DDI-DrugBank.d270.s21.e0
DDI-DrugBank.d270.s22;;
Efavirenz;I-drug;I-DDI-DrugBank.d270.s22.e0
DDI-DrugBank.d270.s23;;
Appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
are;O;O
not;O;O
established;O;O
.;O;O
DDI-DrugBank.d270.s24;;
Ethinyl;B-drug;B-DDI-DrugBank.d270.s24.e0
estradiol;I-drug;I-DDI-DrugBank.d270.s24.e0
and;O;O
Norethindrone;B-drug;B-DDI-DrugBank.d270.s24.e1
DDI-DrugBank.d270.s25;;
Ethinyl;I-drug;I-DDI-DrugBank.d270.s25.e0
estradiol;I-drug;I-DDI-DrugBank.d270.s25.e0
Norethindrone;I-drug;I-DDI-DrugBank.d270.s25.e1
DDI-DrugBank.d270.s26;;
Oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d270.s26.e0
and;O;O
other;O;O
hormonalmethods;O;O
of;O;O
birth;O;O
control;O;O
should;O;O
not;O;O
be;O;O
usedas;O;O
the;O;O
sole;O;O
method;O;O
of;O;O
contraception;O;O
inwomen;O;O
taking;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s26.e1
,;O;O
since;O;O
nevirapinemay;O;O
lower;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
thesemedications;O;O
.;O;O
DDI-DrugBank.d270.s27;;
An;O;O
alternative;O;O
or;O;O
additional;O;O
method;O;O
of;O;O
contraception;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d270.s28;;
Fluconazole;B-drug;B-DDI-DrugBank.d270.s28.e0
DDI-DrugBank.d270.s29;;
Nevirapine;I-drug;I-DDI-DrugBank.d270.s29.e0
DDI-DrugBank.d270.s30;;
Because;O;O
of;O;O
the;O;O
risk;O;O
of;O;O
increased;O;O
exposure;O;O
tonevirapine;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
inconcomitant;O;O
administration;O;O
,;O;O
and;O;O
patients;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
for;O;O
nevirapine;O;O
-;O;O
associated;O;O
adverse;O;O
events;O;O
.;O;O
DDI-DrugBank.d270.s31;;
Indinavir;B-drug;B-DDI-DrugBank.d270.s31.e0
DDI-DrugBank.d270.s32;;
Indinavir;I-drug;I-DDI-DrugBank.d270.s32.e0
DDI-DrugBank.d270.s33;;
Appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
arenot;O;O
established;O;O
,;O;O
but;O;O
an;O;O
increase;O;O
in;O;O
thedosage;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d270.s33.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d270.s34;;
Ketoconazole;B-drug;B-DDI-DrugBank.d270.s34.e0
DDI-DrugBank.d270.s35;;
Ketoconazole;I-drug;I-DDI-DrugBank.d270.s35.e0
DDI-DrugBank.d270.s36;;
Nevirapine;I-drug;I-DDI-DrugBank.d270.s36.e0
and;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d270.s36.e1
should;O;O
not;O;O
beadministered;O;O
concomitantly;O;O
becausedecreases;O;O
in;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d270.s36.e2
plasmaconcentrations;O;O
may;O;O
reduce;O;O
the;O;O
efficacy;O;O
of;O;O
the;O;O
drug;O;O
.;O;O
DDI-DrugBank.d270.s37;;
Lopinavir;B-drug;B-DDI-DrugBank.d270.s37.e0
/;O;O
Ritonavir;B-drug;B-DDI-DrugBank.d270.s37.e1
DDI-DrugBank.d270.s38;;
Lopinavir;I-drug;I-DDI-DrugBank.d270.s38.e0
DDI-DrugBank.d270.s39;;
A;O;O
dose;O;O
increase;O;O
of;O;O
lopinavir;B-drug;B-DDI-DrugBank.d270.s39.e0
/;O;O
ritonavir;B-drug;B-DDI-DrugBank.d270.s39.e1
to;O;O
533;O;O
/;O;O
133;O;O
mg;O;O
twice;O;O
daily;O;O
with;O;O
food;O;O
isrecommended;O;O
in;O;O
combination;O;O
with;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s39.e2
.;O;O
DDI-DrugBank.d270.s40;;
Methadone;B-drug;B-DDI-DrugBank.d270.s40.e0
DDI-DrugBank.d270.s41;;
Methadonea;O;O
DDI-DrugBank.d270.s42;;
Methadone;B-drug;B-DDI-DrugBank.d270.s42.e0
levels;O;O
may;O;O
be;O;O
decreased;O;O
,;O;O
increased;O;O
dosages;O;O
may;O;O
be;O;O
required;O;O
to;O;O
prevent;O;O
symptoms;O;O
of;O;O
opiate;B-group;B-DDI-DrugBank.d270.s42.e1
withdrawal;O;O
.;O;O
Methadone;B-drug;B-DDI-DrugBank.d270.s42.e2
maintained;O;O
patients;O;O
beginning;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s42.e3
therapy;O;O
should;O;O
be;O;O
monitored;O;O
forevidence;O;O
of;O;O
withdrawal;O;O
and;O;O
methadone;B-drug;B-DDI-DrugBank.d270.s42.e4
dose;O;O
should;O;O
be;O;O
adjusted;O;O
accordingly;O;O
.;O;O
DDI-DrugBank.d270.s43;;
Nelfinavir;B-drug;B-DDI-DrugBank.d270.s43.e0
DDI-DrugBank.d270.s44;;
Nelfinavir;I-drug;I-DDI-DrugBank.d270.s44.e0
M8;O;O
DDI-DrugBank.d270.s45;;
The;O;O
appropriate;O;O
dose;O;O
for;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d270.s45.e0
incombination;O;O
with;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s45.e1
,;O;O
with;O;O
respectto;O;O
safety;O;O
and;O;O
efficacy;O;O
,;O;O
has;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d270.s46;;
Rifabutin;B-drug;B-DDI-DrugBank.d270.s46.e0
DDI-DrugBank.d270.s47;;
Rifabutin;I-drug;I-DDI-DrugBank.d270.s47.e0
DDI-DrugBank.d270.s48;;
Rifabutin;I-drug;I-DDI-DrugBank.d270.s48.e0
and;O;O
its;O;O
metabolite;O;O
concentrationswere;O;O
moderately;O;O
increased;O;O
.;O;O
DDI-DrugBank.d270.s49;;
Due;O;O
to;O;O
highintersubject;O;O
variability;O;O
,;O;O
however;O;O
,;O;O
somepatients;O;O
may;O;O
experience;O;O
large;O;O
increases;O;O
inrifabutin;O;O
exposure;O;O
and;O;O
may;O;O
be;O;O
at;O;O
higher;O;O
riskfor;O;O
rifabutin;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d270.s50;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
in;O;O
concomitant;O;O
administration;O;O
.;O;O
DDI-DrugBank.d270.s51;;
Rifampin;B-drug;B-DDI-DrugBank.d270.s51.e0
DDI-DrugBank.d270.s52;;
Nevirapine;I-drug;I-DDI-DrugBank.d270.s52.e0
DDI-DrugBank.d270.s53;;
Nevirapine;I-drug;I-DDI-DrugBank.d270.s53.e0
and;O;O
rifampin;B-drug;B-DDI-DrugBank.d270.s53.e1
should;O;O
not;O;O
beadministered;O;O
concomitantly;O;O
becausedecreases;O;O
in;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s53.e2
plasmaconcentrations;O;O
may;O;O
reduce;O;O
the;O;O
efficacy;O;O
ofthe;O;O
drug;O;O
.;O;O
DDI-DrugBank.d270.s54;;
Physicians;O;O
needing;O;O
to;O;O
treatpatients;O;O
co;O;O
-;O;O
infected;O;O
with;O;O
tuberculosis;O;O
andusing;O;O
a;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s54.e0
containing;O;O
regimen;O;O
mayuse;O;O
rifabutin;B-drug;B-DDI-DrugBank.d270.s54.e1
instead;O;O
.;O;O
DDI-DrugBank.d270.s55;;
Saquinavir;B-drug;B-DDI-DrugBank.d270.s55.e0
DDI-DrugBank.d270.s56;;
Saquinavir;I-drug;I-DDI-DrugBank.d270.s56.e0
DDI-DrugBank.d270.s57;;
Appropriate;O;O
doses;O;O
for;O;O
this;O;O
combination;O;O
arenot;O;O
established;O;O
,;O;O
but;O;O
an;O;O
increase;O;O
in;O;O
thedosage;O;O
of;O;O
saquinavir;B-drug;B-DDI-DrugBank.d270.s57.e0
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d270.s58;;
aBased;O;O
on;O;O
reports;O;O
of;O;O
narcotic;O;O
withdrawal;O;O
syndrome;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
nevirapine;B-drug;B-DDI-DrugBank.d270.s58.e0
and;O;O
methadone;B-drug;B-DDI-DrugBank.d270.s58.e1
concurrently;O;O
,;O;O
and;O;O
evidence;O;O
of;O;O
decreased;O;O
plasma;O;O
concentrations;O;O
of;O;O
methadone;B-drug;B-DDI-DrugBank.d270.s58.e2
.;O;O
DDI-DrugBank.d270.s59;;
Table;O;O
4;O;O
Potential;O;O
Drug;O;O
Interactions;O;O
:;O;O
Use;O;O
With;O;O
Caution;O;O
,;O;O
Dose;O;O
Adjustment;O;O
of;O;O
Co;O;O
-;O;O
administered;O;O
Drug;O;O
May;O;O
Be;O;O
Needed;O;O
due;O;O
to;O;O
Possible;O;O
Decrease;O;O
in;O;O
Clinical;O;O
Effect;O;O
DDI-DrugBank.d270.s60;;
Examples;O;O
of;O;O
Drugs;O;O
in;O;O
Which;O;O
Plasma;O;O
Concentrations;O;O
May;O;O
Be;O;O
Decreased;O;O
By;O;O
Co;O;O
-;O;O
administration;O;O
With;O;O
Nevirapine;B-drug;B-DDI-DrugBank.d270.s60.e0
DDI-DrugBank.d270.s61;;
Drug;O;O
Class;O;O
Examples;O;O
of;O;O
Drugs;O;O
DDI-DrugBank.d270.s62;;
Antiarrhythmics;B-group;B-DDI-DrugBank.d270.s62.e0
DDI-DrugBank.d270.s63;;
Amiodarone;I-drug;I-DDI-DrugBank.d270.s63.e0
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d270.s63.e1
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d270.s63.e2
DDI-DrugBank.d270.s64;;
Anticonvulsants;I-group;I-DDI-DrugBank.d270.s64.e0
DDI-DrugBank.d270.s65;;
Carbamazepine;I-drug;I-DDI-DrugBank.d270.s65.e0
,;O;O
clonazepam;B-drug;B-DDI-DrugBank.d270.s65.e1
,;O;O
ethosuximide;B-drug;B-DDI-DrugBank.d270.s65.e2
DDI-DrugBank.d270.s66;;
Antifungals;I-group;I-DDI-DrugBank.d270.s66.e0
DDI-DrugBank.d270.s67;;
Itraconazole;I-drug;I-DDI-DrugBank.d270.s67.e0
DDI-DrugBank.d270.s68;;
Calcium;I-group;I-DDI-DrugBank.d270.s68.e0
channel;I-group;I-DDI-DrugBank.d270.s68.e0
blockers;I-group;I-DDI-DrugBank.d270.s68.e0
DDI-DrugBank.d270.s69;;
Diltiazem;I-drug;I-DDI-DrugBank.d270.s69.e0
,;O;O
nifedipine;B-drug;B-DDI-DrugBank.d270.s69.e1
,;O;O
verapamil;B-drug;B-DDI-DrugBank.d270.s69.e2
DDI-DrugBank.d270.s70;;
Cancer;O;O
chemotherapy;O;O
DDI-DrugBank.d270.s71;;
Cyclophosphamide;B-drug;B-DDI-DrugBank.d270.s71.e0
DDI-DrugBank.d270.s72;;
Ergot;I-group;I-DDI-DrugBank.d270.s72.e0
alkaloids;I-group;I-DDI-DrugBank.d270.s72.e0
DDI-DrugBank.d270.s73;;
Ergotamine;I-drug;I-DDI-DrugBank.d270.s73.e0
DDI-DrugBank.d270.s74;;
Immunosuppressants;I-group;I-DDI-DrugBank.d270.s74.e0
DDI-DrugBank.d270.s75;;
Cyclosporin;I-drug;I-DDI-DrugBank.d270.s75.e0
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d270.s75.e1
,;O;O
sirolimus;B-drug;B-DDI-DrugBank.d270.s75.e2
DDI-DrugBank.d270.s76;;
Motility;O;O
agents;O;O
DDI-DrugBank.d270.s77;;
Cisapride;B-drug;B-DDI-DrugBank.d270.s77.e0
DDI-DrugBank.d270.s78;;
Opiate;I-group;I-DDI-DrugBank.d270.s78.e0
agonists;I-group;I-DDI-DrugBank.d270.s78.e0
DDI-DrugBank.d270.s79;;
Fentanyl;I-drug;I-DDI-DrugBank.d270.s79.e0
DDI-DrugBank.d270.s80;;
Examples;O;O
of;O;O
Drugs;O;O
in;O;O
Which;O;O
Plasma;O;O
Concentrations;O;O
May;O;O
Be;O;O
Increased;O;O
By;O;O
Co;O;O
-;O;O
administration;O;O
With;O;O
Nevirapine;B-drug;B-DDI-DrugBank.d270.s80.e0
DDI-DrugBank.d270.s81;;
Antithrombotics;I-group;I-DDI-DrugBank.d270.s81.e0
DDI-DrugBank.d270.s82;;
Warfarin;I-drug;I-DDI-DrugBank.d270.s82.e0
DDI-DrugBank.d270.s83;;
Potential;O;O
effect;O;O
on;O;O
anticoagulation;O;O
.;O;O
DDI-DrugBank.d270.s84;;
Monitoring;O;O
of;O;O
anticoagulation;O;O
levels;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d270.s85;;
Fat;O;O
redistribution;O;O
:;O;O
Redistribution;O;O
/;O;O
accumulation;O;O
of;O;O
body;O;O
fat;O;O
including;O;O
central;O;O
obesity;O;O
,;O;O
dorsocervical;O;O
fat;O;O
enlargement;O;O
(;O;O
buffalo;O;O
hump;O;O
);O;O
,;O;O
peripheral;O;O
wasting;O;O
,;O;O
facial;O;O
wasting;O;O
,;O;O
breast;O;O
enlargement;O;O
,;O;O
and;O;O
cushingoid;O;O
appearance;O;O
have;O;O
been;O;O
observed;O;O
in;O;O
patients;O;O
receiving;O;O
antiretroviral;B-group;B-DDI-DrugBank.d270.s85.e0
therapy;O;O
.;O;O
DDI-DrugBank.d270.s86;;
The;O;O
mechanism;O;O
and;O;O
long;O;O
-;O;O
term;O;O
consequences;O;O
of;O;O
these;O;O
events;O;O
are;O;O
currently;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d270.s87;;
A;O;O
causal;O;O
relationship;O;O
has;O;O
not;O;O
been;O;O
established;O;O
DDI-DrugBank.d270.s88;;
.;O;O
DDI-DrugBank.d270.s89;;
DDI-DrugBank.d542.s0;;
Interactions;O;O
for;O;O
Vitamin;B-drug;B-DDI-DrugBank.d542.s0.e0
B3;I-drug;I-DDI-DrugBank.d542.s0.e0
(;O;O
Niacin;B-drug;B-DDI-DrugBank.d542.s0.e1
);O;O
:;O;O
Antihypertensive;B-group;B-DDI-DrugBank.d542.s0.e2
Therapy;O;O
:;O;O
Nicotinic;B-drug;B-DDI-DrugBank.d542.s0.e3
acid;I-drug;I-DDI-DrugBank.d542.s0.e3
may;O;O
potentiate;O;O
the;O;O
effects;O;O
of;O;O
ganglionic;B-group;B-DDI-DrugBank.d542.s0.e4
blocking;I-group;I-DDI-DrugBank.d542.s0.e4
agents;I-group;I-DDI-DrugBank.d542.s0.e4
and;O;O
vasoactive;O;O
drugs;O;O
resulting;O;O
in;O;O
postural;O;O
hypotension;O;O
.;O;O
DDI-DrugBank.d542.s1;;
Aspirin;B-brand;B-DDI-DrugBank.d542.s1.e0
:;O;O
Concomitant;O;O
aspirin;B-brand;B-DDI-DrugBank.d542.s1.e1
may;O;O
decrease;O;O
the;O;O
metabolic;O;O
clearance;O;O
of;O;O
nicotinic;B-drug;B-DDI-DrugBank.d542.s1.e2
acid;I-drug;I-DDI-DrugBank.d542.s1.e2
.;O;O
DDI-DrugBank.d542.s2;;
The;O;O
clinical;O;O
relevance;O;O
of;O;O
this;O;O
finding;O;O
is;O;O
unclear;O;O
.;O;O
DDI-DrugBank.d542.s3;;
Other;O;O
:;O;O
Concomitant;O;O
alcohol;B-drug;B-DDI-DrugBank.d542.s3.e0
or;O;O
hot;O;O
drinks;O;O
may;O;O
increase;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
flushing;O;O
and;O;O
pruritus;O;O
and;O;O
should;O;O
be;O;O
avoided;O;O
at;O;O
the;O;O
time;O;O
of;O;O
drug;O;O
ingestion;O;O
.;O;O
DDI-DrugBank.d468.s0;;
Beta;B-group;B-DDI-DrugBank.d468.s0.e0
-;I-group;I-DDI-DrugBank.d468.s0.e0
Blockers;I-group;I-DDI-DrugBank.d468.s0.e0
:;O;O
In;O;O
controlled;O;O
clinical;O;O
studies;O;O
,;O;O
adrenergic;B-group;B-DDI-DrugBank.d468.s0.e1
beta;I-group;I-DDI-DrugBank.d468.s0.e1
-;I-group;I-DDI-DrugBank.d468.s0.e1
receptor;I-group;I-DDI-DrugBank.d468.s0.e1
blockers;I-group;I-DDI-DrugBank.d468.s0.e1
have;O;O
been;O;O
frequently;O;O
administered;O;O
concomitantly;O;O
with;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s0.e2
HCl;I-drug;I-DDI-DrugBank.d468.s0.e2
.;O;O
DDI-DrugBank.d468.s1;;
The;O;O
combination;O;O
is;O;O
well;O;O
tolerated;O;O
.;O;O
DDI-DrugBank.d468.s2;;
Cimetidine;B-drug;B-DDI-DrugBank.d468.s2.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d468.s2.e1
increases;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s2.e2
HCl;I-drug;I-DDI-DrugBank.d468.s2.e2
plasma;O;O
levels;O;O
.;O;O
DDI-DrugBank.d468.s3;;
Patients;O;O
receiving;O;O
the;O;O
two;O;O
drugs;O;O
concomitantly;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d468.s4;;
Digoxin;B-drug;B-DDI-DrugBank.d468.s4.e0
:;O;O
Some;O;O
calcium;B-group;B-DDI-DrugBank.d468.s4.e1
blockers;I-group;I-DDI-DrugBank.d468.s4.e1
may;O;O
increase;O;O
the;O;O
concentration;O;O
of;O;O
digitalis;B-group;B-DDI-DrugBank.d468.s4.e2
preparations;I-group;I-DDI-DrugBank.d468.s4.e2
in;O;O
the;O;O
blood;O;O
.;O;O
DDI-DrugBank.d468.s5;;
Nicardipine;B-drug;B-DDI-DrugBank.d468.s5.e0
HCl;I-drug;I-DDI-DrugBank.d468.s5.e0
usually;O;O
does;O;O
not;O;O
alter;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d468.s5.e1
,;O;O
however;O;O
,;O;O
serum;O;O
digoxin;B-drug;B-DDI-DrugBank.d468.s5.e2
levels;O;O
should;O;O
be;O;O
evaluated;O;O
after;O;O
concomitant;O;O
therapy;O;O
with;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s5.e3
HCl;I-drug;I-DDI-DrugBank.d468.s5.e3
is;O;O
initiated;O;O
.;O;O
DDI-DrugBank.d468.s6;;
Maalox;B-brand;B-DDI-DrugBank.d468.s6.e0
*;O;O
Coadministration;O;O
of;O;O
Maalox;B-brand;B-DDI-DrugBank.d468.s6.e1
TC;I-brand;I-DDI-DrugBank.d468.s6.e1
had;O;O
no;O;O
effect;O;O
on;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s6.e2
HCl;I-drug;I-DDI-DrugBank.d468.s6.e2
absorption;O;O
.;O;O
DDI-DrugBank.d468.s7;;
Even;O;O
though;O;O
such;O;O
interactions;O;O
were;O;O
not;O;O
seen;O;O
during;O;O
clinical;O;O
studies;O;O
with;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s7.e0
HCl;I-drug;I-DDI-DrugBank.d468.s7.e0
,;O;O
an;O;O
increased;O;O
volume;O;O
of;O;O
circulating;O;O
fluids;O;O
might;O;O
be;O;O
required;O;O
if;O;O
such;O;O
an;O;O
interaction;O;O
were;O;O
to;O;O
occur;O;O
.;O;O
DDI-DrugBank.d468.s8;;
Cyclosporine;B-drug;B-DDI-DrugBank.d468.s8.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s8.e1
and;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d468.s8.e2
levels;O;O
.;O;O
DDI-DrugBank.d468.s9;;
Plasma;O;O
concentrations;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d468.s9.e0
should;O;O
therefore;O;O
be;O;O
closely;O;O
monitored;O;O
,;O;O
and;O;O
its;O;O
dosage;O;O
reduced;O;O
accordingly;O;O
,;O;O
in;O;O
patients;O;O
treated;O;O
with;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s9.e1
.;O;O
DDI-DrugBank.d468.s10;;
When;O;O
therapeutic;O;O
concentrations;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d468.s10.e0
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d468.s10.e1
,;O;O
dipyridamole;B-drug;B-DDI-DrugBank.d468.s10.e2
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d468.s10.e3
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d468.s10.e4
,;O;O
or;O;O
naproxen;B-drug;B-DDI-DrugBank.d468.s10.e5
were;O;O
added;O;O
to;O;O
human;O;O
plasma;O;O
(;O;O
in;O;O
vitro;O;O
);O;O
,;O;O
the;O;O
plasma;O;O
protein;O;O
binding;O;O
of;O;O
nicardipine;B-drug;B-DDI-DrugBank.d468.s10.e6
HCl;I-drug;I-DDI-DrugBank.d468.s10.e6
was;O;O
not;O;O
altered;O;O
.;O;O
DDI-DrugBank.d271.s0;;
Physiological;O;O
changes;O;O
resulting;O;O
from;O;O
smoking;O;O
cessation;O;O
,;O;O
with;O;O
or;O;O
without;O;O
nicotine;B-drug;B-DDI-DrugBank.d271.s0.e0
replacement;O;O
,;O;O
may;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
certain;O;O
concomitant;O;O
medications;O;O
,;O;O
such;O;O
as;O;O
tricyclic;B-group;B-DDI-DrugBank.d271.s0.e1
antidepressants;I-group;I-DDI-DrugBank.d271.s0.e1
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d271.s0.e2
.;O;O
DDI-DrugBank.d271.s1;;
Doses;O;O
of;O;O
these;O;O
and;O;O
perhaps;O;O
other;O;O
medications;O;O
may;O;O
need;O;O
to;O;O
be;O;O
adjusted;O;O
in;O;O
patients;O;O
who;O;O
successfully;O;O
quit;O;O
smoking;O;O
.;O;O
DDI-DrugBank.d373.s0;;
Beta;B-group;B-DDI-DrugBank.d373.s0.e0
-;I-group;I-DDI-DrugBank.d373.s0.e0
adrenergic;I-group;I-DDI-DrugBank.d373.s0.e0
Blocking;I-group;I-DDI-DrugBank.d373.s0.e0
Agents;I-group;I-DDI-DrugBank.d373.s0.e0
:;O;O
Experience;O;O
in;O;O
over;O;O
1400;O;O
patients;O;O
in;O;O
a;O;O
non;O;O
-;O;O
comparative;O;O
clinical;O;O
trial;O;O
has;O;O
shown;O;O
that;O;O
concomitant;O;O
administration;O;O
of;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s0.e1
and;O;O
beta;B-group;B-DDI-DrugBank.d373.s0.e2
-;I-group;I-DDI-DrugBank.d373.s0.e2
blocking;I-group;I-DDI-DrugBank.d373.s0.e2
agents;I-group;I-DDI-DrugBank.d373.s0.e2
is;O;O
usually;O;O
well;O;O
tolerated;O;O
,;O;O
but;O;O
there;O;O
have;O;O
been;O;O
occasional;O;O
literature;O;O
reports;O;O
suggesting;O;O
that;O;O
the;O;O
combination;O;O
may;O;O
increase;O;O
the;O;O
likelihood;O;O
of;O;O
congestive;O;O
heart;O;O
failure;O;O
,;O;O
severe;O;O
hypotension;O;O
or;O;O
exacerbation;O;O
of;O;O
angina;O;O
.;O;O
DDI-DrugBank.d373.s1;;
Long;O;O
Acting;O;O
Nitrates;B-group;B-DDI-DrugBank.d373.s1.e0
:;O;O
Nifedipine;B-drug;B-DDI-DrugBank.d373.s1.e1
may;O;O
be;O;O
safely;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
nitrates;B-group;B-DDI-DrugBank.d373.s1.e2
,;O;O
but;O;O
there;O;O
have;O;O
been;O;O
no;O;O
controlled;O;O
studies;O;O
to;O;O
evaluate;O;O
the;O;O
antianginal;O;O
effectiveness;O;O
of;O;O
this;O;O
combination;O;O
.;O;O
DDI-DrugBank.d373.s2;;
Digitalis;B-group;B-DDI-DrugBank.d373.s2.e0
:;O;O
Immediate;O;O
Release;O;O
Capsules;O;O
:;O;O
Since;O;O
there;O;O
have;O;O
been;O;O
isolated;O;O
reports;O;O
of;O;O
patients;O;O
with;O;O
elevated;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s2.e1
levels;O;O
,;O;O
and;O;O
there;O;O
is;O;O
a;O;O
possible;O;O
interaction;O;O
between;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s2.e2
and;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s2.e3
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s2.e4
levels;O;O
be;O;O
monitored;O;O
when;O;O
initiating;O;O
,;O;O
adjusting;O;O
,;O;O
and;O;O
discontinuing;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s2.e5
to;O;O
avoid;O;O
possible;O;O
over;O;O
-;O;O
or;O;O
under;O;O
-;O;O
digitalization;O;O
.;O;O
DDI-DrugBank.d373.s3;;
Extended;O;O
Release;O;O
Tablets;O;O
:;O;O
Administration;O;O
of;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s3.e0
with;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s3.e1
increased;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s3.e2
levels;O;O
in;O;O
9;O;O
of;O;O
12;O;O
normal;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d373.s4;;
The;O;O
average;O;O
increase;O;O
was;O;O
45;O;O
%;O;O
.;O;O
DDI-DrugBank.d373.s5;;
Another;O;O
investigator;O;O
found;O;O
no;O;O
increase;O;O
in;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s5.e0
levels;O;O
in;O;O
13;O;O
patients;O;O
with;O;O
coronary;O;O
artery;O;O
disease;O;O
.;O;O
DDI-DrugBank.d373.s6;;
In;O;O
an;O;O
uncontrolled;O;O
study;O;O
of;O;O
over;O;O
200;O;O
patients;O;O
with;O;O
congestive;O;O
heart;O;O
failure;O;O
during;O;O
which;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s6.e0
blood;O;O
levels;O;O
were;O;O
not;O;O
measured;O;O
,;O;O
digitalis;O;O
toxicity;O;O
was;O;O
not;O;O
observed;O;O
.;O;O
DDI-DrugBank.d373.s7;;
Since;O;O
there;O;O
have;O;O
been;O;O
isolated;O;O
reports;O;O
of;O;O
patients;O;O
with;O;O
elevated;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s7.e0
levels;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
digoxin;B-drug;B-DDI-DrugBank.d373.s7.e1
levels;O;O
be;O;O
monitored;O;O
when;O;O
initiating;O;O
,;O;O
adjusting;O;O
,;O;O
and;O;O
discontinuing;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s7.e2
to;O;O
avoid;O;O
possible;O;O
over;O;O
-;O;O
or;O;O
under;O;O
-;O;O
digitalization;O;O
.;O;O
DDI-DrugBank.d373.s8;;
Quinidine;B-drug;B-DDI-DrugBank.d373.s8.e0
:;O;O
Immediate;O;O
Release;O;O
Capsules;O;O
:;O;O
There;O;O
have;O;O
been;O;O
rare;O;O
reports;O;O
of;O;O
an;O;O
interaction;O;O
between;O;O
quinidine;B-drug;B-DDI-DrugBank.d373.s8.e1
and;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s8.e2
(;O;O
with;O;O
a;O;O
decreased;O;O
plasma;O;O
level;O;O
of;O;O
quinidine;B-drug;B-DDI-DrugBank.d373.s8.e3
);O;O
.;O;O
DDI-DrugBank.d373.s9;;
Coumarin;B-group;B-DDI-DrugBank.d373.s9.e0
Anticoagulants;I-group;I-DDI-DrugBank.d373.s9.e0
:;O;O
There;O;O
have;O;O
been;O;O
rare;O;O
reports;O;O
of;O;O
increased;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
taking;O;O
coumarin;B-group;B-DDI-DrugBank.d373.s9.e1
anticoagulants;I-group;I-DDI-DrugBank.d373.s9.e1
to;O;O
whom;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s9.e2
was;O;O
administered;O;O
.;O;O
DDI-DrugBank.d373.s10;;
However;O;O
,;O;O
the;O;O
relationship;O;O
to;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s10.e0
therapy;O;O
is;O;O
uncertain;O;O
.;O;O
DDI-DrugBank.d373.s11;;
Cimetidine;B-drug;B-DDI-DrugBank.d373.s11.e0
:;O;O
A;O;O
study;O;O
in;O;O
6;O;O
healthy;O;O
volunteers;O;O
has;O;O
shown;O;O
a;O;O
significant;O;O
increase;O;O
in;O;O
peak;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s11.e1
plasma;O;O
levels;O;O
(;O;O
80;O;O
%;O;O
);O;O
and;O;O
area;O;O
-;O;O
under;O;O
-;O;O
the;O;O
-;O;O
curve;O;O
(;O;O
74;O;O
%;O;O
);O;O
after;O;O
a;O;O
1;O;O
week;O;O
course;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d373.s11.e2
at;O;O
1000;O;O
mg;O;O
per;O;O
day;O;O
and;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s11.e3
at;O;O
40;O;O
mg;O;O
per;O;O
day;O;O
.;O;O
DDI-DrugBank.d373.s12;;
Ranitidine;B-drug;B-DDI-DrugBank.d373.s12.e0
produced;O;O
smaller;O;O
,;O;O
non;O;O
-;O;O
significant;O;O
increases;O;O
.;O;O
DDI-DrugBank.d373.s13;;
The;O;O
effect;O;O
may;O;O
be;O;O
mediated;O;O
by;O;O
the;O;O
known;O;O
inhibition;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d373.s13.e0
on;O;O
hepatic;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
,;O;O
the;O;O
enzyme;O;O
system;O;O
probably;O;O
responsible;O;O
for;O;O
the;O;O
first;O;O
-;O;O
pass;O;O
metabolism;O;O
of;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s13.e1
.;O;O
DDI-DrugBank.d373.s14;;
If;O;O
nifedipine;B-drug;B-DDI-DrugBank.d373.s14.e0
therapy;O;O
is;O;O
initiated;O;O
in;O;O
a;O;O
patient;O;O
currently;O;O
receiving;O;O
cimetidine;B-drug;B-DDI-DrugBank.d373.s14.e1
,;O;O
cautious;O;O
titration;O;O
is;O;O
advised;O;O
.;O;O
DDI-DrugBank.d177.s0;;
In;O;O
vitro;O;O
,;O;O
nilutamide;B-drug;B-DDI-DrugBank.d177.s0.e0
has;O;O
been;O;O
shown;O;O
to;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
liver;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
isoenzymes;O;O
and;O;O
therefore;O;O
,;O;O
may;O;O
reduce;O;O
the;O;O
metabolism;O;O
of;O;O
compounds;O;O
requiring;O;O
these;O;O
systems;O;O
.;O;O
DDI-DrugBank.d177.s1;;
Consequently;O;O
,;O;O
drugs;O;O
with;O;O
a;O;O
low;O;O
therapeutic;O;O
margin;O;O
,;O;O
such;O;O
as;O;O
vitamin;B-group;B-DDI-DrugBank.d177.s1.e0
K;I-group;I-DDI-DrugBank.d177.s1.e0
antagonists;I-group;I-DDI-DrugBank.d177.s1.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d177.s1.e1
,;O;O
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d177.s1.e2
,;O;O
could;O;O
have;O;O
a;O;O
delayed;O;O
elimination;O;O
and;O;O
increases;O;O
in;O;O
their;O;O
serum;O;O
half;O;O
-;O;O
life;O;O
leading;O;O
to;O;O
a;O;O
toxic;O;O
level;O;O
.;O;O
DDI-DrugBank.d177.s2;;
The;O;O
dosage;O;O
of;O;O
these;O;O
drugs;O;O
or;O;O
others;O;O
with;O;O
a;O;O
similar;O;O
metabolism;O;O
may;O;O
need;O;O
to;O;O
be;O;O
modified;O;O
if;O;O
they;O;O
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
nilutamide;B-drug;B-DDI-DrugBank.d177.s2.e0
.;O;O
DDI-DrugBank.d177.s3;;
For;O;O
example;O;O
,;O;O
when;O;O
vitamin;B-group;B-DDI-DrugBank.d177.s3.e0
K;I-group;I-DDI-DrugBank.d177.s3.e0
antagonists;I-group;I-DDI-DrugBank.d177.s3.e0
are;O;O
administered;O;O
concomitantly;O;O
with;O;O
nilutamide;B-drug;B-DDI-DrugBank.d177.s3.e1
,;O;O
prothrombin;O;O
time;O;O
should;O;O
be;O;O
carefully;O;O
monitored;O;O
and;O;O
if;O;O
necessary;O;O
,;O;O
the;O;O
dosage;O;O
of;O;O
vitamin;B-group;B-DDI-DrugBank.d177.s3.e2
K;I-group;I-DDI-DrugBank.d177.s3.e2
antagonists;I-group;I-DDI-DrugBank.d177.s3.e2
should;O;O
be;O;O
reduced;O;O
.;O;O
DDI-DrugBank.d310.s0;;
It;O;O
is;O;O
possible;O;O
that;O;O
the;O;O
cardiovascular;O;O
action;O;O
of;O;O
other;O;O
calcium;B-group;B-DDI-DrugBank.d310.s0.e0
channel;I-group;I-DDI-DrugBank.d310.s0.e0
blockers;I-group;I-DDI-DrugBank.d310.s0.e0
could;O;O
be;O;O
enhanced;O;O
by;O;O
the;O;O
addition;O;O
of;O;O
Nimotop;B-brand;B-DDI-DrugBank.d310.s0.e1
.;O;O
DDI-DrugBank.d310.s1;;
In;O;O
Europe;O;O
,;O;O
Nimotop;B-brand;B-DDI-DrugBank.d310.s1.e0
was;O;O
observed;O;O
to;O;O
occasionally;O;O
intensify;O;O
the;O;O
effect;O;O
of;O;O
antihypertensive;B-group;B-DDI-DrugBank.d310.s1.e1
compounds;I-group;I-DDI-DrugBank.d310.s1.e1
taken;O;O
concomitantly;O;O
by;O;O
patients;O;O
suffering;O;O
from;O;O
hypertension;O;O
,;O;O
DDI-DrugBank.d310.s2;;
this;O;O
phenomenon;O;O
was;O;O
not;O;O
observed;O;O
in;O;O
North;O;O
American;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d310.s3;;
A;O;O
study;O;O
in;O;O
eight;O;O
healthy;O;O
volunteers;O;O
has;O;O
shown;O;O
a;O;O
50;O;O
%;O;O
increase;O;O
in;O;O
mean;O;O
peak;O;O
nimodipine;B-drug;B-DDI-DrugBank.d310.s3.e0
plasma;O;O
concentrations;O;O
and;O;O
a;O;O
90;O;O
%;O;O
increase;O;O
in;O;O
mean;O;O
area;O;O
under;O;O
the;O;O
curve;O;O
,;O;O
after;O;O
a;O;O
one;O;O
week;O;O
course;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d310.s3.e1
at;O;O
1,000;O;O
mg;O;O
/;O;O
day;O;O
and;O;O
nimodipine;B-drug;B-DDI-DrugBank.d310.s3.e2
at;O;O
90;O;O
mg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d310.s4;;
This;O;O
effect;O;O
may;O;O
be;O;O
mediated;O;O
by;O;O
the;O;O
known;O;O
inhibition;O;O
of;O;O
hepatic;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
by;O;O
cimetidine;B-drug;B-DDI-DrugBank.d310.s4.e0
,;O;O
which;O;O
could;O;O
decrease;O;O
first;O;O
pass;O;O
metabolism;O;O
of;O;O
nimodipine;B-drug;B-DDI-DrugBank.d310.s4.e1
.;O;O
DDI-DrugBank.d106.s0;;
A;O;O
30;O;O
to;O;O
45;O;O
%;O;O
increase;O;O
in;O;O
AUC;O;O
and;O;O
Cmax;O;O
of;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s0.e0
was;O;O
observed;O;O
with;O;O
concomitant;O;O
administration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d106.s0.e1
400;I-drug;I-DDI-DrugBank.d106.s0.e1
mg;I-drug;I-DDI-DrugBank.d106.s0.e1
twice;O;O
daily;O;O
.;O;O
DDI-DrugBank.d106.s1;;
Ranitidine;B-drug;B-DDI-DrugBank.d106.s1.e0
150;O;O
mg;O;O
twice;O;O
daily;O;O
did;O;O
not;O;O
interact;O;O
significantly;O;O
with;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s1.e1
(;O;O
AUC;O;O
was;O;O
decreased;O;O
by;O;O
15;O;O
-;O;O
20;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d106.s2;;
No;O;O
pharmacodynamic;O;O
effects;O;O
of;O;O
either;O;O
histamine;B-group;B-DDI-DrugBank.d106.s2.e0
H2;I-group;I-DDI-DrugBank.d106.s2.e0
receptor;I-group;I-DDI-DrugBank.d106.s2.e0
antagonist;I-group;I-DDI-DrugBank.d106.s2.e0
were;O;O
observed;O;O
.;O;O
DDI-DrugBank.d106.s3;;
Coadministration;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d106.s3.e0
with;O;O
40;O;O
mg;O;O
SULAR;B-brand;B-DDI-DrugBank.d106.s3.e1
tablets;O;O
in;O;O
epileptic;O;O
patients;O;O
lowered;O;O
the;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s3.e2
plasma;O;O
concentrations;O;O
to;O;O
undetectable;O;O
levels;O;O
.;O;O
DDI-DrugBank.d106.s4;;
Coadministration;O;O
of;O;O
SULAR;B-brand;B-DDI-DrugBank.d106.s4.e0
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d106.s4.e1
or;O;O
any;O;O
known;O;O
CYP3A4;O;O
inducer;O;O
should;O;O
be;O;O
avoided;O;O
and;O;O
alternative;O;O
antihypertensive;B-group;B-DDI-DrugBank.d106.s4.e2
therapy;O;O
should;O;O
be;O;O
considered;O;O
.;O;O
DDI-DrugBank.d106.s5;;
Pharmacokinetic;O;O
interactions;O;O
between;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s5.e0
and;O;O
beta;B-group;B-DDI-DrugBank.d106.s5.e1
-;I-group;I-DDI-DrugBank.d106.s5.e1
blockers;I-group;I-DDI-DrugBank.d106.s5.e1
(;O;O
atenolol;B-drug;B-DDI-DrugBank.d106.s5.e2
,;O;O
propranolol;B-drug;B-DDI-DrugBank.d106.s5.e3
);O;O
were;O;O
variable;O;O
and;O;O
not;O;O
significant;O;O
.;O;O
DDI-DrugBank.d106.s6;;
Propranolol;B-drug;B-DDI-DrugBank.d106.s6.e0
attenuated;O;O
the;O;O
heart;O;O
rate;O;O
increase;O;O
following;O;O
administration;O;O
of;O;O
immediate;O;O
release;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s6.e1
.;O;O
DDI-DrugBank.d106.s7;;
The;O;O
blood;O;O
pressure;O;O
effect;O;O
of;O;O
SULAR;B-brand;B-DDI-DrugBank.d106.s7.e0
tended;O;O
to;O;O
be;O;O
greater;O;O
in;O;O
patients;O;O
on;O;O
atenolol;B-drug;B-DDI-DrugBank.d106.s7.e1
than;O;O
in;O;O
patients;O;O
on;O;O
no;O;O
other;O;O
antihypertensive;B-group;B-DDI-DrugBank.d106.s7.e2
therapy;O;O
.;O;O
DDI-DrugBank.d106.s8;;
Quinidine;B-drug;B-DDI-DrugBank.d106.s8.e0
at;O;O
648;O;O
mg;O;O
bid;O;O
decreased;O;O
the;O;O
bioavailability;O;O
(;O;O
AUC;O;O
);O;O
of;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s8.e1
by;O;O
26;O;O
%;O;O
,;O;O
but;O;O
not;O;O
the;O;O
peak;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d106.s9;;
The;O;O
immediate;O;O
release;O;O
,;O;O
but;O;O
not;O;O
the;O;O
coat;O;O
-;O;O
core;O;O
formulation;O;O
of;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s9.e0
increased;O;O
plasma;O;O
quinidine;B-drug;B-DDI-DrugBank.d106.s9.e1
concentrations;O;O
by;O;O
about;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d106.s10;;
This;O;O
interaction;O;O
was;O;O
not;O;O
accompanied;O;O
by;O;O
ECG;O;O
changes;O;O
and;O;O
its;O;O
clinical;O;O
significance;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d106.s11;;
No;O;O
significant;O;O
interactions;O;O
were;O;O
found;O;O
between;O;O
nisoldipine;B-drug;B-DDI-DrugBank.d106.s11.e0
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d106.s11.e1
or;O;O
digoxin;B-drug;B-DDI-DrugBank.d106.s11.e2
.;O;O
DDI-DrugBank.d354.s0;;
Tizoxanide;B-drug;B-DDI-DrugBank.d354.s0.e0
is;O;O
highly;O;O
bound;O;O
to;O;O
plasma;O;O
protein;O;O
(;O;O
99.9;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d354.s1;;
Therefore;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
used;O;O
when;O;O
administering;O;O
nitazoxanide;B-drug;B-DDI-DrugBank.d354.s1.e0
concurrently;O;O
with;O;O
other;O;O
highly;O;O
plasma;O;O
protein;O;O
-;O;O
bound;O;O
drugs;O;O
with;O;O
narrow;O;O
therapeutic;O;O
indices;O;O
,;O;O
as;O;O
competition;O;O
for;O;O
binding;O;O
sites;O;O
may;O;O
occur;O;O
(;O;O
e.g.;O;O
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d354.s1.e1
);O;O
.;O;O
DDI-DrugBank.d354.s2;;
In;O;O
vitro;O;O
metabolism;O;O
studies;O;O
have;O;O
demonstrated;O;O
that;O;O
tizoxanide;B-drug;B-DDI-DrugBank.d354.s2.e0
has;O;O
no;O;O
significant;O;O
inhibitory;O;O
effect;O;O
on;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d354.s3;;
Although;O;O
no;O;O
drug;O;O
-;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
conducted;O;O
in;O;O
vivo;O;O
,;O;O
it;O;O
is;O;O
expected;O;O
that;O;O
no;O;O
significant;O;O
interaction;O;O
would;O;O
occur;O;O
when;O;O
nitazoxanide;B-drug;B-DDI-DrugBank.d354.s3.e0
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
drugs;O;O
that;O;O
either;O;O
are;O;O
metabolized;O;O
by;O;O
or;O;O
inhibit;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
.;O;O
DDI-DrugBank.d183.s0;;
No;O;O
formal;O;O
drug;O;O
-;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
,;O;O
and;O;O
a;O;O
clinically;O;O
significant;O;O
interaction;O;O
with;O;O
other;O;O
medications;O;O
used;O;O
in;O;O
the;O;O
treatment;O;O
of;O;O
hypoxic;O;O
respiratory;O;O
failure;O;O
can;O;O
not;O;O
be;O;O
excluded;O;O
based;O;O
on;O;O
the;O;O
available;O;O
data;O;O
.;O;O
DDI-DrugBank.d183.s1;;
INOmax;B-brand;B-DDI-DrugBank.d183.s1.e0
has;O;O
been;O;O
administered;O;O
with;O;O
tolazoline;B-drug;B-DDI-DrugBank.d183.s1.e1
,;O;O
dopamine;B-drug;B-DDI-DrugBank.d183.s1.e2
,;O;O
dobutamine;B-drug;B-DDI-DrugBank.d183.s1.e3
,;O;O
steroids;B-group;B-DDI-DrugBank.d183.s1.e4
,;O;O
surfactant;B-drug;B-DDI-DrugBank.d183.s1.e5
,;O;O
and;O;O
high;O;O
-;O;O
frequency;O;O
ventilation;O;O
.;O;O
DDI-DrugBank.d183.s2;;
Although;O;O
there;O;O
are;O;O
no;O;O
study;O;O
data;O;O
to;O;O
evaluate;O;O
the;O;O
possibility;O;O
,;O;O
nitric;B-group;B-DDI-DrugBank.d183.s2.e0
oxide;I-group;I-DDI-DrugBank.d183.s2.e0
donor;I-group;I-DDI-DrugBank.d183.s2.e0
compounds;I-group;I-DDI-DrugBank.d183.s2.e0
,;O;O
including;O;O
sodium;B-drug;B-DDI-DrugBank.d183.s2.e1
nitroprusside;I-drug;I-DDI-DrugBank.d183.s2.e1
and;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d183.s2.e2
,;O;O
may;O;O
have;O;O
an;O;O
additive;O;O
effect;O;O
with;O;O
INOmax;B-brand;B-DDI-DrugBank.d183.s2.e3
on;O;O
the;O;O
risk;O;O
of;O;O
developing;O;O
methemoglobinemia;O;O
.;O;O
DDI-DrugBank.d183.s3;;
An;O;O
association;O;O
between;O;O
prilocaine;B-drug;B-DDI-DrugBank.d183.s3.e0
and;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
methaemoglobinaemia;O;O
,;O;O
particularly;O;O
in;O;O
infants;O;O
,;O;O
has;O;O
specifically;O;O
been;O;O
described;O;O
in;O;O
a;O;O
literature;O;O
case;O;O
report;O;O
.;O;O
DDI-DrugBank.d183.s4;;
This;O;O
risk;O;O
is;O;O
present;O;O
whether;O;O
the;O;O
drugs;O;O
are;O;O
administered;O;O
as;O;O
oral;O;O
,;O;O
parenteral;O;O
,;O;O
or;O;O
topical;O;O
formulations;O;O
.;O;O
DDI-DrugBank.d276.s0;;
Antacids;B-group;B-DDI-DrugBank.d276.s0.e0
containing;O;O
magnesium;B-drug;B-DDI-DrugBank.d276.s0.e1
trisilicate;I-drug;I-DDI-DrugBank.d276.s0.e1
,;O;O
when;O;O
administered;O;O
concomitantly;O;O
with;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d276.s0.e2
,;O;O
reduce;O;O
both;O;O
the;O;O
rate;O;O
and;O;O
extent;O;O
of;O;O
absorption;O;O
.;O;O
DDI-DrugBank.d276.s1;;
The;O;O
mechanism;O;O
for;O;O
this;O;O
interaction;O;O
probably;O;O
is;O;O
adsorption;O;O
of;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d276.s1.e0
onto;O;O
the;O;O
surface;O;O
of;O;O
magnesium;B-drug;B-DDI-DrugBank.d276.s1.e1
trisilicate;I-drug;I-DDI-DrugBank.d276.s1.e1
.;O;O
DDI-DrugBank.d276.s2;;
Uricosuric;B-group;B-DDI-DrugBank.d276.s2.e0
drugs;I-group;I-DDI-DrugBank.d276.s2.e0
,;O;O
such;O;O
as;O;O
probenecid;B-drug;B-DDI-DrugBank.d276.s2.e1
and;O;O
sulfinpyrazone;B-drug;B-DDI-DrugBank.d276.s2.e2
,;O;O
can;O;O
inhibit;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d276.s2.e3
.;O;O
DDI-DrugBank.d276.s3;;
The;O;O
resulting;O;O
increase;O;O
in;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d276.s3.e0
serum;O;O
levels;O;O
may;O;O
increase;O;O
toxicity;O;O
,;O;O
and;O;O
the;O;O
decreased;O;O
urinary;O;O
levels;O;O
could;O;O
lessen;O;O
its;O;O
efficacy;O;O
as;O;O
a;O;O
urinary;O;O
tract;O;O
antibacterial;B-group;B-DDI-DrugBank.d276.s3.e1
.;O;O
DDI-DrugBank.d276.s4;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
As;O;O
a;O;O
result;O;O
of;O;O
the;O;O
presence;O;O
of;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d276.s4.e0
,;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
may;O;O
occur;O;O
.;O;O
DDI-DrugBank.d276.s5;;
This;O;O
has;O;O
been;O;O
observed;O;O
with;O;O
Benedict;O;O
s;O;O
and;O;O
Fehling;O;O
s;O;O
solutions;O;O
but;O;O
not;O;O
with;O;O
the;O;O
glucose;O;O
enzymatic;O;O
test;O;O
.;O;O
DDI-DrugBank.d14.s0;;
The;O;O
vasodilating;O;O
effects;O;O
of;O;O
nitroglycerin;B-drug;B-DDI-DrugBank.d14.s0.e0
may;O;O
be;O;O
additive;O;O
with;O;O
those;O;O
of;O;O
other;O;O
vasodilators;B-group;B-DDI-DrugBank.d14.s0.e1
.;O;O
DDI-DrugBank.d14.s1;;
Alcohol;B-drug;B-DDI-DrugBank.d14.s1.e0
,;O;O
in;O;O
particular;O;O
,;O;O
has;O;O
been;O;O
found;O;O
to;O;O
exhibit;O;O
additive;O;O
effects;O;O
of;O;O
this;O;O
variety;O;O
.;O;O
DDI-DrugBank.d14.s2;;
Marked;O;O
symptomatic;O;O
orthostatic;O;O
hypotension;O;O
has;O;O
been;O;O
reported;O;O
when;O;O
calcium;B-group;B-DDI-DrugBank.d14.s2.e0
channel;I-group;I-DDI-DrugBank.d14.s2.e0
blockers;I-group;I-DDI-DrugBank.d14.s2.e0
and;O;O
organic;O;O
nitrates;B-group;B-DDI-DrugBank.d14.s2.e1
were;O;O
used;O;O
in;O;O
combination;O;O
.;O;O
DDI-DrugBank.d14.s3;;
Dose;O;O
adjustments;O;O
of;O;O
either;O;O
class;O;O
of;O;O
agents;O;O
may;O;O
be;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d394.s0;;
The;O;O
hypotensive;O;O
effect;O;O
of;O;O
sodium;B-drug;B-DDI-DrugBank.d394.s0.e0
nitroprusside;I-drug;I-DDI-DrugBank.d394.s0.e0
is;O;O
augmented;O;O
by;O;O
that;O;O
of;O;O
most;O;O
other;O;O
hypotensive;B-group;B-DDI-DrugBank.d394.s0.e1
drugs;I-group;I-DDI-DrugBank.d394.s0.e1
,;O;O
including;O;O
ganglionic;B-group;B-DDI-DrugBank.d394.s0.e2
blocking;I-group;I-DDI-DrugBank.d394.s0.e2
agents;I-group;I-DDI-DrugBank.d394.s0.e2
,;O;O
negative;O;O
inotropic;O;O
agents;O;O
,;O;O
and;O;O
inhaled;O;O
anesthetics;B-group;B-DDI-DrugBank.d394.s0.e3
.;O;O
DDI-DrugBank.d475.s0;;
No;O;O
interactions;O;O
have;O;O
been;O;O
observed;O;O
between;O;O
nizatidine;B-drug;B-DDI-DrugBank.d475.s0.e0
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d475.s0.e1
,;O;O
chlordiazepoxide;B-drug;B-DDI-DrugBank.d475.s0.e2
,;O;O
lorazepam;B-drug;B-DDI-DrugBank.d475.s0.e3
,;O;O
lidocaine;B-drug;B-DDI-DrugBank.d475.s0.e4
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d475.s0.e5
,;O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d475.s0.e6
.;O;O
DDI-DrugBank.d475.s1;;
Nizatidine;B-drug;B-DDI-DrugBank.d475.s1.e0
does;O;O
not;O;O
inhibit;O;O
the;O;O
cytochrome;O;O
P;O;O
-;O;O
450;O;O
-;O;O
linked;O;O
drug;O;O
-;O;O
metabolizing;O;O
enzyme;O;O
system;O;O
,;O;O
DDI-DrugBank.d475.s2;;
therefore;O;O
,;O;O
drug;O;O
interactions;O;O
mediated;O;O
by;O;O
inhibition;O;O
of;O;O
hepatic;O;O
metabolism;O;O
are;O;O
not;O;O
expected;O;O
to;O;O
occur;O;O
.;O;O
DDI-DrugBank.d475.s3;;
In;O;O
patients;O;O
given;O;O
very;O;O
high;O;O
doses;O;O
(;O;O
3900;O;O
mg;O;O
);O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d475.s3.e0
daily;O;O
,;O;O
increases;O;O
in;O;O
serum;O;O
salicylate;B-group;B-DDI-DrugBank.d475.s3.e1
levels;O;O
were;O;O
seen;O;O
when;O;O
nizatidine;B-drug;B-DDI-DrugBank.d475.s3.e2
,;O;O
150;O;O
mg;O;O
b.i.d;O;O
.;O;O
,;O;O
was;O;O
administered;O;O
concurrently;O;O
.;O;O
DDI-DrugBank.d306.s0;;
The;O;O
effectiveness;O;O
of;O;O
progestin;B-group;B-DDI-DrugBank.d306.s0.e0
-;O;O
only;O;O
pills;O;O
is;O;O
reduced;O;O
by;O;O
hepatic;O;O
enzyme;O;O
-;O;O
inducing;O;O
drugs;O;O
such;O;O
as;O;O
the;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d306.s0.e1
phenytoin;I-drug;I-DDI-DrugBank.d306.s0.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d306.s0.e3
,;O;O
and;O;O
barbiturates;B-group;B-DDI-DrugBank.d306.s0.e4
,;O;O
and;O;O
the;O;O
antituberculosis;B-group;B-DDI-DrugBank.d306.s0.e5
drug;I-group;I-DDI-DrugBank.d306.s0.e5
rifampin;I-drug;I-DDI-DrugBank.d306.s0.e6
.;O;O
DDI-DrugBank.d306.s1;;
No;O;O
significant;O;O
interaction;O;O
has;O;O
been;O;O
found;O;O
with;O;O
broad;O;O
-;O;O
spectrum;O;O
antibiotics;B-group;B-DDI-DrugBank.d306.s1.e0
.;O;O
DDI-DrugBank.d217.s0;;
Elevated;O;O
plasma;O;O
levels;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d217.s0.e0
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
quinolone;B-group;B-DDI-DrugBank.d217.s0.e1
use;O;O
.;O;O
DDI-DrugBank.d217.s1;;
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d217.s1.e0
-;O;O
related;O;O
side;O;O
effects;O;O
in;O;O
patients;O;O
on;O;O
concomitant;O;O
therapy;O;O
with;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s1.e1
and;O;O
theophylline;B-drug;B-DDI-DrugBank.d217.s1.e2
.;O;O
DDI-DrugBank.d217.s2;;
Therefore;O;O
,;O;O
monitoring;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d217.s2.e0
plasma;O;O
levels;O;O
should;O;O
be;O;O
considered;O;O
and;O;O
dosage;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d217.s2.e1
adjusted;O;O
as;O;O
required;O;O
.;O;O
DDI-DrugBank.d217.s3;;
Elevated;O;O
serum;O;O
levels;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d217.s3.e0
have;O;O
been;O;O
reported;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d217.s3.e1
with;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s3.e2
.;O;O
DDI-DrugBank.d217.s4;;
Therefore;O;O
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d217.s4.e0
serum;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
and;O;O
appropriate;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d217.s4.e1
dosage;O;O
adjustments;O;O
made;O;O
when;O;O
these;O;O
drugs;O;O
are;O;O
used;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d217.s5;;
Quinolones;B-group;B-DDI-DrugBank.d217.s5.e0
,;O;O
including;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s5.e1
,;O;O
may;O;O
enhance;O;O
the;O;O
effects;O;O
of;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d217.s5.e2
,;O;O
including;O;O
warfarin;B-drug;B-DDI-DrugBank.d217.s5.e3
or;O;O
its;O;O
derivatives;O;O
or;O;O
similar;O;O
agents;O;O
.;O;O
DDI-DrugBank.d217.s6;;
When;O;O
these;O;O
products;O;O
are;O;O
administered;O;O
concomitantly;O;O
,;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
suitable;O;O
coagulation;O;O
tests;O;O
should;O;O
be;O;O
closely;O;O
monitored;O;O
.;O;O
DDI-DrugBank.d217.s7;;
The;O;O
concomitant;O;O
administration;O;O
of;O;O
quinolones;B-group;B-DDI-DrugBank.d217.s7.e0
including;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s7.e1
with;O;O
glyburide;B-drug;B-DDI-DrugBank.d217.s7.e2
(;O;O
a;O;O
sulfonylurea;B-group;B-DDI-DrugBank.d217.s7.e3
agent;I-group;I-DDI-DrugBank.d217.s7.e3
);O;O
has;O;O
,;O;O
on;O;O
rare;O;O
occasions;O;O
,;O;O
resulted;O;O
in;O;O
severe;O;O
hypoglycemia;O;O
.;O;O
DDI-DrugBank.d217.s8;;
Therefore;O;O
,;O;O
monitoring;O;O
of;O;O
blood;O;O
glucose;O;O
is;O;O
recommended;O;O
when;O;O
these;O;O
agents;O;O
are;O;O
co;O;O
-;O;O
administered;O;O
.;O;O
DDI-DrugBank.d217.s9;;
Diminished;O;O
urinary;O;O
excretion;O;O
of;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s9.e0
has;O;O
been;O;O
reported;O;O
during;O;O
the;O;O
concomitant;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d217.s9.e1
and;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s9.e2
.;O;O
DDI-DrugBank.d217.s10;;
The;O;O
concomitant;O;O
use;O;O
of;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d217.s10.e0
is;O;O
not;O;O
recommended;O;O
since;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d217.s10.e1
may;O;O
antagonize;O;O
the;O;O
antibacterial;O;O
effect;O;O
of;O;O
Norfloxacin;B-drug;B-DDI-DrugBank.d217.s10.e2
in;O;O
the;O;O
urinary;O;O
tract;O;O
.;O;O
DDI-DrugBank.d217.s11;;
Multivitamins;B-group;B-DDI-DrugBank.d217.s11.e0
,;O;O
or;O;O
other;O;O
products;O;O
containing;O;O
iron;B-drug;B-DDI-DrugBank.d217.s11.e1
or;O;O
zinc;B-drug;B-DDI-DrugBank.d217.s11.e2
,;O;O
antacids;B-group;B-DDI-DrugBank.d217.s11.e3
or;O;O
sucralfate;B-drug;B-DDI-DrugBank.d217.s11.e4
should;O;O
not;O;O
be;O;O
administered;O;O
concomitantly;O;O
with;O;O
,;O;O
or;O;O
within;O;O
2;O;O
hours;O;O
of;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s11.e5
,;O;O
because;O;O
they;O;O
may;O;O
interfere;O;O
with;O;O
absorption;O;O
resulting;O;O
in;O;O
lower;O;O
serum;O;O
and;O;O
urine;O;O
levels;O;O
of;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s11.e6
.;O;O
DDI-DrugBank.d217.s12;;
Videx;B-brand;B-DDI-DrugBank.d217.s12.e0
(;O;O
Didanosine;B-drug;B-DDI-DrugBank.d217.s12.e1
);O;O
chewable;O;O
/;O;O
buffered;O;O
tablets;O;O
or;O;O
the;O;O
pediatric;O;O
powder;O;O
for;O;O
oral;O;O
solution;O;O
should;O;O
not;O;O
be;O;O
administered;O;O
concomitantly;O;O
with;O;O
,;O;O
or;O;O
within;O;O
2;O;O
hours;O;O
of;O;O
,;O;O
the;O;O
administration;O;O
of;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s12.e2
,;O;O
because;O;O
these;O;O
products;O;O
may;O;O
interfere;O;O
with;O;O
absorption;O;O
resulting;O;O
in;O;O
lower;O;O
serum;O;O
and;O;O
urine;O;O
levels;O;O
of;O;O
norfloxacin;B-drug;B-DDI-DrugBank.d217.s12.e3
.;O;O
DDI-DrugBank.d217.s13;;
Some;O;O
quinolones;B-group;B-DDI-DrugBank.d217.s13.e0
have;O;O
also;O;O
been;O;O
shown;O;O
to;O;O
interfere;O;O
with;O;O
the;O;O
metabolism;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d217.s13.e1
.;O;O
DDI-DrugBank.d217.s14;;
This;O;O
may;O;O
lead;O;O
to;O;O
reduced;O;O
clearance;O;O
of;O;O
caffeine;B-drug;B-DDI-DrugBank.d217.s14.e0
and;O;O
a;O;O
prolongation;O;O
of;O;O
its;O;O
plasma;O;O
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d360.s0;;
Reduced;O;O
efficacy;O;O
and;O;O
increased;O;O
incidence;O;O
of;O;O
breakthrough;O;O
bleeding;O;O
and;O;O
menstrual;O;O
irregularities;O;O
have;O;O
been;O;O
associated;O;O
with;O;O
concomitant;O;O
use;O;O
of;O;O
rifampin;B-drug;B-DDI-DrugBank.d360.s0.e0
.;O;O
DDI-DrugBank.d360.s1;;
A;O;O
similar;O;O
association;O;O
,;O;O
though;O;O
less;O;O
marked;O;O
,;O;O
has;O;O
been;O;O
suggested;O;O
with;O;O
barbiturates;B-group;B-DDI-DrugBank.d360.s1.e0
,;O;O
phenylbutazone;B-drug;B-DDI-DrugBank.d360.s1.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d360.s1.e2
sodium;I-drug;I-DDI-DrugBank.d360.s1.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d360.s1.e3
,;O;O
griseofulvin;B-drug;B-DDI-DrugBank.d360.s1.e4
,;O;O
topiramate;B-drug;B-DDI-DrugBank.d360.s1.e5
,;O;O
and;O;O
possibly;O;O
with;O;O
ampicillin;B-drug;B-DDI-DrugBank.d360.s1.e6
and;O;O
tetracyclines;B-group;B-DDI-DrugBank.d360.s1.e7
72;O;O
.;O;O
DDI-DrugBank.d360.s2;;
A;O;O
possible;O;O
interaction;O;O
has;O;O
been;O;O
suggested;O;O
with;O;O
hormonal;B-group;B-DDI-DrugBank.d360.s2.e0
contraceptives;I-group;I-DDI-DrugBank.d360.s2.e0
and;O;O
the;O;O
herbal;O;O
supplement;O;O
St.;O;O
Johns;O;O
Wort;O;O
based;O;O
on;O;O
some;O;O
reports;O;O
of;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d360.s2.e1
users;O;O
experiencing;O;O
breakthrough;O;O
bleeding;O;O
shortly;O;O
after;O;O
starting;O;O
St.;O;O
Johns;O;O
Wort;O;O
.;O;O
DDI-DrugBank.d360.s3;;
Pregnancies;O;O
have;O;O
been;O;O
reported;O;O
by;O;O
users;O;O
of;O;O
combined;B-group;B-DDI-DrugBank.d360.s3.e0
hormonal;I-group;I-DDI-DrugBank.d360.s3.e0
contraceptives;I-group;I-DDI-DrugBank.d360.s3.e0
who;O;O
also;O;O
used;O;O
some;O;O
form;O;O
of;O;O
St.;O;O
Johns;O;O
Wort;O;O
.;O;O
DDI-DrugBank.d360.s4;;
Healthcare;O;O
prescribers;O;O
are;O;O
advised;O;O
to;O;O
consult;O;O
the;O;O
package;O;O
inserts;O;O
of;O;O
medication;O;O
administered;O;O
concomitantly;O;O
with;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d360.s4.e0
.;O;O
DDI-DrugBank.d202.s0;;
Steady;O;O
-;O;O
state;O;O
serum;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s0.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s0.e0
are;O;O
reported;O;O
to;O;O
fluctuate;O;O
significantly;O;O
when;O;O
cimetidine;B-drug;B-DDI-DrugBank.d202.s0.e1
is;O;O
either;O;O
added;O;O
or;O;O
deleted;O;O
from;O;O
the;O;O
drug;O;O
regimen;O;O
.;O;O
DDI-DrugBank.d202.s1;;
Serious;O;O
anticholinergic;O;O
symptoms;O;O
(;O;O
severe;O;O
dry;O;O
mouth;O;O
,;O;O
urinary;O;O
retention;O;O
,;O;O
blurred;O;O
vision;O;O
);O;O
have;O;O
been;O;O
associated;O;O
with;O;O
elevations;O;O
in;O;O
the;O;O
serum;O;O
levels;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s1.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s1.e0
when;O;O
cimetidine;B-drug;B-DDI-DrugBank.d202.s1.e1
is;O;O
added;O;O
to;O;O
the;O;O
drug;O;O
regimen;O;O
.;O;O
DDI-DrugBank.d202.s2;;
In;O;O
addition;O;O
,;O;O
higher;O;O
-;O;O
than;O;O
expected;O;O
steady;O;O
-;O;O
state;O;O
serum;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s2.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s2.e0
have;O;O
been;O;O
observed;O;O
when;O;O
therapy;O;O
is;O;O
initiated;O;O
in;O;O
patients;O;O
already;O;O
taking;O;O
cimetidine;B-drug;B-DDI-DrugBank.d202.s2.e1
.;O;O
DDI-DrugBank.d202.s3;;
In;O;O
well;O;O
-;O;O
controlled;O;O
patients;O;O
undergoing;O;O
concurrent;O;O
therapy;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d202.s3.e0
,;O;O
a;O;O
decrease;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
serum;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s3.e1
antidepressants;I-group;I-DDI-DrugBank.d202.s3.e1
may;O;O
occur;O;O
when;O;O
cime;O;O
-;O;O
tidine;O;O
therapy;O;O
is;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d202.s4;;
The;O;O
therapeutic;O;O
efficacy;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s4.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s4.e0
may;O;O
be;O;O
compromised;O;O
in;O;O
these;O;O
patients;O;O
when;O;O
cimetidine;B-drug;B-DDI-DrugBank.d202.s4.e1
is;O;O
discontinued;O;O
.;O;O
DDI-DrugBank.d202.s5;;
Several;O;O
of;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s5.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s5.e0
have;O;O
been;O;O
cited;O;O
in;O;O
these;O;O
reports;O;O
.;O;O
DDI-DrugBank.d202.s6;;
There;O;O
have;O;O
been;O;O
greater;O;O
than;O;O
2;O;O
-;O;O
fold;O;O
increases;O;O
in;O;O
previously;O;O
stable;O;O
plasma;O;O
levels;O;O
of;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d202.s6.e0
,;O;O
including;O;O
nortriptyline;B-drug;B-DDI-DrugBank.d202.s6.e1
,;O;O
when;O;O
fluoxetine;B-drug;B-DDI-DrugBank.d202.s6.e2
hydrochloride;I-drug;I-DDI-DrugBank.d202.s6.e2
has;O;O
been;O;O
administered;O;O
in;O;O
combination;O;O
with;O;O
these;O;O
agents;O;O
.;O;O
DDI-DrugBank.d202.s7;;
Fluoxetine;B-drug;B-DDI-DrugBank.d202.s7.e0
and;O;O
its;O;O
active;O;O
metabolite;O;O
,;O;O
norfluoxe;O;O
-;O;O
tine;O;O
,;O;O
have;O;O
long;O;O
half;O;O
-;O;O
lives;O;O
(;O;O
4;O;O
to;O;O
16;O;O
days;O;O
for;O;O
norfluoxetine;B-drug_n;B-DDI-DrugBank.d202.s7.e1
);O;O
,;O;O
that;O;O
may;O;O
affect;O;O
strategies;O;O
during;O;O
conversion;O;O
from;O;O
one;O;O
drug;O;O
to;O;O
the;O;O
other;O;O
.;O;O
DDI-DrugBank.d202.s8;;
Administration;O;O
of;O;O
reserpine;B-drug;B-DDI-DrugBank.d202.s8.e0
during;O;O
therapy;O;O
with;O;O
a;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s8.e1
antidepressant;I-group;I-DDI-DrugBank.d202.s8.e1
has;O;O
been;O;O
shown;O;O
to;O;O
produce;O;O
a;O;O
stimulating;O;O
effect;O;O
in;O;O
some;O;O
depressed;O;O
patients;O;O
.;O;O
DDI-DrugBank.d202.s9;;
Close;O;O
supervision;O;O
and;O;O
careful;O;O
adjustment;O;O
of;O;O
the;O;O
dosage;O;O
are;O;O
required;O;O
when;O;O
nortriptyline;B-drug;B-DDI-DrugBank.d202.s9.e0
hydrochloride;I-drug;I-DDI-DrugBank.d202.s9.e0
is;O;O
used;O;O
with;O;O
other;O;O
anticholinergic;B-group;B-DDI-DrugBank.d202.s9.e1
drugs;I-group;I-DDI-DrugBank.d202.s9.e1
or;O;O
sympathomimetic;B-group;B-DDI-DrugBank.d202.s9.e2
drugs;I-group;I-DDI-DrugBank.d202.s9.e2
.;O;O
DDI-DrugBank.d202.s10;;
The;O;O
patient;O;O
should;O;O
be;O;O
informed;O;O
that;O;O
the;O;O
response;O;O
to;O;O
alcohol;B-drug;B-DDI-DrugBank.d202.s10.e0
may;O;O
be;O;O
exaggerated;O;O
.;O;O
DDI-DrugBank.d202.s11;;
Drugs;O;O
Metabolized;O;O
by;O;O
P450IID6;O;O
A;O;O
subset;O;O
(;O;O
3;O;O
%;O;O
to;O;O
10;O;O
%;O;O
);O;O
of;O;O
the;O;O
population;O;O
has;O;O
reduced;O;O
activity;O;O
of;O;O
certain;O;O
drug;O;O
metabolizing;O;O
enzymes;O;O
such;O;O
as;O;O
the;O;O
cytochrome;O;O
P450;O;O
isoenzyme;O;O
P450IID6;O;O
.;O;O
DDI-DrugBank.d202.s12;;
Such;O;O
individuals;O;O
are;O;O
referred;O;O
to;O;O
as;O;O
poor;O;O
metabolizers;O;O
of;O;O
drugs;O;O
such;O;O
as;O;O
debrisoquin;B-drug;B-DDI-DrugBank.d202.s12.e0
,;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d202.s12.e1
,;O;O
and;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s12.e2
antidepressants;I-group;I-DDI-DrugBank.d202.s12.e2
.;O;O
DDI-DrugBank.d202.s13;;
These;O;O
individuals;O;O
may;O;O
have;O;O
higher;O;O
than;O;O
expected;O;O
plasma;O;O
concentrations;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s13.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s13.e0
when;O;O
given;O;O
usual;O;O
doses;O;O
.;O;O
DDI-DrugBank.d202.s14;;
In;O;O
addition;O;O
,;O;O
certain;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
this;O;O
isoenzyme;O;O
,;O;O
including;O;O
many;O;O
antidepressants;B-group;B-DDI-DrugBank.d202.s14.e0
(;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s14.e1
antidepressants;I-group;I-DDI-DrugBank.d202.s14.e1
,;O;O
selective;B-group;B-DDI-DrugBank.d202.s14.e2
serotonin;I-group;I-DDI-DrugBank.d202.s14.e2
reuptake;I-group;I-DDI-DrugBank.d202.s14.e2
inhibitors;I-group;I-DDI-DrugBank.d202.s14.e2
,;O;O
and;O;O
others;O;O
);O;O
,;O;O
may;O;O
inhibit;O;O
the;O;O
activity;O;O
of;O;O
this;O;O
isoenzyme;O;O
,;O;O
and;O;O
thus;O;O
may;O;O
make;O;O
normal;O;O
metab;O;O
-;O;O
olizers;O;O
resemble;O;O
poor;O;O
metabolizers;O;O
with;O;O
regard;O;O
to;O;O
concomitant;O;O
therapy;O;O
with;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
this;O;O
enzyme;O;O
system;O;O
,;O;O
leading;O;O
to;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d202.s15;;
Concomitant;O;O
use;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s15.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s15.e0
with;O;O
other;O;O
drugs;O;O
metabolized;O;O
by;O;O
cytochrome;O;O
P450IID6;O;O
may;O;O
require;O;O
lower;O;O
doses;O;O
than;O;O
usually;O;O
prescribed;O;O
for;O;O
either;O;O
the;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s15.e1
antidepressant;I-group;I-DDI-DrugBank.d202.s15.e1
or;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d202.s16;;
Therefore;O;O
,;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
tricyclic;B-group;B-DDI-DrugBank.d202.s16.e0
antidepressants;I-group;I-DDI-DrugBank.d202.s16.e0
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
this;O;O
isoenzyme;O;O
,;O;O
including;O;O
other;O;O
antidepressants;B-group;B-DDI-DrugBank.d202.s16.e1
,;O;O
phenothiazines;B-group;B-DDI-DrugBank.d202.s16.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d202.s16.e3
,;O;O
and;O;O
Type;B-group;B-DDI-DrugBank.d202.s16.e4
1C;I-group;I-DDI-DrugBank.d202.s16.e4
antiarrhythmics;I-group;I-DDI-DrugBank.d202.s16.e4
(;O;O
eg;O;O
,;O;O
propafenone;B-drug;B-DDI-DrugBank.d202.s16.e5
,;O;O
flecainide;B-drug;B-DDI-DrugBank.d202.s16.e6
,;O;O
and;O;O
encainide;B-drug;B-DDI-DrugBank.d202.s16.e7
);O;O
,;O;O
or;O;O
that;O;O
inhibit;O;O
this;O;O
enzyme;O;O
(;O;O
eg;O;O
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d202.s16.e8
);O;O
,;O;O
should;O;O
be;O;O
approached;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d307.s0;;
Oxcarbazepine;B-drug;B-DDI-DrugBank.d307.s0.e0
can;O;O
inhibit;O;O
CYP2C19;O;O
and;O;O
induce;O;O
CYP3A4;O;O
/;O;O
5;O;O
with;O;O
potentially;O;O
important;O;O
effects;O;O
on;O;O
plasma;O;O
concentrations;O;O
of;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d307.s1;;
In;O;O
addition;O;O
,;O;O
several;O;O
AED;B-group;B-DDI-DrugBank.d307.s1.e0
s;O;O
that;O;O
are;O;O
cytochrome;O;O
P450;O;O
inducers;O;O
can;O;O
decrease;O;O
plasma;O;O
concentrations;O;O
of;O;O
oxcarbazepine;B-drug;B-DDI-DrugBank.d307.s1.e1
and;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s1.e2
.;O;O
DDI-DrugBank.d307.s2;;
Oxcarbazepine;B-drug;B-DDI-DrugBank.d307.s2.e0
was;O;O
evaluated;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
to;O;O
determine;O;O
its;O;O
capacity;O;O
to;O;O
inhibit;O;O
the;O;O
major;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
responsible;O;O
for;O;O
the;O;O
metabolism;O;O
of;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d307.s3;;
Results;O;O
demonstrate;O;O
that;O;O
oxcarbazepine;B-drug;B-DDI-DrugBank.d307.s3.e0
and;O;O
its;O;O
pharmacologically;O;O
active;O;O
10;O;O
-;O;O
monohydroxy;O;O
metabolite;O;O
(;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s3.e1
);O;O
have;O;O
little;O;O
or;O;O
no;O;O
capacity;O;O
to;O;O
function;O;O
as;O;O
inhibitors;O;O
for;O;O
most;O;O
of;O;O
the;O;O
human;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
evaluated;O;O
(;O;O
CYP1A2;O;O
,;O;O
CYP2A6;O;O
,;O;O
CYP2C9;O;O
,;O;O
CYP2D6;O;O
,;O;O
CYP2E1;O;O
,;O;O
CYP4A9;O;O
and;O;O
CYP4A11;O;O
);O;O
with;O;O
the;O;O
exception;O;O
of;O;O
CYP2C19;O;O
and;O;O
CYP3A4;O;O
/;O;O
5;O;O
.;O;O
DDI-DrugBank.d307.s4;;
Although;O;O
inhibition;O;O
of;O;O
CYP;O;O
3A4;O;O
/;O;O
5;O;O
by;O;O
OXC;B-drug;B-DDI-DrugBank.d307.s4.e0
and;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s4.e1
did;O;O
occur;O;O
at;O;O
high;O;O
concentrations;O;O
,;O;O
it;O;O
is;O;O
not;O;O
likely;O;O
to;O;O
be;O;O
of;O;O
clinical;O;O
significance;O;O
.;O;O
DDI-DrugBank.d307.s5;;
The;O;O
inhibition;O;O
of;O;O
CYP;O;O
-;O;O
2C19;O;O
by;O;O
OXC;B-drug;B-DDI-DrugBank.d307.s5.e0
and;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s5.e1
,;O;O
however;O;O
,;O;O
is;O;O
clinically;O;O
relevant;O;O
.;O;O
DDI-DrugBank.d307.s6;;
In;O;O
vitro;O;O
,;O;O
the;O;O
UDP;O;O
-;O;O
glucuronyl;O;O
transferase;O;O
level;O;O
was;O;O
increased;O;O
,;O;O
indicating;O;O
induction;O;O
of;O;O
this;O;O
enzyme;O;O
.;O;O
DDI-DrugBank.d307.s7;;
Increases;O;O
of;O;O
22;O;O
%;O;O
with;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s7.e0
and;O;O
47;O;O
%;O;O
with;O;O
oxcarbazepine;B-drug;B-DDI-DrugBank.d307.s7.e1
were;O;O
observed;O;O
.;O;O
DDI-DrugBank.d307.s8;;
As;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s8.e0
,;O;O
the;O;O
predominant;O;O
plasma;O;O
substrate;O;O
,;O;O
is;O;O
only;O;O
a;O;O
weak;O;O
inducer;O;O
of;O;O
UDP;O;O
-;O;O
glucuronyl;O;O
transferase;O;O
,;O;O
it;O;O
is;O;O
unlikely;O;O
to;O;O
have;O;O
an;O;O
effect;O;O
on;O;O
drugs;O;O
that;O;O
are;O;O
mainly;O;O
eliminated;O;O
by;O;O
conjugation;O;O
through;O;O
UDP;O;O
-;O;O
glucuronyl;O;O
transferase;O;O
(;O;O
e.g.;O;O
,;O;O
valproic;B-drug;B-DDI-DrugBank.d307.s8.e1
acid;I-drug;I-DDI-DrugBank.d307.s8.e1
,;O;O
lamotrigine;B-drug;B-DDI-DrugBank.d307.s8.e2
);O;O
.;O;O
DDI-DrugBank.d307.s9;;
In;O;O
addition;O;O
,;O;O
oxcarbazepine;B-drug;B-DDI-DrugBank.d307.s9.e0
and;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s9.e1
induce;O;O
a;O;O
subgroup;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
3A;O;O
family;O;O
(;O;O
CYP3A4;O;O
and;O;O
CYP3A5;O;O
);O;O
responsible;O;O
for;O;O
the;O;O
metabolism;O;O
of;O;O
dihydropyridine;B-group;B-DDI-DrugBank.d307.s9.e2
calcium;I-group;I-DDI-DrugBank.d307.s9.e2
antagonists;I-group;I-DDI-DrugBank.d307.s9.e2
and;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d307.s9.e3
,;O;O
resulting;O;O
in;O;O
a;O;O
lower;O;O
plasma;O;O
concentration;O;O
of;O;O
these;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d307.s10;;
As;O;O
binding;O;O
of;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s10.e0
to;O;O
plasma;O;O
proteins;O;O
is;O;O
low;O;O
(;O;O
40;O;O
%;O;O
);O;O
,;O;O
clinically;O;O
significant;O;O
interactions;O;O
with;O;O
other;O;O
drugs;O;O
through;O;O
competition;O;O
for;O;O
protein;O;O
binding;O;O
sites;O;O
are;O;O
unlikely;O;O
.;O;O
DDI-DrugBank.d307.s11;;
Antiepileptic;B-group;B-DDI-DrugBank.d307.s11.e0
drugs;I-group;I-DDI-DrugBank.d307.s11.e0
:;O;O
Potential;O;O
interactions;O;O
between;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s11.e1
and;O;O
other;O;O
AEDs;B-group;B-DDI-DrugBank.d307.s11.e2
were;O;O
assessed;O;O
in;O;O
clinical;O;O
studies;O;O
.;O;O
DDI-DrugBank.d307.s12;;
The;O;O
effect;O;O
of;O;O
these;O;O
interactions;O;O
on;O;O
mean;O;O
AUCs;O;O
and;O;O
Cmin;O;O
are;O;O
summarized;O;O
in;O;O
Table;O;O
2;O;O
:;O;O
Table;O;O
2;O;O
:;O;O
Summary;O;O
of;O;O
AED;O;O
interactions;O;O
with;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s12.e0
DDI-DrugBank.d307.s13;;
AED;I-group;I-DDI-DrugBank.d307.s13.e0
Co;O;O
-;O;O
administered;O;O
DDI-DrugBank.d307.s14;;
Dose;O;O
of;O;O
AED;B-group;B-DDI-DrugBank.d307.s14.e0
(;O;O
mg;O;O
/;O;O
day;O;O
);O;O
DDI-DrugBank.d307.s15;;
Trileptal;B-brand;B-DDI-DrugBank.d307.s15.e0
dose;O;O
(;O;O
mg;O;O
/;O;O
day;O;O
);O;O
DDI-DrugBank.d307.s16;;
Influence;O;O
of;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s16.e0
on;O;O
AED;B-group;B-DDI-DrugBank.d307.s16.e1
Concentration;O;O
(;O;O
Mean;O;O
change;O;O
,;O;O
90;O;O
%;O;O
Confidence;O;O
Interval;O;O
);O;O
DDI-DrugBank.d307.s17;;
Influence;O;O
of;O;O
AED;B-group;B-DDI-DrugBank.d307.s17.e0
On;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s17.e1
Concentration;O;O
(;O;O
Mean;O;O
change;O;O
,;O;O
90;O;O
%;O;O
Confidence;O;O
Interval;O;O
);O;O
DDI-DrugBank.d307.s18;;
Carbamazepine;B-drug;B-DDI-DrugBank.d307.s18.e0
DDI-DrugBank.d307.s19;;
400;O;O
-;O;O
2000;O;O
DDI-DrugBank.d307.s20;;
900;O;O
DDI-DrugBank.d307.s21;;
nc1;O;O
40;O;O
%;O;O
decrease;O;O
[;O;O
CI;O;O
:;O;O
17;O;O
%;O;O
decrease;O;O
,;O;O
57;O;O
%;O;O
decrease;O;O
];O;O
DDI-DrugBank.d307.s22;;
Phenobarbital;B-drug;B-DDI-DrugBank.d307.s22.e0
DDI-DrugBank.d307.s23;;
100;O;O
-;O;O
150;O;O
DDI-DrugBank.d307.s24;;
600;O;O
-;O;O
1800;O;O
DDI-DrugBank.d307.s25;;
14;O;O
%;O;O
increase;O;O
[;O;O
CI;O;O
:;O;O
2;O;O
%;O;O
increase;O;O
,;O;O
24;O;O
%;O;O
increase;O;O
];O;O
25;O;O
%;O;O
decrease;O;O
[;O;O
CI;O;O
:;O;O
12;O;O
%;O;O
decrease;O;O
,;O;O
51;O;O
%;O;O
decrease;O;O
];O;O
DDI-DrugBank.d307.s26;;
Phenytoin;B-drug;B-DDI-DrugBank.d307.s26.e0
DDI-DrugBank.d307.s27;;
250;O;O
-;O;O
500;O;O
DDI-DrugBank.d307.s28;;
600;O;O
-;O;O
1800;O;O
DDI-DrugBank.d307.s29;;
nc1,2;O;O
30;O;O
%;O;O
decrease;O;O
[;O;O
CI;O;O
:;O;O
3;O;O
%;O;O
decrease;O;O
,;O;O
48;O;O
%;O;O
decrease;O;O
];O;O
DDI-DrugBank.d307.s30;;
1200;O;O
-;O;O
2400;O;O
up;O;O
to;O;O
40;O;O
%;O;O
increase3;O;O
[;O;O
CI;O;O
:;O;O
12;O;O
%;O;O
increase;O;O
,;O;O
60;O;O
%;O;O
increase;O;O
];O;O
DDI-DrugBank.d307.s31;;
Valproic;B-drug;B-DDI-DrugBank.d307.s31.e0
acid;I-drug;I-DDI-DrugBank.d307.s31.e0
DDI-DrugBank.d307.s32;;
400;O;O
-;O;O
2800;O;O
DDI-DrugBank.d307.s33;;
600;O;O
-;O;O
1800;O;O
DDI-DrugBank.d307.s34;;
nc1;O;O
18;O;O
%;O;O
decrease;O;O
[;O;O
CI;O;O
:;O;O
13;O;O
%;O;O
decrease;O;O
,;O;O
40;O;O
%;O;O
decrease;O;O
];O;O
DDI-DrugBank.d307.s35;;
1;O;O
-;O;O
nc;O;O
denotes;O;O
a;O;O
mean;O;O
change;O;O
of;O;O
less;O;O
than;O;O
10;O;O
%;O;O
2;O;O
-;O;O
Pediatrics;O;O
3;O;O
-;O;O
Mean;O;O
increase;O;O
in;O;O
adults;O;O
at;O;O
high;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s35.e0
doses;O;O
In;O;O
vivo;O;O
,;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d307.s35.e1
increased;O;O
by;O;O
up;O;O
to;O;O
40;O;O
%;O;O
,;O;O
when;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s35.e2
was;O;O
given;O;O
at;O;O
doses;O;O
above;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d307.s36;;
Therefore;O;O
,;O;O
when;O;O
using;O;O
doses;O;O
of;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s36.e0
greater;O;O
than;O;O
1200;O;O
mg;O;O
/;O;O
day;O;O
during;O;O
adjunctive;O;O
therapy;O;O
,;O;O
a;O;O
decrease;O;O
in;O;O
the;O;O
dose;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d307.s36.e1
may;O;O
be;O;O
required;O;O
.;O;O
DDI-DrugBank.d307.s37;;
The;O;O
increase;O;O
of;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d307.s37.e0
level;O;O
,;O;O
however;O;O
,;O;O
is;O;O
small;O;O
(;O;O
15;O;O
%;O;O
);O;O
when;O;O
given;O;O
with;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s37.e1
.;O;O
DDI-DrugBank.d307.s38;;
Strong;O;O
inducers;O;O
of;O;O
cytochrome;O;O
P450;O;O
enzymes;O;O
(;O;O
i.e.;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d307.s38.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d307.s38.e1
and;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d307.s38.e2
);O;O
have;O;O
been;O;O
shown;O;O
to;O;O
decrease;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s38.e3
(;O;O
29;O;O
-;O;O
40;O;O
%;O;O
);O;O
.;O;O
DDI-DrugBank.d307.s39;;
No;O;O
autoinduction;O;O
has;O;O
been;O;O
observed;O;O
with;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s39.e0
.;O;O
DDI-DrugBank.d307.s40;;
Hormonal;O;O
contraceptives;B-group;B-DDI-DrugBank.d307.s40.e0
Co;O;O
-;O;O
administration;O;O
of;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s40.e1
with;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d307.s40.e2
has;O;O
been;O;O
shown;O;O
to;O;O
influence;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
the;O;O
two;O;O
hormonal;O;O
components;O;O
,;O;O
ethinylestradiol;B-drug;B-DDI-DrugBank.d307.s40.e3
(;O;O
EE;O;O
);O;O
and;O;O
levonorgestrel;B-drug;B-DDI-DrugBank.d307.s40.e4
(;O;O
LNG;O;O
);O;O
.;O;O
DDI-DrugBank.d307.s41;;
The;O;O
mean;O;O
AUC;O;O
values;O;O
of;O;O
EE;O;O
were;O;O
decreased;O;O
by;O;O
48;O;O
%;O;O
[;O;O
90;O;O
%;O;O
CI;O;O
:;O;O
22;O;O
-;O;O
65;O;O
];O;O
in;O;O
one;O;O
study;O;O
and;O;O
52;O;O
%;O;O
[;O;O
90;O;O
%;O;O
CI;O;O
:;O;O
38;O;O
-;O;O
52;O;O
];O;O
in;O;O
another;O;O
study;O;O
[;O;O
1,2;O;O
];O;O
.;O;O
DDI-DrugBank.d307.s42;;
The;O;O
mean;O;O
AUC;O;O
values;O;O
of;O;O
LNG;O;O
were;O;O
decreased;O;O
by;O;O
32;O;O
%;O;O
[;O;O
90;O;O
%;O;O
CI;O;O
:;O;O
20;O;O
-;O;O
45;O;O
];O;O
in;O;O
one;O;O
study;O;O
and;O;O
52;O;O
%;O;O
[;O;O
90;O;O
%;O;O
CI;O;O
:;O;O
42;O;O
-;O;O
52;O;O
];O;O
in;O;O
another;O;O
study;O;O
.;O;O
DDI-DrugBank.d307.s43;;
Therefore;O;O
,;O;O
concurrent;O;O
use;O;O
of;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s43.e0
with;O;O
hormonal;B-group;B-DDI-DrugBank.d307.s43.e1
contraceptives;I-group;I-DDI-DrugBank.d307.s43.e1
may;O;O
render;O;O
these;O;O
contraceptives;B-group;B-DDI-DrugBank.d307.s43.e2
less;O;O
effective;O;O
.;O;O
DDI-DrugBank.d307.s44;;
Studies;O;O
with;O;O
other;O;O
oral;O;O
or;O;O
implant;O;O
contraceptives;B-group;B-DDI-DrugBank.d307.s44.e0
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d307.s45;;
Calcium;B-group;B-DDI-DrugBank.d307.s45.e0
Antagonists;I-group;I-DDI-DrugBank.d307.s45.e0
:;O;O
After;O;O
repeated;O;O
co;O;O
-;O;O
administration;O;O
of;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s45.e1
,;O;O
the;O;O
AUC;O;O
of;O;O
felodipine;B-drug;B-DDI-DrugBank.d307.s45.e2
was;O;O
lowered;O;O
by;O;O
28;O;O
%;O;O
[;O;O
90;O;O
%;O;O
CI;O;O
:;O;O
20;O;O
-;O;O
33;O;O
];O;O
.;O;O
DDI-DrugBank.d307.s46;;
Verapamil;B-drug;B-DDI-DrugBank.d307.s46.e0
produced;O;O
a;O;O
decrease;O;O
of;O;O
20;O;O
%;O;O
[;O;O
90;O;O
%;O;O
CI;O;O
:;O;O
18;O;O
-;O;O
27;O;O
];O;O
of;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s46.e1
.;O;O
DDI-DrugBank.d307.s47;;
Other;O;O
drug;O;O
interactions;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d307.s47.e0
,;O;O
erythromycin;B-drug;B-DDI-DrugBank.d307.s47.e1
and;O;O
dextropropoxyphene;B-drug;B-DDI-DrugBank.d307.s47.e2
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
MHD;B-drug_n;B-DDI-DrugBank.d307.s47.e3
.;O;O
DDI-DrugBank.d307.s48;;
Results;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d307.s48.e0
wshow;O;O
no;O;O
evidence;O;O
of;O;O
interaction;O;O
with;O;O
either;O;O
single;O;O
or;O;O
repeated;O;O
doses;O;O
of;O;O
Trileptal;B-brand;B-DDI-DrugBank.d307.s48.e1
.;O;O
DDI-DrugBank.d288.s0;;
In;O;O
a;O;O
Phase;O;O
I;O;O
trial;O;O
using;O;O
escalating;O;O
doses;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s0.e0
(;O;O
110;O;O
-;O;O
200;O;O
mg;O;O
/;O;O
m2;O;O
);O;O
and;O;O
cisplatin;B-drug;B-DDI-DrugBank.d288.s0.e1
(;O;O
50;O;O
or;O;O
75;O;O
mg;O;O
/;O;O
m2;O;O
);O;O
given;O;O
as;O;O
sequential;O;O
infusions;O;O
,;O;O
myelosuppression;O;O
was;O;O
more;O;O
profound;O;O
when;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s0.e2
was;O;O
given;O;O
after;O;O
cisplatin;B-drug;B-DDI-DrugBank.d288.s0.e3
than;O;O
with;O;O
the;O;O
alternate;O;O
sequence;O;O
(;O;O
ie;O;O
,;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s0.e4
before;O;O
cisplatin;B-drug;B-DDI-DrugBank.d288.s0.e5
);O;O
.;O;O
DDI-DrugBank.d288.s1;;
Pharmacokinetic;O;O
data;O;O
from;O;O
these;O;O
patients;O;O
demonstrated;O;O
a;O;O
decrease;O;O
in;O;O
paclitaxel;B-drug;B-DDI-DrugBank.d288.s1.e0
clearance;O;O
of;O;O
approximately;O;O
33;O;O
%;O;O
when;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s1.e1
was;O;O
administered;O;O
following;O;O
cisplatin;B-drug;B-DDI-DrugBank.d288.s1.e2
.;O;O
DDI-DrugBank.d288.s2;;
The;O;O
metabolism;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s2.e0
is;O;O
catalyzed;O;O
by;O;O
cytochrome;O;O
P450;O;O
isoen;O;O
-;O;O
zymes;O;O
CYP2C8;O;O
and;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d288.s3;;
In;O;O
the;O;O
absence;O;O
of;O;O
formal;O;O
clinical;O;O
drug;O;O
interaction;O;O
studies;O;O
,;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
administering;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s3.e0
concomitantly;O;O
with;O;O
known;O;O
substrates;O;O
or;O;O
inhibitors;O;O
of;O;O
the;O;O
cytochrome;O;O
P450;O;O
isoenzymes;O;O
CYP2C8;O;O
and;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d288.s4;;
Potential;O;O
interactions;O;O
between;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s4.e0
,;O;O
a;O;O
substrate;O;O
of;O;O
CYP3A4;O;O
,;O;O
and;O;O
protease;B-group;B-DDI-DrugBank.d288.s4.e1
inhibitors;I-group;I-DDI-DrugBank.d288.s4.e1
(;O;O
ritonavir;B-drug;B-DDI-DrugBank.d288.s4.e2
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d288.s4.e3
,;O;O
indinavir;B-drug;B-DDI-DrugBank.d288.s4.e4
,;O;O
and;O;O
nelfinavir;B-drug;B-DDI-DrugBank.d288.s4.e5
);O;O
,;O;O
which;O;O
are;O;O
substrates;O;O
and/or;O;O
inhibitors;O;O
of;O;O
CYP3A4;O;O
,;O;O
have;O;O
not;O;O
been;O;O
evaluated;O;O
in;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d288.s5;;
Reports;O;O
in;O;O
the;O;O
literature;O;O
suggest;O;O
that;O;O
plasma;O;O
levels;O;O
of;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d288.s5.e0
(;O;O
and;O;O
its;O;O
active;O;O
metabolite;O;O
doxorubicinol;B-drug_n;B-DDI-DrugBank.d288.s5.e1
);O;O
may;O;O
be;O;O
increased;O;O
when;O;O
paclitaxel;B-drug;B-DDI-DrugBank.d288.s5.e2
and;O;O
doxorubicin;B-drug;B-DDI-DrugBank.d288.s5.e3
are;O;O
used;O;O
in;O;O
combination;O;O
.;O;O
DDI-DrugBank.d288.s6;;
Hematology;O;O
:;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s6.e0
therapy;O;O
should;O;O
not;O;O
be;O;O
administered;O;O
to;O;O
patients;O;O
with;O;O
baseline;O;O
neutrophil;O;O
counts;O;O
of;O;O
less;O;O
than;O;O
1,500;O;O
cells;O;O
/;O;O
mm3;O;O
.;O;O
DDI-DrugBank.d288.s7;;
In;O;O
order;O;O
to;O;O
monitor;O;O
the;O;O
occurrence;O;O
of;O;O
myelotoxicity;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
that;O;O
frequent;O;O
peripheral;O;O
blood;O;O
cell;O;O
counts;O;O
be;O;O
performed;O;O
on;O;O
all;O;O
patients;O;O
receiving;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s7.e0
.;O;O
DDI-DrugBank.d288.s8;;
Patients;O;O
should;O;O
not;O;O
be;O;O
re;O;O
-;O;O
treated;O;O
with;O;O
subsequent;O;O
cycles;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s8.e0
until;O;O
neutrophils;O;O
recover;O;O
to;O;O
a;O;O
level;O;O
1500;O;O
cells;O;O
/;O;O
mm3;O;O
and;O;O
platelets;O;O
recover;O;O
to;O;O
a;O;O
level;O;O
100,000;O;O
cells;O;O
/;O;O
mm3;O;O
.;O;O
DDI-DrugBank.d288.s9;;
In;O;O
the;O;O
case;O;O
of;O;O
severe;O;O
neutropenia;O;O
(;O;O
500;O;O
cells;O;O
/;O;O
mm3;O;O
for;O;O
seven;O;O
days;O;O
or;O;O
more;O;O
);O;O
during;O;O
a;O;O
course;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s9.e0
therapy;O;O
,;O;O
a;O;O
20;O;O
%;O;O
reduction;O;O
in;O;O
dose;O;O
for;O;O
subsequent;O;O
courses;O;O
of;O;O
therapy;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d288.s10;;
For;O;O
patients;O;O
with;O;O
advanced;O;O
HIV;O;O
disease;O;O
and;O;O
poor;O;O
-;O;O
risk;O;O
AIDS;O;O
-;O;O
related;O;O
Kaposi;O;O
s;O;O
sarcoma;O;O
,;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s10.e0
,;O;O
at;O;O
the;O;O
recommended;O;O
dose;O;O
for;O;O
this;O;O
disease;O;O
,;O;O
can;O;O
be;O;O
initiated;O;O
and;O;O
repeated;O;O
if;O;O
the;O;O
neutrophil;O;O
count;O;O
is;O;O
at;O;O
least;O;O
1000;O;O
cells;O;O
/;O;O
mm3;O;O
.;O;O
DDI-DrugBank.d288.s11;;
Hypersensitivity;O;O
Reactions;O;O
:;O;O
Patients;O;O
with;O;O
a;O;O
history;O;O
of;O;O
severe;O;O
hypersensitivity;O;O
reactions;O;O
to;O;O
products;O;O
containing;O;O
Cremophor;O;O
EL;O;O
(;O;O
eg;O;O
,;O;O
cyclosporin;B-drug;B-DDI-DrugBank.d288.s11.e0
for;O;O
injection;O;O
concentrate;O;O
and;O;O
teniposide;B-drug;B-DDI-DrugBank.d288.s11.e1
for;O;O
injection;O;O
concentrate;O;O
);O;O
should;O;O
not;O;O
be;O;O
treated;O;O
with;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s11.e2
.;O;O
DDI-DrugBank.d288.s12;;
In;O;O
order;O;O
to;O;O
avoid;O;O
the;O;O
occurrence;O;O
of;O;O
severe;O;O
hypersensitivity;O;O
reactions;O;O
,;O;O
all;O;O
patients;O;O
treated;O;O
with;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s12.e0
should;O;O
be;O;O
premedicated;O;O
with;O;O
corticosteroids;B-group;B-DDI-DrugBank.d288.s12.e1
(;O;O
such;O;O
as;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d288.s12.e2
);O;O
,;O;O
diphen;O;O
-;O;O
hydramine;O;O
and;O;O
H2;B-group;B-DDI-DrugBank.d288.s12.e3
antagonists;I-group;I-DDI-DrugBank.d288.s12.e3
(;O;O
such;O;O
as;O;O
cimetidine;B-drug;B-DDI-DrugBank.d288.s12.e4
or;O;O
ranitidine;B-drug;B-DDI-DrugBank.d288.s12.e5
);O;O
.;O;O
DDI-DrugBank.d288.s13;;
Minor;O;O
symptoms;O;O
such;O;O
as;O;O
flushing;O;O
,;O;O
skin;O;O
reactions;O;O
,;O;O
dyspnea;O;O
,;O;O
hypotension;O;O
,;O;O
or;O;O
tachycardia;O;O
do;O;O
not;O;O
require;O;O
interruption;O;O
of;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d288.s14;;
However;O;O
,;O;O
severe;O;O
reactions;O;O
,;O;O
such;O;O
as;O;O
hypotension;O;O
requiring;O;O
treatment;O;O
,;O;O
dyspnea;O;O
requiring;O;O
bronchodilators;B-group;B-DDI-DrugBank.d288.s14.e0
,;O;O
angioedema;O;O
,;O;O
or;O;O
generalized;O;O
urticaria;O;O
require;O;O
immediate;O;O
discontinuation;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s14.e1
and;O;O
aggressive;O;O
symptomatic;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d288.s15;;
Patients;O;O
who;O;O
have;O;O
developed;O;O
severe;O;O
hypersensitivity;O;O
reactions;O;O
should;O;O
not;O;O
be;O;O
rechallenged;O;O
with;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s15.e0
.;O;O
DDI-DrugBank.d288.s16;;
Cardiovascular;O;O
:;O;O
Hypotension;O;O
,;O;O
bradycardia;O;O
,;O;O
and;O;O
hypertension;O;O
have;O;O
been;O;O
observed;O;O
during;O;O
administration;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s16.e0
,;O;O
but;O;O
generally;O;O
do;O;O
not;O;O
require;O;O
treatment;O;O
.;O;O
DDI-DrugBank.d288.s17;;
Occasionally;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s17.e0
infusions;O;O
must;O;O
be;O;O
interrupted;O;O
or;O;O
discontinued;O;O
because;O;O
of;O;O
initial;O;O
or;O;O
recurrent;O;O
hypertension;O;O
.;O;O
DDI-DrugBank.d288.s18;;
Frequent;O;O
vital;O;O
sign;O;O
monitoring;O;O
,;O;O
particularly;O;O
during;O;O
the;O;O
first;O;O
hour;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s18.e0
infusion;O;O
,;O;O
is;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d288.s19;;
Continuous;O;O
cardiac;O;O
monitoring;O;O
is;O;O
not;O;O
required;O;O
except;O;O
for;O;O
patients;O;O
with;O;O
serious;O;O
conduction;O;O
abnormalities;O;O
.;O;O
DDI-DrugBank.d288.s20;;
Nervous;O;O
System;O;O
:;O;O
Although;O;O
the;O;O
occurrence;O;O
of;O;O
peripheral;O;O
neuropathy;O;O
is;O;O
frequent;O;O
,;O;O
the;O;O
development;O;O
of;O;O
severe;O;O
symptomatology;O;O
is;O;O
unusual;O;O
and;O;O
requires;O;O
a;O;O
dose;O;O
reduction;O;O
of;O;O
20;O;O
%;O;O
for;O;O
all;O;O
subsequentcourses;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s20.e0
.;O;O
DDI-DrugBank.d288.s21;;
TAXOL;B-brand;B-DDI-DrugBank.d288.s21.e0
contains;O;O
dehydrated;O;O
alcohol;O;O
USP;O;O
,;O;O
396;O;O
mg;O;O
/;O;O
mL;O;O
,;O;O
DDI-DrugBank.d288.s22;;
consideration;O;O
should;O;O
be;O;O
given;O;O
to;O;O
possible;O;O
CNS;O;O
and;O;O
other;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d288.s22.e0
.;O;O
DDI-DrugBank.d288.s23;;
Hepatic;O;O
:;O;O
There;O;O
is;O;O
limited;O;O
evidence;O;O
that;O;O
the;O;O
myelotoxicity;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s23.e0
may;O;O
be;O;O
exacerbated;O;O
in;O;O
patients;O;O
with;O;O
serum;O;O
total;O;O
bilirubin;O;O
2;O;O
times;O;O
ULN;O;O
.;O;O
DDI-DrugBank.d288.s24;;
Extreme;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
administering;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s24.e0
to;O;O
such;O;O
patients;O;O
,;O;O
with;O;O
dose;O;O
reduction;O;O
as;O;O
recommended;O;O
in;O;O
DOSAGE;O;O
AND;O;O
ADMINISTRATION;O;O
,;O;O
Table;O;O
17;O;O
.;O;O
DDI-DrugBank.d288.s25;;
InjectionSite;O;O
Reaction;O;O
:;O;O
Injection;O;O
site;O;O
reactions;O;O
,;O;O
including;O;O
reactions;O;O
secondary;O;O
to;O;O
extravasation;O;O
,;O;O
were;O;O
usually;O;O
mild;O;O
and;O;O
consisted;O;O
of;O;O
erythema;O;O
,;O;O
tenderness;O;O
,;O;O
skin;O;O
discoloration;O;O
,;O;O
or;O;O
swelling;O;O
at;O;O
the;O;O
injection;O;O
site;O;O
.;O;O
DDI-DrugBank.d288.s26;;
These;O;O
reactions;O;O
have;O;O
been;O;O
observed;O;O
more;O;O
frequently;O;O
with;O;O
the;O;O
24;O;O
-;O;O
hour;O;O
infusion;O;O
than;O;O
with;O;O
the;O;O
3;O;O
-;O;O
hour;O;O
infusion;O;O
.;O;O
DDI-DrugBank.d288.s27;;
Recurrence;O;O
of;O;O
skin;O;O
reactions;O;O
at;O;O
a;O;O
site;O;O
of;O;O
previous;O;O
extravasation;O;O
following;O;O
administration;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s27.e0
at;O;O
a;O;O
different;O;O
site;O;O
,;O;O
ie;O;O
,;O;O
recall;O;O
,;O;O
has;O;O
been;O;O
reported;O;O
rarely;O;O
.;O;O
DDI-DrugBank.d288.s28;;
Rare;O;O
reports;O;O
of;O;O
more;O;O
severe;O;O
events;O;O
such;O;O
as;O;O
phlebitis;O;O
,;O;O
cellulitis;O;O
,;O;O
induration;O;O
,;O;O
skin;O;O
exfoliation;O;O
,;O;O
necrosis;O;O
,;O;O
and;O;O
fibrosis;O;O
have;O;O
been;O;O
received;O;O
as;O;O
part;O;O
of;O;O
the;O;O
continuing;O;O
surveillance;O;O
of;O;O
TAXOL;B-brand;B-DDI-DrugBank.d288.s28.e0
safety;O;O
.;O;O
DDI-DrugBank.d288.s29;;
In;O;O
some;O;O
cases;O;O
the;O;O
onset;O;O
of;O;O
the;O;O
injection;O;O
site;O;O
reaction;O;O
either;O;O
occurred;O;O
during;O;O
a;O;O
prolonged;O;O
infusion;O;O
or;O;O
was;O;O
delayed;O;O
by;O;O
a;O;O
week;O;O
to;O;O
ten;O;O
days;O;O
.;O;O
DDI-DrugBank.d288.s30;;
A;O;O
specific;O;O
treatment;O;O
for;O;O
extravasation;O;O
reactions;O;O
is;O;O
unknown;O;O
at;O;O
this;O;O
time;O;O
.;O;O
DDI-DrugBank.d288.s31;;
Given;O;O
the;O;O
possibility;O;O
of;O;O
extravasation;O;O
,;O;O
it;O;O
is;O;O
advisable;O;O
to;O;O
closely;O;O
monitor;O;O
the;O;O
infusion;O;O
site;O;O
for;O;O
possible;O;O
infiltration;O;O
during;O;O
drug;O;O
administration;O;O
.;O;O
DDI-DrugBank.d196.s0;;
Treatment;O;O
with;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s0.e0
once;O;O
weekly;O;O
for;O;O
4;O;O
weeks;O;O
in;O;O
healthy;O;O
subjects;O;O
was;O;O
associated;O;O
with;O;O
an;O;O
inhibition;O;O
of;O;O
P450;O;O
1A2;O;O
and;O;O
a;O;O
25;O;O
%;O;O
increase;O;O
in;O;O
theophylline;B-drug;B-DDI-DrugBank.d196.s0.e1
AUC;O;O
.;O;O
DDI-DrugBank.d196.s1;;
Theophylline;B-drug;B-DDI-DrugBank.d196.s1.e0
serum;O;O
levels;O;O
should;O;O
be;O;O
monitored;O;O
and;O;O
appropriate;O;O
dose;O;O
adjustments;O;O
considered;O;O
for;O;O
patients;O;O
given;O;O
both;O;O
theophylline;B-drug;B-DDI-DrugBank.d196.s1.e1
and;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s1.e2
.;O;O
DDI-DrugBank.d196.s2;;
There;O;O
was;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
representative;O;O
drugs;O;O
metabolized;O;O
by;O;O
CYP;O;O
2C9;O;O
,;O;O
CYP;O;O
2C19;O;O
,;O;O
CYP;O;O
2D6;O;O
or;O;O
CYP;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d196.s3;;
In;O;O
patients;O;O
with;O;O
chronic;O;O
hepatitis;O;O
C;O;O
treated;O;O
with;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s3.e0
in;O;O
combination;O;O
with;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s3.e1
,;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s3.e2
treatment;O;O
did;O;O
not;O;O
affect;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s3.e3
distribution;O;O
or;O;O
clearance;O;O
.;O;O
DDI-DrugBank.d196.s4;;
Nucleoside;O;O
Analogues;O;O
Didanosine;B-drug;B-DDI-DrugBank.d196.s4.e0
Co;O;O
-;O;O
administration;O;O
of;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s4.e1
and;O;O
didanosine;B-drug;B-DDI-DrugBank.d196.s4.e2
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d196.s5;;
Reports;O;O
of;O;O
fatal;O;O
hepatic;O;O
failure;O;O
,;O;O
as;O;O
well;O;O
as;O;O
peripheral;O;O
neuropathy;O;O
,;O;O
pancreatitis;O;O
,;O;O
and;O;O
symptomatic;O;O
hyperlactatemia;O;O
/;O;O
lactic;O;O
acidosis;O;O
have;O;O
been;O;O
reported;O;O
in;O;O
clinical;O;O
trials;O;O
.;O;O
DDI-DrugBank.d196.s6;;
Stavudine;B-drug;B-DDI-DrugBank.d196.s6.e0
and;O;O
Zidovudine;B-drug;B-DDI-DrugBank.d196.s6.e1
Ribavirin;I-drug;I-DDI-DrugBank.d196.s6.e2
can;O;O
antagonize;O;O
the;O;O
in;O;O
vitro;O;O
antiviral;O;O
activity;O;O
of;O;O
stavudine;B-drug;B-DDI-DrugBank.d196.s6.e3
and;O;O
zidovudine;B-drug;B-DDI-DrugBank.d196.s6.e4
against;O;O
HIV;O;O
.;O;O
DDI-DrugBank.d196.s7;;
Therefore;O;O
,;O;O
concomitant;O;O
use;O;O
of;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s7.e0
with;O;O
either;O;O
of;O;O
these;O;O
drugs;O;O
should;O;O
be;O;O
avoided;O;O
.;O;O
DDI-DrugBank.d196.s8;;
Carcinogenesis;O;O
,;O;O
Mutagenesis;O;O
,;O;O
Impairment;O;O
of;O;O
Fertility;O;O
Carcinogenesis;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s8.e0
has;O;O
not;O;O
been;O;O
tested;O;O
for;O;O
its;O;O
carcinogenic;O;O
potential;O;O
.;O;O
DDI-DrugBank.d196.s9;;
Mutagenesis;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s9.e0
did;O;O
not;O;O
cause;O;O
DNA;O;O
damage;O;O
when;O;O
tested;O;O
in;O;O
the;O;O
Ames;O;O
bacterial;O;O
mutagenicity;O;O
assay;O;O
and;O;O
in;O;O
the;O;O
in;O;O
vitro;O;O
chromosomal;O;O
aberration;O;O
assay;O;O
in;O;O
human;O;O
lymphocytes;O;O
,;O;O
either;O;O
in;O;O
the;O;O
presence;O;O
or;O;O
absence;O;O
of;O;O
metabolic;O;O
activation;O;O
.;O;O
DDI-DrugBank.d196.s10;;
Use;O;O
With;O;O
Ribavirin;B-drug;B-DDI-DrugBank.d196.s10.e0
Ribavirin;I-drug;I-DDI-DrugBank.d196.s10.e1
is;O;O
genotoxic;O;O
and;O;O
mutagenic;O;O
.;O;O
DDI-DrugBank.d196.s11;;
The;O;O
carcinogenic;O;O
potential;O;O
of;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s11.e0
has;O;O
not;O;O
been;O;O
fully;O;O
determined;O;O
.;O;O
DDI-DrugBank.d196.s12;;
In;O;O
a;O;O
p53;O;O
(;O;O
+;O;O
/;O;O
-;O;O
);O;O
mouse;O;O
carcinogenicity;O;O
study;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
the;O;O
maximum;O;O
tolerated;O;O
dose;O;O
of;O;O
100;O;O
mg;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s12.e0
was;O;O
not;O;O
oncogenic;O;O
.;O;O
DDI-DrugBank.d196.s13;;
However;O;O
,;O;O
on;O;O
a;O;O
body;O;O
surface;O;O
area;O;O
basis;O;O
,;O;O
this;O;O
dose;O;O
was;O;O
0.5;O;O
times;O;O
maximum;O;O
recommended;O;O
human;O;O
24;O;O
-;O;O
hour;O;O
dose;O;O
of;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s13.e0
.;O;O
DDI-DrugBank.d196.s14;;
A;O;O
study;O;O
in;O;O
rats;O;O
to;O;O
assess;O;O
the;O;O
carcinogenic;O;O
potential;O;O
of;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s14.e0
is;O;O
ongoing;O;O
.;O;O
DDI-DrugBank.d196.s15;;
Mutagenesis;O;O
Impairment;O;O
of;O;O
Fertility;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s15.e0
may;O;O
impair;O;O
fertility;O;O
in;O;O
women;O;O
.;O;O
DDI-DrugBank.d196.s16;;
Prolonged;O;O
menstrual;O;O
cycles;O;O
and/or;O;O
amenorrhea;O;O
were;O;O
observed;O;O
in;O;O
female;O;O
cynomolgus;O;O
monkeys;O;O
given;O;O
sc;O;O
injections;O;O
of;O;O
600;O;O
m;O;O
g;O;O
/;O;O
kg;O;O
/;O;O
dose;O;O
(;O;O
7200;O;O
m;O;O
g;O;O
/;O;O
m2;O;O
/;O;O
dose;O;O
);O;O
of;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s16.e0
every;O;O
other;O;O
day;O;O
for;O;O
one;O;O
month;O;O
,;O;O
at;O;O
approximately;O;O
180;O;O
times;O;O
the;O;O
recommended;O;O
weekly;O;O
human;O;O
dose;O;O
for;O;O
a;O;O
60;O;O
kg;O;O
person;O;O
(;O;O
based;O;O
on;O;O
body;O;O
surface;O;O
area;O;O
);O;O
.;O;O
DDI-DrugBank.d196.s17;;
Menstrual;O;O
cycle;O;O
irregularities;O;O
were;O;O
accompanied;O;O
by;O;O
both;O;O
a;O;O
decrease;O;O
and;O;O
delay;O;O
in;O;O
the;O;O
peak;O;O
17b;O;O
-estradiol;O;O
and;O;O
progesterone;O;O
levels;O;O
following;O;O
administration;O;O
of;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s17.e0
to;O;O
female;O;O
monkeys;O;O
.;O;O
DDI-DrugBank.d196.s18;;
A;O;O
return;O;O
to;O;O
normal;O;O
menstrual;O;O
rhythm;O;O
followed;O;O
cessation;O;O
of;O;O
treatment;O;O
.;O;O
DDI-DrugBank.d196.s19;;
Every;O;O
other;O;O
day;O;O
dosing;O;O
with;O;O
100;O;O
m;O;O
g;O;O
/;O;O
kg;O;O
(;O;O
1200;O;O
m;O;O
g;O;O
/;O;O
m2;O;O
);O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s19.e0
(;O;O
equivalent;O;O
to;O;O
approximately;O;O
30;O;O
times;O;O
the;O;O
recommended;O;O
human;O;O
dose;O;O
);O;O
had;O;O
no;O;O
effects;O;O
on;O;O
cycle;O;O
duration;O;O
or;O;O
reproductive;O;O
hormone;O;O
status;O;O
.;O;O
DDI-DrugBank.d196.s20;;
The;O;O
effects;O;O
of;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s20.e0
on;O;O
male;O;O
fertility;O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d196.s21;;
However;O;O
,;O;O
no;O;O
adverse;O;O
effects;O;O
on;O;O
fertility;O;O
were;O;O
observed;O;O
in;O;O
male;O;O
Rhesus;O;O
monkeys;O;O
treated;O;O
with;O;O
non;O;O
-;O;O
pegylated;B-drug;B-DDI-DrugBank.d196.s21.e0
interferon;I-drug;I-DDI-DrugBank.d196.s21.e0
alfa;I-drug;I-DDI-DrugBank.d196.s21.e0
-;I-drug;I-DDI-DrugBank.d196.s21.e0
2a;I-drug;I-DDI-DrugBank.d196.s21.e0
for;O;O
5;O;O
months;O;O
at;O;O
doses;O;O
up;O;O
to;O;O
25;O;O
x;O;O
106;O;O
IU;O;O
/;O;O
kg;O;O
/;O;O
day;O;O
.;O;O
DDI-DrugBank.d196.s22;;
Pregnancy;O;O
Pregnancy;O;O
:;O;O
Category;O;O
C;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s22.e0
has;O;O
not;O;O
been;O;O
studied;O;O
for;O;O
its;O;O
teratogenic;O;O
effect;O;O
.;O;O
DDI-DrugBank.d196.s23;;
Non;B-drug;B-DDI-DrugBank.d196.s23.e0
-;I-drug;I-DDI-DrugBank.d196.s23.e0
pegylated;I-drug;I-DDI-DrugBank.d196.s23.e0
interferon;I-drug;I-DDI-DrugBank.d196.s23.e0
alfa;I-drug;I-DDI-DrugBank.d196.s23.e0
-;I-drug;I-DDI-DrugBank.d196.s23.e0
2a;I-drug;I-DDI-DrugBank.d196.s23.e0
treatment;O;O
of;O;O
pregnant;O;O
Rhesus;O;O
monkeys;O;O
at;O;O
approximately;O;O
20;O;O
to;O;O
500;O;O
times;O;O
the;O;O
human;O;O
weekly;O;O
dose;O;O
resulted;O;O
in;O;O
a;O;O
statistically;O;O
significant;O;O
increase;O;O
in;O;O
abortions;O;O
.;O;O
DDI-DrugBank.d196.s24;;
No;O;O
teratogenic;O;O
effects;O;O
were;O;O
seen;O;O
in;O;O
the;O;O
offspring;O;O
delivered;O;O
at;O;O
term;O;O
.;O;O
DDI-DrugBank.d196.s25;;
PEGASYS;B-brand;B-DDI-DrugBank.d196.s25.e0
should;O;O
be;O;O
assumed;O;O
to;O;O
have;O;O
abortifacient;O;O
potential;O;O
.;O;O
DDI-DrugBank.d196.s26;;
There;O;O
are;O;O
no;O;O
adequate;O;O
and;O;O
well;O;O
-;O;O
controlled;O;O
studies;O;O
of;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s26.e0
in;O;O
pregnant;O;O
women;O;O
.;O;O
DDI-DrugBank.d196.s27;;
PEGASYS;B-brand;B-DDI-DrugBank.d196.s27.e0
is;O;O
to;O;O
be;O;O
used;O;O
during;O;O
pregnancy;O;O
only;O;O
if;O;O
the;O;O
potential;O;O
benefit;O;O
justifies;O;O
the;O;O
potential;O;O
risk;O;O
to;O;O
the;O;O
fetus;O;O
.;O;O
DDI-DrugBank.d196.s28;;
PEGASYS;B-brand;B-DDI-DrugBank.d196.s28.e0
is;O;O
recommended;O;O
for;O;O
use;O;O
in;O;O
women;O;O
of;O;O
childbearing;O;O
potential;O;O
only;O;O
when;O;O
they;O;O
are;O;O
using;O;O
effective;O;O
contraception;O;O
during;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d196.s29;;
Pregnancy;O;O
:;O;O
Category;O;O
X;O;O
:;O;O
Use;O;O
With;O;O
Ribavirin;B-drug;B-DDI-DrugBank.d196.s29.e0
(;O;O
see;O;O
CONTRAINDICATIONS;O;O
);O;O
Significant;O;O
teratogenic;O;O
and/or;O;O
embryocidal;O;O
effects;O;O
have;O;O
been;O;O
demonstrated;O;O
in;O;O
all;O;O
animal;O;O
species;O;O
exposed;O;O
to;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s29.e1
.;O;O
DDI-DrugBank.d196.s30;;
COPEGUS;B-brand;B-DDI-DrugBank.d196.s30.e0
therapy;O;O
is;O;O
contraindicated;O;O
in;O;O
women;O;O
who;O;O
are;O;O
pregnant;O;O
and;O;O
in;O;O
the;O;O
male;O;O
partners;O;O
of;O;O
women;O;O
who;O;O
are;O;O
pregnant;O;O
.;O;O
DDI-DrugBank.d196.s31;;
If;O;O
pregnancy;O;O
occurs;O;O
in;O;O
a;O;O
patient;O;O
or;O;O
partner;O;O
of;O;O
a;O;O
patient;O;O
during;O;O
treatment;O;O
or;O;O
during;O;O
the;O;O
6;O;O
months;O;O
after;O;O
treatment;O;O
cessation;O;O
,;O;O
such;O;O
cases;O;O
should;O;O
be;O;O
reported;O;O
to;O;O
the;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s31.e0
Pregnancy;O;O
Registry;O;O
at;O;O
1;O;O
-;O;O
800;O;O
-;O;O
526;O;O
-;O;O
6367;O;O
.;O;O
DDI-DrugBank.d196.s32;;
Nursing;O;O
Mothers;O;O
It;O;O
is;O;O
not;O;O
known;O;O
whether;O;O
peginterferon;B-drug;B-DDI-DrugBank.d196.s32.e0
or;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s32.e1
or;O;O
its;O;O
components;O;O
are;O;O
excreted;O;O
in;O;O
human;O;O
milk;O;O
.;O;O
DDI-DrugBank.d196.s33;;
The;O;O
effect;O;O
of;O;O
orally;O;O
ingested;O;O
peginterferon;B-drug;B-DDI-DrugBank.d196.s33.e0
or;O;O
ribavirin;B-drug;B-DDI-DrugBank.d196.s33.e1
from;O;O
breast;O;O
milk;O;O
on;O;O
the;O;O
nursing;O;O
infant;O;O
has;O;O
not;O;O
been;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d196.s34;;
Because;O;O
of;O;O
the;O;O
potential;O;O
for;O;O
adverse;O;O
reactions;O;O
from;O;O
the;O;O
drugs;O;O
in;O;O
nursing;O;O
infants;O;O
,;O;O
a;O;O
decision;O;O
must;O;O
be;O;O
made;O;O
whether;O;O
to;O;O
discontinue;O;O
nursing;O;O
or;O;O
discontinue;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s34.e0
and;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s34.e1
treatment;O;O
.;O;O
DDI-DrugBank.d196.s35;;
Pediatric;O;O
Use;O;O
The;O;O
safety;O;O
and;O;O
effectiveness;O;O
of;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s35.e0
,;O;O
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s35.e1
in;O;O
patients;O;O
below;O;O
the;O;O
age;O;O
of;O;O
18;O;O
years;O;O
have;O;O
not;O;O
been;O;O
established;O;O
.;O;O
DDI-DrugBank.d196.s36;;
PEGASYS;B-brand;B-DDI-DrugBank.d196.s36.e0
contains;O;O
benzyl;B-drug_n;B-DDI-DrugBank.d196.s36.e1
alcohol;I-drug_n;I-DDI-DrugBank.d196.s36.e1
.;O;O
DDI-DrugBank.d196.s37;;
Benzyl;B-drug_n;B-DDI-DrugBank.d196.s37.e0
alcohol;I-drug_n;I-DDI-DrugBank.d196.s37.e0
has;O;O
been;O;O
reported;O;O
to;O;O
be;O;O
associated;O;O
with;O;O
an;O;O
increased;O;O
incidence;O;O
of;O;O
neurological;O;O
and;O;O
other;O;O
complications;O;O
in;O;O
neonates;O;O
and;O;O
infants;O;O
,;O;O
which;O;O
are;O;O
sometimes;O;O
fatal;O;O
.;O;O
DDI-DrugBank.d196.s38;;
Geriatric;O;O
Use;O;O
Younger;O;O
patients;O;O
have;O;O
higher;O;O
virologic;O;O
response;O;O
rates;O;O
than;O;O
older;O;O
patients;O;O
.;O;O
DDI-DrugBank.d196.s39;;
Clinical;O;O
studies;O;O
of;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s39.e0
alone;O;O
or;O;O
in;O;O
combination;O;O
with;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s39.e1
did;O;O
not;O;O
include;O;O
sufficient;O;O
numbers;O;O
of;O;O
subjects;O;O
aged;O;O
65;O;O
or;O;O
over;O;O
to;O;O
determine;O;O
whether;O;O
they;O;O
respond;O;O
differently;O;O
from;O;O
younger;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d196.s40;;
Adverse;O;O
reactions;O;O
related;O;O
to;O;O
alpha;B-drug;B-DDI-DrugBank.d196.s40.e0
interferons;I-drug;I-DDI-DrugBank.d196.s40.e0
,;O;O
such;O;O
as;O;O
CNS;O;O
,;O;O
cardiac;O;O
,;O;O
and;O;O
systemic;O;O
(;O;O
eg;O;O
,;O;O
flu;O;O
-;O;O
like;O;O
);O;O
effects;O;O
may;O;O
be;O;O
more;O;O
severe;O;O
in;O;O
the;O;O
elderly;O;O
and;O;O
caution;O;O
should;O;O
be;O;O
exercised;O;O
in;O;O
the;O;O
use;O;O
of;O;O
PEGASYS;B-brand;B-DDI-DrugBank.d196.s40.e1
in;O;O
this;O;O
population;O;O
.;O;O
DDI-DrugBank.d196.s41;;
PEGASYS;B-brand;B-DDI-DrugBank.d196.s41.e0
and;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s41.e1
are;O;O
excreted;O;O
by;O;O
the;O;O
kidney;O;O
,;O;O
and;O;O
the;O;O
risk;O;O
of;O;O
toxic;O;O
reactions;O;O
to;O;O
this;O;O
therapy;O;O
may;O;O
be;O;O
greater;O;O
in;O;O
patients;O;O
with;O;O
impaired;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d196.s42;;
Because;O;O
elderly;O;O
patients;O;O
are;O;O
more;O;O
likely;O;O
to;O;O
have;O;O
decreased;O;O
renal;O;O
function;O;O
,;O;O
care;O;O
should;O;O
be;O;O
taken;O;O
in;O;O
dose;O;O
selection;O;O
and;O;O
it;O;O
may;O;O
be;O;O
useful;O;O
to;O;O
monitor;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d196.s43;;
PEGASYS;B-brand;B-DDI-DrugBank.d196.s43.e0
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
in;O;O
patients;O;O
with;O;O
creatinine;O;O
clearance;O;O
50;O;O
mL;O;O
/;O;O
min;O;O
and;O;O
COPEGUS;B-brand;B-DDI-DrugBank.d196.s43.e1
should;O;O
not;O;O
be;O;O
administered;O;O
to;O;O
patients;O;O
with;O;O
creatinine;O;O
clearance;O;O
50;O;O
mL;O;O
/;O;O
min;O;O
DDI-DrugBank.d196.s44;;
.;O;O
DDI-DrugBank.d196.s45;;
DDI-DrugBank.d462.s0;;
Aminoglycosides;B-group;B-DDI-DrugBank.d462.s0.e0
:;O;O
The;O;O
mixing;O;O
of;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s0.e1
with;O;O
an;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d462.s0.e2
in;O;O
vitro;O;O
can;O;O
result;O;O
in;O;O
substantial;O;O
inactivation;O;O
of;O;O
the;O;O
aminoglycoside;B-group;B-DDI-DrugBank.d462.s0.e3
.;O;O
DDI-DrugBank.d462.s1;;
Vecuronium;B-drug;B-DDI-DrugBank.d462.s1.e0
:;O;O
When;O;O
used;O;O
in;O;O
the;O;O
perioperative;O;O
period;O;O
,;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s1.e1
has;O;O
been;O;O
implicated;O;O
in;O;O
the;O;O
prolongation;O;O
of;O;O
the;O;O
neuromuscular;O;O
blockade;O;O
of;O;O
vecuronium;B-drug;B-DDI-DrugBank.d462.s1.e2
.;O;O
DDI-DrugBank.d462.s2;;
Caution;O;O
is;O;O
indicated;O;O
when;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s2.e0
is;O;O
used;O;O
perioperatively;O;O
.;O;O
DDI-DrugBank.d462.s3;;
In;O;O
one;O;O
controlled;O;O
clinical;O;O
study;O;O
,;O;O
the;O;O
ureidopenicillins;O;O
,;O;O
including;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s3.e0
,;O;O
were;O;O
reported;O;O
to;O;O
prolong;O;O
the;O;O
action;O;O
of;O;O
vecuronium;B-drug;B-DDI-DrugBank.d462.s3.e1
.;O;O
DDI-DrugBank.d462.s4;;
Due;O;O
to;O;O
their;O;O
similar;O;O
mechanism;O;O
of;O;O
action;O;O
,;O;O
it;O;O
is;O;O
expected;O;O
that;O;O
the;O;O
neuromuscular;O;O
blockade;O;O
produced;O;O
by;O;O
any;O;O
of;O;O
the;O;O
non;B-group;B-DDI-DrugBank.d462.s4.e0
-;I-group;I-DDI-DrugBank.d462.s4.e0
depolarizing;I-group;I-DDI-DrugBank.d462.s4.e0
muscle;I-group;I-DDI-DrugBank.d462.s4.e0
relaxants;I-group;I-DDI-DrugBank.d462.s4.e0
could;O;O
be;O;O
prolonged;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s4.e1
.;O;O
DDI-DrugBank.d462.s5;;
Probenecid;B-drug;B-DDI-DrugBank.d462.s5.e0
:;O;O
The;O;O
oral;O;O
combination;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d462.s5.e1
before;O;O
intramuscular;O;O
injection;O;O
of;O;O
PIPRACIL;B-brand;B-DDI-DrugBank.d462.s5.e2
produces;O;O
an;O;O
increase;O;O
in;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s5.e3
peak;O;O
serum;O;O
level;O;O
of;O;O
about;O;O
30;O;O
%;O;O
.;O;O
DDI-DrugBank.d462.s6;;
Anticoagulants;B-group;B-DDI-DrugBank.d462.s6.e0
:;O;O
Coagulation;O;O
parameters;O;O
should;O;O
be;O;O
tested;O;O
more;O;O
frequently;O;O
and;O;O
monitored;O;O
regularly;O;O
during;O;O
simultaneous;O;O
administration;O;O
of;O;O
high;O;O
doses;O;O
of;O;O
heparin;B-drug;B-DDI-DrugBank.d462.s6.e1
,;O;O
oral;O;O
anticoagulants;B-group;B-DDI-DrugBank.d462.s6.e2
,;O;O
or;O;O
other;O;O
drugs;O;O
that;O;O
may;O;O
affect;O;O
the;O;O
blood;O;O
coagulation;O;O
system;O;O
or;O;O
the;O;O
thrombocyte;O;O
function;O;O
.;O;O
DDI-DrugBank.d462.s7;;
Methotrexate;B-drug;B-DDI-DrugBank.d462.s7.e0
:;O;O
Piperacillin;B-drug;B-DDI-DrugBank.d462.s7.e1
sodium;I-drug;I-DDI-DrugBank.d462.s7.e1
may;O;O
reduce;O;O
the;O;O
excretion;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d462.s7.e2
.;O;O
DDI-DrugBank.d462.s8;;
Therefore;O;O
,;O;O
serum;O;O
levels;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d462.s8.e0
should;O;O
be;O;O
monitored;O;O
in;O;O
patients;O;O
to;O;O
avoid;O;O
drug;O;O
toxicity;O;O
.;O;O
DDI-DrugBank.d462.s9;;
Drug;O;O
/;O;O
Laboratory;O;O
Test;O;O
Interactions;O;O
As;O;O
with;O;O
other;O;O
penicillins;B-drug;B-DDI-DrugBank.d462.s9.e0
,;O;O
the;O;O
administration;O;O
of;O;O
PIPRACIL;B-brand;B-DDI-DrugBank.d462.s9.e1
may;O;O
result;O;O
in;O;O
a;O;O
false;O;O
-;O;O
positive;O;O
reaction;O;O
for;O;O
glucose;O;O
in;O;O
the;O;O
urine;O;O
using;O;O
a;O;O
copper;O;O
-;O;O
reduction;O;O
method;O;O
.;O;O
DDI-DrugBank.d462.s10;;
It;O;O
is;O;O
recommended;O;O
that;O;O
glucose;O;O
tests;O;O
based;O;O
on;O;O
enzymatic;O;O
glucose;O;O
oxidase;O;O
reactions;O;O
be;O;O
used;O;O
.;O;O
DDI-DrugBank.d462.s11;;
There;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
positive;O;O
test;O;O
results;O;O
using;O;O
the;O;O
Bio;O;O
-;O;O
Rad;O;O
Laboratories;O;O
Platelia;O;O
Aspergillus;O;O
EIA;O;O
test;O;O
in;O;O
patients;O;O
receiving;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s11.e0
/;O;O
tazobactam;B-drug;B-DDI-DrugBank.d462.s11.e1
injection;O;O
who;O;O
were;O;O
subsequently;O;O
found;O;O
to;O;O
be;O;O
free;O;O
of;O;O
Aspergillus;O;O
infection;O;O
.;O;O
DDI-DrugBank.d462.s12;;
Cross;O;O
-;O;O
reactions;O;O
with;O;O
non;O;O
-;O;O
Aspergillus;O;O
polysaccharides;O;O
and;O;O
polyfuranoses;O;O
with;O;O
the;O;O
Bio;O;O
-;O;O
Rad;O;O
Laboratories;O;O
Platelia;O;O
Aspergillus;O;O
EIA;O;O
test;O;O
have;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d462.s13;;
Therefore;O;O
,;O;O
positive;O;O
test;O;O
results;O;O
in;O;O
patients;O;O
receiving;O;O
piperacillin;B-drug;B-DDI-DrugBank.d462.s13.e0
should;O;O
be;O;O
interpreted;O;O
cautiously;O;O
and;O;O
confirmed;O;O
by;O;O
other;O;O
diagnostic;O;O
methods;O;O
.;O;O
DDI-DrugBank.d326.s0;;
Phenothiazines;B-group;B-DDI-DrugBank.d326.s0.e0
-;O;O
Taking;O;O
piperazine;B-drug;B-DDI-DrugBank.d326.s0.e1
and;O;O
a;O;O
phenothiazine;B-group;B-DDI-DrugBank.d326.s0.e2
together;O;O
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
convulsions;O;O
(;O;O
seizures;O;O
);O;O
.;O;O
DDI-DrugBank.d326.s1;;
Pyrantel;B-drug;B-DDI-DrugBank.d326.s1.e0
(;O;O
e.g.;O;O
,;O;O
Antiminth;B-drug;B-DDI-DrugBank.d326.s1.e1
);O;O
-;O;O
Taking;O;O
piperazine;B-drug;B-DDI-DrugBank.d326.s1.e2
and;O;O
pyrantel;B-drug;B-DDI-DrugBank.d326.s1.e3
together;O;O
may;O;O
decrease;O;O
the;O;O
effects;O;O
of;O;O
piperazine;B-drug;B-DDI-DrugBank.d326.s1.e4
.;O;O
DDI-DrugBank.d210.s0;;
ACE;B-group;B-DDI-DrugBank.d210.s0.e0
inhibitors;I-group;I-DDI-DrugBank.d210.s0.e0
:;O;O
Reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d210.s0.e1
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
Angiotensin;B-group;B-DDI-DrugBank.d210.s0.e2
Converting;I-group;I-DDI-DrugBank.d210.s0.e2
Enzyme;I-group;I-DDI-DrugBank.d210.s0.e2
(;I-group;I-DDI-DrugBank.d210.s0.e2
ACE;I-group;I-DDI-DrugBank.d210.s0.e2
);I-group;I-DDI-DrugBank.d210.s0.e2
inhibitors;I-group;I-DDI-DrugBank.d210.s0.e2
.;O;O
DDI-DrugBank.d210.s1;;
In;O;O
patients;O;O
with;O;O
mild;O;O
to;O;O
moderate;O;O
hypertension;O;O
,;O;O
administration;O;O
of;O;O
25;O;O
mg;O;O
daily;O;O
of;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s1.e0
with;O;O
the;O;O
ACE;B-group;B-DDI-DrugBank.d210.s1.e1
inhibitor;I-group;I-DDI-DrugBank.d210.s1.e1
benazepril;I-drug;I-DDI-DrugBank.d210.s1.e2
,;O;O
10;O;O
to;O;O
40;O;O
mg;O;O
for;O;O
4;O;O
weeks;O;O
,;O;O
was;O;O
associated;O;O
with;O;O
an;O;O
average;O;O
increase;O;O
in;O;O
mean;O;O
arterial;O;O
pressure;O;O
of;O;O
about;O;O
3;O;O
mm;O;O
Hg;O;O
compared;O;O
to;O;O
ACE;B-group;B-DDI-DrugBank.d210.s1.e3
inhibitor;I-group;I-DDI-DrugBank.d210.s1.e3
alone;O;O
.;O;O
DDI-DrugBank.d210.s2;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s2.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d210.s2.e1
inhibitors;I-group;I-DDI-DrugBank.d210.s2.e1
.;O;O
DDI-DrugBank.d210.s3;;
Aspirin;B-brand;B-DDI-DrugBank.d210.s3.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
low;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d210.s3.e1
with;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s3.e2
may;O;O
result;O;O
in;O;O
an;O;O
increased;O;O
rate;O;O
of;O;O
GI;O;O
ulceration;O;O
or;O;O
other;O;O
complications;O;O
,;O;O
compared;O;O
to;O;O
use;O;O
of;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s3.e3
alone;O;O
.;O;O
DDI-DrugBank.d210.s4;;
In;O;O
a;O;O
12;O;O
-;O;O
week;O;O
endoscopy;O;O
study;O;O
conducted;O;O
in;O;O
OA;O;O
patients;O;O
there;O;O
was;O;O
no;O;O
difference;O;O
in;O;O
the;O;O
cumulative;O;O
incidence;O;O
of;O;O
endoscopic;O;O
gastroduodenal;O;O
ulcers;O;O
in;O;O
patients;O;O
taking;O;O
low;O;O
-;O;O
dose;O;O
(;O;O
81;O;O
mg;O;O
);O;O
enteric;O;O
coated;O;O
aspirin;B-brand;B-DDI-DrugBank.d210.s4.e0
plus;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s4.e1
25;O;O
mg;O;O
daily;O;O
,;O;O
as;O;O
compared;O;O
to;O;O
those;O;O
taking;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d210.s4.e2
2400;O;O
mg;O;O
daily;O;O
alone;O;O
.;O;O
DDI-DrugBank.d210.s5;;
Patients;O;O
taking;O;O
low;O;O
-;O;O
dose;O;O
aspirin;B-brand;B-DDI-DrugBank.d210.s5.e0
plus;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d210.s5.e1
were;O;O
not;O;O
studied;O;O
.;O;O
DDI-DrugBank.d210.s6;;
At;O;O
steady;O;O
state;O;O
,;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s6.e0
50;O;O
mg;O;O
once;O;O
daily;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
anti;O;O
-;O;O
platelet;O;O
activity;O;O
of;O;O
low;O;O
-;O;O
dose;O;O
(;O;O
81;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
aspirin;B-brand;B-DDI-DrugBank.d210.s6.e1
,;O;O
as;O;O
assessed;O;O
by;O;O
ex;O;O
vivo;O;O
platelet;O;O
aggregation;O;O
and;O;O
serum;O;O
TXB2;O;O
generation;O;O
in;O;O
clotting;O;O
blood;O;O
.;O;O
DDI-DrugBank.d210.s7;;
Because;O;O
of;O;O
its;O;O
lack;O;O
of;O;O
platelet;O;O
effects;O;O
,;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s7.e0
is;O;O
not;O;O
a;O;O
substitute;O;O
for;O;O
aspirin;B-brand;B-DDI-DrugBank.d210.s7.e1
for;O;O
cardiovascular;O;O
prophylaxis;O;O
.;O;O
DDI-DrugBank.d210.s8;;
Therefore;O;O
,;O;O
in;O;O
patients;O;O
taking;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s8.e0
,;O;O
antiplatelet;O;O
therapies;O;O
should;O;O
not;O;O
be;O;O
discontinued;O;O
and;O;O
should;O;O
be;O;O
considered;O;O
in;O;O
patients;O;O
with;O;O
an;O;O
indication;O;O
for;O;O
cardiovascular;O;O
prophylaxis;O;O
.;O;O
DDI-DrugBank.d210.s9;;
Prospective;O;O
,;O;O
long;O;O
-;O;O
term;O;O
studies;O;O
on;O;O
concomitant;O;O
administration;O;O
of;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s9.e0
and;O;O
aspirin;B-brand;B-DDI-DrugBank.d210.s9.e1
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d210.s10;;
Cimetidine;B-drug;B-DDI-DrugBank.d210.s10.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
with;O;O
high;O;O
doses;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d210.s10.e1
[;O;O
800;O;O
mg;O;O
twice;O;O
daily;O;O
];O;O
increased;O;O
the;O;O
Cmax;O;O
of;O;O
rofecoxib;B-drug;B-DDI-DrugBank.d210.s10.e2
by;O;O
21;O;O
%;O;O
,;O;O
the;O;O
AUC0;O;O
-;O;O
120hr;O;O
by;O;O
23;O;O
%;O;O
and;O;O
the;O;O
t1;O;O
/;O;O
2;O;O
by;O;O
15;O;O
%;O;O
.;O;O
DDI-DrugBank.d210.s11;;
These;O;O
small;O;O
changes;O;O
are;O;O
not;O;O
clinically;O;O
significant;O;O
and;O;O
no;O;O
dose;O;O
adjustment;O;O
is;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d210.s12;;
Digoxin;B-drug;B-DDI-DrugBank.d210.s12.e0
:;O;O
Rofecoxib;B-drug;B-DDI-DrugBank.d210.s12.e1
75;O;O
mg;O;O
once;O;O
daily;O;O
for;O;O
11;O;O
days;O;O
does;O;O
not;O;O
alter;O;O
the;O;O
plasma;O;O
concentration;O;O
profile;O;O
or;O;O
renal;O;O
elimination;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d210.s12.e2
after;O;O
a;O;O
single;O;O
0.5;O;O
mg;O;O
oral;O;O
dose;O;O
.;O;O
DDI-DrugBank.d210.s13;;
Furosemide;B-drug;B-DDI-DrugBank.d210.s13.e0
:;O;O
Clinical;O;O
studies;O;O
,;O;O
as;O;O
well;O;O
as;O;O
post;O;O
-;O;O
marketing;O;O
observations;O;O
,;O;O
have;O;O
shown;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d210.s13.e1
can;O;O
reduce;O;O
the;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d210.s13.e2
and;O;O
thiazides;B-group;B-DDI-DrugBank.d210.s13.e3
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d210.s14;;
This;O;O
response;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d210.s15;;
Ketoconazole;B-drug;B-DDI-DrugBank.d210.s15.e0
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d210.s15.e1
400;O;O
mg;O;O
daily;O;O
did;O;O
not;O;O
have;O;O
any;O;O
clinically;O;O
important;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
rofecoxib;B-drug;B-DDI-DrugBank.d210.s15.e2
.;O;O
DDI-DrugBank.d210.s16;;
Lithium;B-drug;B-DDI-DrugBank.d210.s16.e0
:;O;O
NSAIDs;B-group;B-DDI-DrugBank.d210.s16.e1
have;O;O
produced;O;O
an;O;O
elevation;O;O
of;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d210.s16.e2
levels;O;O
and;O;O
a;O;O
reduction;O;O
in;O;O
renal;O;O
lithium;B-drug;B-DDI-DrugBank.d210.s16.e3
clearance;O;O
.;O;O
DDI-DrugBank.d210.s17;;
In;O;O
post;O;O
-;O;O
marketing;O;O
experience;O;O
there;O;O
have;O;O
been;O;O
reports;O;O
of;O;O
increases;O;O
in;O;O
plasma;O;O
lithium;B-drug;B-DDI-DrugBank.d210.s17.e0
levels;O;O
.;O;O
DDI-DrugBank.d210.s18;;
Thus;O;O
,;O;O
when;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s18.e0
and;O;O
lithium;B-drug;B-DDI-DrugBank.d210.s18.e1
are;O;O
administered;O;O
concurrently;O;O
,;O;O
subjects;O;O
should;O;O
be;O;O
observed;O;O
carefully;O;O
for;O;O
signs;O;O
of;O;O
lithium;B-drug;B-DDI-DrugBank.d210.s18.e2
toxicity;O;O
.;O;O
DDI-DrugBank.d210.s19;;
Methotrexate;B-drug;B-DDI-DrugBank.d210.s19.e0
VIOXX;I-brand;I-DDI-DrugBank.d210.s19.e1
12.5;O;O
,;O;O
25;O;O
,;O;O
and;O;O
50;O;O
mg;O;O
,;O;O
each;O;O
dose;O;O
administered;O;O
once;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
,;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
plasma;O;O
concentration;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s19.e2
as;O;O
measured;O;O
by;O;O
AUC0;O;O
-;O;O
24hr;O;O
in;O;O
patients;O;O
receiving;O;O
single;O;O
weekly;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s19.e3
doses;O;O
of;O;O
7.5;O;O
to;O;O
20;O;O
mg;O;O
for;O;O
rheumatoid;O;O
arthritis;O;O
.;O;O
DDI-DrugBank.d210.s20;;
At;O;O
higher;O;O
than;O;O
recommended;O;O
doses;O;O
,;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s20.e0
75;O;O
mg;O;O
administered;O;O
once;O;O
daily;O;O
for;O;O
10;O;O
days;O;O
increased;O;O
plasma;O;O
concentrations;O;O
by;O;O
23;O;O
%;O;O
as;O;O
measured;O;O
by;O;O
AUC0;O;O
-;O;O
24hr;O;O
in;O;O
patients;O;O
receiving;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s20.e1
7.5;O;O
to;O;O
15;O;O
mg;O;O
/;O;O
week;O;O
for;O;O
rheumatoid;O;O
arthritis;O;O
.;O;O
DDI-DrugBank.d210.s21;;
At;O;O
24;O;O
hours;O;O
postdose;O;O
,;O;O
a;O;O
similar;O;O
proportion;O;O
of;O;O
patients;O;O
treated;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s21.e0
alone;O;O
(;O;O
94;O;O
%;O;O
);O;O
and;O;O
subsequently;O;O
treated;O;O
with;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s21.e1
co;O;O
-;O;O
administered;O;O
with;O;O
75;O;O
mg;O;O
of;O;O
rofecoxib;B-drug;B-DDI-DrugBank.d210.s21.e2
(;O;O
88;O;O
%;O;O
);O;O
had;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s21.e3
plasma;O;O
concentrations;O;O
below;O;O
the;O;O
measurable;O;O
limit;O;O
(;O;O
5;O;O
ng;O;O
/;O;O
mL;O;O
);O;O
.;O;O
DDI-DrugBank.d210.s22;;
Standard;O;O
monitoring;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s22.e0
-;O;O
related;O;O
toxicity;O;O
should;O;O
be;O;O
continued;O;O
if;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s22.e1
and;O;O
methotrexate;B-drug;B-DDI-DrugBank.d210.s22.e2
are;O;O
administered;O;O
concomitantly;O;O
.;O;O
DDI-DrugBank.d210.s23;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d210.s23.e0
Rofecoxib;I-drug;I-DDI-DrugBank.d210.s23.e1
did;O;O
not;O;O
have;O;O
any;O;O
clinically;O;O
important;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
ethinyl;B-drug;B-DDI-DrugBank.d210.s23.e2
estradiol;I-drug;I-DDI-DrugBank.d210.s23.e2
and;O;O
norethindrone;B-drug;B-DDI-DrugBank.d210.s23.e3
.;O;O
DDI-DrugBank.d210.s24;;
Prednisone;B-drug;B-DDI-DrugBank.d210.s24.e0
/;O;O
prednisolone;B-drug;B-DDI-DrugBank.d210.s24.e1
:;O;O
Rofecoxib;B-drug;B-DDI-DrugBank.d210.s24.e2
did;O;O
not;O;O
have;O;O
any;O;O
clinically;O;O
important;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
prednisolone;B-drug;B-DDI-DrugBank.d210.s24.e3
or;O;O
prednisone;B-drug;B-DDI-DrugBank.d210.s24.e4
.;O;O
DDI-DrugBank.d210.s25;;
Rifampin;B-drug;B-DDI-DrugBank.d210.s25.e0
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s25.e1
with;O;O
rifampin;B-drug;B-DDI-DrugBank.d210.s25.e2
600;O;O
mg;O;O
daily;O;O
,;O;O
a;O;O
potent;O;O
inducer;O;O
of;O;O
hepatic;O;O
metabolism;O;O
,;O;O
produced;O;O
an;O;O
approximate;O;O
50;O;O
%;O;O
decrease;O;O
in;O;O
rofecoxib;B-drug;B-DDI-DrugBank.d210.s25.e3
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d210.s26;;
Therefore;O;O
,;O;O
a;O;O
starting;O;O
daily;O;O
dose;O;O
of;O;O
25;O;O
mg;O;O
of;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s26.e0
should;O;O
be;O;O
considered;O;O
for;O;O
the;O;O
treatment;O;O
of;O;O
osteoarthritis;O;O
when;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s26.e1
is;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
potent;O;O
inducers;O;O
of;O;O
hepatic;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d210.s27;;
Theophylline;B-drug;B-DDI-DrugBank.d210.s27.e0
VIOXX;I-brand;I-DDI-DrugBank.d210.s27.e1
12.5;O;O
,;O;O
25;O;O
,;O;O
and;O;O
50;O;O
mg;O;O
administered;O;O
once;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
increased;O;O
plasma;O;O
theophylline;B-drug;B-DDI-DrugBank.d210.s27.e2
concentrations;O;O
(;O;O
AUC(0;O;O
-;O;O
);O;O
);O;O
by;O;O
38;O;O
to;O;O
60;O;O
%;O;O
in;O;O
healthy;O;O
subjects;O;O
administered;O;O
a;O;O
single;O;O
300;O;O
-;O;O
mg;O;O
dose;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d210.s27.e3
.;O;O
DDI-DrugBank.d210.s28;;
Adequate;O;O
monitoring;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d210.s28.e0
plasma;O;O
concentrations;O;O
should;O;O
be;O;O
considered;O;O
when;O;O
therapy;O;O
with;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s28.e1
is;O;O
initiated;O;O
or;O;O
changed;O;O
in;O;O
patients;O;O
receiving;O;O
theophylline;B-drug;B-DDI-DrugBank.d210.s28.e2
.;O;O
DDI-DrugBank.d210.s29;;
These;O;O
data;O;O
suggest;O;O
that;O;O
rofecoxib;B-drug;B-DDI-DrugBank.d210.s29.e0
may;O;O
produce;O;O
a;O;O
modest;O;O
inhibition;O;O
of;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
1A2;O;O
.;O;O
DDI-DrugBank.d210.s30;;
Therefore;O;O
,;O;O
there;O;O
is;O;O
a;O;O
potential;O;O
for;O;O
an;O;O
interaction;O;O
with;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
metabolized;O;O
by;O;O
CYP;O;O
1A2;O;O
(;O;O
e.g.;O;O
,;O;O
amitriptyline;B-drug;B-DDI-DrugBank.d210.s30.e0
,;O;O
tacrine;B-drug;B-DDI-DrugBank.d210.s30.e1
,;O;O
and;O;O
zileuton;B-drug;B-DDI-DrugBank.d210.s30.e2
);O;O
.;O;O
DDI-DrugBank.d210.s31;;
Warfarin;B-drug;B-DDI-DrugBank.d210.s31.e0
:;O;O
Anticoagulant;O;O
activity;O;O
should;O;O
be;O;O
monitored;O;O
,;O;O
particularly;O;O
in;O;O
the;O;O
first;O;O
few;O;O
days;O;O
after;O;O
initiating;O;O
or;O;O
changing;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s31.e1
therapy;O;O
in;O;O
patients;O;O
receiving;O;O
warfarin;B-drug;B-DDI-DrugBank.d210.s31.e2
or;O;O
similar;O;O
agents;O;O
,;O;O
since;O;O
these;O;O
patients;O;O
are;O;O
at;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
bleeding;O;O
complications;O;O
.;O;O
DDI-DrugBank.d210.s32;;
In;O;O
single;O;O
and;O;O
multiple;O;O
dose;O;O
studies;O;O
in;O;O
healthy;O;O
subjects;O;O
receiving;O;O
both;O;O
warfarin;B-drug;B-DDI-DrugBank.d210.s32.e0
and;O;O
rofecoxib;B-drug;B-DDI-DrugBank.d210.s32.e1
,;O;O
prothrombin;O;O
time;O;O
(;O;O
measured;O;O
as;O;O
INR;O;O
);O;O
was;O;O
increased;O;O
by;O;O
approximately;O;O
8;O;O
%;O;O
to;O;O
11;O;O
%;O;O
.;O;O
DDI-DrugBank.d210.s33;;
In;O;O
post;O;O
-;O;O
marketing;O;O
experience;O;O
,;O;O
bleeding;O;O
events;O;O
have;O;O
been;O;O
reported;O;O
,;O;O
predominantly;O;O
in;O;O
the;O;O
elderly;O;O
,;O;O
in;O;O
association;O;O
with;O;O
increases;O;O
in;O;O
prothrombin;O;O
time;O;O
in;O;O
patients;O;O
receiving;O;O
VIOXX;B-brand;B-DDI-DrugBank.d210.s33.e0
concurrently;O;O
with;O;O
warfarin;B-drug;B-DDI-DrugBank.d210.s33.e1
.;O;O
DDI-DrugBank.d124.s0;;
DRUG;O;O
INTERACTIONS;O;O
DDI-DrugBank.d124.s1;;
Several;O;O
drug;O;O
interaction;O;O
studies;O;O
have;O;O
been;O;O
completed;O;O
with;O;O
both;O;O
INVIRASE;B-brand;B-DDI-DrugBank.d124.s1.e0
and;O;O
FORTOVASE;B-brand;B-DDI-DrugBank.d124.s1.e1
.;O;O
DDI-DrugBank.d124.s2;;
Observations;O;O
from;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
FORTOVASE;B-brand;B-DDI-DrugBank.d124.s2.e0
may;O;O
not;O;O
be;O;O
predictive;O;O
for;O;O
INVIRASE;B-brand;B-DDI-DrugBank.d124.s2.e1
.;O;O
DDI-DrugBank.d124.s3;;
Because;O;O
ritonavir;B-drug;B-DDI-DrugBank.d124.s3.e0
is;O;O
coadministered;O;O
,;O;O
prescribers;O;O
should;O;O
also;O;O
refer;O;O
to;O;O
the;O;O
prescribing;O;O
information;O;O
for;O;O
ritonavir;B-drug;B-DDI-DrugBank.d124.s3.e1
regarding;O;O
drug;O;O
interactions;O;O
associated;O;O
with;O;O
this;O;O
agent;O;O
.;O;O
DDI-DrugBank.d124.s4;;
The;O;O
metabolism;O;O
of;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s4.e0
is;O;O
mediated;O;O
by;O;O
cytochrome;O;O
P450;O;O
,;O;O
with;O;O
the;O;O
specific;O;O
isoenzyme;O;O
CYP3A4;O;O
responsible;O;O
for;O;O
90;O;O
%;O;O
of;O;O
the;O;O
hepatic;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d124.s5;;
Additionally;O;O
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s5.e0
is;O;O
a;O;O
substrate;O;O
for;O;O
P;O;O
-;O;O
Glycoprotein;O;O
(;O;O
Pgp;O;O
);O;O
.;O;O
DDI-DrugBank.d124.s6;;
Therefore;O;O
,;O;O
drugs;O;O
that;O;O
affect;O;O
CYP3A4;O;O
and/or;O;O
Pgp;O;O
,;O;O
may;O;O
modify;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s6.e0
.;O;O
DDI-DrugBank.d124.s7;;
Similarly;O;O
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s7.e0
might;O;O
also;O;O
modify;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
other;O;O
drugs;O;O
that;O;O
are;O;O
substrates;O;O
for;O;O
CYP3A4;O;O
or;O;O
Pgp;O;O
.;O;O
DDI-DrugBank.d124.s8;;
Drugs;O;O
that;O;O
are;O;O
contraindicated;O;O
specifically;O;O
due;O;O
to;O;O
the;O;O
expected;O;O
magnitude;O;O
of;O;O
interaction;O;O
and;O;O
potential;O;O
for;O;O
serious;O;O
adverse;O;O
events;O;O
are;O;O
listed;O;O
CONTRAINDICATIONS;O;O
.;O;O
DDI-DrugBank.d124.s9;;
Additional;O;O
drugs;O;O
that;O;O
are;O;O
not;O;O
recommended;O;O
for;O;O
coadministration;O;O
with;O;O
INVIRASE;B-brand;B-DDI-DrugBank.d124.s9.e0
and;O;O
ritonavir;B-drug;B-DDI-DrugBank.d124.s9.e1
are;O;O
included;O;O
below;O;O
.;O;O
DDI-DrugBank.d124.s10;;
These;O;O
recommendations;O;O
are;O;O
based;O;O
on;O;O
either;O;O
drug;O;O
interaction;O;O
studies;O;O
or;O;O
predicted;O;O
interactions;O;O
due;O;O
to;O;O
the;O;O
expected;O;O
magnitude;O;O
of;O;O
interaction;O;O
and;O;O
potential;O;O
for;O;O
serious;O;O
events;O;O
or;O;O
loss;O;O
of;O;O
efficacy;O;O
.;O;O
DDI-DrugBank.d124.s11;;
With;O;O
some;O;O
agents;O;O
,;O;O
the;O;O
metabolism;O;O
may;O;O
be;O;O
induced;O;O
,;O;O
resulting;O;O
in;O;O
decreased;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d124.s12;;
Drugs;O;O
That;O;O
Should;O;O
Not;O;O
Be;O;O
Coadministered;O;O
With;O;O
INVIRASE;B-brand;B-DDI-DrugBank.d124.s12.e0
/;O;O
Ritonavir;B-drug;B-DDI-DrugBank.d124.s12.e1
DDI-DrugBank.d124.s13;;
Drug;O;O
Class;O;O
:;O;O
Drug;O;O
Name;O;O
Clinical;O;O
Comment;O;O
DDI-DrugBank.d124.s14;;
Antiarrhythmics;B-group;B-DDI-DrugBank.d124.s14.e0
:;O;O
Amiodarone;B-drug;B-DDI-DrugBank.d124.s14.e1
,;O;O
bepridil;B-drug;B-DDI-DrugBank.d124.s14.e2
,;O;O
flecainide;B-drug;B-DDI-DrugBank.d124.s14.e3
,;O;O
propafenone;B-drug;B-DDI-DrugBank.d124.s14.e4
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d124.s14.e5
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
.;O;O
DDI-DrugBank.d124.s15;;
Antihistamines;B-drug;B-DDI-DrugBank.d124.s15.e0
:;O;O
astemizole;B-drug;B-DDI-DrugBank.d124.s15.e1
*;O;O
,;O;O
terfenadine;B-drug;B-DDI-DrugBank.d124.s15.e2
*;O;O
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d124.s16;;
Ergot;B-group;B-DDI-DrugBank.d124.s16.e0
Derivatives;I-group;I-DDI-DrugBank.d124.s16.e0
:;O;O
Dihydroergotamine;B-drug;B-DDI-DrugBank.d124.s16.e1
,;O;O
ergonovine;B-drug;B-DDI-DrugBank.d124.s16.e2
,;O;O
ergotamine;B-drug;B-DDI-DrugBank.d124.s16.e3
,;O;O
methylergonovine;B-drug;B-DDI-DrugBank.d124.s16.e4
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
acute;O;O
ergot;B-group;B-DDI-DrugBank.d124.s16.e5
toxicity;O;O
characterized;O;O
by;O;O
peripheral;O;O
vasospasm;O;O
and;O;O
ischemia;O;O
of;O;O
the;O;O
extremities;O;O
and;O;O
other;O;O
tissues;O;O
.;O;O
DDI-DrugBank.d124.s17;;
Antimycobacterial;B-group;B-DDI-DrugBank.d124.s17.e0
Agents;I-group;I-DDI-DrugBank.d124.s17.e0
:;O;O
rifampin;B-drug;B-DDI-DrugBank.d124.s17.e1
CONTRAINDICATED;O;O
since;O;O
the;O;O
coadministration;O;O
of;O;O
this;O;O
product;O;O
with;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s17.e2
in;O;O
an;O;O
antiretroviral;B-group;B-DDI-DrugBank.d124.s17.e3
regimen;O;O
reduces;O;O
the;O;O
plasma;O;O
concentrations;O;O
of;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s17.e4
.;O;O
DDI-DrugBank.d124.s18;;
Garlic;O;O
Capsules;O;O
Garlic;O;O
capsules;O;O
should;O;O
not;O;O
be;O;O
used;O;O
while;O;O
taking;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s18.e0
(;O;O
FORTOVASE;B-brand;B-DDI-DrugBank.d124.s18.e1
);O;O
as;O;O
the;O;O
sole;O;O
protease;B-group;B-DDI-DrugBank.d124.s18.e2
inhibitor;I-group;I-DDI-DrugBank.d124.s18.e2
due;O;O
to;O;O
the;O;O
risk;O;O
of;O;O
decreased;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s18.e3
plasma;O;O
concentrations;O;O
.;O;O
DDI-DrugBank.d124.s19;;
No;O;O
data;O;O
are;O;O
available;O;O
for;O;O
the;O;O
coadministration;O;O
of;O;O
INVIRASE;B-brand;B-DDI-DrugBank.d124.s19.e0
/;O;O
ritonavir;B-drug;B-DDI-DrugBank.d124.s19.e1
or;O;O
FORTOVASE;B-brand;B-DDI-DrugBank.d124.s19.e2
/;O;O
ritonavir;B-drug;B-DDI-DrugBank.d124.s19.e3
and;O;O
garlic;O;O
capsules;O;O
.;O;O
DDI-DrugBank.d124.s20;;
GI;O;O
Motility;O;O
Agent;O;O
:;O;O
cisapride;B-drug;B-DDI-DrugBank.d124.s20.e0
*;O;O
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
cardiac;O;O
arrhythmias;O;O
.;O;O
DDI-DrugBank.d124.s21;;
Herbal;O;O
Products;O;O
:;O;O
St.;O;O
John;O;O
s;O;O
wort;O;O
(;O;O
hypericum;O;O
perforatum;O;O
);O;O
WARNING;O;O
coadministration;O;O
may;O;O
lead;O;O
to;O;O
loss;O;O
of;O;O
virologic;O;O
response;O;O
and;O;O
possible;O;O
resistance;O;O
to;O;O
INVIRASE;B-brand;B-DDI-DrugBank.d124.s21.e0
or;O;O
to;O;O
the;O;O
class;O;O
of;O;O
protease;O;O
inhibitors;O;O
.;O;O
DDI-DrugBank.d124.s22;;
HMG;B-group;B-DDI-DrugBank.d124.s22.e0
-;I-group;I-DDI-DrugBank.d124.s22.e0
CoA;I-group;I-DDI-DrugBank.d124.s22.e0
Reductase;I-group;I-DDI-DrugBank.d124.s22.e0
Inhibitors;I-group;I-DDI-DrugBank.d124.s22.e0
:;O;O
lovastatin;B-drug;B-DDI-DrugBank.d124.s22.e1
,;O;O
simvastatin;B-drug;B-DDI-DrugBank.d124.s22.e2
WARNING;O;O
potential;O;O
for;O;O
serious;O;O
reactions;O;O
such;O;O
as;O;O
risk;O;O
of;O;O
myopathy;O;O
including;O;O
rhabdomyolysis;O;O
.;O;O
DDI-DrugBank.d124.s23;;
Sedatives;B-group;B-DDI-DrugBank.d124.s23.e0
/;O;O
Hypnotics;B-group;B-DDI-DrugBank.d124.s23.e1
:;O;O
triazolam;B-drug;B-DDI-DrugBank.d124.s23.e2
,;O;O
midazolam;B-drug;B-DDI-DrugBank.d124.s23.e3
CONTRAINDICATED;O;O
due;O;O
to;O;O
potential;O;O
for;O;O
serious;O;O
and/or;O;O
life;O;O
-;O;O
threatening;O;O
reactions;O;O
such;O;O
as;O;O
prolonged;O;O
or;O;O
increased;O;O
sedation;O;O
or;O;O
respiratory;O;O
depression;O;O
.;O;O
DDI-DrugBank.d124.s24;;
*;O;O
No;O;O
longer;O;O
marketed;O;O
in;O;O
the;O;O
US;O;O
.;O;O
DDI-DrugBank.d124.s25;;
Drugs;O;O
That;O;O
Are;O;O
Mainly;O;O
Metabolized;O;O
by;O;O
CYP3A4;O;O
DDI-DrugBank.d124.s26;;
Although;O;O
specific;O;O
studies;O;O
have;O;O
not;O;O
been;O;O
performed;O;O
,;O;O
coadministration;O;O
with;O;O
drugs;O;O
that;O;O
are;O;O
mainly;O;O
metabolized;O;O
by;O;O
CYP3A4;O;O
(;O;O
eg;O;O
,;O;O
calcium;B-group;B-DDI-DrugBank.d124.s26.e0
channel;I-group;I-DDI-DrugBank.d124.s26.e0
blockers;I-group;I-DDI-DrugBank.d124.s26.e0
,;O;O
dapsone;B-drug;B-DDI-DrugBank.d124.s26.e1
,;O;O
disopyramide;B-drug;B-DDI-DrugBank.d124.s26.e2
,;O;O
quinine;B-drug;B-DDI-DrugBank.d124.s26.e3
,;O;O
amiodarone;B-drug;B-DDI-DrugBank.d124.s26.e4
,;O;O
quinidine;B-drug;B-DDI-DrugBank.d124.s26.e5
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d124.s26.e6
,;O;O
tacrolimus;B-drug;B-DDI-DrugBank.d124.s26.e7
,;O;O
cyclosporine;B-drug;B-DDI-DrugBank.d124.s26.e8
,;O;O
ergot;B-group;B-DDI-DrugBank.d124.s26.e9
derivatives;I-group;I-DDI-DrugBank.d124.s26.e9
,;O;O
pimozide;B-drug;B-DDI-DrugBank.d124.s26.e10
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d124.s26.e11
,;O;O
fentanyl;B-drug;B-DDI-DrugBank.d124.s26.e12
,;O;O
alfentanyl;B-drug;B-DDI-DrugBank.d124.s26.e13
,;O;O
alprazolam;B-drug;B-DDI-DrugBank.d124.s26.e14
,;O;O
and;O;O
triazolam;B-drug;B-DDI-DrugBank.d124.s26.e15
);O;O
may;O;O
have;O;O
elevated;O;O
plasma;O;O
concentrations;O;O
when;O;O
coadministered;O;O
with;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s26.e16
,;O;O
DDI-DrugBank.d124.s27;;
therefore;O;O
,;O;O
these;O;O
combinations;O;O
should;O;O
be;O;O
used;O;O
with;O;O
caution;O;O
.;O;O
DDI-DrugBank.d124.s28;;
Since;O;O
INVIRASE;B-brand;B-DDI-DrugBank.d124.s28.e0
is;O;O
coadministered;O;O
with;O;O
ritonavir;B-drug;B-DDI-DrugBank.d124.s28.e1
,;O;O
the;O;O
ritonavir;B-drug;B-DDI-DrugBank.d124.s28.e2
label;O;O
should;O;O
be;O;O
reviewed;O;O
for;O;O
additional;O;O
drugs;O;O
that;O;O
should;O;O
not;O;O
be;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d124.s29;;
Inducers;O;O
of;O;O
CYP3A4;O;O
DDI-DrugBank.d124.s30;;
Coadministration;O;O
with;O;O
compounds;O;O
that;O;O
are;O;O
potent;O;O
inducers;O;O
of;O;O
CYP3A4;O;O
(;O;O
eg;O;O
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d124.s30.e0
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d124.s30.e1
,;O;O
dexamethasone;B-drug;B-DDI-DrugBank.d124.s30.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d124.s30.e3
);O;O
may;O;O
result;O;O
in;O;O
decreased;O;O
plasma;O;O
levels;O;O
of;O;O
saquinavir;B-drug;B-DDI-DrugBank.d124.s30.e4
.;O;O
DDI-DrugBank.d65.s0;;
Sulfacetamide;B-drug;B-DDI-DrugBank.d65.s0.e0
preparations;O;O
are;O;O
incompatible;O;O
with;O;O
silver;B-drug;B-DDI-DrugBank.d65.s0.e1
preparations;O;O
.;O;O
DDI-DrugBank.d179.s0;;
Interations;O;O
DDI-DrugBank.d179.s1;;
Sulfapyridine;B-drug;B-DDI-DrugBank.d179.s1.e0
may;O;O
interact;O;O
with;O;O
any;O;O
of;O;O
the;O;O
following;O;O
:;O;O
-;O;O
Acetaminophen;B-drug;B-DDI-DrugBank.d179.s1.e1
(;O;O
e.g.;O;O
,;O;O
Tylenol;B-brand;B-DDI-DrugBank.d179.s1.e2
);O;O
(;O;O
with;O;O
long;O;O
-;O;O
term;O;O
,;O;O
high;O;O
-;O;O
dose;O;O
use;O;O
);O;O
or;O;O
DDI-DrugBank.d179.s2;;
-;O;O
Amiodarone;B-drug;B-DDI-DrugBank.d179.s2.e0
(;O;O
e.g.;O;O
,;O;O
Cordarone;B-brand;B-DDI-DrugBank.d179.s2.e1
);O;O
or;O;O
DDI-DrugBank.d179.s3;;
-;O;O
Anabolic;B-group;B-DDI-DrugBank.d179.s3.e0
steroids;I-group;I-DDI-DrugBank.d179.s3.e0
(;O;O
nandrolone;B-drug;B-DDI-DrugBank.d179.s3.e1
[;O;O
e.g.;O;O
,;O;O
Anabolin;B-brand;B-DDI-DrugBank.d179.s3.e2
];O;O
,;O;O
oxandrolone;B-drug;B-DDI-DrugBank.d179.s3.e3
[;O;O
e.g.;O;O
,;O;O
Anavar;B-brand;B-DDI-DrugBank.d179.s3.e4
];O;O
,;O;O
oxymetholone;B-drug;B-DDI-DrugBank.d179.s3.e5
[;O;O
e.g.;O;O
,;O;O
Anadrol;B-brand;B-DDI-DrugBank.d179.s3.e6
];O;O
,;O;O
stanozolol;B-drug;B-DDI-DrugBank.d179.s3.e7
[;O;O
e.g.;O;O
,;O;O
Winstrol;B-brand;B-DDI-DrugBank.d179.s3.e8
];O;O
);O;O
or;O;O
DDI-DrugBank.d179.s4;;
-;O;O
Androgens;B-group;B-DDI-DrugBank.d179.s4.e0
(;O;O
male;O;O
hormones;O;O
);O;O
or;O;O
DDI-DrugBank.d179.s5;;
-;O;O
Antithyroid;B-group;B-DDI-DrugBank.d179.s5.e0
agents;I-group;I-DDI-DrugBank.d179.s5.e0
(;O;O
medicine;O;O
for;O;O
overactive;O;O
thyroid;O;O
);O;O
or;O;O
DDI-DrugBank.d179.s6;;
-;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d179.s6.e0
(;O;O
e.g.;O;O
,;O;O
Tegretol;B-brand;B-DDI-DrugBank.d179.s6.e1
);O;O
or;O;O
DDI-DrugBank.d179.s7;;
-;O;O
Carmustine;B-drug;B-DDI-DrugBank.d179.s7.e0
(;O;O
e.g.;O;O
,;O;O
BiCNU;B-brand;B-DDI-DrugBank.d179.s7.e1
);O;O
or;O;O
DDI-DrugBank.d179.s8;;
-;O;O
Chloroquine;B-drug;B-DDI-DrugBank.d179.s8.e0
(;O;O
e.g.;O;O
,;O;O
Aralen;B-brand;B-DDI-DrugBank.d179.s8.e1
);O;O
or;O;O
DDI-DrugBank.d179.s9;;
-;O;O
Dantrolene;B-drug;B-DDI-DrugBank.d179.s9.e0
(;O;O
e.g.;O;O
,;O;O
Dantrium;B-brand;B-DDI-DrugBank.d179.s9.e1
);O;O
or;O;O
DDI-DrugBank.d179.s10;;
-;O;O
Daunorubicin;B-drug;B-DDI-DrugBank.d179.s10.e0
(;O;O
e.g.;O;O
,;O;O
Cerubidine;B-brand;B-DDI-DrugBank.d179.s10.e1
);O;O
or;O;O
DDI-DrugBank.d179.s11;;
-;O;O
Disulfiram;B-drug;B-DDI-DrugBank.d179.s11.e0
(;O;O
e.g.;O;O
,;O;O
Antabuse;B-brand;B-DDI-DrugBank.d179.s11.e1
);O;O
or;O;O
DDI-DrugBank.d179.s12;;
-;O;O
Divalproex;B-drug;B-DDI-DrugBank.d179.s12.e0
(;O;O
e.g.;O;O
,;O;O
Depakote;B-brand;B-DDI-DrugBank.d179.s12.e1
);O;O
or;O;O
DDI-DrugBank.d179.s13;;
-;O;O
Estrogens;B-group;B-DDI-DrugBank.d179.s13.e0
(;O;O
female;O;O
hormones;O;O
);O;O
or;O;O
DDI-DrugBank.d179.s14;;
-;O;O
Etretinate;B-drug;B-DDI-DrugBank.d179.s14.e0
(;O;O
e.g.;O;O
,;O;O
Tegison;B-brand;B-DDI-DrugBank.d179.s14.e1
);O;O
or;O;O
DDI-DrugBank.d179.s15;;
-;O;O
Gold;B-drug;B-DDI-DrugBank.d179.s15.e0
salts;O;O
(;O;O
medicine;O;O
for;O;O
arthritis;O;O
);O;O
or;O;O
DDI-DrugBank.d179.s16;;
-;O;O
Hydroxychloroquine;B-drug;B-DDI-DrugBank.d179.s16.e0
(;O;O
e.g.;O;O
,;O;O
Plaquenil;B-brand;B-DDI-DrugBank.d179.s16.e1
);O;O
or;O;O
DDI-DrugBank.d179.s17;;
-;O;O
Mercaptopurine;B-drug;B-DDI-DrugBank.d179.s17.e0
(;O;O
e.g.;O;O
,;O;O
Purinethol;B-brand;B-DDI-DrugBank.d179.s17.e1
);O;O
or;O;O
DDI-DrugBank.d179.s18;;
-;O;O
Naltrexone;B-drug;B-DDI-DrugBank.d179.s18.e0
(;O;O
e.g.;O;O
,;O;O
Trexan;B-brand;B-DDI-DrugBank.d179.s18.e1
);O;O
(;O;O
with;O;O
long;O;O
-;O;O
term;O;O
,;O;O
high;O;O
-;O;O
dose;O;O
use;O;O
);O;O
or;O;O
DDI-DrugBank.d179.s19;;
-;O;O
Oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d179.s19.e0
(;O;O
birth;O;O
control;O;O
pills;O;O
);O;O
containing;O;O
estrogen;B-group;B-DDI-DrugBank.d179.s19.e1
or;O;O
DDI-DrugBank.d179.s20;;
-;O;O
Other;O;O
anti;B-group;B-DDI-DrugBank.d179.s20.e0
-;I-group;I-DDI-DrugBank.d179.s20.e0
infectives;I-group;I-DDI-DrugBank.d179.s20.e0
by;O;O
mouth;O;O
or;O;O
by;O;O
injection;O;O
(;O;O
medicine;O;O
for;O;O
infection;O;O
);O;O
or;O;O
DDI-DrugBank.d179.s21;;
-;O;O
Phenothiazines;B-group;B-DDI-DrugBank.d179.s21.e0
(;O;O
acetophenazine;B-drug;B-DDI-DrugBank.d179.s21.e1
[;O;O
e.g.;O;O
,;O;O
Tindal;B-brand;B-DDI-DrugBank.d179.s21.e2
];O;O
,;O;O
chlorpromazine;B-drug;B-DDI-DrugBank.d179.s21.e3
[;O;O
e.g.;O;O
,;O;O
Thorazine;B-brand;B-DDI-DrugBank.d179.s21.e4
];O;O
,;O;O
fluphenazine;B-drug;B-DDI-DrugBank.d179.s21.e5
[;O;O
e.g.;O;O
,;O;O
Prolixin;B-brand;B-DDI-DrugBank.d179.s21.e6
];O;O
,;O;O
mesoridazine;B-brand;B-DDI-DrugBank.d179.s21.e7
[;O;O
e.g.;O;O
,;O;O
Serentil;B-brand;B-DDI-DrugBank.d179.s21.e8
];O;O
,;O;O
perphenazine;B-drug;B-DDI-DrugBank.d179.s21.e9
[;O;O
e.g.;O;O
,;O;O
Trilafon;B-brand;B-DDI-DrugBank.d179.s21.e10
];O;O
,;O;O
prochlorperazine;B-drug;B-DDI-DrugBank.d179.s21.e11
[;O;O
e.g.;O;O
,;O;O
Compazine;B-brand;B-DDI-DrugBank.d179.s21.e12
];O;O
,;O;O
promazine;B-drug;B-DDI-DrugBank.d179.s21.e13
[;O;O
e.g.;O;O
,;O;O
Sparine;B-brand;B-DDI-DrugBank.d179.s21.e14
];O;O
,;O;O
promethazine;B-drug;B-DDI-DrugBank.d179.s21.e15
[;O;O
e.g.;O;O
,;O;O
Phenergan;B-brand;B-DDI-DrugBank.d179.s21.e16
];O;O
,;O;O
thioridazine;B-drug;B-DDI-DrugBank.d179.s21.e17
[;O;O
e.g.;O;O
,;O;O
Mellaril;B-brand;B-DDI-DrugBank.d179.s21.e18
];O;O
,;O;O
trifluoperazine;B-drug;B-DDI-DrugBank.d179.s21.e19
[;O;O
e.g.;O;O
,;O;O
Stelazine;B-brand;B-DDI-DrugBank.d179.s21.e20
];O;O
,;O;O
triflupromazine;B-drug;B-DDI-DrugBank.d179.s21.e21
[;O;O
e.g.;O;O
,;O;O
Vesprin;B-brand;B-DDI-DrugBank.d179.s21.e22
];O;O
,;O;O
trimeprazine;B-drug;B-DDI-DrugBank.d179.s21.e23
[;O;O
e.g.;O;O
,;O;O
Temaril;B-brand;B-DDI-DrugBank.d179.s21.e24
];O;O
);O;O
or;O;O
DDI-DrugBank.d179.s22;;
-;O;O
Plicamycin;B-drug;B-DDI-DrugBank.d179.s22.e0
(;O;O
e.g.;O;O
,;O;O
Mithracin;B-brand;B-DDI-DrugBank.d179.s22.e1
);O;O
or;O;O
DDI-DrugBank.d179.s23;;
-;O;O
Valproic;B-drug;B-DDI-DrugBank.d179.s23.e0
acid;I-drug;I-DDI-DrugBank.d179.s23.e0
(;O;O
e.g.;O;O
,;O;O
Depakene;B-brand;B-DDI-DrugBank.d179.s23.e1
);O;O
Use;O;O
of;O;O
sulfapyridine;B-drug;B-DDI-DrugBank.d179.s23.e2
with;O;O
these;O;O
medicines;O;O
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
affecting;O;O
the;O;O
liver;O;O
DDI-DrugBank.d179.s24;;
-;O;O
Acetohydroxamic;B-drug;B-DDI-DrugBank.d179.s24.e0
acid;I-drug;I-DDI-DrugBank.d179.s24.e0
(;O;O
e.g.;O;O
,;O;O
Lithostat;B-brand;B-DDI-DrugBank.d179.s24.e1
);O;O
or;O;O
DDI-DrugBank.d179.s25;;
-;O;O
Dapsone;B-drug;B-DDI-DrugBank.d179.s25.e0
or;O;O
DDI-DrugBank.d179.s26;;
-;O;O
Furazolidone;B-drug;B-DDI-DrugBank.d179.s26.e0
(;O;O
e.g.;O;O
,;O;O
Furoxone;B-brand;B-DDI-DrugBank.d179.s26.e1
);O;O
or;O;O
DDI-DrugBank.d179.s27;;
-;O;O
Nitrofurantoin;B-drug;B-DDI-DrugBank.d179.s27.e0
(;O;O
e.g.;O;O
,;O;O
Furadantin;B-brand;B-DDI-DrugBank.d179.s27.e1
);O;O
or;O;O
DDI-DrugBank.d179.s28;;
-;O;O
Primaquine;B-drug;B-DDI-DrugBank.d179.s28.e0
or;O;O
DDI-DrugBank.d179.s29;;
-;O;O
Procainamide;B-drug;B-DDI-DrugBank.d179.s29.e0
(;O;O
e.g.;O;O
,;O;O
Pronestyl;B-brand;B-DDI-DrugBank.d179.s29.e1
);O;O
or;O;O
DDI-DrugBank.d179.s30;;
-;O;O
Quinidine;B-drug;B-DDI-DrugBank.d179.s30.e0
(;O;O
e.g.;O;O
,;O;O
Quinidex;B-brand;B-DDI-DrugBank.d179.s30.e1
);O;O
or;O;O
DDI-DrugBank.d179.s31;;
-;O;O
Quinine;B-drug;B-DDI-DrugBank.d179.s31.e0
(;O;O
e.g.;O;O
,;O;O
Quinamm;B-brand;B-DDI-DrugBank.d179.s31.e1
);O;O
or;O;O
DDI-DrugBank.d179.s32;;
-;O;O
Sulfoxone;B-drug;B-DDI-DrugBank.d179.s32.e0
(;O;O
e.g.;O;O
,;O;O
Diasone;B-brand;B-DDI-DrugBank.d179.s32.e1
);O;O
or;O;O
DDI-DrugBank.d179.s33;;
-;O;O
Vitamin;B-group;B-DDI-DrugBank.d179.s33.e0
K;I-group;I-DDI-DrugBank.d179.s33.e0
(;O;O
e.g.;O;O
,;O;O
AquaMEPHYTON;B-brand;B-DDI-DrugBank.d179.s33.e1
,;O;O
Synkayvite;B-brand;B-DDI-DrugBank.d179.s33.e2
);O;O
Use;O;O
of;O;O
sulfapyridine;B-drug;B-DDI-DrugBank.d179.s33.e3
with;O;O
these;O;O
medicines;O;O
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
affecting;O;O
the;O;O
blood;O;O
DDI-DrugBank.d179.s34;;
-;O;O
Anticoagulants;B-group;B-DDI-DrugBank.d179.s34.e0
(;O;O
blood;B-group;B-DDI-DrugBank.d179.s34.e1
thinners;I-group;I-DDI-DrugBank.d179.s34.e1
);O;O
or;O;O
DDI-DrugBank.d179.s35;;
-;O;O
Ethotoin;B-drug;B-DDI-DrugBank.d179.s35.e0
(;O;O
e.g.;O;O
,;O;O
Peganone;B-brand;B-DDI-DrugBank.d179.s35.e1
);O;O
or;O;O
DDI-DrugBank.d179.s36;;
-;O;O
Mephenytoin;B-drug;B-DDI-DrugBank.d179.s36.e0
(;O;O
e.g.;O;O
,;O;O
Mesantoin;B-brand;B-DDI-DrugBank.d179.s36.e1
);O;O
Use;O;O
of;O;O
sulfapyridine;B-drug;B-DDI-DrugBank.d179.s36.e2
with;O;O
these;O;O
medicines;O;O
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
of;O;O
these;O;O
medicines;O;O
DDI-DrugBank.d179.s37;;
-;O;O
Antidiabetics;B-group;B-DDI-DrugBank.d179.s37.e0
,;O;O
oral;O;O
(;O;O
diabetes;O;O
medicine;O;O
you;O;O
take;O;O
by;O;O
mouth;O;O
);O;O
Use;O;O
of;O;O
oral;O;O
antidiabetics;B-group;B-DDI-DrugBank.d179.s37.e1
with;O;O
sulfapyridine;B-drug;B-DDI-DrugBank.d179.s37.e2
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
affecting;O;O
the;O;O
blood;O;O
and/or;O;O
the;O;O
side;O;O
effects;O;O
or;O;O
oral;O;O
antidiabetics;B-group;B-DDI-DrugBank.d179.s37.e3
DDI-DrugBank.d179.s38;;
-;O;O
Methotrexate;B-drug;B-DDI-DrugBank.d179.s38.e0
(;O;O
e.g.;O;O
,;O;O
Mexate;B-brand;B-DDI-DrugBank.d179.s38.e1
);O;O
Use;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d179.s38.e2
with;O;O
sulfapyridine;B-drug;B-DDI-DrugBank.d179.s38.e3
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
affecting;O;O
the;O;O
liver;O;O
and/or;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d179.s38.e4
DDI-DrugBank.d179.s39;;
-;O;O
Methyldopa;B-drug;B-DDI-DrugBank.d179.s39.e0
(;O;O
e.g.;O;O
,;O;O
Aldomet;B-brand;B-DDI-DrugBank.d179.s39.e1
);O;O
Use;O;O
of;O;O
methyldopa;B-drug;B-DDI-DrugBank.d179.s39.e2
with;O;O
sulfapyridine;B-drug;B-DDI-DrugBank.d179.s39.e3
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
affecting;O;O
the;O;O
liver;O;O
and/or;O;O
the;O;O
blood;O;O
DDI-DrugBank.d179.s40;;
-;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d179.s40.e0
(;O;O
e.g.;O;O
,;O;O
Dilantin;B-brand;B-DDI-DrugBank.d179.s40.e1
);O;O
Use;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d179.s40.e2
with;O;O
sulfapyridine;B-drug;B-DDI-DrugBank.d179.s40.e3
may;O;O
increase;O;O
the;O;O
chance;O;O
of;O;O
side;O;O
effects;O;O
affecting;O;O
the;O;O
liver;O;O
and/or;O;O
the;O;O
side;O;O
effects;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d179.s40.e4
DDI-DrugBank.d277.s0;;
In;O;O
evaluating;O;O
the;O;O
potential;O;O
for;O;O
interactions;O;O
among;O;O
co;O;O
-;O;O
administered;O;O
antiepilepsy;O;O
drugs;O;O
(;O;O
AEDs;B-group;B-DDI-DrugBank.d277.s0.e0
);O;O
,;O;O
whether;O;O
or;O;O
not;O;O
an;O;O
AED;B-group;B-DDI-DrugBank.d277.s0.e1
induces;O;O
or;O;O
does;O;O
not;O;O
induce;O;O
metabolic;O;O
enzymes;O;O
is;O;O
an;O;O
important;O;O
consideration;O;O
.;O;O
DDI-DrugBank.d277.s1;;
Phenytoin;B-drug;B-DDI-DrugBank.d277.s1.e0
,;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d277.s1.e1
and;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d277.s1.e2
are;O;O
ge;O;O
nerally;O;O
classified;O;O
as;O;O
enzyme;O;O
inducers;O;O
,;O;O
DDI-DrugBank.d277.s2;;
valproate;B-drug;B-DDI-DrugBank.d277.s2.e0
and;O;O
gabapentin;B-drug;B-DDI-DrugBank.d277.s2.e1
are;O;O
not;O;O
.;O;O
DDI-DrugBank.d277.s3;;
GABITRIL;B-brand;B-DDI-DrugBank.d277.s3.e0
is;O;O
considered;O;O
to;O;O
be;O;O
a;O;O
non;O;O
-;O;O
enzyme;O;O
inducing;O;O
AED;B-group;B-DDI-DrugBank.d277.s3.e1
.;O;O
DDI-DrugBank.d277.s4;;
The;O;O
drug;O;O
interaction;O;O
data;O;O
described;O;O
in;O;O
this;O;O
section;O;O
were;O;O
obtained;O;O
from;O;O
studies;O;O
involving;O;O
either;O;O
healthy;O;O
subjects;O;O
or;O;O
patients;O;O
with;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d277.s5;;
Effects;O;O
of;O;O
GABITRIL;B-brand;B-DDI-DrugBank.d277.s5.e0
on;O;O
other;O;O
Antiepilepsy;O;O
Drugs;O;O
(;O;O
AEDs;B-group;B-DDI-DrugBank.d277.s5.e1
);O;O
:;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d277.s5.e2
:;O;O
Tiagabine;B-drug;B-DDI-DrugBank.d277.s5.e3
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
plasma;O;O
concentrations;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d277.s5.e4
in;O;O
patients;O;O
with;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d277.s6;;
Carbamazepine;B-drug;B-DDI-DrugBank.d277.s6.e0
:;O;O
Tiagabine;B-drug;B-DDI-DrugBank.d277.s6.e1
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
plasma;O;O
concentrations;O;O
of;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d277.s6.e2
or;O;O
its;O;O
epoxide;O;O
metabolite;O;O
in;O;O
patients;O;O
with;O;O
epilepsy;O;O
.;O;O
DDI-DrugBank.d277.s7;;
Valproate;B-drug;B-DDI-DrugBank.d277.s7.e0
:;O;O
Tiagabine;B-drug;B-DDI-DrugBank.d277.s7.e1
causes;O;O
a;O;O
slight;O;O
decrease;O;O
(;O;O
about;O;O
10;O;O
%;O;O
);O;O
in;O;O
steady;O;O
-;O;O
state;O;O
valproate;B-drug;B-DDI-DrugBank.d277.s7.e2
concentrations;O;O
.;O;O
DDI-DrugBank.d277.s8;;
Phenobarbital;B-drug;B-DDI-DrugBank.d277.s8.e0
or;O;O
Primidone;B-drug;B-DDI-DrugBank.d277.s8.e1
:;O;O
No;O;O
formal;O;O
pharmacokinetic;O;O
studies;O;O
have;O;O
been;O;O
performed;O;O
examining;O;O
the;O;O
addition;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s8.e2
to;O;O
regimens;O;O
containing;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d277.s8.e3
or;O;O
primidone;B-drug;B-DDI-DrugBank.d277.s8.e4
.;O;O
DDI-DrugBank.d277.s9;;
The;O;O
addition;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s9.e0
in;O;O
a;O;O
limited;O;O
number;O;O
of;O;O
patients;O;O
in;O;O
three;O;O
well;O;O
-;O;O
controlled;O;O
studies;O;O
caused;O;O
no;O;O
systematic;O;O
changes;O;O
in;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d277.s9.e1
or;O;O
primidone;B-drug;B-DDI-DrugBank.d277.s9.e2
concentrations;O;O
when;O;O
compared;O;O
to;O;O
placebo;O;O
.;O;O
DDI-DrugBank.d277.s10;;
Effects;O;O
of;O;O
other;O;O
Antiepilepsy;O;O
Drugs;O;O
(;O;O
AEDs;B-group;B-DDI-DrugBank.d277.s10.e0
);O;O
on;O;O
GABITRIL;B-brand;B-DDI-DrugBank.d277.s10.e1
:;O;O
Carbamazepine;B-drug;B-DDI-DrugBank.d277.s10.e2
:;O;O
Population;O;O
pharmacokinetic;O;O
analyses;O;O
indicate;O;O
that;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s10.e3
clearance;O;O
is;O;O
60;O;O
%;O;O
greater;O;O
in;O;O
patients;O;O
taking;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d277.s10.e4
with;O;O
or;O;O
without;O;O
other;O;O
enzyme;O;O
-;O;O
inducing;O;O
AEDs;B-group;B-DDI-DrugBank.d277.s10.e5
.;O;O
DDI-DrugBank.d277.s11;;
Phenytoin;B-drug;B-DDI-DrugBank.d277.s11.e0
:;O;O
Population;O;O
pharmacokinetic;O;O
analyses;O;O
indicate;O;O
that;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s11.e1
clearance;O;O
is;O;O
60;O;O
%;O;O
greater;O;O
in;O;O
patients;O;O
taking;O;O
phenytoin;B-drug;B-DDI-DrugBank.d277.s11.e2
with;O;O
or;O;O
without;O;O
other;O;O
enzyme;O;O
-;O;O
inducing;O;O
AEDs;B-group;B-DDI-DrugBank.d277.s11.e3
.;O;O
DDI-DrugBank.d277.s12;;
Phenobarbital;B-drug;B-DDI-DrugBank.d277.s12.e0
(;O;O
Primidone;B-drug;B-DDI-DrugBank.d277.s12.e1
);O;O
:;O;O
Population;O;O
pharmacokinetic;O;O
analyses;O;O
indicate;O;O
that;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s12.e2
clearance;O;O
is;O;O
60;O;O
%;O;O
greater;O;O
in;O;O
patients;O;O
taking;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d277.s12.e3
(;O;O
primidone;B-drug;B-DDI-DrugBank.d277.s12.e4
);O;O
with;O;O
or;O;O
without;O;O
other;O;O
enzyme;O;O
-;O;O
inducing;O;O
AEDs;B-group;B-DDI-DrugBank.d277.s12.e5
.;O;O
DDI-DrugBank.d277.s13;;
Valproate;B-drug;B-DDI-DrugBank.d277.s13.e0
:;O;O
The;O;O
addition;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s13.e1
to;O;O
patients;O;O
taking;O;O
valproate;B-drug;B-DDI-DrugBank.d277.s13.e2
chronically;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s13.e3
pharmacokinetics;O;O
,;O;O
but;O;O
valproate;B-drug;B-DDI-DrugBank.d277.s13.e4
significantly;O;O
decreased;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s13.e5
binding;O;O
in;O;O
vitro;O;O
from;O;O
96.3;O;O
to;O;O
94.8;O;O
%;O;O
,;O;O
which;O;O
resulted;O;O
in;O;O
an;O;O
increase;O;O
of;O;O
approximately;O;O
40;O;O
%;O;O
in;O;O
the;O;O
free;O;O
tiagabine;O;O
concentration;O;O
.;O;O
DDI-DrugBank.d277.s14;;
The;O;O
clinical;O;O
relevance;O;O
of;O;O
this;O;O
in;O;O
vitro;O;O
finding;O;O
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d277.s15;;
Interaction;O;O
of;O;O
GABITRIL;B-brand;B-DDI-DrugBank.d277.s15.e0
with;O;O
Other;O;O
Drugs;O;O
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d277.s15.e1
:;O;O
Co;O;O
-;O;O
administration;O;O
of;O;O
cimetidine;B-drug;B-DDI-DrugBank.d277.s15.e2
(;O;O
800;O;O
mg;O;O
/;O;O
day;O;O
);O;O
to;O;O
patients;O;O
taking;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s15.e3
chronically;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s15.e4
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d277.s16;;
Theophylline;B-drug;B-DDI-DrugBank.d277.s16.e0
:;O;O
A;O;O
single;O;O
10;O;O
mg;O;O
dose;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s16.e1
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
theophylline;B-drug;B-DDI-DrugBank.d277.s16.e2
at;O;O
steady;O;O
state;O;O
.;O;O
DDI-DrugBank.d277.s17;;
Warfarin;B-drug;B-DDI-DrugBank.d277.s17.e0
:;O;O
No;O;O
significant;O;O
differences;O;O
were;O;O
observed;O;O
in;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
pharmacokinetics;O;O
of;O;O
R;B-drug;B-DDI-DrugBank.d277.s17.e1
-;I-drug;I-DDI-DrugBank.d277.s17.e1
warfarin;I-drug;I-DDI-DrugBank.d277.s17.e1
or;O;O
S;B-drug;B-DDI-DrugBank.d277.s17.e2
-;I-drug;I-DDI-DrugBank.d277.s17.e2
warfarin;I-drug;I-DDI-DrugBank.d277.s17.e2
with;O;O
the;O;O
addition;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s17.e3
given;O;O
as;O;O
a;O;O
single;O;O
dose;O;O
.;O;O
DDI-DrugBank.d277.s18;;
Prothrombin;O;O
times;O;O
were;O;O
not;O;O
affected;O;O
by;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s18.e0
.;O;O
DDI-DrugBank.d277.s19;;
Digoxin;B-drug;B-DDI-DrugBank.d277.s19.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s19.e1
did;O;O
not;O;O
affect;O;O
the;O;O
steady;O;O
-;O;O
state;O;O
pharmacokinetics;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d277.s19.e2
or;O;O
the;O;O
mean;O;O
daily;O;O
trough;O;O
serum;O;O
level;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d277.s19.e3
.;O;O
DDI-DrugBank.d277.s20;;
Ethanol;B-drug;B-DDI-DrugBank.d277.s20.e0
or;O;O
Triazolam;B-drug;B-DDI-DrugBank.d277.s20.e1
:;O;O
No;O;O
significant;O;O
differences;O;O
were;O;O
observed;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
triazolam;B-drug;B-DDI-DrugBank.d277.s20.e2
(;O;O
0.125;O;O
mg;O;O
);O;O
and;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s20.e3
(;O;O
10;O;O
mg;O;O
);O;O
when;O;O
given;O;O
together;O;O
as;O;O
a;O;O
single;O;O
dose;O;O
.;O;O
DDI-DrugBank.d277.s21;;
The;O;O
pharmacokinetics;O;O
of;O;O
ethanol;B-drug;B-DDI-DrugBank.d277.s21.e0
were;O;O
not;O;O
affected;O;O
by;O;O
multiple;O;O
-;O;O
dose;O;O
administration;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s21.e1
.;O;O
DDI-DrugBank.d277.s22;;
Tiagabine;B-drug;B-DDI-DrugBank.d277.s22.e0
has;O;O
shown;O;O
no;O;O
clinically;O;O
important;O;O
potentiation;O;O
of;O;O
the;O;O
pharmacodynamic;O;O
effects;O;O
of;O;O
triazo;O;O
lam;O;O
or;O;O
alcohol;B-drug;B-DDI-DrugBank.d277.s22.e1
.;O;O
DDI-DrugBank.d277.s23;;
Because;O;O
of;O;O
the;O;O
possible;O;O
additive;O;O
effects;O;O
of;O;O
drugs;O;O
that;O;O
may;O;O
depress;O;O
the;O;O
nervous;O;O
system;O;O
,;O;O
ethanol;B-drug;B-DDI-DrugBank.d277.s23.e0
or;O;O
triazolam;B-drug;B-DDI-DrugBank.d277.s23.e1
should;O;O
be;O;O
used;O;O
cautiously;O;O
in;O;O
combination;O;O
with;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s23.e2
.;O;O
DDI-DrugBank.d277.s24;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d277.s24.e0
:;O;O
Multiple;O;O
dose;O;O
administration;O;O
of;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s24.e1
(;O;O
8;O;O
mg;O;O
/;O;O
day;O;O
monotherapy;O;O
);O;O
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
oral;O;O
contraceptives;B-group;B-DDI-DrugBank.d277.s24.e2
in;O;O
healthy;O;O
women;O;O
of;O;O
childbearing;O;O
age;O;O
.;O;O
DDI-DrugBank.d277.s25;;
Antipyrine;B-drug;B-DDI-DrugBank.d277.s25.e0
:;O;O
Antipyrine;B-drug;B-DDI-DrugBank.d277.s25.e1
pharmacokinetics;O;O
were;O;O
not;O;O
significantly;O;O
different;O;O
before;O;O
and;O;O
after;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s25.e2
multiple;O;O
-;O;O
dose;O;O
regimens;O;O
.;O;O
DDI-DrugBank.d277.s26;;
This;O;O
indicates;O;O
that;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s26.e0
does;O;O
not;O;O
cause;O;O
induction;O;O
or;O;O
inhibition;O;O
of;O;O
the;O;O
hepatic;O;O
microsomal;O;O
enzyme;O;O
systems;O;O
responsible;O;O
for;O;O
the;O;O
metabolism;O;O
of;O;O
antipyrine;B-drug;B-DDI-DrugBank.d277.s26.e1
.;O;O
DDI-DrugBank.d277.s27;;
Interaction;O;O
of;O;O
GABITRIL;B-brand;B-DDI-DrugBank.d277.s27.e0
with;O;O
Highly;O;O
Protein;O;O
Bound;O;O
Drugs;O;O
:;O;O
In;O;O
vitro;O;O
data;O;O
showed;O;O
that;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s27.e1
is;O;O
96;O;O
%;O;O
bound;O;O
to;O;O
human;O;O
plasma;O;O
protein;O;O
and;O;O
therefore;O;O
has;O;O
the;O;O
potential;O;O
to;O;O
interact;O;O
with;O;O
other;O;O
highly;O;O
protein;O;O
bound;O;O
compounds;O;O
.;O;O
DDI-DrugBank.d277.s28;;
Such;O;O
an;O;O
interaction;O;O
can;O;O
potentially;O;O
lead;O;O
to;O;O
higher;O;O
free;O;O
fractions;O;O
of;O;O
either;O;O
tiagabine;B-drug;B-DDI-DrugBank.d277.s28.e0
or;O;O
the;O;O
competing;O;O
drug;O;O
.;O;O
DDI-DrugBank.d328.s0;;
The;O;O
drug;O;O
interaction;O;O
studies;O;O
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s0.e0
were;O;O
performed;O;O
both;O;O
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s0.e1
and;O;O
a;O;O
rapidly;O;O
hydrolyzed;O;O
intravenous;O;O
prodrug;O;O
form;O;O
.;O;O
DDI-DrugBank.d328.s1;;
The;O;O
results;O;O
from;O;O
trials;O;O
using;O;O
the;O;O
intravenous;O;O
prodrug;O;O
are;O;O
reported;O;O
in;O;O
this;O;O
section;O;O
as;O;O
they;O;O
relate;O;O
to;O;O
the;O;O
role;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s1.e0
in;O;O
drug;O;O
interactions;O;O
.;O;O
DDI-DrugBank.d328.s2;;
General;O;O
:;O;O
In;O;O
humans;O;O
,;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s2.e0
metabolism;O;O
is;O;O
predominantly;O;O
mediated;O;O
via;O;O
CYP;O;O
3A4;O;O
and;O;O
2C9;O;O
with;O;O
glucuronidation;O;O
being;O;O
a;O;O
further;O;O
(;O;O
20;O;O
%;O;O
);O;O
route;O;O
of;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d328.s3;;
In;O;O
vitro;O;O
studies;O;O
indicate;O;O
that;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s3.e0
is;O;O
a;O;O
moderate;O;O
inhibitor;O;O
of;O;O
CYP;O;O
2C19;O;O
(;O;O
IC50;O;O
=;O;O
6;O;O
g;O;O
/;O;O
mL;O;O
or;O;O
19;O;O
M;O;O
);O;O
and;O;O
2C9;O;O
(;O;O
IC50;O;O
=;O;O
13;O;O
g;O;O
/;O;O
mL;O;O
or;O;O
41;O;O
M;O;O
);O;O
,;O;O
and;O;O
a;O;O
weak;O;O
inhibitor;O;O
of;O;O
CYP;O;O
2D6;O;O
(;O;O
IC50;O;O
=;O;O
31;O;O
g;O;O
/;O;O
mL;O;O
or;O;O
100;O;O
M;O;O
);O;O
and;O;O
3A4;O;O
(;O;O
IC50;O;O
=;O;O
44;O;O
g;O;O
/;O;O
mL;O;O
or;O;O
141;O;O
M;O;O
);O;O
..;O;O
DDI-DrugBank.d328.s4;;
Aspirin;B-brand;B-DDI-DrugBank.d328.s4.e0
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
aspirin;B-brand;B-DDI-DrugBank.d328.s4.e1
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s4.e2
may;O;O
result;O;O
in;O;O
an;O;O
increased;O;O
risk;O;O
of;O;O
GI;O;O
ulceration;O;O
and;O;O
complications;O;O
compared;O;O
to;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s4.e3
alone;O;O
.;O;O
DDI-DrugBank.d328.s5;;
Because;O;O
of;O;O
its;O;O
lack;O;O
of;O;O
anti;O;O
-;O;O
platelet;O;O
effect;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s5.e0
is;O;O
not;O;O
a;O;O
substitute;O;O
for;O;O
aspirin;B-brand;B-DDI-DrugBank.d328.s5.e1
for;O;O
cardiovascular;O;O
prophylaxis;O;O
.;O;O
DDI-DrugBank.d328.s6;;
In;O;O
a;O;O
parallel;O;O
group;O;O
drug;O;O
interaction;O;O
study;O;O
comparing;O;O
the;O;O
intravenous;O;O
prodrug;O;O
form;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s6.e0
at;O;O
40;O;O
mg;O;O
BID;O;O
(;O;O
n=10;O;O
);O;O
vs;O;O
placebo;O;O
(;O;O
n=9;O;O
);O;O
,;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s6.e1
had;O;O
no;O;O
effect;O;O
on;O;O
in;O;O
vitro;O;O
aspirin;B-brand;B-DDI-DrugBank.d328.s6.e2
-;O;O
mediated;O;O
inhibition;O;O
of;O;O
arachidonate;O;O
-;O;O
or;O;O
collagen;O;O
-;O;O
stimulated;O;O
platelet;O;O
aggregation;O;O
.;O;O
DDI-DrugBank.d328.s7;;
Methotrexate;B-drug;B-DDI-DrugBank.d328.s7.e0
:;O;O
Valdecoxib;B-drug;B-DDI-DrugBank.d328.s7.e1
10;I-drug;I-DDI-DrugBank.d328.s7.e1
mg;I-drug;I-DDI-DrugBank.d328.s7.e1
BID;O;O
did;O;O
not;O;O
show;O;O
a;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
plasma;O;O
exposure;O;O
or;O;O
renal;O;O
clearance;O;O
of;O;O
methotrexate;B-drug;B-DDI-DrugBank.d328.s7.e2
.;O;O
DDI-DrugBank.d328.s8;;
ACE;B-group;B-DDI-DrugBank.d328.s8.e0
-;I-group;I-DDI-DrugBank.d328.s8.e0
inhibitors;I-group;I-DDI-DrugBank.d328.s8.e0
:;O;O
Reports;O;O
suggest;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d328.s8.e1
may;O;O
diminish;O;O
the;O;O
antihypertensive;O;O
effect;O;O
of;O;O
ACE;B-group;B-DDI-DrugBank.d328.s8.e2
-;I-group;I-DDI-DrugBank.d328.s8.e2
inhibitors;I-group;I-DDI-DrugBank.d328.s8.e2
.;O;O
DDI-DrugBank.d328.s9;;
This;O;O
interaction;O;O
should;O;O
be;O;O
given;O;O
consideration;O;O
in;O;O
patients;O;O
taking;O;O
BEXTRA;B-brand;B-DDI-DrugBank.d328.s9.e0
concomitantly;O;O
with;O;O
ACE;B-group;B-DDI-DrugBank.d328.s9.e1
-;I-group;I-DDI-DrugBank.d328.s9.e1
inhibitors;I-group;I-DDI-DrugBank.d328.s9.e1
.;O;O
DDI-DrugBank.d328.s10;;
Furosemide;B-drug;B-DDI-DrugBank.d328.s10.e0
:;O;O
Clinical;O;O
studies;O;O
,;O;O
as;O;O
well;O;O
as;O;O
post;O;O
-;O;O
marketing;O;O
observations;O;O
,;O;O
have;O;O
shown;O;O
that;O;O
NSAIDs;B-group;B-DDI-DrugBank.d328.s10.e1
can;O;O
reduce;O;O
the;O;O
natriuretic;O;O
effect;O;O
of;O;O
furosemide;B-drug;B-DDI-DrugBank.d328.s10.e2
and;O;O
thiazides;B-group;B-DDI-DrugBank.d328.s10.e3
in;O;O
some;O;O
patients;O;O
.;O;O
DDI-DrugBank.d328.s11;;
This;O;O
response;O;O
has;O;O
been;O;O
attributed;O;O
to;O;O
inhibition;O;O
of;O;O
renal;O;O
prostaglandin;O;O
synthesis;O;O
.;O;O
DDI-DrugBank.d328.s12;;
Anticonvulsants;B-group;B-DDI-DrugBank.d328.s12.e0
(;O;O
Phenytoin;B-drug;B-DDI-DrugBank.d328.s12.e1
);O;O
:;O;O
Steady;O;O
state;O;O
plasma;O;O
exposure;O;O
(;O;O
AUC;O;O
);O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s12.e2
(;O;O
40;O;O
mg;O;O
BID;O;O
for;O;O
12;O;O
days;O;O
);O;O
was;O;O
decreased;O;O
by;O;O
27;O;O
%;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
multiple;O;O
doses;O;O
(;O;O
300;O;O
mg;O;O
QD;O;O
for;O;O
12;O;O
days;O;O
);O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d328.s12.e3
(;O;O
a;O;O
CYP;O;O
3A4;O;O
inducer;O;O
);O;O
.;O;O
DDI-DrugBank.d328.s13;;
Patients;O;O
already;O;O
stabilized;O;O
on;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s13.e0
should;O;O
be;O;O
closely;O;O
monitored;O;O
for;O;O
loss;O;O
of;O;O
symptom;O;O
control;O;O
with;O;O
phenytoin;B-drug;B-DDI-DrugBank.d328.s13.e1
coadministration;O;O
.;O;O
DDI-DrugBank.d328.s14;;
Valdecoxib;B-drug;B-DDI-DrugBank.d328.s14.e0
did;O;O
not;O;O
have;O;O
a;O;O
statistically;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
phenytoin;B-drug;B-DDI-DrugBank.d328.s14.e1
(;O;O
a;O;O
CYP;O;O
2C9;O;O
and;O;O
CYP;O;O
2C19;O;O
substrate;O;O
);O;O
.;O;O
DDI-DrugBank.d328.s15;;
Drug;O;O
interaction;O;O
studies;O;O
with;O;O
other;O;O
anticonvulsants;B-group;B-DDI-DrugBank.d328.s15.e0
have;O;O
not;O;O
been;O;O
conducted;O;O
.;O;O
DDI-DrugBank.d328.s16;;
Routine;O;O
monitoring;O;O
should;O;O
be;O;O
performed;O;O
when;O;O
therapy;O;O
with;O;O
BEXTRA;B-brand;B-DDI-DrugBank.d328.s16.e0
is;O;O
either;O;O
initiated;O;O
or;O;O
discontinued;O;O
in;O;O
patients;O;O
on;O;O
anticonvulsant;O;O
therapy;O;O
.;O;O
DDI-DrugBank.d328.s17;;
Dextromethorphan;B-drug;B-DDI-DrugBank.d328.s17.e0
:;O;O
Dextromethorphan;B-drug;B-DDI-DrugBank.d328.s17.e1
is;O;O
primarily;O;O
metabolized;O;O
by;O;O
CYP;O;O
2D6;O;O
and;O;O
to;O;O
a;O;O
lesser;O;O
extent;O;O
by;O;O
3A4;O;O
.;O;O
DDI-DrugBank.d328.s18;;
Coadministration;O;O
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s18.e0
(;O;O
40;O;O
mg;O;O
BID;O;O
for;O;O
7;O;O
days;O;O
);O;O
resulted;O;O
in;O;O
a;O;O
significant;O;O
increase;O;O
in;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d328.s18.e1
plasma;O;O
levels;O;O
suggesting;O;O
that;O;O
,;O;O
at;O;O
these;O;O
doses;O;O
,;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s18.e2
is;O;O
a;O;O
weak;O;O
inhibitor;O;O
of;O;O
2D6;O;O
.;O;O
DDI-DrugBank.d328.s19;;
Even;O;O
so;O;O
dextromethorphan;B-drug;B-DDI-DrugBank.d328.s19.e0
plasma;O;O
concentrations;O;O
in;O;O
the;O;O
presence;O;O
of;O;O
high;O;O
doses;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s19.e1
were;O;O
almost;O;O
5;O;O
-;O;O
fold;O;O
lower;O;O
than;O;O
those;O;O
seen;O;O
in;O;O
CYP;O;O
2D6;O;O
poor;O;O
metabolizers;O;O
suggesting;O;O
that;O;O
dose;O;O
adjustment;O;O
is;O;O
not;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d328.s20;;
Lithium;B-drug;B-DDI-DrugBank.d328.s20.e0
:;O;O
Valdecoxib;B-drug;B-DDI-DrugBank.d328.s20.e1
40;O;O
mg;O;O
BID;O;O
for;O;O
7;O;O
days;O;O
produced;O;O
significant;O;O
decreases;O;O
in;O;O
lithium;B-drug;B-DDI-DrugBank.d328.s20.e2
serum;O;O
clearance;O;O
(;O;O
25;O;O
%;O;O
);O;O
and;O;O
renal;O;O
clearance;O;O
(;O;O
30;O;O
%;O;O
);O;O
with;O;O
a;O;O
34;O;O
%;O;O
higher;O;O
serum;O;O
exposure;O;O
compared;O;O
to;O;O
lithium;B-drug;B-DDI-DrugBank.d328.s20.e3
alone;O;O
.;O;O
DDI-DrugBank.d328.s21;;
Lithium;B-drug;B-DDI-DrugBank.d328.s21.e0
serum;O;O
concentrations;O;O
should;O;O
be;O;O
monitored;O;O
closely;O;O
when;O;O
initiating;O;O
or;O;O
changing;O;O
therapy;O;O
with;O;O
BEXTRA;B-brand;B-DDI-DrugBank.d328.s21.e1
in;O;O
patients;O;O
receiving;O;O
lithium;B-drug;B-DDI-DrugBank.d328.s21.e2
.;O;O
DDI-DrugBank.d328.s22;;
Lithium;B-drug;B-DDI-DrugBank.d328.s22.e0
carbonate;I-drug;I-DDI-DrugBank.d328.s22.e0
(;O;O
450;O;O
mg;O;O
BID;O;O
for;O;O
7;O;O
days;O;O
);O;O
had;O;O
no;O;O
effect;O;O
on;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s22.e1
pharmacokinetics;O;O
.;O;O
DDI-DrugBank.d328.s23;;
Warfarin;B-drug;B-DDI-DrugBank.d328.s23.e0
:;O;O
The;O;O
effect;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s23.e1
on;O;O
the;O;O
anticoagulant;O;O
effect;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d328.s23.e2
(;O;O
1;O;O
-;O;O
8;O;O
mg;O;O
/;O;O
day;O;O
);O;O
was;O;O
studied;O;O
in;O;O
healthy;O;O
subjects;O;O
by;O;O
coadministration;O;O
of;O;O
BEXTRA;B-brand;B-DDI-DrugBank.d328.s23.e3
40;O;O
mg;O;O
BID;O;O
for;O;O
7;O;O
days;O;O
.;O;O
DDI-DrugBank.d328.s24;;
Valdecoxib;B-drug;B-DDI-DrugBank.d328.s24.e0
caused;O;O
a;O;O
statistically;O;O
significant;O;O
increase;O;O
in;O;O
plasma;O;O
exposures;O;O
of;O;O
R;B-drug;B-DDI-DrugBank.d328.s24.e1
-;I-drug;I-DDI-DrugBank.d328.s24.e1
warfarin;I-drug;I-DDI-DrugBank.d328.s24.e1
and;O;O
S;B-drug;B-DDI-DrugBank.d328.s24.e2
-;I-drug;I-DDI-DrugBank.d328.s24.e2
warfarin;I-drug;I-DDI-DrugBank.d328.s24.e2
(;O;O
12;O;O
%;O;O
and;O;O
15;O;O
%;O;O
,;O;O
respectively;O;O
);O;O
,;O;O
and;O;O
in;O;O
the;O;O
pharmacodynamic;O;O
effects;O;O
(;O;O
prothrombin;O;O
time;O;O
,;O;O
measured;O;O
as;O;O
INR;O;O
);O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d328.s24.e3
.;O;O
DDI-DrugBank.d328.s25;;
While;O;O
mean;O;O
INR;O;O
values;O;O
were;O;O
only;O;O
slightly;O;O
increased;O;O
with;O;O
coadministration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s25.e0
,;O;O
the;O;O
day;O;O
-;O;O
to;O;O
-;O;O
day;O;O
variability;O;O
in;O;O
individual;O;O
INR;O;O
values;O;O
was;O;O
increased;O;O
.;O;O
DDI-DrugBank.d328.s26;;
Anticoagulant;B-brand;B-DDI-DrugBank.d328.s26.e0
therapy;O;O
should;O;O
be;O;O
monitored;O;O
,;O;O
particularly;O;O
during;O;O
the;O;O
first;O;O
few;O;O
weeks;O;O
,;O;O
after;O;O
initiating;O;O
therapy;O;O
with;O;O
BEXTRA;B-brand;B-DDI-DrugBank.d328.s26.e1
in;O;O
patients;O;O
receiving;O;O
warfarin;B-drug;B-DDI-DrugBank.d328.s26.e2
or;O;O
similar;O;O
agents;O;O
.;O;O
DDI-DrugBank.d328.s27;;
Fluconazole;B-drug;B-DDI-DrugBank.d328.s27.e0
and;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d328.s27.e1
:;O;O
Ketoconazole;B-drug;B-DDI-DrugBank.d328.s27.e2
and;O;O
fluconazole;B-drug;B-DDI-DrugBank.d328.s27.e3
are;O;O
predominantly;O;O
CYP;O;O
3A4;O;O
and;O;O
2C9;O;O
inhibitors;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d328.s28;;
Concomitant;O;O
single;O;O
dose;O;O
administration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s28.e0
20;O;O
mg;O;O
with;O;O
multiple;O;O
doses;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d328.s28.e1
and;O;O
fluconazole;B-drug;B-DDI-DrugBank.d328.s28.e2
produced;O;O
a;O;O
significant;O;O
increase;O;O
in;O;O
exposure;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s28.e3
.;O;O
DDI-DrugBank.d328.s29;;
Plasma;O;O
exposure;O;O
(;O;O
AUC;O;O
);O;O
to;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s29.e0
was;O;O
increased;O;O
62;O;O
%;O;O
when;O;O
coadministered;O;O
with;O;O
fluconazole;B-drug;B-DDI-DrugBank.d328.s29.e1
and;O;O
38;O;O
%;O;O
when;O;O
coadministered;O;O
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d328.s29.e2
.;O;O
DDI-DrugBank.d328.s30;;
Glyburide;B-drug;B-DDI-DrugBank.d328.s30.e0
:;O;O
Glyburide;B-drug;B-DDI-DrugBank.d328.s30.e1
is;O;O
a;O;O
CYP;O;O
2C9;O;O
substrate;O;O
.;O;O
DDI-DrugBank.d328.s31;;
Coadministration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s31.e0
(;O;O
10;O;O
mg;O;O
BID;O;O
for;O;O
7;O;O
days;O;O
);O;O
with;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s31.e1
(;O;O
5;O;O
mg;O;O
QD;O;O
or;O;O
10;O;O
mg;O;O
BID;O;O
);O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
(;O;O
exposure;O;O
);O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s31.e2
.;O;O
DDI-DrugBank.d328.s32;;
Coadministration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s32.e0
(;O;O
40;O;O
mg;O;O
BID;O;O
(;O;O
day;O;O
1;O;O
);O;O
and;O;O
40;O;O
mg;O;O
QD;O;O
(;O;O
days;O;O
2;O;O
-;O;O
7;O;O
);O;O
);O;O
with;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s32.e1
(;O;O
5;O;O
mg;O;O
QD;O;O
);O;O
did;O;O
not;O;O
affect;O;O
either;O;O
the;O;O
pharmacokinetics;O;O
(;O;O
exposure;O;O
);O;O
or;O;O
the;O;O
pharmacodynamics;O;O
(;O;O
blood;O;O
glucose;O;O
and;O;O
insulin;O;O
levels;O;O
);O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s32.e2
.;O;O
DDI-DrugBank.d328.s33;;
Coadministration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s33.e0
(;O;O
40;O;O
mg;O;O
BID;O;O
(;O;O
day;O;O
1;O;O
);O;O
and;O;O
40;O;O
mg;O;O
QD;O;O
(;O;O
days;O;O
2;O;O
-;O;O
7;O;O
);O;O
);O;O
with;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s33.e1
(;O;O
10;O;O
mg;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s33.e2
BID;O;O
);O;O
resulted;O;O
in;O;O
21;O;O
%;O;O
increase;O;O
in;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s33.e3
AUC0;O;O
-;O;O
12;O;O
and;O;O
a;O;O
16;O;O
%;O;O
increase;O;O
in;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s33.e4
Cmax;O;O
leading;O;O
to;O;O
a;O;O
16;O;O
%;O;O
decrease;O;O
in;O;O
glucose;O;O
AUC0;O;O
-;O;O
24;O;O
.;O;O
DDI-DrugBank.d328.s34;;
Insulin;O;O
parameters;O;O
were;O;O
not;O;O
affected;O;O
.;O;O
DDI-DrugBank.d328.s35;;
Because;O;O
changes;O;O
in;O;O
glucose;O;O
concentrations;O;O
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s35.e0
coadministration;O;O
were;O;O
within;O;O
the;O;O
normal;O;O
variability;O;O
and;O;O
individual;O;O
glucose;O;O
concentrations;O;O
were;O;O
above;O;O
or;O;O
near;O;O
70;O;O
mg;O;O
/;O;O
dL;O;O
,;O;O
dose;O;O
adjustment;O;O
for;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s35.e1
(;O;O
5;O;O
mg;O;O
QD;O;O
and;O;O
10;O;O
mg;O;O
BID;O;O
);O;O
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s35.e2
coadministration;O;O
(;O;O
up;O;O
to;O;O
40;O;O
mg;O;O
QD;O;O
);O;O
is;O;O
not;O;O
indicated;O;O
.;O;O
DDI-DrugBank.d328.s36;;
Coadministration;O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d328.s36.e0
with;O;O
doses;O;O
higher;O;O
than;O;O
40;O;O
mg;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s36.e1
(;O;O
e.g.;O;O
,;O;O
40;O;O
mg;O;O
BID;O;O
);O;O
have;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d328.s37;;
Omeprazole;B-drug;B-DDI-DrugBank.d328.s37.e0
:;O;O
Omeprazole;B-drug;B-DDI-DrugBank.d328.s37.e1
is;O;O
a;O;O
CYP;O;O
3A4;O;O
substrate;O;O
and;O;O
CYP;O;O
2C19;O;O
substrate;O;O
and;O;O
inhibitor;O;O
.;O;O
DDI-DrugBank.d328.s38;;
Valdecoxib;B-drug;B-DDI-DrugBank.d328.s38.e0
steady;O;O
state;O;O
plasma;O;O
concentrations;O;O
(;O;O
40;O;O
mg;O;O
BID;O;O
);O;O
were;O;O
not;O;O
affected;O;O
significantly;O;O
with;O;O
multiple;O;O
doses;O;O
of;O;O
omeprazole;B-drug;B-DDI-DrugBank.d328.s38.e1
(;O;O
40;O;O
mg;O;O
QD;O;O
);O;O
.;O;O
DDI-DrugBank.d328.s39;;
Coadministration;O;O
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s39.e0
increased;O;O
exposure;O;O
of;O;O
omeprazole;B-drug;B-DDI-DrugBank.d328.s39.e1
(;O;O
AUC;O;O
);O;O
by;O;O
46;O;O
%;O;O
.;O;O
DDI-DrugBank.d328.s40;;
Drugs;O;O
whose;O;O
absorption;O;O
is;O;O
sensitive;O;O
to;O;O
pH;O;O
may;O;O
be;O;O
negatively;O;O
impacted;O;O
by;O;O
concomitant;O;O
administration;O;O
of;O;O
omeprazole;B-drug;B-DDI-DrugBank.d328.s40.e0
and;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s40.e1
.;O;O
DDI-DrugBank.d328.s41;;
However;O;O
,;O;O
because;O;O
higher;O;O
doses;O;O
(;O;O
up;O;O
to;O;O
360;O;O
mg;O;O
QD;O;O
);O;O
of;O;O
omeprazole;B-drug;B-DDI-DrugBank.d328.s41.e0
are;O;O
tolerated;O;O
in;O;O
Zollinger;O;O
-;O;O
Ellison;O;O
(;O;O
ZE;O;O
);O;O
patients;O;O
,;O;O
no;O;O
dose;O;O
adjustment;O;O
for;O;O
omeprazole;B-drug;B-DDI-DrugBank.d328.s41.e1
is;O;O
recommended;O;O
at;O;O
current;O;O
doses;O;O
.;O;O
DDI-DrugBank.d328.s42;;
Coadministration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s42.e0
with;O;O
doses;O;O
higher;O;O
than;O;O
40;O;O
mg;O;O
QD;O;O
omeprazole;B-drug;B-DDI-DrugBank.d328.s42.e1
has;O;O
not;O;O
been;O;O
studied;O;O
.;O;O
DDI-DrugBank.d328.s43;;
Oral;O;O
Contraceptives;B-group;B-DDI-DrugBank.d328.s43.e0
:;O;O
Valdecoxib;B-drug;B-DDI-DrugBank.d328.s43.e1
(;O;O
40;O;O
mg;O;O
BID;O;O
);O;O
did;O;O
not;O;O
induce;O;O
the;O;O
metabolism;O;O
of;O;O
the;O;O
combination;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d328.s43.e2
norethindrone;I-drug;I-DDI-DrugBank.d328.s43.e3
/;O;O
ethinyl;B-drug;B-DDI-DrugBank.d328.s43.e4
estradiol;I-drug;I-DDI-DrugBank.d328.s43.e4
(;O;O
1;O;O
mg;O;O
/35;O;O
mcg;O;O
combination;O;O
,;O;O
Ortho;B-brand;B-DDI-DrugBank.d328.s43.e5
-;I-brand;I-DDI-DrugBank.d328.s43.e5
Novum;I-brand;I-DDI-DrugBank.d328.s43.e5
1;O;O
/;O;O
35;O;O
);O;O
.;O;O
DDI-DrugBank.d328.s44;;
Coadministration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s44.e0
and;O;O
Ortho;B-brand;B-DDI-DrugBank.d328.s44.e1
-;I-brand;I-DDI-DrugBank.d328.s44.e1
Novum;I-brand;I-DDI-DrugBank.d328.s44.e1
1;O;O
/;O;O
35;O;O
increased;O;O
the;O;O
exposure;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d328.s44.e2
and;O;O
ethinyl;B-drug;B-DDI-DrugBank.d328.s44.e3
estradiol;I-drug;I-DDI-DrugBank.d328.s44.e3
by;O;O
20;O;O
%;O;O
and;O;O
34;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d328.s45;;
Although;O;O
there;O;O
is;O;O
little;O;O
risk;O;O
for;O;O
loss;O;O
of;O;O
contraceptive;O;O
efficacy;O;O
,;O;O
the;O;O
clinical;O;O
significance;O;O
of;O;O
these;O;O
increased;O;O
exposures;O;O
in;O;O
terms;O;O
of;O;O
safety;O;O
is;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d328.s46;;
These;O;O
increased;O;O
exposures;O;O
of;O;O
norethindrone;B-drug;B-DDI-DrugBank.d328.s46.e0
and;O;O
ethinyl;B-drug;B-DDI-DrugBank.d328.s46.e1
estradiol;I-drug;I-DDI-DrugBank.d328.s46.e1
should;O;O
be;O;O
taken;O;O
into;O;O
consideration;O;O
when;O;O
selecting;O;O
an;O;O
oral;O;O
contraceptive;B-group;B-DDI-DrugBank.d328.s46.e2
for;O;O
women;O;O
taking;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s46.e3
.;O;O
DDI-DrugBank.d328.s47;;
Diazepam;B-drug;B-DDI-DrugBank.d328.s47.e0
:;O;O
Diazepam;B-drug;B-DDI-DrugBank.d328.s47.e1
(;O;O
Valium;B-brand;B-DDI-DrugBank.d328.s47.e2
);O;O
is;O;O
a;O;O
CYP;O;O
3A4;O;O
and;O;O
CYP;O;O
2C19;O;O
substrate;O;O
.;O;O
DDI-DrugBank.d328.s48;;
Plasma;O;O
exposure;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d328.s48.e0
(;O;O
10;O;O
mg;O;O
BID;O;O
);O;O
was;O;O
increased;O;O
by;O;O
28;O;O
%;O;O
following;O;O
administration;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s48.e1
(;O;O
40;O;O
mg;O;O
BID;O;O
);O;O
for;O;O
12;O;O
days;O;O
,;O;O
while;O;O
plasma;O;O
exposure;O;O
of;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s48.e2
(;O;O
40;O;O
mg;O;O
BID;O;O
);O;O
was;O;O
not;O;O
substantially;O;O
increased;O;O
following;O;O
administration;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d328.s48.e3
(;O;O
10;O;O
mg;O;O
BID;O;O
);O;O
for;O;O
12;O;O
days;O;O
.;O;O
DDI-DrugBank.d328.s49;;
Although;O;O
the;O;O
magnitude;O;O
of;O;O
changes;O;O
in;O;O
diazepam;B-drug;B-DDI-DrugBank.d328.s49.e0
plasma;O;O
exposure;O;O
when;O;O
coadministered;O;O
with;O;O
valdecoxib;B-drug;B-DDI-DrugBank.d328.s49.e1
were;O;O
not;O;O
sufficient;O;O
to;O;O
warrant;O;O
dosage;O;O
adjustments;O;O
,;O;O
patients;O;O
may;O;O
experience;O;O
enhanced;O;O
sedative;O;O
side;O;O
effects;O;O
caused;O;O
by;O;O
increased;O;O
exposure;O;O
of;O;O
diazepam;B-drug;B-DDI-DrugBank.d328.s49.e2
under;O;O
this;O;O
circumstance;O;O
.;O;O
DDI-DrugBank.d328.s50;;
Patients;O;O
should;O;O
be;O;O
cautioned;O;O
against;O;O
engaging;O;O
in;O;O
hazardous;O;O
activities;O;O
requiring;O;O
complete;O;O
mental;O;O
alertness;O;O
such;O;O
as;O;O
operating;O;O
machinery;O;O
or;O;O
driving;O;O
a;O;O
motor;O;O
vehicle;O;O
.;O;O
DDI-DrugBank.d198.s0;;
Effect;O;O
of;O;O
other;O;O
drugs;O;O
on;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s0.e0
DDI-DrugBank.d198.s1;;
In;O;O
vitro;O;O
studies;O;O
:;O;O
Studies;O;O
in;O;O
human;O;O
liver;O;O
microsomes;O;O
showed;O;O
that;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s1.e0
is;O;O
metabolized;O;O
primarily;O;O
by;O;O
cytochrome;O;O
P450;O;O
(;O;O
CYP;O;O
);O;O
isoforms;O;O
3A4;O;O
/;O;O
5;O;O
,;O;O
and;O;O
to;O;O
a;O;O
lesser;O;O
degree;O;O
by;O;O
CYP2C9;O;O
.;O;O
DDI-DrugBank.d198.s2;;
Therefore;O;O
,;O;O
inhibitors;O;O
of;O;O
these;O;O
enzymes;O;O
are;O;O
expected;O;O
to;O;O
reduce;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s2.e0
clearance;O;O
.;O;O
DDI-DrugBank.d198.s3;;
In;O;O
vivo;O;O
studies;O;O
:;O;O
Cytochrome;O;O
P450;O;O
Inhibitors;O;O
DDI-DrugBank.d198.s4;;
Cimetidine;B-drug;B-DDI-DrugBank.d198.s4.e0
(;O;O
400;O;O
mg;O;O
b.i.d;O;O
.;O;O
);O;O
had;O;O
no;O;O
effect;O;O
on;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s4.e1
bioavailability;O;O
(;O;O
AUC;O;O
);O;O
and;O;O
maximum;O;O
concentration;O;O
(;O;O
Cmax;O;O
);O;O
of;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s4.e2
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
20;O;O
mg;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s4.e3
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d198.s5;;
Erythromycin;B-drug;B-DDI-DrugBank.d198.s5.e0
(;O;O
500;O;O
mg;O;O
t.i.d;O;O
);O;O
produced;O;O
a;O;O
4;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s5.e1
AUC;O;O
and;O;O
a;O;O
3;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
Cmax;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s5.e2
5;O;O
mg;O;O
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d198.s6;;
It;O;O
is;O;O
recommended;O;O
not;O;O
to;O;O
exceed;O;O
a;O;O
single;O;O
5;O;O
mg;O;O
dose;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s6.e0
in;O;O
a;O;O
24;O;O
-;O;O
hour;O;O
period;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
erythromycin;B-drug;B-DDI-DrugBank.d198.s6.e1
.;O;O
DDI-DrugBank.d198.s7;;
Ketoconazole;B-drug;B-DDI-DrugBank.d198.s7.e0
(;O;O
200;O;O
mg;O;O
once;O;O
daily;O;O
);O;O
produced;O;O
a;O;O
10;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s7.e1
AUC;O;O
and;O;O
a;O;O
4;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
Cmax;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s7.e2
(;O;O
5;O;O
mg;O;O
);O;O
in;O;O
healthy;O;O
volunteers;O;O
.;O;O
DDI-DrugBank.d198.s8;;
A;O;O
5;O;O
-;O;O
mg;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s8.e0
dose;O;O
should;O;O
not;O;O
be;O;O
exceeded;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
200;O;O
mg;O;O
once;O;O
daily;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d198.s8.e1
.;O;O
DDI-DrugBank.d198.s9;;
Since;O;O
higher;O;O
doses;O;O
of;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d198.s9.e0
(;O;O
400;O;O
mg;O;O
daily;O;O
);O;O
may;O;O
result;O;O
in;O;O
higher;O;O
increases;O;O
in;O;O
Cmax;O;O
and;O;O
AUC;O;O
,;O;O
a;O;O
single;O;O
2.5;O;O
mg;O;O
dose;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s9.e1
should;O;O
not;O;O
be;O;O
exceeded;O;O
in;O;O
a;O;O
24;O;O
-;O;O
hour;O;O
period;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d198.s9.e2
400;O;O
mg;O;O
daily;O;O
.;O;O
DDI-DrugBank.d198.s10;;
HIV;B-group;B-DDI-DrugBank.d198.s10.e0
Protease;I-group;I-DDI-DrugBank.d198.s10.e0
Inhibitors;I-group;I-DDI-DrugBank.d198.s10.e0
:;O;O
Indinavir;B-drug;B-DDI-DrugBank.d198.s10.e1
(;O;O
800;O;O
mg;O;O
t.i.d;O;O
.;O;O
);O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s10.e2
10;O;O
mg;O;O
resulted;O;O
in;O;O
a;O;O
16;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s10.e3
AUC;O;O
,;O;O
a;O;O
7;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s10.e4
Cmax;O;O
and;O;O
a;O;O
2;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s10.e5
half;O;O
-;O;O
life;O;O
.;O;O
DDI-DrugBank.d198.s11;;
It;O;O
is;O;O
recommended;O;O
not;O;O
to;O;O
exceed;O;O
a;O;O
single;O;O
2.5;O;O
mg;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s11.e0
dose;O;O
in;O;O
a;O;O
24;O;O
-;O;O
hour;O;O
period;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
indinavir;B-drug;B-DDI-DrugBank.d198.s11.e1
.;O;O
DDI-DrugBank.d198.s12;;
Ritonavir;B-drug;B-DDI-DrugBank.d198.s12.e0
(;O;O
600;O;O
mg;O;O
b.i.d;O;O
.;O;O
);O;O
co;O;O
-;O;O
administered;O;O
with;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s12.e1
5;O;O
mg;O;O
resulted;O;O
in;O;O
a;O;O
49;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s12.e2
AUC;O;O
and;O;O
a;O;O
13;O;O
-;O;O
fold;O;O
increase;O;O
in;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s12.e3
Cmax;O;O
.;O;O
DDI-DrugBank.d198.s13;;
The;O;O
interaction;O;O
is;O;O
a;O;O
consequence;O;O
of;O;O
blocking;O;O
hepatic;O;O
metabolism;O;O
of;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s13.e0
by;O;O
ritonavir;B-drug;B-DDI-DrugBank.d198.s13.e1
,;O;O
a;O;O
highly;O;O
potent;O;O
CYP3A4;O;O
inhibitor;O;O
,;O;O
which;O;O
also;O;O
inhibits;O;O
CYP2C9;O;O
.;O;O
DDI-DrugBank.d198.s14;;
Ritonavir;B-drug;B-DDI-DrugBank.d198.s14.e0
significantly;O;O
prolonged;O;O
the;O;O
half;O;O
-;O;O
life;O;O
of;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s14.e1
to;O;O
26;O;O
hours;O;O
.;O;O
DDI-DrugBank.d198.s15;;
Consequently;O;O
,;O;O
it;O;O
is;O;O
recommended;O;O
not;O;O
to;O;O
exceed;O;O
a;O;O
single;O;O
2.5;O;O
mg;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s15.e0
dose;O;O
in;O;O
a;O;O
72;O;O
-;O;O
hour;O;O
period;O;O
when;O;O
used;O;O
in;O;O
combination;O;O
with;O;O
ritonavir;B-drug;B-DDI-DrugBank.d198.s15.e1
.;O;O
DDI-DrugBank.d198.s16;;
Other;O;O
Drug;O;O
Interactions;O;O
:;O;O
No;O;O
pharmacokinetic;O;O
interactions;O;O
were;O;O
observed;O;O
between;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s16.e0
and;O;O
the;O;O
following;O;O
drugs;O;O
:;O;O
glyburide;B-drug;B-DDI-DrugBank.d198.s16.e1
,;O;O
warfarin;B-drug;B-DDI-DrugBank.d198.s16.e2
,;O;O
digoxin;B-drug;B-DDI-DrugBank.d198.s16.e3
,;O;O
Maalox;B-brand;B-DDI-DrugBank.d198.s16.e4
,;O;O
and;O;O
ranitidine;B-drug;B-DDI-DrugBank.d198.s16.e5
.;O;O
DDI-DrugBank.d198.s17;;
In;O;O
the;O;O
warfarin;B-drug;B-DDI-DrugBank.d198.s17.e0
study;O;O
,;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s17.e1
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
pharmacodynamic;O;O
parameters;O;O
.;O;O
DDI-DrugBank.d198.s18;;
Effects;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s18.e0
on;O;O
other;O;O
drugs;O;O
DDI-DrugBank.d198.s19;;
In;O;O
vitro;O;O
studies;O;O
:;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s19.e0
and;O;O
its;O;O
metabolites;O;O
had;O;O
no;O;O
effect;O;O
on;O;O
CYP1A2;O;O
,;O;O
2A6;O;O
,;O;O
and;O;O
2E1;O;O
(;O;O
Ki;O;O
100uM;O;O
);O;O
.;O;O
DDI-DrugBank.d198.s20;;
Weak;O;O
inhibitory;O;O
effects;O;O
toward;O;O
other;O;O
isoforms;O;O
(;O;O
CYP2C8;O;O
,;O;O
2C9;O;O
,;O;O
2C19;O;O
,;O;O
2D6;O;O
,;O;O
3A4;O;O
);O;O
were;O;O
found;O;O
,;O;O
but;O;O
Ki;O;O
values;O;O
were;O;O
in;O;O
excess;O;O
of;O;O
plasma;O;O
concentrations;O;O
achieved;O;O
following;O;O
dosing;O;O
.;O;O
DDI-DrugBank.d198.s21;;
The;O;O
most;O;O
potent;O;O
inhibitory;O;O
activity;O;O
was;O;O
observed;O;O
for;O;O
vardenafil;O;O
metabolite;O;O
M1;O;O
,;O;O
which;O;O
had;O;O
a;O;O
Ki;O;O
of;O;O
1.4;O;O
uM;O;O
toward;O;O
CYP3A4;O;O
,;O;O
which;O;O
is;O;O
about;O;O
20;O;O
times;O;O
higher;O;O
than;O;O
the;O;O
M1;O;O
Cmax;O;O
values;O;O
after;O;O
an;O;O
80;O;O
mg;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s21.e0
dose;O;O
.;O;O
DDI-DrugBank.d198.s22;;
In;O;O
vivo;O;O
studies;O;O
:;O;O
Nitrates;B-group;B-DDI-DrugBank.d198.s22.e0
:;O;O
The;O;O
blood;O;O
pressure;O;O
lowering;O;O
effects;O;O
of;O;O
sublingual;O;O
nitrates;B-group;B-DDI-DrugBank.d198.s22.e1
(;O;O
0.4;O;O
mg;O;O
);O;O
taken;O;O
1;O;O
and;O;O
4;O;O
hours;O;O
after;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s22.e2
and;O;O
increases;O;O
in;O;O
heart;O;O
rate;O;O
when;O;O
taken;O;O
at;O;O
1;O;O
,;O;O
4;O;O
and;O;O
8;O;O
hours;O;O
were;O;O
potentiated;O;O
by;O;O
a;O;O
20;O;O
mg;O;O
dose;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s22.e3
in;O;O
healthy;O;O
middle;O;O
-;O;O
aged;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d198.s23;;
These;O;O
effects;O;O
were;O;O
not;O;O
observed;O;O
when;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s23.e0
20;O;O
mg;O;O
was;O;O
taken;O;O
24;O;O
hours;O;O
before;O;O
the;O;O
NTG;B-drug;B-DDI-DrugBank.d198.s23.e1
.;O;O
DDI-DrugBank.d198.s24;;
Potentiation;O;O
of;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
nitrates;B-group;B-DDI-DrugBank.d198.s24.e0
for;O;O
patients;O;O
with;O;O
ischemic;O;O
heart;O;O
disease;O;O
has;O;O
not;O;O
been;O;O
evaluated;O;O
,;O;O
and;O;O
concomitant;O;O
use;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s24.e1
and;O;O
nitrates;B-group;B-DDI-DrugBank.d198.s24.e2
is;O;O
contraindicated;O;O
.;O;O
DDI-DrugBank.d198.s25;;
Nifedipine;B-drug;B-DDI-DrugBank.d198.s25.e0
:;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s25.e1
20;O;O
mg;O;O
,;O;O
when;O;O
co;O;O
-;O;O
administered;O;O
with;O;O
slow;O;O
-;O;O
release;O;O
nifedipine;B-drug;B-DDI-DrugBank.d198.s25.e2
30;O;O
mg;O;O
or;O;O
60;O;O
mg;O;O
once;O;O
daily;O;O
,;O;O
did;O;O
not;O;O
affect;O;O
the;O;O
relative;O;O
bioavailability;O;O
(;O;O
AUC;O;O
);O;O
or;O;O
maximum;O;O
concentration;O;O
(;O;O
Cmax;O;O
);O;O
of;O;O
nifedipine;B-drug;B-DDI-DrugBank.d198.s25.e3
,;O;O
a;O;O
drug;O;O
that;O;O
is;O;O
metabolized;O;O
via;O;O
CYP3A4;O;O
.;O;O
DDI-DrugBank.d198.s26;;
Nifedipine;B-drug;B-DDI-DrugBank.d198.s26.e0
did;O;O
not;O;O
alter;O;O
the;O;O
plasma;O;O
levels;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s26.e1
when;O;O
taken;O;O
in;O;O
combination;O;O
.;O;O
DDI-DrugBank.d198.s27;;
In;O;O
these;O;O
patients;O;O
whose;O;O
hypertension;O;O
was;O;O
controlled;O;O
with;O;O
nifedipine;B-drug;B-DDI-DrugBank.d198.s27.e0
,;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s27.e1
20;O;O
mg;O;O
produced;O;O
mean;O;O
additional;O;O
supine;O;O
systolic;O;O
/;O;O
diastolic;O;O
blood;O;O
pressure;O;O
reductions;O;O
of;O;O
6;O;O
/;O;O
5;O;O
mm;O;O
Hg;O;O
compared;O;O
to;O;O
placebo;O;O
.;O;O
DDI-DrugBank.d198.s28;;
Alpha;B-group;B-DDI-DrugBank.d198.s28.e0
-;I-group;I-DDI-DrugBank.d198.s28.e0
blockers;I-group;I-DDI-DrugBank.d198.s28.e0
:;O;O
When;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s28.e1
10;O;O
or;O;O
20;O;O
mg;O;O
was;O;O
given;O;O
to;O;O
healthy;O;O
volunteers;O;O
either;O;O
simultaneously;O;O
or;O;O
6;O;O
hours;O;O
after;O;O
a;O;O
10;O;O
mg;O;O
dose;O;O
of;O;O
terazosin;B-drug;B-DDI-DrugBank.d198.s28.e2
,;O;O
significant;O;O
hypotension;O;O
developed;O;O
in;O;O
a;O;O
substantial;O;O
number;O;O
of;O;O
subjects;O;O
.;O;O
DDI-DrugBank.d198.s29;;
With;O;O
simultaneous;O;O
dosing;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s29.e0
10;O;O
mg;O;O
and;O;O
terazosin;B-drug;B-DDI-DrugBank.d198.s29.e1
10;O;O
mg;O;O
,;O;O
6;O;O
of;O;O
8;O;O
subjects;O;O
experienced;O;O
a;O;O
standing;O;O
systolic;O;O
blood;O;O
pressure;O;O
of;O;O
less;O;O
than;O;O
85;O;O
mm;O;O
Hg;O;O
.;O;O
DDI-DrugBank.d198.s30;;
With;O;O
simultaneous;O;O
dosing;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s30.e0
20;O;O
mg;O;O
and;O;O
terazosin;B-drug;B-DDI-DrugBank.d198.s30.e1
10;O;O
mg;O;O
,;O;O
2;O;O
of;O;O
9;O;O
subjects;O;O
experienced;O;O
a;O;O
standing;O;O
systolic;O;O
blood;O;O
pressure;O;O
of;O;O
less;O;O
than;O;O
85;O;O
mm;O;O
Hg;O;O
.;O;O
DDI-DrugBank.d198.s31;;
When;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s31.e0
dosing;O;O
was;O;O
separated;O;O
from;O;O
terazosin;B-drug;B-DDI-DrugBank.d198.s31.e1
10;O;O
mg;O;O
by;O;O
6;O;O
hours;O;O
,;O;O
7;O;O
of;O;O
28;O;O
subjects;O;O
who;O;O
received;O;O
20;O;O
mg;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s31.e2
experienced;O;O
a;O;O
decrease;O;O
in;O;O
standing;O;O
systolic;O;O
blood;O;O
pressure;O;O
below;O;O
85;O;O
mm;O;O
Hg;O;O
.;O;O
DDI-DrugBank.d198.s32;;
In;O;O
a;O;O
similar;O;O
study;O;O
with;O;O
tamsulosin;B-drug;B-DDI-DrugBank.d198.s32.e0
in;O;O
healthy;O;O
volunteers;O;O
,;O;O
1;O;O
of;O;O
24;O;O
subjects;O;O
dosed;O;O
with;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s32.e1
20;O;O
mg;O;O
and;O;O
tamsulosin;B-drug;B-DDI-DrugBank.d198.s32.e2
0.4;O;O
mg;O;O
separated;O;O
by;O;O
6;O;O
hours;O;O
experienced;O;O
a;O;O
standing;O;O
systolic;O;O
blood;O;O
pressure;O;O
below;O;O
85;O;O
mm;O;O
Hg;O;O
.;O;O
DDI-DrugBank.d198.s33;;
Two;O;O
of;O;O
16;O;O
subjects;O;O
dosed;O;O
simultaneously;O;O
with;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s33.e0
10;O;O
mg;O;O
and;O;O
tamsulosin;B-drug;B-DDI-DrugBank.d198.s33.e1
0.4;O;O
mg;O;O
experienced;O;O
a;O;O
standing;O;O
systolic;O;O
blood;O;O
pressure;O;O
below;O;O
85;O;O
mm;O;O
Hg;O;O
.;O;O
DDI-DrugBank.d198.s34;;
The;O;O
administration;O;O
of;O;O
lower;O;O
doses;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s34.e0
with;O;O
alpha;B-group;B-DDI-DrugBank.d198.s34.e1
-;I-group;I-DDI-DrugBank.d198.s34.e1
blockers;I-group;I-DDI-DrugBank.d198.s34.e1
has;O;O
not;O;O
been;O;O
completely;O;O
evaluated;O;O
to;O;O
determine;O;O
if;O;O
they;O;O
can;O;O
be;O;O
safely;O;O
administered;O;O
together;O;O
.;O;O
DDI-DrugBank.d198.s35;;
Based;O;O
on;O;O
these;O;O
data;O;O
,;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s35.e0
should;O;O
not;O;O
be;O;O
used;O;O
in;O;O
patients;O;O
on;O;O
alpha;B-group;B-DDI-DrugBank.d198.s35.e1
-;I-group;I-DDI-DrugBank.d198.s35.e1
blocker;I-group;I-DDI-DrugBank.d198.s35.e1
therapy;O;O
.;O;O
DDI-DrugBank.d198.s36;;
Ritonavir;B-drug;B-DDI-DrugBank.d198.s36.e0
and;O;O
indinavir;B-drug;B-DDI-DrugBank.d198.s36.e1
:;O;O
Upon;O;O
concomitant;O;O
administration;O;O
of;O;O
5;O;O
mg;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s36.e2
with;O;O
600;O;O
mg;O;O
BID;O;O
ritonavir;B-drug;B-DDI-DrugBank.d198.s36.e3
,;O;O
the;O;O
Cmax;O;O
and;O;O
AUC;O;O
of;O;O
ritonavir;B-drug;B-DDI-DrugBank.d198.s36.e4
were;O;O
reduced;O;O
by;O;O
approximately;O;O
20;O;O
%;O;O
.;O;O
DDI-DrugBank.d198.s37;;
Upon;O;O
administration;O;O
of;O;O
10;O;O
mg;O;O
of;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s37.e0
with;O;O
800;O;O
mg;O;O
TID;O;O
indinavir;B-drug;B-DDI-DrugBank.d198.s37.e1
,;O;O
the;O;O
Cmax;O;O
and;O;O
AUC;O;O
of;O;O
indinavir;B-drug;B-DDI-DrugBank.d198.s37.e2
were;O;O
reduced;O;O
by;O;O
40;O;O
%;O;O
and;O;O
30;O;O
%;O;O
,;O;O
respectively;O;O
.;O;O
DDI-DrugBank.d198.s38;;
Alcohol;B-drug;B-DDI-DrugBank.d198.s38.e0
:;O;O
Alcohol;B-drug;B-DDI-DrugBank.d198.s38.e1
(;O;O
0.5;O;O
g;O;O
/;O;O
kg;O;O
body;O;O
weight;O;O
:;O;O
approximately;O;O
40;O;O
mL;O;O
of;O;O
absolute;O;O
alcohol;O;O
in;O;O
a;O;O
70;O;O
kg;O;O
person;O;O
);O;O
and;O;O
vardenafil;B-drug;B-DDI-DrugBank.d198.s38.e2
plasma;O;O
levels;O;O
were;O;O
not;O;O
altered;O;O
when;O;O
dosed;O;O
simultaneously;O;O
.;O;O
DDI-DrugBank.d198.s39;;
Vardenafil;B-drug;B-DDI-DrugBank.d198.s39.e0
(;O;O
20;O;O
mg;O;O
);O;O
did;O;O
not;O;O
potentiate;O;O
the;O;O
hypotensive;O;O
effects;O;O
of;O;O
alcohol;B-drug;B-DDI-DrugBank.d198.s39.e1
during;O;O
the;O;O
4;O;O
-;O;O
hour;O;O
observation;O;O
period;O;O
in;O;O
healthy;O;O
volunteers;O;O
when;O;O
administered;O;O
with;O;O
alcohol;B-drug;B-DDI-DrugBank.d198.s39.e2
(;O;O
0.5;O;O
g;O;O
/;O;O
kg;O;O
body;O;O
weight;O;O
);O;O
.;O;O
DDI-DrugBank.d198.s40;;
Aspirin;B-brand;B-DDI-DrugBank.d198.s40.e0
:;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s40.e1
(;O;O
10;O;O
mg;O;O
and;O;O
20;O;O
mg;O;O
);O;O
did;O;O
not;O;O
potentiate;O;O
the;O;O
increase;O;O
in;O;O
bleeding;O;O
time;O;O
caused;O;O
by;O;O
aspirin;B-brand;B-DDI-DrugBank.d198.s40.e2
(;O;O
two;O;O
81;O;O
mg;O;O
tablets;O;O
);O;O
.;O;O
DDI-DrugBank.d198.s41;;
Other;O;O
interactions;O;O
:;O;O
Vardenafil;B-drug;B-DDI-DrugBank.d198.s41.e0
had;O;O
no;O;O
effect;O;O
on;O;O
the;O;O
pharmacodynamics;O;O
of;O;O
glyburide;B-drug;B-DDI-DrugBank.d198.s41.e1
(;O;O
glucose;O;O
and;O;O
insulin;O;O
concentrations;O;O
);O;O
and;O;O
warfarin;B-drug;B-DDI-DrugBank.d198.s41.e2
(;O;O
prothrombin;O;O
time;O;O
or;O;O
other;O;O
pharmacodynamic;O;O
parameters;O;O
);O;O
.;O;O
DDI-DrugBank.d263.s0;;
Zidovudine;B-drug;B-DDI-DrugBank.d263.s0.e0
:;O;O
There;O;O
is;O;O
no;O;O
significant;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
ZDV;B-drug;B-DDI-DrugBank.d263.s0.e1
and;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s0.e2
which;O;O
has;O;O
been;O;O
confirmed;O;O
clinically;O;O
.;O;O
DDI-DrugBank.d263.s1;;
Zalcitabine;B-drug;B-DDI-DrugBank.d263.s1.e0
also;O;O
has;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
intracellular;O;O
phosphorylation;O;O
of;O;O
ZDV;B-drug;B-DDI-DrugBank.d263.s1.e1
,;O;O
as;O;O
shown;O;O
in;O;O
vitro;O;O
in;O;O
peripheral;O;O
blood;O;O
mononuclear;O;O
cells;O;O
or;O;O
in;O;O
two;O;O
other;O;O
cell;O;O
lines;O;O
(;O;O
U937;O;O
and;O;O
Molt;O;O
-;O;O
4;O;O
);O;O
.;O;O
DDI-DrugBank.d263.s2;;
In;O;O
the;O;O
same;O;O
study;O;O
it;O;O
was;O;O
shown;O;O
that;O;O
didanosine;B-drug;B-DDI-DrugBank.d263.s2.e0
and;O;O
stavudine;B-drug;B-DDI-DrugBank.d263.s2.e1
had;O;O
no;O;O
significant;O;O
effect;O;O
on;O;O
the;O;O
intracellular;O;O
phosphorylation;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s2.e2
in;O;O
peripheral;O;O
blood;O;O
mononuclear;O;O
cells;O;O
.;O;O
DDI-DrugBank.d263.s3;;
Lamivudine;B-drug;B-DDI-DrugBank.d263.s3.e0
:;O;O
In;O;O
vitro;O;O
studies;O;O
in;O;O
peripheral;O;O
blood;O;O
mononuclear;O;O
cells;O;O
,;O;O
U937;O;O
and;O;O
Molt;O;O
-;O;O
4;O;O
cells;O;O
revealed;O;O
that;O;O
lamivudine;B-drug;B-DDI-DrugBank.d263.s3.e1
significantly;O;O
inhibited;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s3.e2
phosphorylation;O;O
in;O;O
a;O;O
dose;O;O
dependent;O;O
manner;O;O
.;O;O
DDI-DrugBank.d263.s4;;
Effects;O;O
were;O;O
already;O;O
seen;O;O
with;O;O
doses;O;O
corresponding;O;O
to;O;O
relevant;O;O
plasma;O;O
levels;O;O
in;O;O
humans;O;O
,;O;O
and;O;O
the;O;O
intracellular;O;O
phosphorylation;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s4.e0
to;O;O
its;O;O
three;O;O
metabolites;O;O
(;O;O
including;O;O
the;O;O
active;O;O
zalcitabine;O;O
triphosphate;O;O
metabolite;O;O
);O;O
was;O;O
significantly;O;O
inhibited;O;O
.;O;O
DDI-DrugBank.d263.s5;;
Zalcitabine;B-drug;B-DDI-DrugBank.d263.s5.e0
inhibited;O;O
lamivudine;B-drug;B-DDI-DrugBank.d263.s5.e1
phosphorylation;O;O
at;O;O
high;O;O
concentration;O;O
ratios;O;O
(;O;O
10;O;O
and;O;O
100;O;O
);O;O
,;O;O
DDI-DrugBank.d263.s6;;
however;O;O
,;O;O
it;O;O
is;O;O
considered;O;O
to;O;O
be;O;O
unlikely;O;O
that;O;O
this;O;O
decrease;O;O
of;O;O
phosphorylated;O;O
lamivudine;B-drug;B-DDI-DrugBank.d263.s6.e0
concentration;O;O
is;O;O
of;O;O
clinical;O;O
significance;O;O
,;O;O
as;O;O
lamivudine;B-drug;B-DDI-DrugBank.d263.s6.e1
is;O;O
a;O;O
more;O;O
efficient;O;O
substrate;O;O
for;O;O
deoxycytidine;O;O
kinase;O;O
than;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s6.e2
.;O;O
DDI-DrugBank.d263.s7;;
These;O;O
in;O;O
vitro;O;O
studies;O;O
suggest;O;O
that;O;O
concomitant;O;O
administration;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s7.e0
and;O;O
lamivudine;B-drug;B-DDI-DrugBank.d263.s7.e1
in;O;O
humans;O;O
may;O;O
result;O;O
in;O;O
sub;O;O
-;O;O
therapeutic;O;O
concentrations;O;O
of;O;O
active;O;O
phosphorylated;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s7.e2
,;O;O
which;O;O
may;O;O
lead;O;O
to;O;O
a;O;O
decreased;O;O
antiretroviral;B-group;B-DDI-DrugBank.d263.s7.e3
effect;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s7.e4
.;O;O
DDI-DrugBank.d263.s8;;
It;O;O
is;O;O
unknown;O;O
how;O;O
the;O;O
effect;O;O
seen;O;O
in;O;O
these;O;O
in;O;O
vitro;O;O
studies;O;O
translates;O;O
into;O;O
clinical;O;O
consequences;O;O
.;O;O
DDI-DrugBank.d263.s9;;
Concomitant;O;O
use;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s9.e0
and;O;O
lamivudine;B-drug;B-DDI-DrugBank.d263.s9.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d263.s10;;
Saquinavir;B-drug;B-DDI-DrugBank.d263.s10.e0
:;O;O
The;O;O
combination;O;O
of;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s10.e1
,;O;O
saquinavir;B-drug;B-DDI-DrugBank.d263.s10.e2
,;O;O
and;O;O
ZDV;B-drug;B-DDI-DrugBank.d263.s10.e3
has;O;O
been;O;O
studied;O;O
(;O;O
as;O;O
triple;O;O
combination;O;O
);O;O
in;O;O
adults;O;O
.;O;O
DDI-DrugBank.d263.s11;;
Pharmacokinetic;O;O
data;O;O
suggest;O;O
that;O;O
absorption;O;O
,;O;O
metabolism;O;O
,;O;O
and;O;O
elimination;O;O
of;O;O
each;O;O
of;O;O
these;O;O
drugs;O;O
are;O;O
unchanged;O;O
when;O;O
they;O;O
are;O;O
used;O;O
together;O;O
.;O;O
DDI-DrugBank.d263.s12;;
Drugs;O;O
Associated;O;O
With;O;O
Peripheral;O;O
Neuropathy;O;O
:;O;O
The;O;O
concomitant;O;O
use;O;O
of;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s12.e0
with;O;O
drugs;O;O
that;O;O
have;O;O
the;O;O
potential;O;O
to;O;O
cause;O;O
peripheral;O;O
neuropathy;O;O
should;O;O
be;O;O
avoided;O;O
where;O;O
possible;O;O
.;O;O
DDI-DrugBank.d263.s13;;
Drugs;O;O
that;O;O
have;O;O
been;O;O
associated;O;O
with;O;O
peripheral;O;O
neuropathy;O;O
include;O;O
antiretroviral;B-drug;B-DDI-DrugBank.d263.s13.e0
nucleoside;I-drug;I-DDI-DrugBank.d263.s13.e0
analogues;I-drug;I-DDI-DrugBank.d263.s13.e0
,;O;O
chloramphenicol;B-drug;B-DDI-DrugBank.d263.s13.e1
,;O;O
cisplatin;B-drug;B-DDI-DrugBank.d263.s13.e2
,;O;O
dapsone;B-drug;B-DDI-DrugBank.d263.s13.e3
,;O;O
disulfiram;B-drug;B-DDI-DrugBank.d263.s13.e4
,;O;O
ethionamide;B-drug;B-DDI-DrugBank.d263.s13.e5
,;O;O
glutethimide;B-drug;B-DDI-DrugBank.d263.s13.e6
,;O;O
gold;B-drug;B-DDI-DrugBank.d263.s13.e7
,;O;O
hydralazine;B-drug;B-DDI-DrugBank.d263.s13.e8
,;O;O
iodoquinol;B-drug;B-DDI-DrugBank.d263.s13.e9
,;O;O
isoniazid;B-drug;B-DDI-DrugBank.d263.s13.e10
,;O;O
metronidazole;B-drug;B-DDI-DrugBank.d263.s13.e11
,;O;O
nitrofurantoin;B-drug;B-DDI-DrugBank.d263.s13.e12
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d263.s13.e13
,;O;O
ribavirin;B-drug;B-DDI-DrugBank.d263.s13.e14
,;O;O
and;O;O
vincristine;B-drug;B-DDI-DrugBank.d263.s13.e15
.;O;O
DDI-DrugBank.d263.s14;;
Concomitant;O;O
use;O;O
of;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s14.e0
with;O;O
didanosine;B-drug;B-DDI-DrugBank.d263.s14.e1
is;O;O
not;O;O
recommended;O;O
.;O;O
DDI-DrugBank.d263.s15;;
Intravenous;O;O
Pentamidine;B-drug;B-DDI-DrugBank.d263.s15.e0
:;O;O
Treatment;O;O
with;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s15.e1
should;O;O
be;O;O
interrupted;O;O
when;O;O
the;O;O
use;O;O
of;O;O
a;O;O
drug;O;O
that;O;O
has;O;O
the;O;O
potential;O;O
to;O;O
cause;O;O
pancreatitis;O;O
is;O;O
required;O;O
.;O;O
DDI-DrugBank.d263.s16;;
Death;O;O
due;O;O
to;O;O
fulminant;O;O
pancreatitis;O;O
possibly;O;O
related;O;O
to;O;O
intravenous;O;O
pentamidine;B-drug;B-DDI-DrugBank.d263.s16.e0
and;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s16.e1
has;O;O
been;O;O
reported;O;O
.;O;O
DDI-DrugBank.d263.s17;;
If;O;O
intravenous;O;O
pentamidine;B-drug;B-DDI-DrugBank.d263.s17.e0
is;O;O
required;O;O
to;O;O
treat;O;O
Pneumocystis;O;O
carinii;O;O
pneumonia;O;O
,;O;O
treatment;O;O
with;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s17.e1
should;O;O
be;O;O
interrupted;O;O
.;O;O
DDI-DrugBank.d263.s18;;
Amphotericin;B-drug;B-DDI-DrugBank.d263.s18.e0
,;O;O
Foscarnet;B-drug;B-DDI-DrugBank.d263.s18.e1
,;O;O
and;O;O
Aminoglycosides;B-group;B-DDI-DrugBank.d263.s18.e2
:;O;O
Drugs;O;O
such;O;O
as;O;O
amphotericin;B-drug;B-DDI-DrugBank.d263.s18.e3
,;O;O
foscarnet;B-drug;B-DDI-DrugBank.d263.s18.e4
,;O;O
and;O;O
aminoglycosides;B-group;B-DDI-DrugBank.d263.s18.e5
may;O;O
increase;O;O
the;O;O
risk;O;O
of;O;O
developing;O;O
peripheral;O;O
neuropathy;O;O
or;O;O
other;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s18.e6
-;O;O
associated;O;O
adverse;O;O
events;O;O
by;O;O
interfering;O;O
with;O;O
the;O;O
renal;O;O
clearance;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s18.e7
(;O;O
thereby;O;O
raising;O;O
systemic;O;O
exposure;O;O
);O;O
.;O;O
DDI-DrugBank.d263.s19;;
Patients;O;O
who;O;O
require;O;O
the;O;O
use;O;O
of;O;O
one;O;O
of;O;O
these;O;O
drugs;O;O
with;O;O
HIVID;B-drug;B-DDI-DrugBank.d263.s19.e0
should;O;O
have;O;O
frequent;O;O
clinical;O;O
and;O;O
laboratory;O;O
monitoring;O;O
with;O;O
dosage;O;O
adjustment;O;O
for;O;O
any;O;O
significant;O;O
change;O;O
in;O;O
renal;O;O
function;O;O
.;O;O
DDI-DrugBank.d263.s20;;
Probenecid;B-drug;B-DDI-DrugBank.d263.s20.e0
or;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d263.s20.e1
:;O;O
Concomitant;O;O
administration;O;O
of;O;O
probenecid;B-drug;B-DDI-DrugBank.d263.s20.e2
or;O;O
cimetidine;B-drug;B-DDI-DrugBank.d263.s20.e3
decreases;O;O
the;O;O
elimination;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s20.e4
,;O;O
most;O;O
likely;O;O
by;O;O
inhibition;O;O
of;O;O
renal;O;O
tubular;O;O
secretion;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s20.e5
.;O;O
DDI-DrugBank.d263.s21;;
Patients;O;O
receiving;O;O
these;O;O
drugs;O;O
in;O;O
combination;O;O
with;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s21.e0
should;O;O
be;O;O
monitored;O;O
for;O;O
signs;O;O
of;O;O
toxicity;O;O
and;O;O
the;O;O
dose;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s21.e1
reduced;O;O
if;O;O
warranted;O;O
.;O;O
DDI-DrugBank.d263.s22;;
Magnesium;B-drug;B-DDI-DrugBank.d263.s22.e0
/;O;O
Aluminum;B-drug;B-DDI-DrugBank.d263.s22.e1
-;O;O
containing;O;O
Antacid;B-group;B-DDI-DrugBank.d263.s22.e2
Products;I-group;I-DDI-DrugBank.d263.s22.e2
:;O;O
Absorption;O;O
of;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s22.e3
is;O;O
moderately;O;O
reduced;O;O
(;O;O
approximately;O;O
25;O;O
%;O;O
);O;O
when;O;O
coadministered;O;O
with;O;O
magnesium;B-drug;B-DDI-DrugBank.d263.s22.e4
/;O;O
aluminum;B-drug;B-DDI-DrugBank.d263.s22.e5
-;O;O
containing;O;O
antacid;B-group;B-DDI-DrugBank.d263.s22.e6
products;I-group;I-DDI-DrugBank.d263.s22.e6
.;O;O
DDI-DrugBank.d263.s23;;
The;O;O
clinical;O;O
significance;O;O
of;O;O
this;O;O
reduction;O;O
is;O;O
not;O;O
known;O;O
,;O;O
hence;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s23.e0
is;O;O
not;O;O
recommended;O;O
to;O;O
be;O;O
ingested;O;O
simultaneously;O;O
with;O;O
magnesium;B-drug;B-DDI-DrugBank.d263.s23.e1
/;O;O
aluminum;B-drug;B-DDI-DrugBank.d263.s23.e2
-;O;O
containing;O;O
antacids;B-group;B-DDI-DrugBank.d263.s23.e3
.;O;O
DDI-DrugBank.d263.s24;;
Metoclopramide;B-drug;B-DDI-DrugBank.d263.s24.e0
:;O;O
Bioavailability;O;O
is;O;O
mildly;O;O
reduced;O;O
(;O;O
approximately;O;O
10;O;O
%;O;O
);O;O
when;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s24.e1
and;O;O
metoclopramide;B-drug;B-DDI-DrugBank.d263.s24.e2
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d263.s25;;
Doxorubicin;B-drug;B-DDI-DrugBank.d263.s25.e0
:;O;O
Doxorubicin;B-drug;B-DDI-DrugBank.d263.s25.e1
caused;O;O
a;O;O
decrease;O;O
in;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s25.e2
phosphorylation;O;O
(;O;O
50;O;O
%;O;O
inhibition;O;O
of;O;O
total;O;O
phosphate;O;O
formation;O;O
);O;O
in;O;O
U937;O;O
/;O;O
Molt;O;O
4;O;O
cells;O;O
.;O;O
DDI-DrugBank.d263.s26;;
Although;O;O
there;O;O
may;O;O
be;O;O
decreased;O;O
zalcitabine;B-drug;B-DDI-DrugBank.d263.s26.e0
activity;O;O
because;O;O
of;O;O
lessened;O;O
active;O;O
metabolite;O;O
formation;O;O
,;O;O
the;O;O
clinical;O;O
relevance;O;O
of;O;O
these;O;O
in;O;O
vitro;O;O
results;O;O
are;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d324.s0;;
As;O;O
with;O;O
all;O;O
drugs;O;O
,;O;O
the;O;O
potential;O;O
exists;O;O
for;O;O
interaction;O;O
with;O;O
other;O;O
drugs;O;O
by;O;O
a;O;O
variety;O;O
of;O;O
mechanisms;O;O
.;O;O
DDI-DrugBank.d324.s1;;
CNS;O;O
-;O;O
Active;O;O
Drugs;O;O
Ethanol;B-drug;B-DDI-DrugBank.d324.s1.e0
:;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s1.e1
10;O;O
mg;O;O
potentiated;O;O
the;O;O
CNS;O;O
-;O;O
impairing;O;O
effects;O;O
of;O;O
ethanol;B-drug;B-DDI-DrugBank.d324.s1.e2
0.75;O;O
g;O;O
/;O;O
kg;O;O
on;O;O
balance;O;O
testing;O;O
and;O;O
reaction;O;O
time;O;O
for;O;O
1;O;O
hour;O;O
after;O;O
ethanol;B-drug;B-DDI-DrugBank.d324.s1.e3
administration;O;O
and;O;O
on;O;O
the;O;O
digit;O;O
symbol;O;O
substitution;O;O
test;O;O
(;O;O
DSST;O;O
);O;O
,;O;O
symbol;O;O
copying;O;O
test;O;O
,;O;O
and;O;O
the;O;O
variability;O;O
component;O;O
of;O;O
the;O;O
divided;O;O
attention;O;O
test;O;O
for;O;O
2.5;O;O
hours;O;O
after;O;O
ethanol;B-drug;B-DDI-DrugBank.d324.s1.e4
administration;O;O
.;O;O
DDI-DrugBank.d324.s2;;
The;O;O
potentiation;O;O
resulted;O;O
from;O;O
a;O;O
CNS;O;O
pharmacodynamic;O;O
interaction;O;O
,;O;O
DDI-DrugBank.d324.s3;;
zaleplon;B-drug;B-DDI-DrugBank.d324.s3.e0
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
ethanol;B-drug;B-DDI-DrugBank.d324.s3.e1
.;O;O
DDI-DrugBank.d324.s4;;
Imipramine;B-drug;B-DDI-DrugBank.d324.s4.e0
:;O;O
Coadministration;O;O
of;O;O
single;O;O
doses;O;O
of;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s4.e1
20;O;O
mg;O;O
and;O;O
imipramine;B-drug;B-DDI-DrugBank.d324.s4.e2
75;O;O
mg;O;O
produced;O;O
additive;O;O
effects;O;O
on;O;O
decreased;O;O
alertness;O;O
and;O;O
impaired;O;O
psychomotor;O;O
performance;O;O
for;O;O
2;O;O
to;O;O
4;O;O
hours;O;O
after;O;O
administration;O;O
.;O;O
DDI-DrugBank.d324.s5;;
The;O;O
interaction;O;O
was;O;O
pharmacodynamic;O;O
with;O;O
no;O;O
alteration;O;O
of;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d324.s6;;
Paroxetine;B-drug;B-DDI-DrugBank.d324.s6.e0
:;O;O
Coadministration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s6.e1
20;O;O
mg;O;O
and;O;O
paroxetine;B-drug;B-DDI-DrugBank.d324.s6.e2
20;O;O
mg;O;O
daily;O;O
for;O;O
7;O;O
days;O;O
did;O;O
not;O;O
produce;O;O
any;O;O
interaction;O;O
on;O;O
psychomotor;O;O
performance;O;O
.;O;O
DDI-DrugBank.d324.s7;;
Additionally;O;O
,;O;O
paroxetine;B-drug;B-DDI-DrugBank.d324.s7.e0
did;O;O
not;O;O
alter;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s7.e1
,;O;O
reflecting;O;O
the;O;O
absence;O;O
of;O;O
a;O;O
role;O;O
of;O;O
CYP2D6;O;O
in;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s7.e2
s;O;O
metabolism;O;O
.;O;O
DDI-DrugBank.d324.s8;;
Thioridazine;B-drug;B-DDI-DrugBank.d324.s8.e0
:;O;O
Coadministration;O;O
of;O;O
single;O;O
doses;O;O
of;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s8.e1
20;O;O
mg;O;O
and;O;O
thioridazine;B-drug;B-DDI-DrugBank.d324.s8.e2
50;O;O
mg;O;O
produced;O;O
additive;O;O
effects;O;O
on;O;O
decreased;O;O
alertness;O;O
and;O;O
impaired;O;O
psychomotor;O;O
performance;O;O
for;O;O
2;O;O
to;O;O
4;O;O
hours;O;O
after;O;O
administration;O;O
.;O;O
DDI-DrugBank.d324.s9;;
The;O;O
interaction;O;O
was;O;O
pharmacodynamic;O;O
with;O;O
no;O;O
alteration;O;O
of;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
drug;O;O
.;O;O
DDI-DrugBank.d324.s10;;
Venlafaxine;B-drug;B-DDI-DrugBank.d324.s10.e0
:;O;O
Coadministration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s10.e1
10;O;O
mg;O;O
and;O;O
multiple;O;O
doses;O;O
of;O;O
venlafaxine;B-drug;B-DDI-DrugBank.d324.s10.e2
ER;O;O
(;O;O
extended;O;O
release;O;O
);O;O
150;O;O
mg;O;O
did;O;O
not;O;O
result;O;O
in;O;O
any;O;O
significant;O;O
changes;O;O
in;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
either;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s10.e3
or;O;O
venlafaxine;B-drug;B-DDI-DrugBank.d324.s10.e4
.;O;O
DDI-DrugBank.d324.s11;;
In;O;O
addition;O;O
,;O;O
there;O;O
was;O;O
no;O;O
pharmacodynamic;O;O
interaction;O;O
as;O;O
a;O;O
result;O;O
of;O;O
coadministration;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s11.e0
and;O;O
venlafaxine;B-drug;B-DDI-DrugBank.d324.s11.e1
ER;O;O
.;O;O
DDI-DrugBank.d324.s12;;
Promethazine;B-drug;B-DDI-DrugBank.d324.s12.e0
:;O;O
Coadministration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s12.e1
and;O;O
promethazine;B-drug;B-DDI-DrugBank.d324.s12.e2
(;O;O
10;O;O
and;O;O
25;O;O
mg;O;O
,;O;O
respectively;O;O
);O;O
resulted;O;O
in;O;O
a;O;O
15;O;O
%;O;O
decrease;O;O
in;O;O
maximal;O;O
plasma;O;O
concentrations;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s12.e3
,;O;O
but;O;O
no;O;O
change;O;O
in;O;O
the;O;O
area;O;O
under;O;O
the;O;O
plasma;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
.;O;O
DDI-DrugBank.d324.s13;;
However;O;O
,;O;O
the;O;O
pharmacodynamics;O;O
of;O;O
coadministration;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s13.e0
and;O;O
promethazine;B-drug;B-DDI-DrugBank.d324.s13.e1
have;O;O
not;O;O
been;O;O
evaluated;O;O
.;O;O
DDI-DrugBank.d324.s14;;
Caution;O;O
should;O;O
be;O;O
exercised;O;O
when;O;O
these;O;O
2;O;O
agents;O;O
are;O;O
coadministered;O;O
.;O;O
DDI-DrugBank.d324.s15;;
Drugs;O;O
That;O;O
Induce;O;O
CYP3A4;O;O
Rifampin;B-drug;B-DDI-DrugBank.d324.s15.e0
:;O;O
CYP3A4;O;O
is;O;O
ordinarily;O;O
a;O;O
minor;O;O
metabolizing;O;O
enzyme;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s15.e1
.;O;O
DDI-DrugBank.d324.s16;;
Multiple;O;O
-;O;O
dose;O;O
administration;O;O
of;O;O
the;O;O
potent;O;O
CYP3A4;O;O
inducer;O;O
rifampin;B-drug;B-DDI-DrugBank.d324.s16.e0
(;O;O
600;O;O
mg;O;O
every;O;O
24;O;O
hours;O;O
,;O;O
q24h;O;O
,;O;O
for;O;O
14;O;O
days;O;O
);O;O
,;O;O
however;O;O
,;O;O
reduced;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s16.e1
Cmax;O;O
and;O;O
AUC;O;O
by;O;O
approximately;O;O
80;O;O
%;O;O
.;O;O
DDI-DrugBank.d324.s17;;
The;O;O
coadministration;O;O
of;O;O
a;O;O
potent;O;O
CYP3A4;O;O
enzyme;O;O
inducer;O;O
,;O;O
although;O;O
not;O;O
posing;O;O
a;O;O
safety;O;O
concern;O;O
,;O;O
thus;O;O
could;O;O
lead;O;O
to;O;O
ineffectiveness;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s17.e0
.;O;O
DDI-DrugBank.d324.s18;;
An;O;O
alternative;O;O
non;O;O
-;O;O
CYP3A4;O;O
substrate;O;O
hypnotic;B-group;B-DDI-DrugBank.d324.s18.e0
agent;I-group;I-DDI-DrugBank.d324.s18.e0
may;O;O
be;O;O
considered;O;O
in;O;O
patients;O;O
taking;O;O
CYP3A4;O;O
inducers;O;O
such;O;O
as;O;O
rifampin;B-drug;B-DDI-DrugBank.d324.s18.e1
,;O;O
phenytoin;B-drug;B-DDI-DrugBank.d324.s18.e2
,;O;O
carbamazepine;B-drug;B-DDI-DrugBank.d324.s18.e3
,;O;O
and;O;O
phenobarbital;B-drug;B-DDI-DrugBank.d324.s18.e4
.;O;O
DDI-DrugBank.d324.s19;;
Drugs;O;O
That;O;O
Inhibit;O;O
CYP3A4;O;O
CYP3A4;O;O
is;O;O
a;O;O
minor;O;O
metabolic;O;O
pathway;O;O
for;O;O
the;O;O
elimination;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s19.e0
because;O;O
the;O;O
sum;O;O
of;O;O
desethylzaleplon;O;O
(;O;O
formed;O;O
via;O;O
CYP3A4;O;O
in;O;O
vitro;O;O
);O;O
and;O;O
its;O;O
metabolites;O;O
,;O;O
5;B-drug_n;B-DDI-DrugBank.d324.s19.e1
-;I-drug_n;I-DDI-DrugBank.d324.s19.e1
oxo;I-drug_n;I-DDI-DrugBank.d324.s19.e1
-;I-drug_n;I-DDI-DrugBank.d324.s19.e1
desethylzaleplon;I-drug_n;I-DDI-DrugBank.d324.s19.e1
and;O;O
5;B-drug_n;B-DDI-DrugBank.d324.s19.e2
-;I-drug_n;I-DDI-DrugBank.d324.s19.e2
oxo;I-drug_n;I-DDI-DrugBank.d324.s19.e2
-;I-drug_n;I-DDI-DrugBank.d324.s19.e2
desethylzaleplon;I-drug_n;I-DDI-DrugBank.d324.s19.e2
glucuronide;I-drug_n;I-DDI-DrugBank.d324.s19.e2
,;O;O
account;O;O
for;O;O
only;O;O
9;O;O
%;O;O
of;O;O
the;O;O
urinary;O;O
recovery;O;O
of;O;O
a;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s19.e3
dose;O;O
.;O;O
DDI-DrugBank.d324.s20;;
Coadministration;O;O
of;O;O
single;O;O
,;O;O
oral;O;O
doses;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s20.e0
with;O;O
erythromycin;B-drug;B-DDI-DrugBank.d324.s20.e1
(;O;O
10;O;O
mg;O;O
and;O;O
800;O;O
mg;O;O
,;O;O
respectively;O;O
);O;O
,;O;O
a;O;O
strong;O;O
,;O;O
selective;O;O
CYP3A4;O;O
inhibitor;O;O
produced;O;O
a;O;O
34;O;O
%;O;O
increase;O;O
in;O;O
zaleplons;B-drug;B-DDI-DrugBank.d324.s20.e2
maximal;O;O
plasma;O;O
concentrations;O;O
and;O;O
a;O;O
20;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
area;O;O
under;O;O
the;O;O
plasma;O;O
concentration;O;O
-;O;O
time;O;O
curve;O;O
.;O;O
DDI-DrugBank.d324.s21;;
The;O;O
magnitude;O;O
of;O;O
interaction;O;O
with;O;O
multiple;O;O
doses;O;O
of;O;O
erythromycin;B-drug;B-DDI-DrugBank.d324.s21.e0
is;O;O
unknown;O;O
.;O;O
DDI-DrugBank.d324.s22;;
Other;O;O
strong;O;O
selective;O;O
CYP3A4;O;O
inhibitors;O;O
such;O;O
as;O;O
ketoconazole;B-drug;B-DDI-DrugBank.d324.s22.e0
can;O;O
also;O;O
be;O;O
expected;O;O
to;O;O
increase;O;O
the;O;O
exposure;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s22.e1
.;O;O
DDI-DrugBank.d324.s23;;
A;O;O
routine;O;O
dosage;O;O
adjustment;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s23.e0
is;O;O
not;O;O
considered;O;O
necessary;O;O
.;O;O
DDI-DrugBank.d324.s24;;
Drugs;O;O
That;O;O
Inhibit;O;O
Aldehyde;O;O
Oxidase;O;O
The;O;O
aldehyde;O;O
oxidase;O;O
enzyme;O;O
system;O;O
is;O;O
less;O;O
well;O;O
studied;O;O
than;O;O
the;O;O
cytochrome;O;O
P450;O;O
enzyme;O;O
system;O;O
.;O;O
DDI-DrugBank.d324.s25;;
Diphenhydramine;B-drug;B-DDI-DrugBank.d324.s25.e0
:;O;O
Diphenhydramine;B-drug;B-DDI-DrugBank.d324.s25.e1
is;O;O
reported;O;O
to;O;O
be;O;O
a;O;O
weak;O;O
inhibitor;O;O
of;O;O
aldehyde;O;O
oxidase;O;O
in;O;O
rat;O;O
liver;O;O
,;O;O
but;O;O
its;O;O
inhibitory;O;O
effects;O;O
in;O;O
human;O;O
liver;O;O
are;O;O
not;O;O
known;O;O
.;O;O
DDI-DrugBank.d324.s26;;
There;O;O
is;O;O
no;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s26.e0
and;O;O
diphenhydramine;B-drug;B-DDI-DrugBank.d324.s26.e1
following;O;O
the;O;O
administration;O;O
of;O;O
a;O;O
single;O;O
dose;O;O
(;O;O
10;O;O
mg;O;O
and;O;O
50;O;O
mg;O;O
,;O;O
respectively;O;O
);O;O
of;O;O
each;O;O
drug;O;O
.;O;O
DDI-DrugBank.d324.s27;;
However;O;O
,;O;O
because;O;O
both;O;O
of;O;O
these;O;O
compounds;O;O
have;O;O
CNS;O;O
effects;O;O
,;O;O
an;O;O
additive;O;O
pharmacodynamic;O;O
effect;O;O
is;O;O
possible;O;O
.;O;O
DDI-DrugBank.d324.s28;;
Drugs;O;O
That;O;O
Inhibit;O;O
Both;O;O
Aldehyde;O;O
Oxidase;O;O
and;O;O
CYP3A4;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d324.s28.e0
:;O;O
Cimetidine;B-drug;B-DDI-DrugBank.d324.s28.e1
inhibits;O;O
both;O;O
aldehyde;O;O
oxidase;O;O
(;O;O
in;O;O
vitro;O;O
);O;O
and;O;O
CYP3A4;O;O
(;O;O
in;O;O
vitro;O;O
and;O;O
in;O;O
vivo;O;O
);O;O
,;O;O
the;O;O
primary;O;O
and;O;O
secondary;O;O
enzymes;O;O
,;O;O
respectively;O;O
,;O;O
responsible;O;O
for;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s28.e2
metabolism;O;O
.;O;O
DDI-DrugBank.d324.s29;;
Concomitant;O;O
administration;O;O
of;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s29.e0
(;O;O
10;O;O
mg;O;O
);O;O
and;O;O
cimetidine;B-drug;B-DDI-DrugBank.d324.s29.e1
(;O;O
800;O;O
mg;O;O
);O;O
produced;O;O
an;O;O
85;O;O
%;O;O
increase;O;O
in;O;O
the;O;O
mean;O;O
Cmax;O;O
and;O;O
AUC;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s29.e2
.;O;O
DDI-DrugBank.d324.s30;;
An;O;O
initial;O;O
dose;O;O
of;O;O
5;O;O
mg;O;O
should;O;O
be;O;O
given;O;O
to;O;O
patients;O;O
who;O;O
are;O;O
concomitantly;O;O
being;O;O
treated;O;O
with;O;O
cimetidine;B-drug;B-DDI-DrugBank.d324.s30.e0
.;O;O
DDI-DrugBank.d324.s31;;
Drugs;O;O
Highly;O;O
Bound;O;O
to;O;O
Plasma;O;O
Protein;O;O
Zaleplon;B-drug;B-DDI-DrugBank.d324.s31.e0
is;O;O
not;O;O
highly;O;O
bound;O;O
to;O;O
plasma;O;O
proteins;O;O
(;O;O
fraction;O;O
bound;O;O
60;O;O
%;O;O
15;O;O
%;O;O
);O;O
,;O;O
DDI-DrugBank.d324.s32;;
therefore;O;O
,;O;O
the;O;O
disposition;O;O
of;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s32.e0
is;O;O
not;O;O
expected;O;O
to;O;O
be;O;O
sensitive;O;O
to;O;O
alterations;O;O
in;O;O
protein;O;O
binding;O;O
.;O;O
DDI-DrugBank.d324.s33;;
In;O;O
addition;O;O
,;O;O
administration;O;O
of;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s33.e0
to;O;O
a;O;O
patient;O;O
taking;O;O
another;O;O
drug;O;O
that;O;O
is;O;O
highly;O;O
protein;O;O
bound;O;O
should;O;O
not;O;O
cause;O;O
transient;O;O
increase;O;O
in;O;O
free;O;O
concentrations;O;O
of;O;O
the;O;O
other;O;O
drug;O;O
.;O;O
DDI-DrugBank.d324.s34;;
Drugs;O;O
with;O;O
a;O;O
Narrow;O;O
Therapeutic;O;O
Index;O;O
Digoxin;B-drug;B-DDI-DrugBank.d324.s34.e0
:;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s34.e1
(;O;O
10;O;O
mg;O;O
);O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetic;O;O
or;O;O
pharmacodynamic;O;O
profile;O;O
of;O;O
digoxin;B-drug;B-DDI-DrugBank.d324.s34.e2
(;O;O
0.375;O;O
mg;O;O
q24h;O;O
for;O;O
8;O;O
days;O;O
);O;O
.;O;O
DDI-DrugBank.d324.s35;;
Warfarin;B-drug;B-DDI-DrugBank.d324.s35.e0
:;O;O
Multiple;O;O
oral;O;O
doses;O;O
of;O;O
Sonata;B-brand;B-DDI-DrugBank.d324.s35.e1
(;O;O
20;O;O
mg;O;O
q24h;O;O
for;O;O
13;O;O
days;O;O
);O;O
did;O;O
not;O;O
affect;O;O
the;O;O
pharmacokinetics;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d324.s35.e2
(;O;O
R+);O;O
-;O;O
or;O;O
(;O;O
S;O;O
-;O;O
);O;O
-;O;O
enantiomers;O;O
or;O;O
the;O;O
pharmacodynamics;O;O
(;O;O
prothrombin;O;O
time;O;O
);O;O
following;O;O
a;O;O
single;O;O
25;O;O
-;O;O
mg;O;O
oral;O;O
dose;O;O
of;O;O
warfarin;B-drug;B-DDI-DrugBank.d324.s35.e3
.;O;O
DDI-DrugBank.d324.s36;;
Drugs;O;O
That;O;O
Alter;O;O
Renal;O;O
Excretion;O;O
Ibuprofen;B-drug;B-DDI-DrugBank.d324.s36.e0
:;O;O
Ibuprofen;B-drug;B-DDI-DrugBank.d324.s36.e1
is;O;O
known;O;O
to;O;O
affect;O;O
renal;O;O
function;O;O
and;O;O
,;O;O
consequently;O;O
,;O;O
alter;O;O
the;O;O
renal;O;O
excretion;O;O
of;O;O
other;O;O
drugs;O;O
.;O;O
DDI-DrugBank.d324.s37;;
There;O;O
was;O;O
no;O;O
apparent;O;O
pharmacokinetic;O;O
interaction;O;O
between;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s37.e0
and;O;O
ibuprofen;B-drug;B-DDI-DrugBank.d324.s37.e1
following;O;O
single;O;O
dose;O;O
administration;O;O
(;O;O
10;O;O
mg;O;O
and;O;O
600;O;O
mg;O;O
,;O;O
respectively;O;O
);O;O
of;O;O
each;O;O
drug;O;O
.;O;O
DDI-DrugBank.d324.s38;;
This;O;O
was;O;O
expected;O;O
because;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s38.e0
is;O;O
primarily;O;O
metabolized;O;O
and;O;O
renal;O;O
excretion;O;O
of;O;O
unchanged;O;O
zaleplon;B-drug;B-DDI-DrugBank.d324.s38.e1
accounts;O;O
for;O;O
less;O;O
than;O;O
1;O;O
%;O;O
of;O;O
the;O;O
administered;O;O
dose;O;O
.;O;O
